6	NEURACEQ.xml:S1:4:1	O
ADVERSE	NEURACEQ.xml:S1:6:7	O
REACTIONS	NEURACEQ.xml:S1:14:9	O

EXCERPT	NEURACEQ.xml:S1:34:7	O

:	NEURACEQ.xml:S1:41:1	O
The	NEURACEQ.xml:S1:45:3	O
most	NEURACEQ.xml:S1:49:4	O
commonly	NEURACEQ.xml:S1:54:8	O
reported	NEURACEQ.xml:S1:63:8	O
adverse	NEURACEQ.xml:S1:72:7	O
reactions	NEURACEQ.xml:S1:80:9	O
were	NEURACEQ.xml:S1:90:4	O
:	NEURACEQ.xml:S1:94:1	O
injection	NEURACEQ.xml:S1:96:9	B-AdverseReaction
site	NEURACEQ.xml:S1:106:4	I-AdverseReaction
reaction	NEURACEQ.xml:S1:111:8	I-AdverseReaction
consisting	NEURACEQ.xml:S1:120:10	O
of	NEURACEQ.xml:S1:131:2	O
erythema	NEURACEQ.xml:S1:134:8	I-AdverseReaction
(	NEURACEQ.xml:S1:143:1	O
1.7	NEURACEQ.xml:S1:144:3	O
)	NEURACEQ.xml:S1:149:1	O
,	NEURACEQ.xml:S1:150:1	O
irritation	NEURACEQ.xml:S1:152:10	I-AdverseReaction
(	NEURACEQ.xml:S1:163:1	O
1.2	NEURACEQ.xml:S1:164:3	O
)	NEURACEQ.xml:S1:169:1	O
,	NEURACEQ.xml:S1:170:1	O
and	NEURACEQ.xml:S1:172:3	O
pain	NEURACEQ.xml:S1:176:4	I-AdverseReaction
(	NEURACEQ.xml:S1:181:1	O
3.9	NEURACEQ.xml:S1:182:3	O
)	NEURACEQ.xml:S1:187:1	O
.	NEURACEQ.xml:S1:188:1	O

To	NEURACEQ.xml:S1:196:2	O
report	NEURACEQ.xml:S1:199:6	O
SUSPECTED	NEURACEQ.xml:S1:206:9	O
ADVERSE	NEURACEQ.xml:S1:216:7	O
REACTIONS	NEURACEQ.xml:S1:224:9	O
,	NEURACEQ.xml:S1:233:1	O
contact	NEURACEQ.xml:S1:235:7	O
Piramal	NEURACEQ.xml:S1:243:7	O
at	NEURACEQ.xml:S1:251:2	O
1	NEURACEQ.xml:S1:254:1	O
-	NEURACEQ.xml:S1:255:1	O
855	NEURACEQ.xml:S1:256:3	O
-	NEURACEQ.xml:S1:259:1	O
545	NEURACEQ.xml:S1:260:3	O
-	NEURACEQ.xml:S1:263:1	O
5245	NEURACEQ.xml:S1:264:4	O
or	NEURACEQ.xml:S1:269:2	O
FDA	NEURACEQ.xml:S1:272:3	O
at	NEURACEQ.xml:S1:276:2	O
1	NEURACEQ.xml:S1:279:1	O
-	NEURACEQ.xml:S1:280:1	O
800	NEURACEQ.xml:S1:281:3	O
-	NEURACEQ.xml:S1:284:1	O
FDA	NEURACEQ.xml:S1:285:3	O
-	NEURACEQ.xml:S1:288:1	O
1088	NEURACEQ.xml:S1:289:4	O
or	NEURACEQ.xml:S1:294:2	O
www	NEURACEQ.xml:S1:297:3	O
.	NEURACEQ.xml:S1:300:1	O
fda	NEURACEQ.xml:S1:301:3	O
.	NEURACEQ.xml:S1:304:1	O
gov	NEURACEQ.xml:S1:305:3	O
medwatch	NEURACEQ.xml:S1:309:8	O
.	NEURACEQ.xml:S1:317:1	O

6.1	NEURACEQ.xml:S1:329:3	O

Clinical	NEURACEQ.xml:S1:333:8	O
Trials	NEURACEQ.xml:S1:342:6	O
Experience	NEURACEQ.xml:S1:349:10	O

Because	NEURACEQ.xml:S1:363:7	O
clinical	NEURACEQ.xml:S1:371:8	O
trials	NEURACEQ.xml:S1:380:6	O
are	NEURACEQ.xml:S1:387:3	O
conducted	NEURACEQ.xml:S1:391:9	O
under	NEURACEQ.xml:S1:401:5	O
widely	NEURACEQ.xml:S1:407:6	O
varying	NEURACEQ.xml:S1:414:7	O
conditions	NEURACEQ.xml:S1:422:10	O
,	NEURACEQ.xml:S1:432:1	O
adverse	NEURACEQ.xml:S1:434:7	O
reaction	NEURACEQ.xml:S1:442:8	O
rates	NEURACEQ.xml:S1:451:5	O
observed	NEURACEQ.xml:S1:457:8	O
in	NEURACEQ.xml:S1:466:2	O
the	NEURACEQ.xml:S1:469:3	O
clinical	NEURACEQ.xml:S1:473:8	O
trials	NEURACEQ.xml:S1:482:6	O
of	NEURACEQ.xml:S1:489:2	O
a	NEURACEQ.xml:S1:492:1	O
drug	NEURACEQ.xml:S1:494:4	O
cannot	NEURACEQ.xml:S1:499:6	O
be	NEURACEQ.xml:S1:506:2	O
directly	NEURACEQ.xml:S1:509:8	O
compared	NEURACEQ.xml:S1:518:8	O
to	NEURACEQ.xml:S1:527:2	O
rates	NEURACEQ.xml:S1:530:5	O
in	NEURACEQ.xml:S1:536:2	O
the	NEURACEQ.xml:S1:539:3	O
clinical	NEURACEQ.xml:S1:543:8	O
trials	NEURACEQ.xml:S1:552:6	O
of	NEURACEQ.xml:S1:559:2	O
another	NEURACEQ.xml:S1:562:7	O
drug	NEURACEQ.xml:S1:570:4	O
and	NEURACEQ.xml:S1:575:3	O
may	NEURACEQ.xml:S1:579:3	O
not	NEURACEQ.xml:S1:583:3	O
reflect	NEURACEQ.xml:S1:587:7	O
the	NEURACEQ.xml:S1:595:3	O
rate	NEURACEQ.xml:S1:599:4	O
observed	NEURACEQ.xml:S1:604:8	O
in	NEURACEQ.xml:S1:613:2	O
clinical	NEURACEQ.xml:S1:616:8	O
practice	NEURACEQ.xml:S1:625:8	O
.	NEURACEQ.xml:S1:633:1	O

The	NEURACEQ.xml:S1:639:3	O
overall	NEURACEQ.xml:S1:643:7	O
safety	NEURACEQ.xml:S1:651:6	O
profile	NEURACEQ.xml:S1:658:7	O
of	NEURACEQ.xml:S1:666:2	O
Neuraceq	NEURACEQ.xml:S1:669:8	O
is	NEURACEQ.xml:S1:678:2	O
based	NEURACEQ.xml:S1:681:5	O
on	NEURACEQ.xml:S1:687:2	O
data	NEURACEQ.xml:S1:690:4	O
from	NEURACEQ.xml:S1:695:4	O
978	NEURACEQ.xml:S1:700:3	O
administrations	NEURACEQ.xml:S1:704:15	O
of	NEURACEQ.xml:S1:720:2	O
Neuraceq	NEURACEQ.xml:S1:723:8	O
to	NEURACEQ.xml:S1:732:2	O
872	NEURACEQ.xml:S1:735:3	O
subjects	NEURACEQ.xml:S1:739:8	O
and	NEURACEQ.xml:S1:748:3	O
12	NEURACEQ.xml:S1:752:2	O
subjects	NEURACEQ.xml:S1:755:8	O
who	NEURACEQ.xml:S1:764:3	O
received	NEURACEQ.xml:S1:768:8	O
vehicle	NEURACEQ.xml:S1:777:7	O
only	NEURACEQ.xml:S1:785:4	O
.	NEURACEQ.xml:S1:789:1	O

No	NEURACEQ.xml:S1:791:2	O
serious	NEURACEQ.xml:S1:794:7	O
adverse	NEURACEQ.xml:S1:802:7	O
reactions	NEURACEQ.xml:S1:810:9	O
related	NEURACEQ.xml:S1:820:7	O
to	NEURACEQ.xml:S1:828:2	O
Neuraceq	NEURACEQ.xml:S1:831:8	O
administration	NEURACEQ.xml:S1:840:14	O
have	NEURACEQ.xml:S1:855:4	O
been	NEURACEQ.xml:S1:860:4	O
reported	NEURACEQ.xml:S1:865:8	O
.	NEURACEQ.xml:S1:873:1	O

The	NEURACEQ.xml:S1:875:3	O
most	NEURACEQ.xml:S1:879:4	O
frequently	NEURACEQ.xml:S1:884:10	O
observed	NEURACEQ.xml:S1:895:8	O
adverse	NEURACEQ.xml:S1:904:7	O
drug	NEURACEQ.xml:S1:912:4	O
reactions	NEURACEQ.xml:S1:917:9	O
in	NEURACEQ.xml:S1:927:2	O
subjects	NEURACEQ.xml:S1:930:8	O
receiving	NEURACEQ.xml:S1:939:9	O
Neuraceq	NEURACEQ.xml:S1:949:8	O
were	NEURACEQ.xml:S1:958:4	O
injection	NEURACEQ.xml:S1:963:9	B-AdverseReaction
site	NEURACEQ.xml:S1:973:4	I-AdverseReaction
reactions	NEURACEQ.xml:S1:978:9	I-AdverseReaction
consisting	NEURACEQ.xml:S1:988:10	O
of	NEURACEQ.xml:S1:999:2	O
erythema	NEURACEQ.xml:S1:1002:8	I-AdverseReaction
,	NEURACEQ.xml:S1:1010:1	O
irritation	NEURACEQ.xml:S1:1012:10	I-AdverseReaction
and	NEURACEQ.xml:S1:1023:3	O
pain	NEURACEQ.xml:S1:1027:4	I-AdverseReaction
.	NEURACEQ.xml:S1:1031:1	O

All	NEURACEQ.xml:S1:1033:3	O
adverse	NEURACEQ.xml:S1:1037:7	O
reactions	NEURACEQ.xml:S1:1045:9	O
were	NEURACEQ.xml:S1:1055:4	O
mild	NEURACEQ.xml:S1:1060:4	O
to	NEURACEQ.xml:S1:1065:2	O
moderate	NEURACEQ.xml:S1:1068:8	O
in	NEURACEQ.xml:S1:1077:2	O
severity	NEURACEQ.xml:S1:1080:8	O
and	NEURACEQ.xml:S1:1089:3	O
of	NEURACEQ.xml:S1:1093:2	O
short	NEURACEQ.xml:S1:1096:5	O
duration	NEURACEQ.xml:S1:1102:8	O
.	NEURACEQ.xml:S1:1110:1	O

The	NEURACEQ.xml:S1:1112:3	O
most	NEURACEQ.xml:S1:1116:4	O
commonly	NEURACEQ.xml:S1:1121:8	O
reported	NEURACEQ.xml:S1:1130:8	O
adverse	NEURACEQ.xml:S1:1139:7	O
reactions	NEURACEQ.xml:S1:1147:9	O
(	NEURACEQ.xml:S1:1157:1	O
occurring	NEURACEQ.xml:S1:1158:9	O
in	NEURACEQ.xml:S1:1168:2	O
at	NEURACEQ.xml:S1:1171:2	O
least	NEURACEQ.xml:S1:1174:5	O
0.5%	NEURACEQ.xml:S1:1180:4	O
of	NEURACEQ.xml:S1:1185:2	O
subjects	NEURACEQ.xml:S1:1188:8	O
)	NEURACEQ.xml:S1:1196:1	O
during	NEURACEQ.xml:S1:1198:6	O
Neuraceq	NEURACEQ.xml:S1:1205:8	O
clinical	NEURACEQ.xml:S1:1214:8	O
trials	NEURACEQ.xml:S1:1223:6	O
are	NEURACEQ.xml:S1:1230:3	O
shown	NEURACEQ.xml:S1:1234:5	O
in	NEURACEQ.xml:S1:1240:2	O
Table	NEURACEQ.xml:S1:1243:5	O
2	NEURACEQ.xml:S1:1249:1	O
.	NEURACEQ.xml:S1:1250:1	O

Table	NEURACEQ.xml:S1:1256:5	O
2	NEURACEQ.xml:S1:1262:1	O
Adverse	NEURACEQ.xml:S1:1264:7	O
Reactions	NEURACEQ.xml:S1:1272:9	O
with	NEURACEQ.xml:S1:1282:4	O
a	NEURACEQ.xml:S1:1287:1	O
Frequency	NEURACEQ.xml:S1:1289:9	O
0.5%	NEURACEQ.xml:S1:1301:4	O
Reported	NEURACEQ.xml:S1:1306:8	O
in	NEURACEQ.xml:S1:1315:2	O
Clinical	NEURACEQ.xml:S1:1318:8	O
Trials	NEURACEQ.xml:S1:1327:6	O
(	NEURACEQ.xml:S1:1334:1	O
n	NEURACEQ.xml:S1:1335:1	O
978	NEURACEQ.xml:S1:1339:3	O
Administrations	NEURACEQ.xml:S1:1343:15	O
in	NEURACEQ.xml:S1:1359:2	O
872	NEURACEQ.xml:S1:1362:3	O
Subjects	NEURACEQ.xml:S1:1366:8	O
)	NEURACEQ.xml:S1:1374:1	O

Adverse	NEURACEQ.xml:S1:1380:7	O
drug	NEURACEQ.xml:S1:1388:4	O
reaction	NEURACEQ.xml:S1:1393:8	O
n	NEURACEQ.xml:S1:1407:1	O
(	NEURACEQ.xml:S1:1409:1	O
)	NEURACEQ.xml:S1:1411:1	O

Injection	NEURACEQ.xml:S1:1435:9	B-AdverseReaction
application	NEURACEQ.xml:S1:1447:11	B-AdverseReaction
site	NEURACEQ.xml:S1:1459:4	I-AdverseReaction
erythema	NEURACEQ.xml:S1:1464:8	I-AdverseReaction
17	NEURACEQ.xml:S1:1474:2	O
(	NEURACEQ.xml:S1:1477:1	O
1.7	NEURACEQ.xml:S1:1478:3	O
)	NEURACEQ.xml:S1:1481:1	O

Injection	NEURACEQ.xml:S1:1504:9	B-AdverseReaction
site	NEURACEQ.xml:S1:1514:4	I-AdverseReaction
irritation	NEURACEQ.xml:S1:1519:10	I-AdverseReaction
12	NEURACEQ.xml:S1:1531:2	O
(	NEURACEQ.xml:S1:1534:1	O
1.2	NEURACEQ.xml:S1:1535:3	O
)	NEURACEQ.xml:S1:1538:1	O

Injection	NEURACEQ.xml:S1:1561:9	B-AdverseReaction
site	NEURACEQ.xml:S1:1571:4	I-AdverseReaction
pain	NEURACEQ.xml:S1:1576:4	I-AdverseReaction
38	NEURACEQ.xml:S1:1588:2	O
(	NEURACEQ.xml:S1:1591:1	O
3.9	NEURACEQ.xml:S1:1592:3	O
)	NEURACEQ.xml:S1:1595:1	O
5	NEURACEQ.xml:S2:4:1	O
WARNINGS	NEURACEQ.xml:S2:6:8	O
AND	NEURACEQ.xml:S2:15:3	O
PRECAUTIONS	NEURACEQ.xml:S2:19:11	O

EXCERPT	NEURACEQ.xml:S2:43:7	O

:	NEURACEQ.xml:S2:50:1	O
Image	NEURACEQ.xml:S2:55:5	O
interpretation	NEURACEQ.xml:S2:61:14	O
errors	NEURACEQ.xml:S2:76:6	O
(	NEURACEQ.xml:S2:83:1	O
especially	NEURACEQ.xml:S2:84:10	O
false	NEURACEQ.xml:S2:95:5	O
positives	NEURACEQ.xml:S2:101:9	O
)	NEURACEQ.xml:S2:110:1	O
have	NEURACEQ.xml:S2:112:4	O
been	NEURACEQ.xml:S2:117:4	O
observed	NEURACEQ.xml:S2:122:8	O
(	NEURACEQ.xml:S2:131:1	O
5.1	NEURACEQ.xml:S2:134:3	O
)	NEURACEQ.xml:S2:139:1	O
.	NEURACEQ.xml:S2:140:1	O

Neuraceq	NEURACEQ.xml:S2:147:8	O
,	NEURACEQ.xml:S2:155:1	O
like	NEURACEQ.xml:S2:157:4	O
all	NEURACEQ.xml:S2:162:3	O
radiopharmaceuticals	NEURACEQ.xml:S2:166:20	O
,	NEURACEQ.xml:S2:186:1	O
contributes	NEURACEQ.xml:S2:188:11	O
to	NEURACEQ.xml:S2:200:2	O
a	NEURACEQ.xml:S2:203:1	O
patient	NEURACEQ.xml:S2:205:7	O
's	NEURACEQ.xml:S2:212:2	O
long	NEURACEQ.xml:S2:215:4	B-AdverseReaction
-	NEURACEQ.xml:S2:219:1	I-AdverseReaction
term	NEURACEQ.xml:S2:220:4	I-AdverseReaction
cumulative	NEURACEQ.xml:S2:225:10	I-AdverseReaction
radiation	NEURACEQ.xml:S2:236:9	I-AdverseReaction
exposure	NEURACEQ.xml:S2:246:8	I-AdverseReaction
.	NEURACEQ.xml:S2:254:1	O

Ensure	NEURACEQ.xml:S2:256:6	O
safe	NEURACEQ.xml:S2:263:4	O
handling	NEURACEQ.xml:S2:268:8	O
to	NEURACEQ.xml:S2:277:2	O
protect	NEURACEQ.xml:S2:280:7	O
patients	NEURACEQ.xml:S2:288:8	O
and	NEURACEQ.xml:S2:297:3	O
health	NEURACEQ.xml:S2:301:6	O
care	NEURACEQ.xml:S2:308:4	O
workers	NEURACEQ.xml:S2:313:7	O
from	NEURACEQ.xml:S2:321:4	O
unintentional	NEURACEQ.xml:S2:326:13	O
radiation	NEURACEQ.xml:S2:340:9	O
exposure	NEURACEQ.xml:S2:350:8	O
(	NEURACEQ.xml:S2:359:1	O
5.2	NEURACEQ.xml:S2:362:3	O
)	NEURACEQ.xml:S2:367:1	O
.	NEURACEQ.xml:S2:368:1	O

5.1	NEURACEQ.xml:S2:381:3	O

Risk	NEURACEQ.xml:S2:385:4	O
for	NEURACEQ.xml:S2:390:3	O
Image	NEURACEQ.xml:S2:394:5	O
Misinterpretation	NEURACEQ.xml:S2:400:17	O
and	NEURACEQ.xml:S2:418:3	O
Other	NEURACEQ.xml:S2:422:5	O
Errors	NEURACEQ.xml:S2:428:6	O

Errors	NEURACEQ.xml:S2:440:6	O
may	NEURACEQ.xml:S2:447:3	O
occur	NEURACEQ.xml:S2:451:5	O
in	NEURACEQ.xml:S2:457:2	O
the	NEURACEQ.xml:S2:460:3	O
Neuraceq	NEURACEQ.xml:S2:464:8	O
estimation	NEURACEQ.xml:S2:473:10	O
of	NEURACEQ.xml:S2:484:2	O
brain	NEURACEQ.xml:S2:487:5	O
neuritic	NEURACEQ.xml:S2:493:8	O
beta	NEURACEQ.xml:S2:502:4	O
-	NEURACEQ.xml:S2:506:1	O
amyloid	NEURACEQ.xml:S2:507:7	O
plaque	NEURACEQ.xml:S2:515:6	O
density	NEURACEQ.xml:S2:522:7	O
during	NEURACEQ.xml:S2:530:6	O
image	NEURACEQ.xml:S2:537:5	O
interpretation	NEURACEQ.xml:S2:543:14	O
[	NEURACEQ.xml:S2:558:1	O
see	NEURACEQ.xml:S2:560:3	O
Clinical	NEURACEQ.xml:S2:565:8	O
Studies	NEURACEQ.xml:S2:574:7	O
(	NEURACEQ.xml:S2:582:1	O
14	NEURACEQ.xml:S2:583:2	O
)	NEURACEQ.xml:S2:585:1	O
]	NEURACEQ.xml:S2:590:1	O
.	NEURACEQ.xml:S2:591:1	O

Image	NEURACEQ.xml:S2:593:5	O
interpretation	NEURACEQ.xml:S2:599:14	O
should	NEURACEQ.xml:S2:614:6	O
be	NEURACEQ.xml:S2:621:2	O
performed	NEURACEQ.xml:S2:624:9	O
independently	NEURACEQ.xml:S2:634:13	O
of	NEURACEQ.xml:S2:648:2	O
the	NEURACEQ.xml:S2:651:3	O
patient	NEURACEQ.xml:S2:655:7	O
's	NEURACEQ.xml:S2:662:2	O
clinical	NEURACEQ.xml:S2:665:8	O
information	NEURACEQ.xml:S2:674:11	O
.	NEURACEQ.xml:S2:685:1	O

The	NEURACEQ.xml:S2:687:3	O
use	NEURACEQ.xml:S2:691:3	O
of	NEURACEQ.xml:S2:695:2	O
clinical	NEURACEQ.xml:S2:698:8	O
information	NEURACEQ.xml:S2:707:11	O
in	NEURACEQ.xml:S2:719:2	O
the	NEURACEQ.xml:S2:722:3	O
interpretation	NEURACEQ.xml:S2:726:14	O
of	NEURACEQ.xml:S2:741:2	O
Neuraceq	NEURACEQ.xml:S2:744:8	O
images	NEURACEQ.xml:S2:753:6	O
has	NEURACEQ.xml:S2:760:3	O
not	NEURACEQ.xml:S2:764:3	O
been	NEURACEQ.xml:S2:768:4	O
evaluated	NEURACEQ.xml:S2:773:9	O
and	NEURACEQ.xml:S2:783:3	O
may	NEURACEQ.xml:S2:787:3	O
lead	NEURACEQ.xml:S2:791:4	O
to	NEURACEQ.xml:S2:796:2	O
errors	NEURACEQ.xml:S2:799:6	O
.	NEURACEQ.xml:S2:805:1	O

Errors	NEURACEQ.xml:S2:807:6	O
may	NEURACEQ.xml:S2:814:3	O
also	NEURACEQ.xml:S2:818:4	O
occur	NEURACEQ.xml:S2:823:5	O
in	NEURACEQ.xml:S2:829:2	O
cases	NEURACEQ.xml:S2:832:5	O
with	NEURACEQ.xml:S2:838:4	O
severe	NEURACEQ.xml:S2:843:6	O
brain	NEURACEQ.xml:S2:850:5	O
atrophy	NEURACEQ.xml:S2:856:7	O
that	NEURACEQ.xml:S2:864:4	O
limits	NEURACEQ.xml:S2:869:6	O
the	NEURACEQ.xml:S2:876:3	O
ability	NEURACEQ.xml:S2:880:7	O
to	NEURACEQ.xml:S2:888:2	O
distinguish	NEURACEQ.xml:S2:891:11	O
gray	NEURACEQ.xml:S2:903:4	O
and	NEURACEQ.xml:S2:908:3	O
white	NEURACEQ.xml:S2:912:5	O
matter	NEURACEQ.xml:S2:918:6	O
on	NEURACEQ.xml:S2:925:2	O
the	NEURACEQ.xml:S2:928:3	O
Neuraceq	NEURACEQ.xml:S2:932:8	O
scan	NEURACEQ.xml:S2:941:4	O
.	NEURACEQ.xml:S2:945:1	O

Errors	NEURACEQ.xml:S2:947:6	O
may	NEURACEQ.xml:S2:954:3	O
also	NEURACEQ.xml:S2:958:4	O
occur	NEURACEQ.xml:S2:963:5	O
due	NEURACEQ.xml:S2:969:3	O
to	NEURACEQ.xml:S2:973:2	O
motion	NEURACEQ.xml:S2:976:6	O
artifacts	NEURACEQ.xml:S2:983:9	O
that	NEURACEQ.xml:S2:993:4	O
result	NEURACEQ.xml:S2:998:6	O
in	NEURACEQ.xml:S2:1005:2	O
image	NEURACEQ.xml:S2:1008:5	O
distortion	NEURACEQ.xml:S2:1014:10	O
.	NEURACEQ.xml:S2:1024:1	O

Neuraceq	NEURACEQ.xml:S2:1026:8	O
scan	NEURACEQ.xml:S2:1035:4	O
results	NEURACEQ.xml:S2:1040:7	O
are	NEURACEQ.xml:S2:1048:3	O
indicative	NEURACEQ.xml:S2:1052:10	O
of	NEURACEQ.xml:S2:1063:2	O
the	NEURACEQ.xml:S2:1066:3	O
presence	NEURACEQ.xml:S2:1070:8	O
of	NEURACEQ.xml:S2:1079:2	O
brain	NEURACEQ.xml:S2:1082:5	O
neuritic	NEURACEQ.xml:S2:1088:8	O
beta	NEURACEQ.xml:S2:1097:4	O
-	NEURACEQ.xml:S2:1101:1	O
amyloid	NEURACEQ.xml:S2:1102:7	O
plaques	NEURACEQ.xml:S2:1110:7	O
only	NEURACEQ.xml:S2:1118:4	O
at	NEURACEQ.xml:S2:1123:2	O
the	NEURACEQ.xml:S2:1126:3	O
time	NEURACEQ.xml:S2:1130:4	O
of	NEURACEQ.xml:S2:1135:2	O
image	NEURACEQ.xml:S2:1138:5	O
acquisition	NEURACEQ.xml:S2:1144:11	O
and	NEURACEQ.xml:S2:1156:3	O
a	NEURACEQ.xml:S2:1160:1	O
negative	NEURACEQ.xml:S2:1162:8	O
scan	NEURACEQ.xml:S2:1171:4	O
result	NEURACEQ.xml:S2:1176:6	O
does	NEURACEQ.xml:S2:1183:4	O
not	NEURACEQ.xml:S2:1188:3	O
preclude	NEURACEQ.xml:S2:1192:8	O
the	NEURACEQ.xml:S2:1201:3	O
development	NEURACEQ.xml:S2:1205:11	O
of	NEURACEQ.xml:S2:1217:2	O
brain	NEURACEQ.xml:S2:1220:5	O
neuritic	NEURACEQ.xml:S2:1226:8	O
beta	NEURACEQ.xml:S2:1235:4	O
-	NEURACEQ.xml:S2:1239:1	O
amyloid	NEURACEQ.xml:S2:1240:7	O
plaques	NEURACEQ.xml:S2:1248:7	O
in	NEURACEQ.xml:S2:1256:2	O
the	NEURACEQ.xml:S2:1259:3	O
future	NEURACEQ.xml:S2:1263:6	O
.	NEURACEQ.xml:S2:1269:1	O

5.2	NEURACEQ.xml:S2:1278:3	O
Radiation	NEURACEQ.xml:S2:1282:9	O
Risk	NEURACEQ.xml:S2:1292:4	O

Neuraceq	NEURACEQ.xml:S2:1302:8	O
,	NEURACEQ.xml:S2:1310:1	O
similar	NEURACEQ.xml:S2:1312:7	O
to	NEURACEQ.xml:S2:1320:2	O
other	NEURACEQ.xml:S2:1323:5	O
radiopharmaceuticals	NEURACEQ.xml:S2:1329:20	O
,	NEURACEQ.xml:S2:1349:1	O
contributes	NEURACEQ.xml:S2:1351:11	O
to	NEURACEQ.xml:S2:1363:2	O
a	NEURACEQ.xml:S2:1366:1	O
patient	NEURACEQ.xml:S2:1368:7	O
's	NEURACEQ.xml:S2:1375:2	O
overall	NEURACEQ.xml:S2:1378:7	O
long	NEURACEQ.xml:S2:1386:4	B-AdverseReaction
-	NEURACEQ.xml:S2:1390:1	I-AdverseReaction
term	NEURACEQ.xml:S2:1391:4	I-AdverseReaction
cumulative	NEURACEQ.xml:S2:1396:10	I-AdverseReaction
radiation	NEURACEQ.xml:S2:1407:9	I-AdverseReaction
exposure	NEURACEQ.xml:S2:1417:8	I-AdverseReaction
.	NEURACEQ.xml:S2:1425:1	O

Long	NEURACEQ.xml:S2:1427:4	B-AdverseReaction
-	NEURACEQ.xml:S2:1431:1	I-AdverseReaction
term	NEURACEQ.xml:S2:1432:4	I-AdverseReaction
cumulative	NEURACEQ.xml:S2:1437:10	I-AdverseReaction
radiation	NEURACEQ.xml:S2:1448:9	I-AdverseReaction
exposure	NEURACEQ.xml:S2:1458:8	I-AdverseReaction
is	NEURACEQ.xml:S2:1467:2	O
associated	NEURACEQ.xml:S2:1470:10	O
with	NEURACEQ.xml:S2:1481:4	O
an	NEURACEQ.xml:S2:1486:2	O
increased	NEURACEQ.xml:S2:1489:9	O
risk	NEURACEQ.xml:S2:1499:4	B-Factor
of	NEURACEQ.xml:S2:1504:2	O
cancer	NEURACEQ.xml:S2:1507:6	B-AdverseReaction
.	NEURACEQ.xml:S2:1513:1	O

Ensure	NEURACEQ.xml:S2:1515:6	O
safe	NEURACEQ.xml:S2:1522:4	O
handling	NEURACEQ.xml:S2:1527:8	O
to	NEURACEQ.xml:S2:1536:2	O
protect	NEURACEQ.xml:S2:1539:7	O
patients	NEURACEQ.xml:S2:1547:8	O
and	NEURACEQ.xml:S2:1556:3	O
health	NEURACEQ.xml:S2:1560:6	O
care	NEURACEQ.xml:S2:1567:4	O
workers	NEURACEQ.xml:S2:1572:7	O
from	NEURACEQ.xml:S2:1580:4	O
unintentional	NEURACEQ.xml:S2:1585:13	O
radiation	NEURACEQ.xml:S2:1599:9	O
exposure	NEURACEQ.xml:S2:1609:8	O
[	NEURACEQ.xml:S2:1618:1	O
see	NEURACEQ.xml:S2:1620:3	O
Dosage	NEURACEQ.xml:S2:1625:6	O
and	NEURACEQ.xml:S2:1632:3	O
Administration	NEURACEQ.xml:S2:1636:14	O
(	NEURACEQ.xml:S2:1651:1	O
2.1	NEURACEQ.xml:S2:1652:3	O
)	NEURACEQ.xml:S2:1655:1	O
]	NEURACEQ.xml:S2:1660:1	O
.	NEURACEQ.xml:S2:1661:1	O
6	NORTHERA.xml:S1:4:1	O
ADVERSE	NORTHERA.xml:S1:6:7	O
REACTIONS	NORTHERA.xml:S1:14:9	O

The	NORTHERA.xml:S1:27:3	O
following	NORTHERA.xml:S1:31:9	O
adverse	NORTHERA.xml:S1:41:7	O
reactions	NORTHERA.xml:S1:49:9	O
with	NORTHERA.xml:S1:59:4	O
NORTHERA	NORTHERA.xml:S1:64:8	O
are	NORTHERA.xml:S1:73:3	O
included	NORTHERA.xml:S1:77:8	O
in	NORTHERA.xml:S1:86:2	O
more	NORTHERA.xml:S1:89:4	O
detail	NORTHERA.xml:S1:94:6	O
in	NORTHERA.xml:S1:101:2	O
the	NORTHERA.xml:S1:104:3	O
Warnings	NORTHERA.xml:S1:108:8	O
and	NORTHERA.xml:S1:117:3	O
Precautions	NORTHERA.xml:S1:121:11	O
section	NORTHERA.xml:S1:133:7	O
of	NORTHERA.xml:S1:141:2	O
the	NORTHERA.xml:S1:144:3	O
label	NORTHERA.xml:S1:148:5	O
:	NORTHERA.xml:S1:153:1	O

Supine	NORTHERA.xml:S1:162:6	B-AdverseReaction
Hypertension	NORTHERA.xml:S1:169:12	I-AdverseReaction
[	NORTHERA.xml:S1:182:1	O
see	NORTHERA.xml:S1:183:3	O
Warnings	NORTHERA.xml:S1:187:8	O
and	NORTHERA.xml:S1:196:3	O
Precautions	NORTHERA.xml:S1:200:11	O
(	NORTHERA.xml:S1:212:1	O
5.1	NORTHERA.xml:S1:215:3	O
)]	NORTHERA.xml:S1:220:2	O

Hyperpyrexia	NORTHERA.xml:S1:229:12	B-AdverseReaction
and	NORTHERA.xml:S1:242:3	O
Confusion	NORTHERA.xml:S1:246:9	B-AdverseReaction
[	NORTHERA.xml:S1:256:1	O
see	NORTHERA.xml:S1:257:3	O
Warnings	NORTHERA.xml:S1:261:8	O
and	NORTHERA.xml:S1:270:3	O
Precautions	NORTHERA.xml:S1:274:11	O
(	NORTHERA.xml:S1:286:1	O
5.2	NORTHERA.xml:S1:289:3	O
)]	NORTHERA.xml:S1:294:2	O

May	NORTHERA.xml:S1:303:3	B-Factor
exacerbate	NORTHERA.xml:S1:307:10	B-AdverseReaction
existing	NORTHERA.xml:S1:318:8	O
ischemic	NORTHERA.xml:S1:327:8	I-AdverseReaction
heart	NORTHERA.xml:S1:336:5	I-AdverseReaction
disease	NORTHERA.xml:S1:342:7	I-AdverseReaction
,	NORTHERA.xml:S1:349:1	O
arrhythmias	NORTHERA.xml:S1:351:11	I-AdverseReaction
,	NORTHERA.xml:S1:362:1	O
and	NORTHERA.xml:S1:364:3	O
congestive	NORTHERA.xml:S1:368:10	I-AdverseReaction
heart	NORTHERA.xml:S1:379:5	I-AdverseReaction
failure	NORTHERA.xml:S1:385:7	I-AdverseReaction
[	NORTHERA.xml:S1:393:1	O
see	NORTHERA.xml:S1:394:3	O
Warnings	NORTHERA.xml:S1:398:8	O
and	NORTHERA.xml:S1:407:3	O
Precautions	NORTHERA.xml:S1:411:11	O
(	NORTHERA.xml:S1:423:1	O
5.3	NORTHERA.xml:S1:426:3	O
)]	NORTHERA.xml:S1:431:2	O

EXCERPT	NORTHERA.xml:S1:442:7	O
:	NORTHERA.xml:S1:449:1	O
Headache	NORTHERA.xml:S1:453:8	B-AdverseReaction
,	NORTHERA.xml:S1:461:1	O
dizziness	NORTHERA.xml:S1:463:9	B-AdverseReaction
,	NORTHERA.xml:S1:472:1	O
nausea	NORTHERA.xml:S1:474:6	B-AdverseReaction
,	NORTHERA.xml:S1:480:1	O
hypertension	NORTHERA.xml:S1:482:12	B-AdverseReaction
,	NORTHERA.xml:S1:494:1	O
and	NORTHERA.xml:S1:496:3	O
fatigue	NORTHERA.xml:S1:500:7	B-AdverseReaction
(	NORTHERA.xml:S1:508:1	O
greater	NORTHERA.xml:S1:509:7	O
than	NORTHERA.xml:S1:517:4	O
5%	NORTHERA.xml:S1:522:2	O
)	NORTHERA.xml:S1:524:1	O
(	NORTHERA.xml:S1:526:1	O
6.1	NORTHERA.xml:S1:529:3	O
)	NORTHERA.xml:S1:534:1	O

To	NORTHERA.xml:S1:542:2	O

report	NORTHERA.xml:S1:545:6	O
SUSPECTED	NORTHERA.xml:S1:552:9	O
ADVERSE	NORTHERA.xml:S1:562:7	O
REACTIONS	NORTHERA.xml:S1:570:9	O
,	NORTHERA.xml:S1:579:1	O
contact	NORTHERA.xml:S1:581:7	O
Lundbeck	NORTHERA.xml:S1:589:8	O
at	NORTHERA.xml:S1:598:2	O
1	NORTHERA.xml:S1:601:1	O
-	NORTHERA.xml:S1:602:1	O
800	NORTHERA.xml:S1:603:3	O
-	NORTHERA.xml:S1:606:1	O
455	NORTHERA.xml:S1:607:3	O
-	NORTHERA.xml:S1:610:1	O
1141	NORTHERA.xml:S1:611:4	O
or	NORTHERA.xml:S1:616:2	O
FDA	NORTHERA.xml:S1:619:3	O
at	NORTHERA.xml:S1:623:2	O
1	NORTHERA.xml:S1:626:1	O
-	NORTHERA.xml:S1:627:1	O
800	NORTHERA.xml:S1:628:3	O
-	NORTHERA.xml:S1:631:1	O
FDA	NORTHERA.xml:S1:632:3	O
-	NORTHERA.xml:S1:635:1	O
1088	NORTHERA.xml:S1:636:4	O
or	NORTHERA.xml:S1:641:2	O
www	NORTHERA.xml:S1:645:3	O
.	NORTHERA.xml:S1:648:1	O
fda	NORTHERA.xml:S1:649:3	O
.	NORTHERA.xml:S1:652:1	O
gov	NORTHERA.xml:S1:653:3	O
medwatch	NORTHERA.xml:S1:657:8	O
.	NORTHERA.xml:S1:665:1	O

6.1	NORTHERA.xml:S1:681:3	O

Clinical	NORTHERA.xml:S1:685:8	O
Trials	NORTHERA.xml:S1:694:6	O
Experience	NORTHERA.xml:S1:701:10	O

Because	NORTHERA.xml:S1:715:7	O
clinical	NORTHERA.xml:S1:723:8	O
trials	NORTHERA.xml:S1:732:6	O
are	NORTHERA.xml:S1:739:3	O
conducted	NORTHERA.xml:S1:743:9	O
under	NORTHERA.xml:S1:753:5	O
widely	NORTHERA.xml:S1:759:6	O
varying	NORTHERA.xml:S1:766:7	O
conditions	NORTHERA.xml:S1:774:10	O
,	NORTHERA.xml:S1:784:1	O
adverse	NORTHERA.xml:S1:786:7	O
reaction	NORTHERA.xml:S1:794:8	O
rates	NORTHERA.xml:S1:803:5	O
observed	NORTHERA.xml:S1:809:8	O
in	NORTHERA.xml:S1:818:2	O
the	NORTHERA.xml:S1:821:3	O
clinical	NORTHERA.xml:S1:825:8	O
trials	NORTHERA.xml:S1:834:6	O
of	NORTHERA.xml:S1:841:2	O
a	NORTHERA.xml:S1:844:1	O
drug	NORTHERA.xml:S1:846:4	O
cannot	NORTHERA.xml:S1:851:6	O
be	NORTHERA.xml:S1:858:2	O
directly	NORTHERA.xml:S1:861:8	O
compared	NORTHERA.xml:S1:870:8	O
to	NORTHERA.xml:S1:879:2	O
rates	NORTHERA.xml:S1:882:5	O
in	NORTHERA.xml:S1:888:2	O
the	NORTHERA.xml:S1:891:3	O
clinical	NORTHERA.xml:S1:895:8	O
trials	NORTHERA.xml:S1:904:6	O
of	NORTHERA.xml:S1:911:2	O
another	NORTHERA.xml:S1:914:7	O
drug	NORTHERA.xml:S1:922:4	O
and	NORTHERA.xml:S1:927:3	O
may	NORTHERA.xml:S1:931:3	O
not	NORTHERA.xml:S1:935:3	O
reflect	NORTHERA.xml:S1:939:7	O
the	NORTHERA.xml:S1:947:3	O
rates	NORTHERA.xml:S1:951:5	O
observed	NORTHERA.xml:S1:957:8	O
in	NORTHERA.xml:S1:966:2	O
clinical	NORTHERA.xml:S1:969:8	O
practice	NORTHERA.xml:S1:978:8	O
.	NORTHERA.xml:S1:986:1	O

The	NORTHERA.xml:S1:992:3	O
safety	NORTHERA.xml:S1:996:6	O
evaluation	NORTHERA.xml:S1:1003:10	O
of	NORTHERA.xml:S1:1014:2	O
NORTHERA	NORTHERA.xml:S1:1017:8	O
is	NORTHERA.xml:S1:1026:2	O
based	NORTHERA.xml:S1:1029:5	O
on	NORTHERA.xml:S1:1035:2	O
two	NORTHERA.xml:S1:1038:3	O
placebo	NORTHERA.xml:S1:1042:7	O
-	NORTHERA.xml:S1:1049:1	O
controlled	NORTHERA.xml:S1:1050:10	O
studies	NORTHERA.xml:S1:1061:7	O
1	NORTHERA.xml:S1:1069:1	O
to	NORTHERA.xml:S1:1071:2	O
2	NORTHERA.xml:S1:1074:1	O
weeks	NORTHERA.xml:S1:1076:5	O
in	NORTHERA.xml:S1:1082:2	O
duration	NORTHERA.xml:S1:1085:8	O
(	NORTHERA.xml:S1:1094:1	O
Studies	NORTHERA.xml:S1:1095:7	O
301	NORTHERA.xml:S1:1103:3	O
and	NORTHERA.xml:S1:1107:3	O
302	NORTHERA.xml:S1:1111:3	O
)	NORTHERA.xml:S1:1114:1	O
,	NORTHERA.xml:S1:1115:1	O
one	NORTHERA.xml:S1:1117:3	O
8	NORTHERA.xml:S1:1121:1	O
-	NORTHERA.xml:S1:1122:1	O
week	NORTHERA.xml:S1:1123:4	O
placebo	NORTHERA.xml:S1:1128:7	O
-	NORTHERA.xml:S1:1135:1	O
controlled	NORTHERA.xml:S1:1136:10	O
study	NORTHERA.xml:S1:1147:5	O
(	NORTHERA.xml:S1:1153:1	O
Study	NORTHERA.xml:S1:1154:5	O
306	NORTHERA.xml:S1:1160:3	O
)	NORTHERA.xml:S1:1163:1	O
,	NORTHERA.xml:S1:1164:1	O
and	NORTHERA.xml:S1:1166:3	O
two	NORTHERA.xml:S1:1170:3	O
long	NORTHERA.xml:S1:1174:4	O
-	NORTHERA.xml:S1:1178:1	O
term	NORTHERA.xml:S1:1179:4	O
,	NORTHERA.xml:S1:1183:1	O
open	NORTHERA.xml:S1:1185:4	O
-	NORTHERA.xml:S1:1189:1	O
label	NORTHERA.xml:S1:1190:5	O
extension	NORTHERA.xml:S1:1196:9	O
studies	NORTHERA.xml:S1:1206:7	O
(	NORTHERA.xml:S1:1214:1	O
Studies	NORTHERA.xml:S1:1215:7	O
303	NORTHERA.xml:S1:1223:3	O
and	NORTHERA.xml:S1:1227:3	O
304	NORTHERA.xml:S1:1231:3	O
)	NORTHERA.xml:S1:1234:1	O
.	NORTHERA.xml:S1:1235:1	O

In	NORTHERA.xml:S1:1238:2	O
the	NORTHERA.xml:S1:1241:3	O
placebo	NORTHERA.xml:S1:1245:7	O
-	NORTHERA.xml:S1:1252:1	O
controlled	NORTHERA.xml:S1:1253:10	O
studies	NORTHERA.xml:S1:1264:7	O
,	NORTHERA.xml:S1:1271:1	O
a	NORTHERA.xml:S1:1273:1	O
total	NORTHERA.xml:S1:1275:5	O
of	NORTHERA.xml:S1:1281:2	O
485	NORTHERA.xml:S1:1284:3	O
patients	NORTHERA.xml:S1:1288:8	O
with	NORTHERA.xml:S1:1297:4	O
Parkinson	NORTHERA.xml:S1:1302:9	O
's	NORTHERA.xml:S1:1311:2	O
disease	NORTHERA.xml:S1:1314:7	O
,	NORTHERA.xml:S1:1321:1	O
multiple	NORTHERA.xml:S1:1323:8	O
system	NORTHERA.xml:S1:1332:6	O
atrophy	NORTHERA.xml:S1:1339:7	O
,	NORTHERA.xml:S1:1346:1	O
pure	NORTHERA.xml:S1:1348:4	O
autonomic	NORTHERA.xml:S1:1353:9	O
failure	NORTHERA.xml:S1:1363:7	O
,	NORTHERA.xml:S1:1370:1	O
dopamine	NORTHERA.xml:S1:1372:8	O
beta	NORTHERA.xml:S1:1381:4	O
-	NORTHERA.xml:S1:1385:1	O
hydroxylase	NORTHERA.xml:S1:1386:11	O
deficiency	NORTHERA.xml:S1:1398:10	O
,	NORTHERA.xml:S1:1408:1	O
or	NORTHERA.xml:S1:1410:2	O
non	NORTHERA.xml:S1:1413:3	O
-	NORTHERA.xml:S1:1416:1	O
diabetic	NORTHERA.xml:S1:1417:8	O
autonomic	NORTHERA.xml:S1:1426:9	O
neuropathy	NORTHERA.xml:S1:1436:10	O
were	NORTHERA.xml:S1:1447:4	O
randomized	NORTHERA.xml:S1:1452:10	O
and	NORTHERA.xml:S1:1463:3	O
treated	NORTHERA.xml:S1:1467:7	O
,	NORTHERA.xml:S1:1474:1	O
245	NORTHERA.xml:S1:1476:3	O
with	NORTHERA.xml:S1:1480:4	O
NORTHERA	NORTHERA.xml:S1:1485:8	O
and	NORTHERA.xml:S1:1494:3	O
240	NORTHERA.xml:S1:1498:3	O
with	NORTHERA.xml:S1:1502:4	O
placebo	NORTHERA.xml:S1:1507:7	O
[	NORTHERA.xml:S1:1516:1	O
see	NORTHERA.xml:S1:1517:3	O
Clinical	NORTHERA.xml:S1:1521:8	O
Studies	NORTHERA.xml:S1:1530:7	O
(	NORTHERA.xml:S1:1538:1	O
14	NORTHERA.xml:S1:1541:2	O
)]	NORTHERA.xml:S1:1545:2	O
.	NORTHERA.xml:S1:1549:1	O

Placebo	NORTHERA.xml:S1:1560:7	O
-	NORTHERA.xml:S1:1567:1	O
Controlled	NORTHERA.xml:S1:1568:10	O
Experience	NORTHERA.xml:S1:1586:10	O

The	NORTHERA.xml:S1:1605:3	O
most	NORTHERA.xml:S1:1609:4	O
commonly	NORTHERA.xml:S1:1614:8	O
observed	NORTHERA.xml:S1:1623:8	O
adverse	NORTHERA.xml:S1:1632:7	O
reactions	NORTHERA.xml:S1:1640:9	O
(	NORTHERA.xml:S1:1650:1	O
those	NORTHERA.xml:S1:1651:5	O
occurring	NORTHERA.xml:S1:1657:9	O
at	NORTHERA.xml:S1:1667:2	O
an	NORTHERA.xml:S1:1670:2	O
incidence	NORTHERA.xml:S1:1673:9	O
of	NORTHERA.xml:S1:1683:2	O
greater	NORTHERA.xml:S1:1686:7	O
than	NORTHERA.xml:S1:1694:4	O
5%	NORTHERA.xml:S1:1699:2	O
in	NORTHERA.xml:S1:1703:2	O
the	NORTHERA.xml:S1:1706:3	O
NORTHERA	NORTHERA.xml:S1:1710:8	O
group	NORTHERA.xml:S1:1719:5	O
and	NORTHERA.xml:S1:1725:3	O
with	NORTHERA.xml:S1:1729:4	O
at	NORTHERA.xml:S1:1734:2	O
least	NORTHERA.xml:S1:1737:5	O
a	NORTHERA.xml:S1:1743:1	O
3%	NORTHERA.xml:S1:1745:2	O
greater	NORTHERA.xml:S1:1748:7	O
incidence	NORTHERA.xml:S1:1756:9	O
in	NORTHERA.xml:S1:1766:2	O
the	NORTHERA.xml:S1:1769:3	O
NORTHERA	NORTHERA.xml:S1:1773:8	O
group	NORTHERA.xml:S1:1782:5	O
than	NORTHERA.xml:S1:1788:4	O
in	NORTHERA.xml:S1:1793:2	O
the	NORTHERA.xml:S1:1796:3	O
placebo	NORTHERA.xml:S1:1800:7	O
group	NORTHERA.xml:S1:1808:5	O
)	NORTHERA.xml:S1:1813:1	O
in	NORTHERA.xml:S1:1815:2	O
NORTHERA	NORTHERA.xml:S1:1818:8	O
-	NORTHERA.xml:S1:1826:1	O
treated	NORTHERA.xml:S1:1827:7	O
patients	NORTHERA.xml:S1:1835:8	O
during	NORTHERA.xml:S1:1844:6	O
the	NORTHERA.xml:S1:1851:3	O
three	NORTHERA.xml:S1:1855:5	O
placebo	NORTHERA.xml:S1:1861:7	O
-	NORTHERA.xml:S1:1868:1	O
controlled	NORTHERA.xml:S1:1869:10	O
trials	NORTHERA.xml:S1:1880:6	O
were	NORTHERA.xml:S1:1887:4	O
headache	NORTHERA.xml:S1:1892:8	B-AdverseReaction
,	NORTHERA.xml:S1:1900:1	O
dizziness	NORTHERA.xml:S1:1902:9	B-AdverseReaction
,	NORTHERA.xml:S1:1911:1	O
nausea	NORTHERA.xml:S1:1913:6	B-AdverseReaction
,	NORTHERA.xml:S1:1919:1	O
hypertension	NORTHERA.xml:S1:1921:12	B-AdverseReaction
.	NORTHERA.xml:S1:1933:1	O

The	NORTHERA.xml:S1:1936:3	O
most	NORTHERA.xml:S1:1940:4	O
common	NORTHERA.xml:S1:1945:6	O
adverse	NORTHERA.xml:S1:1952:7	O
reactions	NORTHERA.xml:S1:1960:9	O
leading	NORTHERA.xml:S1:1970:7	O
to	NORTHERA.xml:S1:1978:2	O
discontinuation	NORTHERA.xml:S1:1981:15	O
from	NORTHERA.xml:S1:1997:4	O
NORTHERA	NORTHERA.xml:S1:2002:8	O
were	NORTHERA.xml:S1:2011:4	O
hypertension	NORTHERA.xml:S1:2016:12	B-AdverseReaction
or	NORTHERA.xml:S1:2029:2	O
increased	NORTHERA.xml:S1:2032:9	B-AdverseReaction
blood	NORTHERA.xml:S1:2042:5	I-AdverseReaction
pressure	NORTHERA.xml:S1:2048:8	I-AdverseReaction
and	NORTHERA.xml:S1:2057:3	O
nausea	NORTHERA.xml:S1:2061:6	B-AdverseReaction
.	NORTHERA.xml:S1:2067:1	O

Table	NORTHERA.xml:S1:2073:5	O
1	NORTHERA.xml:S1:2079:1	O
.	NORTHERA.xml:S1:2080:1	O

Most	NORTHERA.xml:S1:2082:4	O
Common	NORTHERA.xml:S1:2087:6	O
Adverse	NORTHERA.xml:S1:2094:7	O
Reactions	NORTHERA.xml:S1:2102:9	O
Occurring	NORTHERA.xml:S1:2112:9	O
More	NORTHERA.xml:S1:2122:4	O
Frequently	NORTHERA.xml:S1:2127:10	O
in	NORTHERA.xml:S1:2138:2	O
the	NORTHERA.xml:S1:2141:3	O
NORTHERA	NORTHERA.xml:S1:2145:8	O
Group	NORTHERA.xml:S1:2154:5	O

Study	NORTHERA.xml:S1:2183:5	O
301	NORTHERA.xml:S1:2189:3	O
and	NORTHERA.xml:S1:2193:3	O
Study	NORTHERA.xml:S1:2197:5	O
302	NORTHERA.xml:S1:2203:3	O
(	NORTHERA.xml:S1:2210:1	O
1	NORTHERA.xml:S1:2211:1	O
to	NORTHERA.xml:S1:2213:2	O
2	NORTHERA.xml:S1:2216:1	O
Weeks	NORTHERA.xml:S1:2218:5	O
Randomized	NORTHERA.xml:S1:2224:10	O
Treatment	NORTHERA.xml:S1:2235:9	O
)	NORTHERA.xml:S1:2244:1	O
Study	NORTHERA.xml:S1:2253:5	O
306	NORTHERA.xml:S1:2259:3	O
(	NORTHERA.xml:S1:2266:1	O
8	NORTHERA.xml:S1:2267:1	O
to	NORTHERA.xml:S1:2269:2	O
10	NORTHERA.xml:S1:2272:2	O
Weeks	NORTHERA.xml:S1:2275:5	O
Randomized	NORTHERA.xml:S1:2281:10	O
Treatment	NORTHERA.xml:S1:2292:9	O
)	NORTHERA.xml:S1:2301:1	O

Placebo	NORTHERA.xml:S1:2313:7	O
(	NORTHERA.xml:S1:2324:1	O
N	NORTHERA.xml:S1:2325:1	O
132	NORTHERA.xml:S1:2327:3	O
)	NORTHERA.xml:S1:2330:1	O
n	NORTHERA.xml:S1:2337:1	O
(	NORTHERA.xml:S1:2339:1	O
)	NORTHERA.xml:S1:2341:1	O
NORTHERA	NORTHERA.xml:S1:2350:8	O
(	NORTHERA.xml:S1:2362:1	O
N	NORTHERA.xml:S1:2363:1	O
131	NORTHERA.xml:S1:2365:3	O
)	NORTHERA.xml:S1:2368:1	O
n	NORTHERA.xml:S1:2375:1	O
(	NORTHERA.xml:S1:2377:1	O
)	NORTHERA.xml:S1:2379:1	O
Placebo	NORTHERA.xml:S1:2388:7	O
(	NORTHERA.xml:S1:2399:1	O
N	NORTHERA.xml:S1:2400:1	O
108	NORTHERA.xml:S1:2402:3	O
)	NORTHERA.xml:S1:2405:1	O
n	NORTHERA.xml:S1:2412:1	O
(	NORTHERA.xml:S1:2414:1	O
)	NORTHERA.xml:S1:2416:1	O
NORTHERA	NORTHERA.xml:S1:2425:8	O
(	NORTHERA.xml:S1:2437:1	O
N	NORTHERA.xml:S1:2438:1	O
114	NORTHERA.xml:S1:2440:3	O
)	NORTHERA.xml:S1:2443:1	O

n	NORTHERA.xml:S1:2455:1	O
(	NORTHERA.xml:S1:2457:1	O
)	NORTHERA.xml:S1:2459:1	O

Headache	NORTHERA.xml:S1:2474:8	B-AdverseReaction
4	NORTHERA.xml:S1:2491:1	O
(	NORTHERA.xml:S1:2493:1	O
3.0	NORTHERA.xml:S1:2494:3	O
)	NORTHERA.xml:S1:2497:1	O
8	NORTHERA.xml:S1:2508:1	O
(	NORTHERA.xml:S1:2510:1	O
6.1	NORTHERA.xml:S1:2511:3	O
)	NORTHERA.xml:S1:2514:1	O
8	NORTHERA.xml:S1:2525:1	O
(	NORTHERA.xml:S1:2527:1	O
7.4	NORTHERA.xml:S1:2528:3	O
)	NORTHERA.xml:S1:2531:1	O
15	NORTHERA.xml:S1:2542:2	O
(	NORTHERA.xml:S1:2545:1	O
13.2	NORTHERA.xml:S1:2546:4	O
)	NORTHERA.xml:S1:2550:1	O

Dizziness	NORTHERA.xml:S1:2562:9	B-AdverseReaction
2	NORTHERA.xml:S1:2579:1	O
(	NORTHERA.xml:S1:2581:1	O
1.5	NORTHERA.xml:S1:2582:3	O
)	NORTHERA.xml:S1:2585:1	O
5	NORTHERA.xml:S1:2596:1	O
(	NORTHERA.xml:S1:2598:1	O
3.8	NORTHERA.xml:S1:2599:3	O
)	NORTHERA.xml:S1:2602:1	O
5	NORTHERA.xml:S1:2613:1	O
(	NORTHERA.xml:S1:2615:1	O
4.6	NORTHERA.xml:S1:2616:3	O
)	NORTHERA.xml:S1:2619:1	O
11	NORTHERA.xml:S1:2630:2	O
(	NORTHERA.xml:S1:2633:1	O
9.6	NORTHERA.xml:S1:2634:3	O
)	NORTHERA.xml:S1:2637:1	O

Nausea	NORTHERA.xml:S1:2650:6	B-AdverseReaction
2	NORTHERA.xml:S1:2667:1	O
(	NORTHERA.xml:S1:2669:1	O
1.5	NORTHERA.xml:S1:2670:3	O
)	NORTHERA.xml:S1:2673:1	O
2	NORTHERA.xml:S1:2684:1	O
(	NORTHERA.xml:S1:2686:1	O
1.5	NORTHERA.xml:S1:2687:3	O
)	NORTHERA.xml:S1:2690:1	O
5	NORTHERA.xml:S1:2701:1	O
(	NORTHERA.xml:S1:2703:1	O
4.6	NORTHERA.xml:S1:2704:3	O
)	NORTHERA.xml:S1:2707:1	O
10	NORTHERA.xml:S1:2718:2	O
(	NORTHERA.xml:S1:2721:1	O
8.8	NORTHERA.xml:S1:2722:3	O
)	NORTHERA.xml:S1:2725:1	O

Hypertension	NORTHERA.xml:S1:2738:12	B-AdverseReaction
0	NORTHERA.xml:S1:2755:1	O
2	NORTHERA.xml:S1:2772:1	O
(	NORTHERA.xml:S1:2774:1	O
1.5	NORTHERA.xml:S1:2775:3	O
)	NORTHERA.xml:S1:2778:1	O
1	NORTHERA.xml:S1:2789:1	O
(	NORTHERA.xml:S1:2791:1	O
0.9	NORTHERA.xml:S1:2792:3	O
)	NORTHERA.xml:S1:2795:1	O
8	NORTHERA.xml:S1:2806:1	O
(	NORTHERA.xml:S1:2808:1	O
7.0	NORTHERA.xml:S1:2809:3	O
)	NORTHERA.xml:S1:2812:1	O

Note	NORTHERA.xml:S1:2833:4	O
:	NORTHERA.xml:S1:2837:1	O
n	NORTHERA.xml:S1:2839:1	O
number	NORTHERA.xml:S1:2841:6	O
of	NORTHERA.xml:S1:2848:2	O
patients	NORTHERA.xml:S1:2851:8	O
.	NORTHERA.xml:S1:2859:1	O

Table	NORTHERA.xml:S1:2862:5	O
displays	NORTHERA.xml:S1:2868:8	O
adverse	NORTHERA.xml:S1:2877:7	O
reactions	NORTHERA.xml:S1:2885:9	O
that	NORTHERA.xml:S1:2895:4	O
were	NORTHERA.xml:S1:2900:4	O
reported	NORTHERA.xml:S1:2905:8	O
in	NORTHERA.xml:S1:2914:2	O
greater	NORTHERA.xml:S1:2917:7	O
than	NORTHERA.xml:S1:2925:4	O
5%	NORTHERA.xml:S1:2930:2	O
of	NORTHERA.xml:S1:2933:2	O
patients	NORTHERA.xml:S1:2936:8	O
in	NORTHERA.xml:S1:2945:2	O
the	NORTHERA.xml:S1:2948:3	O
NORTHERA	NORTHERA.xml:S1:2952:8	O
group	NORTHERA.xml:S1:2961:5	O
and	NORTHERA.xml:S1:2967:3	O
with	NORTHERA.xml:S1:2971:4	O
at	NORTHERA.xml:S1:2976:2	O
least	NORTHERA.xml:S1:2979:5	O
a	NORTHERA.xml:S1:2985:1	O
3%	NORTHERA.xml:S1:2987:2	O
greater	NORTHERA.xml:S1:2990:7	O
incidence	NORTHERA.xml:S1:2998:9	O
in	NORTHERA.xml:S1:3008:2	O
the	NORTHERA.xml:S1:3011:3	O
NORTHERA	NORTHERA.xml:S1:3015:8	O
group	NORTHERA.xml:S1:3024:5	O
than	NORTHERA.xml:S1:3030:4	O
in	NORTHERA.xml:S1:3035:2	O
the	NORTHERA.xml:S1:3038:3	O
placebo	NORTHERA.xml:S1:3042:7	O
group	NORTHERA.xml:S1:3050:5	O
.	NORTHERA.xml:S1:3055:1	O

Long	NORTHERA.xml:S1:3065:4	O

-	NORTHERA.xml:S1:3069:1	O
Term	NORTHERA.xml:S1:3070:4	O
,	NORTHERA.xml:S1:3074:1	O
Open	NORTHERA.xml:S1:3076:4	O
-	NORTHERA.xml:S1:3080:1	O
Label	NORTHERA.xml:S1:3081:5	O
Trials	NORTHERA.xml:S1:3087:6	O
with	NORTHERA.xml:S1:3094:4	O
NORTHERA	NORTHERA.xml:S1:3099:8	O
In	NORTHERA.xml:S1:3111:2	O
the	NORTHERA.xml:S1:3114:3	O
long	NORTHERA.xml:S1:3118:4	O
-	NORTHERA.xml:S1:3122:1	O
term	NORTHERA.xml:S1:3123:4	O
,	NORTHERA.xml:S1:3127:1	O
open	NORTHERA.xml:S1:3129:4	O
-	NORTHERA.xml:S1:3133:1	O
label	NORTHERA.xml:S1:3134:5	O
extension	NORTHERA.xml:S1:3140:9	O
studies	NORTHERA.xml:S1:3150:7	O
,	NORTHERA.xml:S1:3157:1	O
a	NORTHERA.xml:S1:3159:1	O
total	NORTHERA.xml:S1:3161:5	O
of	NORTHERA.xml:S1:3167:2	O
422	NORTHERA.xml:S1:3170:3	O
patients	NORTHERA.xml:S1:3174:8	O
,	NORTHERA.xml:S1:3182:1	O
mean	NORTHERA.xml:S1:3184:4	O
age	NORTHERA.xml:S1:3189:3	O
65	NORTHERA.xml:S1:3193:2	O
years	NORTHERA.xml:S1:3196:5	O
,	NORTHERA.xml:S1:3201:1	O
were	NORTHERA.xml:S1:3203:4	O
treated	NORTHERA.xml:S1:3208:7	O
with	NORTHERA.xml:S1:3216:4	O
NORTHERA	NORTHERA.xml:S1:3221:8	O
for	NORTHERA.xml:S1:3230:3	O
a	NORTHERA.xml:S1:3234:1	O
mean	NORTHERA.xml:S1:3236:4	O
total	NORTHERA.xml:S1:3241:5	O
exposure	NORTHERA.xml:S1:3247:8	O
of	NORTHERA.xml:S1:3256:2	O
approximately	NORTHERA.xml:S1:3259:13	O
one	NORTHERA.xml:S1:3273:3	O
year	NORTHERA.xml:S1:3277:4	O
.	NORTHERA.xml:S1:3281:1	O

The	NORTHERA.xml:S1:3283:3	O
commonly	NORTHERA.xml:S1:3287:8	O
reported	NORTHERA.xml:S1:3296:8	O
adverse	NORTHERA.xml:S1:3305:7	O
events	NORTHERA.xml:S1:3313:6	O
were	NORTHERA.xml:S1:3320:4	O
falls	NORTHERA.xml:S1:3325:5	B-AdverseReaction
(	NORTHERA.xml:S1:3331:1	O
24%	NORTHERA.xml:S1:3332:3	O
)	NORTHERA.xml:S1:3335:1	O
,	NORTHERA.xml:S1:3336:1	O
urinary	NORTHERA.xml:S1:3338:7	B-AdverseReaction
tract	NORTHERA.xml:S1:3346:5	I-AdverseReaction
infections	NORTHERA.xml:S1:3352:10	I-AdverseReaction
(	NORTHERA.xml:S1:3363:1	O
15%	NORTHERA.xml:S1:3364:3	O
)	NORTHERA.xml:S1:3367:1	O
,	NORTHERA.xml:S1:3368:1	O
headache	NORTHERA.xml:S1:3370:8	B-AdverseReaction
(	NORTHERA.xml:S1:3379:1	O
13%	NORTHERA.xml:S1:3380:3	O
)	NORTHERA.xml:S1:3383:1	O
,	NORTHERA.xml:S1:3384:1	O
syncope	NORTHERA.xml:S1:3386:7	B-AdverseReaction
(	NORTHERA.xml:S1:3394:1	O
13%	NORTHERA.xml:S1:3395:3	O
)	NORTHERA.xml:S1:3398:1	O
,	NORTHERA.xml:S1:3399:1	O
and	NORTHERA.xml:S1:3401:3	O
dizziness	NORTHERA.xml:S1:3405:9	B-AdverseReaction
(	NORTHERA.xml:S1:3415:1	O
10%	NORTHERA.xml:S1:3416:3	O
)	NORTHERA.xml:S1:3419:1	O
.	NORTHERA.xml:S1:3420:1	O
\n\n	NORTHERA.xml:S2:0:2	O
BOXED	NORTHERA.xml:S2:6:5	O
WARNING	NORTHERA.xml:S2:12:7	O
:	NORTHERA.xml:S2:19:1	O
WARNING	NORTHERA.xml:S2:21:7	O
:	NORTHERA.xml:S2:28:1	O
SUPINE	NORTHERA.xml:S2:30:6	B-AdverseReaction
HYPERTENSION	NORTHERA.xml:S2:37:12	I-AdverseReaction
\n\n	NORTHERA.xml:S2:49:2	O
WARNING	NORTHERA.xml:S2:55:7	O
:	NORTHERA.xml:S2:62:1	O
SUPINE	NORTHERA.xml:S2:64:6	B-AdverseReaction
HYPERTENSION	NORTHERA.xml:S2:71:12	I-AdverseReaction
\n\n	NORTHERA.xml:S2:85:2	O
Monitor	NORTHERA.xml:S2:91:7	O
supine	NORTHERA.xml:S2:99:6	O
blood	NORTHERA.xml:S2:106:5	O
pressure	NORTHERA.xml:S2:112:8	O
prior	NORTHERA.xml:S2:121:5	O
to	NORTHERA.xml:S2:127:2	O
and	NORTHERA.xml:S2:130:3	O
during	NORTHERA.xml:S2:134:6	O
treatment	NORTHERA.xml:S2:141:9	O
and	NORTHERA.xml:S2:151:3	O
more	NORTHERA.xml:S2:155:4	O
frequently	NORTHERA.xml:S2:160:10	O
when	NORTHERA.xml:S2:171:4	O
increasing	NORTHERA.xml:S2:176:10	O
doses	NORTHERA.xml:S2:187:5	O
.	NORTHERA.xml:S2:192:1	O

Elevating	NORTHERA.xml:S2:195:9	O
the	NORTHERA.xml:S2:205:3	O
head	NORTHERA.xml:S2:209:4	O
of	NORTHERA.xml:S2:214:2	O
the	NORTHERA.xml:S2:217:3	O
bed	NORTHERA.xml:S2:221:3	O
lessens	NORTHERA.xml:S2:225:7	O
the	NORTHERA.xml:S2:233:3	O
risk	NORTHERA.xml:S2:237:4	O
of	NORTHERA.xml:S2:242:2	O
supine	NORTHERA.xml:S2:245:6	O
hypertension	NORTHERA.xml:S2:252:12	O
,	NORTHERA.xml:S2:264:1	O
and	NORTHERA.xml:S2:266:3	O
blood	NORTHERA.xml:S2:270:5	O
pressure	NORTHERA.xml:S2:276:8	O
should	NORTHERA.xml:S2:285:6	O
be	NORTHERA.xml:S2:292:2	O
measured	NORTHERA.xml:S2:295:8	O
in	NORTHERA.xml:S2:304:2	O
this	NORTHERA.xml:S2:307:4	O
position	NORTHERA.xml:S2:312:8	O
.	NORTHERA.xml:S2:320:1	O

If	NORTHERA.xml:S2:323:2	O
supine	NORTHERA.xml:S2:326:6	O
hypertension	NORTHERA.xml:S2:333:12	O
cannot	NORTHERA.xml:S2:346:6	O
be	NORTHERA.xml:S2:353:2	O
managed	NORTHERA.xml:S2:356:7	O
by	NORTHERA.xml:S2:364:2	O
elevation	NORTHERA.xml:S2:367:9	O
of	NORTHERA.xml:S2:377:2	O
the	NORTHERA.xml:S2:380:3	O
head	NORTHERA.xml:S2:384:4	O
of	NORTHERA.xml:S2:389:2	O
the	NORTHERA.xml:S2:392:3	O
bed	NORTHERA.xml:S2:396:3	O
,	NORTHERA.xml:S2:399:1	O
reduce	NORTHERA.xml:S2:401:6	O
or	NORTHERA.xml:S2:408:2	O
discontinue	NORTHERA.xml:S2:411:11	O
NORTHERA	NORTHERA.xml:S2:423:8	O
[	NORTHERA.xml:S2:438:1	O
see	NORTHERA.xml:S2:439:3	O
Warnings	NORTHERA.xml:S2:443:8	O
and	NORTHERA.xml:S2:452:3	O
Precautions	NORTHERA.xml:S2:456:11	O
(	NORTHERA.xml:S2:468:1	O
5.1	NORTHERA.xml:S2:471:3	O
)]	NORTHERA.xml:S2:476:2	O
.	NORTHERA.xml:S2:478:1	O

EXCERPT	NORTHERA.xml:S2:490:7	O
:	NORTHERA.xml:S2:497:1	O
WARNING	NORTHERA.xml:S2:505:7	O
:	NORTHERA.xml:S2:512:1	O
SUPINE	NORTHERA.xml:S2:514:6	B-AdverseReaction
HYPERTENSION	NORTHERA.xml:S2:521:12	I-AdverseReaction
See	NORTHERA.xml:S2:541:3	O
full	NORTHERA.xml:S2:545:4	O
prescribing	NORTHERA.xml:S2:550:11	O
information	NORTHERA.xml:S2:562:11	O
for	NORTHERA.xml:S2:574:3	O
complete	NORTHERA.xml:S2:578:8	O
boxed	NORTHERA.xml:S2:587:5	O
warning	NORTHERA.xml:S2:593:7	O
.	NORTHERA.xml:S2:600:1	O

Monitor	NORTHERA.xml:S2:626:7	O
supine	NORTHERA.xml:S2:634:6	O
blood	NORTHERA.xml:S2:641:5	O
pressure	NORTHERA.xml:S2:647:8	O
prior	NORTHERA.xml:S2:656:5	O
to	NORTHERA.xml:S2:662:2	O
and	NORTHERA.xml:S2:665:3	O
during	NORTHERA.xml:S2:669:6	O
treatment	NORTHERA.xml:S2:676:9	O
and	NORTHERA.xml:S2:686:3	O
more	NORTHERA.xml:S2:690:4	O
frequently	NORTHERA.xml:S2:695:10	O
when	NORTHERA.xml:S2:706:4	O
increasing	NORTHERA.xml:S2:711:10	O
doses	NORTHERA.xml:S2:722:5	O
.	NORTHERA.xml:S2:727:1	O

Elevating	NORTHERA.xml:S2:730:9	O
the	NORTHERA.xml:S2:740:3	O
head	NORTHERA.xml:S2:744:4	O
of	NORTHERA.xml:S2:749:2	O
the	NORTHERA.xml:S2:752:3	O
bed	NORTHERA.xml:S2:756:3	O
lessens	NORTHERA.xml:S2:760:7	O
the	NORTHERA.xml:S2:768:3	O
risk	NORTHERA.xml:S2:772:4	O
of	NORTHERA.xml:S2:777:2	O
supine	NORTHERA.xml:S2:780:6	O
hypertension	NORTHERA.xml:S2:791:12	O
,	NORTHERA.xml:S2:803:1	O
and	NORTHERA.xml:S2:805:3	O
blood	NORTHERA.xml:S2:809:5	O
pressure	NORTHERA.xml:S2:815:8	O
should	NORTHERA.xml:S2:824:6	O
be	NORTHERA.xml:S2:831:2	O
measured	NORTHERA.xml:S2:834:8	O
in	NORTHERA.xml:S2:843:2	O
this	NORTHERA.xml:S2:846:4	O
position	NORTHERA.xml:S2:851:8	O
.	NORTHERA.xml:S2:859:1	O

If	NORTHERA.xml:S2:862:2	O
supine	NORTHERA.xml:S2:865:6	O
hypertension	NORTHERA.xml:S2:872:12	O
cannot	NORTHERA.xml:S2:885:6	O
be	NORTHERA.xml:S2:892:2	O
managed	NORTHERA.xml:S2:895:7	O
by	NORTHERA.xml:S2:903:2	O
elevation	NORTHERA.xml:S2:906:9	O
of	NORTHERA.xml:S2:916:2	O
the	NORTHERA.xml:S2:919:3	O
head	NORTHERA.xml:S2:923:4	O
of	NORTHERA.xml:S2:928:2	O
the	NORTHERA.xml:S2:931:3	O
bed	NORTHERA.xml:S2:935:3	O
,	NORTHERA.xml:S2:938:1	O
reduce	NORTHERA.xml:S2:940:6	O
or	NORTHERA.xml:S2:947:2	O
discontinue	NORTHERA.xml:S2:950:11	O
NORTHERA	NORTHERA.xml:S2:962:8	O
[	NORTHERA.xml:S2:973:1	O
see	NORTHERA.xml:S2:974:3	O
Warnings	NORTHERA.xml:S2:978:8	O
and	NORTHERA.xml:S2:987:3	O
Precautions	NORTHERA.xml:S2:999:11	O
(	NORTHERA.xml:S2:1011:1	O
5.1	NORTHERA.xml:S2:1014:3	O
)]	NORTHERA.xml:S2:1019:2	O
.	NORTHERA.xml:S2:1021:1	O
\n	NORTHERA.xml:S2:1026:1	O
5	NORTHERA.xml:S3:4:1	O
WARNINGS	NORTHERA.xml:S3:6:8	O
AND	NORTHERA.xml:S3:15:3	O
PRECAUTIONS	NORTHERA.xml:S3:19:11	O

EXCERPT	NORTHERA.xml:S3:37:7	O
:	NORTHERA.xml:S3:44:1	O
NORTHERA	NORTHERA.xml:S3:52:8	O
can	NORTHERA.xml:S3:61:3	B-Factor
cause	NORTHERA.xml:S3:65:5	O
supine	NORTHERA.xml:S3:71:6	B-AdverseReaction
hypertension	NORTHERA.xml:S3:78:12	I-AdverseReaction
and	NORTHERA.xml:S3:91:3	O
may	NORTHERA.xml:S3:95:3	B-Factor
increase	NORTHERA.xml:S3:99:8	O
cardiovascular	NORTHERA.xml:S3:108:14	B-AdverseReaction
risk	NORTHERA.xml:S3:123:4	I-AdverseReaction
if	NORTHERA.xml:S3:128:2	O
supine	NORTHERA.xml:S3:131:6	B-AdverseReaction
hypertension	NORTHERA.xml:S3:138:12	I-AdverseReaction
is	NORTHERA.xml:S3:151:2	O
not	NORTHERA.xml:S3:154:3	O
well	NORTHERA.xml:S3:158:4	O
-	NORTHERA.xml:S3:162:1	O
managed	NORTHERA.xml:S3:163:7	O
(	NORTHERA.xml:S3:171:1	O
5.1	NORTHERA.xml:S3:174:3	O
)	NORTHERA.xml:S3:179:1	O
.	NORTHERA.xml:S3:180:1	O

Hyperpyrexia	NORTHERA.xml:S3:187:12	B-AdverseReaction
and	NORTHERA.xml:S3:200:3	O
confusion	NORTHERA.xml:S3:204:9	B-AdverseReaction
(	NORTHERA.xml:S3:214:1	O
5.2	NORTHERA.xml:S3:217:3	O
)	NORTHERA.xml:S3:222:1	O

May	NORTHERA.xml:S3:229:3	B-Factor
exacerbate	NORTHERA.xml:S3:233:10	B-AdverseReaction
symptoms	NORTHERA.xml:S3:244:8	O
in	NORTHERA.xml:S3:253:2	O
patients	NORTHERA.xml:S3:256:8	O
with	NORTHERA.xml:S3:265:4	O
existing	NORTHERA.xml:S3:270:8	O
ischemic	NORTHERA.xml:S3:279:8	I-AdverseReaction
heart	NORTHERA.xml:S3:288:5	I-AdverseReaction
disease	NORTHERA.xml:S3:294:7	I-AdverseReaction
,	NORTHERA.xml:S3:301:1	O
arrhythmias	NORTHERA.xml:S3:303:11	I-AdverseReaction
,	NORTHERA.xml:S3:314:1	O
and	NORTHERA.xml:S3:316:3	O
congestive	NORTHERA.xml:S3:320:10	I-AdverseReaction
heart	NORTHERA.xml:S3:331:5	I-AdverseReaction
failure	NORTHERA.xml:S3:337:7	I-AdverseReaction
(	NORTHERA.xml:S3:345:1	O
5.3	NORTHERA.xml:S3:348:3	O
)	NORTHERA.xml:S3:353:1	O

Allergic	NORTHERA.xml:S3:360:8	B-AdverseReaction
reactions	NORTHERA.xml:S3:369:9	I-AdverseReaction
(	NORTHERA.xml:S3:379:1	O
5.4	NORTHERA.xml:S3:382:3	O
)	NORTHERA.xml:S3:387:1	O

5.1	NORTHERA.xml:S3:401:3	O

Supine	NORTHERA.xml:S3:405:6	O

Hypertension	NORTHERA.xml:S3:412:12	O

NORTHERA	NORTHERA.xml:S3:430:8	O
therapy	NORTHERA.xml:S3:439:7	O
may	NORTHERA.xml:S3:447:3	B-Factor
cause	NORTHERA.xml:S3:451:5	O
or	NORTHERA.xml:S3:457:2	O
exacerbate	NORTHERA.xml:S3:460:10	O
supine	NORTHERA.xml:S3:471:6	B-AdverseReaction
hypertension	NORTHERA.xml:S3:478:12	I-AdverseReaction
in	NORTHERA.xml:S3:491:2	O
patients	NORTHERA.xml:S3:494:8	O
with	NORTHERA.xml:S3:503:4	O
NOH	NORTHERA.xml:S3:508:3	O
.	NORTHERA.xml:S3:511:1	O

Patients	NORTHERA.xml:S3:513:8	O
should	NORTHERA.xml:S3:522:6	O
be	NORTHERA.xml:S3:529:2	O
advised	NORTHERA.xml:S3:532:7	O
to	NORTHERA.xml:S3:540:2	O
elevate	NORTHERA.xml:S3:543:7	O
the	NORTHERA.xml:S3:551:3	O
head	NORTHERA.xml:S3:555:4	O
of	NORTHERA.xml:S3:560:2	O
the	NORTHERA.xml:S3:563:3	O
bed	NORTHERA.xml:S3:567:3	O
when	NORTHERA.xml:S3:571:4	O
resting	NORTHERA.xml:S3:576:7	O
or	NORTHERA.xml:S3:584:2	O
sleeping	NORTHERA.xml:S3:587:8	O
.	NORTHERA.xml:S3:595:1	O

Monitor	NORTHERA.xml:S3:597:7	O
blood	NORTHERA.xml:S3:605:5	O
pressure	NORTHERA.xml:S3:611:8	O
,	NORTHERA.xml:S3:619:1	O
both	NORTHERA.xml:S3:621:4	O
in	NORTHERA.xml:S3:626:2	O
the	NORTHERA.xml:S3:629:3	O
supine	NORTHERA.xml:S3:633:6	O
position	NORTHERA.xml:S3:640:8	O
and	NORTHERA.xml:S3:649:3	O
in	NORTHERA.xml:S3:653:2	O
the	NORTHERA.xml:S3:656:3	O
recommended	NORTHERA.xml:S3:660:11	O
head	NORTHERA.xml:S3:672:4	O
-	NORTHERA.xml:S3:676:1	O
elevated	NORTHERA.xml:S3:677:8	O
sleeping	NORTHERA.xml:S3:686:8	O
position	NORTHERA.xml:S3:695:8	O
.	NORTHERA.xml:S3:703:1	O

Reduce	NORTHERA.xml:S3:705:6	O
or	NORTHERA.xml:S3:712:2	O
discontinue	NORTHERA.xml:S3:715:11	O
NORTHERA	NORTHERA.xml:S3:727:8	O
if	NORTHERA.xml:S3:736:2	O
supine	NORTHERA.xml:S3:739:6	O
hypertension	NORTHERA.xml:S3:746:12	O
persists	NORTHERA.xml:S3:759:8	O
.	NORTHERA.xml:S3:767:1	O

If	NORTHERA.xml:S3:769:2	O
supine	NORTHERA.xml:S3:772:6	O
hypertension	NORTHERA.xml:S3:779:12	O
is	NORTHERA.xml:S3:792:2	O
not	NORTHERA.xml:S3:795:3	O
well	NORTHERA.xml:S3:799:4	O
-	NORTHERA.xml:S3:803:1	O
managed	NORTHERA.xml:S3:804:7	O
,	NORTHERA.xml:S3:811:1	O
NORTHERA	NORTHERA.xml:S3:813:8	O
may	NORTHERA.xml:S3:822:3	O
increase	NORTHERA.xml:S3:826:8	O
the	NORTHERA.xml:S3:835:3	O
risk	NORTHERA.xml:S3:839:4	O
of	NORTHERA.xml:S3:844:2	O
cardiovascular	NORTHERA.xml:S3:847:14	O
events	NORTHERA.xml:S3:862:6	O
.	NORTHERA.xml:S3:868:1	O

5.2	NORTHERA.xml:S3:877:3	O
Hyperpyrexia	NORTHERA.xml:S3:881:12	O
and	NORTHERA.xml:S3:894:3	O
Confusion	NORTHERA.xml:S3:898:9	O

Post	NORTHERA.xml:S3:913:4	O
-	NORTHERA.xml:S3:917:1	O
marketing	NORTHERA.xml:S3:918:9	O
cases	NORTHERA.xml:S3:928:5	O
of	NORTHERA.xml:S3:934:2	O
a	NORTHERA.xml:S3:937:1	O
symptom	NORTHERA.xml:S3:939:7	O
complex	NORTHERA.xml:S3:947:7	O
resembling	NORTHERA.xml:S3:955:10	O
neuroleptic	NORTHERA.xml:S3:966:11	B-AdverseReaction
malignant	NORTHERA.xml:S3:978:9	I-AdverseReaction
syndrome	NORTHERA.xml:S3:988:8	I-AdverseReaction
(	NORTHERA.xml:S3:997:1	O
NMS	NORTHERA.xml:S3:998:3	B-AdverseReaction
)	NORTHERA.xml:S3:1001:1	O
have	NORTHERA.xml:S3:1003:4	O
been	NORTHERA.xml:S3:1008:4	O
reported	NORTHERA.xml:S3:1013:8	O
with	NORTHERA.xml:S3:1022:4	O
NORTHERA	NORTHERA.xml:S3:1027:8	O
use	NORTHERA.xml:S3:1036:3	O
during	NORTHERA.xml:S3:1040:6	O
post	NORTHERA.xml:S3:1047:4	O
-	NORTHERA.xml:S3:1051:1	O
marketing	NORTHERA.xml:S3:1052:9	O
surveillance	NORTHERA.xml:S3:1062:12	O
in	NORTHERA.xml:S3:1075:2	O
Japan	NORTHERA.xml:S3:1078:5	O
.	NORTHERA.xml:S3:1083:1	O

Observe	NORTHERA.xml:S3:1086:7	O
patients	NORTHERA.xml:S3:1094:8	O
carefully	NORTHERA.xml:S3:1103:9	O
when	NORTHERA.xml:S3:1113:4	O
the	NORTHERA.xml:S3:1118:3	O
dosage	NORTHERA.xml:S3:1122:6	O
of	NORTHERA.xml:S3:1129:2	O
NORTHERA	NORTHERA.xml:S3:1132:8	O
is	NORTHERA.xml:S3:1141:2	O
changed	NORTHERA.xml:S3:1144:7	O
or	NORTHERA.xml:S3:1152:2	O
when	NORTHERA.xml:S3:1155:4	O
concomitant	NORTHERA.xml:S3:1160:11	O
levodopa	NORTHERA.xml:S3:1172:8	O
is	NORTHERA.xml:S3:1181:2	O
reduced	NORTHERA.xml:S3:1184:7	O
abruptly	NORTHERA.xml:S3:1192:8	O
or	NORTHERA.xml:S3:1201:2	O
discontinued	NORTHERA.xml:S3:1204:12	O
,	NORTHERA.xml:S3:1216:1	O
especially	NORTHERA.xml:S3:1218:10	O
if	NORTHERA.xml:S3:1229:2	O
the	NORTHERA.xml:S3:1232:3	O
patient	NORTHERA.xml:S3:1236:7	O
is	NORTHERA.xml:S3:1244:2	O
receiving	NORTHERA.xml:S3:1247:9	O
neuroleptics	NORTHERA.xml:S3:1257:12	O
.	NORTHERA.xml:S3:1269:1	O

NMS	NORTHERA.xml:S3:1275:3	B-AdverseReaction
is	NORTHERA.xml:S3:1279:2	O
an	NORTHERA.xml:S3:1282:2	O
uncommon	NORTHERA.xml:S3:1285:8	O
but	NORTHERA.xml:S3:1294:3	O
life	NORTHERA.xml:S3:1298:4	B-Severity
-	NORTHERA.xml:S3:1302:1	I-Severity
threatening	NORTHERA.xml:S3:1303:11	I-Severity
syndrome	NORTHERA.xml:S3:1315:8	O
characterized	NORTHERA.xml:S3:1324:13	O
by	NORTHERA.xml:S3:1338:2	O
fever	NORTHERA.xml:S3:1341:5	B-AdverseReaction
or	NORTHERA.xml:S3:1347:2	O
hyperthermia	NORTHERA.xml:S3:1350:12	B-AdverseReaction
,	NORTHERA.xml:S3:1362:1	O
muscle	NORTHERA.xml:S3:1364:6	B-AdverseReaction
rigidity	NORTHERA.xml:S3:1371:8	I-AdverseReaction
,	NORTHERA.xml:S3:1379:1	O
involuntary	NORTHERA.xml:S3:1381:11	B-AdverseReaction
movements	NORTHERA.xml:S3:1393:9	I-AdverseReaction
,	NORTHERA.xml:S3:1402:1	O
altered	NORTHERA.xml:S3:1404:7	B-AdverseReaction
consciousness	NORTHERA.xml:S3:1412:13	I-AdverseReaction
,	NORTHERA.xml:S3:1425:1	O
and	NORTHERA.xml:S3:1427:3	O
mental	NORTHERA.xml:S3:1431:6	B-AdverseReaction
status	NORTHERA.xml:S3:1438:6	I-AdverseReaction
changes	NORTHERA.xml:S3:1445:7	I-AdverseReaction
.	NORTHERA.xml:S3:1452:1	O

The	NORTHERA.xml:S3:1455:3	O
early	NORTHERA.xml:S3:1459:5	O
diagnosis	NORTHERA.xml:S3:1465:9	O
of	NORTHERA.xml:S3:1475:2	O
this	NORTHERA.xml:S3:1478:4	O
condition	NORTHERA.xml:S3:1483:9	O
is	NORTHERA.xml:S3:1493:2	O
important	NORTHERA.xml:S3:1496:9	O
for	NORTHERA.xml:S3:1506:3	O
the	NORTHERA.xml:S3:1510:3	O
appropriate	NORTHERA.xml:S3:1514:11	O
management	NORTHERA.xml:S3:1526:10	O
of	NORTHERA.xml:S3:1537:2	O
these	NORTHERA.xml:S3:1540:5	O
patients	NORTHERA.xml:S3:1546:8	O
.	NORTHERA.xml:S3:1554:1	O

5.3	NORTHERA.xml:S3:1563:3	O
Ischemic	NORTHERA.xml:S3:1567:8	O
Heart	NORTHERA.xml:S3:1576:5	O
Disease	NORTHERA.xml:S3:1582:7	O
,	NORTHERA.xml:S3:1589:1	O
Arrhythmias	NORTHERA.xml:S3:1591:11	O
,	NORTHERA.xml:S3:1602:1	O
and	NORTHERA.xml:S3:1604:3	O
Congestive	NORTHERA.xml:S3:1608:10	O
Heart	NORTHERA.xml:S3:1619:5	O
Failure	NORTHERA.xml:S3:1625:7	O

NORTHERA	NORTHERA.xml:S3:1638:8	O
may	NORTHERA.xml:S3:1647:3	B-Factor
exacerbate	NORTHERA.xml:S3:1651:10	B-AdverseReaction
existing	NORTHERA.xml:S3:1662:8	O
ischemic	NORTHERA.xml:S3:1671:8	I-AdverseReaction
heart	NORTHERA.xml:S3:1680:5	I-AdverseReaction
disease	NORTHERA.xml:S3:1686:7	I-AdverseReaction
,	NORTHERA.xml:S3:1693:1	O
arrhythmias	NORTHERA.xml:S3:1695:11	I-AdverseReaction
,	NORTHERA.xml:S3:1706:1	O
and	NORTHERA.xml:S3:1708:3	O
congestive	NORTHERA.xml:S3:1712:10	I-AdverseReaction
heart	NORTHERA.xml:S3:1723:5	I-AdverseReaction
failure	NORTHERA.xml:S3:1729:7	I-AdverseReaction
.	NORTHERA.xml:S3:1736:1	O

Careful	NORTHERA.xml:S3:1739:7	O
consideration	NORTHERA.xml:S3:1747:13	O
should	NORTHERA.xml:S3:1761:6	O
be	NORTHERA.xml:S3:1768:2	O
given	NORTHERA.xml:S3:1771:5	O
to	NORTHERA.xml:S3:1777:2	O
this	NORTHERA.xml:S3:1780:4	O
potential	NORTHERA.xml:S3:1785:9	O
risk	NORTHERA.xml:S3:1795:4	O
prior	NORTHERA.xml:S3:1800:5	O
to	NORTHERA.xml:S3:1806:2	O
initiating	NORTHERA.xml:S3:1809:10	O
therapy	NORTHERA.xml:S3:1820:7	O
in	NORTHERA.xml:S3:1828:2	O
patients	NORTHERA.xml:S3:1831:8	O
with	NORTHERA.xml:S3:1840:4	O
these	NORTHERA.xml:S3:1845:5	O
conditions	NORTHERA.xml:S3:1851:10	O
.	NORTHERA.xml:S3:1861:1	O

5.4	NORTHERA.xml:S3:1870:3	O
Allergic	NORTHERA.xml:S3:1874:8	O
Reactions	NORTHERA.xml:S3:1883:9	O

This	NORTHERA.xml:S3:1898:4	O
product	NORTHERA.xml:S3:1903:7	O
contains	NORTHERA.xml:S3:1911:8	O
FD	NORTHERA.xml:S3:1920:2	O
C	NORTHERA.xml:S3:1923:1	O
Yellow	NORTHERA.xml:S3:1925:6	O
No	NORTHERA.xml:S3:1932:2	O
.	NORTHERA.xml:S3:1934:1	O

5	NORTHERA.xml:S3:1936:1	O
(	NORTHERA.xml:S3:1938:1	O
tartrazine	NORTHERA.xml:S3:1939:10	O
)	NORTHERA.xml:S3:1949:1	O
which	NORTHERA.xml:S3:1951:5	O
may	NORTHERA.xml:S3:1957:3	B-Factor
cause	NORTHERA.xml:S3:1961:5	O
allergic	NORTHERA.xml:S3:1967:8	B-AdverseReaction
-	NORTHERA.xml:S3:1975:1	I-AdverseReaction
type	NORTHERA.xml:S3:1976:4	I-AdverseReaction
reactions	NORTHERA.xml:S3:1981:9	I-AdverseReaction
(	NORTHERA.xml:S3:1991:1	O
including	NORTHERA.xml:S3:1992:9	O
bronchial	NORTHERA.xml:S3:2002:9	B-AdverseReaction
asthma	NORTHERA.xml:S3:2012:6	I-AdverseReaction
)	NORTHERA.xml:S3:2018:1	O
in	NORTHERA.xml:S3:2020:2	O
certain	NORTHERA.xml:S3:2023:7	O
susceptible	NORTHERA.xml:S3:2031:11	O
persons	NORTHERA.xml:S3:2043:7	O
.	NORTHERA.xml:S3:2050:1	O

Although	NORTHERA.xml:S3:2052:8	O
the	NORTHERA.xml:S3:2061:3	O
overall	NORTHERA.xml:S3:2065:7	O
incidence	NORTHERA.xml:S3:2073:9	O
of	NORTHERA.xml:S3:2083:2	O
FD	NORTHERA.xml:S3:2086:2	O
C	NORTHERA.xml:S3:2089:1	O
Yellow	NORTHERA.xml:S3:2091:6	O
No	NORTHERA.xml:S3:2098:2	O
.	NORTHERA.xml:S3:2100:1	O

5	NORTHERA.xml:S3:2102:1	O
(	NORTHERA.xml:S3:2104:1	O
tartrazine	NORTHERA.xml:S3:2105:10	O
)	NORTHERA.xml:S3:2115:1	O
sensitivity	NORTHERA.xml:S3:2117:11	O
in	NORTHERA.xml:S3:2129:2	O
the	NORTHERA.xml:S3:2132:3	O
general	NORTHERA.xml:S3:2136:7	O
population	NORTHERA.xml:S3:2144:10	O
is	NORTHERA.xml:S3:2155:2	O
low	NORTHERA.xml:S3:2158:3	O
,	NORTHERA.xml:S3:2161:1	O
it	NORTHERA.xml:S3:2163:2	O
is	NORTHERA.xml:S3:2166:2	O
frequently	NORTHERA.xml:S3:2169:10	O
seen	NORTHERA.xml:S3:2180:4	O
in	NORTHERA.xml:S3:2185:2	O
patients	NORTHERA.xml:S3:2188:8	O
who	NORTHERA.xml:S3:2197:3	O
also	NORTHERA.xml:S3:2201:4	O
have	NORTHERA.xml:S3:2206:4	O
aspirin	NORTHERA.xml:S3:2211:7	O
hypersensitivity	NORTHERA.xml:S3:2219:16	O
.	NORTHERA.xml:S3:2235:1	O
6	NULOJIX.xml:S1:4:1	O
ADVERSE	NULOJIX.xml:S1:6:7	O
REACTIONS	NULOJIX.xml:S1:14:9	O

The	NULOJIX.xml:S1:27:3	O
most	NULOJIX.xml:S1:31:4	O
serious	NULOJIX.xml:S1:36:7	O
adverse	NULOJIX.xml:S1:44:7	O
reactions	NULOJIX.xml:S1:52:9	O
reported	NULOJIX.xml:S1:62:8	O
with	NULOJIX.xml:S1:71:4	O
NULOJIX	NULOJIX.xml:S1:76:7	O
are	NULOJIX.xml:S1:84:3	O
:	NULOJIX.xml:S1:87:1	O

PTLD	NULOJIX.xml:S1:98:4	B-AdverseReaction
,	NULOJIX.xml:S1:102:1	O
predominantly	NULOJIX.xml:S1:104:13	O
CNS	NULOJIX.xml:S1:118:3	B-AdverseReaction
PTLD	NULOJIX.xml:S1:122:4	I-AdverseReaction
,	NULOJIX.xml:S1:126:1	O
and	NULOJIX.xml:S1:128:3	O
other	NULOJIX.xml:S1:132:5	O
malignancies	NULOJIX.xml:S1:138:12	B-AdverseReaction
[	NULOJIX.xml:S1:151:1	O
see	NULOJIX.xml:S1:152:3	O
Boxed	NULOJIX.xml:S1:158:5	O
Warning	NULOJIX.xml:S1:164:7	O
and	NULOJIX.xml:S1:174:3	O
Warnings	NULOJIX.xml:S1:180:8	O
and	NULOJIX.xml:S1:189:3	O
Precautions	NULOJIX.xml:S1:193:11	O
(	NULOJIX.xml:S1:205:1	O
5.1	NULOJIX.xml:S1:206:3	O
,	NULOJIX.xml:S1:211:1	O
5.3	NULOJIX.xml:S1:214:3	O
)	NULOJIX.xml:S1:217:1	O
]	NULOJIX.xml:S1:221:1	O

Serious	NULOJIX.xml:S1:230:7	B-Severity
infections	NULOJIX.xml:S1:238:10	B-AdverseReaction
,	NULOJIX.xml:S1:248:1	O
including	NULOJIX.xml:S1:250:9	O
JC	NULOJIX.xml:S1:260:2	B-AdverseReaction
virus	NULOJIX.xml:S1:263:5	I-AdverseReaction
-	NULOJIX.xml:S1:268:1	O
associated	NULOJIX.xml:S1:269:10	O
PML	NULOJIX.xml:S1:280:3	B-AdverseReaction
and	NULOJIX.xml:S1:284:3	O
polyoma	NULOJIX.xml:S1:288:7	B-AdverseReaction
virus	NULOJIX.xml:S1:296:5	I-AdverseReaction
nephropathy	NULOJIX.xml:S1:302:11	I-AdverseReaction
[	NULOJIX.xml:S1:314:1	O
see	NULOJIX.xml:S1:315:3	O
Warnings	NULOJIX.xml:S1:321:8	O
and	NULOJIX.xml:S1:330:3	O
Precautions	NULOJIX.xml:S1:334:11	O
(	NULOJIX.xml:S1:346:1	O
5.4	NULOJIX.xml:S1:347:3	O
,	NULOJIX.xml:S1:352:1	O
5.5	NULOJIX.xml:S1:355:3	O
,	NULOJIX.xml:S1:360:1	O
5.6	NULOJIX.xml:S1:363:3	O
)	NULOJIX.xml:S1:366:1	O
]	NULOJIX.xml:S1:370:1	O

EXCERPT	NULOJIX.xml:S1:379:7	O
:	NULOJIX.xml:S1:386:1	O
Most	NULOJIX.xml:S1:390:4	O
common	NULOJIX.xml:S1:395:6	O
adverse	NULOJIX.xml:S1:402:7	O
reactions	NULOJIX.xml:S1:410:9	O
(	NULOJIX.xml:S1:420:1	O
20%	NULOJIX.xml:S1:423:3	O
on	NULOJIX.xml:S1:427:2	O
NULOJIX	NULOJIX.xml:S1:430:7	O
treatment	NULOJIX.xml:S1:438:9	O
)	NULOJIX.xml:S1:447:1	O
are	NULOJIX.xml:S1:449:3	O
anemia	NULOJIX.xml:S1:453:6	B-AdverseReaction
,	NULOJIX.xml:S1:459:1	O
diarrhea	NULOJIX.xml:S1:461:8	B-AdverseReaction
,	NULOJIX.xml:S1:469:1	O
urinary	NULOJIX.xml:S1:471:7	B-AdverseReaction
tract	NULOJIX.xml:S1:479:5	I-AdverseReaction
infection	NULOJIX.xml:S1:485:9	I-AdverseReaction
,	NULOJIX.xml:S1:494:1	O
peripheral	NULOJIX.xml:S1:496:10	B-AdverseReaction
edema	NULOJIX.xml:S1:507:5	I-AdverseReaction
,	NULOJIX.xml:S1:512:1	O
constipation	NULOJIX.xml:S1:514:12	B-AdverseReaction
,	NULOJIX.xml:S1:526:1	O
hypertension	NULOJIX.xml:S1:528:12	B-AdverseReaction
,	NULOJIX.xml:S1:540:1	O
pyrexia	NULOJIX.xml:S1:542:7	B-AdverseReaction
,	NULOJIX.xml:S1:549:1	O
graft	NULOJIX.xml:S1:551:5	B-AdverseReaction
dysfunction	NULOJIX.xml:S1:557:11	I-AdverseReaction
,	NULOJIX.xml:S1:568:1	O
cough	NULOJIX.xml:S1:570:5	B-AdverseReaction
,	NULOJIX.xml:S1:575:1	O
nausea	NULOJIX.xml:S1:577:6	B-AdverseReaction
,	NULOJIX.xml:S1:583:1	O
vomiting	NULOJIX.xml:S1:585:8	B-AdverseReaction
,	NULOJIX.xml:S1:593:1	O
headache	NULOJIX.xml:S1:595:8	B-AdverseReaction
,	NULOJIX.xml:S1:603:1	O
hypokalemia	NULOJIX.xml:S1:605:11	B-AdverseReaction
,	NULOJIX.xml:S1:616:1	O
hyperkalemia	NULOJIX.xml:S1:618:12	B-AdverseReaction
,	NULOJIX.xml:S1:630:1	O
and	NULOJIX.xml:S1:632:3	O
leukopenia	NULOJIX.xml:S1:636:10	B-AdverseReaction
.	NULOJIX.xml:S1:646:1	O

(	NULOJIX.xml:S1:649:1	O
6.1	NULOJIX.xml:S1:650:3	O
)	NULOJIX.xml:S1:653:1	O

To	NULOJIX.xml:S1:663:2	O

report	NULOJIX.xml:S1:666:6	O
SUSPECTED	NULOJIX.xml:S1:673:9	O
ADVERSE	NULOJIX.xml:S1:683:7	O
REACTIONS	NULOJIX.xml:S1:691:9	O
,	NULOJIX.xml:S1:700:1	O
contact	NULOJIX.xml:S1:702:7	O
Bristol	NULOJIX.xml:S1:710:7	O
-	NULOJIX.xml:S1:717:1	O
Myers	NULOJIX.xml:S1:718:5	O
Squibb	NULOJIX.xml:S1:724:6	O
at	NULOJIX.xml:S1:731:2	O
1	NULOJIX.xml:S1:734:1	O
-	NULOJIX.xml:S1:735:1	O
800	NULOJIX.xml:S1:736:3	O
-	NULOJIX.xml:S1:739:1	O
721	NULOJIX.xml:S1:740:3	O
-	NULOJIX.xml:S1:743:1	O
5072	NULOJIX.xml:S1:744:4	O
or	NULOJIX.xml:S1:749:2	O
FDA	NULOJIX.xml:S1:752:3	O
at	NULOJIX.xml:S1:756:2	O
1	NULOJIX.xml:S1:759:1	O
-	NULOJIX.xml:S1:760:1	O
800	NULOJIX.xml:S1:761:3	O
-	NULOJIX.xml:S1:764:1	O
FDA	NULOJIX.xml:S1:765:3	O
-	NULOJIX.xml:S1:768:1	O
1088	NULOJIX.xml:S1:769:4	O
or	NULOJIX.xml:S1:774:2	O
www	NULOJIX.xml:S1:780:3	O
.	NULOJIX.xml:S1:783:1	O
fda	NULOJIX.xml:S1:784:3	O
.	NULOJIX.xml:S1:787:1	O
gov	NULOJIX.xml:S1:788:3	O
medwatch	NULOJIX.xml:S1:792:8	O
.	NULOJIX.xml:S1:804:1	O

6.1	NULOJIX.xml:S1:816:3	O

Clinical	NULOJIX.xml:S1:820:8	O
Studies	NULOJIX.xml:S1:829:7	O
Experience	NULOJIX.xml:S1:837:10	O

The	NULOJIX.xml:S1:851:3	O
data	NULOJIX.xml:S1:855:4	O
described	NULOJIX.xml:S1:860:9	O
below	NULOJIX.xml:S1:870:5	O
primarily	NULOJIX.xml:S1:876:9	O
derive	NULOJIX.xml:S1:886:6	O
from	NULOJIX.xml:S1:893:4	O
two	NULOJIX.xml:S1:898:3	O
randomized	NULOJIX.xml:S1:902:10	O
,	NULOJIX.xml:S1:912:1	O
active	NULOJIX.xml:S1:914:6	O
-	NULOJIX.xml:S1:920:1	O
controlled	NULOJIX.xml:S1:921:10	O
three	NULOJIX.xml:S1:932:5	O
-	NULOJIX.xml:S1:937:1	O
year	NULOJIX.xml:S1:938:4	O
trials	NULOJIX.xml:S1:943:6	O
of	NULOJIX.xml:S1:950:2	O
NULOJIX	NULOJIX.xml:S1:953:7	O
in	NULOJIX.xml:S1:961:2	O
de	NULOJIX.xml:S1:965:2	O
novo	NULOJIX.xml:S1:968:4	O
kidney	NULOJIX.xml:S1:974:6	O
transplant	NULOJIX.xml:S1:981:10	O
patients	NULOJIX.xml:S1:992:8	O
.	NULOJIX.xml:S1:1000:1	O

In	NULOJIX.xml:S1:1002:2	O
Study	NULOJIX.xml:S1:1005:5	O
1	NULOJIX.xml:S1:1011:1	O
and	NULOJIX.xml:S1:1013:3	O
Study	NULOJIX.xml:S1:1017:5	O
2	NULOJIX.xml:S1:1023:1	O
,	NULOJIX.xml:S1:1024:1	O
NULOJIX	NULOJIX.xml:S1:1026:7	O
was	NULOJIX.xml:S1:1034:3	O
studied	NULOJIX.xml:S1:1038:7	O
at	NULOJIX.xml:S1:1046:2	O
the	NULOJIX.xml:S1:1049:3	O
recommended	NULOJIX.xml:S1:1053:11	O
dose	NULOJIX.xml:S1:1065:4	O
and	NULOJIX.xml:S1:1070:3	O
frequency	NULOJIX.xml:S1:1074:9	O
[	NULOJIX.xml:S1:1084:1	O
see	NULOJIX.xml:S1:1085:3	O
Dosage	NULOJIX.xml:S1:1092:6	O
and	NULOJIX.xml:S1:1099:3	O
Administration	NULOJIX.xml:S1:1103:14	O
(	NULOJIX.xml:S1:1118:1	O
2.1	NULOJIX.xml:S1:1119:3	O
)	NULOJIX.xml:S1:1122:1	O
]	NULOJIX.xml:S1:1127:1	O
in	NULOJIX.xml:S1:1129:2	O
a	NULOJIX.xml:S1:1132:1	O
total	NULOJIX.xml:S1:1134:5	O
of	NULOJIX.xml:S1:1140:2	O
401	NULOJIX.xml:S1:1143:3	O
patients	NULOJIX.xml:S1:1147:8	O
compared	NULOJIX.xml:S1:1156:8	O
to	NULOJIX.xml:S1:1165:2	O
a	NULOJIX.xml:S1:1168:1	O
cyclosporine	NULOJIX.xml:S1:1170:12	O
control	NULOJIX.xml:S1:1183:7	O
regimen	NULOJIX.xml:S1:1191:7	O
in	NULOJIX.xml:S1:1199:2	O
a	NULOJIX.xml:S1:1202:1	O
total	NULOJIX.xml:S1:1204:5	O
of	NULOJIX.xml:S1:1210:2	O
405	NULOJIX.xml:S1:1213:3	O
patients	NULOJIX.xml:S1:1217:8	O
.	NULOJIX.xml:S1:1225:1	O

These	NULOJIX.xml:S1:1227:5	O
two	NULOJIX.xml:S1:1233:3	O
trials	NULOJIX.xml:S1:1237:6	O
also	NULOJIX.xml:S1:1244:4	O
included	NULOJIX.xml:S1:1249:8	O
a	NULOJIX.xml:S1:1258:1	O
total	NULOJIX.xml:S1:1260:5	O
of	NULOJIX.xml:S1:1266:2	O
403	NULOJIX.xml:S1:1269:3	O
patients	NULOJIX.xml:S1:1273:8	O
treated	NULOJIX.xml:S1:1282:7	O
with	NULOJIX.xml:S1:1290:4	O
a	NULOJIX.xml:S1:1295:1	O
NULOJIX	NULOJIX.xml:S1:1297:7	O
regimen	NULOJIX.xml:S1:1305:7	O
of	NULOJIX.xml:S1:1313:2	O
higher	NULOJIX.xml:S1:1316:6	O
cumulative	NULOJIX.xml:S1:1323:10	O
dose	NULOJIX.xml:S1:1334:4	O
and	NULOJIX.xml:S1:1339:3	O
more	NULOJIX.xml:S1:1343:4	O
frequent	NULOJIX.xml:S1:1348:8	O
dosing	NULOJIX.xml:S1:1357:6	O
than	NULOJIX.xml:S1:1364:4	O
recommended	NULOJIX.xml:S1:1369:11	O
[	NULOJIX.xml:S1:1381:1	O
see	NULOJIX.xml:S1:1382:3	O
Clinical	NULOJIX.xml:S1:1389:8	O
Studies	NULOJIX.xml:S1:1398:7	O
(	NULOJIX.xml:S1:1406:1	O
14.1	NULOJIX.xml:S1:1407:4	O
)	NULOJIX.xml:S1:1411:1	O
]	NULOJIX.xml:S1:1416:1	O
.	NULOJIX.xml:S1:1417:1	O

All	NULOJIX.xml:S1:1419:3	O
patients	NULOJIX.xml:S1:1423:8	O
also	NULOJIX.xml:S1:1432:4	O
received	NULOJIX.xml:S1:1437:8	O
basiliximab	NULOJIX.xml:S1:1446:11	O
induction	NULOJIX.xml:S1:1458:9	O
,	NULOJIX.xml:S1:1467:1	O
mycophenolate	NULOJIX.xml:S1:1469:13	O
mofetil	NULOJIX.xml:S1:1483:7	O
,	NULOJIX.xml:S1:1490:1	O
and	NULOJIX.xml:S1:1492:3	O
corticosteroids	NULOJIX.xml:S1:1496:15	O
.	NULOJIX.xml:S1:1511:1	O

Patients	NULOJIX.xml:S1:1513:8	O
were	NULOJIX.xml:S1:1522:4	O
treated	NULOJIX.xml:S1:1527:7	O
and	NULOJIX.xml:S1:1535:3	O
followed	NULOJIX.xml:S1:1539:8	O
for	NULOJIX.xml:S1:1548:3	O
3	NULOJIX.xml:S1:1552:1	O
years	NULOJIX.xml:S1:1554:5	O
.	NULOJIX.xml:S1:1559:1	O

CNS	NULOJIX.xml:S1:1565:3	B-AdverseReaction
PTLD	NULOJIX.xml:S1:1569:4	I-AdverseReaction
,	NULOJIX.xml:S1:1573:1	O
PML	NULOJIX.xml:S1:1575:3	B-AdverseReaction
,	NULOJIX.xml:S1:1578:1	O
and	NULOJIX.xml:S1:1580:3	O
other	NULOJIX.xml:S1:1584:5	O
CNS	NULOJIX.xml:S1:1590:3	B-AdverseReaction
infections	NULOJIX.xml:S1:1594:10	I-AdverseReaction
were	NULOJIX.xml:S1:1605:4	O
more	NULOJIX.xml:S1:1610:4	O
frequently	NULOJIX.xml:S1:1615:10	O
observed	NULOJIX.xml:S1:1626:8	O
in	NULOJIX.xml:S1:1635:2	O
association	NULOJIX.xml:S1:1638:11	O
with	NULOJIX.xml:S1:1650:4	O
a	NULOJIX.xml:S1:1655:1	O
NULOJIX	NULOJIX.xml:S1:1657:7	O
regimen	NULOJIX.xml:S1:1665:7	O
of	NULOJIX.xml:S1:1673:2	O
higher	NULOJIX.xml:S1:1676:6	O
cumulative	NULOJIX.xml:S1:1683:10	O
dose	NULOJIX.xml:S1:1694:4	O
and	NULOJIX.xml:S1:1699:3	O
more	NULOJIX.xml:S1:1703:4	O
frequent	NULOJIX.xml:S1:1708:8	O
dosing	NULOJIX.xml:S1:1717:6	O
compared	NULOJIX.xml:S1:1724:8	O
to	NULOJIX.xml:S1:1733:2	O
the	NULOJIX.xml:S1:1736:3	O
recommended	NULOJIX.xml:S1:1740:11	O
regimen	NULOJIX.xml:S1:1752:7	O
;	NULOJIX.xml:S1:1759:1	O
therefore	NULOJIX.xml:S1:1761:9	O
,	NULOJIX.xml:S1:1770:1	O
administration	NULOJIX.xml:S1:1772:14	O
of	NULOJIX.xml:S1:1787:2	O
higher	NULOJIX.xml:S1:1790:6	O
than	NULOJIX.xml:S1:1797:4	O
the	NULOJIX.xml:S1:1802:3	O
recommended	NULOJIX.xml:S1:1806:11	O
doses	NULOJIX.xml:S1:1818:5	O
and	NULOJIX.xml:S1:1824:3	O
or	NULOJIX.xml:S1:1828:2	O
more	NULOJIX.xml:S1:1831:4	O
frequent	NULOJIX.xml:S1:1836:8	O
dosing	NULOJIX.xml:S1:1845:6	O
of	NULOJIX.xml:S1:1852:2	O
NULOJIX	NULOJIX.xml:S1:1855:7	O
is	NULOJIX.xml:S1:1863:2	O
not	NULOJIX.xml:S1:1866:3	O
recommended	NULOJIX.xml:S1:1870:11	O
[	NULOJIX.xml:S1:1882:1	O
see	NULOJIX.xml:S1:1883:3	O
Dosage	NULOJIX.xml:S1:1890:6	O
and	NULOJIX.xml:S1:1897:3	O
Administration	NULOJIX.xml:S1:1901:14	O
(	NULOJIX.xml:S1:1916:1	O
2.1	NULOJIX.xml:S1:1917:3	O
)	NULOJIX.xml:S1:1920:1	O
]	NULOJIX.xml:S1:1925:1	O
.	NULOJIX.xml:S1:1926:1	O

The	NULOJIX.xml:S1:1932:3	O
average	NULOJIX.xml:S1:1936:7	O
age	NULOJIX.xml:S1:1944:3	O
of	NULOJIX.xml:S1:1948:2	O
patients	NULOJIX.xml:S1:1951:8	O
in	NULOJIX.xml:S1:1960:2	O
Studies	NULOJIX.xml:S1:1963:7	O
1	NULOJIX.xml:S1:1971:1	O
and	NULOJIX.xml:S1:1973:3	O
2	NULOJIX.xml:S1:1977:1	O
in	NULOJIX.xml:S1:1979:2	O
the	NULOJIX.xml:S1:1982:3	O
NULOJIX	NULOJIX.xml:S1:1986:7	O
recommended	NULOJIX.xml:S1:1994:11	O
dose	NULOJIX.xml:S1:2006:4	O
and	NULOJIX.xml:S1:2011:3	O
cyclosporine	NULOJIX.xml:S1:2015:12	O
control	NULOJIX.xml:S1:2028:7	O
regimens	NULOJIX.xml:S1:2036:8	O
was	NULOJIX.xml:S1:2045:3	O
49	NULOJIX.xml:S1:2049:2	O
years	NULOJIX.xml:S1:2052:5	O
,	NULOJIX.xml:S1:2057:1	O
ranging	NULOJIX.xml:S1:2059:7	O
from	NULOJIX.xml:S1:2067:4	O
18	NULOJIX.xml:S1:2072:2	O
to	NULOJIX.xml:S1:2075:2	O
79	NULOJIX.xml:S1:2078:2	O
years	NULOJIX.xml:S1:2081:5	O
.	NULOJIX.xml:S1:2086:1	O

Approximately	NULOJIX.xml:S1:2088:13	O
70%	NULOJIX.xml:S1:2102:3	O
of	NULOJIX.xml:S1:2106:2	O
patients	NULOJIX.xml:S1:2109:8	O
were	NULOJIX.xml:S1:2118:4	O
male	NULOJIX.xml:S1:2123:4	O
;	NULOJIX.xml:S1:2127:1	O
67%	NULOJIX.xml:S1:2129:3	O
were	NULOJIX.xml:S1:2133:4	O
white	NULOJIX.xml:S1:2138:5	O
,	NULOJIX.xml:S1:2143:1	O
11%	NULOJIX.xml:S1:2145:3	O
were	NULOJIX.xml:S1:2149:4	O
black	NULOJIX.xml:S1:2154:5	O
,	NULOJIX.xml:S1:2159:1	O
and	NULOJIX.xml:S1:2161:3	O
22%	NULOJIX.xml:S1:2165:3	O
other	NULOJIX.xml:S1:2169:5	O
races	NULOJIX.xml:S1:2175:5	O
.	NULOJIX.xml:S1:2180:1	O

About	NULOJIX.xml:S1:2182:5	O
25%	NULOJIX.xml:S1:2188:3	O
of	NULOJIX.xml:S1:2192:2	O
patients	NULOJIX.xml:S1:2195:8	O
were	NULOJIX.xml:S1:2204:4	O
from	NULOJIX.xml:S1:2209:4	O
the	NULOJIX.xml:S1:2214:3	O
United	NULOJIX.xml:S1:2218:6	O
States	NULOJIX.xml:S1:2225:6	O
and	NULOJIX.xml:S1:2232:3	O
75%	NULOJIX.xml:S1:2236:3	O
from	NULOJIX.xml:S1:2240:4	O
other	NULOJIX.xml:S1:2245:5	O
countries	NULOJIX.xml:S1:2251:9	O
.	NULOJIX.xml:S1:2260:1	O

Because	NULOJIX.xml:S1:2266:7	O
clinical	NULOJIX.xml:S1:2274:8	O
trials	NULOJIX.xml:S1:2283:6	O
are	NULOJIX.xml:S1:2290:3	O
conducted	NULOJIX.xml:S1:2294:9	O
under	NULOJIX.xml:S1:2304:5	O
widely	NULOJIX.xml:S1:2310:6	O
varying	NULOJIX.xml:S1:2317:7	O
conditions	NULOJIX.xml:S1:2325:10	O
,	NULOJIX.xml:S1:2335:1	O
the	NULOJIX.xml:S1:2337:3	O
adverse	NULOJIX.xml:S1:2341:7	O
reaction	NULOJIX.xml:S1:2349:8	O
rates	NULOJIX.xml:S1:2358:5	O
observed	NULOJIX.xml:S1:2364:8	O
cannot	NULOJIX.xml:S1:2373:6	O
be	NULOJIX.xml:S1:2380:2	O
directly	NULOJIX.xml:S1:2383:8	O
compared	NULOJIX.xml:S1:2392:8	O
to	NULOJIX.xml:S1:2401:2	O
rates	NULOJIX.xml:S1:2404:5	O
in	NULOJIX.xml:S1:2410:2	O
other	NULOJIX.xml:S1:2413:5	O
trials	NULOJIX.xml:S1:2419:6	O
and	NULOJIX.xml:S1:2426:3	O
may	NULOJIX.xml:S1:2430:3	O
not	NULOJIX.xml:S1:2434:3	O
reflect	NULOJIX.xml:S1:2438:7	O
the	NULOJIX.xml:S1:2446:3	O
rates	NULOJIX.xml:S1:2450:5	O
observed	NULOJIX.xml:S1:2456:8	O
in	NULOJIX.xml:S1:2465:2	O
clinical	NULOJIX.xml:S1:2468:8	O
practice	NULOJIX.xml:S1:2477:8	O
.	NULOJIX.xml:S1:2485:1	O

The	NULOJIX.xml:S1:2491:3	O
most	NULOJIX.xml:S1:2495:4	O
commonly	NULOJIX.xml:S1:2500:8	O
reported	NULOJIX.xml:S1:2509:8	O
adverse	NULOJIX.xml:S1:2518:7	O
reactions	NULOJIX.xml:S1:2526:9	O
occurring	NULOJIX.xml:S1:2536:9	O
in	NULOJIX.xml:S1:2546:2	O
20%	NULOJIX.xml:S1:2551:3	O
of	NULOJIX.xml:S1:2555:2	O
patients	NULOJIX.xml:S1:2558:8	O
treated	NULOJIX.xml:S1:2567:7	O
with	NULOJIX.xml:S1:2575:4	O
the	NULOJIX.xml:S1:2580:3	O
recommended	NULOJIX.xml:S1:2584:11	O
dose	NULOJIX.xml:S1:2596:4	O
and	NULOJIX.xml:S1:2601:3	O
frequency	NULOJIX.xml:S1:2605:9	O
of	NULOJIX.xml:S1:2615:2	O
NULOJIX	NULOJIX.xml:S1:2618:7	O
were	NULOJIX.xml:S1:2626:4	O
anemia	NULOJIX.xml:S1:2631:6	B-AdverseReaction
,	NULOJIX.xml:S1:2637:1	O
diarrhea	NULOJIX.xml:S1:2639:8	B-AdverseReaction
,	NULOJIX.xml:S1:2647:1	O
urinary	NULOJIX.xml:S1:2649:7	B-AdverseReaction
tract	NULOJIX.xml:S1:2657:5	I-AdverseReaction
infection	NULOJIX.xml:S1:2663:9	I-AdverseReaction
,	NULOJIX.xml:S1:2672:1	O
peripheral	NULOJIX.xml:S1:2674:10	B-AdverseReaction
edema	NULOJIX.xml:S1:2685:5	I-AdverseReaction
,	NULOJIX.xml:S1:2690:1	O
constipation	NULOJIX.xml:S1:2692:12	B-AdverseReaction
,	NULOJIX.xml:S1:2704:1	O
hypertension	NULOJIX.xml:S1:2706:12	B-AdverseReaction
,	NULOJIX.xml:S1:2718:1	O
pyrexia	NULOJIX.xml:S1:2720:7	B-AdverseReaction
,	NULOJIX.xml:S1:2727:1	O
graft	NULOJIX.xml:S1:2729:5	B-AdverseReaction
dysfunction	NULOJIX.xml:S1:2735:11	I-AdverseReaction
,	NULOJIX.xml:S1:2746:1	O
cough	NULOJIX.xml:S1:2748:5	B-AdverseReaction
,	NULOJIX.xml:S1:2753:1	O
nausea	NULOJIX.xml:S1:2755:6	B-AdverseReaction
,	NULOJIX.xml:S1:2761:1	O
vomiting	NULOJIX.xml:S1:2763:8	B-AdverseReaction
,	NULOJIX.xml:S1:2771:1	O
headache	NULOJIX.xml:S1:2773:8	B-AdverseReaction
,	NULOJIX.xml:S1:2781:1	O
hypokalemia	NULOJIX.xml:S1:2783:11	B-AdverseReaction
,	NULOJIX.xml:S1:2794:1	O
hyperkalemia	NULOJIX.xml:S1:2796:12	B-AdverseReaction
,	NULOJIX.xml:S1:2808:1	O
and	NULOJIX.xml:S1:2810:3	O
leukopenia	NULOJIX.xml:S1:2814:10	B-AdverseReaction
.	NULOJIX.xml:S1:2824:1	O

The	NULOJIX.xml:S1:2830:3	O
proportion	NULOJIX.xml:S1:2834:10	O
of	NULOJIX.xml:S1:2845:2	O
patients	NULOJIX.xml:S1:2848:8	O
who	NULOJIX.xml:S1:2857:3	O
discontinued	NULOJIX.xml:S1:2861:12	O
treatment	NULOJIX.xml:S1:2874:9	O
due	NULOJIX.xml:S1:2884:3	O
to	NULOJIX.xml:S1:2888:2	O
adverse	NULOJIX.xml:S1:2891:7	O
reactions	NULOJIX.xml:S1:2899:9	O
was	NULOJIX.xml:S1:2909:3	O
13%	NULOJIX.xml:S1:2913:3	O
for	NULOJIX.xml:S1:2917:3	O
the	NULOJIX.xml:S1:2921:3	O
recommended	NULOJIX.xml:S1:2925:11	O
NULOJIX	NULOJIX.xml:S1:2937:7	O
regimen	NULOJIX.xml:S1:2945:7	O
and	NULOJIX.xml:S1:2953:3	O
19%	NULOJIX.xml:S1:2957:3	O
for	NULOJIX.xml:S1:2961:3	O
the	NULOJIX.xml:S1:2965:3	O
cyclosporine	NULOJIX.xml:S1:2969:12	O
control	NULOJIX.xml:S1:2982:7	O
arm	NULOJIX.xml:S1:2990:3	O
through	NULOJIX.xml:S1:2994:7	O
three	NULOJIX.xml:S1:3002:5	O
years	NULOJIX.xml:S1:3008:5	O
of	NULOJIX.xml:S1:3014:2	O
treatment	NULOJIX.xml:S1:3017:9	O
.	NULOJIX.xml:S1:3026:1	O

The	NULOJIX.xml:S1:3028:3	O
most	NULOJIX.xml:S1:3032:4	O
common	NULOJIX.xml:S1:3037:6	O
adverse	NULOJIX.xml:S1:3044:7	O
reactions	NULOJIX.xml:S1:3052:9	O
leading	NULOJIX.xml:S1:3062:7	O
to	NULOJIX.xml:S1:3070:2	O
discontinuation	NULOJIX.xml:S1:3073:15	O
in	NULOJIX.xml:S1:3089:2	O
NULOJIX	NULOJIX.xml:S1:3092:7	O
-	NULOJIX.xml:S1:3099:1	O
treated	NULOJIX.xml:S1:3100:7	O
patients	NULOJIX.xml:S1:3108:8	O
were	NULOJIX.xml:S1:3117:4	O
cytomegalovirus	NULOJIX.xml:S1:3122:15	B-AdverseReaction
infection	NULOJIX.xml:S1:3138:9	I-AdverseReaction
(	NULOJIX.xml:S1:3148:1	O
1.5%	NULOJIX.xml:S1:3149:4	O
)	NULOJIX.xml:S1:3153:1	O
and	NULOJIX.xml:S1:3155:3	O
complications	NULOJIX.xml:S1:3159:13	B-AdverseReaction
of	NULOJIX.xml:S1:3173:2	I-AdverseReaction
transplanted	NULOJIX.xml:S1:3176:12	I-AdverseReaction
kidney	NULOJIX.xml:S1:3189:6	I-AdverseReaction
(	NULOJIX.xml:S1:3196:1	O
1.5%	NULOJIX.xml:S1:3197:4	O
)	NULOJIX.xml:S1:3201:1	O
.	NULOJIX.xml:S1:3202:1	O

Information	NULOJIX.xml:S1:3208:11	O
on	NULOJIX.xml:S1:3220:2	O
selected	NULOJIX.xml:S1:3223:8	O
significant	NULOJIX.xml:S1:3232:11	O
adverse	NULOJIX.xml:S1:3244:7	O
reactions	NULOJIX.xml:S1:3252:9	O
observed	NULOJIX.xml:S1:3262:8	O
during	NULOJIX.xml:S1:3271:6	O
clinical	NULOJIX.xml:S1:3278:8	O
trials	NULOJIX.xml:S1:3287:6	O
is	NULOJIX.xml:S1:3294:2	O
summarized	NULOJIX.xml:S1:3297:10	O
below	NULOJIX.xml:S1:3308:5	O
.	NULOJIX.xml:S1:3313:1	O

Post	NULOJIX.xml:S1:3321:4	O
-	NULOJIX.xml:S1:3325:1	O
Transplant	NULOJIX.xml:S1:3326:10	O
Lymphoproliferative	NULOJIX.xml:S1:3337:19	O
Disorder	NULOJIX.xml:S1:3357:8	O

Reported	NULOJIX.xml:S1:3369:8	O
cases	NULOJIX.xml:S1:3378:5	O
of	NULOJIX.xml:S1:3384:2	O
post	NULOJIX.xml:S1:3387:4	B-AdverseReaction
-	NULOJIX.xml:S1:3391:1	I-AdverseReaction
transplant	NULOJIX.xml:S1:3392:10	I-AdverseReaction
lymphoproliferative	NULOJIX.xml:S1:3403:19	I-AdverseReaction
disorder	NULOJIX.xml:S1:3423:8	I-AdverseReaction
(	NULOJIX.xml:S1:3432:1	O
PTLD	NULOJIX.xml:S1:3433:4	B-AdverseReaction
)	NULOJIX.xml:S1:3437:1	O
up	NULOJIX.xml:S1:3439:2	O
to	NULOJIX.xml:S1:3442:2	O
36	NULOJIX.xml:S1:3445:2	O
months	NULOJIX.xml:S1:3448:6	O
post	NULOJIX.xml:S1:3455:4	O
transplant	NULOJIX.xml:S1:3460:10	O
were	NULOJIX.xml:S1:3471:4	O
obtained	NULOJIX.xml:S1:3476:8	O
for	NULOJIX.xml:S1:3485:3	O
NULOJIX	NULOJIX.xml:S1:3489:7	O
by	NULOJIX.xml:S1:3497:2	O
pooling	NULOJIX.xml:S1:3500:7	O
both	NULOJIX.xml:S1:3508:4	O
dosage	NULOJIX.xml:S1:3513:6	O
regimens	NULOJIX.xml:S1:3520:8	O
of	NULOJIX.xml:S1:3529:2	O
NULOJIX	NULOJIX.xml:S1:3532:7	O
in	NULOJIX.xml:S1:3540:2	O
Studies	NULOJIX.xml:S1:3543:7	O
1	NULOJIX.xml:S1:3551:1	O
and	NULOJIX.xml:S1:3553:3	O
2	NULOJIX.xml:S1:3557:1	O
(	NULOJIX.xml:S1:3559:1	O
804	NULOJIX.xml:S1:3560:3	O
patients	NULOJIX.xml:S1:3564:8	O
)	NULOJIX.xml:S1:3572:1	O
with	NULOJIX.xml:S1:3574:4	O
data	NULOJIX.xml:S1:3579:4	O
from	NULOJIX.xml:S1:3584:4	O
a	NULOJIX.xml:S1:3589:1	O
third	NULOJIX.xml:S1:3591:5	O
study	NULOJIX.xml:S1:3597:5	O
in	NULOJIX.xml:S1:3603:2	O
kidney	NULOJIX.xml:S1:3606:6	O
transplantation	NULOJIX.xml:S1:3613:15	O
(	NULOJIX.xml:S1:3629:1	O
Study	NULOJIX.xml:S1:3630:5	O
3	NULOJIX.xml:S1:3636:1	O
,	NULOJIX.xml:S1:3637:1	O
145	NULOJIX.xml:S1:3639:3	O
patients	NULOJIX.xml:S1:3643:8	O
)	NULOJIX.xml:S1:3651:1	O
which	NULOJIX.xml:S1:3653:5	O
evaluated	NULOJIX.xml:S1:3659:9	O
two	NULOJIX.xml:S1:3669:3	O
NULOJIX	NULOJIX.xml:S1:3673:7	O
dosage	NULOJIX.xml:S1:3681:6	O
regimens	NULOJIX.xml:S1:3688:8	O
similar	NULOJIX.xml:S1:3697:7	O
,	NULOJIX.xml:S1:3704:1	O
but	NULOJIX.xml:S1:3706:3	O
slightly	NULOJIX.xml:S1:3710:8	O
different	NULOJIX.xml:S1:3719:9	O
,	NULOJIX.xml:S1:3728:1	O
from	NULOJIX.xml:S1:3730:4	O
those	NULOJIX.xml:S1:3735:5	O
of	NULOJIX.xml:S1:3741:2	O
Studies	NULOJIX.xml:S1:3744:7	O
1	NULOJIX.xml:S1:3752:1	O
and	NULOJIX.xml:S1:3754:3	O
2	NULOJIX.xml:S1:3758:1	O
(	NULOJIX.xml:S1:3760:1	O
see	NULOJIX.xml:S1:3761:3	O
Table	NULOJIX.xml:S1:3765:5	O
2	NULOJIX.xml:S1:3771:1	O
)	NULOJIX.xml:S1:3772:1	O
.	NULOJIX.xml:S1:3773:1	O

The	NULOJIX.xml:S1:3775:3	O
total	NULOJIX.xml:S1:3779:5	O
number	NULOJIX.xml:S1:3785:6	O
of	NULOJIX.xml:S1:3792:2	O
NULOJIX	NULOJIX.xml:S1:3795:7	O
patients	NULOJIX.xml:S1:3803:8	O
from	NULOJIX.xml:S1:3812:4	O
these	NULOJIX.xml:S1:3817:5	O
three	NULOJIX.xml:S1:3823:5	O
studies	NULOJIX.xml:S1:3829:7	O
(	NULOJIX.xml:S1:3837:1	O
949	NULOJIX.xml:S1:3838:3	O
)	NULOJIX.xml:S1:3841:1	O
was	NULOJIX.xml:S1:3843:3	O
compared	NULOJIX.xml:S1:3847:8	O
to	NULOJIX.xml:S1:3856:2	O
the	NULOJIX.xml:S1:3859:3	O
pooled	NULOJIX.xml:S1:3863:6	O
cyclosporine	NULOJIX.xml:S1:3870:12	O
control	NULOJIX.xml:S1:3883:7	O
groups	NULOJIX.xml:S1:3891:6	O
from	NULOJIX.xml:S1:3898:4	O
all	NULOJIX.xml:S1:3903:3	O
three	NULOJIX.xml:S1:3907:5	O
studies	NULOJIX.xml:S1:3913:7	O
(	NULOJIX.xml:S1:3921:1	O
476	NULOJIX.xml:S1:3922:3	O
patients	NULOJIX.xml:S1:3926:8	O
)	NULOJIX.xml:S1:3934:1	O
.	NULOJIX.xml:S1:3935:1	O

Among	NULOJIX.xml:S1:3941:5	O
401	NULOJIX.xml:S1:3947:3	O
patients	NULOJIX.xml:S1:3951:8	O
in	NULOJIX.xml:S1:3960:2	O
Studies	NULOJIX.xml:S1:3963:7	O
1	NULOJIX.xml:S1:3971:1	O
and	NULOJIX.xml:S1:3973:3	O
2	NULOJIX.xml:S1:3977:1	O
treated	NULOJIX.xml:S1:3979:7	O
with	NULOJIX.xml:S1:3987:4	O
the	NULOJIX.xml:S1:3992:3	O
recommended	NULOJIX.xml:S1:3996:11	O
regimen	NULOJIX.xml:S1:4008:7	O
of	NULOJIX.xml:S1:4016:2	O
NULOJIX	NULOJIX.xml:S1:4019:7	O
and	NULOJIX.xml:S1:4027:3	O
the	NULOJIX.xml:S1:4031:3	O
71	NULOJIX.xml:S1:4035:2	O
patients	NULOJIX.xml:S1:4038:8	O
in	NULOJIX.xml:S1:4047:2	O
Study	NULOJIX.xml:S1:4050:5	O
3	NULOJIX.xml:S1:4056:1	O
treated	NULOJIX.xml:S1:4058:7	O
with	NULOJIX.xml:S1:4066:4	O
a	NULOJIX.xml:S1:4071:1	O
very	NULOJIX.xml:S1:4073:4	O
similar	NULOJIX.xml:S1:4078:7	O
(	NULOJIX.xml:S1:4086:1	O
but	NULOJIX.xml:S1:4087:3	O
non	NULOJIX.xml:S1:4091:3	O
-	NULOJIX.xml:S1:4094:1	O
identical	NULOJIX.xml:S1:4095:9	O
)	NULOJIX.xml:S1:4104:1	O
NULOJIX	NULOJIX.xml:S1:4106:7	O
regimen	NULOJIX.xml:S1:4114:7	O
,	NULOJIX.xml:S1:4121:1	O
there	NULOJIX.xml:S1:4123:5	O
were	NULOJIX.xml:S1:4129:4	O
5	NULOJIX.xml:S1:4134:1	O
cases	NULOJIX.xml:S1:4136:5	O
of	NULOJIX.xml:S1:4142:2	O
PTLD	NULOJIX.xml:S1:4145:4	B-AdverseReaction
:	NULOJIX.xml:S1:4149:1	O
3	NULOJIX.xml:S1:4151:1	O
in	NULOJIX.xml:S1:4153:2	O
EBV	NULOJIX.xml:S1:4156:3	O
seropositive	NULOJIX.xml:S1:4160:12	O
patients	NULOJIX.xml:S1:4173:8	O
and	NULOJIX.xml:S1:4182:3	O
2	NULOJIX.xml:S1:4186:1	O
in	NULOJIX.xml:S1:4188:2	O
EBV	NULOJIX.xml:S1:4191:3	O
seronegative	NULOJIX.xml:S1:4195:12	O
patients	NULOJIX.xml:S1:4208:8	O
.	NULOJIX.xml:S1:4216:1	O

Two	NULOJIX.xml:S1:4218:3	O
of	NULOJIX.xml:S1:4222:2	O
the	NULOJIX.xml:S1:4225:3	O
5	NULOJIX.xml:S1:4229:1	O
cases	NULOJIX.xml:S1:4231:5	O
presented	NULOJIX.xml:S1:4237:9	O
with	NULOJIX.xml:S1:4247:4	O
CNS	NULOJIX.xml:S1:4252:3	O
involvement	NULOJIX.xml:S1:4256:11	O
.	NULOJIX.xml:S1:4267:1	O

Among	NULOJIX.xml:S1:4273:5	O
the	NULOJIX.xml:S1:4279:3	O
477	NULOJIX.xml:S1:4283:3	O
patients	NULOJIX.xml:S1:4287:8	O
in	NULOJIX.xml:S1:4296:2	O
Studies	NULOJIX.xml:S1:4299:7	O
1	NULOJIX.xml:S1:4307:1	O
,	NULOJIX.xml:S1:4308:1	O
2	NULOJIX.xml:S1:4310:1	O
,	NULOJIX.xml:S1:4311:1	O
and	NULOJIX.xml:S1:4313:3	O
3	NULOJIX.xml:S1:4317:1	O
treated	NULOJIX.xml:S1:4319:7	O
with	NULOJIX.xml:S1:4327:4	O
the	NULOJIX.xml:S1:4332:3	O
NULOJIX	NULOJIX.xml:S1:4336:7	O
regimen	NULOJIX.xml:S1:4344:7	O
of	NULOJIX.xml:S1:4352:2	O
higher	NULOJIX.xml:S1:4355:6	O
cumulative	NULOJIX.xml:S1:4362:10	O
dose	NULOJIX.xml:S1:4373:4	O
and	NULOJIX.xml:S1:4378:3	O
more	NULOJIX.xml:S1:4382:4	O
frequent	NULOJIX.xml:S1:4387:8	O
dosing	NULOJIX.xml:S1:4396:6	O
than	NULOJIX.xml:S1:4403:4	O
recommended	NULOJIX.xml:S1:4408:11	O
,	NULOJIX.xml:S1:4419:1	O
there	NULOJIX.xml:S1:4421:5	O
were	NULOJIX.xml:S1:4427:4	O
8	NULOJIX.xml:S1:4432:1	O
cases	NULOJIX.xml:S1:4434:5	O
of	NULOJIX.xml:S1:4440:2	O
PTLD	NULOJIX.xml:S1:4443:4	B-AdverseReaction
:	NULOJIX.xml:S1:4447:1	O
2	NULOJIX.xml:S1:4449:1	O
in	NULOJIX.xml:S1:4451:2	O
EBV	NULOJIX.xml:S1:4454:3	O
seropositive	NULOJIX.xml:S1:4458:12	O
patients	NULOJIX.xml:S1:4471:8	O
and	NULOJIX.xml:S1:4480:3	O
6	NULOJIX.xml:S1:4484:1	O
in	NULOJIX.xml:S1:4486:2	O
EBV	NULOJIX.xml:S1:4489:3	O
seronegative	NULOJIX.xml:S1:4493:12	O
or	NULOJIX.xml:S1:4506:2	O
serostatus	NULOJIX.xml:S1:4509:10	O
unknown	NULOJIX.xml:S1:4520:7	O
patients	NULOJIX.xml:S1:4528:8	O
.	NULOJIX.xml:S1:4536:1	O

Six	NULOJIX.xml:S1:4538:3	O
of	NULOJIX.xml:S1:4542:2	O
the	NULOJIX.xml:S1:4545:3	O
8	NULOJIX.xml:S1:4549:1	O
cases	NULOJIX.xml:S1:4551:5	O
presented	NULOJIX.xml:S1:4557:9	O
with	NULOJIX.xml:S1:4567:4	O
CNS	NULOJIX.xml:S1:4572:3	O
involvement	NULOJIX.xml:S1:4576:11	O
.	NULOJIX.xml:S1:4587:1	O

Therefore	NULOJIX.xml:S1:4589:9	O
,	NULOJIX.xml:S1:4598:1	O
administration	NULOJIX.xml:S1:4600:14	O
of	NULOJIX.xml:S1:4615:2	O
higher	NULOJIX.xml:S1:4618:6	O
than	NULOJIX.xml:S1:4625:4	O
the	NULOJIX.xml:S1:4630:3	O
recommended	NULOJIX.xml:S1:4634:11	O
doses	NULOJIX.xml:S1:4646:5	O
or	NULOJIX.xml:S1:4652:2	O
more	NULOJIX.xml:S1:4655:4	O
frequent	NULOJIX.xml:S1:4660:8	O
dosing	NULOJIX.xml:S1:4669:6	O
of	NULOJIX.xml:S1:4676:2	O
NULOJIX	NULOJIX.xml:S1:4679:7	O
is	NULOJIX.xml:S1:4687:2	O
not	NULOJIX.xml:S1:4690:3	O
recommended	NULOJIX.xml:S1:4694:11	O
.	NULOJIX.xml:S1:4705:1	O

[	NULOJIX.xml:S1:4707:1	O
See	NULOJIX.xml:S1:4708:3	O
Dosage	NULOJIX.xml:S1:4715:6	O
and	NULOJIX.xml:S1:4722:3	O
Administration	NULOJIX.xml:S1:4726:14	O
(	NULOJIX.xml:S1:4741:1	O
2.1	NULOJIX.xml:S1:4742:3	O
)	NULOJIX.xml:S1:4745:1	O
and	NULOJIX.xml:S1:4750:3	O
Warnings	NULOJIX.xml:S1:4757:8	O
and	NULOJIX.xml:S1:4766:3	O
Precautions	NULOJIX.xml:S1:4770:11	O
(	NULOJIX.xml:S1:4782:1	O
5.1	NULOJIX.xml:S1:4783:3	O
)	NULOJIX.xml:S1:4786:1	O
.	NULOJIX.xml:S1:4791:1	O
]	NULOJIX.xml:S1:4792:1	O

One	NULOJIX.xml:S1:4798:3	O
of	NULOJIX.xml:S1:4802:2	O
the	NULOJIX.xml:S1:4805:3	O
476	NULOJIX.xml:S1:4809:3	O
patients	NULOJIX.xml:S1:4813:8	O
treated	NULOJIX.xml:S1:4822:7	O
with	NULOJIX.xml:S1:4830:4	O
cyclosporine	NULOJIX.xml:S1:4835:12	O
developed	NULOJIX.xml:S1:4848:9	O
PTLD	NULOJIX.xml:S1:4858:4	B-AdverseReaction
,	NULOJIX.xml:S1:4862:1	O
without	NULOJIX.xml:S1:4864:7	O
CNS	NULOJIX.xml:S1:4872:3	O
involvement	NULOJIX.xml:S1:4876:11	O
.	NULOJIX.xml:S1:4887:1	O

All	NULOJIX.xml:S1:4893:3	O
cases	NULOJIX.xml:S1:4897:5	O
of	NULOJIX.xml:S1:4903:2	O
PTLD	NULOJIX.xml:S1:4906:4	B-AdverseReaction
reported	NULOJIX.xml:S1:4911:8	O
up	NULOJIX.xml:S1:4920:2	O
to	NULOJIX.xml:S1:4923:2	O
36	NULOJIX.xml:S1:4926:2	O
months	NULOJIX.xml:S1:4929:6	O
post	NULOJIX.xml:S1:4936:4	O
transplant	NULOJIX.xml:S1:4941:10	O
in	NULOJIX.xml:S1:4952:2	O
NULOJIX	NULOJIX.xml:S1:4955:7	O
-	NULOJIX.xml:S1:4962:1	O
or	NULOJIX.xml:S1:4964:2	O
cyclosporine	NULOJIX.xml:S1:4967:12	O
-	NULOJIX.xml:S1:4979:1	O
treated	NULOJIX.xml:S1:4980:7	O
patients	NULOJIX.xml:S1:4988:8	O
presented	NULOJIX.xml:S1:4997:9	O
within	NULOJIX.xml:S1:5007:6	O
18	NULOJIX.xml:S1:5014:2	O
months	NULOJIX.xml:S1:5017:6	O
of	NULOJIX.xml:S1:5024:2	O
transplantation	NULOJIX.xml:S1:5027:15	O
.	NULOJIX.xml:S1:5042:1	O

Overall	NULOJIX.xml:S1:5048:7	O
,	NULOJIX.xml:S1:5055:1	O
the	NULOJIX.xml:S1:5057:3	O
rate	NULOJIX.xml:S1:5061:4	O
of	NULOJIX.xml:S1:5066:2	O
PTLD	NULOJIX.xml:S1:5069:4	B-AdverseReaction
in	NULOJIX.xml:S1:5074:2	O
949	NULOJIX.xml:S1:5077:3	O
patients	NULOJIX.xml:S1:5081:8	O
treated	NULOJIX.xml:S1:5090:7	O
with	NULOJIX.xml:S1:5098:4	O
any	NULOJIX.xml:S1:5103:3	O
of	NULOJIX.xml:S1:5107:2	O
the	NULOJIX.xml:S1:5110:3	O
NULOJIX	NULOJIX.xml:S1:5114:7	O
regimens	NULOJIX.xml:S1:5122:8	O
was	NULOJIX.xml:S1:5131:3	O
9	NULOJIX.xml:S1:5135:1	O
-	NULOJIX.xml:S1:5136:1	O
fold	NULOJIX.xml:S1:5137:4	O
higher	NULOJIX.xml:S1:5142:6	O
in	NULOJIX.xml:S1:5149:2	O
those	NULOJIX.xml:S1:5152:5	O
who	NULOJIX.xml:S1:5158:3	O
were	NULOJIX.xml:S1:5162:4	O
EBV	NULOJIX.xml:S1:5167:3	O
seronegative	NULOJIX.xml:S1:5171:12	O
or	NULOJIX.xml:S1:5184:2	O
EBV	NULOJIX.xml:S1:5187:3	O
serostatus	NULOJIX.xml:S1:5191:10	O
unknown	NULOJIX.xml:S1:5202:7	O
(	NULOJIX.xml:S1:5210:1	O
8	NULOJIX.xml:S1:5211:1	O
139	NULOJIX.xml:S1:5213:3	O
)	NULOJIX.xml:S1:5216:1	O
compared	NULOJIX.xml:S1:5218:8	O
to	NULOJIX.xml:S1:5227:2	O
those	NULOJIX.xml:S1:5230:5	O
who	NULOJIX.xml:S1:5236:3	O
were	NULOJIX.xml:S1:5240:4	O
EBV	NULOJIX.xml:S1:5245:3	O
seropositive	NULOJIX.xml:S1:5249:12	O
(	NULOJIX.xml:S1:5262:1	O
5	NULOJIX.xml:S1:5263:1	O
810	NULOJIX.xml:S1:5265:3	O
patients	NULOJIX.xml:S1:5269:8	O
)	NULOJIX.xml:S1:5277:1	O
.	NULOJIX.xml:S1:5278:1	O

Therefore	NULOJIX.xml:S1:5280:9	O
NULOJIX	NULOJIX.xml:S1:5290:7	O
is	NULOJIX.xml:S1:5298:2	O
recommended	NULOJIX.xml:S1:5301:11	O
for	NULOJIX.xml:S1:5313:3	O
use	NULOJIX.xml:S1:5317:3	O
only	NULOJIX.xml:S1:5321:4	O
in	NULOJIX.xml:S1:5326:2	O
patients	NULOJIX.xml:S1:5329:8	O
who	NULOJIX.xml:S1:5338:3	O
are	NULOJIX.xml:S1:5342:3	O
EBV	NULOJIX.xml:S1:5346:3	O
seropositive	NULOJIX.xml:S1:5350:12	O
[	NULOJIX.xml:S1:5363:1	O
see	NULOJIX.xml:S1:5364:3	O
Boxed	NULOJIX.xml:S1:5371:5	O
Warning	NULOJIX.xml:S1:5377:7	O
and	NULOJIX.xml:S1:5388:3	O
Contraindications	NULOJIX.xml:S1:5395:17	O
(	NULOJIX.xml:S1:5413:1	O
4	NULOJIX.xml:S1:5414:1	O
)	NULOJIX.xml:S1:5415:1	O
]	NULOJIX.xml:S1:5420:1	O
.	NULOJIX.xml:S1:5421:1	O

Table	NULOJIX.xml:S1:5427:5	O
2	NULOJIX.xml:S1:5433:1	O
:	NULOJIX.xml:S1:5434:1	O
Summary	NULOJIX.xml:S1:5436:7	O
of	NULOJIX.xml:S1:5444:2	O
PTLD	NULOJIX.xml:S1:5447:4	B-AdverseReaction
Reported	NULOJIX.xml:S1:5452:8	O
in	NULOJIX.xml:S1:5461:2	O
Studies	NULOJIX.xml:S1:5464:7	O
1	NULOJIX.xml:S1:5472:1	O
,	NULOJIX.xml:S1:5473:1	O
2	NULOJIX.xml:S1:5475:1	O
,	NULOJIX.xml:S1:5476:1	O
and	NULOJIX.xml:S1:5478:3	O
3	NULOJIX.xml:S1:5482:1	O
Through	NULOJIX.xml:S1:5484:7	O
Three	NULOJIX.xml:S1:5492:5	O
Years	NULOJIX.xml:S1:5498:5	O
of	NULOJIX.xml:S1:5504:2	O
Treatment	NULOJIX.xml:S1:5507:9	O

NULOJIX	NULOJIX.xml:S1:5538:7	O
Non	NULOJIX.xml:S1:5549:3	O
-	NULOJIX.xml:S1:5552:1	O
Recommended	NULOJIX.xml:S1:5553:11	O
Regimen	NULOJIX.xml:S1:5568:7	O
(	NULOJIX.xml:S1:5580:1	O
N	NULOJIX.xml:S1:5581:1	O
477	NULOJIX.xml:S1:5583:3	O
)	NULOJIX.xml:S1:5586:1	O
NULOJIX	NULOJIX.xml:S1:5593:7	O
Recommended	NULOJIX.xml:S1:5604:11	O
Regimen	NULOJIX.xml:S1:5619:7	O
(	NULOJIX.xml:S1:5634:1	O
N	NULOJIX.xml:S1:5635:1	O
472	NULOJIX.xml:S1:5637:3	O
)	NULOJIX.xml:S1:5640:1	O
Cyclosporine	NULOJIX.xml:S1:5647:12	O
(	NULOJIX.xml:S1:5663:1	O
N	NULOJIX.xml:S1:5664:1	O
476	NULOJIX.xml:S1:5666:3	O
)	NULOJIX.xml:S1:5669:1	O

Trial	NULOJIX.xml:S1:5679:5	O
EBV	NULOJIX.xml:S1:5696:3	O
Positive	NULOJIX.xml:S1:5703:8	O
(	NULOJIX.xml:S1:5715:1	O
n	NULOJIX.xml:S1:5716:1	O
406	NULOJIX.xml:S1:5718:3	O
)	NULOJIX.xml:S1:5721:1	O
EBV	NULOJIX.xml:S1:5728:3	O
Negative	NULOJIX.xml:S1:5735:8	O
(	NULOJIX.xml:S1:5747:1	O
n	NULOJIX.xml:S1:5748:1	O
43	NULOJIX.xml:S1:5750:2	O
)	NULOJIX.xml:S1:5752:1	O
EBV	NULOJIX.xml:S1:5759:3	O
Unknown	NULOJIX.xml:S1:5766:7	O
(	NULOJIX.xml:S1:5777:1	O
n	NULOJIX.xml:S1:5778:1	O
28	NULOJIX.xml:S1:5780:2	O
)	NULOJIX.xml:S1:5782:1	O
EBV	NULOJIX.xml:S1:5789:3	O
Positive	NULOJIX.xml:S1:5796:8	O
(	NULOJIX.xml:S1:5808:1	O
n	NULOJIX.xml:S1:5809:1	O
404	NULOJIX.xml:S1:5811:3	O
)	NULOJIX.xml:S1:5814:1	O
EBV	NULOJIX.xml:S1:5821:3	O
Negative	NULOJIX.xml:S1:5828:8	O
(	NULOJIX.xml:S1:5840:1	O
n	NULOJIX.xml:S1:5841:1	O
48	NULOJIX.xml:S1:5843:2	O
)	NULOJIX.xml:S1:5845:1	O
EBV	NULOJIX.xml:S1:5852:3	O
Unknown	NULOJIX.xml:S1:5859:7	O
(	NULOJIX.xml:S1:5870:1	O
n	NULOJIX.xml:S1:5871:1	O
20	NULOJIX.xml:S1:5873:2	O
)	NULOJIX.xml:S1:5875:1	O
EBV	NULOJIX.xml:S1:5882:3	O
Positive	NULOJIX.xml:S1:5889:8	O
(	NULOJIX.xml:S1:5901:1	O
n	NULOJIX.xml:S1:5902:1	O
399	NULOJIX.xml:S1:5904:3	O
)	NULOJIX.xml:S1:5907:1	O
EBV	NULOJIX.xml:S1:5914:3	O
Negative	NULOJIX.xml:S1:5921:8	O
(	NULOJIX.xml:S1:5933:1	O
n	NULOJIX.xml:S1:5934:1	O
57	NULOJIX.xml:S1:5936:2	O
)	NULOJIX.xml:S1:5938:1	O
EBV	NULOJIX.xml:S1:5945:3	O
Unknown	NULOJIX.xml:S1:5952:7	O
(	NULOJIX.xml:S1:5963:1	O
n	NULOJIX.xml:S1:5964:1	O
20	NULOJIX.xml:S1:5966:2	O
)	NULOJIX.xml:S1:5968:1	O

Regimen	NULOJIX.xml:S1:5982:7	O

with	NULOJIX.xml:S1:5990:4	O
higher	NULOJIX.xml:S1:5995:6	O
cumulative	NULOJIX.xml:S1:6002:10	O
dose	NULOJIX.xml:S1:6013:4	O
and	NULOJIX.xml:S1:6018:3	O
more	NULOJIX.xml:S1:6022:4	O
frequent	NULOJIX.xml:S1:6027:8	O
dosing	NULOJIX.xml:S1:6036:6	O
than	NULOJIX.xml:S1:6043:4	O
the	NULOJIX.xml:S1:6048:3	O
recommended	NULOJIX.xml:S1:6052:11	O
NULOJIX	NULOJIX.xml:S1:6064:7	O
regimen	NULOJIX.xml:S1:6072:7	O
.	NULOJIX.xml:S1:6079:1	O

In	NULOJIX.xml:S1:6086:2	O
Studies	NULOJIX.xml:S1:6089:7	O
1	NULOJIX.xml:S1:6097:1	O
and	NULOJIX.xml:S1:6099:3	O
2	NULOJIX.xml:S1:6103:1	O
the	NULOJIX.xml:S1:6105:3	O
NULOJIX	NULOJIX.xml:S1:6109:7	O
regimen	NULOJIX.xml:S1:6117:7	O
is	NULOJIX.xml:S1:6125:2	O
identical	NULOJIX.xml:S1:6128:9	O
to	NULOJIX.xml:S1:6138:2	O
the	NULOJIX.xml:S1:6141:3	O
recommended	NULOJIX.xml:S1:6145:11	O
regimen	NULOJIX.xml:S1:6157:7	O
,	NULOJIX.xml:S1:6164:1	O
but	NULOJIX.xml:S1:6166:3	O
is	NULOJIX.xml:S1:6170:2	O
slightly	NULOJIX.xml:S1:6173:8	O
different	NULOJIX.xml:S1:6182:9	O
in	NULOJIX.xml:S1:6192:2	O
Study	NULOJIX.xml:S1:6195:5	O
3	NULOJIX.xml:S1:6201:1	O
.	NULOJIX.xml:S1:6202:1	O

Study	NULOJIX.xml:S1:6212:5	O

1	NULOJIX.xml:S1:6218:1	O

CNS	NULOJIX.xml:S1:6232:3	B-AdverseReaction
PTLD	NULOJIX.xml:S1:6236:4	I-AdverseReaction
1	NULOJIX.xml:S1:6249:1	O
1	NULOJIX.xml:S1:6261:1	O

Non	NULOJIX.xml:S1:6355:3	B-AdverseReaction
-	NULOJIX.xml:S1:6358:1	I-AdverseReaction
CNSPTLD	NULOJIX.xml:S1:6359:7	I-AdverseReaction
1	NULOJIX.xml:S1:6384:1	O
2	NULOJIX.xml:S1:6407:1	O
1	NULOJIX.xml:S1:6453:1	O

Study	NULOJIX.xml:S1:6478:5	O
2	NULOJIX.xml:S1:6484:1	O

CNS	NULOJIX.xml:S1:6498:3	B-AdverseReaction
PTLD	NULOJIX.xml:S1:6502:4	I-AdverseReaction
1	NULOJIX.xml:S1:6515:1	O
1	NULOJIX.xml:S1:6527:1	O
1	NULOJIX.xml:S1:6550:1	O
1	NULOJIX.xml:S1:6562:1	O

Non	NULOJIX.xml:S1:6621:3	B-AdverseReaction
-	NULOJIX.xml:S1:6624:1	I-AdverseReaction
CNSPTLD	NULOJIX.xml:S1:6625:7	I-AdverseReaction
1	NULOJIX.xml:S1:6685:1	O

Study	NULOJIX.xml:S1:6744:5	O
3	NULOJIX.xml:S1:6750:1	O

CNS	NULOJIX.xml:S1:6764:3	B-AdverseReaction
PTLD	NULOJIX.xml:S1:6768:4	I-AdverseReaction
2	NULOJIX.xml:S1:6793:1	O

Non	NULOJIX.xml:S1:6887:3	B-AdverseReaction
-	NULOJIX.xml:S1:6890:1	I-AdverseReaction
CNSPTLD	NULOJIX.xml:S1:6891:7	I-AdverseReaction
1	NULOJIX.xml:S1:6927:1	O

Total	NULOJIX.xml:S1:7010:5	O
(	NULOJIX.xml:S1:7016:1	O
)	NULOJIX.xml:S1:7018:1	O
2	NULOJIX.xml:S1:7027:1	O
(	NULOJIX.xml:S1:7029:1	O
0.5	NULOJIX.xml:S1:7030:3	O
)	NULOJIX.xml:S1:7033:1	O
5	NULOJIX.xml:S1:7039:1	O
(	NULOJIX.xml:S1:7041:1	O
11.6	NULOJIX.xml:S1:7042:4	O
)	NULOJIX.xml:S1:7046:1	O
1	NULOJIX.xml:S1:7051:1	O
(	NULOJIX.xml:S1:7053:1	O
3.6	NULOJIX.xml:S1:7054:3	O
)	NULOJIX.xml:S1:7057:1	O
3	NULOJIX.xml:S1:7063:1	O
(	NULOJIX.xml:S1:7065:1	O
0.7	NULOJIX.xml:S1:7066:3	O
)	NULOJIX.xml:S1:7069:1	O
2	NULOJIX.xml:S1:7075:1	O
(	NULOJIX.xml:S1:7077:1	O
4.1	NULOJIX.xml:S1:7078:3	O
)	NULOJIX.xml:S1:7081:1	O
0	NULOJIX.xml:S1:7086:1	O
0	NULOJIX.xml:S1:7098:1	O
1	NULOJIX.xml:S1:7110:1	O
(	NULOJIX.xml:S1:7112:1	O
1.8	NULOJIX.xml:S1:7113:3	O
)	NULOJIX.xml:S1:7116:1	O
0	NULOJIX.xml:S1:7121:1	O

EBV	NULOJIX.xml:S1:7152:3	O
Seropositive	NULOJIX.xml:S1:7156:12	O
Subpopulation	NULOJIX.xml:S1:7169:13	O

Among	NULOJIX.xml:S1:7186:5	O
the	NULOJIX.xml:S1:7192:3	O
806	NULOJIX.xml:S1:7196:3	O
EBV	NULOJIX.xml:S1:7200:3	O
seropositive	NULOJIX.xml:S1:7204:12	O
patients	NULOJIX.xml:S1:7217:8	O
with	NULOJIX.xml:S1:7226:4	O
known	NULOJIX.xml:S1:7231:5	O
CMV	NULOJIX.xml:S1:7237:3	O
serostatus	NULOJIX.xml:S1:7241:10	O
treated	NULOJIX.xml:S1:7252:7	O
with	NULOJIX.xml:S1:7260:4	O
either	NULOJIX.xml:S1:7265:6	O
NULOJIX	NULOJIX.xml:S1:7272:7	O
regimen	NULOJIX.xml:S1:7280:7	O
in	NULOJIX.xml:S1:7288:2	O
Studies	NULOJIX.xml:S1:7291:7	O
1	NULOJIX.xml:S1:7299:1	O
,	NULOJIX.xml:S1:7300:1	O
2	NULOJIX.xml:S1:7302:1	O
,	NULOJIX.xml:S1:7303:1	O
and	NULOJIX.xml:S1:7305:3	O
3	NULOJIX.xml:S1:7309:1	O
,	NULOJIX.xml:S1:7310:1	O
two	NULOJIX.xml:S1:7312:3	O
percent	NULOJIX.xml:S1:7316:7	O
(	NULOJIX.xml:S1:7324:1	O
2%	NULOJIX.xml:S1:7325:2	O
;	NULOJIX.xml:S1:7327:1	O
4	NULOJIX.xml:S1:7329:1	O
210	NULOJIX.xml:S1:7331:3	O
)	NULOJIX.xml:S1:7334:1	O
of	NULOJIX.xml:S1:7336:2	O
CMV	NULOJIX.xml:S1:7339:3	O
seronegative	NULOJIX.xml:S1:7343:12	O
patients	NULOJIX.xml:S1:7356:8	O
developed	NULOJIX.xml:S1:7365:9	O
PTLD	NULOJIX.xml:S1:7375:4	B-AdverseReaction
compared	NULOJIX.xml:S1:7380:8	O
to	NULOJIX.xml:S1:7389:2	O
0.2%	NULOJIX.xml:S1:7392:4	O
(	NULOJIX.xml:S1:7397:1	O
1	NULOJIX.xml:S1:7398:1	O
596	NULOJIX.xml:S1:7400:3	O
)	NULOJIX.xml:S1:7403:1	O
of	NULOJIX.xml:S1:7405:2	O
CMV	NULOJIX.xml:S1:7408:3	O
seropositive	NULOJIX.xml:S1:7412:12	O
patients	NULOJIX.xml:S1:7425:8	O
.	NULOJIX.xml:S1:7433:1	O

Among	NULOJIX.xml:S1:7435:5	O
the	NULOJIX.xml:S1:7441:3	O
404	NULOJIX.xml:S1:7445:3	O
EBV	NULOJIX.xml:S1:7449:3	O
seropositive	NULOJIX.xml:S1:7453:12	O
recipients	NULOJIX.xml:S1:7466:10	O
treated	NULOJIX.xml:S1:7477:7	O
with	NULOJIX.xml:S1:7485:4	O
the	NULOJIX.xml:S1:7490:3	O
recommended	NULOJIX.xml:S1:7494:11	O
dosage	NULOJIX.xml:S1:7506:6	O
regimen	NULOJIX.xml:S1:7513:7	O
of	NULOJIX.xml:S1:7521:2	O
NULOJIX	NULOJIX.xml:S1:7524:7	O
,	NULOJIX.xml:S1:7531:1	O
three	NULOJIX.xml:S1:7533:5	O
PTLD	NULOJIX.xml:S1:7539:4	B-AdverseReaction
cases	NULOJIX.xml:S1:7544:5	O
were	NULOJIX.xml:S1:7550:4	O
detected	NULOJIX.xml:S1:7555:8	O
among	NULOJIX.xml:S1:7564:5	O
99	NULOJIX.xml:S1:7570:2	O
CMV	NULOJIX.xml:S1:7573:3	O
seronegative	NULOJIX.xml:S1:7577:12	O
patients	NULOJIX.xml:S1:7590:8	O
(	NULOJIX.xml:S1:7599:1	O
3%	NULOJIX.xml:S1:7600:2	O
)	NULOJIX.xml:S1:7602:1	O
and	NULOJIX.xml:S1:7604:3	O
there	NULOJIX.xml:S1:7608:5	O
was	NULOJIX.xml:S1:7614:3	O
no	NULOJIX.xml:S1:7618:2	O
case	NULOJIX.xml:S1:7621:4	O
detected	NULOJIX.xml:S1:7626:8	O
among	NULOJIX.xml:S1:7635:5	O
303	NULOJIX.xml:S1:7641:3	O
CMV	NULOJIX.xml:S1:7645:3	O
seropositive	NULOJIX.xml:S1:7649:12	O
patients	NULOJIX.xml:S1:7662:8	O
.	NULOJIX.xml:S1:7670:1	O

The	NULOJIX.xml:S1:7672:3	O
clinical	NULOJIX.xml:S1:7676:8	O
significance	NULOJIX.xml:S1:7685:12	O
of	NULOJIX.xml:S1:7698:2	O
CMV	NULOJIX.xml:S1:7701:3	O
serology	NULOJIX.xml:S1:7705:8	O
as	NULOJIX.xml:S1:7714:2	O
a	NULOJIX.xml:S1:7717:1	O
risk	NULOJIX.xml:S1:7719:4	O
factor	NULOJIX.xml:S1:7724:6	O
for	NULOJIX.xml:S1:7731:3	O
PTLD	NULOJIX.xml:S1:7735:4	B-AdverseReaction
remains	NULOJIX.xml:S1:7740:7	O
to	NULOJIX.xml:S1:7748:2	O
be	NULOJIX.xml:S1:7751:2	O
determined	NULOJIX.xml:S1:7754:10	O
;	NULOJIX.xml:S1:7764:1	O
however	NULOJIX.xml:S1:7766:7	O
,	NULOJIX.xml:S1:7773:1	O
these	NULOJIX.xml:S1:7775:5	O
findings	NULOJIX.xml:S1:7781:8	O
should	NULOJIX.xml:S1:7790:6	O
be	NULOJIX.xml:S1:7797:2	O
considered	NULOJIX.xml:S1:7800:10	O
when	NULOJIX.xml:S1:7811:4	O
prescribing	NULOJIX.xml:S1:7816:11	O
NULOJIX	NULOJIX.xml:S1:7828:7	O
[	NULOJIX.xml:S1:7836:1	O
see	NULOJIX.xml:S1:7837:3	O
Warnings	NULOJIX.xml:S1:7844:8	O
and	NULOJIX.xml:S1:7853:3	O
Precautions	NULOJIX.xml:S1:7857:11	O
(	NULOJIX.xml:S1:7869:1	O
5.1	NULOJIX.xml:S1:7870:3	O
)	NULOJIX.xml:S1:7873:1	O
]	NULOJIX.xml:S1:7878:1	O
.	NULOJIX.xml:S1:7879:1	O

Other	NULOJIX.xml:S1:7887:5	O
Malignancies	NULOJIX.xml:S1:7893:12	O

Malignancies	NULOJIX.xml:S1:7909:12	B-AdverseReaction
,	NULOJIX.xml:S1:7921:1	O
excluding	NULOJIX.xml:S1:7923:9	B-Negation
non	NULOJIX.xml:S1:7933:3	B-AdverseReaction
-	NULOJIX.xml:S1:7936:1	I-AdverseReaction
melanoma	NULOJIX.xml:S1:7937:8	I-AdverseReaction
skin	NULOJIX.xml:S1:7946:4	I-AdverseReaction
cancer	NULOJIX.xml:S1:7951:6	I-AdverseReaction
and	NULOJIX.xml:S1:7958:3	O
PTLD	NULOJIX.xml:S1:7962:4	B-AdverseReaction
,	NULOJIX.xml:S1:7966:1	O
were	NULOJIX.xml:S1:7968:4	O
reported	NULOJIX.xml:S1:7973:8	O
in	NULOJIX.xml:S1:7982:2	O
Study	NULOJIX.xml:S1:7985:5	O
1	NULOJIX.xml:S1:7991:1	O
and	NULOJIX.xml:S1:7993:3	O
Study	NULOJIX.xml:S1:7997:5	O
2	NULOJIX.xml:S1:8003:1	O
in	NULOJIX.xml:S1:8005:2	O
3.5%	NULOJIX.xml:S1:8008:4	O
(	NULOJIX.xml:S1:8013:1	O
14	NULOJIX.xml:S1:8014:2	O
401	NULOJIX.xml:S1:8017:3	O
)	NULOJIX.xml:S1:8020:1	O
of	NULOJIX.xml:S1:8022:2	O
patients	NULOJIX.xml:S1:8025:8	O
treated	NULOJIX.xml:S1:8034:7	O
with	NULOJIX.xml:S1:8042:4	O
the	NULOJIX.xml:S1:8047:3	O
recommended	NULOJIX.xml:S1:8051:11	O
NULOJIX	NULOJIX.xml:S1:8063:7	O
regimen	NULOJIX.xml:S1:8071:7	O
and	NULOJIX.xml:S1:8079:3	O
3.7%	NULOJIX.xml:S1:8083:4	O
(	NULOJIX.xml:S1:8088:1	O
15	NULOJIX.xml:S1:8089:2	O
405	NULOJIX.xml:S1:8092:3	O
)	NULOJIX.xml:S1:8095:1	O
of	NULOJIX.xml:S1:8097:2	O
patients	NULOJIX.xml:S1:8100:8	O
treated	NULOJIX.xml:S1:8109:7	O
with	NULOJIX.xml:S1:8117:4	O
the	NULOJIX.xml:S1:8122:3	O
cyclosporine	NULOJIX.xml:S1:8126:12	O
control	NULOJIX.xml:S1:8139:7	O
regimen	NULOJIX.xml:S1:8147:7	O
.	NULOJIX.xml:S1:8154:1	O

Non	NULOJIX.xml:S1:8156:3	B-AdverseReaction
-	NULOJIX.xml:S1:8159:1	I-AdverseReaction
melanoma	NULOJIX.xml:S1:8160:8	I-AdverseReaction
skin	NULOJIX.xml:S1:8169:4	I-AdverseReaction
cancer	NULOJIX.xml:S1:8174:6	I-AdverseReaction
was	NULOJIX.xml:S1:8181:3	O
reported	NULOJIX.xml:S1:8185:8	O
in	NULOJIX.xml:S1:8194:2	O
1.5%	NULOJIX.xml:S1:8197:4	O
(	NULOJIX.xml:S1:8202:1	O
6	NULOJIX.xml:S1:8203:1	O
401	NULOJIX.xml:S1:8205:3	O
)	NULOJIX.xml:S1:8208:1	O
of	NULOJIX.xml:S1:8210:2	O
patients	NULOJIX.xml:S1:8213:8	O
treated	NULOJIX.xml:S1:8222:7	O
with	NULOJIX.xml:S1:8230:4	O
the	NULOJIX.xml:S1:8235:3	O
recommended	NULOJIX.xml:S1:8239:11	O
NULOJIX	NULOJIX.xml:S1:8251:7	O
regimen	NULOJIX.xml:S1:8259:7	O
and	NULOJIX.xml:S1:8267:3	O
in	NULOJIX.xml:S1:8271:2	O
3.7%	NULOJIX.xml:S1:8274:4	O
(	NULOJIX.xml:S1:8279:1	O
15	NULOJIX.xml:S1:8280:2	O
405	NULOJIX.xml:S1:8283:3	O
)	NULOJIX.xml:S1:8286:1	O
of	NULOJIX.xml:S1:8288:2	O
patients	NULOJIX.xml:S1:8291:8	O
treated	NULOJIX.xml:S1:8300:7	O
with	NULOJIX.xml:S1:8308:4	O
cyclosporine	NULOJIX.xml:S1:8313:12	O
[	NULOJIX.xml:S1:8326:1	O
see	NULOJIX.xml:S1:8327:3	O
Warnings	NULOJIX.xml:S1:8334:8	O
and	NULOJIX.xml:S1:8343:3	O
Precautions	NULOJIX.xml:S1:8347:11	O
(	NULOJIX.xml:S1:8359:1	O
5.3	NULOJIX.xml:S1:8360:3	O
)	NULOJIX.xml:S1:8363:1	O
]	NULOJIX.xml:S1:8368:1	O
.	NULOJIX.xml:S1:8369:1	O

Progressive	NULOJIX.xml:S1:8377:11	O
Multifocal	NULOJIX.xml:S1:8389:10	O
Leukoencephalopathy	NULOJIX.xml:S1:8400:19	O

Two	NULOJIX.xml:S1:8423:3	O
fatal	NULOJIX.xml:S1:8427:5	B-AdverseReaction
cases	NULOJIX.xml:S1:8433:5	O
of	NULOJIX.xml:S1:8439:2	O
progressive	NULOJIX.xml:S1:8442:11	B-AdverseReaction
multifocal	NULOJIX.xml:S1:8454:10	I-AdverseReaction
leukoencephalopathy	NULOJIX.xml:S1:8465:19	I-AdverseReaction
(	NULOJIX.xml:S1:8485:1	O
PML	NULOJIX.xml:S1:8486:3	B-AdverseReaction
)	NULOJIX.xml:S1:8489:1	O
have	NULOJIX.xml:S1:8491:4	O
been	NULOJIX.xml:S1:8496:4	O
reported	NULOJIX.xml:S1:8501:8	O
among	NULOJIX.xml:S1:8510:5	O
1096	NULOJIX.xml:S1:8516:4	O
patients	NULOJIX.xml:S1:8521:8	O
treated	NULOJIX.xml:S1:8530:7	O
with	NULOJIX.xml:S1:8538:4	O
a	NULOJIX.xml:S1:8543:1	O
NULOJIX	NULOJIX.xml:S1:8545:7	O
-	NULOJIX.xml:S1:8552:1	O
containing	NULOJIX.xml:S1:8553:10	O
regimen	NULOJIX.xml:S1:8564:7	O
:	NULOJIX.xml:S1:8571:1	O
one	NULOJIX.xml:S1:8573:3	O
patient	NULOJIX.xml:S1:8577:7	O
in	NULOJIX.xml:S1:8585:2	O
clinical	NULOJIX.xml:S1:8588:8	O
trials	NULOJIX.xml:S1:8597:6	O
of	NULOJIX.xml:S1:8604:2	O
kidney	NULOJIX.xml:S1:8607:6	O
transplant	NULOJIX.xml:S1:8614:10	O
(	NULOJIX.xml:S1:8625:1	O
Studies	NULOJIX.xml:S1:8626:7	O
1	NULOJIX.xml:S1:8634:1	O
,	NULOJIX.xml:S1:8635:1	O
2	NULOJIX.xml:S1:8637:1	O
,	NULOJIX.xml:S1:8638:1	O
and	NULOJIX.xml:S1:8640:3	O
3	NULOJIX.xml:S1:8644:1	O
described	NULOJIX.xml:S1:8646:9	O
above	NULOJIX.xml:S1:8656:5	O
)	NULOJIX.xml:S1:8661:1	O
and	NULOJIX.xml:S1:8663:3	O
one	NULOJIX.xml:S1:8667:3	O
patient	NULOJIX.xml:S1:8671:7	O
in	NULOJIX.xml:S1:8679:2	O
a	NULOJIX.xml:S1:8682:1	O
trial	NULOJIX.xml:S1:8684:5	O
of	NULOJIX.xml:S1:8690:2	O
liver	NULOJIX.xml:S1:8693:5	O
transplant	NULOJIX.xml:S1:8699:10	O
(	NULOJIX.xml:S1:8710:1	O
trial	NULOJIX.xml:S1:8711:5	O
of	NULOJIX.xml:S1:8717:2	O
250	NULOJIX.xml:S1:8720:3	O
patients	NULOJIX.xml:S1:8724:8	O
)	NULOJIX.xml:S1:8732:1	O
.	NULOJIX.xml:S1:8733:1	O

No	NULOJIX.xml:S1:8735:2	B-Negation
cases	NULOJIX.xml:S1:8738:5	O
of	NULOJIX.xml:S1:8744:2	O
PML	NULOJIX.xml:S1:8747:3	B-AdverseReaction
were	NULOJIX.xml:S1:8751:4	O
reported	NULOJIX.xml:S1:8756:8	O
in	NULOJIX.xml:S1:8765:2	O
patients	NULOJIX.xml:S1:8768:8	O
treated	NULOJIX.xml:S1:8777:7	O
with	NULOJIX.xml:S1:8785:4	O
the	NULOJIX.xml:S1:8790:3	O
recommended	NULOJIX.xml:S1:8794:11	O
NULOJIX	NULOJIX.xml:S1:8806:7	O
regimen	NULOJIX.xml:S1:8814:7	O
or	NULOJIX.xml:S1:8822:2	O
the	NULOJIX.xml:S1:8825:3	O
control	NULOJIX.xml:S1:8829:7	O
regimen	NULOJIX.xml:S1:8837:7	O
in	NULOJIX.xml:S1:8845:2	O
these	NULOJIX.xml:S1:8848:5	O
trials	NULOJIX.xml:S1:8854:6	O
.	NULOJIX.xml:S1:8860:1	O

The	NULOJIX.xml:S1:8866:3	O
kidney	NULOJIX.xml:S1:8870:6	O
transplant	NULOJIX.xml:S1:8877:10	O
recipient	NULOJIX.xml:S1:8888:9	O
was	NULOJIX.xml:S1:8898:3	O
treated	NULOJIX.xml:S1:8902:7	O
with	NULOJIX.xml:S1:8910:4	O
the	NULOJIX.xml:S1:8915:3	O
NULOJIX	NULOJIX.xml:S1:8919:7	O
regimen	NULOJIX.xml:S1:8927:7	O
of	NULOJIX.xml:S1:8935:2	O
higher	NULOJIX.xml:S1:8938:6	O
cumulative	NULOJIX.xml:S1:8945:10	O
dose	NULOJIX.xml:S1:8956:4	O
and	NULOJIX.xml:S1:8961:3	O
more	NULOJIX.xml:S1:8965:4	O
frequent	NULOJIX.xml:S1:8970:8	O
dosing	NULOJIX.xml:S1:8979:6	O
than	NULOJIX.xml:S1:8986:4	O
recommended	NULOJIX.xml:S1:8991:11	O
,	NULOJIX.xml:S1:9002:1	O
mycophenolate	NULOJIX.xml:S1:9004:13	O
mofetil	NULOJIX.xml:S1:9018:7	O
(	NULOJIX.xml:S1:9026:1	O
MMF	NULOJIX.xml:S1:9027:3	O
)	NULOJIX.xml:S1:9030:1	O
,	NULOJIX.xml:S1:9031:1	O
and	NULOJIX.xml:S1:9033:3	O
corticosteroids	NULOJIX.xml:S1:9037:15	O
for	NULOJIX.xml:S1:9053:3	O
2	NULOJIX.xml:S1:9057:1	O
years	NULOJIX.xml:S1:9059:5	O
.	NULOJIX.xml:S1:9064:1	O

The	NULOJIX.xml:S1:9066:3	O
liver	NULOJIX.xml:S1:9070:5	O
transplant	NULOJIX.xml:S1:9076:10	O
recipient	NULOJIX.xml:S1:9087:9	O
was	NULOJIX.xml:S1:9097:3	O
treated	NULOJIX.xml:S1:9101:7	O
with	NULOJIX.xml:S1:9109:4	O
6	NULOJIX.xml:S1:9114:1	O
months	NULOJIX.xml:S1:9116:6	O
of	NULOJIX.xml:S1:9123:2	O
a	NULOJIX.xml:S1:9126:1	O
NULOJIX	NULOJIX.xml:S1:9128:7	O
dosage	NULOJIX.xml:S1:9136:6	O
regimen	NULOJIX.xml:S1:9143:7	O
that	NULOJIX.xml:S1:9151:4	O
was	NULOJIX.xml:S1:9156:3	O
more	NULOJIX.xml:S1:9160:4	O
intensive	NULOJIX.xml:S1:9165:9	O
than	NULOJIX.xml:S1:9175:4	O
that	NULOJIX.xml:S1:9180:4	O
studied	NULOJIX.xml:S1:9185:7	O
in	NULOJIX.xml:S1:9193:2	O
kidney	NULOJIX.xml:S1:9196:6	O
transplant	NULOJIX.xml:S1:9203:10	O
recipients	NULOJIX.xml:S1:9214:10	O
,	NULOJIX.xml:S1:9224:1	O
MMF	NULOJIX.xml:S1:9226:3	O
at	NULOJIX.xml:S1:9230:2	O
doses	NULOJIX.xml:S1:9233:5	O
higher	NULOJIX.xml:S1:9239:6	O
than	NULOJIX.xml:S1:9246:4	O
the	NULOJIX.xml:S1:9251:3	O
recommended	NULOJIX.xml:S1:9255:11	O
dose	NULOJIX.xml:S1:9267:4	O
,	NULOJIX.xml:S1:9271:1	O
and	NULOJIX.xml:S1:9273:3	O
corticosteroids	NULOJIX.xml:S1:9277:15	O
[	NULOJIX.xml:S1:9293:1	O
see	NULOJIX.xml:S1:9294:3	O
Warnings	NULOJIX.xml:S1:9301:8	O
and	NULOJIX.xml:S1:9310:3	O
Precautions	NULOJIX.xml:S1:9314:11	O
(	NULOJIX.xml:S1:9326:1	O
5.4	NULOJIX.xml:S1:9327:3	O
)	NULOJIX.xml:S1:9330:1	O
]	NULOJIX.xml:S1:9335:1	O
.	NULOJIX.xml:S1:9336:1	O

Bacterial	NULOJIX.xml:S1:9344:9	O
,	NULOJIX.xml:S1:9353:1	O
Mycobacterial	NULOJIX.xml:S1:9355:13	O
,	NULOJIX.xml:S1:9368:1	O
Viral	NULOJIX.xml:S1:9370:5	O
,	NULOJIX.xml:S1:9375:1	O
and	NULOJIX.xml:S1:9377:3	O
Fungal	NULOJIX.xml:S1:9381:6	O
Infections	NULOJIX.xml:S1:9388:10	O

Adverse	NULOJIX.xml:S1:9402:7	O
reactions	NULOJIX.xml:S1:9410:9	O
of	NULOJIX.xml:S1:9420:2	O
infectious	NULOJIX.xml:S1:9423:10	B-AdverseReaction
etiology	NULOJIX.xml:S1:9434:8	I-AdverseReaction
were	NULOJIX.xml:S1:9443:4	O
reported	NULOJIX.xml:S1:9448:8	O
based	NULOJIX.xml:S1:9457:5	O
on	NULOJIX.xml:S1:9463:2	O
clinical	NULOJIX.xml:S1:9466:8	O
assessment	NULOJIX.xml:S1:9475:10	O
by	NULOJIX.xml:S1:9486:2	O
physicians	NULOJIX.xml:S1:9489:10	O
.	NULOJIX.xml:S1:9499:1	O

The	NULOJIX.xml:S1:9501:3	O
causative	NULOJIX.xml:S1:9505:9	O
organisms	NULOJIX.xml:S1:9515:9	O
for	NULOJIX.xml:S1:9525:3	O
these	NULOJIX.xml:S1:9529:5	O
reactions	NULOJIX.xml:S1:9535:9	O
are	NULOJIX.xml:S1:9545:3	O
identified	NULOJIX.xml:S1:9549:10	O
when	NULOJIX.xml:S1:9560:4	O
provided	NULOJIX.xml:S1:9565:8	O
by	NULOJIX.xml:S1:9574:2	O
the	NULOJIX.xml:S1:9577:3	O
physician	NULOJIX.xml:S1:9581:9	O
.	NULOJIX.xml:S1:9590:1	O

The	NULOJIX.xml:S1:9592:3	O
overall	NULOJIX.xml:S1:9596:7	O
number	NULOJIX.xml:S1:9604:6	O
of	NULOJIX.xml:S1:9611:2	O
infections	NULOJIX.xml:S1:9614:10	B-AdverseReaction
,	NULOJIX.xml:S1:9624:1	O
serious	NULOJIX.xml:S1:9626:7	B-Severity
infections	NULOJIX.xml:S1:9634:10	B-AdverseReaction
,	NULOJIX.xml:S1:9644:1	O
and	NULOJIX.xml:S1:9646:3	O
select	NULOJIX.xml:S1:9650:6	O
infections	NULOJIX.xml:S1:9657:10	B-AdverseReaction
with	NULOJIX.xml:S1:9668:4	O
identified	NULOJIX.xml:S1:9673:10	O
etiology	NULOJIX.xml:S1:9684:8	O
reported	NULOJIX.xml:S1:9693:8	O
in	NULOJIX.xml:S1:9702:2	O
patients	NULOJIX.xml:S1:9705:8	O
treated	NULOJIX.xml:S1:9714:7	O
with	NULOJIX.xml:S1:9722:4	O
the	NULOJIX.xml:S1:9727:3	O
NULOJIX	NULOJIX.xml:S1:9731:7	O
recommended	NULOJIX.xml:S1:9739:11	O
regimen	NULOJIX.xml:S1:9751:7	O
or	NULOJIX.xml:S1:9759:2	O
the	NULOJIX.xml:S1:9762:3	O
cyclosporine	NULOJIX.xml:S1:9766:12	O
control	NULOJIX.xml:S1:9779:7	O
in	NULOJIX.xml:S1:9787:2	O
Studies	NULOJIX.xml:S1:9790:7	O
1	NULOJIX.xml:S1:9798:1	O
and	NULOJIX.xml:S1:9800:3	O
2	NULOJIX.xml:S1:9804:1	O
are	NULOJIX.xml:S1:9806:3	O
shown	NULOJIX.xml:S1:9810:5	O
in	NULOJIX.xml:S1:9816:2	O
Table	NULOJIX.xml:S1:9819:5	O
3	NULOJIX.xml:S1:9825:1	O
.	NULOJIX.xml:S1:9826:1	O

Fungal	NULOJIX.xml:S1:9828:6	B-AdverseReaction
infections	NULOJIX.xml:S1:9835:10	I-AdverseReaction
were	NULOJIX.xml:S1:9846:4	O
reported	NULOJIX.xml:S1:9851:8	O
in	NULOJIX.xml:S1:9860:2	O
18%	NULOJIX.xml:S1:9863:3	O
of	NULOJIX.xml:S1:9867:2	O
patients	NULOJIX.xml:S1:9870:8	O
receiving	NULOJIX.xml:S1:9879:9	O
NULOJIX	NULOJIX.xml:S1:9889:7	O
compared	NULOJIX.xml:S1:9897:8	O
to	NULOJIX.xml:S1:9906:2	O
22%	NULOJIX.xml:S1:9909:3	O
receiving	NULOJIX.xml:S1:9913:9	O
cyclosporine	NULOJIX.xml:S1:9923:12	O
,	NULOJIX.xml:S1:9935:1	O
primarily	NULOJIX.xml:S1:9937:9	O
due	NULOJIX.xml:S1:9947:3	O
to	NULOJIX.xml:S1:9951:2	O
skin	NULOJIX.xml:S1:9954:4	B-AdverseReaction
and	NULOJIX.xml:S1:9959:3	O
mucocutaneous	NULOJIX.xml:S1:9963:13	B-AdverseReaction
fungal	NULOJIX.xml:S1:9977:6	I-AdverseReaction
infections	NULOJIX.xml:S1:9984:10	I-AdverseReaction
.	NULOJIX.xml:S1:9994:1	O

Tuberculosis	NULOJIX.xml:S1:9996:12	B-AdverseReaction
and	NULOJIX.xml:S1:10009:3	O
herpes	NULOJIX.xml:S1:10013:6	B-AdverseReaction
infections	NULOJIX.xml:S1:10020:10	I-AdverseReaction
were	NULOJIX.xml:S1:10031:4	O
reported	NULOJIX.xml:S1:10036:8	O
more	NULOJIX.xml:S1:10045:4	O
frequently	NULOJIX.xml:S1:10050:10	O
in	NULOJIX.xml:S1:10061:2	O
patients	NULOJIX.xml:S1:10064:8	O
receiving	NULOJIX.xml:S1:10073:9	O
NULOJIX	NULOJIX.xml:S1:10083:7	O
than	NULOJIX.xml:S1:10091:4	O
cyclosporine	NULOJIX.xml:S1:10096:12	O
.	NULOJIX.xml:S1:10108:1	O

Of	NULOJIX.xml:S1:10110:2	O
the	NULOJIX.xml:S1:10113:3	O
patients	NULOJIX.xml:S1:10117:8	O
who	NULOJIX.xml:S1:10126:3	O
developed	NULOJIX.xml:S1:10130:9	O
tuberculosis	NULOJIX.xml:S1:10140:12	B-AdverseReaction
through	NULOJIX.xml:S1:10153:7	O
3	NULOJIX.xml:S1:10161:1	O
years	NULOJIX.xml:S1:10163:5	O
,	NULOJIX.xml:S1:10168:1	O
all	NULOJIX.xml:S1:10170:3	O
but	NULOJIX.xml:S1:10174:3	O
one	NULOJIX.xml:S1:10178:3	O
NULOJIX	NULOJIX.xml:S1:10182:7	O
patient	NULOJIX.xml:S1:10190:7	O
lived	NULOJIX.xml:S1:10198:5	O
in	NULOJIX.xml:S1:10204:2	O
countries	NULOJIX.xml:S1:10207:9	O
with	NULOJIX.xml:S1:10217:4	O
a	NULOJIX.xml:S1:10222:1	O
high	NULOJIX.xml:S1:10224:4	O
prevalence	NULOJIX.xml:S1:10229:10	O
of	NULOJIX.xml:S1:10240:2	O
tuberculosis	NULOJIX.xml:S1:10243:12	O
[	NULOJIX.xml:S1:10256:1	O
see	NULOJIX.xml:S1:10257:3	O
Warnings	NULOJIX.xml:S1:10264:8	O
and	NULOJIX.xml:S1:10273:3	O
Precautions	NULOJIX.xml:S1:10277:11	O
(	NULOJIX.xml:S1:10289:1	O
5.5	NULOJIX.xml:S1:10290:3	O
)	NULOJIX.xml:S1:10293:1	O
]	NULOJIX.xml:S1:10298:1	O
.	NULOJIX.xml:S1:10299:1	O

Table	NULOJIX.xml:S1:10305:5	O
3	NULOJIX.xml:S1:10311:1	O
:	NULOJIX.xml:S1:10312:1	O
Overall	NULOJIX.xml:S1:10314:7	O
Infections	NULOJIX.xml:S1:10322:10	B-AdverseReaction
and	NULOJIX.xml:S1:10333:3	O
Select	NULOJIX.xml:S1:10337:6	O
Infections	NULOJIX.xml:S1:10344:10	B-AdverseReaction
with	NULOJIX.xml:S1:10355:4	O
Identified	NULOJIX.xml:S1:10360:10	O
Etiology	NULOJIX.xml:S1:10371:8	O
by	NULOJIX.xml:S1:10380:2	O
Treatment	NULOJIX.xml:S1:10383:9	O
Group	NULOJIX.xml:S1:10393:5	O
following	NULOJIX.xml:S1:10399:9	O
One	NULOJIX.xml:S1:10409:3	O
and	NULOJIX.xml:S1:10413:3	O
Three	NULOJIX.xml:S1:10417:5	O
Years	NULOJIX.xml:S1:10423:5	O
of	NULOJIX.xml:S1:10429:2	O
Treatment	NULOJIX.xml:S1:10432:9	O
in	NULOJIX.xml:S1:10442:2	O
Studies	NULOJIX.xml:S1:10445:7	O
1	NULOJIX.xml:S1:10453:1	O
and	NULOJIX.xml:S1:10455:3	O
2	NULOJIX.xml:S1:10459:1	O

Up	NULOJIX.xml:S1:10496:2	O
to	NULOJIX.xml:S1:10499:2	O
Year	NULOJIX.xml:S1:10502:4	O
1	NULOJIX.xml:S1:10507:1	O
Up	NULOJIX.xml:S1:10516:2	O
to	NULOJIX.xml:S1:10519:2	O
Year	NULOJIX.xml:S1:10522:4	O
3	NULOJIX.xml:S1:10527:1	O

NULOJIX	NULOJIX.xml:S1:10571:7	O
Recommended	NULOJIX.xml:S1:10582:11	O
Regimen	NULOJIX.xml:S1:10597:7	O
N	NULOJIX.xml:S1:10608:1	O
401	NULOJIX.xml:S1:10610:3	O
n	NULOJIX.xml:S1:10617:1	O
(	NULOJIX.xml:S1:10619:1	O
)	NULOJIX.xml:S1:10621:1	O
Cyclosporine	NULOJIX.xml:S1:10628:12	O
N	NULOJIX.xml:S1:10644:1	O
405	NULOJIX.xml:S1:10646:3	O
n	NULOJIX.xml:S1:10653:1	O
(	NULOJIX.xml:S1:10655:1	O
)	NULOJIX.xml:S1:10657:1	O
NULOJIX	NULOJIX.xml:S1:10664:7	O
Recommended	NULOJIX.xml:S1:10675:11	O
Regimen	NULOJIX.xml:S1:10690:7	O
N	NULOJIX.xml:S1:10701:1	O
401	NULOJIX.xml:S1:10703:3	O
n	NULOJIX.xml:S1:10710:1	O
(	NULOJIX.xml:S1:10712:1	O
)	NULOJIX.xml:S1:10714:1	O
Cyclosporine	NULOJIX.xml:S1:10721:12	O
N	NULOJIX.xml:S1:10737:1	O
405	NULOJIX.xml:S1:10739:3	O
n	NULOJIX.xml:S1:10746:1	O
(	NULOJIX.xml:S1:10748:1	O
)	NULOJIX.xml:S1:10750:1	O

Studies	NULOJIX.xml:S1:10764:7	O

1	NULOJIX.xml:S1:10772:1	O
and	NULOJIX.xml:S1:10774:3	O
2	NULOJIX.xml:S1:10778:1	O
were	NULOJIX.xml:S1:10780:4	O
not	NULOJIX.xml:S1:10785:3	O
designed	NULOJIX.xml:S1:10789:8	O
to	NULOJIX.xml:S1:10798:2	O
support	NULOJIX.xml:S1:10801:7	O
comparative	NULOJIX.xml:S1:10809:11	O
claims	NULOJIX.xml:S1:10821:6	O
for	NULOJIX.xml:S1:10828:3	O
NULOJIX	NULOJIX.xml:S1:10832:7	O
for	NULOJIX.xml:S1:10840:3	O
the	NULOJIX.xml:S1:10844:3	O
adverse	NULOJIX.xml:S1:10848:7	O
reactions	NULOJIX.xml:S1:10856:9	O
reported	NULOJIX.xml:S1:10866:8	O
in	NULOJIX.xml:S1:10875:2	O
this	NULOJIX.xml:S1:10878:4	O
table	NULOJIX.xml:S1:10883:5	O
.	NULOJIX.xml:S1:10888:1	O

Median	NULOJIX.xml:S1:10895:6	O
exposure	NULOJIX.xml:S1:10902:8	O
in	NULOJIX.xml:S1:10911:2	O
days	NULOJIX.xml:S1:10914:4	O
for	NULOJIX.xml:S1:10919:3	O
pooled	NULOJIX.xml:S1:10923:6	O
studies	NULOJIX.xml:S1:10930:7	O
:	NULOJIX.xml:S1:10937:1	O
1203	NULOJIX.xml:S1:10939:4	O
for	NULOJIX.xml:S1:10944:3	O
NULOJIX	NULOJIX.xml:S1:10948:7	O
recommended	NULOJIX.xml:S1:10956:11	O
regimen	NULOJIX.xml:S1:10968:7	O
and	NULOJIX.xml:S1:10976:3	O
1163	NULOJIX.xml:S1:10980:4	O
for	NULOJIX.xml:S1:10985:3	O
cyclosporine	NULOJIX.xml:S1:10989:12	O
in	NULOJIX.xml:S1:11002:2	O
Studies	NULOJIX.xml:S1:11005:7	O
1	NULOJIX.xml:S1:11013:1	O
and	NULOJIX.xml:S1:11015:3	O
2	NULOJIX.xml:S1:11019:1	O
.	NULOJIX.xml:S1:11020:1	O
?	NULOJIX.xml:S1:11023:1	O

All	NULOJIX.xml:S1:11028:3	O
infections	NULOJIX.xml:S1:11032:10	B-AdverseReaction
include	NULOJIX.xml:S1:11043:7	O
bacterial	NULOJIX.xml:S1:11051:9	I-AdverseReaction
,	NULOJIX.xml:S1:11060:1	O
viral	NULOJIX.xml:S1:11062:5	I-AdverseReaction
,	NULOJIX.xml:S1:11067:1	O
fungal	NULOJIX.xml:S1:11069:6	I-AdverseReaction
,	NULOJIX.xml:S1:11075:1	O
and	NULOJIX.xml:S1:11077:3	O
other	NULOJIX.xml:S1:11081:5	O
organisms	NULOJIX.xml:S1:11087:9	O
.	NULOJIX.xml:S1:11096:1	O

For	NULOJIX.xml:S1:11098:3	O
infectious	NULOJIX.xml:S1:11102:10	B-AdverseReaction
adverse	NULOJIX.xml:S1:11113:7	I-AdverseReaction
reactions	NULOJIX.xml:S1:11121:9	I-AdverseReaction
,	NULOJIX.xml:S1:11130:1	O
the	NULOJIX.xml:S1:11132:3	O
causative	NULOJIX.xml:S1:11136:9	O
organism	NULOJIX.xml:S1:11146:8	O
is	NULOJIX.xml:S1:11155:2	O
reported	NULOJIX.xml:S1:11158:8	O
if	NULOJIX.xml:S1:11167:2	O
specified	NULOJIX.xml:S1:11170:9	O
by	NULOJIX.xml:S1:11180:2	O
the	NULOJIX.xml:S1:11183:3	O
physician	NULOJIX.xml:S1:11187:9	O
in	NULOJIX.xml:S1:11197:2	O
the	NULOJIX.xml:S1:11200:3	O
clinical	NULOJIX.xml:S1:11204:8	O
trials	NULOJIX.xml:S1:11213:6	O
.	NULOJIX.xml:S1:11219:1	O

S	NULOJIX.xml:S1:11222:1	O
A	NULOJIX.xml:S1:11227:1	O
medically	NULOJIX.xml:S1:11229:9	O
important	NULOJIX.xml:S1:11239:9	O
event	NULOJIX.xml:S1:11249:5	O
that	NULOJIX.xml:S1:11255:4	O
may	NULOJIX.xml:S1:11260:3	O
be	NULOJIX.xml:S1:11264:2	O
life	NULOJIX.xml:S1:11267:4	O
-	NULOJIX.xml:S1:11271:1	O
threatening	NULOJIX.xml:S1:11272:11	O
or	NULOJIX.xml:S1:11284:2	O
result	NULOJIX.xml:S1:11287:6	O
in	NULOJIX.xml:S1:11294:2	O
death	NULOJIX.xml:S1:11297:5	B-AdverseReaction
or	NULOJIX.xml:S1:11303:2	O
hospitalization	NULOJIX.xml:S1:11306:15	O
or	NULOJIX.xml:S1:11322:2	O
prolongation	NULOJIX.xml:S1:11325:12	O
of	NULOJIX.xml:S1:11338:2	O
existing	NULOJIX.xml:S1:11341:8	O
hospitalization	NULOJIX.xml:S1:11350:15	O
.	NULOJIX.xml:S1:11365:1	O

Infections	NULOJIX.xml:S1:11367:10	B-AdverseReaction
not	NULOJIX.xml:S1:11378:3	O
meeting	NULOJIX.xml:S1:11382:7	O
these	NULOJIX.xml:S1:11390:5	O
criteria	NULOJIX.xml:S1:11396:8	O
are	NULOJIX.xml:S1:11405:3	O
considered	NULOJIX.xml:S1:11409:10	O
non	NULOJIX.xml:S1:11420:3	O
-	NULOJIX.xml:S1:11423:1	O
serious	NULOJIX.xml:S1:11424:7	O
.	NULOJIX.xml:S1:11431:1	O

BK	NULOJIX.xml:S1:11439:2	B-AdverseReaction
virus	NULOJIX.xml:S1:11442:5	I-AdverseReaction
-	NULOJIX.xml:S1:11447:1	I-AdverseReaction
associated	NULOJIX.xml:S1:11448:10	I-AdverseReaction
nephropathy	NULOJIX.xml:S1:11459:11	I-AdverseReaction
was	NULOJIX.xml:S1:11471:3	O
reported	NULOJIX.xml:S1:11475:8	O
in	NULOJIX.xml:S1:11484:2	O
6	NULOJIX.xml:S1:11487:1	O
NULOJIX	NULOJIX.xml:S1:11489:7	O
patients	NULOJIX.xml:S1:11497:8	O
(	NULOJIX.xml:S1:11506:1	O
4	NULOJIX.xml:S1:11507:1	O
of	NULOJIX.xml:S1:11509:2	O
which	NULOJIX.xml:S1:11512:5	O
resulted	NULOJIX.xml:S1:11518:8	O
in	NULOJIX.xml:S1:11527:2	O
graft	NULOJIX.xml:S1:11530:5	O
loss	NULOJIX.xml:S1:11536:4	O
)	NULOJIX.xml:S1:11540:1	O
and	NULOJIX.xml:S1:11542:3	O
6	NULOJIX.xml:S1:11546:1	O
cyclosporine	NULOJIX.xml:S1:11548:12	O
patients	NULOJIX.xml:S1:11561:8	O
(	NULOJIX.xml:S1:11570:1	O
none	NULOJIX.xml:S1:11571:4	O
of	NULOJIX.xml:S1:11576:2	O
which	NULOJIX.xml:S1:11579:5	O
resulted	NULOJIX.xml:S1:11585:8	O
in	NULOJIX.xml:S1:11594:2	O
graft	NULOJIX.xml:S1:11597:5	O
loss	NULOJIX.xml:S1:11603:4	O
)	NULOJIX.xml:S1:11607:1	O
by	NULOJIX.xml:S1:11609:2	O
Year	NULOJIX.xml:S1:11612:4	O
3	NULOJIX.xml:S1:11617:1	O
.	NULOJIX.xml:S1:11618:1	O

Most	NULOJIX.xml:S1:11626:4	O
herpes	NULOJIX.xml:S1:11631:6	B-AdverseReaction
infections	NULOJIX.xml:S1:11638:10	I-AdverseReaction
were	NULOJIX.xml:S1:11649:4	O
non	NULOJIX.xml:S1:11654:3	B-Severity
-	NULOJIX.xml:S1:11657:1	I-Severity
serious	NULOJIX.xml:S1:11658:7	I-Severity
and	NULOJIX.xml:S1:11666:3	O
1	NULOJIX.xml:S1:11670:1	O
led	NULOJIX.xml:S1:11672:3	O
to	NULOJIX.xml:S1:11676:2	O
treatment	NULOJIX.xml:S1:11679:9	O
discontinuation	NULOJIX.xml:S1:11689:15	O
.	NULOJIX.xml:S1:11704:1	O

All	NULOJIX.xml:S1:11714:3	O

infections	NULOJIX.xml:S1:11718:10	B-AdverseReaction
?	NULOJIX.xml:S1:11728:1	O

287	NULOJIX.xml:S1:11744:3	O
(	NULOJIX.xml:S1:11748:1	O
72	NULOJIX.xml:S1:11749:2	O
)	NULOJIX.xml:S1:11751:1	O
299	NULOJIX.xml:S1:11764:3	O
(	NULOJIX.xml:S1:11768:1	O
74	NULOJIX.xml:S1:11769:2	O
)	NULOJIX.xml:S1:11771:1	O
329	NULOJIX.xml:S1:11784:3	O
(	NULOJIX.xml:S1:11788:1	O
82	NULOJIX.xml:S1:11789:2	O
)	NULOJIX.xml:S1:11791:1	O
327	NULOJIX.xml:S1:11804:3	O
(	NULOJIX.xml:S1:11808:1	O
81	NULOJIX.xml:S1:11809:2	O
)	NULOJIX.xml:S1:11811:1	O

Serious	NULOJIX.xml:S1:11830:7	B-Severity
infectionsS	NULOJIX.xml:S1:11838:11	B-AdverseReaction
98	NULOJIX.xml:S1:11857:2	O
(	NULOJIX.xml:S1:11860:1	O
24	NULOJIX.xml:S1:11861:2	O
)	NULOJIX.xml:S1:11863:1	O
113	NULOJIX.xml:S1:11877:3	O
(	NULOJIX.xml:S1:11881:1	O
28	NULOJIX.xml:S1:11882:2	O
)	NULOJIX.xml:S1:11884:1	O
144	NULOJIX.xml:S1:11897:3	O
(	NULOJIX.xml:S1:11901:1	O
36	NULOJIX.xml:S1:11902:2	O
)	NULOJIX.xml:S1:11904:1	O
157	NULOJIX.xml:S1:11917:3	O
(	NULOJIX.xml:S1:11921:1	O
39	NULOJIX.xml:S1:11922:2	O
)	NULOJIX.xml:S1:11924:1	O

CMV	NULOJIX.xml:S1:11940:3	I-AdverseReaction
44	NULOJIX.xml:S1:11970:2	O
(	NULOJIX.xml:S1:11973:1	O
11	NULOJIX.xml:S1:11974:2	O
)	NULOJIX.xml:S1:11976:1	O
52	NULOJIX.xml:S1:11990:2	O
(	NULOJIX.xml:S1:11993:1	O
13	NULOJIX.xml:S1:11994:2	O
)	NULOJIX.xml:S1:11996:1	O
53	NULOJIX.xml:S1:12010:2	O
(	NULOJIX.xml:S1:12013:1	O
13	NULOJIX.xml:S1:12014:2	O
)	NULOJIX.xml:S1:12016:1	O
56	NULOJIX.xml:S1:12030:2	O
(	NULOJIX.xml:S1:12033:1	O
14	NULOJIX.xml:S1:12034:2	O
)	NULOJIX.xml:S1:12036:1	O

Polyoma	NULOJIX.xml:S1:12053:7	I-AdverseReaction
virus	NULOJIX.xml:S1:12061:5	I-AdverseReaction
10	NULOJIX.xml:S1:12083:2	O
(	NULOJIX.xml:S1:12086:1	O
3	NULOJIX.xml:S1:12087:1	O
)	NULOJIX.xml:S1:12088:1	O
23	NULOJIX.xml:S1:12103:2	O
(	NULOJIX.xml:S1:12106:1	O
6	NULOJIX.xml:S1:12107:1	O
)	NULOJIX.xml:S1:12108:1	O
17	NULOJIX.xml:S1:12123:2	O
(	NULOJIX.xml:S1:12126:1	O
4	NULOJIX.xml:S1:12127:1	O
)	NULOJIX.xml:S1:12128:1	O
27	NULOJIX.xml:S1:12143:2	O
(	NULOJIX.xml:S1:12146:1	O
7	NULOJIX.xml:S1:12147:1	O
)	NULOJIX.xml:S1:12148:1	O

Herpes	NULOJIX.xml:S1:12166:6	I-AdverseReaction
27	NULOJIX.xml:S1:12196:2	O
(	NULOJIX.xml:S1:12199:1	O
7	NULOJIX.xml:S1:12200:1	O
)	NULOJIX.xml:S1:12201:1	O
26	NULOJIX.xml:S1:12216:2	O
(	NULOJIX.xml:S1:12219:1	O
6	NULOJIX.xml:S1:12220:1	O
)	NULOJIX.xml:S1:12221:1	O
55	NULOJIX.xml:S1:12236:2	O
(	NULOJIX.xml:S1:12239:1	O
14	NULOJIX.xml:S1:12240:2	O
)	NULOJIX.xml:S1:12242:1	O
46	NULOJIX.xml:S1:12256:2	O
(	NULOJIX.xml:S1:12259:1	O
11	NULOJIX.xml:S1:12260:2	O
)	NULOJIX.xml:S1:12262:1	O

Tuberculosis	NULOJIX.xml:S1:12279:12	B-AdverseReaction
2	NULOJIX.xml:S1:12309:1	O
(	NULOJIX.xml:S1:12311:1	O
1	NULOJIX.xml:S1:12312:1	O
)	NULOJIX.xml:S1:12313:1	O
1	NULOJIX.xml:S1:12329:1	O
(	NULOJIX.xml:S1:12331:1	O
1	NULOJIX.xml:S1:12333:1	O
)	NULOJIX.xml:S1:12334:1	O
6	NULOJIX.xml:S1:12349:1	O
(	NULOJIX.xml:S1:12351:1	O
2	NULOJIX.xml:S1:12352:1	O
)	NULOJIX.xml:S1:12353:1	O
1	NULOJIX.xml:S1:12369:1	O
(	NULOJIX.xml:S1:12371:1	O
1	NULOJIX.xml:S1:12373:1	O
)	NULOJIX.xml:S1:12374:1	O

Infections	NULOJIX.xml:S1:12403:10	O
Reported	NULOJIX.xml:S1:12414:8	O
in	NULOJIX.xml:S1:12423:2	O
the	NULOJIX.xml:S1:12426:3	O
CNS	NULOJIX.xml:S1:12430:3	O

Following	NULOJIX.xml:S1:12437:9	O
three	NULOJIX.xml:S1:12447:5	O
years	NULOJIX.xml:S1:12453:5	O
of	NULOJIX.xml:S1:12459:2	O
treatment	NULOJIX.xml:S1:12462:9	O
in	NULOJIX.xml:S1:12472:2	O
Studies	NULOJIX.xml:S1:12475:7	O
1	NULOJIX.xml:S1:12483:1	O
and	NULOJIX.xml:S1:12485:3	O
2	NULOJIX.xml:S1:12489:1	O
,	NULOJIX.xml:S1:12490:1	O
cryptococcal	NULOJIX.xml:S1:12492:12	B-AdverseReaction
meningitis	NULOJIX.xml:S1:12505:10	I-AdverseReaction
was	NULOJIX.xml:S1:12516:3	O
reported	NULOJIX.xml:S1:12520:8	O
in	NULOJIX.xml:S1:12529:2	O
one	NULOJIX.xml:S1:12532:3	O
patient	NULOJIX.xml:S1:12536:7	O
out	NULOJIX.xml:S1:12544:3	O
of	NULOJIX.xml:S1:12548:2	O
401	NULOJIX.xml:S1:12551:3	O
patients	NULOJIX.xml:S1:12555:8	O
treated	NULOJIX.xml:S1:12564:7	O
with	NULOJIX.xml:S1:12572:4	O
the	NULOJIX.xml:S1:12577:3	O
NULOJIX	NULOJIX.xml:S1:12581:7	O
recommended	NULOJIX.xml:S1:12589:11	O
regimen	NULOJIX.xml:S1:12601:7	O
(	NULOJIX.xml:S1:12609:1	O
0.2%	NULOJIX.xml:S1:12610:4	O
)	NULOJIX.xml:S1:12614:1	O
and	NULOJIX.xml:S1:12616:3	O
one	NULOJIX.xml:S1:12620:3	O
patient	NULOJIX.xml:S1:12624:7	O
out	NULOJIX.xml:S1:12632:3	O
of	NULOJIX.xml:S1:12636:2	O
the	NULOJIX.xml:S1:12639:3	O
405	NULOJIX.xml:S1:12643:3	O
treated	NULOJIX.xml:S1:12647:7	O
with	NULOJIX.xml:S1:12655:4	O
the	NULOJIX.xml:S1:12660:3	O
cyclosporine	NULOJIX.xml:S1:12664:12	O
control	NULOJIX.xml:S1:12677:7	O
(	NULOJIX.xml:S1:12685:1	O
0.2%	NULOJIX.xml:S1:12686:4	O
)	NULOJIX.xml:S1:12690:1	O
.	NULOJIX.xml:S1:12691:1	O

Six	NULOJIX.xml:S1:12697:3	O
patients	NULOJIX.xml:S1:12701:8	O
out	NULOJIX.xml:S1:12710:3	O
of	NULOJIX.xml:S1:12714:2	O
the	NULOJIX.xml:S1:12717:3	O
403	NULOJIX.xml:S1:12721:3	O
who	NULOJIX.xml:S1:12725:3	O
were	NULOJIX.xml:S1:12729:4	O
treated	NULOJIX.xml:S1:12734:7	O
with	NULOJIX.xml:S1:12742:4	O
the	NULOJIX.xml:S1:12747:3	O
NULOJIX	NULOJIX.xml:S1:12751:7	O
regimen	NULOJIX.xml:S1:12759:7	O
of	NULOJIX.xml:S1:12767:2	O
higher	NULOJIX.xml:S1:12770:6	O
cumulative	NULOJIX.xml:S1:12777:10	O
dose	NULOJIX.xml:S1:12788:4	O
and	NULOJIX.xml:S1:12793:3	O
more	NULOJIX.xml:S1:12797:4	O
frequent	NULOJIX.xml:S1:12802:8	O
dosing	NULOJIX.xml:S1:12811:6	O
than	NULOJIX.xml:S1:12818:4	O
recommended	NULOJIX.xml:S1:12823:11	O
in	NULOJIX.xml:S1:12835:2	O
Studies	NULOJIX.xml:S1:12838:7	O
1	NULOJIX.xml:S1:12846:1	O
and	NULOJIX.xml:S1:12848:3	O
2	NULOJIX.xml:S1:12852:1	O
(	NULOJIX.xml:S1:12854:1	O
1.5%	NULOJIX.xml:S1:12855:4	O
)	NULOJIX.xml:S1:12859:1	O
were	NULOJIX.xml:S1:12861:4	O
reported	NULOJIX.xml:S1:12866:8	O
to	NULOJIX.xml:S1:12875:2	O
have	NULOJIX.xml:S1:12878:4	O
developed	NULOJIX.xml:S1:12883:9	O
CNS	NULOJIX.xml:S1:12893:3	B-AdverseReaction
infections	NULOJIX.xml:S1:12897:10	I-AdverseReaction
,	NULOJIX.xml:S1:12907:1	O
including	NULOJIX.xml:S1:12909:9	O
2	NULOJIX.xml:S1:12919:1	O
cases	NULOJIX.xml:S1:12921:5	O
of	NULOJIX.xml:S1:12927:2	O
cryptococcal	NULOJIX.xml:S1:12930:12	B-AdverseReaction
meningitis	NULOJIX.xml:S1:12943:10	I-AdverseReaction
,	NULOJIX.xml:S1:12953:1	O
one	NULOJIX.xml:S1:12955:3	O
case	NULOJIX.xml:S1:12959:4	O
of	NULOJIX.xml:S1:12964:2	O
Chagas	NULOJIX.xml:S1:12967:6	B-AdverseReaction
encephalitis	NULOJIX.xml:S1:12974:12	I-AdverseReaction
with	NULOJIX.xml:S1:12987:4	O
cryptococcal	NULOJIX.xml:S1:12992:12	B-AdverseReaction
meningitis	NULOJIX.xml:S1:13005:10	I-AdverseReaction
,	NULOJIX.xml:S1:13015:1	O
one	NULOJIX.xml:S1:13017:3	O
case	NULOJIX.xml:S1:13021:4	O
of	NULOJIX.xml:S1:13026:2	O
cerebral	NULOJIX.xml:S1:13029:8	B-AdverseReaction
aspergillosis	NULOJIX.xml:S1:13038:13	I-AdverseReaction
,	NULOJIX.xml:S1:13051:1	O
one	NULOJIX.xml:S1:13053:3	O
case	NULOJIX.xml:S1:13057:4	O
of	NULOJIX.xml:S1:13062:2	O
West	NULOJIX.xml:S1:13065:4	B-AdverseReaction
Nile	NULOJIX.xml:S1:13070:4	I-AdverseReaction
encephalitis	NULOJIX.xml:S1:13075:12	I-AdverseReaction
,	NULOJIX.xml:S1:13087:1	O
and	NULOJIX.xml:S1:13089:3	O
one	NULOJIX.xml:S1:13093:3	O
case	NULOJIX.xml:S1:13097:4	O
of	NULOJIX.xml:S1:13102:2	O
PML	NULOJIX.xml:S1:13105:3	B-AdverseReaction
(	NULOJIX.xml:S1:13109:1	O
discussed	NULOJIX.xml:S1:13110:9	O
above	NULOJIX.xml:S1:13120:5	O
)	NULOJIX.xml:S1:13125:1	O
.	NULOJIX.xml:S1:13126:1	O

Infusion	NULOJIX.xml:S1:13134:8	O
Reactions	NULOJIX.xml:S1:13143:9	O

There	NULOJIX.xml:S1:13156:5	O
were	NULOJIX.xml:S1:13162:4	O
no	NULOJIX.xml:S1:13167:2	B-Negation
reports	NULOJIX.xml:S1:13170:7	O
of	NULOJIX.xml:S1:13178:2	O
anaphylaxis	NULOJIX.xml:S1:13181:11	B-AdverseReaction
or	NULOJIX.xml:S1:13193:2	O
drug	NULOJIX.xml:S1:13196:4	B-AdverseReaction
hypersensitivity	NULOJIX.xml:S1:13201:16	I-AdverseReaction
in	NULOJIX.xml:S1:13218:2	O
patients	NULOJIX.xml:S1:13221:8	O
treated	NULOJIX.xml:S1:13230:7	O
with	NULOJIX.xml:S1:13238:4	O
NULOJIX	NULOJIX.xml:S1:13243:7	O
in	NULOJIX.xml:S1:13251:2	O
Studies	NULOJIX.xml:S1:13254:7	O
1	NULOJIX.xml:S1:13262:1	O
and	NULOJIX.xml:S1:13264:3	O
2	NULOJIX.xml:S1:13268:1	O
through	NULOJIX.xml:S1:13270:7	O
three	NULOJIX.xml:S1:13278:5	O
years	NULOJIX.xml:S1:13284:5	O
.	NULOJIX.xml:S1:13289:1	O

Infusion	NULOJIX.xml:S1:13295:8	B-AdverseReaction
-	NULOJIX.xml:S1:13303:1	I-AdverseReaction
related	NULOJIX.xml:S1:13304:7	I-AdverseReaction
reactions	NULOJIX.xml:S1:13312:9	I-AdverseReaction
within	NULOJIX.xml:S1:13322:6	O
one	NULOJIX.xml:S1:13329:3	O
hour	NULOJIX.xml:S1:13333:4	O
of	NULOJIX.xml:S1:13338:2	O
infusion	NULOJIX.xml:S1:13341:8	O
were	NULOJIX.xml:S1:13350:4	O
reported	NULOJIX.xml:S1:13355:8	O
in	NULOJIX.xml:S1:13364:2	O
5%	NULOJIX.xml:S1:13367:2	O
of	NULOJIX.xml:S1:13370:2	O
patients	NULOJIX.xml:S1:13373:8	O
treated	NULOJIX.xml:S1:13382:7	O
with	NULOJIX.xml:S1:13390:4	O
the	NULOJIX.xml:S1:13395:3	O
recommended	NULOJIX.xml:S1:13399:11	O
dose	NULOJIX.xml:S1:13411:4	O
of	NULOJIX.xml:S1:13416:2	O
NULOJIX	NULOJIX.xml:S1:13419:7	O
,	NULOJIX.xml:S1:13426:1	O
similar	NULOJIX.xml:S1:13428:7	O
to	NULOJIX.xml:S1:13436:2	O
the	NULOJIX.xml:S1:13439:3	O
placebo	NULOJIX.xml:S1:13443:7	O
rate	NULOJIX.xml:S1:13451:4	O
.	NULOJIX.xml:S1:13455:1	O

No	NULOJIX.xml:S1:13457:2	O
serious	NULOJIX.xml:S1:13460:7	O
events	NULOJIX.xml:S1:13468:6	O
were	NULOJIX.xml:S1:13475:4	O
reported	NULOJIX.xml:S1:13480:8	O
through	NULOJIX.xml:S1:13489:7	O
Year	NULOJIX.xml:S1:13497:4	O
3	NULOJIX.xml:S1:13502:1	O
.	NULOJIX.xml:S1:13503:1	O

The	NULOJIX.xml:S1:13505:3	O
most	NULOJIX.xml:S1:13509:4	O
frequent	NULOJIX.xml:S1:13514:8	O
reactions	NULOJIX.xml:S1:13523:9	O
were	NULOJIX.xml:S1:13533:4	O
hypotension	NULOJIX.xml:S1:13538:11	B-AdverseReaction
and	NULOJIX.xml:S1:13550:3	O
hypertension	NULOJIX.xml:S1:13554:12	B-AdverseReaction
.	NULOJIX.xml:S1:13566:1	O

Proteinuria	NULOJIX.xml:S1:13574:11	O

At	NULOJIX.xml:S1:13589:2	O
Month	NULOJIX.xml:S1:13592:5	O
1	NULOJIX.xml:S1:13598:1	O
after	NULOJIX.xml:S1:13600:5	O
transplantation	NULOJIX.xml:S1:13606:15	O
in	NULOJIX.xml:S1:13622:2	O
Studies	NULOJIX.xml:S1:13625:7	O
1	NULOJIX.xml:S1:13633:1	O
and	NULOJIX.xml:S1:13635:3	O
2	NULOJIX.xml:S1:13639:1	O
,	NULOJIX.xml:S1:13640:1	O
the	NULOJIX.xml:S1:13642:3	O
frequency	NULOJIX.xml:S1:13646:9	O
of	NULOJIX.xml:S1:13656:2	O
2	NULOJIX.xml:S1:13659:1	B-Severity
proteinuria	NULOJIX.xml:S1:13662:11	B-AdverseReaction
on	NULOJIX.xml:S1:13674:2	O
urine	NULOJIX.xml:S1:13677:5	O
dipstick	NULOJIX.xml:S1:13683:8	O
in	NULOJIX.xml:S1:13692:2	O
patients	NULOJIX.xml:S1:13695:8	O
treated	NULOJIX.xml:S1:13704:7	O
with	NULOJIX.xml:S1:13712:4	O
the	NULOJIX.xml:S1:13717:3	O
NULOJIX	NULOJIX.xml:S1:13721:7	O
recommended	NULOJIX.xml:S1:13729:11	O
regimen	NULOJIX.xml:S1:13741:7	O
was	NULOJIX.xml:S1:13749:3	O
33%	NULOJIX.xml:S1:13753:3	O
(	NULOJIX.xml:S1:13757:1	O
130	NULOJIX.xml:S1:13758:3	O
390	NULOJIX.xml:S1:13762:3	O
)	NULOJIX.xml:S1:13765:1	O
and	NULOJIX.xml:S1:13767:3	O
28%	NULOJIX.xml:S1:13771:3	O
(	NULOJIX.xml:S1:13775:1	O
107	NULOJIX.xml:S1:13776:3	O
384	NULOJIX.xml:S1:13780:3	O
)	NULOJIX.xml:S1:13783:1	O
in	NULOJIX.xml:S1:13785:2	O
patients	NULOJIX.xml:S1:13788:8	O
treated	NULOJIX.xml:S1:13797:7	O
with	NULOJIX.xml:S1:13805:4	O
the	NULOJIX.xml:S1:13810:3	O
cyclosporine	NULOJIX.xml:S1:13814:12	O
control	NULOJIX.xml:S1:13827:7	O
regimen	NULOJIX.xml:S1:13835:7	O
.	NULOJIX.xml:S1:13842:1	O

The	NULOJIX.xml:S1:13844:3	O
frequency	NULOJIX.xml:S1:13848:9	O
of	NULOJIX.xml:S1:13858:2	O
2	NULOJIX.xml:S1:13861:1	B-Severity
proteinuria	NULOJIX.xml:S1:13864:11	B-AdverseReaction
was	NULOJIX.xml:S1:13876:3	O
similar	NULOJIX.xml:S1:13880:7	O
between	NULOJIX.xml:S1:13888:7	O
the	NULOJIX.xml:S1:13896:3	O
two	NULOJIX.xml:S1:13900:3	O
treatment	NULOJIX.xml:S1:13904:9	O
groups	NULOJIX.xml:S1:13914:6	O
between	NULOJIX.xml:S1:13921:7	O
one	NULOJIX.xml:S1:13929:3	O
and	NULOJIX.xml:S1:13933:3	O
three	NULOJIX.xml:S1:13937:5	O
years	NULOJIX.xml:S1:13943:5	O
after	NULOJIX.xml:S1:13949:5	O
transplantation	NULOJIX.xml:S1:13955:15	O
(	NULOJIX.xml:S1:13971:1	O
10%	NULOJIX.xml:S1:13973:3	O
in	NULOJIX.xml:S1:13977:2	O
both	NULOJIX.xml:S1:13980:4	O
studies	NULOJIX.xml:S1:13985:7	O
)	NULOJIX.xml:S1:13992:1	O
.	NULOJIX.xml:S1:13993:1	O

There	NULOJIX.xml:S1:13995:5	O
were	NULOJIX.xml:S1:14001:4	O
no	NULOJIX.xml:S1:14006:2	O
differences	NULOJIX.xml:S1:14009:11	O
in	NULOJIX.xml:S1:14021:2	O
the	NULOJIX.xml:S1:14024:3	O
occurrence	NULOJIX.xml:S1:14028:10	O
of	NULOJIX.xml:S1:14039:2	O
3	NULOJIX.xml:S1:14042:1	B-Severity
proteinuria	NULOJIX.xml:S1:14045:11	B-AdverseReaction
(	NULOJIX.xml:S1:14057:1	O
4%	NULOJIX.xml:S1:14059:2	O
in	NULOJIX.xml:S1:14062:2	O
both	NULOJIX.xml:S1:14065:4	O
studies	NULOJIX.xml:S1:14070:7	O
)	NULOJIX.xml:S1:14077:1	O
at	NULOJIX.xml:S1:14079:2	O
any	NULOJIX.xml:S1:14082:3	O
time	NULOJIX.xml:S1:14086:4	O
point	NULOJIX.xml:S1:14091:5	O
,	NULOJIX.xml:S1:14096:1	O
and	NULOJIX.xml:S1:14098:3	O
no	NULOJIX.xml:S1:14102:2	B-Negation
patients	NULOJIX.xml:S1:14105:8	O
experienced	NULOJIX.xml:S1:14114:11	O
4	NULOJIX.xml:S1:14126:1	B-Severity
proteinuria	NULOJIX.xml:S1:14129:11	B-AdverseReaction
.	NULOJIX.xml:S1:14140:1	O

The	NULOJIX.xml:S1:14142:3	O
clinical	NULOJIX.xml:S1:14146:8	O
significance	NULOJIX.xml:S1:14155:12	O
of	NULOJIX.xml:S1:14168:2	O
this	NULOJIX.xml:S1:14171:4	O
increase	NULOJIX.xml:S1:14176:8	O
in	NULOJIX.xml:S1:14185:2	O
early	NULOJIX.xml:S1:14188:5	B-AdverseReaction
proteinuria	NULOJIX.xml:S1:14194:11	I-AdverseReaction
is	NULOJIX.xml:S1:14206:2	O
unknown	NULOJIX.xml:S1:14209:7	O
.	NULOJIX.xml:S1:14216:1	O

Immunogenicity	NULOJIX.xml:S1:14224:14	O

Antibodies	NULOJIX.xml:S1:14242:10	O
directed	NULOJIX.xml:S1:14253:8	O
against	NULOJIX.xml:S1:14262:7	O
the	NULOJIX.xml:S1:14270:3	O
belatacept	NULOJIX.xml:S1:14274:10	O
molecule	NULOJIX.xml:S1:14285:8	O
were	NULOJIX.xml:S1:14294:4	O
assessed	NULOJIX.xml:S1:14299:8	O
in	NULOJIX.xml:S1:14308:2	O
398	NULOJIX.xml:S1:14311:3	O
patients	NULOJIX.xml:S1:14315:8	O
treated	NULOJIX.xml:S1:14324:7	O
with	NULOJIX.xml:S1:14332:4	O
the	NULOJIX.xml:S1:14337:3	O
NULOJIX	NULOJIX.xml:S1:14341:7	O
recommended	NULOJIX.xml:S1:14349:11	O
regimen	NULOJIX.xml:S1:14361:7	O
in	NULOJIX.xml:S1:14369:2	O
Studies	NULOJIX.xml:S1:14372:7	O
1	NULOJIX.xml:S1:14380:1	O
and	NULOJIX.xml:S1:14382:3	O
2	NULOJIX.xml:S1:14386:1	O
(	NULOJIX.xml:S1:14388:1	O
212	NULOJIX.xml:S1:14389:3	O
of	NULOJIX.xml:S1:14393:2	O
these	NULOJIX.xml:S1:14396:5	O
patients	NULOJIX.xml:S1:14402:8	O
were	NULOJIX.xml:S1:14411:4	O
treated	NULOJIX.xml:S1:14416:7	O
for	NULOJIX.xml:S1:14424:3	O
at	NULOJIX.xml:S1:14428:2	O
least	NULOJIX.xml:S1:14431:5	O
2	NULOJIX.xml:S1:14437:1	O
years	NULOJIX.xml:S1:14439:5	O
)	NULOJIX.xml:S1:14444:1	O
.	NULOJIX.xml:S1:14445:1	O

Of	NULOJIX.xml:S1:14447:2	O
the	NULOJIX.xml:S1:14450:3	O
372	NULOJIX.xml:S1:14454:3	O
patients	NULOJIX.xml:S1:14458:8	O
with	NULOJIX.xml:S1:14467:4	O
immunogenicity	NULOJIX.xml:S1:14472:14	O
assessment	NULOJIX.xml:S1:14487:10	O
at	NULOJIX.xml:S1:14498:2	O
baseline	NULOJIX.xml:S1:14501:8	O
(	NULOJIX.xml:S1:14510:1	O
prior	NULOJIX.xml:S1:14511:5	O
to	NULOJIX.xml:S1:14517:2	O
receiving	NULOJIX.xml:S1:14520:9	O
belatacept	NULOJIX.xml:S1:14530:10	O
treatment	NULOJIX.xml:S1:14541:9	O
)	NULOJIX.xml:S1:14550:1	O
,	NULOJIX.xml:S1:14551:1	O
29	NULOJIX.xml:S1:14553:2	O
patients	NULOJIX.xml:S1:14556:8	O
tested	NULOJIX.xml:S1:14565:6	O
positive	NULOJIX.xml:S1:14572:8	O
for	NULOJIX.xml:S1:14581:3	O
anti	NULOJIX.xml:S1:14585:4	O
-	NULOJIX.xml:S1:14589:1	O
belatacept	NULOJIX.xml:S1:14590:10	O
antibodies	NULOJIX.xml:S1:14601:10	O
;	NULOJIX.xml:S1:14611:1	O
13	NULOJIX.xml:S1:14613:2	O
of	NULOJIX.xml:S1:14616:2	O
these	NULOJIX.xml:S1:14619:5	O
patients	NULOJIX.xml:S1:14625:8	O
had	NULOJIX.xml:S1:14634:3	O
antibodies	NULOJIX.xml:S1:14638:10	O
to	NULOJIX.xml:S1:14649:2	O
the	NULOJIX.xml:S1:14652:3	O
modified	NULOJIX.xml:S1:14656:8	O
cytotoxic	NULOJIX.xml:S1:14665:9	O
T	NULOJIX.xml:S1:14675:1	O
-	NULOJIX.xml:S1:14676:1	O
lymphocyte	NULOJIX.xml:S1:14677:10	O
-	NULOJIX.xml:S1:14687:1	O
associated	NULOJIX.xml:S1:14688:10	O
antigen	NULOJIX.xml:S1:14699:7	O
4	NULOJIX.xml:S1:14707:1	O
(	NULOJIX.xml:S1:14709:1	O
CTLA	NULOJIX.xml:S1:14710:4	O
-	NULOJIX.xml:S1:14714:1	O
4	NULOJIX.xml:S1:14715:1	O
)	NULOJIX.xml:S1:14716:1	O
.	NULOJIX.xml:S1:14717:1	O

Anti	NULOJIX.xml:S1:14719:4	O
-	NULOJIX.xml:S1:14723:1	O
belatacept	NULOJIX.xml:S1:14724:10	O
antibody	NULOJIX.xml:S1:14735:8	O
titers	NULOJIX.xml:S1:14744:6	O
did	NULOJIX.xml:S1:14751:3	O
not	NULOJIX.xml:S1:14755:3	O
increase	NULOJIX.xml:S1:14759:8	O
during	NULOJIX.xml:S1:14768:6	O
treatment	NULOJIX.xml:S1:14775:9	O
in	NULOJIX.xml:S1:14785:2	O
these	NULOJIX.xml:S1:14788:5	O
29	NULOJIX.xml:S1:14794:2	O
patients	NULOJIX.xml:S1:14797:8	O
.	NULOJIX.xml:S1:14805:1	O

Eight	NULOJIX.xml:S1:14811:5	O
(	NULOJIX.xml:S1:14817:1	O
2%	NULOJIX.xml:S1:14818:2	O
)	NULOJIX.xml:S1:14820:1	O
patients	NULOJIX.xml:S1:14822:8	O
developed	NULOJIX.xml:S1:14831:9	O
antibodies	NULOJIX.xml:S1:14841:10	O
during	NULOJIX.xml:S1:14852:6	O
treatment	NULOJIX.xml:S1:14859:9	O
with	NULOJIX.xml:S1:14869:4	O
the	NULOJIX.xml:S1:14874:3	O
NULOJIX	NULOJIX.xml:S1:14878:7	O
recommended	NULOJIX.xml:S1:14886:11	O
regimen	NULOJIX.xml:S1:14898:7	O
.	NULOJIX.xml:S1:14905:1	O

In	NULOJIX.xml:S1:14907:2	O
the	NULOJIX.xml:S1:14910:3	O
patients	NULOJIX.xml:S1:14914:8	O
who	NULOJIX.xml:S1:14923:3	O
developed	NULOJIX.xml:S1:14927:9	O
antibodies	NULOJIX.xml:S1:14937:10	O
during	NULOJIX.xml:S1:14948:6	O
treatment	NULOJIX.xml:S1:14955:9	O
,	NULOJIX.xml:S1:14964:1	O
the	NULOJIX.xml:S1:14966:3	O
median	NULOJIX.xml:S1:14970:6	O
titer	NULOJIX.xml:S1:14977:5	O
(	NULOJIX.xml:S1:14983:1	O
by	NULOJIX.xml:S1:14984:2	O
dilution	NULOJIX.xml:S1:14987:8	O
method	NULOJIX.xml:S1:14996:6	O
)	NULOJIX.xml:S1:15002:1	O
was	NULOJIX.xml:S1:15004:3	O
8	NULOJIX.xml:S1:15008:1	O
,	NULOJIX.xml:S1:15009:1	O
with	NULOJIX.xml:S1:15011:4	O
a	NULOJIX.xml:S1:15016:1	O
range	NULOJIX.xml:S1:15018:5	O
of	NULOJIX.xml:S1:15024:2	O
5	NULOJIX.xml:S1:15027:1	O
to	NULOJIX.xml:S1:15029:2	O
80	NULOJIX.xml:S1:15032:2	O
.	NULOJIX.xml:S1:15034:1	O

Of	NULOJIX.xml:S1:15036:2	O
56	NULOJIX.xml:S1:15039:2	O
patients	NULOJIX.xml:S1:15042:8	O
who	NULOJIX.xml:S1:15051:3	O
tested	NULOJIX.xml:S1:15055:6	O
negative	NULOJIX.xml:S1:15062:8	O
for	NULOJIX.xml:S1:15071:3	O
antibodies	NULOJIX.xml:S1:15075:10	O
during	NULOJIX.xml:S1:15086:6	O
treatment	NULOJIX.xml:S1:15093:9	O
and	NULOJIX.xml:S1:15103:3	O
reassessed	NULOJIX.xml:S1:15107:10	O
approximately	NULOJIX.xml:S1:15118:13	O
7	NULOJIX.xml:S1:15132:1	O
half	NULOJIX.xml:S1:15134:4	O
-	NULOJIX.xml:S1:15138:1	O
lives	NULOJIX.xml:S1:15139:5	O
after	NULOJIX.xml:S1:15145:5	O
discontinuation	NULOJIX.xml:S1:15151:15	O
of	NULOJIX.xml:S1:15167:2	O
NULOJIX	NULOJIX.xml:S1:15170:7	O
,	NULOJIX.xml:S1:15177:1	O
1	NULOJIX.xml:S1:15179:1	O
tested	NULOJIX.xml:S1:15181:6	O
antibody	NULOJIX.xml:S1:15188:8	O
positive	NULOJIX.xml:S1:15197:8	O
.	NULOJIX.xml:S1:15205:1	O

Anti	NULOJIX.xml:S1:15207:4	O
-	NULOJIX.xml:S1:15211:1	O
belatacept	NULOJIX.xml:S1:15212:10	O
antibody	NULOJIX.xml:S1:15223:8	O
development	NULOJIX.xml:S1:15232:11	O
was	NULOJIX.xml:S1:15244:3	O
not	NULOJIX.xml:S1:15248:3	O
associated	NULOJIX.xml:S1:15252:10	O
with	NULOJIX.xml:S1:15263:4	O
altered	NULOJIX.xml:S1:15268:7	O
clearance	NULOJIX.xml:S1:15276:9	O
of	NULOJIX.xml:S1:15286:2	O
belatacept	NULOJIX.xml:S1:15289:10	O
.	NULOJIX.xml:S1:15299:1	O

Samples	NULOJIX.xml:S1:15305:7	O
from	NULOJIX.xml:S1:15313:4	O
6	NULOJIX.xml:S1:15318:1	O
patients	NULOJIX.xml:S1:15320:8	O
with	NULOJIX.xml:S1:15329:4	O
confirmed	NULOJIX.xml:S1:15334:9	O
binding	NULOJIX.xml:S1:15344:7	O
activity	NULOJIX.xml:S1:15352:8	O
to	NULOJIX.xml:S1:15361:2	O
the	NULOJIX.xml:S1:15364:3	O
modified	NULOJIX.xml:S1:15368:8	O
cytotoxic	NULOJIX.xml:S1:15377:9	O
T	NULOJIX.xml:S1:15387:1	O
-	NULOJIX.xml:S1:15388:1	O
lymphocyte	NULOJIX.xml:S1:15389:10	O
-	NULOJIX.xml:S1:15399:1	O
associated	NULOJIX.xml:S1:15400:10	O
antigen	NULOJIX.xml:S1:15411:7	O
4	NULOJIX.xml:S1:15419:1	O
(	NULOJIX.xml:S1:15421:1	O
CTLA	NULOJIX.xml:S1:15422:4	O
-	NULOJIX.xml:S1:15426:1	O
4	NULOJIX.xml:S1:15427:1	O
)	NULOJIX.xml:S1:15428:1	O
region	NULOJIX.xml:S1:15430:6	O
of	NULOJIX.xml:S1:15437:2	O
the	NULOJIX.xml:S1:15440:3	O
belatacept	NULOJIX.xml:S1:15444:10	O
molecule	NULOJIX.xml:S1:15455:8	O
were	NULOJIX.xml:S1:15464:4	O
assessed	NULOJIX.xml:S1:15469:8	O
by	NULOJIX.xml:S1:15478:2	O
an	NULOJIX.xml:S1:15481:2	O
in	NULOJIX.xml:S1:15485:2	O
vitro	NULOJIX.xml:S1:15488:5	O
bioassay	NULOJIX.xml:S1:15495:8	O
for	NULOJIX.xml:S1:15504:3	O
the	NULOJIX.xml:S1:15508:3	O
presence	NULOJIX.xml:S1:15512:8	O
of	NULOJIX.xml:S1:15521:2	O
neutralizing	NULOJIX.xml:S1:15524:12	O
antibodies	NULOJIX.xml:S1:15537:10	O
.	NULOJIX.xml:S1:15547:1	O

Three	NULOJIX.xml:S1:15549:5	O
of	NULOJIX.xml:S1:15555:2	O
these	NULOJIX.xml:S1:15558:5	O
6	NULOJIX.xml:S1:15564:1	O
patients	NULOJIX.xml:S1:15566:8	O
tested	NULOJIX.xml:S1:15575:6	O
positive	NULOJIX.xml:S1:15582:8	O
for	NULOJIX.xml:S1:15591:3	O
neutralizing	NULOJIX.xml:S1:15595:12	O
antibodies	NULOJIX.xml:S1:15608:10	O
.	NULOJIX.xml:S1:15618:1	O

However	NULOJIX.xml:S1:15620:7	O
,	NULOJIX.xml:S1:15627:1	O
the	NULOJIX.xml:S1:15629:3	O
development	NULOJIX.xml:S1:15633:11	O
of	NULOJIX.xml:S1:15645:2	O
neutralizing	NULOJIX.xml:S1:15648:12	O
antibodies	NULOJIX.xml:S1:15661:10	O
may	NULOJIX.xml:S1:15672:3	O
be	NULOJIX.xml:S1:15676:2	O
underreported	NULOJIX.xml:S1:15679:13	O
due	NULOJIX.xml:S1:15693:3	O
to	NULOJIX.xml:S1:15697:2	O
lack	NULOJIX.xml:S1:15700:4	O
of	NULOJIX.xml:S1:15705:2	O
assay	NULOJIX.xml:S1:15708:5	O
sensitivity	NULOJIX.xml:S1:15714:11	O
.	NULOJIX.xml:S1:15725:1	O

The	NULOJIX.xml:S1:15731:3	O
clinical	NULOJIX.xml:S1:15735:8	O
impact	NULOJIX.xml:S1:15744:6	O
of	NULOJIX.xml:S1:15751:2	O
anti	NULOJIX.xml:S1:15754:4	O
-	NULOJIX.xml:S1:15758:1	O
belatacept	NULOJIX.xml:S1:15759:10	O
antibodies	NULOJIX.xml:S1:15770:10	O
(	NULOJIX.xml:S1:15781:1	O
including	NULOJIX.xml:S1:15782:9	O
neutralizing	NULOJIX.xml:S1:15792:12	O
anti	NULOJIX.xml:S1:15805:4	O
-	NULOJIX.xml:S1:15809:1	O
belatacept	NULOJIX.xml:S1:15810:10	O
antibodies	NULOJIX.xml:S1:15821:10	O
)	NULOJIX.xml:S1:15831:1	O
could	NULOJIX.xml:S1:15833:5	O
not	NULOJIX.xml:S1:15839:3	O
be	NULOJIX.xml:S1:15843:2	O
determined	NULOJIX.xml:S1:15846:10	O
in	NULOJIX.xml:S1:15857:2	O
the	NULOJIX.xml:S1:15860:3	O
studies	NULOJIX.xml:S1:15864:7	O
.	NULOJIX.xml:S1:15871:1	O

The	NULOJIX.xml:S1:15877:3	O
data	NULOJIX.xml:S1:15881:4	O
reflect	NULOJIX.xml:S1:15886:7	O
the	NULOJIX.xml:S1:15894:3	O
percentage	NULOJIX.xml:S1:15898:10	O
of	NULOJIX.xml:S1:15909:2	O
patients	NULOJIX.xml:S1:15912:8	O
whose	NULOJIX.xml:S1:15921:5	O
test	NULOJIX.xml:S1:15927:4	O
results	NULOJIX.xml:S1:15932:7	O
were	NULOJIX.xml:S1:15940:4	O
positive	NULOJIX.xml:S1:15945:8	O
for	NULOJIX.xml:S1:15954:3	O
antibodies	NULOJIX.xml:S1:15958:10	O
to	NULOJIX.xml:S1:15969:2	O
belatacept	NULOJIX.xml:S1:15972:10	O
in	NULOJIX.xml:S1:15983:2	O
specific	NULOJIX.xml:S1:15986:8	O
assays	NULOJIX.xml:S1:15995:6	O
.	NULOJIX.xml:S1:16001:1	O

The	NULOJIX.xml:S1:16003:3	O
observed	NULOJIX.xml:S1:16007:8	O
incidence	NULOJIX.xml:S1:16016:9	O
of	NULOJIX.xml:S1:16026:2	O
antibody	NULOJIX.xml:S1:16029:8	O
(	NULOJIX.xml:S1:16038:1	O
including	NULOJIX.xml:S1:16039:9	O
neutralizing	NULOJIX.xml:S1:16049:12	O
antibody	NULOJIX.xml:S1:16062:8	O
)	NULOJIX.xml:S1:16070:1	O
positivity	NULOJIX.xml:S1:16072:10	O
in	NULOJIX.xml:S1:16083:2	O
an	NULOJIX.xml:S1:16086:2	O
assay	NULOJIX.xml:S1:16089:5	O
may	NULOJIX.xml:S1:16095:3	O
be	NULOJIX.xml:S1:16099:2	O
influenced	NULOJIX.xml:S1:16102:10	O
by	NULOJIX.xml:S1:16113:2	O
several	NULOJIX.xml:S1:16116:7	O
factors	NULOJIX.xml:S1:16124:7	O
including	NULOJIX.xml:S1:16132:9	O
assay	NULOJIX.xml:S1:16142:5	O
sensitivity	NULOJIX.xml:S1:16148:11	O
and	NULOJIX.xml:S1:16160:3	O
specificity	NULOJIX.xml:S1:16164:11	O
,	NULOJIX.xml:S1:16175:1	O
assay	NULOJIX.xml:S1:16177:5	O
methodology	NULOJIX.xml:S1:16183:11	O
,	NULOJIX.xml:S1:16194:1	O
sample	NULOJIX.xml:S1:16196:6	O
handling	NULOJIX.xml:S1:16203:8	O
,	NULOJIX.xml:S1:16211:1	O
timing	NULOJIX.xml:S1:16213:6	O
of	NULOJIX.xml:S1:16220:2	O
sample	NULOJIX.xml:S1:16223:6	O
collection	NULOJIX.xml:S1:16230:10	O
,	NULOJIX.xml:S1:16240:1	O
concomitant	NULOJIX.xml:S1:16242:11	O
medications	NULOJIX.xml:S1:16254:11	O
,	NULOJIX.xml:S1:16265:1	O
and	NULOJIX.xml:S1:16267:3	O
underlying	NULOJIX.xml:S1:16271:10	O
disease	NULOJIX.xml:S1:16282:7	O
.	NULOJIX.xml:S1:16289:1	O

For	NULOJIX.xml:S1:16291:3	O
these	NULOJIX.xml:S1:16295:5	O
reasons	NULOJIX.xml:S1:16301:7	O
,	NULOJIX.xml:S1:16308:1	O
comparison	NULOJIX.xml:S1:16310:10	O
of	NULOJIX.xml:S1:16321:2	O
the	NULOJIX.xml:S1:16324:3	O
incidence	NULOJIX.xml:S1:16328:9	O
of	NULOJIX.xml:S1:16338:2	O
antibodies	NULOJIX.xml:S1:16341:10	O
to	NULOJIX.xml:S1:16352:2	O
belatacept	NULOJIX.xml:S1:16355:10	O
with	NULOJIX.xml:S1:16366:4	O
the	NULOJIX.xml:S1:16371:3	O
incidence	NULOJIX.xml:S1:16375:9	O
of	NULOJIX.xml:S1:16385:2	O
antibodies	NULOJIX.xml:S1:16388:10	O
to	NULOJIX.xml:S1:16399:2	O
other	NULOJIX.xml:S1:16402:5	O
products	NULOJIX.xml:S1:16408:8	O
may	NULOJIX.xml:S1:16417:3	O
be	NULOJIX.xml:S1:16421:2	O
misleading	NULOJIX.xml:S1:16424:10	O
.	NULOJIX.xml:S1:16434:1	O

New	NULOJIX.xml:S1:16442:3	O
-	NULOJIX.xml:S1:16445:1	O
Onset	NULOJIX.xml:S1:16446:5	O
Diabetes	NULOJIX.xml:S1:16452:8	O
After	NULOJIX.xml:S1:16461:5	O
Transplantation	NULOJIX.xml:S1:16467:15	O

The	NULOJIX.xml:S1:16486:3	O
incidence	NULOJIX.xml:S1:16490:9	O
of	NULOJIX.xml:S1:16500:2	O
new	NULOJIX.xml:S1:16503:3	B-AdverseReaction
-	NULOJIX.xml:S1:16506:1	I-AdverseReaction
onset	NULOJIX.xml:S1:16507:5	I-AdverseReaction
diabetes	NULOJIX.xml:S1:16513:8	I-AdverseReaction
after	NULOJIX.xml:S1:16522:5	I-AdverseReaction
transplantation	NULOJIX.xml:S1:16528:15	I-AdverseReaction
(	NULOJIX.xml:S1:16544:1	O
NODAT	NULOJIX.xml:S1:16545:5	B-AdverseReaction
)	NULOJIX.xml:S1:16550:1	O
was	NULOJIX.xml:S1:16552:3	O
defined	NULOJIX.xml:S1:16556:7	O
in	NULOJIX.xml:S1:16564:2	O
Studies	NULOJIX.xml:S1:16567:7	O
1	NULOJIX.xml:S1:16575:1	O
and	NULOJIX.xml:S1:16577:3	O
2	NULOJIX.xml:S1:16581:1	O
as	NULOJIX.xml:S1:16583:2	O
use	NULOJIX.xml:S1:16586:3	O
of	NULOJIX.xml:S1:16590:2	O
an	NULOJIX.xml:S1:16593:2	O
antidiabetic	NULOJIX.xml:S1:16596:12	O
agent	NULOJIX.xml:S1:16609:5	O
for	NULOJIX.xml:S1:16615:3	O
30	NULOJIX.xml:S1:16621:2	O
days	NULOJIX.xml:S1:16624:4	O
or	NULOJIX.xml:S1:16629:2	O
2	NULOJIX.xml:S1:16634:1	O
fasting	NULOJIX.xml:S1:16636:7	O
plasma	NULOJIX.xml:S1:16644:6	O
glucose	NULOJIX.xml:S1:16651:7	O
values	NULOJIX.xml:S1:16659:6	O
126	NULOJIX.xml:S1:16668:3	O
mg	NULOJIX.xml:S1:16672:2	O
dL	NULOJIX.xml:S1:16675:2	O
(	NULOJIX.xml:S1:16678:1	O
7.0	NULOJIX.xml:S1:16679:3	O
mmol	NULOJIX.xml:S1:16683:4	O
L	NULOJIX.xml:S1:16688:1	O
)	NULOJIX.xml:S1:16689:1	O
post	NULOJIX.xml:S1:16691:4	O
-	NULOJIX.xml:S1:16695:1	O
transplantation	NULOJIX.xml:S1:16696:15	O
.	NULOJIX.xml:S1:16711:1	O

Of	NULOJIX.xml:S1:16713:2	O
the	NULOJIX.xml:S1:16716:3	O
patients	NULOJIX.xml:S1:16720:8	O
treated	NULOJIX.xml:S1:16729:7	O
with	NULOJIX.xml:S1:16737:4	O
the	NULOJIX.xml:S1:16742:3	O
NULOJIX	NULOJIX.xml:S1:16746:7	O
recommended	NULOJIX.xml:S1:16754:11	O
regimen	NULOJIX.xml:S1:16766:7	O
,	NULOJIX.xml:S1:16773:1	O
5%	NULOJIX.xml:S1:16775:2	O
(	NULOJIX.xml:S1:16778:1	O
14	NULOJIX.xml:S1:16779:2	O
304	NULOJIX.xml:S1:16782:3	O
)	NULOJIX.xml:S1:16785:1	O
developed	NULOJIX.xml:S1:16787:9	O
NODAT	NULOJIX.xml:S1:16797:5	B-AdverseReaction
by	NULOJIX.xml:S1:16803:2	O
the	NULOJIX.xml:S1:16806:3	O
end	NULOJIX.xml:S1:16810:3	O
of	NULOJIX.xml:S1:16814:2	O
one	NULOJIX.xml:S1:16817:3	O
year	NULOJIX.xml:S1:16821:4	O
compared	NULOJIX.xml:S1:16826:8	O
to	NULOJIX.xml:S1:16835:2	O
10%	NULOJIX.xml:S1:16838:3	O
(	NULOJIX.xml:S1:16842:1	O
27	NULOJIX.xml:S1:16843:2	O
280	NULOJIX.xml:S1:16846:3	O
)	NULOJIX.xml:S1:16849:1	O
of	NULOJIX.xml:S1:16851:2	O
patients	NULOJIX.xml:S1:16854:8	O
on	NULOJIX.xml:S1:16863:2	O
the	NULOJIX.xml:S1:16866:3	O
cyclosporine	NULOJIX.xml:S1:16870:12	O
control	NULOJIX.xml:S1:16883:7	O
regimen	NULOJIX.xml:S1:16891:7	O
.	NULOJIX.xml:S1:16898:1	O

However	NULOJIX.xml:S1:16900:7	O
,	NULOJIX.xml:S1:16907:1	O
by	NULOJIX.xml:S1:16909:2	O
the	NULOJIX.xml:S1:16912:3	O
end	NULOJIX.xml:S1:16916:3	O
of	NULOJIX.xml:S1:16920:2	O
the	NULOJIX.xml:S1:16923:3	O
third	NULOJIX.xml:S1:16927:5	O
year	NULOJIX.xml:S1:16933:4	O
,	NULOJIX.xml:S1:16937:1	O
the	NULOJIX.xml:S1:16939:3	O
cumulative	NULOJIX.xml:S1:16943:10	O
incidence	NULOJIX.xml:S1:16954:9	O
of	NULOJIX.xml:S1:16964:2	O
NODAT	NULOJIX.xml:S1:16967:5	B-AdverseReaction
was	NULOJIX.xml:S1:16973:3	O
8%	NULOJIX.xml:S1:16977:2	O
(	NULOJIX.xml:S1:16980:1	O
24	NULOJIX.xml:S1:16981:2	O
304	NULOJIX.xml:S1:16984:3	O
)	NULOJIX.xml:S1:16987:1	O
in	NULOJIX.xml:S1:16989:2	O
patients	NULOJIX.xml:S1:16992:8	O
treated	NULOJIX.xml:S1:17001:7	O
with	NULOJIX.xml:S1:17009:4	O
the	NULOJIX.xml:S1:17014:3	O
NULOJIX	NULOJIX.xml:S1:17018:7	O
recommended	NULOJIX.xml:S1:17026:11	O
regimen	NULOJIX.xml:S1:17038:7	O
and	NULOJIX.xml:S1:17046:3	O
10%	NULOJIX.xml:S1:17050:3	O
(	NULOJIX.xml:S1:17054:1	O
29	NULOJIX.xml:S1:17055:2	O
280	NULOJIX.xml:S1:17058:3	O
)	NULOJIX.xml:S1:17061:1	O
in	NULOJIX.xml:S1:17063:2	O
patients	NULOJIX.xml:S1:17066:8	O
treated	NULOJIX.xml:S1:17075:7	O
with	NULOJIX.xml:S1:17083:4	O
the	NULOJIX.xml:S1:17088:3	O
cyclosporine	NULOJIX.xml:S1:17092:12	O
regimen	NULOJIX.xml:S1:17105:7	O
.	NULOJIX.xml:S1:17112:1	O

Hypertension	NULOJIX.xml:S1:17120:12	O

Blood	NULOJIX.xml:S1:17136:5	O
pressure	NULOJIX.xml:S1:17142:8	O
and	NULOJIX.xml:S1:17151:3	O
use	NULOJIX.xml:S1:17155:3	O
of	NULOJIX.xml:S1:17159:2	O
antihypertensive	NULOJIX.xml:S1:17162:16	O
medications	NULOJIX.xml:S1:17179:11	O
were	NULOJIX.xml:S1:17191:4	O
reported	NULOJIX.xml:S1:17196:8	O
in	NULOJIX.xml:S1:17205:2	O
Studies	NULOJIX.xml:S1:17208:7	O
1	NULOJIX.xml:S1:17216:1	O
and	NULOJIX.xml:S1:17218:3	O
2	NULOJIX.xml:S1:17222:1	O
.	NULOJIX.xml:S1:17223:1	O

By	NULOJIX.xml:S1:17225:2	O
Year	NULOJIX.xml:S1:17228:4	O
3	NULOJIX.xml:S1:17233:1	O
,	NULOJIX.xml:S1:17234:1	O
one	NULOJIX.xml:S1:17236:3	O
or	NULOJIX.xml:S1:17240:2	O
more	NULOJIX.xml:S1:17243:4	O
antihypertensive	NULOJIX.xml:S1:17248:16	O
medications	NULOJIX.xml:S1:17265:11	O
were	NULOJIX.xml:S1:17277:4	O
used	NULOJIX.xml:S1:17282:4	O
in	NULOJIX.xml:S1:17287:2	O
85%	NULOJIX.xml:S1:17290:3	O
of	NULOJIX.xml:S1:17294:2	O
NULOJIX	NULOJIX.xml:S1:17297:7	O
-	NULOJIX.xml:S1:17304:1	O
treated	NULOJIX.xml:S1:17305:7	O
patients	NULOJIX.xml:S1:17313:8	O
and	NULOJIX.xml:S1:17322:3	O
92%	NULOJIX.xml:S1:17326:3	O
of	NULOJIX.xml:S1:17330:2	O
cyclosporine	NULOJIX.xml:S1:17333:12	O
-	NULOJIX.xml:S1:17345:1	O
treated	NULOJIX.xml:S1:17346:7	O
patients	NULOJIX.xml:S1:17354:8	O
.	NULOJIX.xml:S1:17362:1	O

At	NULOJIX.xml:S1:17364:2	O
one	NULOJIX.xml:S1:17367:3	O
year	NULOJIX.xml:S1:17371:4	O
after	NULOJIX.xml:S1:17376:5	O
transplantation	NULOJIX.xml:S1:17382:15	O
,	NULOJIX.xml:S1:17397:1	O
systolic	NULOJIX.xml:S1:17399:8	O
blood	NULOJIX.xml:S1:17408:5	O
pressures	NULOJIX.xml:S1:17414:9	O
were	NULOJIX.xml:S1:17424:4	O
8	NULOJIX.xml:S1:17429:1	O
mmHg	NULOJIX.xml:S1:17431:4	O
lower	NULOJIX.xml:S1:17436:5	O
and	NULOJIX.xml:S1:17442:3	O
diastolic	NULOJIX.xml:S1:17446:9	O
blood	NULOJIX.xml:S1:17456:5	O
pressures	NULOJIX.xml:S1:17462:9	O
were	NULOJIX.xml:S1:17472:4	O
3	NULOJIX.xml:S1:17477:1	O
mmHg	NULOJIX.xml:S1:17479:4	O
lower	NULOJIX.xml:S1:17484:5	O
in	NULOJIX.xml:S1:17490:2	O
patients	NULOJIX.xml:S1:17493:8	O
treated	NULOJIX.xml:S1:17502:7	O
with	NULOJIX.xml:S1:17510:4	O
the	NULOJIX.xml:S1:17515:3	O
NULOJIX	NULOJIX.xml:S1:17519:7	O
recommended	NULOJIX.xml:S1:17527:11	O
regimen	NULOJIX.xml:S1:17539:7	O
compared	NULOJIX.xml:S1:17547:8	O
to	NULOJIX.xml:S1:17556:2	O
the	NULOJIX.xml:S1:17559:3	O
cyclosporine	NULOJIX.xml:S1:17563:12	O
control	NULOJIX.xml:S1:17576:7	O
regimen	NULOJIX.xml:S1:17584:7	O
.	NULOJIX.xml:S1:17591:1	O

At	NULOJIX.xml:S1:17593:2	O
three	NULOJIX.xml:S1:17596:5	O
years	NULOJIX.xml:S1:17602:5	O
after	NULOJIX.xml:S1:17608:5	O
transplantation	NULOJIX.xml:S1:17614:15	O
,	NULOJIX.xml:S1:17629:1	O
systolic	NULOJIX.xml:S1:17631:8	O
blood	NULOJIX.xml:S1:17640:5	O
pressures	NULOJIX.xml:S1:17646:9	O
were	NULOJIX.xml:S1:17656:4	O
6	NULOJIX.xml:S1:17661:1	O
mmHg	NULOJIX.xml:S1:17663:4	O
lower	NULOJIX.xml:S1:17668:5	O
and	NULOJIX.xml:S1:17674:3	O
diastolic	NULOJIX.xml:S1:17678:9	O
blood	NULOJIX.xml:S1:17688:5	O
pressures	NULOJIX.xml:S1:17694:9	O
were	NULOJIX.xml:S1:17704:4	O
3	NULOJIX.xml:S1:17709:1	O
mmHg	NULOJIX.xml:S1:17711:4	O
lower	NULOJIX.xml:S1:17716:5	O
in	NULOJIX.xml:S1:17722:2	O
NULOJIX	NULOJIX.xml:S1:17725:7	O
-	NULOJIX.xml:S1:17732:1	O
treated	NULOJIX.xml:S1:17733:7	O
patients	NULOJIX.xml:S1:17741:8	O
compared	NULOJIX.xml:S1:17750:8	O
to	NULOJIX.xml:S1:17759:2	O
cyclosporine	NULOJIX.xml:S1:17762:12	O
-	NULOJIX.xml:S1:17774:1	O
treated	NULOJIX.xml:S1:17775:7	O
patients	NULOJIX.xml:S1:17783:8	O
.	NULOJIX.xml:S1:17791:1	O

Hypertension	NULOJIX.xml:S1:17793:12	B-AdverseReaction
was	NULOJIX.xml:S1:17806:3	O
reported	NULOJIX.xml:S1:17810:8	O
as	NULOJIX.xml:S1:17819:2	O
an	NULOJIX.xml:S1:17822:2	O
adverse	NULOJIX.xml:S1:17825:7	O
reaction	NULOJIX.xml:S1:17833:8	O
in	NULOJIX.xml:S1:17842:2	O
32%	NULOJIX.xml:S1:17845:3	O
of	NULOJIX.xml:S1:17849:2	O
NULOJIX	NULOJIX.xml:S1:17852:7	O
-	NULOJIX.xml:S1:17859:1	O
treated	NULOJIX.xml:S1:17860:7	O
patients	NULOJIX.xml:S1:17868:8	O
and	NULOJIX.xml:S1:17877:3	O
37%	NULOJIX.xml:S1:17881:3	O
of	NULOJIX.xml:S1:17885:2	O
cyclosporine	NULOJIX.xml:S1:17888:12	O
-	NULOJIX.xml:S1:17900:1	O
treated	NULOJIX.xml:S1:17901:7	O
patients	NULOJIX.xml:S1:17909:8	O
(	NULOJIX.xml:S1:17918:1	O
see	NULOJIX.xml:S1:17919:3	O
Table	NULOJIX.xml:S1:17923:5	O
4	NULOJIX.xml:S1:17929:1	O
)	NULOJIX.xml:S1:17930:1	O
.	NULOJIX.xml:S1:17931:1	O

Dyslipidemia	NULOJIX.xml:S1:17939:12	O

Mean	NULOJIX.xml:S1:17955:4	O
values	NULOJIX.xml:S1:17960:6	O
of	NULOJIX.xml:S1:17967:2	O
total	NULOJIX.xml:S1:17970:5	O
cholesterol	NULOJIX.xml:S1:17976:11	O
,	NULOJIX.xml:S1:17987:1	O
HDL	NULOJIX.xml:S1:17989:3	O
,	NULOJIX.xml:S1:17992:1	O
LDL	NULOJIX.xml:S1:17994:3	O
,	NULOJIX.xml:S1:17997:1	O
and	NULOJIX.xml:S1:17999:3	O
triglycerides	NULOJIX.xml:S1:18003:13	O
were	NULOJIX.xml:S1:18017:4	O
reported	NULOJIX.xml:S1:18022:8	O
in	NULOJIX.xml:S1:18031:2	O
Studies	NULOJIX.xml:S1:18034:7	O
1	NULOJIX.xml:S1:18042:1	O
and	NULOJIX.xml:S1:18044:3	O
2	NULOJIX.xml:S1:18048:1	O
.	NULOJIX.xml:S1:18049:1	O

At	NULOJIX.xml:S1:18051:2	O
one	NULOJIX.xml:S1:18054:3	O
year	NULOJIX.xml:S1:18058:4	O
after	NULOJIX.xml:S1:18063:5	O
transplantation	NULOJIX.xml:S1:18069:15	O
these	NULOJIX.xml:S1:18085:5	O
values	NULOJIX.xml:S1:18091:6	O
were	NULOJIX.xml:S1:18098:4	O
183	NULOJIX.xml:S1:18103:3	O
mg	NULOJIX.xml:S1:18107:2	O
dL	NULOJIX.xml:S1:18110:2	O
,	NULOJIX.xml:S1:18112:1	O
50	NULOJIX.xml:S1:18114:2	O
mg	NULOJIX.xml:S1:18117:2	O
dL	NULOJIX.xml:S1:18120:2	O
,	NULOJIX.xml:S1:18122:1	O
102	NULOJIX.xml:S1:18124:3	O
mg	NULOJIX.xml:S1:18128:2	O
dL	NULOJIX.xml:S1:18131:2	O
,	NULOJIX.xml:S1:18133:1	O
and	NULOJIX.xml:S1:18135:3	O
151	NULOJIX.xml:S1:18139:3	O
mg	NULOJIX.xml:S1:18143:2	O
dL	NULOJIX.xml:S1:18146:2	O
,	NULOJIX.xml:S1:18148:1	O
respectively	NULOJIX.xml:S1:18150:12	O
,	NULOJIX.xml:S1:18162:1	O
in	NULOJIX.xml:S1:18164:2	O
401	NULOJIX.xml:S1:18167:3	O
patients	NULOJIX.xml:S1:18171:8	O
treated	NULOJIX.xml:S1:18180:7	O
with	NULOJIX.xml:S1:18188:4	O
the	NULOJIX.xml:S1:18193:3	O
NULOJIX	NULOJIX.xml:S1:18197:7	O
recommended	NULOJIX.xml:S1:18205:11	O
regimen	NULOJIX.xml:S1:18217:7	O
and	NULOJIX.xml:S1:18225:3	O
196	NULOJIX.xml:S1:18229:3	O
mg	NULOJIX.xml:S1:18233:2	O
dL	NULOJIX.xml:S1:18236:2	O
,	NULOJIX.xml:S1:18238:1	O
48	NULOJIX.xml:S1:18240:2	O
mg	NULOJIX.xml:S1:18243:2	O
dL	NULOJIX.xml:S1:18246:2	O
,	NULOJIX.xml:S1:18248:1	O
108	NULOJIX.xml:S1:18250:3	O
mg	NULOJIX.xml:S1:18254:2	O
dL	NULOJIX.xml:S1:18257:2	O
,	NULOJIX.xml:S1:18259:1	O
and	NULOJIX.xml:S1:18261:3	O
195	NULOJIX.xml:S1:18265:3	O
mg	NULOJIX.xml:S1:18269:2	O
dL	NULOJIX.xml:S1:18272:2	O
,	NULOJIX.xml:S1:18274:1	O
respectively	NULOJIX.xml:S1:18276:12	O
,	NULOJIX.xml:S1:18288:1	O
in	NULOJIX.xml:S1:18290:2	O
405	NULOJIX.xml:S1:18293:3	O
patients	NULOJIX.xml:S1:18297:8	O
treated	NULOJIX.xml:S1:18306:7	O
with	NULOJIX.xml:S1:18314:4	O
the	NULOJIX.xml:S1:18319:3	O
cyclosporine	NULOJIX.xml:S1:18323:12	O
control	NULOJIX.xml:S1:18336:7	O
regimen	NULOJIX.xml:S1:18344:7	O
.	NULOJIX.xml:S1:18351:1	O

At	NULOJIX.xml:S1:18353:2	O
three	NULOJIX.xml:S1:18356:5	O
years	NULOJIX.xml:S1:18362:5	O
after	NULOJIX.xml:S1:18368:5	O
transplantation	NULOJIX.xml:S1:18374:15	O
,	NULOJIX.xml:S1:18389:1	O
the	NULOJIX.xml:S1:18391:3	O
total	NULOJIX.xml:S1:18395:5	O
cholesterol	NULOJIX.xml:S1:18401:11	O
,	NULOJIX.xml:S1:18412:1	O
HDL	NULOJIX.xml:S1:18414:3	O
,	NULOJIX.xml:S1:18417:1	O
LDL	NULOJIX.xml:S1:18419:3	O
,	NULOJIX.xml:S1:18422:1	O
and	NULOJIX.xml:S1:18424:3	O
triglycerides	NULOJIX.xml:S1:18428:13	O
were	NULOJIX.xml:S1:18442:4	O
176	NULOJIX.xml:S1:18447:3	O
mg	NULOJIX.xml:S1:18451:2	O
dL	NULOJIX.xml:S1:18454:2	O
,	NULOJIX.xml:S1:18456:1	O
49	NULOJIX.xml:S1:18458:2	O
mg	NULOJIX.xml:S1:18461:2	O
dL	NULOJIX.xml:S1:18464:2	O
,	NULOJIX.xml:S1:18466:1	O
100	NULOJIX.xml:S1:18468:3	O
mg	NULOJIX.xml:S1:18472:2	O
dL	NULOJIX.xml:S1:18475:2	O
,	NULOJIX.xml:S1:18477:1	O
and	NULOJIX.xml:S1:18479:3	O
141	NULOJIX.xml:S1:18483:3	O
mg	NULOJIX.xml:S1:18487:2	O
dL	NULOJIX.xml:S1:18490:2	O
,	NULOJIX.xml:S1:18492:1	O
respectively	NULOJIX.xml:S1:18494:12	O
,	NULOJIX.xml:S1:18506:1	O
in	NULOJIX.xml:S1:18508:2	O
NULOJIX	NULOJIX.xml:S1:18511:7	O
-	NULOJIX.xml:S1:18518:1	O
treated	NULOJIX.xml:S1:18519:7	O
patients	NULOJIX.xml:S1:18527:8	O
compared	NULOJIX.xml:S1:18536:8	O
to	NULOJIX.xml:S1:18545:2	O
193	NULOJIX.xml:S1:18548:3	O
mg	NULOJIX.xml:S1:18552:2	O
dL	NULOJIX.xml:S1:18555:2	O
,	NULOJIX.xml:S1:18557:1	O
48	NULOJIX.xml:S1:18559:2	O
mg	NULOJIX.xml:S1:18562:2	O
dL	NULOJIX.xml:S1:18565:2	O
,	NULOJIX.xml:S1:18567:1	O
106	NULOJIX.xml:S1:18569:3	O
mg	NULOJIX.xml:S1:18573:2	O
dL	NULOJIX.xml:S1:18576:2	O
,	NULOJIX.xml:S1:18578:1	O
and	NULOJIX.xml:S1:18580:3	O
180	NULOJIX.xml:S1:18584:3	O
mg	NULOJIX.xml:S1:18588:2	O
dL	NULOJIX.xml:S1:18591:2	O
in	NULOJIX.xml:S1:18594:2	O
cyclosporine	NULOJIX.xml:S1:18597:12	O
-	NULOJIX.xml:S1:18609:1	O
treated	NULOJIX.xml:S1:18610:7	O
patients	NULOJIX.xml:S1:18618:8	O
.	NULOJIX.xml:S1:18626:1	O

The	NULOJIX.xml:S1:18632:3	O
clinical	NULOJIX.xml:S1:18636:8	O
significance	NULOJIX.xml:S1:18645:12	O
of	NULOJIX.xml:S1:18658:2	O
the	NULOJIX.xml:S1:18661:3	O
lower	NULOJIX.xml:S1:18665:5	O
mean	NULOJIX.xml:S1:18671:4	O
triglyceride	NULOJIX.xml:S1:18676:12	O
values	NULOJIX.xml:S1:18689:6	O
in	NULOJIX.xml:S1:18696:2	O
NULOJIX	NULOJIX.xml:S1:18699:7	O
-	NULOJIX.xml:S1:18706:1	O
treated	NULOJIX.xml:S1:18707:7	O
patients	NULOJIX.xml:S1:18715:8	O
at	NULOJIX.xml:S1:18724:2	O
one	NULOJIX.xml:S1:18727:3	O
and	NULOJIX.xml:S1:18731:3	O
three	NULOJIX.xml:S1:18735:5	O
years	NULOJIX.xml:S1:18741:5	O
is	NULOJIX.xml:S1:18747:2	O
unknown	NULOJIX.xml:S1:18750:7	O
.	NULOJIX.xml:S1:18757:1	O

Other	NULOJIX.xml:S1:18765:5	O
Adverse	NULOJIX.xml:S1:18771:7	O
Reactions	NULOJIX.xml:S1:18779:9	O

Adverse	NULOJIX.xml:S1:18792:7	O
reactions	NULOJIX.xml:S1:18800:9	O
that	NULOJIX.xml:S1:18810:4	O
occurred	NULOJIX.xml:S1:18815:8	O
at	NULOJIX.xml:S1:18824:2	O
a	NULOJIX.xml:S1:18827:1	O
frequency	NULOJIX.xml:S1:18829:9	O
of	NULOJIX.xml:S1:18839:2	O
10%	NULOJIX.xml:S1:18844:3	O
in	NULOJIX.xml:S1:18848:2	O
patients	NULOJIX.xml:S1:18851:8	O
treated	NULOJIX.xml:S1:18860:7	O
with	NULOJIX.xml:S1:18868:4	O
the	NULOJIX.xml:S1:18873:3	O
NULOJIX	NULOJIX.xml:S1:18877:7	O
recommended	NULOJIX.xml:S1:18885:11	O
regimen	NULOJIX.xml:S1:18897:7	O
or	NULOJIX.xml:S1:18905:2	O
cyclosporine	NULOJIX.xml:S1:18908:12	O
control	NULOJIX.xml:S1:18921:7	O
regimen	NULOJIX.xml:S1:18929:7	O
in	NULOJIX.xml:S1:18937:2	O
Studies	NULOJIX.xml:S1:18940:7	O
1	NULOJIX.xml:S1:18948:1	O
and	NULOJIX.xml:S1:18950:3	O
2	NULOJIX.xml:S1:18954:1	O
through	NULOJIX.xml:S1:18956:7	O
three	NULOJIX.xml:S1:18964:5	O
years	NULOJIX.xml:S1:18970:5	O
are	NULOJIX.xml:S1:18976:3	O
summarized	NULOJIX.xml:S1:18980:10	O
by	NULOJIX.xml:S1:18991:2	O
preferred	NULOJIX.xml:S1:18994:9	O
term	NULOJIX.xml:S1:19004:4	O
in	NULOJIX.xml:S1:19009:2	O
decreasing	NULOJIX.xml:S1:19012:10	O
order	NULOJIX.xml:S1:19023:5	O
of	NULOJIX.xml:S1:19029:2	O
frequency	NULOJIX.xml:S1:19032:9	O
within	NULOJIX.xml:S1:19042:6	O
Table	NULOJIX.xml:S1:19049:5	O
4	NULOJIX.xml:S1:19055:1	O
.	NULOJIX.xml:S1:19056:1	O

Table	NULOJIX.xml:S1:19062:5	O
4	NULOJIX.xml:S1:19068:1	O
:	NULOJIX.xml:S1:19069:1	O
Adverse	NULOJIX.xml:S1:19071:7	O
Reactions	NULOJIX.xml:S1:19079:9	O
Reported	NULOJIX.xml:S1:19089:8	O
by	NULOJIX.xml:S1:19098:2	O
10%	NULOJIX.xml:S1:19103:3	O
of	NULOJIX.xml:S1:19107:2	O
Patients	NULOJIX.xml:S1:19110:8	O
Treated	NULOJIX.xml:S1:19119:7	O
with	NULOJIX.xml:S1:19127:4	O
Either	NULOJIX.xml:S1:19132:6	O
the	NULOJIX.xml:S1:19139:3	O
NULOJIX	NULOJIX.xml:S1:19143:7	O
Recommended	NULOJIX.xml:S1:19151:11	O
Regimen	NULOJIX.xml:S1:19163:7	O
or	NULOJIX.xml:S1:19171:2	O
Control	NULOJIX.xml:S1:19174:7	O
in	NULOJIX.xml:S1:19182:2	O
Studies	NULOJIX.xml:S1:19185:7	O
1	NULOJIX.xml:S1:19193:1	O
and	NULOJIX.xml:S1:19195:3	O
2	NULOJIX.xml:S1:19199:1	O
Through	NULOJIX.xml:S1:19201:7	O
Three	NULOJIX.xml:S1:19209:5	O
Years	NULOJIX.xml:S1:19215:5	O
,	NULOJIX.xml:S1:19221:1	O

Adverse	NULOJIX.xml:S1:19227:7	O
Reaction	NULOJIX.xml:S1:19235:8	O
NULOJIX	NULOJIX.xml:S1:19275:7	O
Recommended	NULOJIX.xml:S1:19286:11	O
Regimen	NULOJIX.xml:S1:19298:7	O
N	NULOJIX.xml:S1:19309:1	O
401	NULOJIX.xml:S1:19311:3	O
Cyclosporine	NULOJIX.xml:S1:19325:12	O
N	NULOJIX.xml:S1:19341:1	O
405	NULOJIX.xml:S1:19343:3	O

All	NULOJIX.xml:S1:19363:3	O

randomized	NULOJIX.xml:S1:19367:10	O
and	NULOJIX.xml:S1:19378:3	O
transplanted	NULOJIX.xml:S1:19382:12	O
patients	NULOJIX.xml:S1:19395:8	O
in	NULOJIX.xml:S1:19404:2	O
Studies	NULOJIX.xml:S1:19407:7	O
1	NULOJIX.xml:S1:19415:1	O
and	NULOJIX.xml:S1:19417:3	O
2	NULOJIX.xml:S1:19421:1	O
.	NULOJIX.xml:S1:19422:1	O

Studies	NULOJIX.xml:S1:19427:7	O
1	NULOJIX.xml:S1:19435:1	O
and	NULOJIX.xml:S1:19437:3	O
2	NULOJIX.xml:S1:19441:1	O
were	NULOJIX.xml:S1:19443:4	O
not	NULOJIX.xml:S1:19448:3	O
designed	NULOJIX.xml:S1:19452:8	O
to	NULOJIX.xml:S1:19461:2	O
support	NULOJIX.xml:S1:19464:7	O
comparative	NULOJIX.xml:S1:19472:11	O
claims	NULOJIX.xml:S1:19484:6	O
for	NULOJIX.xml:S1:19491:3	O
NULOJIX	NULOJIX.xml:S1:19495:7	O
for	NULOJIX.xml:S1:19503:3	O
the	NULOJIX.xml:S1:19507:3	O
adverse	NULOJIX.xml:S1:19511:7	O
reactions	NULOJIX.xml:S1:19519:9	O
reported	NULOJIX.xml:S1:19529:8	O
in	NULOJIX.xml:S1:19538:2	O
this	NULOJIX.xml:S1:19541:4	O
table	NULOJIX.xml:S1:19546:5	O
.	NULOJIX.xml:S1:19551:1	O

Infections	NULOJIX.xml:S1:19561:10	O

and	NULOJIX.xml:S1:19572:3	O
Infestations	NULOJIX.xml:S1:19576:12	O

Urinary	NULOJIX.xml:S1:19674:7	B-AdverseReaction
tract	NULOJIX.xml:S1:19682:5	I-AdverseReaction
infection	NULOJIX.xml:S1:19688:9	I-AdverseReaction
37	NULOJIX.xml:S1:19718:2	O
36	NULOJIX.xml:S1:19747:2	O

Upper	NULOJIX.xml:S1:19783:5	B-AdverseReaction
respiratory	NULOJIX.xml:S1:19789:11	I-AdverseReaction
infection	NULOJIX.xml:S1:19801:9	I-AdverseReaction
15	NULOJIX.xml:S1:19827:2	O
16	NULOJIX.xml:S1:19856:2	O

Nasopharyngitis	NULOJIX.xml:S1:19892:15	B-AdverseReaction
13	NULOJIX.xml:S1:19936:2	O
16	NULOJIX.xml:S1:19965:2	O

Cytomegalovirus	NULOJIX.xml:S1:20001:15	B-AdverseReaction
infection	NULOJIX.xml:S1:20017:9	I-AdverseReaction
12	NULOJIX.xml:S1:20045:2	O
12	NULOJIX.xml:S1:20074:2	O

Influenza	NULOJIX.xml:S1:20110:9	B-AdverseReaction
11	NULOJIX.xml:S1:20154:2	O
8	NULOJIX.xml:S1:20183:1	O

Bronchitis	NULOJIX.xml:S1:20219:10	B-AdverseReaction
10	NULOJIX.xml:S1:20263:2	O
7	NULOJIX.xml:S1:20292:1	O

Gastrointestinal	NULOJIX.xml:S1:20324:16	O
Disorders	NULOJIX.xml:S1:20341:9	O

Diarrhea	NULOJIX.xml:S1:20437:8	B-AdverseReaction
39	NULOJIX.xml:S1:20481:2	O
36	NULOJIX.xml:S1:20510:2	O

Constipation	NULOJIX.xml:S1:20546:12	B-AdverseReaction
33	NULOJIX.xml:S1:20590:2	O
35	NULOJIX.xml:S1:20619:2	O

Nausea	NULOJIX.xml:S1:20655:6	B-AdverseReaction
24	NULOJIX.xml:S1:20699:2	O
27	NULOJIX.xml:S1:20728:2	O

Vomiting	NULOJIX.xml:S1:20764:8	B-AdverseReaction
22	NULOJIX.xml:S1:20808:2	O
20	NULOJIX.xml:S1:20837:2	O

Abdominal	NULOJIX.xml:S1:20873:9	B-AdverseReaction
pain	NULOJIX.xml:S1:20883:4	I-AdverseReaction
19	NULOJIX.xml:S1:20917:2	O
16	NULOJIX.xml:S1:20946:2	O

Abdominal	NULOJIX.xml:S1:20982:9	B-AdverseReaction
pain	NULOJIX.xml:S1:20992:4	I-AdverseReaction
upper	NULOJIX.xml:S1:20997:5	I-AdverseReaction
9	NULOJIX.xml:S1:21026:1	O
10	NULOJIX.xml:S1:21055:2	O

Metabolism	NULOJIX.xml:S1:21087:10	O
and	NULOJIX.xml:S1:21098:3	O
Nutrition	NULOJIX.xml:S1:21102:9	O
Disorders	NULOJIX.xml:S1:21112:9	O

Hyperkalemia	NULOJIX.xml:S1:21200:12	B-AdverseReaction
20	NULOJIX.xml:S1:21244:2	O
20	NULOJIX.xml:S1:21273:2	O

Hypokalemia	NULOJIX.xml:S1:21309:11	B-AdverseReaction
21	NULOJIX.xml:S1:21353:2	O
14	NULOJIX.xml:S1:21382:2	O

Hypophosphatemia	NULOJIX.xml:S1:21418:16	B-AdverseReaction
19	NULOJIX.xml:S1:21462:2	O
13	NULOJIX.xml:S1:21491:2	O

Dyslipidemia	NULOJIX.xml:S1:21527:12	B-AdverseReaction
19	NULOJIX.xml:S1:21571:2	O
24	NULOJIX.xml:S1:21600:2	O

Hyperglycemia	NULOJIX.xml:S1:21636:13	B-AdverseReaction
16	NULOJIX.xml:S1:21680:2	O
17	NULOJIX.xml:S1:21709:2	O

Hypocalcemia	NULOJIX.xml:S1:21745:12	B-AdverseReaction
13	NULOJIX.xml:S1:21789:2	O
11	NULOJIX.xml:S1:21818:2	O

Hypercholesterolemia	NULOJIX.xml:S1:21854:20	B-AdverseReaction
11	NULOJIX.xml:S1:21898:2	O
11	NULOJIX.xml:S1:21927:2	O

Hypomagnesemia	NULOJIX.xml:S1:21963:14	B-AdverseReaction
7	NULOJIX.xml:S1:22007:1	O
10	NULOJIX.xml:S1:22036:2	O

Hyperuricemia	NULOJIX.xml:S1:22072:13	B-AdverseReaction
5	NULOJIX.xml:S1:22116:1	O
12	NULOJIX.xml:S1:22145:2	O

Procedural	NULOJIX.xml:S1:22177:10	O
Complications	NULOJIX.xml:S1:22188:13	O

Graft	NULOJIX.xml:S1:22290:5	B-AdverseReaction
dysfunction	NULOJIX.xml:S1:22296:11	I-AdverseReaction
25	NULOJIX.xml:S1:22334:2	O
34	NULOJIX.xml:S1:22363:2	O

General	NULOJIX.xml:S1:22395:7	O
Disorders	NULOJIX.xml:S1:22403:9	O

Peripheral	NULOJIX.xml:S1:22508:10	B-AdverseReaction
edema	NULOJIX.xml:S1:22519:5	I-AdverseReaction
34	NULOJIX.xml:S1:22552:2	O
42	NULOJIX.xml:S1:22581:2	O

Pyrexia	NULOJIX.xml:S1:22617:7	B-AdverseReaction
28	NULOJIX.xml:S1:22661:2	O
26	NULOJIX.xml:S1:22690:2	O

Blood	NULOJIX.xml:S1:22722:5	O
and	NULOJIX.xml:S1:22728:3	O
Lymphatic	NULOJIX.xml:S1:22732:9	O
System	NULOJIX.xml:S1:22742:6	O
Disorders	NULOJIX.xml:S1:22749:9	O

Anemia	NULOJIX.xml:S1:22835:6	B-AdverseReaction
45	NULOJIX.xml:S1:22879:2	O
44	NULOJIX.xml:S1:22908:2	O

Leukopenia	NULOJIX.xml:S1:22944:10	B-AdverseReaction
20	NULOJIX.xml:S1:22988:2	O
23	NULOJIX.xml:S1:23017:2	O

Renal	NULOJIX.xml:S1:23049:5	O
and	NULOJIX.xml:S1:23055:3	O
Urinary	NULOJIX.xml:S1:23059:7	O
Disorders	NULOJIX.xml:S1:23067:9	O

Hematuria	NULOJIX.xml:S1:23162:9	B-AdverseReaction
16	NULOJIX.xml:S1:23206:2	O
18	NULOJIX.xml:S1:23235:2	O

Proteinuria	NULOJIX.xml:S1:23271:11	B-AdverseReaction
16	NULOJIX.xml:S1:23315:2	O
12	NULOJIX.xml:S1:23344:2	O

Dysuria	NULOJIX.xml:S1:23380:7	B-AdverseReaction
11	NULOJIX.xml:S1:23424:2	O
11	NULOJIX.xml:S1:23453:2	O

Renal	NULOJIX.xml:S1:23489:5	B-AdverseReaction
tubular	NULOJIX.xml:S1:23495:7	I-AdverseReaction
necrosis	NULOJIX.xml:S1:23503:8	I-AdverseReaction
9	NULOJIX.xml:S1:23533:1	O
13	NULOJIX.xml:S1:23562:2	O

Vascular	NULOJIX.xml:S1:23594:8	O
Disorders	NULOJIX.xml:S1:23603:9	O

Hypertension	NULOJIX.xml:S1:23707:12	B-AdverseReaction
32	NULOJIX.xml:S1:23751:2	O
37	NULOJIX.xml:S1:23780:2	O

Hypotension	NULOJIX.xml:S1:23816:11	B-AdverseReaction
18	NULOJIX.xml:S1:23860:2	O
12	NULOJIX.xml:S1:23889:2	O

Respiratory	NULOJIX.xml:S1:23921:11	O
,	NULOJIX.xml:S1:23932:1	O
Thoracic	NULOJIX.xml:S1:23934:8	O
,	NULOJIX.xml:S1:23942:1	O
and	NULOJIX.xml:S1:23944:3	O
Mediastinal	NULOJIX.xml:S1:23948:11	O
Disorders	NULOJIX.xml:S1:23960:9	O

Cough	NULOJIX.xml:S1:24038:5	B-AdverseReaction
24	NULOJIX.xml:S1:24082:2	O
18	NULOJIX.xml:S1:24111:2	O

Dyspnea	NULOJIX.xml:S1:24147:7	B-AdverseReaction
12	NULOJIX.xml:S1:24191:2	O
15	NULOJIX.xml:S1:24220:2	O

Investigations	NULOJIX.xml:S1:24252:14	O

Blood	NULOJIX.xml:S1:24365:5	B-AdverseReaction
creatinine	NULOJIX.xml:S1:24371:10	I-AdverseReaction
increased	NULOJIX.xml:S1:24382:9	I-AdverseReaction
15	NULOJIX.xml:S1:24409:2	O
20	NULOJIX.xml:S1:24438:2	O

Musculoskeletal	NULOJIX.xml:S1:24470:15	O
and	NULOJIX.xml:S1:24486:3	O
Connective	NULOJIX.xml:S1:24490:10	O
Tissue	NULOJIX.xml:S1:24501:6	O
Disorders	NULOJIX.xml:S1:24508:9	O

Arthralgia	NULOJIX.xml:S1:24586:10	B-AdverseReaction
17	NULOJIX.xml:S1:24630:2	O
13	NULOJIX.xml:S1:24659:2	O

Back	NULOJIX.xml:S1:24695:4	B-AdverseReaction
pain	NULOJIX.xml:S1:24700:4	I-AdverseReaction
13	NULOJIX.xml:S1:24739:2	O
13	NULOJIX.xml:S1:24768:2	O

Nervous	NULOJIX.xml:S1:24800:7	O
System	NULOJIX.xml:S1:24808:6	O
Disorders	NULOJIX.xml:S1:24815:9	O

Headache	NULOJIX.xml:S1:24913:8	B-AdverseReaction
21	NULOJIX.xml:S1:24957:2	O
18	NULOJIX.xml:S1:24986:2	O

Dizziness	NULOJIX.xml:S1:25022:9	B-AdverseReaction
9	NULOJIX.xml:S1:25066:1	O
10	NULOJIX.xml:S1:25095:2	O

Tremor	NULOJIX.xml:S1:25131:6	B-AdverseReaction
8	NULOJIX.xml:S1:25175:1	O
17	NULOJIX.xml:S1:25204:2	O

Skin	NULOJIX.xml:S1:25236:4	O
and	NULOJIX.xml:S1:25241:3	O
Subcutaneous	NULOJIX.xml:S1:25245:12	O
Tissue	NULOJIX.xml:S1:25258:6	O
Disorders	NULOJIX.xml:S1:25265:9	O

Acne	NULOJIX.xml:S1:25349:4	B-AdverseReaction
8	NULOJIX.xml:S1:25393:1	O
11	NULOJIX.xml:S1:25422:2	O

Psychiatric	NULOJIX.xml:S1:25454:11	O
Disorders	NULOJIX.xml:S1:25466:9	O

Insomnia	NULOJIX.xml:S1:25567:8	B-AdverseReaction
15	NULOJIX.xml:S1:25611:2	O
18	NULOJIX.xml:S1:25640:2	O

Anxiety	NULOJIX.xml:S1:25676:7	B-AdverseReaction
10	NULOJIX.xml:S1:25720:2	O
11	NULOJIX.xml:S1:25749:2	O

Selected	NULOJIX.xml:S1:25788:8	O
adverse	NULOJIX.xml:S1:25797:7	O
reactions	NULOJIX.xml:S1:25805:9	O
occurring	NULOJIX.xml:S1:25815:9	O
in	NULOJIX.xml:S1:25825:2	O
10%	NULOJIX.xml:S1:25829:3	O
from	NULOJIX.xml:S1:25833:4	O
NULOJIX	NULOJIX.xml:S1:25838:7	O
-	NULOJIX.xml:S1:25845:1	O
treated	NULOJIX.xml:S1:25846:7	O
patients	NULOJIX.xml:S1:25854:8	O
in	NULOJIX.xml:S1:25863:2	O
either	NULOJIX.xml:S1:25866:6	O
regimen	NULOJIX.xml:S1:25873:7	O
through	NULOJIX.xml:S1:25881:7	O
three	NULOJIX.xml:S1:25889:5	O
years	NULOJIX.xml:S1:25895:5	O
in	NULOJIX.xml:S1:25901:2	O
Studies	NULOJIX.xml:S1:25904:7	O
1	NULOJIX.xml:S1:25912:1	O
and	NULOJIX.xml:S1:25914:3	O
2	NULOJIX.xml:S1:25918:1	O
are	NULOJIX.xml:S1:25920:3	O
listed	NULOJIX.xml:S1:25924:6	O
below	NULOJIX.xml:S1:25931:5	O
:	NULOJIX.xml:S1:25936:1	O

Immune	NULOJIX.xml:S1:25944:6	O

System	NULOJIX.xml:S1:25951:6	O
Disorders	NULOJIX.xml:S1:25958:9	O
:	NULOJIX.xml:S1:25967:1	O
Guillain	NULOJIX.xml:S1:25970:8	B-AdverseReaction
-	NULOJIX.xml:S1:25978:1	I-AdverseReaction
Barre	NULOJIX.xml:S1:25979:5	I-AdverseReaction
syndrome	NULOJIX.xml:S1:25985:8	I-AdverseReaction

Infections	NULOJIX.xml:S1:26000:10	O
and	NULOJIX.xml:S1:26011:3	O
Infestations	NULOJIX.xml:S1:26015:12	O
:	NULOJIX.xml:S1:26027:1	O
see	NULOJIX.xml:S1:26030:3	O
Table	NULOJIX.xml:S1:26034:5	O
3	NULOJIX.xml:S1:26040:1	O

Gastrointestinal	NULOJIX.xml:S1:26048:16	O
Disorders	NULOJIX.xml:S1:26065:9	O
:	NULOJIX.xml:S1:26074:1	O
stomatitis	NULOJIX.xml:S1:26077:10	B-AdverseReaction
,	NULOJIX.xml:S1:26087:1	O
including	NULOJIX.xml:S1:26089:9	O
aphthous	NULOJIX.xml:S1:26099:8	B-AdverseReaction
stomatitis	NULOJIX.xml:S1:26108:10	I-AdverseReaction

Injury	NULOJIX.xml:S1:26125:6	O
,	NULOJIX.xml:S1:26131:1	O
Poisoning	NULOJIX.xml:S1:26133:9	O
,	NULOJIX.xml:S1:26142:1	O
and	NULOJIX.xml:S1:26144:3	O
Procedural	NULOJIX.xml:S1:26148:10	O
Complications	NULOJIX.xml:S1:26159:13	O
:	NULOJIX.xml:S1:26172:1	O
chronic	NULOJIX.xml:S1:26175:7	B-AdverseReaction
allograft	NULOJIX.xml:S1:26183:9	I-AdverseReaction
nephropathy	NULOJIX.xml:S1:26193:11	I-AdverseReaction
,	NULOJIX.xml:S1:26204:1	O
complications	NULOJIX.xml:S1:26206:13	B-AdverseReaction
of	NULOJIX.xml:S1:26220:2	I-AdverseReaction
transplanted	NULOJIX.xml:S1:26223:12	I-AdverseReaction
kidney	NULOJIX.xml:S1:26236:6	I-AdverseReaction
,	NULOJIX.xml:S1:26242:1	O
including	NULOJIX.xml:S1:26244:9	O
wound	NULOJIX.xml:S1:26254:5	B-AdverseReaction
dehiscence	NULOJIX.xml:S1:26260:10	I-AdverseReaction
,	NULOJIX.xml:S1:26270:1	O
arteriovenous	NULOJIX.xml:S1:26272:13	B-AdverseReaction
fistula	NULOJIX.xml:S1:26286:7	I-AdverseReaction
thrombosis	NULOJIX.xml:S1:26294:10	I-AdverseReaction

Blood	NULOJIX.xml:S1:26311:5	O
and	NULOJIX.xml:S1:26317:3	O
Lymphatic	NULOJIX.xml:S1:26321:9	O
System	NULOJIX.xml:S1:26331:6	O
Disorders	NULOJIX.xml:S1:26338:9	O
:	NULOJIX.xml:S1:26347:1	O
neutropenia	NULOJIX.xml:S1:26350:11	B-AdverseReaction

Renal	NULOJIX.xml:S1:26368:5	O
and	NULOJIX.xml:S1:26374:3	O
Urinary	NULOJIX.xml:S1:26378:7	O
Disorders	NULOJIX.xml:S1:26386:9	O
:	NULOJIX.xml:S1:26395:1	O
renal	NULOJIX.xml:S1:26398:5	B-AdverseReaction
impairment	NULOJIX.xml:S1:26404:10	I-AdverseReaction
,	NULOJIX.xml:S1:26414:1	O
including	NULOJIX.xml:S1:26416:9	O
acute	NULOJIX.xml:S1:26426:5	B-AdverseReaction
renal	NULOJIX.xml:S1:26432:5	I-AdverseReaction
failure	NULOJIX.xml:S1:26438:7	I-AdverseReaction
,	NULOJIX.xml:S1:26445:1	O
renal	NULOJIX.xml:S1:26447:5	B-AdverseReaction
artery	NULOJIX.xml:S1:26453:6	I-AdverseReaction
stenosis	NULOJIX.xml:S1:26460:8	I-AdverseReaction
,	NULOJIX.xml:S1:26468:1	O
urinary	NULOJIX.xml:S1:26470:7	B-AdverseReaction
incontinence	NULOJIX.xml:S1:26478:12	I-AdverseReaction
,	NULOJIX.xml:S1:26490:1	O
hydronephrosis	NULOJIX.xml:S1:26492:14	B-AdverseReaction

Vascular	NULOJIX.xml:S1:26513:8	O
Disorders	NULOJIX.xml:S1:26522:9	O
:	NULOJIX.xml:S1:26531:1	O
hematoma	NULOJIX.xml:S1:26534:8	B-AdverseReaction
,	NULOJIX.xml:S1:26542:1	O
lymphocele	NULOJIX.xml:S1:26544:10	B-AdverseReaction

Musculoskeletal	NULOJIX.xml:S1:26561:15	O
and	NULOJIX.xml:S1:26577:3	O
Connective	NULOJIX.xml:S1:26581:10	O
Tissue	NULOJIX.xml:S1:26592:6	O
Disorders	NULOJIX.xml:S1:26599:9	O
:	NULOJIX.xml:S1:26608:1	O
musculoskeletal	NULOJIX.xml:S1:26611:15	B-AdverseReaction
pain	NULOJIX.xml:S1:26627:4	I-AdverseReaction

Skin	NULOJIX.xml:S1:26638:4	O
and	NULOJIX.xml:S1:26643:3	O
Subcutaneous	NULOJIX.xml:S1:26647:12	O
Tissue	NULOJIX.xml:S1:26660:6	O
Disorders	NULOJIX.xml:S1:26667:9	O
:	NULOJIX.xml:S1:26676:1	O
alopecia	NULOJIX.xml:S1:26679:8	B-AdverseReaction
,	NULOJIX.xml:S1:26687:1	O
hyperhidrosis	NULOJIX.xml:S1:26689:13	B-AdverseReaction

Cardiac	NULOJIX.xml:S1:26709:7	O
Disorders	NULOJIX.xml:S1:26717:9	O
:	NULOJIX.xml:S1:26726:1	O
atrial	NULOJIX.xml:S1:26729:6	B-AdverseReaction
fibrillation	NULOJIX.xml:S1:26736:12	I-AdverseReaction
\n\n	NULOJIX.xml:S2:0:2	O
BOXED	NULOJIX.xml:S2:6:5	O
WARNING	NULOJIX.xml:S2:12:7	O
:	NULOJIX.xml:S2:19:1	O
WARNING	NULOJIX.xml:S2:21:7	O
:	NULOJIX.xml:S2:28:1	O
POST	NULOJIX.xml:S2:30:4	B-AdverseReaction
-	NULOJIX.xml:S2:34:1	I-AdverseReaction
TRANSPLANT	NULOJIX.xml:S2:35:10	I-AdverseReaction
LYMPHOPROLIFERATIVE	NULOJIX.xml:S2:46:19	I-AdverseReaction
DISORDER	NULOJIX.xml:S2:66:8	I-AdverseReaction
,	NULOJIX.xml:S2:74:1	O
OTHER	NULOJIX.xml:S2:76:5	O
MALIGNANCIES	NULOJIX.xml:S2:82:12	B-AdverseReaction
,	NULOJIX.xml:S2:94:1	O
AND	NULOJIX.xml:S2:96:3	O
SERIOUS	NULOJIX.xml:S2:100:7	B-Severity
INFECTIONS	NULOJIX.xml:S2:108:10	B-AdverseReaction
\n\n	NULOJIX.xml:S2:118:2	O
WARNING	NULOJIX.xml:S2:122:7	O
:	NULOJIX.xml:S2:129:1	O
POST	NULOJIX.xml:S2:131:4	B-AdverseReaction
-	NULOJIX.xml:S2:135:1	I-AdverseReaction
TRANSPLANT	NULOJIX.xml:S2:136:10	I-AdverseReaction
LYMPHOPROLIFERATIVE	NULOJIX.xml:S2:147:19	I-AdverseReaction
DISORDER	NULOJIX.xml:S2:167:8	I-AdverseReaction
,	NULOJIX.xml:S2:175:1	O
OTHER	NULOJIX.xml:S2:177:5	O
MALIGNANCIES	NULOJIX.xml:S2:183:12	B-AdverseReaction
,	NULOJIX.xml:S2:195:1	O
AND	NULOJIX.xml:S2:197:3	O
SERIOUS	NULOJIX.xml:S2:201:7	B-Severity
INFECTIONS	NULOJIX.xml:S2:209:10	B-AdverseReaction
\n\n	NULOJIX.xml:S2:219:2	O
Increased	NULOJIX.xml:S2:225:9	O
risk	NULOJIX.xml:S2:235:4	B-Factor
for	NULOJIX.xml:S2:240:3	O
developing	NULOJIX.xml:S2:244:10	O
post	NULOJIX.xml:S2:255:4	B-AdverseReaction
-	NULOJIX.xml:S2:259:1	I-AdverseReaction
transplant	NULOJIX.xml:S2:260:10	I-AdverseReaction
lymphoproliferative	NULOJIX.xml:S2:271:19	I-AdverseReaction
disorder	NULOJIX.xml:S2:291:8	I-AdverseReaction
(	NULOJIX.xml:S2:300:1	O
PTLD	NULOJIX.xml:S2:301:4	B-AdverseReaction
)	NULOJIX.xml:S2:305:1	O
,	NULOJIX.xml:S2:306:1	O
predominantly	NULOJIX.xml:S2:308:13	O
involving	NULOJIX.xml:S2:322:9	O
the	NULOJIX.xml:S2:332:3	O
central	NULOJIX.xml:S2:336:7	O
nervous	NULOJIX.xml:S2:344:7	O
system	NULOJIX.xml:S2:352:6	O
(	NULOJIX.xml:S2:359:1	O
CNS	NULOJIX.xml:S2:360:3	O
)	NULOJIX.xml:S2:363:1	O
.	NULOJIX.xml:S2:364:1	O

Recipients	NULOJIX.xml:S2:366:10	O
without	NULOJIX.xml:S2:377:7	O
immunity	NULOJIX.xml:S2:385:8	O
to	NULOJIX.xml:S2:394:2	O
Epstein	NULOJIX.xml:S2:397:7	O
-	NULOJIX.xml:S2:404:1	O
Barr	NULOJIX.xml:S2:405:4	O
virus	NULOJIX.xml:S2:410:5	O
(	NULOJIX.xml:S2:416:1	O
EBV	NULOJIX.xml:S2:417:3	O
)	NULOJIX.xml:S2:420:1	O
are	NULOJIX.xml:S2:422:3	O
at	NULOJIX.xml:S2:426:2	O
a	NULOJIX.xml:S2:429:1	O
particularly	NULOJIX.xml:S2:431:12	O
increased	NULOJIX.xml:S2:444:9	O
risk	NULOJIX.xml:S2:454:4	O
;	NULOJIX.xml:S2:458:1	O
therefore	NULOJIX.xml:S2:460:9	O
,	NULOJIX.xml:S2:469:1	O
use	NULOJIX.xml:S2:471:3	O
in	NULOJIX.xml:S2:475:2	O
EBV	NULOJIX.xml:S2:478:3	O
seropositive	NULOJIX.xml:S2:482:12	O
patients	NULOJIX.xml:S2:495:8	O
only	NULOJIX.xml:S2:504:4	O
.	NULOJIX.xml:S2:508:1	O

Do	NULOJIX.xml:S2:510:2	O
not	NULOJIX.xml:S2:513:3	O
use	NULOJIX.xml:S2:517:3	O
NULOJIX	NULOJIX.xml:S2:521:7	O
in	NULOJIX.xml:S2:529:2	O
transplant	NULOJIX.xml:S2:532:10	O
recipients	NULOJIX.xml:S2:543:10	O
who	NULOJIX.xml:S2:554:3	O
are	NULOJIX.xml:S2:558:3	O
EBV	NULOJIX.xml:S2:562:3	O
seronegative	NULOJIX.xml:S2:566:12	O
or	NULOJIX.xml:S2:579:2	O
with	NULOJIX.xml:S2:582:4	O
unknown	NULOJIX.xml:S2:587:7	O
EBV	NULOJIX.xml:S2:595:3	O
serostatus	NULOJIX.xml:S2:599:10	O
[	NULOJIX.xml:S2:610:1	O
see	NULOJIX.xml:S2:611:3	O
Contraindications	NULOJIX.xml:S2:619:17	O
(	NULOJIX.xml:S2:637:1	O
4	NULOJIX.xml:S2:638:1	O
)	NULOJIX.xml:S2:639:1	O
and	NULOJIX.xml:S2:645:3	O
Warnings	NULOJIX.xml:S2:653:8	O
and	NULOJIX.xml:S2:662:3	O
Precautions	NULOJIX.xml:S2:666:11	O
(	NULOJIX.xml:S2:678:1	O
5.1	NULOJIX.xml:S2:679:3	O
)	NULOJIX.xml:S2:682:1	O
]	NULOJIX.xml:S2:687:1	O
.	NULOJIX.xml:S2:688:1	O

Only	NULOJIX.xml:S2:698:4	O
physicians	NULOJIX.xml:S2:703:10	O
experienced	NULOJIX.xml:S2:714:11	O
in	NULOJIX.xml:S2:726:2	O
immunosuppressive	NULOJIX.xml:S2:729:17	O
therapy	NULOJIX.xml:S2:747:7	O
and	NULOJIX.xml:S2:755:3	O
management	NULOJIX.xml:S2:759:10	O
of	NULOJIX.xml:S2:770:2	O
kidney	NULOJIX.xml:S2:773:6	O
transplant	NULOJIX.xml:S2:780:10	O
patients	NULOJIX.xml:S2:791:8	O
should	NULOJIX.xml:S2:800:6	O
prescribe	NULOJIX.xml:S2:807:9	O
NULOJIX	NULOJIX.xml:S2:817:7	O
.	NULOJIX.xml:S2:824:1	O

Patients	NULOJIX.xml:S2:826:8	O
receiving	NULOJIX.xml:S2:835:9	O
the	NULOJIX.xml:S2:845:3	O
drug	NULOJIX.xml:S2:849:4	O
should	NULOJIX.xml:S2:854:6	O
be	NULOJIX.xml:S2:861:2	O
managed	NULOJIX.xml:S2:864:7	O
in	NULOJIX.xml:S2:872:2	O
facilities	NULOJIX.xml:S2:875:10	O
equipped	NULOJIX.xml:S2:886:8	O
and	NULOJIX.xml:S2:895:3	O
staffed	NULOJIX.xml:S2:899:7	O
with	NULOJIX.xml:S2:907:4	O
adequate	NULOJIX.xml:S2:912:8	O
laboratory	NULOJIX.xml:S2:921:10	O
and	NULOJIX.xml:S2:932:3	O
supportive	NULOJIX.xml:S2:936:10	O
medical	NULOJIX.xml:S2:947:7	O
resources	NULOJIX.xml:S2:955:9	O
.	NULOJIX.xml:S2:964:1	O

The	NULOJIX.xml:S2:966:3	O
physician	NULOJIX.xml:S2:970:9	O
responsible	NULOJIX.xml:S2:980:11	O
for	NULOJIX.xml:S2:992:3	O
maintenance	NULOJIX.xml:S2:996:11	O
therapy	NULOJIX.xml:S2:1008:7	O
should	NULOJIX.xml:S2:1016:6	O
have	NULOJIX.xml:S2:1023:4	O
complete	NULOJIX.xml:S2:1028:8	O
information	NULOJIX.xml:S2:1037:11	O
requisite	NULOJIX.xml:S2:1049:9	O
for	NULOJIX.xml:S2:1059:3	O
the	NULOJIX.xml:S2:1063:3	O
follow	NULOJIX.xml:S2:1067:6	O
-	NULOJIX.xml:S2:1073:1	O
up	NULOJIX.xml:S2:1074:2	O
of	NULOJIX.xml:S2:1077:2	O
the	NULOJIX.xml:S2:1080:3	O
patient	NULOJIX.xml:S2:1084:7	O
[	NULOJIX.xml:S2:1092:1	O
see	NULOJIX.xml:S2:1093:3	O
Warnings	NULOJIX.xml:S2:1101:8	O
and	NULOJIX.xml:S2:1110:3	O
Precautions	NULOJIX.xml:S2:1114:11	O
(	NULOJIX.xml:S2:1126:1	O
5.2	NULOJIX.xml:S2:1127:3	O
)	NULOJIX.xml:S2:1130:1	O
]	NULOJIX.xml:S2:1135:1	O
.	NULOJIX.xml:S2:1136:1	O

Increased	NULOJIX.xml:S2:1146:9	B-AdverseReaction
susceptibility	NULOJIX.xml:S2:1156:14	I-AdverseReaction
to	NULOJIX.xml:S2:1171:2	I-AdverseReaction
infection	NULOJIX.xml:S2:1174:9	I-AdverseReaction
and	NULOJIX.xml:S2:1184:3	O
the	NULOJIX.xml:S2:1188:3	O
possible	NULOJIX.xml:S2:1192:8	O
development	NULOJIX.xml:S2:1201:11	O
of	NULOJIX.xml:S2:1213:2	O
malignancies	NULOJIX.xml:S2:1216:12	B-AdverseReaction
may	NULOJIX.xml:S2:1229:3	B-Factor
result	NULOJIX.xml:S2:1233:6	O
from	NULOJIX.xml:S2:1240:4	O
immunosuppression	NULOJIX.xml:S2:1245:17	O
[	NULOJIX.xml:S2:1263:1	O
see	NULOJIX.xml:S2:1264:3	O
Warnings	NULOJIX.xml:S2:1272:8	O
and	NULOJIX.xml:S2:1281:3	O
Precautions	NULOJIX.xml:S2:1285:11	O
(	NULOJIX.xml:S2:1297:1	O
5.1	NULOJIX.xml:S2:1298:3	O
,	NULOJIX.xml:S2:1303:1	O
5.3	NULOJIX.xml:S2:1307:3	O
,	NULOJIX.xml:S2:1312:1	O
5.4	NULOJIX.xml:S2:1316:3	O
,	NULOJIX.xml:S2:1321:1	O
5.5	NULOJIX.xml:S2:1325:3	O
)	NULOJIX.xml:S2:1328:1	O
]	NULOJIX.xml:S2:1333:1	O
.	NULOJIX.xml:S2:1334:1	O

Use	NULOJIX.xml:S2:1344:3	O
in	NULOJIX.xml:S2:1348:2	O
liver	NULOJIX.xml:S2:1351:5	O
transplant	NULOJIX.xml:S2:1357:10	O
patients	NULOJIX.xml:S2:1368:8	O
is	NULOJIX.xml:S2:1377:2	O
not	NULOJIX.xml:S2:1380:3	O
recommended	NULOJIX.xml:S2:1384:11	O
due	NULOJIX.xml:S2:1396:3	O
to	NULOJIX.xml:S2:1400:2	O
an	NULOJIX.xml:S2:1403:2	O
increased	NULOJIX.xml:S2:1406:9	O
risk	NULOJIX.xml:S2:1416:4	O
of	NULOJIX.xml:S2:1421:2	O
graft	NULOJIX.xml:S2:1424:5	O
loss	NULOJIX.xml:S2:1430:4	O
and	NULOJIX.xml:S2:1435:3	O
death	NULOJIX.xml:S2:1439:5	O
[	NULOJIX.xml:S2:1445:1	O
see	NULOJIX.xml:S2:1446:3	O
Warnings	NULOJIX.xml:S2:1454:8	O
and	NULOJIX.xml:S2:1463:3	O
Precautions	NULOJIX.xml:S2:1467:11	O
(	NULOJIX.xml:S2:1479:1	O
5.6	NULOJIX.xml:S2:1480:3	O
)	NULOJIX.xml:S2:1483:1	O
]	NULOJIX.xml:S2:1488:1	O
.	NULOJIX.xml:S2:1489:1	O

EXCERPT	NULOJIX.xml:S2:1499:7	O
:	NULOJIX.xml:S2:1506:1	O
WARNING	NULOJIX.xml:S2:1510:7	O
:	NULOJIX.xml:S2:1517:1	O
POST	NULOJIX.xml:S2:1519:4	B-AdverseReaction
-	NULOJIX.xml:S2:1523:1	I-AdverseReaction
TRANSPLANT	NULOJIX.xml:S2:1524:10	I-AdverseReaction
LYMPHOPROLIFERATIVE	NULOJIX.xml:S2:1535:19	I-AdverseReaction
DISORDER	NULOJIX.xml:S2:1555:8	I-AdverseReaction
,	NULOJIX.xml:S2:1563:1	O
OTHER	NULOJIX.xml:S2:1565:5	O
MALIGNANCIES	NULOJIX.xml:S2:1571:12	B-AdverseReaction
,	NULOJIX.xml:S2:1583:1	O
AND	NULOJIX.xml:S2:1585:3	O
SERIOUS	NULOJIX.xml:S2:1589:7	B-Severity
INFECTIONS	NULOJIX.xml:S2:1597:10	B-AdverseReaction
\n\n\n\n	NULOJIX.xml:S2:1607:4	O
See	NULOJIX.xml:S2:1616:3	O
full	NULOJIX.xml:S2:1620:4	O
prescribing	NULOJIX.xml:S2:1625:11	O
information	NULOJIX.xml:S2:1637:11	O
for	NULOJIX.xml:S2:1649:3	O
complete	NULOJIX.xml:S2:1653:8	O
boxed	NULOJIX.xml:S2:1662:5	O
warning	NULOJIX.xml:S2:1668:7	O
.	NULOJIX.xml:S2:1675:1	O

Increased	NULOJIX.xml:S2:1688:9	O
risk	NULOJIX.xml:S2:1698:4	B-Factor
for	NULOJIX.xml:S2:1703:3	O
developing	NULOJIX.xml:S2:1707:10	O
post	NULOJIX.xml:S2:1718:4	B-AdverseReaction
-	NULOJIX.xml:S2:1722:1	I-AdverseReaction
transplant	NULOJIX.xml:S2:1723:10	I-AdverseReaction
lymphoproliferative	NULOJIX.xml:S2:1734:19	I-AdverseReaction
disorder	NULOJIX.xml:S2:1754:8	I-AdverseReaction
(	NULOJIX.xml:S2:1763:1	O
PTLD	NULOJIX.xml:S2:1764:4	B-AdverseReaction
)	NULOJIX.xml:S2:1768:1	O
,	NULOJIX.xml:S2:1769:1	O
predominantly	NULOJIX.xml:S2:1771:13	O
involving	NULOJIX.xml:S2:1785:9	O
the	NULOJIX.xml:S2:1795:3	O
central	NULOJIX.xml:S2:1799:7	O
nervous	NULOJIX.xml:S2:1807:7	O
system	NULOJIX.xml:S2:1815:6	O
(	NULOJIX.xml:S2:1822:1	O
CNS	NULOJIX.xml:S2:1823:3	O
)	NULOJIX.xml:S2:1826:1	O
.	NULOJIX.xml:S2:1827:1	O

Recipients	NULOJIX.xml:S2:1829:10	O
without	NULOJIX.xml:S2:1840:7	O
immunity	NULOJIX.xml:S2:1848:8	O
to	NULOJIX.xml:S2:1857:2	O
Epstein	NULOJIX.xml:S2:1860:7	O
-	NULOJIX.xml:S2:1867:1	O
Barr	NULOJIX.xml:S2:1868:4	O
virus	NULOJIX.xml:S2:1873:5	O
(	NULOJIX.xml:S2:1879:1	O
EBV	NULOJIX.xml:S2:1880:3	O
)	NULOJIX.xml:S2:1883:1	O
are	NULOJIX.xml:S2:1885:3	O
at	NULOJIX.xml:S2:1889:2	O
a	NULOJIX.xml:S2:1892:1	O
particularly	NULOJIX.xml:S2:1894:12	O
increased	NULOJIX.xml:S2:1907:9	O
risk	NULOJIX.xml:S2:1917:4	O
;	NULOJIX.xml:S2:1921:1	O
therefore	NULOJIX.xml:S2:1923:9	O
,	NULOJIX.xml:S2:1932:1	O
use	NULOJIX.xml:S2:1934:3	O
in	NULOJIX.xml:S2:1938:2	O
EBV	NULOJIX.xml:S2:1941:3	O
seropositive	NULOJIX.xml:S2:1945:12	O
patients	NULOJIX.xml:S2:1958:8	O
only	NULOJIX.xml:S2:1967:4	O
.	NULOJIX.xml:S2:1971:1	O

Do	NULOJIX.xml:S2:1973:2	O
not	NULOJIX.xml:S2:1976:3	O
use	NULOJIX.xml:S2:1980:3	O
NULOJIX	NULOJIX.xml:S2:1984:7	O
in	NULOJIX.xml:S2:1992:2	O
transplant	NULOJIX.xml:S2:1995:10	O
recipients	NULOJIX.xml:S2:2006:10	O
who	NULOJIX.xml:S2:2017:3	O
are	NULOJIX.xml:S2:2021:3	O
EBV	NULOJIX.xml:S2:2025:3	O
seronegative	NULOJIX.xml:S2:2029:12	O
or	NULOJIX.xml:S2:2042:2	O
with	NULOJIX.xml:S2:2045:4	O
unknown	NULOJIX.xml:S2:2050:7	O
serostatus	NULOJIX.xml:S2:2058:10	O
.	NULOJIX.xml:S2:2068:1	O

(	NULOJIX.xml:S2:2070:1	O
4	NULOJIX.xml:S2:2071:1	O
,	NULOJIX.xml:S2:2072:1	O
5.1	NULOJIX.xml:S2:2074:3	O
)	NULOJIX.xml:S2:2077:1	O
\n	NULOJIX.xml:S2:2079:1	O
Only	NULOJIX.xml:S2:2084:4	O
physicians	NULOJIX.xml:S2:2089:10	O
experienced	NULOJIX.xml:S2:2100:11	O
in	NULOJIX.xml:S2:2112:2	O
immunosuppressive	NULOJIX.xml:S2:2115:17	O
therapy	NULOJIX.xml:S2:2133:7	O
and	NULOJIX.xml:S2:2141:3	O
management	NULOJIX.xml:S2:2145:10	O
of	NULOJIX.xml:S2:2156:2	O
kidney	NULOJIX.xml:S2:2159:6	O
transplant	NULOJIX.xml:S2:2166:10	O
patients	NULOJIX.xml:S2:2177:8	O
should	NULOJIX.xml:S2:2186:6	O
prescribe	NULOJIX.xml:S2:2193:9	O
NULOJIX	NULOJIX.xml:S2:2203:7	O
.	NULOJIX.xml:S2:2210:1	O

(	NULOJIX.xml:S2:2212:1	O
5.2	NULOJIX.xml:S2:2213:3	O
)	NULOJIX.xml:S2:2216:1	O
\n	NULOJIX.xml:S2:2218:1	O
Increased	NULOJIX.xml:S2:2223:9	B-AdverseReaction
susceptibility	NULOJIX.xml:S2:2233:14	I-AdverseReaction
to	NULOJIX.xml:S2:2248:2	I-AdverseReaction
infection	NULOJIX.xml:S2:2251:9	I-AdverseReaction
and	NULOJIX.xml:S2:2261:3	O
the	NULOJIX.xml:S2:2265:3	O
possible	NULOJIX.xml:S2:2269:8	O
development	NULOJIX.xml:S2:2278:11	O
of	NULOJIX.xml:S2:2290:2	O
malignancies	NULOJIX.xml:S2:2293:12	B-AdverseReaction
may	NULOJIX.xml:S2:2306:3	B-Factor
result	NULOJIX.xml:S2:2310:6	O
from	NULOJIX.xml:S2:2317:4	O
immunosuppression	NULOJIX.xml:S2:2322:17	O
.	NULOJIX.xml:S2:2339:1	O

(	NULOJIX.xml:S2:2341:1	O
5.1	NULOJIX.xml:S2:2342:3	O
,	NULOJIX.xml:S2:2345:1	O
5.3	NULOJIX.xml:S2:2347:3	O
,	NULOJIX.xml:S2:2350:1	O
5.4	NULOJIX.xml:S2:2352:3	O
,	NULOJIX.xml:S2:2355:1	O
5.5	NULOJIX.xml:S2:2357:3	O
)	NULOJIX.xml:S2:2360:1	O
\n	NULOJIX.xml:S2:2362:1	O
Use	NULOJIX.xml:S2:2367:3	O
in	NULOJIX.xml:S2:2371:2	O
liver	NULOJIX.xml:S2:2374:5	O
transplant	NULOJIX.xml:S2:2380:10	O
patients	NULOJIX.xml:S2:2391:8	O
is	NULOJIX.xml:S2:2400:2	O
not	NULOJIX.xml:S2:2403:3	O
recommended	NULOJIX.xml:S2:2407:11	O
due	NULOJIX.xml:S2:2419:3	O
to	NULOJIX.xml:S2:2423:2	O
an	NULOJIX.xml:S2:2426:2	O
increased	NULOJIX.xml:S2:2429:9	O
risk	NULOJIX.xml:S2:2439:4	O
of	NULOJIX.xml:S2:2444:2	O
graft	NULOJIX.xml:S2:2447:5	O
loss	NULOJIX.xml:S2:2453:4	O
and	NULOJIX.xml:S2:2458:3	O
death	NULOJIX.xml:S2:2462:5	O
.	NULOJIX.xml:S2:2467:1	O

(	NULOJIX.xml:S2:2469:1	O
5.6	NULOJIX.xml:S2:2470:3	O
)	NULOJIX.xml:S2:2473:1	O
\n	NULOJIX.xml:S2:2475:1	O
5	NULOJIX.xml:S3:4:1	O
WARNINGS	NULOJIX.xml:S3:6:8	O
AND	NULOJIX.xml:S3:15:3	O
PRECAUTIONS	NULOJIX.xml:S3:19:11	O

EXCERPT	NULOJIX.xml:S3:37:7	O
:	NULOJIX.xml:S3:44:1	O
Post	NULOJIX.xml:S3:55:4	B-AdverseReaction
-	NULOJIX.xml:S3:59:1	I-AdverseReaction
Transplant	NULOJIX.xml:S3:60:10	I-AdverseReaction
Lymphoproliferative	NULOJIX.xml:S3:71:19	I-AdverseReaction
Disorder	NULOJIX.xml:S3:91:8	I-AdverseReaction
(	NULOJIX.xml:S3:100:1	O
PTLD	NULOJIX.xml:S3:101:4	B-AdverseReaction
)	NULOJIX.xml:S3:105:1	O
:	NULOJIX.xml:S3:107:1	O
increased	NULOJIX.xml:S3:109:9	O
risk	NULOJIX.xml:S3:119:4	B-Factor
,	NULOJIX.xml:S3:123:1	O
predominantly	NULOJIX.xml:S3:125:13	O
involving	NULOJIX.xml:S3:139:9	O
the	NULOJIX.xml:S3:149:3	O
CNS	NULOJIX.xml:S3:153:3	O
;	NULOJIX.xml:S3:156:1	O
monitor	NULOJIX.xml:S3:158:7	O
for	NULOJIX.xml:S3:166:3	O
new	NULOJIX.xml:S3:170:3	O
or	NULOJIX.xml:S3:174:2	O
worsening	NULOJIX.xml:S3:177:9	O
neurological	NULOJIX.xml:S3:187:12	O
,	NULOJIX.xml:S3:199:1	O
cognitive	NULOJIX.xml:S3:201:9	O
,	NULOJIX.xml:S3:210:1	O
or	NULOJIX.xml:S3:212:2	O
behavioral	NULOJIX.xml:S3:215:10	O
signs	NULOJIX.xml:S3:226:5	O
and	NULOJIX.xml:S3:232:3	O
symptoms	NULOJIX.xml:S3:236:8	O
.	NULOJIX.xml:S3:244:1	O

(	NULOJIX.xml:S3:247:1	O
Boxed	NULOJIX.xml:S3:248:5	O
Warning	NULOJIX.xml:S3:254:7	O
,	NULOJIX.xml:S3:263:1	O
4	NULOJIX.xml:S3:266:1	O
,	NULOJIX.xml:S3:269:1	O
5.1	NULOJIX.xml:S3:272:3	O
,	NULOJIX.xml:S3:277:1	O
5.6	NULOJIX.xml:S3:280:3	O
)	NULOJIX.xml:S3:283:1	O

Other	NULOJIX.xml:S3:295:5	O
malignancies	NULOJIX.xml:S3:301:12	B-AdverseReaction
:	NULOJIX.xml:S3:314:1	O
increased	NULOJIX.xml:S3:316:9	O
risk	NULOJIX.xml:S3:326:4	O
with	NULOJIX.xml:S3:331:4	O
all	NULOJIX.xml:S3:336:3	O
immunosuppressants	NULOJIX.xml:S3:340:18	B-DrugClass
;	NULOJIX.xml:S3:358:1	O
appears	NULOJIX.xml:S3:360:7	O
related	NULOJIX.xml:S3:368:7	O
to	NULOJIX.xml:S3:376:2	O
intensity	NULOJIX.xml:S3:379:9	O
and	NULOJIX.xml:S3:389:3	O
duration	NULOJIX.xml:S3:393:8	O
of	NULOJIX.xml:S3:402:2	O
use	NULOJIX.xml:S3:405:3	O
.	NULOJIX.xml:S3:408:1	O

Avoid	NULOJIX.xml:S3:410:5	O
prolonged	NULOJIX.xml:S3:416:9	O
exposure	NULOJIX.xml:S3:426:8	O
to	NULOJIX.xml:S3:435:2	O
UV	NULOJIX.xml:S3:438:2	O
light	NULOJIX.xml:S3:441:5	O
and	NULOJIX.xml:S3:447:3	O
sunlight	NULOJIX.xml:S3:451:8	O
.	NULOJIX.xml:S3:459:1	O

(	NULOJIX.xml:S3:462:1	O
5.3	NULOJIX.xml:S3:463:3	O
)	NULOJIX.xml:S3:466:1	O

Progressive	NULOJIX.xml:S3:478:11	B-AdverseReaction
Multifocal	NULOJIX.xml:S3:490:10	I-AdverseReaction
Leukoencephalopathy	NULOJIX.xml:S3:501:19	I-AdverseReaction
(	NULOJIX.xml:S3:521:1	O
PML	NULOJIX.xml:S3:522:3	B-AdverseReaction
)	NULOJIX.xml:S3:525:1	O
:	NULOJIX.xml:S3:527:1	O
increased	NULOJIX.xml:S3:529:9	O
risk	NULOJIX.xml:S3:539:4	B-Factor
;	NULOJIX.xml:S3:543:1	O
consider	NULOJIX.xml:S3:545:8	O
in	NULOJIX.xml:S3:554:2	O
the	NULOJIX.xml:S3:557:3	O
diagnosis	NULOJIX.xml:S3:561:9	O
of	NULOJIX.xml:S3:571:2	O
patients	NULOJIX.xml:S3:574:8	O
reporting	NULOJIX.xml:S3:583:9	O
new	NULOJIX.xml:S3:593:3	O
or	NULOJIX.xml:S3:597:2	O
worsening	NULOJIX.xml:S3:600:9	O
neurological	NULOJIX.xml:S3:610:12	O
,	NULOJIX.xml:S3:622:1	O
cognitive	NULOJIX.xml:S3:624:9	O
,	NULOJIX.xml:S3:633:1	O
or	NULOJIX.xml:S3:635:2	O
behavioral	NULOJIX.xml:S3:638:10	O
signs	NULOJIX.xml:S3:649:5	O
and	NULOJIX.xml:S3:655:3	O
symptoms	NULOJIX.xml:S3:659:8	O
.	NULOJIX.xml:S3:667:1	O

Recommended	NULOJIX.xml:S3:669:11	O
doses	NULOJIX.xml:S3:681:5	O
of	NULOJIX.xml:S3:687:2	O
immunosuppressants	NULOJIX.xml:S3:690:18	O
should	NULOJIX.xml:S3:709:6	O
not	NULOJIX.xml:S3:716:3	O
be	NULOJIX.xml:S3:720:2	O
exceeded	NULOJIX.xml:S3:723:8	O
.	NULOJIX.xml:S3:731:1	O

(	NULOJIX.xml:S3:734:1	O
5.4	NULOJIX.xml:S3:735:3	O
)	NULOJIX.xml:S3:738:1	O

Other	NULOJIX.xml:S3:750:5	O
serious	NULOJIX.xml:S3:756:7	B-Severity
infections	NULOJIX.xml:S3:764:10	B-AdverseReaction
:	NULOJIX.xml:S3:775:1	O
increased	NULOJIX.xml:S3:777:9	O
risk	NULOJIX.xml:S3:787:4	B-Factor
of	NULOJIX.xml:S3:792:2	O
bacterial	NULOJIX.xml:S3:795:9	B-AdverseReaction
,	NULOJIX.xml:S3:804:1	O
viral	NULOJIX.xml:S3:806:5	B-AdverseReaction
,	NULOJIX.xml:S3:811:1	O
fungal	NULOJIX.xml:S3:813:6	B-AdverseReaction
,	NULOJIX.xml:S3:819:1	O
and	NULOJIX.xml:S3:821:3	O
protozoal	NULOJIX.xml:S3:825:9	B-AdverseReaction
infections	NULOJIX.xml:S3:835:10	I-AdverseReaction
,	NULOJIX.xml:S3:845:1	O
including	NULOJIX.xml:S3:847:9	O
opportunistic	NULOJIX.xml:S3:857:13	B-AdverseReaction
infections	NULOJIX.xml:S3:871:10	I-AdverseReaction
and	NULOJIX.xml:S3:882:3	O
tuberculosis	NULOJIX.xml:S3:886:12	B-AdverseReaction
.	NULOJIX.xml:S3:898:1	O

Some	NULOJIX.xml:S3:900:4	O
infections	NULOJIX.xml:S3:905:10	B-AdverseReaction
were	NULOJIX.xml:S3:916:4	O
fatal	NULOJIX.xml:S3:921:5	B-AdverseReaction
.	NULOJIX.xml:S3:926:1	O

Polyoma	NULOJIX.xml:S3:928:7	B-AdverseReaction
virus	NULOJIX.xml:S3:936:5	I-AdverseReaction
-	NULOJIX.xml:S3:941:1	I-AdverseReaction
associated	NULOJIX.xml:S3:942:10	I-AdverseReaction
nephropathy	NULOJIX.xml:S3:953:11	I-AdverseReaction
can	NULOJIX.xml:S3:965:3	B-Factor
lead	NULOJIX.xml:S3:969:4	O
to	NULOJIX.xml:S3:974:2	O
kidney	NULOJIX.xml:S3:977:6	B-AdverseReaction
graft	NULOJIX.xml:S3:984:5	I-AdverseReaction
loss	NULOJIX.xml:S3:990:4	I-AdverseReaction
;	NULOJIX.xml:S3:994:1	O
consider	NULOJIX.xml:S3:996:8	O
reduction	NULOJIX.xml:S3:1005:9	O
in	NULOJIX.xml:S3:1015:2	O
immunosuppression	NULOJIX.xml:S3:1018:17	O
.	NULOJIX.xml:S3:1035:1	O

Evaluate	NULOJIX.xml:S3:1037:8	O
for	NULOJIX.xml:S3:1046:3	O
tuberculosis	NULOJIX.xml:S3:1050:12	O
and	NULOJIX.xml:S3:1063:3	O
initiate	NULOJIX.xml:S3:1067:8	O
treatment	NULOJIX.xml:S3:1076:9	O
for	NULOJIX.xml:S3:1086:3	O
latent	NULOJIX.xml:S3:1090:6	O
infection	NULOJIX.xml:S3:1097:9	O
prior	NULOJIX.xml:S3:1107:5	O
to	NULOJIX.xml:S3:1113:2	O
NULOJIX	NULOJIX.xml:S3:1116:7	O
use	NULOJIX.xml:S3:1124:3	O
.	NULOJIX.xml:S3:1127:1	O

Cytomegalovirus	NULOJIX.xml:S3:1129:15	O
and	NULOJIX.xml:S3:1145:3	O
pneumocystis	NULOJIX.xml:S3:1149:12	O
prophylaxis	NULOJIX.xml:S3:1162:11	O
are	NULOJIX.xml:S3:1174:3	O
recommended	NULOJIX.xml:S3:1178:11	O
after	NULOJIX.xml:S3:1190:5	O
transplantation	NULOJIX.xml:S3:1196:15	O
.	NULOJIX.xml:S3:1211:1	O

(	NULOJIX.xml:S3:1214:1	O
5.1	NULOJIX.xml:S3:1215:3	O
,	NULOJIX.xml:S3:1220:1	O
5.4	NULOJIX.xml:S3:1223:3	O
,	NULOJIX.xml:S3:1228:1	O
5.5	NULOJIX.xml:S3:1231:3	O
)	NULOJIX.xml:S3:1234:1	O

Liver	NULOJIX.xml:S3:1246:5	O
transplant	NULOJIX.xml:S3:1252:10	O
:	NULOJIX.xml:S3:1263:1	O
use	NULOJIX.xml:S3:1265:3	O
is	NULOJIX.xml:S3:1269:2	O
not	NULOJIX.xml:S3:1272:3	O
recommended	NULOJIX.xml:S3:1276:11	O
.	NULOJIX.xml:S3:1287:1	O

(	NULOJIX.xml:S3:1290:1	O
5.6	NULOJIX.xml:S3:1291:3	O
)	NULOJIX.xml:S3:1294:1	O

Acute	NULOJIX.xml:S3:1306:5	B-AdverseReaction
Rejection	NULOJIX.xml:S3:1312:9	I-AdverseReaction
and	NULOJIX.xml:S3:1322:3	O
Graft	NULOJIX.xml:S3:1326:5	I-AdverseReaction
Loss	NULOJIX.xml:S3:1332:4	I-AdverseReaction
with	NULOJIX.xml:S3:1337:4	O
Corticosteroid	NULOJIX.xml:S3:1342:14	O
Minimization	NULOJIX.xml:S3:1357:12	O
:	NULOJIX.xml:S3:1370:1	O
corticosteroid	NULOJIX.xml:S3:1372:14	O
utilization	NULOJIX.xml:S3:1387:11	O
should	NULOJIX.xml:S3:1399:6	O
be	NULOJIX.xml:S3:1406:2	O
consistent	NULOJIX.xml:S3:1409:10	O
with	NULOJIX.xml:S3:1420:4	O
the	NULOJIX.xml:S3:1425:3	O
NULOJIX	NULOJIX.xml:S3:1429:7	O
clinical	NULOJIX.xml:S3:1437:8	O
trial	NULOJIX.xml:S3:1446:5	O
experience	NULOJIX.xml:S3:1452:10	O
.	NULOJIX.xml:S3:1462:1	O

(	NULOJIX.xml:S3:1465:1	O
2.1	NULOJIX.xml:S3:1466:3	O
,	NULOJIX.xml:S3:1471:1	O
5.7	NULOJIX.xml:S3:1474:3	O
,	NULOJIX.xml:S3:1479:1	O
14.1	NULOJIX.xml:S3:1482:4	O
)	NULOJIX.xml:S3:1486:1	O

Immunizations	NULOJIX.xml:S3:1498:13	O
:	NULOJIX.xml:S3:1512:1	O
avoid	NULOJIX.xml:S3:1514:5	O
use	NULOJIX.xml:S3:1520:3	O
of	NULOJIX.xml:S3:1524:2	O
live	NULOJIX.xml:S3:1527:4	O
vaccines	NULOJIX.xml:S3:1532:8	O
during	NULOJIX.xml:S3:1541:6	O
treatment	NULOJIX.xml:S3:1548:9	O
.	NULOJIX.xml:S3:1557:1	O

(	NULOJIX.xml:S3:1560:1	O
5.8	NULOJIX.xml:S3:1561:3	O
)	NULOJIX.xml:S3:1564:1	O

5.1	NULOJIX.xml:S3:1580:3	O

Post	NULOJIX.xml:S3:1584:4	O

-	NULOJIX.xml:S3:1588:1	O
Transplant	NULOJIX.xml:S3:1589:10	O
Lymphoproliferative	NULOJIX.xml:S3:1600:19	O
Disorder	NULOJIX.xml:S3:1620:8	O

NULOJIX	NULOJIX.xml:S3:1634:7	O
-	NULOJIX.xml:S3:1641:1	O
treated	NULOJIX.xml:S3:1642:7	O
patients	NULOJIX.xml:S3:1650:8	O
have	NULOJIX.xml:S3:1659:4	O
an	NULOJIX.xml:S3:1664:2	O
increased	NULOJIX.xml:S3:1667:9	O
risk	NULOJIX.xml:S3:1677:4	B-Factor
for	NULOJIX.xml:S3:1682:3	O
developing	NULOJIX.xml:S3:1686:10	O
post	NULOJIX.xml:S3:1697:4	B-AdverseReaction
-	NULOJIX.xml:S3:1701:1	I-AdverseReaction
transplant	NULOJIX.xml:S3:1702:10	I-AdverseReaction
lymphoproliferative	NULOJIX.xml:S3:1713:19	I-AdverseReaction
disorder	NULOJIX.xml:S3:1733:8	I-AdverseReaction
(	NULOJIX.xml:S3:1742:1	O
PTLD	NULOJIX.xml:S3:1743:4	B-AdverseReaction
)	NULOJIX.xml:S3:1747:1	O
,	NULOJIX.xml:S3:1748:1	O
predominantly	NULOJIX.xml:S3:1750:13	O
involving	NULOJIX.xml:S3:1764:9	O
the	NULOJIX.xml:S3:1774:3	O
CNS	NULOJIX.xml:S3:1778:3	O
,	NULOJIX.xml:S3:1781:1	O
compared	NULOJIX.xml:S3:1783:8	O
to	NULOJIX.xml:S3:1792:2	O
patients	NULOJIX.xml:S3:1795:8	O
on	NULOJIX.xml:S3:1804:2	O
a	NULOJIX.xml:S3:1807:1	O
cyclosporine	NULOJIX.xml:S3:1809:12	O
-	NULOJIX.xml:S3:1821:1	O
based	NULOJIX.xml:S3:1822:5	O
regimen	NULOJIX.xml:S3:1828:7	O
[	NULOJIX.xml:S3:1836:1	O
see	NULOJIX.xml:S3:1837:3	O
Adverse	NULOJIX.xml:S3:1843:7	O
Reactions	NULOJIX.xml:S3:1851:9	O
(	NULOJIX.xml:S3:1861:1	O
6.1	NULOJIX.xml:S3:1862:3	O
)	NULOJIX.xml:S3:1865:1	O
and	NULOJIX.xml:S3:1870:3	O
Table	NULOJIX.xml:S3:1874:5	O
2	NULOJIX.xml:S3:1880:1	O
]	NULOJIX.xml:S3:1883:1	O
.	NULOJIX.xml:S3:1884:1	O

As	NULOJIX.xml:S3:1886:2	O
the	NULOJIX.xml:S3:1889:3	O
total	NULOJIX.xml:S3:1893:5	O
burden	NULOJIX.xml:S3:1899:6	O
of	NULOJIX.xml:S3:1906:2	O
immunosuppression	NULOJIX.xml:S3:1909:17	O
is	NULOJIX.xml:S3:1927:2	O
a	NULOJIX.xml:S3:1930:1	O
risk	NULOJIX.xml:S3:1932:4	O
factor	NULOJIX.xml:S3:1937:6	O
for	NULOJIX.xml:S3:1944:3	O
PTLD	NULOJIX.xml:S3:1948:4	O
,	NULOJIX.xml:S3:1952:1	O
higher	NULOJIX.xml:S3:1954:6	O
than	NULOJIX.xml:S3:1961:4	O
the	NULOJIX.xml:S3:1966:3	O
recommended	NULOJIX.xml:S3:1970:11	O
doses	NULOJIX.xml:S3:1982:5	O
or	NULOJIX.xml:S3:1988:2	O
more	NULOJIX.xml:S3:1991:4	O
frequent	NULOJIX.xml:S3:1996:8	O
dosing	NULOJIX.xml:S3:2005:6	O
of	NULOJIX.xml:S3:2012:2	O
NULOJIX	NULOJIX.xml:S3:2015:7	O
and	NULOJIX.xml:S3:2023:3	O
higher	NULOJIX.xml:S3:2027:6	O
than	NULOJIX.xml:S3:2034:4	O
recommended	NULOJIX.xml:S3:2039:11	O
doses	NULOJIX.xml:S3:2051:5	O
of	NULOJIX.xml:S3:2057:2	O
concomitant	NULOJIX.xml:S3:2060:11	O
immunosuppressive	NULOJIX.xml:S3:2072:17	O
agents	NULOJIX.xml:S3:2090:6	O
are	NULOJIX.xml:S3:2097:3	O
not	NULOJIX.xml:S3:2101:3	O
recommended	NULOJIX.xml:S3:2105:11	O
[	NULOJIX.xml:S3:2117:1	O
see	NULOJIX.xml:S3:2118:3	O
Dosage	NULOJIX.xml:S3:2124:6	O
and	NULOJIX.xml:S3:2131:3	O
Administration	NULOJIX.xml:S3:2135:14	O
(	NULOJIX.xml:S3:2150:1	O
2.1	NULOJIX.xml:S3:2151:3	O
)	NULOJIX.xml:S3:2154:1	O
and	NULOJIX.xml:S3:2159:3	O
Warnings	NULOJIX.xml:S3:2165:8	O
and	NULOJIX.xml:S3:2174:3	O
Precautions	NULOJIX.xml:S3:2178:11	O
(	NULOJIX.xml:S3:2190:1	O
5.6	NULOJIX.xml:S3:2191:3	O
)	NULOJIX.xml:S3:2194:1	O
]	NULOJIX.xml:S3:2199:1	O
.	NULOJIX.xml:S3:2200:1	O

Physicians	NULOJIX.xml:S3:2202:10	O
should	NULOJIX.xml:S3:2213:6	O
consider	NULOJIX.xml:S3:2220:8	O
PTLD	NULOJIX.xml:S3:2229:4	O
in	NULOJIX.xml:S3:2234:2	O
patients	NULOJIX.xml:S3:2237:8	O
reporting	NULOJIX.xml:S3:2246:9	O
new	NULOJIX.xml:S3:2256:3	O
or	NULOJIX.xml:S3:2260:2	O
worsening	NULOJIX.xml:S3:2263:9	O
neurological	NULOJIX.xml:S3:2273:12	O
,	NULOJIX.xml:S3:2285:1	O
cognitive	NULOJIX.xml:S3:2287:9	O
,	NULOJIX.xml:S3:2296:1	O
or	NULOJIX.xml:S3:2298:2	O
behavioral	NULOJIX.xml:S3:2301:10	O
signs	NULOJIX.xml:S3:2312:5	O
or	NULOJIX.xml:S3:2318:2	O
symptoms	NULOJIX.xml:S3:2321:8	O
.	NULOJIX.xml:S3:2329:1	O

EBV	NULOJIX.xml:S3:2338:3	O
Serostatus	NULOJIX.xml:S3:2342:10	O

The	NULOJIX.xml:S3:2358:3	O
risk	NULOJIX.xml:S3:2362:4	B-Factor
of	NULOJIX.xml:S3:2367:2	O
PTLD	NULOJIX.xml:S3:2370:4	B-AdverseReaction
was	NULOJIX.xml:S3:2375:3	O
higher	NULOJIX.xml:S3:2379:6	O
in	NULOJIX.xml:S3:2386:2	O
EBV	NULOJIX.xml:S3:2389:3	O
seronegative	NULOJIX.xml:S3:2393:12	O
patients	NULOJIX.xml:S3:2406:8	O
compared	NULOJIX.xml:S3:2415:8	O
to	NULOJIX.xml:S3:2424:2	O
EBV	NULOJIX.xml:S3:2427:3	O
seropositive	NULOJIX.xml:S3:2431:12	O
patients	NULOJIX.xml:S3:2444:8	O
.	NULOJIX.xml:S3:2452:1	O

EBV	NULOJIX.xml:S3:2454:3	O
seropositive	NULOJIX.xml:S3:2458:12	O
patients	NULOJIX.xml:S3:2471:8	O
are	NULOJIX.xml:S3:2480:3	O
defined	NULOJIX.xml:S3:2484:7	O
as	NULOJIX.xml:S3:2492:2	O
having	NULOJIX.xml:S3:2495:6	O
evidence	NULOJIX.xml:S3:2502:8	O
of	NULOJIX.xml:S3:2511:2	O
acquired	NULOJIX.xml:S3:2514:8	O
immunity	NULOJIX.xml:S3:2523:8	O
shown	NULOJIX.xml:S3:2532:5	O
by	NULOJIX.xml:S3:2538:2	O
the	NULOJIX.xml:S3:2541:3	O
presence	NULOJIX.xml:S3:2545:8	O
of	NULOJIX.xml:S3:2554:2	O
IgG	NULOJIX.xml:S3:2557:3	O
antibodies	NULOJIX.xml:S3:2561:10	O
to	NULOJIX.xml:S3:2572:2	O
viral	NULOJIX.xml:S3:2575:5	O
capsid	NULOJIX.xml:S3:2581:6	O
antigen	NULOJIX.xml:S3:2588:7	O
(	NULOJIX.xml:S3:2596:1	O
VCA	NULOJIX.xml:S3:2597:3	O
)	NULOJIX.xml:S3:2600:1	O
and	NULOJIX.xml:S3:2602:3	O
EBV	NULOJIX.xml:S3:2606:3	O
nuclear	NULOJIX.xml:S3:2610:7	O
antigen	NULOJIX.xml:S3:2618:7	O
(	NULOJIX.xml:S3:2626:1	O
EBNA	NULOJIX.xml:S3:2627:4	O
)	NULOJIX.xml:S3:2631:1	O
.	NULOJIX.xml:S3:2632:1	O

Epstein	NULOJIX.xml:S3:2638:7	O
-	NULOJIX.xml:S3:2645:1	O
Barr	NULOJIX.xml:S3:2646:4	O
virus	NULOJIX.xml:S3:2651:5	O
serology	NULOJIX.xml:S3:2657:8	O
should	NULOJIX.xml:S3:2666:6	O
be	NULOJIX.xml:S3:2673:2	O
ascertained	NULOJIX.xml:S3:2676:11	O
before	NULOJIX.xml:S3:2688:6	O
starting	NULOJIX.xml:S3:2695:8	O
administration	NULOJIX.xml:S3:2704:14	O
of	NULOJIX.xml:S3:2719:2	O
NULOJIX	NULOJIX.xml:S3:2722:7	O
,	NULOJIX.xml:S3:2729:1	O
and	NULOJIX.xml:S3:2731:3	O
only	NULOJIX.xml:S3:2735:4	O
patients	NULOJIX.xml:S3:2740:8	O
who	NULOJIX.xml:S3:2749:3	O
are	NULOJIX.xml:S3:2753:3	O
EBV	NULOJIX.xml:S3:2757:3	O
seropositive	NULOJIX.xml:S3:2761:12	O
should	NULOJIX.xml:S3:2774:6	O
receive	NULOJIX.xml:S3:2781:7	O
NULOJIX	NULOJIX.xml:S3:2789:7	O
.	NULOJIX.xml:S3:2796:1	O

Transplant	NULOJIX.xml:S3:2798:10	O
recipients	NULOJIX.xml:S3:2809:10	O
who	NULOJIX.xml:S3:2820:3	O
are	NULOJIX.xml:S3:2824:3	O
EBV	NULOJIX.xml:S3:2828:3	O
seronegative	NULOJIX.xml:S3:2832:12	O
,	NULOJIX.xml:S3:2844:1	O
or	NULOJIX.xml:S3:2846:2	O
with	NULOJIX.xml:S3:2849:4	O
unknown	NULOJIX.xml:S3:2854:7	O
serostatus	NULOJIX.xml:S3:2862:10	O
,	NULOJIX.xml:S3:2872:1	O
should	NULOJIX.xml:S3:2874:6	O
not	NULOJIX.xml:S3:2881:3	O
receive	NULOJIX.xml:S3:2885:7	O
NULOJIX	NULOJIX.xml:S3:2893:7	O
[	NULOJIX.xml:S3:2901:1	O
see	NULOJIX.xml:S3:2902:3	O
Boxed	NULOJIX.xml:S3:2908:5	O
Warning	NULOJIX.xml:S3:2914:7	O
and	NULOJIX.xml:S3:2925:3	O
Contraindications	NULOJIX.xml:S3:2931:17	O
(	NULOJIX.xml:S3:2949:1	O
4	NULOJIX.xml:S3:2950:1	O
)	NULOJIX.xml:S3:2951:1	O
]	NULOJIX.xml:S3:2956:1	O
.	NULOJIX.xml:S3:2957:1	O

Other	NULOJIX.xml:S3:2966:5	O
Risk	NULOJIX.xml:S3:2972:4	O
Factors	NULOJIX.xml:S3:2977:7	O

Other	NULOJIX.xml:S3:2990:5	O
known	NULOJIX.xml:S3:2996:5	O
risk	NULOJIX.xml:S3:3002:4	O
factors	NULOJIX.xml:S3:3007:7	O
for	NULOJIX.xml:S3:3015:3	O
PTLD	NULOJIX.xml:S3:3019:4	O
include	NULOJIX.xml:S3:3024:7	O
cytomegalovirus	NULOJIX.xml:S3:3032:15	O
(	NULOJIX.xml:S3:3048:1	O
CMV	NULOJIX.xml:S3:3049:3	O
)	NULOJIX.xml:S3:3052:1	O
infection	NULOJIX.xml:S3:3054:9	O
and	NULOJIX.xml:S3:3064:3	O
T	NULOJIX.xml:S3:3068:1	O
-	NULOJIX.xml:S3:3069:1	O
cell	NULOJIX.xml:S3:3070:4	O
-	NULOJIX.xml:S3:3074:1	O
depleting	NULOJIX.xml:S3:3075:9	O
therapy	NULOJIX.xml:S3:3085:7	O
.	NULOJIX.xml:S3:3092:1	O

T	NULOJIX.xml:S3:3094:1	O
-	NULOJIX.xml:S3:3095:1	O
cell	NULOJIX.xml:S3:3096:4	O
-	NULOJIX.xml:S3:3100:1	O
depleting	NULOJIX.xml:S3:3101:9	O
therapies	NULOJIX.xml:S3:3111:9	O
to	NULOJIX.xml:S3:3121:2	O
treat	NULOJIX.xml:S3:3124:5	O
acute	NULOJIX.xml:S3:3130:5	O
rejection	NULOJIX.xml:S3:3136:9	O
should	NULOJIX.xml:S3:3146:6	O
be	NULOJIX.xml:S3:3153:2	O
used	NULOJIX.xml:S3:3156:4	O
cautiously	NULOJIX.xml:S3:3161:10	O
.	NULOJIX.xml:S3:3171:1	O

CMV	NULOJIX.xml:S3:3173:3	O
prophylaxis	NULOJIX.xml:S3:3177:11	O
is	NULOJIX.xml:S3:3189:2	O
recommended	NULOJIX.xml:S3:3192:11	O
for	NULOJIX.xml:S3:3204:3	O
at	NULOJIX.xml:S3:3208:2	O
least	NULOJIX.xml:S3:3211:5	O
3	NULOJIX.xml:S3:3217:1	O
months	NULOJIX.xml:S3:3219:6	O
after	NULOJIX.xml:S3:3226:5	O
transplantation	NULOJIX.xml:S3:3232:15	O
[	NULOJIX.xml:S3:3248:1	O
see	NULOJIX.xml:S3:3249:3	O
Warnings	NULOJIX.xml:S3:3255:8	O
and	NULOJIX.xml:S3:3264:3	O
Precautions	NULOJIX.xml:S3:3268:11	O
(	NULOJIX.xml:S3:3280:1	O
5.5	NULOJIX.xml:S3:3281:3	O
)	NULOJIX.xml:S3:3284:1	O
]	NULOJIX.xml:S3:3289:1	O
.	NULOJIX.xml:S3:3290:1	O

Patients	NULOJIX.xml:S3:3296:8	O
who	NULOJIX.xml:S3:3305:3	O
are	NULOJIX.xml:S3:3309:3	O
EBV	NULOJIX.xml:S3:3313:3	O
seropositive	NULOJIX.xml:S3:3317:12	O
and	NULOJIX.xml:S3:3330:3	O
CMV	NULOJIX.xml:S3:3334:3	O
seronegative	NULOJIX.xml:S3:3338:12	O
may	NULOJIX.xml:S3:3351:3	O
be	NULOJIX.xml:S3:3355:2	O
at	NULOJIX.xml:S3:3358:2	O
increased	NULOJIX.xml:S3:3361:9	O
risk	NULOJIX.xml:S3:3371:4	O
for	NULOJIX.xml:S3:3376:3	O
PTLD	NULOJIX.xml:S3:3380:4	O
compared	NULOJIX.xml:S3:3385:8	O
to	NULOJIX.xml:S3:3394:2	O
patients	NULOJIX.xml:S3:3397:8	O
who	NULOJIX.xml:S3:3406:3	O
are	NULOJIX.xml:S3:3410:3	O
EBV	NULOJIX.xml:S3:3414:3	O
seropositive	NULOJIX.xml:S3:3418:12	O
and	NULOJIX.xml:S3:3431:3	O
CMV	NULOJIX.xml:S3:3435:3	O
seropositive	NULOJIX.xml:S3:3439:12	O
[	NULOJIX.xml:S3:3452:1	O
see	NULOJIX.xml:S3:3453:3	O
Adverse	NULOJIX.xml:S3:3459:7	O
Reactions	NULOJIX.xml:S3:3467:9	O
(	NULOJIX.xml:S3:3477:1	O
6.1	NULOJIX.xml:S3:3478:3	O
)	NULOJIX.xml:S3:3481:1	O
]	NULOJIX.xml:S3:3486:1	O
.	NULOJIX.xml:S3:3487:1	O

Since	NULOJIX.xml:S3:3489:5	O
CMV	NULOJIX.xml:S3:3495:3	O
seronegative	NULOJIX.xml:S3:3499:12	O
patients	NULOJIX.xml:S3:3512:8	O
are	NULOJIX.xml:S3:3521:3	O
at	NULOJIX.xml:S3:3525:2	O
increased	NULOJIX.xml:S3:3528:9	O
risk	NULOJIX.xml:S3:3538:4	O
for	NULOJIX.xml:S3:3543:3	O
CMV	NULOJIX.xml:S3:3547:3	O
disease	NULOJIX.xml:S3:3551:7	O
(	NULOJIX.xml:S3:3559:1	O
a	NULOJIX.xml:S3:3560:1	O
known	NULOJIX.xml:S3:3562:5	O
risk	NULOJIX.xml:S3:3568:4	O
factor	NULOJIX.xml:S3:3573:6	O
for	NULOJIX.xml:S3:3580:3	O
PTLD	NULOJIX.xml:S3:3584:4	O
)	NULOJIX.xml:S3:3588:1	O
,	NULOJIX.xml:S3:3589:1	O
the	NULOJIX.xml:S3:3591:3	O
clinical	NULOJIX.xml:S3:3595:8	O
significance	NULOJIX.xml:S3:3604:12	O
of	NULOJIX.xml:S3:3617:2	O
CMV	NULOJIX.xml:S3:3620:3	O
serology	NULOJIX.xml:S3:3624:8	O
for	NULOJIX.xml:S3:3633:3	O
PTLD	NULOJIX.xml:S3:3637:4	O
remains	NULOJIX.xml:S3:3642:7	O
to	NULOJIX.xml:S3:3650:2	O
be	NULOJIX.xml:S3:3653:2	O
determined	NULOJIX.xml:S3:3656:10	O
;	NULOJIX.xml:S3:3666:1	O
however	NULOJIX.xml:S3:3668:7	O
,	NULOJIX.xml:S3:3675:1	O
these	NULOJIX.xml:S3:3677:5	O
findings	NULOJIX.xml:S3:3683:8	O
should	NULOJIX.xml:S3:3692:6	O
be	NULOJIX.xml:S3:3699:2	O
considered	NULOJIX.xml:S3:3702:10	O
when	NULOJIX.xml:S3:3713:4	O
prescribing	NULOJIX.xml:S3:3718:11	O
NULOJIX	NULOJIX.xml:S3:3730:7	O
.	NULOJIX.xml:S3:3737:1	O

5.2	NULOJIX.xml:S3:3746:3	O
Management	NULOJIX.xml:S3:3750:10	O
of	NULOJIX.xml:S3:3761:2	O
Immunosuppression	NULOJIX.xml:S3:3764:17	O

Only	NULOJIX.xml:S3:3787:4	O
physicians	NULOJIX.xml:S3:3792:10	O
experienced	NULOJIX.xml:S3:3803:11	O
in	NULOJIX.xml:S3:3815:2	O
management	NULOJIX.xml:S3:3818:10	O
of	NULOJIX.xml:S3:3829:2	O
systemic	NULOJIX.xml:S3:3832:8	O
immunosuppressant	NULOJIX.xml:S3:3841:17	O
therapy	NULOJIX.xml:S3:3859:7	O
in	NULOJIX.xml:S3:3867:2	O
transplantation	NULOJIX.xml:S3:3870:15	O
should	NULOJIX.xml:S3:3886:6	O
prescribe	NULOJIX.xml:S3:3893:9	O
NULOJIX	NULOJIX.xml:S3:3903:7	O
.	NULOJIX.xml:S3:3910:1	O

Patients	NULOJIX.xml:S3:3912:8	O
receiving	NULOJIX.xml:S3:3921:9	O
the	NULOJIX.xml:S3:3931:3	O
drug	NULOJIX.xml:S3:3935:4	O
should	NULOJIX.xml:S3:3940:6	O
be	NULOJIX.xml:S3:3947:2	O
managed	NULOJIX.xml:S3:3950:7	O
in	NULOJIX.xml:S3:3958:2	O
facilities	NULOJIX.xml:S3:3961:10	O
equipped	NULOJIX.xml:S3:3972:8	O
and	NULOJIX.xml:S3:3981:3	O
staffed	NULOJIX.xml:S3:3985:7	O
with	NULOJIX.xml:S3:3993:4	O
adequate	NULOJIX.xml:S3:3998:8	O
laboratory	NULOJIX.xml:S3:4007:10	O
and	NULOJIX.xml:S3:4018:3	O
supportive	NULOJIX.xml:S3:4022:10	O
medical	NULOJIX.xml:S3:4033:7	O
resources	NULOJIX.xml:S3:4041:9	O
.	NULOJIX.xml:S3:4050:1	O

The	NULOJIX.xml:S3:4052:3	O
physician	NULOJIX.xml:S3:4056:9	O
responsible	NULOJIX.xml:S3:4066:11	O
for	NULOJIX.xml:S3:4078:3	O
the	NULOJIX.xml:S3:4082:3	O
maintenance	NULOJIX.xml:S3:4086:11	O
therapy	NULOJIX.xml:S3:4098:7	O
should	NULOJIX.xml:S3:4106:6	O
have	NULOJIX.xml:S3:4113:4	O
complete	NULOJIX.xml:S3:4118:8	O
information	NULOJIX.xml:S3:4127:11	O
requisite	NULOJIX.xml:S3:4139:9	O
for	NULOJIX.xml:S3:4149:3	O
the	NULOJIX.xml:S3:4153:3	O
follow	NULOJIX.xml:S3:4157:6	O
-	NULOJIX.xml:S3:4163:1	O
up	NULOJIX.xml:S3:4164:2	O
of	NULOJIX.xml:S3:4167:2	O
the	NULOJIX.xml:S3:4170:3	O
patient	NULOJIX.xml:S3:4174:7	O
[	NULOJIX.xml:S3:4182:1	O
see	NULOJIX.xml:S3:4183:3	O
Boxed	NULOJIX.xml:S3:4189:5	O
Warning	NULOJIX.xml:S3:4195:7	O
]	NULOJIX.xml:S3:4206:1	O
.	NULOJIX.xml:S3:4207:1	O

5.3	NULOJIX.xml:S3:4216:3	O
Other	NULOJIX.xml:S3:4220:5	O
Malignancies	NULOJIX.xml:S3:4226:12	O

Patients	NULOJIX.xml:S3:4244:8	O
receiving	NULOJIX.xml:S3:4253:9	O
immunosuppressants	NULOJIX.xml:S3:4263:18	O
,	NULOJIX.xml:S3:4281:1	O
including	NULOJIX.xml:S3:4283:9	O
NULOJIX	NULOJIX.xml:S3:4293:7	O
,	NULOJIX.xml:S3:4300:1	O
are	NULOJIX.xml:S3:4302:3	O
at	NULOJIX.xml:S3:4306:2	O
increased	NULOJIX.xml:S3:4309:9	O
risk	NULOJIX.xml:S3:4319:4	O
of	NULOJIX.xml:S3:4324:2	O
developing	NULOJIX.xml:S3:4327:10	O
malignancies	NULOJIX.xml:S3:4338:12	B-AdverseReaction
,	NULOJIX.xml:S3:4350:1	O
in	NULOJIX.xml:S3:4352:2	O
addition	NULOJIX.xml:S3:4355:8	O
to	NULOJIX.xml:S3:4364:2	O
PTLD	NULOJIX.xml:S3:4367:4	B-AdverseReaction
,	NULOJIX.xml:S3:4371:1	O
including	NULOJIX.xml:S3:4373:9	O
the	NULOJIX.xml:S3:4383:3	O
skin	NULOJIX.xml:S3:4387:4	I-AdverseReaction
[	NULOJIX.xml:S3:4392:1	O
see	NULOJIX.xml:S3:4393:3	O
Boxed	NULOJIX.xml:S3:4399:5	O
Warning	NULOJIX.xml:S3:4405:7	O
and	NULOJIX.xml:S3:4416:3	O
Warnings	NULOJIX.xml:S3:4422:8	O
and	NULOJIX.xml:S3:4431:3	O
Precautions	NULOJIX.xml:S3:4435:11	O
(	NULOJIX.xml:S3:4447:1	O
5.1	NULOJIX.xml:S3:4448:3	O
)	NULOJIX.xml:S3:4451:1	O
]	NULOJIX.xml:S3:4456:1	O
.	NULOJIX.xml:S3:4457:1	O

Exposure	NULOJIX.xml:S3:4459:8	O
to	NULOJIX.xml:S3:4468:2	O
sunlight	NULOJIX.xml:S3:4471:8	O
and	NULOJIX.xml:S3:4480:3	O
ultraviolet	NULOJIX.xml:S3:4484:11	O
(	NULOJIX.xml:S3:4496:1	O
UV	NULOJIX.xml:S3:4497:2	O
)	NULOJIX.xml:S3:4499:1	O
light	NULOJIX.xml:S3:4501:5	O
should	NULOJIX.xml:S3:4507:6	O
be	NULOJIX.xml:S3:4514:2	O
limited	NULOJIX.xml:S3:4517:7	O
by	NULOJIX.xml:S3:4525:2	O
wearing	NULOJIX.xml:S3:4528:7	O
protective	NULOJIX.xml:S3:4536:10	O
clothing	NULOJIX.xml:S3:4547:8	O
and	NULOJIX.xml:S3:4556:3	O
using	NULOJIX.xml:S3:4560:5	O
a	NULOJIX.xml:S3:4566:1	O
sunscreen	NULOJIX.xml:S3:4568:9	O
with	NULOJIX.xml:S3:4578:4	O
a	NULOJIX.xml:S3:4583:1	O
high	NULOJIX.xml:S3:4585:4	O
protection	NULOJIX.xml:S3:4590:10	O
factor	NULOJIX.xml:S3:4601:6	O
.	NULOJIX.xml:S3:4607:1	O

5.4	NULOJIX.xml:S3:4616:3	O
Progressive	NULOJIX.xml:S3:4620:11	O
Multifocal	NULOJIX.xml:S3:4632:10	O
Leukoencephalopathy	NULOJIX.xml:S3:4643:19	O

Progressive	NULOJIX.xml:S3:4668:11	O
multifocal	NULOJIX.xml:S3:4680:10	O
leukoencephalopathy	NULOJIX.xml:S3:4691:19	O
(	NULOJIX.xml:S3:4711:1	O
PML	NULOJIX.xml:S3:4712:3	O
)	NULOJIX.xml:S3:4715:1	O
is	NULOJIX.xml:S3:4717:2	O
an	NULOJIX.xml:S3:4720:2	O
often	NULOJIX.xml:S3:4723:5	O
rapidly	NULOJIX.xml:S3:4729:7	O
progressive	NULOJIX.xml:S3:4737:11	O
and	NULOJIX.xml:S3:4749:3	O
fatal	NULOJIX.xml:S3:4753:5	O
opportunistic	NULOJIX.xml:S3:4759:13	O
infection	NULOJIX.xml:S3:4773:9	O
of	NULOJIX.xml:S3:4783:2	O
the	NULOJIX.xml:S3:4786:3	O
CNS	NULOJIX.xml:S3:4790:3	O
that	NULOJIX.xml:S3:4794:4	O
is	NULOJIX.xml:S3:4799:2	O
caused	NULOJIX.xml:S3:4802:6	O
by	NULOJIX.xml:S3:4809:2	O
the	NULOJIX.xml:S3:4812:3	O
JC	NULOJIX.xml:S3:4816:2	O
virus	NULOJIX.xml:S3:4819:5	O
,	NULOJIX.xml:S3:4824:1	O
a	NULOJIX.xml:S3:4826:1	O
human	NULOJIX.xml:S3:4828:5	O
polyoma	NULOJIX.xml:S3:4834:7	O
virus	NULOJIX.xml:S3:4842:5	O
.	NULOJIX.xml:S3:4847:1	O

In	NULOJIX.xml:S3:4849:2	O
clinical	NULOJIX.xml:S3:4852:8	O
trials	NULOJIX.xml:S3:4861:6	O
with	NULOJIX.xml:S3:4868:4	O
NULOJIX	NULOJIX.xml:S3:4873:7	O
,	NULOJIX.xml:S3:4880:1	O
two	NULOJIX.xml:S3:4882:3	O
cases	NULOJIX.xml:S3:4886:5	O
of	NULOJIX.xml:S3:4892:2	O
PML	NULOJIX.xml:S3:4895:3	B-AdverseReaction
were	NULOJIX.xml:S3:4899:4	O
reported	NULOJIX.xml:S3:4904:8	O
in	NULOJIX.xml:S3:4913:2	O
patients	NULOJIX.xml:S3:4916:8	O
receiving	NULOJIX.xml:S3:4925:9	O
NULOJIX	NULOJIX.xml:S3:4935:7	O
at	NULOJIX.xml:S3:4943:2	O
higher	NULOJIX.xml:S3:4946:6	O
cumulative	NULOJIX.xml:S3:4953:10	O
doses	NULOJIX.xml:S3:4964:5	O
and	NULOJIX.xml:S3:4970:3	O
more	NULOJIX.xml:S3:4974:4	O
frequently	NULOJIX.xml:S3:4979:10	O
than	NULOJIX.xml:S3:4990:4	O
the	NULOJIX.xml:S3:4995:3	O
recommended	NULOJIX.xml:S3:4999:11	O
regimen	NULOJIX.xml:S3:5011:7	O
,	NULOJIX.xml:S3:5018:1	O
along	NULOJIX.xml:S3:5020:5	O
with	NULOJIX.xml:S3:5026:4	O
mycophenolate	NULOJIX.xml:S3:5031:13	O
mofetil	NULOJIX.xml:S3:5045:7	O
(	NULOJIX.xml:S3:5053:1	O
MMF	NULOJIX.xml:S3:5054:3	O
)	NULOJIX.xml:S3:5057:1	O
and	NULOJIX.xml:S3:5059:3	O
corticosteroids	NULOJIX.xml:S3:5063:15	O
;	NULOJIX.xml:S3:5078:1	O
one	NULOJIX.xml:S3:5080:3	O
case	NULOJIX.xml:S3:5084:4	O
occurred	NULOJIX.xml:S3:5089:8	O
in	NULOJIX.xml:S3:5098:2	O
a	NULOJIX.xml:S3:5101:1	O
kidney	NULOJIX.xml:S3:5103:6	O
transplant	NULOJIX.xml:S3:5110:10	O
recipient	NULOJIX.xml:S3:5121:9	O
and	NULOJIX.xml:S3:5131:3	O
the	NULOJIX.xml:S3:5135:3	O
second	NULOJIX.xml:S3:5139:6	O
case	NULOJIX.xml:S3:5146:4	O
occurred	NULOJIX.xml:S3:5151:8	O
in	NULOJIX.xml:S3:5160:2	O
a	NULOJIX.xml:S3:5163:1	O
liver	NULOJIX.xml:S3:5165:5	O
transplant	NULOJIX.xml:S3:5171:10	O
recipient	NULOJIX.xml:S3:5182:9	O
[	NULOJIX.xml:S3:5192:1	O
see	NULOJIX.xml:S3:5193:3	O
Warnings	NULOJIX.xml:S3:5199:8	O
and	NULOJIX.xml:S3:5208:3	O
Precautions	NULOJIX.xml:S3:5212:11	O
(	NULOJIX.xml:S3:5224:1	O
5.6	NULOJIX.xml:S3:5225:3	O
)	NULOJIX.xml:S3:5228:1	O
]	NULOJIX.xml:S3:5233:1	O
.	NULOJIX.xml:S3:5234:1	O

As	NULOJIX.xml:S3:5236:2	O
PML	NULOJIX.xml:S3:5239:3	O
has	NULOJIX.xml:S3:5243:3	O
been	NULOJIX.xml:S3:5247:4	O
associated	NULOJIX.xml:S3:5252:10	O
with	NULOJIX.xml:S3:5263:4	O
high	NULOJIX.xml:S3:5268:4	O
levels	NULOJIX.xml:S3:5273:6	O
of	NULOJIX.xml:S3:5280:2	O
overall	NULOJIX.xml:S3:5283:7	O
immunosuppression	NULOJIX.xml:S3:5291:17	O
,	NULOJIX.xml:S3:5308:1	O
the	NULOJIX.xml:S3:5310:3	O
recommended	NULOJIX.xml:S3:5314:11	O
doses	NULOJIX.xml:S3:5326:5	O
and	NULOJIX.xml:S3:5332:3	O
frequency	NULOJIX.xml:S3:5336:9	O
of	NULOJIX.xml:S3:5346:2	O
NULOJIX	NULOJIX.xml:S3:5349:7	O
and	NULOJIX.xml:S3:5357:3	O
concomitant	NULOJIX.xml:S3:5361:11	O
immunosuppressives	NULOJIX.xml:S3:5373:18	O
,	NULOJIX.xml:S3:5391:1	O
including	NULOJIX.xml:S3:5393:9	O
MMF	NULOJIX.xml:S3:5403:3	O
,	NULOJIX.xml:S3:5406:1	O
should	NULOJIX.xml:S3:5408:6	O
not	NULOJIX.xml:S3:5415:3	O
be	NULOJIX.xml:S3:5419:2	O
exceeded	NULOJIX.xml:S3:5422:8	O
.	NULOJIX.xml:S3:5430:1	O

Physicians	NULOJIX.xml:S3:5436:10	O
should	NULOJIX.xml:S3:5447:6	O
consider	NULOJIX.xml:S3:5454:8	O
PML	NULOJIX.xml:S3:5463:3	O
in	NULOJIX.xml:S3:5467:2	O
the	NULOJIX.xml:S3:5470:3	O
differential	NULOJIX.xml:S3:5474:12	O
diagnosis	NULOJIX.xml:S3:5487:9	O
in	NULOJIX.xml:S3:5497:2	O
patients	NULOJIX.xml:S3:5500:8	O
with	NULOJIX.xml:S3:5509:4	O
new	NULOJIX.xml:S3:5514:3	O
or	NULOJIX.xml:S3:5518:2	O
worsening	NULOJIX.xml:S3:5521:9	O
neurological	NULOJIX.xml:S3:5531:12	O
,	NULOJIX.xml:S3:5543:1	O
cognitive	NULOJIX.xml:S3:5545:9	O
,	NULOJIX.xml:S3:5554:1	O
or	NULOJIX.xml:S3:5556:2	O
behavioral	NULOJIX.xml:S3:5559:10	O
signs	NULOJIX.xml:S3:5570:5	O
or	NULOJIX.xml:S3:5576:2	O
symptoms	NULOJIX.xml:S3:5579:8	O
.	NULOJIX.xml:S3:5587:1	O

PML	NULOJIX.xml:S3:5589:3	O
is	NULOJIX.xml:S3:5593:2	O
usually	NULOJIX.xml:S3:5596:7	O
diagnosed	NULOJIX.xml:S3:5604:9	O
by	NULOJIX.xml:S3:5614:2	O
brain	NULOJIX.xml:S3:5617:5	O
imaging	NULOJIX.xml:S3:5623:7	O
,	NULOJIX.xml:S3:5630:1	O
cerebrospinal	NULOJIX.xml:S3:5632:13	O
fluid	NULOJIX.xml:S3:5646:5	O
(	NULOJIX.xml:S3:5652:1	O
CSF	NULOJIX.xml:S3:5653:3	O
)	NULOJIX.xml:S3:5656:1	O
testing	NULOJIX.xml:S3:5658:7	O
for	NULOJIX.xml:S3:5666:3	O
JC	NULOJIX.xml:S3:5670:2	O
viral	NULOJIX.xml:S3:5673:5	O
DNA	NULOJIX.xml:S3:5679:3	O
by	NULOJIX.xml:S3:5683:2	O
polymerase	NULOJIX.xml:S3:5686:10	O
chain	NULOJIX.xml:S3:5697:5	O
reaction	NULOJIX.xml:S3:5703:8	O
(	NULOJIX.xml:S3:5712:1	O
PCR	NULOJIX.xml:S3:5713:3	O
)	NULOJIX.xml:S3:5716:1	O
,	NULOJIX.xml:S3:5717:1	O
and	NULOJIX.xml:S3:5719:3	O
or	NULOJIX.xml:S3:5723:2	O
brain	NULOJIX.xml:S3:5726:5	O
biopsy	NULOJIX.xml:S3:5732:6	O
.	NULOJIX.xml:S3:5738:1	O

Consultation	NULOJIX.xml:S3:5740:12	O
with	NULOJIX.xml:S3:5753:4	O
a	NULOJIX.xml:S3:5758:1	O
specialist	NULOJIX.xml:S3:5760:10	O
(	NULOJIX.xml:S3:5771:1	O
e	NULOJIX.xml:S3:5772:1	O
.	NULOJIX.xml:S3:5773:1	O
g	NULOJIX.xml:S3:5774:1	O
.	NULOJIX.xml:S3:5775:1	O
,	NULOJIX.xml:S3:5776:1	O
neurologist	NULOJIX.xml:S3:5778:11	O
and	NULOJIX.xml:S3:5790:3	O
or	NULOJIX.xml:S3:5794:2	O
infectious	NULOJIX.xml:S3:5797:10	O
disease	NULOJIX.xml:S3:5808:7	O
)	NULOJIX.xml:S3:5815:1	O
should	NULOJIX.xml:S3:5817:6	O
be	NULOJIX.xml:S3:5824:2	O
considered	NULOJIX.xml:S3:5827:10	O
for	NULOJIX.xml:S3:5838:3	O
any	NULOJIX.xml:S3:5842:3	O
suspected	NULOJIX.xml:S3:5846:9	O
or	NULOJIX.xml:S3:5856:2	O
confirmed	NULOJIX.xml:S3:5859:9	O
cases	NULOJIX.xml:S3:5869:5	O
of	NULOJIX.xml:S3:5875:2	O
PML	NULOJIX.xml:S3:5878:3	O
.	NULOJIX.xml:S3:5881:1	O

If	NULOJIX.xml:S3:5887:2	O
PML	NULOJIX.xml:S3:5890:3	O
is	NULOJIX.xml:S3:5894:2	O
diagnosed	NULOJIX.xml:S3:5897:9	O
,	NULOJIX.xml:S3:5906:1	O
consideration	NULOJIX.xml:S3:5908:13	O
should	NULOJIX.xml:S3:5922:6	O
be	NULOJIX.xml:S3:5929:2	O
given	NULOJIX.xml:S3:5932:5	O
to	NULOJIX.xml:S3:5938:2	O
reduction	NULOJIX.xml:S3:5941:9	O
or	NULOJIX.xml:S3:5951:2	O
withdrawal	NULOJIX.xml:S3:5954:10	O
of	NULOJIX.xml:S3:5965:2	O
immunosuppression	NULOJIX.xml:S3:5968:17	O
taking	NULOJIX.xml:S3:5986:6	O
into	NULOJIX.xml:S3:5993:4	O
account	NULOJIX.xml:S3:5998:7	O
the	NULOJIX.xml:S3:6006:3	O
risk	NULOJIX.xml:S3:6010:4	O
to	NULOJIX.xml:S3:6015:2	O
the	NULOJIX.xml:S3:6018:3	O
allograft	NULOJIX.xml:S3:6022:9	O
.	NULOJIX.xml:S3:6031:1	O

5.5	NULOJIX.xml:S3:6040:3	O
Other	NULOJIX.xml:S3:6044:5	O
Serious	NULOJIX.xml:S3:6050:7	O
Infections	NULOJIX.xml:S3:6058:10	O

Patients	NULOJIX.xml:S3:6074:8	O
receiving	NULOJIX.xml:S3:6083:9	O
immunosuppressants	NULOJIX.xml:S3:6093:18	O
,	NULOJIX.xml:S3:6111:1	O
including	NULOJIX.xml:S3:6113:9	O
NULOJIX	NULOJIX.xml:S3:6123:7	O
,	NULOJIX.xml:S3:6130:1	O
are	NULOJIX.xml:S3:6132:3	O
at	NULOJIX.xml:S3:6136:2	O
increased	NULOJIX.xml:S3:6139:9	O
risk	NULOJIX.xml:S3:6149:4	B-Factor
of	NULOJIX.xml:S3:6154:2	O
developing	NULOJIX.xml:S3:6157:10	O
bacterial	NULOJIX.xml:S3:6168:9	B-AdverseReaction
,	NULOJIX.xml:S3:6177:1	O
viral	NULOJIX.xml:S3:6179:5	B-AdverseReaction
(	NULOJIX.xml:S3:6185:1	O
cytomegalovirus	NULOJIX.xml:S3:6186:15	B-AdverseReaction
[	NULOJIX.xml:S3:6202:1	O
CMV	NULOJIX.xml:S3:6203:3	B-AdverseReaction
]	NULOJIX.xml:S3:6206:1	O
and	NULOJIX.xml:S3:6208:3	O
herpes	NULOJIX.xml:S3:6212:6	B-AdverseReaction
)	NULOJIX.xml:S3:6218:1	O
,	NULOJIX.xml:S3:6219:1	O
fungal	NULOJIX.xml:S3:6221:6	B-AdverseReaction
,	NULOJIX.xml:S3:6227:1	O
and	NULOJIX.xml:S3:6229:3	O
protozoal	NULOJIX.xml:S3:6233:9	B-AdverseReaction
infections	NULOJIX.xml:S3:6243:10	I-AdverseReaction
,	NULOJIX.xml:S3:6253:1	O
including	NULOJIX.xml:S3:6255:9	O
opportunistic	NULOJIX.xml:S3:6265:13	B-AdverseReaction
infections	NULOJIX.xml:S3:6279:10	I-AdverseReaction
.	NULOJIX.xml:S3:6289:1	O

These	NULOJIX.xml:S3:6291:5	O
infections	NULOJIX.xml:S3:6297:10	B-AdverseReaction
may	NULOJIX.xml:S3:6308:3	O
lead	NULOJIX.xml:S3:6312:4	O
to	NULOJIX.xml:S3:6317:2	O
serious	NULOJIX.xml:S3:6320:7	B-Severity
,	NULOJIX.xml:S3:6327:1	O
including	NULOJIX.xml:S3:6329:9	O
fatal	NULOJIX.xml:S3:6339:5	B-AdverseReaction
,	NULOJIX.xml:S3:6344:1	O
outcomes	NULOJIX.xml:S3:6346:8	O
[	NULOJIX.xml:S3:6355:1	O
see	NULOJIX.xml:S3:6356:3	O
Boxed	NULOJIX.xml:S3:6362:5	O
Warning	NULOJIX.xml:S3:6368:7	O
and	NULOJIX.xml:S3:6379:3	O
Adverse	NULOJIX.xml:S3:6385:7	O
Reactions	NULOJIX.xml:S3:6393:9	O
(	NULOJIX.xml:S3:6403:1	O
6.1	NULOJIX.xml:S3:6404:3	O
)	NULOJIX.xml:S3:6407:1	O
]	NULOJIX.xml:S3:6412:1	O
.	NULOJIX.xml:S3:6413:1	O

Prophylaxis	NULOJIX.xml:S3:6419:11	O
for	NULOJIX.xml:S3:6431:3	O
cytomegalovirus	NULOJIX.xml:S3:6435:15	O
is	NULOJIX.xml:S3:6451:2	O
recommended	NULOJIX.xml:S3:6454:11	O
for	NULOJIX.xml:S3:6466:3	O
at	NULOJIX.xml:S3:6470:2	O
least	NULOJIX.xml:S3:6473:5	O
3	NULOJIX.xml:S3:6479:1	O
months	NULOJIX.xml:S3:6481:6	O
after	NULOJIX.xml:S3:6488:5	O
transplantation	NULOJIX.xml:S3:6494:15	O
.	NULOJIX.xml:S3:6509:1	O

Prophylaxis	NULOJIX.xml:S3:6511:11	O
for	NULOJIX.xml:S3:6523:3	O
Pneumocystis	NULOJIX.xml:S3:6527:12	O
jiroveci	NULOJIX.xml:S3:6540:8	O
is	NULOJIX.xml:S3:6550:2	O
recommended	NULOJIX.xml:S3:6553:11	O
after	NULOJIX.xml:S3:6565:5	O
transplantation	NULOJIX.xml:S3:6571:15	O
.	NULOJIX.xml:S3:6586:1	O

Tuberculosis	NULOJIX.xml:S3:6595:12	O

Tuberculosis	NULOJIX.xml:S3:6613:12	B-AdverseReaction
was	NULOJIX.xml:S3:6626:3	O
more	NULOJIX.xml:S3:6630:4	O
frequently	NULOJIX.xml:S3:6635:10	O
observed	NULOJIX.xml:S3:6646:8	O
in	NULOJIX.xml:S3:6655:2	O
patients	NULOJIX.xml:S3:6658:8	O
receiving	NULOJIX.xml:S3:6667:9	O
NULOJIX	NULOJIX.xml:S3:6677:7	O
than	NULOJIX.xml:S3:6685:4	O
cyclosporine	NULOJIX.xml:S3:6690:12	O
in	NULOJIX.xml:S3:6703:2	O
clinical	NULOJIX.xml:S3:6706:8	O
trials	NULOJIX.xml:S3:6715:6	O
[	NULOJIX.xml:S3:6722:1	O
see	NULOJIX.xml:S3:6723:3	O
Adverse	NULOJIX.xml:S3:6729:7	O
Reactions	NULOJIX.xml:S3:6737:9	O
(	NULOJIX.xml:S3:6747:1	O
6.1	NULOJIX.xml:S3:6748:3	O
)	NULOJIX.xml:S3:6751:1	O
]	NULOJIX.xml:S3:6756:1	O
.	NULOJIX.xml:S3:6757:1	O

Patients	NULOJIX.xml:S3:6759:8	O
should	NULOJIX.xml:S3:6768:6	O
be	NULOJIX.xml:S3:6775:2	O
evaluated	NULOJIX.xml:S3:6778:9	O
for	NULOJIX.xml:S3:6788:3	O
tuberculosis	NULOJIX.xml:S3:6792:12	O
and	NULOJIX.xml:S3:6805:3	O
tested	NULOJIX.xml:S3:6809:6	O
for	NULOJIX.xml:S3:6816:3	O
latent	NULOJIX.xml:S3:6820:6	O
infection	NULOJIX.xml:S3:6827:9	O
prior	NULOJIX.xml:S3:6837:5	O
to	NULOJIX.xml:S3:6843:2	O
initiating	NULOJIX.xml:S3:6846:10	O
NULOJIX	NULOJIX.xml:S3:6857:7	O
.	NULOJIX.xml:S3:6864:1	O

Treatment	NULOJIX.xml:S3:6866:9	O
of	NULOJIX.xml:S3:6876:2	O
latent	NULOJIX.xml:S3:6879:6	O
tuberculosis	NULOJIX.xml:S3:6886:12	O
infection	NULOJIX.xml:S3:6899:9	O
should	NULOJIX.xml:S3:6909:6	O
be	NULOJIX.xml:S3:6916:2	O
initiated	NULOJIX.xml:S3:6919:9	O
prior	NULOJIX.xml:S3:6929:5	O
to	NULOJIX.xml:S3:6935:2	O
NULOJIX	NULOJIX.xml:S3:6938:7	O
use	NULOJIX.xml:S3:6946:3	O
.	NULOJIX.xml:S3:6949:1	O

Polyoma	NULOJIX.xml:S3:6958:7	O
Virus	NULOJIX.xml:S3:6966:5	O
Nephropathy	NULOJIX.xml:S3:6972:11	O

In	NULOJIX.xml:S3:6989:2	O
addition	NULOJIX.xml:S3:6992:8	O
to	NULOJIX.xml:S3:7001:2	O
cases	NULOJIX.xml:S3:7004:5	O
of	NULOJIX.xml:S3:7010:2	O
JC	NULOJIX.xml:S3:7013:2	B-AdverseReaction
virus	NULOJIX.xml:S3:7016:5	I-AdverseReaction
-	NULOJIX.xml:S3:7021:1	O
associated	NULOJIX.xml:S3:7022:10	O
PML	NULOJIX.xml:S3:7033:3	B-AdverseReaction
[	NULOJIX.xml:S3:7037:1	O
see	NULOJIX.xml:S3:7038:3	O
Warnings	NULOJIX.xml:S3:7044:8	O
and	NULOJIX.xml:S3:7053:3	O
Precautions	NULOJIX.xml:S3:7057:11	O
(	NULOJIX.xml:S3:7069:1	O
5.4	NULOJIX.xml:S3:7070:3	O
)	NULOJIX.xml:S3:7073:1	O
]	NULOJIX.xml:S3:7078:1	O
,	NULOJIX.xml:S3:7079:1	O
cases	NULOJIX.xml:S3:7081:5	O
of	NULOJIX.xml:S3:7087:2	O
polyoma	NULOJIX.xml:S3:7090:7	B-AdverseReaction
virus	NULOJIX.xml:S3:7098:5	I-AdverseReaction
-	NULOJIX.xml:S3:7103:1	I-AdverseReaction
associated	NULOJIX.xml:S3:7104:10	I-AdverseReaction
nephropathy	NULOJIX.xml:S3:7115:11	I-AdverseReaction
(	NULOJIX.xml:S3:7127:1	O
PVAN	NULOJIX.xml:S3:7128:4	B-AdverseReaction
)	NULOJIX.xml:S3:7132:1	O
,	NULOJIX.xml:S3:7133:1	O
mostly	NULOJIX.xml:S3:7135:6	O
due	NULOJIX.xml:S3:7142:3	O
to	NULOJIX.xml:S3:7146:2	O
BK	NULOJIX.xml:S3:7149:2	B-AdverseReaction
virus	NULOJIX.xml:S3:7152:5	I-AdverseReaction
infection	NULOJIX.xml:S3:7158:9	I-AdverseReaction
,	NULOJIX.xml:S3:7167:1	O
have	NULOJIX.xml:S3:7169:4	O
been	NULOJIX.xml:S3:7174:4	O
reported	NULOJIX.xml:S3:7179:8	O
.	NULOJIX.xml:S3:7187:1	O

PVAN	NULOJIX.xml:S3:7189:4	B-AdverseReaction
is	NULOJIX.xml:S3:7194:2	O
associated	NULOJIX.xml:S3:7197:10	O
with	NULOJIX.xml:S3:7208:4	O
serious	NULOJIX.xml:S3:7213:7	O
outcomes	NULOJIX.xml:S3:7221:8	O
;	NULOJIX.xml:S3:7229:1	O
including	NULOJIX.xml:S3:7231:9	O
deteriorating	NULOJIX.xml:S3:7241:13	B-AdverseReaction
renal	NULOJIX.xml:S3:7255:5	I-AdverseReaction
function	NULOJIX.xml:S3:7261:8	I-AdverseReaction
and	NULOJIX.xml:S3:7270:3	O
kidney	NULOJIX.xml:S3:7274:6	B-AdverseReaction
graft	NULOJIX.xml:S3:7281:5	I-AdverseReaction
loss	NULOJIX.xml:S3:7287:4	I-AdverseReaction
[	NULOJIX.xml:S3:7292:1	O
see	NULOJIX.xml:S3:7293:3	O
Adverse	NULOJIX.xml:S3:7299:7	O
Reactions	NULOJIX.xml:S3:7307:9	O
(	NULOJIX.xml:S3:7317:1	O
6.1	NULOJIX.xml:S3:7318:3	O
)	NULOJIX.xml:S3:7321:1	O
]	NULOJIX.xml:S3:7326:1	O
.	NULOJIX.xml:S3:7327:1	O

Patient	NULOJIX.xml:S3:7329:7	O
monitoring	NULOJIX.xml:S3:7337:10	O
may	NULOJIX.xml:S3:7348:3	O
help	NULOJIX.xml:S3:7352:4	O
detect	NULOJIX.xml:S3:7357:6	O
patients	NULOJIX.xml:S3:7364:8	O
at	NULOJIX.xml:S3:7373:2	O
risk	NULOJIX.xml:S3:7376:4	O
for	NULOJIX.xml:S3:7381:3	O
PVAN	NULOJIX.xml:S3:7385:4	O
.	NULOJIX.xml:S3:7389:1	O

Reductions	NULOJIX.xml:S3:7391:10	O
in	NULOJIX.xml:S3:7402:2	O
immunosuppression	NULOJIX.xml:S3:7405:17	O
should	NULOJIX.xml:S3:7423:6	O
be	NULOJIX.xml:S3:7430:2	O
considered	NULOJIX.xml:S3:7433:10	O
for	NULOJIX.xml:S3:7444:3	O
patients	NULOJIX.xml:S3:7448:8	O
who	NULOJIX.xml:S3:7457:3	O
develop	NULOJIX.xml:S3:7461:7	O
evidence	NULOJIX.xml:S3:7469:8	O
of	NULOJIX.xml:S3:7478:2	O
PVAN	NULOJIX.xml:S3:7481:4	O
.	NULOJIX.xml:S3:7485:1	O

Physicians	NULOJIX.xml:S3:7487:10	O
should	NULOJIX.xml:S3:7498:6	O
also	NULOJIX.xml:S3:7505:4	O
consider	NULOJIX.xml:S3:7510:8	O
the	NULOJIX.xml:S3:7519:3	O
risk	NULOJIX.xml:S3:7523:4	O
that	NULOJIX.xml:S3:7528:4	O
reduced	NULOJIX.xml:S3:7533:7	O
immunosuppression	NULOJIX.xml:S3:7541:17	O
represents	NULOJIX.xml:S3:7559:10	O
to	NULOJIX.xml:S3:7570:2	O
the	NULOJIX.xml:S3:7573:3	O
functioning	NULOJIX.xml:S3:7577:11	O
allograft	NULOJIX.xml:S3:7589:9	O
.	NULOJIX.xml:S3:7598:1	O

5.6	NULOJIX.xml:S3:7607:3	O
Liver	NULOJIX.xml:S3:7611:5	O
Transplant	NULOJIX.xml:S3:7617:10	O

Use	NULOJIX.xml:S3:7633:3	O
of	NULOJIX.xml:S3:7637:2	O
NULOJIX	NULOJIX.xml:S3:7640:7	O
in	NULOJIX.xml:S3:7648:2	O
liver	NULOJIX.xml:S3:7651:5	O
transplant	NULOJIX.xml:S3:7657:10	O
patients	NULOJIX.xml:S3:7668:8	O
is	NULOJIX.xml:S3:7677:2	O
not	NULOJIX.xml:S3:7680:3	O
recommended	NULOJIX.xml:S3:7684:11	O
[	NULOJIX.xml:S3:7696:1	O
see	NULOJIX.xml:S3:7697:3	O
Boxed	NULOJIX.xml:S3:7703:5	O
Warning	NULOJIX.xml:S3:7709:7	O
]	NULOJIX.xml:S3:7720:1	O
.	NULOJIX.xml:S3:7721:1	O

In	NULOJIX.xml:S3:7723:2	O
a	NULOJIX.xml:S3:7726:1	O
clinical	NULOJIX.xml:S3:7728:8	O
trial	NULOJIX.xml:S3:7737:5	O
of	NULOJIX.xml:S3:7743:2	O
liver	NULOJIX.xml:S3:7746:5	O
transplant	NULOJIX.xml:S3:7752:10	O
patients	NULOJIX.xml:S3:7763:8	O
,	NULOJIX.xml:S3:7771:1	O
use	NULOJIX.xml:S3:7773:3	O
of	NULOJIX.xml:S3:7777:2	O
NULOJIX	NULOJIX.xml:S3:7780:7	O
regimens	NULOJIX.xml:S3:7788:8	O
with	NULOJIX.xml:S3:7797:4	O
more	NULOJIX.xml:S3:7802:4	O
frequent	NULOJIX.xml:S3:7807:8	O
administration	NULOJIX.xml:S3:7816:14	O
of	NULOJIX.xml:S3:7831:2	O
belatacept	NULOJIX.xml:S3:7834:10	O
than	NULOJIX.xml:S3:7845:4	O
any	NULOJIX.xml:S3:7850:3	O
of	NULOJIX.xml:S3:7854:2	O
those	NULOJIX.xml:S3:7857:5	O
studied	NULOJIX.xml:S3:7863:7	O
in	NULOJIX.xml:S3:7871:2	O
kidney	NULOJIX.xml:S3:7874:6	O
transplant	NULOJIX.xml:S3:7881:10	O
,	NULOJIX.xml:S3:7891:1	O
along	NULOJIX.xml:S3:7893:5	O
with	NULOJIX.xml:S3:7899:4	O
mycophenolate	NULOJIX.xml:S3:7904:13	O
mofetil	NULOJIX.xml:S3:7918:7	O
(	NULOJIX.xml:S3:7926:1	O
MMF	NULOJIX.xml:S3:7927:3	O
)	NULOJIX.xml:S3:7930:1	O
and	NULOJIX.xml:S3:7932:3	O
corticosteroids	NULOJIX.xml:S3:7936:15	O
,	NULOJIX.xml:S3:7951:1	O
was	NULOJIX.xml:S3:7953:3	O
associated	NULOJIX.xml:S3:7957:10	O
with	NULOJIX.xml:S3:7968:4	O
a	NULOJIX.xml:S3:7973:1	O
higher	NULOJIX.xml:S3:7975:6	O
rate	NULOJIX.xml:S3:7982:4	O
of	NULOJIX.xml:S3:7987:2	O
graft	NULOJIX.xml:S3:7990:5	B-AdverseReaction
loss	NULOJIX.xml:S3:7996:4	I-AdverseReaction
and	NULOJIX.xml:S3:8001:3	O
death	NULOJIX.xml:S3:8005:5	B-AdverseReaction
compared	NULOJIX.xml:S3:8011:8	O
to	NULOJIX.xml:S3:8020:2	O
the	NULOJIX.xml:S3:8023:3	O
tacrolimus	NULOJIX.xml:S3:8027:10	O
control	NULOJIX.xml:S3:8038:7	O
arms	NULOJIX.xml:S3:8046:4	O
.	NULOJIX.xml:S3:8050:1	O

In	NULOJIX.xml:S3:8052:2	O
addition	NULOJIX.xml:S3:8055:8	O
,	NULOJIX.xml:S3:8063:1	O
two	NULOJIX.xml:S3:8065:3	O
cases	NULOJIX.xml:S3:8069:5	O
of	NULOJIX.xml:S3:8075:2	O
PTLD	NULOJIX.xml:S3:8078:4	B-AdverseReaction
involving	NULOJIX.xml:S3:8083:9	O
the	NULOJIX.xml:S3:8093:3	O
liver	NULOJIX.xml:S3:8097:5	O
allograft	NULOJIX.xml:S3:8103:9	O
(	NULOJIX.xml:S3:8113:1	O
one	NULOJIX.xml:S3:8114:3	O
fatal	NULOJIX.xml:S3:8118:5	B-AdverseReaction
)	NULOJIX.xml:S3:8123:1	O
and	NULOJIX.xml:S3:8125:3	O
one	NULOJIX.xml:S3:8129:3	O
fatal	NULOJIX.xml:S3:8133:5	B-AdverseReaction
case	NULOJIX.xml:S3:8139:4	O
of	NULOJIX.xml:S3:8144:2	O
PML	NULOJIX.xml:S3:8147:3	B-AdverseReaction
were	NULOJIX.xml:S3:8151:4	O
observed	NULOJIX.xml:S3:8156:8	O
among	NULOJIX.xml:S3:8165:5	O
the	NULOJIX.xml:S3:8171:3	O
147	NULOJIX.xml:S3:8175:3	O
patients	NULOJIX.xml:S3:8179:8	O
randomized	NULOJIX.xml:S3:8188:10	O
to	NULOJIX.xml:S3:8199:2	O
NULOJIX	NULOJIX.xml:S3:8202:7	O
.	NULOJIX.xml:S3:8209:1	O

The	NULOJIX.xml:S3:8211:3	O
two	NULOJIX.xml:S3:8215:3	O
cases	NULOJIX.xml:S3:8219:5	O
of	NULOJIX.xml:S3:8225:2	O
PTLD	NULOJIX.xml:S3:8228:4	B-AdverseReaction
were	NULOJIX.xml:S3:8233:4	O
reported	NULOJIX.xml:S3:8238:8	O
among	NULOJIX.xml:S3:8247:5	O
the	NULOJIX.xml:S3:8253:3	O
140	NULOJIX.xml:S3:8257:3	O
EBV	NULOJIX.xml:S3:8261:3	O
seropositive	NULOJIX.xml:S3:8265:12	O
patients	NULOJIX.xml:S3:8278:8	O
(	NULOJIX.xml:S3:8287:1	O
1.4%	NULOJIX.xml:S3:8288:4	O
)	NULOJIX.xml:S3:8292:1	O
.	NULOJIX.xml:S3:8293:1	O

The	NULOJIX.xml:S3:8295:3	O
fatal	NULOJIX.xml:S3:8299:5	B-AdverseReaction
case	NULOJIX.xml:S3:8305:4	O
of	NULOJIX.xml:S3:8310:2	O
PML	NULOJIX.xml:S3:8313:3	B-AdverseReaction
was	NULOJIX.xml:S3:8317:3	O
reported	NULOJIX.xml:S3:8321:8	O
in	NULOJIX.xml:S3:8330:2	O
a	NULOJIX.xml:S3:8333:1	O
patient	NULOJIX.xml:S3:8335:7	O
receiving	NULOJIX.xml:S3:8343:9	O
higher	NULOJIX.xml:S3:8353:6	O
than	NULOJIX.xml:S3:8360:4	O
recommended	NULOJIX.xml:S3:8365:11	O
doses	NULOJIX.xml:S3:8377:5	O
of	NULOJIX.xml:S3:8383:2	O
NULOJIX	NULOJIX.xml:S3:8386:7	O
and	NULOJIX.xml:S3:8394:3	O
MMF	NULOJIX.xml:S3:8398:3	O
[	NULOJIX.xml:S3:8402:1	O
see	NULOJIX.xml:S3:8403:3	O
Warnings	NULOJIX.xml:S3:8409:8	O
and	NULOJIX.xml:S3:8418:3	O
Precautions	NULOJIX.xml:S3:8422:11	O
(	NULOJIX.xml:S3:8434:1	O
5.4	NULOJIX.xml:S3:8435:3	O
)	NULOJIX.xml:S3:8438:1	O
]	NULOJIX.xml:S3:8443:1	O
.	NULOJIX.xml:S3:8444:1	O

5.7	NULOJIX.xml:S3:8453:3	O
Acute	NULOJIX.xml:S3:8457:5	O
Rejection	NULOJIX.xml:S3:8463:9	O
and	NULOJIX.xml:S3:8473:3	O
Graft	NULOJIX.xml:S3:8477:5	B-AdverseReaction
Loss	NULOJIX.xml:S3:8483:4	O
with	NULOJIX.xml:S3:8488:4	O
Corticosteroid	NULOJIX.xml:S3:8493:14	O
Minimization	NULOJIX.xml:S3:8508:12	O

In	NULOJIX.xml:S3:8526:2	O
postmarketing	NULOJIX.xml:S3:8529:13	O
experience	NULOJIX.xml:S3:8543:10	O
,	NULOJIX.xml:S3:8553:1	O
use	NULOJIX.xml:S3:8555:3	O
of	NULOJIX.xml:S3:8559:2	O
NULOJIX	NULOJIX.xml:S3:8562:7	O
in	NULOJIX.xml:S3:8570:2	O
conjunction	NULOJIX.xml:S3:8573:11	O
with	NULOJIX.xml:S3:8585:4	O
basiliximab	NULOJIX.xml:S3:8590:11	O
induction	NULOJIX.xml:S3:8602:9	O
,	NULOJIX.xml:S3:8611:1	O
MMF	NULOJIX.xml:S3:8613:3	O
,	NULOJIX.xml:S3:8616:1	O
and	NULOJIX.xml:S3:8618:3	O
corticosteroid	NULOJIX.xml:S3:8622:14	O
minimization	NULOJIX.xml:S3:8637:12	O
to	NULOJIX.xml:S3:8650:2	O
5	NULOJIX.xml:S3:8653:1	O
mg	NULOJIX.xml:S3:8655:2	O
per	NULOJIX.xml:S3:8658:3	O
day	NULOJIX.xml:S3:8662:3	O
between	NULOJIX.xml:S3:8666:7	O
Day	NULOJIX.xml:S3:8674:3	O
3	NULOJIX.xml:S3:8678:1	O
and	NULOJIX.xml:S3:8680:3	O
Week	NULOJIX.xml:S3:8684:4	O
6	NULOJIX.xml:S3:8689:1	O
post	NULOJIX.xml:S3:8691:4	B-AdverseReaction
-	NULOJIX.xml:S3:8695:1	I-AdverseReaction
transplant	NULOJIX.xml:S3:8696:10	I-AdverseReaction
was	NULOJIX.xml:S3:8707:3	O
associated	NULOJIX.xml:S3:8711:10	O
with	NULOJIX.xml:S3:8722:4	O
an	NULOJIX.xml:S3:8727:2	O
increased	NULOJIX.xml:S3:8730:9	O
rate	NULOJIX.xml:S3:8740:4	O
and	NULOJIX.xml:S3:8745:3	O
grade	NULOJIX.xml:S3:8749:5	O
of	NULOJIX.xml:S3:8755:2	O
acute	NULOJIX.xml:S3:8758:5	I-AdverseReaction
rejection	NULOJIX.xml:S3:8764:9	I-AdverseReaction
,	NULOJIX.xml:S3:8773:1	O
particularly	NULOJIX.xml:S3:8775:12	O
Grade	NULOJIX.xml:S3:8788:5	B-Severity
III	NULOJIX.xml:S3:8794:3	I-Severity
rejection	NULOJIX.xml:S3:8798:9	O
.	NULOJIX.xml:S3:8807:1	O

These	NULOJIX.xml:S3:8809:5	O
Grade	NULOJIX.xml:S3:8815:5	B-Severity
III	NULOJIX.xml:S3:8821:3	I-Severity
rejections	NULOJIX.xml:S3:8825:10	I-AdverseReaction
occurred	NULOJIX.xml:S3:8836:8	O
in	NULOJIX.xml:S3:8845:2	O
patients	NULOJIX.xml:S3:8848:8	O
with	NULOJIX.xml:S3:8857:4	O
4	NULOJIX.xml:S3:8862:1	O
to	NULOJIX.xml:S3:8864:2	O
6	NULOJIX.xml:S3:8867:1	O
HLA	NULOJIX.xml:S3:8869:3	O
mismatches	NULOJIX.xml:S3:8873:10	O
.	NULOJIX.xml:S3:8883:1	O

Graft	NULOJIX.xml:S3:8885:5	B-AdverseReaction
loss	NULOJIX.xml:S3:8891:4	I-AdverseReaction
was	NULOJIX.xml:S3:8896:3	O
a	NULOJIX.xml:S3:8900:1	O
consequence	NULOJIX.xml:S3:8902:11	O
of	NULOJIX.xml:S3:8914:2	O
Grade	NULOJIX.xml:S3:8917:5	B-Severity
III	NULOJIX.xml:S3:8923:3	I-Severity
rejection	NULOJIX.xml:S3:8927:9	I-AdverseReaction
in	NULOJIX.xml:S3:8937:2	O
some	NULOJIX.xml:S3:8940:4	O
patients	NULOJIX.xml:S3:8945:8	O
.	NULOJIX.xml:S3:8953:1	O

Corticosteroid	NULOJIX.xml:S3:8959:14	O
utilization	NULOJIX.xml:S3:8974:11	O
should	NULOJIX.xml:S3:8986:6	O
be	NULOJIX.xml:S3:8993:2	O
consistent	NULOJIX.xml:S3:8996:10	O
with	NULOJIX.xml:S3:9007:4	O
the	NULOJIX.xml:S3:9012:3	O
NULOJIX	NULOJIX.xml:S3:9016:7	O
clinical	NULOJIX.xml:S3:9024:8	O
trial	NULOJIX.xml:S3:9033:5	O
experience	NULOJIX.xml:S3:9039:10	O
[	NULOJIX.xml:S3:9050:1	O
see	NULOJIX.xml:S3:9051:3	O
Dosage	NULOJIX.xml:S3:9057:6	O
and	NULOJIX.xml:S3:9064:3	O
Administration	NULOJIX.xml:S3:9068:14	O
(	NULOJIX.xml:S3:9083:1	O
2.1	NULOJIX.xml:S3:9084:3	O
)	NULOJIX.xml:S3:9087:1	O
and	NULOJIX.xml:S3:9092:3	O
Clinical	NULOJIX.xml:S3:9098:8	O
Studies	NULOJIX.xml:S3:9107:7	O
(	NULOJIX.xml:S3:9115:1	O
14.1	NULOJIX.xml:S3:9116:4	O
)	NULOJIX.xml:S3:9120:1	O
]	NULOJIX.xml:S3:9125:1	O
.	NULOJIX.xml:S3:9126:1	O

5.8	NULOJIX.xml:S3:9135:3	O
Immunizations	NULOJIX.xml:S3:9139:13	O

The	NULOJIX.xml:S3:9158:3	O
use	NULOJIX.xml:S3:9162:3	O
of	NULOJIX.xml:S3:9166:2	O
live	NULOJIX.xml:S3:9169:4	O
vaccines	NULOJIX.xml:S3:9174:8	O
should	NULOJIX.xml:S3:9183:6	O
be	NULOJIX.xml:S3:9190:2	O
avoided	NULOJIX.xml:S3:9193:7	O
during	NULOJIX.xml:S3:9201:6	O
treatment	NULOJIX.xml:S3:9208:9	O
with	NULOJIX.xml:S3:9218:4	O
NULOJIX	NULOJIX.xml:S3:9223:7	O
,	NULOJIX.xml:S3:9230:1	O
including	NULOJIX.xml:S3:9232:9	O
but	NULOJIX.xml:S3:9242:3	O
not	NULOJIX.xml:S3:9246:3	O
limited	NULOJIX.xml:S3:9250:7	O
to	NULOJIX.xml:S3:9258:2	O
the	NULOJIX.xml:S3:9261:3	O
following	NULOJIX.xml:S3:9265:9	O
:	NULOJIX.xml:S3:9274:1	O
intranasal	NULOJIX.xml:S3:9276:10	O
influenza	NULOJIX.xml:S3:9287:9	O
,	NULOJIX.xml:S3:9296:1	O
measles	NULOJIX.xml:S3:9298:7	O
,	NULOJIX.xml:S3:9305:1	O
mumps	NULOJIX.xml:S3:9307:5	O
,	NULOJIX.xml:S3:9312:1	O
rubella	NULOJIX.xml:S3:9314:7	O
,	NULOJIX.xml:S3:9321:1	O
oral	NULOJIX.xml:S3:9323:4	O
polio	NULOJIX.xml:S3:9328:5	O
,	NULOJIX.xml:S3:9333:1	O
BCG	NULOJIX.xml:S3:9335:3	O
,	NULOJIX.xml:S3:9338:1	O
yellow	NULOJIX.xml:S3:9340:6	O
fever	NULOJIX.xml:S3:9347:5	O
,	NULOJIX.xml:S3:9352:1	O
varicella	NULOJIX.xml:S3:9354:9	O
,	NULOJIX.xml:S3:9363:1	O
and	NULOJIX.xml:S3:9365:3	O
TY21a	NULOJIX.xml:S3:9369:5	O
typhoid	NULOJIX.xml:S3:9375:7	O
vaccines	NULOJIX.xml:S3:9383:8	O
.	NULOJIX.xml:S3:9391:1	O
6	ONFI.xml:S1:6:1	O
ADVERSE	ONFI.xml:S1:8:7	O
REACTIONS	ONFI.xml:S1:16:9	O

Clinically	ONFI.xml:S1:31:10	O
significant	ONFI.xml:S1:42:11	O
adverse	ONFI.xml:S1:54:7	O
reactions	ONFI.xml:S1:62:9	O
that	ONFI.xml:S1:72:4	O
appear	ONFI.xml:S1:77:6	O
in	ONFI.xml:S1:84:2	O
other	ONFI.xml:S1:87:5	O
sections	ONFI.xml:S1:93:8	O
of	ONFI.xml:S1:102:2	O
the	ONFI.xml:S1:105:3	O
labeling	ONFI.xml:S1:109:8	O
include	ONFI.xml:S1:118:7	O
the	ONFI.xml:S1:126:3	O
following	ONFI.xml:S1:130:9	O
:	ONFI.xml:S1:139:1	O

Somnolence	ONFI.xml:S1:148:10	B-AdverseReaction
or	ONFI.xml:S1:159:2	O
Sedation	ONFI.xml:S1:162:8	B-AdverseReaction
[	ONFI.xml:S1:171:1	O
see	ONFI.xml:S1:172:3	O
Warnings	ONFI.xml:S1:176:8	O
and	ONFI.xml:S1:185:3	O
Precautions	ONFI.xml:S1:189:11	O
(	ONFI.xml:S1:201:1	O
5.1	ONFI.xml:S1:204:3	O
)]	ONFI.xml:S1:209:2	O

Potentiation	ONFI.xml:S1:218:12	B-AdverseReaction
of	ONFI.xml:S1:231:2	I-AdverseReaction
Sedation	ONFI.xml:S1:234:8	I-AdverseReaction
from	ONFI.xml:S1:243:4	O
Concomitant	ONFI.xml:S1:248:11	O
Use	ONFI.xml:S1:260:3	O
with	ONFI.xml:S1:264:4	O
Central	ONFI.xml:S1:269:7	O
Nervous	ONFI.xml:S1:277:7	O
System	ONFI.xml:S1:285:6	O
Depressants	ONFI.xml:S1:292:11	O
[	ONFI.xml:S1:304:1	O
see	ONFI.xml:S1:305:3	O
Warnings	ONFI.xml:S1:309:8	O
and	ONFI.xml:S1:318:3	O
Precautions	ONFI.xml:S1:322:11	O
(	ONFI.xml:S1:334:1	O
5.2	ONFI.xml:S1:337:3	O
)]	ONFI.xml:S1:342:2	O

Withdrawal	ONFI.xml:S1:351:10	O
Symptoms	ONFI.xml:S1:362:8	O
[	ONFI.xml:S1:371:1	O
see	ONFI.xml:S1:372:3	O
Warnings	ONFI.xml:S1:376:8	O
and	ONFI.xml:S1:385:3	O
Precautions	ONFI.xml:S1:389:11	O
(	ONFI.xml:S1:401:1	O
5.3	ONFI.xml:S1:406:3	O
)]	ONFI.xml:S1:413:2	O

Serious	ONFI.xml:S1:422:7	B-Severity
Dermatological	ONFI.xml:S1:430:14	B-AdverseReaction
Reactions	ONFI.xml:S1:445:9	I-AdverseReaction
[	ONFI.xml:S1:455:1	O
see	ONFI.xml:S1:456:3	O
Contraindications	ONFI.xml:S1:460:17	O
(	ONFI.xml:S1:478:1	O
4	ONFI.xml:S1:481:1	O
)	ONFI.xml:S1:484:1	O
,	ONFI.xml:S1:485:1	O
Warnings	ONFI.xml:S1:487:8	O
and	ONFI.xml:S1:496:3	O
Precautions	ONFI.xml:S1:500:11	O
(	ONFI.xml:S1:512:1	O
5.4	ONFI.xml:S1:517:3	O
)]	ONFI.xml:S1:524:2	O

Physical	ONFI.xml:S1:533:8	B-AdverseReaction
and	ONFI.xml:S1:542:3	O
Psychological	ONFI.xml:S1:546:13	B-AdverseReaction
Dependence	ONFI.xml:S1:560:10	I-AdverseReaction
[	ONFI.xml:S1:571:1	O
see	ONFI.xml:S1:572:3	O
Warnings	ONFI.xml:S1:576:8	O
and	ONFI.xml:S1:585:3	O
Precautions	ONFI.xml:S1:589:11	O
(	ONFI.xml:S1:601:1	O
5.5	ONFI.xml:S1:604:3	O
)]	ONFI.xml:S1:609:2	O

Suicidal	ONFI.xml:S1:618:8	B-AdverseReaction
Behavior	ONFI.xml:S1:627:8	I-AdverseReaction
and	ONFI.xml:S1:636:3	O
Ideation	ONFI.xml:S1:640:8	I-AdverseReaction
[	ONFI.xml:S1:649:1	O
see	ONFI.xml:S1:650:3	O
Warnings	ONFI.xml:S1:654:8	O
and	ONFI.xml:S1:663:3	O
Precautions	ONFI.xml:S1:667:11	O
(	ONFI.xml:S1:679:1	O
5.6	ONFI.xml:S1:682:3	O
)]	ONFI.xml:S1:687:2	O

EXCERPT	ONFI.xml:S1:698:7	O
:	ONFI.xml:S1:705:1	O
Adverse	ONFI.xml:S1:709:7	O
reactions	ONFI.xml:S1:717:9	O
that	ONFI.xml:S1:727:4	O
occurred	ONFI.xml:S1:732:8	O
at	ONFI.xml:S1:741:2	O
least	ONFI.xml:S1:744:5	O
10%	ONFI.xml:S1:750:3	O
more	ONFI.xml:S1:754:4	O
frequently	ONFI.xml:S1:759:10	O
than	ONFI.xml:S1:770:4	O
placebo	ONFI.xml:S1:775:7	O
in	ONFI.xml:S1:783:2	O
any	ONFI.xml:S1:786:3	O
ONFI	ONFI.xml:S1:790:4	O
dose	ONFI.xml:S1:795:4	O
included	ONFI.xml:S1:800:8	O
constipation	ONFI.xml:S1:809:12	B-AdverseReaction
,	ONFI.xml:S1:821:1	O
somnolence	ONFI.xml:S1:823:10	B-AdverseReaction
or	ONFI.xml:S1:834:2	O
sedation	ONFI.xml:S1:837:8	B-AdverseReaction
,	ONFI.xml:S1:845:1	O
pyrexia	ONFI.xml:S1:847:7	B-AdverseReaction
,	ONFI.xml:S1:854:1	O
lethargy	ONFI.xml:S1:856:8	B-AdverseReaction
,	ONFI.xml:S1:864:1	O
and	ONFI.xml:S1:866:3	O
drooling	ONFI.xml:S1:870:8	B-AdverseReaction
(	ONFI.xml:S1:879:1	O
6.1	ONFI.xml:S1:882:3	O
)	ONFI.xml:S1:887:1	O

To	ONFI.xml:S1:898:2	O

report	ONFI.xml:S1:901:6	O
SUSPECTED	ONFI.xml:S1:908:9	O
ADVERSE	ONFI.xml:S1:918:7	O
REACTIONS	ONFI.xml:S1:926:9	O
,	ONFI.xml:S1:935:1	O
contact	ONFI.xml:S1:937:7	O
Lundbeck	ONFI.xml:S1:945:8	O
at	ONFI.xml:S1:954:2	O
1	ONFI.xml:S1:957:1	O
-	ONFI.xml:S1:958:1	O
800	ONFI.xml:S1:959:3	O
-	ONFI.xml:S1:962:1	O
455	ONFI.xml:S1:963:3	O
-	ONFI.xml:S1:966:1	O
1141	ONFI.xml:S1:967:4	O
or	ONFI.xml:S1:972:2	O
FDA	ONFI.xml:S1:975:3	O
at	ONFI.xml:S1:979:2	O
1	ONFI.xml:S1:982:1	O
-	ONFI.xml:S1:983:1	O
800	ONFI.xml:S1:984:3	O
-	ONFI.xml:S1:987:1	O
FDA	ONFI.xml:S1:988:3	O
-	ONFI.xml:S1:991:1	O
1088	ONFI.xml:S1:992:4	O
or	ONFI.xml:S1:997:2	O
www	ONFI.xml:S1:1003:3	O
.	ONFI.xml:S1:1006:1	O
fda	ONFI.xml:S1:1007:3	O
.	ONFI.xml:S1:1010:1	O
gov	ONFI.xml:S1:1011:3	O
medwatch	ONFI.xml:S1:1015:8	O
.	ONFI.xml:S1:1025:1	O

6.1	ONFI.xml:S1:1037:3	O

Clinical	ONFI.xml:S1:1041:8	O
Trials	ONFI.xml:S1:1050:6	O
Experience	ONFI.xml:S1:1057:10	O

Because	ONFI.xml:S1:1073:7	O
clinical	ONFI.xml:S1:1081:8	O
trials	ONFI.xml:S1:1090:6	O
are	ONFI.xml:S1:1097:3	O
conducted	ONFI.xml:S1:1101:9	O
under	ONFI.xml:S1:1111:5	O
widely	ONFI.xml:S1:1117:6	O
varying	ONFI.xml:S1:1124:7	O
conditions	ONFI.xml:S1:1132:10	O
,	ONFI.xml:S1:1142:1	O
adverse	ONFI.xml:S1:1144:7	O
reaction	ONFI.xml:S1:1152:8	O
rates	ONFI.xml:S1:1161:5	O
observed	ONFI.xml:S1:1167:8	O
in	ONFI.xml:S1:1176:2	O
the	ONFI.xml:S1:1179:3	O
clinical	ONFI.xml:S1:1183:8	O
trials	ONFI.xml:S1:1192:6	O
of	ONFI.xml:S1:1199:2	O
a	ONFI.xml:S1:1202:1	O
drug	ONFI.xml:S1:1204:4	O
cannot	ONFI.xml:S1:1209:6	O
be	ONFI.xml:S1:1216:2	O
directly	ONFI.xml:S1:1219:8	O
compared	ONFI.xml:S1:1228:8	O
to	ONFI.xml:S1:1237:2	O
rates	ONFI.xml:S1:1240:5	O
in	ONFI.xml:S1:1246:2	O
the	ONFI.xml:S1:1249:3	O
clinical	ONFI.xml:S1:1253:8	O
trials	ONFI.xml:S1:1262:6	O
of	ONFI.xml:S1:1269:2	O
another	ONFI.xml:S1:1272:7	O
drug	ONFI.xml:S1:1280:4	O
and	ONFI.xml:S1:1285:3	O
may	ONFI.xml:S1:1289:3	O
not	ONFI.xml:S1:1293:3	O
reflect	ONFI.xml:S1:1297:7	O
the	ONFI.xml:S1:1305:3	O
rates	ONFI.xml:S1:1309:5	O
observed	ONFI.xml:S1:1315:8	O
in	ONFI.xml:S1:1324:2	O
practice	ONFI.xml:S1:1327:8	O
.	ONFI.xml:S1:1335:1	O

During	ONFI.xml:S1:1341:6	O
its	ONFI.xml:S1:1348:3	O
development	ONFI.xml:S1:1352:11	O
for	ONFI.xml:S1:1364:3	O
the	ONFI.xml:S1:1368:3	O
adjunctive	ONFI.xml:S1:1372:10	O
treatment	ONFI.xml:S1:1383:9	O
of	ONFI.xml:S1:1393:2	O
seizures	ONFI.xml:S1:1396:8	O
associated	ONFI.xml:S1:1405:10	O
with	ONFI.xml:S1:1416:4	O
LGS	ONFI.xml:S1:1421:3	O
,	ONFI.xml:S1:1424:1	O
ONFI	ONFI.xml:S1:1426:4	O
was	ONFI.xml:S1:1431:3	O
administered	ONFI.xml:S1:1435:12	O
to	ONFI.xml:S1:1448:2	O
333	ONFI.xml:S1:1451:3	O
healthy	ONFI.xml:S1:1455:7	O
volunteers	ONFI.xml:S1:1463:10	O
and	ONFI.xml:S1:1474:3	O
300	ONFI.xml:S1:1478:3	O
patients	ONFI.xml:S1:1482:8	O
with	ONFI.xml:S1:1491:4	O
a	ONFI.xml:S1:1496:1	O
current	ONFI.xml:S1:1498:7	O
or	ONFI.xml:S1:1506:2	O
prior	ONFI.xml:S1:1509:5	O
diagnosis	ONFI.xml:S1:1515:9	O
of	ONFI.xml:S1:1525:2	O
LGS	ONFI.xml:S1:1528:3	O
,	ONFI.xml:S1:1531:1	O
including	ONFI.xml:S1:1533:9	O
197	ONFI.xml:S1:1543:3	O
patients	ONFI.xml:S1:1547:8	O
treated	ONFI.xml:S1:1556:7	O
for	ONFI.xml:S1:1564:3	O
12	ONFI.xml:S1:1568:2	O
months	ONFI.xml:S1:1571:6	O
or	ONFI.xml:S1:1578:2	O
more	ONFI.xml:S1:1581:4	O
.	ONFI.xml:S1:1585:1	O

The	ONFI.xml:S1:1587:3	O
conditions	ONFI.xml:S1:1591:10	O
and	ONFI.xml:S1:1602:3	O
duration	ONFI.xml:S1:1606:8	O
of	ONFI.xml:S1:1615:2	O
exposure	ONFI.xml:S1:1618:8	O
varied	ONFI.xml:S1:1627:6	O
greatly	ONFI.xml:S1:1634:7	O
and	ONFI.xml:S1:1642:3	O
included	ONFI.xml:S1:1646:8	O
single	ONFI.xml:S1:1655:6	O
-	ONFI.xml:S1:1661:1	O
and	ONFI.xml:S1:1663:3	O
multiple	ONFI.xml:S1:1667:8	O
-	ONFI.xml:S1:1675:1	O
dose	ONFI.xml:S1:1676:4	O
clinical	ONFI.xml:S1:1681:8	O
pharmacology	ONFI.xml:S1:1690:12	O
studies	ONFI.xml:S1:1703:7	O
in	ONFI.xml:S1:1711:2	O
healthy	ONFI.xml:S1:1714:7	O
volunteers	ONFI.xml:S1:1722:10	O
and	ONFI.xml:S1:1733:3	O
two	ONFI.xml:S1:1737:3	O
double	ONFI.xml:S1:1741:6	O
-	ONFI.xml:S1:1747:1	O
blind	ONFI.xml:S1:1748:5	O
studies	ONFI.xml:S1:1754:7	O
in	ONFI.xml:S1:1762:2	O
patients	ONFI.xml:S1:1765:8	O
with	ONFI.xml:S1:1774:4	O
LGS	ONFI.xml:S1:1779:3	O
(	ONFI.xml:S1:1783:1	O
Study	ONFI.xml:S1:1784:5	O
1	ONFI.xml:S1:1790:1	O
and	ONFI.xml:S1:1792:3	O
2	ONFI.xml:S1:1796:1	O
)	ONFI.xml:S1:1797:1	O
[	ONFI.xml:S1:1800:1	O
see	ONFI.xml:S1:1801:3	O
Clinical	ONFI.xml:S1:1805:8	O
Studies	ONFI.xml:S1:1814:7	O
(	ONFI.xml:S1:1822:1	O
14	ONFI.xml:S1:1825:2	O
)]	ONFI.xml:S1:1829:2	O
.	ONFI.xml:S1:1833:1	O

Only	ONFI.xml:S1:1835:4	O
Study	ONFI.xml:S1:1840:5	O
1	ONFI.xml:S1:1846:1	O
included	ONFI.xml:S1:1848:8	O
a	ONFI.xml:S1:1857:1	O
placebo	ONFI.xml:S1:1859:7	O
group	ONFI.xml:S1:1867:5	O
,	ONFI.xml:S1:1872:1	O
allowing	ONFI.xml:S1:1874:8	O
comparison	ONFI.xml:S1:1883:10	O
of	ONFI.xml:S1:1894:2	O
adverse	ONFI.xml:S1:1897:7	O
reaction	ONFI.xml:S1:1905:8	O
rates	ONFI.xml:S1:1914:5	O
on	ONFI.xml:S1:1920:2	O
ONFI	ONFI.xml:S1:1923:4	O
at	ONFI.xml:S1:1928:2	O
several	ONFI.xml:S1:1931:7	O
doses	ONFI.xml:S1:1939:5	O
to	ONFI.xml:S1:1945:2	O
placebo	ONFI.xml:S1:1948:7	O
.	ONFI.xml:S1:1955:1	O

Adverse	ONFI.xml:S1:1963:7	O
Reactions	ONFI.xml:S1:1971:9	O
Leading	ONFI.xml:S1:1981:7	O
to	ONFI.xml:S1:1989:2	O
Discontinuation	ONFI.xml:S1:1992:15	O
in	ONFI.xml:S1:2008:2	O
an	ONFI.xml:S1:2011:2	O
LGS	ONFI.xml:S1:2014:3	O
Placebo	ONFI.xml:S1:2018:7	O
Controlled	ONFI.xml:S1:2026:10	O
Clinical	ONFI.xml:S1:2037:8	O
Trial	ONFI.xml:S1:2046:5	O
(	ONFI.xml:S1:2052:1	O
Study	ONFI.xml:S1:2053:5	O
1	ONFI.xml:S1:2059:1	O
)	ONFI.xml:S1:2060:1	O
The	ONFI.xml:S1:2063:3	O
adverse	ONFI.xml:S1:2067:7	O
reactions	ONFI.xml:S1:2075:9	O
associated	ONFI.xml:S1:2085:10	O
with	ONFI.xml:S1:2096:4	O
ONFI	ONFI.xml:S1:2101:4	O
treatment	ONFI.xml:S1:2106:9	O
discontinuation	ONFI.xml:S1:2116:15	O
in	ONFI.xml:S1:2132:2	O
1%	ONFI.xml:S1:2137:2	O
of	ONFI.xml:S1:2140:2	O
patients	ONFI.xml:S1:2143:8	O
in	ONFI.xml:S1:2152:2	O
decreasing	ONFI.xml:S1:2155:10	O
order	ONFI.xml:S1:2166:5	O
of	ONFI.xml:S1:2172:2	O
frequency	ONFI.xml:S1:2175:9	O
included	ONFI.xml:S1:2185:8	O
lethargy	ONFI.xml:S1:2194:8	B-AdverseReaction
,	ONFI.xml:S1:2202:1	O
somnolence	ONFI.xml:S1:2204:10	B-AdverseReaction
,	ONFI.xml:S1:2214:1	O
ataxia	ONFI.xml:S1:2216:6	B-AdverseReaction
,	ONFI.xml:S1:2222:1	O
aggression	ONFI.xml:S1:2224:10	B-AdverseReaction
,	ONFI.xml:S1:2234:1	O
fatigue	ONFI.xml:S1:2236:7	B-AdverseReaction
,	ONFI.xml:S1:2243:1	O
and	ONFI.xml:S1:2245:3	O
insomnia	ONFI.xml:S1:2249:8	B-AdverseReaction
.	ONFI.xml:S1:2257:1	O

Most	ONFI.xml:S1:2265:4	O
Common	ONFI.xml:S1:2270:6	O
Adverse	ONFI.xml:S1:2277:7	O
Reactions	ONFI.xml:S1:2285:9	O
in	ONFI.xml:S1:2295:2	O
an	ONFI.xml:S1:2298:2	O
LGS	ONFI.xml:S1:2301:3	O
Placebo	ONFI.xml:S1:2305:7	O
Controlled	ONFI.xml:S1:2313:10	O
Clinical	ONFI.xml:S1:2324:8	O
Trial	ONFI.xml:S1:2333:5	O
(	ONFI.xml:S1:2339:1	O
Study	ONFI.xml:S1:2340:5	O
1	ONFI.xml:S1:2346:1	O
)	ONFI.xml:S1:2347:1	O
Table	ONFI.xml:S1:2350:5	O
3	ONFI.xml:S1:2356:1	O
lists	ONFI.xml:S1:2358:5	O
the	ONFI.xml:S1:2364:3	O
adverse	ONFI.xml:S1:2368:7	O
reactions	ONFI.xml:S1:2376:9	O
that	ONFI.xml:S1:2386:4	O
occurred	ONFI.xml:S1:2391:8	O
in	ONFI.xml:S1:2400:2	O
5%	ONFI.xml:S1:2405:2	O
of	ONFI.xml:S1:2408:2	O
ONFI	ONFI.xml:S1:2411:4	O
treated	ONFI.xml:S1:2416:7	O
patients	ONFI.xml:S1:2424:8	O
(	ONFI.xml:S1:2433:1	O
at	ONFI.xml:S1:2434:2	O
any	ONFI.xml:S1:2437:3	O
dose	ONFI.xml:S1:2441:4	O
)	ONFI.xml:S1:2445:1	O
,	ONFI.xml:S1:2446:1	O
and	ONFI.xml:S1:2448:3	O
at	ONFI.xml:S1:2452:2	O
a	ONFI.xml:S1:2455:1	O
rate	ONFI.xml:S1:2457:4	O
greater	ONFI.xml:S1:2462:7	O
than	ONFI.xml:S1:2470:4	O
placebo	ONFI.xml:S1:2475:7	O
treated	ONFI.xml:S1:2483:7	O
patients	ONFI.xml:S1:2491:8	O
,	ONFI.xml:S1:2499:1	O
in	ONFI.xml:S1:2501:2	O
the	ONFI.xml:S1:2504:3	O
randomized	ONFI.xml:S1:2508:10	O
,	ONFI.xml:S1:2518:1	O
double	ONFI.xml:S1:2520:6	O
-	ONFI.xml:S1:2526:1	O
blind	ONFI.xml:S1:2527:5	O
,	ONFI.xml:S1:2532:1	O
placebo	ONFI.xml:S1:2534:7	O
-	ONFI.xml:S1:2541:1	O
controlled	ONFI.xml:S1:2542:10	O
,	ONFI.xml:S1:2552:1	O
parallel	ONFI.xml:S1:2554:8	O
group	ONFI.xml:S1:2563:5	O
clinical	ONFI.xml:S1:2569:8	O
study	ONFI.xml:S1:2578:5	O
of	ONFI.xml:S1:2584:2	O
adjunctive	ONFI.xml:S1:2587:10	O
AED	ONFI.xml:S1:2598:3	O
therapy	ONFI.xml:S1:2602:7	O
for	ONFI.xml:S1:2610:3	O
15	ONFI.xml:S1:2614:2	O
weeks	ONFI.xml:S1:2617:5	O
(	ONFI.xml:S1:2623:1	O
Study	ONFI.xml:S1:2624:5	O
1	ONFI.xml:S1:2630:1	O
)	ONFI.xml:S1:2631:1	O
.	ONFI.xml:S1:2632:1	O

Table	ONFI.xml:S1:2638:5	O
3	ONFI.xml:S1:2644:1	O
.	ONFI.xml:S1:2645:1	O

Adverse	ONFI.xml:S1:2647:7	O
Reactions	ONFI.xml:S1:2655:9	O
Reported	ONFI.xml:S1:2665:8	O
for	ONFI.xml:S1:2674:3	O
5%	ONFI.xml:S1:2680:2	O
of	ONFI.xml:S1:2683:2	O
Patients	ONFI.xml:S1:2686:8	O
and	ONFI.xml:S1:2695:3	O
More	ONFI.xml:S1:2699:4	O
Frequently	ONFI.xml:S1:2704:10	O
than	ONFI.xml:S1:2715:4	O
Placebo	ONFI.xml:S1:2720:7	O
in	ONFI.xml:S1:2728:2	O
Any	ONFI.xml:S1:2731:3	O
Treatment	ONFI.xml:S1:2735:9	O
Group	ONFI.xml:S1:2745:5	O

a	ONFI.xml:S1:2755:1	O
Maximum	ONFI.xml:S1:2758:7	O
daily	ONFI.xml:S1:2766:5	O
dose	ONFI.xml:S1:2772:4	O
of	ONFI.xml:S1:2777:2	O
5	ONFI.xml:S1:2780:1	O
mg	ONFI.xml:S1:2782:2	O
for	ONFI.xml:S1:2785:3	O
30	ONFI.xml:S1:2791:2	O
kg	ONFI.xml:S1:2794:2	O
body	ONFI.xml:S1:2797:4	O
weight	ONFI.xml:S1:2802:6	O
;	ONFI.xml:S1:2808:1	O
10	ONFI.xml:S1:2810:2	O
mg	ONFI.xml:S1:2813:2	O
for	ONFI.xml:S1:2816:3	O
30	ONFI.xml:S1:2821:2	O
kg	ONFI.xml:S1:2824:2	O
body	ONFI.xml:S1:2827:4	O
weight	ONFI.xml:S1:2832:6	O
b	ONFI.xml:S1:2840:1	O
Maximum	ONFI.xml:S1:2843:7	O
daily	ONFI.xml:S1:2851:5	O
dose	ONFI.xml:S1:2857:4	O
of	ONFI.xml:S1:2862:2	O
10	ONFI.xml:S1:2865:2	O
mg	ONFI.xml:S1:2868:2	O
for	ONFI.xml:S1:2871:3	O
30	ONFI.xml:S1:2877:2	O
kg	ONFI.xml:S1:2880:2	O
body	ONFI.xml:S1:2883:4	O
weight	ONFI.xml:S1:2888:6	O
;	ONFI.xml:S1:2894:1	O
20	ONFI.xml:S1:2896:2	O
mg	ONFI.xml:S1:2899:2	O
for	ONFI.xml:S1:2902:3	O
30	ONFI.xml:S1:2907:2	O
kg	ONFI.xml:S1:2910:2	O
body	ONFI.xml:S1:2913:4	O
weight	ONFI.xml:S1:2918:6	O
c	ONFI.xml:S1:2926:1	O
Maximum	ONFI.xml:S1:2929:7	O
daily	ONFI.xml:S1:2937:5	O
dose	ONFI.xml:S1:2943:4	O
of	ONFI.xml:S1:2948:2	O
20	ONFI.xml:S1:2951:2	O
mg	ONFI.xml:S1:2954:2	O
for	ONFI.xml:S1:2957:3	O
30	ONFI.xml:S1:2963:2	O
kg	ONFI.xml:S1:2966:2	O
body	ONFI.xml:S1:2969:4	O
weight	ONFI.xml:S1:2974:6	O
;	ONFI.xml:S1:2980:1	O
40	ONFI.xml:S1:2982:2	O
mg	ONFI.xml:S1:2985:2	O
for	ONFI.xml:S1:2988:3	O
30	ONFI.xml:S1:2993:2	O
kg	ONFI.xml:S1:2996:2	O
body	ONFI.xml:S1:2999:4	O
weight	ONFI.xml:S1:3004:6	O

Placebo	ONFI.xml:S1:3038:7	O

N	ONFI.xml:S1:3049:1	O
59	ONFI.xml:S1:3051:2	O
ONFI	ONFI.xml:S1:3061:4	O
Dose	ONFI.xml:S1:3066:4	O
Level	ONFI.xml:S1:3071:5	O
All	ONFI.xml:S1:3083:3	O
ONFI	ONFI.xml:S1:3087:4	O
N	ONFI.xml:S1:3095:1	O
179	ONFI.xml:S1:3097:3	O

Low	ONFI.xml:S1:3111:3	O
a	ONFI.xml:S1:3116:1	O
N	ONFI.xml:S1:3123:1	O
58	ONFI.xml:S1:3125:2	O
Medium	ONFI.xml:S1:3135:6	O
b	ONFI.xml:S1:3143:1	O
N	ONFI.xml:S1:3150:1	O
62	ONFI.xml:S1:3152:2	O
High	ONFI.xml:S1:3162:4	O
c	ONFI.xml:S1:3168:1	O
N	ONFI.xml:S1:3175:1	O
59	ONFI.xml:S1:3177:2	O

Gastrointestinal	ONFI.xml:S1:3190:16	O
Disorders	ONFI.xml:S1:3207:9	O

Vomiting	ONFI.xml:S1:3229:8	B-AdverseReaction
5	ONFI.xml:S1:3242:1	O
9	ONFI.xml:S1:3259:1	O
5	ONFI.xml:S1:3276:1	O
7	ONFI.xml:S1:3293:1	O
7	ONFI.xml:S1:3310:1	O

Constipation	ONFI.xml:S1:3334:12	B-AdverseReaction
0	ONFI.xml:S1:3350:1	O
2	ONFI.xml:S1:3367:1	O
2	ONFI.xml:S1:3384:1	O
10	ONFI.xml:S1:3401:2	O
5	ONFI.xml:S1:3418:1	O

Dysphagia	ONFI.xml:S1:3442:9	B-AdverseReaction
0	ONFI.xml:S1:3455:1	O
0	ONFI.xml:S1:3472:1	O
0	ONFI.xml:S1:3489:1	O
5	ONFI.xml:S1:3506:1	O
2	ONFI.xml:S1:3523:1	O

General	ONFI.xml:S1:3544:7	O
Disorders	ONFI.xml:S1:3552:9	O
and	ONFI.xml:S1:3562:3	O
Administration	ONFI.xml:S1:3566:14	O
Site	ONFI.xml:S1:3581:4	O
Conditions	ONFI.xml:S1:3586:10	O

Pyrexia	ONFI.xml:S1:3609:7	B-AdverseReaction
3	ONFI.xml:S1:3622:1	O
17	ONFI.xml:S1:3639:2	O
10	ONFI.xml:S1:3656:2	O
12	ONFI.xml:S1:3673:2	O
13	ONFI.xml:S1:3690:2	O

Irritability	ONFI.xml:S1:3714:12	B-AdverseReaction
5	ONFI.xml:S1:3730:1	O
3	ONFI.xml:S1:3747:1	O
11	ONFI.xml:S1:3764:2	O
5	ONFI.xml:S1:3781:1	O
7	ONFI.xml:S1:3798:1	O

Fatigue	ONFI.xml:S1:3822:7	B-AdverseReaction
2	ONFI.xml:S1:3835:1	O
5	ONFI.xml:S1:3852:1	O
5	ONFI.xml:S1:3869:1	O
3	ONFI.xml:S1:3886:1	O
5	ONFI.xml:S1:3903:1	O

Infections	ONFI.xml:S1:3924:10	O
and	ONFI.xml:S1:3935:3	O
Infestations	ONFI.xml:S1:3939:12	O

Upper	ONFI.xml:S1:3964:5	B-AdverseReaction
respiratory	ONFI.xml:S1:3970:11	I-AdverseReaction
tract	ONFI.xml:S1:3982:5	I-AdverseReaction
infection	ONFI.xml:S1:3988:9	I-AdverseReaction
10	ONFI.xml:S1:4001:2	O
10	ONFI.xml:S1:4018:2	O
13	ONFI.xml:S1:4035:2	O
14	ONFI.xml:S1:4052:2	O
12	ONFI.xml:S1:4069:2	O

Pneumonia	ONFI.xml:S1:4093:9	B-AdverseReaction
2	ONFI.xml:S1:4106:1	O
3	ONFI.xml:S1:4123:1	O
3	ONFI.xml:S1:4140:1	O
7	ONFI.xml:S1:4157:1	O
4	ONFI.xml:S1:4174:1	O

Urinary	ONFI.xml:S1:4198:7	B-AdverseReaction
tract	ONFI.xml:S1:4206:5	I-AdverseReaction
infection	ONFI.xml:S1:4212:9	I-AdverseReaction
0	ONFI.xml:S1:4225:1	O
2	ONFI.xml:S1:4242:1	O
5	ONFI.xml:S1:4259:1	O
5	ONFI.xml:S1:4276:1	O
4	ONFI.xml:S1:4293:1	O

Bronchitis	ONFI.xml:S1:4317:10	B-AdverseReaction
0	ONFI.xml:S1:4331:1	O
2	ONFI.xml:S1:4348:1	O
0	ONFI.xml:S1:4365:1	O
5	ONFI.xml:S1:4382:1	O
2	ONFI.xml:S1:4399:1	O

Metabolism	ONFI.xml:S1:4420:10	O
and	ONFI.xml:S1:4431:3	O
Nutrition	ONFI.xml:S1:4435:9	O
Disorders	ONFI.xml:S1:4445:9	O

Decreased	ONFI.xml:S1:4467:9	B-AdverseReaction
appetite	ONFI.xml:S1:4477:8	I-AdverseReaction
3	ONFI.xml:S1:4489:1	O
3	ONFI.xml:S1:4506:1	O
0	ONFI.xml:S1:4523:1	O
7	ONFI.xml:S1:4540:1	O
3	ONFI.xml:S1:4557:1	O

Increased	ONFI.xml:S1:4581:9	B-AdverseReaction
appetite	ONFI.xml:S1:4591:8	I-AdverseReaction
0	ONFI.xml:S1:4603:1	O
2	ONFI.xml:S1:4620:1	O
3	ONFI.xml:S1:4637:1	O
5	ONFI.xml:S1:4654:1	O
3	ONFI.xml:S1:4671:1	O

Nervous	ONFI.xml:S1:4692:7	O
System	ONFI.xml:S1:4700:6	O
Disorders	ONFI.xml:S1:4707:9	O

Somnolence	ONFI.xml:S1:4729:10	B-AdverseReaction
or	ONFI.xml:S1:4740:2	O
Sedation	ONFI.xml:S1:4743:8	B-AdverseReaction
15	ONFI.xml:S1:4755:2	O
17	ONFI.xml:S1:4772:2	O
27	ONFI.xml:S1:4789:2	O
32	ONFI.xml:S1:4806:2	O
26	ONFI.xml:S1:4823:2	O

Somnolence	ONFI.xml:S1:4851:10	B-AdverseReaction
12	ONFI.xml:S1:4865:2	O
16	ONFI.xml:S1:4882:2	O
24	ONFI.xml:S1:4899:2	O
25	ONFI.xml:S1:4916:2	O
22	ONFI.xml:S1:4933:2	O

Sedation	ONFI.xml:S1:4961:8	B-AdverseReaction
3	ONFI.xml:S1:4973:1	O
2	ONFI.xml:S1:4990:1	O
3	ONFI.xml:S1:5007:1	O
9	ONFI.xml:S1:5024:1	O
5	ONFI.xml:S1:5041:1	O

Lethargy	ONFI.xml:S1:5065:8	B-AdverseReaction
5	ONFI.xml:S1:5078:1	O
10	ONFI.xml:S1:5095:2	O
5	ONFI.xml:S1:5112:1	O
15	ONFI.xml:S1:5129:2	O
10	ONFI.xml:S1:5146:2	O

Drooling	ONFI.xml:S1:5170:8	B-AdverseReaction
3	ONFI.xml:S1:5183:1	O
0	ONFI.xml:S1:5200:1	O
13	ONFI.xml:S1:5217:2	O
14	ONFI.xml:S1:5234:2	O
9	ONFI.xml:S1:5251:1	O

Ataxia	ONFI.xml:S1:5275:6	B-AdverseReaction
3	ONFI.xml:S1:5288:1	O
3	ONFI.xml:S1:5305:1	O
2	ONFI.xml:S1:5322:1	O
10	ONFI.xml:S1:5339:2	O
5	ONFI.xml:S1:5356:1	O

Psychomotor	ONFI.xml:S1:5380:11	B-AdverseReaction
hyperactivity	ONFI.xml:S1:5392:13	I-AdverseReaction
3	ONFI.xml:S1:5409:1	O
3	ONFI.xml:S1:5426:1	O
3	ONFI.xml:S1:5443:1	O
5	ONFI.xml:S1:5460:1	O
4	ONFI.xml:S1:5477:1	O

Dysarthria	ONFI.xml:S1:5501:10	B-AdverseReaction
0	ONFI.xml:S1:5515:1	O
2	ONFI.xml:S1:5532:1	O
2	ONFI.xml:S1:5549:1	O
5	ONFI.xml:S1:5566:1	O
3	ONFI.xml:S1:5583:1	O

Psychiatric	ONFI.xml:S1:5604:11	O
Disorders	ONFI.xml:S1:5616:9	O

Aggression	ONFI.xml:S1:5638:10	B-AdverseReaction
5	ONFI.xml:S1:5652:1	O
3	ONFI.xml:S1:5669:1	O
8	ONFI.xml:S1:5686:1	O
14	ONFI.xml:S1:5703:2	O
8	ONFI.xml:S1:5720:1	O

Insomnia	ONFI.xml:S1:5744:8	B-AdverseReaction
2	ONFI.xml:S1:5757:1	O
2	ONFI.xml:S1:5774:1	O
5	ONFI.xml:S1:5791:1	O
7	ONFI.xml:S1:5808:1	O
5	ONFI.xml:S1:5825:1	O

Respiratory	ONFI.xml:S1:5846:11	O
Disorders	ONFI.xml:S1:5858:9	O

Cough	ONFI.xml:S1:5880:5	B-AdverseReaction
0	ONFI.xml:S1:5893:1	O
3	ONFI.xml:S1:5910:1	O
5	ONFI.xml:S1:5927:1	O
7	ONFI.xml:S1:5944:1	O
5	ONFI.xml:S1:5961:1	O

6.2	ONFI.xml:S1:5994:3	O
Post	ONFI.xml:S1:5998:4	O
Marketing	ONFI.xml:S1:6003:9	O
Experience	ONFI.xml:S1:6013:10	O

These	ONFI.xml:S1:6029:5	O
reactions	ONFI.xml:S1:6035:9	O
are	ONFI.xml:S1:6045:3	O
reported	ONFI.xml:S1:6049:8	O
voluntarily	ONFI.xml:S1:6058:11	O
from	ONFI.xml:S1:6070:4	O
a	ONFI.xml:S1:6075:1	O
population	ONFI.xml:S1:6077:10	O
of	ONFI.xml:S1:6088:2	O
uncertain	ONFI.xml:S1:6091:9	O
size	ONFI.xml:S1:6101:4	O
;	ONFI.xml:S1:6105:1	O
therefore	ONFI.xml:S1:6107:9	O
,	ONFI.xml:S1:6116:1	O
it	ONFI.xml:S1:6118:2	O
is	ONFI.xml:S1:6121:2	O
not	ONFI.xml:S1:6124:3	O
possible	ONFI.xml:S1:6128:8	O
to	ONFI.xml:S1:6137:2	O
estimate	ONFI.xml:S1:6140:8	O
their	ONFI.xml:S1:6149:5	O
frequency	ONFI.xml:S1:6155:9	O
or	ONFI.xml:S1:6165:2	O
establish	ONFI.xml:S1:6168:9	O
a	ONFI.xml:S1:6178:1	O
causal	ONFI.xml:S1:6180:6	O
relationship	ONFI.xml:S1:6187:12	O
to	ONFI.xml:S1:6200:2	O
drug	ONFI.xml:S1:6203:4	O
exposure	ONFI.xml:S1:6208:8	O
.	ONFI.xml:S1:6216:1	O

Adverse	ONFI.xml:S1:6218:7	O
reactions	ONFI.xml:S1:6226:9	O
are	ONFI.xml:S1:6236:3	O
categorized	ONFI.xml:S1:6240:11	O
by	ONFI.xml:S1:6252:2	O
system	ONFI.xml:S1:6255:6	O
organ	ONFI.xml:S1:6262:5	O
class	ONFI.xml:S1:6268:5	O
.	ONFI.xml:S1:6273:1	O

Blood	ONFI.xml:S1:6283:5	O
Disorders	ONFI.xml:S1:6289:9	O
:	ONFI.xml:S1:6298:1	O
Anemia	ONFI.xml:S1:6303:6	B-AdverseReaction
,	ONFI.xml:S1:6309:1	O
eosinophilia	ONFI.xml:S1:6311:12	B-AdverseReaction
,	ONFI.xml:S1:6323:1	O
leukopenia	ONFI.xml:S1:6325:10	B-AdverseReaction
,	ONFI.xml:S1:6335:1	O
thrombocytopenia	ONFI.xml:S1:6337:16	B-AdverseReaction
Eye	ONFI.xml:S1:6357:3	O
Disorders	ONFI.xml:S1:6361:9	O
:	ONFI.xml:S1:6370:1	O
Diplopia	ONFI.xml:S1:6375:8	B-AdverseReaction
,	ONFI.xml:S1:6383:1	O
vision	ONFI.xml:S1:6385:6	B-AdverseReaction
blurred	ONFI.xml:S1:6392:7	I-AdverseReaction
Gastrointestinal	ONFI.xml:S1:6403:16	O
Disorders	ONFI.xml:S1:6420:9	O
:	ONFI.xml:S1:6429:1	O
Abdominal	ONFI.xml:S1:6434:9	B-AdverseReaction
distention	ONFI.xml:S1:6444:10	I-AdverseReaction
General	ONFI.xml:S1:6458:7	O
Disorders	ONFI.xml:S1:6466:9	O
and	ONFI.xml:S1:6476:3	O
Administration	ONFI.xml:S1:6480:14	O
Site	ONFI.xml:S1:6495:4	O
Conditions	ONFI.xml:S1:6500:10	O
:	ONFI.xml:S1:6510:1	O
Hypothermia	ONFI.xml:S1:6515:11	B-AdverseReaction
Investigations	ONFI.xml:S1:6530:14	O
:	ONFI.xml:S1:6544:1	O
Hepatic	ONFI.xml:S1:6549:7	B-AdverseReaction
enzyme	ONFI.xml:S1:6557:6	I-AdverseReaction
increased	ONFI.xml:S1:6564:9	I-AdverseReaction
Musculoskeletal	ONFI.xml:S1:6577:15	O
:	ONFI.xml:S1:6592:1	O
Muscle	ONFI.xml:S1:6597:6	B-AdverseReaction
spasms	ONFI.xml:S1:6604:6	I-AdverseReaction
Psychiatric	ONFI.xml:S1:6614:11	O
Disorders	ONFI.xml:S1:6626:9	O
:	ONFI.xml:S1:6635:1	O
Agitation	ONFI.xml:S1:6640:9	B-AdverseReaction
,	ONFI.xml:S1:6649:1	O
anxiety	ONFI.xml:S1:6651:7	B-AdverseReaction
,	ONFI.xml:S1:6658:1	O
apathy	ONFI.xml:S1:6660:6	B-AdverseReaction
,	ONFI.xml:S1:6666:1	O
confusional	ONFI.xml:S1:6668:11	B-AdverseReaction
state	ONFI.xml:S1:6680:5	I-AdverseReaction
,	ONFI.xml:S1:6685:1	O
depression	ONFI.xml:S1:6687:10	B-AdverseReaction
,	ONFI.xml:S1:6697:1	O
delirium	ONFI.xml:S1:6699:8	B-AdverseReaction
,	ONFI.xml:S1:6707:1	O
delusion	ONFI.xml:S1:6709:8	B-AdverseReaction
,	ONFI.xml:S1:6717:1	O
hallucination	ONFI.xml:S1:6719:13	B-AdverseReaction
Renal	ONFI.xml:S1:6736:5	O
and	ONFI.xml:S1:6742:3	O
Urinary	ONFI.xml:S1:6746:7	O
Disorders	ONFI.xml:S1:6754:9	O
:	ONFI.xml:S1:6763:1	O
Urinary	ONFI.xml:S1:6768:7	B-AdverseReaction
retention	ONFI.xml:S1:6776:9	I-AdverseReaction
Respiratory	ONFI.xml:S1:6789:11	O
Disorders	ONFI.xml:S1:6801:9	O
:	ONFI.xml:S1:6810:1	O
Aspiration	ONFI.xml:S1:6815:10	B-AdverseReaction
,	ONFI.xml:S1:6825:1	O
respiratory	ONFI.xml:S1:6827:11	B-AdverseReaction
depression	ONFI.xml:S1:6839:10	I-AdverseReaction
Skin	ONFI.xml:S1:6853:4	O
and	ONFI.xml:S1:6858:3	O
Subcutaneous	ONFI.xml:S1:6862:12	O
Tissue	ONFI.xml:S1:6875:6	O
Disorders	ONFI.xml:S1:6882:9	O
:	ONFI.xml:S1:6891:1	O
Rash	ONFI.xml:S1:6896:4	B-AdverseReaction
,	ONFI.xml:S1:6900:1	O
urticaria	ONFI.xml:S1:6902:9	B-AdverseReaction
,	ONFI.xml:S1:6911:1	O
angioedema	ONFI.xml:S1:6913:10	B-AdverseReaction
,	ONFI.xml:S1:6923:1	O
and	ONFI.xml:S1:6925:3	O
facial	ONFI.xml:S1:6929:6	B-AdverseReaction
and	ONFI.xml:S1:6936:3	O
lip	ONFI.xml:S1:6940:3	B-AdverseReaction
edema	ONFI.xml:S1:6944:5	I-AdverseReaction
5	ONFI.xml:S2:5:1	O
WARNINGS	ONFI.xml:S2:7:8	O
AND	ONFI.xml:S2:16:3	O
PRECAUTIONS	ONFI.xml:S2:20:11	O

EXCERPT	ONFI.xml:S2:40:7	O
:	ONFI.xml:S2:47:1	O
Somnolence	ONFI.xml:S2:55:10	B-AdverseReaction
or	ONFI.xml:S2:66:2	O
Sedation	ONFI.xml:S2:69:8	B-AdverseReaction
:	ONFI.xml:S2:77:1	O
Monitor	ONFI.xml:S2:79:7	O
for	ONFI.xml:S2:87:3	O
central	ONFI.xml:S2:91:7	O
nervous	ONFI.xml:S2:99:7	O
system	ONFI.xml:S2:107:6	O
(	ONFI.xml:S2:114:1	O
CNS	ONFI.xml:S2:115:3	O
)	ONFI.xml:S2:118:1	O
depression	ONFI.xml:S2:120:10	O
.	ONFI.xml:S2:130:1	O

Risk	ONFI.xml:S2:132:4	O
may	ONFI.xml:S2:137:3	O
be	ONFI.xml:S2:141:2	O
increased	ONFI.xml:S2:144:9	O
with	ONFI.xml:S2:154:4	O
concomitant	ONFI.xml:S2:159:11	O
use	ONFI.xml:S2:171:3	O
of	ONFI.xml:S2:175:2	O
other	ONFI.xml:S2:178:5	O
CNS	ONFI.xml:S2:184:3	O
depressants	ONFI.xml:S2:188:11	O
.	ONFI.xml:S2:199:1	O

(	ONFI.xml:S2:201:1	O
5.1	ONFI.xml:S2:204:3	O
,	ONFI.xml:S2:209:1	O
5.2	ONFI.xml:S2:212:3	O
)	ONFI.xml:S2:217:1	O

Withdrawal	ONFI.xml:S2:224:10	O
:	ONFI.xml:S2:234:1	O
Symptoms	ONFI.xml:S2:236:8	O
may	ONFI.xml:S2:245:3	O
occur	ONFI.xml:S2:249:5	O
with	ONFI.xml:S2:255:4	O
rapid	ONFI.xml:S2:260:5	O
dose	ONFI.xml:S2:266:4	O
reduction	ONFI.xml:S2:271:9	O
or	ONFI.xml:S2:281:2	O
discontinuation	ONFI.xml:S2:284:15	O
.	ONFI.xml:S2:299:1	O

Discontinue	ONFI.xml:S2:301:11	O
ONFI	ONFI.xml:S2:313:4	O
gradually	ONFI.xml:S2:318:9	O
.	ONFI.xml:S2:327:1	O

(	ONFI.xml:S2:329:1	O
5.3	ONFI.xml:S2:332:3	O
)	ONFI.xml:S2:337:1	O

Serious	ONFI.xml:S2:344:7	B-Severity
Dermatological	ONFI.xml:S2:352:14	B-AdverseReaction
Reactions	ONFI.xml:S2:367:9	I-AdverseReaction
(	ONFI.xml:S2:376:1	O
including	ONFI.xml:S2:377:9	O
Stevens	ONFI.xml:S2:387:7	B-AdverseReaction
-	ONFI.xml:S2:394:1	I-AdverseReaction
Johnson	ONFI.xml:S2:395:7	I-AdverseReaction
syndrome	ONFI.xml:S2:403:8	I-AdverseReaction
and	ONFI.xml:S2:412:3	O
toxic	ONFI.xml:S2:416:5	B-AdverseReaction
epidermal	ONFI.xml:S2:422:9	I-AdverseReaction
necrolysis	ONFI.xml:S2:432:10	I-AdverseReaction
)	ONFI.xml:S2:442:1	O
:	ONFI.xml:S2:443:1	O
Discontinue	ONFI.xml:S2:444:11	O
ONFI	ONFI.xml:S2:456:4	O
at	ONFI.xml:S2:461:2	O
first	ONFI.xml:S2:464:5	O
sign	ONFI.xml:S2:470:4	O
of	ONFI.xml:S2:475:2	O
rash	ONFI.xml:S2:478:4	O
unless	ONFI.xml:S2:483:6	O
the	ONFI.xml:S2:490:3	O
rash	ONFI.xml:S2:494:4	O
is	ONFI.xml:S2:499:2	O
clearly	ONFI.xml:S2:502:7	O
not	ONFI.xml:S2:510:3	O
drug	ONFI.xml:S2:514:4	O
-	ONFI.xml:S2:518:1	O
related	ONFI.xml:S2:519:7	O
.	ONFI.xml:S2:526:1	O

(	ONFI.xml:S2:528:1	O
5.4	ONFI.xml:S2:531:3	O
)	ONFI.xml:S2:536:1	O

Physical	ONFI.xml:S2:543:8	B-AdverseReaction
and	ONFI.xml:S2:552:3	O
Psychological	ONFI.xml:S2:556:13	B-AdverseReaction
Dependence	ONFI.xml:S2:570:10	I-AdverseReaction
:	ONFI.xml:S2:580:1	O
Monitor	ONFI.xml:S2:582:7	O
patients	ONFI.xml:S2:590:8	O
with	ONFI.xml:S2:599:4	O
a	ONFI.xml:S2:604:1	O
history	ONFI.xml:S2:606:7	O
of	ONFI.xml:S2:614:2	O
substance	ONFI.xml:S2:617:9	O
abuse	ONFI.xml:S2:627:5	O
for	ONFI.xml:S2:633:3	O
signs	ONFI.xml:S2:637:5	O
of	ONFI.xml:S2:643:2	O
habituation	ONFI.xml:S2:646:11	O
and	ONFI.xml:S2:658:3	O
dependence	ONFI.xml:S2:662:10	O
(	ONFI.xml:S2:673:1	O
5.5	ONFI.xml:S2:676:3	O
,	ONFI.xml:S2:681:1	O
9	ONFI.xml:S2:684:1	O
)	ONFI.xml:S2:687:1	O

Suicidal	ONFI.xml:S2:694:8	B-AdverseReaction
Behavior	ONFI.xml:S2:703:8	I-AdverseReaction
and	ONFI.xml:S2:712:3	O
Ideation	ONFI.xml:S2:716:8	I-AdverseReaction
:	ONFI.xml:S2:724:1	O
Monitor	ONFI.xml:S2:726:7	O
for	ONFI.xml:S2:734:3	O
suicidal	ONFI.xml:S2:738:8	O
thoughts	ONFI.xml:S2:747:8	O
or	ONFI.xml:S2:756:2	O
behaviors	ONFI.xml:S2:759:9	O
(	ONFI.xml:S2:769:1	O
5.6	ONFI.xml:S2:772:3	O
)	ONFI.xml:S2:777:1	O

5.1	ONFI.xml:S2:792:3	O

Somnolence	ONFI.xml:S2:796:10	O

or	ONFI.xml:S2:807:2	O
Sedation	ONFI.xml:S2:810:8	O

ONFI	ONFI.xml:S2:826:4	O
causes	ONFI.xml:S2:831:6	O
somnolence	ONFI.xml:S2:838:10	B-AdverseReaction
and	ONFI.xml:S2:849:3	O
sedation	ONFI.xml:S2:853:8	B-AdverseReaction
.	ONFI.xml:S2:861:1	O

In	ONFI.xml:S2:863:2	O
clinical	ONFI.xml:S2:866:8	O
trials	ONFI.xml:S2:875:6	O
,	ONFI.xml:S2:881:1	O
somnolence	ONFI.xml:S2:883:10	B-AdverseReaction
or	ONFI.xml:S2:894:2	O
sedation	ONFI.xml:S2:897:8	B-AdverseReaction
was	ONFI.xml:S2:906:3	O
reported	ONFI.xml:S2:910:8	O
at	ONFI.xml:S2:919:2	O
all	ONFI.xml:S2:922:3	O
effective	ONFI.xml:S2:926:9	O
doses	ONFI.xml:S2:936:5	O
and	ONFI.xml:S2:942:3	O
was	ONFI.xml:S2:946:3	O
dose	ONFI.xml:S2:950:4	O
-	ONFI.xml:S2:954:1	O
related	ONFI.xml:S2:955:7	O
.	ONFI.xml:S2:962:1	O

In	ONFI.xml:S2:968:2	O
general	ONFI.xml:S2:971:7	O
,	ONFI.xml:S2:978:1	O
somnolence	ONFI.xml:S2:980:10	B-AdverseReaction
and	ONFI.xml:S2:991:3	O
sedation	ONFI.xml:S2:995:8	B-AdverseReaction
begin	ONFI.xml:S2:1004:5	O
within	ONFI.xml:S2:1010:6	O
the	ONFI.xml:S2:1017:3	O
first	ONFI.xml:S2:1021:5	O
month	ONFI.xml:S2:1027:5	O
of	ONFI.xml:S2:1033:2	O
treatment	ONFI.xml:S2:1036:9	O
and	ONFI.xml:S2:1046:3	O
may	ONFI.xml:S2:1050:3	O
diminish	ONFI.xml:S2:1054:8	O
with	ONFI.xml:S2:1063:4	O
continued	ONFI.xml:S2:1068:9	O
treatment	ONFI.xml:S2:1078:9	O
.	ONFI.xml:S2:1087:1	O

Prescribers	ONFI.xml:S2:1089:11	O
should	ONFI.xml:S2:1101:6	O
monitor	ONFI.xml:S2:1108:7	O
patients	ONFI.xml:S2:1116:8	O
for	ONFI.xml:S2:1125:3	O
somnolence	ONFI.xml:S2:1129:10	O
and	ONFI.xml:S2:1140:3	O
sedation	ONFI.xml:S2:1144:8	O
,	ONFI.xml:S2:1152:1	O
particularly	ONFI.xml:S2:1154:12	O
with	ONFI.xml:S2:1167:4	O
concomitant	ONFI.xml:S2:1172:11	O
use	ONFI.xml:S2:1184:3	O
of	ONFI.xml:S2:1188:2	O
other	ONFI.xml:S2:1191:5	O
central	ONFI.xml:S2:1197:7	O
nervous	ONFI.xml:S2:1205:7	O
system	ONFI.xml:S2:1213:6	O
depressants	ONFI.xml:S2:1220:11	O
.	ONFI.xml:S2:1231:1	O

Prescribers	ONFI.xml:S2:1233:11	O
should	ONFI.xml:S2:1245:6	O
caution	ONFI.xml:S2:1252:7	O
patients	ONFI.xml:S2:1260:8	O
against	ONFI.xml:S2:1269:7	O
engaging	ONFI.xml:S2:1277:8	O
in	ONFI.xml:S2:1286:2	O
hazardous	ONFI.xml:S2:1289:9	O
activities	ONFI.xml:S2:1299:10	O
requiring	ONFI.xml:S2:1310:9	O
mental	ONFI.xml:S2:1320:6	O
alertness	ONFI.xml:S2:1327:9	O
,	ONFI.xml:S2:1336:1	O
such	ONFI.xml:S2:1338:4	O
as	ONFI.xml:S2:1343:2	O
operating	ONFI.xml:S2:1346:9	O
dangerous	ONFI.xml:S2:1356:9	O
machinery	ONFI.xml:S2:1366:9	O
or	ONFI.xml:S2:1376:2	O
motor	ONFI.xml:S2:1379:5	O
vehicles	ONFI.xml:S2:1385:8	O
,	ONFI.xml:S2:1393:1	O
until	ONFI.xml:S2:1395:5	O
the	ONFI.xml:S2:1401:3	O
effect	ONFI.xml:S2:1405:6	O
of	ONFI.xml:S2:1412:2	O
ONFI	ONFI.xml:S2:1415:4	O
is	ONFI.xml:S2:1420:2	O
known	ONFI.xml:S2:1423:5	O
.	ONFI.xml:S2:1428:1	O

5.2	ONFI.xml:S2:1438:3	O
Potentiation	ONFI.xml:S2:1442:12	O
of	ONFI.xml:S2:1455:2	O
Sedation	ONFI.xml:S2:1458:8	O
from	ONFI.xml:S2:1467:4	O
Concomitant	ONFI.xml:S2:1472:11	O
Use	ONFI.xml:S2:1484:3	O
with	ONFI.xml:S2:1488:4	O
Central	ONFI.xml:S2:1493:7	O
Nervous	ONFI.xml:S2:1501:7	O
System	ONFI.xml:S2:1509:6	O
Depressants	ONFI.xml:S2:1516:11	O

Since	ONFI.xml:S2:1535:5	O
ONFI	ONFI.xml:S2:1541:4	O
has	ONFI.xml:S2:1546:3	O
a	ONFI.xml:S2:1550:1	O
central	ONFI.xml:S2:1552:7	O
nervous	ONFI.xml:S2:1560:7	O
system	ONFI.xml:S2:1568:6	O
(	ONFI.xml:S2:1575:1	O
CNS	ONFI.xml:S2:1576:3	O
)	ONFI.xml:S2:1579:1	O
depressant	ONFI.xml:S2:1581:10	O
effect	ONFI.xml:S2:1592:6	O
,	ONFI.xml:S2:1598:1	O
patients	ONFI.xml:S2:1600:8	O
or	ONFI.xml:S2:1609:2	O
their	ONFI.xml:S2:1612:5	O
caregivers	ONFI.xml:S2:1618:10	O
should	ONFI.xml:S2:1629:6	O
be	ONFI.xml:S2:1636:2	O
cautioned	ONFI.xml:S2:1639:9	O
against	ONFI.xml:S2:1649:7	O
simultaneous	ONFI.xml:S2:1657:12	O
use	ONFI.xml:S2:1670:3	O
with	ONFI.xml:S2:1674:4	O
other	ONFI.xml:S2:1679:5	O
CNS	ONFI.xml:S2:1685:3	O
depressant	ONFI.xml:S2:1689:10	O
drugs	ONFI.xml:S2:1700:5	O
or	ONFI.xml:S2:1706:2	O
alcohol	ONFI.xml:S2:1709:7	O
,	ONFI.xml:S2:1716:1	O
and	ONFI.xml:S2:1718:3	O
cautioned	ONFI.xml:S2:1722:9	O
that	ONFI.xml:S2:1732:4	O
the	ONFI.xml:S2:1737:3	O
effects	ONFI.xml:S2:1741:7	O
of	ONFI.xml:S2:1749:2	O
other	ONFI.xml:S2:1752:5	O
CNS	ONFI.xml:S2:1758:3	O
depressant	ONFI.xml:S2:1762:10	O
drugs	ONFI.xml:S2:1773:5	O
or	ONFI.xml:S2:1779:2	O
alcohol	ONFI.xml:S2:1782:7	O
may	ONFI.xml:S2:1790:3	O
be	ONFI.xml:S2:1794:2	O
potentiated	ONFI.xml:S2:1797:11	O
.	ONFI.xml:S2:1808:1	O

5.3	ONFI.xml:S2:1818:3	O
Withdrawal	ONFI.xml:S2:1822:10	O
Symptoms	ONFI.xml:S2:1833:8	O

Abrupt	ONFI.xml:S2:1849:6	O
discontinuation	ONFI.xml:S2:1856:15	O
of	ONFI.xml:S2:1872:2	O
ONFI	ONFI.xml:S2:1875:4	O
should	ONFI.xml:S2:1880:6	O
be	ONFI.xml:S2:1887:2	O
avoided	ONFI.xml:S2:1890:7	O
.	ONFI.xml:S2:1897:1	O

ONFI	ONFI.xml:S2:1899:4	O
should	ONFI.xml:S2:1904:6	O
be	ONFI.xml:S2:1911:2	O
tapered	ONFI.xml:S2:1914:7	O
by	ONFI.xml:S2:1922:2	O
decreasing	ONFI.xml:S2:1925:10	O
the	ONFI.xml:S2:1936:3	O
dose	ONFI.xml:S2:1940:4	O
every	ONFI.xml:S2:1945:5	O
week	ONFI.xml:S2:1951:4	O
by	ONFI.xml:S2:1956:2	O
5	ONFI.xml:S2:1959:1	O
-	ONFI.xml:S2:1960:1	O
10	ONFI.xml:S2:1961:2	O
mg	ONFI.xml:S2:1964:2	O
day	ONFI.xml:S2:1967:3	O
until	ONFI.xml:S2:1971:5	O
discontinuation	ONFI.xml:S2:1977:15	O
[	ONFI.xml:S2:1993:1	O
see	ONFI.xml:S2:1994:3	O
Dosage	ONFI.xml:S2:1998:6	O
and	ONFI.xml:S2:2005:3	O
Administration	ONFI.xml:S2:2009:14	O
(	ONFI.xml:S2:2024:1	O
2.2	ONFI.xml:S2:2027:3	O
)]	ONFI.xml:S2:2032:2	O
.	ONFI.xml:S2:2036:1	O

Withdrawal	ONFI.xml:S2:2042:10	O
symptoms	ONFI.xml:S2:2053:8	O
occurred	ONFI.xml:S2:2062:8	O
following	ONFI.xml:S2:2071:9	O
abrupt	ONFI.xml:S2:2081:6	O
discontinuation	ONFI.xml:S2:2088:15	O
of	ONFI.xml:S2:2104:2	O
ONFI	ONFI.xml:S2:2107:4	O
;	ONFI.xml:S2:2111:1	O
the	ONFI.xml:S2:2113:3	O
risk	ONFI.xml:S2:2117:4	O
of	ONFI.xml:S2:2122:2	O
withdrawal	ONFI.xml:S2:2125:10	O
symptoms	ONFI.xml:S2:2136:8	O
is	ONFI.xml:S2:2145:2	O
greater	ONFI.xml:S2:2148:7	O
with	ONFI.xml:S2:2156:4	O
higher	ONFI.xml:S2:2161:6	O
doses	ONFI.xml:S2:2168:5	O
.	ONFI.xml:S2:2173:1	O

As	ONFI.xml:S2:2179:2	O
with	ONFI.xml:S2:2182:4	O
all	ONFI.xml:S2:2187:3	O
antiepileptic	ONFI.xml:S2:2191:13	O
drugs	ONFI.xml:S2:2205:5	O
,	ONFI.xml:S2:2210:1	O
ONFI	ONFI.xml:S2:2212:4	O
should	ONFI.xml:S2:2217:6	O
be	ONFI.xml:S2:2224:2	O
withdrawn	ONFI.xml:S2:2227:9	O
gradually	ONFI.xml:S2:2237:9	O
to	ONFI.xml:S2:2247:2	O
minimize	ONFI.xml:S2:2250:8	O
the	ONFI.xml:S2:2259:3	O
risk	ONFI.xml:S2:2263:4	O
of	ONFI.xml:S2:2268:2	O
precipitating	ONFI.xml:S2:2271:13	O
seizures	ONFI.xml:S2:2285:8	O
,	ONFI.xml:S2:2293:1	O
seizure	ONFI.xml:S2:2295:7	O
exacerbation	ONFI.xml:S2:2303:12	O
,	ONFI.xml:S2:2315:1	O
or	ONFI.xml:S2:2317:2	O
status	ONFI.xml:S2:2320:6	O
epilepticus	ONFI.xml:S2:2327:11	O
.	ONFI.xml:S2:2338:1	O

Withdrawal	ONFI.xml:S2:2344:10	O
symptoms	ONFI.xml:S2:2355:8	O
(	ONFI.xml:S2:2364:1	O
e	ONFI.xml:S2:2365:1	O
.	ONFI.xml:S2:2366:1	O
g	ONFI.xml:S2:2367:1	O
.	ONFI.xml:S2:2368:1	O
,	ONFI.xml:S2:2369:1	O
convulsions	ONFI.xml:S2:2371:11	O
,	ONFI.xml:S2:2382:1	O
psychosis	ONFI.xml:S2:2384:9	O
,	ONFI.xml:S2:2393:1	O
hallucinations	ONFI.xml:S2:2395:14	O
,	ONFI.xml:S2:2409:1	O
behavioral	ONFI.xml:S2:2411:10	O
disorder	ONFI.xml:S2:2422:8	O
,	ONFI.xml:S2:2430:1	O
tremor	ONFI.xml:S2:2432:6	O
,	ONFI.xml:S2:2438:1	O
and	ONFI.xml:S2:2440:3	O
anxiety	ONFI.xml:S2:2444:7	O
)	ONFI.xml:S2:2451:1	O
have	ONFI.xml:S2:2453:4	O
been	ONFI.xml:S2:2458:4	O
reported	ONFI.xml:S2:2463:8	O
following	ONFI.xml:S2:2472:9	O
abrupt	ONFI.xml:S2:2482:6	O
discontinuance	ONFI.xml:S2:2489:14	O
of	ONFI.xml:S2:2504:2	O
benzodiazepines	ONFI.xml:S2:2507:15	O
.	ONFI.xml:S2:2522:1	O

The	ONFI.xml:S2:2524:3	O
more	ONFI.xml:S2:2528:4	O
severe	ONFI.xml:S2:2533:6	O
withdrawal	ONFI.xml:S2:2540:10	O
symptoms	ONFI.xml:S2:2551:8	O
have	ONFI.xml:S2:2560:4	O
usually	ONFI.xml:S2:2565:7	O
been	ONFI.xml:S2:2573:4	O
limited	ONFI.xml:S2:2578:7	O
to	ONFI.xml:S2:2586:2	O
patients	ONFI.xml:S2:2589:8	O
who	ONFI.xml:S2:2598:3	O
received	ONFI.xml:S2:2602:8	O
excessive	ONFI.xml:S2:2611:9	O
doses	ONFI.xml:S2:2621:5	O
over	ONFI.xml:S2:2627:4	O
an	ONFI.xml:S2:2632:2	O
extended	ONFI.xml:S2:2635:8	O
period	ONFI.xml:S2:2644:6	O
of	ONFI.xml:S2:2651:2	O
time	ONFI.xml:S2:2654:4	O
,	ONFI.xml:S2:2658:1	O
followed	ONFI.xml:S2:2660:8	O
by	ONFI.xml:S2:2669:2	O
an	ONFI.xml:S2:2672:2	O
abrupt	ONFI.xml:S2:2675:6	O
discontinuation	ONFI.xml:S2:2682:15	O
.	ONFI.xml:S2:2697:1	O

Generally	ONFI.xml:S2:2699:9	O
milder	ONFI.xml:S2:2709:6	O
withdrawal	ONFI.xml:S2:2716:10	O
symptoms	ONFI.xml:S2:2727:8	O
(	ONFI.xml:S2:2736:1	O
e	ONFI.xml:S2:2737:1	O
.	ONFI.xml:S2:2738:1	O
g	ONFI.xml:S2:2739:1	O
.	ONFI.xml:S2:2740:1	O
,	ONFI.xml:S2:2741:1	O
dysphoria	ONFI.xml:S2:2743:9	O
,	ONFI.xml:S2:2752:1	O
anxiety	ONFI.xml:S2:2754:7	O
,	ONFI.xml:S2:2761:1	O
and	ONFI.xml:S2:2763:3	O
insomnia	ONFI.xml:S2:2767:8	O
)	ONFI.xml:S2:2775:1	O
have	ONFI.xml:S2:2777:4	O
been	ONFI.xml:S2:2782:4	O
reported	ONFI.xml:S2:2787:8	O
following	ONFI.xml:S2:2796:9	O
abrupt	ONFI.xml:S2:2806:6	O
discontinuance	ONFI.xml:S2:2813:14	O
of	ONFI.xml:S2:2828:2	O
benzodiazepines	ONFI.xml:S2:2831:15	O
taken	ONFI.xml:S2:2847:5	O
continuously	ONFI.xml:S2:2853:12	O
at	ONFI.xml:S2:2866:2	O
therapeutic	ONFI.xml:S2:2869:11	O
doses	ONFI.xml:S2:2881:5	O
for	ONFI.xml:S2:2887:3	O
several	ONFI.xml:S2:2891:7	O
months	ONFI.xml:S2:2899:6	O
.	ONFI.xml:S2:2905:1	O

5.4	ONFI.xml:S2:2915:3	O
Serious	ONFI.xml:S2:2919:7	O
Dermatological	ONFI.xml:S2:2927:14	O
Reactions	ONFI.xml:S2:2942:9	O

Serious	ONFI.xml:S2:2959:7	B-Severity
skin	ONFI.xml:S2:2967:4	B-AdverseReaction
reactions	ONFI.xml:S2:2972:9	I-AdverseReaction
,	ONFI.xml:S2:2981:1	O
including	ONFI.xml:S2:2983:9	O
Stevens	ONFI.xml:S2:2993:7	B-AdverseReaction
-	ONFI.xml:S2:3000:1	I-AdverseReaction
Johnson	ONFI.xml:S2:3001:7	I-AdverseReaction
syndrome	ONFI.xml:S2:3009:8	I-AdverseReaction
(	ONFI.xml:S2:3018:1	O
SJS	ONFI.xml:S2:3019:3	B-AdverseReaction
)	ONFI.xml:S2:3022:1	O
and	ONFI.xml:S2:3024:3	O
toxic	ONFI.xml:S2:3028:5	B-AdverseReaction
epidermal	ONFI.xml:S2:3034:9	I-AdverseReaction
necrolysis	ONFI.xml:S2:3044:10	I-AdverseReaction
(	ONFI.xml:S2:3055:1	O
TEN	ONFI.xml:S2:3056:3	B-AdverseReaction
)	ONFI.xml:S2:3059:1	O
,	ONFI.xml:S2:3060:1	O
have	ONFI.xml:S2:3062:4	O
been	ONFI.xml:S2:3067:4	O
reported	ONFI.xml:S2:3072:8	O
with	ONFI.xml:S2:3081:4	O
ONFI	ONFI.xml:S2:3086:4	O
in	ONFI.xml:S2:3091:2	O
both	ONFI.xml:S2:3094:4	O
children	ONFI.xml:S2:3099:8	O
and	ONFI.xml:S2:3108:3	O
adults	ONFI.xml:S2:3112:6	O
during	ONFI.xml:S2:3119:6	O
the	ONFI.xml:S2:3126:3	O
post	ONFI.xml:S2:3130:4	O
-	ONFI.xml:S2:3134:1	O
marketing	ONFI.xml:S2:3135:9	O
period	ONFI.xml:S2:3145:6	O
.	ONFI.xml:S2:3151:1	O

Patients	ONFI.xml:S2:3154:8	O
should	ONFI.xml:S2:3163:6	O
be	ONFI.xml:S2:3170:2	O
closely	ONFI.xml:S2:3173:7	O
monitored	ONFI.xml:S2:3181:9	O
for	ONFI.xml:S2:3191:3	O
signs	ONFI.xml:S2:3195:5	O
or	ONFI.xml:S2:3201:2	O
symptoms	ONFI.xml:S2:3204:8	O
of	ONFI.xml:S2:3213:2	O
SJS	ONFI.xml:S2:3216:3	O
TEN	ONFI.xml:S2:3220:3	O
,	ONFI.xml:S2:3223:1	O
especially	ONFI.xml:S2:3225:10	O
during	ONFI.xml:S2:3236:6	O
the	ONFI.xml:S2:3243:3	O
first	ONFI.xml:S2:3247:5	O
8	ONFI.xml:S2:3253:1	O
weeks	ONFI.xml:S2:3255:5	O
of	ONFI.xml:S2:3261:2	O
treatment	ONFI.xml:S2:3264:9	O
initiation	ONFI.xml:S2:3274:10	O
or	ONFI.xml:S2:3285:2	O
when	ONFI.xml:S2:3288:4	O
re	ONFI.xml:S2:3293:2	O
-	ONFI.xml:S2:3295:1	O
introducing	ONFI.xml:S2:3296:11	O
therapy	ONFI.xml:S2:3308:7	O
.	ONFI.xml:S2:3315:1	O

ONFI	ONFI.xml:S2:3317:4	O
should	ONFI.xml:S2:3322:6	O
be	ONFI.xml:S2:3329:2	O
discontinued	ONFI.xml:S2:3332:12	O
at	ONFI.xml:S2:3345:2	O
the	ONFI.xml:S2:3348:3	O
first	ONFI.xml:S2:3352:5	O
sign	ONFI.xml:S2:3358:4	O
of	ONFI.xml:S2:3363:2	O
rash	ONFI.xml:S2:3366:4	O
,	ONFI.xml:S2:3370:1	O
unless	ONFI.xml:S2:3372:6	O
the	ONFI.xml:S2:3379:3	O
rash	ONFI.xml:S2:3383:4	O
is	ONFI.xml:S2:3388:2	O
clearly	ONFI.xml:S2:3391:7	O
not	ONFI.xml:S2:3399:3	O
drug	ONFI.xml:S2:3403:4	O
-	ONFI.xml:S2:3407:1	O
related	ONFI.xml:S2:3408:7	O
.	ONFI.xml:S2:3415:1	O

If	ONFI.xml:S2:3417:2	O
signs	ONFI.xml:S2:3420:5	O
or	ONFI.xml:S2:3426:2	O
symptoms	ONFI.xml:S2:3429:8	O
suggest	ONFI.xml:S2:3438:7	O
SJS	ONFI.xml:S2:3446:3	O
TEN	ONFI.xml:S2:3450:3	O
,	ONFI.xml:S2:3453:1	O
use	ONFI.xml:S2:3455:3	O
of	ONFI.xml:S2:3459:2	O
this	ONFI.xml:S2:3462:4	O
drug	ONFI.xml:S2:3467:4	O
should	ONFI.xml:S2:3472:6	O
not	ONFI.xml:S2:3479:3	O
be	ONFI.xml:S2:3483:2	O
resumed	ONFI.xml:S2:3486:7	O
and	ONFI.xml:S2:3494:3	O
alternative	ONFI.xml:S2:3498:11	O
therapy	ONFI.xml:S2:3510:7	O
should	ONFI.xml:S2:3518:6	O
be	ONFI.xml:S2:3525:2	O
considered	ONFI.xml:S2:3528:10	O
[	ONFI.xml:S2:3539:1	O
see	ONFI.xml:S2:3540:3	O
Contraindications	ONFI.xml:S2:3544:17	O
(	ONFI.xml:S2:3562:1	O
4	ONFI.xml:S2:3565:1	O
)]	ONFI.xml:S2:3568:2	O
.	ONFI.xml:S2:3570:1	O

5.5	ONFI.xml:S2:3582:3	O
Physical	ONFI.xml:S2:3586:8	O
and	ONFI.xml:S2:3595:3	O
Psychological	ONFI.xml:S2:3599:13	O
Dependence	ONFI.xml:S2:3613:10	O

Patients	ONFI.xml:S2:3631:8	O
with	ONFI.xml:S2:3640:4	O
a	ONFI.xml:S2:3645:1	O
history	ONFI.xml:S2:3647:7	O
of	ONFI.xml:S2:3655:2	O
substance	ONFI.xml:S2:3658:9	O
abuse	ONFI.xml:S2:3668:5	O
should	ONFI.xml:S2:3674:6	O
be	ONFI.xml:S2:3681:2	O
under	ONFI.xml:S2:3684:5	O
careful	ONFI.xml:S2:3690:7	O
surveillance	ONFI.xml:S2:3698:12	O
when	ONFI.xml:S2:3711:4	O
receiving	ONFI.xml:S2:3716:9	O
ONFI	ONFI.xml:S2:3726:4	O
or	ONFI.xml:S2:3731:2	O
other	ONFI.xml:S2:3734:5	O
psychotropic	ONFI.xml:S2:3740:12	O
agents	ONFI.xml:S2:3753:6	O
because	ONFI.xml:S2:3760:7	O
of	ONFI.xml:S2:3768:2	O
the	ONFI.xml:S2:3771:3	O
predisposition	ONFI.xml:S2:3775:14	O
of	ONFI.xml:S2:3790:2	O
such	ONFI.xml:S2:3793:4	O
patients	ONFI.xml:S2:3798:8	O
to	ONFI.xml:S2:3807:2	O
habituation	ONFI.xml:S2:3810:11	O
and	ONFI.xml:S2:3822:3	O
dependence	ONFI.xml:S2:3826:10	O
[	ONFI.xml:S2:3837:1	O
see	ONFI.xml:S2:3838:3	O
Drug	ONFI.xml:S2:3844:4	O
Abuse	ONFI.xml:S2:3849:5	O
and	ONFI.xml:S2:3855:3	O
Dependence	ONFI.xml:S2:3859:10	O
(	ONFI.xml:S2:3870:1	O
9	ONFI.xml:S2:3873:1	O
)]	ONFI.xml:S2:3876:2	O
.	ONFI.xml:S2:3880:1	O

5.6	ONFI.xml:S2:3890:3	O
Suicidal	ONFI.xml:S2:3894:8	O
Behavior	ONFI.xml:S2:3903:8	O
and	ONFI.xml:S2:3912:3	O
Ideation	ONFI.xml:S2:3916:8	O

Antiepileptic	ONFI.xml:S2:3932:13	O
drugs	ONFI.xml:S2:3946:5	O
(	ONFI.xml:S2:3952:1	O
AEDs	ONFI.xml:S2:3953:4	O
)	ONFI.xml:S2:3957:1	O
,	ONFI.xml:S2:3958:1	O
including	ONFI.xml:S2:3960:9	O
ONFI	ONFI.xml:S2:3970:4	O
,	ONFI.xml:S2:3974:1	O
increase	ONFI.xml:S2:3976:8	O
the	ONFI.xml:S2:3985:3	O
risk	ONFI.xml:S2:3989:4	B-Factor
of	ONFI.xml:S2:3994:2	O
suicidal	ONFI.xml:S2:3997:8	B-AdverseReaction
thoughts	ONFI.xml:S2:4006:8	I-AdverseReaction
or	ONFI.xml:S2:4015:2	O
behavior	ONFI.xml:S2:4018:8	I-AdverseReaction
in	ONFI.xml:S2:4027:2	O
patients	ONFI.xml:S2:4030:8	O
taking	ONFI.xml:S2:4039:6	O
these	ONFI.xml:S2:4046:5	O
drugs	ONFI.xml:S2:4052:5	O
for	ONFI.xml:S2:4058:3	O
any	ONFI.xml:S2:4062:3	O
indication	ONFI.xml:S2:4066:10	O
.	ONFI.xml:S2:4076:1	O

Patients	ONFI.xml:S2:4078:8	O
treated	ONFI.xml:S2:4087:7	O
with	ONFI.xml:S2:4095:4	O
any	ONFI.xml:S2:4100:3	O
AED	ONFI.xml:S2:4104:3	O
for	ONFI.xml:S2:4108:3	O
any	ONFI.xml:S2:4112:3	O
indication	ONFI.xml:S2:4116:10	O
should	ONFI.xml:S2:4127:6	O
be	ONFI.xml:S2:4134:2	O
monitored	ONFI.xml:S2:4137:9	O
for	ONFI.xml:S2:4147:3	O
the	ONFI.xml:S2:4151:3	O
emergence	ONFI.xml:S2:4155:9	O
or	ONFI.xml:S2:4165:2	O
worsening	ONFI.xml:S2:4168:9	O
of	ONFI.xml:S2:4178:2	O
depression	ONFI.xml:S2:4181:10	O
,	ONFI.xml:S2:4191:1	O
suicidal	ONFI.xml:S2:4193:8	O
thoughts	ONFI.xml:S2:4202:8	O
or	ONFI.xml:S2:4211:2	O
behavior	ONFI.xml:S2:4214:8	O
,	ONFI.xml:S2:4222:1	O
and	ONFI.xml:S2:4224:3	O
or	ONFI.xml:S2:4228:2	O
any	ONFI.xml:S2:4231:3	O
unusual	ONFI.xml:S2:4235:7	O
changes	ONFI.xml:S2:4243:7	O
in	ONFI.xml:S2:4251:2	O
mood	ONFI.xml:S2:4254:4	O
or	ONFI.xml:S2:4259:2	O
behavior	ONFI.xml:S2:4262:8	O
.	ONFI.xml:S2:4270:1	O

Pooled	ONFI.xml:S2:4276:6	O
analyses	ONFI.xml:S2:4283:8	O
of	ONFI.xml:S2:4292:2	O
199	ONFI.xml:S2:4295:3	O
placebo	ONFI.xml:S2:4299:7	O
-	ONFI.xml:S2:4306:1	O
controlled	ONFI.xml:S2:4307:10	O
clinical	ONFI.xml:S2:4318:8	O
trials	ONFI.xml:S2:4327:6	O
(	ONFI.xml:S2:4334:1	O
mono	ONFI.xml:S2:4335:4	O
-	ONFI.xml:S2:4339:1	O
and	ONFI.xml:S2:4341:3	O
adjunctive	ONFI.xml:S2:4345:10	O
therapy	ONFI.xml:S2:4356:7	O
)	ONFI.xml:S2:4363:1	O
of	ONFI.xml:S2:4365:2	O
11	ONFI.xml:S2:4368:2	O
different	ONFI.xml:S2:4371:9	O
AEDs	ONFI.xml:S2:4381:4	B-DrugClass
showed	ONFI.xml:S2:4386:6	O
that	ONFI.xml:S2:4393:4	O
patients	ONFI.xml:S2:4398:8	O
randomized	ONFI.xml:S2:4407:10	O
to	ONFI.xml:S2:4418:2	O
one	ONFI.xml:S2:4421:3	O
of	ONFI.xml:S2:4425:2	O
the	ONFI.xml:S2:4428:3	O
AEDs	ONFI.xml:S2:4432:4	O
had	ONFI.xml:S2:4437:3	O
approximately	ONFI.xml:S2:4441:13	O
twice	ONFI.xml:S2:4455:5	O
the	ONFI.xml:S2:4461:3	O
risk	ONFI.xml:S2:4465:4	O
(	ONFI.xml:S2:4470:1	O
adjusted	ONFI.xml:S2:4471:8	O
relative	ONFI.xml:S2:4480:8	O
risk	ONFI.xml:S2:4489:4	O
1.8	ONFI.xml:S2:4494:3	O
,	ONFI.xml:S2:4497:1	O
95%	ONFI.xml:S2:4499:3	O
confidence	ONFI.xml:S2:4503:10	O
interval	ONFI.xml:S2:4514:8	O
[	ONFI.xml:S2:4523:1	O
CI	ONFI.xml:S2:4524:2	O
]	ONFI.xml:S2:4526:1	O
:	ONFI.xml:S2:4527:1	O
1.2	ONFI.xml:S2:4529:3	O
,	ONFI.xml:S2:4532:1	O
2.7	ONFI.xml:S2:4534:3	O
)	ONFI.xml:S2:4537:1	O
of	ONFI.xml:S2:4539:2	O
suicidal	ONFI.xml:S2:4542:8	B-AdverseReaction
thinking	ONFI.xml:S2:4551:8	I-AdverseReaction
or	ONFI.xml:S2:4560:2	O
behavior	ONFI.xml:S2:4563:8	I-AdverseReaction
compared	ONFI.xml:S2:4572:8	O
to	ONFI.xml:S2:4581:2	O
patients	ONFI.xml:S2:4584:8	O
randomized	ONFI.xml:S2:4593:10	O
to	ONFI.xml:S2:4604:2	O
placebo	ONFI.xml:S2:4607:7	O
.	ONFI.xml:S2:4614:1	O

In	ONFI.xml:S2:4616:2	O
these	ONFI.xml:S2:4619:5	O
trials	ONFI.xml:S2:4625:6	O
,	ONFI.xml:S2:4631:1	O
which	ONFI.xml:S2:4633:5	O
had	ONFI.xml:S2:4639:3	O
a	ONFI.xml:S2:4643:1	O
median	ONFI.xml:S2:4645:6	O
treatment	ONFI.xml:S2:4652:9	O
duration	ONFI.xml:S2:4662:8	O
of	ONFI.xml:S2:4671:2	O
12	ONFI.xml:S2:4674:2	O
weeks	ONFI.xml:S2:4677:5	O
,	ONFI.xml:S2:4682:1	O
the	ONFI.xml:S2:4684:3	O
estimated	ONFI.xml:S2:4688:9	O
incidence	ONFI.xml:S2:4698:9	O
rate	ONFI.xml:S2:4708:4	O
of	ONFI.xml:S2:4713:2	O
suicidal	ONFI.xml:S2:4716:8	B-AdverseReaction
behavior	ONFI.xml:S2:4725:8	I-AdverseReaction
or	ONFI.xml:S2:4734:2	O
ideation	ONFI.xml:S2:4737:8	I-AdverseReaction
among	ONFI.xml:S2:4746:5	O
27	ONFI.xml:S2:4752:2	O
,	ONFI.xml:S2:4754:1	O
863	ONFI.xml:S2:4755:3	O
AED	ONFI.xml:S2:4759:3	B-DrugClass
treated	ONFI.xml:S2:4763:7	O
patients	ONFI.xml:S2:4771:8	O
was	ONFI.xml:S2:4780:3	O
0.43%	ONFI.xml:S2:4784:5	O
,	ONFI.xml:S2:4789:1	O
compared	ONFI.xml:S2:4791:8	O
to	ONFI.xml:S2:4800:2	O
0.24%	ONFI.xml:S2:4803:5	O
among	ONFI.xml:S2:4809:5	O
16	ONFI.xml:S2:4815:2	O
,	ONFI.xml:S2:4817:1	O
029	ONFI.xml:S2:4818:3	O
placebo	ONFI.xml:S2:4822:7	O
treated	ONFI.xml:S2:4830:7	O
patients	ONFI.xml:S2:4838:8	O
,	ONFI.xml:S2:4846:1	O
representing	ONFI.xml:S2:4848:12	O
an	ONFI.xml:S2:4861:2	O
increase	ONFI.xml:S2:4864:8	O
of	ONFI.xml:S2:4873:2	O
approximately	ONFI.xml:S2:4876:13	O
one	ONFI.xml:S2:4890:3	O
case	ONFI.xml:S2:4894:4	O
of	ONFI.xml:S2:4899:2	O
suicidal	ONFI.xml:S2:4902:8	B-AdverseReaction
thinking	ONFI.xml:S2:4911:8	I-AdverseReaction
or	ONFI.xml:S2:4920:2	O
behavior	ONFI.xml:S2:4923:8	I-AdverseReaction
for	ONFI.xml:S2:4932:3	O
every	ONFI.xml:S2:4936:5	O
530	ONFI.xml:S2:4942:3	O
patients	ONFI.xml:S2:4946:8	O
treated	ONFI.xml:S2:4955:7	O
.	ONFI.xml:S2:4962:1	O

There	ONFI.xml:S2:4964:5	O
were	ONFI.xml:S2:4970:4	O
four	ONFI.xml:S2:4975:4	O
suicides	ONFI.xml:S2:4980:8	B-AdverseReaction
in	ONFI.xml:S2:4989:2	O
drug	ONFI.xml:S2:4992:4	O
treated	ONFI.xml:S2:4997:7	O
patients	ONFI.xml:S2:5005:8	O
in	ONFI.xml:S2:5014:2	O
the	ONFI.xml:S2:5017:3	O
trials	ONFI.xml:S2:5021:6	O
and	ONFI.xml:S2:5028:3	O
none	ONFI.xml:S2:5032:4	O
in	ONFI.xml:S2:5037:2	O
placebo	ONFI.xml:S2:5040:7	O
treated	ONFI.xml:S2:5048:7	O
patients	ONFI.xml:S2:5056:8	O
,	ONFI.xml:S2:5064:1	O
but	ONFI.xml:S2:5066:3	O
the	ONFI.xml:S2:5070:3	O
number	ONFI.xml:S2:5074:6	O
is	ONFI.xml:S2:5081:2	O
too	ONFI.xml:S2:5084:3	O
small	ONFI.xml:S2:5088:5	O
to	ONFI.xml:S2:5094:2	O
allow	ONFI.xml:S2:5097:5	O
any	ONFI.xml:S2:5103:3	O
conclusion	ONFI.xml:S2:5107:10	O
about	ONFI.xml:S2:5118:5	O
drug	ONFI.xml:S2:5124:4	O
effect	ONFI.xml:S2:5129:6	O
on	ONFI.xml:S2:5136:2	O
suicide	ONFI.xml:S2:5139:7	B-AdverseReaction
.	ONFI.xml:S2:5146:1	O

The	ONFI.xml:S2:5152:3	O
increased	ONFI.xml:S2:5156:9	O
risk	ONFI.xml:S2:5166:4	O
of	ONFI.xml:S2:5171:2	O
suicidal	ONFI.xml:S2:5174:8	B-AdverseReaction
thoughts	ONFI.xml:S2:5183:8	I-AdverseReaction
or	ONFI.xml:S2:5192:2	O
behavior	ONFI.xml:S2:5195:8	I-AdverseReaction
with	ONFI.xml:S2:5204:4	O
AEDs	ONFI.xml:S2:5209:4	B-DrugClass
was	ONFI.xml:S2:5214:3	O
observed	ONFI.xml:S2:5218:8	O
as	ONFI.xml:S2:5227:2	O
early	ONFI.xml:S2:5230:5	O
as	ONFI.xml:S2:5236:2	O
one	ONFI.xml:S2:5239:3	O
week	ONFI.xml:S2:5243:4	O
after	ONFI.xml:S2:5248:5	O
starting	ONFI.xml:S2:5254:8	O
drug	ONFI.xml:S2:5263:4	O
treatment	ONFI.xml:S2:5268:9	O
with	ONFI.xml:S2:5278:4	O
AEDs	ONFI.xml:S2:5283:4	O
and	ONFI.xml:S2:5288:3	O
persisted	ONFI.xml:S2:5292:9	O
for	ONFI.xml:S2:5302:3	O
the	ONFI.xml:S2:5306:3	O
duration	ONFI.xml:S2:5310:8	O
of	ONFI.xml:S2:5319:2	O
treatment	ONFI.xml:S2:5322:9	O
assessed	ONFI.xml:S2:5332:8	O
.	ONFI.xml:S2:5340:1	O

Because	ONFI.xml:S2:5342:7	O
most	ONFI.xml:S2:5350:4	O
trials	ONFI.xml:S2:5355:6	O
included	ONFI.xml:S2:5362:8	O
in	ONFI.xml:S2:5371:2	O
the	ONFI.xml:S2:5374:3	O
analysis	ONFI.xml:S2:5378:8	O
did	ONFI.xml:S2:5387:3	O
not	ONFI.xml:S2:5391:3	O
extend	ONFI.xml:S2:5395:6	O
beyond	ONFI.xml:S2:5402:6	O
24	ONFI.xml:S2:5409:2	O
weeks	ONFI.xml:S2:5412:5	O
,	ONFI.xml:S2:5417:1	O
the	ONFI.xml:S2:5419:3	O
risk	ONFI.xml:S2:5423:4	B-Factor
of	ONFI.xml:S2:5428:2	O
suicidal	ONFI.xml:S2:5431:8	B-AdverseReaction
thoughts	ONFI.xml:S2:5440:8	I-AdverseReaction
or	ONFI.xml:S2:5449:2	O
behavior	ONFI.xml:S2:5452:8	I-AdverseReaction
beyond	ONFI.xml:S2:5461:6	O
24	ONFI.xml:S2:5468:2	O
weeks	ONFI.xml:S2:5471:5	O
could	ONFI.xml:S2:5477:5	O
not	ONFI.xml:S2:5483:3	O
be	ONFI.xml:S2:5487:2	O
assessed	ONFI.xml:S2:5490:8	O
.	ONFI.xml:S2:5498:1	O

The	ONFI.xml:S2:5504:3	O
risk	ONFI.xml:S2:5508:4	B-Factor
of	ONFI.xml:S2:5513:2	O
suicidal	ONFI.xml:S2:5516:8	B-AdverseReaction
thoughts	ONFI.xml:S2:5525:8	I-AdverseReaction
or	ONFI.xml:S2:5534:2	O
behavior	ONFI.xml:S2:5537:8	I-AdverseReaction
was	ONFI.xml:S2:5546:3	O
generally	ONFI.xml:S2:5550:9	O
consistent	ONFI.xml:S2:5560:10	O
among	ONFI.xml:S2:5571:5	O
drugs	ONFI.xml:S2:5577:5	O
in	ONFI.xml:S2:5583:2	O
the	ONFI.xml:S2:5586:3	O
data	ONFI.xml:S2:5590:4	O
analyzed	ONFI.xml:S2:5595:8	O
.	ONFI.xml:S2:5603:1	O

The	ONFI.xml:S2:5605:3	O
finding	ONFI.xml:S2:5609:7	O
of	ONFI.xml:S2:5617:2	O
increased	ONFI.xml:S2:5620:9	O
risk	ONFI.xml:S2:5630:4	O
with	ONFI.xml:S2:5635:4	O
AEDs	ONFI.xml:S2:5640:4	O
of	ONFI.xml:S2:5645:2	O
varying	ONFI.xml:S2:5648:7	O
mechanisms	ONFI.xml:S2:5656:10	O
of	ONFI.xml:S2:5667:2	O
action	ONFI.xml:S2:5670:6	O
and	ONFI.xml:S2:5677:3	O
across	ONFI.xml:S2:5681:6	O
a	ONFI.xml:S2:5688:1	O
range	ONFI.xml:S2:5690:5	O
of	ONFI.xml:S2:5696:2	O
indications	ONFI.xml:S2:5699:11	O
suggests	ONFI.xml:S2:5711:8	O
that	ONFI.xml:S2:5720:4	O
the	ONFI.xml:S2:5725:3	O
risk	ONFI.xml:S2:5729:4	O
applies	ONFI.xml:S2:5734:7	O
to	ONFI.xml:S2:5742:2	O
all	ONFI.xml:S2:5745:3	O
AEDs	ONFI.xml:S2:5749:4	O
used	ONFI.xml:S2:5754:4	O
for	ONFI.xml:S2:5759:3	O
any	ONFI.xml:S2:5763:3	O
indication	ONFI.xml:S2:5767:10	O
.	ONFI.xml:S2:5777:1	O

The	ONFI.xml:S2:5779:3	O
risk	ONFI.xml:S2:5783:4	O
did	ONFI.xml:S2:5788:3	O
not	ONFI.xml:S2:5792:3	O
vary	ONFI.xml:S2:5796:4	O
substantially	ONFI.xml:S2:5801:13	O
by	ONFI.xml:S2:5815:2	O
age	ONFI.xml:S2:5818:3	O
(	ONFI.xml:S2:5822:1	O
5	ONFI.xml:S2:5823:1	O
-	ONFI.xml:S2:5824:1	O
100	ONFI.xml:S2:5825:3	O
years	ONFI.xml:S2:5829:5	O
)	ONFI.xml:S2:5834:1	O
in	ONFI.xml:S2:5836:2	O
the	ONFI.xml:S2:5839:3	O
clinical	ONFI.xml:S2:5843:8	O
trials	ONFI.xml:S2:5852:6	O
analyzed	ONFI.xml:S2:5859:8	O
.	ONFI.xml:S2:5867:1	O

Table	ONFI.xml:S2:5869:5	O
2	ONFI.xml:S2:5875:1	O
shows	ONFI.xml:S2:5877:5	O
absolute	ONFI.xml:S2:5883:8	O
and	ONFI.xml:S2:5892:3	O
relative	ONFI.xml:S2:5896:8	O
risk	ONFI.xml:S2:5905:4	O
by	ONFI.xml:S2:5910:2	O
indication	ONFI.xml:S2:5913:10	O
for	ONFI.xml:S2:5924:3	O
all	ONFI.xml:S2:5928:3	O
evaluated	ONFI.xml:S2:5932:9	O
AEDs	ONFI.xml:S2:5942:4	O
.	ONFI.xml:S2:5946:1	O

Table	ONFI.xml:S2:5952:5	O
2	ONFI.xml:S2:5958:1	O
.	ONFI.xml:S2:5959:1	O

Risk	ONFI.xml:S2:5961:4	O
by	ONFI.xml:S2:5966:2	O
Indication	ONFI.xml:S2:5969:10	O
for	ONFI.xml:S2:5980:3	O
Antiepileptic	ONFI.xml:S2:5984:13	O
Drugs	ONFI.xml:S2:5998:5	O
in	ONFI.xml:S2:6004:2	O
the	ONFI.xml:S2:6007:3	O
Pooled	ONFI.xml:S2:6011:6	O
Analysis	ONFI.xml:S2:6018:8	O

Indication	ONFI.xml:S2:6030:10	O
Placebo	ONFI.xml:S2:6049:7	O
Patients	ONFI.xml:S2:6057:8	O
with	ONFI.xml:S2:6066:4	O
Events	ONFI.xml:S2:6074:6	O
per	ONFI.xml:S2:6081:3	O
1000	ONFI.xml:S2:6085:4	O
Patients	ONFI.xml:S2:6090:8	O
Drug	ONFI.xml:S2:6105:4	O
Patients	ONFI.xml:S2:6110:8	O
with	ONFI.xml:S2:6119:4	O
Events	ONFI.xml:S2:6126:6	O
per	ONFI.xml:S2:6133:3	O
1000	ONFI.xml:S2:6137:4	O
Patients	ONFI.xml:S2:6142:8	O
Relative	ONFI.xml:S2:6159:8	O
Risk	ONFI.xml:S2:6168:4	O
:	ONFI.xml:S2:6172:1	O
Incidence	ONFI.xml:S2:6174:9	O
of	ONFI.xml:S2:6184:2	O
Drug	ONFI.xml:S2:6187:4	O
Events	ONFI.xml:S2:6193:6	O
in	ONFI.xml:S2:6200:2	O
Drug	ONFI.xml:S2:6203:4	O
Patients	ONFI.xml:S2:6208:8	O
Incidencein	ONFI.xml:S2:6217:11	O
Placebo	ONFI.xml:S2:6229:7	O
Patients	ONFI.xml:S2:6237:8	O
Risk	ONFI.xml:S2:6254:4	O
Difference	ONFI.xml:S2:6259:10	O
:	ONFI.xml:S2:6269:1	O
Additional	ONFI.xml:S2:6271:10	O
Drug	ONFI.xml:S2:6283:4	O
Patients	ONFI.xml:S2:6288:8	O
with	ONFI.xml:S2:6297:4	O
Events	ONFI.xml:S2:6302:6	O
per	ONFI.xml:S2:6309:3	O
1000	ONFI.xml:S2:6313:4	O
Patients	ONFI.xml:S2:6318:8	O

Epilepsy	ONFI.xml:S2:6338:8	O
1.0	ONFI.xml:S2:6352:3	O
3.4	ONFI.xml:S2:6369:3	O
3.5	ONFI.xml:S2:6386:3	O
2.4	ONFI.xml:S2:6403:3	O

Psychiatric	ONFI.xml:S2:6426:11	O
5.7	ONFI.xml:S2:6442:3	O
8.5	ONFI.xml:S2:6459:3	O
1.5	ONFI.xml:S2:6476:3	O
2.9	ONFI.xml:S2:6493:3	O

Other	ONFI.xml:S2:6516:5	O
1.0	ONFI.xml:S2:6530:3	O
1.8	ONFI.xml:S2:6547:3	O
1.9	ONFI.xml:S2:6564:3	O
0.9	ONFI.xml:S2:6581:3	O

Total	ONFI.xml:S2:6604:5	O
2.4	ONFI.xml:S2:6618:3	O
4.3	ONFI.xml:S2:6635:3	O
1.8	ONFI.xml:S2:6652:3	O
1.9	ONFI.xml:S2:6669:3	O

The	ONFI.xml:S2:6699:3	O
relative	ONFI.xml:S2:6703:8	O
risk	ONFI.xml:S2:6712:4	B-Factor
for	ONFI.xml:S2:6717:3	O
suicidal	ONFI.xml:S2:6721:8	B-AdverseReaction
thoughts	ONFI.xml:S2:6730:8	I-AdverseReaction
or	ONFI.xml:S2:6739:2	O
behavior	ONFI.xml:S2:6742:8	I-AdverseReaction
was	ONFI.xml:S2:6751:3	O
higher	ONFI.xml:S2:6755:6	O
in	ONFI.xml:S2:6762:2	O
clinical	ONFI.xml:S2:6765:8	O
trials	ONFI.xml:S2:6774:6	O
for	ONFI.xml:S2:6781:3	O
epilepsy	ONFI.xml:S2:6785:8	O
than	ONFI.xml:S2:6794:4	O
in	ONFI.xml:S2:6799:2	O
clinical	ONFI.xml:S2:6802:8	O
trials	ONFI.xml:S2:6811:6	O
for	ONFI.xml:S2:6818:3	O
psychiatric	ONFI.xml:S2:6822:11	O
or	ONFI.xml:S2:6834:2	O
other	ONFI.xml:S2:6837:5	O
conditions	ONFI.xml:S2:6843:10	O
,	ONFI.xml:S2:6853:1	O
but	ONFI.xml:S2:6855:3	O
the	ONFI.xml:S2:6859:3	O
absolute	ONFI.xml:S2:6863:8	O
risk	ONFI.xml:S2:6872:4	O
differences	ONFI.xml:S2:6877:11	O
were	ONFI.xml:S2:6889:4	O
similar	ONFI.xml:S2:6894:7	O
for	ONFI.xml:S2:6902:3	O
the	ONFI.xml:S2:6906:3	O
epilepsy	ONFI.xml:S2:6910:8	O
and	ONFI.xml:S2:6919:3	O
psychiatric	ONFI.xml:S2:6923:11	O
indications	ONFI.xml:S2:6935:11	O
.	ONFI.xml:S2:6946:1	O

Anyone	ONFI.xml:S2:6952:6	O

considering	ONFI.xml:S2:6959:11	O
prescribing	ONFI.xml:S2:6971:11	O
ONFI	ONFI.xml:S2:6983:4	O
or	ONFI.xml:S2:6988:2	O
any	ONFI.xml:S2:6991:3	O
other	ONFI.xml:S2:6995:5	O
AED	ONFI.xml:S2:7001:3	O
must	ONFI.xml:S2:7005:4	O
balance	ONFI.xml:S2:7010:7	O
the	ONFI.xml:S2:7018:3	O
risk	ONFI.xml:S2:7022:4	O
of	ONFI.xml:S2:7027:2	O
suicidal	ONFI.xml:S2:7030:8	O
thoughts	ONFI.xml:S2:7039:8	O
or	ONFI.xml:S2:7048:2	O
behavior	ONFI.xml:S2:7051:8	O
with	ONFI.xml:S2:7060:4	O
the	ONFI.xml:S2:7065:3	O
risk	ONFI.xml:S2:7069:4	O
of	ONFI.xml:S2:7074:2	O
untreated	ONFI.xml:S2:7077:9	O
illness	ONFI.xml:S2:7087:7	O
.	ONFI.xml:S2:7094:1	O

Epilepsy	ONFI.xml:S2:7096:8	O
and	ONFI.xml:S2:7105:3	O
many	ONFI.xml:S2:7109:4	O
other	ONFI.xml:S2:7114:5	O
illnesses	ONFI.xml:S2:7120:9	O
for	ONFI.xml:S2:7130:3	O
which	ONFI.xml:S2:7134:5	O
AEDs	ONFI.xml:S2:7140:4	O
are	ONFI.xml:S2:7145:3	O
prescribed	ONFI.xml:S2:7149:10	O
are	ONFI.xml:S2:7160:3	O
themselves	ONFI.xml:S2:7164:10	O
associated	ONFI.xml:S2:7175:10	O
with	ONFI.xml:S2:7186:4	O
morbidity	ONFI.xml:S2:7191:9	O
and	ONFI.xml:S2:7201:3	O
mortality	ONFI.xml:S2:7205:9	O
and	ONFI.xml:S2:7215:3	O
an	ONFI.xml:S2:7219:2	O
increased	ONFI.xml:S2:7222:9	O
risk	ONFI.xml:S2:7232:4	O
of	ONFI.xml:S2:7237:2	O
suicidal	ONFI.xml:S2:7240:8	O
thoughts	ONFI.xml:S2:7249:8	O
and	ONFI.xml:S2:7258:3	O
behavior	ONFI.xml:S2:7262:8	O
.	ONFI.xml:S2:7270:1	O

Should	ONFI.xml:S2:7272:6	O
suicidal	ONFI.xml:S2:7279:8	O
thoughts	ONFI.xml:S2:7288:8	O
and	ONFI.xml:S2:7297:3	O
behavior	ONFI.xml:S2:7301:8	O
emerge	ONFI.xml:S2:7310:6	O
during	ONFI.xml:S2:7317:6	O
treatment	ONFI.xml:S2:7324:9	O
,	ONFI.xml:S2:7333:1	O
the	ONFI.xml:S2:7335:3	O
prescriber	ONFI.xml:S2:7339:10	O
needs	ONFI.xml:S2:7350:5	O
to	ONFI.xml:S2:7356:2	O
consider	ONFI.xml:S2:7359:8	O
whether	ONFI.xml:S2:7368:7	O
the	ONFI.xml:S2:7376:3	O
emergence	ONFI.xml:S2:7380:9	O
of	ONFI.xml:S2:7390:2	O
these	ONFI.xml:S2:7393:5	O
symptoms	ONFI.xml:S2:7399:8	O
in	ONFI.xml:S2:7408:2	O
any	ONFI.xml:S2:7411:3	O
given	ONFI.xml:S2:7415:5	O
patient	ONFI.xml:S2:7421:7	O
may	ONFI.xml:S2:7429:3	O
be	ONFI.xml:S2:7433:2	O
related	ONFI.xml:S2:7436:7	O
to	ONFI.xml:S2:7444:2	O
the	ONFI.xml:S2:7447:3	O
illness	ONFI.xml:S2:7451:7	O
being	ONFI.xml:S2:7459:5	O
treated	ONFI.xml:S2:7465:7	O
.	ONFI.xml:S2:7472:1	O

Patients	ONFI.xml:S2:7478:8	O
,	ONFI.xml:S2:7486:1	O
their	ONFI.xml:S2:7488:5	O
caregivers	ONFI.xml:S2:7494:10	O
,	ONFI.xml:S2:7504:1	O
and	ONFI.xml:S2:7506:3	O
families	ONFI.xml:S2:7510:8	O
should	ONFI.xml:S2:7519:6	O
be	ONFI.xml:S2:7526:2	O
informed	ONFI.xml:S2:7529:8	O
that	ONFI.xml:S2:7538:4	O
AEDs	ONFI.xml:S2:7543:4	O
increase	ONFI.xml:S2:7548:8	O
the	ONFI.xml:S2:7557:3	O
risk	ONFI.xml:S2:7561:4	O
of	ONFI.xml:S2:7566:2	O
suicidal	ONFI.xml:S2:7569:8	O
thoughts	ONFI.xml:S2:7578:8	O
and	ONFI.xml:S2:7587:3	O
behavior	ONFI.xml:S2:7591:8	O
and	ONFI.xml:S2:7600:3	O
should	ONFI.xml:S2:7604:6	O
be	ONFI.xml:S2:7611:2	O
advised	ONFI.xml:S2:7614:7	O
of	ONFI.xml:S2:7622:2	O
the	ONFI.xml:S2:7625:3	O
need	ONFI.xml:S2:7629:4	O
to	ONFI.xml:S2:7634:2	O
be	ONFI.xml:S2:7637:2	O
alert	ONFI.xml:S2:7640:5	O
for	ONFI.xml:S2:7646:3	O
the	ONFI.xml:S2:7650:3	O
emergence	ONFI.xml:S2:7654:9	O
or	ONFI.xml:S2:7664:2	O
worsening	ONFI.xml:S2:7667:9	O
of	ONFI.xml:S2:7677:2	O
the	ONFI.xml:S2:7680:3	O
signs	ONFI.xml:S2:7684:5	O
and	ONFI.xml:S2:7690:3	O
symptoms	ONFI.xml:S2:7694:8	O
of	ONFI.xml:S2:7703:2	O
depression	ONFI.xml:S2:7706:10	O
,	ONFI.xml:S2:7716:1	O
any	ONFI.xml:S2:7718:3	O
unusual	ONFI.xml:S2:7722:7	O
changes	ONFI.xml:S2:7730:7	O
in	ONFI.xml:S2:7738:2	O
mood	ONFI.xml:S2:7741:4	O
or	ONFI.xml:S2:7746:2	O
behavior	ONFI.xml:S2:7749:8	O
,	ONFI.xml:S2:7757:1	O
or	ONFI.xml:S2:7759:2	O
the	ONFI.xml:S2:7762:3	O
emergence	ONFI.xml:S2:7766:9	O
of	ONFI.xml:S2:7776:2	O
suicidal	ONFI.xml:S2:7779:8	O
thoughts	ONFI.xml:S2:7788:8	O
,	ONFI.xml:S2:7796:1	O
behavior	ONFI.xml:S2:7798:8	O
,	ONFI.xml:S2:7806:1	O
or	ONFI.xml:S2:7808:2	O
thoughts	ONFI.xml:S2:7811:8	O
about	ONFI.xml:S2:7820:5	O
self	ONFI.xml:S2:7826:4	O
-	ONFI.xml:S2:7830:1	O
harm	ONFI.xml:S2:7831:4	O
.	ONFI.xml:S2:7835:1	O

Behaviors	ONFI.xml:S2:7837:9	O
of	ONFI.xml:S2:7847:2	O
concern	ONFI.xml:S2:7850:7	O
should	ONFI.xml:S2:7858:6	O
be	ONFI.xml:S2:7865:2	O
reported	ONFI.xml:S2:7868:8	O
immediately	ONFI.xml:S2:7877:11	O
to	ONFI.xml:S2:7889:2	O
healthcare	ONFI.xml:S2:7892:10	O
providers	ONFI.xml:S2:7903:9	O
.	ONFI.xml:S2:7912:1	O
6	OTEZLA.xml:S1:4:1	O
ADVERSE	OTEZLA.xml:S1:6:7	O
REACTIONS	OTEZLA.xml:S1:14:9	O

EXCERPT	OTEZLA.xml:S1:28:7	O
:	OTEZLA.xml:S1:35:1	O
Psoriatic	OTEZLA.xml:S1:44:9	O
Arthritis	OTEZLA.xml:S1:54:9	O
:	OTEZLA.xml:S1:64:1	O
The	OTEZLA.xml:S1:66:3	O
most	OTEZLA.xml:S1:70:4	O
common	OTEZLA.xml:S1:75:6	O
adverse	OTEZLA.xml:S1:82:7	O
reactions	OTEZLA.xml:S1:90:9	O
(	OTEZLA.xml:S1:100:1	O
5%	OTEZLA.xml:S1:103:2	O
)	OTEZLA.xml:S1:105:1	O
are	OTEZLA.xml:S1:107:3	O
diarrhea	OTEZLA.xml:S1:111:8	B-AdverseReaction
,	OTEZLA.xml:S1:119:1	O
nausea	OTEZLA.xml:S1:121:6	B-AdverseReaction
,	OTEZLA.xml:S1:127:1	O
and	OTEZLA.xml:S1:129:3	O
headache	OTEZLA.xml:S1:133:8	B-AdverseReaction
(	OTEZLA.xml:S1:142:1	O
6.1	OTEZLA.xml:S1:143:3	O
)	OTEZLA.xml:S1:146:1	O

Psoriasis	OTEZLA.xml:S1:154:9	O
:	OTEZLA.xml:S1:164:1	O
The	OTEZLA.xml:S1:166:3	O
most	OTEZLA.xml:S1:170:4	O
common	OTEZLA.xml:S1:175:6	O
adverse	OTEZLA.xml:S1:182:7	O
reactions	OTEZLA.xml:S1:190:9	O
(	OTEZLA.xml:S1:200:1	O
5%	OTEZLA.xml:S1:203:2	O
)	OTEZLA.xml:S1:205:1	O
are	OTEZLA.xml:S1:207:3	O
diarrhea	OTEZLA.xml:S1:211:8	B-AdverseReaction
,	OTEZLA.xml:S1:219:1	O
nausea	OTEZLA.xml:S1:221:6	B-AdverseReaction
,	OTEZLA.xml:S1:227:1	O
upper	OTEZLA.xml:S1:229:5	B-AdverseReaction
respiratory	OTEZLA.xml:S1:235:11	I-AdverseReaction
tract	OTEZLA.xml:S1:247:5	I-AdverseReaction
infection	OTEZLA.xml:S1:253:9	I-AdverseReaction
,	OTEZLA.xml:S1:262:1	O
and	OTEZLA.xml:S1:264:3	O
headache	OTEZLA.xml:S1:268:8	B-AdverseReaction
,	OTEZLA.xml:S1:276:1	O
including	OTEZLA.xml:S1:278:9	O
tension	OTEZLA.xml:S1:288:7	B-AdverseReaction
headache	OTEZLA.xml:S1:296:8	I-AdverseReaction
(	OTEZLA.xml:S1:305:1	O
6.1	OTEZLA.xml:S1:306:3	O
)	OTEZLA.xml:S1:309:1	O

To	OTEZLA.xml:S1:316:2	O
report	OTEZLA.xml:S1:319:6	O
SUSPECTED	OTEZLA.xml:S1:326:9	O
ADVERSE	OTEZLA.xml:S1:336:7	O
REACTIONS	OTEZLA.xml:S1:344:9	O
,	OTEZLA.xml:S1:353:1	O
contact	OTEZLA.xml:S1:355:7	O
Celgene	OTEZLA.xml:S1:363:7	O
Corporation	OTEZLA.xml:S1:371:11	O
at	OTEZLA.xml:S1:383:2	O
1	OTEZLA.xml:S1:386:1	O
-	OTEZLA.xml:S1:387:1	O
888	OTEZLA.xml:S1:388:3	O
-	OTEZLA.xml:S1:391:1	O
423	OTEZLA.xml:S1:392:3	O
-	OTEZLA.xml:S1:395:1	O
5436	OTEZLA.xml:S1:396:4	O
or	OTEZLA.xml:S1:401:2	O
FDA	OTEZLA.xml:S1:404:3	O
at	OTEZLA.xml:S1:408:2	O
1	OTEZLA.xml:S1:411:1	O
-	OTEZLA.xml:S1:412:1	O
800	OTEZLA.xml:S1:413:3	O
-	OTEZLA.xml:S1:416:1	O
FDA	OTEZLA.xml:S1:417:3	O
-	OTEZLA.xml:S1:420:1	O
1088	OTEZLA.xml:S1:421:4	O
or	OTEZLA.xml:S1:426:2	O
www	OTEZLA.xml:S1:429:3	O
.	OTEZLA.xml:S1:432:1	O
fda	OTEZLA.xml:S1:433:3	O
.	OTEZLA.xml:S1:436:1	O
gov	OTEZLA.xml:S1:437:3	O
medwatch	OTEZLA.xml:S1:441:8	O

6.1	OTEZLA.xml:S1:458:3	O

Clinical	OTEZLA.xml:S1:462:8	O

Trials	OTEZLA.xml:S1:471:6	O
Experience	OTEZLA.xml:S1:478:10	O

Because	OTEZLA.xml:S1:492:7	O
clinical	OTEZLA.xml:S1:500:8	O
trials	OTEZLA.xml:S1:509:6	O
are	OTEZLA.xml:S1:516:3	O
conducted	OTEZLA.xml:S1:520:9	O
under	OTEZLA.xml:S1:530:5	O
widely	OTEZLA.xml:S1:536:6	O
varying	OTEZLA.xml:S1:543:7	O
conditions	OTEZLA.xml:S1:551:10	O
,	OTEZLA.xml:S1:561:1	O
adverse	OTEZLA.xml:S1:563:7	O
reaction	OTEZLA.xml:S1:571:8	O
rates	OTEZLA.xml:S1:580:5	O
observed	OTEZLA.xml:S1:586:8	O
in	OTEZLA.xml:S1:595:2	O
the	OTEZLA.xml:S1:598:3	O
clinical	OTEZLA.xml:S1:602:8	O
trial	OTEZLA.xml:S1:611:5	O
of	OTEZLA.xml:S1:617:2	O
a	OTEZLA.xml:S1:620:1	O
drug	OTEZLA.xml:S1:622:4	O
cannot	OTEZLA.xml:S1:627:6	O
be	OTEZLA.xml:S1:634:2	O
directly	OTEZLA.xml:S1:637:8	O
compared	OTEZLA.xml:S1:646:8	O
to	OTEZLA.xml:S1:655:2	O
rates	OTEZLA.xml:S1:658:5	O
in	OTEZLA.xml:S1:664:2	O
the	OTEZLA.xml:S1:667:3	O
clinical	OTEZLA.xml:S1:671:8	O
trials	OTEZLA.xml:S1:680:6	O
of	OTEZLA.xml:S1:687:2	O
another	OTEZLA.xml:S1:690:7	O
drug	OTEZLA.xml:S1:698:4	O
and	OTEZLA.xml:S1:703:3	O
may	OTEZLA.xml:S1:707:3	O
not	OTEZLA.xml:S1:711:3	O
reflect	OTEZLA.xml:S1:715:7	O
the	OTEZLA.xml:S1:723:3	O
rates	OTEZLA.xml:S1:727:5	O
observed	OTEZLA.xml:S1:733:8	O
in	OTEZLA.xml:S1:742:2	O
clinical	OTEZLA.xml:S1:745:8	O
practice	OTEZLA.xml:S1:754:8	O
.	OTEZLA.xml:S1:762:1	O

Psoriatic	OTEZLA.xml:S1:770:9	O
Arthritis	OTEZLA.xml:S1:780:9	O
Clinical	OTEZLA.xml:S1:790:8	O
Trials	OTEZLA.xml:S1:799:6	O
OTEZLA	OTEZLA.xml:S1:807:6	O
was	OTEZLA.xml:S1:814:3	O
evaluated	OTEZLA.xml:S1:818:9	O
in	OTEZLA.xml:S1:828:2	O
3	OTEZLA.xml:S1:831:1	O
multicenter	OTEZLA.xml:S1:833:11	O
,	OTEZLA.xml:S1:844:1	O
randomized	OTEZLA.xml:S1:846:10	O
,	OTEZLA.xml:S1:856:1	O
double	OTEZLA.xml:S1:858:6	O
-	OTEZLA.xml:S1:864:1	O
blind	OTEZLA.xml:S1:865:5	O
,	OTEZLA.xml:S1:870:1	O
placebo	OTEZLA.xml:S1:872:7	O
-	OTEZLA.xml:S1:879:1	O
controlled	OTEZLA.xml:S1:880:10	O
trials	OTEZLA.xml:S1:891:6	O
[	OTEZLA.xml:S1:898:1	O
Studies	OTEZLA.xml:S1:899:7	O
PsA	OTEZLA.xml:S1:907:3	O
-	OTEZLA.xml:S1:910:1	O
1	OTEZLA.xml:S1:911:1	O
,	OTEZLA.xml:S1:912:1	O
PsA	OTEZLA.xml:S1:914:3	O
-	OTEZLA.xml:S1:917:1	O
2	OTEZLA.xml:S1:918:1	O
,	OTEZLA.xml:S1:919:1	O
and	OTEZLA.xml:S1:921:3	O
PsA	OTEZLA.xml:S1:925:3	O
-	OTEZLA.xml:S1:928:1	O
3	OTEZLA.xml:S1:929:1	O
]	OTEZLA.xml:S1:930:1	O
of	OTEZLA.xml:S1:932:2	O
similar	OTEZLA.xml:S1:935:7	O
design	OTEZLA.xml:S1:943:6	O
in	OTEZLA.xml:S1:950:2	O
adult	OTEZLA.xml:S1:953:5	O
patients	OTEZLA.xml:S1:959:8	O
with	OTEZLA.xml:S1:968:4	O
active	OTEZLA.xml:S1:973:6	O
psoriatic	OTEZLA.xml:S1:980:9	O
arthritis	OTEZLA.xml:S1:990:9	O
[	OTEZLA.xml:S1:1001:1	O
see	OTEZLA.xml:S1:1002:3	O
Clinical	OTEZLA.xml:S1:1006:8	O
Studies	OTEZLA.xml:S1:1015:7	O
(	OTEZLA.xml:S1:1023:1	O
14.1	OTEZLA.xml:S1:1024:4	O
)]	OTEZLA.xml:S1:1028:2	O
.	OTEZLA.xml:S1:1032:1	O

Across	OTEZLA.xml:S1:1034:6	O
the	OTEZLA.xml:S1:1041:3	O
3	OTEZLA.xml:S1:1045:1	O
studies	OTEZLA.xml:S1:1047:7	O
,	OTEZLA.xml:S1:1054:1	O
there	OTEZLA.xml:S1:1056:5	O
were	OTEZLA.xml:S1:1062:4	O
1493	OTEZLA.xml:S1:1067:4	O
patients	OTEZLA.xml:S1:1072:8	O
randomized	OTEZLA.xml:S1:1081:10	O
equally	OTEZLA.xml:S1:1092:7	O
to	OTEZLA.xml:S1:1100:2	O
placebo	OTEZLA.xml:S1:1103:7	O
,	OTEZLA.xml:S1:1110:1	O
OTEZLA	OTEZLA.xml:S1:1112:6	O
20	OTEZLA.xml:S1:1119:2	O
mg	OTEZLA.xml:S1:1122:2	O
twice	OTEZLA.xml:S1:1125:5	O
daily	OTEZLA.xml:S1:1131:5	O
or	OTEZLA.xml:S1:1137:2	O
OTEZLA	OTEZLA.xml:S1:1140:6	O
30	OTEZLA.xml:S1:1147:2	O
mg	OTEZLA.xml:S1:1150:2	O
twice	OTEZLA.xml:S1:1153:5	O
daily	OTEZLA.xml:S1:1159:5	O
.	OTEZLA.xml:S1:1164:1	O

Titration	OTEZLA.xml:S1:1166:9	O
was	OTEZLA.xml:S1:1176:3	O
used	OTEZLA.xml:S1:1180:4	O
over	OTEZLA.xml:S1:1185:4	O
the	OTEZLA.xml:S1:1190:3	O
first	OTEZLA.xml:S1:1194:5	O
5	OTEZLA.xml:S1:1200:1	O
days	OTEZLA.xml:S1:1202:4	O
[	OTEZLA.xml:S1:1208:1	O
see	OTEZLA.xml:S1:1209:3	O
Dosage	OTEZLA.xml:S1:1213:6	O
and	OTEZLA.xml:S1:1220:3	O
Administration	OTEZLA.xml:S1:1224:14	O
(	OTEZLA.xml:S1:1239:1	O
2.1	OTEZLA.xml:S1:1240:3	O
)	OTEZLA.xml:S1:1243:1	O
]	OTEZLA.xml:S1:1246:1	O
.	OTEZLA.xml:S1:1247:1	O

Placebo	OTEZLA.xml:S1:1249:7	O
patients	OTEZLA.xml:S1:1257:8	O
whose	OTEZLA.xml:S1:1266:5	O
tender	OTEZLA.xml:S1:1272:6	O
and	OTEZLA.xml:S1:1279:3	O
swollen	OTEZLA.xml:S1:1283:7	O
joint	OTEZLA.xml:S1:1291:5	O
counts	OTEZLA.xml:S1:1297:6	O
had	OTEZLA.xml:S1:1304:3	O
not	OTEZLA.xml:S1:1308:3	O
improved	OTEZLA.xml:S1:1312:8	O
by	OTEZLA.xml:S1:1321:2	O
at	OTEZLA.xml:S1:1324:2	O
least	OTEZLA.xml:S1:1327:5	O
20%	OTEZLA.xml:S1:1333:3	O
were	OTEZLA.xml:S1:1337:4	O
re	OTEZLA.xml:S1:1342:2	O
-	OTEZLA.xml:S1:1344:1	O
randomized	OTEZLA.xml:S1:1345:10	O
1	OTEZLA.xml:S1:1356:1	O
:	OTEZLA.xml:S1:1357:1	O
1	OTEZLA.xml:S1:1358:1	O
in	OTEZLA.xml:S1:1360:2	O
a	OTEZLA.xml:S1:1363:1	O
blinded	OTEZLA.xml:S1:1365:7	O
fashion	OTEZLA.xml:S1:1373:7	O
to	OTEZLA.xml:S1:1381:2	O
either	OTEZLA.xml:S1:1384:6	O
OTEZLA	OTEZLA.xml:S1:1391:6	O
20	OTEZLA.xml:S1:1398:2	O
mg	OTEZLA.xml:S1:1401:2	O
twice	OTEZLA.xml:S1:1404:5	O
daily	OTEZLA.xml:S1:1410:5	O
or	OTEZLA.xml:S1:1416:2	O
30	OTEZLA.xml:S1:1419:2	O
mg	OTEZLA.xml:S1:1422:2	O
twice	OTEZLA.xml:S1:1425:5	O
daily	OTEZLA.xml:S1:1431:5	O
at	OTEZLA.xml:S1:1437:2	O
week	OTEZLA.xml:S1:1440:4	O
16	OTEZLA.xml:S1:1445:2	O
while	OTEZLA.xml:S1:1448:5	O
OTEZLA	OTEZLA.xml:S1:1454:6	O
patients	OTEZLA.xml:S1:1461:8	O
remained	OTEZLA.xml:S1:1470:8	O
on	OTEZLA.xml:S1:1479:2	O
their	OTEZLA.xml:S1:1482:5	O
initial	OTEZLA.xml:S1:1488:7	O
treatment	OTEZLA.xml:S1:1496:9	O
.	OTEZLA.xml:S1:1505:1	O

Patients	OTEZLA.xml:S1:1507:8	O
ranged	OTEZLA.xml:S1:1516:6	O
in	OTEZLA.xml:S1:1523:2	O
age	OTEZLA.xml:S1:1526:3	O
from	OTEZLA.xml:S1:1530:4	O
18	OTEZLA.xml:S1:1535:2	O
to	OTEZLA.xml:S1:1538:2	O
83	OTEZLA.xml:S1:1541:2	O
years	OTEZLA.xml:S1:1544:5	O
,	OTEZLA.xml:S1:1549:1	O
with	OTEZLA.xml:S1:1551:4	O
an	OTEZLA.xml:S1:1556:2	O
overall	OTEZLA.xml:S1:1559:7	O
median	OTEZLA.xml:S1:1567:6	O
age	OTEZLA.xml:S1:1574:3	O
of	OTEZLA.xml:S1:1578:2	O
51	OTEZLA.xml:S1:1581:2	O
years	OTEZLA.xml:S1:1584:5	O
.	OTEZLA.xml:S1:1589:1	O

The	OTEZLA.xml:S1:1595:3	O
majority	OTEZLA.xml:S1:1599:8	O
of	OTEZLA.xml:S1:1608:2	O
the	OTEZLA.xml:S1:1611:3	O
most	OTEZLA.xml:S1:1615:4	O
common	OTEZLA.xml:S1:1620:6	O
adverse	OTEZLA.xml:S1:1627:7	O
reactions	OTEZLA.xml:S1:1635:9	O
presented	OTEZLA.xml:S1:1645:9	O
inTable	OTEZLA.xml:S1:1655:7	O
2	OTEZLA.xml:S1:1663:1	O
occurred	OTEZLA.xml:S1:1664:8	O
within	OTEZLA.xml:S1:1673:6	O
the	OTEZLA.xml:S1:1680:3	O
first	OTEZLA.xml:S1:1684:5	O
2	OTEZLA.xml:S1:1690:1	O
weeks	OTEZLA.xml:S1:1692:5	O
of	OTEZLA.xml:S1:1698:2	O
treatment	OTEZLA.xml:S1:1701:9	O
and	OTEZLA.xml:S1:1711:3	O
tended	OTEZLA.xml:S1:1715:6	O
to	OTEZLA.xml:S1:1722:2	O
resolve	OTEZLA.xml:S1:1725:7	O
over	OTEZLA.xml:S1:1733:4	O
time	OTEZLA.xml:S1:1738:4	O
with	OTEZLA.xml:S1:1743:4	O
continued	OTEZLA.xml:S1:1748:9	O
dosing	OTEZLA.xml:S1:1758:6	O
.	OTEZLA.xml:S1:1764:1	O

Diarrhea	OTEZLA.xml:S1:1766:8	B-AdverseReaction
,	OTEZLA.xml:S1:1774:1	O
headache	OTEZLA.xml:S1:1776:8	B-AdverseReaction
,	OTEZLA.xml:S1:1784:1	O
and	OTEZLA.xml:S1:1786:3	O
nausea	OTEZLA.xml:S1:1790:6	B-AdverseReaction
were	OTEZLA.xml:S1:1797:4	O
the	OTEZLA.xml:S1:1802:3	O
most	OTEZLA.xml:S1:1806:4	O
commonly	OTEZLA.xml:S1:1811:8	O
reported	OTEZLA.xml:S1:1820:8	O
adverse	OTEZLA.xml:S1:1829:7	O
reactions	OTEZLA.xml:S1:1837:9	O
.	OTEZLA.xml:S1:1846:1	O

The	OTEZLA.xml:S1:1848:3	O
most	OTEZLA.xml:S1:1852:4	O
common	OTEZLA.xml:S1:1857:6	O
adverse	OTEZLA.xml:S1:1864:7	O
reactions	OTEZLA.xml:S1:1872:9	O
leading	OTEZLA.xml:S1:1882:7	O
to	OTEZLA.xml:S1:1890:2	O
discontinuation	OTEZLA.xml:S1:1893:15	O
for	OTEZLA.xml:S1:1909:3	O
patients	OTEZLA.xml:S1:1913:8	O
taking	OTEZLA.xml:S1:1922:6	O
OTEZLA	OTEZLA.xml:S1:1929:6	O
were	OTEZLA.xml:S1:1936:4	O
nausea	OTEZLA.xml:S1:1941:6	B-AdverseReaction
(	OTEZLA.xml:S1:1948:1	O
1.8%	OTEZLA.xml:S1:1949:4	O
)	OTEZLA.xml:S1:1953:1	O
,	OTEZLA.xml:S1:1954:1	O
diarrhea	OTEZLA.xml:S1:1956:8	B-AdverseReaction
(	OTEZLA.xml:S1:1965:1	O
1.8%	OTEZLA.xml:S1:1966:4	O
)	OTEZLA.xml:S1:1970:1	O
,	OTEZLA.xml:S1:1971:1	O
and	OTEZLA.xml:S1:1973:3	O
headache	OTEZLA.xml:S1:1977:8	B-AdverseReaction
(	OTEZLA.xml:S1:1986:1	O
1.2%	OTEZLA.xml:S1:1987:4	O
)	OTEZLA.xml:S1:1991:1	O
.	OTEZLA.xml:S1:1992:1	O

The	OTEZLA.xml:S1:1994:3	O
proportion	OTEZLA.xml:S1:1998:10	O
of	OTEZLA.xml:S1:2009:2	O
patients	OTEZLA.xml:S1:2012:8	O
with	OTEZLA.xml:S1:2021:4	O
psoriatic	OTEZLA.xml:S1:2026:9	O
arthritis	OTEZLA.xml:S1:2036:9	O
who	OTEZLA.xml:S1:2046:3	O
discontinued	OTEZLA.xml:S1:2050:12	O
treatment	OTEZLA.xml:S1:2063:9	O
due	OTEZLA.xml:S1:2073:3	O
to	OTEZLA.xml:S1:2077:2	O
any	OTEZLA.xml:S1:2080:3	O
adverse	OTEZLA.xml:S1:2084:7	O
reaction	OTEZLA.xml:S1:2092:8	O
was	OTEZLA.xml:S1:2101:3	O
4.6%	OTEZLA.xml:S1:2105:4	O
for	OTEZLA.xml:S1:2110:3	O
patients	OTEZLA.xml:S1:2114:8	O
taking	OTEZLA.xml:S1:2123:6	O
OTEZLA	OTEZLA.xml:S1:2130:6	O
30	OTEZLA.xml:S1:2137:2	O
mg	OTEZLA.xml:S1:2140:2	O
twice	OTEZLA.xml:S1:2143:5	O
daily	OTEZLA.xml:S1:2149:5	O
and	OTEZLA.xml:S1:2155:3	O
1.2%	OTEZLA.xml:S1:2159:4	O
for	OTEZLA.xml:S1:2164:3	O
placebo	OTEZLA.xml:S1:2168:7	O
-	OTEZLA.xml:S1:2175:1	O
treated	OTEZLA.xml:S1:2176:7	O
patients	OTEZLA.xml:S1:2184:8	O
.	OTEZLA.xml:S1:2192:1	O

Table	OTEZLA.xml:S1:2198:5	O
2	OTEZLA.xml:S1:2204:1	O
:	OTEZLA.xml:S1:2205:1	O
Adverse	OTEZLA.xml:S1:2207:7	O
Reactions	OTEZLA.xml:S1:2215:9	O
Reported	OTEZLA.xml:S1:2225:8	O
in	OTEZLA.xml:S1:2234:2	O
2%	OTEZLA.xml:S1:2239:2	O
of	OTEZLA.xml:S1:2242:2	O
Patients	OTEZLA.xml:S1:2245:8	O
on	OTEZLA.xml:S1:2254:2	O
OTEZLA	OTEZLA.xml:S1:2257:6	O
30	OTEZLA.xml:S1:2264:2	O
mg	OTEZLA.xml:S1:2267:2	O
Twice	OTEZLA.xml:S1:2270:5	O
Daily	OTEZLA.xml:S1:2276:5	O
and	OTEZLA.xml:S1:2282:3	O
1%	OTEZLA.xml:S1:2288:2	O
Than	OTEZLA.xml:S1:2291:4	O
That	OTEZLA.xml:S1:2296:4	O
Observed	OTEZLA.xml:S1:2301:8	O
in	OTEZLA.xml:S1:2310:2	O
Patients	OTEZLA.xml:S1:2313:8	O
on	OTEZLA.xml:S1:2322:2	O
Placebo	OTEZLA.xml:S1:2325:7	O
for	OTEZLA.xml:S1:2333:3	O
up	OTEZLA.xml:S1:2337:2	O
to	OTEZLA.xml:S1:2340:2	O
Day	OTEZLA.xml:S1:2343:3	O
112	OTEZLA.xml:S1:2347:3	O
(	OTEZLA.xml:S1:2351:1	O
Week	OTEZLA.xml:S1:2352:4	O
16	OTEZLA.xml:S1:2357:2	O
)	OTEZLA.xml:S1:2359:1	O

a	OTEZLA.xml:S1:2365:1	O
Of	OTEZLA.xml:S1:2368:2	O
the	OTEZLA.xml:S1:2371:3	O
reported	OTEZLA.xml:S1:2375:8	O
gastrointestinal	OTEZLA.xml:S1:2384:16	B-AdverseReaction
adverse	OTEZLA.xml:S1:2401:7	I-AdverseReaction
reactions	OTEZLA.xml:S1:2409:9	I-AdverseReaction
,	OTEZLA.xml:S1:2418:1	O
1	OTEZLA.xml:S1:2420:1	O
subject	OTEZLA.xml:S1:2422:7	O
experienced	OTEZLA.xml:S1:2430:11	O
a	OTEZLA.xml:S1:2442:1	O
serious	OTEZLA.xml:S1:2444:7	B-Severity
adverse	OTEZLA.xml:S1:2452:7	O
reaction	OTEZLA.xml:S1:2460:8	O
of	OTEZLA.xml:S1:2469:2	O
nausea	OTEZLA.xml:S1:2472:6	B-AdverseReaction
and	OTEZLA.xml:S1:2479:3	O
vomiting	OTEZLA.xml:S1:2483:8	B-AdverseReaction
in	OTEZLA.xml:S1:2492:2	O
OTEZLA	OTEZLA.xml:S1:2495:6	O
30	OTEZLA.xml:S1:2502:2	O
mg	OTEZLA.xml:S1:2505:2	O
twice	OTEZLA.xml:S1:2508:5	O
daily	OTEZLA.xml:S1:2514:5	O
;	OTEZLA.xml:S1:2519:1	O
1	OTEZLA.xml:S1:2521:1	O
subject	OTEZLA.xml:S1:2523:7	O
treated	OTEZLA.xml:S1:2531:7	O
with	OTEZLA.xml:S1:2539:4	O
OTEZLA	OTEZLA.xml:S1:2544:6	O
20	OTEZLA.xml:S1:2551:2	O
mg	OTEZLA.xml:S1:2554:2	O
twice	OTEZLA.xml:S1:2557:5	O
daily	OTEZLA.xml:S1:2563:5	O
experienced	OTEZLA.xml:S1:2569:11	O
a	OTEZLA.xml:S1:2581:1	O
serious	OTEZLA.xml:S1:2583:7	B-Severity
adverse	OTEZLA.xml:S1:2591:7	O
reaction	OTEZLA.xml:S1:2599:8	O
of	OTEZLA.xml:S1:2608:2	O
diarrhea	OTEZLA.xml:S1:2611:8	B-AdverseReaction
;	OTEZLA.xml:S1:2619:1	O
1	OTEZLA.xml:S1:2621:1	O
patient	OTEZLA.xml:S1:2623:7	O
treated	OTEZLA.xml:S1:2631:7	O
with	OTEZLA.xml:S1:2639:4	O
OTEZLA	OTEZLA.xml:S1:2644:6	O
30	OTEZLA.xml:S1:2651:2	O
mg	OTEZLA.xml:S1:2654:2	O
twice	OTEZLA.xml:S1:2657:5	O
daily	OTEZLA.xml:S1:2663:5	O
experienced	OTEZLA.xml:S1:2669:11	O
a	OTEZLA.xml:S1:2681:1	O
serious	OTEZLA.xml:S1:2683:7	B-Severity
adverse	OTEZLA.xml:S1:2691:7	O
reaction	OTEZLA.xml:S1:2699:8	O
of	OTEZLA.xml:S1:2708:2	O
headache	OTEZLA.xml:S1:2711:8	B-AdverseReaction
.	OTEZLA.xml:S1:2719:1	O

b	OTEZLA.xml:S1:2727:1	O
Of	OTEZLA.xml:S1:2730:2	O
the	OTEZLA.xml:S1:2733:3	O
reported	OTEZLA.xml:S1:2737:8	O
adverse	OTEZLA.xml:S1:2746:7	O
drug	OTEZLA.xml:S1:2754:4	O
reactions	OTEZLA.xml:S1:2759:9	O
none	OTEZLA.xml:S1:2769:4	O
were	OTEZLA.xml:S1:2774:4	O
serious	OTEZLA.xml:S1:2779:7	O
.	OTEZLA.xml:S1:2786:1	O

c	OTEZLA.xml:S1:2794:1	O
n	OTEZLA.xml:S1:2797:1	O
(	OTEZLA.xml:S1:2799:1	O
)	OTEZLA.xml:S1:2801:1	O
indicates	OTEZLA.xml:S1:2803:9	O
number	OTEZLA.xml:S1:2813:6	O
of	OTEZLA.xml:S1:2820:2	O
patients	OTEZLA.xml:S1:2823:8	O
and	OTEZLA.xml:S1:2832:3	O
percent	OTEZLA.xml:S1:2836:7	O
.	OTEZLA.xml:S1:2843:1	O

Placebo	OTEZLA.xml:S1:2879:7	O

OTEZLA	OTEZLA.xml:S1:2906:6	O
30	OTEZLA.xml:S1:2913:2	O
mg	OTEZLA.xml:S1:2916:2	O
BID	OTEZLA.xml:S1:2919:3	O

Preferred	OTEZLA.xml:S1:2936:9	O
Term	OTEZLA.xml:S1:2946:4	O
Day	OTEZLA.xml:S1:2963:3	O
1	OTEZLA.xml:S1:2967:1	O
to	OTEZLA.xml:S1:2969:2	O
5	OTEZLA.xml:S1:2972:1	O
(	OTEZLA.xml:S1:2973:1	O
N	OTEZLA.xml:S1:2974:1	O
495	OTEZLA.xml:S1:2976:3	O
)	OTEZLA.xml:S1:2979:1	O
n	OTEZLA.xml:S1:2980:1	O
(	OTEZLA.xml:S1:2982:1	O
)	OTEZLA.xml:S1:2984:1	O
c	OTEZLA.xml:S1:2987:1	O
Day	OTEZLA.xml:S1:2992:3	O
6	OTEZLA.xml:S1:2996:1	O
to	OTEZLA.xml:S1:2998:2	O
Day	OTEZLA.xml:S1:3001:3	O
112	OTEZLA.xml:S1:3005:3	O
(	OTEZLA.xml:S1:3008:1	O
N	OTEZLA.xml:S1:3009:1	O
490	OTEZLA.xml:S1:3011:3	O
)	OTEZLA.xml:S1:3014:1	O
n	OTEZLA.xml:S1:3015:1	O
(	OTEZLA.xml:S1:3017:1	O
)	OTEZLA.xml:S1:3019:1	O
Day	OTEZLA.xml:S1:3022:3	O
1	OTEZLA.xml:S1:3026:1	O
to	OTEZLA.xml:S1:3028:2	O
5	OTEZLA.xml:S1:3031:1	O
(	OTEZLA.xml:S1:3032:1	O
N	OTEZLA.xml:S1:3033:1	O
497	OTEZLA.xml:S1:3035:3	O
)	OTEZLA.xml:S1:3038:1	O
n	OTEZLA.xml:S1:3039:1	O
(	OTEZLA.xml:S1:3041:1	O
)	OTEZLA.xml:S1:3043:1	O
Day	OTEZLA.xml:S1:3049:3	O
6	OTEZLA.xml:S1:3053:1	O
to	OTEZLA.xml:S1:3055:2	O
Day	OTEZLA.xml:S1:3058:3	O
112	OTEZLA.xml:S1:3062:3	O
(	OTEZLA.xml:S1:3065:1	O
N	OTEZLA.xml:S1:3066:1	O
493	OTEZLA.xml:S1:3068:3	O
)	OTEZLA.xml:S1:3071:1	O
n	OTEZLA.xml:S1:3072:1	O
(	OTEZLA.xml:S1:3074:1	O
)	OTEZLA.xml:S1:3076:1	O

Diarrhea	OTEZLA.xml:S1:3082:8	B-AdverseReaction
a	OTEZLA.xml:S1:3092:1	O
6	OTEZLA.xml:S1:3109:1	O
(	OTEZLA.xml:S1:3111:1	O
1.2	OTEZLA.xml:S1:3113:3	O
)	OTEZLA.xml:S1:3116:1	O
8	OTEZLA.xml:S1:3136:1	O
(	OTEZLA.xml:S1:3138:1	O
1.6	OTEZLA.xml:S1:3140:3	O
)	OTEZLA.xml:S1:3143:1	O
46	OTEZLA.xml:S1:3163:2	O
(	OTEZLA.xml:S1:3166:1	O
9.3	OTEZLA.xml:S1:3168:3	O
)	OTEZLA.xml:S1:3171:1	O
38	OTEZLA.xml:S1:3190:2	O
(	OTEZLA.xml:S1:3193:1	O
7.7	OTEZLA.xml:S1:3195:3	O
)	OTEZLA.xml:S1:3198:1	O

Nausea	OTEZLA.xml:S1:3220:6	B-AdverseReaction
a	OTEZLA.xml:S1:3228:1	O
7	OTEZLA.xml:S1:3247:1	O
(	OTEZLA.xml:S1:3249:1	O
1.4	OTEZLA.xml:S1:3251:3	O
)	OTEZLA.xml:S1:3254:1	O
15	OTEZLA.xml:S1:3274:2	O
(	OTEZLA.xml:S1:3277:1	O
3.1	OTEZLA.xml:S1:3279:3	O
)	OTEZLA.xml:S1:3282:1	O
37	OTEZLA.xml:S1:3301:2	O
(	OTEZLA.xml:S1:3304:1	O
7.4	OTEZLA.xml:S1:3306:3	O
)	OTEZLA.xml:S1:3309:1	O
44	OTEZLA.xml:S1:3328:2	O
(	OTEZLA.xml:S1:3331:1	O
8.9	OTEZLA.xml:S1:3333:3	O
)	OTEZLA.xml:S1:3336:1	O

Headache	OTEZLA.xml:S1:3358:8	B-AdverseReaction
a	OTEZLA.xml:S1:3368:1	O
9	OTEZLA.xml:S1:3385:1	O
(	OTEZLA.xml:S1:3387:1	O
1.8	OTEZLA.xml:S1:3389:3	O
)	OTEZLA.xml:S1:3392:1	O
11	OTEZLA.xml:S1:3412:2	O
(	OTEZLA.xml:S1:3415:1	O
2.2	OTEZLA.xml:S1:3417:3	O
)	OTEZLA.xml:S1:3420:1	O
24	OTEZLA.xml:S1:3439:2	O
(	OTEZLA.xml:S1:3442:1	O
4.8	OTEZLA.xml:S1:3444:3	O
)	OTEZLA.xml:S1:3447:1	O
29	OTEZLA.xml:S1:3466:2	O
(	OTEZLA.xml:S1:3469:1	O
5.9	OTEZLA.xml:S1:3471:3	O
)	OTEZLA.xml:S1:3474:1	O

Upper	OTEZLA.xml:S1:3496:5	B-AdverseReaction
respiratory	OTEZLA.xml:S1:3502:11	I-AdverseReaction
tractinfection	OTEZLA.xml:S1:3514:14	I-AdverseReaction
b	OTEZLA.xml:S1:3530:1	O
3	OTEZLA.xml:S1:3535:1	O
(	OTEZLA.xml:S1:3537:1	O
0.6	OTEZLA.xml:S1:3539:3	O
)	OTEZLA.xml:S1:3542:1	O
9	OTEZLA.xml:S1:3562:1	O
(	OTEZLA.xml:S1:3564:1	O
1.8	OTEZLA.xml:S1:3566:3	O
)	OTEZLA.xml:S1:3569:1	O
3	OTEZLA.xml:S1:3589:1	O
(	OTEZLA.xml:S1:3591:1	O
0.6	OTEZLA.xml:S1:3593:3	O
)	OTEZLA.xml:S1:3596:1	O
19	OTEZLA.xml:S1:3616:2	O
(	OTEZLA.xml:S1:3619:1	O
3.9	OTEZLA.xml:S1:3621:3	O
)	OTEZLA.xml:S1:3624:1	O

Vomiting	OTEZLA.xml:S1:3646:8	B-AdverseReaction
a	OTEZLA.xml:S1:3656:1	O
2	OTEZLA.xml:S1:3673:1	O
(	OTEZLA.xml:S1:3675:1	O
0.4	OTEZLA.xml:S1:3677:3	O
)	OTEZLA.xml:S1:3680:1	O
2	OTEZLA.xml:S1:3700:1	O
(	OTEZLA.xml:S1:3702:1	O
0.4	OTEZLA.xml:S1:3704:3	O
)	OTEZLA.xml:S1:3707:1	O
4	OTEZLA.xml:S1:3727:1	O
(	OTEZLA.xml:S1:3729:1	O
0.8	OTEZLA.xml:S1:3731:3	O
)	OTEZLA.xml:S1:3734:1	O
16	OTEZLA.xml:S1:3754:2	O
(	OTEZLA.xml:S1:3757:1	O
3.2	OTEZLA.xml:S1:3759:3	O
)	OTEZLA.xml:S1:3762:1	O

Nasopharyngitis	OTEZLA.xml:S1:3784:15	B-AdverseReaction
b	OTEZLA.xml:S1:3801:1	O
1	OTEZLA.xml:S1:3811:1	O
(	OTEZLA.xml:S1:3813:1	O
0.2	OTEZLA.xml:S1:3815:3	O
)	OTEZLA.xml:S1:3818:1	O
8	OTEZLA.xml:S1:3838:1	O
(	OTEZLA.xml:S1:3840:1	O
1.6	OTEZLA.xml:S1:3842:3	O
)	OTEZLA.xml:S1:3845:1	O
1	OTEZLA.xml:S1:3865:1	O
(	OTEZLA.xml:S1:3867:1	O
0.2	OTEZLA.xml:S1:3869:3	O
)	OTEZLA.xml:S1:3872:1	O
13	OTEZLA.xml:S1:3892:2	O
(	OTEZLA.xml:S1:3895:1	O
2.6	OTEZLA.xml:S1:3897:3	O
)	OTEZLA.xml:S1:3900:1	O

Abdominal	OTEZLA.xml:S1:3922:9	B-AdverseReaction
pain	OTEZLA.xml:S1:3932:4	I-AdverseReaction
upper	OTEZLA.xml:S1:3937:5	I-AdverseReaction
b	OTEZLA.xml:S1:3944:1	O
0	OTEZLA.xml:S1:3949:1	O
(	OTEZLA.xml:S1:3951:1	O
0.0	OTEZLA.xml:S1:3953:3	O
)	OTEZLA.xml:S1:3956:1	O
1	OTEZLA.xml:S1:3976:1	O
(	OTEZLA.xml:S1:3978:1	O
0.2	OTEZLA.xml:S1:3980:3	O
)	OTEZLA.xml:S1:3983:1	O
3	OTEZLA.xml:S1:4003:1	O
(	OTEZLA.xml:S1:4005:1	O
0.6	OTEZLA.xml:S1:4007:3	O
)	OTEZLA.xml:S1:4010:1	O
10	OTEZLA.xml:S1:4030:2	O
(	OTEZLA.xml:S1:4033:1	O
2.0	OTEZLA.xml:S1:4035:3	O
)	OTEZLA.xml:S1:4038:1	O

Other	OTEZLA.xml:S1:4065:5	O
adverse	OTEZLA.xml:S1:4071:7	O
reactions	OTEZLA.xml:S1:4079:9	O
reported	OTEZLA.xml:S1:4089:8	O
in	OTEZLA.xml:S1:4098:2	O
patients	OTEZLA.xml:S1:4101:8	O
on	OTEZLA.xml:S1:4110:2	O
OTEZLA	OTEZLA.xml:S1:4113:6	O
in	OTEZLA.xml:S1:4120:2	O
clinical	OTEZLA.xml:S1:4123:8	O
studies	OTEZLA.xml:S1:4132:7	O
including	OTEZLA.xml:S1:4140:9	O
extension	OTEZLA.xml:S1:4150:9	O
studies	OTEZLA.xml:S1:4160:7	O
:	OTEZLA.xml:S1:4167:1	O
Immune	OTEZLA.xml:S1:4170:6	O
system	OTEZLA.xml:S1:4177:6	O
disorders	OTEZLA.xml:S1:4184:9	O
:	OTEZLA.xml:S1:4193:1	O
Hypersensitivity	OTEZLA.xml:S1:4196:16	B-AdverseReaction
Investigations	OTEZLA.xml:S1:4214:14	O
:	OTEZLA.xml:S1:4228:1	O
Weight	OTEZLA.xml:S1:4231:6	B-AdverseReaction
decrease	OTEZLA.xml:S1:4238:8	I-AdverseReaction
Gastrointestinal	OTEZLA.xml:S1:4248:16	O
Disorders	OTEZLA.xml:S1:4265:9	O
:	OTEZLA.xml:S1:4274:1	O
Frequent	OTEZLA.xml:S1:4277:8	B-AdverseReaction
bowel	OTEZLA.xml:S1:4286:5	I-AdverseReaction
movement	OTEZLA.xml:S1:4292:8	I-AdverseReaction
,	OTEZLA.xml:S1:4300:1	O
gastroesophageal	OTEZLA.xml:S1:4302:16	B-AdverseReaction
reflux	OTEZLA.xml:S1:4319:6	I-AdverseReaction
disease	OTEZLA.xml:S1:4326:7	I-AdverseReaction
,	OTEZLA.xml:S1:4333:1	O
dyspepsia	OTEZLA.xml:S1:4335:9	B-AdverseReaction
Metabolism	OTEZLA.xml:S1:4346:10	O
and	OTEZLA.xml:S1:4357:3	O
Nutrition	OTEZLA.xml:S1:4361:9	O
Disorders	OTEZLA.xml:S1:4371:9	O
:	OTEZLA.xml:S1:4380:1	O
Decreased	OTEZLA.xml:S1:4383:9	B-AdverseReaction
appetite	OTEZLA.xml:S1:4393:8	I-AdverseReaction
Nervous	OTEZLA.xml:S1:4404:7	O
System	OTEZLA.xml:S1:4412:6	O
Disorders	OTEZLA.xml:S1:4419:9	O
:	OTEZLA.xml:S1:4428:1	O
Migraine	OTEZLA.xml:S1:4431:8	B-AdverseReaction
Respiratory	OTEZLA.xml:S1:4441:11	O
,	OTEZLA.xml:S1:4452:1	O
Thoracic	OTEZLA.xml:S1:4454:8	O
,	OTEZLA.xml:S1:4462:1	O
and	OTEZLA.xml:S1:4464:3	O
Mediastinal	OTEZLA.xml:S1:4468:11	O
Disorders	OTEZLA.xml:S1:4480:9	O
:	OTEZLA.xml:S1:4489:1	O
Cough	OTEZLA.xml:S1:4492:5	B-AdverseReaction
Skin	OTEZLA.xml:S1:4499:4	O
and	OTEZLA.xml:S1:4504:3	O
Subcutaneous	OTEZLA.xml:S1:4508:12	O
Tissue	OTEZLA.xml:S1:4521:6	O
Disorders	OTEZLA.xml:S1:4528:9	O
:	OTEZLA.xml:S1:4537:1	O
Rash	OTEZLA.xml:S1:4540:4	B-AdverseReaction
1	OTEZLA.xml:S1:4545:1	O
patient	OTEZLA.xml:S1:4547:7	O
treated	OTEZLA.xml:S1:4555:7	O
with	OTEZLA.xml:S1:4563:4	O
OTEZLA	OTEZLA.xml:S1:4568:6	O
30	OTEZLA.xml:S1:4575:2	O
mg	OTEZLA.xml:S1:4578:2	O
twice	OTEZLA.xml:S1:4581:5	O
daily	OTEZLA.xml:S1:4587:5	O
experienced	OTEZLA.xml:S1:4593:11	O
a	OTEZLA.xml:S1:4605:1	O
serious	OTEZLA.xml:S1:4607:7	O
adverse	OTEZLA.xml:S1:4615:7	O
reaction	OTEZLA.xml:S1:4623:8	O
.	OTEZLA.xml:S1:4631:1	O

Psoriasis	OTEZLA.xml:S1:4639:9	O

Clinical	OTEZLA.xml:S1:4649:8	O
Trials	OTEZLA.xml:S1:4658:6	O
The	OTEZLA.xml:S1:4666:3	O
safety	OTEZLA.xml:S1:4670:6	O
of	OTEZLA.xml:S1:4677:2	O
OTEZLA	OTEZLA.xml:S1:4680:6	O
(	OTEZLA.xml:S1:4688:1	O
r	OTEZLA.xml:S1:4689:1	O
)	OTEZLA.xml:S1:4690:1	O
was	OTEZLA.xml:S1:4693:3	O
assessed	OTEZLA.xml:S1:4697:8	O
in	OTEZLA.xml:S1:4706:2	O
1426	OTEZLA.xml:S1:4709:4	O
subjects	OTEZLA.xml:S1:4714:8	O
in	OTEZLA.xml:S1:4723:2	O
3	OTEZLA.xml:S1:4726:1	O
randomized	OTEZLA.xml:S1:4728:10	O
,	OTEZLA.xml:S1:4738:1	O
double	OTEZLA.xml:S1:4740:6	O
-	OTEZLA.xml:S1:4746:1	O
blind	OTEZLA.xml:S1:4747:5	O
,	OTEZLA.xml:S1:4752:1	O
placebo	OTEZLA.xml:S1:4754:7	O
-	OTEZLA.xml:S1:4761:1	O
controlled	OTEZLA.xml:S1:4762:10	O
trials	OTEZLA.xml:S1:4773:6	O
in	OTEZLA.xml:S1:4780:2	O
adult	OTEZLA.xml:S1:4783:5	O
subjects	OTEZLA.xml:S1:4789:8	O
with	OTEZLA.xml:S1:4798:4	O
moderate	OTEZLA.xml:S1:4803:8	O
to	OTEZLA.xml:S1:4812:2	O
severe	OTEZLA.xml:S1:4815:6	O
plaque	OTEZLA.xml:S1:4822:6	O
psoriasis	OTEZLA.xml:S1:4829:9	O
who	OTEZLA.xml:S1:4839:3	O
were	OTEZLA.xml:S1:4843:4	O
candidates	OTEZLA.xml:S1:4848:10	O
for	OTEZLA.xml:S1:4859:3	O
phototherapy	OTEZLA.xml:S1:4863:12	O
or	OTEZLA.xml:S1:4876:2	O
systemic	OTEZLA.xml:S1:4879:8	O
therapy	OTEZLA.xml:S1:4888:7	O
.	OTEZLA.xml:S1:4895:1	O

Subjects	OTEZLA.xml:S1:4897:8	O
were	OTEZLA.xml:S1:4906:4	O
randomized	OTEZLA.xml:S1:4911:10	O
to	OTEZLA.xml:S1:4922:2	O
receive	OTEZLA.xml:S1:4925:7	O
OTEZLA	OTEZLA.xml:S1:4933:6	O
30	OTEZLA.xml:S1:4940:2	O
mg	OTEZLA.xml:S1:4943:2	O
twice	OTEZLA.xml:S1:4946:5	O
daily	OTEZLA.xml:S1:4952:5	O
or	OTEZLA.xml:S1:4958:2	O
placebo	OTEZLA.xml:S1:4961:7	O
twice	OTEZLA.xml:S1:4969:5	O
daily	OTEZLA.xml:S1:4975:5	O
.	OTEZLA.xml:S1:4980:1	O

Titration	OTEZLA.xml:S1:4982:9	O
was	OTEZLA.xml:S1:4992:3	O
used	OTEZLA.xml:S1:4996:4	O
over	OTEZLA.xml:S1:5001:4	O
the	OTEZLA.xml:S1:5006:3	O
first	OTEZLA.xml:S1:5010:5	O
5	OTEZLA.xml:S1:5016:1	O
days	OTEZLA.xml:S1:5018:4	O
[	OTEZLA.xml:S1:5024:1	O
see	OTEZLA.xml:S1:5025:3	O
Dosage	OTEZLA.xml:S1:5029:6	O
and	OTEZLA.xml:S1:5036:3	O
Administration	OTEZLA.xml:S1:5040:14	O
(	OTEZLA.xml:S1:5055:1	O
2.1	OTEZLA.xml:S1:5056:3	O
)	OTEZLA.xml:S1:5059:1	O
]	OTEZLA.xml:S1:5062:1	O
.	OTEZLA.xml:S1:5063:1	O

Subjects	OTEZLA.xml:S1:5065:8	O
ranged	OTEZLA.xml:S1:5074:6	O
in	OTEZLA.xml:S1:5081:2	O
age	OTEZLA.xml:S1:5084:3	O
from	OTEZLA.xml:S1:5088:4	O
18	OTEZLA.xml:S1:5093:2	O
to	OTEZLA.xml:S1:5096:2	O
83	OTEZLA.xml:S1:5099:2	O
years	OTEZLA.xml:S1:5102:5	O
,	OTEZLA.xml:S1:5107:1	O
with	OTEZLA.xml:S1:5109:4	O
an	OTEZLA.xml:S1:5114:2	O
overall	OTEZLA.xml:S1:5117:7	O
median	OTEZLA.xml:S1:5125:6	O
age	OTEZLA.xml:S1:5132:3	O
of	OTEZLA.xml:S1:5136:2	O
46	OTEZLA.xml:S1:5139:2	O
years	OTEZLA.xml:S1:5142:5	O
.	OTEZLA.xml:S1:5147:1	O

Diarrhea	OTEZLA.xml:S1:5153:8	B-AdverseReaction
,	OTEZLA.xml:S1:5161:1	O
nausea	OTEZLA.xml:S1:5163:6	B-AdverseReaction
,	OTEZLA.xml:S1:5169:1	O
and	OTEZLA.xml:S1:5171:3	O
upper	OTEZLA.xml:S1:5175:5	B-AdverseReaction
respiratory	OTEZLA.xml:S1:5181:11	I-AdverseReaction
tract	OTEZLA.xml:S1:5193:5	I-AdverseReaction
infection	OTEZLA.xml:S1:5199:9	I-AdverseReaction
were	OTEZLA.xml:S1:5209:4	O
the	OTEZLA.xml:S1:5214:3	O
most	OTEZLA.xml:S1:5218:4	O
commonly	OTEZLA.xml:S1:5223:8	O
reported	OTEZLA.xml:S1:5232:8	O
adverse	OTEZLA.xml:S1:5241:7	O
reactions	OTEZLA.xml:S1:5249:9	O
.	OTEZLA.xml:S1:5258:1	O

The	OTEZLA.xml:S1:5260:3	O
most	OTEZLA.xml:S1:5264:4	O
common	OTEZLA.xml:S1:5269:6	O
adverse	OTEZLA.xml:S1:5276:7	O
reactions	OTEZLA.xml:S1:5284:9	O
leading	OTEZLA.xml:S1:5294:7	O
to	OTEZLA.xml:S1:5302:2	O
discontinuation	OTEZLA.xml:S1:5305:15	O
for	OTEZLA.xml:S1:5321:3	O
subjects	OTEZLA.xml:S1:5325:8	O
taking	OTEZLA.xml:S1:5334:6	O
OTEZLA	OTEZLA.xml:S1:5341:6	O
were	OTEZLA.xml:S1:5348:4	O
nausea	OTEZLA.xml:S1:5353:6	B-AdverseReaction
(	OTEZLA.xml:S1:5360:1	O
1.6%	OTEZLA.xml:S1:5361:4	O
)	OTEZLA.xml:S1:5365:1	O
,	OTEZLA.xml:S1:5366:1	O
diarrhea	OTEZLA.xml:S1:5368:8	B-AdverseReaction
(	OTEZLA.xml:S1:5377:1	O
1.0%	OTEZLA.xml:S1:5378:4	O
)	OTEZLA.xml:S1:5382:1	O
,	OTEZLA.xml:S1:5383:1	O
and	OTEZLA.xml:S1:5385:3	O
headache	OTEZLA.xml:S1:5389:8	B-AdverseReaction
(	OTEZLA.xml:S1:5398:1	O
0.8%	OTEZLA.xml:S1:5399:4	O
)	OTEZLA.xml:S1:5403:1	O
.	OTEZLA.xml:S1:5404:1	O

The	OTEZLA.xml:S1:5406:3	O
proportion	OTEZLA.xml:S1:5410:10	O
of	OTEZLA.xml:S1:5421:2	O
subjects	OTEZLA.xml:S1:5424:8	O
with	OTEZLA.xml:S1:5433:4	O
psoriasis	OTEZLA.xml:S1:5438:9	O
who	OTEZLA.xml:S1:5448:3	O
discontinued	OTEZLA.xml:S1:5452:12	O
treatment	OTEZLA.xml:S1:5465:9	O
due	OTEZLA.xml:S1:5475:3	O
to	OTEZLA.xml:S1:5479:2	O
any	OTEZLA.xml:S1:5482:3	O
adverse	OTEZLA.xml:S1:5486:7	O
reaction	OTEZLA.xml:S1:5494:8	O
was	OTEZLA.xml:S1:5503:3	O
6.1%	OTEZLA.xml:S1:5507:4	O
for	OTEZLA.xml:S1:5512:3	O
subjects	OTEZLA.xml:S1:5516:8	O
treated	OTEZLA.xml:S1:5525:7	O
with	OTEZLA.xml:S1:5533:4	O
OTEZLA	OTEZLA.xml:S1:5538:6	O
30	OTEZLA.xml:S1:5545:2	O
mg	OTEZLA.xml:S1:5548:2	O
twice	OTEZLA.xml:S1:5551:5	O
daily	OTEZLA.xml:S1:5557:5	O
and	OTEZLA.xml:S1:5563:3	O
4.1%	OTEZLA.xml:S1:5567:4	O
for	OTEZLA.xml:S1:5572:3	O
placebo	OTEZLA.xml:S1:5576:7	O
-	OTEZLA.xml:S1:5583:1	O
treated	OTEZLA.xml:S1:5584:7	O
subjects	OTEZLA.xml:S1:5592:8	O
.	OTEZLA.xml:S1:5600:1	O

Table	OTEZLA.xml:S1:5606:5	O
3	OTEZLA.xml:S1:5612:1	O
:	OTEZLA.xml:S1:5613:1	O
Adverse	OTEZLA.xml:S1:5615:7	O
Reactions	OTEZLA.xml:S1:5623:9	O
Reported	OTEZLA.xml:S1:5633:8	O
in	OTEZLA.xml:S1:5642:2	O
1%	OTEZLA.xml:S1:5647:2	O
of	OTEZLA.xml:S1:5650:2	O
Subjects	OTEZLA.xml:S1:5653:8	O
on	OTEZLA.xml:S1:5662:2	O
OTEZLA	OTEZLA.xml:S1:5665:6	O
and	OTEZLA.xml:S1:5672:3	O
With	OTEZLA.xml:S1:5676:4	O
Greater	OTEZLA.xml:S1:5681:7	O
Frequency	OTEZLA.xml:S1:5689:9	O
Than	OTEZLA.xml:S1:5699:4	O
in	OTEZLA.xml:S1:5704:2	O
Subjects	OTEZLA.xml:S1:5707:8	O
on	OTEZLA.xml:S1:5716:2	O
Placebo	OTEZLA.xml:S1:5719:7	O
;	OTEZLA.xml:S1:5726:1	O
up	OTEZLA.xml:S1:5728:2	O
to	OTEZLA.xml:S1:5731:2	O
Day	OTEZLA.xml:S1:5734:3	O
112	OTEZLA.xml:S1:5738:3	O
(	OTEZLA.xml:S1:5742:1	O
Week	OTEZLA.xml:S1:5743:4	O
16	OTEZLA.xml:S1:5748:2	O
)	OTEZLA.xml:S1:5750:1	O

Two	OTEZLA.xml:S1:5759:3	O
subjects	OTEZLA.xml:S1:5763:8	O
treated	OTEZLA.xml:S1:5772:7	O
with	OTEZLA.xml:S1:5780:4	O
OTEZLA	OTEZLA.xml:S1:5785:6	O
experienced	OTEZLA.xml:S1:5792:11	O
serious	OTEZLA.xml:S1:5804:7	B-Severity
adverse	OTEZLA.xml:S1:5812:7	O
reaction	OTEZLA.xml:S1:5820:8	O
of	OTEZLA.xml:S1:5829:2	O
abdominal	OTEZLA.xml:S1:5832:9	B-AdverseReaction
pain	OTEZLA.xml:S1:5842:4	I-AdverseReaction
.	OTEZLA.xml:S1:5846:1	O

Preferred	OTEZLA.xml:S1:5855:9	O

Term	OTEZLA.xml:S1:5865:4	O
Placebo	OTEZLA.xml:S1:5877:7	O
(	OTEZLA.xml:S1:5885:1	O
N	OTEZLA.xml:S1:5886:1	O
506	OTEZLA.xml:S1:5888:3	O
)	OTEZLA.xml:S1:5891:1	O
n	OTEZLA.xml:S1:5892:1	O
(	OTEZLA.xml:S1:5894:1	O
)	OTEZLA.xml:S1:5896:1	O
OTEZLA	OTEZLA.xml:S1:5899:6	O
30	OTEZLA.xml:S1:5906:2	O
mg	OTEZLA.xml:S1:5909:2	O
BID	OTEZLA.xml:S1:5912:3	O
(	OTEZLA.xml:S1:5916:1	O
N	OTEZLA.xml:S1:5917:1	O
920	OTEZLA.xml:S1:5919:3	O
)	OTEZLA.xml:S1:5922:1	O
n	OTEZLA.xml:S1:5923:1	O
(	OTEZLA.xml:S1:5925:1	O
)	OTEZLA.xml:S1:5927:1	O

Diarrhea	OTEZLA.xml:S1:5933:8	B-AdverseReaction
32	OTEZLA.xml:S1:5955:2	O
(	OTEZLA.xml:S1:5958:1	O
6	OTEZLA.xml:S1:5959:1	O
)	OTEZLA.xml:S1:5960:1	O
160	OTEZLA.xml:S1:5977:3	O
(	OTEZLA.xml:S1:5981:1	O
17	OTEZLA.xml:S1:5982:2	O
)	OTEZLA.xml:S1:5984:1	O

Nausea	OTEZLA.xml:S1:6002:6	B-AdverseReaction
35	OTEZLA.xml:S1:6024:2	O
(	OTEZLA.xml:S1:6027:1	O
7	OTEZLA.xml:S1:6028:1	O
)	OTEZLA.xml:S1:6029:1	O
155	OTEZLA.xml:S1:6046:3	O
(	OTEZLA.xml:S1:6050:1	O
17	OTEZLA.xml:S1:6051:2	O
)	OTEZLA.xml:S1:6053:1	O

Upper	OTEZLA.xml:S1:6071:5	B-AdverseReaction
respiratory	OTEZLA.xml:S1:6077:11	I-AdverseReaction
tract	OTEZLA.xml:S1:6089:5	I-AdverseReaction
infection	OTEZLA.xml:S1:6095:9	I-AdverseReaction
31	OTEZLA.xml:S1:6106:2	O
(	OTEZLA.xml:S1:6109:1	O
6	OTEZLA.xml:S1:6110:1	O
)	OTEZLA.xml:S1:6111:1	O
84	OTEZLA.xml:S1:6128:2	O
(	OTEZLA.xml:S1:6131:1	O
9	OTEZLA.xml:S1:6132:1	O
)	OTEZLA.xml:S1:6133:1	O

Tension	OTEZLA.xml:S1:6153:7	B-AdverseReaction
headache	OTEZLA.xml:S1:6161:8	I-AdverseReaction
21	OTEZLA.xml:S1:6175:2	O
(	OTEZLA.xml:S1:6178:1	O
4	OTEZLA.xml:S1:6179:1	O
)	OTEZLA.xml:S1:6180:1	O
75	OTEZLA.xml:S1:6197:2	O
(	OTEZLA.xml:S1:6200:1	O
8	OTEZLA.xml:S1:6201:1	O
)	OTEZLA.xml:S1:6202:1	O

Headache	OTEZLA.xml:S1:6222:8	B-AdverseReaction
19	OTEZLA.xml:S1:6244:2	O
(	OTEZLA.xml:S1:6247:1	O
4	OTEZLA.xml:S1:6248:1	O
)	OTEZLA.xml:S1:6249:1	O
55	OTEZLA.xml:S1:6266:2	O
(	OTEZLA.xml:S1:6269:1	O
6	OTEZLA.xml:S1:6270:1	O
)	OTEZLA.xml:S1:6271:1	O

Abdominal	OTEZLA.xml:S1:6291:9	B-AdverseReaction
pain	OTEZLA.xml:S1:6301:4	I-AdverseReaction
11	OTEZLA.xml:S1:6313:2	O
(	OTEZLA.xml:S1:6316:1	O
2	OTEZLA.xml:S1:6317:1	O
)	OTEZLA.xml:S1:6318:1	O
39	OTEZLA.xml:S1:6335:2	O
(	OTEZLA.xml:S1:6338:1	O
4	OTEZLA.xml:S1:6339:1	O
)	OTEZLA.xml:S1:6340:1	O

Vomiting	OTEZLA.xml:S1:6360:8	B-AdverseReaction
8	OTEZLA.xml:S1:6382:1	O
(	OTEZLA.xml:S1:6384:1	O
2	OTEZLA.xml:S1:6385:1	O
)	OTEZLA.xml:S1:6386:1	O
35	OTEZLA.xml:S1:6404:2	O
(	OTEZLA.xml:S1:6407:1	O
4	OTEZLA.xml:S1:6408:1	O
)	OTEZLA.xml:S1:6409:1	O

Fatigue	OTEZLA.xml:S1:6429:7	B-AdverseReaction
9	OTEZLA.xml:S1:6451:1	O
(	OTEZLA.xml:S1:6453:1	O
2	OTEZLA.xml:S1:6454:1	O
)	OTEZLA.xml:S1:6455:1	O
29	OTEZLA.xml:S1:6473:2	O
(	OTEZLA.xml:S1:6476:1	O
3	OTEZLA.xml:S1:6477:1	O
)	OTEZLA.xml:S1:6478:1	O

Dyspepsia	OTEZLA.xml:S1:6498:9	B-AdverseReaction
6	OTEZLA.xml:S1:6520:1	O
(	OTEZLA.xml:S1:6522:1	O
1	OTEZLA.xml:S1:6523:1	O
)	OTEZLA.xml:S1:6524:1	O
29	OTEZLA.xml:S1:6542:2	O
(	OTEZLA.xml:S1:6545:1	O
3	OTEZLA.xml:S1:6546:1	O
)	OTEZLA.xml:S1:6547:1	O

Decrease	OTEZLA.xml:S1:6567:8	B-AdverseReaction
appetite	OTEZLA.xml:S1:6576:8	I-AdverseReaction
5	OTEZLA.xml:S1:6589:1	O
(	OTEZLA.xml:S1:6591:1	O
1	OTEZLA.xml:S1:6592:1	O
)	OTEZLA.xml:S1:6593:1	O
26	OTEZLA.xml:S1:6611:2	O
(	OTEZLA.xml:S1:6614:1	O
3	OTEZLA.xml:S1:6615:1	O
)	OTEZLA.xml:S1:6616:1	O

Insomnia	OTEZLA.xml:S1:6636:8	B-AdverseReaction
4	OTEZLA.xml:S1:6658:1	O
(	OTEZLA.xml:S1:6660:1	O
1	OTEZLA.xml:S1:6661:1	O
)	OTEZLA.xml:S1:6662:1	O
21	OTEZLA.xml:S1:6680:2	O
(	OTEZLA.xml:S1:6683:1	O
2	OTEZLA.xml:S1:6684:1	O
)	OTEZLA.xml:S1:6685:1	O

Back	OTEZLA.xml:S1:6705:4	B-AdverseReaction
pain	OTEZLA.xml:S1:6710:4	I-AdverseReaction
4	OTEZLA.xml:S1:6727:1	O
(	OTEZLA.xml:S1:6729:1	O
1	OTEZLA.xml:S1:6730:1	O
)	OTEZLA.xml:S1:6731:1	O
20	OTEZLA.xml:S1:6749:2	O
(	OTEZLA.xml:S1:6752:1	O
2	OTEZLA.xml:S1:6753:1	O
)	OTEZLA.xml:S1:6754:1	O

Migraine	OTEZLA.xml:S1:6774:8	B-AdverseReaction
5	OTEZLA.xml:S1:6796:1	O
(	OTEZLA.xml:S1:6798:1	O
1	OTEZLA.xml:S1:6799:1	O
)	OTEZLA.xml:S1:6800:1	O
19	OTEZLA.xml:S1:6818:2	O
(	OTEZLA.xml:S1:6821:1	O
2	OTEZLA.xml:S1:6822:1	O
)	OTEZLA.xml:S1:6823:1	O

Frequent	OTEZLA.xml:S1:6843:8	B-AdverseReaction
bowel	OTEZLA.xml:S1:6852:5	I-AdverseReaction
movements	OTEZLA.xml:S1:6858:9	I-AdverseReaction
1	OTEZLA.xml:S1:6869:1	O
(	OTEZLA.xml:S1:6871:1	O
0	OTEZLA.xml:S1:6872:1	O
)	OTEZLA.xml:S1:6873:1	O
17	OTEZLA.xml:S1:6891:2	O
(	OTEZLA.xml:S1:6894:1	O
2	OTEZLA.xml:S1:6895:1	O
)	OTEZLA.xml:S1:6896:1	O

Depression	OTEZLA.xml:S1:6916:10	B-AdverseReaction
2	OTEZLA.xml:S1:6938:1	O
(	OTEZLA.xml:S1:6940:1	O
0	OTEZLA.xml:S1:6941:1	O
)	OTEZLA.xml:S1:6942:1	O
12	OTEZLA.xml:S1:6960:2	O
(	OTEZLA.xml:S1:6963:1	O
1	OTEZLA.xml:S1:6964:1	O
)	OTEZLA.xml:S1:6965:1	O

Bronchitis	OTEZLA.xml:S1:6985:10	B-AdverseReaction
2	OTEZLA.xml:S1:7007:1	O
(	OTEZLA.xml:S1:7009:1	O
0	OTEZLA.xml:S1:7010:1	O
)	OTEZLA.xml:S1:7011:1	O
12	OTEZLA.xml:S1:7029:2	O
(	OTEZLA.xml:S1:7032:1	O
1	OTEZLA.xml:S1:7033:1	O
)	OTEZLA.xml:S1:7034:1	O

Tooth	OTEZLA.xml:S1:7054:5	B-AdverseReaction
abscess	OTEZLA.xml:S1:7060:7	I-AdverseReaction
0	OTEZLA.xml:S1:7076:1	O
(	OTEZLA.xml:S1:7078:1	O
0	OTEZLA.xml:S1:7079:1	O
)	OTEZLA.xml:S1:7080:1	O
10	OTEZLA.xml:S1:7098:2	O
(	OTEZLA.xml:S1:7101:1	O
1	OTEZLA.xml:S1:7102:1	O
)	OTEZLA.xml:S1:7103:1	O

Folliculitis	OTEZLA.xml:S1:7123:12	B-AdverseReaction
0	OTEZLA.xml:S1:7145:1	O
(	OTEZLA.xml:S1:7147:1	O
0	OTEZLA.xml:S1:7148:1	O
)	OTEZLA.xml:S1:7149:1	O
9	OTEZLA.xml:S1:7167:1	O
(	OTEZLA.xml:S1:7169:1	O
1	OTEZLA.xml:S1:7170:1	O
)	OTEZLA.xml:S1:7171:1	O

Sinus	OTEZLA.xml:S1:7192:5	B-AdverseReaction
headache	OTEZLA.xml:S1:7198:8	I-AdverseReaction
0	OTEZLA.xml:S1:7214:1	O
(	OTEZLA.xml:S1:7216:1	O
0	OTEZLA.xml:S1:7217:1	O
)	OTEZLA.xml:S1:7218:1	O
9	OTEZLA.xml:S1:7236:1	O
(	OTEZLA.xml:S1:7238:1	O
1	OTEZLA.xml:S1:7239:1	O
)	OTEZLA.xml:S1:7240:1	O

Severe	OTEZLA.xml:S1:7269:6	O
worsening	OTEZLA.xml:S1:7276:9	O
of	OTEZLA.xml:S1:7286:2	O
psoriasis	OTEZLA.xml:S1:7289:9	O
(	OTEZLA.xml:S1:7299:1	O
rebound	OTEZLA.xml:S1:7300:7	O
)	OTEZLA.xml:S1:7307:1	O
occurred	OTEZLA.xml:S1:7309:8	O
in	OTEZLA.xml:S1:7318:2	O
0.3%	OTEZLA.xml:S1:7321:4	O
(	OTEZLA.xml:S1:7326:1	O
4	OTEZLA.xml:S1:7327:1	O
1184	OTEZLA.xml:S1:7329:4	O
)	OTEZLA.xml:S1:7333:1	O
subjects	OTEZLA.xml:S1:7335:8	O
following	OTEZLA.xml:S1:7344:9	O
discontinuation	OTEZLA.xml:S1:7354:15	O
of	OTEZLA.xml:S1:7370:2	O
treatment	OTEZLA.xml:S1:7373:9	O
with	OTEZLA.xml:S1:7383:4	O
OTEZLA	OTEZLA.xml:S1:7388:6	O
.	OTEZLA.xml:S1:7394:1	O
5	OTEZLA.xml:S2:4:1	O
WARNINGS	OTEZLA.xml:S2:6:8	O
AND	OTEZLA.xml:S2:15:3	O
PRECAUTIONS	OTEZLA.xml:S2:19:11	O

EXCERPT	OTEZLA.xml:S2:37:7	O
:	OTEZLA.xml:S2:44:1	O
Depression	OTEZLA.xml:S2:53:10	B-AdverseReaction
:	OTEZLA.xml:S2:64:1	O
Advise	OTEZLA.xml:S2:66:6	O
patients	OTEZLA.xml:S2:73:8	O
,	OTEZLA.xml:S2:81:1	O
their	OTEZLA.xml:S2:83:5	O
caregivers	OTEZLA.xml:S2:89:10	O
,	OTEZLA.xml:S2:99:1	O
and	OTEZLA.xml:S2:101:3	O
families	OTEZLA.xml:S2:105:8	O
to	OTEZLA.xml:S2:114:2	O
be	OTEZLA.xml:S2:117:2	O
alert	OTEZLA.xml:S2:120:5	O
for	OTEZLA.xml:S2:126:3	O
the	OTEZLA.xml:S2:130:3	O
emergence	OTEZLA.xml:S2:134:9	O
or	OTEZLA.xml:S2:144:2	O
worsening	OTEZLA.xml:S2:147:9	O
of	OTEZLA.xml:S2:157:2	O
depression	OTEZLA.xml:S2:160:10	O
,	OTEZLA.xml:S2:170:1	O
suicidal	OTEZLA.xml:S2:172:8	O
thoughts	OTEZLA.xml:S2:181:8	O
or	OTEZLA.xml:S2:190:2	O
other	OTEZLA.xml:S2:193:5	O
mood	OTEZLA.xml:S2:199:4	O
changes	OTEZLA.xml:S2:204:7	O
and	OTEZLA.xml:S2:212:3	O
if	OTEZLA.xml:S2:216:2	O
such	OTEZLA.xml:S2:219:4	O
changes	OTEZLA.xml:S2:224:7	O
occur	OTEZLA.xml:S2:232:5	O
to	OTEZLA.xml:S2:238:2	O
contact	OTEZLA.xml:S2:241:7	O
their	OTEZLA.xml:S2:249:5	O
healthcare	OTEZLA.xml:S2:255:10	O
provider	OTEZLA.xml:S2:266:8	O
.	OTEZLA.xml:S2:274:1	O

Carefully	OTEZLA.xml:S2:276:9	O
weigh	OTEZLA.xml:S2:286:5	O
risks	OTEZLA.xml:S2:292:5	O
and	OTEZLA.xml:S2:298:3	O
benefits	OTEZLA.xml:S2:302:8	O
of	OTEZLA.xml:S2:311:2	O
treatment	OTEZLA.xml:S2:314:9	O
with	OTEZLA.xml:S2:324:4	O
OTEZLA	OTEZLA.xml:S2:329:6	O
in	OTEZLA.xml:S2:336:2	O
patients	OTEZLA.xml:S2:339:8	O
with	OTEZLA.xml:S2:348:4	O
a	OTEZLA.xml:S2:353:1	O
history	OTEZLA.xml:S2:355:7	O
of	OTEZLA.xml:S2:363:2	O
depression	OTEZLA.xml:S2:366:10	O
and	OTEZLA.xml:S2:377:3	O
or	OTEZLA.xml:S2:381:2	O
suicidal	OTEZLA.xml:S2:384:8	O
thoughts	OTEZLA.xml:S2:393:8	O
or	OTEZLA.xml:S2:402:2	O
behavior	OTEZLA.xml:S2:405:8	O
.	OTEZLA.xml:S2:413:1	O

(	OTEZLA.xml:S2:415:1	O
5.1	OTEZLA.xml:S2:416:3	O
)	OTEZLA.xml:S2:419:1	O

Weight	OTEZLA.xml:S2:427:6	B-AdverseReaction
Decrease	OTEZLA.xml:S2:434:8	I-AdverseReaction
:	OTEZLA.xml:S2:443:1	O
Monitor	OTEZLA.xml:S2:445:7	O
weight	OTEZLA.xml:S2:453:6	O
regularly	OTEZLA.xml:S2:460:9	O
.	OTEZLA.xml:S2:469:1	O

If	OTEZLA.xml:S2:471:2	O
unexplained	OTEZLA.xml:S2:474:11	O
or	OTEZLA.xml:S2:486:2	O
clinically	OTEZLA.xml:S2:489:10	O
significant	OTEZLA.xml:S2:500:11	O
weight	OTEZLA.xml:S2:512:6	O
loss	OTEZLA.xml:S2:519:4	O
occurs	OTEZLA.xml:S2:524:6	O
,	OTEZLA.xml:S2:530:1	O
evaluate	OTEZLA.xml:S2:532:8	O
weight	OTEZLA.xml:S2:541:6	O
loss	OTEZLA.xml:S2:548:4	O
and	OTEZLA.xml:S2:553:3	O
consider	OTEZLA.xml:S2:557:8	O
discontinuation	OTEZLA.xml:S2:566:15	O
of	OTEZLA.xml:S2:582:2	O
OTEZLA	OTEZLA.xml:S2:585:6	O
(	OTEZLA.xml:S2:592:1	O
5.2	OTEZLA.xml:S2:593:3	O
)	OTEZLA.xml:S2:596:1	O

Drug	OTEZLA.xml:S2:604:4	O
Interactions	OTEZLA.xml:S2:609:12	O
:	OTEZLA.xml:S2:622:1	O
Use	OTEZLA.xml:S2:624:3	O
with	OTEZLA.xml:S2:628:4	O
strong	OTEZLA.xml:S2:633:6	O
cytochrome	OTEZLA.xml:S2:640:10	O
P450	OTEZLA.xml:S2:651:4	O
enzyme	OTEZLA.xml:S2:656:6	O
inducers	OTEZLA.xml:S2:663:8	O
(	OTEZLA.xml:S2:672:1	O
e	OTEZLA.xml:S2:673:1	O
.	OTEZLA.xml:S2:674:1	O
g	OTEZLA.xml:S2:675:1	O
.	OTEZLA.xml:S2:676:1	O
,	OTEZLA.xml:S2:677:1	O
rifampin	OTEZLA.xml:S2:679:8	O
,	OTEZLA.xml:S2:687:1	O
phenobarbital	OTEZLA.xml:S2:689:13	O
,	OTEZLA.xml:S2:702:1	O
carbamazepine	OTEZLA.xml:S2:704:13	O
,	OTEZLA.xml:S2:717:1	O
phenytoin	OTEZLA.xml:S2:719:9	O
)	OTEZLA.xml:S2:728:1	O
is	OTEZLA.xml:S2:730:2	O
not	OTEZLA.xml:S2:733:3	O
recommended	OTEZLA.xml:S2:737:11	O
because	OTEZLA.xml:S2:749:7	O
loss	OTEZLA.xml:S2:757:4	O
of	OTEZLA.xml:S2:762:2	O
efficacy	OTEZLA.xml:S2:765:8	O
may	OTEZLA.xml:S2:774:3	O
occur	OTEZLA.xml:S2:778:5	O
(	OTEZLA.xml:S2:784:1	O
5.3	OTEZLA.xml:S2:785:3	O
,	OTEZLA.xml:S2:788:1	O
7.1	OTEZLA.xml:S2:789:3	O
)	OTEZLA.xml:S2:792:1	O

5.1	OTEZLA.xml:S2:803:3	O

Depression	OTEZLA.xml:S2:807:10	O

Treatment	OTEZLA.xml:S2:821:9	O
with	OTEZLA.xml:S2:831:4	O
OTEZLA	OTEZLA.xml:S2:836:6	O
is	OTEZLA.xml:S2:843:2	O
associated	OTEZLA.xml:S2:846:10	O
with	OTEZLA.xml:S2:857:4	O
an	OTEZLA.xml:S2:862:2	O
increase	OTEZLA.xml:S2:865:8	O
in	OTEZLA.xml:S2:874:2	O
adverse	OTEZLA.xml:S2:877:7	O
reactions	OTEZLA.xml:S2:885:9	O
of	OTEZLA.xml:S2:895:2	O
depression	OTEZLA.xml:S2:898:10	B-AdverseReaction
.	OTEZLA.xml:S2:908:1	O

Before	OTEZLA.xml:S2:910:6	O
using	OTEZLA.xml:S2:917:5	O
OTEZLA	OTEZLA.xml:S2:923:6	O
in	OTEZLA.xml:S2:930:2	O
patients	OTEZLA.xml:S2:933:8	O
with	OTEZLA.xml:S2:942:4	O
a	OTEZLA.xml:S2:947:1	O
history	OTEZLA.xml:S2:949:7	O
of	OTEZLA.xml:S2:957:2	O
depression	OTEZLA.xml:S2:960:10	O
and	OTEZLA.xml:S2:971:3	O
or	OTEZLA.xml:S2:975:2	O
suicidal	OTEZLA.xml:S2:978:8	O
thoughts	OTEZLA.xml:S2:987:8	O
or	OTEZLA.xml:S2:996:2	O
behavior	OTEZLA.xml:S2:999:8	O
prescribers	OTEZLA.xml:S2:1008:11	O
should	OTEZLA.xml:S2:1020:6	O
carefully	OTEZLA.xml:S2:1027:9	O
weigh	OTEZLA.xml:S2:1037:5	O
the	OTEZLA.xml:S2:1043:3	O
risks	OTEZLA.xml:S2:1047:5	O
and	OTEZLA.xml:S2:1053:3	O
benefits	OTEZLA.xml:S2:1057:8	O
of	OTEZLA.xml:S2:1066:2	O
treatment	OTEZLA.xml:S2:1069:9	O
with	OTEZLA.xml:S2:1079:4	O
OTEZLA	OTEZLA.xml:S2:1084:6	O
in	OTEZLA.xml:S2:1091:2	O
such	OTEZLA.xml:S2:1094:4	O
patients	OTEZLA.xml:S2:1099:8	O
.	OTEZLA.xml:S2:1107:1	O

Patients	OTEZLA.xml:S2:1109:8	O
,	OTEZLA.xml:S2:1117:1	O
their	OTEZLA.xml:S2:1119:5	O
caregivers	OTEZLA.xml:S2:1125:10	O
,	OTEZLA.xml:S2:1135:1	O
and	OTEZLA.xml:S2:1137:3	O
families	OTEZLA.xml:S2:1141:8	O
should	OTEZLA.xml:S2:1150:6	O
be	OTEZLA.xml:S2:1157:2	O
advised	OTEZLA.xml:S2:1160:7	O
of	OTEZLA.xml:S2:1168:2	O
the	OTEZLA.xml:S2:1171:3	O
need	OTEZLA.xml:S2:1175:4	O
to	OTEZLA.xml:S2:1180:2	O
be	OTEZLA.xml:S2:1183:2	O
alert	OTEZLA.xml:S2:1186:5	O
for	OTEZLA.xml:S2:1192:3	O
the	OTEZLA.xml:S2:1196:3	O
emergence	OTEZLA.xml:S2:1200:9	O
or	OTEZLA.xml:S2:1210:2	O
worsening	OTEZLA.xml:S2:1213:9	O
of	OTEZLA.xml:S2:1223:2	O
depression	OTEZLA.xml:S2:1226:10	O
,	OTEZLA.xml:S2:1236:1	O
suicidal	OTEZLA.xml:S2:1238:8	O
thoughts	OTEZLA.xml:S2:1247:8	O
or	OTEZLA.xml:S2:1256:2	O
other	OTEZLA.xml:S2:1259:5	O
mood	OTEZLA.xml:S2:1265:4	O
changes	OTEZLA.xml:S2:1270:7	O
,	OTEZLA.xml:S2:1277:1	O
and	OTEZLA.xml:S2:1279:3	O
if	OTEZLA.xml:S2:1283:2	O
such	OTEZLA.xml:S2:1286:4	O
changes	OTEZLA.xml:S2:1291:7	O
occur	OTEZLA.xml:S2:1299:5	O
to	OTEZLA.xml:S2:1305:2	O
contact	OTEZLA.xml:S2:1308:7	O
their	OTEZLA.xml:S2:1316:5	O
healthcare	OTEZLA.xml:S2:1322:10	O
provider	OTEZLA.xml:S2:1333:8	O
.	OTEZLA.xml:S2:1341:1	O

Prescribers	OTEZLA.xml:S2:1343:11	O
should	OTEZLA.xml:S2:1355:6	O
carefully	OTEZLA.xml:S2:1362:9	O
evaluate	OTEZLA.xml:S2:1372:8	O
the	OTEZLA.xml:S2:1381:3	O
risks	OTEZLA.xml:S2:1385:5	O
and	OTEZLA.xml:S2:1391:3	O
benefits	OTEZLA.xml:S2:1395:8	O
of	OTEZLA.xml:S2:1404:2	O
continuing	OTEZLA.xml:S2:1407:10	O
treatment	OTEZLA.xml:S2:1418:9	O
with	OTEZLA.xml:S2:1428:4	O
OTEZLA	OTEZLA.xml:S2:1433:6	O
if	OTEZLA.xml:S2:1440:2	O
such	OTEZLA.xml:S2:1443:4	O
events	OTEZLA.xml:S2:1448:6	O
occur	OTEZLA.xml:S2:1455:5	O
.	OTEZLA.xml:S2:1460:1	O

Psoriatic	OTEZLA.xml:S2:1468:9	O
arthritis	OTEZLA.xml:S2:1478:9	O
:	OTEZLA.xml:S2:1489:1	O
During	OTEZLA.xml:S2:1491:6	O
the	OTEZLA.xml:S2:1498:3	O
0	OTEZLA.xml:S2:1502:1	O
to	OTEZLA.xml:S2:1504:2	O
16	OTEZLA.xml:S2:1507:2	O
week	OTEZLA.xml:S2:1510:4	O
placebo	OTEZLA.xml:S2:1515:7	O
-	OTEZLA.xml:S2:1522:1	O
controlled	OTEZLA.xml:S2:1523:10	O
period	OTEZLA.xml:S2:1534:6	O
of	OTEZLA.xml:S2:1541:2	O
the	OTEZLA.xml:S2:1544:3	O
3	OTEZLA.xml:S2:1548:1	O
controlled	OTEZLA.xml:S2:1550:10	O
clinical	OTEZLA.xml:S2:1561:8	O
trials	OTEZLA.xml:S2:1570:6	O
,	OTEZLA.xml:S2:1576:1	O
1.0%	OTEZLA.xml:S2:1578:4	O
(	OTEZLA.xml:S2:1583:1	O
10	OTEZLA.xml:S2:1584:2	O
998	OTEZLA.xml:S2:1587:3	O
)	OTEZLA.xml:S2:1590:1	O
of	OTEZLA.xml:S2:1592:2	O
subjects	OTEZLA.xml:S2:1595:8	O
treated	OTEZLA.xml:S2:1604:7	O
with	OTEZLA.xml:S2:1612:4	O
OTEZLA	OTEZLA.xml:S2:1617:6	O
reported	OTEZLA.xml:S2:1624:8	O
depression	OTEZLA.xml:S2:1633:10	B-AdverseReaction
or	OTEZLA.xml:S2:1644:2	O
depressed	OTEZLA.xml:S2:1647:9	B-AdverseReaction
mood	OTEZLA.xml:S2:1657:4	I-AdverseReaction
compared	OTEZLA.xml:S2:1662:8	O
to	OTEZLA.xml:S2:1671:2	O
0.8%	OTEZLA.xml:S2:1674:4	O
(	OTEZLA.xml:S2:1679:1	O
4	OTEZLA.xml:S2:1680:1	O
495	OTEZLA.xml:S2:1682:3	O
)	OTEZLA.xml:S2:1685:1	O
treated	OTEZLA.xml:S2:1687:7	O
with	OTEZLA.xml:S2:1695:4	O
placebo	OTEZLA.xml:S2:1700:7	O
.	OTEZLA.xml:S2:1707:1	O

During	OTEZLA.xml:S2:1709:6	O
the	OTEZLA.xml:S2:1716:3	O
clinical	OTEZLA.xml:S2:1720:8	O
trials	OTEZLA.xml:S2:1729:6	O
,	OTEZLA.xml:S2:1735:1	O
0.3%	OTEZLA.xml:S2:1737:4	O
(	OTEZLA.xml:S2:1742:1	O
4	OTEZLA.xml:S2:1743:1	O
1441	OTEZLA.xml:S2:1745:4	O
)	OTEZLA.xml:S2:1749:1	O
of	OTEZLA.xml:S2:1751:2	O
subjects	OTEZLA.xml:S2:1754:8	O
treated	OTEZLA.xml:S2:1763:7	O
with	OTEZLA.xml:S2:1771:4	O
OTEZLA	OTEZLA.xml:S2:1776:6	O
discontinued	OTEZLA.xml:S2:1783:12	O
treatment	OTEZLA.xml:S2:1796:9	O
due	OTEZLA.xml:S2:1806:3	O
to	OTEZLA.xml:S2:1810:2	O
depression	OTEZLA.xml:S2:1813:10	B-AdverseReaction
or	OTEZLA.xml:S2:1824:2	O
depressed	OTEZLA.xml:S2:1827:9	B-AdverseReaction
mood	OTEZLA.xml:S2:1837:4	I-AdverseReaction
compared	OTEZLA.xml:S2:1842:8	O
with	OTEZLA.xml:S2:1851:4	O
none	OTEZLA.xml:S2:1856:4	O
in	OTEZLA.xml:S2:1861:2	O
placebo	OTEZLA.xml:S2:1864:7	O
treated	OTEZLA.xml:S2:1872:7	O
subjects	OTEZLA.xml:S2:1880:8	O
(	OTEZLA.xml:S2:1889:1	O
0	OTEZLA.xml:S2:1890:1	O
495	OTEZLA.xml:S2:1892:3	O
)	OTEZLA.xml:S2:1895:1	O
.	OTEZLA.xml:S2:1896:1	O

Depression	OTEZLA.xml:S2:1898:10	B-AdverseReaction
was	OTEZLA.xml:S2:1909:3	O
reported	OTEZLA.xml:S2:1913:8	O
as	OTEZLA.xml:S2:1922:2	O
serious	OTEZLA.xml:S2:1925:7	B-Severity
in	OTEZLA.xml:S2:1933:2	O
0.2%	OTEZLA.xml:S2:1936:4	O
(	OTEZLA.xml:S2:1941:1	O
3	OTEZLA.xml:S2:1942:1	O
1441	OTEZLA.xml:S2:1944:4	O
)	OTEZLA.xml:S2:1948:1	O
of	OTEZLA.xml:S2:1950:2	O
subjects	OTEZLA.xml:S2:1953:8	O
exposed	OTEZLA.xml:S2:1962:7	O
to	OTEZLA.xml:S2:1970:2	O
OTEZLA	OTEZLA.xml:S2:1973:6	O
,	OTEZLA.xml:S2:1979:1	O
compared	OTEZLA.xml:S2:1981:8	O
to	OTEZLA.xml:S2:1990:2	O
none	OTEZLA.xml:S2:1993:4	O
in	OTEZLA.xml:S2:1998:2	O
placebo	OTEZLA.xml:S2:2001:7	O
-	OTEZLA.xml:S2:2008:1	O
treated	OTEZLA.xml:S2:2009:7	O
subjects	OTEZLA.xml:S2:2017:8	O
(	OTEZLA.xml:S2:2026:1	O
0	OTEZLA.xml:S2:2027:1	O
495	OTEZLA.xml:S2:2029:3	O
)	OTEZLA.xml:S2:2032:1	O
.	OTEZLA.xml:S2:2033:1	O

Instances	OTEZLA.xml:S2:2035:9	O
of	OTEZLA.xml:S2:2045:2	O
suicidal	OTEZLA.xml:S2:2048:8	B-AdverseReaction
ideation	OTEZLA.xml:S2:2057:8	I-AdverseReaction
and	OTEZLA.xml:S2:2066:3	O
behavior	OTEZLA.xml:S2:2070:8	I-AdverseReaction
have	OTEZLA.xml:S2:2079:4	O
been	OTEZLA.xml:S2:2084:4	O
observed	OTEZLA.xml:S2:2089:8	O
in	OTEZLA.xml:S2:2098:2	O
0.2%	OTEZLA.xml:S2:2101:4	O
(	OTEZLA.xml:S2:2106:1	O
3	OTEZLA.xml:S2:2107:1	O
1441	OTEZLA.xml:S2:2109:4	O
)	OTEZLA.xml:S2:2113:1	O
of	OTEZLA.xml:S2:2115:2	O
subjects	OTEZLA.xml:S2:2118:8	O
while	OTEZLA.xml:S2:2127:5	O
receiving	OTEZLA.xml:S2:2133:9	O
OTEZLA	OTEZLA.xml:S2:2143:6	O
,	OTEZLA.xml:S2:2149:1	O
compared	OTEZLA.xml:S2:2151:8	O
to	OTEZLA.xml:S2:2160:2	O
none	OTEZLA.xml:S2:2163:4	O
in	OTEZLA.xml:S2:2168:2	O
placebo	OTEZLA.xml:S2:2171:7	O
treated	OTEZLA.xml:S2:2179:7	O
subjects	OTEZLA.xml:S2:2187:8	O
(	OTEZLA.xml:S2:2196:1	O
0	OTEZLA.xml:S2:2197:1	O
495	OTEZLA.xml:S2:2199:3	O
)	OTEZLA.xml:S2:2202:1	O
.	OTEZLA.xml:S2:2203:1	O

In	OTEZLA.xml:S2:2205:2	O
the	OTEZLA.xml:S2:2208:3	O
clinical	OTEZLA.xml:S2:2212:8	O
trials	OTEZLA.xml:S2:2221:6	O
,	OTEZLA.xml:S2:2227:1	O
2	OTEZLA.xml:S2:2229:1	O
subjects	OTEZLA.xml:S2:2231:8	O
who	OTEZLA.xml:S2:2240:3	O
received	OTEZLA.xml:S2:2244:8	O
placebo	OTEZLA.xml:S2:2253:7	O
committed	OTEZLA.xml:S2:2261:9	O
suicide	OTEZLA.xml:S2:2271:7	B-AdverseReaction
compared	OTEZLA.xml:S2:2279:8	O
to	OTEZLA.xml:S2:2288:2	O
none	OTEZLA.xml:S2:2291:4	B-Negation
in	OTEZLA.xml:S2:2296:2	O
OTEZLA	OTEZLA.xml:S2:2299:6	O
-	OTEZLA.xml:S2:2305:1	O
treated	OTEZLA.xml:S2:2306:7	O
subjects	OTEZLA.xml:S2:2314:8	O
.	OTEZLA.xml:S2:2322:1	O

Psoriasis	OTEZLA.xml:S2:2330:9	O
:	OTEZLA.xml:S2:2341:1	O
During	OTEZLA.xml:S2:2343:6	O
the	OTEZLA.xml:S2:2350:3	O
0	OTEZLA.xml:S2:2354:1	O
to	OTEZLA.xml:S2:2356:2	O
16	OTEZLA.xml:S2:2359:2	O
week	OTEZLA.xml:S2:2362:4	O
placebo	OTEZLA.xml:S2:2367:7	O
-	OTEZLA.xml:S2:2374:1	O
controlled	OTEZLA.xml:S2:2375:10	O
period	OTEZLA.xml:S2:2386:6	O
of	OTEZLA.xml:S2:2393:2	O
the	OTEZLA.xml:S2:2396:3	O
3	OTEZLA.xml:S2:2400:1	O
controlled	OTEZLA.xml:S2:2402:10	O
clinical	OTEZLA.xml:S2:2413:8	O
trials	OTEZLA.xml:S2:2422:6	O
,	OTEZLA.xml:S2:2428:1	O
1.3%	OTEZLA.xml:S2:2430:4	O
(	OTEZLA.xml:S2:2435:1	O
12	OTEZLA.xml:S2:2436:2	O
920	OTEZLA.xml:S2:2439:3	O
)	OTEZLA.xml:S2:2442:1	O
of	OTEZLA.xml:S2:2444:2	O
subjects	OTEZLA.xml:S2:2447:8	O
treated	OTEZLA.xml:S2:2456:7	O
with	OTEZLA.xml:S2:2464:4	O
OTEZLA	OTEZLA.xml:S2:2469:6	O
reported	OTEZLA.xml:S2:2476:8	O
depression	OTEZLA.xml:S2:2485:10	B-AdverseReaction
compared	OTEZLA.xml:S2:2496:8	O
to	OTEZLA.xml:S2:2505:2	O
0.4%	OTEZLA.xml:S2:2508:4	O
(	OTEZLA.xml:S2:2513:1	O
2	OTEZLA.xml:S2:2514:1	O
506	OTEZLA.xml:S2:2516:3	O
)	OTEZLA.xml:S2:2519:1	O
treated	OTEZLA.xml:S2:2521:7	O
with	OTEZLA.xml:S2:2529:4	O
placebo	OTEZLA.xml:S2:2534:7	O
.	OTEZLA.xml:S2:2541:1	O

During	OTEZLA.xml:S2:2543:6	O
the	OTEZLA.xml:S2:2550:3	O
clinical	OTEZLA.xml:S2:2554:8	O
trials	OTEZLA.xml:S2:2563:6	O
,	OTEZLA.xml:S2:2569:1	O
0.1%	OTEZLA.xml:S2:2571:4	O
(	OTEZLA.xml:S2:2576:1	O
1	OTEZLA.xml:S2:2577:1	O
1308	OTEZLA.xml:S2:2579:4	O
)	OTEZLA.xml:S2:2583:1	O
of	OTEZLA.xml:S2:2585:2	O
subjects	OTEZLA.xml:S2:2588:8	O
treated	OTEZLA.xml:S2:2597:7	O
with	OTEZLA.xml:S2:2605:4	O
OTEZLA	OTEZLA.xml:S2:2610:6	O
discontinued	OTEZLA.xml:S2:2617:12	O
treatment	OTEZLA.xml:S2:2630:9	O
due	OTEZLA.xml:S2:2640:3	O
to	OTEZLA.xml:S2:2644:2	O
depression	OTEZLA.xml:S2:2647:10	B-AdverseReaction
compared	OTEZLA.xml:S2:2658:8	O
with	OTEZLA.xml:S2:2667:4	O
none	OTEZLA.xml:S2:2672:4	O
in	OTEZLA.xml:S2:2677:2	O
placebo	OTEZLA.xml:S2:2680:7	O
-	OTEZLA.xml:S2:2687:1	O
treated	OTEZLA.xml:S2:2688:7	O
subjects	OTEZLA.xml:S2:2696:8	O
(	OTEZLA.xml:S2:2704:1	O
0	OTEZLA.xml:S2:2705:1	O
506	OTEZLA.xml:S2:2707:3	O
)	OTEZLA.xml:S2:2710:1	O
.	OTEZLA.xml:S2:2711:1	O

Depression	OTEZLA.xml:S2:2713:10	B-AdverseReaction
was	OTEZLA.xml:S2:2724:3	O
reported	OTEZLA.xml:S2:2728:8	O
as	OTEZLA.xml:S2:2737:2	O
serious	OTEZLA.xml:S2:2740:7	B-Severity
in	OTEZLA.xml:S2:2748:2	O
0.1%	OTEZLA.xml:S2:2751:4	O
(	OTEZLA.xml:S2:2756:1	O
1	OTEZLA.xml:S2:2757:1	O
1308	OTEZLA.xml:S2:2759:4	O
)	OTEZLA.xml:S2:2763:1	O
of	OTEZLA.xml:S2:2765:2	O
subjects	OTEZLA.xml:S2:2768:8	O
exposed	OTEZLA.xml:S2:2777:7	O
to	OTEZLA.xml:S2:2785:2	O
OTEZLA	OTEZLA.xml:S2:2788:6	O
,	OTEZLA.xml:S2:2794:1	O
compared	OTEZLA.xml:S2:2796:8	O
to	OTEZLA.xml:S2:2805:2	O
none	OTEZLA.xml:S2:2808:4	O
in	OTEZLA.xml:S2:2813:2	O
placebo	OTEZLA.xml:S2:2816:7	O
-	OTEZLA.xml:S2:2823:1	O
treated	OTEZLA.xml:S2:2824:7	O
subjects	OTEZLA.xml:S2:2832:8	O
(	OTEZLA.xml:S2:2841:1	O
0	OTEZLA.xml:S2:2842:1	O
506	OTEZLA.xml:S2:2844:3	O
)	OTEZLA.xml:S2:2847:1	O
.	OTEZLA.xml:S2:2848:1	O

Instances	OTEZLA.xml:S2:2850:9	O
of	OTEZLA.xml:S2:2860:2	O
suicidal	OTEZLA.xml:S2:2863:8	B-AdverseReaction
behavior	OTEZLA.xml:S2:2872:8	I-AdverseReaction
have	OTEZLA.xml:S2:2881:4	O
been	OTEZLA.xml:S2:2886:4	O
observed	OTEZLA.xml:S2:2891:8	O
in	OTEZLA.xml:S2:2900:2	O
0.1%	OTEZLA.xml:S2:2903:4	O
(	OTEZLA.xml:S2:2908:1	O
1	OTEZLA.xml:S2:2909:1	O
1308	OTEZLA.xml:S2:2911:4	O
)	OTEZLA.xml:S2:2915:1	O
of	OTEZLA.xml:S2:2917:2	O
subjects	OTEZLA.xml:S2:2920:8	O
while	OTEZLA.xml:S2:2929:5	O
receiving	OTEZLA.xml:S2:2935:9	O
OTEZLA	OTEZLA.xml:S2:2945:6	O
,	OTEZLA.xml:S2:2951:1	O
compared	OTEZLA.xml:S2:2953:8	O
to	OTEZLA.xml:S2:2962:2	O
0.2%	OTEZLA.xml:S2:2965:4	O
(	OTEZLA.xml:S2:2970:1	O
1	OTEZLA.xml:S2:2971:1	O
506	OTEZLA.xml:S2:2973:3	O
)	OTEZLA.xml:S2:2976:1	O
in	OTEZLA.xml:S2:2978:2	O
placebo	OTEZLA.xml:S2:2981:7	O
-	OTEZLA.xml:S2:2988:1	O
treated	OTEZLA.xml:S2:2989:7	O
subjects	OTEZLA.xml:S2:2997:8	O
.	OTEZLA.xml:S2:3005:1	O

In	OTEZLA.xml:S2:3007:2	O
the	OTEZLA.xml:S2:3010:3	O
clinical	OTEZLA.xml:S2:3014:8	O
trials	OTEZLA.xml:S2:3023:6	O
,	OTEZLA.xml:S2:3029:1	O
one	OTEZLA.xml:S2:3031:3	O
subject	OTEZLA.xml:S2:3035:7	O
treated	OTEZLA.xml:S2:3043:7	O
with	OTEZLA.xml:S2:3051:4	O
OTEZLA	OTEZLA.xml:S2:3056:6	O
attempted	OTEZLA.xml:S2:3063:9	B-AdverseReaction
suicide	OTEZLA.xml:S2:3073:7	I-AdverseReaction
while	OTEZLA.xml:S2:3081:5	O
one	OTEZLA.xml:S2:3087:3	O
who	OTEZLA.xml:S2:3091:3	O
received	OTEZLA.xml:S2:3095:8	O
placebo	OTEZLA.xml:S2:3104:7	B-Factor
committed	OTEZLA.xml:S2:3112:9	O
suicide	OTEZLA.xml:S2:3122:7	B-AdverseReaction
.	OTEZLA.xml:S2:3129:1	O

5.2	OTEZLA.xml:S2:3137:3	O
Weight	OTEZLA.xml:S2:3141:6	O
Decrease	OTEZLA.xml:S2:3148:8	O

During	OTEZLA.xml:S2:3160:6	O
the	OTEZLA.xml:S2:3167:3	O
controlled	OTEZLA.xml:S2:3171:10	O
period	OTEZLA.xml:S2:3182:6	O
of	OTEZLA.xml:S2:3189:2	O
the	OTEZLA.xml:S2:3192:3	O
studies	OTEZLA.xml:S2:3196:7	O
in	OTEZLA.xml:S2:3204:2	O
psoriatic	OTEZLA.xml:S2:3207:9	O
arthritis	OTEZLA.xml:S2:3217:9	O
(	OTEZLA.xml:S2:3227:1	O
PsA	OTEZLA.xml:S2:3228:3	O
)	OTEZLA.xml:S2:3231:1	O
,	OTEZLA.xml:S2:3232:1	O
weight	OTEZLA.xml:S2:3234:6	B-AdverseReaction
decrease	OTEZLA.xml:S2:3241:8	I-AdverseReaction
between	OTEZLA.xml:S2:3250:7	O
5%	OTEZLA.xml:S2:3258:2	O
-	OTEZLA.xml:S2:3260:1	O
10%	OTEZLA.xml:S2:3261:3	O
of	OTEZLA.xml:S2:3265:2	O
body	OTEZLA.xml:S2:3268:4	O
weight	OTEZLA.xml:S2:3273:6	O
was	OTEZLA.xml:S2:3280:3	O
reported	OTEZLA.xml:S2:3284:8	O
in	OTEZLA.xml:S2:3293:2	O
10%	OTEZLA.xml:S2:3296:3	O
(	OTEZLA.xml:S2:3300:1	O
49	OTEZLA.xml:S2:3301:2	O
497	OTEZLA.xml:S2:3304:3	O
)	OTEZLA.xml:S2:3307:1	O
of	OTEZLA.xml:S2:3309:2	O
subjects	OTEZLA.xml:S2:3312:8	O
treated	OTEZLA.xml:S2:3321:7	O
with	OTEZLA.xml:S2:3329:4	O
OTEZLA	OTEZLA.xml:S2:3334:6	O
30	OTEZLA.xml:S2:3341:2	O
mg	OTEZLA.xml:S2:3344:2	O
twice	OTEZLA.xml:S2:3347:5	O
daily	OTEZLA.xml:S2:3353:5	O
compared	OTEZLA.xml:S2:3359:8	O
to	OTEZLA.xml:S2:3368:2	O
3.3%	OTEZLA.xml:S2:3371:4	O
(	OTEZLA.xml:S2:3376:1	O
16	OTEZLA.xml:S2:3377:2	O
495	OTEZLA.xml:S2:3380:3	O
)	OTEZLA.xml:S2:3383:1	O
treated	OTEZLA.xml:S2:3385:7	O
with	OTEZLA.xml:S2:3393:4	O
placebo	OTEZLA.xml:S2:3398:7	O
[	OTEZLA.xml:S2:3406:1	O
see	OTEZLA.xml:S2:3409:3	O
Adverse	OTEZLA.xml:S2:3413:7	O
Reactions	OTEZLA.xml:S2:3421:9	O
(	OTEZLA.xml:S2:3431:1	O
6.1	OTEZLA.xml:S2:3432:3	O
)	OTEZLA.xml:S2:3435:1	O
]	OTEZLA.xml:S2:3438:1	O
.	OTEZLA.xml:S2:3439:1	O

During	OTEZLA.xml:S2:3447:6	O
the	OTEZLA.xml:S2:3454:3	O
controlled	OTEZLA.xml:S2:3458:10	O
period	OTEZLA.xml:S2:3469:6	O
of	OTEZLA.xml:S2:3476:2	O
the	OTEZLA.xml:S2:3479:3	O
trials	OTEZLA.xml:S2:3483:6	O
in	OTEZLA.xml:S2:3490:2	O
psoriasis	OTEZLA.xml:S2:3493:9	O
,	OTEZLA.xml:S2:3502:1	O
weight	OTEZLA.xml:S2:3504:6	B-AdverseReaction
decrease	OTEZLA.xml:S2:3511:8	I-AdverseReaction
between	OTEZLA.xml:S2:3520:7	B-Severity
5%	OTEZLA.xml:S2:3528:2	I-Severity
-	OTEZLA.xml:S2:3530:1	I-Severity
10%	OTEZLA.xml:S2:3531:3	I-Severity
of	OTEZLA.xml:S2:3535:2	I-Severity
body	OTEZLA.xml:S2:3538:4	I-Severity
weight	OTEZLA.xml:S2:3543:6	I-Severity
occurred	OTEZLA.xml:S2:3550:8	O
in	OTEZLA.xml:S2:3559:2	O
12%	OTEZLA.xml:S2:3562:3	O
(	OTEZLA.xml:S2:3566:1	O
96	OTEZLA.xml:S2:3567:2	O
784	OTEZLA.xml:S2:3570:3	O
)	OTEZLA.xml:S2:3573:1	O
of	OTEZLA.xml:S2:3575:2	O
subjects	OTEZLA.xml:S2:3578:8	O
treated	OTEZLA.xml:S2:3587:7	O
with	OTEZLA.xml:S2:3595:4	O
OTEZLA	OTEZLA.xml:S2:3600:6	O
compared	OTEZLA.xml:S2:3607:8	O
to	OTEZLA.xml:S2:3616:2	O
5%	OTEZLA.xml:S2:3619:2	O
(	OTEZLA.xml:S2:3622:1	O
19	OTEZLA.xml:S2:3623:2	O
382	OTEZLA.xml:S2:3626:3	O
)	OTEZLA.xml:S2:3629:1	O
treated	OTEZLA.xml:S2:3631:7	O
with	OTEZLA.xml:S2:3639:4	O
placebo	OTEZLA.xml:S2:3644:7	O
.	OTEZLA.xml:S2:3651:1	O

Weight	OTEZLA.xml:S2:3653:6	B-AdverseReaction
decrease	OTEZLA.xml:S2:3660:8	I-AdverseReaction
of	OTEZLA.xml:S2:3669:2	O
10%	OTEZLA.xml:S2:3674:3	B-Severity
of	OTEZLA.xml:S2:3678:2	I-Severity
body	OTEZLA.xml:S2:3681:4	I-Severity
weight	OTEZLA.xml:S2:3686:6	I-Severity
occurred	OTEZLA.xml:S2:3693:8	O
in	OTEZLA.xml:S2:3702:2	O
2%	OTEZLA.xml:S2:3705:2	O
(	OTEZLA.xml:S2:3708:1	O
16	OTEZLA.xml:S2:3709:2	O
784	OTEZLA.xml:S2:3712:3	O
)	OTEZLA.xml:S2:3715:1	O
of	OTEZLA.xml:S2:3717:2	O
subjects	OTEZLA.xml:S2:3720:8	O
treated	OTEZLA.xml:S2:3729:7	O
with	OTEZLA.xml:S2:3737:4	O
OTEZLA	OTEZLA.xml:S2:3742:6	O
30	OTEZLA.xml:S2:3749:2	O
mg	OTEZLA.xml:S2:3752:2	O
twice	OTEZLA.xml:S2:3755:5	O
daily	OTEZLA.xml:S2:3761:5	O
compared	OTEZLA.xml:S2:3767:8	O
to	OTEZLA.xml:S2:3776:2	O
1%	OTEZLA.xml:S2:3779:2	O
(	OTEZLA.xml:S2:3782:1	O
3	OTEZLA.xml:S2:3783:1	O
382	OTEZLA.xml:S2:3785:3	O
)	OTEZLA.xml:S2:3788:1	O
subjects	OTEZLA.xml:S2:3790:8	O
treated	OTEZLA.xml:S2:3799:7	O
with	OTEZLA.xml:S2:3807:4	O
placebo	OTEZLA.xml:S2:3812:7	O
.	OTEZLA.xml:S2:3819:1	O

Patients	OTEZLA.xml:S2:3827:8	O
treated	OTEZLA.xml:S2:3836:7	O
with	OTEZLA.xml:S2:3844:4	O
OTEZLA	OTEZLA.xml:S2:3849:6	O
should	OTEZLA.xml:S2:3856:6	O
have	OTEZLA.xml:S2:3863:4	O
their	OTEZLA.xml:S2:3868:5	O
weight	OTEZLA.xml:S2:3874:6	O
monitored	OTEZLA.xml:S2:3881:9	O
regularly	OTEZLA.xml:S2:3891:9	O
.	OTEZLA.xml:S2:3900:1	O

If	OTEZLA.xml:S2:3902:2	O
unexplained	OTEZLA.xml:S2:3905:11	O
or	OTEZLA.xml:S2:3917:2	O
clinically	OTEZLA.xml:S2:3920:10	O
significant	OTEZLA.xml:S2:3931:11	O
weight	OTEZLA.xml:S2:3943:6	O
loss	OTEZLA.xml:S2:3950:4	O
occurs	OTEZLA.xml:S2:3955:6	O
,	OTEZLA.xml:S2:3961:1	O
weight	OTEZLA.xml:S2:3963:6	O
loss	OTEZLA.xml:S2:3970:4	O
should	OTEZLA.xml:S2:3975:6	O
be	OTEZLA.xml:S2:3982:2	O
evaluated	OTEZLA.xml:S2:3985:9	O
,	OTEZLA.xml:S2:3994:1	O
and	OTEZLA.xml:S2:3996:3	O
discontinuation	OTEZLA.xml:S2:4000:15	O
of	OTEZLA.xml:S2:4016:2	O
OTEZLA	OTEZLA.xml:S2:4019:6	O
should	OTEZLA.xml:S2:4026:6	O
be	OTEZLA.xml:S2:4033:2	O
considered	OTEZLA.xml:S2:4036:10	O
.	OTEZLA.xml:S2:4046:1	O

5.3	OTEZLA.xml:S2:4054:3	O
Drug	OTEZLA.xml:S2:4058:4	O
Interactions	OTEZLA.xml:S2:4063:12	O

Co	OTEZLA.xml:S2:4079:2	O
-	OTEZLA.xml:S2:4081:1	O
administration	OTEZLA.xml:S2:4082:14	O
of	OTEZLA.xml:S2:4097:2	O
strong	OTEZLA.xml:S2:4100:6	O
cytochrome	OTEZLA.xml:S2:4107:10	O
P450	OTEZLA.xml:S2:4118:4	O
enzyme	OTEZLA.xml:S2:4123:6	O
inducer	OTEZLA.xml:S2:4130:7	O
,	OTEZLA.xml:S2:4137:1	O
rifampin	OTEZLA.xml:S2:4139:8	O
,	OTEZLA.xml:S2:4147:1	O
resulted	OTEZLA.xml:S2:4149:8	O
in	OTEZLA.xml:S2:4158:2	O
a	OTEZLA.xml:S2:4161:1	O
reduction	OTEZLA.xml:S2:4163:9	O
of	OTEZLA.xml:S2:4173:2	O
systemic	OTEZLA.xml:S2:4176:8	O
exposure	OTEZLA.xml:S2:4185:8	O
of	OTEZLA.xml:S2:4194:2	O
apremilast	OTEZLA.xml:S2:4197:10	O
,	OTEZLA.xml:S2:4207:1	O
which	OTEZLA.xml:S2:4209:5	O
may	OTEZLA.xml:S2:4215:3	O
result	OTEZLA.xml:S2:4219:6	O
in	OTEZLA.xml:S2:4226:2	O
a	OTEZLA.xml:S2:4229:1	O
loss	OTEZLA.xml:S2:4231:4	O
of	OTEZLA.xml:S2:4236:2	O
efficacy	OTEZLA.xml:S2:4239:8	O
of	OTEZLA.xml:S2:4248:2	O
OTEZLA	OTEZLA.xml:S2:4251:6	O
.	OTEZLA.xml:S2:4257:1	O

Therefore	OTEZLA.xml:S2:4259:9	O
,	OTEZLA.xml:S2:4268:1	O
the	OTEZLA.xml:S2:4270:3	O
use	OTEZLA.xml:S2:4274:3	O
of	OTEZLA.xml:S2:4278:2	O
cytochrome	OTEZLA.xml:S2:4281:10	O
P450	OTEZLA.xml:S2:4292:4	O
enzyme	OTEZLA.xml:S2:4297:6	O
inducers	OTEZLA.xml:S2:4304:8	O
(	OTEZLA.xml:S2:4313:1	O
e	OTEZLA.xml:S2:4314:1	O
.	OTEZLA.xml:S2:4315:1	O
g	OTEZLA.xml:S2:4316:1	O
.	OTEZLA.xml:S2:4317:1	O
,	OTEZLA.xml:S2:4318:1	O
rifampin	OTEZLA.xml:S2:4320:8	O
,	OTEZLA.xml:S2:4328:1	O
phenobarbital	OTEZLA.xml:S2:4330:13	O
,	OTEZLA.xml:S2:4343:1	O
carbamazepine	OTEZLA.xml:S2:4345:13	O
,	OTEZLA.xml:S2:4358:1	O
phenytoin	OTEZLA.xml:S2:4360:9	O
)	OTEZLA.xml:S2:4369:1	O
with	OTEZLA.xml:S2:4371:4	O
OTEZLA	OTEZLA.xml:S2:4376:6	O
is	OTEZLA.xml:S2:4383:2	O
not	OTEZLA.xml:S2:4386:3	O
recommended	OTEZLA.xml:S2:4390:11	O
[	OTEZLA.xml:S2:4402:1	O
see	OTEZLA.xml:S2:4403:3	O
Drug	OTEZLA.xml:S2:4408:4	O
Interactions	OTEZLA.xml:S2:4413:12	O
(	OTEZLA.xml:S2:4426:1	O
7.1	OTEZLA.xml:S2:4427:3	O
)	OTEZLA.xml:S2:4430:1	O
and	OTEZLA.xml:S2:4433:3	O
Clinical	OTEZLA.xml:S2:4438:8	O
Pharmacology	OTEZLA.xml:S2:4447:12	O
(	OTEZLA.xml:S2:4460:1	O
12.3	OTEZLA.xml:S2:4461:4	O
)	OTEZLA.xml:S2:4465:1	O
]	OTEZLA.xml:S2:4468:1	O
.	OTEZLA.xml:S2:4469:1	O
6	PICATO.xml:S1:6:1	O
ADVERSE	PICATO.xml:S1:8:7	O
REACTIONS	PICATO.xml:S1:16:9	O

The	PICATO.xml:S1:40:3	O

following	PICATO.xml:S1:44:9	O
serious	PICATO.xml:S1:54:7	O
adverse	PICATO.xml:S1:62:7	O
reactions	PICATO.xml:S1:70:9	O
are	PICATO.xml:S1:80:3	O
discussed	PICATO.xml:S1:84:9	O
in	PICATO.xml:S1:94:2	O
more	PICATO.xml:S1:97:4	O
detail	PICATO.xml:S1:102:6	O
in	PICATO.xml:S1:109:2	O
other	PICATO.xml:S1:112:5	O
sections	PICATO.xml:S1:118:8	O
of	PICATO.xml:S1:127:2	O
the	PICATO.xml:S1:130:3	O
labeling	PICATO.xml:S1:134:8	O
:	PICATO.xml:S1:142:1	O

Ophthalmic	PICATO.xml:S1:160:10	B-AdverseReaction

Adverse	PICATO.xml:S1:171:7	I-AdverseReaction
Reaction	PICATO.xml:S1:179:8	I-AdverseReaction
[	PICATO.xml:S1:188:1	O
see	PICATO.xml:S1:189:3	O
Warnings	PICATO.xml:S1:193:8	O
and	PICATO.xml:S1:202:3	O
Precautions	PICATO.xml:S1:206:11	O
(	PICATO.xml:S1:218:1	O
5.1	PICATO.xml:S1:221:3	O
)]	PICATO.xml:S1:226:2	O

Hypersensitivity	PICATO.xml:S1:235:16	B-AdverseReaction
Reactions	PICATO.xml:S1:252:9	I-AdverseReaction
[	PICATO.xml:S1:262:1	O
see	PICATO.xml:S1:263:3	O
Warnings	PICATO.xml:S1:267:8	O
and	PICATO.xml:S1:276:3	O
Precautions	PICATO.xml:S1:280:11	O
(	PICATO.xml:S1:292:1	O
5.2	PICATO.xml:S1:295:3	O
)]	PICATO.xml:S1:300:2	O

EXCERPT	PICATO.xml:S1:316:7	O

:	PICATO.xml:S1:323:1	O

The	PICATO.xml:S1:327:3	O
most	PICATO.xml:S1:331:4	O
common	PICATO.xml:S1:336:6	O
adverse	PICATO.xml:S1:343:7	O
reactions	PICATO.xml:S1:351:9	O
(	PICATO.xml:S1:361:1	O
2	PICATO.xml:S1:364:1	O
)	PICATO.xml:S1:367:1	O
are	PICATO.xml:S1:369:3	O
local	PICATO.xml:S1:373:5	B-AdverseReaction
skin	PICATO.xml:S1:379:4	I-AdverseReaction
reactions	PICATO.xml:S1:384:9	I-AdverseReaction
,	PICATO.xml:S1:393:1	O
application	PICATO.xml:S1:395:11	B-AdverseReaction
site	PICATO.xml:S1:407:4	I-AdverseReaction
pain	PICATO.xml:S1:412:4	I-AdverseReaction
,	PICATO.xml:S1:416:1	O
application	PICATO.xml:S1:418:11	B-AdverseReaction
site	PICATO.xml:S1:430:4	I-AdverseReaction
pruritus	PICATO.xml:S1:435:8	I-AdverseReaction
,	PICATO.xml:S1:443:1	O
application	PICATO.xml:S1:445:11	B-AdverseReaction
site	PICATO.xml:S1:457:4	I-AdverseReaction
irritation	PICATO.xml:S1:462:10	I-AdverseReaction
,	PICATO.xml:S1:472:1	O
application	PICATO.xml:S1:474:11	B-AdverseReaction
site	PICATO.xml:S1:486:4	I-AdverseReaction
infection	PICATO.xml:S1:491:9	I-AdverseReaction
,	PICATO.xml:S1:500:1	O
periorbital	PICATO.xml:S1:502:11	B-AdverseReaction
edema	PICATO.xml:S1:514:5	I-AdverseReaction
,	PICATO.xml:S1:519:1	O
nasopharyngitis	PICATO.xml:S1:521:15	B-AdverseReaction
and	PICATO.xml:S1:537:3	O
headache	PICATO.xml:S1:541:8	B-AdverseReaction
.	PICATO.xml:S1:549:1	O

(	PICATO.xml:S1:551:1	O
6.1	PICATO.xml:S1:556:3	O
)	PICATO.xml:S1:563:1	O

To	PICATO.xml:S1:571:2	O
report	PICATO.xml:S1:574:6	O
SUSPECTED	PICATO.xml:S1:581:9	O
ADVERSE	PICATO.xml:S1:591:7	O
REACTIONS	PICATO.xml:S1:599:9	O
,	PICATO.xml:S1:608:1	O
contact	PICATO.xml:S1:610:7	O
LEO	PICATO.xml:S1:618:3	O
Pharma	PICATO.xml:S1:622:6	O
Inc	PICATO.xml:S1:629:3	O
.	PICATO.xml:S1:632:1	O

at	PICATO.xml:S1:634:2	O
1	PICATO.xml:S1:637:1	O
-	PICATO.xml:S1:638:1	O
877	PICATO.xml:S1:639:3	O
-	PICATO.xml:S1:642:1	O
494	PICATO.xml:S1:643:3	O
-	PICATO.xml:S1:646:1	O
4536	PICATO.xml:S1:647:4	O
or	PICATO.xml:S1:652:2	O
FDA	PICATO.xml:S1:655:3	O
at	PICATO.xml:S1:659:2	O
1	PICATO.xml:S1:662:1	O
-	PICATO.xml:S1:663:1	O
800	PICATO.xml:S1:664:3	O
-	PICATO.xml:S1:667:1	O
FDA	PICATO.xml:S1:668:3	O
-	PICATO.xml:S1:671:1	O
1088	PICATO.xml:S1:672:4	O
or	PICATO.xml:S1:677:2	O
www	PICATO.xml:S1:681:3	O
.	PICATO.xml:S1:684:1	O
fda	PICATO.xml:S1:685:3	O
.	PICATO.xml:S1:688:1	O
gov	PICATO.xml:S1:689:3	O
medwatch	PICATO.xml:S1:693:8	O
.	PICATO.xml:S1:701:1	O

6.1	PICATO.xml:S1:715:3	O

Clinical	PICATO.xml:S1:719:8	O
Trials	PICATO.xml:S1:728:6	O
Experience	PICATO.xml:S1:735:10	O

Because	PICATO.xml:S1:749:7	O
clinical	PICATO.xml:S1:757:8	O
trials	PICATO.xml:S1:766:6	O
are	PICATO.xml:S1:773:3	O
conducted	PICATO.xml:S1:777:9	O
under	PICATO.xml:S1:787:5	O
widely	PICATO.xml:S1:793:6	O
varying	PICATO.xml:S1:800:7	O
conditions	PICATO.xml:S1:808:10	O
,	PICATO.xml:S1:818:1	O
adverse	PICATO.xml:S1:820:7	O
reaction	PICATO.xml:S1:828:8	O
rates	PICATO.xml:S1:837:5	O
observed	PICATO.xml:S1:843:8	O
in	PICATO.xml:S1:852:2	O
the	PICATO.xml:S1:855:3	O
clinical	PICATO.xml:S1:859:8	O
trials	PICATO.xml:S1:868:6	O
of	PICATO.xml:S1:875:2	O
a	PICATO.xml:S1:878:1	O
drug	PICATO.xml:S1:880:4	O
cannot	PICATO.xml:S1:885:6	O
be	PICATO.xml:S1:892:2	O
directly	PICATO.xml:S1:895:8	O
compared	PICATO.xml:S1:904:8	O
to	PICATO.xml:S1:913:2	O
rates	PICATO.xml:S1:916:5	O
in	PICATO.xml:S1:922:2	O
the	PICATO.xml:S1:925:3	O
clinical	PICATO.xml:S1:929:8	O
trials	PICATO.xml:S1:938:6	O
of	PICATO.xml:S1:945:2	O
another	PICATO.xml:S1:948:7	O
drug	PICATO.xml:S1:956:4	O
and	PICATO.xml:S1:961:3	O
may	PICATO.xml:S1:965:3	O
not	PICATO.xml:S1:969:3	O
reflect	PICATO.xml:S1:973:7	O
the	PICATO.xml:S1:981:3	O
rates	PICATO.xml:S1:985:5	O
observed	PICATO.xml:S1:991:8	O
in	PICATO.xml:S1:1000:2	O
clinical	PICATO.xml:S1:1003:8	O
practice	PICATO.xml:S1:1012:8	O
.	PICATO.xml:S1:1020:1	O

The	PICATO.xml:S1:1031:3	O

data	PICATO.xml:S1:1035:4	O
described	PICATO.xml:S1:1040:9	O
below	PICATO.xml:S1:1050:5	O
reflect	PICATO.xml:S1:1056:7	O
exposure	PICATO.xml:S1:1064:8	O
to	PICATO.xml:S1:1073:2	O
Picato	PICATO.xml:S1:1076:6	O
(	PICATO.xml:S1:1084:1	O
r	PICATO.xml:S1:1085:1	O
)	PICATO.xml:S1:1086:1	O
gel	PICATO.xml:S1:1089:3	O
in	PICATO.xml:S1:1093:2	O
499	PICATO.xml:S1:1096:3	O
subjects	PICATO.xml:S1:1100:8	O
with	PICATO.xml:S1:1109:4	O
actinic	PICATO.xml:S1:1114:7	O
keratosis	PICATO.xml:S1:1122:9	O
,	PICATO.xml:S1:1131:1	O
including	PICATO.xml:S1:1133:9	O
274	PICATO.xml:S1:1143:3	O
subjects	PICATO.xml:S1:1147:8	O
exposed	PICATO.xml:S1:1156:7	O
to	PICATO.xml:S1:1164:2	O
Picato	PICATO.xml:S1:1167:6	O
(	PICATO.xml:S1:1175:1	O
r	PICATO.xml:S1:1176:1	O
)	PICATO.xml:S1:1177:1	O
gel	PICATO.xml:S1:1180:3	O
field	PICATO.xml:S1:1184:5	O
treatment	PICATO.xml:S1:1190:9	O
(	PICATO.xml:S1:1200:1	O
skin	PICATO.xml:S1:1201:4	O
area	PICATO.xml:S1:1206:4	O
of	PICATO.xml:S1:1211:2	O
25	PICATO.xml:S1:1214:2	O
cm	PICATO.xml:S1:1217:2	O
2	PICATO.xml:S1:1221:1	O
in	PICATO.xml:S1:1224:2	O
the	PICATO.xml:S1:1227:3	O
face	PICATO.xml:S1:1231:4	O
or	PICATO.xml:S1:1236:2	O
scalp	PICATO.xml:S1:1239:5	O
regions	PICATO.xml:S1:1245:7	O
)	PICATO.xml:S1:1252:1	O
at	PICATO.xml:S1:1254:2	O
a	PICATO.xml:S1:1257:1	O
concentration	PICATO.xml:S1:1259:13	O
of	PICATO.xml:S1:1273:2	O
0.015%	PICATO.xml:S1:1276:6	O
once	PICATO.xml:S1:1283:4	O
daily	PICATO.xml:S1:1288:5	O
for	PICATO.xml:S1:1294:3	O
3	PICATO.xml:S1:1298:1	O
consecutive	PICATO.xml:S1:1300:11	O
days	PICATO.xml:S1:1312:4	O
,	PICATO.xml:S1:1316:1	O
and	PICATO.xml:S1:1318:3	O
225	PICATO.xml:S1:1322:3	O
subjects	PICATO.xml:S1:1326:8	O
exposed	PICATO.xml:S1:1335:7	O
to	PICATO.xml:S1:1343:2	O
Picato	PICATO.xml:S1:1346:6	O
(	PICATO.xml:S1:1354:1	O
r	PICATO.xml:S1:1355:1	O
)	PICATO.xml:S1:1356:1	O
gel	PICATO.xml:S1:1359:3	O
field	PICATO.xml:S1:1363:5	O
treatment	PICATO.xml:S1:1369:9	O
(	PICATO.xml:S1:1379:1	O
skin	PICATO.xml:S1:1380:4	O
area	PICATO.xml:S1:1385:4	O
of	PICATO.xml:S1:1390:2	O
25	PICATO.xml:S1:1393:2	O
cm	PICATO.xml:S1:1396:2	O
2	PICATO.xml:S1:1400:1	O
in	PICATO.xml:S1:1403:2	O
the	PICATO.xml:S1:1406:3	O
trunk	PICATO.xml:S1:1410:5	O
or	PICATO.xml:S1:1416:2	O
extremities	PICATO.xml:S1:1419:11	O
regions	PICATO.xml:S1:1431:7	O
)	PICATO.xml:S1:1438:1	O
at	PICATO.xml:S1:1440:2	O
a	PICATO.xml:S1:1443:1	O
concentration	PICATO.xml:S1:1445:13	O
of	PICATO.xml:S1:1459:2	O
0.05%	PICATO.xml:S1:1462:5	O
once	PICATO.xml:S1:1468:4	O
daily	PICATO.xml:S1:1473:5	O
for	PICATO.xml:S1:1479:3	O
2	PICATO.xml:S1:1483:1	O
consecutive	PICATO.xml:S1:1485:11	O
days	PICATO.xml:S1:1497:4	O
.	PICATO.xml:S1:1501:1	O

Local	PICATO.xml:S1:1512:5	B-AdverseReaction

skin	PICATO.xml:S1:1518:4	I-AdverseReaction
reactions	PICATO.xml:S1:1523:9	I-AdverseReaction
,	PICATO.xml:S1:1532:1	O
including	PICATO.xml:S1:1534:9	O
erythema	PICATO.xml:S1:1544:8	I-AdverseReaction
,	PICATO.xml:S1:1552:1	O
flaking	PICATO.xml:S1:1554:7	I-AdverseReaction
scaling	PICATO.xml:S1:1562:7	I-AdverseReaction
,	PICATO.xml:S1:1569:1	O
crusting	PICATO.xml:S1:1571:8	I-AdverseReaction
,	PICATO.xml:S1:1579:1	O
swelling	PICATO.xml:S1:1581:8	I-AdverseReaction
,	PICATO.xml:S1:1589:1	O
vesiculation	PICATO.xml:S1:1591:12	I-AdverseReaction
pustulation	PICATO.xml:S1:1604:11	I-AdverseReaction
,	PICATO.xml:S1:1615:1	O
and	PICATO.xml:S1:1617:3	O
erosion	PICATO.xml:S1:1621:7	I-AdverseReaction
ulceration	PICATO.xml:S1:1629:10	I-AdverseReaction
were	PICATO.xml:S1:1640:4	O
assessed	PICATO.xml:S1:1645:8	O
within	PICATO.xml:S1:1654:6	O
the	PICATO.xml:S1:1661:3	O
selected	PICATO.xml:S1:1665:8	O
treatment	PICATO.xml:S1:1674:9	O
area	PICATO.xml:S1:1684:4	O
and	PICATO.xml:S1:1689:3	O
graded	PICATO.xml:S1:1693:6	O
by	PICATO.xml:S1:1700:2	O
the	PICATO.xml:S1:1703:3	O
investigator	PICATO.xml:S1:1707:12	O
on	PICATO.xml:S1:1720:2	O
a	PICATO.xml:S1:1723:1	O
scale	PICATO.xml:S1:1725:5	O
of	PICATO.xml:S1:1731:2	O
0	PICATO.xml:S1:1734:1	O
to	PICATO.xml:S1:1736:2	O
4	PICATO.xml:S1:1739:1	O
.	PICATO.xml:S1:1740:1	O

A	PICATO.xml:S1:1742:1	O
grade	PICATO.xml:S1:1744:5	O
of	PICATO.xml:S1:1750:2	O
0	PICATO.xml:S1:1753:1	O
represented	PICATO.xml:S1:1755:11	O
no	PICATO.xml:S1:1767:2	O
reaction	PICATO.xml:S1:1770:8	O
present	PICATO.xml:S1:1779:7	O
in	PICATO.xml:S1:1787:2	O
the	PICATO.xml:S1:1790:3	O
treated	PICATO.xml:S1:1794:7	O
area	PICATO.xml:S1:1802:4	O
,	PICATO.xml:S1:1806:1	O
and	PICATO.xml:S1:1808:3	O
a	PICATO.xml:S1:1812:1	O
grade	PICATO.xml:S1:1814:5	O
of	PICATO.xml:S1:1820:2	O
4	PICATO.xml:S1:1823:1	O
indicated	PICATO.xml:S1:1825:9	O
a	PICATO.xml:S1:1835:1	O
marked	PICATO.xml:S1:1837:6	O
and	PICATO.xml:S1:1844:3	O
severe	PICATO.xml:S1:1848:6	O
skin	PICATO.xml:S1:1855:4	O
reaction	PICATO.xml:S1:1860:8	O
that	PICATO.xml:S1:1869:4	O
extended	PICATO.xml:S1:1874:8	O
beyond	PICATO.xml:S1:1883:6	O
the	PICATO.xml:S1:1890:3	O
treated	PICATO.xml:S1:1894:7	O
area	PICATO.xml:S1:1902:4	O
.	PICATO.xml:S1:1906:1	O

Table	PICATO.xml:S1:1919:5	O

1	PICATO.xml:S1:1925:1	O
Investigator	PICATO.xml:S1:1927:12	O
Assessment	PICATO.xml:S1:1940:10	O
of	PICATO.xml:S1:1951:2	O
Maximal	PICATO.xml:S1:1954:7	O
Local	PICATO.xml:S1:1962:5	B-AdverseReaction
Skin	PICATO.xml:S1:1968:4	I-AdverseReaction
Reactions	PICATO.xml:S1:1973:9	I-AdverseReaction
in	PICATO.xml:S1:1983:2	O
the	PICATO.xml:S1:1986:3	O
Treatment	PICATO.xml:S1:1990:9	O
Area	PICATO.xml:S1:2000:4	O
during	PICATO.xml:S1:2005:6	O
the	PICATO.xml:S1:2012:3	O
57	PICATO.xml:S1:2016:2	O
Days	PICATO.xml:S1:2019:4	O
Post	PICATO.xml:S1:2024:4	O
Treatment	PICATO.xml:S1:2029:9	O
Period	PICATO.xml:S1:2039:6	O
(	PICATO.xml:S1:2046:1	O
face	PICATO.xml:S1:2047:4	O
scalp	PICATO.xml:S1:2052:5	O
trials	PICATO.xml:S1:2058:6	O
)	PICATO.xml:S1:2064:1	O

Face	PICATO.xml:S1:2074:4	O
and	PICATO.xml:S1:2079:3	O
Scalp	PICATO.xml:S1:2083:5	O
(	PICATO.xml:S1:2090:1	O
n	PICATO.xml:S1:2091:1	O
545	PICATO.xml:S1:2093:3	O
)	PICATO.xml:S1:2096:1	O
Picato	PICATO.xml:S1:2099:6	O
(	PICATO.xml:S1:2105:1	O
r	PICATO.xml:S1:2106:1	O
)	PICATO.xml:S1:2107:1	O
gel	PICATO.xml:S1:2109:3	O
,	PICATO.xml:S1:2112:1	O
0.015%	PICATO.xml:S1:2114:6	O
once	PICATO.xml:S1:2121:4	O
daily	PICATO.xml:S1:2126:5	O
for	PICATO.xml:S1:2132:3	O
3	PICATO.xml:S1:2136:1	O
days	PICATO.xml:S1:2138:4	O

Skin	PICATO.xml:S1:2149:4	B-AdverseReaction
reactions	PICATO.xml:S1:2154:9	O
Any	PICATO.xml:S1:2176:3	O
Gradea	PICATO.xml:S1:2180:6	O
Baseline	PICATO.xml:S1:2189:8	O
Grade	PICATO.xml:S1:2203:5	O
4	PICATO.xml:S1:2209:1	O

Picato	PICATO.xml:S1:2260:6	O
(	PICATO.xml:S1:2266:1	O
r	PICATO.xml:S1:2267:1	O
)	PICATO.xml:S1:2268:1	O
gel	PICATO.xml:S1:2270:3	O
(	PICATO.xml:S1:2275:1	O
n	PICATO.xml:S1:2276:1	O
274	PICATO.xml:S1:2278:3	O
)	PICATO.xml:S1:2281:1	O
Vehicle	PICATO.xml:S1:2287:7	O
(	PICATO.xml:S1:2296:1	O
n	PICATO.xml:S1:2297:1	O
271	PICATO.xml:S1:2299:3	O
)	PICATO.xml:S1:2302:1	O
Picato	PICATO.xml:S1:2314:6	O
(	PICATO.xml:S1:2320:1	O
r	PICATO.xml:S1:2321:1	O
)	PICATO.xml:S1:2322:1	O
gel	PICATO.xml:S1:2324:3	O
(	PICATO.xml:S1:2329:1	O
n	PICATO.xml:S1:2330:1	O
274	PICATO.xml:S1:2332:3	O
)	PICATO.xml:S1:2335:1	O
Vehicle	PICATO.xml:S1:2342:7	O
(	PICATO.xml:S1:2351:1	O
n	PICATO.xml:S1:2352:1	O
271	PICATO.xml:S1:2354:3	O
)	PICATO.xml:S1:2357:1	O

Erythema	PICATO.xml:S1:2372:8	I-AdverseReaction
258	PICATO.xml:S1:2399:3	O
(	PICATO.xml:S1:2403:1	O
94%	PICATO.xml:S1:2404:3	O
)	PICATO.xml:S1:2407:1	O
69	PICATO.xml:S1:2426:2	O
(	PICATO.xml:S1:2429:1	O
25%	PICATO.xml:S1:2430:3	O
)	PICATO.xml:S1:2433:1	O
66	PICATO.xml:S1:2453:2	O
(	PICATO.xml:S1:2456:1	O
24%	PICATO.xml:S1:2457:3	O
)	PICATO.xml:S1:2460:1	O
0	PICATO.xml:S1:2480:1	O
(	PICATO.xml:S1:2482:1	O
0%	PICATO.xml:S1:2483:2	O
)	PICATO.xml:S1:2485:1	O

Flaking	PICATO.xml:S1:2510:7	I-AdverseReaction
Scaling	PICATO.xml:S1:2518:7	I-AdverseReaction
233	PICATO.xml:S1:2537:3	O
(	PICATO.xml:S1:2541:1	O
85%	PICATO.xml:S1:2542:3	O
)	PICATO.xml:S1:2545:1	O
67	PICATO.xml:S1:2564:2	O
(	PICATO.xml:S1:2567:1	O
25%	PICATO.xml:S1:2568:3	O
)	PICATO.xml:S1:2571:1	O
25	PICATO.xml:S1:2591:2	O
(	PICATO.xml:S1:2594:1	O
9%	PICATO.xml:S1:2595:2	O
)	PICATO.xml:S1:2597:1	O
0	PICATO.xml:S1:2618:1	O
(	PICATO.xml:S1:2620:1	O
0%	PICATO.xml:S1:2621:2	O
)	PICATO.xml:S1:2623:1	O

Crusting	PICATO.xml:S1:2648:8	I-AdverseReaction
220	PICATO.xml:S1:2675:3	O
(	PICATO.xml:S1:2679:1	O
80%	PICATO.xml:S1:2680:3	O
)	PICATO.xml:S1:2683:1	O
46	PICATO.xml:S1:2702:2	O
(	PICATO.xml:S1:2705:1	O
17%	PICATO.xml:S1:2706:3	O
)	PICATO.xml:S1:2709:1	O
16	PICATO.xml:S1:2729:2	O
(	PICATO.xml:S1:2732:1	O
6%	PICATO.xml:S1:2733:2	O
)	PICATO.xml:S1:2735:1	O
0	PICATO.xml:S1:2756:1	O
(	PICATO.xml:S1:2758:1	O
0%	PICATO.xml:S1:2759:2	O
)	PICATO.xml:S1:2761:1	O

Swelling	PICATO.xml:S1:2786:8	I-AdverseReaction
217	PICATO.xml:S1:2813:3	O
(	PICATO.xml:S1:2817:1	O
79%	PICATO.xml:S1:2818:3	O
)	PICATO.xml:S1:2821:1	O
11	PICATO.xml:S1:2840:2	O
(	PICATO.xml:S1:2843:1	O
4%	PICATO.xml:S1:2844:2	O
)	PICATO.xml:S1:2846:1	O
14	PICATO.xml:S1:2867:2	O
(	PICATO.xml:S1:2870:1	O
5%	PICATO.xml:S1:2871:2	O
)	PICATO.xml:S1:2873:1	O
0	PICATO.xml:S1:2894:1	O
(	PICATO.xml:S1:2896:1	O
0%	PICATO.xml:S1:2897:2	O
)	PICATO.xml:S1:2899:1	O

Vesiculation	PICATO.xml:S1:2924:12	I-AdverseReaction
Pustulation	PICATO.xml:S1:2937:11	I-AdverseReaction
154	PICATO.xml:S1:2952:3	O
(	PICATO.xml:S1:2956:1	O
56%	PICATO.xml:S1:2957:3	O
)	PICATO.xml:S1:2960:1	O
1	PICATO.xml:S1:2979:1	O
(	PICATO.xml:S1:2981:1	O
0%	PICATO.xml:S1:2982:2	O
)	PICATO.xml:S1:2984:1	O
15	PICATO.xml:S1:3006:2	O
(	PICATO.xml:S1:3009:1	O
5%	PICATO.xml:S1:3010:2	O
)	PICATO.xml:S1:3012:1	O
0	PICATO.xml:S1:3033:1	O
(	PICATO.xml:S1:3035:1	O
0%	PICATO.xml:S1:3036:2	O
)	PICATO.xml:S1:3038:1	O

Erosion	PICATO.xml:S1:3063:7	I-AdverseReaction
Ulceration	PICATO.xml:S1:3071:10	I-AdverseReaction
87	PICATO.xml:S1:3090:2	O
(	PICATO.xml:S1:3093:1	O
32%	PICATO.xml:S1:3094:3	O
)	PICATO.xml:S1:3097:1	O
3	PICATO.xml:S1:3117:1	O
(	PICATO.xml:S1:3119:1	O
1%	PICATO.xml:S1:3120:2	O
)	PICATO.xml:S1:3122:1	O
1	PICATO.xml:S1:3144:1	O
(	PICATO.xml:S1:3146:1	O
0%	PICATO.xml:S1:3147:2	O
)	PICATO.xml:S1:3149:1	O
0	PICATO.xml:S1:3171:1	O
(	PICATO.xml:S1:3173:1	O
0%	PICATO.xml:S1:3174:2	O
)	PICATO.xml:S1:3176:1	O

a	PICATO.xml:S1:3207:1	O
Mild	PICATO.xml:S1:3210:4	O
(	PICATO.xml:S1:3215:1	O
grade	PICATO.xml:S1:3216:5	O
1	PICATO.xml:S1:3222:1	O
)	PICATO.xml:S1:3223:1	O
,	PICATO.xml:S1:3224:1	O
Moderate	PICATO.xml:S1:3226:8	O
(	PICATO.xml:S1:3235:1	O
grade	PICATO.xml:S1:3236:5	O
2	PICATO.xml:S1:3242:1	O
-	PICATO.xml:S1:3243:1	O
3	PICATO.xml:S1:3244:1	O
)	PICATO.xml:S1:3245:1	O
or	PICATO.xml:S1:3247:2	O
Severe	PICATO.xml:S1:3250:6	O
(	PICATO.xml:S1:3257:1	O
grade	PICATO.xml:S1:3258:5	O
4	PICATO.xml:S1:3264:1	O
)	PICATO.xml:S1:3265:1	O
.	PICATO.xml:S1:3266:1	O

Table	PICATO.xml:S1:3279:5	O

2	PICATO.xml:S1:3285:1	O

Investigator	PICATO.xml:S1:3287:12	O
Assessment	PICATO.xml:S1:3300:10	O
of	PICATO.xml:S1:3311:2	O
Maximal	PICATO.xml:S1:3314:7	O
Local	PICATO.xml:S1:3322:5	B-AdverseReaction
Skin	PICATO.xml:S1:3328:4	I-AdverseReaction
Reactions	PICATO.xml:S1:3333:9	I-AdverseReaction
in	PICATO.xml:S1:3343:2	O
the	PICATO.xml:S1:3346:3	O
Treatment	PICATO.xml:S1:3350:9	O
Area	PICATO.xml:S1:3360:4	O
during	PICATO.xml:S1:3365:6	O
the	PICATO.xml:S1:3372:3	O
57	PICATO.xml:S1:3376:2	O
Days	PICATO.xml:S1:3379:4	O
Post	PICATO.xml:S1:3384:4	O
Treatment	PICATO.xml:S1:3389:9	O
Period	PICATO.xml:S1:3399:6	O
(	PICATO.xml:S1:3406:1	O
trunk	PICATO.xml:S1:3407:5	O
extremities	PICATO.xml:S1:3413:11	O
trials	PICATO.xml:S1:3425:6	O
)	PICATO.xml:S1:3431:1	O

Trunk	PICATO.xml:S1:3441:5	O
and	PICATO.xml:S1:3447:3	O
Extremities	PICATO.xml:S1:3451:11	O
(	PICATO.xml:S1:3464:1	O
n	PICATO.xml:S1:3465:1	O
457	PICATO.xml:S1:3467:3	O
)	PICATO.xml:S1:3470:1	O
Picato	PICATO.xml:S1:3473:6	O
(	PICATO.xml:S1:3479:1	O
r	PICATO.xml:S1:3480:1	O
)	PICATO.xml:S1:3481:1	O
gel	PICATO.xml:S1:3483:3	O
,	PICATO.xml:S1:3486:1	O
0.05%	PICATO.xml:S1:3488:5	O
once	PICATO.xml:S1:3494:4	O
daily	PICATO.xml:S1:3499:5	O
for	PICATO.xml:S1:3505:3	O
2	PICATO.xml:S1:3509:1	O
days	PICATO.xml:S1:3511:4	O

Skin	PICATO.xml:S1:3522:4	B-AdverseReaction
reactions	PICATO.xml:S1:3527:9	O
Any	PICATO.xml:S1:3549:3	O
Gradea	PICATO.xml:S1:3553:6	O
Baseline	PICATO.xml:S1:3562:8	O
Grade	PICATO.xml:S1:3576:5	O
4	PICATO.xml:S1:3582:1	O

Picato	PICATO.xml:S1:3633:6	O
(	PICATO.xml:S1:3639:1	O
r	PICATO.xml:S1:3640:1	O
)	PICATO.xml:S1:3641:1	O
gel	PICATO.xml:S1:3643:3	O
(	PICATO.xml:S1:3648:1	O
n	PICATO.xml:S1:3649:1	O
225	PICATO.xml:S1:3651:3	O
)	PICATO.xml:S1:3654:1	O
Vehicle	PICATO.xml:S1:3660:7	O
(	PICATO.xml:S1:3669:1	O
n	PICATO.xml:S1:3670:1	O
232	PICATO.xml:S1:3672:3	O
)	PICATO.xml:S1:3675:1	O
Picato	PICATO.xml:S1:3687:6	O
(	PICATO.xml:S1:3693:1	O
r	PICATO.xml:S1:3694:1	O
)	PICATO.xml:S1:3695:1	O
gel	PICATO.xml:S1:3697:3	O
(	PICATO.xml:S1:3702:1	O
n	PICATO.xml:S1:3703:1	O
225	PICATO.xml:S1:3705:3	O
)	PICATO.xml:S1:3708:1	O
Vehicle	PICATO.xml:S1:3714:7	O
(	PICATO.xml:S1:3723:1	O
n	PICATO.xml:S1:3724:1	O
232	PICATO.xml:S1:3726:3	O
)	PICATO.xml:S1:3729:1	O

Erythema	PICATO.xml:S1:3744:8	I-AdverseReaction
207	PICATO.xml:S1:3771:3	O
(	PICATO.xml:S1:3775:1	O
92%	PICATO.xml:S1:3776:3	O
)	PICATO.xml:S1:3779:1	O
43	PICATO.xml:S1:3798:2	O
(	PICATO.xml:S1:3801:1	O
19%	PICATO.xml:S1:3802:3	O
)	PICATO.xml:S1:3805:1	O
34	PICATO.xml:S1:3825:2	O
(	PICATO.xml:S1:3828:1	O
15%	PICATO.xml:S1:3829:3	O
)	PICATO.xml:S1:3832:1	O
0	PICATO.xml:S1:3852:1	O
(	PICATO.xml:S1:3854:1	O
0%	PICATO.xml:S1:3855:2	O
)	PICATO.xml:S1:3857:1	O

Flaking	PICATO.xml:S1:3882:7	I-AdverseReaction
Scaling	PICATO.xml:S1:3890:7	I-AdverseReaction
203	PICATO.xml:S1:3909:3	O
(	PICATO.xml:S1:3913:1	O
90%	PICATO.xml:S1:3914:3	O
)	PICATO.xml:S1:3917:1	O
44	PICATO.xml:S1:3936:2	O
(	PICATO.xml:S1:3939:1	O
19%	PICATO.xml:S1:3940:3	O
)	PICATO.xml:S1:3943:1	O
18	PICATO.xml:S1:3963:2	O
(	PICATO.xml:S1:3966:1	O
8%	PICATO.xml:S1:3967:2	O
)	PICATO.xml:S1:3969:1	O
0	PICATO.xml:S1:3990:1	O
(	PICATO.xml:S1:3992:1	O
0%	PICATO.xml:S1:3993:2	O
)	PICATO.xml:S1:3995:1	O

Crusting	PICATO.xml:S1:4020:8	I-AdverseReaction
167	PICATO.xml:S1:4047:3	O
(	PICATO.xml:S1:4051:1	O
74%	PICATO.xml:S1:4052:3	O
)	PICATO.xml:S1:4055:1	O
23	PICATO.xml:S1:4074:2	O
(	PICATO.xml:S1:4077:1	O
10%	PICATO.xml:S1:4078:3	O
)	PICATO.xml:S1:4081:1	O
8	PICATO.xml:S1:4101:1	O
(	PICATO.xml:S1:4103:1	O
4%	PICATO.xml:S1:4104:2	O
)	PICATO.xml:S1:4106:1	O
0	PICATO.xml:S1:4128:1	O
(	PICATO.xml:S1:4130:1	O
0%	PICATO.xml:S1:4131:2	O
)	PICATO.xml:S1:4133:1	O

Swelling	PICATO.xml:S1:4158:8	I-AdverseReaction
143	PICATO.xml:S1:4185:3	O
(	PICATO.xml:S1:4189:1	O
64%	PICATO.xml:S1:4190:3	O
)	PICATO.xml:S1:4193:1	O
13	PICATO.xml:S1:4212:2	O
(	PICATO.xml:S1:4215:1	O
6%	PICATO.xml:S1:4216:2	O
)	PICATO.xml:S1:4218:1	O
7	PICATO.xml:S1:4239:1	O
(	PICATO.xml:S1:4241:1	O
3%	PICATO.xml:S1:4242:2	O
)	PICATO.xml:S1:4244:1	O
0	PICATO.xml:S1:4266:1	O
(	PICATO.xml:S1:4268:1	O
0%	PICATO.xml:S1:4269:2	O
)	PICATO.xml:S1:4271:1	O

Vesiculation	PICATO.xml:S1:4296:12	I-AdverseReaction
Pustulation	PICATO.xml:S1:4309:11	I-AdverseReaction
98	PICATO.xml:S1:4324:2	O
(	PICATO.xml:S1:4327:1	O
44%	PICATO.xml:S1:4328:3	O
)	PICATO.xml:S1:4331:1	O
2	PICATO.xml:S1:4351:1	O
(	PICATO.xml:S1:4353:1	O
1%	PICATO.xml:S1:4354:2	O
)	PICATO.xml:S1:4356:1	O
3	PICATO.xml:S1:4378:1	O
(	PICATO.xml:S1:4380:1	O
1%	PICATO.xml:S1:4381:2	O
)	PICATO.xml:S1:4383:1	O
0	PICATO.xml:S1:4405:1	O
(	PICATO.xml:S1:4407:1	O
0%	PICATO.xml:S1:4408:2	O
)	PICATO.xml:S1:4410:1	O

Erosion	PICATO.xml:S1:4435:7	I-AdverseReaction
Ulceration	PICATO.xml:S1:4443:10	I-AdverseReaction
58	PICATO.xml:S1:4462:2	O
(	PICATO.xml:S1:4465:1	O
26%	PICATO.xml:S1:4466:3	O
)	PICATO.xml:S1:4469:1	O
6	PICATO.xml:S1:4489:1	O
(	PICATO.xml:S1:4491:1	O
3%	PICATO.xml:S1:4492:2	O
)	PICATO.xml:S1:4494:1	O
2	PICATO.xml:S1:4516:1	O
(	PICATO.xml:S1:4518:1	O
1%	PICATO.xml:S1:4519:2	O
)	PICATO.xml:S1:4521:1	O
0	PICATO.xml:S1:4543:1	O
(	PICATO.xml:S1:4545:1	O
0%	PICATO.xml:S1:4546:2	O
)	PICATO.xml:S1:4548:1	O

a	PICATO.xml:S1:4579:1	O
Mild	PICATO.xml:S1:4582:4	O
(	PICATO.xml:S1:4587:1	O
grade	PICATO.xml:S1:4588:5	O
1	PICATO.xml:S1:4594:1	O
)	PICATO.xml:S1:4595:1	O
,	PICATO.xml:S1:4596:1	O
Moderate	PICATO.xml:S1:4598:8	O
(	PICATO.xml:S1:4607:1	O
grade	PICATO.xml:S1:4608:5	O
2	PICATO.xml:S1:4614:1	O
-	PICATO.xml:S1:4615:1	O
3	PICATO.xml:S1:4616:1	O
)	PICATO.xml:S1:4617:1	O
or	PICATO.xml:S1:4619:2	O
Severe	PICATO.xml:S1:4622:6	O
(	PICATO.xml:S1:4629:1	O
grade	PICATO.xml:S1:4630:5	O
4	PICATO.xml:S1:4636:1	O
)	PICATO.xml:S1:4637:1	O
.	PICATO.xml:S1:4638:1	O

Local	PICATO.xml:S1:4649:5	B-AdverseReaction

skin	PICATO.xml:S1:4655:4	I-AdverseReaction

reactions	PICATO.xml:S1:4660:9	I-AdverseReaction
typically	PICATO.xml:S1:4670:9	O
occurred	PICATO.xml:S1:4680:8	O
within	PICATO.xml:S1:4689:6	O
1	PICATO.xml:S1:4696:1	O
day	PICATO.xml:S1:4698:3	O
of	PICATO.xml:S1:4702:2	O
treatment	PICATO.xml:S1:4705:9	O
initiation	PICATO.xml:S1:4715:10	O
,	PICATO.xml:S1:4725:1	O
peaked	PICATO.xml:S1:4727:6	O
in	PICATO.xml:S1:4734:2	O
intensity	PICATO.xml:S1:4737:9	O
up	PICATO.xml:S1:4747:2	O
to	PICATO.xml:S1:4750:2	O
1	PICATO.xml:S1:4753:1	O
week	PICATO.xml:S1:4755:4	O
following	PICATO.xml:S1:4760:9	O
completion	PICATO.xml:S1:4770:10	O
of	PICATO.xml:S1:4781:2	O
treatment	PICATO.xml:S1:4784:9	O
,	PICATO.xml:S1:4793:1	O
and	PICATO.xml:S1:4795:3	O
resolved	PICATO.xml:S1:4799:8	O
within	PICATO.xml:S1:4808:6	O
2	PICATO.xml:S1:4815:1	O
weeks	PICATO.xml:S1:4817:5	O
for	PICATO.xml:S1:4823:3	O
areas	PICATO.xml:S1:4827:5	O
treated	PICATO.xml:S1:4833:7	O
on	PICATO.xml:S1:4841:2	O
the	PICATO.xml:S1:4844:3	O
face	PICATO.xml:S1:4848:4	O
and	PICATO.xml:S1:4853:3	O
scalp	PICATO.xml:S1:4857:5	O
,	PICATO.xml:S1:4862:1	O
and	PICATO.xml:S1:4864:3	O
within	PICATO.xml:S1:4868:6	O
4	PICATO.xml:S1:4875:1	O
weeks	PICATO.xml:S1:4877:5	O
for	PICATO.xml:S1:4883:3	O
areas	PICATO.xml:S1:4887:5	O
treated	PICATO.xml:S1:4893:7	O
on	PICATO.xml:S1:4901:2	O
the	PICATO.xml:S1:4904:3	O
trunk	PICATO.xml:S1:4908:5	O
and	PICATO.xml:S1:4914:3	O
extremities	PICATO.xml:S1:4918:11	O
.	PICATO.xml:S1:4929:1	O

Adverse	PICATO.xml:S1:4940:7	O

reactions	PICATO.xml:S1:4948:9	O
that	PICATO.xml:S1:4958:4	O
occurred	PICATO.xml:S1:4963:8	O
in	PICATO.xml:S1:4972:2	O
2%	PICATO.xml:S1:4977:2	O
of	PICATO.xml:S1:4980:2	O
subjects	PICATO.xml:S1:4983:8	O
treated	PICATO.xml:S1:4992:7	O
with	PICATO.xml:S1:5000:4	O
Picato	PICATO.xml:S1:5005:6	O
(	PICATO.xml:S1:5013:1	O
r	PICATO.xml:S1:5014:1	O
)	PICATO.xml:S1:5015:1	O
gel	PICATO.xml:S1:5018:3	O
and	PICATO.xml:S1:5022:3	O
at	PICATO.xml:S1:5026:2	O
a	PICATO.xml:S1:5029:1	O
higher	PICATO.xml:S1:5031:6	O
frequency	PICATO.xml:S1:5038:9	O
than	PICATO.xml:S1:5048:4	O
the	PICATO.xml:S1:5053:3	O
vehicle	PICATO.xml:S1:5057:7	O
are	PICATO.xml:S1:5065:3	O
presented	PICATO.xml:S1:5069:9	O
in	PICATO.xml:S1:5079:2	O
Table	PICATO.xml:S1:5082:5	O
3	PICATO.xml:S1:5088:1	O
and	PICATO.xml:S1:5090:3	O
Table	PICATO.xml:S1:5094:5	O
4	PICATO.xml:S1:5100:1	O
.	PICATO.xml:S1:5101:1	O

Table	PICATO.xml:S1:5114:5	O

3	PICATO.xml:S1:5120:1	O
Adverse	PICATO.xml:S1:5122:7	O
reactions	PICATO.xml:S1:5130:9	O
occurring	PICATO.xml:S1:5140:9	O
in	PICATO.xml:S1:5150:2	O
2%	PICATO.xml:S1:5156:2	O
of	PICATO.xml:S1:5159:2	O
subjects	PICATO.xml:S1:5162:8	O
treated	PICATO.xml:S1:5171:7	O
with	PICATO.xml:S1:5179:4	O
Picato	PICATO.xml:S1:5184:6	O
(	PICATO.xml:S1:5192:1	O
r	PICATO.xml:S1:5193:1	O
)	PICATO.xml:S1:5194:1	O
gel	PICATO.xml:S1:5197:3	O
and	PICATO.xml:S1:5201:3	O
at	PICATO.xml:S1:5205:2	O
higher	PICATO.xml:S1:5208:6	O
frequency	PICATO.xml:S1:5215:9	O
than	PICATO.xml:S1:5225:4	O
vehicle	PICATO.xml:S1:5230:7	O
(	PICATO.xml:S1:5238:1	O
face	PICATO.xml:S1:5239:4	O
scalp	PICATO.xml:S1:5244:5	O
trials	PICATO.xml:S1:5250:6	O
)	PICATO.xml:S1:5256:1	O

Face	PICATO.xml:S1:5293:4	O
Scalp	PICATO.xml:S1:5298:5	O

Adverse	PICATO.xml:S1:5323:7	O
Reactions	PICATO.xml:S1:5331:9	O
Picato	PICATO.xml:S1:5350:6	O
(	PICATO.xml:S1:5356:1	O
r	PICATO.xml:S1:5357:1	O
)	PICATO.xml:S1:5358:1	O
gel	PICATO.xml:S1:5360:3	O
,	PICATO.xml:S1:5363:1	O
0.015%	PICATO.xml:S1:5365:6	O
(	PICATO.xml:S1:5373:1	O
N	PICATO.xml:S1:5374:1	O
274	PICATO.xml:S1:5376:3	O
)	PICATO.xml:S1:5379:1	O
Vehicle	PICATO.xml:S1:5384:7	O
(	PICATO.xml:S1:5393:1	O
N	PICATO.xml:S1:5394:1	O
271	PICATO.xml:S1:5396:3	O
)	PICATO.xml:S1:5399:1	O

Application	PICATO.xml:S1:5417:11	B-AdverseReaction

Site	PICATO.xml:S1:5429:4	I-AdverseReaction
Pain	PICATO.xml:S1:5434:4	I-AdverseReaction
42	PICATO.xml:S1:5444:2	O
(	PICATO.xml:S1:5447:1	O
15%	PICATO.xml:S1:5448:3	O
)	PICATO.xml:S1:5451:1	O
1	PICATO.xml:S1:5471:1	O
(	PICATO.xml:S1:5473:1	O
0%	PICATO.xml:S1:5474:2	O
)	PICATO.xml:S1:5476:1	O

Application	PICATO.xml:S1:5501:11	B-AdverseReaction
Site	PICATO.xml:S1:5513:4	I-AdverseReaction
Pruritus	PICATO.xml:S1:5518:8	I-AdverseReaction
22	PICATO.xml:S1:5530:2	O
(	PICATO.xml:S1:5533:1	O
8%	PICATO.xml:S1:5534:2	O
)	PICATO.xml:S1:5536:1	O
3	PICATO.xml:S1:5557:1	O
(	PICATO.xml:S1:5559:1	O
1%	PICATO.xml:S1:5560:2	O
)	PICATO.xml:S1:5562:1	O

Application	PICATO.xml:S1:5587:11	B-AdverseReaction
Site	PICATO.xml:S1:5599:4	I-AdverseReaction
Infection	PICATO.xml:S1:5604:9	I-AdverseReaction
7	PICATO.xml:S1:5617:1	O
(	PICATO.xml:S1:5619:1	O
3%	PICATO.xml:S1:5620:2	O
)	PICATO.xml:S1:5622:1	O
0	PICATO.xml:S1:5644:1	O
(	PICATO.xml:S1:5646:1	O
0%	PICATO.xml:S1:5647:2	O
)	PICATO.xml:S1:5649:1	O

Periorbital	PICATO.xml:S1:5674:11	B-AdverseReaction
Edema	PICATO.xml:S1:5686:5	I-AdverseReaction
7	PICATO.xml:S1:5701:1	O
(	PICATO.xml:S1:5703:1	O
3%	PICATO.xml:S1:5704:2	O
)	PICATO.xml:S1:5706:1	O
0	PICATO.xml:S1:5728:1	O
(	PICATO.xml:S1:5730:1	O
0%	PICATO.xml:S1:5731:2	O
)	PICATO.xml:S1:5733:1	O

Headache	PICATO.xml:S1:5758:8	B-AdverseReaction
6	PICATO.xml:S1:5785:1	O
(	PICATO.xml:S1:5787:1	O
2%	PICATO.xml:S1:5788:2	O
)	PICATO.xml:S1:5790:1	O
3	PICATO.xml:S1:5812:1	O
(	PICATO.xml:S1:5814:1	O
1%	PICATO.xml:S1:5815:2	O
)	PICATO.xml:S1:5817:1	O

Table	PICATO.xml:S1:5853:5	O

4	PICATO.xml:S1:5859:1	O

Adverse	PICATO.xml:S1:5861:7	O
reactions	PICATO.xml:S1:5869:9	O
occurring	PICATO.xml:S1:5879:9	O
in	PICATO.xml:S1:5889:2	O
2%	PICATO.xml:S1:5895:2	O
of	PICATO.xml:S1:5898:2	O
subjects	PICATO.xml:S1:5901:8	O
treated	PICATO.xml:S1:5910:7	O
with	PICATO.xml:S1:5918:4	O
Picato	PICATO.xml:S1:5923:6	O
(	PICATO.xml:S1:5931:1	O
r	PICATO.xml:S1:5932:1	O
)	PICATO.xml:S1:5933:1	O
gel	PICATO.xml:S1:5936:3	O
and	PICATO.xml:S1:5940:3	O
at	PICATO.xml:S1:5944:2	O
higher	PICATO.xml:S1:5947:6	O
frequency	PICATO.xml:S1:5954:9	O
than	PICATO.xml:S1:5964:4	O
vehicle	PICATO.xml:S1:5969:7	O
(	PICATO.xml:S1:5977:1	O
trunk	PICATO.xml:S1:5978:5	O
extremities	PICATO.xml:S1:5984:11	O
trials	PICATO.xml:S1:5996:6	O
)	PICATO.xml:S1:6002:1	O

Trunk	PICATO.xml:S1:6039:5	O
Extremities	PICATO.xml:S1:6045:11	O

Adverse	PICATO.xml:S1:6069:7	O
Reactions	PICATO.xml:S1:6077:9	O
Picato	PICATO.xml:S1:6096:6	O
(	PICATO.xml:S1:6102:1	O
r	PICATO.xml:S1:6103:1	O
)	PICATO.xml:S1:6104:1	O
gel	PICATO.xml:S1:6106:3	O
,	PICATO.xml:S1:6109:1	O
0.05%	PICATO.xml:S1:6111:5	O
(	PICATO.xml:S1:6118:1	O
N	PICATO.xml:S1:6119:1	O
225	PICATO.xml:S1:6121:3	O
)	PICATO.xml:S1:6124:1	O
Vehicle	PICATO.xml:S1:6129:7	O
(	PICATO.xml:S1:6138:1	O
N	PICATO.xml:S1:6139:1	O
232	PICATO.xml:S1:6141:3	O
)	PICATO.xml:S1:6144:1	O

Application	PICATO.xml:S1:6159:11	B-AdverseReaction
Site	PICATO.xml:S1:6171:4	I-AdverseReaction
Pruritus	PICATO.xml:S1:6176:8	I-AdverseReaction
18	PICATO.xml:S1:6188:2	O
(	PICATO.xml:S1:6191:1	O
8%	PICATO.xml:S1:6192:2	O
)	PICATO.xml:S1:6194:1	O
0	PICATO.xml:S1:6215:1	O
(	PICATO.xml:S1:6217:1	O
0%	PICATO.xml:S1:6218:2	O
)	PICATO.xml:S1:6220:1	O

Application	PICATO.xml:S1:6245:11	B-AdverseReaction
Site	PICATO.xml:S1:6257:4	I-AdverseReaction
Irritation	PICATO.xml:S1:6262:10	I-AdverseReaction
8	PICATO.xml:S1:6276:1	O
(	PICATO.xml:S1:6278:1	O
4%	PICATO.xml:S1:6279:2	O
)	PICATO.xml:S1:6281:1	O
1	PICATO.xml:S1:6303:1	O
(	PICATO.xml:S1:6305:1	O
0%	PICATO.xml:S1:6306:2	O
)	PICATO.xml:S1:6308:1	O

Nasopharyngitis	PICATO.xml:S1:6333:15	B-AdverseReaction
4	PICATO.xml:S1:6360:1	O
(	PICATO.xml:S1:6362:1	O
2%	PICATO.xml:S1:6363:2	O
)	PICATO.xml:S1:6365:1	O
2	PICATO.xml:S1:6387:1	O
(	PICATO.xml:S1:6389:1	O
1%	PICATO.xml:S1:6390:2	O
)	PICATO.xml:S1:6392:1	O

Application	PICATO.xml:S1:6417:11	B-AdverseReaction
Site	PICATO.xml:S1:6429:4	I-AdverseReaction
Pain	PICATO.xml:S1:6434:4	I-AdverseReaction
5	PICATO.xml:S1:6444:1	O
(	PICATO.xml:S1:6446:1	O
2%	PICATO.xml:S1:6447:2	O
)	PICATO.xml:S1:6449:1	O
0	PICATO.xml:S1:6471:1	O
(	PICATO.xml:S1:6473:1	O
0%	PICATO.xml:S1:6474:2	O
)	PICATO.xml:S1:6476:1	O

Less	PICATO.xml:S1:6510:4	O

common	PICATO.xml:S1:6515:6	O

adverse	PICATO.xml:S1:6522:7	O
reactions	PICATO.xml:S1:6530:9	O
in	PICATO.xml:S1:6540:2	O
subjects	PICATO.xml:S1:6543:8	O
treated	PICATO.xml:S1:6552:7	O
with	PICATO.xml:S1:6560:4	O
Picato	PICATO.xml:S1:6565:6	O
(	PICATO.xml:S1:6573:1	O
r	PICATO.xml:S1:6574:1	O
)	PICATO.xml:S1:6575:1	O
included	PICATO.xml:S1:6578:8	O
:	PICATO.xml:S1:6586:1	O
eyelid	PICATO.xml:S1:6588:6	B-AdverseReaction
edema	PICATO.xml:S1:6595:5	I-AdverseReaction
,	PICATO.xml:S1:6600:1	O
eye	PICATO.xml:S1:6602:3	B-AdverseReaction
pain	PICATO.xml:S1:6606:4	I-AdverseReaction
,	PICATO.xml:S1:6610:1	O
conjunctivitis	PICATO.xml:S1:6612:14	B-AdverseReaction
.	PICATO.xml:S1:6626:1	O

A	PICATO.xml:S1:6637:1	O

total	PICATO.xml:S1:6639:5	O
of	PICATO.xml:S1:6645:2	O
108	PICATO.xml:S1:6648:3	O
subjects	PICATO.xml:S1:6652:8	O
treated	PICATO.xml:S1:6661:7	O
with	PICATO.xml:S1:6669:4	O
Picato	PICATO.xml:S1:6674:6	O
(	PICATO.xml:S1:6682:1	O
r	PICATO.xml:S1:6683:1	O
)	PICATO.xml:S1:6684:1	O
gel	PICATO.xml:S1:6687:3	O
on	PICATO.xml:S1:6691:2	O
the	PICATO.xml:S1:6694:3	O
face	PICATO.xml:S1:6698:4	O
scalp	PICATO.xml:S1:6703:5	O
and	PICATO.xml:S1:6709:3	O
38	PICATO.xml:S1:6713:2	O
subjects	PICATO.xml:S1:6716:8	O
treated	PICATO.xml:S1:6725:7	O
on	PICATO.xml:S1:6733:2	O
the	PICATO.xml:S1:6736:3	O
trunk	PICATO.xml:S1:6740:5	O
extremities	PICATO.xml:S1:6746:11	O
were	PICATO.xml:S1:6758:4	O
followed	PICATO.xml:S1:6763:8	O
for	PICATO.xml:S1:6772:3	O
12	PICATO.xml:S1:6776:2	O
months	PICATO.xml:S1:6779:6	O
.	PICATO.xml:S1:6785:1	O

Results	PICATO.xml:S1:6787:7	O
from	PICATO.xml:S1:6795:4	O
these	PICATO.xml:S1:6800:5	O
studies	PICATO.xml:S1:6806:7	O
did	PICATO.xml:S1:6814:3	O
not	PICATO.xml:S1:6818:3	O
change	PICATO.xml:S1:6822:6	O
the	PICATO.xml:S1:6829:3	O
safety	PICATO.xml:S1:6833:6	O
profile	PICATO.xml:S1:6840:7	O
of	PICATO.xml:S1:6848:2	O
Picato	PICATO.xml:S1:6851:6	O
(	PICATO.xml:S1:6859:1	O
r	PICATO.xml:S1:6860:1	O
)	PICATO.xml:S1:6861:1	O
gel	PICATO.xml:S1:6864:3	O
.	PICATO.xml:S1:6867:1	O

6.2	PICATO.xml:S1:6875:3	O
Postmarketing	PICATO.xml:S1:6879:13	O
Experience	PICATO.xml:S1:6893:10	O

The	PICATO.xml:S1:6907:3	O
following	PICATO.xml:S1:6911:9	O
adverse	PICATO.xml:S1:6921:7	O
reactions	PICATO.xml:S1:6929:9	O
have	PICATO.xml:S1:6939:4	O
been	PICATO.xml:S1:6944:4	O
identified	PICATO.xml:S1:6949:10	O
during	PICATO.xml:S1:6960:6	O
post	PICATO.xml:S1:6967:4	O
approval	PICATO.xml:S1:6972:8	O
use	PICATO.xml:S1:6981:3	O
of	PICATO.xml:S1:6985:2	O
Picato	PICATO.xml:S1:6988:6	O
(	PICATO.xml:S1:6996:1	O
r	PICATO.xml:S1:6997:1	O
)	PICATO.xml:S1:6998:1	O
(	PICATO.xml:S1:7001:1	O
ingenol	PICATO.xml:S1:7002:7	O
mebutate	PICATO.xml:S1:7010:8	O
)	PICATO.xml:S1:7018:1	O
gel	PICATO.xml:S1:7020:3	O
,	PICATO.xml:S1:7023:1	O
0.015%	PICATO.xml:S1:7025:6	O
and	PICATO.xml:S1:7032:3	O
0.05%	PICATO.xml:S1:7036:5	O
:	PICATO.xml:S1:7041:1	O
hypersensitivity	PICATO.xml:S1:7043:16	B-AdverseReaction
,	PICATO.xml:S1:7059:1	O
allergic	PICATO.xml:S1:7061:8	B-AdverseReaction
contact	PICATO.xml:S1:7070:7	I-AdverseReaction
dermatitis	PICATO.xml:S1:7078:10	I-AdverseReaction
,	PICATO.xml:S1:7088:1	O
herpes	PICATO.xml:S1:7090:6	B-AdverseReaction
zoster	PICATO.xml:S1:7097:6	I-AdverseReaction
,	PICATO.xml:S1:7103:1	O
chemical	PICATO.xml:S1:7105:8	B-AdverseReaction
conjunctivitis	PICATO.xml:S1:7114:14	I-AdverseReaction
,	PICATO.xml:S1:7128:1	O
and	PICATO.xml:S1:7130:3	O
corneal	PICATO.xml:S1:7134:7	B-AdverseReaction
burn	PICATO.xml:S1:7142:4	I-AdverseReaction
.	PICATO.xml:S1:7146:1	O

Because	PICATO.xml:S1:7152:7	O
these	PICATO.xml:S1:7160:5	O
reactions	PICATO.xml:S1:7166:9	O
are	PICATO.xml:S1:7176:3	O
reported	PICATO.xml:S1:7180:8	O
voluntarily	PICATO.xml:S1:7189:11	O
from	PICATO.xml:S1:7201:4	O
a	PICATO.xml:S1:7206:1	O
population	PICATO.xml:S1:7208:10	O
of	PICATO.xml:S1:7219:2	O
uncertain	PICATO.xml:S1:7222:9	O
size	PICATO.xml:S1:7232:4	O
,	PICATO.xml:S1:7236:1	O
it	PICATO.xml:S1:7238:2	O
is	PICATO.xml:S1:7241:2	O
not	PICATO.xml:S1:7244:3	O
always	PICATO.xml:S1:7248:6	O
possible	PICATO.xml:S1:7255:8	O
to	PICATO.xml:S1:7264:2	O
reliably	PICATO.xml:S1:7267:8	O
estimate	PICATO.xml:S1:7276:8	O
their	PICATO.xml:S1:7285:5	O
frequency	PICATO.xml:S1:7291:9	O
or	PICATO.xml:S1:7301:2	O
establish	PICATO.xml:S1:7304:9	O
a	PICATO.xml:S1:7314:1	O
causal	PICATO.xml:S1:7316:6	O
relationship	PICATO.xml:S1:7323:12	O
to	PICATO.xml:S1:7336:2	O
drug	PICATO.xml:S1:7339:4	O
exposure	PICATO.xml:S1:7344:8	O
.	PICATO.xml:S1:7352:1	O
5	PICATO.xml:S2:5:1	O
WARNINGS	PICATO.xml:S2:7:8	O
AND	PICATO.xml:S2:16:3	O
PRECAUTIONS	PICATO.xml:S2:20:11	O

EXCERPT	PICATO.xml:S2:39:7	O
:	PICATO.xml:S2:46:1	O
Avoid	PICATO.xml:S2:50:5	O
treatment	PICATO.xml:S2:56:9	O
in	PICATO.xml:S2:66:2	O
the	PICATO.xml:S2:69:3	O
periocular	PICATO.xml:S2:73:10	O
area	PICATO.xml:S2:84:4	O
.	PICATO.xml:S2:88:1	O

Eye	PICATO.xml:S2:90:3	B-AdverseReaction
disorders	PICATO.xml:S2:94:9	I-AdverseReaction
,	PICATO.xml:S2:103:1	O
including	PICATO.xml:S2:105:9	O
severe	PICATO.xml:S2:115:6	B-Severity
eye	PICATO.xml:S2:122:3	B-AdverseReaction
pain	PICATO.xml:S2:126:4	I-AdverseReaction
,	PICATO.xml:S2:130:1	O
chemical	PICATO.xml:S2:132:8	B-AdverseReaction
conjunctivitis	PICATO.xml:S2:141:14	I-AdverseReaction
,	PICATO.xml:S2:155:1	O
corneal	PICATO.xml:S2:157:7	B-AdverseReaction
burn	PICATO.xml:S2:165:4	I-AdverseReaction
,	PICATO.xml:S2:169:1	O
eyelid	PICATO.xml:S2:171:6	B-AdverseReaction
edema	PICATO.xml:S2:178:5	I-AdverseReaction
,	PICATO.xml:S2:183:1	O
eyelid	PICATO.xml:S2:185:6	B-AdverseReaction
ptosis	PICATO.xml:S2:192:6	I-AdverseReaction
,	PICATO.xml:S2:198:1	O
periorbital	PICATO.xml:S2:200:11	B-AdverseReaction
edema	PICATO.xml:S2:212:5	I-AdverseReaction
can	PICATO.xml:S2:218:3	B-Factor
occur	PICATO.xml:S2:222:5	O
after	PICATO.xml:S2:228:5	O
exposure	PICATO.xml:S2:234:8	O
.	PICATO.xml:S2:242:1	O

Avoid	PICATO.xml:S2:244:5	O
accidental	PICATO.xml:S2:250:10	O
transfer	PICATO.xml:S2:261:8	O
of	PICATO.xml:S2:270:2	O
the	PICATO.xml:S2:273:3	O
drug	PICATO.xml:S2:277:4	O
into	PICATO.xml:S2:282:4	O
the	PICATO.xml:S2:287:3	O
eyes	PICATO.xml:S2:291:4	O
and	PICATO.xml:S2:296:3	O
to	PICATO.xml:S2:300:2	O
the	PICATO.xml:S2:303:3	O
periocular	PICATO.xml:S2:307:10	O
area	PICATO.xml:S2:318:4	O
.	PICATO.xml:S2:322:1	O

If	PICATO.xml:S2:324:2	O
accidental	PICATO.xml:S2:327:10	O
exposure	PICATO.xml:S2:338:8	O
occurs	PICATO.xml:S2:347:6	O
,	PICATO.xml:S2:353:1	O
flush	PICATO.xml:S2:355:5	O
eyes	PICATO.xml:S2:361:4	O
with	PICATO.xml:S2:366:4	O
water	PICATO.xml:S2:371:5	O
and	PICATO.xml:S2:377:3	O
seek	PICATO.xml:S2:381:4	O
medical	PICATO.xml:S2:386:7	O
care	PICATO.xml:S2:394:4	O
.	PICATO.xml:S2:398:1	O

(	PICATO.xml:S2:400:1	O
5.1	PICATO.xml:S2:403:3	O
)	PICATO.xml:S2:408:1	O

Local	PICATO.xml:S2:419:5	B-AdverseReaction

skin	PICATO.xml:S2:425:4	I-AdverseReaction
reactions	PICATO.xml:S2:430:9	I-AdverseReaction
can	PICATO.xml:S2:440:3	B-Factor
occur	PICATO.xml:S2:444:5	O
including	PICATO.xml:S2:450:9	O
severe	PICATO.xml:S2:460:6	B-Severity
reactions	PICATO.xml:S2:467:9	O
(	PICATO.xml:S2:477:1	O
e	PICATO.xml:S2:478:1	O
.	PICATO.xml:S2:479:1	O
g	PICATO.xml:S2:480:1	O
.	PICATO.xml:S2:481:1	O
,	PICATO.xml:S2:482:1	O
vesiculation	PICATO.xml:S2:484:12	I-AdverseReaction
pustulation	PICATO.xml:S2:497:11	I-AdverseReaction
,	PICATO.xml:S2:508:1	O
erosion	PICATO.xml:S2:510:7	I-AdverseReaction
ulceration	PICATO.xml:S2:518:10	I-AdverseReaction
)	PICATO.xml:S2:528:1	O
.	PICATO.xml:S2:529:1	O

Administration	PICATO.xml:S2:531:14	O
of	PICATO.xml:S2:546:2	O
Picato	PICATO.xml:S2:549:6	O
(	PICATO.xml:S2:557:1	O
r	PICATO.xml:S2:558:1	O
)	PICATO.xml:S2:559:1	O
gel	PICATO.xml:S2:562:3	O
is	PICATO.xml:S2:566:2	O
not	PICATO.xml:S2:569:3	O
recommended	PICATO.xml:S2:573:11	O
until	PICATO.xml:S2:585:5	O
skin	PICATO.xml:S2:591:4	O
is	PICATO.xml:S2:596:2	O
healed	PICATO.xml:S2:599:6	O
from	PICATO.xml:S2:606:4	O
any	PICATO.xml:S2:611:3	O
previous	PICATO.xml:S2:615:8	O
drug	PICATO.xml:S2:624:4	O
or	PICATO.xml:S2:629:2	O
surgical	PICATO.xml:S2:632:8	O
treatment	PICATO.xml:S2:641:9	O
.	PICATO.xml:S2:650:1	O

(	PICATO.xml:S2:652:1	O
5.3	PICATO.xml:S2:655:3	O
)	PICATO.xml:S2:660:1	O

5.1	PICATO.xml:S2:673:3	O

Ophthalmic	PICATO.xml:S2:677:10	O
Adverse	PICATO.xml:S2:688:7	O
Reactions	PICATO.xml:S2:696:9	O

Avoid	PICATO.xml:S2:711:5	O
treatment	PICATO.xml:S2:717:9	O
in	PICATO.xml:S2:727:2	O
the	PICATO.xml:S2:730:3	O
periocular	PICATO.xml:S2:734:10	O
area	PICATO.xml:S2:745:4	O
.	PICATO.xml:S2:749:1	O

Eye	PICATO.xml:S2:751:3	B-AdverseReaction
disorders	PICATO.xml:S2:755:9	I-AdverseReaction
,	PICATO.xml:S2:764:1	O
including	PICATO.xml:S2:766:9	O
severe	PICATO.xml:S2:776:6	B-Severity
eye	PICATO.xml:S2:783:3	B-AdverseReaction
pain	PICATO.xml:S2:787:4	I-AdverseReaction
,	PICATO.xml:S2:791:1	O
chemical	PICATO.xml:S2:793:8	B-AdverseReaction
conjunctivitis	PICATO.xml:S2:802:14	I-AdverseReaction
,	PICATO.xml:S2:816:1	O
corneal	PICATO.xml:S2:818:7	B-AdverseReaction
burn	PICATO.xml:S2:826:4	I-AdverseReaction
,	PICATO.xml:S2:830:1	O
eyelid	PICATO.xml:S2:832:6	B-AdverseReaction
edema	PICATO.xml:S2:839:5	I-AdverseReaction
,	PICATO.xml:S2:844:1	O
eyelid	PICATO.xml:S2:846:6	B-AdverseReaction
ptosis	PICATO.xml:S2:853:6	I-AdverseReaction
,	PICATO.xml:S2:859:1	O
periorbital	PICATO.xml:S2:861:11	B-AdverseReaction
edema	PICATO.xml:S2:873:5	I-AdverseReaction
can	PICATO.xml:S2:879:3	B-Factor
occur	PICATO.xml:S2:883:5	O
after	PICATO.xml:S2:889:5	O
exposure	PICATO.xml:S2:895:8	O
[	PICATO.xml:S2:904:1	O
see	PICATO.xml:S2:905:3	O
Adverse	PICATO.xml:S2:909:7	O
Reactions	PICATO.xml:S2:917:9	O
(	PICATO.xml:S2:927:1	O
6	PICATO.xml:S2:930:1	O
)]	PICATO.xml:S2:933:2	O
.	PICATO.xml:S2:938:1	O

To	PICATO.xml:S2:951:2	O

avoid	PICATO.xml:S2:954:5	O
transfer	PICATO.xml:S2:960:8	O
of	PICATO.xml:S2:969:2	O
the	PICATO.xml:S2:972:3	O
drug	PICATO.xml:S2:976:4	O
into	PICATO.xml:S2:981:4	O
the	PICATO.xml:S2:986:3	O
eyes	PICATO.xml:S2:990:4	O
and	PICATO.xml:S2:995:3	O
to	PICATO.xml:S2:999:2	O
the	PICATO.xml:S2:1002:3	O
periocular	PICATO.xml:S2:1006:10	O
area	PICATO.xml:S2:1017:4	O
during	PICATO.xml:S2:1022:6	O
and	PICATO.xml:S2:1029:3	O
after	PICATO.xml:S2:1033:5	O
application	PICATO.xml:S2:1039:11	O
,	PICATO.xml:S2:1050:1	O
patients	PICATO.xml:S2:1052:8	O
should	PICATO.xml:S2:1061:6	O
wash	PICATO.xml:S2:1068:4	O
hands	PICATO.xml:S2:1073:5	O
well	PICATO.xml:S2:1079:4	O
after	PICATO.xml:S2:1084:5	O
applying	PICATO.xml:S2:1090:8	O
Picato	PICATO.xml:S2:1099:6	O
(	PICATO.xml:S2:1107:1	O
r	PICATO.xml:S2:1108:1	O
)	PICATO.xml:S2:1109:1	O
gel	PICATO.xml:S2:1113:3	O
.	PICATO.xml:S2:1116:1	O

If	PICATO.xml:S2:1118:2	O
accidental	PICATO.xml:S2:1121:10	O
exposure	PICATO.xml:S2:1132:8	O
occurs	PICATO.xml:S2:1141:6	O
,	PICATO.xml:S2:1147:1	O
the	PICATO.xml:S2:1149:3	O
area	PICATO.xml:S2:1153:4	O
should	PICATO.xml:S2:1158:6	O
be	PICATO.xml:S2:1165:2	O
flushed	PICATO.xml:S2:1168:7	O
with	PICATO.xml:S2:1176:4	O
water	PICATO.xml:S2:1181:5	O
and	PICATO.xml:S2:1187:3	O
the	PICATO.xml:S2:1191:3	O
patient	PICATO.xml:S2:1195:7	O
should	PICATO.xml:S2:1203:6	O
seek	PICATO.xml:S2:1210:4	O
medical	PICATO.xml:S2:1215:7	O
care	PICATO.xml:S2:1223:4	O
as	PICATO.xml:S2:1228:2	O
soon	PICATO.xml:S2:1231:4	O
as	PICATO.xml:S2:1236:2	O
possible	PICATO.xml:S2:1239:8	O
.	PICATO.xml:S2:1247:1	O

5.2	PICATO.xml:S2:1258:3	O
Hypersensitivity	PICATO.xml:S2:1262:16	O
Reactions	PICATO.xml:S2:1279:9	O

Hypersensitivity	PICATO.xml:S2:1294:16	B-AdverseReaction
reactions	PICATO.xml:S2:1311:9	I-AdverseReaction
,	PICATO.xml:S2:1320:1	O
including	PICATO.xml:S2:1322:9	O
anaphylaxis	PICATO.xml:S2:1332:11	B-AdverseReaction
and	PICATO.xml:S2:1344:3	O
allergic	PICATO.xml:S2:1348:8	B-AdverseReaction
contact	PICATO.xml:S2:1357:7	I-AdverseReaction
dermatitis	PICATO.xml:S2:1365:10	I-AdverseReaction
,	PICATO.xml:S2:1375:1	O
have	PICATO.xml:S2:1377:4	O
been	PICATO.xml:S2:1382:4	O
reported	PICATO.xml:S2:1387:8	O
post	PICATO.xml:S2:1396:4	O
-	PICATO.xml:S2:1400:1	O
marketing	PICATO.xml:S2:1401:9	O
[	PICATO.xml:S2:1411:1	O
see	PICATO.xml:S2:1412:3	O
Adverse	PICATO.xml:S2:1416:7	O
Reactions	PICATO.xml:S2:1424:9	O
(	PICATO.xml:S2:1434:1	O
6.2	PICATO.xml:S2:1437:3	O
)]	PICATO.xml:S2:1442:2	O
.	PICATO.xml:S2:1446:1	O

If	PICATO.xml:S2:1448:2	O
anaphylactic	PICATO.xml:S2:1451:12	O
or	PICATO.xml:S2:1464:2	O
other	PICATO.xml:S2:1467:5	O
clinically	PICATO.xml:S2:1473:10	O
significant	PICATO.xml:S2:1484:11	O
hypersensitivity	PICATO.xml:S2:1496:16	O
reactions	PICATO.xml:S2:1513:9	O
occur	PICATO.xml:S2:1523:5	O
,	PICATO.xml:S2:1528:1	O
discontinue	PICATO.xml:S2:1530:11	O
Picato	PICATO.xml:S2:1542:6	O
(	PICATO.xml:S2:1550:1	O
r	PICATO.xml:S2:1551:1	O
)	PICATO.xml:S2:1552:1	O
immediately	PICATO.xml:S2:1555:11	O
and	PICATO.xml:S2:1567:3	O
institute	PICATO.xml:S2:1571:9	O
appropriate	PICATO.xml:S2:1581:11	O
medical	PICATO.xml:S2:1593:7	O
therapy	PICATO.xml:S2:1601:7	O
.	PICATO.xml:S2:1608:1	O

5.3	PICATO.xml:S2:1617:3	O
Local	PICATO.xml:S2:1621:5	O
Skin	PICATO.xml:S2:1627:4	O
Reactions	PICATO.xml:S2:1632:9	O

Severe	PICATO.xml:S2:1647:6	B-Severity
skin	PICATO.xml:S2:1654:4	B-AdverseReaction
reactions	PICATO.xml:S2:1659:9	I-AdverseReaction
in	PICATO.xml:S2:1669:2	I-AdverseReaction
the	PICATO.xml:S2:1672:3	I-AdverseReaction
treated	PICATO.xml:S2:1676:7	I-AdverseReaction
area	PICATO.xml:S2:1684:4	I-AdverseReaction
,	PICATO.xml:S2:1688:1	O
including	PICATO.xml:S2:1690:9	O
erythema	PICATO.xml:S2:1700:8	I-AdverseReaction
,	PICATO.xml:S2:1708:1	O
crusting	PICATO.xml:S2:1710:8	I-AdverseReaction
,	PICATO.xml:S2:1718:1	O
swelling	PICATO.xml:S2:1720:8	I-AdverseReaction
,	PICATO.xml:S2:1728:1	O
vesiculation	PICATO.xml:S2:1730:12	I-AdverseReaction
postulation	PICATO.xml:S2:1743:11	I-AdverseReaction
,	PICATO.xml:S2:1754:1	O
and	PICATO.xml:S2:1756:3	O
erosion	PICATO.xml:S2:1760:7	I-AdverseReaction
ulceration	PICATO.xml:S2:1768:10	I-AdverseReaction
,	PICATO.xml:S2:1778:1	O
can	PICATO.xml:S2:1780:3	B-Factor
occur	PICATO.xml:S2:1784:5	O
after	PICATO.xml:S2:1790:5	O
topical	PICATO.xml:S2:1796:7	O
application	PICATO.xml:S2:1804:11	O
of	PICATO.xml:S2:1816:2	O
Picato	PICATO.xml:S2:1819:6	O
(	PICATO.xml:S2:1827:1	O
r	PICATO.xml:S2:1828:1	O
)	PICATO.xml:S2:1829:1	O
gel	PICATO.xml:S2:1832:3	O
[	PICATO.xml:S2:1836:1	O
see	PICATO.xml:S2:1837:3	O
Adverse	PICATO.xml:S2:1841:7	O
Reactions	PICATO.xml:S2:1849:9	O
(	PICATO.xml:S2:1859:1	O
6	PICATO.xml:S2:1862:1	O
)]	PICATO.xml:S2:1868:2	O
.	PICATO.xml:S2:1872:1	O

Administration	PICATO.xml:S2:1874:14	O
of	PICATO.xml:S2:1889:2	O
Picato	PICATO.xml:S2:1892:6	O
(	PICATO.xml:S2:1900:1	O
r	PICATO.xml:S2:1901:1	O
)	PICATO.xml:S2:1902:1	O
gel	PICATO.xml:S2:1905:3	O
is	PICATO.xml:S2:1909:2	O
not	PICATO.xml:S2:1912:3	O
recommended	PICATO.xml:S2:1916:11	O
until	PICATO.xml:S2:1928:5	O
the	PICATO.xml:S2:1934:3	O
skin	PICATO.xml:S2:1938:4	O
is	PICATO.xml:S2:1943:2	O
healed	PICATO.xml:S2:1946:6	O
from	PICATO.xml:S2:1953:4	O
any	PICATO.xml:S2:1958:3	O
previous	PICATO.xml:S2:1962:8	O
drug	PICATO.xml:S2:1971:4	O
or	PICATO.xml:S2:1976:2	O
surgical	PICATO.xml:S2:1979:8	O
treatment	PICATO.xml:S2:1988:9	O
.	PICATO.xml:S2:1997:1	O
6	POTIGA.xml:S1:4:1	O
ADVERSE	POTIGA.xml:S1:6:7	O
REACTIONS	POTIGA.xml:S1:14:9	O

The	POTIGA.xml:S1:27:3	O
following	POTIGA.xml:S1:31:9	O
adverse	POTIGA.xml:S1:41:7	O
reactions	POTIGA.xml:S1:49:9	O
are	POTIGA.xml:S1:59:3	O
described	POTIGA.xml:S1:63:9	O
in	POTIGA.xml:S1:73:2	O
more	POTIGA.xml:S1:76:4	O
detail	POTIGA.xml:S1:81:6	O
in	POTIGA.xml:S1:88:2	O
the	POTIGA.xml:S1:91:3	O
Warnings	POTIGA.xml:S1:96:8	O
and	POTIGA.xml:S1:105:3	O
Precautions	POTIGA.xml:S1:109:11	O
section	POTIGA.xml:S1:122:7	O
of	POTIGA.xml:S1:130:2	O
the	POTIGA.xml:S1:133:3	O
label	POTIGA.xml:S1:137:5	O
:	POTIGA.xml:S1:142:1	O

Retinal	POTIGA.xml:S1:153:7	B-AdverseReaction
abnormalities	POTIGA.xml:S1:161:13	I-AdverseReaction
and	POTIGA.xml:S1:175:3	O
potential	POTIGA.xml:S1:179:9	B-Factor
vision	POTIGA.xml:S1:189:6	B-AdverseReaction
loss	POTIGA.xml:S1:196:4	I-AdverseReaction
[	POTIGA.xml:S1:201:1	O
see	POTIGA.xml:S1:202:3	O
Warnings	POTIGA.xml:S1:206:8	O
and	POTIGA.xml:S1:215:3	O
Precautions	POTIGA.xml:S1:219:11	O
(	POTIGA.xml:S1:231:1	O
5.1	POTIGA.xml:S1:232:3	O
)]	POTIGA.xml:S1:235:2	O

Urinary	POTIGA.xml:S1:246:7	B-AdverseReaction
retention	POTIGA.xml:S1:254:9	I-AdverseReaction
[	POTIGA.xml:S1:264:1	O
see	POTIGA.xml:S1:265:3	O
Warnings	POTIGA.xml:S1:269:8	O
and	POTIGA.xml:S1:278:3	O
Precautions	POTIGA.xml:S1:282:11	O
(	POTIGA.xml:S1:294:1	O
5.2	POTIGA.xml:S1:295:3	O
)]	POTIGA.xml:S1:298:2	O

Skin	POTIGA.xml:S1:309:4	B-AdverseReaction
discoloration	POTIGA.xml:S1:314:13	I-AdverseReaction
[	POTIGA.xml:S1:328:1	O
see	POTIGA.xml:S1:329:3	O
Warnings	POTIGA.xml:S1:333:8	O
and	POTIGA.xml:S1:342:3	O
Precautions	POTIGA.xml:S1:346:11	O
(	POTIGA.xml:S1:358:1	O
5.3	POTIGA.xml:S1:359:3	O
)]	POTIGA.xml:S1:362:2	O

Neuropsychiatric	POTIGA.xml:S1:373:16	B-AdverseReaction
symptoms	POTIGA.xml:S1:390:8	I-AdverseReaction
[	POTIGA.xml:S1:399:1	O
see	POTIGA.xml:S1:400:3	O
Warnings	POTIGA.xml:S1:404:8	O
and	POTIGA.xml:S1:413:3	O
Precautions	POTIGA.xml:S1:417:11	O
(	POTIGA.xml:S1:429:1	O
5.4	POTIGA.xml:S1:430:3	O
)]	POTIGA.xml:S1:433:2	O

Dizziness	POTIGA.xml:S1:444:9	B-AdverseReaction
and	POTIGA.xml:S1:454:3	O
somnolence	POTIGA.xml:S1:458:10	B-AdverseReaction
[	POTIGA.xml:S1:469:1	O
see	POTIGA.xml:S1:470:3	O
Warnings	POTIGA.xml:S1:474:8	O
and	POTIGA.xml:S1:483:3	O
Precautions	POTIGA.xml:S1:487:11	O
(	POTIGA.xml:S1:499:1	O
5.5	POTIGA.xml:S1:500:3	O
)]	POTIGA.xml:S1:503:2	O

QT	POTIGA.xml:S1:514:2	B-AdverseReaction
interval	POTIGA.xml:S1:517:8	I-AdverseReaction
effect	POTIGA.xml:S1:526:6	I-AdverseReaction
[	POTIGA.xml:S1:533:1	O
see	POTIGA.xml:S1:534:3	O
Warnings	POTIGA.xml:S1:538:8	O
and	POTIGA.xml:S1:547:3	O
Precautions	POTIGA.xml:S1:551:11	O
(	POTIGA.xml:S1:563:1	O
5.6	POTIGA.xml:S1:564:3	O
)]	POTIGA.xml:S1:567:2	O

Suicidal	POTIGA.xml:S1:578:8	B-AdverseReaction
behavior	POTIGA.xml:S1:587:8	I-AdverseReaction
and	POTIGA.xml:S1:596:3	O
ideation	POTIGA.xml:S1:600:8	I-AdverseReaction
[	POTIGA.xml:S1:609:1	O
see	POTIGA.xml:S1:610:3	O
Warnings	POTIGA.xml:S1:614:8	O
and	POTIGA.xml:S1:623:3	O
Precautions	POTIGA.xml:S1:627:11	O
(	POTIGA.xml:S1:639:1	O
5.7	POTIGA.xml:S1:640:3	O
)]	POTIGA.xml:S1:643:2	O

Withdrawal	POTIGA.xml:S1:654:10	B-AdverseReaction
seizures	POTIGA.xml:S1:665:8	I-AdverseReaction
[	POTIGA.xml:S1:674:1	O
see	POTIGA.xml:S1:675:3	O
Warnings	POTIGA.xml:S1:679:8	O
and	POTIGA.xml:S1:688:3	O
Precautions	POTIGA.xml:S1:692:11	O
(	POTIGA.xml:S1:704:1	O
5.8	POTIGA.xml:S1:705:3	O
)]	POTIGA.xml:S1:708:2	O

EXCERPT	POTIGA.xml:S1:719:7	O
:	POTIGA.xml:S1:726:1	O
Most	POTIGA.xml:S1:730:4	O
common	POTIGA.xml:S1:735:6	O
adverse	POTIGA.xml:S1:742:7	O
reactions	POTIGA.xml:S1:750:9	O
(	POTIGA.xml:S1:760:1	O
incidence	POTIGA.xml:S1:761:9	O
4%	POTIGA.xml:S1:773:2	O
and	POTIGA.xml:S1:776:3	O
twice	POTIGA.xml:S1:780:5	O
placebo	POTIGA.xml:S1:786:7	O
)	POTIGA.xml:S1:793:1	O
were	POTIGA.xml:S1:795:4	O
dizziness	POTIGA.xml:S1:800:9	B-AdverseReaction
,	POTIGA.xml:S1:809:1	O
somnolence	POTIGA.xml:S1:811:10	B-AdverseReaction
,	POTIGA.xml:S1:821:1	O
fatigue	POTIGA.xml:S1:823:7	B-AdverseReaction
,	POTIGA.xml:S1:830:1	O
confusional	POTIGA.xml:S1:832:11	B-AdverseReaction
state	POTIGA.xml:S1:844:5	I-AdverseReaction
,	POTIGA.xml:S1:849:1	O
vertigo	POTIGA.xml:S1:851:7	B-AdverseReaction
,	POTIGA.xml:S1:858:1	O
tremor	POTIGA.xml:S1:860:6	B-AdverseReaction
,	POTIGA.xml:S1:866:1	O
abnormal	POTIGA.xml:S1:868:8	B-AdverseReaction
coordination	POTIGA.xml:S1:877:12	I-AdverseReaction
,	POTIGA.xml:S1:889:1	O
diplopia	POTIGA.xml:S1:891:8	B-AdverseReaction
,	POTIGA.xml:S1:899:1	O
disturbance	POTIGA.xml:S1:901:11	B-AdverseReaction
in	POTIGA.xml:S1:913:2	I-AdverseReaction
attention	POTIGA.xml:S1:916:9	I-AdverseReaction
,	POTIGA.xml:S1:925:1	O
memory	POTIGA.xml:S1:927:6	B-AdverseReaction
impairment	POTIGA.xml:S1:934:10	I-AdverseReaction
,	POTIGA.xml:S1:944:1	O
asthenia	POTIGA.xml:S1:946:8	B-AdverseReaction
,	POTIGA.xml:S1:954:1	O
blurred	POTIGA.xml:S1:956:7	B-AdverseReaction
vision	POTIGA.xml:S1:964:6	I-AdverseReaction
,	POTIGA.xml:S1:970:1	O
gait	POTIGA.xml:S1:972:4	B-AdverseReaction
disturbance	POTIGA.xml:S1:977:11	I-AdverseReaction
,	POTIGA.xml:S1:988:1	O
aphasia	POTIGA.xml:S1:990:7	B-AdverseReaction
,	POTIGA.xml:S1:997:1	O
dysarthria	POTIGA.xml:S1:999:10	B-AdverseReaction
,	POTIGA.xml:S1:1009:1	O
and	POTIGA.xml:S1:1011:3	O
balance	POTIGA.xml:S1:1015:7	B-AdverseReaction
disorder	POTIGA.xml:S1:1023:8	I-AdverseReaction
.	POTIGA.xml:S1:1031:1	O

(	POTIGA.xml:S1:1033:1	O
6.1	POTIGA.xml:S1:1036:3	O
)	POTIGA.xml:S1:1041:1	O

To	POTIGA.xml:S1:1049:2	O

report	POTIGA.xml:S1:1052:6	O
SUSPECTED	POTIGA.xml:S1:1059:9	O
ADVERSE	POTIGA.xml:S1:1069:7	O
REACTIONS	POTIGA.xml:S1:1077:9	O
,	POTIGA.xml:S1:1086:1	O
contact	POTIGA.xml:S1:1088:7	O
GlaxoSmithKline	POTIGA.xml:S1:1096:15	O
at	POTIGA.xml:S1:1112:2	O
1	POTIGA.xml:S1:1115:1	O
-	POTIGA.xml:S1:1116:1	O
888	POTIGA.xml:S1:1117:3	O
-	POTIGA.xml:S1:1120:1	O
825	POTIGA.xml:S1:1121:3	O
-	POTIGA.xml:S1:1124:1	O
5249	POTIGA.xml:S1:1125:4	O
or	POTIGA.xml:S1:1130:2	O
FDA	POTIGA.xml:S1:1133:3	O
at	POTIGA.xml:S1:1137:2	O
1	POTIGA.xml:S1:1140:1	O
-	POTIGA.xml:S1:1141:1	O
800	POTIGA.xml:S1:1142:3	O
-	POTIGA.xml:S1:1145:1	O
FDA	POTIGA.xml:S1:1146:3	O
-	POTIGA.xml:S1:1149:1	O
1088	POTIGA.xml:S1:1150:4	O
or	POTIGA.xml:S1:1155:2	O
www	POTIGA.xml:S1:1159:3	O
.	POTIGA.xml:S1:1162:1	O
fda	POTIGA.xml:S1:1163:3	O
.	POTIGA.xml:S1:1166:1	O
gov	POTIGA.xml:S1:1167:3	O
medwatch	POTIGA.xml:S1:1171:8	O
.	POTIGA.xml:S1:1181:1	O

6.1	POTIGA.xml:S1:1193:3	O

Clinical	POTIGA.xml:S1:1197:8	O
Trials	POTIGA.xml:S1:1206:6	O
Experience	POTIGA.xml:S1:1213:10	O

Because	POTIGA.xml:S1:1227:7	O
clinical	POTIGA.xml:S1:1235:8	O
trials	POTIGA.xml:S1:1244:6	O
are	POTIGA.xml:S1:1251:3	O
conducted	POTIGA.xml:S1:1255:9	O
under	POTIGA.xml:S1:1265:5	O
widely	POTIGA.xml:S1:1271:6	O
varying	POTIGA.xml:S1:1278:7	O
conditions	POTIGA.xml:S1:1286:10	O
,	POTIGA.xml:S1:1296:1	O
adverse	POTIGA.xml:S1:1298:7	O
reaction	POTIGA.xml:S1:1306:8	O
rates	POTIGA.xml:S1:1315:5	O
observed	POTIGA.xml:S1:1321:8	O
in	POTIGA.xml:S1:1330:2	O
the	POTIGA.xml:S1:1333:3	O
clinical	POTIGA.xml:S1:1337:8	O
trials	POTIGA.xml:S1:1346:6	O
of	POTIGA.xml:S1:1353:2	O
a	POTIGA.xml:S1:1356:1	O
drug	POTIGA.xml:S1:1358:4	O
cannot	POTIGA.xml:S1:1363:6	O
be	POTIGA.xml:S1:1370:2	O
directly	POTIGA.xml:S1:1373:8	O
compared	POTIGA.xml:S1:1382:8	O
with	POTIGA.xml:S1:1391:4	O
rates	POTIGA.xml:S1:1396:5	O
in	POTIGA.xml:S1:1402:2	O
the	POTIGA.xml:S1:1405:3	O
clinical	POTIGA.xml:S1:1409:8	O
trials	POTIGA.xml:S1:1418:6	O
of	POTIGA.xml:S1:1425:2	O
another	POTIGA.xml:S1:1428:7	O
drug	POTIGA.xml:S1:1436:4	O
and	POTIGA.xml:S1:1441:3	O
may	POTIGA.xml:S1:1445:3	O
not	POTIGA.xml:S1:1449:3	O
reflect	POTIGA.xml:S1:1453:7	O
the	POTIGA.xml:S1:1461:3	O
rates	POTIGA.xml:S1:1465:5	O
observed	POTIGA.xml:S1:1471:8	O
in	POTIGA.xml:S1:1480:2	O
practice	POTIGA.xml:S1:1483:8	O
.	POTIGA.xml:S1:1491:1	O

POTIGA	POTIGA.xml:S1:1497:6	O
was	POTIGA.xml:S1:1504:3	O
administered	POTIGA.xml:S1:1508:12	O
as	POTIGA.xml:S1:1521:2	O
adjunctive	POTIGA.xml:S1:1524:10	O
therapy	POTIGA.xml:S1:1535:7	O
to	POTIGA.xml:S1:1543:2	O
1	POTIGA.xml:S1:1546:1	O
,	POTIGA.xml:S1:1547:1	O
365	POTIGA.xml:S1:1548:3	O
patients	POTIGA.xml:S1:1552:8	O
with	POTIGA.xml:S1:1561:4	O
epilepsy	POTIGA.xml:S1:1566:8	O
in	POTIGA.xml:S1:1575:2	O
all	POTIGA.xml:S1:1578:3	O
controlled	POTIGA.xml:S1:1582:10	O
and	POTIGA.xml:S1:1593:3	O
uncontrolled	POTIGA.xml:S1:1597:12	O
clinical	POTIGA.xml:S1:1610:8	O
studies	POTIGA.xml:S1:1619:7	O
during	POTIGA.xml:S1:1627:6	O
the	POTIGA.xml:S1:1634:3	O
premarketing	POTIGA.xml:S1:1638:12	O
development	POTIGA.xml:S1:1651:11	O
.	POTIGA.xml:S1:1662:1	O

A	POTIGA.xml:S1:1664:1	O
total	POTIGA.xml:S1:1666:5	O
of	POTIGA.xml:S1:1672:2	O
801	POTIGA.xml:S1:1675:3	O
patients	POTIGA.xml:S1:1679:8	O
were	POTIGA.xml:S1:1688:4	O
treated	POTIGA.xml:S1:1693:7	O
for	POTIGA.xml:S1:1701:3	O
at	POTIGA.xml:S1:1705:2	O
least	POTIGA.xml:S1:1708:5	O
6	POTIGA.xml:S1:1714:1	O
months	POTIGA.xml:S1:1716:6	O
,	POTIGA.xml:S1:1722:1	O
585	POTIGA.xml:S1:1724:3	O
patients	POTIGA.xml:S1:1728:8	O
were	POTIGA.xml:S1:1737:4	O
treated	POTIGA.xml:S1:1742:7	O
for	POTIGA.xml:S1:1750:3	O
1	POTIGA.xml:S1:1754:1	O
year	POTIGA.xml:S1:1756:4	O
or	POTIGA.xml:S1:1761:2	O
longer	POTIGA.xml:S1:1764:6	O
,	POTIGA.xml:S1:1770:1	O
and	POTIGA.xml:S1:1772:3	O
311	POTIGA.xml:S1:1776:3	O
patients	POTIGA.xml:S1:1780:8	O
were	POTIGA.xml:S1:1789:4	O
treated	POTIGA.xml:S1:1794:7	O
for	POTIGA.xml:S1:1802:3	O
at	POTIGA.xml:S1:1806:2	O
least	POTIGA.xml:S1:1809:5	O
2	POTIGA.xml:S1:1815:1	O
years	POTIGA.xml:S1:1817:5	O
.	POTIGA.xml:S1:1822:1	O

Adverse	POTIGA.xml:S1:1830:7	O
Reactions	POTIGA.xml:S1:1838:9	O
Leading	POTIGA.xml:S1:1848:7	O
to	POTIGA.xml:S1:1856:2	O
Discontinuation	POTIGA.xml:S1:1859:15	O
in	POTIGA.xml:S1:1875:2	O
All	POTIGA.xml:S1:1878:3	O
Controlled	POTIGA.xml:S1:1882:10	O
Clinical	POTIGA.xml:S1:1893:8	O
Studies	POTIGA.xml:S1:1902:7	O

In	POTIGA.xml:S1:1916:2	O
the	POTIGA.xml:S1:1919:3	O
3	POTIGA.xml:S1:1923:1	O
randomized	POTIGA.xml:S1:1925:10	O
,	POTIGA.xml:S1:1935:1	O
double	POTIGA.xml:S1:1937:6	O
-	POTIGA.xml:S1:1943:1	O
blind	POTIGA.xml:S1:1944:5	O
,	POTIGA.xml:S1:1949:1	O
placebo	POTIGA.xml:S1:1951:7	O
-	POTIGA.xml:S1:1958:1	O
controlled	POTIGA.xml:S1:1959:10	O
studies	POTIGA.xml:S1:1970:7	O
,	POTIGA.xml:S1:1977:1	O
199	POTIGA.xml:S1:1979:3	O
of	POTIGA.xml:S1:1983:2	O
813	POTIGA.xml:S1:1986:3	O
patients	POTIGA.xml:S1:1990:8	O
(	POTIGA.xml:S1:1999:1	O
25%	POTIGA.xml:S1:2000:3	O
)	POTIGA.xml:S1:2003:1	O
receiving	POTIGA.xml:S1:2005:9	O
POTIGA	POTIGA.xml:S1:2015:6	O
and	POTIGA.xml:S1:2022:3	O
45	POTIGA.xml:S1:2026:2	O
of	POTIGA.xml:S1:2029:2	O
427	POTIGA.xml:S1:2032:3	O
patients	POTIGA.xml:S1:2036:8	O
(	POTIGA.xml:S1:2045:1	O
11%	POTIGA.xml:S1:2046:3	O
)	POTIGA.xml:S1:2049:1	O
receiving	POTIGA.xml:S1:2051:9	O
placebo	POTIGA.xml:S1:2061:7	O
discontinued	POTIGA.xml:S1:2069:12	O
treatment	POTIGA.xml:S1:2082:9	O
because	POTIGA.xml:S1:2092:7	O
of	POTIGA.xml:S1:2100:2	O
adverse	POTIGA.xml:S1:2103:7	O
reactions	POTIGA.xml:S1:2111:9	O
.	POTIGA.xml:S1:2120:1	O

The	POTIGA.xml:S1:2122:3	O
most	POTIGA.xml:S1:2126:4	O
common	POTIGA.xml:S1:2131:6	O
adverse	POTIGA.xml:S1:2138:7	O
reactions	POTIGA.xml:S1:2146:9	O
leading	POTIGA.xml:S1:2156:7	O
to	POTIGA.xml:S1:2164:2	O
withdrawal	POTIGA.xml:S1:2167:10	O
in	POTIGA.xml:S1:2178:2	O
patients	POTIGA.xml:S1:2181:8	O
receiving	POTIGA.xml:S1:2190:9	O
POTIGA	POTIGA.xml:S1:2200:6	O
were	POTIGA.xml:S1:2207:4	O
dizziness	POTIGA.xml:S1:2212:9	B-AdverseReaction
(	POTIGA.xml:S1:2222:1	O
6%	POTIGA.xml:S1:2223:2	O
)	POTIGA.xml:S1:2225:1	O
,	POTIGA.xml:S1:2226:1	O
confusional	POTIGA.xml:S1:2228:11	B-AdverseReaction
state	POTIGA.xml:S1:2240:5	I-AdverseReaction
(	POTIGA.xml:S1:2246:1	O
4%	POTIGA.xml:S1:2247:2	O
)	POTIGA.xml:S1:2249:1	O
,	POTIGA.xml:S1:2250:1	O
fatigue	POTIGA.xml:S1:2252:7	B-AdverseReaction
(	POTIGA.xml:S1:2260:1	O
3%	POTIGA.xml:S1:2261:2	O
)	POTIGA.xml:S1:2263:1	O
,	POTIGA.xml:S1:2264:1	O
and	POTIGA.xml:S1:2266:3	O
somnolence	POTIGA.xml:S1:2270:10	B-AdverseReaction
(	POTIGA.xml:S1:2281:1	O
3%	POTIGA.xml:S1:2282:2	O
)	POTIGA.xml:S1:2284:1	O
.	POTIGA.xml:S1:2285:1	O

Common	POTIGA.xml:S1:2293:6	O
Adverse	POTIGA.xml:S1:2300:7	O
Reactions	POTIGA.xml:S1:2308:9	O
in	POTIGA.xml:S1:2318:2	O
All	POTIGA.xml:S1:2321:3	O
Controlled	POTIGA.xml:S1:2325:10	O
Clinical	POTIGA.xml:S1:2336:8	O
Studies	POTIGA.xml:S1:2345:7	O

Overall	POTIGA.xml:S1:2359:7	O
,	POTIGA.xml:S1:2366:1	O
the	POTIGA.xml:S1:2368:3	O
most	POTIGA.xml:S1:2372:4	O
frequently	POTIGA.xml:S1:2377:10	O
reported	POTIGA.xml:S1:2388:8	O
adverse	POTIGA.xml:S1:2397:7	O
reactions	POTIGA.xml:S1:2405:9	O
in	POTIGA.xml:S1:2415:2	O
patients	POTIGA.xml:S1:2418:8	O
receiving	POTIGA.xml:S1:2427:9	O
POTIGA	POTIGA.xml:S1:2437:6	O
(	POTIGA.xml:S1:2444:1	O
4%	POTIGA.xml:S1:2447:2	O
and	POTIGA.xml:S1:2450:3	O
occurring	POTIGA.xml:S1:2454:9	O
approximately	POTIGA.xml:S1:2464:13	O
twice	POTIGA.xml:S1:2478:5	O
the	POTIGA.xml:S1:2484:3	O
placebo	POTIGA.xml:S1:2488:7	O
rate	POTIGA.xml:S1:2496:4	O
)	POTIGA.xml:S1:2500:1	O
were	POTIGA.xml:S1:2502:4	O
dizziness	POTIGA.xml:S1:2507:9	B-AdverseReaction
(	POTIGA.xml:S1:2517:1	O
23%	POTIGA.xml:S1:2518:3	O
)	POTIGA.xml:S1:2521:1	O
,	POTIGA.xml:S1:2522:1	O
somnolence	POTIGA.xml:S1:2524:10	B-AdverseReaction
(	POTIGA.xml:S1:2535:1	O
22%	POTIGA.xml:S1:2536:3	O
)	POTIGA.xml:S1:2539:1	O
,	POTIGA.xml:S1:2540:1	O
fatigue	POTIGA.xml:S1:2542:7	B-AdverseReaction
(	POTIGA.xml:S1:2550:1	O
15%	POTIGA.xml:S1:2551:3	O
)	POTIGA.xml:S1:2554:1	O
,	POTIGA.xml:S1:2555:1	O
confusional	POTIGA.xml:S1:2557:11	B-AdverseReaction
state	POTIGA.xml:S1:2569:5	I-AdverseReaction
(	POTIGA.xml:S1:2575:1	O
9%	POTIGA.xml:S1:2576:2	O
)	POTIGA.xml:S1:2578:1	O
,	POTIGA.xml:S1:2579:1	O
vertigo	POTIGA.xml:S1:2581:7	B-AdverseReaction
(	POTIGA.xml:S1:2589:1	O
8%	POTIGA.xml:S1:2590:2	O
)	POTIGA.xml:S1:2592:1	O
,	POTIGA.xml:S1:2593:1	O
tremor	POTIGA.xml:S1:2595:6	B-AdverseReaction
(	POTIGA.xml:S1:2602:1	O
8%	POTIGA.xml:S1:2603:2	O
)	POTIGA.xml:S1:2605:1	O
,	POTIGA.xml:S1:2606:1	O
abnormal	POTIGA.xml:S1:2608:8	B-AdverseReaction
coordination	POTIGA.xml:S1:2617:12	I-AdverseReaction
(	POTIGA.xml:S1:2630:1	O
7%	POTIGA.xml:S1:2631:2	O
)	POTIGA.xml:S1:2633:1	O
,	POTIGA.xml:S1:2634:1	O
diplopia	POTIGA.xml:S1:2636:8	B-AdverseReaction
(	POTIGA.xml:S1:2645:1	O
7%	POTIGA.xml:S1:2646:2	O
)	POTIGA.xml:S1:2648:1	O
,	POTIGA.xml:S1:2649:1	O
disturbance	POTIGA.xml:S1:2651:11	B-AdverseReaction
in	POTIGA.xml:S1:2663:2	I-AdverseReaction
attention	POTIGA.xml:S1:2666:9	I-AdverseReaction
(	POTIGA.xml:S1:2676:1	O
6%	POTIGA.xml:S1:2677:2	O
)	POTIGA.xml:S1:2679:1	O
,	POTIGA.xml:S1:2680:1	O
memory	POTIGA.xml:S1:2682:6	B-AdverseReaction
impairment	POTIGA.xml:S1:2689:10	I-AdverseReaction
(	POTIGA.xml:S1:2700:1	O
6%	POTIGA.xml:S1:2701:2	O
)	POTIGA.xml:S1:2703:1	O
,	POTIGA.xml:S1:2704:1	O
asthenia	POTIGA.xml:S1:2706:8	B-AdverseReaction
(	POTIGA.xml:S1:2715:1	O
5%	POTIGA.xml:S1:2716:2	O
)	POTIGA.xml:S1:2718:1	O
,	POTIGA.xml:S1:2719:1	O
blurred	POTIGA.xml:S1:2721:7	B-AdverseReaction
vision	POTIGA.xml:S1:2729:6	I-AdverseReaction
(	POTIGA.xml:S1:2736:1	O
5%	POTIGA.xml:S1:2737:2	O
)	POTIGA.xml:S1:2739:1	O
,	POTIGA.xml:S1:2740:1	O
gait	POTIGA.xml:S1:2742:4	B-AdverseReaction
disturbance	POTIGA.xml:S1:2747:11	I-AdverseReaction
(	POTIGA.xml:S1:2759:1	O
4%	POTIGA.xml:S1:2760:2	O
)	POTIGA.xml:S1:2762:1	O
,	POTIGA.xml:S1:2763:1	O
aphasia	POTIGA.xml:S1:2765:7	B-AdverseReaction
(	POTIGA.xml:S1:2773:1	O
4%	POTIGA.xml:S1:2774:2	O
)	POTIGA.xml:S1:2776:1	O
,	POTIGA.xml:S1:2777:1	O
dysarthria	POTIGA.xml:S1:2779:10	B-AdverseReaction
(	POTIGA.xml:S1:2790:1	O
4%	POTIGA.xml:S1:2791:2	O
)	POTIGA.xml:S1:2793:1	O
,	POTIGA.xml:S1:2794:1	O
and	POTIGA.xml:S1:2796:3	O
balance	POTIGA.xml:S1:2800:7	B-AdverseReaction
disorder	POTIGA.xml:S1:2808:8	I-AdverseReaction
(	POTIGA.xml:S1:2817:1	O
4%	POTIGA.xml:S1:2818:2	O
)	POTIGA.xml:S1:2820:1	O
(	POTIGA.xml:S1:2822:1	O
see	POTIGA.xml:S1:2823:3	O
Table	POTIGA.xml:S1:2827:5	O
4	POTIGA.xml:S1:2833:1	O
)	POTIGA.xml:S1:2834:1	O
.	POTIGA.xml:S1:2835:1	O

In	POTIGA.xml:S1:2837:2	O
most	POTIGA.xml:S1:2840:4	O
cases	POTIGA.xml:S1:2845:5	O
the	POTIGA.xml:S1:2851:3	O
reactions	POTIGA.xml:S1:2855:9	O
were	POTIGA.xml:S1:2865:4	O
of	POTIGA.xml:S1:2870:2	O
mild	POTIGA.xml:S1:2873:4	O
or	POTIGA.xml:S1:2878:2	O
moderate	POTIGA.xml:S1:2881:8	O
intensity	POTIGA.xml:S1:2890:9	O
.	POTIGA.xml:S1:2899:1	O

Table	POTIGA.xml:S1:2907:5	O
4	POTIGA.xml:S1:2913:1	O
.	POTIGA.xml:S1:2914:1	O

Adverse	POTIGA.xml:S1:2916:7	O
Reactions	POTIGA.xml:S1:2924:9	O
Incidence	POTIGA.xml:S1:2934:9	O
in	POTIGA.xml:S1:2944:2	O
Placebo	POTIGA.xml:S1:2947:7	O
-	POTIGA.xml:S1:2954:1	O
Controlled	POTIGA.xml:S1:2955:10	O
Adjunctive	POTIGA.xml:S1:2966:10	O
Trials	POTIGA.xml:S1:2977:6	O
in	POTIGA.xml:S1:2984:2	O
Adult	POTIGA.xml:S1:2987:5	O
Patients	POTIGA.xml:S1:2993:8	O
with	POTIGA.xml:S1:3002:4	O
Partial	POTIGA.xml:S1:3007:7	O
-	POTIGA.xml:S1:3014:1	O
Onset	POTIGA.xml:S1:3015:5	O
Seizures	POTIGA.xml:S1:3021:8	O
(	POTIGA.xml:S1:3030:1	O
Adverse	POTIGA.xml:S1:3031:7	O
reactions	POTIGA.xml:S1:3039:9	O
in	POTIGA.xml:S1:3049:2	O
at	POTIGA.xml:S1:3052:2	O
least	POTIGA.xml:S1:3055:5	O
2%	POTIGA.xml:S1:3061:2	O
of	POTIGA.xml:S1:3064:2	O
patients	POTIGA.xml:S1:3067:8	O
treated	POTIGA.xml:S1:3076:7	O
with	POTIGA.xml:S1:3084:4	O
POTIGA	POTIGA.xml:S1:3089:6	O
in	POTIGA.xml:S1:3096:2	O
any	POTIGA.xml:S1:3099:3	O
treatment	POTIGA.xml:S1:3103:9	O
group	POTIGA.xml:S1:3113:5	O
and	POTIGA.xml:S1:3119:3	O
numerically	POTIGA.xml:S1:3123:11	O
more	POTIGA.xml:S1:3135:4	O
frequent	POTIGA.xml:S1:3140:8	O
than	POTIGA.xml:S1:3149:4	O
in	POTIGA.xml:S1:3154:2	O
the	POTIGA.xml:S1:3157:3	O
placebo	POTIGA.xml:S1:3161:7	O
group	POTIGA.xml:S1:3169:5	O
.	POTIGA.xml:S1:3174:1	O
)	POTIGA.xml:S1:3175:1	O

Body	POTIGA.xml:S1:3185:4	O
System	POTIGA.xml:S1:3190:6	O
Adverse	POTIGA.xml:S1:3197:7	O
Reaction	POTIGA.xml:S1:3205:8	O
Placebo	POTIGA.xml:S1:3217:7	O
POTIGA	POTIGA.xml:S1:3230:6	O

600	POTIGA.xml:S1:3249:3	O
mg	POTIGA.xml:S1:3253:2	O
day	POTIGA.xml:S1:3256:3	O
900	POTIGA.xml:S1:3278:3	O
mg	POTIGA.xml:S1:3282:2	O
day	POTIGA.xml:S1:3285:3	O
1	POTIGA.xml:S1:3292:1	O
,	POTIGA.xml:S1:3293:1	O
200	POTIGA.xml:S1:3294:3	O
mg	POTIGA.xml:S1:3298:2	O
day	POTIGA.xml:S1:3301:3	O
All	POTIGA.xml:S1:3308:3	O

(	POTIGA.xml:S1:3327:1	O
N	POTIGA.xml:S1:3328:1	O
427	POTIGA.xml:S1:3332:3	O
)	POTIGA.xml:S1:3335:1	O
(	POTIGA.xml:S1:3356:1	O
n	POTIGA.xml:S1:3357:1	O
281	POTIGA.xml:S1:3361:3	O
)	POTIGA.xml:S1:3364:1	O
(	POTIGA.xml:S1:3372:1	O
n	POTIGA.xml:S1:3373:1	O
273	POTIGA.xml:S1:3377:3	O
)	POTIGA.xml:S1:3380:1	O
(	POTIGA.xml:S1:3388:1	O
n	POTIGA.xml:S1:3389:1	O
259	POTIGA.xml:S1:3393:3	O
)	POTIGA.xml:S1:3396:1	O
(	POTIGA.xml:S1:3404:1	O
N	POTIGA.xml:S1:3405:1	O
813	POTIGA.xml:S1:3409:3	O
)	POTIGA.xml:S1:3412:1	O

Eye	POTIGA.xml:S1:3452:3	O

Diplopia	POTIGA.xml:S1:3647:8	B-AdverseReaction

2	POTIGA.xml:S1:3736:1	O

8	POTIGA.xml:S1:3749:1	O
6	POTIGA.xml:S1:3765:1	O
7	POTIGA.xml:S1:3781:1	O
7	POTIGA.xml:S1:3798:1	O

Blurred	POTIGA.xml:S1:3842:7	B-AdverseReaction
vision	POTIGA.xml:S1:3850:6	I-AdverseReaction

2	POTIGA.xml:S1:3931:1	O
2	POTIGA.xml:S1:3944:1	O
4	POTIGA.xml:S1:3960:1	O
10	POTIGA.xml:S1:3976:2	O
5	POTIGA.xml:S1:3993:1	O

Gastrointestinal	POTIGA.xml:S1:4037:16	O

Nausea	POTIGA.xml:S1:4232:6	B-AdverseReaction

5	POTIGA.xml:S1:4321:1	O

6	POTIGA.xml:S1:4334:1	O
6	POTIGA.xml:S1:4350:1	O
9	POTIGA.xml:S1:4366:1	O
7	POTIGA.xml:S1:4383:1	O

Constipation	POTIGA.xml:S1:4427:12	B-AdverseReaction

1	POTIGA.xml:S1:4516:1	O
1	POTIGA.xml:S1:4529:1	O
4	POTIGA.xml:S1:4545:1	O
5	POTIGA.xml:S1:4561:1	O
3	POTIGA.xml:S1:4578:1	O

Dyspepsia	POTIGA.xml:S1:4622:9	B-AdverseReaction

2	POTIGA.xml:S1:4711:1	O
3	POTIGA.xml:S1:4724:1	O
2	POTIGA.xml:S1:4740:1	O
3	POTIGA.xml:S1:4756:1	O
2	POTIGA.xml:S1:4773:1	O

General	POTIGA.xml:S1:4817:7	O

Fatigue	POTIGA.xml:S1:5012:7	B-AdverseReaction

6	POTIGA.xml:S1:5101:1	O

16	POTIGA.xml:S1:5114:2	O
15	POTIGA.xml:S1:5130:2	O
13	POTIGA.xml:S1:5146:2	O
15	POTIGA.xml:S1:5163:2	O

Asthenia	POTIGA.xml:S1:5207:8	B-AdverseReaction

2	POTIGA.xml:S1:5296:1	O
4	POTIGA.xml:S1:5309:1	O
6	POTIGA.xml:S1:5325:1	O
4	POTIGA.xml:S1:5341:1	O
5	POTIGA.xml:S1:5358:1	O

Infections	POTIGA.xml:S1:5402:10	O
and	POTIGA.xml:S1:5413:3	O
infestations	POTIGA.xml:S1:5417:12	O

Influenza	POTIGA.xml:S1:5597:9	B-AdverseReaction

2	POTIGA.xml:S1:5686:1	O

4	POTIGA.xml:S1:5699:1	O
1	POTIGA.xml:S1:5715:1	O
5	POTIGA.xml:S1:5731:1	O
3	POTIGA.xml:S1:5748:1	O

Investigations	POTIGA.xml:S1:5792:14	O

Weight	POTIGA.xml:S1:5987:6	B-AdverseReaction

increased	POTIGA.xml:S1:5994:9	I-AdverseReaction

1	POTIGA.xml:S1:6076:1	O
2	POTIGA.xml:S1:6089:1	O
3	POTIGA.xml:S1:6105:1	O
3	POTIGA.xml:S1:6121:1	O
3	POTIGA.xml:S1:6138:1	O

Nervous	POTIGA.xml:S1:6182:7	O
system	POTIGA.xml:S1:6190:6	O

Dizziness	POTIGA.xml:S1:6377:9	B-AdverseReaction

9	POTIGA.xml:S1:6466:1	O

15	POTIGA.xml:S1:6479:2	O
23	POTIGA.xml:S1:6495:2	O
32	POTIGA.xml:S1:6511:2	O
23	POTIGA.xml:S1:6528:2	O

Somnolence	POTIGA.xml:S1:6572:10	B-AdverseReaction

12	POTIGA.xml:S1:6661:2	O
15	POTIGA.xml:S1:6674:2	O
25	POTIGA.xml:S1:6690:2	O
27	POTIGA.xml:S1:6706:2	O
22	POTIGA.xml:S1:6723:2	O

Memory	POTIGA.xml:S1:6767:6	B-AdverseReaction
impairment	POTIGA.xml:S1:6774:10	I-AdverseReaction

3	POTIGA.xml:S1:6856:1	O
3	POTIGA.xml:S1:6869:1	O
6	POTIGA.xml:S1:6885:1	O
9	POTIGA.xml:S1:6901:1	O
6	POTIGA.xml:S1:6918:1	O

Tremor	POTIGA.xml:S1:6962:6	B-AdverseReaction

3	POTIGA.xml:S1:7051:1	O
3	POTIGA.xml:S1:7064:1	O
10	POTIGA.xml:S1:7080:2	O
12	POTIGA.xml:S1:7096:2	O
8	POTIGA.xml:S1:7113:1	O

Vertigo	POTIGA.xml:S1:7157:7	B-AdverseReaction

2	POTIGA.xml:S1:7246:1	O
8	POTIGA.xml:S1:7259:1	O
8	POTIGA.xml:S1:7275:1	O
9	POTIGA.xml:S1:7291:1	O
8	POTIGA.xml:S1:7308:1	O

Abnormal	POTIGA.xml:S1:7352:8	B-AdverseReaction
coordination	POTIGA.xml:S1:7361:12	I-AdverseReaction

3	POTIGA.xml:S1:7441:1	O
5	POTIGA.xml:S1:7454:1	O
5	POTIGA.xml:S1:7470:1	O
12	POTIGA.xml:S1:7486:2	O
7	POTIGA.xml:S1:7503:1	O

Disturbance	POTIGA.xml:S1:7547:11	B-AdverseReaction
in	POTIGA.xml:S1:7559:2	I-AdverseReaction
attention	POTIGA.xml:S1:7562:9	I-AdverseReaction

1	POTIGA.xml:S1:7637:1	O
6	POTIGA.xml:S1:7649:1	O
6	POTIGA.xml:S1:7665:1	O
7	POTIGA.xml:S1:7681:1	O
6	POTIGA.xml:S1:7698:1	O

Gait	POTIGA.xml:S1:7742:4	B-AdverseReaction
disturbance	POTIGA.xml:S1:7747:11	I-AdverseReaction

1	POTIGA.xml:S1:7831:1	O
2	POTIGA.xml:S1:7844:1	O
5	POTIGA.xml:S1:7860:1	O
6	POTIGA.xml:S1:7876:1	O
4	POTIGA.xml:S1:7893:1	O

Aphasia	POTIGA.xml:S1:7937:7	B-AdverseReaction

1	POTIGA.xml:S1:8027:1	O
1	POTIGA.xml:S1:8039:1	O
3	POTIGA.xml:S1:8055:1	O
7	POTIGA.xml:S1:8071:1	O
4	POTIGA.xml:S1:8088:1	O

Dysarthria	POTIGA.xml:S1:8132:10	B-AdverseReaction

1	POTIGA.xml:S1:8222:1	O
4	POTIGA.xml:S1:8234:1	O
2	POTIGA.xml:S1:8250:1	O
8	POTIGA.xml:S1:8266:1	O
4	POTIGA.xml:S1:8283:1	O

Balance	POTIGA.xml:S1:8327:7	B-AdverseReaction
disorder	POTIGA.xml:S1:8335:8	I-AdverseReaction

1	POTIGA.xml:S1:8417:1	O
3	POTIGA.xml:S1:8429:1	O
3	POTIGA.xml:S1:8445:1	O
5	POTIGA.xml:S1:8461:1	O
4	POTIGA.xml:S1:8478:1	O

Paresthesia	POTIGA.xml:S1:8522:11	B-AdverseReaction

2	POTIGA.xml:S1:8611:1	O
3	POTIGA.xml:S1:8624:1	O
2	POTIGA.xml:S1:8640:1	O
5	POTIGA.xml:S1:8656:1	O
3	POTIGA.xml:S1:8673:1	O

Amnesia	POTIGA.xml:S1:8717:7	B-AdverseReaction

1	POTIGA.xml:S1:8807:1	O
1	POTIGA.xml:S1:8820:1	O
3	POTIGA.xml:S1:8835:1	O
3	POTIGA.xml:S1:8851:1	O
2	POTIGA.xml:S1:8868:1	O

Dysphasia	POTIGA.xml:S1:8912:9	B-AdverseReaction

1	POTIGA.xml:S1:9002:1	O
1	POTIGA.xml:S1:9014:1	O
1	POTIGA.xml:S1:9030:1	O
3	POTIGA.xml:S1:9046:1	O
2	POTIGA.xml:S1:9063:1	O

Psychiatric	POTIGA.xml:S1:9107:11	O

Confusional	POTIGA.xml:S1:9302:11	B-AdverseReaction

state	POTIGA.xml:S1:9314:5	I-AdverseReaction

3	POTIGA.xml:S1:9391:1	O
4	POTIGA.xml:S1:9404:1	O
8	POTIGA.xml:S1:9420:1	O
16	POTIGA.xml:S1:9436:2	O
9	POTIGA.xml:S1:9453:1	O

Anxiety	POTIGA.xml:S1:9497:7	B-AdverseReaction

2	POTIGA.xml:S1:9586:1	O
3	POTIGA.xml:S1:9599:1	O
2	POTIGA.xml:S1:9615:1	O
5	POTIGA.xml:S1:9631:1	O
3	POTIGA.xml:S1:9648:1	O

Disorientation	POTIGA.xml:S1:9692:14	B-AdverseReaction

1	POTIGA.xml:S1:9782:1	O
1	POTIGA.xml:S1:9795:1	O
1	POTIGA.xml:S1:9811:1	O
5	POTIGA.xml:S1:9826:1	O
2	POTIGA.xml:S1:9843:1	O

Psychotic	POTIGA.xml:S1:9887:9	B-AdverseReaction
disorder	POTIGA.xml:S1:9897:8	I-AdverseReaction

0	POTIGA.xml:S1:9976:1	O
0	POTIGA.xml:S1:9989:1	O
1	POTIGA.xml:S1:10006:1	O
2	POTIGA.xml:S1:10021:1	O
1	POTIGA.xml:S1:10039:1	O

Renal	POTIGA.xml:S1:10082:5	O
and	POTIGA.xml:S1:10088:3	O
urinary	POTIGA.xml:S1:10092:7	O

Dysuria	POTIGA.xml:S1:10277:7	B-AdverseReaction

1	POTIGA.xml:S1:10367:1	O

1	POTIGA.xml:S1:10379:1	O
2	POTIGA.xml:S1:10395:1	O
4	POTIGA.xml:S1:10411:1	O
2	POTIGA.xml:S1:10428:1	O

Urinary	POTIGA.xml:S1:10472:7	B-AdverseReaction
hesitation	POTIGA.xml:S1:10480:10	I-AdverseReaction

1	POTIGA.xml:S1:10562:1	O
2	POTIGA.xml:S1:10574:1	O
1	POTIGA.xml:S1:10590:1	O
4	POTIGA.xml:S1:10606:1	O
2	POTIGA.xml:S1:10623:1	O

Hematuria	POTIGA.xml:S1:10667:9	B-AdverseReaction

1	POTIGA.xml:S1:10757:1	O
2	POTIGA.xml:S1:10769:1	O
1	POTIGA.xml:S1:10785:1	O
2	POTIGA.xml:S1:10801:1	O
2	POTIGA.xml:S1:10818:1	O

Chromaturia	POTIGA.xml:S1:10862:11	B-AdverseReaction

1	POTIGA.xml:S1:10952:1	O
1	POTIGA.xml:S1:10965:1	O
2	POTIGA.xml:S1:10980:1	O
3	POTIGA.xml:S1:10996:1	O
2	POTIGA.xml:S1:11013:1	O

Other	POTIGA.xml:S1:11039:5	O
adverse	POTIGA.xml:S1:11045:7	O
reactions	POTIGA.xml:S1:11053:9	O
reported	POTIGA.xml:S1:11063:8	O
in	POTIGA.xml:S1:11072:2	O
these	POTIGA.xml:S1:11075:5	O
3	POTIGA.xml:S1:11081:1	O
studies	POTIGA.xml:S1:11083:7	O
in	POTIGA.xml:S1:11091:2	O
2%	POTIGA.xml:S1:11095:2	O
of	POTIGA.xml:S1:11098:2	O
patients	POTIGA.xml:S1:11101:8	O
treated	POTIGA.xml:S1:11110:7	O
with	POTIGA.xml:S1:11118:4	O
POTIGA	POTIGA.xml:S1:11123:6	O
and	POTIGA.xml:S1:11130:3	O
numerically	POTIGA.xml:S1:11134:11	O
greater	POTIGA.xml:S1:11146:7	O
than	POTIGA.xml:S1:11154:4	O
placebo	POTIGA.xml:S1:11159:7	O
were	POTIGA.xml:S1:11167:4	O
increased	POTIGA.xml:S1:11172:9	B-AdverseReaction
appetite	POTIGA.xml:S1:11182:8	I-AdverseReaction
,	POTIGA.xml:S1:11190:1	O
hallucinations	POTIGA.xml:S1:11192:14	B-AdverseReaction
,	POTIGA.xml:S1:11206:1	O
myoclonus	POTIGA.xml:S1:11208:9	B-AdverseReaction
,	POTIGA.xml:S1:11217:1	O
peripheral	POTIGA.xml:S1:11219:10	B-AdverseReaction
edema	POTIGA.xml:S1:11230:5	I-AdverseReaction
,	POTIGA.xml:S1:11235:1	O
hypokinesia	POTIGA.xml:S1:11237:11	B-AdverseReaction
,	POTIGA.xml:S1:11248:1	O
dry	POTIGA.xml:S1:11250:3	B-AdverseReaction
mouth	POTIGA.xml:S1:11254:5	I-AdverseReaction
,	POTIGA.xml:S1:11259:1	O
dysphagia	POTIGA.xml:S1:11261:9	B-AdverseReaction
,	POTIGA.xml:S1:11270:1	O
hyperhydrosis	POTIGA.xml:S1:11272:13	B-AdverseReaction
,	POTIGA.xml:S1:11285:1	O
urinary	POTIGA.xml:S1:11287:7	B-AdverseReaction
retention	POTIGA.xml:S1:11295:9	I-AdverseReaction
,	POTIGA.xml:S1:11304:1	O
malaise	POTIGA.xml:S1:11306:7	B-AdverseReaction
,	POTIGA.xml:S1:11313:1	O
and	POTIGA.xml:S1:11315:3	O
increased	POTIGA.xml:S1:11319:9	B-AdverseReaction
liver	POTIGA.xml:S1:11329:5	I-AdverseReaction
enzymes	POTIGA.xml:S1:11335:7	I-AdverseReaction
.	POTIGA.xml:S1:11342:1	O

Most	POTIGA.xml:S1:11348:4	O

of	POTIGA.xml:S1:11353:2	O
the	POTIGA.xml:S1:11356:3	O
adverse	POTIGA.xml:S1:11360:7	O
reactions	POTIGA.xml:S1:11368:9	O
appear	POTIGA.xml:S1:11378:6	O
to	POTIGA.xml:S1:11385:2	O
be	POTIGA.xml:S1:11388:2	O
dose	POTIGA.xml:S1:11391:4	O
related	POTIGA.xml:S1:11396:7	O
(	POTIGA.xml:S1:11404:1	O
especially	POTIGA.xml:S1:11405:10	O
those	POTIGA.xml:S1:11416:5	O
classified	POTIGA.xml:S1:11422:10	O
as	POTIGA.xml:S1:11433:2	O
psychiatric	POTIGA.xml:S1:11436:11	O
and	POTIGA.xml:S1:11448:3	O
nervous	POTIGA.xml:S1:11452:7	O
system	POTIGA.xml:S1:11460:6	O
symptoms	POTIGA.xml:S1:11467:8	O
)	POTIGA.xml:S1:11475:1	O
,	POTIGA.xml:S1:11476:1	O
including	POTIGA.xml:S1:11478:9	O
dizziness	POTIGA.xml:S1:11488:9	B-AdverseReaction
,	POTIGA.xml:S1:11497:1	O
somnolence	POTIGA.xml:S1:11499:10	B-AdverseReaction
,	POTIGA.xml:S1:11509:1	O
confusional	POTIGA.xml:S1:11511:11	B-AdverseReaction
state	POTIGA.xml:S1:11523:5	I-AdverseReaction
,	POTIGA.xml:S1:11528:1	O
tremor	POTIGA.xml:S1:11530:6	B-AdverseReaction
,	POTIGA.xml:S1:11536:1	O
abnormal	POTIGA.xml:S1:11538:8	B-AdverseReaction
coordination	POTIGA.xml:S1:11547:12	I-AdverseReaction
,	POTIGA.xml:S1:11559:1	O
memory	POTIGA.xml:S1:11561:6	B-AdverseReaction
impairment	POTIGA.xml:S1:11568:10	I-AdverseReaction
,	POTIGA.xml:S1:11578:1	O
blurred	POTIGA.xml:S1:11580:7	B-AdverseReaction
vision	POTIGA.xml:S1:11588:6	I-AdverseReaction
,	POTIGA.xml:S1:11594:1	O
gait	POTIGA.xml:S1:11596:4	B-AdverseReaction
disturbance	POTIGA.xml:S1:11601:11	I-AdverseReaction
,	POTIGA.xml:S1:11612:1	O
aphasia	POTIGA.xml:S1:11614:7	B-AdverseReaction
,	POTIGA.xml:S1:11621:1	O
balance	POTIGA.xml:S1:11623:7	B-AdverseReaction
disorder	POTIGA.xml:S1:11631:8	I-AdverseReaction
,	POTIGA.xml:S1:11639:1	O
constipation	POTIGA.xml:S1:11641:12	B-AdverseReaction
,	POTIGA.xml:S1:11653:1	O
dysuria	POTIGA.xml:S1:11655:7	B-AdverseReaction
,	POTIGA.xml:S1:11662:1	O
and	POTIGA.xml:S1:11664:3	O
chromaturia	POTIGA.xml:S1:11668:11	B-AdverseReaction
.	POTIGA.xml:S1:11679:1	O

POTIGA	POTIGA.xml:S1:11685:6	O
was	POTIGA.xml:S1:11692:3	O
associated	POTIGA.xml:S1:11696:10	O
with	POTIGA.xml:S1:11707:4	O
dose	POTIGA.xml:S1:11712:4	O
-	POTIGA.xml:S1:11716:1	O
related	POTIGA.xml:S1:11717:7	O
weight	POTIGA.xml:S1:11725:6	B-AdverseReaction
gain	POTIGA.xml:S1:11732:4	I-AdverseReaction
,	POTIGA.xml:S1:11736:1	O
with	POTIGA.xml:S1:11738:4	O
mean	POTIGA.xml:S1:11743:4	O
weight	POTIGA.xml:S1:11748:6	B-AdverseReaction
increasing	POTIGA.xml:S1:11755:10	I-AdverseReaction
by	POTIGA.xml:S1:11766:2	O
0.2	POTIGA.xml:S1:11769:3	O
kg	POTIGA.xml:S1:11773:2	O
,	POTIGA.xml:S1:11775:1	O
1.2	POTIGA.xml:S1:11777:3	O
kg	POTIGA.xml:S1:11781:2	O
,	POTIGA.xml:S1:11783:1	O
1.6	POTIGA.xml:S1:11785:3	O
kg	POTIGA.xml:S1:11789:2	O
,	POTIGA.xml:S1:11791:1	O
and	POTIGA.xml:S1:11793:3	O
2.7	POTIGA.xml:S1:11797:3	O
kg	POTIGA.xml:S1:11801:2	O
in	POTIGA.xml:S1:11804:2	O
the	POTIGA.xml:S1:11807:3	O
placebo	POTIGA.xml:S1:11811:7	O
,	POTIGA.xml:S1:11818:1	O
600	POTIGA.xml:S1:11820:3	O
mg	POTIGA.xml:S1:11824:2	O
per	POTIGA.xml:S1:11827:3	O
day	POTIGA.xml:S1:11831:3	O
,	POTIGA.xml:S1:11834:1	O
900	POTIGA.xml:S1:11836:3	O
mg	POTIGA.xml:S1:11840:2	O
per	POTIGA.xml:S1:11843:3	O
day	POTIGA.xml:S1:11847:3	O
,	POTIGA.xml:S1:11850:1	O
and	POTIGA.xml:S1:11852:3	O
1	POTIGA.xml:S1:11856:1	O
,	POTIGA.xml:S1:11857:1	O
200	POTIGA.xml:S1:11858:3	O
mg	POTIGA.xml:S1:11862:2	O
per	POTIGA.xml:S1:11865:3	O
day	POTIGA.xml:S1:11869:3	O
groups	POTIGA.xml:S1:11873:6	O
,	POTIGA.xml:S1:11879:1	O
respectively	POTIGA.xml:S1:11881:12	O
.	POTIGA.xml:S1:11893:1	O

Additional	POTIGA.xml:S1:11901:10	O
Adverse	POTIGA.xml:S1:11912:7	O
Reactions	POTIGA.xml:S1:11920:9	O
Observed	POTIGA.xml:S1:11930:8	O
during	POTIGA.xml:S1:11939:6	O
All	POTIGA.xml:S1:11946:3	O
Phase	POTIGA.xml:S1:11950:5	O
2	POTIGA.xml:S1:11956:1	O
and	POTIGA.xml:S1:11958:3	O
3	POTIGA.xml:S1:11962:1	O
Clinical	POTIGA.xml:S1:11964:8	O
Trials	POTIGA.xml:S1:11973:6	O

Following	POTIGA.xml:S1:11986:9	O
is	POTIGA.xml:S1:11996:2	O
a	POTIGA.xml:S1:11999:1	O
list	POTIGA.xml:S1:12001:4	O
of	POTIGA.xml:S1:12006:2	O
adverse	POTIGA.xml:S1:12009:7	O
reactions	POTIGA.xml:S1:12017:9	O
reported	POTIGA.xml:S1:12027:8	O
by	POTIGA.xml:S1:12036:2	O
patients	POTIGA.xml:S1:12039:8	O
treated	POTIGA.xml:S1:12048:7	O
with	POTIGA.xml:S1:12056:4	O
POTIGA	POTIGA.xml:S1:12061:6	O
during	POTIGA.xml:S1:12068:6	O
all	POTIGA.xml:S1:12075:3	O
clinical	POTIGA.xml:S1:12079:8	O
trials	POTIGA.xml:S1:12088:6	O
:	POTIGA.xml:S1:12094:1	O
rash	POTIGA.xml:S1:12096:4	B-AdverseReaction
,	POTIGA.xml:S1:12100:1	O
nystagmus	POTIGA.xml:S1:12102:9	B-AdverseReaction
,	POTIGA.xml:S1:12111:1	O
dyspnea	POTIGA.xml:S1:12113:7	B-AdverseReaction
,	POTIGA.xml:S1:12120:1	O
leukopenia	POTIGA.xml:S1:12122:10	B-AdverseReaction
,	POTIGA.xml:S1:12132:1	O
muscle	POTIGA.xml:S1:12134:6	B-AdverseReaction
spasms	POTIGA.xml:S1:12141:6	I-AdverseReaction
,	POTIGA.xml:S1:12147:1	O
alopecia	POTIGA.xml:S1:12149:8	B-AdverseReaction
,	POTIGA.xml:S1:12157:1	O
nephrolithiasis	POTIGA.xml:S1:12159:15	B-AdverseReaction
,	POTIGA.xml:S1:12174:1	O
syncope	POTIGA.xml:S1:12176:7	B-AdverseReaction
,	POTIGA.xml:S1:12183:1	O
neutropenia	POTIGA.xml:S1:12185:11	B-AdverseReaction
,	POTIGA.xml:S1:12196:1	O
thrombocytopenia	POTIGA.xml:S1:12198:16	B-AdverseReaction
,	POTIGA.xml:S1:12214:1	O
euphoric	POTIGA.xml:S1:12216:8	B-AdverseReaction
mood	POTIGA.xml:S1:12225:4	I-AdverseReaction
,	POTIGA.xml:S1:12229:1	O
renal	POTIGA.xml:S1:12231:5	B-AdverseReaction
colic	POTIGA.xml:S1:12237:5	I-AdverseReaction
,	POTIGA.xml:S1:12242:1	O
coma	POTIGA.xml:S1:12244:4	B-AdverseReaction
,	POTIGA.xml:S1:12248:1	O
encephalopathy	POTIGA.xml:S1:12250:14	B-AdverseReaction
.	POTIGA.xml:S1:12264:1	O

Comparison	POTIGA.xml:S1:12272:10	O
of	POTIGA.xml:S1:12283:2	O
Gender	POTIGA.xml:S1:12286:6	O
,	POTIGA.xml:S1:12292:1	O
Age	POTIGA.xml:S1:12294:3	O
,	POTIGA.xml:S1:12297:1	O
and	POTIGA.xml:S1:12299:3	O
Race	POTIGA.xml:S1:12303:4	O

The	POTIGA.xml:S1:12314:3	O
overall	POTIGA.xml:S1:12318:7	O
adverse	POTIGA.xml:S1:12326:7	O
reaction	POTIGA.xml:S1:12334:8	O
profile	POTIGA.xml:S1:12343:7	O
of	POTIGA.xml:S1:12351:2	O
POTIGA	POTIGA.xml:S1:12354:6	O
was	POTIGA.xml:S1:12361:3	O
similar	POTIGA.xml:S1:12365:7	O
for	POTIGA.xml:S1:12373:3	O
females	POTIGA.xml:S1:12377:7	O
and	POTIGA.xml:S1:12385:3	O
males	POTIGA.xml:S1:12389:5	O
.	POTIGA.xml:S1:12394:1	O

There	POTIGA.xml:S1:12400:5	O
are	POTIGA.xml:S1:12406:3	O
insufficient	POTIGA.xml:S1:12410:12	O
data	POTIGA.xml:S1:12423:4	O
to	POTIGA.xml:S1:12428:2	O
support	POTIGA.xml:S1:12431:7	O
meaningful	POTIGA.xml:S1:12439:10	O
analyses	POTIGA.xml:S1:12450:8	O
of	POTIGA.xml:S1:12459:2	O
adverse	POTIGA.xml:S1:12462:7	O
reactions	POTIGA.xml:S1:12470:9	O
by	POTIGA.xml:S1:12480:2	O
age	POTIGA.xml:S1:12483:3	O
or	POTIGA.xml:S1:12487:2	O
race	POTIGA.xml:S1:12490:4	O
.	POTIGA.xml:S1:12494:1	O

Approximately	POTIGA.xml:S1:12496:13	O
86%	POTIGA.xml:S1:12510:3	O
of	POTIGA.xml:S1:12514:2	O
the	POTIGA.xml:S1:12517:3	O
population	POTIGA.xml:S1:12521:10	O
studied	POTIGA.xml:S1:12532:7	O
was	POTIGA.xml:S1:12540:3	O
Caucasian	POTIGA.xml:S1:12544:9	O
,	POTIGA.xml:S1:12553:1	O
and	POTIGA.xml:S1:12555:3	O
0.8%	POTIGA.xml:S1:12559:4	O
of	POTIGA.xml:S1:12564:2	O
the	POTIGA.xml:S1:12567:3	O
population	POTIGA.xml:S1:12571:10	O
was	POTIGA.xml:S1:12582:3	O
aged	POTIGA.xml:S1:12586:4	O
65	POTIGA.xml:S1:12591:2	O
years	POTIGA.xml:S1:12594:5	O
or	POTIGA.xml:S1:12600:2	O
older	POTIGA.xml:S1:12603:5	O
.	POTIGA.xml:S1:12608:1	O
\n\n	POTIGA.xml:S2:0:2	O
BOXED	POTIGA.xml:S2:6:5	O
WARNING	POTIGA.xml:S2:12:7	O
:	POTIGA.xml:S2:19:1	O
WARNING	POTIGA.xml:S2:21:7	O
:	POTIGA.xml:S2:28:1	O
RETINAL	POTIGA.xml:S2:30:7	B-AdverseReaction
ABNORMALITIES	POTIGA.xml:S2:38:13	I-AdverseReaction
AND	POTIGA.xml:S2:52:3	O
POTENTIAL	POTIGA.xml:S2:56:9	B-Factor
VISION	POTIGA.xml:S2:66:6	B-AdverseReaction
LOSS	POTIGA.xml:S2:73:4	I-AdverseReaction
\n\n	POTIGA.xml:S2:77:2	O
WARNING	POTIGA.xml:S2:81:7	O
:	POTIGA.xml:S2:88:1	O
RETINAL	POTIGA.xml:S2:90:7	B-AdverseReaction
ABNORMALITIES	POTIGA.xml:S2:98:13	I-AdverseReaction
AND	POTIGA.xml:S2:112:3	O
POTENTIAL	POTIGA.xml:S2:116:9	B-Factor
VISION	POTIGA.xml:S2:126:6	B-AdverseReaction
LOSS	POTIGA.xml:S2:133:4	I-AdverseReaction
\n\n	POTIGA.xml:S2:137:2	O
POTIGA	POTIGA.xml:S2:143:6	O
can	POTIGA.xml:S2:150:3	B-Factor
cause	POTIGA.xml:S2:154:5	O
retinal	POTIGA.xml:S2:160:7	B-AdverseReaction
abnormalities	POTIGA.xml:S2:168:13	I-AdverseReaction
with	POTIGA.xml:S2:182:4	O
funduscopic	POTIGA.xml:S2:187:11	O
features	POTIGA.xml:S2:199:8	O
similar	POTIGA.xml:S2:208:7	I-AdverseReaction
to	POTIGA.xml:S2:216:2	I-AdverseReaction
those	POTIGA.xml:S2:219:5	O
seen	POTIGA.xml:S2:225:4	O
in	POTIGA.xml:S2:230:2	O
retinal	POTIGA.xml:S2:233:7	I-AdverseReaction
pigment	POTIGA.xml:S2:241:7	I-AdverseReaction
dystrophies	POTIGA.xml:S2:249:11	I-AdverseReaction
,	POTIGA.xml:S2:260:1	O
which	POTIGA.xml:S2:262:5	O
are	POTIGA.xml:S2:268:3	O
known	POTIGA.xml:S2:272:5	O
to	POTIGA.xml:S2:278:2	O
result	POTIGA.xml:S2:281:6	O
in	POTIGA.xml:S2:288:2	O
damage	POTIGA.xml:S2:291:6	B-AdverseReaction
to	POTIGA.xml:S2:298:2	I-AdverseReaction
the	POTIGA.xml:S2:301:3	I-AdverseReaction
photoreceptors	POTIGA.xml:S2:305:14	I-AdverseReaction
and	POTIGA.xml:S2:320:3	O
vision	POTIGA.xml:S2:324:6	B-AdverseReaction
loss	POTIGA.xml:S2:331:4	I-AdverseReaction
.	POTIGA.xml:S2:335:1	O

Some	POTIGA.xml:S2:345:4	O
patients	POTIGA.xml:S2:350:8	O
with	POTIGA.xml:S2:359:4	O
retinal	POTIGA.xml:S2:364:7	B-AdverseReaction
abnormalities	POTIGA.xml:S2:372:13	I-AdverseReaction
have	POTIGA.xml:S2:386:4	O
been	POTIGA.xml:S2:391:4	O
found	POTIGA.xml:S2:396:5	O
to	POTIGA.xml:S2:402:2	O
have	POTIGA.xml:S2:405:4	O
abnormal	POTIGA.xml:S2:410:8	B-AdverseReaction
visual	POTIGA.xml:S2:419:6	I-AdverseReaction
acuity	POTIGA.xml:S2:426:6	I-AdverseReaction
.	POTIGA.xml:S2:432:1	O

It	POTIGA.xml:S2:434:2	O
is	POTIGA.xml:S2:437:2	O
not	POTIGA.xml:S2:440:3	B-Factor
possible	POTIGA.xml:S2:444:8	I-Factor
to	POTIGA.xml:S2:453:2	I-Factor
determine	POTIGA.xml:S2:456:9	I-Factor
whether	POTIGA.xml:S2:466:7	O
POTIGA	POTIGA.xml:S2:474:6	O
caused	POTIGA.xml:S2:481:6	O
this	POTIGA.xml:S2:488:4	O
decreased	POTIGA.xml:S2:493:9	B-AdverseReaction
visual	POTIGA.xml:S2:503:6	I-AdverseReaction
acuity	POTIGA.xml:S2:510:6	I-AdverseReaction
,	POTIGA.xml:S2:516:1	O
as	POTIGA.xml:S2:518:2	O
baseline	POTIGA.xml:S2:521:8	O
assessments	POTIGA.xml:S2:530:11	O
are	POTIGA.xml:S2:542:3	O
not	POTIGA.xml:S2:546:3	O
available	POTIGA.xml:S2:550:9	O
for	POTIGA.xml:S2:560:3	O
these	POTIGA.xml:S2:564:5	O
patients	POTIGA.xml:S2:570:8	O
.	POTIGA.xml:S2:578:1	O

Approximately	POTIGA.xml:S2:588:13	O
one	POTIGA.xml:S2:602:3	O
third	POTIGA.xml:S2:606:5	O
of	POTIGA.xml:S2:612:2	O
the	POTIGA.xml:S2:615:3	O
patients	POTIGA.xml:S2:619:8	O
who	POTIGA.xml:S2:628:3	O
had	POTIGA.xml:S2:632:3	O
eye	POTIGA.xml:S2:636:3	O
examinations	POTIGA.xml:S2:640:12	O
performed	POTIGA.xml:S2:653:9	O
after	POTIGA.xml:S2:663:5	O
approximately	POTIGA.xml:S2:669:13	O
4	POTIGA.xml:S2:683:1	O
years	POTIGA.xml:S2:685:5	O
of	POTIGA.xml:S2:691:2	O
treatment	POTIGA.xml:S2:694:9	O
were	POTIGA.xml:S2:704:4	O
found	POTIGA.xml:S2:709:5	O
to	POTIGA.xml:S2:715:2	O
have	POTIGA.xml:S2:718:4	O
retinal	POTIGA.xml:S2:723:7	B-AdverseReaction
pigmentary	POTIGA.xml:S2:731:10	I-AdverseReaction
abnormalities	POTIGA.xml:S2:742:13	I-AdverseReaction
.	POTIGA.xml:S2:755:1	O

An	POTIGA.xml:S2:757:2	O
earlier	POTIGA.xml:S2:760:7	O
onset	POTIGA.xml:S2:768:5	O
cannot	POTIGA.xml:S2:774:6	O
be	POTIGA.xml:S2:781:2	O
ruled	POTIGA.xml:S2:784:5	O
out	POTIGA.xml:S2:790:3	O
,	POTIGA.xml:S2:793:1	O
and	POTIGA.xml:S2:795:3	O
it	POTIGA.xml:S2:799:2	O
is	POTIGA.xml:S2:802:2	O
possible	POTIGA.xml:S2:805:8	O
that	POTIGA.xml:S2:814:4	O
retinal	POTIGA.xml:S2:819:7	B-AdverseReaction
abnormalities	POTIGA.xml:S2:827:13	I-AdverseReaction
were	POTIGA.xml:S2:841:4	O
present	POTIGA.xml:S2:846:7	O
earlier	POTIGA.xml:S2:854:7	O
in	POTIGA.xml:S2:862:2	O
the	POTIGA.xml:S2:865:3	O
course	POTIGA.xml:S2:869:6	O
of	POTIGA.xml:S2:876:2	O
exposure	POTIGA.xml:S2:879:8	O
to	POTIGA.xml:S2:888:2	O
POTIGA	POTIGA.xml:S2:891:6	O
.	POTIGA.xml:S2:897:1	O

The	POTIGA.xml:S2:899:3	O
rate	POTIGA.xml:S2:903:4	O
of	POTIGA.xml:S2:908:2	O
progression	POTIGA.xml:S2:911:11	O
of	POTIGA.xml:S2:923:2	O
retinal	POTIGA.xml:S2:926:7	B-AdverseReaction
abnormalities	POTIGA.xml:S2:934:13	I-AdverseReaction
and	POTIGA.xml:S2:948:3	O
their	POTIGA.xml:S2:952:5	O
reversibility	POTIGA.xml:S2:958:13	O
are	POTIGA.xml:S2:972:3	O
unknown	POTIGA.xml:S2:976:7	O
.	POTIGA.xml:S2:983:1	O

POTIGA	POTIGA.xml:S2:993:6	O
should	POTIGA.xml:S2:1000:6	O
only	POTIGA.xml:S2:1007:4	O
be	POTIGA.xml:S2:1012:2	O
used	POTIGA.xml:S2:1015:4	O
in	POTIGA.xml:S2:1020:2	O
patients	POTIGA.xml:S2:1023:8	O
who	POTIGA.xml:S2:1032:3	O
have	POTIGA.xml:S2:1036:4	O
responded	POTIGA.xml:S2:1041:9	O
inadequately	POTIGA.xml:S2:1051:12	O
to	POTIGA.xml:S2:1064:2	O
several	POTIGA.xml:S2:1067:7	O
alternative	POTIGA.xml:S2:1075:11	O
treatments	POTIGA.xml:S2:1087:10	O
and	POTIGA.xml:S2:1098:3	O
for	POTIGA.xml:S2:1102:3	O
whom	POTIGA.xml:S2:1106:4	O
the	POTIGA.xml:S2:1111:3	O
benefits	POTIGA.xml:S2:1115:8	O
outweigh	POTIGA.xml:S2:1124:8	O
the	POTIGA.xml:S2:1133:3	O
potential	POTIGA.xml:S2:1137:9	O
risk	POTIGA.xml:S2:1147:4	O
of	POTIGA.xml:S2:1152:2	O
vision	POTIGA.xml:S2:1155:6	O
loss	POTIGA.xml:S2:1162:4	O
.	POTIGA.xml:S2:1166:1	O

Patients	POTIGA.xml:S2:1168:8	O
who	POTIGA.xml:S2:1177:3	O
fail	POTIGA.xml:S2:1181:4	O
to	POTIGA.xml:S2:1186:2	O
show	POTIGA.xml:S2:1189:4	O
substantial	POTIGA.xml:S2:1194:11	O
clinical	POTIGA.xml:S2:1206:8	O
benefit	POTIGA.xml:S2:1215:7	O
after	POTIGA.xml:S2:1223:5	O
adequate	POTIGA.xml:S2:1229:8	O
titration	POTIGA.xml:S2:1238:9	O
should	POTIGA.xml:S2:1248:6	O
be	POTIGA.xml:S2:1255:2	O
discontinued	POTIGA.xml:S2:1258:12	O
from	POTIGA.xml:S2:1271:4	O
POTIGA	POTIGA.xml:S2:1276:6	O
.	POTIGA.xml:S2:1282:1	O

All	POTIGA.xml:S2:1292:3	O
patients	POTIGA.xml:S2:1296:8	O
taking	POTIGA.xml:S2:1305:6	O
POTIGA	POTIGA.xml:S2:1312:6	O
should	POTIGA.xml:S2:1319:6	O
have	POTIGA.xml:S2:1326:4	O
baseline	POTIGA.xml:S2:1331:8	O
and	POTIGA.xml:S2:1340:3	O
periodic	POTIGA.xml:S2:1344:8	O
(	POTIGA.xml:S2:1353:1	O
every	POTIGA.xml:S2:1354:5	O
6	POTIGA.xml:S2:1360:1	O
months	POTIGA.xml:S2:1362:6	O
)	POTIGA.xml:S2:1368:1	O
systematic	POTIGA.xml:S2:1370:10	O
visual	POTIGA.xml:S2:1381:6	O
monitoring	POTIGA.xml:S2:1388:10	O
by	POTIGA.xml:S2:1399:2	O
an	POTIGA.xml:S2:1402:2	O
ophthalmic	POTIGA.xml:S2:1405:10	O
professional	POTIGA.xml:S2:1416:12	O
.	POTIGA.xml:S2:1428:1	O

Testing	POTIGA.xml:S2:1430:7	O
should	POTIGA.xml:S2:1438:6	O
include	POTIGA.xml:S2:1445:7	O
visual	POTIGA.xml:S2:1453:6	O
acuity	POTIGA.xml:S2:1460:6	O
and	POTIGA.xml:S2:1467:3	O
dilated	POTIGA.xml:S2:1471:7	O
fundus	POTIGA.xml:S2:1479:6	O
photography	POTIGA.xml:S2:1486:11	O
.	POTIGA.xml:S2:1497:1	O

Additional	POTIGA.xml:S2:1499:10	O
testing	POTIGA.xml:S2:1510:7	O
may	POTIGA.xml:S2:1518:3	O
include	POTIGA.xml:S2:1522:7	O
fluorescein	POTIGA.xml:S2:1530:11	O
angiograms	POTIGA.xml:S2:1542:10	O
(	POTIGA.xml:S2:1553:1	O
FA	POTIGA.xml:S2:1554:2	O
)	POTIGA.xml:S2:1556:1	O
,	POTIGA.xml:S2:1557:1	O
optical	POTIGA.xml:S2:1559:7	O
coherence	POTIGA.xml:S2:1567:9	O
tomography	POTIGA.xml:S2:1577:10	O
(	POTIGA.xml:S2:1588:1	O
OCT	POTIGA.xml:S2:1589:3	O
)	POTIGA.xml:S2:1592:1	O
,	POTIGA.xml:S2:1593:1	O
perimetry	POTIGA.xml:S2:1595:9	O
,	POTIGA.xml:S2:1604:1	O
and	POTIGA.xml:S2:1606:3	O
electroretinograms	POTIGA.xml:S2:1610:18	O
(	POTIGA.xml:S2:1629:1	O
ERG	POTIGA.xml:S2:1630:3	O
)	POTIGA.xml:S2:1633:1	O
.	POTIGA.xml:S2:1634:1	O

If	POTIGA.xml:S2:1644:2	O
retinal	POTIGA.xml:S2:1647:7	O
pigmentary	POTIGA.xml:S2:1655:10	O
abnormalities	POTIGA.xml:S2:1666:13	O
or	POTIGA.xml:S2:1680:2	O
vision	POTIGA.xml:S2:1683:6	O
changes	POTIGA.xml:S2:1690:7	O
are	POTIGA.xml:S2:1698:3	O
detected	POTIGA.xml:S2:1702:8	O
,	POTIGA.xml:S2:1710:1	O
POTIGA	POTIGA.xml:S2:1712:6	O
should	POTIGA.xml:S2:1719:6	O
be	POTIGA.xml:S2:1726:2	O
discontinued	POTIGA.xml:S2:1729:12	O
unless	POTIGA.xml:S2:1742:6	O
no	POTIGA.xml:S2:1749:2	O
other	POTIGA.xml:S2:1752:5	O
suitable	POTIGA.xml:S2:1758:8	O
treatment	POTIGA.xml:S2:1767:9	O
options	POTIGA.xml:S2:1777:7	O
are	POTIGA.xml:S2:1785:3	O
available	POTIGA.xml:S2:1789:9	O
and	POTIGA.xml:S2:1799:3	O
the	POTIGA.xml:S2:1803:3	O
benefits	POTIGA.xml:S2:1807:8	O
of	POTIGA.xml:S2:1816:2	O
treatment	POTIGA.xml:S2:1819:9	O
outweigh	POTIGA.xml:S2:1829:8	O
the	POTIGA.xml:S2:1838:3	O
potential	POTIGA.xml:S2:1842:9	O
risk	POTIGA.xml:S2:1852:4	O
of	POTIGA.xml:S2:1857:2	O
vision	POTIGA.xml:S2:1860:6	O
loss	POTIGA.xml:S2:1867:4	O
.	POTIGA.xml:S2:1871:1	O

EXCERPT	POTIGA.xml:S2:1881:7	O
:	POTIGA.xml:S2:1888:1	O
WARNING	POTIGA.xml:S2:1892:7	O
:	POTIGA.xml:S2:1899:1	O
RETINAL	POTIGA.xml:S2:1901:7	B-AdverseReaction
ABNORMALITIES	POTIGA.xml:S2:1909:13	I-AdverseReaction
AND	POTIGA.xml:S2:1923:3	O
POTENTIAL	POTIGA.xml:S2:1927:9	B-Factor
VISION	POTIGA.xml:S2:1937:6	B-AdverseReaction
LOSS	POTIGA.xml:S2:1944:4	I-AdverseReaction
\n\n\n\n	POTIGA.xml:S2:1948:4	O
See	POTIGA.xml:S2:1955:3	O
full	POTIGA.xml:S2:1959:4	O
prescribing	POTIGA.xml:S2:1964:11	O
information	POTIGA.xml:S2:1976:11	O
for	POTIGA.xml:S2:1988:3	O
complete	POTIGA.xml:S2:1992:8	O
boxed	POTIGA.xml:S2:2001:5	O
warning	POTIGA.xml:S2:2007:7	O
.	POTIGA.xml:S2:2014:1	O

POTIGA	POTIGA.xml:S2:2025:6	O
can	POTIGA.xml:S2:2032:3	O
cause	POTIGA.xml:S2:2036:5	O
retinal	POTIGA.xml:S2:2042:7	B-AdverseReaction
abnormalities	POTIGA.xml:S2:2050:13	I-AdverseReaction
with	POTIGA.xml:S2:2064:4	O
funduscopic	POTIGA.xml:S2:2069:11	O
features	POTIGA.xml:S2:2081:8	O
similar	POTIGA.xml:S2:2090:7	I-AdverseReaction
to	POTIGA.xml:S2:2098:2	I-AdverseReaction
those	POTIGA.xml:S2:2101:5	O
seen	POTIGA.xml:S2:2107:4	O
in	POTIGA.xml:S2:2112:2	O
retinal	POTIGA.xml:S2:2115:7	O
pigment	POTIGA.xml:S2:2123:7	I-AdverseReaction
dystrophies	POTIGA.xml:S2:2131:11	I-AdverseReaction
,	POTIGA.xml:S2:2142:1	O
which	POTIGA.xml:S2:2144:5	O
are	POTIGA.xml:S2:2150:3	O
known	POTIGA.xml:S2:2154:5	O
to	POTIGA.xml:S2:2160:2	O
result	POTIGA.xml:S2:2163:6	O
in	POTIGA.xml:S2:2170:2	O
damage	POTIGA.xml:S2:2173:6	B-AdverseReaction
to	POTIGA.xml:S2:2180:2	I-AdverseReaction
the	POTIGA.xml:S2:2183:3	I-AdverseReaction
photoreceptors	POTIGA.xml:S2:2187:14	I-AdverseReaction
and	POTIGA.xml:S2:2202:3	O
vision	POTIGA.xml:S2:2206:6	B-AdverseReaction
loss	POTIGA.xml:S2:2213:4	I-AdverseReaction
.	POTIGA.xml:S2:2217:1	O

(	POTIGA.xml:S2:2219:1	O
5.1	POTIGA.xml:S2:2220:3	O
)	POTIGA.xml:S2:2223:1	O
\n	POTIGA.xml:S2:2225:1	O
Some	POTIGA.xml:S2:2230:4	O
patients	POTIGA.xml:S2:2235:8	O
with	POTIGA.xml:S2:2244:4	O
retinal	POTIGA.xml:S2:2249:7	O
abnormalities	POTIGA.xml:S2:2257:13	O
have	POTIGA.xml:S2:2271:4	O
been	POTIGA.xml:S2:2276:4	O
found	POTIGA.xml:S2:2281:5	O
to	POTIGA.xml:S2:2287:2	O
have	POTIGA.xml:S2:2290:4	O
abnormal	POTIGA.xml:S2:2295:8	O
visual	POTIGA.xml:S2:2304:6	O
acuity	POTIGA.xml:S2:2311:6	O
.	POTIGA.xml:S2:2317:1	O

It	POTIGA.xml:S2:2319:2	O
is	POTIGA.xml:S2:2322:2	O
not	POTIGA.xml:S2:2325:3	B-Factor
possible	POTIGA.xml:S2:2329:8	I-Factor
to	POTIGA.xml:S2:2338:2	I-Factor
determine	POTIGA.xml:S2:2341:9	I-Factor
whether	POTIGA.xml:S2:2351:7	O
POTIGA	POTIGA.xml:S2:2359:6	O
caused	POTIGA.xml:S2:2366:6	O
this	POTIGA.xml:S2:2373:4	O
decreased	POTIGA.xml:S2:2378:9	B-AdverseReaction
visual	POTIGA.xml:S2:2388:6	I-AdverseReaction
acuity	POTIGA.xml:S2:2395:6	I-AdverseReaction
.	POTIGA.xml:S2:2401:1	O

(	POTIGA.xml:S2:2403:1	O
5.1	POTIGA.xml:S2:2404:3	O
)	POTIGA.xml:S2:2407:1	O
\n	POTIGA.xml:S2:2409:1	O
The	POTIGA.xml:S2:2414:3	O
rate	POTIGA.xml:S2:2418:4	O
of	POTIGA.xml:S2:2423:2	O
progression	POTIGA.xml:S2:2426:11	O
of	POTIGA.xml:S2:2438:2	O
retinal	POTIGA.xml:S2:2441:7	O
abnormalities	POTIGA.xml:S2:2449:13	O
and	POTIGA.xml:S2:2463:3	O
their	POTIGA.xml:S2:2467:5	O
reversibility	POTIGA.xml:S2:2473:13	O
are	POTIGA.xml:S2:2487:3	O
unknown	POTIGA.xml:S2:2491:7	O
.	POTIGA.xml:S2:2498:1	O

(	POTIGA.xml:S2:2500:1	O
5.1	POTIGA.xml:S2:2501:3	O
)	POTIGA.xml:S2:2504:1	O
\n	POTIGA.xml:S2:2506:1	O
Patients	POTIGA.xml:S2:2511:8	O
who	POTIGA.xml:S2:2520:3	O
fail	POTIGA.xml:S2:2524:4	O
to	POTIGA.xml:S2:2529:2	O
show	POTIGA.xml:S2:2532:4	O
substantial	POTIGA.xml:S2:2537:11	O
clinical	POTIGA.xml:S2:2549:8	O
benefit	POTIGA.xml:S2:2558:7	O
after	POTIGA.xml:S2:2566:5	O
adequate	POTIGA.xml:S2:2572:8	O
titration	POTIGA.xml:S2:2581:9	O
should	POTIGA.xml:S2:2591:6	O
be	POTIGA.xml:S2:2598:2	O
discontinued	POTIGA.xml:S2:2601:12	O
from	POTIGA.xml:S2:2614:4	O
POTIGA	POTIGA.xml:S2:2619:6	O
.	POTIGA.xml:S2:2625:1	O

(	POTIGA.xml:S2:2627:1	O
5.1	POTIGA.xml:S2:2628:3	O
)	POTIGA.xml:S2:2631:1	O
\n	POTIGA.xml:S2:2633:1	O
All	POTIGA.xml:S2:2638:3	O
patients	POTIGA.xml:S2:2642:8	O
taking	POTIGA.xml:S2:2651:6	O
POTIGA	POTIGA.xml:S2:2658:6	O
should	POTIGA.xml:S2:2665:6	O
have	POTIGA.xml:S2:2672:4	O
baseline	POTIGA.xml:S2:2677:8	O
and	POTIGA.xml:S2:2686:3	O
periodic	POTIGA.xml:S2:2690:8	O
(	POTIGA.xml:S2:2699:1	O
every	POTIGA.xml:S2:2700:5	O
6	POTIGA.xml:S2:2706:1	O
months	POTIGA.xml:S2:2708:6	O
)	POTIGA.xml:S2:2714:1	O
systematic	POTIGA.xml:S2:2716:10	O
visual	POTIGA.xml:S2:2727:6	O
monitoring	POTIGA.xml:S2:2734:10	O
by	POTIGA.xml:S2:2745:2	O
an	POTIGA.xml:S2:2748:2	O
ophthalmic	POTIGA.xml:S2:2751:10	O
professional	POTIGA.xml:S2:2762:12	O
.	POTIGA.xml:S2:2774:1	O

Testing	POTIGA.xml:S2:2776:7	O
should	POTIGA.xml:S2:2784:6	O
include	POTIGA.xml:S2:2791:7	O
visual	POTIGA.xml:S2:2799:6	O
acuity	POTIGA.xml:S2:2806:6	O
and	POTIGA.xml:S2:2813:3	O
dilated	POTIGA.xml:S2:2817:7	O
fundus	POTIGA.xml:S2:2825:6	O
photography	POTIGA.xml:S2:2832:11	O
.	POTIGA.xml:S2:2843:1	O

(	POTIGA.xml:S2:2845:1	O
5.1	POTIGA.xml:S2:2846:3	O
)	POTIGA.xml:S2:2849:1	O
\n	POTIGA.xml:S2:2851:1	O
If	POTIGA.xml:S2:2856:2	O
retinal	POTIGA.xml:S2:2859:7	O
pigmentary	POTIGA.xml:S2:2867:10	O
abnormalities	POTIGA.xml:S2:2878:13	O
or	POTIGA.xml:S2:2892:2	O
vision	POTIGA.xml:S2:2895:6	O
changes	POTIGA.xml:S2:2902:7	O
are	POTIGA.xml:S2:2910:3	O
detected	POTIGA.xml:S2:2914:8	O
,	POTIGA.xml:S2:2922:1	O
POTIGA	POTIGA.xml:S2:2924:6	O
should	POTIGA.xml:S2:2931:6	O
be	POTIGA.xml:S2:2938:2	O
discontinued	POTIGA.xml:S2:2941:12	O
unless	POTIGA.xml:S2:2954:6	O
no	POTIGA.xml:S2:2961:2	O
other	POTIGA.xml:S2:2964:5	O
suitable	POTIGA.xml:S2:2970:8	O
treatment	POTIGA.xml:S2:2979:9	O
options	POTIGA.xml:S2:2989:7	O
are	POTIGA.xml:S2:2997:3	O
available	POTIGA.xml:S2:3001:9	O
and	POTIGA.xml:S2:3011:3	O
the	POTIGA.xml:S2:3015:3	O
benefits	POTIGA.xml:S2:3019:8	O
of	POTIGA.xml:S2:3028:2	O
treatment	POTIGA.xml:S2:3031:9	O
outweigh	POTIGA.xml:S2:3041:8	O
the	POTIGA.xml:S2:3050:3	O
potential	POTIGA.xml:S2:3054:9	O
risk	POTIGA.xml:S2:3064:4	O
of	POTIGA.xml:S2:3069:2	O
vision	POTIGA.xml:S2:3072:6	O
loss	POTIGA.xml:S2:3079:4	O
.	POTIGA.xml:S2:3083:1	O

(	POTIGA.xml:S2:3085:1	O
5.1	POTIGA.xml:S2:3086:3	O
)	POTIGA.xml:S2:3089:1	O
\n	POTIGA.xml:S2:3091:1	O
5	POTIGA.xml:S3:4:1	O
WARNINGS	POTIGA.xml:S3:6:8	O
AND	POTIGA.xml:S3:15:3	O
PRECAUTIONS	POTIGA.xml:S3:19:11	O

EXCERPT	POTIGA.xml:S3:37:7	O
:	POTIGA.xml:S3:44:1	O
Urinary	POTIGA.xml:S3:54:7	B-AdverseReaction
retention	POTIGA.xml:S3:62:9	I-AdverseReaction
:	POTIGA.xml:S3:71:1	O
Patients	POTIGA.xml:S3:73:8	O
should	POTIGA.xml:S3:82:6	O
be	POTIGA.xml:S3:89:2	O
carefully	POTIGA.xml:S3:92:9	O
monitored	POTIGA.xml:S3:102:9	O
for	POTIGA.xml:S3:112:3	O
urologic	POTIGA.xml:S3:116:8	O
symptoms	POTIGA.xml:S3:125:8	O
.	POTIGA.xml:S3:133:1	O

(	POTIGA.xml:S3:135:1	O
5.2	POTIGA.xml:S3:138:3	O
)	POTIGA.xml:S3:143:1	O

POTIGA	POTIGA.xml:S3:152:6	O
can	POTIGA.xml:S3:159:3	B-Factor
cause	POTIGA.xml:S3:163:5	O
skin	POTIGA.xml:S3:169:4	B-AdverseReaction
discoloration	POTIGA.xml:S3:174:13	I-AdverseReaction
.	POTIGA.xml:S3:187:1	O

If	POTIGA.xml:S3:189:2	O
a	POTIGA.xml:S3:192:1	O
patient	POTIGA.xml:S3:194:7	O
develops	POTIGA.xml:S3:202:8	O
skin	POTIGA.xml:S3:211:4	O
discoloration	POTIGA.xml:S3:216:13	O
,	POTIGA.xml:S3:229:1	O
serious	POTIGA.xml:S3:231:7	O
consideration	POTIGA.xml:S3:239:13	O
should	POTIGA.xml:S3:253:6	O
be	POTIGA.xml:S3:260:2	O
given	POTIGA.xml:S3:263:5	O
to	POTIGA.xml:S3:269:2	O
an	POTIGA.xml:S3:272:2	O
alternative	POTIGA.xml:S3:275:11	O
treatment	POTIGA.xml:S3:287:9	O
.	POTIGA.xml:S3:296:1	O

(	POTIGA.xml:S3:298:1	O
5.3	POTIGA.xml:S3:301:3	O
)	POTIGA.xml:S3:306:1	O

Neuropsychiatric	POTIGA.xml:S3:315:16	B-AdverseReaction
symptoms	POTIGA.xml:S3:332:8	I-AdverseReaction
:	POTIGA.xml:S3:340:1	O
Monitor	POTIGA.xml:S3:342:7	O
for	POTIGA.xml:S3:350:3	O
confusional	POTIGA.xml:S3:354:11	O
state	POTIGA.xml:S3:366:5	O
,	POTIGA.xml:S3:371:1	O
psychotic	POTIGA.xml:S3:373:9	O
symptoms	POTIGA.xml:S3:383:8	O
,	POTIGA.xml:S3:391:1	O
and	POTIGA.xml:S3:393:3	O
hallucinations	POTIGA.xml:S3:397:14	O
.	POTIGA.xml:S3:411:1	O

(	POTIGA.xml:S3:413:1	O
5.4	POTIGA.xml:S3:416:3	O
)	POTIGA.xml:S3:421:1	O

Monitor	POTIGA.xml:S3:430:7	O
for	POTIGA.xml:S3:438:3	O
dizziness	POTIGA.xml:S3:442:9	O
and	POTIGA.xml:S3:452:3	O
somnolence	POTIGA.xml:S3:456:10	O
.	POTIGA.xml:S3:466:1	O

(	POTIGA.xml:S3:468:1	O
5.5	POTIGA.xml:S3:471:3	O
)	POTIGA.xml:S3:476:1	O

QT	POTIGA.xml:S3:485:2	B-AdverseReaction
prolongation	POTIGA.xml:S3:488:12	I-AdverseReaction
:	POTIGA.xml:S3:500:1	O
QT	POTIGA.xml:S3:502:2	O
interval	POTIGA.xml:S3:505:8	O
should	POTIGA.xml:S3:514:6	O
be	POTIGA.xml:S3:521:2	O
monitored	POTIGA.xml:S3:524:9	O
in	POTIGA.xml:S3:534:2	O
patients	POTIGA.xml:S3:537:8	O
taking	POTIGA.xml:S3:546:6	O
concomitant	POTIGA.xml:S3:553:11	O
medications	POTIGA.xml:S3:565:11	O
known	POTIGA.xml:S3:577:5	O
to	POTIGA.xml:S3:583:2	O
increase	POTIGA.xml:S3:586:8	O
the	POTIGA.xml:S3:595:3	O
QT	POTIGA.xml:S3:599:2	O
interval	POTIGA.xml:S3:602:8	O
or	POTIGA.xml:S3:611:2	O
with	POTIGA.xml:S3:614:4	O
certain	POTIGA.xml:S3:619:7	O
heart	POTIGA.xml:S3:627:5	O
conditions	POTIGA.xml:S3:633:10	O
.	POTIGA.xml:S3:643:1	O

(	POTIGA.xml:S3:645:1	O
5.6	POTIGA.xml:S3:648:3	O
)	POTIGA.xml:S3:653:1	O

Monitor	POTIGA.xml:S3:662:7	O
for	POTIGA.xml:S3:670:3	O
suicidal	POTIGA.xml:S3:674:8	O
thoughts	POTIGA.xml:S3:683:8	O
or	POTIGA.xml:S3:692:2	O
behaviors	POTIGA.xml:S3:695:9	O
.	POTIGA.xml:S3:704:1	O

(	POTIGA.xml:S3:706:1	O
5.7	POTIGA.xml:S3:709:3	O
)	POTIGA.xml:S3:714:1	O

5.1	POTIGA.xml:S3:728:3	O

Retinal	POTIGA.xml:S3:732:7	O

Abnormalities	POTIGA.xml:S3:740:13	O
and	POTIGA.xml:S3:754:3	O
Potential	POTIGA.xml:S3:758:9	O
Vision	POTIGA.xml:S3:768:6	O
Loss	POTIGA.xml:S3:775:4	O

POTIGA	POTIGA.xml:S3:785:6	O
can	POTIGA.xml:S3:792:3	B-Factor
cause	POTIGA.xml:S3:796:5	O
abnormalities	POTIGA.xml:S3:802:13	B-AdverseReaction
of	POTIGA.xml:S3:816:2	I-AdverseReaction
the	POTIGA.xml:S3:819:3	I-AdverseReaction
retina	POTIGA.xml:S3:823:6	I-AdverseReaction
.	POTIGA.xml:S3:829:1	O

The	POTIGA.xml:S3:831:3	O
abnormalities	POTIGA.xml:S3:835:13	O
seen	POTIGA.xml:S3:849:4	O
in	POTIGA.xml:S3:854:2	O
patients	POTIGA.xml:S3:857:8	O
treated	POTIGA.xml:S3:866:7	O
with	POTIGA.xml:S3:874:4	O
POTIGA	POTIGA.xml:S3:879:6	O
have	POTIGA.xml:S3:886:4	O
funduscopic	POTIGA.xml:S3:891:11	B-AdverseReaction
features	POTIGA.xml:S3:903:8	I-AdverseReaction
similar	POTIGA.xml:S3:912:7	I-AdverseReaction
to	POTIGA.xml:S3:920:2	I-AdverseReaction
those	POTIGA.xml:S3:923:5	O
seen	POTIGA.xml:S3:929:4	O
in	POTIGA.xml:S3:934:2	O
retinal	POTIGA.xml:S3:937:7	I-AdverseReaction
pigment	POTIGA.xml:S3:945:7	I-AdverseReaction
dystrophies	POTIGA.xml:S3:953:11	I-AdverseReaction
that	POTIGA.xml:S3:965:4	O
are	POTIGA.xml:S3:970:3	O
known	POTIGA.xml:S3:974:5	O
to	POTIGA.xml:S3:980:2	O
result	POTIGA.xml:S3:983:6	O
in	POTIGA.xml:S3:990:2	O
damage	POTIGA.xml:S3:993:6	B-AdverseReaction
to	POTIGA.xml:S3:1000:2	I-AdverseReaction
photoreceptors	POTIGA.xml:S3:1003:14	I-AdverseReaction
and	POTIGA.xml:S3:1018:3	O
vision	POTIGA.xml:S3:1022:6	B-AdverseReaction
loss	POTIGA.xml:S3:1029:4	I-AdverseReaction
.	POTIGA.xml:S3:1033:1	O

The	POTIGA.xml:S3:1039:3	O
retinal	POTIGA.xml:S3:1043:7	B-AdverseReaction
abnormalities	POTIGA.xml:S3:1051:13	I-AdverseReaction
observed	POTIGA.xml:S3:1065:8	O
with	POTIGA.xml:S3:1074:4	O
POTIGA	POTIGA.xml:S3:1079:6	O
have	POTIGA.xml:S3:1086:4	O
been	POTIGA.xml:S3:1091:4	O
reported	POTIGA.xml:S3:1096:8	O
in	POTIGA.xml:S3:1105:2	O
patients	POTIGA.xml:S3:1108:8	O
who	POTIGA.xml:S3:1117:3	O
were	POTIGA.xml:S3:1121:4	O
originally	POTIGA.xml:S3:1126:10	O
enrolled	POTIGA.xml:S3:1137:8	O
in	POTIGA.xml:S3:1146:2	O
clinical	POTIGA.xml:S3:1149:8	O
trials	POTIGA.xml:S3:1158:6	O
with	POTIGA.xml:S3:1165:4	O
POTIGA	POTIGA.xml:S3:1170:6	O
and	POTIGA.xml:S3:1177:3	O
who	POTIGA.xml:S3:1181:3	O
have	POTIGA.xml:S3:1185:4	O
generally	POTIGA.xml:S3:1190:9	O
taken	POTIGA.xml:S3:1200:5	O
the	POTIGA.xml:S3:1206:3	O
drug	POTIGA.xml:S3:1210:4	O
for	POTIGA.xml:S3:1215:3	O
a	POTIGA.xml:S3:1219:1	O
long	POTIGA.xml:S3:1221:4	O
period	POTIGA.xml:S3:1226:6	O
of	POTIGA.xml:S3:1233:2	O
time	POTIGA.xml:S3:1236:4	O
in	POTIGA.xml:S3:1241:2	O
2	POTIGA.xml:S3:1244:1	O
ongoing	POTIGA.xml:S3:1246:7	O
extension	POTIGA.xml:S3:1254:9	O
trials	POTIGA.xml:S3:1264:6	O
.	POTIGA.xml:S3:1270:1	O

Approximately	POTIGA.xml:S3:1272:13	O
one	POTIGA.xml:S3:1286:3	O
third	POTIGA.xml:S3:1290:5	O
of	POTIGA.xml:S3:1296:2	O
the	POTIGA.xml:S3:1299:3	O
patients	POTIGA.xml:S3:1303:8	O
who	POTIGA.xml:S3:1312:3	O
had	POTIGA.xml:S3:1316:3	O
eye	POTIGA.xml:S3:1320:3	O
examinations	POTIGA.xml:S3:1324:12	O
performed	POTIGA.xml:S3:1337:9	O
after	POTIGA.xml:S3:1347:5	O
approximately	POTIGA.xml:S3:1353:13	O
4	POTIGA.xml:S3:1367:1	O
years	POTIGA.xml:S3:1369:5	O
of	POTIGA.xml:S3:1375:2	O
treatment	POTIGA.xml:S3:1378:9	O
were	POTIGA.xml:S3:1388:4	O
found	POTIGA.xml:S3:1393:5	O
to	POTIGA.xml:S3:1399:2	O
have	POTIGA.xml:S3:1402:4	O
retinal	POTIGA.xml:S3:1407:7	B-AdverseReaction
pigmentary	POTIGA.xml:S3:1415:10	I-AdverseReaction
abnormalities	POTIGA.xml:S3:1426:13	I-AdverseReaction
.	POTIGA.xml:S3:1439:1	O

However	POTIGA.xml:S3:1441:7	O
,	POTIGA.xml:S3:1448:1	O
an	POTIGA.xml:S3:1450:2	O
earlier	POTIGA.xml:S3:1453:7	O
onset	POTIGA.xml:S3:1461:5	O
cannot	POTIGA.xml:S3:1467:6	O
be	POTIGA.xml:S3:1474:2	O
ruled	POTIGA.xml:S3:1477:5	O
out	POTIGA.xml:S3:1483:3	O
,	POTIGA.xml:S3:1486:1	O
and	POTIGA.xml:S3:1488:3	O
it	POTIGA.xml:S3:1492:2	O
is	POTIGA.xml:S3:1495:2	O
possible	POTIGA.xml:S3:1498:8	O
that	POTIGA.xml:S3:1507:4	O
retinal	POTIGA.xml:S3:1512:7	B-AdverseReaction
abnormalities	POTIGA.xml:S3:1520:13	I-AdverseReaction
were	POTIGA.xml:S3:1534:4	O
present	POTIGA.xml:S3:1539:7	O
earlier	POTIGA.xml:S3:1547:7	O
in	POTIGA.xml:S3:1555:2	O
the	POTIGA.xml:S3:1558:3	O
course	POTIGA.xml:S3:1562:6	O
of	POTIGA.xml:S3:1569:2	O
exposure	POTIGA.xml:S3:1572:8	O
to	POTIGA.xml:S3:1581:2	O
POTIGA	POTIGA.xml:S3:1584:6	O
.	POTIGA.xml:S3:1590:1	O

POTIGA	POTIGA.xml:S3:1592:6	O
causes	POTIGA.xml:S3:1599:6	O
skin	POTIGA.xml:S3:1606:4	B-AdverseReaction
,	POTIGA.xml:S3:1610:1	O
scleral	POTIGA.xml:S3:1612:7	B-AdverseReaction
,	POTIGA.xml:S3:1619:1	O
nail	POTIGA.xml:S3:1621:4	B-AdverseReaction
,	POTIGA.xml:S3:1625:1	O
and	POTIGA.xml:S3:1627:3	O
mucous	POTIGA.xml:S3:1631:6	B-AdverseReaction
membrane	POTIGA.xml:S3:1638:8	I-AdverseReaction
discoloration	POTIGA.xml:S3:1647:13	I-AdverseReaction
and	POTIGA.xml:S3:1661:3	O
it	POTIGA.xml:S3:1665:2	O
is	POTIGA.xml:S3:1668:2	O
not	POTIGA.xml:S3:1671:3	O
clear	POTIGA.xml:S3:1675:5	O
whether	POTIGA.xml:S3:1681:7	O
this	POTIGA.xml:S3:1689:4	O
discoloration	POTIGA.xml:S3:1694:13	B-AdverseReaction
is	POTIGA.xml:S3:1708:2	O
related	POTIGA.xml:S3:1711:7	O
to	POTIGA.xml:S3:1719:2	O
retinal	POTIGA.xml:S3:1722:7	B-AdverseReaction
abnormalities	POTIGA.xml:S3:1730:13	I-AdverseReaction
[	POTIGA.xml:S3:1744:1	O
see	POTIGA.xml:S3:1745:3	O
Warnings	POTIGA.xml:S3:1749:8	O
and	POTIGA.xml:S3:1758:3	O
Precautions	POTIGA.xml:S3:1762:11	O
(	POTIGA.xml:S3:1774:1	O
5.3	POTIGA.xml:S3:1775:3	O
)]	POTIGA.xml:S3:1778:2	O
.	POTIGA.xml:S3:1782:1	O

Approximately	POTIGA.xml:S3:1784:13	O
15%	POTIGA.xml:S3:1798:3	O
of	POTIGA.xml:S3:1802:2	O
patients	POTIGA.xml:S3:1805:8	O
with	POTIGA.xml:S3:1814:4	O
retinal	POTIGA.xml:S3:1819:7	B-AdverseReaction
pigmentary	POTIGA.xml:S3:1827:10	I-AdverseReaction
abnormalities	POTIGA.xml:S3:1838:13	I-AdverseReaction
had	POTIGA.xml:S3:1852:3	O
no	POTIGA.xml:S3:1856:2	B-Negation
such	POTIGA.xml:S3:1859:4	O
discoloration	POTIGA.xml:S3:1864:13	B-AdverseReaction
.	POTIGA.xml:S3:1877:1	O

Funduscopic	POTIGA.xml:S3:1883:11	B-AdverseReaction
abnormalities	POTIGA.xml:S3:1895:13	I-AdverseReaction
have	POTIGA.xml:S3:1909:4	O
most	POTIGA.xml:S3:1914:4	O
commonly	POTIGA.xml:S3:1919:8	O
been	POTIGA.xml:S3:1928:4	O
described	POTIGA.xml:S3:1933:9	O
as	POTIGA.xml:S3:1943:2	O
perivascular	POTIGA.xml:S3:1946:12	B-AdverseReaction
pigmentation	POTIGA.xml:S3:1959:12	I-AdverseReaction
(	POTIGA.xml:S3:1972:1	O
bone	POTIGA.xml:S3:1973:4	I-AdverseReaction
spicule	POTIGA.xml:S3:1978:7	I-AdverseReaction
pattern	POTIGA.xml:S3:1986:7	I-AdverseReaction
)	POTIGA.xml:S3:1993:1	O
in	POTIGA.xml:S3:1995:2	I-AdverseReaction
the	POTIGA.xml:S3:1998:3	I-AdverseReaction
retinal	POTIGA.xml:S3:2002:7	I-AdverseReaction
periphery	POTIGA.xml:S3:2010:9	I-AdverseReaction
and	POTIGA.xml:S3:2020:3	O
or	POTIGA.xml:S3:2024:2	O
as	POTIGA.xml:S3:2027:2	O
areas	POTIGA.xml:S3:2030:5	O
of	POTIGA.xml:S3:2036:2	O
focal	POTIGA.xml:S3:2039:5	B-AdverseReaction
retinal	POTIGA.xml:S3:2045:7	I-AdverseReaction
pigment	POTIGA.xml:S3:2053:7	I-AdverseReaction
epithelium	POTIGA.xml:S3:2061:10	I-AdverseReaction
clumping	POTIGA.xml:S3:2072:8	I-AdverseReaction
.	POTIGA.xml:S3:2080:1	O

Although	POTIGA.xml:S3:2082:8	O
some	POTIGA.xml:S3:2091:4	O
of	POTIGA.xml:S3:2096:2	O
the	POTIGA.xml:S3:2099:3	O
patients	POTIGA.xml:S3:2103:8	O
with	POTIGA.xml:S3:2112:4	O
retinal	POTIGA.xml:S3:2117:7	B-AdverseReaction
abnormalities	POTIGA.xml:S3:2125:13	I-AdverseReaction
have	POTIGA.xml:S3:2139:4	O
been	POTIGA.xml:S3:2144:4	O
found	POTIGA.xml:S3:2149:5	O
to	POTIGA.xml:S3:2155:2	O
have	POTIGA.xml:S3:2158:4	O
abnormal	POTIGA.xml:S3:2163:8	B-AdverseReaction
visual	POTIGA.xml:S3:2172:6	I-AdverseReaction
acuity	POTIGA.xml:S3:2179:6	I-AdverseReaction
,	POTIGA.xml:S3:2185:1	O
it	POTIGA.xml:S3:2187:2	O
is	POTIGA.xml:S3:2190:2	O
not	POTIGA.xml:S3:2193:3	O
possible	POTIGA.xml:S3:2197:8	O
to	POTIGA.xml:S3:2206:2	O
assess	POTIGA.xml:S3:2209:6	O
whether	POTIGA.xml:S3:2216:7	B-Factor
POTIGA	POTIGA.xml:S3:2224:6	O
caused	POTIGA.xml:S3:2231:6	O
their	POTIGA.xml:S3:2238:5	O
decreased	POTIGA.xml:S3:2244:9	B-AdverseReaction
visual	POTIGA.xml:S3:2254:6	I-AdverseReaction
acuity	POTIGA.xml:S3:2261:6	I-AdverseReaction
,	POTIGA.xml:S3:2267:1	O
as	POTIGA.xml:S3:2269:2	O
baseline	POTIGA.xml:S3:2272:8	O
assessments	POTIGA.xml:S3:2281:11	O
are	POTIGA.xml:S3:2293:3	O
not	POTIGA.xml:S3:2297:3	O
available	POTIGA.xml:S3:2301:9	O
for	POTIGA.xml:S3:2311:3	O
these	POTIGA.xml:S3:2315:5	O
patients	POTIGA.xml:S3:2321:8	O
.	POTIGA.xml:S3:2329:1	O

Two	POTIGA.xml:S3:2331:3	O
patients	POTIGA.xml:S3:2335:8	O
with	POTIGA.xml:S3:2344:4	O
retinal	POTIGA.xml:S3:2349:7	B-AdverseReaction
abnormalities	POTIGA.xml:S3:2357:13	I-AdverseReaction
have	POTIGA.xml:S3:2371:4	O
had	POTIGA.xml:S3:2376:3	O
more	POTIGA.xml:S3:2380:4	O
extensive	POTIGA.xml:S3:2385:9	O
diagnostic	POTIGA.xml:S3:2395:10	O
retinal	POTIGA.xml:S3:2406:7	O
evaluations	POTIGA.xml:S3:2414:11	O
.	POTIGA.xml:S3:2425:1	O

The	POTIGA.xml:S3:2427:3	O
results	POTIGA.xml:S3:2431:7	O
of	POTIGA.xml:S3:2439:2	O
these	POTIGA.xml:S3:2442:5	O
evaluations	POTIGA.xml:S3:2448:11	O
were	POTIGA.xml:S3:2460:4	O
consistent	POTIGA.xml:S3:2465:10	O
with	POTIGA.xml:S3:2476:4	O
a	POTIGA.xml:S3:2481:1	O
retinal	POTIGA.xml:S3:2483:7	B-AdverseReaction
dystrophy	POTIGA.xml:S3:2491:9	I-AdverseReaction
,	POTIGA.xml:S3:2500:1	O
including	POTIGA.xml:S3:2502:9	O
abnormalities	POTIGA.xml:S3:2512:13	B-AdverseReaction
in	POTIGA.xml:S3:2526:2	I-AdverseReaction
the	POTIGA.xml:S3:2529:3	I-AdverseReaction
electroretinogram	POTIGA.xml:S3:2533:17	I-AdverseReaction
and	POTIGA.xml:S3:2551:3	O
electrooculogram	POTIGA.xml:S3:2555:16	I-AdverseReaction
of	POTIGA.xml:S3:2572:2	O
both	POTIGA.xml:S3:2575:4	O
patients	POTIGA.xml:S3:2580:8	O
,	POTIGA.xml:S3:2588:1	O
with	POTIGA.xml:S3:2590:4	O
abnormal	POTIGA.xml:S3:2595:8	B-AdverseReaction
fluorescein	POTIGA.xml:S3:2604:11	I-AdverseReaction
angiography	POTIGA.xml:S3:2616:11	I-AdverseReaction
and	POTIGA.xml:S3:2628:3	O
diminished	POTIGA.xml:S3:2632:10	B-AdverseReaction
sensitivity	POTIGA.xml:S3:2643:11	I-AdverseReaction
on	POTIGA.xml:S3:2655:2	I-AdverseReaction
visual	POTIGA.xml:S3:2658:6	I-AdverseReaction
field	POTIGA.xml:S3:2665:5	I-AdverseReaction
testing	POTIGA.xml:S3:2671:7	O
in	POTIGA.xml:S3:2679:2	O
one	POTIGA.xml:S3:2682:3	O
patient	POTIGA.xml:S3:2686:7	O
.	POTIGA.xml:S3:2693:1	O

The	POTIGA.xml:S3:2699:3	O
rate	POTIGA.xml:S3:2703:4	O
of	POTIGA.xml:S3:2708:2	O
progression	POTIGA.xml:S3:2711:11	O
of	POTIGA.xml:S3:2723:2	O
retinal	POTIGA.xml:S3:2726:7	B-AdverseReaction
abnormalities	POTIGA.xml:S3:2734:13	I-AdverseReaction
and	POTIGA.xml:S3:2748:3	O
the	POTIGA.xml:S3:2752:3	O
reversibility	POTIGA.xml:S3:2756:13	O
after	POTIGA.xml:S3:2770:5	O
drug	POTIGA.xml:S3:2776:4	O
discontinuation	POTIGA.xml:S3:2781:15	O
are	POTIGA.xml:S3:2797:3	O
unknown	POTIGA.xml:S3:2801:7	O
.	POTIGA.xml:S3:2808:1	O

Because	POTIGA.xml:S3:2814:7	B-Factor
of	POTIGA.xml:S3:2822:2	O
the	POTIGA.xml:S3:2825:3	O
observed	POTIGA.xml:S3:2829:8	O
ophthalmologic	POTIGA.xml:S3:2838:14	O
adverse	POTIGA.xml:S3:2853:7	O
reactions	POTIGA.xml:S3:2861:9	O
,	POTIGA.xml:S3:2870:1	O
POTIGA	POTIGA.xml:S3:2872:6	O
should	POTIGA.xml:S3:2879:6	O
only	POTIGA.xml:S3:2886:4	O
be	POTIGA.xml:S3:2891:2	O
used	POTIGA.xml:S3:2894:4	O
in	POTIGA.xml:S3:2899:2	O
patients	POTIGA.xml:S3:2902:8	O
who	POTIGA.xml:S3:2911:3	O
have	POTIGA.xml:S3:2915:4	O
responded	POTIGA.xml:S3:2920:9	O
inadequately	POTIGA.xml:S3:2930:12	O
to	POTIGA.xml:S3:2943:2	O
several	POTIGA.xml:S3:2946:7	O
alternative	POTIGA.xml:S3:2954:11	O
treatments	POTIGA.xml:S3:2966:10	O
and	POTIGA.xml:S3:2977:3	O
for	POTIGA.xml:S3:2981:3	O
whom	POTIGA.xml:S3:2985:4	O
the	POTIGA.xml:S3:2990:3	O
benefits	POTIGA.xml:S3:2994:8	O
outweigh	POTIGA.xml:S3:3003:8	O
the	POTIGA.xml:S3:3012:3	O
risk	POTIGA.xml:S3:3016:4	O
of	POTIGA.xml:S3:3021:2	O
retinal	POTIGA.xml:S3:3024:7	O
abnormalities	POTIGA.xml:S3:3032:13	O
and	POTIGA.xml:S3:3046:3	O
potential	POTIGA.xml:S3:3050:9	O
vision	POTIGA.xml:S3:3060:6	O
loss	POTIGA.xml:S3:3067:4	O
.	POTIGA.xml:S3:3071:1	O

Patients	POTIGA.xml:S3:3073:8	O
who	POTIGA.xml:S3:3082:3	O
fail	POTIGA.xml:S3:3086:4	O
to	POTIGA.xml:S3:3091:2	O
show	POTIGA.xml:S3:3094:4	O
substantial	POTIGA.xml:S3:3099:11	O
clinical	POTIGA.xml:S3:3111:8	O
benefit	POTIGA.xml:S3:3120:7	O
after	POTIGA.xml:S3:3128:5	O
adequate	POTIGA.xml:S3:3134:8	O
titration	POTIGA.xml:S3:3143:9	O
should	POTIGA.xml:S3:3153:6	O
be	POTIGA.xml:S3:3160:2	O
discontinued	POTIGA.xml:S3:3163:12	O
from	POTIGA.xml:S3:3176:4	O
POTIGA	POTIGA.xml:S3:3181:6	O
.	POTIGA.xml:S3:3187:1	O

Patients	POTIGA.xml:S3:3193:8	O
should	POTIGA.xml:S3:3202:6	O
have	POTIGA.xml:S3:3209:4	O
baseline	POTIGA.xml:S3:3214:8	O
ophthalmologic	POTIGA.xml:S3:3223:14	O
testing	POTIGA.xml:S3:3238:7	O
by	POTIGA.xml:S3:3246:2	O
an	POTIGA.xml:S3:3249:2	O
ophthalmic	POTIGA.xml:S3:3252:10	O
professional	POTIGA.xml:S3:3263:12	O
and	POTIGA.xml:S3:3276:3	O
follow	POTIGA.xml:S3:3280:6	O
-	POTIGA.xml:S3:3286:1	O
up	POTIGA.xml:S3:3287:2	O
testing	POTIGA.xml:S3:3290:7	O
every	POTIGA.xml:S3:3298:5	O
6	POTIGA.xml:S3:3304:1	O
months	POTIGA.xml:S3:3306:6	O
.	POTIGA.xml:S3:3312:1	O

The	POTIGA.xml:S3:3314:3	O
best	POTIGA.xml:S3:3318:4	O
method	POTIGA.xml:S3:3323:6	O
of	POTIGA.xml:S3:3330:2	O
detection	POTIGA.xml:S3:3333:9	O
of	POTIGA.xml:S3:3343:2	O
these	POTIGA.xml:S3:3346:5	O
abnormalities	POTIGA.xml:S3:3352:13	O
and	POTIGA.xml:S3:3366:3	O
the	POTIGA.xml:S3:3370:3	O
optimal	POTIGA.xml:S3:3374:7	O
frequency	POTIGA.xml:S3:3382:9	O
of	POTIGA.xml:S3:3392:2	O
periodic	POTIGA.xml:S3:3395:8	O
ophthalmologic	POTIGA.xml:S3:3404:14	O
monitoring	POTIGA.xml:S3:3419:10	O
are	POTIGA.xml:S3:3430:3	O
unknown	POTIGA.xml:S3:3434:7	O
.	POTIGA.xml:S3:3441:1	O

Patients	POTIGA.xml:S3:3443:8	O
who	POTIGA.xml:S3:3452:3	O
cannot	POTIGA.xml:S3:3456:6	O
be	POTIGA.xml:S3:3463:2	O
monitored	POTIGA.xml:S3:3466:9	O
should	POTIGA.xml:S3:3476:6	O
usually	POTIGA.xml:S3:3483:7	O
not	POTIGA.xml:S3:3491:3	O
be	POTIGA.xml:S3:3495:2	O
treated	POTIGA.xml:S3:3498:7	O
with	POTIGA.xml:S3:3506:4	O
POTIGA	POTIGA.xml:S3:3511:6	O
.	POTIGA.xml:S3:3517:1	O

The	POTIGA.xml:S3:3519:3	O
ophthalmologic	POTIGA.xml:S3:3523:14	O
monitoring	POTIGA.xml:S3:3538:10	O
program	POTIGA.xml:S3:3549:7	O
should	POTIGA.xml:S3:3557:6	O
include	POTIGA.xml:S3:3564:7	O
visual	POTIGA.xml:S3:3572:6	O
acuity	POTIGA.xml:S3:3579:6	O
testing	POTIGA.xml:S3:3586:7	O
and	POTIGA.xml:S3:3594:3	O
dilated	POTIGA.xml:S3:3598:7	O
fundus	POTIGA.xml:S3:3606:6	O
photography	POTIGA.xml:S3:3613:11	O
.	POTIGA.xml:S3:3624:1	O

Additional	POTIGA.xml:S3:3626:10	O
testing	POTIGA.xml:S3:3637:7	O
may	POTIGA.xml:S3:3645:3	O
include	POTIGA.xml:S3:3649:7	O
fluorescein	POTIGA.xml:S3:3657:11	O
angiograms	POTIGA.xml:S3:3669:10	O
(	POTIGA.xml:S3:3680:1	O
FA	POTIGA.xml:S3:3681:2	O
)	POTIGA.xml:S3:3683:1	O
,	POTIGA.xml:S3:3684:1	O
optical	POTIGA.xml:S3:3686:7	O
coherence	POTIGA.xml:S3:3694:9	O
tomography	POTIGA.xml:S3:3704:10	O
(	POTIGA.xml:S3:3715:1	O
OCT	POTIGA.xml:S3:3716:3	O
)	POTIGA.xml:S3:3719:1	O
,	POTIGA.xml:S3:3720:1	O
perimetry	POTIGA.xml:S3:3722:9	O
,	POTIGA.xml:S3:3731:1	O
and	POTIGA.xml:S3:3733:3	O
electroretinograms	POTIGA.xml:S3:3737:18	O
(	POTIGA.xml:S3:3756:1	O
ERG	POTIGA.xml:S3:3757:3	O
)	POTIGA.xml:S3:3760:1	O
.	POTIGA.xml:S3:3761:1	O

If	POTIGA.xml:S3:3763:2	O
retinal	POTIGA.xml:S3:3766:7	O
pigmentary	POTIGA.xml:S3:3774:10	O
abnormalities	POTIGA.xml:S3:3785:13	O
or	POTIGA.xml:S3:3799:2	O
vision	POTIGA.xml:S3:3802:6	O
changes	POTIGA.xml:S3:3809:7	O
are	POTIGA.xml:S3:3817:3	O
detected	POTIGA.xml:S3:3821:8	O
,	POTIGA.xml:S3:3829:1	O
POTIGA	POTIGA.xml:S3:3831:6	O
should	POTIGA.xml:S3:3838:6	O
be	POTIGA.xml:S3:3845:2	O
discontinued	POTIGA.xml:S3:3848:12	O
unless	POTIGA.xml:S3:3861:6	O
no	POTIGA.xml:S3:3868:2	O
other	POTIGA.xml:S3:3871:5	O
suitable	POTIGA.xml:S3:3877:8	O
treatment	POTIGA.xml:S3:3886:9	O
options	POTIGA.xml:S3:3896:7	O
are	POTIGA.xml:S3:3904:3	O
available	POTIGA.xml:S3:3908:9	O
and	POTIGA.xml:S3:3918:3	O
the	POTIGA.xml:S3:3922:3	O
benefits	POTIGA.xml:S3:3926:8	O
of	POTIGA.xml:S3:3935:2	O
treatment	POTIGA.xml:S3:3938:9	O
outweigh	POTIGA.xml:S3:3948:8	O
the	POTIGA.xml:S3:3957:3	O
potential	POTIGA.xml:S3:3961:9	O
risk	POTIGA.xml:S3:3971:4	O
of	POTIGA.xml:S3:3976:2	O
vision	POTIGA.xml:S3:3979:6	O
loss	POTIGA.xml:S3:3986:4	B-Factor
.	POTIGA.xml:S3:3990:1	O

5.2	POTIGA.xml:S3:3999:3	O
Urinary	POTIGA.xml:S3:4003:7	O
Retention	POTIGA.xml:S3:4011:9	O

POTIGA	POTIGA.xml:S3:4026:6	O
caused	POTIGA.xml:S3:4033:6	O
urinary	POTIGA.xml:S3:4040:7	B-AdverseReaction
retention	POTIGA.xml:S3:4048:9	I-AdverseReaction
in	POTIGA.xml:S3:4058:2	O
clinical	POTIGA.xml:S3:4061:8	O
trials	POTIGA.xml:S3:4070:6	O
.	POTIGA.xml:S3:4076:1	O

Urinary	POTIGA.xml:S3:4078:7	B-AdverseReaction
retention	POTIGA.xml:S3:4086:9	I-AdverseReaction
was	POTIGA.xml:S3:4096:3	O
generally	POTIGA.xml:S3:4100:9	O
reported	POTIGA.xml:S3:4110:8	O
within	POTIGA.xml:S3:4119:6	O
the	POTIGA.xml:S3:4126:3	O
first	POTIGA.xml:S3:4130:5	O
6	POTIGA.xml:S3:4136:1	O
months	POTIGA.xml:S3:4138:6	O
of	POTIGA.xml:S3:4145:2	O
treatment	POTIGA.xml:S3:4148:9	O
,	POTIGA.xml:S3:4157:1	O
but	POTIGA.xml:S3:4159:3	O
was	POTIGA.xml:S3:4163:3	O
also	POTIGA.xml:S3:4167:4	O
observed	POTIGA.xml:S3:4172:8	O
later	POTIGA.xml:S3:4181:5	O
.	POTIGA.xml:S3:4186:1	O

Urinary	POTIGA.xml:S3:4188:7	B-AdverseReaction
retention	POTIGA.xml:S3:4196:9	I-AdverseReaction
was	POTIGA.xml:S3:4206:3	O
reported	POTIGA.xml:S3:4210:8	O
as	POTIGA.xml:S3:4219:2	O
an	POTIGA.xml:S3:4222:2	O
adverse	POTIGA.xml:S3:4225:7	O
event	POTIGA.xml:S3:4233:5	O
in	POTIGA.xml:S3:4239:2	O
29	POTIGA.xml:S3:4242:2	O
of	POTIGA.xml:S3:4245:2	O
1	POTIGA.xml:S3:4248:1	O
,	POTIGA.xml:S3:4249:1	O
365	POTIGA.xml:S3:4250:3	O
(	POTIGA.xml:S3:4254:1	O
approximately	POTIGA.xml:S3:4255:13	O
2%	POTIGA.xml:S3:4269:2	O
)	POTIGA.xml:S3:4271:1	O
patients	POTIGA.xml:S3:4273:8	O
treated	POTIGA.xml:S3:4282:7	O
with	POTIGA.xml:S3:4290:4	O
POTIGA	POTIGA.xml:S3:4295:6	O
in	POTIGA.xml:S3:4302:2	O
the	POTIGA.xml:S3:4305:3	O
open	POTIGA.xml:S3:4309:4	O
-	POTIGA.xml:S3:4313:1	O
label	POTIGA.xml:S3:4314:5	O
and	POTIGA.xml:S3:4320:3	O
placebo	POTIGA.xml:S3:4324:7	O
-	POTIGA.xml:S3:4331:1	O
controlled	POTIGA.xml:S3:4332:10	O
epilepsy	POTIGA.xml:S3:4343:8	O
database	POTIGA.xml:S3:4352:8	O
[	POTIGA.xml:S3:4361:1	O
see	POTIGA.xml:S3:4362:3	O
Clinical	POTIGA.xml:S3:4366:8	O
Studies	POTIGA.xml:S3:4375:7	O
(	POTIGA.xml:S3:4383:1	O
14	POTIGA.xml:S3:4384:2	O
)]	POTIGA.xml:S3:4386:2	O
.	POTIGA.xml:S3:4390:1	O

Of	POTIGA.xml:S3:4392:2	O
these	POTIGA.xml:S3:4395:5	O
29	POTIGA.xml:S3:4401:2	O
patients	POTIGA.xml:S3:4404:8	O
,	POTIGA.xml:S3:4412:1	O
5	POTIGA.xml:S3:4414:1	O
(	POTIGA.xml:S3:4416:1	O
17%	POTIGA.xml:S3:4417:3	O
)	POTIGA.xml:S3:4420:1	O
required	POTIGA.xml:S3:4422:8	O
catheterization	POTIGA.xml:S3:4431:15	O
,	POTIGA.xml:S3:4446:1	O
with	POTIGA.xml:S3:4448:4	O
post	POTIGA.xml:S3:4453:4	O
-	POTIGA.xml:S3:4457:1	O
voiding	POTIGA.xml:S3:4458:7	O
residuals	POTIGA.xml:S3:4466:9	O
of	POTIGA.xml:S3:4476:2	O
up	POTIGA.xml:S3:4479:2	O
to	POTIGA.xml:S3:4482:2	O
1	POTIGA.xml:S3:4485:1	O
,	POTIGA.xml:S3:4486:1	O
500	POTIGA.xml:S3:4487:3	O
mL	POTIGA.xml:S3:4491:2	O
.	POTIGA.xml:S3:4493:1	O

POTIGA	POTIGA.xml:S3:4495:6	O
was	POTIGA.xml:S3:4502:3	O
discontinued	POTIGA.xml:S3:4506:12	O
in	POTIGA.xml:S3:4519:2	O
3	POTIGA.xml:S3:4522:1	O
of	POTIGA.xml:S3:4524:2	O
the	POTIGA.xml:S3:4527:3	O
5	POTIGA.xml:S3:4531:1	O
patients	POTIGA.xml:S3:4533:8	O
who	POTIGA.xml:S3:4542:3	O
required	POTIGA.xml:S3:4546:8	O
catheterization	POTIGA.xml:S3:4555:15	O
,	POTIGA.xml:S3:4570:1	O
and	POTIGA.xml:S3:4572:3	O
all	POTIGA.xml:S3:4576:3	O
were	POTIGA.xml:S3:4580:4	O
able	POTIGA.xml:S3:4585:4	O
to	POTIGA.xml:S3:4590:2	O
void	POTIGA.xml:S3:4593:4	O
spontaneously	POTIGA.xml:S3:4598:13	O
;	POTIGA.xml:S3:4611:1	O
however	POTIGA.xml:S3:4613:7	O
,	POTIGA.xml:S3:4620:1	O
1	POTIGA.xml:S3:4622:1	O
of	POTIGA.xml:S3:4624:2	O
the	POTIGA.xml:S3:4627:3	O
3	POTIGA.xml:S3:4631:1	O
patients	POTIGA.xml:S3:4633:8	O
continued	POTIGA.xml:S3:4642:9	O
intermittent	POTIGA.xml:S3:4652:12	O
self	POTIGA.xml:S3:4665:4	O
-	POTIGA.xml:S3:4669:1	O
catheterization	POTIGA.xml:S3:4670:15	O
.	POTIGA.xml:S3:4685:1	O

Two	POTIGA.xml:S3:4687:3	O
patients	POTIGA.xml:S3:4691:8	O
continued	POTIGA.xml:S3:4700:9	O
treatment	POTIGA.xml:S3:4710:9	O
with	POTIGA.xml:S3:4720:4	O
POTIGA	POTIGA.xml:S3:4725:6	O
and	POTIGA.xml:S3:4732:3	O
were	POTIGA.xml:S3:4736:4	O
able	POTIGA.xml:S3:4741:4	O
to	POTIGA.xml:S3:4746:2	O
void	POTIGA.xml:S3:4749:4	O
spontaneously	POTIGA.xml:S3:4754:13	O
after	POTIGA.xml:S3:4768:5	O
catheter	POTIGA.xml:S3:4774:8	O
removal	POTIGA.xml:S3:4783:7	O
.	POTIGA.xml:S3:4790:1	O

Hydronephrosis	POTIGA.xml:S3:4792:14	B-AdverseReaction
occurred	POTIGA.xml:S3:4807:8	O
in	POTIGA.xml:S3:4816:2	O
2	POTIGA.xml:S3:4819:1	O
patients	POTIGA.xml:S3:4821:8	O
,	POTIGA.xml:S3:4829:1	O
one	POTIGA.xml:S3:4831:3	O
of	POTIGA.xml:S3:4835:2	O
whom	POTIGA.xml:S3:4838:4	O
had	POTIGA.xml:S3:4843:3	O
associated	POTIGA.xml:S3:4847:10	O
renal	POTIGA.xml:S3:4858:5	B-AdverseReaction
function	POTIGA.xml:S3:4864:8	I-AdverseReaction
impairment	POTIGA.xml:S3:4873:10	I-AdverseReaction
that	POTIGA.xml:S3:4884:4	O
resolved	POTIGA.xml:S3:4889:8	O
upon	POTIGA.xml:S3:4898:4	O
discontinuation	POTIGA.xml:S3:4903:15	O
of	POTIGA.xml:S3:4919:2	O
POTIGA	POTIGA.xml:S3:4922:6	O
.	POTIGA.xml:S3:4928:1	O

Hydronephrosis	POTIGA.xml:S3:4930:14	B-AdverseReaction
was	POTIGA.xml:S3:4945:3	O
not	POTIGA.xml:S3:4949:3	B-Negation
reported	POTIGA.xml:S3:4953:8	O
in	POTIGA.xml:S3:4962:2	O
placebo	POTIGA.xml:S3:4965:7	B-Factor
patients	POTIGA.xml:S3:4973:8	O
.	POTIGA.xml:S3:4981:1	O

In	POTIGA.xml:S3:4987:2	O
the	POTIGA.xml:S3:4990:3	O
placebo	POTIGA.xml:S3:4994:7	O
-	POTIGA.xml:S3:5001:1	O
controlled	POTIGA.xml:S3:5002:10	O
epilepsy	POTIGA.xml:S3:5013:8	O
trials	POTIGA.xml:S3:5022:6	O
,	POTIGA.xml:S3:5028:1	O
"	POTIGA.xml:S3:5030:1	O
urinary	POTIGA.xml:S3:5031:7	B-AdverseReaction
retention	POTIGA.xml:S3:5039:9	I-AdverseReaction
,	POTIGA.xml:S3:5048:1	O
"	POTIGA.xml:S3:5049:1	O
"	POTIGA.xml:S3:5051:1	O
urinary	POTIGA.xml:S3:5052:7	B-AdverseReaction
hesitation	POTIGA.xml:S3:5060:10	I-AdverseReaction
,	POTIGA.xml:S3:5070:1	O
"	POTIGA.xml:S3:5071:1	O
and	POTIGA.xml:S3:5073:3	O
"	POTIGA.xml:S3:5077:1	O
dysuria	POTIGA.xml:S3:5078:7	B-AdverseReaction
"	POTIGA.xml:S3:5085:1	O
were	POTIGA.xml:S3:5087:4	O
reported	POTIGA.xml:S3:5092:8	O
in	POTIGA.xml:S3:5101:2	O
0.9%	POTIGA.xml:S3:5104:4	O
,	POTIGA.xml:S3:5108:1	O
2.2%	POTIGA.xml:S3:5110:4	O
,	POTIGA.xml:S3:5114:1	O
and	POTIGA.xml:S3:5116:3	O
2.3%	POTIGA.xml:S3:5120:4	O
of	POTIGA.xml:S3:5125:2	O
patients	POTIGA.xml:S3:5128:8	O
on	POTIGA.xml:S3:5137:2	O
POTIGA	POTIGA.xml:S3:5140:6	O
,	POTIGA.xml:S3:5146:1	O
respectively	POTIGA.xml:S3:5148:12	O
,	POTIGA.xml:S3:5160:1	O
and	POTIGA.xml:S3:5162:3	O
in	POTIGA.xml:S3:5166:2	O
0.5%	POTIGA.xml:S3:5169:4	O
,	POTIGA.xml:S3:5173:1	O
0.9%	POTIGA.xml:S3:5175:4	O
,	POTIGA.xml:S3:5179:1	O
and	POTIGA.xml:S3:5181:3	O
0.7%	POTIGA.xml:S3:5185:4	O
of	POTIGA.xml:S3:5190:2	O
patients	POTIGA.xml:S3:5193:8	O
on	POTIGA.xml:S3:5202:2	O
placebo	POTIGA.xml:S3:5205:7	O
,	POTIGA.xml:S3:5212:1	O
respectively	POTIGA.xml:S3:5214:12	O
.	POTIGA.xml:S3:5226:1	O

Because	POTIGA.xml:S3:5232:7	B-Factor
of	POTIGA.xml:S3:5240:2	O
the	POTIGA.xml:S3:5243:3	O
increased	POTIGA.xml:S3:5247:9	O
risk	POTIGA.xml:S3:5257:4	O
of	POTIGA.xml:S3:5262:2	O
urinary	POTIGA.xml:S3:5265:7	O
retention	POTIGA.xml:S3:5273:9	O
on	POTIGA.xml:S3:5283:2	O
POTIGA	POTIGA.xml:S3:5286:6	O
,	POTIGA.xml:S3:5292:1	O
urologic	POTIGA.xml:S3:5294:8	O
symptoms	POTIGA.xml:S3:5303:8	O
should	POTIGA.xml:S3:5312:6	O
be	POTIGA.xml:S3:5319:2	O
carefully	POTIGA.xml:S3:5322:9	O
monitored	POTIGA.xml:S3:5332:9	O
.	POTIGA.xml:S3:5341:1	O

Closer	POTIGA.xml:S3:5343:6	O
monitoring	POTIGA.xml:S3:5350:10	O
is	POTIGA.xml:S3:5361:2	O
recommended	POTIGA.xml:S3:5364:11	O
for	POTIGA.xml:S3:5376:3	O
patients	POTIGA.xml:S3:5380:8	O
who	POTIGA.xml:S3:5389:3	O
have	POTIGA.xml:S3:5393:4	O
other	POTIGA.xml:S3:5398:5	O
risk	POTIGA.xml:S3:5404:4	O
factors	POTIGA.xml:S3:5409:7	O
for	POTIGA.xml:S3:5417:3	O
urinary	POTIGA.xml:S3:5421:7	O
retention	POTIGA.xml:S3:5429:9	O
(	POTIGA.xml:S3:5439:1	O
e	POTIGA.xml:S3:5440:1	O
.	POTIGA.xml:S3:5441:1	O
g	POTIGA.xml:S3:5442:1	O
.	POTIGA.xml:S3:5443:1	O
,	POTIGA.xml:S3:5444:1	O
benign	POTIGA.xml:S3:5446:6	O
prostatic	POTIGA.xml:S3:5453:9	O
hyperplasia	POTIGA.xml:S3:5463:11	O
[	POTIGA.xml:S3:5475:1	O
BPH	POTIGA.xml:S3:5476:3	O
])	POTIGA.xml:S3:5479:2	O
,	POTIGA.xml:S3:5481:1	O
patients	POTIGA.xml:S3:5483:8	O
who	POTIGA.xml:S3:5492:3	O
are	POTIGA.xml:S3:5496:3	O
unable	POTIGA.xml:S3:5500:6	O
to	POTIGA.xml:S3:5507:2	O
communicate	POTIGA.xml:S3:5510:11	O
clinical	POTIGA.xml:S3:5522:8	O
symptoms	POTIGA.xml:S3:5531:8	O
(	POTIGA.xml:S3:5540:1	O
e	POTIGA.xml:S3:5541:1	O
.	POTIGA.xml:S3:5542:1	O
g	POTIGA.xml:S3:5543:1	O
.	POTIGA.xml:S3:5544:1	O
,	POTIGA.xml:S3:5545:1	O
cognitively	POTIGA.xml:S3:5547:11	O
impaired	POTIGA.xml:S3:5559:8	O
patients	POTIGA.xml:S3:5568:8	O
)	POTIGA.xml:S3:5576:1	O
,	POTIGA.xml:S3:5577:1	O
or	POTIGA.xml:S3:5579:2	O
patients	POTIGA.xml:S3:5582:8	O
who	POTIGA.xml:S3:5591:3	O
use	POTIGA.xml:S3:5595:3	O
concomitant	POTIGA.xml:S3:5599:11	O
medications	POTIGA.xml:S3:5611:11	O
that	POTIGA.xml:S3:5623:4	O
may	POTIGA.xml:S3:5628:3	O
affect	POTIGA.xml:S3:5632:6	O
voiding	POTIGA.xml:S3:5639:7	O
(	POTIGA.xml:S3:5647:1	O
e	POTIGA.xml:S3:5648:1	O
.	POTIGA.xml:S3:5649:1	O
g	POTIGA.xml:S3:5650:1	O
.	POTIGA.xml:S3:5651:1	O
,	POTIGA.xml:S3:5652:1	O
anticholinergics	POTIGA.xml:S3:5654:16	O
)	POTIGA.xml:S3:5670:1	O
.	POTIGA.xml:S3:5671:1	O

In	POTIGA.xml:S3:5673:2	O
these	POTIGA.xml:S3:5676:5	O
patients	POTIGA.xml:S3:5682:8	O
,	POTIGA.xml:S3:5690:1	O
a	POTIGA.xml:S3:5692:1	O
comprehensive	POTIGA.xml:S3:5694:13	O
evaluation	POTIGA.xml:S3:5708:10	O
of	POTIGA.xml:S3:5719:2	O
urologic	POTIGA.xml:S3:5722:8	O
symptoms	POTIGA.xml:S3:5731:8	O
prior	POTIGA.xml:S3:5740:5	O
to	POTIGA.xml:S3:5746:2	O
and	POTIGA.xml:S3:5749:3	O
during	POTIGA.xml:S3:5753:6	O
treatment	POTIGA.xml:S3:5760:9	O
with	POTIGA.xml:S3:5770:4	O
POTIGA	POTIGA.xml:S3:5775:6	O
may	POTIGA.xml:S3:5782:3	O
be	POTIGA.xml:S3:5786:2	O
appropriate	POTIGA.xml:S3:5789:11	B-Factor
.	POTIGA.xml:S3:5800:1	O

5.3	POTIGA.xml:S3:5809:3	O
Skin	POTIGA.xml:S3:5813:4	O
Discoloration	POTIGA.xml:S3:5818:13	O

POTIGA	POTIGA.xml:S3:5837:6	O
can	POTIGA.xml:S3:5844:3	B-Factor
cause	POTIGA.xml:S3:5848:5	O
skin	POTIGA.xml:S3:5854:4	B-AdverseReaction
discoloration	POTIGA.xml:S3:5859:13	I-AdverseReaction
.	POTIGA.xml:S3:5872:1	O

The	POTIGA.xml:S3:5874:3	O
skin	POTIGA.xml:S3:5878:4	B-AdverseReaction
discoloration	POTIGA.xml:S3:5883:13	I-AdverseReaction
is	POTIGA.xml:S3:5897:2	O
generally	POTIGA.xml:S3:5900:9	O
described	POTIGA.xml:S3:5910:9	O
as	POTIGA.xml:S3:5920:2	O
blue	POTIGA.xml:S3:5923:4	O
,	POTIGA.xml:S3:5927:1	O
but	POTIGA.xml:S3:5929:3	O
has	POTIGA.xml:S3:5933:3	O
also	POTIGA.xml:S3:5937:4	O
been	POTIGA.xml:S3:5942:4	O
described	POTIGA.xml:S3:5947:9	O
as	POTIGA.xml:S3:5957:2	O
grey	POTIGA.xml:S3:5960:4	O
-	POTIGA.xml:S3:5964:1	O
blue	POTIGA.xml:S3:5965:4	O
or	POTIGA.xml:S3:5970:2	O
brown	POTIGA.xml:S3:5973:5	O
.	POTIGA.xml:S3:5978:1	O

It	POTIGA.xml:S3:5980:2	O
is	POTIGA.xml:S3:5983:2	O
predominantly	POTIGA.xml:S3:5986:13	O
on	POTIGA.xml:S3:6000:2	O
or	POTIGA.xml:S3:6003:2	O
around	POTIGA.xml:S3:6006:6	O
the	POTIGA.xml:S3:6013:3	O
lips	POTIGA.xml:S3:6017:4	O
or	POTIGA.xml:S3:6022:2	O
in	POTIGA.xml:S3:6025:2	O
the	POTIGA.xml:S3:6028:3	O
nail	POTIGA.xml:S3:6032:4	O
beds	POTIGA.xml:S3:6037:4	O
of	POTIGA.xml:S3:6042:2	O
the	POTIGA.xml:S3:6045:3	O
fingers	POTIGA.xml:S3:6049:7	O
or	POTIGA.xml:S3:6057:2	O
toes	POTIGA.xml:S3:6060:4	O
,	POTIGA.xml:S3:6064:1	O
but	POTIGA.xml:S3:6066:3	O
more	POTIGA.xml:S3:6070:4	O
widespread	POTIGA.xml:S3:6075:10	O
involvement	POTIGA.xml:S3:6086:11	O
of	POTIGA.xml:S3:6098:2	O
the	POTIGA.xml:S3:6101:3	O
face	POTIGA.xml:S3:6105:4	O
and	POTIGA.xml:S3:6110:3	O
legs	POTIGA.xml:S3:6114:4	O
has	POTIGA.xml:S3:6119:3	O
also	POTIGA.xml:S3:6123:4	O
been	POTIGA.xml:S3:6128:4	O
reported	POTIGA.xml:S3:6133:8	O
.	POTIGA.xml:S3:6141:1	O

Discoloration	POTIGA.xml:S3:6143:13	B-AdverseReaction
of	POTIGA.xml:S3:6157:2	I-AdverseReaction
the	POTIGA.xml:S3:6160:3	I-AdverseReaction
palate	POTIGA.xml:S3:6164:6	I-AdverseReaction
,	POTIGA.xml:S3:6170:1	O
sclera	POTIGA.xml:S3:6172:6	I-AdverseReaction
,	POTIGA.xml:S3:6178:1	O
and	POTIGA.xml:S3:6180:3	O
conjunctiva	POTIGA.xml:S3:6184:11	I-AdverseReaction
has	POTIGA.xml:S3:6196:3	O
also	POTIGA.xml:S3:6200:4	O
been	POTIGA.xml:S3:6205:4	O
reported	POTIGA.xml:S3:6210:8	O
.	POTIGA.xml:S3:6218:1	O

Approximately	POTIGA.xml:S3:6224:13	O
10%	POTIGA.xml:S3:6238:3	O
of	POTIGA.xml:S3:6242:2	O
patients	POTIGA.xml:S3:6245:8	O
in	POTIGA.xml:S3:6254:2	O
long	POTIGA.xml:S3:6257:4	O
-	POTIGA.xml:S3:6261:1	O
term	POTIGA.xml:S3:6262:4	O
clinical	POTIGA.xml:S3:6267:8	O
trials	POTIGA.xml:S3:6276:6	O
developed	POTIGA.xml:S3:6283:9	O
skin	POTIGA.xml:S3:6293:4	B-AdverseReaction
discoloration	POTIGA.xml:S3:6298:13	I-AdverseReaction
,	POTIGA.xml:S3:6311:1	O
generally	POTIGA.xml:S3:6313:9	O
after	POTIGA.xml:S3:6323:5	O
2	POTIGA.xml:S3:6329:1	O
or	POTIGA.xml:S3:6331:2	O
more	POTIGA.xml:S3:6334:4	O
years	POTIGA.xml:S3:6339:5	O
of	POTIGA.xml:S3:6345:2	O
treatment	POTIGA.xml:S3:6348:9	O
and	POTIGA.xml:S3:6358:3	O
at	POTIGA.xml:S3:6362:2	O
higher	POTIGA.xml:S3:6365:6	O
doses	POTIGA.xml:S3:6372:5	O
(	POTIGA.xml:S3:6378:1	O
900	POTIGA.xml:S3:6379:3	O
mg	POTIGA.xml:S3:6383:2	O
or	POTIGA.xml:S3:6386:2	O
greater	POTIGA.xml:S3:6389:7	O
)	POTIGA.xml:S3:6396:1	O
of	POTIGA.xml:S3:6398:2	O
POTIGA	POTIGA.xml:S3:6401:6	O
.	POTIGA.xml:S3:6407:1	O

Among	POTIGA.xml:S3:6409:5	O
patients	POTIGA.xml:S3:6415:8	O
in	POTIGA.xml:S3:6424:2	O
whom	POTIGA.xml:S3:6427:4	O
the	POTIGA.xml:S3:6432:3	O
status	POTIGA.xml:S3:6436:6	O
of	POTIGA.xml:S3:6443:2	O
both	POTIGA.xml:S3:6446:4	O
skin	POTIGA.xml:S3:6451:4	B-AdverseReaction
,	POTIGA.xml:S3:6455:1	O
nail	POTIGA.xml:S3:6457:4	B-AdverseReaction
,	POTIGA.xml:S3:6461:1	O
lip	POTIGA.xml:S3:6463:3	B-AdverseReaction
,	POTIGA.xml:S3:6466:1	O
or	POTIGA.xml:S3:6468:2	O
mucous	POTIGA.xml:S3:6471:6	B-AdverseReaction
membrane	POTIGA.xml:S3:6478:8	I-AdverseReaction
discoloration	POTIGA.xml:S3:6487:13	I-AdverseReaction
and	POTIGA.xml:S3:6501:3	O
retinal	POTIGA.xml:S3:6505:7	B-AdverseReaction
pigmentary	POTIGA.xml:S3:6513:10	I-AdverseReaction
abnormalities	POTIGA.xml:S3:6524:13	I-AdverseReaction
are	POTIGA.xml:S3:6538:3	O
reported	POTIGA.xml:S3:6542:8	O
,	POTIGA.xml:S3:6550:1	O
approximately	POTIGA.xml:S3:6552:13	O
a	POTIGA.xml:S3:6566:1	O
quarter	POTIGA.xml:S3:6568:7	O
of	POTIGA.xml:S3:6576:2	O
those	POTIGA.xml:S3:6579:5	O
with	POTIGA.xml:S3:6585:4	O
skin	POTIGA.xml:S3:6590:4	B-AdverseReaction
,	POTIGA.xml:S3:6594:1	O
nail	POTIGA.xml:S3:6596:4	B-AdverseReaction
,	POTIGA.xml:S3:6600:1	O
lip	POTIGA.xml:S3:6602:3	B-AdverseReaction
,	POTIGA.xml:S3:6605:1	O
or	POTIGA.xml:S3:6607:2	O
mucous	POTIGA.xml:S3:6610:6	B-AdverseReaction
membrane	POTIGA.xml:S3:6617:8	I-AdverseReaction
discoloration	POTIGA.xml:S3:6626:13	I-AdverseReaction
had	POTIGA.xml:S3:6640:3	O
concurrent	POTIGA.xml:S3:6644:10	O
retinal	POTIGA.xml:S3:6655:7	B-AdverseReaction
pigmentary	POTIGA.xml:S3:6663:10	I-AdverseReaction
abnormalities	POTIGA.xml:S3:6674:13	I-AdverseReaction
[	POTIGA.xml:S3:6688:1	O
see	POTIGA.xml:S3:6689:3	O
Warnings	POTIGA.xml:S3:6693:8	O
and	POTIGA.xml:S3:6702:3	O
Precautions	POTIGA.xml:S3:6706:11	O
(	POTIGA.xml:S3:6718:1	O
5.1	POTIGA.xml:S3:6719:3	O
)]	POTIGA.xml:S3:6722:2	O
.	POTIGA.xml:S3:6726:1	O

Information	POTIGA.xml:S3:6732:11	O
on	POTIGA.xml:S3:6744:2	O
the	POTIGA.xml:S3:6747:3	O
consequences	POTIGA.xml:S3:6751:12	O
,	POTIGA.xml:S3:6763:1	O
reversibility	POTIGA.xml:S3:6765:13	O
,	POTIGA.xml:S3:6778:1	O
time	POTIGA.xml:S3:6780:4	O
to	POTIGA.xml:S3:6785:2	O
onset	POTIGA.xml:S3:6788:5	O
,	POTIGA.xml:S3:6793:1	O
and	POTIGA.xml:S3:6795:3	O
pathophysiology	POTIGA.xml:S3:6799:15	O
of	POTIGA.xml:S3:6815:2	O
the	POTIGA.xml:S3:6818:3	O
skin	POTIGA.xml:S3:6822:4	B-AdverseReaction
abnormalities	POTIGA.xml:S3:6827:13	I-AdverseReaction
remains	POTIGA.xml:S3:6841:7	O
incomplete	POTIGA.xml:S3:6849:10	O
.	POTIGA.xml:S3:6859:1	O

The	POTIGA.xml:S3:6861:3	O
possibility	POTIGA.xml:S3:6865:11	O
of	POTIGA.xml:S3:6877:2	O
more	POTIGA.xml:S3:6880:4	O
extensive	POTIGA.xml:S3:6885:9	O
systemic	POTIGA.xml:S3:6895:8	O
involvement	POTIGA.xml:S3:6904:11	O
has	POTIGA.xml:S3:6916:3	O
not	POTIGA.xml:S3:6920:3	O
been	POTIGA.xml:S3:6924:4	O
excluded	POTIGA.xml:S3:6929:8	O
.	POTIGA.xml:S3:6937:1	O

If	POTIGA.xml:S3:6939:2	O
a	POTIGA.xml:S3:6942:1	O
patient	POTIGA.xml:S3:6944:7	O
develops	POTIGA.xml:S3:6952:8	O
skin	POTIGA.xml:S3:6961:4	O
discoloration	POTIGA.xml:S3:6966:13	O
,	POTIGA.xml:S3:6979:1	O
serious	POTIGA.xml:S3:6981:7	O
consideration	POTIGA.xml:S3:6989:13	O
should	POTIGA.xml:S3:7003:6	O
be	POTIGA.xml:S3:7010:2	O
given	POTIGA.xml:S3:7013:5	O
to	POTIGA.xml:S3:7019:2	O
changing	POTIGA.xml:S3:7022:8	O
to	POTIGA.xml:S3:7031:2	O
an	POTIGA.xml:S3:7034:2	O
alternate	POTIGA.xml:S3:7037:9	O
medication	POTIGA.xml:S3:7047:10	O
.	POTIGA.xml:S3:7057:1	O

5.4	POTIGA.xml:S3:7066:3	O
Neuropsychiatric	POTIGA.xml:S3:7070:16	O
Symptoms	POTIGA.xml:S3:7087:8	O

Confusional	POTIGA.xml:S3:7101:11	B-AdverseReaction
state	POTIGA.xml:S3:7113:5	I-AdverseReaction
,	POTIGA.xml:S3:7118:1	O
psychotic	POTIGA.xml:S3:7120:9	B-AdverseReaction
symptoms	POTIGA.xml:S3:7130:8	I-AdverseReaction
,	POTIGA.xml:S3:7138:1	O
and	POTIGA.xml:S3:7140:3	O
hallucinations	POTIGA.xml:S3:7144:14	B-AdverseReaction
were	POTIGA.xml:S3:7159:4	O
reported	POTIGA.xml:S3:7164:8	O
more	POTIGA.xml:S3:7173:4	O
frequently	POTIGA.xml:S3:7178:10	O
as	POTIGA.xml:S3:7189:2	O
adverse	POTIGA.xml:S3:7192:7	O
reactions	POTIGA.xml:S3:7200:9	O
in	POTIGA.xml:S3:7210:2	O
patients	POTIGA.xml:S3:7213:8	O
treated	POTIGA.xml:S3:7222:7	O
with	POTIGA.xml:S3:7230:4	O
POTIGA	POTIGA.xml:S3:7235:6	O
than	POTIGA.xml:S3:7242:4	O
in	POTIGA.xml:S3:7247:2	O
those	POTIGA.xml:S3:7250:5	O
treated	POTIGA.xml:S3:7256:7	O
with	POTIGA.xml:S3:7264:4	O
placebo	POTIGA.xml:S3:7269:7	O
in	POTIGA.xml:S3:7277:2	O
placebo	POTIGA.xml:S3:7280:7	O
-	POTIGA.xml:S3:7287:1	O
controlled	POTIGA.xml:S3:7288:10	O
epilepsy	POTIGA.xml:S3:7299:8	O
trials	POTIGA.xml:S3:7308:6	O
(	POTIGA.xml:S3:7315:1	O
see	POTIGA.xml:S3:7316:3	O
Table	POTIGA.xml:S3:7320:5	O
2	POTIGA.xml:S3:7326:1	O
)	POTIGA.xml:S3:7327:1	O
.	POTIGA.xml:S3:7328:1	O

Discontinuations	POTIGA.xml:S3:7330:16	O
resulting	POTIGA.xml:S3:7347:9	O
from	POTIGA.xml:S3:7357:4	O
these	POTIGA.xml:S3:7362:5	O
reactions	POTIGA.xml:S3:7368:9	O
were	POTIGA.xml:S3:7378:4	O
more	POTIGA.xml:S3:7383:4	O
common	POTIGA.xml:S3:7388:6	O
in	POTIGA.xml:S3:7395:2	O
the	POTIGA.xml:S3:7398:3	O
drug	POTIGA.xml:S3:7402:4	O
-	POTIGA.xml:S3:7406:1	O
treated	POTIGA.xml:S3:7407:7	O
group	POTIGA.xml:S3:7415:5	O
(	POTIGA.xml:S3:7421:1	O
see	POTIGA.xml:S3:7422:3	O
Table	POTIGA.xml:S3:7426:5	O
2	POTIGA.xml:S3:7432:1	O
)	POTIGA.xml:S3:7433:1	O
.	POTIGA.xml:S3:7434:1	O

These	POTIGA.xml:S3:7436:5	O
effects	POTIGA.xml:S3:7442:7	O
were	POTIGA.xml:S3:7450:4	O
dose	POTIGA.xml:S3:7455:4	O
-	POTIGA.xml:S3:7459:1	O
related	POTIGA.xml:S3:7460:7	O
and	POTIGA.xml:S3:7468:3	O
generally	POTIGA.xml:S3:7472:9	O
appeared	POTIGA.xml:S3:7482:8	O
within	POTIGA.xml:S3:7491:6	O
the	POTIGA.xml:S3:7498:3	O
first	POTIGA.xml:S3:7502:5	O
8	POTIGA.xml:S3:7508:1	O
weeks	POTIGA.xml:S3:7510:5	O
of	POTIGA.xml:S3:7516:2	O
treatment	POTIGA.xml:S3:7519:9	O
.	POTIGA.xml:S3:7528:1	O

Half	POTIGA.xml:S3:7530:4	O
of	POTIGA.xml:S3:7535:2	O
the	POTIGA.xml:S3:7538:3	O
patients	POTIGA.xml:S3:7542:8	O
in	POTIGA.xml:S3:7551:2	O
the	POTIGA.xml:S3:7554:3	O
controlled	POTIGA.xml:S3:7558:10	O
trials	POTIGA.xml:S3:7569:6	O
who	POTIGA.xml:S3:7576:3	O
discontinued	POTIGA.xml:S3:7580:12	O
POTIGA	POTIGA.xml:S3:7593:6	O
due	POTIGA.xml:S3:7600:3	O
to	POTIGA.xml:S3:7604:2	O
hallucinations	POTIGA.xml:S3:7607:14	B-AdverseReaction
or	POTIGA.xml:S3:7622:2	O
psychosis	POTIGA.xml:S3:7625:9	B-AdverseReaction
required	POTIGA.xml:S3:7635:8	O
hospitalization	POTIGA.xml:S3:7644:15	O
.	POTIGA.xml:S3:7659:1	O

Approximately	POTIGA.xml:S3:7661:13	O
two	POTIGA.xml:S3:7675:3	O
-	POTIGA.xml:S3:7678:1	O
thirds	POTIGA.xml:S3:7679:6	O
of	POTIGA.xml:S3:7686:2	O
patients	POTIGA.xml:S3:7689:8	O
with	POTIGA.xml:S3:7698:4	O
psychosis	POTIGA.xml:S3:7703:9	B-AdverseReaction
in	POTIGA.xml:S3:7713:2	O
controlled	POTIGA.xml:S3:7716:10	O
trials	POTIGA.xml:S3:7727:6	O
had	POTIGA.xml:S3:7734:3	O
no	POTIGA.xml:S3:7738:2	O
prior	POTIGA.xml:S3:7741:5	O
psychiatric	POTIGA.xml:S3:7747:11	O
history	POTIGA.xml:S3:7759:7	O
.	POTIGA.xml:S3:7766:1	O

The	POTIGA.xml:S3:7768:3	O
psychiatric	POTIGA.xml:S3:7772:11	B-AdverseReaction
symptoms	POTIGA.xml:S3:7784:8	I-AdverseReaction
in	POTIGA.xml:S3:7793:2	O
the	POTIGA.xml:S3:7796:3	O
vast	POTIGA.xml:S3:7800:4	O
majority	POTIGA.xml:S3:7805:8	O
of	POTIGA.xml:S3:7814:2	O
patients	POTIGA.xml:S3:7817:8	O
in	POTIGA.xml:S3:7826:2	O
both	POTIGA.xml:S3:7829:4	O
controlled	POTIGA.xml:S3:7834:10	O
and	POTIGA.xml:S3:7845:3	O
open	POTIGA.xml:S3:7849:4	O
-	POTIGA.xml:S3:7853:1	O
label	POTIGA.xml:S3:7854:5	O
trials	POTIGA.xml:S3:7860:6	O
resolved	POTIGA.xml:S3:7867:8	O
within	POTIGA.xml:S3:7876:6	O
7	POTIGA.xml:S3:7883:1	O
days	POTIGA.xml:S3:7885:4	O
of	POTIGA.xml:S3:7890:2	O
discontinuation	POTIGA.xml:S3:7893:15	O
of	POTIGA.xml:S3:7909:2	O
POTIGA	POTIGA.xml:S3:7912:6	O
.	POTIGA.xml:S3:7918:1	O

Rapid	POTIGA.xml:S3:7920:5	O
titration	POTIGA.xml:S3:7926:9	O
at	POTIGA.xml:S3:7936:2	O
greater	POTIGA.xml:S3:7939:7	O
than	POTIGA.xml:S3:7947:4	O
the	POTIGA.xml:S3:7952:3	O
recommended	POTIGA.xml:S3:7956:11	O
doses	POTIGA.xml:S3:7968:5	O
appeared	POTIGA.xml:S3:7974:8	O
to	POTIGA.xml:S3:7983:2	O
increase	POTIGA.xml:S3:7986:8	O
the	POTIGA.xml:S3:7995:3	O
risk	POTIGA.xml:S3:7999:4	B-Factor
of	POTIGA.xml:S3:8004:2	O
psychosis	POTIGA.xml:S3:8007:9	B-AdverseReaction
and	POTIGA.xml:S3:8017:3	O
hallucinations	POTIGA.xml:S3:8021:14	B-AdverseReaction
.	POTIGA.xml:S3:8035:1	O

Table	POTIGA.xml:S3:8042:5	O
2	POTIGA.xml:S3:8048:1	O
.	POTIGA.xml:S3:8049:1	O

Major	POTIGA.xml:S3:8051:5	O
Neuropsychiatric	POTIGA.xml:S3:8057:16	B-AdverseReaction
Symptoms	POTIGA.xml:S3:8074:8	I-AdverseReaction
in	POTIGA.xml:S3:8083:2	O
Placebo	POTIGA.xml:S3:8086:7	O
-	POTIGA.xml:S3:8093:1	O
Controlled	POTIGA.xml:S3:8094:10	O
Epilepsy	POTIGA.xml:S3:8105:8	O
Trials	POTIGA.xml:S3:8114:6	O

Adverse	POTIGA.xml:S3:8129:7	O
Reaction	POTIGA.xml:S3:8137:8	O
Number	POTIGA.xml:S3:8151:6	O
(	POTIGA.xml:S3:8158:1	O
)	POTIGA.xml:S3:8160:1	O
with	POTIGA.xml:S3:8162:4	O
Adverse	POTIGA.xml:S3:8167:7	O
Reaction	POTIGA.xml:S3:8175:8	O
Number	POTIGA.xml:S3:8187:6	O
(	POTIGA.xml:S3:8194:1	O
)	POTIGA.xml:S3:8196:1	O
Discontinuing	POTIGA.xml:S3:8198:13	O

POTIGA	POTIGA.xml:S3:8218:6	O
(	POTIGA.xml:S3:8226:1	O
n	POTIGA.xml:S3:8227:1	O
813	POTIGA.xml:S3:8231:3	O
)	POTIGA.xml:S3:8234:1	O
Placebo	POTIGA.xml:S3:8240:7	O
(	POTIGA.xml:S3:8249:1	O
n	POTIGA.xml:S3:8250:1	O
427	POTIGA.xml:S3:8254:3	O
)	POTIGA.xml:S3:8257:1	O
POTIGA	POTIGA.xml:S3:8262:6	O
(	POTIGA.xml:S3:8270:1	O
n	POTIGA.xml:S3:8271:1	O
813	POTIGA.xml:S3:8275:3	O
)	POTIGA.xml:S3:8278:1	O
Placebo	POTIGA.xml:S3:8283:7	O
(	POTIGA.xml:S3:8292:1	O
n	POTIGA.xml:S3:8293:1	O
427	POTIGA.xml:S3:8297:3	O
)	POTIGA.xml:S3:8300:1	O

Confusional	POTIGA.xml:S3:8308:11	B-AdverseReaction
state	POTIGA.xml:S3:8320:5	I-AdverseReaction
75	POTIGA.xml:S3:8330:2	O
(	POTIGA.xml:S3:8333:1	O
9%	POTIGA.xml:S3:8334:2	O
)	POTIGA.xml:S3:8336:1	O
11	POTIGA.xml:S3:8351:2	O
(	POTIGA.xml:S3:8354:1	O
3%	POTIGA.xml:S3:8355:2	O
)	POTIGA.xml:S3:8357:1	O
32	POTIGA.xml:S3:8372:2	O
(	POTIGA.xml:S3:8375:1	O
4%	POTIGA.xml:S3:8376:2	O
)	POTIGA.xml:S3:8378:1	O
4	POTIGA.xml:S3:8389:1	O
(	POTIGA.xml:S3:8391:1	O
1%	POTIGA.xml:S3:8393:2	O
)	POTIGA.xml:S3:8395:1	O

Psychosis	POTIGA.xml:S3:8408:9	B-AdverseReaction
9	POTIGA.xml:S3:8430:1	O
(	POTIGA.xml:S3:8432:1	O
1%	POTIGA.xml:S3:8433:2	O
)	POTIGA.xml:S3:8435:1	O
0	POTIGA.xml:S3:8451:1	O
6	POTIGA.xml:S3:8472:1	O
(	POTIGA.xml:S3:8474:1	O
1%	POTIGA.xml:S3:8476:2	O
)	POTIGA.xml:S3:8478:1	O
0	POTIGA.xml:S3:8489:1	O

Hallucinationsa	POTIGA.xml:S3:8508:15	B-AdverseReaction
14	POTIGA.xml:S3:8530:2	O
(	POTIGA.xml:S3:8533:1	O
2%	POTIGA.xml:S3:8534:2	O
)	POTIGA.xml:S3:8536:1	O
2	POTIGA.xml:S3:8551:1	O
(	POTIGA.xml:S3:8553:1	O
1%	POTIGA.xml:S3:8555:2	O
)	POTIGA.xml:S3:8557:1	O
6	POTIGA.xml:S3:8572:1	O
(	POTIGA.xml:S3:8574:1	O
1%	POTIGA.xml:S3:8576:2	O
)	POTIGA.xml:S3:8578:1	O
0	POTIGA.xml:S3:8589:1	O

a	POTIGA.xml:S3:8619:1	O
Hallucinations	POTIGA.xml:S3:8622:14	B-AdverseReaction
includes	POTIGA.xml:S3:8637:8	O
visual	POTIGA.xml:S3:8646:6	B-AdverseReaction
,	POTIGA.xml:S3:8652:1	O
auditory	POTIGA.xml:S3:8654:8	B-AdverseReaction
,	POTIGA.xml:S3:8662:1	O
and	POTIGA.xml:S3:8664:3	O
mixed	POTIGA.xml:S3:8668:5	B-AdverseReaction
hallucinations	POTIGA.xml:S3:8674:14	I-AdverseReaction
.	POTIGA.xml:S3:8688:1	O

5.5	POTIGA.xml:S3:8697:3	O

Dizziness	POTIGA.xml:S3:8701:9	O
and	POTIGA.xml:S3:8711:3	O
Somnolence	POTIGA.xml:S3:8715:10	O

POTIGA	POTIGA.xml:S3:8731:6	O
causes	POTIGA.xml:S3:8738:6	O
dose	POTIGA.xml:S3:8745:4	O
-	POTIGA.xml:S3:8749:1	O
related	POTIGA.xml:S3:8750:7	O
increases	POTIGA.xml:S3:8758:9	O
in	POTIGA.xml:S3:8768:2	O
dizziness	POTIGA.xml:S3:8771:9	B-AdverseReaction
and	POTIGA.xml:S3:8781:3	O
somnolence	POTIGA.xml:S3:8785:10	B-AdverseReaction
[	POTIGA.xml:S3:8796:1	O
see	POTIGA.xml:S3:8797:3	O
Adverse	POTIGA.xml:S3:8801:7	O
Reactions	POTIGA.xml:S3:8809:9	O
(	POTIGA.xml:S3:8819:1	O
6.1	POTIGA.xml:S3:8820:3	O
)]	POTIGA.xml:S3:8823:2	O
.	POTIGA.xml:S3:8827:1	O

In	POTIGA.xml:S3:8829:2	O
placebo	POTIGA.xml:S3:8832:7	O
-	POTIGA.xml:S3:8839:1	O
controlled	POTIGA.xml:S3:8840:10	O
trials	POTIGA.xml:S3:8851:6	O
in	POTIGA.xml:S3:8858:2	O
patients	POTIGA.xml:S3:8861:8	O
with	POTIGA.xml:S3:8870:4	O
epilepsy	POTIGA.xml:S3:8875:8	O
,	POTIGA.xml:S3:8883:1	O
dizziness	POTIGA.xml:S3:8885:9	B-AdverseReaction
was	POTIGA.xml:S3:8895:3	O
reported	POTIGA.xml:S3:8899:8	O
in	POTIGA.xml:S3:8908:2	O
23%	POTIGA.xml:S3:8911:3	O
of	POTIGA.xml:S3:8915:2	O
patients	POTIGA.xml:S3:8918:8	O
treated	POTIGA.xml:S3:8927:7	O
with	POTIGA.xml:S3:8935:4	O
POTIGA	POTIGA.xml:S3:8940:6	O
and	POTIGA.xml:S3:8947:3	O
9%	POTIGA.xml:S3:8951:2	O
of	POTIGA.xml:S3:8954:2	O
patients	POTIGA.xml:S3:8957:8	O
treated	POTIGA.xml:S3:8966:7	O
with	POTIGA.xml:S3:8974:4	O
placebo	POTIGA.xml:S3:8979:7	O
.	POTIGA.xml:S3:8986:1	O

Somnolence	POTIGA.xml:S3:8988:10	B-AdverseReaction
was	POTIGA.xml:S3:8999:3	O
reported	POTIGA.xml:S3:9003:8	O
in	POTIGA.xml:S3:9012:2	O
22%	POTIGA.xml:S3:9015:3	O
of	POTIGA.xml:S3:9019:2	O
patients	POTIGA.xml:S3:9022:8	O
treated	POTIGA.xml:S3:9031:7	O
with	POTIGA.xml:S3:9039:4	O
POTIGA	POTIGA.xml:S3:9044:6	O
and	POTIGA.xml:S3:9051:3	O
12%	POTIGA.xml:S3:9055:3	O
of	POTIGA.xml:S3:9059:2	O
patients	POTIGA.xml:S3:9062:8	O
treated	POTIGA.xml:S3:9071:7	O
with	POTIGA.xml:S3:9079:4	O
placebo	POTIGA.xml:S3:9084:7	O
.	POTIGA.xml:S3:9091:1	O

In	POTIGA.xml:S3:9093:2	O
these	POTIGA.xml:S3:9096:5	O
trials	POTIGA.xml:S3:9102:6	O
6%	POTIGA.xml:S3:9109:2	O
of	POTIGA.xml:S3:9112:2	O
patients	POTIGA.xml:S3:9115:8	O
on	POTIGA.xml:S3:9124:2	O
POTIGA	POTIGA.xml:S3:9127:6	O
and	POTIGA.xml:S3:9134:3	O
1.2%	POTIGA.xml:S3:9138:4	O
on	POTIGA.xml:S3:9143:2	O
placebo	POTIGA.xml:S3:9146:7	O
discontinued	POTIGA.xml:S3:9154:12	O
treatment	POTIGA.xml:S3:9167:9	O
because	POTIGA.xml:S3:9177:7	O
of	POTIGA.xml:S3:9185:2	O
dizziness	POTIGA.xml:S3:9188:9	B-AdverseReaction
;	POTIGA.xml:S3:9197:1	O
3%	POTIGA.xml:S3:9199:2	O
of	POTIGA.xml:S3:9202:2	O
patients	POTIGA.xml:S3:9205:8	O
on	POTIGA.xml:S3:9214:2	O
POTIGA	POTIGA.xml:S3:9217:6	O
and	POTIGA.xml:S3:9224:3	O
1.0%	POTIGA.xml:S3:9229:4	O
on	POTIGA.xml:S3:9234:2	O
placebo	POTIGA.xml:S3:9237:7	O
discontinued	POTIGA.xml:S3:9245:12	O
because	POTIGA.xml:S3:9258:7	O
of	POTIGA.xml:S3:9266:2	O
somnolence	POTIGA.xml:S3:9269:10	B-AdverseReaction
.	POTIGA.xml:S3:9279:1	O

Most	POTIGA.xml:S3:9285:4	O
of	POTIGA.xml:S3:9290:2	O
these	POTIGA.xml:S3:9293:5	O
adverse	POTIGA.xml:S3:9299:7	O
reactions	POTIGA.xml:S3:9307:9	O
were	POTIGA.xml:S3:9317:4	O
mild	POTIGA.xml:S3:9322:4	O
to	POTIGA.xml:S3:9327:2	O
moderate	POTIGA.xml:S3:9330:8	O
in	POTIGA.xml:S3:9339:2	O
intensity	POTIGA.xml:S3:9342:9	O
and	POTIGA.xml:S3:9352:3	O
occurred	POTIGA.xml:S3:9356:8	O
during	POTIGA.xml:S3:9365:6	O
the	POTIGA.xml:S3:9372:3	O
titration	POTIGA.xml:S3:9376:9	O
phase	POTIGA.xml:S3:9386:5	O
.	POTIGA.xml:S3:9391:1	O

For	POTIGA.xml:S3:9393:3	O
those	POTIGA.xml:S3:9397:5	O
patients	POTIGA.xml:S3:9403:8	O
continued	POTIGA.xml:S3:9412:9	O
on	POTIGA.xml:S3:9422:2	O
POTIGA	POTIGA.xml:S3:9425:6	O
,	POTIGA.xml:S3:9431:1	O
dizziness	POTIGA.xml:S3:9433:9	B-AdverseReaction
and	POTIGA.xml:S3:9443:3	O
somnolence	POTIGA.xml:S3:9447:10	B-AdverseReaction
appeared	POTIGA.xml:S3:9458:8	O
to	POTIGA.xml:S3:9467:2	O
diminish	POTIGA.xml:S3:9470:8	O
with	POTIGA.xml:S3:9479:4	O
continued	POTIGA.xml:S3:9484:9	O
use	POTIGA.xml:S3:9494:3	O
.	POTIGA.xml:S3:9497:1	O

5.6	POTIGA.xml:S3:9506:3	O
QT	POTIGA.xml:S3:9510:2	O
Interval	POTIGA.xml:S3:9513:8	O
Effect	POTIGA.xml:S3:9522:6	O

A	POTIGA.xml:S3:9534:1	O
study	POTIGA.xml:S3:9536:5	O
of	POTIGA.xml:S3:9542:2	O
cardiac	POTIGA.xml:S3:9545:7	O
conduction	POTIGA.xml:S3:9553:10	O
showed	POTIGA.xml:S3:9564:6	O
that	POTIGA.xml:S3:9571:4	O
POTIGA	POTIGA.xml:S3:9576:6	O
produced	POTIGA.xml:S3:9583:8	O
a	POTIGA.xml:S3:9592:1	O
mean	POTIGA.xml:S3:9594:4	O
7.7	POTIGA.xml:S3:9599:3	B-Severity
-	POTIGA.xml:S3:9602:1	I-Severity
msec	POTIGA.xml:S3:9603:4	I-Severity
QT	POTIGA.xml:S3:9608:2	B-AdverseReaction
prolongation	POTIGA.xml:S3:9611:12	I-AdverseReaction
in	POTIGA.xml:S3:9624:2	O
healthy	POTIGA.xml:S3:9627:7	O
volunteers	POTIGA.xml:S3:9635:10	O
titrated	POTIGA.xml:S3:9646:8	O
to	POTIGA.xml:S3:9655:2	O
400	POTIGA.xml:S3:9658:3	O
mg	POTIGA.xml:S3:9662:2	O
3	POTIGA.xml:S3:9665:1	O
times	POTIGA.xml:S3:9667:5	O
daily	POTIGA.xml:S3:9673:5	O
.	POTIGA.xml:S3:9678:1	O

The	POTIGA.xml:S3:9680:3	O
QT	POTIGA.xml:S3:9684:2	B-AdverseReaction
-	POTIGA.xml:S3:9686:1	I-AdverseReaction
prolonging	POTIGA.xml:S3:9687:10	I-AdverseReaction
effect	POTIGA.xml:S3:9698:6	O
occurred	POTIGA.xml:S3:9705:8	O
within	POTIGA.xml:S3:9714:6	O
3	POTIGA.xml:S3:9721:1	O
hours	POTIGA.xml:S3:9723:5	O
.	POTIGA.xml:S3:9728:1	O

The	POTIGA.xml:S3:9730:3	O
QT	POTIGA.xml:S3:9734:2	O
interval	POTIGA.xml:S3:9737:8	O
should	POTIGA.xml:S3:9746:6	O
be	POTIGA.xml:S3:9753:2	O
monitored	POTIGA.xml:S3:9756:9	O
when	POTIGA.xml:S3:9766:4	O
POTIGA	POTIGA.xml:S3:9771:6	O
is	POTIGA.xml:S3:9778:2	O
prescribed	POTIGA.xml:S3:9781:10	O
with	POTIGA.xml:S3:9792:4	O
medicines	POTIGA.xml:S3:9797:9	O
known	POTIGA.xml:S3:9807:5	O
to	POTIGA.xml:S3:9813:2	O
increase	POTIGA.xml:S3:9816:8	O
QT	POTIGA.xml:S3:9825:2	O
interval	POTIGA.xml:S3:9828:8	O
and	POTIGA.xml:S3:9837:3	O
in	POTIGA.xml:S3:9841:2	O
patients	POTIGA.xml:S3:9844:8	O
with	POTIGA.xml:S3:9853:4	O
known	POTIGA.xml:S3:9858:5	O
prolonged	POTIGA.xml:S3:9864:9	O
QT	POTIGA.xml:S3:9874:2	O
interval	POTIGA.xml:S3:9877:8	O
,	POTIGA.xml:S3:9885:1	O
congestive	POTIGA.xml:S3:9887:10	O
heart	POTIGA.xml:S3:9898:5	O
failure	POTIGA.xml:S3:9904:7	O
,	POTIGA.xml:S3:9911:1	O
ventricular	POTIGA.xml:S3:9913:11	O
hypertrophy	POTIGA.xml:S3:9925:11	O
,	POTIGA.xml:S3:9936:1	O
hypokalemia	POTIGA.xml:S3:9938:11	O
,	POTIGA.xml:S3:9949:1	O
or	POTIGA.xml:S3:9951:2	O
hypomagnesemia	POTIGA.xml:S3:9954:14	O
[	POTIGA.xml:S3:9969:1	O
see	POTIGA.xml:S3:9970:3	O
Clinical	POTIGA.xml:S3:9974:8	O
Pharmacology	POTIGA.xml:S3:9983:12	O
(	POTIGA.xml:S3:9996:1	O
12.2	POTIGA.xml:S3:9997:4	O
)]	POTIGA.xml:S3:10001:2	O
.	POTIGA.xml:S3:10005:1	O

5.7	POTIGA.xml:S3:10014:3	O
Suicidal	POTIGA.xml:S3:10018:8	O
Behavior	POTIGA.xml:S3:10027:8	O
and	POTIGA.xml:S3:10036:3	O
Ideation	POTIGA.xml:S3:10040:8	O

Antiepileptic	POTIGA.xml:S3:10054:13	O
drugs	POTIGA.xml:S3:10068:5	O
(	POTIGA.xml:S3:10074:1	O
AEDs	POTIGA.xml:S3:10075:4	O
)	POTIGA.xml:S3:10079:1	O
,	POTIGA.xml:S3:10080:1	O
including	POTIGA.xml:S3:10082:9	O
POTIGA	POTIGA.xml:S3:10092:6	O
,	POTIGA.xml:S3:10098:1	O
increase	POTIGA.xml:S3:10100:8	O
the	POTIGA.xml:S3:10109:3	O
risk	POTIGA.xml:S3:10113:4	B-Factor
of	POTIGA.xml:S3:10118:2	O
suicidal	POTIGA.xml:S3:10121:8	B-AdverseReaction
thoughts	POTIGA.xml:S3:10130:8	I-AdverseReaction
or	POTIGA.xml:S3:10139:2	O
behavior	POTIGA.xml:S3:10142:8	I-AdverseReaction
in	POTIGA.xml:S3:10151:2	O
patients	POTIGA.xml:S3:10154:8	O
taking	POTIGA.xml:S3:10163:6	O
these	POTIGA.xml:S3:10170:5	O
drugs	POTIGA.xml:S3:10176:5	O
for	POTIGA.xml:S3:10182:3	O
any	POTIGA.xml:S3:10186:3	O
indication	POTIGA.xml:S3:10190:10	O
.	POTIGA.xml:S3:10200:1	O

Patients	POTIGA.xml:S3:10202:8	O
treated	POTIGA.xml:S3:10211:7	O
with	POTIGA.xml:S3:10219:4	O
any	POTIGA.xml:S3:10224:3	O
AED	POTIGA.xml:S3:10228:3	O
for	POTIGA.xml:S3:10232:3	O
any	POTIGA.xml:S3:10236:3	O
indication	POTIGA.xml:S3:10240:10	O
should	POTIGA.xml:S3:10251:6	O
be	POTIGA.xml:S3:10258:2	O
monitored	POTIGA.xml:S3:10261:9	O
for	POTIGA.xml:S3:10271:3	O
the	POTIGA.xml:S3:10275:3	O
emergence	POTIGA.xml:S3:10279:9	O
or	POTIGA.xml:S3:10289:2	O
worsening	POTIGA.xml:S3:10292:9	O
of	POTIGA.xml:S3:10302:2	O
depression	POTIGA.xml:S3:10305:10	O
,	POTIGA.xml:S3:10315:1	O
suicidal	POTIGA.xml:S3:10317:8	O
thoughts	POTIGA.xml:S3:10326:8	O
or	POTIGA.xml:S3:10335:2	O
behavior	POTIGA.xml:S3:10338:8	O
,	POTIGA.xml:S3:10346:1	O
and	POTIGA.xml:S3:10348:3	O
or	POTIGA.xml:S3:10352:2	O
any	POTIGA.xml:S3:10355:3	O
unusual	POTIGA.xml:S3:10359:7	O
changes	POTIGA.xml:S3:10367:7	O
in	POTIGA.xml:S3:10375:2	O
mood	POTIGA.xml:S3:10378:4	O
or	POTIGA.xml:S3:10383:2	O
behavior	POTIGA.xml:S3:10386:8	O
.	POTIGA.xml:S3:10394:1	O

Pooled	POTIGA.xml:S3:10400:6	O
analyses	POTIGA.xml:S3:10407:8	O
of	POTIGA.xml:S3:10416:2	O
199	POTIGA.xml:S3:10419:3	O
placebo	POTIGA.xml:S3:10423:7	O
-	POTIGA.xml:S3:10430:1	O
controlled	POTIGA.xml:S3:10431:10	O
clinical	POTIGA.xml:S3:10442:8	O
trials	POTIGA.xml:S3:10451:6	O
(	POTIGA.xml:S3:10458:1	O
mono	POTIGA.xml:S3:10459:4	O
-	POTIGA.xml:S3:10463:1	O
and	POTIGA.xml:S3:10465:3	O
adjunctive	POTIGA.xml:S3:10469:10	O
-	POTIGA.xml:S3:10479:1	O
therapy	POTIGA.xml:S3:10480:7	O
)	POTIGA.xml:S3:10487:1	O
of	POTIGA.xml:S3:10489:2	O
11	POTIGA.xml:S3:10492:2	O
different	POTIGA.xml:S3:10495:9	O
AEDs	POTIGA.xml:S3:10505:4	O
showed	POTIGA.xml:S3:10510:6	O
that	POTIGA.xml:S3:10517:4	O
patients	POTIGA.xml:S3:10522:8	O
randomized	POTIGA.xml:S3:10531:10	O
to	POTIGA.xml:S3:10542:2	O
one	POTIGA.xml:S3:10545:3	O
of	POTIGA.xml:S3:10549:2	O
the	POTIGA.xml:S3:10552:3	O
AEDs	POTIGA.xml:S3:10556:4	O
had	POTIGA.xml:S3:10561:3	O
approximately	POTIGA.xml:S3:10565:13	O
twice	POTIGA.xml:S3:10579:5	O
the	POTIGA.xml:S3:10585:3	O
risk	POTIGA.xml:S3:10589:4	B-Factor
(	POTIGA.xml:S3:10594:1	O
adjusted	POTIGA.xml:S3:10595:8	O
relative	POTIGA.xml:S3:10604:8	O
risk	POTIGA.xml:S3:10613:4	O
1.8	POTIGA.xml:S3:10618:3	O
,	POTIGA.xml:S3:10621:1	O
95%	POTIGA.xml:S3:10623:3	O
confidence	POTIGA.xml:S3:10627:10	O
interval	POTIGA.xml:S3:10638:8	O
[	POTIGA.xml:S3:10647:1	O
CI	POTIGA.xml:S3:10648:2	O
]	POTIGA.xml:S3:10650:1	O
:	POTIGA.xml:S3:10651:1	O
1.2	POTIGA.xml:S3:10653:3	O
,	POTIGA.xml:S3:10656:1	O
2.7	POTIGA.xml:S3:10658:3	O
)	POTIGA.xml:S3:10661:1	O
of	POTIGA.xml:S3:10663:2	O
suicidal	POTIGA.xml:S3:10666:8	B-AdverseReaction
thinking	POTIGA.xml:S3:10675:8	I-AdverseReaction
or	POTIGA.xml:S3:10684:2	O
behavior	POTIGA.xml:S3:10687:8	I-AdverseReaction
compared	POTIGA.xml:S3:10696:8	O
with	POTIGA.xml:S3:10705:4	O
patients	POTIGA.xml:S3:10710:8	O
randomized	POTIGA.xml:S3:10719:10	O
to	POTIGA.xml:S3:10730:2	O
placebo	POTIGA.xml:S3:10733:7	O
.	POTIGA.xml:S3:10740:1	O

In	POTIGA.xml:S3:10742:2	O
these	POTIGA.xml:S3:10745:5	O
trials	POTIGA.xml:S3:10751:6	O
,	POTIGA.xml:S3:10757:1	O
which	POTIGA.xml:S3:10759:5	O
had	POTIGA.xml:S3:10765:3	O
a	POTIGA.xml:S3:10769:1	O
median	POTIGA.xml:S3:10771:6	O
treatment	POTIGA.xml:S3:10778:9	O
duration	POTIGA.xml:S3:10788:8	O
of	POTIGA.xml:S3:10797:2	O
12	POTIGA.xml:S3:10800:2	O
weeks	POTIGA.xml:S3:10803:5	O
,	POTIGA.xml:S3:10808:1	O
the	POTIGA.xml:S3:10810:3	O
estimated	POTIGA.xml:S3:10814:9	O
incidence	POTIGA.xml:S3:10824:9	O
of	POTIGA.xml:S3:10834:2	O
suicidal	POTIGA.xml:S3:10837:8	B-AdverseReaction
behavior	POTIGA.xml:S3:10846:8	I-AdverseReaction
or	POTIGA.xml:S3:10855:2	O
ideation	POTIGA.xml:S3:10858:8	I-AdverseReaction
among	POTIGA.xml:S3:10867:5	O
27	POTIGA.xml:S3:10873:2	O
,	POTIGA.xml:S3:10875:1	O
863	POTIGA.xml:S3:10876:3	O
AED	POTIGA.xml:S3:10880:3	O
-	POTIGA.xml:S3:10883:1	O
treated	POTIGA.xml:S3:10884:7	O
patients	POTIGA.xml:S3:10892:8	O
was	POTIGA.xml:S3:10901:3	O
0.43%	POTIGA.xml:S3:10905:5	O
compared	POTIGA.xml:S3:10911:8	O
with	POTIGA.xml:S3:10920:4	O
0.24%	POTIGA.xml:S3:10925:5	O
among	POTIGA.xml:S3:10931:5	O
16	POTIGA.xml:S3:10937:2	O
,	POTIGA.xml:S3:10939:1	O
029	POTIGA.xml:S3:10940:3	O
placebo	POTIGA.xml:S3:10944:7	O
-	POTIGA.xml:S3:10951:1	O
treated	POTIGA.xml:S3:10952:7	O
patients	POTIGA.xml:S3:10960:8	O
,	POTIGA.xml:S3:10968:1	O
representing	POTIGA.xml:S3:10970:12	O
an	POTIGA.xml:S3:10983:2	O
increase	POTIGA.xml:S3:10986:8	O
of	POTIGA.xml:S3:10995:2	O
approximately	POTIGA.xml:S3:10998:13	O
1	POTIGA.xml:S3:11012:1	O
case	POTIGA.xml:S3:11014:4	O
of	POTIGA.xml:S3:11019:2	O
suicidal	POTIGA.xml:S3:11022:8	B-AdverseReaction
thinking	POTIGA.xml:S3:11031:8	I-AdverseReaction
or	POTIGA.xml:S3:11040:2	O
behavior	POTIGA.xml:S3:11043:8	I-AdverseReaction
for	POTIGA.xml:S3:11052:3	O
every	POTIGA.xml:S3:11056:5	O
530	POTIGA.xml:S3:11062:3	O
patients	POTIGA.xml:S3:11066:8	O
treated	POTIGA.xml:S3:11075:7	O
.	POTIGA.xml:S3:11082:1	O

There	POTIGA.xml:S3:11084:5	O
were	POTIGA.xml:S3:11090:4	O
4	POTIGA.xml:S3:11095:1	O
suicides	POTIGA.xml:S3:11097:8	B-AdverseReaction
in	POTIGA.xml:S3:11106:2	O
drug	POTIGA.xml:S3:11109:4	O
-	POTIGA.xml:S3:11113:1	O
treated	POTIGA.xml:S3:11114:7	O
patients	POTIGA.xml:S3:11122:8	O
in	POTIGA.xml:S3:11131:2	O
the	POTIGA.xml:S3:11134:3	O
trials	POTIGA.xml:S3:11138:6	O
and	POTIGA.xml:S3:11145:3	O
none	POTIGA.xml:S3:11149:4	O
in	POTIGA.xml:S3:11154:2	O
placebo	POTIGA.xml:S3:11157:7	O
-	POTIGA.xml:S3:11164:1	O
treated	POTIGA.xml:S3:11165:7	O
patients	POTIGA.xml:S3:11173:8	O
,	POTIGA.xml:S3:11181:1	O
but	POTIGA.xml:S3:11183:3	O
the	POTIGA.xml:S3:11187:3	O
number	POTIGA.xml:S3:11191:6	B-Factor
is	POTIGA.xml:S3:11198:2	I-Factor
too	POTIGA.xml:S3:11201:3	I-Factor
small	POTIGA.xml:S3:11205:5	I-Factor
to	POTIGA.xml:S3:11211:2	O
allow	POTIGA.xml:S3:11214:5	O
any	POTIGA.xml:S3:11220:3	O
conclusion	POTIGA.xml:S3:11224:10	O
about	POTIGA.xml:S3:11235:5	O
drug	POTIGA.xml:S3:11241:4	O
effect	POTIGA.xml:S3:11246:6	O
on	POTIGA.xml:S3:11253:2	O
suicide	POTIGA.xml:S3:11256:7	B-AdverseReaction
.	POTIGA.xml:S3:11263:1	O

The	POTIGA.xml:S3:11269:3	O
increased	POTIGA.xml:S3:11273:9	O
risk	POTIGA.xml:S3:11283:4	O
of	POTIGA.xml:S3:11288:2	O
suicidal	POTIGA.xml:S3:11291:8	B-AdverseReaction
thoughts	POTIGA.xml:S3:11300:8	I-AdverseReaction
or	POTIGA.xml:S3:11309:2	O
behavior	POTIGA.xml:S3:11312:8	I-AdverseReaction
with	POTIGA.xml:S3:11321:4	O
AEDs	POTIGA.xml:S3:11326:4	B-DrugClass
was	POTIGA.xml:S3:11331:3	O
observed	POTIGA.xml:S3:11335:8	O
as	POTIGA.xml:S3:11344:2	O
early	POTIGA.xml:S3:11347:5	O
as	POTIGA.xml:S3:11353:2	O
1	POTIGA.xml:S3:11356:1	O
week	POTIGA.xml:S3:11358:4	O
after	POTIGA.xml:S3:11363:5	O
starting	POTIGA.xml:S3:11369:8	O
treatment	POTIGA.xml:S3:11378:9	O
with	POTIGA.xml:S3:11388:4	O
AEDs	POTIGA.xml:S3:11393:4	O
and	POTIGA.xml:S3:11398:3	O
persisted	POTIGA.xml:S3:11402:9	O
for	POTIGA.xml:S3:11412:3	O
the	POTIGA.xml:S3:11416:3	O
duration	POTIGA.xml:S3:11420:8	O
of	POTIGA.xml:S3:11429:2	O
treatment	POTIGA.xml:S3:11432:9	O
assessed	POTIGA.xml:S3:11442:8	O
.	POTIGA.xml:S3:11450:1	O

Because	POTIGA.xml:S3:11452:7	O
most	POTIGA.xml:S3:11460:4	O
trials	POTIGA.xml:S3:11465:6	O
included	POTIGA.xml:S3:11472:8	O
in	POTIGA.xml:S3:11481:2	O
the	POTIGA.xml:S3:11484:3	O
analysis	POTIGA.xml:S3:11488:8	O
did	POTIGA.xml:S3:11497:3	O
not	POTIGA.xml:S3:11501:3	O
extend	POTIGA.xml:S3:11505:6	O
beyond	POTIGA.xml:S3:11512:6	O
24	POTIGA.xml:S3:11519:2	O
weeks	POTIGA.xml:S3:11522:5	O
,	POTIGA.xml:S3:11527:1	O
the	POTIGA.xml:S3:11529:3	O
risk	POTIGA.xml:S3:11533:4	O
of	POTIGA.xml:S3:11538:2	O
suicidal	POTIGA.xml:S3:11541:8	O
thoughts	POTIGA.xml:S3:11550:8	O
or	POTIGA.xml:S3:11559:2	O
behavior	POTIGA.xml:S3:11562:8	O
beyond	POTIGA.xml:S3:11571:6	O
24	POTIGA.xml:S3:11578:2	O
weeks	POTIGA.xml:S3:11581:5	O
could	POTIGA.xml:S3:11587:5	O
not	POTIGA.xml:S3:11593:3	O
be	POTIGA.xml:S3:11597:2	O
assessed	POTIGA.xml:S3:11600:8	O
.	POTIGA.xml:S3:11608:1	O

The	POTIGA.xml:S3:11614:3	O
risk	POTIGA.xml:S3:11618:4	B-Factor
of	POTIGA.xml:S3:11623:2	O
suicidal	POTIGA.xml:S3:11626:8	B-AdverseReaction
thoughts	POTIGA.xml:S3:11635:8	I-AdverseReaction
or	POTIGA.xml:S3:11644:2	O
behavior	POTIGA.xml:S3:11647:8	I-AdverseReaction
was	POTIGA.xml:S3:11656:3	O
generally	POTIGA.xml:S3:11660:9	O
consistent	POTIGA.xml:S3:11670:10	O
among	POTIGA.xml:S3:11681:5	O
drugs	POTIGA.xml:S3:11687:5	O
in	POTIGA.xml:S3:11693:2	O
the	POTIGA.xml:S3:11696:3	O
data	POTIGA.xml:S3:11700:4	O
analyzed	POTIGA.xml:S3:11705:8	O
.	POTIGA.xml:S3:11713:1	O

The	POTIGA.xml:S3:11715:3	O
finding	POTIGA.xml:S3:11719:7	O
of	POTIGA.xml:S3:11727:2	O
increased	POTIGA.xml:S3:11730:9	O
risk	POTIGA.xml:S3:11740:4	O
with	POTIGA.xml:S3:11745:4	O
AEDs	POTIGA.xml:S3:11750:4	O
of	POTIGA.xml:S3:11755:2	O
varying	POTIGA.xml:S3:11758:7	O
mechanism	POTIGA.xml:S3:11766:9	O
of	POTIGA.xml:S3:11776:2	O
action	POTIGA.xml:S3:11779:6	O
and	POTIGA.xml:S3:11786:3	O
across	POTIGA.xml:S3:11790:6	O
a	POTIGA.xml:S3:11797:1	O
range	POTIGA.xml:S3:11799:5	O
of	POTIGA.xml:S3:11805:2	O
indications	POTIGA.xml:S3:11808:11	O
suggests	POTIGA.xml:S3:11820:8	O
that	POTIGA.xml:S3:11829:4	O
the	POTIGA.xml:S3:11834:3	O
risk	POTIGA.xml:S3:11838:4	O
applies	POTIGA.xml:S3:11843:7	O
to	POTIGA.xml:S3:11851:2	O
all	POTIGA.xml:S3:11854:3	O
AEDs	POTIGA.xml:S3:11858:4	O
used	POTIGA.xml:S3:11863:4	O
for	POTIGA.xml:S3:11868:3	O
any	POTIGA.xml:S3:11872:3	O
indication	POTIGA.xml:S3:11876:10	O
.	POTIGA.xml:S3:11886:1	O

The	POTIGA.xml:S3:11888:3	O
risk	POTIGA.xml:S3:11892:4	O
did	POTIGA.xml:S3:11897:3	O
not	POTIGA.xml:S3:11901:3	O
vary	POTIGA.xml:S3:11905:4	O
substantially	POTIGA.xml:S3:11910:13	O
by	POTIGA.xml:S3:11924:2	O
age	POTIGA.xml:S3:11927:3	O
(	POTIGA.xml:S3:11931:1	O
5	POTIGA.xml:S3:11932:1	O
to	POTIGA.xml:S3:11934:2	O
100	POTIGA.xml:S3:11937:3	O
years	POTIGA.xml:S3:11941:5	O
)	POTIGA.xml:S3:11946:1	O
in	POTIGA.xml:S3:11948:2	O
the	POTIGA.xml:S3:11951:3	O
clinical	POTIGA.xml:S3:11955:8	O
trials	POTIGA.xml:S3:11964:6	O
analyzed	POTIGA.xml:S3:11971:8	O
.	POTIGA.xml:S3:11979:1	O

Table	POTIGA.xml:S3:11985:5	O
3	POTIGA.xml:S3:11991:1	O
shows	POTIGA.xml:S3:11993:5	O
absolute	POTIGA.xml:S3:11999:8	O
and	POTIGA.xml:S3:12008:3	O
relative	POTIGA.xml:S3:12012:8	O
risk	POTIGA.xml:S3:12021:4	O
by	POTIGA.xml:S3:12026:2	O
indication	POTIGA.xml:S3:12029:10	O
for	POTIGA.xml:S3:12040:3	O
all	POTIGA.xml:S3:12044:3	O
evaluated	POTIGA.xml:S3:12048:9	O
AEDs	POTIGA.xml:S3:12058:4	O
.	POTIGA.xml:S3:12062:1	O

Table	POTIGA.xml:S3:12069:5	O
3	POTIGA.xml:S3:12075:1	O
.	POTIGA.xml:S3:12076:1	O

Risk	POTIGA.xml:S3:12078:4	B-Factor
of	POTIGA.xml:S3:12083:2	O
Suicidal	POTIGA.xml:S3:12086:8	B-AdverseReaction
Thoughts	POTIGA.xml:S3:12095:8	I-AdverseReaction
or	POTIGA.xml:S3:12104:2	O
Behaviors	POTIGA.xml:S3:12107:9	I-AdverseReaction
by	POTIGA.xml:S3:12117:2	O
Indication	POTIGA.xml:S3:12120:10	O
for	POTIGA.xml:S3:12131:3	O
Antiepileptic	POTIGA.xml:S3:12135:13	O
Drugs	POTIGA.xml:S3:12149:5	O
in	POTIGA.xml:S3:12155:2	O
the	POTIGA.xml:S3:12158:3	O
Pooled	POTIGA.xml:S3:12162:6	O
Analysis	POTIGA.xml:S3:12169:8	O

Indication	POTIGA.xml:S3:12186:10	O
Placebo	POTIGA.xml:S3:12200:7	O
Patients	POTIGA.xml:S3:12208:8	O
with	POTIGA.xml:S3:12217:4	O
Events	POTIGA.xml:S3:12222:6	O
per	POTIGA.xml:S3:12229:3	O
1	POTIGA.xml:S3:12233:1	O
,	POTIGA.xml:S3:12234:1	O
000	POTIGA.xml:S3:12235:3	O
Patients	POTIGA.xml:S3:12239:8	O
Drug	POTIGA.xml:S3:12251:4	O
Patients	POTIGA.xml:S3:12256:8	O
with	POTIGA.xml:S3:12265:4	O
Events	POTIGA.xml:S3:12270:6	O
per	POTIGA.xml:S3:12277:3	O
1	POTIGA.xml:S3:12281:1	O
,	POTIGA.xml:S3:12282:1	O
000	POTIGA.xml:S3:12283:3	O
Patients	POTIGA.xml:S3:12287:8	O
Relative	POTIGA.xml:S3:12299:8	O
Risk	POTIGA.xml:S3:12308:4	O
:	POTIGA.xml:S3:12312:1	O
Incidence	POTIGA.xml:S3:12314:9	O
of	POTIGA.xml:S3:12324:2	O
Events	POTIGA.xml:S3:12327:6	O
in	POTIGA.xml:S3:12334:2	O
Drug	POTIGA.xml:S3:12337:4	O
Patients	POTIGA.xml:S3:12342:8	O
Incidence	POTIGA.xml:S3:12351:9	O
in	POTIGA.xml:S3:12361:2	O
Placebo	POTIGA.xml:S3:12364:7	O
Patients	POTIGA.xml:S3:12372:8	O
Risk	POTIGA.xml:S3:12384:4	O
Difference	POTIGA.xml:S3:12389:10	O
:	POTIGA.xml:S3:12399:1	O
Additional	POTIGA.xml:S3:12401:10	O
Drug	POTIGA.xml:S3:12412:4	O
Patients	POTIGA.xml:S3:12417:8	O
with	POTIGA.xml:S3:12426:4	O
Events	POTIGA.xml:S3:12431:6	O
per	POTIGA.xml:S3:12438:3	O
1	POTIGA.xml:S3:12442:1	O
,	POTIGA.xml:S3:12443:1	O
000	POTIGA.xml:S3:12444:3	O
Patients	POTIGA.xml:S3:12448:8	O

Epilepsy	POTIGA.xml:S3:12463:8	O
1.0	POTIGA.xml:S3:12476:3	O
3.4	POTIGA.xml:S3:12495:3	O
3.5	POTIGA.xml:S3:12514:3	O
2.4	POTIGA.xml:S3:12547:3	O

Psychiatric	POTIGA.xml:S3:12577:11	O
5.7	POTIGA.xml:S3:12592:3	O
8.5	POTIGA.xml:S3:12611:3	O
1.5	POTIGA.xml:S3:12630:3	O
2.9	POTIGA.xml:S3:12663:3	O

Other	POTIGA.xml:S3:12693:5	O
1.0	POTIGA.xml:S3:12706:3	O
1.8	POTIGA.xml:S3:12725:3	O
1.9	POTIGA.xml:S3:12744:3	O
0.9	POTIGA.xml:S3:12777:3	O

Total	POTIGA.xml:S3:12807:5	O
2.4	POTIGA.xml:S3:12820:3	O
4.3	POTIGA.xml:S3:12839:3	O
1.8	POTIGA.xml:S3:12858:3	O
1.9	POTIGA.xml:S3:12891:3	O

The	POTIGA.xml:S3:12930:3	O
relative	POTIGA.xml:S3:12934:8	O
risk	POTIGA.xml:S3:12943:4	B-Factor
for	POTIGA.xml:S3:12948:3	O
suicidal	POTIGA.xml:S3:12952:8	B-AdverseReaction
thoughts	POTIGA.xml:S3:12961:8	I-AdverseReaction
or	POTIGA.xml:S3:12970:2	O
behavior	POTIGA.xml:S3:12973:8	I-AdverseReaction
was	POTIGA.xml:S3:12982:3	O
higher	POTIGA.xml:S3:12986:6	O
in	POTIGA.xml:S3:12993:2	O
clinical	POTIGA.xml:S3:12996:8	O
trials	POTIGA.xml:S3:13005:6	O
in	POTIGA.xml:S3:13012:2	O
patients	POTIGA.xml:S3:13015:8	O
with	POTIGA.xml:S3:13024:4	O
epilepsy	POTIGA.xml:S3:13029:8	O
than	POTIGA.xml:S3:13038:4	O
in	POTIGA.xml:S3:13043:2	O
clinical	POTIGA.xml:S3:13046:8	O
trials	POTIGA.xml:S3:13055:6	O
in	POTIGA.xml:S3:13062:2	O
patients	POTIGA.xml:S3:13065:8	O
with	POTIGA.xml:S3:13074:4	O
psychiatric	POTIGA.xml:S3:13079:11	O
or	POTIGA.xml:S3:13091:2	O
other	POTIGA.xml:S3:13094:5	O
conditions	POTIGA.xml:S3:13100:10	O
,	POTIGA.xml:S3:13110:1	O
but	POTIGA.xml:S3:13112:3	O
the	POTIGA.xml:S3:13116:3	O
absolute	POTIGA.xml:S3:13120:8	O
risk	POTIGA.xml:S3:13129:4	O
differences	POTIGA.xml:S3:13134:11	O
were	POTIGA.xml:S3:13146:4	O
similar	POTIGA.xml:S3:13151:7	O
for	POTIGA.xml:S3:13159:3	O
epilepsy	POTIGA.xml:S3:13163:8	O
and	POTIGA.xml:S3:13172:3	O
psychiatric	POTIGA.xml:S3:13176:11	O
indications	POTIGA.xml:S3:13188:11	O
.	POTIGA.xml:S3:13199:1	O

Anyone	POTIGA.xml:S3:13205:6	O

considering	POTIGA.xml:S3:13212:11	O
prescribing	POTIGA.xml:S3:13224:11	O
POTIGA	POTIGA.xml:S3:13236:6	O
or	POTIGA.xml:S3:13243:2	O
any	POTIGA.xml:S3:13246:3	O
other	POTIGA.xml:S3:13250:5	O
AED	POTIGA.xml:S3:13256:3	O
must	POTIGA.xml:S3:13260:4	O
balance	POTIGA.xml:S3:13265:7	O
this	POTIGA.xml:S3:13273:4	O
risk	POTIGA.xml:S3:13278:4	O
with	POTIGA.xml:S3:13283:4	O
the	POTIGA.xml:S3:13288:3	O
risk	POTIGA.xml:S3:13292:4	O
of	POTIGA.xml:S3:13297:2	O
untreated	POTIGA.xml:S3:13300:9	O
illness	POTIGA.xml:S3:13310:7	O
.	POTIGA.xml:S3:13317:1	O

Epilepsy	POTIGA.xml:S3:13319:8	O
and	POTIGA.xml:S3:13328:3	O
many	POTIGA.xml:S3:13332:4	O
other	POTIGA.xml:S3:13337:5	O
illnesses	POTIGA.xml:S3:13343:9	O
for	POTIGA.xml:S3:13353:3	O
which	POTIGA.xml:S3:13357:5	O
AEDs	POTIGA.xml:S3:13363:4	O
are	POTIGA.xml:S3:13368:3	O
prescribed	POTIGA.xml:S3:13372:10	O
are	POTIGA.xml:S3:13383:3	O
themselves	POTIGA.xml:S3:13387:10	O
associated	POTIGA.xml:S3:13398:10	O
with	POTIGA.xml:S3:13409:4	O
morbidity	POTIGA.xml:S3:13414:9	O
and	POTIGA.xml:S3:13424:3	O
mortality	POTIGA.xml:S3:13428:9	O
and	POTIGA.xml:S3:13438:3	O
an	POTIGA.xml:S3:13442:2	O
increased	POTIGA.xml:S3:13445:9	O
risk	POTIGA.xml:S3:13455:4	O
of	POTIGA.xml:S3:13460:2	O
suicidal	POTIGA.xml:S3:13463:8	O
thoughts	POTIGA.xml:S3:13472:8	O
and	POTIGA.xml:S3:13481:3	O
behavior	POTIGA.xml:S3:13485:8	O
.	POTIGA.xml:S3:13493:1	O

Should	POTIGA.xml:S3:13495:6	O
suicidal	POTIGA.xml:S3:13502:8	O
thoughts	POTIGA.xml:S3:13511:8	O
and	POTIGA.xml:S3:13520:3	O
behavior	POTIGA.xml:S3:13524:8	O
emerge	POTIGA.xml:S3:13533:6	O
during	POTIGA.xml:S3:13540:6	O
treatment	POTIGA.xml:S3:13547:9	O
,	POTIGA.xml:S3:13556:1	O
the	POTIGA.xml:S3:13558:3	O
prescriber	POTIGA.xml:S3:13562:10	O
needs	POTIGA.xml:S3:13573:5	O
to	POTIGA.xml:S3:13579:2	O
consider	POTIGA.xml:S3:13582:8	O
whether	POTIGA.xml:S3:13591:7	O
the	POTIGA.xml:S3:13599:3	O
emergence	POTIGA.xml:S3:13603:9	O
of	POTIGA.xml:S3:13613:2	O
these	POTIGA.xml:S3:13616:5	O
symptoms	POTIGA.xml:S3:13622:8	O
in	POTIGA.xml:S3:13631:2	O
any	POTIGA.xml:S3:13634:3	O
given	POTIGA.xml:S3:13638:5	O
patient	POTIGA.xml:S3:13644:7	O
may	POTIGA.xml:S3:13652:3	O
be	POTIGA.xml:S3:13656:2	O
related	POTIGA.xml:S3:13659:7	O
to	POTIGA.xml:S3:13667:2	O
the	POTIGA.xml:S3:13670:3	O
illness	POTIGA.xml:S3:13674:7	O
being	POTIGA.xml:S3:13682:5	O
treated	POTIGA.xml:S3:13688:7	O
.	POTIGA.xml:S3:13695:1	O

Patients	POTIGA.xml:S3:13701:8	O
,	POTIGA.xml:S3:13709:1	O
their	POTIGA.xml:S3:13711:5	O
caregivers	POTIGA.xml:S3:13717:10	O
,	POTIGA.xml:S3:13727:1	O
and	POTIGA.xml:S3:13729:3	O
families	POTIGA.xml:S3:13733:8	O
should	POTIGA.xml:S3:13742:6	O
be	POTIGA.xml:S3:13749:2	O
informed	POTIGA.xml:S3:13752:8	O
that	POTIGA.xml:S3:13761:4	O
AEDs	POTIGA.xml:S3:13766:4	O
increase	POTIGA.xml:S3:13771:8	O
the	POTIGA.xml:S3:13780:3	O
risk	POTIGA.xml:S3:13784:4	O
of	POTIGA.xml:S3:13789:2	O
suicidal	POTIGA.xml:S3:13792:8	O
thoughts	POTIGA.xml:S3:13801:8	O
and	POTIGA.xml:S3:13810:3	O
behavior	POTIGA.xml:S3:13814:8	O
and	POTIGA.xml:S3:13823:3	O
should	POTIGA.xml:S3:13827:6	O
be	POTIGA.xml:S3:13834:2	O
advised	POTIGA.xml:S3:13837:7	O
of	POTIGA.xml:S3:13845:2	O
the	POTIGA.xml:S3:13848:3	O
need	POTIGA.xml:S3:13852:4	O
to	POTIGA.xml:S3:13857:2	O
be	POTIGA.xml:S3:13860:2	O
alert	POTIGA.xml:S3:13863:5	O
for	POTIGA.xml:S3:13869:3	O
the	POTIGA.xml:S3:13873:3	O
emergence	POTIGA.xml:S3:13877:9	O
or	POTIGA.xml:S3:13887:2	O
worsening	POTIGA.xml:S3:13890:9	O
of	POTIGA.xml:S3:13900:2	O
the	POTIGA.xml:S3:13903:3	O
signs	POTIGA.xml:S3:13907:5	O
and	POTIGA.xml:S3:13913:3	O
symptoms	POTIGA.xml:S3:13917:8	O
of	POTIGA.xml:S3:13926:2	O
depression	POTIGA.xml:S3:13929:10	O
;	POTIGA.xml:S3:13939:1	O
any	POTIGA.xml:S3:13941:3	O
unusual	POTIGA.xml:S3:13945:7	O
changes	POTIGA.xml:S3:13953:7	O
in	POTIGA.xml:S3:13961:2	O
mood	POTIGA.xml:S3:13964:4	O
or	POTIGA.xml:S3:13969:2	O
behavior	POTIGA.xml:S3:13972:8	O
;	POTIGA.xml:S3:13980:1	O
or	POTIGA.xml:S3:13982:2	O
the	POTIGA.xml:S3:13985:3	O
emergence	POTIGA.xml:S3:13989:9	O
of	POTIGA.xml:S3:13999:2	O
suicidal	POTIGA.xml:S3:14002:8	O
thoughts	POTIGA.xml:S3:14011:8	O
,	POTIGA.xml:S3:14019:1	O
behavior	POTIGA.xml:S3:14021:8	O
,	POTIGA.xml:S3:14029:1	O
or	POTIGA.xml:S3:14031:2	O
thoughts	POTIGA.xml:S3:14034:8	O
about	POTIGA.xml:S3:14043:5	O
self	POTIGA.xml:S3:14049:4	O
-	POTIGA.xml:S3:14053:1	O
harm	POTIGA.xml:S3:14054:4	O
.	POTIGA.xml:S3:14058:1	O

Behaviors	POTIGA.xml:S3:14060:9	O
of	POTIGA.xml:S3:14070:2	O
concern	POTIGA.xml:S3:14073:7	O
should	POTIGA.xml:S3:14081:6	O
be	POTIGA.xml:S3:14088:2	O
reported	POTIGA.xml:S3:14091:8	O
immediately	POTIGA.xml:S3:14100:11	O
to	POTIGA.xml:S3:14112:2	O
healthcare	POTIGA.xml:S3:14115:10	O
providers	POTIGA.xml:S3:14126:9	O
.	POTIGA.xml:S3:14135:1	O

5.8	POTIGA.xml:S3:14144:3	O
Withdrawal	POTIGA.xml:S3:14148:10	O
Seizures	POTIGA.xml:S3:14159:8	O

As	POTIGA.xml:S3:14173:2	O
with	POTIGA.xml:S3:14176:4	O
all	POTIGA.xml:S3:14181:3	O
AEDs	POTIGA.xml:S3:14185:4	O
,	POTIGA.xml:S3:14189:1	O
when	POTIGA.xml:S3:14191:4	O
POTIGA	POTIGA.xml:S3:14196:6	O
is	POTIGA.xml:S3:14203:2	O
discontinued	POTIGA.xml:S3:14206:12	O
,	POTIGA.xml:S3:14218:1	O
it	POTIGA.xml:S3:14220:2	O
should	POTIGA.xml:S3:14223:6	O
be	POTIGA.xml:S3:14230:2	O
withdrawn	POTIGA.xml:S3:14233:9	O
gradually	POTIGA.xml:S3:14243:9	O
when	POTIGA.xml:S3:14253:4	O
possible	POTIGA.xml:S3:14258:8	O
to	POTIGA.xml:S3:14267:2	O
minimize	POTIGA.xml:S3:14270:8	O
the	POTIGA.xml:S3:14279:3	O
potential	POTIGA.xml:S3:14283:9	O
of	POTIGA.xml:S3:14293:2	O
increased	POTIGA.xml:S3:14296:9	O
seizure	POTIGA.xml:S3:14306:7	O
frequency	POTIGA.xml:S3:14314:9	O
[	POTIGA.xml:S3:14324:1	O
see	POTIGA.xml:S3:14325:3	O
Dosage	POTIGA.xml:S3:14329:6	O
and	POTIGA.xml:S3:14336:3	O
Administration	POTIGA.xml:S3:14340:14	O
(	POTIGA.xml:S3:14355:1	O
2.1	POTIGA.xml:S3:14356:3	O
)]	POTIGA.xml:S3:14359:2	O
.	POTIGA.xml:S3:14363:1	O

The	POTIGA.xml:S3:14365:3	O
dosage	POTIGA.xml:S3:14369:6	O
of	POTIGA.xml:S3:14376:2	O
POTIGA	POTIGA.xml:S3:14379:6	O
should	POTIGA.xml:S3:14386:6	O
be	POTIGA.xml:S3:14393:2	O
reduced	POTIGA.xml:S3:14396:7	O
over	POTIGA.xml:S3:14404:4	O
a	POTIGA.xml:S3:14409:1	O
period	POTIGA.xml:S3:14411:6	O
of	POTIGA.xml:S3:14418:2	O
at	POTIGA.xml:S3:14421:2	O
least	POTIGA.xml:S3:14424:5	O
3	POTIGA.xml:S3:14430:1	O
weeks	POTIGA.xml:S3:14432:5	O
,	POTIGA.xml:S3:14437:1	O
unless	POTIGA.xml:S3:14439:6	O
safety	POTIGA.xml:S3:14446:6	O
concerns	POTIGA.xml:S3:14453:8	O
require	POTIGA.xml:S3:14462:7	O
abrupt	POTIGA.xml:S3:14470:6	O
withdrawal	POTIGA.xml:S3:14477:10	O
.	POTIGA.xml:S3:14487:1	O
6	PRADAXA.xml:S1:4:1	O
ADVERSE	PRADAXA.xml:S1:7:7	O
REACTIONS	PRADAXA.xml:S1:15:9	O

The	PRADAXA.xml:S1:28:3	O
most	PRADAXA.xml:S1:32:4	O
serious	PRADAXA.xml:S1:37:7	O
adverse	PRADAXA.xml:S1:45:7	O
reactions	PRADAXA.xml:S1:53:9	O
reported	PRADAXA.xml:S1:63:8	O
with	PRADAXA.xml:S1:72:4	O
PRADAXA	PRADAXA.xml:S1:77:7	O
were	PRADAXA.xml:S1:85:4	O
related	PRADAXA.xml:S1:90:7	O
to	PRADAXA.xml:S1:98:2	O
bleeding	PRADAXA.xml:S1:101:8	B-AdverseReaction
[	PRADAXA.xml:S1:111:1	O
see	PRADAXA.xml:S1:112:3	O
Warnings	PRADAXA.xml:S1:116:8	O
and	PRADAXA.xml:S1:125:3	O
Precautions	PRADAXA.xml:S1:129:11	O
(	PRADAXA.xml:S1:142:1	O
5.2	PRADAXA.xml:S1:143:3	O
)	PRADAXA.xml:S1:146:1	O
]	PRADAXA.xml:S1:149:1	O
.	PRADAXA.xml:S1:152:1	O

EXCERPT	PRADAXA.xml:S1:160:7	O
:	PRADAXA.xml:S1:167:1	O
Most	PRADAXA.xml:S1:171:4	O
common	PRADAXA.xml:S1:176:6	O
adverse	PRADAXA.xml:S1:183:7	O
reactions	PRADAXA.xml:S1:191:9	O
(	PRADAXA.xml:S1:201:1	O
15%	PRADAXA.xml:S1:203:3	O
)	PRADAXA.xml:S1:206:1	O
are	PRADAXA.xml:S1:208:3	O
gastritis	PRADAXA.xml:S1:212:9	B-AdverseReaction
-	PRADAXA.xml:S1:221:1	O
like	PRADAXA.xml:S1:222:4	O
symptoms	PRADAXA.xml:S1:227:8	O
and	PRADAXA.xml:S1:236:3	O
bleeding	PRADAXA.xml:S1:240:8	B-AdverseReaction
(	PRADAXA.xml:S1:250:1	O
6.1	PRADAXA.xml:S1:251:3	O
)	PRADAXA.xml:S1:254:1	O

To	PRADAXA.xml:S1:266:2	O
report	PRADAXA.xml:S1:269:6	O
SUSPECTED	PRADAXA.xml:S1:276:9	O
ADVERSE	PRADAXA.xml:S1:286:7	O
REACTIONS	PRADAXA.xml:S1:294:9	O
,	PRADAXA.xml:S1:303:1	O
contact	PRADAXA.xml:S1:305:7	O
Boehringer	PRADAXA.xml:S1:313:10	O
Ingelheim	PRADAXA.xml:S1:324:9	O
Pharmaceuticals	PRADAXA.xml:S1:334:15	O
,	PRADAXA.xml:S1:349:1	O
Inc	PRADAXA.xml:S1:351:3	O
.	PRADAXA.xml:S1:354:1	O

at	PRADAXA.xml:S1:356:2	O
(	PRADAXA.xml:S1:359:1	O
800	PRADAXA.xml:S1:360:3	O
)	PRADAXA.xml:S1:363:1	O
542	PRADAXA.xml:S1:365:3	O
-	PRADAXA.xml:S1:368:1	O
6257	PRADAXA.xml:S1:369:4	O
or	PRADAXA.xml:S1:374:2	O
(	PRADAXA.xml:S1:377:1	O
800	PRADAXA.xml:S1:378:3	O
)	PRADAXA.xml:S1:381:1	O
459	PRADAXA.xml:S1:383:3	O
-	PRADAXA.xml:S1:386:1	O
9906	PRADAXA.xml:S1:387:4	O
TTY	PRADAXA.xml:S1:392:3	O
or	PRADAXA.xml:S1:396:2	O
FDA	PRADAXA.xml:S1:399:3	O
at	PRADAXA.xml:S1:403:2	O
1	PRADAXA.xml:S1:406:1	O
-	PRADAXA.xml:S1:407:1	O
800	PRADAXA.xml:S1:408:3	O
-	PRADAXA.xml:S1:411:1	O
FDA	PRADAXA.xml:S1:412:3	O
-	PRADAXA.xml:S1:415:1	O
1088	PRADAXA.xml:S1:416:4	O
or	PRADAXA.xml:S1:421:2	O
www	PRADAXA.xml:S1:431:3	O
.	PRADAXA.xml:S1:434:1	O
fda	PRADAXA.xml:S1:435:3	O
.	PRADAXA.xml:S1:438:1	O
gov	PRADAXA.xml:S1:439:3	O
medwatch	PRADAXA.xml:S1:443:8	O
.	PRADAXA.xml:S1:455:1	O

6.1	PRADAXA.xml:S1:465:3	O

Clinical	PRADAXA.xml:S1:469:8	O
Trials	PRADAXA.xml:S1:478:6	O
Experience	PRADAXA.xml:S1:485:10	O

Because	PRADAXA.xml:S1:499:7	O
clinical	PRADAXA.xml:S1:507:8	O
trials	PRADAXA.xml:S1:516:6	O
are	PRADAXA.xml:S1:523:3	O
conducted	PRADAXA.xml:S1:527:9	O
under	PRADAXA.xml:S1:537:5	O
widely	PRADAXA.xml:S1:543:6	O
varying	PRADAXA.xml:S1:550:7	O
conditions	PRADAXA.xml:S1:558:10	O
,	PRADAXA.xml:S1:568:1	O
adverse	PRADAXA.xml:S1:570:7	O
reactions	PRADAXA.xml:S1:578:9	O
rates	PRADAXA.xml:S1:588:5	O
observed	PRADAXA.xml:S1:594:8	O
in	PRADAXA.xml:S1:603:2	O
the	PRADAXA.xml:S1:606:3	O
clinical	PRADAXA.xml:S1:610:8	O
trials	PRADAXA.xml:S1:619:6	O
of	PRADAXA.xml:S1:626:2	O
a	PRADAXA.xml:S1:629:1	O
drug	PRADAXA.xml:S1:631:4	O
cannot	PRADAXA.xml:S1:636:6	O
be	PRADAXA.xml:S1:643:2	O
directly	PRADAXA.xml:S1:646:8	O
compared	PRADAXA.xml:S1:655:8	O
to	PRADAXA.xml:S1:664:2	O
rates	PRADAXA.xml:S1:667:5	O
in	PRADAXA.xml:S1:673:2	O
the	PRADAXA.xml:S1:676:3	O
clinical	PRADAXA.xml:S1:680:8	O
trials	PRADAXA.xml:S1:689:6	O
of	PRADAXA.xml:S1:696:2	O
another	PRADAXA.xml:S1:699:7	O
drug	PRADAXA.xml:S1:707:4	O
and	PRADAXA.xml:S1:712:3	O
may	PRADAXA.xml:S1:716:3	O
not	PRADAXA.xml:S1:720:3	O
reflect	PRADAXA.xml:S1:724:7	O
the	PRADAXA.xml:S1:732:3	O
rates	PRADAXA.xml:S1:736:5	O
observed	PRADAXA.xml:S1:742:8	O
in	PRADAXA.xml:S1:751:2	O
practice	PRADAXA.xml:S1:754:8	O
.	PRADAXA.xml:S1:762:1	O

Reduction	PRADAXA.xml:S1:772:9	O
of	PRADAXA.xml:S1:782:2	O
Risk	PRADAXA.xml:S1:785:4	O
of	PRADAXA.xml:S1:790:2	O
Stroke	PRADAXA.xml:S1:793:6	O
and	PRADAXA.xml:S1:800:3	O
Systemic	PRADAXA.xml:S1:804:8	O
Embolism	PRADAXA.xml:S1:813:8	O
in	PRADAXA.xml:S1:822:2	O
Non	PRADAXA.xml:S1:825:3	O
-	PRADAXA.xml:S1:828:1	O
valvular	PRADAXA.xml:S1:829:8	O
Atrial	PRADAXA.xml:S1:838:6	O
Fibrillation	PRADAXA.xml:S1:845:12	O

The	PRADAXA.xml:S1:866:3	O
RE	PRADAXA.xml:S1:870:2	O
-	PRADAXA.xml:S1:872:1	O
LY	PRADAXA.xml:S1:873:2	O
(	PRADAXA.xml:S1:876:1	O
Randomized	PRADAXA.xml:S1:877:10	O
Evaluation	PRADAXA.xml:S1:888:10	O
of	PRADAXA.xml:S1:899:2	O
Long	PRADAXA.xml:S1:902:4	O
-	PRADAXA.xml:S1:906:1	O
term	PRADAXA.xml:S1:907:4	O
Anticoagulant	PRADAXA.xml:S1:912:13	O
Therapy	PRADAXA.xml:S1:926:7	O
)	PRADAXA.xml:S1:933:1	O
study	PRADAXA.xml:S1:935:5	O
provided	PRADAXA.xml:S1:941:8	O
safety	PRADAXA.xml:S1:950:6	O
information	PRADAXA.xml:S1:957:11	O
on	PRADAXA.xml:S1:969:2	O
the	PRADAXA.xml:S1:972:3	O
use	PRADAXA.xml:S1:976:3	O
of	PRADAXA.xml:S1:980:2	O
two	PRADAXA.xml:S1:983:3	O
doses	PRADAXA.xml:S1:987:5	O
of	PRADAXA.xml:S1:993:2	O
PRADAXA	PRADAXA.xml:S1:996:7	O
and	PRADAXA.xml:S1:1004:3	O
warfarin	PRADAXA.xml:S1:1008:8	O
[	PRADAXA.xml:S1:1018:1	O
see	PRADAXA.xml:S1:1019:3	O
Clinical	PRADAXA.xml:S1:1023:8	O
Studies	PRADAXA.xml:S1:1032:7	O
(	PRADAXA.xml:S1:1041:1	O
14.1	PRADAXA.xml:S1:1042:4	O
)	PRADAXA.xml:S1:1046:1	O
]	PRADAXA.xml:S1:1049:1	O
.	PRADAXA.xml:S1:1052:1	O

The	PRADAXA.xml:S1:1054:3	O
numbers	PRADAXA.xml:S1:1058:7	O
of	PRADAXA.xml:S1:1066:2	O
patients	PRADAXA.xml:S1:1069:8	O
and	PRADAXA.xml:S1:1078:3	O
their	PRADAXA.xml:S1:1082:5	O
exposures	PRADAXA.xml:S1:1088:9	O
are	PRADAXA.xml:S1:1098:3	O
described	PRADAXA.xml:S1:1102:9	O
in	PRADAXA.xml:S1:1112:2	O
Table	PRADAXA.xml:S1:1115:5	O
1	PRADAXA.xml:S1:1121:1	O
.	PRADAXA.xml:S1:1122:1	O

Limited	PRADAXA.xml:S1:1124:7	O
information	PRADAXA.xml:S1:1132:11	O
is	PRADAXA.xml:S1:1144:2	O
presented	PRADAXA.xml:S1:1147:9	O
on	PRADAXA.xml:S1:1157:2	O
the	PRADAXA.xml:S1:1160:3	O
110	PRADAXA.xml:S1:1164:3	O
mg	PRADAXA.xml:S1:1168:2	O
dosing	PRADAXA.xml:S1:1171:6	O
arm	PRADAXA.xml:S1:1178:3	O
because	PRADAXA.xml:S1:1182:7	O
this	PRADAXA.xml:S1:1190:4	O
dose	PRADAXA.xml:S1:1195:4	O
is	PRADAXA.xml:S1:1200:2	O
not	PRADAXA.xml:S1:1203:3	O
approved	PRADAXA.xml:S1:1207:8	O
.	PRADAXA.xml:S1:1215:1	O

Table	PRADAXA.xml:S1:1221:5	O
1	PRADAXA.xml:S1:1227:1	O
Summary	PRADAXA.xml:S1:1229:7	O
of	PRADAXA.xml:S1:1237:2	O
Treatment	PRADAXA.xml:S1:1240:9	O
Exposure	PRADAXA.xml:S1:1250:8	O
in	PRADAXA.xml:S1:1259:2	O
RE	PRADAXA.xml:S1:1262:2	O
-	PRADAXA.xml:S1:1264:1	O
LY	PRADAXA.xml:S1:1265:2	O

PRADAXA	PRADAXA.xml:S1:1283:7	O
110	PRADAXA.xml:S1:1291:3	O
mg	PRADAXA.xml:S1:1295:2	O
twice	PRADAXA.xml:S1:1298:5	O
daily	PRADAXA.xml:S1:1304:5	O
PRADAXA	PRADAXA.xml:S1:1319:7	O
150	PRADAXA.xml:S1:1327:3	O
mg	PRADAXA.xml:S1:1331:2	O
twice	PRADAXA.xml:S1:1334:5	O
daily	PRADAXA.xml:S1:1340:5	O
Warfarin	PRADAXA.xml:S1:1359:8	O

Total	PRADAXA.xml:S1:1381:5	O
number	PRADAXA.xml:S1:1387:6	O
treated	PRADAXA.xml:S1:1394:7	O
5983	PRADAXA.xml:S1:1403:4	O
6059	PRADAXA.xml:S1:1430:4	O
5998	PRADAXA.xml:S1:1457:4	O

Exposure	PRADAXA.xml:S1:1477:8	O

12	PRADAXA.xml:S1:1572:2	O
months	PRADAXA.xml:S1:1575:6	O
4936	PRADAXA.xml:S1:1597:4	O
4939	PRADAXA.xml:S1:1624:4	O
5193	PRADAXA.xml:S1:1651:4	O

24	PRADAXA.xml:S1:1682:2	O
months	PRADAXA.xml:S1:1685:6	O
2387	PRADAXA.xml:S1:1707:4	O
2405	PRADAXA.xml:S1:1734:4	O
2470	PRADAXA.xml:S1:1761:4	O

Mean	PRADAXA.xml:S1:1781:4	O
exposure	PRADAXA.xml:S1:1786:8	O
(	PRADAXA.xml:S1:1795:1	O
months	PRADAXA.xml:S1:1796:6	O
)	PRADAXA.xml:S1:1802:1	O
20.5	PRADAXA.xml:S1:1805:4	O
20.3	PRADAXA.xml:S1:1832:4	O
21.3	PRADAXA.xml:S1:1859:4	O

Total	PRADAXA.xml:S1:1879:5	O
patient	PRADAXA.xml:S1:1885:7	O
-	PRADAXA.xml:S1:1892:1	O
years	PRADAXA.xml:S1:1893:5	O
10	PRADAXA.xml:S1:1900:2	O
,	PRADAXA.xml:S1:1902:1	O
242	PRADAXA.xml:S1:1903:3	O
10	PRADAXA.xml:S1:1926:2	O
,	PRADAXA.xml:S1:1928:1	O
261	PRADAXA.xml:S1:1929:3	O
10	PRADAXA.xml:S1:1953:2	O
,	PRADAXA.xml:S1:1955:1	O
659	PRADAXA.xml:S1:1956:3	O

Drug	PRADAXA.xml:S1:1991:4	O

Discontinuation	PRADAXA.xml:S1:1996:15	O
in	PRADAXA.xml:S1:2012:2	O
RE	PRADAXA.xml:S1:2015:2	O
-	PRADAXA.xml:S1:2017:1	O
LY	PRADAXA.xml:S1:2018:2	O

The	PRADAXA.xml:S1:2031:3	O
rates	PRADAXA.xml:S1:2035:5	O
of	PRADAXA.xml:S1:2041:2	O
adverse	PRADAXA.xml:S1:2044:7	O
reactions	PRADAXA.xml:S1:2052:9	O
leading	PRADAXA.xml:S1:2062:7	O
to	PRADAXA.xml:S1:2070:2	O
treatment	PRADAXA.xml:S1:2073:9	O
discontinuation	PRADAXA.xml:S1:2083:15	O
were	PRADAXA.xml:S1:2099:4	O
21%	PRADAXA.xml:S1:2104:3	O
for	PRADAXA.xml:S1:2108:3	O
PRADAXA	PRADAXA.xml:S1:2112:7	O
150	PRADAXA.xml:S1:2120:3	O
mg	PRADAXA.xml:S1:2124:2	O
and	PRADAXA.xml:S1:2127:3	O
16%	PRADAXA.xml:S1:2131:3	O
for	PRADAXA.xml:S1:2135:3	O
warfarin	PRADAXA.xml:S1:2139:8	O
.	PRADAXA.xml:S1:2147:1	O

The	PRADAXA.xml:S1:2149:3	O
most	PRADAXA.xml:S1:2153:4	O
frequent	PRADAXA.xml:S1:2158:8	O
adverse	PRADAXA.xml:S1:2167:7	O
reactions	PRADAXA.xml:S1:2175:9	O
leading	PRADAXA.xml:S1:2185:7	O
to	PRADAXA.xml:S1:2193:2	O
discontinuation	PRADAXA.xml:S1:2196:15	O
of	PRADAXA.xml:S1:2212:2	O
PRADAXA	PRADAXA.xml:S1:2215:7	O
were	PRADAXA.xml:S1:2223:4	O
bleeding	PRADAXA.xml:S1:2228:8	B-AdverseReaction
and	PRADAXA.xml:S1:2237:3	O
gastrointestinal	PRADAXA.xml:S1:2241:16	B-AdverseReaction
events	PRADAXA.xml:S1:2258:6	I-AdverseReaction
(	PRADAXA.xml:S1:2265:1	O
i	PRADAXA.xml:S1:2266:1	O
.	PRADAXA.xml:S1:2267:1	O
e	PRADAXA.xml:S1:2268:1	O
.	PRADAXA.xml:S1:2269:1	O
,	PRADAXA.xml:S1:2270:1	O
dyspepsia	PRADAXA.xml:S1:2272:9	B-AdverseReaction
,	PRADAXA.xml:S1:2281:1	O
nausea	PRADAXA.xml:S1:2283:6	B-AdverseReaction
,	PRADAXA.xml:S1:2289:1	O
upper	PRADAXA.xml:S1:2291:5	B-AdverseReaction
abdominal	PRADAXA.xml:S1:2297:9	I-AdverseReaction
pain	PRADAXA.xml:S1:2307:4	I-AdverseReaction
,	PRADAXA.xml:S1:2311:1	O
gastrointestinal	PRADAXA.xml:S1:2313:16	B-AdverseReaction
hemorrhage	PRADAXA.xml:S1:2330:10	I-AdverseReaction
,	PRADAXA.xml:S1:2340:1	O
and	PRADAXA.xml:S1:2342:3	O
diarrhea	PRADAXA.xml:S1:2346:8	B-AdverseReaction
)	PRADAXA.xml:S1:2354:1	O
.	PRADAXA.xml:S1:2355:1	O

Bleeding	PRADAXA.xml:S1:2373:8	O

[	PRADAXA.xml:S1:2391:1	O
see	PRADAXA.xml:S1:2392:3	O
Warnings	PRADAXA.xml:S1:2396:8	O
and	PRADAXA.xml:S1:2405:3	O
Precautions	PRADAXA.xml:S1:2409:11	O
(	PRADAXA.xml:S1:2422:1	O
5.2	PRADAXA.xml:S1:2423:3	O
)	PRADAXA.xml:S1:2426:1	O
]	PRADAXA.xml:S1:2429:1	O

Table	PRADAXA.xml:S1:2439:5	O
2	PRADAXA.xml:S1:2445:1	O
shows	PRADAXA.xml:S1:2447:5	O
the	PRADAXA.xml:S1:2453:3	O
number	PRADAXA.xml:S1:2457:6	O
of	PRADAXA.xml:S1:2464:2	O
adjudicated	PRADAXA.xml:S1:2467:11	O
major	PRADAXA.xml:S1:2479:5	B-Severity
bleeding	PRADAXA.xml:S1:2485:8	B-AdverseReaction
events	PRADAXA.xml:S1:2494:6	O
during	PRADAXA.xml:S1:2501:6	O
the	PRADAXA.xml:S1:2508:3	O
treatment	PRADAXA.xml:S1:2512:9	O
period	PRADAXA.xml:S1:2522:6	O
in	PRADAXA.xml:S1:2529:2	O
the	PRADAXA.xml:S1:2532:3	O
RE	PRADAXA.xml:S1:2536:2	O
-	PRADAXA.xml:S1:2538:1	O
LY	PRADAXA.xml:S1:2539:2	O
study	PRADAXA.xml:S1:2542:5	O
,	PRADAXA.xml:S1:2547:1	O
with	PRADAXA.xml:S1:2549:4	O
the	PRADAXA.xml:S1:2554:3	O
bleeding	PRADAXA.xml:S1:2558:8	B-AdverseReaction
rate	PRADAXA.xml:S1:2567:4	O
per	PRADAXA.xml:S1:2572:3	O
100	PRADAXA.xml:S1:2576:3	O
subject	PRADAXA.xml:S1:2580:7	O
-	PRADAXA.xml:S1:2587:1	O
years	PRADAXA.xml:S1:2588:5	O
(	PRADAXA.xml:S1:2594:1	O
)	PRADAXA.xml:S1:2596:1	O
.	PRADAXA.xml:S1:2597:1	O

Major	PRADAXA.xml:S1:2599:5	B-Severity
bleeding	PRADAXA.xml:S1:2605:8	B-AdverseReaction
is	PRADAXA.xml:S1:2614:2	O
defined	PRADAXA.xml:S1:2617:7	O
as	PRADAXA.xml:S1:2625:2	O
bleeding	PRADAXA.xml:S1:2628:8	B-AdverseReaction
accompanied	PRADAXA.xml:S1:2637:11	O
by	PRADAXA.xml:S1:2649:2	O
one	PRADAXA.xml:S1:2652:3	O
or	PRADAXA.xml:S1:2656:2	O
more	PRADAXA.xml:S1:2659:4	O
of	PRADAXA.xml:S1:2664:2	O
the	PRADAXA.xml:S1:2667:3	O
following	PRADAXA.xml:S1:2671:9	O
:	PRADAXA.xml:S1:2680:1	O
a	PRADAXA.xml:S1:2682:1	O
decrease	PRADAXA.xml:S1:2684:8	B-AdverseReaction
in	PRADAXA.xml:S1:2693:2	I-AdverseReaction
hemoglobin	PRADAXA.xml:S1:2696:10	I-AdverseReaction
of	PRADAXA.xml:S1:2707:2	O
2	PRADAXA.xml:S1:2712:1	B-Severity
g	PRADAXA.xml:S1:2714:1	I-Severity
dL	PRADAXA.xml:S1:2716:2	I-Severity
,	PRADAXA.xml:S1:2718:1	O
a	PRADAXA.xml:S1:2720:1	O
transfusion	PRADAXA.xml:S1:2722:11	O
of	PRADAXA.xml:S1:2734:2	O
2	PRADAXA.xml:S1:2739:1	O
units	PRADAXA.xml:S1:2741:5	O
of	PRADAXA.xml:S1:2747:2	O
packed	PRADAXA.xml:S1:2750:6	O
red	PRADAXA.xml:S1:2757:3	O
blood	PRADAXA.xml:S1:2761:5	O
cells	PRADAXA.xml:S1:2767:5	O
,	PRADAXA.xml:S1:2772:1	O
bleeding	PRADAXA.xml:S1:2774:8	B-AdverseReaction
at	PRADAXA.xml:S1:2783:2	I-AdverseReaction
a	PRADAXA.xml:S1:2786:1	I-AdverseReaction
critical	PRADAXA.xml:S1:2788:8	I-AdverseReaction
site	PRADAXA.xml:S1:2797:4	I-AdverseReaction
or	PRADAXA.xml:S1:2802:2	O
with	PRADAXA.xml:S1:2805:4	O
a	PRADAXA.xml:S1:2810:1	O
fatal	PRADAXA.xml:S1:2812:5	B-AdverseReaction
outcome	PRADAXA.xml:S1:2818:7	O
.	PRADAXA.xml:S1:2825:1	O

Intracranial	PRADAXA.xml:S1:2827:12	B-AdverseReaction
hemorrhage	PRADAXA.xml:S1:2840:10	I-AdverseReaction
included	PRADAXA.xml:S1:2851:8	O
intracerebral	PRADAXA.xml:S1:2860:13	B-AdverseReaction
(	PRADAXA.xml:S1:2874:1	O
hemorrhagic	PRADAXA.xml:S1:2875:11	B-AdverseReaction
stroke	PRADAXA.xml:S1:2887:6	I-AdverseReaction
)	PRADAXA.xml:S1:2893:1	O
,	PRADAXA.xml:S1:2894:1	O
subarachnoid	PRADAXA.xml:S1:2896:12	B-AdverseReaction
,	PRADAXA.xml:S1:2908:1	O
and	PRADAXA.xml:S1:2910:3	O
subdural	PRADAXA.xml:S1:2914:8	B-AdverseReaction
bleeds	PRADAXA.xml:S1:2923:6	I-AdverseReaction
.	PRADAXA.xml:S1:2929:1	O

Table	PRADAXA.xml:S1:2935:5	O
2	PRADAXA.xml:S1:2941:1	O
Adjudicated	PRADAXA.xml:S1:2943:11	O
Major	PRADAXA.xml:S1:2955:5	B-Severity
Bleeding	PRADAXA.xml:S1:2961:8	B-AdverseReaction
Events	PRADAXA.xml:S1:2970:6	O
in	PRADAXA.xml:S1:2977:2	O
Treated	PRADAXA.xml:S1:2980:7	O
Patientsa	PRADAXA.xml:S1:2988:9	O

aPatients	PRADAXA.xml:S1:3001:9	O
during	PRADAXA.xml:S1:3011:6	O
treatment	PRADAXA.xml:S1:3018:9	O
or	PRADAXA.xml:S1:3028:2	O
within	PRADAXA.xml:S1:3031:6	O
2	PRADAXA.xml:S1:3038:1	O
days	PRADAXA.xml:S1:3040:4	O
of	PRADAXA.xml:S1:3045:2	O
stopping	PRADAXA.xml:S1:3048:8	O
study	PRADAXA.xml:S1:3057:5	O
treatment	PRADAXA.xml:S1:3063:9	O
.	PRADAXA.xml:S1:3072:1	O

Major	PRADAXA.xml:S1:3074:5	B-Severity
bleeding	PRADAXA.xml:S1:3080:8	B-AdverseReaction
events	PRADAXA.xml:S1:3089:6	O
within	PRADAXA.xml:S1:3096:6	O
each	PRADAXA.xml:S1:3103:4	O
subcategory	PRADAXA.xml:S1:3108:11	O
were	PRADAXA.xml:S1:3120:4	O
counted	PRADAXA.xml:S1:3125:7	O
once	PRADAXA.xml:S1:3133:4	O
per	PRADAXA.xml:S1:3138:3	O
patient	PRADAXA.xml:S1:3142:7	O
,	PRADAXA.xml:S1:3149:1	O
but	PRADAXA.xml:S1:3151:3	O
patients	PRADAXA.xml:S1:3155:8	O
may	PRADAXA.xml:S1:3164:3	O
have	PRADAXA.xml:S1:3168:4	O
contributed	PRADAXA.xml:S1:3173:11	O
events	PRADAXA.xml:S1:3185:6	O
to	PRADAXA.xml:S1:3192:2	O
multiple	PRADAXA.xml:S1:3195:8	O
subcategories	PRADAXA.xml:S1:3204:13	O
.	PRADAXA.xml:S1:3217:1	O

bAnnual	PRADAXA.xml:S1:3220:7	O
event	PRADAXA.xml:S1:3228:5	O
rate	PRADAXA.xml:S1:3234:4	O
per	PRADAXA.xml:S1:3239:3	O
100	PRADAXA.xml:S1:3243:3	O
pt	PRADAXA.xml:S1:3247:2	O
-	PRADAXA.xml:S1:3249:1	O
years	PRADAXA.xml:S1:3250:5	O
100	PRADAXA.xml:S1:3258:3	O
number	PRADAXA.xml:S1:3264:6	O
of	PRADAXA.xml:S1:3271:2	O
subjects	PRADAXA.xml:S1:3274:8	O
with	PRADAXA.xml:S1:3283:4	O
event	PRADAXA.xml:S1:3288:5	O
subject	PRADAXA.xml:S1:3294:7	O
-	PRADAXA.xml:S1:3301:1	O
years	PRADAXA.xml:S1:3302:5	O
.	PRADAXA.xml:S1:3307:1	O

Subject	PRADAXA.xml:S1:3309:7	O
-	PRADAXA.xml:S1:3316:1	O
years	PRADAXA.xml:S1:3317:5	O
is	PRADAXA.xml:S1:3323:2	O
defined	PRADAXA.xml:S1:3326:7	O
as	PRADAXA.xml:S1:3334:2	O
cumulative	PRADAXA.xml:S1:3337:10	O
number	PRADAXA.xml:S1:3348:6	O
of	PRADAXA.xml:S1:3355:2	O
days	PRADAXA.xml:S1:3358:4	O
from	PRADAXA.xml:S1:3363:4	O
first	PRADAXA.xml:S1:3368:5	O
drug	PRADAXA.xml:S1:3374:4	O
intake	PRADAXA.xml:S1:3379:6	O
to	PRADAXA.xml:S1:3386:2	O
event	PRADAXA.xml:S1:3389:5	O
date	PRADAXA.xml:S1:3395:4	O
,	PRADAXA.xml:S1:3399:1	O
date	PRADAXA.xml:S1:3401:4	O
of	PRADAXA.xml:S1:3406:2	O
last	PRADAXA.xml:S1:3409:4	O
drug	PRADAXA.xml:S1:3414:4	O
intake	PRADAXA.xml:S1:3419:6	O
2	PRADAXA.xml:S1:3428:1	O
,	PRADAXA.xml:S1:3429:1	O
death	PRADAXA.xml:S1:3431:5	O
date	PRADAXA.xml:S1:3437:4	O
(	PRADAXA.xml:S1:3442:1	O
whatever	PRADAXA.xml:S1:3443:8	O
occurred	PRADAXA.xml:S1:3452:8	O
first	PRADAXA.xml:S1:3461:5	O
)	PRADAXA.xml:S1:3466:1	O
across	PRADAXA.xml:S1:3468:6	O
all	PRADAXA.xml:S1:3475:3	O
treated	PRADAXA.xml:S1:3479:7	O
subjects	PRADAXA.xml:S1:3487:8	O
divided	PRADAXA.xml:S1:3496:7	O
by	PRADAXA.xml:S1:3504:2	O
365.25	PRADAXA.xml:S1:3507:6	O
.	PRADAXA.xml:S1:3513:1	O

In	PRADAXA.xml:S1:3515:2	O
case	PRADAXA.xml:S1:3518:4	O
of	PRADAXA.xml:S1:3523:2	O
recurrent	PRADAXA.xml:S1:3526:9	O
events	PRADAXA.xml:S1:3536:6	O
of	PRADAXA.xml:S1:3543:2	O
the	PRADAXA.xml:S1:3546:3	O
same	PRADAXA.xml:S1:3550:4	O
category	PRADAXA.xml:S1:3555:8	O
,	PRADAXA.xml:S1:3563:1	O
the	PRADAXA.xml:S1:3565:3	O
first	PRADAXA.xml:S1:3569:5	O
event	PRADAXA.xml:S1:3575:5	O
was	PRADAXA.xml:S1:3581:3	O
considered	PRADAXA.xml:S1:3585:10	O
.	PRADAXA.xml:S1:3595:1	O

cDefined	PRADAXA.xml:S1:3598:8	O
as	PRADAXA.xml:S1:3607:2	O
bleeding	PRADAXA.xml:S1:3610:8	B-AdverseReaction
accompanied	PRADAXA.xml:S1:3619:11	O
by	PRADAXA.xml:S1:3631:2	O
one	PRADAXA.xml:S1:3634:3	O
or	PRADAXA.xml:S1:3638:2	O
more	PRADAXA.xml:S1:3641:4	O
of	PRADAXA.xml:S1:3646:2	O
the	PRADAXA.xml:S1:3649:3	O
following	PRADAXA.xml:S1:3653:9	O
:	PRADAXA.xml:S1:3662:1	O
a	PRADAXA.xml:S1:3664:1	O
decrease	PRADAXA.xml:S1:3666:8	B-AdverseReaction
in	PRADAXA.xml:S1:3675:2	I-AdverseReaction
hemoglobin	PRADAXA.xml:S1:3678:10	I-AdverseReaction
of	PRADAXA.xml:S1:3689:2	O
2	PRADAXA.xml:S1:3694:1	B-Severity
g	PRADAXA.xml:S1:3696:1	I-Severity
dL	PRADAXA.xml:S1:3698:2	I-Severity
,	PRADAXA.xml:S1:3700:1	O
a	PRADAXA.xml:S1:3702:1	O
transfusion	PRADAXA.xml:S1:3704:11	O
of	PRADAXA.xml:S1:3716:2	O
2	PRADAXA.xml:S1:3719:1	O
or	PRADAXA.xml:S1:3721:2	O
more	PRADAXA.xml:S1:3724:4	O
units	PRADAXA.xml:S1:3729:5	O
of	PRADAXA.xml:S1:3735:2	O
packed	PRADAXA.xml:S1:3738:6	O
red	PRADAXA.xml:S1:3745:3	O
blood	PRADAXA.xml:S1:3749:5	O
cells	PRADAXA.xml:S1:3755:5	O
,	PRADAXA.xml:S1:3760:1	O
bleeding	PRADAXA.xml:S1:3762:8	B-AdverseReaction
at	PRADAXA.xml:S1:3771:2	I-AdverseReaction
a	PRADAXA.xml:S1:3774:1	I-AdverseReaction
critical	PRADAXA.xml:S1:3776:8	I-AdverseReaction
site	PRADAXA.xml:S1:3785:4	I-AdverseReaction
or	PRADAXA.xml:S1:3790:2	O
with	PRADAXA.xml:S1:3793:4	O
fatal	PRADAXA.xml:S1:3798:5	B-AdverseReaction
outcome	PRADAXA.xml:S1:3804:7	O
.	PRADAXA.xml:S1:3811:1	O

dIntracranial	PRADAXA.xml:S1:3814:13	B-AdverseReaction
bleed	PRADAXA.xml:S1:3828:5	I-AdverseReaction
included	PRADAXA.xml:S1:3834:8	O
intracerebral	PRADAXA.xml:S1:3843:13	B-AdverseReaction
(	PRADAXA.xml:S1:3857:1	O
hemorrhagic	PRADAXA.xml:S1:3858:11	B-AdverseReaction
stroke	PRADAXA.xml:S1:3870:6	I-AdverseReaction
)	PRADAXA.xml:S1:3876:1	O
,	PRADAXA.xml:S1:3877:1	O
subarachnoid	PRADAXA.xml:S1:3879:12	B-AdverseReaction
,	PRADAXA.xml:S1:3891:1	O
and	PRADAXA.xml:S1:3893:3	O
subdural	PRADAXA.xml:S1:3897:8	B-AdverseReaction
bleeds	PRADAXA.xml:S1:3906:6	I-AdverseReaction
.	PRADAXA.xml:S1:3912:1	O

eOn	PRADAXA.xml:S1:3915:3	O
-	PRADAXA.xml:S1:3918:1	O
treatment	PRADAXA.xml:S1:3919:9	O
analysis	PRADAXA.xml:S1:3929:8	O
based	PRADAXA.xml:S1:3938:5	O
on	PRADAXA.xml:S1:3944:2	O
the	PRADAXA.xml:S1:3947:3	O
safety	PRADAXA.xml:S1:3951:6	O
population	PRADAXA.xml:S1:3958:10	O
,	PRADAXA.xml:S1:3968:1	O
compared	PRADAXA.xml:S1:3970:8	O
to	PRADAXA.xml:S1:3979:2	O
ITT	PRADAXA.xml:S1:3982:3	O
analysis	PRADAXA.xml:S1:3986:8	O
presented	PRADAXA.xml:S1:3995:9	O
in	PRADAXA.xml:S1:4005:2	O
Section	PRADAXA.xml:S1:4008:7	O
14	PRADAXA.xml:S1:4016:2	O
Clinical	PRADAXA.xml:S1:4019:8	O
Studies	PRADAXA.xml:S1:4028:7	O
.	PRADAXA.xml:S1:4035:1	O

fFatal	PRADAXA.xml:S1:4038:6	B-AdverseReaction
bleed	PRADAXA.xml:S1:4045:5	B-AdverseReaction
:	PRADAXA.xml:S1:4050:1	O
Adjudicated	PRADAXA.xml:S1:4052:11	O
major	PRADAXA.xml:S1:4064:5	B-Severity
bleed	PRADAXA.xml:S1:4070:5	B-AdverseReaction
as	PRADAXA.xml:S1:4076:2	O
defined	PRADAXA.xml:S1:4079:7	O
above	PRADAXA.xml:S1:4087:5	O
with	PRADAXA.xml:S1:4093:4	O
investigator	PRADAXA.xml:S1:4098:12	O
reported	PRADAXA.xml:S1:4111:8	O
fatal	PRADAXA.xml:S1:4120:5	B-AdverseReaction
outcome	PRADAXA.xml:S1:4126:7	O
and	PRADAXA.xml:S1:4134:3	O
adjudicated	PRADAXA.xml:S1:4138:11	O
death	PRADAXA.xml:S1:4150:5	B-AdverseReaction
with	PRADAXA.xml:S1:4156:4	O
primary	PRADAXA.xml:S1:4161:7	O
cause	PRADAXA.xml:S1:4169:5	O
from	PRADAXA.xml:S1:4175:4	O
bleeding	PRADAXA.xml:S1:4180:8	B-AdverseReaction
.	PRADAXA.xml:S1:4188:1	O

gNon	PRADAXA.xml:S1:4191:4	B-AdverseReaction
-	PRADAXA.xml:S1:4195:1	I-AdverseReaction
intracranial	PRADAXA.xml:S1:4196:12	I-AdverseReaction
fatal	PRADAXA.xml:S1:4209:5	B-AdverseReaction
bleed	PRADAXA.xml:S1:4215:5	I-AdverseReaction
:	PRADAXA.xml:S1:4220:1	O
Adjudicated	PRADAXA.xml:S1:4222:11	O
major	PRADAXA.xml:S1:4234:5	B-Severity
bleed	PRADAXA.xml:S1:4240:5	B-AdverseReaction
as	PRADAXA.xml:S1:4246:2	O
defined	PRADAXA.xml:S1:4249:7	O
above	PRADAXA.xml:S1:4257:5	O
and	PRADAXA.xml:S1:4263:3	O
adjudicated	PRADAXA.xml:S1:4267:11	O
death	PRADAXA.xml:S1:4279:5	B-AdverseReaction
with	PRADAXA.xml:S1:4285:4	O
primary	PRADAXA.xml:S1:4290:7	O
cause	PRADAXA.xml:S1:4298:5	O
from	PRADAXA.xml:S1:4304:4	O
bleeding	PRADAXA.xml:S1:4309:8	B-AdverseReaction
but	PRADAXA.xml:S1:4318:3	O
without	PRADAXA.xml:S1:4322:7	B-Negation
symptomatic	PRADAXA.xml:S1:4330:11	B-AdverseReaction
intracranial	PRADAXA.xml:S1:4342:12	I-AdverseReaction
bleed	PRADAXA.xml:S1:4355:5	I-AdverseReaction
based	PRADAXA.xml:S1:4361:5	O
on	PRADAXA.xml:S1:4367:2	O
investigator	PRADAXA.xml:S1:4370:12	O
's	PRADAXA.xml:S1:4382:2	O
clinical	PRADAXA.xml:S1:4385:8	O
assessment	PRADAXA.xml:S1:4394:10	O
.	PRADAXA.xml:S1:4404:1	O

Event	PRADAXA.xml:S1:4417:5	O

PRADAXA	PRADAXA.xml:S1:4443:7	O
150	PRADAXA.xml:S1:4451:3	O
mgN	PRADAXA.xml:S1:4455:3	O
6059	PRADAXA.xml:S1:4461:4	O
n	PRADAXA.xml:S1:4465:1	O
(	PRADAXA.xml:S1:4468:1	O
year	PRADAXA.xml:S1:4471:4	O
b	PRADAXA.xml:S1:4477:1	O
)	PRADAXA.xml:S1:4480:1	O
WarfarinN	PRADAXA.xml:S1:4487:9	O
5998	PRADAXA.xml:S1:4499:4	O
n	PRADAXA.xml:S1:4503:1	O
(	PRADAXA.xml:S1:4505:1	O
year	PRADAXA.xml:S1:4508:4	O
b	PRADAXA.xml:S1:4514:1	O
)	PRADAXA.xml:S1:4517:1	O
PRADAXA	PRADAXA.xml:S1:4524:7	O
150	PRADAXA.xml:S1:4532:3	O
mgvs	PRADAXA.xml:S1:4536:4	O
.	PRADAXA.xml:S1:4540:1	O

WarfarinHR	PRADAXA.xml:S1:4542:10	O
(	PRADAXA.xml:S1:4553:1	O
95%	PRADAXA.xml:S1:4554:3	O
CI	PRADAXA.xml:S1:4558:2	O
)	PRADAXA.xml:S1:4560:1	O

Major	PRADAXA.xml:S1:4568:5	B-Severity
Bleeding	PRADAXA.xml:S1:4574:8	B-AdverseReaction
c	PRADAXA.xml:S1:4584:1	O
350	PRADAXA.xml:S1:4602:3	O
(	PRADAXA.xml:S1:4606:1	O
3.47	PRADAXA.xml:S1:4607:4	O
)	PRADAXA.xml:S1:4611:1	O
374	PRADAXA.xml:S1:4629:3	O
(	PRADAXA.xml:S1:4633:1	O
3.58	PRADAXA.xml:S1:4634:4	O
)	PRADAXA.xml:S1:4638:1	O
0.97	PRADAXA.xml:S1:4653:4	O
(	PRADAXA.xml:S1:4658:1	O
0.84	PRADAXA.xml:S1:4659:4	O
,	PRADAXA.xml:S1:4663:1	O
1.12	PRADAXA.xml:S1:4665:4	O
)	PRADAXA.xml:S1:4669:1	O

Intracranial	PRADAXA.xml:S1:4682:12	B-AdverseReaction
Hemorrhage	PRADAXA.xml:S1:4695:10	I-AdverseReaction
(	PRADAXA.xml:S1:4706:1	O
ICH	PRADAXA.xml:S1:4707:3	B-AdverseReaction
)	PRADAXA.xml:S1:4710:1	O
d	PRADAXA.xml:S1:4713:1	O
23	PRADAXA.xml:S1:4726:2	O
(	PRADAXA.xml:S1:4729:1	O
0.22	PRADAXA.xml:S1:4730:4	O
)	PRADAXA.xml:S1:4734:1	O
82	PRADAXA.xml:S1:4753:2	O
(	PRADAXA.xml:S1:4756:1	O
0.77	PRADAXA.xml:S1:4757:4	O
)	PRADAXA.xml:S1:4761:1	O
0.29	PRADAXA.xml:S1:4775:4	O
(	PRADAXA.xml:S1:4780:1	O
0.18	PRADAXA.xml:S1:4781:4	O
,	PRADAXA.xml:S1:4785:1	O
0.46	PRADAXA.xml:S1:4787:4	O
)	PRADAXA.xml:S1:4791:1	O

Hemorrhagic	PRADAXA.xml:S1:4808:11	B-AdverseReaction
Stroke	PRADAXA.xml:S1:4820:6	I-AdverseReaction
e	PRADAXA.xml:S1:4828:1	O
6	PRADAXA.xml:S1:4841:1	O
(	PRADAXA.xml:S1:4843:1	O
0.06	PRADAXA.xml:S1:4844:4	O
)	PRADAXA.xml:S1:4848:1	O
40	PRADAXA.xml:S1:4868:2	O
(	PRADAXA.xml:S1:4871:1	O
0.37	PRADAXA.xml:S1:4872:4	O
)	PRADAXA.xml:S1:4876:1	O
0.16	PRADAXA.xml:S1:4890:4	O
(	PRADAXA.xml:S1:4895:1	O
0.07	PRADAXA.xml:S1:4896:4	O
,	PRADAXA.xml:S1:4900:1	O
0.37	PRADAXA.xml:S1:4902:4	O
)	PRADAXA.xml:S1:4906:1	O

Other	PRADAXA.xml:S1:4923:5	O
ICH	PRADAXA.xml:S1:4929:3	B-AdverseReaction
17	PRADAXA.xml:S1:4952:2	O
(	PRADAXA.xml:S1:4955:1	O
0.17	PRADAXA.xml:S1:4956:4	O
)	PRADAXA.xml:S1:4960:1	O
46	PRADAXA.xml:S1:4979:2	O
(	PRADAXA.xml:S1:4982:1	O
0.43	PRADAXA.xml:S1:4983:4	O
)	PRADAXA.xml:S1:4987:1	O
0.38	PRADAXA.xml:S1:5002:4	O
(	PRADAXA.xml:S1:5007:1	O
0.22	PRADAXA.xml:S1:5008:4	O
,	PRADAXA.xml:S1:5012:1	O
0.67	PRADAXA.xml:S1:5014:4	O
)	PRADAXA.xml:S1:5018:1	O

Gastrointestinal	PRADAXA.xml:S1:5031:16	O
162	PRADAXA.xml:S1:5062:3	O
(	PRADAXA.xml:S1:5066:1	O
1.59	PRADAXA.xml:S1:5067:4	O
)	PRADAXA.xml:S1:5071:1	O
111	PRADAXA.xml:S1:5089:3	O
(	PRADAXA.xml:S1:5093:1	O
1.05	PRADAXA.xml:S1:5094:4	O
)	PRADAXA.xml:S1:5098:1	O
1.51	PRADAXA.xml:S1:5113:4	O
(	PRADAXA.xml:S1:5118:1	O
1.19	PRADAXA.xml:S1:5119:4	O
,	PRADAXA.xml:S1:5123:1	O
1.92	PRADAXA.xml:S1:5125:4	O
)	PRADAXA.xml:S1:5129:1	O

Fatal	PRADAXA.xml:S1:5142:5	B-AdverseReaction
Bleeding	PRADAXA.xml:S1:5148:8	B-AdverseReaction
f	PRADAXA.xml:S1:5158:1	O
7	PRADAXA.xml:S1:5174:1	O
(	PRADAXA.xml:S1:5176:1	O
0.07	PRADAXA.xml:S1:5177:4	O
)	PRADAXA.xml:S1:5181:1	O
16	PRADAXA.xml:S1:5201:2	O
(	PRADAXA.xml:S1:5204:1	O
0.15	PRADAXA.xml:S1:5205:4	O
)	PRADAXA.xml:S1:5209:1	O
0.45	PRADAXA.xml:S1:5224:4	O
(	PRADAXA.xml:S1:5229:1	O
0.19	PRADAXA.xml:S1:5230:4	O
,	PRADAXA.xml:S1:5234:1	O
1.10	PRADAXA.xml:S1:5236:4	O
)	PRADAXA.xml:S1:5240:1	O

ICH	PRADAXA.xml:S1:5256:3	B-AdverseReaction
3	PRADAXA.xml:S1:5285:1	O
(	PRADAXA.xml:S1:5287:1	O
0.03	PRADAXA.xml:S1:5288:4	O
)	PRADAXA.xml:S1:5292:1	O
9	PRADAXA.xml:S1:5312:1	O
(	PRADAXA.xml:S1:5314:1	O
0.08	PRADAXA.xml:S1:5315:4	O
)	PRADAXA.xml:S1:5319:1	O
0.35	PRADAXA.xml:S1:5335:4	O
(	PRADAXA.xml:S1:5340:1	O
0.09	PRADAXA.xml:S1:5341:4	O
,	PRADAXA.xml:S1:5345:1	O
1.28	PRADAXA.xml:S1:5347:4	O
)	PRADAXA.xml:S1:5351:1	O

Non	PRADAXA.xml:S1:5367:3	O
-	PRADAXA.xml:S1:5370:1	O
intracranial	PRADAXA.xml:S1:5371:12	O
g	PRADAXA.xml:S1:5385:1	O
4	PRADAXA.xml:S1:5398:1	O
(	PRADAXA.xml:S1:5400:1	O
0.04	PRADAXA.xml:S1:5401:4	O
)	PRADAXA.xml:S1:5405:1	O
7	PRADAXA.xml:S1:5425:1	O
(	PRADAXA.xml:S1:5427:1	O
0.07	PRADAXA.xml:S1:5428:4	O
)	PRADAXA.xml:S1:5432:1	O
0.59	PRADAXA.xml:S1:5448:4	O
(	PRADAXA.xml:S1:5453:1	O
0.17	PRADAXA.xml:S1:5454:4	O
,	PRADAXA.xml:S1:5458:1	O
2.02	PRADAXA.xml:S1:5460:4	O
)	PRADAXA.xml:S1:5464:1	O

There	PRADAXA.xml:S1:5479:5	O
was	PRADAXA.xml:S1:5485:3	O
a	PRADAXA.xml:S1:5489:1	O
higher	PRADAXA.xml:S1:5491:6	O
rate	PRADAXA.xml:S1:5498:4	O
of	PRADAXA.xml:S1:5503:2	O
any	PRADAXA.xml:S1:5506:3	O
gastrointestinal	PRADAXA.xml:S1:5510:16	B-AdverseReaction
bleeds	PRADAXA.xml:S1:5527:6	I-AdverseReaction
in	PRADAXA.xml:S1:5534:2	O
patients	PRADAXA.xml:S1:5537:8	O
receiving	PRADAXA.xml:S1:5546:9	O
PRADAXA	PRADAXA.xml:S1:5556:7	O
150	PRADAXA.xml:S1:5564:3	O
mg	PRADAXA.xml:S1:5568:2	O
than	PRADAXA.xml:S1:5571:4	O
in	PRADAXA.xml:S1:5576:2	O
patients	PRADAXA.xml:S1:5579:8	O
receiving	PRADAXA.xml:S1:5588:9	O
warfarin	PRADAXA.xml:S1:5598:8	O
(	PRADAXA.xml:S1:5607:1	O
6.6%	PRADAXA.xml:S1:5608:4	O
vs	PRADAXA.xml:S1:5613:2	O
.	PRADAXA.xml:S1:5615:1	O

4.2%	PRADAXA.xml:S1:5617:4	O
,	PRADAXA.xml:S1:5621:1	O
respectively	PRADAXA.xml:S1:5623:12	O
)	PRADAXA.xml:S1:5635:1	O
.	PRADAXA.xml:S1:5636:1	O

The	PRADAXA.xml:S1:5642:3	O

risk	PRADAXA.xml:S1:5646:4	B-Factor
of	PRADAXA.xml:S1:5651:2	O
major	PRADAXA.xml:S1:5654:5	B-Severity
bleeds	PRADAXA.xml:S1:5660:6	B-AdverseReaction
was	PRADAXA.xml:S1:5667:3	O
similar	PRADAXA.xml:S1:5671:7	O
with	PRADAXA.xml:S1:5679:4	O
PRADAXA	PRADAXA.xml:S1:5684:7	O
150	PRADAXA.xml:S1:5692:3	O
mg	PRADAXA.xml:S1:5696:2	O
and	PRADAXA.xml:S1:5699:3	O
warfarin	PRADAXA.xml:S1:5703:8	O
across	PRADAXA.xml:S1:5712:6	O
major	PRADAXA.xml:S1:5719:5	O
subgroups	PRADAXA.xml:S1:5725:9	O
defined	PRADAXA.xml:S1:5735:7	O
by	PRADAXA.xml:S1:5743:2	O
baseline	PRADAXA.xml:S1:5746:8	O
characteristics	PRADAXA.xml:S1:5755:15	O
(	PRADAXA.xml:S1:5771:1	O
see	PRADAXA.xml:S1:5772:3	O
Figure	PRADAXA.xml:S1:5776:6	O
1	PRADAXA.xml:S1:5783:1	O
)	PRADAXA.xml:S1:5784:1	O
,	PRADAXA.xml:S1:5785:1	O
with	PRADAXA.xml:S1:5787:4	O
the	PRADAXA.xml:S1:5792:3	O
exception	PRADAXA.xml:S1:5796:9	O
of	PRADAXA.xml:S1:5806:2	O
age	PRADAXA.xml:S1:5809:3	O
,	PRADAXA.xml:S1:5812:1	O
where	PRADAXA.xml:S1:5814:5	O
there	PRADAXA.xml:S1:5820:5	O
was	PRADAXA.xml:S1:5826:3	O
a	PRADAXA.xml:S1:5830:1	O
trend	PRADAXA.xml:S1:5832:5	O
towards	PRADAXA.xml:S1:5838:7	O
a	PRADAXA.xml:S1:5846:1	O
higher	PRADAXA.xml:S1:5848:6	O
incidence	PRADAXA.xml:S1:5855:9	O
of	PRADAXA.xml:S1:5865:2	O
major	PRADAXA.xml:S1:5868:5	B-Severity
bleeding	PRADAXA.xml:S1:5874:8	B-AdverseReaction
on	PRADAXA.xml:S1:5883:2	O
PRADAXA	PRADAXA.xml:S1:5886:7	O
(	PRADAXA.xml:S1:5894:1	O
hazard	PRADAXA.xml:S1:5895:6	O
ratio	PRADAXA.xml:S1:5902:5	O
1.2	PRADAXA.xml:S1:5908:3	O
,	PRADAXA.xml:S1:5911:1	O
95%	PRADAXA.xml:S1:5913:3	O
CI	PRADAXA.xml:S1:5917:2	O
:	PRADAXA.xml:S1:5919:1	O
1.0	PRADAXA.xml:S1:5921:3	O
to	PRADAXA.xml:S1:5925:2	O
1.5	PRADAXA.xml:S1:5928:3	O
)	PRADAXA.xml:S1:5931:1	O
for	PRADAXA.xml:S1:5933:3	O
patients	PRADAXA.xml:S1:5937:8	O
75	PRADAXA.xml:S1:5948:2	O
years	PRADAXA.xml:S1:5951:5	O
of	PRADAXA.xml:S1:5957:2	O
age	PRADAXA.xml:S1:5960:3	O
.	PRADAXA.xml:S1:5963:1	O

Figure	PRADAXA.xml:S1:5971:6	O
1	PRADAXA.xml:S1:5978:1	O
Adjudicated	PRADAXA.xml:S1:5980:11	O
Major	PRADAXA.xml:S1:5992:5	B-Severity
Bleeding	PRADAXA.xml:S1:5998:8	B-AdverseReaction
by	PRADAXA.xml:S1:6007:2	O
Baseline	PRADAXA.xml:S1:6010:8	O
Characteristics	PRADAXA.xml:S1:6019:15	O
Including	PRADAXA.xml:S1:6035:9	O
Hemorrhagic	PRADAXA.xml:S1:6045:11	O
Stroke	PRADAXA.xml:S1:6057:6	O
Treated	PRADAXA.xml:S1:6064:7	O
Patients	PRADAXA.xml:S1:6072:8	O

Note	PRADAXA.xml:S1:6087:4	O
:	PRADAXA.xml:S1:6091:1	O
The	PRADAXA.xml:S1:6093:3	O
figure	PRADAXA.xml:S1:6097:6	O
above	PRADAXA.xml:S1:6104:5	O
presents	PRADAXA.xml:S1:6110:8	O
effects	PRADAXA.xml:S1:6119:7	O
in	PRADAXA.xml:S1:6127:2	O
various	PRADAXA.xml:S1:6130:7	O
subgroups	PRADAXA.xml:S1:6138:9	O
all	PRADAXA.xml:S1:6148:3	O
of	PRADAXA.xml:S1:6152:2	O
which	PRADAXA.xml:S1:6155:5	O
are	PRADAXA.xml:S1:6161:3	O
baseline	PRADAXA.xml:S1:6165:8	O
characteristics	PRADAXA.xml:S1:6174:15	O
and	PRADAXA.xml:S1:6190:3	O
all	PRADAXA.xml:S1:6194:3	O
of	PRADAXA.xml:S1:6198:2	O
which	PRADAXA.xml:S1:6201:5	O
were	PRADAXA.xml:S1:6207:4	O
pre	PRADAXA.xml:S1:6212:3	O
-	PRADAXA.xml:S1:6215:1	O
specified	PRADAXA.xml:S1:6216:9	O
.	PRADAXA.xml:S1:6225:1	O

The	PRADAXA.xml:S1:6227:3	O
95%	PRADAXA.xml:S1:6231:3	O
confidence	PRADAXA.xml:S1:6235:10	O
limits	PRADAXA.xml:S1:6246:6	O
that	PRADAXA.xml:S1:6253:4	O
are	PRADAXA.xml:S1:6258:3	O
shown	PRADAXA.xml:S1:6262:5	O
do	PRADAXA.xml:S1:6268:2	O
not	PRADAXA.xml:S1:6271:3	O
take	PRADAXA.xml:S1:6275:4	O
into	PRADAXA.xml:S1:6280:4	O
account	PRADAXA.xml:S1:6285:7	O
how	PRADAXA.xml:S1:6293:3	O
many	PRADAXA.xml:S1:6297:4	O
comparisons	PRADAXA.xml:S1:6302:11	O
were	PRADAXA.xml:S1:6314:4	O
made	PRADAXA.xml:S1:6319:4	O
,	PRADAXA.xml:S1:6323:1	O
nor	PRADAXA.xml:S1:6325:3	O
do	PRADAXA.xml:S1:6329:2	O
they	PRADAXA.xml:S1:6332:4	O
reflect	PRADAXA.xml:S1:6337:7	O
the	PRADAXA.xml:S1:6345:3	O
effect	PRADAXA.xml:S1:6349:6	O
of	PRADAXA.xml:S1:6356:2	O
a	PRADAXA.xml:S1:6359:1	O
particular	PRADAXA.xml:S1:6361:10	O
factor	PRADAXA.xml:S1:6372:6	O
after	PRADAXA.xml:S1:6379:5	O
adjustment	PRADAXA.xml:S1:6385:10	O
for	PRADAXA.xml:S1:6396:3	O
all	PRADAXA.xml:S1:6400:3	O
other	PRADAXA.xml:S1:6404:5	O
factors	PRADAXA.xml:S1:6410:7	O
.	PRADAXA.xml:S1:6417:1	O

Apparent	PRADAXA.xml:S1:6419:8	O
homogeneity	PRADAXA.xml:S1:6428:11	O
or	PRADAXA.xml:S1:6440:2	O
heterogeneity	PRADAXA.xml:S1:6443:13	O
among	PRADAXA.xml:S1:6457:5	O
groups	PRADAXA.xml:S1:6463:6	O
should	PRADAXA.xml:S1:6470:6	O
not	PRADAXA.xml:S1:6477:3	O
be	PRADAXA.xml:S1:6481:2	O
over	PRADAXA.xml:S1:6484:4	O
-	PRADAXA.xml:S1:6488:1	O
interpreted	PRADAXA.xml:S1:6489:11	O
.	PRADAXA.xml:S1:6500:1	O

Figure	PRADAXA.xml:S1:6507:6	O
1	PRADAXA.xml:S1:6514:1	O

Gastrointestinal	PRADAXA.xml:S1:6528:16	O
Adverse	PRADAXA.xml:S1:6545:7	O
Reactions	PRADAXA.xml:S1:6553:9	O

Patients	PRADAXA.xml:S1:6573:8	O
on	PRADAXA.xml:S1:6582:2	O
PRADAXA	PRADAXA.xml:S1:6585:7	O
150	PRADAXA.xml:S1:6593:3	O
mg	PRADAXA.xml:S1:6597:2	O
had	PRADAXA.xml:S1:6600:3	O
an	PRADAXA.xml:S1:6604:2	O
increased	PRADAXA.xml:S1:6607:9	O
incidence	PRADAXA.xml:S1:6617:9	O
of	PRADAXA.xml:S1:6627:2	O
gastrointestinal	PRADAXA.xml:S1:6630:16	B-AdverseReaction
adverse	PRADAXA.xml:S1:6647:7	I-AdverseReaction
reactions	PRADAXA.xml:S1:6655:9	I-AdverseReaction
(	PRADAXA.xml:S1:6665:1	O
35%	PRADAXA.xml:S1:6666:3	O
vs	PRADAXA.xml:S1:6670:2	O
.	PRADAXA.xml:S1:6672:1	O

24%	PRADAXA.xml:S1:6674:3	O
on	PRADAXA.xml:S1:6678:2	O
warfarin	PRADAXA.xml:S1:6681:8	O
)	PRADAXA.xml:S1:6689:1	O
.	PRADAXA.xml:S1:6690:1	O

These	PRADAXA.xml:S1:6692:5	O
were	PRADAXA.xml:S1:6698:4	O
commonly	PRADAXA.xml:S1:6703:8	O
dyspepsia	PRADAXA.xml:S1:6712:9	B-AdverseReaction
(	PRADAXA.xml:S1:6722:1	O
including	PRADAXA.xml:S1:6723:9	O
abdominal	PRADAXA.xml:S1:6733:9	B-AdverseReaction
pain	PRADAXA.xml:S1:6743:4	I-AdverseReaction
upper	PRADAXA.xml:S1:6748:5	I-AdverseReaction
,	PRADAXA.xml:S1:6753:1	O
abdominal	PRADAXA.xml:S1:6755:9	B-AdverseReaction
pain	PRADAXA.xml:S1:6765:4	I-AdverseReaction
,	PRADAXA.xml:S1:6769:1	O
abdominal	PRADAXA.xml:S1:6771:9	B-AdverseReaction
discomfort	PRADAXA.xml:S1:6781:10	I-AdverseReaction
,	PRADAXA.xml:S1:6791:1	O
and	PRADAXA.xml:S1:6793:3	O
epigastric	PRADAXA.xml:S1:6797:10	B-AdverseReaction
discomfort	PRADAXA.xml:S1:6808:10	I-AdverseReaction
)	PRADAXA.xml:S1:6818:1	O
and	PRADAXA.xml:S1:6820:3	O
gastritis	PRADAXA.xml:S1:6824:9	B-AdverseReaction
-	PRADAXA.xml:S1:6833:1	O
like	PRADAXA.xml:S1:6834:4	O
symptoms	PRADAXA.xml:S1:6839:8	O
(	PRADAXA.xml:S1:6848:1	O
including	PRADAXA.xml:S1:6849:9	O
GERD	PRADAXA.xml:S1:6859:4	B-AdverseReaction
,	PRADAXA.xml:S1:6863:1	O
esophagitis	PRADAXA.xml:S1:6865:11	B-AdverseReaction
,	PRADAXA.xml:S1:6876:1	O
erosive	PRADAXA.xml:S1:6878:7	B-AdverseReaction
gastritis	PRADAXA.xml:S1:6886:9	I-AdverseReaction
,	PRADAXA.xml:S1:6895:1	O
gastric	PRADAXA.xml:S1:6897:7	B-AdverseReaction
hemorrhage	PRADAXA.xml:S1:6905:10	I-AdverseReaction
,	PRADAXA.xml:S1:6915:1	O
hemorrhagic	PRADAXA.xml:S1:6917:11	B-AdverseReaction
gastritis	PRADAXA.xml:S1:6929:9	I-AdverseReaction
,	PRADAXA.xml:S1:6938:1	O
hemorrhagic	PRADAXA.xml:S1:6940:11	B-AdverseReaction
erosive	PRADAXA.xml:S1:6952:7	I-AdverseReaction
gastritis	PRADAXA.xml:S1:6960:9	I-AdverseReaction
,	PRADAXA.xml:S1:6969:1	O
and	PRADAXA.xml:S1:6971:3	O
gastrointestinal	PRADAXA.xml:S1:6975:16	B-AdverseReaction
ulcer	PRADAXA.xml:S1:6992:5	I-AdverseReaction
)	PRADAXA.xml:S1:6997:1	O
.	PRADAXA.xml:S1:6998:1	O

Hypersensitivity	PRADAXA.xml:S1:7016:16	O

Reactions	PRADAXA.xml:S1:7033:9	O

In	PRADAXA.xml:S1:7053:2	O
the	PRADAXA.xml:S1:7056:3	O
RE	PRADAXA.xml:S1:7060:2	O
-	PRADAXA.xml:S1:7062:1	O
LY	PRADAXA.xml:S1:7063:2	O
study	PRADAXA.xml:S1:7066:5	O
,	PRADAXA.xml:S1:7071:1	O
drug	PRADAXA.xml:S1:7073:4	O
hypersensitivity	PRADAXA.xml:S1:7078:16	B-AdverseReaction
(	PRADAXA.xml:S1:7095:1	O
including	PRADAXA.xml:S1:7096:9	O
urticaria	PRADAXA.xml:S1:7106:9	B-AdverseReaction
,	PRADAXA.xml:S1:7115:1	O
rash	PRADAXA.xml:S1:7117:4	B-AdverseReaction
,	PRADAXA.xml:S1:7121:1	O
and	PRADAXA.xml:S1:7123:3	O
pruritus	PRADAXA.xml:S1:7127:8	B-AdverseReaction
)	PRADAXA.xml:S1:7135:1	O
,	PRADAXA.xml:S1:7136:1	O
allergic	PRADAXA.xml:S1:7138:8	B-AdverseReaction
edema	PRADAXA.xml:S1:7147:5	I-AdverseReaction
,	PRADAXA.xml:S1:7152:1	O
anaphylactic	PRADAXA.xml:S1:7154:12	B-AdverseReaction
reaction	PRADAXA.xml:S1:7167:8	I-AdverseReaction
,	PRADAXA.xml:S1:7175:1	O
and	PRADAXA.xml:S1:7177:3	O
anaphylactic	PRADAXA.xml:S1:7181:12	B-AdverseReaction
shock	PRADAXA.xml:S1:7194:5	I-AdverseReaction
were	PRADAXA.xml:S1:7200:4	O
reported	PRADAXA.xml:S1:7205:8	O
in	PRADAXA.xml:S1:7214:2	O
0.1%	PRADAXA.xml:S1:7218:4	O
of	PRADAXA.xml:S1:7223:2	O
patients	PRADAXA.xml:S1:7226:8	O
receiving	PRADAXA.xml:S1:7235:9	O
PRADAXA	PRADAXA.xml:S1:7245:7	O
.	PRADAXA.xml:S1:7252:1	O

Treatment	PRADAXA.xml:S1:7268:9	O

and	PRADAXA.xml:S1:7278:3	O
Reduction	PRADAXA.xml:S1:7282:9	O
in	PRADAXA.xml:S1:7292:2	O
the	PRADAXA.xml:S1:7295:3	O
Risk	PRADAXA.xml:S1:7299:4	O
of	PRADAXA.xml:S1:7304:2	O
Recurrence	PRADAXA.xml:S1:7307:10	O
of	PRADAXA.xml:S1:7318:2	O
Deep	PRADAXA.xml:S1:7321:4	O
Venous	PRADAXA.xml:S1:7326:6	O
Thrombosis	PRADAXA.xml:S1:7333:10	O
and	PRADAXA.xml:S1:7344:3	O
Pulmonary	PRADAXA.xml:S1:7348:9	O
Embolism	PRADAXA.xml:S1:7358:8	O

PRADAXA	PRADAXA.xml:S1:7375:7	O
was	PRADAXA.xml:S1:7383:3	O
studied	PRADAXA.xml:S1:7387:7	O
in	PRADAXA.xml:S1:7395:2	O
4387	PRADAXA.xml:S1:7398:4	O
patients	PRADAXA.xml:S1:7403:8	O
in	PRADAXA.xml:S1:7412:2	O
4	PRADAXA.xml:S1:7415:1	O
pivotal	PRADAXA.xml:S1:7417:7	O
,	PRADAXA.xml:S1:7424:1	O
parallel	PRADAXA.xml:S1:7426:8	O
,	PRADAXA.xml:S1:7434:1	O
randomized	PRADAXA.xml:S1:7436:10	O
,	PRADAXA.xml:S1:7446:1	O
double	PRADAXA.xml:S1:7448:6	O
-	PRADAXA.xml:S1:7454:1	O
blind	PRADAXA.xml:S1:7455:5	O
trials	PRADAXA.xml:S1:7461:6	O
.	PRADAXA.xml:S1:7467:1	O

Three	PRADAXA.xml:S1:7469:5	O
of	PRADAXA.xml:S1:7475:2	O
these	PRADAXA.xml:S1:7478:5	O
trials	PRADAXA.xml:S1:7484:6	O
were	PRADAXA.xml:S1:7491:4	O
active	PRADAXA.xml:S1:7496:6	O
-	PRADAXA.xml:S1:7502:1	O
controlled	PRADAXA.xml:S1:7503:10	O
(	PRADAXA.xml:S1:7514:1	O
warfarin	PRADAXA.xml:S1:7515:8	O
)	PRADAXA.xml:S1:7523:1	O
(	PRADAXA.xml:S1:7525:1	O
RE	PRADAXA.xml:S1:7526:2	O
-	PRADAXA.xml:S1:7528:1	O
COVER	PRADAXA.xml:S1:7529:5	O
,	PRADAXA.xml:S1:7534:1	O
RE	PRADAXA.xml:S1:7536:2	O
-	PRADAXA.xml:S1:7538:1	O
COVER	PRADAXA.xml:S1:7539:5	O
II	PRADAXA.xml:S1:7545:2	O
,	PRADAXA.xml:S1:7547:1	O
and	PRADAXA.xml:S1:7549:3	O
RE	PRADAXA.xml:S1:7553:2	O
-	PRADAXA.xml:S1:7555:1	O
MEDY	PRADAXA.xml:S1:7556:4	O
)	PRADAXA.xml:S1:7560:1	O
,	PRADAXA.xml:S1:7561:1	O
and	PRADAXA.xml:S1:7563:3	O
one	PRADAXA.xml:S1:7567:3	O
study	PRADAXA.xml:S1:7571:5	O
(	PRADAXA.xml:S1:7577:1	O
RE	PRADAXA.xml:S1:7578:2	O
-	PRADAXA.xml:S1:7580:1	O
SONATE	PRADAXA.xml:S1:7581:6	O
)	PRADAXA.xml:S1:7587:1	O
was	PRADAXA.xml:S1:7589:3	O
placebo	PRADAXA.xml:S1:7593:7	O
-	PRADAXA.xml:S1:7600:1	O
controlled	PRADAXA.xml:S1:7601:10	O
.	PRADAXA.xml:S1:7611:1	O

The	PRADAXA.xml:S1:7613:3	O
demographic	PRADAXA.xml:S1:7617:11	O
characteristics	PRADAXA.xml:S1:7629:15	O
were	PRADAXA.xml:S1:7645:4	O
similar	PRADAXA.xml:S1:7650:7	O
among	PRADAXA.xml:S1:7658:5	O
the	PRADAXA.xml:S1:7664:3	O
4	PRADAXA.xml:S1:7668:1	O
pivotal	PRADAXA.xml:S1:7670:7	O
studies	PRADAXA.xml:S1:7678:7	O
and	PRADAXA.xml:S1:7686:3	O
between	PRADAXA.xml:S1:7690:7	O
the	PRADAXA.xml:S1:7698:3	O
treatment	PRADAXA.xml:S1:7702:9	O
groups	PRADAXA.xml:S1:7712:6	O
within	PRADAXA.xml:S1:7719:6	O
these	PRADAXA.xml:S1:7726:5	O
studies	PRADAXA.xml:S1:7732:7	O
.	PRADAXA.xml:S1:7739:1	O

Approximately	PRADAXA.xml:S1:7741:13	O
60%	PRADAXA.xml:S1:7755:3	O
of	PRADAXA.xml:S1:7759:2	O
the	PRADAXA.xml:S1:7762:3	O
treated	PRADAXA.xml:S1:7766:7	O
patients	PRADAXA.xml:S1:7774:8	O
were	PRADAXA.xml:S1:7783:4	O
male	PRADAXA.xml:S1:7788:4	O
,	PRADAXA.xml:S1:7792:1	O
with	PRADAXA.xml:S1:7794:4	O
a	PRADAXA.xml:S1:7799:1	O
mean	PRADAXA.xml:S1:7801:4	O
age	PRADAXA.xml:S1:7806:3	O
of	PRADAXA.xml:S1:7810:2	O
55.1	PRADAXA.xml:S1:7813:4	O
years	PRADAXA.xml:S1:7818:5	O
.	PRADAXA.xml:S1:7823:1	O

The	PRADAXA.xml:S1:7825:3	O
majority	PRADAXA.xml:S1:7829:8	O
of	PRADAXA.xml:S1:7838:2	O
the	PRADAXA.xml:S1:7841:3	O
patients	PRADAXA.xml:S1:7845:8	O
were	PRADAXA.xml:S1:7854:4	O
white	PRADAXA.xml:S1:7859:5	O
(	PRADAXA.xml:S1:7865:1	O
87.7%	PRADAXA.xml:S1:7866:5	O
)	PRADAXA.xml:S1:7871:1	O
,	PRADAXA.xml:S1:7872:1	O
10.3%	PRADAXA.xml:S1:7874:5	O
were	PRADAXA.xml:S1:7880:4	O
Asian	PRADAXA.xml:S1:7885:5	O
,	PRADAXA.xml:S1:7890:1	O
and	PRADAXA.xml:S1:7892:3	O
1.9%	PRADAXA.xml:S1:7896:4	O
were	PRADAXA.xml:S1:7901:4	O
black	PRADAXA.xml:S1:7906:5	O
with	PRADAXA.xml:S1:7912:4	O
a	PRADAXA.xml:S1:7917:1	O
mean	PRADAXA.xml:S1:7919:4	O
CrCl	PRADAXA.xml:S1:7924:4	O
of	PRADAXA.xml:S1:7929:2	O
105.6	PRADAXA.xml:S1:7932:5	O
mL	PRADAXA.xml:S1:7938:2	O
min	PRADAXA.xml:S1:7941:3	O
.	PRADAXA.xml:S1:7944:1	O

Bleeding	PRADAXA.xml:S1:7950:8	B-AdverseReaction
events	PRADAXA.xml:S1:7959:6	O
for	PRADAXA.xml:S1:7966:3	O
the	PRADAXA.xml:S1:7970:3	O
4	PRADAXA.xml:S1:7974:1	O
pivotal	PRADAXA.xml:S1:7976:7	O
studies	PRADAXA.xml:S1:7984:7	O
were	PRADAXA.xml:S1:7992:4	O
classified	PRADAXA.xml:S1:7997:10	O
as	PRADAXA.xml:S1:8008:2	O
major	PRADAXA.xml:S1:8011:5	B-Severity
bleeding	PRADAXA.xml:S1:8017:8	B-AdverseReaction
events	PRADAXA.xml:S1:8026:6	O
if	PRADAXA.xml:S1:8033:2	O
at	PRADAXA.xml:S1:8036:2	O
least	PRADAXA.xml:S1:8039:5	O
one	PRADAXA.xml:S1:8045:3	O
of	PRADAXA.xml:S1:8049:2	O
the	PRADAXA.xml:S1:8052:3	O
following	PRADAXA.xml:S1:8056:9	O
criteria	PRADAXA.xml:S1:8066:8	O
applied	PRADAXA.xml:S1:8075:7	O
:	PRADAXA.xml:S1:8082:1	O
fatal	PRADAXA.xml:S1:8084:5	B-AdverseReaction
bleeding	PRADAXA.xml:S1:8090:8	B-AdverseReaction
,	PRADAXA.xml:S1:8098:1	O
symptomatic	PRADAXA.xml:S1:8100:11	B-AdverseReaction
bleeding	PRADAXA.xml:S1:8112:8	I-AdverseReaction
in	PRADAXA.xml:S1:8121:2	I-AdverseReaction
a	PRADAXA.xml:S1:8124:1	I-AdverseReaction
critical	PRADAXA.xml:S1:8126:8	I-AdverseReaction
area	PRADAXA.xml:S1:8135:4	I-AdverseReaction
or	PRADAXA.xml:S1:8140:2	O
organ	PRADAXA.xml:S1:8143:5	I-AdverseReaction
(	PRADAXA.xml:S1:8149:1	O
intraocular	PRADAXA.xml:S1:8150:11	I-AdverseReaction
,	PRADAXA.xml:S1:8161:1	O
intracranial	PRADAXA.xml:S1:8163:12	I-AdverseReaction
,	PRADAXA.xml:S1:8175:1	O
intraspinal	PRADAXA.xml:S1:8177:11	I-AdverseReaction
or	PRADAXA.xml:S1:8189:2	O
intramuscular	PRADAXA.xml:S1:8192:13	I-AdverseReaction
with	PRADAXA.xml:S1:8206:4	O
compartment	PRADAXA.xml:S1:8211:11	B-AdverseReaction
syndrome	PRADAXA.xml:S1:8223:8	I-AdverseReaction
,	PRADAXA.xml:S1:8231:1	O
retroperitoneal	PRADAXA.xml:S1:8233:15	B-AdverseReaction
bleeding	PRADAXA.xml:S1:8249:8	I-AdverseReaction
,	PRADAXA.xml:S1:8257:1	O
intra	PRADAXA.xml:S1:8259:5	B-AdverseReaction
-	PRADAXA.xml:S1:8264:1	I-AdverseReaction
articular	PRADAXA.xml:S1:8265:9	I-AdverseReaction
bleeding	PRADAXA.xml:S1:8275:8	I-AdverseReaction
,	PRADAXA.xml:S1:8283:1	O
or	PRADAXA.xml:S1:8285:2	O
pericardial	PRADAXA.xml:S1:8288:11	B-AdverseReaction
bleeding	PRADAXA.xml:S1:8300:8	I-AdverseReaction
)	PRADAXA.xml:S1:8308:1	O
,	PRADAXA.xml:S1:8309:1	O
bleeding	PRADAXA.xml:S1:8311:8	B-AdverseReaction
causing	PRADAXA.xml:S1:8320:7	O
a	PRADAXA.xml:S1:8328:1	O
fall	PRADAXA.xml:S1:8330:4	B-AdverseReaction
in	PRADAXA.xml:S1:8335:2	I-AdverseReaction
hemoglobin	PRADAXA.xml:S1:8338:10	I-AdverseReaction
level	PRADAXA.xml:S1:8349:5	I-AdverseReaction
of	PRADAXA.xml:S1:8355:2	O
2.0	PRADAXA.xml:S1:8358:3	B-Severity
g	PRADAXA.xml:S1:8362:1	I-Severity
dL	PRADAXA.xml:S1:8364:2	I-Severity
(	PRADAXA.xml:S1:8367:1	O
1.24	PRADAXA.xml:S1:8368:4	O
mmol	PRADAXA.xml:S1:8373:4	O
L	PRADAXA.xml:S1:8378:1	O
or	PRADAXA.xml:S1:8380:2	O
more	PRADAXA.xml:S1:8383:4	O
,	PRADAXA.xml:S1:8387:1	O
or	PRADAXA.xml:S1:8389:2	O
leading	PRADAXA.xml:S1:8392:7	O
to	PRADAXA.xml:S1:8400:2	O
transfusion	PRADAXA.xml:S1:8403:11	O
of	PRADAXA.xml:S1:8415:2	O
2	PRADAXA.xml:S1:8418:1	O
or	PRADAXA.xml:S1:8420:2	O
more	PRADAXA.xml:S1:8423:4	O
units	PRADAXA.xml:S1:8428:5	O
of	PRADAXA.xml:S1:8434:2	O
whole	PRADAXA.xml:S1:8437:5	O
blood	PRADAXA.xml:S1:8443:5	O
or	PRADAXA.xml:S1:8449:2	O
red	PRADAXA.xml:S1:8452:3	O
cells	PRADAXA.xml:S1:8456:5	O
)	PRADAXA.xml:S1:8461:1	O
.	PRADAXA.xml:S1:8462:1	O

RE	PRADAXA.xml:S1:8468:2	O
-	PRADAXA.xml:S1:8470:1	O
COVER	PRADAXA.xml:S1:8471:5	O
and	PRADAXA.xml:S1:8477:3	O
RE	PRADAXA.xml:S1:8481:2	O
-	PRADAXA.xml:S1:8483:1	O
COVER	PRADAXA.xml:S1:8484:5	O
II	PRADAXA.xml:S1:8490:2	O
studies	PRADAXA.xml:S1:8493:7	O
compared	PRADAXA.xml:S1:8501:8	O
PRADAXA	PRADAXA.xml:S1:8510:7	O
150	PRADAXA.xml:S1:8518:3	O
mg	PRADAXA.xml:S1:8522:2	O
twice	PRADAXA.xml:S1:8525:5	O
daily	PRADAXA.xml:S1:8531:5	O
and	PRADAXA.xml:S1:8537:3	O
warfarin	PRADAXA.xml:S1:8541:8	O
for	PRADAXA.xml:S1:8550:3	O
the	PRADAXA.xml:S1:8554:3	O
treatment	PRADAXA.xml:S1:8558:9	O
of	PRADAXA.xml:S1:8568:2	O
deep	PRADAXA.xml:S1:8571:4	O
vein	PRADAXA.xml:S1:8576:4	O
thrombosis	PRADAXA.xml:S1:8581:10	O
and	PRADAXA.xml:S1:8592:3	O
pulmonary	PRADAXA.xml:S1:8596:9	O
embolism	PRADAXA.xml:S1:8606:8	O
.	PRADAXA.xml:S1:8614:1	O

Patients	PRADAXA.xml:S1:8616:8	O
received	PRADAXA.xml:S1:8625:8	O
5	PRADAXA.xml:S1:8634:1	O
-	PRADAXA.xml:S1:8635:1	O
10	PRADAXA.xml:S1:8636:2	O
days	PRADAXA.xml:S1:8639:4	O
of	PRADAXA.xml:S1:8644:2	O
an	PRADAXA.xml:S1:8647:2	O
approved	PRADAXA.xml:S1:8650:8	O
parenteral	PRADAXA.xml:S1:8659:10	O
anticoagulant	PRADAXA.xml:S1:8670:13	O
therapy	PRADAXA.xml:S1:8684:7	O
followed	PRADAXA.xml:S1:8692:8	O
by	PRADAXA.xml:S1:8701:2	O
6	PRADAXA.xml:S1:8704:1	O
months	PRADAXA.xml:S1:8706:6	O
,	PRADAXA.xml:S1:8712:1	O
with	PRADAXA.xml:S1:8714:4	O
mean	PRADAXA.xml:S1:8719:4	O
exposure	PRADAXA.xml:S1:8724:8	O
of	PRADAXA.xml:S1:8733:2	O
164	PRADAXA.xml:S1:8736:3	O
days	PRADAXA.xml:S1:8740:4	O
,	PRADAXA.xml:S1:8744:1	O
of	PRADAXA.xml:S1:8746:2	O
oral	PRADAXA.xml:S1:8749:4	O
only	PRADAXA.xml:S1:8754:4	O
treatment	PRADAXA.xml:S1:8759:9	O
;	PRADAXA.xml:S1:8768:1	O
warfarin	PRADAXA.xml:S1:8770:8	O
was	PRADAXA.xml:S1:8779:3	O
overlapped	PRADAXA.xml:S1:8783:10	O
with	PRADAXA.xml:S1:8794:4	O
parenteral	PRADAXA.xml:S1:8799:10	O
therapy	PRADAXA.xml:S1:8810:7	O
.	PRADAXA.xml:S1:8817:1	O

Table	PRADAXA.xml:S1:8819:5	O
3	PRADAXA.xml:S1:8825:1	O
shows	PRADAXA.xml:S1:8827:5	O
the	PRADAXA.xml:S1:8833:3	O
number	PRADAXA.xml:S1:8837:6	O
of	PRADAXA.xml:S1:8844:2	O
patients	PRADAXA.xml:S1:8847:8	O
experiencing	PRADAXA.xml:S1:8856:12	O
bleeding	PRADAXA.xml:S1:8869:8	B-AdverseReaction
events	PRADAXA.xml:S1:8878:6	O
in	PRADAXA.xml:S1:8885:2	O
the	PRADAXA.xml:S1:8888:3	O
pooled	PRADAXA.xml:S1:8892:6	O
analysis	PRADAXA.xml:S1:8899:8	O
of	PRADAXA.xml:S1:8908:2	O
RE	PRADAXA.xml:S1:8911:2	O
-	PRADAXA.xml:S1:8913:1	O
COVER	PRADAXA.xml:S1:8914:5	O
and	PRADAXA.xml:S1:8920:3	O
RE	PRADAXA.xml:S1:8924:2	O
-	PRADAXA.xml:S1:8926:1	O
COVER	PRADAXA.xml:S1:8927:5	O
II	PRADAXA.xml:S1:8933:2	O
studies	PRADAXA.xml:S1:8936:7	O
during	PRADAXA.xml:S1:8944:6	O
the	PRADAXA.xml:S1:8951:3	O
full	PRADAXA.xml:S1:8955:4	O
treatment	PRADAXA.xml:S1:8960:9	O
including	PRADAXA.xml:S1:8970:9	O
parenteral	PRADAXA.xml:S1:8980:10	O
and	PRADAXA.xml:S1:8991:3	O
oral	PRADAXA.xml:S1:8995:4	O
only	PRADAXA.xml:S1:9000:4	O
treatment	PRADAXA.xml:S1:9005:9	O
periods	PRADAXA.xml:S1:9015:7	O
after	PRADAXA.xml:S1:9023:5	O
randomization	PRADAXA.xml:S1:9029:13	O
.	PRADAXA.xml:S1:9042:1	O

Table	PRADAXA.xml:S1:9048:5	O
3	PRADAXA.xml:S1:9054:1	O
Bleeding	PRADAXA.xml:S1:9056:8	B-AdverseReaction
Events	PRADAXA.xml:S1:9065:6	O
in	PRADAXA.xml:S1:9072:2	O
RE	PRADAXA.xml:S1:9075:2	O
-	PRADAXA.xml:S1:9077:1	O
COVER	PRADAXA.xml:S1:9078:5	O
and	PRADAXA.xml:S1:9084:3	O
RE	PRADAXA.xml:S1:9088:2	O
-	PRADAXA.xml:S1:9090:1	O
COVER	PRADAXA.xml:S1:9091:5	O
II	PRADAXA.xml:S1:9097:2	O
Treated	PRADAXA.xml:S1:9100:7	O
Patients	PRADAXA.xml:S1:9108:8	O

Note	PRADAXA.xml:S1:9119:4	O
:	PRADAXA.xml:S1:9123:1	O
MBE	PRADAXA.xml:S1:9125:3	B-AdverseReaction
can	PRADAXA.xml:S1:9129:3	O
belong	PRADAXA.xml:S1:9133:6	O
to	PRADAXA.xml:S1:9140:2	O
more	PRADAXA.xml:S1:9143:4	O
than	PRADAXA.xml:S1:9148:4	O
one	PRADAXA.xml:S1:9153:3	O
criterion	PRADAXA.xml:S1:9157:9	O
.	PRADAXA.xml:S1:9166:1	O

a	PRADAXA.xml:S1:9169:1	O
Patients	PRADAXA.xml:S1:9172:8	O
with	PRADAXA.xml:S1:9181:4	O
at	PRADAXA.xml:S1:9186:2	O
least	PRADAXA.xml:S1:9189:5	O
one	PRADAXA.xml:S1:9195:3	O
MBE	PRADAXA.xml:S1:9199:3	B-AdverseReaction
.	PRADAXA.xml:S1:9202:1	O

b	PRADAXA.xml:S1:9205:1	O
Bleeding	PRADAXA.xml:S1:9208:8	B-AdverseReaction
site	PRADAXA.xml:S1:9217:4	O
based	PRADAXA.xml:S1:9222:5	O
on	PRADAXA.xml:S1:9228:2	O
investigator	PRADAXA.xml:S1:9231:12	O
assessment	PRADAXA.xml:S1:9244:10	O
.	PRADAXA.xml:S1:9254:1	O

Patients	PRADAXA.xml:S1:9256:8	O
can	PRADAXA.xml:S1:9265:3	O
have	PRADAXA.xml:S1:9269:4	O
more	PRADAXA.xml:S1:9274:4	O
than	PRADAXA.xml:S1:9279:4	O
one	PRADAXA.xml:S1:9284:3	O
site	PRADAXA.xml:S1:9288:4	O
of	PRADAXA.xml:S1:9293:2	O
bleeding	PRADAXA.xml:S1:9296:8	B-AdverseReaction
.	PRADAXA.xml:S1:9304:1	O

c	PRADAXA.xml:S1:9307:1	O
Confidence	PRADAXA.xml:S1:9310:10	O
interval	PRADAXA.xml:S1:9321:8	O

Patients	PRADAXA.xml:S1:9380:8	O

Major	PRADAXA.xml:S1:9397:5	B-Severity

bleeding	PRADAXA.xml:S1:9403:8	B-AdverseReaction

event	PRADAXA.xml:S1:9412:5	O

a	PRADAXA.xml:S1:9419:1	O

Bleeding	PRADAXA.xml:S1:9487:8	B-AdverseReaction

sites	PRADAXA.xml:S1:9496:5	O

for	PRADAXA.xml:S1:9502:3	O

MBE	PRADAXA.xml:S1:9506:3	B-AdverseReaction
b	PRADAXA.xml:S1:9511:1	O

Clinically	PRADAXA.xml:S1:9659:10	O

relevant	PRADAXA.xml:S1:9670:8	O

non	PRADAXA.xml:S1:9679:3	B-Severity

-	PRADAXA.xml:S1:9682:1	I-Severity

major	PRADAXA.xml:S1:9683:5	I-Severity

bleeding	PRADAXA.xml:S1:9689:8	B-AdverseReaction

Any	PRADAXA.xml:S1:9703:3	O

bleeding	PRADAXA.xml:S1:9707:8	B-AdverseReaction

The	PRADAXA.xml:S1:9727:3	O

rate	PRADAXA.xml:S1:9731:4	O
of	PRADAXA.xml:S1:9736:2	O
any	PRADAXA.xml:S1:9739:3	O
gastrointestinal	PRADAXA.xml:S1:9743:16	B-AdverseReaction
bleeds	PRADAXA.xml:S1:9760:6	I-AdverseReaction
in	PRADAXA.xml:S1:9767:2	O
patients	PRADAXA.xml:S1:9770:8	O
receiving	PRADAXA.xml:S1:9779:9	O
PRADAXA	PRADAXA.xml:S1:9789:7	O
150	PRADAXA.xml:S1:9797:3	O
mg	PRADAXA.xml:S1:9801:2	O
in	PRADAXA.xml:S1:9804:2	O
the	PRADAXA.xml:S1:9807:3	O
full	PRADAXA.xml:S1:9811:4	O
treatment	PRADAXA.xml:S1:9816:9	O
period	PRADAXA.xml:S1:9826:6	O
was	PRADAXA.xml:S1:9833:3	O
3.1%	PRADAXA.xml:S1:9837:4	O
(	PRADAXA.xml:S1:9842:1	O
2.4%	PRADAXA.xml:S1:9843:4	O
on	PRADAXA.xml:S1:9848:2	O
warfarin	PRADAXA.xml:S1:9851:8	O
)	PRADAXA.xml:S1:9859:1	O
.	PRADAXA.xml:S1:9860:1	O

The	PRADAXA.xml:S1:9866:3	O

RE	PRADAXA.xml:S1:9870:2	O
-	PRADAXA.xml:S1:9872:1	O
MEDY	PRADAXA.xml:S1:9873:4	O
and	PRADAXA.xml:S1:9878:3	O
RE	PRADAXA.xml:S1:9882:2	O
-	PRADAXA.xml:S1:9884:1	O
SONATE	PRADAXA.xml:S1:9885:6	O
studies	PRADAXA.xml:S1:9892:7	O
provided	PRADAXA.xml:S1:9900:8	O
safety	PRADAXA.xml:S1:9909:6	O
information	PRADAXA.xml:S1:9916:11	O
on	PRADAXA.xml:S1:9928:2	O
the	PRADAXA.xml:S1:9931:3	O
use	PRADAXA.xml:S1:9935:3	O
of	PRADAXA.xml:S1:9939:2	O
PRADAXA	PRADAXA.xml:S1:9942:7	O
for	PRADAXA.xml:S1:9950:3	O
the	PRADAXA.xml:S1:9954:3	O
reduction	PRADAXA.xml:S1:9958:9	O
in	PRADAXA.xml:S1:9968:2	O
the	PRADAXA.xml:S1:9971:3	O
risk	PRADAXA.xml:S1:9975:4	O
of	PRADAXA.xml:S1:9980:2	O
recurrence	PRADAXA.xml:S1:9983:10	O
of	PRADAXA.xml:S1:9994:2	O
deep	PRADAXA.xml:S1:9997:4	O
vein	PRADAXA.xml:S1:10002:4	O
thrombosis	PRADAXA.xml:S1:10007:10	O
and	PRADAXA.xml:S1:10018:3	O
pulmonary	PRADAXA.xml:S1:10022:9	O
embolism	PRADAXA.xml:S1:10032:8	O
.	PRADAXA.xml:S1:10040:1	O

RE	PRADAXA.xml:S1:10046:2	O
-	PRADAXA.xml:S1:10048:1	O
MEDY	PRADAXA.xml:S1:10049:4	O
was	PRADAXA.xml:S1:10054:3	O
an	PRADAXA.xml:S1:10058:2	O
active	PRADAXA.xml:S1:10061:6	O
-	PRADAXA.xml:S1:10067:1	O
controlled	PRADAXA.xml:S1:10068:10	O
study	PRADAXA.xml:S1:10079:5	O
(	PRADAXA.xml:S1:10085:1	O
warfarin	PRADAXA.xml:S1:10086:8	O
)	PRADAXA.xml:S1:10094:1	O
in	PRADAXA.xml:S1:10096:2	O
which	PRADAXA.xml:S1:10099:5	O
1430	PRADAXA.xml:S1:10105:4	O
patients	PRADAXA.xml:S1:10110:8	O
received	PRADAXA.xml:S1:10119:8	O
PRADAXA	PRADAXA.xml:S1:10128:7	O
150	PRADAXA.xml:S1:10136:3	O
mg	PRADAXA.xml:S1:10140:2	O
twice	PRADAXA.xml:S1:10143:5	O
daily	PRADAXA.xml:S1:10149:5	O
following	PRADAXA.xml:S1:10155:9	O
3	PRADAXA.xml:S1:10165:1	O
to	PRADAXA.xml:S1:10167:2	O
12	PRADAXA.xml:S1:10170:2	O
months	PRADAXA.xml:S1:10173:6	O
of	PRADAXA.xml:S1:10180:2	O
oral	PRADAXA.xml:S1:10183:4	O
anticoagulant	PRADAXA.xml:S1:10188:13	O
regimen	PRADAXA.xml:S1:10202:7	O
.	PRADAXA.xml:S1:10209:1	O

Patients	PRADAXA.xml:S1:10211:8	O
in	PRADAXA.xml:S1:10220:2	O
the	PRADAXA.xml:S1:10223:3	O
treatment	PRADAXA.xml:S1:10227:9	O
studies	PRADAXA.xml:S1:10237:7	O
who	PRADAXA.xml:S1:10245:3	O
rolled	PRADAXA.xml:S1:10249:6	O
over	PRADAXA.xml:S1:10256:4	O
into	PRADAXA.xml:S1:10261:4	O
the	PRADAXA.xml:S1:10266:3	O
RE	PRADAXA.xml:S1:10270:2	O
-	PRADAXA.xml:S1:10272:1	O
MEDY	PRADAXA.xml:S1:10273:4	O
study	PRADAXA.xml:S1:10278:5	O
had	PRADAXA.xml:S1:10284:3	O
a	PRADAXA.xml:S1:10288:1	O
combined	PRADAXA.xml:S1:10290:8	O
treatment	PRADAXA.xml:S1:10299:9	O
duration	PRADAXA.xml:S1:10309:8	O
of	PRADAXA.xml:S1:10318:2	O
up	PRADAXA.xml:S1:10321:2	O
to	PRADAXA.xml:S1:10324:2	O
more	PRADAXA.xml:S1:10327:4	O
than	PRADAXA.xml:S1:10332:4	O
3	PRADAXA.xml:S1:10337:1	O
years	PRADAXA.xml:S1:10339:5	O
,	PRADAXA.xml:S1:10344:1	O
with	PRADAXA.xml:S1:10346:4	O
mean	PRADAXA.xml:S1:10351:4	O
exposure	PRADAXA.xml:S1:10356:8	O
of	PRADAXA.xml:S1:10365:2	O
473	PRADAXA.xml:S1:10368:3	O
days	PRADAXA.xml:S1:10372:4	O
.	PRADAXA.xml:S1:10376:1	O

Table	PRADAXA.xml:S1:10378:5	O
4	PRADAXA.xml:S1:10384:1	O
shows	PRADAXA.xml:S1:10386:5	O
the	PRADAXA.xml:S1:10392:3	O
number	PRADAXA.xml:S1:10396:6	O
of	PRADAXA.xml:S1:10403:2	O
patients	PRADAXA.xml:S1:10406:8	O
experiencing	PRADAXA.xml:S1:10415:12	O
bleeding	PRADAXA.xml:S1:10428:8	B-AdverseReaction
events	PRADAXA.xml:S1:10437:6	O
in	PRADAXA.xml:S1:10444:2	O
the	PRADAXA.xml:S1:10447:3	O
study	PRADAXA.xml:S1:10451:5	O
.	PRADAXA.xml:S1:10456:1	O

Table	PRADAXA.xml:S1:10462:5	O
4	PRADAXA.xml:S1:10468:1	O
Bleeding	PRADAXA.xml:S1:10470:8	B-AdverseReaction
Events	PRADAXA.xml:S1:10479:6	O
in	PRADAXA.xml:S1:10486:2	O
RE	PRADAXA.xml:S1:10489:2	O
-	PRADAXA.xml:S1:10491:1	O
MEDY	PRADAXA.xml:S1:10492:4	O
Treated	PRADAXA.xml:S1:10497:7	O
Patients	PRADAXA.xml:S1:10505:8	O

Note	PRADAXA.xml:S1:10516:4	O
:	PRADAXA.xml:S1:10520:1	O
MBE	PRADAXA.xml:S1:10522:3	B-AdverseReaction
can	PRADAXA.xml:S1:10526:3	O
belong	PRADAXA.xml:S1:10530:6	O
to	PRADAXA.xml:S1:10537:2	O
more	PRADAXA.xml:S1:10540:4	O
than	PRADAXA.xml:S1:10545:4	O
one	PRADAXA.xml:S1:10550:3	O
criterion	PRADAXA.xml:S1:10554:9	O
.	PRADAXA.xml:S1:10563:1	O

a	PRADAXA.xml:S1:10566:1	O
Patients	PRADAXA.xml:S1:10569:8	O
with	PRADAXA.xml:S1:10578:4	O
at	PRADAXA.xml:S1:10583:2	O
least	PRADAXA.xml:S1:10586:5	O
one	PRADAXA.xml:S1:10592:3	O
MBE	PRADAXA.xml:S1:10596:3	B-AdverseReaction
.	PRADAXA.xml:S1:10599:1	O

b	PRADAXA.xml:S1:10602:1	O
Bleeding	PRADAXA.xml:S1:10605:8	B-AdverseReaction
site	PRADAXA.xml:S1:10614:4	O
based	PRADAXA.xml:S1:10619:5	O
on	PRADAXA.xml:S1:10625:2	O
investigator	PRADAXA.xml:S1:10628:12	O
assessment	PRADAXA.xml:S1:10641:10	O
.	PRADAXA.xml:S1:10651:1	O

Patients	PRADAXA.xml:S1:10653:8	O
can	PRADAXA.xml:S1:10662:3	O
have	PRADAXA.xml:S1:10666:4	O
more	PRADAXA.xml:S1:10671:4	O
than	PRADAXA.xml:S1:10676:4	O
one	PRADAXA.xml:S1:10681:3	O
site	PRADAXA.xml:S1:10685:4	O
of	PRADAXA.xml:S1:10690:2	O
bleeding	PRADAXA.xml:S1:10693:8	B-AdverseReaction
.	PRADAXA.xml:S1:10701:1	O

c	PRADAXA.xml:S1:10704:1	O
Confidence	PRADAXA.xml:S1:10707:10	O
interval	PRADAXA.xml:S1:10718:8	O

Patients	PRADAXA.xml:S1:10757:8	O

Major	PRADAXA.xml:S1:10774:5	B-Severity

bleeding	PRADAXA.xml:S1:10780:8	B-AdverseReaction

event	PRADAXA.xml:S1:10789:5	O
a	PRADAXA.xml:S1:10796:1	O

Bleeding	PRADAXA.xml:S1:10864:8	B-AdverseReaction

sites	PRADAXA.xml:S1:10873:5	O

for	PRADAXA.xml:S1:10879:3	O

MBE	PRADAXA.xml:S1:10883:3	B-AdverseReaction
b	PRADAXA.xml:S1:10888:1	O

Clinically	PRADAXA.xml:S1:11056:10	O

relevant	PRADAXA.xml:S1:11067:8	O

non	PRADAXA.xml:S1:11076:3	B-Severity

-	PRADAXA.xml:S1:11079:1	I-Severity

major	PRADAXA.xml:S1:11080:5	I-Severity

bleeding	PRADAXA.xml:S1:11086:8	B-AdverseReaction

Any	PRADAXA.xml:S1:11100:3	O

bleeding	PRADAXA.xml:S1:11104:8	B-AdverseReaction

In	PRADAXA.xml:S1:11124:2	O

the	PRADAXA.xml:S1:11127:3	O

RE	PRADAXA.xml:S1:11131:2	O
-	PRADAXA.xml:S1:11133:1	O
MEDY	PRADAXA.xml:S1:11134:4	O
study	PRADAXA.xml:S1:11139:5	O
,	PRADAXA.xml:S1:11144:1	O
the	PRADAXA.xml:S1:11146:3	O
rate	PRADAXA.xml:S1:11150:4	O
of	PRADAXA.xml:S1:11155:2	O
any	PRADAXA.xml:S1:11158:3	O
gastrointestinal	PRADAXA.xml:S1:11162:16	B-AdverseReaction
bleeds	PRADAXA.xml:S1:11179:6	I-AdverseReaction
in	PRADAXA.xml:S1:11186:2	O
patients	PRADAXA.xml:S1:11189:8	O
receiving	PRADAXA.xml:S1:11198:9	O
PRADAXA	PRADAXA.xml:S1:11208:7	O
150	PRADAXA.xml:S1:11216:3	O
mg	PRADAXA.xml:S1:11220:2	O
was	PRADAXA.xml:S1:11223:3	O
3.1%	PRADAXA.xml:S1:11227:4	O
(	PRADAXA.xml:S1:11232:1	O
2.2%	PRADAXA.xml:S1:11233:4	O
on	PRADAXA.xml:S1:11238:2	O
warfarin	PRADAXA.xml:S1:11241:8	O
)	PRADAXA.xml:S1:11249:1	O
.	PRADAXA.xml:S1:11250:1	O

RE	PRADAXA.xml:S1:11256:2	O

-	PRADAXA.xml:S1:11258:1	O
SONATE	PRADAXA.xml:S1:11259:6	O
was	PRADAXA.xml:S1:11266:3	O
a	PRADAXA.xml:S1:11270:1	O
placebo	PRADAXA.xml:S1:11272:7	O
-	PRADAXA.xml:S1:11279:1	O
controlled	PRADAXA.xml:S1:11280:10	O
study	PRADAXA.xml:S1:11291:5	O
in	PRADAXA.xml:S1:11297:2	O
which	PRADAXA.xml:S1:11300:5	O
684	PRADAXA.xml:S1:11306:3	O
patients	PRADAXA.xml:S1:11310:8	O
received	PRADAXA.xml:S1:11319:8	O
PRADAXA	PRADAXA.xml:S1:11328:7	O
150	PRADAXA.xml:S1:11336:3	O
mg	PRADAXA.xml:S1:11340:2	O
twice	PRADAXA.xml:S1:11343:5	O
daily	PRADAXA.xml:S1:11349:5	O
following	PRADAXA.xml:S1:11355:9	O
6	PRADAXA.xml:S1:11365:1	O
to	PRADAXA.xml:S1:11367:2	O
18	PRADAXA.xml:S1:11370:2	O
months	PRADAXA.xml:S1:11373:6	O
of	PRADAXA.xml:S1:11380:2	O
oral	PRADAXA.xml:S1:11383:4	O
anticoagulant	PRADAXA.xml:S1:11388:13	O
regimen	PRADAXA.xml:S1:11402:7	O
.	PRADAXA.xml:S1:11409:1	O

Patients	PRADAXA.xml:S1:11411:8	O
in	PRADAXA.xml:S1:11420:2	O
the	PRADAXA.xml:S1:11423:3	O
treatment	PRADAXA.xml:S1:11427:9	O
studies	PRADAXA.xml:S1:11437:7	O
who	PRADAXA.xml:S1:11445:3	O
rolled	PRADAXA.xml:S1:11449:6	O
over	PRADAXA.xml:S1:11456:4	O
into	PRADAXA.xml:S1:11461:4	O
the	PRADAXA.xml:S1:11466:3	O
RE	PRADAXA.xml:S1:11470:2	O
-	PRADAXA.xml:S1:11472:1	O
SONATE	PRADAXA.xml:S1:11473:6	O
study	PRADAXA.xml:S1:11480:5	O
had	PRADAXA.xml:S1:11486:3	O
combined	PRADAXA.xml:S1:11490:8	O
treatment	PRADAXA.xml:S1:11499:9	O
duration	PRADAXA.xml:S1:11509:8	O
up	PRADAXA.xml:S1:11518:2	O
to	PRADAXA.xml:S1:11521:2	O
9	PRADAXA.xml:S1:11524:1	O
months	PRADAXA.xml:S1:11526:6	O
,	PRADAXA.xml:S1:11532:1	O
with	PRADAXA.xml:S1:11534:4	O
mean	PRADAXA.xml:S1:11539:4	O
exposure	PRADAXA.xml:S1:11544:8	O
of	PRADAXA.xml:S1:11553:2	O
165	PRADAXA.xml:S1:11556:3	O
days	PRADAXA.xml:S1:11560:4	O
.	PRADAXA.xml:S1:11564:1	O

Table	PRADAXA.xml:S1:11566:5	O
5	PRADAXA.xml:S1:11572:1	O
shows	PRADAXA.xml:S1:11574:5	O
the	PRADAXA.xml:S1:11580:3	O
number	PRADAXA.xml:S1:11584:6	O
of	PRADAXA.xml:S1:11591:2	O
patients	PRADAXA.xml:S1:11594:8	O
experiencing	PRADAXA.xml:S1:11603:12	O
bleeding	PRADAXA.xml:S1:11616:8	B-AdverseReaction
events	PRADAXA.xml:S1:11625:6	O
in	PRADAXA.xml:S1:11632:2	O
the	PRADAXA.xml:S1:11635:3	O
study	PRADAXA.xml:S1:11639:5	O
.	PRADAXA.xml:S1:11644:1	O

Table	PRADAXA.xml:S1:11650:5	O
5	PRADAXA.xml:S1:11656:1	O
Bleeding	PRADAXA.xml:S1:11658:8	B-AdverseReaction
Events	PRADAXA.xml:S1:11667:6	O
in	PRADAXA.xml:S1:11674:2	O
RE	PRADAXA.xml:S1:11677:2	O
-	PRADAXA.xml:S1:11679:1	O
SONATE	PRADAXA.xml:S1:11680:6	O
Treated	PRADAXA.xml:S1:11687:7	O
Patients	PRADAXA.xml:S1:11695:8	O

Note	PRADAXA.xml:S1:11706:4	O
:	PRADAXA.xml:S1:11710:1	O
MBE	PRADAXA.xml:S1:11712:3	B-AdverseReaction
can	PRADAXA.xml:S1:11716:3	O
belong	PRADAXA.xml:S1:11720:6	O
to	PRADAXA.xml:S1:11727:2	O
more	PRADAXA.xml:S1:11730:4	O
than	PRADAXA.xml:S1:11735:4	O
one	PRADAXA.xml:S1:11740:3	O
criterion	PRADAXA.xml:S1:11744:9	O
.	PRADAXA.xml:S1:11753:1	O

a	PRADAXA.xml:S1:11756:1	O
Patients	PRADAXA.xml:S1:11759:8	O
with	PRADAXA.xml:S1:11768:4	O
at	PRADAXA.xml:S1:11773:2	O
least	PRADAXA.xml:S1:11776:5	O
one	PRADAXA.xml:S1:11782:3	O
MBE	PRADAXA.xml:S1:11786:3	B-AdverseReaction
.	PRADAXA.xml:S1:11789:1	O

b	PRADAXA.xml:S1:11792:1	O
Bleeding	PRADAXA.xml:S1:11795:8	B-AdverseReaction
site	PRADAXA.xml:S1:11804:4	O
based	PRADAXA.xml:S1:11809:5	O
on	PRADAXA.xml:S1:11815:2	O
investigator	PRADAXA.xml:S1:11818:12	O
assessment	PRADAXA.xml:S1:11831:10	O
.	PRADAXA.xml:S1:11841:1	O

Patients	PRADAXA.xml:S1:11843:8	O
can	PRADAXA.xml:S1:11852:3	O
have	PRADAXA.xml:S1:11856:4	O
more	PRADAXA.xml:S1:11861:4	O
than	PRADAXA.xml:S1:11866:4	O
one	PRADAXA.xml:S1:11871:3	O
site	PRADAXA.xml:S1:11875:4	O
of	PRADAXA.xml:S1:11880:2	O
bleeding	PRADAXA.xml:S1:11883:8	B-AdverseReaction
.	PRADAXA.xml:S1:11891:1	O

c	PRADAXA.xml:S1:11894:1	O
Confidence	PRADAXA.xml:S1:11897:10	O
interval	PRADAXA.xml:S1:11908:8	O

Patients	PRADAXA.xml:S1:11947:8	O

Major	PRADAXA.xml:S1:11964:5	B-Severity

bleeding	PRADAXA.xml:S1:11970:8	B-AdverseReaction

event	PRADAXA.xml:S1:11979:5	O
a	PRADAXA.xml:S1:11986:1	O

Clinically	PRADAXA.xml:S1:12034:10	O

relevant	PRADAXA.xml:S1:12045:8	O

non	PRADAXA.xml:S1:12054:3	B-Severity
-	PRADAXA.xml:S1:12057:1	I-Severity
major	PRADAXA.xml:S1:12058:5	I-Severity
bleeding	PRADAXA.xml:S1:12064:8	B-AdverseReaction

Any	PRADAXA.xml:S1:12078:3	O
bleeding	PRADAXA.xml:S1:12082:8	B-AdverseReaction

In	PRADAXA.xml:S1:12102:2	O
the	PRADAXA.xml:S1:12105:3	O
RE	PRADAXA.xml:S1:12109:2	O
-	PRADAXA.xml:S1:12111:1	O
SONATE	PRADAXA.xml:S1:12112:6	O
study	PRADAXA.xml:S1:12119:5	O
,	PRADAXA.xml:S1:12124:1	O
the	PRADAXA.xml:S1:12126:3	O
rate	PRADAXA.xml:S1:12130:4	O
of	PRADAXA.xml:S1:12135:2	O
any	PRADAXA.xml:S1:12138:3	O
gastrointestinal	PRADAXA.xml:S1:12142:16	B-AdverseReaction
bleeds	PRADAXA.xml:S1:12159:6	I-AdverseReaction
in	PRADAXA.xml:S1:12166:2	O
patients	PRADAXA.xml:S1:12169:8	O
receiving	PRADAXA.xml:S1:12178:9	O
PRADAXA	PRADAXA.xml:S1:12188:7	O
150	PRADAXA.xml:S1:12196:3	O
mg	PRADAXA.xml:S1:12200:2	O
was	PRADAXA.xml:S1:12203:3	O
0.7%	PRADAXA.xml:S1:12207:4	O
(	PRADAXA.xml:S1:12212:1	O
0.3%	PRADAXA.xml:S1:12213:4	O
on	PRADAXA.xml:S1:12218:2	O
placebo	PRADAXA.xml:S1:12221:7	O
)	PRADAXA.xml:S1:12228:1	O
.	PRADAXA.xml:S1:12229:1	O

Clinical	PRADAXA.xml:S1:12237:8	O

Myocardial	PRADAXA.xml:S1:12246:10	O
Infarction	PRADAXA.xml:S1:12257:10	O
Events	PRADAXA.xml:S1:12268:6	O
In	PRADAXA.xml:S1:12276:2	O
the	PRADAXA.xml:S1:12279:3	O
active	PRADAXA.xml:S1:12283:6	O
-	PRADAXA.xml:S1:12289:1	O
controlled	PRADAXA.xml:S1:12290:10	O
VTE	PRADAXA.xml:S1:12301:3	O
studies	PRADAXA.xml:S1:12305:7	O
,	PRADAXA.xml:S1:12312:1	O
a	PRADAXA.xml:S1:12314:1	O
higher	PRADAXA.xml:S1:12316:6	O
rate	PRADAXA.xml:S1:12323:4	O
of	PRADAXA.xml:S1:12328:2	O
clinical	PRADAXA.xml:S1:12331:8	O
myocardial	PRADAXA.xml:S1:12340:10	B-AdverseReaction
infarction	PRADAXA.xml:S1:12351:10	I-AdverseReaction
was	PRADAXA.xml:S1:12362:3	O
reported	PRADAXA.xml:S1:12366:8	O
in	PRADAXA.xml:S1:12375:2	O
patients	PRADAXA.xml:S1:12378:8	O
who	PRADAXA.xml:S1:12387:3	O
received	PRADAXA.xml:S1:12391:8	O
PRADAXA	PRADAXA.xml:S1:12400:7	O
[	PRADAXA.xml:S1:12408:1	O
20	PRADAXA.xml:S1:12409:2	O
(	PRADAXA.xml:S1:12412:1	O
0.66	PRADAXA.xml:S1:12413:4	O
per	PRADAXA.xml:S1:12418:3	O
100	PRADAXA.xml:S1:12422:3	O
patient	PRADAXA.xml:S1:12426:7	O
-	PRADAXA.xml:S1:12433:1	O
years	PRADAXA.xml:S1:12434:5	O
)]	PRADAXA.xml:S1:12439:2	O
than	PRADAXA.xml:S1:12442:4	O
in	PRADAXA.xml:S1:12447:2	O
those	PRADAXA.xml:S1:12450:5	O
who	PRADAXA.xml:S1:12456:3	O
received	PRADAXA.xml:S1:12460:8	O
warfarin	PRADAXA.xml:S1:12469:8	O
[	PRADAXA.xml:S1:12478:1	O
5	PRADAXA.xml:S1:12479:1	O
(	PRADAXA.xml:S1:12481:1	O
0.17	PRADAXA.xml:S1:12482:4	O
per	PRADAXA.xml:S1:12487:3	O
100	PRADAXA.xml:S1:12491:3	O
patient	PRADAXA.xml:S1:12495:7	O
-	PRADAXA.xml:S1:12502:1	O
years	PRADAXA.xml:S1:12503:5	O
)]	PRADAXA.xml:S1:12508:2	O
.	PRADAXA.xml:S1:12510:1	O

In	PRADAXA.xml:S1:12512:2	O
the	PRADAXA.xml:S1:12515:3	O
placebo	PRADAXA.xml:S1:12519:7	O
-	PRADAXA.xml:S1:12526:1	O
controlled	PRADAXA.xml:S1:12527:10	O
study	PRADAXA.xml:S1:12538:5	O
,	PRADAXA.xml:S1:12543:1	O
a	PRADAXA.xml:S1:12545:1	O
similar	PRADAXA.xml:S1:12547:7	O
rate	PRADAXA.xml:S1:12555:4	O
of	PRADAXA.xml:S1:12560:2	O
non	PRADAXA.xml:S1:12563:3	B-Severity
-	PRADAXA.xml:S1:12566:1	I-Severity
fatal	PRADAXA.xml:S1:12567:5	I-Severity
and	PRADAXA.xml:S1:12573:3	O
fatal	PRADAXA.xml:S1:12577:5	B-AdverseReaction
clinical	PRADAXA.xml:S1:12583:8	O
myocardial	PRADAXA.xml:S1:12592:10	B-AdverseReaction
infarction	PRADAXA.xml:S1:12603:10	I-AdverseReaction
was	PRADAXA.xml:S1:12614:3	O
reported	PRADAXA.xml:S1:12618:8	O
in	PRADAXA.xml:S1:12627:2	O
patients	PRADAXA.xml:S1:12630:8	O
who	PRADAXA.xml:S1:12639:3	O
received	PRADAXA.xml:S1:12643:8	O
PRADAXA	PRADAXA.xml:S1:12652:7	O
[	PRADAXA.xml:S1:12660:1	O
1	PRADAXA.xml:S1:12661:1	O
(	PRADAXA.xml:S1:12663:1	O
0.32	PRADAXA.xml:S1:12664:4	O
per	PRADAXA.xml:S1:12669:3	O
100	PRADAXA.xml:S1:12673:3	O
patient	PRADAXA.xml:S1:12677:7	O
-	PRADAXA.xml:S1:12684:1	O
years	PRADAXA.xml:S1:12685:5	O
)]	PRADAXA.xml:S1:12690:2	O
and	PRADAXA.xml:S1:12693:3	O
in	PRADAXA.xml:S1:12697:2	O
those	PRADAXA.xml:S1:12700:5	O
who	PRADAXA.xml:S1:12706:3	O
received	PRADAXA.xml:S1:12710:8	O
placebo	PRADAXA.xml:S1:12719:7	O
[	PRADAXA.xml:S1:12727:1	O
1	PRADAXA.xml:S1:12728:1	O
(	PRADAXA.xml:S1:12730:1	O
0.34	PRADAXA.xml:S1:12731:4	O
per	PRADAXA.xml:S1:12736:3	O
100	PRADAXA.xml:S1:12740:3	O
patient	PRADAXA.xml:S1:12744:7	O
-	PRADAXA.xml:S1:12751:1	O
years	PRADAXA.xml:S1:12752:5	O
)]	PRADAXA.xml:S1:12757:2	O
.	PRADAXA.xml:S1:12759:1	O

Gastrointestinal	PRADAXA.xml:S1:12767:16	O
Adverse	PRADAXA.xml:S1:12784:7	O
Reactions	PRADAXA.xml:S1:12792:9	O
In	PRADAXA.xml:S1:12803:2	O
the	PRADAXA.xml:S1:12806:3	O
four	PRADAXA.xml:S1:12810:4	O
pivotal	PRADAXA.xml:S1:12815:7	O
studies	PRADAXA.xml:S1:12823:7	O
,	PRADAXA.xml:S1:12830:1	O
patients	PRADAXA.xml:S1:12832:8	O
on	PRADAXA.xml:S1:12841:2	O
PRADAXA	PRADAXA.xml:S1:12844:7	O
150	PRADAXA.xml:S1:12852:3	O
mg	PRADAXA.xml:S1:12856:2	O
had	PRADAXA.xml:S1:12859:3	O
a	PRADAXA.xml:S1:12863:1	O
similar	PRADAXA.xml:S1:12865:7	O
incidence	PRADAXA.xml:S1:12873:9	O
of	PRADAXA.xml:S1:12883:2	O
gastrointestinal	PRADAXA.xml:S1:12886:16	B-AdverseReaction
adverse	PRADAXA.xml:S1:12903:7	I-AdverseReaction
reactions	PRADAXA.xml:S1:12911:9	I-AdverseReaction
(	PRADAXA.xml:S1:12921:1	O
24.7%	PRADAXA.xml:S1:12922:5	O
vs	PRADAXA.xml:S1:12928:2	O
.	PRADAXA.xml:S1:12930:1	O

22.7%	PRADAXA.xml:S1:12932:5	O
on	PRADAXA.xml:S1:12938:2	O
warfarin	PRADAXA.xml:S1:12941:8	O
)	PRADAXA.xml:S1:12949:1	O
.	PRADAXA.xml:S1:12950:1	O

Dyspepsia	PRADAXA.xml:S1:12952:9	B-AdverseReaction
(	PRADAXA.xml:S1:12962:1	O
including	PRADAXA.xml:S1:12963:9	O
abdominal	PRADAXA.xml:S1:12973:9	B-AdverseReaction
pain	PRADAXA.xml:S1:12983:4	I-AdverseReaction
upper	PRADAXA.xml:S1:12988:5	I-AdverseReaction
,	PRADAXA.xml:S1:12993:1	O
abdominal	PRADAXA.xml:S1:12995:9	B-AdverseReaction
pain	PRADAXA.xml:S1:13005:4	I-AdverseReaction
,	PRADAXA.xml:S1:13009:1	O
abdominal	PRADAXA.xml:S1:13011:9	B-AdverseReaction
discomfort	PRADAXA.xml:S1:13021:10	I-AdverseReaction
,	PRADAXA.xml:S1:13031:1	O
and	PRADAXA.xml:S1:13033:3	O
epigastric	PRADAXA.xml:S1:13037:10	B-AdverseReaction
discomfort	PRADAXA.xml:S1:13048:10	I-AdverseReaction
)	PRADAXA.xml:S1:13058:1	O
occurred	PRADAXA.xml:S1:13060:8	O
in	PRADAXA.xml:S1:13069:2	O
patients	PRADAXA.xml:S1:13072:8	O
on	PRADAXA.xml:S1:13081:2	O
PRADAXA	PRADAXA.xml:S1:13084:7	O
in	PRADAXA.xml:S1:13092:2	O
7.5%	PRADAXA.xml:S1:13095:4	O
vs	PRADAXA.xml:S1:13100:2	O
.	PRADAXA.xml:S1:13102:1	O

5.5%	PRADAXA.xml:S1:13104:4	O
on	PRADAXA.xml:S1:13109:2	O
warfarin	PRADAXA.xml:S1:13112:8	O
,	PRADAXA.xml:S1:13120:1	O
and	PRADAXA.xml:S1:13122:3	O
gastritis	PRADAXA.xml:S1:13126:9	B-AdverseReaction
-	PRADAXA.xml:S1:13135:1	O
like	PRADAXA.xml:S1:13136:4	O
symptoms	PRADAXA.xml:S1:13141:8	O
(	PRADAXA.xml:S1:13150:1	O
including	PRADAXA.xml:S1:13151:9	O
gastritis	PRADAXA.xml:S1:13161:9	B-AdverseReaction
,	PRADAXA.xml:S1:13170:1	O
GERD	PRADAXA.xml:S1:13172:4	B-AdverseReaction
,	PRADAXA.xml:S1:13176:1	O
esophagitis	PRADAXA.xml:S1:13178:11	B-AdverseReaction
,	PRADAXA.xml:S1:13189:1	O
erosive	PRADAXA.xml:S1:13191:7	B-AdverseReaction
gastritis	PRADAXA.xml:S1:13199:9	I-AdverseReaction
and	PRADAXA.xml:S1:13209:3	O
gastric	PRADAXA.xml:S1:13213:7	B-AdverseReaction
hemorrhage	PRADAXA.xml:S1:13221:10	I-AdverseReaction
)	PRADAXA.xml:S1:13231:1	O
occurred	PRADAXA.xml:S1:13233:8	O
at	PRADAXA.xml:S1:13242:2	O
3.0%	PRADAXA.xml:S1:13245:4	O
vs	PRADAXA.xml:S1:13250:2	O
.	PRADAXA.xml:S1:13252:1	O

1.7%	PRADAXA.xml:S1:13254:4	O
,	PRADAXA.xml:S1:13258:1	O
respectively	PRADAXA.xml:S1:13260:12	O
.	PRADAXA.xml:S1:13272:1	O

Hypersensitivity	PRADAXA.xml:S1:13280:16	O
Reactions	PRADAXA.xml:S1:13297:9	O
In	PRADAXA.xml:S1:13308:2	O
the	PRADAXA.xml:S1:13311:3	O
4	PRADAXA.xml:S1:13315:1	O
pivotal	PRADAXA.xml:S1:13317:7	O
studies	PRADAXA.xml:S1:13325:7	O
,	PRADAXA.xml:S1:13332:1	O
drug	PRADAXA.xml:S1:13334:4	O
hypersensitivity	PRADAXA.xml:S1:13339:16	B-AdverseReaction
(	PRADAXA.xml:S1:13356:1	O
including	PRADAXA.xml:S1:13357:9	O
urticaria	PRADAXA.xml:S1:13367:9	B-AdverseReaction
,	PRADAXA.xml:S1:13376:1	O
rash	PRADAXA.xml:S1:13378:4	B-AdverseReaction
,	PRADAXA.xml:S1:13382:1	O
and	PRADAXA.xml:S1:13384:3	O
pruritus	PRADAXA.xml:S1:13388:8	B-AdverseReaction
)	PRADAXA.xml:S1:13396:1	O
,	PRADAXA.xml:S1:13397:1	O
allergic	PRADAXA.xml:S1:13399:8	B-AdverseReaction
edema	PRADAXA.xml:S1:13408:5	I-AdverseReaction
,	PRADAXA.xml:S1:13413:1	O
anaphylactic	PRADAXA.xml:S1:13415:12	B-AdverseReaction
reaction	PRADAXA.xml:S1:13428:8	I-AdverseReaction
,	PRADAXA.xml:S1:13436:1	O
and	PRADAXA.xml:S1:13438:3	O
anaphylactic	PRADAXA.xml:S1:13442:12	B-AdverseReaction
shock	PRADAXA.xml:S1:13455:5	I-AdverseReaction
were	PRADAXA.xml:S1:13461:4	O
reported	PRADAXA.xml:S1:13466:8	O
in	PRADAXA.xml:S1:13475:2	O
0.1%	PRADAXA.xml:S1:13478:4	O
of	PRADAXA.xml:S1:13483:2	O
patients	PRADAXA.xml:S1:13486:8	O
receiving	PRADAXA.xml:S1:13495:9	O
PRADAXA	PRADAXA.xml:S1:13505:7	O
.	PRADAXA.xml:S1:13512:1	O

6.2	PRADAXA.xml:S1:13520:3	O
Postmarketing	PRADAXA.xml:S1:13524:13	O
Experience	PRADAXA.xml:S1:13538:10	O

The	PRADAXA.xml:S1:13552:3	O
following	PRADAXA.xml:S1:13556:9	O
adverse	PRADAXA.xml:S1:13566:7	O
reactions	PRADAXA.xml:S1:13574:9	O
have	PRADAXA.xml:S1:13584:4	O
been	PRADAXA.xml:S1:13589:4	O
identified	PRADAXA.xml:S1:13594:10	O
during	PRADAXA.xml:S1:13605:6	O
post	PRADAXA.xml:S1:13612:4	O
approval	PRADAXA.xml:S1:13617:8	O
use	PRADAXA.xml:S1:13626:3	O
of	PRADAXA.xml:S1:13630:2	O
PRADAXA	PRADAXA.xml:S1:13633:7	O
.	PRADAXA.xml:S1:13640:1	O

Because	PRADAXA.xml:S1:13642:7	O
these	PRADAXA.xml:S1:13650:5	O
reactions	PRADAXA.xml:S1:13656:9	O
are	PRADAXA.xml:S1:13666:3	O
reported	PRADAXA.xml:S1:13670:8	O
voluntarily	PRADAXA.xml:S1:13679:11	O
from	PRADAXA.xml:S1:13691:4	O
a	PRADAXA.xml:S1:13696:1	O
population	PRADAXA.xml:S1:13698:10	O
of	PRADAXA.xml:S1:13709:2	O
uncertain	PRADAXA.xml:S1:13712:9	O
size	PRADAXA.xml:S1:13722:4	O
,	PRADAXA.xml:S1:13726:1	O
it	PRADAXA.xml:S1:13728:2	O
is	PRADAXA.xml:S1:13731:2	O
not	PRADAXA.xml:S1:13734:3	O
always	PRADAXA.xml:S1:13738:6	O
possible	PRADAXA.xml:S1:13745:8	O
to	PRADAXA.xml:S1:13754:2	O
reliably	PRADAXA.xml:S1:13757:8	O
estimate	PRADAXA.xml:S1:13766:8	O
their	PRADAXA.xml:S1:13775:5	O
frequency	PRADAXA.xml:S1:13781:9	O
or	PRADAXA.xml:S1:13791:2	O
establish	PRADAXA.xml:S1:13794:9	O
a	PRADAXA.xml:S1:13804:1	O
causal	PRADAXA.xml:S1:13806:6	O
relationship	PRADAXA.xml:S1:13813:12	O
to	PRADAXA.xml:S1:13826:2	O
drug	PRADAXA.xml:S1:13829:4	O
exposure	PRADAXA.xml:S1:13834:8	O
.	PRADAXA.xml:S1:13842:1	O

The	PRADAXA.xml:S1:13844:3	O
following	PRADAXA.xml:S1:13848:9	O
adverse	PRADAXA.xml:S1:13858:7	O
reactions	PRADAXA.xml:S1:13866:9	O
have	PRADAXA.xml:S1:13876:4	O
been	PRADAXA.xml:S1:13881:4	O
identified	PRADAXA.xml:S1:13886:10	O
during	PRADAXA.xml:S1:13897:6	O
post	PRADAXA.xml:S1:13904:4	O
approval	PRADAXA.xml:S1:13909:8	O
use	PRADAXA.xml:S1:13918:3	O
of	PRADAXA.xml:S1:13922:2	O
PRADAXA	PRADAXA.xml:S1:13925:7	O
:	PRADAXA.xml:S1:13932:1	O
angioedema	PRADAXA.xml:S1:13934:10	B-AdverseReaction
,	PRADAXA.xml:S1:13944:1	O
thrombocytopenia	PRADAXA.xml:S1:13946:16	B-AdverseReaction
,	PRADAXA.xml:S1:13962:1	O
esophageal	PRADAXA.xml:S1:13964:10	B-AdverseReaction
ulcer	PRADAXA.xml:S1:13975:5	I-AdverseReaction
.	PRADAXA.xml:S1:13980:1	O
\n\n	PRADAXA.xml:S2:0:2	O
BOXED	PRADAXA.xml:S2:6:5	O
WARNING	PRADAXA.xml:S2:12:7	O
:	PRADAXA.xml:S2:19:1	O
WARNING	PRADAXA.xml:S2:21:7	O
:	PRADAXA.xml:S2:28:1	O
(	PRADAXA.xml:S2:30:1	O
A	PRADAXA.xml:S2:31:1	O
)	PRADAXA.xml:S2:32:1	O
PREMATURE	PRADAXA.xml:S2:34:9	O
DISCONTINUATION	PRADAXA.xml:S2:44:15	O
OF	PRADAXA.xml:S2:60:2	O
PRADAXA	PRADAXA.xml:S2:63:7	O
INCREASES	PRADAXA.xml:S2:71:9	O
THE	PRADAXA.xml:S2:81:3	O
RISK	PRADAXA.xml:S2:85:4	O
\n\n	PRADAXA.xml:S2:89:2	O
OF	PRADAXA.xml:S2:91:2	O
THROMBOTIC	PRADAXA.xml:S2:94:10	O
EVENTS	PRADAXA.xml:S2:105:6	O
,	PRADAXA.xml:S2:111:1	O
(	PRADAXA.xml:S2:113:1	O
B	PRADAXA.xml:S2:114:1	O
)	PRADAXA.xml:S2:115:1	O
SPINAL	PRADAXA.xml:S2:117:6	B-AdverseReaction
EPIDURAL	PRADAXA.xml:S2:124:8	B-AdverseReaction
HEMATOMA	PRADAXA.xml:S2:133:8	I-AdverseReaction
\n\n	PRADAXA.xml:S2:141:2	O
WARNING	PRADAXA.xml:S2:145:7	O
:	PRADAXA.xml:S2:152:1	O
(	PRADAXA.xml:S2:154:1	O
A	PRADAXA.xml:S2:155:1	O
)	PRADAXA.xml:S2:156:1	O
PREMATURE	PRADAXA.xml:S2:158:9	O
DISCONTINUATION	PRADAXA.xml:S2:168:15	O
OF	PRADAXA.xml:S2:184:2	O
PRADAXA	PRADAXA.xml:S2:187:7	O
INCREASES	PRADAXA.xml:S2:195:9	O
THE	PRADAXA.xml:S2:205:3	O
RISK	PRADAXA.xml:S2:209:4	O
\n\n	PRADAXA.xml:S2:213:2	O
OF	PRADAXA.xml:S2:215:2	O
THROMBOTIC	PRADAXA.xml:S2:218:10	O
EVENTS	PRADAXA.xml:S2:229:6	O
,	PRADAXA.xml:S2:235:1	O
(	PRADAXA.xml:S2:237:1	O
B	PRADAXA.xml:S2:238:1	O
)	PRADAXA.xml:S2:239:1	O
SPINAL	PRADAXA.xml:S2:241:6	B-AdverseReaction
EPIDURAL	PRADAXA.xml:S2:248:8	B-AdverseReaction
HEMATOMA	PRADAXA.xml:S2:257:8	I-AdverseReaction
\n\n	PRADAXA.xml:S2:265:2	O
(	PRADAXA.xml:S2:271:1	O
A	PRADAXA.xml:S2:272:1	O
)	PRADAXA.xml:S2:273:1	O
PREMATURE	PRADAXA.xml:S2:275:9	O
DISCONTINUATION	PRADAXA.xml:S2:285:15	O
\n\n	PRADAXA.xml:S2:300:2	O
OF	PRADAXA.xml:S2:302:2	O
PRADAXA	PRADAXA.xml:S2:305:7	O
INCREASES	PRADAXA.xml:S2:313:9	O
THE	PRADAXA.xml:S2:323:3	O
RISK	PRADAXA.xml:S2:327:4	O
OF	PRADAXA.xml:S2:332:2	O
THROMBOTIC	PRADAXA.xml:S2:335:10	O
EVENTSPremature	PRADAXA.xml:S2:346:15	O
\n\n	PRADAXA.xml:S2:361:2	O
discontinuation	PRADAXA.xml:S2:363:15	O
of	PRADAXA.xml:S2:379:2	O
any	PRADAXA.xml:S2:382:3	O
oral	PRADAXA.xml:S2:386:4	O
anticoagulant	PRADAXA.xml:S2:391:13	O
,	PRADAXA.xml:S2:404:1	O
including	PRADAXA.xml:S2:406:9	O
PRADAXA	PRADAXA.xml:S2:416:7	O
,	PRADAXA.xml:S2:423:1	O
increases	PRADAXA.xml:S2:425:9	O
\n\n	PRADAXA.xml:S2:434:2	O
the	PRADAXA.xml:S2:436:3	O
risk	PRADAXA.xml:S2:440:4	O
of	PRADAXA.xml:S2:445:2	O
thrombotic	PRADAXA.xml:S2:448:10	O
events	PRADAXA.xml:S2:459:6	O
.	PRADAXA.xml:S2:465:1	O

If	PRADAXA.xml:S2:467:2	O
anticoagulation	PRADAXA.xml:S2:470:15	O
with	PRADAXA.xml:S2:486:4	O
PRADAXA	PRADAXA.xml:S2:491:7	O
is	PRADAXA.xml:S2:499:2	O
\n\n	PRADAXA.xml:S2:501:2	O
discontinued	PRADAXA.xml:S2:503:12	O
for	PRADAXA.xml:S2:516:3	O
a	PRADAXA.xml:S2:520:1	O
reason	PRADAXA.xml:S2:522:6	O
other	PRADAXA.xml:S2:529:5	O
than	PRADAXA.xml:S2:535:4	O
pathological	PRADAXA.xml:S2:540:12	O
bleeding	PRADAXA.xml:S2:553:8	O
or	PRADAXA.xml:S2:562:2	O
completion	PRADAXA.xml:S2:565:10	O
\n\n	PRADAXA.xml:S2:575:2	O
of	PRADAXA.xml:S2:577:2	O
a	PRADAXA.xml:S2:580:1	O
course	PRADAXA.xml:S2:582:6	O
of	PRADAXA.xml:S2:589:2	O
therapy	PRADAXA.xml:S2:592:7	O
,	PRADAXA.xml:S2:599:1	O
consider	PRADAXA.xml:S2:601:8	O
coverage	PRADAXA.xml:S2:610:8	O
with	PRADAXA.xml:S2:619:4	O
another	PRADAXA.xml:S2:624:7	O
anticoagulant	PRADAXA.xml:S2:632:13	O
[	PRADAXA.xml:S2:648:1	O
see	PRADAXA.xml:S2:649:3	O
Dosage	PRADAXA.xml:S2:653:6	O
and	PRADAXA.xml:S2:660:3	O
Administration	PRADAXA.xml:S2:664:14	O
(	PRADAXA.xml:S2:681:1	O
2.4	PRADAXA.xml:S2:682:3	O
,	PRADAXA.xml:S2:687:1	O
2.5	PRADAXA.xml:S2:691:3	O
,	PRADAXA.xml:S2:696:1	O
2.6	PRADAXA.xml:S2:700:3	O
)	PRADAXA.xml:S2:703:1	O
and	PRADAXA.xml:S2:707:3	O
Warnings	PRADAXA.xml:S2:711:8	O
and	PRADAXA.xml:S2:720:3	O
Precautions	PRADAXA.xml:S2:724:11	O
(	PRADAXA.xml:S2:738:1	O
5.1	PRADAXA.xml:S2:739:3	O
)	PRADAXA.xml:S2:742:1	O
]	PRADAXA.xml:S2:745:1	O
.	PRADAXA.xml:S2:748:1	O

(	PRADAXA.xml:S2:753:1	O
B	PRADAXA.xml:S2:754:1	O
)	PRADAXA.xml:S2:755:1	O
SPINAL	PRADAXA.xml:S2:757:6	O
EPIDURAL	PRADAXA.xml:S2:764:8	O
\n\n	PRADAXA.xml:S2:772:2	O
HEMATOMAEpidural	PRADAXA.xml:S2:774:16	B-AdverseReaction
or	PRADAXA.xml:S2:791:2	O
spinal	PRADAXA.xml:S2:794:6	B-AdverseReaction
hematomas	PRADAXA.xml:S2:801:9	I-AdverseReaction
may	PRADAXA.xml:S2:811:3	B-Factor
occur	PRADAXA.xml:S2:815:5	O
in	PRADAXA.xml:S2:821:2	O
patients	PRADAXA.xml:S2:824:8	O
\n\n	PRADAXA.xml:S2:832:2	O
treated	PRADAXA.xml:S2:834:7	O
with	PRADAXA.xml:S2:842:4	O
PRADAXA	PRADAXA.xml:S2:847:7	O
who	PRADAXA.xml:S2:855:3	O
are	PRADAXA.xml:S2:859:3	O
receiving	PRADAXA.xml:S2:863:9	O
neuraxial	PRADAXA.xml:S2:873:9	O
anesthesia	PRADAXA.xml:S2:883:10	O
or	PRADAXA.xml:S2:894:2	O
undergoing	PRADAXA.xml:S2:897:10	O
\n\n	PRADAXA.xml:S2:907:2	O
spinal	PRADAXA.xml:S2:909:6	O
puncture	PRADAXA.xml:S2:916:8	O
.	PRADAXA.xml:S2:924:1	O

These	PRADAXA.xml:S2:926:5	O
hematomas	PRADAXA.xml:S2:932:9	B-AdverseReaction
may	PRADAXA.xml:S2:942:3	B-Factor
result	PRADAXA.xml:S2:946:6	O
in	PRADAXA.xml:S2:953:2	O
long	PRADAXA.xml:S2:956:4	B-AdverseReaction
-	PRADAXA.xml:S2:960:1	I-AdverseReaction
term	PRADAXA.xml:S2:961:4	I-AdverseReaction
or	PRADAXA.xml:S2:966:2	O
permanent	PRADAXA.xml:S2:969:9	B-AdverseReaction
\n\n	PRADAXA.xml:S2:978:2	I-AdverseReaction
paralysis	PRADAXA.xml:S2:980:9	I-AdverseReaction
.	PRADAXA.xml:S2:989:1	O

Consider	PRADAXA.xml:S2:991:8	O
these	PRADAXA.xml:S2:1000:5	O
risks	PRADAXA.xml:S2:1006:5	O
when	PRADAXA.xml:S2:1012:4	O
scheduling	PRADAXA.xml:S2:1017:10	O
patients	PRADAXA.xml:S2:1028:8	O
for	PRADAXA.xml:S2:1037:3	O
spinal	PRADAXA.xml:S2:1041:6	O
\n\n	PRADAXA.xml:S2:1047:2	O
procedures	PRADAXA.xml:S2:1049:10	O
.	PRADAXA.xml:S2:1059:1	O

Factors	PRADAXA.xml:S2:1061:7	O
that	PRADAXA.xml:S2:1069:4	O
can	PRADAXA.xml:S2:1074:3	O
increase	PRADAXA.xml:S2:1078:8	O
the	PRADAXA.xml:S2:1087:3	O
risk	PRADAXA.xml:S2:1091:4	O
of	PRADAXA.xml:S2:1096:2	O
developing	PRADAXA.xml:S2:1099:10	O
epidural	PRADAXA.xml:S2:1110:8	O
\n\n	PRADAXA.xml:S2:1118:2	O
or	PRADAXA.xml:S2:1120:2	O
spinal	PRADAXA.xml:S2:1123:6	O
hematomas	PRADAXA.xml:S2:1130:9	O
in	PRADAXA.xml:S2:1140:2	O
these	PRADAXA.xml:S2:1143:5	O
patients	PRADAXA.xml:S2:1149:8	O
include	PRADAXA.xml:S2:1158:7	O
:	PRADAXA.xml:S2:1165:1	O
\n\n\n\n	PRADAXA.xml:S2:1168:4	O
use	PRADAXA.xml:S2:1177:3	O
of	PRADAXA.xml:S2:1181:2	O
indwelling	PRADAXA.xml:S2:1184:10	O
epidural	PRADAXA.xml:S2:1195:8	O
catheters	PRADAXA.xml:S2:1204:9	O
concomitant	PRADAXA.xml:S2:1215:11	O
use	PRADAXA.xml:S2:1227:3	O
of	PRADAXA.xml:S2:1231:2	O
other	PRADAXA.xml:S2:1234:5	O
drugs	PRADAXA.xml:S2:1240:5	O
that	PRADAXA.xml:S2:1246:4	O
affect	PRADAXA.xml:S2:1251:6	O
hemostasis	PRADAXA.xml:S2:1258:10	O
,	PRADAXA.xml:S2:1268:1	O
such	PRADAXA.xml:S2:1270:4	O
as	PRADAXA.xml:S2:1275:2	O
\n\n	PRADAXA.xml:S2:1277:2	O
non	PRADAXA.xml:S2:1279:3	O
-	PRADAXA.xml:S2:1282:1	O
steroidal	PRADAXA.xml:S2:1283:9	O
anti	PRADAXA.xml:S2:1293:4	O
-	PRADAXA.xml:S2:1297:1	O
inflammatory	PRADAXA.xml:S2:1298:12	O
drugs	PRADAXA.xml:S2:1311:5	O
(	PRADAXA.xml:S2:1317:1	O
NSAIDs	PRADAXA.xml:S2:1318:6	O
)	PRADAXA.xml:S2:1324:1	O
,	PRADAXA.xml:S2:1325:1	O
platelet	PRADAXA.xml:S2:1327:8	O
inhibitors	PRADAXA.xml:S2:1336:10	O
,	PRADAXA.xml:S2:1346:1	O
\n\n	PRADAXA.xml:S2:1347:2	O
other	PRADAXA.xml:S2:1349:5	O
anticoagulants	PRADAXA.xml:S2:1355:14	O
a	PRADAXA.xml:S2:1371:1	O
history	PRADAXA.xml:S2:1373:7	O
of	PRADAXA.xml:S2:1381:2	O
traumatic	PRADAXA.xml:S2:1384:9	O
or	PRADAXA.xml:S2:1394:2	O
repeated	PRADAXA.xml:S2:1397:8	O
\n\n	PRADAXA.xml:S2:1405:2	O
epidural	PRADAXA.xml:S2:1407:8	O
or	PRADAXA.xml:S2:1416:2	O
spinal	PRADAXA.xml:S2:1419:6	O
punctures	PRADAXA.xml:S2:1426:9	O
a	PRADAXA.xml:S2:1437:1	O
history	PRADAXA.xml:S2:1439:7	O
of	PRADAXA.xml:S2:1447:2	O
spinal	PRADAXA.xml:S2:1450:6	O
deformity	PRADAXA.xml:S2:1457:9	O
\n\n	PRADAXA.xml:S2:1466:2	O
or	PRADAXA.xml:S2:1468:2	O
spinal	PRADAXA.xml:S2:1471:6	O
surgery	PRADAXA.xml:S2:1478:7	O
optimal	PRADAXA.xml:S2:1487:7	O
timing	PRADAXA.xml:S2:1495:6	O
between	PRADAXA.xml:S2:1502:7	O
the	PRADAXA.xml:S2:1510:3	O
administration	PRADAXA.xml:S2:1514:14	O
\n\n	PRADAXA.xml:S2:1528:2	O
of	PRADAXA.xml:S2:1530:2	O
PRADAXA	PRADAXA.xml:S2:1533:7	O
and	PRADAXA.xml:S2:1541:3	O
neuraxial	PRADAXA.xml:S2:1545:9	O
procedures	PRADAXA.xml:S2:1555:10	O
is	PRADAXA.xml:S2:1566:2	O
not	PRADAXA.xml:S2:1569:3	O
known	PRADAXA.xml:S2:1573:5	O
[	PRADAXA.xml:S2:1581:1	O
see	PRADAXA.xml:S2:1582:3	O
Warnings	PRADAXA.xml:S2:1586:8	O
\n\n	PRADAXA.xml:S2:1594:2	O
and	PRADAXA.xml:S2:1596:3	O
Precautions	PRADAXA.xml:S2:1600:11	O
(	PRADAXA.xml:S2:1614:1	O
5.3	PRADAXA.xml:S2:1615:3	O
)	PRADAXA.xml:S2:1618:1	O
]	PRADAXA.xml:S2:1621:1	O
.	PRADAXA.xml:S2:1624:1	O

Monitor	PRADAXA.xml:S2:1634:7	O
patients	PRADAXA.xml:S2:1642:8	O
\n\n	PRADAXA.xml:S2:1650:2	O
frequently	PRADAXA.xml:S2:1652:10	O
for	PRADAXA.xml:S2:1663:3	O
signs	PRADAXA.xml:S2:1667:5	O
and	PRADAXA.xml:S2:1673:3	O
symptoms	PRADAXA.xml:S2:1677:8	O
of	PRADAXA.xml:S2:1686:2	O
neurological	PRADAXA.xml:S2:1689:12	O
impairment	PRADAXA.xml:S2:1702:10	O
.	PRADAXA.xml:S2:1712:1	O

If	PRADAXA.xml:S2:1714:2	O
neurological	PRADAXA.xml:S2:1717:12	O
\n\n	PRADAXA.xml:S2:1729:2	O
compromise	PRADAXA.xml:S2:1731:10	O
is	PRADAXA.xml:S2:1742:2	O
noted	PRADAXA.xml:S2:1745:5	O
,	PRADAXA.xml:S2:1750:1	O
urgent	PRADAXA.xml:S2:1752:6	O
treatment	PRADAXA.xml:S2:1759:9	O
is	PRADAXA.xml:S2:1769:2	O
necessary	PRADAXA.xml:S2:1772:9	O
[	PRADAXA.xml:S2:1784:1	O
see	PRADAXA.xml:S2:1785:3	O
Warnings	PRADAXA.xml:S2:1789:8	O
\n\n	PRADAXA.xml:S2:1797:2	O
and	PRADAXA.xml:S2:1799:3	O
Precautions	PRADAXA.xml:S2:1803:11	O
(	PRADAXA.xml:S2:1817:1	O
5.3	PRADAXA.xml:S2:1818:3	O
)	PRADAXA.xml:S2:1821:1	O
]	PRADAXA.xml:S2:1824:1	O
.	PRADAXA.xml:S2:1827:1	O
Consider	PRADAXA.xml:S2:1828:8	O
the	PRADAXA.xml:S2:1837:3	O
benefits	PRADAXA.xml:S2:1841:8	O
and	PRADAXA.xml:S2:1850:3	O
risks	PRADAXA.xml:S2:1854:5	O
before	PRADAXA.xml:S2:1860:6	O
neuraxial	PRADAXA.xml:S2:1867:9	O
intervention	PRADAXA.xml:S2:1877:12	O
\n\n	PRADAXA.xml:S2:1889:2	O
in	PRADAXA.xml:S2:1891:2	O
patients	PRADAXA.xml:S2:1894:8	O
anticoagulated	PRADAXA.xml:S2:1903:14	O
or	PRADAXA.xml:S2:1918:2	O
to	PRADAXA.xml:S2:1921:2	O
be	PRADAXA.xml:S2:1924:2	O
anticoagulated	PRADAXA.xml:S2:1927:14	O
[	PRADAXA.xml:S2:1944:1	O
see	PRADAXA.xml:S2:1945:3	O
Warnings	PRADAXA.xml:S2:1949:8	O
\n\n	PRADAXA.xml:S2:1957:2	O
and	PRADAXA.xml:S2:1959:3	O
Precautions	PRADAXA.xml:S2:1963:11	O
(	PRADAXA.xml:S2:1977:1	O
5.3	PRADAXA.xml:S2:1978:3	O
)	PRADAXA.xml:S2:1981:1	O
]	PRADAXA.xml:S2:1984:1	O
.	PRADAXA.xml:S2:1987:1	O

EXCERPT	PRADAXA.xml:S2:1997:7	O
:	PRADAXA.xml:S2:2004:1	O
WARNING	PRADAXA.xml:S2:2010:7	O
:	PRADAXA.xml:S2:2017:1	O
(	PRADAXA.xml:S2:2019:1	O
A	PRADAXA.xml:S2:2020:1	O
)	PRADAXA.xml:S2:2021:1	O
PREMATURE	PRADAXA.xml:S2:2023:9	O
DISCONTINUATION	PRADAXA.xml:S2:2033:15	O
\n\n	PRADAXA.xml:S2:2048:2	O
OF	PRADAXA.xml:S2:2050:2	O
PRADAXA	PRADAXA.xml:S2:2053:7	O
INCREASES	PRADAXA.xml:S2:2061:9	O
THE	PRADAXA.xml:S2:2071:3	O
RISK	PRADAXA.xml:S2:2075:4	O
OF	PRADAXA.xml:S2:2080:2	O
THROMBOTIC	PRADAXA.xml:S2:2083:10	O
EVENTS	PRADAXA.xml:S2:2094:6	O
,	PRADAXA.xml:S2:2100:1	O
and	PRADAXA.xml:S2:2102:3	O
(	PRADAXA.xml:S2:2106:1	O
B	PRADAXA.xml:S2:2107:1	O
)	PRADAXA.xml:S2:2108:1	O
SPINAL	PRADAXA.xml:S2:2110:6	B-AdverseReaction
EPIDURAL	PRADAXA.xml:S2:2117:8	B-AdverseReaction
\n\n	PRADAXA.xml:S2:2125:2	I-AdverseReaction
HEMATOMA	PRADAXA.xml:S2:2127:8	I-AdverseReaction
See	PRADAXA.xml:S2:2139:3	O
full	PRADAXA.xml:S2:2143:4	O
prescribing	PRADAXA.xml:S2:2148:11	O
information	PRADAXA.xml:S2:2160:11	O
\n\n	PRADAXA.xml:S2:2171:2	O
for	PRADAXA.xml:S2:2173:3	O
complete	PRADAXA.xml:S2:2177:8	O
boxed	PRADAXA.xml:S2:2186:5	O
warning	PRADAXA.xml:S2:2192:7	O
(	PRADAXA.xml:S2:2203:1	O
A	PRADAXA.xml:S2:2204:1	O
)\n\n	PRADAXA.xml:S2:2205:3	O
PREMATURE	PRADAXA.xml:S2:2208:9	O
DISCONTINUATION	PRADAXA.xml:S2:2218:15	O
OF	PRADAXA.xml:S2:2234:2	O
PRADAXA	PRADAXA.xml:S2:2237:7	O
INCREASES	PRADAXA.xml:S2:2245:9	O
THE	PRADAXA.xml:S2:2255:3	O
RISK	PRADAXA.xml:S2:2259:4	O
OF	PRADAXA.xml:S2:2264:2	O
THROMBOTIC	PRADAXA.xml:S2:2267:10	O
\n\n	PRADAXA.xml:S2:2277:2	O
EVENTS	PRADAXA.xml:S2:2279:6	O
:	PRADAXA.xml:S2:2285:1	O
Premature	PRADAXA.xml:S2:2287:9	O
discontinuation	PRADAXA.xml:S2:2297:15	O
of	PRADAXA.xml:S2:2313:2	O
any	PRADAXA.xml:S2:2316:3	O
oral	PRADAXA.xml:S2:2320:4	O
anticoagulant	PRADAXA.xml:S2:2325:13	O
,	PRADAXA.xml:S2:2338:1	O
including	PRADAXA.xml:S2:2340:9	O
\n\n	PRADAXA.xml:S2:2349:2	O
PRADAXA	PRADAXA.xml:S2:2351:7	O
,	PRADAXA.xml:S2:2358:1	O
increases	PRADAXA.xml:S2:2360:9	O
the	PRADAXA.xml:S2:2370:3	O
risk	PRADAXA.xml:S2:2374:4	O
of	PRADAXA.xml:S2:2379:2	O
thrombotic	PRADAXA.xml:S2:2382:10	O
events	PRADAXA.xml:S2:2393:6	O
.	PRADAXA.xml:S2:2399:1	O

To	PRADAXA.xml:S2:2402:2	O
reduce	PRADAXA.xml:S2:2405:6	O
this	PRADAXA.xml:S2:2412:4	O
\n\n	PRADAXA.xml:S2:2416:2	O
risk	PRADAXA.xml:S2:2418:4	O
,	PRADAXA.xml:S2:2422:1	O
consider	PRADAXA.xml:S2:2424:8	O
coverage	PRADAXA.xml:S2:2433:8	O
with	PRADAXA.xml:S2:2442:4	O
another	PRADAXA.xml:S2:2447:7	O
anticoagulant	PRADAXA.xml:S2:2455:13	O
if	PRADAXA.xml:S2:2469:2	O
PRADAXA	PRADAXA.xml:S2:2472:7	O
is	PRADAXA.xml:S2:2480:2	O
discontinued	PRADAXA.xml:S2:2483:12	O
\n\n	PRADAXA.xml:S2:2495:2	O
for	PRADAXA.xml:S2:2497:3	O
a	PRADAXA.xml:S2:2501:1	O
reason	PRADAXA.xml:S2:2503:6	O
other	PRADAXA.xml:S2:2510:5	O
than	PRADAXA.xml:S2:2516:4	O
pathological	PRADAXA.xml:S2:2521:12	O
bleeding	PRADAXA.xml:S2:2534:8	O
or	PRADAXA.xml:S2:2543:2	O
completion	PRADAXA.xml:S2:2546:10	O
of	PRADAXA.xml:S2:2557:2	O
a	PRADAXA.xml:S2:2560:1	O
course	PRADAXA.xml:S2:2562:6	O
\n\n	PRADAXA.xml:S2:2568:2	O
of	PRADAXA.xml:S2:2570:2	O
therapy	PRADAXA.xml:S2:2573:7	O
(	PRADAXA.xml:S2:2581:1	O
2.4	PRADAXA.xml:S2:2584:3	O
,	PRADAXA.xml:S2:2589:1	O
2.5	PRADAXA.xml:S2:2593:3	O
,	PRADAXA.xml:S2:2598:1	O
2.6	PRADAXA.xml:S2:2602:3	O
,	PRADAXA.xml:S2:2607:1	O
5.1	PRADAXA.xml:S2:2611:3	O
)	PRADAXA.xml:S2:2616:1	O
.	PRADAXA.xml:S2:2617:1	O

(	PRADAXA.xml:S2:2622:1	O
B	PRADAXA.xml:S2:2623:1	O
)	PRADAXA.xml:S2:2624:1	O
SPINAL	PRADAXA.xml:S2:2626:6	O
EPIDURAL	PRADAXA.xml:S2:2633:8	O
HEMATOMA	PRADAXA.xml:S2:2642:8	O
:	PRADAXA.xml:S2:2650:1	O
Epidural	PRADAXA.xml:S2:2652:8	B-AdverseReaction
or	PRADAXA.xml:S2:2661:2	O
spinal	PRADAXA.xml:S2:2664:6	B-AdverseReaction
hematomas	PRADAXA.xml:S2:2671:9	I-AdverseReaction
\n\n	PRADAXA.xml:S2:2680:2	O
may	PRADAXA.xml:S2:2682:3	B-Factor
occur	PRADAXA.xml:S2:2686:5	O
in	PRADAXA.xml:S2:2692:2	O
patients	PRADAXA.xml:S2:2695:8	O
treated	PRADAXA.xml:S2:2704:7	O
with	PRADAXA.xml:S2:2712:4	O
PRADAXA	PRADAXA.xml:S2:2717:7	O
who	PRADAXA.xml:S2:2725:3	O
are	PRADAXA.xml:S2:2729:3	O
receiving	PRADAXA.xml:S2:2733:9	O
neuraxial	PRADAXA.xml:S2:2743:9	O
\n\n	PRADAXA.xml:S2:2752:2	O
anesthesia	PRADAXA.xml:S2:2754:10	O
or	PRADAXA.xml:S2:2765:2	O
undergoing	PRADAXA.xml:S2:2768:10	O
spinal	PRADAXA.xml:S2:2779:6	O
puncture	PRADAXA.xml:S2:2786:8	O
.	PRADAXA.xml:S2:2794:1	O

These	PRADAXA.xml:S2:2796:5	O
hematomas	PRADAXA.xml:S2:2802:9	B-AdverseReaction
may	PRADAXA.xml:S2:2812:3	B-Factor
result	PRADAXA.xml:S2:2816:6	O
\n\n	PRADAXA.xml:S2:2822:2	O
in	PRADAXA.xml:S2:2824:2	O
long	PRADAXA.xml:S2:2827:4	B-AdverseReaction
-	PRADAXA.xml:S2:2831:1	I-AdverseReaction
term	PRADAXA.xml:S2:2832:4	I-AdverseReaction
or	PRADAXA.xml:S2:2837:2	O
permanent	PRADAXA.xml:S2:2840:9	B-AdverseReaction
paralysis	PRADAXA.xml:S2:2850:9	I-AdverseReaction
(	PRADAXA.xml:S2:2860:1	O
5.3	PRADAXA.xml:S2:2863:3	O
)	PRADAXA.xml:S2:2868:1	O
.	PRADAXA.xml:S2:2869:1	O

Monitor	PRADAXA.xml:S2:2871:7	O
patients	PRADAXA.xml:S2:2879:8	O
frequently	PRADAXA.xml:S2:2888:10	O
for	PRADAXA.xml:S2:2899:3	O
signs	PRADAXA.xml:S2:2903:5	O
and	PRADAXA.xml:S2:2909:3	O
symptoms	PRADAXA.xml:S2:2913:8	O
of	PRADAXA.xml:S2:2922:2	O
neurological	PRADAXA.xml:S2:2925:12	O
\n\n	PRADAXA.xml:S2:2937:2	O
impairment	PRADAXA.xml:S2:2939:10	O
and	PRADAXA.xml:S2:2950:3	O
if	PRADAXA.xml:S2:2954:2	O
observed	PRADAXA.xml:S2:2957:8	O
,	PRADAXA.xml:S2:2965:1	O
treat	PRADAXA.xml:S2:2967:5	O
urgently	PRADAXA.xml:S2:2973:8	O
.	PRADAXA.xml:S2:2981:1	O

Consider	PRADAXA.xml:S2:2983:8	O
the	PRADAXA.xml:S2:2992:3	O
benefits	PRADAXA.xml:S2:2996:8	O
\n\n	PRADAXA.xml:S2:3004:2	O
and	PRADAXA.xml:S2:3006:3	O
risks	PRADAXA.xml:S2:3010:5	O
before	PRADAXA.xml:S2:3016:6	O
neuraxial	PRADAXA.xml:S2:3023:9	O
intervention	PRADAXA.xml:S2:3033:12	O
in	PRADAXA.xml:S2:3046:2	O
patients	PRADAXA.xml:S2:3049:8	O
who	PRADAXA.xml:S2:3058:3	O
are	PRADAXA.xml:S2:3062:3	O
or	PRADAXA.xml:S2:3066:2	O
who	PRADAXA.xml:S2:3069:3	O
\n\n	PRADAXA.xml:S2:3072:2	O
need	PRADAXA.xml:S2:3074:4	O
to	PRADAXA.xml:S2:3079:2	O
be	PRADAXA.xml:S2:3082:2	O
anticoagulated	PRADAXA.xml:S2:3085:14	O
(	PRADAXA.xml:S2:3100:1	O
5.3	PRADAXA.xml:S2:3103:3	O
)	PRADAXA.xml:S2:3108:1	O
.	PRADAXA.xml:S2:3109:1	O
\n	PRADAXA.xml:S2:3112:1	O
5	PRADAXA.xml:S3:4:1	O
WARNINGS	PRADAXA.xml:S3:7:8	O
AND	PRADAXA.xml:S3:16:3	O
PRECAUTIONS	PRADAXA.xml:S3:20:11	O

EXCERPT	PRADAXA.xml:S3:38:7	O
:	PRADAXA.xml:S3:45:1	O
Bleeding	PRADAXA.xml:S3:53:8	B-AdverseReaction
:	PRADAXA.xml:S3:61:1	O
PRADAXA	PRADAXA.xml:S3:63:7	O
can	PRADAXA.xml:S3:71:3	B-Factor
cause	PRADAXA.xml:S3:75:5	O
serious	PRADAXA.xml:S3:81:7	B-Severity
and	PRADAXA.xml:S3:89:3	O
fatal	PRADAXA.xml:S3:93:5	B-AdverseReaction
bleeding	PRADAXA.xml:S3:99:8	B-AdverseReaction
(	PRADAXA.xml:S3:109:1	O
5.2	PRADAXA.xml:S3:110:3	O
)	PRADAXA.xml:S3:113:1	O

Bioprosthetic	PRADAXA.xml:S3:122:13	O
heart	PRADAXA.xml:S3:136:5	O
valves	PRADAXA.xml:S3:142:6	O
:	PRADAXA.xml:S3:148:1	O
PRADAXA	PRADAXA.xml:S3:150:7	O
use	PRADAXA.xml:S3:158:3	O
not	PRADAXA.xml:S3:162:3	O
recommended	PRADAXA.xml:S3:166:11	O
(	PRADAXA.xml:S3:179:1	O
5.4	PRADAXA.xml:S3:180:3	O
)	PRADAXA.xml:S3:183:1	O

5.1	PRADAXA.xml:S3:199:3	O

Increased	PRADAXA.xml:S3:203:9	O

Risk	PRADAXA.xml:S3:213:4	O
of	PRADAXA.xml:S3:218:2	O
Thrombotic	PRADAXA.xml:S3:221:10	O
Events	PRADAXA.xml:S3:232:6	O
after	PRADAXA.xml:S3:239:5	O
Premature	PRADAXA.xml:S3:245:9	O
Discontinuation	PRADAXA.xml:S3:255:15	O

Premature	PRADAXA.xml:S3:276:9	O
discontinuation	PRADAXA.xml:S3:286:15	O
of	PRADAXA.xml:S3:302:2	O
any	PRADAXA.xml:S3:305:3	O
oral	PRADAXA.xml:S3:309:4	O
anticoagulant	PRADAXA.xml:S3:314:13	O
,	PRADAXA.xml:S3:327:1	O
including	PRADAXA.xml:S3:329:9	O
PRADAXA	PRADAXA.xml:S3:339:7	O
,	PRADAXA.xml:S3:346:1	O
in	PRADAXA.xml:S3:348:2	O
the	PRADAXA.xml:S3:351:3	O
absence	PRADAXA.xml:S3:355:7	O
of	PRADAXA.xml:S3:363:2	O
adequate	PRADAXA.xml:S3:366:8	O
alternative	PRADAXA.xml:S3:375:11	O
anticoagulation	PRADAXA.xml:S3:387:15	O
increases	PRADAXA.xml:S3:403:9	O
the	PRADAXA.xml:S3:413:3	O
risk	PRADAXA.xml:S3:417:4	O
of	PRADAXA.xml:S3:422:2	O
thrombotic	PRADAXA.xml:S3:425:10	O
events	PRADAXA.xml:S3:436:6	O
.	PRADAXA.xml:S3:442:1	O

If	PRADAXA.xml:S3:444:2	O
PRADAXA	PRADAXA.xml:S3:447:7	O
is	PRADAXA.xml:S3:455:2	O
discontinued	PRADAXA.xml:S3:458:12	O
for	PRADAXA.xml:S3:471:3	O
a	PRADAXA.xml:S3:475:1	O
reason	PRADAXA.xml:S3:477:6	O
other	PRADAXA.xml:S3:484:5	O
than	PRADAXA.xml:S3:490:4	O
pathological	PRADAXA.xml:S3:495:12	O
bleeding	PRADAXA.xml:S3:508:8	O
or	PRADAXA.xml:S3:517:2	O
completion	PRADAXA.xml:S3:520:10	O
of	PRADAXA.xml:S3:531:2	O
a	PRADAXA.xml:S3:534:1	O
course	PRADAXA.xml:S3:536:6	O
of	PRADAXA.xml:S3:543:2	O
therapy	PRADAXA.xml:S3:546:7	O
,	PRADAXA.xml:S3:553:1	O
consider	PRADAXA.xml:S3:555:8	O
coverage	PRADAXA.xml:S3:564:8	O
with	PRADAXA.xml:S3:573:4	O
another	PRADAXA.xml:S3:578:7	O
anticoagulant	PRADAXA.xml:S3:586:13	O
[	PRADAXA.xml:S3:600:1	O
see	PRADAXA.xml:S3:601:3	O
Dosage	PRADAXA.xml:S3:605:6	O
and	PRADAXA.xml:S3:612:3	O
Administration	PRADAXA.xml:S3:616:14	O
(	PRADAXA.xml:S3:632:1	O
2.4	PRADAXA.xml:S3:633:3	O
,	PRADAXA.xml:S3:638:1	O
2.5	PRADAXA.xml:S3:641:3	O
,	PRADAXA.xml:S3:646:1	O
2.6	PRADAXA.xml:S3:649:3	O
)	PRADAXA.xml:S3:652:1	O
]	PRADAXA.xml:S3:655:1	O
.	PRADAXA.xml:S3:656:1	O

5.2	PRADAXA.xml:S3:667:3	O
Risk	PRADAXA.xml:S3:671:4	O
of	PRADAXA.xml:S3:676:2	O
Bleeding	PRADAXA.xml:S3:679:8	O

PRADAXA	PRADAXA.xml:S3:693:7	O
increases	PRADAXA.xml:S3:701:9	O
the	PRADAXA.xml:S3:711:3	O
risk	PRADAXA.xml:S3:715:4	B-Factor
of	PRADAXA.xml:S3:720:2	O
bleeding	PRADAXA.xml:S3:723:8	B-AdverseReaction
and	PRADAXA.xml:S3:732:3	O
can	PRADAXA.xml:S3:736:3	B-Factor
cause	PRADAXA.xml:S3:740:5	O
significant	PRADAXA.xml:S3:746:11	B-Severity
and	PRADAXA.xml:S3:758:3	O
,	PRADAXA.xml:S3:761:1	O
sometimes	PRADAXA.xml:S3:763:9	O
,	PRADAXA.xml:S3:772:1	O
fatal	PRADAXA.xml:S3:774:5	B-AdverseReaction
bleeding	PRADAXA.xml:S3:780:8	B-AdverseReaction
.	PRADAXA.xml:S3:788:1	O

Promptly	PRADAXA.xml:S3:790:8	O
evaluate	PRADAXA.xml:S3:799:8	O
any	PRADAXA.xml:S3:808:3	O
signs	PRADAXA.xml:S3:812:5	O
or	PRADAXA.xml:S3:818:2	O
symptoms	PRADAXA.xml:S3:821:8	O
of	PRADAXA.xml:S3:830:2	O
blood	PRADAXA.xml:S3:833:5	O
loss	PRADAXA.xml:S3:839:4	O
(	PRADAXA.xml:S3:844:1	O
e	PRADAXA.xml:S3:845:1	O
.	PRADAXA.xml:S3:846:1	O
g	PRADAXA.xml:S3:847:1	O
.	PRADAXA.xml:S3:848:1	O
,	PRADAXA.xml:S3:849:1	O
a	PRADAXA.xml:S3:851:1	O
drop	PRADAXA.xml:S3:853:4	O
in	PRADAXA.xml:S3:858:2	O
hemoglobin	PRADAXA.xml:S3:861:10	O
and	PRADAXA.xml:S3:872:3	O
or	PRADAXA.xml:S3:876:2	O
hematocrit	PRADAXA.xml:S3:879:10	O
or	PRADAXA.xml:S3:890:2	O
hypotension	PRADAXA.xml:S3:893:11	O
)	PRADAXA.xml:S3:904:1	O
.	PRADAXA.xml:S3:905:1	O

Discontinue	PRADAXA.xml:S3:907:11	O
PRADAXA	PRADAXA.xml:S3:919:7	O
in	PRADAXA.xml:S3:927:2	O
patients	PRADAXA.xml:S3:930:8	O
with	PRADAXA.xml:S3:939:4	O
active	PRADAXA.xml:S3:944:6	O
pathological	PRADAXA.xml:S3:951:12	O
bleeding	PRADAXA.xml:S3:964:8	O
[	PRADAXA.xml:S3:974:1	O
see	PRADAXA.xml:S3:975:3	O
Dosage	PRADAXA.xml:S3:979:6	O
and	PRADAXA.xml:S3:986:3	O
Administration	PRADAXA.xml:S3:990:14	O
(	PRADAXA.xml:S3:1006:1	O
2.2	PRADAXA.xml:S3:1007:3	O
)	PRADAXA.xml:S3:1010:1	O
]	PRADAXA.xml:S3:1013:1	O
.	PRADAXA.xml:S3:1018:1	O

Risk	PRADAXA.xml:S3:1024:4	O
factors	PRADAXA.xml:S3:1029:7	O
for	PRADAXA.xml:S3:1037:3	O
bleeding	PRADAXA.xml:S3:1041:8	O
include	PRADAXA.xml:S3:1050:7	O
the	PRADAXA.xml:S3:1058:3	O
concomitant	PRADAXA.xml:S3:1062:11	O
use	PRADAXA.xml:S3:1074:3	O
of	PRADAXA.xml:S3:1078:2	O
other	PRADAXA.xml:S3:1081:5	O
drugs	PRADAXA.xml:S3:1087:5	O
that	PRADAXA.xml:S3:1093:4	O
increase	PRADAXA.xml:S3:1098:8	O
the	PRADAXA.xml:S3:1107:3	O
risk	PRADAXA.xml:S3:1111:4	O
of	PRADAXA.xml:S3:1116:2	O
bleeding	PRADAXA.xml:S3:1119:8	O
(	PRADAXA.xml:S3:1128:1	O
e	PRADAXA.xml:S3:1129:1	O
.	PRADAXA.xml:S3:1130:1	O
g	PRADAXA.xml:S3:1131:1	O
.	PRADAXA.xml:S3:1132:1	O
,	PRADAXA.xml:S3:1133:1	O
anti	PRADAXA.xml:S3:1135:4	O
-	PRADAXA.xml:S3:1139:1	O
platelet	PRADAXA.xml:S3:1140:8	O
agents	PRADAXA.xml:S3:1149:6	O
,	PRADAXA.xml:S3:1155:1	O
heparin	PRADAXA.xml:S3:1157:7	O
,	PRADAXA.xml:S3:1164:1	O
fibrinolytic	PRADAXA.xml:S3:1166:12	O
therapy	PRADAXA.xml:S3:1179:7	O
,	PRADAXA.xml:S3:1186:1	O
and	PRADAXA.xml:S3:1188:3	O
chronic	PRADAXA.xml:S3:1192:7	O
use	PRADAXA.xml:S3:1200:3	O
of	PRADAXA.xml:S3:1204:2	O
NSAIDs	PRADAXA.xml:S3:1207:6	O
)	PRADAXA.xml:S3:1213:1	O
.	PRADAXA.xml:S3:1214:1	O

PRADAXA	PRADAXA.xml:S3:1216:7	O
's	PRADAXA.xml:S3:1223:2	O
anticoagulant	PRADAXA.xml:S3:1226:13	O
activity	PRADAXA.xml:S3:1240:8	O
and	PRADAXA.xml:S3:1249:3	O
half	PRADAXA.xml:S3:1253:4	O
-	PRADAXA.xml:S3:1257:1	O
life	PRADAXA.xml:S3:1258:4	O
are	PRADAXA.xml:S3:1263:3	O
increased	PRADAXA.xml:S3:1267:9	O
in	PRADAXA.xml:S3:1277:2	O
patients	PRADAXA.xml:S3:1280:8	O
with	PRADAXA.xml:S3:1289:4	O
renal	PRADAXA.xml:S3:1294:5	O
impairment	PRADAXA.xml:S3:1300:10	O
[	PRADAXA.xml:S3:1312:1	O
see	PRADAXA.xml:S3:1313:3	O
Clinical	PRADAXA.xml:S3:1317:8	O
Pharmacology	PRADAXA.xml:S3:1326:12	O
(	PRADAXA.xml:S3:1340:1	O
12.2	PRADAXA.xml:S3:1341:4	O
)	PRADAXA.xml:S3:1345:1	O
]	PRADAXA.xml:S3:1348:1	O
.	PRADAXA.xml:S3:1353:1	O

Reversal	PRADAXA.xml:S3:1360:8	O
of	PRADAXA.xml:S3:1369:2	O
Anticoagulant	PRADAXA.xml:S3:1372:13	O
Effect	PRADAXA.xml:S3:1386:6	O
:	PRADAXA.xml:S3:1392:1	O
A	PRADAXA.xml:S3:1395:1	O
specific	PRADAXA.xml:S3:1397:8	O
reversal	PRADAXA.xml:S3:1406:8	O
agent	PRADAXA.xml:S3:1415:5	O
for	PRADAXA.xml:S3:1421:3	O
dabigatran	PRADAXA.xml:S3:1425:10	O
is	PRADAXA.xml:S3:1436:2	O
not	PRADAXA.xml:S3:1439:3	O
available	PRADAXA.xml:S3:1443:9	O
.	PRADAXA.xml:S3:1452:1	O

Hemodialysis	PRADAXA.xml:S3:1454:12	O
can	PRADAXA.xml:S3:1467:3	O
remove	PRADAXA.xml:S3:1471:6	O
dabigatran	PRADAXA.xml:S3:1478:10	O
;	PRADAXA.xml:S3:1488:1	O
however	PRADAXA.xml:S3:1490:7	O
the	PRADAXA.xml:S3:1498:3	O
clinical	PRADAXA.xml:S3:1502:8	O
experience	PRADAXA.xml:S3:1511:10	O
supporting	PRADAXA.xml:S3:1522:10	O
the	PRADAXA.xml:S3:1533:3	O
use	PRADAXA.xml:S3:1537:3	O
of	PRADAXA.xml:S3:1541:2	O
hemodialysis	PRADAXA.xml:S3:1544:12	O
as	PRADAXA.xml:S3:1557:2	O
a	PRADAXA.xml:S3:1560:1	O
treatment	PRADAXA.xml:S3:1562:9	O
for	PRADAXA.xml:S3:1572:3	O
bleeding	PRADAXA.xml:S3:1576:8	O
is	PRADAXA.xml:S3:1585:2	O
limited	PRADAXA.xml:S3:1588:7	O
[	PRADAXA.xml:S3:1596:1	O
see	PRADAXA.xml:S3:1597:3	O
Overdosage	PRADAXA.xml:S3:1601:10	O
(	PRADAXA.xml:S3:1613:1	O
10	PRADAXA.xml:S3:1614:2	O
)	PRADAXA.xml:S3:1616:1	O
]	PRADAXA.xml:S3:1619:1	O
.	PRADAXA.xml:S3:1622:1	O

Activated	PRADAXA.xml:S3:1624:9	O
prothrombin	PRADAXA.xml:S3:1634:11	O
complex	PRADAXA.xml:S3:1646:7	O
concentrates	PRADAXA.xml:S3:1654:12	O
(	PRADAXA.xml:S3:1667:1	O
aPCCs	PRADAXA.xml:S3:1668:5	O
,	PRADAXA.xml:S3:1673:1	O
e	PRADAXA.xml:S3:1675:1	O
.	PRADAXA.xml:S3:1676:1	O
g	PRADAXA.xml:S3:1677:1	O
.	PRADAXA.xml:S3:1678:1	O
,	PRADAXA.xml:S3:1679:1	O
FEIBA	PRADAXA.xml:S3:1681:5	O
)	PRADAXA.xml:S3:1686:1	O
,	PRADAXA.xml:S3:1687:1	O
or	PRADAXA.xml:S3:1689:2	O
recombinant	PRADAXA.xml:S3:1692:11	O
Factor	PRADAXA.xml:S3:1704:6	O
VIIa	PRADAXA.xml:S3:1711:4	O
,	PRADAXA.xml:S3:1715:1	O
or	PRADAXA.xml:S3:1717:2	O
concentrates	PRADAXA.xml:S3:1720:12	O
of	PRADAXA.xml:S3:1733:2	O
coagulation	PRADAXA.xml:S3:1736:11	O
factors	PRADAXA.xml:S3:1748:7	O
II	PRADAXA.xml:S3:1756:2	O
,	PRADAXA.xml:S3:1758:1	O
IX	PRADAXA.xml:S3:1760:2	O
or	PRADAXA.xml:S3:1763:2	O
X	PRADAXA.xml:S3:1766:1	O
may	PRADAXA.xml:S3:1768:3	O
be	PRADAXA.xml:S3:1772:2	O
considered	PRADAXA.xml:S3:1775:10	O
but	PRADAXA.xml:S3:1786:3	O
their	PRADAXA.xml:S3:1790:5	O
use	PRADAXA.xml:S3:1796:3	O
has	PRADAXA.xml:S3:1800:3	O
not	PRADAXA.xml:S3:1804:3	O
been	PRADAXA.xml:S3:1808:4	O
evaluated	PRADAXA.xml:S3:1813:9	O
in	PRADAXA.xml:S3:1823:2	O
clinical	PRADAXA.xml:S3:1826:8	O
trials	PRADAXA.xml:S3:1835:6	O
.	PRADAXA.xml:S3:1841:1	O

Protamine	PRADAXA.xml:S3:1843:9	O
sulfate	PRADAXA.xml:S3:1853:7	O
and	PRADAXA.xml:S3:1861:3	O
vitamin	PRADAXA.xml:S3:1865:7	O
K	PRADAXA.xml:S3:1873:1	O
are	PRADAXA.xml:S3:1875:3	O
not	PRADAXA.xml:S3:1879:3	O
expected	PRADAXA.xml:S3:1883:8	O
to	PRADAXA.xml:S3:1892:2	O
affect	PRADAXA.xml:S3:1895:6	O
the	PRADAXA.xml:S3:1902:3	O
anticoagulant	PRADAXA.xml:S3:1906:13	O
activity	PRADAXA.xml:S3:1920:8	O
of	PRADAXA.xml:S3:1929:2	O
dabigatran	PRADAXA.xml:S3:1932:10	O
.	PRADAXA.xml:S3:1942:1	O

Consider	PRADAXA.xml:S3:1944:8	O
administration	PRADAXA.xml:S3:1953:14	O
of	PRADAXA.xml:S3:1968:2	O
platelet	PRADAXA.xml:S3:1971:8	O
concentrates	PRADAXA.xml:S3:1980:12	O
in	PRADAXA.xml:S3:1993:2	O
cases	PRADAXA.xml:S3:1996:5	O
where	PRADAXA.xml:S3:2002:5	O
thrombocytopenia	PRADAXA.xml:S3:2008:16	O
is	PRADAXA.xml:S3:2025:2	O
present	PRADAXA.xml:S3:2028:7	O
or	PRADAXA.xml:S3:2036:2	O
long	PRADAXA.xml:S3:2039:4	O
-	PRADAXA.xml:S3:2043:1	O
acting	PRADAXA.xml:S3:2044:6	O
antiplatelet	PRADAXA.xml:S3:2051:12	O
drugs	PRADAXA.xml:S3:2064:5	O
have	PRADAXA.xml:S3:2070:4	O
been	PRADAXA.xml:S3:2075:4	O
used	PRADAXA.xml:S3:2080:4	O
.	PRADAXA.xml:S3:2084:1	O

5.3	PRADAXA.xml:S3:2093:3	O
Spinal	PRADAXA.xml:S3:2097:6	O
Epidural	PRADAXA.xml:S3:2104:8	O
Anesthesia	PRADAXA.xml:S3:2113:10	O
or	PRADAXA.xml:S3:2124:2	O
Puncture	PRADAXA.xml:S3:2127:8	O

When	PRADAXA.xml:S3:2141:4	O
neuraxial	PRADAXA.xml:S3:2146:9	O
anesthesia	PRADAXA.xml:S3:2156:10	O
(	PRADAXA.xml:S3:2167:1	O
spinal	PRADAXA.xml:S3:2168:6	O
epidural	PRADAXA.xml:S3:2175:8	O
anesthesia	PRADAXA.xml:S3:2184:10	O
)	PRADAXA.xml:S3:2194:1	O
or	PRADAXA.xml:S3:2196:2	O
spinal	PRADAXA.xml:S3:2199:6	O
puncture	PRADAXA.xml:S3:2206:8	O
is	PRADAXA.xml:S3:2215:2	O
employed	PRADAXA.xml:S3:2218:8	O
,	PRADAXA.xml:S3:2226:1	O
patients	PRADAXA.xml:S3:2228:8	O
treated	PRADAXA.xml:S3:2237:7	O
with	PRADAXA.xml:S3:2245:4	O
anticoagulant	PRADAXA.xml:S3:2250:13	B-DrugClass
agents	PRADAXA.xml:S3:2264:6	I-DrugClass
are	PRADAXA.xml:S3:2271:3	O
at	PRADAXA.xml:S3:2275:2	O
risk	PRADAXA.xml:S3:2278:4	O
of	PRADAXA.xml:S3:2283:2	O
developing	PRADAXA.xml:S3:2286:10	O
an	PRADAXA.xml:S3:2297:2	O
epidural	PRADAXA.xml:S3:2300:8	B-AdverseReaction
or	PRADAXA.xml:S3:2309:2	O
spinal	PRADAXA.xml:S3:2312:6	B-AdverseReaction
hematoma	PRADAXA.xml:S3:2319:8	I-AdverseReaction
which	PRADAXA.xml:S3:2328:5	O
can	PRADAXA.xml:S3:2334:3	O
result	PRADAXA.xml:S3:2338:6	O
in	PRADAXA.xml:S3:2345:2	O
long	PRADAXA.xml:S3:2348:4	O
-	PRADAXA.xml:S3:2352:1	O
term	PRADAXA.xml:S3:2353:4	O
or	PRADAXA.xml:S3:2358:2	O
permanent	PRADAXA.xml:S3:2361:9	B-AdverseReaction
paralysis	PRADAXA.xml:S3:2371:9	I-AdverseReaction
[	PRADAXA.xml:S3:2381:1	O
see	PRADAXA.xml:S3:2382:3	O
Boxed	PRADAXA.xml:S3:2387:5	O
Warning	PRADAXA.xml:S3:2393:7	O
]	PRADAXA.xml:S3:2402:1	O
.	PRADAXA.xml:S3:2405:1	O

To	PRADAXA.xml:S3:2411:2	O
reduce	PRADAXA.xml:S3:2414:6	O
the	PRADAXA.xml:S3:2421:3	O
potential	PRADAXA.xml:S3:2425:9	O
risk	PRADAXA.xml:S3:2435:4	O
of	PRADAXA.xml:S3:2440:2	O
bleeding	PRADAXA.xml:S3:2443:8	O
associated	PRADAXA.xml:S3:2452:10	O
with	PRADAXA.xml:S3:2463:4	O
the	PRADAXA.xml:S3:2468:3	O
concurrent	PRADAXA.xml:S3:2472:10	O
use	PRADAXA.xml:S3:2483:3	O
of	PRADAXA.xml:S3:2487:2	O
dabigatran	PRADAXA.xml:S3:2490:10	O
and	PRADAXA.xml:S3:2501:3	O
epidural	PRADAXA.xml:S3:2505:8	O
or	PRADAXA.xml:S3:2514:2	O
spinal	PRADAXA.xml:S3:2517:6	O
anesthesia	PRADAXA.xml:S3:2524:10	O
analgesia	PRADAXA.xml:S3:2535:9	O
or	PRADAXA.xml:S3:2545:2	O
spinal	PRADAXA.xml:S3:2548:6	O
puncture	PRADAXA.xml:S3:2555:8	O
,	PRADAXA.xml:S3:2563:1	O
consider	PRADAXA.xml:S3:2565:8	O
the	PRADAXA.xml:S3:2574:3	O
pharmacokinetic	PRADAXA.xml:S3:2578:15	O
profile	PRADAXA.xml:S3:2594:7	O
of	PRADAXA.xml:S3:2602:2	O
dabigatran	PRADAXA.xml:S3:2605:10	O
[	PRADAXA.xml:S3:2616:1	O
see	PRADAXA.xml:S3:2617:3	O
Clinical	PRADAXA.xml:S3:2621:8	O
Pharmacology	PRADAXA.xml:S3:2630:12	O
(	PRADAXA.xml:S3:2644:1	O
12.3	PRADAXA.xml:S3:2645:4	O
)	PRADAXA.xml:S3:2649:1	O
]	PRADAXA.xml:S3:2652:1	O
.	PRADAXA.xml:S3:2655:1	O

Placement	PRADAXA.xml:S3:2657:9	O
or	PRADAXA.xml:S3:2667:2	O
removal	PRADAXA.xml:S3:2670:7	O
of	PRADAXA.xml:S3:2678:2	O
an	PRADAXA.xml:S3:2681:2	O
epidural	PRADAXA.xml:S3:2684:8	O
catheter	PRADAXA.xml:S3:2693:8	O
or	PRADAXA.xml:S3:2702:2	O
lumbar	PRADAXA.xml:S3:2705:6	O
puncture	PRADAXA.xml:S3:2712:8	O
is	PRADAXA.xml:S3:2721:2	O
best	PRADAXA.xml:S3:2724:4	O
performed	PRADAXA.xml:S3:2729:9	O
when	PRADAXA.xml:S3:2739:4	O
the	PRADAXA.xml:S3:2744:3	O
anticoagulant	PRADAXA.xml:S3:2748:13	O
effect	PRADAXA.xml:S3:2762:6	O
of	PRADAXA.xml:S3:2769:2	O
dabigatran	PRADAXA.xml:S3:2772:10	O
is	PRADAXA.xml:S3:2783:2	O
low	PRADAXA.xml:S3:2786:3	O
;	PRADAXA.xml:S3:2789:1	O
however	PRADAXA.xml:S3:2791:7	O
,	PRADAXA.xml:S3:2798:1	O
the	PRADAXA.xml:S3:2800:3	O
exact	PRADAXA.xml:S3:2804:5	O
timing	PRADAXA.xml:S3:2810:6	O
to	PRADAXA.xml:S3:2817:2	O
reach	PRADAXA.xml:S3:2820:5	O
a	PRADAXA.xml:S3:2826:1	O
sufficiently	PRADAXA.xml:S3:2828:12	O
low	PRADAXA.xml:S3:2841:3	O
anticoagulant	PRADAXA.xml:S3:2845:13	O
effect	PRADAXA.xml:S3:2859:6	O
in	PRADAXA.xml:S3:2866:2	O
each	PRADAXA.xml:S3:2869:4	O
patient	PRADAXA.xml:S3:2874:7	O
is	PRADAXA.xml:S3:2882:2	O
not	PRADAXA.xml:S3:2885:3	O
known	PRADAXA.xml:S3:2889:5	O
.	PRADAXA.xml:S3:2894:1	O

Should	PRADAXA.xml:S3:2900:6	O
the	PRADAXA.xml:S3:2907:3	O
physician	PRADAXA.xml:S3:2911:9	O
decide	PRADAXA.xml:S3:2921:6	O
to	PRADAXA.xml:S3:2928:2	O
administer	PRADAXA.xml:S3:2931:10	O
anticoagulation	PRADAXA.xml:S3:2942:15	O
in	PRADAXA.xml:S3:2958:2	O
the	PRADAXA.xml:S3:2961:3	O
context	PRADAXA.xml:S3:2965:7	O
of	PRADAXA.xml:S3:2973:2	O
epidural	PRADAXA.xml:S3:2976:8	O
or	PRADAXA.xml:S3:2985:2	O
spinal	PRADAXA.xml:S3:2988:6	O
anesthesia	PRADAXA.xml:S3:2995:10	O
analgesia	PRADAXA.xml:S3:3006:9	O
or	PRADAXA.xml:S3:3016:2	O
lumbar	PRADAXA.xml:S3:3019:6	O
puncture	PRADAXA.xml:S3:3026:8	O
,	PRADAXA.xml:S3:3034:1	O
monitor	PRADAXA.xml:S3:3036:7	O
frequently	PRADAXA.xml:S3:3044:10	O
to	PRADAXA.xml:S3:3055:2	O
detect	PRADAXA.xml:S3:3058:6	O
any	PRADAXA.xml:S3:3065:3	O
signs	PRADAXA.xml:S3:3069:5	O
or	PRADAXA.xml:S3:3075:2	O
symptoms	PRADAXA.xml:S3:3078:8	O
of	PRADAXA.xml:S3:3087:2	O
neurological	PRADAXA.xml:S3:3090:12	O
impairment	PRADAXA.xml:S3:3103:10	O
,	PRADAXA.xml:S3:3113:1	O
such	PRADAXA.xml:S3:3115:4	O
as	PRADAXA.xml:S3:3120:2	O
midline	PRADAXA.xml:S3:3123:7	O
back	PRADAXA.xml:S3:3131:4	O
pain	PRADAXA.xml:S3:3136:4	O
,	PRADAXA.xml:S3:3140:1	O
sensory	PRADAXA.xml:S3:3142:7	O
and	PRADAXA.xml:S3:3150:3	O
motor	PRADAXA.xml:S3:3154:5	O
deficits	PRADAXA.xml:S3:3160:8	O
(	PRADAXA.xml:S3:3169:1	O
numbness	PRADAXA.xml:S3:3170:8	O
,	PRADAXA.xml:S3:3178:1	O
tingling	PRADAXA.xml:S3:3180:8	O
,	PRADAXA.xml:S3:3188:1	O
or	PRADAXA.xml:S3:3190:2	O
weakness	PRADAXA.xml:S3:3193:8	O
in	PRADAXA.xml:S3:3202:2	O
lower	PRADAXA.xml:S3:3205:5	O
limbs	PRADAXA.xml:S3:3211:5	O
)	PRADAXA.xml:S3:3216:1	O
,	PRADAXA.xml:S3:3217:1	O
bowel	PRADAXA.xml:S3:3219:5	O
and	PRADAXA.xml:S3:3225:3	O
or	PRADAXA.xml:S3:3229:2	O
bladder	PRADAXA.xml:S3:3232:7	O
dysfunction	PRADAXA.xml:S3:3240:11	O
.	PRADAXA.xml:S3:3251:1	O

Instruct	PRADAXA.xml:S3:3253:8	O
patients	PRADAXA.xml:S3:3262:8	O
to	PRADAXA.xml:S3:3271:2	O
immediately	PRADAXA.xml:S3:3274:11	O
report	PRADAXA.xml:S3:3286:6	O
if	PRADAXA.xml:S3:3293:2	O
they	PRADAXA.xml:S3:3296:4	O
experience	PRADAXA.xml:S3:3301:10	O
any	PRADAXA.xml:S3:3312:3	O
of	PRADAXA.xml:S3:3316:2	O
the	PRADAXA.xml:S3:3319:3	O
above	PRADAXA.xml:S3:3323:5	O
signs	PRADAXA.xml:S3:3329:5	O
or	PRADAXA.xml:S3:3335:2	O
symptoms	PRADAXA.xml:S3:3338:8	O
.	PRADAXA.xml:S3:3346:1	O

If	PRADAXA.xml:S3:3348:2	O
signs	PRADAXA.xml:S3:3351:5	O
or	PRADAXA.xml:S3:3357:2	O
symptoms	PRADAXA.xml:S3:3360:8	O
of	PRADAXA.xml:S3:3369:2	O
spinal	PRADAXA.xml:S3:3372:6	O
hematoma	PRADAXA.xml:S3:3379:8	O
are	PRADAXA.xml:S3:3388:3	O
suspected	PRADAXA.xml:S3:3392:9	O
,	PRADAXA.xml:S3:3401:1	O
initiate	PRADAXA.xml:S3:3403:8	O
urgent	PRADAXA.xml:S3:3412:6	O
diagnosis	PRADAXA.xml:S3:3419:9	O
and	PRADAXA.xml:S3:3429:3	O
treatment	PRADAXA.xml:S3:3433:9	O
including	PRADAXA.xml:S3:3443:9	O
consideration	PRADAXA.xml:S3:3453:13	O
for	PRADAXA.xml:S3:3467:3	O
spinal	PRADAXA.xml:S3:3471:6	O
cord	PRADAXA.xml:S3:3478:4	O
decompression	PRADAXA.xml:S3:3483:13	O
even	PRADAXA.xml:S3:3497:4	O
though	PRADAXA.xml:S3:3502:6	O
such	PRADAXA.xml:S3:3509:4	O
treatment	PRADAXA.xml:S3:3514:9	O
may	PRADAXA.xml:S3:3524:3	O
not	PRADAXA.xml:S3:3528:3	O
prevent	PRADAXA.xml:S3:3532:7	O
or	PRADAXA.xml:S3:3540:2	O
reverse	PRADAXA.xml:S3:3543:7	O
neurological	PRADAXA.xml:S3:3551:12	O
sequelae	PRADAXA.xml:S3:3564:8	O
.	PRADAXA.xml:S3:3572:1	O

5.4	PRADAXA.xml:S3:3581:3	O
Thromboembolic	PRADAXA.xml:S3:3585:14	O
and	PRADAXA.xml:S3:3600:3	O
Bleeding	PRADAXA.xml:S3:3604:8	O
Events	PRADAXA.xml:S3:3613:6	O
in	PRADAXA.xml:S3:3620:2	O
Patients	PRADAXA.xml:S3:3623:8	O
with	PRADAXA.xml:S3:3632:4	O
Prosthetic	PRADAXA.xml:S3:3637:10	B-AdverseReaction
Heart	PRADAXA.xml:S3:3648:5	I-AdverseReaction
Valves	PRADAXA.xml:S3:3654:6	O

The	PRADAXA.xml:S3:3666:3	O
safety	PRADAXA.xml:S3:3670:6	O
and	PRADAXA.xml:S3:3677:3	O
efficacy	PRADAXA.xml:S3:3681:8	O
of	PRADAXA.xml:S3:3690:2	O
PRADAXA	PRADAXA.xml:S3:3693:7	O
in	PRADAXA.xml:S3:3701:2	O
patients	PRADAXA.xml:S3:3704:8	O
with	PRADAXA.xml:S3:3713:4	O
bileaflet	PRADAXA.xml:S3:3718:9	O
mechanical	PRADAXA.xml:S3:3728:10	O
prosthetic	PRADAXA.xml:S3:3739:10	O
heart	PRADAXA.xml:S3:3750:5	O
valves	PRADAXA.xml:S3:3756:6	O
was	PRADAXA.xml:S3:3763:3	O
evaluated	PRADAXA.xml:S3:3767:9	O
in	PRADAXA.xml:S3:3777:2	O
the	PRADAXA.xml:S3:3780:3	O
RE	PRADAXA.xml:S3:3784:2	O
-	PRADAXA.xml:S3:3786:1	O
ALIGN	PRADAXA.xml:S3:3787:5	O
trial	PRADAXA.xml:S3:3793:5	O
,	PRADAXA.xml:S3:3798:1	O
in	PRADAXA.xml:S3:3800:2	O
which	PRADAXA.xml:S3:3803:5	O
patients	PRADAXA.xml:S3:3809:8	O
with	PRADAXA.xml:S3:3818:4	O
bileaflet	PRADAXA.xml:S3:3823:9	O
mechanical	PRADAXA.xml:S3:3833:10	O
prosthetic	PRADAXA.xml:S3:3844:10	O
heart	PRADAXA.xml:S3:3855:5	O
valves	PRADAXA.xml:S3:3861:6	O
(	PRADAXA.xml:S3:3868:1	O
recently	PRADAXA.xml:S3:3869:8	O
implanted	PRADAXA.xml:S3:3878:9	O
or	PRADAXA.xml:S3:3888:2	O
implanted	PRADAXA.xml:S3:3891:9	O
more	PRADAXA.xml:S3:3901:4	O
than	PRADAXA.xml:S3:3906:4	O
three	PRADAXA.xml:S3:3911:5	O
months	PRADAXA.xml:S3:3917:6	O
prior	PRADAXA.xml:S3:3924:5	O
to	PRADAXA.xml:S3:3930:2	O
enrollment	PRADAXA.xml:S3:3933:10	O
)	PRADAXA.xml:S3:3943:1	O
were	PRADAXA.xml:S3:3945:4	O
randomized	PRADAXA.xml:S3:3950:10	O
to	PRADAXA.xml:S3:3961:2	O
dose	PRADAXA.xml:S3:3964:4	O
adjusted	PRADAXA.xml:S3:3969:8	O
warfarin	PRADAXA.xml:S3:3978:8	O
or	PRADAXA.xml:S3:3987:2	O
150	PRADAXA.xml:S3:3990:3	O
,	PRADAXA.xml:S3:3993:1	O
220	PRADAXA.xml:S3:3995:3	O
,	PRADAXA.xml:S3:3998:1	O
or	PRADAXA.xml:S3:4000:2	O
300	PRADAXA.xml:S3:4003:3	O
mg	PRADAXA.xml:S3:4007:2	O
of	PRADAXA.xml:S3:4010:2	O
PRADAXA	PRADAXA.xml:S3:4013:7	O
twice	PRADAXA.xml:S3:4021:5	O
a	PRADAXA.xml:S3:4027:1	O
day	PRADAXA.xml:S3:4029:3	O
.	PRADAXA.xml:S3:4032:1	O

RE	PRADAXA.xml:S3:4034:2	O
-	PRADAXA.xml:S3:4036:1	O
ALIGN	PRADAXA.xml:S3:4037:5	O
was	PRADAXA.xml:S3:4043:3	O
terminated	PRADAXA.xml:S3:4047:10	O
early	PRADAXA.xml:S3:4058:5	O
due	PRADAXA.xml:S3:4064:3	O
to	PRADAXA.xml:S3:4068:2	O
the	PRADAXA.xml:S3:4071:3	O
occurrence	PRADAXA.xml:S3:4075:10	O
of	PRADAXA.xml:S3:4086:2	O
significantly	PRADAXA.xml:S3:4089:13	O
more	PRADAXA.xml:S3:4103:4	O
thromboembolic	PRADAXA.xml:S3:4108:14	B-AdverseReaction
events	PRADAXA.xml:S3:4123:6	I-AdverseReaction
(	PRADAXA.xml:S3:4130:1	O
valve	PRADAXA.xml:S3:4131:5	I-AdverseReaction
thrombosis	PRADAXA.xml:S3:4137:10	I-AdverseReaction
,	PRADAXA.xml:S3:4147:1	O
stroke	PRADAXA.xml:S3:4149:6	I-AdverseReaction
,	PRADAXA.xml:S3:4155:1	O
transient	PRADAXA.xml:S3:4157:9	B-AdverseReaction
ischemic	PRADAXA.xml:S3:4167:8	I-AdverseReaction
attack	PRADAXA.xml:S3:4176:6	I-AdverseReaction
,	PRADAXA.xml:S3:4182:1	O
and	PRADAXA.xml:S3:4184:3	O
myocardial	PRADAXA.xml:S3:4188:10	B-AdverseReaction
infarction	PRADAXA.xml:S3:4199:10	I-AdverseReaction
)	PRADAXA.xml:S3:4209:1	O
and	PRADAXA.xml:S3:4211:3	O
an	PRADAXA.xml:S3:4215:2	O
excess	PRADAXA.xml:S3:4218:6	O
of	PRADAXA.xml:S3:4225:2	O
major	PRADAXA.xml:S3:4228:5	B-Severity
bleeding	PRADAXA.xml:S3:4234:8	B-AdverseReaction
(	PRADAXA.xml:S3:4243:1	O
predominantly	PRADAXA.xml:S3:4244:13	O
post	PRADAXA.xml:S3:4258:4	O
-	PRADAXA.xml:S3:4262:1	O
operative	PRADAXA.xml:S3:4263:9	O
pericardial	PRADAXA.xml:S3:4273:11	B-AdverseReaction
effusions	PRADAXA.xml:S3:4285:9	I-AdverseReaction
requiring	PRADAXA.xml:S3:4295:9	O
intervention	PRADAXA.xml:S3:4305:12	O
for	PRADAXA.xml:S3:4318:3	O
hemodynamic	PRADAXA.xml:S3:4322:11	O
compromise	PRADAXA.xml:S3:4334:10	O
)	PRADAXA.xml:S3:4344:1	O
in	PRADAXA.xml:S3:4346:2	O
the	PRADAXA.xml:S3:4349:3	O
PRADAXA	PRADAXA.xml:S3:4353:7	O
treatment	PRADAXA.xml:S3:4361:9	O
arm	PRADAXA.xml:S3:4371:3	O
as	PRADAXA.xml:S3:4375:2	O
compared	PRADAXA.xml:S3:4378:8	O
to	PRADAXA.xml:S3:4387:2	O
the	PRADAXA.xml:S3:4390:3	O
warfarin	PRADAXA.xml:S3:4394:8	O
treatment	PRADAXA.xml:S3:4403:9	O
arm	PRADAXA.xml:S3:4413:3	O
.	PRADAXA.xml:S3:4416:1	O

These	PRADAXA.xml:S3:4418:5	O
bleeding	PRADAXA.xml:S3:4424:8	B-AdverseReaction
and	PRADAXA.xml:S3:4433:3	O
thromboembolic	PRADAXA.xml:S3:4437:14	B-AdverseReaction
events	PRADAXA.xml:S3:4452:6	I-AdverseReaction
were	PRADAXA.xml:S3:4459:4	O
seen	PRADAXA.xml:S3:4464:4	O
both	PRADAXA.xml:S3:4469:4	O
in	PRADAXA.xml:S3:4474:2	O
patients	PRADAXA.xml:S3:4477:8	O
who	PRADAXA.xml:S3:4486:3	O
were	PRADAXA.xml:S3:4490:4	O
initiated	PRADAXA.xml:S3:4495:9	O
on	PRADAXA.xml:S3:4505:2	O
PRADAXA	PRADAXA.xml:S3:4508:7	O
post	PRADAXA.xml:S3:4516:4	O
-	PRADAXA.xml:S3:4520:1	O
operatively	PRADAXA.xml:S3:4521:11	O
within	PRADAXA.xml:S3:4533:6	O
three	PRADAXA.xml:S3:4540:5	O
days	PRADAXA.xml:S3:4546:4	O
of	PRADAXA.xml:S3:4551:2	O
mechanical	PRADAXA.xml:S3:4554:10	O
bileaflet	PRADAXA.xml:S3:4565:9	O
valve	PRADAXA.xml:S3:4575:5	O
implantation	PRADAXA.xml:S3:4581:12	O
,	PRADAXA.xml:S3:4593:1	O
as	PRADAXA.xml:S3:4595:2	O
well	PRADAXA.xml:S3:4598:4	O
as	PRADAXA.xml:S3:4603:2	O
in	PRADAXA.xml:S3:4606:2	O
patients	PRADAXA.xml:S3:4609:8	O
whose	PRADAXA.xml:S3:4618:5	O
valves	PRADAXA.xml:S3:4624:6	O
had	PRADAXA.xml:S3:4631:3	O
been	PRADAXA.xml:S3:4635:4	O
implanted	PRADAXA.xml:S3:4640:9	O
more	PRADAXA.xml:S3:4650:4	O
than	PRADAXA.xml:S3:4655:4	O
three	PRADAXA.xml:S3:4660:5	O
months	PRADAXA.xml:S3:4666:6	O
prior	PRADAXA.xml:S3:4673:5	O
to	PRADAXA.xml:S3:4679:2	O
enrollment	PRADAXA.xml:S3:4682:10	O
.	PRADAXA.xml:S3:4692:1	O

Therefore	PRADAXA.xml:S3:4694:9	O
,	PRADAXA.xml:S3:4703:1	O
the	PRADAXA.xml:S3:4705:3	O
use	PRADAXA.xml:S3:4709:3	O
of	PRADAXA.xml:S3:4713:2	O
PRADAXA	PRADAXA.xml:S3:4716:7	O
is	PRADAXA.xml:S3:4724:2	O
contraindicated	PRADAXA.xml:S3:4727:15	O
in	PRADAXA.xml:S3:4743:2	O
patients	PRADAXA.xml:S3:4746:8	O
with	PRADAXA.xml:S3:4755:4	O
mechanical	PRADAXA.xml:S3:4760:10	O
prosthetic	PRADAXA.xml:S3:4771:10	O
valves	PRADAXA.xml:S3:4782:6	O
[	PRADAXA.xml:S3:4789:1	O
see	PRADAXA.xml:S3:4790:3	O
Contraindications	PRADAXA.xml:S3:4794:17	O
(	PRADAXA.xml:S3:4813:1	O
4	PRADAXA.xml:S3:4814:1	O
)	PRADAXA.xml:S3:4815:1	O
]	PRADAXA.xml:S3:4818:1	O
.	PRADAXA.xml:S3:4819:1	O

The	PRADAXA.xml:S3:4827:3	O
use	PRADAXA.xml:S3:4831:3	O
of	PRADAXA.xml:S3:4835:2	O
PRADAXA	PRADAXA.xml:S3:4838:7	O
for	PRADAXA.xml:S3:4846:3	O
the	PRADAXA.xml:S3:4850:3	O
prophylaxis	PRADAXA.xml:S3:4854:11	O
of	PRADAXA.xml:S3:4866:2	O
thromboembolic	PRADAXA.xml:S3:4869:14	O
events	PRADAXA.xml:S3:4884:6	O
in	PRADAXA.xml:S3:4891:2	O
patients	PRADAXA.xml:S3:4894:8	O
with	PRADAXA.xml:S3:4903:4	O
atrial	PRADAXA.xml:S3:4908:6	O
fibrillation	PRADAXA.xml:S3:4915:12	O
in	PRADAXA.xml:S3:4928:2	O
the	PRADAXA.xml:S3:4931:3	O
setting	PRADAXA.xml:S3:4935:7	O
of	PRADAXA.xml:S3:4943:2	O
other	PRADAXA.xml:S3:4946:5	O
forms	PRADAXA.xml:S3:4952:5	O
of	PRADAXA.xml:S3:4958:2	O
valvular	PRADAXA.xml:S3:4961:8	O
heart	PRADAXA.xml:S3:4970:5	O
disease	PRADAXA.xml:S3:4976:7	O
,	PRADAXA.xml:S3:4983:1	O
including	PRADAXA.xml:S3:4985:9	O
the	PRADAXA.xml:S3:4995:3	O
presence	PRADAXA.xml:S3:4999:8	O
of	PRADAXA.xml:S3:5008:2	O
a	PRADAXA.xml:S3:5011:1	O
bioprosthetic	PRADAXA.xml:S3:5013:13	O
heart	PRADAXA.xml:S3:5027:5	O
valve	PRADAXA.xml:S3:5033:5	O
,	PRADAXA.xml:S3:5038:1	O
has	PRADAXA.xml:S3:5040:3	O
not	PRADAXA.xml:S3:5044:3	O
been	PRADAXA.xml:S3:5048:4	O
studied	PRADAXA.xml:S3:5053:7	O
and	PRADAXA.xml:S3:5061:3	O
is	PRADAXA.xml:S3:5065:2	O
not	PRADAXA.xml:S3:5068:3	O
recommended	PRADAXA.xml:S3:5072:11	O
.	PRADAXA.xml:S3:5083:1	O

5.5	PRADAXA.xml:S3:5092:3	O
Effect	PRADAXA.xml:S3:5096:6	O
of	PRADAXA.xml:S3:5103:2	O
P	PRADAXA.xml:S3:5106:1	O
-	PRADAXA.xml:S3:5107:1	O
gp	PRADAXA.xml:S3:5108:2	O
Inducers	PRADAXA.xml:S3:5111:8	O
and	PRADAXA.xml:S3:5120:3	O
Inhibitors	PRADAXA.xml:S3:5124:10	O
on	PRADAXA.xml:S3:5135:2	O
Dabigatran	PRADAXA.xml:S3:5138:10	O
Exposure	PRADAXA.xml:S3:5149:8	O

The	PRADAXA.xml:S3:5163:3	O
concomitant	PRADAXA.xml:S3:5167:11	O
use	PRADAXA.xml:S3:5179:3	O
of	PRADAXA.xml:S3:5183:2	O
PRADAXA	PRADAXA.xml:S3:5186:7	O
with	PRADAXA.xml:S3:5194:4	O
P	PRADAXA.xml:S3:5199:1	O
-	PRADAXA.xml:S3:5200:1	O
gp	PRADAXA.xml:S3:5201:2	O
inducers	PRADAXA.xml:S3:5204:8	O
(	PRADAXA.xml:S3:5213:1	O
e	PRADAXA.xml:S3:5214:1	O
.	PRADAXA.xml:S3:5215:1	O
g	PRADAXA.xml:S3:5216:1	O
.	PRADAXA.xml:S3:5217:1	O
,	PRADAXA.xml:S3:5218:1	O
rifampin	PRADAXA.xml:S3:5220:8	O
)	PRADAXA.xml:S3:5228:1	O
reduces	PRADAXA.xml:S3:5230:7	O
exposure	PRADAXA.xml:S3:5238:8	O
to	PRADAXA.xml:S3:5247:2	O
dabigatran	PRADAXA.xml:S3:5250:10	O
and	PRADAXA.xml:S3:5261:3	O
should	PRADAXA.xml:S3:5265:6	O
generally	PRADAXA.xml:S3:5272:9	O
be	PRADAXA.xml:S3:5282:2	O
avoided	PRADAXA.xml:S3:5285:7	O
[	PRADAXA.xml:S3:5293:1	O
see	PRADAXA.xml:S3:5294:3	O
Clinical	PRADAXA.xml:S3:5298:8	O
Pharmacology	PRADAXA.xml:S3:5307:12	O
(	PRADAXA.xml:S3:5321:1	O
12.3	PRADAXA.xml:S3:5322:4	O
)	PRADAXA.xml:S3:5326:1	O
]	PRADAXA.xml:S3:5329:1	O
.	PRADAXA.xml:S3:5332:1	O

P	PRADAXA.xml:S3:5338:1	O
-	PRADAXA.xml:S3:5339:1	O
gp	PRADAXA.xml:S3:5340:2	O
inhibition	PRADAXA.xml:S3:5343:10	O
and	PRADAXA.xml:S3:5354:3	O
impaired	PRADAXA.xml:S3:5358:8	O
renal	PRADAXA.xml:S3:5367:5	O
function	PRADAXA.xml:S3:5373:8	O
are	PRADAXA.xml:S3:5382:3	O
the	PRADAXA.xml:S3:5386:3	O
major	PRADAXA.xml:S3:5390:5	O
independent	PRADAXA.xml:S3:5396:11	O
factors	PRADAXA.xml:S3:5408:7	O
that	PRADAXA.xml:S3:5416:4	O
result	PRADAXA.xml:S3:5421:6	O
in	PRADAXA.xml:S3:5428:2	O
increased	PRADAXA.xml:S3:5431:9	O
exposure	PRADAXA.xml:S3:5441:8	O
to	PRADAXA.xml:S3:5450:2	O
dabigatran	PRADAXA.xml:S3:5453:10	O
[	PRADAXA.xml:S3:5464:1	O
see	PRADAXA.xml:S3:5465:3	O
Clinical	PRADAXA.xml:S3:5469:8	O
Pharmacology	PRADAXA.xml:S3:5478:12	O
(	PRADAXA.xml:S3:5492:1	O
12.3	PRADAXA.xml:S3:5493:4	O
)	PRADAXA.xml:S3:5497:1	O
]	PRADAXA.xml:S3:5500:1	O
.	PRADAXA.xml:S3:5501:1	O

Concomitant	PRADAXA.xml:S3:5504:11	O
use	PRADAXA.xml:S3:5516:3	O
of	PRADAXA.xml:S3:5520:2	O
P	PRADAXA.xml:S3:5523:1	O
-	PRADAXA.xml:S3:5524:1	O
gp	PRADAXA.xml:S3:5525:2	O
inhibitors	PRADAXA.xml:S3:5528:10	O
in	PRADAXA.xml:S3:5539:2	O
patients	PRADAXA.xml:S3:5542:8	O
with	PRADAXA.xml:S3:5551:4	O
renal	PRADAXA.xml:S3:5556:5	O
impairment	PRADAXA.xml:S3:5562:10	O
is	PRADAXA.xml:S3:5573:2	O
expected	PRADAXA.xml:S3:5576:8	O
to	PRADAXA.xml:S3:5585:2	O
produce	PRADAXA.xml:S3:5588:7	O
increased	PRADAXA.xml:S3:5596:9	O
exposure	PRADAXA.xml:S3:5606:8	O
of	PRADAXA.xml:S3:5615:2	O
dabigatran	PRADAXA.xml:S3:5618:10	O
compared	PRADAXA.xml:S3:5629:8	O
to	PRADAXA.xml:S3:5638:2	O
that	PRADAXA.xml:S3:5641:4	O
seen	PRADAXA.xml:S3:5646:4	O
with	PRADAXA.xml:S3:5651:4	O
either	PRADAXA.xml:S3:5656:6	O
factor	PRADAXA.xml:S3:5663:6	O
alone	PRADAXA.xml:S3:5670:5	O
.	PRADAXA.xml:S3:5675:1	O

Reduction	PRADAXA.xml:S3:5683:9	O
of	PRADAXA.xml:S3:5693:2	O
Risk	PRADAXA.xml:S3:5696:4	O
of	PRADAXA.xml:S3:5701:2	O
Stroke	PRADAXA.xml:S3:5704:6	O
and	PRADAXA.xml:S3:5711:3	O
Systemic	PRADAXA.xml:S3:5715:8	O
Embolism	PRADAXA.xml:S3:5724:8	O
in	PRADAXA.xml:S3:5733:2	O
Non	PRADAXA.xml:S3:5736:3	O
-	PRADAXA.xml:S3:5739:1	O
valvular	PRADAXA.xml:S3:5740:8	O
Atrial	PRADAXA.xml:S3:5749:6	O
Fibrillation	PRADAXA.xml:S3:5756:12	O

Reduce	PRADAXA.xml:S3:5777:6	O
the	PRADAXA.xml:S3:5784:3	O
dose	PRADAXA.xml:S3:5788:4	O
of	PRADAXA.xml:S3:5793:2	O
PRADAXA	PRADAXA.xml:S3:5796:7	O
to	PRADAXA.xml:S3:5804:2	O
75	PRADAXA.xml:S3:5807:2	O
mg	PRADAXA.xml:S3:5810:2	O
twice	PRADAXA.xml:S3:5813:5	O
daily	PRADAXA.xml:S3:5819:5	O
when	PRADAXA.xml:S3:5825:4	O
dronedarone	PRADAXA.xml:S3:5830:11	O
or	PRADAXA.xml:S3:5842:2	O
systemic	PRADAXA.xml:S3:5845:8	O
ketoconazole	PRADAXA.xml:S3:5854:12	O
is	PRADAXA.xml:S3:5867:2	O
coadministered	PRADAXA.xml:S3:5870:14	O
with	PRADAXA.xml:S3:5885:4	O
PRADAXA	PRADAXA.xml:S3:5890:7	O
in	PRADAXA.xml:S3:5898:2	O
patients	PRADAXA.xml:S3:5901:8	O
with	PRADAXA.xml:S3:5910:4	O
moderate	PRADAXA.xml:S3:5915:8	O
renal	PRADAXA.xml:S3:5924:5	O
impairment	PRADAXA.xml:S3:5930:10	O
(	PRADAXA.xml:S3:5941:1	O
CrCl	PRADAXA.xml:S3:5942:4	O
30	PRADAXA.xml:S3:5947:2	O
-	PRADAXA.xml:S3:5949:1	O
50	PRADAXA.xml:S3:5950:2	O
mL	PRADAXA.xml:S3:5953:2	O
min	PRADAXA.xml:S3:5956:3	O
)	PRADAXA.xml:S3:5959:1	O
.	PRADAXA.xml:S3:5960:1	O

Avoid	PRADAXA.xml:S3:5962:5	O
use	PRADAXA.xml:S3:5968:3	O
of	PRADAXA.xml:S3:5972:2	O
PRADAXA	PRADAXA.xml:S3:5975:7	O
and	PRADAXA.xml:S3:5983:3	O
P	PRADAXA.xml:S3:5987:1	O
-	PRADAXA.xml:S3:5988:1	O
gp	PRADAXA.xml:S3:5989:2	O
inhibitors	PRADAXA.xml:S3:5992:10	O
in	PRADAXA.xml:S3:6003:2	O
patients	PRADAXA.xml:S3:6006:8	O
with	PRADAXA.xml:S3:6015:4	O
severe	PRADAXA.xml:S3:6020:6	O
renal	PRADAXA.xml:S3:6027:5	O
impairment	PRADAXA.xml:S3:6033:10	O
(	PRADAXA.xml:S3:6044:1	O
CrCl	PRADAXA.xml:S3:6045:4	O
15	PRADAXA.xml:S3:6050:2	O
-	PRADAXA.xml:S3:6052:1	O
30	PRADAXA.xml:S3:6053:2	O
mL	PRADAXA.xml:S3:6056:2	O
min	PRADAXA.xml:S3:6059:3	O
)	PRADAXA.xml:S3:6062:1	O
[	PRADAXA.xml:S3:6064:1	O
see	PRADAXA.xml:S3:6065:3	O
Drug	PRADAXA.xml:S3:6069:4	O
Interactions	PRADAXA.xml:S3:6074:12	O
(	PRADAXA.xml:S3:6088:1	O
7.1	PRADAXA.xml:S3:6089:3	O
)	PRADAXA.xml:S3:6092:1	O
and	PRADAXA.xml:S3:6095:3	O
Use	PRADAXA.xml:S3:6099:3	O
in	PRADAXA.xml:S3:6103:2	O
Specific	PRADAXA.xml:S3:6106:8	O
Populations	PRADAXA.xml:S3:6115:11	O
(	PRADAXA.xml:S3:6128:1	O
8.6	PRADAXA.xml:S3:6129:3	O
)	PRADAXA.xml:S3:6132:1	O
]	PRADAXA.xml:S3:6135:1	O
.	PRADAXA.xml:S3:6138:1	O

Treatment	PRADAXA.xml:S3:6146:9	O
and	PRADAXA.xml:S3:6156:3	O
Reduction	PRADAXA.xml:S3:6160:9	O
in	PRADAXA.xml:S3:6170:2	O
the	PRADAXA.xml:S3:6173:3	O
Risk	PRADAXA.xml:S3:6177:4	O
of	PRADAXA.xml:S3:6182:2	O
Recurrence	PRADAXA.xml:S3:6185:10	O
of	PRADAXA.xml:S3:6196:2	O
Deep	PRADAXA.xml:S3:6199:4	O
Venous	PRADAXA.xml:S3:6204:6	O
Thrombosis	PRADAXA.xml:S3:6211:10	O
and	PRADAXA.xml:S3:6222:3	O
Pulmonary	PRADAXA.xml:S3:6226:9	O
Embolism	PRADAXA.xml:S3:6236:8	O

Avoid	PRADAXA.xml:S3:6253:5	O
use	PRADAXA.xml:S3:6259:3	O
of	PRADAXA.xml:S3:6263:2	O
PRADAXA	PRADAXA.xml:S3:6266:7	O
and	PRADAXA.xml:S3:6274:3	O
concomitant	PRADAXA.xml:S3:6278:11	O
P	PRADAXA.xml:S3:6290:1	O
-	PRADAXA.xml:S3:6291:1	O
gp	PRADAXA.xml:S3:6292:2	O
inhibitors	PRADAXA.xml:S3:6295:10	O
in	PRADAXA.xml:S3:6306:2	O
patients	PRADAXA.xml:S3:6309:8	O
with	PRADAXA.xml:S3:6318:4	O
CrCl	PRADAXA.xml:S3:6323:4	O
50	PRADAXA.xml:S3:6329:2	O
mL	PRADAXA.xml:S3:6332:2	O
min	PRADAXA.xml:S3:6335:3	O
[	PRADAXA.xml:S3:6339:1	O
see	PRADAXA.xml:S3:6340:3	O
Drug	PRADAXA.xml:S3:6344:4	O
Interactions	PRADAXA.xml:S3:6349:12	O
(	PRADAXA.xml:S3:6363:1	O
7.2	PRADAXA.xml:S3:6364:3	O
)	PRADAXA.xml:S3:6367:1	O
and	PRADAXA.xml:S3:6370:3	O
Use	PRADAXA.xml:S3:6374:3	O
in	PRADAXA.xml:S3:6378:2	O
Specific	PRADAXA.xml:S3:6381:8	O
Populations	PRADAXA.xml:S3:6390:11	O
(	PRADAXA.xml:S3:6403:1	O
8.6	PRADAXA.xml:S3:6404:3	O
)	PRADAXA.xml:S3:6407:1	O
]	PRADAXA.xml:S3:6410:1	O
.	PRADAXA.xml:S3:6413:1	O
6	PRISTIQ.xml:S1:4:1	O
ADVERSE	PRISTIQ.xml:S1:6:7	O
REACTIONS	PRISTIQ.xml:S1:14:9	O

The	PRISTIQ.xml:S1:27:3	O
following	PRISTIQ.xml:S1:31:9	O
adverse	PRISTIQ.xml:S1:41:7	O
reactions	PRISTIQ.xml:S1:49:9	O
are	PRISTIQ.xml:S1:59:3	O
discussed	PRISTIQ.xml:S1:63:9	O
in	PRISTIQ.xml:S1:73:2	O
greater	PRISTIQ.xml:S1:76:7	O
detail	PRISTIQ.xml:S1:84:6	O
in	PRISTIQ.xml:S1:91:2	O
other	PRISTIQ.xml:S1:94:5	O
sections	PRISTIQ.xml:S1:100:8	O
of	PRISTIQ.xml:S1:109:2	O
the	PRISTIQ.xml:S1:112:3	O
label	PRISTIQ.xml:S1:116:5	O
.	PRISTIQ.xml:S1:121:1	O

Hypersensitivity	PRISTIQ.xml:S1:132:16	B-AdverseReaction
[	PRISTIQ.xml:S1:149:1	O
see	PRISTIQ.xml:S1:150:3	O
Contraindications	PRISTIQ.xml:S1:155:17	O
(	PRISTIQ.xml:S1:173:1	O
4	PRISTIQ.xml:S1:174:1	O
)	PRISTIQ.xml:S1:175:1	O
]	PRISTIQ.xml:S1:178:1	O

Suicidal	PRISTIQ.xml:S1:188:8	B-AdverseReaction
Thoughts	PRISTIQ.xml:S1:197:8	I-AdverseReaction
and	PRISTIQ.xml:S1:206:3	O
Behaviors	PRISTIQ.xml:S1:210:9	I-AdverseReaction
in	PRISTIQ.xml:S1:220:2	O
Adolescents	PRISTIQ.xml:S1:223:11	O
and	PRISTIQ.xml:S1:235:3	O
Young	PRISTIQ.xml:S1:239:5	O
Adults	PRISTIQ.xml:S1:245:6	O
[	PRISTIQ.xml:S1:252:1	O
see	PRISTIQ.xml:S1:253:3	O
Warnings	PRISTIQ.xml:S1:258:8	O
and	PRISTIQ.xml:S1:267:3	O
Precautions	PRISTIQ.xml:S1:271:11	O
(	PRISTIQ.xml:S1:283:1	O
5.1	PRISTIQ.xml:S1:284:3	O
)	PRISTIQ.xml:S1:287:1	O
]	PRISTIQ.xml:S1:290:1	O

Serotonin	PRISTIQ.xml:S1:300:9	B-AdverseReaction
Syndrome	PRISTIQ.xml:S1:310:8	I-AdverseReaction
[	PRISTIQ.xml:S1:319:1	O
see	PRISTIQ.xml:S1:320:3	O
Warnings	PRISTIQ.xml:S1:325:8	O
and	PRISTIQ.xml:S1:334:3	O
Precautions	PRISTIQ.xml:S1:338:11	O
(	PRISTIQ.xml:S1:350:1	O
5.2	PRISTIQ.xml:S1:351:3	O
)	PRISTIQ.xml:S1:354:1	O
]	PRISTIQ.xml:S1:357:1	O

Elevated	PRISTIQ.xml:S1:367:8	B-AdverseReaction
Blood	PRISTIQ.xml:S1:376:5	I-AdverseReaction
Pressure	PRISTIQ.xml:S1:382:8	I-AdverseReaction
[	PRISTIQ.xml:S1:391:1	O
see	PRISTIQ.xml:S1:392:3	O
Warnings	PRISTIQ.xml:S1:397:8	O
and	PRISTIQ.xml:S1:406:3	O
Precautions	PRISTIQ.xml:S1:410:11	O
(	PRISTIQ.xml:S1:422:1	O
5.3	PRISTIQ.xml:S1:423:3	O
)	PRISTIQ.xml:S1:426:1	O
]	PRISTIQ.xml:S1:429:1	O

Abnormal	PRISTIQ.xml:S1:439:8	B-AdverseReaction
Bleeding	PRISTIQ.xml:S1:448:8	I-AdverseReaction
[	PRISTIQ.xml:S1:457:1	O
see	PRISTIQ.xml:S1:458:3	O
Warnings	PRISTIQ.xml:S1:463:8	O
and	PRISTIQ.xml:S1:472:3	O
Precautions	PRISTIQ.xml:S1:476:11	O
(	PRISTIQ.xml:S1:488:1	O
5.4	PRISTIQ.xml:S1:489:3	O
)	PRISTIQ.xml:S1:492:1	O
]	PRISTIQ.xml:S1:495:1	O

Angle	PRISTIQ.xml:S1:505:5	B-AdverseReaction
Closure	PRISTIQ.xml:S1:511:7	I-AdverseReaction
Glaucoma	PRISTIQ.xml:S1:519:8	I-AdverseReaction
[	PRISTIQ.xml:S1:528:1	O
see	PRISTIQ.xml:S1:530:3	O
Warnings	PRISTIQ.xml:S1:535:8	O
and	PRISTIQ.xml:S1:544:3	O
Precautions	PRISTIQ.xml:S1:548:11	O
(	PRISTIQ.xml:S1:560:1	O
5.5	PRISTIQ.xml:S1:561:3	O
)	PRISTIQ.xml:S1:564:1	O
]	PRISTIQ.xml:S1:567:1	O

Activation	PRISTIQ.xml:S1:577:10	O
of	PRISTIQ.xml:S1:588:2	O
Mania	PRISTIQ.xml:S1:591:5	B-AdverseReaction
Hypomania	PRISTIQ.xml:S1:597:9	B-AdverseReaction
[	PRISTIQ.xml:S1:607:1	O
see	PRISTIQ.xml:S1:608:3	O
Warnings	PRISTIQ.xml:S1:613:8	O
and	PRISTIQ.xml:S1:622:3	O
Precautions	PRISTIQ.xml:S1:626:11	O
(	PRISTIQ.xml:S1:638:1	O
5.6	PRISTIQ.xml:S1:639:3	O
)	PRISTIQ.xml:S1:642:1	O
]	PRISTIQ.xml:S1:645:1	O

Discontinuation	PRISTIQ.xml:S1:655:15	B-AdverseReaction
Syndrome	PRISTIQ.xml:S1:671:8	I-AdverseReaction
[	PRISTIQ.xml:S1:680:1	O
see	PRISTIQ.xml:S1:681:3	O
Warnings	PRISTIQ.xml:S1:686:8	O
and	PRISTIQ.xml:S1:695:3	O
Precautions	PRISTIQ.xml:S1:699:11	O
(	PRISTIQ.xml:S1:711:1	O
5.7	PRISTIQ.xml:S1:712:3	O
)	PRISTIQ.xml:S1:715:1	O
]	PRISTIQ.xml:S1:718:1	O

Seizure	PRISTIQ.xml:S1:728:7	B-AdverseReaction
[	PRISTIQ.xml:S1:736:1	O
see	PRISTIQ.xml:S1:737:3	O
Warnings	PRISTIQ.xml:S1:742:8	O
and	PRISTIQ.xml:S1:751:3	O
Precautions	PRISTIQ.xml:S1:755:11	O
(	PRISTIQ.xml:S1:767:1	O
5.8	PRISTIQ.xml:S1:768:3	O
)	PRISTIQ.xml:S1:771:1	O
]	PRISTIQ.xml:S1:774:1	O

Hyponatremia	PRISTIQ.xml:S1:784:12	B-AdverseReaction
[	PRISTIQ.xml:S1:797:1	O
see	PRISTIQ.xml:S1:798:3	O
Warnings	PRISTIQ.xml:S1:803:8	O
and	PRISTIQ.xml:S1:812:3	O
Precautions	PRISTIQ.xml:S1:816:11	O
(	PRISTIQ.xml:S1:828:1	O
5.9	PRISTIQ.xml:S1:829:3	O
)	PRISTIQ.xml:S1:832:1	O
]	PRISTIQ.xml:S1:835:1	O

Interstitial	PRISTIQ.xml:S1:845:12	B-AdverseReaction
Lung	PRISTIQ.xml:S1:858:4	I-AdverseReaction
Disease	PRISTIQ.xml:S1:863:7	I-AdverseReaction
and	PRISTIQ.xml:S1:871:3	O
Eosinophilic	PRISTIQ.xml:S1:875:12	B-AdverseReaction
Pneumonia	PRISTIQ.xml:S1:888:9	I-AdverseReaction
[	PRISTIQ.xml:S1:898:1	O
see	PRISTIQ.xml:S1:899:3	O
Warnings	PRISTIQ.xml:S1:904:8	O
and	PRISTIQ.xml:S1:913:3	O
Precautions	PRISTIQ.xml:S1:917:11	O
(	PRISTIQ.xml:S1:929:1	O
5.10	PRISTIQ.xml:S1:930:4	O
)	PRISTIQ.xml:S1:934:1	O
]	PRISTIQ.xml:S1:937:1	O

EXCERPT	PRISTIQ.xml:S1:947:7	O
:	PRISTIQ.xml:S1:954:1	O
Most	PRISTIQ.xml:S1:958:4	O
common	PRISTIQ.xml:S1:963:6	O
adverse	PRISTIQ.xml:S1:970:7	O
reactions	PRISTIQ.xml:S1:978:9	O
(	PRISTIQ.xml:S1:988:1	O
incidence	PRISTIQ.xml:S1:989:9	O
5%	PRISTIQ.xml:S1:1001:2	O
and	PRISTIQ.xml:S1:1004:3	O
twice	PRISTIQ.xml:S1:1008:5	O
the	PRISTIQ.xml:S1:1014:3	O
rate	PRISTIQ.xml:S1:1018:4	O
of	PRISTIQ.xml:S1:1023:2	O
placebo	PRISTIQ.xml:S1:1026:7	O
in	PRISTIQ.xml:S1:1034:2	O
the	PRISTIQ.xml:S1:1037:3	O
50	PRISTIQ.xml:S1:1041:2	O
or	PRISTIQ.xml:S1:1044:2	O
100	PRISTIQ.xml:S1:1047:3	O
mg	PRISTIQ.xml:S1:1051:2	O
dose	PRISTIQ.xml:S1:1054:4	O
groups	PRISTIQ.xml:S1:1059:6	O
)	PRISTIQ.xml:S1:1065:1	O
were	PRISTIQ.xml:S1:1067:4	O
:	PRISTIQ.xml:S1:1071:1	O
nausea	PRISTIQ.xml:S1:1073:6	B-AdverseReaction
,	PRISTIQ.xml:S1:1079:1	O
dizziness	PRISTIQ.xml:S1:1081:9	B-AdverseReaction
,	PRISTIQ.xml:S1:1090:1	O
insomnia	PRISTIQ.xml:S1:1092:8	B-AdverseReaction
,	PRISTIQ.xml:S1:1100:1	O
hyperhidrosis	PRISTIQ.xml:S1:1102:13	B-AdverseReaction
,	PRISTIQ.xml:S1:1115:1	O
constipation	PRISTIQ.xml:S1:1117:12	B-AdverseReaction
,	PRISTIQ.xml:S1:1129:1	O
somnolence	PRISTIQ.xml:S1:1131:10	B-AdverseReaction
,	PRISTIQ.xml:S1:1141:1	O
decreased	PRISTIQ.xml:S1:1143:9	B-AdverseReaction
appetite	PRISTIQ.xml:S1:1153:8	I-AdverseReaction
,	PRISTIQ.xml:S1:1161:1	O
anxiety	PRISTIQ.xml:S1:1163:7	B-AdverseReaction
,	PRISTIQ.xml:S1:1170:1	O
and	PRISTIQ.xml:S1:1172:3	O
specific	PRISTIQ.xml:S1:1176:8	O
male	PRISTIQ.xml:S1:1185:4	B-AdverseReaction
sexual	PRISTIQ.xml:S1:1190:6	I-AdverseReaction
function	PRISTIQ.xml:S1:1197:8	I-AdverseReaction
disorders	PRISTIQ.xml:S1:1206:9	I-AdverseReaction
(	PRISTIQ.xml:S1:1216:1	O
6.1	PRISTIQ.xml:S1:1219:3	O
)	PRISTIQ.xml:S1:1224:1	O
.	PRISTIQ.xml:S1:1225:1	O

To	PRISTIQ.xml:S1:1233:2	O

report	PRISTIQ.xml:S1:1236:6	O
SUSPECTED	PRISTIQ.xml:S1:1243:9	O
ADVERSE	PRISTIQ.xml:S1:1253:7	O
REACTIONS	PRISTIQ.xml:S1:1261:9	O
,	PRISTIQ.xml:S1:1270:1	O
contact	PRISTIQ.xml:S1:1272:7	O
Wyeth	PRISTIQ.xml:S1:1280:5	O
Pharmaceuticals	PRISTIQ.xml:S1:1286:15	O
Inc	PRISTIQ.xml:S1:1302:3	O
.	PRISTIQ.xml:S1:1305:1	O
,	PRISTIQ.xml:S1:1306:1	O
a	PRISTIQ.xml:S1:1308:1	O
subsidiary	PRISTIQ.xml:S1:1310:10	O
of	PRISTIQ.xml:S1:1321:2	O
Pfizer	PRISTIQ.xml:S1:1324:6	O
Inc	PRISTIQ.xml:S1:1331:3	O
.	PRISTIQ.xml:S1:1334:1	O
,	PRISTIQ.xml:S1:1335:1	O
at	PRISTIQ.xml:S1:1337:2	O
1	PRISTIQ.xml:S1:1340:1	O
-	PRISTIQ.xml:S1:1341:1	O
800	PRISTIQ.xml:S1:1342:3	O
-	PRISTIQ.xml:S1:1345:1	O
438	PRISTIQ.xml:S1:1346:3	O
-	PRISTIQ.xml:S1:1349:1	O
1985	PRISTIQ.xml:S1:1350:4	O
or	PRISTIQ.xml:S1:1355:2	O
FDA	PRISTIQ.xml:S1:1358:3	O
at	PRISTIQ.xml:S1:1362:2	O
1	PRISTIQ.xml:S1:1365:1	O
-	PRISTIQ.xml:S1:1366:1	O
800	PRISTIQ.xml:S1:1367:3	O
-	PRISTIQ.xml:S1:1370:1	O
FDA	PRISTIQ.xml:S1:1371:3	O
-	PRISTIQ.xml:S1:1374:1	O
1088	PRISTIQ.xml:S1:1375:4	O
or	PRISTIQ.xml:S1:1380:2	O
www	PRISTIQ.xml:S1:1383:3	O
.	PRISTIQ.xml:S1:1386:1	O
fda	PRISTIQ.xml:S1:1387:3	O
.	PRISTIQ.xml:S1:1390:1	O
gov	PRISTIQ.xml:S1:1391:3	O
medwatch	PRISTIQ.xml:S1:1395:8	O

6.1	PRISTIQ.xml:S1:1414:3	O

Clinical	PRISTIQ.xml:S1:1418:8	O
Studies	PRISTIQ.xml:S1:1427:7	O
Experience	PRISTIQ.xml:S1:1435:10	O

Because	PRISTIQ.xml:S1:1449:7	O
clinical	PRISTIQ.xml:S1:1457:8	O
trials	PRISTIQ.xml:S1:1466:6	O
are	PRISTIQ.xml:S1:1473:3	O
conducted	PRISTIQ.xml:S1:1477:9	O
under	PRISTIQ.xml:S1:1487:5	O
widely	PRISTIQ.xml:S1:1493:6	O
varying	PRISTIQ.xml:S1:1500:7	O
conditions	PRISTIQ.xml:S1:1508:10	O
,	PRISTIQ.xml:S1:1518:1	O
adverse	PRISTIQ.xml:S1:1520:7	O
reaction	PRISTIQ.xml:S1:1528:8	O
rates	PRISTIQ.xml:S1:1537:5	O
observed	PRISTIQ.xml:S1:1543:8	O
in	PRISTIQ.xml:S1:1552:2	O
the	PRISTIQ.xml:S1:1555:3	O
clinical	PRISTIQ.xml:S1:1559:8	O
trials	PRISTIQ.xml:S1:1568:6	O
of	PRISTIQ.xml:S1:1575:2	O
a	PRISTIQ.xml:S1:1578:1	O
drug	PRISTIQ.xml:S1:1580:4	O
cannot	PRISTIQ.xml:S1:1585:6	O
be	PRISTIQ.xml:S1:1592:2	O
directly	PRISTIQ.xml:S1:1595:8	O
compared	PRISTIQ.xml:S1:1604:8	O
to	PRISTIQ.xml:S1:1613:2	O
rates	PRISTIQ.xml:S1:1616:5	O
in	PRISTIQ.xml:S1:1622:2	O
the	PRISTIQ.xml:S1:1625:3	O
clinical	PRISTIQ.xml:S1:1629:8	O
studies	PRISTIQ.xml:S1:1638:7	O
of	PRISTIQ.xml:S1:1646:2	O
another	PRISTIQ.xml:S1:1649:7	O
drug	PRISTIQ.xml:S1:1657:4	O
and	PRISTIQ.xml:S1:1662:3	O
may	PRISTIQ.xml:S1:1666:3	O
not	PRISTIQ.xml:S1:1670:3	O
reflect	PRISTIQ.xml:S1:1674:7	O
the	PRISTIQ.xml:S1:1682:3	O
rates	PRISTIQ.xml:S1:1686:5	O
observed	PRISTIQ.xml:S1:1692:8	O
in	PRISTIQ.xml:S1:1701:2	O
clinical	PRISTIQ.xml:S1:1704:8	O
practice	PRISTIQ.xml:S1:1713:8	O
.	PRISTIQ.xml:S1:1721:1	O

Patient	PRISTIQ.xml:S1:1731:7	O
exposure	PRISTIQ.xml:S1:1739:8	O

PRISTIQ	PRISTIQ.xml:S1:1754:7	O
was	PRISTIQ.xml:S1:1762:3	O
evaluated	PRISTIQ.xml:S1:1766:9	O
for	PRISTIQ.xml:S1:1776:3	O
safety	PRISTIQ.xml:S1:1780:6	O
in	PRISTIQ.xml:S1:1787:2	O
8	PRISTIQ.xml:S1:1790:1	O
,	PRISTIQ.xml:S1:1791:1	O
394	PRISTIQ.xml:S1:1792:3	O
patients	PRISTIQ.xml:S1:1796:8	O
diagnosed	PRISTIQ.xml:S1:1805:9	O
with	PRISTIQ.xml:S1:1815:4	O
major	PRISTIQ.xml:S1:1820:5	O
depressive	PRISTIQ.xml:S1:1826:10	O
disorder	PRISTIQ.xml:S1:1837:8	O
who	PRISTIQ.xml:S1:1846:3	O
participated	PRISTIQ.xml:S1:1850:12	O
in	PRISTIQ.xml:S1:1863:2	O
multiple	PRISTIQ.xml:S1:1866:8	O
-	PRISTIQ.xml:S1:1874:1	O
dose	PRISTIQ.xml:S1:1875:4	O
pre	PRISTIQ.xml:S1:1880:3	O
-	PRISTIQ.xml:S1:1883:1	O
marketing	PRISTIQ.xml:S1:1884:9	O
studies	PRISTIQ.xml:S1:1894:7	O
,	PRISTIQ.xml:S1:1901:1	O
representing	PRISTIQ.xml:S1:1903:12	O
2	PRISTIQ.xml:S1:1916:1	O
,	PRISTIQ.xml:S1:1917:1	O
784	PRISTIQ.xml:S1:1918:3	O
patient	PRISTIQ.xml:S1:1922:7	O
-	PRISTIQ.xml:S1:1929:1	O
years	PRISTIQ.xml:S1:1930:5	O
of	PRISTIQ.xml:S1:1936:2	O
exposure	PRISTIQ.xml:S1:1939:8	O
.	PRISTIQ.xml:S1:1947:1	O

Of	PRISTIQ.xml:S1:1949:2	O
the	PRISTIQ.xml:S1:1952:3	O
total	PRISTIQ.xml:S1:1956:5	O
8	PRISTIQ.xml:S1:1962:1	O
,	PRISTIQ.xml:S1:1963:1	O
394	PRISTIQ.xml:S1:1964:3	O
patients	PRISTIQ.xml:S1:1968:8	O
exposed	PRISTIQ.xml:S1:1977:7	O
to	PRISTIQ.xml:S1:1985:2	O
at	PRISTIQ.xml:S1:1988:2	O
least	PRISTIQ.xml:S1:1991:5	O
one	PRISTIQ.xml:S1:1997:3	O
dose	PRISTIQ.xml:S1:2001:4	O
of	PRISTIQ.xml:S1:2006:2	O
PRISTIQ	PRISTIQ.xml:S1:2009:7	O
;	PRISTIQ.xml:S1:2016:1	O
2	PRISTIQ.xml:S1:2018:1	O
,	PRISTIQ.xml:S1:2019:1	O
116	PRISTIQ.xml:S1:2020:3	O
were	PRISTIQ.xml:S1:2024:4	O
exposed	PRISTIQ.xml:S1:2029:7	O
to	PRISTIQ.xml:S1:2037:2	O
PRISTIQ	PRISTIQ.xml:S1:2040:7	O
for	PRISTIQ.xml:S1:2048:3	O
6	PRISTIQ.xml:S1:2052:1	O
months	PRISTIQ.xml:S1:2054:6	O
,	PRISTIQ.xml:S1:2060:1	O
representing	PRISTIQ.xml:S1:2062:12	O
1	PRISTIQ.xml:S1:2075:1	O
,	PRISTIQ.xml:S1:2076:1	O
658	PRISTIQ.xml:S1:2077:3	O
patient	PRISTIQ.xml:S1:2081:7	O
-	PRISTIQ.xml:S1:2088:1	O
years	PRISTIQ.xml:S1:2089:5	O
of	PRISTIQ.xml:S1:2095:2	O
exposure	PRISTIQ.xml:S1:2098:8	O
,	PRISTIQ.xml:S1:2106:1	O
and	PRISTIQ.xml:S1:2108:3	O
421	PRISTIQ.xml:S1:2112:3	O
were	PRISTIQ.xml:S1:2116:4	O
exposed	PRISTIQ.xml:S1:2121:7	O
for	PRISTIQ.xml:S1:2129:3	O
one	PRISTIQ.xml:S1:2133:3	O
year	PRISTIQ.xml:S1:2137:4	O
,	PRISTIQ.xml:S1:2141:1	O
representing	PRISTIQ.xml:S1:2143:12	O
416	PRISTIQ.xml:S1:2156:3	O
patient	PRISTIQ.xml:S1:2160:7	O
-	PRISTIQ.xml:S1:2167:1	O
years	PRISTIQ.xml:S1:2168:5	O
of	PRISTIQ.xml:S1:2174:2	O
exposure	PRISTIQ.xml:S1:2177:8	O
.	PRISTIQ.xml:S1:2185:1	O

Adverse	PRISTIQ.xml:S1:2195:7	O
reactions	PRISTIQ.xml:S1:2203:9	O
reported	PRISTIQ.xml:S1:2213:8	O
as	PRISTIQ.xml:S1:2222:2	O
reasons	PRISTIQ.xml:S1:2225:7	O
for	PRISTIQ.xml:S1:2233:3	O
discontinuation	PRISTIQ.xml:S1:2237:15	O
of	PRISTIQ.xml:S1:2253:2	O
treatment	PRISTIQ.xml:S1:2256:9	O

In	PRISTIQ.xml:S1:2272:2	O
the	PRISTIQ.xml:S1:2275:3	O
pre	PRISTIQ.xml:S1:2279:3	O
-	PRISTIQ.xml:S1:2282:1	O
marketing	PRISTIQ.xml:S1:2283:9	O
pooled	PRISTIQ.xml:S1:2293:6	O
8	PRISTIQ.xml:S1:2300:1	O
-	PRISTIQ.xml:S1:2301:1	O
week	PRISTIQ.xml:S1:2302:4	O
placebo	PRISTIQ.xml:S1:2307:7	O
-	PRISTIQ.xml:S1:2314:1	O
controlled	PRISTIQ.xml:S1:2315:10	O
studies	PRISTIQ.xml:S1:2326:7	O
in	PRISTIQ.xml:S1:2334:2	O
patients	PRISTIQ.xml:S1:2337:8	O
with	PRISTIQ.xml:S1:2346:4	O
MDD	PRISTIQ.xml:S1:2351:3	O
,	PRISTIQ.xml:S1:2354:1	O
1	PRISTIQ.xml:S1:2356:1	O
,	PRISTIQ.xml:S1:2357:1	O
834	PRISTIQ.xml:S1:2358:3	O
patients	PRISTIQ.xml:S1:2362:8	O
were	PRISTIQ.xml:S1:2371:4	O
exposed	PRISTIQ.xml:S1:2376:7	O
to	PRISTIQ.xml:S1:2384:2	O
PRISTIQ	PRISTIQ.xml:S1:2387:7	O
(	PRISTIQ.xml:S1:2395:1	O
50	PRISTIQ.xml:S1:2396:2	O
to	PRISTIQ.xml:S1:2399:2	O
400	PRISTIQ.xml:S1:2402:3	O
mg	PRISTIQ.xml:S1:2406:2	O
)	PRISTIQ.xml:S1:2408:1	O
.	PRISTIQ.xml:S1:2409:1	O

Of	PRISTIQ.xml:S1:2411:2	O
the	PRISTIQ.xml:S1:2414:3	O
1	PRISTIQ.xml:S1:2418:1	O
,	PRISTIQ.xml:S1:2419:1	O
834	PRISTIQ.xml:S1:2420:3	O
patients	PRISTIQ.xml:S1:2424:8	O
,	PRISTIQ.xml:S1:2432:1	O
12%	PRISTIQ.xml:S1:2434:3	O
discontinued	PRISTIQ.xml:S1:2438:12	O
treatment	PRISTIQ.xml:S1:2451:9	O
due	PRISTIQ.xml:S1:2461:3	O
to	PRISTIQ.xml:S1:2465:2	O
an	PRISTIQ.xml:S1:2468:2	O
adverse	PRISTIQ.xml:S1:2471:7	O
reaction	PRISTIQ.xml:S1:2479:8	O
,	PRISTIQ.xml:S1:2487:1	O
compared	PRISTIQ.xml:S1:2489:8	O
with	PRISTIQ.xml:S1:2498:4	O
3%	PRISTIQ.xml:S1:2503:2	O
of	PRISTIQ.xml:S1:2506:2	O
the	PRISTIQ.xml:S1:2509:3	O
1	PRISTIQ.xml:S1:2513:1	O
,	PRISTIQ.xml:S1:2514:1	O
116	PRISTIQ.xml:S1:2515:3	O
placebo	PRISTIQ.xml:S1:2519:7	O
-	PRISTIQ.xml:S1:2526:1	O
treated	PRISTIQ.xml:S1:2527:7	O
patients	PRISTIQ.xml:S1:2535:8	O
.	PRISTIQ.xml:S1:2543:1	O

At	PRISTIQ.xml:S1:2545:2	O
the	PRISTIQ.xml:S1:2548:3	O
recommended	PRISTIQ.xml:S1:2552:11	O
dose	PRISTIQ.xml:S1:2564:4	O
of	PRISTIQ.xml:S1:2569:2	O
50	PRISTIQ.xml:S1:2572:2	O
mg	PRISTIQ.xml:S1:2575:2	O
,	PRISTIQ.xml:S1:2577:1	O
the	PRISTIQ.xml:S1:2579:3	O
discontinuation	PRISTIQ.xml:S1:2583:15	O
rate	PRISTIQ.xml:S1:2599:4	O
due	PRISTIQ.xml:S1:2604:3	O
to	PRISTIQ.xml:S1:2608:2	O
an	PRISTIQ.xml:S1:2611:2	O
adverse	PRISTIQ.xml:S1:2614:7	O
reaction	PRISTIQ.xml:S1:2622:8	O
for	PRISTIQ.xml:S1:2631:3	O
PRISTIQ	PRISTIQ.xml:S1:2635:7	O
(	PRISTIQ.xml:S1:2643:1	O
4.1%	PRISTIQ.xml:S1:2644:4	O
)	PRISTIQ.xml:S1:2648:1	O
was	PRISTIQ.xml:S1:2650:3	O
similar	PRISTIQ.xml:S1:2654:7	O
to	PRISTIQ.xml:S1:2662:2	O
the	PRISTIQ.xml:S1:2665:3	O
rate	PRISTIQ.xml:S1:2669:4	O
for	PRISTIQ.xml:S1:2674:3	O
placebo	PRISTIQ.xml:S1:2678:7	O
(	PRISTIQ.xml:S1:2686:1	O
3.8%	PRISTIQ.xml:S1:2687:4	O
)	PRISTIQ.xml:S1:2691:1	O
.	PRISTIQ.xml:S1:2692:1	O

For	PRISTIQ.xml:S1:2694:3	O
the	PRISTIQ.xml:S1:2698:3	O
100	PRISTIQ.xml:S1:2702:3	O
mg	PRISTIQ.xml:S1:2706:2	O
dose	PRISTIQ.xml:S1:2709:4	O
of	PRISTIQ.xml:S1:2714:2	O
PRISTIQ	PRISTIQ.xml:S1:2717:7	O
the	PRISTIQ.xml:S1:2725:3	O
discontinuation	PRISTIQ.xml:S1:2729:15	O
rate	PRISTIQ.xml:S1:2745:4	O
due	PRISTIQ.xml:S1:2750:3	O
to	PRISTIQ.xml:S1:2754:2	O
an	PRISTIQ.xml:S1:2757:2	O
adverse	PRISTIQ.xml:S1:2760:7	O
reaction	PRISTIQ.xml:S1:2768:8	O
was	PRISTIQ.xml:S1:2777:3	O
8.7%	PRISTIQ.xml:S1:2781:4	O
.	PRISTIQ.xml:S1:2785:1	O

The	PRISTIQ.xml:S1:2791:3	O
most	PRISTIQ.xml:S1:2795:4	O
common	PRISTIQ.xml:S1:2800:6	O
adverse	PRISTIQ.xml:S1:2807:7	O
reactions	PRISTIQ.xml:S1:2815:9	O
leading	PRISTIQ.xml:S1:2825:7	O
to	PRISTIQ.xml:S1:2833:2	O
discontinuation	PRISTIQ.xml:S1:2836:15	O
in	PRISTIQ.xml:S1:2852:2	O
at	PRISTIQ.xml:S1:2855:2	O
least	PRISTIQ.xml:S1:2858:5	O
2%	PRISTIQ.xml:S1:2864:2	O
and	PRISTIQ.xml:S1:2867:3	O
at	PRISTIQ.xml:S1:2871:2	O
a	PRISTIQ.xml:S1:2874:1	O
rate	PRISTIQ.xml:S1:2876:4	O
greater	PRISTIQ.xml:S1:2881:7	O
than	PRISTIQ.xml:S1:2889:4	O
placebo	PRISTIQ.xml:S1:2894:7	O
of	PRISTIQ.xml:S1:2902:2	O
the	PRISTIQ.xml:S1:2905:3	O
PRISTIQ	PRISTIQ.xml:S1:2909:7	O
treated	PRISTIQ.xml:S1:2917:7	O
patients	PRISTIQ.xml:S1:2925:8	O
in	PRISTIQ.xml:S1:2934:2	O
the	PRISTIQ.xml:S1:2937:3	O
short	PRISTIQ.xml:S1:2941:5	O
-	PRISTIQ.xml:S1:2946:1	O
term	PRISTIQ.xml:S1:2947:4	O
studies	PRISTIQ.xml:S1:2952:7	O
,	PRISTIQ.xml:S1:2959:1	O
up	PRISTIQ.xml:S1:2961:2	O
to	PRISTIQ.xml:S1:2964:2	O
8	PRISTIQ.xml:S1:2967:1	O
weeks	PRISTIQ.xml:S1:2969:5	O
,	PRISTIQ.xml:S1:2974:1	O
were	PRISTIQ.xml:S1:2976:4	O
:	PRISTIQ.xml:S1:2980:1	O
nausea	PRISTIQ.xml:S1:2982:6	B-AdverseReaction
(	PRISTIQ.xml:S1:2989:1	O
4%	PRISTIQ.xml:S1:2990:2	O
)	PRISTIQ.xml:S1:2992:1	O
;	PRISTIQ.xml:S1:2993:1	O
dizziness	PRISTIQ.xml:S1:2995:9	B-AdverseReaction
,	PRISTIQ.xml:S1:3004:1	O
headache	PRISTIQ.xml:S1:3006:8	B-AdverseReaction
and	PRISTIQ.xml:S1:3015:3	O
vomiting	PRISTIQ.xml:S1:3019:8	B-AdverseReaction
(	PRISTIQ.xml:S1:3028:1	O
2%	PRISTIQ.xml:S1:3029:2	O
each	PRISTIQ.xml:S1:3032:4	O
)	PRISTIQ.xml:S1:3036:1	O
.	PRISTIQ.xml:S1:3037:1	O

In	PRISTIQ.xml:S1:3039:2	O
a	PRISTIQ.xml:S1:3042:1	O
longer	PRISTIQ.xml:S1:3044:6	O
-	PRISTIQ.xml:S1:3050:1	O
term	PRISTIQ.xml:S1:3051:4	O
study	PRISTIQ.xml:S1:3056:5	O
,	PRISTIQ.xml:S1:3061:1	O
up	PRISTIQ.xml:S1:3063:2	O
to	PRISTIQ.xml:S1:3066:2	O
9	PRISTIQ.xml:S1:3069:1	O
months	PRISTIQ.xml:S1:3071:6	O
,	PRISTIQ.xml:S1:3077:1	O
the	PRISTIQ.xml:S1:3079:3	O
most	PRISTIQ.xml:S1:3083:4	O
common	PRISTIQ.xml:S1:3088:6	O
was	PRISTIQ.xml:S1:3095:3	O
vomiting	PRISTIQ.xml:S1:3099:8	B-AdverseReaction
(	PRISTIQ.xml:S1:3108:1	O
2%	PRISTIQ.xml:S1:3109:2	O
)	PRISTIQ.xml:S1:3111:1	O
.	PRISTIQ.xml:S1:3112:1	O

Common	PRISTIQ.xml:S1:3122:6	O
adverse	PRISTIQ.xml:S1:3129:7	O
reactions	PRISTIQ.xml:S1:3137:9	O
in	PRISTIQ.xml:S1:3147:2	O
placebo	PRISTIQ.xml:S1:3150:7	O
-	PRISTIQ.xml:S1:3157:1	O
controlled	PRISTIQ.xml:S1:3158:10	O
MDD	PRISTIQ.xml:S1:3169:3	O
studies	PRISTIQ.xml:S1:3173:7	O

The	PRISTIQ.xml:S1:3187:3	O
most	PRISTIQ.xml:S1:3191:4	O
commonly	PRISTIQ.xml:S1:3196:8	O
observed	PRISTIQ.xml:S1:3205:8	O
adverse	PRISTIQ.xml:S1:3214:7	O
reactions	PRISTIQ.xml:S1:3222:9	O
in	PRISTIQ.xml:S1:3232:2	O
PRISTIQ	PRISTIQ.xml:S1:3235:7	O
treated	PRISTIQ.xml:S1:3243:7	O
MDD	PRISTIQ.xml:S1:3251:3	O
patients	PRISTIQ.xml:S1:3255:8	O
in	PRISTIQ.xml:S1:3264:2	O
pre	PRISTIQ.xml:S1:3267:3	O
-	PRISTIQ.xml:S1:3270:1	O
marketing	PRISTIQ.xml:S1:3271:9	O
pooled	PRISTIQ.xml:S1:3281:6	O
8	PRISTIQ.xml:S1:3288:1	O
-	PRISTIQ.xml:S1:3289:1	O
week	PRISTIQ.xml:S1:3290:4	O
,	PRISTIQ.xml:S1:3294:1	O
placebo	PRISTIQ.xml:S1:3296:7	O
-	PRISTIQ.xml:S1:3303:1	O
controlled	PRISTIQ.xml:S1:3304:10	O
,	PRISTIQ.xml:S1:3314:1	O
fixed	PRISTIQ.xml:S1:3316:5	O
-	PRISTIQ.xml:S1:3321:1	O
dose	PRISTIQ.xml:S1:3322:4	O
studies	PRISTIQ.xml:S1:3327:7	O
(	PRISTIQ.xml:S1:3335:1	O
incidence	PRISTIQ.xml:S1:3336:9	O
5%	PRISTIQ.xml:S1:3349:2	O
and	PRISTIQ.xml:S1:3352:3	O
at	PRISTIQ.xml:S1:3356:2	O
least	PRISTIQ.xml:S1:3359:5	O
twice	PRISTIQ.xml:S1:3365:5	O
the	PRISTIQ.xml:S1:3371:3	O
rate	PRISTIQ.xml:S1:3375:4	O
of	PRISTIQ.xml:S1:3380:2	O
placebo	PRISTIQ.xml:S1:3383:7	O
in	PRISTIQ.xml:S1:3391:2	O
the	PRISTIQ.xml:S1:3394:3	O
50	PRISTIQ.xml:S1:3398:2	O
or	PRISTIQ.xml:S1:3401:2	O
100	PRISTIQ.xml:S1:3404:3	O
mg	PRISTIQ.xml:S1:3408:2	O
dose	PRISTIQ.xml:S1:3411:4	O
groups	PRISTIQ.xml:S1:3416:6	O
)	PRISTIQ.xml:S1:3422:1	O
were	PRISTIQ.xml:S1:3424:4	O
:	PRISTIQ.xml:S1:3428:1	O
nausea	PRISTIQ.xml:S1:3430:6	B-AdverseReaction
,	PRISTIQ.xml:S1:3436:1	O
dizziness	PRISTIQ.xml:S1:3438:9	B-AdverseReaction
,	PRISTIQ.xml:S1:3447:1	O
insomnia	PRISTIQ.xml:S1:3449:8	B-AdverseReaction
,	PRISTIQ.xml:S1:3457:1	O
hyperhidrosis	PRISTIQ.xml:S1:3459:13	B-AdverseReaction
,	PRISTIQ.xml:S1:3472:1	O
constipation	PRISTIQ.xml:S1:3474:12	B-AdverseReaction
,	PRISTIQ.xml:S1:3486:1	O
somnolence	PRISTIQ.xml:S1:3488:10	B-AdverseReaction
,	PRISTIQ.xml:S1:3498:1	O
decreased	PRISTIQ.xml:S1:3500:9	B-AdverseReaction
appetite	PRISTIQ.xml:S1:3510:8	I-AdverseReaction
,	PRISTIQ.xml:S1:3518:1	O
anxiety	PRISTIQ.xml:S1:3520:7	B-AdverseReaction
,	PRISTIQ.xml:S1:3527:1	O
and	PRISTIQ.xml:S1:3529:3	O
specific	PRISTIQ.xml:S1:3533:8	O
male	PRISTIQ.xml:S1:3542:4	B-AdverseReaction
sexual	PRISTIQ.xml:S1:3547:6	I-AdverseReaction
function	PRISTIQ.xml:S1:3554:8	I-AdverseReaction
disorders	PRISTIQ.xml:S1:3563:9	I-AdverseReaction
.	PRISTIQ.xml:S1:3572:1	O

Table	PRISTIQ.xml:S1:3578:5	O
2	PRISTIQ.xml:S1:3584:1	O
shows	PRISTIQ.xml:S1:3586:5	O
the	PRISTIQ.xml:S1:3592:3	O
incidence	PRISTIQ.xml:S1:3596:9	O
of	PRISTIQ.xml:S1:3606:2	O
common	PRISTIQ.xml:S1:3609:6	O
adverse	PRISTIQ.xml:S1:3616:7	O
reactions	PRISTIQ.xml:S1:3624:9	O
that	PRISTIQ.xml:S1:3634:4	O
occurred	PRISTIQ.xml:S1:3639:8	O
in	PRISTIQ.xml:S1:3648:2	O
2%	PRISTIQ.xml:S1:3654:2	O
of	PRISTIQ.xml:S1:3657:2	O
PRISTIQ	PRISTIQ.xml:S1:3660:7	O
treated	PRISTIQ.xml:S1:3668:7	O
MDD	PRISTIQ.xml:S1:3676:3	O
patients	PRISTIQ.xml:S1:3680:8	O
and	PRISTIQ.xml:S1:3689:3	O
twice	PRISTIQ.xml:S1:3693:5	O
the	PRISTIQ.xml:S1:3699:3	O
rate	PRISTIQ.xml:S1:3703:4	O
of	PRISTIQ.xml:S1:3708:2	O
placebo	PRISTIQ.xml:S1:3711:7	O
at	PRISTIQ.xml:S1:3719:2	O
any	PRISTIQ.xml:S1:3722:3	O
dose	PRISTIQ.xml:S1:3726:4	O
in	PRISTIQ.xml:S1:3731:2	O
the	PRISTIQ.xml:S1:3734:3	O
pre	PRISTIQ.xml:S1:3738:3	O
-	PRISTIQ.xml:S1:3741:1	O
marketing	PRISTIQ.xml:S1:3742:9	O
pooled	PRISTIQ.xml:S1:3752:6	O
8	PRISTIQ.xml:S1:3759:1	O
-	PRISTIQ.xml:S1:3760:1	O
week	PRISTIQ.xml:S1:3761:4	O
,	PRISTIQ.xml:S1:3765:1	O
placebo	PRISTIQ.xml:S1:3767:7	O
-	PRISTIQ.xml:S1:3774:1	O
controlled	PRISTIQ.xml:S1:3775:10	O
,	PRISTIQ.xml:S1:3785:1	O
fixed	PRISTIQ.xml:S1:3787:5	O
dose	PRISTIQ.xml:S1:3793:4	O
clinical	PRISTIQ.xml:S1:3798:8	O
studies	PRISTIQ.xml:S1:3807:7	O

Table	PRISTIQ.xml:S1:3819:5	O
2	PRISTIQ.xml:S1:3825:1	O
:	PRISTIQ.xml:S1:3826:1	O
Common	PRISTIQ.xml:S1:3828:6	O
Adverse	PRISTIQ.xml:S1:3835:7	O
Reactions	PRISTIQ.xml:S1:3843:9	O
(	PRISTIQ.xml:S1:3853:1	O
2%	PRISTIQ.xml:S1:3857:2	O
in	PRISTIQ.xml:S1:3860:2	O
any	PRISTIQ.xml:S1:3863:3	O
Fixed	PRISTIQ.xml:S1:3867:5	O
-	PRISTIQ.xml:S1:3872:1	O
Dose	PRISTIQ.xml:S1:3873:4	O
Group	PRISTIQ.xml:S1:3878:5	O
and	PRISTIQ.xml:S1:3884:3	O
Twice	PRISTIQ.xml:S1:3888:5	O
the	PRISTIQ.xml:S1:3894:3	O
Rate	PRISTIQ.xml:S1:3898:4	O
of	PRISTIQ.xml:S1:3903:2	O
Placebo	PRISTIQ.xml:S1:3906:7	O
)	PRISTIQ.xml:S1:3913:1	O
in	PRISTIQ.xml:S1:3915:2	O
Pre	PRISTIQ.xml:S1:3918:3	O
-	PRISTIQ.xml:S1:3921:1	O
marketing	PRISTIQ.xml:S1:3922:9	O
Pooled	PRISTIQ.xml:S1:3932:6	O
MDD	PRISTIQ.xml:S1:3939:3	O
8	PRISTIQ.xml:S1:3943:1	O
-	PRISTIQ.xml:S1:3944:1	O
Week	PRISTIQ.xml:S1:3945:4	O
Placebo	PRISTIQ.xml:S1:3950:7	O
-	PRISTIQ.xml:S1:3957:1	O
Controlled	PRISTIQ.xml:S1:3958:10	O
Studies	PRISTIQ.xml:S1:3969:7	O

Percentage	PRISTIQ.xml:S1:4008:10	O
of	PRISTIQ.xml:S1:4019:2	O
Patients	PRISTIQ.xml:S1:4022:8	O
Reporting	PRISTIQ.xml:S1:4031:9	O
Reaction	PRISTIQ.xml:S1:4041:8	O

PRISTIQ	PRISTIQ.xml:S1:4102:7	O

System	PRISTIQ.xml:S1:4122:6	O
Organ	PRISTIQ.xml:S1:4129:5	O
Class	PRISTIQ.xml:S1:4135:5	O
Preferred	PRISTIQ.xml:S1:4144:9	O
Term	PRISTIQ.xml:S1:4154:4	O
Placebo	PRISTIQ.xml:S1:4164:7	O
(	PRISTIQ.xml:S1:4175:1	O
n	PRISTIQ.xml:S1:4176:1	O
636	PRISTIQ.xml:S1:4178:3	O
)	PRISTIQ.xml:S1:4181:1	O
50	PRISTIQ.xml:S1:4188:2	O
mg	PRISTIQ.xml:S1:4191:2	O
(	PRISTIQ.xml:S1:4197:1	O
n	PRISTIQ.xml:S1:4198:1	O
317	PRISTIQ.xml:S1:4200:3	O
)	PRISTIQ.xml:S1:4203:1	O
100	PRISTIQ.xml:S1:4210:3	O
mg	PRISTIQ.xml:S1:4214:2	O
(	PRISTIQ.xml:S1:4220:1	O
n	PRISTIQ.xml:S1:4221:1	O
424	PRISTIQ.xml:S1:4223:3	O
)	PRISTIQ.xml:S1:4226:1	O
200	PRISTIQ.xml:S1:4233:3	O
mg	PRISTIQ.xml:S1:4237:2	O
(	PRISTIQ.xml:S1:4243:1	O
n	PRISTIQ.xml:S1:4244:1	O
307	PRISTIQ.xml:S1:4246:3	O
)	PRISTIQ.xml:S1:4249:1	O
400	PRISTIQ.xml:S1:4256:3	O
mg	PRISTIQ.xml:S1:4260:2	O
(	PRISTIQ.xml:S1:4266:1	O
n	PRISTIQ.xml:S1:4267:1	O
317	PRISTIQ.xml:S1:4269:3	O
)	PRISTIQ.xml:S1:4272:1	O

Cardiac	PRISTIQ.xml:S1:4284:7	O

disorders	PRISTIQ.xml:S1:4292:9	O

Blood	PRISTIQ.xml:S1:4316:5	B-AdverseReaction
pressure	PRISTIQ.xml:S1:4322:8	I-AdverseReaction
increased	PRISTIQ.xml:S1:4331:9	I-AdverseReaction
1	PRISTIQ.xml:S1:4344:1	O
1	PRISTIQ.xml:S1:4361:1	O
1	PRISTIQ.xml:S1:4378:1	O
2	PRISTIQ.xml:S1:4395:1	O
2	PRISTIQ.xml:S1:4412:1	O

Gastrointestinal	PRISTIQ.xml:S1:4432:16	O
disorders	PRISTIQ.xml:S1:4449:9	O

Nausea	PRISTIQ.xml:S1:4467:6	B-AdverseReaction
10	PRISTIQ.xml:S1:4492:2	O
22	PRISTIQ.xml:S1:4509:2	O
26	PRISTIQ.xml:S1:4526:2	O
36	PRISTIQ.xml:S1:4543:2	O
41	PRISTIQ.xml:S1:4560:2	O

Dry	PRISTIQ.xml:S1:4582:3	B-AdverseReaction
mouth	PRISTIQ.xml:S1:4586:5	I-AdverseReaction
9	PRISTIQ.xml:S1:4607:1	O
11	PRISTIQ.xml:S1:4624:2	O
17	PRISTIQ.xml:S1:4641:2	O
21	PRISTIQ.xml:S1:4658:2	O
25	PRISTIQ.xml:S1:4675:2	O

Constipation	PRISTIQ.xml:S1:4697:12	B-AdverseReaction
4	PRISTIQ.xml:S1:4722:1	O
9	PRISTIQ.xml:S1:4739:1	O
9	PRISTIQ.xml:S1:4756:1	O
10	PRISTIQ.xml:S1:4773:2	O
14	PRISTIQ.xml:S1:4790:2	O

Vomiting	PRISTIQ.xml:S1:4812:8	B-AdverseReaction
3	PRISTIQ.xml:S1:4837:1	O
3	PRISTIQ.xml:S1:4854:1	O
4	PRISTIQ.xml:S1:4871:1	O
6	PRISTIQ.xml:S1:4888:1	O
9	PRISTIQ.xml:S1:4905:1	O

General	PRISTIQ.xml:S1:4925:7	O
disorders	PRISTIQ.xml:S1:4933:9	O
and	PRISTIQ.xml:S1:4943:3	O
administration	PRISTIQ.xml:S1:4947:14	O
site	PRISTIQ.xml:S1:4962:4	O
conditions	PRISTIQ.xml:S1:4967:10	O

Fatigue	PRISTIQ.xml:S1:4986:7	B-AdverseReaction
4	PRISTIQ.xml:S1:5011:1	O
7	PRISTIQ.xml:S1:5028:1	O
7	PRISTIQ.xml:S1:5045:1	O
10	PRISTIQ.xml:S1:5062:2	O
11	PRISTIQ.xml:S1:5079:2	O

Chills	PRISTIQ.xml:S1:5101:6	B-AdverseReaction
1	PRISTIQ.xml:S1:5126:1	O
1	PRISTIQ.xml:S1:5143:1	O
1	PRISTIQ.xml:S1:5161:1	O
3	PRISTIQ.xml:S1:5177:1	O
4	PRISTIQ.xml:S1:5194:1	O

Feeling	PRISTIQ.xml:S1:5216:7	B-AdverseReaction
jittery	PRISTIQ.xml:S1:5224:7	I-AdverseReaction
1	PRISTIQ.xml:S1:5241:1	O
1	PRISTIQ.xml:S1:5258:1	O
2	PRISTIQ.xml:S1:5275:1	O
3	PRISTIQ.xml:S1:5292:1	O
3	PRISTIQ.xml:S1:5309:1	O

Metabolism	PRISTIQ.xml:S1:5329:10	O
and	PRISTIQ.xml:S1:5340:3	O
nutrition	PRISTIQ.xml:S1:5344:9	O
disorders	PRISTIQ.xml:S1:5354:9	O

Decreased	PRISTIQ.xml:S1:5372:9	B-AdverseReaction
appetite	PRISTIQ.xml:S1:5382:8	I-AdverseReaction
2	PRISTIQ.xml:S1:5397:1	O
5	PRISTIQ.xml:S1:5414:1	O
8	PRISTIQ.xml:S1:5431:1	O
10	PRISTIQ.xml:S1:5448:2	O
10	PRISTIQ.xml:S1:5465:2	O

Nervous	PRISTIQ.xml:S1:5485:7	O
system	PRISTIQ.xml:S1:5493:6	O
disorders	PRISTIQ.xml:S1:5500:9	O

Dizziness	PRISTIQ.xml:S1:5518:9	B-AdverseReaction
5	PRISTIQ.xml:S1:5543:1	O
13	PRISTIQ.xml:S1:5560:2	O
10	PRISTIQ.xml:S1:5577:2	O
15	PRISTIQ.xml:S1:5594:2	O
16	PRISTIQ.xml:S1:5611:2	O

Somnolence	PRISTIQ.xml:S1:5633:10	B-AdverseReaction
4	PRISTIQ.xml:S1:5658:1	O
4	PRISTIQ.xml:S1:5675:1	O
9	PRISTIQ.xml:S1:5692:1	O
12	PRISTIQ.xml:S1:5709:2	O
12	PRISTIQ.xml:S1:5726:2	O

Tremor	PRISTIQ.xml:S1:5748:6	B-AdverseReaction
2	PRISTIQ.xml:S1:5773:1	O
2	PRISTIQ.xml:S1:5790:1	O
3	PRISTIQ.xml:S1:5807:1	O
9	PRISTIQ.xml:S1:5824:1	O
9	PRISTIQ.xml:S1:5841:1	O

Disturbance	PRISTIQ.xml:S1:5863:11	B-AdverseReaction
in	PRISTIQ.xml:S1:5875:2	I-AdverseReaction
attention	PRISTIQ.xml:S1:5878:9	I-AdverseReaction
1	PRISTIQ.xml:S1:5892:1	O
1	PRISTIQ.xml:S1:5909:1	O
1	PRISTIQ.xml:S1:5925:1	O
2	PRISTIQ.xml:S1:5942:1	O
1	PRISTIQ.xml:S1:5959:1	O

Psychiatric	PRISTIQ.xml:S1:5979:11	O
disorders	PRISTIQ.xml:S1:5991:9	O

Insomnia	PRISTIQ.xml:S1:6011:8	B-AdverseReaction
6	PRISTIQ.xml:S1:6036:1	O
9	PRISTIQ.xml:S1:6053:1	O
12	PRISTIQ.xml:S1:6070:2	O
14	PRISTIQ.xml:S1:6087:2	O
15	PRISTIQ.xml:S1:6104:2	O

Anxiety	PRISTIQ.xml:S1:6126:7	B-AdverseReaction
2	PRISTIQ.xml:S1:6151:1	O
3	PRISTIQ.xml:S1:6168:1	O
5	PRISTIQ.xml:S1:6185:1	O
4	PRISTIQ.xml:S1:6202:1	O
4	PRISTIQ.xml:S1:6219:1	O

Nervousness	PRISTIQ.xml:S1:6241:11	B-AdverseReaction
1	PRISTIQ.xml:S1:6266:1	O
1	PRISTIQ.xml:S1:6284:1	O
1	PRISTIQ.xml:S1:6300:1	O
2	PRISTIQ.xml:S1:6317:1	O
2	PRISTIQ.xml:S1:6334:1	O

Abnormal	PRISTIQ.xml:S1:6356:8	B-AdverseReaction
dreams	PRISTIQ.xml:S1:6365:6	I-AdverseReaction
1	PRISTIQ.xml:S1:6381:1	O
2	PRISTIQ.xml:S1:6398:1	O
3	PRISTIQ.xml:S1:6415:1	O
2	PRISTIQ.xml:S1:6432:1	O
4	PRISTIQ.xml:S1:6449:1	O

Renal	PRISTIQ.xml:S1:6469:5	O
and	PRISTIQ.xml:S1:6475:3	O
urinary	PRISTIQ.xml:S1:6479:7	O
disorders	PRISTIQ.xml:S1:6487:9	O

Urinary	PRISTIQ.xml:S1:6505:7	B-AdverseReaction
hesitation	PRISTIQ.xml:S1:6513:10	I-AdverseReaction
0	PRISTIQ.xml:S1:6530:1	O
1	PRISTIQ.xml:S1:6548:1	O
1	PRISTIQ.xml:S1:6564:1	O
2	PRISTIQ.xml:S1:6581:1	O
2	PRISTIQ.xml:S1:6598:1	O

Respiratory	PRISTIQ.xml:S1:6618:11	O
,	PRISTIQ.xml:S1:6629:1	O
thoracic	PRISTIQ.xml:S1:6631:8	O
and	PRISTIQ.xml:S1:6640:3	O
mediastinal	PRISTIQ.xml:S1:6644:11	O
disorders	PRISTIQ.xml:S1:6656:9	O

Yawning	PRISTIQ.xml:S1:6674:7	B-AdverseReaction
1	PRISTIQ.xml:S1:6700:1	O
1	PRISTIQ.xml:S1:6716:1	O
1	PRISTIQ.xml:S1:6733:1	O
4	PRISTIQ.xml:S1:6750:1	O
3	PRISTIQ.xml:S1:6767:1	O

Skin	PRISTIQ.xml:S1:6787:4	O
and	PRISTIQ.xml:S1:6792:3	O
subcutaneous	PRISTIQ.xml:S1:6796:12	O
tissue	PRISTIQ.xml:S1:6809:6	O
disorders	PRISTIQ.xml:S1:6816:9	O

Hyperhidrosis	PRISTIQ.xml:S1:6834:13	B-AdverseReaction
4	PRISTIQ.xml:S1:6859:1	O
10	PRISTIQ.xml:S1:6876:2	O
11	PRISTIQ.xml:S1:6893:2	O
18	PRISTIQ.xml:S1:6910:2	O
21	PRISTIQ.xml:S1:6927:2	O

Special	PRISTIQ.xml:S1:6947:7	O
Senses	PRISTIQ.xml:S1:6955:6	O

Vision	PRISTIQ.xml:S1:6979:6	B-AdverseReaction
blurred	PRISTIQ.xml:S1:6986:7	I-AdverseReaction
1	PRISTIQ.xml:S1:7004:1	O
3	PRISTIQ.xml:S1:7021:1	O
4	PRISTIQ.xml:S1:7038:1	O
4	PRISTIQ.xml:S1:7055:1	O
4	PRISTIQ.xml:S1:7072:1	O

Mydriasis	PRISTIQ.xml:S1:7094:9	B-AdverseReaction
1	PRISTIQ.xml:S1:7120:1	O
2	PRISTIQ.xml:S1:7136:1	O
2	PRISTIQ.xml:S1:7153:1	O
6	PRISTIQ.xml:S1:7170:1	O
6	PRISTIQ.xml:S1:7187:1	O

Vertigo	PRISTIQ.xml:S1:7209:7	B-AdverseReaction
1	PRISTIQ.xml:S1:7234:1	O
2	PRISTIQ.xml:S1:7251:1	O
1	PRISTIQ.xml:S1:7268:1	O
5	PRISTIQ.xml:S1:7285:1	O
3	PRISTIQ.xml:S1:7302:1	O

Tinnitus	PRISTIQ.xml:S1:7324:8	B-AdverseReaction
1	PRISTIQ.xml:S1:7349:1	O
2	PRISTIQ.xml:S1:7366:1	O
1	PRISTIQ.xml:S1:7383:1	O
1	PRISTIQ.xml:S1:7400:1	O
2	PRISTIQ.xml:S1:7417:1	O

Dysgeusia	PRISTIQ.xml:S1:7439:9	B-AdverseReaction
1	PRISTIQ.xml:S1:7464:1	O
1	PRISTIQ.xml:S1:7481:1	O
1	PRISTIQ.xml:S1:7498:1	O
1	PRISTIQ.xml:S1:7515:1	O
2	PRISTIQ.xml:S1:7532:1	O

Vascular	PRISTIQ.xml:S1:7552:8	O
disorders	PRISTIQ.xml:S1:7561:9	O

Hot	PRISTIQ.xml:S1:7584:3	B-AdverseReaction
flush	PRISTIQ.xml:S1:7588:5	I-AdverseReaction
1	PRISTIQ.xml:S1:7610:1	O
1	PRISTIQ.xml:S1:7626:1	O
1	PRISTIQ.xml:S1:7643:1	O
2	PRISTIQ.xml:S1:7660:1	O
2	PRISTIQ.xml:S1:7677:1	O

Sexual	PRISTIQ.xml:S1:7711:6	O
function	PRISTIQ.xml:S1:7718:8	O
adverse	PRISTIQ.xml:S1:7727:7	O
reactions	PRISTIQ.xml:S1:7735:9	O

Table	PRISTIQ.xml:S1:7751:5	O

3	PRISTIQ.xml:S1:7757:1	O
shows	PRISTIQ.xml:S1:7759:5	O
the	PRISTIQ.xml:S1:7765:3	O
incidence	PRISTIQ.xml:S1:7769:9	O
of	PRISTIQ.xml:S1:7779:2	O
sexual	PRISTIQ.xml:S1:7782:6	B-AdverseReaction
function	PRISTIQ.xml:S1:7789:8	I-AdverseReaction
adverse	PRISTIQ.xml:S1:7798:7	I-AdverseReaction
reactions	PRISTIQ.xml:S1:7806:9	I-AdverseReaction
that	PRISTIQ.xml:S1:7816:4	O
occurred	PRISTIQ.xml:S1:7821:8	O
in	PRISTIQ.xml:S1:7830:2	O
2%	PRISTIQ.xml:S1:7836:2	O
of	PRISTIQ.xml:S1:7839:2	O
PRISTIQ	PRISTIQ.xml:S1:7842:7	O
treated	PRISTIQ.xml:S1:7850:7	O
MDD	PRISTIQ.xml:S1:7858:3	O
patients	PRISTIQ.xml:S1:7862:8	O
in	PRISTIQ.xml:S1:7871:2	O
any	PRISTIQ.xml:S1:7874:3	O
fixed	PRISTIQ.xml:S1:7878:5	O
-	PRISTIQ.xml:S1:7883:1	O
dose	PRISTIQ.xml:S1:7884:4	O
group	PRISTIQ.xml:S1:7889:5	O
(	PRISTIQ.xml:S1:7895:1	O
pre	PRISTIQ.xml:S1:7896:3	O
-	PRISTIQ.xml:S1:7899:1	O
marketing	PRISTIQ.xml:S1:7900:9	O
pooled	PRISTIQ.xml:S1:7910:6	O
8	PRISTIQ.xml:S1:7917:1	O
-	PRISTIQ.xml:S1:7918:1	O
week	PRISTIQ.xml:S1:7919:4	O
,	PRISTIQ.xml:S1:7923:1	O
placebo	PRISTIQ.xml:S1:7925:7	O
-	PRISTIQ.xml:S1:7932:1	O
controlled	PRISTIQ.xml:S1:7933:10	O
,	PRISTIQ.xml:S1:7943:1	O
fixed	PRISTIQ.xml:S1:7945:5	O
-	PRISTIQ.xml:S1:7951:1	O
dose	PRISTIQ.xml:S1:7952:4	O
,	PRISTIQ.xml:S1:7956:1	O
clinical	PRISTIQ.xml:S1:7958:8	O
studies	PRISTIQ.xml:S1:7967:7	O
)	PRISTIQ.xml:S1:7974:1	O
.	PRISTIQ.xml:S1:7975:1	O

Table	PRISTIQ.xml:S1:7981:5	O
3	PRISTIQ.xml:S1:7987:1	O
:	PRISTIQ.xml:S1:7988:1	O
Sexual	PRISTIQ.xml:S1:7990:6	B-AdverseReaction
Function	PRISTIQ.xml:S1:7997:8	I-AdverseReaction
Adverse	PRISTIQ.xml:S1:8006:7	I-AdverseReaction
Reactions	PRISTIQ.xml:S1:8014:9	I-AdverseReaction
(	PRISTIQ.xml:S1:8024:1	O
2%	PRISTIQ.xml:S1:8028:2	O
in	PRISTIQ.xml:S1:8031:2	O
Men	PRISTIQ.xml:S1:8034:3	O
or	PRISTIQ.xml:S1:8038:2	O
Women	PRISTIQ.xml:S1:8041:5	O
in	PRISTIQ.xml:S1:8047:2	O
any	PRISTIQ.xml:S1:8050:3	O
PRISTIQ	PRISTIQ.xml:S1:8054:7	O
Group	PRISTIQ.xml:S1:8062:5	O
)	PRISTIQ.xml:S1:8067:1	O
During	PRISTIQ.xml:S1:8069:6	O
the	PRISTIQ.xml:S1:8076:3	O
On	PRISTIQ.xml:S1:8080:2	O
-	PRISTIQ.xml:S1:8082:1	O
Therapy	PRISTIQ.xml:S1:8083:7	O
Period	PRISTIQ.xml:S1:8091:6	O

PRISTIQ	PRISTIQ.xml:S1:8141:7	O

Placebo	PRISTIQ.xml:S1:8184:7	O
(	PRISTIQ.xml:S1:8191:1	O
n	PRISTIQ.xml:S1:8192:1	O
239	PRISTIQ.xml:S1:8194:3	O
)	PRISTIQ.xml:S1:8197:1	O
50	PRISTIQ.xml:S1:8202:2	O
mg	PRISTIQ.xml:S1:8205:2	O
(	PRISTIQ.xml:S1:8207:1	O
n	PRISTIQ.xml:S1:8208:1	O
108	PRISTIQ.xml:S1:8210:3	O
)	PRISTIQ.xml:S1:8213:1	O
100	PRISTIQ.xml:S1:8220:3	O
mg	PRISTIQ.xml:S1:8224:2	O
(	PRISTIQ.xml:S1:8226:1	O
n	PRISTIQ.xml:S1:8227:1	O
157	PRISTIQ.xml:S1:8229:3	O
)	PRISTIQ.xml:S1:8232:1	O
200	PRISTIQ.xml:S1:8238:3	O
mg	PRISTIQ.xml:S1:8242:2	O
(	PRISTIQ.xml:S1:8244:1	O
n	PRISTIQ.xml:S1:8245:1	O
131	PRISTIQ.xml:S1:8247:3	O
)	PRISTIQ.xml:S1:8250:1	O
400	PRISTIQ.xml:S1:8256:3	O
mg	PRISTIQ.xml:S1:8260:2	O
(	PRISTIQ.xml:S1:8262:1	O
n	PRISTIQ.xml:S1:8263:1	O
154	PRISTIQ.xml:S1:8265:3	O
)	PRISTIQ.xml:S1:8268:1	O

Men	PRISTIQ.xml:S1:8277:3	O
only	PRISTIQ.xml:S1:8281:4	O

Anorgasmia	PRISTIQ.xml:S1:8304:10	B-AdverseReaction
0	PRISTIQ.xml:S1:8324:1	O
0	PRISTIQ.xml:S1:8342:1	O
3	PRISTIQ.xml:S1:8360:1	O
5	PRISTIQ.xml:S1:8378:1	O
8	PRISTIQ.xml:S1:8396:1	O

Libido	PRISTIQ.xml:S1:8419:6	B-AdverseReaction
decreased	PRISTIQ.xml:S1:8426:9	I-AdverseReaction
1	PRISTIQ.xml:S1:8439:1	O
4	PRISTIQ.xml:S1:8457:1	O
5	PRISTIQ.xml:S1:8475:1	O
6	PRISTIQ.xml:S1:8493:1	O
3	PRISTIQ.xml:S1:8511:1	O

Orgasm	PRISTIQ.xml:S1:8534:6	B-AdverseReaction
abnormal	PRISTIQ.xml:S1:8541:8	I-AdverseReaction
0	PRISTIQ.xml:S1:8554:1	O
0	PRISTIQ.xml:S1:8572:1	O
1	PRISTIQ.xml:S1:8590:1	O
2	PRISTIQ.xml:S1:8608:1	O
3	PRISTIQ.xml:S1:8626:1	O

Ejaculation	PRISTIQ.xml:S1:8649:11	B-AdverseReaction
delayed	PRISTIQ.xml:S1:8661:7	I-AdverseReaction
1	PRISTIQ.xml:S1:8673:1	O
1	PRISTIQ.xml:S1:8690:1	O
5	PRISTIQ.xml:S1:8708:1	O
7	PRISTIQ.xml:S1:8726:1	O
6	PRISTIQ.xml:S1:8744:1	O

Erectile	PRISTIQ.xml:S1:8767:8	B-AdverseReaction
dysfunction	PRISTIQ.xml:S1:8776:11	I-AdverseReaction
1	PRISTIQ.xml:S1:8791:1	O
3	PRISTIQ.xml:S1:8809:1	O
6	PRISTIQ.xml:S1:8827:1	O
8	PRISTIQ.xml:S1:8845:1	O
11	PRISTIQ.xml:S1:8863:2	O

Ejaculation	PRISTIQ.xml:S1:8886:11	B-AdverseReaction
disorder	PRISTIQ.xml:S1:8898:8	I-AdverseReaction
0	PRISTIQ.xml:S1:8910:1	O
0	PRISTIQ.xml:S1:8928:1	O
1	PRISTIQ.xml:S1:8946:1	O
2	PRISTIQ.xml:S1:8964:1	O
5	PRISTIQ.xml:S1:8982:1	O

Ejaculation	PRISTIQ.xml:S1:9005:11	B-AdverseReaction
failure	PRISTIQ.xml:S1:9017:7	I-AdverseReaction
0	PRISTIQ.xml:S1:9028:1	O
1	PRISTIQ.xml:S1:9046:1	O
0	PRISTIQ.xml:S1:9064:1	O
2	PRISTIQ.xml:S1:9082:1	O
2	PRISTIQ.xml:S1:9100:1	O

Sexual	PRISTIQ.xml:S1:9123:6	B-AdverseReaction
dysfunction	PRISTIQ.xml:S1:9130:11	I-AdverseReaction
0	PRISTIQ.xml:S1:9145:1	O
1	PRISTIQ.xml:S1:9163:1	O
0	PRISTIQ.xml:S1:9181:1	O
0	PRISTIQ.xml:S1:9199:1	O
2	PRISTIQ.xml:S1:9217:1	O

PRISTIQ	PRISTIQ.xml:S1:9278:7	O

Placebo	PRISTIQ.xml:S1:9321:7	O
(	PRISTIQ.xml:S1:9328:1	O
n	PRISTIQ.xml:S1:9329:1	O
397	PRISTIQ.xml:S1:9331:3	O
)	PRISTIQ.xml:S1:9334:1	O
50	PRISTIQ.xml:S1:9339:2	O
mg	PRISTIQ.xml:S1:9342:2	O
(	PRISTIQ.xml:S1:9344:1	O
n	PRISTIQ.xml:S1:9345:1	O
209	PRISTIQ.xml:S1:9347:3	O
)	PRISTIQ.xml:S1:9350:1	O
100	PRISTIQ.xml:S1:9357:3	O
mg	PRISTIQ.xml:S1:9361:2	O
(	PRISTIQ.xml:S1:9363:1	O
n	PRISTIQ.xml:S1:9364:1	O
267	PRISTIQ.xml:S1:9366:3	O
)	PRISTIQ.xml:S1:9369:1	O
200	PRISTIQ.xml:S1:9375:3	O
mg	PRISTIQ.xml:S1:9379:2	O
(	PRISTIQ.xml:S1:9381:1	O
n	PRISTIQ.xml:S1:9382:1	O
176	PRISTIQ.xml:S1:9384:3	O
)	PRISTIQ.xml:S1:9387:1	O
400	PRISTIQ.xml:S1:9393:3	O
mg	PRISTIQ.xml:S1:9397:2	O
(	PRISTIQ.xml:S1:9399:1	O
n	PRISTIQ.xml:S1:9400:1	O
163	PRISTIQ.xml:S1:9402:3	O
)	PRISTIQ.xml:S1:9405:1	O

Women	PRISTIQ.xml:S1:9416:5	O
only	PRISTIQ.xml:S1:9422:4	O

Anorgasmia	PRISTIQ.xml:S1:9441:10	B-AdverseReaction
0	PRISTIQ.xml:S1:9461:1	O
1	PRISTIQ.xml:S1:9479:1	O
1	PRISTIQ.xml:S1:9497:1	O
0	PRISTIQ.xml:S1:9515:1	O
3	PRISTIQ.xml:S1:9533:1	O

Other	PRISTIQ.xml:S1:9568:5	O
adverse	PRISTIQ.xml:S1:9574:7	O
reactions	PRISTIQ.xml:S1:9582:9	O
observed	PRISTIQ.xml:S1:9592:8	O
in	PRISTIQ.xml:S1:9601:2	O
premarketing	PRISTIQ.xml:S1:9604:12	O
and	PRISTIQ.xml:S1:9617:3	O
postmarketing	PRISTIQ.xml:S1:9621:13	O
clinical	PRISTIQ.xml:S1:9635:8	O
studies	PRISTIQ.xml:S1:9644:7	O

Other	PRISTIQ.xml:S1:9658:5	O

infrequent	PRISTIQ.xml:S1:9664:10	O
adverse	PRISTIQ.xml:S1:9675:7	O
reactions	PRISTIQ.xml:S1:9683:9	O
,	PRISTIQ.xml:S1:9692:1	O
not	PRISTIQ.xml:S1:9694:3	O
described	PRISTIQ.xml:S1:9698:9	O
elsewhere	PRISTIQ.xml:S1:9708:9	O
in	PRISTIQ.xml:S1:9718:2	O
the	PRISTIQ.xml:S1:9721:3	O
label	PRISTIQ.xml:S1:9725:5	O
,	PRISTIQ.xml:S1:9730:1	O
occurring	PRISTIQ.xml:S1:9732:9	O
at	PRISTIQ.xml:S1:9742:2	O
an	PRISTIQ.xml:S1:9745:2	O
incidence	PRISTIQ.xml:S1:9748:9	O
of	PRISTIQ.xml:S1:9758:2	O
2%	PRISTIQ.xml:S1:9763:2	O
in	PRISTIQ.xml:S1:9766:2	O
MDD	PRISTIQ.xml:S1:9769:3	O
patients	PRISTIQ.xml:S1:9773:8	O
treated	PRISTIQ.xml:S1:9782:7	O
with	PRISTIQ.xml:S1:9790:4	O
PRISTIQ	PRISTIQ.xml:S1:9795:7	O
were	PRISTIQ.xml:S1:9803:4	O
:	PRISTIQ.xml:S1:9807:1	O

Cardiac	PRISTIQ.xml:S1:9817:7	O
disorders	PRISTIQ.xml:S1:9825:9	O
-	PRISTIQ.xml:S1:9838:1	O
Tachycardia	PRISTIQ.xml:S1:9840:11	B-AdverseReaction
.	PRISTIQ.xml:S1:9851:1	O

General	PRISTIQ.xml:S1:9861:7	O
disorders	PRISTIQ.xml:S1:9869:9	O
and	PRISTIQ.xml:S1:9879:3	O
administration	PRISTIQ.xml:S1:9883:14	O
site	PRISTIQ.xml:S1:9898:4	O
conditions	PRISTIQ.xml:S1:9903:10	O
-	PRISTIQ.xml:S1:9917:1	O
Asthenia	PRISTIQ.xml:S1:9919:8	B-AdverseReaction
.	PRISTIQ.xml:S1:9927:1	O

Investigations	PRISTIQ.xml:S1:9937:14	O
-	PRISTIQ.xml:S1:9952:1	O
Weight	PRISTIQ.xml:S1:9957:6	B-AdverseReaction
increased	PRISTIQ.xml:S1:9964:9	I-AdverseReaction
,	PRISTIQ.xml:S1:9973:1	O
liver	PRISTIQ.xml:S1:9975:5	B-AdverseReaction
function	PRISTIQ.xml:S1:9981:8	I-AdverseReaction
test	PRISTIQ.xml:S1:9990:4	I-AdverseReaction
abnormal	PRISTIQ.xml:S1:9995:8	I-AdverseReaction
,	PRISTIQ.xml:S1:10003:1	O
blood	PRISTIQ.xml:S1:10005:5	B-AdverseReaction
prolactin	PRISTIQ.xml:S1:10011:9	I-AdverseReaction
increased	PRISTIQ.xml:S1:10021:9	I-AdverseReaction
.	PRISTIQ.xml:S1:10030:1	O

Musculoskeletal	PRISTIQ.xml:S1:10040:15	O
and	PRISTIQ.xml:S1:10056:3	O
connective	PRISTIQ.xml:S1:10060:10	O
tissue	PRISTIQ.xml:S1:10071:6	O
disorders	PRISTIQ.xml:S1:10078:9	O
-	PRISTIQ.xml:S1:10088:1	O
Musculoskeletal	PRISTIQ.xml:S1:10093:15	B-AdverseReaction
stiffness	PRISTIQ.xml:S1:10109:9	I-AdverseReaction
.	PRISTIQ.xml:S1:10118:1	O

Nervous	PRISTIQ.xml:S1:10128:7	O
system	PRISTIQ.xml:S1:10136:6	O
disorders	PRISTIQ.xml:S1:10143:9	O
-	PRISTIQ.xml:S1:10153:1	O
Syncope	PRISTIQ.xml:S1:10158:7	B-AdverseReaction
,	PRISTIQ.xml:S1:10165:1	O
convulsion	PRISTIQ.xml:S1:10167:10	B-AdverseReaction
,	PRISTIQ.xml:S1:10177:1	O
dystonia	PRISTIQ.xml:S1:10179:8	B-AdverseReaction
.	PRISTIQ.xml:S1:10187:1	O

Psychiatric	PRISTIQ.xml:S1:10197:11	O
disorders	PRISTIQ.xml:S1:10209:9	O
-	PRISTIQ.xml:S1:10219:1	O
Depersonalization	PRISTIQ.xml:S1:10224:17	B-AdverseReaction
,	PRISTIQ.xml:S1:10241:1	O
bruxism	PRISTIQ.xml:S1:10243:7	B-AdverseReaction
.	PRISTIQ.xml:S1:10250:1	O

Renal	PRISTIQ.xml:S1:10260:5	O
and	PRISTIQ.xml:S1:10266:3	O
urinary	PRISTIQ.xml:S1:10270:7	O
disorders	PRISTIQ.xml:S1:10278:9	O
-	PRISTIQ.xml:S1:10291:1	O
Urinary	PRISTIQ.xml:S1:10293:7	B-AdverseReaction
retention	PRISTIQ.xml:S1:10301:9	I-AdverseReaction
.	PRISTIQ.xml:S1:10310:1	O

Skin	PRISTIQ.xml:S1:10320:4	O
and	PRISTIQ.xml:S1:10325:3	O
subcutaneous	PRISTIQ.xml:S1:10329:12	O
tissue	PRISTIQ.xml:S1:10342:6	O
disorders	PRISTIQ.xml:S1:10349:9	O
-	PRISTIQ.xml:S1:10360:1	O
Rash	PRISTIQ.xml:S1:10363:4	B-AdverseReaction
,	PRISTIQ.xml:S1:10367:1	O
alopecia	PRISTIQ.xml:S1:10369:8	B-AdverseReaction
,	PRISTIQ.xml:S1:10377:1	O
photosensitivity	PRISTIQ.xml:S1:10379:16	B-AdverseReaction
reaction	PRISTIQ.xml:S1:10396:8	O
,	PRISTIQ.xml:S1:10404:1	O
angioedema	PRISTIQ.xml:S1:10406:10	B-AdverseReaction
.	PRISTIQ.xml:S1:10416:1	O

In	PRISTIQ.xml:S1:10422:2	O
clinical	PRISTIQ.xml:S1:10425:8	O
studies	PRISTIQ.xml:S1:10434:7	O
,	PRISTIQ.xml:S1:10441:1	O
there	PRISTIQ.xml:S1:10443:5	O
were	PRISTIQ.xml:S1:10449:4	O
uncommon	PRISTIQ.xml:S1:10454:8	O
reports	PRISTIQ.xml:S1:10463:7	O
of	PRISTIQ.xml:S1:10471:2	O
ischemic	PRISTIQ.xml:S1:10474:8	B-AdverseReaction
cardiac	PRISTIQ.xml:S1:10483:7	I-AdverseReaction
adverse	PRISTIQ.xml:S1:10491:7	I-AdverseReaction
reactions	PRISTIQ.xml:S1:10499:9	I-AdverseReaction
,	PRISTIQ.xml:S1:10508:1	O
including	PRISTIQ.xml:S1:10510:9	O
myocardial	PRISTIQ.xml:S1:10520:10	B-AdverseReaction
ischemia	PRISTIQ.xml:S1:10531:8	I-AdverseReaction
,	PRISTIQ.xml:S1:10539:1	O
myocardial	PRISTIQ.xml:S1:10541:10	B-AdverseReaction
infarction	PRISTIQ.xml:S1:10552:10	I-AdverseReaction
,	PRISTIQ.xml:S1:10562:1	O
and	PRISTIQ.xml:S1:10564:3	O
coronary	PRISTIQ.xml:S1:10568:8	B-AdverseReaction
occlusion	PRISTIQ.xml:S1:10577:9	I-AdverseReaction
requiring	PRISTIQ.xml:S1:10587:9	O
revascularization	PRISTIQ.xml:S1:10597:17	O
;	PRISTIQ.xml:S1:10614:1	O
these	PRISTIQ.xml:S1:10616:5	O
patients	PRISTIQ.xml:S1:10622:8	O
had	PRISTIQ.xml:S1:10631:3	O
multiple	PRISTIQ.xml:S1:10635:8	O
underlying	PRISTIQ.xml:S1:10644:10	O
cardiac	PRISTIQ.xml:S1:10655:7	O
risk	PRISTIQ.xml:S1:10663:4	O
factors	PRISTIQ.xml:S1:10668:7	O
.	PRISTIQ.xml:S1:10675:1	O

More	PRISTIQ.xml:S1:10677:4	O
patients	PRISTIQ.xml:S1:10682:8	O
experienced	PRISTIQ.xml:S1:10691:11	O
these	PRISTIQ.xml:S1:10703:5	O
events	PRISTIQ.xml:S1:10709:6	O
during	PRISTIQ.xml:S1:10716:6	O
PRISTIQ	PRISTIQ.xml:S1:10723:7	O
treatment	PRISTIQ.xml:S1:10731:9	O
as	PRISTIQ.xml:S1:10741:2	O
compared	PRISTIQ.xml:S1:10744:8	O
to	PRISTIQ.xml:S1:10753:2	O
placebo	PRISTIQ.xml:S1:10756:7	O
.	PRISTIQ.xml:S1:10763:1	O

Laboratory	PRISTIQ.xml:S1:10775:10	O
,	PRISTIQ.xml:S1:10785:1	O
ECG	PRISTIQ.xml:S1:10787:3	O
and	PRISTIQ.xml:S1:10791:3	O
vital	PRISTIQ.xml:S1:10795:5	O
sign	PRISTIQ.xml:S1:10801:4	O
changes	PRISTIQ.xml:S1:10806:7	O
observed	PRISTIQ.xml:S1:10814:8	O
in	PRISTIQ.xml:S1:10823:2	O
MDD	PRISTIQ.xml:S1:10826:3	O
clinical	PRISTIQ.xml:S1:10830:8	O
studies	PRISTIQ.xml:S1:10839:7	O

The	PRISTIQ.xml:S1:10855:3	O
following	PRISTIQ.xml:S1:10859:9	O
changes	PRISTIQ.xml:S1:10869:7	O
were	PRISTIQ.xml:S1:10877:4	O
observed	PRISTIQ.xml:S1:10882:8	O
in	PRISTIQ.xml:S1:10891:2	O
pre	PRISTIQ.xml:S1:10894:3	O
-	PRISTIQ.xml:S1:10897:1	O
marketing	PRISTIQ.xml:S1:10898:9	O
placebo	PRISTIQ.xml:S1:10908:7	O
-	PRISTIQ.xml:S1:10915:1	O
controlled	PRISTIQ.xml:S1:10916:10	O
,	PRISTIQ.xml:S1:10926:1	O
short	PRISTIQ.xml:S1:10928:5	O
-	PRISTIQ.xml:S1:10933:1	O
term	PRISTIQ.xml:S1:10934:4	O
MDD	PRISTIQ.xml:S1:10939:3	O
studies	PRISTIQ.xml:S1:10943:7	O
with	PRISTIQ.xml:S1:10951:4	O
PRISTIQ	PRISTIQ.xml:S1:10956:7	O
.	PRISTIQ.xml:S1:10963:1	O

Lipids	PRISTIQ.xml:S1:10975:6	O

Elevations	PRISTIQ.xml:S1:10990:10	B-AdverseReaction
in	PRISTIQ.xml:S1:11001:2	I-AdverseReaction
fasting	PRISTIQ.xml:S1:11004:7	I-AdverseReaction
serum	PRISTIQ.xml:S1:11012:5	I-AdverseReaction
total	PRISTIQ.xml:S1:11018:5	I-AdverseReaction
cholesterol	PRISTIQ.xml:S1:11024:11	I-AdverseReaction
,	PRISTIQ.xml:S1:11035:1	O
LDL	PRISTIQ.xml:S1:11037:3	I-AdverseReaction
(	PRISTIQ.xml:S1:11041:1	O
low	PRISTIQ.xml:S1:11042:3	I-AdverseReaction
density	PRISTIQ.xml:S1:11046:7	I-AdverseReaction
lipoproteins	PRISTIQ.xml:S1:11054:12	I-AdverseReaction
)	PRISTIQ.xml:S1:11066:1	O
cholesterol	PRISTIQ.xml:S1:11068:11	I-AdverseReaction
,	PRISTIQ.xml:S1:11079:1	O
and	PRISTIQ.xml:S1:11081:3	O
triglycerides	PRISTIQ.xml:S1:11085:13	I-AdverseReaction
occurred	PRISTIQ.xml:S1:11099:8	O
in	PRISTIQ.xml:S1:11108:2	O
the	PRISTIQ.xml:S1:11111:3	O
controlled	PRISTIQ.xml:S1:11115:10	O
studies	PRISTIQ.xml:S1:11126:7	O
.	PRISTIQ.xml:S1:11133:1	O

Some	PRISTIQ.xml:S1:11135:4	O
of	PRISTIQ.xml:S1:11140:2	O
these	PRISTIQ.xml:S1:11143:5	O
abnormalities	PRISTIQ.xml:S1:11149:13	O
were	PRISTIQ.xml:S1:11163:4	O
considered	PRISTIQ.xml:S1:11168:10	O
potentially	PRISTIQ.xml:S1:11179:11	O
clinically	PRISTIQ.xml:S1:11191:10	O
significant	PRISTIQ.xml:S1:11202:11	O
.	PRISTIQ.xml:S1:11213:1	O

The	PRISTIQ.xml:S1:11219:3	O
percentage	PRISTIQ.xml:S1:11223:10	O
of	PRISTIQ.xml:S1:11234:2	O
patients	PRISTIQ.xml:S1:11237:8	O
who	PRISTIQ.xml:S1:11246:3	O
exceeded	PRISTIQ.xml:S1:11250:8	O
a	PRISTIQ.xml:S1:11259:1	O
predetermined	PRISTIQ.xml:S1:11261:13	O
threshold	PRISTIQ.xml:S1:11275:9	O
value	PRISTIQ.xml:S1:11285:5	O
is	PRISTIQ.xml:S1:11291:2	O
shown	PRISTIQ.xml:S1:11294:5	O
in	PRISTIQ.xml:S1:11300:2	O
Table	PRISTIQ.xml:S1:11303:5	O
4	PRISTIQ.xml:S1:11309:1	O
.	PRISTIQ.xml:S1:11310:1	O

Table	PRISTIQ.xml:S1:11316:5	O
4	PRISTIQ.xml:S1:11322:1	O
:	PRISTIQ.xml:S1:11323:1	O
Incidence	PRISTIQ.xml:S1:11325:9	O
(	PRISTIQ.xml:S1:11335:1	O
)	PRISTIQ.xml:S1:11337:1	O
of	PRISTIQ.xml:S1:11339:2	O
Patients	PRISTIQ.xml:S1:11342:8	O
With	PRISTIQ.xml:S1:11351:4	O
Lipid	PRISTIQ.xml:S1:11356:5	B-AdverseReaction
Abnormalities	PRISTIQ.xml:S1:11362:13	I-AdverseReaction
of	PRISTIQ.xml:S1:11376:2	O
Potential	PRISTIQ.xml:S1:11379:9	O
Clinical	PRISTIQ.xml:S1:11389:8	O
Significance	PRISTIQ.xml:S1:11398:12	O

PRISTIQ	PRISTIQ.xml:S1:11465:7	O

Placebo	PRISTIQ.xml:S1:11516:7	O
50	PRISTIQ.xml:S1:11531:2	O
mg	PRISTIQ.xml:S1:11534:2	O
100	PRISTIQ.xml:S1:11545:3	O
mg	PRISTIQ.xml:S1:11549:2	O
200	PRISTIQ.xml:S1:11559:3	O
mg	PRISTIQ.xml:S1:11563:2	O
400	PRISTIQ.xml:S1:11573:3	O
mg	PRISTIQ.xml:S1:11577:2	O

Total	PRISTIQ.xml:S1:11592:5	B-AdverseReaction

Cholesterol	PRISTIQ.xml:S1:11598:11	I-AdverseReaction
(	PRISTIQ.xml:S1:11610:1	O
Increase	PRISTIQ.xml:S1:11611:8	O
of	PRISTIQ.xml:S1:11620:2	O
50	PRISTIQ.xml:S1:11626:2	O
mg	PRISTIQ.xml:S1:11629:2	O
dl	PRISTIQ.xml:S1:11632:2	O
and	PRISTIQ.xml:S1:11635:3	O
an	PRISTIQ.xml:S1:11639:2	O
absolute	PRISTIQ.xml:S1:11642:8	O
value	PRISTIQ.xml:S1:11651:5	O
of	PRISTIQ.xml:S1:11657:2	O
261	PRISTIQ.xml:S1:11663:3	I-AdverseReaction
mg	PRISTIQ.xml:S1:11667:2	I-AdverseReaction
dl	PRISTIQ.xml:S1:11670:2	I-AdverseReaction
)	PRISTIQ.xml:S1:11672:1	O
2	PRISTIQ.xml:S1:11677:1	O
3	PRISTIQ.xml:S1:11692:1	O
4	PRISTIQ.xml:S1:11706:1	O
4	PRISTIQ.xml:S1:11720:1	O
10	PRISTIQ.xml:S1:11734:2	O

LDL	PRISTIQ.xml:S1:11751:3	B-AdverseReaction
Cholesterol	PRISTIQ.xml:S1:11755:11	I-AdverseReaction
(	PRISTIQ.xml:S1:11767:1	O
Increase	PRISTIQ.xml:S1:11768:8	O
50	PRISTIQ.xml:S1:11780:2	O
mg	PRISTIQ.xml:S1:11783:2	O
dl	PRISTIQ.xml:S1:11786:2	O
and	PRISTIQ.xml:S1:11789:3	O
an	PRISTIQ.xml:S1:11793:2	O
absolute	PRISTIQ.xml:S1:11796:8	O
value	PRISTIQ.xml:S1:11805:5	O
of	PRISTIQ.xml:S1:11811:2	O
190	PRISTIQ.xml:S1:11817:3	I-AdverseReaction
mg	PRISTIQ.xml:S1:11821:2	I-AdverseReaction
dl	PRISTIQ.xml:S1:11824:2	I-AdverseReaction
)	PRISTIQ.xml:S1:11826:1	O
0	PRISTIQ.xml:S1:11831:1	O
1	PRISTIQ.xml:S1:11846:1	O
0	PRISTIQ.xml:S1:11860:1	O
1	PRISTIQ.xml:S1:11874:1	O
2	PRISTIQ.xml:S1:11888:1	O

Triglycerides	PRISTIQ.xml:S1:11905:13	B-AdverseReaction
,	PRISTIQ.xml:S1:11918:1	I-AdverseReaction
fasting	PRISTIQ.xml:S1:11920:7	I-AdverseReaction
(	PRISTIQ.xml:S1:11928:1	O
Fasting	PRISTIQ.xml:S1:11929:7	O
:	PRISTIQ.xml:S1:11936:1	O
327	PRISTIQ.xml:S1:11941:3	I-AdverseReaction
mg	PRISTIQ.xml:S1:11945:2	I-AdverseReaction
dl	PRISTIQ.xml:S1:11948:2	I-AdverseReaction
)	PRISTIQ.xml:S1:11950:1	O
3	PRISTIQ.xml:S1:11955:1	O
2	PRISTIQ.xml:S1:11970:1	O
1	PRISTIQ.xml:S1:11984:1	O
4	PRISTIQ.xml:S1:11998:1	O
6	PRISTIQ.xml:S1:12012:1	O

Proteinuria	PRISTIQ.xml:S1:12045:11	O

Proteinuria	PRISTIQ.xml:S1:12065:11	B-AdverseReaction

,	PRISTIQ.xml:S1:12076:1	O
greater	PRISTIQ.xml:S1:12078:7	O
than	PRISTIQ.xml:S1:12086:4	O
or	PRISTIQ.xml:S1:12091:2	O
equal	PRISTIQ.xml:S1:12094:5	O
to	PRISTIQ.xml:S1:12100:2	O
trace	PRISTIQ.xml:S1:12103:5	O
,	PRISTIQ.xml:S1:12108:1	O
was	PRISTIQ.xml:S1:12110:3	O
observed	PRISTIQ.xml:S1:12114:8	O
in	PRISTIQ.xml:S1:12123:2	O
the	PRISTIQ.xml:S1:12126:3	O
pre	PRISTIQ.xml:S1:12130:3	O
-	PRISTIQ.xml:S1:12133:1	O
marketing	PRISTIQ.xml:S1:12134:9	O
fixed	PRISTIQ.xml:S1:12144:5	O
-	PRISTIQ.xml:S1:12149:1	O
dose	PRISTIQ.xml:S1:12150:4	O
controlled	PRISTIQ.xml:S1:12155:10	O
studies	PRISTIQ.xml:S1:12166:7	O
(	PRISTIQ.xml:S1:12174:1	O
see	PRISTIQ.xml:S1:12175:3	O
Table	PRISTIQ.xml:S1:12180:5	O
5	PRISTIQ.xml:S1:12186:1	O
)	PRISTIQ.xml:S1:12189:1	O
.	PRISTIQ.xml:S1:12190:1	O

This	PRISTIQ.xml:S1:12192:4	O
proteinuria	PRISTIQ.xml:S1:12197:11	B-AdverseReaction
was	PRISTIQ.xml:S1:12209:3	O
not	PRISTIQ.xml:S1:12213:3	B-Negation
associated	PRISTIQ.xml:S1:12217:10	O
with	PRISTIQ.xml:S1:12228:4	O
increases	PRISTIQ.xml:S1:12233:9	B-AdverseReaction
in	PRISTIQ.xml:S1:12243:2	I-AdverseReaction
BUN	PRISTIQ.xml:S1:12246:3	I-AdverseReaction
or	PRISTIQ.xml:S1:12250:2	O
creatinine	PRISTIQ.xml:S1:12253:10	I-AdverseReaction
and	PRISTIQ.xml:S1:12264:3	O
was	PRISTIQ.xml:S1:12268:3	O
generally	PRISTIQ.xml:S1:12272:9	O
transient	PRISTIQ.xml:S1:12282:9	B-Severity
.	PRISTIQ.xml:S1:12291:1	O

Table	PRISTIQ.xml:S1:12297:5	O
5	PRISTIQ.xml:S1:12303:1	O
:	PRISTIQ.xml:S1:12304:1	O
Incidence	PRISTIQ.xml:S1:12306:9	O
(	PRISTIQ.xml:S1:12316:1	O
)	PRISTIQ.xml:S1:12318:1	O
of	PRISTIQ.xml:S1:12320:2	O
Patients	PRISTIQ.xml:S1:12323:8	O
with	PRISTIQ.xml:S1:12332:4	O
Proteinuria	PRISTIQ.xml:S1:12337:11	B-AdverseReaction
in	PRISTIQ.xml:S1:12349:2	O
the	PRISTIQ.xml:S1:12352:3	O
Fixed	PRISTIQ.xml:S1:12356:5	O
-	PRISTIQ.xml:S1:12361:1	O
dose	PRISTIQ.xml:S1:12362:4	O
Clinical	PRISTIQ.xml:S1:12367:8	O
Studies	PRISTIQ.xml:S1:12376:7	O

PRISTIQ	PRISTIQ.xml:S1:12426:7	O

Placebo	PRISTIQ.xml:S1:12467:7	O
50	PRISTIQ.xml:S1:12484:2	O
mg	PRISTIQ.xml:S1:12487:2	O
100	PRISTIQ.xml:S1:12501:3	O
mg	PRISTIQ.xml:S1:12505:2	O
200	PRISTIQ.xml:S1:12518:3	O
mg	PRISTIQ.xml:S1:12522:2	O
400	PRISTIQ.xml:S1:12535:3	O
mg	PRISTIQ.xml:S1:12539:2	O

Proteinuria	PRISTIQ.xml:S1:12557:11	B-AdverseReaction

4	PRISTIQ.xml:S1:12578:1	O
6	PRISTIQ.xml:S1:12595:1	O
8	PRISTIQ.xml:S1:12612:1	O
5	PRISTIQ.xml:S1:12629:1	O
7	PRISTIQ.xml:S1:12646:1	O

Vital	PRISTIQ.xml:S1:12682:5	O
sign	PRISTIQ.xml:S1:12688:4	O
changes	PRISTIQ.xml:S1:12693:7	O

Table	PRISTIQ.xml:S1:12709:5	O

6	PRISTIQ.xml:S1:12715:1	O
summarizes	PRISTIQ.xml:S1:12717:10	O
the	PRISTIQ.xml:S1:12728:3	O
changes	PRISTIQ.xml:S1:12732:7	O
that	PRISTIQ.xml:S1:12740:4	O
were	PRISTIQ.xml:S1:12745:4	O
observed	PRISTIQ.xml:S1:12750:8	O
in	PRISTIQ.xml:S1:12759:2	O
placebo	PRISTIQ.xml:S1:12762:7	O
-	PRISTIQ.xml:S1:12769:1	O
controlled	PRISTIQ.xml:S1:12770:10	O
,	PRISTIQ.xml:S1:12780:1	O
short	PRISTIQ.xml:S1:12782:5	O
-	PRISTIQ.xml:S1:12787:1	O
term	PRISTIQ.xml:S1:12788:4	O
,	PRISTIQ.xml:S1:12792:1	O
pre	PRISTIQ.xml:S1:12794:3	O
-	PRISTIQ.xml:S1:12797:1	O
marketing	PRISTIQ.xml:S1:12798:9	O
studies	PRISTIQ.xml:S1:12808:7	O
with	PRISTIQ.xml:S1:12816:4	O
PRISTIQ	PRISTIQ.xml:S1:12821:7	O
in	PRISTIQ.xml:S1:12829:2	O
patients	PRISTIQ.xml:S1:12832:8	O
with	PRISTIQ.xml:S1:12841:4	O
MDD	PRISTIQ.xml:S1:12846:3	O
(	PRISTIQ.xml:S1:12850:1	O
doses	PRISTIQ.xml:S1:12851:5	O
50	PRISTIQ.xml:S1:12857:2	O
to	PRISTIQ.xml:S1:12860:2	O
400	PRISTIQ.xml:S1:12863:3	O
mg	PRISTIQ.xml:S1:12867:2	O
)	PRISTIQ.xml:S1:12869:1	O
.	PRISTIQ.xml:S1:12870:1	O

Table	PRISTIQ.xml:S1:12876:5	O
6	PRISTIQ.xml:S1:12882:1	O
:	PRISTIQ.xml:S1:12883:1	O
Mean	PRISTIQ.xml:S1:12885:4	O
Changes	PRISTIQ.xml:S1:12890:7	O
in	PRISTIQ.xml:S1:12898:2	O
Vital	PRISTIQ.xml:S1:12901:5	O
Signs	PRISTIQ.xml:S1:12907:5	O
at	PRISTIQ.xml:S1:12913:2	O
Final	PRISTIQ.xml:S1:12916:5	O
on	PRISTIQ.xml:S1:12922:2	O
Therapy	PRISTIQ.xml:S1:12925:7	O
for	PRISTIQ.xml:S1:12933:3	O
All	PRISTIQ.xml:S1:12937:3	O
Short	PRISTIQ.xml:S1:12941:5	O
-	PRISTIQ.xml:S1:12946:1	O
term	PRISTIQ.xml:S1:12947:4	O
,	PRISTIQ.xml:S1:12951:1	O
Fixed	PRISTIQ.xml:S1:12953:5	O
-	PRISTIQ.xml:S1:12958:1	O
dose	PRISTIQ.xml:S1:12959:4	O
Controlled	PRISTIQ.xml:S1:12964:10	O
Studies	PRISTIQ.xml:S1:12975:7	O

PRISTIQ	PRISTIQ.xml:S1:13025:7	O

Placebo	PRISTIQ.xml:S1:13066:7	O
50	PRISTIQ.xml:S1:13083:2	O
mg	PRISTIQ.xml:S1:13086:2	O
100	PRISTIQ.xml:S1:13100:3	O
mg	PRISTIQ.xml:S1:13104:2	O
200	PRISTIQ.xml:S1:13117:3	O
mg	PRISTIQ.xml:S1:13121:2	O
400	PRISTIQ.xml:S1:13134:3	O
mg	PRISTIQ.xml:S1:13138:2	O

Blood	PRISTIQ.xml:S1:13156:5	O

pressure	PRISTIQ.xml:S1:13162:8	O

Supine	PRISTIQ.xml:S1:13180:6	O
systolic	PRISTIQ.xml:S1:13187:8	O
bp	PRISTIQ.xml:S1:13196:2	O
(	PRISTIQ.xml:S1:13199:1	O
mm	PRISTIQ.xml:S1:13200:2	O
Hg	PRISTIQ.xml:S1:13203:2	O
)	PRISTIQ.xml:S1:13205:1	O
-	PRISTIQ.xml:S1:13210:1	O
1.4	PRISTIQ.xml:S1:13211:3	O
1.2	PRISTIQ.xml:S1:13227:3	O
2.0	PRISTIQ.xml:S1:13244:3	O
2.5	PRISTIQ.xml:S1:13261:3	O
2.1	PRISTIQ.xml:S1:13278:3	O

Supine	PRISTIQ.xml:S1:13298:6	O
diastolic	PRISTIQ.xml:S1:13305:9	O
bp	PRISTIQ.xml:S1:13315:2	O
(	PRISTIQ.xml:S1:13318:1	O
mm	PRISTIQ.xml:S1:13319:2	O
Hg	PRISTIQ.xml:S1:13322:2	O
)	PRISTIQ.xml:S1:13324:1	O
-	PRISTIQ.xml:S1:13329:1	O
0.6	PRISTIQ.xml:S1:13330:3	O
0.7	PRISTIQ.xml:S1:13346:3	O
0.8	PRISTIQ.xml:S1:13363:3	O
1.8	PRISTIQ.xml:S1:13380:3	O
2.3	PRISTIQ.xml:S1:13397:3	O

Pulse	PRISTIQ.xml:S1:13417:5	O
rate	PRISTIQ.xml:S1:13423:4	O

Supine	PRISTIQ.xml:S1:13441:6	O
pulse	PRISTIQ.xml:S1:13448:5	O
(	PRISTIQ.xml:S1:13454:1	O
bpm	PRISTIQ.xml:S1:13455:3	O
)	PRISTIQ.xml:S1:13458:1	O
-	PRISTIQ.xml:S1:13463:1	O
0.3	PRISTIQ.xml:S1:13464:3	O
1.3	PRISTIQ.xml:S1:13480:3	O
1.3	PRISTIQ.xml:S1:13497:3	O
0.9	PRISTIQ.xml:S1:13514:3	O
4.1	PRISTIQ.xml:S1:13531:3	O

Weight	PRISTIQ.xml:S1:13551:6	O
(	PRISTIQ.xml:S1:13558:1	O
kg	PRISTIQ.xml:S1:13559:2	O
)	PRISTIQ.xml:S1:13561:1	O
0.0	PRISTIQ.xml:S1:13572:3	O
-	PRISTIQ.xml:S1:13589:1	O
0.4	PRISTIQ.xml:S1:13590:3	O
-	PRISTIQ.xml:S1:13606:1	O
0.6	PRISTIQ.xml:S1:13607:3	O
-	PRISTIQ.xml:S1:13623:1	O
0.9	PRISTIQ.xml:S1:13624:3	O
-	PRISTIQ.xml:S1:13640:1	O
1.1	PRISTIQ.xml:S1:13641:3	O

Treatment	PRISTIQ.xml:S1:13670:9	O
with	PRISTIQ.xml:S1:13680:4	O
PRISTIQ	PRISTIQ.xml:S1:13685:7	O
at	PRISTIQ.xml:S1:13693:2	O
all	PRISTIQ.xml:S1:13696:3	O
doses	PRISTIQ.xml:S1:13700:5	O
from	PRISTIQ.xml:S1:13706:4	O
50	PRISTIQ.xml:S1:13711:2	O
mg	PRISTIQ.xml:S1:13714:2	O
per	PRISTIQ.xml:S1:13717:3	O
day	PRISTIQ.xml:S1:13721:3	O
to	PRISTIQ.xml:S1:13725:2	O
400	PRISTIQ.xml:S1:13728:3	O
mg	PRISTIQ.xml:S1:13732:2	O
per	PRISTIQ.xml:S1:13735:3	O
day	PRISTIQ.xml:S1:13739:3	O
in	PRISTIQ.xml:S1:13743:2	O
controlled	PRISTIQ.xml:S1:13746:10	O
studies	PRISTIQ.xml:S1:13757:7	O
was	PRISTIQ.xml:S1:13765:3	O
associated	PRISTIQ.xml:S1:13769:10	O
with	PRISTIQ.xml:S1:13780:4	O
sustained	PRISTIQ.xml:S1:13785:9	B-Severity
hypertension	PRISTIQ.xml:S1:13795:12	B-AdverseReaction
,	PRISTIQ.xml:S1:13807:1	O
defined	PRISTIQ.xml:S1:13809:7	O
as	PRISTIQ.xml:S1:13817:2	O
treatment	PRISTIQ.xml:S1:13820:9	O
-	PRISTIQ.xml:S1:13829:1	O
emergent	PRISTIQ.xml:S1:13830:8	O
supine	PRISTIQ.xml:S1:13839:6	B-AdverseReaction
diastolic	PRISTIQ.xml:S1:13846:9	I-AdverseReaction
blood	PRISTIQ.xml:S1:13856:5	I-AdverseReaction
pressure	PRISTIQ.xml:S1:13862:8	I-AdverseReaction
(	PRISTIQ.xml:S1:13871:1	O
SDBP	PRISTIQ.xml:S1:13872:4	O
)	PRISTIQ.xml:S1:13876:1	O
90	PRISTIQ.xml:S1:13880:2	I-AdverseReaction
mm	PRISTIQ.xml:S1:13883:2	I-AdverseReaction
Hg	PRISTIQ.xml:S1:13886:2	I-AdverseReaction
and	PRISTIQ.xml:S1:13889:3	O
10	PRISTIQ.xml:S1:13895:2	O
mm	PRISTIQ.xml:S1:13898:2	O
Hg	PRISTIQ.xml:S1:13901:2	O
above	PRISTIQ.xml:S1:13904:5	O
baseline	PRISTIQ.xml:S1:13910:8	O
for	PRISTIQ.xml:S1:13919:3	O
3	PRISTIQ.xml:S1:13923:1	O
consecutive	PRISTIQ.xml:S1:13925:11	O
on	PRISTIQ.xml:S1:13937:2	O
-	PRISTIQ.xml:S1:13939:1	O
therapy	PRISTIQ.xml:S1:13940:7	O
visits	PRISTIQ.xml:S1:13948:6	O
(	PRISTIQ.xml:S1:13955:1	O
see	PRISTIQ.xml:S1:13956:3	O
Table	PRISTIQ.xml:S1:13961:5	O
7	PRISTIQ.xml:S1:13967:1	O
)	PRISTIQ.xml:S1:13970:1	O
.	PRISTIQ.xml:S1:13971:1	O

Analyses	PRISTIQ.xml:S1:13973:8	O
of	PRISTIQ.xml:S1:13982:2	O
patients	PRISTIQ.xml:S1:13985:8	O
in	PRISTIQ.xml:S1:13994:2	O
PRISTIQ	PRISTIQ.xml:S1:13997:7	O
pre	PRISTIQ.xml:S1:14005:3	O
-	PRISTIQ.xml:S1:14008:1	O
marketing	PRISTIQ.xml:S1:14009:9	O
short	PRISTIQ.xml:S1:14019:5	O
-	PRISTIQ.xml:S1:14024:1	O
term	PRISTIQ.xml:S1:14025:4	O
controlled	PRISTIQ.xml:S1:14030:10	O
studies	PRISTIQ.xml:S1:14041:7	O
who	PRISTIQ.xml:S1:14049:3	O
met	PRISTIQ.xml:S1:14053:3	O
criteria	PRISTIQ.xml:S1:14057:8	O
for	PRISTIQ.xml:S1:14066:3	O
sustained	PRISTIQ.xml:S1:14070:9	B-Severity
hypertension	PRISTIQ.xml:S1:14080:12	B-AdverseReaction
revealed	PRISTIQ.xml:S1:14093:8	O
a	PRISTIQ.xml:S1:14102:1	O
consistent	PRISTIQ.xml:S1:14104:10	O
increase	PRISTIQ.xml:S1:14115:8	O
in	PRISTIQ.xml:S1:14124:2	O
the	PRISTIQ.xml:S1:14127:3	O
proportion	PRISTIQ.xml:S1:14131:10	O
of	PRISTIQ.xml:S1:14142:2	O
patients	PRISTIQ.xml:S1:14145:8	O
who	PRISTIQ.xml:S1:14154:3	O
developed	PRISTIQ.xml:S1:14158:9	O
sustained	PRISTIQ.xml:S1:14168:9	B-Severity
hypertension	PRISTIQ.xml:S1:14178:12	B-AdverseReaction
.	PRISTIQ.xml:S1:14190:1	O

This	PRISTIQ.xml:S1:14192:4	O
was	PRISTIQ.xml:S1:14197:3	O
seen	PRISTIQ.xml:S1:14201:4	O
at	PRISTIQ.xml:S1:14206:2	O
all	PRISTIQ.xml:S1:14209:3	O
doses	PRISTIQ.xml:S1:14213:5	O
with	PRISTIQ.xml:S1:14219:4	O
a	PRISTIQ.xml:S1:14224:1	O
suggestion	PRISTIQ.xml:S1:14226:10	O
of	PRISTIQ.xml:S1:14237:2	O
a	PRISTIQ.xml:S1:14240:1	O
higher	PRISTIQ.xml:S1:14242:6	O
rate	PRISTIQ.xml:S1:14249:4	O
at	PRISTIQ.xml:S1:14254:2	O
400	PRISTIQ.xml:S1:14257:3	O
mg	PRISTIQ.xml:S1:14261:2	O
per	PRISTIQ.xml:S1:14264:3	O
day	PRISTIQ.xml:S1:14268:3	O
.	PRISTIQ.xml:S1:14271:1	O

Table	PRISTIQ.xml:S1:14277:5	O

7	PRISTIQ.xml:S1:14283:1	O
:	PRISTIQ.xml:S1:14284:1	O
Proportion	PRISTIQ.xml:S1:14286:10	O
of	PRISTIQ.xml:S1:14297:2	O
Patients	PRISTIQ.xml:S1:14300:8	O
with	PRISTIQ.xml:S1:14309:4	O
Sustained	PRISTIQ.xml:S1:14314:9	B-Severity
Elevation	PRISTIQ.xml:S1:14324:9	B-AdverseReaction
of	PRISTIQ.xml:S1:14334:2	I-AdverseReaction
Supine	PRISTIQ.xml:S1:14337:6	I-AdverseReaction
Diastolic	PRISTIQ.xml:S1:14344:9	I-AdverseReaction
Blood	PRISTIQ.xml:S1:14354:5	I-AdverseReaction
Pressure	PRISTIQ.xml:S1:14360:8	I-AdverseReaction

Treatment	PRISTIQ.xml:S1:14373:9	O
Group	PRISTIQ.xml:S1:14383:5	O
Proportion	PRISTIQ.xml:S1:14412:10	O
of	PRISTIQ.xml:S1:14423:2	O
Patients	PRISTIQ.xml:S1:14426:8	O
with	PRISTIQ.xml:S1:14435:4	O
Sustained	PRISTIQ.xml:S1:14440:9	O
Hypertension	PRISTIQ.xml:S1:14450:12	O

Placebo	PRISTIQ.xml:S1:14474:7	O

0.5%	PRISTIQ.xml:S1:14513:4	O

PRISTIQ	PRISTIQ.xml:S1:14573:7	O
50	PRISTIQ.xml:S1:14581:2	O
mg	PRISTIQ.xml:S1:14584:2	O
per	PRISTIQ.xml:S1:14587:3	O
day	PRISTIQ.xml:S1:14591:3	O
1.3%	PRISTIQ.xml:S1:14612:4	O

PRISTIQ	PRISTIQ.xml:S1:14672:7	O
100	PRISTIQ.xml:S1:14680:3	O
mg	PRISTIQ.xml:S1:14684:2	O
per	PRISTIQ.xml:S1:14687:3	O
day	PRISTIQ.xml:S1:14691:3	O
0.7%	PRISTIQ.xml:S1:14711:4	O

PRISTIQ	PRISTIQ.xml:S1:14771:7	O
200	PRISTIQ.xml:S1:14779:3	O
mg	PRISTIQ.xml:S1:14783:2	O
per	PRISTIQ.xml:S1:14786:3	O
day	PRISTIQ.xml:S1:14790:3	O
1.1%	PRISTIQ.xml:S1:14810:4	O

PRISTIQ	PRISTIQ.xml:S1:14870:7	O
400	PRISTIQ.xml:S1:14878:3	O
mg	PRISTIQ.xml:S1:14882:2	O
per	PRISTIQ.xml:S1:14885:3	O
day	PRISTIQ.xml:S1:14889:3	O
2.3%	PRISTIQ.xml:S1:14909:4	O

Orthostatic	PRISTIQ.xml:S1:14981:11	O
hypotension	PRISTIQ.xml:S1:14993:11	O

In	PRISTIQ.xml:S1:15013:2	O

the	PRISTIQ.xml:S1:15016:3	O
pre	PRISTIQ.xml:S1:15020:3	O
-	PRISTIQ.xml:S1:15023:1	O
marketing	PRISTIQ.xml:S1:15024:9	O
short	PRISTIQ.xml:S1:15034:5	O
-	PRISTIQ.xml:S1:15039:1	O
term	PRISTIQ.xml:S1:15040:4	O
,	PRISTIQ.xml:S1:15044:1	O
placebo	PRISTIQ.xml:S1:15046:7	O
-	PRISTIQ.xml:S1:15053:1	O
controlled	PRISTIQ.xml:S1:15054:10	O
clinical	PRISTIQ.xml:S1:15065:8	O
studies	PRISTIQ.xml:S1:15074:7	O
with	PRISTIQ.xml:S1:15082:4	O
doses	PRISTIQ.xml:S1:15087:5	O
of	PRISTIQ.xml:S1:15093:2	O
50	PRISTIQ.xml:S1:15096:2	O
to	PRISTIQ.xml:S1:15099:2	O
400	PRISTIQ.xml:S1:15102:3	O
mg	PRISTIQ.xml:S1:15106:2	O
,	PRISTIQ.xml:S1:15108:1	O
systolic	PRISTIQ.xml:S1:15110:8	B-AdverseReaction
orthostatic	PRISTIQ.xml:S1:15119:11	I-AdverseReaction
hypotension	PRISTIQ.xml:S1:15131:11	I-AdverseReaction
(	PRISTIQ.xml:S1:15143:1	O
decrease	PRISTIQ.xml:S1:15144:8	O
30	PRISTIQ.xml:S1:15155:2	O
mm	PRISTIQ.xml:S1:15158:2	O
Hg	PRISTIQ.xml:S1:15161:2	O
from	PRISTIQ.xml:S1:15164:4	O
supine	PRISTIQ.xml:S1:15169:6	O
to	PRISTIQ.xml:S1:15176:2	O
standing	PRISTIQ.xml:S1:15179:8	O
position	PRISTIQ.xml:S1:15188:8	O
)	PRISTIQ.xml:S1:15196:1	O
occurred	PRISTIQ.xml:S1:15198:8	O
more	PRISTIQ.xml:S1:15207:4	O
frequently	PRISTIQ.xml:S1:15212:10	O
in	PRISTIQ.xml:S1:15223:2	O
patients	PRISTIQ.xml:S1:15226:8	O
65	PRISTIQ.xml:S1:15237:2	O
years	PRISTIQ.xml:S1:15240:5	O
of	PRISTIQ.xml:S1:15246:2	O
age	PRISTIQ.xml:S1:15249:3	O
receiving	PRISTIQ.xml:S1:15253:9	O
PRISTIQ	PRISTIQ.xml:S1:15263:7	O
(	PRISTIQ.xml:S1:15271:1	O
8%	PRISTIQ.xml:S1:15272:2	O
,	PRISTIQ.xml:S1:15274:1	O
7	PRISTIQ.xml:S1:15276:1	O
87	PRISTIQ.xml:S1:15278:2	O
)	PRISTIQ.xml:S1:15280:1	O
versus	PRISTIQ.xml:S1:15282:6	O
placebo	PRISTIQ.xml:S1:15289:7	O
(	PRISTIQ.xml:S1:15297:1	O
2.5%	PRISTIQ.xml:S1:15298:4	O
,	PRISTIQ.xml:S1:15302:1	O
1	PRISTIQ.xml:S1:15304:1	O
40	PRISTIQ.xml:S1:15306:2	O
)	PRISTIQ.xml:S1:15308:1	O
,	PRISTIQ.xml:S1:15309:1	O
compared	PRISTIQ.xml:S1:15311:8	O
to	PRISTIQ.xml:S1:15320:2	O
patients	PRISTIQ.xml:S1:15323:8	O
65	PRISTIQ.xml:S1:15333:2	O
years	PRISTIQ.xml:S1:15336:5	O
of	PRISTIQ.xml:S1:15342:2	O
age	PRISTIQ.xml:S1:15345:3	O
receiving	PRISTIQ.xml:S1:15349:9	O
PRISTIQ	PRISTIQ.xml:S1:15359:7	O
(	PRISTIQ.xml:S1:15367:1	O
0.9%	PRISTIQ.xml:S1:15368:4	O
,	PRISTIQ.xml:S1:15372:1	O
18	PRISTIQ.xml:S1:15374:2	O
1	PRISTIQ.xml:S1:15377:1	O
,	PRISTIQ.xml:S1:15378:1	O
937	PRISTIQ.xml:S1:15379:3	O
)	PRISTIQ.xml:S1:15382:1	O
versus	PRISTIQ.xml:S1:15384:6	O
placebo	PRISTIQ.xml:S1:15391:7	O
(	PRISTIQ.xml:S1:15399:1	O
0.7%	PRISTIQ.xml:S1:15400:4	O
,	PRISTIQ.xml:S1:15404:1	O
8	PRISTIQ.xml:S1:15406:1	O
1	PRISTIQ.xml:S1:15408:1	O
,	PRISTIQ.xml:S1:15409:1	O
218	PRISTIQ.xml:S1:15410:3	O
)	PRISTIQ.xml:S1:15413:1	O
.	PRISTIQ.xml:S1:15414:1	O

6.2	PRISTIQ.xml:S1:15422:3	O
Postmarketing	PRISTIQ.xml:S1:15426:13	O
Experience	PRISTIQ.xml:S1:15440:10	O

The	PRISTIQ.xml:S1:15454:3	O
following	PRISTIQ.xml:S1:15458:9	O
adverse	PRISTIQ.xml:S1:15468:7	O
reaction	PRISTIQ.xml:S1:15476:8	O
has	PRISTIQ.xml:S1:15485:3	O
been	PRISTIQ.xml:S1:15489:4	O
identified	PRISTIQ.xml:S1:15494:10	O
during	PRISTIQ.xml:S1:15505:6	O
post	PRISTIQ.xml:S1:15512:4	O
-	PRISTIQ.xml:S1:15516:1	O
approval	PRISTIQ.xml:S1:15517:8	O
use	PRISTIQ.xml:S1:15526:3	O
of	PRISTIQ.xml:S1:15530:2	O
PRISTIQ	PRISTIQ.xml:S1:15533:7	O
.	PRISTIQ.xml:S1:15540:1	O

Because	PRISTIQ.xml:S1:15542:7	O
these	PRISTIQ.xml:S1:15550:5	O
reactions	PRISTIQ.xml:S1:15556:9	O
are	PRISTIQ.xml:S1:15566:3	O
reported	PRISTIQ.xml:S1:15570:8	O
voluntarily	PRISTIQ.xml:S1:15579:11	O
from	PRISTIQ.xml:S1:15591:4	O
a	PRISTIQ.xml:S1:15596:1	O
population	PRISTIQ.xml:S1:15598:10	O
of	PRISTIQ.xml:S1:15609:2	O
uncertain	PRISTIQ.xml:S1:15612:9	O
size	PRISTIQ.xml:S1:15622:4	O
,	PRISTIQ.xml:S1:15626:1	O
it	PRISTIQ.xml:S1:15628:2	O
is	PRISTIQ.xml:S1:15631:2	O
not	PRISTIQ.xml:S1:15634:3	O
always	PRISTIQ.xml:S1:15638:6	O
possible	PRISTIQ.xml:S1:15645:8	O
to	PRISTIQ.xml:S1:15654:2	O
reliably	PRISTIQ.xml:S1:15657:8	O
estimate	PRISTIQ.xml:S1:15666:8	O
their	PRISTIQ.xml:S1:15675:5	O
frequency	PRISTIQ.xml:S1:15681:9	O
or	PRISTIQ.xml:S1:15691:2	O
establish	PRISTIQ.xml:S1:15694:9	O
a	PRISTIQ.xml:S1:15704:1	O
causal	PRISTIQ.xml:S1:15706:6	O
relationship	PRISTIQ.xml:S1:15713:12	O
to	PRISTIQ.xml:S1:15726:2	O
drug	PRISTIQ.xml:S1:15729:4	O
exposure	PRISTIQ.xml:S1:15734:8	O
:	PRISTIQ.xml:S1:15742:1	O

Skin	PRISTIQ.xml:S1:15752:4	O
and	PRISTIQ.xml:S1:15757:3	O
subcutaneous	PRISTIQ.xml:S1:15761:12	O
tissue	PRISTIQ.xml:S1:15774:6	O
disorders	PRISTIQ.xml:S1:15781:9	O
-	PRISTIQ.xml:S1:15794:1	O
Stevens	PRISTIQ.xml:S1:15796:7	B-AdverseReaction
-	PRISTIQ.xml:S1:15803:1	I-AdverseReaction
Johnson	PRISTIQ.xml:S1:15804:7	I-AdverseReaction
syndrome	PRISTIQ.xml:S1:15812:8	I-AdverseReaction
.	PRISTIQ.xml:S1:15820:1	O
\n\n	PRISTIQ.xml:S2:0:2	O
BOXED	PRISTIQ.xml:S2:6:5	O
WARNING	PRISTIQ.xml:S2:12:7	O
:	PRISTIQ.xml:S2:19:1	O
WARNING	PRISTIQ.xml:S2:21:7	O
:	PRISTIQ.xml:S2:28:1	O
SUICIDAL	PRISTIQ.xml:S2:30:8	B-AdverseReaction
THOUGHTS	PRISTIQ.xml:S2:39:8	I-AdverseReaction
AND	PRISTIQ.xml:S2:48:3	O
BEHAVIORS	PRISTIQ.xml:S2:52:9	I-AdverseReaction
\n\n	PRISTIQ.xml:S2:61:2	O
WARNING	PRISTIQ.xml:S2:67:7	O
:	PRISTIQ.xml:S2:74:1	O
SUICIDAL	PRISTIQ.xml:S2:76:8	B-AdverseReaction
THOUGHTS	PRISTIQ.xml:S2:85:8	I-AdverseReaction
AND	PRISTIQ.xml:S2:94:3	O
BEHAVIORS	PRISTIQ.xml:S2:98:9	I-AdverseReaction
\n\n	PRISTIQ.xml:S2:109:2	O
Antidepressants	PRISTIQ.xml:S2:115:15	B-DrugClass
increased	PRISTIQ.xml:S2:131:9	O
the	PRISTIQ.xml:S2:141:3	O
risk	PRISTIQ.xml:S2:145:4	O
of	PRISTIQ.xml:S2:150:2	O
suicidal	PRISTIQ.xml:S2:153:8	B-AdverseReaction
thoughts	PRISTIQ.xml:S2:162:8	I-AdverseReaction
and	PRISTIQ.xml:S2:171:3	O
behavior	PRISTIQ.xml:S2:175:8	I-AdverseReaction
in	PRISTIQ.xml:S2:184:2	O
children	PRISTIQ.xml:S2:187:8	O
,	PRISTIQ.xml:S2:195:1	O
adolescents	PRISTIQ.xml:S2:197:11	O
,	PRISTIQ.xml:S2:208:1	O
and	PRISTIQ.xml:S2:210:3	O
young	PRISTIQ.xml:S2:214:5	O
adults	PRISTIQ.xml:S2:220:6	O
in	PRISTIQ.xml:S2:227:2	O
short	PRISTIQ.xml:S2:230:5	O
-	PRISTIQ.xml:S2:235:1	O
term	PRISTIQ.xml:S2:236:4	O
studies	PRISTIQ.xml:S2:241:7	O
.	PRISTIQ.xml:S2:248:1	O

These	PRISTIQ.xml:S2:250:5	O
studies	PRISTIQ.xml:S2:256:7	O
did	PRISTIQ.xml:S2:264:3	O
not	PRISTIQ.xml:S2:268:3	B-Negation
show	PRISTIQ.xml:S2:272:4	O
an	PRISTIQ.xml:S2:277:2	O
increase	PRISTIQ.xml:S2:280:8	O
in	PRISTIQ.xml:S2:289:2	O
the	PRISTIQ.xml:S2:292:3	O
risk	PRISTIQ.xml:S2:296:4	O
of	PRISTIQ.xml:S2:301:2	O
suicidal	PRISTIQ.xml:S2:304:8	B-AdverseReaction
thoughts	PRISTIQ.xml:S2:313:8	I-AdverseReaction
and	PRISTIQ.xml:S2:322:3	O
behavior	PRISTIQ.xml:S2:326:8	I-AdverseReaction
with	PRISTIQ.xml:S2:335:4	O
antidepressant	PRISTIQ.xml:S2:340:14	O
use	PRISTIQ.xml:S2:355:3	O
in	PRISTIQ.xml:S2:359:2	O
patients	PRISTIQ.xml:S2:362:8	O
over	PRISTIQ.xml:S2:371:4	O
age	PRISTIQ.xml:S2:376:3	O
24	PRISTIQ.xml:S2:380:2	O
;	PRISTIQ.xml:S2:382:1	O
there	PRISTIQ.xml:S2:384:5	O
was	PRISTIQ.xml:S2:390:3	O
a	PRISTIQ.xml:S2:394:1	O
reduction	PRISTIQ.xml:S2:396:9	O
in	PRISTIQ.xml:S2:406:2	O
risk	PRISTIQ.xml:S2:409:4	O
with	PRISTIQ.xml:S2:414:4	O
antidepressant	PRISTIQ.xml:S2:419:14	O
use	PRISTIQ.xml:S2:434:3	O
in	PRISTIQ.xml:S2:438:2	O
patients	PRISTIQ.xml:S2:441:8	O
aged	PRISTIQ.xml:S2:450:4	O
65	PRISTIQ.xml:S2:455:2	O
and	PRISTIQ.xml:S2:458:3	O
older	PRISTIQ.xml:S2:462:5	O
[	PRISTIQ.xml:S2:468:1	O
see	PRISTIQ.xml:S2:471:3	O
Warnings	PRISTIQ.xml:S2:477:8	O
and	PRISTIQ.xml:S2:486:3	O
Precautions	PRISTIQ.xml:S2:490:11	O
(	PRISTIQ.xml:S2:502:1	O
5.1	PRISTIQ.xml:S2:503:3	O
)	PRISTIQ.xml:S2:506:1	O
]	PRISTIQ.xml:S2:511:1	O
.	PRISTIQ.xml:S2:512:1	O

In	PRISTIQ.xml:S2:523:2	O
patients	PRISTIQ.xml:S2:526:8	O
of	PRISTIQ.xml:S2:535:2	O
all	PRISTIQ.xml:S2:538:3	O
ages	PRISTIQ.xml:S2:542:4	O
who	PRISTIQ.xml:S2:547:3	O
are	PRISTIQ.xml:S2:551:3	O
started	PRISTIQ.xml:S2:555:7	O
on	PRISTIQ.xml:S2:563:2	O
antidepressant	PRISTIQ.xml:S2:566:14	O
therapy	PRISTIQ.xml:S2:581:7	O
,	PRISTIQ.xml:S2:588:1	O
monitor	PRISTIQ.xml:S2:590:7	O
closely	PRISTIQ.xml:S2:598:7	O
for	PRISTIQ.xml:S2:606:3	O
worsening	PRISTIQ.xml:S2:610:9	O
,	PRISTIQ.xml:S2:619:1	O
and	PRISTIQ.xml:S2:621:3	O
for	PRISTIQ.xml:S2:625:3	O
emergence	PRISTIQ.xml:S2:629:9	O
of	PRISTIQ.xml:S2:639:2	O
suicidal	PRISTIQ.xml:S2:642:8	O
thoughts	PRISTIQ.xml:S2:651:8	O
and	PRISTIQ.xml:S2:660:3	O
behaviors	PRISTIQ.xml:S2:664:9	O
.	PRISTIQ.xml:S2:673:1	O

Advise	PRISTIQ.xml:S2:675:6	O
families	PRISTIQ.xml:S2:682:8	O
and	PRISTIQ.xml:S2:691:3	O
caregivers	PRISTIQ.xml:S2:695:10	O
of	PRISTIQ.xml:S2:706:2	O
the	PRISTIQ.xml:S2:709:3	O
need	PRISTIQ.xml:S2:713:4	O
for	PRISTIQ.xml:S2:718:3	O
close	PRISTIQ.xml:S2:722:5	O
observation	PRISTIQ.xml:S2:728:11	O
and	PRISTIQ.xml:S2:740:3	O
communication	PRISTIQ.xml:S2:744:13	O
with	PRISTIQ.xml:S2:758:4	O
the	PRISTIQ.xml:S2:763:3	O
prescriber	PRISTIQ.xml:S2:767:10	O
[	PRISTIQ.xml:S2:778:1	O
see	PRISTIQ.xml:S2:781:3	O
Warnings	PRISTIQ.xml:S2:787:8	O
and	PRISTIQ.xml:S2:796:3	O
Precautions	PRISTIQ.xml:S2:800:11	O
(	PRISTIQ.xml:S2:812:1	O
5.1	PRISTIQ.xml:S2:813:3	O
)	PRISTIQ.xml:S2:816:1	O
]	PRISTIQ.xml:S2:821:1	O
.	PRISTIQ.xml:S2:822:1	O

PRISTIQ	PRISTIQ.xml:S2:833:7	O
is	PRISTIQ.xml:S2:841:2	O
not	PRISTIQ.xml:S2:844:3	O
approved	PRISTIQ.xml:S2:848:8	O
for	PRISTIQ.xml:S2:857:3	O
use	PRISTIQ.xml:S2:861:3	O
in	PRISTIQ.xml:S2:865:2	O
pediatric	PRISTIQ.xml:S2:868:9	O
patients	PRISTIQ.xml:S2:878:8	O
[	PRISTIQ.xml:S2:887:1	O
see	PRISTIQ.xml:S2:890:3	O
Use	PRISTIQ.xml:S2:896:3	O
in	PRISTIQ.xml:S2:900:2	O
Specific	PRISTIQ.xml:S2:903:8	O
Populations	PRISTIQ.xml:S2:912:11	O
(	PRISTIQ.xml:S2:924:1	O
8.4	PRISTIQ.xml:S2:925:3	O
)	PRISTIQ.xml:S2:928:1	O
]	PRISTIQ.xml:S2:933:1	O
.	PRISTIQ.xml:S2:934:1	O

EXCERPT	PRISTIQ.xml:S2:944:7	O
:	PRISTIQ.xml:S2:951:1	O
WARNING	PRISTIQ.xml:S2:955:7	O
:	PRISTIQ.xml:S2:962:1	O
SUICIDAL	PRISTIQ.xml:S2:964:8	B-AdverseReaction
THOUGHTS	PRISTIQ.xml:S2:973:8	I-AdverseReaction
AND	PRISTIQ.xml:S2:982:3	O
BEHAVIORS	PRISTIQ.xml:S2:986:9	I-AdverseReaction
\n\n\n\n	PRISTIQ.xml:S2:995:4	O
See	PRISTIQ.xml:S2:1004:3	O
full	PRISTIQ.xml:S2:1008:4	O
prescribing	PRISTIQ.xml:S2:1013:11	O
information	PRISTIQ.xml:S2:1025:11	O
for	PRISTIQ.xml:S2:1037:3	O
complete	PRISTIQ.xml:S2:1041:8	O
boxed	PRISTIQ.xml:S2:1050:5	O
warning	PRISTIQ.xml:S2:1056:7	O
.	PRISTIQ.xml:S2:1063:1	O

Increased	PRISTIQ.xml:S2:1076:9	O
risk	PRISTIQ.xml:S2:1086:4	O
of	PRISTIQ.xml:S2:1091:2	O
suicidal	PRISTIQ.xml:S2:1094:8	B-AdverseReaction
thinking	PRISTIQ.xml:S2:1103:8	I-AdverseReaction
and	PRISTIQ.xml:S2:1112:3	O
behavior	PRISTIQ.xml:S2:1116:8	I-AdverseReaction
in	PRISTIQ.xml:S2:1125:2	O
children	PRISTIQ.xml:S2:1128:8	O
,	PRISTIQ.xml:S2:1136:1	O
adolescents	PRISTIQ.xml:S2:1138:11	O
and	PRISTIQ.xml:S2:1150:3	O
young	PRISTIQ.xml:S2:1154:5	O
adults	PRISTIQ.xml:S2:1160:6	O
taking	PRISTIQ.xml:S2:1167:6	O
antidepressants	PRISTIQ.xml:S2:1174:15	B-DrugClass
(	PRISTIQ.xml:S2:1190:1	O
5.1	PRISTIQ.xml:S2:1191:3	O
)	PRISTIQ.xml:S2:1194:1	O
.	PRISTIQ.xml:S2:1195:1	O

Monitor	PRISTIQ.xml:S2:1202:7	O
for	PRISTIQ.xml:S2:1210:3	O
worsening	PRISTIQ.xml:S2:1214:9	O
and	PRISTIQ.xml:S2:1224:3	O
emergence	PRISTIQ.xml:S2:1228:9	O
of	PRISTIQ.xml:S2:1238:2	O
suicidal	PRISTIQ.xml:S2:1241:8	O
thoughts	PRISTIQ.xml:S2:1250:8	O
and	PRISTIQ.xml:S2:1259:3	O
behaviors	PRISTIQ.xml:S2:1263:9	O
(	PRISTIQ.xml:S2:1273:1	O
5.1	PRISTIQ.xml:S2:1274:3	O
)	PRISTIQ.xml:S2:1277:1	O
.	PRISTIQ.xml:S2:1278:1	O

PRISTIQ	PRISTIQ.xml:S2:1285:7	O
is	PRISTIQ.xml:S2:1293:2	O
not	PRISTIQ.xml:S2:1296:3	O
approved	PRISTIQ.xml:S2:1300:8	O
for	PRISTIQ.xml:S2:1309:3	O
use	PRISTIQ.xml:S2:1313:3	O
in	PRISTIQ.xml:S2:1317:2	O
pediatric	PRISTIQ.xml:S2:1320:9	O
patients	PRISTIQ.xml:S2:1330:8	O
(	PRISTIQ.xml:S2:1339:1	O
8.4	PRISTIQ.xml:S2:1340:3	O
)	PRISTIQ.xml:S2:1343:1	O
.	PRISTIQ.xml:S2:1344:1	O
\n	PRISTIQ.xml:S2:1346:1	O
5	PRISTIQ.xml:S3:4:1	O
WARNINGS	PRISTIQ.xml:S3:6:8	O
AND	PRISTIQ.xml:S3:15:3	O
PRECAUTIONS	PRISTIQ.xml:S3:19:11	O

EXCERPT	PRISTIQ.xml:S3:37:7	O
:	PRISTIQ.xml:S3:44:1	O
Clinical	PRISTIQ.xml:S3:55:8	B-AdverseReaction
Worsening	PRISTIQ.xml:S3:64:9	I-AdverseReaction
Suicide	PRISTIQ.xml:S3:74:7	B-AdverseReaction
Risk	PRISTIQ.xml:S3:82:4	I-AdverseReaction
:	PRISTIQ.xml:S3:86:1	O
Monitor	PRISTIQ.xml:S3:88:7	O
for	PRISTIQ.xml:S3:96:3	O
clinical	PRISTIQ.xml:S3:100:8	O
worsening	PRISTIQ.xml:S3:109:9	O
and	PRISTIQ.xml:S3:119:3	O
suicide	PRISTIQ.xml:S3:123:7	O
risk	PRISTIQ.xml:S3:131:4	O
(	PRISTIQ.xml:S3:136:1	O
5.1	PRISTIQ.xml:S3:139:3	O
)	PRISTIQ.xml:S3:144:1	O
.	PRISTIQ.xml:S3:145:1	O

Serotonin	PRISTIQ.xml:S3:155:9	B-AdverseReaction
Syndrome	PRISTIQ.xml:S3:165:8	I-AdverseReaction
:	PRISTIQ.xml:S3:173:1	O
Serotonin	PRISTIQ.xml:S3:175:9	B-AdverseReaction
syndrome	PRISTIQ.xml:S3:185:8	I-AdverseReaction
has	PRISTIQ.xml:S3:194:3	O
been	PRISTIQ.xml:S3:198:4	O
reported	PRISTIQ.xml:S3:203:8	O
with	PRISTIQ.xml:S3:212:4	O
SSRIs	PRISTIQ.xml:S3:217:5	O
and	PRISTIQ.xml:S3:223:3	O
SNRIs	PRISTIQ.xml:S3:227:5	O
,	PRISTIQ.xml:S3:232:1	O
including	PRISTIQ.xml:S3:234:9	O
with	PRISTIQ.xml:S3:244:4	O
PRISTIQ	PRISTIQ.xml:S3:249:7	O
,	PRISTIQ.xml:S3:256:1	O
both	PRISTIQ.xml:S3:258:4	O
when	PRISTIQ.xml:S3:263:4	O
taken	PRISTIQ.xml:S3:268:5	O
alone	PRISTIQ.xml:S3:274:5	O
,	PRISTIQ.xml:S3:279:1	O
but	PRISTIQ.xml:S3:281:3	O
especially	PRISTIQ.xml:S3:285:10	O
when	PRISTIQ.xml:S3:296:4	O
co	PRISTIQ.xml:S3:301:2	O
-	PRISTIQ.xml:S3:303:1	O
administered	PRISTIQ.xml:S3:304:12	O
with	PRISTIQ.xml:S3:317:4	O
other	PRISTIQ.xml:S3:322:5	O
serotonergic	PRISTIQ.xml:S3:328:12	O
agents	PRISTIQ.xml:S3:341:6	O
(	PRISTIQ.xml:S3:348:1	O
including	PRISTIQ.xml:S3:349:9	O
triptans	PRISTIQ.xml:S3:359:8	O
,	PRISTIQ.xml:S3:367:1	O
tricyclic	PRISTIQ.xml:S3:369:9	O
antidepressants	PRISTIQ.xml:S3:379:15	O
,	PRISTIQ.xml:S3:394:1	O
fentanyl	PRISTIQ.xml:S3:396:8	O
,	PRISTIQ.xml:S3:404:1	O
lithium	PRISTIQ.xml:S3:406:7	O
,	PRISTIQ.xml:S3:413:1	O
tramadol	PRISTIQ.xml:S3:415:8	O
,	PRISTIQ.xml:S3:423:1	O
tryptophan	PRISTIQ.xml:S3:425:10	O
,	PRISTIQ.xml:S3:435:1	O
buspirone	PRISTIQ.xml:S3:437:9	O
,	PRISTIQ.xml:S3:446:1	O
and	PRISTIQ.xml:S3:448:3	O
St	PRISTIQ.xml:S3:452:2	O
.	PRISTIQ.xml:S3:454:1	O

John	PRISTIQ.xml:S3:456:4	O
's	PRISTIQ.xml:S3:460:2	O
Wort	PRISTIQ.xml:S3:463:4	O
)	PRISTIQ.xml:S3:467:1	O
.	PRISTIQ.xml:S3:468:1	O

If	PRISTIQ.xml:S3:470:2	O
such	PRISTIQ.xml:S3:473:4	O
symptoms	PRISTIQ.xml:S3:478:8	O
occur	PRISTIQ.xml:S3:487:5	O
,	PRISTIQ.xml:S3:492:1	O
discontinue	PRISTIQ.xml:S3:494:11	O
PRISTIQ	PRISTIQ.xml:S3:506:7	O
and	PRISTIQ.xml:S3:514:3	O
initiate	PRISTIQ.xml:S3:518:8	O
supportive	PRISTIQ.xml:S3:527:10	O
treatment	PRISTIQ.xml:S3:538:9	O
.	PRISTIQ.xml:S3:547:1	O

If	PRISTIQ.xml:S3:549:2	O
concomitant	PRISTIQ.xml:S3:552:11	O
use	PRISTIQ.xml:S3:564:3	O
of	PRISTIQ.xml:S3:568:2	O
PRISTIQ	PRISTIQ.xml:S3:571:7	O
with	PRISTIQ.xml:S3:579:4	O
other	PRISTIQ.xml:S3:584:5	O
serotonergic	PRISTIQ.xml:S3:590:12	O
drugs	PRISTIQ.xml:S3:603:5	O
is	PRISTIQ.xml:S3:609:2	O
clinically	PRISTIQ.xml:S3:612:10	O
warranted	PRISTIQ.xml:S3:623:9	O
,	PRISTIQ.xml:S3:632:1	O
patients	PRISTIQ.xml:S3:634:8	O
should	PRISTIQ.xml:S3:643:6	O
be	PRISTIQ.xml:S3:650:2	O
made	PRISTIQ.xml:S3:653:4	O
aware	PRISTIQ.xml:S3:658:5	O
of	PRISTIQ.xml:S3:664:2	O
a	PRISTIQ.xml:S3:667:1	O
potential	PRISTIQ.xml:S3:669:9	O
increased	PRISTIQ.xml:S3:679:9	O
risk	PRISTIQ.xml:S3:689:4	O
for	PRISTIQ.xml:S3:694:3	O
serotonin	PRISTIQ.xml:S3:698:9	O
syndrome	PRISTIQ.xml:S3:708:8	O
,	PRISTIQ.xml:S3:716:1	O
particularly	PRISTIQ.xml:S3:718:12	O
during	PRISTIQ.xml:S3:731:6	O
treatment	PRISTIQ.xml:S3:738:9	O
initiation	PRISTIQ.xml:S3:748:10	O
and	PRISTIQ.xml:S3:759:3	O
dose	PRISTIQ.xml:S3:763:4	O
increases	PRISTIQ.xml:S3:768:9	O
(	PRISTIQ.xml:S3:778:1	O
5.2	PRISTIQ.xml:S3:781:3	O
)	PRISTIQ.xml:S3:786:1	O
.	PRISTIQ.xml:S3:787:1	O

Elevated	PRISTIQ.xml:S3:797:8	B-AdverseReaction
Blood	PRISTIQ.xml:S3:806:5	I-AdverseReaction
Pressure	PRISTIQ.xml:S3:812:8	I-AdverseReaction
:	PRISTIQ.xml:S3:820:1	O
Control	PRISTIQ.xml:S3:822:7	O
hypertension	PRISTIQ.xml:S3:830:12	O
before	PRISTIQ.xml:S3:843:6	O
initiating	PRISTIQ.xml:S3:850:10	O
treatment	PRISTIQ.xml:S3:861:9	O
.	PRISTIQ.xml:S3:870:1	O

Monitor	PRISTIQ.xml:S3:872:7	O
blood	PRISTIQ.xml:S3:880:5	O
pressure	PRISTIQ.xml:S3:886:8	O
regularly	PRISTIQ.xml:S3:895:9	O
during	PRISTIQ.xml:S3:905:6	O
treatment	PRISTIQ.xml:S3:912:9	O
(	PRISTIQ.xml:S3:922:1	O
5.3	PRISTIQ.xml:S3:925:3	O
)	PRISTIQ.xml:S3:930:1	O
.	PRISTIQ.xml:S3:931:1	O

Abnormal	PRISTIQ.xml:S3:941:8	B-AdverseReaction
Bleeding	PRISTIQ.xml:S3:950:8	I-AdverseReaction
:	PRISTIQ.xml:S3:958:1	O
PRISTIQ	PRISTIQ.xml:S3:960:7	O
may	PRISTIQ.xml:S3:968:3	B-Factor
increase	PRISTIQ.xml:S3:972:8	O
risk	PRISTIQ.xml:S3:981:4	O
of	PRISTIQ.xml:S3:986:2	O
bleeding	PRISTIQ.xml:S3:989:8	B-AdverseReaction
events	PRISTIQ.xml:S3:998:6	O
.	PRISTIQ.xml:S3:1004:1	O

Caution	PRISTIQ.xml:S3:1006:7	O
patients	PRISTIQ.xml:S3:1014:8	O
about	PRISTIQ.xml:S3:1023:5	O
risk	PRISTIQ.xml:S3:1029:4	O
of	PRISTIQ.xml:S3:1034:2	O
bleeding	PRISTIQ.xml:S3:1037:8	O
associated	PRISTIQ.xml:S3:1046:10	O
with	PRISTIQ.xml:S3:1057:4	O
concomitant	PRISTIQ.xml:S3:1062:11	O
use	PRISTIQ.xml:S3:1074:3	O
of	PRISTIQ.xml:S3:1078:2	O
PRISTIQ	PRISTIQ.xml:S3:1081:7	O
and	PRISTIQ.xml:S3:1089:3	O
NSAIDs	PRISTIQ.xml:S3:1093:6	O
,	PRISTIQ.xml:S3:1099:1	O
aspirin	PRISTIQ.xml:S3:1101:7	O
,	PRISTIQ.xml:S3:1108:1	O
or	PRISTIQ.xml:S3:1110:2	O
other	PRISTIQ.xml:S3:1113:5	O
drugs	PRISTIQ.xml:S3:1119:5	O
that	PRISTIQ.xml:S3:1125:4	O
affect	PRISTIQ.xml:S3:1130:6	O
coagulation	PRISTIQ.xml:S3:1137:11	O
(	PRISTIQ.xml:S3:1149:1	O
5.4	PRISTIQ.xml:S3:1152:3	O
)	PRISTIQ.xml:S3:1157:1	O
.	PRISTIQ.xml:S3:1158:1	O

Angle	PRISTIQ.xml:S3:1168:5	B-AdverseReaction
Closure	PRISTIQ.xml:S3:1174:7	I-AdverseReaction
Glaucoma	PRISTIQ.xml:S3:1182:8	I-AdverseReaction
:	PRISTIQ.xml:S3:1190:1	O
Angle	PRISTIQ.xml:S3:1192:5	B-AdverseReaction
closure	PRISTIQ.xml:S3:1198:7	I-AdverseReaction
glaucoma	PRISTIQ.xml:S3:1206:8	I-AdverseReaction
has	PRISTIQ.xml:S3:1215:3	O
occurred	PRISTIQ.xml:S3:1219:8	O
in	PRISTIQ.xml:S3:1228:2	O
patients	PRISTIQ.xml:S3:1231:8	O
with	PRISTIQ.xml:S3:1240:4	O
untreated	PRISTIQ.xml:S3:1245:9	O
anatomically	PRISTIQ.xml:S3:1255:12	O
narrow	PRISTIQ.xml:S3:1268:6	O
angles	PRISTIQ.xml:S3:1275:6	O
treated	PRISTIQ.xml:S3:1282:7	O
with	PRISTIQ.xml:S3:1290:4	O
antidepressants	PRISTIQ.xml:S3:1295:15	B-DrugClass
.	PRISTIQ.xml:S3:1310:1	O

(	PRISTIQ.xml:S3:1312:1	O
5.5	PRISTIQ.xml:S3:1315:3	O
)	PRISTIQ.xml:S3:1320:1	O

Activation	PRISTIQ.xml:S3:1330:10	B-AdverseReaction
of	PRISTIQ.xml:S3:1341:2	I-AdverseReaction
Mania	PRISTIQ.xml:S3:1344:5	I-AdverseReaction
Hypomania	PRISTIQ.xml:S3:1350:9	I-AdverseReaction
:	PRISTIQ.xml:S3:1359:1	O
Use	PRISTIQ.xml:S3:1361:3	O
cautiously	PRISTIQ.xml:S3:1365:10	O
in	PRISTIQ.xml:S3:1376:2	O
patients	PRISTIQ.xml:S3:1379:8	O
with	PRISTIQ.xml:S3:1388:4	O
Bipolar	PRISTIQ.xml:S3:1393:7	O
Disorder	PRISTIQ.xml:S3:1401:8	O
.	PRISTIQ.xml:S3:1409:1	O

Caution	PRISTIQ.xml:S3:1411:7	O
patients	PRISTIQ.xml:S3:1419:8	O
about	PRISTIQ.xml:S3:1428:5	O
risk	PRISTIQ.xml:S3:1434:4	O
of	PRISTIQ.xml:S3:1439:2	O
activation	PRISTIQ.xml:S3:1442:10	O
of	PRISTIQ.xml:S3:1453:2	O
mania	PRISTIQ.xml:S3:1456:5	O
hypomania	PRISTIQ.xml:S3:1462:9	O
(	PRISTIQ.xml:S3:1472:1	O
5.6	PRISTIQ.xml:S3:1475:3	O
)	PRISTIQ.xml:S3:1480:1	O
.	PRISTIQ.xml:S3:1481:1	O

Discontinuation	PRISTIQ.xml:S3:1491:15	B-AdverseReaction
Syndrome	PRISTIQ.xml:S3:1507:8	I-AdverseReaction
:	PRISTIQ.xml:S3:1515:1	O
Taper	PRISTIQ.xml:S3:1517:5	O
dose	PRISTIQ.xml:S3:1523:4	O
when	PRISTIQ.xml:S3:1528:4	O
possible	PRISTIQ.xml:S3:1533:8	O
and	PRISTIQ.xml:S3:1542:3	O
monitor	PRISTIQ.xml:S3:1546:7	O
for	PRISTIQ.xml:S3:1554:3	O
discontinuation	PRISTIQ.xml:S3:1558:15	O
symptoms	PRISTIQ.xml:S3:1574:8	O
(	PRISTIQ.xml:S3:1583:1	O
5.7	PRISTIQ.xml:S3:1586:3	O
)	PRISTIQ.xml:S3:1591:1	O
.	PRISTIQ.xml:S3:1592:1	O

Seizure	PRISTIQ.xml:S3:1602:7	B-AdverseReaction
:	PRISTIQ.xml:S3:1609:1	O
Can	PRISTIQ.xml:S3:1611:3	O
occur	PRISTIQ.xml:S3:1615:5	O
.	PRISTIQ.xml:S3:1620:1	O

Use	PRISTIQ.xml:S3:1622:3	O
cautiously	PRISTIQ.xml:S3:1626:10	O
in	PRISTIQ.xml:S3:1637:2	O
patients	PRISTIQ.xml:S3:1640:8	O
with	PRISTIQ.xml:S3:1649:4	O
seizure	PRISTIQ.xml:S3:1654:7	O
disorder	PRISTIQ.xml:S3:1662:8	O
(	PRISTIQ.xml:S3:1671:1	O
5.8	PRISTIQ.xml:S3:1674:3	O
)	PRISTIQ.xml:S3:1679:1	O
.	PRISTIQ.xml:S3:1680:1	O

Hyponatremia	PRISTIQ.xml:S3:1690:12	B-AdverseReaction
:	PRISTIQ.xml:S3:1702:1	O
Can	PRISTIQ.xml:S3:1704:3	O
occur	PRISTIQ.xml:S3:1708:5	O
in	PRISTIQ.xml:S3:1714:2	O
association	PRISTIQ.xml:S3:1717:11	O
with	PRISTIQ.xml:S3:1729:4	O
SIADH	PRISTIQ.xml:S3:1734:5	O
(	PRISTIQ.xml:S3:1740:1	O
5.9	PRISTIQ.xml:S3:1743:3	O
)	PRISTIQ.xml:S3:1748:1	O
.	PRISTIQ.xml:S3:1749:1	O

Interstitial	PRISTIQ.xml:S3:1759:12	B-AdverseReaction
Lung	PRISTIQ.xml:S3:1772:4	I-AdverseReaction
Disease	PRISTIQ.xml:S3:1777:7	I-AdverseReaction
and	PRISTIQ.xml:S3:1785:3	O
Eosinophilic	PRISTIQ.xml:S3:1789:12	B-AdverseReaction
Pneumonia	PRISTIQ.xml:S3:1802:9	I-AdverseReaction
:	PRISTIQ.xml:S3:1811:1	O
Can	PRISTIQ.xml:S3:1813:3	O
occur	PRISTIQ.xml:S3:1817:5	O
(	PRISTIQ.xml:S3:1823:1	O
5.10	PRISTIQ.xml:S3:1826:4	O
)	PRISTIQ.xml:S3:1832:1	O
.	PRISTIQ.xml:S3:1833:1	O

5.1	PRISTIQ.xml:S3:1847:3	O

Suicidal	PRISTIQ.xml:S3:1851:8	O

Thoughts	PRISTIQ.xml:S3:1860:8	O
and	PRISTIQ.xml:S3:1869:3	O
Behaviors	PRISTIQ.xml:S3:1873:9	O
in	PRISTIQ.xml:S3:1883:2	O
Children	PRISTIQ.xml:S3:1886:8	O
,	PRISTIQ.xml:S3:1894:1	O
Adolescents	PRISTIQ.xml:S3:1896:11	O
and	PRISTIQ.xml:S3:1908:3	O
Young	PRISTIQ.xml:S3:1912:5	O
Adults	PRISTIQ.xml:S3:1918:6	O

Patients	PRISTIQ.xml:S3:1930:8	O
with	PRISTIQ.xml:S3:1939:4	O
major	PRISTIQ.xml:S3:1944:5	O
depressive	PRISTIQ.xml:S3:1950:10	O
disorder	PRISTIQ.xml:S3:1961:8	O
(	PRISTIQ.xml:S3:1970:1	O
MDD	PRISTIQ.xml:S3:1971:3	O
)	PRISTIQ.xml:S3:1974:1	O
,	PRISTIQ.xml:S3:1975:1	O
both	PRISTIQ.xml:S3:1977:4	O
adult	PRISTIQ.xml:S3:1982:5	O
and	PRISTIQ.xml:S3:1988:3	O
pediatric	PRISTIQ.xml:S3:1992:9	O
,	PRISTIQ.xml:S3:2001:1	O
may	PRISTIQ.xml:S3:2003:3	O
experience	PRISTIQ.xml:S3:2007:10	O
worsening	PRISTIQ.xml:S3:2018:9	O
of	PRISTIQ.xml:S3:2028:2	O
their	PRISTIQ.xml:S3:2031:5	O
depression	PRISTIQ.xml:S3:2037:10	O
and	PRISTIQ.xml:S3:2048:3	O
or	PRISTIQ.xml:S3:2052:2	O
the	PRISTIQ.xml:S3:2055:3	O
emergence	PRISTIQ.xml:S3:2059:9	O
of	PRISTIQ.xml:S3:2069:2	O
suicidal	PRISTIQ.xml:S3:2072:8	O
ideation	PRISTIQ.xml:S3:2081:8	O
and	PRISTIQ.xml:S3:2090:3	O
behavior	PRISTIQ.xml:S3:2094:8	O
(	PRISTIQ.xml:S3:2103:1	O
suicidality	PRISTIQ.xml:S3:2104:11	O
)	PRISTIQ.xml:S3:2115:1	O
or	PRISTIQ.xml:S3:2117:2	O
unusual	PRISTIQ.xml:S3:2120:7	O
changes	PRISTIQ.xml:S3:2128:7	O
in	PRISTIQ.xml:S3:2136:2	O
behavior	PRISTIQ.xml:S3:2139:8	O
,	PRISTIQ.xml:S3:2147:1	O
whether	PRISTIQ.xml:S3:2149:7	O
or	PRISTIQ.xml:S3:2157:2	O
not	PRISTIQ.xml:S3:2160:3	O
they	PRISTIQ.xml:S3:2164:4	O
are	PRISTIQ.xml:S3:2169:3	O
taking	PRISTIQ.xml:S3:2173:6	O
antidepressant	PRISTIQ.xml:S3:2180:14	O
medications	PRISTIQ.xml:S3:2195:11	O
,	PRISTIQ.xml:S3:2206:1	O
and	PRISTIQ.xml:S3:2208:3	O
this	PRISTIQ.xml:S3:2212:4	O
risk	PRISTIQ.xml:S3:2217:4	O
may	PRISTIQ.xml:S3:2222:3	O
persist	PRISTIQ.xml:S3:2226:7	O
until	PRISTIQ.xml:S3:2234:5	O
significant	PRISTIQ.xml:S3:2240:11	O
remission	PRISTIQ.xml:S3:2252:9	O
occurs	PRISTIQ.xml:S3:2262:6	O
.	PRISTIQ.xml:S3:2268:1	O

Suicide	PRISTIQ.xml:S3:2270:7	O
is	PRISTIQ.xml:S3:2278:2	O
a	PRISTIQ.xml:S3:2281:1	O
known	PRISTIQ.xml:S3:2283:5	O
risk	PRISTIQ.xml:S3:2289:4	O
of	PRISTIQ.xml:S3:2294:2	O
depression	PRISTIQ.xml:S3:2297:10	O
and	PRISTIQ.xml:S3:2308:3	O
certain	PRISTIQ.xml:S3:2312:7	O
other	PRISTIQ.xml:S3:2320:5	O
psychiatric	PRISTIQ.xml:S3:2326:11	O
disorders	PRISTIQ.xml:S3:2338:9	O
,	PRISTIQ.xml:S3:2347:1	O
and	PRISTIQ.xml:S3:2349:3	O
these	PRISTIQ.xml:S3:2353:5	O
disorders	PRISTIQ.xml:S3:2359:9	O
themselves	PRISTIQ.xml:S3:2369:10	O
are	PRISTIQ.xml:S3:2380:3	O
the	PRISTIQ.xml:S3:2384:3	O
strongest	PRISTIQ.xml:S3:2388:9	O
predictors	PRISTIQ.xml:S3:2398:10	O
of	PRISTIQ.xml:S3:2409:2	O
suicide	PRISTIQ.xml:S3:2412:7	O
.	PRISTIQ.xml:S3:2419:1	O

There	PRISTIQ.xml:S3:2421:5	O
has	PRISTIQ.xml:S3:2427:3	O
been	PRISTIQ.xml:S3:2431:4	O
a	PRISTIQ.xml:S3:2436:1	O
long	PRISTIQ.xml:S3:2438:4	O
-	PRISTIQ.xml:S3:2442:1	O
standing	PRISTIQ.xml:S3:2443:8	O
concern	PRISTIQ.xml:S3:2452:7	O
,	PRISTIQ.xml:S3:2459:1	O
however	PRISTIQ.xml:S3:2461:7	O
,	PRISTIQ.xml:S3:2468:1	O
that	PRISTIQ.xml:S3:2470:4	O
antidepressants	PRISTIQ.xml:S3:2475:15	B-DrugClass
may	PRISTIQ.xml:S3:2491:3	O
have	PRISTIQ.xml:S3:2495:4	O
a	PRISTIQ.xml:S3:2500:1	O
role	PRISTIQ.xml:S3:2502:4	O
in	PRISTIQ.xml:S3:2507:2	O
inducing	PRISTIQ.xml:S3:2510:8	O
worsening	PRISTIQ.xml:S3:2519:9	B-AdverseReaction
of	PRISTIQ.xml:S3:2529:2	I-AdverseReaction
depression	PRISTIQ.xml:S3:2532:10	I-AdverseReaction
and	PRISTIQ.xml:S3:2543:3	O
the	PRISTIQ.xml:S3:2547:3	O
emergence	PRISTIQ.xml:S3:2551:9	O
of	PRISTIQ.xml:S3:2561:2	O
suicidality	PRISTIQ.xml:S3:2564:11	B-AdverseReaction
in	PRISTIQ.xml:S3:2576:2	O
certain	PRISTIQ.xml:S3:2579:7	O
patients	PRISTIQ.xml:S3:2587:8	O
during	PRISTIQ.xml:S3:2596:6	O
the	PRISTIQ.xml:S3:2603:3	O
early	PRISTIQ.xml:S3:2607:5	O
phases	PRISTIQ.xml:S3:2613:6	O
of	PRISTIQ.xml:S3:2620:2	O
treatment	PRISTIQ.xml:S3:2623:9	O
.	PRISTIQ.xml:S3:2632:1	O

Pooled	PRISTIQ.xml:S3:2634:6	O
analyses	PRISTIQ.xml:S3:2641:8	O
of	PRISTIQ.xml:S3:2650:2	O
short	PRISTIQ.xml:S3:2653:5	O
-	PRISTIQ.xml:S3:2658:1	O
term	PRISTIQ.xml:S3:2659:4	O
placebo	PRISTIQ.xml:S3:2664:7	O
-	PRISTIQ.xml:S3:2671:1	O
controlled	PRISTIQ.xml:S3:2672:10	O
studies	PRISTIQ.xml:S3:2683:7	O
of	PRISTIQ.xml:S3:2691:2	O
antidepressant	PRISTIQ.xml:S3:2694:14	B-DrugClass
drugs	PRISTIQ.xml:S3:2709:5	I-DrugClass
(	PRISTIQ.xml:S3:2715:1	O
SSRIs	PRISTIQ.xml:S3:2716:5	O
and	PRISTIQ.xml:S3:2722:3	O
others	PRISTIQ.xml:S3:2726:6	O
)	PRISTIQ.xml:S3:2732:1	O
showed	PRISTIQ.xml:S3:2734:6	O
that	PRISTIQ.xml:S3:2741:4	O
these	PRISTIQ.xml:S3:2746:5	O
drugs	PRISTIQ.xml:S3:2752:5	O
increase	PRISTIQ.xml:S3:2758:8	O
the	PRISTIQ.xml:S3:2767:3	O
risk	PRISTIQ.xml:S3:2771:4	O
of	PRISTIQ.xml:S3:2776:2	O
suicidal	PRISTIQ.xml:S3:2779:8	B-AdverseReaction
thinking	PRISTIQ.xml:S3:2788:8	I-AdverseReaction
and	PRISTIQ.xml:S3:2797:3	O
behavior	PRISTIQ.xml:S3:2801:8	I-AdverseReaction
(	PRISTIQ.xml:S3:2810:1	O
suicidality	PRISTIQ.xml:S3:2811:11	B-AdverseReaction
)	PRISTIQ.xml:S3:2822:1	O
in	PRISTIQ.xml:S3:2824:2	O
children	PRISTIQ.xml:S3:2827:8	O
,	PRISTIQ.xml:S3:2835:1	O
adolescents	PRISTIQ.xml:S3:2837:11	O
,	PRISTIQ.xml:S3:2848:1	O
and	PRISTIQ.xml:S3:2850:3	O
young	PRISTIQ.xml:S3:2854:5	O
adults	PRISTIQ.xml:S3:2860:6	O
(	PRISTIQ.xml:S3:2867:1	O
ages	PRISTIQ.xml:S3:2868:4	O
18	PRISTIQ.xml:S3:2873:2	O
to	PRISTIQ.xml:S3:2876:2	O
24	PRISTIQ.xml:S3:2879:2	O
)	PRISTIQ.xml:S3:2881:1	O
with	PRISTIQ.xml:S3:2883:4	O
major	PRISTIQ.xml:S3:2888:5	O
depressive	PRISTIQ.xml:S3:2894:10	O
disorder	PRISTIQ.xml:S3:2905:8	O
(	PRISTIQ.xml:S3:2914:1	O
MDD	PRISTIQ.xml:S3:2915:3	O
)	PRISTIQ.xml:S3:2918:1	O
and	PRISTIQ.xml:S3:2920:3	O
other	PRISTIQ.xml:S3:2924:5	O
psychiatric	PRISTIQ.xml:S3:2930:11	O
disorders	PRISTIQ.xml:S3:2942:9	O
.	PRISTIQ.xml:S3:2951:1	O

Short	PRISTIQ.xml:S3:2953:5	O
-	PRISTIQ.xml:S3:2958:1	O
term	PRISTIQ.xml:S3:2959:4	O
studies	PRISTIQ.xml:S3:2964:7	O
did	PRISTIQ.xml:S3:2972:3	O
not	PRISTIQ.xml:S3:2976:3	B-Negation
show	PRISTIQ.xml:S3:2980:4	O
an	PRISTIQ.xml:S3:2985:2	O
increase	PRISTIQ.xml:S3:2988:8	O
in	PRISTIQ.xml:S3:2997:2	O
the	PRISTIQ.xml:S3:3000:3	O
risk	PRISTIQ.xml:S3:3004:4	O
of	PRISTIQ.xml:S3:3009:2	O
suicidality	PRISTIQ.xml:S3:3012:11	B-AdverseReaction
with	PRISTIQ.xml:S3:3024:4	O
antidepressants	PRISTIQ.xml:S3:3029:15	O
compared	PRISTIQ.xml:S3:3045:8	O
to	PRISTIQ.xml:S3:3054:2	O
placebo	PRISTIQ.xml:S3:3057:7	O
in	PRISTIQ.xml:S3:3065:2	O
adults	PRISTIQ.xml:S3:3068:6	O
beyond	PRISTIQ.xml:S3:3075:6	O
age	PRISTIQ.xml:S3:3082:3	O
24	PRISTIQ.xml:S3:3086:2	O
;	PRISTIQ.xml:S3:3088:1	O
there	PRISTIQ.xml:S3:3090:5	O
was	PRISTIQ.xml:S3:3096:3	O
a	PRISTIQ.xml:S3:3100:1	O
reduction	PRISTIQ.xml:S3:3102:9	O
with	PRISTIQ.xml:S3:3112:4	O
antidepressants	PRISTIQ.xml:S3:3117:15	O
compared	PRISTIQ.xml:S3:3133:8	O
to	PRISTIQ.xml:S3:3142:2	O
placebo	PRISTIQ.xml:S3:3145:7	O
in	PRISTIQ.xml:S3:3153:2	O
adults	PRISTIQ.xml:S3:3156:6	O
aged	PRISTIQ.xml:S3:3163:4	O
65	PRISTIQ.xml:S3:3168:2	O
and	PRISTIQ.xml:S3:3171:3	O
older	PRISTIQ.xml:S3:3175:5	O
.	PRISTIQ.xml:S3:3180:1	O

The	PRISTIQ.xml:S3:3186:3	O
pooled	PRISTIQ.xml:S3:3190:6	O
analyses	PRISTIQ.xml:S3:3197:8	O
of	PRISTIQ.xml:S3:3206:2	O
placebo	PRISTIQ.xml:S3:3209:7	O
-	PRISTIQ.xml:S3:3216:1	O
controlled	PRISTIQ.xml:S3:3217:10	O
studies	PRISTIQ.xml:S3:3228:7	O
in	PRISTIQ.xml:S3:3236:2	O
children	PRISTIQ.xml:S3:3239:8	O
and	PRISTIQ.xml:S3:3248:3	O
adolescents	PRISTIQ.xml:S3:3252:11	O
with	PRISTIQ.xml:S3:3264:4	O
MDD	PRISTIQ.xml:S3:3269:3	O
,	PRISTIQ.xml:S3:3272:1	O
obsessive	PRISTIQ.xml:S3:3274:9	O
compulsive	PRISTIQ.xml:S3:3284:10	O
disorder	PRISTIQ.xml:S3:3295:8	O
(	PRISTIQ.xml:S3:3304:1	O
OCD	PRISTIQ.xml:S3:3305:3	O
)	PRISTIQ.xml:S3:3308:1	O
,	PRISTIQ.xml:S3:3309:1	O
or	PRISTIQ.xml:S3:3311:2	O
other	PRISTIQ.xml:S3:3314:5	O
psychiatric	PRISTIQ.xml:S3:3320:11	O
disorders	PRISTIQ.xml:S3:3332:9	O
included	PRISTIQ.xml:S3:3342:8	O
a	PRISTIQ.xml:S3:3351:1	O
total	PRISTIQ.xml:S3:3353:5	O
of	PRISTIQ.xml:S3:3359:2	O
24	PRISTIQ.xml:S3:3362:2	O
short	PRISTIQ.xml:S3:3365:5	O
-	PRISTIQ.xml:S3:3370:1	O
term	PRISTIQ.xml:S3:3371:4	O
studies	PRISTIQ.xml:S3:3376:7	O
of	PRISTIQ.xml:S3:3384:2	O
9	PRISTIQ.xml:S3:3387:1	O
antidepressant	PRISTIQ.xml:S3:3389:14	O
drugs	PRISTIQ.xml:S3:3404:5	O
in	PRISTIQ.xml:S3:3410:2	O
over	PRISTIQ.xml:S3:3413:4	O
4	PRISTIQ.xml:S3:3418:1	O
,	PRISTIQ.xml:S3:3419:1	O
400	PRISTIQ.xml:S3:3420:3	O
patients	PRISTIQ.xml:S3:3424:8	O
.	PRISTIQ.xml:S3:3432:1	O

The	PRISTIQ.xml:S3:3434:3	O
pooled	PRISTIQ.xml:S3:3438:6	O
analyses	PRISTIQ.xml:S3:3445:8	O
of	PRISTIQ.xml:S3:3454:2	O
placebo	PRISTIQ.xml:S3:3457:7	O
-	PRISTIQ.xml:S3:3464:1	O
controlled	PRISTIQ.xml:S3:3465:10	O
studies	PRISTIQ.xml:S3:3476:7	O
in	PRISTIQ.xml:S3:3484:2	O
adults	PRISTIQ.xml:S3:3487:6	O
with	PRISTIQ.xml:S3:3494:4	O
MDD	PRISTIQ.xml:S3:3499:3	O
or	PRISTIQ.xml:S3:3503:2	O
other	PRISTIQ.xml:S3:3506:5	O
psychiatric	PRISTIQ.xml:S3:3512:11	O
disorders	PRISTIQ.xml:S3:3524:9	O
included	PRISTIQ.xml:S3:3534:8	O
a	PRISTIQ.xml:S3:3543:1	O
total	PRISTIQ.xml:S3:3545:5	O
of	PRISTIQ.xml:S3:3551:2	O
295	PRISTIQ.xml:S3:3554:3	O
short	PRISTIQ.xml:S3:3558:5	O
-	PRISTIQ.xml:S3:3563:1	O
term	PRISTIQ.xml:S3:3564:4	O
studies	PRISTIQ.xml:S3:3569:7	O
(	PRISTIQ.xml:S3:3577:1	O
median	PRISTIQ.xml:S3:3578:6	O
duration	PRISTIQ.xml:S3:3585:8	O
of	PRISTIQ.xml:S3:3594:2	O
2	PRISTIQ.xml:S3:3597:1	O
months	PRISTIQ.xml:S3:3599:6	O
)	PRISTIQ.xml:S3:3605:1	O
of	PRISTIQ.xml:S3:3607:2	O
11	PRISTIQ.xml:S3:3610:2	O
antidepressant	PRISTIQ.xml:S3:3613:14	O
drugs	PRISTIQ.xml:S3:3628:5	O
in	PRISTIQ.xml:S3:3634:2	O
over	PRISTIQ.xml:S3:3637:4	O
77	PRISTIQ.xml:S3:3642:2	O
,	PRISTIQ.xml:S3:3644:1	O
000	PRISTIQ.xml:S3:3645:3	O
patients	PRISTIQ.xml:S3:3649:8	O
.	PRISTIQ.xml:S3:3657:1	O

There	PRISTIQ.xml:S3:3659:5	O
was	PRISTIQ.xml:S3:3665:3	O
considerable	PRISTIQ.xml:S3:3669:12	O
variation	PRISTIQ.xml:S3:3682:9	O
in	PRISTIQ.xml:S3:3692:2	O
risk	PRISTIQ.xml:S3:3695:4	O
of	PRISTIQ.xml:S3:3700:2	O
suicidality	PRISTIQ.xml:S3:3703:11	B-AdverseReaction
among	PRISTIQ.xml:S3:3715:5	O
drugs	PRISTIQ.xml:S3:3721:5	B-DrugClass
,	PRISTIQ.xml:S3:3726:1	O
but	PRISTIQ.xml:S3:3728:3	O
a	PRISTIQ.xml:S3:3732:1	O
tendency	PRISTIQ.xml:S3:3734:8	O
toward	PRISTIQ.xml:S3:3743:6	O
an	PRISTIQ.xml:S3:3750:2	O
increase	PRISTIQ.xml:S3:3753:8	O
in	PRISTIQ.xml:S3:3762:2	O
the	PRISTIQ.xml:S3:3765:3	O
younger	PRISTIQ.xml:S3:3769:7	O
patients	PRISTIQ.xml:S3:3777:8	O
for	PRISTIQ.xml:S3:3786:3	O
almost	PRISTIQ.xml:S3:3790:6	O
all	PRISTIQ.xml:S3:3797:3	O
drugs	PRISTIQ.xml:S3:3801:5	O
studied	PRISTIQ.xml:S3:3807:7	O
.	PRISTIQ.xml:S3:3814:1	O

There	PRISTIQ.xml:S3:3816:5	O
were	PRISTIQ.xml:S3:3822:4	O
differences	PRISTIQ.xml:S3:3827:11	O
in	PRISTIQ.xml:S3:3839:2	O
absolute	PRISTIQ.xml:S3:3842:8	O
risk	PRISTIQ.xml:S3:3851:4	O
of	PRISTIQ.xml:S3:3856:2	O
suicidality	PRISTIQ.xml:S3:3859:11	B-AdverseReaction
across	PRISTIQ.xml:S3:3871:6	O
the	PRISTIQ.xml:S3:3878:3	O
different	PRISTIQ.xml:S3:3882:9	O
indications	PRISTIQ.xml:S3:3892:11	O
,	PRISTIQ.xml:S3:3903:1	O
with	PRISTIQ.xml:S3:3905:4	O
the	PRISTIQ.xml:S3:3910:3	O
highest	PRISTIQ.xml:S3:3914:7	O
incidence	PRISTIQ.xml:S3:3922:9	O
in	PRISTIQ.xml:S3:3932:2	O
MDD	PRISTIQ.xml:S3:3935:3	O
.	PRISTIQ.xml:S3:3938:1	O

The	PRISTIQ.xml:S3:3940:3	O
risk	PRISTIQ.xml:S3:3944:4	O
differences	PRISTIQ.xml:S3:3949:11	O
(	PRISTIQ.xml:S3:3961:1	O
drug	PRISTIQ.xml:S3:3962:4	O
vs	PRISTIQ.xml:S3:3967:2	O
.	PRISTIQ.xml:S3:3969:1	O

placebo	PRISTIQ.xml:S3:3971:7	O
)	PRISTIQ.xml:S3:3978:1	O
,	PRISTIQ.xml:S3:3979:1	O
however	PRISTIQ.xml:S3:3981:7	O
,	PRISTIQ.xml:S3:3988:1	O
were	PRISTIQ.xml:S3:3990:4	O
relatively	PRISTIQ.xml:S3:3995:10	O
stable	PRISTIQ.xml:S3:4006:6	O
within	PRISTIQ.xml:S3:4013:6	O
age	PRISTIQ.xml:S3:4020:3	O
strata	PRISTIQ.xml:S3:4024:6	O
and	PRISTIQ.xml:S3:4031:3	O
across	PRISTIQ.xml:S3:4035:6	O
indications	PRISTIQ.xml:S3:4042:11	O
.	PRISTIQ.xml:S3:4053:1	O

These	PRISTIQ.xml:S3:4055:5	O
risk	PRISTIQ.xml:S3:4061:4	O
differences	PRISTIQ.xml:S3:4066:11	O
(	PRISTIQ.xml:S3:4078:1	O
drug	PRISTIQ.xml:S3:4079:4	O
-	PRISTIQ.xml:S3:4083:1	O
placebo	PRISTIQ.xml:S3:4084:7	O
difference	PRISTIQ.xml:S3:4092:10	O
in	PRISTIQ.xml:S3:4103:2	O
the	PRISTIQ.xml:S3:4106:3	O
number	PRISTIQ.xml:S3:4110:6	O
of	PRISTIQ.xml:S3:4117:2	O
cases	PRISTIQ.xml:S3:4120:5	O
of	PRISTIQ.xml:S3:4126:2	O
suicidality	PRISTIQ.xml:S3:4129:11	B-AdverseReaction
per	PRISTIQ.xml:S3:4141:3	O
1	PRISTIQ.xml:S3:4145:1	O
,	PRISTIQ.xml:S3:4146:1	O
000	PRISTIQ.xml:S3:4147:3	O
patients	PRISTIQ.xml:S3:4151:8	O
treated	PRISTIQ.xml:S3:4160:7	O
)	PRISTIQ.xml:S3:4167:1	O
are	PRISTIQ.xml:S3:4169:3	O
provided	PRISTIQ.xml:S3:4173:8	O
in	PRISTIQ.xml:S3:4182:2	O
Table	PRISTIQ.xml:S3:4185:5	O
1	PRISTIQ.xml:S3:4191:1	O
.	PRISTIQ.xml:S3:4192:1	O

Table	PRISTIQ.xml:S3:4198:5	O
1	PRISTIQ.xml:S3:4204:1	O

Age	PRISTIQ.xml:S3:4209:3	O
Range	PRISTIQ.xml:S3:4213:5	O
Drug	PRISTIQ.xml:S3:4229:4	O
-	PRISTIQ.xml:S3:4233:1	O
Placebo	PRISTIQ.xml:S3:4234:7	O
Difference	PRISTIQ.xml:S3:4242:10	O
in	PRISTIQ.xml:S3:4253:2	O
Number	PRISTIQ.xml:S3:4256:6	O
of	PRISTIQ.xml:S3:4263:2	O
Cases	PRISTIQ.xml:S3:4266:5	O
of	PRISTIQ.xml:S3:4272:2	O
Suicidality	PRISTIQ.xml:S3:4275:11	B-AdverseReaction
per	PRISTIQ.xml:S3:4287:3	O
1	PRISTIQ.xml:S3:4291:1	O
,	PRISTIQ.xml:S3:4292:1	O
000	PRISTIQ.xml:S3:4293:3	O
Patients	PRISTIQ.xml:S3:4297:8	O
Treated	PRISTIQ.xml:S3:4306:7	O

Increases	PRISTIQ.xml:S3:4344:9	O

Compared	PRISTIQ.xml:S3:4354:8	O
to	PRISTIQ.xml:S3:4363:2	O
Placebo	PRISTIQ.xml:S3:4366:7	O

18	PRISTIQ.xml:S3:4419:2	O
14	PRISTIQ.xml:S3:4438:2	O
additional	PRISTIQ.xml:S3:4441:10	O
cases	PRISTIQ.xml:S3:4452:5	O

18	PRISTIQ.xml:S3:4512:2	O
to	PRISTIQ.xml:S3:4515:2	O
24	PRISTIQ.xml:S3:4518:2	O
5	PRISTIQ.xml:S3:4532:1	O
additional	PRISTIQ.xml:S3:4534:10	O
cases	PRISTIQ.xml:S3:4545:5	O

Decreases	PRISTIQ.xml:S3:4626:9	O
Compared	PRISTIQ.xml:S3:4636:8	O
to	PRISTIQ.xml:S3:4645:2	O
Placebo	PRISTIQ.xml:S3:4648:7	O

25	PRISTIQ.xml:S3:4700:2	O
to	PRISTIQ.xml:S3:4703:2	O
64	PRISTIQ.xml:S3:4706:2	O
1	PRISTIQ.xml:S3:4720:1	O
fewer	PRISTIQ.xml:S3:4722:5	O
case	PRISTIQ.xml:S3:4728:4	O

65	PRISTIQ.xml:S3:4796:2	O
6	PRISTIQ.xml:S3:4814:1	O
fewer	PRISTIQ.xml:S3:4816:5	O
cases	PRISTIQ.xml:S3:4822:5	O

No	PRISTIQ.xml:S3:4894:2	B-Negation
suicides	PRISTIQ.xml:S3:4897:8	B-AdverseReaction
occurred	PRISTIQ.xml:S3:4906:8	O
in	PRISTIQ.xml:S3:4915:2	O
any	PRISTIQ.xml:S3:4918:3	O
of	PRISTIQ.xml:S3:4922:2	O
the	PRISTIQ.xml:S3:4925:3	O
pediatric	PRISTIQ.xml:S3:4929:9	O
studies	PRISTIQ.xml:S3:4939:7	O
.	PRISTIQ.xml:S3:4946:1	O

There	PRISTIQ.xml:S3:4948:5	O
were	PRISTIQ.xml:S3:4954:4	O
suicides	PRISTIQ.xml:S3:4959:8	B-AdverseReaction
in	PRISTIQ.xml:S3:4968:2	O
the	PRISTIQ.xml:S3:4971:3	O
adult	PRISTIQ.xml:S3:4975:5	O
studies	PRISTIQ.xml:S3:4981:7	O
,	PRISTIQ.xml:S3:4988:1	O
but	PRISTIQ.xml:S3:4990:3	O
the	PRISTIQ.xml:S3:4994:3	O
number	PRISTIQ.xml:S3:4998:6	O
was	PRISTIQ.xml:S3:5005:3	O
not	PRISTIQ.xml:S3:5009:3	O
sufficient	PRISTIQ.xml:S3:5013:10	O
to	PRISTIQ.xml:S3:5024:2	O
reach	PRISTIQ.xml:S3:5027:5	O
any	PRISTIQ.xml:S3:5033:3	O
conclusion	PRISTIQ.xml:S3:5037:10	O
about	PRISTIQ.xml:S3:5048:5	O
drug	PRISTIQ.xml:S3:5054:4	O
effect	PRISTIQ.xml:S3:5059:6	O
on	PRISTIQ.xml:S3:5066:2	O
suicide	PRISTIQ.xml:S3:5069:7	O
.	PRISTIQ.xml:S3:5076:1	O

It	PRISTIQ.xml:S3:5082:2	O

is	PRISTIQ.xml:S3:5085:2	O
unknown	PRISTIQ.xml:S3:5088:7	O
whether	PRISTIQ.xml:S3:5096:7	O
the	PRISTIQ.xml:S3:5104:3	O
suicidality	PRISTIQ.xml:S3:5108:11	B-AdverseReaction
risk	PRISTIQ.xml:S3:5120:4	B-Factor
extends	PRISTIQ.xml:S3:5125:7	O
to	PRISTIQ.xml:S3:5133:2	O
longer	PRISTIQ.xml:S3:5136:6	O
-	PRISTIQ.xml:S3:5142:1	O
term	PRISTIQ.xml:S3:5143:4	O
use	PRISTIQ.xml:S3:5148:3	O
,	PRISTIQ.xml:S3:5151:1	O
i	PRISTIQ.xml:S3:5153:1	O
.	PRISTIQ.xml:S3:5154:1	O
e	PRISTIQ.xml:S3:5155:1	O
.	PRISTIQ.xml:S3:5156:1	O
,	PRISTIQ.xml:S3:5157:1	O
beyond	PRISTIQ.xml:S3:5159:6	O
several	PRISTIQ.xml:S3:5166:7	O
months	PRISTIQ.xml:S3:5174:6	O
.	PRISTIQ.xml:S3:5180:1	O

However	PRISTIQ.xml:S3:5182:7	O
,	PRISTIQ.xml:S3:5189:1	O
there	PRISTIQ.xml:S3:5191:5	O
is	PRISTIQ.xml:S3:5197:2	O
substantial	PRISTIQ.xml:S3:5200:11	O
evidence	PRISTIQ.xml:S3:5212:8	O
from	PRISTIQ.xml:S3:5221:4	O
placebo	PRISTIQ.xml:S3:5226:7	O
-	PRISTIQ.xml:S3:5233:1	O
controlled	PRISTIQ.xml:S3:5234:10	O
maintenance	PRISTIQ.xml:S3:5245:11	O
studies	PRISTIQ.xml:S3:5257:7	O
in	PRISTIQ.xml:S3:5265:2	O
adults	PRISTIQ.xml:S3:5268:6	O
with	PRISTIQ.xml:S3:5275:4	O
depression	PRISTIQ.xml:S3:5280:10	O
that	PRISTIQ.xml:S3:5291:4	O
the	PRISTIQ.xml:S3:5296:3	O
use	PRISTIQ.xml:S3:5300:3	O
of	PRISTIQ.xml:S3:5304:2	O
antidepressants	PRISTIQ.xml:S3:5307:15	O
can	PRISTIQ.xml:S3:5323:3	O
delay	PRISTIQ.xml:S3:5327:5	O
the	PRISTIQ.xml:S3:5333:3	O
recurrence	PRISTIQ.xml:S3:5337:10	O
of	PRISTIQ.xml:S3:5348:2	O
depression	PRISTIQ.xml:S3:5351:10	O
.	PRISTIQ.xml:S3:5361:1	O

All	PRISTIQ.xml:S3:5368:3	O
patients	PRISTIQ.xml:S3:5372:8	O
being	PRISTIQ.xml:S3:5381:5	O
treated	PRISTIQ.xml:S3:5387:7	O
with	PRISTIQ.xml:S3:5395:4	O
antidepressants	PRISTIQ.xml:S3:5400:15	O
for	PRISTIQ.xml:S3:5416:3	O
any	PRISTIQ.xml:S3:5420:3	O
indication	PRISTIQ.xml:S3:5424:10	O
should	PRISTIQ.xml:S3:5435:6	O
be	PRISTIQ.xml:S3:5442:2	O
monitored	PRISTIQ.xml:S3:5445:9	O
appropriately	PRISTIQ.xml:S3:5455:13	O
and	PRISTIQ.xml:S3:5469:3	O
observed	PRISTIQ.xml:S3:5473:8	O
closely	PRISTIQ.xml:S3:5482:7	O
for	PRISTIQ.xml:S3:5490:3	O
clinical	PRISTIQ.xml:S3:5494:8	O
worsening	PRISTIQ.xml:S3:5503:9	O
,	PRISTIQ.xml:S3:5512:1	O
suicidality	PRISTIQ.xml:S3:5514:11	O
,	PRISTIQ.xml:S3:5525:1	O
and	PRISTIQ.xml:S3:5527:3	O
unusual	PRISTIQ.xml:S3:5531:7	O
changes	PRISTIQ.xml:S3:5539:7	O
in	PRISTIQ.xml:S3:5547:2	O
behavior	PRISTIQ.xml:S3:5550:8	O
,	PRISTIQ.xml:S3:5558:1	O
especially	PRISTIQ.xml:S3:5560:10	O
during	PRISTIQ.xml:S3:5571:6	O
the	PRISTIQ.xml:S3:5578:3	O
initial	PRISTIQ.xml:S3:5582:7	O
few	PRISTIQ.xml:S3:5590:3	O
months	PRISTIQ.xml:S3:5594:6	O
of	PRISTIQ.xml:S3:5601:2	O
a	PRISTIQ.xml:S3:5604:1	O
course	PRISTIQ.xml:S3:5606:6	O
of	PRISTIQ.xml:S3:5613:2	O
drug	PRISTIQ.xml:S3:5616:4	O
therapy	PRISTIQ.xml:S3:5621:7	O
,	PRISTIQ.xml:S3:5628:1	O
or	PRISTIQ.xml:S3:5630:2	O
at	PRISTIQ.xml:S3:5633:2	O
times	PRISTIQ.xml:S3:5636:5	O
of	PRISTIQ.xml:S3:5642:2	O
dose	PRISTIQ.xml:S3:5645:4	O
changes	PRISTIQ.xml:S3:5650:7	O
,	PRISTIQ.xml:S3:5657:1	O
either	PRISTIQ.xml:S3:5659:6	O
increases	PRISTIQ.xml:S3:5666:9	O
or	PRISTIQ.xml:S3:5676:2	O
decreases	PRISTIQ.xml:S3:5679:9	O
.	PRISTIQ.xml:S3:5688:1	O

The	PRISTIQ.xml:S3:5696:3	O
following	PRISTIQ.xml:S3:5700:9	O
symptoms	PRISTIQ.xml:S3:5710:8	O
,	PRISTIQ.xml:S3:5718:1	O
anxiety	PRISTIQ.xml:S3:5720:7	B-AdverseReaction
,	PRISTIQ.xml:S3:5727:1	O
agitation	PRISTIQ.xml:S3:5729:9	B-AdverseReaction
,	PRISTIQ.xml:S3:5738:1	O
panic	PRISTIQ.xml:S3:5740:5	B-AdverseReaction
attacks	PRISTIQ.xml:S3:5746:7	I-AdverseReaction
,	PRISTIQ.xml:S3:5753:1	O
insomnia	PRISTIQ.xml:S3:5755:8	B-AdverseReaction
,	PRISTIQ.xml:S3:5763:1	O
irritability	PRISTIQ.xml:S3:5765:12	B-AdverseReaction
,	PRISTIQ.xml:S3:5777:1	O
hostility	PRISTIQ.xml:S3:5779:9	B-AdverseReaction
,	PRISTIQ.xml:S3:5788:1	O
aggressiveness	PRISTIQ.xml:S3:5790:14	B-AdverseReaction
,	PRISTIQ.xml:S3:5804:1	O
impulsivity	PRISTIQ.xml:S3:5806:11	B-AdverseReaction
,	PRISTIQ.xml:S3:5817:1	O
akathisia	PRISTIQ.xml:S3:5819:9	B-AdverseReaction
(	PRISTIQ.xml:S3:5829:1	O
psychomotor	PRISTIQ.xml:S3:5830:11	B-AdverseReaction
restlessness	PRISTIQ.xml:S3:5842:12	I-AdverseReaction
)	PRISTIQ.xml:S3:5854:1	O
,	PRISTIQ.xml:S3:5855:1	O
hypomania	PRISTIQ.xml:S3:5857:9	B-AdverseReaction
,	PRISTIQ.xml:S3:5866:1	O
and	PRISTIQ.xml:S3:5868:3	O
mania	PRISTIQ.xml:S3:5872:5	B-AdverseReaction
,	PRISTIQ.xml:S3:5877:1	O
have	PRISTIQ.xml:S3:5879:4	O
been	PRISTIQ.xml:S3:5884:4	O
reported	PRISTIQ.xml:S3:5889:8	O
in	PRISTIQ.xml:S3:5898:2	O
adult	PRISTIQ.xml:S3:5901:5	O
and	PRISTIQ.xml:S3:5907:3	O
pediatric	PRISTIQ.xml:S3:5911:9	O
patients	PRISTIQ.xml:S3:5921:8	O
being	PRISTIQ.xml:S3:5930:5	O
treated	PRISTIQ.xml:S3:5936:7	O
with	PRISTIQ.xml:S3:5944:4	O
antidepressants	PRISTIQ.xml:S3:5949:15	B-DrugClass
for	PRISTIQ.xml:S3:5965:3	O
major	PRISTIQ.xml:S3:5969:5	O
depressive	PRISTIQ.xml:S3:5975:10	O
disorder	PRISTIQ.xml:S3:5986:8	O
as	PRISTIQ.xml:S3:5995:2	O
well	PRISTIQ.xml:S3:5998:4	O
as	PRISTIQ.xml:S3:6003:2	O
for	PRISTIQ.xml:S3:6006:3	O
other	PRISTIQ.xml:S3:6010:5	O
indications	PRISTIQ.xml:S3:6016:11	O
,	PRISTIQ.xml:S3:6027:1	O
both	PRISTIQ.xml:S3:6029:4	O
psychiatric	PRISTIQ.xml:S3:6034:11	O
and	PRISTIQ.xml:S3:6046:3	O
nonpsychiatric	PRISTIQ.xml:S3:6050:14	O
.	PRISTIQ.xml:S3:6064:1	O

Although	PRISTIQ.xml:S3:6066:8	O
a	PRISTIQ.xml:S3:6075:1	O
causal	PRISTIQ.xml:S3:6077:6	O
link	PRISTIQ.xml:S3:6084:4	O
between	PRISTIQ.xml:S3:6089:7	O
the	PRISTIQ.xml:S3:6097:3	O
emergence	PRISTIQ.xml:S3:6101:9	O
of	PRISTIQ.xml:S3:6111:2	O
such	PRISTIQ.xml:S3:6114:4	O
symptoms	PRISTIQ.xml:S3:6119:8	O
and	PRISTIQ.xml:S3:6128:3	O
either	PRISTIQ.xml:S3:6132:6	O
the	PRISTIQ.xml:S3:6139:3	O
worsening	PRISTIQ.xml:S3:6143:9	B-AdverseReaction
of	PRISTIQ.xml:S3:6153:2	I-AdverseReaction
depression	PRISTIQ.xml:S3:6156:10	I-AdverseReaction
and	PRISTIQ.xml:S3:6167:3	O
or	PRISTIQ.xml:S3:6171:2	O
the	PRISTIQ.xml:S3:6174:3	O
emergence	PRISTIQ.xml:S3:6178:9	O
of	PRISTIQ.xml:S3:6188:2	O
suicidal	PRISTIQ.xml:S3:6191:8	B-AdverseReaction
impulses	PRISTIQ.xml:S3:6200:8	I-AdverseReaction
has	PRISTIQ.xml:S3:6209:3	O
not	PRISTIQ.xml:S3:6213:3	B-Negation
been	PRISTIQ.xml:S3:6217:4	I-Negation
established	PRISTIQ.xml:S3:6222:11	I-Negation
,	PRISTIQ.xml:S3:6233:1	O
there	PRISTIQ.xml:S3:6235:5	O
is	PRISTIQ.xml:S3:6241:2	O
concern	PRISTIQ.xml:S3:6244:7	O
that	PRISTIQ.xml:S3:6252:4	O
such	PRISTIQ.xml:S3:6257:4	O
symptoms	PRISTIQ.xml:S3:6262:8	O
may	PRISTIQ.xml:S3:6271:3	B-Factor
represent	PRISTIQ.xml:S3:6275:9	O
precursors	PRISTIQ.xml:S3:6285:10	O
to	PRISTIQ.xml:S3:6296:2	O
emerging	PRISTIQ.xml:S3:6299:8	O
suicidality	PRISTIQ.xml:S3:6308:11	B-AdverseReaction
.	PRISTIQ.xml:S3:6319:1	O

Consideration	PRISTIQ.xml:S3:6325:13	O
should	PRISTIQ.xml:S3:6339:6	O
be	PRISTIQ.xml:S3:6346:2	O
given	PRISTIQ.xml:S3:6349:5	O
to	PRISTIQ.xml:S3:6355:2	O
changing	PRISTIQ.xml:S3:6358:8	O
the	PRISTIQ.xml:S3:6367:3	O
therapeutic	PRISTIQ.xml:S3:6371:11	O
regimen	PRISTIQ.xml:S3:6383:7	O
,	PRISTIQ.xml:S3:6390:1	O
including	PRISTIQ.xml:S3:6392:9	O
possibly	PRISTIQ.xml:S3:6402:8	O
discontinuing	PRISTIQ.xml:S3:6411:13	O
the	PRISTIQ.xml:S3:6425:3	O
medication	PRISTIQ.xml:S3:6429:10	O
,	PRISTIQ.xml:S3:6439:1	O
in	PRISTIQ.xml:S3:6441:2	O
patients	PRISTIQ.xml:S3:6444:8	O
whose	PRISTIQ.xml:S3:6453:5	O
depression	PRISTIQ.xml:S3:6459:10	O
is	PRISTIQ.xml:S3:6470:2	O
persistently	PRISTIQ.xml:S3:6473:12	O
worse	PRISTIQ.xml:S3:6486:5	O
,	PRISTIQ.xml:S3:6491:1	O
or	PRISTIQ.xml:S3:6493:2	O
who	PRISTIQ.xml:S3:6496:3	O
are	PRISTIQ.xml:S3:6500:3	O
experiencing	PRISTIQ.xml:S3:6504:12	O
emergent	PRISTIQ.xml:S3:6517:8	O
suicidality	PRISTIQ.xml:S3:6526:11	O
or	PRISTIQ.xml:S3:6538:2	O
symptoms	PRISTIQ.xml:S3:6541:8	O
that	PRISTIQ.xml:S3:6550:4	O
might	PRISTIQ.xml:S3:6555:5	O
be	PRISTIQ.xml:S3:6561:2	O
precursors	PRISTIQ.xml:S3:6564:10	O
to	PRISTIQ.xml:S3:6575:2	O
worsening	PRISTIQ.xml:S3:6578:9	O
depression	PRISTIQ.xml:S3:6588:10	O
or	PRISTIQ.xml:S3:6599:2	O
suicidality	PRISTIQ.xml:S3:6602:11	O
,	PRISTIQ.xml:S3:6613:1	O
especially	PRISTIQ.xml:S3:6615:10	O
if	PRISTIQ.xml:S3:6626:2	O
these	PRISTIQ.xml:S3:6629:5	O
symptoms	PRISTIQ.xml:S3:6635:8	O
are	PRISTIQ.xml:S3:6644:3	O
severe	PRISTIQ.xml:S3:6648:6	O
,	PRISTIQ.xml:S3:6654:1	O
abrupt	PRISTIQ.xml:S3:6656:6	O
in	PRISTIQ.xml:S3:6663:2	O
onset	PRISTIQ.xml:S3:6666:5	O
,	PRISTIQ.xml:S3:6671:1	O
or	PRISTIQ.xml:S3:6673:2	O
were	PRISTIQ.xml:S3:6676:4	O
not	PRISTIQ.xml:S3:6681:3	O
part	PRISTIQ.xml:S3:6685:4	O
of	PRISTIQ.xml:S3:6690:2	O
the	PRISTIQ.xml:S3:6693:3	O
patient	PRISTIQ.xml:S3:6697:7	O
's	PRISTIQ.xml:S3:6704:2	O
presenting	PRISTIQ.xml:S3:6707:10	O
symptoms	PRISTIQ.xml:S3:6718:8	O
.	PRISTIQ.xml:S3:6726:1	O

If	PRISTIQ.xml:S3:6732:2	O
the	PRISTIQ.xml:S3:6735:3	O
decision	PRISTIQ.xml:S3:6739:8	O
has	PRISTIQ.xml:S3:6748:3	O
been	PRISTIQ.xml:S3:6752:4	O
made	PRISTIQ.xml:S3:6757:4	O
to	PRISTIQ.xml:S3:6762:2	O
discontinue	PRISTIQ.xml:S3:6765:11	O
treatment	PRISTIQ.xml:S3:6777:9	O
,	PRISTIQ.xml:S3:6786:1	O
medication	PRISTIQ.xml:S3:6788:10	O
should	PRISTIQ.xml:S3:6799:6	O
be	PRISTIQ.xml:S3:6806:2	O
tapered	PRISTIQ.xml:S3:6809:7	O
,	PRISTIQ.xml:S3:6816:1	O
as	PRISTIQ.xml:S3:6818:2	O
rapidly	PRISTIQ.xml:S3:6821:7	O
as	PRISTIQ.xml:S3:6829:2	O
is	PRISTIQ.xml:S3:6832:2	O
feasible	PRISTIQ.xml:S3:6835:8	O
,	PRISTIQ.xml:S3:6843:1	O
but	PRISTIQ.xml:S3:6845:3	O
with	PRISTIQ.xml:S3:6849:4	O
recognition	PRISTIQ.xml:S3:6854:11	O
that	PRISTIQ.xml:S3:6866:4	O
abrupt	PRISTIQ.xml:S3:6871:6	O
discontinuation	PRISTIQ.xml:S3:6878:15	O
can	PRISTIQ.xml:S3:6894:3	O
be	PRISTIQ.xml:S3:6898:2	O
associated	PRISTIQ.xml:S3:6901:10	O
with	PRISTIQ.xml:S3:6912:4	O
certain	PRISTIQ.xml:S3:6917:7	O
symptoms	PRISTIQ.xml:S3:6925:8	O
[	PRISTIQ.xml:S3:6934:1	O
see	PRISTIQ.xml:S3:6935:3	O
Dosage	PRISTIQ.xml:S3:6940:6	O
and	PRISTIQ.xml:S3:6947:3	O
Administration	PRISTIQ.xml:S3:6951:14	O
(	PRISTIQ.xml:S3:6966:1	O
2.4	PRISTIQ.xml:S3:6967:3	O
)	PRISTIQ.xml:S3:6970:1	O
and	PRISTIQ.xml:S3:6973:3	O
Warnings	PRISTIQ.xml:S3:6978:8	O
and	PRISTIQ.xml:S3:6987:3	O
Precautions	PRISTIQ.xml:S3:6991:11	O
(	PRISTIQ.xml:S3:7003:1	O
5.7	PRISTIQ.xml:S3:7004:3	O
)	PRISTIQ.xml:S3:7007:1	O
for	PRISTIQ.xml:S3:7010:3	O
a	PRISTIQ.xml:S3:7014:1	O
description	PRISTIQ.xml:S3:7016:11	O
of	PRISTIQ.xml:S3:7028:2	O
the	PRISTIQ.xml:S3:7031:3	O
risks	PRISTIQ.xml:S3:7035:5	O
of	PRISTIQ.xml:S3:7041:2	O
discontinuation	PRISTIQ.xml:S3:7044:15	O
of	PRISTIQ.xml:S3:7060:2	O
PRISTIQ	PRISTIQ.xml:S3:7063:7	O
]	PRISTIQ.xml:S3:7070:1	O
.	PRISTIQ.xml:S3:7073:1	O

Families	PRISTIQ.xml:S3:7080:8	O
and	PRISTIQ.xml:S3:7089:3	O
caregivers	PRISTIQ.xml:S3:7093:10	O
of	PRISTIQ.xml:S3:7104:2	O
patients	PRISTIQ.xml:S3:7107:8	O
being	PRISTIQ.xml:S3:7116:5	O
treated	PRISTIQ.xml:S3:7122:7	O
with	PRISTIQ.xml:S3:7130:4	O
antidepressants	PRISTIQ.xml:S3:7135:15	O
for	PRISTIQ.xml:S3:7151:3	O
major	PRISTIQ.xml:S3:7155:5	O
depressive	PRISTIQ.xml:S3:7161:10	O
disorder	PRISTIQ.xml:S3:7172:8	O
or	PRISTIQ.xml:S3:7181:2	O
other	PRISTIQ.xml:S3:7184:5	O
indications	PRISTIQ.xml:S3:7190:11	O
,	PRISTIQ.xml:S3:7201:1	O
both	PRISTIQ.xml:S3:7203:4	O
psychiatric	PRISTIQ.xml:S3:7208:11	O
and	PRISTIQ.xml:S3:7220:3	O
nonpsychiatric	PRISTIQ.xml:S3:7224:14	O
,	PRISTIQ.xml:S3:7238:1	O
should	PRISTIQ.xml:S3:7240:6	O
be	PRISTIQ.xml:S3:7247:2	O
alerted	PRISTIQ.xml:S3:7250:7	O
about	PRISTIQ.xml:S3:7258:5	O
the	PRISTIQ.xml:S3:7264:3	O
need	PRISTIQ.xml:S3:7268:4	O
to	PRISTIQ.xml:S3:7273:2	O
monitor	PRISTIQ.xml:S3:7276:7	O
patients	PRISTIQ.xml:S3:7284:8	O
for	PRISTIQ.xml:S3:7293:3	O
the	PRISTIQ.xml:S3:7297:3	O
emergence	PRISTIQ.xml:S3:7301:9	O
of	PRISTIQ.xml:S3:7311:2	O
agitation	PRISTIQ.xml:S3:7314:9	O
,	PRISTIQ.xml:S3:7323:1	O
irritability	PRISTIQ.xml:S3:7325:12	O
,	PRISTIQ.xml:S3:7337:1	O
unusual	PRISTIQ.xml:S3:7339:7	O
changes	PRISTIQ.xml:S3:7347:7	O
in	PRISTIQ.xml:S3:7355:2	O
behavior	PRISTIQ.xml:S3:7358:8	O
,	PRISTIQ.xml:S3:7366:1	O
and	PRISTIQ.xml:S3:7368:3	O
the	PRISTIQ.xml:S3:7372:3	O
other	PRISTIQ.xml:S3:7376:5	O
symptoms	PRISTIQ.xml:S3:7382:8	O
described	PRISTIQ.xml:S3:7391:9	O
above	PRISTIQ.xml:S3:7401:5	O
,	PRISTIQ.xml:S3:7406:1	O
as	PRISTIQ.xml:S3:7408:2	O
well	PRISTIQ.xml:S3:7411:4	O
as	PRISTIQ.xml:S3:7416:2	O
the	PRISTIQ.xml:S3:7419:3	O
emergence	PRISTIQ.xml:S3:7423:9	O
of	PRISTIQ.xml:S3:7433:2	O
suicidality	PRISTIQ.xml:S3:7436:11	O
,	PRISTIQ.xml:S3:7447:1	O
and	PRISTIQ.xml:S3:7449:3	O
to	PRISTIQ.xml:S3:7453:2	O
report	PRISTIQ.xml:S3:7456:6	O
such	PRISTIQ.xml:S3:7463:4	O
symptoms	PRISTIQ.xml:S3:7468:8	O
immediately	PRISTIQ.xml:S3:7477:11	O
to	PRISTIQ.xml:S3:7489:2	O
healthcare	PRISTIQ.xml:S3:7492:10	O
providers	PRISTIQ.xml:S3:7503:9	O
.	PRISTIQ.xml:S3:7512:1	O

Such	PRISTIQ.xml:S3:7514:4	O
monitoring	PRISTIQ.xml:S3:7519:10	O
should	PRISTIQ.xml:S3:7530:6	O
include	PRISTIQ.xml:S3:7537:7	O
daily	PRISTIQ.xml:S3:7545:5	O
observation	PRISTIQ.xml:S3:7551:11	O
by	PRISTIQ.xml:S3:7563:2	O
families	PRISTIQ.xml:S3:7566:8	O
and	PRISTIQ.xml:S3:7575:3	O
caregivers	PRISTIQ.xml:S3:7579:10	O
.	PRISTIQ.xml:S3:7591:1	O

Prescriptions	PRISTIQ.xml:S3:7597:13	O
for	PRISTIQ.xml:S3:7611:3	O
PRISTIQ	PRISTIQ.xml:S3:7615:7	O
should	PRISTIQ.xml:S3:7623:6	O
be	PRISTIQ.xml:S3:7630:2	O
written	PRISTIQ.xml:S3:7633:7	O
for	PRISTIQ.xml:S3:7641:3	O
the	PRISTIQ.xml:S3:7645:3	O
smallest	PRISTIQ.xml:S3:7649:8	O
quantity	PRISTIQ.xml:S3:7658:8	O
of	PRISTIQ.xml:S3:7667:2	O
tablets	PRISTIQ.xml:S3:7670:7	O
consistent	PRISTIQ.xml:S3:7678:10	O
with	PRISTIQ.xml:S3:7689:4	O
good	PRISTIQ.xml:S3:7694:4	O
patient	PRISTIQ.xml:S3:7699:7	O
management	PRISTIQ.xml:S3:7707:10	O
,	PRISTIQ.xml:S3:7717:1	O
in	PRISTIQ.xml:S3:7719:2	O
order	PRISTIQ.xml:S3:7722:5	O
to	PRISTIQ.xml:S3:7728:2	O
reduce	PRISTIQ.xml:S3:7731:6	O
the	PRISTIQ.xml:S3:7738:3	O
risk	PRISTIQ.xml:S3:7742:4	O
of	PRISTIQ.xml:S3:7747:2	O
overdose	PRISTIQ.xml:S3:7750:8	O
.	PRISTIQ.xml:S3:7758:1	O

Screening	PRISTIQ.xml:S3:7767:9	O
patients	PRISTIQ.xml:S3:7777:8	O
for	PRISTIQ.xml:S3:7786:3	O
bipolar	PRISTIQ.xml:S3:7790:7	O
disorder	PRISTIQ.xml:S3:7798:8	O

A	PRISTIQ.xml:S3:7813:1	O
major	PRISTIQ.xml:S3:7815:5	O
depressive	PRISTIQ.xml:S3:7821:10	O
episode	PRISTIQ.xml:S3:7832:7	O
may	PRISTIQ.xml:S3:7840:3	O
be	PRISTIQ.xml:S3:7844:2	O
the	PRISTIQ.xml:S3:7847:3	O
initial	PRISTIQ.xml:S3:7851:7	O
presentation	PRISTIQ.xml:S3:7859:12	O
of	PRISTIQ.xml:S3:7872:2	O
bipolar	PRISTIQ.xml:S3:7875:7	O
disorder	PRISTIQ.xml:S3:7883:8	O
.	PRISTIQ.xml:S3:7891:1	O

It	PRISTIQ.xml:S3:7893:2	O
is	PRISTIQ.xml:S3:7896:2	O
generally	PRISTIQ.xml:S3:7899:9	O
believed	PRISTIQ.xml:S3:7909:8	O
(	PRISTIQ.xml:S3:7918:1	O
though	PRISTIQ.xml:S3:7919:6	O
not	PRISTIQ.xml:S3:7926:3	O
established	PRISTIQ.xml:S3:7930:11	O
in	PRISTIQ.xml:S3:7942:2	O
controlled	PRISTIQ.xml:S3:7945:10	O
studies	PRISTIQ.xml:S3:7956:7	O
)	PRISTIQ.xml:S3:7963:1	O
that	PRISTIQ.xml:S3:7965:4	O
treating	PRISTIQ.xml:S3:7970:8	O
such	PRISTIQ.xml:S3:7979:4	O
an	PRISTIQ.xml:S3:7984:2	O
episode	PRISTIQ.xml:S3:7987:7	O
with	PRISTIQ.xml:S3:7995:4	O
an	PRISTIQ.xml:S3:8000:2	O
antidepressant	PRISTIQ.xml:S3:8003:14	B-DrugClass
alone	PRISTIQ.xml:S3:8018:5	O
may	PRISTIQ.xml:S3:8024:3	O
increase	PRISTIQ.xml:S3:8028:8	O
the	PRISTIQ.xml:S3:8037:3	O
likelihood	PRISTIQ.xml:S3:8041:10	O
of	PRISTIQ.xml:S3:8052:2	O
precipitation	PRISTIQ.xml:S3:8055:13	B-AdverseReaction
of	PRISTIQ.xml:S3:8069:2	I-AdverseReaction
a	PRISTIQ.xml:S3:8072:1	I-AdverseReaction
mixed	PRISTIQ.xml:S3:8074:5	I-AdverseReaction
manic	PRISTIQ.xml:S3:8080:5	I-AdverseReaction
episode	PRISTIQ.xml:S3:8086:7	I-AdverseReaction
in	PRISTIQ.xml:S3:8094:2	O
patients	PRISTIQ.xml:S3:8097:8	O
at	PRISTIQ.xml:S3:8106:2	O
risk	PRISTIQ.xml:S3:8109:4	O
for	PRISTIQ.xml:S3:8114:3	O
bipolar	PRISTIQ.xml:S3:8118:7	O
disorder	PRISTIQ.xml:S3:8126:8	O
.	PRISTIQ.xml:S3:8134:1	O

Whether	PRISTIQ.xml:S3:8136:7	O
any	PRISTIQ.xml:S3:8144:3	O
of	PRISTIQ.xml:S3:8148:2	O
the	PRISTIQ.xml:S3:8151:3	O
symptoms	PRISTIQ.xml:S3:8155:8	O
described	PRISTIQ.xml:S3:8164:9	O
above	PRISTIQ.xml:S3:8174:5	O
represent	PRISTIQ.xml:S3:8180:9	O
such	PRISTIQ.xml:S3:8190:4	O
a	PRISTIQ.xml:S3:8195:1	O
conversion	PRISTIQ.xml:S3:8197:10	O
is	PRISTIQ.xml:S3:8208:2	O
unknown	PRISTIQ.xml:S3:8211:7	O
.	PRISTIQ.xml:S3:8218:1	O

However	PRISTIQ.xml:S3:8220:7	O
,	PRISTIQ.xml:S3:8227:1	O
prior	PRISTIQ.xml:S3:8229:5	O
to	PRISTIQ.xml:S3:8235:2	O
initiating	PRISTIQ.xml:S3:8238:10	O
treatment	PRISTIQ.xml:S3:8249:9	O
with	PRISTIQ.xml:S3:8259:4	O
an	PRISTIQ.xml:S3:8264:2	O
antidepressant	PRISTIQ.xml:S3:8267:14	O
,	PRISTIQ.xml:S3:8281:1	O
patients	PRISTIQ.xml:S3:8283:8	O
with	PRISTIQ.xml:S3:8292:4	O
depressive	PRISTIQ.xml:S3:8297:10	O
symptoms	PRISTIQ.xml:S3:8308:8	O
should	PRISTIQ.xml:S3:8317:6	O
be	PRISTIQ.xml:S3:8324:2	O
adequately	PRISTIQ.xml:S3:8327:10	O
screened	PRISTIQ.xml:S3:8338:8	O
to	PRISTIQ.xml:S3:8347:2	O
determine	PRISTIQ.xml:S3:8350:9	O
if	PRISTIQ.xml:S3:8360:2	O
they	PRISTIQ.xml:S3:8363:4	O
are	PRISTIQ.xml:S3:8368:3	O
at	PRISTIQ.xml:S3:8372:2	O
risk	PRISTIQ.xml:S3:8375:4	O
for	PRISTIQ.xml:S3:8380:3	O
bipolar	PRISTIQ.xml:S3:8384:7	O
disorder	PRISTIQ.xml:S3:8392:8	O
;	PRISTIQ.xml:S3:8400:1	O
such	PRISTIQ.xml:S3:8402:4	O
screening	PRISTIQ.xml:S3:8407:9	O
should	PRISTIQ.xml:S3:8417:6	O
include	PRISTIQ.xml:S3:8424:7	O
a	PRISTIQ.xml:S3:8432:1	O
detailed	PRISTIQ.xml:S3:8434:8	O
psychiatric	PRISTIQ.xml:S3:8443:11	O
history	PRISTIQ.xml:S3:8455:7	O
,	PRISTIQ.xml:S3:8462:1	O
including	PRISTIQ.xml:S3:8464:9	O
a	PRISTIQ.xml:S3:8474:1	O
family	PRISTIQ.xml:S3:8476:6	O
history	PRISTIQ.xml:S3:8483:7	O
of	PRISTIQ.xml:S3:8491:2	O
suicide	PRISTIQ.xml:S3:8494:7	O
,	PRISTIQ.xml:S3:8501:1	O
bipolar	PRISTIQ.xml:S3:8503:7	O
disorder	PRISTIQ.xml:S3:8511:8	O
,	PRISTIQ.xml:S3:8519:1	O
and	PRISTIQ.xml:S3:8521:3	O
depression	PRISTIQ.xml:S3:8525:10	O
.	PRISTIQ.xml:S3:8535:1	O

It	PRISTIQ.xml:S3:8537:2	O
should	PRISTIQ.xml:S3:8540:6	O
be	PRISTIQ.xml:S3:8547:2	O
noted	PRISTIQ.xml:S3:8550:5	O
that	PRISTIQ.xml:S3:8556:4	O
PRISTIQ	PRISTIQ.xml:S3:8561:7	O
is	PRISTIQ.xml:S3:8569:2	O
not	PRISTIQ.xml:S3:8572:3	O
approved	PRISTIQ.xml:S3:8576:8	O
for	PRISTIQ.xml:S3:8585:3	O
use	PRISTIQ.xml:S3:8589:3	O
in	PRISTIQ.xml:S3:8593:2	O
treating	PRISTIQ.xml:S3:8596:8	O
bipolar	PRISTIQ.xml:S3:8605:7	O
depression	PRISTIQ.xml:S3:8613:10	O
.	PRISTIQ.xml:S3:8623:1	O

5.2	PRISTIQ.xml:S3:8632:3	O
Serotonin	PRISTIQ.xml:S3:8636:9	O
Syndrome	PRISTIQ.xml:S3:8646:8	O

The	PRISTIQ.xml:S3:8660:3	O
development	PRISTIQ.xml:S3:8664:11	O
of	PRISTIQ.xml:S3:8676:2	O
a	PRISTIQ.xml:S3:8679:1	O
potentially	PRISTIQ.xml:S3:8681:11	B-Factor
life	PRISTIQ.xml:S3:8693:4	B-Severity
-	PRISTIQ.xml:S3:8697:1	I-Severity
threatening	PRISTIQ.xml:S3:8698:11	I-Severity
serotonin	PRISTIQ.xml:S3:8710:9	B-AdverseReaction
syndrome	PRISTIQ.xml:S3:8720:8	I-AdverseReaction
has	PRISTIQ.xml:S3:8729:3	O
been	PRISTIQ.xml:S3:8733:4	O
reported	PRISTIQ.xml:S3:8738:8	O
with	PRISTIQ.xml:S3:8747:4	O
SNRIs	PRISTIQ.xml:S3:8752:5	O
and	PRISTIQ.xml:S3:8758:3	O
SSRIs	PRISTIQ.xml:S3:8762:5	O
,	PRISTIQ.xml:S3:8767:1	O
including	PRISTIQ.xml:S3:8769:9	O
PRISTIQ	PRISTIQ.xml:S3:8779:7	O
,	PRISTIQ.xml:S3:8786:1	O
alone	PRISTIQ.xml:S3:8788:5	O
but	PRISTIQ.xml:S3:8794:3	O
particularly	PRISTIQ.xml:S3:8798:12	O
with	PRISTIQ.xml:S3:8811:4	O
concomitant	PRISTIQ.xml:S3:8816:11	O
use	PRISTIQ.xml:S3:8828:3	O
of	PRISTIQ.xml:S3:8832:2	O
other	PRISTIQ.xml:S3:8835:5	O
serotonergic	PRISTIQ.xml:S3:8841:12	O
drugs	PRISTIQ.xml:S3:8854:5	O
(	PRISTIQ.xml:S3:8860:1	O
including	PRISTIQ.xml:S3:8861:9	O
triptans	PRISTIQ.xml:S3:8871:8	O
,	PRISTIQ.xml:S3:8879:1	O
tricyclic	PRISTIQ.xml:S3:8881:9	O
antidepressants	PRISTIQ.xml:S3:8891:15	O
,	PRISTIQ.xml:S3:8906:1	O
fentanyl	PRISTIQ.xml:S3:8908:8	O
,	PRISTIQ.xml:S3:8916:1	O
lithium	PRISTIQ.xml:S3:8918:7	O
,	PRISTIQ.xml:S3:8925:1	O
tramadol	PRISTIQ.xml:S3:8927:8	O
,	PRISTIQ.xml:S3:8935:1	O
tryptophan	PRISTIQ.xml:S3:8937:10	O
,	PRISTIQ.xml:S3:8947:1	O
buspirone	PRISTIQ.xml:S3:8949:9	O
,	PRISTIQ.xml:S3:8958:1	O
and	PRISTIQ.xml:S3:8960:3	O
St	PRISTIQ.xml:S3:8964:2	O
.	PRISTIQ.xml:S3:8966:1	O

John	PRISTIQ.xml:S3:8968:4	O
's	PRISTIQ.xml:S3:8972:2	O
Wort	PRISTIQ.xml:S3:8975:4	O
)	PRISTIQ.xml:S3:8979:1	O
,	PRISTIQ.xml:S3:8980:1	O
and	PRISTIQ.xml:S3:8982:3	O
with	PRISTIQ.xml:S3:8986:4	O
drugs	PRISTIQ.xml:S3:8991:5	O
that	PRISTIQ.xml:S3:8997:4	O
impair	PRISTIQ.xml:S3:9002:6	O
metabolism	PRISTIQ.xml:S3:9009:10	O
of	PRISTIQ.xml:S3:9020:2	O
serotonin	PRISTIQ.xml:S3:9023:9	O
(	PRISTIQ.xml:S3:9033:1	O
in	PRISTIQ.xml:S3:9034:2	O
particular	PRISTIQ.xml:S3:9037:10	O
,	PRISTIQ.xml:S3:9047:1	O
MAOIs	PRISTIQ.xml:S3:9049:5	O
,	PRISTIQ.xml:S3:9054:1	O
both	PRISTIQ.xml:S3:9056:4	O
those	PRISTIQ.xml:S3:9061:5	O
intended	PRISTIQ.xml:S3:9067:8	O
to	PRISTIQ.xml:S3:9076:2	O
treat	PRISTIQ.xml:S3:9079:5	O
psychiatric	PRISTIQ.xml:S3:9085:11	O
disorders	PRISTIQ.xml:S3:9097:9	O
and	PRISTIQ.xml:S3:9107:3	O
also	PRISTIQ.xml:S3:9111:4	O
others	PRISTIQ.xml:S3:9116:6	O
,	PRISTIQ.xml:S3:9122:1	O
such	PRISTIQ.xml:S3:9124:4	O
as	PRISTIQ.xml:S3:9129:2	O
linezolid	PRISTIQ.xml:S3:9132:9	O
and	PRISTIQ.xml:S3:9142:3	O
intravenous	PRISTIQ.xml:S3:9146:11	O
methylene	PRISTIQ.xml:S3:9158:9	O
blue	PRISTIQ.xml:S3:9168:4	O
)	PRISTIQ.xml:S3:9172:1	O
.	PRISTIQ.xml:S3:9173:1	O

Serotonin	PRISTIQ.xml:S3:9179:9	B-AdverseReaction
syndrome	PRISTIQ.xml:S3:9189:8	I-AdverseReaction
symptoms	PRISTIQ.xml:S3:9198:8	O
may	PRISTIQ.xml:S3:9207:3	B-Factor
include	PRISTIQ.xml:S3:9211:7	O
mental	PRISTIQ.xml:S3:9219:6	B-AdverseReaction
status	PRISTIQ.xml:S3:9226:6	I-AdverseReaction
changes	PRISTIQ.xml:S3:9233:7	I-AdverseReaction
(	PRISTIQ.xml:S3:9241:1	O
e	PRISTIQ.xml:S3:9242:1	O
.	PRISTIQ.xml:S3:9243:1	O
g	PRISTIQ.xml:S3:9244:1	O
.	PRISTIQ.xml:S3:9245:1	O
,	PRISTIQ.xml:S3:9246:1	O
agitation	PRISTIQ.xml:S3:9248:9	B-AdverseReaction
,	PRISTIQ.xml:S3:9257:1	O
hallucinations	PRISTIQ.xml:S3:9259:14	B-AdverseReaction
,	PRISTIQ.xml:S3:9273:1	O
delirium	PRISTIQ.xml:S3:9275:8	B-AdverseReaction
,	PRISTIQ.xml:S3:9283:1	O
and	PRISTIQ.xml:S3:9285:3	O
coma	PRISTIQ.xml:S3:9289:4	B-AdverseReaction
)	PRISTIQ.xml:S3:9293:1	O
,	PRISTIQ.xml:S3:9294:1	O
autonomic	PRISTIQ.xml:S3:9296:9	B-AdverseReaction
instability	PRISTIQ.xml:S3:9306:11	I-AdverseReaction
(	PRISTIQ.xml:S3:9318:1	O
e	PRISTIQ.xml:S3:9319:1	O
.	PRISTIQ.xml:S3:9320:1	O
g	PRISTIQ.xml:S3:9321:1	O
.	PRISTIQ.xml:S3:9322:1	O
,	PRISTIQ.xml:S3:9323:1	O
tachycardia	PRISTIQ.xml:S3:9325:11	B-AdverseReaction
,	PRISTIQ.xml:S3:9336:1	O
labile	PRISTIQ.xml:S3:9338:6	B-AdverseReaction
blood	PRISTIQ.xml:S3:9345:5	I-AdverseReaction
pressure	PRISTIQ.xml:S3:9351:8	I-AdverseReaction
,	PRISTIQ.xml:S3:9359:1	O
dizziness	PRISTIQ.xml:S3:9361:9	B-AdverseReaction
,	PRISTIQ.xml:S3:9370:1	O
diaphoresis	PRISTIQ.xml:S3:9372:11	B-AdverseReaction
,	PRISTIQ.xml:S3:9383:1	O
flushing	PRISTIQ.xml:S3:9385:8	B-AdverseReaction
,	PRISTIQ.xml:S3:9393:1	O
hyperthermia	PRISTIQ.xml:S3:9395:12	B-AdverseReaction
)	PRISTIQ.xml:S3:9407:1	O
,	PRISTIQ.xml:S3:9408:1	O
neuromuscular	PRISTIQ.xml:S3:9410:13	B-AdverseReaction
symptoms	PRISTIQ.xml:S3:9424:8	I-AdverseReaction
(	PRISTIQ.xml:S3:9433:1	O
e	PRISTIQ.xml:S3:9434:1	O
.	PRISTIQ.xml:S3:9435:1	O
g	PRISTIQ.xml:S3:9436:1	O
.	PRISTIQ.xml:S3:9437:1	O
,	PRISTIQ.xml:S3:9438:1	O
tremor	PRISTIQ.xml:S3:9440:6	B-AdverseReaction
,	PRISTIQ.xml:S3:9446:1	O
rigidity	PRISTIQ.xml:S3:9448:8	B-AdverseReaction
,	PRISTIQ.xml:S3:9456:1	O
myoclonus	PRISTIQ.xml:S3:9458:9	B-AdverseReaction
,	PRISTIQ.xml:S3:9467:1	O
hyperreflexia	PRISTIQ.xml:S3:9469:13	B-AdverseReaction
,	PRISTIQ.xml:S3:9482:1	O
incoordination	PRISTIQ.xml:S3:9484:14	B-AdverseReaction
)	PRISTIQ.xml:S3:9498:1	O
,	PRISTIQ.xml:S3:9499:1	O
seizures	PRISTIQ.xml:S3:9501:8	B-AdverseReaction
,	PRISTIQ.xml:S3:9509:1	O
and	PRISTIQ.xml:S3:9511:3	O
or	PRISTIQ.xml:S3:9515:2	O
gastrointestinal	PRISTIQ.xml:S3:9518:16	B-AdverseReaction
symptoms	PRISTIQ.xml:S3:9535:8	I-AdverseReaction
(	PRISTIQ.xml:S3:9544:1	O
e	PRISTIQ.xml:S3:9545:1	O
.	PRISTIQ.xml:S3:9546:1	O
g	PRISTIQ.xml:S3:9547:1	O
.	PRISTIQ.xml:S3:9548:1	O
,	PRISTIQ.xml:S3:9549:1	O
nausea	PRISTIQ.xml:S3:9551:6	B-AdverseReaction
,	PRISTIQ.xml:S3:9557:1	O
vomiting	PRISTIQ.xml:S3:9559:8	B-AdverseReaction
,	PRISTIQ.xml:S3:9567:1	O
diarrhea	PRISTIQ.xml:S3:9569:8	B-AdverseReaction
)	PRISTIQ.xml:S3:9577:1	O
.	PRISTIQ.xml:S3:9578:1	O

Patients	PRISTIQ.xml:S3:9580:8	O
should	PRISTIQ.xml:S3:9589:6	O
be	PRISTIQ.xml:S3:9596:2	O
monitored	PRISTIQ.xml:S3:9599:9	O
for	PRISTIQ.xml:S3:9609:3	O
the	PRISTIQ.xml:S3:9613:3	O
emergence	PRISTIQ.xml:S3:9617:9	O
of	PRISTIQ.xml:S3:9627:2	O
serotonin	PRISTIQ.xml:S3:9630:9	O
syndrome	PRISTIQ.xml:S3:9640:8	O
.	PRISTIQ.xml:S3:9648:1	O

The	PRISTIQ.xml:S3:9654:3	O
concomitant	PRISTIQ.xml:S3:9658:11	O
use	PRISTIQ.xml:S3:9670:3	O
of	PRISTIQ.xml:S3:9674:2	O
PRISTIQ	PRISTIQ.xml:S3:9677:7	O
with	PRISTIQ.xml:S3:9685:4	O
MAOIs	PRISTIQ.xml:S3:9690:5	O
intended	PRISTIQ.xml:S3:9696:8	O
to	PRISTIQ.xml:S3:9705:2	O
treat	PRISTIQ.xml:S3:9708:5	O
psychiatric	PRISTIQ.xml:S3:9714:11	O
disorders	PRISTIQ.xml:S3:9726:9	O
is	PRISTIQ.xml:S3:9736:2	O
contraindicated	PRISTIQ.xml:S3:9739:15	O
.	PRISTIQ.xml:S3:9754:1	O

PRISTIQ	PRISTIQ.xml:S3:9756:7	O
should	PRISTIQ.xml:S3:9764:6	O
also	PRISTIQ.xml:S3:9771:4	O
not	PRISTIQ.xml:S3:9776:3	O
be	PRISTIQ.xml:S3:9780:2	O
started	PRISTIQ.xml:S3:9783:7	O
in	PRISTIQ.xml:S3:9791:2	O
a	PRISTIQ.xml:S3:9794:1	O
patient	PRISTIQ.xml:S3:9796:7	O
who	PRISTIQ.xml:S3:9804:3	O
is	PRISTIQ.xml:S3:9808:2	O
being	PRISTIQ.xml:S3:9811:5	O
treated	PRISTIQ.xml:S3:9817:7	O
with	PRISTIQ.xml:S3:9825:4	O
MAOIs	PRISTIQ.xml:S3:9830:5	O
such	PRISTIQ.xml:S3:9836:4	O
as	PRISTIQ.xml:S3:9841:2	O
linezolid	PRISTIQ.xml:S3:9844:9	O
or	PRISTIQ.xml:S3:9854:2	O
intravenous	PRISTIQ.xml:S3:9857:11	O
methylene	PRISTIQ.xml:S3:9869:9	O
blue	PRISTIQ.xml:S3:9879:4	O
.	PRISTIQ.xml:S3:9883:1	O

All	PRISTIQ.xml:S3:9885:3	O
reports	PRISTIQ.xml:S3:9889:7	O
with	PRISTIQ.xml:S3:9897:4	O
methylene	PRISTIQ.xml:S3:9902:9	O
blue	PRISTIQ.xml:S3:9912:4	O
that	PRISTIQ.xml:S3:9917:4	O
provided	PRISTIQ.xml:S3:9922:8	O
information	PRISTIQ.xml:S3:9931:11	O
on	PRISTIQ.xml:S3:9943:2	O
the	PRISTIQ.xml:S3:9946:3	O
route	PRISTIQ.xml:S3:9950:5	O
of	PRISTIQ.xml:S3:9956:2	O
administration	PRISTIQ.xml:S3:9959:14	O
involved	PRISTIQ.xml:S3:9974:8	O
intravenous	PRISTIQ.xml:S3:9983:11	O
administration	PRISTIQ.xml:S3:9995:14	O
in	PRISTIQ.xml:S3:10010:2	O
the	PRISTIQ.xml:S3:10013:3	O
dose	PRISTIQ.xml:S3:10017:4	O
range	PRISTIQ.xml:S3:10022:5	O
of	PRISTIQ.xml:S3:10028:2	O
1	PRISTIQ.xml:S3:10031:1	O
mg	PRISTIQ.xml:S3:10033:2	O
kg	PRISTIQ.xml:S3:10036:2	O
to	PRISTIQ.xml:S3:10039:2	O
8	PRISTIQ.xml:S3:10042:1	O
mg	PRISTIQ.xml:S3:10044:2	O
kg	PRISTIQ.xml:S3:10047:2	O
.	PRISTIQ.xml:S3:10049:1	O

No	PRISTIQ.xml:S3:10051:2	O
reports	PRISTIQ.xml:S3:10054:7	O
involved	PRISTIQ.xml:S3:10062:8	O
the	PRISTIQ.xml:S3:10071:3	O
administration	PRISTIQ.xml:S3:10075:14	O
of	PRISTIQ.xml:S3:10090:2	O
methylene	PRISTIQ.xml:S3:10093:9	O
blue	PRISTIQ.xml:S3:10103:4	O
by	PRISTIQ.xml:S3:10108:2	O
other	PRISTIQ.xml:S3:10111:5	O
routes	PRISTIQ.xml:S3:10117:6	O
(	PRISTIQ.xml:S3:10124:1	O
such	PRISTIQ.xml:S3:10125:4	O
as	PRISTIQ.xml:S3:10130:2	O
oral	PRISTIQ.xml:S3:10133:4	O
tablets	PRISTIQ.xml:S3:10138:7	O
or	PRISTIQ.xml:S3:10146:2	O
local	PRISTIQ.xml:S3:10149:5	O
tissue	PRISTIQ.xml:S3:10155:6	O
injection	PRISTIQ.xml:S3:10162:9	O
)	PRISTIQ.xml:S3:10171:1	O
or	PRISTIQ.xml:S3:10173:2	O
at	PRISTIQ.xml:S3:10176:2	O
lower	PRISTIQ.xml:S3:10179:5	O
doses	PRISTIQ.xml:S3:10185:5	O
.	PRISTIQ.xml:S3:10190:1	O

There	PRISTIQ.xml:S3:10192:5	O
may	PRISTIQ.xml:S3:10198:3	O
be	PRISTIQ.xml:S3:10202:2	O
circumstances	PRISTIQ.xml:S3:10205:13	O
when	PRISTIQ.xml:S3:10219:4	O
it	PRISTIQ.xml:S3:10224:2	O
is	PRISTIQ.xml:S3:10227:2	O
necessary	PRISTIQ.xml:S3:10230:9	O
to	PRISTIQ.xml:S3:10240:2	O
initiate	PRISTIQ.xml:S3:10243:8	O
treatment	PRISTIQ.xml:S3:10252:9	O
with	PRISTIQ.xml:S3:10262:4	O
a	PRISTIQ.xml:S3:10267:1	O
MAOI	PRISTIQ.xml:S3:10269:4	O
such	PRISTIQ.xml:S3:10274:4	O
as	PRISTIQ.xml:S3:10279:2	O
linezolid	PRISTIQ.xml:S3:10282:9	O
or	PRISTIQ.xml:S3:10292:2	O
intravenous	PRISTIQ.xml:S3:10295:11	O
methylene	PRISTIQ.xml:S3:10307:9	O
blue	PRISTIQ.xml:S3:10317:4	O
in	PRISTIQ.xml:S3:10322:2	O
a	PRISTIQ.xml:S3:10325:1	O
patient	PRISTIQ.xml:S3:10327:7	O
taking	PRISTIQ.xml:S3:10335:6	O
PRISTIQ	PRISTIQ.xml:S3:10342:7	O
.	PRISTIQ.xml:S3:10349:1	O

PRISTIQ	PRISTIQ.xml:S3:10351:7	O
should	PRISTIQ.xml:S3:10359:6	O
be	PRISTIQ.xml:S3:10366:2	O
discontinued	PRISTIQ.xml:S3:10369:12	O
before	PRISTIQ.xml:S3:10382:6	O
initiating	PRISTIQ.xml:S3:10389:10	O
treatment	PRISTIQ.xml:S3:10400:9	O
with	PRISTIQ.xml:S3:10410:4	O
the	PRISTIQ.xml:S3:10415:3	O
MAOI	PRISTIQ.xml:S3:10419:4	O
[	PRISTIQ.xml:S3:10424:1	O
see	PRISTIQ.xml:S3:10425:3	O
Contraindications	PRISTIQ.xml:S3:10429:17	O
(	PRISTIQ.xml:S3:10447:1	O
4.2	PRISTIQ.xml:S3:10448:3	O
)	PRISTIQ.xml:S3:10451:1	O
and	PRISTIQ.xml:S3:10454:3	O
Dosage	PRISTIQ.xml:S3:10460:6	O
and	PRISTIQ.xml:S3:10467:3	O
Administration	PRISTIQ.xml:S3:10471:14	O
(	PRISTIQ.xml:S3:10486:1	O
2.6	PRISTIQ.xml:S3:10487:3	O
)	PRISTIQ.xml:S3:10490:1	O
]	PRISTIQ.xml:S3:10493:1	O
.	PRISTIQ.xml:S3:10496:1	O

If	PRISTIQ.xml:S3:10502:2	O
concomitant	PRISTIQ.xml:S3:10505:11	O
use	PRISTIQ.xml:S3:10517:3	O
of	PRISTIQ.xml:S3:10521:2	O
PRISTIQ	PRISTIQ.xml:S3:10524:7	O
with	PRISTIQ.xml:S3:10532:4	O
other	PRISTIQ.xml:S3:10537:5	O
serotonergic	PRISTIQ.xml:S3:10543:12	O
drugs	PRISTIQ.xml:S3:10556:5	O
,	PRISTIQ.xml:S3:10561:1	O
including	PRISTIQ.xml:S3:10563:9	O
triptans	PRISTIQ.xml:S3:10573:8	O
,	PRISTIQ.xml:S3:10581:1	O
tricyclic	PRISTIQ.xml:S3:10583:9	O
antidepressants	PRISTIQ.xml:S3:10593:15	O
,	PRISTIQ.xml:S3:10608:1	O
fentanyl	PRISTIQ.xml:S3:10610:8	O
,	PRISTIQ.xml:S3:10618:1	O
lithium	PRISTIQ.xml:S3:10620:7	O
,	PRISTIQ.xml:S3:10627:1	O
tramadol	PRISTIQ.xml:S3:10629:8	O
,	PRISTIQ.xml:S3:10637:1	O
buspirone	PRISTIQ.xml:S3:10639:9	O
,	PRISTIQ.xml:S3:10648:1	O
tryptophan	PRISTIQ.xml:S3:10650:10	O
,	PRISTIQ.xml:S3:10660:1	O
and	PRISTIQ.xml:S3:10662:3	O
St	PRISTIQ.xml:S3:10666:2	O
.	PRISTIQ.xml:S3:10668:1	O

John	PRISTIQ.xml:S3:10670:4	O
's	PRISTIQ.xml:S3:10674:2	O
Wort	PRISTIQ.xml:S3:10677:4	O
is	PRISTIQ.xml:S3:10682:2	O
clinically	PRISTIQ.xml:S3:10685:10	O
warranted	PRISTIQ.xml:S3:10696:9	O
,	PRISTIQ.xml:S3:10705:1	O
patients	PRISTIQ.xml:S3:10707:8	O
should	PRISTIQ.xml:S3:10716:6	O
be	PRISTIQ.xml:S3:10723:2	O
made	PRISTIQ.xml:S3:10726:4	O
aware	PRISTIQ.xml:S3:10731:5	O
of	PRISTIQ.xml:S3:10737:2	O
a	PRISTIQ.xml:S3:10740:1	O
potential	PRISTIQ.xml:S3:10742:9	O
increased	PRISTIQ.xml:S3:10752:9	O
risk	PRISTIQ.xml:S3:10762:4	O
for	PRISTIQ.xml:S3:10767:3	O
serotonin	PRISTIQ.xml:S3:10771:9	O
syndrome	PRISTIQ.xml:S3:10781:8	O
,	PRISTIQ.xml:S3:10789:1	O
particularly	PRISTIQ.xml:S3:10791:12	O
during	PRISTIQ.xml:S3:10804:6	O
treatment	PRISTIQ.xml:S3:10811:9	O
initiation	PRISTIQ.xml:S3:10821:10	O
and	PRISTIQ.xml:S3:10832:3	O
dose	PRISTIQ.xml:S3:10836:4	O
increases	PRISTIQ.xml:S3:10841:9	O
.	PRISTIQ.xml:S3:10850:1	O

Treatment	PRISTIQ.xml:S3:10856:9	O
with	PRISTIQ.xml:S3:10866:4	O
PRISTIQ	PRISTIQ.xml:S3:10871:7	O
and	PRISTIQ.xml:S3:10879:3	O
any	PRISTIQ.xml:S3:10883:3	O
concomitant	PRISTIQ.xml:S3:10887:11	O
serotonergic	PRISTIQ.xml:S3:10899:12	O
agents	PRISTIQ.xml:S3:10912:6	O
should	PRISTIQ.xml:S3:10919:6	O
be	PRISTIQ.xml:S3:10926:2	O
discontinued	PRISTIQ.xml:S3:10929:12	O
immediately	PRISTIQ.xml:S3:10942:11	O
if	PRISTIQ.xml:S3:10954:2	O
the	PRISTIQ.xml:S3:10957:3	O
above	PRISTIQ.xml:S3:10961:5	O
events	PRISTIQ.xml:S3:10967:6	O
occur	PRISTIQ.xml:S3:10974:5	O
and	PRISTIQ.xml:S3:10980:3	O
supportive	PRISTIQ.xml:S3:10984:10	O
symptomatic	PRISTIQ.xml:S3:10995:11	O
treatment	PRISTIQ.xml:S3:11007:9	O
should	PRISTIQ.xml:S3:11017:6	O
be	PRISTIQ.xml:S3:11024:2	O
initiated	PRISTIQ.xml:S3:11027:9	O
.	PRISTIQ.xml:S3:11036:1	O

5.3	PRISTIQ.xml:S3:11045:3	O
Elevated	PRISTIQ.xml:S3:11049:8	O
Blood	PRISTIQ.xml:S3:11058:5	O
Pressure	PRISTIQ.xml:S3:11064:8	O

Patients	PRISTIQ.xml:S3:11078:8	O
receiving	PRISTIQ.xml:S3:11087:9	O
PRISTIQ	PRISTIQ.xml:S3:11097:7	O
should	PRISTIQ.xml:S3:11105:6	O
have	PRISTIQ.xml:S3:11112:4	O
regular	PRISTIQ.xml:S3:11117:7	O
monitoring	PRISTIQ.xml:S3:11125:10	O
of	PRISTIQ.xml:S3:11136:2	O
blood	PRISTIQ.xml:S3:11139:5	O
pressure	PRISTIQ.xml:S3:11145:8	O
since	PRISTIQ.xml:S3:11154:5	O
increases	PRISTIQ.xml:S3:11160:9	B-AdverseReaction
in	PRISTIQ.xml:S3:11170:2	I-AdverseReaction
blood	PRISTIQ.xml:S3:11173:5	I-AdverseReaction
pressure	PRISTIQ.xml:S3:11179:8	I-AdverseReaction
were	PRISTIQ.xml:S3:11188:4	O
observed	PRISTIQ.xml:S3:11193:8	O
in	PRISTIQ.xml:S3:11202:2	O
clinical	PRISTIQ.xml:S3:11205:8	O
studies	PRISTIQ.xml:S3:11214:7	O
[	PRISTIQ.xml:S3:11222:1	O
see	PRISTIQ.xml:S3:11223:3	O
Adverse	PRISTIQ.xml:S3:11228:7	O
Reactions	PRISTIQ.xml:S3:11236:9	O
(	PRISTIQ.xml:S3:11246:1	O
6.1	PRISTIQ.xml:S3:11247:3	O
)	PRISTIQ.xml:S3:11250:1	O
]	PRISTIQ.xml:S3:11253:1	O
.	PRISTIQ.xml:S3:11256:1	O

Pre	PRISTIQ.xml:S3:11258:3	O
-	PRISTIQ.xml:S3:11261:1	O
existing	PRISTIQ.xml:S3:11262:8	O
hypertension	PRISTIQ.xml:S3:11271:12	O
should	PRISTIQ.xml:S3:11284:6	O
be	PRISTIQ.xml:S3:11291:2	O
controlled	PRISTIQ.xml:S3:11294:10	O
before	PRISTIQ.xml:S3:11305:6	O
initiating	PRISTIQ.xml:S3:11312:10	O
treatment	PRISTIQ.xml:S3:11323:9	O
with	PRISTIQ.xml:S3:11333:4	O
PRISTIQ	PRISTIQ.xml:S3:11338:7	O
.	PRISTIQ.xml:S3:11345:1	O

Caution	PRISTIQ.xml:S3:11347:7	O
should	PRISTIQ.xml:S3:11355:6	O
be	PRISTIQ.xml:S3:11362:2	O
exercised	PRISTIQ.xml:S3:11365:9	O
in	PRISTIQ.xml:S3:11375:2	O
treating	PRISTIQ.xml:S3:11378:8	O
patients	PRISTIQ.xml:S3:11387:8	O
with	PRISTIQ.xml:S3:11396:4	O
pre	PRISTIQ.xml:S3:11401:3	O
-	PRISTIQ.xml:S3:11404:1	O
existing	PRISTIQ.xml:S3:11405:8	O
hypertension	PRISTIQ.xml:S3:11414:12	O
,	PRISTIQ.xml:S3:11426:1	O
cardiovascular	PRISTIQ.xml:S3:11428:14	O
,	PRISTIQ.xml:S3:11442:1	O
or	PRISTIQ.xml:S3:11444:2	O
cerebrovascular	PRISTIQ.xml:S3:11447:15	O
conditions	PRISTIQ.xml:S3:11463:10	O
that	PRISTIQ.xml:S3:11474:4	O
might	PRISTIQ.xml:S3:11479:5	O
be	PRISTIQ.xml:S3:11485:2	O
compromised	PRISTIQ.xml:S3:11488:11	O
by	PRISTIQ.xml:S3:11500:2	O
increases	PRISTIQ.xml:S3:11503:9	O
in	PRISTIQ.xml:S3:11513:2	O
blood	PRISTIQ.xml:S3:11516:5	O
pressure	PRISTIQ.xml:S3:11522:8	O
.	PRISTIQ.xml:S3:11530:1	O

Cases	PRISTIQ.xml:S3:11532:5	O
of	PRISTIQ.xml:S3:11538:2	O
elevated	PRISTIQ.xml:S3:11541:8	B-AdverseReaction
blood	PRISTIQ.xml:S3:11550:5	I-AdverseReaction
pressure	PRISTIQ.xml:S3:11556:8	I-AdverseReaction
requiring	PRISTIQ.xml:S3:11565:9	O
immediate	PRISTIQ.xml:S3:11575:9	O
treatment	PRISTIQ.xml:S3:11585:9	O
have	PRISTIQ.xml:S3:11595:4	O
been	PRISTIQ.xml:S3:11600:4	O
reported	PRISTIQ.xml:S3:11605:8	O
with	PRISTIQ.xml:S3:11614:4	O
PRISTIQ	PRISTIQ.xml:S3:11619:7	O
.	PRISTIQ.xml:S3:11626:1	O

Sustained	PRISTIQ.xml:S3:11632:9	B-Severity
blood	PRISTIQ.xml:S3:11642:5	B-AdverseReaction
pressure	PRISTIQ.xml:S3:11648:8	I-AdverseReaction
increases	PRISTIQ.xml:S3:11657:9	I-AdverseReaction
could	PRISTIQ.xml:S3:11667:5	O
have	PRISTIQ.xml:S3:11673:4	O
adverse	PRISTIQ.xml:S3:11678:7	O
consequences	PRISTIQ.xml:S3:11686:12	O
.	PRISTIQ.xml:S3:11698:1	O

For	PRISTIQ.xml:S3:11700:3	O
patients	PRISTIQ.xml:S3:11704:8	O
who	PRISTIQ.xml:S3:11713:3	O
experience	PRISTIQ.xml:S3:11717:10	O
a	PRISTIQ.xml:S3:11728:1	O
sustained	PRISTIQ.xml:S3:11730:9	O
increase	PRISTIQ.xml:S3:11740:8	O
in	PRISTIQ.xml:S3:11749:2	O
blood	PRISTIQ.xml:S3:11752:5	O
pressure	PRISTIQ.xml:S3:11758:8	O
while	PRISTIQ.xml:S3:11767:5	O
receiving	PRISTIQ.xml:S3:11773:9	O
PRISTIQ	PRISTIQ.xml:S3:11783:7	O
,	PRISTIQ.xml:S3:11790:1	O
either	PRISTIQ.xml:S3:11792:6	O
dose	PRISTIQ.xml:S3:11799:4	O
reduction	PRISTIQ.xml:S3:11804:9	O
or	PRISTIQ.xml:S3:11814:2	O
discontinuation	PRISTIQ.xml:S3:11817:15	O
should	PRISTIQ.xml:S3:11833:6	O
be	PRISTIQ.xml:S3:11840:2	O
considered	PRISTIQ.xml:S3:11843:10	O
[	PRISTIQ.xml:S3:11854:1	O
see	PRISTIQ.xml:S3:11855:3	O
Adverse	PRISTIQ.xml:S3:11860:7	O
Reactions	PRISTIQ.xml:S3:11868:9	O
(	PRISTIQ.xml:S3:11878:1	O
6.1	PRISTIQ.xml:S3:11879:3	O
)	PRISTIQ.xml:S3:11882:1	O
]	PRISTIQ.xml:S3:11885:1	O
.	PRISTIQ.xml:S3:11888:1	O

5.4	PRISTIQ.xml:S3:11897:3	O
Abnormal	PRISTIQ.xml:S3:11901:8	O
Bleeding	PRISTIQ.xml:S3:11910:8	O

SSRIs	PRISTIQ.xml:S3:11924:5	O
and	PRISTIQ.xml:S3:11930:3	O
SNRIs	PRISTIQ.xml:S3:11934:5	O
,	PRISTIQ.xml:S3:11939:1	O
including	PRISTIQ.xml:S3:11941:9	O
PRISTIQ	PRISTIQ.xml:S3:11951:7	O
,	PRISTIQ.xml:S3:11958:1	O
may	PRISTIQ.xml:S3:11960:3	O
increase	PRISTIQ.xml:S3:11964:8	O
the	PRISTIQ.xml:S3:11973:3	O
risk	PRISTIQ.xml:S3:11977:4	B-Factor
of	PRISTIQ.xml:S3:11982:2	O
bleeding	PRISTIQ.xml:S3:11985:8	B-AdverseReaction
events	PRISTIQ.xml:S3:11994:6	O
.	PRISTIQ.xml:S3:12000:1	O

Concomitant	PRISTIQ.xml:S3:12002:11	O
use	PRISTIQ.xml:S3:12014:3	O
of	PRISTIQ.xml:S3:12018:2	O
aspirin	PRISTIQ.xml:S3:12021:7	O
,	PRISTIQ.xml:S3:12028:1	O
nonsteroidal	PRISTIQ.xml:S3:12030:12	O
anti	PRISTIQ.xml:S3:12043:4	O
-	PRISTIQ.xml:S3:12047:1	O
inflammatory	PRISTIQ.xml:S3:12048:12	O
drugs	PRISTIQ.xml:S3:12061:5	O
,	PRISTIQ.xml:S3:12066:1	O
warfarin	PRISTIQ.xml:S3:12068:8	O
,	PRISTIQ.xml:S3:12076:1	O
and	PRISTIQ.xml:S3:12078:3	O
other	PRISTIQ.xml:S3:12082:5	O
anticoagulants	PRISTIQ.xml:S3:12088:14	O
may	PRISTIQ.xml:S3:12103:3	O
add	PRISTIQ.xml:S3:12107:3	O
to	PRISTIQ.xml:S3:12111:2	O
this	PRISTIQ.xml:S3:12114:4	O
risk	PRISTIQ.xml:S3:12119:4	O
.	PRISTIQ.xml:S3:12123:1	O

Case	PRISTIQ.xml:S3:12125:4	O
reports	PRISTIQ.xml:S3:12130:7	O
and	PRISTIQ.xml:S3:12138:3	O
epidemiological	PRISTIQ.xml:S3:12142:15	O
studies	PRISTIQ.xml:S3:12158:7	O
(	PRISTIQ.xml:S3:12166:1	O
case	PRISTIQ.xml:S3:12167:4	O
-	PRISTIQ.xml:S3:12171:1	O
control	PRISTIQ.xml:S3:12172:7	O
and	PRISTIQ.xml:S3:12180:3	O
cohort	PRISTIQ.xml:S3:12184:6	O
design	PRISTIQ.xml:S3:12191:6	O
)	PRISTIQ.xml:S3:12197:1	O
have	PRISTIQ.xml:S3:12199:4	O
demonstrated	PRISTIQ.xml:S3:12204:12	O
an	PRISTIQ.xml:S3:12217:2	O
association	PRISTIQ.xml:S3:12220:11	O
between	PRISTIQ.xml:S3:12232:7	O
use	PRISTIQ.xml:S3:12240:3	O
of	PRISTIQ.xml:S3:12244:2	O
drugs	PRISTIQ.xml:S3:12247:5	B-DrugClass
that	PRISTIQ.xml:S3:12253:4	I-DrugClass
interfere	PRISTIQ.xml:S3:12258:9	I-DrugClass
with	PRISTIQ.xml:S3:12268:4	I-DrugClass
serotonin	PRISTIQ.xml:S3:12273:9	I-DrugClass
reuptake	PRISTIQ.xml:S3:12283:8	I-DrugClass
and	PRISTIQ.xml:S3:12292:3	O
the	PRISTIQ.xml:S3:12296:3	O
occurrence	PRISTIQ.xml:S3:12300:10	O
of	PRISTIQ.xml:S3:12311:2	O
gastrointestinal	PRISTIQ.xml:S3:12314:16	B-AdverseReaction
bleeding	PRISTIQ.xml:S3:12331:8	I-AdverseReaction
.	PRISTIQ.xml:S3:12339:1	O

Bleeding	PRISTIQ.xml:S3:12341:8	B-AdverseReaction
events	PRISTIQ.xml:S3:12350:6	O
related	PRISTIQ.xml:S3:12357:7	O
to	PRISTIQ.xml:S3:12365:2	O
SSRIs	PRISTIQ.xml:S3:12368:5	O
and	PRISTIQ.xml:S3:12374:3	O
SNRIs	PRISTIQ.xml:S3:12378:5	B-DrugClass
have	PRISTIQ.xml:S3:12384:4	O
ranged	PRISTIQ.xml:S3:12389:6	O
from	PRISTIQ.xml:S3:12396:4	O
ecchymosis	PRISTIQ.xml:S3:12401:10	B-AdverseReaction
,	PRISTIQ.xml:S3:12411:1	O
hematoma	PRISTIQ.xml:S3:12413:8	B-AdverseReaction
,	PRISTIQ.xml:S3:12421:1	O
epistaxis	PRISTIQ.xml:S3:12423:9	B-AdverseReaction
,	PRISTIQ.xml:S3:12432:1	O
and	PRISTIQ.xml:S3:12434:3	O
petechiae	PRISTIQ.xml:S3:12438:9	B-AdverseReaction
to	PRISTIQ.xml:S3:12448:2	O
life	PRISTIQ.xml:S3:12451:4	B-Severity
-	PRISTIQ.xml:S3:12455:1	I-Severity
threatening	PRISTIQ.xml:S3:12456:11	I-Severity
hemorrhages	PRISTIQ.xml:S3:12468:11	B-AdverseReaction
.	PRISTIQ.xml:S3:12479:1	O

Patients	PRISTIQ.xml:S3:12481:8	O
should	PRISTIQ.xml:S3:12490:6	O
be	PRISTIQ.xml:S3:12497:2	O
cautioned	PRISTIQ.xml:S3:12500:9	O
about	PRISTIQ.xml:S3:12510:5	O
the	PRISTIQ.xml:S3:12516:3	O
risk	PRISTIQ.xml:S3:12520:4	O
of	PRISTIQ.xml:S3:12525:2	O
bleeding	PRISTIQ.xml:S3:12528:8	O
associated	PRISTIQ.xml:S3:12537:10	O
with	PRISTIQ.xml:S3:12548:4	O
the	PRISTIQ.xml:S3:12553:3	O
concomitant	PRISTIQ.xml:S3:12557:11	O
use	PRISTIQ.xml:S3:12569:3	O
of	PRISTIQ.xml:S3:12573:2	O
PRISTIQ	PRISTIQ.xml:S3:12576:7	O
and	PRISTIQ.xml:S3:12584:3	O
NSAIDs	PRISTIQ.xml:S3:12588:6	O
,	PRISTIQ.xml:S3:12594:1	O
aspirin	PRISTIQ.xml:S3:12596:7	O
,	PRISTIQ.xml:S3:12603:1	O
or	PRISTIQ.xml:S3:12605:2	O
other	PRISTIQ.xml:S3:12608:5	O
drugs	PRISTIQ.xml:S3:12614:5	O
that	PRISTIQ.xml:S3:12620:4	O
affect	PRISTIQ.xml:S3:12625:6	O
coagulation	PRISTIQ.xml:S3:12632:11	O
or	PRISTIQ.xml:S3:12644:2	O
bleeding	PRISTIQ.xml:S3:12647:8	O
.	PRISTIQ.xml:S3:12655:1	O

5.5	PRISTIQ.xml:S3:12664:3	O
Angle	PRISTIQ.xml:S3:12668:5	O
Closure	PRISTIQ.xml:S3:12674:7	O
Glaucoma	PRISTIQ.xml:S3:12682:8	O

Angle	PRISTIQ.xml:S3:12697:5	B-AdverseReaction
-	PRISTIQ.xml:S3:12702:1	I-AdverseReaction
Closure	PRISTIQ.xml:S3:12703:7	I-AdverseReaction
Glaucoma	PRISTIQ.xml:S3:12711:8	I-AdverseReaction
:	PRISTIQ.xml:S3:12719:1	O
The	PRISTIQ.xml:S3:12721:3	O
pupillary	PRISTIQ.xml:S3:12725:9	O
dilation	PRISTIQ.xml:S3:12735:8	O
that	PRISTIQ.xml:S3:12744:4	O
occurs	PRISTIQ.xml:S3:12749:6	O
following	PRISTIQ.xml:S3:12756:9	O
use	PRISTIQ.xml:S3:12766:3	O
of	PRISTIQ.xml:S3:12770:2	O
many	PRISTIQ.xml:S3:12773:4	O
antidepressant	PRISTIQ.xml:S3:12778:14	O
drugs	PRISTIQ.xml:S3:12793:5	O
including	PRISTIQ.xml:S3:12799:9	O
Pristiq	PRISTIQ.xml:S3:12809:7	O
may	PRISTIQ.xml:S3:12817:3	B-Factor
trigger	PRISTIQ.xml:S3:12821:7	O
an	PRISTIQ.xml:S3:12829:2	O
angle	PRISTIQ.xml:S3:12832:5	B-AdverseReaction
closure	PRISTIQ.xml:S3:12838:7	I-AdverseReaction
attack	PRISTIQ.xml:S3:12846:6	I-AdverseReaction
in	PRISTIQ.xml:S3:12853:2	O
a	PRISTIQ.xml:S3:12856:1	O
patient	PRISTIQ.xml:S3:12858:7	O
with	PRISTIQ.xml:S3:12866:4	O
anatomically	PRISTIQ.xml:S3:12871:12	O
narrow	PRISTIQ.xml:S3:12884:6	O
angles	PRISTIQ.xml:S3:12891:6	O
who	PRISTIQ.xml:S3:12898:3	O
does	PRISTIQ.xml:S3:12902:4	O
not	PRISTIQ.xml:S3:12907:3	O
have	PRISTIQ.xml:S3:12911:4	O
a	PRISTIQ.xml:S3:12916:1	O
patent	PRISTIQ.xml:S3:12918:6	O
iridectomy	PRISTIQ.xml:S3:12925:10	O
.	PRISTIQ.xml:S3:12935:1	O

5.6	PRISTIQ.xml:S3:12946:3	O
Activation	PRISTIQ.xml:S3:12950:10	O
of	PRISTIQ.xml:S3:12961:2	O
Mania	PRISTIQ.xml:S3:12964:5	O
Hypomania	PRISTIQ.xml:S3:12970:9	O

During	PRISTIQ.xml:S3:12985:6	O
all	PRISTIQ.xml:S3:12992:3	O
MDD	PRISTIQ.xml:S3:12996:3	O
phase	PRISTIQ.xml:S3:13000:5	O
2	PRISTIQ.xml:S3:13006:1	O
and	PRISTIQ.xml:S3:13008:3	O
phase	PRISTIQ.xml:S3:13012:5	O
3	PRISTIQ.xml:S3:13018:1	O
studies	PRISTIQ.xml:S3:13020:7	O
,	PRISTIQ.xml:S3:13027:1	O
mania	PRISTIQ.xml:S3:13029:5	B-AdverseReaction
was	PRISTIQ.xml:S3:13035:3	O
reported	PRISTIQ.xml:S3:13039:8	O
for	PRISTIQ.xml:S3:13048:3	O
approximately	PRISTIQ.xml:S3:13052:13	O
0.02%	PRISTIQ.xml:S3:13066:5	O
of	PRISTIQ.xml:S3:13072:2	O
patients	PRISTIQ.xml:S3:13075:8	O
treated	PRISTIQ.xml:S3:13084:7	O
with	PRISTIQ.xml:S3:13092:4	O
PRISTIQ	PRISTIQ.xml:S3:13097:7	O
.	PRISTIQ.xml:S3:13104:1	O

Activation	PRISTIQ.xml:S3:13106:10	B-AdverseReaction
of	PRISTIQ.xml:S3:13117:2	I-AdverseReaction
mania	PRISTIQ.xml:S3:13120:5	I-AdverseReaction
hypomania	PRISTIQ.xml:S3:13126:9	I-AdverseReaction
has	PRISTIQ.xml:S3:13136:3	O
also	PRISTIQ.xml:S3:13140:4	O
been	PRISTIQ.xml:S3:13145:4	O
reported	PRISTIQ.xml:S3:13150:8	O
in	PRISTIQ.xml:S3:13159:2	O
a	PRISTIQ.xml:S3:13162:1	O
small	PRISTIQ.xml:S3:13164:5	O
proportion	PRISTIQ.xml:S3:13170:10	O
of	PRISTIQ.xml:S3:13181:2	O
patients	PRISTIQ.xml:S3:13184:8	O
with	PRISTIQ.xml:S3:13193:4	O
major	PRISTIQ.xml:S3:13198:5	O
affective	PRISTIQ.xml:S3:13204:9	O
disorder	PRISTIQ.xml:S3:13214:8	O
who	PRISTIQ.xml:S3:13223:3	O
were	PRISTIQ.xml:S3:13227:4	O
treated	PRISTIQ.xml:S3:13232:7	O
with	PRISTIQ.xml:S3:13240:4	O
other	PRISTIQ.xml:S3:13245:5	O
marketed	PRISTIQ.xml:S3:13251:8	O
antidepressants	PRISTIQ.xml:S3:13260:15	B-DrugClass
.	PRISTIQ.xml:S3:13275:1	O

As	PRISTIQ.xml:S3:13277:2	O
with	PRISTIQ.xml:S3:13280:4	O
all	PRISTIQ.xml:S3:13285:3	O
antidepressants	PRISTIQ.xml:S3:13289:15	O
,	PRISTIQ.xml:S3:13304:1	O
PRISTIQ	PRISTIQ.xml:S3:13306:7	O
should	PRISTIQ.xml:S3:13314:6	O
be	PRISTIQ.xml:S3:13321:2	O
used	PRISTIQ.xml:S3:13324:4	O
cautiously	PRISTIQ.xml:S3:13329:10	O
in	PRISTIQ.xml:S3:13340:2	O
patients	PRISTIQ.xml:S3:13343:8	O
with	PRISTIQ.xml:S3:13352:4	O
a	PRISTIQ.xml:S3:13357:1	O
history	PRISTIQ.xml:S3:13359:7	O
or	PRISTIQ.xml:S3:13367:2	O
family	PRISTIQ.xml:S3:13370:6	O
history	PRISTIQ.xml:S3:13377:7	O
of	PRISTIQ.xml:S3:13385:2	O
mania	PRISTIQ.xml:S3:13388:5	O
or	PRISTIQ.xml:S3:13394:2	O
hypomania	PRISTIQ.xml:S3:13397:9	O
.	PRISTIQ.xml:S3:13406:1	O

5.7	PRISTIQ.xml:S3:13415:3	O
Discontinuation	PRISTIQ.xml:S3:13419:15	O
Syndrome	PRISTIQ.xml:S3:13435:8	O

Discontinuation	PRISTIQ.xml:S3:13449:15	O
symptoms	PRISTIQ.xml:S3:13465:8	O
have	PRISTIQ.xml:S3:13474:4	O
been	PRISTIQ.xml:S3:13479:4	O
systematically	PRISTIQ.xml:S3:13484:14	O
and	PRISTIQ.xml:S3:13499:3	O
prospectively	PRISTIQ.xml:S3:13503:13	O
evaluated	PRISTIQ.xml:S3:13517:9	O
in	PRISTIQ.xml:S3:13527:2	O
patients	PRISTIQ.xml:S3:13530:8	O
treated	PRISTIQ.xml:S3:13539:7	O
with	PRISTIQ.xml:S3:13547:4	O
PRISTIQ	PRISTIQ.xml:S3:13552:7	O
during	PRISTIQ.xml:S3:13560:6	O
clinical	PRISTIQ.xml:S3:13567:8	O
studies	PRISTIQ.xml:S3:13576:7	O
in	PRISTIQ.xml:S3:13584:2	O
Major	PRISTIQ.xml:S3:13587:5	O
Depressive	PRISTIQ.xml:S3:13593:10	O
Disorder	PRISTIQ.xml:S3:13604:8	O
.	PRISTIQ.xml:S3:13612:1	O

Abrupt	PRISTIQ.xml:S3:13614:6	O
discontinuation	PRISTIQ.xml:S3:13621:15	O
or	PRISTIQ.xml:S3:13637:2	O
dose	PRISTIQ.xml:S3:13640:4	O
reduction	PRISTIQ.xml:S3:13645:9	O
has	PRISTIQ.xml:S3:13655:3	O
been	PRISTIQ.xml:S3:13659:4	O
associated	PRISTIQ.xml:S3:13664:10	O
with	PRISTIQ.xml:S3:13675:4	O
the	PRISTIQ.xml:S3:13680:3	O
appearance	PRISTIQ.xml:S3:13684:10	O
of	PRISTIQ.xml:S3:13695:2	O
new	PRISTIQ.xml:S3:13698:3	O
symptoms	PRISTIQ.xml:S3:13702:8	O
that	PRISTIQ.xml:S3:13711:4	O
include	PRISTIQ.xml:S3:13716:7	O
dizziness	PRISTIQ.xml:S3:13724:9	B-AdverseReaction
,	PRISTIQ.xml:S3:13733:1	O
nausea	PRISTIQ.xml:S3:13735:6	B-AdverseReaction
,	PRISTIQ.xml:S3:13741:1	O
headache	PRISTIQ.xml:S3:13743:8	B-AdverseReaction
,	PRISTIQ.xml:S3:13751:1	O
irritability	PRISTIQ.xml:S3:13753:12	B-AdverseReaction
,	PRISTIQ.xml:S3:13765:1	O
insomnia	PRISTIQ.xml:S3:13767:8	B-AdverseReaction
,	PRISTIQ.xml:S3:13775:1	O
diarrhea	PRISTIQ.xml:S3:13777:8	B-AdverseReaction
,	PRISTIQ.xml:S3:13785:1	O
anxiety	PRISTIQ.xml:S3:13787:7	B-AdverseReaction
,	PRISTIQ.xml:S3:13794:1	O
fatigue	PRISTIQ.xml:S3:13796:7	B-AdverseReaction
,	PRISTIQ.xml:S3:13803:1	O
abnormal	PRISTIQ.xml:S3:13805:8	B-AdverseReaction
dreams	PRISTIQ.xml:S3:13814:6	I-AdverseReaction
,	PRISTIQ.xml:S3:13820:1	O
and	PRISTIQ.xml:S3:13822:3	O
hyperhidrosis	PRISTIQ.xml:S3:13826:13	B-AdverseReaction
.	PRISTIQ.xml:S3:13839:1	O

In	PRISTIQ.xml:S3:13841:2	O
general	PRISTIQ.xml:S3:13844:7	O
,	PRISTIQ.xml:S3:13851:1	O
discontinuation	PRISTIQ.xml:S3:13853:15	O
events	PRISTIQ.xml:S3:13869:6	O
occurred	PRISTIQ.xml:S3:13876:8	O
more	PRISTIQ.xml:S3:13885:4	O
frequently	PRISTIQ.xml:S3:13890:10	O
with	PRISTIQ.xml:S3:13901:4	O
longer	PRISTIQ.xml:S3:13906:6	O
duration	PRISTIQ.xml:S3:13913:8	O
of	PRISTIQ.xml:S3:13922:2	O
therapy	PRISTIQ.xml:S3:13925:7	O
.	PRISTIQ.xml:S3:13932:1	O

During	PRISTIQ.xml:S3:13938:6	O
marketing	PRISTIQ.xml:S3:13945:9	O
of	PRISTIQ.xml:S3:13955:2	O
SNRIs	PRISTIQ.xml:S3:13958:5	O
(	PRISTIQ.xml:S3:13964:1	O
Serotonin	PRISTIQ.xml:S3:13965:9	O
and	PRISTIQ.xml:S3:13975:3	O
Norepinephrine	PRISTIQ.xml:S3:13979:14	O
Reuptake	PRISTIQ.xml:S3:13994:8	O
Inhibitors	PRISTIQ.xml:S3:14003:10	O
)	PRISTIQ.xml:S3:14013:1	O
,	PRISTIQ.xml:S3:14014:1	O
and	PRISTIQ.xml:S3:14016:3	O
SSRIs	PRISTIQ.xml:S3:14020:5	O
(	PRISTIQ.xml:S3:14026:1	O
Selective	PRISTIQ.xml:S3:14027:9	O
Serotonin	PRISTIQ.xml:S3:14037:9	O
Reuptake	PRISTIQ.xml:S3:14047:8	O
Inhibitors	PRISTIQ.xml:S3:14056:10	O
)	PRISTIQ.xml:S3:14066:1	O
,	PRISTIQ.xml:S3:14067:1	O
there	PRISTIQ.xml:S3:14069:5	O
have	PRISTIQ.xml:S3:14075:4	O
been	PRISTIQ.xml:S3:14080:4	O
spontaneous	PRISTIQ.xml:S3:14085:11	O
reports	PRISTIQ.xml:S3:14097:7	O
of	PRISTIQ.xml:S3:14105:2	O
adverse	PRISTIQ.xml:S3:14108:7	O
events	PRISTIQ.xml:S3:14116:6	O
occurring	PRISTIQ.xml:S3:14123:9	O
upon	PRISTIQ.xml:S3:14133:4	O
discontinuation	PRISTIQ.xml:S3:14138:15	O
of	PRISTIQ.xml:S3:14154:2	O
these	PRISTIQ.xml:S3:14157:5	O
drugs	PRISTIQ.xml:S3:14163:5	O
,	PRISTIQ.xml:S3:14168:1	O
particularly	PRISTIQ.xml:S3:14170:12	O
when	PRISTIQ.xml:S3:14183:4	O
abrupt	PRISTIQ.xml:S3:14188:6	O
,	PRISTIQ.xml:S3:14194:1	O
including	PRISTIQ.xml:S3:14196:9	O
the	PRISTIQ.xml:S3:14206:3	O
following	PRISTIQ.xml:S3:14210:9	O
:	PRISTIQ.xml:S3:14219:1	O
dysphoric	PRISTIQ.xml:S3:14221:9	O
mood	PRISTIQ.xml:S3:14231:4	O
,	PRISTIQ.xml:S3:14235:1	O
irritability	PRISTIQ.xml:S3:14237:12	O
,	PRISTIQ.xml:S3:14249:1	O
agitation	PRISTIQ.xml:S3:14251:9	O
,	PRISTIQ.xml:S3:14260:1	O
dizziness	PRISTIQ.xml:S3:14262:9	O
,	PRISTIQ.xml:S3:14271:1	O
sensory	PRISTIQ.xml:S3:14273:7	O
disturbances	PRISTIQ.xml:S3:14281:12	O
(	PRISTIQ.xml:S3:14294:1	O
e	PRISTIQ.xml:S3:14295:1	O
.	PRISTIQ.xml:S3:14296:1	O
g	PRISTIQ.xml:S3:14297:1	O
.	PRISTIQ.xml:S3:14298:1	O
,	PRISTIQ.xml:S3:14299:1	O
paresthesia	PRISTIQ.xml:S3:14301:11	O
,	PRISTIQ.xml:S3:14312:1	O
such	PRISTIQ.xml:S3:14314:4	O
as	PRISTIQ.xml:S3:14319:2	O
electric	PRISTIQ.xml:S3:14322:8	O
shock	PRISTIQ.xml:S3:14331:5	O
sensations	PRISTIQ.xml:S3:14337:10	O
)	PRISTIQ.xml:S3:14347:1	O
,	PRISTIQ.xml:S3:14348:1	O
anxiety	PRISTIQ.xml:S3:14350:7	O
,	PRISTIQ.xml:S3:14357:1	O
confusion	PRISTIQ.xml:S3:14359:9	O
,	PRISTIQ.xml:S3:14368:1	O
headache	PRISTIQ.xml:S3:14370:8	O
,	PRISTIQ.xml:S3:14378:1	O
lethargy	PRISTIQ.xml:S3:14380:8	O
,	PRISTIQ.xml:S3:14388:1	O
emotional	PRISTIQ.xml:S3:14390:9	O
lability	PRISTIQ.xml:S3:14400:8	O
,	PRISTIQ.xml:S3:14408:1	O
insomnia	PRISTIQ.xml:S3:14410:8	O
,	PRISTIQ.xml:S3:14418:1	O
hypomania	PRISTIQ.xml:S3:14420:9	O
,	PRISTIQ.xml:S3:14429:1	O
tinnitus	PRISTIQ.xml:S3:14431:8	O
,	PRISTIQ.xml:S3:14439:1	O
and	PRISTIQ.xml:S3:14441:3	O
seizures	PRISTIQ.xml:S3:14445:8	O
.	PRISTIQ.xml:S3:14453:1	O

While	PRISTIQ.xml:S3:14455:5	O
these	PRISTIQ.xml:S3:14461:5	O
events	PRISTIQ.xml:S3:14467:6	O
are	PRISTIQ.xml:S3:14474:3	O
generally	PRISTIQ.xml:S3:14478:9	O
self	PRISTIQ.xml:S3:14488:4	O
-	PRISTIQ.xml:S3:14492:1	O
limiting	PRISTIQ.xml:S3:14493:8	O
,	PRISTIQ.xml:S3:14501:1	O
there	PRISTIQ.xml:S3:14503:5	O
have	PRISTIQ.xml:S3:14509:4	O
been	PRISTIQ.xml:S3:14514:4	O
reports	PRISTIQ.xml:S3:14519:7	O
of	PRISTIQ.xml:S3:14527:2	O
serious	PRISTIQ.xml:S3:14530:7	O
discontinuation	PRISTIQ.xml:S3:14538:15	O
symptoms	PRISTIQ.xml:S3:14554:8	O
.	PRISTIQ.xml:S3:14562:1	O

Patients	PRISTIQ.xml:S3:14568:8	O
should	PRISTIQ.xml:S3:14577:6	O
be	PRISTIQ.xml:S3:14584:2	O
monitored	PRISTIQ.xml:S3:14587:9	O
for	PRISTIQ.xml:S3:14597:3	O
these	PRISTIQ.xml:S3:14601:5	O
symptoms	PRISTIQ.xml:S3:14607:8	O
when	PRISTIQ.xml:S3:14616:4	O
discontinuing	PRISTIQ.xml:S3:14621:13	O
treatment	PRISTIQ.xml:S3:14635:9	O
with	PRISTIQ.xml:S3:14645:4	O
PRISTIQ	PRISTIQ.xml:S3:14650:7	O
.	PRISTIQ.xml:S3:14657:1	O

A	PRISTIQ.xml:S3:14659:1	O
gradual	PRISTIQ.xml:S3:14661:7	O
reduction	PRISTIQ.xml:S3:14669:9	O
in	PRISTIQ.xml:S3:14679:2	O
the	PRISTIQ.xml:S3:14682:3	O
dose	PRISTIQ.xml:S3:14686:4	O
rather	PRISTIQ.xml:S3:14691:6	O
than	PRISTIQ.xml:S3:14698:4	O
abrupt	PRISTIQ.xml:S3:14703:6	O
cessation	PRISTIQ.xml:S3:14710:9	O
is	PRISTIQ.xml:S3:14720:2	O
recommended	PRISTIQ.xml:S3:14723:11	O
whenever	PRISTIQ.xml:S3:14735:8	O
possible	PRISTIQ.xml:S3:14744:8	O
.	PRISTIQ.xml:S3:14752:1	O

If	PRISTIQ.xml:S3:14754:2	O
intolerable	PRISTIQ.xml:S3:14757:11	O
symptoms	PRISTIQ.xml:S3:14769:8	O
occur	PRISTIQ.xml:S3:14778:5	O
following	PRISTIQ.xml:S3:14784:9	O
a	PRISTIQ.xml:S3:14794:1	O
decrease	PRISTIQ.xml:S3:14796:8	O
in	PRISTIQ.xml:S3:14805:2	O
the	PRISTIQ.xml:S3:14808:3	O
dose	PRISTIQ.xml:S3:14812:4	O
or	PRISTIQ.xml:S3:14817:2	O
upon	PRISTIQ.xml:S3:14820:4	O
discontinuation	PRISTIQ.xml:S3:14825:15	O
of	PRISTIQ.xml:S3:14841:2	O
treatment	PRISTIQ.xml:S3:14844:9	O
,	PRISTIQ.xml:S3:14853:1	O
then	PRISTIQ.xml:S3:14855:4	O
resuming	PRISTIQ.xml:S3:14860:8	O
the	PRISTIQ.xml:S3:14869:3	O
previously	PRISTIQ.xml:S3:14873:10	O
prescribed	PRISTIQ.xml:S3:14884:10	O
dose	PRISTIQ.xml:S3:14895:4	O
may	PRISTIQ.xml:S3:14900:3	O
be	PRISTIQ.xml:S3:14904:2	O
considered	PRISTIQ.xml:S3:14907:10	O
.	PRISTIQ.xml:S3:14917:1	O

Subsequently	PRISTIQ.xml:S3:14919:12	O
,	PRISTIQ.xml:S3:14931:1	O
the	PRISTIQ.xml:S3:14933:3	O
physician	PRISTIQ.xml:S3:14937:9	O
may	PRISTIQ.xml:S3:14947:3	O
continue	PRISTIQ.xml:S3:14951:8	O
decreasing	PRISTIQ.xml:S3:14960:10	O
the	PRISTIQ.xml:S3:14971:3	O
dose	PRISTIQ.xml:S3:14975:4	O
,	PRISTIQ.xml:S3:14979:1	O
but	PRISTIQ.xml:S3:14981:3	O
at	PRISTIQ.xml:S3:14985:2	O
a	PRISTIQ.xml:S3:14988:1	O
more	PRISTIQ.xml:S3:14990:4	O
gradual	PRISTIQ.xml:S3:14995:7	O
rate	PRISTIQ.xml:S3:15003:4	O
[	PRISTIQ.xml:S3:15008:1	O
see	PRISTIQ.xml:S3:15009:3	O
Dosage	PRISTIQ.xml:S3:15014:6	O
and	PRISTIQ.xml:S3:15021:3	O
Administration	PRISTIQ.xml:S3:15025:14	O
(	PRISTIQ.xml:S3:15040:1	O
2.4	PRISTIQ.xml:S3:15041:3	O
)	PRISTIQ.xml:S3:15044:1	O
and	PRISTIQ.xml:S3:15047:3	O
Adverse	PRISTIQ.xml:S3:15052:7	O
Reactions	PRISTIQ.xml:S3:15060:9	O
(	PRISTIQ.xml:S3:15070:1	O
6.1	PRISTIQ.xml:S3:15071:3	O
)	PRISTIQ.xml:S3:15074:1	O
]	PRISTIQ.xml:S3:15077:1	O
.	PRISTIQ.xml:S3:15080:1	O

5.8	PRISTIQ.xml:S3:15089:3	O
Seizure	PRISTIQ.xml:S3:15093:7	O

Cases	PRISTIQ.xml:S3:15106:5	O
of	PRISTIQ.xml:S3:15112:2	O
seizure	PRISTIQ.xml:S3:15115:7	B-AdverseReaction
have	PRISTIQ.xml:S3:15123:4	O
been	PRISTIQ.xml:S3:15128:4	O
reported	PRISTIQ.xml:S3:15133:8	O
in	PRISTIQ.xml:S3:15142:2	O
pre	PRISTIQ.xml:S3:15145:3	O
-	PRISTIQ.xml:S3:15148:1	O
marketing	PRISTIQ.xml:S3:15149:9	O
clinical	PRISTIQ.xml:S3:15159:8	O
studies	PRISTIQ.xml:S3:15168:7	O
with	PRISTIQ.xml:S3:15176:4	O
PRISTIQ	PRISTIQ.xml:S3:15181:7	O
.	PRISTIQ.xml:S3:15188:1	O

PRISTIQ	PRISTIQ.xml:S3:15190:7	O
has	PRISTIQ.xml:S3:15198:3	O
not	PRISTIQ.xml:S3:15202:3	O
been	PRISTIQ.xml:S3:15206:4	O
systematically	PRISTIQ.xml:S3:15211:14	O
evaluated	PRISTIQ.xml:S3:15226:9	O
in	PRISTIQ.xml:S3:15236:2	O
patients	PRISTIQ.xml:S3:15239:8	O
with	PRISTIQ.xml:S3:15248:4	O
a	PRISTIQ.xml:S3:15253:1	O
seizure	PRISTIQ.xml:S3:15255:7	O
disorder	PRISTIQ.xml:S3:15263:8	O
.	PRISTIQ.xml:S3:15271:1	O

Patients	PRISTIQ.xml:S3:15273:8	O
with	PRISTIQ.xml:S3:15282:4	O
a	PRISTIQ.xml:S3:15287:1	O
history	PRISTIQ.xml:S3:15289:7	O
of	PRISTIQ.xml:S3:15297:2	O
seizures	PRISTIQ.xml:S3:15300:8	O
were	PRISTIQ.xml:S3:15309:4	O
excluded	PRISTIQ.xml:S3:15314:8	O
from	PRISTIQ.xml:S3:15323:4	O
pre	PRISTIQ.xml:S3:15328:3	O
-	PRISTIQ.xml:S3:15331:1	O
marketing	PRISTIQ.xml:S3:15332:9	O
clinical	PRISTIQ.xml:S3:15342:8	O
studies	PRISTIQ.xml:S3:15351:7	O
.	PRISTIQ.xml:S3:15358:1	O

PRISTIQ	PRISTIQ.xml:S3:15360:7	O
should	PRISTIQ.xml:S3:15368:6	O
be	PRISTIQ.xml:S3:15375:2	O
prescribed	PRISTIQ.xml:S3:15378:10	O
with	PRISTIQ.xml:S3:15389:4	O
caution	PRISTIQ.xml:S3:15394:7	O
in	PRISTIQ.xml:S3:15402:2	O
patients	PRISTIQ.xml:S3:15405:8	O
with	PRISTIQ.xml:S3:15414:4	O
a	PRISTIQ.xml:S3:15419:1	O
seizure	PRISTIQ.xml:S3:15421:7	O
disorder	PRISTIQ.xml:S3:15429:8	O
.	PRISTIQ.xml:S3:15437:1	O

5.9	PRISTIQ.xml:S3:15446:3	O
Hyponatremia	PRISTIQ.xml:S3:15450:12	O

Hyponatremia	PRISTIQ.xml:S3:15468:12	B-AdverseReaction
may	PRISTIQ.xml:S3:15481:3	B-Factor
occur	PRISTIQ.xml:S3:15485:5	O
as	PRISTIQ.xml:S3:15491:2	O
a	PRISTIQ.xml:S3:15494:1	O
result	PRISTIQ.xml:S3:15496:6	O
of	PRISTIQ.xml:S3:15503:2	O
treatment	PRISTIQ.xml:S3:15506:9	O
with	PRISTIQ.xml:S3:15516:4	O
SSRIs	PRISTIQ.xml:S3:15521:5	O
and	PRISTIQ.xml:S3:15527:3	O
SNRIs	PRISTIQ.xml:S3:15531:5	O
,	PRISTIQ.xml:S3:15536:1	O
including	PRISTIQ.xml:S3:15538:9	O
PRISTIQ	PRISTIQ.xml:S3:15548:7	O
.	PRISTIQ.xml:S3:15555:1	O

In	PRISTIQ.xml:S3:15557:2	O
many	PRISTIQ.xml:S3:15560:4	O
cases	PRISTIQ.xml:S3:15565:5	O
,	PRISTIQ.xml:S3:15570:1	O
this	PRISTIQ.xml:S3:15572:4	O
hyponatremia	PRISTIQ.xml:S3:15577:12	B-AdverseReaction
appears	PRISTIQ.xml:S3:15590:7	O
to	PRISTIQ.xml:S3:15598:2	O
be	PRISTIQ.xml:S3:15601:2	O
the	PRISTIQ.xml:S3:15604:3	O
result	PRISTIQ.xml:S3:15608:6	O
of	PRISTIQ.xml:S3:15615:2	O
the	PRISTIQ.xml:S3:15618:3	O
syndrome	PRISTIQ.xml:S3:15622:8	B-AdverseReaction
of	PRISTIQ.xml:S3:15631:2	I-AdverseReaction
inappropriate	PRISTIQ.xml:S3:15634:13	I-AdverseReaction
antidiuretic	PRISTIQ.xml:S3:15648:12	I-AdverseReaction
hormone	PRISTIQ.xml:S3:15661:7	I-AdverseReaction
secretion	PRISTIQ.xml:S3:15669:9	I-AdverseReaction
(	PRISTIQ.xml:S3:15679:1	O
SIADH	PRISTIQ.xml:S3:15680:5	B-AdverseReaction
)	PRISTIQ.xml:S3:15685:1	O
.	PRISTIQ.xml:S3:15686:1	O

Cases	PRISTIQ.xml:S3:15688:5	O
with	PRISTIQ.xml:S3:15694:4	O
serum	PRISTIQ.xml:S3:15699:5	B-AdverseReaction
sodium	PRISTIQ.xml:S3:15705:6	I-AdverseReaction
lower	PRISTIQ.xml:S3:15712:5	I-AdverseReaction
than	PRISTIQ.xml:S3:15718:4	I-AdverseReaction
110	PRISTIQ.xml:S3:15723:3	I-AdverseReaction
mmol	PRISTIQ.xml:S3:15727:4	I-AdverseReaction
L	PRISTIQ.xml:S3:15732:1	I-AdverseReaction
have	PRISTIQ.xml:S3:15734:4	O
been	PRISTIQ.xml:S3:15739:4	O
reported	PRISTIQ.xml:S3:15744:8	O
.	PRISTIQ.xml:S3:15752:1	O

Elderly	PRISTIQ.xml:S3:15754:7	O
patients	PRISTIQ.xml:S3:15762:8	O
may	PRISTIQ.xml:S3:15771:3	O
be	PRISTIQ.xml:S3:15775:2	O
at	PRISTIQ.xml:S3:15778:2	O
greater	PRISTIQ.xml:S3:15781:7	O
risk	PRISTIQ.xml:S3:15789:4	O
of	PRISTIQ.xml:S3:15794:2	O
developing	PRISTIQ.xml:S3:15797:10	O
hyponatremia	PRISTIQ.xml:S3:15808:12	B-AdverseReaction
with	PRISTIQ.xml:S3:15821:4	O
SSRIs	PRISTIQ.xml:S3:15826:5	O
and	PRISTIQ.xml:S3:15832:3	O
SNRIs	PRISTIQ.xml:S3:15836:5	B-DrugClass
.	PRISTIQ.xml:S3:15841:1	O

Also	PRISTIQ.xml:S3:15843:4	O
,	PRISTIQ.xml:S3:15847:1	O
patients	PRISTIQ.xml:S3:15849:8	O
taking	PRISTIQ.xml:S3:15858:6	O
diuretics	PRISTIQ.xml:S3:15865:9	O
or	PRISTIQ.xml:S3:15875:2	O
who	PRISTIQ.xml:S3:15878:3	O
are	PRISTIQ.xml:S3:15882:3	O
otherwise	PRISTIQ.xml:S3:15886:9	O
volume	PRISTIQ.xml:S3:15896:6	O
depleted	PRISTIQ.xml:S3:15903:8	O
can	PRISTIQ.xml:S3:15912:3	O
be	PRISTIQ.xml:S3:15916:2	O
at	PRISTIQ.xml:S3:15919:2	O
greater	PRISTIQ.xml:S3:15922:7	O
risk	PRISTIQ.xml:S3:15930:4	O
[	PRISTIQ.xml:S3:15935:1	O
see	PRISTIQ.xml:S3:15936:3	O
Use	PRISTIQ.xml:S3:15941:3	O
in	PRISTIQ.xml:S3:15945:2	O
Specific	PRISTIQ.xml:S3:15948:8	O
Populations	PRISTIQ.xml:S3:15957:11	O
(	PRISTIQ.xml:S3:15969:1	O
8.5	PRISTIQ.xml:S3:15970:3	O
)	PRISTIQ.xml:S3:15973:1	O
and	PRISTIQ.xml:S3:15976:3	O
Clinical	PRISTIQ.xml:S3:15980:8	O
Pharmacology	PRISTIQ.xml:S3:15989:12	O
(	PRISTIQ.xml:S3:16002:1	O
12.6	PRISTIQ.xml:S3:16003:4	O
)]	PRISTIQ.xml:S3:16007:2	O
.	PRISTIQ.xml:S3:16011:1	O

Discontinuation	PRISTIQ.xml:S3:16013:15	O
of	PRISTIQ.xml:S3:16029:2	O
PRISTIQ	PRISTIQ.xml:S3:16032:7	O
should	PRISTIQ.xml:S3:16040:6	O
be	PRISTIQ.xml:S3:16047:2	O
considered	PRISTIQ.xml:S3:16050:10	O
in	PRISTIQ.xml:S3:16061:2	O
patients	PRISTIQ.xml:S3:16064:8	O
with	PRISTIQ.xml:S3:16073:4	O
symptomatic	PRISTIQ.xml:S3:16078:11	O
hyponatremia	PRISTIQ.xml:S3:16090:12	O
and	PRISTIQ.xml:S3:16103:3	O
appropriate	PRISTIQ.xml:S3:16107:11	O
medical	PRISTIQ.xml:S3:16119:7	O
intervention	PRISTIQ.xml:S3:16127:12	O
should	PRISTIQ.xml:S3:16140:6	O
be	PRISTIQ.xml:S3:16147:2	O
instituted	PRISTIQ.xml:S3:16150:10	O
.	PRISTIQ.xml:S3:16160:1	O

Signs	PRISTIQ.xml:S3:16166:5	O
and	PRISTIQ.xml:S3:16172:3	O
symptoms	PRISTIQ.xml:S3:16176:8	O
of	PRISTIQ.xml:S3:16185:2	O
hyponatremia	PRISTIQ.xml:S3:16188:12	B-AdverseReaction
include	PRISTIQ.xml:S3:16201:7	O
headache	PRISTIQ.xml:S3:16209:8	B-AdverseReaction
,	PRISTIQ.xml:S3:16217:1	O
difficulty	PRISTIQ.xml:S3:16219:10	B-AdverseReaction
concentrating	PRISTIQ.xml:S3:16230:13	I-AdverseReaction
,	PRISTIQ.xml:S3:16243:1	O
memory	PRISTIQ.xml:S3:16245:6	B-AdverseReaction
impairment	PRISTIQ.xml:S3:16252:10	I-AdverseReaction
,	PRISTIQ.xml:S3:16262:1	O
confusion	PRISTIQ.xml:S3:16264:9	B-AdverseReaction
,	PRISTIQ.xml:S3:16273:1	O
weakness	PRISTIQ.xml:S3:16275:8	B-AdverseReaction
,	PRISTIQ.xml:S3:16283:1	O
and	PRISTIQ.xml:S3:16285:3	O
unsteadiness	PRISTIQ.xml:S3:16289:12	B-AdverseReaction
,	PRISTIQ.xml:S3:16301:1	O
which	PRISTIQ.xml:S3:16303:5	O
can	PRISTIQ.xml:S3:16309:3	B-Factor
lead	PRISTIQ.xml:S3:16313:4	O
to	PRISTIQ.xml:S3:16318:2	O
falls	PRISTIQ.xml:S3:16321:5	B-AdverseReaction
.	PRISTIQ.xml:S3:16326:1	O

Signs	PRISTIQ.xml:S3:16328:5	O
and	PRISTIQ.xml:S3:16334:3	O
symptoms	PRISTIQ.xml:S3:16338:8	O
associated	PRISTIQ.xml:S3:16347:10	O
with	PRISTIQ.xml:S3:16358:4	O
more	PRISTIQ.xml:S3:16363:4	O
severe	PRISTIQ.xml:S3:16368:6	O
and	PRISTIQ.xml:S3:16375:3	O
or	PRISTIQ.xml:S3:16379:2	O
acute	PRISTIQ.xml:S3:16382:5	O
cases	PRISTIQ.xml:S3:16388:5	O
have	PRISTIQ.xml:S3:16394:4	O
included	PRISTIQ.xml:S3:16399:8	O
hallucination	PRISTIQ.xml:S3:16408:13	B-AdverseReaction
,	PRISTIQ.xml:S3:16421:1	O
syncope	PRISTIQ.xml:S3:16423:7	B-AdverseReaction
,	PRISTIQ.xml:S3:16430:1	O
seizure	PRISTIQ.xml:S3:16432:7	B-AdverseReaction
,	PRISTIQ.xml:S3:16439:1	O
coma	PRISTIQ.xml:S3:16441:4	B-AdverseReaction
,	PRISTIQ.xml:S3:16445:1	O
respiratory	PRISTIQ.xml:S3:16447:11	B-AdverseReaction
arrest	PRISTIQ.xml:S3:16459:6	I-AdverseReaction
,	PRISTIQ.xml:S3:16465:1	O
and	PRISTIQ.xml:S3:16467:3	O
death	PRISTIQ.xml:S3:16471:5	B-AdverseReaction
.	PRISTIQ.xml:S3:16476:1	O

5.10	PRISTIQ.xml:S3:16485:4	O
Interstitial	PRISTIQ.xml:S3:16490:12	O
Lung	PRISTIQ.xml:S3:16503:4	O
Disease	PRISTIQ.xml:S3:16508:7	O
and	PRISTIQ.xml:S3:16516:3	O
Eosinophilic	PRISTIQ.xml:S3:16520:12	O
Pneumonia	PRISTIQ.xml:S3:16533:9	O

Interstitial	PRISTIQ.xml:S3:16548:12	B-AdverseReaction
lung	PRISTIQ.xml:S3:16561:4	I-AdverseReaction
disease	PRISTIQ.xml:S3:16566:7	I-AdverseReaction
and	PRISTIQ.xml:S3:16574:3	O
eosinophilic	PRISTIQ.xml:S3:16578:12	B-AdverseReaction
pneumonia	PRISTIQ.xml:S3:16591:9	I-AdverseReaction
associated	PRISTIQ.xml:S3:16601:10	O
with	PRISTIQ.xml:S3:16612:4	O
venlafaxine	PRISTIQ.xml:S3:16617:11	B-DrugClass
(	PRISTIQ.xml:S3:16629:1	O
the	PRISTIQ.xml:S3:16630:3	O
parent	PRISTIQ.xml:S3:16634:6	O
drug	PRISTIQ.xml:S3:16641:4	O
of	PRISTIQ.xml:S3:16646:2	O
PRISTIQ	PRISTIQ.xml:S3:16649:7	O
)	PRISTIQ.xml:S3:16656:1	O
therapy	PRISTIQ.xml:S3:16658:7	O
have	PRISTIQ.xml:S3:16666:4	O
been	PRISTIQ.xml:S3:16671:4	O
rarely	PRISTIQ.xml:S3:16676:6	O
reported	PRISTIQ.xml:S3:16683:8	O
.	PRISTIQ.xml:S3:16691:1	O

The	PRISTIQ.xml:S3:16693:3	O
possibility	PRISTIQ.xml:S3:16697:11	O
of	PRISTIQ.xml:S3:16709:2	O
these	PRISTIQ.xml:S3:16712:5	O
adverse	PRISTIQ.xml:S3:16718:7	O
events	PRISTIQ.xml:S3:16726:6	O
should	PRISTIQ.xml:S3:16733:6	O
be	PRISTIQ.xml:S3:16740:2	O
considered	PRISTIQ.xml:S3:16743:10	O
in	PRISTIQ.xml:S3:16754:2	O
patients	PRISTIQ.xml:S3:16757:8	O
treated	PRISTIQ.xml:S3:16766:7	O
with	PRISTIQ.xml:S3:16774:4	O
PRISTIQ	PRISTIQ.xml:S3:16779:7	O
who	PRISTIQ.xml:S3:16787:3	O
present	PRISTIQ.xml:S3:16791:7	O
with	PRISTIQ.xml:S3:16799:4	O
progressive	PRISTIQ.xml:S3:16804:11	O
dyspnea	PRISTIQ.xml:S3:16816:7	O
,	PRISTIQ.xml:S3:16823:1	O
cough	PRISTIQ.xml:S3:16825:5	O
,	PRISTIQ.xml:S3:16830:1	O
or	PRISTIQ.xml:S3:16832:2	O
chest	PRISTIQ.xml:S3:16835:5	O
discomfort	PRISTIQ.xml:S3:16841:10	O
.	PRISTIQ.xml:S3:16851:1	O

Such	PRISTIQ.xml:S3:16853:4	O
patients	PRISTIQ.xml:S3:16858:8	O
should	PRISTIQ.xml:S3:16867:6	O
undergo	PRISTIQ.xml:S3:16874:7	O
a	PRISTIQ.xml:S3:16882:1	O
prompt	PRISTIQ.xml:S3:16884:6	O
medical	PRISTIQ.xml:S3:16891:7	O
evaluation	PRISTIQ.xml:S3:16899:10	O
,	PRISTIQ.xml:S3:16909:1	O
and	PRISTIQ.xml:S3:16911:3	O
discontinuation	PRISTIQ.xml:S3:16915:15	O
of	PRISTIQ.xml:S3:16931:2	O
PRISTIQ	PRISTIQ.xml:S3:16934:7	O
should	PRISTIQ.xml:S3:16942:6	O
be	PRISTIQ.xml:S3:16949:2	O
considered	PRISTIQ.xml:S3:16952:10	O
.	PRISTIQ.xml:S3:16962:1	O
6	PROLIA.xml:S1:4:1	O
ADVERSE	PROLIA.xml:S1:6:7	O
REACTIONS	PROLIA.xml:S1:14:9	O

The	PROLIA.xml:S1:27:3	O
following	PROLIA.xml:S1:31:9	O
serious	PROLIA.xml:S1:41:7	O
adverse	PROLIA.xml:S1:49:7	O
reactions	PROLIA.xml:S1:57:9	O
are	PROLIA.xml:S1:67:3	O
discussed	PROLIA.xml:S1:71:9	O
below	PROLIA.xml:S1:81:5	O
and	PROLIA.xml:S1:87:3	O
also	PROLIA.xml:S1:91:4	O
elsewhere	PROLIA.xml:S1:96:9	O
in	PROLIA.xml:S1:106:2	O
the	PROLIA.xml:S1:109:3	O
labeling	PROLIA.xml:S1:113:8	O
:	PROLIA.xml:S1:121:1	O

Hypocalcemia	PROLIA.xml:S1:130:12	B-AdverseReaction
[	PROLIA.xml:S1:143:1	O
see	PROLIA.xml:S1:144:3	O
Warnings	PROLIA.xml:S1:148:8	O
and	PROLIA.xml:S1:157:3	O
Precautions	PROLIA.xml:S1:161:11	O
(	PROLIA.xml:S1:173:1	O
5.3	PROLIA.xml:S1:176:3	O
)]	PROLIA.xml:S1:181:2	O

Serious	PROLIA.xml:S1:190:7	B-Severity
Infections	PROLIA.xml:S1:198:10	B-AdverseReaction
[	PROLIA.xml:S1:209:1	O
see	PROLIA.xml:S1:210:3	O
Warnings	PROLIA.xml:S1:214:8	O
and	PROLIA.xml:S1:223:3	O
Precautions	PROLIA.xml:S1:227:11	O
(	PROLIA.xml:S1:239:1	O
5.6	PROLIA.xml:S1:242:3	O
)]	PROLIA.xml:S1:247:2	O

Dermatologic	PROLIA.xml:S1:256:12	B-AdverseReaction
Adverse	PROLIA.xml:S1:269:7	I-AdverseReaction
Reactions	PROLIA.xml:S1:277:9	I-AdverseReaction
[	PROLIA.xml:S1:287:1	O
see	PROLIA.xml:S1:288:3	O
Warnings	PROLIA.xml:S1:292:8	O
and	PROLIA.xml:S1:301:3	O
Precautions	PROLIA.xml:S1:305:11	O
(	PROLIA.xml:S1:317:1	O
5.7	PROLIA.xml:S1:320:3	O
)]	PROLIA.xml:S1:325:2	O

Osteonecrosis	PROLIA.xml:S1:334:13	B-AdverseReaction
of	PROLIA.xml:S1:348:2	I-AdverseReaction
the	PROLIA.xml:S1:351:3	I-AdverseReaction
Jaw	PROLIA.xml:S1:355:3	I-AdverseReaction
[	PROLIA.xml:S1:359:1	O
see	PROLIA.xml:S1:360:3	O
Warnings	PROLIA.xml:S1:364:8	O
and	PROLIA.xml:S1:373:3	O
Precautions	PROLIA.xml:S1:377:11	O
(	PROLIA.xml:S1:389:1	O
5.4	PROLIA.xml:S1:392:3	O
)]	PROLIA.xml:S1:397:2	O

Atypical	PROLIA.xml:S1:406:8	B-AdverseReaction
Subtrochanteric	PROLIA.xml:S1:415:15	I-AdverseReaction
and	PROLIA.xml:S1:431:3	O
Diaphyseal	PROLIA.xml:S1:435:10	I-AdverseReaction
Femoral	PROLIA.xml:S1:446:7	I-AdverseReaction
Fractures	PROLIA.xml:S1:454:9	I-AdverseReaction
[	PROLIA.xml:S1:464:1	O
see	PROLIA.xml:S1:465:3	O
Warnings	PROLIA.xml:S1:469:8	O
and	PROLIA.xml:S1:478:3	O
Precautions	PROLIA.xml:S1:482:11	O
(	PROLIA.xml:S1:494:1	O
5.5	PROLIA.xml:S1:497:3	O
)]	PROLIA.xml:S1:502:2	O

The	PROLIA.xml:S1:511:3	O
most	PROLIA.xml:S1:515:4	O
common	PROLIA.xml:S1:520:6	O
adverse	PROLIA.xml:S1:527:7	O
reactions	PROLIA.xml:S1:535:9	O
reported	PROLIA.xml:S1:545:8	O
with	PROLIA.xml:S1:554:4	O
Prolia	PROLIA.xml:S1:559:6	O
in	PROLIA.xml:S1:566:2	O
patients	PROLIA.xml:S1:569:8	O
with	PROLIA.xml:S1:578:4	O
postmenopausal	PROLIA.xml:S1:583:14	O
osteoporosis	PROLIA.xml:S1:598:12	O
are	PROLIA.xml:S1:611:3	O
back	PROLIA.xml:S1:615:4	B-AdverseReaction
pain	PROLIA.xml:S1:620:4	I-AdverseReaction
,	PROLIA.xml:S1:624:1	O
pain	PROLIA.xml:S1:626:4	B-AdverseReaction
in	PROLIA.xml:S1:631:2	I-AdverseReaction
extremity	PROLIA.xml:S1:634:9	I-AdverseReaction
,	PROLIA.xml:S1:643:1	O
musculoskeletal	PROLIA.xml:S1:645:15	B-AdverseReaction
pain	PROLIA.xml:S1:661:4	I-AdverseReaction
,	PROLIA.xml:S1:665:1	O
hypercholesterolemia	PROLIA.xml:S1:667:20	B-AdverseReaction
,	PROLIA.xml:S1:687:1	O
and	PROLIA.xml:S1:689:3	O
cystitis	PROLIA.xml:S1:693:8	B-AdverseReaction
.	PROLIA.xml:S1:701:1	O

The	PROLIA.xml:S1:707:3	O

most	PROLIA.xml:S1:711:4	O
common	PROLIA.xml:S1:716:6	O
adverse	PROLIA.xml:S1:723:7	O
reactions	PROLIA.xml:S1:731:9	O
reported	PROLIA.xml:S1:741:8	O
with	PROLIA.xml:S1:750:4	O
Prolia	PROLIA.xml:S1:755:6	O
in	PROLIA.xml:S1:762:2	O
men	PROLIA.xml:S1:765:3	O
with	PROLIA.xml:S1:769:4	O
osteoporosis	PROLIA.xml:S1:774:12	O
are	PROLIA.xml:S1:787:3	O
back	PROLIA.xml:S1:791:4	B-AdverseReaction
pain	PROLIA.xml:S1:796:4	I-AdverseReaction
,	PROLIA.xml:S1:800:1	O
arthralgia	PROLIA.xml:S1:802:10	B-AdverseReaction
,	PROLIA.xml:S1:812:1	O
and	PROLIA.xml:S1:814:3	O
nasopharyngitis	PROLIA.xml:S1:818:15	B-AdverseReaction
.	PROLIA.xml:S1:833:1	O

The	PROLIA.xml:S1:839:3	O
most	PROLIA.xml:S1:843:4	O
common	PROLIA.xml:S1:848:6	O
(	PROLIA.xml:S1:855:1	O
per	PROLIA.xml:S1:856:3	O
patient	PROLIA.xml:S1:860:7	O
incidence	PROLIA.xml:S1:868:9	O
10%	PROLIA.xml:S1:881:3	O
)	PROLIA.xml:S1:884:1	O
adverse	PROLIA.xml:S1:886:7	O
reactions	PROLIA.xml:S1:894:9	O
reported	PROLIA.xml:S1:904:8	O
with	PROLIA.xml:S1:913:4	O
Prolia	PROLIA.xml:S1:918:6	O
in	PROLIA.xml:S1:925:2	O
patients	PROLIA.xml:S1:928:8	O
with	PROLIA.xml:S1:937:4	O
bone	PROLIA.xml:S1:942:4	O
loss	PROLIA.xml:S1:947:4	O
receiving	PROLIA.xml:S1:952:9	O
androgen	PROLIA.xml:S1:962:8	O
deprivation	PROLIA.xml:S1:971:11	O
therapy	PROLIA.xml:S1:983:7	O
for	PROLIA.xml:S1:991:3	O
prostate	PROLIA.xml:S1:995:8	O
cancer	PROLIA.xml:S1:1004:6	O
or	PROLIA.xml:S1:1011:2	O
adjuvant	PROLIA.xml:S1:1014:8	O
aromatase	PROLIA.xml:S1:1023:9	O
inhibitor	PROLIA.xml:S1:1033:9	O
therapy	PROLIA.xml:S1:1043:7	O
for	PROLIA.xml:S1:1051:3	O
breast	PROLIA.xml:S1:1055:6	O
cancer	PROLIA.xml:S1:1062:6	O
are	PROLIA.xml:S1:1069:3	O
arthralgia	PROLIA.xml:S1:1073:10	B-AdverseReaction
and	PROLIA.xml:S1:1084:3	O
back	PROLIA.xml:S1:1088:4	B-AdverseReaction
pain	PROLIA.xml:S1:1093:4	I-AdverseReaction
.	PROLIA.xml:S1:1097:1	O

Pain	PROLIA.xml:S1:1100:4	B-AdverseReaction
in	PROLIA.xml:S1:1105:2	I-AdverseReaction
extremity	PROLIA.xml:S1:1108:9	I-AdverseReaction
and	PROLIA.xml:S1:1118:3	O
musculoskeletal	PROLIA.xml:S1:1122:15	B-AdverseReaction
pain	PROLIA.xml:S1:1138:4	I-AdverseReaction
have	PROLIA.xml:S1:1143:4	O
also	PROLIA.xml:S1:1148:4	O
been	PROLIA.xml:S1:1153:4	O
reported	PROLIA.xml:S1:1158:8	O
in	PROLIA.xml:S1:1167:2	O
clinical	PROLIA.xml:S1:1170:8	O
trials	PROLIA.xml:S1:1179:6	O
.	PROLIA.xml:S1:1185:1	O

The	PROLIA.xml:S1:1192:3	O
most	PROLIA.xml:S1:1196:4	O
common	PROLIA.xml:S1:1201:6	O
adverse	PROLIA.xml:S1:1208:7	O
reactions	PROLIA.xml:S1:1216:9	O
leading	PROLIA.xml:S1:1226:7	O
to	PROLIA.xml:S1:1234:2	O
discontinuation	PROLIA.xml:S1:1237:15	O
of	PROLIA.xml:S1:1253:2	O
Prolia	PROLIA.xml:S1:1256:6	O
in	PROLIA.xml:S1:1263:2	O
patients	PROLIA.xml:S1:1266:8	O
with	PROLIA.xml:S1:1275:4	O
postmenopausal	PROLIA.xml:S1:1280:14	O
osteoporosis	PROLIA.xml:S1:1295:12	O
are	PROLIA.xml:S1:1308:3	O
back	PROLIA.xml:S1:1312:4	B-AdverseReaction
pain	PROLIA.xml:S1:1317:4	I-AdverseReaction
and	PROLIA.xml:S1:1322:3	O
constipation	PROLIA.xml:S1:1326:12	B-AdverseReaction
.	PROLIA.xml:S1:1338:1	O

The	PROLIA.xml:S1:1344:3	O
Prolia	PROLIA.xml:S1:1348:6	O
Postmarketing	PROLIA.xml:S1:1355:13	O
Active	PROLIA.xml:S1:1369:6	O
Safety	PROLIA.xml:S1:1376:6	O
Surveillance	PROLIA.xml:S1:1383:12	O
Program	PROLIA.xml:S1:1396:7	O
is	PROLIA.xml:S1:1404:2	O
available	PROLIA.xml:S1:1407:9	O
to	PROLIA.xml:S1:1417:2	O
collect	PROLIA.xml:S1:1420:7	O
information	PROLIA.xml:S1:1428:11	O
from	PROLIA.xml:S1:1440:4	O
prescribers	PROLIA.xml:S1:1445:11	O
on	PROLIA.xml:S1:1457:2	O
specific	PROLIA.xml:S1:1460:8	O
adverse	PROLIA.xml:S1:1469:7	O
events	PROLIA.xml:S1:1477:6	O
.	PROLIA.xml:S1:1483:1	O

Please	PROLIA.xml:S1:1486:6	O
see	PROLIA.xml:S1:1493:3	O
www	PROLIA.xml:S1:1497:3	O
.	PROLIA.xml:S1:1500:1	O
proliasafety	PROLIA.xml:S1:1501:12	O
.	PROLIA.xml:S1:1513:1	O
com	PROLIA.xml:S1:1514:3	O
or	PROLIA.xml:S1:1518:2	O
call	PROLIA.xml:S1:1521:4	O
1	PROLIA.xml:S1:1526:1	O
-	PROLIA.xml:S1:1527:1	O
800	PROLIA.xml:S1:1528:3	O
-	PROLIA.xml:S1:1531:1	O
772	PROLIA.xml:S1:1532:3	O
-	PROLIA.xml:S1:1535:1	O
6436	PROLIA.xml:S1:1536:4	O
for	PROLIA.xml:S1:1541:3	O
more	PROLIA.xml:S1:1545:4	O
information	PROLIA.xml:S1:1550:11	O
about	PROLIA.xml:S1:1562:5	O
this	PROLIA.xml:S1:1568:4	O
program	PROLIA.xml:S1:1573:7	O
.	PROLIA.xml:S1:1580:1	O

EXCERPT	PROLIA.xml:S1:1590:7	O
:	PROLIA.xml:S1:1597:1	O
Postmenopausal	PROLIA.xml:S1:1605:14	O
osteoporosis	PROLIA.xml:S1:1620:12	O
:	PROLIA.xml:S1:1632:1	O
Most	PROLIA.xml:S1:1634:4	O
common	PROLIA.xml:S1:1639:6	O
adverse	PROLIA.xml:S1:1646:7	O
reactions	PROLIA.xml:S1:1654:9	O
(	PROLIA.xml:S1:1664:1	O
5%	PROLIA.xml:S1:1667:2	O
and	PROLIA.xml:S1:1670:3	O
more	PROLIA.xml:S1:1674:4	O
common	PROLIA.xml:S1:1679:6	O
than	PROLIA.xml:S1:1686:4	O
placebo	PROLIA.xml:S1:1691:7	O
)	PROLIA.xml:S1:1698:1	O
were	PROLIA.xml:S1:1700:4	O
:	PROLIA.xml:S1:1704:1	O
back	PROLIA.xml:S1:1706:4	B-AdverseReaction
pain	PROLIA.xml:S1:1711:4	I-AdverseReaction
,	PROLIA.xml:S1:1715:1	O
pain	PROLIA.xml:S1:1717:4	B-AdverseReaction
in	PROLIA.xml:S1:1722:2	I-AdverseReaction
extremity	PROLIA.xml:S1:1725:9	I-AdverseReaction
,	PROLIA.xml:S1:1734:1	O
hypercholesterolemia	PROLIA.xml:S1:1736:20	B-AdverseReaction
,	PROLIA.xml:S1:1756:1	O
musculoskeletal	PROLIA.xml:S1:1758:15	B-AdverseReaction
pain	PROLIA.xml:S1:1774:4	I-AdverseReaction
,	PROLIA.xml:S1:1778:1	O
and	PROLIA.xml:S1:1780:3	O
cystitis	PROLIA.xml:S1:1784:8	B-AdverseReaction
.	PROLIA.xml:S1:1792:1	O

Pancreatitis	PROLIA.xml:S1:1794:12	B-AdverseReaction
has	PROLIA.xml:S1:1807:3	O
been	PROLIA.xml:S1:1811:4	O
reported	PROLIA.xml:S1:1816:8	O
in	PROLIA.xml:S1:1825:2	O
clinical	PROLIA.xml:S1:1828:8	O
trials	PROLIA.xml:S1:1837:6	O
(	PROLIA.xml:S1:1844:1	O
6.1	PROLIA.xml:S1:1847:3	O
)	PROLIA.xml:S1:1852:1	O

Male	PROLIA.xml:S1:1859:4	O
Osteoporosis	PROLIA.xml:S1:1864:12	O
:	PROLIA.xml:S1:1876:1	O
Most	PROLIA.xml:S1:1878:4	O
common	PROLIA.xml:S1:1883:6	O
adverse	PROLIA.xml:S1:1890:7	O
reactions	PROLIA.xml:S1:1898:9	O
(	PROLIA.xml:S1:1908:1	O
5%	PROLIA.xml:S1:1911:2	O
and	PROLIA.xml:S1:1914:3	O
more	PROLIA.xml:S1:1918:4	O
common	PROLIA.xml:S1:1923:6	O
than	PROLIA.xml:S1:1930:4	O
placebo	PROLIA.xml:S1:1935:7	O
)	PROLIA.xml:S1:1942:1	O
were	PROLIA.xml:S1:1944:4	O
:	PROLIA.xml:S1:1948:1	O
back	PROLIA.xml:S1:1950:4	B-AdverseReaction
pain	PROLIA.xml:S1:1955:4	I-AdverseReaction
,	PROLIA.xml:S1:1959:1	O
arthralgia	PROLIA.xml:S1:1961:10	B-AdverseReaction
,	PROLIA.xml:S1:1971:1	O
and	PROLIA.xml:S1:1973:3	O
nasopharyngitis	PROLIA.xml:S1:1977:15	B-AdverseReaction
(	PROLIA.xml:S1:1993:1	O
6.1	PROLIA.xml:S1:1996:3	O
)	PROLIA.xml:S1:2001:1	O

Bone	PROLIA.xml:S1:2008:4	O
loss	PROLIA.xml:S1:2013:4	O
due	PROLIA.xml:S1:2018:3	O
to	PROLIA.xml:S1:2022:2	O
hormone	PROLIA.xml:S1:2025:7	O
ablation	PROLIA.xml:S1:2033:8	O
for	PROLIA.xml:S1:2042:3	O
cancer	PROLIA.xml:S1:2046:6	O
:	PROLIA.xml:S1:2052:1	O
Most	PROLIA.xml:S1:2054:4	O
common	PROLIA.xml:S1:2059:6	O
adverse	PROLIA.xml:S1:2066:7	O
reactions	PROLIA.xml:S1:2074:9	O
(	PROLIA.xml:S1:2084:1	O
10%	PROLIA.xml:S1:2088:3	O
and	PROLIA.xml:S1:2092:3	O
more	PROLIA.xml:S1:2096:4	O
common	PROLIA.xml:S1:2101:6	O
than	PROLIA.xml:S1:2108:4	O
placebo	PROLIA.xml:S1:2113:7	O
)	PROLIA.xml:S1:2120:1	O
were	PROLIA.xml:S1:2122:4	O
:	PROLIA.xml:S1:2126:1	O
arthralgia	PROLIA.xml:S1:2128:10	B-AdverseReaction
and	PROLIA.xml:S1:2139:3	O
back	PROLIA.xml:S1:2143:4	B-AdverseReaction
pain	PROLIA.xml:S1:2148:4	I-AdverseReaction
.	PROLIA.xml:S1:2152:1	O

Pain	PROLIA.xml:S1:2154:4	B-AdverseReaction
in	PROLIA.xml:S1:2159:2	I-AdverseReaction
extremity	PROLIA.xml:S1:2162:9	I-AdverseReaction
and	PROLIA.xml:S1:2172:3	O
musculoskeletal	PROLIA.xml:S1:2176:15	B-AdverseReaction
pain	PROLIA.xml:S1:2192:4	I-AdverseReaction
have	PROLIA.xml:S1:2197:4	O
also	PROLIA.xml:S1:2202:4	O
been	PROLIA.xml:S1:2207:4	O
reported	PROLIA.xml:S1:2212:8	O
in	PROLIA.xml:S1:2221:2	O
clinical	PROLIA.xml:S1:2224:8	O
trials	PROLIA.xml:S1:2233:6	O
(	PROLIA.xml:S1:2240:1	O
6.1	PROLIA.xml:S1:2243:3	O
)	PROLIA.xml:S1:2248:1	O

To	PROLIA.xml:S1:2257:2	O
report	PROLIA.xml:S1:2260:6	O
SUSPECTED	PROLIA.xml:S1:2267:9	O
ADVERSE	PROLIA.xml:S1:2277:7	O
REACTIONS	PROLIA.xml:S1:2285:9	O
,	PROLIA.xml:S1:2294:1	O
contact	PROLIA.xml:S1:2296:7	O
Amgen	PROLIA.xml:S1:2304:5	O
Inc	PROLIA.xml:S1:2310:3	O
.	PROLIA.xml:S1:2313:1	O

at	PROLIA.xml:S1:2315:2	O
1	PROLIA.xml:S1:2318:1	O
-	PROLIA.xml:S1:2319:1	O
800	PROLIA.xml:S1:2320:3	O
-	PROLIA.xml:S1:2323:1	O
77	PROLIA.xml:S1:2324:2	O
-	PROLIA.xml:S1:2326:1	O
AMGEN	PROLIA.xml:S1:2327:5	O
(	PROLIA.xml:S1:2333:1	O
1	PROLIA.xml:S1:2334:1	O
-	PROLIA.xml:S1:2335:1	O
800	PROLIA.xml:S1:2336:3	O
-	PROLIA.xml:S1:2339:1	O
772	PROLIA.xml:S1:2340:3	O
-	PROLIA.xml:S1:2343:1	O
6436	PROLIA.xml:S1:2344:4	O
)	PROLIA.xml:S1:2348:1	O
or	PROLIA.xml:S1:2350:2	O
FDA	PROLIA.xml:S1:2353:3	O
at	PROLIA.xml:S1:2357:2	O
1	PROLIA.xml:S1:2360:1	O
-	PROLIA.xml:S1:2361:1	O
800	PROLIA.xml:S1:2362:3	O
-	PROLIA.xml:S1:2365:1	O
FDA	PROLIA.xml:S1:2366:3	O
-	PROLIA.xml:S1:2369:1	O
1088	PROLIA.xml:S1:2370:4	O
or	PROLIA.xml:S1:2375:2	O
www	PROLIA.xml:S1:2381:3	O
.	PROLIA.xml:S1:2384:1	O
fda	PROLIA.xml:S1:2385:3	O
.	PROLIA.xml:S1:2388:1	O
gov	PROLIA.xml:S1:2389:3	O
medwatch	PROLIA.xml:S1:2393:8	O
.	PROLIA.xml:S1:2407:1	O

6.1	PROLIA.xml:S1:2423:3	O

Clinical	PROLIA.xml:S1:2427:8	O

Trials	PROLIA.xml:S1:2436:6	O
Experience	PROLIA.xml:S1:2443:10	O

Because	PROLIA.xml:S1:2457:7	O
clinical	PROLIA.xml:S1:2465:8	O
studies	PROLIA.xml:S1:2474:7	O
are	PROLIA.xml:S1:2482:3	O
conducted	PROLIA.xml:S1:2486:9	O
under	PROLIA.xml:S1:2496:5	O
widely	PROLIA.xml:S1:2502:6	O
varying	PROLIA.xml:S1:2509:7	O
conditions	PROLIA.xml:S1:2517:10	O
,	PROLIA.xml:S1:2527:1	O
adverse	PROLIA.xml:S1:2529:7	O
reaction	PROLIA.xml:S1:2537:8	O
rates	PROLIA.xml:S1:2546:5	O
observed	PROLIA.xml:S1:2552:8	O
in	PROLIA.xml:S1:2561:2	O
the	PROLIA.xml:S1:2564:3	O
clinical	PROLIA.xml:S1:2568:8	O
studies	PROLIA.xml:S1:2577:7	O
of	PROLIA.xml:S1:2585:2	O
a	PROLIA.xml:S1:2588:1	O
drug	PROLIA.xml:S1:2590:4	O
cannot	PROLIA.xml:S1:2595:6	O
be	PROLIA.xml:S1:2602:2	O
directly	PROLIA.xml:S1:2605:8	O
compared	PROLIA.xml:S1:2614:8	O
to	PROLIA.xml:S1:2623:2	O
rates	PROLIA.xml:S1:2626:5	O
in	PROLIA.xml:S1:2632:2	O
the	PROLIA.xml:S1:2635:3	O
clinical	PROLIA.xml:S1:2639:8	O
studies	PROLIA.xml:S1:2648:7	O
of	PROLIA.xml:S1:2656:2	O
another	PROLIA.xml:S1:2659:7	O
drug	PROLIA.xml:S1:2667:4	O
and	PROLIA.xml:S1:2672:3	O
may	PROLIA.xml:S1:2676:3	O
not	PROLIA.xml:S1:2680:3	O
reflect	PROLIA.xml:S1:2684:7	O
the	PROLIA.xml:S1:2692:3	O
rates	PROLIA.xml:S1:2696:5	O
observed	PROLIA.xml:S1:2702:8	O
in	PROLIA.xml:S1:2711:2	O
clinical	PROLIA.xml:S1:2714:8	O
practice	PROLIA.xml:S1:2723:8	O
.	PROLIA.xml:S1:2731:1	O

Treatment	PROLIA.xml:S1:2740:9	O
of	PROLIA.xml:S1:2750:2	O
Postmenopausal	PROLIA.xml:S1:2753:14	O
Women	PROLIA.xml:S1:2768:5	O
with	PROLIA.xml:S1:2774:4	O
Osteoporosis	PROLIA.xml:S1:2779:12	O

The	PROLIA.xml:S1:2798:3	O
safety	PROLIA.xml:S1:2802:6	O
of	PROLIA.xml:S1:2809:2	O
Prolia	PROLIA.xml:S1:2812:6	O
in	PROLIA.xml:S1:2819:2	O
the	PROLIA.xml:S1:2822:3	O
treatment	PROLIA.xml:S1:2826:9	O
of	PROLIA.xml:S1:2836:2	O
postmenopausal	PROLIA.xml:S1:2839:14	O
osteoporosis	PROLIA.xml:S1:2854:12	O
was	PROLIA.xml:S1:2867:3	O
assessed	PROLIA.xml:S1:2871:8	O
in	PROLIA.xml:S1:2880:2	O
a	PROLIA.xml:S1:2883:1	O
3	PROLIA.xml:S1:2885:1	O
-	PROLIA.xml:S1:2886:1	O
year	PROLIA.xml:S1:2887:4	O
,	PROLIA.xml:S1:2891:1	O
randomized	PROLIA.xml:S1:2893:10	O
,	PROLIA.xml:S1:2903:1	O
double	PROLIA.xml:S1:2905:6	O
-	PROLIA.xml:S1:2911:1	O
blind	PROLIA.xml:S1:2912:5	O
,	PROLIA.xml:S1:2917:1	O
placebo	PROLIA.xml:S1:2919:7	O
-	PROLIA.xml:S1:2926:1	O
controlled	PROLIA.xml:S1:2927:10	O
,	PROLIA.xml:S1:2937:1	O
multinational	PROLIA.xml:S1:2939:13	O
study	PROLIA.xml:S1:2953:5	O
of	PROLIA.xml:S1:2959:2	O
7808	PROLIA.xml:S1:2962:4	O
postmenopausal	PROLIA.xml:S1:2967:14	O
women	PROLIA.xml:S1:2982:5	O
aged	PROLIA.xml:S1:2988:4	O
60	PROLIA.xml:S1:2993:2	O
to	PROLIA.xml:S1:2996:2	O
91	PROLIA.xml:S1:2999:2	O
years	PROLIA.xml:S1:3002:5	O
.	PROLIA.xml:S1:3007:1	O

A	PROLIA.xml:S1:3009:1	O
total	PROLIA.xml:S1:3011:5	O
of	PROLIA.xml:S1:3017:2	O
3876	PROLIA.xml:S1:3020:4	O
women	PROLIA.xml:S1:3025:5	O
were	PROLIA.xml:S1:3031:4	O
exposed	PROLIA.xml:S1:3036:7	O
to	PROLIA.xml:S1:3044:2	O
placebo	PROLIA.xml:S1:3047:7	O
and	PROLIA.xml:S1:3055:3	O
3886	PROLIA.xml:S1:3059:4	O
women	PROLIA.xml:S1:3064:5	O
were	PROLIA.xml:S1:3070:4	O
exposed	PROLIA.xml:S1:3075:7	O
to	PROLIA.xml:S1:3083:2	O
Prolia	PROLIA.xml:S1:3086:6	O
administered	PROLIA.xml:S1:3093:12	O
subcutaneously	PROLIA.xml:S1:3106:14	O
once	PROLIA.xml:S1:3121:4	O
every	PROLIA.xml:S1:3126:5	O
6	PROLIA.xml:S1:3132:1	O
months	PROLIA.xml:S1:3134:6	O
as	PROLIA.xml:S1:3141:2	O
a	PROLIA.xml:S1:3144:1	O
single	PROLIA.xml:S1:3146:6	O
60	PROLIA.xml:S1:3153:2	O
mg	PROLIA.xml:S1:3156:2	O
dose	PROLIA.xml:S1:3159:4	O
.	PROLIA.xml:S1:3163:1	O

All	PROLIA.xml:S1:3165:3	O
women	PROLIA.xml:S1:3169:5	O
were	PROLIA.xml:S1:3175:4	O
instructed	PROLIA.xml:S1:3180:10	O
to	PROLIA.xml:S1:3191:2	O
take	PROLIA.xml:S1:3194:4	O
at	PROLIA.xml:S1:3199:2	O
least	PROLIA.xml:S1:3202:5	O
1000	PROLIA.xml:S1:3208:4	O
mg	PROLIA.xml:S1:3213:2	O
of	PROLIA.xml:S1:3216:2	O
calcium	PROLIA.xml:S1:3219:7	O
and	PROLIA.xml:S1:3227:3	O
400	PROLIA.xml:S1:3231:3	O
IU	PROLIA.xml:S1:3235:2	O
of	PROLIA.xml:S1:3238:2	O
vitamin	PROLIA.xml:S1:3241:7	O
D	PROLIA.xml:S1:3249:1	O
supplementation	PROLIA.xml:S1:3251:15	O
per	PROLIA.xml:S1:3267:3	O
day	PROLIA.xml:S1:3271:3	O
.	PROLIA.xml:S1:3274:1	O

The	PROLIA.xml:S1:3280:3	O
incidence	PROLIA.xml:S1:3284:9	O
of	PROLIA.xml:S1:3294:2	O
all	PROLIA.xml:S1:3297:3	O
-	PROLIA.xml:S1:3300:1	O
cause	PROLIA.xml:S1:3301:5	O
mortality	PROLIA.xml:S1:3307:9	B-AdverseReaction
was	PROLIA.xml:S1:3317:3	O
2.3%	PROLIA.xml:S1:3321:4	O
(	PROLIA.xml:S1:3326:1	O
n	PROLIA.xml:S1:3327:1	O
90	PROLIA.xml:S1:3331:2	O
)	PROLIA.xml:S1:3333:1	O
in	PROLIA.xml:S1:3335:2	O
the	PROLIA.xml:S1:3338:3	O
placebo	PROLIA.xml:S1:3342:7	O
group	PROLIA.xml:S1:3350:5	O
and	PROLIA.xml:S1:3356:3	O
1.8%	PROLIA.xml:S1:3360:4	O
(	PROLIA.xml:S1:3365:1	O
n	PROLIA.xml:S1:3366:1	O
70	PROLIA.xml:S1:3370:2	O
)	PROLIA.xml:S1:3372:1	O
in	PROLIA.xml:S1:3374:2	O
the	PROLIA.xml:S1:3377:3	O
Prolia	PROLIA.xml:S1:3381:6	O
group	PROLIA.xml:S1:3388:5	O
.	PROLIA.xml:S1:3393:1	O

The	PROLIA.xml:S1:3395:3	O
incidence	PROLIA.xml:S1:3399:9	O
of	PROLIA.xml:S1:3409:2	O
nonfatal	PROLIA.xml:S1:3412:8	O
serious	PROLIA.xml:S1:3421:7	O
adverse	PROLIA.xml:S1:3429:7	O
events	PROLIA.xml:S1:3437:6	O
was	PROLIA.xml:S1:3444:3	O
24.2%	PROLIA.xml:S1:3448:5	O
in	PROLIA.xml:S1:3454:2	O
the	PROLIA.xml:S1:3457:3	O
placebo	PROLIA.xml:S1:3461:7	O
group	PROLIA.xml:S1:3469:5	O
and	PROLIA.xml:S1:3475:3	O
25.0%	PROLIA.xml:S1:3479:5	O
in	PROLIA.xml:S1:3485:2	O
the	PROLIA.xml:S1:3488:3	O
Prolia	PROLIA.xml:S1:3492:6	O
group	PROLIA.xml:S1:3499:5	O
.	PROLIA.xml:S1:3504:1	O

The	PROLIA.xml:S1:3506:3	O
percentage	PROLIA.xml:S1:3510:10	O
of	PROLIA.xml:S1:3521:2	O
patients	PROLIA.xml:S1:3524:8	O
who	PROLIA.xml:S1:3533:3	O
withdrew	PROLIA.xml:S1:3537:8	O
from	PROLIA.xml:S1:3546:4	O
the	PROLIA.xml:S1:3551:3	O
study	PROLIA.xml:S1:3555:5	O
due	PROLIA.xml:S1:3561:3	O
to	PROLIA.xml:S1:3565:2	O
adverse	PROLIA.xml:S1:3568:7	O
events	PROLIA.xml:S1:3576:6	O
was	PROLIA.xml:S1:3583:3	O
2.1%	PROLIA.xml:S1:3587:4	O
and	PROLIA.xml:S1:3592:3	O
2.4%	PROLIA.xml:S1:3596:4	O
for	PROLIA.xml:S1:3601:3	O
the	PROLIA.xml:S1:3605:3	O
placebo	PROLIA.xml:S1:3609:7	O
and	PROLIA.xml:S1:3617:3	O
Prolia	PROLIA.xml:S1:3621:6	O
groups	PROLIA.xml:S1:3628:6	O
,	PROLIA.xml:S1:3634:1	O
respectively	PROLIA.xml:S1:3636:12	O
.	PROLIA.xml:S1:3648:1	O

Adverse	PROLIA.xml:S1:3654:7	O
reactions	PROLIA.xml:S1:3662:9	O
reported	PROLIA.xml:S1:3672:8	O
in	PROLIA.xml:S1:3681:2	O
2%	PROLIA.xml:S1:3687:2	O
of	PROLIA.xml:S1:3690:2	O
postmenopausal	PROLIA.xml:S1:3693:14	O
women	PROLIA.xml:S1:3708:5	O
with	PROLIA.xml:S1:3714:4	O
osteoporosis	PROLIA.xml:S1:3719:12	O
and	PROLIA.xml:S1:3732:3	O
more	PROLIA.xml:S1:3736:4	O
frequently	PROLIA.xml:S1:3741:10	O
in	PROLIA.xml:S1:3752:2	O
the	PROLIA.xml:S1:3755:3	O
Prolia	PROLIA.xml:S1:3759:6	O
-	PROLIA.xml:S1:3765:1	O
treated	PROLIA.xml:S1:3766:7	O
women	PROLIA.xml:S1:3774:5	O
than	PROLIA.xml:S1:3780:4	O
in	PROLIA.xml:S1:3785:2	O
the	PROLIA.xml:S1:3788:3	O
placebo	PROLIA.xml:S1:3792:7	O
-	PROLIA.xml:S1:3799:1	O
treated	PROLIA.xml:S1:3800:7	O
women	PROLIA.xml:S1:3808:5	O
are	PROLIA.xml:S1:3814:3	O
shown	PROLIA.xml:S1:3818:5	O
in	PROLIA.xml:S1:3824:2	O
the	PROLIA.xml:S1:3827:3	O
table	PROLIA.xml:S1:3831:5	O
below	PROLIA.xml:S1:3837:5	O
.	PROLIA.xml:S1:3842:1	O

Table	PROLIA.xml:S1:3848:5	O
1	PROLIA.xml:S1:3854:1	O
.	PROLIA.xml:S1:3855:1	O

Adverse	PROLIA.xml:S1:3857:7	O
Reactions	PROLIA.xml:S1:3865:9	O
Occurring	PROLIA.xml:S1:3875:9	O
in	PROLIA.xml:S1:3885:2	O
2%	PROLIA.xml:S1:3891:2	O
of	PROLIA.xml:S1:3894:2	O
Patients	PROLIA.xml:S1:3897:8	O
with	PROLIA.xml:S1:3906:4	O
Osteoporosis	PROLIA.xml:S1:3911:12	O
and	PROLIA.xml:S1:3924:3	O
More	PROLIA.xml:S1:3928:4	O
Frequently	PROLIA.xml:S1:3933:10	O
than	PROLIA.xml:S1:3944:4	O
in	PROLIA.xml:S1:3949:2	O
Placebo	PROLIA.xml:S1:3952:7	O
-	PROLIA.xml:S1:3959:1	O
treated	PROLIA.xml:S1:3960:7	O
Patients	PROLIA.xml:S1:3968:8	O

SYSTEM	PROLIA.xml:S1:3981:6	O
ORGAN	PROLIA.xml:S1:3988:5	O
CLASS	PROLIA.xml:S1:3994:5	O
Preferred	PROLIA.xml:S1:4002:9	O
Term	PROLIA.xml:S1:4012:4	O
Prolia	PROLIA.xml:S1:4023:6	O
(	PROLIA.xml:S1:4029:1	O
N	PROLIA.xml:S1:4030:1	O
3886	PROLIA.xml:S1:4034:4	O
)	PROLIA.xml:S1:4038:1	O
n	PROLIA.xml:S1:4039:1	O
(	PROLIA.xml:S1:4041:1	O
)	PROLIA.xml:S1:4043:1	O
Placebo	PROLIA.xml:S1:4051:7	O
(	PROLIA.xml:S1:4058:1	O
N	PROLIA.xml:S1:4059:1	O
3876	PROLIA.xml:S1:4063:4	O
)	PROLIA.xml:S1:4067:1	O
n	PROLIA.xml:S1:4068:1	O
(	PROLIA.xml:S1:4070:1	O
)	PROLIA.xml:S1:4072:1	O

BLOOD	PROLIA.xml:S1:4083:5	O
AND	PROLIA.xml:S1:4089:3	O
LYMPHATIC	PROLIA.xml:S1:4093:9	O
SYSTEM	PROLIA.xml:S1:4103:6	O
DISORDERS	PROLIA.xml:S1:4110:9	O

Anemia	PROLIA.xml:S1:4130:6	B-AdverseReaction
129	PROLIA.xml:S1:4139:3	O
(	PROLIA.xml:S1:4143:1	O
3.3	PROLIA.xml:S1:4144:3	O
)	PROLIA.xml:S1:4147:1	O
107	PROLIA.xml:S1:4151:3	O
(	PROLIA.xml:S1:4155:1	O
2.8	PROLIA.xml:S1:4156:3	O
)	PROLIA.xml:S1:4159:1	O

CARDIAC	PROLIA.xml:S1:4168:7	O
DISORDERS	PROLIA.xml:S1:4176:9	O

Angina	PROLIA.xml:S1:4196:6	B-AdverseReaction
pectoris	PROLIA.xml:S1:4203:8	I-AdverseReaction
101	PROLIA.xml:S1:4214:3	O
(	PROLIA.xml:S1:4218:1	O
2.6	PROLIA.xml:S1:4219:3	O
)	PROLIA.xml:S1:4222:1	O
87	PROLIA.xml:S1:4226:2	O
(	PROLIA.xml:S1:4229:1	O
2.2	PROLIA.xml:S1:4230:3	O
)	PROLIA.xml:S1:4233:1	O

Atrial	PROLIA.xml:S1:4243:6	B-AdverseReaction
fibrillation	PROLIA.xml:S1:4250:12	I-AdverseReaction
79	PROLIA.xml:S1:4265:2	O
(	PROLIA.xml:S1:4268:1	O
2.0	PROLIA.xml:S1:4269:3	O
)	PROLIA.xml:S1:4272:1	O
77	PROLIA.xml:S1:4276:2	O
(	PROLIA.xml:S1:4279:1	O
2.0	PROLIA.xml:S1:4280:3	O
)	PROLIA.xml:S1:4283:1	O

EAR	PROLIA.xml:S1:4292:3	O
AND	PROLIA.xml:S1:4296:3	O
LABYRINTH	PROLIA.xml:S1:4300:9	O
DISORDERS	PROLIA.xml:S1:4310:9	O

Vertigo	PROLIA.xml:S1:4330:7	B-AdverseReaction
195	PROLIA.xml:S1:4340:3	O
(	PROLIA.xml:S1:4344:1	O
5.0	PROLIA.xml:S1:4345:3	O
)	PROLIA.xml:S1:4348:1	O
187	PROLIA.xml:S1:4352:3	O
(	PROLIA.xml:S1:4356:1	O
4.8	PROLIA.xml:S1:4357:3	O
)	PROLIA.xml:S1:4360:1	O

GASTROINTESTINAL	PROLIA.xml:S1:4369:16	O
DISORDERS	PROLIA.xml:S1:4386:9	O

Abdominal	PROLIA.xml:S1:4406:9	B-AdverseReaction
pain	PROLIA.xml:S1:4416:4	I-AdverseReaction
upper	PROLIA.xml:S1:4421:5	I-AdverseReaction
129	PROLIA.xml:S1:4429:3	O
(	PROLIA.xml:S1:4433:1	O
3.3	PROLIA.xml:S1:4434:3	O
)	PROLIA.xml:S1:4437:1	O
111	PROLIA.xml:S1:4441:3	O
(	PROLIA.xml:S1:4445:1	O
2.9	PROLIA.xml:S1:4446:3	O
)	PROLIA.xml:S1:4449:1	O

Flatulence	PROLIA.xml:S1:4459:10	B-AdverseReaction
84	PROLIA.xml:S1:4472:2	O
(	PROLIA.xml:S1:4475:1	O
2.2	PROLIA.xml:S1:4476:3	O
)	PROLIA.xml:S1:4479:1	O
53	PROLIA.xml:S1:4483:2	O
(	PROLIA.xml:S1:4486:1	O
1.4	PROLIA.xml:S1:4487:3	O
)	PROLIA.xml:S1:4490:1	O

Gastroesophageal	PROLIA.xml:S1:4500:16	B-AdverseReaction
reflux	PROLIA.xml:S1:4517:6	I-AdverseReaction
disease	PROLIA.xml:S1:4524:7	I-AdverseReaction
80	PROLIA.xml:S1:4534:2	O
(	PROLIA.xml:S1:4537:1	O
2.1	PROLIA.xml:S1:4538:3	O
)	PROLIA.xml:S1:4541:1	O
66	PROLIA.xml:S1:4545:2	O
(	PROLIA.xml:S1:4548:1	O
1.7	PROLIA.xml:S1:4549:3	O
)	PROLIA.xml:S1:4552:1	O

GENERAL	PROLIA.xml:S1:4561:7	O
DISORDERS	PROLIA.xml:S1:4569:9	O
AND	PROLIA.xml:S1:4579:3	O
ADMINISTRATION	PROLIA.xml:S1:4583:14	O
SITE	PROLIA.xml:S1:4598:4	O
CONDITIONS	PROLIA.xml:S1:4603:10	O

Edema	PROLIA.xml:S1:4624:5	B-AdverseReaction
peripheral	PROLIA.xml:S1:4630:10	I-AdverseReaction
189	PROLIA.xml:S1:4643:3	O
(	PROLIA.xml:S1:4647:1	O
4.9	PROLIA.xml:S1:4648:3	O
)	PROLIA.xml:S1:4651:1	O
155	PROLIA.xml:S1:4655:3	O
(	PROLIA.xml:S1:4659:1	O
4.0	PROLIA.xml:S1:4660:3	O
)	PROLIA.xml:S1:4663:1	O

Asthenia	PROLIA.xml:S1:4673:8	B-AdverseReaction
90	PROLIA.xml:S1:4684:2	O
(	PROLIA.xml:S1:4687:1	O
2.3	PROLIA.xml:S1:4688:3	O
)	PROLIA.xml:S1:4691:1	O
73	PROLIA.xml:S1:4695:2	O
(	PROLIA.xml:S1:4698:1	O
1.9	PROLIA.xml:S1:4699:3	O
)	PROLIA.xml:S1:4702:1	O

INFECTIONS	PROLIA.xml:S1:4711:10	O
AND	PROLIA.xml:S1:4722:3	O
INFESTATIONS	PROLIA.xml:S1:4726:12	O

Cystitis	PROLIA.xml:S1:4749:8	B-AdverseReaction
228	PROLIA.xml:S1:4760:3	O
(	PROLIA.xml:S1:4764:1	O
5.9	PROLIA.xml:S1:4765:3	O
)	PROLIA.xml:S1:4768:1	O
225	PROLIA.xml:S1:4772:3	O
(	PROLIA.xml:S1:4776:1	O
5.8	PROLIA.xml:S1:4777:3	O
)	PROLIA.xml:S1:4780:1	O

Upper	PROLIA.xml:S1:4790:5	B-AdverseReaction
respiratory	PROLIA.xml:S1:4796:11	I-AdverseReaction
tract	PROLIA.xml:S1:4808:5	I-AdverseReaction
infection	PROLIA.xml:S1:4814:9	I-AdverseReaction
190	PROLIA.xml:S1:4826:3	O
(	PROLIA.xml:S1:4830:1	O
4.9	PROLIA.xml:S1:4831:3	O
)	PROLIA.xml:S1:4834:1	O
167	PROLIA.xml:S1:4838:3	O
(	PROLIA.xml:S1:4842:1	O
4.3	PROLIA.xml:S1:4843:3	O
)	PROLIA.xml:S1:4846:1	O

Pneumonia	PROLIA.xml:S1:4856:9	B-AdverseReaction
152	PROLIA.xml:S1:4868:3	O
(	PROLIA.xml:S1:4872:1	O
3.9	PROLIA.xml:S1:4873:3	O
)	PROLIA.xml:S1:4876:1	O
150	PROLIA.xml:S1:4880:3	O
(	PROLIA.xml:S1:4884:1	O
3.9	PROLIA.xml:S1:4885:3	O
)	PROLIA.xml:S1:4888:1	O

Pharyngitis	PROLIA.xml:S1:4898:11	B-AdverseReaction
91	PROLIA.xml:S1:4912:2	O
(	PROLIA.xml:S1:4915:1	O
2.3	PROLIA.xml:S1:4916:3	O
)	PROLIA.xml:S1:4919:1	O
78	PROLIA.xml:S1:4923:2	O
(	PROLIA.xml:S1:4926:1	O
2.0	PROLIA.xml:S1:4927:3	O
)	PROLIA.xml:S1:4930:1	O

Herpes	PROLIA.xml:S1:4940:6	B-AdverseReaction
zoster	PROLIA.xml:S1:4947:6	I-AdverseReaction
79	PROLIA.xml:S1:4956:2	O
(	PROLIA.xml:S1:4959:1	O
2.0	PROLIA.xml:S1:4960:3	O
)	PROLIA.xml:S1:4963:1	O
72	PROLIA.xml:S1:4967:2	O
(	PROLIA.xml:S1:4970:1	O
1.9	PROLIA.xml:S1:4971:3	O
)	PROLIA.xml:S1:4974:1	O

METABOLISM	PROLIA.xml:S1:4983:10	O
AND	PROLIA.xml:S1:4994:3	O
NUTRITION	PROLIA.xml:S1:4998:9	O
DISORDERS	PROLIA.xml:S1:5008:9	O

Hypercholesterolemia	PROLIA.xml:S1:5028:20	B-AdverseReaction
280	PROLIA.xml:S1:5051:3	O
(	PROLIA.xml:S1:5055:1	O
7.2	PROLIA.xml:S1:5056:3	O
)	PROLIA.xml:S1:5059:1	O
236	PROLIA.xml:S1:5063:3	O
(	PROLIA.xml:S1:5067:1	O
6.1	PROLIA.xml:S1:5068:3	O
)	PROLIA.xml:S1:5071:1	O

MUSCULOSKELETAL	PROLIA.xml:S1:5080:15	O
AND	PROLIA.xml:S1:5096:3	O
CONNECTIVE	PROLIA.xml:S1:5100:10	O
TISSUE	PROLIA.xml:S1:5111:6	O
DISORDERS	PROLIA.xml:S1:5118:9	O

Back	PROLIA.xml:S1:5138:4	B-AdverseReaction
pain	PROLIA.xml:S1:5143:4	I-AdverseReaction
1347	PROLIA.xml:S1:5150:4	O
(	PROLIA.xml:S1:5155:1	O
34.7	PROLIA.xml:S1:5156:4	O
)	PROLIA.xml:S1:5160:1	O
1340	PROLIA.xml:S1:5164:4	O
(	PROLIA.xml:S1:5169:1	O
34.6	PROLIA.xml:S1:5170:4	O
)	PROLIA.xml:S1:5174:1	O

Pain	PROLIA.xml:S1:5184:4	B-AdverseReaction
in	PROLIA.xml:S1:5189:2	I-AdverseReaction
extremity	PROLIA.xml:S1:5192:9	I-AdverseReaction
453	PROLIA.xml:S1:5204:3	O
(	PROLIA.xml:S1:5208:1	O
11.7	PROLIA.xml:S1:5209:4	O
)	PROLIA.xml:S1:5213:1	O
430	PROLIA.xml:S1:5217:3	O
(	PROLIA.xml:S1:5221:1	O
11.1	PROLIA.xml:S1:5222:4	O
)	PROLIA.xml:S1:5226:1	O

Musculoskeletal	PROLIA.xml:S1:5236:15	B-AdverseReaction
pain	PROLIA.xml:S1:5252:4	I-AdverseReaction
297	PROLIA.xml:S1:5259:3	O
(	PROLIA.xml:S1:5263:1	O
7.6	PROLIA.xml:S1:5264:3	O
)	PROLIA.xml:S1:5267:1	O
291	PROLIA.xml:S1:5271:3	O
(	PROLIA.xml:S1:5275:1	O
7.5	PROLIA.xml:S1:5276:3	O
)	PROLIA.xml:S1:5279:1	O

Bone	PROLIA.xml:S1:5289:4	B-AdverseReaction
pain	PROLIA.xml:S1:5294:4	I-AdverseReaction
142	PROLIA.xml:S1:5301:3	O
(	PROLIA.xml:S1:5305:1	O
3.7	PROLIA.xml:S1:5306:3	O
)	PROLIA.xml:S1:5309:1	O
117	PROLIA.xml:S1:5313:3	O
(	PROLIA.xml:S1:5317:1	O
3.0	PROLIA.xml:S1:5318:3	O
)	PROLIA.xml:S1:5321:1	O

Myalgia	PROLIA.xml:S1:5331:7	B-AdverseReaction
114	PROLIA.xml:S1:5341:3	O
(	PROLIA.xml:S1:5345:1	O
2.9	PROLIA.xml:S1:5346:3	O
)	PROLIA.xml:S1:5349:1	O
94	PROLIA.xml:S1:5353:2	O
(	PROLIA.xml:S1:5356:1	O
2.4	PROLIA.xml:S1:5357:3	O
)	PROLIA.xml:S1:5360:1	O

Spinal	PROLIA.xml:S1:5370:6	B-AdverseReaction
osteoarthritis	PROLIA.xml:S1:5377:14	I-AdverseReaction
82	PROLIA.xml:S1:5394:2	O
(	PROLIA.xml:S1:5397:1	O
2.1	PROLIA.xml:S1:5398:3	O
)	PROLIA.xml:S1:5401:1	O
64	PROLIA.xml:S1:5405:2	O
(	PROLIA.xml:S1:5408:1	O
1.7	PROLIA.xml:S1:5409:3	O
)	PROLIA.xml:S1:5412:1	O

NERVOUS	PROLIA.xml:S1:5421:7	O
SYSTEM	PROLIA.xml:S1:5429:6	O
DISORDERS	PROLIA.xml:S1:5436:9	O

Sciatica	PROLIA.xml:S1:5456:8	B-AdverseReaction
178	PROLIA.xml:S1:5467:3	O
(	PROLIA.xml:S1:5471:1	O
4.6	PROLIA.xml:S1:5472:3	O
)	PROLIA.xml:S1:5475:1	O
149	PROLIA.xml:S1:5479:3	O
(	PROLIA.xml:S1:5483:1	O
3.8	PROLIA.xml:S1:5484:3	O
)	PROLIA.xml:S1:5487:1	O

PSYCHIATRIC	PROLIA.xml:S1:5496:11	O
DISORDERS	PROLIA.xml:S1:5508:9	O

Insomnia	PROLIA.xml:S1:5528:8	B-AdverseReaction
126	PROLIA.xml:S1:5539:3	O
(	PROLIA.xml:S1:5543:1	O
3.2	PROLIA.xml:S1:5544:3	O
)	PROLIA.xml:S1:5547:1	O
122	PROLIA.xml:S1:5551:3	O
(	PROLIA.xml:S1:5555:1	O
3.1	PROLIA.xml:S1:5556:3	O
)	PROLIA.xml:S1:5559:1	O

SKIN	PROLIA.xml:S1:5568:4	O
AND	PROLIA.xml:S1:5573:3	O
SUBCUTANEOUS	PROLIA.xml:S1:5577:12	O
TISSUE	PROLIA.xml:S1:5590:6	O
DISORDERS	PROLIA.xml:S1:5597:9	O

Rash	PROLIA.xml:S1:5617:4	B-AdverseReaction
96	PROLIA.xml:S1:5624:2	O
(	PROLIA.xml:S1:5627:1	O
2.5	PROLIA.xml:S1:5628:3	O
)	PROLIA.xml:S1:5631:1	O
79	PROLIA.xml:S1:5635:2	O
(	PROLIA.xml:S1:5638:1	O
2.0	PROLIA.xml:S1:5639:3	O
)	PROLIA.xml:S1:5642:1	O

Pruritus	PROLIA.xml:S1:5652:8	B-AdverseReaction
87	PROLIA.xml:S1:5663:2	O
(	PROLIA.xml:S1:5666:1	O
2.2	PROLIA.xml:S1:5667:3	O
)	PROLIA.xml:S1:5670:1	O
82	PROLIA.xml:S1:5674:2	O
(	PROLIA.xml:S1:5677:1	O
2.1	PROLIA.xml:S1:5678:3	O
)	PROLIA.xml:S1:5681:1	O

Hypocalcemia	PROLIA.xml:S1:5697:12	B-AdverseReaction
Decreases	PROLIA.xml:S1:5711:9	B-AdverseReaction
in	PROLIA.xml:S1:5721:2	I-AdverseReaction
serum	PROLIA.xml:S1:5724:5	I-AdverseReaction
calcium	PROLIA.xml:S1:5730:7	I-AdverseReaction
levels	PROLIA.xml:S1:5738:6	I-AdverseReaction
to	PROLIA.xml:S1:5745:2	O
less	PROLIA.xml:S1:5748:4	O
than	PROLIA.xml:S1:5753:4	O
8.5	PROLIA.xml:S1:5758:3	O
mg	PROLIA.xml:S1:5762:2	O
dL	PROLIA.xml:S1:5765:2	O
at	PROLIA.xml:S1:5768:2	O
any	PROLIA.xml:S1:5771:3	O
visit	PROLIA.xml:S1:5775:5	O
were	PROLIA.xml:S1:5781:4	O
reported	PROLIA.xml:S1:5786:8	O
in	PROLIA.xml:S1:5795:2	O
0.4%	PROLIA.xml:S1:5798:4	O
women	PROLIA.xml:S1:5803:5	O
in	PROLIA.xml:S1:5809:2	O
the	PROLIA.xml:S1:5812:3	O
placebo	PROLIA.xml:S1:5816:7	O
group	PROLIA.xml:S1:5824:5	O
and	PROLIA.xml:S1:5830:3	O
1.7%	PROLIA.xml:S1:5834:4	O
women	PROLIA.xml:S1:5839:5	O
in	PROLIA.xml:S1:5845:2	O
the	PROLIA.xml:S1:5848:3	O
Prolia	PROLIA.xml:S1:5852:6	O
group	PROLIA.xml:S1:5859:5	O
.	PROLIA.xml:S1:5864:1	O

The	PROLIA.xml:S1:5866:3	O
nadir	PROLIA.xml:S1:5870:5	O
in	PROLIA.xml:S1:5876:2	O
serum	PROLIA.xml:S1:5879:5	O
calcium	PROLIA.xml:S1:5885:7	O
level	PROLIA.xml:S1:5893:5	O
occurs	PROLIA.xml:S1:5899:6	O
at	PROLIA.xml:S1:5906:2	O
approximately	PROLIA.xml:S1:5909:13	O
day	PROLIA.xml:S1:5923:3	O
10	PROLIA.xml:S1:5927:2	O
after	PROLIA.xml:S1:5930:5	O
Prolia	PROLIA.xml:S1:5936:6	O
dosing	PROLIA.xml:S1:5943:6	O
in	PROLIA.xml:S1:5950:2	O
subjects	PROLIA.xml:S1:5953:8	O
with	PROLIA.xml:S1:5962:4	O
normal	PROLIA.xml:S1:5967:6	O
renal	PROLIA.xml:S1:5974:5	O
function	PROLIA.xml:S1:5980:8	O
.	PROLIA.xml:S1:5988:1	O

In	PROLIA.xml:S1:5994:2	O

clinical	PROLIA.xml:S1:5997:8	O
studies	PROLIA.xml:S1:6006:7	O
,	PROLIA.xml:S1:6013:1	O
subjects	PROLIA.xml:S1:6015:8	O
with	PROLIA.xml:S1:6024:4	O
impaired	PROLIA.xml:S1:6029:8	O
renal	PROLIA.xml:S1:6038:5	O
function	PROLIA.xml:S1:6044:8	O
were	PROLIA.xml:S1:6053:4	O
more	PROLIA.xml:S1:6058:4	O
likely	PROLIA.xml:S1:6063:6	O
to	PROLIA.xml:S1:6070:2	O
have	PROLIA.xml:S1:6073:4	O
greater	PROLIA.xml:S1:6078:7	O
reductions	PROLIA.xml:S1:6086:10	O
in	PROLIA.xml:S1:6097:2	O
serum	PROLIA.xml:S1:6100:5	O
calcium	PROLIA.xml:S1:6106:7	O
levels	PROLIA.xml:S1:6114:6	O
compared	PROLIA.xml:S1:6121:8	O
to	PROLIA.xml:S1:6130:2	O
subjects	PROLIA.xml:S1:6133:8	O
with	PROLIA.xml:S1:6142:4	O
normal	PROLIA.xml:S1:6147:6	O
renal	PROLIA.xml:S1:6154:5	O
function	PROLIA.xml:S1:6160:8	O
.	PROLIA.xml:S1:6168:1	O

In	PROLIA.xml:S1:6170:2	O
a	PROLIA.xml:S1:6173:1	O
study	PROLIA.xml:S1:6175:5	O
of	PROLIA.xml:S1:6181:2	O
55	PROLIA.xml:S1:6184:2	O
subjects	PROLIA.xml:S1:6187:8	O
with	PROLIA.xml:S1:6196:4	O
varying	PROLIA.xml:S1:6201:7	O
degrees	PROLIA.xml:S1:6209:7	O
of	PROLIA.xml:S1:6217:2	O
renal	PROLIA.xml:S1:6220:5	O
function	PROLIA.xml:S1:6226:8	O
,	PROLIA.xml:S1:6234:1	O
serum	PROLIA.xml:S1:6236:5	O
calcium	PROLIA.xml:S1:6242:7	O
levels	PROLIA.xml:S1:6250:6	O
7.5	PROLIA.xml:S1:6259:3	O
mg	PROLIA.xml:S1:6263:2	O
dL	PROLIA.xml:S1:6266:2	O
or	PROLIA.xml:S1:6269:2	O
symptomatic	PROLIA.xml:S1:6272:11	B-AdverseReaction
hypocalcemia	PROLIA.xml:S1:6284:12	I-AdverseReaction
were	PROLIA.xml:S1:6297:4	O
observed	PROLIA.xml:S1:6302:8	O
in	PROLIA.xml:S1:6311:2	O
5	PROLIA.xml:S1:6314:1	O
subjects	PROLIA.xml:S1:6316:8	O
.	PROLIA.xml:S1:6324:1	O

These	PROLIA.xml:S1:6326:5	O
included	PROLIA.xml:S1:6332:8	O
no	PROLIA.xml:S1:6341:2	O
subjects	PROLIA.xml:S1:6344:8	O
in	PROLIA.xml:S1:6353:2	O
the	PROLIA.xml:S1:6356:3	O
normal	PROLIA.xml:S1:6360:6	O
renal	PROLIA.xml:S1:6367:5	O
function	PROLIA.xml:S1:6373:8	O
group	PROLIA.xml:S1:6382:5	O
,	PROLIA.xml:S1:6387:1	O
10%	PROLIA.xml:S1:6389:3	O
of	PROLIA.xml:S1:6393:2	O
subjects	PROLIA.xml:S1:6396:8	O
in	PROLIA.xml:S1:6405:2	O
the	PROLIA.xml:S1:6408:3	O
creatinine	PROLIA.xml:S1:6412:10	O
clearance	PROLIA.xml:S1:6423:9	O
50	PROLIA.xml:S1:6433:2	O
to	PROLIA.xml:S1:6436:2	O
80	PROLIA.xml:S1:6439:2	O
mL	PROLIA.xml:S1:6442:2	O
min	PROLIA.xml:S1:6445:3	O
group	PROLIA.xml:S1:6449:5	O
,	PROLIA.xml:S1:6454:1	O
29%	PROLIA.xml:S1:6456:3	O
of	PROLIA.xml:S1:6460:2	O
subjects	PROLIA.xml:S1:6463:8	O
in	PROLIA.xml:S1:6472:2	O
the	PROLIA.xml:S1:6475:3	O
creatinine	PROLIA.xml:S1:6479:10	O
clearance	PROLIA.xml:S1:6490:9	O
30	PROLIA.xml:S1:6502:2	O
mL	PROLIA.xml:S1:6505:2	O
min	PROLIA.xml:S1:6508:3	O
group	PROLIA.xml:S1:6512:5	O
,	PROLIA.xml:S1:6517:1	O
and	PROLIA.xml:S1:6519:3	O
29%	PROLIA.xml:S1:6523:3	O
of	PROLIA.xml:S1:6527:2	O
subjects	PROLIA.xml:S1:6530:8	O
in	PROLIA.xml:S1:6539:2	O
the	PROLIA.xml:S1:6542:3	O
hemodialysis	PROLIA.xml:S1:6546:12	O
group	PROLIA.xml:S1:6559:5	O
.	PROLIA.xml:S1:6564:1	O

These	PROLIA.xml:S1:6566:5	O
subjects	PROLIA.xml:S1:6572:8	O
did	PROLIA.xml:S1:6581:3	O
not	PROLIA.xml:S1:6585:3	O
receive	PROLIA.xml:S1:6589:7	O
calcium	PROLIA.xml:S1:6597:7	O
and	PROLIA.xml:S1:6605:3	O
vitamin	PROLIA.xml:S1:6609:7	O
D	PROLIA.xml:S1:6617:1	O
supplementation	PROLIA.xml:S1:6619:15	O
.	PROLIA.xml:S1:6634:1	O

In	PROLIA.xml:S1:6636:2	O
a	PROLIA.xml:S1:6639:1	O
study	PROLIA.xml:S1:6641:5	O
of	PROLIA.xml:S1:6647:2	O
4550	PROLIA.xml:S1:6650:4	O
postmenopausal	PROLIA.xml:S1:6655:14	O
women	PROLIA.xml:S1:6670:5	O
with	PROLIA.xml:S1:6676:4	O
osteoporosis	PROLIA.xml:S1:6681:12	O
,	PROLIA.xml:S1:6693:1	O
the	PROLIA.xml:S1:6695:3	O
mean	PROLIA.xml:S1:6699:4	O
change	PROLIA.xml:S1:6704:6	O
from	PROLIA.xml:S1:6711:4	O
baseline	PROLIA.xml:S1:6716:8	O
in	PROLIA.xml:S1:6725:2	O
serum	PROLIA.xml:S1:6728:5	O
calcium	PROLIA.xml:S1:6734:7	O
level	PROLIA.xml:S1:6742:5	O
10	PROLIA.xml:S1:6748:2	O
days	PROLIA.xml:S1:6751:4	O
after	PROLIA.xml:S1:6756:5	O
Prolia	PROLIA.xml:S1:6762:6	O
dosing	PROLIA.xml:S1:6769:6	O
was	PROLIA.xml:S1:6776:3	O
-	PROLIA.xml:S1:6780:1	O
5.5%	PROLIA.xml:S1:6781:4	O
in	PROLIA.xml:S1:6786:2	O
subjects	PROLIA.xml:S1:6789:8	O
with	PROLIA.xml:S1:6798:4	O
creatinine	PROLIA.xml:S1:6803:10	O
clearance	PROLIA.xml:S1:6814:9	O
30	PROLIA.xml:S1:6826:2	O
mL	PROLIA.xml:S1:6829:2	O
min	PROLIA.xml:S1:6832:3	O
vs	PROLIA.xml:S1:6836:2	O
.	PROLIA.xml:S1:6838:1	O

-	PROLIA.xml:S1:6840:1	O
3.1%	PROLIA.xml:S1:6841:4	O
in	PROLIA.xml:S1:6846:2	O
subjects	PROLIA.xml:S1:6849:8	O
with	PROLIA.xml:S1:6858:4	O
creatinine	PROLIA.xml:S1:6863:10	O
clearance	PROLIA.xml:S1:6874:9	O
30	PROLIA.xml:S1:6887:2	O
mL	PROLIA.xml:S1:6890:2	O
min	PROLIA.xml:S1:6893:3	O
.	PROLIA.xml:S1:6896:1	O

Serious	PROLIA.xml:S1:6905:7	O
Infections	PROLIA.xml:S1:6913:10	O
Receptor	PROLIA.xml:S1:6925:8	O
activator	PROLIA.xml:S1:6934:9	O
of	PROLIA.xml:S1:6944:2	O
nuclear	PROLIA.xml:S1:6947:7	O
factor	PROLIA.xml:S1:6955:6	O
kappa	PROLIA.xml:S1:6962:5	O
-	PROLIA.xml:S1:6967:1	O
B	PROLIA.xml:S1:6968:1	O
ligand	PROLIA.xml:S1:6970:6	O
(	PROLIA.xml:S1:6977:1	O
RANKL	PROLIA.xml:S1:6978:5	O
)	PROLIA.xml:S1:6983:1	O
is	PROLIA.xml:S1:6985:2	O
expressed	PROLIA.xml:S1:6988:9	O
on	PROLIA.xml:S1:6998:2	O
activated	PROLIA.xml:S1:7001:9	O
T	PROLIA.xml:S1:7011:1	O
and	PROLIA.xml:S1:7013:3	O
B	PROLIA.xml:S1:7017:1	O
lymphocytes	PROLIA.xml:S1:7019:11	O
and	PROLIA.xml:S1:7031:3	O
in	PROLIA.xml:S1:7035:2	O
lymph	PROLIA.xml:S1:7038:5	O
nodes	PROLIA.xml:S1:7044:5	O
.	PROLIA.xml:S1:7049:1	O

Therefore	PROLIA.xml:S1:7051:9	O
,	PROLIA.xml:S1:7060:1	O
a	PROLIA.xml:S1:7062:1	O
RANKL	PROLIA.xml:S1:7064:5	O
inhibitor	PROLIA.xml:S1:7070:9	O
such	PROLIA.xml:S1:7080:4	O
as	PROLIA.xml:S1:7085:2	O
Prolia	PROLIA.xml:S1:7088:6	O
may	PROLIA.xml:S1:7095:3	O
increase	PROLIA.xml:S1:7099:8	O
the	PROLIA.xml:S1:7108:3	O
risk	PROLIA.xml:S1:7112:4	B-Factor
of	PROLIA.xml:S1:7117:2	O
infection	PROLIA.xml:S1:7120:9	B-AdverseReaction
.	PROLIA.xml:S1:7129:1	O

In	PROLIA.xml:S1:7137:2	O
the	PROLIA.xml:S1:7140:3	O
clinical	PROLIA.xml:S1:7144:8	O
study	PROLIA.xml:S1:7153:5	O
of	PROLIA.xml:S1:7159:2	O
7808	PROLIA.xml:S1:7162:4	O
postmenopausal	PROLIA.xml:S1:7167:14	O
women	PROLIA.xml:S1:7182:5	O
with	PROLIA.xml:S1:7188:4	O
osteoporosis	PROLIA.xml:S1:7193:12	O
,	PROLIA.xml:S1:7205:1	O
the	PROLIA.xml:S1:7207:3	O
incidence	PROLIA.xml:S1:7211:9	O
of	PROLIA.xml:S1:7221:2	O
infections	PROLIA.xml:S1:7224:10	B-AdverseReaction
resulting	PROLIA.xml:S1:7235:9	O
in	PROLIA.xml:S1:7245:2	O
death	PROLIA.xml:S1:7248:5	B-AdverseReaction
was	PROLIA.xml:S1:7254:3	O
0.2%	PROLIA.xml:S1:7258:4	O
in	PROLIA.xml:S1:7263:2	O
both	PROLIA.xml:S1:7266:4	O
placebo	PROLIA.xml:S1:7271:7	O
and	PROLIA.xml:S1:7279:3	O
Prolia	PROLIA.xml:S1:7283:6	O
treatment	PROLIA.xml:S1:7290:9	O
groups	PROLIA.xml:S1:7300:6	O
.	PROLIA.xml:S1:7306:1	O

However	PROLIA.xml:S1:7308:7	O
,	PROLIA.xml:S1:7315:1	O
the	PROLIA.xml:S1:7317:3	O
incidence	PROLIA.xml:S1:7321:9	O
of	PROLIA.xml:S1:7331:2	O
nonfatal	PROLIA.xml:S1:7334:8	O
serious	PROLIA.xml:S1:7343:7	B-Severity
infections	PROLIA.xml:S1:7351:10	B-AdverseReaction
was	PROLIA.xml:S1:7362:3	O
3.3%	PROLIA.xml:S1:7366:4	O
in	PROLIA.xml:S1:7371:2	O
the	PROLIA.xml:S1:7374:3	O
placebo	PROLIA.xml:S1:7378:7	O
and	PROLIA.xml:S1:7386:3	O
4.0%	PROLIA.xml:S1:7390:4	O
in	PROLIA.xml:S1:7395:2	O
the	PROLIA.xml:S1:7398:3	O
Prolia	PROLIA.xml:S1:7402:6	O
groups	PROLIA.xml:S1:7409:6	O
.	PROLIA.xml:S1:7415:1	O

Hospitalizations	PROLIA.xml:S1:7417:16	O
due	PROLIA.xml:S1:7434:3	O
to	PROLIA.xml:S1:7438:2	O
serious	PROLIA.xml:S1:7441:7	B-Severity
infections	PROLIA.xml:S1:7449:10	B-AdverseReaction
in	PROLIA.xml:S1:7460:2	I-AdverseReaction
the	PROLIA.xml:S1:7463:3	I-AdverseReaction
abdomen	PROLIA.xml:S1:7467:7	I-AdverseReaction
(	PROLIA.xml:S1:7475:1	O
0.7%	PROLIA.xml:S1:7476:4	O
placebo	PROLIA.xml:S1:7481:7	O
vs	PROLIA.xml:S1:7489:2	O
.	PROLIA.xml:S1:7491:1	O

0.9%	PROLIA.xml:S1:7493:4	O
Prolia	PROLIA.xml:S1:7498:6	O
)	PROLIA.xml:S1:7504:1	O
,	PROLIA.xml:S1:7505:1	O
urinary	PROLIA.xml:S1:7507:7	I-AdverseReaction
tract	PROLIA.xml:S1:7515:5	I-AdverseReaction
(	PROLIA.xml:S1:7521:1	O
0.5%	PROLIA.xml:S1:7522:4	O
placebo	PROLIA.xml:S1:7527:7	O
vs	PROLIA.xml:S1:7535:2	O
.	PROLIA.xml:S1:7537:1	O

0.7%	PROLIA.xml:S1:7539:4	O
Prolia	PROLIA.xml:S1:7544:6	O
)	PROLIA.xml:S1:7550:1	O
,	PROLIA.xml:S1:7551:1	O
and	PROLIA.xml:S1:7553:3	O
ear	PROLIA.xml:S1:7557:3	I-AdverseReaction
(	PROLIA.xml:S1:7561:1	O
0.0%	PROLIA.xml:S1:7562:4	O
placebo	PROLIA.xml:S1:7567:7	O
vs	PROLIA.xml:S1:7575:2	O
.	PROLIA.xml:S1:7577:1	O

0.1%	PROLIA.xml:S1:7579:4	O
Prolia	PROLIA.xml:S1:7584:6	O
)	PROLIA.xml:S1:7590:1	O
were	PROLIA.xml:S1:7592:4	O
reported	PROLIA.xml:S1:7597:8	O
.	PROLIA.xml:S1:7605:1	O

Endocarditis	PROLIA.xml:S1:7607:12	B-AdverseReaction
was	PROLIA.xml:S1:7620:3	O
reported	PROLIA.xml:S1:7624:8	O
in	PROLIA.xml:S1:7633:2	O
no	PROLIA.xml:S1:7636:2	O
placebo	PROLIA.xml:S1:7639:7	O
patients	PROLIA.xml:S1:7647:8	O
and	PROLIA.xml:S1:7656:3	O
3	PROLIA.xml:S1:7660:1	O
patients	PROLIA.xml:S1:7662:8	O
receiving	PROLIA.xml:S1:7671:9	O
Prolia	PROLIA.xml:S1:7681:6	O
.	PROLIA.xml:S1:7687:1	O

Skin	PROLIA.xml:S1:7693:4	B-AdverseReaction
infections	PROLIA.xml:S1:7698:10	I-AdverseReaction
,	PROLIA.xml:S1:7708:1	O
including	PROLIA.xml:S1:7710:9	O
erysipelas	PROLIA.xml:S1:7720:10	B-AdverseReaction
and	PROLIA.xml:S1:7731:3	O
cellulitis	PROLIA.xml:S1:7735:10	B-AdverseReaction
,	PROLIA.xml:S1:7745:1	O
leading	PROLIA.xml:S1:7747:7	O
to	PROLIA.xml:S1:7755:2	O
hospitalization	PROLIA.xml:S1:7758:15	O
were	PROLIA.xml:S1:7774:4	O
reported	PROLIA.xml:S1:7779:8	O
more	PROLIA.xml:S1:7788:4	O
frequently	PROLIA.xml:S1:7793:10	O
in	PROLIA.xml:S1:7804:2	O
patients	PROLIA.xml:S1:7807:8	O
treated	PROLIA.xml:S1:7816:7	O
with	PROLIA.xml:S1:7824:4	O
Prolia	PROLIA.xml:S1:7829:6	O
(	PROLIA.xml:S1:7836:1	O
0.1%	PROLIA.xml:S1:7839:4	O
placebo	PROLIA.xml:S1:7844:7	O
vs	PROLIA.xml:S1:7852:2	O
.	PROLIA.xml:S1:7854:1	O

0.4%	PROLIA.xml:S1:7856:4	O
Prolia	PROLIA.xml:S1:7861:6	O
)	PROLIA.xml:S1:7867:1	O
.	PROLIA.xml:S1:7868:1	O

The	PROLIA.xml:S1:7874:3	O
incidence	PROLIA.xml:S1:7878:9	O
of	PROLIA.xml:S1:7888:2	O
opportunistic	PROLIA.xml:S1:7891:13	B-AdverseReaction
infections	PROLIA.xml:S1:7905:10	I-AdverseReaction
was	PROLIA.xml:S1:7916:3	O
similar	PROLIA.xml:S1:7920:7	O
to	PROLIA.xml:S1:7928:2	O
that	PROLIA.xml:S1:7931:4	O
reported	PROLIA.xml:S1:7936:8	O
with	PROLIA.xml:S1:7945:4	O
placebo	PROLIA.xml:S1:7950:7	O
.	PROLIA.xml:S1:7957:1	O

Dermatologic	PROLIA.xml:S1:7965:12	O
Reactions	PROLIA.xml:S1:7978:9	O
A	PROLIA.xml:S1:7989:1	O
significantly	PROLIA.xml:S1:7991:13	O
higher	PROLIA.xml:S1:8005:6	O
number	PROLIA.xml:S1:8012:6	O
of	PROLIA.xml:S1:8019:2	O
patients	PROLIA.xml:S1:8022:8	O
treated	PROLIA.xml:S1:8031:7	O
with	PROLIA.xml:S1:8039:4	O
Prolia	PROLIA.xml:S1:8044:6	O
developed	PROLIA.xml:S1:8051:9	O
epidermal	PROLIA.xml:S1:8061:9	B-AdverseReaction
and	PROLIA.xml:S1:8071:3	O
dermal	PROLIA.xml:S1:8075:6	B-AdverseReaction
adverse	PROLIA.xml:S1:8082:7	I-AdverseReaction
events	PROLIA.xml:S1:8090:6	I-AdverseReaction
(	PROLIA.xml:S1:8097:1	O
such	PROLIA.xml:S1:8098:4	O
as	PROLIA.xml:S1:8103:2	O
dermatitis	PROLIA.xml:S1:8106:10	B-AdverseReaction
,	PROLIA.xml:S1:8116:1	O
eczema	PROLIA.xml:S1:8118:6	B-AdverseReaction
,	PROLIA.xml:S1:8124:1	O
and	PROLIA.xml:S1:8126:3	O
rashes	PROLIA.xml:S1:8130:6	B-AdverseReaction
)	PROLIA.xml:S1:8136:1	O
,	PROLIA.xml:S1:8137:1	O
with	PROLIA.xml:S1:8139:4	O
these	PROLIA.xml:S1:8144:5	O
events	PROLIA.xml:S1:8150:6	O
reported	PROLIA.xml:S1:8157:8	O
in	PROLIA.xml:S1:8166:2	O
8.2%	PROLIA.xml:S1:8169:4	O
of	PROLIA.xml:S1:8174:2	O
the	PROLIA.xml:S1:8177:3	O
placebo	PROLIA.xml:S1:8181:7	O
and	PROLIA.xml:S1:8189:3	O
10.8%	PROLIA.xml:S1:8193:5	O
of	PROLIA.xml:S1:8199:2	O
the	PROLIA.xml:S1:8202:3	O
Prolia	PROLIA.xml:S1:8206:6	O
groups	PROLIA.xml:S1:8213:6	O
(	PROLIA.xml:S1:8220:1	O
p	PROLIA.xml:S1:8221:1	O
0.0001	PROLIA.xml:S1:8225:6	O
)	PROLIA.xml:S1:8231:1	O
.	PROLIA.xml:S1:8232:1	O

Most	PROLIA.xml:S1:8234:4	O
of	PROLIA.xml:S1:8239:2	O
these	PROLIA.xml:S1:8242:5	O
events	PROLIA.xml:S1:8248:6	O
were	PROLIA.xml:S1:8255:4	O
not	PROLIA.xml:S1:8260:3	O
specific	PROLIA.xml:S1:8264:8	O
to	PROLIA.xml:S1:8273:2	O
the	PROLIA.xml:S1:8276:3	O
injection	PROLIA.xml:S1:8280:9	O
site	PROLIA.xml:S1:8290:4	O
[	PROLIA.xml:S1:8296:1	O
see	PROLIA.xml:S1:8297:3	O
Warnings	PROLIA.xml:S1:8301:8	O
and	PROLIA.xml:S1:8310:3	O
Precautions	PROLIA.xml:S1:8314:11	O
(	PROLIA.xml:S1:8326:1	O
5.7	PROLIA.xml:S1:8329:3	O
)]	PROLIA.xml:S1:8334:2	O
.	PROLIA.xml:S1:8336:1	O

Osteonecrosis	PROLIA.xml:S1:8346:13	B-AdverseReaction
of	PROLIA.xml:S1:8360:2	I-AdverseReaction
the	PROLIA.xml:S1:8363:3	I-AdverseReaction
Jaw	PROLIA.xml:S1:8367:3	I-AdverseReaction
ONJ	PROLIA.xml:S1:8372:3	B-AdverseReaction
has	PROLIA.xml:S1:8376:3	O
been	PROLIA.xml:S1:8380:4	O
reported	PROLIA.xml:S1:8385:8	O
in	PROLIA.xml:S1:8394:2	O
the	PROLIA.xml:S1:8397:3	O
osteoporosis	PROLIA.xml:S1:8401:12	O
clinical	PROLIA.xml:S1:8414:8	O
trial	PROLIA.xml:S1:8423:5	O
program	PROLIA.xml:S1:8429:7	O
in	PROLIA.xml:S1:8437:2	O
patients	PROLIA.xml:S1:8440:8	O
treated	PROLIA.xml:S1:8449:7	O
with	PROLIA.xml:S1:8457:4	O
Prolia	PROLIA.xml:S1:8462:6	O
[	PROLIA.xml:S1:8470:1	O
see	PROLIA.xml:S1:8471:3	O
Warnings	PROLIA.xml:S1:8475:8	O
and	PROLIA.xml:S1:8484:3	O
Precautions	PROLIA.xml:S1:8488:11	O
(	PROLIA.xml:S1:8500:1	O
5.4	PROLIA.xml:S1:8503:3	O
)]	PROLIA.xml:S1:8508:2	O
.	PROLIA.xml:S1:8510:1	O

Atypical	PROLIA.xml:S1:8520:8	O
Subtrochanteric	PROLIA.xml:S1:8529:15	O
and	PROLIA.xml:S1:8545:3	O
Diaphyseal	PROLIA.xml:S1:8549:10	O
Fractures	PROLIA.xml:S1:8560:9	O
In	PROLIA.xml:S1:8571:2	O
the	PROLIA.xml:S1:8574:3	O
osteoporosis	PROLIA.xml:S1:8578:12	O
clinical	PROLIA.xml:S1:8591:8	O
trial	PROLIA.xml:S1:8600:5	O
program	PROLIA.xml:S1:8606:7	O
,	PROLIA.xml:S1:8613:1	O
atypical	PROLIA.xml:S1:8615:8	B-AdverseReaction
femoral	PROLIA.xml:S1:8624:7	I-AdverseReaction
fractures	PROLIA.xml:S1:8632:9	I-AdverseReaction
were	PROLIA.xml:S1:8642:4	O
reported	PROLIA.xml:S1:8647:8	O
in	PROLIA.xml:S1:8656:2	O
patients	PROLIA.xml:S1:8659:8	O
treated	PROLIA.xml:S1:8668:7	O
with	PROLIA.xml:S1:8676:4	O
Prolia	PROLIA.xml:S1:8681:6	O
.	PROLIA.xml:S1:8687:1	O

The	PROLIA.xml:S1:8689:3	O
duration	PROLIA.xml:S1:8693:8	O
of	PROLIA.xml:S1:8702:2	O
Prolia	PROLIA.xml:S1:8705:6	O
exposure	PROLIA.xml:S1:8712:8	O
to	PROLIA.xml:S1:8721:2	O
time	PROLIA.xml:S1:8724:4	O
of	PROLIA.xml:S1:8729:2	O
atypical	PROLIA.xml:S1:8732:8	B-AdverseReaction
femoral	PROLIA.xml:S1:8741:7	I-AdverseReaction
fracture	PROLIA.xml:S1:8749:8	I-AdverseReaction
diagnosis	PROLIA.xml:S1:8758:9	O
was	PROLIA.xml:S1:8768:3	O
as	PROLIA.xml:S1:8772:2	O
early	PROLIA.xml:S1:8775:5	O
as	PROLIA.xml:S1:8781:2	O
21	PROLIA.xml:S1:8784:2	O
2	PROLIA.xml:S1:8787:1	O
years	PROLIA.xml:S1:8789:5	O
[	PROLIA.xml:S1:8796:1	O
see	PROLIA.xml:S1:8797:3	O
Warnings	PROLIA.xml:S1:8801:8	O
and	PROLIA.xml:S1:8810:3	O
Precautions	PROLIA.xml:S1:8814:11	O
(	PROLIA.xml:S1:8826:1	O
5.5	PROLIA.xml:S1:8829:3	O
)]	PROLIA.xml:S1:8834:2	O
.	PROLIA.xml:S1:8838:1	O

Pancreatitis	PROLIA.xml:S1:8846:12	O
Pancreatitis	PROLIA.xml:S1:8860:12	B-AdverseReaction
was	PROLIA.xml:S1:8873:3	O
reported	PROLIA.xml:S1:8877:8	O
in	PROLIA.xml:S1:8886:2	O
4	PROLIA.xml:S1:8889:1	O
patients	PROLIA.xml:S1:8891:8	O
(	PROLIA.xml:S1:8900:1	O
0.1%	PROLIA.xml:S1:8901:4	O
)	PROLIA.xml:S1:8905:1	O
in	PROLIA.xml:S1:8907:2	O
the	PROLIA.xml:S1:8910:3	O
placebo	PROLIA.xml:S1:8914:7	O
and	PROLIA.xml:S1:8922:3	O
8	PROLIA.xml:S1:8926:1	O
patients	PROLIA.xml:S1:8928:8	O
(	PROLIA.xml:S1:8937:1	O
0.2%	PROLIA.xml:S1:8938:4	O
)	PROLIA.xml:S1:8942:1	O
in	PROLIA.xml:S1:8944:2	O
the	PROLIA.xml:S1:8947:3	O
Prolia	PROLIA.xml:S1:8951:6	O
groups	PROLIA.xml:S1:8958:6	O
.	PROLIA.xml:S1:8964:1	O

Of	PROLIA.xml:S1:8966:2	O
these	PROLIA.xml:S1:8969:5	O
reports	PROLIA.xml:S1:8975:7	O
,	PROLIA.xml:S1:8982:1	O
1	PROLIA.xml:S1:8984:1	O
patient	PROLIA.xml:S1:8986:7	O
in	PROLIA.xml:S1:8994:2	O
the	PROLIA.xml:S1:8997:3	O
placebo	PROLIA.xml:S1:9001:7	O
group	PROLIA.xml:S1:9009:5	O
and	PROLIA.xml:S1:9015:3	O
all	PROLIA.xml:S1:9019:3	O
8	PROLIA.xml:S1:9023:1	O
patients	PROLIA.xml:S1:9025:8	O
in	PROLIA.xml:S1:9034:2	O
the	PROLIA.xml:S1:9037:3	O
Prolia	PROLIA.xml:S1:9041:6	O
group	PROLIA.xml:S1:9048:5	O
had	PROLIA.xml:S1:9054:3	O
serious	PROLIA.xml:S1:9058:7	O
events	PROLIA.xml:S1:9066:6	O
,	PROLIA.xml:S1:9072:1	O
including	PROLIA.xml:S1:9074:9	O
one	PROLIA.xml:S1:9084:3	O
death	PROLIA.xml:S1:9088:5	B-AdverseReaction
in	PROLIA.xml:S1:9094:2	O
the	PROLIA.xml:S1:9097:3	O
Prolia	PROLIA.xml:S1:9101:6	O
group	PROLIA.xml:S1:9108:5	O
.	PROLIA.xml:S1:9113:1	O

Several	PROLIA.xml:S1:9115:7	O
patients	PROLIA.xml:S1:9123:8	O
had	PROLIA.xml:S1:9132:3	O
a	PROLIA.xml:S1:9136:1	O
prior	PROLIA.xml:S1:9138:5	O
history	PROLIA.xml:S1:9144:7	O
of	PROLIA.xml:S1:9152:2	O
pancreatitis	PROLIA.xml:S1:9155:12	O
.	PROLIA.xml:S1:9167:1	O

The	PROLIA.xml:S1:9169:3	O
time	PROLIA.xml:S1:9173:4	O
from	PROLIA.xml:S1:9178:4	O
product	PROLIA.xml:S1:9183:7	O
administration	PROLIA.xml:S1:9191:14	O
to	PROLIA.xml:S1:9206:2	O
event	PROLIA.xml:S1:9209:5	O
occurrence	PROLIA.xml:S1:9215:10	O
was	PROLIA.xml:S1:9226:3	O
variable	PROLIA.xml:S1:9230:8	O
.	PROLIA.xml:S1:9238:1	O

New	PROLIA.xml:S1:9246:3	O
Malignancies	PROLIA.xml:S1:9250:12	O
The	PROLIA.xml:S1:9264:3	O
overall	PROLIA.xml:S1:9268:7	O
incidence	PROLIA.xml:S1:9276:9	O
of	PROLIA.xml:S1:9286:2	O
new	PROLIA.xml:S1:9289:3	O
malignancies	PROLIA.xml:S1:9293:12	B-AdverseReaction
was	PROLIA.xml:S1:9306:3	O
4.3%	PROLIA.xml:S1:9310:4	O
in	PROLIA.xml:S1:9315:2	O
the	PROLIA.xml:S1:9318:3	O
placebo	PROLIA.xml:S1:9322:7	O
and	PROLIA.xml:S1:9330:3	O
4.8%	PROLIA.xml:S1:9334:4	O
in	PROLIA.xml:S1:9339:2	O
the	PROLIA.xml:S1:9342:3	O
Prolia	PROLIA.xml:S1:9346:6	O
groups	PROLIA.xml:S1:9353:6	O
.	PROLIA.xml:S1:9359:1	O

New	PROLIA.xml:S1:9361:3	O
malignancies	PROLIA.xml:S1:9365:12	B-AdverseReaction
related	PROLIA.xml:S1:9378:7	O
to	PROLIA.xml:S1:9386:2	I-AdverseReaction
the	PROLIA.xml:S1:9389:3	I-AdverseReaction
breast	PROLIA.xml:S1:9393:6	I-AdverseReaction
(	PROLIA.xml:S1:9400:1	O
0.7%	PROLIA.xml:S1:9401:4	O
placebo	PROLIA.xml:S1:9406:7	O
vs	PROLIA.xml:S1:9414:2	O
.	PROLIA.xml:S1:9416:1	O

0.9%	PROLIA.xml:S1:9418:4	O
Prolia	PROLIA.xml:S1:9423:6	O
)	PROLIA.xml:S1:9429:1	O
,	PROLIA.xml:S1:9430:1	O
reproductive	PROLIA.xml:S1:9432:12	I-AdverseReaction
system	PROLIA.xml:S1:9445:6	I-AdverseReaction
(	PROLIA.xml:S1:9452:1	O
0.2%	PROLIA.xml:S1:9453:4	O
placebo	PROLIA.xml:S1:9458:7	O
vs	PROLIA.xml:S1:9466:2	O
.	PROLIA.xml:S1:9468:1	O

0.5%	PROLIA.xml:S1:9470:4	O
Prolia	PROLIA.xml:S1:9475:6	O
)	PROLIA.xml:S1:9481:1	O
,	PROLIA.xml:S1:9482:1	O
and	PROLIA.xml:S1:9484:3	O
gastrointestinal	PROLIA.xml:S1:9488:16	I-AdverseReaction
system	PROLIA.xml:S1:9505:6	I-AdverseReaction
(	PROLIA.xml:S1:9512:1	O
0.6%	PROLIA.xml:S1:9513:4	O
placebo	PROLIA.xml:S1:9518:7	O
vs	PROLIA.xml:S1:9526:2	O
.	PROLIA.xml:S1:9528:1	O

0.9%	PROLIA.xml:S1:9530:4	O
Prolia	PROLIA.xml:S1:9535:6	O
)	PROLIA.xml:S1:9541:1	O
were	PROLIA.xml:S1:9543:4	O
reported	PROLIA.xml:S1:9548:8	O
.	PROLIA.xml:S1:9556:1	O

A	PROLIA.xml:S1:9558:1	O
causal	PROLIA.xml:S1:9560:6	O
relationship	PROLIA.xml:S1:9567:12	O
to	PROLIA.xml:S1:9580:2	O
drug	PROLIA.xml:S1:9583:4	O
exposure	PROLIA.xml:S1:9588:8	O
has	PROLIA.xml:S1:9597:3	O
not	PROLIA.xml:S1:9601:3	O
been	PROLIA.xml:S1:9605:4	O
established	PROLIA.xml:S1:9610:11	O
.	PROLIA.xml:S1:9621:1	O

Treatment	PROLIA.xml:S1:9629:9	O
to	PROLIA.xml:S1:9639:2	O
Increase	PROLIA.xml:S1:9642:8	O
Bone	PROLIA.xml:S1:9651:4	O
Mass	PROLIA.xml:S1:9656:4	O
in	PROLIA.xml:S1:9661:2	O
Men	PROLIA.xml:S1:9667:3	O
with	PROLIA.xml:S1:9671:4	O
Osteoporosis	PROLIA.xml:S1:9676:12	O

The	PROLIA.xml:S1:9695:3	O
safety	PROLIA.xml:S1:9699:6	O
of	PROLIA.xml:S1:9706:2	O
Prolia	PROLIA.xml:S1:9709:6	O
in	PROLIA.xml:S1:9716:2	O
the	PROLIA.xml:S1:9719:3	O
treatment	PROLIA.xml:S1:9723:9	O
of	PROLIA.xml:S1:9733:2	O
men	PROLIA.xml:S1:9736:3	O
with	PROLIA.xml:S1:9740:4	O
osteoporosis	PROLIA.xml:S1:9745:12	O
was	PROLIA.xml:S1:9758:3	O
assessed	PROLIA.xml:S1:9762:8	O
in	PROLIA.xml:S1:9771:2	O
a	PROLIA.xml:S1:9774:1	O
1	PROLIA.xml:S1:9776:1	O
-	PROLIA.xml:S1:9777:1	O
year	PROLIA.xml:S1:9778:4	O
randomized	PROLIA.xml:S1:9783:10	O
,	PROLIA.xml:S1:9793:1	O
double	PROLIA.xml:S1:9795:6	O
-	PROLIA.xml:S1:9801:1	O
blind	PROLIA.xml:S1:9802:5	O
,	PROLIA.xml:S1:9807:1	O
placebo	PROLIA.xml:S1:9809:7	O
-	PROLIA.xml:S1:9816:1	O
controlled	PROLIA.xml:S1:9817:10	O
study	PROLIA.xml:S1:9828:5	O
.	PROLIA.xml:S1:9833:1	O

A	PROLIA.xml:S1:9835:1	O
total	PROLIA.xml:S1:9837:5	O
of	PROLIA.xml:S1:9843:2	O
120	PROLIA.xml:S1:9846:3	O
men	PROLIA.xml:S1:9850:3	O
were	PROLIA.xml:S1:9854:4	O
exposed	PROLIA.xml:S1:9859:7	O
to	PROLIA.xml:S1:9867:2	O
placebo	PROLIA.xml:S1:9870:7	O
and	PROLIA.xml:S1:9878:3	O
120	PROLIA.xml:S1:9882:3	O
men	PROLIA.xml:S1:9886:3	O
were	PROLIA.xml:S1:9890:4	O
exposed	PROLIA.xml:S1:9895:7	O
to	PROLIA.xml:S1:9903:2	O
Prolia	PROLIA.xml:S1:9906:6	O
administered	PROLIA.xml:S1:9913:12	O
subcutaneously	PROLIA.xml:S1:9926:14	O
once	PROLIA.xml:S1:9941:4	O
every	PROLIA.xml:S1:9946:5	O
6	PROLIA.xml:S1:9952:1	O
months	PROLIA.xml:S1:9954:6	O
as	PROLIA.xml:S1:9961:2	O
a	PROLIA.xml:S1:9964:1	O
single	PROLIA.xml:S1:9966:6	O
60	PROLIA.xml:S1:9973:2	O
mg	PROLIA.xml:S1:9976:2	O
dose	PROLIA.xml:S1:9979:4	O
.	PROLIA.xml:S1:9983:1	O

All	PROLIA.xml:S1:9985:3	O
men	PROLIA.xml:S1:9989:3	O
were	PROLIA.xml:S1:9993:4	O
instructed	PROLIA.xml:S1:9998:10	O
to	PROLIA.xml:S1:10009:2	O
take	PROLIA.xml:S1:10012:4	O
at	PROLIA.xml:S1:10017:2	O
least	PROLIA.xml:S1:10020:5	O
1000	PROLIA.xml:S1:10026:4	O
mg	PROLIA.xml:S1:10031:2	O
of	PROLIA.xml:S1:10034:2	O
calcium	PROLIA.xml:S1:10037:7	O
and	PROLIA.xml:S1:10045:3	O
800	PROLIA.xml:S1:10049:3	O
IU	PROLIA.xml:S1:10053:2	O
of	PROLIA.xml:S1:10056:2	O
vitamin	PROLIA.xml:S1:10059:7	O
D	PROLIA.xml:S1:10067:1	O
supplementation	PROLIA.xml:S1:10069:15	O
per	PROLIA.xml:S1:10085:3	O
day	PROLIA.xml:S1:10089:3	O
.	PROLIA.xml:S1:10092:1	O

The	PROLIA.xml:S1:10098:3	O
incidence	PROLIA.xml:S1:10102:9	O
of	PROLIA.xml:S1:10112:2	O
all	PROLIA.xml:S1:10115:3	O
-	PROLIA.xml:S1:10118:1	O
cause	PROLIA.xml:S1:10119:5	O
mortality	PROLIA.xml:S1:10125:9	B-AdverseReaction
was	PROLIA.xml:S1:10135:3	O
0.8%	PROLIA.xml:S1:10139:4	O
(	PROLIA.xml:S1:10144:1	O
n	PROLIA.xml:S1:10145:1	O
1	PROLIA.xml:S1:10149:1	O
)	PROLIA.xml:S1:10150:1	O
in	PROLIA.xml:S1:10152:2	O
the	PROLIA.xml:S1:10155:3	O
placebo	PROLIA.xml:S1:10159:7	O
group	PROLIA.xml:S1:10167:5	O
and	PROLIA.xml:S1:10173:3	O
0.8%	PROLIA.xml:S1:10177:4	O
(	PROLIA.xml:S1:10182:1	O
n	PROLIA.xml:S1:10183:1	O
1	PROLIA.xml:S1:10187:1	O
)	PROLIA.xml:S1:10188:1	O
in	PROLIA.xml:S1:10190:2	O
the	PROLIA.xml:S1:10193:3	O
Prolia	PROLIA.xml:S1:10197:6	O
group	PROLIA.xml:S1:10204:5	O
.	PROLIA.xml:S1:10209:1	O

The	PROLIA.xml:S1:10211:3	O
incidence	PROLIA.xml:S1:10215:9	O
of	PROLIA.xml:S1:10225:2	O
nonfatal	PROLIA.xml:S1:10228:8	O
serious	PROLIA.xml:S1:10237:7	O
adverse	PROLIA.xml:S1:10245:7	O
events	PROLIA.xml:S1:10253:6	O
was	PROLIA.xml:S1:10260:3	O
7.5%	PROLIA.xml:S1:10264:4	O
in	PROLIA.xml:S1:10269:2	O
the	PROLIA.xml:S1:10272:3	O
placebo	PROLIA.xml:S1:10276:7	O
group	PROLIA.xml:S1:10284:5	O
and	PROLIA.xml:S1:10290:3	O
8.3%	PROLIA.xml:S1:10294:4	O
in	PROLIA.xml:S1:10299:2	O
the	PROLIA.xml:S1:10302:3	O
Prolia	PROLIA.xml:S1:10306:6	O
group	PROLIA.xml:S1:10313:5	O
.	PROLIA.xml:S1:10318:1	O

The	PROLIA.xml:S1:10320:3	O
percentage	PROLIA.xml:S1:10324:10	O
of	PROLIA.xml:S1:10335:2	O
patients	PROLIA.xml:S1:10338:8	O
who	PROLIA.xml:S1:10347:3	O
withdrew	PROLIA.xml:S1:10351:8	O
from	PROLIA.xml:S1:10360:4	O
the	PROLIA.xml:S1:10365:3	O
study	PROLIA.xml:S1:10369:5	O
due	PROLIA.xml:S1:10375:3	O
to	PROLIA.xml:S1:10379:2	O
adverse	PROLIA.xml:S1:10382:7	O
events	PROLIA.xml:S1:10390:6	O
was	PROLIA.xml:S1:10397:3	O
0%	PROLIA.xml:S1:10401:2	O
and	PROLIA.xml:S1:10404:3	O
2.5%	PROLIA.xml:S1:10408:4	O
for	PROLIA.xml:S1:10413:3	O
the	PROLIA.xml:S1:10417:3	O
placebo	PROLIA.xml:S1:10421:7	O
and	PROLIA.xml:S1:10429:3	O
Prolia	PROLIA.xml:S1:10433:6	O
groups	PROLIA.xml:S1:10440:6	O
,	PROLIA.xml:S1:10446:1	O
respectively	PROLIA.xml:S1:10448:12	O
.	PROLIA.xml:S1:10460:1	O

Adverse	PROLIA.xml:S1:10466:7	O
reactions	PROLIA.xml:S1:10474:9	O
reported	PROLIA.xml:S1:10484:8	O
in	PROLIA.xml:S1:10493:2	O
5%	PROLIA.xml:S1:10499:2	O
of	PROLIA.xml:S1:10502:2	O
men	PROLIA.xml:S1:10505:3	O
with	PROLIA.xml:S1:10509:4	O
osteoporosis	PROLIA.xml:S1:10514:12	O
and	PROLIA.xml:S1:10527:3	O
more	PROLIA.xml:S1:10531:4	O
frequently	PROLIA.xml:S1:10536:10	O
with	PROLIA.xml:S1:10547:4	O
Prolia	PROLIA.xml:S1:10552:6	O
than	PROLIA.xml:S1:10559:4	O
in	PROLIA.xml:S1:10564:2	O
the	PROLIA.xml:S1:10567:3	O
placebo	PROLIA.xml:S1:10571:7	O
-	PROLIA.xml:S1:10578:1	O
treated	PROLIA.xml:S1:10579:7	O
patients	PROLIA.xml:S1:10587:8	O
were	PROLIA.xml:S1:10596:4	O
:	PROLIA.xml:S1:10600:1	O
back	PROLIA.xml:S1:10602:4	B-AdverseReaction
pain	PROLIA.xml:S1:10607:4	I-AdverseReaction
(	PROLIA.xml:S1:10612:1	O
6.7%	PROLIA.xml:S1:10613:4	O
placebo	PROLIA.xml:S1:10618:7	O
vs	PROLIA.xml:S1:10626:2	O
.	PROLIA.xml:S1:10628:1	O

8.3%	PROLIA.xml:S1:10630:4	O
Prolia	PROLIA.xml:S1:10635:6	O
)	PROLIA.xml:S1:10641:1	O
,	PROLIA.xml:S1:10642:1	O
arthralgia	PROLIA.xml:S1:10644:10	B-AdverseReaction
(	PROLIA.xml:S1:10655:1	O
5.8%	PROLIA.xml:S1:10656:4	O
placebo	PROLIA.xml:S1:10661:7	O
vs	PROLIA.xml:S1:10669:2	O
.	PROLIA.xml:S1:10671:1	O

6.7%	PROLIA.xml:S1:10673:4	O
Prolia	PROLIA.xml:S1:10678:6	O
)	PROLIA.xml:S1:10684:1	O
,	PROLIA.xml:S1:10685:1	O
and	PROLIA.xml:S1:10687:3	O
nasopharyngitis	PROLIA.xml:S1:10691:15	B-AdverseReaction
(	PROLIA.xml:S1:10707:1	O
5.8%	PROLIA.xml:S1:10708:4	O
placebo	PROLIA.xml:S1:10713:7	O
vs	PROLIA.xml:S1:10721:2	O
.	PROLIA.xml:S1:10723:1	O

6.7%	PROLIA.xml:S1:10725:4	O
Prolia	PROLIA.xml:S1:10730:6	O
)	PROLIA.xml:S1:10736:1	O
.	PROLIA.xml:S1:10737:1	O

Serious	PROLIA.xml:S1:10745:7	O
Infections	PROLIA.xml:S1:10753:10	O
S	PROLIA.xml:S1:10767:1	B-Severity
erious	PROLIA.xml:S1:10770:6	I-Severity
infection	PROLIA.xml:S1:10777:9	B-AdverseReaction
was	PROLIA.xml:S1:10787:3	O
reported	PROLIA.xml:S1:10791:8	O
in	PROLIA.xml:S1:10800:2	O
1	PROLIA.xml:S1:10803:1	O
patient	PROLIA.xml:S1:10805:7	O
(	PROLIA.xml:S1:10813:1	O
0.8%	PROLIA.xml:S1:10814:4	O
)	PROLIA.xml:S1:10818:1	O
in	PROLIA.xml:S1:10820:2	O
the	PROLIA.xml:S1:10823:3	O
placebo	PROLIA.xml:S1:10827:7	O
group	PROLIA.xml:S1:10835:5	O
and	PROLIA.xml:S1:10841:3	O
no	PROLIA.xml:S1:10845:2	B-Negation
patients	PROLIA.xml:S1:10848:8	O
in	PROLIA.xml:S1:10857:2	O
the	PROLIA.xml:S1:10860:3	O
Prolia	PROLIA.xml:S1:10864:6	O
group	PROLIA.xml:S1:10871:5	O
.	PROLIA.xml:S1:10876:1	O

Dermatologic	PROLIA.xml:S1:10884:12	O
Reactions	PROLIA.xml:S1:10897:9	O
Epidermal	PROLIA.xml:S1:10908:9	B-AdverseReaction
and	PROLIA.xml:S1:10918:3	O
dermal	PROLIA.xml:S1:10922:6	B-AdverseReaction
adverse	PROLIA.xml:S1:10929:7	I-AdverseReaction
events	PROLIA.xml:S1:10937:6	I-AdverseReaction
(	PROLIA.xml:S1:10944:1	O
such	PROLIA.xml:S1:10945:4	O
as	PROLIA.xml:S1:10950:2	O
dermatitis	PROLIA.xml:S1:10953:10	B-AdverseReaction
,	PROLIA.xml:S1:10963:1	O
eczema	PROLIA.xml:S1:10965:6	B-AdverseReaction
,	PROLIA.xml:S1:10971:1	O
and	PROLIA.xml:S1:10973:3	O
rashes	PROLIA.xml:S1:10977:6	B-AdverseReaction
)	PROLIA.xml:S1:10983:1	O
were	PROLIA.xml:S1:10985:4	O
reported	PROLIA.xml:S1:10990:8	O
in	PROLIA.xml:S1:10999:2	O
4	PROLIA.xml:S1:11002:1	O
patients	PROLIA.xml:S1:11004:8	O
(	PROLIA.xml:S1:11013:1	O
3.3%	PROLIA.xml:S1:11014:4	O
)	PROLIA.xml:S1:11018:1	O
in	PROLIA.xml:S1:11020:2	O
the	PROLIA.xml:S1:11023:3	O
placebo	PROLIA.xml:S1:11027:7	O
group	PROLIA.xml:S1:11035:5	O
and	PROLIA.xml:S1:11041:3	O
5	PROLIA.xml:S1:11045:1	O
patients	PROLIA.xml:S1:11047:8	O
(	PROLIA.xml:S1:11056:1	O
4.2%	PROLIA.xml:S1:11057:4	O
)	PROLIA.xml:S1:11061:1	O
in	PROLIA.xml:S1:11063:2	O
the	PROLIA.xml:S1:11066:3	O
Prolia	PROLIA.xml:S1:11070:6	O
group	PROLIA.xml:S1:11077:5	O
.	PROLIA.xml:S1:11082:1	O

Osteonecrosis	PROLIA.xml:S1:11090:13	O
of	PROLIA.xml:S1:11104:2	O
the	PROLIA.xml:S1:11107:3	O
Jaw	PROLIA.xml:S1:11111:3	O
No	PROLIA.xml:S1:11116:2	B-Negation
cases	PROLIA.xml:S1:11119:5	O
of	PROLIA.xml:S1:11125:2	O
ONJ	PROLIA.xml:S1:11128:3	B-AdverseReaction
were	PROLIA.xml:S1:11132:4	O
reported	PROLIA.xml:S1:11137:8	O
.	PROLIA.xml:S1:11145:1	O

Pancreatitis	PROLIA.xml:S1:11153:12	O
Pancreatitis	PROLIA.xml:S1:11167:12	B-AdverseReaction
was	PROLIA.xml:S1:11180:3	O
reported	PROLIA.xml:S1:11184:8	O
in	PROLIA.xml:S1:11193:2	O
1	PROLIA.xml:S1:11196:1	O
patient	PROLIA.xml:S1:11198:7	O
(	PROLIA.xml:S1:11206:1	O
0.8%	PROLIA.xml:S1:11207:4	O
)	PROLIA.xml:S1:11211:1	O
in	PROLIA.xml:S1:11213:2	O
the	PROLIA.xml:S1:11216:3	O
placebo	PROLIA.xml:S1:11220:7	O
group	PROLIA.xml:S1:11228:5	O
and	PROLIA.xml:S1:11234:3	O
1	PROLIA.xml:S1:11238:1	O
patient	PROLIA.xml:S1:11240:7	O
(	PROLIA.xml:S1:11248:1	O
0.8%	PROLIA.xml:S1:11249:4	O
)	PROLIA.xml:S1:11253:1	O
in	PROLIA.xml:S1:11255:2	O
the	PROLIA.xml:S1:11258:3	O
Prolia	PROLIA.xml:S1:11262:6	O
group	PROLIA.xml:S1:11269:5	O
.	PROLIA.xml:S1:11274:1	O

New	PROLIA.xml:S1:11283:3	O
Malignancies	PROLIA.xml:S1:11287:12	O
New	PROLIA.xml:S1:11301:3	O
malignancies	PROLIA.xml:S1:11305:12	B-AdverseReaction
were	PROLIA.xml:S1:11318:4	O
reported	PROLIA.xml:S1:11323:8	O
in	PROLIA.xml:S1:11332:2	O
no	PROLIA.xml:S1:11335:2	O
patients	PROLIA.xml:S1:11338:8	O
in	PROLIA.xml:S1:11347:2	O
the	PROLIA.xml:S1:11350:3	O
placebo	PROLIA.xml:S1:11354:7	O
group	PROLIA.xml:S1:11362:5	O
and	PROLIA.xml:S1:11368:3	O
4	PROLIA.xml:S1:11372:1	O
(	PROLIA.xml:S1:11374:1	O
3.3%	PROLIA.xml:S1:11375:4	O
)	PROLIA.xml:S1:11379:1	O
patients	PROLIA.xml:S1:11381:8	O
(	PROLIA.xml:S1:11390:1	O
3	PROLIA.xml:S1:11391:1	O
prostate	PROLIA.xml:S1:11393:8	B-AdverseReaction
cancers	PROLIA.xml:S1:11402:7	I-AdverseReaction
,	PROLIA.xml:S1:11409:1	O
1	PROLIA.xml:S1:11411:1	O
basal	PROLIA.xml:S1:11413:5	B-AdverseReaction
cell	PROLIA.xml:S1:11419:4	I-AdverseReaction
carcinoma	PROLIA.xml:S1:11424:9	I-AdverseReaction
)	PROLIA.xml:S1:11433:1	O
in	PROLIA.xml:S1:11435:2	O
the	PROLIA.xml:S1:11438:3	O
Prolia	PROLIA.xml:S1:11442:6	O
group	PROLIA.xml:S1:11449:5	O
.	PROLIA.xml:S1:11454:1	O

Treatment	PROLIA.xml:S1:11462:9	O
of	PROLIA.xml:S1:11472:2	O
Bone	PROLIA.xml:S1:11475:4	O
Loss	PROLIA.xml:S1:11480:4	O
in	PROLIA.xml:S1:11485:2	O
Patients	PROLIA.xml:S1:11488:8	O
Receiving	PROLIA.xml:S1:11497:9	O
Androgen	PROLIA.xml:S1:11507:8	O
Deprivation	PROLIA.xml:S1:11516:11	O
Therapy	PROLIA.xml:S1:11528:7	O
for	PROLIA.xml:S1:11536:3	O
Prostate	PROLIA.xml:S1:11540:8	O
Cancer	PROLIA.xml:S1:11549:6	O
or	PROLIA.xml:S1:11556:2	O
Adjuvant	PROLIA.xml:S1:11559:8	O
Aromatase	PROLIA.xml:S1:11568:9	O
Inhibitor	PROLIA.xml:S1:11578:9	O
Therapy	PROLIA.xml:S1:11588:7	O
for	PROLIA.xml:S1:11596:3	O
Breast	PROLIA.xml:S1:11600:6	O
Cancer	PROLIA.xml:S1:11607:6	O

The	PROLIA.xml:S1:11620:3	O
safety	PROLIA.xml:S1:11624:6	O
of	PROLIA.xml:S1:11631:2	O
Prolia	PROLIA.xml:S1:11634:6	O
in	PROLIA.xml:S1:11641:2	O
the	PROLIA.xml:S1:11644:3	O
treatment	PROLIA.xml:S1:11648:9	O
of	PROLIA.xml:S1:11658:2	O
bone	PROLIA.xml:S1:11661:4	O
loss	PROLIA.xml:S1:11666:4	O
in	PROLIA.xml:S1:11671:2	O
men	PROLIA.xml:S1:11674:3	O
with	PROLIA.xml:S1:11678:4	O
nonmetastatic	PROLIA.xml:S1:11683:13	O
prostate	PROLIA.xml:S1:11697:8	O
cancer	PROLIA.xml:S1:11706:6	O
receiving	PROLIA.xml:S1:11713:9	O
androgen	PROLIA.xml:S1:11723:8	O
deprivation	PROLIA.xml:S1:11732:11	O
therapy	PROLIA.xml:S1:11744:7	O
(	PROLIA.xml:S1:11752:1	O
ADT	PROLIA.xml:S1:11753:3	O
)	PROLIA.xml:S1:11756:1	O
was	PROLIA.xml:S1:11758:3	O
assessed	PROLIA.xml:S1:11762:8	O
in	PROLIA.xml:S1:11771:2	O
a	PROLIA.xml:S1:11774:1	O
3	PROLIA.xml:S1:11776:1	O
-	PROLIA.xml:S1:11777:1	O
year	PROLIA.xml:S1:11778:4	O
,	PROLIA.xml:S1:11782:1	O
randomized	PROLIA.xml:S1:11784:10	O
,	PROLIA.xml:S1:11794:1	O
double	PROLIA.xml:S1:11796:6	O
-	PROLIA.xml:S1:11802:1	O
blind	PROLIA.xml:S1:11803:5	O
,	PROLIA.xml:S1:11808:1	O
placebo	PROLIA.xml:S1:11810:7	O
-	PROLIA.xml:S1:11817:1	O
controlled	PROLIA.xml:S1:11818:10	O
,	PROLIA.xml:S1:11828:1	O
multinational	PROLIA.xml:S1:11830:13	O
study	PROLIA.xml:S1:11844:5	O
of	PROLIA.xml:S1:11850:2	O
1468	PROLIA.xml:S1:11853:4	O
men	PROLIA.xml:S1:11858:3	O
aged	PROLIA.xml:S1:11862:4	O
48	PROLIA.xml:S1:11867:2	O
to	PROLIA.xml:S1:11870:2	O
97	PROLIA.xml:S1:11873:2	O
years	PROLIA.xml:S1:11876:5	O
.	PROLIA.xml:S1:11881:1	O

A	PROLIA.xml:S1:11883:1	O
total	PROLIA.xml:S1:11885:5	O
of	PROLIA.xml:S1:11891:2	O
725	PROLIA.xml:S1:11894:3	O
men	PROLIA.xml:S1:11898:3	O
were	PROLIA.xml:S1:11902:4	O
exposed	PROLIA.xml:S1:11907:7	O
to	PROLIA.xml:S1:11915:2	O
placebo	PROLIA.xml:S1:11918:7	O
and	PROLIA.xml:S1:11926:3	O
731	PROLIA.xml:S1:11930:3	O
men	PROLIA.xml:S1:11934:3	O
were	PROLIA.xml:S1:11938:4	O
exposed	PROLIA.xml:S1:11943:7	O
to	PROLIA.xml:S1:11951:2	O
Prolia	PROLIA.xml:S1:11954:6	O
administered	PROLIA.xml:S1:11961:12	O
once	PROLIA.xml:S1:11974:4	O
every	PROLIA.xml:S1:11979:5	O
6	PROLIA.xml:S1:11985:1	O
months	PROLIA.xml:S1:11987:6	O
as	PROLIA.xml:S1:11994:2	O
a	PROLIA.xml:S1:11997:1	O
single	PROLIA.xml:S1:11999:6	O
60	PROLIA.xml:S1:12006:2	O
mg	PROLIA.xml:S1:12009:2	O
subcutaneous	PROLIA.xml:S1:12012:12	O
dose	PROLIA.xml:S1:12025:4	O
.	PROLIA.xml:S1:12029:1	O

All	PROLIA.xml:S1:12031:3	O
men	PROLIA.xml:S1:12035:3	O
were	PROLIA.xml:S1:12039:4	O
instructed	PROLIA.xml:S1:12044:10	O
to	PROLIA.xml:S1:12055:2	O
take	PROLIA.xml:S1:12058:4	O
at	PROLIA.xml:S1:12063:2	O
least	PROLIA.xml:S1:12066:5	O
1000	PROLIA.xml:S1:12072:4	O
mg	PROLIA.xml:S1:12077:2	O
of	PROLIA.xml:S1:12080:2	O
calcium	PROLIA.xml:S1:12083:7	O
and	PROLIA.xml:S1:12091:3	O
400	PROLIA.xml:S1:12095:3	O
IU	PROLIA.xml:S1:12099:2	O
of	PROLIA.xml:S1:12102:2	O
vitamin	PROLIA.xml:S1:12105:7	O
D	PROLIA.xml:S1:12113:1	O
supplementation	PROLIA.xml:S1:12115:15	O
per	PROLIA.xml:S1:12131:3	O
day	PROLIA.xml:S1:12135:3	O
.	PROLIA.xml:S1:12138:1	O

The	PROLIA.xml:S1:12144:3	O
incidence	PROLIA.xml:S1:12148:9	O
of	PROLIA.xml:S1:12158:2	O
serious	PROLIA.xml:S1:12161:7	O
adverse	PROLIA.xml:S1:12169:7	O
events	PROLIA.xml:S1:12177:6	O
was	PROLIA.xml:S1:12184:3	O
30.6%	PROLIA.xml:S1:12188:5	O
in	PROLIA.xml:S1:12194:2	O
the	PROLIA.xml:S1:12197:3	O
placebo	PROLIA.xml:S1:12201:7	O
group	PROLIA.xml:S1:12209:5	O
and	PROLIA.xml:S1:12215:3	O
34.6%	PROLIA.xml:S1:12219:5	O
in	PROLIA.xml:S1:12225:2	O
the	PROLIA.xml:S1:12228:3	O
Prolia	PROLIA.xml:S1:12232:6	O
group	PROLIA.xml:S1:12239:5	O
.	PROLIA.xml:S1:12244:1	O

The	PROLIA.xml:S1:12246:3	O
percentage	PROLIA.xml:S1:12250:10	O
of	PROLIA.xml:S1:12261:2	O
patients	PROLIA.xml:S1:12264:8	O
who	PROLIA.xml:S1:12273:3	O
withdrew	PROLIA.xml:S1:12277:8	O
from	PROLIA.xml:S1:12286:4	O
the	PROLIA.xml:S1:12291:3	O
study	PROLIA.xml:S1:12295:5	O
due	PROLIA.xml:S1:12301:3	O
to	PROLIA.xml:S1:12305:2	O
adverse	PROLIA.xml:S1:12308:7	O
events	PROLIA.xml:S1:12316:6	O
was	PROLIA.xml:S1:12323:3	O
6.1%	PROLIA.xml:S1:12327:4	O
and	PROLIA.xml:S1:12332:3	O
7.0%	PROLIA.xml:S1:12336:4	O
for	PROLIA.xml:S1:12341:3	O
the	PROLIA.xml:S1:12345:3	O
placebo	PROLIA.xml:S1:12349:7	O
and	PROLIA.xml:S1:12357:3	O
Prolia	PROLIA.xml:S1:12361:6	O
groups	PROLIA.xml:S1:12368:6	O
,	PROLIA.xml:S1:12374:1	O
respectively	PROLIA.xml:S1:12376:12	O
.	PROLIA.xml:S1:12388:1	O

The	PROLIA.xml:S1:12394:3	O
safety	PROLIA.xml:S1:12398:6	O
of	PROLIA.xml:S1:12405:2	O
Prolia	PROLIA.xml:S1:12408:6	O
in	PROLIA.xml:S1:12415:2	O
the	PROLIA.xml:S1:12418:3	O
treatment	PROLIA.xml:S1:12422:9	O
of	PROLIA.xml:S1:12432:2	O
bone	PROLIA.xml:S1:12435:4	O
loss	PROLIA.xml:S1:12440:4	O
in	PROLIA.xml:S1:12445:2	O
women	PROLIA.xml:S1:12448:5	O
with	PROLIA.xml:S1:12454:4	O
nonmetastatic	PROLIA.xml:S1:12459:13	O
breast	PROLIA.xml:S1:12473:6	O
cancer	PROLIA.xml:S1:12480:6	O
receiving	PROLIA.xml:S1:12487:9	O
aromatase	PROLIA.xml:S1:12497:9	O
inhibitor	PROLIA.xml:S1:12507:9	O
(	PROLIA.xml:S1:12517:1	O
AI	PROLIA.xml:S1:12518:2	O
)	PROLIA.xml:S1:12520:1	O
therapy	PROLIA.xml:S1:12523:7	O
was	PROLIA.xml:S1:12531:3	O
assessed	PROLIA.xml:S1:12535:8	O
in	PROLIA.xml:S1:12544:2	O
a	PROLIA.xml:S1:12547:1	O
2	PROLIA.xml:S1:12549:1	O
-	PROLIA.xml:S1:12550:1	O
year	PROLIA.xml:S1:12551:4	O
,	PROLIA.xml:S1:12555:1	O
randomized	PROLIA.xml:S1:12557:10	O
,	PROLIA.xml:S1:12567:1	O
double	PROLIA.xml:S1:12569:6	O
-	PROLIA.xml:S1:12575:1	O
blind	PROLIA.xml:S1:12576:5	O
,	PROLIA.xml:S1:12581:1	O
placebo	PROLIA.xml:S1:12583:7	O
-	PROLIA.xml:S1:12590:1	O
controlled	PROLIA.xml:S1:12591:10	O
,	PROLIA.xml:S1:12601:1	O
multinational	PROLIA.xml:S1:12603:13	O
study	PROLIA.xml:S1:12617:5	O
of	PROLIA.xml:S1:12623:2	O
252	PROLIA.xml:S1:12626:3	O
postmenopausal	PROLIA.xml:S1:12630:14	O
women	PROLIA.xml:S1:12645:5	O
aged	PROLIA.xml:S1:12651:4	O
35	PROLIA.xml:S1:12656:2	O
to	PROLIA.xml:S1:12659:2	O
84	PROLIA.xml:S1:12662:2	O
years	PROLIA.xml:S1:12665:5	O
.	PROLIA.xml:S1:12670:1	O

A	PROLIA.xml:S1:12672:1	O
total	PROLIA.xml:S1:12674:5	O
of	PROLIA.xml:S1:12680:2	O
120	PROLIA.xml:S1:12683:3	O
women	PROLIA.xml:S1:12687:5	O
were	PROLIA.xml:S1:12693:4	O
exposed	PROLIA.xml:S1:12698:7	O
to	PROLIA.xml:S1:12706:2	O
placebo	PROLIA.xml:S1:12709:7	O
and	PROLIA.xml:S1:12717:3	O
129	PROLIA.xml:S1:12721:3	O
women	PROLIA.xml:S1:12725:5	O
were	PROLIA.xml:S1:12731:4	O
exposed	PROLIA.xml:S1:12736:7	O
to	PROLIA.xml:S1:12744:2	O
Prolia	PROLIA.xml:S1:12747:6	O
administered	PROLIA.xml:S1:12754:12	O
once	PROLIA.xml:S1:12767:4	O
every	PROLIA.xml:S1:12772:5	O
6	PROLIA.xml:S1:12778:1	O
months	PROLIA.xml:S1:12780:6	O
as	PROLIA.xml:S1:12787:2	O
a	PROLIA.xml:S1:12790:1	O
single	PROLIA.xml:S1:12792:6	O
60	PROLIA.xml:S1:12799:2	O
mg	PROLIA.xml:S1:12802:2	O
subcutaneous	PROLIA.xml:S1:12805:12	O
dose	PROLIA.xml:S1:12818:4	O
.	PROLIA.xml:S1:12822:1	O

All	PROLIA.xml:S1:12824:3	O
women	PROLIA.xml:S1:12828:5	O
were	PROLIA.xml:S1:12834:4	O
instructed	PROLIA.xml:S1:12839:10	O
to	PROLIA.xml:S1:12850:2	O
take	PROLIA.xml:S1:12853:4	O
at	PROLIA.xml:S1:12858:2	O
least	PROLIA.xml:S1:12861:5	O
1000	PROLIA.xml:S1:12867:4	O
mg	PROLIA.xml:S1:12872:2	O
of	PROLIA.xml:S1:12875:2	O
calcium	PROLIA.xml:S1:12878:7	O
and	PROLIA.xml:S1:12886:3	O
400	PROLIA.xml:S1:12890:3	O
IU	PROLIA.xml:S1:12894:2	O
of	PROLIA.xml:S1:12897:2	O
vitamin	PROLIA.xml:S1:12900:7	O
D	PROLIA.xml:S1:12908:1	O
supplementation	PROLIA.xml:S1:12910:15	O
per	PROLIA.xml:S1:12926:3	O
day	PROLIA.xml:S1:12930:3	O
.	PROLIA.xml:S1:12933:1	O

The	PROLIA.xml:S1:12939:3	O
incidence	PROLIA.xml:S1:12943:9	O
of	PROLIA.xml:S1:12953:2	O
serious	PROLIA.xml:S1:12956:7	O
adverse	PROLIA.xml:S1:12964:7	O
events	PROLIA.xml:S1:12972:6	O
was	PROLIA.xml:S1:12979:3	O
9.2%	PROLIA.xml:S1:12983:4	O
in	PROLIA.xml:S1:12988:2	O
the	PROLIA.xml:S1:12991:3	O
placebo	PROLIA.xml:S1:12995:7	O
group	PROLIA.xml:S1:13003:5	O
and	PROLIA.xml:S1:13009:3	O
14.7%	PROLIA.xml:S1:13013:5	O
in	PROLIA.xml:S1:13019:2	O
the	PROLIA.xml:S1:13022:3	O
Prolia	PROLIA.xml:S1:13026:6	O
group	PROLIA.xml:S1:13033:5	O
.	PROLIA.xml:S1:13038:1	O

The	PROLIA.xml:S1:13040:3	O
percentage	PROLIA.xml:S1:13044:10	O
of	PROLIA.xml:S1:13055:2	O
patients	PROLIA.xml:S1:13058:8	O
who	PROLIA.xml:S1:13067:3	O
withdrew	PROLIA.xml:S1:13071:8	O
from	PROLIA.xml:S1:13080:4	O
the	PROLIA.xml:S1:13085:3	O
study	PROLIA.xml:S1:13089:5	O
due	PROLIA.xml:S1:13095:3	O
to	PROLIA.xml:S1:13099:2	O
adverse	PROLIA.xml:S1:13102:7	O
events	PROLIA.xml:S1:13110:6	O
was	PROLIA.xml:S1:13117:3	O
4.2%	PROLIA.xml:S1:13121:4	O
and	PROLIA.xml:S1:13126:3	O
0.8%	PROLIA.xml:S1:13130:4	O
for	PROLIA.xml:S1:13135:3	O
the	PROLIA.xml:S1:13139:3	O
placebo	PROLIA.xml:S1:13143:7	O
and	PROLIA.xml:S1:13151:3	O
Prolia	PROLIA.xml:S1:13155:6	O
groups	PROLIA.xml:S1:13162:6	O
,	PROLIA.xml:S1:13168:1	O
respectively	PROLIA.xml:S1:13170:12	O
.	PROLIA.xml:S1:13182:1	O

Adverse	PROLIA.xml:S1:13188:7	O
reactions	PROLIA.xml:S1:13196:9	O
reported	PROLIA.xml:S1:13206:8	O
in	PROLIA.xml:S1:13215:2	O
10%	PROLIA.xml:S1:13221:3	O
of	PROLIA.xml:S1:13225:2	O
Prolia	PROLIA.xml:S1:13228:6	O
-	PROLIA.xml:S1:13234:1	O
treated	PROLIA.xml:S1:13235:7	O
patients	PROLIA.xml:S1:13243:8	O
receiving	PROLIA.xml:S1:13252:9	O
ADT	PROLIA.xml:S1:13262:3	O
for	PROLIA.xml:S1:13266:3	O
prostate	PROLIA.xml:S1:13270:8	O
cancer	PROLIA.xml:S1:13279:6	O
or	PROLIA.xml:S1:13286:2	O
adjuvant	PROLIA.xml:S1:13289:8	O
AI	PROLIA.xml:S1:13298:2	O
therapy	PROLIA.xml:S1:13301:7	O
for	PROLIA.xml:S1:13309:3	O
breast	PROLIA.xml:S1:13313:6	O
cancer	PROLIA.xml:S1:13320:6	O
,	PROLIA.xml:S1:13326:1	O
and	PROLIA.xml:S1:13328:3	O
more	PROLIA.xml:S1:13332:4	O
frequently	PROLIA.xml:S1:13337:10	O
than	PROLIA.xml:S1:13348:4	O
in	PROLIA.xml:S1:13353:2	O
the	PROLIA.xml:S1:13356:3	O
placebo	PROLIA.xml:S1:13360:7	O
-	PROLIA.xml:S1:13367:1	O
treated	PROLIA.xml:S1:13368:7	O
patients	PROLIA.xml:S1:13376:8	O
were	PROLIA.xml:S1:13385:4	O
:	PROLIA.xml:S1:13389:1	O
arthralgia	PROLIA.xml:S1:13391:10	B-AdverseReaction
(	PROLIA.xml:S1:13402:1	O
13.0%	PROLIA.xml:S1:13403:5	O
placebo	PROLIA.xml:S1:13409:7	O
vs	PROLIA.xml:S1:13417:2	O
.	PROLIA.xml:S1:13419:1	O

14.3%	PROLIA.xml:S1:13421:5	O
Prolia	PROLIA.xml:S1:13427:6	O
)	PROLIA.xml:S1:13433:1	O
and	PROLIA.xml:S1:13435:3	O
back	PROLIA.xml:S1:13439:4	B-AdverseReaction
pain	PROLIA.xml:S1:13444:4	I-AdverseReaction
(	PROLIA.xml:S1:13449:1	O
10.5%	PROLIA.xml:S1:13450:5	O
placebo	PROLIA.xml:S1:13456:7	O
vs	PROLIA.xml:S1:13464:2	O
.	PROLIA.xml:S1:13466:1	O

11.5%	PROLIA.xml:S1:13468:5	O
Prolia	PROLIA.xml:S1:13474:6	O
)	PROLIA.xml:S1:13480:1	O
.	PROLIA.xml:S1:13481:1	O

Pain	PROLIA.xml:S1:13483:4	B-AdverseReaction
in	PROLIA.xml:S1:13488:2	I-AdverseReaction
extremity	PROLIA.xml:S1:13491:9	I-AdverseReaction
(	PROLIA.xml:S1:13501:1	O
7.7%	PROLIA.xml:S1:13502:4	O
placebo	PROLIA.xml:S1:13507:7	O
vs	PROLIA.xml:S1:13515:2	O
.	PROLIA.xml:S1:13517:1	O

9.9%	PROLIA.xml:S1:13519:4	O
Prolia	PROLIA.xml:S1:13524:6	O
)	PROLIA.xml:S1:13530:1	O
and	PROLIA.xml:S1:13532:3	O
musculoskeletal	PROLIA.xml:S1:13536:15	B-AdverseReaction
pain	PROLIA.xml:S1:13552:4	I-AdverseReaction
(	PROLIA.xml:S1:13557:1	O
3.8%	PROLIA.xml:S1:13558:4	O
placebo	PROLIA.xml:S1:13563:7	O
vs	PROLIA.xml:S1:13571:2	O
.	PROLIA.xml:S1:13573:1	O

6.0%	PROLIA.xml:S1:13575:4	O
Prolia	PROLIA.xml:S1:13580:6	O
)	PROLIA.xml:S1:13586:1	O
have	PROLIA.xml:S1:13588:4	O
also	PROLIA.xml:S1:13593:4	O
been	PROLIA.xml:S1:13598:4	O
reported	PROLIA.xml:S1:13603:8	O
in	PROLIA.xml:S1:13612:2	O
clinical	PROLIA.xml:S1:13615:8	O
trials	PROLIA.xml:S1:13624:6	O
.	PROLIA.xml:S1:13630:1	O

Additionally	PROLIA.xml:S1:13632:12	O
in	PROLIA.xml:S1:13645:2	O
Prolia	PROLIA.xml:S1:13648:6	O
-	PROLIA.xml:S1:13654:1	O
treated	PROLIA.xml:S1:13655:7	O
men	PROLIA.xml:S1:13663:3	O
with	PROLIA.xml:S1:13667:4	O
nonmetastatic	PROLIA.xml:S1:13672:13	O
prostate	PROLIA.xml:S1:13686:8	O
cancer	PROLIA.xml:S1:13695:6	O
receiving	PROLIA.xml:S1:13702:9	O
ADT	PROLIA.xml:S1:13712:3	O
,	PROLIA.xml:S1:13715:1	O
a	PROLIA.xml:S1:13717:1	O
greater	PROLIA.xml:S1:13719:7	O
incidence	PROLIA.xml:S1:13727:9	O
of	PROLIA.xml:S1:13737:2	O
cataracts	PROLIA.xml:S1:13740:9	B-AdverseReaction
was	PROLIA.xml:S1:13750:3	O
observed	PROLIA.xml:S1:13754:8	O
(	PROLIA.xml:S1:13763:1	O
1.2%	PROLIA.xml:S1:13764:4	O
placebo	PROLIA.xml:S1:13769:7	O
vs	PROLIA.xml:S1:13777:2	O
.	PROLIA.xml:S1:13779:1	O

4.7%	PROLIA.xml:S1:13781:4	O
Prolia	PROLIA.xml:S1:13786:6	O
)	PROLIA.xml:S1:13792:1	O
.	PROLIA.xml:S1:13793:1	O

Hypocalcemia	PROLIA.xml:S1:13795:12	B-AdverseReaction
(	PROLIA.xml:S1:13808:1	O
serum	PROLIA.xml:S1:13809:5	O
calcium	PROLIA.xml:S1:13815:7	O
8.4	PROLIA.xml:S1:13825:3	O
mg	PROLIA.xml:S1:13829:2	O
dL	PROLIA.xml:S1:13832:2	O
)	PROLIA.xml:S1:13834:1	O
was	PROLIA.xml:S1:13836:3	O
reported	PROLIA.xml:S1:13840:8	O
only	PROLIA.xml:S1:13849:4	O
in	PROLIA.xml:S1:13854:2	O
Prolia	PROLIA.xml:S1:13857:6	O
-	PROLIA.xml:S1:13863:1	O
treated	PROLIA.xml:S1:13864:7	O
patients	PROLIA.xml:S1:13872:8	O
(	PROLIA.xml:S1:13881:1	O
2.4%	PROLIA.xml:S1:13882:4	O
vs	PROLIA.xml:S1:13887:2	O
.	PROLIA.xml:S1:13889:1	O

0%	PROLIA.xml:S1:13891:2	O
)	PROLIA.xml:S1:13893:1	O
at	PROLIA.xml:S1:13895:2	O
the	PROLIA.xml:S1:13898:3	O
month	PROLIA.xml:S1:13902:5	O
1	PROLIA.xml:S1:13908:1	O
visit	PROLIA.xml:S1:13910:5	O
.	PROLIA.xml:S1:13915:1	O

6.2	PROLIA.xml:S1:13923:3	O
Postmarketing	PROLIA.xml:S1:13927:13	O
Experience	PROLIA.xml:S1:13941:10	O

Because	PROLIA.xml:S1:13955:7	O
postmarketing	PROLIA.xml:S1:13963:13	O
reactions	PROLIA.xml:S1:13977:9	O
are	PROLIA.xml:S1:13987:3	O
reported	PROLIA.xml:S1:13991:8	O
voluntarily	PROLIA.xml:S1:14000:11	O
from	PROLIA.xml:S1:14012:4	O
a	PROLIA.xml:S1:14017:1	O
population	PROLIA.xml:S1:14019:10	O
of	PROLIA.xml:S1:14030:2	O
uncertain	PROLIA.xml:S1:14033:9	O
size	PROLIA.xml:S1:14043:4	O
,	PROLIA.xml:S1:14047:1	O
it	PROLIA.xml:S1:14049:2	O
is	PROLIA.xml:S1:14052:2	O
not	PROLIA.xml:S1:14055:3	O
always	PROLIA.xml:S1:14059:6	O
possible	PROLIA.xml:S1:14066:8	O
to	PROLIA.xml:S1:14075:2	O
reliably	PROLIA.xml:S1:14078:8	O
estimate	PROLIA.xml:S1:14087:8	O
their	PROLIA.xml:S1:14096:5	O
frequency	PROLIA.xml:S1:14102:9	O
or	PROLIA.xml:S1:14112:2	O
establish	PROLIA.xml:S1:14115:9	O
a	PROLIA.xml:S1:14125:1	O
causal	PROLIA.xml:S1:14127:6	O
relationship	PROLIA.xml:S1:14134:12	O
to	PROLIA.xml:S1:14147:2	O
drug	PROLIA.xml:S1:14150:4	O
exposure	PROLIA.xml:S1:14155:8	O
.	PROLIA.xml:S1:14163:1	O

The	PROLIA.xml:S1:14169:3	O
following	PROLIA.xml:S1:14173:9	O
adverse	PROLIA.xml:S1:14183:7	O
reactions	PROLIA.xml:S1:14191:9	O
have	PROLIA.xml:S1:14201:4	O
been	PROLIA.xml:S1:14206:4	O
identified	PROLIA.xml:S1:14211:10	O
during	PROLIA.xml:S1:14222:6	O
post	PROLIA.xml:S1:14229:4	O
approval	PROLIA.xml:S1:14234:8	O
use	PROLIA.xml:S1:14243:3	O
of	PROLIA.xml:S1:14247:2	O
Prolia	PROLIA.xml:S1:14250:6	O
:	PROLIA.xml:S1:14256:1	O

Drug	PROLIA.xml:S1:14265:4	O
-	PROLIA.xml:S1:14269:1	O
related	PROLIA.xml:S1:14270:7	O
hypersensitivity	PROLIA.xml:S1:14278:16	B-AdverseReaction
reactions	PROLIA.xml:S1:14295:9	I-AdverseReaction
:	PROLIA.xml:S1:14304:1	O
anaphylaxis	PROLIA.xml:S1:14306:11	B-AdverseReaction
,	PROLIA.xml:S1:14317:1	O
rash	PROLIA.xml:S1:14319:4	B-AdverseReaction
,	PROLIA.xml:S1:14323:1	O
urticaria	PROLIA.xml:S1:14325:9	B-AdverseReaction
,	PROLIA.xml:S1:14334:1	O
facial	PROLIA.xml:S1:14336:6	B-AdverseReaction
swelling	PROLIA.xml:S1:14343:8	I-AdverseReaction
,	PROLIA.xml:S1:14351:1	O
and	PROLIA.xml:S1:14353:3	O
erythema	PROLIA.xml:S1:14357:8	B-AdverseReaction

Hypocalcemia	PROLIA.xml:S1:14373:12	B-AdverseReaction
:	PROLIA.xml:S1:14385:1	O
severe	PROLIA.xml:S1:14387:6	B-Severity
symptomatic	PROLIA.xml:S1:14394:11	B-AdverseReaction
hypocalcemia	PROLIA.xml:S1:14406:12	I-AdverseReaction

Musculoskeletal	PROLIA.xml:S1:14424:15	B-AdverseReaction
pain	PROLIA.xml:S1:14440:4	I-AdverseReaction
,	PROLIA.xml:S1:14444:1	O
including	PROLIA.xml:S1:14446:9	O
severe	PROLIA.xml:S1:14456:6	B-Severity
cases	PROLIA.xml:S1:14463:5	O

Parathyroid	PROLIA.xml:S1:14474:11	O
Hormone	PROLIA.xml:S1:14486:7	O
(	PROLIA.xml:S1:14494:1	O
PTH	PROLIA.xml:S1:14495:3	O
)	PROLIA.xml:S1:14498:1	O
:	PROLIA.xml:S1:14499:1	O
Marked	PROLIA.xml:S1:14501:6	B-Severity
elevation	PROLIA.xml:S1:14508:9	B-AdverseReaction
in	PROLIA.xml:S1:14518:2	I-AdverseReaction
serum	PROLIA.xml:S1:14521:5	I-AdverseReaction
PTH	PROLIA.xml:S1:14527:3	I-AdverseReaction
in	PROLIA.xml:S1:14531:2	O
patients	PROLIA.xml:S1:14534:8	O
with	PROLIA.xml:S1:14543:4	O
severe	PROLIA.xml:S1:14548:6	O
renal	PROLIA.xml:S1:14555:5	O
impairment	PROLIA.xml:S1:14561:10	O
(	PROLIA.xml:S1:14572:1	O
creatinine	PROLIA.xml:S1:14573:10	O
clearance	PROLIA.xml:S1:14584:9	O
30	PROLIA.xml:S1:14596:2	O
mL	PROLIA.xml:S1:14599:2	O
min	PROLIA.xml:S1:14602:3	O
)	PROLIA.xml:S1:14605:1	O
or	PROLIA.xml:S1:14607:2	O
receiving	PROLIA.xml:S1:14610:9	O
dialysis	PROLIA.xml:S1:14620:8	O
.	PROLIA.xml:S1:14628:1	O

6.3	PROLIA.xml:S1:14637:3	O
Immunogenicity	PROLIA.xml:S1:14641:14	O

Denosumab	PROLIA.xml:S1:14659:9	O
is	PROLIA.xml:S1:14669:2	O
a	PROLIA.xml:S1:14672:1	O
human	PROLIA.xml:S1:14674:5	O
monoclonal	PROLIA.xml:S1:14680:10	O
antibody	PROLIA.xml:S1:14691:8	O
.	PROLIA.xml:S1:14699:1	O

As	PROLIA.xml:S1:14701:2	O
with	PROLIA.xml:S1:14704:4	O
all	PROLIA.xml:S1:14709:3	O
therapeutic	PROLIA.xml:S1:14713:11	O
proteins	PROLIA.xml:S1:14725:8	O
,	PROLIA.xml:S1:14733:1	O
there	PROLIA.xml:S1:14735:5	O
is	PROLIA.xml:S1:14741:2	O
potential	PROLIA.xml:S1:14744:9	O
for	PROLIA.xml:S1:14754:3	O
immunogenicity	PROLIA.xml:S1:14758:14	O
.	PROLIA.xml:S1:14772:1	O

Using	PROLIA.xml:S1:14774:5	O
an	PROLIA.xml:S1:14780:2	O
electrochemiluminescent	PROLIA.xml:S1:14783:23	O
bridging	PROLIA.xml:S1:14807:8	O
immunoassay	PROLIA.xml:S1:14816:11	O
,	PROLIA.xml:S1:14827:1	O
less	PROLIA.xml:S1:14829:4	O
than	PROLIA.xml:S1:14834:4	O
1%	PROLIA.xml:S1:14839:2	O
(	PROLIA.xml:S1:14842:1	O
55	PROLIA.xml:S1:14843:2	O
out	PROLIA.xml:S1:14846:3	O
of	PROLIA.xml:S1:14850:2	O
8113	PROLIA.xml:S1:14853:4	O
)	PROLIA.xml:S1:14857:1	O
of	PROLIA.xml:S1:14859:2	O
patients	PROLIA.xml:S1:14862:8	O
treated	PROLIA.xml:S1:14871:7	O
with	PROLIA.xml:S1:14879:4	O
Prolia	PROLIA.xml:S1:14884:6	O
for	PROLIA.xml:S1:14891:3	O
up	PROLIA.xml:S1:14895:2	O
to	PROLIA.xml:S1:14898:2	O
5	PROLIA.xml:S1:14901:1	O
years	PROLIA.xml:S1:14903:5	O
tested	PROLIA.xml:S1:14909:6	O
positive	PROLIA.xml:S1:14916:8	O
for	PROLIA.xml:S1:14925:3	O
binding	PROLIA.xml:S1:14929:7	O
antibodies	PROLIA.xml:S1:14937:10	O
(	PROLIA.xml:S1:14948:1	O
including	PROLIA.xml:S1:14949:9	O
pre	PROLIA.xml:S1:14959:3	O
-	PROLIA.xml:S1:14962:1	O
existing	PROLIA.xml:S1:14963:8	O
,	PROLIA.xml:S1:14971:1	O
transient	PROLIA.xml:S1:14973:9	O
,	PROLIA.xml:S1:14982:1	O
and	PROLIA.xml:S1:14984:3	O
developing	PROLIA.xml:S1:14988:10	O
antibodies	PROLIA.xml:S1:14999:10	O
)	PROLIA.xml:S1:15009:1	O
.	PROLIA.xml:S1:15010:1	O

None	PROLIA.xml:S1:15012:4	O
of	PROLIA.xml:S1:15017:2	O
the	PROLIA.xml:S1:15020:3	O
patients	PROLIA.xml:S1:15024:8	O
tested	PROLIA.xml:S1:15033:6	O
positive	PROLIA.xml:S1:15040:8	O
for	PROLIA.xml:S1:15049:3	O
neutralizing	PROLIA.xml:S1:15053:12	O
antibodies	PROLIA.xml:S1:15066:10	O
,	PROLIA.xml:S1:15076:1	O
as	PROLIA.xml:S1:15078:2	O
was	PROLIA.xml:S1:15081:3	O
assessed	PROLIA.xml:S1:15085:8	O
using	PROLIA.xml:S1:15094:5	O
a	PROLIA.xml:S1:15100:1	O
chemiluminescent	PROLIA.xml:S1:15102:16	O
cell	PROLIA.xml:S1:15119:4	O
-	PROLIA.xml:S1:15123:1	O
based	PROLIA.xml:S1:15124:5	O
in	PROLIA.xml:S1:15130:2	O
vitro	PROLIA.xml:S1:15133:5	O
biological	PROLIA.xml:S1:15139:10	O
assay	PROLIA.xml:S1:15150:5	O
.	PROLIA.xml:S1:15155:1	O

No	PROLIA.xml:S1:15157:2	B-Negation
evidence	PROLIA.xml:S1:15160:8	O
of	PROLIA.xml:S1:15169:2	O
altered	PROLIA.xml:S1:15172:7	O
pharmacokinetic	PROLIA.xml:S1:15180:15	O
profile	PROLIA.xml:S1:15196:7	O
,	PROLIA.xml:S1:15203:1	O
toxicity	PROLIA.xml:S1:15205:8	B-AdverseReaction
profile	PROLIA.xml:S1:15214:7	O
,	PROLIA.xml:S1:15221:1	O
or	PROLIA.xml:S1:15223:2	O
clinical	PROLIA.xml:S1:15226:8	O
response	PROLIA.xml:S1:15235:8	O
was	PROLIA.xml:S1:15244:3	O
associated	PROLIA.xml:S1:15248:10	O
with	PROLIA.xml:S1:15259:4	O
binding	PROLIA.xml:S1:15264:7	O
antibody	PROLIA.xml:S1:15272:8	O
development	PROLIA.xml:S1:15281:11	O
.	PROLIA.xml:S1:15292:1	O

The	PROLIA.xml:S1:15298:3	O
incidence	PROLIA.xml:S1:15302:9	O
of	PROLIA.xml:S1:15312:2	O
antibody	PROLIA.xml:S1:15315:8	O
formation	PROLIA.xml:S1:15324:9	O
is	PROLIA.xml:S1:15334:2	O
highly	PROLIA.xml:S1:15337:6	O
dependent	PROLIA.xml:S1:15344:9	O
on	PROLIA.xml:S1:15354:2	O
the	PROLIA.xml:S1:15357:3	O
sensitivity	PROLIA.xml:S1:15361:11	O
and	PROLIA.xml:S1:15373:3	O
specificity	PROLIA.xml:S1:15377:11	O
of	PROLIA.xml:S1:15389:2	O
the	PROLIA.xml:S1:15392:3	O
assay	PROLIA.xml:S1:15396:5	O
.	PROLIA.xml:S1:15401:1	O

Additionally	PROLIA.xml:S1:15403:12	O
,	PROLIA.xml:S1:15415:1	O
the	PROLIA.xml:S1:15417:3	O
observed	PROLIA.xml:S1:15421:8	O
incidence	PROLIA.xml:S1:15430:9	O
of	PROLIA.xml:S1:15440:2	O
a	PROLIA.xml:S1:15443:1	O
positive	PROLIA.xml:S1:15445:8	O
antibody	PROLIA.xml:S1:15454:8	O
(	PROLIA.xml:S1:15463:1	O
including	PROLIA.xml:S1:15464:9	O
neutralizing	PROLIA.xml:S1:15474:12	O
antibody	PROLIA.xml:S1:15487:8	O
)	PROLIA.xml:S1:15495:1	O
test	PROLIA.xml:S1:15497:4	O
result	PROLIA.xml:S1:15502:6	O
may	PROLIA.xml:S1:15509:3	O
be	PROLIA.xml:S1:15513:2	O
influenced	PROLIA.xml:S1:15516:10	O
by	PROLIA.xml:S1:15527:2	O
several	PROLIA.xml:S1:15530:7	O
factors	PROLIA.xml:S1:15538:7	O
,	PROLIA.xml:S1:15545:1	O
including	PROLIA.xml:S1:15547:9	O
assay	PROLIA.xml:S1:15557:5	O
methodology	PROLIA.xml:S1:15563:11	O
,	PROLIA.xml:S1:15574:1	O
sample	PROLIA.xml:S1:15576:6	O
handling	PROLIA.xml:S1:15583:8	O
,	PROLIA.xml:S1:15591:1	O
timing	PROLIA.xml:S1:15593:6	O
of	PROLIA.xml:S1:15600:2	O
sample	PROLIA.xml:S1:15603:6	O
collection	PROLIA.xml:S1:15610:10	O
,	PROLIA.xml:S1:15620:1	O
concomitant	PROLIA.xml:S1:15622:11	O
medications	PROLIA.xml:S1:15634:11	O
,	PROLIA.xml:S1:15645:1	O
and	PROLIA.xml:S1:15647:3	O
underlying	PROLIA.xml:S1:15651:10	O
disease	PROLIA.xml:S1:15662:7	O
.	PROLIA.xml:S1:15669:1	O

For	PROLIA.xml:S1:15671:3	O
these	PROLIA.xml:S1:15675:5	O
reasons	PROLIA.xml:S1:15681:7	O
,	PROLIA.xml:S1:15688:1	O
comparison	PROLIA.xml:S1:15690:10	O
of	PROLIA.xml:S1:15701:2	O
antibodies	PROLIA.xml:S1:15704:10	O
to	PROLIA.xml:S1:15715:2	O
denosumab	PROLIA.xml:S1:15718:9	O
with	PROLIA.xml:S1:15728:4	O
the	PROLIA.xml:S1:15733:3	O
incidence	PROLIA.xml:S1:15737:9	O
of	PROLIA.xml:S1:15747:2	O
antibodies	PROLIA.xml:S1:15750:10	O
to	PROLIA.xml:S1:15761:2	O
other	PROLIA.xml:S1:15764:5	O
products	PROLIA.xml:S1:15770:8	O
may	PROLIA.xml:S1:15779:3	O
be	PROLIA.xml:S1:15783:2	O
misleading	PROLIA.xml:S1:15786:10	O
.	PROLIA.xml:S1:15796:1	O
5	PROLIA.xml:S2:4:1	O
WARNINGS	PROLIA.xml:S2:6:8	O
AND	PROLIA.xml:S2:15:3	O
PRECAUTIONS	PROLIA.xml:S2:19:11	O

EXCERPT	PROLIA.xml:S2:37:7	O
:	PROLIA.xml:S2:44:1	O
Same	PROLIA.xml:S2:52:4	O
Active	PROLIA.xml:S2:57:6	O
Ingredient	PROLIA.xml:S2:64:10	O
:	PROLIA.xml:S2:74:1	O
Patients	PROLIA.xml:S2:76:8	O
receiving	PROLIA.xml:S2:85:9	O
Prolia	PROLIA.xml:S2:95:6	O
should	PROLIA.xml:S2:102:6	O
not	PROLIA.xml:S2:109:3	O
receive	PROLIA.xml:S2:113:7	O
XGEVA	PROLIA.xml:S2:121:5	O
(	PROLIA.xml:S2:128:1	O
r	PROLIA.xml:S2:129:1	O
)	PROLIA.xml:S2:130:1	O
(	PROLIA.xml:S2:133:1	O
5.1	PROLIA.xml:S2:136:3	O
)	PROLIA.xml:S2:141:1	O

Hypersensitivity	PROLIA.xml:S2:148:16	B-AdverseReaction
including	PROLIA.xml:S2:165:9	O
anaphylactic	PROLIA.xml:S2:175:12	B-AdverseReaction
reactions	PROLIA.xml:S2:188:9	I-AdverseReaction
may	PROLIA.xml:S2:198:3	O
occur	PROLIA.xml:S2:202:5	O
.	PROLIA.xml:S2:207:1	O

Discontinue	PROLIA.xml:S2:209:11	O
permanently	PROLIA.xml:S2:221:11	O
if	PROLIA.xml:S2:233:2	O
a	PROLIA.xml:S2:236:1	O
clinically	PROLIA.xml:S2:238:10	O
significant	PROLIA.xml:S2:249:11	O
reaction	PROLIA.xml:S2:261:8	O
occurs	PROLIA.xml:S2:270:6	O
(	PROLIA.xml:S2:277:1	O
5.2	PROLIA.xml:S2:280:3	O
)	PROLIA.xml:S2:285:1	O

Hypocalcemia	PROLIA.xml:S2:292:12	B-AdverseReaction
:	PROLIA.xml:S2:304:1	O
Must	PROLIA.xml:S2:306:4	O
be	PROLIA.xml:S2:311:2	O
corrected	PROLIA.xml:S2:314:9	O
before	PROLIA.xml:S2:324:6	O
initiating	PROLIA.xml:S2:331:10	O
Prolia	PROLIA.xml:S2:342:6	O
.	PROLIA.xml:S2:348:1	O

May	PROLIA.xml:S2:350:3	O
worsen	PROLIA.xml:S2:354:6	O
,	PROLIA.xml:S2:360:1	O
especially	PROLIA.xml:S2:362:10	O
in	PROLIA.xml:S2:373:2	O
patients	PROLIA.xml:S2:376:8	O
with	PROLIA.xml:S2:385:4	O
renal	PROLIA.xml:S2:390:5	O
impairment	PROLIA.xml:S2:396:10	O
.	PROLIA.xml:S2:406:1	O

Adequately	PROLIA.xml:S2:408:10	O
supplement	PROLIA.xml:S2:419:10	O
patients	PROLIA.xml:S2:430:8	O
with	PROLIA.xml:S2:439:4	O
calcium	PROLIA.xml:S2:444:7	O
and	PROLIA.xml:S2:452:3	O
vitamin	PROLIA.xml:S2:456:7	O
D	PROLIA.xml:S2:464:1	O
(	PROLIA.xml:S2:466:1	O
5.3	PROLIA.xml:S2:469:3	O
)	PROLIA.xml:S2:474:1	O

Osteonecrosis	PROLIA.xml:S2:481:13	B-AdverseReaction
of	PROLIA.xml:S2:495:2	I-AdverseReaction
the	PROLIA.xml:S2:498:3	I-AdverseReaction
jaw	PROLIA.xml:S2:502:3	I-AdverseReaction
:	PROLIA.xml:S2:505:1	O
Has	PROLIA.xml:S2:507:3	O
been	PROLIA.xml:S2:511:4	O
reported	PROLIA.xml:S2:516:8	O
with	PROLIA.xml:S2:525:4	O
Prolia	PROLIA.xml:S2:530:6	O
.	PROLIA.xml:S2:536:1	O

Monitor	PROLIA.xml:S2:538:7	O
for	PROLIA.xml:S2:546:3	O
symptoms	PROLIA.xml:S2:550:8	O
(	PROLIA.xml:S2:559:1	O
5.4	PROLIA.xml:S2:562:3	O
)	PROLIA.xml:S2:567:1	O

Atypical	PROLIA.xml:S2:574:8	B-AdverseReaction
femoral	PROLIA.xml:S2:583:7	I-AdverseReaction
fractures	PROLIA.xml:S2:591:9	I-AdverseReaction
:	PROLIA.xml:S2:600:1	O
Have	PROLIA.xml:S2:602:4	O
been	PROLIA.xml:S2:607:4	O
reported	PROLIA.xml:S2:612:8	O
.	PROLIA.xml:S2:620:1	O

Evaluate	PROLIA.xml:S2:622:8	O
patients	PROLIA.xml:S2:631:8	O
with	PROLIA.xml:S2:640:4	O
thigh	PROLIA.xml:S2:645:5	O
or	PROLIA.xml:S2:651:2	O
groin	PROLIA.xml:S2:654:5	O
pain	PROLIA.xml:S2:660:4	O
to	PROLIA.xml:S2:665:2	O
rule	PROLIA.xml:S2:668:4	O
out	PROLIA.xml:S2:673:3	O
a	PROLIA.xml:S2:677:1	O
femoral	PROLIA.xml:S2:679:7	O
fracture	PROLIA.xml:S2:687:8	O
(	PROLIA.xml:S2:696:1	O
5.5	PROLIA.xml:S2:699:3	O
)	PROLIA.xml:S2:704:1	O

Serious	PROLIA.xml:S2:711:7	B-Severity
infections	PROLIA.xml:S2:719:10	B-AdverseReaction
including	PROLIA.xml:S2:730:9	O
skin	PROLIA.xml:S2:740:4	B-AdverseReaction
infections	PROLIA.xml:S2:745:10	I-AdverseReaction
:	PROLIA.xml:S2:755:1	O
May	PROLIA.xml:S2:757:3	O
occur	PROLIA.xml:S2:761:5	O
,	PROLIA.xml:S2:766:1	O
including	PROLIA.xml:S2:768:9	O
those	PROLIA.xml:S2:778:5	O
leading	PROLIA.xml:S2:784:7	O
to	PROLIA.xml:S2:792:2	O
hospitalization	PROLIA.xml:S2:795:15	O
.	PROLIA.xml:S2:810:1	O

Advise	PROLIA.xml:S2:812:6	O
patients	PROLIA.xml:S2:819:8	O
to	PROLIA.xml:S2:828:2	O
seek	PROLIA.xml:S2:831:4	O
prompt	PROLIA.xml:S2:836:6	O
medical	PROLIA.xml:S2:843:7	O
attention	PROLIA.xml:S2:851:9	O
if	PROLIA.xml:S2:861:2	O
they	PROLIA.xml:S2:864:4	O
develop	PROLIA.xml:S2:869:7	O
signs	PROLIA.xml:S2:877:5	O
or	PROLIA.xml:S2:883:2	O
symptoms	PROLIA.xml:S2:886:8	O
of	PROLIA.xml:S2:895:2	O
infection	PROLIA.xml:S2:898:9	O
,	PROLIA.xml:S2:907:1	O
including	PROLIA.xml:S2:909:9	O
cellulitis	PROLIA.xml:S2:919:10	O
(	PROLIA.xml:S2:930:1	O
5.6	PROLIA.xml:S2:933:3	O
)	PROLIA.xml:S2:938:1	O

Dermatologic	PROLIA.xml:S2:945:12	B-AdverseReaction
reactions	PROLIA.xml:S2:958:9	I-AdverseReaction
:	PROLIA.xml:S2:967:1	O
Dermatitis	PROLIA.xml:S2:969:10	B-AdverseReaction
,	PROLIA.xml:S2:979:1	O
rashes	PROLIA.xml:S2:981:6	B-AdverseReaction
,	PROLIA.xml:S2:987:1	O
and	PROLIA.xml:S2:989:3	O
eczema	PROLIA.xml:S2:993:6	B-AdverseReaction
have	PROLIA.xml:S2:1000:4	O
been	PROLIA.xml:S2:1005:4	O
reported	PROLIA.xml:S2:1010:8	O
.	PROLIA.xml:S2:1018:1	O

Consider	PROLIA.xml:S2:1020:8	O
discontinuing	PROLIA.xml:S2:1029:13	O
Prolia	PROLIA.xml:S2:1043:6	O
if	PROLIA.xml:S2:1050:2	O
severe	PROLIA.xml:S2:1053:6	O
symptoms	PROLIA.xml:S2:1060:8	O
develop	PROLIA.xml:S2:1069:7	O
(	PROLIA.xml:S2:1077:1	O
5.7	PROLIA.xml:S2:1080:3	O
)	PROLIA.xml:S2:1085:1	O

Severe	PROLIA.xml:S2:1092:6	B-Severity
Bone	PROLIA.xml:S2:1099:4	B-AdverseReaction
,	PROLIA.xml:S2:1103:1	O
Joint	PROLIA.xml:S2:1105:5	B-AdverseReaction
,	PROLIA.xml:S2:1110:1	O
Muscle	PROLIA.xml:S2:1112:6	B-AdverseReaction
Pain	PROLIA.xml:S2:1119:4	I-AdverseReaction
may	PROLIA.xml:S2:1124:3	O
occur	PROLIA.xml:S2:1128:5	O
.	PROLIA.xml:S2:1133:1	O

Discontinue	PROLIA.xml:S2:1135:11	O
use	PROLIA.xml:S2:1147:3	O
if	PROLIA.xml:S2:1151:2	O
severe	PROLIA.xml:S2:1154:6	O
symptoms	PROLIA.xml:S2:1161:8	O
develop	PROLIA.xml:S2:1170:7	O
(	PROLIA.xml:S2:1178:1	O
5.8	PROLIA.xml:S2:1181:3	O
)	PROLIA.xml:S2:1186:1	O

Suppression	PROLIA.xml:S2:1193:11	B-AdverseReaction
of	PROLIA.xml:S2:1205:2	I-AdverseReaction
bone	PROLIA.xml:S2:1208:4	I-AdverseReaction
turnover	PROLIA.xml:S2:1213:8	I-AdverseReaction
:	PROLIA.xml:S2:1221:1	O
Significant	PROLIA.xml:S2:1223:11	O
suppression	PROLIA.xml:S2:1235:11	O
has	PROLIA.xml:S2:1247:3	O
been	PROLIA.xml:S2:1251:4	O
demonstrated	PROLIA.xml:S2:1256:12	O
.	PROLIA.xml:S2:1268:1	O

Monitor	PROLIA.xml:S2:1270:7	O
for	PROLIA.xml:S2:1278:3	O
consequences	PROLIA.xml:S2:1282:12	O
of	PROLIA.xml:S2:1295:2	O
bone	PROLIA.xml:S2:1298:4	O
oversuppression	PROLIA.xml:S2:1303:15	O
(	PROLIA.xml:S2:1319:1	O
5.9	PROLIA.xml:S2:1322:3	O
)	PROLIA.xml:S2:1327:1	O

5.1	PROLIA.xml:S2:1341:3	O

Drug	PROLIA.xml:S2:1345:4	O

Products	PROLIA.xml:S2:1350:8	O
with	PROLIA.xml:S2:1359:4	O
Same	PROLIA.xml:S2:1364:4	O
Active	PROLIA.xml:S2:1369:6	O
Ingredient	PROLIA.xml:S2:1376:10	O

Prolia	PROLIA.xml:S2:1392:6	O
contains	PROLIA.xml:S2:1399:8	O
the	PROLIA.xml:S2:1408:3	O
same	PROLIA.xml:S2:1412:4	O
active	PROLIA.xml:S2:1417:6	O
ingredient	PROLIA.xml:S2:1424:10	O
(	PROLIA.xml:S2:1435:1	O
denosumab	PROLIA.xml:S2:1436:9	O
)	PROLIA.xml:S2:1445:1	O
found	PROLIA.xml:S2:1447:5	O
in	PROLIA.xml:S2:1453:2	O
Xgeva	PROLIA.xml:S2:1456:5	O
.	PROLIA.xml:S2:1461:1	O

Patients	PROLIA.xml:S2:1463:8	O
receiving	PROLIA.xml:S2:1472:9	O
Prolia	PROLIA.xml:S2:1482:6	O
should	PROLIA.xml:S2:1489:6	O
not	PROLIA.xml:S2:1496:3	O
receive	PROLIA.xml:S2:1500:7	O
Xgeva	PROLIA.xml:S2:1508:5	O
.	PROLIA.xml:S2:1513:1	O

5.2	PROLIA.xml:S2:1522:3	O
Hypersensitivity	PROLIA.xml:S2:1526:16	O

Clinically	PROLIA.xml:S2:1548:10	O
significant	PROLIA.xml:S2:1559:11	O
hypersensitivity	PROLIA.xml:S2:1571:16	B-AdverseReaction
including	PROLIA.xml:S2:1588:9	O
anaphylaxis	PROLIA.xml:S2:1598:11	B-AdverseReaction
has	PROLIA.xml:S2:1610:3	O
been	PROLIA.xml:S2:1614:4	O
reported	PROLIA.xml:S2:1619:8	O
with	PROLIA.xml:S2:1628:4	O
Prolia	PROLIA.xml:S2:1633:6	O
.	PROLIA.xml:S2:1639:1	O

Symptoms	PROLIA.xml:S2:1641:8	O
have	PROLIA.xml:S2:1650:4	O
included	PROLIA.xml:S2:1655:8	O
hypotension	PROLIA.xml:S2:1664:11	B-AdverseReaction
,	PROLIA.xml:S2:1675:1	O
dyspnea	PROLIA.xml:S2:1677:7	B-AdverseReaction
,	PROLIA.xml:S2:1684:1	O
throat	PROLIA.xml:S2:1686:6	B-AdverseReaction
tightness	PROLIA.xml:S2:1693:9	I-AdverseReaction
,	PROLIA.xml:S2:1702:1	O
facial	PROLIA.xml:S2:1704:6	B-AdverseReaction
and	PROLIA.xml:S2:1711:3	O
upper	PROLIA.xml:S2:1715:5	B-AdverseReaction
airway	PROLIA.xml:S2:1721:6	I-AdverseReaction
edema	PROLIA.xml:S2:1728:5	I-AdverseReaction
,	PROLIA.xml:S2:1733:1	O
pruritus	PROLIA.xml:S2:1735:8	B-AdverseReaction
,	PROLIA.xml:S2:1743:1	O
and	PROLIA.xml:S2:1745:3	O
urticaria	PROLIA.xml:S2:1749:9	B-AdverseReaction
.	PROLIA.xml:S2:1758:1	O

If	PROLIA.xml:S2:1760:2	O
an	PROLIA.xml:S2:1763:2	O
anaphylactic	PROLIA.xml:S2:1766:12	O
or	PROLIA.xml:S2:1779:2	O
other	PROLIA.xml:S2:1782:5	O
clinically	PROLIA.xml:S2:1788:10	O
significant	PROLIA.xml:S2:1799:11	O
allergic	PROLIA.xml:S2:1811:8	O
reaction	PROLIA.xml:S2:1820:8	O
occurs	PROLIA.xml:S2:1829:6	O
,	PROLIA.xml:S2:1835:1	O
initiate	PROLIA.xml:S2:1837:8	O
appropriate	PROLIA.xml:S2:1846:11	O
therapy	PROLIA.xml:S2:1858:7	O
and	PROLIA.xml:S2:1866:3	O
discontinue	PROLIA.xml:S2:1870:11	O
further	PROLIA.xml:S2:1882:7	O
use	PROLIA.xml:S2:1890:3	O
of	PROLIA.xml:S2:1894:2	O
Prolia	PROLIA.xml:S2:1897:6	O
[	PROLIA.xml:S2:1904:1	O
see	PROLIA.xml:S2:1905:3	O
Contraindications	PROLIA.xml:S2:1909:17	O
(	PROLIA.xml:S2:1927:1	O
4.3	PROLIA.xml:S2:1930:3	O
)	PROLIA.xml:S2:1935:1	O
,	PROLIA.xml:S2:1936:1	O
Adverse	PROLIA.xml:S2:1938:7	O
Reactions	PROLIA.xml:S2:1946:9	O
(	PROLIA.xml:S2:1956:1	O
6.2	PROLIA.xml:S2:1959:3	O
)]	PROLIA.xml:S2:1964:2	O
.	PROLIA.xml:S2:1968:1	O

5.3	PROLIA.xml:S2:1977:3	O
Hypocalcemia	PROLIA.xml:S2:1981:12	O
and	PROLIA.xml:S2:1994:3	O
Mineral	PROLIA.xml:S2:1998:7	O
Metabolism	PROLIA.xml:S2:2006:10	O

Hypocalcemia	PROLIA.xml:S2:2023:12	B-AdverseReaction
may	PROLIA.xml:S2:2036:3	B-Factor
be	PROLIA.xml:S2:2040:2	O
exacerbated	PROLIA.xml:S2:2043:11	I-AdverseReaction
by	PROLIA.xml:S2:2055:2	O
the	PROLIA.xml:S2:2058:3	O
use	PROLIA.xml:S2:2062:3	O
of	PROLIA.xml:S2:2066:2	O
Prolia	PROLIA.xml:S2:2069:6	O
.	PROLIA.xml:S2:2075:1	O

Pre	PROLIA.xml:S2:2077:3	O
-	PROLIA.xml:S2:2080:1	O
existing	PROLIA.xml:S2:2081:8	O
hypocalcemia	PROLIA.xml:S2:2090:12	O
must	PROLIA.xml:S2:2103:4	O
be	PROLIA.xml:S2:2108:2	O
corrected	PROLIA.xml:S2:2111:9	O
prior	PROLIA.xml:S2:2121:5	O
to	PROLIA.xml:S2:2127:2	O
initiating	PROLIA.xml:S2:2130:10	O
therapy	PROLIA.xml:S2:2141:7	O
with	PROLIA.xml:S2:2149:4	O
Prolia	PROLIA.xml:S2:2154:6	O
.	PROLIA.xml:S2:2160:1	O

In	PROLIA.xml:S2:2162:2	O
patients	PROLIA.xml:S2:2165:8	O
predisposed	PROLIA.xml:S2:2174:11	O
to	PROLIA.xml:S2:2186:2	O
hypocalcemia	PROLIA.xml:S2:2189:12	O
and	PROLIA.xml:S2:2202:3	O
disturbances	PROLIA.xml:S2:2206:12	O
of	PROLIA.xml:S2:2219:2	O
mineral	PROLIA.xml:S2:2222:7	O
metabolism	PROLIA.xml:S2:2230:10	O
(	PROLIA.xml:S2:2241:1	O
e	PROLIA.xml:S2:2242:1	O
.	PROLIA.xml:S2:2243:1	O
g	PROLIA.xml:S2:2244:1	O
.	PROLIA.xml:S2:2245:1	O

history	PROLIA.xml:S2:2247:7	O
of	PROLIA.xml:S2:2255:2	O
hypoparathyroidism	PROLIA.xml:S2:2258:18	O
,	PROLIA.xml:S2:2276:1	O
thyroid	PROLIA.xml:S2:2278:7	O
surgery	PROLIA.xml:S2:2286:7	O
,	PROLIA.xml:S2:2293:1	O
parathyroid	PROLIA.xml:S2:2295:11	O
surgery	PROLIA.xml:S2:2307:7	O
,	PROLIA.xml:S2:2314:1	O
malabsorption	PROLIA.xml:S2:2316:13	O
syndromes	PROLIA.xml:S2:2330:9	O
,	PROLIA.xml:S2:2339:1	O
excision	PROLIA.xml:S2:2341:8	O
of	PROLIA.xml:S2:2350:2	O
small	PROLIA.xml:S2:2353:5	O
intestine	PROLIA.xml:S2:2359:9	O
,	PROLIA.xml:S2:2368:1	O
severe	PROLIA.xml:S2:2370:6	O
renal	PROLIA.xml:S2:2377:5	O
impairment	PROLIA.xml:S2:2383:10	O
[	PROLIA.xml:S2:2394:1	O
creatinine	PROLIA.xml:S2:2395:10	O
clearance	PROLIA.xml:S2:2406:9	O
30	PROLIA.xml:S2:2418:2	O
mL	PROLIA.xml:S2:2421:2	O
min	PROLIA.xml:S2:2424:3	O
]	PROLIA.xml:S2:2427:1	O
or	PROLIA.xml:S2:2429:2	O
receiving	PROLIA.xml:S2:2432:9	O
dialysis	PROLIA.xml:S2:2442:8	O
)	PROLIA.xml:S2:2450:1	O
,	PROLIA.xml:S2:2451:1	O
clinical	PROLIA.xml:S2:2453:8	O
monitoring	PROLIA.xml:S2:2462:10	O
of	PROLIA.xml:S2:2473:2	O
calcium	PROLIA.xml:S2:2476:7	O
and	PROLIA.xml:S2:2484:3	O
mineral	PROLIA.xml:S2:2488:7	O
levels	PROLIA.xml:S2:2496:6	O
(	PROLIA.xml:S2:2503:1	O
phosphorus	PROLIA.xml:S2:2504:10	O
and	PROLIA.xml:S2:2515:3	O
magnesium	PROLIA.xml:S2:2519:9	O
)	PROLIA.xml:S2:2528:1	O
is	PROLIA.xml:S2:2530:2	O
highly	PROLIA.xml:S2:2533:6	O
recommended	PROLIA.xml:S2:2540:11	O
within	PROLIA.xml:S2:2552:6	O
14	PROLIA.xml:S2:2559:2	O
days	PROLIA.xml:S2:2562:4	O
of	PROLIA.xml:S2:2567:2	O
Prolia	PROLIA.xml:S2:2570:6	O
injection	PROLIA.xml:S2:2577:9	O
.	PROLIA.xml:S2:2586:1	O

In	PROLIA.xml:S2:2588:2	O
some	PROLIA.xml:S2:2591:4	O
postmarketing	PROLIA.xml:S2:2596:13	O
cases	PROLIA.xml:S2:2610:5	O
,	PROLIA.xml:S2:2615:1	O
hypocalcemia	PROLIA.xml:S2:2617:12	B-AdverseReaction
persisted	PROLIA.xml:S2:2630:9	O
for	PROLIA.xml:S2:2640:3	O
weeks	PROLIA.xml:S2:2644:5	O
or	PROLIA.xml:S2:2650:2	O
months	PROLIA.xml:S2:2653:6	O
and	PROLIA.xml:S2:2660:3	O
required	PROLIA.xml:S2:2664:8	O
frequent	PROLIA.xml:S2:2673:8	O
monitoring	PROLIA.xml:S2:2682:10	O
and	PROLIA.xml:S2:2693:3	O
intravenous	PROLIA.xml:S2:2697:11	O
and	PROLIA.xml:S2:2709:3	O
or	PROLIA.xml:S2:2713:2	O
oral	PROLIA.xml:S2:2716:4	O
calcium	PROLIA.xml:S2:2721:7	O
replacement	PROLIA.xml:S2:2729:11	O
,	PROLIA.xml:S2:2740:1	O
with	PROLIA.xml:S2:2742:4	O
or	PROLIA.xml:S2:2747:2	O
without	PROLIA.xml:S2:2750:7	O
vitamin	PROLIA.xml:S2:2758:7	O
D.	PROLIA.xml:S2:2766:2	O

Hypocalcemia	PROLIA.xml:S2:2775:12	B-AdverseReaction
following	PROLIA.xml:S2:2788:9	O
Prolia	PROLIA.xml:S2:2798:6	O
administration	PROLIA.xml:S2:2805:14	O
is	PROLIA.xml:S2:2820:2	O
a	PROLIA.xml:S2:2823:1	O
significant	PROLIA.xml:S2:2825:11	O
risk	PROLIA.xml:S2:2837:4	O
in	PROLIA.xml:S2:2842:2	O
patients	PROLIA.xml:S2:2845:8	O
with	PROLIA.xml:S2:2854:4	O
severe	PROLIA.xml:S2:2859:6	O
renal	PROLIA.xml:S2:2866:5	O
impairment	PROLIA.xml:S2:2872:10	O
[	PROLIA.xml:S2:2883:1	O
creatinine	PROLIA.xml:S2:2884:10	O
clearance	PROLIA.xml:S2:2895:9	O
30	PROLIA.xml:S2:2907:2	O
mL	PROLIA.xml:S2:2910:2	O
min	PROLIA.xml:S2:2913:3	O
]	PROLIA.xml:S2:2916:1	O
or	PROLIA.xml:S2:2918:2	O
receiving	PROLIA.xml:S2:2921:9	O
dialysis	PROLIA.xml:S2:2931:8	O
.	PROLIA.xml:S2:2939:1	O

These	PROLIA.xml:S2:2941:5	O
patients	PROLIA.xml:S2:2947:8	O
may	PROLIA.xml:S2:2956:3	B-Factor
also	PROLIA.xml:S2:2960:4	O
develop	PROLIA.xml:S2:2965:7	O
marked	PROLIA.xml:S2:2973:6	B-Severity
elevations	PROLIA.xml:S2:2980:10	B-AdverseReaction
of	PROLIA.xml:S2:2991:2	I-AdverseReaction
serum	PROLIA.xml:S2:2994:5	I-AdverseReaction
parathyroid	PROLIA.xml:S2:3000:11	I-AdverseReaction
hormone	PROLIA.xml:S2:3012:7	I-AdverseReaction
(	PROLIA.xml:S2:3020:1	O
PTH	PROLIA.xml:S2:3021:3	O
)	PROLIA.xml:S2:3024:1	O
.	PROLIA.xml:S2:3025:1	O

Instruct	PROLIA.xml:S2:3029:8	O
all	PROLIA.xml:S2:3038:3	O
patients	PROLIA.xml:S2:3042:8	O
with	PROLIA.xml:S2:3051:4	O
severe	PROLIA.xml:S2:3056:6	O
renal	PROLIA.xml:S2:3063:5	O
impairment	PROLIA.xml:S2:3069:10	O
,	PROLIA.xml:S2:3079:1	O
including	PROLIA.xml:S2:3081:9	O
those	PROLIA.xml:S2:3091:5	O
receiving	PROLIA.xml:S2:3097:9	O
dialysis	PROLIA.xml:S2:3107:8	O
,	PROLIA.xml:S2:3115:1	O
about	PROLIA.xml:S2:3117:5	O
the	PROLIA.xml:S2:3123:3	O
symptoms	PROLIA.xml:S2:3127:8	O
of	PROLIA.xml:S2:3136:2	O
hypocalcemia	PROLIA.xml:S2:3139:12	O
and	PROLIA.xml:S2:3152:3	O
the	PROLIA.xml:S2:3156:3	O
importance	PROLIA.xml:S2:3160:10	O
of	PROLIA.xml:S2:3171:2	O
maintaining	PROLIA.xml:S2:3174:11	O
calcium	PROLIA.xml:S2:3186:7	O
levels	PROLIA.xml:S2:3194:6	O
with	PROLIA.xml:S2:3201:4	O
adequate	PROLIA.xml:S2:3206:8	O
calcium	PROLIA.xml:S2:3215:7	O
and	PROLIA.xml:S2:3223:3	O
vitamin	PROLIA.xml:S2:3227:7	O
D	PROLIA.xml:S2:3235:1	O
supplementation	PROLIA.xml:S2:3237:15	O
.	PROLIA.xml:S2:3252:1	O

Adequately	PROLIA.xml:S2:3258:10	O
supplement	PROLIA.xml:S2:3269:10	O
all	PROLIA.xml:S2:3280:3	O
patients	PROLIA.xml:S2:3284:8	O
with	PROLIA.xml:S2:3293:4	O
calcium	PROLIA.xml:S2:3298:7	O
and	PROLIA.xml:S2:3306:3	O
vitamin	PROLIA.xml:S2:3310:7	O
D	PROLIA.xml:S2:3318:1	O
[	PROLIA.xml:S2:3320:1	O
see	PROLIA.xml:S2:3321:3	O
Dosage	PROLIA.xml:S2:3325:6	O
and	PROLIA.xml:S2:3332:3	O
Administration	PROLIA.xml:S2:3336:14	O
(	PROLIA.xml:S2:3351:1	O
2.1	PROLIA.xml:S2:3354:3	O
)	PROLIA.xml:S2:3359:1	O
,	PROLIA.xml:S2:3360:1	O
Contraindications	PROLIA.xml:S2:3362:17	O
(	PROLIA.xml:S2:3380:1	O
4.1	PROLIA.xml:S2:3383:3	O
)	PROLIA.xml:S2:3388:1	O
,	PROLIA.xml:S2:3389:1	O
Adverse	PROLIA.xml:S2:3391:7	O
Reactions	PROLIA.xml:S2:3399:9	O
(	PROLIA.xml:S2:3409:1	O
6.1	PROLIA.xml:S2:3412:3	O
)	PROLIA.xml:S2:3417:1	O
,	PROLIA.xml:S2:3418:1	O
and	PROLIA.xml:S2:3420:3	O
Patient	PROLIA.xml:S2:3424:7	O
Counseling	PROLIA.xml:S2:3432:10	O
Information	PROLIA.xml:S2:3443:11	O
(	PROLIA.xml:S2:3455:1	O
17.3	PROLIA.xml:S2:3458:4	O
)]	PROLIA.xml:S2:3464:2	O
.	PROLIA.xml:S2:3468:1	O

5.4	PROLIA.xml:S2:3477:3	O
Osteonecrosis	PROLIA.xml:S2:3481:13	O
of	PROLIA.xml:S2:3495:2	O
the	PROLIA.xml:S2:3498:3	O
Jaw	PROLIA.xml:S2:3502:3	O

Osteonecrosis	PROLIA.xml:S2:3512:13	O
of	PROLIA.xml:S2:3526:2	O
the	PROLIA.xml:S2:3529:3	O
jaw	PROLIA.xml:S2:3533:3	O
(	PROLIA.xml:S2:3537:1	O
ONJ	PROLIA.xml:S2:3538:3	O
)	PROLIA.xml:S2:3541:1	O
,	PROLIA.xml:S2:3542:1	O
which	PROLIA.xml:S2:3544:5	O
can	PROLIA.xml:S2:3550:3	O
occur	PROLIA.xml:S2:3554:5	O
spontaneously	PROLIA.xml:S2:3560:13	O
,	PROLIA.xml:S2:3573:1	O
is	PROLIA.xml:S2:3575:2	O
generally	PROLIA.xml:S2:3578:9	O
associated	PROLIA.xml:S2:3588:10	O
with	PROLIA.xml:S2:3599:4	O
tooth	PROLIA.xml:S2:3604:5	O
extraction	PROLIA.xml:S2:3610:10	O
and	PROLIA.xml:S2:3621:3	O
or	PROLIA.xml:S2:3625:2	O
local	PROLIA.xml:S2:3628:5	O
infection	PROLIA.xml:S2:3634:9	O
with	PROLIA.xml:S2:3644:4	O
delayed	PROLIA.xml:S2:3649:7	O
healing	PROLIA.xml:S2:3657:7	O
.	PROLIA.xml:S2:3664:1	O

ONJ	PROLIA.xml:S2:3666:3	B-AdverseReaction
has	PROLIA.xml:S2:3670:3	O
been	PROLIA.xml:S2:3674:4	O
reported	PROLIA.xml:S2:3679:8	O
in	PROLIA.xml:S2:3688:2	O
patients	PROLIA.xml:S2:3691:8	O
receiving	PROLIA.xml:S2:3700:9	O
denosumab	PROLIA.xml:S2:3710:9	O
[	PROLIA.xml:S2:3720:1	O
see	PROLIA.xml:S2:3721:3	O
Adverse	PROLIA.xml:S2:3725:7	O
Reactions	PROLIA.xml:S2:3733:9	O
(	PROLIA.xml:S2:3743:1	O
6.1	PROLIA.xml:S2:3746:3	O
)]	PROLIA.xml:S2:3751:2	O
.	PROLIA.xml:S2:3753:1	O

A	PROLIA.xml:S2:3756:1	O
routine	PROLIA.xml:S2:3758:7	O
oral	PROLIA.xml:S2:3766:4	O
exam	PROLIA.xml:S2:3771:4	O
should	PROLIA.xml:S2:3776:6	O
be	PROLIA.xml:S2:3783:2	O
performed	PROLIA.xml:S2:3786:9	O
by	PROLIA.xml:S2:3796:2	O
the	PROLIA.xml:S2:3799:3	O
prescriber	PROLIA.xml:S2:3803:10	O
prior	PROLIA.xml:S2:3814:5	O
to	PROLIA.xml:S2:3820:2	O
initiation	PROLIA.xml:S2:3823:10	O
of	PROLIA.xml:S2:3834:2	O
Prolia	PROLIA.xml:S2:3837:6	O
treatment	PROLIA.xml:S2:3844:9	O
.	PROLIA.xml:S2:3853:1	O

A	PROLIA.xml:S2:3855:1	O
dental	PROLIA.xml:S2:3857:6	O
examination	PROLIA.xml:S2:3864:11	O
with	PROLIA.xml:S2:3876:4	O
appropriate	PROLIA.xml:S2:3881:11	O
preventive	PROLIA.xml:S2:3893:10	O
dentistry	PROLIA.xml:S2:3904:9	O
is	PROLIA.xml:S2:3914:2	O
recommended	PROLIA.xml:S2:3917:11	O
prior	PROLIA.xml:S2:3929:5	O
to	PROLIA.xml:S2:3935:2	O
treatment	PROLIA.xml:S2:3938:9	O
with	PROLIA.xml:S2:3948:4	O
Prolia	PROLIA.xml:S2:3953:6	O
in	PROLIA.xml:S2:3960:2	O
patients	PROLIA.xml:S2:3963:8	O
with	PROLIA.xml:S2:3972:4	O
risk	PROLIA.xml:S2:3977:4	O
factors	PROLIA.xml:S2:3982:7	O
for	PROLIA.xml:S2:3990:3	O
ONJ	PROLIA.xml:S2:3994:3	O
such	PROLIA.xml:S2:3998:4	O
as	PROLIA.xml:S2:4003:2	O
invasive	PROLIA.xml:S2:4006:8	O
dental	PROLIA.xml:S2:4015:6	O
procedures	PROLIA.xml:S2:4022:10	O
(	PROLIA.xml:S2:4033:1	O
e	PROLIA.xml:S2:4034:1	O
.	PROLIA.xml:S2:4035:1	O
g	PROLIA.xml:S2:4036:1	O
.	PROLIA.xml:S2:4037:1	O

tooth	PROLIA.xml:S2:4039:5	O
extraction	PROLIA.xml:S2:4045:10	O
,	PROLIA.xml:S2:4055:1	O
dental	PROLIA.xml:S2:4057:6	O
implants	PROLIA.xml:S2:4064:8	O
,	PROLIA.xml:S2:4072:1	O
oral	PROLIA.xml:S2:4074:4	O
surgery	PROLIA.xml:S2:4079:7	O
)	PROLIA.xml:S2:4086:1	O
,	PROLIA.xml:S2:4087:1	O
diagnosis	PROLIA.xml:S2:4089:9	O
of	PROLIA.xml:S2:4099:2	O
cancer	PROLIA.xml:S2:4102:6	O
,	PROLIA.xml:S2:4108:1	O
concomitant	PROLIA.xml:S2:4110:11	O
therapies	PROLIA.xml:S2:4122:9	O
(	PROLIA.xml:S2:4132:1	O
e	PROLIA.xml:S2:4133:1	O
.	PROLIA.xml:S2:4134:1	O
g	PROLIA.xml:S2:4135:1	O
.	PROLIA.xml:S2:4136:1	O

chemotherapy	PROLIA.xml:S2:4138:12	O
,	PROLIA.xml:S2:4150:1	O
corticosteroids	PROLIA.xml:S2:4152:15	O
,	PROLIA.xml:S2:4167:1	O
angiogenesis	PROLIA.xml:S2:4169:12	O
inhibitors	PROLIA.xml:S2:4182:10	O
)	PROLIA.xml:S2:4192:1	O
,	PROLIA.xml:S2:4193:1	O
poor	PROLIA.xml:S2:4195:4	O
oral	PROLIA.xml:S2:4200:4	O
hygiene	PROLIA.xml:S2:4205:7	O
,	PROLIA.xml:S2:4212:1	O
and	PROLIA.xml:S2:4214:3	O
co	PROLIA.xml:S2:4218:2	O
-	PROLIA.xml:S2:4220:1	O
morbid	PROLIA.xml:S2:4221:6	O
disorders	PROLIA.xml:S2:4228:9	O
(	PROLIA.xml:S2:4238:1	O
e	PROLIA.xml:S2:4239:1	O
.	PROLIA.xml:S2:4240:1	O
g	PROLIA.xml:S2:4241:1	O
.	PROLIA.xml:S2:4242:1	O

periodontal	PROLIA.xml:S2:4244:11	O
and	PROLIA.xml:S2:4256:3	O
or	PROLIA.xml:S2:4260:2	O
other	PROLIA.xml:S2:4263:5	O
pre	PROLIA.xml:S2:4269:3	O
-	PROLIA.xml:S2:4272:1	O
existing	PROLIA.xml:S2:4273:8	O
dental	PROLIA.xml:S2:4282:6	O
disease	PROLIA.xml:S2:4289:7	O
,	PROLIA.xml:S2:4296:1	O
anemia	PROLIA.xml:S2:4298:6	O
,	PROLIA.xml:S2:4304:1	O
coagulopathy	PROLIA.xml:S2:4306:12	O
,	PROLIA.xml:S2:4318:1	O
infection	PROLIA.xml:S2:4320:9	O
,	PROLIA.xml:S2:4329:1	O
ill	PROLIA.xml:S2:4331:3	O
-	PROLIA.xml:S2:4334:1	O
fitting	PROLIA.xml:S2:4335:7	O
dentures	PROLIA.xml:S2:4343:8	O
)	PROLIA.xml:S2:4351:1	O
.	PROLIA.xml:S2:4352:1	O

Good	PROLIA.xml:S2:4354:4	O
oral	PROLIA.xml:S2:4359:4	O
hygiene	PROLIA.xml:S2:4364:7	O
practices	PROLIA.xml:S2:4372:9	O
should	PROLIA.xml:S2:4382:6	O
be	PROLIA.xml:S2:4389:2	O
maintained	PROLIA.xml:S2:4392:10	O
during	PROLIA.xml:S2:4403:6	O
treatment	PROLIA.xml:S2:4410:9	O
with	PROLIA.xml:S2:4420:4	O
Prolia	PROLIA.xml:S2:4425:6	O
.	PROLIA.xml:S2:4431:1	O

Concomitant	PROLIA.xml:S2:4433:11	O
administration	PROLIA.xml:S2:4445:14	O
of	PROLIA.xml:S2:4460:2	O
drugs	PROLIA.xml:S2:4463:5	O
associated	PROLIA.xml:S2:4469:10	O
with	PROLIA.xml:S2:4480:4	O
ONJ	PROLIA.xml:S2:4485:3	O
may	PROLIA.xml:S2:4489:3	O
increase	PROLIA.xml:S2:4493:8	O
the	PROLIA.xml:S2:4502:3	O
risk	PROLIA.xml:S2:4506:4	O
of	PROLIA.xml:S2:4511:2	O
developing	PROLIA.xml:S2:4514:10	O
ONJ	PROLIA.xml:S2:4525:3	O
.	PROLIA.xml:S2:4528:1	O

For	PROLIA.xml:S2:4536:3	O
patients	PROLIA.xml:S2:4540:8	O
requiring	PROLIA.xml:S2:4549:9	O
invasive	PROLIA.xml:S2:4559:8	O
dental	PROLIA.xml:S2:4568:6	O
procedures	PROLIA.xml:S2:4575:10	O
,	PROLIA.xml:S2:4585:1	O
clinical	PROLIA.xml:S2:4587:8	O
judgment	PROLIA.xml:S2:4596:8	O
of	PROLIA.xml:S2:4605:2	O
the	PROLIA.xml:S2:4608:3	O
treating	PROLIA.xml:S2:4612:8	O
physician	PROLIA.xml:S2:4621:9	O
and	PROLIA.xml:S2:4631:3	O
or	PROLIA.xml:S2:4635:2	O
oral	PROLIA.xml:S2:4638:4	O
surgeon	PROLIA.xml:S2:4643:7	O
should	PROLIA.xml:S2:4651:6	O
guide	PROLIA.xml:S2:4658:5	O
the	PROLIA.xml:S2:4664:3	O
management	PROLIA.xml:S2:4668:10	O
plan	PROLIA.xml:S2:4679:4	O
of	PROLIA.xml:S2:4684:2	O
each	PROLIA.xml:S2:4687:4	O
patient	PROLIA.xml:S2:4692:7	O
based	PROLIA.xml:S2:4700:5	O
on	PROLIA.xml:S2:4706:2	O
individual	PROLIA.xml:S2:4709:10	O
benefit	PROLIA.xml:S2:4720:7	O
-	PROLIA.xml:S2:4727:1	O
risk	PROLIA.xml:S2:4728:4	O
assessment	PROLIA.xml:S2:4733:10	O
.	PROLIA.xml:S2:4743:1	O

Patients	PROLIA.xml:S2:4749:8	O
who	PROLIA.xml:S2:4758:3	O
are	PROLIA.xml:S2:4762:3	O
suspected	PROLIA.xml:S2:4766:9	O
of	PROLIA.xml:S2:4776:2	O
having	PROLIA.xml:S2:4779:6	O
or	PROLIA.xml:S2:4786:2	O
who	PROLIA.xml:S2:4789:3	O
develop	PROLIA.xml:S2:4793:7	O
ONJ	PROLIA.xml:S2:4801:3	O
while	PROLIA.xml:S2:4805:5	O
on	PROLIA.xml:S2:4811:2	O
Prolia	PROLIA.xml:S2:4814:6	O
should	PROLIA.xml:S2:4821:6	O
receive	PROLIA.xml:S2:4828:7	O
care	PROLIA.xml:S2:4836:4	O
by	PROLIA.xml:S2:4841:2	O
a	PROLIA.xml:S2:4844:1	O
dentist	PROLIA.xml:S2:4846:7	O
or	PROLIA.xml:S2:4854:2	O
an	PROLIA.xml:S2:4857:2	O
oral	PROLIA.xml:S2:4860:4	O
surgeon	PROLIA.xml:S2:4865:7	O
.	PROLIA.xml:S2:4872:1	O

In	PROLIA.xml:S2:4874:2	O
these	PROLIA.xml:S2:4877:5	O
patients	PROLIA.xml:S2:4883:8	O
,	PROLIA.xml:S2:4891:1	O
extensive	PROLIA.xml:S2:4893:9	O
dental	PROLIA.xml:S2:4903:6	O
surgery	PROLIA.xml:S2:4910:7	O
to	PROLIA.xml:S2:4918:2	O
treat	PROLIA.xml:S2:4921:5	O
ONJ	PROLIA.xml:S2:4927:3	O
may	PROLIA.xml:S2:4931:3	O
exacerbate	PROLIA.xml:S2:4935:10	O
the	PROLIA.xml:S2:4946:3	O
condition	PROLIA.xml:S2:4950:9	O
.	PROLIA.xml:S2:4959:1	O

Discontinuation	PROLIA.xml:S2:4961:15	O
of	PROLIA.xml:S2:4977:2	O
Prolia	PROLIA.xml:S2:4980:6	O
therapy	PROLIA.xml:S2:4987:7	O
should	PROLIA.xml:S2:4995:6	O
be	PROLIA.xml:S2:5002:2	O
considered	PROLIA.xml:S2:5005:10	O
based	PROLIA.xml:S2:5016:5	O
on	PROLIA.xml:S2:5022:2	O
individual	PROLIA.xml:S2:5025:10	O
benefit	PROLIA.xml:S2:5036:7	O
-	PROLIA.xml:S2:5043:1	O
risk	PROLIA.xml:S2:5044:4	O
assessment	PROLIA.xml:S2:5049:10	O
.	PROLIA.xml:S2:5059:1	O

5.5	PROLIA.xml:S2:5068:3	O
Atypical	PROLIA.xml:S2:5072:8	O
Subtrochanteric	PROLIA.xml:S2:5081:15	O
and	PROLIA.xml:S2:5097:3	O
Diaphyseal	PROLIA.xml:S2:5101:10	O
Femoral	PROLIA.xml:S2:5112:7	B-AdverseReaction
Fractures	PROLIA.xml:S2:5120:9	O

Atypical	PROLIA.xml:S2:5135:8	I-AdverseReaction
low	PROLIA.xml:S2:5144:3	O
-	PROLIA.xml:S2:5147:1	O
energy	PROLIA.xml:S2:5148:6	O
or	PROLIA.xml:S2:5155:2	O
low	PROLIA.xml:S2:5158:3	O
trauma	PROLIA.xml:S2:5162:6	O
fractures	PROLIA.xml:S2:5169:9	I-AdverseReaction
of	PROLIA.xml:S2:5179:2	I-AdverseReaction
the	PROLIA.xml:S2:5182:3	I-AdverseReaction
shaft	PROLIA.xml:S2:5186:5	I-AdverseReaction
have	PROLIA.xml:S2:5192:4	O
been	PROLIA.xml:S2:5197:4	O
reported	PROLIA.xml:S2:5202:8	O
in	PROLIA.xml:S2:5211:2	O
patients	PROLIA.xml:S2:5214:8	O
receiving	PROLIA.xml:S2:5223:9	O
Prolia	PROLIA.xml:S2:5233:6	O
[	PROLIA.xml:S2:5240:1	O
see	PROLIA.xml:S2:5241:3	O
Adverse	PROLIA.xml:S2:5245:7	O
Reactions	PROLIA.xml:S2:5253:9	O
(	PROLIA.xml:S2:5263:1	O
6.1	PROLIA.xml:S2:5266:3	O
)]	PROLIA.xml:S2:5271:2	O
.	PROLIA.xml:S2:5275:1	O

These	PROLIA.xml:S2:5277:5	O
fractures	PROLIA.xml:S2:5283:9	B-AdverseReaction
can	PROLIA.xml:S2:5293:3	O
occur	PROLIA.xml:S2:5297:5	O
anywhere	PROLIA.xml:S2:5303:8	O
in	PROLIA.xml:S2:5312:2	I-AdverseReaction
the	PROLIA.xml:S2:5315:3	I-AdverseReaction
femoral	PROLIA.xml:S2:5319:7	I-AdverseReaction
shaft	PROLIA.xml:S2:5327:5	I-AdverseReaction
from	PROLIA.xml:S2:5333:4	O
just	PROLIA.xml:S2:5338:4	O
below	PROLIA.xml:S2:5343:5	O
the	PROLIA.xml:S2:5349:3	O
lesser	PROLIA.xml:S2:5353:6	O
trochanter	PROLIA.xml:S2:5360:10	O
to	PROLIA.xml:S2:5371:2	O
above	PROLIA.xml:S2:5374:5	O
the	PROLIA.xml:S2:5380:3	O
supracondylar	PROLIA.xml:S2:5384:13	O
flare	PROLIA.xml:S2:5398:5	O
and	PROLIA.xml:S2:5404:3	O
are	PROLIA.xml:S2:5408:3	O
transverse	PROLIA.xml:S2:5412:10	O
or	PROLIA.xml:S2:5423:2	O
short	PROLIA.xml:S2:5426:5	O
oblique	PROLIA.xml:S2:5432:7	O
in	PROLIA.xml:S2:5440:2	O
orientation	PROLIA.xml:S2:5443:11	O
without	PROLIA.xml:S2:5455:7	O
evidence	PROLIA.xml:S2:5463:8	O
of	PROLIA.xml:S2:5472:2	O
comminution	PROLIA.xml:S2:5475:11	O
.	PROLIA.xml:S2:5486:1	O

Causality	PROLIA.xml:S2:5488:9	O
has	PROLIA.xml:S2:5498:3	O
not	PROLIA.xml:S2:5502:3	O
been	PROLIA.xml:S2:5506:4	O
established	PROLIA.xml:S2:5511:11	O
as	PROLIA.xml:S2:5523:2	O
these	PROLIA.xml:S2:5526:5	O
fractures	PROLIA.xml:S2:5532:9	O
also	PROLIA.xml:S2:5542:4	O
occur	PROLIA.xml:S2:5547:5	O
in	PROLIA.xml:S2:5553:2	O
osteoporotic	PROLIA.xml:S2:5556:12	O
patients	PROLIA.xml:S2:5569:8	O
who	PROLIA.xml:S2:5578:3	O
have	PROLIA.xml:S2:5582:4	O
not	PROLIA.xml:S2:5587:3	O
been	PROLIA.xml:S2:5591:4	O
treated	PROLIA.xml:S2:5596:7	O
with	PROLIA.xml:S2:5604:4	O
anti	PROLIA.xml:S2:5609:4	O
-	PROLIA.xml:S2:5613:1	O
resorptive	PROLIA.xml:S2:5614:10	O
agents	PROLIA.xml:S2:5625:6	O
.	PROLIA.xml:S2:5631:1	O

Atypical	PROLIA.xml:S2:5637:8	B-AdverseReaction
femoral	PROLIA.xml:S2:5646:7	I-AdverseReaction
fractures	PROLIA.xml:S2:5654:9	I-AdverseReaction
most	PROLIA.xml:S2:5664:4	O
commonly	PROLIA.xml:S2:5669:8	O
occur	PROLIA.xml:S2:5678:5	O
with	PROLIA.xml:S2:5684:4	O
minimal	PROLIA.xml:S2:5689:7	O
or	PROLIA.xml:S2:5697:2	O
no	PROLIA.xml:S2:5700:2	O
trauma	PROLIA.xml:S2:5703:6	O
to	PROLIA.xml:S2:5710:2	O
the	PROLIA.xml:S2:5713:3	O
affected	PROLIA.xml:S2:5717:8	O
area	PROLIA.xml:S2:5726:4	O
.	PROLIA.xml:S2:5730:1	O

They	PROLIA.xml:S2:5732:4	O
may	PROLIA.xml:S2:5737:3	O
be	PROLIA.xml:S2:5741:2	O
bilateral	PROLIA.xml:S2:5744:9	O
and	PROLIA.xml:S2:5754:3	O
many	PROLIA.xml:S2:5758:4	O
patients	PROLIA.xml:S2:5763:8	O
report	PROLIA.xml:S2:5772:6	O
prodromal	PROLIA.xml:S2:5779:9	O
pain	PROLIA.xml:S2:5789:4	O
in	PROLIA.xml:S2:5794:2	O
the	PROLIA.xml:S2:5797:3	O
affected	PROLIA.xml:S2:5801:8	O
area	PROLIA.xml:S2:5810:4	O
,	PROLIA.xml:S2:5814:1	O
usually	PROLIA.xml:S2:5816:7	O
presenting	PROLIA.xml:S2:5824:10	O
as	PROLIA.xml:S2:5835:2	O
dull	PROLIA.xml:S2:5838:4	O
,	PROLIA.xml:S2:5842:1	O
aching	PROLIA.xml:S2:5844:6	O
thigh	PROLIA.xml:S2:5851:5	B-AdverseReaction
pain	PROLIA.xml:S2:5857:4	I-AdverseReaction
,	PROLIA.xml:S2:5861:1	O
weeks	PROLIA.xml:S2:5863:5	O
to	PROLIA.xml:S2:5869:2	O
months	PROLIA.xml:S2:5872:6	O
before	PROLIA.xml:S2:5879:6	O
a	PROLIA.xml:S2:5886:1	O
complete	PROLIA.xml:S2:5888:8	O
fracture	PROLIA.xml:S2:5897:8	O
occurs	PROLIA.xml:S2:5906:6	O
.	PROLIA.xml:S2:5912:1	O

A	PROLIA.xml:S2:5915:1	O
number	PROLIA.xml:S2:5917:6	O
of	PROLIA.xml:S2:5924:2	O
reports	PROLIA.xml:S2:5927:7	O
note	PROLIA.xml:S2:5935:4	O
that	PROLIA.xml:S2:5940:4	O
patients	PROLIA.xml:S2:5945:8	O
were	PROLIA.xml:S2:5954:4	O
also	PROLIA.xml:S2:5959:4	O
receiving	PROLIA.xml:S2:5964:9	O
treatment	PROLIA.xml:S2:5974:9	O
with	PROLIA.xml:S2:5984:4	O
glucocorticoids	PROLIA.xml:S2:5989:15	O
(	PROLIA.xml:S2:6005:1	O
e	PROLIA.xml:S2:6006:1	O
.	PROLIA.xml:S2:6007:1	O
g	PROLIA.xml:S2:6008:1	O
.	PROLIA.xml:S2:6009:1	O

prednisone	PROLIA.xml:S2:6011:10	O
)	PROLIA.xml:S2:6021:1	O
at	PROLIA.xml:S2:6023:2	O
the	PROLIA.xml:S2:6026:3	O
time	PROLIA.xml:S2:6030:4	O
of	PROLIA.xml:S2:6035:2	O
fracture	PROLIA.xml:S2:6038:8	O
.	PROLIA.xml:S2:6046:1	O

During	PROLIA.xml:S2:6052:6	O
Prolia	PROLIA.xml:S2:6059:6	O
treatment	PROLIA.xml:S2:6066:9	O
,	PROLIA.xml:S2:6075:1	O
patients	PROLIA.xml:S2:6077:8	O
should	PROLIA.xml:S2:6086:6	O
be	PROLIA.xml:S2:6093:2	O
advised	PROLIA.xml:S2:6096:7	O
to	PROLIA.xml:S2:6104:2	O
report	PROLIA.xml:S2:6107:6	O
new	PROLIA.xml:S2:6114:3	O
or	PROLIA.xml:S2:6118:2	O
unusual	PROLIA.xml:S2:6121:7	O
thigh	PROLIA.xml:S2:6129:5	O
,	PROLIA.xml:S2:6134:1	O
hip	PROLIA.xml:S2:6136:3	O
,	PROLIA.xml:S2:6139:1	O
or	PROLIA.xml:S2:6141:2	O
groin	PROLIA.xml:S2:6144:5	O
pain	PROLIA.xml:S2:6150:4	O
.	PROLIA.xml:S2:6154:1	O

Any	PROLIA.xml:S2:6156:3	O
patient	PROLIA.xml:S2:6160:7	O
who	PROLIA.xml:S2:6168:3	O
presents	PROLIA.xml:S2:6172:8	O
with	PROLIA.xml:S2:6181:4	O
thigh	PROLIA.xml:S2:6186:5	O
or	PROLIA.xml:S2:6192:2	O
groin	PROLIA.xml:S2:6195:5	O
pain	PROLIA.xml:S2:6201:4	O
should	PROLIA.xml:S2:6206:6	O
be	PROLIA.xml:S2:6213:2	O
suspected	PROLIA.xml:S2:6216:9	O
of	PROLIA.xml:S2:6226:2	O
having	PROLIA.xml:S2:6229:6	O
an	PROLIA.xml:S2:6236:2	O
atypical	PROLIA.xml:S2:6239:8	O
fracture	PROLIA.xml:S2:6248:8	O
and	PROLIA.xml:S2:6257:3	O
should	PROLIA.xml:S2:6261:6	O
be	PROLIA.xml:S2:6268:2	O
evaluated	PROLIA.xml:S2:6271:9	O
to	PROLIA.xml:S2:6281:2	O
rule	PROLIA.xml:S2:6284:4	O
out	PROLIA.xml:S2:6289:3	O
an	PROLIA.xml:S2:6293:2	O
incomplete	PROLIA.xml:S2:6296:10	O
femur	PROLIA.xml:S2:6307:5	O
fracture	PROLIA.xml:S2:6313:8	O
.	PROLIA.xml:S2:6321:1	O

Patient	PROLIA.xml:S2:6323:7	O
presenting	PROLIA.xml:S2:6331:10	O
with	PROLIA.xml:S2:6342:4	O
an	PROLIA.xml:S2:6347:2	O
atypical	PROLIA.xml:S2:6350:8	O
femur	PROLIA.xml:S2:6359:5	O
fracture	PROLIA.xml:S2:6365:8	O
should	PROLIA.xml:S2:6374:6	O
also	PROLIA.xml:S2:6381:4	O
be	PROLIA.xml:S2:6386:2	O
assessed	PROLIA.xml:S2:6389:8	O
for	PROLIA.xml:S2:6398:3	O
symptoms	PROLIA.xml:S2:6402:8	O
and	PROLIA.xml:S2:6411:3	O
signs	PROLIA.xml:S2:6415:5	O
of	PROLIA.xml:S2:6421:2	O
fracture	PROLIA.xml:S2:6424:8	O
in	PROLIA.xml:S2:6433:2	O
the	PROLIA.xml:S2:6436:3	O
contralateral	PROLIA.xml:S2:6440:13	O
limb	PROLIA.xml:S2:6454:4	O
.	PROLIA.xml:S2:6458:1	O

Interruption	PROLIA.xml:S2:6460:12	O
of	PROLIA.xml:S2:6473:2	O
Prolia	PROLIA.xml:S2:6476:6	O
therapy	PROLIA.xml:S2:6483:7	O
should	PROLIA.xml:S2:6491:6	O
be	PROLIA.xml:S2:6498:2	O
considered	PROLIA.xml:S2:6501:10	O
,	PROLIA.xml:S2:6511:1	O
pending	PROLIA.xml:S2:6513:7	O
a	PROLIA.xml:S2:6521:1	O
risk	PROLIA.xml:S2:6523:4	O
benefit	PROLIA.xml:S2:6528:7	O
assessment	PROLIA.xml:S2:6536:10	O
,	PROLIA.xml:S2:6546:1	O
on	PROLIA.xml:S2:6548:2	O
an	PROLIA.xml:S2:6551:2	O
individual	PROLIA.xml:S2:6554:10	O
basis	PROLIA.xml:S2:6565:5	O
.	PROLIA.xml:S2:6570:1	O

5.6	PROLIA.xml:S2:6579:3	O
Serious	PROLIA.xml:S2:6583:7	O
Infections	PROLIA.xml:S2:6591:10	O

In	PROLIA.xml:S2:6607:2	O
a	PROLIA.xml:S2:6610:1	O
clinical	PROLIA.xml:S2:6612:8	O
trial	PROLIA.xml:S2:6621:5	O
of	PROLIA.xml:S2:6627:2	O
over	PROLIA.xml:S2:6630:4	O
7800	PROLIA.xml:S2:6635:4	O
women	PROLIA.xml:S2:6640:5	O
with	PROLIA.xml:S2:6646:4	O
postmenopausal	PROLIA.xml:S2:6651:14	O
osteoporosis	PROLIA.xml:S2:6666:12	O
,	PROLIA.xml:S2:6678:1	O
serious	PROLIA.xml:S2:6680:7	B-Severity
infections	PROLIA.xml:S2:6688:10	B-AdverseReaction
leading	PROLIA.xml:S2:6699:7	O
to	PROLIA.xml:S2:6707:2	O
hospitalization	PROLIA.xml:S2:6710:15	O
were	PROLIA.xml:S2:6726:4	O
reported	PROLIA.xml:S2:6731:8	O
more	PROLIA.xml:S2:6740:4	O
frequently	PROLIA.xml:S2:6745:10	O
in	PROLIA.xml:S2:6756:2	O
the	PROLIA.xml:S2:6759:3	O
Prolia	PROLIA.xml:S2:6763:6	O
group	PROLIA.xml:S2:6770:5	O
than	PROLIA.xml:S2:6776:4	O
in	PROLIA.xml:S2:6781:2	O
the	PROLIA.xml:S2:6784:3	O
placebo	PROLIA.xml:S2:6788:7	O
group	PROLIA.xml:S2:6796:5	O
[	PROLIA.xml:S2:6802:1	O
see	PROLIA.xml:S2:6803:3	O
Adverse	PROLIA.xml:S2:6807:7	O
Reactions	PROLIA.xml:S2:6815:9	O
(	PROLIA.xml:S2:6825:1	O
6.1	PROLIA.xml:S2:6828:3	O
)]	PROLIA.xml:S2:6833:2	O
.	PROLIA.xml:S2:6837:1	O

Serious	PROLIA.xml:S2:6839:7	B-Severity
skin	PROLIA.xml:S2:6847:4	B-AdverseReaction
infections	PROLIA.xml:S2:6852:10	I-AdverseReaction
,	PROLIA.xml:S2:6862:1	O
as	PROLIA.xml:S2:6864:2	O
well	PROLIA.xml:S2:6867:4	O
as	PROLIA.xml:S2:6872:2	O
infections	PROLIA.xml:S2:6875:10	B-AdverseReaction
of	PROLIA.xml:S2:6886:2	I-AdverseReaction
the	PROLIA.xml:S2:6889:3	I-AdverseReaction
abdomen	PROLIA.xml:S2:6893:7	I-AdverseReaction
,	PROLIA.xml:S2:6900:1	O
urinary	PROLIA.xml:S2:6902:7	I-AdverseReaction
tract	PROLIA.xml:S2:6910:5	I-AdverseReaction
,	PROLIA.xml:S2:6915:1	O
and	PROLIA.xml:S2:6917:3	O
ear	PROLIA.xml:S2:6921:3	I-AdverseReaction
,	PROLIA.xml:S2:6924:1	O
were	PROLIA.xml:S2:6926:4	O
more	PROLIA.xml:S2:6931:4	O
frequent	PROLIA.xml:S2:6936:8	O
in	PROLIA.xml:S2:6945:2	O
patients	PROLIA.xml:S2:6948:8	O
treated	PROLIA.xml:S2:6957:7	O
with	PROLIA.xml:S2:6965:4	O
Prolia	PROLIA.xml:S2:6970:6	O
.	PROLIA.xml:S2:6976:1	O

Endocarditis	PROLIA.xml:S2:6978:12	B-AdverseReaction
was	PROLIA.xml:S2:6991:3	O
also	PROLIA.xml:S2:6995:4	O
reported	PROLIA.xml:S2:7000:8	O
more	PROLIA.xml:S2:7009:4	O
frequently	PROLIA.xml:S2:7014:10	O
in	PROLIA.xml:S2:7025:2	O
Prolia	PROLIA.xml:S2:7028:6	O
-	PROLIA.xml:S2:7034:1	O
treated	PROLIA.xml:S2:7035:7	O
patients	PROLIA.xml:S2:7043:8	O
.	PROLIA.xml:S2:7051:1	O

The	PROLIA.xml:S2:7053:3	O
incidence	PROLIA.xml:S2:7057:9	O
of	PROLIA.xml:S2:7067:2	O
opportunistic	PROLIA.xml:S2:7070:13	B-AdverseReaction
infections	PROLIA.xml:S2:7084:10	I-AdverseReaction
was	PROLIA.xml:S2:7095:3	O
similar	PROLIA.xml:S2:7099:7	O
between	PROLIA.xml:S2:7107:7	O
placebo	PROLIA.xml:S2:7115:7	O
and	PROLIA.xml:S2:7123:3	O
Prolia	PROLIA.xml:S2:7127:6	O
groups	PROLIA.xml:S2:7134:6	O
,	PROLIA.xml:S2:7140:1	O
and	PROLIA.xml:S2:7142:3	O
the	PROLIA.xml:S2:7146:3	O
overall	PROLIA.xml:S2:7150:7	O
incidence	PROLIA.xml:S2:7158:9	O
of	PROLIA.xml:S2:7168:2	O
infections	PROLIA.xml:S2:7171:10	B-AdverseReaction
was	PROLIA.xml:S2:7182:3	O
similar	PROLIA.xml:S2:7186:7	O
between	PROLIA.xml:S2:7194:7	O
the	PROLIA.xml:S2:7202:3	O
treatment	PROLIA.xml:S2:7206:9	O
groups	PROLIA.xml:S2:7216:6	O
.	PROLIA.xml:S2:7222:1	O

Advise	PROLIA.xml:S2:7224:6	O
patients	PROLIA.xml:S2:7231:8	O
to	PROLIA.xml:S2:7240:2	O
seek	PROLIA.xml:S2:7243:4	O
prompt	PROLIA.xml:S2:7248:6	O
medical	PROLIA.xml:S2:7255:7	O
attention	PROLIA.xml:S2:7263:9	O
if	PROLIA.xml:S2:7273:2	O
they	PROLIA.xml:S2:7276:4	O
develop	PROLIA.xml:S2:7281:7	O
signs	PROLIA.xml:S2:7289:5	O
or	PROLIA.xml:S2:7295:2	O
symptoms	PROLIA.xml:S2:7298:8	O
of	PROLIA.xml:S2:7307:2	O
severe	PROLIA.xml:S2:7310:6	O
infection	PROLIA.xml:S2:7317:9	O
,	PROLIA.xml:S2:7326:1	O
including	PROLIA.xml:S2:7328:9	O
cellulitis	PROLIA.xml:S2:7338:10	O
.	PROLIA.xml:S2:7348:1	O

Patients	PROLIA.xml:S2:7355:8	O
on	PROLIA.xml:S2:7364:2	O
concomitant	PROLIA.xml:S2:7367:11	O
immunosuppressant	PROLIA.xml:S2:7379:17	O
agents	PROLIA.xml:S2:7397:6	O
or	PROLIA.xml:S2:7404:2	O
with	PROLIA.xml:S2:7407:4	O
impaired	PROLIA.xml:S2:7412:8	O
immune	PROLIA.xml:S2:7421:6	O
systems	PROLIA.xml:S2:7428:7	O
may	PROLIA.xml:S2:7436:3	B-Factor
be	PROLIA.xml:S2:7440:2	O
at	PROLIA.xml:S2:7443:2	O
increased	PROLIA.xml:S2:7446:9	O
risk	PROLIA.xml:S2:7456:4	O
for	PROLIA.xml:S2:7461:3	O
serious	PROLIA.xml:S2:7465:7	B-Severity
infections	PROLIA.xml:S2:7473:10	B-AdverseReaction
.	PROLIA.xml:S2:7483:1	O

Consider	PROLIA.xml:S2:7485:8	O
the	PROLIA.xml:S2:7494:3	O
benefit	PROLIA.xml:S2:7498:7	O
-	PROLIA.xml:S2:7505:1	O
risk	PROLIA.xml:S2:7506:4	O
profile	PROLIA.xml:S2:7511:7	O
in	PROLIA.xml:S2:7519:2	O
such	PROLIA.xml:S2:7522:4	O
patients	PROLIA.xml:S2:7527:8	O
before	PROLIA.xml:S2:7536:6	O
treating	PROLIA.xml:S2:7543:8	O
with	PROLIA.xml:S2:7552:4	O
Prolia	PROLIA.xml:S2:7557:6	O
.	PROLIA.xml:S2:7563:1	O

In	PROLIA.xml:S2:7565:2	O
patients	PROLIA.xml:S2:7568:8	O
who	PROLIA.xml:S2:7577:3	O
develop	PROLIA.xml:S2:7581:7	O
serious	PROLIA.xml:S2:7589:7	O
infections	PROLIA.xml:S2:7597:10	O
while	PROLIA.xml:S2:7608:5	O
on	PROLIA.xml:S2:7614:2	O
Prolia	PROLIA.xml:S2:7617:6	O
,	PROLIA.xml:S2:7623:1	O
prescribers	PROLIA.xml:S2:7625:11	O
should	PROLIA.xml:S2:7637:6	O
assess	PROLIA.xml:S2:7644:6	O
the	PROLIA.xml:S2:7651:3	O
need	PROLIA.xml:S2:7655:4	O
for	PROLIA.xml:S2:7660:3	O
continued	PROLIA.xml:S2:7664:9	O
Prolia	PROLIA.xml:S2:7674:6	O
therapy	PROLIA.xml:S2:7681:7	O
.	PROLIA.xml:S2:7688:1	O

5.7	PROLIA.xml:S2:7697:3	O
Dermatologic	PROLIA.xml:S2:7701:12	O
Adverse	PROLIA.xml:S2:7714:7	O
Reactions	PROLIA.xml:S2:7722:9	O

In	PROLIA.xml:S2:7737:2	O
a	PROLIA.xml:S2:7740:1	O
large	PROLIA.xml:S2:7742:5	O
clinical	PROLIA.xml:S2:7748:8	O
trial	PROLIA.xml:S2:7757:5	O
of	PROLIA.xml:S2:7763:2	O
over	PROLIA.xml:S2:7766:4	O
7800	PROLIA.xml:S2:7771:4	O
women	PROLIA.xml:S2:7776:5	O
with	PROLIA.xml:S2:7782:4	O
postmenopausal	PROLIA.xml:S2:7787:14	O
osteoporosis	PROLIA.xml:S2:7802:12	O
,	PROLIA.xml:S2:7814:1	O
epidermal	PROLIA.xml:S2:7816:9	B-AdverseReaction
and	PROLIA.xml:S2:7826:3	O
dermal	PROLIA.xml:S2:7830:6	B-AdverseReaction
adverse	PROLIA.xml:S2:7837:7	I-AdverseReaction
events	PROLIA.xml:S2:7845:6	I-AdverseReaction
such	PROLIA.xml:S2:7852:4	O
as	PROLIA.xml:S2:7857:2	O
dermatitis	PROLIA.xml:S2:7860:10	B-AdverseReaction
,	PROLIA.xml:S2:7870:1	O
eczema	PROLIA.xml:S2:7872:6	B-AdverseReaction
,	PROLIA.xml:S2:7878:1	O
and	PROLIA.xml:S2:7880:3	O
rashes	PROLIA.xml:S2:7884:6	B-AdverseReaction
occurred	PROLIA.xml:S2:7891:8	O
at	PROLIA.xml:S2:7900:2	O
a	PROLIA.xml:S2:7903:1	O
significantly	PROLIA.xml:S2:7905:13	O
higher	PROLIA.xml:S2:7919:6	O
rate	PROLIA.xml:S2:7926:4	O
in	PROLIA.xml:S2:7931:2	O
the	PROLIA.xml:S2:7934:3	O
Prolia	PROLIA.xml:S2:7938:6	O
group	PROLIA.xml:S2:7945:5	O
compared	PROLIA.xml:S2:7951:8	O
to	PROLIA.xml:S2:7960:2	O
the	PROLIA.xml:S2:7963:3	O
placebo	PROLIA.xml:S2:7967:7	O
group	PROLIA.xml:S2:7975:5	O
.	PROLIA.xml:S2:7980:1	O

Most	PROLIA.xml:S2:7982:4	O
of	PROLIA.xml:S2:7987:2	O
these	PROLIA.xml:S2:7990:5	O
events	PROLIA.xml:S2:7996:6	O
were	PROLIA.xml:S2:8003:4	O
not	PROLIA.xml:S2:8008:3	O
specific	PROLIA.xml:S2:8012:8	O
to	PROLIA.xml:S2:8021:2	O
the	PROLIA.xml:S2:8024:3	O
injection	PROLIA.xml:S2:8028:9	O
site	PROLIA.xml:S2:8038:4	O
[	PROLIA.xml:S2:8043:1	O
see	PROLIA.xml:S2:8044:3	O
Adverse	PROLIA.xml:S2:8048:7	O
Reactions	PROLIA.xml:S2:8056:9	O
(	PROLIA.xml:S2:8066:1	O
6.1	PROLIA.xml:S2:8069:3	O
)]	PROLIA.xml:S2:8074:2	O
.	PROLIA.xml:S2:8078:1	O

Consider	PROLIA.xml:S2:8080:8	O
discontinuing	PROLIA.xml:S2:8089:13	O
Prolia	PROLIA.xml:S2:8103:6	O
if	PROLIA.xml:S2:8110:2	O
severe	PROLIA.xml:S2:8113:6	O
symptoms	PROLIA.xml:S2:8120:8	O
develop	PROLIA.xml:S2:8129:7	O
.	PROLIA.xml:S2:8136:1	O

5.8	PROLIA.xml:S2:8145:3	O
Musculoskeletal	PROLIA.xml:S2:8149:15	O
Pain	PROLIA.xml:S2:8165:4	O

In	PROLIA.xml:S2:8176:2	O
post	PROLIA.xml:S2:8179:4	O
-	PROLIA.xml:S2:8183:1	O
marketing	PROLIA.xml:S2:8184:9	O
experience	PROLIA.xml:S2:8194:10	O
,	PROLIA.xml:S2:8204:1	O
severe	PROLIA.xml:S2:8206:6	B-Severity
and	PROLIA.xml:S2:8213:3	O
occasionally	PROLIA.xml:S2:8217:12	O
incapacitating	PROLIA.xml:S2:8230:14	B-Severity
bone	PROLIA.xml:S2:8245:4	B-AdverseReaction
,	PROLIA.xml:S2:8249:1	O
joint	PROLIA.xml:S2:8251:5	B-AdverseReaction
,	PROLIA.xml:S2:8256:1	O
and	PROLIA.xml:S2:8258:3	O
or	PROLIA.xml:S2:8262:2	O
muscle	PROLIA.xml:S2:8265:6	B-AdverseReaction
pain	PROLIA.xml:S2:8272:4	I-AdverseReaction
has	PROLIA.xml:S2:8277:3	O
been	PROLIA.xml:S2:8281:4	O
reported	PROLIA.xml:S2:8286:8	O
in	PROLIA.xml:S2:8295:2	O
patients	PROLIA.xml:S2:8298:8	O
taking	PROLIA.xml:S2:8307:6	O
Prolia	PROLIA.xml:S2:8314:6	O
[	PROLIA.xml:S2:8321:1	O
see	PROLIA.xml:S2:8322:3	O
Adverse	PROLIA.xml:S2:8326:7	O
Reactions	PROLIA.xml:S2:8334:9	O
(	PROLIA.xml:S2:8344:1	O
6.2	PROLIA.xml:S2:8347:3	O
)]	PROLIA.xml:S2:8352:2	O
.	PROLIA.xml:S2:8356:1	O

The	PROLIA.xml:S2:8358:3	O
time	PROLIA.xml:S2:8362:4	O
to	PROLIA.xml:S2:8367:2	O
onset	PROLIA.xml:S2:8370:5	O
of	PROLIA.xml:S2:8376:2	O
symptoms	PROLIA.xml:S2:8379:8	O
varied	PROLIA.xml:S2:8388:6	O
from	PROLIA.xml:S2:8395:4	O
one	PROLIA.xml:S2:8400:3	O
day	PROLIA.xml:S2:8404:3	O
to	PROLIA.xml:S2:8408:2	O
several	PROLIA.xml:S2:8411:7	O
months	PROLIA.xml:S2:8419:6	O
after	PROLIA.xml:S2:8426:5	O
starting	PROLIA.xml:S2:8432:8	O
Prolia	PROLIA.xml:S2:8441:6	O
.	PROLIA.xml:S2:8447:1	O

Consider	PROLIA.xml:S2:8449:8	O
discontinuing	PROLIA.xml:S2:8458:13	O
use	PROLIA.xml:S2:8472:3	O
if	PROLIA.xml:S2:8476:2	O
severe	PROLIA.xml:S2:8479:6	O
symptoms	PROLIA.xml:S2:8486:8	O
develop	PROLIA.xml:S2:8495:7	O
[	PROLIA.xml:S2:8503:1	O
see	PROLIA.xml:S2:8504:3	O
Patient	PROLIA.xml:S2:8508:7	O
Counseling	PROLIA.xml:S2:8516:10	O
Information	PROLIA.xml:S2:8527:11	O
(	PROLIA.xml:S2:8539:1	O
17.8	PROLIA.xml:S2:8542:4	O
)]	PROLIA.xml:S2:8548:2	O
.	PROLIA.xml:S2:8552:1	O

5.9	PROLIA.xml:S2:8563:3	O
Suppression	PROLIA.xml:S2:8567:11	O
of	PROLIA.xml:S2:8579:2	O
Bone	PROLIA.xml:S2:8582:4	O
Turnover	PROLIA.xml:S2:8587:8	O

In	PROLIA.xml:S2:8601:2	O
clinical	PROLIA.xml:S2:8604:8	O
trials	PROLIA.xml:S2:8613:6	O
in	PROLIA.xml:S2:8620:2	O
women	PROLIA.xml:S2:8623:5	O
with	PROLIA.xml:S2:8629:4	O
postmenopausal	PROLIA.xml:S2:8634:14	O
osteoporosis	PROLIA.xml:S2:8649:12	O
,	PROLIA.xml:S2:8661:1	O
treatment	PROLIA.xml:S2:8663:9	O
with	PROLIA.xml:S2:8673:4	O
Prolia	PROLIA.xml:S2:8678:6	O
resulted	PROLIA.xml:S2:8685:8	O
in	PROLIA.xml:S2:8694:2	O
significant	PROLIA.xml:S2:8697:11	O
suppression	PROLIA.xml:S2:8709:11	B-AdverseReaction
of	PROLIA.xml:S2:8721:2	I-AdverseReaction
bone	PROLIA.xml:S2:8724:4	I-AdverseReaction
remodeling	PROLIA.xml:S2:8729:10	I-AdverseReaction
as	PROLIA.xml:S2:8740:2	O
evidenced	PROLIA.xml:S2:8743:9	O
by	PROLIA.xml:S2:8753:2	O
markers	PROLIA.xml:S2:8756:7	O
of	PROLIA.xml:S2:8764:2	O
bone	PROLIA.xml:S2:8767:4	O
turnover	PROLIA.xml:S2:8772:8	O
and	PROLIA.xml:S2:8781:3	O
bone	PROLIA.xml:S2:8785:4	O
histomorphometry	PROLIA.xml:S2:8790:16	O
[	PROLIA.xml:S2:8807:1	O
see	PROLIA.xml:S2:8808:3	O
Clinical	PROLIA.xml:S2:8812:8	O
Pharmacology	PROLIA.xml:S2:8821:12	O
(	PROLIA.xml:S2:8834:1	O
12.2	PROLIA.xml:S2:8837:4	O
)	PROLIA.xml:S2:8843:1	O
and	PROLIA.xml:S2:8845:3	O
Clinical	PROLIA.xml:S2:8849:8	O
Studies	PROLIA.xml:S2:8858:7	O
(	PROLIA.xml:S2:8866:1	O
14.1	PROLIA.xml:S2:8869:4	O
)]	PROLIA.xml:S2:8875:2	O
.	PROLIA.xml:S2:8879:1	O

The	PROLIA.xml:S2:8881:3	O
significance	PROLIA.xml:S2:8885:12	O
of	PROLIA.xml:S2:8898:2	O
these	PROLIA.xml:S2:8901:5	O
findings	PROLIA.xml:S2:8907:8	O
and	PROLIA.xml:S2:8916:3	O
the	PROLIA.xml:S2:8920:3	O
effect	PROLIA.xml:S2:8924:6	O
of	PROLIA.xml:S2:8931:2	O
long	PROLIA.xml:S2:8934:4	O
-	PROLIA.xml:S2:8938:1	O
term	PROLIA.xml:S2:8939:4	O
treatment	PROLIA.xml:S2:8944:9	O
with	PROLIA.xml:S2:8954:4	O
Prolia	PROLIA.xml:S2:8959:6	O
are	PROLIA.xml:S2:8966:3	O
unknown	PROLIA.xml:S2:8970:7	O
.	PROLIA.xml:S2:8977:1	O

The	PROLIA.xml:S2:8979:3	O
long	PROLIA.xml:S2:8983:4	O
-	PROLIA.xml:S2:8987:1	O
term	PROLIA.xml:S2:8988:4	O
consequences	PROLIA.xml:S2:8993:12	O
of	PROLIA.xml:S2:9006:2	O
the	PROLIA.xml:S2:9009:3	O
degree	PROLIA.xml:S2:9013:6	O
of	PROLIA.xml:S2:9020:2	O
suppression	PROLIA.xml:S2:9023:11	B-AdverseReaction
of	PROLIA.xml:S2:9035:2	I-AdverseReaction
bone	PROLIA.xml:S2:9038:4	I-AdverseReaction
remodeling	PROLIA.xml:S2:9043:10	I-AdverseReaction
observed	PROLIA.xml:S2:9054:8	O
with	PROLIA.xml:S2:9063:4	O
Prolia	PROLIA.xml:S2:9068:6	O
may	PROLIA.xml:S2:9075:3	B-Factor
contribute	PROLIA.xml:S2:9079:10	O
to	PROLIA.xml:S2:9090:2	O
adverse	PROLIA.xml:S2:9093:7	O
outcomes	PROLIA.xml:S2:9101:8	O
such	PROLIA.xml:S2:9110:4	O
as	PROLIA.xml:S2:9115:2	O
osteonecrosis	PROLIA.xml:S2:9118:13	B-AdverseReaction
of	PROLIA.xml:S2:9132:2	I-AdverseReaction
the	PROLIA.xml:S2:9135:3	I-AdverseReaction
jaw	PROLIA.xml:S2:9139:3	I-AdverseReaction
,	PROLIA.xml:S2:9142:1	O
atypical	PROLIA.xml:S2:9144:8	B-AdverseReaction
fractures	PROLIA.xml:S2:9153:9	I-AdverseReaction
,	PROLIA.xml:S2:9162:1	O
and	PROLIA.xml:S2:9164:3	O
delayed	PROLIA.xml:S2:9168:7	B-AdverseReaction
fracture	PROLIA.xml:S2:9176:8	I-AdverseReaction
healing	PROLIA.xml:S2:9185:7	I-AdverseReaction
.	PROLIA.xml:S2:9192:1	O

Monitor	PROLIA.xml:S2:9194:7	O
patients	PROLIA.xml:S2:9202:8	O
for	PROLIA.xml:S2:9211:3	O
these	PROLIA.xml:S2:9215:5	O
consequences	PROLIA.xml:S2:9221:12	O
.	PROLIA.xml:S2:9233:1	O
6	PROMACTA.xml:S1:4:1	O
ADVERSE	PROMACTA.xml:S1:6:7	O
REACTIONS	PROMACTA.xml:S1:14:9	O

The	PROMACTA.xml:S1:27:3	O
following	PROMACTA.xml:S1:31:9	O
serious	PROMACTA.xml:S1:41:7	O
adverse	PROMACTA.xml:S1:49:7	O
reactions	PROMACTA.xml:S1:57:9	O
associated	PROMACTA.xml:S1:67:10	O
with	PROMACTA.xml:S1:78:4	O
PROMACTA	PROMACTA.xml:S1:83:8	O
are	PROMACTA.xml:S1:92:3	O
described	PROMACTA.xml:S1:96:9	O
in	PROMACTA.xml:S1:106:2	O
other	PROMACTA.xml:S1:109:5	O
sections	PROMACTA.xml:S1:115:8	O
.	PROMACTA.xml:S1:123:1	O

Hepatic	PROMACTA.xml:S1:134:7	B-AdverseReaction
Decompensation	PROMACTA.xml:S1:142:14	I-AdverseReaction
in	PROMACTA.xml:S1:157:2	O
Patients	PROMACTA.xml:S1:160:8	O
with	PROMACTA.xml:S1:169:4	O
Chronic	PROMACTA.xml:S1:174:7	O
Hepatitis	PROMACTA.xml:S1:182:9	O
C	PROMACTA.xml:S1:192:1	O
[	PROMACTA.xml:S1:194:1	O
see	PROMACTA.xml:S1:195:3	O
Warnings	PROMACTA.xml:S1:199:8	O
and	PROMACTA.xml:S1:208:3	O
Precautions	PROMACTA.xml:S1:212:11	O
(	PROMACTA.xml:S1:224:1	O
5.1	PROMACTA.xml:S1:225:3	O
)]	PROMACTA.xml:S1:228:2	O

Hepatotoxicity	PROMACTA.xml:S1:239:14	B-AdverseReaction
[	PROMACTA.xml:S1:254:1	O
see	PROMACTA.xml:S1:255:3	O
Warnings	PROMACTA.xml:S1:259:8	O
and	PROMACTA.xml:S1:268:3	O
Precautions	PROMACTA.xml:S1:272:11	O
(	PROMACTA.xml:S1:284:1	O
5.2	PROMACTA.xml:S1:285:3	O
)]	PROMACTA.xml:S1:288:2	O

Thrombotic	PROMACTA.xml:S1:299:10	B-AdverseReaction
Thromboembolic	PROMACTA.xml:S1:310:14	B-AdverseReaction
Complications	PROMACTA.xml:S1:325:13	I-AdverseReaction
[	PROMACTA.xml:S1:339:1	O
see	PROMACTA.xml:S1:340:3	O
Warnings	PROMACTA.xml:S1:344:8	O
and	PROMACTA.xml:S1:353:3	O
Precautions	PROMACTA.xml:S1:357:11	O
(	PROMACTA.xml:S1:369:1	O
5.3	PROMACTA.xml:S1:370:3	O
)]	PROMACTA.xml:S1:373:2	O

Cataracts	PROMACTA.xml:S1:384:9	B-AdverseReaction
[	PROMACTA.xml:S1:394:1	O
see	PROMACTA.xml:S1:395:3	O
Warnings	PROMACTA.xml:S1:399:8	O
and	PROMACTA.xml:S1:408:3	O
Precautions	PROMACTA.xml:S1:412:11	O
(	PROMACTA.xml:S1:424:1	O
5.4	PROMACTA.xml:S1:425:3	O
)]	PROMACTA.xml:S1:428:2	O

In	PROMACTA.xml:S1:441:2	O
adult	PROMACTA.xml:S1:444:5	O
patients	PROMACTA.xml:S1:450:8	O
with	PROMACTA.xml:S1:459:4	O
ITP	PROMACTA.xml:S1:464:3	O
,	PROMACTA.xml:S1:467:1	O
the	PROMACTA.xml:S1:469:3	O
most	PROMACTA.xml:S1:473:4	O
common	PROMACTA.xml:S1:478:6	O
adverse	PROMACTA.xml:S1:485:7	O
reactions	PROMACTA.xml:S1:493:9	O
(	PROMACTA.xml:S1:503:1	O
greater	PROMACTA.xml:S1:504:7	O
than	PROMACTA.xml:S1:512:4	O
or	PROMACTA.xml:S1:517:2	O
equal	PROMACTA.xml:S1:520:5	O
to	PROMACTA.xml:S1:526:2	O
5%	PROMACTA.xml:S1:529:2	O
and	PROMACTA.xml:S1:532:3	O
greater	PROMACTA.xml:S1:536:7	O
than	PROMACTA.xml:S1:544:4	O
placebo	PROMACTA.xml:S1:549:7	O
)	PROMACTA.xml:S1:556:1	O
were	PROMACTA.xml:S1:558:4	O
:	PROMACTA.xml:S1:562:1	O
nausea	PROMACTA.xml:S1:564:6	B-AdverseReaction
,	PROMACTA.xml:S1:570:1	O
diarrhea	PROMACTA.xml:S1:572:8	B-AdverseReaction
,	PROMACTA.xml:S1:580:1	O
upper	PROMACTA.xml:S1:582:5	B-AdverseReaction
respiratory	PROMACTA.xml:S1:588:11	I-AdverseReaction
tract	PROMACTA.xml:S1:600:5	I-AdverseReaction
infection	PROMACTA.xml:S1:606:9	I-AdverseReaction
,	PROMACTA.xml:S1:615:1	O
vomiting	PROMACTA.xml:S1:617:8	B-AdverseReaction
,	PROMACTA.xml:S1:625:1	O
increased	PROMACTA.xml:S1:627:9	B-AdverseReaction
ALT	PROMACTA.xml:S1:637:3	I-AdverseReaction
,	PROMACTA.xml:S1:640:1	O
myalgia	PROMACTA.xml:S1:642:7	B-AdverseReaction
,	PROMACTA.xml:S1:649:1	O
and	PROMACTA.xml:S1:651:3	O
urinary	PROMACTA.xml:S1:655:7	B-AdverseReaction
tract	PROMACTA.xml:S1:663:5	I-AdverseReaction
infection	PROMACTA.xml:S1:669:9	I-AdverseReaction
.	PROMACTA.xml:S1:678:1	O

(	PROMACTA.xml:S1:680:1	O
6.1	PROMACTA.xml:S1:683:3	O
)	PROMACTA.xml:S1:688:1	O

In	PROMACTA.xml:S1:697:2	O
pediatric	PROMACTA.xml:S1:700:9	O
patients	PROMACTA.xml:S1:710:8	O
age	PROMACTA.xml:S1:719:3	O
6	PROMACTA.xml:S1:723:1	O
years	PROMACTA.xml:S1:725:5	O
and	PROMACTA.xml:S1:731:3	O
older	PROMACTA.xml:S1:735:5	O
with	PROMACTA.xml:S1:741:4	O
ITP	PROMACTA.xml:S1:746:3	O
,	PROMACTA.xml:S1:749:1	O
the	PROMACTA.xml:S1:751:3	O
most	PROMACTA.xml:S1:755:4	O
common	PROMACTA.xml:S1:760:6	O
adverse	PROMACTA.xml:S1:767:7	O
reactions	PROMACTA.xml:S1:775:9	O
(	PROMACTA.xml:S1:785:1	O
greater	PROMACTA.xml:S1:786:7	O
than	PROMACTA.xml:S1:794:4	O
or	PROMACTA.xml:S1:799:2	O
equal	PROMACTA.xml:S1:802:5	O
to	PROMACTA.xml:S1:808:2	O
10%	PROMACTA.xml:S1:811:3	O
and	PROMACTA.xml:S1:815:3	O
greater	PROMACTA.xml:S1:819:7	O
than	PROMACTA.xml:S1:827:4	O
placebo	PROMACTA.xml:S1:832:7	O
)	PROMACTA.xml:S1:839:1	O
were	PROMACTA.xml:S1:841:4	O
upper	PROMACTA.xml:S1:846:5	B-AdverseReaction
respiratory	PROMACTA.xml:S1:852:11	I-AdverseReaction
tract	PROMACTA.xml:S1:864:5	I-AdverseReaction
infection	PROMACTA.xml:S1:870:9	I-AdverseReaction
,	PROMACTA.xml:S1:879:1	O
nasopharyngitis	PROMACTA.xml:S1:881:15	B-AdverseReaction
,	PROMACTA.xml:S1:896:1	O
and	PROMACTA.xml:S1:898:3	O
rhinitis	PROMACTA.xml:S1:902:8	B-AdverseReaction
.	PROMACTA.xml:S1:910:1	O

(	PROMACTA.xml:S1:912:1	O
6.1	PROMACTA.xml:S1:915:3	O
)	PROMACTA.xml:S1:920:1	O

In	PROMACTA.xml:S1:929:2	O
patients	PROMACTA.xml:S1:932:8	O
with	PROMACTA.xml:S1:941:4	O
chronic	PROMACTA.xml:S1:946:7	O
hepatitis	PROMACTA.xml:S1:954:9	O
C	PROMACTA.xml:S1:964:1	O
-	PROMACTA.xml:S1:965:1	O
associated	PROMACTA.xml:S1:966:10	O
thrombocytopenia	PROMACTA.xml:S1:977:16	O
,	PROMACTA.xml:S1:993:1	O
the	PROMACTA.xml:S1:995:3	O
most	PROMACTA.xml:S1:999:4	O
common	PROMACTA.xml:S1:1004:6	O
adverse	PROMACTA.xml:S1:1011:7	O
reactions	PROMACTA.xml:S1:1019:9	O
(	PROMACTA.xml:S1:1029:1	O
greater	PROMACTA.xml:S1:1030:7	O
than	PROMACTA.xml:S1:1038:4	O
or	PROMACTA.xml:S1:1043:2	O
equal	PROMACTA.xml:S1:1046:5	O
to	PROMACTA.xml:S1:1052:2	O
10%	PROMACTA.xml:S1:1055:3	O
and	PROMACTA.xml:S1:1059:3	O
greater	PROMACTA.xml:S1:1063:7	O
than	PROMACTA.xml:S1:1071:4	O
placebo	PROMACTA.xml:S1:1076:7	O
)	PROMACTA.xml:S1:1083:1	O
were	PROMACTA.xml:S1:1085:4	O
:	PROMACTA.xml:S1:1089:1	O
anemia	PROMACTA.xml:S1:1091:6	B-AdverseReaction
,	PROMACTA.xml:S1:1097:1	O
pyrexia	PROMACTA.xml:S1:1099:7	B-AdverseReaction
,	PROMACTA.xml:S1:1106:1	O
fatigue	PROMACTA.xml:S1:1108:7	B-AdverseReaction
,	PROMACTA.xml:S1:1115:1	O
headache	PROMACTA.xml:S1:1117:8	B-AdverseReaction
,	PROMACTA.xml:S1:1125:1	O
nausea	PROMACTA.xml:S1:1127:6	B-AdverseReaction
,	PROMACTA.xml:S1:1133:1	O
diarrhea	PROMACTA.xml:S1:1135:8	B-AdverseReaction
,	PROMACTA.xml:S1:1143:1	O
decreased	PROMACTA.xml:S1:1145:9	B-AdverseReaction
appetite	PROMACTA.xml:S1:1155:8	I-AdverseReaction
,	PROMACTA.xml:S1:1163:1	O
influenza	PROMACTA.xml:S1:1165:9	B-AdverseReaction
-	PROMACTA.xml:S1:1174:1	I-AdverseReaction
like	PROMACTA.xml:S1:1175:4	I-AdverseReaction
illness	PROMACTA.xml:S1:1180:7	I-AdverseReaction
,	PROMACTA.xml:S1:1187:1	O
asthenia	PROMACTA.xml:S1:1189:8	B-AdverseReaction
,	PROMACTA.xml:S1:1197:1	O
insomnia	PROMACTA.xml:S1:1199:8	B-AdverseReaction
,	PROMACTA.xml:S1:1207:1	O
cough	PROMACTA.xml:S1:1209:5	B-AdverseReaction
,	PROMACTA.xml:S1:1214:1	O
pruritus	PROMACTA.xml:S1:1216:8	B-AdverseReaction
,	PROMACTA.xml:S1:1224:1	O
chills	PROMACTA.xml:S1:1226:6	B-AdverseReaction
,	PROMACTA.xml:S1:1232:1	O
myalgia	PROMACTA.xml:S1:1234:7	B-AdverseReaction
,	PROMACTA.xml:S1:1241:1	O
alopecia	PROMACTA.xml:S1:1243:8	B-AdverseReaction
,	PROMACTA.xml:S1:1251:1	O
and	PROMACTA.xml:S1:1253:3	O
peripheral	PROMACTA.xml:S1:1257:10	B-AdverseReaction
edema	PROMACTA.xml:S1:1268:5	I-AdverseReaction
.	PROMACTA.xml:S1:1273:1	O

(	PROMACTA.xml:S1:1275:1	O
6.1	PROMACTA.xml:S1:1278:3	O
)	PROMACTA.xml:S1:1283:1	O

In	PROMACTA.xml:S1:1292:2	O
patients	PROMACTA.xml:S1:1295:8	O
with	PROMACTA.xml:S1:1304:4	O
severe	PROMACTA.xml:S1:1309:6	O
aplastic	PROMACTA.xml:S1:1316:8	O
anemia	PROMACTA.xml:S1:1325:6	O
,	PROMACTA.xml:S1:1331:1	O
the	PROMACTA.xml:S1:1333:3	O
most	PROMACTA.xml:S1:1337:4	O
common	PROMACTA.xml:S1:1342:6	O
adverse	PROMACTA.xml:S1:1349:7	O
reactions	PROMACTA.xml:S1:1357:9	O
(	PROMACTA.xml:S1:1367:1	O
greater	PROMACTA.xml:S1:1368:7	O
than	PROMACTA.xml:S1:1376:4	O
or	PROMACTA.xml:S1:1381:2	O
equal	PROMACTA.xml:S1:1384:5	O
to	PROMACTA.xml:S1:1390:2	O
20%	PROMACTA.xml:S1:1393:3	O
)	PROMACTA.xml:S1:1396:1	O
were	PROMACTA.xml:S1:1398:4	O
:	PROMACTA.xml:S1:1402:1	O
nausea	PROMACTA.xml:S1:1404:6	B-AdverseReaction
,	PROMACTA.xml:S1:1410:1	O
fatigue	PROMACTA.xml:S1:1412:7	B-AdverseReaction
,	PROMACTA.xml:S1:1419:1	O
cough	PROMACTA.xml:S1:1421:5	B-AdverseReaction
,	PROMACTA.xml:S1:1426:1	O
diarrhea	PROMACTA.xml:S1:1428:8	B-AdverseReaction
,	PROMACTA.xml:S1:1436:1	O
and	PROMACTA.xml:S1:1438:3	O
headache	PROMACTA.xml:S1:1442:8	B-AdverseReaction
.	PROMACTA.xml:S1:1450:1	O

(	PROMACTA.xml:S1:1452:1	O
6.1	PROMACTA.xml:S1:1455:3	O
)	PROMACTA.xml:S1:1460:1	O

EXCERPT	PROMACTA.xml:S1:1469:7	O
:	PROMACTA.xml:S1:1476:1	O
To	PROMACTA.xml:S1:1482:2	O
report	PROMACTA.xml:S1:1485:6	O
SUSPECTED	PROMACTA.xml:S1:1492:9	O
ADVERSE	PROMACTA.xml:S1:1502:7	O
REACTIONS	PROMACTA.xml:S1:1510:9	O
,	PROMACTA.xml:S1:1519:1	O
contact	PROMACTA.xml:S1:1521:7	O
GlaxoSmithKline	PROMACTA.xml:S1:1529:15	O
at	PROMACTA.xml:S1:1545:2	O
1	PROMACTA.xml:S1:1548:1	O
-	PROMACTA.xml:S1:1549:1	O
888	PROMACTA.xml:S1:1550:3	O
-	PROMACTA.xml:S1:1553:1	O
825	PROMACTA.xml:S1:1554:3	O
-	PROMACTA.xml:S1:1557:1	O
5249	PROMACTA.xml:S1:1558:4	O
or	PROMACTA.xml:S1:1563:2	O
FDA	PROMACTA.xml:S1:1566:3	O
at	PROMACTA.xml:S1:1570:2	O
1	PROMACTA.xml:S1:1573:1	O
-	PROMACTA.xml:S1:1574:1	O
800	PROMACTA.xml:S1:1575:3	O
-	PROMACTA.xml:S1:1578:1	O
FDA	PROMACTA.xml:S1:1579:3	O
-	PROMACTA.xml:S1:1582:1	O
1088	PROMACTA.xml:S1:1583:4	O
or	PROMACTA.xml:S1:1588:2	O
www	PROMACTA.xml:S1:1592:3	O
.	PROMACTA.xml:S1:1595:1	O
fda	PROMACTA.xml:S1:1596:3	O
.	PROMACTA.xml:S1:1599:1	O
gov	PROMACTA.xml:S1:1600:3	O
medwatch	PROMACTA.xml:S1:1604:8	O
.	PROMACTA.xml:S1:1614:1	O

6.1	PROMACTA.xml:S1:1626:3	O

Clinical	PROMACTA.xml:S1:1630:8	O

Trials	PROMACTA.xml:S1:1639:6	O
Experience	PROMACTA.xml:S1:1646:10	O

Because	PROMACTA.xml:S1:1660:7	O
clinical	PROMACTA.xml:S1:1668:8	O
trials	PROMACTA.xml:S1:1677:6	O
are	PROMACTA.xml:S1:1684:3	O
conducted	PROMACTA.xml:S1:1688:9	O
under	PROMACTA.xml:S1:1698:5	O
widely	PROMACTA.xml:S1:1704:6	O
varying	PROMACTA.xml:S1:1711:7	O
conditions	PROMACTA.xml:S1:1719:10	O
,	PROMACTA.xml:S1:1729:1	O
adverse	PROMACTA.xml:S1:1731:7	O
reaction	PROMACTA.xml:S1:1739:8	O
rates	PROMACTA.xml:S1:1748:5	O
observed	PROMACTA.xml:S1:1754:8	O
in	PROMACTA.xml:S1:1763:2	O
the	PROMACTA.xml:S1:1766:3	O
clinical	PROMACTA.xml:S1:1770:8	O
trials	PROMACTA.xml:S1:1779:6	O
of	PROMACTA.xml:S1:1786:2	O
a	PROMACTA.xml:S1:1789:1	O
drug	PROMACTA.xml:S1:1791:4	O
cannot	PROMACTA.xml:S1:1796:6	O
be	PROMACTA.xml:S1:1803:2	O
directly	PROMACTA.xml:S1:1806:8	O
compared	PROMACTA.xml:S1:1815:8	O
with	PROMACTA.xml:S1:1824:4	O
rates	PROMACTA.xml:S1:1829:5	O
in	PROMACTA.xml:S1:1835:2	O
the	PROMACTA.xml:S1:1838:3	O
clinical	PROMACTA.xml:S1:1842:8	O
trials	PROMACTA.xml:S1:1851:6	O
of	PROMACTA.xml:S1:1858:2	O
another	PROMACTA.xml:S1:1861:7	O
drug	PROMACTA.xml:S1:1869:4	O
and	PROMACTA.xml:S1:1874:3	O
may	PROMACTA.xml:S1:1878:3	O
not	PROMACTA.xml:S1:1882:3	O
reflect	PROMACTA.xml:S1:1886:7	O
the	PROMACTA.xml:S1:1894:3	O
rates	PROMACTA.xml:S1:1898:5	O
observed	PROMACTA.xml:S1:1904:8	O
in	PROMACTA.xml:S1:1913:2	O
practice	PROMACTA.xml:S1:1916:8	O
.	PROMACTA.xml:S1:1924:1	O

Chronic	PROMACTA.xml:S1:1932:7	O
Immune	PROMACTA.xml:S1:1940:6	O
(	PROMACTA.xml:S1:1947:1	O
Idiopathic	PROMACTA.xml:S1:1948:10	O
)	PROMACTA.xml:S1:1958:1	O
Thrombocytopenia	PROMACTA.xml:S1:1960:16	O
:	PROMACTA.xml:S1:1976:1	O
Adults	PROMACTA.xml:S1:1981:6	O
:	PROMACTA.xml:S1:1987:1	O
In	PROMACTA.xml:S1:1990:2	O
clinical	PROMACTA.xml:S1:1993:8	O
trials	PROMACTA.xml:S1:2002:6	O
,	PROMACTA.xml:S1:2008:1	O
hemorrhage	PROMACTA.xml:S1:2010:10	B-AdverseReaction
was	PROMACTA.xml:S1:2021:3	O
the	PROMACTA.xml:S1:2025:3	O
most	PROMACTA.xml:S1:2029:4	O
common	PROMACTA.xml:S1:2034:6	O
serious	PROMACTA.xml:S1:2041:7	O
adverse	PROMACTA.xml:S1:2049:7	O
reaction	PROMACTA.xml:S1:2057:8	O
and	PROMACTA.xml:S1:2066:3	O
most	PROMACTA.xml:S1:2070:4	O
hemorrhagic	PROMACTA.xml:S1:2075:11	B-AdverseReaction
reactions	PROMACTA.xml:S1:2087:9	I-AdverseReaction
followed	PROMACTA.xml:S1:2097:8	O
discontinuation	PROMACTA.xml:S1:2106:15	O
of	PROMACTA.xml:S1:2122:2	O
PROMACTA	PROMACTA.xml:S1:2125:8	O
.	PROMACTA.xml:S1:2133:1	O

Other	PROMACTA.xml:S1:2135:5	O
serious	PROMACTA.xml:S1:2141:7	O
adverse	PROMACTA.xml:S1:2149:7	O
reactions	PROMACTA.xml:S1:2157:9	O
included	PROMACTA.xml:S1:2167:8	O
thrombotic	PROMACTA.xml:S1:2176:10	B-AdverseReaction
thromboembolic	PROMACTA.xml:S1:2187:14	B-AdverseReaction
complications	PROMACTA.xml:S1:2202:13	I-AdverseReaction
[	PROMACTA.xml:S1:2217:1	O
see	PROMACTA.xml:S1:2218:3	O
Warnings	PROMACTA.xml:S1:2222:8	O
and	PROMACTA.xml:S1:2231:3	O
Precautions	PROMACTA.xml:S1:2235:11	O
(	PROMACTA.xml:S1:2247:1	O
5.3	PROMACTA.xml:S1:2248:3	O
)]	PROMACTA.xml:S1:2251:2	O
.	PROMACTA.xml:S1:2255:1	O

The	PROMACTA.xml:S1:2257:3	O
data	PROMACTA.xml:S1:2261:4	O
described	PROMACTA.xml:S1:2266:9	O
below	PROMACTA.xml:S1:2276:5	O
reflect	PROMACTA.xml:S1:2282:7	O
exposure	PROMACTA.xml:S1:2290:8	O
of	PROMACTA.xml:S1:2299:2	O
PROMACTA	PROMACTA.xml:S1:2302:8	O
to	PROMACTA.xml:S1:2311:2	O
446	PROMACTA.xml:S1:2314:3	O
patients	PROMACTA.xml:S1:2318:8	O
with	PROMACTA.xml:S1:2327:4	O
chronic	PROMACTA.xml:S1:2332:7	O
ITP	PROMACTA.xml:S1:2340:3	O
aged	PROMACTA.xml:S1:2344:4	O
18	PROMACTA.xml:S1:2349:2	O
to	PROMACTA.xml:S1:2352:2	O
85	PROMACTA.xml:S1:2355:2	O
years	PROMACTA.xml:S1:2358:5	O
,	PROMACTA.xml:S1:2363:1	O
of	PROMACTA.xml:S1:2365:2	O
whom	PROMACTA.xml:S1:2368:4	O
65%	PROMACTA.xml:S1:2373:3	O
were	PROMACTA.xml:S1:2377:4	O
female	PROMACTA.xml:S1:2382:6	O
,	PROMACTA.xml:S1:2388:1	O
across	PROMACTA.xml:S1:2390:6	O
the	PROMACTA.xml:S1:2397:3	O
ITP	PROMACTA.xml:S1:2401:3	O
clinical	PROMACTA.xml:S1:2405:8	O
development	PROMACTA.xml:S1:2414:11	O
program	PROMACTA.xml:S1:2426:7	O
including	PROMACTA.xml:S1:2434:9	O
three	PROMACTA.xml:S1:2444:5	O
placebo	PROMACTA.xml:S1:2450:7	O
-	PROMACTA.xml:S1:2457:1	O
controlled	PROMACTA.xml:S1:2458:10	O
trials	PROMACTA.xml:S1:2469:6	O
.	PROMACTA.xml:S1:2475:1	O

PROMACTA	PROMACTA.xml:S1:2477:8	O
was	PROMACTA.xml:S1:2486:3	O
administered	PROMACTA.xml:S1:2490:12	O
to	PROMACTA.xml:S1:2503:2	O
277	PROMACTA.xml:S1:2506:3	O
patients	PROMACTA.xml:S1:2510:8	O
for	PROMACTA.xml:S1:2519:3	O
at	PROMACTA.xml:S1:2523:2	O
least	PROMACTA.xml:S1:2526:5	O
6	PROMACTA.xml:S1:2532:1	O
months	PROMACTA.xml:S1:2534:6	O
and	PROMACTA.xml:S1:2541:3	O
202	PROMACTA.xml:S1:2545:3	O
patients	PROMACTA.xml:S1:2549:8	O
for	PROMACTA.xml:S1:2558:3	O
at	PROMACTA.xml:S1:2562:2	O
least	PROMACTA.xml:S1:2565:5	O
1	PROMACTA.xml:S1:2571:1	O
year	PROMACTA.xml:S1:2573:4	O
.	PROMACTA.xml:S1:2577:1	O

Table	PROMACTA.xml:S1:2583:5	O
4	PROMACTA.xml:S1:2589:1	O
presents	PROMACTA.xml:S1:2591:8	O
the	PROMACTA.xml:S1:2600:3	O
most	PROMACTA.xml:S1:2604:4	O
common	PROMACTA.xml:S1:2609:6	O
adverse	PROMACTA.xml:S1:2616:7	O
drug	PROMACTA.xml:S1:2624:4	O
reactions	PROMACTA.xml:S1:2629:9	O
(	PROMACTA.xml:S1:2639:1	O
experienced	PROMACTA.xml:S1:2640:11	O
by	PROMACTA.xml:S1:2652:2	O
greater	PROMACTA.xml:S1:2655:7	O
than	PROMACTA.xml:S1:2663:4	O
or	PROMACTA.xml:S1:2668:2	O
equal	PROMACTA.xml:S1:2671:5	O
to	PROMACTA.xml:S1:2677:2	O
3%	PROMACTA.xml:S1:2680:2	O
of	PROMACTA.xml:S1:2683:2	O
patients	PROMACTA.xml:S1:2686:8	O
receiving	PROMACTA.xml:S1:2695:9	O
PROMACTA	PROMACTA.xml:S1:2705:8	O
)	PROMACTA.xml:S1:2713:1	O
from	PROMACTA.xml:S1:2715:4	O
the	PROMACTA.xml:S1:2720:3	O
three	PROMACTA.xml:S1:2724:5	O
placebo	PROMACTA.xml:S1:2730:7	O
-	PROMACTA.xml:S1:2737:1	O
controlled	PROMACTA.xml:S1:2738:10	O
trials	PROMACTA.xml:S1:2749:6	O
,	PROMACTA.xml:S1:2755:1	O
with	PROMACTA.xml:S1:2757:4	O
a	PROMACTA.xml:S1:2762:1	O
higher	PROMACTA.xml:S1:2764:6	O
incidence	PROMACTA.xml:S1:2771:9	O
in	PROMACTA.xml:S1:2781:2	O
PROMACTA	PROMACTA.xml:S1:2784:8	O
versus	PROMACTA.xml:S1:2793:6	O
placebo	PROMACTA.xml:S1:2800:7	O
.	PROMACTA.xml:S1:2807:1	O

Table	PROMACTA.xml:S1:2813:5	O
4	PROMACTA.xml:S1:2819:1	O
.	PROMACTA.xml:S1:2820:1	O

Adverse	PROMACTA.xml:S1:2822:7	O
Reactions	PROMACTA.xml:S1:2830:9	O
(	PROMACTA.xml:S1:2840:1	O
3%	PROMACTA.xml:S1:2843:2	O
)	PROMACTA.xml:S1:2845:1	O
from	PROMACTA.xml:S1:2847:4	O
Three	PROMACTA.xml:S1:2852:5	O
Placebo	PROMACTA.xml:S1:2858:7	O
-	PROMACTA.xml:S1:2865:1	O
controlled	PROMACTA.xml:S1:2866:10	O
Trials	PROMACTA.xml:S1:2877:6	O
in	PROMACTA.xml:S1:2884:2	O
Adults	PROMACTA.xml:S1:2887:6	O
with	PROMACTA.xml:S1:2894:4	O
Chronic	PROMACTA.xml:S1:2899:7	O
Immune	PROMACTA.xml:S1:2907:6	O
(	PROMACTA.xml:S1:2914:1	O
Idiopathic	PROMACTA.xml:S1:2915:10	O
)	PROMACTA.xml:S1:2925:1	O
Thrombocytopenia	PROMACTA.xml:S1:2927:16	O

Adverse	PROMACTA.xml:S1:2947:7	O
Reaction	PROMACTA.xml:S1:2955:8	O
PROMACTA	PROMACTA.xml:S1:2999:8	O
50	PROMACTA.xml:S1:3008:2	O
mg	PROMACTA.xml:S1:3011:2	O
n	PROMACTA.xml:S1:3015:1	O
241	PROMACTA.xml:S1:3019:3	O
(	PROMACTA.xml:S1:3024:1	O
)	PROMACTA.xml:S1:3026:1	O
Placebo	PROMACTA.xml:S1:3036:7	O
n	PROMACTA.xml:S1:3045:1	O
128	PROMACTA.xml:S1:3049:3	O
(	PROMACTA.xml:S1:3054:1	O
)	PROMACTA.xml:S1:3056:1	O

Nausea	PROMACTA.xml:S1:3064:6	B-AdverseReaction
9	PROMACTA.xml:S1:3116:1	O
3	PROMACTA.xml:S1:3153:1	O

Diarrhea	PROMACTA.xml:S1:3173:8	B-AdverseReaction
9	PROMACTA.xml:S1:3225:1	O
7	PROMACTA.xml:S1:3262:1	O

Upper	PROMACTA.xml:S1:3282:5	B-AdverseReaction
respiratory	PROMACTA.xml:S1:3288:11	I-AdverseReaction
tract	PROMACTA.xml:S1:3300:5	I-AdverseReaction
infection	PROMACTA.xml:S1:3306:9	I-AdverseReaction
7	PROMACTA.xml:S1:3334:1	O
6	PROMACTA.xml:S1:3371:1	O

Vomiting	PROMACTA.xml:S1:3391:8	B-AdverseReaction
6	PROMACTA.xml:S1:3443:1	O
1	PROMACTA.xml:S1:3481:1	O

Increased	PROMACTA.xml:S1:3500:9	B-AdverseReaction
ALT	PROMACTA.xml:S1:3510:3	I-AdverseReaction
5	PROMACTA.xml:S1:3552:1	O
3	PROMACTA.xml:S1:3589:1	O

Myalgia	PROMACTA.xml:S1:3609:7	B-AdverseReaction
5	PROMACTA.xml:S1:3661:1	O
2	PROMACTA.xml:S1:3698:1	O

Urinary	PROMACTA.xml:S1:3718:7	B-AdverseReaction
tract	PROMACTA.xml:S1:3726:5	I-AdverseReaction
infection	PROMACTA.xml:S1:3732:9	I-AdverseReaction
5	PROMACTA.xml:S1:3770:1	O
3	PROMACTA.xml:S1:3807:1	O

Oropharyngeal	PROMACTA.xml:S1:3827:13	B-AdverseReaction
pain	PROMACTA.xml:S1:3841:4	I-AdverseReaction
4	PROMACTA.xml:S1:3879:1	O
3	PROMACTA.xml:S1:3916:1	O

Increased	PROMACTA.xml:S1:3936:9	B-AdverseReaction
AST	PROMACTA.xml:S1:3946:3	I-AdverseReaction
4	PROMACTA.xml:S1:3988:1	O
2	PROMACTA.xml:S1:4025:1	O

Pharyngitis	PROMACTA.xml:S1:4045:11	B-AdverseReaction
4	PROMACTA.xml:S1:4097:1	O
2	PROMACTA.xml:S1:4134:1	O

Back	PROMACTA.xml:S1:4154:4	B-AdverseReaction
pain	PROMACTA.xml:S1:4159:4	I-AdverseReaction
3	PROMACTA.xml:S1:4206:1	O
2	PROMACTA.xml:S1:4243:1	O

Influenza	PROMACTA.xml:S1:4263:9	B-AdverseReaction
3	PROMACTA.xml:S1:4315:1	O
2	PROMACTA.xml:S1:4352:1	O

Paresthesia	PROMACTA.xml:S1:4372:11	B-AdverseReaction
3	PROMACTA.xml:S1:4424:1	O
2	PROMACTA.xml:S1:4461:1	O

Rash	PROMACTA.xml:S1:4481:4	B-AdverseReaction
3	PROMACTA.xml:S1:4533:1	O
2	PROMACTA.xml:S1:4570:1	O

In	PROMACTA.xml:S1:4597:2	O
the	PROMACTA.xml:S1:4600:3	O
three	PROMACTA.xml:S1:4604:5	O
controlled	PROMACTA.xml:S1:4610:10	O
clinical	PROMACTA.xml:S1:4621:8	O
chronic	PROMACTA.xml:S1:4630:7	O
ITP	PROMACTA.xml:S1:4638:3	O
trials	PROMACTA.xml:S1:4642:6	O
,	PROMACTA.xml:S1:4648:1	O
alopecia	PROMACTA.xml:S1:4650:8	B-AdverseReaction
,	PROMACTA.xml:S1:4658:1	O
musculoskeletal	PROMACTA.xml:S1:4660:15	B-AdverseReaction
pain	PROMACTA.xml:S1:4676:4	I-AdverseReaction
,	PROMACTA.xml:S1:4680:1	O
blood	PROMACTA.xml:S1:4682:5	B-AdverseReaction
alkaline	PROMACTA.xml:S1:4688:8	I-AdverseReaction
phosphatase	PROMACTA.xml:S1:4697:11	I-AdverseReaction
increased	PROMACTA.xml:S1:4709:9	I-AdverseReaction
,	PROMACTA.xml:S1:4718:1	O
and	PROMACTA.xml:S1:4720:3	O
dry	PROMACTA.xml:S1:4724:3	B-AdverseReaction
mouth	PROMACTA.xml:S1:4728:5	I-AdverseReaction
were	PROMACTA.xml:S1:4734:4	O
the	PROMACTA.xml:S1:4739:3	O
adverse	PROMACTA.xml:S1:4743:7	O
reactions	PROMACTA.xml:S1:4751:9	O
reported	PROMACTA.xml:S1:4761:8	O
in	PROMACTA.xml:S1:4770:2	O
2%	PROMACTA.xml:S1:4773:2	O
of	PROMACTA.xml:S1:4776:2	O
patients	PROMACTA.xml:S1:4779:8	O
treated	PROMACTA.xml:S1:4788:7	O
with	PROMACTA.xml:S1:4796:4	O
PROMACTA	PROMACTA.xml:S1:4801:8	O
and	PROMACTA.xml:S1:4810:3	O
in	PROMACTA.xml:S1:4814:2	O
no	PROMACTA.xml:S1:4817:2	O
patients	PROMACTA.xml:S1:4820:8	O
who	PROMACTA.xml:S1:4829:3	O
received	PROMACTA.xml:S1:4833:8	O
placebo	PROMACTA.xml:S1:4842:7	O
.	PROMACTA.xml:S1:4849:1	O

Among	PROMACTA.xml:S1:4855:5	O

299	PROMACTA.xml:S1:4861:3	O
patients	PROMACTA.xml:S1:4865:8	O
with	PROMACTA.xml:S1:4874:4	O
chronic	PROMACTA.xml:S1:4879:7	O
ITP	PROMACTA.xml:S1:4887:3	O
who	PROMACTA.xml:S1:4891:3	O
received	PROMACTA.xml:S1:4895:8	O
PROMACTA	PROMACTA.xml:S1:4904:8	O
in	PROMACTA.xml:S1:4913:2	O
the	PROMACTA.xml:S1:4916:3	O
single	PROMACTA.xml:S1:4920:6	O
-	PROMACTA.xml:S1:4926:1	O
arm	PROMACTA.xml:S1:4927:3	O
extension	PROMACTA.xml:S1:4931:9	O
trial	PROMACTA.xml:S1:4941:5	O
,	PROMACTA.xml:S1:4946:1	O
the	PROMACTA.xml:S1:4948:3	O
adverse	PROMACTA.xml:S1:4952:7	O
reactions	PROMACTA.xml:S1:4960:9	O
occurred	PROMACTA.xml:S1:4970:8	O
in	PROMACTA.xml:S1:4979:2	O
a	PROMACTA.xml:S1:4982:1	O
pattern	PROMACTA.xml:S1:4984:7	O
similar	PROMACTA.xml:S1:4992:7	O
to	PROMACTA.xml:S1:5000:2	O
that	PROMACTA.xml:S1:5003:4	O
seen	PROMACTA.xml:S1:5008:4	O
in	PROMACTA.xml:S1:5013:2	O
the	PROMACTA.xml:S1:5016:3	O
placebo	PROMACTA.xml:S1:5020:7	O
-	PROMACTA.xml:S1:5027:1	O
controlled	PROMACTA.xml:S1:5028:10	O
trials	PROMACTA.xml:S1:5039:6	O
.	PROMACTA.xml:S1:5045:1	O

Table	PROMACTA.xml:S1:5047:5	O
5	PROMACTA.xml:S1:5053:1	O
presents	PROMACTA.xml:S1:5055:8	O
the	PROMACTA.xml:S1:5064:3	O
most	PROMACTA.xml:S1:5068:4	O
common	PROMACTA.xml:S1:5073:6	O
treatment	PROMACTA.xml:S1:5080:9	O
-	PROMACTA.xml:S1:5089:1	O
related	PROMACTA.xml:S1:5090:7	O
adverse	PROMACTA.xml:S1:5098:7	O
reactions	PROMACTA.xml:S1:5106:9	O
(	PROMACTA.xml:S1:5116:1	O
experienced	PROMACTA.xml:S1:5117:11	O
by	PROMACTA.xml:S1:5129:2	O
greater	PROMACTA.xml:S1:5132:7	O
than	PROMACTA.xml:S1:5140:4	O
or	PROMACTA.xml:S1:5145:2	O
equal	PROMACTA.xml:S1:5148:5	O
to	PROMACTA.xml:S1:5154:2	O
3%	PROMACTA.xml:S1:5157:2	O
of	PROMACTA.xml:S1:5160:2	O
patients	PROMACTA.xml:S1:5163:8	O
receiving	PROMACTA.xml:S1:5172:9	O
PROMACTA	PROMACTA.xml:S1:5182:8	O
)	PROMACTA.xml:S1:5190:1	O
from	PROMACTA.xml:S1:5192:4	O
the	PROMACTA.xml:S1:5197:3	O
extension	PROMACTA.xml:S1:5201:9	O
trial	PROMACTA.xml:S1:5211:5	O
.	PROMACTA.xml:S1:5216:1	O

Table	PROMACTA.xml:S1:5222:5	O
5	PROMACTA.xml:S1:5228:1	O
.	PROMACTA.xml:S1:5229:1	O

Treatment	PROMACTA.xml:S1:5231:9	O
-	PROMACTA.xml:S1:5240:1	O
related	PROMACTA.xml:S1:5241:7	O
Adverse	PROMACTA.xml:S1:5249:7	O
Reactions	PROMACTA.xml:S1:5257:9	O
(	PROMACTA.xml:S1:5267:1	O
3%	PROMACTA.xml:S1:5270:2	O
)	PROMACTA.xml:S1:5272:1	O
from	PROMACTA.xml:S1:5274:4	O
Extension	PROMACTA.xml:S1:5279:9	O
Trial	PROMACTA.xml:S1:5289:5	O
in	PROMACTA.xml:S1:5295:2	O
Adults	PROMACTA.xml:S1:5298:6	O
with	PROMACTA.xml:S1:5305:4	O
Chronic	PROMACTA.xml:S1:5310:7	O
Immune	PROMACTA.xml:S1:5318:6	O
(	PROMACTA.xml:S1:5325:1	O
Idiopathic	PROMACTA.xml:S1:5326:10	O
)	PROMACTA.xml:S1:5336:1	O
Thrombocytopenia	PROMACTA.xml:S1:5338:16	O

Adverse	PROMACTA.xml:S1:5358:7	O
Reaction	PROMACTA.xml:S1:5366:8	O
PROMACTA	PROMACTA.xml:S1:5408:8	O
50	PROMACTA.xml:S1:5417:2	O
mg	PROMACTA.xml:S1:5420:2	O
n	PROMACTA.xml:S1:5424:1	O
299	PROMACTA.xml:S1:5428:3	O
(	PROMACTA.xml:S1:5433:1	O
)	PROMACTA.xml:S1:5435:1	O

Headache	PROMACTA.xml:S1:5465:8	B-AdverseReaction
10	PROMACTA.xml:S1:5515:2	O

Hyperbilirubinemia	PROMACTA.xml:S1:5572:18	B-AdverseReaction
6	PROMACTA.xml:S1:5622:1	O

ALT	PROMACTA.xml:S1:5679:3	B-AdverseReaction
increased	PROMACTA.xml:S1:5683:9	I-AdverseReaction
6	PROMACTA.xml:S1:5729:1	O

Cataract	PROMACTA.xml:S1:5786:8	B-AdverseReaction
5	PROMACTA.xml:S1:5836:1	O

AST	PROMACTA.xml:S1:5893:3	B-AdverseReaction
increased	PROMACTA.xml:S1:5897:9	I-AdverseReaction
4	PROMACTA.xml:S1:5943:1	O

Fatigue	PROMACTA.xml:S1:6000:7	B-AdverseReaction
4	PROMACTA.xml:S1:6050:1	O

Nausea	PROMACTA.xml:S1:6107:6	B-AdverseReaction
4	PROMACTA.xml:S1:6157:1	O

In	PROMACTA.xml:S1:6220:2	O
the	PROMACTA.xml:S1:6223:3	O
three	PROMACTA.xml:S1:6227:5	O
controlled	PROMACTA.xml:S1:6233:10	O
chronic	PROMACTA.xml:S1:6244:7	O
ITP	PROMACTA.xml:S1:6252:3	O
trials	PROMACTA.xml:S1:6256:6	O
,	PROMACTA.xml:S1:6262:1	O
serum	PROMACTA.xml:S1:6264:5	B-AdverseReaction
liver	PROMACTA.xml:S1:6270:5	I-AdverseReaction
test	PROMACTA.xml:S1:6276:4	I-AdverseReaction
abnormalities	PROMACTA.xml:S1:6281:13	I-AdverseReaction
(	PROMACTA.xml:S1:6295:1	O
predominantly	PROMACTA.xml:S1:6296:13	O
Grade	PROMACTA.xml:S1:6310:5	B-Severity
2	PROMACTA.xml:S1:6316:1	I-Severity
or	PROMACTA.xml:S1:6318:2	O
less	PROMACTA.xml:S1:6321:4	O
in	PROMACTA.xml:S1:6326:2	O
severity	PROMACTA.xml:S1:6329:8	O
)	PROMACTA.xml:S1:6337:1	O
were	PROMACTA.xml:S1:6339:4	O
reported	PROMACTA.xml:S1:6344:8	O
in	PROMACTA.xml:S1:6353:2	O
11%	PROMACTA.xml:S1:6356:3	O
and	PROMACTA.xml:S1:6360:3	O
7%	PROMACTA.xml:S1:6364:2	O
of	PROMACTA.xml:S1:6367:2	O
patients	PROMACTA.xml:S1:6370:8	O
for	PROMACTA.xml:S1:6379:3	O
PROMACTA	PROMACTA.xml:S1:6383:8	O
and	PROMACTA.xml:S1:6392:3	O
placebo	PROMACTA.xml:S1:6396:7	O
,	PROMACTA.xml:S1:6403:1	O
respectively	PROMACTA.xml:S1:6405:12	O
.	PROMACTA.xml:S1:6417:1	O

Four	PROMACTA.xml:S1:6419:4	O
patients	PROMACTA.xml:S1:6424:8	O
(	PROMACTA.xml:S1:6433:1	O
1%	PROMACTA.xml:S1:6434:2	O
)	PROMACTA.xml:S1:6436:1	O
treated	PROMACTA.xml:S1:6438:7	O
with	PROMACTA.xml:S1:6446:4	O
PROMACTA	PROMACTA.xml:S1:6451:8	O
and	PROMACTA.xml:S1:6460:3	O
three	PROMACTA.xml:S1:6464:5	O
patients	PROMACTA.xml:S1:6470:8	O
in	PROMACTA.xml:S1:6479:2	O
the	PROMACTA.xml:S1:6482:3	O
placebo	PROMACTA.xml:S1:6486:7	O
group	PROMACTA.xml:S1:6494:5	O
(	PROMACTA.xml:S1:6500:1	O
2%	PROMACTA.xml:S1:6501:2	O
)	PROMACTA.xml:S1:6503:1	O
discontinued	PROMACTA.xml:S1:6505:12	O
treatment	PROMACTA.xml:S1:6518:9	O
due	PROMACTA.xml:S1:6528:3	O
to	PROMACTA.xml:S1:6532:2	O
hepatobiliary	PROMACTA.xml:S1:6535:13	B-AdverseReaction
laboratory	PROMACTA.xml:S1:6549:10	I-AdverseReaction
abnormalities	PROMACTA.xml:S1:6560:13	I-AdverseReaction
.	PROMACTA.xml:S1:6573:1	O

Seven	PROMACTA.xml:S1:6575:5	O
of	PROMACTA.xml:S1:6581:2	O
the	PROMACTA.xml:S1:6584:3	O
patients	PROMACTA.xml:S1:6588:8	O
treated	PROMACTA.xml:S1:6597:7	O
with	PROMACTA.xml:S1:6605:4	O
PROMACTA	PROMACTA.xml:S1:6610:8	O
in	PROMACTA.xml:S1:6619:2	O
the	PROMACTA.xml:S1:6622:3	O
controlled	PROMACTA.xml:S1:6626:10	O
trials	PROMACTA.xml:S1:6637:6	O
with	PROMACTA.xml:S1:6644:4	O
hepatobiliary	PROMACTA.xml:S1:6649:13	B-AdverseReaction
laboratory	PROMACTA.xml:S1:6663:10	I-AdverseReaction
abnormalities	PROMACTA.xml:S1:6674:13	I-AdverseReaction
were	PROMACTA.xml:S1:6688:4	O
re	PROMACTA.xml:S1:6693:2	O
-	PROMACTA.xml:S1:6695:1	O
exposed	PROMACTA.xml:S1:6696:7	O
to	PROMACTA.xml:S1:6704:2	O
PROMACTA	PROMACTA.xml:S1:6707:8	O
in	PROMACTA.xml:S1:6716:2	O
the	PROMACTA.xml:S1:6719:3	O
extension	PROMACTA.xml:S1:6723:9	O
trial	PROMACTA.xml:S1:6733:5	O
.	PROMACTA.xml:S1:6738:1	O

Six	PROMACTA.xml:S1:6740:3	O
of	PROMACTA.xml:S1:6744:2	O
these	PROMACTA.xml:S1:6747:5	O
patients	PROMACTA.xml:S1:6753:8	O
again	PROMACTA.xml:S1:6762:5	O
experienced	PROMACTA.xml:S1:6768:11	O
liver	PROMACTA.xml:S1:6780:5	B-AdverseReaction
test	PROMACTA.xml:S1:6786:4	I-AdverseReaction
abnormalities	PROMACTA.xml:S1:6791:13	I-AdverseReaction
(	PROMACTA.xml:S1:6805:1	O
predominantly	PROMACTA.xml:S1:6806:13	O
Grade	PROMACTA.xml:S1:6820:5	B-Severity
1	PROMACTA.xml:S1:6826:1	I-Severity
)	PROMACTA.xml:S1:6827:1	O
resulting	PROMACTA.xml:S1:6829:9	O
in	PROMACTA.xml:S1:6839:2	O
discontinuation	PROMACTA.xml:S1:6842:15	O
of	PROMACTA.xml:S1:6858:2	O
PROMACTA	PROMACTA.xml:S1:6861:8	O
in	PROMACTA.xml:S1:6870:2	O
one	PROMACTA.xml:S1:6873:3	O
patient	PROMACTA.xml:S1:6877:7	O
.	PROMACTA.xml:S1:6884:1	O

In	PROMACTA.xml:S1:6886:2	O
the	PROMACTA.xml:S1:6889:3	O
extension	PROMACTA.xml:S1:6893:9	O
chronic	PROMACTA.xml:S1:6903:7	O
ITP	PROMACTA.xml:S1:6911:3	O
trial	PROMACTA.xml:S1:6915:5	O
,	PROMACTA.xml:S1:6920:1	O
one	PROMACTA.xml:S1:6922:3	O
additional	PROMACTA.xml:S1:6926:10	O
patient	PROMACTA.xml:S1:6937:7	O
had	PROMACTA.xml:S1:6945:3	O
PROMACTA	PROMACTA.xml:S1:6949:8	O
discontinued	PROMACTA.xml:S1:6958:12	O
due	PROMACTA.xml:S1:6971:3	O
to	PROMACTA.xml:S1:6975:2	O
liver	PROMACTA.xml:S1:6978:5	B-AdverseReaction
test	PROMACTA.xml:S1:6984:4	I-AdverseReaction
abnormalities	PROMACTA.xml:S1:6989:13	I-AdverseReaction
(	PROMACTA.xml:S1:7003:1	O
less	PROMACTA.xml:S1:7004:4	O
than	PROMACTA.xml:S1:7009:4	O
or	PROMACTA.xml:S1:7014:2	O
equal	PROMACTA.xml:S1:7017:5	O
to	PROMACTA.xml:S1:7023:2	O
Grade	PROMACTA.xml:S1:7026:5	B-Severity
3	PROMACTA.xml:S1:7032:1	I-Severity
)	PROMACTA.xml:S1:7033:1	O
.	PROMACTA.xml:S1:7034:1	O

In	PROMACTA.xml:S1:7040:2	O

a	PROMACTA.xml:S1:7043:1	O
placebo	PROMACTA.xml:S1:7045:7	O
-	PROMACTA.xml:S1:7052:1	O
controlled	PROMACTA.xml:S1:7053:10	O
trial	PROMACTA.xml:S1:7064:5	O
of	PROMACTA.xml:S1:7070:2	O
PROMACTA	PROMACTA.xml:S1:7073:8	O
in	PROMACTA.xml:S1:7082:2	O
patients	PROMACTA.xml:S1:7085:8	O
with	PROMACTA.xml:S1:7094:4	O
chronic	PROMACTA.xml:S1:7099:7	O
liver	PROMACTA.xml:S1:7107:5	O
diseaseand	PROMACTA.xml:S1:7113:10	O
thrombocytopenia	PROMACTA.xml:S1:7124:16	O
not	PROMACTA.xml:S1:7141:3	O
related	PROMACTA.xml:S1:7145:7	O
to	PROMACTA.xml:S1:7153:2	O
ITP	PROMACTA.xml:S1:7156:3	O
,	PROMACTA.xml:S1:7159:1	O
six	PROMACTA.xml:S1:7161:3	O
patients	PROMACTA.xml:S1:7165:8	O
treated	PROMACTA.xml:S1:7174:7	O
with	PROMACTA.xml:S1:7182:4	O
PROMACTA	PROMACTA.xml:S1:7187:8	O
and	PROMACTA.xml:S1:7196:3	O
one	PROMACTA.xml:S1:7200:3	O
patient	PROMACTA.xml:S1:7204:7	O
in	PROMACTA.xml:S1:7212:2	O
the	PROMACTA.xml:S1:7215:3	O
placebo	PROMACTA.xml:S1:7219:7	O
group	PROMACTA.xml:S1:7227:5	O
developed	PROMACTA.xml:S1:7233:9	O
portal	PROMACTA.xml:S1:7243:6	B-AdverseReaction
vein	PROMACTA.xml:S1:7250:4	I-AdverseReaction
thromboses	PROMACTA.xml:S1:7255:10	I-AdverseReaction
[	PROMACTA.xml:S1:7267:1	O
see	PROMACTA.xml:S1:7268:3	O
Warnings	PROMACTA.xml:S1:7272:8	O
and	PROMACTA.xml:S1:7281:3	O
Precautions	PROMACTA.xml:S1:7285:11	O
(	PROMACTA.xml:S1:7297:1	O
5.3	PROMACTA.xml:S1:7298:3	O
)]	PROMACTA.xml:S1:7301:2	O
.	PROMACTA.xml:S1:7305:1	O

Pediatric	PROMACTA.xml:S1:7313:9	O
Patients	PROMACTA.xml:S1:7323:8	O
:	PROMACTA.xml:S1:7331:1	O
The	PROMACTA.xml:S1:7334:3	O
data	PROMACTA.xml:S1:7338:4	O
described	PROMACTA.xml:S1:7343:9	O
below	PROMACTA.xml:S1:7353:5	O
reflect	PROMACTA.xml:S1:7359:7	O
median	PROMACTA.xml:S1:7367:6	O
exposure	PROMACTA.xml:S1:7374:8	O
to	PROMACTA.xml:S1:7383:2	O
PROMACTA	PROMACTA.xml:S1:7386:8	O
of	PROMACTA.xml:S1:7395:2	O
91	PROMACTA.xml:S1:7398:2	O
days	PROMACTA.xml:S1:7401:4	O
for	PROMACTA.xml:S1:7406:3	O
82	PROMACTA.xml:S1:7410:2	O
pediatric	PROMACTA.xml:S1:7413:9	O
patients	PROMACTA.xml:S1:7423:8	O
(	PROMACTA.xml:S1:7432:1	O
aged	PROMACTA.xml:S1:7433:4	O
6	PROMACTA.xml:S1:7438:1	O
to	PROMACTA.xml:S1:7440:2	O
17	PROMACTA.xml:S1:7443:2	O
years	PROMACTA.xml:S1:7446:5	O
)	PROMACTA.xml:S1:7451:1	O
with	PROMACTA.xml:S1:7453:4	O
chronic	PROMACTA.xml:S1:7458:7	O
ITP	PROMACTA.xml:S1:7466:3	O
,	PROMACTA.xml:S1:7469:1	O
of	PROMACTA.xml:S1:7471:2	O
whom	PROMACTA.xml:S1:7474:4	O
52%	PROMACTA.xml:S1:7479:3	O
were	PROMACTA.xml:S1:7483:4	O
female	PROMACTA.xml:S1:7488:6	O
,	PROMACTA.xml:S1:7494:1	O
across	PROMACTA.xml:S1:7496:6	O
the	PROMACTA.xml:S1:7503:3	O
randomized	PROMACTA.xml:S1:7507:10	O
phase	PROMACTA.xml:S1:7518:5	O
of	PROMACTA.xml:S1:7524:2	O
two	PROMACTA.xml:S1:7527:3	O
placebo	PROMACTA.xml:S1:7531:7	O
-	PROMACTA.xml:S1:7538:1	O
controlled	PROMACTA.xml:S1:7539:10	O
trials	PROMACTA.xml:S1:7550:6	O
.	PROMACTA.xml:S1:7556:1	O

Table	PROMACTA.xml:S1:7562:5	O
6	PROMACTA.xml:S1:7568:1	O
presents	PROMACTA.xml:S1:7570:8	O
the	PROMACTA.xml:S1:7579:3	O
most	PROMACTA.xml:S1:7583:4	O
common	PROMACTA.xml:S1:7588:6	O
adverse	PROMACTA.xml:S1:7595:7	O
drug	PROMACTA.xml:S1:7603:4	O
reactions	PROMACTA.xml:S1:7608:9	O
(	PROMACTA.xml:S1:7618:1	O
experienced	PROMACTA.xml:S1:7619:11	O
by	PROMACTA.xml:S1:7631:2	O
greater	PROMACTA.xml:S1:7634:7	O
than	PROMACTA.xml:S1:7642:4	O
or	PROMACTA.xml:S1:7647:2	O
equal	PROMACTA.xml:S1:7650:5	O
to	PROMACTA.xml:S1:7656:2	O
3%	PROMACTA.xml:S1:7659:2	O
of	PROMACTA.xml:S1:7662:2	O
pediatric	PROMACTA.xml:S1:7665:9	O
patients	PROMACTA.xml:S1:7675:8	O
6	PROMACTA.xml:S1:7684:1	O
years	PROMACTA.xml:S1:7686:5	O
and	PROMACTA.xml:S1:7692:3	O
older	PROMACTA.xml:S1:7696:5	O
receiving	PROMACTA.xml:S1:7702:9	O
PROMACTA	PROMACTA.xml:S1:7712:8	O
)	PROMACTA.xml:S1:7720:1	O
across	PROMACTA.xml:S1:7722:6	O
the	PROMACTA.xml:S1:7729:3	O
two	PROMACTA.xml:S1:7733:3	O
placebo	PROMACTA.xml:S1:7737:7	O
-	PROMACTA.xml:S1:7744:1	O
controlled	PROMACTA.xml:S1:7745:10	O
trials	PROMACTA.xml:S1:7756:6	O
,	PROMACTA.xml:S1:7762:1	O
with	PROMACTA.xml:S1:7764:4	O
a	PROMACTA.xml:S1:7769:1	O
higher	PROMACTA.xml:S1:7771:6	O
incidence	PROMACTA.xml:S1:7778:9	O
for	PROMACTA.xml:S1:7788:3	O
PROMACTA	PROMACTA.xml:S1:7792:8	O
versus	PROMACTA.xml:S1:7801:6	O
placebo	PROMACTA.xml:S1:7808:7	O
.	PROMACTA.xml:S1:7815:1	O

Table	PROMACTA.xml:S1:7821:5	O
6	PROMACTA.xml:S1:7827:1	O
.	PROMACTA.xml:S1:7828:1	O

Adverse	PROMACTA.xml:S1:7830:7	O
Reactions	PROMACTA.xml:S1:7838:9	O
(	PROMACTA.xml:S1:7848:1	O
3%	PROMACTA.xml:S1:7851:2	O
)	PROMACTA.xml:S1:7853:1	O
with	PROMACTA.xml:S1:7855:4	O
a	PROMACTA.xml:S1:7860:1	O
Higher	PROMACTA.xml:S1:7862:6	O
Incidence	PROMACTA.xml:S1:7869:9	O
for	PROMACTA.xml:S1:7879:3	O
PROMACTA	PROMACTA.xml:S1:7883:8	O
versus	PROMACTA.xml:S1:7892:6	O
Placebo	PROMACTA.xml:S1:7899:7	O
from	PROMACTA.xml:S1:7907:4	O
Two	PROMACTA.xml:S1:7912:3	O
Placebo	PROMACTA.xml:S1:7916:7	O
-	PROMACTA.xml:S1:7923:1	O
controlled	PROMACTA.xml:S1:7924:10	O
Trials	PROMACTA.xml:S1:7935:6	O
in	PROMACTA.xml:S1:7942:2	O
Pediatric	PROMACTA.xml:S1:7945:9	O
Patients	PROMACTA.xml:S1:7955:8	O
6	PROMACTA.xml:S1:7964:1	O
Years	PROMACTA.xml:S1:7966:5	O
and	PROMACTA.xml:S1:7972:3	O
Older	PROMACTA.xml:S1:7976:5	O
with	PROMACTA.xml:S1:7982:4	O
Chronic	PROMACTA.xml:S1:7987:7	O
Immune	PROMACTA.xml:S1:7995:6	O
(	PROMACTA.xml:S1:8002:1	O
Idiopathic	PROMACTA.xml:S1:8003:10	O
)	PROMACTA.xml:S1:8013:1	O
Thrombocytopenia	PROMACTA.xml:S1:8015:16	O

PROMACTA	PROMACTA.xml:S1:8076:8	O
Placebo	PROMACTA.xml:S1:8109:7	O

n	PROMACTA.xml:S1:8186:1	O
82	PROMACTA.xml:S1:8190:2	O
n	PROMACTA.xml:S1:8219:1	O
40	PROMACTA.xml:S1:8223:2	O

Adverse	PROMACTA.xml:S1:8255:7	O
Reaction	PROMACTA.xml:S1:8263:8	O
(	PROMACTA.xml:S1:8296:1	O
)	PROMACTA.xml:S1:8298:1	O
(	PROMACTA.xml:S1:8329:1	O
)	PROMACTA.xml:S1:8331:1	O

Upper	PROMACTA.xml:S1:8365:5	B-AdverseReaction
respiratory	PROMACTA.xml:S1:8371:11	I-AdverseReaction
tract	PROMACTA.xml:S1:8383:5	I-AdverseReaction
infection	PROMACTA.xml:S1:8389:9	I-AdverseReaction
16	PROMACTA.xml:S1:8406:2	O
5	PROMACTA.xml:S1:8439:1	O

Nasopharyngitis	PROMACTA.xml:S1:8475:15	B-AdverseReaction
12	PROMACTA.xml:S1:8516:2	O
5	PROMACTA.xml:S1:8549:1	O

Rhinitis	PROMACTA.xml:S1:8585:8	B-AdverseReaction
11	PROMACTA.xml:S1:8626:2	O
8	PROMACTA.xml:S1:8659:1	O

Abdominal	PROMACTA.xml:S1:8695:9	B-AdverseReaction
pain	PROMACTA.xml:S1:8705:4	I-AdverseReaction
9	PROMACTA.xml:S1:8736:1	O
5	PROMACTA.xml:S1:8769:1	O

Cough	PROMACTA.xml:S1:8805:5	B-AdverseReaction
9	PROMACTA.xml:S1:8846:1	O
0	PROMACTA.xml:S1:8879:1	O

Oropharyngeal	PROMACTA.xml:S1:8915:13	B-AdverseReaction
pain	PROMACTA.xml:S1:8929:4	I-AdverseReaction
9	PROMACTA.xml:S1:8956:1	O
3	PROMACTA.xml:S1:8989:1	O

Toothache	PROMACTA.xml:S1:9025:9	B-AdverseReaction
6	PROMACTA.xml:S1:9066:1	O
0	PROMACTA.xml:S1:9099:1	O

AST	PROMACTA.xml:S1:9135:3	B-AdverseReaction
increased	PROMACTA.xml:S1:9139:9	I-AdverseReaction
5	PROMACTA.xml:S1:9176:1	O
0	PROMACTA.xml:S1:9209:1	O

Diarrhea	PROMACTA.xml:S1:9245:8	B-AdverseReaction
5	PROMACTA.xml:S1:9286:1	O
3	PROMACTA.xml:S1:9319:1	O

Rash	PROMACTA.xml:S1:9355:4	B-AdverseReaction
5	PROMACTA.xml:S1:9396:1	O
3	PROMACTA.xml:S1:9429:1	O

ALT	PROMACTA.xml:S1:9465:3	B-AdverseReaction
increaseda	PROMACTA.xml:S1:9469:10	I-AdverseReaction
6	PROMACTA.xml:S1:9506:1	O
0	PROMACTA.xml:S1:9539:1	O

Vitamin	PROMACTA.xml:S1:9575:7	B-AdverseReaction
D	PROMACTA.xml:S1:9583:1	I-AdverseReaction
deficiency	PROMACTA.xml:S1:9585:10	I-AdverseReaction
4	PROMACTA.xml:S1:9616:1	O
0	PROMACTA.xml:S1:9649:1	O

a	PROMACTA.xml:S1:9699:1	O
Includes	PROMACTA.xml:S1:9702:8	O
adverse	PROMACTA.xml:S1:9711:7	O
reactions	PROMACTA.xml:S1:9719:9	O
or	PROMACTA.xml:S1:9729:2	O
laboratory	PROMACTA.xml:S1:9732:10	O
abnormalities	PROMACTA.xml:S1:9743:13	O
3	PROMACTA.xml:S1:9758:1	O
x	PROMACTA.xml:S1:9760:1	O
ULN	PROMACTA.xml:S1:9762:3	O
.	PROMACTA.xml:S1:9765:1	O

Chronic	PROMACTA.xml:S1:9774:7	O
Hepatitis	PROMACTA.xml:S1:9782:9	O
C	PROMACTA.xml:S1:9792:1	O
-	PROMACTA.xml:S1:9793:1	O
associated	PROMACTA.xml:S1:9794:10	O
Thrombocytopenia	PROMACTA.xml:S1:9805:16	O
:	PROMACTA.xml:S1:9821:1	O
In	PROMACTA.xml:S1:9824:2	O
the	PROMACTA.xml:S1:9827:3	O
two	PROMACTA.xml:S1:9831:3	O
placebo	PROMACTA.xml:S1:9835:7	O
-	PROMACTA.xml:S1:9842:1	O
controlled	PROMACTA.xml:S1:9843:10	O
trials	PROMACTA.xml:S1:9854:6	O
,	PROMACTA.xml:S1:9860:1	O
955	PROMACTA.xml:S1:9862:3	O
patients	PROMACTA.xml:S1:9866:8	O
with	PROMACTA.xml:S1:9875:4	O
chronic	PROMACTA.xml:S1:9880:7	O
hepatitis	PROMACTA.xml:S1:9888:9	O
C	PROMACTA.xml:S1:9898:1	O
-	PROMACTA.xml:S1:9899:1	O
associated	PROMACTA.xml:S1:9900:10	O
thrombocytopenia	PROMACTA.xml:S1:9911:16	O
received	PROMACTA.xml:S1:9928:8	O
PROMACTA	PROMACTA.xml:S1:9937:8	O
.	PROMACTA.xml:S1:9945:1	O

Table	PROMACTA.xml:S1:9947:5	O
7	PROMACTA.xml:S1:9953:1	O
presents	PROMACTA.xml:S1:9955:8	O
the	PROMACTA.xml:S1:9964:3	O
most	PROMACTA.xml:S1:9968:4	O
common	PROMACTA.xml:S1:9973:6	O
adverse	PROMACTA.xml:S1:9980:7	O
drug	PROMACTA.xml:S1:9988:4	O
reactions	PROMACTA.xml:S1:9993:9	O
(	PROMACTA.xml:S1:10003:1	O
experienced	PROMACTA.xml:S1:10004:11	O
by	PROMACTA.xml:S1:10016:2	O
greater	PROMACTA.xml:S1:10019:7	O
than	PROMACTA.xml:S1:10027:4	O
or	PROMACTA.xml:S1:10032:2	O
equal	PROMACTA.xml:S1:10035:5	O
to	PROMACTA.xml:S1:10041:2	O
10%	PROMACTA.xml:S1:10044:3	O
of	PROMACTA.xml:S1:10048:2	O
patients	PROMACTA.xml:S1:10051:8	O
receiving	PROMACTA.xml:S1:10060:9	O
PROMACTA	PROMACTA.xml:S1:10070:8	O
compared	PROMACTA.xml:S1:10079:8	O
with	PROMACTA.xml:S1:10088:4	O
placebo	PROMACTA.xml:S1:10093:7	O
)	PROMACTA.xml:S1:10100:1	O
.	PROMACTA.xml:S1:10101:1	O

Table	PROMACTA.xml:S1:10107:5	O

7	PROMACTA.xml:S1:10113:1	O
.	PROMACTA.xml:S1:10114:1	O

Adverse	PROMACTA.xml:S1:10116:7	O
Reactions	PROMACTA.xml:S1:10124:9	O
(	PROMACTA.xml:S1:10134:1	O
10%	PROMACTA.xml:S1:10137:3	O
and	PROMACTA.xml:S1:10141:3	O
Greater	PROMACTA.xml:S1:10145:7	O
than	PROMACTA.xml:S1:10153:4	O
Placebo	PROMACTA.xml:S1:10158:7	O
)	PROMACTA.xml:S1:10165:1	O
from	PROMACTA.xml:S1:10167:4	O
Two	PROMACTA.xml:S1:10172:3	O
Placebo	PROMACTA.xml:S1:10176:7	O
-	PROMACTA.xml:S1:10183:1	O
controlled	PROMACTA.xml:S1:10184:10	O
Trials	PROMACTA.xml:S1:10195:6	O
in	PROMACTA.xml:S1:10202:2	O
Adults	PROMACTA.xml:S1:10205:6	O
with	PROMACTA.xml:S1:10212:4	O
Chronic	PROMACTA.xml:S1:10217:7	O
Hepatitis	PROMACTA.xml:S1:10225:9	O
C	PROMACTA.xml:S1:10235:1	O

Adverse	PROMACTA.xml:S1:10240:7	O
Reaction	PROMACTA.xml:S1:10248:8	O
PROMACTA	PROMACTA.xml:S1:10270:8	O
Peginterferon	PROMACTA.xml:S1:10282:13	O
Ribavirin	PROMACTA.xml:S1:10296:9	O
n	PROMACTA.xml:S1:10307:1	O
955	PROMACTA.xml:S1:10311:3	O
(	PROMACTA.xml:S1:10316:1	O
)	PROMACTA.xml:S1:10318:1	O
Placebo	PROMACTA.xml:S1:10323:7	O
Peginterferon	PROMACTA.xml:S1:10334:13	O
Ribavirin	PROMACTA.xml:S1:10348:9	O
n	PROMACTA.xml:S1:10359:1	O
484	PROMACTA.xml:S1:10363:3	O
(	PROMACTA.xml:S1:10368:1	O
)	PROMACTA.xml:S1:10370:1	O

Anemia	PROMACTA.xml:S1:10378:6	B-AdverseReaction
40	PROMACTA.xml:S1:10408:2	O
35	PROMACTA.xml:S1:10446:2	O

Pyrexia	PROMACTA.xml:S1:10487:7	B-AdverseReaction
30	PROMACTA.xml:S1:10517:2	O
24	PROMACTA.xml:S1:10555:2	O

Fatigue	PROMACTA.xml:S1:10596:7	B-AdverseReaction
28	PROMACTA.xml:S1:10626:2	O
23	PROMACTA.xml:S1:10664:2	O

Headache	PROMACTA.xml:S1:10705:8	B-AdverseReaction
21	PROMACTA.xml:S1:10735:2	O
20	PROMACTA.xml:S1:10773:2	O

Nausea	PROMACTA.xml:S1:10814:6	B-AdverseReaction
19	PROMACTA.xml:S1:10844:2	O
14	PROMACTA.xml:S1:10882:2	O

Diarrhea	PROMACTA.xml:S1:10923:8	B-AdverseReaction
19	PROMACTA.xml:S1:10953:2	O
11	PROMACTA.xml:S1:10991:2	O

Decreased	PROMACTA.xml:S1:11032:9	B-AdverseReaction
appetite	PROMACTA.xml:S1:11042:8	I-AdverseReaction
18	PROMACTA.xml:S1:11062:2	O
14	PROMACTA.xml:S1:11100:2	O

Influenza	PROMACTA.xml:S1:11141:9	B-AdverseReaction
-	PROMACTA.xml:S1:11150:1	I-AdverseReaction
like	PROMACTA.xml:S1:11151:4	I-AdverseReaction
illness	PROMACTA.xml:S1:11156:7	I-AdverseReaction
18	PROMACTA.xml:S1:11171:2	O
16	PROMACTA.xml:S1:11209:2	O

Asthenia	PROMACTA.xml:S1:11250:8	B-AdverseReaction
16	PROMACTA.xml:S1:11280:2	O
13	PROMACTA.xml:S1:11318:2	O

Insomnia	PROMACTA.xml:S1:11359:8	B-AdverseReaction
16	PROMACTA.xml:S1:11389:2	O
15	PROMACTA.xml:S1:11427:2	O

Cough	PROMACTA.xml:S1:11468:5	B-AdverseReaction
15	PROMACTA.xml:S1:11498:2	O
12	PROMACTA.xml:S1:11536:2	O

Pruritus	PROMACTA.xml:S1:11577:8	B-AdverseReaction
15	PROMACTA.xml:S1:11607:2	O
13	PROMACTA.xml:S1:11645:2	O

Chills	PROMACTA.xml:S1:11686:6	B-AdverseReaction
14	PROMACTA.xml:S1:11716:2	O
9	PROMACTA.xml:S1:11754:1	O

Myalgia	PROMACTA.xml:S1:11795:7	B-AdverseReaction
12	PROMACTA.xml:S1:11825:2	O
10	PROMACTA.xml:S1:11863:2	O

Alopecia	PROMACTA.xml:S1:11904:8	B-AdverseReaction
10	PROMACTA.xml:S1:11934:2	O
6	PROMACTA.xml:S1:11972:1	O

Peripheral	PROMACTA.xml:S1:12013:10	B-AdverseReaction
edema	PROMACTA.xml:S1:12024:5	I-AdverseReaction
10	PROMACTA.xml:S1:12043:2	O
5	PROMACTA.xml:S1:12081:1	O

In	PROMACTA.xml:S1:12129:2	O
the	PROMACTA.xml:S1:12132:3	O
two	PROMACTA.xml:S1:12136:3	O
controlled	PROMACTA.xml:S1:12140:10	O
clinical	PROMACTA.xml:S1:12151:8	O
trials	PROMACTA.xml:S1:12160:6	O
in	PROMACTA.xml:S1:12167:2	O
patients	PROMACTA.xml:S1:12170:8	O
with	PROMACTA.xml:S1:12179:4	O
chronic	PROMACTA.xml:S1:12184:7	O
hepatitis	PROMACTA.xml:S1:12192:9	O
C	PROMACTA.xml:S1:12202:1	O
,	PROMACTA.xml:S1:12203:1	O
hyperbilirubinemia	PROMACTA.xml:S1:12205:18	B-AdverseReaction
was	PROMACTA.xml:S1:12224:3	O
reported	PROMACTA.xml:S1:12228:8	O
in	PROMACTA.xml:S1:12237:2	O
8%	PROMACTA.xml:S1:12240:2	O
of	PROMACTA.xml:S1:12243:2	O
patients	PROMACTA.xml:S1:12246:8	O
receiving	PROMACTA.xml:S1:12255:9	O
PROMACTA	PROMACTA.xml:S1:12265:8	O
compared	PROMACTA.xml:S1:12274:8	O
with	PROMACTA.xml:S1:12283:4	O
3%	PROMACTA.xml:S1:12288:2	O
for	PROMACTA.xml:S1:12291:3	O
placebo	PROMACTA.xml:S1:12295:7	O
.	PROMACTA.xml:S1:12302:1	O

Total	PROMACTA.xml:S1:12304:5	B-AdverseReaction
bilirubin	PROMACTA.xml:S1:12310:9	I-AdverseReaction
greater	PROMACTA.xml:S1:12320:7	I-AdverseReaction
than	PROMACTA.xml:S1:12328:4	I-AdverseReaction
or	PROMACTA.xml:S1:12333:2	I-AdverseReaction
equal	PROMACTA.xml:S1:12336:5	I-AdverseReaction
to	PROMACTA.xml:S1:12342:2	I-AdverseReaction
1.5	PROMACTA.xml:S1:12345:3	I-AdverseReaction
x	PROMACTA.xml:S1:12349:1	I-AdverseReaction
ULN	PROMACTA.xml:S1:12351:3	I-AdverseReaction
was	PROMACTA.xml:S1:12355:3	O
reported	PROMACTA.xml:S1:12359:8	O
in	PROMACTA.xml:S1:12368:2	O
76%	PROMACTA.xml:S1:12371:3	O
and	PROMACTA.xml:S1:12375:3	O
50%	PROMACTA.xml:S1:12379:3	O
of	PROMACTA.xml:S1:12383:2	O
patients	PROMACTA.xml:S1:12386:8	O
receiving	PROMACTA.xml:S1:12395:9	O
PROMACTA	PROMACTA.xml:S1:12405:8	O
and	PROMACTA.xml:S1:12414:3	O
placebo	PROMACTA.xml:S1:12418:7	O
,	PROMACTA.xml:S1:12425:1	O
respectively	PROMACTA.xml:S1:12427:12	O
.	PROMACTA.xml:S1:12439:1	O

ALT	PROMACTA.xml:S1:12441:3	B-AdverseReaction
or	PROMACTA.xml:S1:12445:2	O
AST	PROMACTA.xml:S1:12448:3	B-AdverseReaction
greater	PROMACTA.xml:S1:12452:7	I-AdverseReaction
than	PROMACTA.xml:S1:12460:4	I-AdverseReaction
or	PROMACTA.xml:S1:12465:2	I-AdverseReaction
equal	PROMACTA.xml:S1:12468:5	I-AdverseReaction
to	PROMACTA.xml:S1:12474:2	I-AdverseReaction
3	PROMACTA.xml:S1:12477:1	I-AdverseReaction
x	PROMACTA.xml:S1:12479:1	I-AdverseReaction
ULN	PROMACTA.xml:S1:12481:3	I-AdverseReaction
was	PROMACTA.xml:S1:12485:3	O
reported	PROMACTA.xml:S1:12489:8	O
in	PROMACTA.xml:S1:12498:2	O
34%	PROMACTA.xml:S1:12501:3	O
and	PROMACTA.xml:S1:12505:3	O
38%	PROMACTA.xml:S1:12509:3	O
of	PROMACTA.xml:S1:12513:2	O
patients	PROMACTA.xml:S1:12516:8	O
for	PROMACTA.xml:S1:12525:3	O
PROMACTA	PROMACTA.xml:S1:12529:8	O
and	PROMACTA.xml:S1:12538:3	O
placebo	PROMACTA.xml:S1:12542:7	O
,	PROMACTA.xml:S1:12549:1	O
respectively	PROMACTA.xml:S1:12551:12	O
.	PROMACTA.xml:S1:12563:1	O

Severe	PROMACTA.xml:S1:12571:6	O

Aplastic	PROMACTA.xml:S1:12578:8	O
Anemia	PROMACTA.xml:S1:12587:6	O
:	PROMACTA.xml:S1:12593:1	O
In	PROMACTA.xml:S1:12596:2	O
the	PROMACTA.xml:S1:12599:3	O
single	PROMACTA.xml:S1:12603:6	O
-	PROMACTA.xml:S1:12609:1	O
arm	PROMACTA.xml:S1:12610:3	O
,	PROMACTA.xml:S1:12613:1	O
open	PROMACTA.xml:S1:12615:4	O
-	PROMACTA.xml:S1:12619:1	O
label	PROMACTA.xml:S1:12620:5	O
trial	PROMACTA.xml:S1:12626:5	O
,	PROMACTA.xml:S1:12631:1	O
43	PROMACTA.xml:S1:12633:2	O
patients	PROMACTA.xml:S1:12636:8	O
with	PROMACTA.xml:S1:12645:4	O
severe	PROMACTA.xml:S1:12650:6	O
aplastic	PROMACTA.xml:S1:12657:8	O
anemia	PROMACTA.xml:S1:12666:6	O
received	PROMACTA.xml:S1:12673:8	O
PROMACTA	PROMACTA.xml:S1:12682:8	O
.	PROMACTA.xml:S1:12690:1	O

Eleven	PROMACTA.xml:S1:12692:6	O
patients	PROMACTA.xml:S1:12699:8	O
(	PROMACTA.xml:S1:12708:1	O
26%	PROMACTA.xml:S1:12709:3	O
)	PROMACTA.xml:S1:12712:1	O
were	PROMACTA.xml:S1:12714:4	O
treated	PROMACTA.xml:S1:12719:7	O
for	PROMACTA.xml:S1:12727:3	O
greater	PROMACTA.xml:S1:12731:7	O
than	PROMACTA.xml:S1:12739:4	O
6	PROMACTA.xml:S1:12744:1	O
months	PROMACTA.xml:S1:12746:6	O
and	PROMACTA.xml:S1:12753:3	O
7	PROMACTA.xml:S1:12757:1	O
patients	PROMACTA.xml:S1:12759:8	O
(	PROMACTA.xml:S1:12768:1	O
16%	PROMACTA.xml:S1:12769:3	O
)	PROMACTA.xml:S1:12772:1	O
were	PROMACTA.xml:S1:12774:4	O
treated	PROMACTA.xml:S1:12779:7	O
for	PROMACTA.xml:S1:12787:3	O
greater	PROMACTA.xml:S1:12791:7	O
than	PROMACTA.xml:S1:12799:4	O
1	PROMACTA.xml:S1:12804:1	O
year	PROMACTA.xml:S1:12806:4	O
.	PROMACTA.xml:S1:12810:1	O

The	PROMACTA.xml:S1:12812:3	O
most	PROMACTA.xml:S1:12816:4	O
common	PROMACTA.xml:S1:12821:6	O
adverse	PROMACTA.xml:S1:12828:7	O
reactions	PROMACTA.xml:S1:12836:9	O
(	PROMACTA.xml:S1:12846:1	O
greater	PROMACTA.xml:S1:12847:7	O
than	PROMACTA.xml:S1:12855:4	O
or	PROMACTA.xml:S1:12860:2	O
equal	PROMACTA.xml:S1:12863:5	O
to	PROMACTA.xml:S1:12869:2	O
20%	PROMACTA.xml:S1:12872:3	O
)	PROMACTA.xml:S1:12875:1	O
were	PROMACTA.xml:S1:12877:4	O
nausea	PROMACTA.xml:S1:12882:6	B-AdverseReaction
,	PROMACTA.xml:S1:12888:1	O
fatigue	PROMACTA.xml:S1:12890:7	B-AdverseReaction
,	PROMACTA.xml:S1:12897:1	O
cough	PROMACTA.xml:S1:12899:5	B-AdverseReaction
,	PROMACTA.xml:S1:12904:1	O
diarrhea	PROMACTA.xml:S1:12906:8	B-AdverseReaction
,	PROMACTA.xml:S1:12914:1	O
and	PROMACTA.xml:S1:12916:3	O
headache	PROMACTA.xml:S1:12920:8	B-AdverseReaction
.	PROMACTA.xml:S1:12928:1	O

Table	PROMACTA.xml:S1:12934:5	O
8	PROMACTA.xml:S1:12940:1	O
.	PROMACTA.xml:S1:12941:1	O

Adverse	PROMACTA.xml:S1:12943:7	O
Reactions	PROMACTA.xml:S1:12951:9	O
(	PROMACTA.xml:S1:12961:1	O
10%	PROMACTA.xml:S1:12964:3	O
)	PROMACTA.xml:S1:12967:1	O
from	PROMACTA.xml:S1:12969:4	O
One	PROMACTA.xml:S1:12974:3	O
Open	PROMACTA.xml:S1:12978:4	O
-	PROMACTA.xml:S1:12982:1	O
label	PROMACTA.xml:S1:12983:5	O
Trial	PROMACTA.xml:S1:12989:5	O
in	PROMACTA.xml:S1:12995:2	O
Adults	PROMACTA.xml:S1:12998:6	O
with	PROMACTA.xml:S1:13005:4	O
Severe	PROMACTA.xml:S1:13010:6	O
Aplastic	PROMACTA.xml:S1:13017:8	O
Anemia	PROMACTA.xml:S1:13026:6	O

Adverse	PROMACTA.xml:S1:13036:7	O
Reaction	PROMACTA.xml:S1:13044:8	O
PROMACTA	PROMACTA.xml:S1:13099:8	O
(	PROMACTA.xml:S1:13109:1	O
n	PROMACTA.xml:S1:13110:1	O
43	PROMACTA.xml:S1:13114:2	O
)	PROMACTA.xml:S1:13116:1	O
(	PROMACTA.xml:S1:13119:1	O
)	PROMACTA.xml:S1:13121:1	O

Nausea	PROMACTA.xml:S1:13143:6	B-AdverseReaction
33	PROMACTA.xml:S1:13206:2	O

Fatigue	PROMACTA.xml:S1:13250:7	B-AdverseReaction
28	PROMACTA.xml:S1:13313:2	O

Cough	PROMACTA.xml:S1:13357:5	B-AdverseReaction
23	PROMACTA.xml:S1:13420:2	O

Diarrhea	PROMACTA.xml:S1:13464:8	B-AdverseReaction
21	PROMACTA.xml:S1:13527:2	O

Headache	PROMACTA.xml:S1:13571:8	B-AdverseReaction
21	PROMACTA.xml:S1:13634:2	O

Pain	PROMACTA.xml:S1:13678:4	B-AdverseReaction
in	PROMACTA.xml:S1:13683:2	I-AdverseReaction
extremity	PROMACTA.xml:S1:13686:9	I-AdverseReaction
19	PROMACTA.xml:S1:13741:2	O

Dyspnea	PROMACTA.xml:S1:13785:7	B-AdverseReaction
14	PROMACTA.xml:S1:13848:2	O

Pyrexia	PROMACTA.xml:S1:13892:7	B-AdverseReaction
14	PROMACTA.xml:S1:13955:2	O

Dizziness	PROMACTA.xml:S1:13999:9	B-AdverseReaction
14	PROMACTA.xml:S1:14062:2	O

Oropharyngeal	PROMACTA.xml:S1:14106:13	B-AdverseReaction
pain	PROMACTA.xml:S1:14120:4	I-AdverseReaction
14	PROMACTA.xml:S1:14169:2	O

Febrile	PROMACTA.xml:S1:14213:7	B-AdverseReaction
neutropenia	PROMACTA.xml:S1:14221:11	I-AdverseReaction
14	PROMACTA.xml:S1:14276:2	O

Abdominal	PROMACTA.xml:S1:14320:9	B-AdverseReaction
pain	PROMACTA.xml:S1:14330:4	I-AdverseReaction
12	PROMACTA.xml:S1:14383:2	O

Ecchymosis	PROMACTA.xml:S1:14427:10	B-AdverseReaction
12	PROMACTA.xml:S1:14490:2	O

Muscle	PROMACTA.xml:S1:14534:6	B-AdverseReaction
spasms	PROMACTA.xml:S1:14541:6	I-AdverseReaction
12	PROMACTA.xml:S1:14597:2	O

Transaminases	PROMACTA.xml:S1:14641:13	B-AdverseReaction
increased	PROMACTA.xml:S1:14655:9	I-AdverseReaction
12	PROMACTA.xml:S1:14704:2	O

Arthralgia	PROMACTA.xml:S1:14748:10	B-AdverseReaction
12	PROMACTA.xml:S1:14811:2	O

Rhinorrhea	PROMACTA.xml:S1:14855:10	B-AdverseReaction
12	PROMACTA.xml:S1:14918:2	O

In	PROMACTA.xml:S1:14968:2	O
this	PROMACTA.xml:S1:14971:4	O
trial	PROMACTA.xml:S1:14976:5	O
,	PROMACTA.xml:S1:14981:1	O
patients	PROMACTA.xml:S1:14983:8	O
had	PROMACTA.xml:S1:14992:3	O
bone	PROMACTA.xml:S1:14996:4	O
marrow	PROMACTA.xml:S1:15001:6	O
aspirates	PROMACTA.xml:S1:15008:9	O
evaluated	PROMACTA.xml:S1:15018:9	O
for	PROMACTA.xml:S1:15028:3	O
cytogenetic	PROMACTA.xml:S1:15032:11	O
abnormalities	PROMACTA.xml:S1:15044:13	O
.	PROMACTA.xml:S1:15057:1	O

Eight	PROMACTA.xml:S1:15059:5	O
patients	PROMACTA.xml:S1:15065:8	O
had	PROMACTA.xml:S1:15074:3	O
a	PROMACTA.xml:S1:15078:1	O
new	PROMACTA.xml:S1:15080:3	O
cytogenetic	PROMACTA.xml:S1:15084:11	B-AdverseReaction
abnormality	PROMACTA.xml:S1:15096:11	I-AdverseReaction
reported	PROMACTA.xml:S1:15108:8	O
on	PROMACTA.xml:S1:15117:2	O
therapy	PROMACTA.xml:S1:15120:7	O
,	PROMACTA.xml:S1:15127:1	O
including	PROMACTA.xml:S1:15129:9	O
5	PROMACTA.xml:S1:15139:1	O
patients	PROMACTA.xml:S1:15141:8	O
who	PROMACTA.xml:S1:15150:3	O
had	PROMACTA.xml:S1:15154:3	O
complex	PROMACTA.xml:S1:15158:7	O
changes	PROMACTA.xml:S1:15166:7	B-AdverseReaction
in	PROMACTA.xml:S1:15174:2	I-AdverseReaction
chromosome	PROMACTA.xml:S1:15177:10	I-AdverseReaction
7	PROMACTA.xml:S1:15188:1	I-AdverseReaction
.	PROMACTA.xml:S1:15189:1	O

6.2	PROMACTA.xml:S1:15197:3	O

Postmarketing	PROMACTA.xml:S1:15201:13	O
Experience	PROMACTA.xml:S1:15215:10	O

The	PROMACTA.xml:S1:15229:3	O
following	PROMACTA.xml:S1:15233:9	O
adverse	PROMACTA.xml:S1:15243:7	O
reactions	PROMACTA.xml:S1:15251:9	O
have	PROMACTA.xml:S1:15261:4	O
been	PROMACTA.xml:S1:15266:4	O
identified	PROMACTA.xml:S1:15271:10	O
during	PROMACTA.xml:S1:15282:6	O
post	PROMACTA.xml:S1:15289:4	O
approval	PROMACTA.xml:S1:15294:8	O
use	PROMACTA.xml:S1:15303:3	O
of	PROMACTA.xml:S1:15307:2	O
PROMACTA	PROMACTA.xml:S1:15310:8	O
.	PROMACTA.xml:S1:15318:1	O

Because	PROMACTA.xml:S1:15320:7	O
these	PROMACTA.xml:S1:15328:5	O
reactions	PROMACTA.xml:S1:15334:9	O
are	PROMACTA.xml:S1:15344:3	O
reported	PROMACTA.xml:S1:15348:8	O
voluntarily	PROMACTA.xml:S1:15357:11	O
from	PROMACTA.xml:S1:15369:4	O
a	PROMACTA.xml:S1:15374:1	O
population	PROMACTA.xml:S1:15376:10	O
of	PROMACTA.xml:S1:15387:2	O
uncertain	PROMACTA.xml:S1:15390:9	O
size	PROMACTA.xml:S1:15400:4	O
,	PROMACTA.xml:S1:15404:1	O
it	PROMACTA.xml:S1:15406:2	O
is	PROMACTA.xml:S1:15409:2	O
not	PROMACTA.xml:S1:15412:3	O
always	PROMACTA.xml:S1:15416:6	O
possible	PROMACTA.xml:S1:15423:8	O
to	PROMACTA.xml:S1:15432:2	O
reliably	PROMACTA.xml:S1:15435:8	O
estimate	PROMACTA.xml:S1:15444:8	O
the	PROMACTA.xml:S1:15453:3	O
frequency	PROMACTA.xml:S1:15457:9	O
or	PROMACTA.xml:S1:15467:2	O
establish	PROMACTA.xml:S1:15470:9	O
a	PROMACTA.xml:S1:15480:1	O
causal	PROMACTA.xml:S1:15482:6	O
relationship	PROMACTA.xml:S1:15489:12	O
to	PROMACTA.xml:S1:15502:2	O
drug	PROMACTA.xml:S1:15505:4	O
exposure	PROMACTA.xml:S1:15510:8	O
.	PROMACTA.xml:S1:15518:1	O

Vascular	PROMACTA.xml:S1:15526:8	O
Disorders	PROMACTA.xml:S1:15535:9	O
:	PROMACTA.xml:S1:15544:1	O
Thrombotic	PROMACTA.xml:S1:15547:10	B-AdverseReaction
microangiopathy	PROMACTA.xml:S1:15558:15	I-AdverseReaction
with	PROMACTA.xml:S1:15574:4	O
acute	PROMACTA.xml:S1:15579:5	B-AdverseReaction
renal	PROMACTA.xml:S1:15585:5	I-AdverseReaction
failure	PROMACTA.xml:S1:15591:7	I-AdverseReaction
.	PROMACTA.xml:S1:15598:1	O
\n\n	PROMACTA.xml:S2:0:2	O
BOXED	PROMACTA.xml:S2:6:5	O
WARNING	PROMACTA.xml:S2:12:7	O
:	PROMACTA.xml:S2:19:1	O
WARNING	PROMACTA.xml:S2:21:7	O
:	PROMACTA.xml:S2:28:1	O
RISK	PROMACTA.xml:S2:30:4	B-Factor
FOR	PROMACTA.xml:S2:35:3	O
HEPATIC	PROMACTA.xml:S2:39:7	B-AdverseReaction
DECOMPENSATION	PROMACTA.xml:S2:47:14	I-AdverseReaction
IN	PROMACTA.xml:S2:62:2	O
PATIENTS	PROMACTA.xml:S2:65:8	O
WITH	PROMACTA.xml:S2:74:4	O
CHRONIC	PROMACTA.xml:S2:79:7	O
HEPATITIS	PROMACTA.xml:S2:87:9	O
C	PROMACTA.xml:S2:97:1	O
\n\n	PROMACTA.xml:S2:98:2	O
WARNING	PROMACTA.xml:S2:102:7	O
:	PROMACTA.xml:S2:109:1	O
RISK	PROMACTA.xml:S2:111:4	B-Factor
FOR	PROMACTA.xml:S2:116:3	O
HEPATIC	PROMACTA.xml:S2:120:7	B-AdverseReaction
DECOMPENSATION	PROMACTA.xml:S2:128:14	I-AdverseReaction
IN	PROMACTA.xml:S2:143:2	O
PATIENTS	PROMACTA.xml:S2:146:8	O
WITH	PROMACTA.xml:S2:155:4	O
CHRONIC	PROMACTA.xml:S2:160:7	O
HEPATITIS	PROMACTA.xml:S2:168:9	O
C	PROMACTA.xml:S2:178:1	O
\n\n	PROMACTA.xml:S2:179:2	O
In	PROMACTA.xml:S2:185:2	O
patients	PROMACTA.xml:S2:188:8	O
with	PROMACTA.xml:S2:197:4	O
chronic	PROMACTA.xml:S2:202:7	O
hepatitis	PROMACTA.xml:S2:210:9	O
C	PROMACTA.xml:S2:220:1	O
,	PROMACTA.xml:S2:221:1	O
PROMACTA	PROMACTA.xml:S2:223:8	O
(	PROMACTA.xml:S2:233:1	O
r	PROMACTA.xml:S2:234:1	O
)	PROMACTA.xml:S2:235:1	O
in	PROMACTA.xml:S2:239:2	O
combination	PROMACTA.xml:S2:242:11	O
with	PROMACTA.xml:S2:254:4	O
interferon	PROMACTA.xml:S2:259:10	O
and	PROMACTA.xml:S2:270:3	O
ribavirin	PROMACTA.xml:S2:274:9	O
may	PROMACTA.xml:S2:284:3	O
increase	PROMACTA.xml:S2:288:8	O
the	PROMACTA.xml:S2:297:3	O
risk	PROMACTA.xml:S2:301:4	B-Factor
of	PROMACTA.xml:S2:306:2	O
hepatic	PROMACTA.xml:S2:309:7	B-AdverseReaction
decompensation	PROMACTA.xml:S2:317:14	I-AdverseReaction
[	PROMACTA.xml:S2:334:1	O
see	PROMACTA.xml:S2:335:3	O
Warnings	PROMACTA.xml:S2:339:8	O
and	PROMACTA.xml:S2:348:3	O
Precautions	PROMACTA.xml:S2:352:11	O
(	PROMACTA.xml:S2:364:1	O
5.1	PROMACTA.xml:S2:365:3	O
)]	PROMACTA.xml:S2:368:2	O
.	PROMACTA.xml:S2:372:1	O

EXCERPT	PROMACTA.xml:S2:382:7	O
:	PROMACTA.xml:S2:389:1	O
WARNING	PROMACTA.xml:S2:393:7	O
:	PROMACTA.xml:S2:400:1	O
RISK	PROMACTA.xml:S2:402:4	B-Factor
FOR	PROMACTA.xml:S2:407:3	O
HEPATIC	PROMACTA.xml:S2:411:7	B-AdverseReaction
DECOMPENSATION	PROMACTA.xml:S2:419:14	I-AdverseReaction
IN	PROMACTA.xml:S2:434:2	O
PATIENTS	PROMACTA.xml:S2:437:8	O
WITH	PROMACTA.xml:S2:446:4	O
CHRONIC	PROMACTA.xml:S2:451:7	O
HEPATITIS	PROMACTA.xml:S2:459:9	O
C	PROMACTA.xml:S2:469:1	O
\n\n\n\n	PROMACTA.xml:S2:470:4	O
See	PROMACTA.xml:S2:477:3	O
full	PROMACTA.xml:S2:481:4	O
prescribing	PROMACTA.xml:S2:486:11	O
information	PROMACTA.xml:S2:498:11	O
for	PROMACTA.xml:S2:510:3	O
complete	PROMACTA.xml:S2:514:8	O
boxed	PROMACTA.xml:S2:523:5	O
warning	PROMACTA.xml:S2:529:7	O
.	PROMACTA.xml:S2:536:1	O

In	PROMACTA.xml:S2:546:2	O
patients	PROMACTA.xml:S2:549:8	O
with	PROMACTA.xml:S2:558:4	O
chronic	PROMACTA.xml:S2:563:7	O
hepatitis	PROMACTA.xml:S2:571:9	O
C	PROMACTA.xml:S2:581:1	O
,	PROMACTA.xml:S2:582:1	O
PROMACTA	PROMACTA.xml:S2:584:8	O
in	PROMACTA.xml:S2:593:2	O
combination	PROMACTA.xml:S2:596:11	O
with	PROMACTA.xml:S2:608:4	O
interferon	PROMACTA.xml:S2:613:10	O
and	PROMACTA.xml:S2:624:3	O
ribavirin	PROMACTA.xml:S2:628:9	O
may	PROMACTA.xml:S2:638:3	O
increase	PROMACTA.xml:S2:642:8	O
the	PROMACTA.xml:S2:651:3	O
risk	PROMACTA.xml:S2:655:4	B-Factor
of	PROMACTA.xml:S2:660:2	O
hepatic	PROMACTA.xml:S2:663:7	B-AdverseReaction
decompensation	PROMACTA.xml:S2:671:14	I-AdverseReaction
.	PROMACTA.xml:S2:685:1	O

(	PROMACTA.xml:S2:687:1	O
5.1	PROMACTA.xml:S2:690:3	O
)	PROMACTA.xml:S2:695:1	O
\n	PROMACTA.xml:S2:698:1	O
5	PROMACTA.xml:S3:4:1	O
WARNINGS	PROMACTA.xml:S3:6:8	O
AND	PROMACTA.xml:S3:15:3	O
PRECAUTIONS	PROMACTA.xml:S3:19:11	O

EXCERPT	PROMACTA.xml:S3:37:7	O
:	PROMACTA.xml:S3:44:1	O
Hepatotoxicity	PROMACTA.xml:S3:54:14	B-AdverseReaction
:	PROMACTA.xml:S3:68:1	O
Monitor	PROMACTA.xml:S3:70:7	O
liver	PROMACTA.xml:S3:78:5	O
function	PROMACTA.xml:S3:84:8	O
before	PROMACTA.xml:S3:93:6	O
and	PROMACTA.xml:S3:100:3	O
during	PROMACTA.xml:S3:104:6	O
therapy	PROMACTA.xml:S3:111:7	O
.	PROMACTA.xml:S3:118:1	O

(	PROMACTA.xml:S3:120:1	O
5.2	PROMACTA.xml:S3:123:3	O
)	PROMACTA.xml:S3:128:1	O

Thrombotic	PROMACTA.xml:S3:137:10	B-AdverseReaction
Thromboembolic	PROMACTA.xml:S3:148:14	B-AdverseReaction
Complications	PROMACTA.xml:S3:163:13	I-AdverseReaction
:	PROMACTA.xml:S3:176:1	O
Portal	PROMACTA.xml:S3:178:6	B-AdverseReaction
vein	PROMACTA.xml:S3:185:4	I-AdverseReaction
thrombosis	PROMACTA.xml:S3:190:10	I-AdverseReaction
has	PROMACTA.xml:S3:201:3	O
been	PROMACTA.xml:S3:205:4	O
reported	PROMACTA.xml:S3:210:8	O
in	PROMACTA.xml:S3:219:2	O
patients	PROMACTA.xml:S3:222:8	O
with	PROMACTA.xml:S3:231:4	O
chronic	PROMACTA.xml:S3:236:7	O
liver	PROMACTA.xml:S3:244:5	O
disease	PROMACTA.xml:S3:250:7	O
receiving	PROMACTA.xml:S3:258:9	O
PROMACTA	PROMACTA.xml:S3:268:8	O
.	PROMACTA.xml:S3:276:1	O

Monitor	PROMACTA.xml:S3:278:7	O
platelet	PROMACTA.xml:S3:286:8	O
counts	PROMACTA.xml:S3:295:6	O
regularly	PROMACTA.xml:S3:302:9	O
.	PROMACTA.xml:S3:311:1	O

(	PROMACTA.xml:S3:313:1	O
5.3	PROMACTA.xml:S3:316:3	O
)	PROMACTA.xml:S3:321:1	O

5.1	PROMACTA.xml:S3:335:3	O

Hepatic	PROMACTA.xml:S3:339:7	O

Decompensation	PROMACTA.xml:S3:347:14	O
in	PROMACTA.xml:S3:362:2	O
Patients	PROMACTA.xml:S3:365:8	O
with	PROMACTA.xml:S3:374:4	O
Chronic	PROMACTA.xml:S3:379:7	O
Hepatitis	PROMACTA.xml:S3:387:9	O
C	PROMACTA.xml:S3:397:1	O

In	PROMACTA.xml:S3:404:2	O
patients	PROMACTA.xml:S3:407:8	O
with	PROMACTA.xml:S3:416:4	O
chronic	PROMACTA.xml:S3:421:7	O
hepatitis	PROMACTA.xml:S3:429:9	O
C	PROMACTA.xml:S3:439:1	O
,	PROMACTA.xml:S3:440:1	O
PROMACTA	PROMACTA.xml:S3:442:8	O
in	PROMACTA.xml:S3:451:2	O
combination	PROMACTA.xml:S3:454:11	O
with	PROMACTA.xml:S3:466:4	O
interferon	PROMACTA.xml:S3:471:10	O
and	PROMACTA.xml:S3:482:3	O
ribavirin	PROMACTA.xml:S3:486:9	O
may	PROMACTA.xml:S3:496:3	O
increase	PROMACTA.xml:S3:500:8	O
the	PROMACTA.xml:S3:509:3	O
risk	PROMACTA.xml:S3:513:4	B-Factor
of	PROMACTA.xml:S3:518:2	O
hepatic	PROMACTA.xml:S3:521:7	B-AdverseReaction
decompensation	PROMACTA.xml:S3:529:14	I-AdverseReaction
.	PROMACTA.xml:S3:543:1	O

In	PROMACTA.xml:S3:545:2	O
two	PROMACTA.xml:S3:548:3	O
controlled	PROMACTA.xml:S3:552:10	O
clinical	PROMACTA.xml:S3:563:8	O
trials	PROMACTA.xml:S3:572:6	O
in	PROMACTA.xml:S3:579:2	O
patients	PROMACTA.xml:S3:582:8	O
with	PROMACTA.xml:S3:591:4	O
chronic	PROMACTA.xml:S3:596:7	O
hepatitis	PROMACTA.xml:S3:604:9	O
C	PROMACTA.xml:S3:614:1	O
and	PROMACTA.xml:S3:616:3	O
thrombocytopenia	PROMACTA.xml:S3:620:16	O
,	PROMACTA.xml:S3:636:1	O
ascites	PROMACTA.xml:S3:638:7	B-AdverseReaction
and	PROMACTA.xml:S3:646:3	O
encephalopathy	PROMACTA.xml:S3:650:14	B-AdverseReaction
occurred	PROMACTA.xml:S3:665:8	O
more	PROMACTA.xml:S3:674:4	O
frequently	PROMACTA.xml:S3:679:10	O
on	PROMACTA.xml:S3:690:2	O
the	PROMACTA.xml:S3:693:3	O
arm	PROMACTA.xml:S3:697:3	O
receiving	PROMACTA.xml:S3:701:9	O
treatment	PROMACTA.xml:S3:711:9	O
with	PROMACTA.xml:S3:721:4	O
PROMACTA	PROMACTA.xml:S3:726:8	O
plus	PROMACTA.xml:S3:735:4	O
antivirals	PROMACTA.xml:S3:740:10	O
(	PROMACTA.xml:S3:751:1	O
7%	PROMACTA.xml:S3:752:2	O
)	PROMACTA.xml:S3:754:1	O
than	PROMACTA.xml:S3:756:4	O
the	PROMACTA.xml:S3:761:3	O
placebo	PROMACTA.xml:S3:765:7	O
plus	PROMACTA.xml:S3:773:4	O
antivirals	PROMACTA.xml:S3:778:10	O
arm	PROMACTA.xml:S3:789:3	O
(	PROMACTA.xml:S3:793:1	O
4%	PROMACTA.xml:S3:794:2	O
)	PROMACTA.xml:S3:796:1	O
.	PROMACTA.xml:S3:797:1	O

Patients	PROMACTA.xml:S3:799:8	O
with	PROMACTA.xml:S3:808:4	O
low	PROMACTA.xml:S3:813:3	O
albumin	PROMACTA.xml:S3:817:7	O
levels	PROMACTA.xml:S3:825:6	O
(	PROMACTA.xml:S3:832:1	O
less	PROMACTA.xml:S3:833:4	O
than	PROMACTA.xml:S3:838:4	O
3.5	PROMACTA.xml:S3:843:3	O
g	PROMACTA.xml:S3:847:1	O
dL	PROMACTA.xml:S3:849:2	O
)	PROMACTA.xml:S3:851:1	O
or	PROMACTA.xml:S3:853:2	O
Model	PROMACTA.xml:S3:856:5	O
for	PROMACTA.xml:S3:862:3	O
End	PROMACTA.xml:S3:866:3	O
-	PROMACTA.xml:S3:869:1	O
Stage	PROMACTA.xml:S3:870:5	O
Liver	PROMACTA.xml:S3:876:5	O
Disease	PROMACTA.xml:S3:882:7	O
(	PROMACTA.xml:S3:890:1	O
MELD	PROMACTA.xml:S3:891:4	O
)	PROMACTA.xml:S3:895:1	O
score	PROMACTA.xml:S3:897:5	O
greater	PROMACTA.xml:S3:903:7	O
than	PROMACTA.xml:S3:911:4	O
or	PROMACTA.xml:S3:916:2	O
equal	PROMACTA.xml:S3:919:5	O
to	PROMACTA.xml:S3:925:2	O
10	PROMACTA.xml:S3:928:2	O
at	PROMACTA.xml:S3:931:2	O
baseline	PROMACTA.xml:S3:934:8	O
had	PROMACTA.xml:S3:943:3	O
a	PROMACTA.xml:S3:947:1	O
greater	PROMACTA.xml:S3:949:7	O
risk	PROMACTA.xml:S3:957:4	B-Factor
for	PROMACTA.xml:S3:962:3	O
hepatic	PROMACTA.xml:S3:966:7	B-AdverseReaction
decompensation	PROMACTA.xml:S3:974:14	I-AdverseReaction
on	PROMACTA.xml:S3:989:2	O
the	PROMACTA.xml:S3:992:3	O
arm	PROMACTA.xml:S3:996:3	O
receiving	PROMACTA.xml:S3:1000:9	O
treatment	PROMACTA.xml:S3:1010:9	O
with	PROMACTA.xml:S3:1020:4	O
PROMACTA	PROMACTA.xml:S3:1025:8	O
plus	PROMACTA.xml:S3:1034:4	O
antivirals	PROMACTA.xml:S3:1039:10	O
.	PROMACTA.xml:S3:1049:1	O

Discontinue	PROMACTA.xml:S3:1051:11	O
PROMACTA	PROMACTA.xml:S3:1063:8	O
if	PROMACTA.xml:S3:1072:2	O
antiviral	PROMACTA.xml:S3:1075:9	O
therapy	PROMACTA.xml:S3:1085:7	O
is	PROMACTA.xml:S3:1093:2	O
discontinued	PROMACTA.xml:S3:1096:12	O
.	PROMACTA.xml:S3:1108:1	O

5.2	PROMACTA.xml:S3:1117:3	O
Hepatotoxicity	PROMACTA.xml:S3:1121:14	O

PROMACTA	PROMACTA.xml:S3:1141:8	O
can	PROMACTA.xml:S3:1150:3	B-Factor
cause	PROMACTA.xml:S3:1154:5	O
liver	PROMACTA.xml:S3:1160:5	B-AdverseReaction
enzyme	PROMACTA.xml:S3:1166:6	I-AdverseReaction
elevations	PROMACTA.xml:S3:1173:10	I-AdverseReaction
[	PROMACTA.xml:S3:1184:1	O
see	PROMACTA.xml:S3:1185:3	O
Adverse	PROMACTA.xml:S3:1189:7	O
Reactions	PROMACTA.xml:S3:1197:9	O
(	PROMACTA.xml:S3:1207:1	O
6.1	PROMACTA.xml:S3:1208:3	O
)]	PROMACTA.xml:S3:1211:2	O
.	PROMACTA.xml:S3:1215:1	O

Measure	PROMACTA.xml:S3:1217:7	O
serum	PROMACTA.xml:S3:1225:5	O
ALT	PROMACTA.xml:S3:1231:3	O
,	PROMACTA.xml:S3:1234:1	O
AST	PROMACTA.xml:S3:1236:3	O
,	PROMACTA.xml:S3:1239:1	O
and	PROMACTA.xml:S3:1241:3	O
bilirubin	PROMACTA.xml:S3:1245:9	O
prior	PROMACTA.xml:S3:1255:5	O
to	PROMACTA.xml:S3:1261:2	O
initiation	PROMACTA.xml:S3:1264:10	O
of	PROMACTA.xml:S3:1275:2	O
PROMACTA	PROMACTA.xml:S3:1278:8	O
,	PROMACTA.xml:S3:1286:1	O
every	PROMACTA.xml:S3:1288:5	O
2	PROMACTA.xml:S3:1294:1	O
weeks	PROMACTA.xml:S3:1296:5	O
during	PROMACTA.xml:S3:1302:6	O
the	PROMACTA.xml:S3:1309:3	O
dose	PROMACTA.xml:S3:1313:4	O
adjustment	PROMACTA.xml:S3:1318:10	O
phase	PROMACTA.xml:S3:1329:5	O
,	PROMACTA.xml:S3:1334:1	O
and	PROMACTA.xml:S3:1336:3	O
monthly	PROMACTA.xml:S3:1340:7	O
following	PROMACTA.xml:S3:1348:9	O
establishment	PROMACTA.xml:S3:1358:13	O
of	PROMACTA.xml:S3:1372:2	O
a	PROMACTA.xml:S3:1375:1	O
stable	PROMACTA.xml:S3:1377:6	O
dose	PROMACTA.xml:S3:1384:4	O
.	PROMACTA.xml:S3:1388:1	O

PROMACTA	PROMACTA.xml:S3:1390:8	O
inhibits	PROMACTA.xml:S3:1399:8	O
UDP	PROMACTA.xml:S3:1408:3	O
-	PROMACTA.xml:S3:1411:1	O
glucuronosyltransferase	PROMACTA.xml:S3:1412:23	O
(	PROMACTA.xml:S3:1436:1	O
UGT	PROMACTA.xml:S3:1437:3	O
)	PROMACTA.xml:S3:1440:1	O
1	PROMACTA.xml:S3:1441:1	O
A1	PROMACTA.xml:S3:1442:2	O
and	PROMACTA.xml:S3:1445:3	O
organic	PROMACTA.xml:S3:1449:7	O
anion	PROMACTA.xml:S3:1457:5	O
-	PROMACTA.xml:S3:1462:1	O
transporting	PROMACTA.xml:S3:1463:12	O
polypeptide	PROMACTA.xml:S3:1476:11	O
(	PROMACTA.xml:S3:1488:1	O
OATP	PROMACTA.xml:S3:1489:4	O
)	PROMACTA.xml:S3:1493:1	O
1	PROMACTA.xml:S3:1494:1	O
B1	PROMACTA.xml:S3:1495:2	O
,	PROMACTA.xml:S3:1497:1	O
which	PROMACTA.xml:S3:1499:5	O
may	PROMACTA.xml:S3:1505:3	B-Factor
lead	PROMACTA.xml:S3:1509:4	O
to	PROMACTA.xml:S3:1514:2	O
indirect	PROMACTA.xml:S3:1517:8	B-AdverseReaction
hyperbilirubinemia	PROMACTA.xml:S3:1526:18	I-AdverseReaction
.	PROMACTA.xml:S3:1544:1	O

If	PROMACTA.xml:S3:1546:2	O
bilirubin	PROMACTA.xml:S3:1549:9	O
is	PROMACTA.xml:S3:1559:2	O
elevated	PROMACTA.xml:S3:1562:8	O
,	PROMACTA.xml:S3:1570:1	O
perform	PROMACTA.xml:S3:1572:7	O
fractionation	PROMACTA.xml:S3:1580:13	O
.	PROMACTA.xml:S3:1593:1	O

Evaluate	PROMACTA.xml:S3:1595:8	O
abnormal	PROMACTA.xml:S3:1604:8	O
serum	PROMACTA.xml:S3:1613:5	O
liver	PROMACTA.xml:S3:1619:5	O
tests	PROMACTA.xml:S3:1625:5	O
with	PROMACTA.xml:S3:1631:4	O
repeat	PROMACTA.xml:S3:1636:6	O
testing	PROMACTA.xml:S3:1643:7	O
within	PROMACTA.xml:S3:1651:6	O
3	PROMACTA.xml:S3:1658:1	O
to	PROMACTA.xml:S3:1660:2	O
5	PROMACTA.xml:S3:1663:1	O
days	PROMACTA.xml:S3:1665:4	O
.	PROMACTA.xml:S3:1669:1	O

If	PROMACTA.xml:S3:1671:2	O
the	PROMACTA.xml:S3:1674:3	O
abnormalities	PROMACTA.xml:S3:1678:13	O
are	PROMACTA.xml:S3:1692:3	O
confirmed	PROMACTA.xml:S3:1696:9	O
,	PROMACTA.xml:S3:1705:1	O
monitor	PROMACTA.xml:S3:1707:7	O
serum	PROMACTA.xml:S3:1715:5	O
liver	PROMACTA.xml:S3:1721:5	O
tests	PROMACTA.xml:S3:1727:5	O
weekly	PROMACTA.xml:S3:1733:6	O
until	PROMACTA.xml:S3:1740:5	O
resolved	PROMACTA.xml:S3:1746:8	O
or	PROMACTA.xml:S3:1755:2	O
stabilized	PROMACTA.xml:S3:1758:10	O
.	PROMACTA.xml:S3:1768:1	O

Discontinue	PROMACTA.xml:S3:1770:11	O
PROMACTA	PROMACTA.xml:S3:1782:8	O
if	PROMACTA.xml:S3:1791:2	O
ALT	PROMACTA.xml:S3:1794:3	O
levels	PROMACTA.xml:S3:1798:6	O
increase	PROMACTA.xml:S3:1805:8	O
to	PROMACTA.xml:S3:1814:2	O
greater	PROMACTA.xml:S3:1817:7	O
than	PROMACTA.xml:S3:1825:4	O
or	PROMACTA.xml:S3:1830:2	O
equal	PROMACTA.xml:S3:1833:5	O
to	PROMACTA.xml:S3:1839:2	O
3	PROMACTA.xml:S3:1842:1	O
x	PROMACTA.xml:S3:1844:1	O
ULN	PROMACTA.xml:S3:1846:3	O
in	PROMACTA.xml:S3:1850:2	O
patients	PROMACTA.xml:S3:1853:8	O
with	PROMACTA.xml:S3:1862:4	O
normal	PROMACTA.xml:S3:1867:6	O
liver	PROMACTA.xml:S3:1874:5	O
function	PROMACTA.xml:S3:1880:8	O
or	PROMACTA.xml:S3:1889:2	O
greater	PROMACTA.xml:S3:1892:7	O
than	PROMACTA.xml:S3:1900:4	O
or	PROMACTA.xml:S3:1905:2	O
equal	PROMACTA.xml:S3:1908:5	O
to	PROMACTA.xml:S3:1914:2	O
3	PROMACTA.xml:S3:1917:1	O
x	PROMACTA.xml:S3:1919:1	O
baseline	PROMACTA.xml:S3:1921:8	O
in	PROMACTA.xml:S3:1930:2	O
patients	PROMACTA.xml:S3:1933:8	O
with	PROMACTA.xml:S3:1942:4	O
pre	PROMACTA.xml:S3:1947:3	O
-	PROMACTA.xml:S3:1950:1	O
treatment	PROMACTA.xml:S3:1951:9	O
elevations	PROMACTA.xml:S3:1961:10	O
in	PROMACTA.xml:S3:1972:2	O
transaminases	PROMACTA.xml:S3:1975:13	O
and	PROMACTA.xml:S3:1989:3	O
are	PROMACTA.xml:S3:1993:3	O
:	PROMACTA.xml:S3:1996:1	O

progressively	PROMACTA.xml:S3:2007:13	O
increasing	PROMACTA.xml:S3:2021:10	O
,	PROMACTA.xml:S3:2031:1	O
or	PROMACTA.xml:S3:2033:2	O

persistent	PROMACTA.xml:S3:2043:10	O
for	PROMACTA.xml:S3:2054:3	O
greater	PROMACTA.xml:S3:2058:7	O
than	PROMACTA.xml:S3:2066:4	O
or	PROMACTA.xml:S3:2071:2	O
equal	PROMACTA.xml:S3:2074:5	O
to	PROMACTA.xml:S3:2080:2	O
4	PROMACTA.xml:S3:2083:1	O
weeks	PROMACTA.xml:S3:2085:5	O
,	PROMACTA.xml:S3:2090:1	O
or	PROMACTA.xml:S3:2092:2	O

accompanied	PROMACTA.xml:S3:2102:11	O
by	PROMACTA.xml:S3:2114:2	O
increased	PROMACTA.xml:S3:2117:9	O
direct	PROMACTA.xml:S3:2127:6	O
bilirubin	PROMACTA.xml:S3:2134:9	O
,	PROMACTA.xml:S3:2143:1	O
or	PROMACTA.xml:S3:2145:2	O

accompanied	PROMACTA.xml:S3:2155:11	O
by	PROMACTA.xml:S3:2167:2	O
clinical	PROMACTA.xml:S3:2170:8	O
symptoms	PROMACTA.xml:S3:2179:8	O
of	PROMACTA.xml:S3:2188:2	O
liver	PROMACTA.xml:S3:2191:5	O
injury	PROMACTA.xml:S3:2197:6	O
or	PROMACTA.xml:S3:2204:2	O
evidence	PROMACTA.xml:S3:2207:8	O
for	PROMACTA.xml:S3:2216:3	O
hepatic	PROMACTA.xml:S3:2220:7	O
decompensation	PROMACTA.xml:S3:2228:14	O
.	PROMACTA.xml:S3:2242:1	O

If	PROMACTA.xml:S3:2249:2	O
the	PROMACTA.xml:S3:2252:3	O
potential	PROMACTA.xml:S3:2256:9	O
benefit	PROMACTA.xml:S3:2266:7	O
for	PROMACTA.xml:S3:2274:3	O
reinitiating	PROMACTA.xml:S3:2278:12	O
treatment	PROMACTA.xml:S3:2291:9	O
with	PROMACTA.xml:S3:2301:4	O
PROMACTA	PROMACTA.xml:S3:2306:8	O
is	PROMACTA.xml:S3:2315:2	O
considered	PROMACTA.xml:S3:2318:10	O
to	PROMACTA.xml:S3:2329:2	O
outweigh	PROMACTA.xml:S3:2332:8	O
the	PROMACTA.xml:S3:2341:3	O
risk	PROMACTA.xml:S3:2345:4	O
for	PROMACTA.xml:S3:2350:3	O
hepatotoxicity	PROMACTA.xml:S3:2354:14	O
,	PROMACTA.xml:S3:2368:1	O
then	PROMACTA.xml:S3:2370:4	O
consider	PROMACTA.xml:S3:2375:8	O
cautiously	PROMACTA.xml:S3:2384:10	O
reintroducing	PROMACTA.xml:S3:2395:13	O
PROMACTA	PROMACTA.xml:S3:2409:8	O
and	PROMACTA.xml:S3:2418:3	O
measure	PROMACTA.xml:S3:2422:7	O
serum	PROMACTA.xml:S3:2430:5	O
liver	PROMACTA.xml:S3:2436:5	O
tests	PROMACTA.xml:S3:2442:5	O
weekly	PROMACTA.xml:S3:2448:6	O
during	PROMACTA.xml:S3:2455:6	O
the	PROMACTA.xml:S3:2462:3	O
dose	PROMACTA.xml:S3:2466:4	O
adjustment	PROMACTA.xml:S3:2471:10	O
phase	PROMACTA.xml:S3:2482:5	O
.	PROMACTA.xml:S3:2487:1	O

Hepatotoxicity	PROMACTA.xml:S3:2489:14	B-AdverseReaction
may	PROMACTA.xml:S3:2504:3	B-Factor
reoccur	PROMACTA.xml:S3:2508:7	O
if	PROMACTA.xml:S3:2516:2	O
PROMACTA	PROMACTA.xml:S3:2519:8	O
is	PROMACTA.xml:S3:2528:2	O
reinitiated	PROMACTA.xml:S3:2531:11	O
.	PROMACTA.xml:S3:2542:1	O

If	PROMACTA.xml:S3:2544:2	O
liver	PROMACTA.xml:S3:2547:5	O
test	PROMACTA.xml:S3:2553:4	O
abnormalities	PROMACTA.xml:S3:2558:13	O
persist	PROMACTA.xml:S3:2572:7	O
,	PROMACTA.xml:S3:2579:1	O
worsen	PROMACTA.xml:S3:2581:6	O
or	PROMACTA.xml:S3:2588:2	O
recur	PROMACTA.xml:S3:2591:5	O
,	PROMACTA.xml:S3:2596:1	O
then	PROMACTA.xml:S3:2598:4	O
permanently	PROMACTA.xml:S3:2603:11	O
discontinue	PROMACTA.xml:S3:2615:11	O
PROMACTA	PROMACTA.xml:S3:2627:8	O
.	PROMACTA.xml:S3:2635:1	O

5.3	PROMACTA.xml:S3:2644:3	O

Thrombotic	PROMACTA.xml:S3:2648:10	O
Thromboembolic	PROMACTA.xml:S3:2659:14	O
Complications	PROMACTA.xml:S3:2674:13	O

In	PROMACTA.xml:S3:2693:2	O
two	PROMACTA.xml:S3:2696:3	O
controlled	PROMACTA.xml:S3:2700:10	O
clinical	PROMACTA.xml:S3:2711:8	O
trials	PROMACTA.xml:S3:2720:6	O
in	PROMACTA.xml:S3:2727:2	O
patients	PROMACTA.xml:S3:2730:8	O
with	PROMACTA.xml:S3:2739:4	O
chronic	PROMACTA.xml:S3:2744:7	O
hepatitis	PROMACTA.xml:S3:2752:9	O
C	PROMACTA.xml:S3:2762:1	O
and	PROMACTA.xml:S3:2764:3	O
thrombocytopenia	PROMACTA.xml:S3:2768:16	O
,	PROMACTA.xml:S3:2784:1	O
3%	PROMACTA.xml:S3:2786:2	O
(	PROMACTA.xml:S3:2789:1	O
31	PROMACTA.xml:S3:2790:2	O
955	PROMACTA.xml:S3:2793:3	O
)	PROMACTA.xml:S3:2796:1	O
treated	PROMACTA.xml:S3:2798:7	O
with	PROMACTA.xml:S3:2806:4	O
PROMACTA	PROMACTA.xml:S3:2811:8	O
experienced	PROMACTA.xml:S3:2820:11	O
a	PROMACTA.xml:S3:2832:1	O
thrombotic	PROMACTA.xml:S3:2834:10	B-AdverseReaction
event	PROMACTA.xml:S3:2845:5	I-AdverseReaction
compared	PROMACTA.xml:S3:2851:8	O
with	PROMACTA.xml:S3:2860:4	O
1%	PROMACTA.xml:S3:2865:2	O
(	PROMACTA.xml:S3:2868:1	O
5	PROMACTA.xml:S3:2869:1	O
484	PROMACTA.xml:S3:2871:3	O
)	PROMACTA.xml:S3:2874:1	O
on	PROMACTA.xml:S3:2876:2	O
placebo	PROMACTA.xml:S3:2879:7	O
.	PROMACTA.xml:S3:2886:1	O

The	PROMACTA.xml:S3:2888:3	O
majority	PROMACTA.xml:S3:2892:8	O
of	PROMACTA.xml:S3:2901:2	O
events	PROMACTA.xml:S3:2904:6	I-AdverseReaction
were	PROMACTA.xml:S3:2911:4	O
of	PROMACTA.xml:S3:2916:2	I-AdverseReaction
the	PROMACTA.xml:S3:2919:3	I-AdverseReaction
portal	PROMACTA.xml:S3:2923:6	I-AdverseReaction
venous	PROMACTA.xml:S3:2930:6	I-AdverseReaction
system	PROMACTA.xml:S3:2937:6	I-AdverseReaction
(	PROMACTA.xml:S3:2944:1	O
1%	PROMACTA.xml:S3:2945:2	O
in	PROMACTA.xml:S3:2948:2	O
patients	PROMACTA.xml:S3:2951:8	O
treated	PROMACTA.xml:S3:2960:7	O
with	PROMACTA.xml:S3:2968:4	O
PROMACTA	PROMACTA.xml:S3:2973:8	O
versus	PROMACTA.xml:S3:2982:6	O
less	PROMACTA.xml:S3:2989:4	O
than	PROMACTA.xml:S3:2994:4	O
1%	PROMACTA.xml:S3:2999:2	O
for	PROMACTA.xml:S3:3002:3	O
placebo	PROMACTA.xml:S3:3006:7	O
)	PROMACTA.xml:S3:3013:1	O
.	PROMACTA.xml:S3:3014:1	O

Thrombotic	PROMACTA.xml:S3:3020:10	B-AdverseReaction
thromboembolic	PROMACTA.xml:S3:3031:14	B-AdverseReaction
complications	PROMACTA.xml:S3:3046:13	I-AdverseReaction
may	PROMACTA.xml:S3:3060:3	B-Factor
result	PROMACTA.xml:S3:3064:6	O
from	PROMACTA.xml:S3:3071:4	O
increases	PROMACTA.xml:S3:3076:9	B-AdverseReaction
in	PROMACTA.xml:S3:3086:2	I-AdverseReaction
platelet	PROMACTA.xml:S3:3089:8	I-AdverseReaction
counts	PROMACTA.xml:S3:3098:6	I-AdverseReaction
with	PROMACTA.xml:S3:3105:4	O
PROMACTA	PROMACTA.xml:S3:3110:8	O
.	PROMACTA.xml:S3:3118:1	O

Reported	PROMACTA.xml:S3:3120:8	O
thrombotic	PROMACTA.xml:S3:3129:10	B-AdverseReaction
thromboembolic	PROMACTA.xml:S3:3140:14	B-AdverseReaction
complications	PROMACTA.xml:S3:3155:13	I-AdverseReaction
included	PROMACTA.xml:S3:3169:8	O
both	PROMACTA.xml:S3:3178:4	O
venous	PROMACTA.xml:S3:3183:6	I-AdverseReaction
and	PROMACTA.xml:S3:3190:3	O
arterial	PROMACTA.xml:S3:3194:8	I-AdverseReaction
events	PROMACTA.xml:S3:3203:6	I-AdverseReaction
and	PROMACTA.xml:S3:3210:3	O
were	PROMACTA.xml:S3:3214:4	O
observed	PROMACTA.xml:S3:3219:8	O
at	PROMACTA.xml:S3:3228:2	O
low	PROMACTA.xml:S3:3231:3	O
and	PROMACTA.xml:S3:3235:3	O
at	PROMACTA.xml:S3:3239:2	O
normal	PROMACTA.xml:S3:3242:6	O
platelet	PROMACTA.xml:S3:3249:8	O
counts	PROMACTA.xml:S3:3258:6	O
.	PROMACTA.xml:S3:3264:1	O

Consider	PROMACTA.xml:S3:3270:8	O
the	PROMACTA.xml:S3:3279:3	O
potential	PROMACTA.xml:S3:3283:9	O
for	PROMACTA.xml:S3:3293:3	O
an	PROMACTA.xml:S3:3297:2	O
increased	PROMACTA.xml:S3:3300:9	O
risk	PROMACTA.xml:S3:3310:4	O
of	PROMACTA.xml:S3:3315:2	O
thromboembolism	PROMACTA.xml:S3:3318:15	O
when	PROMACTA.xml:S3:3334:4	O
administering	PROMACTA.xml:S3:3339:13	O
PROMACTA	PROMACTA.xml:S3:3353:8	O
to	PROMACTA.xml:S3:3362:2	O
patients	PROMACTA.xml:S3:3365:8	O
with	PROMACTA.xml:S3:3374:4	O
known	PROMACTA.xml:S3:3379:5	O
risk	PROMACTA.xml:S3:3385:4	O
factors	PROMACTA.xml:S3:3390:7	O
for	PROMACTA.xml:S3:3398:3	O
thromboembolism	PROMACTA.xml:S3:3402:15	O
(	PROMACTA.xml:S3:3418:1	O
e	PROMACTA.xml:S3:3419:1	O
.	PROMACTA.xml:S3:3420:1	O
g	PROMACTA.xml:S3:3421:1	O
.	PROMACTA.xml:S3:3422:1	O
,	PROMACTA.xml:S3:3423:1	O
Factor	PROMACTA.xml:S3:3425:6	O
V	PROMACTA.xml:S3:3432:1	O
Leiden	PROMACTA.xml:S3:3434:6	O
,	PROMACTA.xml:S3:3440:1	O
ATIII	PROMACTA.xml:S3:3442:5	O
deficiency	PROMACTA.xml:S3:3448:10	O
,	PROMACTA.xml:S3:3458:1	O
antiphospholipid	PROMACTA.xml:S3:3460:16	O
syndrome	PROMACTA.xml:S3:3477:8	O
,	PROMACTA.xml:S3:3485:1	O
chronic	PROMACTA.xml:S3:3487:7	O
liver	PROMACTA.xml:S3:3495:5	O
disease	PROMACTA.xml:S3:3501:7	O
)	PROMACTA.xml:S3:3508:1	O
.	PROMACTA.xml:S3:3509:1	O

To	PROMACTA.xml:S3:3511:2	O
minimize	PROMACTA.xml:S3:3514:8	O
the	PROMACTA.xml:S3:3523:3	O
risk	PROMACTA.xml:S3:3527:4	O
for	PROMACTA.xml:S3:3532:3	O
thrombotic	PROMACTA.xml:S3:3536:10	O
thromboembolic	PROMACTA.xml:S3:3547:14	O
complications	PROMACTA.xml:S3:3562:13	O
,	PROMACTA.xml:S3:3575:1	O
do	PROMACTA.xml:S3:3577:2	O
not	PROMACTA.xml:S3:3580:3	O
use	PROMACTA.xml:S3:3584:3	O
PROMACTA	PROMACTA.xml:S3:3588:8	O
in	PROMACTA.xml:S3:3597:2	O
an	PROMACTA.xml:S3:3600:2	O
attempt	PROMACTA.xml:S3:3603:7	O
to	PROMACTA.xml:S3:3611:2	O
normalize	PROMACTA.xml:S3:3614:9	O
platelet	PROMACTA.xml:S3:3624:8	O
counts	PROMACTA.xml:S3:3633:6	O
.	PROMACTA.xml:S3:3639:1	O

Follow	PROMACTA.xml:S3:3641:6	O
the	PROMACTA.xml:S3:3648:3	O
dose	PROMACTA.xml:S3:3652:4	O
adjustment	PROMACTA.xml:S3:3657:10	O
guidelines	PROMACTA.xml:S3:3668:10	O
to	PROMACTA.xml:S3:3679:2	O
achieve	PROMACTA.xml:S3:3682:7	O
and	PROMACTA.xml:S3:3690:3	O
maintain	PROMACTA.xml:S3:3694:8	O
target	PROMACTA.xml:S3:3703:6	O
platelet	PROMACTA.xml:S3:3710:8	O
counts	PROMACTA.xml:S3:3719:6	O
[	PROMACTA.xml:S3:3726:1	O
see	PROMACTA.xml:S3:3727:3	O
Dosage	PROMACTA.xml:S3:3731:6	O
and	PROMACTA.xml:S3:3738:3	O
Administration	PROMACTA.xml:S3:3742:14	O
(	PROMACTA.xml:S3:3757:1	O
2.1	PROMACTA.xml:S3:3758:3	O
,	PROMACTA.xml:S3:3761:1	O
2.2	PROMACTA.xml:S3:3763:3	O
,	PROMACTA.xml:S3:3766:1	O
2.3	PROMACTA.xml:S3:3768:3	O
)]	PROMACTA.xml:S3:3771:2	O
.	PROMACTA.xml:S3:3775:1	O

In	PROMACTA.xml:S3:3781:2	O
a	PROMACTA.xml:S3:3784:1	O
controlled	PROMACTA.xml:S3:3786:10	O
trial	PROMACTA.xml:S3:3797:5	O
in	PROMACTA.xml:S3:3803:2	O
patients	PROMACTA.xml:S3:3806:8	O
with	PROMACTA.xml:S3:3815:4	O
chronic	PROMACTA.xml:S3:3820:7	O
liver	PROMACTA.xml:S3:3828:5	O
disease	PROMACTA.xml:S3:3834:7	O
and	PROMACTA.xml:S3:3842:3	O
thrombocytopenia	PROMACTA.xml:S3:3846:16	O
not	PROMACTA.xml:S3:3863:3	O
related	PROMACTA.xml:S3:3867:7	O
to	PROMACTA.xml:S3:3875:2	O
ITP	PROMACTA.xml:S3:3878:3	O
undergoing	PROMACTA.xml:S3:3882:10	O
elective	PROMACTA.xml:S3:3893:8	O
invasive	PROMACTA.xml:S3:3902:8	O
procedures	PROMACTA.xml:S3:3911:10	O
(	PROMACTA.xml:S3:3922:1	O
N	PROMACTA.xml:S3:3923:1	O
292	PROMACTA.xml:S3:3927:3	O
)	PROMACTA.xml:S3:3930:1	O
,	PROMACTA.xml:S3:3931:1	O
the	PROMACTA.xml:S3:3933:3	O
risk	PROMACTA.xml:S3:3937:4	B-Factor
of	PROMACTA.xml:S3:3942:2	O
thrombotic	PROMACTA.xml:S3:3945:10	B-AdverseReaction
events	PROMACTA.xml:S3:3956:6	I-AdverseReaction
was	PROMACTA.xml:S3:3963:3	O
increased	PROMACTA.xml:S3:3967:9	O
in	PROMACTA.xml:S3:3977:2	O
patients	PROMACTA.xml:S3:3980:8	O
treated	PROMACTA.xml:S3:3989:7	O
with	PROMACTA.xml:S3:3997:4	O
75	PROMACTA.xml:S3:4002:2	O
mg	PROMACTA.xml:S3:4005:2	O
of	PROMACTA.xml:S3:4008:2	O
PROMACTA	PROMACTA.xml:S3:4011:8	O
once	PROMACTA.xml:S3:4020:4	O
daily	PROMACTA.xml:S3:4025:5	O
.	PROMACTA.xml:S3:4030:1	O

Seven	PROMACTA.xml:S3:4032:5	O
thrombotic	PROMACTA.xml:S3:4038:10	B-AdverseReaction
complications	PROMACTA.xml:S3:4049:13	I-AdverseReaction
(	PROMACTA.xml:S3:4063:1	O
six	PROMACTA.xml:S3:4064:3	O
patients	PROMACTA.xml:S3:4068:8	O
)	PROMACTA.xml:S3:4076:1	O
were	PROMACTA.xml:S3:4078:4	O
reported	PROMACTA.xml:S3:4083:8	O
in	PROMACTA.xml:S3:4092:2	O
the	PROMACTA.xml:S3:4095:3	O
group	PROMACTA.xml:S3:4099:5	O
that	PROMACTA.xml:S3:4105:4	O
received	PROMACTA.xml:S3:4110:8	O
PROMACTA	PROMACTA.xml:S3:4119:8	O
and	PROMACTA.xml:S3:4128:3	O
three	PROMACTA.xml:S3:4132:5	O
thrombotic	PROMACTA.xml:S3:4138:10	B-AdverseReaction
complications	PROMACTA.xml:S3:4149:13	I-AdverseReaction
were	PROMACTA.xml:S3:4163:4	O
reported	PROMACTA.xml:S3:4168:8	O
in	PROMACTA.xml:S3:4177:2	O
the	PROMACTA.xml:S3:4180:3	O
placebo	PROMACTA.xml:S3:4184:7	B-Factor
group	PROMACTA.xml:S3:4192:5	O
(	PROMACTA.xml:S3:4198:1	O
two	PROMACTA.xml:S3:4199:3	O
patients	PROMACTA.xml:S3:4203:8	O
)	PROMACTA.xml:S3:4211:1	O
.	PROMACTA.xml:S3:4212:1	O

All	PROMACTA.xml:S3:4214:3	O
of	PROMACTA.xml:S3:4218:2	O
the	PROMACTA.xml:S3:4221:3	O
thrombotic	PROMACTA.xml:S3:4225:10	B-AdverseReaction
complications	PROMACTA.xml:S3:4236:13	I-AdverseReaction
reported	PROMACTA.xml:S3:4250:8	O
in	PROMACTA.xml:S3:4259:2	O
the	PROMACTA.xml:S3:4262:3	O
group	PROMACTA.xml:S3:4266:5	O
that	PROMACTA.xml:S3:4272:4	O
received	PROMACTA.xml:S3:4277:8	O
PROMACTA	PROMACTA.xml:S3:4286:8	O
were	PROMACTA.xml:S3:4295:4	O
portal	PROMACTA.xml:S3:4300:6	B-AdverseReaction
vein	PROMACTA.xml:S3:4307:4	I-AdverseReaction
thrombosis	PROMACTA.xml:S3:4312:10	I-AdverseReaction
(	PROMACTA.xml:S3:4323:1	O
PVT	PROMACTA.xml:S3:4324:3	B-AdverseReaction
)	PROMACTA.xml:S3:4327:1	O
.	PROMACTA.xml:S3:4328:1	O

Symptoms	PROMACTA.xml:S3:4330:8	O
of	PROMACTA.xml:S3:4339:2	O
PVT	PROMACTA.xml:S3:4342:3	B-AdverseReaction
included	PROMACTA.xml:S3:4346:8	O
abdominal	PROMACTA.xml:S3:4355:9	B-AdverseReaction
pain	PROMACTA.xml:S3:4365:4	I-AdverseReaction
,	PROMACTA.xml:S3:4369:1	O
nausea	PROMACTA.xml:S3:4371:6	B-AdverseReaction
,	PROMACTA.xml:S3:4377:1	O
vomiting	PROMACTA.xml:S3:4379:8	B-AdverseReaction
,	PROMACTA.xml:S3:4387:1	O
and	PROMACTA.xml:S3:4389:3	O
diarrhea	PROMACTA.xml:S3:4393:8	B-AdverseReaction
.	PROMACTA.xml:S3:4401:1	O

Five	PROMACTA.xml:S3:4403:4	O
of	PROMACTA.xml:S3:4408:2	O
the	PROMACTA.xml:S3:4411:3	O
six	PROMACTA.xml:S3:4415:3	O
patients	PROMACTA.xml:S3:4419:8	O
in	PROMACTA.xml:S3:4428:2	O
the	PROMACTA.xml:S3:4431:3	O
group	PROMACTA.xml:S3:4435:5	O
that	PROMACTA.xml:S3:4441:4	O
received	PROMACTA.xml:S3:4446:8	O
PROMACTA	PROMACTA.xml:S3:4455:8	O
experienced	PROMACTA.xml:S3:4464:11	O
a	PROMACTA.xml:S3:4476:1	O
thrombotic	PROMACTA.xml:S3:4478:10	B-AdverseReaction
complication	PROMACTA.xml:S3:4489:12	I-AdverseReaction
within	PROMACTA.xml:S3:4502:6	O
30	PROMACTA.xml:S3:4509:2	O
days	PROMACTA.xml:S3:4512:4	O
of	PROMACTA.xml:S3:4517:2	O
completing	PROMACTA.xml:S3:4520:10	O
treatment	PROMACTA.xml:S3:4531:9	O
with	PROMACTA.xml:S3:4541:4	O
PROMACTA	PROMACTA.xml:S3:4546:8	O
and	PROMACTA.xml:S3:4555:3	O
at	PROMACTA.xml:S3:4559:2	O
a	PROMACTA.xml:S3:4562:1	O
platelet	PROMACTA.xml:S3:4564:8	O
count	PROMACTA.xml:S3:4573:5	O
above	PROMACTA.xml:S3:4579:5	O
200	PROMACTA.xml:S3:4585:3	O
x	PROMACTA.xml:S3:4589:1	O
10	PROMACTA.xml:S3:4591:2	O
9	PROMACTA.xml:S3:4595:1	O
L.	PROMACTA.xml:S3:4599:2	O

The	PROMACTA.xml:S3:4602:3	O
risk	PROMACTA.xml:S3:4606:4	B-Factor
of	PROMACTA.xml:S3:4611:2	O
portal	PROMACTA.xml:S3:4614:6	B-AdverseReaction
venous	PROMACTA.xml:S3:4621:6	I-AdverseReaction
thrombosis	PROMACTA.xml:S3:4628:10	I-AdverseReaction
was	PROMACTA.xml:S3:4639:3	O
increased	PROMACTA.xml:S3:4643:9	O
in	PROMACTA.xml:S3:4653:2	O
thrombocytopenic	PROMACTA.xml:S3:4656:16	O
patients	PROMACTA.xml:S3:4673:8	O
with	PROMACTA.xml:S3:4682:4	O
chronic	PROMACTA.xml:S3:4687:7	O
liver	PROMACTA.xml:S3:4695:5	O
disease	PROMACTA.xml:S3:4701:7	O
treated	PROMACTA.xml:S3:4709:7	O
with	PROMACTA.xml:S3:4717:4	O
75	PROMACTA.xml:S3:4722:2	O
mg	PROMACTA.xml:S3:4725:2	O
of	PROMACTA.xml:S3:4728:2	O
PROMACTA	PROMACTA.xml:S3:4731:8	O
once	PROMACTA.xml:S3:4740:4	O
daily	PROMACTA.xml:S3:4745:5	O
for	PROMACTA.xml:S3:4751:3	O
2	PROMACTA.xml:S3:4755:1	O
weeks	PROMACTA.xml:S3:4757:5	O
in	PROMACTA.xml:S3:4763:2	O
preparation	PROMACTA.xml:S3:4766:11	O
for	PROMACTA.xml:S3:4778:3	O
invasive	PROMACTA.xml:S3:4782:8	O
procedures	PROMACTA.xml:S3:4791:10	O
.	PROMACTA.xml:S3:4801:1	O

5.4	PROMACTA.xml:S3:4810:3	O
Cataracts	PROMACTA.xml:S3:4814:9	O

In	PROMACTA.xml:S3:4829:2	O
the	PROMACTA.xml:S3:4832:3	O
three	PROMACTA.xml:S3:4836:5	O
controlled	PROMACTA.xml:S3:4842:10	O
clinical	PROMACTA.xml:S3:4853:8	O
trials	PROMACTA.xml:S3:4862:6	O
in	PROMACTA.xml:S3:4869:2	O
adults	PROMACTA.xml:S3:4872:6	O
with	PROMACTA.xml:S3:4879:4	O
chronic	PROMACTA.xml:S3:4884:7	O
ITP	PROMACTA.xml:S3:4892:3	O
,	PROMACTA.xml:S3:4895:1	O
cataracts	PROMACTA.xml:S3:4897:9	B-AdverseReaction
developed	PROMACTA.xml:S3:4907:9	O
or	PROMACTA.xml:S3:4917:2	O
worsened	PROMACTA.xml:S3:4920:8	O
in	PROMACTA.xml:S3:4929:2	O
15	PROMACTA.xml:S3:4932:2	O
(	PROMACTA.xml:S3:4935:1	O
7%	PROMACTA.xml:S3:4936:2	O
)	PROMACTA.xml:S3:4938:1	O
patients	PROMACTA.xml:S3:4940:8	O
who	PROMACTA.xml:S3:4949:3	O
received	PROMACTA.xml:S3:4953:8	O
50	PROMACTA.xml:S3:4962:2	O
mg	PROMACTA.xml:S3:4965:2	O
of	PROMACTA.xml:S3:4968:2	O
PROMACTA	PROMACTA.xml:S3:4971:8	O
daily	PROMACTA.xml:S3:4980:5	O
and	PROMACTA.xml:S3:4986:3	O
8	PROMACTA.xml:S3:4990:1	O
(	PROMACTA.xml:S3:4992:1	O
7%	PROMACTA.xml:S3:4993:2	O
)	PROMACTA.xml:S3:4995:1	O
placebo	PROMACTA.xml:S3:4997:7	O
-	PROMACTA.xml:S3:5004:1	O
group	PROMACTA.xml:S3:5005:5	O
patients	PROMACTA.xml:S3:5011:8	O
.	PROMACTA.xml:S3:5019:1	O

In	PROMACTA.xml:S3:5021:2	O
the	PROMACTA.xml:S3:5024:3	O
extension	PROMACTA.xml:S3:5028:9	O
trial	PROMACTA.xml:S3:5038:5	O
,	PROMACTA.xml:S3:5043:1	O
cataracts	PROMACTA.xml:S3:5045:9	B-AdverseReaction
developed	PROMACTA.xml:S3:5055:9	O
or	PROMACTA.xml:S3:5065:2	O
worsened	PROMACTA.xml:S3:5068:8	O
in	PROMACTA.xml:S3:5077:2	O
4%	PROMACTA.xml:S3:5080:2	O
of	PROMACTA.xml:S3:5083:2	O
patients	PROMACTA.xml:S3:5086:8	O
who	PROMACTA.xml:S3:5095:3	O
underwent	PROMACTA.xml:S3:5099:9	O
ocular	PROMACTA.xml:S3:5109:6	O
examination	PROMACTA.xml:S3:5116:11	O
prior	PROMACTA.xml:S3:5128:5	O
to	PROMACTA.xml:S3:5134:2	O
therapy	PROMACTA.xml:S3:5137:7	O
with	PROMACTA.xml:S3:5145:4	O
PROMACTA	PROMACTA.xml:S3:5150:8	O
.	PROMACTA.xml:S3:5158:1	O

In	PROMACTA.xml:S3:5160:2	O
the	PROMACTA.xml:S3:5163:3	O
two	PROMACTA.xml:S3:5167:3	O
controlled	PROMACTA.xml:S3:5171:10	O
clinical	PROMACTA.xml:S3:5182:8	O
trials	PROMACTA.xml:S3:5191:6	O
in	PROMACTA.xml:S3:5198:2	O
patients	PROMACTA.xml:S3:5201:8	O
with	PROMACTA.xml:S3:5210:4	O
chronic	PROMACTA.xml:S3:5215:7	O
hepatitis	PROMACTA.xml:S3:5223:9	O
C	PROMACTA.xml:S3:5233:1	O
and	PROMACTA.xml:S3:5235:3	O
thrombocytopenia	PROMACTA.xml:S3:5239:16	O
,	PROMACTA.xml:S3:5255:1	O
cataracts	PROMACTA.xml:S3:5257:9	B-AdverseReaction
developed	PROMACTA.xml:S3:5267:9	O
or	PROMACTA.xml:S3:5277:2	O
worsened	PROMACTA.xml:S3:5280:8	O
in	PROMACTA.xml:S3:5289:2	O
8%	PROMACTA.xml:S3:5292:2	O
patients	PROMACTA.xml:S3:5295:8	O
treated	PROMACTA.xml:S3:5304:7	O
with	PROMACTA.xml:S3:5312:4	O
PROMACTA	PROMACTA.xml:S3:5317:8	O
and	PROMACTA.xml:S3:5326:3	O
5%	PROMACTA.xml:S3:5330:2	O
patients	PROMACTA.xml:S3:5333:8	O
treated	PROMACTA.xml:S3:5342:7	O
with	PROMACTA.xml:S3:5350:4	O
placebo	PROMACTA.xml:S3:5355:7	O
.	PROMACTA.xml:S3:5362:1	O

Cataracts	PROMACTA.xml:S3:5368:9	B-AdverseReaction
were	PROMACTA.xml:S3:5378:4	O
observed	PROMACTA.xml:S3:5383:8	O
in	PROMACTA.xml:S3:5392:2	O
toxicology	PROMACTA.xml:S3:5395:10	O
studies	PROMACTA.xml:S3:5406:7	O
of	PROMACTA.xml:S3:5414:2	O
eltrombopag	PROMACTA.xml:S3:5417:11	O
in	PROMACTA.xml:S3:5429:2	O
rodents	PROMACTA.xml:S3:5432:7	B-Animal
[	PROMACTA.xml:S3:5440:1	O
see	PROMACTA.xml:S3:5441:3	O
Nonclinical	PROMACTA.xml:S3:5445:11	O
Toxicology	PROMACTA.xml:S3:5457:10	O
(	PROMACTA.xml:S3:5468:1	O
13.2	PROMACTA.xml:S3:5469:4	O
)]	PROMACTA.xml:S3:5473:2	O
.	PROMACTA.xml:S3:5477:1	O

Perform	PROMACTA.xml:S3:5479:7	O
a	PROMACTA.xml:S3:5487:1	O
baseline	PROMACTA.xml:S3:5489:8	O
ocular	PROMACTA.xml:S3:5498:6	O
examination	PROMACTA.xml:S3:5505:11	O
prior	PROMACTA.xml:S3:5517:5	O
to	PROMACTA.xml:S3:5523:2	O
administration	PROMACTA.xml:S3:5526:14	O
of	PROMACTA.xml:S3:5541:2	O
PROMACTA	PROMACTA.xml:S3:5544:8	O
and	PROMACTA.xml:S3:5553:3	O
,	PROMACTA.xml:S3:5556:1	O
during	PROMACTA.xml:S3:5558:6	O
therapy	PROMACTA.xml:S3:5565:7	O
with	PROMACTA.xml:S3:5573:4	O
PROMACTA	PROMACTA.xml:S3:5578:8	O
,	PROMACTA.xml:S3:5586:1	O
regularly	PROMACTA.xml:S3:5588:9	O
monitor	PROMACTA.xml:S3:5598:7	O
patients	PROMACTA.xml:S3:5606:8	O
for	PROMACTA.xml:S3:5615:3	O
signs	PROMACTA.xml:S3:5619:5	O
and	PROMACTA.xml:S3:5625:3	O
symptoms	PROMACTA.xml:S3:5629:8	O
of	PROMACTA.xml:S3:5638:2	O
cataracts	PROMACTA.xml:S3:5641:9	O
.	PROMACTA.xml:S3:5650:1	O
6	QUTENZA.xml:S1:4:1	O
ADVERSE	QUTENZA.xml:S1:6:7	O
REACTIONS	QUTENZA.xml:S1:14:9	O

The	QUTENZA.xml:S1:27:3	O
following	QUTENZA.xml:S1:31:9	O
serious	QUTENZA.xml:S1:41:7	O
adverse	QUTENZA.xml:S1:49:7	O
reactions	QUTENZA.xml:S1:57:9	O
are	QUTENZA.xml:S1:67:3	O
discussed	QUTENZA.xml:S1:71:9	O
elsewhere	QUTENZA.xml:S1:81:9	O
in	QUTENZA.xml:S1:91:2	O
the	QUTENZA.xml:S1:94:3	O
labeling	QUTENZA.xml:S1:98:8	O
:	QUTENZA.xml:S1:106:1	O

Application	QUTENZA.xml:S1:112:11	B-AdverseReaction
-	QUTENZA.xml:S1:123:1	I-AdverseReaction
Associated	QUTENZA.xml:S1:124:10	I-AdverseReaction
Pain	QUTENZA.xml:S1:135:4	I-AdverseReaction
[	QUTENZA.xml:S1:140:1	O
see	QUTENZA.xml:S1:143:3	O
Warnings	QUTENZA.xml:S1:148:8	O
and	QUTENZA.xml:S1:157:3	O
Precautions	QUTENZA.xml:S1:161:11	O
(	QUTENZA.xml:S1:173:1	O
5.4	QUTENZA.xml:S1:174:3	O
)]	QUTENZA.xml:S1:179:2	O

Increase	QUTENZA.xml:S1:188:8	B-AdverseReaction
in	QUTENZA.xml:S1:197:2	I-AdverseReaction
Blood	QUTENZA.xml:S1:200:5	I-AdverseReaction
Pressure	QUTENZA.xml:S1:206:8	I-AdverseReaction
[	QUTENZA.xml:S1:215:1	O
see	QUTENZA.xml:S1:218:3	O
Warnings	QUTENZA.xml:S1:223:8	O
and	QUTENZA.xml:S1:232:3	O
Precautions	QUTENZA.xml:S1:236:11	O
(	QUTENZA.xml:S1:248:1	O
5.5	QUTENZA.xml:S1:249:3	O
)]	QUTENZA.xml:S1:254:2	O

EXCERPT	QUTENZA.xml:S1:265:7	O
:	QUTENZA.xml:S1:272:1	O
The	QUTENZA.xml:S1:276:3	O
most	QUTENZA.xml:S1:280:4	O
common	QUTENZA.xml:S1:285:6	O
adverse	QUTENZA.xml:S1:292:7	O
reactions	QUTENZA.xml:S1:300:9	O
(	QUTENZA.xml:S1:310:1	O
5%	QUTENZA.xml:S1:314:2	O
and	QUTENZA.xml:S1:317:3	O
greater	QUTENZA.xml:S1:321:7	O
than	QUTENZA.xml:S1:329:4	O
control	QUTENZA.xml:S1:334:7	O
)	QUTENZA.xml:S1:341:1	O
are	QUTENZA.xml:S1:343:3	O
application	QUTENZA.xml:S1:347:11	B-AdverseReaction
site	QUTENZA.xml:S1:359:4	I-AdverseReaction
erythema	QUTENZA.xml:S1:364:8	I-AdverseReaction
,	QUTENZA.xml:S1:372:1	O
application	QUTENZA.xml:S1:374:11	B-AdverseReaction
site	QUTENZA.xml:S1:386:4	I-AdverseReaction
pain	QUTENZA.xml:S1:391:4	I-AdverseReaction
,	QUTENZA.xml:S1:395:1	O
application	QUTENZA.xml:S1:397:11	B-AdverseReaction
site	QUTENZA.xml:S1:409:4	I-AdverseReaction
pruritus	QUTENZA.xml:S1:414:8	I-AdverseReaction
and	QUTENZA.xml:S1:423:3	O
application	QUTENZA.xml:S1:427:11	B-AdverseReaction
site	QUTENZA.xml:S1:439:4	I-AdverseReaction
papules	QUTENZA.xml:S1:444:7	I-AdverseReaction
.	QUTENZA.xml:S1:451:1	O

(	QUTENZA.xml:S1:453:1	O
6.1	QUTENZA.xml:S1:456:3	O
)	QUTENZA.xml:S1:461:1	O

To	QUTENZA.xml:S1:469:2	O
report	QUTENZA.xml:S1:472:6	O
SUSPECTED	QUTENZA.xml:S1:479:9	O
ADVERSE	QUTENZA.xml:S1:489:7	O
REACTIONS	QUTENZA.xml:S1:497:9	O
,	QUTENZA.xml:S1:506:1	O
contact	QUTENZA.xml:S1:508:7	O
Acorda	QUTENZA.xml:S1:516:6	O
Therapeutics	QUTENZA.xml:S1:523:12	O
at	QUTENZA.xml:S1:536:2	O
1	QUTENZA.xml:S1:539:1	O
-	QUTENZA.xml:S1:540:1	O
877	QUTENZA.xml:S1:541:3	O
-	QUTENZA.xml:S1:544:1	O
900	QUTENZA.xml:S1:545:3	O
-	QUTENZA.xml:S1:548:1	O
6479	QUTENZA.xml:S1:549:4	O
or	QUTENZA.xml:S1:554:2	O
FDA	QUTENZA.xml:S1:557:3	O
at	QUTENZA.xml:S1:561:2	O
1	QUTENZA.xml:S1:564:1	O
-	QUTENZA.xml:S1:565:1	O
800	QUTENZA.xml:S1:566:3	O
-	QUTENZA.xml:S1:569:1	O
FDA	QUTENZA.xml:S1:570:3	O
-	QUTENZA.xml:S1:573:1	O
1088	QUTENZA.xml:S1:574:4	O
or	QUTENZA.xml:S1:579:2	O
www	QUTENZA.xml:S1:582:3	O
.	QUTENZA.xml:S1:585:1	O
fda	QUTENZA.xml:S1:586:3	O
.	QUTENZA.xml:S1:589:1	O
gov	QUTENZA.xml:S1:590:3	O
medwatch	QUTENZA.xml:S1:594:8	O
.	QUTENZA.xml:S1:602:1	O

6.1	QUTENZA.xml:S1:614:3	O

Clinical	QUTENZA.xml:S1:618:8	O
Trials	QUTENZA.xml:S1:627:6	O
Experience	QUTENZA.xml:S1:634:10	O

Because	QUTENZA.xml:S1:648:7	O
clinical	QUTENZA.xml:S1:656:8	O
trials	QUTENZA.xml:S1:665:6	O
are	QUTENZA.xml:S1:672:3	O
conducted	QUTENZA.xml:S1:676:9	O
under	QUTENZA.xml:S1:686:5	O
widely	QUTENZA.xml:S1:692:6	O
varying	QUTENZA.xml:S1:699:7	O
conditions	QUTENZA.xml:S1:707:10	O
,	QUTENZA.xml:S1:717:1	O
adverse	QUTENZA.xml:S1:719:7	O
reaction	QUTENZA.xml:S1:727:8	O
rates	QUTENZA.xml:S1:736:5	O
observed	QUTENZA.xml:S1:742:8	O
in	QUTENZA.xml:S1:751:2	O
the	QUTENZA.xml:S1:754:3	O
clinical	QUTENZA.xml:S1:758:8	O
trials	QUTENZA.xml:S1:767:6	O
of	QUTENZA.xml:S1:774:2	O
a	QUTENZA.xml:S1:777:1	O
drug	QUTENZA.xml:S1:779:4	O
cannot	QUTENZA.xml:S1:784:6	O
be	QUTENZA.xml:S1:791:2	O
directly	QUTENZA.xml:S1:794:8	O
compared	QUTENZA.xml:S1:803:8	O
to	QUTENZA.xml:S1:812:2	O
rates	QUTENZA.xml:S1:815:5	O
in	QUTENZA.xml:S1:821:2	O
the	QUTENZA.xml:S1:824:3	O
clinical	QUTENZA.xml:S1:828:8	O
trials	QUTENZA.xml:S1:837:6	O
of	QUTENZA.xml:S1:844:2	O
other	QUTENZA.xml:S1:847:5	O
drugs	QUTENZA.xml:S1:853:5	O
and	QUTENZA.xml:S1:859:3	O
may	QUTENZA.xml:S1:863:3	O
not	QUTENZA.xml:S1:867:3	O
reflect	QUTENZA.xml:S1:871:7	O
the	QUTENZA.xml:S1:879:3	O
rates	QUTENZA.xml:S1:883:5	O
observed	QUTENZA.xml:S1:889:8	O
in	QUTENZA.xml:S1:898:2	O
clinical	QUTENZA.xml:S1:901:8	O
practice	QUTENZA.xml:S1:910:8	O
.	QUTENZA.xml:S1:918:1	O

Across	QUTENZA.xml:S1:924:6	O
all	QUTENZA.xml:S1:931:3	O
controlled	QUTENZA.xml:S1:935:10	O
and	QUTENZA.xml:S1:946:3	O
uncontrolled	QUTENZA.xml:S1:950:12	O
trials	QUTENZA.xml:S1:963:6	O
,	QUTENZA.xml:S1:969:1	O
more	QUTENZA.xml:S1:971:4	O
than	QUTENZA.xml:S1:976:4	O
1	QUTENZA.xml:S1:981:1	O
,	QUTENZA.xml:S1:982:1	O
600	QUTENZA.xml:S1:983:3	O
patients	QUTENZA.xml:S1:987:8	O
have	QUTENZA.xml:S1:996:4	O
received	QUTENZA.xml:S1:1001:8	O
Qutenza	QUTENZA.xml:S1:1010:7	O
.	QUTENZA.xml:S1:1017:1	O

A	QUTENZA.xml:S1:1019:1	O
total	QUTENZA.xml:S1:1021:5	O
of	QUTENZA.xml:S1:1027:2	O
394	QUTENZA.xml:S1:1030:3	O
patients	QUTENZA.xml:S1:1034:8	O
received	QUTENZA.xml:S1:1043:8	O
more	QUTENZA.xml:S1:1052:4	O
than	QUTENZA.xml:S1:1057:4	O
one	QUTENZA.xml:S1:1062:3	O
treatment	QUTENZA.xml:S1:1066:9	O
application	QUTENZA.xml:S1:1076:11	O
and	QUTENZA.xml:S1:1088:3	O
274	QUTENZA.xml:S1:1092:3	O
patients	QUTENZA.xml:S1:1096:8	O
were	QUTENZA.xml:S1:1105:4	O
followed	QUTENZA.xml:S1:1110:8	O
for	QUTENZA.xml:S1:1119:3	O
48	QUTENZA.xml:S1:1123:2	O
weeks	QUTENZA.xml:S1:1126:5	O
or	QUTENZA.xml:S1:1132:2	O
longer	QUTENZA.xml:S1:1135:6	O
.	QUTENZA.xml:S1:1141:1	O

In	QUTENZA.xml:S1:1147:2	O
controlled	QUTENZA.xml:S1:1150:10	O
clinical	QUTENZA.xml:S1:1161:8	O
studies	QUTENZA.xml:S1:1170:7	O
,	QUTENZA.xml:S1:1177:1	O
98%	QUTENZA.xml:S1:1179:3	O
of	QUTENZA.xml:S1:1183:2	O
patients	QUTENZA.xml:S1:1186:8	O
completed	QUTENZA.xml:S1:1195:9	O
90%	QUTENZA.xml:S1:1208:3	O
of	QUTENZA.xml:S1:1212:2	O
the	QUTENZA.xml:S1:1215:3	O
intended	QUTENZA.xml:S1:1219:8	O
patch	QUTENZA.xml:S1:1228:5	O
application	QUTENZA.xml:S1:1234:11	O
duration	QUTENZA.xml:S1:1246:8	O
.	QUTENZA.xml:S1:1254:1	O

Among	QUTENZA.xml:S1:1256:5	O
patients	QUTENZA.xml:S1:1262:8	O
treated	QUTENZA.xml:S1:1271:7	O
with	QUTENZA.xml:S1:1279:4	O
Qutenza	QUTENZA.xml:S1:1284:7	O
,	QUTENZA.xml:S1:1291:1	O
1%	QUTENZA.xml:S1:1293:2	O
discontinued	QUTENZA.xml:S1:1296:12	O
prematurely	QUTENZA.xml:S1:1309:11	O
due	QUTENZA.xml:S1:1321:3	O
to	QUTENZA.xml:S1:1325:2	O
an	QUTENZA.xml:S1:1328:2	O
adverse	QUTENZA.xml:S1:1331:7	O
event	QUTENZA.xml:S1:1339:5	O
.	QUTENZA.xml:S1:1344:1	O

Controlled	QUTENZA.xml:S1:1354:10	O
Clinical	QUTENZA.xml:S1:1365:8	O
Studies	QUTENZA.xml:S1:1374:7	O

Common	QUTENZA.xml:S1:1392:6	O
Adverse	QUTENZA.xml:S1:1399:7	O
Reactions	QUTENZA.xml:S1:1407:9	O

Adverse	QUTENZA.xml:S1:1423:7	O
reactions	QUTENZA.xml:S1:1431:9	O
occurring	QUTENZA.xml:S1:1441:9	O
in	QUTENZA.xml:S1:1451:2	O
5%	QUTENZA.xml:S1:1457:2	O
of	QUTENZA.xml:S1:1460:2	O
patients	QUTENZA.xml:S1:1463:8	O
in	QUTENZA.xml:S1:1472:2	O
the	QUTENZA.xml:S1:1475:3	O
Qutenza	QUTENZA.xml:S1:1479:7	O
group	QUTENZA.xml:S1:1487:5	O
and	QUTENZA.xml:S1:1493:3	O
at	QUTENZA.xml:S1:1497:2	O
an	QUTENZA.xml:S1:1500:2	O
incidence	QUTENZA.xml:S1:1503:9	O
greater	QUTENZA.xml:S1:1513:7	O
than	QUTENZA.xml:S1:1521:4	O
in	QUTENZA.xml:S1:1526:2	O
the	QUTENZA.xml:S1:1529:3	O
control	QUTENZA.xml:S1:1533:7	O
group	QUTENZA.xml:S1:1541:5	O
were	QUTENZA.xml:S1:1547:4	O
application	QUTENZA.xml:S1:1552:11	B-AdverseReaction
site	QUTENZA.xml:S1:1564:4	I-AdverseReaction
erythema	QUTENZA.xml:S1:1569:8	I-AdverseReaction
,	QUTENZA.xml:S1:1577:1	O
application	QUTENZA.xml:S1:1579:11	B-AdverseReaction
site	QUTENZA.xml:S1:1591:4	I-AdverseReaction
pain	QUTENZA.xml:S1:1596:4	I-AdverseReaction
,	QUTENZA.xml:S1:1600:1	O
application	QUTENZA.xml:S1:1602:11	B-AdverseReaction
site	QUTENZA.xml:S1:1614:4	I-AdverseReaction
pruritus	QUTENZA.xml:S1:1619:8	I-AdverseReaction
and	QUTENZA.xml:S1:1628:3	O
application	QUTENZA.xml:S1:1632:11	B-AdverseReaction
site	QUTENZA.xml:S1:1644:4	I-AdverseReaction
papules	QUTENZA.xml:S1:1649:7	I-AdverseReaction
.	QUTENZA.xml:S1:1656:1	O

Table	QUTENZA.xml:S1:1662:5	O
1	QUTENZA.xml:S1:1668:1	O
summarizes	QUTENZA.xml:S1:1670:10	O
all	QUTENZA.xml:S1:1681:3	O
adverse	QUTENZA.xml:S1:1685:7	O
reactions	QUTENZA.xml:S1:1693:9	O
,	QUTENZA.xml:S1:1702:1	O
regardless	QUTENZA.xml:S1:1704:10	O
of	QUTENZA.xml:S1:1715:2	O
causality	QUTENZA.xml:S1:1718:9	O
,	QUTENZA.xml:S1:1727:1	O
occurring	QUTENZA.xml:S1:1729:9	O
in	QUTENZA.xml:S1:1739:2	O
1%	QUTENZA.xml:S1:1745:2	O
of	QUTENZA.xml:S1:1748:2	O
patients	QUTENZA.xml:S1:1751:8	O
with	QUTENZA.xml:S1:1760:4	O
postherpetic	QUTENZA.xml:S1:1765:12	O
neuralgia	QUTENZA.xml:S1:1778:9	O
in	QUTENZA.xml:S1:1788:2	O
the	QUTENZA.xml:S1:1791:3	O
Qutenza	QUTENZA.xml:S1:1795:7	O
group	QUTENZA.xml:S1:1803:5	O
for	QUTENZA.xml:S1:1809:3	O
which	QUTENZA.xml:S1:1813:5	O
the	QUTENZA.xml:S1:1819:3	O
incidence	QUTENZA.xml:S1:1823:9	O
was	QUTENZA.xml:S1:1833:3	O
greater	QUTENZA.xml:S1:1837:7	O
than	QUTENZA.xml:S1:1845:4	O
in	QUTENZA.xml:S1:1850:2	O
the	QUTENZA.xml:S1:1853:3	O
control	QUTENZA.xml:S1:1857:7	O
group	QUTENZA.xml:S1:1865:5	O
.	QUTENZA.xml:S1:1870:1	O

The	QUTENZA.xml:S1:1872:3	O
majority	QUTENZA.xml:S1:1876:8	O
of	QUTENZA.xml:S1:1885:2	O
application	QUTENZA.xml:S1:1888:11	B-AdverseReaction
site	QUTENZA.xml:S1:1900:4	I-AdverseReaction
reactions	QUTENZA.xml:S1:1905:9	I-AdverseReaction
were	QUTENZA.xml:S1:1915:4	O
transient	QUTENZA.xml:S1:1920:9	B-Severity
and	QUTENZA.xml:S1:1930:3	O
self	QUTENZA.xml:S1:1934:4	O
-	QUTENZA.xml:S1:1938:1	O
limited	QUTENZA.xml:S1:1939:7	O
.	QUTENZA.xml:S1:1946:1	O

Transient	QUTENZA.xml:S1:1948:9	B-Severity
increases	QUTENZA.xml:S1:1958:9	B-AdverseReaction
in	QUTENZA.xml:S1:1968:2	I-AdverseReaction
pain	QUTENZA.xml:S1:1971:4	I-AdverseReaction
were	QUTENZA.xml:S1:1976:4	O
commonly	QUTENZA.xml:S1:1981:8	O
observed	QUTENZA.xml:S1:1990:8	O
on	QUTENZA.xml:S1:1999:2	O
the	QUTENZA.xml:S1:2002:3	O
day	QUTENZA.xml:S1:2006:3	O
of	QUTENZA.xml:S1:2010:2	O
treatment	QUTENZA.xml:S1:2013:9	O
in	QUTENZA.xml:S1:2023:2	O
patients	QUTENZA.xml:S1:2026:8	O
treated	QUTENZA.xml:S1:2035:7	O
with	QUTENZA.xml:S1:2043:4	O
Qutenza	QUTENZA.xml:S1:2048:7	O
.	QUTENZA.xml:S1:2055:1	O

Pain	QUTENZA.xml:S1:2057:4	B-AdverseReaction
increases	QUTENZA.xml:S1:2062:9	I-AdverseReaction
occurring	QUTENZA.xml:S1:2072:9	O
during	QUTENZA.xml:S1:2082:6	O
patch	QUTENZA.xml:S1:2089:5	O
application	QUTENZA.xml:S1:2095:11	O
usually	QUTENZA.xml:S1:2107:7	O
began	QUTENZA.xml:S1:2115:5	O
to	QUTENZA.xml:S1:2121:2	O
resolve	QUTENZA.xml:S1:2124:7	O
after	QUTENZA.xml:S1:2132:5	O
patch	QUTENZA.xml:S1:2138:5	O
removal	QUTENZA.xml:S1:2144:7	O
.	QUTENZA.xml:S1:2151:1	O

On	QUTENZA.xml:S1:2153:2	O
average	QUTENZA.xml:S1:2156:7	O
,	QUTENZA.xml:S1:2163:1	O
pain	QUTENZA.xml:S1:2165:4	O
scores	QUTENZA.xml:S1:2170:6	O
returned	QUTENZA.xml:S1:2177:8	O
to	QUTENZA.xml:S1:2186:2	O
baseline	QUTENZA.xml:S1:2189:8	O
by	QUTENZA.xml:S1:2198:2	O
the	QUTENZA.xml:S1:2201:3	O
end	QUTENZA.xml:S1:2205:3	O
of	QUTENZA.xml:S1:2209:2	O
the	QUTENZA.xml:S1:2212:3	O
treatment	QUTENZA.xml:S1:2216:9	O
day	QUTENZA.xml:S1:2226:3	O
and	QUTENZA.xml:S1:2230:3	O
then	QUTENZA.xml:S1:2234:4	O
remained	QUTENZA.xml:S1:2239:8	O
at	QUTENZA.xml:S1:2248:2	O
or	QUTENZA.xml:S1:2251:2	O
below	QUTENZA.xml:S1:2254:5	O
baseline	QUTENZA.xml:S1:2260:8	O
levels	QUTENZA.xml:S1:2269:6	O
.	QUTENZA.xml:S1:2275:1	O

A	QUTENZA.xml:S1:2277:1	O
majority	QUTENZA.xml:S1:2279:8	O
of	QUTENZA.xml:S1:2288:2	O
Qutenza	QUTENZA.xml:S1:2291:7	O
-	QUTENZA.xml:S1:2298:1	O
treated	QUTENZA.xml:S1:2299:7	O
patients	QUTENZA.xml:S1:2307:8	O
in	QUTENZA.xml:S1:2316:2	O
clinical	QUTENZA.xml:S1:2319:8	O
studies	QUTENZA.xml:S1:2328:7	O
had	QUTENZA.xml:S1:2336:3	O
adverse	QUTENZA.xml:S1:2340:7	O
reactions	QUTENZA.xml:S1:2348:9	O
with	QUTENZA.xml:S1:2358:4	O
a	QUTENZA.xml:S1:2363:1	O
maximum	QUTENZA.xml:S1:2365:7	O
intensity	QUTENZA.xml:S1:2373:9	O
of	QUTENZA.xml:S1:2383:2	O
"	QUTENZA.xml:S1:2386:1	O
mild	QUTENZA.xml:S1:2387:4	O
"	QUTENZA.xml:S1:2391:1	O
or	QUTENZA.xml:S1:2393:2	O
"	QUTENZA.xml:S1:2396:1	O
moderate	QUTENZA.xml:S1:2397:8	O
"	QUTENZA.xml:S1:2405:1	O
.	QUTENZA.xml:S1:2406:1	O

TABLE	QUTENZA.xml:S1:2412:5	O
1	QUTENZA.xml:S1:2418:1	O
:	QUTENZA.xml:S1:2419:1	O
Treatment	QUTENZA.xml:S1:2421:9	O
-	QUTENZA.xml:S1:2430:1	O
emergent	QUTENZA.xml:S1:2431:8	O
adverse	QUTENZA.xml:S1:2440:7	O
reaction	QUTENZA.xml:S1:2448:8	O
incidence	QUTENZA.xml:S1:2457:9	O
(	QUTENZA.xml:S1:2467:1	O
)	QUTENZA.xml:S1:2469:1	O
in	QUTENZA.xml:S1:2471:2	O
controlled	QUTENZA.xml:S1:2474:10	O
trials	QUTENZA.xml:S1:2485:6	O
in	QUTENZA.xml:S1:2492:2	O
Postherpetic	QUTENZA.xml:S1:2495:12	O
Neuralgia	QUTENZA.xml:S1:2508:9	O
(	QUTENZA.xml:S1:2518:1	O
Events	QUTENZA.xml:S1:2519:6	O
in	QUTENZA.xml:S1:2526:2	O
1%	QUTENZA.xml:S1:2532:2	O
of	QUTENZA.xml:S1:2535:2	O
Qutenza	QUTENZA.xml:S1:2538:7	O
-	QUTENZA.xml:S1:2545:1	O
treated	QUTENZA.xml:S1:2546:7	O
patients	QUTENZA.xml:S1:2554:8	O
and	QUTENZA.xml:S1:2563:3	O
at	QUTENZA.xml:S1:2567:2	O
least	QUTENZA.xml:S1:2570:5	O
1%	QUTENZA.xml:S1:2576:2	O
greater	QUTENZA.xml:S1:2579:7	O
in	QUTENZA.xml:S1:2587:2	O
the	QUTENZA.xml:S1:2590:3	O
Qutenza	QUTENZA.xml:S1:2594:7	O
group	QUTENZA.xml:S1:2602:5	O
than	QUTENZA.xml:S1:2608:4	O
in	QUTENZA.xml:S1:2613:2	O
the	QUTENZA.xml:S1:2616:3	O
Control	QUTENZA.xml:S1:2620:7	O
group	QUTENZA.xml:S1:2628:5	O
)	QUTENZA.xml:S1:2633:1	O

Body	QUTENZA.xml:S1:2637:4	O
SystemPreferred	QUTENZA.xml:S1:2642:15	O
Term	QUTENZA.xml:S1:2658:4	O
Qutenza60	QUTENZA.xml:S1:2689:9	O
minutes	QUTENZA.xml:S1:2699:7	O
(	QUTENZA.xml:S1:2706:1	O
N	QUTENZA.xml:S1:2707:1	O
622	QUTENZA.xml:S1:2711:3	O
)	QUTENZA.xml:S1:2714:1	O
Control60	QUTENZA.xml:S1:2718:9	O
minutes	QUTENZA.xml:S1:2728:7	O
(	QUTENZA.xml:S1:2735:1	O
N	QUTENZA.xml:S1:2736:1	O
495	QUTENZA.xml:S1:2740:3	O
)	QUTENZA.xml:S1:2743:1	O

General	QUTENZA.xml:S1:2755:7	O

Disorders	QUTENZA.xml:S1:2763:9	O
and	QUTENZA.xml:S1:2773:3	O
Administration	QUTENZA.xml:S1:2777:14	O
Site	QUTENZA.xml:S1:2792:4	O
Conditions	QUTENZA.xml:S1:2797:10	O

Application	QUTENZA.xml:S1:2868:11	B-AdverseReaction
Site	QUTENZA.xml:S1:2880:4	I-AdverseReaction
Erythema	QUTENZA.xml:S1:2885:8	I-AdverseReaction
63	QUTENZA.xml:S1:2931:2	O
54	QUTENZA.xml:S1:2958:2	O

Application	QUTENZA.xml:S1:2977:11	B-AdverseReaction
Site	QUTENZA.xml:S1:2989:4	I-AdverseReaction
Pain	QUTENZA.xml:S1:2994:4	I-AdverseReaction
42	QUTENZA.xml:S1:3040:2	O
21	QUTENZA.xml:S1:3067:2	O

Application	QUTENZA.xml:S1:3086:11	B-AdverseReaction
Site	QUTENZA.xml:S1:3098:4	I-AdverseReaction
Pruritus	QUTENZA.xml:S1:3103:8	I-AdverseReaction
6	QUTENZA.xml:S1:3150:1	O
4	QUTENZA.xml:S1:3177:1	O

Application	QUTENZA.xml:S1:3195:11	B-AdverseReaction
Site	QUTENZA.xml:S1:3207:4	I-AdverseReaction
Papules	QUTENZA.xml:S1:3212:7	I-AdverseReaction
6	QUTENZA.xml:S1:3259:1	O
3	QUTENZA.xml:S1:3286:1	O

Application	QUTENZA.xml:S1:3304:11	B-AdverseReaction
Site	QUTENZA.xml:S1:3316:4	I-AdverseReaction
Edema	QUTENZA.xml:S1:3321:5	I-AdverseReaction
4	QUTENZA.xml:S1:3368:1	O
1	QUTENZA.xml:S1:3395:1	O

Application	QUTENZA.xml:S1:3413:11	B-AdverseReaction
Site	QUTENZA.xml:S1:3425:4	I-AdverseReaction
Swelling	QUTENZA.xml:S1:3430:8	I-AdverseReaction
2	QUTENZA.xml:S1:3477:1	O
1	QUTENZA.xml:S1:3504:1	O

Application	QUTENZA.xml:S1:3522:11	B-AdverseReaction
Site	QUTENZA.xml:S1:3534:4	I-AdverseReaction
Dryness	QUTENZA.xml:S1:3539:7	I-AdverseReaction
2	QUTENZA.xml:S1:3586:1	O
1	QUTENZA.xml:S1:3613:1	O

Infections	QUTENZA.xml:S1:3633:10	O
and	QUTENZA.xml:S1:3644:3	O
Infestations	QUTENZA.xml:S1:3648:12	O

Nasopharyngitis	QUTENZA.xml:S1:3740:15	B-AdverseReaction
4	QUTENZA.xml:S1:3804:1	O
2	QUTENZA.xml:S1:3831:1	O

Bronchitis	QUTENZA.xml:S1:3849:10	B-AdverseReaction
2	QUTENZA.xml:S1:3913:1	O
1	QUTENZA.xml:S1:3940:1	O

Sinusitis	QUTENZA.xml:S1:3958:9	B-AdverseReaction
3	QUTENZA.xml:S1:4022:1	O
1	QUTENZA.xml:S1:4049:1	O

Gastrointestinal	QUTENZA.xml:S1:4069:16	O
Disorders	QUTENZA.xml:S1:4086:9	O

Nausea	QUTENZA.xml:S1:4176:6	B-AdverseReaction
5	QUTENZA.xml:S1:4240:1	O
2	QUTENZA.xml:S1:4267:1	O

Vomiting	QUTENZA.xml:S1:4285:8	B-AdverseReaction
3	QUTENZA.xml:S1:4349:1	O
1	QUTENZA.xml:S1:4376:1	O

Skin	QUTENZA.xml:S1:4396:4	O
and	QUTENZA.xml:S1:4401:3	O
Subcutaneous	QUTENZA.xml:S1:4405:12	O
Tissue	QUTENZA.xml:S1:4418:6	O
Disorder	QUTENZA.xml:S1:4425:8	O

Pruritus	QUTENZA.xml:S1:4503:8	B-AdverseReaction
2	QUTENZA.xml:S1:4567:1	O
1	QUTENZA.xml:S1:4595:1	O

Vascular	QUTENZA.xml:S1:4614:8	O
Disorders	QUTENZA.xml:S1:4623:9	O

Hypertension	QUTENZA.xml:S1:4721:12	B-AdverseReaction
2	QUTENZA.xml:S1:4785:1	O
1	QUTENZA.xml:S1:4812:1	O

Other	QUTENZA.xml:S1:4842:5	O
Adverse	QUTENZA.xml:S1:4848:7	O
Reactions	QUTENZA.xml:S1:4856:9	O
Observed	QUTENZA.xml:S1:4866:8	O
During	QUTENZA.xml:S1:4875:6	O
the	QUTENZA.xml:S1:4882:3	O
Clinical	QUTENZA.xml:S1:4886:8	O
Studies	QUTENZA.xml:S1:4895:7	O
of	QUTENZA.xml:S1:4903:2	O
Qutenza	QUTENZA.xml:S1:4906:7	O

General	QUTENZA.xml:S1:4920:7	O

Disorders	QUTENZA.xml:S1:4928:9	O
and	QUTENZA.xml:S1:4938:3	O
Administration	QUTENZA.xml:S1:4942:14	O
Site	QUTENZA.xml:S1:4957:4	O
Conditions	QUTENZA.xml:S1:4962:10	O
:	QUTENZA.xml:S1:4972:1	O
Application	QUTENZA.xml:S1:4974:11	B-AdverseReaction
site	QUTENZA.xml:S1:4986:4	I-AdverseReaction
urticaria	QUTENZA.xml:S1:4991:9	I-AdverseReaction
,	QUTENZA.xml:S1:5000:1	O
Application	QUTENZA.xml:S1:5002:11	B-AdverseReaction
site	QUTENZA.xml:S1:5014:4	I-AdverseReaction
paresthesia	QUTENZA.xml:S1:5019:11	I-AdverseReaction
,	QUTENZA.xml:S1:5030:1	O
Application	QUTENZA.xml:S1:5032:11	B-AdverseReaction
site	QUTENZA.xml:S1:5044:4	I-AdverseReaction
dermatitis	QUTENZA.xml:S1:5049:10	I-AdverseReaction
,	QUTENZA.xml:S1:5059:1	O
Application	QUTENZA.xml:S1:5061:11	B-AdverseReaction
site	QUTENZA.xml:S1:5073:4	I-AdverseReaction
hyperesthesia	QUTENZA.xml:S1:5078:13	I-AdverseReaction
,	QUTENZA.xml:S1:5091:1	O
Application	QUTENZA.xml:S1:5093:11	B-AdverseReaction
site	QUTENZA.xml:S1:5105:4	I-AdverseReaction
excoriation	QUTENZA.xml:S1:5110:11	I-AdverseReaction
,	QUTENZA.xml:S1:5121:1	O
Application	QUTENZA.xml:S1:5123:11	B-AdverseReaction
site	QUTENZA.xml:S1:5135:4	I-AdverseReaction
warmth	QUTENZA.xml:S1:5140:6	I-AdverseReaction
,	QUTENZA.xml:S1:5146:1	O
Application	QUTENZA.xml:S1:5148:11	B-AdverseReaction
site	QUTENZA.xml:S1:5160:4	I-AdverseReaction
anesthesia	QUTENZA.xml:S1:5165:10	I-AdverseReaction
,	QUTENZA.xml:S1:5175:1	O
Application	QUTENZA.xml:S1:5177:11	B-AdverseReaction
site	QUTENZA.xml:S1:5189:4	I-AdverseReaction
bruising	QUTENZA.xml:S1:5194:8	I-AdverseReaction
,	QUTENZA.xml:S1:5202:1	O
Application	QUTENZA.xml:S1:5204:11	B-AdverseReaction
site	QUTENZA.xml:S1:5216:4	I-AdverseReaction
inflammation	QUTENZA.xml:S1:5221:12	I-AdverseReaction
,	QUTENZA.xml:S1:5233:1	O
Application	QUTENZA.xml:S1:5235:11	B-AdverseReaction
site	QUTENZA.xml:S1:5247:4	I-AdverseReaction
exfoliation	QUTENZA.xml:S1:5252:11	I-AdverseReaction
,	QUTENZA.xml:S1:5263:1	O
Peripheral	QUTENZA.xml:S1:5265:10	B-AdverseReaction
edema	QUTENZA.xml:S1:5276:5	I-AdverseReaction

Nervous	QUTENZA.xml:S1:5286:7	O
System	QUTENZA.xml:S1:5294:6	O
Disorders	QUTENZA.xml:S1:5301:9	O
:	QUTENZA.xml:S1:5310:1	O
Headache	QUTENZA.xml:S1:5312:8	B-AdverseReaction
,	QUTENZA.xml:S1:5320:1	O
Burning	QUTENZA.xml:S1:5322:7	B-AdverseReaction
sensation	QUTENZA.xml:S1:5330:9	I-AdverseReaction
,	QUTENZA.xml:S1:5339:1	O
Peripheral	QUTENZA.xml:S1:5341:10	B-AdverseReaction
sensory	QUTENZA.xml:S1:5352:7	I-AdverseReaction
neuropathy	QUTENZA.xml:S1:5360:10	I-AdverseReaction
,	QUTENZA.xml:S1:5370:1	O
Dizziness	QUTENZA.xml:S1:5372:9	B-AdverseReaction
,	QUTENZA.xml:S1:5381:1	O
Dysgeusia	QUTENZA.xml:S1:5383:9	B-AdverseReaction
,	QUTENZA.xml:S1:5392:1	O
Hyperesthesia	QUTENZA.xml:S1:5394:13	B-AdverseReaction
,	QUTENZA.xml:S1:5407:1	O
Hypoesthesia	QUTENZA.xml:S1:5409:12	B-AdverseReaction

Respiratory	QUTENZA.xml:S1:5426:11	O
,	QUTENZA.xml:S1:5437:1	O
Thoracic	QUTENZA.xml:S1:5439:8	O
and	QUTENZA.xml:S1:5448:3	O
Mediastinal	QUTENZA.xml:S1:5452:11	O
Disorders	QUTENZA.xml:S1:5464:9	O
:	QUTENZA.xml:S1:5473:1	O
Cough	QUTENZA.xml:S1:5475:5	B-AdverseReaction
,	QUTENZA.xml:S1:5480:1	O
Throat	QUTENZA.xml:S1:5482:6	B-AdverseReaction
irritation	QUTENZA.xml:S1:5489:10	I-AdverseReaction

Skin	QUTENZA.xml:S1:5504:4	O
and	QUTENZA.xml:S1:5509:3	O
Subcutaneous	QUTENZA.xml:S1:5513:12	O
Tissue	QUTENZA.xml:S1:5526:6	O
Disorders	QUTENZA.xml:S1:5533:9	O
:	QUTENZA.xml:S1:5542:1	O
Abnormal	QUTENZA.xml:S1:5544:8	B-AdverseReaction
skin	QUTENZA.xml:S1:5553:4	I-AdverseReaction
odor	QUTENZA.xml:S1:5558:4	I-AdverseReaction
5	QUTENZA.xml:S2:4:1	O
WARNINGS	QUTENZA.xml:S2:6:8	O
AND	QUTENZA.xml:S2:15:3	O
PRECAUTIONS	QUTENZA.xml:S2:19:11	O

EXCERPT	QUTENZA.xml:S2:37:7	O
:	QUTENZA.xml:S2:44:1	O
Do	QUTENZA.xml:S2:52:2	O
not	QUTENZA.xml:S2:55:3	O
use	QUTENZA.xml:S2:59:3	O
near	QUTENZA.xml:S2:63:4	O
eyes	QUTENZA.xml:S2:68:4	O
or	QUTENZA.xml:S2:73:2	O
mucous	QUTENZA.xml:S2:76:6	O
membranes	QUTENZA.xml:S2:83:9	O
.	QUTENZA.xml:S2:92:1	O

(	QUTENZA.xml:S2:94:1	O
5.1	QUTENZA.xml:S2:97:3	O
)	QUTENZA.xml:S2:102:1	O

Inhalation	QUTENZA.xml:S2:109:10	O
of	QUTENZA.xml:S2:120:2	O
airborne	QUTENZA.xml:S2:123:8	O
capsaicin	QUTENZA.xml:S2:132:9	O
can	QUTENZA.xml:S2:142:3	B-Factor
result	QUTENZA.xml:S2:146:6	O
in	QUTENZA.xml:S2:153:2	O
coughing	QUTENZA.xml:S2:156:8	B-AdverseReaction
or	QUTENZA.xml:S2:165:2	O
sneezing	QUTENZA.xml:S2:168:8	B-AdverseReaction
.	QUTENZA.xml:S2:176:1	O

(	QUTENZA.xml:S2:178:1	O
5.2	QUTENZA.xml:S2:181:3	O
)	QUTENZA.xml:S2:186:1	O

If	QUTENZA.xml:S2:193:2	O
irritation	QUTENZA.xml:S2:196:10	O
of	QUTENZA.xml:S2:207:2	O
eyes	QUTENZA.xml:S2:210:4	O
or	QUTENZA.xml:S2:215:2	O
airway	QUTENZA.xml:S2:218:6	O
occurs	QUTENZA.xml:S2:225:6	O
,	QUTENZA.xml:S2:231:1	O
remove	QUTENZA.xml:S2:233:6	O
the	QUTENZA.xml:S2:240:3	O
affected	QUTENZA.xml:S2:244:8	O
individual	QUTENZA.xml:S2:253:10	O
from	QUTENZA.xml:S2:264:4	O
the	QUTENZA.xml:S2:269:3	O
vicinity	QUTENZA.xml:S2:273:8	O
of	QUTENZA.xml:S2:282:2	O
Qutenza	QUTENZA.xml:S2:285:7	O
and	QUTENZA.xml:S2:293:3	O
flush	QUTENZA.xml:S2:297:5	O
the	QUTENZA.xml:S2:303:3	O
mucous	QUTENZA.xml:S2:307:6	O
membranes	QUTENZA.xml:S2:314:9	O
or	QUTENZA.xml:S2:324:2	O
eyes	QUTENZA.xml:S2:327:4	O
with	QUTENZA.xml:S2:332:4	O
water	QUTENZA.xml:S2:337:5	O
.	QUTENZA.xml:S2:342:1	O

If	QUTENZA.xml:S2:344:2	O
skin	QUTENZA.xml:S2:347:4	O
not	QUTENZA.xml:S2:352:3	O
intended	QUTENZA.xml:S2:356:8	O
to	QUTENZA.xml:S2:365:2	O
be	QUTENZA.xml:S2:368:2	O
treated	QUTENZA.xml:S2:371:7	O
comes	QUTENZA.xml:S2:379:5	O
into	QUTENZA.xml:S2:385:4	O
contact	QUTENZA.xml:S2:390:7	O
with	QUTENZA.xml:S2:398:4	O
Qutenza	QUTENZA.xml:S2:403:7	O
,	QUTENZA.xml:S2:410:1	O
apply	QUTENZA.xml:S2:412:5	O
Cleansing	QUTENZA.xml:S2:418:9	O
Gel	QUTENZA.xml:S2:428:3	O
and	QUTENZA.xml:S2:432:3	O
then	QUTENZA.xml:S2:436:4	O
wipe	QUTENZA.xml:S2:441:4	O
off	QUTENZA.xml:S2:446:3	O
with	QUTENZA.xml:S2:450:4	O
dry	QUTENZA.xml:S2:455:3	O
gauze	QUTENZA.xml:S2:459:5	O
.	QUTENZA.xml:S2:464:1	O

(	QUTENZA.xml:S2:466:1	O
5.2	QUTENZA.xml:S2:469:3	O
,	QUTENZA.xml:S2:474:1	O
5.3	QUTENZA.xml:S2:477:3	O
)	QUTENZA.xml:S2:482:1	O

Transient	QUTENZA.xml:S2:489:9	B-Severity
increases	QUTENZA.xml:S2:499:9	B-AdverseReaction
in	QUTENZA.xml:S2:509:2	I-AdverseReaction
blood	QUTENZA.xml:S2:512:5	I-AdverseReaction
pressure	QUTENZA.xml:S2:518:8	I-AdverseReaction
may	QUTENZA.xml:S2:527:3	B-Factor
occur	QUTENZA.xml:S2:531:5	O
in	QUTENZA.xml:S2:537:2	O
patients	QUTENZA.xml:S2:540:8	O
during	QUTENZA.xml:S2:549:6	O
and	QUTENZA.xml:S2:556:3	O
shortly	QUTENZA.xml:S2:560:7	O
after	QUTENZA.xml:S2:568:5	O
the	QUTENZA.xml:S2:574:3	O
Qutenza	QUTENZA.xml:S2:578:7	O
treatment	QUTENZA.xml:S2:586:9	O
.	QUTENZA.xml:S2:595:1	O

Monitor	QUTENZA.xml:S2:597:7	O
blood	QUTENZA.xml:S2:605:5	O
pressure	QUTENZA.xml:S2:611:8	O
during	QUTENZA.xml:S2:620:6	O
and	QUTENZA.xml:S2:627:3	O
following	QUTENZA.xml:S2:631:9	O
the	QUTENZA.xml:S2:641:3	O
treatment	QUTENZA.xml:S2:645:9	O
procedure	QUTENZA.xml:S2:655:9	O
.	QUTENZA.xml:S2:664:1	O

For	QUTENZA.xml:S2:666:3	O
those	QUTENZA.xml:S2:670:5	O
patients	QUTENZA.xml:S2:676:8	O
who	QUTENZA.xml:S2:685:3	O
require	QUTENZA.xml:S2:689:7	O
the	QUTENZA.xml:S2:697:3	O
use	QUTENZA.xml:S2:701:3	O
of	QUTENZA.xml:S2:705:2	O
opioids	QUTENZA.xml:S2:708:7	O
to	QUTENZA.xml:S2:716:2	O
treat	QUTENZA.xml:S2:719:5	O
pain	QUTENZA.xml:S2:725:4	O
during	QUTENZA.xml:S2:730:6	O
or	QUTENZA.xml:S2:737:2	O
following	QUTENZA.xml:S2:740:9	O
the	QUTENZA.xml:S2:750:3	O
procedure	QUTENZA.xml:S2:754:9	O
,	QUTENZA.xml:S2:763:1	O
their	QUTENZA.xml:S2:765:5	O
ability	QUTENZA.xml:S2:771:7	O
to	QUTENZA.xml:S2:779:2	O
perform	QUTENZA.xml:S2:782:7	O
potentially	QUTENZA.xml:S2:790:11	O
hazardous	QUTENZA.xml:S2:802:9	O
activities	QUTENZA.xml:S2:812:10	O
such	QUTENZA.xml:S2:823:4	O
as	QUTENZA.xml:S2:828:2	O
driving	QUTENZA.xml:S2:831:7	O
or	QUTENZA.xml:S2:839:2	O
operating	QUTENZA.xml:S2:842:9	O
machinery	QUTENZA.xml:S2:852:9	O
may	QUTENZA.xml:S2:862:3	O
be	QUTENZA.xml:S2:866:2	O
affected	QUTENZA.xml:S2:869:8	O
.	QUTENZA.xml:S2:877:1	O

(	QUTENZA.xml:S2:879:1	O
5.4	QUTENZA.xml:S2:882:3	O
,	QUTENZA.xml:S2:887:1	O
5.5	QUTENZA.xml:S2:890:3	O
)	QUTENZA.xml:S2:895:1	O

5.1	QUTENZA.xml:S2:909:3	O

Eye	QUTENZA.xml:S2:913:3	O

and	QUTENZA.xml:S2:917:3	O
Mucous	QUTENZA.xml:S2:921:6	O
Membrane	QUTENZA.xml:S2:928:8	O
Exposure	QUTENZA.xml:S2:937:8	O

Do	QUTENZA.xml:S2:951:2	O
not	QUTENZA.xml:S2:954:3	O
apply	QUTENZA.xml:S2:958:5	O
Qutenza	QUTENZA.xml:S2:964:7	O
to	QUTENZA.xml:S2:972:2	O
the	QUTENZA.xml:S2:975:3	O
face	QUTENZA.xml:S2:979:4	O
or	QUTENZA.xml:S2:984:2	O
scalp	QUTENZA.xml:S2:987:5	O
to	QUTENZA.xml:S2:993:2	O
avoid	QUTENZA.xml:S2:996:5	O
risk	QUTENZA.xml:S2:1002:4	O
of	QUTENZA.xml:S2:1007:2	O
exposure	QUTENZA.xml:S2:1010:8	O
to	QUTENZA.xml:S2:1019:2	O
the	QUTENZA.xml:S2:1022:3	O
eyes	QUTENZA.xml:S2:1026:4	O
or	QUTENZA.xml:S2:1031:2	O
mucous	QUTENZA.xml:S2:1034:6	O
membranes	QUTENZA.xml:S2:1041:9	O
.	QUTENZA.xml:S2:1050:1	O

5.2	QUTENZA.xml:S2:1059:3	O
Aerosolization	QUTENZA.xml:S2:1063:14	O
of	QUTENZA.xml:S2:1078:2	O
Capsaicin	QUTENZA.xml:S2:1081:9	O

Aerosolization	QUTENZA.xml:S2:1096:14	O
of	QUTENZA.xml:S2:1111:2	O
capsaicin	QUTENZA.xml:S2:1114:9	O
can	QUTENZA.xml:S2:1124:3	O
occur	QUTENZA.xml:S2:1128:5	O
upon	QUTENZA.xml:S2:1134:4	O
rapid	QUTENZA.xml:S2:1139:5	O
removal	QUTENZA.xml:S2:1145:7	O
of	QUTENZA.xml:S2:1153:2	O
Qutenza	QUTENZA.xml:S2:1156:7	O
patches	QUTENZA.xml:S2:1164:7	O
.	QUTENZA.xml:S2:1171:1	O

Therefore	QUTENZA.xml:S2:1173:9	O
,	QUTENZA.xml:S2:1182:1	O
remove	QUTENZA.xml:S2:1184:6	O
Qutenza	QUTENZA.xml:S2:1191:7	O
patches	QUTENZA.xml:S2:1199:7	O
gently	QUTENZA.xml:S2:1207:6	O
and	QUTENZA.xml:S2:1214:3	O
slowly	QUTENZA.xml:S2:1218:6	O
by	QUTENZA.xml:S2:1225:2	O
rolling	QUTENZA.xml:S2:1228:7	O
the	QUTENZA.xml:S2:1236:3	O
adhesive	QUTENZA.xml:S2:1240:8	O
side	QUTENZA.xml:S2:1249:4	O
inward	QUTENZA.xml:S2:1254:6	O
[	QUTENZA.xml:S2:1261:1	O
see	QUTENZA.xml:S2:1262:3	O
Dosage	QUTENZA.xml:S2:1267:6	O
and	QUTENZA.xml:S2:1274:3	O
Administration	QUTENZA.xml:S2:1278:14	O
(	QUTENZA.xml:S2:1293:1	O
2.3	QUTENZA.xml:S2:1294:3	O
)]	QUTENZA.xml:S2:1299:2	O
.	QUTENZA.xml:S2:1303:1	O

If	QUTENZA.xml:S2:1309:2	O
irritation	QUTENZA.xml:S2:1312:10	O
of	QUTENZA.xml:S2:1323:2	O
eyes	QUTENZA.xml:S2:1326:4	O
or	QUTENZA.xml:S2:1331:2	O
airways	QUTENZA.xml:S2:1334:7	O
occurs	QUTENZA.xml:S2:1342:6	O
,	QUTENZA.xml:S2:1348:1	O
remove	QUTENZA.xml:S2:1350:6	O
the	QUTENZA.xml:S2:1357:3	O
affected	QUTENZA.xml:S2:1361:8	O
individual	QUTENZA.xml:S2:1370:10	O
from	QUTENZA.xml:S2:1381:4	O
the	QUTENZA.xml:S2:1386:3	O
vicinity	QUTENZA.xml:S2:1390:8	O
of	QUTENZA.xml:S2:1399:2	O
Qutenza	QUTENZA.xml:S2:1402:7	O
.	QUTENZA.xml:S2:1409:1	O

Flush	QUTENZA.xml:S2:1411:5	O
eyes	QUTENZA.xml:S2:1417:4	O
and	QUTENZA.xml:S2:1422:3	O
mucous	QUTENZA.xml:S2:1426:6	O
membranes	QUTENZA.xml:S2:1433:9	O
with	QUTENZA.xml:S2:1443:4	O
cool	QUTENZA.xml:S2:1448:4	O
water	QUTENZA.xml:S2:1453:5	O
.	QUTENZA.xml:S2:1458:1	O

Inhalation	QUTENZA.xml:S2:1464:10	O
of	QUTENZA.xml:S2:1475:2	O
airborne	QUTENZA.xml:S2:1478:8	O
capsaicin	QUTENZA.xml:S2:1487:9	O
can	QUTENZA.xml:S2:1497:3	B-Factor
result	QUTENZA.xml:S2:1501:6	O
in	QUTENZA.xml:S2:1508:2	O
coughing	QUTENZA.xml:S2:1511:8	B-AdverseReaction
or	QUTENZA.xml:S2:1520:2	O
sneezing	QUTENZA.xml:S2:1523:8	B-AdverseReaction
.	QUTENZA.xml:S2:1531:1	O

Provide	QUTENZA.xml:S2:1533:7	O
supportive	QUTENZA.xml:S2:1541:10	O
medical	QUTENZA.xml:S2:1552:7	O
care	QUTENZA.xml:S2:1560:4	O
if	QUTENZA.xml:S2:1565:2	O
shortness	QUTENZA.xml:S2:1568:9	O
of	QUTENZA.xml:S2:1578:2	O
breath	QUTENZA.xml:S2:1581:6	O
develops	QUTENZA.xml:S2:1588:8	O
.	QUTENZA.xml:S2:1596:1	O

5.3	QUTENZA.xml:S2:1605:3	O
Unintended	QUTENZA.xml:S2:1609:10	O
Skin	QUTENZA.xml:S2:1620:4	O
Exposure	QUTENZA.xml:S2:1625:8	O

If	QUTENZA.xml:S2:1639:2	O
skin	QUTENZA.xml:S2:1642:4	O
not	QUTENZA.xml:S2:1647:3	O
intended	QUTENZA.xml:S2:1651:8	O
to	QUTENZA.xml:S2:1660:2	O
be	QUTENZA.xml:S2:1663:2	O
treated	QUTENZA.xml:S2:1666:7	O
comes	QUTENZA.xml:S2:1674:5	O
in	QUTENZA.xml:S2:1680:2	O
contact	QUTENZA.xml:S2:1683:7	O
with	QUTENZA.xml:S2:1691:4	O
Qutenza	QUTENZA.xml:S2:1696:7	O
,	QUTENZA.xml:S2:1703:1	O
apply	QUTENZA.xml:S2:1705:5	O
Cleansing	QUTENZA.xml:S2:1711:9	O
Gel	QUTENZA.xml:S2:1721:3	O
for	QUTENZA.xml:S2:1725:3	O
one	QUTENZA.xml:S2:1729:3	O
minute	QUTENZA.xml:S2:1733:6	O
and	QUTENZA.xml:S2:1740:3	O
wipe	QUTENZA.xml:S2:1744:4	O
off	QUTENZA.xml:S2:1749:3	O
with	QUTENZA.xml:S2:1753:4	O
dry	QUTENZA.xml:S2:1758:3	O
gauze	QUTENZA.xml:S2:1762:5	O
.	QUTENZA.xml:S2:1767:1	O

After	QUTENZA.xml:S2:1769:5	O
the	QUTENZA.xml:S2:1775:3	O
Cleansing	QUTENZA.xml:S2:1779:9	O
Gel	QUTENZA.xml:S2:1789:3	O
has	QUTENZA.xml:S2:1793:3	O
been	QUTENZA.xml:S2:1797:4	O
wiped	QUTENZA.xml:S2:1802:5	O
off	QUTENZA.xml:S2:1808:3	O
,	QUTENZA.xml:S2:1811:1	O
wash	QUTENZA.xml:S2:1813:4	O
the	QUTENZA.xml:S2:1818:3	O
area	QUTENZA.xml:S2:1822:4	O
with	QUTENZA.xml:S2:1827:4	O
soap	QUTENZA.xml:S2:1832:4	O
and	QUTENZA.xml:S2:1837:3	O
water	QUTENZA.xml:S2:1841:5	O
.	QUTENZA.xml:S2:1846:1	O

5.4	QUTENZA.xml:S2:1855:3	O
Application	QUTENZA.xml:S2:1859:11	O
Associated	QUTENZA.xml:S2:1871:10	O
Pain	QUTENZA.xml:S2:1882:4	O

Even	QUTENZA.xml:S2:1892:4	O
following	QUTENZA.xml:S2:1897:9	O
use	QUTENZA.xml:S2:1907:3	O
of	QUTENZA.xml:S2:1911:2	O
a	QUTENZA.xml:S2:1914:1	O
local	QUTENZA.xml:S2:1916:5	O
anesthetic	QUTENZA.xml:S2:1922:10	O
prior	QUTENZA.xml:S2:1933:5	O
to	QUTENZA.xml:S2:1939:2	O
administration	QUTENZA.xml:S2:1942:14	O
of	QUTENZA.xml:S2:1957:2	O
Qutenza	QUTENZA.xml:S2:1960:7	O
,	QUTENZA.xml:S2:1967:1	O
patients	QUTENZA.xml:S2:1969:8	O
may	QUTENZA.xml:S2:1978:3	B-Factor
experience	QUTENZA.xml:S2:1982:10	O
substantial	QUTENZA.xml:S2:1993:11	B-Severity
procedural	QUTENZA.xml:S2:2005:10	B-AdverseReaction
pain	QUTENZA.xml:S2:2016:4	I-AdverseReaction
.	QUTENZA.xml:S2:2020:1	O

Prepare	QUTENZA.xml:S2:2022:7	O
to	QUTENZA.xml:S2:2030:2	O
treat	QUTENZA.xml:S2:2033:5	O
acute	QUTENZA.xml:S2:2039:5	O
pain	QUTENZA.xml:S2:2045:4	O
during	QUTENZA.xml:S2:2050:6	O
and	QUTENZA.xml:S2:2057:3	O
following	QUTENZA.xml:S2:2061:9	O
the	QUTENZA.xml:S2:2071:3	O
application	QUTENZA.xml:S2:2075:11	O
procedure	QUTENZA.xml:S2:2087:9	O
with	QUTENZA.xml:S2:2097:4	O
local	QUTENZA.xml:S2:2102:5	O
cooling	QUTENZA.xml:S2:2108:7	O
(	QUTENZA.xml:S2:2116:1	O
such	QUTENZA.xml:S2:2117:4	O
as	QUTENZA.xml:S2:2122:2	O
an	QUTENZA.xml:S2:2125:2	O
ice	QUTENZA.xml:S2:2128:3	O
pack	QUTENZA.xml:S2:2132:4	O
)	QUTENZA.xml:S2:2136:1	O
and	QUTENZA.xml:S2:2138:3	O
or	QUTENZA.xml:S2:2142:2	O
appropriate	QUTENZA.xml:S2:2145:11	O
analgesic	QUTENZA.xml:S2:2157:9	O
medication	QUTENZA.xml:S2:2167:10	O
,	QUTENZA.xml:S2:2177:1	O
such	QUTENZA.xml:S2:2179:4	O
as	QUTENZA.xml:S2:2184:2	O
opioids	QUTENZA.xml:S2:2187:7	O
.	QUTENZA.xml:S2:2194:1	O

Opioids	QUTENZA.xml:S2:2196:7	O
may	QUTENZA.xml:S2:2204:3	O
affect	QUTENZA.xml:S2:2208:6	O
the	QUTENZA.xml:S2:2215:3	O
ability	QUTENZA.xml:S2:2219:7	O
to	QUTENZA.xml:S2:2227:2	O
perform	QUTENZA.xml:S2:2230:7	O
potentially	QUTENZA.xml:S2:2238:11	O
hazardous	QUTENZA.xml:S2:2250:9	O
activities	QUTENZA.xml:S2:2260:10	O
such	QUTENZA.xml:S2:2271:4	O
as	QUTENZA.xml:S2:2276:2	O
driving	QUTENZA.xml:S2:2279:7	O
or	QUTENZA.xml:S2:2287:2	O
operating	QUTENZA.xml:S2:2290:9	O
machinery	QUTENZA.xml:S2:2300:9	O
.	QUTENZA.xml:S2:2309:1	O

5.5	QUTENZA.xml:S2:2318:3	O
Increase	QUTENZA.xml:S2:2322:8	O
in	QUTENZA.xml:S2:2331:2	O
Blood	QUTENZA.xml:S2:2334:5	O
Pressure	QUTENZA.xml:S2:2340:8	O

In	QUTENZA.xml:S2:2354:2	O
clinical	QUTENZA.xml:S2:2357:8	O
trials	QUTENZA.xml:S2:2366:6	O
,	QUTENZA.xml:S2:2372:1	O
increases	QUTENZA.xml:S2:2374:9	B-AdverseReaction
in	QUTENZA.xml:S2:2384:2	I-AdverseReaction
blood	QUTENZA.xml:S2:2387:5	I-AdverseReaction
pressure	QUTENZA.xml:S2:2393:8	I-AdverseReaction
occurred	QUTENZA.xml:S2:2402:8	O
during	QUTENZA.xml:S2:2411:6	O
or	QUTENZA.xml:S2:2418:2	O
shortly	QUTENZA.xml:S2:2421:7	O
after	QUTENZA.xml:S2:2429:5	O
exposure	QUTENZA.xml:S2:2435:8	O
to	QUTENZA.xml:S2:2444:2	O
Qutenza	QUTENZA.xml:S2:2447:7	O
.	QUTENZA.xml:S2:2454:1	O

The	QUTENZA.xml:S2:2456:3	O
changes	QUTENZA.xml:S2:2460:7	O
averaged	QUTENZA.xml:S2:2468:8	O
less	QUTENZA.xml:S2:2477:4	O
than	QUTENZA.xml:S2:2482:4	O
10	QUTENZA.xml:S2:2487:2	O
mm	QUTENZA.xml:S2:2490:2	O
Hg	QUTENZA.xml:S2:2493:2	O
,	QUTENZA.xml:S2:2495:1	O
although	QUTENZA.xml:S2:2497:8	O
some	QUTENZA.xml:S2:2506:4	O
patients	QUTENZA.xml:S2:2511:8	O
had	QUTENZA.xml:S2:2520:3	O
greater	QUTENZA.xml:S2:2524:7	O
increases	QUTENZA.xml:S2:2532:9	O
and	QUTENZA.xml:S2:2542:3	O
these	QUTENZA.xml:S2:2546:5	O
changes	QUTENZA.xml:S2:2552:7	O
lasted	QUTENZA.xml:S2:2560:6	O
for	QUTENZA.xml:S2:2567:3	O
approximately	QUTENZA.xml:S2:2571:13	O
two	QUTENZA.xml:S2:2585:3	O
hours	QUTENZA.xml:S2:2589:5	O
after	QUTENZA.xml:S2:2595:5	O
patch	QUTENZA.xml:S2:2601:5	O
removal	QUTENZA.xml:S2:2607:7	O
.	QUTENZA.xml:S2:2614:1	O

Increases	QUTENZA.xml:S2:2616:9	B-AdverseReaction
in	QUTENZA.xml:S2:2626:2	I-AdverseReaction
blood	QUTENZA.xml:S2:2629:5	I-AdverseReaction
pressure	QUTENZA.xml:S2:2635:8	I-AdverseReaction
were	QUTENZA.xml:S2:2644:4	O
unrelated	QUTENZA.xml:S2:2649:9	O
to	QUTENZA.xml:S2:2659:2	O
the	QUTENZA.xml:S2:2662:3	O
pretreatment	QUTENZA.xml:S2:2666:12	O
blood	QUTENZA.xml:S2:2679:5	O
pressure	QUTENZA.xml:S2:2685:8	O
but	QUTENZA.xml:S2:2694:3	O
were	QUTENZA.xml:S2:2698:4	O
related	QUTENZA.xml:S2:2703:7	O
to	QUTENZA.xml:S2:2711:2	O
treatment	QUTENZA.xml:S2:2714:9	O
-	QUTENZA.xml:S2:2723:1	O
related	QUTENZA.xml:S2:2724:7	O
increases	QUTENZA.xml:S2:2732:9	B-AdverseReaction
in	QUTENZA.xml:S2:2742:2	I-AdverseReaction
pain	QUTENZA.xml:S2:2745:4	I-AdverseReaction
.	QUTENZA.xml:S2:2749:1	O

Monitor	QUTENZA.xml:S2:2751:7	O
blood	QUTENZA.xml:S2:2759:5	O
pressure	QUTENZA.xml:S2:2765:8	O
periodically	QUTENZA.xml:S2:2774:12	O
during	QUTENZA.xml:S2:2787:6	O
the	QUTENZA.xml:S2:2794:3	O
treatment	QUTENZA.xml:S2:2798:9	O
and	QUTENZA.xml:S2:2808:3	O
provide	QUTENZA.xml:S2:2812:7	O
adequate	QUTENZA.xml:S2:2820:8	O
support	QUTENZA.xml:S2:2829:7	O
for	QUTENZA.xml:S2:2837:3	O
treatment	QUTENZA.xml:S2:2841:9	O
related	QUTENZA.xml:S2:2851:7	O
pain	QUTENZA.xml:S2:2859:4	O
.	QUTENZA.xml:S2:2863:1	O

Patients	QUTENZA.xml:S2:2869:8	O
with	QUTENZA.xml:S2:2878:4	O
unstable	QUTENZA.xml:S2:2883:8	O
or	QUTENZA.xml:S2:2892:2	O
poorly	QUTENZA.xml:S2:2895:6	O
controlled	QUTENZA.xml:S2:2902:10	O
hypertension	QUTENZA.xml:S2:2913:12	O
,	QUTENZA.xml:S2:2925:1	O
a	QUTENZA.xml:S2:2927:1	O
recent	QUTENZA.xml:S2:2929:6	O
history	QUTENZA.xml:S2:2936:7	O
of	QUTENZA.xml:S2:2944:2	O
cardiovascular	QUTENZA.xml:S2:2947:14	O
or	QUTENZA.xml:S2:2962:2	O
cerebrovascular	QUTENZA.xml:S2:2965:15	O
events	QUTENZA.xml:S2:2981:6	O
may	QUTENZA.xml:S2:2988:3	O
be	QUTENZA.xml:S2:2992:2	O
at	QUTENZA.xml:S2:2995:2	O
an	QUTENZA.xml:S2:2998:2	O
increased	QUTENZA.xml:S2:3001:9	O
risk	QUTENZA.xml:S2:3011:4	B-Factor
of	QUTENZA.xml:S2:3016:2	O
adverse	QUTENZA.xml:S2:3019:7	B-AdverseReaction
cardiovascular	QUTENZA.xml:S2:3027:14	I-AdverseReaction
effects	QUTENZA.xml:S2:3042:7	I-AdverseReaction
.	QUTENZA.xml:S2:3049:1	O

Consider	QUTENZA.xml:S2:3051:8	O
these	QUTENZA.xml:S2:3060:5	O
factors	QUTENZA.xml:S2:3066:7	O
prior	QUTENZA.xml:S2:3074:5	O
to	QUTENZA.xml:S2:3080:2	O
initiating	QUTENZA.xml:S2:3083:10	O
Qutenza	QUTENZA.xml:S2:3094:7	O
treatment	QUTENZA.xml:S2:3102:9	O
.	QUTENZA.xml:S2:3111:1	O
6	SAPHRIS.xml:S1:4:1	O
ADVERSE	SAPHRIS.xml:S1:6:7	O
REACTIONS	SAPHRIS.xml:S1:14:9	O

The	SAPHRIS.xml:S1:27:3	O
following	SAPHRIS.xml:S1:31:9	O
adverse	SAPHRIS.xml:S1:41:7	O
reactions	SAPHRIS.xml:S1:49:9	O
are	SAPHRIS.xml:S1:59:3	O
discussed	SAPHRIS.xml:S1:63:9	O
in	SAPHRIS.xml:S1:73:2	O
more	SAPHRIS.xml:S1:76:4	O
detail	SAPHRIS.xml:S1:81:6	O
in	SAPHRIS.xml:S1:88:2	O
other	SAPHRIS.xml:S1:91:5	O
sections	SAPHRIS.xml:S1:97:8	O
of	SAPHRIS.xml:S1:106:2	O
the	SAPHRIS.xml:S1:109:3	O
labeling	SAPHRIS.xml:S1:113:8	O
:	SAPHRIS.xml:S1:121:1	O

Use	SAPHRIS.xml:S1:130:3	O
in	SAPHRIS.xml:S1:134:2	O
Elderly	SAPHRIS.xml:S1:137:7	O
Patients	SAPHRIS.xml:S1:145:8	O
with	SAPHRIS.xml:S1:154:4	O
Dementia	SAPHRIS.xml:S1:159:8	O
-	SAPHRIS.xml:S1:167:1	O
Related	SAPHRIS.xml:S1:168:7	O
Psychosis	SAPHRIS.xml:S1:176:9	O
[	SAPHRIS.xml:S1:186:1	O
seeBoxed	SAPHRIS.xml:S1:187:8	O
Warningand	SAPHRIS.xml:S1:196:10	O
Warnings	SAPHRIS.xml:S1:207:8	O
and	SAPHRIS.xml:S1:216:3	O
Precautions	SAPHRIS.xml:S1:220:11	O
(	SAPHRIS.xml:S1:232:1	O
5.1	SAPHRIS.xml:S1:233:3	O
and5	SAPHRIS.xml:S1:236:4	O
.	SAPHRIS.xml:S1:240:1	O
2	SAPHRIS.xml:S1:241:1	O
)]	SAPHRIS.xml:S1:242:2	O

Neuroleptic	SAPHRIS.xml:S1:251:11	B-AdverseReaction
Malignant	SAPHRIS.xml:S1:263:9	I-AdverseReaction
Syndrome	SAPHRIS.xml:S1:273:8	I-AdverseReaction
[	SAPHRIS.xml:S1:282:1	O
see	SAPHRIS.xml:S1:283:3	O
Warnings	SAPHRIS.xml:S1:287:8	O
and	SAPHRIS.xml:S1:296:3	O
Precautions	SAPHRIS.xml:S1:300:11	O
(	SAPHRIS.xml:S1:312:1	O
5.3	SAPHRIS.xml:S1:313:3	O
)]	SAPHRIS.xml:S1:316:2	O

Tardive	SAPHRIS.xml:S1:325:7	B-AdverseReaction
Dyskinesia	SAPHRIS.xml:S1:333:10	I-AdverseReaction
[	SAPHRIS.xml:S1:344:1	O
see	SAPHRIS.xml:S1:345:3	O
Warnings	SAPHRIS.xml:S1:349:8	O
and	SAPHRIS.xml:S1:358:3	O
Precautions	SAPHRIS.xml:S1:362:11	O
(	SAPHRIS.xml:S1:374:1	O
5.4	SAPHRIS.xml:S1:375:3	O
)]	SAPHRIS.xml:S1:378:2	O

Metabolic	SAPHRIS.xml:S1:387:9	B-AdverseReaction
Changes	SAPHRIS.xml:S1:397:7	I-AdverseReaction
[	SAPHRIS.xml:S1:405:1	O
see	SAPHRIS.xml:S1:406:3	O
Warnings	SAPHRIS.xml:S1:410:8	O
and	SAPHRIS.xml:S1:419:3	O
Precautions	SAPHRIS.xml:S1:423:11	O
(	SAPHRIS.xml:S1:435:1	O
5.5	SAPHRIS.xml:S1:436:3	O
)]	SAPHRIS.xml:S1:439:2	O

Hypersensitivity	SAPHRIS.xml:S1:448:16	B-AdverseReaction
Reactions	SAPHRIS.xml:S1:465:9	I-AdverseReaction
[	SAPHRIS.xml:S1:475:1	O
see	SAPHRIS.xml:S1:476:3	O
Contraindications	SAPHRIS.xml:S1:480:17	O
,	SAPHRIS.xml:S1:497:1	O
Warnings	SAPHRIS.xml:S1:499:8	O
and	SAPHRIS.xml:S1:508:3	O
Precautions	SAPHRIS.xml:S1:512:11	O
(	SAPHRIS.xml:S1:524:1	O
5.6	SAPHRIS.xml:S1:525:3	O
)	SAPHRIS.xml:S1:528:1	O
and	SAPHRIS.xml:S1:530:3	O
Patient	SAPHRIS.xml:S1:534:7	O
Counseling	SAPHRIS.xml:S1:542:10	O
Information	SAPHRIS.xml:S1:553:11	O
(	SAPHRIS.xml:S1:565:1	O
17	SAPHRIS.xml:S1:566:2	O
)]	SAPHRIS.xml:S1:568:2	O

Application	SAPHRIS.xml:S1:577:11	B-AdverseReaction
site	SAPHRIS.xml:S1:589:4	I-AdverseReaction
reactions	SAPHRIS.xml:S1:594:9	I-AdverseReaction
including	SAPHRIS.xml:S1:604:9	O
oral	SAPHRIS.xml:S1:614:4	I-AdverseReaction
ulcers	SAPHRIS.xml:S1:619:6	I-AdverseReaction
,	SAPHRIS.xml:S1:625:1	O
blisters	SAPHRIS.xml:S1:627:8	I-AdverseReaction
,	SAPHRIS.xml:S1:635:1	O
peeling	SAPHRIS.xml:S1:637:7	I-AdverseReaction
sloughing	SAPHRIS.xml:S1:645:9	I-AdverseReaction
and	SAPHRIS.xml:S1:655:3	O
inflammation	SAPHRIS.xml:S1:659:12	I-AdverseReaction
[	SAPHRIS.xml:S1:672:1	O
see	SAPHRIS.xml:S1:673:3	O
Adverse	SAPHRIS.xml:S1:677:7	O
Reactions	SAPHRIS.xml:S1:685:9	O
(	SAPHRIS.xml:S1:695:1	O
6.2	SAPHRIS.xml:S1:696:3	O
)]	SAPHRIS.xml:S1:699:2	O

Orthostatic	SAPHRIS.xml:S1:708:11	B-AdverseReaction
Hypotension	SAPHRIS.xml:S1:720:11	I-AdverseReaction
,	SAPHRIS.xml:S1:731:1	O
Syncope	SAPHRIS.xml:S1:733:7	B-AdverseReaction
,	SAPHRIS.xml:S1:740:1	O
and	SAPHRIS.xml:S1:742:3	O
other	SAPHRIS.xml:S1:746:5	O
Hemodynamic	SAPHRIS.xml:S1:752:11	B-AdverseReaction
Effects	SAPHRIS.xml:S1:764:7	I-AdverseReaction
[	SAPHRIS.xml:S1:772:1	O
see	SAPHRIS.xml:S1:773:3	O
Warnings	SAPHRIS.xml:S1:777:8	O
and	SAPHRIS.xml:S1:786:3	O
Precautions	SAPHRIS.xml:S1:790:11	O
(	SAPHRIS.xml:S1:802:1	O
5.7	SAPHRIS.xml:S1:803:3	O
)]	SAPHRIS.xml:S1:806:2	O

Leukopenia	SAPHRIS.xml:S1:815:10	B-AdverseReaction
,	SAPHRIS.xml:S1:825:1	O
Neutropenia	SAPHRIS.xml:S1:827:11	B-AdverseReaction
,	SAPHRIS.xml:S1:838:1	O
and	SAPHRIS.xml:S1:840:3	O
Agranulocytosis	SAPHRIS.xml:S1:844:15	B-AdverseReaction
[	SAPHRIS.xml:S1:860:1	O
see	SAPHRIS.xml:S1:861:3	O
Warnings	SAPHRIS.xml:S1:865:8	O
and	SAPHRIS.xml:S1:874:3	O
Precautions	SAPHRIS.xml:S1:878:11	O
(	SAPHRIS.xml:S1:890:1	O
5.8	SAPHRIS.xml:S1:891:3	O
)]	SAPHRIS.xml:S1:894:2	O

QT	SAPHRIS.xml:S1:903:2	B-AdverseReaction
Interval	SAPHRIS.xml:S1:906:8	I-AdverseReaction
Prolongation	SAPHRIS.xml:S1:915:12	I-AdverseReaction
[	SAPHRIS.xml:S1:928:1	O
see	SAPHRIS.xml:S1:929:3	O
Warnings	SAPHRIS.xml:S1:933:8	O
and	SAPHRIS.xml:S1:942:3	O
Precautions	SAPHRIS.xml:S1:946:11	O
(	SAPHRIS.xml:S1:958:1	O
5.9	SAPHRIS.xml:S1:959:3	O
)]	SAPHRIS.xml:S1:962:2	O

Hyperprolactinemia	SAPHRIS.xml:S1:971:18	B-AdverseReaction
[	SAPHRIS.xml:S1:990:1	O
see	SAPHRIS.xml:S1:991:3	O
Warnings	SAPHRIS.xml:S1:995:8	O
and	SAPHRIS.xml:S1:1004:3	O
Precautions	SAPHRIS.xml:S1:1008:11	O
(	SAPHRIS.xml:S1:1020:1	O
5.10	SAPHRIS.xml:S1:1021:4	O
)]	SAPHRIS.xml:S1:1025:2	O

Seizures	SAPHRIS.xml:S1:1034:8	B-AdverseReaction
[	SAPHRIS.xml:S1:1043:1	O
see	SAPHRIS.xml:S1:1044:3	O
Warnings	SAPHRIS.xml:S1:1048:8	O
and	SAPHRIS.xml:S1:1057:3	O
Precautions	SAPHRIS.xml:S1:1061:11	O
(	SAPHRIS.xml:S1:1073:1	O
5.11	SAPHRIS.xml:S1:1074:4	O
)]	SAPHRIS.xml:S1:1078:2	O

Potential	SAPHRIS.xml:S1:1087:9	B-Factor
for	SAPHRIS.xml:S1:1097:3	O
Cognitive	SAPHRIS.xml:S1:1101:9	B-AdverseReaction
and	SAPHRIS.xml:S1:1111:3	O
Motor	SAPHRIS.xml:S1:1115:5	B-AdverseReaction
Impairment	SAPHRIS.xml:S1:1121:10	I-AdverseReaction
[	SAPHRIS.xml:S1:1132:1	O
see	SAPHRIS.xml:S1:1133:3	O
Warnings	SAPHRIS.xml:S1:1137:8	O
and	SAPHRIS.xml:S1:1146:3	O
Precautions	SAPHRIS.xml:S1:1150:11	O
(	SAPHRIS.xml:S1:1162:1	O
5.12	SAPHRIS.xml:S1:1163:4	O
)]	SAPHRIS.xml:S1:1167:2	O

Body	SAPHRIS.xml:S1:1176:4	O
Temperature	SAPHRIS.xml:S1:1181:11	O
Regulation	SAPHRIS.xml:S1:1193:10	O
[	SAPHRIS.xml:S1:1204:1	O
see	SAPHRIS.xml:S1:1205:3	O
Warnings	SAPHRIS.xml:S1:1209:8	O
and	SAPHRIS.xml:S1:1218:3	O
Precautions	SAPHRIS.xml:S1:1222:11	O
(	SAPHRIS.xml:S1:1234:1	O
5.13	SAPHRIS.xml:S1:1235:4	O
)]	SAPHRIS.xml:S1:1239:2	O

Suicide	SAPHRIS.xml:S1:1248:7	B-AdverseReaction
[	SAPHRIS.xml:S1:1256:1	O
see	SAPHRIS.xml:S1:1257:3	O
Warnings	SAPHRIS.xml:S1:1261:8	O
and	SAPHRIS.xml:S1:1270:3	O
Precautions	SAPHRIS.xml:S1:1274:11	O
(	SAPHRIS.xml:S1:1286:1	O
5.14	SAPHRIS.xml:S1:1287:4	O
)]	SAPHRIS.xml:S1:1291:2	O

Dysphagia	SAPHRIS.xml:S1:1300:9	B-AdverseReaction
[	SAPHRIS.xml:S1:1310:1	O
see	SAPHRIS.xml:S1:1311:3	O
Warnings	SAPHRIS.xml:S1:1315:8	O
and	SAPHRIS.xml:S1:1324:3	O
Precautions	SAPHRIS.xml:S1:1328:11	O
(	SAPHRIS.xml:S1:1340:1	O
5.15	SAPHRIS.xml:S1:1341:4	O
)]	SAPHRIS.xml:S1:1345:2	O

Use	SAPHRIS.xml:S1:1354:3	O
in	SAPHRIS.xml:S1:1358:2	O
Patients	SAPHRIS.xml:S1:1361:8	O
with	SAPHRIS.xml:S1:1370:4	O
Concomitant	SAPHRIS.xml:S1:1375:11	O
Illness	SAPHRIS.xml:S1:1387:7	O
[	SAPHRIS.xml:S1:1395:1	O
see	SAPHRIS.xml:S1:1396:3	O
Warnings	SAPHRIS.xml:S1:1400:8	O
and	SAPHRIS.xml:S1:1409:3	O
Precautions	SAPHRIS.xml:S1:1413:11	O
(	SAPHRIS.xml:S1:1425:1	O
5.16	SAPHRIS.xml:S1:1426:4	O
)]	SAPHRIS.xml:S1:1430:2	O

The	SAPHRIS.xml:S1:1439:3	O
most	SAPHRIS.xml:S1:1443:4	O
common	SAPHRIS.xml:S1:1448:6	O
adverse	SAPHRIS.xml:S1:1455:7	O
reactions	SAPHRIS.xml:S1:1463:9	O
(	SAPHRIS.xml:S1:1473:1	O
5%	SAPHRIS.xml:S1:1476:2	O
and	SAPHRIS.xml:S1:1479:3	O
at	SAPHRIS.xml:S1:1483:2	O
least	SAPHRIS.xml:S1:1486:5	O
twice	SAPHRIS.xml:S1:1492:5	O
the	SAPHRIS.xml:S1:1498:3	O
rate	SAPHRIS.xml:S1:1502:4	O
of	SAPHRIS.xml:S1:1507:2	O
placebo	SAPHRIS.xml:S1:1510:7	O
)	SAPHRIS.xml:S1:1517:1	O
reported	SAPHRIS.xml:S1:1519:8	O
with	SAPHRIS.xml:S1:1528:4	O
acute	SAPHRIS.xml:S1:1533:5	O
treatment	SAPHRIS.xml:S1:1539:9	O
in	SAPHRIS.xml:S1:1549:2	O
adults	SAPHRIS.xml:S1:1552:6	O
with	SAPHRIS.xml:S1:1559:4	O
schizophrenia	SAPHRIS.xml:S1:1564:13	O
were	SAPHRIS.xml:S1:1578:4	O
akathisia	SAPHRIS.xml:S1:1583:9	B-AdverseReaction
,	SAPHRIS.xml:S1:1592:1	O
oral	SAPHRIS.xml:S1:1594:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:1599:12	I-AdverseReaction
,	SAPHRIS.xml:S1:1611:1	O
and	SAPHRIS.xml:S1:1613:3	O
somnolence	SAPHRIS.xml:S1:1617:10	B-AdverseReaction
.	SAPHRIS.xml:S1:1627:1	O

The	SAPHRIS.xml:S1:1629:3	O
safety	SAPHRIS.xml:S1:1633:6	O
profile	SAPHRIS.xml:S1:1640:7	O
of	SAPHRIS.xml:S1:1648:2	O
SAPHRIS	SAPHRIS.xml:S1:1651:7	O
in	SAPHRIS.xml:S1:1659:2	O
the	SAPHRIS.xml:S1:1662:3	O
maintenance	SAPHRIS.xml:S1:1666:11	O
treatment	SAPHRIS.xml:S1:1678:9	O
of	SAPHRIS.xml:S1:1688:2	O
schizophrenia	SAPHRIS.xml:S1:1691:13	O
in	SAPHRIS.xml:S1:1705:2	O
adults	SAPHRIS.xml:S1:1708:6	O
was	SAPHRIS.xml:S1:1715:3	O
similar	SAPHRIS.xml:S1:1719:7	O
to	SAPHRIS.xml:S1:1727:2	O
that	SAPHRIS.xml:S1:1730:4	O
seen	SAPHRIS.xml:S1:1735:4	O
with	SAPHRIS.xml:S1:1740:4	O
acute	SAPHRIS.xml:S1:1745:5	O
treatment	SAPHRIS.xml:S1:1751:9	O
.	SAPHRIS.xml:S1:1760:1	O

The	SAPHRIS.xml:S1:1766:3	O

most	SAPHRIS.xml:S1:1770:4	O
common	SAPHRIS.xml:S1:1775:6	O
adverse	SAPHRIS.xml:S1:1782:7	O
reactions	SAPHRIS.xml:S1:1790:9	O
(	SAPHRIS.xml:S1:1800:1	O
5%	SAPHRIS.xml:S1:1803:2	O
and	SAPHRIS.xml:S1:1806:3	O
at	SAPHRIS.xml:S1:1810:2	O
least	SAPHRIS.xml:S1:1813:5	O
twice	SAPHRIS.xml:S1:1819:5	O
the	SAPHRIS.xml:S1:1825:3	O
rate	SAPHRIS.xml:S1:1829:4	O
of	SAPHRIS.xml:S1:1834:2	O
placebo	SAPHRIS.xml:S1:1837:7	O
)	SAPHRIS.xml:S1:1844:1	O
reported	SAPHRIS.xml:S1:1846:8	O
with	SAPHRIS.xml:S1:1855:4	O
acute	SAPHRIS.xml:S1:1860:5	O
monotherapy	SAPHRIS.xml:S1:1866:11	O
treatment	SAPHRIS.xml:S1:1878:9	O
of	SAPHRIS.xml:S1:1888:2	O
manic	SAPHRIS.xml:S1:1891:5	O
or	SAPHRIS.xml:S1:1897:2	O
mixed	SAPHRIS.xml:S1:1900:5	O
episodes	SAPHRIS.xml:S1:1906:8	O
associated	SAPHRIS.xml:S1:1915:10	O
with	SAPHRIS.xml:S1:1926:4	O
bipolar	SAPHRIS.xml:S1:1931:7	O
I	SAPHRIS.xml:S1:1939:1	O
disorder	SAPHRIS.xml:S1:1941:8	O
in	SAPHRIS.xml:S1:1950:2	O
adults	SAPHRIS.xml:S1:1953:6	O
were	SAPHRIS.xml:S1:1960:4	O
somnolence	SAPHRIS.xml:S1:1965:10	B-AdverseReaction
,	SAPHRIS.xml:S1:1975:1	O
dizziness	SAPHRIS.xml:S1:1977:9	B-AdverseReaction
,	SAPHRIS.xml:S1:1986:1	O
extrapyramidal	SAPHRIS.xml:S1:1988:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:2003:8	I-AdverseReaction
other	SAPHRIS.xml:S1:2012:5	B-Factor
than	SAPHRIS.xml:S1:2018:4	I-Factor
akathisia	SAPHRIS.xml:S1:2023:9	B-AdverseReaction
,	SAPHRIS.xml:S1:2032:1	O
and	SAPHRIS.xml:S1:2034:3	O
increased	SAPHRIS.xml:S1:2038:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:2048:6	I-AdverseReaction
and	SAPHRIS.xml:S1:2055:3	O
during	SAPHRIS.xml:S1:2059:6	O
the	SAPHRIS.xml:S1:2066:3	O
adjunctive	SAPHRIS.xml:S1:2070:10	O
therapy	SAPHRIS.xml:S1:2081:7	O
trial	SAPHRIS.xml:S1:2089:5	O
in	SAPHRIS.xml:S1:2095:2	O
bipolar	SAPHRIS.xml:S1:2098:7	O
I	SAPHRIS.xml:S1:2106:1	O
disorder	SAPHRIS.xml:S1:2108:8	O
in	SAPHRIS.xml:S1:2117:2	O
adults	SAPHRIS.xml:S1:2120:6	O
were	SAPHRIS.xml:S1:2127:4	O
somnolence	SAPHRIS.xml:S1:2132:10	B-AdverseReaction
and	SAPHRIS.xml:S1:2143:3	O
oral	SAPHRIS.xml:S1:2147:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:2152:12	I-AdverseReaction
.	SAPHRIS.xml:S1:2164:1	O

The	SAPHRIS.xml:S1:2170:3	O
adult	SAPHRIS.xml:S1:2174:5	O
information	SAPHRIS.xml:S1:2180:11	O
below	SAPHRIS.xml:S1:2192:5	O
is	SAPHRIS.xml:S1:2198:2	O
derived	SAPHRIS.xml:S1:2201:7	O
from	SAPHRIS.xml:S1:2209:4	O
a	SAPHRIS.xml:S1:2214:1	O
clinical	SAPHRIS.xml:S1:2216:8	O
trial	SAPHRIS.xml:S1:2225:5	O
database	SAPHRIS.xml:S1:2231:8	O
for	SAPHRIS.xml:S1:2240:3	O
SAPHRIS	SAPHRIS.xml:S1:2244:7	O
consisting	SAPHRIS.xml:S1:2252:10	O
of	SAPHRIS.xml:S1:2263:2	O
over	SAPHRIS.xml:S1:2266:4	O
4565	SAPHRIS.xml:S1:2271:4	O
patients	SAPHRIS.xml:S1:2276:8	O
and	SAPHRIS.xml:S1:2285:3	O
or	SAPHRIS.xml:S1:2289:2	O
healthy	SAPHRIS.xml:S1:2292:7	O
subjects	SAPHRIS.xml:S1:2300:8	O
exposed	SAPHRIS.xml:S1:2309:7	O
to	SAPHRIS.xml:S1:2317:2	O
one	SAPHRIS.xml:S1:2320:3	O
or	SAPHRIS.xml:S1:2324:2	O
more	SAPHRIS.xml:S1:2327:4	O
sublingual	SAPHRIS.xml:S1:2332:10	O
doses	SAPHRIS.xml:S1:2343:5	O
of	SAPHRIS.xml:S1:2349:2	O
SAPHRIS	SAPHRIS.xml:S1:2352:7	O
.	SAPHRIS.xml:S1:2359:1	O

A	SAPHRIS.xml:S1:2361:1	O
total	SAPHRIS.xml:S1:2363:5	O
of	SAPHRIS.xml:S1:2369:2	O
1314	SAPHRIS.xml:S1:2372:4	O
SAPHRIS	SAPHRIS.xml:S1:2377:7	O
-	SAPHRIS.xml:S1:2384:1	O
treated	SAPHRIS.xml:S1:2385:7	O
patients	SAPHRIS.xml:S1:2393:8	O
were	SAPHRIS.xml:S1:2402:4	O
treated	SAPHRIS.xml:S1:2407:7	O
for	SAPHRIS.xml:S1:2415:3	O
at	SAPHRIS.xml:S1:2419:2	O
least	SAPHRIS.xml:S1:2422:5	O
24	SAPHRIS.xml:S1:2428:2	O
weeks	SAPHRIS.xml:S1:2431:5	O
and	SAPHRIS.xml:S1:2437:3	O
785	SAPHRIS.xml:S1:2441:3	O
SAPHRIS	SAPHRIS.xml:S1:2445:7	O
-	SAPHRIS.xml:S1:2452:1	O
treated	SAPHRIS.xml:S1:2453:7	O
patients	SAPHRIS.xml:S1:2461:8	O
had	SAPHRIS.xml:S1:2470:3	O
at	SAPHRIS.xml:S1:2474:2	O
least	SAPHRIS.xml:S1:2477:5	O
52	SAPHRIS.xml:S1:2483:2	O
weeks	SAPHRIS.xml:S1:2486:5	O
of	SAPHRIS.xml:S1:2492:2	O
exposure	SAPHRIS.xml:S1:2495:8	O
at	SAPHRIS.xml:S1:2504:2	O
therapeutic	SAPHRIS.xml:S1:2507:11	O
doses	SAPHRIS.xml:S1:2519:5	O
.	SAPHRIS.xml:S1:2524:1	O

In	SAPHRIS.xml:S1:2530:2	O
a	SAPHRIS.xml:S1:2533:1	O
3	SAPHRIS.xml:S1:2535:1	O
-	SAPHRIS.xml:S1:2536:1	O
week	SAPHRIS.xml:S1:2537:4	O
monotherapy	SAPHRIS.xml:S1:2542:11	O
trial	SAPHRIS.xml:S1:2554:5	O
,	SAPHRIS.xml:S1:2559:1	O
the	SAPHRIS.xml:S1:2561:3	O
most	SAPHRIS.xml:S1:2565:4	O
common	SAPHRIS.xml:S1:2570:6	O
adverse	SAPHRIS.xml:S1:2577:7	O
reactions	SAPHRIS.xml:S1:2585:9	O
(	SAPHRIS.xml:S1:2595:1	O
5%	SAPHRIS.xml:S1:2598:2	O
and	SAPHRIS.xml:S1:2601:3	O
at	SAPHRIS.xml:S1:2605:2	O
least	SAPHRIS.xml:S1:2608:5	O
twice	SAPHRIS.xml:S1:2614:5	O
the	SAPHRIS.xml:S1:2620:3	O
rate	SAPHRIS.xml:S1:2624:4	O
of	SAPHRIS.xml:S1:2629:2	O
placebo	SAPHRIS.xml:S1:2632:7	O
)	SAPHRIS.xml:S1:2639:1	O
reported	SAPHRIS.xml:S1:2641:8	O
in	SAPHRIS.xml:S1:2650:2	O
pediatric	SAPHRIS.xml:S1:2653:9	O
patients	SAPHRIS.xml:S1:2663:8	O
with	SAPHRIS.xml:S1:2672:4	O
bipolar	SAPHRIS.xml:S1:2677:7	O
I	SAPHRIS.xml:S1:2685:1	O
disorder	SAPHRIS.xml:S1:2687:8	O
treated	SAPHRIS.xml:S1:2696:7	O
with	SAPHRIS.xml:S1:2704:4	O
SAPHRIS	SAPHRIS.xml:S1:2709:7	O
were	SAPHRIS.xml:S1:2717:4	O
somnolence	SAPHRIS.xml:S1:2722:10	B-AdverseReaction
,	SAPHRIS.xml:S1:2732:1	O
dizziness	SAPHRIS.xml:S1:2734:9	B-AdverseReaction
,	SAPHRIS.xml:S1:2743:1	O
dysgeusia	SAPHRIS.xml:S1:2745:9	B-AdverseReaction
,	SAPHRIS.xml:S1:2754:1	O
oral	SAPHRIS.xml:S1:2756:4	B-AdverseReaction
paresthesia	SAPHRIS.xml:S1:2761:11	I-AdverseReaction
,	SAPHRIS.xml:S1:2772:1	O
nausea	SAPHRIS.xml:S1:2774:6	B-AdverseReaction
,	SAPHRIS.xml:S1:2780:1	O
increased	SAPHRIS.xml:S1:2782:9	B-AdverseReaction
appetite	SAPHRIS.xml:S1:2792:8	I-AdverseReaction
,	SAPHRIS.xml:S1:2800:1	O
fatigue	SAPHRIS.xml:S1:2802:7	B-AdverseReaction
,	SAPHRIS.xml:S1:2809:1	O
and	SAPHRIS.xml:S1:2811:3	O
increased	SAPHRIS.xml:S1:2815:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:2825:6	I-AdverseReaction
.	SAPHRIS.xml:S1:2831:1	O

No	SAPHRIS.xml:S1:2833:2	O
new	SAPHRIS.xml:S1:2836:3	O
major	SAPHRIS.xml:S1:2840:5	O
safety	SAPHRIS.xml:S1:2846:6	O
findings	SAPHRIS.xml:S1:2853:8	O
were	SAPHRIS.xml:S1:2862:4	O
reported	SAPHRIS.xml:S1:2867:8	O
from	SAPHRIS.xml:S1:2876:4	O
a	SAPHRIS.xml:S1:2881:1	O
50	SAPHRIS.xml:S1:2883:2	O
-	SAPHRIS.xml:S1:2885:1	O
week	SAPHRIS.xml:S1:2886:4	O
,	SAPHRIS.xml:S1:2890:1	O
open	SAPHRIS.xml:S1:2892:4	O
-	SAPHRIS.xml:S1:2896:1	O
label	SAPHRIS.xml:S1:2897:5	O
,	SAPHRIS.xml:S1:2902:1	O
uncontrolled	SAPHRIS.xml:S1:2904:12	O
safety	SAPHRIS.xml:S1:2917:6	O
trial	SAPHRIS.xml:S1:2924:5	O
.	SAPHRIS.xml:S1:2929:1	O

A	SAPHRIS.xml:S1:2935:1	O
total	SAPHRIS.xml:S1:2937:5	O
of	SAPHRIS.xml:S1:2943:2	O
651	SAPHRIS.xml:S1:2946:3	O
pediatric	SAPHRIS.xml:S1:2950:9	O
patients	SAPHRIS.xml:S1:2960:8	O
were	SAPHRIS.xml:S1:2969:4	O
treated	SAPHRIS.xml:S1:2974:7	O
with	SAPHRIS.xml:S1:2982:4	O
SAPHRIS	SAPHRIS.xml:S1:2987:7	O
.	SAPHRIS.xml:S1:2994:1	O

Of	SAPHRIS.xml:S1:2996:2	O
these	SAPHRIS.xml:S1:2999:5	O
patients	SAPHRIS.xml:S1:3005:8	O
,	SAPHRIS.xml:S1:3013:1	O
352	SAPHRIS.xml:S1:3015:3	O
pediatric	SAPHRIS.xml:S1:3019:9	O
patients	SAPHRIS.xml:S1:3029:8	O
were	SAPHRIS.xml:S1:3038:4	O
treated	SAPHRIS.xml:S1:3043:7	O
with	SAPHRIS.xml:S1:3051:4	O
SAPHRIS	SAPHRIS.xml:S1:3056:7	O
for	SAPHRIS.xml:S1:3064:3	O
at	SAPHRIS.xml:S1:3068:2	O
least	SAPHRIS.xml:S1:3071:5	O
180	SAPHRIS.xml:S1:3077:3	O
days	SAPHRIS.xml:S1:3081:4	O
and	SAPHRIS.xml:S1:3086:3	O
58	SAPHRIS.xml:S1:3090:2	O
pediatric	SAPHRIS.xml:S1:3093:9	O
patients	SAPHRIS.xml:S1:3103:8	O
treated	SAPHRIS.xml:S1:3112:7	O
with	SAPHRIS.xml:S1:3120:4	O
SAPHRIS	SAPHRIS.xml:S1:3125:7	O
had	SAPHRIS.xml:S1:3133:3	O
at	SAPHRIS.xml:S1:3137:2	O
least	SAPHRIS.xml:S1:3140:5	O
1	SAPHRIS.xml:S1:3146:1	O
year	SAPHRIS.xml:S1:3148:4	O
of	SAPHRIS.xml:S1:3153:2	O
exposure	SAPHRIS.xml:S1:3156:8	O
.	SAPHRIS.xml:S1:3164:1	O

The	SAPHRIS.xml:S1:3166:3	O
safety	SAPHRIS.xml:S1:3170:6	O
of	SAPHRIS.xml:S1:3177:2	O
SAPHRIS	SAPHRIS.xml:S1:3180:7	O
was	SAPHRIS.xml:S1:3188:3	O
evaluated	SAPHRIS.xml:S1:3192:9	O
in	SAPHRIS.xml:S1:3202:2	O
403	SAPHRIS.xml:S1:3205:3	O
pediatric	SAPHRIS.xml:S1:3209:9	O
patients	SAPHRIS.xml:S1:3219:8	O
with	SAPHRIS.xml:S1:3228:4	O
bipolar	SAPHRIS.xml:S1:3233:7	O
I	SAPHRIS.xml:S1:3241:1	O
disorder	SAPHRIS.xml:S1:3243:8	O
who	SAPHRIS.xml:S1:3252:3	O
participated	SAPHRIS.xml:S1:3256:12	O
in	SAPHRIS.xml:S1:3269:2	O
a	SAPHRIS.xml:S1:3272:1	O
3	SAPHRIS.xml:S1:3274:1	O
-	SAPHRIS.xml:S1:3275:1	O
week	SAPHRIS.xml:S1:3276:4	O
,	SAPHRIS.xml:S1:3280:1	O
placebo	SAPHRIS.xml:S1:3282:7	O
-	SAPHRIS.xml:S1:3289:1	O
controlled	SAPHRIS.xml:S1:3290:10	O
,	SAPHRIS.xml:S1:3300:1	O
double	SAPHRIS.xml:S1:3302:6	O
-	SAPHRIS.xml:S1:3308:1	O
blind	SAPHRIS.xml:S1:3309:5	O
trial	SAPHRIS.xml:S1:3315:5	O
,	SAPHRIS.xml:S1:3320:1	O
of	SAPHRIS.xml:S1:3322:2	O
whom	SAPHRIS.xml:S1:3325:4	O
302	SAPHRIS.xml:S1:3330:3	O
patients	SAPHRIS.xml:S1:3334:8	O
received	SAPHRIS.xml:S1:3343:8	O
SAPHRIS	SAPHRIS.xml:S1:3352:7	O
at	SAPHRIS.xml:S1:3360:2	O
fixed	SAPHRIS.xml:S1:3363:5	O
doses	SAPHRIS.xml:S1:3369:5	O
ranging	SAPHRIS.xml:S1:3375:7	O
from	SAPHRIS.xml:S1:3383:4	O
2.5	SAPHRIS.xml:S1:3388:3	O
mg	SAPHRIS.xml:S1:3392:2	O
to	SAPHRIS.xml:S1:3395:2	O
10	SAPHRIS.xml:S1:3398:2	O
mg	SAPHRIS.xml:S1:3401:2	O
twice	SAPHRIS.xml:S1:3404:5	O
daily	SAPHRIS.xml:S1:3410:5	O
.	SAPHRIS.xml:S1:3415:1	O

The	SAPHRIS.xml:S1:3421:3	O
stated	SAPHRIS.xml:S1:3425:6	O
frequencies	SAPHRIS.xml:S1:3432:11	O
of	SAPHRIS.xml:S1:3444:2	O
adverse	SAPHRIS.xml:S1:3447:7	O
reactions	SAPHRIS.xml:S1:3455:9	O
represent	SAPHRIS.xml:S1:3465:9	O
the	SAPHRIS.xml:S1:3475:3	O
proportion	SAPHRIS.xml:S1:3479:10	O
of	SAPHRIS.xml:S1:3490:2	O
individuals	SAPHRIS.xml:S1:3493:11	O
who	SAPHRIS.xml:S1:3505:3	O
experienced	SAPHRIS.xml:S1:3509:11	O
a	SAPHRIS.xml:S1:3521:1	O
treatment	SAPHRIS.xml:S1:3523:9	O
-	SAPHRIS.xml:S1:3532:1	O
emergent	SAPHRIS.xml:S1:3533:8	O
adverse	SAPHRIS.xml:S1:3542:7	O
event	SAPHRIS.xml:S1:3550:5	O
of	SAPHRIS.xml:S1:3556:2	O
the	SAPHRIS.xml:S1:3559:3	O
type	SAPHRIS.xml:S1:3563:4	O
listed	SAPHRIS.xml:S1:3568:6	O
.	SAPHRIS.xml:S1:3574:1	O

A	SAPHRIS.xml:S1:3576:1	O
reaction	SAPHRIS.xml:S1:3578:8	O
was	SAPHRIS.xml:S1:3587:3	O
considered	SAPHRIS.xml:S1:3591:10	O
treatment	SAPHRIS.xml:S1:3602:9	O
emergent	SAPHRIS.xml:S1:3612:8	O
if	SAPHRIS.xml:S1:3621:2	O
it	SAPHRIS.xml:S1:3624:2	O
occurred	SAPHRIS.xml:S1:3627:8	O
for	SAPHRIS.xml:S1:3636:3	O
the	SAPHRIS.xml:S1:3640:3	O
first	SAPHRIS.xml:S1:3644:5	O
time	SAPHRIS.xml:S1:3650:4	O
or	SAPHRIS.xml:S1:3655:2	O
worsened	SAPHRIS.xml:S1:3658:8	O
while	SAPHRIS.xml:S1:3667:5	O
receiving	SAPHRIS.xml:S1:3673:9	O
therapy	SAPHRIS.xml:S1:3683:7	O
following	SAPHRIS.xml:S1:3691:9	O
baseline	SAPHRIS.xml:S1:3701:8	O
evaluation	SAPHRIS.xml:S1:3710:10	O
.	SAPHRIS.xml:S1:3720:1	O

EXCERPT	SAPHRIS.xml:S1:3728:7	O
:	SAPHRIS.xml:S1:3735:1	O
Commonly	SAPHRIS.xml:S1:3739:8	O
observed	SAPHRIS.xml:S1:3748:8	O
adverse	SAPHRIS.xml:S1:3757:7	O
reactions	SAPHRIS.xml:S1:3765:9	O
(	SAPHRIS.xml:S1:3775:1	O
incidence	SAPHRIS.xml:S1:3776:9	O
5%	SAPHRIS.xml:S1:3788:2	O
and	SAPHRIS.xml:S1:3791:3	O
at	SAPHRIS.xml:S1:3795:2	O
least	SAPHRIS.xml:S1:3798:5	O
twice	SAPHRIS.xml:S1:3804:5	O
that	SAPHRIS.xml:S1:3810:4	O
for	SAPHRIS.xml:S1:3815:3	O
placebo	SAPHRIS.xml:S1:3819:7	O
)	SAPHRIS.xml:S1:3826:1	O
were	SAPHRIS.xml:S1:3828:4	O
(	SAPHRIS.xml:S1:3833:1	O
6.1	SAPHRIS.xml:S1:3834:3	O
)	SAPHRIS.xml:S1:3837:1	O
:	SAPHRIS.xml:S1:3838:1	O

Schizophrenia	SAPHRIS.xml:S1:3848:13	O
Adults	SAPHRIS.xml:S1:3862:6	O
:	SAPHRIS.xml:S1:3868:1	O
akathisia	SAPHRIS.xml:S1:3870:9	B-AdverseReaction
,	SAPHRIS.xml:S1:3879:1	O
oral	SAPHRIS.xml:S1:3881:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:3886:12	I-AdverseReaction
,	SAPHRIS.xml:S1:3898:1	O
somnolence	SAPHRIS.xml:S1:3900:10	B-AdverseReaction
.	SAPHRIS.xml:S1:3910:1	O

Bipolar	SAPHRIS.xml:S1:3918:7	O
Disorder	SAPHRIS.xml:S1:3926:8	O
Adults	SAPHRIS.xml:S1:3935:6	O
(	SAPHRIS.xml:S1:3942:1	O
Monotherapy	SAPHRIS.xml:S1:3943:11	O
)	SAPHRIS.xml:S1:3954:1	O
:	SAPHRIS.xml:S1:3955:1	O
somnolence	SAPHRIS.xml:S1:3957:10	B-AdverseReaction
,	SAPHRIS.xml:S1:3967:1	O
dizziness	SAPHRIS.xml:S1:3969:9	B-AdverseReaction
,	SAPHRIS.xml:S1:3978:1	O
extrapyramidal	SAPHRIS.xml:S1:3980:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:3995:8	I-AdverseReaction
other	SAPHRIS.xml:S1:4004:5	B-Factor
than	SAPHRIS.xml:S1:4010:4	I-Factor
akathisia	SAPHRIS.xml:S1:4015:9	B-AdverseReaction
,	SAPHRIS.xml:S1:4024:1	O
increased	SAPHRIS.xml:S1:4026:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:4036:6	I-AdverseReaction
.	SAPHRIS.xml:S1:4042:1	O

Bipolar	SAPHRIS.xml:S1:4050:7	O
Disorder	SAPHRIS.xml:S1:4058:8	O
Pediatric	SAPHRIS.xml:S1:4067:9	O
Patients	SAPHRIS.xml:S1:4077:8	O
(	SAPHRIS.xml:S1:4086:1	O
Monotherapy	SAPHRIS.xml:S1:4087:11	O
)	SAPHRIS.xml:S1:4098:1	O
:	SAPHRIS.xml:S1:4099:1	O
somnolence	SAPHRIS.xml:S1:4101:10	B-AdverseReaction
,	SAPHRIS.xml:S1:4111:1	O
dizziness	SAPHRIS.xml:S1:4113:9	B-AdverseReaction
,	SAPHRIS.xml:S1:4122:1	O
dysgeusia	SAPHRIS.xml:S1:4124:9	B-AdverseReaction
,	SAPHRIS.xml:S1:4133:1	O
oral	SAPHRIS.xml:S1:4135:4	B-AdverseReaction
paresthesia	SAPHRIS.xml:S1:4140:11	I-AdverseReaction
,	SAPHRIS.xml:S1:4151:1	O
nausea	SAPHRIS.xml:S1:4153:6	B-AdverseReaction
,	SAPHRIS.xml:S1:4159:1	O
increased	SAPHRIS.xml:S1:4161:9	B-AdverseReaction
appetite	SAPHRIS.xml:S1:4171:8	I-AdverseReaction
,	SAPHRIS.xml:S1:4179:1	O
fatigue	SAPHRIS.xml:S1:4181:7	B-AdverseReaction
,	SAPHRIS.xml:S1:4188:1	O
increased	SAPHRIS.xml:S1:4190:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:4200:6	I-AdverseReaction
.	SAPHRIS.xml:S1:4206:1	O

Bipolar	SAPHRIS.xml:S1:4214:7	O
Disorder	SAPHRIS.xml:S1:4222:8	O
Adults	SAPHRIS.xml:S1:4231:6	O
(	SAPHRIS.xml:S1:4238:1	O
Adjunctive	SAPHRIS.xml:S1:4239:10	O
)	SAPHRIS.xml:S1:4249:1	O
:	SAPHRIS.xml:S1:4250:1	O
somnolence	SAPHRIS.xml:S1:4252:10	B-AdverseReaction
,	SAPHRIS.xml:S1:4262:1	O
oral	SAPHRIS.xml:S1:4264:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:4269:12	I-AdverseReaction
.	SAPHRIS.xml:S1:4281:1	O

To	SAPHRIS.xml:S1:4290:2	O
report	SAPHRIS.xml:S1:4293:6	O
SUSPECTED	SAPHRIS.xml:S1:4300:9	O
ADVERSE	SAPHRIS.xml:S1:4310:7	O
REACTIONS	SAPHRIS.xml:S1:4318:9	O
,	SAPHRIS.xml:S1:4327:1	O
contact	SAPHRIS.xml:S1:4329:7	O
Forest	SAPHRIS.xml:S1:4337:6	O
Laboratories	SAPHRIS.xml:S1:4344:12	O
,	SAPHRIS.xml:S1:4356:1	O
LLC	SAPHRIS.xml:S1:4358:3	O
.	SAPHRIS.xml:S1:4361:1	O

at	SAPHRIS.xml:S1:4363:2	O
1	SAPHRIS.xml:S1:4366:1	O
-	SAPHRIS.xml:S1:4367:1	O
800	SAPHRIS.xml:S1:4368:3	O
-	SAPHRIS.xml:S1:4371:1	O
678	SAPHRIS.xml:S1:4372:3	O
-	SAPHRIS.xml:S1:4375:1	O
1605	SAPHRIS.xml:S1:4376:4	O
or	SAPHRIS.xml:S1:4381:2	O
FDA	SAPHRIS.xml:S1:4384:3	O
at	SAPHRIS.xml:S1:4388:2	O
1	SAPHRIS.xml:S1:4391:1	O
-	SAPHRIS.xml:S1:4392:1	O
800	SAPHRIS.xml:S1:4393:3	O
-	SAPHRIS.xml:S1:4396:1	O
FDA	SAPHRIS.xml:S1:4397:3	O
-	SAPHRIS.xml:S1:4400:1	O
1088	SAPHRIS.xml:S1:4401:4	O
or	SAPHRIS.xml:S1:4406:2	O
www	SAPHRIS.xml:S1:4409:3	O
.	SAPHRIS.xml:S1:4412:1	O
fda	SAPHRIS.xml:S1:4413:3	O
.	SAPHRIS.xml:S1:4416:1	O
gov	SAPHRIS.xml:S1:4417:3	O
medwatch	SAPHRIS.xml:S1:4421:8	O
.	SAPHRIS.xml:S1:4429:1	O

6.1	SAPHRIS.xml:S1:4441:3	O

Clinical	SAPHRIS.xml:S1:4445:8	O

Trials	SAPHRIS.xml:S1:4454:6	O
Experience	SAPHRIS.xml:S1:4461:10	O

Because	SAPHRIS.xml:S1:4475:7	O
clinical	SAPHRIS.xml:S1:4483:8	O
trials	SAPHRIS.xml:S1:4492:6	O
are	SAPHRIS.xml:S1:4499:3	O
conducted	SAPHRIS.xml:S1:4503:9	O
under	SAPHRIS.xml:S1:4513:5	O
widely	SAPHRIS.xml:S1:4519:6	O
varying	SAPHRIS.xml:S1:4526:7	O
conditions	SAPHRIS.xml:S1:4534:10	O
,	SAPHRIS.xml:S1:4544:1	O
adverse	SAPHRIS.xml:S1:4546:7	O
reaction	SAPHRIS.xml:S1:4554:8	O
rates	SAPHRIS.xml:S1:4563:5	O
observed	SAPHRIS.xml:S1:4569:8	O
in	SAPHRIS.xml:S1:4578:2	O
the	SAPHRIS.xml:S1:4581:3	O
clinical	SAPHRIS.xml:S1:4585:8	O
trials	SAPHRIS.xml:S1:4594:6	O
of	SAPHRIS.xml:S1:4601:2	O
a	SAPHRIS.xml:S1:4604:1	O
drug	SAPHRIS.xml:S1:4606:4	O
cannot	SAPHRIS.xml:S1:4611:6	O
be	SAPHRIS.xml:S1:4618:2	O
directly	SAPHRIS.xml:S1:4621:8	O
compared	SAPHRIS.xml:S1:4630:8	O
to	SAPHRIS.xml:S1:4639:2	O
rates	SAPHRIS.xml:S1:4642:5	O
in	SAPHRIS.xml:S1:4648:2	O
the	SAPHRIS.xml:S1:4651:3	O
clinical	SAPHRIS.xml:S1:4655:8	O
trials	SAPHRIS.xml:S1:4664:6	O
of	SAPHRIS.xml:S1:4671:2	O
another	SAPHRIS.xml:S1:4674:7	O
drug	SAPHRIS.xml:S1:4682:4	O
and	SAPHRIS.xml:S1:4687:3	O
may	SAPHRIS.xml:S1:4691:3	O
not	SAPHRIS.xml:S1:4695:3	O
reflect	SAPHRIS.xml:S1:4699:7	O
the	SAPHRIS.xml:S1:4707:3	O
rates	SAPHRIS.xml:S1:4711:5	O
observed	SAPHRIS.xml:S1:4717:8	O
in	SAPHRIS.xml:S1:4726:2	O
practice	SAPHRIS.xml:S1:4729:8	O
.	SAPHRIS.xml:S1:4737:1	O

Adult	SAPHRIS.xml:S1:4747:5	O
Patients	SAPHRIS.xml:S1:4753:8	O
with	SAPHRIS.xml:S1:4762:4	O
Schizophrenia	SAPHRIS.xml:S1:4767:13	O
:	SAPHRIS.xml:S1:4780:1	O
The	SAPHRIS.xml:S1:4783:3	O
following	SAPHRIS.xml:S1:4787:9	O
findings	SAPHRIS.xml:S1:4797:8	O
are	SAPHRIS.xml:S1:4806:3	O
based	SAPHRIS.xml:S1:4810:5	O
on	SAPHRIS.xml:S1:4816:2	O
the	SAPHRIS.xml:S1:4819:3	O
short	SAPHRIS.xml:S1:4823:5	O
-	SAPHRIS.xml:S1:4828:1	O
term	SAPHRIS.xml:S1:4829:4	O
placebo	SAPHRIS.xml:S1:4834:7	O
-	SAPHRIS.xml:S1:4841:1	O
controlled	SAPHRIS.xml:S1:4842:10	O
pre	SAPHRIS.xml:S1:4853:3	O
-	SAPHRIS.xml:S1:4856:1	O
marketing	SAPHRIS.xml:S1:4857:9	O
trials	SAPHRIS.xml:S1:4867:6	O
for	SAPHRIS.xml:S1:4874:3	O
schizophrenia	SAPHRIS.xml:S1:4878:13	O
(	SAPHRIS.xml:S1:4892:1	O
a	SAPHRIS.xml:S1:4893:1	O
pool	SAPHRIS.xml:S1:4895:4	O
of	SAPHRIS.xml:S1:4900:2	O
three	SAPHRIS.xml:S1:4903:5	O
6	SAPHRIS.xml:S1:4909:1	O
-	SAPHRIS.xml:S1:4910:1	O
week	SAPHRIS.xml:S1:4911:4	O
fixed	SAPHRIS.xml:S1:4916:5	O
-	SAPHRIS.xml:S1:4921:1	O
dose	SAPHRIS.xml:S1:4922:4	O
trials	SAPHRIS.xml:S1:4927:6	O
and	SAPHRIS.xml:S1:4934:3	O
one	SAPHRIS.xml:S1:4938:3	O
6	SAPHRIS.xml:S1:4942:1	O
-	SAPHRIS.xml:S1:4943:1	O
week	SAPHRIS.xml:S1:4944:4	O
flexible	SAPHRIS.xml:S1:4949:8	O
-	SAPHRIS.xml:S1:4957:1	O
dose	SAPHRIS.xml:S1:4958:4	O
trial	SAPHRIS.xml:S1:4963:5	O
)	SAPHRIS.xml:S1:4968:1	O
in	SAPHRIS.xml:S1:4970:2	O
which	SAPHRIS.xml:S1:4973:5	O
sublingual	SAPHRIS.xml:S1:4979:10	O
SAPHRIS	SAPHRIS.xml:S1:4990:7	O
was	SAPHRIS.xml:S1:4998:3	O
administered	SAPHRIS.xml:S1:5002:12	O
in	SAPHRIS.xml:S1:5015:2	O
doses	SAPHRIS.xml:S1:5018:5	O
ranging	SAPHRIS.xml:S1:5024:7	O
from	SAPHRIS.xml:S1:5032:4	O
5	SAPHRIS.xml:S1:5037:1	O
to	SAPHRIS.xml:S1:5039:2	O
10	SAPHRIS.xml:S1:5042:2	O
mg	SAPHRIS.xml:S1:5045:2	O
twice	SAPHRIS.xml:S1:5048:5	O
daily	SAPHRIS.xml:S1:5054:5	O
.	SAPHRIS.xml:S1:5059:1	O

Adverse	SAPHRIS.xml:S1:5069:7	O
Reactions	SAPHRIS.xml:S1:5077:9	O
Associated	SAPHRIS.xml:S1:5087:10	O
with	SAPHRIS.xml:S1:5098:4	O
Discontinuation	SAPHRIS.xml:S1:5103:15	O
of	SAPHRIS.xml:S1:5119:2	O
Treatment	SAPHRIS.xml:S1:5122:9	O
:	SAPHRIS.xml:S1:5131:1	O
A	SAPHRIS.xml:S1:5134:1	O
total	SAPHRIS.xml:S1:5136:5	O
of	SAPHRIS.xml:S1:5142:2	O
9%	SAPHRIS.xml:S1:5145:2	O
of	SAPHRIS.xml:S1:5148:2	O
SAPHRIS	SAPHRIS.xml:S1:5151:7	O
-	SAPHRIS.xml:S1:5158:1	O
treated	SAPHRIS.xml:S1:5159:7	O
patients	SAPHRIS.xml:S1:5167:8	O
and	SAPHRIS.xml:S1:5176:3	O
10%	SAPHRIS.xml:S1:5180:3	O
of	SAPHRIS.xml:S1:5184:2	O
placebo	SAPHRIS.xml:S1:5187:7	O
-	SAPHRIS.xml:S1:5194:1	O
treated	SAPHRIS.xml:S1:5195:7	O
patients	SAPHRIS.xml:S1:5203:8	O
discontinued	SAPHRIS.xml:S1:5212:12	O
due	SAPHRIS.xml:S1:5225:3	O
to	SAPHRIS.xml:S1:5229:2	O
adverse	SAPHRIS.xml:S1:5232:7	O
reactions	SAPHRIS.xml:S1:5240:9	O
.	SAPHRIS.xml:S1:5249:1	O

There	SAPHRIS.xml:S1:5251:5	O
were	SAPHRIS.xml:S1:5257:4	O
no	SAPHRIS.xml:S1:5262:2	O
drug	SAPHRIS.xml:S1:5265:4	O
-	SAPHRIS.xml:S1:5269:1	O
related	SAPHRIS.xml:S1:5270:7	O
adverse	SAPHRIS.xml:S1:5278:7	O
reactions	SAPHRIS.xml:S1:5286:9	O
associated	SAPHRIS.xml:S1:5296:10	O
with	SAPHRIS.xml:S1:5307:4	O
discontinuation	SAPHRIS.xml:S1:5312:15	O
in	SAPHRIS.xml:S1:5328:2	O
patients	SAPHRIS.xml:S1:5331:8	O
treated	SAPHRIS.xml:S1:5340:7	O
with	SAPHRIS.xml:S1:5348:4	O
SAPHRIS	SAPHRIS.xml:S1:5353:7	O
at	SAPHRIS.xml:S1:5361:2	O
the	SAPHRIS.xml:S1:5364:3	O
rate	SAPHRIS.xml:S1:5368:4	O
of	SAPHRIS.xml:S1:5373:2	O
at	SAPHRIS.xml:S1:5376:2	O
least	SAPHRIS.xml:S1:5379:5	O
1%	SAPHRIS.xml:S1:5385:2	O
and	SAPHRIS.xml:S1:5388:3	O
at	SAPHRIS.xml:S1:5392:2	O
least	SAPHRIS.xml:S1:5395:5	O
twice	SAPHRIS.xml:S1:5401:5	O
the	SAPHRIS.xml:S1:5407:3	O
placebo	SAPHRIS.xml:S1:5411:7	O
rate	SAPHRIS.xml:S1:5419:4	O
.	SAPHRIS.xml:S1:5423:1	O

Adverse	SAPHRIS.xml:S1:5433:7	O
Reactions	SAPHRIS.xml:S1:5441:9	O
Occurring	SAPHRIS.xml:S1:5451:9	O
at	SAPHRIS.xml:S1:5461:2	O
an	SAPHRIS.xml:S1:5464:2	O
Incidence	SAPHRIS.xml:S1:5467:9	O
of	SAPHRIS.xml:S1:5477:2	O
2%	SAPHRIS.xml:S1:5480:2	O
or	SAPHRIS.xml:S1:5483:2	O
More	SAPHRIS.xml:S1:5486:4	O
in	SAPHRIS.xml:S1:5491:2	O
SAPHRIS	SAPHRIS.xml:S1:5494:7	O
-	SAPHRIS.xml:S1:5501:1	O
Treated	SAPHRIS.xml:S1:5502:7	O
Patients	SAPHRIS.xml:S1:5510:8	O
with	SAPHRIS.xml:S1:5519:4	O
Schizophrenia	SAPHRIS.xml:S1:5524:13	O
:	SAPHRIS.xml:S1:5537:1	O
Adverse	SAPHRIS.xml:S1:5540:7	O
reactions	SAPHRIS.xml:S1:5548:9	O
associated	SAPHRIS.xml:S1:5558:10	O
with	SAPHRIS.xml:S1:5569:4	O
the	SAPHRIS.xml:S1:5574:3	O
use	SAPHRIS.xml:S1:5578:3	O
of	SAPHRIS.xml:S1:5582:2	O
SAPHRIS	SAPHRIS.xml:S1:5585:7	O
(	SAPHRIS.xml:S1:5593:1	O
incidence	SAPHRIS.xml:S1:5594:9	O
of	SAPHRIS.xml:S1:5604:2	O
2%	SAPHRIS.xml:S1:5607:2	O
or	SAPHRIS.xml:S1:5610:2	O
greater	SAPHRIS.xml:S1:5613:7	O
,	SAPHRIS.xml:S1:5620:1	O
rounded	SAPHRIS.xml:S1:5622:7	O
to	SAPHRIS.xml:S1:5630:2	O
the	SAPHRIS.xml:S1:5633:3	O
nearest	SAPHRIS.xml:S1:5637:7	O
percent	SAPHRIS.xml:S1:5645:7	O
,	SAPHRIS.xml:S1:5652:1	O
and	SAPHRIS.xml:S1:5654:3	O
SAPHRIS	SAPHRIS.xml:S1:5658:7	O
incidence	SAPHRIS.xml:S1:5666:9	O
greater	SAPHRIS.xml:S1:5676:7	O
than	SAPHRIS.xml:S1:5684:4	O
placebo	SAPHRIS.xml:S1:5689:7	O
)	SAPHRIS.xml:S1:5696:1	O
that	SAPHRIS.xml:S1:5698:4	O
occurred	SAPHRIS.xml:S1:5703:8	O
during	SAPHRIS.xml:S1:5712:6	O
acute	SAPHRIS.xml:S1:5719:5	O
therapy	SAPHRIS.xml:S1:5725:7	O
(	SAPHRIS.xml:S1:5733:1	O
up	SAPHRIS.xml:S1:5734:2	O
to	SAPHRIS.xml:S1:5737:2	O
6	SAPHRIS.xml:S1:5740:1	O
-	SAPHRIS.xml:S1:5741:1	O
weeks	SAPHRIS.xml:S1:5742:5	O
in	SAPHRIS.xml:S1:5748:2	O
patients	SAPHRIS.xml:S1:5751:8	O
with	SAPHRIS.xml:S1:5760:4	O
schizophrenia	SAPHRIS.xml:S1:5765:13	O
)	SAPHRIS.xml:S1:5778:1	O
are	SAPHRIS.xml:S1:5780:3	O
shown	SAPHRIS.xml:S1:5784:5	O
in	SAPHRIS.xml:S1:5790:2	O
Table	SAPHRIS.xml:S1:5794:5	O
8	SAPHRIS.xml:S1:5800:1	O
.	SAPHRIS.xml:S1:5803:1	O

Table	SAPHRIS.xml:S1:5809:5	O
8	SAPHRIS.xml:S1:5815:1	O
:	SAPHRIS.xml:S1:5816:1	O
Adverse	SAPHRIS.xml:S1:5818:7	O
Reactions	SAPHRIS.xml:S1:5826:9	O
Reported	SAPHRIS.xml:S1:5836:8	O
in	SAPHRIS.xml:S1:5845:2	O
2%	SAPHRIS.xml:S1:5848:2	O
or	SAPHRIS.xml:S1:5851:2	O
More	SAPHRIS.xml:S1:5854:4	O
of	SAPHRIS.xml:S1:5859:2	O
Adult	SAPHRIS.xml:S1:5862:5	O
Patients	SAPHRIS.xml:S1:5868:8	O
in	SAPHRIS.xml:S1:5877:2	O
Any	SAPHRIS.xml:S1:5880:3	O
SAPHRIS	SAPHRIS.xml:S1:5884:7	O
Dose	SAPHRIS.xml:S1:5892:4	O
Group	SAPHRIS.xml:S1:5897:5	O
and	SAPHRIS.xml:S1:5903:3	O
Which	SAPHRIS.xml:S1:5907:5	O
Occurred	SAPHRIS.xml:S1:5913:8	O
at	SAPHRIS.xml:S1:5922:2	O
Greater	SAPHRIS.xml:S1:5925:7	O
Incidence	SAPHRIS.xml:S1:5933:9	O
Than	SAPHRIS.xml:S1:5943:4	O
in	SAPHRIS.xml:S1:5948:2	O
the	SAPHRIS.xml:S1:5951:3	O
Placebo	SAPHRIS.xml:S1:5955:7	O
Group	SAPHRIS.xml:S1:5963:5	O
in	SAPHRIS.xml:S1:5969:2	O
6	SAPHRIS.xml:S1:5972:1	O
-	SAPHRIS.xml:S1:5973:1	O
Week	SAPHRIS.xml:S1:5974:4	O
Schizophrenia	SAPHRIS.xml:S1:5979:13	O
Trials	SAPHRIS.xml:S1:5993:6	O

Akathisia	SAPHRIS.xml:S1:6005:9	B-AdverseReaction
includes	SAPHRIS.xml:S1:6015:8	O
:	SAPHRIS.xml:S1:6023:1	O
akathisia	SAPHRIS.xml:S1:6025:9	B-AdverseReaction
and	SAPHRIS.xml:S1:6035:3	O
hyperkinesia	SAPHRIS.xml:S1:6039:12	B-AdverseReaction
.	SAPHRIS.xml:S1:6051:1	O

Extrapyramidal	SAPHRIS.xml:S1:6060:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:6075:8	I-AdverseReaction
included	SAPHRIS.xml:S1:6084:8	O
dystonia	SAPHRIS.xml:S1:6093:8	B-AdverseReaction
,	SAPHRIS.xml:S1:6101:1	O
oculogyration	SAPHRIS.xml:S1:6103:13	B-AdverseReaction
,	SAPHRIS.xml:S1:6116:1	O
dyskinesia	SAPHRIS.xml:S1:6118:10	B-AdverseReaction
,	SAPHRIS.xml:S1:6128:1	O
tardive	SAPHRIS.xml:S1:6130:7	B-AdverseReaction
dyskinesia	SAPHRIS.xml:S1:6138:10	I-AdverseReaction
,	SAPHRIS.xml:S1:6148:1	O
muscle	SAPHRIS.xml:S1:6150:6	B-AdverseReaction
rigidity	SAPHRIS.xml:S1:6157:8	I-AdverseReaction
,	SAPHRIS.xml:S1:6165:1	O
parkinsonism	SAPHRIS.xml:S1:6167:12	B-AdverseReaction
,	SAPHRIS.xml:S1:6179:1	O
tremor	SAPHRIS.xml:S1:6181:6	B-AdverseReaction
,	SAPHRIS.xml:S1:6187:1	O
and	SAPHRIS.xml:S1:6189:3	O
extrapyramidal	SAPHRIS.xml:S1:6193:14	B-AdverseReaction
disorder	SAPHRIS.xml:S1:6208:8	I-AdverseReaction
(	SAPHRIS.xml:S1:6217:1	O
excluding	SAPHRIS.xml:S1:6218:9	B-Negation
akathisia	SAPHRIS.xml:S1:6228:9	B-AdverseReaction
)	SAPHRIS.xml:S1:6237:1	O
.	SAPHRIS.xml:S1:6238:1	O

?	SAPHRIS.xml:S1:6246:1	O

Somnolence	SAPHRIS.xml:S1:6248:10	B-AdverseReaction
includes	SAPHRIS.xml:S1:6259:8	O
the	SAPHRIS.xml:S1:6268:3	O
following	SAPHRIS.xml:S1:6272:9	O
events	SAPHRIS.xml:S1:6282:6	O
:	SAPHRIS.xml:S1:6288:1	O
somnolence	SAPHRIS.xml:S1:6290:10	B-AdverseReaction
,	SAPHRIS.xml:S1:6300:1	O
sedation	SAPHRIS.xml:S1:6302:8	B-AdverseReaction
,	SAPHRIS.xml:S1:6310:1	O
and	SAPHRIS.xml:S1:6312:3	O
hypersomnia	SAPHRIS.xml:S1:6316:11	B-AdverseReaction
.	SAPHRIS.xml:S1:6327:1	O

S	SAPHRIS.xml:S1:6335:1	O
Also	SAPHRIS.xml:S1:6337:4	O
includes	SAPHRIS.xml:S1:6342:8	O
the	SAPHRIS.xml:S1:6351:3	O
Flexible	SAPHRIS.xml:S1:6355:8	O
-	SAPHRIS.xml:S1:6363:1	O
dose	SAPHRIS.xml:S1:6364:4	O
trial	SAPHRIS.xml:S1:6369:5	O
(	SAPHRIS.xml:S1:6375:1	O
N	SAPHRIS.xml:S1:6376:1	O
90	SAPHRIS.xml:S1:6378:2	O
)	SAPHRIS.xml:S1:6380:1	O
.	SAPHRIS.xml:S1:6381:1	O

System	SAPHRIS.xml:S1:6393:6	O

Organ	SAPHRIS.xml:S1:6400:5	O
Class	SAPHRIS.xml:S1:6406:5	O
Preferred	SAPHRIS.xml:S1:6413:9	O
Term	SAPHRIS.xml:S1:6423:4	O
Placebo	SAPHRIS.xml:S1:6433:7	O
N	SAPHRIS.xml:S1:6444:1	O
378	SAPHRIS.xml:S1:6446:3	O
SAPHRIS	SAPHRIS.xml:S1:6460:7	O
5	SAPHRIS.xml:S1:6468:1	O
mg	SAPHRIS.xml:S1:6470:2	O
twice	SAPHRIS.xml:S1:6473:5	O
daily	SAPHRIS.xml:S1:6479:5	O
N	SAPHRIS.xml:S1:6488:1	O
274	SAPHRIS.xml:S1:6490:3	O
SAPHRIS	SAPHRIS.xml:S1:6504:7	O
10	SAPHRIS.xml:S1:6512:2	O
mg	SAPHRIS.xml:S1:6515:2	O
twice	SAPHRIS.xml:S1:6518:5	O
daily	SAPHRIS.xml:S1:6524:5	O
N	SAPHRIS.xml:S1:6533:1	O
208	SAPHRIS.xml:S1:6535:3	O
All	SAPHRIS.xml:S1:6549:3	O
SAPHRIS	SAPHRIS.xml:S1:6553:7	O
S	SAPHRIS.xml:S1:6564:1	O
5	SAPHRIS.xml:S1:6569:1	O
mg	SAPHRIS.xml:S1:6571:2	O
or	SAPHRIS.xml:S1:6574:2	O
10	SAPHRIS.xml:S1:6580:2	O
mg	SAPHRIS.xml:S1:6583:2	O
twice	SAPHRIS.xml:S1:6586:5	O
daily	SAPHRIS.xml:S1:6592:5	O
N	SAPHRIS.xml:S1:6601:1	O
572	SAPHRIS.xml:S1:6603:3	O

Gastrointestinal	SAPHRIS.xml:S1:6620:16	O
disorders	SAPHRIS.xml:S1:6637:9	O

Constipation	SAPHRIS.xml:S1:6734:12	B-AdverseReaction
6	SAPHRIS.xml:S1:6769:1	O
7	SAPHRIS.xml:S1:6785:1	O
4	SAPHRIS.xml:S1:6800:1	O
5	SAPHRIS.xml:S1:6817:1	O

Dry	SAPHRIS.xml:S1:6845:3	B-AdverseReaction
mouth	SAPHRIS.xml:S1:6849:5	I-AdverseReaction
1	SAPHRIS.xml:S1:6880:1	O
3	SAPHRIS.xml:S1:6896:1	O
1	SAPHRIS.xml:S1:6911:1	O
2	SAPHRIS.xml:S1:6928:1	O

Oral	SAPHRIS.xml:S1:6956:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:6961:12	I-AdverseReaction
1	SAPHRIS.xml:S1:6991:1	O
6	SAPHRIS.xml:S1:7007:1	O
7	SAPHRIS.xml:S1:7022:1	O
5	SAPHRIS.xml:S1:7039:1	O

Salivary	SAPHRIS.xml:S1:7067:8	B-AdverseReaction
hypersecretion	SAPHRIS.xml:S1:7076:14	I-AdverseReaction
0	SAPHRIS.xml:S1:7102:1	O
1	SAPHRIS.xml:S1:7119:1	O
4	SAPHRIS.xml:S1:7133:1	O
2	SAPHRIS.xml:S1:7150:1	O

Stomach	SAPHRIS.xml:S1:7178:7	B-AdverseReaction
discomfort	SAPHRIS.xml:S1:7186:10	I-AdverseReaction
1	SAPHRIS.xml:S1:7213:1	O
1	SAPHRIS.xml:S1:7230:1	O
3	SAPHRIS.xml:S1:7244:1	O
2	SAPHRIS.xml:S1:7261:1	O

Vomiting	SAPHRIS.xml:S1:7289:8	B-AdverseReaction
5	SAPHRIS.xml:S1:7324:1	O
4	SAPHRIS.xml:S1:7340:1	O
7	SAPHRIS.xml:S1:7355:1	O
5	SAPHRIS.xml:S1:7372:1	O

General	SAPHRIS.xml:S1:7397:7	O
disorders	SAPHRIS.xml:S1:7405:9	O

Fatigue	SAPHRIS.xml:S1:7511:7	B-AdverseReaction
3	SAPHRIS.xml:S1:7546:1	O
4	SAPHRIS.xml:S1:7562:1	O
3	SAPHRIS.xml:S1:7577:1	O
3	SAPHRIS.xml:S1:7594:1	O

Irritability	SAPHRIS.xml:S1:7622:12	B-AdverseReaction
1	SAPHRIS.xml:S1:7658:1	O
2	SAPHRIS.xml:S1:7673:1	O
1	SAPHRIS.xml:S1:7688:1	O
2	SAPHRIS.xml:S1:7705:1	O

Investigations	SAPHRIS.xml:S1:7730:14	O

Increased	SAPHRIS.xml:S1:7844:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:7854:6	I-AdverseReaction
1	SAPHRIS.xml:S1:7880:1	O
2	SAPHRIS.xml:S1:7895:1	O
2	SAPHRIS.xml:S1:7910:1	O
3	SAPHRIS.xml:S1:7927:1	O

Metabolism	SAPHRIS.xml:S1:7952:10	O
disorders	SAPHRIS.xml:S1:7963:9	O

Increased	SAPHRIS.xml:S1:8066:9	B-AdverseReaction
appetite	SAPHRIS.xml:S1:8076:8	I-AdverseReaction
1	SAPHRIS.xml:S1:8102:1	O
3	SAPHRIS.xml:S1:8117:1	O
0	SAPHRIS.xml:S1:8132:1	O
2	SAPHRIS.xml:S1:8149:1	O

Nervous	SAPHRIS.xml:S1:8174:7	O
system	SAPHRIS.xml:S1:8182:6	O
disorders	SAPHRIS.xml:S1:8189:9	O

Akathisia	SAPHRIS.xml:S1:8288:9	B-AdverseReaction
3	SAPHRIS.xml:S1:8323:1	O
4	SAPHRIS.xml:S1:8339:1	O
11	SAPHRIS.xml:S1:8354:2	O
6	SAPHRIS.xml:S1:8371:1	O

Dizziness	SAPHRIS.xml:S1:8399:9	B-AdverseReaction
4	SAPHRIS.xml:S1:8434:1	O
7	SAPHRIS.xml:S1:8450:1	O
3	SAPHRIS.xml:S1:8465:1	O
5	SAPHRIS.xml:S1:8482:1	O

Extrapyramidal	SAPHRIS.xml:S1:8510:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:8525:8	I-AdverseReaction
(	SAPHRIS.xml:S1:8534:1	O
excluding	SAPHRIS.xml:S1:8535:9	B-Negation
akathisia	SAPHRIS.xml:S1:8545:9	B-AdverseReaction
)	SAPHRIS.xml:S1:8554:1	O
7	SAPHRIS.xml:S1:8561:1	O
9	SAPHRIS.xml:S1:8577:1	O
12	SAPHRIS.xml:S1:8592:2	O
10	SAPHRIS.xml:S1:8609:2	O

Somnolence	SAPHRIS.xml:S1:8637:10	B-AdverseReaction
?	SAPHRIS.xml:S1:8649:1	O

7	SAPHRIS.xml:S1:8672:1	O
15	SAPHRIS.xml:S1:8688:2	O
13	SAPHRIS.xml:S1:8703:2	O
13	SAPHRIS.xml:S1:8720:2	O

Psychiatric	SAPHRIS.xml:S1:8745:11	O
disorders	SAPHRIS.xml:S1:8757:9	O

Insomnia	SAPHRIS.xml:S1:8859:8	B-AdverseReaction
13	SAPHRIS.xml:S1:8894:2	O
16	SAPHRIS.xml:S1:8910:2	O
15	SAPHRIS.xml:S1:8925:2	O
15	SAPHRIS.xml:S1:8942:2	O

Vascular	SAPHRIS.xml:S1:8967:8	O
disorders	SAPHRIS.xml:S1:8976:9	O

Hypertension	SAPHRIS.xml:S1:9081:12	B-AdverseReaction
2	SAPHRIS.xml:S1:9116:1	O
2	SAPHRIS.xml:S1:9132:1	O
3	SAPHRIS.xml:S1:9147:1	O
2	SAPHRIS.xml:S1:9164:1	O

Dose	SAPHRIS.xml:S1:9201:4	O
-	SAPHRIS.xml:S1:9205:1	O
Related	SAPHRIS.xml:S1:9206:7	O
Adverse	SAPHRIS.xml:S1:9214:7	O
Reactions	SAPHRIS.xml:S1:9222:9	O
:	SAPHRIS.xml:S1:9231:1	O
In	SAPHRIS.xml:S1:9234:2	O
the	SAPHRIS.xml:S1:9237:3	O
short	SAPHRIS.xml:S1:9241:5	O
term	SAPHRIS.xml:S1:9247:4	O
schizophrenia	SAPHRIS.xml:S1:9252:13	O
trials	SAPHRIS.xml:S1:9266:6	O
the	SAPHRIS.xml:S1:9273:3	O
incidence	SAPHRIS.xml:S1:9277:9	O
of	SAPHRIS.xml:S1:9287:2	O
akathisia	SAPHRIS.xml:S1:9290:9	B-AdverseReaction
appeared	SAPHRIS.xml:S1:9300:8	O
to	SAPHRIS.xml:S1:9309:2	O
be	SAPHRIS.xml:S1:9312:2	O
dose	SAPHRIS.xml:S1:9315:4	O
-	SAPHRIS.xml:S1:9319:1	O
related	SAPHRIS.xml:S1:9320:7	O
(	SAPHRIS.xml:S1:9328:1	O
seeTable	SAPHRIS.xml:S1:9329:8	O
8	SAPHRIS.xml:S1:9338:1	O
)	SAPHRIS.xml:S1:9339:1	O
.	SAPHRIS.xml:S1:9340:1	O

Monotherapy	SAPHRIS.xml:S1:9350:11	O

in	SAPHRIS.xml:S1:9362:2	O
Adult	SAPHRIS.xml:S1:9365:5	O
Patients	SAPHRIS.xml:S1:9371:8	O
with	SAPHRIS.xml:S1:9380:4	O
Bipolar	SAPHRIS.xml:S1:9385:7	O
Mania	SAPHRIS.xml:S1:9393:5	O
:	SAPHRIS.xml:S1:9398:1	O
The	SAPHRIS.xml:S1:9401:3	O
following	SAPHRIS.xml:S1:9405:9	O
findings	SAPHRIS.xml:S1:9415:8	O
are	SAPHRIS.xml:S1:9424:3	O
based	SAPHRIS.xml:S1:9428:5	O
on	SAPHRIS.xml:S1:9434:2	O
the	SAPHRIS.xml:S1:9437:3	O
short	SAPHRIS.xml:S1:9441:5	O
-	SAPHRIS.xml:S1:9446:1	O
term	SAPHRIS.xml:S1:9447:4	O
placebo	SAPHRIS.xml:S1:9452:7	O
-	SAPHRIS.xml:S1:9459:1	O
controlled	SAPHRIS.xml:S1:9460:10	O
trials	SAPHRIS.xml:S1:9471:6	O
for	SAPHRIS.xml:S1:9478:3	O
bipolar	SAPHRIS.xml:S1:9482:7	O
mania	SAPHRIS.xml:S1:9490:5	O
(	SAPHRIS.xml:S1:9496:1	O
a	SAPHRIS.xml:S1:9497:1	O
pool	SAPHRIS.xml:S1:9499:4	O
of	SAPHRIS.xml:S1:9504:2	O
two	SAPHRIS.xml:S1:9507:3	O
3	SAPHRIS.xml:S1:9511:1	O
-	SAPHRIS.xml:S1:9512:1	O
week	SAPHRIS.xml:S1:9513:4	O
flexible	SAPHRIS.xml:S1:9518:8	O
-	SAPHRIS.xml:S1:9526:1	O
dose	SAPHRIS.xml:S1:9527:4	O
trials	SAPHRIS.xml:S1:9532:6	O
)	SAPHRIS.xml:S1:9538:1	O
in	SAPHRIS.xml:S1:9540:2	O
which	SAPHRIS.xml:S1:9543:5	O
sublingual	SAPHRIS.xml:S1:9549:10	O
SAPHRIS	SAPHRIS.xml:S1:9560:7	O
was	SAPHRIS.xml:S1:9568:3	O
administered	SAPHRIS.xml:S1:9572:12	O
in	SAPHRIS.xml:S1:9585:2	O
doses	SAPHRIS.xml:S1:9588:5	O
of	SAPHRIS.xml:S1:9594:2	O
5	SAPHRIS.xml:S1:9597:1	O
mg	SAPHRIS.xml:S1:9599:2	O
or	SAPHRIS.xml:S1:9602:2	O
10	SAPHRIS.xml:S1:9605:2	O
mg	SAPHRIS.xml:S1:9608:2	O
twice	SAPHRIS.xml:S1:9611:5	O
daily	SAPHRIS.xml:S1:9617:5	O
.	SAPHRIS.xml:S1:9622:1	O

Adverse	SAPHRIS.xml:S1:9632:7	O
Reactions	SAPHRIS.xml:S1:9640:9	O
Associated	SAPHRIS.xml:S1:9650:10	O
with	SAPHRIS.xml:S1:9661:4	O
Discontinuation	SAPHRIS.xml:S1:9666:15	O
of	SAPHRIS.xml:S1:9682:2	O
Treatment	SAPHRIS.xml:S1:9685:9	O
:	SAPHRIS.xml:S1:9694:1	O
Approximately	SAPHRIS.xml:S1:9697:13	O
10%	SAPHRIS.xml:S1:9711:3	O
(	SAPHRIS.xml:S1:9715:1	O
38	SAPHRIS.xml:S1:9716:2	O
379	SAPHRIS.xml:S1:9719:3	O
)	SAPHRIS.xml:S1:9722:1	O
of	SAPHRIS.xml:S1:9724:2	O
SAPHRIS	SAPHRIS.xml:S1:9727:7	O
-	SAPHRIS.xml:S1:9734:1	O
treated	SAPHRIS.xml:S1:9735:7	O
patients	SAPHRIS.xml:S1:9743:8	O
in	SAPHRIS.xml:S1:9752:2	O
short	SAPHRIS.xml:S1:9755:5	O
-	SAPHRIS.xml:S1:9760:1	O
term	SAPHRIS.xml:S1:9761:4	O
,	SAPHRIS.xml:S1:9765:1	O
placebo	SAPHRIS.xml:S1:9767:7	O
-	SAPHRIS.xml:S1:9774:1	O
controlled	SAPHRIS.xml:S1:9775:10	O
trials	SAPHRIS.xml:S1:9786:6	O
discontinued	SAPHRIS.xml:S1:9793:12	O
treatment	SAPHRIS.xml:S1:9806:9	O
due	SAPHRIS.xml:S1:9816:3	O
to	SAPHRIS.xml:S1:9820:2	O
an	SAPHRIS.xml:S1:9823:2	O
adverse	SAPHRIS.xml:S1:9826:7	O
reaction	SAPHRIS.xml:S1:9834:8	O
,	SAPHRIS.xml:S1:9842:1	O
compared	SAPHRIS.xml:S1:9844:8	O
with	SAPHRIS.xml:S1:9853:4	O
about	SAPHRIS.xml:S1:9858:5	O
6%	SAPHRIS.xml:S1:9864:2	O
(	SAPHRIS.xml:S1:9867:1	O
12	SAPHRIS.xml:S1:9868:2	O
203	SAPHRIS.xml:S1:9871:3	O
)	SAPHRIS.xml:S1:9874:1	O
on	SAPHRIS.xml:S1:9876:2	O
placebo	SAPHRIS.xml:S1:9879:7	O
.	SAPHRIS.xml:S1:9886:1	O

The	SAPHRIS.xml:S1:9888:3	O
most	SAPHRIS.xml:S1:9892:4	O
common	SAPHRIS.xml:S1:9897:6	O
adverse	SAPHRIS.xml:S1:9904:7	O
reactions	SAPHRIS.xml:S1:9912:9	O
associated	SAPHRIS.xml:S1:9922:10	O
with	SAPHRIS.xml:S1:9933:4	O
discontinuation	SAPHRIS.xml:S1:9938:15	O
in	SAPHRIS.xml:S1:9954:2	O
patients	SAPHRIS.xml:S1:9957:8	O
treated	SAPHRIS.xml:S1:9966:7	O
with	SAPHRIS.xml:S1:9974:4	O
SAPHRIS	SAPHRIS.xml:S1:9979:7	O
(	SAPHRIS.xml:S1:9987:1	O
rates	SAPHRIS.xml:S1:9988:5	O
at	SAPHRIS.xml:S1:9994:2	O
least	SAPHRIS.xml:S1:9997:5	O
1%	SAPHRIS.xml:S1:10003:2	O
and	SAPHRIS.xml:S1:10006:3	O
at	SAPHRIS.xml:S1:10010:2	O
least	SAPHRIS.xml:S1:10013:5	O
twice	SAPHRIS.xml:S1:10019:5	O
the	SAPHRIS.xml:S1:10025:3	O
placebo	SAPHRIS.xml:S1:10029:7	O
rate	SAPHRIS.xml:S1:10037:4	O
)	SAPHRIS.xml:S1:10041:1	O
were	SAPHRIS.xml:S1:10043:4	O
anxiety	SAPHRIS.xml:S1:10048:7	B-AdverseReaction
(	SAPHRIS.xml:S1:10056:1	O
1.1%	SAPHRIS.xml:S1:10057:4	O
)	SAPHRIS.xml:S1:10061:1	O
and	SAPHRIS.xml:S1:10063:3	O
oral	SAPHRIS.xml:S1:10067:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:10072:12	I-AdverseReaction
(	SAPHRIS.xml:S1:10085:1	O
1.1%	SAPHRIS.xml:S1:10086:4	O
)	SAPHRIS.xml:S1:10090:1	O
compared	SAPHRIS.xml:S1:10092:8	O
to	SAPHRIS.xml:S1:10101:2	O
placebo	SAPHRIS.xml:S1:10104:7	O
(	SAPHRIS.xml:S1:10112:1	O
0%	SAPHRIS.xml:S1:10113:2	O
)	SAPHRIS.xml:S1:10115:1	O
.	SAPHRIS.xml:S1:10116:1	O

Adverse	SAPHRIS.xml:S1:10126:7	O
Reactions	SAPHRIS.xml:S1:10134:9	O
Occurring	SAPHRIS.xml:S1:10144:9	O
at	SAPHRIS.xml:S1:10154:2	O
an	SAPHRIS.xml:S1:10157:2	O
Incidence	SAPHRIS.xml:S1:10160:9	O
of	SAPHRIS.xml:S1:10170:2	O
2%	SAPHRIS.xml:S1:10173:2	O
or	SAPHRIS.xml:S1:10176:2	O
More	SAPHRIS.xml:S1:10179:4	O
Among	SAPHRIS.xml:S1:10184:5	O
SAPHRIS	SAPHRIS.xml:S1:10190:7	O
-	SAPHRIS.xml:S1:10197:1	O
Treated	SAPHRIS.xml:S1:10198:7	O
(	SAPHRIS.xml:S1:10206:1	O
Monotherapy	SAPHRIS.xml:S1:10207:11	O
)	SAPHRIS.xml:S1:10218:1	O
patients	SAPHRIS.xml:S1:10220:8	O
with	SAPHRIS.xml:S1:10229:4	O
Bipolar	SAPHRIS.xml:S1:10234:7	O
I	SAPHRIS.xml:S1:10242:1	O
Disorder	SAPHRIS.xml:S1:10244:8	O
:	SAPHRIS.xml:S1:10252:1	O
Adverse	SAPHRIS.xml:S1:10255:7	O
reactions	SAPHRIS.xml:S1:10263:9	O
associated	SAPHRIS.xml:S1:10273:10	O
with	SAPHRIS.xml:S1:10284:4	O
the	SAPHRIS.xml:S1:10289:3	O
use	SAPHRIS.xml:S1:10293:3	O
of	SAPHRIS.xml:S1:10297:2	O
SAPHRIS	SAPHRIS.xml:S1:10300:7	O
(	SAPHRIS.xml:S1:10308:1	O
incidence	SAPHRIS.xml:S1:10309:9	O
of	SAPHRIS.xml:S1:10319:2	O
2%	SAPHRIS.xml:S1:10322:2	O
or	SAPHRIS.xml:S1:10325:2	O
greater	SAPHRIS.xml:S1:10328:7	O
,	SAPHRIS.xml:S1:10335:1	O
rounded	SAPHRIS.xml:S1:10337:7	O
to	SAPHRIS.xml:S1:10345:2	O
the	SAPHRIS.xml:S1:10348:3	O
nearest	SAPHRIS.xml:S1:10352:7	O
percent	SAPHRIS.xml:S1:10360:7	O
,	SAPHRIS.xml:S1:10367:1	O
and	SAPHRIS.xml:S1:10369:3	O
SAPHRIS	SAPHRIS.xml:S1:10373:7	O
incidence	SAPHRIS.xml:S1:10381:9	O
greater	SAPHRIS.xml:S1:10391:7	O
than	SAPHRIS.xml:S1:10399:4	O
placebo	SAPHRIS.xml:S1:10404:7	O
)	SAPHRIS.xml:S1:10411:1	O
that	SAPHRIS.xml:S1:10413:4	O
occurred	SAPHRIS.xml:S1:10418:8	O
during	SAPHRIS.xml:S1:10427:6	O
acute	SAPHRIS.xml:S1:10434:5	O
monotherapy	SAPHRIS.xml:S1:10440:11	O
(	SAPHRIS.xml:S1:10452:1	O
up	SAPHRIS.xml:S1:10453:2	O
to	SAPHRIS.xml:S1:10456:2	O
3	SAPHRIS.xml:S1:10459:1	O
-	SAPHRIS.xml:S1:10460:1	O
weeks	SAPHRIS.xml:S1:10461:5	O
in	SAPHRIS.xml:S1:10467:2	O
patients	SAPHRIS.xml:S1:10470:8	O
with	SAPHRIS.xml:S1:10479:4	O
bipolar	SAPHRIS.xml:S1:10484:7	O
mania	SAPHRIS.xml:S1:10492:5	O
)	SAPHRIS.xml:S1:10497:1	O
are	SAPHRIS.xml:S1:10499:3	O
shown	SAPHRIS.xml:S1:10503:5	O
in	SAPHRIS.xml:S1:10509:2	O
Table	SAPHRIS.xml:S1:10513:5	O
9	SAPHRIS.xml:S1:10519:1	O
.	SAPHRIS.xml:S1:10522:1	O

Table	SAPHRIS.xml:S1:10528:5	O
9	SAPHRIS.xml:S1:10534:1	O
:	SAPHRIS.xml:S1:10535:1	O
Adverse	SAPHRIS.xml:S1:10537:7	O
Reactions	SAPHRIS.xml:S1:10545:9	O
Reported	SAPHRIS.xml:S1:10555:8	O
in	SAPHRIS.xml:S1:10564:2	O
2%	SAPHRIS.xml:S1:10567:2	O
or	SAPHRIS.xml:S1:10570:2	O
More	SAPHRIS.xml:S1:10573:4	O
of	SAPHRIS.xml:S1:10578:2	O
Adult	SAPHRIS.xml:S1:10581:5	O
Patients	SAPHRIS.xml:S1:10587:8	O
in	SAPHRIS.xml:S1:10596:2	O
Any	SAPHRIS.xml:S1:10599:3	O
SAPHRIS	SAPHRIS.xml:S1:10603:7	O
Dose	SAPHRIS.xml:S1:10611:4	O
Group	SAPHRIS.xml:S1:10616:5	O
and	SAPHRIS.xml:S1:10622:3	O
Which	SAPHRIS.xml:S1:10626:5	O
Occurred	SAPHRIS.xml:S1:10632:8	O
at	SAPHRIS.xml:S1:10641:2	O
Greater	SAPHRIS.xml:S1:10644:7	O
Incidence	SAPHRIS.xml:S1:10652:9	O
Than	SAPHRIS.xml:S1:10662:4	O
in	SAPHRIS.xml:S1:10667:2	O
the	SAPHRIS.xml:S1:10670:3	O
Placebo	SAPHRIS.xml:S1:10674:7	O
Group	SAPHRIS.xml:S1:10682:5	O
in	SAPHRIS.xml:S1:10688:2	O
3	SAPHRIS.xml:S1:10691:1	O
-	SAPHRIS.xml:S1:10692:1	O
Week	SAPHRIS.xml:S1:10693:4	O
Bipolar	SAPHRIS.xml:S1:10698:7	O
Mania	SAPHRIS.xml:S1:10706:5	O
Trials	SAPHRIS.xml:S1:10712:6	O

SAPHRIS	SAPHRIS.xml:S1:10724:7	O
5	SAPHRIS.xml:S1:10732:1	O
mg	SAPHRIS.xml:S1:10734:2	O
to	SAPHRIS.xml:S1:10737:2	O
10	SAPHRIS.xml:S1:10740:2	O
mg	SAPHRIS.xml:S1:10743:2	O
twice	SAPHRIS.xml:S1:10746:5	O
daily	SAPHRIS.xml:S1:10752:5	O
with	SAPHRIS.xml:S1:10758:4	O
flexible	SAPHRIS.xml:S1:10763:8	O
dosing	SAPHRIS.xml:S1:10772:6	O
.	SAPHRIS.xml:S1:10778:1	O

Extrapyramidal	SAPHRIS.xml:S1:10787:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:10802:8	I-AdverseReaction
included	SAPHRIS.xml:S1:10811:8	O
:	SAPHRIS.xml:S1:10819:1	O
dystonia	SAPHRIS.xml:S1:10821:8	B-AdverseReaction
,	SAPHRIS.xml:S1:10829:1	O
blepharospasm	SAPHRIS.xml:S1:10831:13	B-AdverseReaction
,	SAPHRIS.xml:S1:10844:1	O
torticollis	SAPHRIS.xml:S1:10846:11	B-AdverseReaction
,	SAPHRIS.xml:S1:10857:1	O
dyskinesia	SAPHRIS.xml:S1:10859:10	B-AdverseReaction
,	SAPHRIS.xml:S1:10869:1	O
tardive	SAPHRIS.xml:S1:10871:7	B-AdverseReaction
dyskinesia	SAPHRIS.xml:S1:10879:10	I-AdverseReaction
,	SAPHRIS.xml:S1:10889:1	O
muscle	SAPHRIS.xml:S1:10891:6	B-AdverseReaction
rigidity	SAPHRIS.xml:S1:10898:8	I-AdverseReaction
,	SAPHRIS.xml:S1:10906:1	O
parkinsonism	SAPHRIS.xml:S1:10908:12	B-AdverseReaction
,	SAPHRIS.xml:S1:10920:1	O
gait	SAPHRIS.xml:S1:10922:4	B-AdverseReaction
disturbance	SAPHRIS.xml:S1:10927:11	I-AdverseReaction
,	SAPHRIS.xml:S1:10938:1	O
masked	SAPHRIS.xml:S1:10940:6	B-AdverseReaction
facies	SAPHRIS.xml:S1:10947:6	I-AdverseReaction
,	SAPHRIS.xml:S1:10953:1	O
and	SAPHRIS.xml:S1:10955:3	O
tremor	SAPHRIS.xml:S1:10959:6	B-AdverseReaction
(	SAPHRIS.xml:S1:10966:1	O
excluding	SAPHRIS.xml:S1:10967:9	B-Negation
akathisia	SAPHRIS.xml:S1:10977:9	B-AdverseReaction
)	SAPHRIS.xml:S1:10986:1	O
.	SAPHRIS.xml:S1:10987:1	O

?	SAPHRIS.xml:S1:10995:1	O

Somnolence	SAPHRIS.xml:S1:10997:10	B-AdverseReaction
includes	SAPHRIS.xml:S1:11008:8	O
the	SAPHRIS.xml:S1:11017:3	O
following	SAPHRIS.xml:S1:11021:9	O
events	SAPHRIS.xml:S1:11031:6	O
:	SAPHRIS.xml:S1:11037:1	O
somnolence	SAPHRIS.xml:S1:11039:10	B-AdverseReaction
,	SAPHRIS.xml:S1:11049:1	O
sedation	SAPHRIS.xml:S1:11051:8	B-AdverseReaction
,	SAPHRIS.xml:S1:11059:1	O
and	SAPHRIS.xml:S1:11061:3	O
hypersomnia	SAPHRIS.xml:S1:11065:11	B-AdverseReaction
.	SAPHRIS.xml:S1:11076:1	O

System	SAPHRIS.xml:S1:11088:6	O

Organ	SAPHRIS.xml:S1:11095:5	O
Class	SAPHRIS.xml:S1:11101:5	O
Preferred	SAPHRIS.xml:S1:11107:9	O
Term	SAPHRIS.xml:S1:11117:4	O
Placebo	SAPHRIS.xml:S1:11137:7	O
N	SAPHRIS.xml:S1:11148:1	O
203	SAPHRIS.xml:S1:11150:3	O
SAPHRIS	SAPHRIS.xml:S1:11164:7	O
5	SAPHRIS.xml:S1:11175:1	O
mg	SAPHRIS.xml:S1:11177:2	O
or	SAPHRIS.xml:S1:11180:2	O
10	SAPHRIS.xml:S1:11183:2	O
mg	SAPHRIS.xml:S1:11186:2	O
twice	SAPHRIS.xml:S1:11189:5	O
daily	SAPHRIS.xml:S1:11195:5	O
N	SAPHRIS.xml:S1:11205:1	O
379	SAPHRIS.xml:S1:11207:3	O

Gastrointestinal	SAPHRIS.xml:S1:11224:16	O
disorders	SAPHRIS.xml:S1:11241:9	O

Dry	SAPHRIS.xml:S1:11279:3	B-AdverseReaction
mouth	SAPHRIS.xml:S1:11283:5	I-AdverseReaction
1	SAPHRIS.xml:S1:11323:1	O
3	SAPHRIS.xml:S1:11346:1	O

Dyspepsia	SAPHRIS.xml:S1:11386:9	B-AdverseReaction
2	SAPHRIS.xml:S1:11430:1	O
4	SAPHRIS.xml:S1:11453:1	O

Oral	SAPHRIS.xml:S1:11493:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:11498:12	I-AdverseReaction
1	SAPHRIS.xml:S1:11538:1	O
4	SAPHRIS.xml:S1:11560:1	O

Toothache	SAPHRIS.xml:S1:11600:9	B-AdverseReaction
2	SAPHRIS.xml:S1:11644:1	O
3	SAPHRIS.xml:S1:11667:1	O

General	SAPHRIS.xml:S1:11704:7	O
disorders	SAPHRIS.xml:S1:11712:9	O

Fatigue	SAPHRIS.xml:S1:11759:7	B-AdverseReaction
2	SAPHRIS.xml:S1:11803:1	O
4	SAPHRIS.xml:S1:11826:1	O

Investigations	SAPHRIS.xml:S1:11863:14	O

Increased	SAPHRIS.xml:S1:11918:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:11928:6	I-AdverseReaction
1	SAPHRIS.xml:S1:11963:1	O
5	SAPHRIS.xml:S1:11985:1	O

Metabolism	SAPHRIS.xml:S1:12022:10	O
disorders	SAPHRIS.xml:S1:12033:9	O

Increased	SAPHRIS.xml:S1:12077:9	B-AdverseReaction
appetite	SAPHRIS.xml:S1:12087:8	I-AdverseReaction
1	SAPHRIS.xml:S1:12121:1	O
4	SAPHRIS.xml:S1:12144:1	O

Musculoskeletal	SAPHRIS.xml:S1:12181:15	O
and	SAPHRIS.xml:S1:12197:3	O
connective	SAPHRIS.xml:S1:12201:10	O
tissue	SAPHRIS.xml:S1:12212:6	O
disorders	SAPHRIS.xml:S1:12219:9	O

Arthralgia	SAPHRIS.xml:S1:12240:10	B-AdverseReaction
1	SAPHRIS.xml:S1:12284:1	O
3	SAPHRIS.xml:S1:12307:1	O

Pain	SAPHRIS.xml:S1:12347:4	B-AdverseReaction
in	SAPHRIS.xml:S1:12352:2	I-AdverseReaction
extremity	SAPHRIS.xml:S1:12355:9	I-AdverseReaction
1	SAPHRIS.xml:S1:12392:1	O
2	SAPHRIS.xml:S1:12414:1	O

Nervous	SAPHRIS.xml:S1:12451:7	O
system	SAPHRIS.xml:S1:12459:6	O
disorders	SAPHRIS.xml:S1:12466:9	O

Akathisia	SAPHRIS.xml:S1:12506:9	B-AdverseReaction
2	SAPHRIS.xml:S1:12550:1	O
4	SAPHRIS.xml:S1:12573:1	O

Dizziness	SAPHRIS.xml:S1:12613:9	B-AdverseReaction
3	SAPHRIS.xml:S1:12657:1	O
11	SAPHRIS.xml:S1:12680:2	O

Dysgeusia	SAPHRIS.xml:S1:12720:9	B-AdverseReaction
1	SAPHRIS.xml:S1:12765:1	O
3	SAPHRIS.xml:S1:12787:1	O

Headache	SAPHRIS.xml:S1:12827:8	B-AdverseReaction
11	SAPHRIS.xml:S1:12871:2	O
12	SAPHRIS.xml:S1:12894:2	O

Other	SAPHRIS.xml:S1:12934:5	O
extrapyramidal	SAPHRIS.xml:S1:12940:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:12955:8	I-AdverseReaction
(	SAPHRIS.xml:S1:12964:1	O
excluding	SAPHRIS.xml:S1:12965:9	B-Negation
akathisia	SAPHRIS.xml:S1:12975:9	B-AdverseReaction
)	SAPHRIS.xml:S1:12984:1	O
2	SAPHRIS.xml:S1:12991:1	O
7	SAPHRIS.xml:S1:13014:1	O

Somnolence	SAPHRIS.xml:S1:13054:10	B-AdverseReaction
?	SAPHRIS.xml:S1:13066:1	O

6	SAPHRIS.xml:S1:13098:1	O
24	SAPHRIS.xml:S1:13121:2	O

Psychiatric	SAPHRIS.xml:S1:13158:11	O
disorders	SAPHRIS.xml:S1:13170:9	O

Anxiety	SAPHRIS.xml:S1:13213:7	B-AdverseReaction
2	SAPHRIS.xml:S1:13257:1	O
4	SAPHRIS.xml:S1:13280:1	O

Depression	SAPHRIS.xml:S1:13320:10	B-AdverseReaction
1	SAPHRIS.xml:S1:13364:1	O
2	SAPHRIS.xml:S1:13387:1	O

Insomnia	SAPHRIS.xml:S1:13427:8	B-AdverseReaction
5	SAPHRIS.xml:S1:13471:1	O
6	SAPHRIS.xml:S1:13494:1	O

Monotherapy	SAPHRIS.xml:S1:13541:11	O
in	SAPHRIS.xml:S1:13553:2	O
Pediatric	SAPHRIS.xml:S1:13556:9	O
Patients	SAPHRIS.xml:S1:13566:8	O
with	SAPHRIS.xml:S1:13575:4	O
Bipolar	SAPHRIS.xml:S1:13580:7	O
Mania	SAPHRIS.xml:S1:13588:5	O
:	SAPHRIS.xml:S1:13593:1	O
The	SAPHRIS.xml:S1:13596:3	O
following	SAPHRIS.xml:S1:13600:9	O
findings	SAPHRIS.xml:S1:13610:8	O
are	SAPHRIS.xml:S1:13619:3	O
based	SAPHRIS.xml:S1:13623:5	O
on	SAPHRIS.xml:S1:13629:2	O
a	SAPHRIS.xml:S1:13632:1	O
3	SAPHRIS.xml:S1:13634:1	O
-	SAPHRIS.xml:S1:13635:1	O
week	SAPHRIS.xml:S1:13636:4	O
,	SAPHRIS.xml:S1:13641:1	O
placebo	SAPHRIS.xml:S1:13643:7	O
-	SAPHRIS.xml:S1:13650:1	O
controlled	SAPHRIS.xml:S1:13651:10	O
trial	SAPHRIS.xml:S1:13662:5	O
for	SAPHRIS.xml:S1:13668:3	O
bipolar	SAPHRIS.xml:S1:13672:7	O
mania	SAPHRIS.xml:S1:13680:5	O
in	SAPHRIS.xml:S1:13686:2	O
which	SAPHRIS.xml:S1:13689:5	O
SAPHRIS	SAPHRIS.xml:S1:13695:7	O
was	SAPHRIS.xml:S1:13703:3	O
administered	SAPHRIS.xml:S1:13707:12	O
at	SAPHRIS.xml:S1:13720:2	O
doses	SAPHRIS.xml:S1:13723:5	O
of	SAPHRIS.xml:S1:13729:2	O
2.5	SAPHRIS.xml:S1:13732:3	O
mg	SAPHRIS.xml:S1:13736:2	O
,	SAPHRIS.xml:S1:13738:1	O
5	SAPHRIS.xml:S1:13740:1	O
mg	SAPHRIS.xml:S1:13742:2	O
,	SAPHRIS.xml:S1:13744:1	O
or	SAPHRIS.xml:S1:13746:2	O
10	SAPHRIS.xml:S1:13749:2	O
mg	SAPHRIS.xml:S1:13752:2	O
twice	SAPHRIS.xml:S1:13755:5	O
daily	SAPHRIS.xml:S1:13761:5	O
.	SAPHRIS.xml:S1:13766:1	O

Adverse	SAPHRIS.xml:S1:13776:7	O

Reactions	SAPHRIS.xml:S1:13784:9	O
Leading	SAPHRIS.xml:S1:13794:7	O
to	SAPHRIS.xml:S1:13802:2	O
Discontinuation	SAPHRIS.xml:S1:13805:15	O
of	SAPHRIS.xml:S1:13821:2	O
Treatment	SAPHRIS.xml:S1:13824:9	O
:	SAPHRIS.xml:S1:13833:1	O
A	SAPHRIS.xml:S1:13836:1	O
total	SAPHRIS.xml:S1:13838:5	O
of	SAPHRIS.xml:S1:13844:2	O
6.7%	SAPHRIS.xml:S1:13847:4	O
(	SAPHRIS.xml:S1:13852:1	O
7	SAPHRIS.xml:S1:13853:1	O
104	SAPHRIS.xml:S1:13855:3	O
)	SAPHRIS.xml:S1:13858:1	O
of	SAPHRIS.xml:S1:13860:2	O
patients	SAPHRIS.xml:S1:13863:8	O
treated	SAPHRIS.xml:S1:13872:7	O
with	SAPHRIS.xml:S1:13880:4	O
SAPHRIS	SAPHRIS.xml:S1:13885:7	O
2.5	SAPHRIS.xml:S1:13893:3	O
mg	SAPHRIS.xml:S1:13897:2	O
twice	SAPHRIS.xml:S1:13900:5	O
daily	SAPHRIS.xml:S1:13906:5	O
,	SAPHRIS.xml:S1:13911:1	O
5.1%	SAPHRIS.xml:S1:13913:4	O
(	SAPHRIS.xml:S1:13918:1	O
5	SAPHRIS.xml:S1:13919:1	O
99	SAPHRIS.xml:S1:13921:2	O
)	SAPHRIS.xml:S1:13923:1	O
of	SAPHRIS.xml:S1:13925:2	O
patients	SAPHRIS.xml:S1:13928:8	O
treated	SAPHRIS.xml:S1:13937:7	O
with	SAPHRIS.xml:S1:13945:4	O
SAPHRIS	SAPHRIS.xml:S1:13950:7	O
5	SAPHRIS.xml:S1:13958:1	O
mg	SAPHRIS.xml:S1:13960:2	O
twice	SAPHRIS.xml:S1:13963:5	O
daily	SAPHRIS.xml:S1:13969:5	O
,	SAPHRIS.xml:S1:13974:1	O
and	SAPHRIS.xml:S1:13976:3	O
5.1%	SAPHRIS.xml:S1:13980:4	O
(	SAPHRIS.xml:S1:13985:1	O
5	SAPHRIS.xml:S1:13986:1	O
99	SAPHRIS.xml:S1:13988:2	O
)	SAPHRIS.xml:S1:13990:1	O
of	SAPHRIS.xml:S1:13992:2	O
patients	SAPHRIS.xml:S1:13995:8	O
treated	SAPHRIS.xml:S1:14004:7	O
with	SAPHRIS.xml:S1:14012:4	O
SAPHRIS	SAPHRIS.xml:S1:14017:7	O
10	SAPHRIS.xml:S1:14025:2	O
mg	SAPHRIS.xml:S1:14028:2	O
twice	SAPHRIS.xml:S1:14031:5	O
daily	SAPHRIS.xml:S1:14037:5	O
discontinued	SAPHRIS.xml:S1:14043:12	O
treatment	SAPHRIS.xml:S1:14056:9	O
due	SAPHRIS.xml:S1:14066:3	O
to	SAPHRIS.xml:S1:14070:2	O
adverse	SAPHRIS.xml:S1:14073:7	O
reactions	SAPHRIS.xml:S1:14081:9	O
compared	SAPHRIS.xml:S1:14091:8	O
to	SAPHRIS.xml:S1:14100:2	O
4%	SAPHRIS.xml:S1:14103:2	O
(	SAPHRIS.xml:S1:14106:1	O
4	SAPHRIS.xml:S1:14107:1	O
101	SAPHRIS.xml:S1:14109:3	O
)	SAPHRIS.xml:S1:14112:1	O
on	SAPHRIS.xml:S1:14114:2	O
placebo	SAPHRIS.xml:S1:14117:7	O
.	SAPHRIS.xml:S1:14124:1	O

The	SAPHRIS.xml:S1:14126:3	O
most	SAPHRIS.xml:S1:14130:4	O
common	SAPHRIS.xml:S1:14135:6	O
adverse	SAPHRIS.xml:S1:14142:7	O
reactions	SAPHRIS.xml:S1:14150:9	O
that	SAPHRIS.xml:S1:14160:4	O
led	SAPHRIS.xml:S1:14165:3	O
to	SAPHRIS.xml:S1:14169:2	O
discontinuation	SAPHRIS.xml:S1:14172:15	O
in	SAPHRIS.xml:S1:14188:2	O
pediatric	SAPHRIS.xml:S1:14191:9	O
patients	SAPHRIS.xml:S1:14201:8	O
treated	SAPHRIS.xml:S1:14210:7	O
with	SAPHRIS.xml:S1:14218:4	O
SAPHRIS	SAPHRIS.xml:S1:14223:7	O
(	SAPHRIS.xml:S1:14231:1	O
rates	SAPHRIS.xml:S1:14232:5	O
at	SAPHRIS.xml:S1:14238:2	O
least	SAPHRIS.xml:S1:14241:5	O
2%	SAPHRIS.xml:S1:14247:2	O
in	SAPHRIS.xml:S1:14250:2	O
any	SAPHRIS.xml:S1:14253:3	O
SAPHRIS	SAPHRIS.xml:S1:14257:7	O
arm	SAPHRIS.xml:S1:14265:3	O
and	SAPHRIS.xml:S1:14269:3	O
at	SAPHRIS.xml:S1:14273:2	O
least	SAPHRIS.xml:S1:14276:5	O
twice	SAPHRIS.xml:S1:14282:5	O
the	SAPHRIS.xml:S1:14288:3	O
placebo	SAPHRIS.xml:S1:14292:7	O
rate	SAPHRIS.xml:S1:14300:4	O
)	SAPHRIS.xml:S1:14304:1	O
were	SAPHRIS.xml:S1:14306:4	O
somnolence	SAPHRIS.xml:S1:14311:10	B-AdverseReaction
(	SAPHRIS.xml:S1:14322:1	O
3%	SAPHRIS.xml:S1:14323:2	O
in	SAPHRIS.xml:S1:14326:2	O
the	SAPHRIS.xml:S1:14329:3	O
2.5	SAPHRIS.xml:S1:14333:3	O
mg	SAPHRIS.xml:S1:14336:2	O
twice	SAPHRIS.xml:S1:14339:5	O
daily	SAPHRIS.xml:S1:14345:5	O
group	SAPHRIS.xml:S1:14351:5	O
,	SAPHRIS.xml:S1:14356:1	O
1%	SAPHRIS.xml:S1:14358:2	O
in	SAPHRIS.xml:S1:14361:2	O
the	SAPHRIS.xml:S1:14364:3	O
5	SAPHRIS.xml:S1:14368:1	O
mg	SAPHRIS.xml:S1:14369:2	O
twice	SAPHRIS.xml:S1:14372:5	O
daily	SAPHRIS.xml:S1:14378:5	O
group	SAPHRIS.xml:S1:14384:5	O
,	SAPHRIS.xml:S1:14389:1	O
and	SAPHRIS.xml:S1:14391:3	O
2%	SAPHRIS.xml:S1:14395:2	O
in	SAPHRIS.xml:S1:14398:2	O
the	SAPHRIS.xml:S1:14401:3	O
10	SAPHRIS.xml:S1:14405:2	O
mg	SAPHRIS.xml:S1:14407:2	O
twice	SAPHRIS.xml:S1:14410:5	O
daily	SAPHRIS.xml:S1:14416:5	O
group	SAPHRIS.xml:S1:14422:5	O
)	SAPHRIS.xml:S1:14427:1	O
,	SAPHRIS.xml:S1:14428:1	O
abdominal	SAPHRIS.xml:S1:14430:9	B-AdverseReaction
pain	SAPHRIS.xml:S1:14440:4	I-AdverseReaction
(	SAPHRIS.xml:S1:14445:1	O
2%	SAPHRIS.xml:S1:14446:2	O
in	SAPHRIS.xml:S1:14449:2	O
the	SAPHRIS.xml:S1:14452:3	O
10	SAPHRIS.xml:S1:14456:2	O
mg	SAPHRIS.xml:S1:14458:2	O
twice	SAPHRIS.xml:S1:14461:5	O
daily	SAPHRIS.xml:S1:14467:5	O
group	SAPHRIS.xml:S1:14473:5	O
)	SAPHRIS.xml:S1:14478:1	O
,	SAPHRIS.xml:S1:14479:1	O
and	SAPHRIS.xml:S1:14481:3	O
nausea	SAPHRIS.xml:S1:14485:6	B-AdverseReaction
(	SAPHRIS.xml:S1:14492:1	O
2%	SAPHRIS.xml:S1:14493:2	O
in	SAPHRIS.xml:S1:14496:2	O
the	SAPHRIS.xml:S1:14499:3	O
10	SAPHRIS.xml:S1:14503:2	O
mg	SAPHRIS.xml:S1:14505:2	O
twice	SAPHRIS.xml:S1:14508:5	O
daily	SAPHRIS.xml:S1:14514:5	O
group	SAPHRIS.xml:S1:14520:5	O
)	SAPHRIS.xml:S1:14525:1	O
No	SAPHRIS.xml:S1:14527:2	O
placebo	SAPHRIS.xml:S1:14530:7	O
-	SAPHRIS.xml:S1:14537:1	O
treated	SAPHRIS.xml:S1:14538:7	O
patients	SAPHRIS.xml:S1:14546:8	O
dropped	SAPHRIS.xml:S1:14555:7	O
out	SAPHRIS.xml:S1:14563:3	O
for	SAPHRIS.xml:S1:14567:3	O
these	SAPHRIS.xml:S1:14571:5	O
events	SAPHRIS.xml:S1:14577:6	O
.	SAPHRIS.xml:S1:14583:1	O

Adverse	SAPHRIS.xml:S1:14593:7	O
Reactions	SAPHRIS.xml:S1:14601:9	O
Occurring	SAPHRIS.xml:S1:14611:9	O
with	SAPHRIS.xml:S1:14621:4	O
SAPHRIS	SAPHRIS.xml:S1:14626:7	O
at	SAPHRIS.xml:S1:14634:2	O
an	SAPHRIS.xml:S1:14637:2	O
Incidence	SAPHRIS.xml:S1:14640:9	O
of	SAPHRIS.xml:S1:14650:2	O
2%	SAPHRIS.xml:S1:14653:2	O
or	SAPHRIS.xml:S1:14656:2	O
More	SAPHRIS.xml:S1:14659:4	O
in	SAPHRIS.xml:S1:14664:2	O
SAPHRIS	SAPHRIS.xml:S1:14667:7	O
-	SAPHRIS.xml:S1:14674:1	O
treated	SAPHRIS.xml:S1:14675:7	O
Bipolar	SAPHRIS.xml:S1:14683:7	O
Patients	SAPHRIS.xml:S1:14691:8	O
:	SAPHRIS.xml:S1:14699:1	O
Adverse	SAPHRIS.xml:S1:14702:7	O
reactions	SAPHRIS.xml:S1:14710:9	O
associated	SAPHRIS.xml:S1:14720:10	O
with	SAPHRIS.xml:S1:14731:4	O
the	SAPHRIS.xml:S1:14736:3	O
use	SAPHRIS.xml:S1:14740:3	O
of	SAPHRIS.xml:S1:14744:2	O
SAPHRIS	SAPHRIS.xml:S1:14747:7	O
(	SAPHRIS.xml:S1:14755:1	O
incidence	SAPHRIS.xml:S1:14756:9	O
of	SAPHRIS.xml:S1:14766:2	O
2%	SAPHRIS.xml:S1:14771:2	O
in	SAPHRIS.xml:S1:14774:2	O
any	SAPHRIS.xml:S1:14777:3	O
SAPHRIS	SAPHRIS.xml:S1:14781:7	O
dose	SAPHRIS.xml:S1:14789:4	O
group	SAPHRIS.xml:S1:14794:5	O
and	SAPHRIS.xml:S1:14800:3	O
greater	SAPHRIS.xml:S1:14804:7	O
than	SAPHRIS.xml:S1:14812:4	O
placebo	SAPHRIS.xml:S1:14817:7	O
)	SAPHRIS.xml:S1:14824:1	O
that	SAPHRIS.xml:S1:14826:4	O
occurred	SAPHRIS.xml:S1:14831:8	O
during	SAPHRIS.xml:S1:14840:6	O
acute	SAPHRIS.xml:S1:14847:5	O
therapy	SAPHRIS.xml:S1:14853:7	O
are	SAPHRIS.xml:S1:14861:3	O
shown	SAPHRIS.xml:S1:14865:5	O
in	SAPHRIS.xml:S1:14871:2	O
Table	SAPHRIS.xml:S1:14875:5	O
10	SAPHRIS.xml:S1:14881:2	O
.	SAPHRIS.xml:S1:14885:1	O

Table	SAPHRIS.xml:S1:14891:5	O
10	SAPHRIS.xml:S1:14897:2	O
:	SAPHRIS.xml:S1:14899:1	O
Adverse	SAPHRIS.xml:S1:14901:7	O
Reactions	SAPHRIS.xml:S1:14909:9	O
Reported	SAPHRIS.xml:S1:14919:8	O
in	SAPHRIS.xml:S1:14928:2	O
2%	SAPHRIS.xml:S1:14931:2	O
or	SAPHRIS.xml:S1:14934:2	O
More	SAPHRIS.xml:S1:14937:4	O
of	SAPHRIS.xml:S1:14942:2	O
Pediatric	SAPHRIS.xml:S1:14945:9	O
Patients	SAPHRIS.xml:S1:14955:8	O
(	SAPHRIS.xml:S1:14964:1	O
Ages	SAPHRIS.xml:S1:14965:4	O
10	SAPHRIS.xml:S1:14970:2	O
to	SAPHRIS.xml:S1:14973:2	O
17	SAPHRIS.xml:S1:14976:2	O
Years	SAPHRIS.xml:S1:14979:5	O
)	SAPHRIS.xml:S1:14984:1	O
in	SAPHRIS.xml:S1:14986:2	O
Any	SAPHRIS.xml:S1:14989:3	O
SAPHRIS	SAPHRIS.xml:S1:14993:7	O
Dose	SAPHRIS.xml:S1:15001:4	O
Group	SAPHRIS.xml:S1:15006:5	O
and	SAPHRIS.xml:S1:15012:3	O
Which	SAPHRIS.xml:S1:15016:5	O
Occurred	SAPHRIS.xml:S1:15022:8	O
at	SAPHRIS.xml:S1:15031:2	O
Greater	SAPHRIS.xml:S1:15034:7	O
Incidence	SAPHRIS.xml:S1:15042:9	O
Than	SAPHRIS.xml:S1:15052:4	O
in	SAPHRIS.xml:S1:15057:2	O
the	SAPHRIS.xml:S1:15060:3	O
Placebo	SAPHRIS.xml:S1:15064:7	O
Group	SAPHRIS.xml:S1:15072:5	O
in	SAPHRIS.xml:S1:15078:2	O
a	SAPHRIS.xml:S1:15081:1	O
3	SAPHRIS.xml:S1:15083:1	O
-	SAPHRIS.xml:S1:15084:1	O
Week	SAPHRIS.xml:S1:15085:4	O
Bipolar	SAPHRIS.xml:S1:15090:7	O
Mania	SAPHRIS.xml:S1:15098:5	O
Trial	SAPHRIS.xml:S1:15104:5	O

1	SAPHRIS.xml:S1:15113:1	O
Includes	SAPHRIS.xml:S1:15114:8	O
the	SAPHRIS.xml:S1:15123:3	O
preferred	SAPHRIS.xml:S1:15127:9	O
terms	SAPHRIS.xml:S1:15137:5	O
tachycardia	SAPHRIS.xml:S1:15143:11	B-AdverseReaction
and	SAPHRIS.xml:S1:15155:3	O
heart	SAPHRIS.xml:S1:15159:5	B-AdverseReaction
rate	SAPHRIS.xml:S1:15165:4	I-AdverseReaction
increased	SAPHRIS.xml:S1:15170:9	I-AdverseReaction
.	SAPHRIS.xml:S1:15179:1	O

2	SAPHRIS.xml:S1:15187:1	O
Includes	SAPHRIS.xml:S1:15188:8	O
the	SAPHRIS.xml:S1:15197:3	O
preferred	SAPHRIS.xml:S1:15201:9	O
terms	SAPHRIS.xml:S1:15211:5	O
oral	SAPHRIS.xml:S1:15217:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:15222:12	I-AdverseReaction
,	SAPHRIS.xml:S1:15234:1	O
oral	SAPHRIS.xml:S1:15236:4	B-AdverseReaction
paresthesia	SAPHRIS.xml:S1:15241:11	I-AdverseReaction
,	SAPHRIS.xml:S1:15252:1	O
and	SAPHRIS.xml:S1:15254:3	O
oral	SAPHRIS.xml:S1:15258:4	B-AdverseReaction
dysesthesia	SAPHRIS.xml:S1:15263:11	I-AdverseReaction
.	SAPHRIS.xml:S1:15274:1	O

3	SAPHRIS.xml:S1:15282:1	O
Includes	SAPHRIS.xml:S1:15283:8	O
the	SAPHRIS.xml:S1:15292:3	O
preferred	SAPHRIS.xml:S1:15296:9	O
terms	SAPHRIS.xml:S1:15306:5	O
abdominal	SAPHRIS.xml:S1:15312:9	B-AdverseReaction
pain	SAPHRIS.xml:S1:15322:4	I-AdverseReaction
,	SAPHRIS.xml:S1:15326:1	O
abdominal	SAPHRIS.xml:S1:15328:9	B-AdverseReaction
pain	SAPHRIS.xml:S1:15338:4	I-AdverseReaction
upper	SAPHRIS.xml:S1:15343:5	I-AdverseReaction
,	SAPHRIS.xml:S1:15348:1	O
abdominal	SAPHRIS.xml:S1:15350:9	B-AdverseReaction
pain	SAPHRIS.xml:S1:15360:4	I-AdverseReaction
lower	SAPHRIS.xml:S1:15365:5	I-AdverseReaction
,	SAPHRIS.xml:S1:15370:1	O
and	SAPHRIS.xml:S1:15372:3	O
abdominal	SAPHRIS.xml:S1:15376:9	B-AdverseReaction
discomfort	SAPHRIS.xml:S1:15386:10	I-AdverseReaction
.	SAPHRIS.xml:S1:15396:1	O

4	SAPHRIS.xml:S1:15404:1	O
Includes	SAPHRIS.xml:S1:15405:8	O
the	SAPHRIS.xml:S1:15414:3	O
preferred	SAPHRIS.xml:S1:15418:9	O
terms	SAPHRIS.xml:S1:15428:5	O
fatigue	SAPHRIS.xml:S1:15434:7	B-AdverseReaction
and	SAPHRIS.xml:S1:15442:3	O
lethargy	SAPHRIS.xml:S1:15446:8	B-AdverseReaction
.	SAPHRIS.xml:S1:15454:1	O

5	SAPHRIS.xml:S1:15462:1	O
Includes	SAPHRIS.xml:S1:15463:8	O
the	SAPHRIS.xml:S1:15472:3	O
preferred	SAPHRIS.xml:S1:15476:9	O
terms	SAPHRIS.xml:S1:15486:5	O
hyperinsulinemia	SAPHRIS.xml:S1:15492:16	B-AdverseReaction
and	SAPHRIS.xml:S1:15509:3	O
blood	SAPHRIS.xml:S1:15513:5	B-AdverseReaction
insulin	SAPHRIS.xml:S1:15519:7	I-AdverseReaction
increased	SAPHRIS.xml:S1:15527:9	I-AdverseReaction
.	SAPHRIS.xml:S1:15536:1	O

6	SAPHRIS.xml:S1:15544:1	O
Includes	SAPHRIS.xml:S1:15545:8	O
the	SAPHRIS.xml:S1:15554:3	O
preferred	SAPHRIS.xml:S1:15558:9	O
terms	SAPHRIS.xml:S1:15568:5	O
somnolence	SAPHRIS.xml:S1:15574:10	B-AdverseReaction
,	SAPHRIS.xml:S1:15584:1	O
sedation	SAPHRIS.xml:S1:15586:8	B-AdverseReaction
,	SAPHRIS.xml:S1:15594:1	O
and	SAPHRIS.xml:S1:15596:3	O
hypersomnia	SAPHRIS.xml:S1:15600:11	B-AdverseReaction
.	SAPHRIS.xml:S1:15611:1	O

System	SAPHRIS.xml:S1:15623:6	O

Organ	SAPHRIS.xml:S1:15630:5	O
Class	SAPHRIS.xml:S1:15636:5	O
AE	SAPHRIS.xml:S1:15646:2	O
Preferred	SAPHRIS.xml:S1:15649:9	O
Term	SAPHRIS.xml:S1:15659:4	O
Placebo	SAPHRIS.xml:S1:15669:7	O
N	SAPHRIS.xml:S1:15680:1	O
101	SAPHRIS.xml:S1:15682:3	O
Placebo	SAPHRIS.xml:S1:15689:7	O
SAPHRIS	SAPHRIS.xml:S1:15702:7	O
2.5	SAPHRIS.xml:S1:15713:3	O
mg	SAPHRIS.xml:S1:15717:2	O
twice	SAPHRIS.xml:S1:15723:5	O
daily	SAPHRIS.xml:S1:15729:5	O
N	SAPHRIS.xml:S1:15738:1	O
104	SAPHRIS.xml:S1:15740:3	O
2.5	SAPHRIS.xml:S1:15747:3	O
mg	SAPHRIS.xml:S1:15750:2	O
SAPHRIS	SAPHRIS.xml:S1:15758:7	O
5	SAPHRIS.xml:S1:15769:1	O
mg	SAPHRIS.xml:S1:15771:2	O
twice	SAPHRIS.xml:S1:15777:5	O
daily	SAPHRIS.xml:S1:15783:5	O
N	SAPHRIS.xml:S1:15792:1	O
99	SAPHRIS.xml:S1:15794:2	O
5	SAPHRIS.xml:S1:15800:1	O
mg	SAPHRIS.xml:S1:15801:2	O
SAPHRIS	SAPHRIS.xml:S1:15809:7	O
10	SAPHRIS.xml:S1:15820:2	O
mg	SAPHRIS.xml:S1:15823:2	O
twice	SAPHRIS.xml:S1:15829:5	O
daily	SAPHRIS.xml:S1:15835:5	O
N	SAPHRIS.xml:S1:15844:1	O
99	SAPHRIS.xml:S1:15846:2	O
10	SAPHRIS.xml:S1:15852:2	O
mg	SAPHRIS.xml:S1:15854:2	O
All	SAPHRIS.xml:S1:15862:3	O
SAPHRIS	SAPHRIS.xml:S1:15866:7	O
2.5	SAPHRIS.xml:S1:15877:3	O
,	SAPHRIS.xml:S1:15880:1	O
5	SAPHRIS.xml:S1:15882:1	O
,	SAPHRIS.xml:S1:15883:1	O
and	SAPHRIS.xml:S1:15885:3	O
10	SAPHRIS.xml:S1:15889:2	O
mg	SAPHRIS.xml:S1:15892:2	O

N	SAPHRIS.xml:S1:15903:1	O
101	SAPHRIS.xml:S1:15905:3	O
N	SAPHRIS.xml:S1:15939:1	O
104	SAPHRIS.xml:S1:15941:3	O
N	SAPHRIS.xml:S1:15955:1	O
99	SAPHRIS.xml:S1:15957:2	O
N	SAPHRIS.xml:S1:15970:1	O
99	SAPHRIS.xml:S1:15972:2	O
N	SAPHRIS.xml:S1:15985:1	O
302	SAPHRIS.xml:S1:15987:3	O

Cardiac	SAPHRIS.xml:S1:16004:7	O
Disorders	SAPHRIS.xml:S1:16012:9	O

Tachycardia	SAPHRIS.xml:S1:16096:11	B-AdverseReaction
1	SAPHRIS.xml:S1:16109:1	O
0	SAPHRIS.xml:S1:16129:1	O
3	SAPHRIS.xml:S1:16140:1	O
0	SAPHRIS.xml:S1:16154:1	O
1	SAPHRIS.xml:S1:16168:1	O
1	SAPHRIS.xml:S1:16181:1	O

Gastrointestinal	SAPHRIS.xml:S1:16208:16	O
Disorders	SAPHRIS.xml:S1:16225:9	O

Oral	SAPHRIS.xml:S1:16300:4	B-AdverseReaction
paraesthesia	SAPHRIS.xml:S1:16305:12	I-AdverseReaction
2	SAPHRIS.xml:S1:16319:1	O
4	SAPHRIS.xml:S1:16333:1	O
25	SAPHRIS.xml:S1:16344:2	O
25	SAPHRIS.xml:S1:16358:2	O
30	SAPHRIS.xml:S1:16372:2	O
27	SAPHRIS.xml:S1:16385:2	O

Nausea	SAPHRIS.xml:S1:16413:6	B-AdverseReaction
3	SAPHRIS.xml:S1:16446:1	O
6	SAPHRIS.xml:S1:16457:1	O
6	SAPHRIS.xml:S1:16471:1	O
6	SAPHRIS.xml:S1:16485:1	O
6	SAPHRIS.xml:S1:16498:1	O

Vomiting	SAPHRIS.xml:S1:16526:8	B-AdverseReaction
3	SAPHRIS.xml:S1:16559:1	O
4	SAPHRIS.xml:S1:16570:1	O
4	SAPHRIS.xml:S1:16584:1	O
4	SAPHRIS.xml:S1:16598:1	O
4	SAPHRIS.xml:S1:16611:1	O

Abdominal	SAPHRIS.xml:S1:16639:9	B-AdverseReaction
pain	SAPHRIS.xml:S1:16649:4	I-AdverseReaction
3	SAPHRIS.xml:S1:16655:1	O
7	SAPHRIS.xml:S1:16672:1	O
9	SAPHRIS.xml:S1:16683:1	O
3	SAPHRIS.xml:S1:16697:1	O
5	SAPHRIS.xml:S1:16711:1	O
6	SAPHRIS.xml:S1:16724:1	O

Glossodynia	SAPHRIS.xml:S1:16752:11	B-AdverseReaction
0	SAPHRIS.xml:S1:16785:1	O
0	SAPHRIS.xml:S1:16796:1	O
2	SAPHRIS.xml:S1:16810:1	O
0	SAPHRIS.xml:S1:16824:1	O
1	SAPHRIS.xml:S1:16837:1	O

General	SAPHRIS.xml:S1:16864:7	O
Disorders	SAPHRIS.xml:S1:16872:9	O
and	SAPHRIS.xml:S1:16882:3	O
Administrative	SAPHRIS.xml:S1:16886:14	O
Site	SAPHRIS.xml:S1:16901:4	O
Disorders	SAPHRIS.xml:S1:16906:9	O

Fatigue	SAPHRIS.xml:S1:16977:7	B-AdverseReaction
4	SAPHRIS.xml:S1:16986:1	O
5	SAPHRIS.xml:S1:17010:1	O
4	SAPHRIS.xml:S1:17021:1	O
8	SAPHRIS.xml:S1:17035:1	O
14	SAPHRIS.xml:S1:17049:2	O
9	SAPHRIS.xml:S1:17062:1	O

Irritability	SAPHRIS.xml:S1:17090:12	B-AdverseReaction
1	SAPHRIS.xml:S1:17123:1	O
1	SAPHRIS.xml:S1:17134:1	O
1	SAPHRIS.xml:S1:17148:1	O
2	SAPHRIS.xml:S1:17162:1	O
1	SAPHRIS.xml:S1:17175:1	O

Injury	SAPHRIS.xml:S1:17202:6	O
,	SAPHRIS.xml:S1:17208:1	O
Poisoning	SAPHRIS.xml:S1:17210:9	O
,	SAPHRIS.xml:S1:17219:1	O
and	SAPHRIS.xml:S1:17221:3	O
Procedural	SAPHRIS.xml:S1:17225:10	O
Complications	SAPHRIS.xml:S1:17236:13	O

Muscle	SAPHRIS.xml:S1:17311:6	B-AdverseReaction
strain	SAPHRIS.xml:S1:17318:6	I-AdverseReaction
0	SAPHRIS.xml:S1:17344:1	O
0	SAPHRIS.xml:S1:17355:1	O
0	SAPHRIS.xml:S1:17369:1	O
2	SAPHRIS.xml:S1:17383:1	O
1	SAPHRIS.xml:S1:17396:1	O

Investigations	SAPHRIS.xml:S1:17423:14	O

Increased	SAPHRIS.xml:S1:17537:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:17547:6	I-AdverseReaction
0	SAPHRIS.xml:S1:17570:1	O
6	SAPHRIS.xml:S1:17581:1	O
2	SAPHRIS.xml:S1:17595:1	O
2	SAPHRIS.xml:S1:17609:1	O
3	SAPHRIS.xml:S1:17622:1	O

Hyperinsulinemia	SAPHRIS.xml:S1:17650:16	B-AdverseReaction
5	SAPHRIS.xml:S1:17668:1	O
0	SAPHRIS.xml:S1:17683:1	O
1	SAPHRIS.xml:S1:17694:1	O
3	SAPHRIS.xml:S1:17708:1	O
1	SAPHRIS.xml:S1:17722:1	O
2	SAPHRIS.xml:S1:17735:1	O

ALT	SAPHRIS.xml:S1:17763:3	B-AdverseReaction
increased	SAPHRIS.xml:S1:17767:9	I-AdverseReaction
0	SAPHRIS.xml:S1:17796:1	O
0	SAPHRIS.xml:S1:17807:1	O
0	SAPHRIS.xml:S1:17821:1	O
2	SAPHRIS.xml:S1:17835:1	O
1	SAPHRIS.xml:S1:17848:1	O

AST	SAPHRIS.xml:S1:17876:3	B-AdverseReaction
increased	SAPHRIS.xml:S1:17880:9	I-AdverseReaction
0	SAPHRIS.xml:S1:17909:1	O
0	SAPHRIS.xml:S1:17920:1	O
0	SAPHRIS.xml:S1:17934:1	O
2	SAPHRIS.xml:S1:17948:1	O
1	SAPHRIS.xml:S1:17961:1	O

Metabolism	SAPHRIS.xml:S1:17988:10	O
and	SAPHRIS.xml:S1:17999:3	O
Nutrition	SAPHRIS.xml:S1:18003:9	O
Disorders	SAPHRIS.xml:S1:18013:9	O

Increased	SAPHRIS.xml:S1:18106:9	B-AdverseReaction
appetite	SAPHRIS.xml:S1:18116:8	I-AdverseReaction
2	SAPHRIS.xml:S1:18139:1	O
10	SAPHRIS.xml:S1:18150:2	O
9	SAPHRIS.xml:S1:18164:1	O
6	SAPHRIS.xml:S1:18178:1	O
8	SAPHRIS.xml:S1:18191:1	O

Dehydration	SAPHRIS.xml:S1:18219:11	B-AdverseReaction
1	SAPHRIS.xml:S1:18252:1	O
0	SAPHRIS.xml:S1:18263:1	O
2	SAPHRIS.xml:S1:18277:1	O
0	SAPHRIS.xml:S1:18291:1	O
1	SAPHRIS.xml:S1:18304:1	O

Musculoskeletal	SAPHRIS.xml:S1:18331:15	O
and	SAPHRIS.xml:S1:18347:3	O
Connective	SAPHRIS.xml:S1:18351:10	O
Tissue	SAPHRIS.xml:S1:18362:6	O
Disorders	SAPHRIS.xml:S1:18369:9	O

Myalgia	SAPHRIS.xml:S1:18440:7	B-AdverseReaction
0	SAPHRIS.xml:S1:18473:1	O
0	SAPHRIS.xml:S1:18484:1	O
2	SAPHRIS.xml:S1:18498:1	O
1	SAPHRIS.xml:S1:18512:1	O
1	SAPHRIS.xml:S1:18525:1	O

Nervous	SAPHRIS.xml:S1:18552:7	O
System	SAPHRIS.xml:S1:18560:6	O
Disorders	SAPHRIS.xml:S1:18567:9	O

Somnolence	SAPHRIS.xml:S1:18644:10	B-AdverseReaction
6	SAPHRIS.xml:S1:18656:1	O
12	SAPHRIS.xml:S1:18677:2	O
46	SAPHRIS.xml:S1:18688:2	O
53	SAPHRIS.xml:S1:18702:2	O
49	SAPHRIS.xml:S1:18716:2	O
49	SAPHRIS.xml:S1:18729:2	O

Headache	SAPHRIS.xml:S1:18757:8	B-AdverseReaction
6	SAPHRIS.xml:S1:18790:1	O
8	SAPHRIS.xml:S1:18801:1	O
11	SAPHRIS.xml:S1:18815:2	O
9	SAPHRIS.xml:S1:18829:1	O
9	SAPHRIS.xml:S1:18842:1	O

Dizziness	SAPHRIS.xml:S1:18870:9	B-AdverseReaction
3	SAPHRIS.xml:S1:18903:1	O
6	SAPHRIS.xml:S1:18914:1	O
10	SAPHRIS.xml:S1:18928:2	O
5	SAPHRIS.xml:S1:18942:1	O
7	SAPHRIS.xml:S1:18955:1	O

Dysgeusia	SAPHRIS.xml:S1:18983:9	B-AdverseReaction
2	SAPHRIS.xml:S1:19016:1	O
4	SAPHRIS.xml:S1:19027:1	O
5	SAPHRIS.xml:S1:19041:1	O
9	SAPHRIS.xml:S1:19055:1	O
6	SAPHRIS.xml:S1:19068:1	O

Akathisia	SAPHRIS.xml:S1:19096:9	B-AdverseReaction
0	SAPHRIS.xml:S1:19129:1	O
2	SAPHRIS.xml:S1:19140:1	O
2	SAPHRIS.xml:S1:19154:1	O
1	SAPHRIS.xml:S1:19168:1	O
2	SAPHRIS.xml:S1:19181:1	O

Parkinsonism	SAPHRIS.xml:S1:19209:12	B-AdverseReaction
0	SAPHRIS.xml:S1:19242:1	O
1	SAPHRIS.xml:S1:19253:1	O
0	SAPHRIS.xml:S1:19267:1	O
2	SAPHRIS.xml:S1:19281:1	O
1	SAPHRIS.xml:S1:19294:1	O

Psychiatric	SAPHRIS.xml:S1:19321:11	O
Disorders	SAPHRIS.xml:S1:19333:9	O

Insomnia	SAPHRIS.xml:S1:19413:8	B-AdverseReaction
3	SAPHRIS.xml:S1:19446:1	O
3	SAPHRIS.xml:S1:19457:1	O
4	SAPHRIS.xml:S1:19471:1	O
3	SAPHRIS.xml:S1:19485:1	O
3	SAPHRIS.xml:S1:19498:1	O

Suicidal	SAPHRIS.xml:S1:19526:8	B-AdverseReaction
ideation	SAPHRIS.xml:S1:19535:8	I-AdverseReaction
1	SAPHRIS.xml:S1:19559:1	O
4	SAPHRIS.xml:S1:19570:1	O
1	SAPHRIS.xml:S1:19584:1	O
3	SAPHRIS.xml:S1:19598:1	O
3	SAPHRIS.xml:S1:19611:1	O

Anger	SAPHRIS.xml:S1:19639:5	B-AdverseReaction
0	SAPHRIS.xml:S1:19672:1	O
0	SAPHRIS.xml:S1:19683:1	O
0	SAPHRIS.xml:S1:19697:1	O
2	SAPHRIS.xml:S1:19711:1	O
1	SAPHRIS.xml:S1:19724:1	O

Reproductive	SAPHRIS.xml:S1:19751:12	O
System	SAPHRIS.xml:S1:19764:6	O
and	SAPHRIS.xml:S1:19771:3	O
Breast	SAPHRIS.xml:S1:19775:6	O
Disorders	SAPHRIS.xml:S1:19782:9	O

Dysmenorrhea	SAPHRIS.xml:S1:19853:12	B-AdverseReaction
1	SAPHRIS.xml:S1:19886:1	O
0	SAPHRIS.xml:S1:19897:1	O
2	SAPHRIS.xml:S1:19911:1	O
0	SAPHRIS.xml:S1:19925:1	O
1	SAPHRIS.xml:S1:19938:1	O

Respiratory	SAPHRIS.xml:S1:19965:11	O
,	SAPHRIS.xml:S1:19976:1	O
Thoracic	SAPHRIS.xml:S1:19978:8	O
,	SAPHRIS.xml:S1:19986:1	O
and	SAPHRIS.xml:S1:19988:3	O
Mediastinal	SAPHRIS.xml:S1:19992:11	O
Disorders	SAPHRIS.xml:S1:20004:9	O

Oropharyngeal	SAPHRIS.xml:S1:20097:13	B-AdverseReaction
pain	SAPHRIS.xml:S1:20111:4	I-AdverseReaction
2	SAPHRIS.xml:S1:20130:1	O
0	SAPHRIS.xml:S1:20141:1	O
3	SAPHRIS.xml:S1:20155:1	O
1	SAPHRIS.xml:S1:20169:1	O
1	SAPHRIS.xml:S1:20182:1	O

Nasal	SAPHRIS.xml:S1:20210:5	B-AdverseReaction
congestion	SAPHRIS.xml:S1:20216:10	I-AdverseReaction
1	SAPHRIS.xml:S1:20243:1	O
0	SAPHRIS.xml:S1:20254:1	O
2	SAPHRIS.xml:S1:20268:1	O
0	SAPHRIS.xml:S1:20282:1	O
1	SAPHRIS.xml:S1:20295:1	O

Dyspnea	SAPHRIS.xml:S1:20323:7	B-AdverseReaction
0	SAPHRIS.xml:S1:20356:1	O
0	SAPHRIS.xml:S1:20367:1	O
2	SAPHRIS.xml:S1:20381:1	O
0	SAPHRIS.xml:S1:20395:1	O
1	SAPHRIS.xml:S1:20408:1	O

Skin	SAPHRIS.xml:S1:20435:4	O
and	SAPHRIS.xml:S1:20440:3	O
Subcutaneous	SAPHRIS.xml:S1:20444:12	O
Tissue	SAPHRIS.xml:S1:20457:6	O
Disorders	SAPHRIS.xml:S1:20464:9	O

Rash	SAPHRIS.xml:S1:20535:4	B-AdverseReaction
1	SAPHRIS.xml:S1:20568:1	O
0	SAPHRIS.xml:S1:20579:1	O
1	SAPHRIS.xml:S1:20593:1	O
2	SAPHRIS.xml:S1:20607:1	O
1	SAPHRIS.xml:S1:20620:1	O

Dose	SAPHRIS.xml:S1:20660:4	O
-	SAPHRIS.xml:S1:20664:1	O
Related	SAPHRIS.xml:S1:20665:7	O
Adverse	SAPHRIS.xml:S1:20673:7	O
Reactions	SAPHRIS.xml:S1:20681:9	O
:	SAPHRIS.xml:S1:20690:1	O
In	SAPHRIS.xml:S1:20693:2	O
the	SAPHRIS.xml:S1:20696:3	O
short	SAPHRIS.xml:S1:20700:5	O
term	SAPHRIS.xml:S1:20706:4	O
pediatric	SAPHRIS.xml:S1:20711:9	O
bipolar	SAPHRIS.xml:S1:20721:7	O
trials	SAPHRIS.xml:S1:20729:6	O
the	SAPHRIS.xml:S1:20736:3	O
incidence	SAPHRIS.xml:S1:20740:9	O
of	SAPHRIS.xml:S1:20750:2	O
fatigue	SAPHRIS.xml:S1:20753:7	B-AdverseReaction
appeared	SAPHRIS.xml:S1:20761:8	O
to	SAPHRIS.xml:S1:20770:2	O
be	SAPHRIS.xml:S1:20773:2	O
dose	SAPHRIS.xml:S1:20776:4	O
-	SAPHRIS.xml:S1:20780:1	O
related	SAPHRIS.xml:S1:20781:7	O
(	SAPHRIS.xml:S1:20789:1	O
see	SAPHRIS.xml:S1:20790:3	O
Table	SAPHRIS.xml:S1:20795:5	O
10	SAPHRIS.xml:S1:20801:2	O
)	SAPHRIS.xml:S1:20805:1	O

Adjunctive	SAPHRIS.xml:S1:20815:10	O

Therapy	SAPHRIS.xml:S1:20826:7	O
in	SAPHRIS.xml:S1:20834:2	O
Adult	SAPHRIS.xml:S1:20837:5	O
Patients	SAPHRIS.xml:S1:20843:8	O
with	SAPHRIS.xml:S1:20852:4	O
Bipolar	SAPHRIS.xml:S1:20857:7	O
Mania	SAPHRIS.xml:S1:20865:5	O
:	SAPHRIS.xml:S1:20870:1	O
The	SAPHRIS.xml:S1:20873:3	O
following	SAPHRIS.xml:S1:20877:9	O
findings	SAPHRIS.xml:S1:20887:8	O
are	SAPHRIS.xml:S1:20896:3	O
based	SAPHRIS.xml:S1:20900:5	O
on	SAPHRIS.xml:S1:20906:2	O
a	SAPHRIS.xml:S1:20909:1	O
12	SAPHRIS.xml:S1:20911:2	O
week	SAPHRIS.xml:S1:20914:4	O
placebo	SAPHRIS.xml:S1:20919:7	O
-	SAPHRIS.xml:S1:20926:1	O
controlled	SAPHRIS.xml:S1:20927:10	O
trial	SAPHRIS.xml:S1:20938:5	O
(	SAPHRIS.xml:S1:20944:1	O
with	SAPHRIS.xml:S1:20945:4	O
a	SAPHRIS.xml:S1:20950:1	O
3	SAPHRIS.xml:S1:20952:1	O
week	SAPHRIS.xml:S1:20954:4	O
efficacy	SAPHRIS.xml:S1:20959:8	O
endpoint	SAPHRIS.xml:S1:20968:8	O
)	SAPHRIS.xml:S1:20976:1	O
in	SAPHRIS.xml:S1:20978:2	O
adult	SAPHRIS.xml:S1:20981:5	O
patients	SAPHRIS.xml:S1:20987:8	O
with	SAPHRIS.xml:S1:20996:4	O
bipolar	SAPHRIS.xml:S1:21001:7	O
mania	SAPHRIS.xml:S1:21009:5	O
in	SAPHRIS.xml:S1:21015:2	O
which	SAPHRIS.xml:S1:21018:5	O
sublingual	SAPHRIS.xml:S1:21024:10	O
SAPHRIS	SAPHRIS.xml:S1:21035:7	O
was	SAPHRIS.xml:S1:21043:3	O
administered	SAPHRIS.xml:S1:21047:12	O
in	SAPHRIS.xml:S1:21060:2	O
doses	SAPHRIS.xml:S1:21063:5	O
of	SAPHRIS.xml:S1:21069:2	O
5	SAPHRIS.xml:S1:21072:1	O
mg	SAPHRIS.xml:S1:21074:2	O
or	SAPHRIS.xml:S1:21077:2	O
10	SAPHRIS.xml:S1:21080:2	O
mg	SAPHRIS.xml:S1:21083:2	O
twice	SAPHRIS.xml:S1:21086:5	O
daily	SAPHRIS.xml:S1:21092:5	O
as	SAPHRIS.xml:S1:21098:2	O
adjunctive	SAPHRIS.xml:S1:21101:10	O
therapy	SAPHRIS.xml:S1:21112:7	O
with	SAPHRIS.xml:S1:21120:4	O
lithium	SAPHRIS.xml:S1:21125:7	O
or	SAPHRIS.xml:S1:21133:2	O
valproate	SAPHRIS.xml:S1:21136:9	O
.	SAPHRIS.xml:S1:21145:1	O

Adverse	SAPHRIS.xml:S1:21155:7	O
Reactions	SAPHRIS.xml:S1:21163:9	O
Associated	SAPHRIS.xml:S1:21173:10	O
with	SAPHRIS.xml:S1:21184:4	O
Discontinuation	SAPHRIS.xml:S1:21189:15	O
of	SAPHRIS.xml:S1:21205:2	O
Treatment	SAPHRIS.xml:S1:21208:9	O
:	SAPHRIS.xml:S1:21217:1	O
Approximately	SAPHRIS.xml:S1:21220:13	O
16%	SAPHRIS.xml:S1:21234:3	O
(	SAPHRIS.xml:S1:21238:1	O
25	SAPHRIS.xml:S1:21239:2	O
158	SAPHRIS.xml:S1:21242:3	O
)	SAPHRIS.xml:S1:21245:1	O
of	SAPHRIS.xml:S1:21247:2	O
SAPHRIS	SAPHRIS.xml:S1:21250:7	O
-	SAPHRIS.xml:S1:21257:1	O
treated	SAPHRIS.xml:S1:21258:7	O
patients	SAPHRIS.xml:S1:21266:8	O
discontinued	SAPHRIS.xml:S1:21275:12	O
treatment	SAPHRIS.xml:S1:21288:9	O
due	SAPHRIS.xml:S1:21298:3	O
to	SAPHRIS.xml:S1:21302:2	O
an	SAPHRIS.xml:S1:21305:2	O
adverse	SAPHRIS.xml:S1:21308:7	O
reaction	SAPHRIS.xml:S1:21316:8	O
,	SAPHRIS.xml:S1:21324:1	O
compared	SAPHRIS.xml:S1:21326:8	O
with	SAPHRIS.xml:S1:21335:4	O
about	SAPHRIS.xml:S1:21340:5	O
11%	SAPHRIS.xml:S1:21346:3	O
(	SAPHRIS.xml:S1:21350:1	O
18	SAPHRIS.xml:S1:21351:2	O
166	SAPHRIS.xml:S1:21354:3	O
)	SAPHRIS.xml:S1:21357:1	O
on	SAPHRIS.xml:S1:21359:2	O
placebo	SAPHRIS.xml:S1:21362:7	O
.	SAPHRIS.xml:S1:21369:1	O

The	SAPHRIS.xml:S1:21371:3	O
most	SAPHRIS.xml:S1:21375:4	O
common	SAPHRIS.xml:S1:21380:6	O
adverse	SAPHRIS.xml:S1:21387:7	O
reactions	SAPHRIS.xml:S1:21395:9	O
associated	SAPHRIS.xml:S1:21405:10	O
with	SAPHRIS.xml:S1:21416:4	O
discontinuation	SAPHRIS.xml:S1:21421:15	O
in	SAPHRIS.xml:S1:21437:2	O
subjects	SAPHRIS.xml:S1:21440:8	O
treated	SAPHRIS.xml:S1:21449:7	O
with	SAPHRIS.xml:S1:21457:4	O
SAPHRIS	SAPHRIS.xml:S1:21462:7	O
(	SAPHRIS.xml:S1:21470:1	O
rates	SAPHRIS.xml:S1:21471:5	O
at	SAPHRIS.xml:S1:21477:2	O
least	SAPHRIS.xml:S1:21480:5	O
1%	SAPHRIS.xml:S1:21486:2	O
and	SAPHRIS.xml:S1:21489:3	O
at	SAPHRIS.xml:S1:21493:2	O
least	SAPHRIS.xml:S1:21496:5	O
twice	SAPHRIS.xml:S1:21502:5	O
the	SAPHRIS.xml:S1:21508:3	O
placebo	SAPHRIS.xml:S1:21512:7	O
rate	SAPHRIS.xml:S1:21520:4	O
)	SAPHRIS.xml:S1:21524:1	O
were	SAPHRIS.xml:S1:21526:4	O
depression	SAPHRIS.xml:S1:21531:10	B-AdverseReaction
(	SAPHRIS.xml:S1:21542:1	O
2.5%	SAPHRIS.xml:S1:21543:4	O
)	SAPHRIS.xml:S1:21547:1	O
,	SAPHRIS.xml:S1:21548:1	O
suicidal	SAPHRIS.xml:S1:21550:8	B-AdverseReaction
ideation	SAPHRIS.xml:S1:21559:8	I-AdverseReaction
(	SAPHRIS.xml:S1:21568:1	O
2.5%	SAPHRIS.xml:S1:21569:4	O
)	SAPHRIS.xml:S1:21573:1	O
,	SAPHRIS.xml:S1:21574:1	O
bipolar	SAPHRIS.xml:S1:21576:7	B-AdverseReaction
I	SAPHRIS.xml:S1:21584:1	I-AdverseReaction
disorder	SAPHRIS.xml:S1:21586:8	I-AdverseReaction
(	SAPHRIS.xml:S1:21595:1	O
1.9%	SAPHRIS.xml:S1:21596:4	O
)	SAPHRIS.xml:S1:21600:1	O
,	SAPHRIS.xml:S1:21601:1	O
insomnia	SAPHRIS.xml:S1:21603:8	B-AdverseReaction
(	SAPHRIS.xml:S1:21612:1	O
1.9%	SAPHRIS.xml:S1:21613:4	O
)	SAPHRIS.xml:S1:21617:1	O
and	SAPHRIS.xml:S1:21619:3	O
depressive	SAPHRIS.xml:S1:21623:10	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:21634:8	I-AdverseReaction
(	SAPHRIS.xml:S1:21643:1	O
1.3%	SAPHRIS.xml:S1:21644:4	O
)	SAPHRIS.xml:S1:21648:1	O
.	SAPHRIS.xml:S1:21649:1	O

Adverse	SAPHRIS.xml:S1:21659:7	O
Reactions	SAPHRIS.xml:S1:21667:9	O
Occurring	SAPHRIS.xml:S1:21677:9	O
at	SAPHRIS.xml:S1:21687:2	O
an	SAPHRIS.xml:S1:21690:2	O
Incidence	SAPHRIS.xml:S1:21693:9	O
of	SAPHRIS.xml:S1:21703:2	O
2%	SAPHRIS.xml:S1:21706:2	O
or	SAPHRIS.xml:S1:21709:2	O
More	SAPHRIS.xml:S1:21712:4	O
Among	SAPHRIS.xml:S1:21717:5	O
SAPHRIS	SAPHRIS.xml:S1:21723:7	O
-	SAPHRIS.xml:S1:21730:1	O
Treated	SAPHRIS.xml:S1:21731:7	O
(	SAPHRIS.xml:S1:21739:1	O
Adjunctive	SAPHRIS.xml:S1:21740:10	O
)	SAPHRIS.xml:S1:21750:1	O
Bipolar	SAPHRIS.xml:S1:21752:7	O
Patients	SAPHRIS.xml:S1:21760:8	O
:	SAPHRIS.xml:S1:21768:1	O
Adverse	SAPHRIS.xml:S1:21771:7	O
reactions	SAPHRIS.xml:S1:21779:9	O
associated	SAPHRIS.xml:S1:21789:10	O
with	SAPHRIS.xml:S1:21800:4	O
the	SAPHRIS.xml:S1:21805:3	O
use	SAPHRIS.xml:S1:21809:3	O
of	SAPHRIS.xml:S1:21813:2	O
SAPHRIS	SAPHRIS.xml:S1:21816:7	O
(	SAPHRIS.xml:S1:21824:1	O
incidence	SAPHRIS.xml:S1:21825:9	O
of	SAPHRIS.xml:S1:21835:2	O
2%	SAPHRIS.xml:S1:21838:2	O
or	SAPHRIS.xml:S1:21841:2	O
greater	SAPHRIS.xml:S1:21844:7	O
,	SAPHRIS.xml:S1:21851:1	O
rounded	SAPHRIS.xml:S1:21853:7	O
to	SAPHRIS.xml:S1:21861:2	O
the	SAPHRIS.xml:S1:21864:3	O
nearest	SAPHRIS.xml:S1:21868:7	O
percent	SAPHRIS.xml:S1:21876:7	O
,	SAPHRIS.xml:S1:21883:1	O
and	SAPHRIS.xml:S1:21885:3	O
SAPHRIS	SAPHRIS.xml:S1:21889:7	O
incidence	SAPHRIS.xml:S1:21897:9	O
greater	SAPHRIS.xml:S1:21907:7	O
than	SAPHRIS.xml:S1:21915:4	O
placebo	SAPHRIS.xml:S1:21920:7	O
)	SAPHRIS.xml:S1:21927:1	O
that	SAPHRIS.xml:S1:21929:4	O
occurred	SAPHRIS.xml:S1:21934:8	O
during	SAPHRIS.xml:S1:21943:6	O
acute	SAPHRIS.xml:S1:21950:5	O
adjunctive	SAPHRIS.xml:S1:21956:10	O
therapy	SAPHRIS.xml:S1:21967:7	O
at	SAPHRIS.xml:S1:21975:2	O
3	SAPHRIS.xml:S1:21978:1	O
weeks	SAPHRIS.xml:S1:21980:5	O
,	SAPHRIS.xml:S1:21985:1	O
a	SAPHRIS.xml:S1:21987:1	O
time	SAPHRIS.xml:S1:21989:4	O
when	SAPHRIS.xml:S1:21994:4	O
most	SAPHRIS.xml:S1:21999:4	O
of	SAPHRIS.xml:S1:22004:2	O
the	SAPHRIS.xml:S1:22007:3	O
patients	SAPHRIS.xml:S1:22011:8	O
were	SAPHRIS.xml:S1:22020:4	O
still	SAPHRIS.xml:S1:22025:5	O
participating	SAPHRIS.xml:S1:22031:13	O
in	SAPHRIS.xml:S1:22045:2	O
the	SAPHRIS.xml:S1:22048:3	O
trial	SAPHRIS.xml:S1:22052:5	O
,	SAPHRIS.xml:S1:22057:1	O
are	SAPHRIS.xml:S1:22059:3	O
shown	SAPHRIS.xml:S1:22063:5	O
in	SAPHRIS.xml:S1:22069:2	O
Table	SAPHRIS.xml:S1:22073:5	O
11	SAPHRIS.xml:S1:22079:2	O
.	SAPHRIS.xml:S1:22083:1	O

Table	SAPHRIS.xml:S1:22089:5	O
11	SAPHRIS.xml:S1:22095:2	O
:	SAPHRIS.xml:S1:22097:1	O
Adverse	SAPHRIS.xml:S1:22099:7	O
Reactions	SAPHRIS.xml:S1:22107:9	O
Reported	SAPHRIS.xml:S1:22117:8	O
in	SAPHRIS.xml:S1:22126:2	O
2%	SAPHRIS.xml:S1:22129:2	O
or	SAPHRIS.xml:S1:22132:2	O
More	SAPHRIS.xml:S1:22135:4	O
of	SAPHRIS.xml:S1:22140:2	O
Adult	SAPHRIS.xml:S1:22143:5	O
Patients	SAPHRIS.xml:S1:22149:8	O
In	SAPHRIS.xml:S1:22158:2	O
Any	SAPHRIS.xml:S1:22161:3	O
SAPHRIS	SAPHRIS.xml:S1:22165:7	O
-	SAPHRIS.xml:S1:22172:1	O
Dose	SAPHRIS.xml:S1:22173:4	O
Group	SAPHRIS.xml:S1:22178:5	O
and	SAPHRIS.xml:S1:22184:3	O
Which	SAPHRIS.xml:S1:22188:5	O
Occurred	SAPHRIS.xml:S1:22194:8	O
at	SAPHRIS.xml:S1:22203:2	O
Greater	SAPHRIS.xml:S1:22206:7	O
Incidence	SAPHRIS.xml:S1:22214:9	O
Than	SAPHRIS.xml:S1:22224:4	O
in	SAPHRIS.xml:S1:22229:2	O
the	SAPHRIS.xml:S1:22232:3	O
Placebo	SAPHRIS.xml:S1:22236:7	O
Group	SAPHRIS.xml:S1:22244:5	O
at	SAPHRIS.xml:S1:22250:2	O
3	SAPHRIS.xml:S1:22253:1	O
Weeks	SAPHRIS.xml:S1:22255:5	O
in	SAPHRIS.xml:S1:22261:2	O
Adjunctive	SAPHRIS.xml:S1:22264:10	O
Bipolar	SAPHRIS.xml:S1:22275:7	O
Mania	SAPHRIS.xml:S1:22283:5	O
Trials	SAPHRIS.xml:S1:22289:6	O

SAPHRIS	SAPHRIS.xml:S1:22301:7	O
5	SAPHRIS.xml:S1:22309:1	O
mg	SAPHRIS.xml:S1:22311:2	O
to	SAPHRIS.xml:S1:22314:2	O
10	SAPHRIS.xml:S1:22317:2	O
mg	SAPHRIS.xml:S1:22320:2	O
twice	SAPHRIS.xml:S1:22323:5	O
daily	SAPHRIS.xml:S1:22329:5	O
with	SAPHRIS.xml:S1:22335:4	O
flexible	SAPHRIS.xml:S1:22340:8	O
dosing	SAPHRIS.xml:S1:22349:6	O
.	SAPHRIS.xml:S1:22355:1	O

Extrapyramidal	SAPHRIS.xml:S1:22364:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:22379:8	I-AdverseReaction
included	SAPHRIS.xml:S1:22388:8	O
:	SAPHRIS.xml:S1:22396:1	O
dystonia	SAPHRIS.xml:S1:22398:8	B-AdverseReaction
,	SAPHRIS.xml:S1:22406:1	O
parkinsonism	SAPHRIS.xml:S1:22408:12	B-AdverseReaction
,	SAPHRIS.xml:S1:22420:1	O
oculogyration	SAPHRIS.xml:S1:22422:13	B-AdverseReaction
,	SAPHRIS.xml:S1:22435:1	O
and	SAPHRIS.xml:S1:22437:3	O
tremor	SAPHRIS.xml:S1:22441:6	B-AdverseReaction
(	SAPHRIS.xml:S1:22448:1	O
excluding	SAPHRIS.xml:S1:22449:9	B-Negation
akathisia	SAPHRIS.xml:S1:22459:9	B-AdverseReaction
)	SAPHRIS.xml:S1:22468:1	O
.	SAPHRIS.xml:S1:22469:1	O

?	SAPHRIS.xml:S1:22477:1	O

Somnolence	SAPHRIS.xml:S1:22479:10	B-AdverseReaction
includes	SAPHRIS.xml:S1:22490:8	O
the	SAPHRIS.xml:S1:22499:3	O
following	SAPHRIS.xml:S1:22503:9	O
events	SAPHRIS.xml:S1:22513:6	O
:	SAPHRIS.xml:S1:22519:1	O
somnolence	SAPHRIS.xml:S1:22521:10	B-AdverseReaction
and	SAPHRIS.xml:S1:22532:3	O
sedation	SAPHRIS.xml:S1:22536:8	B-AdverseReaction
.	SAPHRIS.xml:S1:22544:1	O

System	SAPHRIS.xml:S1:22556:6	O

Organ	SAPHRIS.xml:S1:22563:5	O
Class	SAPHRIS.xml:S1:22569:5	O
Preferred	SAPHRIS.xml:S1:22575:9	O
Term	SAPHRIS.xml:S1:22585:4	O
Placebo	SAPHRIS.xml:S1:22605:7	O
N	SAPHRIS.xml:S1:22616:1	O
166	SAPHRIS.xml:S1:22618:3	O
SAPHRIS	SAPHRIS.xml:S1:22632:7	O
5	SAPHRIS.xml:S1:22643:1	O
mg	SAPHRIS.xml:S1:22645:2	O
or	SAPHRIS.xml:S1:22648:2	O
10	SAPHRIS.xml:S1:22651:2	O
mg	SAPHRIS.xml:S1:22654:2	O
twice	SAPHRIS.xml:S1:22657:5	O
daily	SAPHRIS.xml:S1:22663:5	O
N	SAPHRIS.xml:S1:22673:1	O
158	SAPHRIS.xml:S1:22675:3	O

Gastrointestinal	SAPHRIS.xml:S1:22692:16	O
disorders	SAPHRIS.xml:S1:22709:9	O

Dyspepsia	SAPHRIS.xml:S1:22745:9	B-AdverseReaction
2	SAPHRIS.xml:S1:22791:1	O
3	SAPHRIS.xml:S1:22813:1	O

Oral	SAPHRIS.xml:S1:22853:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:22858:12	I-AdverseReaction
0	SAPHRIS.xml:S1:22899:1	O
5	SAPHRIS.xml:S1:22921:1	O

General	SAPHRIS.xml:S1:22960:7	O
disorders	SAPHRIS.xml:S1:22968:9	O

Fatigue	SAPHRIS.xml:S1:23013:7	B-AdverseReaction
2	SAPHRIS.xml:S1:23059:1	O
4	SAPHRIS.xml:S1:23081:1	O

Edema	SAPHRIS.xml:S1:23121:5	B-AdverseReaction
peripheral	SAPHRIS.xml:S1:23127:10	I-AdverseReaction
1	SAPHRIS.xml:S1:23168:1	O
3	SAPHRIS.xml:S1:23189:1	O

Investigations	SAPHRIS.xml:S1:23228:14	O

Increased	SAPHRIS.xml:S1:23281:9	B-AdverseReaction
weight	SAPHRIS.xml:S1:23291:6	I-AdverseReaction
0	SAPHRIS.xml:S1:23327:1	O
3	SAPHRIS.xml:S1:23349:1	O

Nervous	SAPHRIS.xml:S1:23388:7	O
system	SAPHRIS.xml:S1:23396:6	O
disorders	SAPHRIS.xml:S1:23403:9	O

Dizziness	SAPHRIS.xml:S1:23441:9	B-AdverseReaction
2	SAPHRIS.xml:S1:23487:1	O
4	SAPHRIS.xml:S1:23509:1	O

Other	SAPHRIS.xml:S1:23549:5	O
extrapyramidal	SAPHRIS.xml:S1:23555:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:23570:8	I-AdverseReaction
(	SAPHRIS.xml:S1:23579:1	O
excluding	SAPHRIS.xml:S1:23580:9	B-Negation
akathisia	SAPHRIS.xml:S1:23590:9	B-AdverseReaction
)	SAPHRIS.xml:S1:23599:1	O
5	SAPHRIS.xml:S1:23606:1	O
6	SAPHRIS.xml:S1:23628:1	O

Somnolence	SAPHRIS.xml:S1:23668:10	B-AdverseReaction
?	SAPHRIS.xml:S1:23680:1	O

10	SAPHRIS.xml:S1:23714:2	O
22	SAPHRIS.xml:S1:23736:2	O

Psychiatric	SAPHRIS.xml:S1:23775:11	O
disorders	SAPHRIS.xml:S1:23787:9	O

Insomnia	SAPHRIS.xml:S1:23828:8	B-AdverseReaction
8	SAPHRIS.xml:S1:23874:1	O
10	SAPHRIS.xml:S1:23896:2	O

Vascular	SAPHRIS.xml:S1:23935:8	O
disorders	SAPHRIS.xml:S1:23944:9	O

Hypertension	SAPHRIS.xml:S1:23988:12	B-AdverseReaction
1	SAPHRIS.xml:S1:24035:1	O
3	SAPHRIS.xml:S1:24056:1	O

Dystonia	SAPHRIS.xml:S1:24105:8	O
:	SAPHRIS.xml:S1:24113:1	O
Symptoms	SAPHRIS.xml:S1:24116:8	O
of	SAPHRIS.xml:S1:24125:2	O
dystonia	SAPHRIS.xml:S1:24128:8	B-AdverseReaction
,	SAPHRIS.xml:S1:24136:1	O
prolonged	SAPHRIS.xml:S1:24138:9	B-AdverseReaction
abnormal	SAPHRIS.xml:S1:24148:8	I-AdverseReaction
contractions	SAPHRIS.xml:S1:24157:12	I-AdverseReaction
of	SAPHRIS.xml:S1:24170:2	I-AdverseReaction
muscle	SAPHRIS.xml:S1:24173:6	I-AdverseReaction
groups	SAPHRIS.xml:S1:24180:6	I-AdverseReaction
,	SAPHRIS.xml:S1:24186:1	O
may	SAPHRIS.xml:S1:24188:3	B-Factor
occur	SAPHRIS.xml:S1:24192:5	O
in	SAPHRIS.xml:S1:24198:2	O
susceptible	SAPHRIS.xml:S1:24201:11	O
individuals	SAPHRIS.xml:S1:24213:11	O
during	SAPHRIS.xml:S1:24225:6	O
the	SAPHRIS.xml:S1:24232:3	O
first	SAPHRIS.xml:S1:24236:5	O
few	SAPHRIS.xml:S1:24242:3	O
days	SAPHRIS.xml:S1:24246:4	O
of	SAPHRIS.xml:S1:24251:2	O
treatment	SAPHRIS.xml:S1:24254:9	O
.	SAPHRIS.xml:S1:24263:1	O

Dystonic	SAPHRIS.xml:S1:24265:8	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:24274:8	I-AdverseReaction
include	SAPHRIS.xml:S1:24283:7	O
:	SAPHRIS.xml:S1:24290:1	O
spasm	SAPHRIS.xml:S1:24292:5	B-AdverseReaction
of	SAPHRIS.xml:S1:24298:2	I-AdverseReaction
the	SAPHRIS.xml:S1:24301:3	I-AdverseReaction
neck	SAPHRIS.xml:S1:24305:4	I-AdverseReaction
muscles	SAPHRIS.xml:S1:24310:7	I-AdverseReaction
,	SAPHRIS.xml:S1:24317:1	O
sometimes	SAPHRIS.xml:S1:24319:9	O
progressing	SAPHRIS.xml:S1:24329:11	O
to	SAPHRIS.xml:S1:24341:2	O
tightness	SAPHRIS.xml:S1:24344:9	B-AdverseReaction
of	SAPHRIS.xml:S1:24354:2	I-AdverseReaction
the	SAPHRIS.xml:S1:24357:3	I-AdverseReaction
throat	SAPHRIS.xml:S1:24361:6	I-AdverseReaction
,	SAPHRIS.xml:S1:24367:1	O
swallowing	SAPHRIS.xml:S1:24369:10	B-AdverseReaction
difficulty	SAPHRIS.xml:S1:24380:10	I-AdverseReaction
,	SAPHRIS.xml:S1:24390:1	O
difficulty	SAPHRIS.xml:S1:24392:10	B-AdverseReaction
breathing	SAPHRIS.xml:S1:24403:9	I-AdverseReaction
,	SAPHRIS.xml:S1:24412:1	O
and	SAPHRIS.xml:S1:24414:3	O
or	SAPHRIS.xml:S1:24418:2	O
protrusion	SAPHRIS.xml:S1:24421:10	B-AdverseReaction
of	SAPHRIS.xml:S1:24432:2	I-AdverseReaction
the	SAPHRIS.xml:S1:24435:3	I-AdverseReaction
tongue	SAPHRIS.xml:S1:24439:6	I-AdverseReaction
.	SAPHRIS.xml:S1:24445:1	O

While	SAPHRIS.xml:S1:24447:5	O
these	SAPHRIS.xml:S1:24453:5	O
symptoms	SAPHRIS.xml:S1:24459:8	O
can	SAPHRIS.xml:S1:24468:3	O
occur	SAPHRIS.xml:S1:24472:5	O
at	SAPHRIS.xml:S1:24478:2	O
low	SAPHRIS.xml:S1:24481:3	O
doses	SAPHRIS.xml:S1:24485:5	O
,	SAPHRIS.xml:S1:24490:1	O
they	SAPHRIS.xml:S1:24492:4	O
occur	SAPHRIS.xml:S1:24497:5	O
more	SAPHRIS.xml:S1:24503:4	O
frequently	SAPHRIS.xml:S1:24508:10	O
and	SAPHRIS.xml:S1:24519:3	O
with	SAPHRIS.xml:S1:24523:4	O
greater	SAPHRIS.xml:S1:24528:7	O
severity	SAPHRIS.xml:S1:24536:8	O
with	SAPHRIS.xml:S1:24545:4	O
high	SAPHRIS.xml:S1:24550:4	O
potency	SAPHRIS.xml:S1:24555:7	O
and	SAPHRIS.xml:S1:24563:3	O
at	SAPHRIS.xml:S1:24567:2	O
higher	SAPHRIS.xml:S1:24570:6	O
doses	SAPHRIS.xml:S1:24577:5	O
of	SAPHRIS.xml:S1:24583:2	O
first	SAPHRIS.xml:S1:24586:5	O
generation	SAPHRIS.xml:S1:24592:10	O
antipsychotic	SAPHRIS.xml:S1:24603:13	O
drugs	SAPHRIS.xml:S1:24617:5	O
.	SAPHRIS.xml:S1:24622:1	O

An	SAPHRIS.xml:S1:24624:2	O
elevated	SAPHRIS.xml:S1:24627:8	O
risk	SAPHRIS.xml:S1:24636:4	B-Factor
of	SAPHRIS.xml:S1:24641:2	O
acute	SAPHRIS.xml:S1:24644:5	B-AdverseReaction
dystonia	SAPHRIS.xml:S1:24650:8	I-AdverseReaction
is	SAPHRIS.xml:S1:24659:2	O
observed	SAPHRIS.xml:S1:24662:8	O
in	SAPHRIS.xml:S1:24671:2	O
males	SAPHRIS.xml:S1:24674:5	O
and	SAPHRIS.xml:S1:24680:3	O
younger	SAPHRIS.xml:S1:24684:7	O
age	SAPHRIS.xml:S1:24692:3	O
groups	SAPHRIS.xml:S1:24696:6	O
[	SAPHRIS.xml:S1:24704:1	O
see	SAPHRIS.xml:S1:24705:3	O
Dosage	SAPHRIS.xml:S1:24709:6	O
and	SAPHRIS.xml:S1:24716:3	O
Administration	SAPHRIS.xml:S1:24720:14	O
(	SAPHRIS.xml:S1:24735:1	O
2.3	SAPHRIS.xml:S1:24736:3	O
)	SAPHRIS.xml:S1:24739:1	O
,	SAPHRIS.xml:S1:24740:1	O
Use	SAPHRIS.xml:S1:24742:3	O
in	SAPHRIS.xml:S1:24746:2	O
Specific	SAPHRIS.xml:S1:24749:8	O
Populations	SAPHRIS.xml:S1:24758:11	O
(	SAPHRIS.xml:S1:24770:1	O
8.4	SAPHRIS.xml:S1:24771:3	O
)	SAPHRIS.xml:S1:24774:1	O
,	SAPHRIS.xml:S1:24775:1	O
and	SAPHRIS.xml:S1:24777:3	O
Clinical	SAPHRIS.xml:S1:24781:8	O
Pharmacology	SAPHRIS.xml:S1:24790:12	O
(	SAPHRIS.xml:S1:24803:1	O
12.3	SAPHRIS.xml:S1:24804:4	O
)]	SAPHRIS.xml:S1:24808:2	O
.	SAPHRIS.xml:S1:24812:1	O

Extrapyramidal	SAPHRIS.xml:S1:24822:14	O

Symptoms	SAPHRIS.xml:S1:24837:8	O
:	SAPHRIS.xml:S1:24845:1	O
In	SAPHRIS.xml:S1:24848:2	O
the	SAPHRIS.xml:S1:24851:3	O
short	SAPHRIS.xml:S1:24855:5	O
-	SAPHRIS.xml:S1:24860:1	O
term	SAPHRIS.xml:S1:24861:4	O
,	SAPHRIS.xml:S1:24865:1	O
placebo	SAPHRIS.xml:S1:24867:7	O
-	SAPHRIS.xml:S1:24874:1	O
controlled	SAPHRIS.xml:S1:24875:10	O
schizophrenia	SAPHRIS.xml:S1:24886:13	O
and	SAPHRIS.xml:S1:24900:3	O
bipolar	SAPHRIS.xml:S1:24904:7	O
mania	SAPHRIS.xml:S1:24912:5	O
adult	SAPHRIS.xml:S1:24918:5	O
trials	SAPHRIS.xml:S1:24924:6	O
,	SAPHRIS.xml:S1:24930:1	O
data	SAPHRIS.xml:S1:24932:4	O
was	SAPHRIS.xml:S1:24937:3	O
objectively	SAPHRIS.xml:S1:24941:11	O
collected	SAPHRIS.xml:S1:24953:9	O
on	SAPHRIS.xml:S1:24963:2	O
the	SAPHRIS.xml:S1:24966:3	O
Simpson	SAPHRIS.xml:S1:24970:7	O
Angus	SAPHRIS.xml:S1:24978:5	O
Rating	SAPHRIS.xml:S1:24984:6	O
Scale	SAPHRIS.xml:S1:24991:5	O
for	SAPHRIS.xml:S1:24997:3	O
extrapyramidal	SAPHRIS.xml:S1:25001:14	B-AdverseReaction
symptoms	SAPHRIS.xml:S1:25016:8	I-AdverseReaction
(	SAPHRIS.xml:S1:25025:1	O
EPS	SAPHRIS.xml:S1:25026:3	B-AdverseReaction
)	SAPHRIS.xml:S1:25029:1	O
,	SAPHRIS.xml:S1:25030:1	O
the	SAPHRIS.xml:S1:25032:3	O
Barnes	SAPHRIS.xml:S1:25036:6	O
Akathisia	SAPHRIS.xml:S1:25043:9	O
Scale	SAPHRIS.xml:S1:25053:5	O
(	SAPHRIS.xml:S1:25059:1	O
for	SAPHRIS.xml:S1:25060:3	O
akathisia	SAPHRIS.xml:S1:25064:9	B-AdverseReaction
)	SAPHRIS.xml:S1:25073:1	O
and	SAPHRIS.xml:S1:25075:3	O
the	SAPHRIS.xml:S1:25079:3	O
Assessments	SAPHRIS.xml:S1:25083:11	O
of	SAPHRIS.xml:S1:25095:2	O
Involuntary	SAPHRIS.xml:S1:25098:11	O
Movement	SAPHRIS.xml:S1:25110:8	O
Scales	SAPHRIS.xml:S1:25119:6	O
(	SAPHRIS.xml:S1:25126:1	O
for	SAPHRIS.xml:S1:25127:3	O
dyskinesias	SAPHRIS.xml:S1:25131:11	B-AdverseReaction
)	SAPHRIS.xml:S1:25142:1	O
.	SAPHRIS.xml:S1:25143:1	O

The	SAPHRIS.xml:S1:25145:3	O
mean	SAPHRIS.xml:S1:25149:4	O
change	SAPHRIS.xml:S1:25154:6	O
from	SAPHRIS.xml:S1:25161:4	O
baseline	SAPHRIS.xml:S1:25166:8	O
for	SAPHRIS.xml:S1:25175:3	O
the	SAPHRIS.xml:S1:25179:3	O
all	SAPHRIS.xml:S1:25183:3	O
-	SAPHRIS.xml:S1:25186:1	O
SAPHRIS	SAPHRIS.xml:S1:25187:7	O
5	SAPHRIS.xml:S1:25195:1	O
mg	SAPHRIS.xml:S1:25197:2	O
or	SAPHRIS.xml:S1:25200:2	O
10	SAPHRIS.xml:S1:25203:2	O
mg	SAPHRIS.xml:S1:25206:2	O
twice	SAPHRIS.xml:S1:25209:5	O
daily	SAPHRIS.xml:S1:25215:5	O
treated	SAPHRIS.xml:S1:25221:7	O
group	SAPHRIS.xml:S1:25229:5	O
was	SAPHRIS.xml:S1:25235:3	O
comparable	SAPHRIS.xml:S1:25239:10	O
to	SAPHRIS.xml:S1:25250:2	O
placebo	SAPHRIS.xml:S1:25253:7	O
in	SAPHRIS.xml:S1:25261:2	O
each	SAPHRIS.xml:S1:25264:4	O
of	SAPHRIS.xml:S1:25269:2	O
the	SAPHRIS.xml:S1:25272:3	O
rating	SAPHRIS.xml:S1:25276:6	O
scale	SAPHRIS.xml:S1:25283:5	O
scores	SAPHRIS.xml:S1:25289:6	O
.	SAPHRIS.xml:S1:25295:1	O

In	SAPHRIS.xml:S1:25301:2	O
the	SAPHRIS.xml:S1:25304:3	O
short	SAPHRIS.xml:S1:25308:5	O
-	SAPHRIS.xml:S1:25313:1	O
term	SAPHRIS.xml:S1:25314:4	O
,	SAPHRIS.xml:S1:25318:1	O
placebo	SAPHRIS.xml:S1:25320:7	O
-	SAPHRIS.xml:S1:25327:1	O
controlled	SAPHRIS.xml:S1:25328:10	O
schizophrenia	SAPHRIS.xml:S1:25339:13	O
adult	SAPHRIS.xml:S1:25353:5	O
trials	SAPHRIS.xml:S1:25359:6	O
,	SAPHRIS.xml:S1:25365:1	O
the	SAPHRIS.xml:S1:25367:3	O
incidence	SAPHRIS.xml:S1:25371:9	O
of	SAPHRIS.xml:S1:25381:2	O
reported	SAPHRIS.xml:S1:25384:8	O
EPS	SAPHRIS.xml:S1:25393:3	B-AdverseReaction
-	SAPHRIS.xml:S1:25396:1	I-AdverseReaction
related	SAPHRIS.xml:S1:25397:7	I-AdverseReaction
events	SAPHRIS.xml:S1:25405:6	I-AdverseReaction
,	SAPHRIS.xml:S1:25411:1	O
excluding	SAPHRIS.xml:S1:25413:9	B-Negation
events	SAPHRIS.xml:S1:25423:6	O
related	SAPHRIS.xml:S1:25430:7	O
to	SAPHRIS.xml:S1:25438:2	O
akathisia	SAPHRIS.xml:S1:25441:9	B-AdverseReaction
,	SAPHRIS.xml:S1:25450:1	O
for	SAPHRIS.xml:S1:25452:3	O
SAPHRIS	SAPHRIS.xml:S1:25456:7	O
-	SAPHRIS.xml:S1:25463:1	O
treated	SAPHRIS.xml:S1:25464:7	O
patients	SAPHRIS.xml:S1:25472:8	O
was	SAPHRIS.xml:S1:25481:3	O
10%	SAPHRIS.xml:S1:25485:3	O
versus	SAPHRIS.xml:S1:25489:6	O
7%	SAPHRIS.xml:S1:25496:2	O
for	SAPHRIS.xml:S1:25499:3	O
placebo	SAPHRIS.xml:S1:25503:7	O
;	SAPHRIS.xml:S1:25510:1	O
and	SAPHRIS.xml:S1:25512:3	O
the	SAPHRIS.xml:S1:25516:3	O
incidence	SAPHRIS.xml:S1:25520:9	O
of	SAPHRIS.xml:S1:25530:2	O
akathisia	SAPHRIS.xml:S1:25533:9	B-AdverseReaction
-	SAPHRIS.xml:S1:25542:1	O
related	SAPHRIS.xml:S1:25543:7	O
events	SAPHRIS.xml:S1:25551:6	O
for	SAPHRIS.xml:S1:25558:3	O
SAPHRIS	SAPHRIS.xml:S1:25562:7	O
-	SAPHRIS.xml:S1:25569:1	O
treated	SAPHRIS.xml:S1:25570:7	O
patients	SAPHRIS.xml:S1:25578:8	O
was	SAPHRIS.xml:S1:25587:3	O
6%	SAPHRIS.xml:S1:25591:2	O
versus	SAPHRIS.xml:S1:25594:6	O
3%	SAPHRIS.xml:S1:25601:2	O
for	SAPHRIS.xml:S1:25604:3	O
placebo	SAPHRIS.xml:S1:25608:7	O
.	SAPHRIS.xml:S1:25615:1	O

In	SAPHRIS.xml:S1:25617:2	O
short	SAPHRIS.xml:S1:25620:5	O
-	SAPHRIS.xml:S1:25625:1	O
term	SAPHRIS.xml:S1:25626:4	O
placebo	SAPHRIS.xml:S1:25631:7	O
-	SAPHRIS.xml:S1:25638:1	O
controlled	SAPHRIS.xml:S1:25639:10	O
bipolar	SAPHRIS.xml:S1:25650:7	O
mania	SAPHRIS.xml:S1:25658:5	O
adult	SAPHRIS.xml:S1:25664:5	O
trials	SAPHRIS.xml:S1:25670:6	O
,	SAPHRIS.xml:S1:25676:1	O
the	SAPHRIS.xml:S1:25678:3	O
incidence	SAPHRIS.xml:S1:25682:9	O
of	SAPHRIS.xml:S1:25692:2	O
EPS	SAPHRIS.xml:S1:25695:3	B-AdverseReaction
-	SAPHRIS.xml:S1:25698:1	I-AdverseReaction
related	SAPHRIS.xml:S1:25699:7	I-AdverseReaction
events	SAPHRIS.xml:S1:25707:6	I-AdverseReaction
,	SAPHRIS.xml:S1:25713:1	O
excluding	SAPHRIS.xml:S1:25715:9	B-Negation
events	SAPHRIS.xml:S1:25725:6	O
related	SAPHRIS.xml:S1:25732:7	O
to	SAPHRIS.xml:S1:25740:2	O
akathisia	SAPHRIS.xml:S1:25743:9	B-AdverseReaction
,	SAPHRIS.xml:S1:25752:1	O
for	SAPHRIS.xml:S1:25754:3	O
SAPHRIS	SAPHRIS.xml:S1:25758:7	O
-	SAPHRIS.xml:S1:25765:1	O
treated	SAPHRIS.xml:S1:25766:7	O
patients	SAPHRIS.xml:S1:25774:8	O
was	SAPHRIS.xml:S1:25783:3	O
7%	SAPHRIS.xml:S1:25787:2	O
versus	SAPHRIS.xml:S1:25790:6	O
2%	SAPHRIS.xml:S1:25797:2	O
for	SAPHRIS.xml:S1:25800:3	O
placebo	SAPHRIS.xml:S1:25804:7	O
;	SAPHRIS.xml:S1:25811:1	O
and	SAPHRIS.xml:S1:25813:3	O
the	SAPHRIS.xml:S1:25817:3	O
incidence	SAPHRIS.xml:S1:25821:9	O
of	SAPHRIS.xml:S1:25831:2	O
akathisia	SAPHRIS.xml:S1:25834:9	B-AdverseReaction
-	SAPHRIS.xml:S1:25843:1	O
related	SAPHRIS.xml:S1:25844:7	O
events	SAPHRIS.xml:S1:25852:6	O
for	SAPHRIS.xml:S1:25859:3	O
SAPHRIS	SAPHRIS.xml:S1:25863:7	O
-	SAPHRIS.xml:S1:25870:1	O
treated	SAPHRIS.xml:S1:25871:7	O
patients	SAPHRIS.xml:S1:25879:8	O
was	SAPHRIS.xml:S1:25888:3	O
4%	SAPHRIS.xml:S1:25892:2	O
versus	SAPHRIS.xml:S1:25895:6	O
2%	SAPHRIS.xml:S1:25902:2	O
for	SAPHRIS.xml:S1:25905:3	O
placebo	SAPHRIS.xml:S1:25909:7	O
.	SAPHRIS.xml:S1:25916:1	O

In	SAPHRIS.xml:S1:25922:2	O
a	SAPHRIS.xml:S1:25925:1	O
3	SAPHRIS.xml:S1:25927:1	O
-	SAPHRIS.xml:S1:25928:1	O
week	SAPHRIS.xml:S1:25929:4	O
,	SAPHRIS.xml:S1:25933:1	O
placebo	SAPHRIS.xml:S1:25935:7	O
-	SAPHRIS.xml:S1:25942:1	O
controlled	SAPHRIS.xml:S1:25943:10	O
pediatric	SAPHRIS.xml:S1:25954:9	O
trial	SAPHRIS.xml:S1:25964:5	O
with	SAPHRIS.xml:S1:25970:4	O
bipolar	SAPHRIS.xml:S1:25975:7	O
I	SAPHRIS.xml:S1:25983:1	O
disorder	SAPHRIS.xml:S1:25985:8	O
,	SAPHRIS.xml:S1:25993:1	O
the	SAPHRIS.xml:S1:25995:3	O
incidences	SAPHRIS.xml:S1:25999:10	O
of	SAPHRIS.xml:S1:26010:2	O
EPS	SAPHRIS.xml:S1:26013:3	B-AdverseReaction
-	SAPHRIS.xml:S1:26016:1	I-AdverseReaction
related	SAPHRIS.xml:S1:26017:7	I-AdverseReaction
events	SAPHRIS.xml:S1:26025:6	I-AdverseReaction
,	SAPHRIS.xml:S1:26031:1	O
excluding	SAPHRIS.xml:S1:26033:9	B-Negation
events	SAPHRIS.xml:S1:26043:6	O
related	SAPHRIS.xml:S1:26050:7	O
to	SAPHRIS.xml:S1:26058:2	O
akathisia	SAPHRIS.xml:S1:26061:9	B-AdverseReaction
,	SAPHRIS.xml:S1:26070:1	O
were	SAPHRIS.xml:S1:26072:4	O
4%	SAPHRIS.xml:S1:26077:2	O
,	SAPHRIS.xml:S1:26079:1	O
3%	SAPHRIS.xml:S1:26081:2	O
,	SAPHRIS.xml:S1:26083:1	O
and	SAPHRIS.xml:S1:26085:3	O
5%	SAPHRIS.xml:S1:26089:2	O
for	SAPHRIS.xml:S1:26092:3	O
patients	SAPHRIS.xml:S1:26096:8	O
treated	SAPHRIS.xml:S1:26105:7	O
with	SAPHRIS.xml:S1:26113:4	O
SAPHRIS	SAPHRIS.xml:S1:26118:7	O
2.5	SAPHRIS.xml:S1:26126:3	O
mg	SAPHRIS.xml:S1:26130:2	O
,	SAPHRIS.xml:S1:26132:1	O
5	SAPHRIS.xml:S1:26134:1	O
mg	SAPHRIS.xml:S1:26136:2	O
,	SAPHRIS.xml:S1:26138:1	O
and	SAPHRIS.xml:S1:26140:3	O
10	SAPHRIS.xml:S1:26144:2	O
mg	SAPHRIS.xml:S1:26147:2	O
twice	SAPHRIS.xml:S1:26150:5	O
daily	SAPHRIS.xml:S1:26156:5	O
,	SAPHRIS.xml:S1:26161:1	O
respectively	SAPHRIS.xml:S1:26163:12	O
,	SAPHRIS.xml:S1:26175:1	O
as	SAPHRIS.xml:S1:26177:2	O
compared	SAPHRIS.xml:S1:26180:8	O
to	SAPHRIS.xml:S1:26189:2	O
3%	SAPHRIS.xml:S1:26192:2	O
for	SAPHRIS.xml:S1:26195:3	O
placebo	SAPHRIS.xml:S1:26199:7	O
-	SAPHRIS.xml:S1:26206:1	O
treated	SAPHRIS.xml:S1:26207:7	O
patients	SAPHRIS.xml:S1:26215:8	O
.	SAPHRIS.xml:S1:26223:1	O

EPS	SAPHRIS.xml:S1:26225:3	B-AdverseReaction
-	SAPHRIS.xml:S1:26228:1	I-AdverseReaction
related	SAPHRIS.xml:S1:26229:7	I-AdverseReaction
events	SAPHRIS.xml:S1:26237:6	I-AdverseReaction
include	SAPHRIS.xml:S1:26244:7	O
:	SAPHRIS.xml:S1:26251:1	O
bradykinesia	SAPHRIS.xml:S1:26253:12	B-AdverseReaction
,	SAPHRIS.xml:S1:26265:1	O
dyskinesia	SAPHRIS.xml:S1:26267:10	B-AdverseReaction
,	SAPHRIS.xml:S1:26277:1	O
dystonia	SAPHRIS.xml:S1:26279:8	B-AdverseReaction
,	SAPHRIS.xml:S1:26287:1	O
oromandibular	SAPHRIS.xml:S1:26289:13	B-AdverseReaction
dystonia	SAPHRIS.xml:S1:26303:8	I-AdverseReaction
,	SAPHRIS.xml:S1:26311:1	O
muscle	SAPHRIS.xml:S1:26313:6	B-AdverseReaction
contractions	SAPHRIS.xml:S1:26320:12	I-AdverseReaction
involuntary	SAPHRIS.xml:S1:26333:11	I-AdverseReaction
,	SAPHRIS.xml:S1:26344:1	O
muscle	SAPHRIS.xml:S1:26346:6	B-AdverseReaction
twitching	SAPHRIS.xml:S1:26353:9	I-AdverseReaction
,	SAPHRIS.xml:S1:26362:1	O
musculoskeletal	SAPHRIS.xml:S1:26364:15	B-AdverseReaction
stiffness	SAPHRIS.xml:S1:26380:9	I-AdverseReaction
,	SAPHRIS.xml:S1:26389:1	O
parkinsonism	SAPHRIS.xml:S1:26391:12	B-AdverseReaction
,	SAPHRIS.xml:S1:26403:1	O
protrusion	SAPHRIS.xml:S1:26405:10	B-AdverseReaction
tongue	SAPHRIS.xml:S1:26416:6	I-AdverseReaction
,	SAPHRIS.xml:S1:26422:1	O
resting	SAPHRIS.xml:S1:26424:7	B-AdverseReaction
tremor	SAPHRIS.xml:S1:26432:6	I-AdverseReaction
,	SAPHRIS.xml:S1:26438:1	O
and	SAPHRIS.xml:S1:26440:3	O
tremor	SAPHRIS.xml:S1:26444:6	B-AdverseReaction
.	SAPHRIS.xml:S1:26450:1	O

For	SAPHRIS.xml:S1:26456:3	O
events	SAPHRIS.xml:S1:26460:6	O
of	SAPHRIS.xml:S1:26467:2	O
akathisia	SAPHRIS.xml:S1:26470:9	B-AdverseReaction
,	SAPHRIS.xml:S1:26479:1	O
incidences	SAPHRIS.xml:S1:26481:10	O
were	SAPHRIS.xml:S1:26492:4	O
2%	SAPHRIS.xml:S1:26497:2	O
,	SAPHRIS.xml:S1:26499:1	O
2%	SAPHRIS.xml:S1:26501:2	O
,	SAPHRIS.xml:S1:26503:1	O
and	SAPHRIS.xml:S1:26505:3	O
1%	SAPHRIS.xml:S1:26509:2	O
for	SAPHRIS.xml:S1:26512:3	O
patients	SAPHRIS.xml:S1:26516:8	O
treated	SAPHRIS.xml:S1:26525:7	O
with	SAPHRIS.xml:S1:26533:4	O
SAPHRIS	SAPHRIS.xml:S1:26538:7	O
2.5	SAPHRIS.xml:S1:26546:3	O
mg	SAPHRIS.xml:S1:26550:2	O
,	SAPHRIS.xml:S1:26552:1	O
5	SAPHRIS.xml:S1:26554:1	O
mg	SAPHRIS.xml:S1:26556:2	O
,	SAPHRIS.xml:S1:26558:1	O
and	SAPHRIS.xml:S1:26560:3	O
10	SAPHRIS.xml:S1:26564:2	O
mg	SAPHRIS.xml:S1:26567:2	O
twice	SAPHRIS.xml:S1:26570:5	O
daily	SAPHRIS.xml:S1:26576:5	O
,	SAPHRIS.xml:S1:26581:1	O
respectively	SAPHRIS.xml:S1:26583:12	O
,	SAPHRIS.xml:S1:26595:1	O
as	SAPHRIS.xml:S1:26597:2	O
compared	SAPHRIS.xml:S1:26600:8	O
to	SAPHRIS.xml:S1:26609:2	O
0%	SAPHRIS.xml:S1:26612:2	O
for	SAPHRIS.xml:S1:26615:3	O
placebo	SAPHRIS.xml:S1:26619:7	O
-	SAPHRIS.xml:S1:26626:1	O
treated	SAPHRIS.xml:S1:26627:7	O
patients	SAPHRIS.xml:S1:26635:8	O
.	SAPHRIS.xml:S1:26643:1	O

Other	SAPHRIS.xml:S1:26653:5	O
Findings	SAPHRIS.xml:S1:26659:8	O
:	SAPHRIS.xml:S1:26667:1	O
Oral	SAPHRIS.xml:S1:26670:4	B-AdverseReaction
hypoesthesia	SAPHRIS.xml:S1:26675:12	I-AdverseReaction
and	SAPHRIS.xml:S1:26688:3	O
or	SAPHRIS.xml:S1:26692:2	O
oral	SAPHRIS.xml:S1:26695:4	B-AdverseReaction
paresthesia	SAPHRIS.xml:S1:26700:11	I-AdverseReaction
may	SAPHRIS.xml:S1:26712:3	O
occur	SAPHRIS.xml:S1:26716:5	O
directly	SAPHRIS.xml:S1:26722:8	O
after	SAPHRIS.xml:S1:26731:5	O
administration	SAPHRIS.xml:S1:26737:14	O
of	SAPHRIS.xml:S1:26752:2	O
SAPHRIS	SAPHRIS.xml:S1:26755:7	O
and	SAPHRIS.xml:S1:26763:3	O
usually	SAPHRIS.xml:S1:26767:7	O
resolves	SAPHRIS.xml:S1:26775:8	O
within	SAPHRIS.xml:S1:26784:6	O
1	SAPHRIS.xml:S1:26791:1	O
hour	SAPHRIS.xml:S1:26793:4	O
.	SAPHRIS.xml:S1:26797:1	O

Laboratory	SAPHRIS.xml:S1:26807:10	O
Test	SAPHRIS.xml:S1:26818:4	O
Abnormalities	SAPHRIS.xml:S1:26823:13	O
:	SAPHRIS.xml:S1:26836:1	O

Transaminases	SAPHRIS.xml:S1:26848:13	O
:	SAPHRIS.xml:S1:26861:1	O
Transient	SAPHRIS.xml:S1:26864:9	O
elevations	SAPHRIS.xml:S1:26874:10	B-AdverseReaction
in	SAPHRIS.xml:S1:26885:2	I-AdverseReaction
serum	SAPHRIS.xml:S1:26888:5	I-AdverseReaction
transaminases	SAPHRIS.xml:S1:26894:13	I-AdverseReaction
(	SAPHRIS.xml:S1:26908:1	O
primarily	SAPHRIS.xml:S1:26909:9	O
ALT	SAPHRIS.xml:S1:26919:3	I-AdverseReaction
)	SAPHRIS.xml:S1:26922:1	O
in	SAPHRIS.xml:S1:26924:2	O
the	SAPHRIS.xml:S1:26927:3	O
short	SAPHRIS.xml:S1:26931:5	O
-	SAPHRIS.xml:S1:26936:1	O
term	SAPHRIS.xml:S1:26937:4	O
schizophrenia	SAPHRIS.xml:S1:26942:13	O
and	SAPHRIS.xml:S1:26956:3	O
bipolar	SAPHRIS.xml:S1:26960:7	O
mania	SAPHRIS.xml:S1:26968:5	O
adult	SAPHRIS.xml:S1:26974:5	O
trials	SAPHRIS.xml:S1:26980:6	O
were	SAPHRIS.xml:S1:26987:4	O
more	SAPHRIS.xml:S1:26992:4	O
common	SAPHRIS.xml:S1:26997:6	O
in	SAPHRIS.xml:S1:27004:2	O
treated	SAPHRIS.xml:S1:27007:7	O
patients	SAPHRIS.xml:S1:27015:8	O
.	SAPHRIS.xml:S1:27023:1	O

In	SAPHRIS.xml:S1:27025:2	O
short	SAPHRIS.xml:S1:27028:5	O
-	SAPHRIS.xml:S1:27033:1	O
term	SAPHRIS.xml:S1:27034:4	O
,	SAPHRIS.xml:S1:27038:1	O
placebo	SAPHRIS.xml:S1:27040:7	O
-	SAPHRIS.xml:S1:27047:1	O
controlled	SAPHRIS.xml:S1:27048:10	O
schizophrenia	SAPHRIS.xml:S1:27059:13	O
adult	SAPHRIS.xml:S1:27073:5	O
trials	SAPHRIS.xml:S1:27079:6	O
,	SAPHRIS.xml:S1:27085:1	O
the	SAPHRIS.xml:S1:27087:3	O
mean	SAPHRIS.xml:S1:27091:4	O
increase	SAPHRIS.xml:S1:27096:8	B-AdverseReaction
in	SAPHRIS.xml:S1:27105:2	I-AdverseReaction
transaminase	SAPHRIS.xml:S1:27108:12	I-AdverseReaction
levels	SAPHRIS.xml:S1:27121:6	I-AdverseReaction
for	SAPHRIS.xml:S1:27128:3	O
SAPHRIS	SAPHRIS.xml:S1:27132:7	O
-	SAPHRIS.xml:S1:27139:1	O
treated	SAPHRIS.xml:S1:27140:7	O
patients	SAPHRIS.xml:S1:27148:8	O
was	SAPHRIS.xml:S1:27157:3	O
1.6	SAPHRIS.xml:S1:27161:3	O
units	SAPHRIS.xml:S1:27165:5	O
L	SAPHRIS.xml:S1:27171:1	O
compared	SAPHRIS.xml:S1:27173:8	O
to	SAPHRIS.xml:S1:27182:2	O
a	SAPHRIS.xml:S1:27185:1	O
decrease	SAPHRIS.xml:S1:27187:8	O
of	SAPHRIS.xml:S1:27196:2	O
0.4	SAPHRIS.xml:S1:27199:3	O
units	SAPHRIS.xml:S1:27203:5	O
L	SAPHRIS.xml:S1:27209:1	O
for	SAPHRIS.xml:S1:27211:3	O
placebo	SAPHRIS.xml:S1:27215:7	O
-	SAPHRIS.xml:S1:27222:1	O
treated	SAPHRIS.xml:S1:27223:7	O
patients	SAPHRIS.xml:S1:27231:8	O
.	SAPHRIS.xml:S1:27239:1	O

The	SAPHRIS.xml:S1:27241:3	O
proportion	SAPHRIS.xml:S1:27245:10	O
of	SAPHRIS.xml:S1:27256:2	O
patients	SAPHRIS.xml:S1:27259:8	O
with	SAPHRIS.xml:S1:27268:4	O
transaminase	SAPHRIS.xml:S1:27273:12	B-AdverseReaction
elevations	SAPHRIS.xml:S1:27286:10	I-AdverseReaction
3	SAPHRIS.xml:S1:27299:1	B-Severity
times	SAPHRIS.xml:S1:27301:5	I-Severity
ULN	SAPHRIS.xml:S1:27307:3	I-Severity
(	SAPHRIS.xml:S1:27311:1	O
at	SAPHRIS.xml:S1:27312:2	O
Endpoint	SAPHRIS.xml:S1:27315:8	O
)	SAPHRIS.xml:S1:27323:1	O
was	SAPHRIS.xml:S1:27325:3	O
0.9%	SAPHRIS.xml:S1:27329:4	O
for	SAPHRIS.xml:S1:27334:3	O
SAPHRIS	SAPHRIS.xml:S1:27338:7	O
-	SAPHRIS.xml:S1:27345:1	O
treated	SAPHRIS.xml:S1:27346:7	O
patients	SAPHRIS.xml:S1:27354:8	O
versus	SAPHRIS.xml:S1:27363:6	O
1.3%	SAPHRIS.xml:S1:27370:4	O
for	SAPHRIS.xml:S1:27375:3	O
placebo	SAPHRIS.xml:S1:27379:7	O
-	SAPHRIS.xml:S1:27386:1	O
treated	SAPHRIS.xml:S1:27387:7	O
patients	SAPHRIS.xml:S1:27395:8	O
.	SAPHRIS.xml:S1:27403:1	O

In	SAPHRIS.xml:S1:27405:2	O
short	SAPHRIS.xml:S1:27408:5	O
-	SAPHRIS.xml:S1:27413:1	O
term	SAPHRIS.xml:S1:27414:4	O
,	SAPHRIS.xml:S1:27418:1	O
placebo	SAPHRIS.xml:S1:27420:7	O
-	SAPHRIS.xml:S1:27427:1	O
controlled	SAPHRIS.xml:S1:27428:10	O
bipolar	SAPHRIS.xml:S1:27439:7	O
adult	SAPHRIS.xml:S1:27447:5	O
mania	SAPHRIS.xml:S1:27453:5	O
trials	SAPHRIS.xml:S1:27459:6	O
,	SAPHRIS.xml:S1:27465:1	O
the	SAPHRIS.xml:S1:27467:3	O
mean	SAPHRIS.xml:S1:27471:4	O
increase	SAPHRIS.xml:S1:27476:8	B-AdverseReaction
in	SAPHRIS.xml:S1:27485:2	I-AdverseReaction
transaminase	SAPHRIS.xml:S1:27488:12	I-AdverseReaction
levels	SAPHRIS.xml:S1:27501:6	I-AdverseReaction
for	SAPHRIS.xml:S1:27508:3	O
SAPHRIS	SAPHRIS.xml:S1:27512:7	O
-	SAPHRIS.xml:S1:27519:1	O
treated	SAPHRIS.xml:S1:27520:7	O
patients	SAPHRIS.xml:S1:27528:8	O
was	SAPHRIS.xml:S1:27537:3	O
8.9	SAPHRIS.xml:S1:27541:3	O
units	SAPHRIS.xml:S1:27545:5	O
L	SAPHRIS.xml:S1:27551:1	O
compared	SAPHRIS.xml:S1:27553:8	O
to	SAPHRIS.xml:S1:27562:2	O
a	SAPHRIS.xml:S1:27565:1	O
decrease	SAPHRIS.xml:S1:27567:8	O
of	SAPHRIS.xml:S1:27576:2	O
4.9	SAPHRIS.xml:S1:27579:3	O
units	SAPHRIS.xml:S1:27583:5	O
L	SAPHRIS.xml:S1:27589:1	O
in	SAPHRIS.xml:S1:27591:2	O
placebo	SAPHRIS.xml:S1:27594:7	O
-	SAPHRIS.xml:S1:27601:1	O
treated	SAPHRIS.xml:S1:27602:7	O
patients	SAPHRIS.xml:S1:27610:8	O
.	SAPHRIS.xml:S1:27618:1	O

The	SAPHRIS.xml:S1:27620:3	O
proportion	SAPHRIS.xml:S1:27624:10	O
of	SAPHRIS.xml:S1:27635:2	O
patients	SAPHRIS.xml:S1:27638:8	O
with	SAPHRIS.xml:S1:27647:4	O
transaminase	SAPHRIS.xml:S1:27652:12	B-AdverseReaction
elevations	SAPHRIS.xml:S1:27665:10	I-AdverseReaction
3	SAPHRIS.xml:S1:27678:1	B-Severity
times	SAPHRIS.xml:S1:27680:5	I-Severity
upper	SAPHRIS.xml:S1:27686:5	I-Severity
limit	SAPHRIS.xml:S1:27692:5	I-Severity
of	SAPHRIS.xml:S1:27698:2	I-Severity
normal	SAPHRIS.xml:S1:27701:6	I-Severity
(	SAPHRIS.xml:S1:27708:1	I-Severity
ULN	SAPHRIS.xml:S1:27709:3	I-Severity
)	SAPHRIS.xml:S1:27712:1	I-Severity
(	SAPHRIS.xml:S1:27714:1	O
at	SAPHRIS.xml:S1:27715:2	O
Endpoint	SAPHRIS.xml:S1:27718:8	O
)	SAPHRIS.xml:S1:27726:1	O
was	SAPHRIS.xml:S1:27728:3	O
2.5%	SAPHRIS.xml:S1:27732:4	O
for	SAPHRIS.xml:S1:27737:3	O
SAPHRIS	SAPHRIS.xml:S1:27741:7	O
-	SAPHRIS.xml:S1:27748:1	O
treated	SAPHRIS.xml:S1:27749:7	O
patients	SAPHRIS.xml:S1:27757:8	O
versus	SAPHRIS.xml:S1:27766:6	O
0.6%	SAPHRIS.xml:S1:27773:4	O
for	SAPHRIS.xml:S1:27778:3	O
placebo	SAPHRIS.xml:S1:27782:7	O
-	SAPHRIS.xml:S1:27789:1	O
treated	SAPHRIS.xml:S1:27790:7	O
patients	SAPHRIS.xml:S1:27798:8	O
.	SAPHRIS.xml:S1:27806:1	O

In	SAPHRIS.xml:S1:27812:2	O
a	SAPHRIS.xml:S1:27815:1	O
52	SAPHRIS.xml:S1:27817:2	O
-	SAPHRIS.xml:S1:27819:1	O
week	SAPHRIS.xml:S1:27820:4	O
,	SAPHRIS.xml:S1:27824:1	O
double	SAPHRIS.xml:S1:27826:6	O
-	SAPHRIS.xml:S1:27832:1	O
blind	SAPHRIS.xml:S1:27833:5	O
,	SAPHRIS.xml:S1:27838:1	O
comparator	SAPHRIS.xml:S1:27840:10	O
-	SAPHRIS.xml:S1:27850:1	O
controlled	SAPHRIS.xml:S1:27851:10	O
trial	SAPHRIS.xml:S1:27862:5	O
that	SAPHRIS.xml:S1:27868:4	O
included	SAPHRIS.xml:S1:27873:8	O
primarily	SAPHRIS.xml:S1:27882:9	O
adult	SAPHRIS.xml:S1:27892:5	O
patients	SAPHRIS.xml:S1:27898:8	O
with	SAPHRIS.xml:S1:27907:4	O
schizophrenia	SAPHRIS.xml:S1:27912:13	O
,	SAPHRIS.xml:S1:27925:1	O
the	SAPHRIS.xml:S1:27927:3	O
mean	SAPHRIS.xml:S1:27931:4	O
increase	SAPHRIS.xml:S1:27936:8	B-AdverseReaction
from	SAPHRIS.xml:S1:27945:4	O
baseline	SAPHRIS.xml:S1:27950:8	O
of	SAPHRIS.xml:S1:27959:2	I-AdverseReaction
ALT	SAPHRIS.xml:S1:27962:3	I-AdverseReaction
was	SAPHRIS.xml:S1:27966:3	O
1.7	SAPHRIS.xml:S1:27970:3	B-Severity
units	SAPHRIS.xml:S1:27974:5	I-Severity
L.	SAPHRIS.xml:S1:27980:2	I-Severity

In	SAPHRIS.xml:S1:27987:2	O
a	SAPHRIS.xml:S1:27990:1	O
3	SAPHRIS.xml:S1:27992:1	O
-	SAPHRIS.xml:S1:27993:1	O
week	SAPHRIS.xml:S1:27994:4	O
,	SAPHRIS.xml:S1:27998:1	O
placebo	SAPHRIS.xml:S1:28000:7	O
-	SAPHRIS.xml:S1:28007:1	O
controlled	SAPHRIS.xml:S1:28008:10	O
pediatric	SAPHRIS.xml:S1:28019:9	O
trial	SAPHRIS.xml:S1:28029:5	O
with	SAPHRIS.xml:S1:28035:4	O
bipolar	SAPHRIS.xml:S1:28040:7	O
I	SAPHRIS.xml:S1:28048:1	O
disorder	SAPHRIS.xml:S1:28050:8	O
,	SAPHRIS.xml:S1:28058:1	O
transient	SAPHRIS.xml:S1:28060:9	O
elevations	SAPHRIS.xml:S1:28070:10	B-AdverseReaction
in	SAPHRIS.xml:S1:28081:2	I-AdverseReaction
serum	SAPHRIS.xml:S1:28084:5	I-AdverseReaction
transaminases	SAPHRIS.xml:S1:28090:13	I-AdverseReaction
(	SAPHRIS.xml:S1:28104:1	O
primarily	SAPHRIS.xml:S1:28105:9	O
ALT	SAPHRIS.xml:S1:28115:3	I-AdverseReaction
)	SAPHRIS.xml:S1:28118:1	O
were	SAPHRIS.xml:S1:28120:4	O
more	SAPHRIS.xml:S1:28125:4	O
common	SAPHRIS.xml:S1:28130:6	O
in	SAPHRIS.xml:S1:28137:2	O
treated	SAPHRIS.xml:S1:28140:7	O
patients	SAPHRIS.xml:S1:28148:8	O
.	SAPHRIS.xml:S1:28156:1	O

The	SAPHRIS.xml:S1:28158:3	O
proportion	SAPHRIS.xml:S1:28162:10	O
of	SAPHRIS.xml:S1:28173:2	O
pediatric	SAPHRIS.xml:S1:28176:9	O
patients	SAPHRIS.xml:S1:28186:8	O
with	SAPHRIS.xml:S1:28195:4	O
ALT	SAPHRIS.xml:S1:28200:3	B-AdverseReaction
elevations	SAPHRIS.xml:S1:28204:10	I-AdverseReaction
3	SAPHRIS.xml:S1:28217:1	B-Severity
times	SAPHRIS.xml:S1:28219:5	I-Severity
upper	SAPHRIS.xml:S1:28225:5	I-Severity
limit	SAPHRIS.xml:S1:28231:5	I-Severity
of	SAPHRIS.xml:S1:28237:2	I-Severity
normal	SAPHRIS.xml:S1:28240:6	I-Severity
(	SAPHRIS.xml:S1:28247:1	I-Severity
ULN	SAPHRIS.xml:S1:28248:3	I-Severity
)	SAPHRIS.xml:S1:28251:1	I-Severity
was	SAPHRIS.xml:S1:28253:3	O
2.4%	SAPHRIS.xml:S1:28257:4	O
for	SAPHRIS.xml:S1:28262:3	O
patients	SAPHRIS.xml:S1:28266:8	O
treated	SAPHRIS.xml:S1:28275:7	O
with	SAPHRIS.xml:S1:28283:4	O
SAPHRIS	SAPHRIS.xml:S1:28288:7	O
10	SAPHRIS.xml:S1:28296:2	O
mg	SAPHRIS.xml:S1:28299:2	O
twice	SAPHRIS.xml:S1:28302:5	O
daily	SAPHRIS.xml:S1:28308:5	O
versus	SAPHRIS.xml:S1:28314:6	O
none	SAPHRIS.xml:S1:28321:4	O
for	SAPHRIS.xml:S1:28326:3	O
the	SAPHRIS.xml:S1:28330:3	O
other	SAPHRIS.xml:S1:28334:5	O
SAPHRIS	SAPHRIS.xml:S1:28340:7	O
dose	SAPHRIS.xml:S1:28348:4	O
groups	SAPHRIS.xml:S1:28353:6	O
and	SAPHRIS.xml:S1:28360:3	O
placebo	SAPHRIS.xml:S1:28364:7	O
-	SAPHRIS.xml:S1:28371:1	O
treated	SAPHRIS.xml:S1:28372:7	O
patients	SAPHRIS.xml:S1:28380:8	O
.	SAPHRIS.xml:S1:28388:1	O

Prolactin	SAPHRIS.xml:S1:28398:9	O
:	SAPHRIS.xml:S1:28407:1	O
In	SAPHRIS.xml:S1:28410:2	O
short	SAPHRIS.xml:S1:28413:5	O
-	SAPHRIS.xml:S1:28418:1	O
term	SAPHRIS.xml:S1:28419:4	O
,	SAPHRIS.xml:S1:28423:1	O
placebo	SAPHRIS.xml:S1:28425:7	O
-	SAPHRIS.xml:S1:28432:1	O
controlled	SAPHRIS.xml:S1:28433:10	O
adult	SAPHRIS.xml:S1:28444:5	O
schizophrenia	SAPHRIS.xml:S1:28450:13	O
trials	SAPHRIS.xml:S1:28464:6	O
,	SAPHRIS.xml:S1:28470:1	O
the	SAPHRIS.xml:S1:28472:3	O
mean	SAPHRIS.xml:S1:28476:4	O
decreases	SAPHRIS.xml:S1:28481:9	B-AdverseReaction
in	SAPHRIS.xml:S1:28491:2	I-AdverseReaction
prolactin	SAPHRIS.xml:S1:28494:9	I-AdverseReaction
levels	SAPHRIS.xml:S1:28504:6	I-AdverseReaction
were	SAPHRIS.xml:S1:28511:4	O
6.5	SAPHRIS.xml:S1:28516:3	O
ng	SAPHRIS.xml:S1:28520:2	O
mL	SAPHRIS.xml:S1:28523:2	O
for	SAPHRIS.xml:S1:28526:3	O
SAPHRIS	SAPHRIS.xml:S1:28530:7	O
-	SAPHRIS.xml:S1:28537:1	O
treated	SAPHRIS.xml:S1:28538:7	O
patients	SAPHRIS.xml:S1:28546:8	O
compared	SAPHRIS.xml:S1:28555:8	O
to	SAPHRIS.xml:S1:28564:2	O
10.7	SAPHRIS.xml:S1:28567:4	O
ng	SAPHRIS.xml:S1:28572:2	O
mL	SAPHRIS.xml:S1:28575:2	O
for	SAPHRIS.xml:S1:28578:3	O
placebo	SAPHRIS.xml:S1:28582:7	O
-	SAPHRIS.xml:S1:28589:1	O
treated	SAPHRIS.xml:S1:28590:7	O
patients	SAPHRIS.xml:S1:28598:8	O
.	SAPHRIS.xml:S1:28606:1	O

The	SAPHRIS.xml:S1:28608:3	O
proportion	SAPHRIS.xml:S1:28612:10	O
of	SAPHRIS.xml:S1:28623:2	O
patients	SAPHRIS.xml:S1:28626:8	O
with	SAPHRIS.xml:S1:28635:4	O
prolactin	SAPHRIS.xml:S1:28640:9	B-AdverseReaction
elevations	SAPHRIS.xml:S1:28650:10	I-AdverseReaction
4	SAPHRIS.xml:S1:28663:1	B-Severity
times	SAPHRIS.xml:S1:28665:5	I-Severity
ULN	SAPHRIS.xml:S1:28671:3	I-Severity
(	SAPHRIS.xml:S1:28675:1	O
at	SAPHRIS.xml:S1:28676:2	O
Endpoint	SAPHRIS.xml:S1:28679:8	O
)	SAPHRIS.xml:S1:28687:1	O
were	SAPHRIS.xml:S1:28689:4	O
2.6%	SAPHRIS.xml:S1:28694:4	O
for	SAPHRIS.xml:S1:28699:3	O
SAPHRIS	SAPHRIS.xml:S1:28703:7	O
-	SAPHRIS.xml:S1:28710:1	O
treated	SAPHRIS.xml:S1:28711:7	O
patients	SAPHRIS.xml:S1:28719:8	O
versus	SAPHRIS.xml:S1:28728:6	O
0.6%	SAPHRIS.xml:S1:28735:4	O
for	SAPHRIS.xml:S1:28740:3	O
placebo	SAPHRIS.xml:S1:28744:7	O
-	SAPHRIS.xml:S1:28751:1	O
treated	SAPHRIS.xml:S1:28752:7	O
patients	SAPHRIS.xml:S1:28760:8	O
.	SAPHRIS.xml:S1:28768:1	O

In	SAPHRIS.xml:S1:28770:2	O
short	SAPHRIS.xml:S1:28773:5	O
-	SAPHRIS.xml:S1:28778:1	O
term	SAPHRIS.xml:S1:28779:4	O
,	SAPHRIS.xml:S1:28783:1	O
placebo	SAPHRIS.xml:S1:28785:7	O
-	SAPHRIS.xml:S1:28792:1	O
controlled	SAPHRIS.xml:S1:28793:10	O
bipolar	SAPHRIS.xml:S1:28804:7	O
mania	SAPHRIS.xml:S1:28812:5	O
adult	SAPHRIS.xml:S1:28818:5	O
trials	SAPHRIS.xml:S1:28824:6	O
,	SAPHRIS.xml:S1:28830:1	O
the	SAPHRIS.xml:S1:28832:3	O
mean	SAPHRIS.xml:S1:28836:4	O
increase	SAPHRIS.xml:S1:28841:8	B-AdverseReaction
in	SAPHRIS.xml:S1:28850:2	I-AdverseReaction
prolactin	SAPHRIS.xml:S1:28853:9	I-AdverseReaction
levels	SAPHRIS.xml:S1:28863:6	I-AdverseReaction
was	SAPHRIS.xml:S1:28870:3	O
4.9	SAPHRIS.xml:S1:28874:3	O
ng	SAPHRIS.xml:S1:28878:2	O
mL	SAPHRIS.xml:S1:28881:2	O
for	SAPHRIS.xml:S1:28884:3	O
SAPHRIS	SAPHRIS.xml:S1:28888:7	O
-	SAPHRIS.xml:S1:28895:1	O
treated	SAPHRIS.xml:S1:28896:7	O
patients	SAPHRIS.xml:S1:28904:8	O
compared	SAPHRIS.xml:S1:28913:8	O
to	SAPHRIS.xml:S1:28922:2	O
a	SAPHRIS.xml:S1:28925:1	O
decrease	SAPHRIS.xml:S1:28927:8	O
of	SAPHRIS.xml:S1:28936:2	O
0.2	SAPHRIS.xml:S1:28939:3	O
ng	SAPHRIS.xml:S1:28943:2	O
mL	SAPHRIS.xml:S1:28946:2	O
for	SAPHRIS.xml:S1:28949:3	O
placebo	SAPHRIS.xml:S1:28953:7	O
-	SAPHRIS.xml:S1:28960:1	O
treated	SAPHRIS.xml:S1:28961:7	O
patients	SAPHRIS.xml:S1:28969:8	O
.	SAPHRIS.xml:S1:28977:1	O

The	SAPHRIS.xml:S1:28979:3	O
proportion	SAPHRIS.xml:S1:28983:10	O
of	SAPHRIS.xml:S1:28994:2	O
patients	SAPHRIS.xml:S1:28997:8	O
with	SAPHRIS.xml:S1:29006:4	O
prolactin	SAPHRIS.xml:S1:29011:9	B-AdverseReaction
elevations	SAPHRIS.xml:S1:29021:10	I-AdverseReaction
4	SAPHRIS.xml:S1:29034:1	B-Severity
times	SAPHRIS.xml:S1:29036:5	I-Severity
ULN	SAPHRIS.xml:S1:29042:3	I-Severity
(	SAPHRIS.xml:S1:29046:1	O
at	SAPHRIS.xml:S1:29047:2	O
Endpoint	SAPHRIS.xml:S1:29050:8	O
)	SAPHRIS.xml:S1:29058:1	O
were	SAPHRIS.xml:S1:29060:4	O
2.3%	SAPHRIS.xml:S1:29065:4	O
for	SAPHRIS.xml:S1:29070:3	O
SAPHRIS	SAPHRIS.xml:S1:29074:7	O
-	SAPHRIS.xml:S1:29081:1	O
treated	SAPHRIS.xml:S1:29082:7	O
patients	SAPHRIS.xml:S1:29090:8	O
versus	SAPHRIS.xml:S1:29099:6	O
0.7%	SAPHRIS.xml:S1:29106:4	O
for	SAPHRIS.xml:S1:29111:3	O
placebo	SAPHRIS.xml:S1:29115:7	O
-	SAPHRIS.xml:S1:29122:1	O
treated	SAPHRIS.xml:S1:29123:7	O
patients	SAPHRIS.xml:S1:29131:8	O
.	SAPHRIS.xml:S1:29139:1	O

In	SAPHRIS.xml:S1:29145:2	O
a	SAPHRIS.xml:S1:29148:1	O
long	SAPHRIS.xml:S1:29150:4	O
-	SAPHRIS.xml:S1:29154:1	O
term	SAPHRIS.xml:S1:29155:4	O
(	SAPHRIS.xml:S1:29160:1	O
52	SAPHRIS.xml:S1:29161:2	O
-	SAPHRIS.xml:S1:29163:1	O
week	SAPHRIS.xml:S1:29164:4	O
)	SAPHRIS.xml:S1:29168:1	O
,	SAPHRIS.xml:S1:29169:1	O
double	SAPHRIS.xml:S1:29171:6	O
-	SAPHRIS.xml:S1:29177:1	O
blind	SAPHRIS.xml:S1:29178:5	O
,	SAPHRIS.xml:S1:29183:1	O
comparator	SAPHRIS.xml:S1:29185:10	O
-	SAPHRIS.xml:S1:29195:1	O
controlled	SAPHRIS.xml:S1:29196:10	O
adult	SAPHRIS.xml:S1:29207:5	O
trial	SAPHRIS.xml:S1:29213:5	O
that	SAPHRIS.xml:S1:29219:4	O
included	SAPHRIS.xml:S1:29224:8	O
primarily	SAPHRIS.xml:S1:29233:9	O
patients	SAPHRIS.xml:S1:29243:8	O
with	SAPHRIS.xml:S1:29252:4	O
schizophrenia	SAPHRIS.xml:S1:29257:13	O
,	SAPHRIS.xml:S1:29270:1	O
the	SAPHRIS.xml:S1:29272:3	O
mean	SAPHRIS.xml:S1:29276:4	O
decrease	SAPHRIS.xml:S1:29281:8	B-AdverseReaction
in	SAPHRIS.xml:S1:29290:2	I-AdverseReaction
prolactin	SAPHRIS.xml:S1:29293:9	I-AdverseReaction
from	SAPHRIS.xml:S1:29303:4	O
baseline	SAPHRIS.xml:S1:29308:8	O
for	SAPHRIS.xml:S1:29317:3	O
SAPHRIS	SAPHRIS.xml:S1:29321:7	O
-	SAPHRIS.xml:S1:29328:1	O
treated	SAPHRIS.xml:S1:29329:7	O
patients	SAPHRIS.xml:S1:29337:8	O
was	SAPHRIS.xml:S1:29346:3	O
26.9	SAPHRIS.xml:S1:29350:4	O
ng	SAPHRIS.xml:S1:29355:2	O
mL	SAPHRIS.xml:S1:29358:2	O
.	SAPHRIS.xml:S1:29360:1	O

In	SAPHRIS.xml:S1:29366:2	O
a	SAPHRIS.xml:S1:29369:1	O
3	SAPHRIS.xml:S1:29371:1	O
-	SAPHRIS.xml:S1:29372:1	O
week	SAPHRIS.xml:S1:29373:4	O
,	SAPHRIS.xml:S1:29377:1	O
placebo	SAPHRIS.xml:S1:29379:7	O
-	SAPHRIS.xml:S1:29386:1	O
controlled	SAPHRIS.xml:S1:29387:10	O
pediatric	SAPHRIS.xml:S1:29398:9	O
trial	SAPHRIS.xml:S1:29408:5	O
with	SAPHRIS.xml:S1:29414:4	O
bipolar	SAPHRIS.xml:S1:29419:7	O
I	SAPHRIS.xml:S1:29427:1	O
disorder	SAPHRIS.xml:S1:29429:8	O
,	SAPHRIS.xml:S1:29437:1	O
the	SAPHRIS.xml:S1:29439:3	O
mean	SAPHRIS.xml:S1:29443:4	O
increases	SAPHRIS.xml:S1:29448:9	B-AdverseReaction
(	SAPHRIS.xml:S1:29458:1	O
at	SAPHRIS.xml:S1:29459:2	O
Endpoint	SAPHRIS.xml:S1:29462:8	O
)	SAPHRIS.xml:S1:29470:1	O
in	SAPHRIS.xml:S1:29472:2	I-AdverseReaction
prolactin	SAPHRIS.xml:S1:29475:9	I-AdverseReaction
levels	SAPHRIS.xml:S1:29485:6	I-AdverseReaction
were	SAPHRIS.xml:S1:29492:4	O
3.2	SAPHRIS.xml:S1:29497:3	O
ng	SAPHRIS.xml:S1:29501:2	O
mL	SAPHRIS.xml:S1:29504:2	O
for	SAPHRIS.xml:S1:29507:3	O
patients	SAPHRIS.xml:S1:29511:8	O
treated	SAPHRIS.xml:S1:29520:7	O
with	SAPHRIS.xml:S1:29528:4	O
SAPHRIS	SAPHRIS.xml:S1:29533:7	O
2.5	SAPHRIS.xml:S1:29541:3	O
mg	SAPHRIS.xml:S1:29545:2	O
twice	SAPHRIS.xml:S1:29548:5	O
daily	SAPHRIS.xml:S1:29554:5	O
,	SAPHRIS.xml:S1:29559:1	O
2.1	SAPHRIS.xml:S1:29561:3	O
ng	SAPHRIS.xml:S1:29565:2	O
mL	SAPHRIS.xml:S1:29568:2	O
for	SAPHRIS.xml:S1:29571:3	O
patients	SAPHRIS.xml:S1:29575:8	O
treated	SAPHRIS.xml:S1:29584:7	O
with	SAPHRIS.xml:S1:29592:4	O
SAPHRIS	SAPHRIS.xml:S1:29597:7	O
5	SAPHRIS.xml:S1:29605:1	O
mg	SAPHRIS.xml:S1:29607:2	O
twice	SAPHRIS.xml:S1:29610:5	O
daily	SAPHRIS.xml:S1:29616:5	O
,	SAPHRIS.xml:S1:29621:1	O
and	SAPHRIS.xml:S1:29623:3	O
6.4	SAPHRIS.xml:S1:29627:3	O
ng	SAPHRIS.xml:S1:29631:2	O
mL	SAPHRIS.xml:S1:29634:2	O
for	SAPHRIS.xml:S1:29637:3	O
patients	SAPHRIS.xml:S1:29641:8	O
treated	SAPHRIS.xml:S1:29650:7	O
with	SAPHRIS.xml:S1:29658:4	O
SAPHRIS	SAPHRIS.xml:S1:29663:7	O
10	SAPHRIS.xml:S1:29671:2	O
mg	SAPHRIS.xml:S1:29674:2	O
twice	SAPHRIS.xml:S1:29677:5	O
daily	SAPHRIS.xml:S1:29683:5	O
compared	SAPHRIS.xml:S1:29689:8	O
to	SAPHRIS.xml:S1:29698:2	O
an	SAPHRIS.xml:S1:29701:2	O
increase	SAPHRIS.xml:S1:29704:8	O
of	SAPHRIS.xml:S1:29713:2	O
2.5	SAPHRIS.xml:S1:29716:3	O
ng	SAPHRIS.xml:S1:29720:2	O
mL	SAPHRIS.xml:S1:29723:2	O
for	SAPHRIS.xml:S1:29726:3	O
placebo	SAPHRIS.xml:S1:29730:7	O
-	SAPHRIS.xml:S1:29737:1	O
treated	SAPHRIS.xml:S1:29738:7	O
patients	SAPHRIS.xml:S1:29746:8	O
.	SAPHRIS.xml:S1:29754:1	O

There	SAPHRIS.xml:S1:29756:5	O
were	SAPHRIS.xml:S1:29762:4	O
no	SAPHRIS.xml:S1:29767:2	B-Negation
reports	SAPHRIS.xml:S1:29770:7	O
of	SAPHRIS.xml:S1:29778:2	O
prolactin	SAPHRIS.xml:S1:29781:9	B-AdverseReaction
elevations	SAPHRIS.xml:S1:29791:10	I-AdverseReaction
4	SAPHRIS.xml:S1:29804:1	B-Severity
times	SAPHRIS.xml:S1:29806:5	I-Severity
ULN	SAPHRIS.xml:S1:29812:3	I-Severity
(	SAPHRIS.xml:S1:29816:1	O
at	SAPHRIS.xml:S1:29817:2	O
Endpoint	SAPHRIS.xml:S1:29820:8	O
)	SAPHRIS.xml:S1:29828:1	O
for	SAPHRIS.xml:S1:29830:3	O
patients	SAPHRIS.xml:S1:29834:8	O
treated	SAPHRIS.xml:S1:29843:7	O
with	SAPHRIS.xml:S1:29851:4	O
SAPHRIS	SAPHRIS.xml:S1:29856:7	O
or	SAPHRIS.xml:S1:29864:2	O
placebo	SAPHRIS.xml:S1:29867:7	O
.	SAPHRIS.xml:S1:29874:1	O

Galactorrhea	SAPHRIS.xml:S1:29876:12	B-AdverseReaction
or	SAPHRIS.xml:S1:29889:2	O
dysmenorrhea	SAPHRIS.xml:S1:29892:12	B-AdverseReaction
were	SAPHRIS.xml:S1:29905:4	O
reported	SAPHRIS.xml:S1:29910:8	O
in	SAPHRIS.xml:S1:29919:2	O
0%	SAPHRIS.xml:S1:29922:2	O
of	SAPHRIS.xml:S1:29925:2	O
patients	SAPHRIS.xml:S1:29928:8	O
treated	SAPHRIS.xml:S1:29937:7	O
with	SAPHRIS.xml:S1:29945:4	O
SAPHRIS	SAPHRIS.xml:S1:29950:7	O
2.5	SAPHRIS.xml:S1:29958:3	O
mg	SAPHRIS.xml:S1:29962:2	O
twice	SAPHRIS.xml:S1:29965:5	O
daily	SAPHRIS.xml:S1:29971:5	O
,	SAPHRIS.xml:S1:29976:1	O
2%	SAPHRIS.xml:S1:29978:2	O
of	SAPHRIS.xml:S1:29981:2	O
patients	SAPHRIS.xml:S1:29984:8	O
treated	SAPHRIS.xml:S1:29993:7	O
with	SAPHRIS.xml:S1:30001:4	O
SAPHRIS	SAPHRIS.xml:S1:30006:7	O
5	SAPHRIS.xml:S1:30014:1	O
mg	SAPHRIS.xml:S1:30016:2	O
twice	SAPHRIS.xml:S1:30019:5	O
daily	SAPHRIS.xml:S1:30025:5	O
,	SAPHRIS.xml:S1:30030:1	O
and	SAPHRIS.xml:S1:30032:3	O
1%	SAPHRIS.xml:S1:30036:2	O
of	SAPHRIS.xml:S1:30039:2	O
patients	SAPHRIS.xml:S1:30042:8	O
treated	SAPHRIS.xml:S1:30051:7	O
with	SAPHRIS.xml:S1:30059:4	O
SAPHRIS	SAPHRIS.xml:S1:30064:7	O
10	SAPHRIS.xml:S1:30072:2	O
mg	SAPHRIS.xml:S1:30075:2	O
twice	SAPHRIS.xml:S1:30078:5	O
daily	SAPHRIS.xml:S1:30084:5	O
compared	SAPHRIS.xml:S1:30090:8	O
to	SAPHRIS.xml:S1:30099:2	O
1%	SAPHRIS.xml:S1:30102:2	O
of	SAPHRIS.xml:S1:30105:2	O
placebo	SAPHRIS.xml:S1:30108:7	O
-	SAPHRIS.xml:S1:30115:1	O
treated	SAPHRIS.xml:S1:30116:7	O
patients	SAPHRIS.xml:S1:30124:8	O
.	SAPHRIS.xml:S1:30132:1	O

There	SAPHRIS.xml:S1:30134:5	O
were	SAPHRIS.xml:S1:30140:4	O
no	SAPHRIS.xml:S1:30145:2	B-Negation
reports	SAPHRIS.xml:S1:30148:7	O
of	SAPHRIS.xml:S1:30156:2	O
gynecomastia	SAPHRIS.xml:S1:30159:12	B-AdverseReaction
in	SAPHRIS.xml:S1:30172:2	O
this	SAPHRIS.xml:S1:30175:4	O
trial	SAPHRIS.xml:S1:30180:5	O
.	SAPHRIS.xml:S1:30185:1	O

Creatine	SAPHRIS.xml:S1:30195:8	O
Kinase	SAPHRIS.xml:S1:30204:6	O
(	SAPHRIS.xml:S1:30211:1	O
CK	SAPHRIS.xml:S1:30212:2	O
)	SAPHRIS.xml:S1:30214:1	O
:	SAPHRIS.xml:S1:30215:1	O
The	SAPHRIS.xml:S1:30218:3	O
proportion	SAPHRIS.xml:S1:30222:10	O
of	SAPHRIS.xml:S1:30233:2	O
adult	SAPHRIS.xml:S1:30236:5	O
patients	SAPHRIS.xml:S1:30242:8	O
with	SAPHRIS.xml:S1:30251:4	O
CK	SAPHRIS.xml:S1:30256:2	B-AdverseReaction
elevations	SAPHRIS.xml:S1:30259:10	I-AdverseReaction
3	SAPHRIS.xml:S1:30271:1	B-Severity
times	SAPHRIS.xml:S1:30273:5	I-Severity
ULN	SAPHRIS.xml:S1:30279:3	I-Severity
at	SAPHRIS.xml:S1:30283:2	O
any	SAPHRIS.xml:S1:30286:3	O
time	SAPHRIS.xml:S1:30290:4	O
were	SAPHRIS.xml:S1:30295:4	O
6.4%	SAPHRIS.xml:S1:30300:4	O
and	SAPHRIS.xml:S1:30305:3	O
11.1%	SAPHRIS.xml:S1:30309:5	O
for	SAPHRIS.xml:S1:30315:3	O
patients	SAPHRIS.xml:S1:30319:8	O
treated	SAPHRIS.xml:S1:30328:7	O
with	SAPHRIS.xml:S1:30336:4	O
SAPHRIS	SAPHRIS.xml:S1:30341:7	O
5	SAPHRIS.xml:S1:30349:1	O
mg	SAPHRIS.xml:S1:30351:2	O
twice	SAPHRIS.xml:S1:30354:5	O
daily	SAPHRIS.xml:S1:30360:5	O
and	SAPHRIS.xml:S1:30366:3	O
10	SAPHRIS.xml:S1:30370:2	O
mg	SAPHRIS.xml:S1:30373:2	O
twice	SAPHRIS.xml:S1:30376:5	O
daily	SAPHRIS.xml:S1:30382:5	O
,	SAPHRIS.xml:S1:30387:1	O
respectively	SAPHRIS.xml:S1:30389:12	O
,	SAPHRIS.xml:S1:30401:1	O
as	SAPHRIS.xml:S1:30403:2	O
compared	SAPHRIS.xml:S1:30406:8	O
to	SAPHRIS.xml:S1:30415:2	O
6.7%	SAPHRIS.xml:S1:30418:4	O
for	SAPHRIS.xml:S1:30423:3	O
placebo	SAPHRIS.xml:S1:30427:7	O
-	SAPHRIS.xml:S1:30434:1	O
treated	SAPHRIS.xml:S1:30435:7	O
patients	SAPHRIS.xml:S1:30443:8	O
in	SAPHRIS.xml:S1:30452:2	O
short	SAPHRIS.xml:S1:30455:5	O
-	SAPHRIS.xml:S1:30460:1	O
term	SAPHRIS.xml:S1:30461:4	O
,	SAPHRIS.xml:S1:30465:1	O
fixed	SAPHRIS.xml:S1:30467:5	O
-	SAPHRIS.xml:S1:30472:1	O
dose	SAPHRIS.xml:S1:30473:4	O
trials	SAPHRIS.xml:S1:30478:6	O
in	SAPHRIS.xml:S1:30485:2	O
schizophrenia	SAPHRIS.xml:S1:30488:13	O
and	SAPHRIS.xml:S1:30502:3	O
bipolar	SAPHRIS.xml:S1:30506:7	O
mania	SAPHRIS.xml:S1:30514:5	O
.	SAPHRIS.xml:S1:30519:1	O

The	SAPHRIS.xml:S1:30521:3	O
clinical	SAPHRIS.xml:S1:30525:8	O
relevance	SAPHRIS.xml:S1:30534:9	O
of	SAPHRIS.xml:S1:30544:2	O
this	SAPHRIS.xml:S1:30547:4	O
finding	SAPHRIS.xml:S1:30552:7	O
is	SAPHRIS.xml:S1:30560:2	O
unknown	SAPHRIS.xml:S1:30563:7	O
.	SAPHRIS.xml:S1:30570:1	O

The	SAPHRIS.xml:S1:30576:3	O
proportion	SAPHRIS.xml:S1:30580:10	O
of	SAPHRIS.xml:S1:30591:2	O
patients	SAPHRIS.xml:S1:30594:8	O
with	SAPHRIS.xml:S1:30603:4	O
CK	SAPHRIS.xml:S1:30608:2	B-AdverseReaction
elevations	SAPHRIS.xml:S1:30611:10	I-AdverseReaction
3	SAPHRIS.xml:S1:30624:1	B-Severity
times	SAPHRIS.xml:S1:30626:5	I-Severity
ULN	SAPHRIS.xml:S1:30632:3	I-Severity
during	SAPHRIS.xml:S1:30636:6	O
a	SAPHRIS.xml:S1:30643:1	O
3	SAPHRIS.xml:S1:30645:1	O
-	SAPHRIS.xml:S1:30646:1	O
week	SAPHRIS.xml:S1:30647:4	O
trial	SAPHRIS.xml:S1:30652:5	O
in	SAPHRIS.xml:S1:30658:2	O
pediatric	SAPHRIS.xml:S1:30661:9	O
bipolar	SAPHRIS.xml:S1:30671:7	O
I	SAPHRIS.xml:S1:30679:1	O
disorder	SAPHRIS.xml:S1:30681:8	O
at	SAPHRIS.xml:S1:30690:2	O
any	SAPHRIS.xml:S1:30693:3	O
time	SAPHRIS.xml:S1:30697:4	O
were	SAPHRIS.xml:S1:30702:4	O
1%	SAPHRIS.xml:S1:30707:2	O
,	SAPHRIS.xml:S1:30709:1	O
0%	SAPHRIS.xml:S1:30711:2	O
,	SAPHRIS.xml:S1:30713:1	O
and	SAPHRIS.xml:S1:30715:3	O
1%	SAPHRIS.xml:S1:30719:2	O
for	SAPHRIS.xml:S1:30722:3	O
patients	SAPHRIS.xml:S1:30726:8	O
treated	SAPHRIS.xml:S1:30735:7	O
with	SAPHRIS.xml:S1:30743:4	O
SAPHRIS	SAPHRIS.xml:S1:30748:7	O
2.5	SAPHRIS.xml:S1:30756:3	O
mg	SAPHRIS.xml:S1:30760:2	O
,	SAPHRIS.xml:S1:30762:1	O
5	SAPHRIS.xml:S1:30764:1	O
mg	SAPHRIS.xml:S1:30766:2	O
,	SAPHRIS.xml:S1:30768:1	O
and	SAPHRIS.xml:S1:30770:3	O
10	SAPHRIS.xml:S1:30774:2	O
mg	SAPHRIS.xml:S1:30777:2	O
twice	SAPHRIS.xml:S1:30780:5	O
daily	SAPHRIS.xml:S1:30786:5	O
,	SAPHRIS.xml:S1:30791:1	O
respectively	SAPHRIS.xml:S1:30793:12	O
,	SAPHRIS.xml:S1:30805:1	O
versus	SAPHRIS.xml:S1:30807:6	O
3%	SAPHRIS.xml:S1:30814:2	O
for	SAPHRIS.xml:S1:30817:3	O
placebo	SAPHRIS.xml:S1:30821:7	O
-	SAPHRIS.xml:S1:30828:1	O
treated	SAPHRIS.xml:S1:30829:7	O
patients	SAPHRIS.xml:S1:30837:8	O
.	SAPHRIS.xml:S1:30845:1	O

Other	SAPHRIS.xml:S1:30855:5	O
Adverse	SAPHRIS.xml:S1:30861:7	O
Reactions	SAPHRIS.xml:S1:30869:9	O
Observed	SAPHRIS.xml:S1:30879:8	O
During	SAPHRIS.xml:S1:30888:6	O
the	SAPHRIS.xml:S1:30895:3	O
Premarketing	SAPHRIS.xml:S1:30899:12	O
Evaluation	SAPHRIS.xml:S1:30912:10	O
of	SAPHRIS.xml:S1:30923:2	O
SAPHRIS	SAPHRIS.xml:S1:30926:7	O
:	SAPHRIS.xml:S1:30933:1	O
Following	SAPHRIS.xml:S1:30936:9	O
is	SAPHRIS.xml:S1:30946:2	O
a	SAPHRIS.xml:S1:30949:1	O
list	SAPHRIS.xml:S1:30951:4	O
of	SAPHRIS.xml:S1:30956:2	O
MedDRA	SAPHRIS.xml:S1:30959:6	O
terms	SAPHRIS.xml:S1:30966:5	O
that	SAPHRIS.xml:S1:30972:4	O
reflect	SAPHRIS.xml:S1:30977:7	O
adverse	SAPHRIS.xml:S1:30985:7	O
reactions	SAPHRIS.xml:S1:30993:9	O
reported	SAPHRIS.xml:S1:31003:8	O
by	SAPHRIS.xml:S1:31012:2	O
patients	SAPHRIS.xml:S1:31015:8	O
treated	SAPHRIS.xml:S1:31024:7	O
with	SAPHRIS.xml:S1:31032:4	O
sublingual	SAPHRIS.xml:S1:31037:10	O
SAPHRIS	SAPHRIS.xml:S1:31048:7	O
at	SAPHRIS.xml:S1:31056:2	O
multiple	SAPHRIS.xml:S1:31059:8	O
doses	SAPHRIS.xml:S1:31068:5	O
of	SAPHRIS.xml:S1:31074:2	O
5	SAPHRIS.xml:S1:31079:1	O
mg	SAPHRIS.xml:S1:31081:2	O
twice	SAPHRIS.xml:S1:31084:5	O
daily	SAPHRIS.xml:S1:31090:5	O
during	SAPHRIS.xml:S1:31096:6	O
any	SAPHRIS.xml:S1:31103:3	O
phase	SAPHRIS.xml:S1:31107:5	O
of	SAPHRIS.xml:S1:31113:2	O
a	SAPHRIS.xml:S1:31116:1	O
trial	SAPHRIS.xml:S1:31118:5	O
within	SAPHRIS.xml:S1:31124:6	O
the	SAPHRIS.xml:S1:31131:3	O
database	SAPHRIS.xml:S1:31135:8	O
of	SAPHRIS.xml:S1:31144:2	O
adult	SAPHRIS.xml:S1:31147:5	O
patients	SAPHRIS.xml:S1:31153:8	O
.	SAPHRIS.xml:S1:31161:1	O

The	SAPHRIS.xml:S1:31163:3	O
reactions	SAPHRIS.xml:S1:31167:9	O
listed	SAPHRIS.xml:S1:31177:6	O
are	SAPHRIS.xml:S1:31184:3	O
those	SAPHRIS.xml:S1:31188:5	O
that	SAPHRIS.xml:S1:31194:4	O
could	SAPHRIS.xml:S1:31199:5	O
be	SAPHRIS.xml:S1:31205:2	O
of	SAPHRIS.xml:S1:31208:2	O
clinical	SAPHRIS.xml:S1:31211:8	O
importance	SAPHRIS.xml:S1:31220:10	O
,	SAPHRIS.xml:S1:31230:1	O
as	SAPHRIS.xml:S1:31232:2	O
well	SAPHRIS.xml:S1:31235:4	O
as	SAPHRIS.xml:S1:31240:2	O
reactions	SAPHRIS.xml:S1:31243:9	O
that	SAPHRIS.xml:S1:31253:4	O
are	SAPHRIS.xml:S1:31258:3	O
plausibly	SAPHRIS.xml:S1:31262:9	O
drug	SAPHRIS.xml:S1:31272:4	O
-	SAPHRIS.xml:S1:31276:1	O
related	SAPHRIS.xml:S1:31277:7	O
on	SAPHRIS.xml:S1:31285:2	O
pharmacologic	SAPHRIS.xml:S1:31288:13	O
or	SAPHRIS.xml:S1:31302:2	O
other	SAPHRIS.xml:S1:31305:5	O
grounds	SAPHRIS.xml:S1:31311:7	O
.	SAPHRIS.xml:S1:31318:1	O

Reactions	SAPHRIS.xml:S1:31320:9	O
already	SAPHRIS.xml:S1:31330:7	O
listed	SAPHRIS.xml:S1:31338:6	O
for	SAPHRIS.xml:S1:31345:3	O
either	SAPHRIS.xml:S1:31349:6	O
adults	SAPHRIS.xml:S1:31356:6	O
or	SAPHRIS.xml:S1:31363:2	O
pediatric	SAPHRIS.xml:S1:31366:9	O
patients	SAPHRIS.xml:S1:31376:8	O
in	SAPHRIS.xml:S1:31385:2	O
other	SAPHRIS.xml:S1:31388:5	O
parts	SAPHRIS.xml:S1:31394:5	O
of	SAPHRIS.xml:S1:31400:2	O
Adverse	SAPHRIS.xml:S1:31404:7	O
Reactions	SAPHRIS.xml:S1:31412:9	O
(	SAPHRIS.xml:S1:31422:1	O
6	SAPHRIS.xml:S1:31423:1	O
)	SAPHRIS.xml:S1:31424:1	O
,	SAPHRIS.xml:S1:31427:1	O
or	SAPHRIS.xml:S1:31429:2	O
those	SAPHRIS.xml:S1:31432:5	O
considered	SAPHRIS.xml:S1:31438:10	O
in	SAPHRIS.xml:S1:31449:2	O
Contraindications	SAPHRIS.xml:S1:31453:17	O
(	SAPHRIS.xml:S1:31471:1	O
4	SAPHRIS.xml:S1:31472:1	O
)	SAPHRIS.xml:S1:31473:1	O
,	SAPHRIS.xml:S1:31474:1	O
Warnings	SAPHRIS.xml:S1:31476:8	O
and	SAPHRIS.xml:S1:31485:3	O
Precautions	SAPHRIS.xml:S1:31489:11	O
(	SAPHRIS.xml:S1:31501:1	O
5	SAPHRIS.xml:S1:31502:1	O
)	SAPHRIS.xml:S1:31503:1	O
or	SAPHRIS.xml:S1:31506:2	O
Overdosage	SAPHRIS.xml:S1:31510:10	O
(	SAPHRIS.xml:S1:31521:1	O
10	SAPHRIS.xml:S1:31522:2	O
)	SAPHRIS.xml:S1:31524:1	O
are	SAPHRIS.xml:S1:31527:3	O
not	SAPHRIS.xml:S1:31531:3	O
included	SAPHRIS.xml:S1:31535:8	O
.	SAPHRIS.xml:S1:31543:1	O

Reactions	SAPHRIS.xml:S1:31545:9	O
are	SAPHRIS.xml:S1:31555:3	O
further	SAPHRIS.xml:S1:31559:7	O
categorized	SAPHRIS.xml:S1:31567:11	O
by	SAPHRIS.xml:S1:31579:2	O
MedDRA	SAPHRIS.xml:S1:31582:6	O
system	SAPHRIS.xml:S1:31589:6	O
organ	SAPHRIS.xml:S1:31596:5	O
class	SAPHRIS.xml:S1:31602:5	O
and	SAPHRIS.xml:S1:31608:3	O
listed	SAPHRIS.xml:S1:31612:6	O
in	SAPHRIS.xml:S1:31619:2	O
order	SAPHRIS.xml:S1:31622:5	O
of	SAPHRIS.xml:S1:31628:2	O
decreasing	SAPHRIS.xml:S1:31631:10	O
frequency	SAPHRIS.xml:S1:31642:9	O
according	SAPHRIS.xml:S1:31652:9	O
to	SAPHRIS.xml:S1:31662:2	O
the	SAPHRIS.xml:S1:31665:3	O
following	SAPHRIS.xml:S1:31669:9	O
definitions	SAPHRIS.xml:S1:31679:11	O
:	SAPHRIS.xml:S1:31690:1	O
those	SAPHRIS.xml:S1:31692:5	O
occurring	SAPHRIS.xml:S1:31698:9	O
in	SAPHRIS.xml:S1:31708:2	O
at	SAPHRIS.xml:S1:31711:2	O
least	SAPHRIS.xml:S1:31714:5	O
1	SAPHRIS.xml:S1:31720:1	O
100	SAPHRIS.xml:S1:31722:3	O
patients	SAPHRIS.xml:S1:31726:8	O
(	SAPHRIS.xml:S1:31735:1	O
frequent	SAPHRIS.xml:S1:31736:8	O
)	SAPHRIS.xml:S1:31744:1	O
(	SAPHRIS.xml:S1:31746:1	O
only	SAPHRIS.xml:S1:31747:4	O
those	SAPHRIS.xml:S1:31752:5	O
not	SAPHRIS.xml:S1:31758:3	O
already	SAPHRIS.xml:S1:31762:7	O
listed	SAPHRIS.xml:S1:31770:6	O
in	SAPHRIS.xml:S1:31777:2	O
the	SAPHRIS.xml:S1:31780:3	O
tabulated	SAPHRIS.xml:S1:31784:9	O
results	SAPHRIS.xml:S1:31794:7	O
from	SAPHRIS.xml:S1:31802:4	O
placebo	SAPHRIS.xml:S1:31807:7	O
-	SAPHRIS.xml:S1:31814:1	O
controlled	SAPHRIS.xml:S1:31815:10	O
trials	SAPHRIS.xml:S1:31826:6	O
appear	SAPHRIS.xml:S1:31833:6	O
in	SAPHRIS.xml:S1:31840:2	O
this	SAPHRIS.xml:S1:31843:4	O
listing	SAPHRIS.xml:S1:31848:7	O
)	SAPHRIS.xml:S1:31855:1	O
;	SAPHRIS.xml:S1:31856:1	O
those	SAPHRIS.xml:S1:31858:5	O
occurring	SAPHRIS.xml:S1:31864:9	O
in	SAPHRIS.xml:S1:31874:2	O
1	SAPHRIS.xml:S1:31877:1	O
100	SAPHRIS.xml:S1:31879:3	O
to	SAPHRIS.xml:S1:31883:2	O
1	SAPHRIS.xml:S1:31886:1	O
1000	SAPHRIS.xml:S1:31888:4	O
patients	SAPHRIS.xml:S1:31893:8	O
(	SAPHRIS.xml:S1:31902:1	O
infrequent	SAPHRIS.xml:S1:31903:10	O
)	SAPHRIS.xml:S1:31913:1	O
;	SAPHRIS.xml:S1:31914:1	O
and	SAPHRIS.xml:S1:31916:3	O
those	SAPHRIS.xml:S1:31920:5	O
occurring	SAPHRIS.xml:S1:31926:9	O
in	SAPHRIS.xml:S1:31936:2	O
fewer	SAPHRIS.xml:S1:31939:5	O
than	SAPHRIS.xml:S1:31945:4	O
1	SAPHRIS.xml:S1:31950:1	O
1000	SAPHRIS.xml:S1:31952:4	O
patients	SAPHRIS.xml:S1:31957:8	O
(	SAPHRIS.xml:S1:31966:1	O
rare	SAPHRIS.xml:S1:31967:4	O
)	SAPHRIS.xml:S1:31971:1	O
.	SAPHRIS.xml:S1:31972:1	O

Blood	SAPHRIS.xml:S1:31985:5	O
and	SAPHRIS.xml:S1:31991:3	O
lymphatic	SAPHRIS.xml:S1:31995:9	O
disorders	SAPHRIS.xml:S1:32005:9	O
:	SAPHRIS.xml:S1:32014:1	O
infrequent	SAPHRIS.xml:S1:32017:10	O
:	SAPHRIS.xml:S1:32027:1	O
anemia	SAPHRIS.xml:S1:32029:6	B-AdverseReaction
;	SAPHRIS.xml:S1:32035:1	O
rare	SAPHRIS.xml:S1:32037:4	O
:	SAPHRIS.xml:S1:32041:1	O
thrombocytopenia	SAPHRIS.xml:S1:32043:16	B-AdverseReaction

Cardiac	SAPHRIS.xml:S1:32069:7	O
disorders	SAPHRIS.xml:S1:32077:9	O
:	SAPHRIS.xml:S1:32086:1	O
infrequent	SAPHRIS.xml:S1:32089:10	O
:	SAPHRIS.xml:S1:32099:1	O
temporary	SAPHRIS.xml:S1:32101:9	B-AdverseReaction
bundle	SAPHRIS.xml:S1:32111:6	I-AdverseReaction
branch	SAPHRIS.xml:S1:32118:6	I-AdverseReaction
block	SAPHRIS.xml:S1:32125:5	I-AdverseReaction

Eye	SAPHRIS.xml:S1:32140:3	O
disorders	SAPHRIS.xml:S1:32144:9	O
:	SAPHRIS.xml:S1:32153:1	O
infrequent	SAPHRIS.xml:S1:32156:10	O
:	SAPHRIS.xml:S1:32166:1	O
accommodation	SAPHRIS.xml:S1:32168:13	B-AdverseReaction
disorder	SAPHRIS.xml:S1:32182:8	I-AdverseReaction

Gastrointestinal	SAPHRIS.xml:S1:32200:16	O
disorders	SAPHRIS.xml:S1:32217:9	O
:	SAPHRIS.xml:S1:32226:1	O
infrequent	SAPHRIS.xml:S1:32229:10	O
:	SAPHRIS.xml:S1:32239:1	O
swollen	SAPHRIS.xml:S1:32241:7	B-AdverseReaction
tongue	SAPHRIS.xml:S1:32249:6	I-AdverseReaction

General	SAPHRIS.xml:S1:32265:7	O
disorders	SAPHRIS.xml:S1:32273:9	O
:	SAPHRIS.xml:S1:32282:1	O
rare	SAPHRIS.xml:S1:32285:4	O
:	SAPHRIS.xml:S1:32289:1	O
idiosyncratic	SAPHRIS.xml:S1:32291:13	B-AdverseReaction
drug	SAPHRIS.xml:S1:32305:4	I-AdverseReaction
reaction	SAPHRIS.xml:S1:32310:8	I-AdverseReaction

Investigations	SAPHRIS.xml:S1:32328:14	O
:	SAPHRIS.xml:S1:32342:1	O
infrequent	SAPHRIS.xml:S1:32345:10	O
:	SAPHRIS.xml:S1:32355:1	O
hyponatremia	SAPHRIS.xml:S1:32357:12	B-AdverseReaction

Nervous	SAPHRIS.xml:S1:32379:7	O
system	SAPHRIS.xml:S1:32387:6	O
disorders	SAPHRIS.xml:S1:32394:9	O
:	SAPHRIS.xml:S1:32403:1	O
infrequent	SAPHRIS.xml:S1:32406:10	O
:	SAPHRIS.xml:S1:32416:1	O
dysarthria	SAPHRIS.xml:S1:32418:10	B-AdverseReaction

Following	SAPHRIS.xml:S1:32434:9	O
is	SAPHRIS.xml:S1:32444:2	O
a	SAPHRIS.xml:S1:32447:1	O
list	SAPHRIS.xml:S1:32449:4	O
of	SAPHRIS.xml:S1:32454:2	O
MedDRA	SAPHRIS.xml:S1:32457:6	O
terms	SAPHRIS.xml:S1:32464:5	O
not	SAPHRIS.xml:S1:32470:3	O
already	SAPHRIS.xml:S1:32474:7	O
listed	SAPHRIS.xml:S1:32482:6	O
either	SAPHRIS.xml:S1:32489:6	O
for	SAPHRIS.xml:S1:32496:3	O
adults	SAPHRIS.xml:S1:32500:6	O
or	SAPHRIS.xml:S1:32507:2	O
pediatric	SAPHRIS.xml:S1:32510:9	O
patients	SAPHRIS.xml:S1:32520:8	O
in	SAPHRIS.xml:S1:32529:2	O
other	SAPHRIS.xml:S1:32532:5	O
parts	SAPHRIS.xml:S1:32538:5	O
of	SAPHRIS.xml:S1:32544:2	O
Adverse	SAPHRIS.xml:S1:32548:7	O
Reactions	SAPHRIS.xml:S1:32556:9	O
(	SAPHRIS.xml:S1:32566:1	O
6	SAPHRIS.xml:S1:32567:1	O
)	SAPHRIS.xml:S1:32568:1	O
,	SAPHRIS.xml:S1:32571:1	O
or	SAPHRIS.xml:S1:32573:2	O
those	SAPHRIS.xml:S1:32576:5	O
considered	SAPHRIS.xml:S1:32582:10	O
in	SAPHRIS.xml:S1:32593:2	O
Contraindications	SAPHRIS.xml:S1:32597:17	O
(	SAPHRIS.xml:S1:32615:1	O
4	SAPHRIS.xml:S1:32616:1	O
)	SAPHRIS.xml:S1:32617:1	O
,	SAPHRIS.xml:S1:32618:1	O
Warnings	SAPHRIS.xml:S1:32620:8	O
and	SAPHRIS.xml:S1:32629:3	O
Precautions	SAPHRIS.xml:S1:32633:11	O
(	SAPHRIS.xml:S1:32645:1	O
5	SAPHRIS.xml:S1:32646:1	O
)	SAPHRIS.xml:S1:32647:1	O
or	SAPHRIS.xml:S1:32650:2	O
Overdosage	SAPHRIS.xml:S1:32654:10	O
(	SAPHRIS.xml:S1:32665:1	O
10	SAPHRIS.xml:S1:32666:2	O
)	SAPHRIS.xml:S1:32668:1	O
that	SAPHRIS.xml:S1:32671:4	O
reflect	SAPHRIS.xml:S1:32676:7	O
adverse	SAPHRIS.xml:S1:32684:7	O
reactions	SAPHRIS.xml:S1:32692:9	O
reported	SAPHRIS.xml:S1:32702:8	O
by	SAPHRIS.xml:S1:32711:2	O
pediatric	SAPHRIS.xml:S1:32714:9	O
patients	SAPHRIS.xml:S1:32724:8	O
(	SAPHRIS.xml:S1:32733:1	O
Ages	SAPHRIS.xml:S1:32734:4	O
10	SAPHRIS.xml:S1:32739:2	O
to	SAPHRIS.xml:S1:32742:2	O
17	SAPHRIS.xml:S1:32745:2	O
years	SAPHRIS.xml:S1:32748:5	O
)	SAPHRIS.xml:S1:32753:1	O
treated	SAPHRIS.xml:S1:32755:7	O
with	SAPHRIS.xml:S1:32763:4	O
sublingual	SAPHRIS.xml:S1:32768:10	O
SAPHRIS	SAPHRIS.xml:S1:32779:7	O
at	SAPHRIS.xml:S1:32787:2	O
doses	SAPHRIS.xml:S1:32790:5	O
of	SAPHRIS.xml:S1:32796:2	O
2.5	SAPHRIS.xml:S1:32799:3	O
mg	SAPHRIS.xml:S1:32803:2	O
,	SAPHRIS.xml:S1:32805:1	O
5	SAPHRIS.xml:S1:32807:1	O
mg	SAPHRIS.xml:S1:32809:2	O
,	SAPHRIS.xml:S1:32811:1	O
or	SAPHRIS.xml:S1:32813:2	O
10	SAPHRIS.xml:S1:32816:2	O
mg	SAPHRIS.xml:S1:32819:2	O
twice	SAPHRIS.xml:S1:32822:5	O
daily	SAPHRIS.xml:S1:32828:5	O
during	SAPHRIS.xml:S1:32834:6	O
any	SAPHRIS.xml:S1:32841:3	O
phase	SAPHRIS.xml:S1:32845:5	O
of	SAPHRIS.xml:S1:32851:2	O
a	SAPHRIS.xml:S1:32854:1	O
trial	SAPHRIS.xml:S1:32856:5	O
within	SAPHRIS.xml:S1:32862:6	O
the	SAPHRIS.xml:S1:32869:3	O
database	SAPHRIS.xml:S1:32873:8	O
of	SAPHRIS.xml:S1:32882:2	O
pediatric	SAPHRIS.xml:S1:32885:9	O
patients	SAPHRIS.xml:S1:32895:8	O
.	SAPHRIS.xml:S1:32903:1	O

Eye	SAPHRIS.xml:S1:32916:3	O

disorders	SAPHRIS.xml:S1:32920:9	O
:	SAPHRIS.xml:S1:32929:1	O
infrequent	SAPHRIS.xml:S1:32932:10	O
:	SAPHRIS.xml:S1:32942:1	O
diplopia	SAPHRIS.xml:S1:32944:8	B-AdverseReaction
,	SAPHRIS.xml:S1:32952:1	O
vision	SAPHRIS.xml:S1:32954:6	B-AdverseReaction
blurred	SAPHRIS.xml:S1:32961:7	I-AdverseReaction

Gastrointestinal	SAPHRIS.xml:S1:32978:16	O
disorders	SAPHRIS.xml:S1:32995:9	O
:	SAPHRIS.xml:S1:33004:1	O
infrequent	SAPHRIS.xml:S1:33007:10	O
:	SAPHRIS.xml:S1:33017:1	O
gastroesophageal	SAPHRIS.xml:S1:33019:16	B-AdverseReaction
reflux	SAPHRIS.xml:S1:33036:6	I-AdverseReaction
disease	SAPHRIS.xml:S1:33043:7	I-AdverseReaction

Injury	SAPHRIS.xml:S1:33060:6	O
,	SAPHRIS.xml:S1:33066:1	O
Poisoning	SAPHRIS.xml:S1:33068:9	O
,	SAPHRIS.xml:S1:33077:1	O
and	SAPHRIS.xml:S1:33079:3	O
Procedural	SAPHRIS.xml:S1:33083:10	O
Complications	SAPHRIS.xml:S1:33094:13	O
:	SAPHRIS.xml:S1:33107:1	O
infrequent	SAPHRIS.xml:S1:33110:10	O
:	SAPHRIS.xml:S1:33121:1	O
fall	SAPHRIS.xml:S1:33123:4	B-AdverseReaction

Skin	SAPHRIS.xml:S1:33137:4	O
and	SAPHRIS.xml:S1:33142:3	O
subcutaneous	SAPHRIS.xml:S1:33146:12	O
tissue	SAPHRIS.xml:S1:33159:6	O
disorders	SAPHRIS.xml:S1:33166:9	O
:	SAPHRIS.xml:S1:33175:1	O
infrequent	SAPHRIS.xml:S1:33178:10	O
:	SAPHRIS.xml:S1:33188:1	O
photosensitivity	SAPHRIS.xml:S1:33190:16	B-AdverseReaction
reaction	SAPHRIS.xml:S1:33207:8	I-AdverseReaction

Renal	SAPHRIS.xml:S1:33225:5	O
and	SAPHRIS.xml:S1:33231:3	O
urinary	SAPHRIS.xml:S1:33235:7	O
disorders	SAPHRIS.xml:S1:33243:9	O
:	SAPHRIS.xml:S1:33252:1	O
infrequent	SAPHRIS.xml:S1:33254:10	O
:	SAPHRIS.xml:S1:33264:1	O
enuresis	SAPHRIS.xml:S1:33267:8	B-AdverseReaction

6.2	SAPHRIS.xml:S1:33284:3	O
Postmarketing	SAPHRIS.xml:S1:33288:13	O
Experience	SAPHRIS.xml:S1:33302:10	O

The	SAPHRIS.xml:S1:33316:3	O
following	SAPHRIS.xml:S1:33320:9	O
adverse	SAPHRIS.xml:S1:33330:7	O
reactions	SAPHRIS.xml:S1:33338:9	O
have	SAPHRIS.xml:S1:33348:4	O
been	SAPHRIS.xml:S1:33353:4	O
identified	SAPHRIS.xml:S1:33358:10	O
during	SAPHRIS.xml:S1:33369:6	O
post	SAPHRIS.xml:S1:33376:4	O
-	SAPHRIS.xml:S1:33380:1	O
approval	SAPHRIS.xml:S1:33381:8	O
use	SAPHRIS.xml:S1:33390:3	O
of	SAPHRIS.xml:S1:33394:2	O
SAPHRIS	SAPHRIS.xml:S1:33397:7	O
.	SAPHRIS.xml:S1:33404:1	O

Because	SAPHRIS.xml:S1:33406:7	O
these	SAPHRIS.xml:S1:33414:5	O
reactions	SAPHRIS.xml:S1:33420:9	O
are	SAPHRIS.xml:S1:33430:3	O
reported	SAPHRIS.xml:S1:33434:8	O
voluntarily	SAPHRIS.xml:S1:33443:11	O
from	SAPHRIS.xml:S1:33455:4	O
a	SAPHRIS.xml:S1:33460:1	O
population	SAPHRIS.xml:S1:33462:10	O
of	SAPHRIS.xml:S1:33473:2	O
uncertain	SAPHRIS.xml:S1:33476:9	O
size	SAPHRIS.xml:S1:33486:4	O
,	SAPHRIS.xml:S1:33490:1	O
it	SAPHRIS.xml:S1:33492:2	O
is	SAPHRIS.xml:S1:33495:2	O
not	SAPHRIS.xml:S1:33498:3	O
always	SAPHRIS.xml:S1:33502:6	O
possible	SAPHRIS.xml:S1:33509:8	O
to	SAPHRIS.xml:S1:33518:2	O
establish	SAPHRIS.xml:S1:33521:9	O
a	SAPHRIS.xml:S1:33531:1	O
causal	SAPHRIS.xml:S1:33533:6	O
relationship	SAPHRIS.xml:S1:33540:12	O
to	SAPHRIS.xml:S1:33553:2	O
drug	SAPHRIS.xml:S1:33556:4	O
exposure	SAPHRIS.xml:S1:33561:8	O
.	SAPHRIS.xml:S1:33569:1	O

In	SAPHRIS.xml:S1:33571:2	O
many	SAPHRIS.xml:S1:33574:4	O
cases	SAPHRIS.xml:S1:33579:5	O
,	SAPHRIS.xml:S1:33584:1	O
the	SAPHRIS.xml:S1:33586:3	O
occurrence	SAPHRIS.xml:S1:33590:10	O
of	SAPHRIS.xml:S1:33601:2	O
these	SAPHRIS.xml:S1:33604:5	O
adverse	SAPHRIS.xml:S1:33610:7	O
reactions	SAPHRIS.xml:S1:33618:9	O
led	SAPHRIS.xml:S1:33628:3	O
to	SAPHRIS.xml:S1:33632:2	O
discontinuation	SAPHRIS.xml:S1:33635:15	O
of	SAPHRIS.xml:S1:33651:2	O
therapy	SAPHRIS.xml:S1:33654:7	O
.	SAPHRIS.xml:S1:33661:1	O

Application	SAPHRIS.xml:S1:33670:11	B-AdverseReaction
site	SAPHRIS.xml:S1:33682:4	I-AdverseReaction
reactions	SAPHRIS.xml:S1:33687:9	I-AdverseReaction
,	SAPHRIS.xml:S1:33696:1	O
primarily	SAPHRIS.xml:S1:33698:9	O
in	SAPHRIS.xml:S1:33708:2	O
the	SAPHRIS.xml:S1:33711:3	O
sublingual	SAPHRIS.xml:S1:33715:10	I-AdverseReaction
area	SAPHRIS.xml:S1:33726:4	I-AdverseReaction
,	SAPHRIS.xml:S1:33730:1	O
have	SAPHRIS.xml:S1:33732:4	O
been	SAPHRIS.xml:S1:33737:4	O
reported	SAPHRIS.xml:S1:33742:8	O
.	SAPHRIS.xml:S1:33750:1	O

These	SAPHRIS.xml:S1:33752:5	O
application	SAPHRIS.xml:S1:33758:11	B-AdverseReaction
site	SAPHRIS.xml:S1:33770:4	I-AdverseReaction
reactions	SAPHRIS.xml:S1:33775:9	I-AdverseReaction
included	SAPHRIS.xml:S1:33785:8	O
oral	SAPHRIS.xml:S1:33794:4	I-AdverseReaction
ulcers	SAPHRIS.xml:S1:33799:6	I-AdverseReaction
,	SAPHRIS.xml:S1:33805:1	O
blisters	SAPHRIS.xml:S1:33807:8	I-AdverseReaction
,	SAPHRIS.xml:S1:33815:1	O
peeling	SAPHRIS.xml:S1:33817:7	I-AdverseReaction
sloughing	SAPHRIS.xml:S1:33825:9	I-AdverseReaction
,	SAPHRIS.xml:S1:33834:1	O
and	SAPHRIS.xml:S1:33836:3	O
inflammation	SAPHRIS.xml:S1:33840:12	I-AdverseReaction
.	SAPHRIS.xml:S1:33852:1	O

Choking	SAPHRIS.xml:S1:33859:7	B-AdverseReaction
has	SAPHRIS.xml:S1:33867:3	O
been	SAPHRIS.xml:S1:33871:4	O
reported	SAPHRIS.xml:S1:33876:8	O
by	SAPHRIS.xml:S1:33885:2	O
patients	SAPHRIS.xml:S1:33888:8	O
,	SAPHRIS.xml:S1:33896:1	O
some	SAPHRIS.xml:S1:33898:4	O
of	SAPHRIS.xml:S1:33903:2	O
whom	SAPHRIS.xml:S1:33906:4	O
may	SAPHRIS.xml:S1:33911:3	B-Factor
have	SAPHRIS.xml:S1:33915:4	O
also	SAPHRIS.xml:S1:33920:4	O
experienced	SAPHRIS.xml:S1:33925:11	O
oropharyngeal	SAPHRIS.xml:S1:33937:13	B-AdverseReaction
muscular	SAPHRIS.xml:S1:33951:8	I-AdverseReaction
dysfunction	SAPHRIS.xml:S1:33960:11	I-AdverseReaction
or	SAPHRIS.xml:S1:33972:2	O
hypoesthesia	SAPHRIS.xml:S1:33975:12	B-AdverseReaction
.	SAPHRIS.xml:S1:33987:1	O
\n\n	SAPHRIS.xml:S2:0:2	O
BOXED	SAPHRIS.xml:S2:6:5	O
WARNING	SAPHRIS.xml:S2:12:7	O
:	SAPHRIS.xml:S2:19:1	O
WARNING	SAPHRIS.xml:S2:21:7	O
:	SAPHRIS.xml:S2:28:1	O
INCREASED	SAPHRIS.xml:S2:30:9	B-AdverseReaction
MORTALITY	SAPHRIS.xml:S2:40:9	I-AdverseReaction
IN	SAPHRIS.xml:S2:50:2	O
ELDERLY	SAPHRIS.xml:S2:53:7	O
PATIENTS	SAPHRIS.xml:S2:61:8	O
WITH	SAPHRIS.xml:S2:70:4	O
DEMENTIA	SAPHRIS.xml:S2:75:8	O
-	SAPHRIS.xml:S2:83:1	O
RELATED	SAPHRIS.xml:S2:84:7	O
PSYCHOSIS	SAPHRIS.xml:S2:92:9	O
\n\n\n\n	SAPHRIS.xml:S2:101:4	O
WARNING	SAPHRIS.xml:S2:107:7	O
:	SAPHRIS.xml:S2:114:1	O
INCREASED	SAPHRIS.xml:S2:116:9	B-AdverseReaction
MORTALITY	SAPHRIS.xml:S2:126:9	I-AdverseReaction
IN	SAPHRIS.xml:S2:136:2	O
ELDERLY	SAPHRIS.xml:S2:139:7	O
PATIENTS	SAPHRIS.xml:S2:147:8	O
WITH	SAPHRIS.xml:S2:156:4	O
DEMENTIA	SAPHRIS.xml:S2:161:8	O
-	SAPHRIS.xml:S2:169:1	O
RELATED	SAPHRIS.xml:S2:170:7	O
PSYCHOSIS	SAPHRIS.xml:S2:178:9	O
\n\n\n\n	SAPHRIS.xml:S2:187:4	O
Elderly	SAPHRIS.xml:S2:195:7	O
patients	SAPHRIS.xml:S2:203:8	O
with	SAPHRIS.xml:S2:212:4	O
dementia	SAPHRIS.xml:S2:217:8	O
-	SAPHRIS.xml:S2:225:1	O
related	SAPHRIS.xml:S2:226:7	O
psychosis	SAPHRIS.xml:S2:234:9	O
treated	SAPHRIS.xml:S2:244:7	O
with	SAPHRIS.xml:S2:252:4	O
antipsychotic	SAPHRIS.xml:S2:257:13	B-DrugClass
drugs	SAPHRIS.xml:S2:271:5	I-DrugClass
are	SAPHRIS.xml:S2:277:3	O
at	SAPHRIS.xml:S2:281:2	O
an	SAPHRIS.xml:S2:284:2	O
increased	SAPHRIS.xml:S2:287:9	O
risk	SAPHRIS.xml:S2:297:4	B-Factor
of	SAPHRIS.xml:S2:302:2	O
death	SAPHRIS.xml:S2:305:5	B-AdverseReaction
.	SAPHRIS.xml:S2:310:1	O

SAPHRIS	SAPHRIS.xml:S2:312:7	O
(	SAPHRIS.xml:S2:323:1	O
r	SAPHRIS.xml:S2:324:1	O
)\n\n	SAPHRIS.xml:S2:325:3	O
(	SAPHRIS.xml:S2:332:1	O
asenapine	SAPHRIS.xml:S2:333:9	O
)	SAPHRIS.xml:S2:342:1	O
is	SAPHRIS.xml:S2:344:2	O
not	SAPHRIS.xml:S2:347:3	O
approved	SAPHRIS.xml:S2:351:8	O
for	SAPHRIS.xml:S2:360:3	O
the	SAPHRIS.xml:S2:364:3	O
treatment	SAPHRIS.xml:S2:368:9	O
of	SAPHRIS.xml:S2:378:2	O
patients	SAPHRIS.xml:S2:381:8	O
with	SAPHRIS.xml:S2:390:4	O
dementia	SAPHRIS.xml:S2:395:8	O
-	SAPHRIS.xml:S2:403:1	O
related	SAPHRIS.xml:S2:404:7	O
psychosis	SAPHRIS.xml:S2:412:9	O
\n\n	SAPHRIS.xml:S2:421:2	O
[	SAPHRIS.xml:S2:427:1	O
see	SAPHRIS.xml:S2:428:3	O
Warnings	SAPHRIS.xml:S2:432:8	O
and	SAPHRIS.xml:S2:441:3	O
Precautions	SAPHRIS.xml:S2:445:11	O
(	SAPHRIS.xml:S2:457:1	O
5.1	SAPHRIS.xml:S2:458:3	O
,	SAPHRIS.xml:S2:461:1	O
5.2	SAPHRIS.xml:S2:463:3	O
)]	SAPHRIS.xml:S2:466:2	O
.	SAPHRIS.xml:S2:470:1	O

WARNING	SAPHRIS.xml:S2:482:7	O
:	SAPHRIS.xml:S2:489:1	O
INCREASED	SAPHRIS.xml:S2:491:9	B-AdverseReaction
MORTALITY	SAPHRIS.xml:S2:501:9	I-AdverseReaction
IN	SAPHRIS.xml:S2:511:2	O
ELDERLY	SAPHRIS.xml:S2:514:7	O
PATIENTS	SAPHRIS.xml:S2:522:8	O
WITH	SAPHRIS.xml:S2:531:4	O
DEMENTIA	SAPHRIS.xml:S2:536:8	O
-	SAPHRIS.xml:S2:544:1	O
RELATED	SAPHRIS.xml:S2:545:7	O
PSYCHOSIS	SAPHRIS.xml:S2:553:9	O
\n\n\n\n	SAPHRIS.xml:S2:564:4	O
See	SAPHRIS.xml:S2:571:3	O
full	SAPHRIS.xml:S2:575:4	O
prescribing	SAPHRIS.xml:S2:580:11	O
information	SAPHRIS.xml:S2:592:11	O
for	SAPHRIS.xml:S2:604:3	O
complete	SAPHRIS.xml:S2:608:8	O
boxed	SAPHRIS.xml:S2:617:5	O
warning	SAPHRIS.xml:S2:623:7	O
.	SAPHRIS.xml:S2:630:1	O

Elderly	SAPHRIS.xml:S2:640:7	O
patients	SAPHRIS.xml:S2:648:8	O
with	SAPHRIS.xml:S2:657:4	O
dementia	SAPHRIS.xml:S2:662:8	O
-	SAPHRIS.xml:S2:670:1	O
related	SAPHRIS.xml:S2:671:7	O
psychosis	SAPHRIS.xml:S2:679:9	O
treated	SAPHRIS.xml:S2:689:7	O
with	SAPHRIS.xml:S2:697:4	O
antipsychotic	SAPHRIS.xml:S2:702:13	B-DrugClass
drugs	SAPHRIS.xml:S2:716:5	I-DrugClass
are	SAPHRIS.xml:S2:722:3	O
at	SAPHRIS.xml:S2:726:2	O
an	SAPHRIS.xml:S2:729:2	O
increased	SAPHRIS.xml:S2:732:9	O
risk	SAPHRIS.xml:S2:742:4	O
of	SAPHRIS.xml:S2:747:2	O
death	SAPHRIS.xml:S2:750:5	B-AdverseReaction
.	SAPHRIS.xml:S2:755:1	O

SAPHRIS	SAPHRIS.xml:S2:757:7	O
is	SAPHRIS.xml:S2:765:2	O
not	SAPHRIS.xml:S2:768:3	O
approved	SAPHRIS.xml:S2:772:8	O
for	SAPHRIS.xml:S2:781:3	O
the	SAPHRIS.xml:S2:785:3	O
treatment	SAPHRIS.xml:S2:789:9	O
of	SAPHRIS.xml:S2:799:2	O
patients	SAPHRIS.xml:S2:802:8	O
with	SAPHRIS.xml:S2:811:4	O
dementia	SAPHRIS.xml:S2:816:8	O
-	SAPHRIS.xml:S2:824:1	O
related	SAPHRIS.xml:S2:825:7	O
psychosis	SAPHRIS.xml:S2:833:9	O
.	SAPHRIS.xml:S2:842:1	O

(	SAPHRIS.xml:S2:844:1	O
5.1	SAPHRIS.xml:S2:845:3	O
,	SAPHRIS.xml:S2:848:1	O
5.2	SAPHRIS.xml:S2:850:3	O
)	SAPHRIS.xml:S2:853:1	O
\n	SAPHRIS.xml:S2:856:1	O
5	SAPHRIS.xml:S3:8:1	O
WARNINGS	SAPHRIS.xml:S3:10:8	O
AND	SAPHRIS.xml:S3:19:3	O
PRECAUTIONS	SAPHRIS.xml:S3:23:11	O

EXCERPT	SAPHRIS.xml:S3:39:7	O
:	SAPHRIS.xml:S3:46:1	O
Cerebrovascular	SAPHRIS.xml:S3:55:15	B-AdverseReaction
Adverse	SAPHRIS.xml:S3:71:7	I-AdverseReaction
Events	SAPHRIS.xml:S3:79:6	I-AdverseReaction
:	SAPHRIS.xml:S3:85:1	O
An	SAPHRIS.xml:S3:87:2	O
increased	SAPHRIS.xml:S3:90:9	O
incidence	SAPHRIS.xml:S3:100:9	O
of	SAPHRIS.xml:S3:110:2	O
cerebrovascular	SAPHRIS.xml:S3:113:15	B-AdverseReaction
adverse	SAPHRIS.xml:S3:129:7	I-AdverseReaction
events	SAPHRIS.xml:S3:137:6	I-AdverseReaction
(	SAPHRIS.xml:S3:144:1	O
e	SAPHRIS.xml:S3:145:1	O
.	SAPHRIS.xml:S3:146:1	O
g	SAPHRIS.xml:S3:147:1	O
.	SAPHRIS.xml:S3:148:1	O
,	SAPHRIS.xml:S3:149:1	O
stroke	SAPHRIS.xml:S3:151:6	B-AdverseReaction
,	SAPHRIS.xml:S3:157:1	O
transient	SAPHRIS.xml:S3:159:9	B-AdverseReaction
ischemic	SAPHRIS.xml:S3:169:8	I-AdverseReaction
attack	SAPHRIS.xml:S3:178:6	I-AdverseReaction
)	SAPHRIS.xml:S3:184:1	O
has	SAPHRIS.xml:S3:186:3	O
been	SAPHRIS.xml:S3:190:4	O
seen	SAPHRIS.xml:S3:195:4	O
in	SAPHRIS.xml:S3:200:2	O
elderly	SAPHRIS.xml:S3:203:7	O
patients	SAPHRIS.xml:S3:211:8	O
with	SAPHRIS.xml:S3:220:4	O
dementia	SAPHRIS.xml:S3:225:8	O
-	SAPHRIS.xml:S3:233:1	O
related	SAPHRIS.xml:S3:234:7	O
psychoses	SAPHRIS.xml:S3:242:9	O
treated	SAPHRIS.xml:S3:252:7	O
with	SAPHRIS.xml:S3:260:4	O
atypical	SAPHRIS.xml:S3:265:8	B-DrugClass
antipsychotic	SAPHRIS.xml:S3:274:13	I-DrugClass
drugs	SAPHRIS.xml:S3:288:5	I-DrugClass
.	SAPHRIS.xml:S3:293:1	O

(	SAPHRIS.xml:S3:295:1	O
5.2	SAPHRIS.xml:S3:296:3	O
)	SAPHRIS.xml:S3:299:1	O

Neuroleptic	SAPHRIS.xml:S3:307:11	B-AdverseReaction
Malignant	SAPHRIS.xml:S3:319:9	I-AdverseReaction
Syndrome	SAPHRIS.xml:S3:329:8	I-AdverseReaction
:	SAPHRIS.xml:S3:337:1	O
Manage	SAPHRIS.xml:S3:339:6	O
with	SAPHRIS.xml:S3:346:4	O
immediate	SAPHRIS.xml:S3:351:9	O
discontinuation	SAPHRIS.xml:S3:361:15	O
and	SAPHRIS.xml:S3:377:3	O
close	SAPHRIS.xml:S3:381:5	O
monitoring	SAPHRIS.xml:S3:387:10	O
.	SAPHRIS.xml:S3:397:1	O

(	SAPHRIS.xml:S3:399:1	O
5.3	SAPHRIS.xml:S3:400:3	O
)	SAPHRIS.xml:S3:403:1	O

Tardive	SAPHRIS.xml:S3:411:7	B-AdverseReaction
Dyskinesia	SAPHRIS.xml:S3:419:10	I-AdverseReaction
:	SAPHRIS.xml:S3:429:1	O
Discontinue	SAPHRIS.xml:S3:431:11	O
if	SAPHRIS.xml:S3:443:2	O
clinically	SAPHRIS.xml:S3:446:10	O
appropriate	SAPHRIS.xml:S3:457:11	O
.	SAPHRIS.xml:S3:468:1	O

(	SAPHRIS.xml:S3:470:1	O
5.4	SAPHRIS.xml:S3:471:3	O
)	SAPHRIS.xml:S3:474:1	O

dispatch	SAPHRIS.xml:S3:480:8	O
:	SAPHRIS.xml:S3:488:1	O
unexpected	SAPHRIS.xml:S3:490:10	O
key	SAPHRIS.xml:S3:501:3	O
:	SAPHRIS.xml:S3:504:1	O
list	SAPHRIS.xml:S3:506:4	O
in	SAPHRIS.xml:S3:511:2	O
dispatch	SAPHRIS.xml:S3:514:8	O
table	SAPHRIS.xml:S3:523:5	O
:	SAPHRIS.xml:S3:528:1	O
caption	SAPHRIS.xml:S3:532:7	O
:	SAPHRIS.xml:S3:540:1	O
function	SAPHRIS.xml:S3:543:8	O
print_caption	SAPHRIS.xml:S3:552:13	O
at	SAPHRIS.xml:S3:566:2	O
0	SAPHRIS.xml:S3:569:1	O
x1c6c8c0	SAPHRIS.xml:S3:570:8	O
,	SAPHRIS.xml:S3:579:1	O
text	SAPHRIS.xml:S3:582:4	O
:	SAPHRIS.xml:S3:587:1	O
function	SAPHRIS.xml:S3:590:8	O
print_text	SAPHRIS.xml:S3:599:10	O
at	SAPHRIS.xml:S3:610:2	O
0	SAPHRIS.xml:S3:613:1	O
x1c6c500	SAPHRIS.xml:S3:614:8	O

Metabolic	SAPHRIS.xml:S3:627:9	B-AdverseReaction
Changes	SAPHRIS.xml:S3:637:7	I-AdverseReaction
:	SAPHRIS.xml:S3:644:1	O
Atypical	SAPHRIS.xml:S3:646:8	B-DrugClass
antipsychotic	SAPHRIS.xml:S3:655:13	I-DrugClass
drugs	SAPHRIS.xml:S3:669:5	I-DrugClass
have	SAPHRIS.xml:S3:675:4	O
been	SAPHRIS.xml:S3:680:4	O
associated	SAPHRIS.xml:S3:685:10	O
with	SAPHRIS.xml:S3:696:4	O
metabolic	SAPHRIS.xml:S3:701:9	B-AdverseReaction
changes	SAPHRIS.xml:S3:711:7	I-AdverseReaction
that	SAPHRIS.xml:S3:719:4	O
may	SAPHRIS.xml:S3:724:3	O
increase	SAPHRIS.xml:S3:728:8	O
cardiovascular	SAPHRIS.xml:S3:737:14	B-AdverseReaction
cerebrovascular	SAPHRIS.xml:S3:752:15	B-AdverseReaction
risk	SAPHRIS.xml:S3:768:4	I-AdverseReaction
.	SAPHRIS.xml:S3:772:1	O

These	SAPHRIS.xml:S3:774:5	O
metabolic	SAPHRIS.xml:S3:780:9	B-AdverseReaction
changes	SAPHRIS.xml:S3:790:7	I-AdverseReaction
include	SAPHRIS.xml:S3:798:7	O
hyperglycemia	SAPHRIS.xml:S3:806:13	B-AdverseReaction
,	SAPHRIS.xml:S3:819:1	O
dyslipidemia	SAPHRIS.xml:S3:821:12	B-AdverseReaction
,	SAPHRIS.xml:S3:833:1	O
and	SAPHRIS.xml:S3:835:3	O
weight	SAPHRIS.xml:S3:839:6	B-AdverseReaction
gain	SAPHRIS.xml:S3:846:4	I-AdverseReaction
.	SAPHRIS.xml:S3:850:1	O

(	SAPHRIS.xml:S3:852:1	O
5.5	SAPHRIS.xml:S3:853:3	O
)	SAPHRIS.xml:S3:856:1	O

Hypersensitivity	SAPHRIS.xml:S3:864:16	B-AdverseReaction
Reactions	SAPHRIS.xml:S3:881:9	I-AdverseReaction
:	SAPHRIS.xml:S3:890:1	O
Hypersensitivity	SAPHRIS.xml:S3:892:16	B-AdverseReaction
reactions	SAPHRIS.xml:S3:909:9	I-AdverseReaction
,	SAPHRIS.xml:S3:918:1	O
including	SAPHRIS.xml:S3:920:9	O
anaphylaxis	SAPHRIS.xml:S3:930:11	B-AdverseReaction
and	SAPHRIS.xml:S3:942:3	O
angioedema	SAPHRIS.xml:S3:946:10	B-AdverseReaction
,	SAPHRIS.xml:S3:956:1	O
have	SAPHRIS.xml:S3:958:4	O
been	SAPHRIS.xml:S3:963:4	O
observed	SAPHRIS.xml:S3:968:8	O
.	SAPHRIS.xml:S3:976:1	O

(	SAPHRIS.xml:S3:978:1	O
5.6	SAPHRIS.xml:S3:979:3	O
)	SAPHRIS.xml:S3:982:1	O

Orthostatic	SAPHRIS.xml:S3:990:11	B-AdverseReaction
Hypotension	SAPHRIS.xml:S3:1002:11	I-AdverseReaction
,	SAPHRIS.xml:S3:1013:1	O
Syncope	SAPHRIS.xml:S3:1015:7	B-AdverseReaction
,	SAPHRIS.xml:S3:1022:1	O
and	SAPHRIS.xml:S3:1024:3	O
Other	SAPHRIS.xml:S3:1028:5	O
Hemodynamic	SAPHRIS.xml:S3:1034:11	B-AdverseReaction
Effects	SAPHRIS.xml:S3:1046:7	I-AdverseReaction
:	SAPHRIS.xml:S3:1053:1	O
Dizziness	SAPHRIS.xml:S3:1055:9	B-AdverseReaction
,	SAPHRIS.xml:S3:1064:1	O
tachycardia	SAPHRIS.xml:S3:1066:11	B-AdverseReaction
or	SAPHRIS.xml:S3:1078:2	O
bradycardia	SAPHRIS.xml:S3:1081:11	B-AdverseReaction
,	SAPHRIS.xml:S3:1092:1	O
and	SAPHRIS.xml:S3:1094:3	O
syncope	SAPHRIS.xml:S3:1098:7	B-AdverseReaction
may	SAPHRIS.xml:S3:1106:3	B-Factor
occur	SAPHRIS.xml:S3:1110:5	O
,	SAPHRIS.xml:S3:1115:1	O
especially	SAPHRIS.xml:S3:1117:10	O
early	SAPHRIS.xml:S3:1128:5	O
in	SAPHRIS.xml:S3:1134:2	O
treatment	SAPHRIS.xml:S3:1137:9	O
.	SAPHRIS.xml:S3:1146:1	O

Use	SAPHRIS.xml:S3:1148:3	O
with	SAPHRIS.xml:S3:1152:4	O
caution	SAPHRIS.xml:S3:1157:7	O
in	SAPHRIS.xml:S3:1165:2	O
patients	SAPHRIS.xml:S3:1168:8	O
with	SAPHRIS.xml:S3:1177:4	O
known	SAPHRIS.xml:S3:1182:5	O
cardiovascular	SAPHRIS.xml:S3:1188:14	O
or	SAPHRIS.xml:S3:1203:2	O
cerebrovascular	SAPHRIS.xml:S3:1206:15	O
disease	SAPHRIS.xml:S3:1222:7	O
,	SAPHRIS.xml:S3:1229:1	O
and	SAPHRIS.xml:S3:1231:3	O
in	SAPHRIS.xml:S3:1235:2	O
antipsychotic	SAPHRIS.xml:S3:1238:13	O
-	SAPHRIS.xml:S3:1251:1	O
naive	SAPHRIS.xml:S3:1252:5	O
patients	SAPHRIS.xml:S3:1258:8	O
.	SAPHRIS.xml:S3:1266:1	O

(	SAPHRIS.xml:S3:1268:1	O
5.7	SAPHRIS.xml:S3:1269:3	O
)	SAPHRIS.xml:S3:1272:1	O

Leukopenia	SAPHRIS.xml:S3:1280:10	B-AdverseReaction
,	SAPHRIS.xml:S3:1290:1	O
Neutropenia	SAPHRIS.xml:S3:1292:11	B-AdverseReaction
,	SAPHRIS.xml:S3:1303:1	O
and	SAPHRIS.xml:S3:1305:3	O
Agranulocytosis	SAPHRIS.xml:S3:1309:15	B-AdverseReaction
have	SAPHRIS.xml:S3:1325:4	O
been	SAPHRIS.xml:S3:1330:4	O
reported	SAPHRIS.xml:S3:1335:8	O
with	SAPHRIS.xml:S3:1344:4	O
antipsychotics	SAPHRIS.xml:S3:1349:14	B-DrugClass
.	SAPHRIS.xml:S3:1363:1	O

Patients	SAPHRIS.xml:S3:1365:8	O
with	SAPHRIS.xml:S3:1374:4	O
a	SAPHRIS.xml:S3:1379:1	O
pre	SAPHRIS.xml:S3:1381:3	O
-	SAPHRIS.xml:S3:1384:1	O
existing	SAPHRIS.xml:S3:1385:8	O
low	SAPHRIS.xml:S3:1394:3	O
white	SAPHRIS.xml:S3:1398:5	O
blood	SAPHRIS.xml:S3:1404:5	O
cell	SAPHRIS.xml:S3:1410:4	O
count	SAPHRIS.xml:S3:1415:5	O
(	SAPHRIS.xml:S3:1421:1	O
WBC	SAPHRIS.xml:S3:1422:3	O
)	SAPHRIS.xml:S3:1425:1	O
or	SAPHRIS.xml:S3:1427:2	O
a	SAPHRIS.xml:S3:1430:1	O
history	SAPHRIS.xml:S3:1432:7	O
of	SAPHRIS.xml:S3:1440:2	O
leukopenia	SAPHRIS.xml:S3:1443:10	O
neutropenia	SAPHRIS.xml:S3:1454:11	O
should	SAPHRIS.xml:S3:1466:6	O
have	SAPHRIS.xml:S3:1473:4	O
their	SAPHRIS.xml:S3:1478:5	O
complete	SAPHRIS.xml:S3:1484:8	O
blood	SAPHRIS.xml:S3:1493:5	O
count	SAPHRIS.xml:S3:1499:5	O
(	SAPHRIS.xml:S3:1505:1	O
CBC	SAPHRIS.xml:S3:1506:3	O
)	SAPHRIS.xml:S3:1509:1	O
monitored	SAPHRIS.xml:S3:1511:9	O
frequently	SAPHRIS.xml:S3:1521:10	O
during	SAPHRIS.xml:S3:1532:6	O
the	SAPHRIS.xml:S3:1539:3	O
first	SAPHRIS.xml:S3:1543:5	O
few	SAPHRIS.xml:S3:1549:3	O
months	SAPHRIS.xml:S3:1553:6	O
of	SAPHRIS.xml:S3:1560:2	O
therapy	SAPHRIS.xml:S3:1563:7	O
and	SAPHRIS.xml:S3:1571:3	O
SAPHRIS	SAPHRIS.xml:S3:1575:7	O
should	SAPHRIS.xml:S3:1583:6	O
be	SAPHRIS.xml:S3:1590:2	O
discontinued	SAPHRIS.xml:S3:1593:12	O
at	SAPHRIS.xml:S3:1606:2	O
the	SAPHRIS.xml:S3:1609:3	O
first	SAPHRIS.xml:S3:1613:5	O
sign	SAPHRIS.xml:S3:1619:4	O
of	SAPHRIS.xml:S3:1624:2	O
a	SAPHRIS.xml:S3:1627:1	O
decline	SAPHRIS.xml:S3:1629:7	O
in	SAPHRIS.xml:S3:1637:2	O
WBC	SAPHRIS.xml:S3:1640:3	O
in	SAPHRIS.xml:S3:1644:2	O
the	SAPHRIS.xml:S3:1647:3	O
absence	SAPHRIS.xml:S3:1651:7	O
of	SAPHRIS.xml:S3:1659:2	O
other	SAPHRIS.xml:S3:1662:5	O
causative	SAPHRIS.xml:S3:1668:9	O
factors	SAPHRIS.xml:S3:1678:7	O
.	SAPHRIS.xml:S3:1685:1	O

(	SAPHRIS.xml:S3:1687:1	O
5.8	SAPHRIS.xml:S3:1688:3	O
)	SAPHRIS.xml:S3:1691:1	O

QT	SAPHRIS.xml:S3:1699:2	B-AdverseReaction
Prolongation	SAPHRIS.xml:S3:1702:12	I-AdverseReaction
:	SAPHRIS.xml:S3:1714:1	O
Increases	SAPHRIS.xml:S3:1716:9	B-AdverseReaction
in	SAPHRIS.xml:S3:1726:2	I-AdverseReaction
QT	SAPHRIS.xml:S3:1729:2	I-AdverseReaction
interval	SAPHRIS.xml:S3:1732:8	I-AdverseReaction
;	SAPHRIS.xml:S3:1740:1	O
avoid	SAPHRIS.xml:S3:1742:5	O
use	SAPHRIS.xml:S3:1748:3	O
with	SAPHRIS.xml:S3:1752:4	O
drugs	SAPHRIS.xml:S3:1757:5	O
that	SAPHRIS.xml:S3:1763:4	O
also	SAPHRIS.xml:S3:1768:4	O
increase	SAPHRIS.xml:S3:1773:8	O
the	SAPHRIS.xml:S3:1782:3	O
QT	SAPHRIS.xml:S3:1786:2	O
interval	SAPHRIS.xml:S3:1789:8	O
and	SAPHRIS.xml:S3:1798:3	O
in	SAPHRIS.xml:S3:1802:2	O
patients	SAPHRIS.xml:S3:1805:8	O
with	SAPHRIS.xml:S3:1814:4	O
risk	SAPHRIS.xml:S3:1819:4	O
factors	SAPHRIS.xml:S3:1824:7	O
for	SAPHRIS.xml:S3:1832:3	O
prolonged	SAPHRIS.xml:S3:1836:9	O
QT	SAPHRIS.xml:S3:1846:2	O
interval	SAPHRIS.xml:S3:1849:8	O
.	SAPHRIS.xml:S3:1857:1	O

(	SAPHRIS.xml:S3:1859:1	O
5.9	SAPHRIS.xml:S3:1860:3	O
)	SAPHRIS.xml:S3:1863:1	O

Seizures	SAPHRIS.xml:S3:1871:8	B-AdverseReaction
:	SAPHRIS.xml:S3:1879:1	O
Use	SAPHRIS.xml:S3:1881:3	O
cautiously	SAPHRIS.xml:S3:1885:10	O
in	SAPHRIS.xml:S3:1896:2	O
patients	SAPHRIS.xml:S3:1899:8	O
with	SAPHRIS.xml:S3:1908:4	O
a	SAPHRIS.xml:S3:1913:1	O
history	SAPHRIS.xml:S3:1915:7	O
of	SAPHRIS.xml:S3:1923:2	O
seizures	SAPHRIS.xml:S3:1926:8	O
or	SAPHRIS.xml:S3:1935:2	O
with	SAPHRIS.xml:S3:1938:4	O
conditions	SAPHRIS.xml:S3:1943:10	O
that	SAPHRIS.xml:S3:1954:4	O
lower	SAPHRIS.xml:S3:1959:5	O
the	SAPHRIS.xml:S3:1965:3	O
seizure	SAPHRIS.xml:S3:1969:7	O
threshold	SAPHRIS.xml:S3:1977:9	O
.	SAPHRIS.xml:S3:1986:1	O

(	SAPHRIS.xml:S3:1988:1	O
5.11	SAPHRIS.xml:S3:1989:4	O
)	SAPHRIS.xml:S3:1993:1	O

Potential	SAPHRIS.xml:S3:2001:9	B-Factor
for	SAPHRIS.xml:S3:2011:3	O
Cognitive	SAPHRIS.xml:S3:2015:9	B-AdverseReaction
and	SAPHRIS.xml:S3:2025:3	O
Motor	SAPHRIS.xml:S3:2029:5	B-AdverseReaction
Impairment	SAPHRIS.xml:S3:2035:10	I-AdverseReaction
:	SAPHRIS.xml:S3:2045:1	O
Use	SAPHRIS.xml:S3:2047:3	O
caution	SAPHRIS.xml:S3:2051:7	O
when	SAPHRIS.xml:S3:2059:4	O
operating	SAPHRIS.xml:S3:2064:9	O
machinery	SAPHRIS.xml:S3:2074:9	O
.	SAPHRIS.xml:S3:2083:1	O

(	SAPHRIS.xml:S3:2085:1	O
5.12	SAPHRIS.xml:S3:2086:4	O
)	SAPHRIS.xml:S3:2090:1	O

Suicide	SAPHRIS.xml:S3:2098:7	B-AdverseReaction
:	SAPHRIS.xml:S3:2105:1	O
The	SAPHRIS.xml:S3:2107:3	O
possibility	SAPHRIS.xml:S3:2111:11	O
of	SAPHRIS.xml:S3:2123:2	O
a	SAPHRIS.xml:S3:2126:1	O
suicide	SAPHRIS.xml:S3:2128:7	O
attempt	SAPHRIS.xml:S3:2136:7	O
is	SAPHRIS.xml:S3:2144:2	O
inherent	SAPHRIS.xml:S3:2147:8	O
in	SAPHRIS.xml:S3:2156:2	O
schizophrenia	SAPHRIS.xml:S3:2159:13	O
and	SAPHRIS.xml:S3:2173:3	O
bipolar	SAPHRIS.xml:S3:2177:7	O
disorder	SAPHRIS.xml:S3:2185:8	O
.	SAPHRIS.xml:S3:2193:1	O

Closely	SAPHRIS.xml:S3:2195:7	O
supervise	SAPHRIS.xml:S3:2203:9	O
high	SAPHRIS.xml:S3:2213:4	O
-	SAPHRIS.xml:S3:2217:1	O
risk	SAPHRIS.xml:S3:2218:4	O
patients	SAPHRIS.xml:S3:2223:8	O
.	SAPHRIS.xml:S3:2231:1	O

(	SAPHRIS.xml:S3:2233:1	O
5.14	SAPHRIS.xml:S3:2234:4	O
)	SAPHRIS.xml:S3:2238:1	O

5.1	SAPHRIS.xml:S3:2253:3	O

Increased	SAPHRIS.xml:S3:2257:9	O
Mortality	SAPHRIS.xml:S3:2267:9	O
in	SAPHRIS.xml:S3:2277:2	O
Elderly	SAPHRIS.xml:S3:2280:7	O
Patients	SAPHRIS.xml:S3:2288:8	O
with	SAPHRIS.xml:S3:2297:4	O
Dementia	SAPHRIS.xml:S3:2302:8	O
-	SAPHRIS.xml:S3:2310:1	O
Related	SAPHRIS.xml:S3:2311:7	O
Psychosis	SAPHRIS.xml:S3:2319:9	O

Elderly	SAPHRIS.xml:S3:2336:7	O
patients	SAPHRIS.xml:S3:2344:8	O
with	SAPHRIS.xml:S3:2353:4	O
dementia	SAPHRIS.xml:S3:2358:8	O
-	SAPHRIS.xml:S3:2366:1	O
related	SAPHRIS.xml:S3:2367:7	O
psychosis	SAPHRIS.xml:S3:2375:9	O
treated	SAPHRIS.xml:S3:2385:7	O
with	SAPHRIS.xml:S3:2393:4	O
antipsychotic	SAPHRIS.xml:S3:2398:13	B-DrugClass
drugs	SAPHRIS.xml:S3:2412:5	I-DrugClass
are	SAPHRIS.xml:S3:2418:3	O
at	SAPHRIS.xml:S3:2422:2	O
an	SAPHRIS.xml:S3:2425:2	O
increased	SAPHRIS.xml:S3:2428:9	O
risk	SAPHRIS.xml:S3:2438:4	O
of	SAPHRIS.xml:S3:2443:2	O
death	SAPHRIS.xml:S3:2446:5	B-AdverseReaction
.	SAPHRIS.xml:S3:2451:1	O

Analyses	SAPHRIS.xml:S3:2453:8	O
of	SAPHRIS.xml:S3:2462:2	O
17	SAPHRIS.xml:S3:2465:2	O
placebo	SAPHRIS.xml:S3:2468:7	O
-	SAPHRIS.xml:S3:2475:1	O
controlled	SAPHRIS.xml:S3:2476:10	O
trials	SAPHRIS.xml:S3:2487:6	O
(	SAPHRIS.xml:S3:2494:1	O
modal	SAPHRIS.xml:S3:2495:5	O
duration	SAPHRIS.xml:S3:2501:8	O
of	SAPHRIS.xml:S3:2510:2	O
10	SAPHRIS.xml:S3:2513:2	O
weeks	SAPHRIS.xml:S3:2516:5	O
)	SAPHRIS.xml:S3:2521:1	O
,	SAPHRIS.xml:S3:2522:1	O
largely	SAPHRIS.xml:S3:2524:7	O
in	SAPHRIS.xml:S3:2532:2	O
patients	SAPHRIS.xml:S3:2535:8	O
taking	SAPHRIS.xml:S3:2544:6	O
atypical	SAPHRIS.xml:S3:2551:8	B-DrugClass
antipsychotic	SAPHRIS.xml:S3:2560:13	I-DrugClass
drugs	SAPHRIS.xml:S3:2574:5	I-DrugClass
,	SAPHRIS.xml:S3:2579:1	O
revealed	SAPHRIS.xml:S3:2581:8	O
a	SAPHRIS.xml:S3:2590:1	O
risk	SAPHRIS.xml:S3:2592:4	O
of	SAPHRIS.xml:S3:2597:2	O
death	SAPHRIS.xml:S3:2600:5	B-AdverseReaction
in	SAPHRIS.xml:S3:2606:2	O
the	SAPHRIS.xml:S3:2609:3	O
drug	SAPHRIS.xml:S3:2613:4	O
-	SAPHRIS.xml:S3:2617:1	O
treated	SAPHRIS.xml:S3:2618:7	O
patients	SAPHRIS.xml:S3:2626:8	O
of	SAPHRIS.xml:S3:2635:2	O
between	SAPHRIS.xml:S3:2638:7	O
1.6	SAPHRIS.xml:S3:2646:3	O
to	SAPHRIS.xml:S3:2650:2	O
1.7	SAPHRIS.xml:S3:2653:3	O
times	SAPHRIS.xml:S3:2657:5	O
that	SAPHRIS.xml:S3:2663:4	O
seen	SAPHRIS.xml:S3:2668:4	O
in	SAPHRIS.xml:S3:2673:2	O
placebo	SAPHRIS.xml:S3:2676:7	O
-	SAPHRIS.xml:S3:2683:1	O
treated	SAPHRIS.xml:S3:2684:7	O
patients	SAPHRIS.xml:S3:2692:8	O
.	SAPHRIS.xml:S3:2700:1	O

Over	SAPHRIS.xml:S3:2702:4	O
the	SAPHRIS.xml:S3:2707:3	O
course	SAPHRIS.xml:S3:2711:6	O
of	SAPHRIS.xml:S3:2718:2	O
a	SAPHRIS.xml:S3:2721:1	O
typical	SAPHRIS.xml:S3:2723:7	O
10	SAPHRIS.xml:S3:2731:2	O
-	SAPHRIS.xml:S3:2733:1	O
week	SAPHRIS.xml:S3:2734:4	O
controlled	SAPHRIS.xml:S3:2739:10	O
trial	SAPHRIS.xml:S3:2750:5	O
,	SAPHRIS.xml:S3:2755:1	O
the	SAPHRIS.xml:S3:2757:3	O
rate	SAPHRIS.xml:S3:2761:4	O
of	SAPHRIS.xml:S3:2766:2	O
death	SAPHRIS.xml:S3:2769:5	B-AdverseReaction
in	SAPHRIS.xml:S3:2775:2	O
drug	SAPHRIS.xml:S3:2778:4	O
-	SAPHRIS.xml:S3:2782:1	O
treated	SAPHRIS.xml:S3:2783:7	O
patients	SAPHRIS.xml:S3:2791:8	O
was	SAPHRIS.xml:S3:2800:3	O
about	SAPHRIS.xml:S3:2804:5	O
4.5%	SAPHRIS.xml:S3:2810:4	O
,	SAPHRIS.xml:S3:2814:1	O
compared	SAPHRIS.xml:S3:2816:8	O
to	SAPHRIS.xml:S3:2825:2	O
a	SAPHRIS.xml:S3:2828:1	O
rate	SAPHRIS.xml:S3:2830:4	O
of	SAPHRIS.xml:S3:2835:2	O
about	SAPHRIS.xml:S3:2838:5	O
2.6%	SAPHRIS.xml:S3:2844:4	O
in	SAPHRIS.xml:S3:2849:2	O
the	SAPHRIS.xml:S3:2852:3	O
placebo	SAPHRIS.xml:S3:2856:7	O
group	SAPHRIS.xml:S3:2864:5	O
.	SAPHRIS.xml:S3:2869:1	O

Although	SAPHRIS.xml:S3:2871:8	O
the	SAPHRIS.xml:S3:2880:3	O
causes	SAPHRIS.xml:S3:2884:6	O
of	SAPHRIS.xml:S3:2891:2	O
death	SAPHRIS.xml:S3:2894:5	B-AdverseReaction
were	SAPHRIS.xml:S3:2900:4	O
varied	SAPHRIS.xml:S3:2905:6	O
,	SAPHRIS.xml:S3:2911:1	O
most	SAPHRIS.xml:S3:2913:4	O
of	SAPHRIS.xml:S3:2918:2	O
the	SAPHRIS.xml:S3:2921:3	O
deaths	SAPHRIS.xml:S3:2925:6	B-AdverseReaction
appeared	SAPHRIS.xml:S3:2932:8	O
to	SAPHRIS.xml:S3:2941:2	O
be	SAPHRIS.xml:S3:2944:2	O
either	SAPHRIS.xml:S3:2947:6	O
cardiovascular	SAPHRIS.xml:S3:2954:14	O
(	SAPHRIS.xml:S3:2969:1	O
e	SAPHRIS.xml:S3:2970:1	O
.	SAPHRIS.xml:S3:2971:1	O
g	SAPHRIS.xml:S3:2972:1	O
.	SAPHRIS.xml:S3:2973:1	O
,	SAPHRIS.xml:S3:2974:1	O
heart	SAPHRIS.xml:S3:2976:5	B-AdverseReaction
failure	SAPHRIS.xml:S3:2982:7	I-AdverseReaction
,	SAPHRIS.xml:S3:2989:1	O
sudden	SAPHRIS.xml:S3:2991:6	B-AdverseReaction
death	SAPHRIS.xml:S3:2998:5	I-AdverseReaction
)	SAPHRIS.xml:S3:3003:1	O
or	SAPHRIS.xml:S3:3005:2	O
infectious	SAPHRIS.xml:S3:3008:10	O
(	SAPHRIS.xml:S3:3019:1	O
e	SAPHRIS.xml:S3:3020:1	O
.	SAPHRIS.xml:S3:3021:1	O
g	SAPHRIS.xml:S3:3022:1	O
.	SAPHRIS.xml:S3:3023:1	O
,	SAPHRIS.xml:S3:3024:1	O
pneumonia	SAPHRIS.xml:S3:3026:9	B-AdverseReaction
)	SAPHRIS.xml:S3:3035:1	O
in	SAPHRIS.xml:S3:3037:2	O
nature	SAPHRIS.xml:S3:3040:6	O
.	SAPHRIS.xml:S3:3046:1	O

Observational	SAPHRIS.xml:S3:3048:13	O
studies	SAPHRIS.xml:S3:3062:7	O
suggest	SAPHRIS.xml:S3:3070:7	O
that	SAPHRIS.xml:S3:3078:4	O
,	SAPHRIS.xml:S3:3082:1	O
similar	SAPHRIS.xml:S3:3084:7	O
to	SAPHRIS.xml:S3:3092:2	O
atypical	SAPHRIS.xml:S3:3095:8	O
antipsychotic	SAPHRIS.xml:S3:3104:13	O
drugs	SAPHRIS.xml:S3:3118:5	O
,	SAPHRIS.xml:S3:3123:1	O
treatment	SAPHRIS.xml:S3:3125:9	O
with	SAPHRIS.xml:S3:3135:4	O
conventional	SAPHRIS.xml:S3:3140:12	O
antipsychotic	SAPHRIS.xml:S3:3153:13	O
drugs	SAPHRIS.xml:S3:3167:5	O
may	SAPHRIS.xml:S3:3173:3	O
increase	SAPHRIS.xml:S3:3177:8	O
mortality	SAPHRIS.xml:S3:3186:9	O
.	SAPHRIS.xml:S3:3195:1	O

The	SAPHRIS.xml:S3:3197:3	O
extent	SAPHRIS.xml:S3:3201:6	O
to	SAPHRIS.xml:S3:3208:2	O
which	SAPHRIS.xml:S3:3211:5	O
the	SAPHRIS.xml:S3:3217:3	O
findings	SAPHRIS.xml:S3:3221:8	O
of	SAPHRIS.xml:S3:3230:2	O
increased	SAPHRIS.xml:S3:3233:9	B-AdverseReaction
mortality	SAPHRIS.xml:S3:3243:9	I-AdverseReaction
in	SAPHRIS.xml:S3:3253:2	O
observational	SAPHRIS.xml:S3:3256:13	O
studies	SAPHRIS.xml:S3:3270:7	O
may	SAPHRIS.xml:S3:3278:3	O
be	SAPHRIS.xml:S3:3282:2	O
attributed	SAPHRIS.xml:S3:3285:10	O
to	SAPHRIS.xml:S3:3296:2	O
the	SAPHRIS.xml:S3:3299:3	O
antipsychotic	SAPHRIS.xml:S3:3303:13	B-DrugClass
drug	SAPHRIS.xml:S3:3317:4	I-DrugClass
as	SAPHRIS.xml:S3:3322:2	O
opposed	SAPHRIS.xml:S3:3325:7	O
to	SAPHRIS.xml:S3:3333:2	O
some	SAPHRIS.xml:S3:3336:4	O
characteristic	SAPHRIS.xml:S3:3341:14	O
(	SAPHRIS.xml:S3:3355:1	O
s	SAPHRIS.xml:S3:3356:1	O
)	SAPHRIS.xml:S3:3357:1	O
of	SAPHRIS.xml:S3:3359:2	O
the	SAPHRIS.xml:S3:3362:3	O
patients	SAPHRIS.xml:S3:3366:8	O
is	SAPHRIS.xml:S3:3375:2	O
not	SAPHRIS.xml:S3:3378:3	O
clear	SAPHRIS.xml:S3:3382:5	O
.	SAPHRIS.xml:S3:3387:1	O

SAPHRIS	SAPHRIS.xml:S3:3389:7	O
is	SAPHRIS.xml:S3:3397:2	O
not	SAPHRIS.xml:S3:3400:3	O
approved	SAPHRIS.xml:S3:3404:8	O
for	SAPHRIS.xml:S3:3413:3	O
the	SAPHRIS.xml:S3:3417:3	O
treatment	SAPHRIS.xml:S3:3421:9	O
of	SAPHRIS.xml:S3:3431:2	O
patients	SAPHRIS.xml:S3:3434:8	O
with	SAPHRIS.xml:S3:3443:4	O
dementia	SAPHRIS.xml:S3:3448:8	O
-	SAPHRIS.xml:S3:3456:1	O
related	SAPHRIS.xml:S3:3457:7	O
psychosis	SAPHRIS.xml:S3:3465:9	O
[	SAPHRIS.xml:S3:3476:1	O
seeBoxed	SAPHRIS.xml:S3:3477:8	O
Warningand	SAPHRIS.xml:S3:3486:10	O
Warnings	SAPHRIS.xml:S3:3497:8	O
and	SAPHRIS.xml:S3:3506:3	O
Precautions	SAPHRIS.xml:S3:3510:11	O
(	SAPHRIS.xml:S3:3522:1	O
5.2	SAPHRIS.xml:S3:3523:3	O
)]	SAPHRIS.xml:S3:3526:2	O
.	SAPHRIS.xml:S3:3530:1	O

5.2	SAPHRIS.xml:S3:3542:3	O
Cerebrovascular	SAPHRIS.xml:S3:3546:15	O
Adverse	SAPHRIS.xml:S3:3562:7	O
Events	SAPHRIS.xml:S3:3570:6	O
,	SAPHRIS.xml:S3:3576:1	O
Including	SAPHRIS.xml:S3:3578:9	O
Stroke	SAPHRIS.xml:S3:3588:6	O
,	SAPHRIS.xml:S3:3594:1	O
In	SAPHRIS.xml:S3:3596:2	O
Elderly	SAPHRIS.xml:S3:3599:7	O
Patients	SAPHRIS.xml:S3:3607:8	O
with	SAPHRIS.xml:S3:3616:4	O
Dementia	SAPHRIS.xml:S3:3621:8	O
-	SAPHRIS.xml:S3:3629:1	O
Related	SAPHRIS.xml:S3:3630:7	O
Psychosis	SAPHRIS.xml:S3:3638:9	O

In	SAPHRIS.xml:S3:3655:2	O
placebo	SAPHRIS.xml:S3:3658:7	O
-	SAPHRIS.xml:S3:3665:1	O
controlled	SAPHRIS.xml:S3:3666:10	O
trials	SAPHRIS.xml:S3:3677:6	O
with	SAPHRIS.xml:S3:3684:4	O
risperidone	SAPHRIS.xml:S3:3689:11	B-DrugClass
,	SAPHRIS.xml:S3:3700:1	O
aripiprazole	SAPHRIS.xml:S3:3702:12	B-DrugClass
,	SAPHRIS.xml:S3:3714:1	O
and	SAPHRIS.xml:S3:3716:3	O
olanzapine	SAPHRIS.xml:S3:3720:10	B-DrugClass
in	SAPHRIS.xml:S3:3731:2	O
elderly	SAPHRIS.xml:S3:3734:7	O
subjects	SAPHRIS.xml:S3:3742:8	O
with	SAPHRIS.xml:S3:3751:4	O
dementia	SAPHRIS.xml:S3:3756:8	O
,	SAPHRIS.xml:S3:3764:1	O
there	SAPHRIS.xml:S3:3766:5	O
was	SAPHRIS.xml:S3:3772:3	O
a	SAPHRIS.xml:S3:3776:1	O
higher	SAPHRIS.xml:S3:3778:6	O
incidence	SAPHRIS.xml:S3:3785:9	O
of	SAPHRIS.xml:S3:3795:2	O
cerebrovascular	SAPHRIS.xml:S3:3798:15	B-AdverseReaction
adverse	SAPHRIS.xml:S3:3814:7	I-AdverseReaction
reactions	SAPHRIS.xml:S3:3822:9	I-AdverseReaction
(	SAPHRIS.xml:S3:3832:1	O
cerebrovascular	SAPHRIS.xml:S3:3833:15	B-AdverseReaction
accidents	SAPHRIS.xml:S3:3849:9	I-AdverseReaction
and	SAPHRIS.xml:S3:3859:3	O
transient	SAPHRIS.xml:S3:3863:9	B-AdverseReaction
ischemic	SAPHRIS.xml:S3:3873:8	I-AdverseReaction
attacks	SAPHRIS.xml:S3:3882:7	I-AdverseReaction
)	SAPHRIS.xml:S3:3889:1	O
including	SAPHRIS.xml:S3:3891:9	O
fatalities	SAPHRIS.xml:S3:3901:10	B-AdverseReaction
compared	SAPHRIS.xml:S3:3912:8	O
to	SAPHRIS.xml:S3:3921:2	O
placebo	SAPHRIS.xml:S3:3924:7	O
-	SAPHRIS.xml:S3:3931:1	O
treated	SAPHRIS.xml:S3:3932:7	O
subjects	SAPHRIS.xml:S3:3940:8	O
.	SAPHRIS.xml:S3:3948:1	O

SAPHRIS	SAPHRIS.xml:S3:3950:7	O
is	SAPHRIS.xml:S3:3958:2	O
not	SAPHRIS.xml:S3:3961:3	O
approved	SAPHRIS.xml:S3:3965:8	O
for	SAPHRIS.xml:S3:3974:3	O
the	SAPHRIS.xml:S3:3978:3	O
treatment	SAPHRIS.xml:S3:3982:9	O
of	SAPHRIS.xml:S3:3992:2	O
patients	SAPHRIS.xml:S3:3995:8	O
with	SAPHRIS.xml:S3:4004:4	O
dementia	SAPHRIS.xml:S3:4009:8	O
-	SAPHRIS.xml:S3:4017:1	O
related	SAPHRIS.xml:S3:4018:7	O
psychosis	SAPHRIS.xml:S3:4026:9	O
[	SAPHRIS.xml:S3:4037:1	O
see	SAPHRIS.xml:S3:4038:3	O
alsoBoxed	SAPHRIS.xml:S3:4042:9	O
Warningand	SAPHRIS.xml:S3:4052:10	O
Warnings	SAPHRIS.xml:S3:4063:8	O
and	SAPHRIS.xml:S3:4072:3	O
Precautions	SAPHRIS.xml:S3:4076:11	O
(	SAPHRIS.xml:S3:4088:1	O
5.1	SAPHRIS.xml:S3:4089:3	O
)]	SAPHRIS.xml:S3:4092:2	O
.	SAPHRIS.xml:S3:4096:1	O

5.3	SAPHRIS.xml:S3:4108:3	O
Neuroleptic	SAPHRIS.xml:S3:4112:11	O
Malignant	SAPHRIS.xml:S3:4124:9	O
Syndrome	SAPHRIS.xml:S3:4134:8	O

A	SAPHRIS.xml:S3:4150:1	O
potentially	SAPHRIS.xml:S3:4152:11	B-Factor
fatal	SAPHRIS.xml:S3:4164:5	B-AdverseReaction
symptom	SAPHRIS.xml:S3:4170:7	O
complex	SAPHRIS.xml:S3:4178:7	O
sometimes	SAPHRIS.xml:S3:4186:9	O
referred	SAPHRIS.xml:S3:4196:8	O
to	SAPHRIS.xml:S3:4205:2	O
as	SAPHRIS.xml:S3:4208:2	O
Neuroleptic	SAPHRIS.xml:S3:4211:11	B-AdverseReaction
Malignant	SAPHRIS.xml:S3:4223:9	I-AdverseReaction
Syndrome	SAPHRIS.xml:S3:4233:8	I-AdverseReaction
(	SAPHRIS.xml:S3:4242:1	O
NMS	SAPHRIS.xml:S3:4243:3	B-AdverseReaction
)	SAPHRIS.xml:S3:4246:1	O
has	SAPHRIS.xml:S3:4248:3	O
been	SAPHRIS.xml:S3:4252:4	O
reported	SAPHRIS.xml:S3:4257:8	O
in	SAPHRIS.xml:S3:4266:2	O
association	SAPHRIS.xml:S3:4269:11	O
with	SAPHRIS.xml:S3:4281:4	O
administration	SAPHRIS.xml:S3:4286:14	O
of	SAPHRIS.xml:S3:4301:2	O
antipsychotic	SAPHRIS.xml:S3:4304:13	O
drugs	SAPHRIS.xml:S3:4318:5	O
,	SAPHRIS.xml:S3:4323:1	O
including	SAPHRIS.xml:S3:4325:9	O
SAPHRIS	SAPHRIS.xml:S3:4335:7	O
.	SAPHRIS.xml:S3:4342:1	O

Clinical	SAPHRIS.xml:S3:4344:8	O
manifestations	SAPHRIS.xml:S3:4353:14	O
of	SAPHRIS.xml:S3:4368:2	O
NMS	SAPHRIS.xml:S3:4371:3	B-AdverseReaction
are	SAPHRIS.xml:S3:4375:3	O
hyperpyrexia	SAPHRIS.xml:S3:4379:12	B-AdverseReaction
,	SAPHRIS.xml:S3:4391:1	O
muscle	SAPHRIS.xml:S3:4393:6	B-AdverseReaction
rigidity	SAPHRIS.xml:S3:4400:8	I-AdverseReaction
,	SAPHRIS.xml:S3:4408:1	O
altered	SAPHRIS.xml:S3:4410:7	B-AdverseReaction
mental	SAPHRIS.xml:S3:4418:6	I-AdverseReaction
status	SAPHRIS.xml:S3:4425:6	I-AdverseReaction
,	SAPHRIS.xml:S3:4431:1	O
and	SAPHRIS.xml:S3:4433:3	O
evidence	SAPHRIS.xml:S3:4437:8	O
of	SAPHRIS.xml:S3:4446:2	O
autonomic	SAPHRIS.xml:S3:4449:9	B-AdverseReaction
instability	SAPHRIS.xml:S3:4459:11	I-AdverseReaction
(	SAPHRIS.xml:S3:4471:1	O
irregular	SAPHRIS.xml:S3:4472:9	B-AdverseReaction
pulse	SAPHRIS.xml:S3:4482:5	I-AdverseReaction
or	SAPHRIS.xml:S3:4488:2	O
blood	SAPHRIS.xml:S3:4491:5	I-AdverseReaction
pressure	SAPHRIS.xml:S3:4497:8	I-AdverseReaction
,	SAPHRIS.xml:S3:4505:1	O
tachycardia	SAPHRIS.xml:S3:4507:11	B-AdverseReaction
,	SAPHRIS.xml:S3:4518:1	O
diaphoresis	SAPHRIS.xml:S3:4520:11	B-AdverseReaction
,	SAPHRIS.xml:S3:4531:1	O
and	SAPHRIS.xml:S3:4533:3	O
cardiac	SAPHRIS.xml:S3:4537:7	B-AdverseReaction
dysrhythmia	SAPHRIS.xml:S3:4545:11	I-AdverseReaction
)	SAPHRIS.xml:S3:4556:1	O
.	SAPHRIS.xml:S3:4557:1	O

Additional	SAPHRIS.xml:S3:4559:10	O
signs	SAPHRIS.xml:S3:4570:5	O
may	SAPHRIS.xml:S3:4576:3	B-Factor
include	SAPHRIS.xml:S3:4580:7	O
elevated	SAPHRIS.xml:S3:4588:8	B-AdverseReaction
creatine	SAPHRIS.xml:S3:4597:8	I-AdverseReaction
phosphokinase	SAPHRIS.xml:S3:4606:13	I-AdverseReaction
,	SAPHRIS.xml:S3:4619:1	O
myoglobinuria	SAPHRIS.xml:S3:4621:13	B-AdverseReaction
(	SAPHRIS.xml:S3:4635:1	O
rhabdomyolysis	SAPHRIS.xml:S3:4636:14	B-AdverseReaction
)	SAPHRIS.xml:S3:4650:1	O
,	SAPHRIS.xml:S3:4651:1	O
and	SAPHRIS.xml:S3:4653:3	O
acute	SAPHRIS.xml:S3:4657:5	B-AdverseReaction
renal	SAPHRIS.xml:S3:4663:5	I-AdverseReaction
failure	SAPHRIS.xml:S3:4669:7	I-AdverseReaction
.	SAPHRIS.xml:S3:4676:1	O

The	SAPHRIS.xml:S3:4686:3	O
diagnostic	SAPHRIS.xml:S3:4690:10	O
evaluation	SAPHRIS.xml:S3:4701:10	O
of	SAPHRIS.xml:S3:4712:2	O
patients	SAPHRIS.xml:S3:4715:8	O
with	SAPHRIS.xml:S3:4724:4	O
this	SAPHRIS.xml:S3:4729:4	O
syndrome	SAPHRIS.xml:S3:4734:8	O
is	SAPHRIS.xml:S3:4743:2	O
complicated	SAPHRIS.xml:S3:4746:11	O
.	SAPHRIS.xml:S3:4757:1	O

It	SAPHRIS.xml:S3:4759:2	O
is	SAPHRIS.xml:S3:4762:2	O
important	SAPHRIS.xml:S3:4765:9	O
to	SAPHRIS.xml:S3:4775:2	O
exclude	SAPHRIS.xml:S3:4778:7	O
cases	SAPHRIS.xml:S3:4786:5	O
where	SAPHRIS.xml:S3:4792:5	O
the	SAPHRIS.xml:S3:4798:3	O
clinical	SAPHRIS.xml:S3:4802:8	O
presentation	SAPHRIS.xml:S3:4811:12	O
includes	SAPHRIS.xml:S3:4824:8	O
both	SAPHRIS.xml:S3:4833:4	O
serious	SAPHRIS.xml:S3:4838:7	O
medical	SAPHRIS.xml:S3:4846:7	O
illness	SAPHRIS.xml:S3:4854:7	O
(	SAPHRIS.xml:S3:4862:1	O
e	SAPHRIS.xml:S3:4863:1	O
.	SAPHRIS.xml:S3:4864:1	O
g	SAPHRIS.xml:S3:4865:1	O
.	SAPHRIS.xml:S3:4866:1	O

pneumonia	SAPHRIS.xml:S3:4868:9	O
,	SAPHRIS.xml:S3:4877:1	O
systemic	SAPHRIS.xml:S3:4879:8	O
infection	SAPHRIS.xml:S3:4888:9	O
)	SAPHRIS.xml:S3:4897:1	O
and	SAPHRIS.xml:S3:4899:3	O
untreated	SAPHRIS.xml:S3:4903:9	O
or	SAPHRIS.xml:S3:4913:2	O
inadequately	SAPHRIS.xml:S3:4916:12	O
treated	SAPHRIS.xml:S3:4929:7	O
extrapyramidal	SAPHRIS.xml:S3:4937:14	O
signs	SAPHRIS.xml:S3:4952:5	O
and	SAPHRIS.xml:S3:4958:3	O
symptoms	SAPHRIS.xml:S3:4962:8	O
(	SAPHRIS.xml:S3:4971:1	O
EPS	SAPHRIS.xml:S3:4972:3	O
)	SAPHRIS.xml:S3:4975:1	O
.	SAPHRIS.xml:S3:4976:1	O

Other	SAPHRIS.xml:S3:4978:5	O
important	SAPHRIS.xml:S3:4984:9	O
considerations	SAPHRIS.xml:S3:4994:14	O
in	SAPHRIS.xml:S3:5009:2	O
the	SAPHRIS.xml:S3:5012:3	O
differential	SAPHRIS.xml:S3:5016:12	O
diagnosis	SAPHRIS.xml:S3:5029:9	O
include	SAPHRIS.xml:S3:5039:7	O
central	SAPHRIS.xml:S3:5047:7	O
anticholinergic	SAPHRIS.xml:S3:5055:15	O
toxicity	SAPHRIS.xml:S3:5071:8	O
,	SAPHRIS.xml:S3:5079:1	O
heat	SAPHRIS.xml:S3:5081:4	O
stroke	SAPHRIS.xml:S3:5086:6	O
,	SAPHRIS.xml:S3:5092:1	O
drug	SAPHRIS.xml:S3:5094:4	O
fever	SAPHRIS.xml:S3:5099:5	O
,	SAPHRIS.xml:S3:5104:1	O
and	SAPHRIS.xml:S3:5106:3	O
primary	SAPHRIS.xml:S3:5110:7	O
central	SAPHRIS.xml:S3:5118:7	O
nervous	SAPHRIS.xml:S3:5126:7	O
system	SAPHRIS.xml:S3:5134:6	O
pathology	SAPHRIS.xml:S3:5141:9	O
.	SAPHRIS.xml:S3:5150:1	O

The	SAPHRIS.xml:S3:5160:3	O
management	SAPHRIS.xml:S3:5164:10	O
of	SAPHRIS.xml:S3:5175:2	O
NMS	SAPHRIS.xml:S3:5178:3	O
should	SAPHRIS.xml:S3:5182:6	O
include	SAPHRIS.xml:S3:5189:7	O
:	SAPHRIS.xml:S3:5196:1	O
1	SAPHRIS.xml:S3:5198:1	O
)	SAPHRIS.xml:S3:5199:1	O
immediate	SAPHRIS.xml:S3:5201:9	O
discontinuation	SAPHRIS.xml:S3:5211:15	O
of	SAPHRIS.xml:S3:5227:2	O
antipsychotic	SAPHRIS.xml:S3:5230:13	O
drugs	SAPHRIS.xml:S3:5244:5	O
and	SAPHRIS.xml:S3:5250:3	O
other	SAPHRIS.xml:S3:5254:5	O
drugs	SAPHRIS.xml:S3:5260:5	O
not	SAPHRIS.xml:S3:5266:3	O
essential	SAPHRIS.xml:S3:5270:9	O
to	SAPHRIS.xml:S3:5280:2	O
concurrent	SAPHRIS.xml:S3:5283:10	O
therapy	SAPHRIS.xml:S3:5294:7	O
;	SAPHRIS.xml:S3:5301:1	O
2	SAPHRIS.xml:S3:5303:1	O
)	SAPHRIS.xml:S3:5304:1	O
intensive	SAPHRIS.xml:S3:5306:9	O
symptomatic	SAPHRIS.xml:S3:5316:11	O
treatment	SAPHRIS.xml:S3:5328:9	O
and	SAPHRIS.xml:S3:5338:3	O
medical	SAPHRIS.xml:S3:5342:7	O
monitoring	SAPHRIS.xml:S3:5350:10	O
;	SAPHRIS.xml:S3:5360:1	O
and	SAPHRIS.xml:S3:5362:3	O
3	SAPHRIS.xml:S3:5366:1	O
)	SAPHRIS.xml:S3:5367:1	O
treatment	SAPHRIS.xml:S3:5369:9	O
of	SAPHRIS.xml:S3:5379:2	O
any	SAPHRIS.xml:S3:5382:3	O
concomitant	SAPHRIS.xml:S3:5386:11	O
serious	SAPHRIS.xml:S3:5398:7	O
medical	SAPHRIS.xml:S3:5406:7	O
problems	SAPHRIS.xml:S3:5414:8	O
for	SAPHRIS.xml:S3:5423:3	O
which	SAPHRIS.xml:S3:5427:5	O
specific	SAPHRIS.xml:S3:5433:8	O
treatments	SAPHRIS.xml:S3:5442:10	O
are	SAPHRIS.xml:S3:5453:3	O
available	SAPHRIS.xml:S3:5457:9	O
.	SAPHRIS.xml:S3:5466:1	O

There	SAPHRIS.xml:S3:5468:5	O
is	SAPHRIS.xml:S3:5474:2	O
no	SAPHRIS.xml:S3:5477:2	O
general	SAPHRIS.xml:S3:5480:7	O
agreement	SAPHRIS.xml:S3:5488:9	O
about	SAPHRIS.xml:S3:5498:5	O
specific	SAPHRIS.xml:S3:5504:8	O
pharmacological	SAPHRIS.xml:S3:5513:15	O
treatment	SAPHRIS.xml:S3:5529:9	O
regimens	SAPHRIS.xml:S3:5539:8	O
for	SAPHRIS.xml:S3:5548:3	O
NMS	SAPHRIS.xml:S3:5552:3	O
.	SAPHRIS.xml:S3:5555:1	O

If	SAPHRIS.xml:S3:5565:2	O
a	SAPHRIS.xml:S3:5568:1	O
patient	SAPHRIS.xml:S3:5570:7	O
requires	SAPHRIS.xml:S3:5578:8	O
antipsychotic	SAPHRIS.xml:S3:5587:13	O
drug	SAPHRIS.xml:S3:5601:4	O
treatment	SAPHRIS.xml:S3:5606:9	O
after	SAPHRIS.xml:S3:5616:5	O
recovery	SAPHRIS.xml:S3:5622:8	O
from	SAPHRIS.xml:S3:5631:4	O
NMS	SAPHRIS.xml:S3:5636:3	O
,	SAPHRIS.xml:S3:5639:1	O
the	SAPHRIS.xml:S3:5641:3	O
potential	SAPHRIS.xml:S3:5645:9	O
reintroduction	SAPHRIS.xml:S3:5655:14	O
of	SAPHRIS.xml:S3:5670:2	O
drug	SAPHRIS.xml:S3:5673:4	O
therapy	SAPHRIS.xml:S3:5678:7	O
should	SAPHRIS.xml:S3:5686:6	O
be	SAPHRIS.xml:S3:5693:2	O
carefully	SAPHRIS.xml:S3:5696:9	O
considered	SAPHRIS.xml:S3:5706:10	O
.	SAPHRIS.xml:S3:5716:1	O

The	SAPHRIS.xml:S3:5718:3	O
patient	SAPHRIS.xml:S3:5722:7	O
should	SAPHRIS.xml:S3:5730:6	O
be	SAPHRIS.xml:S3:5737:2	O
carefully	SAPHRIS.xml:S3:5740:9	O
monitored	SAPHRIS.xml:S3:5750:9	O
,	SAPHRIS.xml:S3:5759:1	O
since	SAPHRIS.xml:S3:5761:5	O
recurrences	SAPHRIS.xml:S3:5767:11	O
of	SAPHRIS.xml:S3:5779:2	O
NMS	SAPHRIS.xml:S3:5782:3	O
have	SAPHRIS.xml:S3:5786:4	O
been	SAPHRIS.xml:S3:5791:4	O
reported	SAPHRIS.xml:S3:5796:8	O
.	SAPHRIS.xml:S3:5804:1	O

5.4	SAPHRIS.xml:S3:5816:3	O
Tardive	SAPHRIS.xml:S3:5820:7	O
Dyskinesia	SAPHRIS.xml:S3:5828:10	O

A	SAPHRIS.xml:S3:5846:1	O
syndrome	SAPHRIS.xml:S3:5848:8	O
of	SAPHRIS.xml:S3:5857:2	O
potentially	SAPHRIS.xml:S3:5860:11	B-Severity
irreversible	SAPHRIS.xml:S3:5872:12	I-Severity
,	SAPHRIS.xml:S3:5884:1	O
involuntary	SAPHRIS.xml:S3:5886:11	B-AdverseReaction
,	SAPHRIS.xml:S3:5897:1	I-AdverseReaction
dyskinetic	SAPHRIS.xml:S3:5899:10	I-AdverseReaction
movements	SAPHRIS.xml:S3:5910:9	I-AdverseReaction
can	SAPHRIS.xml:S3:5920:3	O
develop	SAPHRIS.xml:S3:5924:7	O
in	SAPHRIS.xml:S3:5932:2	O
patients	SAPHRIS.xml:S3:5935:8	O
treated	SAPHRIS.xml:S3:5944:7	O
with	SAPHRIS.xml:S3:5952:4	O
antipsychotic	SAPHRIS.xml:S3:5957:13	B-DrugClass
drugs	SAPHRIS.xml:S3:5971:5	I-DrugClass
.	SAPHRIS.xml:S3:5976:1	O

Although	SAPHRIS.xml:S3:5978:8	O
the	SAPHRIS.xml:S3:5987:3	O
prevalence	SAPHRIS.xml:S3:5991:10	O
of	SAPHRIS.xml:S3:6002:2	O
the	SAPHRIS.xml:S3:6005:3	O
syndrome	SAPHRIS.xml:S3:6009:8	O
appears	SAPHRIS.xml:S3:6018:7	O
to	SAPHRIS.xml:S3:6026:2	O
be	SAPHRIS.xml:S3:6029:2	O
highest	SAPHRIS.xml:S3:6032:7	O
among	SAPHRIS.xml:S3:6040:5	O
the	SAPHRIS.xml:S3:6046:3	O
elderly	SAPHRIS.xml:S3:6050:7	O
,	SAPHRIS.xml:S3:6057:1	O
especially	SAPHRIS.xml:S3:6059:10	O
elderly	SAPHRIS.xml:S3:6070:7	O
women	SAPHRIS.xml:S3:6078:5	O
,	SAPHRIS.xml:S3:6083:1	O
it	SAPHRIS.xml:S3:6085:2	O
is	SAPHRIS.xml:S3:6088:2	O
impossible	SAPHRIS.xml:S3:6091:10	O
to	SAPHRIS.xml:S3:6102:2	O
rely	SAPHRIS.xml:S3:6105:4	O
upon	SAPHRIS.xml:S3:6110:4	O
prevalence	SAPHRIS.xml:S3:6115:10	O
estimates	SAPHRIS.xml:S3:6126:9	O
to	SAPHRIS.xml:S3:6136:2	O
predict	SAPHRIS.xml:S3:6139:7	O
,	SAPHRIS.xml:S3:6146:1	O
at	SAPHRIS.xml:S3:6148:2	O
the	SAPHRIS.xml:S3:6151:3	O
inception	SAPHRIS.xml:S3:6155:9	O
of	SAPHRIS.xml:S3:6165:2	O
antipsychotic	SAPHRIS.xml:S3:6168:13	O
treatment	SAPHRIS.xml:S3:6182:9	O
,	SAPHRIS.xml:S3:6191:1	O
which	SAPHRIS.xml:S3:6193:5	O
patients	SAPHRIS.xml:S3:6199:8	O
are	SAPHRIS.xml:S3:6208:3	O
likely	SAPHRIS.xml:S3:6212:6	O
to	SAPHRIS.xml:S3:6219:2	O
develop	SAPHRIS.xml:S3:6222:7	O
the	SAPHRIS.xml:S3:6230:3	O
syndrome	SAPHRIS.xml:S3:6234:8	O
.	SAPHRIS.xml:S3:6242:1	O

Whether	SAPHRIS.xml:S3:6244:7	O
antipsychotic	SAPHRIS.xml:S3:6252:13	B-DrugClass
drug	SAPHRIS.xml:S3:6266:4	I-DrugClass
products	SAPHRIS.xml:S3:6271:8	O
differ	SAPHRIS.xml:S3:6280:6	O
in	SAPHRIS.xml:S3:6287:2	O
their	SAPHRIS.xml:S3:6290:5	O
potential	SAPHRIS.xml:S3:6296:9	O
to	SAPHRIS.xml:S3:6306:2	O
cause	SAPHRIS.xml:S3:6309:5	O
Tardive	SAPHRIS.xml:S3:6315:7	B-AdverseReaction
Dyskinesia	SAPHRIS.xml:S3:6323:10	I-AdverseReaction
(	SAPHRIS.xml:S3:6334:1	O
TD	SAPHRIS.xml:S3:6335:2	B-AdverseReaction
)	SAPHRIS.xml:S3:6337:1	O
is	SAPHRIS.xml:S3:6339:2	O
unknown	SAPHRIS.xml:S3:6342:7	O
.	SAPHRIS.xml:S3:6349:1	O

The	SAPHRIS.xml:S3:6359:3	O
risk	SAPHRIS.xml:S3:6363:4	O
of	SAPHRIS.xml:S3:6368:2	O
developing	SAPHRIS.xml:S3:6371:10	O
TD	SAPHRIS.xml:S3:6382:2	B-AdverseReaction
and	SAPHRIS.xml:S3:6385:3	O
the	SAPHRIS.xml:S3:6389:3	O
likelihood	SAPHRIS.xml:S3:6393:10	O
that	SAPHRIS.xml:S3:6404:4	O
it	SAPHRIS.xml:S3:6409:2	O
will	SAPHRIS.xml:S3:6412:4	O
become	SAPHRIS.xml:S3:6417:6	O
irreversible	SAPHRIS.xml:S3:6424:12	B-Severity
are	SAPHRIS.xml:S3:6437:3	O
believed	SAPHRIS.xml:S3:6441:8	O
to	SAPHRIS.xml:S3:6450:2	O
increase	SAPHRIS.xml:S3:6453:8	O
as	SAPHRIS.xml:S3:6462:2	O
the	SAPHRIS.xml:S3:6465:3	O
duration	SAPHRIS.xml:S3:6469:8	O
of	SAPHRIS.xml:S3:6478:2	O
treatment	SAPHRIS.xml:S3:6481:9	O
and	SAPHRIS.xml:S3:6491:3	O
the	SAPHRIS.xml:S3:6495:3	O
total	SAPHRIS.xml:S3:6499:5	O
cumulative	SAPHRIS.xml:S3:6505:10	O
dose	SAPHRIS.xml:S3:6516:4	O
of	SAPHRIS.xml:S3:6521:2	O
antipsychotic	SAPHRIS.xml:S3:6524:13	B-DrugClass
drugs	SAPHRIS.xml:S3:6538:5	I-DrugClass
administered	SAPHRIS.xml:S3:6544:12	O
to	SAPHRIS.xml:S3:6557:2	O
the	SAPHRIS.xml:S3:6560:3	O
patient	SAPHRIS.xml:S3:6564:7	O
increase	SAPHRIS.xml:S3:6572:8	O
.	SAPHRIS.xml:S3:6580:1	O

However	SAPHRIS.xml:S3:6582:7	O
,	SAPHRIS.xml:S3:6589:1	O
the	SAPHRIS.xml:S3:6591:3	O
syndrome	SAPHRIS.xml:S3:6595:8	O
can	SAPHRIS.xml:S3:6604:3	O
develop	SAPHRIS.xml:S3:6608:7	O
,	SAPHRIS.xml:S3:6615:1	O
although	SAPHRIS.xml:S3:6617:8	O
much	SAPHRIS.xml:S3:6626:4	O
less	SAPHRIS.xml:S3:6631:4	O
commonly	SAPHRIS.xml:S3:6636:8	O
,	SAPHRIS.xml:S3:6644:1	O
after	SAPHRIS.xml:S3:6646:5	O
relatively	SAPHRIS.xml:S3:6652:10	O
brief	SAPHRIS.xml:S3:6663:5	O
treatment	SAPHRIS.xml:S3:6669:9	O
periods	SAPHRIS.xml:S3:6679:7	O
at	SAPHRIS.xml:S3:6687:2	O
low	SAPHRIS.xml:S3:6690:3	O
doses	SAPHRIS.xml:S3:6694:5	O
.	SAPHRIS.xml:S3:6699:1	O

There	SAPHRIS.xml:S3:6709:5	O
is	SAPHRIS.xml:S3:6715:2	O
no	SAPHRIS.xml:S3:6718:2	O
known	SAPHRIS.xml:S3:6721:5	O
treatment	SAPHRIS.xml:S3:6727:9	O
for	SAPHRIS.xml:S3:6737:3	O
established	SAPHRIS.xml:S3:6741:11	O
cases	SAPHRIS.xml:S3:6753:5	O
of	SAPHRIS.xml:S3:6759:2	O
TD	SAPHRIS.xml:S3:6762:2	O
,	SAPHRIS.xml:S3:6764:1	O
although	SAPHRIS.xml:S3:6766:8	O
the	SAPHRIS.xml:S3:6775:3	O
syndrome	SAPHRIS.xml:S3:6779:8	O
may	SAPHRIS.xml:S3:6788:3	O
remit	SAPHRIS.xml:S3:6792:5	O
,	SAPHRIS.xml:S3:6797:1	O
partially	SAPHRIS.xml:S3:6799:9	O
or	SAPHRIS.xml:S3:6809:2	O
completely	SAPHRIS.xml:S3:6812:10	O
,	SAPHRIS.xml:S3:6822:1	O
if	SAPHRIS.xml:S3:6824:2	O
antipsychotic	SAPHRIS.xml:S3:6827:13	O
treatment	SAPHRIS.xml:S3:6841:9	O
is	SAPHRIS.xml:S3:6851:2	O
withdrawn	SAPHRIS.xml:S3:6854:9	O
.	SAPHRIS.xml:S3:6863:1	O

Antipsychotic	SAPHRIS.xml:S3:6865:13	O
treatment	SAPHRIS.xml:S3:6879:9	O
,	SAPHRIS.xml:S3:6888:1	O
itself	SAPHRIS.xml:S3:6890:6	O
,	SAPHRIS.xml:S3:6896:1	O
however	SAPHRIS.xml:S3:6898:7	O
,	SAPHRIS.xml:S3:6905:1	O
may	SAPHRIS.xml:S3:6907:3	O
suppress	SAPHRIS.xml:S3:6911:8	O
(	SAPHRIS.xml:S3:6920:1	O
or	SAPHRIS.xml:S3:6921:2	O
partially	SAPHRIS.xml:S3:6924:9	O
suppress	SAPHRIS.xml:S3:6934:8	O
)	SAPHRIS.xml:S3:6942:1	O
the	SAPHRIS.xml:S3:6944:3	O
signs	SAPHRIS.xml:S3:6948:5	O
and	SAPHRIS.xml:S3:6954:3	O
symptoms	SAPHRIS.xml:S3:6958:8	O
of	SAPHRIS.xml:S3:6967:2	O
the	SAPHRIS.xml:S3:6970:3	O
syndrome	SAPHRIS.xml:S3:6974:8	O
and	SAPHRIS.xml:S3:6983:3	O
thereby	SAPHRIS.xml:S3:6987:7	O
may	SAPHRIS.xml:S3:6995:3	O
possibly	SAPHRIS.xml:S3:6999:8	O
mask	SAPHRIS.xml:S3:7008:4	O
the	SAPHRIS.xml:S3:7013:3	O
underlying	SAPHRIS.xml:S3:7017:10	O
process	SAPHRIS.xml:S3:7028:7	O
.	SAPHRIS.xml:S3:7035:1	O

The	SAPHRIS.xml:S3:7037:3	O
effect	SAPHRIS.xml:S3:7041:6	O
that	SAPHRIS.xml:S3:7048:4	O
symptomatic	SAPHRIS.xml:S3:7053:11	O
suppression	SAPHRIS.xml:S3:7065:11	O
has	SAPHRIS.xml:S3:7077:3	O
upon	SAPHRIS.xml:S3:7081:4	O
the	SAPHRIS.xml:S3:7086:3	O
long	SAPHRIS.xml:S3:7090:4	O
-	SAPHRIS.xml:S3:7094:1	O
term	SAPHRIS.xml:S3:7095:4	O
course	SAPHRIS.xml:S3:7100:6	O
of	SAPHRIS.xml:S3:7107:2	O
the	SAPHRIS.xml:S3:7110:3	O
syndrome	SAPHRIS.xml:S3:7114:8	O
is	SAPHRIS.xml:S3:7123:2	O
unknown	SAPHRIS.xml:S3:7126:7	O
.	SAPHRIS.xml:S3:7133:1	O

Given	SAPHRIS.xml:S3:7143:5	O
these	SAPHRIS.xml:S3:7149:5	O
considerations	SAPHRIS.xml:S3:7155:14	O
,	SAPHRIS.xml:S3:7169:1	O
SAPHRIS	SAPHRIS.xml:S3:7171:7	O
should	SAPHRIS.xml:S3:7179:6	O
be	SAPHRIS.xml:S3:7186:2	O
prescribed	SAPHRIS.xml:S3:7189:10	O
in	SAPHRIS.xml:S3:7200:2	O
a	SAPHRIS.xml:S3:7203:1	O
manner	SAPHRIS.xml:S3:7205:6	O
that	SAPHRIS.xml:S3:7212:4	O
is	SAPHRIS.xml:S3:7217:2	O
most	SAPHRIS.xml:S3:7220:4	O
likely	SAPHRIS.xml:S3:7225:6	O
to	SAPHRIS.xml:S3:7232:2	O
minimize	SAPHRIS.xml:S3:7235:8	O
the	SAPHRIS.xml:S3:7244:3	O
occurrence	SAPHRIS.xml:S3:7248:10	O
of	SAPHRIS.xml:S3:7259:2	O
TD	SAPHRIS.xml:S3:7262:2	O
.	SAPHRIS.xml:S3:7264:1	O

Chronic	SAPHRIS.xml:S3:7266:7	O
antipsychotic	SAPHRIS.xml:S3:7274:13	O
treatment	SAPHRIS.xml:S3:7288:9	O
should	SAPHRIS.xml:S3:7298:6	O
generally	SAPHRIS.xml:S3:7305:9	O
be	SAPHRIS.xml:S3:7315:2	O
reserved	SAPHRIS.xml:S3:7318:8	O
for	SAPHRIS.xml:S3:7327:3	O
patients	SAPHRIS.xml:S3:7331:8	O
who	SAPHRIS.xml:S3:7340:3	O
suffer	SAPHRIS.xml:S3:7344:6	O
from	SAPHRIS.xml:S3:7351:4	O
a	SAPHRIS.xml:S3:7356:1	O
chronic	SAPHRIS.xml:S3:7358:7	O
illness	SAPHRIS.xml:S3:7366:7	O
that	SAPHRIS.xml:S3:7374:4	O
(	SAPHRIS.xml:S3:7379:1	O
1	SAPHRIS.xml:S3:7380:1	O
)	SAPHRIS.xml:S3:7381:1	O
is	SAPHRIS.xml:S3:7383:2	O
known	SAPHRIS.xml:S3:7386:5	O
to	SAPHRIS.xml:S3:7392:2	O
respond	SAPHRIS.xml:S3:7395:7	O
to	SAPHRIS.xml:S3:7403:2	O
antipsychotic	SAPHRIS.xml:S3:7406:13	O
drugs	SAPHRIS.xml:S3:7420:5	O
,	SAPHRIS.xml:S3:7425:1	O
and	SAPHRIS.xml:S3:7427:3	O
(	SAPHRIS.xml:S3:7431:1	O
2	SAPHRIS.xml:S3:7432:1	O
)	SAPHRIS.xml:S3:7433:1	O
for	SAPHRIS.xml:S3:7435:3	O
whom	SAPHRIS.xml:S3:7439:4	O
alternative	SAPHRIS.xml:S3:7444:11	O
,	SAPHRIS.xml:S3:7455:1	O
equally	SAPHRIS.xml:S3:7457:7	O
effective	SAPHRIS.xml:S3:7465:9	O
,	SAPHRIS.xml:S3:7474:1	O
but	SAPHRIS.xml:S3:7476:3	O
potentially	SAPHRIS.xml:S3:7480:11	O
less	SAPHRIS.xml:S3:7492:4	O
harmful	SAPHRIS.xml:S3:7497:7	O
treatments	SAPHRIS.xml:S3:7505:10	O
are	SAPHRIS.xml:S3:7516:3	O
not	SAPHRIS.xml:S3:7520:3	O
available	SAPHRIS.xml:S3:7524:9	O
or	SAPHRIS.xml:S3:7534:2	O
appropriate	SAPHRIS.xml:S3:7537:11	O
.	SAPHRIS.xml:S3:7548:1	O

In	SAPHRIS.xml:S3:7550:2	O
patients	SAPHRIS.xml:S3:7553:8	O
who	SAPHRIS.xml:S3:7562:3	O
do	SAPHRIS.xml:S3:7566:2	O
require	SAPHRIS.xml:S3:7569:7	O
chronic	SAPHRIS.xml:S3:7577:7	O
treatment	SAPHRIS.xml:S3:7585:9	O
,	SAPHRIS.xml:S3:7594:1	O
the	SAPHRIS.xml:S3:7596:3	O
smallest	SAPHRIS.xml:S3:7600:8	O
dose	SAPHRIS.xml:S3:7609:4	O
and	SAPHRIS.xml:S3:7614:3	O
the	SAPHRIS.xml:S3:7618:3	O
shortest	SAPHRIS.xml:S3:7622:8	O
duration	SAPHRIS.xml:S3:7631:8	O
of	SAPHRIS.xml:S3:7640:2	O
treatment	SAPHRIS.xml:S3:7643:9	O
producing	SAPHRIS.xml:S3:7653:9	O
a	SAPHRIS.xml:S3:7663:1	O
satisfactory	SAPHRIS.xml:S3:7665:12	O
clinical	SAPHRIS.xml:S3:7678:8	O
response	SAPHRIS.xml:S3:7687:8	O
should	SAPHRIS.xml:S3:7696:6	O
be	SAPHRIS.xml:S3:7703:2	O
sought	SAPHRIS.xml:S3:7706:6	O
.	SAPHRIS.xml:S3:7712:1	O

The	SAPHRIS.xml:S3:7714:3	O
need	SAPHRIS.xml:S3:7718:4	O
for	SAPHRIS.xml:S3:7723:3	O
continued	SAPHRIS.xml:S3:7727:9	O
treatment	SAPHRIS.xml:S3:7737:9	O
should	SAPHRIS.xml:S3:7747:6	O
be	SAPHRIS.xml:S3:7754:2	O
reassessed	SAPHRIS.xml:S3:7757:10	O
periodically	SAPHRIS.xml:S3:7768:12	O
.	SAPHRIS.xml:S3:7780:1	O

If	SAPHRIS.xml:S3:7790:2	O
signs	SAPHRIS.xml:S3:7793:5	O
and	SAPHRIS.xml:S3:7799:3	O
symptoms	SAPHRIS.xml:S3:7803:8	O
of	SAPHRIS.xml:S3:7812:2	O
TD	SAPHRIS.xml:S3:7815:2	O
appear	SAPHRIS.xml:S3:7818:6	O
in	SAPHRIS.xml:S3:7825:2	O
a	SAPHRIS.xml:S3:7828:1	O
patient	SAPHRIS.xml:S3:7830:7	O
on	SAPHRIS.xml:S3:7838:2	O
SAPHRIS	SAPHRIS.xml:S3:7841:7	O
,	SAPHRIS.xml:S3:7848:1	O
drug	SAPHRIS.xml:S3:7850:4	O
discontinuation	SAPHRIS.xml:S3:7855:15	O
should	SAPHRIS.xml:S3:7871:6	O
be	SAPHRIS.xml:S3:7878:2	O
considered	SAPHRIS.xml:S3:7881:10	O
.	SAPHRIS.xml:S3:7891:1	O

However	SAPHRIS.xml:S3:7893:7	O
,	SAPHRIS.xml:S3:7900:1	O
some	SAPHRIS.xml:S3:7902:4	O
patients	SAPHRIS.xml:S3:7907:8	O
may	SAPHRIS.xml:S3:7916:3	O
require	SAPHRIS.xml:S3:7920:7	O
treatment	SAPHRIS.xml:S3:7928:9	O
with	SAPHRIS.xml:S3:7938:4	O
SAPHRIS	SAPHRIS.xml:S3:7943:7	O
despite	SAPHRIS.xml:S3:7951:7	O
the	SAPHRIS.xml:S3:7959:3	O
presence	SAPHRIS.xml:S3:7963:8	O
of	SAPHRIS.xml:S3:7972:2	O
the	SAPHRIS.xml:S3:7975:3	O
syndrome	SAPHRIS.xml:S3:7979:8	O
.	SAPHRIS.xml:S3:7987:1	O

5.5	SAPHRIS.xml:S3:7999:3	O
Metabolic	SAPHRIS.xml:S3:8003:9	O
Changes	SAPHRIS.xml:S3:8013:7	O

Atypical	SAPHRIS.xml:S3:8028:8	B-DrugClass
antipsychotic	SAPHRIS.xml:S3:8037:13	I-DrugClass
drugs	SAPHRIS.xml:S3:8051:5	I-DrugClass
have	SAPHRIS.xml:S3:8057:4	O
been	SAPHRIS.xml:S3:8062:4	O
associated	SAPHRIS.xml:S3:8067:10	O
with	SAPHRIS.xml:S3:8078:4	O
metabolic	SAPHRIS.xml:S3:8083:9	B-AdverseReaction
changes	SAPHRIS.xml:S3:8093:7	I-AdverseReaction
that	SAPHRIS.xml:S3:8101:4	O
may	SAPHRIS.xml:S3:8106:3	O
increase	SAPHRIS.xml:S3:8110:8	B-AdverseReaction
cardiovascular	SAPHRIS.xml:S3:8119:14	I-AdverseReaction
cerebrovascular	SAPHRIS.xml:S3:8134:15	I-AdverseReaction
risk	SAPHRIS.xml:S3:8150:4	I-AdverseReaction
.	SAPHRIS.xml:S3:8154:1	O

These	SAPHRIS.xml:S3:8156:5	O
metabolic	SAPHRIS.xml:S3:8162:9	B-AdverseReaction
changes	SAPHRIS.xml:S3:8172:7	I-AdverseReaction
include	SAPHRIS.xml:S3:8180:7	O
hyperglycemia	SAPHRIS.xml:S3:8188:13	B-AdverseReaction
,	SAPHRIS.xml:S3:8201:1	O
dyslipidemia	SAPHRIS.xml:S3:8203:12	B-AdverseReaction
,	SAPHRIS.xml:S3:8215:1	O
and	SAPHRIS.xml:S3:8217:3	O
body	SAPHRIS.xml:S3:8221:4	B-AdverseReaction
weight	SAPHRIS.xml:S3:8226:6	I-AdverseReaction
gain	SAPHRIS.xml:S3:8233:4	I-AdverseReaction
.	SAPHRIS.xml:S3:8237:1	O

While	SAPHRIS.xml:S3:8239:5	O
all	SAPHRIS.xml:S3:8245:3	O
of	SAPHRIS.xml:S3:8249:2	O
the	SAPHRIS.xml:S3:8252:3	O
drugs	SAPHRIS.xml:S3:8256:5	B-DrugClass
in	SAPHRIS.xml:S3:8262:2	I-DrugClass
the	SAPHRIS.xml:S3:8265:3	I-DrugClass
class	SAPHRIS.xml:S3:8269:5	I-DrugClass
have	SAPHRIS.xml:S3:8275:4	O
been	SAPHRIS.xml:S3:8280:4	O
shown	SAPHRIS.xml:S3:8285:5	O
to	SAPHRIS.xml:S3:8291:2	O
produce	SAPHRIS.xml:S3:8294:7	O
some	SAPHRIS.xml:S3:8302:4	O
metabolic	SAPHRIS.xml:S3:8307:9	B-AdverseReaction
changes	SAPHRIS.xml:S3:8317:7	I-AdverseReaction
,	SAPHRIS.xml:S3:8324:1	O
each	SAPHRIS.xml:S3:8326:4	O
drug	SAPHRIS.xml:S3:8331:4	O
has	SAPHRIS.xml:S3:8336:3	O
its	SAPHRIS.xml:S3:8340:3	O
own	SAPHRIS.xml:S3:8344:3	O
specific	SAPHRIS.xml:S3:8348:8	O
risk	SAPHRIS.xml:S3:8357:4	O
profile	SAPHRIS.xml:S3:8362:7	O
.	SAPHRIS.xml:S3:8369:1	O

Hyperglycemia	SAPHRIS.xml:S3:8383:13	O
and	SAPHRIS.xml:S3:8397:3	O
Diabetes	SAPHRIS.xml:S3:8401:8	O
Mellitus	SAPHRIS.xml:S3:8410:8	O

Hyperglycemia	SAPHRIS.xml:S3:8429:13	B-AdverseReaction
,	SAPHRIS.xml:S3:8442:1	O
in	SAPHRIS.xml:S3:8444:2	O
some	SAPHRIS.xml:S3:8447:4	O
cases	SAPHRIS.xml:S3:8452:5	O
extreme	SAPHRIS.xml:S3:8458:7	B-Severity
and	SAPHRIS.xml:S3:8466:3	O
associated	SAPHRIS.xml:S3:8470:10	O
with	SAPHRIS.xml:S3:8481:4	O
ketoacidosis	SAPHRIS.xml:S3:8486:12	B-AdverseReaction
or	SAPHRIS.xml:S3:8499:2	O
hyperosmolar	SAPHRIS.xml:S3:8502:12	B-AdverseReaction
coma	SAPHRIS.xml:S3:8515:4	I-AdverseReaction
or	SAPHRIS.xml:S3:8520:2	O
death	SAPHRIS.xml:S3:8523:5	B-AdverseReaction
,	SAPHRIS.xml:S3:8528:1	O
has	SAPHRIS.xml:S3:8530:3	O
been	SAPHRIS.xml:S3:8534:4	O
reported	SAPHRIS.xml:S3:8539:8	O
in	SAPHRIS.xml:S3:8548:2	O
patients	SAPHRIS.xml:S3:8551:8	O
treated	SAPHRIS.xml:S3:8560:7	O
with	SAPHRIS.xml:S3:8568:4	O
atypical	SAPHRIS.xml:S3:8573:8	B-DrugClass
antipsychotics	SAPHRIS.xml:S3:8582:14	I-DrugClass
.	SAPHRIS.xml:S3:8596:1	O

Assessment	SAPHRIS.xml:S3:8598:10	O
of	SAPHRIS.xml:S3:8609:2	O
the	SAPHRIS.xml:S3:8612:3	O
relationship	SAPHRIS.xml:S3:8616:12	O
between	SAPHRIS.xml:S3:8629:7	O
atypical	SAPHRIS.xml:S3:8637:8	O
antipsychotic	SAPHRIS.xml:S3:8646:13	O
use	SAPHRIS.xml:S3:8660:3	O
and	SAPHRIS.xml:S3:8664:3	O
glucose	SAPHRIS.xml:S3:8668:7	O
abnormalities	SAPHRIS.xml:S3:8676:13	O
is	SAPHRIS.xml:S3:8690:2	O
complicated	SAPHRIS.xml:S3:8693:11	O
by	SAPHRIS.xml:S3:8705:2	O
the	SAPHRIS.xml:S3:8708:3	O
possibility	SAPHRIS.xml:S3:8712:11	O
of	SAPHRIS.xml:S3:8724:2	O
an	SAPHRIS.xml:S3:8727:2	O
increased	SAPHRIS.xml:S3:8730:9	O
background	SAPHRIS.xml:S3:8740:10	O
risk	SAPHRIS.xml:S3:8751:4	O
of	SAPHRIS.xml:S3:8756:2	O
diabetes	SAPHRIS.xml:S3:8759:8	O
mellitus	SAPHRIS.xml:S3:8768:8	O
in	SAPHRIS.xml:S3:8777:2	O
patients	SAPHRIS.xml:S3:8780:8	O
with	SAPHRIS.xml:S3:8789:4	O
schizophrenia	SAPHRIS.xml:S3:8794:13	O
and	SAPHRIS.xml:S3:8808:3	O
the	SAPHRIS.xml:S3:8812:3	O
increasing	SAPHRIS.xml:S3:8816:10	O
incidence	SAPHRIS.xml:S3:8827:9	O
of	SAPHRIS.xml:S3:8837:2	O
diabetes	SAPHRIS.xml:S3:8840:8	O
mellitus	SAPHRIS.xml:S3:8849:8	O
in	SAPHRIS.xml:S3:8858:2	O
the	SAPHRIS.xml:S3:8861:3	O
general	SAPHRIS.xml:S3:8865:7	O
population	SAPHRIS.xml:S3:8873:10	O
.	SAPHRIS.xml:S3:8883:1	O

Given	SAPHRIS.xml:S3:8885:5	O
these	SAPHRIS.xml:S3:8891:5	O
confounders	SAPHRIS.xml:S3:8897:11	O
,	SAPHRIS.xml:S3:8908:1	O
the	SAPHRIS.xml:S3:8910:3	O
relationship	SAPHRIS.xml:S3:8914:12	O
between	SAPHRIS.xml:S3:8927:7	O
atypical	SAPHRIS.xml:S3:8935:8	B-DrugClass
antipsychotic	SAPHRIS.xml:S3:8944:13	I-DrugClass
use	SAPHRIS.xml:S3:8958:3	O
and	SAPHRIS.xml:S3:8962:3	O
hyperglycemia	SAPHRIS.xml:S3:8966:13	B-AdverseReaction
-	SAPHRIS.xml:S3:8979:1	O
related	SAPHRIS.xml:S3:8980:7	O
adverse	SAPHRIS.xml:S3:8988:7	O
reactions	SAPHRIS.xml:S3:8996:9	O
is	SAPHRIS.xml:S3:9006:2	O
not	SAPHRIS.xml:S3:9009:3	O
completely	SAPHRIS.xml:S3:9013:10	O
understood	SAPHRIS.xml:S3:9024:10	O
.	SAPHRIS.xml:S3:9034:1	O

However	SAPHRIS.xml:S3:9036:7	O
,	SAPHRIS.xml:S3:9043:1	O
epidemiological	SAPHRIS.xml:S3:9045:15	O
studies	SAPHRIS.xml:S3:9061:7	O
suggest	SAPHRIS.xml:S3:9069:7	O
an	SAPHRIS.xml:S3:9077:2	O
increased	SAPHRIS.xml:S3:9080:9	O
risk	SAPHRIS.xml:S3:9090:4	O
of	SAPHRIS.xml:S3:9095:2	O
treatment	SAPHRIS.xml:S3:9098:9	O
-	SAPHRIS.xml:S3:9107:1	O
emergent	SAPHRIS.xml:S3:9108:8	O
hyperglycemia	SAPHRIS.xml:S3:9117:13	B-AdverseReaction
-	SAPHRIS.xml:S3:9130:1	O
related	SAPHRIS.xml:S3:9131:7	O
adverse	SAPHRIS.xml:S3:9139:7	O
events	SAPHRIS.xml:S3:9147:6	O
in	SAPHRIS.xml:S3:9154:2	O
patients	SAPHRIS.xml:S3:9157:8	O
treated	SAPHRIS.xml:S3:9166:7	O
with	SAPHRIS.xml:S3:9174:4	O
the	SAPHRIS.xml:S3:9179:3	O
atypical	SAPHRIS.xml:S3:9183:8	B-DrugClass
antipsychotics	SAPHRIS.xml:S3:9192:14	I-DrugClass
included	SAPHRIS.xml:S3:9207:8	O
in	SAPHRIS.xml:S3:9216:2	O
these	SAPHRIS.xml:S3:9219:5	O
studies	SAPHRIS.xml:S3:9225:7	O
.	SAPHRIS.xml:S3:9232:1	O

Precise	SAPHRIS.xml:S3:9234:7	O
risk	SAPHRIS.xml:S3:9242:4	O
estimates	SAPHRIS.xml:S3:9247:9	O
for	SAPHRIS.xml:S3:9257:3	O
hyperglycemia	SAPHRIS.xml:S3:9261:13	B-AdverseReaction
-	SAPHRIS.xml:S3:9274:1	O
related	SAPHRIS.xml:S3:9275:7	O
adverse	SAPHRIS.xml:S3:9283:7	O
events	SAPHRIS.xml:S3:9291:6	O
in	SAPHRIS.xml:S3:9298:2	O
patients	SAPHRIS.xml:S3:9301:8	O
treated	SAPHRIS.xml:S3:9310:7	O
with	SAPHRIS.xml:S3:9318:4	O
atypical	SAPHRIS.xml:S3:9323:8	B-DrugClass
antipsychotics	SAPHRIS.xml:S3:9332:14	I-DrugClass
are	SAPHRIS.xml:S3:9347:3	O
not	SAPHRIS.xml:S3:9351:3	O
available	SAPHRIS.xml:S3:9355:9	O
.	SAPHRIS.xml:S3:9364:1	O

Patients	SAPHRIS.xml:S3:9374:8	O
with	SAPHRIS.xml:S3:9383:4	O
an	SAPHRIS.xml:S3:9388:2	O
established	SAPHRIS.xml:S3:9391:11	O
diagnosis	SAPHRIS.xml:S3:9403:9	O
of	SAPHRIS.xml:S3:9413:2	O
diabetes	SAPHRIS.xml:S3:9416:8	O
mellitus	SAPHRIS.xml:S3:9425:8	O
who	SAPHRIS.xml:S3:9434:3	O
are	SAPHRIS.xml:S3:9438:3	O
started	SAPHRIS.xml:S3:9442:7	O
on	SAPHRIS.xml:S3:9450:2	O
atypical	SAPHRIS.xml:S3:9453:8	O
antipsychotics	SAPHRIS.xml:S3:9462:14	O
should	SAPHRIS.xml:S3:9477:6	O
be	SAPHRIS.xml:S3:9484:2	O
monitored	SAPHRIS.xml:S3:9487:9	O
regularly	SAPHRIS.xml:S3:9497:9	O
for	SAPHRIS.xml:S3:9507:3	O
worsening	SAPHRIS.xml:S3:9511:9	O
of	SAPHRIS.xml:S3:9521:2	O
glucose	SAPHRIS.xml:S3:9524:7	O
control	SAPHRIS.xml:S3:9532:7	O
.	SAPHRIS.xml:S3:9539:1	O

Patients	SAPHRIS.xml:S3:9541:8	O
with	SAPHRIS.xml:S3:9550:4	O
risk	SAPHRIS.xml:S3:9555:4	O
factors	SAPHRIS.xml:S3:9560:7	O
for	SAPHRIS.xml:S3:9568:3	O
diabetes	SAPHRIS.xml:S3:9572:8	O
mellitus	SAPHRIS.xml:S3:9581:8	O
(	SAPHRIS.xml:S3:9590:1	O
e	SAPHRIS.xml:S3:9591:1	O
.	SAPHRIS.xml:S3:9592:1	O
g	SAPHRIS.xml:S3:9593:1	O
.	SAPHRIS.xml:S3:9594:1	O
,	SAPHRIS.xml:S3:9595:1	O
obesity	SAPHRIS.xml:S3:9597:7	O
,	SAPHRIS.xml:S3:9604:1	O
family	SAPHRIS.xml:S3:9606:6	O
history	SAPHRIS.xml:S3:9613:7	O
of	SAPHRIS.xml:S3:9621:2	O
diabetes	SAPHRIS.xml:S3:9624:8	O
)	SAPHRIS.xml:S3:9632:1	O
who	SAPHRIS.xml:S3:9634:3	O
are	SAPHRIS.xml:S3:9638:3	O
starting	SAPHRIS.xml:S3:9642:8	O
treatment	SAPHRIS.xml:S3:9651:9	O
with	SAPHRIS.xml:S3:9661:4	O
atypical	SAPHRIS.xml:S3:9666:8	O
antipsychotics	SAPHRIS.xml:S3:9675:14	O
should	SAPHRIS.xml:S3:9690:6	O
undergo	SAPHRIS.xml:S3:9697:7	O
fasting	SAPHRIS.xml:S3:9705:7	O
blood	SAPHRIS.xml:S3:9713:5	O
glucose	SAPHRIS.xml:S3:9719:7	O
testing	SAPHRIS.xml:S3:9727:7	O
at	SAPHRIS.xml:S3:9735:2	O
the	SAPHRIS.xml:S3:9738:3	O
beginning	SAPHRIS.xml:S3:9742:9	O
of	SAPHRIS.xml:S3:9752:2	O
treatment	SAPHRIS.xml:S3:9755:9	O
and	SAPHRIS.xml:S3:9765:3	O
periodically	SAPHRIS.xml:S3:9769:12	O
during	SAPHRIS.xml:S3:9782:6	O
treatment	SAPHRIS.xml:S3:9789:9	O
.	SAPHRIS.xml:S3:9798:1	O

Any	SAPHRIS.xml:S3:9800:3	O
patient	SAPHRIS.xml:S3:9804:7	O
treated	SAPHRIS.xml:S3:9812:7	O
with	SAPHRIS.xml:S3:9820:4	O
atypical	SAPHRIS.xml:S3:9825:8	O
antipsychotics	SAPHRIS.xml:S3:9834:14	O
should	SAPHRIS.xml:S3:9849:6	O
be	SAPHRIS.xml:S3:9856:2	O
monitored	SAPHRIS.xml:S3:9859:9	O
for	SAPHRIS.xml:S3:9869:3	O
symptoms	SAPHRIS.xml:S3:9873:8	O
of	SAPHRIS.xml:S3:9882:2	O
hyperglycemia	SAPHRIS.xml:S3:9885:13	O
including	SAPHRIS.xml:S3:9899:9	O
polydipsia	SAPHRIS.xml:S3:9909:10	O
,	SAPHRIS.xml:S3:9919:1	O
polyuria	SAPHRIS.xml:S3:9921:8	O
,	SAPHRIS.xml:S3:9929:1	O
polyphagia	SAPHRIS.xml:S3:9931:10	O
,	SAPHRIS.xml:S3:9941:1	O
and	SAPHRIS.xml:S3:9943:3	O
weakness	SAPHRIS.xml:S3:9947:8	O
.	SAPHRIS.xml:S3:9955:1	O

Patients	SAPHRIS.xml:S3:9957:8	O
who	SAPHRIS.xml:S3:9966:3	O
develop	SAPHRIS.xml:S3:9970:7	O
symptoms	SAPHRIS.xml:S3:9978:8	O
of	SAPHRIS.xml:S3:9987:2	O
hyperglycemia	SAPHRIS.xml:S3:9990:13	O
during	SAPHRIS.xml:S3:10004:6	O
treatment	SAPHRIS.xml:S3:10011:9	O
with	SAPHRIS.xml:S3:10021:4	O
atypical	SAPHRIS.xml:S3:10026:8	O
antipsychotics	SAPHRIS.xml:S3:10035:14	O
should	SAPHRIS.xml:S3:10050:6	O
undergo	SAPHRIS.xml:S3:10057:7	O
fasting	SAPHRIS.xml:S3:10065:7	O
blood	SAPHRIS.xml:S3:10073:5	O
glucose	SAPHRIS.xml:S3:10079:7	O
testing	SAPHRIS.xml:S3:10087:7	O
.	SAPHRIS.xml:S3:10094:1	O

In	SAPHRIS.xml:S3:10096:2	O
some	SAPHRIS.xml:S3:10099:4	O
cases	SAPHRIS.xml:S3:10104:5	O
,	SAPHRIS.xml:S3:10109:1	O
hyperglycemia	SAPHRIS.xml:S3:10111:13	O
has	SAPHRIS.xml:S3:10125:3	O
resolved	SAPHRIS.xml:S3:10129:8	O
when	SAPHRIS.xml:S3:10138:4	O
the	SAPHRIS.xml:S3:10143:3	O
atypical	SAPHRIS.xml:S3:10147:8	O
antipsychotic	SAPHRIS.xml:S3:10156:13	O
was	SAPHRIS.xml:S3:10170:3	O
discontinued	SAPHRIS.xml:S3:10174:12	O
;	SAPHRIS.xml:S3:10186:1	O
however	SAPHRIS.xml:S3:10188:7	O
,	SAPHRIS.xml:S3:10195:1	O
some	SAPHRIS.xml:S3:10197:4	O
patients	SAPHRIS.xml:S3:10202:8	O
required	SAPHRIS.xml:S3:10211:8	O
continuation	SAPHRIS.xml:S3:10220:12	O
of	SAPHRIS.xml:S3:10233:2	O
anti	SAPHRIS.xml:S3:10236:4	O
-	SAPHRIS.xml:S3:10240:1	O
diabetic	SAPHRIS.xml:S3:10241:8	O
treatment	SAPHRIS.xml:S3:10250:9	O
despite	SAPHRIS.xml:S3:10260:7	O
discontinuation	SAPHRIS.xml:S3:10268:15	O
of	SAPHRIS.xml:S3:10284:2	O
the	SAPHRIS.xml:S3:10287:3	O
antipsychotic	SAPHRIS.xml:S3:10291:13	O
drug	SAPHRIS.xml:S3:10305:4	O
.	SAPHRIS.xml:S3:10309:1	O

Adult	SAPHRIS.xml:S3:10321:5	O
Patients	SAPHRIS.xml:S3:10327:8	O
:	SAPHRIS.xml:S3:10335:1	O
Pooled	SAPHRIS.xml:S3:10338:6	O
data	SAPHRIS.xml:S3:10345:4	O
from	SAPHRIS.xml:S3:10350:4	O
the	SAPHRIS.xml:S3:10355:3	O
short	SAPHRIS.xml:S3:10359:5	O
-	SAPHRIS.xml:S3:10364:1	O
term	SAPHRIS.xml:S3:10365:4	O
placebo	SAPHRIS.xml:S3:10370:7	O
-	SAPHRIS.xml:S3:10377:1	O
controlled	SAPHRIS.xml:S3:10378:10	O
schizophrenia	SAPHRIS.xml:S3:10389:13	O
and	SAPHRIS.xml:S3:10403:3	O
bipolar	SAPHRIS.xml:S3:10407:7	O
mania	SAPHRIS.xml:S3:10415:5	O
trials	SAPHRIS.xml:S3:10421:6	O
are	SAPHRIS.xml:S3:10428:3	O
presented	SAPHRIS.xml:S3:10432:9	O
in	SAPHRIS.xml:S3:10442:2	O
Table	SAPHRIS.xml:S3:10446:5	O
1	SAPHRIS.xml:S3:10452:1	O
.	SAPHRIS.xml:S3:10453:1	O

TABLE	SAPHRIS.xml:S3:10461:5	O
1	SAPHRIS.xml:S3:10467:1	O
:	SAPHRIS.xml:S3:10468:1	O
Changes	SAPHRIS.xml:S3:10470:7	O
in	SAPHRIS.xml:S3:10478:2	O
Fasting	SAPHRIS.xml:S3:10481:7	O
Glucose	SAPHRIS.xml:S3:10489:7	O
in	SAPHRIS.xml:S3:10497:2	O
Adult	SAPHRIS.xml:S3:10500:5	O
Patients	SAPHRIS.xml:S3:10506:8	O

N	SAPHRIS.xml:S3:10518:1	O
Number	SAPHRIS.xml:S3:10523:6	O
of	SAPHRIS.xml:S3:10530:2	O
patients	SAPHRIS.xml:S3:10533:8	O
who	SAPHRIS.xml:S3:10542:3	O
had	SAPHRIS.xml:S3:10546:3	O
assessments	SAPHRIS.xml:S3:10550:11	O
at	SAPHRIS.xml:S3:10562:2	O
both	SAPHRIS.xml:S3:10565:4	O
Baseline	SAPHRIS.xml:S3:10570:8	O
and	SAPHRIS.xml:S3:10579:3	O
Endpoint	SAPHRIS.xml:S3:10583:8	O
.	SAPHRIS.xml:S3:10591:1	O

N	SAPHRIS.xml:S3:10599:1	O
Number	SAPHRIS.xml:S3:10605:6	O
of	SAPHRIS.xml:S3:10612:2	O
patients	SAPHRIS.xml:S3:10615:8	O
at	SAPHRIS.xml:S3:10624:2	O
risk	SAPHRIS.xml:S3:10627:4	O
at	SAPHRIS.xml:S3:10632:2	O
Baseline	SAPHRIS.xml:S3:10635:8	O
with	SAPHRIS.xml:S3:10644:4	O
assessments	SAPHRIS.xml:S3:10649:11	O
at	SAPHRIS.xml:S3:10661:2	O
both	SAPHRIS.xml:S3:10664:4	O
Baseline	SAPHRIS.xml:S3:10669:8	O
and	SAPHRIS.xml:S3:10678:3	O
Endpoint	SAPHRIS.xml:S3:10682:8	O
.	SAPHRIS.xml:S3:10690:1	O

S	SAPHRIS.xml:S3:10698:1	O
Includes	SAPHRIS.xml:S3:10700:8	O
patients	SAPHRIS.xml:S3:10709:8	O
treated	SAPHRIS.xml:S3:10718:7	O
with	SAPHRIS.xml:S3:10726:4	O
flexible	SAPHRIS.xml:S3:10731:8	O
dose	SAPHRIS.xml:S3:10740:4	O
of	SAPHRIS.xml:S3:10745:2	O
SAPHRIS	SAPHRIS.xml:S3:10748:7	O
5	SAPHRIS.xml:S3:10756:1	O
or	SAPHRIS.xml:S3:10758:2	O
10	SAPHRIS.xml:S3:10761:2	O
mg	SAPHRIS.xml:S3:10764:2	O
twice	SAPHRIS.xml:S3:10767:5	O
daily	SAPHRIS.xml:S3:10773:5	O
(	SAPHRIS.xml:S3:10779:1	O
N	SAPHRIS.xml:S3:10780:1	O
90	SAPHRIS.xml:S3:10782:2	O
)	SAPHRIS.xml:S3:10784:1	O
.	SAPHRIS.xml:S3:10785:1	O

SAPHRIS	SAPHRIS.xml:S3:10793:7	O
5	SAPHRIS.xml:S3:10801:1	O
mg	SAPHRIS.xml:S3:10803:2	O
or	SAPHRIS.xml:S3:10806:2	O
10	SAPHRIS.xml:S3:10809:2	O
mg	SAPHRIS.xml:S3:10812:2	O
twice	SAPHRIS.xml:S3:10815:5	O
daily	SAPHRIS.xml:S3:10821:5	O
with	SAPHRIS.xml:S3:10827:4	O
flexible	SAPHRIS.xml:S3:10832:8	O
dosing	SAPHRIS.xml:S3:10841:6	O
.	SAPHRIS.xml:S3:10847:1	O

Schizophrenia	SAPHRIS.xml:S3:10878:13	O

(	SAPHRIS.xml:S3:10892:1	O
6	SAPHRIS.xml:S3:10893:1	O
-	SAPHRIS.xml:S3:10894:1	O
weeks	SAPHRIS.xml:S3:10895:5	O
)	SAPHRIS.xml:S3:10900:1	O
Bipolar	SAPHRIS.xml:S3:10903:7	O
(	SAPHRIS.xml:S3:10911:1	O
3	SAPHRIS.xml:S3:10912:1	O
-	SAPHRIS.xml:S3:10913:1	O
weeks	SAPHRIS.xml:S3:10914:5	O
)	SAPHRIS.xml:S3:10919:1	O

Placebo	SAPHRIS.xml:S3:10925:7	O
SAPHRIS	SAPHRIS.xml:S3:10946:7	O
Placebo	SAPHRIS.xml:S3:10960:7	O
SAPHRIS5	SAPHRIS.xml:S3:10972:8	O
or	SAPHRIS.xml:S3:10981:2	O
10	SAPHRIS.xml:S3:10984:2	O
mgtwice	SAPHRIS.xml:S3:10987:7	O
daily	SAPHRIS.xml:S3:10995:5	O

5	SAPHRIS.xml:S3:11009:1	O
mgtwice	SAPHRIS.xml:S3:11011:7	O
daily	SAPHRIS.xml:S3:11019:5	O
10	SAPHRIS.xml:S3:11030:2	O
mgtwice	SAPHRIS.xml:S3:11033:7	O
daily	SAPHRIS.xml:S3:11041:5	O
5	SAPHRIS.xml:S3:11048:1	O
or	SAPHRIS.xml:S3:11050:2	O
10	SAPHRIS.xml:S3:11053:2	O
mgtwice	SAPHRIS.xml:S3:11056:7	O
daily	SAPHRIS.xml:S3:11064:5	O
S	SAPHRIS.xml:S3:11071:1	O

Mean	SAPHRIS.xml:S3:11079:4	O
Change	SAPHRIS.xml:S3:11084:6	O
from	SAPHRIS.xml:S3:11091:4	O
Baseline	SAPHRIS.xml:S3:11096:8	O
in	SAPHRIS.xml:S3:11105:2	O
Fasting	SAPHRIS.xml:S3:11108:7	O
Glucose	SAPHRIS.xml:S3:11116:7	O
at	SAPHRIS.xml:S3:11124:2	O
Endpoint	SAPHRIS.xml:S3:11127:8	O

Change	SAPHRIS.xml:S3:11247:6	O

from	SAPHRIS.xml:S3:11254:4	O
Baseline	SAPHRIS.xml:S3:11259:8	O
(	SAPHRIS.xml:S3:11268:1	O
mg	SAPHRIS.xml:S3:11269:2	O
dL	SAPHRIS.xml:S3:11272:2	O
)	SAPHRIS.xml:S3:11274:1	O
(	SAPHRIS.xml:S3:11276:1	O
N	SAPHRIS.xml:S3:11277:1	O
)	SAPHRIS.xml:S3:11279:1	O
-	SAPHRIS.xml:S3:11282:1	O
0.2	SAPHRIS.xml:S3:11283:3	O
(	SAPHRIS.xml:S3:11286:1	O
232	SAPHRIS.xml:S3:11287:3	O
)	SAPHRIS.xml:S3:11290:1	O
3.8	SAPHRIS.xml:S3:11296:3	O
(	SAPHRIS.xml:S3:11299:1	O
158	SAPHRIS.xml:S3:11300:3	O
)	SAPHRIS.xml:S3:11303:1	O
1.1	SAPHRIS.xml:S3:11308:3	O
(	SAPHRIS.xml:S3:11311:1	O
153	SAPHRIS.xml:S3:11312:3	O
)	SAPHRIS.xml:S3:11315:1	O
3.2	SAPHRIS.xml:S3:11323:3	O
(	SAPHRIS.xml:S3:11326:1	O
377	SAPHRIS.xml:S3:11327:3	O
)	SAPHRIS.xml:S3:11330:1	O
-	SAPHRIS.xml:S3:11335:1	O
0.6	SAPHRIS.xml:S3:11336:3	O
(	SAPHRIS.xml:S3:11339:1	O
89	SAPHRIS.xml:S3:11340:2	O
)	SAPHRIS.xml:S3:11342:1	O
-	SAPHRIS.xml:S3:11350:1	O
0.6	SAPHRIS.xml:S3:11351:3	O
(	SAPHRIS.xml:S3:11354:1	O
156	SAPHRIS.xml:S3:11355:3	O
)	SAPHRIS.xml:S3:11358:1	O

Proportion	SAPHRIS.xml:S3:11368:10	O
of	SAPHRIS.xml:S3:11379:2	O
Patients	SAPHRIS.xml:S3:11382:8	O
with	SAPHRIS.xml:S3:11391:4	O
Shifts	SAPHRIS.xml:S3:11396:6	O
from	SAPHRIS.xml:S3:11403:4	O
Baseline	SAPHRIS.xml:S3:11408:8	O
to	SAPHRIS.xml:S3:11417:2	O
Endpoint	SAPHRIS.xml:S3:11420:8	O

Normal	SAPHRIS.xml:S3:11433:6	O
to	SAPHRIS.xml:S3:11440:2	O
High	SAPHRIS.xml:S3:11443:4	O
100	SAPHRIS.xml:S3:11448:3	O
to	SAPHRIS.xml:S3:11452:2	O
126	SAPHRIS.xml:S3:11457:3	O
mg	SAPHRIS.xml:S3:11461:2	O
dL	SAPHRIS.xml:S3:11464:2	O
4.1%	SAPHRIS.xml:S3:11468:4	O
4.5%	SAPHRIS.xml:S3:11482:4	O
4.5%	SAPHRIS.xml:S3:11494:4	O
5.0%	SAPHRIS.xml:S3:11509:4	O
3.3%	SAPHRIS.xml:S3:11521:4	O
2.7%	SAPHRIS.xml:S3:11536:4	O

(	SAPHRIS.xml:S3:11554:1	O
n	SAPHRIS.xml:S3:11555:1	O
N	SAPHRIS.xml:S3:11557:1	O
)	SAPHRIS.xml:S3:11560:1	O
(	SAPHRIS.xml:S3:11575:1	O
7	SAPHRIS.xml:S3:11576:1	O
170	SAPHRIS.xml:S3:11578:3	O
)	SAPHRIS.xml:S3:11581:1	O
(	SAPHRIS.xml:S3:11589:1	O
5	SAPHRIS.xml:S3:11590:1	O
111	SAPHRIS.xml:S3:11592:3	O
)	SAPHRIS.xml:S3:11595:1	O
(	SAPHRIS.xml:S3:11601:1	O
5	SAPHRIS.xml:S3:11602:1	O
111	SAPHRIS.xml:S3:11604:3	O
)	SAPHRIS.xml:S3:11607:1	O
(	SAPHRIS.xml:S3:11616:1	O
13	SAPHRIS.xml:S3:11617:2	O
262	SAPHRIS.xml:S3:11620:3	O
)	SAPHRIS.xml:S3:11623:1	O
(	SAPHRIS.xml:S3:11628:1	O
2	SAPHRIS.xml:S3:11629:1	O
61	SAPHRIS.xml:S3:11631:2	O
)	SAPHRIS.xml:S3:11633:1	O
(	SAPHRIS.xml:S3:11643:1	O
3	SAPHRIS.xml:S3:11644:1	O
111	SAPHRIS.xml:S3:11646:3	O
)	SAPHRIS.xml:S3:11649:1	O

Borderline	SAPHRIS.xml:S3:11661:10	O
to	SAPHRIS.xml:S3:11672:2	O
High	SAPHRIS.xml:S3:11675:4	O
100	SAPHRIS.xml:S3:11681:3	O
and	SAPHRIS.xml:S3:11685:3	O
126	SAPHRIS.xml:S3:11690:3	O
to	SAPHRIS.xml:S3:11693:2	O
126	SAPHRIS.xml:S3:11698:3	O
mg	SAPHRIS.xml:S3:11702:2	O
dL	SAPHRIS.xml:S3:11705:2	O
5.9%	SAPHRIS.xml:S3:11709:4	O
6.8%	SAPHRIS.xml:S3:11723:4	O
6.3%	SAPHRIS.xml:S3:11735:4	O
10.5%	SAPHRIS.xml:S3:11750:5	O
0.0%	SAPHRIS.xml:S3:11762:4	O
11.4%	SAPHRIS.xml:S3:11777:5	O

(	SAPHRIS.xml:S3:11795:1	O
n	SAPHRIS.xml:S3:11796:1	O
N	SAPHRIS.xml:S3:11798:1	O
)	SAPHRIS.xml:S3:11801:1	O
(	SAPHRIS.xml:S3:11816:1	O
3	SAPHRIS.xml:S3:11817:1	O
51	SAPHRIS.xml:S3:11819:2	O
)	SAPHRIS.xml:S3:11821:1	O
(	SAPHRIS.xml:S3:11830:1	O
3	SAPHRIS.xml:S3:11831:1	O
44	SAPHRIS.xml:S3:11833:2	O
)	SAPHRIS.xml:S3:11835:1	O
(	SAPHRIS.xml:S3:11842:1	O
2	SAPHRIS.xml:S3:11843:1	O
32	SAPHRIS.xml:S3:11845:2	O
)	SAPHRIS.xml:S3:11847:1	O
(	SAPHRIS.xml:S3:11857:1	O
10	SAPHRIS.xml:S3:11858:2	O
95	SAPHRIS.xml:S3:11861:2	O
)	SAPHRIS.xml:S3:11863:1	O
(	SAPHRIS.xml:S3:11869:1	O
0	SAPHRIS.xml:S3:11870:1	O
23	SAPHRIS.xml:S3:11872:2	O
)	SAPHRIS.xml:S3:11874:1	O
(	SAPHRIS.xml:S3:11884:1	O
4	SAPHRIS.xml:S3:11885:1	O
35	SAPHRIS.xml:S3:11887:2	O
)	SAPHRIS.xml:S3:11889:1	O

In	SAPHRIS.xml:S3:11921:2	O
a	SAPHRIS.xml:S3:11924:1	O
52	SAPHRIS.xml:S3:11926:2	O
-	SAPHRIS.xml:S3:11928:1	O
week	SAPHRIS.xml:S3:11929:4	O
,	SAPHRIS.xml:S3:11933:1	O
double	SAPHRIS.xml:S3:11935:6	O
-	SAPHRIS.xml:S3:11941:1	O
blind	SAPHRIS.xml:S3:11942:5	O
,	SAPHRIS.xml:S3:11947:1	O
comparator	SAPHRIS.xml:S3:11949:10	O
-	SAPHRIS.xml:S3:11959:1	O
controlled	SAPHRIS.xml:S3:11960:10	O
trial	SAPHRIS.xml:S3:11971:5	O
that	SAPHRIS.xml:S3:11977:4	O
included	SAPHRIS.xml:S3:11982:8	O
primarily	SAPHRIS.xml:S3:11991:9	O
patients	SAPHRIS.xml:S3:12001:8	O
with	SAPHRIS.xml:S3:12010:4	O
schizophrenia	SAPHRIS.xml:S3:12015:13	O
,	SAPHRIS.xml:S3:12028:1	O
the	SAPHRIS.xml:S3:12030:3	O
mean	SAPHRIS.xml:S3:12034:4	O
increase	SAPHRIS.xml:S3:12039:8	B-AdverseReaction
from	SAPHRIS.xml:S3:12048:4	O
baseline	SAPHRIS.xml:S3:12053:8	O
of	SAPHRIS.xml:S3:12062:2	I-AdverseReaction
fasting	SAPHRIS.xml:S3:12065:7	I-AdverseReaction
glucose	SAPHRIS.xml:S3:12073:7	I-AdverseReaction
was	SAPHRIS.xml:S3:12081:3	O
2.4	SAPHRIS.xml:S3:12085:3	O
mg	SAPHRIS.xml:S3:12089:2	O
dL	SAPHRIS.xml:S3:12092:2	O
.	SAPHRIS.xml:S3:12094:1	O

Pediatric	SAPHRIS.xml:S3:12106:9	O

Patients	SAPHRIS.xml:S3:12116:8	O
:	SAPHRIS.xml:S3:12124:1	O
Data	SAPHRIS.xml:S3:12127:4	O
from	SAPHRIS.xml:S3:12132:4	O
the	SAPHRIS.xml:S3:12137:3	O
short	SAPHRIS.xml:S3:12141:5	O
-	SAPHRIS.xml:S3:12146:1	O
term	SAPHRIS.xml:S3:12147:4	O
,	SAPHRIS.xml:S3:12151:1	O
placebo	SAPHRIS.xml:S3:12153:7	O
-	SAPHRIS.xml:S3:12160:1	O
controlled	SAPHRIS.xml:S3:12161:10	O
trial	SAPHRIS.xml:S3:12172:5	O
in	SAPHRIS.xml:S3:12178:2	O
pediatric	SAPHRIS.xml:S3:12181:9	O
patients	SAPHRIS.xml:S3:12191:8	O
with	SAPHRIS.xml:S3:12200:4	O
bipolar	SAPHRIS.xml:S3:12205:7	O
I	SAPHRIS.xml:S3:12213:1	O
disorder	SAPHRIS.xml:S3:12215:8	O
are	SAPHRIS.xml:S3:12224:3	O
shown	SAPHRIS.xml:S3:12228:5	O
in	SAPHRIS.xml:S3:12234:2	O
Table	SAPHRIS.xml:S3:12238:5	O
2	SAPHRIS.xml:S3:12244:1	O
.	SAPHRIS.xml:S3:12247:1	O

TABLE	SAPHRIS.xml:S3:12253:5	O
2	SAPHRIS.xml:S3:12259:1	O
:	SAPHRIS.xml:S3:12260:1	O
Changes	SAPHRIS.xml:S3:12262:7	O
in	SAPHRIS.xml:S3:12270:2	O
Fasting	SAPHRIS.xml:S3:12273:7	O
Glucose	SAPHRIS.xml:S3:12281:7	O
in	SAPHRIS.xml:S3:12289:2	O
Pediatric	SAPHRIS.xml:S3:12292:9	O
Subjects	SAPHRIS.xml:S3:12302:8	O

Bipolar	SAPHRIS.xml:S3:12332:7	O
I	SAPHRIS.xml:S3:12340:1	O
Disorder	SAPHRIS.xml:S3:12342:8	O
(	SAPHRIS.xml:S3:12351:1	O
3	SAPHRIS.xml:S3:12352:1	O
-	SAPHRIS.xml:S3:12353:1	O
weeks	SAPHRIS.xml:S3:12354:5	O
)	SAPHRIS.xml:S3:12359:1	O

Placebo	SAPHRIS.xml:S3:12369:7	O
SAPHRIS2	SAPHRIS.xml:S3:12384:8	O
.	SAPHRIS.xml:S3:12392:1	O
5	SAPHRIS.xml:S3:12393:1	O
mgtwice	SAPHRIS.xml:S3:12395:7	O
daily	SAPHRIS.xml:S3:12403:5	O
SAPHRIS5	SAPHRIS.xml:S3:12410:8	O
mgtwice	SAPHRIS.xml:S3:12419:7	O
daily	SAPHRIS.xml:S3:12427:5	O
SAPHRIS10	SAPHRIS.xml:S3:12435:9	O
mgtwice	SAPHRIS.xml:S3:12445:7	O
daily	SAPHRIS.xml:S3:12453:5	O

Mean	SAPHRIS.xml:S3:12482:4	O
Change	SAPHRIS.xml:S3:12487:6	O
from	SAPHRIS.xml:S3:12494:4	O
Baseline	SAPHRIS.xml:S3:12499:8	O
in	SAPHRIS.xml:S3:12508:2	O
Fasting	SAPHRIS.xml:S3:12511:7	O
Glucose	SAPHRIS.xml:S3:12519:7	O
at	SAPHRIS.xml:S3:12527:2	O
Endpoint	SAPHRIS.xml:S3:12530:8	O

Change	SAPHRIS.xml:S3:12547:6	O
from	SAPHRIS.xml:S3:12554:4	O
Baseline	SAPHRIS.xml:S3:12559:8	O
(	SAPHRIS.xml:S3:12568:1	O
mg	SAPHRIS.xml:S3:12569:2	O
dL	SAPHRIS.xml:S3:12572:2	O
)	SAPHRIS.xml:S3:12574:1	O
(	SAPHRIS.xml:S3:12576:1	O
N	SAPHRIS.xml:S3:12577:1	O
)	SAPHRIS.xml:S3:12579:1	O
-	SAPHRIS.xml:S3:12582:1	O
2.24	SAPHRIS.xml:S3:12583:4	O
(	SAPHRIS.xml:S3:12587:1	O
56	SAPHRIS.xml:S3:12588:2	O
)	SAPHRIS.xml:S3:12590:1	O
1.43	SAPHRIS.xml:S3:12604:4	O
(	SAPHRIS.xml:S3:12608:1	O
51	SAPHRIS.xml:S3:12609:2	O
)	SAPHRIS.xml:S3:12611:1	O
-	SAPHRIS.xml:S3:12629:1	O
0.45	SAPHRIS.xml:S3:12630:4	O
(	SAPHRIS.xml:S3:12634:1	O
57	SAPHRIS.xml:S3:12635:2	O
)	SAPHRIS.xml:S3:12637:1	O
0.34	SAPHRIS.xml:S3:12653:4	O
(	SAPHRIS.xml:S3:12657:1	O
52	SAPHRIS.xml:S3:12658:2	O
)	SAPHRIS.xml:S3:12660:1	O

Proportion	SAPHRIS.xml:S3:12691:10	O
of	SAPHRIS.xml:S3:12702:2	O
Subjects	SAPHRIS.xml:S3:12705:8	O
with	SAPHRIS.xml:S3:12714:4	O
Shifts	SAPHRIS.xml:S3:12719:6	O
from	SAPHRIS.xml:S3:12726:4	O
Baseline	SAPHRIS.xml:S3:12731:8	O
to	SAPHRIS.xml:S3:12740:2	O
Endpoint	SAPHRIS.xml:S3:12743:8	O

Normal	SAPHRIS.xml:S3:12760:6	O
to	SAPHRIS.xml:S3:12767:2	O
High	SAPHRIS.xml:S3:12770:4	O
45	SAPHRIS.xml:S3:12775:2	O
100	SAPHRIS.xml:S3:12782:3	O
to	SAPHRIS.xml:S3:12786:2	O
126	SAPHRIS.xml:S3:12791:3	O
mg	SAPHRIS.xml:S3:12795:2	O
dL	SAPHRIS.xml:S3:12798:2	O
0%	SAPHRIS.xml:S3:12802:2	O
0%	SAPHRIS.xml:S3:12824:2	O
1.8%	SAPHRIS.xml:S3:12849:4	O
0%	SAPHRIS.xml:S3:12873:2	O

(	SAPHRIS.xml:S3:12896:1	O
n	SAPHRIS.xml:S3:12897:1	O
N	SAPHRIS.xml:S3:12899:1	O
)	SAPHRIS.xml:S3:12901:1	O
(	SAPHRIS.xml:S3:12911:1	O
0	SAPHRIS.xml:S3:12912:1	O
56	SAPHRIS.xml:S3:12914:2	O
)	SAPHRIS.xml:S3:12916:1	O
(	SAPHRIS.xml:S3:12933:1	O
0	SAPHRIS.xml:S3:12934:1	O
51	SAPHRIS.xml:S3:12936:2	O
)	SAPHRIS.xml:S3:12938:1	O
(	SAPHRIS.xml:S3:12958:1	O
1	SAPHRIS.xml:S3:12959:1	O
57	SAPHRIS.xml:S3:12961:2	O
)	SAPHRIS.xml:S3:12963:1	O
(	SAPHRIS.xml:S3:12982:1	O
0	SAPHRIS.xml:S3:12983:1	O
52	SAPHRIS.xml:S3:12985:2	O
)	SAPHRIS.xml:S3:12987:1	O

Dyslipidemia	SAPHRIS.xml:S3:13019:12	B-AdverseReaction

Undesirable	SAPHRIS.xml:S3:13042:11	B-AdverseReaction

alterations	SAPHRIS.xml:S3:13054:11	I-AdverseReaction
in	SAPHRIS.xml:S3:13066:2	I-AdverseReaction
lipids	SAPHRIS.xml:S3:13069:6	I-AdverseReaction
have	SAPHRIS.xml:S3:13076:4	O
been	SAPHRIS.xml:S3:13081:4	O
observed	SAPHRIS.xml:S3:13086:8	O
in	SAPHRIS.xml:S3:13095:2	O
patients	SAPHRIS.xml:S3:13098:8	O
treated	SAPHRIS.xml:S3:13107:7	O
with	SAPHRIS.xml:S3:13115:4	O
atypical	SAPHRIS.xml:S3:13120:8	B-DrugClass
antipsychotics	SAPHRIS.xml:S3:13129:14	I-DrugClass
.	SAPHRIS.xml:S3:13143:1	O

Adult	SAPHRIS.xml:S3:13155:5	O
Patients	SAPHRIS.xml:S3:13161:8	O
:	SAPHRIS.xml:S3:13169:1	O
Pooled	SAPHRIS.xml:S3:13172:6	O
data	SAPHRIS.xml:S3:13179:4	O
from	SAPHRIS.xml:S3:13184:4	O
the	SAPHRIS.xml:S3:13189:3	O
short	SAPHRIS.xml:S3:13193:5	O
-	SAPHRIS.xml:S3:13198:1	O
term	SAPHRIS.xml:S3:13199:4	O
,	SAPHRIS.xml:S3:13203:1	O
placebo	SAPHRIS.xml:S3:13205:7	O
-	SAPHRIS.xml:S3:13212:1	O
controlled	SAPHRIS.xml:S3:13213:10	O
schizophrenia	SAPHRIS.xml:S3:13224:13	O
and	SAPHRIS.xml:S3:13238:3	O
bipolar	SAPHRIS.xml:S3:13242:7	O
mania	SAPHRIS.xml:S3:13250:5	O
trials	SAPHRIS.xml:S3:13256:6	O
are	SAPHRIS.xml:S3:13263:3	O
presented	SAPHRIS.xml:S3:13267:9	O
in	SAPHRIS.xml:S3:13277:2	O
Table	SAPHRIS.xml:S3:13281:5	O
3	SAPHRIS.xml:S3:13287:1	O
.	SAPHRIS.xml:S3:13288:1	O

TABLE	SAPHRIS.xml:S3:13296:5	O
3	SAPHRIS.xml:S3:13302:1	O
:	SAPHRIS.xml:S3:13303:1	O
Changes	SAPHRIS.xml:S3:13305:7	O
in	SAPHRIS.xml:S3:13313:2	O
Lipids	SAPHRIS.xml:S3:13316:6	O
in	SAPHRIS.xml:S3:13323:2	O
Adult	SAPHRIS.xml:S3:13326:5	O
Patients	SAPHRIS.xml:S3:13332:8	O

N	SAPHRIS.xml:S3:13344:1	O
Number	SAPHRIS.xml:S3:13349:6	O
of	SAPHRIS.xml:S3:13356:2	O
subjects	SAPHRIS.xml:S3:13359:8	O
who	SAPHRIS.xml:S3:13368:3	O
had	SAPHRIS.xml:S3:13372:3	O
assessments	SAPHRIS.xml:S3:13376:11	O
at	SAPHRIS.xml:S3:13388:2	O
both	SAPHRIS.xml:S3:13391:4	O
Baseline	SAPHRIS.xml:S3:13396:8	O
and	SAPHRIS.xml:S3:13405:3	O
Endpoint	SAPHRIS.xml:S3:13409:8	O
.	SAPHRIS.xml:S3:13417:1	O

S	SAPHRIS.xml:S3:13425:1	O
Includes	SAPHRIS.xml:S3:13427:8	O
subjects	SAPHRIS.xml:S3:13436:8	O
treated	SAPHRIS.xml:S3:13445:7	O
with	SAPHRIS.xml:S3:13453:4	O
flexible	SAPHRIS.xml:S3:13458:8	O
dose	SAPHRIS.xml:S3:13467:4	O
of	SAPHRIS.xml:S3:13472:2	O
SAPHRIS	SAPHRIS.xml:S3:13475:7	O
5	SAPHRIS.xml:S3:13483:1	O
or	SAPHRIS.xml:S3:13485:2	O
10	SAPHRIS.xml:S3:13488:2	O
mg	SAPHRIS.xml:S3:13491:2	O
twice	SAPHRIS.xml:S3:13494:5	O
daily	SAPHRIS.xml:S3:13500:5	O
(	SAPHRIS.xml:S3:13506:1	O
N	SAPHRIS.xml:S3:13507:1	O
90	SAPHRIS.xml:S3:13509:2	O
)	SAPHRIS.xml:S3:13511:1	O
.	SAPHRIS.xml:S3:13512:1	O

SAPHRIS	SAPHRIS.xml:S3:13520:7	O
5	SAPHRIS.xml:S3:13528:1	O
mg	SAPHRIS.xml:S3:13530:2	O
or	SAPHRIS.xml:S3:13533:2	O
10	SAPHRIS.xml:S3:13536:2	O
mg	SAPHRIS.xml:S3:13539:2	O
twice	SAPHRIS.xml:S3:13542:5	O
daily	SAPHRIS.xml:S3:13548:5	O
with	SAPHRIS.xml:S3:13554:4	O
flexible	SAPHRIS.xml:S3:13559:8	O
dosing	SAPHRIS.xml:S3:13568:6	O
.	SAPHRIS.xml:S3:13574:1	O

Schizophrenia	SAPHRIS.xml:S3:13603:13	O

(	SAPHRIS.xml:S3:13617:1	O
6	SAPHRIS.xml:S3:13618:1	O
-	SAPHRIS.xml:S3:13619:1	O
weeks	SAPHRIS.xml:S3:13620:5	O
)	SAPHRIS.xml:S3:13625:1	O
Bipolar	SAPHRIS.xml:S3:13628:7	O
(	SAPHRIS.xml:S3:13636:1	O
3	SAPHRIS.xml:S3:13637:1	O
-	SAPHRIS.xml:S3:13638:1	O
weeks	SAPHRIS.xml:S3:13639:5	O
)	SAPHRIS.xml:S3:13644:1	O

Placebo	SAPHRIS.xml:S3:13650:7	O
SAPHRIS	SAPHRIS.xml:S3:13669:7	O
Placebo	SAPHRIS.xml:S3:13684:7	O
SAPHRIS5	SAPHRIS.xml:S3:13700:8	O
or	SAPHRIS.xml:S3:13709:2	O
10	SAPHRIS.xml:S3:13712:2	O
mgtwice	SAPHRIS.xml:S3:13715:7	O
daily	SAPHRIS.xml:S3:13723:5	O

5	SAPHRIS.xml:S3:13737:1	O
mgtwice	SAPHRIS.xml:S3:13739:7	O
daily	SAPHRIS.xml:S3:13747:5	O
10	SAPHRIS.xml:S3:13756:2	O
mgtwice	SAPHRIS.xml:S3:13759:7	O
daily	SAPHRIS.xml:S3:13767:5	O
5	SAPHRIS.xml:S3:13774:1	O
or	SAPHRIS.xml:S3:13776:2	O
10	SAPHRIS.xml:S3:13779:2	O
mgtwice	SAPHRIS.xml:S3:13782:7	O
daily	SAPHRIS.xml:S3:13790:5	O
S	SAPHRIS.xml:S3:13797:1	O

Mean	SAPHRIS.xml:S3:13805:4	O
Change	SAPHRIS.xml:S3:13810:6	O
from	SAPHRIS.xml:S3:13817:4	O
Baseline	SAPHRIS.xml:S3:13822:8	O
(	SAPHRIS.xml:S3:13831:1	O
mg	SAPHRIS.xml:S3:13832:2	O
dL	SAPHRIS.xml:S3:13835:2	O
)	SAPHRIS.xml:S3:13837:1	O

Total	SAPHRIS.xml:S3:13843:5	O
cholesterol	SAPHRIS.xml:S3:13849:11	O
(	SAPHRIS.xml:S3:13860:1	O
N	SAPHRIS.xml:S3:13861:1	O
)	SAPHRIS.xml:S3:13863:1	O
-	SAPHRIS.xml:S3:13866:1	O
2.2	SAPHRIS.xml:S3:13867:3	O
(	SAPHRIS.xml:S3:13870:1	O
351	SAPHRIS.xml:S3:13871:3	O
)	SAPHRIS.xml:S3:13874:1	O
-	SAPHRIS.xml:S3:13881:1	O
2.4	SAPHRIS.xml:S3:13882:3	O
(	SAPHRIS.xml:S3:13885:1	O
258	SAPHRIS.xml:S3:13886:3	O
)	SAPHRIS.xml:S3:13889:1	O
3.3	SAPHRIS.xml:S3:13897:3	O
(	SAPHRIS.xml:S3:13900:1	O
199	SAPHRIS.xml:S3:13901:3	O
)	SAPHRIS.xml:S3:13904:1	O
0.4	SAPHRIS.xml:S3:13913:3	O
(	SAPHRIS.xml:S3:13916:1	O
539	SAPHRIS.xml:S3:13917:3	O
)	SAPHRIS.xml:S3:13920:1	O
-	SAPHRIS.xml:S3:13927:1	O
1.5	SAPHRIS.xml:S3:13928:3	O
(	SAPHRIS.xml:S3:13931:1	O
163	SAPHRIS.xml:S3:13932:3	O
)	SAPHRIS.xml:S3:13935:1	O
1.1	SAPHRIS.xml:S3:13942:3	O
(	SAPHRIS.xml:S3:13945:1	O
322	SAPHRIS.xml:S3:13946:3	O
)	SAPHRIS.xml:S3:13949:1	O

LDL	SAPHRIS.xml:S3:13960:3	O
(	SAPHRIS.xml:S3:13964:1	O
N	SAPHRIS.xml:S3:13965:1	O
)	SAPHRIS.xml:S3:13967:1	O
0.1	SAPHRIS.xml:S3:13979:3	O
(	SAPHRIS.xml:S3:13982:1	O
285	SAPHRIS.xml:S3:13983:3	O
)	SAPHRIS.xml:S3:13986:1	O
-	SAPHRIS.xml:S3:13994:1	O
0.2	SAPHRIS.xml:S3:13995:3	O
(	SAPHRIS.xml:S3:13998:1	O
195	SAPHRIS.xml:S3:13999:3	O
)	SAPHRIS.xml:S3:14002:1	O
2.6	SAPHRIS.xml:S3:14010:3	O
(	SAPHRIS.xml:S3:14013:1	O
195	SAPHRIS.xml:S3:14014:3	O
)	SAPHRIS.xml:S3:14017:1	O
1.3	SAPHRIS.xml:S3:14026:3	O
(	SAPHRIS.xml:S3:14029:1	O
465	SAPHRIS.xml:S3:14030:3	O
)	SAPHRIS.xml:S3:14033:1	O
1.9	SAPHRIS.xml:S3:14040:3	O
(	SAPHRIS.xml:S3:14043:1	O
158	SAPHRIS.xml:S3:14044:3	O
)	SAPHRIS.xml:S3:14047:1	O
1.6	SAPHRIS.xml:S3:14055:3	O
(	SAPHRIS.xml:S3:14058:1	O
304	SAPHRIS.xml:S3:14059:3	O
)	SAPHRIS.xml:S3:14062:1	O

HDL	SAPHRIS.xml:S3:14073:3	O
(	SAPHRIS.xml:S3:14077:1	O
N	SAPHRIS.xml:S3:14078:1	O
)	SAPHRIS.xml:S3:14080:1	O
0.5	SAPHRIS.xml:S3:14092:3	O
(	SAPHRIS.xml:S3:14095:1	O
290	SAPHRIS.xml:S3:14096:3	O
)	SAPHRIS.xml:S3:14099:1	O
0.4	SAPHRIS.xml:S3:14107:3	O
(	SAPHRIS.xml:S3:14110:1	O
199	SAPHRIS.xml:S3:14111:3	O
)	SAPHRIS.xml:S3:14114:1	O
1.0	SAPHRIS.xml:S3:14123:3	O
(	SAPHRIS.xml:S3:14126:1	O
199	SAPHRIS.xml:S3:14127:3	O
)	SAPHRIS.xml:S3:14130:1	O
0.5	SAPHRIS.xml:S3:14139:3	O
(	SAPHRIS.xml:S3:14142:1	O
480	SAPHRIS.xml:S3:14143:3	O
)	SAPHRIS.xml:S3:14146:1	O
0.0	SAPHRIS.xml:S3:14153:3	O
(	SAPHRIS.xml:S3:14156:1	O
163	SAPHRIS.xml:S3:14157:3	O
)	SAPHRIS.xml:S3:14160:1	O
0.9	SAPHRIS.xml:S3:14168:3	O
(	SAPHRIS.xml:S3:14171:1	O
322	SAPHRIS.xml:S3:14172:3	O
)	SAPHRIS.xml:S3:14175:1	O

Fasting	SAPHRIS.xml:S3:14186:7	O
triglycerides	SAPHRIS.xml:S3:14194:13	O
(	SAPHRIS.xml:S3:14208:1	O
N	SAPHRIS.xml:S3:14209:1	O
)	SAPHRIS.xml:S3:14211:1	O
-	SAPHRIS.xml:S3:14214:1	O
7.6	SAPHRIS.xml:S3:14215:3	O
(	SAPHRIS.xml:S3:14218:1	O
233	SAPHRIS.xml:S3:14219:3	O
)	SAPHRIS.xml:S3:14222:1	O
-	SAPHRIS.xml:S3:14229:1	O
1.9	SAPHRIS.xml:S3:14230:3	O
(	SAPHRIS.xml:S3:14233:1	O
159	SAPHRIS.xml:S3:14234:3	O
)	SAPHRIS.xml:S3:14237:1	O
0.1	SAPHRIS.xml:S3:14245:3	O
(	SAPHRIS.xml:S3:14248:1	O
154	SAPHRIS.xml:S3:14249:3	O
)	SAPHRIS.xml:S3:14252:1	O
3.8	SAPHRIS.xml:S3:14261:3	O
(	SAPHRIS.xml:S3:14264:1	O
380	SAPHRIS.xml:S3:14265:3	O
)	SAPHRIS.xml:S3:14268:1	O
-	SAPHRIS.xml:S3:14275:1	O
17.9	SAPHRIS.xml:S3:14276:4	O
(	SAPHRIS.xml:S3:14280:1	O
129	SAPHRIS.xml:S3:14281:3	O
)	SAPHRIS.xml:S3:14284:1	O
-	SAPHRIS.xml:S3:14290:1	O
3.5	SAPHRIS.xml:S3:14291:3	O
(	SAPHRIS.xml:S3:14294:1	O
237	SAPHRIS.xml:S3:14295:3	O
)	SAPHRIS.xml:S3:14298:1	O

Proportion	SAPHRIS.xml:S3:14308:10	O
of	SAPHRIS.xml:S3:14319:2	O
Patients	SAPHRIS.xml:S3:14322:8	O
with	SAPHRIS.xml:S3:14331:4	O
Shifts	SAPHRIS.xml:S3:14336:6	O
from	SAPHRIS.xml:S3:14343:4	O
Baseline	SAPHRIS.xml:S3:14348:8	O
to	SAPHRIS.xml:S3:14357:2	O
Endpoint	SAPHRIS.xml:S3:14360:8	O

Total	SAPHRIS.xml:S3:14373:5	O
cholesterolNormal	SAPHRIS.xml:S3:14379:17	O
to	SAPHRIS.xml:S3:14397:2	O
High	SAPHRIS.xml:S3:14400:4	O
200	SAPHRIS.xml:S3:14405:3	O
to	SAPHRIS.xml:S3:14409:2	O
240	SAPHRIS.xml:S3:14414:3	O
(	SAPHRIS.xml:S3:14417:1	O
mg	SAPHRIS.xml:S3:14418:2	O
dL	SAPHRIS.xml:S3:14421:2	O
)	SAPHRIS.xml:S3:14423:1	O
(	SAPHRIS.xml:S3:14425:1	O
n	SAPHRIS.xml:S3:14426:1	O
N	SAPHRIS.xml:S3:14428:1	O
)	SAPHRIS.xml:S3:14430:1	O
1.3%	SAPHRIS.xml:S3:14433:4	O
(	SAPHRIS.xml:S3:14437:1	O
3	SAPHRIS.xml:S3:14438:1	O
225	SAPHRIS.xml:S3:14440:3	O
)	SAPHRIS.xml:S3:14443:1	O
0.6%	SAPHRIS.xml:S3:14448:4	O
(	SAPHRIS.xml:S3:14452:1	O
1	SAPHRIS.xml:S3:14453:1	O
161	SAPHRIS.xml:S3:14455:3	O
)	SAPHRIS.xml:S3:14458:1	O
2.2%	SAPHRIS.xml:S3:14464:4	O
(	SAPHRIS.xml:S3:14468:1	O
3	SAPHRIS.xml:S3:14469:1	O
134	SAPHRIS.xml:S3:14471:3	O
)	SAPHRIS.xml:S3:14474:1	O
1.7%	SAPHRIS.xml:S3:14480:4	O
(	SAPHRIS.xml:S3:14484:1	O
6	SAPHRIS.xml:S3:14485:1	O
343	SAPHRIS.xml:S3:14487:3	O
)	SAPHRIS.xml:S3:14490:1	O
1.1%	SAPHRIS.xml:S3:14494:4	O
(	SAPHRIS.xml:S3:14498:1	O
1	SAPHRIS.xml:S3:14499:1	O
95	SAPHRIS.xml:S3:14501:2	O
)	SAPHRIS.xml:S3:14503:1	O
2.5%	SAPHRIS.xml:S3:14509:4	O
(	SAPHRIS.xml:S3:14513:1	O
5	SAPHRIS.xml:S3:14514:1	O
204	SAPHRIS.xml:S3:14516:3	O
)	SAPHRIS.xml:S3:14519:1	O

LDLNormal	SAPHRIS.xml:S3:14527:9	O
to	SAPHRIS.xml:S3:14537:2	O
High	SAPHRIS.xml:S3:14540:4	O
100	SAPHRIS.xml:S3:14545:3	O
to	SAPHRIS.xml:S3:14549:2	O
160	SAPHRIS.xml:S3:14554:3	O
(	SAPHRIS.xml:S3:14557:1	O
mg	SAPHRIS.xml:S3:14558:2	O
dL	SAPHRIS.xml:S3:14561:2	O
)	SAPHRIS.xml:S3:14563:1	O
(	SAPHRIS.xml:S3:14565:1	O
n	SAPHRIS.xml:S3:14566:1	O
N	SAPHRIS.xml:S3:14568:1	O
)	SAPHRIS.xml:S3:14570:1	O
1.7%	SAPHRIS.xml:S3:14573:4	O
(	SAPHRIS.xml:S3:14577:1	O
2	SAPHRIS.xml:S3:14578:1	O
117	SAPHRIS.xml:S3:14580:3	O
)	SAPHRIS.xml:S3:14583:1	O
0.0%	SAPHRIS.xml:S3:14588:4	O
(	SAPHRIS.xml:S3:14592:1	O
0	SAPHRIS.xml:S3:14593:1	O
80	SAPHRIS.xml:S3:14595:2	O
)	SAPHRIS.xml:S3:14597:1	O
1.2%	SAPHRIS.xml:S3:14604:4	O
(	SAPHRIS.xml:S3:14608:1	O
1	SAPHRIS.xml:S3:14609:1	O
86	SAPHRIS.xml:S3:14611:2	O
)	SAPHRIS.xml:S3:14613:1	O
1.0%	SAPHRIS.xml:S3:14620:4	O
(	SAPHRIS.xml:S3:14624:1	O
2	SAPHRIS.xml:S3:14625:1	O
196	SAPHRIS.xml:S3:14627:3	O
)	SAPHRIS.xml:S3:14630:1	O
1.9%	SAPHRIS.xml:S3:14634:4	O
(	SAPHRIS.xml:S3:14638:1	O
1	SAPHRIS.xml:S3:14639:1	O
53	SAPHRIS.xml:S3:14641:2	O
)	SAPHRIS.xml:S3:14643:1	O
0.0%	SAPHRIS.xml:S3:14649:4	O
(	SAPHRIS.xml:S3:14653:1	O
0	SAPHRIS.xml:S3:14654:1	O
141	SAPHRIS.xml:S3:14656:3	O
)	SAPHRIS.xml:S3:14659:1	O

HDLNormal	SAPHRIS.xml:S3:14667:9	O
to	SAPHRIS.xml:S3:14677:2	O
Low	SAPHRIS.xml:S3:14680:3	O
40	SAPHRIS.xml:S3:14685:2	O
to	SAPHRIS.xml:S3:14688:2	O
40	SAPHRIS.xml:S3:14692:2	O
(	SAPHRIS.xml:S3:14695:1	O
mg	SAPHRIS.xml:S3:14696:2	O
dL	SAPHRIS.xml:S3:14699:2	O
)	SAPHRIS.xml:S3:14701:1	O
(	SAPHRIS.xml:S3:14703:1	O
n	SAPHRIS.xml:S3:14704:1	O
N	SAPHRIS.xml:S3:14706:1	O
)	SAPHRIS.xml:S3:14708:1	O
10.7%	SAPHRIS.xml:S3:14711:5	O
(	SAPHRIS.xml:S3:14716:1	O
21	SAPHRIS.xml:S3:14717:2	O
196	SAPHRIS.xml:S3:14720:3	O
)	SAPHRIS.xml:S3:14723:1	O
13.3%	SAPHRIS.xml:S3:14726:5	O
(	SAPHRIS.xml:S3:14731:1	O
18	SAPHRIS.xml:S3:14732:2	O
135	SAPHRIS.xml:S3:14735:3	O
)	SAPHRIS.xml:S3:14738:1	O
14.7%	SAPHRIS.xml:S3:14742:5	O
(	SAPHRIS.xml:S3:14747:1	O
20	SAPHRIS.xml:S3:14748:2	O
136	SAPHRIS.xml:S3:14751:3	O
)	SAPHRIS.xml:S3:14754:1	O
14.0%	SAPHRIS.xml:S3:14758:5	O
(	SAPHRIS.xml:S3:14763:1	O
45	SAPHRIS.xml:S3:14764:2	O
322	SAPHRIS.xml:S3:14767:3	O
)	SAPHRIS.xml:S3:14770:1	O
7.4%	SAPHRIS.xml:S3:14773:4	O
(	SAPHRIS.xml:S3:14777:1	O
9	SAPHRIS.xml:S3:14778:1	O
122	SAPHRIS.xml:S3:14780:3	O
)	SAPHRIS.xml:S3:14783:1	O
8.7%	SAPHRIS.xml:S3:14788:4	O
(	SAPHRIS.xml:S3:14792:1	O
21	SAPHRIS.xml:S3:14793:2	O
242	SAPHRIS.xml:S3:14796:3	O
)	SAPHRIS.xml:S3:14799:1	O

Fasting	SAPHRIS.xml:S3:14806:7	O
triglyceridesNormal	SAPHRIS.xml:S3:14814:19	O
to	SAPHRIS.xml:S3:14834:2	O
High	SAPHRIS.xml:S3:14837:4	O
150	SAPHRIS.xml:S3:14842:3	O
to	SAPHRIS.xml:S3:14846:2	O
200	SAPHRIS.xml:S3:14851:3	O
(	SAPHRIS.xml:S3:14855:1	O
mg	SAPHRIS.xml:S3:14856:2	O
dL	SAPHRIS.xml:S3:14859:2	O
)	SAPHRIS.xml:S3:14861:1	O
(	SAPHRIS.xml:S3:14863:1	O
n	SAPHRIS.xml:S3:14864:1	O
N	SAPHRIS.xml:S3:14866:1	O
)	SAPHRIS.xml:S3:14868:1	O
2.4%	SAPHRIS.xml:S3:14871:4	O
(	SAPHRIS.xml:S3:14875:1	O
4	SAPHRIS.xml:S3:14876:1	O
167	SAPHRIS.xml:S3:14878:3	O
)	SAPHRIS.xml:S3:14881:1	O
7.0%	SAPHRIS.xml:S3:14886:4	O
(	SAPHRIS.xml:S3:14890:1	O
8	SAPHRIS.xml:S3:14891:1	O
115	SAPHRIS.xml:S3:14893:3	O
)	SAPHRIS.xml:S3:14896:1	O
8.3%	SAPHRIS.xml:S3:14902:4	O
(	SAPHRIS.xml:S3:14906:1	O
9	SAPHRIS.xml:S3:14907:1	O
108	SAPHRIS.xml:S3:14909:3	O
)	SAPHRIS.xml:S3:14912:1	O
7.7%	SAPHRIS.xml:S3:14918:4	O
(	SAPHRIS.xml:S3:14922:1	O
20	SAPHRIS.xml:S3:14923:2	O
260	SAPHRIS.xml:S3:14926:3	O
)	SAPHRIS.xml:S3:14929:1	O
5.1%	SAPHRIS.xml:S3:14932:4	O
(	SAPHRIS.xml:S3:14936:1	O
4	SAPHRIS.xml:S3:14937:1	O
78	SAPHRIS.xml:S3:14939:2	O
)	SAPHRIS.xml:S3:14941:1	O
7.4%	SAPHRIS.xml:S3:14947:4	O
(	SAPHRIS.xml:S3:14951:1	O
11	SAPHRIS.xml:S3:14952:2	O
148	SAPHRIS.xml:S3:14955:3	O
)	SAPHRIS.xml:S3:14958:1	O

In	SAPHRIS.xml:S3:14981:2	O
short	SAPHRIS.xml:S3:14984:5	O
-	SAPHRIS.xml:S3:14989:1	O
term	SAPHRIS.xml:S3:14990:4	O
schizophrenia	SAPHRIS.xml:S3:14995:13	O
trials	SAPHRIS.xml:S3:15009:6	O
,	SAPHRIS.xml:S3:15015:1	O
the	SAPHRIS.xml:S3:15017:3	O
proportion	SAPHRIS.xml:S3:15021:10	O
of	SAPHRIS.xml:S3:15032:2	O
patients	SAPHRIS.xml:S3:15035:8	O
with	SAPHRIS.xml:S3:15044:4	O
total	SAPHRIS.xml:S3:15049:5	B-AdverseReaction
cholesterol	SAPHRIS.xml:S3:15055:11	I-AdverseReaction
elevations	SAPHRIS.xml:S3:15067:10	I-AdverseReaction
240	SAPHRIS.xml:S3:15080:3	B-Severity
mg	SAPHRIS.xml:S3:15084:2	I-Severity
dL	SAPHRIS.xml:S3:15087:2	I-Severity
(	SAPHRIS.xml:S3:15090:1	O
at	SAPHRIS.xml:S3:15091:2	O
Endpoint	SAPHRIS.xml:S3:15094:8	O
)	SAPHRIS.xml:S3:15102:1	O
was	SAPHRIS.xml:S3:15104:3	O
8.3%	SAPHRIS.xml:S3:15108:4	O
for	SAPHRIS.xml:S3:15113:3	O
SAPHRIS	SAPHRIS.xml:S3:15117:7	O
-	SAPHRIS.xml:S3:15124:1	O
treated	SAPHRIS.xml:S3:15125:7	O
patients	SAPHRIS.xml:S3:15133:8	O
versus	SAPHRIS.xml:S3:15142:6	O
7%	SAPHRIS.xml:S3:15149:2	O
for	SAPHRIS.xml:S3:15152:3	O
placebo	SAPHRIS.xml:S3:15156:7	O
-	SAPHRIS.xml:S3:15163:1	O
treated	SAPHRIS.xml:S3:15164:7	O
patients	SAPHRIS.xml:S3:15172:8	O
.	SAPHRIS.xml:S3:15180:1	O

The	SAPHRIS.xml:S3:15182:3	O
proportion	SAPHRIS.xml:S3:15186:10	O
of	SAPHRIS.xml:S3:15197:2	O
patients	SAPHRIS.xml:S3:15200:8	O
with	SAPHRIS.xml:S3:15209:4	O
elevations	SAPHRIS.xml:S3:15214:10	B-AdverseReaction
in	SAPHRIS.xml:S3:15225:2	I-AdverseReaction
triglycerides	SAPHRIS.xml:S3:15228:13	I-AdverseReaction
200	SAPHRIS.xml:S3:15244:3	B-Severity
mg	SAPHRIS.xml:S3:15248:2	I-Severity
dL	SAPHRIS.xml:S3:15251:2	I-Severity
(	SAPHRIS.xml:S3:15254:1	O
at	SAPHRIS.xml:S3:15255:2	O
Endpoint	SAPHRIS.xml:S3:15258:8	O
)	SAPHRIS.xml:S3:15266:1	O
was	SAPHRIS.xml:S3:15268:3	O
13.2%	SAPHRIS.xml:S3:15272:5	O
for	SAPHRIS.xml:S3:15278:3	O
SAPHRIS	SAPHRIS.xml:S3:15282:7	O
-	SAPHRIS.xml:S3:15289:1	O
treated	SAPHRIS.xml:S3:15290:7	O
patients	SAPHRIS.xml:S3:15298:8	O
versus	SAPHRIS.xml:S3:15307:6	O
10.5%	SAPHRIS.xml:S3:15314:5	O
for	SAPHRIS.xml:S3:15320:3	O
placebo	SAPHRIS.xml:S3:15324:7	O
-	SAPHRIS.xml:S3:15331:1	O
treated	SAPHRIS.xml:S3:15332:7	O
patients	SAPHRIS.xml:S3:15340:8	O
.	SAPHRIS.xml:S3:15348:1	O

In	SAPHRIS.xml:S3:15350:2	O
short	SAPHRIS.xml:S3:15353:5	O
-	SAPHRIS.xml:S3:15358:1	O
term	SAPHRIS.xml:S3:15359:4	O
,	SAPHRIS.xml:S3:15363:1	O
placebo	SAPHRIS.xml:S3:15365:7	O
-	SAPHRIS.xml:S3:15372:1	O
controlled	SAPHRIS.xml:S3:15373:10	O
bipolar	SAPHRIS.xml:S3:15384:7	O
mania	SAPHRIS.xml:S3:15392:5	O
trials	SAPHRIS.xml:S3:15398:6	O
,	SAPHRIS.xml:S3:15404:1	O
the	SAPHRIS.xml:S3:15406:3	O
proportion	SAPHRIS.xml:S3:15410:10	O
of	SAPHRIS.xml:S3:15421:2	O
patients	SAPHRIS.xml:S3:15424:8	O
with	SAPHRIS.xml:S3:15433:4	O
total	SAPHRIS.xml:S3:15438:5	B-AdverseReaction
cholesterol	SAPHRIS.xml:S3:15444:11	I-AdverseReaction
elevations	SAPHRIS.xml:S3:15456:10	I-AdverseReaction
240	SAPHRIS.xml:S3:15469:3	B-Severity
mg	SAPHRIS.xml:S3:15473:2	I-Severity
dL	SAPHRIS.xml:S3:15476:2	I-Severity
(	SAPHRIS.xml:S3:15479:1	O
at	SAPHRIS.xml:S3:15480:2	O
Endpoint	SAPHRIS.xml:S3:15483:8	O
)	SAPHRIS.xml:S3:15491:1	O
was	SAPHRIS.xml:S3:15493:3	O
8.7%	SAPHRIS.xml:S3:15497:4	O
for	SAPHRIS.xml:S3:15502:3	O
SAPHRIS	SAPHRIS.xml:S3:15506:7	O
-	SAPHRIS.xml:S3:15513:1	O
treated	SAPHRIS.xml:S3:15514:7	O
patients	SAPHRIS.xml:S3:15522:8	O
versus	SAPHRIS.xml:S3:15531:6	O
8.6%	SAPHRIS.xml:S3:15538:4	O
for	SAPHRIS.xml:S3:15543:3	O
placebo	SAPHRIS.xml:S3:15547:7	O
-	SAPHRIS.xml:S3:15554:1	O
treated	SAPHRIS.xml:S3:15555:7	O
patients	SAPHRIS.xml:S3:15563:8	O
.	SAPHRIS.xml:S3:15571:1	O

The	SAPHRIS.xml:S3:15573:3	O
proportion	SAPHRIS.xml:S3:15577:10	O
of	SAPHRIS.xml:S3:15588:2	O
patients	SAPHRIS.xml:S3:15591:8	O
with	SAPHRIS.xml:S3:15600:4	O
elevations	SAPHRIS.xml:S3:15605:10	B-AdverseReaction
in	SAPHRIS.xml:S3:15616:2	I-AdverseReaction
triglycerides	SAPHRIS.xml:S3:15619:13	I-AdverseReaction
200	SAPHRIS.xml:S3:15635:3	B-Severity
mg	SAPHRIS.xml:S3:15639:2	I-Severity
dL	SAPHRIS.xml:S3:15642:2	I-Severity
(	SAPHRIS.xml:S3:15645:1	O
at	SAPHRIS.xml:S3:15646:2	O
Endpoint	SAPHRIS.xml:S3:15649:8	O
)	SAPHRIS.xml:S3:15657:1	O
was	SAPHRIS.xml:S3:15659:3	O
15.2%	SAPHRIS.xml:S3:15663:5	O
for	SAPHRIS.xml:S3:15669:3	O
SAPHRIS	SAPHRIS.xml:S3:15673:7	O
-	SAPHRIS.xml:S3:15680:1	O
treated	SAPHRIS.xml:S3:15681:7	O
patients	SAPHRIS.xml:S3:15689:8	O
versus	SAPHRIS.xml:S3:15698:6	O
11.4%	SAPHRIS.xml:S3:15705:5	O
for	SAPHRIS.xml:S3:15711:3	O
placebo	SAPHRIS.xml:S3:15715:7	O
-	SAPHRIS.xml:S3:15722:1	O
treated	SAPHRIS.xml:S3:15723:7	O
patients	SAPHRIS.xml:S3:15731:8	O
.	SAPHRIS.xml:S3:15739:1	O

In	SAPHRIS.xml:S3:15749:2	O

a	SAPHRIS.xml:S3:15752:1	O
52	SAPHRIS.xml:S3:15754:2	O
-	SAPHRIS.xml:S3:15756:1	O
week	SAPHRIS.xml:S3:15757:4	O
,	SAPHRIS.xml:S3:15761:1	O
double	SAPHRIS.xml:S3:15763:6	O
-	SAPHRIS.xml:S3:15769:1	O
blind	SAPHRIS.xml:S3:15770:5	O
,	SAPHRIS.xml:S3:15775:1	O
comparator	SAPHRIS.xml:S3:15777:10	O
-	SAPHRIS.xml:S3:15787:1	O
controlled	SAPHRIS.xml:S3:15788:10	O
trial	SAPHRIS.xml:S3:15799:5	O
that	SAPHRIS.xml:S3:15805:4	O
included	SAPHRIS.xml:S3:15810:8	O
primarily	SAPHRIS.xml:S3:15819:9	O
patients	SAPHRIS.xml:S3:15829:8	O
with	SAPHRIS.xml:S3:15838:4	O
schizophrenia	SAPHRIS.xml:S3:15843:13	O
,	SAPHRIS.xml:S3:15856:1	O
the	SAPHRIS.xml:S3:15858:3	O
mean	SAPHRIS.xml:S3:15862:4	O
decrease	SAPHRIS.xml:S3:15867:8	O
from	SAPHRIS.xml:S3:15876:4	O
baseline	SAPHRIS.xml:S3:15881:8	O
of	SAPHRIS.xml:S3:15890:2	O
total	SAPHRIS.xml:S3:15893:5	O
cholesterol	SAPHRIS.xml:S3:15899:11	O
was	SAPHRIS.xml:S3:15911:3	O
6	SAPHRIS.xml:S3:15915:1	O
mg	SAPHRIS.xml:S3:15917:2	O
dL	SAPHRIS.xml:S3:15920:2	O
and	SAPHRIS.xml:S3:15923:3	O
the	SAPHRIS.xml:S3:15927:3	O
mean	SAPHRIS.xml:S3:15931:4	O
decrease	SAPHRIS.xml:S3:15936:8	O
from	SAPHRIS.xml:S3:15945:4	O
baseline	SAPHRIS.xml:S3:15950:8	O
of	SAPHRIS.xml:S3:15959:2	O
fasting	SAPHRIS.xml:S3:15962:7	O
triglycerides	SAPHRIS.xml:S3:15970:13	O
was	SAPHRIS.xml:S3:15984:3	O
9.8	SAPHRIS.xml:S3:15988:3	O
mg	SAPHRIS.xml:S3:15992:2	O
dL	SAPHRIS.xml:S3:15995:2	O
.	SAPHRIS.xml:S3:15997:1	O

Pediatric	SAPHRIS.xml:S3:16011:9	O
Patients	SAPHRIS.xml:S3:16021:8	O
:	SAPHRIS.xml:S3:16029:1	O
Data	SAPHRIS.xml:S3:16032:4	O
from	SAPHRIS.xml:S3:16037:4	O
the	SAPHRIS.xml:S3:16042:3	O
short	SAPHRIS.xml:S3:16046:5	O
-	SAPHRIS.xml:S3:16051:1	O
term	SAPHRIS.xml:S3:16052:4	O
,	SAPHRIS.xml:S3:16056:1	O
placebo	SAPHRIS.xml:S3:16058:7	O
-	SAPHRIS.xml:S3:16065:1	O
controlled	SAPHRIS.xml:S3:16066:10	O
bipolar	SAPHRIS.xml:S3:16077:7	O
mania	SAPHRIS.xml:S3:16085:5	O
trial	SAPHRIS.xml:S3:16091:5	O
are	SAPHRIS.xml:S3:16097:3	O
presented	SAPHRIS.xml:S3:16101:9	O
in	SAPHRIS.xml:S3:16111:2	O
Table	SAPHRIS.xml:S3:16115:5	O
4	SAPHRIS.xml:S3:16121:1	O
.	SAPHRIS.xml:S3:16124:1	O

TABLE	SAPHRIS.xml:S3:16130:5	O
4	SAPHRIS.xml:S3:16136:1	O
:	SAPHRIS.xml:S3:16137:1	O
Changes	SAPHRIS.xml:S3:16139:7	O
in	SAPHRIS.xml:S3:16147:2	O
Fasting	SAPHRIS.xml:S3:16150:7	O
Lipids	SAPHRIS.xml:S3:16158:6	O
in	SAPHRIS.xml:S3:16165:2	O
Pediatric	SAPHRIS.xml:S3:16168:9	O
Subjects	SAPHRIS.xml:S3:16178:8	O

N	SAPHRIS.xml:S3:16190:1	O
Number	SAPHRIS.xml:S3:16195:6	O
of	SAPHRIS.xml:S3:16202:2	O
patients	SAPHRIS.xml:S3:16205:8	O
who	SAPHRIS.xml:S3:16214:3	O
had	SAPHRIS.xml:S3:16218:3	O
assessments	SAPHRIS.xml:S3:16222:11	O
at	SAPHRIS.xml:S3:16234:2	O
both	SAPHRIS.xml:S3:16237:4	O
Baseline	SAPHRIS.xml:S3:16242:8	O
and	SAPHRIS.xml:S3:16251:3	O
Endpoint	SAPHRIS.xml:S3:16255:8	O

Bipolar	SAPHRIS.xml:S3:16304:7	O

I	SAPHRIS.xml:S3:16312:1	O
Disorder	SAPHRIS.xml:S3:16314:8	O
(	SAPHRIS.xml:S3:16323:1	O
3	SAPHRIS.xml:S3:16324:1	O
-	SAPHRIS.xml:S3:16325:1	O
weeks	SAPHRIS.xml:S3:16326:5	O
)	SAPHRIS.xml:S3:16331:1	O

Placebo	SAPHRIS.xml:S3:16369:7	O
SAPHRIS2	SAPHRIS.xml:S3:16385:8	O
.	SAPHRIS.xml:S3:16393:1	O
5	SAPHRIS.xml:S3:16394:1	O
mgtwice	SAPHRIS.xml:S3:16396:7	O
daily	SAPHRIS.xml:S3:16404:5	O
SAPHRIS5	SAPHRIS.xml:S3:16411:8	O
mgtwice	SAPHRIS.xml:S3:16420:7	O
daily	SAPHRIS.xml:S3:16428:5	O
SAPHRIS10	SAPHRIS.xml:S3:16435:9	O
mgtwice	SAPHRIS.xml:S3:16445:7	O
daily	SAPHRIS.xml:S3:16453:5	O

Mean	SAPHRIS.xml:S3:16463:4	O
Change	SAPHRIS.xml:S3:16468:6	O
from	SAPHRIS.xml:S3:16475:4	O
Baseline	SAPHRIS.xml:S3:16480:8	O
(	SAPHRIS.xml:S3:16489:1	O
mg	SAPHRIS.xml:S3:16490:2	O
dL	SAPHRIS.xml:S3:16493:2	O
)	SAPHRIS.xml:S3:16495:1	O

Total	SAPHRIS.xml:S3:16501:5	O
fasting	SAPHRIS.xml:S3:16507:7	O
cholesterol	SAPHRIS.xml:S3:16515:11	O
(	SAPHRIS.xml:S3:16527:1	O
N	SAPHRIS.xml:S3:16528:1	O
)	SAPHRIS.xml:S3:16530:1	O
-	SAPHRIS.xml:S3:16533:1	O
2.3	SAPHRIS.xml:S3:16534:3	O
(	SAPHRIS.xml:S3:16537:1	O
57	SAPHRIS.xml:S3:16538:2	O
)	SAPHRIS.xml:S3:16540:1	O
3.7	SAPHRIS.xml:S3:16549:3	O
(	SAPHRIS.xml:S3:16552:1	O
50	SAPHRIS.xml:S3:16553:2	O
)	SAPHRIS.xml:S3:16555:1	O
7.2	SAPHRIS.xml:S3:16569:3	O
(	SAPHRIS.xml:S3:16572:1	O
57	SAPHRIS.xml:S3:16573:2	O
)	SAPHRIS.xml:S3:16575:1	O
9.3	SAPHRIS.xml:S3:16589:3	O
(	SAPHRIS.xml:S3:16592:1	O
52	SAPHRIS.xml:S3:16593:2	O
)	SAPHRIS.xml:S3:16595:1	O

Fasting	SAPHRIS.xml:S3:16612:7	O
LDL	SAPHRIS.xml:S3:16620:3	O
(	SAPHRIS.xml:S3:16623:1	O
N	SAPHRIS.xml:S3:16624:1	O
)	SAPHRIS.xml:S3:16626:1	O
-	SAPHRIS.xml:S3:16644:1	O
2.5	SAPHRIS.xml:S3:16645:3	O
(	SAPHRIS.xml:S3:16648:1	O
57	SAPHRIS.xml:S3:16649:2	O
)	SAPHRIS.xml:S3:16651:1	O
-	SAPHRIS.xml:S3:16660:1	O
0.2	SAPHRIS.xml:S3:16661:3	O
(	SAPHRIS.xml:S3:16664:1	O
50	SAPHRIS.xml:S3:16665:2	O
)	SAPHRIS.xml:S3:16667:1	O
3.0	SAPHRIS.xml:S3:16680:3	O
(	SAPHRIS.xml:S3:16683:1	O
57	SAPHRIS.xml:S3:16684:2	O
)	SAPHRIS.xml:S3:16686:1	O
4.9	SAPHRIS.xml:S3:16700:3	O
(	SAPHRIS.xml:S3:16703:1	O
51	SAPHRIS.xml:S3:16704:2	O
)	SAPHRIS.xml:S3:16706:1	O

Fasting	SAPHRIS.xml:S3:16723:7	O
HDL	SAPHRIS.xml:S3:16731:3	O
(	SAPHRIS.xml:S3:16734:1	O
N	SAPHRIS.xml:S3:16735:1	O
)	SAPHRIS.xml:S3:16737:1	O
1.6	SAPHRIS.xml:S3:16755:3	O
(	SAPHRIS.xml:S3:16758:1	O
57	SAPHRIS.xml:S3:16759:2	O
)	SAPHRIS.xml:S3:16761:1	O
2.3	SAPHRIS.xml:S3:16771:3	O
(	SAPHRIS.xml:S3:16774:1	O
50	SAPHRIS.xml:S3:16775:2	O
)	SAPHRIS.xml:S3:16777:1	O
1.5	SAPHRIS.xml:S3:16791:3	O
(	SAPHRIS.xml:S3:16794:1	O
57	SAPHRIS.xml:S3:16795:2	O
)	SAPHRIS.xml:S3:16797:1	O
1.7	SAPHRIS.xml:S3:16811:3	O
(	SAPHRIS.xml:S3:16814:1	O
52	SAPHRIS.xml:S3:16815:2	O
)	SAPHRIS.xml:S3:16817:1	O

Fasting	SAPHRIS.xml:S3:16834:7	O
triglycerides	SAPHRIS.xml:S3:16842:13	O
(	SAPHRIS.xml:S3:16856:1	O
N	SAPHRIS.xml:S3:16857:1	O
)	SAPHRIS.xml:S3:16859:1	O
-	SAPHRIS.xml:S3:16866:1	O
6.6	SAPHRIS.xml:S3:16867:3	O
(	SAPHRIS.xml:S3:16870:1	O
57	SAPHRIS.xml:S3:16871:2	O
)	SAPHRIS.xml:S3:16873:1	O
8.7	SAPHRIS.xml:S3:16882:3	O
(	SAPHRIS.xml:S3:16885:1	O
50	SAPHRIS.xml:S3:16886:2	O
)	SAPHRIS.xml:S3:16888:1	O
13.4	SAPHRIS.xml:S3:16902:4	O
(	SAPHRIS.xml:S3:16906:1	O
57	SAPHRIS.xml:S3:16907:2	O
)	SAPHRIS.xml:S3:16909:1	O
14.7	SAPHRIS.xml:S3:16922:4	O
(	SAPHRIS.xml:S3:16926:1	O
52	SAPHRIS.xml:S3:16927:2	O
)	SAPHRIS.xml:S3:16929:1	O

Proportion	SAPHRIS.xml:S3:16945:10	O
of	SAPHRIS.xml:S3:16956:2	O
Subjects	SAPHRIS.xml:S3:16959:8	O
with	SAPHRIS.xml:S3:16968:4	O
Shifts	SAPHRIS.xml:S3:16973:6	O
from	SAPHRIS.xml:S3:16980:4	O
Baseline	SAPHRIS.xml:S3:16985:8	O
to	SAPHRIS.xml:S3:16994:2	O
Endpoint	SAPHRIS.xml:S3:16997:8	O

Total	SAPHRIS.xml:S3:17010:5	O
fasting	SAPHRIS.xml:S3:17016:7	O
cholesterolNormal	SAPHRIS.xml:S3:17024:17	O
to	SAPHRIS.xml:S3:17042:2	O
High	SAPHRIS.xml:S3:17045:4	O
170	SAPHRIS.xml:S3:17050:3	O
to	SAPHRIS.xml:S3:17054:2	O
200	SAPHRIS.xml:S3:17059:3	O
(	SAPHRIS.xml:S3:17062:1	O
mg	SAPHRIS.xml:S3:17063:2	O
dL	SAPHRIS.xml:S3:17066:2	O
)(	SAPHRIS.xml:S3:17068:2	O
n	SAPHRIS.xml:S3:17070:1	O
N	SAPHRIS.xml:S3:17072:1	O
)	SAPHRIS.xml:S3:17074:1	O
1.8%	SAPHRIS.xml:S3:17077:4	O
(	SAPHRIS.xml:S3:17081:1	O
1	SAPHRIS.xml:S3:17082:1	O
57	SAPHRIS.xml:S3:17084:2	O
)	SAPHRIS.xml:S3:17086:1	O
0%	SAPHRIS.xml:S3:17093:2	O
(	SAPHRIS.xml:S3:17095:1	O
0	SAPHRIS.xml:S3:17096:1	O
50	SAPHRIS.xml:S3:17098:2	O
)	SAPHRIS.xml:S3:17100:1	O
1.8%	SAPHRIS.xml:S3:17113:4	O
(	SAPHRIS.xml:S3:17117:1	O
1	SAPHRIS.xml:S3:17118:1	O
57	SAPHRIS.xml:S3:17120:2	O
)	SAPHRIS.xml:S3:17122:1	O
0%	SAPHRIS.xml:S3:17133:2	O
(	SAPHRIS.xml:S3:17135:1	O
0	SAPHRIS.xml:S3:17136:1	O
52	SAPHRIS.xml:S3:17138:2	O
)	SAPHRIS.xml:S3:17140:1	O

Fasting	SAPHRIS.xml:S3:17156:7	O
LDLNormal	SAPHRIS.xml:S3:17164:9	O
to	SAPHRIS.xml:S3:17174:2	O
High	SAPHRIS.xml:S3:17177:4	O
110	SAPHRIS.xml:S3:17182:3	O
to	SAPHRIS.xml:S3:17186:2	O
130	SAPHRIS.xml:S3:17191:3	O
(	SAPHRIS.xml:S3:17194:1	O
n	SAPHRIS.xml:S3:17195:1	O
N	SAPHRIS.xml:S3:17197:1	O
)	SAPHRIS.xml:S3:17199:1	O
1.8%	SAPHRIS.xml:S3:17202:4	O
(	SAPHRIS.xml:S3:17206:1	O
1	SAPHRIS.xml:S3:17207:1	O
57	SAPHRIS.xml:S3:17209:2	O
)	SAPHRIS.xml:S3:17211:1	O
2.0%	SAPHRIS.xml:S3:17218:4	O
(	SAPHRIS.xml:S3:17222:1	O
1	SAPHRIS.xml:S3:17223:1	O
50	SAPHRIS.xml:S3:17225:2	O
)	SAPHRIS.xml:S3:17227:1	O
1.8%	SAPHRIS.xml:S3:17238:4	O
(	SAPHRIS.xml:S3:17242:1	O
1	SAPHRIS.xml:S3:17243:1	O
57	SAPHRIS.xml:S3:17245:2	O
)	SAPHRIS.xml:S3:17247:1	O
0%	SAPHRIS.xml:S3:17258:2	O
(	SAPHRIS.xml:S3:17260:1	O
0	SAPHRIS.xml:S3:17261:1	O
51	SAPHRIS.xml:S3:17263:2	O
)	SAPHRIS.xml:S3:17265:1	O

Fasting	SAPHRIS.xml:S3:17281:7	O
HDLNormal	SAPHRIS.xml:S3:17289:9	O
to	SAPHRIS.xml:S3:17299:2	O
Low	SAPHRIS.xml:S3:17302:3	O
40	SAPHRIS.xml:S3:17307:2	O
to	SAPHRIS.xml:S3:17310:2	O
40	SAPHRIS.xml:S3:17314:2	O
(	SAPHRIS.xml:S3:17317:1	O
mg	SAPHRIS.xml:S3:17318:2	O
dL	SAPHRIS.xml:S3:17321:2	O
)(	SAPHRIS.xml:S3:17323:2	O
n	SAPHRIS.xml:S3:17325:1	O
N	SAPHRIS.xml:S3:17327:1	O
)	SAPHRIS.xml:S3:17329:1	O
3.5%	SAPHRIS.xml:S3:17332:4	O
(	SAPHRIS.xml:S3:17336:1	O
2	SAPHRIS.xml:S3:17337:1	O
57	SAPHRIS.xml:S3:17339:2	O
)	SAPHRIS.xml:S3:17341:1	O
6.0%	SAPHRIS.xml:S3:17348:4	O
(	SAPHRIS.xml:S3:17352:1	O
3	SAPHRIS.xml:S3:17353:1	O
50	SAPHRIS.xml:S3:17355:2	O
)	SAPHRIS.xml:S3:17357:1	O
3.5%	SAPHRIS.xml:S3:17368:4	O
(	SAPHRIS.xml:S3:17372:1	O
2	SAPHRIS.xml:S3:17373:1	O
57	SAPHRIS.xml:S3:17375:2	O
)	SAPHRIS.xml:S3:17377:1	O
9.6%	SAPHRIS.xml:S3:17388:4	O
(	SAPHRIS.xml:S3:17392:1	O
5	SAPHRIS.xml:S3:17393:1	O
52	SAPHRIS.xml:S3:17395:2	O
)	SAPHRIS.xml:S3:17397:1	O

Fasting	SAPHRIS.xml:S3:17411:7	O
triglyceridesNormal	SAPHRIS.xml:S3:17419:19	O
to	SAPHRIS.xml:S3:17439:2	O
High	SAPHRIS.xml:S3:17442:4	O
150	SAPHRIS.xml:S3:17447:3	O
to	SAPHRIS.xml:S3:17451:2	O
200	SAPHRIS.xml:S3:17456:3	O
(	SAPHRIS.xml:S3:17460:1	O
mg	SAPHRIS.xml:S3:17461:2	O
dL	SAPHRIS.xml:S3:17464:2	O
)(	SAPHRIS.xml:S3:17466:2	O
n	SAPHRIS.xml:S3:17468:1	O
N	SAPHRIS.xml:S3:17470:1	O
)	SAPHRIS.xml:S3:17472:1	O
0%	SAPHRIS.xml:S3:17475:2	O
(	SAPHRIS.xml:S3:17477:1	O
0	SAPHRIS.xml:S3:17478:1	O
57	SAPHRIS.xml:S3:17480:2	O
)	SAPHRIS.xml:S3:17482:1	O
4.0%	SAPHRIS.xml:S3:17491:4	O
(	SAPHRIS.xml:S3:17495:1	O
2	SAPHRIS.xml:S3:17496:1	O
50	SAPHRIS.xml:S3:17498:2	O
)	SAPHRIS.xml:S3:17500:1	O
3.5%	SAPHRIS.xml:S3:17511:4	O
(	SAPHRIS.xml:S3:17515:1	O
2	SAPHRIS.xml:S3:17516:1	O
57	SAPHRIS.xml:S3:17518:2	O
)	SAPHRIS.xml:S3:17520:1	O
1.9%	SAPHRIS.xml:S3:17531:4	O
(	SAPHRIS.xml:S3:17535:1	O
1	SAPHRIS.xml:S3:17536:1	O
52	SAPHRIS.xml:S3:17538:2	O
)	SAPHRIS.xml:S3:17540:1	O

Weight	SAPHRIS.xml:S3:17572:6	O
Gain	SAPHRIS.xml:S3:17579:4	O

Increases	SAPHRIS.xml:S3:17594:9	B-AdverseReaction

in	SAPHRIS.xml:S3:17604:2	I-AdverseReaction
weight	SAPHRIS.xml:S3:17607:6	I-AdverseReaction
have	SAPHRIS.xml:S3:17614:4	O
been	SAPHRIS.xml:S3:17619:4	O
observed	SAPHRIS.xml:S3:17624:8	O
in	SAPHRIS.xml:S3:17633:2	O
pre	SAPHRIS.xml:S3:17636:3	O
-	SAPHRIS.xml:S3:17639:1	O
marketing	SAPHRIS.xml:S3:17640:9	O
clinical	SAPHRIS.xml:S3:17650:8	O
trials	SAPHRIS.xml:S3:17659:6	O
with	SAPHRIS.xml:S3:17666:4	O
SAPHRIS	SAPHRIS.xml:S3:17671:7	O
.	SAPHRIS.xml:S3:17678:1	O

Patients	SAPHRIS.xml:S3:17680:8	O
receiving	SAPHRIS.xml:S3:17689:9	O
SAPHRIS	SAPHRIS.xml:S3:17699:7	O
should	SAPHRIS.xml:S3:17707:6	O
receive	SAPHRIS.xml:S3:17714:7	O
regular	SAPHRIS.xml:S3:17722:7	O
monitoring	SAPHRIS.xml:S3:17730:10	O
of	SAPHRIS.xml:S3:17741:2	O
weight	SAPHRIS.xml:S3:17744:6	O
[	SAPHRIS.xml:S3:17752:1	O
see	SAPHRIS.xml:S3:17753:3	O
Patient	SAPHRIS.xml:S3:17757:7	O
Counseling	SAPHRIS.xml:S3:17765:10	O
Information	SAPHRIS.xml:S3:17776:11	O
(	SAPHRIS.xml:S3:17788:1	O
17	SAPHRIS.xml:S3:17789:2	O
)]	SAPHRIS.xml:S3:17791:2	O
.	SAPHRIS.xml:S3:17795:1	O

Adult	SAPHRIS.xml:S3:17807:5	O
Patients	SAPHRIS.xml:S3:17813:8	O
:	SAPHRIS.xml:S3:17821:1	O
Pooled	SAPHRIS.xml:S3:17824:6	O
data	SAPHRIS.xml:S3:17831:4	O
on	SAPHRIS.xml:S3:17836:2	O
mean	SAPHRIS.xml:S3:17839:4	O
changes	SAPHRIS.xml:S3:17844:7	O
in	SAPHRIS.xml:S3:17852:2	O
body	SAPHRIS.xml:S3:17855:4	O
weight	SAPHRIS.xml:S3:17860:6	O
and	SAPHRIS.xml:S3:17867:3	O
the	SAPHRIS.xml:S3:17871:3	O
proportion	SAPHRIS.xml:S3:17875:10	O
of	SAPHRIS.xml:S3:17886:2	O
subjects	SAPHRIS.xml:S3:17889:8	O
meeting	SAPHRIS.xml:S3:17898:7	O
a	SAPHRIS.xml:S3:17906:1	O
weight	SAPHRIS.xml:S3:17908:6	B-AdverseReaction
gain	SAPHRIS.xml:S3:17915:4	I-AdverseReaction
criterion	SAPHRIS.xml:S3:17920:9	O
of	SAPHRIS.xml:S3:17930:2	O
7%	SAPHRIS.xml:S3:17935:2	B-Severity
of	SAPHRIS.xml:S3:17938:2	O
body	SAPHRIS.xml:S3:17941:4	O
weight	SAPHRIS.xml:S3:17946:6	O
from	SAPHRIS.xml:S3:17953:4	O
the	SAPHRIS.xml:S3:17958:3	O
short	SAPHRIS.xml:S3:17962:5	O
-	SAPHRIS.xml:S3:17967:1	O
term	SAPHRIS.xml:S3:17968:4	O
,	SAPHRIS.xml:S3:17972:1	O
placebo	SAPHRIS.xml:S3:17974:7	O
-	SAPHRIS.xml:S3:17981:1	O
controlled	SAPHRIS.xml:S3:17982:10	O
schizophrenia	SAPHRIS.xml:S3:17993:13	O
and	SAPHRIS.xml:S3:18007:3	O
bipolar	SAPHRIS.xml:S3:18011:7	O
mania	SAPHRIS.xml:S3:18019:5	O
trials	SAPHRIS.xml:S3:18025:6	O
are	SAPHRIS.xml:S3:18032:3	O
presented	SAPHRIS.xml:S3:18036:9	O
in	SAPHRIS.xml:S3:18046:2	O
Table	SAPHRIS.xml:S3:18050:5	O
5	SAPHRIS.xml:S3:18056:1	O
.	SAPHRIS.xml:S3:18057:1	O

Table	SAPHRIS.xml:S3:18065:5	O
5	SAPHRIS.xml:S3:18071:1	O
:	SAPHRIS.xml:S3:18072:1	O
Change	SAPHRIS.xml:S3:18074:6	O
in	SAPHRIS.xml:S3:18081:2	O
Body	SAPHRIS.xml:S3:18084:4	O
Weight	SAPHRIS.xml:S3:18089:6	O
in	SAPHRIS.xml:S3:18096:2	O
Adult	SAPHRIS.xml:S3:18099:5	O
Patients	SAPHRIS.xml:S3:18105:8	O
from	SAPHRIS.xml:S3:18114:4	O
Baseline	SAPHRIS.xml:S3:18119:8	O

N	SAPHRIS.xml:S3:18131:1	O
Number	SAPHRIS.xml:S3:18136:6	O
of	SAPHRIS.xml:S3:18143:2	O
subjects	SAPHRIS.xml:S3:18146:8	O
who	SAPHRIS.xml:S3:18155:3	O
had	SAPHRIS.xml:S3:18159:3	O
assessments	SAPHRIS.xml:S3:18163:11	O
at	SAPHRIS.xml:S3:18175:2	O
both	SAPHRIS.xml:S3:18178:4	O
Baseline	SAPHRIS.xml:S3:18183:8	O
and	SAPHRIS.xml:S3:18192:3	O
Endpoint	SAPHRIS.xml:S3:18196:8	O
.	SAPHRIS.xml:S3:18204:1	O

S	SAPHRIS.xml:S3:18212:1	O
Includes	SAPHRIS.xml:S3:18214:8	O
subjects	SAPHRIS.xml:S3:18223:8	O
treated	SAPHRIS.xml:S3:18232:7	O
with	SAPHRIS.xml:S3:18240:4	O
flexible	SAPHRIS.xml:S3:18245:8	O
dose	SAPHRIS.xml:S3:18254:4	O
of	SAPHRIS.xml:S3:18259:2	O
SAPHRIS	SAPHRIS.xml:S3:18262:7	O
5	SAPHRIS.xml:S3:18270:1	O
or	SAPHRIS.xml:S3:18272:2	O
10	SAPHRIS.xml:S3:18275:2	O
mg	SAPHRIS.xml:S3:18278:2	O
twice	SAPHRIS.xml:S3:18281:5	O
daily	SAPHRIS.xml:S3:18287:5	O
(	SAPHRIS.xml:S3:18293:1	O
N	SAPHRIS.xml:S3:18294:1	O
90	SAPHRIS.xml:S3:18296:2	O
)	SAPHRIS.xml:S3:18298:1	O
.	SAPHRIS.xml:S3:18299:1	O

SAPHRIS	SAPHRIS.xml:S3:18307:7	O
5	SAPHRIS.xml:S3:18315:1	O
mg	SAPHRIS.xml:S3:18317:2	O
or	SAPHRIS.xml:S3:18320:2	O
10	SAPHRIS.xml:S3:18323:2	O
mg	SAPHRIS.xml:S3:18326:2	O
twice	SAPHRIS.xml:S3:18329:5	O
daily	SAPHRIS.xml:S3:18335:5	O
with	SAPHRIS.xml:S3:18341:4	O
flexible	SAPHRIS.xml:S3:18346:8	O
dosing	SAPHRIS.xml:S3:18355:6	O
.	SAPHRIS.xml:S3:18361:1	O

Schizophrenia	SAPHRIS.xml:S3:18391:13	O

(	SAPHRIS.xml:S3:18405:1	O
6	SAPHRIS.xml:S3:18406:1	O
-	SAPHRIS.xml:S3:18407:1	O
weeks	SAPHRIS.xml:S3:18408:5	O
)	SAPHRIS.xml:S3:18413:1	O
Bipolar	SAPHRIS.xml:S3:18416:7	O
(	SAPHRIS.xml:S3:18424:1	O
3	SAPHRIS.xml:S3:18425:1	O
-	SAPHRIS.xml:S3:18426:1	O
weeks	SAPHRIS.xml:S3:18427:5	O
)	SAPHRIS.xml:S3:18432:1	O

Placebo	SAPHRIS.xml:S3:18438:7	O
SAPHRIS	SAPHRIS.xml:S3:18458:7	O
Placebo	SAPHRIS.xml:S3:18473:7	O
SAPHRIS5	SAPHRIS.xml:S3:18487:8	O
or	SAPHRIS.xml:S3:18496:2	O
10	SAPHRIS.xml:S3:18499:2	O
mgtwice	SAPHRIS.xml:S3:18502:7	O
daily	SAPHRIS.xml:S3:18510:5	O

5	SAPHRIS.xml:S3:18524:1	O
mgtwice	SAPHRIS.xml:S3:18526:7	O
daily	SAPHRIS.xml:S3:18534:5	O
10	SAPHRIS.xml:S3:18544:2	O
mgtwice	SAPHRIS.xml:S3:18547:7	O
daily	SAPHRIS.xml:S3:18555:5	O
5	SAPHRIS.xml:S3:18562:1	O
or	SAPHRIS.xml:S3:18564:2	O
10	SAPHRIS.xml:S3:18567:2	O
mgtwice	SAPHRIS.xml:S3:18570:7	O
daily	SAPHRIS.xml:S3:18578:5	O
S	SAPHRIS.xml:S3:18585:1	O

Change	SAPHRIS.xml:S3:18593:6	O
from	SAPHRIS.xml:S3:18600:4	O
Baseline	SAPHRIS.xml:S3:18605:8	O
(	SAPHRIS.xml:S3:18614:1	O
kg	SAPHRIS.xml:S3:18615:2	O
)	SAPHRIS.xml:S3:18617:1	O
(	SAPHRIS.xml:S3:18619:1	O
N	SAPHRIS.xml:S3:18620:1	O
)	SAPHRIS.xml:S3:18622:1	O
0.0	SAPHRIS.xml:S3:18625:3	O
(	SAPHRIS.xml:S3:18628:1	O
348	SAPHRIS.xml:S3:18629:3	O
)	SAPHRIS.xml:S3:18632:1	O
1.0	SAPHRIS.xml:S3:18640:3	O
(	SAPHRIS.xml:S3:18643:1	O
251	SAPHRIS.xml:S3:18644:3	O
)	SAPHRIS.xml:S3:18647:1	O
0.9	SAPHRIS.xml:S3:18654:3	O
(	SAPHRIS.xml:S3:18657:1	O
200	SAPHRIS.xml:S3:18658:3	O
)	SAPHRIS.xml:S3:18661:1	O
1.1	SAPHRIS.xml:S3:18670:3	O
(	SAPHRIS.xml:S3:18673:1	O
532	SAPHRIS.xml:S3:18674:3	O
)	SAPHRIS.xml:S3:18677:1	O
0.2	SAPHRIS.xml:S3:18686:3	O
(	SAPHRIS.xml:S3:18689:1	O
171	SAPHRIS.xml:S3:18690:3	O
)	SAPHRIS.xml:S3:18693:1	O
1.3	SAPHRIS.xml:S3:18700:3	O
(	SAPHRIS.xml:S3:18703:1	O
336	SAPHRIS.xml:S3:18704:3	O
)	SAPHRIS.xml:S3:18707:1	O

Proportion	SAPHRIS.xml:S3:18718:10	O
of	SAPHRIS.xml:S3:18729:2	O
Patients	SAPHRIS.xml:S3:18732:8	O
with	SAPHRIS.xml:S3:18741:4	O
a	SAPHRIS.xml:S3:18746:1	O
7%	SAPHRIS.xml:S3:18750:2	B-Severity
Increase	SAPHRIS.xml:S3:18753:8	B-AdverseReaction
in	SAPHRIS.xml:S3:18762:2	I-AdverseReaction
Body	SAPHRIS.xml:S3:18765:4	I-AdverseReaction
Weight	SAPHRIS.xml:S3:18770:6	I-AdverseReaction

with	SAPHRIS.xml:S3:18783:4	O
7%	SAPHRIS.xml:S3:18790:2	B-Severity
increase	SAPHRIS.xml:S3:18793:8	B-AdverseReaction
in	SAPHRIS.xml:S3:18802:2	I-AdverseReaction
body	SAPHRIS.xml:S3:18805:4	I-AdverseReaction
weight	SAPHRIS.xml:S3:18810:6	I-AdverseReaction
1.6%	SAPHRIS.xml:S3:18818:4	O
4.4%	SAPHRIS.xml:S3:18833:4	O
4.8%	SAPHRIS.xml:S3:18847:4	O
4.9%	SAPHRIS.xml:S3:18863:4	O
0.5%	SAPHRIS.xml:S3:18879:4	O
5.8%	SAPHRIS.xml:S3:18893:4	O

Adult	SAPHRIS.xml:S3:18931:5	O
Patients	SAPHRIS.xml:S3:18937:8	O
:	SAPHRIS.xml:S3:18945:1	O
In	SAPHRIS.xml:S3:18948:2	O
a	SAPHRIS.xml:S3:18951:1	O
52	SAPHRIS.xml:S3:18953:2	O
-	SAPHRIS.xml:S3:18955:1	O
week	SAPHRIS.xml:S3:18956:4	O
,	SAPHRIS.xml:S3:18960:1	O
double	SAPHRIS.xml:S3:18962:6	O
-	SAPHRIS.xml:S3:18968:1	O
blind	SAPHRIS.xml:S3:18969:5	O
,	SAPHRIS.xml:S3:18974:1	O
comparator	SAPHRIS.xml:S3:18976:10	O
-	SAPHRIS.xml:S3:18986:1	O
controlled	SAPHRIS.xml:S3:18987:10	O
adult	SAPHRIS.xml:S3:18998:5	O
trial	SAPHRIS.xml:S3:19004:5	O
that	SAPHRIS.xml:S3:19010:4	O
included	SAPHRIS.xml:S3:19015:8	O
primarily	SAPHRIS.xml:S3:19024:9	O
patients	SAPHRIS.xml:S3:19034:8	O
with	SAPHRIS.xml:S3:19043:4	O
schizophrenia	SAPHRIS.xml:S3:19048:13	O
,	SAPHRIS.xml:S3:19061:1	O
the	SAPHRIS.xml:S3:19063:3	O
mean	SAPHRIS.xml:S3:19067:4	O
weight	SAPHRIS.xml:S3:19072:6	B-AdverseReaction
gain	SAPHRIS.xml:S3:19079:4	I-AdverseReaction
from	SAPHRIS.xml:S3:19084:4	O
baseline	SAPHRIS.xml:S3:19089:8	O
was	SAPHRIS.xml:S3:19098:3	O
0.9	SAPHRIS.xml:S3:19102:3	O
kg	SAPHRIS.xml:S3:19106:2	O
.	SAPHRIS.xml:S3:19108:1	O

The	SAPHRIS.xml:S3:19110:3	O
proportion	SAPHRIS.xml:S3:19114:10	O
of	SAPHRIS.xml:S3:19125:2	O
patients	SAPHRIS.xml:S3:19128:8	O
with	SAPHRIS.xml:S3:19137:4	O
a	SAPHRIS.xml:S3:19142:1	O
7%	SAPHRIS.xml:S3:19146:2	B-Severity
increase	SAPHRIS.xml:S3:19149:8	B-AdverseReaction
in	SAPHRIS.xml:S3:19158:2	I-AdverseReaction
body	SAPHRIS.xml:S3:19161:4	I-AdverseReaction
weight	SAPHRIS.xml:S3:19166:6	I-AdverseReaction
(	SAPHRIS.xml:S3:19173:1	O
at	SAPHRIS.xml:S3:19174:2	O
Endpoint	SAPHRIS.xml:S3:19177:8	O
)	SAPHRIS.xml:S3:19185:1	O
was	SAPHRIS.xml:S3:19187:3	O
14.7%	SAPHRIS.xml:S3:19191:5	O
.	SAPHRIS.xml:S3:19196:1	O
Table	SAPHRIS.xml:S3:19197:5	O
5	SAPHRIS.xml:S3:19203:1	O
provides	SAPHRIS.xml:S3:19204:8	O
the	SAPHRIS.xml:S3:19213:3	O
mean	SAPHRIS.xml:S3:19217:4	O
weight	SAPHRIS.xml:S3:19222:6	B-AdverseReaction
change	SAPHRIS.xml:S3:19229:6	I-AdverseReaction
from	SAPHRIS.xml:S3:19236:4	O
baseline	SAPHRIS.xml:S3:19241:8	O
and	SAPHRIS.xml:S3:19250:3	O
the	SAPHRIS.xml:S3:19254:3	O
proportion	SAPHRIS.xml:S3:19258:10	O
of	SAPHRIS.xml:S3:19269:2	O
patients	SAPHRIS.xml:S3:19272:8	O
with	SAPHRIS.xml:S3:19281:4	O
a	SAPHRIS.xml:S3:19286:1	O
weight	SAPHRIS.xml:S3:19288:6	B-AdverseReaction
gain	SAPHRIS.xml:S3:19295:4	I-AdverseReaction
of	SAPHRIS.xml:S3:19300:2	O
7%	SAPHRIS.xml:S3:19305:2	B-Severity
categorized	SAPHRIS.xml:S3:19308:11	O
by	SAPHRIS.xml:S3:19320:2	O
Body	SAPHRIS.xml:S3:19323:4	O
Mass	SAPHRIS.xml:S3:19328:4	O
Index	SAPHRIS.xml:S3:19333:5	O
(	SAPHRIS.xml:S3:19339:1	O
BMI	SAPHRIS.xml:S3:19340:3	O
)	SAPHRIS.xml:S3:19343:1	O
at	SAPHRIS.xml:S3:19345:2	O
baseline	SAPHRIS.xml:S3:19348:8	O
.	SAPHRIS.xml:S3:19356:1	O

Table	SAPHRIS.xml:S3:19362:5	O

6	SAPHRIS.xml:S3:19368:1	O
:	SAPHRIS.xml:S3:19369:1	O
Weight	SAPHRIS.xml:S3:19371:6	O
Change	SAPHRIS.xml:S3:19378:6	O
Results	SAPHRIS.xml:S3:19385:7	O
Categorized	SAPHRIS.xml:S3:19393:11	O
by	SAPHRIS.xml:S3:19405:2	O
BMI	SAPHRIS.xml:S3:19408:3	O
at	SAPHRIS.xml:S3:19412:2	O
Baseline	SAPHRIS.xml:S3:19415:8	O
:	SAPHRIS.xml:S3:19423:1	O
Comparator	SAPHRIS.xml:S3:19425:10	O
-	SAPHRIS.xml:S3:19435:1	O
Controlled	SAPHRIS.xml:S3:19436:10	O
52	SAPHRIS.xml:S3:19447:2	O
-	SAPHRIS.xml:S3:19449:1	O
Week	SAPHRIS.xml:S3:19450:4	O
Study	SAPHRIS.xml:S3:19455:5	O
in	SAPHRIS.xml:S3:19461:2	O
Adults	SAPHRIS.xml:S3:19464:6	O
with	SAPHRIS.xml:S3:19471:4	O
Schizophrenia	SAPHRIS.xml:S3:19476:13	O

BMI	SAPHRIS.xml:S3:19521:3	O
23	SAPHRIS.xml:S3:19526:2	O
SAPHRIS	SAPHRIS.xml:S3:19532:7	O
N	SAPHRIS.xml:S3:19543:1	O
295	SAPHRIS.xml:S3:19545:3	O
BMI	SAPHRIS.xml:S3:19554:3	O
23	SAPHRIS.xml:S3:19558:2	O
-	SAPHRIS.xml:S3:19561:1	O
27	SAPHRIS.xml:S3:19565:2	O
SAPHRIS	SAPHRIS.xml:S3:19571:7	O
N	SAPHRIS.xml:S3:19582:1	O
290	SAPHRIS.xml:S3:19584:3	O
BMI	SAPHRIS.xml:S3:19593:3	O
27	SAPHRIS.xml:S3:19598:2	O
SAPHRIS	SAPHRIS.xml:S3:19604:7	O
N	SAPHRIS.xml:S3:19615:1	O
302	SAPHRIS.xml:S3:19617:3	O

Mean	SAPHRIS.xml:S3:19627:4	O
change	SAPHRIS.xml:S3:19632:6	O
from	SAPHRIS.xml:S3:19639:4	O
Baseline	SAPHRIS.xml:S3:19644:8	O
(	SAPHRIS.xml:S3:19653:1	O
kg	SAPHRIS.xml:S3:19654:2	O
)	SAPHRIS.xml:S3:19656:1	O
1.7	SAPHRIS.xml:S3:19659:3	O
1	SAPHRIS.xml:S3:19686:1	O
0	SAPHRIS.xml:S3:19713:1	O

with	SAPHRIS.xml:S3:19745:4	O
7%	SAPHRIS.xml:S3:19752:2	B-Severity
increase	SAPHRIS.xml:S3:19755:8	B-AdverseReaction
in	SAPHRIS.xml:S3:19764:2	I-AdverseReaction
body	SAPHRIS.xml:S3:19767:4	I-AdverseReaction
weight	SAPHRIS.xml:S3:19772:6	I-AdverseReaction
22%	SAPHRIS.xml:S3:19780:3	O
13%	SAPHRIS.xml:S3:19807:3	O
9%	SAPHRIS.xml:S3:19834:2	O

Pediatric	SAPHRIS.xml:S3:19881:9	O
Patients	SAPHRIS.xml:S3:19891:8	O
:	SAPHRIS.xml:S3:19899:1	O
Data	SAPHRIS.xml:S3:19902:4	O
on	SAPHRIS.xml:S3:19907:2	O
mean	SAPHRIS.xml:S3:19910:4	O
changes	SAPHRIS.xml:S3:19915:7	B-AdverseReaction
in	SAPHRIS.xml:S3:19923:2	I-AdverseReaction
body	SAPHRIS.xml:S3:19926:4	I-AdverseReaction
weight	SAPHRIS.xml:S3:19931:6	I-AdverseReaction
and	SAPHRIS.xml:S3:19938:3	O
the	SAPHRIS.xml:S3:19942:3	O
proportion	SAPHRIS.xml:S3:19946:10	O
of	SAPHRIS.xml:S3:19957:2	O
pediatric	SAPHRIS.xml:S3:19960:9	O
patients	SAPHRIS.xml:S3:19970:8	O
meeting	SAPHRIS.xml:S3:19979:7	O
a	SAPHRIS.xml:S3:19987:1	O
weight	SAPHRIS.xml:S3:19989:6	B-AdverseReaction
gain	SAPHRIS.xml:S3:19996:4	I-AdverseReaction
criterion	SAPHRIS.xml:S3:20001:9	O
of	SAPHRIS.xml:S3:20011:2	O
7%	SAPHRIS.xml:S3:20016:2	B-Severity
of	SAPHRIS.xml:S3:20019:2	O
body	SAPHRIS.xml:S3:20022:4	O
weight	SAPHRIS.xml:S3:20027:6	O
from	SAPHRIS.xml:S3:20034:4	O
the	SAPHRIS.xml:S3:20039:3	O
short	SAPHRIS.xml:S3:20043:5	O
-	SAPHRIS.xml:S3:20048:1	O
term	SAPHRIS.xml:S3:20049:4	O
,	SAPHRIS.xml:S3:20053:1	O
placebo	SAPHRIS.xml:S3:20055:7	O
-	SAPHRIS.xml:S3:20062:1	O
controlled	SAPHRIS.xml:S3:20063:10	O
bipolar	SAPHRIS.xml:S3:20074:7	O
mania	SAPHRIS.xml:S3:20082:5	O
trial	SAPHRIS.xml:S3:20088:5	O
are	SAPHRIS.xml:S3:20094:3	O
presented	SAPHRIS.xml:S3:20098:9	O
in	SAPHRIS.xml:S3:20108:2	O
Table	SAPHRIS.xml:S3:20112:5	O
7	SAPHRIS.xml:S3:20118:1	O
.	SAPHRIS.xml:S3:20121:1	O

To	SAPHRIS.xml:S3:20123:2	O
adjust	SAPHRIS.xml:S3:20126:6	O
for	SAPHRIS.xml:S3:20133:3	O
normal	SAPHRIS.xml:S3:20137:6	O
growth	SAPHRIS.xml:S3:20144:6	O
,	SAPHRIS.xml:S3:20150:1	O
z	SAPHRIS.xml:S3:20152:1	O
-	SAPHRIS.xml:S3:20153:1	O
scores	SAPHRIS.xml:S3:20154:6	O
were	SAPHRIS.xml:S3:20161:4	O
derived	SAPHRIS.xml:S3:20166:7	O
(	SAPHRIS.xml:S3:20174:1	O
measured	SAPHRIS.xml:S3:20175:8	O
in	SAPHRIS.xml:S3:20184:2	O
standard	SAPHRIS.xml:S3:20187:8	O
deviations	SAPHRIS.xml:S3:20196:10	O
[	SAPHRIS.xml:S3:20207:1	O
SD	SAPHRIS.xml:S3:20208:2	O
])	SAPHRIS.xml:S3:20210:2	O
,	SAPHRIS.xml:S3:20212:1	O
which	SAPHRIS.xml:S3:20214:5	O
normalize	SAPHRIS.xml:S3:20220:9	O
for	SAPHRIS.xml:S3:20230:3	O
the	SAPHRIS.xml:S3:20234:3	O
natural	SAPHRIS.xml:S3:20238:7	O
growth	SAPHRIS.xml:S3:20246:6	O
of	SAPHRIS.xml:S3:20253:2	O
pediatric	SAPHRIS.xml:S3:20256:9	O
patients	SAPHRIS.xml:S3:20266:8	O
by	SAPHRIS.xml:S3:20275:2	O
comparisons	SAPHRIS.xml:S3:20278:11	O
to	SAPHRIS.xml:S3:20290:2	O
age	SAPHRIS.xml:S3:20293:3	O
-	SAPHRIS.xml:S3:20296:1	O
and	SAPHRIS.xml:S3:20298:3	O
sex	SAPHRIS.xml:S3:20302:3	O
-	SAPHRIS.xml:S3:20305:1	O
matched	SAPHRIS.xml:S3:20306:7	O
population	SAPHRIS.xml:S3:20314:10	O
standards	SAPHRIS.xml:S3:20325:9	O
.	SAPHRIS.xml:S3:20334:1	O

The	SAPHRIS.xml:S3:20344:3	O

distance	SAPHRIS.xml:S3:20348:8	O
of	SAPHRIS.xml:S3:20357:2	O
a	SAPHRIS.xml:S3:20360:1	O
z	SAPHRIS.xml:S3:20362:1	O
-	SAPHRIS.xml:S3:20363:1	O
score	SAPHRIS.xml:S3:20364:5	O
from	SAPHRIS.xml:S3:20370:4	O
0	SAPHRIS.xml:S3:20375:1	O
represents	SAPHRIS.xml:S3:20377:10	O
the	SAPHRIS.xml:S3:20388:3	O
distance	SAPHRIS.xml:S3:20392:8	O
of	SAPHRIS.xml:S3:20401:2	O
a	SAPHRIS.xml:S3:20404:1	O
percentile	SAPHRIS.xml:S3:20406:10	O
from	SAPHRIS.xml:S3:20417:4	O
the	SAPHRIS.xml:S3:20422:3	O
median	SAPHRIS.xml:S3:20426:6	O
,	SAPHRIS.xml:S3:20432:1	O
measured	SAPHRIS.xml:S3:20434:8	O
in	SAPHRIS.xml:S3:20443:2	O
standard	SAPHRIS.xml:S3:20446:8	O
deviations	SAPHRIS.xml:S3:20455:10	O
(	SAPHRIS.xml:S3:20466:1	O
SD	SAPHRIS.xml:S3:20467:2	O
)	SAPHRIS.xml:S3:20469:1	O
.	SAPHRIS.xml:S3:20470:1	O

After	SAPHRIS.xml:S3:20472:5	O
adjusting	SAPHRIS.xml:S3:20478:9	O
for	SAPHRIS.xml:S3:20488:3	O
age	SAPHRIS.xml:S3:20492:3	O
and	SAPHRIS.xml:S3:20496:3	O
sex	SAPHRIS.xml:S3:20500:3	O
,	SAPHRIS.xml:S3:20503:1	O
the	SAPHRIS.xml:S3:20505:3	O
mean	SAPHRIS.xml:S3:20509:4	O
change	SAPHRIS.xml:S3:20514:6	O
from	SAPHRIS.xml:S3:20521:4	O
baseline	SAPHRIS.xml:S3:20526:8	O
to	SAPHRIS.xml:S3:20535:2	O
endpoint	SAPHRIS.xml:S3:20538:8	O
in	SAPHRIS.xml:S3:20547:2	O
weight	SAPHRIS.xml:S3:20550:6	O
z	SAPHRIS.xml:S3:20557:1	O
-	SAPHRIS.xml:S3:20558:1	O
score	SAPHRIS.xml:S3:20559:5	O
for	SAPHRIS.xml:S3:20565:3	O
SAPHRS	SAPHRIS.xml:S3:20569:6	O
2.5	SAPHRIS.xml:S3:20576:3	O
mg	SAPHRIS.xml:S3:20580:2	O
,	SAPHRIS.xml:S3:20582:1	O
5	SAPHRIS.xml:S3:20584:1	O
mg	SAPHRIS.xml:S3:20586:2	O
,	SAPHRIS.xml:S3:20588:1	O
and	SAPHRIS.xml:S3:20590:3	O
10	SAPHRIS.xml:S3:20594:2	O
mg	SAPHRIS.xml:S3:20597:2	O
twice	SAPHRIS.xml:S3:20600:5	O
daily	SAPHRIS.xml:S3:20606:5	O
,	SAPHRIS.xml:S3:20611:1	O
was	SAPHRIS.xml:S3:20613:3	O
0.11	SAPHRIS.xml:S3:20617:4	O
,	SAPHRIS.xml:S3:20621:1	O
0.08	SAPHRIS.xml:S3:20623:4	O
and	SAPHRIS.xml:S3:20628:3	O
0.09	SAPHRIS.xml:S3:20632:4	O
SD	SAPHRIS.xml:S3:20637:2	O
versus	SAPHRIS.xml:S3:20640:6	O
0.02	SAPHRIS.xml:S3:20647:4	O
SD	SAPHRIS.xml:S3:20652:2	O
for	SAPHRIS.xml:S3:20655:3	O
placebo	SAPHRIS.xml:S3:20659:7	O
,	SAPHRIS.xml:S3:20666:1	O
respectively	SAPHRIS.xml:S3:20668:12	O
.	SAPHRIS.xml:S3:20680:1	O

When	SAPHRIS.xml:S3:20690:4	O
treating	SAPHRIS.xml:S3:20695:8	O
pediatric	SAPHRIS.xml:S3:20704:9	O
patients	SAPHRIS.xml:S3:20714:8	O
,	SAPHRIS.xml:S3:20722:1	O
weight	SAPHRIS.xml:S3:20724:6	O
gain	SAPHRIS.xml:S3:20731:4	O
should	SAPHRIS.xml:S3:20736:6	O
be	SAPHRIS.xml:S3:20743:2	O
monitored	SAPHRIS.xml:S3:20746:9	O
and	SAPHRIS.xml:S3:20756:3	O
assessed	SAPHRIS.xml:S3:20760:8	O
against	SAPHRIS.xml:S3:20769:7	O
that	SAPHRIS.xml:S3:20777:4	O
expected	SAPHRIS.xml:S3:20782:8	O
for	SAPHRIS.xml:S3:20791:3	O
normal	SAPHRIS.xml:S3:20795:6	O
growth	SAPHRIS.xml:S3:20802:6	O
.	SAPHRIS.xml:S3:20808:1	O

Table	SAPHRIS.xml:S3:20814:5	O
7	SAPHRIS.xml:S3:20820:1	O
:	SAPHRIS.xml:S3:20821:1	O
Change	SAPHRIS.xml:S3:20823:6	O
in	SAPHRIS.xml:S3:20830:2	O
Body	SAPHRIS.xml:S3:20833:4	O
Weight	SAPHRIS.xml:S3:20838:6	O
in	SAPHRIS.xml:S3:20845:2	O
Pediatric	SAPHRIS.xml:S3:20848:9	O
Subjects	SAPHRIS.xml:S3:20858:8	O
from	SAPHRIS.xml:S3:20867:4	O
Baseline	SAPHRIS.xml:S3:20872:8	O

N	SAPHRIS.xml:S3:20884:1	O
Number	SAPHRIS.xml:S3:20889:6	O
of	SAPHRIS.xml:S3:20896:2	O
subjects	SAPHRIS.xml:S3:20899:8	O
who	SAPHRIS.xml:S3:20908:3	O
had	SAPHRIS.xml:S3:20912:3	O
assessments	SAPHRIS.xml:S3:20916:11	O
at	SAPHRIS.xml:S3:20928:2	O
both	SAPHRIS.xml:S3:20931:4	O
Baseline	SAPHRIS.xml:S3:20936:8	O
and	SAPHRIS.xml:S3:20945:3	O
Endpoint	SAPHRIS.xml:S3:20949:8	O
.	SAPHRIS.xml:S3:20957:1	O

Bipolar	SAPHRIS.xml:S3:20985:7	O

I	SAPHRIS.xml:S3:20993:1	O
Disorder	SAPHRIS.xml:S3:20995:8	O
(	SAPHRIS.xml:S3:21004:1	O
3	SAPHRIS.xml:S3:21005:1	O
-	SAPHRIS.xml:S3:21006:1	O
weeks	SAPHRIS.xml:S3:21007:5	O
)	SAPHRIS.xml:S3:21012:1	O

Placebo	SAPHRIS.xml:S3:21018:7	O
SAPHRIS2	SAPHRIS.xml:S3:21036:8	O
.	SAPHRIS.xml:S3:21044:1	O
5	SAPHRIS.xml:S3:21045:1	O
mgtwice	SAPHRIS.xml:S3:21047:7	O
daily	SAPHRIS.xml:S3:21055:5	O
SAPHRIS5	SAPHRIS.xml:S3:21062:8	O
mgtwice	SAPHRIS.xml:S3:21071:7	O
daily	SAPHRIS.xml:S3:21079:5	O
SAPHRIS10	SAPHRIS.xml:S3:21086:9	O
mgtwice	SAPHRIS.xml:S3:21096:7	O
daily	SAPHRIS.xml:S3:21104:5	O

Change	SAPHRIS.xml:S3:21114:6	O
from	SAPHRIS.xml:S3:21121:4	O
Baseline	SAPHRIS.xml:S3:21126:8	O
(	SAPHRIS.xml:S3:21135:1	O
kg	SAPHRIS.xml:S3:21136:2	O
)	SAPHRIS.xml:S3:21138:1	O
(	SAPHRIS.xml:S3:21140:1	O
N	SAPHRIS.xml:S3:21141:1	O
)	SAPHRIS.xml:S3:21143:1	O
0.5	SAPHRIS.xml:S3:21146:3	O
(	SAPHRIS.xml:S3:21149:1	O
89	SAPHRIS.xml:S3:21150:2	O
)	SAPHRIS.xml:S3:21152:1	O
1.7	SAPHRIS.xml:S3:21167:3	O
(	SAPHRIS.xml:S3:21170:1	O
92	SAPHRIS.xml:S3:21171:2	O
)	SAPHRIS.xml:S3:21173:1	O
1.6	SAPHRIS.xml:S3:21190:3	O
(	SAPHRIS.xml:S3:21193:1	O
90	SAPHRIS.xml:S3:21194:2	O
)	SAPHRIS.xml:S3:21196:1	O
1.4	SAPHRIS.xml:S3:21212:3	O
(	SAPHRIS.xml:S3:21215:1	O
87	SAPHRIS.xml:S3:21216:2	O
)	SAPHRIS.xml:S3:21218:1	O

Proportion	SAPHRIS.xml:S3:21256:10	O
of	SAPHRIS.xml:S3:21267:2	O
Subjects	SAPHRIS.xml:S3:21270:8	O
with	SAPHRIS.xml:S3:21279:4	O
a	SAPHRIS.xml:S3:21284:1	O
7%	SAPHRIS.xml:S3:21288:2	B-Severity
Increase	SAPHRIS.xml:S3:21291:8	B-AdverseReaction
in	SAPHRIS.xml:S3:21300:2	I-AdverseReaction
Body	SAPHRIS.xml:S3:21303:4	I-AdverseReaction
Weight	SAPHRIS.xml:S3:21308:6	I-AdverseReaction

with	SAPHRIS.xml:S3:21321:4	O
7%	SAPHRIS.xml:S3:21328:2	B-Severity
increase	SAPHRIS.xml:S3:21331:8	B-AdverseReaction
in	SAPHRIS.xml:S3:21340:2	I-AdverseReaction
body	SAPHRIS.xml:S3:21343:4	I-AdverseReaction
weight	SAPHRIS.xml:S3:21348:6	I-AdverseReaction
1.1%	SAPHRIS.xml:S3:21356:4	O
12.0%	SAPHRIS.xml:S3:21377:5	O
8.9%	SAPHRIS.xml:S3:21400:4	O
8.0%	SAPHRIS.xml:S3:21422:4	O

5.6	SAPHRIS.xml:S3:21464:3	O
Hypersensitivity	SAPHRIS.xml:S3:21468:16	O
Reactions	SAPHRIS.xml:S3:21485:9	O

Hypersensitivity	SAPHRIS.xml:S3:21502:16	B-AdverseReaction
reactions	SAPHRIS.xml:S3:21519:9	I-AdverseReaction
have	SAPHRIS.xml:S3:21529:4	O
been	SAPHRIS.xml:S3:21534:4	O
observed	SAPHRIS.xml:S3:21539:8	O
in	SAPHRIS.xml:S3:21548:2	O
patients	SAPHRIS.xml:S3:21551:8	O
treated	SAPHRIS.xml:S3:21560:7	O
with	SAPHRIS.xml:S3:21568:4	O
SAPHRIS	SAPHRIS.xml:S3:21573:7	O
.	SAPHRIS.xml:S3:21580:1	O

In	SAPHRIS.xml:S3:21582:2	O
several	SAPHRIS.xml:S3:21585:7	O
cases	SAPHRIS.xml:S3:21593:5	O
,	SAPHRIS.xml:S3:21598:1	O
these	SAPHRIS.xml:S3:21600:5	O
reactions	SAPHRIS.xml:S3:21606:9	O
occurred	SAPHRIS.xml:S3:21616:8	O
after	SAPHRIS.xml:S3:21625:5	O
the	SAPHRIS.xml:S3:21631:3	O
first	SAPHRIS.xml:S3:21635:5	O
dose	SAPHRIS.xml:S3:21641:4	O
.	SAPHRIS.xml:S3:21645:1	O

These	SAPHRIS.xml:S3:21647:5	O
hypersensitivity	SAPHRIS.xml:S3:21653:16	B-AdverseReaction
reactions	SAPHRIS.xml:S3:21670:9	I-AdverseReaction
included	SAPHRIS.xml:S3:21680:8	O
:	SAPHRIS.xml:S3:21688:1	O
anaphylaxis	SAPHRIS.xml:S3:21690:11	B-AdverseReaction
,	SAPHRIS.xml:S3:21701:1	O
angioedema	SAPHRIS.xml:S3:21703:10	B-AdverseReaction
,	SAPHRIS.xml:S3:21713:1	O
hypotension	SAPHRIS.xml:S3:21715:11	B-AdverseReaction
,	SAPHRIS.xml:S3:21726:1	O
tachycardia	SAPHRIS.xml:S3:21728:11	B-AdverseReaction
,	SAPHRIS.xml:S3:21739:1	O
swollen	SAPHRIS.xml:S3:21741:7	B-AdverseReaction
tongue	SAPHRIS.xml:S3:21749:6	I-AdverseReaction
,	SAPHRIS.xml:S3:21755:1	O
dyspnea	SAPHRIS.xml:S3:21757:7	B-AdverseReaction
,	SAPHRIS.xml:S3:21764:1	O
wheezing	SAPHRIS.xml:S3:21766:8	B-AdverseReaction
and	SAPHRIS.xml:S3:21775:3	O
rash	SAPHRIS.xml:S3:21779:4	B-AdverseReaction
.	SAPHRIS.xml:S3:21783:1	O

5.7	SAPHRIS.xml:S3:21795:3	O
Orthostatic	SAPHRIS.xml:S3:21799:11	O
Hypotension	SAPHRIS.xml:S3:21811:11	O
,	SAPHRIS.xml:S3:21822:1	O
Syncope	SAPHRIS.xml:S3:21824:7	O
,	SAPHRIS.xml:S3:21831:1	O
and	SAPHRIS.xml:S3:21833:3	O
Other	SAPHRIS.xml:S3:21837:5	O
Hemodynamic	SAPHRIS.xml:S3:21843:11	O
Effects	SAPHRIS.xml:S3:21855:7	O

SAPHRIS	SAPHRIS.xml:S3:21870:7	O
may	SAPHRIS.xml:S3:21878:3	B-Factor
induce	SAPHRIS.xml:S3:21882:6	O
orthostatic	SAPHRIS.xml:S3:21889:11	B-AdverseReaction
hypotension	SAPHRIS.xml:S3:21901:11	I-AdverseReaction
and	SAPHRIS.xml:S3:21913:3	O
syncope	SAPHRIS.xml:S3:21917:7	B-AdverseReaction
in	SAPHRIS.xml:S3:21925:2	O
some	SAPHRIS.xml:S3:21928:4	O
patients	SAPHRIS.xml:S3:21933:8	O
,	SAPHRIS.xml:S3:21941:1	O
especially	SAPHRIS.xml:S3:21943:10	O
early	SAPHRIS.xml:S3:21954:5	O
in	SAPHRIS.xml:S3:21960:2	O
treatment	SAPHRIS.xml:S3:21963:9	O
,	SAPHRIS.xml:S3:21972:1	O
because	SAPHRIS.xml:S3:21974:7	O
of	SAPHRIS.xml:S3:21982:2	O
its	SAPHRIS.xml:S3:21985:3	O
alpha1	SAPHRIS.xml:S3:21989:6	O
-	SAPHRIS.xml:S3:21995:1	O
adrenergic	SAPHRIS.xml:S3:21996:10	O
antagonist	SAPHRIS.xml:S3:22007:10	O
activity	SAPHRIS.xml:S3:22018:8	O
.	SAPHRIS.xml:S3:22026:1	O

In	SAPHRIS.xml:S3:22028:2	O
short	SAPHRIS.xml:S3:22031:5	O
-	SAPHRIS.xml:S3:22036:1	O
term	SAPHRIS.xml:S3:22037:4	O
schizophrenia	SAPHRIS.xml:S3:22042:13	O
adult	SAPHRIS.xml:S3:22056:5	O
trials	SAPHRIS.xml:S3:22062:6	O
,	SAPHRIS.xml:S3:22068:1	O
syncope	SAPHRIS.xml:S3:22070:7	B-AdverseReaction
was	SAPHRIS.xml:S3:22078:3	O
reported	SAPHRIS.xml:S3:22082:8	O
in	SAPHRIS.xml:S3:22091:2	O
0.2%	SAPHRIS.xml:S3:22094:4	O
(	SAPHRIS.xml:S3:22099:1	O
1	SAPHRIS.xml:S3:22100:1	O
572	SAPHRIS.xml:S3:22102:3	O
)	SAPHRIS.xml:S3:22105:1	O
of	SAPHRIS.xml:S3:22107:2	O
patients	SAPHRIS.xml:S3:22110:8	O
treated	SAPHRIS.xml:S3:22119:7	O
with	SAPHRIS.xml:S3:22127:4	O
therapeutic	SAPHRIS.xml:S3:22132:11	O
doses	SAPHRIS.xml:S3:22144:5	O
(	SAPHRIS.xml:S3:22150:1	O
5	SAPHRIS.xml:S3:22151:1	O
mg	SAPHRIS.xml:S3:22153:2	O
or	SAPHRIS.xml:S3:22156:2	O
10	SAPHRIS.xml:S3:22159:2	O
mg	SAPHRIS.xml:S3:22162:2	O
twice	SAPHRIS.xml:S3:22165:5	O
daily	SAPHRIS.xml:S3:22171:5	O
)	SAPHRIS.xml:S3:22176:1	O
of	SAPHRIS.xml:S3:22178:2	O
SAPHRIS	SAPHRIS.xml:S3:22181:7	O
,	SAPHRIS.xml:S3:22188:1	O
compared	SAPHRIS.xml:S3:22190:8	O
to	SAPHRIS.xml:S3:22199:2	O
0.3%	SAPHRIS.xml:S3:22202:4	O
(	SAPHRIS.xml:S3:22207:1	O
1	SAPHRIS.xml:S3:22208:1	O
378	SAPHRIS.xml:S3:22210:3	O
)	SAPHRIS.xml:S3:22213:1	O
of	SAPHRIS.xml:S3:22215:2	O
patients	SAPHRIS.xml:S3:22218:8	O
treated	SAPHRIS.xml:S3:22227:7	O
with	SAPHRIS.xml:S3:22235:4	O
placebo	SAPHRIS.xml:S3:22240:7	O
.	SAPHRIS.xml:S3:22247:1	O

In	SAPHRIS.xml:S3:22249:2	O
short	SAPHRIS.xml:S3:22252:5	O
-	SAPHRIS.xml:S3:22257:1	O
term	SAPHRIS.xml:S3:22258:4	O
bipolar	SAPHRIS.xml:S3:22263:7	O
mania	SAPHRIS.xml:S3:22271:5	O
adult	SAPHRIS.xml:S3:22277:5	O
trials	SAPHRIS.xml:S3:22283:6	O
,	SAPHRIS.xml:S3:22289:1	O
syncope	SAPHRIS.xml:S3:22291:7	B-AdverseReaction
was	SAPHRIS.xml:S3:22299:3	O
reported	SAPHRIS.xml:S3:22303:8	O
in	SAPHRIS.xml:S3:22312:2	O
0.3%	SAPHRIS.xml:S3:22315:4	O
(	SAPHRIS.xml:S3:22320:1	O
1	SAPHRIS.xml:S3:22321:1	O
379	SAPHRIS.xml:S3:22323:3	O
)	SAPHRIS.xml:S3:22326:1	O
of	SAPHRIS.xml:S3:22328:2	O
patients	SAPHRIS.xml:S3:22331:8	O
treated	SAPHRIS.xml:S3:22340:7	O
with	SAPHRIS.xml:S3:22348:4	O
therapeutic	SAPHRIS.xml:S3:22353:11	O
doses	SAPHRIS.xml:S3:22365:5	O
(	SAPHRIS.xml:S3:22371:1	O
5	SAPHRIS.xml:S3:22372:1	O
mg	SAPHRIS.xml:S3:22374:2	O
or	SAPHRIS.xml:S3:22377:2	O
10	SAPHRIS.xml:S3:22380:2	O
mg	SAPHRIS.xml:S3:22383:2	O
twice	SAPHRIS.xml:S3:22386:5	O
daily	SAPHRIS.xml:S3:22392:5	O
)	SAPHRIS.xml:S3:22397:1	O
of	SAPHRIS.xml:S3:22399:2	O
SAPHRIS	SAPHRIS.xml:S3:22402:7	O
,	SAPHRIS.xml:S3:22409:1	O
compared	SAPHRIS.xml:S3:22411:8	O
to	SAPHRIS.xml:S3:22420:2	O
0%	SAPHRIS.xml:S3:22423:2	O
(	SAPHRIS.xml:S3:22426:1	O
0	SAPHRIS.xml:S3:22427:1	O
203	SAPHRIS.xml:S3:22429:3	O
)	SAPHRIS.xml:S3:22432:1	O
of	SAPHRIS.xml:S3:22434:2	O
patients	SAPHRIS.xml:S3:22437:8	O
treated	SAPHRIS.xml:S3:22446:7	O
with	SAPHRIS.xml:S3:22454:4	O
placebo	SAPHRIS.xml:S3:22459:7	O
.	SAPHRIS.xml:S3:22466:1	O

During	SAPHRIS.xml:S3:22468:6	O
adult	SAPHRIS.xml:S3:22475:5	O
pre	SAPHRIS.xml:S3:22481:3	O
-	SAPHRIS.xml:S3:22484:1	O
marketing	SAPHRIS.xml:S3:22485:9	O
clinical	SAPHRIS.xml:S3:22495:8	O
trials	SAPHRIS.xml:S3:22504:6	O
with	SAPHRIS.xml:S3:22511:4	O
SAPHRIS	SAPHRIS.xml:S3:22516:7	O
,	SAPHRIS.xml:S3:22523:1	O
including	SAPHRIS.xml:S3:22525:9	O
long	SAPHRIS.xml:S3:22535:4	O
-	SAPHRIS.xml:S3:22539:1	O
term	SAPHRIS.xml:S3:22540:4	O
trials	SAPHRIS.xml:S3:22545:6	O
without	SAPHRIS.xml:S3:22552:7	O
comparison	SAPHRIS.xml:S3:22560:10	O
to	SAPHRIS.xml:S3:22571:2	O
placebo	SAPHRIS.xml:S3:22574:7	O
,	SAPHRIS.xml:S3:22581:1	O
syncope	SAPHRIS.xml:S3:22583:7	B-AdverseReaction
was	SAPHRIS.xml:S3:22591:3	O
reported	SAPHRIS.xml:S3:22595:8	O
in	SAPHRIS.xml:S3:22604:2	O
0.6%	SAPHRIS.xml:S3:22607:4	O
(	SAPHRIS.xml:S3:22612:1	O
11	SAPHRIS.xml:S3:22613:2	O
1953	SAPHRIS.xml:S3:22616:4	O
)	SAPHRIS.xml:S3:22620:1	O
of	SAPHRIS.xml:S3:22622:2	O
patients	SAPHRIS.xml:S3:22625:8	O
treated	SAPHRIS.xml:S3:22634:7	O
with	SAPHRIS.xml:S3:22642:4	O
SAPHRIS	SAPHRIS.xml:S3:22647:7	O
.	SAPHRIS.xml:S3:22654:1	O

In	SAPHRIS.xml:S3:22656:2	O
a	SAPHRIS.xml:S3:22659:1	O
3	SAPHRIS.xml:S3:22661:1	O
-	SAPHRIS.xml:S3:22662:1	O
week	SAPHRIS.xml:S3:22663:4	O
,	SAPHRIS.xml:S3:22667:1	O
bipolar	SAPHRIS.xml:S3:22669:7	O
mania	SAPHRIS.xml:S3:22677:5	O
pediatric	SAPHRIS.xml:S3:22683:9	O
trial	SAPHRIS.xml:S3:22693:5	O
,	SAPHRIS.xml:S3:22698:1	O
syncope	SAPHRIS.xml:S3:22700:7	B-AdverseReaction
was	SAPHRIS.xml:S3:22708:3	O
reported	SAPHRIS.xml:S3:22712:8	O
in	SAPHRIS.xml:S3:22721:2	O
1%	SAPHRIS.xml:S3:22724:2	O
(	SAPHRIS.xml:S3:22727:1	O
1	SAPHRIS.xml:S3:22728:1	O
104	SAPHRIS.xml:S3:22730:3	O
)	SAPHRIS.xml:S3:22733:1	O
of	SAPHRIS.xml:S3:22735:2	O
patients	SAPHRIS.xml:S3:22738:8	O
treated	SAPHRIS.xml:S3:22747:7	O
with	SAPHRIS.xml:S3:22755:4	O
SAPHRIS	SAPHRIS.xml:S3:22760:7	O
2.5	SAPHRIS.xml:S3:22768:3	O
mg	SAPHRIS.xml:S3:22772:2	O
twice	SAPHRIS.xml:S3:22775:5	O
daily	SAPHRIS.xml:S3:22781:5	O
,	SAPHRIS.xml:S3:22786:1	O
1%	SAPHRIS.xml:S3:22788:2	O
(	SAPHRIS.xml:S3:22791:1	O
1	SAPHRIS.xml:S3:22792:1	O
99	SAPHRIS.xml:S3:22794:2	O
)	SAPHRIS.xml:S3:22796:1	O
of	SAPHRIS.xml:S3:22798:2	O
patients	SAPHRIS.xml:S3:22801:8	O
treated	SAPHRIS.xml:S3:22810:7	O
with	SAPHRIS.xml:S3:22818:4	O
SAPHRIS	SAPHRIS.xml:S3:22823:7	O
5	SAPHRIS.xml:S3:22831:1	O
mg	SAPHRIS.xml:S3:22833:2	O
twice	SAPHRIS.xml:S3:22836:5	O
daily	SAPHRIS.xml:S3:22842:5	O
,	SAPHRIS.xml:S3:22847:1	O
and	SAPHRIS.xml:S3:22849:3	O
0%	SAPHRIS.xml:S3:22853:2	O
(	SAPHRIS.xml:S3:22856:1	O
0	SAPHRIS.xml:S3:22857:1	O
99	SAPHRIS.xml:S3:22859:2	O
)	SAPHRIS.xml:S3:22861:1	O
for	SAPHRIS.xml:S3:22863:3	O
patients	SAPHRIS.xml:S3:22867:8	O
treated	SAPHRIS.xml:S3:22876:7	O
with	SAPHRIS.xml:S3:22884:4	O
SAPHRIS	SAPHRIS.xml:S3:22889:7	O
10	SAPHRIS.xml:S3:22897:2	O
mg	SAPHRIS.xml:S3:22900:2	O
twice	SAPHRIS.xml:S3:22903:5	O
daily	SAPHRIS.xml:S3:22909:5	O
compared	SAPHRIS.xml:S3:22915:8	O
to	SAPHRIS.xml:S3:22924:2	O
0%	SAPHRIS.xml:S3:22927:2	O
(	SAPHRIS.xml:S3:22930:1	O
0	SAPHRIS.xml:S3:22931:1	O
101	SAPHRIS.xml:S3:22933:3	O
)	SAPHRIS.xml:S3:22936:1	O
for	SAPHRIS.xml:S3:22938:3	O
patients	SAPHRIS.xml:S3:22942:8	O
treated	SAPHRIS.xml:S3:22951:7	O
with	SAPHRIS.xml:S3:22959:4	O
placebo	SAPHRIS.xml:S3:22964:7	O
.	SAPHRIS.xml:S3:22971:1	O

Patients	SAPHRIS.xml:S3:22981:8	O
should	SAPHRIS.xml:S3:22990:6	O
be	SAPHRIS.xml:S3:22997:2	O
instructed	SAPHRIS.xml:S3:23000:10	O
about	SAPHRIS.xml:S3:23011:5	O
non	SAPHRIS.xml:S3:23017:3	O
-	SAPHRIS.xml:S3:23020:1	O
pharmacologic	SAPHRIS.xml:S3:23021:13	O
interventions	SAPHRIS.xml:S3:23035:13	O
that	SAPHRIS.xml:S3:23049:4	O
help	SAPHRIS.xml:S3:23054:4	O
to	SAPHRIS.xml:S3:23059:2	O
reduce	SAPHRIS.xml:S3:23062:6	O
the	SAPHRIS.xml:S3:23069:3	O
occurrence	SAPHRIS.xml:S3:23073:10	O
of	SAPHRIS.xml:S3:23084:2	O
orthostatic	SAPHRIS.xml:S3:23087:11	O
hypotension	SAPHRIS.xml:S3:23099:11	O
(	SAPHRIS.xml:S3:23111:1	O
e	SAPHRIS.xml:S3:23112:1	O
.	SAPHRIS.xml:S3:23113:1	O
g	SAPHRIS.xml:S3:23114:1	O
.	SAPHRIS.xml:S3:23115:1	O
,	SAPHRIS.xml:S3:23116:1	O
sitting	SAPHRIS.xml:S3:23118:7	O
on	SAPHRIS.xml:S3:23126:2	O
the	SAPHRIS.xml:S3:23129:3	O
edge	SAPHRIS.xml:S3:23133:4	O
of	SAPHRIS.xml:S3:23138:2	O
the	SAPHRIS.xml:S3:23141:3	O
bed	SAPHRIS.xml:S3:23145:3	O
for	SAPHRIS.xml:S3:23149:3	O
several	SAPHRIS.xml:S3:23153:7	O
minutes	SAPHRIS.xml:S3:23161:7	O
before	SAPHRIS.xml:S3:23169:6	O
attempting	SAPHRIS.xml:S3:23176:10	O
to	SAPHRIS.xml:S3:23187:2	O
stand	SAPHRIS.xml:S3:23190:5	O
in	SAPHRIS.xml:S3:23196:2	O
the	SAPHRIS.xml:S3:23199:3	O
morning	SAPHRIS.xml:S3:23203:7	O
and	SAPHRIS.xml:S3:23211:3	O
slowly	SAPHRIS.xml:S3:23215:6	O
rising	SAPHRIS.xml:S3:23222:6	O
from	SAPHRIS.xml:S3:23229:4	O
a	SAPHRIS.xml:S3:23234:1	O
seated	SAPHRIS.xml:S3:23236:6	O
position	SAPHRIS.xml:S3:23243:8	O
)	SAPHRIS.xml:S3:23251:1	O
.	SAPHRIS.xml:S3:23252:1	O

SAPHRIS	SAPHRIS.xml:S3:23254:7	O
should	SAPHRIS.xml:S3:23262:6	O
be	SAPHRIS.xml:S3:23269:2	O
used	SAPHRIS.xml:S3:23272:4	O
with	SAPHRIS.xml:S3:23277:4	O
caution	SAPHRIS.xml:S3:23282:7	O
in	SAPHRIS.xml:S3:23290:2	O
(	SAPHRIS.xml:S3:23293:1	O
1	SAPHRIS.xml:S3:23294:1	O
)	SAPHRIS.xml:S3:23295:1	O
patients	SAPHRIS.xml:S3:23297:8	O
with	SAPHRIS.xml:S3:23306:4	O
known	SAPHRIS.xml:S3:23311:5	O
cardiovascular	SAPHRIS.xml:S3:23317:14	O
disease	SAPHRIS.xml:S3:23332:7	O
(	SAPHRIS.xml:S3:23340:1	O
history	SAPHRIS.xml:S3:23341:7	O
of	SAPHRIS.xml:S3:23349:2	O
myocardial	SAPHRIS.xml:S3:23352:10	O
infarction	SAPHRIS.xml:S3:23363:10	O
or	SAPHRIS.xml:S3:23374:2	O
ischemic	SAPHRIS.xml:S3:23377:8	O
heart	SAPHRIS.xml:S3:23386:5	O
disease	SAPHRIS.xml:S3:23392:7	O
,	SAPHRIS.xml:S3:23399:1	O
heart	SAPHRIS.xml:S3:23401:5	O
failure	SAPHRIS.xml:S3:23407:7	O
or	SAPHRIS.xml:S3:23415:2	O
conduction	SAPHRIS.xml:S3:23418:10	O
abnormalities	SAPHRIS.xml:S3:23429:13	O
)	SAPHRIS.xml:S3:23442:1	O
,	SAPHRIS.xml:S3:23443:1	O
cerebrovascular	SAPHRIS.xml:S3:23445:15	O
disease	SAPHRIS.xml:S3:23461:7	O
,	SAPHRIS.xml:S3:23468:1	O
or	SAPHRIS.xml:S3:23470:2	O
conditions	SAPHRIS.xml:S3:23473:10	O
which	SAPHRIS.xml:S3:23484:5	O
would	SAPHRIS.xml:S3:23490:5	O
predispose	SAPHRIS.xml:S3:23496:10	O
patients	SAPHRIS.xml:S3:23507:8	O
to	SAPHRIS.xml:S3:23516:2	O
hypotension	SAPHRIS.xml:S3:23519:11	O
(	SAPHRIS.xml:S3:23531:1	O
dehydration	SAPHRIS.xml:S3:23532:11	O
,	SAPHRIS.xml:S3:23543:1	O
hypovolemia	SAPHRIS.xml:S3:23545:11	O
,	SAPHRIS.xml:S3:23556:1	O
and	SAPHRIS.xml:S3:23558:3	O
treatment	SAPHRIS.xml:S3:23562:9	O
with	SAPHRIS.xml:S3:23572:4	O
antihypertensive	SAPHRIS.xml:S3:23577:16	O
medications	SAPHRIS.xml:S3:23594:11	O
)	SAPHRIS.xml:S3:23605:1	O
;	SAPHRIS.xml:S3:23606:1	O
and	SAPHRIS.xml:S3:23608:3	O
(	SAPHRIS.xml:S3:23612:1	O
2	SAPHRIS.xml:S3:23613:1	O
)	SAPHRIS.xml:S3:23614:1	O
in	SAPHRIS.xml:S3:23616:2	O
the	SAPHRIS.xml:S3:23619:3	O
elderly	SAPHRIS.xml:S3:23623:7	O
.	SAPHRIS.xml:S3:23630:1	O

SAPHRIS	SAPHRIS.xml:S3:23632:7	O
should	SAPHRIS.xml:S3:23640:6	O
be	SAPHRIS.xml:S3:23647:2	O
used	SAPHRIS.xml:S3:23650:4	O
cautiously	SAPHRIS.xml:S3:23655:10	O
when	SAPHRIS.xml:S3:23666:4	O
treating	SAPHRIS.xml:S3:23671:8	O
patients	SAPHRIS.xml:S3:23680:8	O
who	SAPHRIS.xml:S3:23689:3	O
receive	SAPHRIS.xml:S3:23693:7	O
treatment	SAPHRIS.xml:S3:23701:9	O
with	SAPHRIS.xml:S3:23711:4	O
other	SAPHRIS.xml:S3:23716:5	O
drugs	SAPHRIS.xml:S3:23722:5	O
that	SAPHRIS.xml:S3:23728:4	O
can	SAPHRIS.xml:S3:23733:3	O
induce	SAPHRIS.xml:S3:23737:6	O
hypotension	SAPHRIS.xml:S3:23744:11	O
,	SAPHRIS.xml:S3:23755:1	O
bradycardia	SAPHRIS.xml:S3:23757:11	O
,	SAPHRIS.xml:S3:23768:1	O
respiratory	SAPHRIS.xml:S3:23770:11	O
or	SAPHRIS.xml:S3:23782:2	O
central	SAPHRIS.xml:S3:23785:7	O
nervous	SAPHRIS.xml:S3:23793:7	O
system	SAPHRIS.xml:S3:23801:6	O
depression	SAPHRIS.xml:S3:23808:10	O
[	SAPHRIS.xml:S3:23820:1	O
see	SAPHRIS.xml:S3:23821:3	O
Drug	SAPHRIS.xml:S3:23825:4	O
Interactions	SAPHRIS.xml:S3:23830:12	O
(	SAPHRIS.xml:S3:23843:1	O
7.1	SAPHRIS.xml:S3:23844:3	O
)]	SAPHRIS.xml:S3:23847:2	O
.	SAPHRIS.xml:S3:23851:1	O

Monitoring	SAPHRIS.xml:S3:23853:10	O
of	SAPHRIS.xml:S3:23864:2	O
orthostatic	SAPHRIS.xml:S3:23867:11	O
vital	SAPHRIS.xml:S3:23879:5	O
signs	SAPHRIS.xml:S3:23885:5	O
should	SAPHRIS.xml:S3:23891:6	O
be	SAPHRIS.xml:S3:23898:2	O
considered	SAPHRIS.xml:S3:23901:10	O
in	SAPHRIS.xml:S3:23912:2	O
all	SAPHRIS.xml:S3:23915:3	O
such	SAPHRIS.xml:S3:23919:4	O
patients	SAPHRIS.xml:S3:23924:8	O
,	SAPHRIS.xml:S3:23932:1	O
and	SAPHRIS.xml:S3:23934:3	O
a	SAPHRIS.xml:S3:23938:1	O
dose	SAPHRIS.xml:S3:23940:4	O
reduction	SAPHRIS.xml:S3:23945:9	O
should	SAPHRIS.xml:S3:23955:6	O
be	SAPHRIS.xml:S3:23962:2	O
considered	SAPHRIS.xml:S3:23965:10	O
if	SAPHRIS.xml:S3:23976:2	O
hypotension	SAPHRIS.xml:S3:23979:11	O
occurs	SAPHRIS.xml:S3:23991:6	O
.	SAPHRIS.xml:S3:23997:1	O

5.8	SAPHRIS.xml:S3:24009:3	O
Leukopenia	SAPHRIS.xml:S3:24013:10	O
,	SAPHRIS.xml:S3:24023:1	O
Neutropenia	SAPHRIS.xml:S3:24025:11	O
,	SAPHRIS.xml:S3:24036:1	O
and	SAPHRIS.xml:S3:24038:3	O
Agranulocytosis	SAPHRIS.xml:S3:24042:15	O

In	SAPHRIS.xml:S3:24065:2	O
clinical	SAPHRIS.xml:S3:24068:8	O
trial	SAPHRIS.xml:S3:24077:5	O
and	SAPHRIS.xml:S3:24083:3	O
postmarketing	SAPHRIS.xml:S3:24087:13	O
experience	SAPHRIS.xml:S3:24101:10	O
,	SAPHRIS.xml:S3:24111:1	O
leukopenia	SAPHRIS.xml:S3:24113:10	B-AdverseReaction
and	SAPHRIS.xml:S3:24124:3	O
neutropenia	SAPHRIS.xml:S3:24128:11	B-AdverseReaction
have	SAPHRIS.xml:S3:24140:4	O
been	SAPHRIS.xml:S3:24145:4	O
reported	SAPHRIS.xml:S3:24150:8	O
temporally	SAPHRIS.xml:S3:24159:10	O
related	SAPHRIS.xml:S3:24170:7	O
to	SAPHRIS.xml:S3:24178:2	O
antipsychotic	SAPHRIS.xml:S3:24181:13	O
agents	SAPHRIS.xml:S3:24195:6	O
,	SAPHRIS.xml:S3:24201:1	O
including	SAPHRIS.xml:S3:24203:9	O
SAPHRIS	SAPHRIS.xml:S3:24213:7	O
.	SAPHRIS.xml:S3:24220:1	O

Agranulocytosis	SAPHRIS.xml:S3:24222:15	B-AdverseReaction
(	SAPHRIS.xml:S3:24238:1	O
including	SAPHRIS.xml:S3:24239:9	O
fatal	SAPHRIS.xml:S3:24249:5	B-AdverseReaction
cases	SAPHRIS.xml:S3:24255:5	O
)	SAPHRIS.xml:S3:24260:1	O
has	SAPHRIS.xml:S3:24262:3	O
been	SAPHRIS.xml:S3:24266:4	O
reported	SAPHRIS.xml:S3:24271:8	O
with	SAPHRIS.xml:S3:24280:4	O
other	SAPHRIS.xml:S3:24285:5	B-DrugClass
agents	SAPHRIS.xml:S3:24291:6	I-DrugClass
in	SAPHRIS.xml:S3:24298:2	I-DrugClass
the	SAPHRIS.xml:S3:24301:3	I-DrugClass
class	SAPHRIS.xml:S3:24305:5	I-DrugClass
.	SAPHRIS.xml:S3:24310:1	O

Possible	SAPHRIS.xml:S3:24320:8	O
risk	SAPHRIS.xml:S3:24329:4	O
factors	SAPHRIS.xml:S3:24334:7	O
for	SAPHRIS.xml:S3:24342:3	O
leukopenia	SAPHRIS.xml:S3:24346:10	O
neutropenia	SAPHRIS.xml:S3:24357:11	O
include	SAPHRIS.xml:S3:24369:7	O
pre	SAPHRIS.xml:S3:24377:3	O
-	SAPHRIS.xml:S3:24380:1	O
existing	SAPHRIS.xml:S3:24381:8	O
low	SAPHRIS.xml:S3:24390:3	O
white	SAPHRIS.xml:S3:24394:5	O
blood	SAPHRIS.xml:S3:24400:5	O
cell	SAPHRIS.xml:S3:24406:4	O
count	SAPHRIS.xml:S3:24411:5	O
(	SAPHRIS.xml:S3:24417:1	O
WBC	SAPHRIS.xml:S3:24418:3	O
)	SAPHRIS.xml:S3:24421:1	O
absolute	SAPHRIS.xml:S3:24423:8	O
neutrophil	SAPHRIS.xml:S3:24432:10	O
count	SAPHRIS.xml:S3:24443:5	O
(	SAPHRIS.xml:S3:24449:1	O
ANC	SAPHRIS.xml:S3:24450:3	O
)	SAPHRIS.xml:S3:24453:1	O
and	SAPHRIS.xml:S3:24455:3	O
history	SAPHRIS.xml:S3:24459:7	O
of	SAPHRIS.xml:S3:24467:2	O
drug	SAPHRIS.xml:S3:24470:4	O
induced	SAPHRIS.xml:S3:24475:7	O
leukopenia	SAPHRIS.xml:S3:24483:10	O
neutropenia	SAPHRIS.xml:S3:24494:11	O
.	SAPHRIS.xml:S3:24505:1	O

In	SAPHRIS.xml:S3:24507:2	O
patients	SAPHRIS.xml:S3:24510:8	O
with	SAPHRIS.xml:S3:24519:4	O
a	SAPHRIS.xml:S3:24524:1	O
pre	SAPHRIS.xml:S3:24526:3	O
-	SAPHRIS.xml:S3:24529:1	O
existing	SAPHRIS.xml:S3:24530:8	O
low	SAPHRIS.xml:S3:24539:3	O
WBC	SAPHRIS.xml:S3:24543:3	O
ANC	SAPHRIS.xml:S3:24547:3	O
or	SAPHRIS.xml:S3:24551:2	O
drug	SAPHRIS.xml:S3:24554:4	O
-	SAPHRIS.xml:S3:24558:1	O
induced	SAPHRIS.xml:S3:24559:7	O
leukopenia	SAPHRIS.xml:S3:24567:10	O
neutropenia	SAPHRIS.xml:S3:24578:11	O
,	SAPHRIS.xml:S3:24589:1	O
perform	SAPHRIS.xml:S3:24591:7	O
a	SAPHRIS.xml:S3:24599:1	O
complete	SAPHRIS.xml:S3:24601:8	O
blood	SAPHRIS.xml:S3:24610:5	O
count	SAPHRIS.xml:S3:24616:5	O
(	SAPHRIS.xml:S3:24622:1	O
CBC	SAPHRIS.xml:S3:24623:3	O
)	SAPHRIS.xml:S3:24626:1	O
frequently	SAPHRIS.xml:S3:24628:10	O
during	SAPHRIS.xml:S3:24639:6	O
the	SAPHRIS.xml:S3:24646:3	O
first	SAPHRIS.xml:S3:24650:5	O
few	SAPHRIS.xml:S3:24656:3	O
months	SAPHRIS.xml:S3:24660:6	O
of	SAPHRIS.xml:S3:24667:2	O
therapy	SAPHRIS.xml:S3:24670:7	O
.	SAPHRIS.xml:S3:24677:1	O

In	SAPHRIS.xml:S3:24679:2	O
such	SAPHRIS.xml:S3:24682:4	O
patients	SAPHRIS.xml:S3:24687:8	O
,	SAPHRIS.xml:S3:24695:1	O
consider	SAPHRIS.xml:S3:24697:8	O
discontinuation	SAPHRIS.xml:S3:24706:15	O
of	SAPHRIS.xml:S3:24722:2	O
SAPHRIS	SAPHRIS.xml:S3:24725:7	O
at	SAPHRIS.xml:S3:24733:2	O
the	SAPHRIS.xml:S3:24736:3	O
first	SAPHRIS.xml:S3:24740:5	O
sign	SAPHRIS.xml:S3:24746:4	O
of	SAPHRIS.xml:S3:24751:2	O
a	SAPHRIS.xml:S3:24754:1	O
clinically	SAPHRIS.xml:S3:24756:10	O
significant	SAPHRIS.xml:S3:24767:11	O
decline	SAPHRIS.xml:S3:24779:7	O
in	SAPHRIS.xml:S3:24787:2	O
WBC	SAPHRIS.xml:S3:24790:3	O
in	SAPHRIS.xml:S3:24794:2	O
the	SAPHRIS.xml:S3:24797:3	O
absence	SAPHRIS.xml:S3:24801:7	O
of	SAPHRIS.xml:S3:24809:2	O
other	SAPHRIS.xml:S3:24812:5	O
causative	SAPHRIS.xml:S3:24818:9	O
factors	SAPHRIS.xml:S3:24828:7	O
.	SAPHRIS.xml:S3:24835:1	O

Monitor	SAPHRIS.xml:S3:24845:7	O
patients	SAPHRIS.xml:S3:24853:8	O
with	SAPHRIS.xml:S3:24862:4	O
clinically	SAPHRIS.xml:S3:24867:10	O
significant	SAPHRIS.xml:S3:24878:11	O
neutropenia	SAPHRIS.xml:S3:24890:11	O
for	SAPHRIS.xml:S3:24902:3	O
fever	SAPHRIS.xml:S3:24906:5	O
or	SAPHRIS.xml:S3:24912:2	O
other	SAPHRIS.xml:S3:24915:5	O
symptoms	SAPHRIS.xml:S3:24921:8	O
or	SAPHRIS.xml:S3:24930:2	O
signs	SAPHRIS.xml:S3:24933:5	O
of	SAPHRIS.xml:S3:24939:2	O
infection	SAPHRIS.xml:S3:24942:9	O
and	SAPHRIS.xml:S3:24952:3	O
treat	SAPHRIS.xml:S3:24956:5	O
promptly	SAPHRIS.xml:S3:24962:8	O
if	SAPHRIS.xml:S3:24971:2	O
such	SAPHRIS.xml:S3:24974:4	O
symptoms	SAPHRIS.xml:S3:24979:8	O
or	SAPHRIS.xml:S3:24988:2	O
signs	SAPHRIS.xml:S3:24991:5	O
occur	SAPHRIS.xml:S3:24997:5	O
.	SAPHRIS.xml:S3:25002:1	O

Discontinue	SAPHRIS.xml:S3:25004:11	O
SAPHRIS	SAPHRIS.xml:S3:25016:7	O
in	SAPHRIS.xml:S3:25024:2	O
patients	SAPHRIS.xml:S3:25027:8	O
with	SAPHRIS.xml:S3:25036:4	O
severe	SAPHRIS.xml:S3:25041:6	O
neutropenia	SAPHRIS.xml:S3:25048:11	O
(	SAPHRIS.xml:S3:25060:1	O
absolute	SAPHRIS.xml:S3:25061:8	O
neutrophil	SAPHRIS.xml:S3:25070:10	O
count	SAPHRIS.xml:S3:25081:5	O
1000	SAPHRIS.xml:S3:25088:4	O
mm	SAPHRIS.xml:S3:25093:2	O
3	SAPHRIS.xml:S3:25097:1	O
)	SAPHRIS.xml:S3:25100:1	O
and	SAPHRIS.xml:S3:25102:3	O
follow	SAPHRIS.xml:S3:25106:6	O
their	SAPHRIS.xml:S3:25113:5	O
WBC	SAPHRIS.xml:S3:25119:3	O
until	SAPHRIS.xml:S3:25123:5	O
recovery	SAPHRIS.xml:S3:25129:8	O
.	SAPHRIS.xml:S3:25137:1	O

5.9	SAPHRIS.xml:S3:25149:3	O
QT	SAPHRIS.xml:S3:25153:2	O
Prolongation	SAPHRIS.xml:S3:25156:12	O

The	SAPHRIS.xml:S3:25176:3	O
effects	SAPHRIS.xml:S3:25180:7	O
of	SAPHRIS.xml:S3:25188:2	O
SAPHRIS	SAPHRIS.xml:S3:25191:7	O
on	SAPHRIS.xml:S3:25199:2	O
the	SAPHRIS.xml:S3:25202:3	O
QT	SAPHRIS.xml:S3:25206:2	O
QTc	SAPHRIS.xml:S3:25209:3	O
interval	SAPHRIS.xml:S3:25213:8	O
were	SAPHRIS.xml:S3:25222:4	O
evaluated	SAPHRIS.xml:S3:25227:9	O
in	SAPHRIS.xml:S3:25237:2	O
a	SAPHRIS.xml:S3:25240:1	O
dedicated	SAPHRIS.xml:S3:25242:9	O
adult	SAPHRIS.xml:S3:25252:5	O
QT	SAPHRIS.xml:S3:25258:2	O
study	SAPHRIS.xml:S3:25261:5	O
.	SAPHRIS.xml:S3:25266:1	O

This	SAPHRIS.xml:S3:25268:4	O
trial	SAPHRIS.xml:S3:25273:5	O
involved	SAPHRIS.xml:S3:25279:8	O
SAPHRIS	SAPHRIS.xml:S3:25288:7	O
doses	SAPHRIS.xml:S3:25296:5	O
of	SAPHRIS.xml:S3:25302:2	O
5	SAPHRIS.xml:S3:25305:1	O
mg	SAPHRIS.xml:S3:25307:2	O
,	SAPHRIS.xml:S3:25309:1	O
10	SAPHRIS.xml:S3:25311:2	O
mg	SAPHRIS.xml:S3:25314:2	O
,	SAPHRIS.xml:S3:25316:1	O
15	SAPHRIS.xml:S3:25318:2	O
mg	SAPHRIS.xml:S3:25321:2	O
,	SAPHRIS.xml:S3:25323:1	O
and	SAPHRIS.xml:S3:25325:3	O
20	SAPHRIS.xml:S3:25329:2	O
mg	SAPHRIS.xml:S3:25332:2	O
twice	SAPHRIS.xml:S3:25335:5	O
daily	SAPHRIS.xml:S3:25341:5	O
,	SAPHRIS.xml:S3:25346:1	O
and	SAPHRIS.xml:S3:25348:3	O
placebo	SAPHRIS.xml:S3:25352:7	O
,	SAPHRIS.xml:S3:25359:1	O
and	SAPHRIS.xml:S3:25361:3	O
was	SAPHRIS.xml:S3:25365:3	O
conducted	SAPHRIS.xml:S3:25369:9	O
in	SAPHRIS.xml:S3:25379:2	O
151	SAPHRIS.xml:S3:25382:3	O
clinically	SAPHRIS.xml:S3:25386:10	O
stable	SAPHRIS.xml:S3:25397:6	O
patients	SAPHRIS.xml:S3:25404:8	O
with	SAPHRIS.xml:S3:25413:4	O
schizophrenia	SAPHRIS.xml:S3:25418:13	O
,	SAPHRIS.xml:S3:25431:1	O
with	SAPHRIS.xml:S3:25433:4	O
electrocardiographic	SAPHRIS.xml:S3:25438:20	O
assessments	SAPHRIS.xml:S3:25459:11	O
throughout	SAPHRIS.xml:S3:25471:10	O
the	SAPHRIS.xml:S3:25482:3	O
dosing	SAPHRIS.xml:S3:25486:6	O
interval	SAPHRIS.xml:S3:25493:8	O
at	SAPHRIS.xml:S3:25502:2	O
baseline	SAPHRIS.xml:S3:25505:8	O
and	SAPHRIS.xml:S3:25514:3	O
steady	SAPHRIS.xml:S3:25518:6	O
state	SAPHRIS.xml:S3:25525:5	O
.	SAPHRIS.xml:S3:25530:1	O

At	SAPHRIS.xml:S3:25532:2	O
these	SAPHRIS.xml:S3:25535:5	O
doses	SAPHRIS.xml:S3:25541:5	O
,	SAPHRIS.xml:S3:25546:1	O
SAPHRIS	SAPHRIS.xml:S3:25548:7	O
was	SAPHRIS.xml:S3:25556:3	O
associated	SAPHRIS.xml:S3:25560:10	O
with	SAPHRIS.xml:S3:25571:4	O
increases	SAPHRIS.xml:S3:25576:9	B-AdverseReaction
in	SAPHRIS.xml:S3:25586:2	I-AdverseReaction
QTc	SAPHRIS.xml:S3:25589:3	I-AdverseReaction
interval	SAPHRIS.xml:S3:25593:8	I-AdverseReaction
ranging	SAPHRIS.xml:S3:25602:7	O
from	SAPHRIS.xml:S3:25610:4	O
2	SAPHRIS.xml:S3:25615:1	B-Severity
to	SAPHRIS.xml:S3:25617:2	I-Severity
5	SAPHRIS.xml:S3:25620:1	I-Severity
msec	SAPHRIS.xml:S3:25622:4	I-Severity
compared	SAPHRIS.xml:S3:25627:8	O
to	SAPHRIS.xml:S3:25636:2	O
placebo	SAPHRIS.xml:S3:25639:7	O
.	SAPHRIS.xml:S3:25646:1	O

No	SAPHRIS.xml:S3:25648:2	B-Negation
patients	SAPHRIS.xml:S3:25651:8	O
treated	SAPHRIS.xml:S3:25660:7	O
with	SAPHRIS.xml:S3:25668:4	O
SAPHRIS	SAPHRIS.xml:S3:25673:7	O
experienced	SAPHRIS.xml:S3:25681:11	O
QTc	SAPHRIS.xml:S3:25693:3	B-AdverseReaction
increases	SAPHRIS.xml:S3:25697:9	I-AdverseReaction
60	SAPHRIS.xml:S3:25709:2	B-Severity
msec	SAPHRIS.xml:S3:25712:4	I-Severity
from	SAPHRIS.xml:S3:25717:4	O
baseline	SAPHRIS.xml:S3:25722:8	O
measurements	SAPHRIS.xml:S3:25731:12	O
,	SAPHRIS.xml:S3:25743:1	O
nor	SAPHRIS.xml:S3:25745:3	B-Negation
did	SAPHRIS.xml:S3:25749:3	O
any	SAPHRIS.xml:S3:25753:3	O
patient	SAPHRIS.xml:S3:25757:7	O
experience	SAPHRIS.xml:S3:25765:10	O
a	SAPHRIS.xml:S3:25776:1	O
QTc	SAPHRIS.xml:S3:25778:3	B-AdverseReaction
of	SAPHRIS.xml:S3:25782:2	I-AdverseReaction
500	SAPHRIS.xml:S3:25787:3	I-AdverseReaction
msec	SAPHRIS.xml:S3:25791:4	I-AdverseReaction
.	SAPHRIS.xml:S3:25795:1	O

Electrocardiogram	SAPHRIS.xml:S3:25805:17	O
(	SAPHRIS.xml:S3:25823:1	O
ECG	SAPHRIS.xml:S3:25824:3	O
)	SAPHRIS.xml:S3:25827:1	O
measurements	SAPHRIS.xml:S3:25829:12	O
were	SAPHRIS.xml:S3:25842:4	O
taken	SAPHRIS.xml:S3:25847:5	O
at	SAPHRIS.xml:S3:25853:2	O
various	SAPHRIS.xml:S3:25856:7	O
time	SAPHRIS.xml:S3:25864:4	O
points	SAPHRIS.xml:S3:25869:6	O
during	SAPHRIS.xml:S3:25876:6	O
the	SAPHRIS.xml:S3:25883:3	O
SAPHRIS	SAPHRIS.xml:S3:25887:7	O
clinical	SAPHRIS.xml:S3:25895:8	O
trial	SAPHRIS.xml:S3:25904:5	O
program	SAPHRIS.xml:S3:25910:7	O
(	SAPHRIS.xml:S3:25918:1	O
5	SAPHRIS.xml:S3:25919:1	O
mg	SAPHRIS.xml:S3:25921:2	O
or	SAPHRIS.xml:S3:25924:2	O
10	SAPHRIS.xml:S3:25927:2	O
mg	SAPHRIS.xml:S3:25930:2	O
twice	SAPHRIS.xml:S3:25933:5	O
daily	SAPHRIS.xml:S3:25939:5	O
doses	SAPHRIS.xml:S3:25945:5	O
)	SAPHRIS.xml:S3:25950:1	O
.	SAPHRIS.xml:S3:25951:1	O

Post	SAPHRIS.xml:S3:25953:4	O
-	SAPHRIS.xml:S3:25957:1	O
baseline	SAPHRIS.xml:S3:25958:8	O
QT	SAPHRIS.xml:S3:25967:2	B-AdverseReaction
prolongations	SAPHRIS.xml:S3:25970:13	I-AdverseReaction
exceeding	SAPHRIS.xml:S3:25984:9	O
500	SAPHRIS.xml:S3:25994:3	B-Severity
msec	SAPHRIS.xml:S3:25998:4	I-Severity
were	SAPHRIS.xml:S3:26003:4	O
reported	SAPHRIS.xml:S3:26008:8	O
at	SAPHRIS.xml:S3:26017:2	O
comparable	SAPHRIS.xml:S3:26020:10	O
rates	SAPHRIS.xml:S3:26031:5	O
for	SAPHRIS.xml:S3:26037:3	O
SAPHRIS	SAPHRIS.xml:S3:26041:7	O
and	SAPHRIS.xml:S3:26049:3	O
placebo	SAPHRIS.xml:S3:26053:7	O
in	SAPHRIS.xml:S3:26061:2	O
these	SAPHRIS.xml:S3:26064:5	O
short	SAPHRIS.xml:S3:26070:5	O
-	SAPHRIS.xml:S3:26075:1	O
term	SAPHRIS.xml:S3:26076:4	O
trials	SAPHRIS.xml:S3:26081:6	O
.	SAPHRIS.xml:S3:26087:1	O

There	SAPHRIS.xml:S3:26089:5	O
were	SAPHRIS.xml:S3:26095:4	O
no	SAPHRIS.xml:S3:26100:2	B-Negation
reports	SAPHRIS.xml:S3:26103:7	O
of	SAPHRIS.xml:S3:26111:2	O
Torsade	SAPHRIS.xml:S3:26114:7	B-AdverseReaction
de	SAPHRIS.xml:S3:26122:2	I-AdverseReaction
Pointes	SAPHRIS.xml:S3:26125:7	I-AdverseReaction
or	SAPHRIS.xml:S3:26133:2	O
any	SAPHRIS.xml:S3:26136:3	O
other	SAPHRIS.xml:S3:26140:5	O
adverse	SAPHRIS.xml:S3:26146:7	O
reactions	SAPHRIS.xml:S3:26154:9	O
associated	SAPHRIS.xml:S3:26164:10	O
with	SAPHRIS.xml:S3:26175:4	O
delayed	SAPHRIS.xml:S3:26180:7	B-AdverseReaction
ventricular	SAPHRIS.xml:S3:26188:11	I-AdverseReaction
repolarization	SAPHRIS.xml:S3:26200:14	I-AdverseReaction
.	SAPHRIS.xml:S3:26214:1	O

The	SAPHRIS.xml:S3:26224:3	O
use	SAPHRIS.xml:S3:26228:3	O
of	SAPHRIS.xml:S3:26232:2	O
SAPHRIS	SAPHRIS.xml:S3:26235:7	O
should	SAPHRIS.xml:S3:26243:6	O
be	SAPHRIS.xml:S3:26250:2	O
avoided	SAPHRIS.xml:S3:26253:7	O
in	SAPHRIS.xml:S3:26261:2	O
combination	SAPHRIS.xml:S3:26264:11	O
with	SAPHRIS.xml:S3:26276:4	O
other	SAPHRIS.xml:S3:26281:5	O
drugs	SAPHRIS.xml:S3:26287:5	O
known	SAPHRIS.xml:S3:26293:5	O
to	SAPHRIS.xml:S3:26299:2	O
prolong	SAPHRIS.xml:S3:26302:7	O
QTc	SAPHRIS.xml:S3:26310:3	O
including	SAPHRIS.xml:S3:26314:9	O
Class	SAPHRIS.xml:S3:26324:5	O
1	SAPHRIS.xml:S3:26330:1	O
A	SAPHRIS.xml:S3:26331:1	O
antiarrhythmics	SAPHRIS.xml:S3:26333:15	O
(	SAPHRIS.xml:S3:26349:1	O
e	SAPHRIS.xml:S3:26350:1	O
.	SAPHRIS.xml:S3:26351:1	O
g	SAPHRIS.xml:S3:26352:1	O
.	SAPHRIS.xml:S3:26353:1	O
,	SAPHRIS.xml:S3:26354:1	O
quinidine	SAPHRIS.xml:S3:26356:9	O
,	SAPHRIS.xml:S3:26365:1	O
procainamide	SAPHRIS.xml:S3:26367:12	O
)	SAPHRIS.xml:S3:26379:1	O
or	SAPHRIS.xml:S3:26381:2	O
Class	SAPHRIS.xml:S3:26384:5	O
3	SAPHRIS.xml:S3:26390:1	O
antiarrhythmics	SAPHRIS.xml:S3:26392:15	O
(	SAPHRIS.xml:S3:26408:1	O
e	SAPHRIS.xml:S3:26409:1	O
.	SAPHRIS.xml:S3:26410:1	O
g	SAPHRIS.xml:S3:26411:1	O
.	SAPHRIS.xml:S3:26412:1	O
,	SAPHRIS.xml:S3:26413:1	O
amiodarone	SAPHRIS.xml:S3:26415:10	O
,	SAPHRIS.xml:S3:26425:1	O
sotalol	SAPHRIS.xml:S3:26427:7	O
)	SAPHRIS.xml:S3:26434:1	O
,	SAPHRIS.xml:S3:26435:1	O
antipsychotic	SAPHRIS.xml:S3:26437:13	O
medications	SAPHRIS.xml:S3:26451:11	O
(	SAPHRIS.xml:S3:26463:1	O
e	SAPHRIS.xml:S3:26464:1	O
.	SAPHRIS.xml:S3:26465:1	O
g	SAPHRIS.xml:S3:26466:1	O
.	SAPHRIS.xml:S3:26467:1	O
,	SAPHRIS.xml:S3:26468:1	O
ziprasidone	SAPHRIS.xml:S3:26470:11	O
,	SAPHRIS.xml:S3:26481:1	O
chlorpromazine	SAPHRIS.xml:S3:26483:14	O
,	SAPHRIS.xml:S3:26497:1	O
thioridazine	SAPHRIS.xml:S3:26499:12	O
)	SAPHRIS.xml:S3:26511:1	O
,	SAPHRIS.xml:S3:26512:1	O
and	SAPHRIS.xml:S3:26514:3	O
antibiotics	SAPHRIS.xml:S3:26518:11	O
(	SAPHRIS.xml:S3:26530:1	O
e	SAPHRIS.xml:S3:26531:1	O
.	SAPHRIS.xml:S3:26532:1	O
g	SAPHRIS.xml:S3:26533:1	O
.	SAPHRIS.xml:S3:26534:1	O
,	SAPHRIS.xml:S3:26535:1	O
gatifloxacin	SAPHRIS.xml:S3:26537:12	O
,	SAPHRIS.xml:S3:26549:1	O
moxifloxacin	SAPHRIS.xml:S3:26551:12	O
)	SAPHRIS.xml:S3:26563:1	O
.	SAPHRIS.xml:S3:26564:1	O

SAPHRIS	SAPHRIS.xml:S3:26566:7	O
should	SAPHRIS.xml:S3:26574:6	O
also	SAPHRIS.xml:S3:26581:4	O
be	SAPHRIS.xml:S3:26586:2	O
avoided	SAPHRIS.xml:S3:26589:7	O
in	SAPHRIS.xml:S3:26597:2	O
patients	SAPHRIS.xml:S3:26600:8	O
with	SAPHRIS.xml:S3:26609:4	O
a	SAPHRIS.xml:S3:26614:1	O
history	SAPHRIS.xml:S3:26616:7	O
of	SAPHRIS.xml:S3:26624:2	O
cardiac	SAPHRIS.xml:S3:26627:7	O
arrhythmias	SAPHRIS.xml:S3:26635:11	O
and	SAPHRIS.xml:S3:26647:3	O
in	SAPHRIS.xml:S3:26651:2	O
other	SAPHRIS.xml:S3:26654:5	O
circumstances	SAPHRIS.xml:S3:26660:13	O
that	SAPHRIS.xml:S3:26674:4	O
may	SAPHRIS.xml:S3:26679:3	O
increase	SAPHRIS.xml:S3:26683:8	O
the	SAPHRIS.xml:S3:26692:3	O
risk	SAPHRIS.xml:S3:26696:4	O
of	SAPHRIS.xml:S3:26701:2	O
the	SAPHRIS.xml:S3:26704:3	O
occurrence	SAPHRIS.xml:S3:26708:10	O
of	SAPHRIS.xml:S3:26719:2	O
torsade	SAPHRIS.xml:S3:26722:7	O
de	SAPHRIS.xml:S3:26730:2	O
pointes	SAPHRIS.xml:S3:26733:7	O
and	SAPHRIS.xml:S3:26741:3	O
or	SAPHRIS.xml:S3:26745:2	O
sudden	SAPHRIS.xml:S3:26748:6	O
death	SAPHRIS.xml:S3:26755:5	O
in	SAPHRIS.xml:S3:26761:2	O
association	SAPHRIS.xml:S3:26764:11	O
with	SAPHRIS.xml:S3:26776:4	O
the	SAPHRIS.xml:S3:26781:3	O
use	SAPHRIS.xml:S3:26785:3	O
of	SAPHRIS.xml:S3:26789:2	O
drugs	SAPHRIS.xml:S3:26792:5	O
that	SAPHRIS.xml:S3:26798:4	O
prolong	SAPHRIS.xml:S3:26803:7	O
the	SAPHRIS.xml:S3:26811:3	O
QTc	SAPHRIS.xml:S3:26815:3	O
interval	SAPHRIS.xml:S3:26819:8	O
,	SAPHRIS.xml:S3:26827:1	O
including	SAPHRIS.xml:S3:26829:9	O
bradycardia	SAPHRIS.xml:S3:26839:11	O
;	SAPHRIS.xml:S3:26850:1	O
hypokalemia	SAPHRIS.xml:S3:26852:11	O
or	SAPHRIS.xml:S3:26864:2	O
hypomagnesemia	SAPHRIS.xml:S3:26867:14	O
;	SAPHRIS.xml:S3:26881:1	O
and	SAPHRIS.xml:S3:26883:3	O
presence	SAPHRIS.xml:S3:26887:8	O
of	SAPHRIS.xml:S3:26896:2	O
congenital	SAPHRIS.xml:S3:26899:10	O
prolongation	SAPHRIS.xml:S3:26910:12	O
of	SAPHRIS.xml:S3:26923:2	O
the	SAPHRIS.xml:S3:26926:3	O
QT	SAPHRIS.xml:S3:26930:2	O
interval	SAPHRIS.xml:S3:26933:8	O
.	SAPHRIS.xml:S3:26941:1	O

5.10	SAPHRIS.xml:S3:26953:4	O
Hyperprolactinemia	SAPHRIS.xml:S3:26958:18	O

Like	SAPHRIS.xml:S3:26984:4	O
other	SAPHRIS.xml:S3:26989:5	O
drugs	SAPHRIS.xml:S3:26995:5	O
that	SAPHRIS.xml:S3:27001:4	O
antagonize	SAPHRIS.xml:S3:27006:10	O
dopamine	SAPHRIS.xml:S3:27017:8	O
D2receptors	SAPHRIS.xml:S3:27026:11	O
,	SAPHRIS.xml:S3:27037:1	O
SAPHRIS	SAPHRIS.xml:S3:27039:7	O
can	SAPHRIS.xml:S3:27047:3	B-Factor
elevate	SAPHRIS.xml:S3:27051:7	B-AdverseReaction
prolactin	SAPHRIS.xml:S3:27059:9	I-AdverseReaction
levels	SAPHRIS.xml:S3:27069:6	I-AdverseReaction
,	SAPHRIS.xml:S3:27075:1	O
and	SAPHRIS.xml:S3:27077:3	O
the	SAPHRIS.xml:S3:27081:3	O
elevation	SAPHRIS.xml:S3:27085:9	O
can	SAPHRIS.xml:S3:27095:3	O
persist	SAPHRIS.xml:S3:27099:7	O
during	SAPHRIS.xml:S3:27107:6	O
chronic	SAPHRIS.xml:S3:27114:7	O
administration	SAPHRIS.xml:S3:27122:14	O
.	SAPHRIS.xml:S3:27136:1	O

Hyperprolactinemia	SAPHRIS.xml:S3:27138:18	B-AdverseReaction
may	SAPHRIS.xml:S3:27157:3	B-Factor
suppress	SAPHRIS.xml:S3:27161:8	B-AdverseReaction
hypothalamic	SAPHRIS.xml:S3:27170:12	I-AdverseReaction
GnRH	SAPHRIS.xml:S3:27183:4	I-AdverseReaction
,	SAPHRIS.xml:S3:27187:1	O
resulting	SAPHRIS.xml:S3:27189:9	O
in	SAPHRIS.xml:S3:27199:2	O
reduced	SAPHRIS.xml:S3:27202:7	B-AdverseReaction
pituitary	SAPHRIS.xml:S3:27210:9	I-AdverseReaction
gonadotropin	SAPHRIS.xml:S3:27220:12	I-AdverseReaction
secretion	SAPHRIS.xml:S3:27233:9	I-AdverseReaction
.	SAPHRIS.xml:S3:27242:1	O

This	SAPHRIS.xml:S3:27244:4	O
,	SAPHRIS.xml:S3:27248:1	O
in	SAPHRIS.xml:S3:27250:2	O
turn	SAPHRIS.xml:S3:27253:4	O
,	SAPHRIS.xml:S3:27257:1	O
may	SAPHRIS.xml:S3:27259:3	B-Factor
inhibit	SAPHRIS.xml:S3:27263:7	B-AdverseReaction
reproductive	SAPHRIS.xml:S3:27271:12	I-AdverseReaction
function	SAPHRIS.xml:S3:27284:8	I-AdverseReaction
by	SAPHRIS.xml:S3:27293:2	O
impairing	SAPHRIS.xml:S3:27296:9	B-AdverseReaction
gonadal	SAPHRIS.xml:S3:27306:7	I-AdverseReaction
steroidogenesis	SAPHRIS.xml:S3:27314:15	I-AdverseReaction
in	SAPHRIS.xml:S3:27330:2	O
both	SAPHRIS.xml:S3:27333:4	O
female	SAPHRIS.xml:S3:27338:6	O
and	SAPHRIS.xml:S3:27345:3	O
male	SAPHRIS.xml:S3:27349:4	O
patients	SAPHRIS.xml:S3:27354:8	O
.	SAPHRIS.xml:S3:27362:1	O

Galactorrhea	SAPHRIS.xml:S3:27364:12	B-AdverseReaction
,	SAPHRIS.xml:S3:27376:1	O
amenorrhea	SAPHRIS.xml:S3:27378:10	B-AdverseReaction
,	SAPHRIS.xml:S3:27388:1	O
gynecomastia	SAPHRIS.xml:S3:27390:12	B-AdverseReaction
,	SAPHRIS.xml:S3:27402:1	O
and	SAPHRIS.xml:S3:27404:3	O
impotence	SAPHRIS.xml:S3:27408:9	B-AdverseReaction
have	SAPHRIS.xml:S3:27418:4	O
been	SAPHRIS.xml:S3:27423:4	O
reported	SAPHRIS.xml:S3:27428:8	O
in	SAPHRIS.xml:S3:27437:2	O
patients	SAPHRIS.xml:S3:27440:8	O
receiving	SAPHRIS.xml:S3:27449:9	O
prolactin	SAPHRIS.xml:S3:27459:9	B-DrugClass
-	SAPHRIS.xml:S3:27468:1	I-DrugClass
elevating	SAPHRIS.xml:S3:27469:9	I-DrugClass
compounds	SAPHRIS.xml:S3:27479:9	I-DrugClass
.	SAPHRIS.xml:S3:27488:1	O

Long	SAPHRIS.xml:S3:27490:4	O
-	SAPHRIS.xml:S3:27494:1	O
standing	SAPHRIS.xml:S3:27495:8	O
hyperprolactinemia	SAPHRIS.xml:S3:27504:18	B-AdverseReaction
when	SAPHRIS.xml:S3:27523:4	O
associated	SAPHRIS.xml:S3:27528:10	O
with	SAPHRIS.xml:S3:27539:4	O
hypogonadism	SAPHRIS.xml:S3:27544:12	B-AdverseReaction
may	SAPHRIS.xml:S3:27557:3	B-Factor
lead	SAPHRIS.xml:S3:27561:4	O
to	SAPHRIS.xml:S3:27566:2	O
decreased	SAPHRIS.xml:S3:27569:9	B-AdverseReaction
bone	SAPHRIS.xml:S3:27579:4	I-AdverseReaction
density	SAPHRIS.xml:S3:27584:7	I-AdverseReaction
in	SAPHRIS.xml:S3:27592:2	O
both	SAPHRIS.xml:S3:27595:4	O
female	SAPHRIS.xml:S3:27600:6	O
and	SAPHRIS.xml:S3:27607:3	O
male	SAPHRIS.xml:S3:27611:4	O
subjects	SAPHRIS.xml:S3:27616:8	O
.	SAPHRIS.xml:S3:27624:1	O

In	SAPHRIS.xml:S3:27626:2	O
SAPHRIS	SAPHRIS.xml:S3:27629:7	O
adult	SAPHRIS.xml:S3:27637:5	O
clinical	SAPHRIS.xml:S3:27643:8	O
trials	SAPHRIS.xml:S3:27652:6	O
,	SAPHRIS.xml:S3:27658:1	O
the	SAPHRIS.xml:S3:27660:3	O
incidences	SAPHRIS.xml:S3:27664:10	O
of	SAPHRIS.xml:S3:27675:2	O
adverse	SAPHRIS.xml:S3:27678:7	O
events	SAPHRIS.xml:S3:27686:6	O
related	SAPHRIS.xml:S3:27693:7	O
to	SAPHRIS.xml:S3:27701:2	O
abnormal	SAPHRIS.xml:S3:27704:8	B-AdverseReaction
prolactin	SAPHRIS.xml:S3:27713:9	I-AdverseReaction
levels	SAPHRIS.xml:S3:27723:6	I-AdverseReaction
were	SAPHRIS.xml:S3:27730:4	O
0.4%	SAPHRIS.xml:S3:27735:4	O
versus	SAPHRIS.xml:S3:27740:6	O
0%	SAPHRIS.xml:S3:27747:2	O
for	SAPHRIS.xml:S3:27750:3	O
placebo	SAPHRIS.xml:S3:27754:7	O
.	SAPHRIS.xml:S3:27761:1	O

In	SAPHRIS.xml:S3:27763:2	O
a	SAPHRIS.xml:S3:27766:1	O
3	SAPHRIS.xml:S3:27768:1	O
-	SAPHRIS.xml:S3:27769:1	O
week	SAPHRIS.xml:S3:27770:4	O
,	SAPHRIS.xml:S3:27774:1	O
bipolar	SAPHRIS.xml:S3:27776:7	O
mania	SAPHRIS.xml:S3:27784:5	O
pediatric	SAPHRIS.xml:S3:27790:9	O
trial	SAPHRIS.xml:S3:27800:5	O
,	SAPHRIS.xml:S3:27805:1	O
the	SAPHRIS.xml:S3:27807:3	O
incidence	SAPHRIS.xml:S3:27811:9	O
of	SAPHRIS.xml:S3:27821:2	O
adverse	SAPHRIS.xml:S3:27824:7	O
events	SAPHRIS.xml:S3:27832:6	O
related	SAPHRIS.xml:S3:27839:7	O
to	SAPHRIS.xml:S3:27847:2	O
abnormal	SAPHRIS.xml:S3:27850:8	B-AdverseReaction
prolactin	SAPHRIS.xml:S3:27859:9	I-AdverseReaction
levels	SAPHRIS.xml:S3:27869:6	I-AdverseReaction
were	SAPHRIS.xml:S3:27876:4	O
0%	SAPHRIS.xml:S3:27881:2	O
in	SAPHRIS.xml:S3:27884:2	O
the	SAPHRIS.xml:S3:27887:3	O
SAPHRIS	SAPHRIS.xml:S3:27891:7	O
2.5	SAPHRIS.xml:S3:27899:3	O
mg	SAPHRIS.xml:S3:27903:2	O
twice	SAPHRIS.xml:S3:27906:5	O
daily	SAPHRIS.xml:S3:27912:5	O
treatment	SAPHRIS.xml:S3:27918:9	O
group	SAPHRIS.xml:S3:27928:5	O
,	SAPHRIS.xml:S3:27933:1	O
2%	SAPHRIS.xml:S3:27935:2	O
in	SAPHRIS.xml:S3:27938:2	O
the	SAPHRIS.xml:S3:27941:3	O
SAPHRIS	SAPHRIS.xml:S3:27945:7	O
5	SAPHRIS.xml:S3:27953:1	O
mg	SAPHRIS.xml:S3:27955:2	O
twice	SAPHRIS.xml:S3:27958:5	O
daily	SAPHRIS.xml:S3:27964:5	O
treatment	SAPHRIS.xml:S3:27970:9	O
group	SAPHRIS.xml:S3:27980:5	O
,	SAPHRIS.xml:S3:27985:1	O
and	SAPHRIS.xml:S3:27987:3	O
1%	SAPHRIS.xml:S3:27991:2	O
in	SAPHRIS.xml:S3:27994:2	O
the	SAPHRIS.xml:S3:27997:3	O
SAPHRIS	SAPHRIS.xml:S3:28001:7	O
10	SAPHRIS.xml:S3:28009:2	O
mg	SAPHRIS.xml:S3:28012:2	O
twice	SAPHRIS.xml:S3:28015:5	O
daily	SAPHRIS.xml:S3:28021:5	O
treatment	SAPHRIS.xml:S3:28027:9	O
group	SAPHRIS.xml:S3:28037:5	O
versus	SAPHRIS.xml:S3:28043:6	O
to	SAPHRIS.xml:S3:28050:2	O
1%	SAPHRIS.xml:S3:28053:2	O
for	SAPHRIS.xml:S3:28056:3	O
patients	SAPHRIS.xml:S3:28060:8	O
treated	SAPHRIS.xml:S3:28069:7	O
with	SAPHRIS.xml:S3:28077:4	O
placebo	SAPHRIS.xml:S3:28082:7	O
[	SAPHRIS.xml:S3:28091:1	O
see	SAPHRIS.xml:S3:28092:3	O
Adverse	SAPHRIS.xml:S3:28096:7	O
Reactions	SAPHRIS.xml:S3:28104:9	O
(	SAPHRIS.xml:S3:28114:1	O
6.1	SAPHRIS.xml:S3:28115:3	O
)]	SAPHRIS.xml:S3:28118:2	O
.	SAPHRIS.xml:S3:28122:1	O

Tissue	SAPHRIS.xml:S3:28132:6	O
culture	SAPHRIS.xml:S3:28139:7	O
experiments	SAPHRIS.xml:S3:28147:11	O
indicate	SAPHRIS.xml:S3:28159:8	O
that	SAPHRIS.xml:S3:28168:4	O
approximately	SAPHRIS.xml:S3:28173:13	O
one	SAPHRIS.xml:S3:28187:3	O
-	SAPHRIS.xml:S3:28190:1	O
third	SAPHRIS.xml:S3:28191:5	O
of	SAPHRIS.xml:S3:28197:2	O
human	SAPHRIS.xml:S3:28200:5	O
breast	SAPHRIS.xml:S3:28206:6	O
cancers	SAPHRIS.xml:S3:28213:7	O
are	SAPHRIS.xml:S3:28221:3	O
prolactin	SAPHRIS.xml:S3:28225:9	O
-	SAPHRIS.xml:S3:28234:1	O
dependent	SAPHRIS.xml:S3:28235:9	O
in	SAPHRIS.xml:S3:28246:2	O
vitro	SAPHRIS.xml:S3:28249:5	O
,	SAPHRIS.xml:S3:28256:1	O
a	SAPHRIS.xml:S3:28258:1	O
factor	SAPHRIS.xml:S3:28260:6	O
of	SAPHRIS.xml:S3:28267:2	O
potential	SAPHRIS.xml:S3:28270:9	O
importance	SAPHRIS.xml:S3:28280:10	O
if	SAPHRIS.xml:S3:28291:2	O
the	SAPHRIS.xml:S3:28294:3	O
prescription	SAPHRIS.xml:S3:28298:12	O
of	SAPHRIS.xml:S3:28311:2	O
these	SAPHRIS.xml:S3:28314:5	O
drugs	SAPHRIS.xml:S3:28320:5	O
is	SAPHRIS.xml:S3:28326:2	O
considered	SAPHRIS.xml:S3:28329:10	O
in	SAPHRIS.xml:S3:28340:2	O
a	SAPHRIS.xml:S3:28343:1	O
patient	SAPHRIS.xml:S3:28345:7	O
with	SAPHRIS.xml:S3:28353:4	O
previously	SAPHRIS.xml:S3:28358:10	O
-	SAPHRIS.xml:S3:28368:1	O
detected	SAPHRIS.xml:S3:28369:8	O
breast	SAPHRIS.xml:S3:28378:6	O
cancer	SAPHRIS.xml:S3:28385:6	O
.	SAPHRIS.xml:S3:28391:1	O

Neither	SAPHRIS.xml:S3:28393:7	B-Negation
clinical	SAPHRIS.xml:S3:28401:8	O
studies	SAPHRIS.xml:S3:28410:7	O
nor	SAPHRIS.xml:S3:28418:3	I-Negation
epidemiologic	SAPHRIS.xml:S3:28422:13	O
studies	SAPHRIS.xml:S3:28436:7	O
conducted	SAPHRIS.xml:S3:28444:9	O
to	SAPHRIS.xml:S3:28454:2	O
date	SAPHRIS.xml:S3:28457:4	O
have	SAPHRIS.xml:S3:28462:4	O
shown	SAPHRIS.xml:S3:28467:5	O
an	SAPHRIS.xml:S3:28473:2	O
association	SAPHRIS.xml:S3:28476:11	O
between	SAPHRIS.xml:S3:28488:7	O
chronic	SAPHRIS.xml:S3:28496:7	O
administration	SAPHRIS.xml:S3:28504:14	O
of	SAPHRIS.xml:S3:28519:2	O
this	SAPHRIS.xml:S3:28522:4	O
class	SAPHRIS.xml:S3:28527:5	O
of	SAPHRIS.xml:S3:28533:2	O
drugs	SAPHRIS.xml:S3:28536:5	O
and	SAPHRIS.xml:S3:28542:3	O
tumorigenesis	SAPHRIS.xml:S3:28546:13	B-AdverseReaction
in	SAPHRIS.xml:S3:28560:2	O
humans	SAPHRIS.xml:S3:28563:6	O
,	SAPHRIS.xml:S3:28569:1	O
but	SAPHRIS.xml:S3:28571:3	O
the	SAPHRIS.xml:S3:28575:3	O
available	SAPHRIS.xml:S3:28579:9	O
evidence	SAPHRIS.xml:S3:28589:8	O
is	SAPHRIS.xml:S3:28598:2	O
too	SAPHRIS.xml:S3:28601:3	O
limited	SAPHRIS.xml:S3:28605:7	O
to	SAPHRIS.xml:S3:28613:2	O
be	SAPHRIS.xml:S3:28616:2	O
conclusive	SAPHRIS.xml:S3:28619:10	O
.	SAPHRIS.xml:S3:28629:1	O

5.11	SAPHRIS.xml:S3:28641:4	O
Seizures	SAPHRIS.xml:S3:28646:8	O

Seizures	SAPHRIS.xml:S3:28662:8	B-AdverseReaction
were	SAPHRIS.xml:S3:28671:4	O
reported	SAPHRIS.xml:S3:28676:8	O
in	SAPHRIS.xml:S3:28685:2	O
0%	SAPHRIS.xml:S3:28688:2	O
and	SAPHRIS.xml:S3:28691:3	O
0.3%	SAPHRIS.xml:S3:28695:4	O
(	SAPHRIS.xml:S3:28700:1	O
0	SAPHRIS.xml:S3:28701:1	O
572	SAPHRIS.xml:S3:28703:3	O
,	SAPHRIS.xml:S3:28706:1	O
1	SAPHRIS.xml:S3:28708:1	O
379	SAPHRIS.xml:S3:28710:3	O
)	SAPHRIS.xml:S3:28713:1	O
of	SAPHRIS.xml:S3:28715:2	O
adult	SAPHRIS.xml:S3:28718:5	O
patients	SAPHRIS.xml:S3:28724:8	O
treated	SAPHRIS.xml:S3:28733:7	O
with	SAPHRIS.xml:S3:28741:4	O
doses	SAPHRIS.xml:S3:28746:5	O
of	SAPHRIS.xml:S3:28752:2	O
5	SAPHRIS.xml:S3:28755:1	O
mg	SAPHRIS.xml:S3:28757:2	O
and	SAPHRIS.xml:S3:28760:3	O
10	SAPHRIS.xml:S3:28764:2	O
mg	SAPHRIS.xml:S3:28767:2	O
twice	SAPHRIS.xml:S3:28770:5	O
daily	SAPHRIS.xml:S3:28776:5	O
of	SAPHRIS.xml:S3:28782:2	O
SAPHRIS	SAPHRIS.xml:S3:28785:7	O
,	SAPHRIS.xml:S3:28792:1	O
respectively	SAPHRIS.xml:S3:28794:12	O
,	SAPHRIS.xml:S3:28806:1	O
compared	SAPHRIS.xml:S3:28808:8	O
to	SAPHRIS.xml:S3:28817:2	O
0%	SAPHRIS.xml:S3:28820:2	O
(	SAPHRIS.xml:S3:28823:1	O
0	SAPHRIS.xml:S3:28824:1	O
503	SAPHRIS.xml:S3:28826:3	O
,	SAPHRIS.xml:S3:28829:1	O
0	SAPHRIS.xml:S3:28831:1	O
203	SAPHRIS.xml:S3:28833:3	O
)	SAPHRIS.xml:S3:28836:1	O
of	SAPHRIS.xml:S3:28838:2	O
patients	SAPHRIS.xml:S3:28841:8	O
treated	SAPHRIS.xml:S3:28850:7	O
with	SAPHRIS.xml:S3:28858:4	O
placebo	SAPHRIS.xml:S3:28863:7	O
in	SAPHRIS.xml:S3:28871:2	O
short	SAPHRIS.xml:S3:28874:5	O
-	SAPHRIS.xml:S3:28879:1	O
term	SAPHRIS.xml:S3:28880:4	O
schizophrenia	SAPHRIS.xml:S3:28885:13	O
and	SAPHRIS.xml:S3:28899:3	O
bipolar	SAPHRIS.xml:S3:28903:7	O
mania	SAPHRIS.xml:S3:28911:5	O
trials	SAPHRIS.xml:S3:28917:6	O
,	SAPHRIS.xml:S3:28923:1	O
respectively	SAPHRIS.xml:S3:28925:12	O
.	SAPHRIS.xml:S3:28937:1	O

During	SAPHRIS.xml:S3:28939:6	O
adult	SAPHRIS.xml:S3:28946:5	O
pre	SAPHRIS.xml:S3:28952:3	O
-	SAPHRIS.xml:S3:28955:1	O
marketing	SAPHRIS.xml:S3:28956:9	O
clinical	SAPHRIS.xml:S3:28966:8	O
trials	SAPHRIS.xml:S3:28975:6	O
with	SAPHRIS.xml:S3:28982:4	O
SAPHRIS	SAPHRIS.xml:S3:28987:7	O
,	SAPHRIS.xml:S3:28994:1	O
including	SAPHRIS.xml:S3:28996:9	O
long	SAPHRIS.xml:S3:29006:4	O
-	SAPHRIS.xml:S3:29010:1	O
term	SAPHRIS.xml:S3:29011:4	O
trials	SAPHRIS.xml:S3:29016:6	O
without	SAPHRIS.xml:S3:29023:7	O
comparison	SAPHRIS.xml:S3:29031:10	O
to	SAPHRIS.xml:S3:29042:2	O
placebo	SAPHRIS.xml:S3:29045:7	O
,	SAPHRIS.xml:S3:29052:1	O
seizures	SAPHRIS.xml:S3:29054:8	B-AdverseReaction
were	SAPHRIS.xml:S3:29063:4	O
reported	SAPHRIS.xml:S3:29068:8	O
in	SAPHRIS.xml:S3:29077:2	O
0.3%	SAPHRIS.xml:S3:29080:4	O
(	SAPHRIS.xml:S3:29085:1	O
5	SAPHRIS.xml:S3:29086:1	O
1953	SAPHRIS.xml:S3:29088:4	O
)	SAPHRIS.xml:S3:29092:1	O
of	SAPHRIS.xml:S3:29094:2	O
patients	SAPHRIS.xml:S3:29097:8	O
treated	SAPHRIS.xml:S3:29106:7	O
with	SAPHRIS.xml:S3:29114:4	O
SAPHRIS	SAPHRIS.xml:S3:29119:7	O
.	SAPHRIS.xml:S3:29126:1	O

There	SAPHRIS.xml:S3:29128:5	O
were	SAPHRIS.xml:S3:29134:4	O
no	SAPHRIS.xml:S3:29139:2	B-Negation
reports	SAPHRIS.xml:S3:29142:7	O
of	SAPHRIS.xml:S3:29150:2	O
seizures	SAPHRIS.xml:S3:29153:8	B-AdverseReaction
in	SAPHRIS.xml:S3:29162:2	O
pediatric	SAPHRIS.xml:S3:29165:9	O
patients	SAPHRIS.xml:S3:29175:8	O
treated	SAPHRIS.xml:S3:29184:7	O
with	SAPHRIS.xml:S3:29192:4	O
SAPHRIS	SAPHRIS.xml:S3:29197:7	O
in	SAPHRIS.xml:S3:29205:2	O
a	SAPHRIS.xml:S3:29208:1	O
3	SAPHRIS.xml:S3:29210:1	O
-	SAPHRIS.xml:S3:29211:1	O
week	SAPHRIS.xml:S3:29212:4	O
-	SAPHRIS.xml:S3:29216:1	O
term	SAPHRIS.xml:S3:29217:4	O
,	SAPHRIS.xml:S3:29221:1	O
bipolar	SAPHRIS.xml:S3:29223:7	O
mania	SAPHRIS.xml:S3:29231:5	O
trial	SAPHRIS.xml:S3:29237:5	O
.	SAPHRIS.xml:S3:29242:1	O

As	SAPHRIS.xml:S3:29252:2	O
with	SAPHRIS.xml:S3:29255:4	O
other	SAPHRIS.xml:S3:29260:5	O
antipsychotic	SAPHRIS.xml:S3:29266:13	O
drugs	SAPHRIS.xml:S3:29280:5	O
,	SAPHRIS.xml:S3:29285:1	O
SAPHRIS	SAPHRIS.xml:S3:29287:7	O
should	SAPHRIS.xml:S3:29295:6	O
be	SAPHRIS.xml:S3:29302:2	O
used	SAPHRIS.xml:S3:29305:4	O
with	SAPHRIS.xml:S3:29310:4	O
caution	SAPHRIS.xml:S3:29315:7	O
in	SAPHRIS.xml:S3:29323:2	O
patients	SAPHRIS.xml:S3:29326:8	O
with	SAPHRIS.xml:S3:29335:4	O
a	SAPHRIS.xml:S3:29340:1	O
history	SAPHRIS.xml:S3:29342:7	O
of	SAPHRIS.xml:S3:29350:2	O
seizures	SAPHRIS.xml:S3:29353:8	O
or	SAPHRIS.xml:S3:29362:2	O
with	SAPHRIS.xml:S3:29365:4	O
conditions	SAPHRIS.xml:S3:29370:10	O
that	SAPHRIS.xml:S3:29381:4	O
potentially	SAPHRIS.xml:S3:29386:11	O
lower	SAPHRIS.xml:S3:29398:5	O
the	SAPHRIS.xml:S3:29404:3	O
seizure	SAPHRIS.xml:S3:29408:7	O
threshold	SAPHRIS.xml:S3:29416:9	O
.	SAPHRIS.xml:S3:29425:1	O

Conditions	SAPHRIS.xml:S3:29427:10	O
that	SAPHRIS.xml:S3:29438:4	O
lower	SAPHRIS.xml:S3:29443:5	O
the	SAPHRIS.xml:S3:29449:3	O
seizure	SAPHRIS.xml:S3:29453:7	O
threshold	SAPHRIS.xml:S3:29461:9	O
may	SAPHRIS.xml:S3:29471:3	O
be	SAPHRIS.xml:S3:29475:2	O
more	SAPHRIS.xml:S3:29478:4	O
prevalent	SAPHRIS.xml:S3:29483:9	O
in	SAPHRIS.xml:S3:29493:2	O
patients	SAPHRIS.xml:S3:29496:8	O
65	SAPHRIS.xml:S3:29505:2	O
years	SAPHRIS.xml:S3:29508:5	O
or	SAPHRIS.xml:S3:29514:2	O
older	SAPHRIS.xml:S3:29517:5	O
.	SAPHRIS.xml:S3:29522:1	O

5.12	SAPHRIS.xml:S3:29534:4	O
Potential	SAPHRIS.xml:S3:29539:9	O
for	SAPHRIS.xml:S3:29549:3	O
Cognitive	SAPHRIS.xml:S3:29553:9	O
and	SAPHRIS.xml:S3:29563:3	O
Motor	SAPHRIS.xml:S3:29567:5	O
Impairment	SAPHRIS.xml:S3:29573:10	O

Somnolence	SAPHRIS.xml:S3:29591:10	B-AdverseReaction
was	SAPHRIS.xml:S3:29602:3	O
reported	SAPHRIS.xml:S3:29606:8	O
in	SAPHRIS.xml:S3:29615:2	O
patients	SAPHRIS.xml:S3:29618:8	O
treated	SAPHRIS.xml:S3:29627:7	O
with	SAPHRIS.xml:S3:29635:4	O
SAPHRIS	SAPHRIS.xml:S3:29640:7	O
.	SAPHRIS.xml:S3:29647:1	O

It	SAPHRIS.xml:S3:29649:2	O
was	SAPHRIS.xml:S3:29652:3	O
usually	SAPHRIS.xml:S3:29656:7	O
transient	SAPHRIS.xml:S3:29664:9	O
with	SAPHRIS.xml:S3:29674:4	O
the	SAPHRIS.xml:S3:29679:3	O
highest	SAPHRIS.xml:S3:29683:7	O
incidence	SAPHRIS.xml:S3:29691:9	O
reported	SAPHRIS.xml:S3:29701:8	O
during	SAPHRIS.xml:S3:29710:6	O
the	SAPHRIS.xml:S3:29717:3	O
first	SAPHRIS.xml:S3:29721:5	O
week	SAPHRIS.xml:S3:29727:4	O
of	SAPHRIS.xml:S3:29732:2	O
treatment	SAPHRIS.xml:S3:29735:9	O
.	SAPHRIS.xml:S3:29744:1	O

In	SAPHRIS.xml:S3:29746:2	O
short	SAPHRIS.xml:S3:29749:5	O
-	SAPHRIS.xml:S3:29754:1	O
term	SAPHRIS.xml:S3:29755:4	O
,	SAPHRIS.xml:S3:29759:1	O
fixed	SAPHRIS.xml:S3:29761:5	O
-	SAPHRIS.xml:S3:29766:1	O
dose	SAPHRIS.xml:S3:29767:4	O
,	SAPHRIS.xml:S3:29771:1	O
placebo	SAPHRIS.xml:S3:29773:7	O
-	SAPHRIS.xml:S3:29780:1	O
controlled	SAPHRIS.xml:S3:29781:10	O
schizophrenia	SAPHRIS.xml:S3:29792:13	O
adult	SAPHRIS.xml:S3:29806:5	O
trials	SAPHRIS.xml:S3:29812:6	O
,	SAPHRIS.xml:S3:29818:1	O
somnolence	SAPHRIS.xml:S3:29820:10	B-AdverseReaction
was	SAPHRIS.xml:S3:29831:3	O
reported	SAPHRIS.xml:S3:29835:8	O
in	SAPHRIS.xml:S3:29844:2	O
15%	SAPHRIS.xml:S3:29847:3	O
(	SAPHRIS.xml:S3:29851:1	O
41	SAPHRIS.xml:S3:29852:2	O
274	SAPHRIS.xml:S3:29855:3	O
)	SAPHRIS.xml:S3:29858:1	O
of	SAPHRIS.xml:S3:29860:2	O
patients	SAPHRIS.xml:S3:29863:8	O
on	SAPHRIS.xml:S3:29872:2	O
SAPHRIS	SAPHRIS.xml:S3:29875:7	O
5	SAPHRIS.xml:S3:29883:1	O
mg	SAPHRIS.xml:S3:29885:2	O
twice	SAPHRIS.xml:S3:29888:5	O
daily	SAPHRIS.xml:S3:29894:5	O
and	SAPHRIS.xml:S3:29900:3	O
in	SAPHRIS.xml:S3:29904:2	O
13%	SAPHRIS.xml:S3:29907:3	O
(	SAPHRIS.xml:S3:29911:1	O
26	SAPHRIS.xml:S3:29912:2	O
208	SAPHRIS.xml:S3:29915:3	O
)	SAPHRIS.xml:S3:29918:1	O
of	SAPHRIS.xml:S3:29920:2	O
patients	SAPHRIS.xml:S3:29923:8	O
on	SAPHRIS.xml:S3:29932:2	O
SAPHRIS	SAPHRIS.xml:S3:29935:7	O
10	SAPHRIS.xml:S3:29943:2	O
mg	SAPHRIS.xml:S3:29946:2	O
twice	SAPHRIS.xml:S3:29949:5	O
daily	SAPHRIS.xml:S3:29955:5	O
compared	SAPHRIS.xml:S3:29961:8	O
to	SAPHRIS.xml:S3:29970:2	O
7%	SAPHRIS.xml:S3:29973:2	O
(	SAPHRIS.xml:S3:29976:1	O
26	SAPHRIS.xml:S3:29977:2	O
378	SAPHRIS.xml:S3:29980:3	O
)	SAPHRIS.xml:S3:29983:1	O
of	SAPHRIS.xml:S3:29985:2	O
placebo	SAPHRIS.xml:S3:29988:7	O
patients	SAPHRIS.xml:S3:29996:8	O
.	SAPHRIS.xml:S3:30004:1	O

In	SAPHRIS.xml:S3:30006:2	O
short	SAPHRIS.xml:S3:30009:5	O
-	SAPHRIS.xml:S3:30014:1	O
term	SAPHRIS.xml:S3:30015:4	O
,	SAPHRIS.xml:S3:30019:1	O
placebo	SAPHRIS.xml:S3:30021:7	O
-	SAPHRIS.xml:S3:30028:1	O
controlled	SAPHRIS.xml:S3:30029:10	O
bipolar	SAPHRIS.xml:S3:30040:7	O
mania	SAPHRIS.xml:S3:30048:5	O
adult	SAPHRIS.xml:S3:30054:5	O
trials	SAPHRIS.xml:S3:30060:6	O
of	SAPHRIS.xml:S3:30067:2	O
therapeutic	SAPHRIS.xml:S3:30070:11	O
doses	SAPHRIS.xml:S3:30082:5	O
(	SAPHRIS.xml:S3:30088:1	O
5	SAPHRIS.xml:S3:30089:1	O
-	SAPHRIS.xml:S3:30090:1	O
10	SAPHRIS.xml:S3:30091:2	O
mg	SAPHRIS.xml:S3:30094:2	O
twice	SAPHRIS.xml:S3:30097:5	O
daily	SAPHRIS.xml:S3:30103:5	O
)	SAPHRIS.xml:S3:30108:1	O
,	SAPHRIS.xml:S3:30109:1	O
somnolence	SAPHRIS.xml:S3:30111:10	B-AdverseReaction
was	SAPHRIS.xml:S3:30122:3	O
reported	SAPHRIS.xml:S3:30126:8	O
in	SAPHRIS.xml:S3:30135:2	O
24%	SAPHRIS.xml:S3:30138:3	O
(	SAPHRIS.xml:S3:30142:1	O
90	SAPHRIS.xml:S3:30143:2	O
379	SAPHRIS.xml:S3:30146:3	O
)	SAPHRIS.xml:S3:30149:1	O
of	SAPHRIS.xml:S3:30151:2	O
patients	SAPHRIS.xml:S3:30154:8	O
on	SAPHRIS.xml:S3:30163:2	O
SAPHRIS	SAPHRIS.xml:S3:30166:7	O
compared	SAPHRIS.xml:S3:30174:8	O
to	SAPHRIS.xml:S3:30183:2	O
6%	SAPHRIS.xml:S3:30186:2	O
(	SAPHRIS.xml:S3:30189:1	O
13	SAPHRIS.xml:S3:30190:2	O
203	SAPHRIS.xml:S3:30193:3	O
)	SAPHRIS.xml:S3:30196:1	O
of	SAPHRIS.xml:S3:30198:2	O
placebo	SAPHRIS.xml:S3:30201:7	O
patients	SAPHRIS.xml:S3:30209:8	O
.	SAPHRIS.xml:S3:30217:1	O

During	SAPHRIS.xml:S3:30219:6	O
adult	SAPHRIS.xml:S3:30226:5	O
pre	SAPHRIS.xml:S3:30232:3	O
-	SAPHRIS.xml:S3:30235:1	O
marketing	SAPHRIS.xml:S3:30236:9	O
clinical	SAPHRIS.xml:S3:30246:8	O
trials	SAPHRIS.xml:S3:30255:6	O
with	SAPHRIS.xml:S3:30262:4	O
SAPHRIS	SAPHRIS.xml:S3:30267:7	O
,	SAPHRIS.xml:S3:30274:1	O
including	SAPHRIS.xml:S3:30276:9	O
long	SAPHRIS.xml:S3:30286:4	O
-	SAPHRIS.xml:S3:30290:1	O
term	SAPHRIS.xml:S3:30291:4	O
trials	SAPHRIS.xml:S3:30296:6	O
without	SAPHRIS.xml:S3:30303:7	O
comparison	SAPHRIS.xml:S3:30311:10	O
to	SAPHRIS.xml:S3:30322:2	O
placebo	SAPHRIS.xml:S3:30325:7	O
,	SAPHRIS.xml:S3:30332:1	O
somnolence	SAPHRIS.xml:S3:30334:10	B-AdverseReaction
was	SAPHRIS.xml:S3:30345:3	O
reported	SAPHRIS.xml:S3:30349:8	O
in	SAPHRIS.xml:S3:30358:2	O
18%	SAPHRIS.xml:S3:30361:3	O
(	SAPHRIS.xml:S3:30365:1	O
358	SAPHRIS.xml:S3:30366:3	O
1953	SAPHRIS.xml:S3:30370:4	O
)	SAPHRIS.xml:S3:30374:1	O
of	SAPHRIS.xml:S3:30376:2	O
patients	SAPHRIS.xml:S3:30379:8	O
treated	SAPHRIS.xml:S3:30388:7	O
with	SAPHRIS.xml:S3:30396:4	O
SAPHRIS	SAPHRIS.xml:S3:30401:7	O
.	SAPHRIS.xml:S3:30408:1	O

Somnolence	SAPHRIS.xml:S3:30410:10	B-AdverseReaction
(	SAPHRIS.xml:S3:30421:1	O
including	SAPHRIS.xml:S3:30422:9	O
sedation	SAPHRIS.xml:S3:30432:8	B-AdverseReaction
)	SAPHRIS.xml:S3:30440:1	O
led	SAPHRIS.xml:S3:30442:3	O
to	SAPHRIS.xml:S3:30446:2	O
discontinuation	SAPHRIS.xml:S3:30449:15	O
in	SAPHRIS.xml:S3:30465:2	O
0.6%	SAPHRIS.xml:S3:30468:4	O
(	SAPHRIS.xml:S3:30473:1	O
12	SAPHRIS.xml:S3:30474:2	O
1953	SAPHRIS.xml:S3:30477:4	O
)	SAPHRIS.xml:S3:30481:1	O
of	SAPHRIS.xml:S3:30483:2	O
patients	SAPHRIS.xml:S3:30486:8	O
in	SAPHRIS.xml:S3:30495:2	O
short	SAPHRIS.xml:S3:30498:5	O
-	SAPHRIS.xml:S3:30503:1	O
term	SAPHRIS.xml:S3:30504:4	O
,	SAPHRIS.xml:S3:30508:1	O
placebo	SAPHRIS.xml:S3:30510:7	O
-	SAPHRIS.xml:S3:30517:1	O
controlled	SAPHRIS.xml:S3:30518:10	O
trials	SAPHRIS.xml:S3:30529:6	O
.	SAPHRIS.xml:S3:30535:1	O

In	SAPHRIS.xml:S3:30545:2	O
a	SAPHRIS.xml:S3:30548:1	O
3	SAPHRIS.xml:S3:30550:1	O
-	SAPHRIS.xml:S3:30551:1	O
week	SAPHRIS.xml:S3:30552:4	O
,	SAPHRIS.xml:S3:30556:1	O
placebo	SAPHRIS.xml:S3:30558:7	O
-	SAPHRIS.xml:S3:30565:1	O
controlled	SAPHRIS.xml:S3:30566:10	O
,	SAPHRIS.xml:S3:30576:1	O
bipolar	SAPHRIS.xml:S3:30578:7	O
I	SAPHRIS.xml:S3:30586:1	O
pediatric	SAPHRIS.xml:S3:30588:9	O
trial	SAPHRIS.xml:S3:30598:5	O
,	SAPHRIS.xml:S3:30603:1	O
the	SAPHRIS.xml:S3:30605:3	O
incidence	SAPHRIS.xml:S3:30609:9	O
of	SAPHRIS.xml:S3:30619:2	O
somnolence	SAPHRIS.xml:S3:30622:10	B-AdverseReaction
(	SAPHRIS.xml:S3:30633:1	O
including	SAPHRIS.xml:S3:30634:9	O
sedation	SAPHRIS.xml:S3:30644:8	B-AdverseReaction
and	SAPHRIS.xml:S3:30653:3	O
hypersomnia	SAPHRIS.xml:S3:30657:11	B-AdverseReaction
)	SAPHRIS.xml:S3:30668:1	O
for	SAPHRIS.xml:S3:30670:3	O
placebo	SAPHRIS.xml:S3:30674:7	O
,	SAPHRIS.xml:S3:30681:1	O
SAPHRIS	SAPHRIS.xml:S3:30683:7	O
2.5	SAPHRIS.xml:S3:30691:3	O
mg	SAPHRIS.xml:S3:30695:2	O
twice	SAPHRIS.xml:S3:30698:5	O
daily	SAPHRIS.xml:S3:30704:5	O
,	SAPHRIS.xml:S3:30709:1	O
5	SAPHRIS.xml:S3:30711:1	O
mg	SAPHRIS.xml:S3:30713:2	O
twice	SAPHRIS.xml:S3:30716:5	O
daily	SAPHRIS.xml:S3:30722:5	O
,	SAPHRIS.xml:S3:30727:1	O
and	SAPHRIS.xml:S3:30729:3	O
10	SAPHRIS.xml:S3:30733:2	O
mg	SAPHRIS.xml:S3:30736:2	O
twice	SAPHRIS.xml:S3:30739:5	O
daily	SAPHRIS.xml:S3:30745:5	O
,	SAPHRIS.xml:S3:30750:1	O
was	SAPHRIS.xml:S3:30752:3	O
12%	SAPHRIS.xml:S3:30756:3	O
(	SAPHRIS.xml:S3:30760:1	O
12	SAPHRIS.xml:S3:30761:2	O
101	SAPHRIS.xml:S3:30764:3	O
)	SAPHRIS.xml:S3:30767:1	O
,	SAPHRIS.xml:S3:30768:1	O
46%	SAPHRIS.xml:S3:30770:3	O
(	SAPHRIS.xml:S3:30774:1	O
48	SAPHRIS.xml:S3:30775:2	O
104	SAPHRIS.xml:S3:30778:3	O
)	SAPHRIS.xml:S3:30781:1	O
,	SAPHRIS.xml:S3:30782:1	O
53%	SAPHRIS.xml:S3:30784:3	O
(	SAPHRIS.xml:S3:30788:1	O
52	SAPHRIS.xml:S3:30789:2	O
99	SAPHRIS.xml:S3:30792:2	O
)	SAPHRIS.xml:S3:30794:1	O
,	SAPHRIS.xml:S3:30795:1	O
and	SAPHRIS.xml:S3:30797:3	O
49%	SAPHRIS.xml:S3:30801:3	O
(	SAPHRIS.xml:S3:30805:1	O
49	SAPHRIS.xml:S3:30806:2	O
99	SAPHRIS.xml:S3:30809:2	O
)	SAPHRIS.xml:S3:30811:1	O
,	SAPHRIS.xml:S3:30812:1	O
respectively	SAPHRIS.xml:S3:30814:12	O
.	SAPHRIS.xml:S3:30826:1	O

Somnolence	SAPHRIS.xml:S3:30828:10	B-AdverseReaction
led	SAPHRIS.xml:S3:30839:3	O
to	SAPHRIS.xml:S3:30843:2	O
discontinuation	SAPHRIS.xml:S3:30846:15	O
in	SAPHRIS.xml:S3:30862:2	O
0%	SAPHRIS.xml:S3:30865:2	O
,	SAPHRIS.xml:S3:30867:1	O
3%	SAPHRIS.xml:S3:30869:2	O
,	SAPHRIS.xml:S3:30871:1	O
1%	SAPHRIS.xml:S3:30873:2	O
,	SAPHRIS.xml:S3:30875:1	O
and	SAPHRIS.xml:S3:30877:3	O
2%	SAPHRIS.xml:S3:30881:2	O
of	SAPHRIS.xml:S3:30884:2	O
patients	SAPHRIS.xml:S3:30887:8	O
treated	SAPHRIS.xml:S3:30896:7	O
with	SAPHRIS.xml:S3:30904:4	O
placebo	SAPHRIS.xml:S3:30909:7	O
,	SAPHRIS.xml:S3:30916:1	O
and	SAPHRIS.xml:S3:30918:3	O
SAPHRIS	SAPHRIS.xml:S3:30922:7	O
2.5	SAPHRIS.xml:S3:30930:3	O
mg	SAPHRIS.xml:S3:30934:2	O
twice	SAPHRIS.xml:S3:30937:5	O
daily	SAPHRIS.xml:S3:30943:5	O
,	SAPHRIS.xml:S3:30948:1	O
5	SAPHRIS.xml:S3:30950:1	O
mg	SAPHRIS.xml:S3:30952:2	O
twice	SAPHRIS.xml:S3:30955:5	O
daily	SAPHRIS.xml:S3:30961:5	O
,	SAPHRIS.xml:S3:30966:1	O
and	SAPHRIS.xml:S3:30968:3	O
10	SAPHRIS.xml:S3:30972:2	O
mg	SAPHRIS.xml:S3:30975:2	O
twice	SAPHRIS.xml:S3:30978:5	O
daily	SAPHRIS.xml:S3:30984:5	O
,	SAPHRIS.xml:S3:30989:1	O
respectively	SAPHRIS.xml:S3:30991:12	O
.	SAPHRIS.xml:S3:31003:1	O

Patients	SAPHRIS.xml:S3:31013:8	O
should	SAPHRIS.xml:S3:31022:6	O
be	SAPHRIS.xml:S3:31029:2	O
cautioned	SAPHRIS.xml:S3:31032:9	O
about	SAPHRIS.xml:S3:31042:5	O
performing	SAPHRIS.xml:S3:31048:10	O
activities	SAPHRIS.xml:S3:31059:10	O
requiring	SAPHRIS.xml:S3:31070:9	O
mental	SAPHRIS.xml:S3:31080:6	O
alertness	SAPHRIS.xml:S3:31087:9	O
,	SAPHRIS.xml:S3:31096:1	O
such	SAPHRIS.xml:S3:31098:4	O
as	SAPHRIS.xml:S3:31103:2	O
operating	SAPHRIS.xml:S3:31106:9	O
hazardous	SAPHRIS.xml:S3:31116:9	O
machinery	SAPHRIS.xml:S3:31126:9	O
or	SAPHRIS.xml:S3:31136:2	O
operating	SAPHRIS.xml:S3:31139:9	O
a	SAPHRIS.xml:S3:31149:1	O
motor	SAPHRIS.xml:S3:31151:5	O
vehicle	SAPHRIS.xml:S3:31157:7	O
,	SAPHRIS.xml:S3:31164:1	O
until	SAPHRIS.xml:S3:31166:5	O
they	SAPHRIS.xml:S3:31172:4	O
are	SAPHRIS.xml:S3:31177:3	O
reasonably	SAPHRIS.xml:S3:31181:10	O
certain	SAPHRIS.xml:S3:31192:7	O
that	SAPHRIS.xml:S3:31200:4	O
SAPHRIS	SAPHRIS.xml:S3:31205:7	O
therapy	SAPHRIS.xml:S3:31213:7	O
does	SAPHRIS.xml:S3:31221:4	O
not	SAPHRIS.xml:S3:31226:3	O
affect	SAPHRIS.xml:S3:31230:6	O
them	SAPHRIS.xml:S3:31237:4	O
adversely	SAPHRIS.xml:S3:31242:9	O
.	SAPHRIS.xml:S3:31251:1	O

5.13	SAPHRIS.xml:S3:31263:4	O
Body	SAPHRIS.xml:S3:31268:4	O
Temperature	SAPHRIS.xml:S3:31273:11	O
Regulation	SAPHRIS.xml:S3:31285:10	O

Disruption	SAPHRIS.xml:S3:31303:10	B-AdverseReaction
of	SAPHRIS.xml:S3:31314:2	I-AdverseReaction
the	SAPHRIS.xml:S3:31317:3	I-AdverseReaction
body	SAPHRIS.xml:S3:31321:4	I-AdverseReaction
's	SAPHRIS.xml:S3:31325:2	I-AdverseReaction
ability	SAPHRIS.xml:S3:31328:7	I-AdverseReaction
to	SAPHRIS.xml:S3:31336:2	I-AdverseReaction
reduce	SAPHRIS.xml:S3:31339:6	I-AdverseReaction
core	SAPHRIS.xml:S3:31346:4	I-AdverseReaction
body	SAPHRIS.xml:S3:31351:4	I-AdverseReaction
temperature	SAPHRIS.xml:S3:31356:11	I-AdverseReaction
has	SAPHRIS.xml:S3:31368:3	O
been	SAPHRIS.xml:S3:31372:4	O
attributed	SAPHRIS.xml:S3:31377:10	O
to	SAPHRIS.xml:S3:31388:2	O
antipsychotic	SAPHRIS.xml:S3:31391:13	B-DrugClass
agents	SAPHRIS.xml:S3:31405:6	I-DrugClass
.	SAPHRIS.xml:S3:31411:1	O

In	SAPHRIS.xml:S3:31413:2	O
the	SAPHRIS.xml:S3:31416:3	O
short	SAPHRIS.xml:S3:31420:5	O
-	SAPHRIS.xml:S3:31425:1	O
term	SAPHRIS.xml:S3:31426:4	O
placebo	SAPHRIS.xml:S3:31431:7	O
-	SAPHRIS.xml:S3:31438:1	O
controlled	SAPHRIS.xml:S3:31439:10	O
trials	SAPHRIS.xml:S3:31450:6	O
for	SAPHRIS.xml:S3:31457:3	O
both	SAPHRIS.xml:S3:31461:4	O
schizophrenia	SAPHRIS.xml:S3:31466:13	O
and	SAPHRIS.xml:S3:31480:3	O
acute	SAPHRIS.xml:S3:31484:5	O
bipolar	SAPHRIS.xml:S3:31490:7	O
disorder	SAPHRIS.xml:S3:31498:8	O
,	SAPHRIS.xml:S3:31506:1	O
the	SAPHRIS.xml:S3:31508:3	O
incidence	SAPHRIS.xml:S3:31512:9	O
of	SAPHRIS.xml:S3:31522:2	O
adverse	SAPHRIS.xml:S3:31525:7	O
reactions	SAPHRIS.xml:S3:31533:9	O
suggestive	SAPHRIS.xml:S3:31543:10	O
of	SAPHRIS.xml:S3:31554:2	O
body	SAPHRIS.xml:S3:31557:4	B-AdverseReaction
temperature	SAPHRIS.xml:S3:31562:11	I-AdverseReaction
increases	SAPHRIS.xml:S3:31574:9	I-AdverseReaction
was	SAPHRIS.xml:S3:31584:3	O
low	SAPHRIS.xml:S3:31588:3	O
(	SAPHRIS.xml:S3:31592:1	O
1%	SAPHRIS.xml:S3:31595:2	O
)	SAPHRIS.xml:S3:31597:1	O
and	SAPHRIS.xml:S3:31599:3	O
comparable	SAPHRIS.xml:S3:31603:10	O
to	SAPHRIS.xml:S3:31614:2	O
placebo	SAPHRIS.xml:S3:31617:7	O
(	SAPHRIS.xml:S3:31625:1	O
0%	SAPHRIS.xml:S3:31626:2	O
)	SAPHRIS.xml:S3:31628:1	O
.	SAPHRIS.xml:S3:31629:1	O

During	SAPHRIS.xml:S3:31631:6	O
clinical	SAPHRIS.xml:S3:31638:8	O
trials	SAPHRIS.xml:S3:31647:6	O
with	SAPHRIS.xml:S3:31654:4	O
SAPHRIS	SAPHRIS.xml:S3:31659:7	O
,	SAPHRIS.xml:S3:31666:1	O
including	SAPHRIS.xml:S3:31668:9	O
long	SAPHRIS.xml:S3:31678:4	O
-	SAPHRIS.xml:S3:31682:1	O
term	SAPHRIS.xml:S3:31683:4	O
trials	SAPHRIS.xml:S3:31688:6	O
without	SAPHRIS.xml:S3:31695:7	O
comparison	SAPHRIS.xml:S3:31703:10	O
to	SAPHRIS.xml:S3:31714:2	O
placebo	SAPHRIS.xml:S3:31717:7	O
,	SAPHRIS.xml:S3:31724:1	O
the	SAPHRIS.xml:S3:31726:3	O
incidence	SAPHRIS.xml:S3:31730:9	O
of	SAPHRIS.xml:S3:31740:2	O
adverse	SAPHRIS.xml:S3:31743:7	O
reactions	SAPHRIS.xml:S3:31751:9	O
suggestive	SAPHRIS.xml:S3:31761:10	O
of	SAPHRIS.xml:S3:31772:2	O
body	SAPHRIS.xml:S3:31775:4	B-AdverseReaction
temperature	SAPHRIS.xml:S3:31780:11	I-AdverseReaction
increases	SAPHRIS.xml:S3:31792:9	I-AdverseReaction
(	SAPHRIS.xml:S3:31802:1	O
pyrexia	SAPHRIS.xml:S3:31803:7	B-AdverseReaction
and	SAPHRIS.xml:S3:31811:3	O
feeling	SAPHRIS.xml:S3:31815:7	B-AdverseReaction
hot	SAPHRIS.xml:S3:31823:3	I-AdverseReaction
)	SAPHRIS.xml:S3:31826:1	O
was	SAPHRIS.xml:S3:31828:3	O
1%	SAPHRIS.xml:S3:31834:2	O
.	SAPHRIS.xml:S3:31836:1	O

Appropriate	SAPHRIS.xml:S3:31846:11	O
care	SAPHRIS.xml:S3:31858:4	O
is	SAPHRIS.xml:S3:31863:2	O
advised	SAPHRIS.xml:S3:31866:7	O
when	SAPHRIS.xml:S3:31874:4	O
prescribing	SAPHRIS.xml:S3:31879:11	O
SAPHRIS	SAPHRIS.xml:S3:31891:7	O
for	SAPHRIS.xml:S3:31899:3	O
patients	SAPHRIS.xml:S3:31903:8	O
who	SAPHRIS.xml:S3:31912:3	O
will	SAPHRIS.xml:S3:31916:4	O
be	SAPHRIS.xml:S3:31921:2	O
experiencing	SAPHRIS.xml:S3:31924:12	O
conditions	SAPHRIS.xml:S3:31937:10	O
that	SAPHRIS.xml:S3:31948:4	O
may	SAPHRIS.xml:S3:31953:3	O
contribute	SAPHRIS.xml:S3:31957:10	O
to	SAPHRIS.xml:S3:31968:2	O
an	SAPHRIS.xml:S3:31971:2	O
elevation	SAPHRIS.xml:S3:31974:9	O
in	SAPHRIS.xml:S3:31984:2	O
core	SAPHRIS.xml:S3:31987:4	O
body	SAPHRIS.xml:S3:31992:4	O
temperature	SAPHRIS.xml:S3:31997:11	O
,	SAPHRIS.xml:S3:32008:1	O
e	SAPHRIS.xml:S3:32010:1	O
.	SAPHRIS.xml:S3:32011:1	O
g	SAPHRIS.xml:S3:32012:1	O
.	SAPHRIS.xml:S3:32013:1	O
,	SAPHRIS.xml:S3:32014:1	O
exercising	SAPHRIS.xml:S3:32016:10	O
strenuously	SAPHRIS.xml:S3:32027:11	O
,	SAPHRIS.xml:S3:32038:1	O
exposure	SAPHRIS.xml:S3:32040:8	O
to	SAPHRIS.xml:S3:32049:2	O
extreme	SAPHRIS.xml:S3:32052:7	O
heat	SAPHRIS.xml:S3:32060:4	O
,	SAPHRIS.xml:S3:32064:1	O
receiving	SAPHRIS.xml:S3:32066:9	O
concomitant	SAPHRIS.xml:S3:32076:11	O
medication	SAPHRIS.xml:S3:32088:10	O
with	SAPHRIS.xml:S3:32099:4	O
anticholinergic	SAPHRIS.xml:S3:32104:15	O
activity	SAPHRIS.xml:S3:32120:8	O
,	SAPHRIS.xml:S3:32128:1	O
or	SAPHRIS.xml:S3:32130:2	O
being	SAPHRIS.xml:S3:32133:5	O
subject	SAPHRIS.xml:S3:32139:7	O
to	SAPHRIS.xml:S3:32147:2	O
dehydration	SAPHRIS.xml:S3:32150:11	O
.	SAPHRIS.xml:S3:32161:1	O

5.14	SAPHRIS.xml:S3:32173:4	O
Suicide	SAPHRIS.xml:S3:32178:7	O

The	SAPHRIS.xml:S3:32193:3	O
possibility	SAPHRIS.xml:S3:32197:11	O
of	SAPHRIS.xml:S3:32209:2	O
a	SAPHRIS.xml:S3:32212:1	O
suicide	SAPHRIS.xml:S3:32214:7	O
attempt	SAPHRIS.xml:S3:32222:7	O
is	SAPHRIS.xml:S3:32230:2	O
inherent	SAPHRIS.xml:S3:32233:8	O
in	SAPHRIS.xml:S3:32242:2	O
psychotic	SAPHRIS.xml:S3:32245:9	O
illnesses	SAPHRIS.xml:S3:32255:9	O
and	SAPHRIS.xml:S3:32265:3	O
bipolar	SAPHRIS.xml:S3:32269:7	O
disorder	SAPHRIS.xml:S3:32277:8	O
,	SAPHRIS.xml:S3:32285:1	O
and	SAPHRIS.xml:S3:32287:3	O
close	SAPHRIS.xml:S3:32291:5	O
supervision	SAPHRIS.xml:S3:32297:11	O
of	SAPHRIS.xml:S3:32309:2	O
high	SAPHRIS.xml:S3:32312:4	O
-	SAPHRIS.xml:S3:32316:1	O
risk	SAPHRIS.xml:S3:32317:4	O
patients	SAPHRIS.xml:S3:32322:8	O
should	SAPHRIS.xml:S3:32331:6	O
accompany	SAPHRIS.xml:S3:32338:9	O
drug	SAPHRIS.xml:S3:32348:4	O
therapy	SAPHRIS.xml:S3:32353:7	O
.	SAPHRIS.xml:S3:32360:1	O

Prescriptions	SAPHRIS.xml:S3:32362:13	O
for	SAPHRIS.xml:S3:32376:3	O
SAPHRIS	SAPHRIS.xml:S3:32380:7	O
should	SAPHRIS.xml:S3:32388:6	O
be	SAPHRIS.xml:S3:32395:2	O
written	SAPHRIS.xml:S3:32398:7	O
for	SAPHRIS.xml:S3:32406:3	O
the	SAPHRIS.xml:S3:32410:3	O
smallest	SAPHRIS.xml:S3:32414:8	O
quantity	SAPHRIS.xml:S3:32423:8	O
of	SAPHRIS.xml:S3:32432:2	O
tablets	SAPHRIS.xml:S3:32435:7	O
consistent	SAPHRIS.xml:S3:32443:10	O
with	SAPHRIS.xml:S3:32454:4	O
good	SAPHRIS.xml:S3:32459:4	O
patient	SAPHRIS.xml:S3:32464:7	O
management	SAPHRIS.xml:S3:32472:10	O
in	SAPHRIS.xml:S3:32483:2	O
order	SAPHRIS.xml:S3:32486:5	O
to	SAPHRIS.xml:S3:32492:2	O
reduce	SAPHRIS.xml:S3:32495:6	O
the	SAPHRIS.xml:S3:32502:3	O
risk	SAPHRIS.xml:S3:32506:4	O
of	SAPHRIS.xml:S3:32511:2	O
overdose	SAPHRIS.xml:S3:32514:8	O
.	SAPHRIS.xml:S3:32522:1	O

5.15	SAPHRIS.xml:S3:32534:4	O
Dysphagia	SAPHRIS.xml:S3:32539:9	O

Esophageal	SAPHRIS.xml:S3:32552:10	B-AdverseReaction
dysmotility	SAPHRIS.xml:S3:32563:11	I-AdverseReaction
and	SAPHRIS.xml:S3:32575:3	O
aspiration	SAPHRIS.xml:S3:32579:10	B-AdverseReaction
have	SAPHRIS.xml:S3:32590:4	O
been	SAPHRIS.xml:S3:32595:4	O
associated	SAPHRIS.xml:S3:32600:10	O
with	SAPHRIS.xml:S3:32611:4	O
antipsychotic	SAPHRIS.xml:S3:32616:13	B-DrugClass
drug	SAPHRIS.xml:S3:32630:4	I-DrugClass
use	SAPHRIS.xml:S3:32635:3	O
.	SAPHRIS.xml:S3:32638:1	O

Dysphagia	SAPHRIS.xml:S3:32640:9	B-AdverseReaction
was	SAPHRIS.xml:S3:32650:3	O
reported	SAPHRIS.xml:S3:32654:8	O
in	SAPHRIS.xml:S3:32663:2	O
0.2%	SAPHRIS.xml:S3:32666:4	O
and	SAPHRIS.xml:S3:32671:3	O
0%	SAPHRIS.xml:S3:32675:2	O
(	SAPHRIS.xml:S3:32678:1	O
1	SAPHRIS.xml:S3:32679:1	O
572	SAPHRIS.xml:S3:32681:3	O
,	SAPHRIS.xml:S3:32684:1	O
0	SAPHRIS.xml:S3:32686:1	O
379	SAPHRIS.xml:S3:32688:3	O
)	SAPHRIS.xml:S3:32691:1	O
of	SAPHRIS.xml:S3:32693:2	O
patients	SAPHRIS.xml:S3:32696:8	O
treated	SAPHRIS.xml:S3:32705:7	O
with	SAPHRIS.xml:S3:32713:4	O
therapeutic	SAPHRIS.xml:S3:32718:11	O
doses	SAPHRIS.xml:S3:32730:5	O
(	SAPHRIS.xml:S3:32736:1	O
5	SAPHRIS.xml:S3:32737:1	O
-	SAPHRIS.xml:S3:32738:1	O
10	SAPHRIS.xml:S3:32739:2	O
mg	SAPHRIS.xml:S3:32742:2	O
twice	SAPHRIS.xml:S3:32745:5	O
daily	SAPHRIS.xml:S3:32751:5	O
)	SAPHRIS.xml:S3:32756:1	O
of	SAPHRIS.xml:S3:32758:2	O
SAPHRIS	SAPHRIS.xml:S3:32761:7	O
as	SAPHRIS.xml:S3:32769:2	O
compared	SAPHRIS.xml:S3:32772:8	O
to	SAPHRIS.xml:S3:32781:2	O
0%	SAPHRIS.xml:S3:32784:2	O
(	SAPHRIS.xml:S3:32787:1	O
0	SAPHRIS.xml:S3:32788:1	O
378	SAPHRIS.xml:S3:32790:3	O
,	SAPHRIS.xml:S3:32793:1	O
0	SAPHRIS.xml:S3:32795:1	O
203	SAPHRIS.xml:S3:32797:3	O
)	SAPHRIS.xml:S3:32800:1	O
of	SAPHRIS.xml:S3:32802:2	O
patients	SAPHRIS.xml:S3:32805:8	O
treated	SAPHRIS.xml:S3:32814:7	O
with	SAPHRIS.xml:S3:32822:4	O
placebo	SAPHRIS.xml:S3:32827:7	O
in	SAPHRIS.xml:S3:32835:2	O
short	SAPHRIS.xml:S3:32838:5	O
-	SAPHRIS.xml:S3:32843:1	O
term	SAPHRIS.xml:S3:32844:4	O
schizophrenia	SAPHRIS.xml:S3:32849:13	O
and	SAPHRIS.xml:S3:32863:3	O
bipolar	SAPHRIS.xml:S3:32867:7	O
mania	SAPHRIS.xml:S3:32875:5	O
adult	SAPHRIS.xml:S3:32881:5	O
trials	SAPHRIS.xml:S3:32887:6	O
,	SAPHRIS.xml:S3:32893:1	O
respectively	SAPHRIS.xml:S3:32895:12	O
.	SAPHRIS.xml:S3:32907:1	O

During	SAPHRIS.xml:S3:32909:6	O
adult	SAPHRIS.xml:S3:32916:5	O
pre	SAPHRIS.xml:S3:32922:3	O
-	SAPHRIS.xml:S3:32925:1	O
marketing	SAPHRIS.xml:S3:32926:9	O
clinical	SAPHRIS.xml:S3:32936:8	O
trials	SAPHRIS.xml:S3:32945:6	O
with	SAPHRIS.xml:S3:32952:4	O
SAPHRIS	SAPHRIS.xml:S3:32957:7	O
,	SAPHRIS.xml:S3:32964:1	O
including	SAPHRIS.xml:S3:32966:9	O
long	SAPHRIS.xml:S3:32976:4	O
-	SAPHRIS.xml:S3:32980:1	O
term	SAPHRIS.xml:S3:32981:4	O
trials	SAPHRIS.xml:S3:32986:6	O
without	SAPHRIS.xml:S3:32993:7	O
comparison	SAPHRIS.xml:S3:33001:10	O
to	SAPHRIS.xml:S3:33012:2	O
placebo	SAPHRIS.xml:S3:33015:7	O
,	SAPHRIS.xml:S3:33022:1	O
dysphagia	SAPHRIS.xml:S3:33024:9	B-AdverseReaction
was	SAPHRIS.xml:S3:33034:3	O
reported	SAPHRIS.xml:S3:33038:8	O
in	SAPHRIS.xml:S3:33047:2	O
0.1%	SAPHRIS.xml:S3:33050:4	O
(	SAPHRIS.xml:S3:33055:1	O
2	SAPHRIS.xml:S3:33056:1	O
1953	SAPHRIS.xml:S3:33058:4	O
)	SAPHRIS.xml:S3:33062:1	O
of	SAPHRIS.xml:S3:33064:2	O
patients	SAPHRIS.xml:S3:33067:8	O
treated	SAPHRIS.xml:S3:33076:7	O
with	SAPHRIS.xml:S3:33084:4	O
SAPHRIS	SAPHRIS.xml:S3:33089:7	O
.	SAPHRIS.xml:S3:33096:1	O

Aspiration	SAPHRIS.xml:S3:33106:10	O
pneumonia	SAPHRIS.xml:S3:33117:9	O
is	SAPHRIS.xml:S3:33127:2	O
a	SAPHRIS.xml:S3:33130:1	O
common	SAPHRIS.xml:S3:33132:6	O
cause	SAPHRIS.xml:S3:33139:5	O
of	SAPHRIS.xml:S3:33145:2	O
morbidity	SAPHRIS.xml:S3:33148:9	O
and	SAPHRIS.xml:S3:33158:3	O
mortality	SAPHRIS.xml:S3:33162:9	O
in	SAPHRIS.xml:S3:33172:2	O
elderly	SAPHRIS.xml:S3:33175:7	O
patients	SAPHRIS.xml:S3:33183:8	O
,	SAPHRIS.xml:S3:33191:1	O
in	SAPHRIS.xml:S3:33193:2	O
particular	SAPHRIS.xml:S3:33196:10	O
those	SAPHRIS.xml:S3:33207:5	O
with	SAPHRIS.xml:S3:33213:4	O
advanced	SAPHRIS.xml:S3:33218:8	O
Alzheimer	SAPHRIS.xml:S3:33227:9	O
's	SAPHRIS.xml:S3:33236:2	O
dementia	SAPHRIS.xml:S3:33239:8	O
.	SAPHRIS.xml:S3:33247:1	O

SAPHRIS	SAPHRIS.xml:S3:33249:7	O
is	SAPHRIS.xml:S3:33257:2	O
not	SAPHRIS.xml:S3:33260:3	O
indicated	SAPHRIS.xml:S3:33264:9	O
for	SAPHRIS.xml:S3:33274:3	O
the	SAPHRIS.xml:S3:33278:3	O
treatment	SAPHRIS.xml:S3:33282:9	O
of	SAPHRIS.xml:S3:33292:2	O
dementia	SAPHRIS.xml:S3:33295:8	O
-	SAPHRIS.xml:S3:33303:1	O
related	SAPHRIS.xml:S3:33304:7	O
psychosis	SAPHRIS.xml:S3:33312:9	O
,	SAPHRIS.xml:S3:33321:1	O
and	SAPHRIS.xml:S3:33323:3	O
should	SAPHRIS.xml:S3:33327:6	O
not	SAPHRIS.xml:S3:33334:3	O
be	SAPHRIS.xml:S3:33338:2	O
used	SAPHRIS.xml:S3:33341:4	O
in	SAPHRIS.xml:S3:33346:2	O
patients	SAPHRIS.xml:S3:33349:8	O
at	SAPHRIS.xml:S3:33358:2	O
risk	SAPHRIS.xml:S3:33361:4	O
for	SAPHRIS.xml:S3:33366:3	O
aspiration	SAPHRIS.xml:S3:33370:10	O
pneumonia	SAPHRIS.xml:S3:33381:9	O
[	SAPHRIS.xml:S3:33392:1	O
see	SAPHRIS.xml:S3:33393:3	O
also	SAPHRIS.xml:S3:33397:4	O
Warnings	SAPHRIS.xml:S3:33402:8	O
and	SAPHRIS.xml:S3:33411:3	O
Precautions	SAPHRIS.xml:S3:33415:11	O
(	SAPHRIS.xml:S3:33427:1	O
5.1	SAPHRIS.xml:S3:33428:3	O
)]	SAPHRIS.xml:S3:33431:2	O
.	SAPHRIS.xml:S3:33435:1	O

5.16	SAPHRIS.xml:S3:33447:4	O
Use	SAPHRIS.xml:S3:33452:3	O
in	SAPHRIS.xml:S3:33456:2	O
Patients	SAPHRIS.xml:S3:33459:8	O
with	SAPHRIS.xml:S3:33468:4	O
Concomitant	SAPHRIS.xml:S3:33473:11	O
Illness	SAPHRIS.xml:S3:33485:7	O

Clinical	SAPHRIS.xml:S3:33500:8	O
experience	SAPHRIS.xml:S3:33509:10	O
with	SAPHRIS.xml:S3:33520:4	O
SAPHRIS	SAPHRIS.xml:S3:33525:7	O
in	SAPHRIS.xml:S3:33533:2	O
patients	SAPHRIS.xml:S3:33536:8	O
with	SAPHRIS.xml:S3:33545:4	O
certain	SAPHRIS.xml:S3:33550:7	O
concomitant	SAPHRIS.xml:S3:33558:11	O
systemic	SAPHRIS.xml:S3:33570:8	O
illnesses	SAPHRIS.xml:S3:33579:9	O
is	SAPHRIS.xml:S3:33589:2	O
limited	SAPHRIS.xml:S3:33592:7	O
[	SAPHRIS.xml:S3:33601:1	O
see	SAPHRIS.xml:S3:33602:3	O
Clinical	SAPHRIS.xml:S3:33606:8	O
Pharmacology	SAPHRIS.xml:S3:33615:12	O
(	SAPHRIS.xml:S3:33628:1	O
12.3	SAPHRIS.xml:S3:33629:4	O
)]	SAPHRIS.xml:S3:33633:2	O
.	SAPHRIS.xml:S3:33637:1	O

SAPHRIS	SAPHRIS.xml:S3:33647:7	O
has	SAPHRIS.xml:S3:33655:3	O
not	SAPHRIS.xml:S3:33659:3	O
been	SAPHRIS.xml:S3:33663:4	O
evaluated	SAPHRIS.xml:S3:33668:9	O
in	SAPHRIS.xml:S3:33678:2	O
patients	SAPHRIS.xml:S3:33681:8	O
with	SAPHRIS.xml:S3:33690:4	O
a	SAPHRIS.xml:S3:33695:1	O
recent	SAPHRIS.xml:S3:33697:6	O
history	SAPHRIS.xml:S3:33704:7	O
of	SAPHRIS.xml:S3:33712:2	O
myocardial	SAPHRIS.xml:S3:33715:10	O
infarction	SAPHRIS.xml:S3:33726:10	O
or	SAPHRIS.xml:S3:33737:2	O
unstable	SAPHRIS.xml:S3:33740:8	O
heart	SAPHRIS.xml:S3:33749:5	O
disease	SAPHRIS.xml:S3:33755:7	O
.	SAPHRIS.xml:S3:33762:1	O

Patients	SAPHRIS.xml:S3:33764:8	O
with	SAPHRIS.xml:S3:33773:4	O
these	SAPHRIS.xml:S3:33778:5	O
diagnoses	SAPHRIS.xml:S3:33784:9	O
were	SAPHRIS.xml:S3:33794:4	O
excluded	SAPHRIS.xml:S3:33799:8	O
from	SAPHRIS.xml:S3:33808:4	O
pre	SAPHRIS.xml:S3:33813:3	O
-	SAPHRIS.xml:S3:33816:1	O
marketing	SAPHRIS.xml:S3:33817:9	O
clinical	SAPHRIS.xml:S3:33827:8	O
trials	SAPHRIS.xml:S3:33836:6	O
.	SAPHRIS.xml:S3:33842:1	O

Because	SAPHRIS.xml:S3:33844:7	O
of	SAPHRIS.xml:S3:33852:2	O
the	SAPHRIS.xml:S3:33855:3	O
risk	SAPHRIS.xml:S3:33859:4	O
of	SAPHRIS.xml:S3:33864:2	O
orthostatic	SAPHRIS.xml:S3:33867:11	O
hypotension	SAPHRIS.xml:S3:33879:11	O
with	SAPHRIS.xml:S3:33891:4	O
SAPHRIS	SAPHRIS.xml:S3:33896:7	O
,	SAPHRIS.xml:S3:33903:1	O
caution	SAPHRIS.xml:S3:33905:7	O
should	SAPHRIS.xml:S3:33913:6	O
be	SAPHRIS.xml:S3:33920:2	O
observed	SAPHRIS.xml:S3:33923:8	O
in	SAPHRIS.xml:S3:33932:2	O
cardiac	SAPHRIS.xml:S3:33935:7	O
patients	SAPHRIS.xml:S3:33943:8	O
[	SAPHRIS.xml:S3:33953:1	O
see	SAPHRIS.xml:S3:33954:3	O
Warnings	SAPHRIS.xml:S3:33958:8	O
and	SAPHRIS.xml:S3:33967:3	O
Precautions	SAPHRIS.xml:S3:33971:11	O
(	SAPHRIS.xml:S3:33983:1	O
5.7	SAPHRIS.xml:S3:33984:3	O
)]	SAPHRIS.xml:S3:33987:2	O
.	SAPHRIS.xml:S3:33991:1	O
6	SIMPONI.xml:S1:4:1	O
ADVERSE	SIMPONI.xml:S1:6:7	O
REACTIONS	SIMPONI.xml:S1:14:9	O

The	SIMPONI.xml:S1:27:3	O
most	SIMPONI.xml:S1:31:4	O
serious	SIMPONI.xml:S1:36:7	O
adverse	SIMPONI.xml:S1:44:7	O
reactions	SIMPONI.xml:S1:52:9	O
were	SIMPONI.xml:S1:62:4	O
:	SIMPONI.xml:S1:66:1	O

Serious	SIMPONI.xml:S1:75:7	B-Severity
Infections	SIMPONI.xml:S1:83:10	B-AdverseReaction
[	SIMPONI.xml:S1:94:1	O
see	SIMPONI.xml:S1:95:3	O
Warnings	SIMPONI.xml:S1:100:8	O
and	SIMPONI.xml:S1:109:3	O
Precautions	SIMPONI.xml:S1:113:11	O
(	SIMPONI.xml:S1:125:1	O
5.1	SIMPONI.xml:S1:126:3	O
)	SIMPONI.xml:S1:129:1	O
]	SIMPONI.xml:S1:132:1	O

Malignancies	SIMPONI.xml:S1:140:12	B-AdverseReaction
[	SIMPONI.xml:S1:153:1	O
see	SIMPONI.xml:S1:154:3	O
Warnings	SIMPONI.xml:S1:159:8	O
and	SIMPONI.xml:S1:168:3	O
Precautions	SIMPONI.xml:S1:172:11	O
(	SIMPONI.xml:S1:184:1	O
5.2	SIMPONI.xml:S1:185:3	O
)	SIMPONI.xml:S1:188:1	O
]	SIMPONI.xml:S1:191:1	O

EXCERPT	SIMPONI.xml:S1:201:7	O
:	SIMPONI.xml:S1:208:1	O
Most	SIMPONI.xml:S1:212:4	O
common	SIMPONI.xml:S1:217:6	O
adverse	SIMPONI.xml:S1:224:7	O
reactions	SIMPONI.xml:S1:232:9	O
(	SIMPONI.xml:S1:242:1	O
incidence	SIMPONI.xml:S1:243:9	O
3%	SIMPONI.xml:S1:255:2	O
)	SIMPONI.xml:S1:257:1	O
are	SIMPONI.xml:S1:259:3	O
:	SIMPONI.xml:S1:262:1	O
upper	SIMPONI.xml:S1:264:5	B-AdverseReaction
respiratory	SIMPONI.xml:S1:270:11	I-AdverseReaction
tract	SIMPONI.xml:S1:282:5	I-AdverseReaction
infection	SIMPONI.xml:S1:288:9	I-AdverseReaction
,	SIMPONI.xml:S1:297:1	O
viral	SIMPONI.xml:S1:299:5	B-AdverseReaction
infection	SIMPONI.xml:S1:305:9	I-AdverseReaction
,	SIMPONI.xml:S1:314:1	O
bronchitis	SIMPONI.xml:S1:316:10	B-AdverseReaction
,	SIMPONI.xml:S1:326:1	O
hypertension	SIMPONI.xml:S1:328:12	B-AdverseReaction
,	SIMPONI.xml:S1:340:1	O
and	SIMPONI.xml:S1:342:3	O
rash	SIMPONI.xml:S1:346:4	B-AdverseReaction
(	SIMPONI.xml:S1:351:1	O
6.1	SIMPONI.xml:S1:354:3	O
)	SIMPONI.xml:S1:359:1	O
.	SIMPONI.xml:S1:360:1	O

To	SIMPONI.xml:S1:368:2	O

report	SIMPONI.xml:S1:371:6	O
SUSPECTED	SIMPONI.xml:S1:378:9	O
ADVERSE	SIMPONI.xml:S1:388:7	O
REACTIONS	SIMPONI.xml:S1:396:9	O
,	SIMPONI.xml:S1:405:1	O
contactJanssen	SIMPONI.xml:S1:407:14	O
Biotech	SIMPONI.xml:S1:422:7	O
,	SIMPONI.xml:S1:429:1	O
Inc	SIMPONI.xml:S1:431:3	O
.	SIMPONI.xml:S1:434:1	O

at	SIMPONI.xml:S1:436:2	O
1	SIMPONI.xml:S1:439:1	O
-	SIMPONI.xml:S1:440:1	O
800	SIMPONI.xml:S1:441:3	O
-	SIMPONI.xml:S1:444:1	O
JANSSEN	SIMPONI.xml:S1:445:7	O
(	SIMPONI.xml:S1:453:1	O
1	SIMPONI.xml:S1:454:1	O
-	SIMPONI.xml:S1:455:1	O
800	SIMPONI.xml:S1:456:3	O
-	SIMPONI.xml:S1:459:1	O
526	SIMPONI.xml:S1:460:3	O
-	SIMPONI.xml:S1:463:1	O
7736	SIMPONI.xml:S1:464:4	O
)	SIMPONI.xml:S1:468:1	O
or	SIMPONI.xml:S1:470:2	O
FDA	SIMPONI.xml:S1:473:3	O
at	SIMPONI.xml:S1:477:2	O
1	SIMPONI.xml:S1:480:1	O
-	SIMPONI.xml:S1:481:1	O
800	SIMPONI.xml:S1:482:3	O
-	SIMPONI.xml:S1:485:1	O
FDA	SIMPONI.xml:S1:486:3	O
-	SIMPONI.xml:S1:489:1	O
1088	SIMPONI.xml:S1:490:4	O
or	SIMPONI.xml:S1:495:2	O
www	SIMPONI.xml:S1:499:3	O
.	SIMPONI.xml:S1:502:1	O
fda	SIMPONI.xml:S1:503:3	O
.	SIMPONI.xml:S1:506:1	O
gov	SIMPONI.xml:S1:507:3	O
medwatch	SIMPONI.xml:S1:511:8	O
.	SIMPONI.xml:S1:519:1	O

6.1	SIMPONI.xml:S1:533:3	O

Clinical	SIMPONI.xml:S1:537:8	O
Trials	SIMPONI.xml:S1:546:6	O
Experience	SIMPONI.xml:S1:553:10	O

Because	SIMPONI.xml:S1:567:7	O
clinical	SIMPONI.xml:S1:575:8	O
trials	SIMPONI.xml:S1:584:6	O
are	SIMPONI.xml:S1:591:3	O
conducted	SIMPONI.xml:S1:595:9	O
under	SIMPONI.xml:S1:605:5	O
widely	SIMPONI.xml:S1:611:6	O
varying	SIMPONI.xml:S1:618:7	O
conditions	SIMPONI.xml:S1:626:10	O
,	SIMPONI.xml:S1:636:1	O
adverse	SIMPONI.xml:S1:638:7	O
reaction	SIMPONI.xml:S1:646:8	O
rates	SIMPONI.xml:S1:655:5	O
observed	SIMPONI.xml:S1:661:8	O
in	SIMPONI.xml:S1:670:2	O
the	SIMPONI.xml:S1:673:3	O
clinical	SIMPONI.xml:S1:677:8	O
trials	SIMPONI.xml:S1:686:6	O
of	SIMPONI.xml:S1:693:2	O
a	SIMPONI.xml:S1:696:1	O
drug	SIMPONI.xml:S1:698:4	O
cannot	SIMPONI.xml:S1:703:6	O
be	SIMPONI.xml:S1:710:2	O
directly	SIMPONI.xml:S1:713:8	O
compared	SIMPONI.xml:S1:722:8	O
to	SIMPONI.xml:S1:731:2	O
rates	SIMPONI.xml:S1:734:5	O
in	SIMPONI.xml:S1:740:2	O
the	SIMPONI.xml:S1:743:3	O
clinical	SIMPONI.xml:S1:747:8	O
trials	SIMPONI.xml:S1:756:6	O
of	SIMPONI.xml:S1:763:2	O
another	SIMPONI.xml:S1:766:7	O
drug	SIMPONI.xml:S1:774:4	O
and	SIMPONI.xml:S1:779:3	O
may	SIMPONI.xml:S1:783:3	O
not	SIMPONI.xml:S1:787:3	O
reflect	SIMPONI.xml:S1:791:7	O
the	SIMPONI.xml:S1:799:3	O
rates	SIMPONI.xml:S1:803:5	O
observed	SIMPONI.xml:S1:809:8	O
in	SIMPONI.xml:S1:818:2	O
clinical	SIMPONI.xml:S1:821:8	O
practice	SIMPONI.xml:S1:830:8	O
.	SIMPONI.xml:S1:838:1	O

The	SIMPONI.xml:S1:844:3	O
safety	SIMPONI.xml:S1:848:6	O
data	SIMPONI.xml:S1:855:4	O
described	SIMPONI.xml:S1:860:9	O
below	SIMPONI.xml:S1:870:5	O
are	SIMPONI.xml:S1:876:3	O
based	SIMPONI.xml:S1:880:5	O
on	SIMPONI.xml:S1:886:2	O
one	SIMPONI.xml:S1:889:3	O
,	SIMPONI.xml:S1:892:1	O
randomized	SIMPONI.xml:S1:894:10	O
,	SIMPONI.xml:S1:904:1	O
double	SIMPONI.xml:S1:906:6	O
-	SIMPONI.xml:S1:912:1	O
blind	SIMPONI.xml:S1:913:5	O
,	SIMPONI.xml:S1:918:1	O
controlled	SIMPONI.xml:S1:920:10	O
Phase	SIMPONI.xml:S1:931:5	O
3	SIMPONI.xml:S1:937:1	O
trial	SIMPONI.xml:S1:939:5	O
in	SIMPONI.xml:S1:945:2	O
patients	SIMPONI.xml:S1:948:8	O
with	SIMPONI.xml:S1:957:4	O
RA	SIMPONI.xml:S1:962:2	O
receiving	SIMPONI.xml:S1:965:9	O
SIMPONI	SIMPONI.xml:S1:975:7	O
ARIA	SIMPONI.xml:S1:983:4	O
by	SIMPONI.xml:S1:988:2	O
intravenous	SIMPONI.xml:S1:991:11	O
infusion	SIMPONI.xml:S1:1003:8	O
(	SIMPONI.xml:S1:1012:1	O
Trial	SIMPONI.xml:S1:1013:5	O
1	SIMPONI.xml:S1:1019:1	O
)	SIMPONI.xml:S1:1020:1	O
.	SIMPONI.xml:S1:1021:1	O

The	SIMPONI.xml:S1:1023:3	O
protocol	SIMPONI.xml:S1:1027:8	O
included	SIMPONI.xml:S1:1036:8	O
provisions	SIMPONI.xml:S1:1045:10	O
for	SIMPONI.xml:S1:1056:3	O
patients	SIMPONI.xml:S1:1060:8	O
taking	SIMPONI.xml:S1:1069:6	O
placebo	SIMPONI.xml:S1:1076:7	O
to	SIMPONI.xml:S1:1084:2	O
receive	SIMPONI.xml:S1:1087:7	O
treatment	SIMPONI.xml:S1:1095:9	O
with	SIMPONI.xml:S1:1105:4	O
SIMPONI	SIMPONI.xml:S1:1110:7	O
ARIA	SIMPONI.xml:S1:1118:4	O
at	SIMPONI.xml:S1:1123:2	O
Week	SIMPONI.xml:S1:1126:4	O
16	SIMPONI.xml:S1:1131:2	O
or	SIMPONI.xml:S1:1134:2	O
Week	SIMPONI.xml:S1:1137:4	O
24	SIMPONI.xml:S1:1142:2	O
either	SIMPONI.xml:S1:1145:6	O
by	SIMPONI.xml:S1:1152:2	O
patient	SIMPONI.xml:S1:1155:7	O
response	SIMPONI.xml:S1:1163:8	O
(	SIMPONI.xml:S1:1172:1	O
based	SIMPONI.xml:S1:1173:5	O
on	SIMPONI.xml:S1:1179:2	O
uncontrolled	SIMPONI.xml:S1:1182:12	O
disease	SIMPONI.xml:S1:1195:7	O
activity	SIMPONI.xml:S1:1203:8	O
)	SIMPONI.xml:S1:1211:1	O
or	SIMPONI.xml:S1:1213:2	O
by	SIMPONI.xml:S1:1216:2	O
design	SIMPONI.xml:S1:1219:6	O
,	SIMPONI.xml:S1:1225:1	O
so	SIMPONI.xml:S1:1227:2	O
that	SIMPONI.xml:S1:1230:4	O
adverse	SIMPONI.xml:S1:1235:7	O
events	SIMPONI.xml:S1:1243:6	O
cannot	SIMPONI.xml:S1:1250:6	O
always	SIMPONI.xml:S1:1257:6	O
be	SIMPONI.xml:S1:1264:2	O
unambiguously	SIMPONI.xml:S1:1267:13	O
attributed	SIMPONI.xml:S1:1281:10	O
to	SIMPONI.xml:S1:1292:2	O
a	SIMPONI.xml:S1:1295:1	O
given	SIMPONI.xml:S1:1297:5	O
treatment	SIMPONI.xml:S1:1303:9	O
.	SIMPONI.xml:S1:1312:1	O

Comparisons	SIMPONI.xml:S1:1314:11	O
between	SIMPONI.xml:S1:1326:7	O
placebo	SIMPONI.xml:S1:1334:7	O
and	SIMPONI.xml:S1:1342:3	O
SIMPONI	SIMPONI.xml:S1:1346:7	O
ARIA	SIMPONI.xml:S1:1354:4	O
were	SIMPONI.xml:S1:1359:4	O
based	SIMPONI.xml:S1:1364:5	O
on	SIMPONI.xml:S1:1370:2	O
the	SIMPONI.xml:S1:1373:3	O
first	SIMPONI.xml:S1:1377:5	O
24	SIMPONI.xml:S1:1383:2	O
weeks	SIMPONI.xml:S1:1386:5	O
of	SIMPONI.xml:S1:1392:2	O
exposure	SIMPONI.xml:S1:1395:8	O
.	SIMPONI.xml:S1:1403:1	O

Trial	SIMPONI.xml:S1:1409:5	O
1	SIMPONI.xml:S1:1415:1	O
included	SIMPONI.xml:S1:1417:8	O
197	SIMPONI.xml:S1:1426:3	O
control	SIMPONI.xml:S1:1430:7	O
-	SIMPONI.xml:S1:1437:1	O
treated	SIMPONI.xml:S1:1438:7	O
patients	SIMPONI.xml:S1:1446:8	O
and	SIMPONI.xml:S1:1455:3	O
463	SIMPONI.xml:S1:1459:3	O
SIMPONI	SIMPONI.xml:S1:1463:7	O
ARIA	SIMPONI.xml:S1:1471:4	O
-	SIMPONI.xml:S1:1475:1	O
treated	SIMPONI.xml:S1:1476:7	O
patients	SIMPONI.xml:S1:1484:8	O
(	SIMPONI.xml:S1:1493:1	O
which	SIMPONI.xml:S1:1494:5	O
includes	SIMPONI.xml:S1:1500:8	O
control	SIMPONI.xml:S1:1509:7	O
-	SIMPONI.xml:S1:1516:1	O
treated	SIMPONI.xml:S1:1517:7	O
patients	SIMPONI.xml:S1:1525:8	O
who	SIMPONI.xml:S1:1534:3	O
switched	SIMPONI.xml:S1:1538:8	O
to	SIMPONI.xml:S1:1547:2	O
SIMPONI	SIMPONI.xml:S1:1550:7	O
ARIA	SIMPONI.xml:S1:1558:4	O
at	SIMPONI.xml:S1:1563:2	O
Week	SIMPONI.xml:S1:1566:4	O
16	SIMPONI.xml:S1:1571:2	O
)	SIMPONI.xml:S1:1573:1	O
.	SIMPONI.xml:S1:1574:1	O

The	SIMPONI.xml:S1:1576:3	O
proportion	SIMPONI.xml:S1:1580:10	O
of	SIMPONI.xml:S1:1591:2	O
patients	SIMPONI.xml:S1:1594:8	O
who	SIMPONI.xml:S1:1603:3	O
discontinued	SIMPONI.xml:S1:1607:12	O
treatment	SIMPONI.xml:S1:1620:9	O
due	SIMPONI.xml:S1:1630:3	O
to	SIMPONI.xml:S1:1634:2	O
adverse	SIMPONI.xml:S1:1637:7	O
reactions	SIMPONI.xml:S1:1645:9	O
in	SIMPONI.xml:S1:1655:2	O
the	SIMPONI.xml:S1:1658:3	O
controlled	SIMPONI.xml:S1:1662:10	O
phase	SIMPONI.xml:S1:1673:5	O
of	SIMPONI.xml:S1:1679:2	O
Trial	SIMPONI.xml:S1:1682:5	O
1	SIMPONI.xml:S1:1688:1	O
through	SIMPONI.xml:S1:1690:7	O
Week	SIMPONI.xml:S1:1698:4	O
24	SIMPONI.xml:S1:1703:2	O
was	SIMPONI.xml:S1:1706:3	O
3.5%	SIMPONI.xml:S1:1710:4	O
for	SIMPONI.xml:S1:1715:3	O
SIMPONI	SIMPONI.xml:S1:1719:7	O
ARIA	SIMPONI.xml:S1:1727:4	O
-	SIMPONI.xml:S1:1731:1	O
treated	SIMPONI.xml:S1:1732:7	O
patients	SIMPONI.xml:S1:1740:8	O
and	SIMPONI.xml:S1:1749:3	O
0.5%	SIMPONI.xml:S1:1753:4	O
for	SIMPONI.xml:S1:1758:3	O
placebo	SIMPONI.xml:S1:1762:7	O
-	SIMPONI.xml:S1:1769:1	O
treated	SIMPONI.xml:S1:1770:7	O
patients	SIMPONI.xml:S1:1778:8	O
.	SIMPONI.xml:S1:1786:1	O

Upper	SIMPONI.xml:S1:1788:5	B-AdverseReaction
respiratory	SIMPONI.xml:S1:1794:11	I-AdverseReaction
tract	SIMPONI.xml:S1:1806:5	I-AdverseReaction
infection	SIMPONI.xml:S1:1812:9	I-AdverseReaction
was	SIMPONI.xml:S1:1822:3	O
the	SIMPONI.xml:S1:1826:3	O
most	SIMPONI.xml:S1:1830:4	O
common	SIMPONI.xml:S1:1835:6	O
adverse	SIMPONI.xml:S1:1842:7	O
reaction	SIMPONI.xml:S1:1850:8	O
reported	SIMPONI.xml:S1:1859:8	O
in	SIMPONI.xml:S1:1868:2	O
the	SIMPONI.xml:S1:1871:3	O
trial	SIMPONI.xml:S1:1875:5	O
through	SIMPONI.xml:S1:1881:7	O
Week	SIMPONI.xml:S1:1889:4	O
24	SIMPONI.xml:S1:1894:2	O
occurring	SIMPONI.xml:S1:1897:9	O
in	SIMPONI.xml:S1:1907:2	O
6.5%	SIMPONI.xml:S1:1910:4	O
of	SIMPONI.xml:S1:1915:2	O
SIMPONI	SIMPONI.xml:S1:1918:7	O
ARIA	SIMPONI.xml:S1:1926:4	O
-	SIMPONI.xml:S1:1930:1	O
treated	SIMPONI.xml:S1:1931:7	O
patients	SIMPONI.xml:S1:1939:8	O
as	SIMPONI.xml:S1:1948:2	O
compared	SIMPONI.xml:S1:1951:8	O
with	SIMPONI.xml:S1:1960:4	O
7.6%	SIMPONI.xml:S1:1965:4	O
of	SIMPONI.xml:S1:1970:2	O
control	SIMPONI.xml:S1:1973:7	O
-	SIMPONI.xml:S1:1980:1	O
treated	SIMPONI.xml:S1:1981:7	O
patients	SIMPONI.xml:S1:1989:8	O
,	SIMPONI.xml:S1:1997:1	O
respectively	SIMPONI.xml:S1:1999:12	O
.	SIMPONI.xml:S1:2011:1	O

Infections	SIMPONI.xml:S1:2021:10	O

Serious	SIMPONI.xml:S1:2038:7	B-Severity
infections	SIMPONI.xml:S1:2046:10	B-AdverseReaction
observed	SIMPONI.xml:S1:2057:8	O
in	SIMPONI.xml:S1:2066:2	O
SIMPONI	SIMPONI.xml:S1:2069:7	O
ARIA	SIMPONI.xml:S1:2077:4	O
-	SIMPONI.xml:S1:2081:1	O
treated	SIMPONI.xml:S1:2082:7	O
patients	SIMPONI.xml:S1:2090:8	O
included	SIMPONI.xml:S1:2099:8	O
sepsis	SIMPONI.xml:S1:2108:6	B-AdverseReaction
,	SIMPONI.xml:S1:2114:1	O
pneumonia	SIMPONI.xml:S1:2116:9	B-AdverseReaction
,	SIMPONI.xml:S1:2125:1	O
cellulitis	SIMPONI.xml:S1:2127:10	B-AdverseReaction
,	SIMPONI.xml:S1:2137:1	O
abscess	SIMPONI.xml:S1:2139:7	B-AdverseReaction
,	SIMPONI.xml:S1:2146:1	O
opportunistic	SIMPONI.xml:S1:2148:13	B-AdverseReaction
infections	SIMPONI.xml:S1:2162:10	I-AdverseReaction
,	SIMPONI.xml:S1:2172:1	O
tuberculosis	SIMPONI.xml:S1:2174:12	B-AdverseReaction
(	SIMPONI.xml:S1:2187:1	O
TB	SIMPONI.xml:S1:2188:2	B-AdverseReaction
)	SIMPONI.xml:S1:2190:1	O
,	SIMPONI.xml:S1:2191:1	O
and	SIMPONI.xml:S1:2193:3	O
invasive	SIMPONI.xml:S1:2197:8	B-AdverseReaction
fungal	SIMPONI.xml:S1:2206:6	I-AdverseReaction
infections	SIMPONI.xml:S1:2213:10	I-AdverseReaction
.	SIMPONI.xml:S1:2223:1	O

Cases	SIMPONI.xml:S1:2225:5	O
of	SIMPONI.xml:S1:2231:2	O
TB	SIMPONI.xml:S1:2234:2	B-AdverseReaction
included	SIMPONI.xml:S1:2237:8	O
pulmonary	SIMPONI.xml:S1:2246:9	B-AdverseReaction
and	SIMPONI.xml:S1:2256:3	O
extrapulmonary	SIMPONI.xml:S1:2260:14	B-AdverseReaction
TB	SIMPONI.xml:S1:2275:2	I-AdverseReaction
.	SIMPONI.xml:S1:2277:1	O

The	SIMPONI.xml:S1:2279:3	O
majority	SIMPONI.xml:S1:2283:8	O
of	SIMPONI.xml:S1:2292:2	O
the	SIMPONI.xml:S1:2295:3	O
TB	SIMPONI.xml:S1:2299:2	B-AdverseReaction
cases	SIMPONI.xml:S1:2302:5	O
occurred	SIMPONI.xml:S1:2308:8	O
in	SIMPONI.xml:S1:2317:2	O
countries	SIMPONI.xml:S1:2320:9	O
with	SIMPONI.xml:S1:2330:4	O
a	SIMPONI.xml:S1:2335:1	O
high	SIMPONI.xml:S1:2337:4	O
incidence	SIMPONI.xml:S1:2342:9	O
rate	SIMPONI.xml:S1:2352:4	O
of	SIMPONI.xml:S1:2357:2	O
TB	SIMPONI.xml:S1:2360:2	O
[	SIMPONI.xml:S1:2364:1	O
see	SIMPONI.xml:S1:2365:3	O
Warnings	SIMPONI.xml:S1:2370:8	O
and	SIMPONI.xml:S1:2379:3	O
Precautions	SIMPONI.xml:S1:2383:11	O
(	SIMPONI.xml:S1:2395:1	O
5.1	SIMPONI.xml:S1:2396:3	O
)	SIMPONI.xml:S1:2399:1	O
]	SIMPONI.xml:S1:2402:1	O
.	SIMPONI.xml:S1:2405:1	O

In	SIMPONI.xml:S1:2411:2	O
the	SIMPONI.xml:S1:2414:3	O
controlled	SIMPONI.xml:S1:2418:10	O
phase	SIMPONI.xml:S1:2429:5	O
of	SIMPONI.xml:S1:2435:2	O
Trial	SIMPONI.xml:S1:2438:5	O
1	SIMPONI.xml:S1:2444:1	O
through	SIMPONI.xml:S1:2446:7	O
Week	SIMPONI.xml:S1:2454:4	O
24	SIMPONI.xml:S1:2459:2	O
,	SIMPONI.xml:S1:2461:1	O
infections	SIMPONI.xml:S1:2463:10	B-AdverseReaction
were	SIMPONI.xml:S1:2474:4	O
observed	SIMPONI.xml:S1:2479:8	O
in	SIMPONI.xml:S1:2488:2	O
27%	SIMPONI.xml:S1:2491:3	O
of	SIMPONI.xml:S1:2495:2	O
SIMPONI	SIMPONI.xml:S1:2498:7	O
ARIA	SIMPONI.xml:S1:2506:4	O
-	SIMPONI.xml:S1:2510:1	O
treated	SIMPONI.xml:S1:2511:7	O
patients	SIMPONI.xml:S1:2519:8	O
compared	SIMPONI.xml:S1:2528:8	O
with	SIMPONI.xml:S1:2537:4	O
24%	SIMPONI.xml:S1:2542:3	O
of	SIMPONI.xml:S1:2546:2	O
control	SIMPONI.xml:S1:2549:7	O
-	SIMPONI.xml:S1:2556:1	O
treated	SIMPONI.xml:S1:2557:7	O
patients	SIMPONI.xml:S1:2565:8	O
,	SIMPONI.xml:S1:2573:1	O
and	SIMPONI.xml:S1:2575:3	O
serious	SIMPONI.xml:S1:2579:7	B-Severity
infections	SIMPONI.xml:S1:2587:10	B-AdverseReaction
were	SIMPONI.xml:S1:2598:4	O
observed	SIMPONI.xml:S1:2603:8	O
in	SIMPONI.xml:S1:2612:2	O
0.9%	SIMPONI.xml:S1:2615:4	O
of	SIMPONI.xml:S1:2620:2	O
SIMPONI	SIMPONI.xml:S1:2623:7	O
ARIA	SIMPONI.xml:S1:2631:4	O
-	SIMPONI.xml:S1:2635:1	O
treated	SIMPONI.xml:S1:2636:7	O
patients	SIMPONI.xml:S1:2644:8	O
and	SIMPONI.xml:S1:2653:3	O
0.0%	SIMPONI.xml:S1:2657:4	O
of	SIMPONI.xml:S1:2662:2	O
control	SIMPONI.xml:S1:2665:7	O
-	SIMPONI.xml:S1:2672:1	O
treated	SIMPONI.xml:S1:2673:7	O
patients	SIMPONI.xml:S1:2681:8	O
.	SIMPONI.xml:S1:2689:1	O

Through	SIMPONI.xml:S1:2691:7	O
Week	SIMPONI.xml:S1:2699:4	O
24	SIMPONI.xml:S1:2704:2	O
,	SIMPONI.xml:S1:2706:1	O
the	SIMPONI.xml:S1:2708:3	O
incidence	SIMPONI.xml:S1:2712:9	O
of	SIMPONI.xml:S1:2722:2	O
serious	SIMPONI.xml:S1:2725:7	B-Severity
infections	SIMPONI.xml:S1:2733:10	B-AdverseReaction
per	SIMPONI.xml:S1:2744:3	O
100	SIMPONI.xml:S1:2748:3	O
patient	SIMPONI.xml:S1:2752:7	O
-	SIMPONI.xml:S1:2759:1	O
years	SIMPONI.xml:S1:2760:5	O
of	SIMPONI.xml:S1:2766:2	O
follow	SIMPONI.xml:S1:2769:6	O
-	SIMPONI.xml:S1:2775:1	O
up	SIMPONI.xml:S1:2776:2	O
was	SIMPONI.xml:S1:2779:3	O
2.2	SIMPONI.xml:S1:2783:3	O
(	SIMPONI.xml:S1:2787:1	O
95%	SIMPONI.xml:S1:2788:3	O
CI	SIMPONI.xml:S1:2792:2	O
0.61	SIMPONI.xml:S1:2795:4	O
,	SIMPONI.xml:S1:2799:1	O
5.71	SIMPONI.xml:S1:2801:4	O
)	SIMPONI.xml:S1:2805:1	O
for	SIMPONI.xml:S1:2807:3	O
the	SIMPONI.xml:S1:2811:3	O
SIMPONI	SIMPONI.xml:S1:2815:7	O
ARIA	SIMPONI.xml:S1:2823:4	O
group	SIMPONI.xml:S1:2828:5	O
,	SIMPONI.xml:S1:2833:1	O
and	SIMPONI.xml:S1:2835:3	O
0	SIMPONI.xml:S1:2839:1	O
(	SIMPONI.xml:S1:2841:1	O
0.00	SIMPONI.xml:S1:2842:4	O
,	SIMPONI.xml:S1:2846:1	O
3.79	SIMPONI.xml:S1:2848:4	O
)	SIMPONI.xml:S1:2852:1	O
for	SIMPONI.xml:S1:2854:3	O
the	SIMPONI.xml:S1:2858:3	O
placebo	SIMPONI.xml:S1:2862:7	O
group	SIMPONI.xml:S1:2870:5	O
.	SIMPONI.xml:S1:2875:1	O

In	SIMPONI.xml:S1:2877:2	O
the	SIMPONI.xml:S1:2880:3	O
controlled	SIMPONI.xml:S1:2884:10	O
and	SIMPONI.xml:S1:2895:3	O
uncontrolled	SIMPONI.xml:S1:2899:12	O
portions	SIMPONI.xml:S1:2912:8	O
of	SIMPONI.xml:S1:2921:2	O
Trial	SIMPONI.xml:S1:2924:5	O
1	SIMPONI.xml:S1:2930:1	O
,	SIMPONI.xml:S1:2931:1	O
958	SIMPONI.xml:S1:2933:3	O
total	SIMPONI.xml:S1:2937:5	O
patient	SIMPONI.xml:S1:2943:7	O
-	SIMPONI.xml:S1:2950:1	O
years	SIMPONI.xml:S1:2951:5	O
of	SIMPONI.xml:S1:2957:2	O
follow	SIMPONI.xml:S1:2960:6	O
-	SIMPONI.xml:S1:2966:1	O
up	SIMPONI.xml:S1:2967:2	O
with	SIMPONI.xml:S1:2970:4	O
a	SIMPONI.xml:S1:2975:1	O
median	SIMPONI.xml:S1:2977:6	O
follow	SIMPONI.xml:S1:2984:6	O
-	SIMPONI.xml:S1:2990:1	O
up	SIMPONI.xml:S1:2991:2	O
of	SIMPONI.xml:S1:2994:2	O
approximately	SIMPONI.xml:S1:2997:13	O
92	SIMPONI.xml:S1:3011:2	O
weeks	SIMPONI.xml:S1:3014:5	O
,	SIMPONI.xml:S1:3019:1	O
the	SIMPONI.xml:S1:3021:3	O
incidence	SIMPONI.xml:S1:3025:9	O
per	SIMPONI.xml:S1:3035:3	O
100	SIMPONI.xml:S1:3039:3	O
patient	SIMPONI.xml:S1:3043:7	O
-	SIMPONI.xml:S1:3050:1	O
years	SIMPONI.xml:S1:3051:5	O
of	SIMPONI.xml:S1:3057:2	O
all	SIMPONI.xml:S1:3060:3	O
serious	SIMPONI.xml:S1:3064:7	B-Severity
infections	SIMPONI.xml:S1:3072:10	B-AdverseReaction
was	SIMPONI.xml:S1:3083:3	O
4.07	SIMPONI.xml:S1:3087:4	O
(	SIMPONI.xml:S1:3092:1	O
CI	SIMPONI.xml:S1:3093:2	O
:	SIMPONI.xml:S1:3095:1	O
2.90	SIMPONI.xml:S1:3097:4	O
,	SIMPONI.xml:S1:3101:1	O
5.57	SIMPONI.xml:S1:3103:4	O
)	SIMPONI.xml:S1:3107:1	O
in	SIMPONI.xml:S1:3109:2	O
patients	SIMPONI.xml:S1:3112:8	O
receiving	SIMPONI.xml:S1:3121:9	O
SIMPONI	SIMPONI.xml:S1:3131:7	O
ARIA	SIMPONI.xml:S1:3139:4	O
[	SIMPONI.xml:S1:3145:1	O
see	SIMPONI.xml:S1:3146:3	O
Warnings	SIMPONI.xml:S1:3151:8	O
and	SIMPONI.xml:S1:3160:3	O
Precautions	SIMPONI.xml:S1:3164:11	O
(	SIMPONI.xml:S1:3176:1	O
5.1	SIMPONI.xml:S1:3177:3	O
)	SIMPONI.xml:S1:3180:1	O
]	SIMPONI.xml:S1:3183:1	O
.	SIMPONI.xml:S1:3186:1	O

In	SIMPONI.xml:S1:3188:2	O
the	SIMPONI.xml:S1:3191:3	O
controlled	SIMPONI.xml:S1:3195:10	O
and	SIMPONI.xml:S1:3206:3	O
uncontrolled	SIMPONI.xml:S1:3210:12	O
portions	SIMPONI.xml:S1:3223:8	O
of	SIMPONI.xml:S1:3232:2	O
Trial	SIMPONI.xml:S1:3235:5	O
1	SIMPONI.xml:S1:3241:1	O
,	SIMPONI.xml:S1:3242:1	O
in	SIMPONI.xml:S1:3244:2	O
SIMPONI	SIMPONI.xml:S1:3247:7	O
ARIA	SIMPONI.xml:S1:3255:4	O
treated	SIMPONI.xml:S1:3260:7	O
patients	SIMPONI.xml:S1:3268:8	O
,	SIMPONI.xml:S1:3276:1	O
the	SIMPONI.xml:S1:3278:3	O
incidence	SIMPONI.xml:S1:3282:9	O
of	SIMPONI.xml:S1:3292:2	O
active	SIMPONI.xml:S1:3295:6	B-AdverseReaction
TB	SIMPONI.xml:S1:3302:2	I-AdverseReaction
per	SIMPONI.xml:S1:3305:3	O
100	SIMPONI.xml:S1:3309:3	O
patient	SIMPONI.xml:S1:3313:7	O
-	SIMPONI.xml:S1:3320:1	O
years	SIMPONI.xml:S1:3321:5	O
was	SIMPONI.xml:S1:3327:3	O
0.31	SIMPONI.xml:S1:3331:4	O
(	SIMPONI.xml:S1:3336:1	O
95%	SIMPONI.xml:S1:3337:3	O
CI	SIMPONI.xml:S1:3341:2	O
:	SIMPONI.xml:S1:3343:1	O
0.06	SIMPONI.xml:S1:3345:4	O
;	SIMPONI.xml:S1:3349:1	O
0.92	SIMPONI.xml:S1:3351:4	O
)	SIMPONI.xml:S1:3355:1	O
and	SIMPONI.xml:S1:3357:3	O
the	SIMPONI.xml:S1:3361:3	O
incidence	SIMPONI.xml:S1:3365:9	O
of	SIMPONI.xml:S1:3375:2	O
other	SIMPONI.xml:S1:3378:5	O
opportunistic	SIMPONI.xml:S1:3384:13	B-AdverseReaction
infections	SIMPONI.xml:S1:3398:10	I-AdverseReaction
per	SIMPONI.xml:S1:3409:3	O
100	SIMPONI.xml:S1:3413:3	O
patient	SIMPONI.xml:S1:3417:7	O
-	SIMPONI.xml:S1:3424:1	O
years	SIMPONI.xml:S1:3425:5	O
was	SIMPONI.xml:S1:3431:3	O
0.42	SIMPONI.xml:S1:3435:4	O
(	SIMPONI.xml:S1:3440:1	O
95%	SIMPONI.xml:S1:3441:3	O
CI	SIMPONI.xml:S1:3445:2	O
:	SIMPONI.xml:S1:3447:1	O
0.11	SIMPONI.xml:S1:3449:4	O
,	SIMPONI.xml:S1:3453:1	O
1.07	SIMPONI.xml:S1:3455:4	O
)	SIMPONI.xml:S1:3459:1	O
.	SIMPONI.xml:S1:3460:1	O

Malignancies	SIMPONI.xml:S1:3470:12	O

One	SIMPONI.xml:S1:3489:3	O
case	SIMPONI.xml:S1:3493:4	O
of	SIMPONI.xml:S1:3498:2	O
malignancy	SIMPONI.xml:S1:3501:10	B-AdverseReaction
other	SIMPONI.xml:S1:3512:5	O
than	SIMPONI.xml:S1:3518:4	O
lymphoma	SIMPONI.xml:S1:3523:8	B-AdverseReaction
and	SIMPONI.xml:S1:3532:3	O
NMSC	SIMPONI.xml:S1:3536:4	B-AdverseReaction
with	SIMPONI.xml:S1:3541:4	O
SIMPONI	SIMPONI.xml:S1:3546:7	O
ARIA	SIMPONI.xml:S1:3554:4	O
was	SIMPONI.xml:S1:3559:3	O
reported	SIMPONI.xml:S1:3563:8	O
through	SIMPONI.xml:S1:3572:7	O
Week	SIMPONI.xml:S1:3580:4	O
24	SIMPONI.xml:S1:3585:2	O
during	SIMPONI.xml:S1:3588:6	O
the	SIMPONI.xml:S1:3595:3	O
controlled	SIMPONI.xml:S1:3599:10	O
phase	SIMPONI.xml:S1:3610:5	O
of	SIMPONI.xml:S1:3616:2	O
Trial	SIMPONI.xml:S1:3619:5	O
1	SIMPONI.xml:S1:3625:1	O
.	SIMPONI.xml:S1:3626:1	O

In	SIMPONI.xml:S1:3628:2	O
the	SIMPONI.xml:S1:3631:3	O
controlled	SIMPONI.xml:S1:3635:10	O
and	SIMPONI.xml:S1:3646:3	O
uncontrolled	SIMPONI.xml:S1:3650:12	O
portions	SIMPONI.xml:S1:3663:8	O
through	SIMPONI.xml:S1:3672:7	O
approximately	SIMPONI.xml:S1:3680:13	O
92	SIMPONI.xml:S1:3694:2	O
weeks	SIMPONI.xml:S1:3697:5	O
,	SIMPONI.xml:S1:3702:1	O
the	SIMPONI.xml:S1:3704:3	O
incidence	SIMPONI.xml:S1:3708:9	O
of	SIMPONI.xml:S1:3718:2	O
malignancies	SIMPONI.xml:S1:3721:12	B-AdverseReaction
per	SIMPONI.xml:S1:3734:3	O
100	SIMPONI.xml:S1:3738:3	O
patient	SIMPONI.xml:S1:3742:7	O
-	SIMPONI.xml:S1:3749:1	O
years	SIMPONI.xml:S1:3750:5	O
,	SIMPONI.xml:S1:3755:1	O
other	SIMPONI.xml:S1:3757:5	O
than	SIMPONI.xml:S1:3763:4	O
lymphoma	SIMPONI.xml:S1:3768:8	B-AdverseReaction
and	SIMPONI.xml:S1:3777:3	O
NMSC	SIMPONI.xml:S1:3781:4	B-AdverseReaction
,	SIMPONI.xml:S1:3785:1	O
in	SIMPONI.xml:S1:3787:2	O
SIMPONI	SIMPONI.xml:S1:3790:7	O
ARIA	SIMPONI.xml:S1:3798:4	O
-	SIMPONI.xml:S1:3802:1	O
treated	SIMPONI.xml:S1:3803:7	O
patients	SIMPONI.xml:S1:3811:8	O
was	SIMPONI.xml:S1:3820:3	O
0.31	SIMPONI.xml:S1:3824:4	O
(	SIMPONI.xml:S1:3829:1	O
CI	SIMPONI.xml:S1:3830:2	O
:	SIMPONI.xml:S1:3832:1	O
0.06	SIMPONI.xml:S1:3834:4	O
,	SIMPONI.xml:S1:3838:1	O
0.92	SIMPONI.xml:S1:3840:4	O
)	SIMPONI.xml:S1:3844:1	O
and	SIMPONI.xml:S1:3846:3	O
the	SIMPONI.xml:S1:3850:3	O
incidence	SIMPONI.xml:S1:3854:9	O
of	SIMPONI.xml:S1:3864:2	O
NMSC	SIMPONI.xml:S1:3867:4	B-AdverseReaction
was	SIMPONI.xml:S1:3872:3	O
0.1	SIMPONI.xml:S1:3876:3	O
(	SIMPONI.xml:S1:3880:1	O
95%	SIMPONI.xml:S1:3881:3	O
CI	SIMPONI.xml:S1:3885:2	O
:	SIMPONI.xml:S1:3887:1	O
0.00	SIMPONI.xml:S1:3889:4	O
,	SIMPONI.xml:S1:3893:1	O
0.58	SIMPONI.xml:S1:3895:4	O
)	SIMPONI.xml:S1:3899:1	O
.	SIMPONI.xml:S1:3900:1	O

Liver	SIMPONI.xml:S1:3910:5	O
Enzyme	SIMPONI.xml:S1:3916:6	O
Elevations	SIMPONI.xml:S1:3923:10	O

There	SIMPONI.xml:S1:3940:5	O
have	SIMPONI.xml:S1:3946:4	O
been	SIMPONI.xml:S1:3951:4	O
reports	SIMPONI.xml:S1:3956:7	O
of	SIMPONI.xml:S1:3964:2	O
severe	SIMPONI.xml:S1:3967:6	B-Severity
hepatic	SIMPONI.xml:S1:3974:7	B-AdverseReaction
reactions	SIMPONI.xml:S1:3982:9	I-AdverseReaction
including	SIMPONI.xml:S1:3992:9	O
acute	SIMPONI.xml:S1:4002:5	B-AdverseReaction
liver	SIMPONI.xml:S1:4008:5	I-AdverseReaction
failure	SIMPONI.xml:S1:4014:7	I-AdverseReaction
in	SIMPONI.xml:S1:4022:2	O
patients	SIMPONI.xml:S1:4025:8	O
receiving	SIMPONI.xml:S1:4034:9	O
TNF	SIMPONI.xml:S1:4044:3	B-DrugClass
-	SIMPONI.xml:S1:4047:1	I-DrugClass
blockers	SIMPONI.xml:S1:4048:8	I-DrugClass
.	SIMPONI.xml:S1:4056:1	O

In	SIMPONI.xml:S1:4062:2	O
the	SIMPONI.xml:S1:4065:3	O
controlled	SIMPONI.xml:S1:4069:10	O
phase	SIMPONI.xml:S1:4080:5	O
of	SIMPONI.xml:S1:4086:2	O
Trial	SIMPONI.xml:S1:4089:5	O
1	SIMPONI.xml:S1:4095:1	O
,	SIMPONI.xml:S1:4096:1	O
through	SIMPONI.xml:S1:4098:7	O
Week	SIMPONI.xml:S1:4106:4	O
24	SIMPONI.xml:S1:4111:2	O
,	SIMPONI.xml:S1:4113:1	O
ALT	SIMPONI.xml:S1:4115:3	B-AdverseReaction
elevations	SIMPONI.xml:S1:4119:10	I-AdverseReaction
5	SIMPONI.xml:S1:4133:1	B-Severity
ULN	SIMPONI.xml:S1:4137:3	I-Severity
occurred	SIMPONI.xml:S1:4141:8	O
in	SIMPONI.xml:S1:4150:2	O
0.8%	SIMPONI.xml:S1:4153:4	O
of	SIMPONI.xml:S1:4158:2	O
SIMPONI	SIMPONI.xml:S1:4161:7	O
ARIA	SIMPONI.xml:S1:4169:4	O
-	SIMPONI.xml:S1:4173:1	O
treated	SIMPONI.xml:S1:4174:7	O
patients	SIMPONI.xml:S1:4182:8	O
and	SIMPONI.xml:S1:4191:3	O
0%	SIMPONI.xml:S1:4195:2	O
of	SIMPONI.xml:S1:4198:2	O
control	SIMPONI.xml:S1:4201:7	O
-	SIMPONI.xml:S1:4208:1	O
treated	SIMPONI.xml:S1:4209:7	O
patients	SIMPONI.xml:S1:4217:8	O
and	SIMPONI.xml:S1:4226:3	O
ALT	SIMPONI.xml:S1:4230:3	B-AdverseReaction
elevations	SIMPONI.xml:S1:4234:10	I-AdverseReaction
3	SIMPONI.xml:S1:4248:1	B-Severity
ULN	SIMPONI.xml:S1:4252:3	I-Severity
occurred	SIMPONI.xml:S1:4256:8	O
in	SIMPONI.xml:S1:4265:2	O
2.3%	SIMPONI.xml:S1:4268:4	O
of	SIMPONI.xml:S1:4273:2	O
SIMPONI	SIMPONI.xml:S1:4276:7	O
ARIA	SIMPONI.xml:S1:4284:4	O
-	SIMPONI.xml:S1:4288:1	O
treated	SIMPONI.xml:S1:4289:7	O
patients	SIMPONI.xml:S1:4297:8	O
and	SIMPONI.xml:S1:4306:3	O
2.5%	SIMPONI.xml:S1:4310:4	O
of	SIMPONI.xml:S1:4315:2	O
control	SIMPONI.xml:S1:4318:7	O
-	SIMPONI.xml:S1:4325:1	O
treated	SIMPONI.xml:S1:4326:7	O
patients	SIMPONI.xml:S1:4334:8	O
.	SIMPONI.xml:S1:4342:1	O

Since	SIMPONI.xml:S1:4348:5	O
many	SIMPONI.xml:S1:4354:4	O
of	SIMPONI.xml:S1:4359:2	O
the	SIMPONI.xml:S1:4362:3	O
patients	SIMPONI.xml:S1:4366:8	O
in	SIMPONI.xml:S1:4375:2	O
the	SIMPONI.xml:S1:4378:3	O
Phase	SIMPONI.xml:S1:4382:5	O
3	SIMPONI.xml:S1:4388:1	O
trial	SIMPONI.xml:S1:4390:5	O
were	SIMPONI.xml:S1:4396:4	O
also	SIMPONI.xml:S1:4401:4	O
taking	SIMPONI.xml:S1:4406:6	O
medications	SIMPONI.xml:S1:4413:11	O
that	SIMPONI.xml:S1:4425:4	O
cause	SIMPONI.xml:S1:4430:5	O
liver	SIMPONI.xml:S1:4436:5	O
enzyme	SIMPONI.xml:S1:4442:6	O
elevations	SIMPONI.xml:S1:4449:10	O
(	SIMPONI.xml:S1:4460:1	O
e	SIMPONI.xml:S1:4461:1	O
.	SIMPONI.xml:S1:4462:1	O
g	SIMPONI.xml:S1:4463:1	O
.	SIMPONI.xml:S1:4464:1	O
,	SIMPONI.xml:S1:4465:1	O
nonsteroidal	SIMPONI.xml:S1:4467:12	O
anti	SIMPONI.xml:S1:4480:4	O
-	SIMPONI.xml:S1:4484:1	O
inflammatory	SIMPONI.xml:S1:4485:12	O
drugs	SIMPONI.xml:S1:4498:5	O
[	SIMPONI.xml:S1:4504:1	O
NSAIDs	SIMPONI.xml:S1:4505:6	O
]	SIMPONI.xml:S1:4511:1	O
,	SIMPONI.xml:S1:4512:1	O
methotrexate	SIMPONI.xml:S1:4514:12	O
[	SIMPONI.xml:S1:4527:1	O
MTX	SIMPONI.xml:S1:4528:3	O
]	SIMPONI.xml:S1:4531:1	O
,	SIMPONI.xml:S1:4532:1	O
or	SIMPONI.xml:S1:4534:2	O
isoniazid	SIMPONI.xml:S1:4537:9	O
prophylaxis	SIMPONI.xml:S1:4547:11	O
)	SIMPONI.xml:S1:4558:1	O
,	SIMPONI.xml:S1:4559:1	O
the	SIMPONI.xml:S1:4561:3	O
relationship	SIMPONI.xml:S1:4565:12	O
between	SIMPONI.xml:S1:4578:7	O
SIMPONI	SIMPONI.xml:S1:4586:7	O
ARIA	SIMPONI.xml:S1:4594:4	O
and	SIMPONI.xml:S1:4599:3	O
liver	SIMPONI.xml:S1:4603:5	O
enzyme	SIMPONI.xml:S1:4609:6	O
elevation	SIMPONI.xml:S1:4616:9	O
is	SIMPONI.xml:S1:4626:2	O
not	SIMPONI.xml:S1:4629:3	O
clear	SIMPONI.xml:S1:4633:5	O
.	SIMPONI.xml:S1:4638:1	O

Autoimmune	SIMPONI.xml:S1:4648:10	O
Disorders	SIMPONI.xml:S1:4659:9	O
and	SIMPONI.xml:S1:4669:3	O
Autoantibodies	SIMPONI.xml:S1:4673:14	O

The	SIMPONI.xml:S1:4694:3	O
use	SIMPONI.xml:S1:4698:3	O
of	SIMPONI.xml:S1:4702:2	O
TNF	SIMPONI.xml:S1:4705:3	B-DrugClass
-	SIMPONI.xml:S1:4708:1	I-DrugClass
blockers	SIMPONI.xml:S1:4709:8	I-DrugClass
,	SIMPONI.xml:S1:4717:1	O
of	SIMPONI.xml:S1:4719:2	O
which	SIMPONI.xml:S1:4722:5	O
SIMPONI	SIMPONI.xml:S1:4728:7	O
ARIA	SIMPONI.xml:S1:4736:4	O
is	SIMPONI.xml:S1:4741:2	O
a	SIMPONI.xml:S1:4744:1	O
member	SIMPONI.xml:S1:4746:6	O
,	SIMPONI.xml:S1:4752:1	O
has	SIMPONI.xml:S1:4754:3	O
been	SIMPONI.xml:S1:4758:4	O
associated	SIMPONI.xml:S1:4763:10	O
with	SIMPONI.xml:S1:4774:4	O
the	SIMPONI.xml:S1:4779:3	O
formation	SIMPONI.xml:S1:4783:9	B-AdverseReaction
of	SIMPONI.xml:S1:4793:2	I-AdverseReaction
autoantibodies	SIMPONI.xml:S1:4796:14	I-AdverseReaction
and	SIMPONI.xml:S1:4811:3	O
,	SIMPONI.xml:S1:4814:1	O
rarely	SIMPONI.xml:S1:4816:6	O
,	SIMPONI.xml:S1:4822:1	O
with	SIMPONI.xml:S1:4824:4	O
the	SIMPONI.xml:S1:4829:3	O
development	SIMPONI.xml:S1:4833:11	O
of	SIMPONI.xml:S1:4845:2	O
a	SIMPONI.xml:S1:4848:1	O
lupus	SIMPONI.xml:S1:4850:5	B-AdverseReaction
-	SIMPONI.xml:S1:4855:1	I-AdverseReaction
like	SIMPONI.xml:S1:4856:4	I-AdverseReaction
syndrome	SIMPONI.xml:S1:4861:8	I-AdverseReaction
.	SIMPONI.xml:S1:4869:1	O

At	SIMPONI.xml:S1:4875:2	O
Week	SIMPONI.xml:S1:4878:4	O
20	SIMPONI.xml:S1:4883:2	O
in	SIMPONI.xml:S1:4886:2	O
Trial	SIMPONI.xml:S1:4889:5	O
1	SIMPONI.xml:S1:4895:1	O
,	SIMPONI.xml:S1:4896:1	O
17%	SIMPONI.xml:S1:4898:3	O
of	SIMPONI.xml:S1:4902:2	O
SIMPONI	SIMPONI.xml:S1:4905:7	O
ARIA	SIMPONI.xml:S1:4913:4	O
-	SIMPONI.xml:S1:4917:1	O
treated	SIMPONI.xml:S1:4918:7	O
patients	SIMPONI.xml:S1:4926:8	O
and	SIMPONI.xml:S1:4935:3	O
13%	SIMPONI.xml:S1:4939:3	O
of	SIMPONI.xml:S1:4943:2	O
control	SIMPONI.xml:S1:4946:7	O
patients	SIMPONI.xml:S1:4954:8	O
were	SIMPONI.xml:S1:4963:4	O
newly	SIMPONI.xml:S1:4968:5	B-AdverseReaction
ANA	SIMPONI.xml:S1:4974:3	I-AdverseReaction
-	SIMPONI.xml:S1:4977:1	I-AdverseReaction
positive	SIMPONI.xml:S1:4978:8	I-AdverseReaction
(	SIMPONI.xml:S1:4987:1	O
at	SIMPONI.xml:S1:4988:2	B-Severity
titers	SIMPONI.xml:S1:4991:6	I-Severity
of	SIMPONI.xml:S1:4998:2	I-Severity
1	SIMPONI.xml:S1:5001:1	I-Severity
:	SIMPONI.xml:S1:5002:1	I-Severity
160	SIMPONI.xml:S1:5003:3	I-Severity
or	SIMPONI.xml:S1:5007:2	O
greater	SIMPONI.xml:S1:5010:7	O
)	SIMPONI.xml:S1:5017:1	O
.	SIMPONI.xml:S1:5018:1	O

Of	SIMPONI.xml:S1:5020:2	O
these	SIMPONI.xml:S1:5023:5	O
patients	SIMPONI.xml:S1:5029:8	O
,	SIMPONI.xml:S1:5037:1	O
one	SIMPONI.xml:S1:5039:3	O
SIMPONI	SIMPONI.xml:S1:5043:7	O
ARIA	SIMPONI.xml:S1:5051:4	O
-	SIMPONI.xml:S1:5055:1	O
treated	SIMPONI.xml:S1:5056:7	O
patient	SIMPONI.xml:S1:5064:7	O
and	SIMPONI.xml:S1:5072:3	O
no	SIMPONI.xml:S1:5076:2	B-Negation
control	SIMPONI.xml:S1:5079:7	O
-	SIMPONI.xml:S1:5086:1	O
treated	SIMPONI.xml:S1:5087:7	O
patients	SIMPONI.xml:S1:5095:8	O
had	SIMPONI.xml:S1:5104:3	O
newly	SIMPONI.xml:S1:5108:5	B-AdverseReaction
positive	SIMPONI.xml:S1:5114:8	I-AdverseReaction
anti	SIMPONI.xml:S1:5123:4	I-AdverseReaction
-	SIMPONI.xml:S1:5127:1	I-AdverseReaction
dsDNA	SIMPONI.xml:S1:5128:5	I-AdverseReaction
antibodies	SIMPONI.xml:S1:5134:10	I-AdverseReaction
.	SIMPONI.xml:S1:5144:1	O

Administration	SIMPONI.xml:S1:5154:14	O
Reactions	SIMPONI.xml:S1:5169:9	O

In	SIMPONI.xml:S1:5185:2	O
the	SIMPONI.xml:S1:5188:3	O
controlled	SIMPONI.xml:S1:5192:10	O
phase	SIMPONI.xml:S1:5203:5	O
of	SIMPONI.xml:S1:5209:2	O
Trial	SIMPONI.xml:S1:5212:5	O
1	SIMPONI.xml:S1:5218:1	O
through	SIMPONI.xml:S1:5220:7	O
Week	SIMPONI.xml:S1:5228:4	O
24	SIMPONI.xml:S1:5233:2	O
,	SIMPONI.xml:S1:5235:1	O
1.1%	SIMPONI.xml:S1:5237:4	O
of	SIMPONI.xml:S1:5242:2	O
SIMPONI	SIMPONI.xml:S1:5245:7	O
ARIA	SIMPONI.xml:S1:5253:4	O
infusions	SIMPONI.xml:S1:5258:9	O
were	SIMPONI.xml:S1:5268:4	O
associated	SIMPONI.xml:S1:5273:10	O
with	SIMPONI.xml:S1:5284:4	O
an	SIMPONI.xml:S1:5289:2	O
infusion	SIMPONI.xml:S1:5292:8	B-AdverseReaction
reaction	SIMPONI.xml:S1:5301:8	I-AdverseReaction
compared	SIMPONI.xml:S1:5310:8	O
with	SIMPONI.xml:S1:5319:4	O
0.2%	SIMPONI.xml:S1:5324:4	O
of	SIMPONI.xml:S1:5329:2	O
infusions	SIMPONI.xml:S1:5332:9	O
in	SIMPONI.xml:S1:5342:2	O
the	SIMPONI.xml:S1:5345:3	O
control	SIMPONI.xml:S1:5349:7	O
group	SIMPONI.xml:S1:5357:5	O
.	SIMPONI.xml:S1:5362:1	O

The	SIMPONI.xml:S1:5364:3	O
most	SIMPONI.xml:S1:5368:4	O
common	SIMPONI.xml:S1:5373:6	O
infusion	SIMPONI.xml:S1:5380:8	O
reaction	SIMPONI.xml:S1:5389:8	O
in	SIMPONI.xml:S1:5398:2	O
SIMPONI	SIMPONI.xml:S1:5401:7	O
ARIA	SIMPONI.xml:S1:5409:4	O
treated	SIMPONI.xml:S1:5414:7	O
patients	SIMPONI.xml:S1:5422:8	O
was	SIMPONI.xml:S1:5431:3	O
rash	SIMPONI.xml:S1:5435:4	B-AdverseReaction
.	SIMPONI.xml:S1:5439:1	O

No	SIMPONI.xml:S1:5441:2	B-Negation
serious	SIMPONI.xml:S1:5444:7	B-Severity
infusion	SIMPONI.xml:S1:5452:8	B-AdverseReaction
reactions	SIMPONI.xml:S1:5461:9	I-AdverseReaction
were	SIMPONI.xml:S1:5471:4	O
reported	SIMPONI.xml:S1:5476:8	O
.	SIMPONI.xml:S1:5484:1	O

Immunogenicity	SIMPONI.xml:S1:5494:14	O

Antibodies	SIMPONI.xml:S1:5515:10	O
to	SIMPONI.xml:S1:5526:2	O
SIMPONI	SIMPONI.xml:S1:5529:7	O
ARIA	SIMPONI.xml:S1:5537:4	O
were	SIMPONI.xml:S1:5542:4	O
detected	SIMPONI.xml:S1:5547:8	O
in	SIMPONI.xml:S1:5556:2	O
13	SIMPONI.xml:S1:5559:2	O
(	SIMPONI.xml:S1:5562:1	O
3%	SIMPONI.xml:S1:5563:2	O
)	SIMPONI.xml:S1:5565:1	O
golimumab	SIMPONI.xml:S1:5567:9	O
-	SIMPONI.xml:S1:5576:1	O
treated	SIMPONI.xml:S1:5577:7	O
patients	SIMPONI.xml:S1:5585:8	O
following	SIMPONI.xml:S1:5594:9	O
IV	SIMPONI.xml:S1:5604:2	O
administration	SIMPONI.xml:S1:5607:14	O
of	SIMPONI.xml:S1:5622:2	O
SIMPONI	SIMPONI.xml:S1:5625:7	O
ARIA	SIMPONI.xml:S1:5633:4	O
in	SIMPONI.xml:S1:5638:2	O
combination	SIMPONI.xml:S1:5641:11	O
with	SIMPONI.xml:S1:5653:4	O
MTX	SIMPONI.xml:S1:5658:3	O
through	SIMPONI.xml:S1:5662:7	O
Week	SIMPONI.xml:S1:5670:4	O
24	SIMPONI.xml:S1:5675:2	O
of	SIMPONI.xml:S1:5678:2	O
Trial	SIMPONI.xml:S1:5681:5	O
1	SIMPONI.xml:S1:5687:1	O
.	SIMPONI.xml:S1:5688:1	O

All	SIMPONI.xml:S1:5694:3	O
patients	SIMPONI.xml:S1:5698:8	O
who	SIMPONI.xml:S1:5707:3	O
were	SIMPONI.xml:S1:5711:4	O
positive	SIMPONI.xml:S1:5716:8	O
for	SIMPONI.xml:S1:5725:3	O
antibodies	SIMPONI.xml:S1:5729:10	O
to	SIMPONI.xml:S1:5740:2	O
golimumab	SIMPONI.xml:S1:5743:9	O
had	SIMPONI.xml:S1:5753:3	O
neutralizing	SIMPONI.xml:S1:5757:12	O
antibodies	SIMPONI.xml:S1:5770:10	O
based	SIMPONI.xml:S1:5781:5	O
on	SIMPONI.xml:S1:5787:2	O
an	SIMPONI.xml:S1:5790:2	O
in	SIMPONI.xml:S1:5793:2	O
vitro	SIMPONI.xml:S1:5796:5	O
cell	SIMPONI.xml:S1:5802:4	O
-	SIMPONI.xml:S1:5806:1	O
based	SIMPONI.xml:S1:5807:5	O
assay	SIMPONI.xml:S1:5813:5	O
.	SIMPONI.xml:S1:5818:1	O

The	SIMPONI.xml:S1:5820:3	O
small	SIMPONI.xml:S1:5824:5	O
number	SIMPONI.xml:S1:5830:6	O
of	SIMPONI.xml:S1:5837:2	O
patients	SIMPONI.xml:S1:5840:8	O
positive	SIMPONI.xml:S1:5849:8	O
for	SIMPONI.xml:S1:5858:3	O
antibodies	SIMPONI.xml:S1:5862:10	O
to	SIMPONI.xml:S1:5873:2	O
SIMPONI	SIMPONI.xml:S1:5876:7	O
ARIA	SIMPONI.xml:S1:5884:4	O
limits	SIMPONI.xml:S1:5889:6	O
the	SIMPONI.xml:S1:5896:3	O
ability	SIMPONI.xml:S1:5900:7	O
to	SIMPONI.xml:S1:5908:2	O
draw	SIMPONI.xml:S1:5911:4	O
definitive	SIMPONI.xml:S1:5916:10	O
conclusions	SIMPONI.xml:S1:5927:11	O
regarding	SIMPONI.xml:S1:5939:9	O
the	SIMPONI.xml:S1:5949:3	O
relationship	SIMPONI.xml:S1:5953:12	O
between	SIMPONI.xml:S1:5966:7	O
antibodies	SIMPONI.xml:S1:5974:10	O
to	SIMPONI.xml:S1:5985:2	O
golimumab	SIMPONI.xml:S1:5988:9	O
and	SIMPONI.xml:S1:5998:3	O
clinical	SIMPONI.xml:S1:6002:8	O
efficacy	SIMPONI.xml:S1:6011:8	O
or	SIMPONI.xml:S1:6020:2	O
safety	SIMPONI.xml:S1:6023:6	O
measures	SIMPONI.xml:S1:6030:8	O
.	SIMPONI.xml:S1:6038:1	O

The	SIMPONI.xml:S1:6044:3	O
data	SIMPONI.xml:S1:6048:4	O
above	SIMPONI.xml:S1:6053:5	O
reflect	SIMPONI.xml:S1:6059:7	O
the	SIMPONI.xml:S1:6067:3	O
percentage	SIMPONI.xml:S1:6071:10	O
of	SIMPONI.xml:S1:6082:2	O
patients	SIMPONI.xml:S1:6085:8	O
whose	SIMPONI.xml:S1:6094:5	O
test	SIMPONI.xml:S1:6100:4	O
results	SIMPONI.xml:S1:6105:7	O
were	SIMPONI.xml:S1:6113:4	O
considered	SIMPONI.xml:S1:6118:10	O
positive	SIMPONI.xml:S1:6129:8	O
for	SIMPONI.xml:S1:6138:3	O
antibodies	SIMPONI.xml:S1:6142:10	O
to	SIMPONI.xml:S1:6153:2	O
SIMPONI	SIMPONI.xml:S1:6156:7	O
ARIA	SIMPONI.xml:S1:6164:4	O
in	SIMPONI.xml:S1:6169:2	O
an	SIMPONI.xml:S1:6172:2	O
ELISA	SIMPONI.xml:S1:6175:5	O
assay	SIMPONI.xml:S1:6181:5	O
.	SIMPONI.xml:S1:6186:1	O

The	SIMPONI.xml:S1:6188:3	O
ELISA	SIMPONI.xml:S1:6192:5	O
assay	SIMPONI.xml:S1:6198:5	O
is	SIMPONI.xml:S1:6204:2	O
subject	SIMPONI.xml:S1:6207:7	O
to	SIMPONI.xml:S1:6215:2	O
interference	SIMPONI.xml:S1:6218:12	O
by	SIMPONI.xml:S1:6231:2	O
co	SIMPONI.xml:S1:6234:2	O
-	SIMPONI.xml:S1:6236:1	O
present	SIMPONI.xml:S1:6237:7	O
golimumab	SIMPONI.xml:S1:6245:9	O
and	SIMPONI.xml:S1:6255:3	O
thus	SIMPONI.xml:S1:6259:4	O
the	SIMPONI.xml:S1:6264:3	O
results	SIMPONI.xml:S1:6268:7	O
are	SIMPONI.xml:S1:6276:3	O
an	SIMPONI.xml:S1:6280:2	O
underestimate	SIMPONI.xml:S1:6283:13	O
of	SIMPONI.xml:S1:6297:2	O
the	SIMPONI.xml:S1:6300:3	O
rate	SIMPONI.xml:S1:6304:4	O
of	SIMPONI.xml:S1:6309:2	O
product	SIMPONI.xml:S1:6312:7	O
immunogenicity	SIMPONI.xml:S1:6320:14	O
and	SIMPONI.xml:S1:6335:3	O
are	SIMPONI.xml:S1:6339:3	O
in	SIMPONI.xml:S1:6343:2	O
addition	SIMPONI.xml:S1:6346:8	O
highly	SIMPONI.xml:S1:6355:6	O
dependent	SIMPONI.xml:S1:6362:9	O
on	SIMPONI.xml:S1:6372:2	O
the	SIMPONI.xml:S1:6375:3	O
sensitivity	SIMPONI.xml:S1:6379:11	O
and	SIMPONI.xml:S1:6391:3	O
specificity	SIMPONI.xml:S1:6395:11	O
of	SIMPONI.xml:S1:6407:2	O
the	SIMPONI.xml:S1:6410:3	O
assay	SIMPONI.xml:S1:6414:5	O
.	SIMPONI.xml:S1:6419:1	O

Additionally	SIMPONI.xml:S1:6421:12	O
,	SIMPONI.xml:S1:6433:1	O
the	SIMPONI.xml:S1:6435:3	O
observed	SIMPONI.xml:S1:6439:8	O
incidence	SIMPONI.xml:S1:6448:9	O
of	SIMPONI.xml:S1:6458:2	O
antibody	SIMPONI.xml:S1:6461:8	O
positivity	SIMPONI.xml:S1:6470:10	O
in	SIMPONI.xml:S1:6481:2	O
an	SIMPONI.xml:S1:6484:2	O
assay	SIMPONI.xml:S1:6487:5	O
may	SIMPONI.xml:S1:6493:3	O
be	SIMPONI.xml:S1:6497:2	O
influenced	SIMPONI.xml:S1:6500:10	O
by	SIMPONI.xml:S1:6511:2	O
several	SIMPONI.xml:S1:6514:7	O
factors	SIMPONI.xml:S1:6522:7	O
including	SIMPONI.xml:S1:6530:9	O
sample	SIMPONI.xml:S1:6540:6	O
handling	SIMPONI.xml:S1:6547:8	O
,	SIMPONI.xml:S1:6555:1	O
timing	SIMPONI.xml:S1:6557:6	O
of	SIMPONI.xml:S1:6564:2	O
sample	SIMPONI.xml:S1:6567:6	O
collection	SIMPONI.xml:S1:6574:10	O
,	SIMPONI.xml:S1:6584:1	O
concomitant	SIMPONI.xml:S1:6586:11	O
medications	SIMPONI.xml:S1:6598:11	O
,	SIMPONI.xml:S1:6609:1	O
and	SIMPONI.xml:S1:6611:3	O
underlying	SIMPONI.xml:S1:6615:10	O
disease	SIMPONI.xml:S1:6626:7	O
.	SIMPONI.xml:S1:6633:1	O

For	SIMPONI.xml:S1:6635:3	O
these	SIMPONI.xml:S1:6639:5	O
reasons	SIMPONI.xml:S1:6645:7	O
,	SIMPONI.xml:S1:6652:1	O
comparison	SIMPONI.xml:S1:6654:10	O
of	SIMPONI.xml:S1:6665:2	O
the	SIMPONI.xml:S1:6668:3	O
incidence	SIMPONI.xml:S1:6672:9	O
of	SIMPONI.xml:S1:6682:2	O
antibodies	SIMPONI.xml:S1:6685:10	O
to	SIMPONI.xml:S1:6696:2	O
SIMPONI	SIMPONI.xml:S1:6699:7	O
ARIA	SIMPONI.xml:S1:6707:4	O
with	SIMPONI.xml:S1:6712:4	O
the	SIMPONI.xml:S1:6717:3	O
incidence	SIMPONI.xml:S1:6721:9	O
of	SIMPONI.xml:S1:6731:2	O
antibodies	SIMPONI.xml:S1:6734:10	O
to	SIMPONI.xml:S1:6745:2	O
other	SIMPONI.xml:S1:6748:5	O
products	SIMPONI.xml:S1:6754:8	O
may	SIMPONI.xml:S1:6763:3	O
be	SIMPONI.xml:S1:6767:2	O
misleading	SIMPONI.xml:S1:6770:10	O
.	SIMPONI.xml:S1:6780:1	O

Other	SIMPONI.xml:S1:6790:5	O
Adverse	SIMPONI.xml:S1:6796:7	O
Reactions	SIMPONI.xml:S1:6804:9	O

Table	SIMPONI.xml:S1:6820:5	O
1	SIMPONI.xml:S1:6826:1	O
summarizes	SIMPONI.xml:S1:6828:10	O
the	SIMPONI.xml:S1:6839:3	O
adverse	SIMPONI.xml:S1:6843:7	O
drug	SIMPONI.xml:S1:6851:4	O
reactions	SIMPONI.xml:S1:6856:9	O
that	SIMPONI.xml:S1:6866:4	O
occurred	SIMPONI.xml:S1:6871:8	O
at	SIMPONI.xml:S1:6880:2	O
a	SIMPONI.xml:S1:6883:1	O
rate	SIMPONI.xml:S1:6885:4	O
of	SIMPONI.xml:S1:6890:2	O
at	SIMPONI.xml:S1:6893:2	O
least	SIMPONI.xml:S1:6896:5	O
1%	SIMPONI.xml:S1:6902:2	O
in	SIMPONI.xml:S1:6905:2	O
the	SIMPONI.xml:S1:6908:3	O
SIMPONI	SIMPONI.xml:S1:6912:7	O
ARIA	SIMPONI.xml:S1:6920:4	O
MTX	SIMPONI.xml:S1:6927:3	O
group	SIMPONI.xml:S1:6931:5	O
with	SIMPONI.xml:S1:6937:4	O
a	SIMPONI.xml:S1:6942:1	O
higher	SIMPONI.xml:S1:6944:6	O
incidence	SIMPONI.xml:S1:6951:9	O
than	SIMPONI.xml:S1:6961:4	O
in	SIMPONI.xml:S1:6966:2	O
the	SIMPONI.xml:S1:6969:3	O
placebo	SIMPONI.xml:S1:6973:7	O
MTX	SIMPONI.xml:S1:6983:3	O
group	SIMPONI.xml:S1:6987:5	O
during	SIMPONI.xml:S1:6993:6	O
the	SIMPONI.xml:S1:7000:3	O
controlled	SIMPONI.xml:S1:7004:10	O
period	SIMPONI.xml:S1:7015:6	O
of	SIMPONI.xml:S1:7022:2	O
Trial	SIMPONI.xml:S1:7025:5	O
1	SIMPONI.xml:S1:7031:1	O
through	SIMPONI.xml:S1:7033:7	O
Week	SIMPONI.xml:S1:7041:4	O
24	SIMPONI.xml:S1:7046:2	O
.	SIMPONI.xml:S1:7048:1	O

Table	SIMPONI.xml:S1:7054:5	O
1	SIMPONI.xml:S1:7060:1	O
:	SIMPONI.xml:S1:7061:1	O
Adverse	SIMPONI.xml:S1:7063:7	O
Drug	SIMPONI.xml:S1:7071:4	O
Reactions	SIMPONI.xml:S1:7076:9	O
Reported	SIMPONI.xml:S1:7086:8	O
by	SIMPONI.xml:S1:7095:2	O
1%	SIMPONI.xml:S1:7101:2	O
of	SIMPONI.xml:S1:7104:2	O
SIMPONI	SIMPONI.xml:S1:7107:7	O
ARIA	SIMPONI.xml:S1:7115:4	O
-	SIMPONI.xml:S1:7119:1	O
Treated	SIMPONI.xml:S1:7120:7	O
Patients	SIMPONI.xml:S1:7128:8	O
and	SIMPONI.xml:S1:7137:3	O
with	SIMPONI.xml:S1:7141:4	O
a	SIMPONI.xml:S1:7146:1	O
Higher	SIMPONI.xml:S1:7148:6	O
Incidence	SIMPONI.xml:S1:7155:9	O
than	SIMPONI.xml:S1:7165:4	O
Placebo	SIMPONI.xml:S1:7170:7	O
-	SIMPONI.xml:S1:7177:1	O
Treated	SIMPONI.xml:S1:7178:7	O
Patients	SIMPONI.xml:S1:7186:8	O
in	SIMPONI.xml:S1:7195:2	O
Trial	SIMPONI.xml:S1:7198:5	O
1	SIMPONI.xml:S1:7204:1	O
through	SIMPONI.xml:S1:7206:7	O
Week	SIMPONI.xml:S1:7214:4	O
24	SIMPONI.xml:S1:7219:2	O

Placebo	SIMPONI.xml:S1:7282:7	O
MTX	SIMPONI.xml:S1:7292:3	O
SIMPONI	SIMPONI.xml:S1:7306:7	O
ARIA	SIMPONI.xml:S1:7314:4	O
MTX	SIMPONI.xml:S1:7321:3	O

Patients	SIMPONI.xml:S1:7336:8	O

treated	SIMPONI.xml:S1:7345:7	O
197	SIMPONI.xml:S1:7399:3	O
463	SIMPONI.xml:S1:7426:3	O

Adverse	SIMPONI.xml:S1:7445:7	O
Reaction	SIMPONI.xml:S1:7453:8	O

Infections	SIMPONI.xml:S1:7502:10	O
and	SIMPONI.xml:S1:7513:3	O
Infestations	SIMPONI.xml:S1:7517:12	O

Upper	SIMPONI.xml:S1:7612:5	B-AdverseReaction
respiratory	SIMPONI.xml:S1:7618:11	I-AdverseReaction
tract	SIMPONI.xml:S1:7630:5	I-AdverseReaction
infection	SIMPONI.xml:S1:7636:9	I-AdverseReaction
(	SIMPONI.xml:S1:7646:1	O
such	SIMPONI.xml:S1:7647:4	O
as	SIMPONI.xml:S1:7652:2	O
upper	SIMPONI.xml:S1:7655:5	B-AdverseReaction
respiratory	SIMPONI.xml:S1:7661:11	I-AdverseReaction
tract	SIMPONI.xml:S1:7673:5	I-AdverseReaction
infection	SIMPONI.xml:S1:7679:9	I-AdverseReaction
,	SIMPONI.xml:S1:7688:1	O
nasopharyngitis	SIMPONI.xml:S1:7690:15	B-AdverseReaction
,	SIMPONI.xml:S1:7705:1	O
pharyngitis	SIMPONI.xml:S1:7707:11	B-AdverseReaction
,	SIMPONI.xml:S1:7718:1	O
laryngitis	SIMPONI.xml:S1:7720:10	B-AdverseReaction
,	SIMPONI.xml:S1:7730:1	O
and	SIMPONI.xml:S1:7732:3	O
rhinitis	SIMPONI.xml:S1:7736:8	B-AdverseReaction
)	SIMPONI.xml:S1:7744:1	O
12%	SIMPONI.xml:S1:7758:3	O
13%	SIMPONI.xml:S1:7785:3	O

Viral	SIMPONI.xml:S1:7807:5	B-AdverseReaction
infections	SIMPONI.xml:S1:7813:10	I-AdverseReaction
(	SIMPONI.xml:S1:7824:1	O
such	SIMPONI.xml:S1:7825:4	O
as	SIMPONI.xml:S1:7830:2	O
influenza	SIMPONI.xml:S1:7833:9	B-AdverseReaction
and	SIMPONI.xml:S1:7843:3	O
herpes	SIMPONI.xml:S1:7847:6	B-AdverseReaction
)	SIMPONI.xml:S1:7853:1	O
3%	SIMPONI.xml:S1:7867:2	O
4%	SIMPONI.xml:S1:7894:2	O

Bacterial	SIMPONI.xml:S1:7916:9	B-AdverseReaction
infections	SIMPONI.xml:S1:7926:10	I-AdverseReaction
0%	SIMPONI.xml:S1:7976:2	O
1%	SIMPONI.xml:S1:8003:2	O

Bronchitis	SIMPONI.xml:S1:8025:10	B-AdverseReaction
1%	SIMPONI.xml:S1:8085:2	O
3%	SIMPONI.xml:S1:8112:2	O

Vascular	SIMPONI.xml:S1:8133:8	B-AdverseReaction
disorders	SIMPONI.xml:S1:8142:9	I-AdverseReaction

Hypertension	SIMPONI.xml:S1:8243:12	B-AdverseReaction
2%	SIMPONI.xml:S1:8303:2	O
3%	SIMPONI.xml:S1:8330:2	O

Skin	SIMPONI.xml:S1:8351:4	O
and	SIMPONI.xml:S1:8356:3	O
subcutaneous	SIMPONI.xml:S1:8360:12	O
disorders	SIMPONI.xml:S1:8373:9	O

Rash	SIMPONI.xml:S1:8461:4	B-AdverseReaction
1%	SIMPONI.xml:S1:8521:2	O
3%	SIMPONI.xml:S1:8548:2	O

General	SIMPONI.xml:S1:8569:7	O
disorders	SIMPONI.xml:S1:8577:9	O
and	SIMPONI.xml:S1:8587:3	O
administration	SIMPONI.xml:S1:8591:14	O
site	SIMPONI.xml:S1:8606:4	O
conditions	SIMPONI.xml:S1:8611:10	O

Pyrexia	SIMPONI.xml:S1:8685:7	B-AdverseReaction
1%	SIMPONI.xml:S1:8745:2	O
2%	SIMPONI.xml:S1:8772:2	O

Blood	SIMPONI.xml:S1:8793:5	B-AdverseReaction
and	SIMPONI.xml:S1:8799:3	O
lymphatic	SIMPONI.xml:S1:8803:9	B-AdverseReaction
disorders	SIMPONI.xml:S1:8813:9	I-AdverseReaction

Leukopenia	SIMPONI.xml:S1:8903:10	B-AdverseReaction
0%	SIMPONI.xml:S1:8963:2	O
1%	SIMPONI.xml:S1:8990:2	O

Other	SIMPONI.xml:S1:9021:5	O
and	SIMPONI.xml:S1:9027:3	O
less	SIMPONI.xml:S1:9031:4	O
common	SIMPONI.xml:S1:9036:6	O
clinical	SIMPONI.xml:S1:9043:8	O
trial	SIMPONI.xml:S1:9052:5	O
adverse	SIMPONI.xml:S1:9058:7	O
drug	SIMPONI.xml:S1:9066:4	O
reactions	SIMPONI.xml:S1:9071:9	O

Adverse	SIMPONI.xml:S1:9087:7	O

drug	SIMPONI.xml:S1:9095:4	O
reactions	SIMPONI.xml:S1:9100:9	O
that	SIMPONI.xml:S1:9110:4	O
do	SIMPONI.xml:S1:9115:2	O
not	SIMPONI.xml:S1:9118:3	O
appear	SIMPONI.xml:S1:9122:6	O
in	SIMPONI.xml:S1:9129:2	O
Table	SIMPONI.xml:S1:9132:5	O
1	SIMPONI.xml:S1:9138:1	O
or	SIMPONI.xml:S1:9140:2	O
that	SIMPONI.xml:S1:9143:4	O
occurred	SIMPONI.xml:S1:9148:8	O
1%	SIMPONI.xml:S1:9158:2	O
in	SIMPONI.xml:S1:9161:2	O
SIMPONI	SIMPONI.xml:S1:9164:7	O
ARIA	SIMPONI.xml:S1:9172:4	O
-	SIMPONI.xml:S1:9176:1	O
treated	SIMPONI.xml:S1:9177:7	O
patients	SIMPONI.xml:S1:9185:8	O
during	SIMPONI.xml:S1:9194:6	O
Trial	SIMPONI.xml:S1:9201:5	O
1	SIMPONI.xml:S1:9207:1	O
through	SIMPONI.xml:S1:9209:7	O
Week	SIMPONI.xml:S1:9217:4	O
24	SIMPONI.xml:S1:9222:2	O
that	SIMPONI.xml:S1:9225:4	O
do	SIMPONI.xml:S1:9230:2	O
not	SIMPONI.xml:S1:9233:3	O
appear	SIMPONI.xml:S1:9237:6	O
in	SIMPONI.xml:S1:9244:2	O
the	SIMPONI.xml:S1:9247:3	O
Warnings	SIMPONI.xml:S1:9251:8	O
and	SIMPONI.xml:S1:9260:3	O
Precautions	SIMPONI.xml:S1:9264:11	O
section	SIMPONI.xml:S1:9276:7	O
included	SIMPONI.xml:S1:9284:8	O
the	SIMPONI.xml:S1:9293:3	O
following	SIMPONI.xml:S1:9297:9	O
events	SIMPONI.xml:S1:9307:6	O
listed	SIMPONI.xml:S1:9314:6	O
by	SIMPONI.xml:S1:9321:2	O
system	SIMPONI.xml:S1:9324:6	O
organ	SIMPONI.xml:S1:9331:5	O
class	SIMPONI.xml:S1:9337:5	O
:	SIMPONI.xml:S1:9342:1	O

Infections	SIMPONI.xml:S1:9350:10	O
and	SIMPONI.xml:S1:9361:3	O
Infestations	SIMPONI.xml:S1:9365:12	O
:	SIMPONI.xml:S1:9379:1	O
Superficial	SIMPONI.xml:S1:9381:11	B-AdverseReaction
fungal	SIMPONI.xml:S1:9393:6	I-AdverseReaction
infection	SIMPONI.xml:S1:9400:9	I-AdverseReaction
,	SIMPONI.xml:S1:9409:1	O
sinusitis	SIMPONI.xml:S1:9411:9	B-AdverseReaction
,	SIMPONI.xml:S1:9420:1	O
abscess	SIMPONI.xml:S1:9422:7	B-AdverseReaction
,	SIMPONI.xml:S1:9429:1	O
lower	SIMPONI.xml:S1:9431:5	B-AdverseReaction
respiratory	SIMPONI.xml:S1:9437:11	I-AdverseReaction
tract	SIMPONI.xml:S1:9449:5	I-AdverseReaction
infection	SIMPONI.xml:S1:9455:9	I-AdverseReaction
(	SIMPONI.xml:S1:9465:1	O
pneumonia	SIMPONI.xml:S1:9466:9	B-AdverseReaction
)	SIMPONI.xml:S1:9475:1	O
,	SIMPONI.xml:S1:9476:1	O
pyelonephritis	SIMPONI.xml:S1:9478:14	B-AdverseReaction

Investigations	SIMPONI.xml:S1:9499:14	O
:	SIMPONI.xml:S1:9515:1	O
Alanine	SIMPONI.xml:S1:9517:7	B-AdverseReaction
aminotransferase	SIMPONI.xml:S1:9525:16	I-AdverseReaction
increased	SIMPONI.xml:S1:9542:9	I-AdverseReaction
,	SIMPONI.xml:S1:9551:1	O
aspartate	SIMPONI.xml:S1:9553:9	B-AdverseReaction
aminotransferase	SIMPONI.xml:S1:9563:16	I-AdverseReaction
increased	SIMPONI.xml:S1:9580:9	I-AdverseReaction
,	SIMPONI.xml:S1:9589:1	O
neutrophil	SIMPONI.xml:S1:9591:10	B-AdverseReaction
count	SIMPONI.xml:S1:9602:5	I-AdverseReaction
decreased	SIMPONI.xml:S1:9608:9	I-AdverseReaction

Nervous	SIMPONI.xml:S1:9624:7	O
system	SIMPONI.xml:S1:9632:6	O
disorders	SIMPONI.xml:S1:9639:9	O
:	SIMPONI.xml:S1:9650:1	O
Dizziness	SIMPONI.xml:S1:9652:9	B-AdverseReaction
,	SIMPONI.xml:S1:9661:1	O
paresthesia	SIMPONI.xml:S1:9663:11	B-AdverseReaction

Gastrointestinal	SIMPONI.xml:S1:9681:16	O
disorders	SIMPONI.xml:S1:9698:9	O
:	SIMPONI.xml:S1:9709:1	O
Constipation	SIMPONI.xml:S1:9711:12	B-AdverseReaction

6.2	SIMPONI.xml:S1:9730:3	O
Post	SIMPONI.xml:S1:9734:4	O
-	SIMPONI.xml:S1:9738:1	O
marketing	SIMPONI.xml:S1:9739:9	O
Experience	SIMPONI.xml:S1:9749:10	O

There	SIMPONI.xml:S1:9763:5	O
is	SIMPONI.xml:S1:9769:2	O
no	SIMPONI.xml:S1:9772:2	O
post	SIMPONI.xml:S1:9775:4	O
-	SIMPONI.xml:S1:9779:1	O
marketing	SIMPONI.xml:S1:9780:9	O
experience	SIMPONI.xml:S1:9790:10	O
available	SIMPONI.xml:S1:9801:9	O
for	SIMPONI.xml:S1:9811:3	O
SIMPONI	SIMPONI.xml:S1:9815:7	O
ARIA	SIMPONI.xml:S1:9823:4	O
.	SIMPONI.xml:S1:9827:1	O

The	SIMPONI.xml:S1:9829:3	O
following	SIMPONI.xml:S1:9833:9	O
adverse	SIMPONI.xml:S1:9843:7	O
reactions	SIMPONI.xml:S1:9851:9	O
have	SIMPONI.xml:S1:9861:4	O
been	SIMPONI.xml:S1:9866:4	O
identified	SIMPONI.xml:S1:9871:10	O
during	SIMPONI.xml:S1:9882:6	O
post	SIMPONI.xml:S1:9889:4	O
-	SIMPONI.xml:S1:9893:1	O
approval	SIMPONI.xml:S1:9894:8	O
use	SIMPONI.xml:S1:9903:3	O
of	SIMPONI.xml:S1:9907:2	O
the	SIMPONI.xml:S1:9910:3	O
subcutaneous	SIMPONI.xml:S1:9914:12	O
formulation	SIMPONI.xml:S1:9927:11	O
of	SIMPONI.xml:S1:9939:2	O
golimumab	SIMPONI.xml:S1:9942:9	O
.	SIMPONI.xml:S1:9951:1	O

Because	SIMPONI.xml:S1:9953:7	O
these	SIMPONI.xml:S1:9961:5	O
reactions	SIMPONI.xml:S1:9967:9	O
are	SIMPONI.xml:S1:9977:3	O
reported	SIMPONI.xml:S1:9981:8	O
voluntarily	SIMPONI.xml:S1:9990:11	O
from	SIMPONI.xml:S1:10002:4	O
a	SIMPONI.xml:S1:10007:1	O
population	SIMPONI.xml:S1:10009:10	O
of	SIMPONI.xml:S1:10020:2	O
uncertain	SIMPONI.xml:S1:10023:9	O
size	SIMPONI.xml:S1:10033:4	O
,	SIMPONI.xml:S1:10037:1	O
it	SIMPONI.xml:S1:10039:2	O
is	SIMPONI.xml:S1:10042:2	O
not	SIMPONI.xml:S1:10045:3	O
always	SIMPONI.xml:S1:10049:6	O
possible	SIMPONI.xml:S1:10056:8	O
to	SIMPONI.xml:S1:10065:2	O
reliably	SIMPONI.xml:S1:10068:8	O
estimate	SIMPONI.xml:S1:10077:8	O
their	SIMPONI.xml:S1:10086:5	O
frequency	SIMPONI.xml:S1:10092:9	O
or	SIMPONI.xml:S1:10102:2	O
establish	SIMPONI.xml:S1:10105:9	O
a	SIMPONI.xml:S1:10115:1	O
causal	SIMPONI.xml:S1:10117:6	O
relationship	SIMPONI.xml:S1:10124:12	O
to	SIMPONI.xml:S1:10137:2	O
golimumab	SIMPONI.xml:S1:10140:9	O
exposure	SIMPONI.xml:S1:10150:8	O
.	SIMPONI.xml:S1:10158:1	O

Neoplasm	SIMPONI.xml:S1:10166:8	O
Benign	SIMPONI.xml:S1:10175:6	O
and	SIMPONI.xml:S1:10182:3	O
Malignant	SIMPONI.xml:S1:10186:9	O
:	SIMPONI.xml:S1:10197:1	O
Melanoma	SIMPONI.xml:S1:10199:8	B-AdverseReaction
[	SIMPONI.xml:S1:10209:1	O
see	SIMPONI.xml:S1:10210:3	O
Warnings	SIMPONI.xml:S1:10215:8	O
and	SIMPONI.xml:S1:10224:3	O
Precautions	SIMPONI.xml:S1:10228:11	O
(	SIMPONI.xml:S1:10240:1	O
5.2	SIMPONI.xml:S1:10241:3	O
)	SIMPONI.xml:S1:10244:1	O
]	SIMPONI.xml:S1:10247:1	O

Immune	SIMPONI.xml:S1:10257:6	O
System	SIMPONI.xml:S1:10264:6	O
Disorders	SIMPONI.xml:S1:10271:9	O
:	SIMPONI.xml:S1:10282:1	O
Serious	SIMPONI.xml:S1:10284:7	B-Severity
systemic	SIMPONI.xml:S1:10292:8	B-AdverseReaction
hypersensitivity	SIMPONI.xml:S1:10301:16	I-AdverseReaction
reactions	SIMPONI.xml:S1:10318:9	I-AdverseReaction
(	SIMPONI.xml:S1:10328:1	O
including	SIMPONI.xml:S1:10329:9	O
anaphylactic	SIMPONI.xml:S1:10339:12	B-AdverseReaction
reaction	SIMPONI.xml:S1:10352:8	I-AdverseReaction
)	SIMPONI.xml:S1:10360:1	O
[	SIMPONI.xml:S1:10363:1	O
see	SIMPONI.xml:S1:10364:3	O
Warnings	SIMPONI.xml:S1:10369:8	O
and	SIMPONI.xml:S1:10378:3	O
Precautions	SIMPONI.xml:S1:10382:11	O
(	SIMPONI.xml:S1:10394:1	O
5.10	SIMPONI.xml:S1:10395:4	O
)	SIMPONI.xml:S1:10399:1	O
]	SIMPONI.xml:S1:10402:1	O
,	SIMPONI.xml:S1:10405:1	O
sarcoidosis	SIMPONI.xml:S1:10407:11	B-AdverseReaction

Respiratory	SIMPONI.xml:S1:10425:11	O
,	SIMPONI.xml:S1:10436:1	O
thoracic	SIMPONI.xml:S1:10438:8	O
and	SIMPONI.xml:S1:10447:3	O
mediastinal	SIMPONI.xml:S1:10451:11	O
disorders	SIMPONI.xml:S1:10463:9	O
:	SIMPONI.xml:S1:10474:1	O
Interstitial	SIMPONI.xml:S1:10476:12	B-AdverseReaction
lung	SIMPONI.xml:S1:10489:4	I-AdverseReaction
disease	SIMPONI.xml:S1:10494:7	I-AdverseReaction

Skin	SIMPONI.xml:S1:10508:4	O
and	SIMPONI.xml:S1:10513:3	O
subcutaneous	SIMPONI.xml:S1:10517:12	O
tissue	SIMPONI.xml:S1:10530:6	O
disorders	SIMPONI.xml:S1:10537:9	O
:	SIMPONI.xml:S1:10548:1	O
Skin	SIMPONI.xml:S1:10550:4	B-AdverseReaction
exfoliation	SIMPONI.xml:S1:10555:11	I-AdverseReaction
,	SIMPONI.xml:S1:10566:1	O
bullous	SIMPONI.xml:S1:10568:7	B-AdverseReaction
skin	SIMPONI.xml:S1:10576:4	I-AdverseReaction
reactions	SIMPONI.xml:S1:10581:9	I-AdverseReaction
\n\n	SIMPONI.xml:S2:0:2	O
BOXED	SIMPONI.xml:S2:6:5	O
WARNING	SIMPONI.xml:S2:12:7	O
:	SIMPONI.xml:S2:19:1	O
WARNING	SIMPONI.xml:S2:21:7	O
:	SIMPONI.xml:S2:28:1	O
SERIOUS	SIMPONI.xml:S2:30:7	B-Severity
INFECTIONS	SIMPONI.xml:S2:38:10	B-AdverseReaction
AND	SIMPONI.xml:S2:49:3	O
MALIGNANCY	SIMPONI.xml:S2:53:10	B-AdverseReaction
\n\n	SIMPONI.xml:S2:63:2	O
WARNING	SIMPONI.xml:S2:69:7	O
:	SIMPONI.xml:S2:76:1	O
SERIOUS	SIMPONI.xml:S2:78:7	B-Severity
INFECTIONS	SIMPONI.xml:S2:86:10	B-AdverseReaction
AND	SIMPONI.xml:S2:97:3	O
MALIGNANCY	SIMPONI.xml:S2:101:10	B-AdverseReaction
\n\n	SIMPONI.xml:S2:113:2	O
EXCERPT	SIMPONI.xml:S2:117:7	O
:	SIMPONI.xml:S2:124:1	O
WARNING	SIMPONI.xml:S2:128:7	O
:	SIMPONI.xml:S2:135:1	O
SERIOUS	SIMPONI.xml:S2:138:7	B-Severity
INFECTIONS	SIMPONI.xml:S2:146:10	B-AdverseReaction
AND	SIMPONI.xml:S2:157:3	O
MALIGNANCY	SIMPONI.xml:S2:161:10	B-AdverseReaction
\n\n\n\n	SIMPONI.xml:S2:171:4	O
See	SIMPONI.xml:S2:178:3	O
full	SIMPONI.xml:S2:182:4	O
prescribing	SIMPONI.xml:S2:187:11	O
information	SIMPONI.xml:S2:199:11	O
for	SIMPONI.xml:S2:211:3	O
complete	SIMPONI.xml:S2:215:8	O
boxed	SIMPONI.xml:S2:224:5	O
warning	SIMPONI.xml:S2:230:7	O
.	SIMPONI.xml:S2:237:1	O

Serious	SIMPONI.xml:S2:248:7	B-Severity
infections	SIMPONI.xml:S2:256:10	B-AdverseReaction
leading	SIMPONI.xml:S2:267:7	O
to	SIMPONI.xml:S2:275:2	O
hospitalization	SIMPONI.xml:S2:278:15	O
or	SIMPONI.xml:S2:294:2	O
death	SIMPONI.xml:S2:297:5	B-AdverseReaction
including	SIMPONI.xml:S2:303:9	O
tuberculosis	SIMPONI.xml:S2:313:12	B-AdverseReaction
(	SIMPONI.xml:S2:326:1	O
TB	SIMPONI.xml:S2:327:2	B-AdverseReaction
)	SIMPONI.xml:S2:329:1	O
,	SIMPONI.xml:S2:330:1	O
bacterial	SIMPONI.xml:S2:332:9	B-AdverseReaction
sepsis	SIMPONI.xml:S2:342:6	I-AdverseReaction
,	SIMPONI.xml:S2:348:1	O
invasive	SIMPONI.xml:S2:350:8	B-AdverseReaction
fungal	SIMPONI.xml:S2:359:6	I-AdverseReaction
(	SIMPONI.xml:S2:366:1	O
such	SIMPONI.xml:S2:367:4	O
as	SIMPONI.xml:S2:372:2	O
histoplasmosis	SIMPONI.xml:S2:375:14	B-AdverseReaction
)	SIMPONI.xml:S2:389:1	O
,	SIMPONI.xml:S2:390:1	O
and	SIMPONI.xml:S2:392:3	O
other	SIMPONI.xml:S2:396:5	O
opportunistic	SIMPONI.xml:S2:402:13	B-AdverseReaction
infections	SIMPONI.xml:S2:416:10	I-AdverseReaction
have	SIMPONI.xml:S2:427:4	O
occurred	SIMPONI.xml:S2:432:8	O
in	SIMPONI.xml:S2:441:2	O
patients	SIMPONI.xml:S2:444:8	O
receiving	SIMPONI.xml:S2:453:9	O
SIMPONI	SIMPONI.xml:S2:463:7	O
ARIA	SIMPONI.xml:S2:471:4	O
(	SIMPONI.xml:S2:476:1	O
5.1	SIMPONI.xml:S2:477:3	O
)	SIMPONI.xml:S2:480:1	O
.	SIMPONI.xml:S2:481:1	O

Discontinue	SIMPONI.xml:S2:488:11	O
SIMPONI	SIMPONI.xml:S2:500:7	O
ARIA	SIMPONI.xml:S2:508:4	O
if	SIMPONI.xml:S2:513:2	O
a	SIMPONI.xml:S2:516:1	O
patient	SIMPONI.xml:S2:518:7	O
develops	SIMPONI.xml:S2:526:8	O
a	SIMPONI.xml:S2:535:1	O
serious	SIMPONI.xml:S2:537:7	O
infection	SIMPONI.xml:S2:545:9	O
or	SIMPONI.xml:S2:555:2	O
sepsis	SIMPONI.xml:S2:558:6	O
(	SIMPONI.xml:S2:565:1	O
5.1	SIMPONI.xml:S2:566:3	O
)	SIMPONI.xml:S2:569:1	O
.	SIMPONI.xml:S2:570:1	O

Perform	SIMPONI.xml:S2:577:7	O
test	SIMPONI.xml:S2:585:4	O
for	SIMPONI.xml:S2:590:3	O
latent	SIMPONI.xml:S2:594:6	O
TB	SIMPONI.xml:S2:601:2	O
;	SIMPONI.xml:S2:603:1	O
if	SIMPONI.xml:S2:605:2	O
positive	SIMPONI.xml:S2:608:8	O
,	SIMPONI.xml:S2:616:1	O
start	SIMPONI.xml:S2:618:5	O
treatment	SIMPONI.xml:S2:624:9	O
for	SIMPONI.xml:S2:634:3	O
TB	SIMPONI.xml:S2:638:2	O
prior	SIMPONI.xml:S2:641:5	O
to	SIMPONI.xml:S2:647:2	O
starting	SIMPONI.xml:S2:650:8	O
SIMPONI	SIMPONI.xml:S2:659:7	O
ARIA	SIMPONI.xml:S2:667:4	O
(	SIMPONI.xml:S2:672:1	O
5.1	SIMPONI.xml:S2:673:3	O
)	SIMPONI.xml:S2:676:1	O
.	SIMPONI.xml:S2:677:1	O

Monitor	SIMPONI.xml:S2:684:7	O
all	SIMPONI.xml:S2:692:3	O
patients	SIMPONI.xml:S2:696:8	O
for	SIMPONI.xml:S2:705:3	O
active	SIMPONI.xml:S2:709:6	O
TB	SIMPONI.xml:S2:716:2	O
during	SIMPONI.xml:S2:719:6	O
treatment	SIMPONI.xml:S2:726:9	O
,	SIMPONI.xml:S2:735:1	O
even	SIMPONI.xml:S2:737:4	O
if	SIMPONI.xml:S2:742:2	O
initial	SIMPONI.xml:S2:745:7	O
latent	SIMPONI.xml:S2:753:6	O
TB	SIMPONI.xml:S2:760:2	O
test	SIMPONI.xml:S2:763:4	O
is	SIMPONI.xml:S2:768:2	O
negative	SIMPONI.xml:S2:771:8	O
(	SIMPONI.xml:S2:780:1	O
5.1	SIMPONI.xml:S2:781:3	O
)	SIMPONI.xml:S2:784:1	O
.	SIMPONI.xml:S2:785:1	O

Lymphoma	SIMPONI.xml:S2:792:8	B-AdverseReaction
and	SIMPONI.xml:S2:801:3	O
other	SIMPONI.xml:S2:805:5	O
malignancies	SIMPONI.xml:S2:811:12	B-AdverseReaction
,	SIMPONI.xml:S2:823:1	O
some	SIMPONI.xml:S2:825:4	O
fatal	SIMPONI.xml:S2:830:5	B-AdverseReaction
,	SIMPONI.xml:S2:835:1	O
have	SIMPONI.xml:S2:837:4	O
been	SIMPONI.xml:S2:842:4	O
reported	SIMPONI.xml:S2:847:8	O
in	SIMPONI.xml:S2:856:2	O
children	SIMPONI.xml:S2:859:8	O
and	SIMPONI.xml:S2:868:3	O
adolescent	SIMPONI.xml:S2:872:10	O
patients	SIMPONI.xml:S2:883:8	O
treated	SIMPONI.xml:S2:892:7	O
with	SIMPONI.xml:S2:900:4	O
TNF	SIMPONI.xml:S2:905:3	O
blockers	SIMPONI.xml:S2:909:8	O
,	SIMPONI.xml:S2:917:1	O
of	SIMPONI.xml:S2:919:2	O
which	SIMPONI.xml:S2:922:5	O
SIMPONI	SIMPONI.xml:S2:928:7	O
ARIA	SIMPONI.xml:S2:936:4	O
is	SIMPONI.xml:S2:941:2	O
a	SIMPONI.xml:S2:944:1	O
member	SIMPONI.xml:S2:946:6	O
(	SIMPONI.xml:S2:953:1	O
5.2	SIMPONI.xml:S2:954:3	O
)	SIMPONI.xml:S2:957:1	O
.	SIMPONI.xml:S2:958:1	O

SERIOUS	SIMPONI.xml:S2:973:7	O
INFECTIONS	SIMPONI.xml:S2:981:10	O
\n\n\n\n	SIMPONI.xml:S2:993:4	O
Patients	SIMPONI.xml:S2:1000:8	O
treated	SIMPONI.xml:S2:1009:7	O
with	SIMPONI.xml:S2:1017:4	O
SIMPONI	SIMPONI.xml:S2:1022:7	O
ARIA	SIMPONI.xml:S2:1030:4	O
are	SIMPONI.xml:S2:1035:3	O
at	SIMPONI.xml:S2:1039:2	O
increased	SIMPONI.xml:S2:1042:9	O
risk	SIMPONI.xml:S2:1052:4	B-Factor
for	SIMPONI.xml:S2:1057:3	O
developing	SIMPONI.xml:S2:1061:10	O
serious	SIMPONI.xml:S2:1072:7	B-Severity
infections	SIMPONI.xml:S2:1080:10	B-AdverseReaction
that	SIMPONI.xml:S2:1091:4	O
may	SIMPONI.xml:S2:1096:3	B-Factor
lead	SIMPONI.xml:S2:1100:4	O
to	SIMPONI.xml:S2:1105:2	O
hospitalization	SIMPONI.xml:S2:1108:15	O
or	SIMPONI.xml:S2:1124:2	O
death	SIMPONI.xml:S2:1127:5	B-AdverseReaction
[	SIMPONI.xml:S2:1135:1	O
see	SIMPONI.xml:S2:1136:3	O
Warnings	SIMPONI.xml:S2:1142:8	O
and	SIMPONI.xml:S2:1151:3	O
Precautions	SIMPONI.xml:S2:1155:11	O
(	SIMPONI.xml:S2:1167:1	O
5.1	SIMPONI.xml:S2:1168:3	O
)	SIMPONI.xml:S2:1171:1	O
]	SIMPONI.xml:S2:1174:1	O
.	SIMPONI.xml:S2:1177:1	O

Most	SIMPONI.xml:S2:1180:4	O
patients	SIMPONI.xml:S2:1185:8	O
who	SIMPONI.xml:S2:1194:3	O
developed	SIMPONI.xml:S2:1198:9	O
these	SIMPONI.xml:S2:1208:5	O
infections	SIMPONI.xml:S2:1214:10	B-AdverseReaction
were	SIMPONI.xml:S2:1225:4	O
taking	SIMPONI.xml:S2:1230:6	O
concomitant	SIMPONI.xml:S2:1237:11	O
immunosuppressants	SIMPONI.xml:S2:1249:18	O
such	SIMPONI.xml:S2:1268:4	O
as	SIMPONI.xml:S2:1273:2	O
methotrexate	SIMPONI.xml:S2:1276:12	O
or	SIMPONI.xml:S2:1289:2	O
corticosteroids	SIMPONI.xml:S2:1292:15	O
.	SIMPONI.xml:S2:1307:1	O

Discontinue	SIMPONI.xml:S2:1317:11	O
SIMPONI	SIMPONI.xml:S2:1329:7	O
ARIA	SIMPONI.xml:S2:1337:4	O
if	SIMPONI.xml:S2:1342:2	O
a	SIMPONI.xml:S2:1345:1	O
patient	SIMPONI.xml:S2:1347:7	O
develops	SIMPONI.xml:S2:1355:8	O
a	SIMPONI.xml:S2:1364:1	O
serious	SIMPONI.xml:S2:1366:7	O
infection	SIMPONI.xml:S2:1374:9	O
.	SIMPONI.xml:S2:1383:1	O

Reported	SIMPONI.xml:S2:1393:8	O
infections	SIMPONI.xml:S2:1402:10	O
with	SIMPONI.xml:S2:1413:4	O
TNF	SIMPONI.xml:S2:1418:3	O
-	SIMPONI.xml:S2:1421:1	O
blockers	SIMPONI.xml:S2:1422:8	O
,	SIMPONI.xml:S2:1430:1	O
of	SIMPONI.xml:S2:1432:2	O
which	SIMPONI.xml:S2:1435:5	O
SIMPONI	SIMPONI.xml:S2:1441:7	O
ARIA	SIMPONI.xml:S2:1449:4	O
is	SIMPONI.xml:S2:1454:2	O
a	SIMPONI.xml:S2:1457:1	O
member	SIMPONI.xml:S2:1459:6	O
,	SIMPONI.xml:S2:1465:1	O
include	SIMPONI.xml:S2:1467:7	O
:	SIMPONI.xml:S2:1474:1	O
\n\n\n\n	SIMPONI.xml:S2:1477:4	O
Active	SIMPONI.xml:S2:1485:6	B-AdverseReaction
tuberculosis	SIMPONI.xml:S2:1492:12	I-AdverseReaction
,	SIMPONI.xml:S2:1504:1	O
including	SIMPONI.xml:S2:1506:9	O
reactivation	SIMPONI.xml:S2:1516:12	B-AdverseReaction
of	SIMPONI.xml:S2:1529:2	I-AdverseReaction
latent	SIMPONI.xml:S2:1532:6	I-AdverseReaction
tuberculosis	SIMPONI.xml:S2:1539:12	I-AdverseReaction
.	SIMPONI.xml:S2:1551:1	O

Patients	SIMPONI.xml:S2:1553:8	O
with	SIMPONI.xml:S2:1562:4	O
tuberculosis	SIMPONI.xml:S2:1567:12	B-AdverseReaction
have	SIMPONI.xml:S2:1580:4	O
frequently	SIMPONI.xml:S2:1585:10	O
presented	SIMPONI.xml:S2:1596:9	O
with	SIMPONI.xml:S2:1606:4	O
disseminated	SIMPONI.xml:S2:1611:12	I-AdverseReaction
or	SIMPONI.xml:S2:1624:2	O
extrapulmonary	SIMPONI.xml:S2:1627:14	I-AdverseReaction
disease	SIMPONI.xml:S2:1642:7	O
.	SIMPONI.xml:S2:1649:1	O

Test	SIMPONI.xml:S2:1651:4	O
patients	SIMPONI.xml:S2:1656:8	O
for	SIMPONI.xml:S2:1665:3	O
latent	SIMPONI.xml:S2:1669:6	O
tuberculosis	SIMPONI.xml:S2:1676:12	O
before	SIMPONI.xml:S2:1689:6	O
SIMPONI	SIMPONI.xml:S2:1696:7	O
ARIA	SIMPONI.xml:S2:1704:4	O
use	SIMPONI.xml:S2:1709:3	O
and	SIMPONI.xml:S2:1713:3	O
during	SIMPONI.xml:S2:1717:6	O
therapy	SIMPONI.xml:S2:1724:7	O
.	SIMPONI.xml:S2:1731:1	O

Initiate	SIMPONI.xml:S2:1733:8	O
treatment	SIMPONI.xml:S2:1742:9	O
for	SIMPONI.xml:S2:1752:3	O
latent	SIMPONI.xml:S2:1756:6	O
tuberculosis	SIMPONI.xml:S2:1763:12	O
prior	SIMPONI.xml:S2:1776:5	O
to	SIMPONI.xml:S2:1782:2	O
SIMPONI	SIMPONI.xml:S2:1785:7	O
ARIA	SIMPONI.xml:S2:1793:4	O
use	SIMPONI.xml:S2:1798:3	O
.	SIMPONI.xml:S2:1801:1	O

Invasive	SIMPONI.xml:S2:1808:8	B-AdverseReaction
fungal	SIMPONI.xml:S2:1817:6	I-AdverseReaction
infections	SIMPONI.xml:S2:1824:10	I-AdverseReaction
,	SIMPONI.xml:S2:1834:1	O
including	SIMPONI.xml:S2:1836:9	O
histoplasmosis	SIMPONI.xml:S2:1846:14	B-AdverseReaction
,	SIMPONI.xml:S2:1860:1	O
coccidioidomycosis	SIMPONI.xml:S2:1862:18	B-AdverseReaction
,	SIMPONI.xml:S2:1880:1	O
candidiasis	SIMPONI.xml:S2:1882:11	B-AdverseReaction
,	SIMPONI.xml:S2:1893:1	O
aspergillosis	SIMPONI.xml:S2:1895:13	B-AdverseReaction
,	SIMPONI.xml:S2:1908:1	O
blastomycosis	SIMPONI.xml:S2:1910:13	B-AdverseReaction
and	SIMPONI.xml:S2:1924:3	O
pneumocystosis	SIMPONI.xml:S2:1928:14	B-AdverseReaction
.	SIMPONI.xml:S2:1942:1	O

Patients	SIMPONI.xml:S2:1944:8	O
with	SIMPONI.xml:S2:1953:4	O
histoplasmosis	SIMPONI.xml:S2:1958:14	O
or	SIMPONI.xml:S2:1973:2	O
other	SIMPONI.xml:S2:1976:5	O
invasive	SIMPONI.xml:S2:1982:8	O
fungal	SIMPONI.xml:S2:1991:6	O
infections	SIMPONI.xml:S2:1998:10	O
may	SIMPONI.xml:S2:2009:3	O
present	SIMPONI.xml:S2:2013:7	O
with	SIMPONI.xml:S2:2021:4	O
disseminated	SIMPONI.xml:S2:2026:12	O
,	SIMPONI.xml:S2:2038:1	O
rather	SIMPONI.xml:S2:2040:6	O
than	SIMPONI.xml:S2:2047:4	O
localized	SIMPONI.xml:S2:2052:9	O
,	SIMPONI.xml:S2:2061:1	O
disease	SIMPONI.xml:S2:2063:7	O
.	SIMPONI.xml:S2:2070:1	O

Antigen	SIMPONI.xml:S2:2072:7	O
and	SIMPONI.xml:S2:2080:3	O
antibody	SIMPONI.xml:S2:2084:8	O
testing	SIMPONI.xml:S2:2093:7	O
for	SIMPONI.xml:S2:2101:3	O
histoplasmosis	SIMPONI.xml:S2:2105:14	O
may	SIMPONI.xml:S2:2120:3	O
be	SIMPONI.xml:S2:2124:2	O
negative	SIMPONI.xml:S2:2127:8	O
in	SIMPONI.xml:S2:2136:2	O
some	SIMPONI.xml:S2:2139:4	O
patients	SIMPONI.xml:S2:2144:8	O
with	SIMPONI.xml:S2:2153:4	O
active	SIMPONI.xml:S2:2158:6	O
infection	SIMPONI.xml:S2:2165:9	O
.	SIMPONI.xml:S2:2174:1	O

Consider	SIMPONI.xml:S2:2176:8	O
empiric	SIMPONI.xml:S2:2185:7	O
anti	SIMPONI.xml:S2:2193:4	O
-	SIMPONI.xml:S2:2197:1	O
fungal	SIMPONI.xml:S2:2198:6	O
therapy	SIMPONI.xml:S2:2205:7	O
in	SIMPONI.xml:S2:2213:2	O
patients	SIMPONI.xml:S2:2216:8	O
at	SIMPONI.xml:S2:2225:2	O
risk	SIMPONI.xml:S2:2228:4	O
for	SIMPONI.xml:S2:2233:3	O
invasive	SIMPONI.xml:S2:2237:8	O
fungal	SIMPONI.xml:S2:2246:6	O
infections	SIMPONI.xml:S2:2253:10	O
who	SIMPONI.xml:S2:2264:3	O
develop	SIMPONI.xml:S2:2268:7	O
severe	SIMPONI.xml:S2:2276:6	O
systemic	SIMPONI.xml:S2:2283:8	O
illness	SIMPONI.xml:S2:2292:7	O
.	SIMPONI.xml:S2:2299:1	O

Bacterial	SIMPONI.xml:S2:2306:9	B-AdverseReaction
,	SIMPONI.xml:S2:2315:1	O
viral	SIMPONI.xml:S2:2317:5	B-AdverseReaction
,	SIMPONI.xml:S2:2322:1	O
and	SIMPONI.xml:S2:2324:3	O
other	SIMPONI.xml:S2:2328:5	O
infections	SIMPONI.xml:S2:2334:10	I-AdverseReaction
due	SIMPONI.xml:S2:2345:3	I-AdverseReaction
to	SIMPONI.xml:S2:2349:2	I-AdverseReaction
opportunistic	SIMPONI.xml:S2:2352:13	I-AdverseReaction
pathogens	SIMPONI.xml:S2:2366:9	I-AdverseReaction
,	SIMPONI.xml:S2:2375:1	O
including	SIMPONI.xml:S2:2377:9	O
Legionella	SIMPONI.xml:S2:2387:10	I-AdverseReaction
and	SIMPONI.xml:S2:2398:3	O
Listeria	SIMPONI.xml:S2:2402:8	I-AdverseReaction
.	SIMPONI.xml:S2:2410:1	O

Consider	SIMPONI.xml:S2:2419:8	O
the	SIMPONI.xml:S2:2428:3	O
risks	SIMPONI.xml:S2:2432:5	O
and	SIMPONI.xml:S2:2438:3	O
benefits	SIMPONI.xml:S2:2442:8	O
of	SIMPONI.xml:S2:2451:2	O
treatment	SIMPONI.xml:S2:2454:9	O
with	SIMPONI.xml:S2:2464:4	O
SIMPONI	SIMPONI.xml:S2:2469:7	O
ARIA	SIMPONI.xml:S2:2477:4	O
prior	SIMPONI.xml:S2:2482:5	O
to	SIMPONI.xml:S2:2488:2	O
initiating	SIMPONI.xml:S2:2491:10	O
therapy	SIMPONI.xml:S2:2502:7	O
in	SIMPONI.xml:S2:2510:2	O
patients	SIMPONI.xml:S2:2513:8	O
with	SIMPONI.xml:S2:2522:4	O
chronic	SIMPONI.xml:S2:2527:7	O
or	SIMPONI.xml:S2:2535:2	O
recurrent	SIMPONI.xml:S2:2538:9	O
infection	SIMPONI.xml:S2:2548:9	O
.	SIMPONI.xml:S2:2557:1	O

Monitor	SIMPONI.xml:S2:2567:7	O
patients	SIMPONI.xml:S2:2575:8	O
closely	SIMPONI.xml:S2:2584:7	O
for	SIMPONI.xml:S2:2592:3	O
the	SIMPONI.xml:S2:2596:3	O
development	SIMPONI.xml:S2:2600:11	O
of	SIMPONI.xml:S2:2612:2	O
signs	SIMPONI.xml:S2:2615:5	O
and	SIMPONI.xml:S2:2621:3	O
symptoms	SIMPONI.xml:S2:2625:8	O
of	SIMPONI.xml:S2:2634:2	O
infection	SIMPONI.xml:S2:2637:9	O
during	SIMPONI.xml:S2:2647:6	O
and	SIMPONI.xml:S2:2654:3	O
after	SIMPONI.xml:S2:2658:5	O
treatment	SIMPONI.xml:S2:2664:9	O
with	SIMPONI.xml:S2:2674:4	O
SIMPONI	SIMPONI.xml:S2:2679:7	O
ARIA	SIMPONI.xml:S2:2687:4	O
,	SIMPONI.xml:S2:2691:1	O
including	SIMPONI.xml:S2:2693:9	O
the	SIMPONI.xml:S2:2703:3	O
possible	SIMPONI.xml:S2:2707:8	O
development	SIMPONI.xml:S2:2716:11	O
of	SIMPONI.xml:S2:2728:2	O
tuberculosis	SIMPONI.xml:S2:2731:12	O
in	SIMPONI.xml:S2:2744:2	O
patients	SIMPONI.xml:S2:2747:8	O
who	SIMPONI.xml:S2:2756:3	O
tested	SIMPONI.xml:S2:2760:6	O
negative	SIMPONI.xml:S2:2767:8	O
for	SIMPONI.xml:S2:2776:3	O
latent	SIMPONI.xml:S2:2780:6	O
tuberculosis	SIMPONI.xml:S2:2787:12	O
infection	SIMPONI.xml:S2:2800:9	O
prior	SIMPONI.xml:S2:2810:5	O
to	SIMPONI.xml:S2:2816:2	O
initiating	SIMPONI.xml:S2:2819:10	O
therapy	SIMPONI.xml:S2:2830:7	O
[	SIMPONI.xml:S2:2840:1	O
see	SIMPONI.xml:S2:2841:3	O
Warnings	SIMPONI.xml:S2:2847:8	O
and	SIMPONI.xml:S2:2856:3	O
Precautions	SIMPONI.xml:S2:2860:11	O
(	SIMPONI.xml:S2:2872:1	O
5.1	SIMPONI.xml:S2:2873:3	O
)	SIMPONI.xml:S2:2876:1	O
]	SIMPONI.xml:S2:2879:1	O
.	SIMPONI.xml:S2:2882:1	O

MALIGNANCY	SIMPONI.xml:S2:2894:10	O
\n\n\n\n	SIMPONI.xml:S2:2906:4	O
Lymphoma	SIMPONI.xml:S2:2913:8	B-AdverseReaction
and	SIMPONI.xml:S2:2922:3	O
other	SIMPONI.xml:S2:2926:5	O
malignancies	SIMPONI.xml:S2:2932:12	B-AdverseReaction
,	SIMPONI.xml:S2:2944:1	O
some	SIMPONI.xml:S2:2946:4	O
fatal	SIMPONI.xml:S2:2951:5	B-AdverseReaction
,	SIMPONI.xml:S2:2956:1	O
have	SIMPONI.xml:S2:2958:4	O
been	SIMPONI.xml:S2:2963:4	O
reported	SIMPONI.xml:S2:2968:8	O
in	SIMPONI.xml:S2:2977:2	O
children	SIMPONI.xml:S2:2980:8	O
and	SIMPONI.xml:S2:2989:3	O
adolescent	SIMPONI.xml:S2:2993:10	O
patients	SIMPONI.xml:S2:3004:8	O
treated	SIMPONI.xml:S2:3013:7	O
with	SIMPONI.xml:S2:3021:4	O
TNF	SIMPONI.xml:S2:3026:3	O
blockers	SIMPONI.xml:S2:3030:8	O
,	SIMPONI.xml:S2:3038:1	O
of	SIMPONI.xml:S2:3040:2	O
which	SIMPONI.xml:S2:3043:5	O
SIMPONI	SIMPONI.xml:S2:3049:7	O
ARIA	SIMPONI.xml:S2:3057:4	O
is	SIMPONI.xml:S2:3062:2	O
a	SIMPONI.xml:S2:3065:1	O
member	SIMPONI.xml:S2:3067:6	O
[	SIMPONI.xml:S2:3076:1	O
see	SIMPONI.xml:S2:3077:3	O
Warnings	SIMPONI.xml:S2:3083:8	O
and	SIMPONI.xml:S2:3092:3	O
Precautions	SIMPONI.xml:S2:3096:11	O
(	SIMPONI.xml:S2:3108:1	O
5.2	SIMPONI.xml:S2:3109:3	O
)	SIMPONI.xml:S2:3112:1	O
]	SIMPONI.xml:S2:3115:1	O
.	SIMPONI.xml:S2:3118:1	O
\n	SIMPONI.xml:S2:3121:1	O
5	SIMPONI.xml:S3:4:1	O
WARNINGS	SIMPONI.xml:S3:6:8	O
AND	SIMPONI.xml:S3:15:3	O
PRECAUTIONS	SIMPONI.xml:S3:19:11	O

EXCERPT	SIMPONI.xml:S3:37:7	O
:	SIMPONI.xml:S3:44:1	O
Serious	SIMPONI.xml:S3:52:7	B-Severity
infections	SIMPONI.xml:S3:60:10	B-AdverseReaction
-	SIMPONI.xml:S3:71:1	O
Do	SIMPONI.xml:S3:73:2	O
not	SIMPONI.xml:S3:76:3	O
start	SIMPONI.xml:S3:80:5	O
SIMPONI	SIMPONI.xml:S3:86:7	O
ARIA	SIMPONI.xml:S3:94:4	O
during	SIMPONI.xml:S3:99:6	O
an	SIMPONI.xml:S3:106:2	O
active	SIMPONI.xml:S3:109:6	O
infection	SIMPONI.xml:S3:116:9	O
.	SIMPONI.xml:S3:125:1	O

If	SIMPONI.xml:S3:127:2	O
an	SIMPONI.xml:S3:130:2	O
infection	SIMPONI.xml:S3:133:9	O
develops	SIMPONI.xml:S3:143:8	O
,	SIMPONI.xml:S3:151:1	O
monitor	SIMPONI.xml:S3:153:7	O
carefully	SIMPONI.xml:S3:161:9	O
,	SIMPONI.xml:S3:170:1	O
and	SIMPONI.xml:S3:172:3	O
stop	SIMPONI.xml:S3:176:4	O
SIMPONI	SIMPONI.xml:S3:181:7	O
ARIA	SIMPONI.xml:S3:189:4	O
if	SIMPONI.xml:S3:194:2	O
infection	SIMPONI.xml:S3:197:9	O
becomes	SIMPONI.xml:S3:207:7	O
serious	SIMPONI.xml:S3:215:7	O
(	SIMPONI.xml:S3:223:1	O
5.1	SIMPONI.xml:S3:226:3	O
)	SIMPONI.xml:S3:231:1	O
.	SIMPONI.xml:S3:232:1	O

Invasive	SIMPONI.xml:S3:239:8	B-AdverseReaction
fungal	SIMPONI.xml:S3:248:6	I-AdverseReaction
infections	SIMPONI.xml:S3:255:10	I-AdverseReaction
-	SIMPONI.xml:S3:266:1	O
For	SIMPONI.xml:S3:268:3	O
patients	SIMPONI.xml:S3:272:8	O
who	SIMPONI.xml:S3:281:3	O
develop	SIMPONI.xml:S3:285:7	O
a	SIMPONI.xml:S3:293:1	O
systemic	SIMPONI.xml:S3:295:8	O
illness	SIMPONI.xml:S3:304:7	O
on	SIMPONI.xml:S3:312:2	O
SIMPONI	SIMPONI.xml:S3:315:7	O
ARIA	SIMPONI.xml:S3:323:4	O
,	SIMPONI.xml:S3:327:1	O
consider	SIMPONI.xml:S3:329:8	O
empiric	SIMPONI.xml:S3:338:7	O
antifungal	SIMPONI.xml:S3:346:10	O
therapy	SIMPONI.xml:S3:357:7	O
for	SIMPONI.xml:S3:365:3	O
those	SIMPONI.xml:S3:369:5	O
who	SIMPONI.xml:S3:375:3	O
reside	SIMPONI.xml:S3:379:6	O
in	SIMPONI.xml:S3:386:2	O
or	SIMPONI.xml:S3:389:2	O
travel	SIMPONI.xml:S3:392:6	O
to	SIMPONI.xml:S3:399:2	O
regions	SIMPONI.xml:S3:402:7	O
where	SIMPONI.xml:S3:410:5	O
mycoses	SIMPONI.xml:S3:416:7	O
are	SIMPONI.xml:S3:424:3	O
endemic	SIMPONI.xml:S3:428:7	O
(	SIMPONI.xml:S3:436:1	O
5.1	SIMPONI.xml:S3:439:3	O
)	SIMPONI.xml:S3:444:1	O
.	SIMPONI.xml:S3:445:1	O

Hepatitis	SIMPONI.xml:S3:452:9	B-AdverseReaction
B	SIMPONI.xml:S3:462:1	I-AdverseReaction
reactivation	SIMPONI.xml:S3:464:12	I-AdverseReaction
-	SIMPONI.xml:S3:477:1	O
Monitor	SIMPONI.xml:S3:479:7	O
HBV	SIMPONI.xml:S3:487:3	O
carriers	SIMPONI.xml:S3:491:8	O
during	SIMPONI.xml:S3:500:6	O
and	SIMPONI.xml:S3:507:3	O
several	SIMPONI.xml:S3:511:7	O
months	SIMPONI.xml:S3:519:6	O
after	SIMPONI.xml:S3:526:5	O
therapy	SIMPONI.xml:S3:532:7	O
.	SIMPONI.xml:S3:539:1	O

If	SIMPONI.xml:S3:541:2	O
reactivation	SIMPONI.xml:S3:544:12	O
occurs	SIMPONI.xml:S3:557:6	O
,	SIMPONI.xml:S3:563:1	O
stop	SIMPONI.xml:S3:565:4	O
SIMPONI	SIMPONI.xml:S3:570:7	O
ARIA	SIMPONI.xml:S3:578:4	O
and	SIMPONI.xml:S3:583:3	O
begin	SIMPONI.xml:S3:587:5	O
anti	SIMPONI.xml:S3:593:4	O
-	SIMPONI.xml:S3:597:1	O
viral	SIMPONI.xml:S3:598:5	O
therapy	SIMPONI.xml:S3:604:7	O
(	SIMPONI.xml:S3:612:1	O
5.1	SIMPONI.xml:S3:615:3	O
)	SIMPONI.xml:S3:620:1	O
.	SIMPONI.xml:S3:621:1	O

Malignancies	SIMPONI.xml:S3:628:12	B-AdverseReaction
-	SIMPONI.xml:S3:641:1	O
More	SIMPONI.xml:S3:643:4	O
cases	SIMPONI.xml:S3:648:5	O
of	SIMPONI.xml:S3:654:2	O
lymphoma	SIMPONI.xml:S3:657:8	B-AdverseReaction
have	SIMPONI.xml:S3:666:4	O
been	SIMPONI.xml:S3:671:4	O
observed	SIMPONI.xml:S3:676:8	O
among	SIMPONI.xml:S3:685:5	O
patients	SIMPONI.xml:S3:691:8	O
receiving	SIMPONI.xml:S3:700:9	O
TNF	SIMPONI.xml:S3:710:3	O
-	SIMPONI.xml:S3:713:1	O
blockers	SIMPONI.xml:S3:714:8	O
compared	SIMPONI.xml:S3:723:8	O
with	SIMPONI.xml:S3:732:4	O
patients	SIMPONI.xml:S3:737:8	O
in	SIMPONI.xml:S3:746:2	O
the	SIMPONI.xml:S3:749:3	O
control	SIMPONI.xml:S3:753:7	O
groups	SIMPONI.xml:S3:761:6	O
.	SIMPONI.xml:S3:767:1	O

Cases	SIMPONI.xml:S3:769:5	O
of	SIMPONI.xml:S3:775:2	O
other	SIMPONI.xml:S3:778:5	O
malignancies	SIMPONI.xml:S3:784:12	B-AdverseReaction
have	SIMPONI.xml:S3:797:4	O
been	SIMPONI.xml:S3:802:4	O
observed	SIMPONI.xml:S3:807:8	O
among	SIMPONI.xml:S3:816:5	O
patients	SIMPONI.xml:S3:822:8	O
receiving	SIMPONI.xml:S3:831:9	O
TNF	SIMPONI.xml:S3:841:3	O
-	SIMPONI.xml:S3:844:1	O
blockers	SIMPONI.xml:S3:845:8	O
(	SIMPONI.xml:S3:854:1	O
5.2	SIMPONI.xml:S3:857:3	O
)	SIMPONI.xml:S3:862:1	O
.	SIMPONI.xml:S3:863:1	O

Heart	SIMPONI.xml:S3:870:5	B-AdverseReaction
failure	SIMPONI.xml:S3:876:7	I-AdverseReaction
-	SIMPONI.xml:S3:884:1	O
Worsening	SIMPONI.xml:S3:886:9	I-AdverseReaction
,	SIMPONI.xml:S3:895:1	O
or	SIMPONI.xml:S3:897:2	O
new	SIMPONI.xml:S3:900:3	I-AdverseReaction
onset	SIMPONI.xml:S3:904:5	I-AdverseReaction
,	SIMPONI.xml:S3:909:1	O
may	SIMPONI.xml:S3:911:3	B-Factor
occur	SIMPONI.xml:S3:915:5	O
.	SIMPONI.xml:S3:920:1	O

Stop	SIMPONI.xml:S3:922:4	O
SIMPONI	SIMPONI.xml:S3:927:7	O
ARIA	SIMPONI.xml:S3:935:4	O
if	SIMPONI.xml:S3:940:2	O
new	SIMPONI.xml:S3:943:3	O
or	SIMPONI.xml:S3:947:2	O
worsening	SIMPONI.xml:S3:950:9	O
symptoms	SIMPONI.xml:S3:960:8	O
occur	SIMPONI.xml:S3:969:5	O
(	SIMPONI.xml:S3:975:1	O
5.3	SIMPONI.xml:S3:978:3	O
)	SIMPONI.xml:S3:983:1	O
.	SIMPONI.xml:S3:984:1	O

Demyelinating	SIMPONI.xml:S3:991:13	B-AdverseReaction
disease	SIMPONI.xml:S3:1005:7	I-AdverseReaction
,	SIMPONI.xml:S3:1012:1	O
exacerbation	SIMPONI.xml:S3:1014:12	I-AdverseReaction
or	SIMPONI.xml:S3:1027:2	O
new	SIMPONI.xml:S3:1030:3	I-AdverseReaction
onset	SIMPONI.xml:S3:1034:5	I-AdverseReaction
,	SIMPONI.xml:S3:1039:1	O
may	SIMPONI.xml:S3:1041:3	B-Factor
occur	SIMPONI.xml:S3:1045:5	O
(	SIMPONI.xml:S3:1051:1	O
5.4	SIMPONI.xml:S3:1054:3	O
)	SIMPONI.xml:S3:1059:1	O
.	SIMPONI.xml:S3:1060:1	O

Hypersensitivity	SIMPONI.xml:S3:1067:16	B-AdverseReaction
reactions	SIMPONI.xml:S3:1084:9	I-AdverseReaction
:	SIMPONI.xml:S3:1093:1	O
Serious	SIMPONI.xml:S3:1095:7	B-Severity
systemic	SIMPONI.xml:S3:1103:8	B-AdverseReaction
hypersensitivity	SIMPONI.xml:S3:1112:16	I-AdverseReaction
reactions	SIMPONI.xml:S3:1129:9	I-AdverseReaction
including	SIMPONI.xml:S3:1139:9	O
anaphylaxis	SIMPONI.xml:S3:1149:11	B-AdverseReaction
may	SIMPONI.xml:S3:1161:3	B-Factor
occur	SIMPONI.xml:S3:1165:5	O
(	SIMPONI.xml:S3:1171:1	O
5.10	SIMPONI.xml:S3:1174:4	O
)	SIMPONI.xml:S3:1180:1	O
.	SIMPONI.xml:S3:1181:1	O

5.1	SIMPONI.xml:S3:1195:3	O

Serious	SIMPONI.xml:S3:1199:7	O

Infections	SIMPONI.xml:S3:1207:10	O

Patients	SIMPONI.xml:S3:1223:8	O
treated	SIMPONI.xml:S3:1232:7	O
with	SIMPONI.xml:S3:1240:4	O
SIMPONI	SIMPONI.xml:S3:1245:7	O
ARIA	SIMPONI.xml:S3:1253:4	O
are	SIMPONI.xml:S3:1258:3	O
at	SIMPONI.xml:S3:1262:2	O
increased	SIMPONI.xml:S3:1265:9	O
risk	SIMPONI.xml:S3:1275:4	B-Factor
for	SIMPONI.xml:S3:1280:3	O
developing	SIMPONI.xml:S3:1284:10	O
serious	SIMPONI.xml:S3:1295:7	B-Severity
infections	SIMPONI.xml:S3:1303:10	B-AdverseReaction
involving	SIMPONI.xml:S3:1314:9	O
various	SIMPONI.xml:S3:1324:7	O
organ	SIMPONI.xml:S3:1332:5	O
systems	SIMPONI.xml:S3:1338:7	O
and	SIMPONI.xml:S3:1346:3	O
sites	SIMPONI.xml:S3:1350:5	O
that	SIMPONI.xml:S3:1356:4	O
may	SIMPONI.xml:S3:1361:3	B-Factor
lead	SIMPONI.xml:S3:1365:4	O
to	SIMPONI.xml:S3:1370:2	O
hospitalization	SIMPONI.xml:S3:1373:15	O
or	SIMPONI.xml:S3:1389:2	O
death	SIMPONI.xml:S3:1392:5	B-AdverseReaction
.	SIMPONI.xml:S3:1397:1	O

Opportunistic	SIMPONI.xml:S3:1403:13	B-AdverseReaction
infections	SIMPONI.xml:S3:1417:10	I-AdverseReaction
due	SIMPONI.xml:S3:1428:3	O
to	SIMPONI.xml:S3:1432:2	O
bacterial	SIMPONI.xml:S3:1435:9	I-AdverseReaction
,	SIMPONI.xml:S3:1444:1	O
mycobacterial	SIMPONI.xml:S3:1446:13	I-AdverseReaction
,	SIMPONI.xml:S3:1459:1	O
invasive	SIMPONI.xml:S3:1461:8	I-AdverseReaction
fungal	SIMPONI.xml:S3:1470:6	I-AdverseReaction
,	SIMPONI.xml:S3:1476:1	O
viral	SIMPONI.xml:S3:1478:5	I-AdverseReaction
,	SIMPONI.xml:S3:1483:1	O
or	SIMPONI.xml:S3:1485:2	O
parasitic	SIMPONI.xml:S3:1488:9	I-AdverseReaction
organisms	SIMPONI.xml:S3:1498:9	O
including	SIMPONI.xml:S3:1508:9	O
aspergillosis	SIMPONI.xml:S3:1518:13	B-AdverseReaction
,	SIMPONI.xml:S3:1531:1	O
blastomycosis	SIMPONI.xml:S3:1533:13	B-AdverseReaction
,	SIMPONI.xml:S3:1546:1	O
candidiasis	SIMPONI.xml:S3:1548:11	B-AdverseReaction
,	SIMPONI.xml:S3:1559:1	O
coccidioidomycosis	SIMPONI.xml:S3:1561:18	B-AdverseReaction
,	SIMPONI.xml:S3:1579:1	O
histoplasmosis	SIMPONI.xml:S3:1581:14	B-AdverseReaction
,	SIMPONI.xml:S3:1595:1	O
legionellosis	SIMPONI.xml:S3:1597:13	B-AdverseReaction
,	SIMPONI.xml:S3:1610:1	O
listeriosis	SIMPONI.xml:S3:1612:11	B-AdverseReaction
,	SIMPONI.xml:S3:1623:1	O
pneumocystosis	SIMPONI.xml:S3:1625:14	B-AdverseReaction
,	SIMPONI.xml:S3:1639:1	O
and	SIMPONI.xml:S3:1641:3	O
tuberculosis	SIMPONI.xml:S3:1645:12	B-AdverseReaction
have	SIMPONI.xml:S3:1658:4	O
been	SIMPONI.xml:S3:1663:4	O
reported	SIMPONI.xml:S3:1668:8	O
with	SIMPONI.xml:S3:1677:4	O
TNF	SIMPONI.xml:S3:1682:3	B-DrugClass
-	SIMPONI.xml:S3:1685:1	I-DrugClass
blockers	SIMPONI.xml:S3:1686:8	I-DrugClass
.	SIMPONI.xml:S3:1694:1	O

Patients	SIMPONI.xml:S3:1696:8	O
have	SIMPONI.xml:S3:1705:4	O
frequently	SIMPONI.xml:S3:1710:10	O
presented	SIMPONI.xml:S3:1721:9	O
with	SIMPONI.xml:S3:1731:4	O
disseminated	SIMPONI.xml:S3:1736:12	O
rather	SIMPONI.xml:S3:1749:6	O
than	SIMPONI.xml:S3:1756:4	O
localized	SIMPONI.xml:S3:1761:9	O
disease	SIMPONI.xml:S3:1771:7	O
.	SIMPONI.xml:S3:1778:1	O

The	SIMPONI.xml:S3:1780:3	O
concomitant	SIMPONI.xml:S3:1784:11	O
use	SIMPONI.xml:S3:1796:3	O
of	SIMPONI.xml:S3:1800:2	O
a	SIMPONI.xml:S3:1803:1	O
TNF	SIMPONI.xml:S3:1805:3	O
-	SIMPONI.xml:S3:1808:1	O
blocker	SIMPONI.xml:S3:1809:7	O
and	SIMPONI.xml:S3:1817:3	O
abatacept	SIMPONI.xml:S3:1821:9	O
or	SIMPONI.xml:S3:1831:2	O
anakinra	SIMPONI.xml:S3:1834:8	O
was	SIMPONI.xml:S3:1843:3	O
associated	SIMPONI.xml:S3:1847:10	O
with	SIMPONI.xml:S3:1858:4	O
a	SIMPONI.xml:S3:1863:1	O
higher	SIMPONI.xml:S3:1865:6	O
risk	SIMPONI.xml:S3:1872:4	O
of	SIMPONI.xml:S3:1877:2	O
serious	SIMPONI.xml:S3:1880:7	O
infections	SIMPONI.xml:S3:1888:10	O
;	SIMPONI.xml:S3:1898:1	O
therefore	SIMPONI.xml:S3:1900:9	O
,	SIMPONI.xml:S3:1909:1	O
the	SIMPONI.xml:S3:1911:3	O
concomitant	SIMPONI.xml:S3:1915:11	O
use	SIMPONI.xml:S3:1927:3	O
of	SIMPONI.xml:S3:1931:2	O
SIMPONI	SIMPONI.xml:S3:1934:7	O
ARIA	SIMPONI.xml:S3:1942:4	O
and	SIMPONI.xml:S3:1947:3	O
these	SIMPONI.xml:S3:1951:5	O
biologic	SIMPONI.xml:S3:1957:8	O
products	SIMPONI.xml:S3:1966:8	O
is	SIMPONI.xml:S3:1975:2	O
not	SIMPONI.xml:S3:1978:3	O
recommended	SIMPONI.xml:S3:1982:11	O
[	SIMPONI.xml:S3:1994:1	O
see	SIMPONI.xml:S3:1995:3	O
Warnings	SIMPONI.xml:S3:2000:8	O
and	SIMPONI.xml:S3:2009:3	O
Precautions	SIMPONI.xml:S3:2013:11	O
(	SIMPONI.xml:S3:2025:1	O
5.5	SIMPONI.xml:S3:2026:3	O
,	SIMPONI.xml:S3:2031:1	O
5.6	SIMPONI.xml:S3:2034:3	O
)	SIMPONI.xml:S3:2039:1	O
and	SIMPONI.xml:S3:2041:3	O
Drug	SIMPONI.xml:S3:2046:4	O
Interactions	SIMPONI.xml:S3:2051:12	O
(	SIMPONI.xml:S3:2064:1	O
7.2	SIMPONI.xml:S3:2065:3	O
)	SIMPONI.xml:S3:2068:1	O
]	SIMPONI.xml:S3:2071:1	O
.	SIMPONI.xml:S3:2074:1	O

Treatment	SIMPONI.xml:S3:2080:9	O
with	SIMPONI.xml:S3:2090:4	O
SIMPONI	SIMPONI.xml:S3:2095:7	O
ARIA	SIMPONI.xml:S3:2103:4	O
should	SIMPONI.xml:S3:2108:6	O
not	SIMPONI.xml:S3:2115:3	O
be	SIMPONI.xml:S3:2119:2	O
initiated	SIMPONI.xml:S3:2122:9	O
in	SIMPONI.xml:S3:2132:2	O
patients	SIMPONI.xml:S3:2135:8	O
with	SIMPONI.xml:S3:2144:4	O
an	SIMPONI.xml:S3:2149:2	O
active	SIMPONI.xml:S3:2152:6	O
infection	SIMPONI.xml:S3:2159:9	O
,	SIMPONI.xml:S3:2168:1	O
including	SIMPONI.xml:S3:2170:9	O
clinically	SIMPONI.xml:S3:2180:10	O
important	SIMPONI.xml:S3:2191:9	O
localized	SIMPONI.xml:S3:2201:9	O
infections	SIMPONI.xml:S3:2211:10	O
.	SIMPONI.xml:S3:2221:1	O

Patients	SIMPONI.xml:S3:2223:8	O
greater	SIMPONI.xml:S3:2232:7	O
than	SIMPONI.xml:S3:2240:4	O
65	SIMPONI.xml:S3:2245:2	O
years	SIMPONI.xml:S3:2248:5	O
of	SIMPONI.xml:S3:2254:2	O
age	SIMPONI.xml:S3:2257:3	O
,	SIMPONI.xml:S3:2260:1	O
patients	SIMPONI.xml:S3:2262:8	O
with	SIMPONI.xml:S3:2271:4	O
co	SIMPONI.xml:S3:2276:2	O
-	SIMPONI.xml:S3:2278:1	O
morbid	SIMPONI.xml:S3:2279:6	O
conditions	SIMPONI.xml:S3:2286:10	O
and	SIMPONI.xml:S3:2297:3	O
or	SIMPONI.xml:S3:2301:2	O
patients	SIMPONI.xml:S3:2304:8	O
taking	SIMPONI.xml:S3:2313:6	O
concomitant	SIMPONI.xml:S3:2320:11	O
immunosuppressants	SIMPONI.xml:S3:2332:18	O
such	SIMPONI.xml:S3:2351:4	O
as	SIMPONI.xml:S3:2356:2	O
corticosteroids	SIMPONI.xml:S3:2359:15	O
or	SIMPONI.xml:S3:2375:2	O
methotrexate	SIMPONI.xml:S3:2378:12	O
may	SIMPONI.xml:S3:2391:3	O
be	SIMPONI.xml:S3:2395:2	O
at	SIMPONI.xml:S3:2398:2	O
greater	SIMPONI.xml:S3:2401:7	O
risk	SIMPONI.xml:S3:2409:4	O
of	SIMPONI.xml:S3:2414:2	O
infection	SIMPONI.xml:S3:2417:9	O
.	SIMPONI.xml:S3:2426:1	O

Consider	SIMPONI.xml:S3:2428:8	O
the	SIMPONI.xml:S3:2437:3	O
risks	SIMPONI.xml:S3:2441:5	O
and	SIMPONI.xml:S3:2447:3	O
benefits	SIMPONI.xml:S3:2451:8	O
of	SIMPONI.xml:S3:2460:2	O
treatment	SIMPONI.xml:S3:2463:9	O
prior	SIMPONI.xml:S3:2473:5	O
to	SIMPONI.xml:S3:2479:2	O
initiating	SIMPONI.xml:S3:2482:10	O
SIMPONI	SIMPONI.xml:S3:2493:7	O
ARIA	SIMPONI.xml:S3:2501:4	O
in	SIMPONI.xml:S3:2506:2	O
patients	SIMPONI.xml:S3:2509:8	O
:	SIMPONI.xml:S3:2517:1	O

with	SIMPONI.xml:S3:2526:4	O
chronic	SIMPONI.xml:S3:2531:7	O
or	SIMPONI.xml:S3:2539:2	O
recurrent	SIMPONI.xml:S3:2542:9	O
infection	SIMPONI.xml:S3:2552:9	O
;	SIMPONI.xml:S3:2561:1	O

who	SIMPONI.xml:S3:2568:3	O
have	SIMPONI.xml:S3:2572:4	O
been	SIMPONI.xml:S3:2577:4	O
exposed	SIMPONI.xml:S3:2582:7	O
to	SIMPONI.xml:S3:2590:2	O
tuberculosis	SIMPONI.xml:S3:2593:12	O
;	SIMPONI.xml:S3:2605:1	O

with	SIMPONI.xml:S3:2612:4	O
a	SIMPONI.xml:S3:2617:1	O
history	SIMPONI.xml:S3:2619:7	O
of	SIMPONI.xml:S3:2627:2	O
an	SIMPONI.xml:S3:2630:2	O
opportunistic	SIMPONI.xml:S3:2633:13	O
infection	SIMPONI.xml:S3:2647:9	O
;	SIMPONI.xml:S3:2656:1	O

who	SIMPONI.xml:S3:2663:3	O
have	SIMPONI.xml:S3:2667:4	O
resided	SIMPONI.xml:S3:2672:7	O
or	SIMPONI.xml:S3:2680:2	O
traveled	SIMPONI.xml:S3:2683:8	O
in	SIMPONI.xml:S3:2692:2	O
areas	SIMPONI.xml:S3:2695:5	O
of	SIMPONI.xml:S3:2701:2	O
endemic	SIMPONI.xml:S3:2704:7	O
tuberculosis	SIMPONI.xml:S3:2712:12	O
or	SIMPONI.xml:S3:2725:2	O
endemic	SIMPONI.xml:S3:2728:7	O
mycoses	SIMPONI.xml:S3:2736:7	O
,	SIMPONI.xml:S3:2743:1	O
such	SIMPONI.xml:S3:2745:4	O
as	SIMPONI.xml:S3:2750:2	O
histoplasmosis	SIMPONI.xml:S3:2753:14	O
,	SIMPONI.xml:S3:2767:1	O
coccidioidomycosis	SIMPONI.xml:S3:2769:18	O
,	SIMPONI.xml:S3:2787:1	O
or	SIMPONI.xml:S3:2789:2	O
blastomycosis	SIMPONI.xml:S3:2792:13	O
;	SIMPONI.xml:S3:2805:1	O
or	SIMPONI.xml:S3:2807:2	O

with	SIMPONI.xml:S3:2815:4	O
underlying	SIMPONI.xml:S3:2820:10	O
conditions	SIMPONI.xml:S3:2831:10	O
that	SIMPONI.xml:S3:2842:4	O
may	SIMPONI.xml:S3:2847:3	O
predispose	SIMPONI.xml:S3:2851:10	O
them	SIMPONI.xml:S3:2862:4	O
to	SIMPONI.xml:S3:2867:2	O
infection	SIMPONI.xml:S3:2870:9	O
.	SIMPONI.xml:S3:2879:1	O

Monitoring	SIMPONI.xml:S3:2889:10	O

Closely	SIMPONI.xml:S3:2906:7	O

monitor	SIMPONI.xml:S3:2914:7	O
patients	SIMPONI.xml:S3:2922:8	O
for	SIMPONI.xml:S3:2931:3	O
the	SIMPONI.xml:S3:2935:3	O
development	SIMPONI.xml:S3:2939:11	O
of	SIMPONI.xml:S3:2951:2	O
signs	SIMPONI.xml:S3:2954:5	O
and	SIMPONI.xml:S3:2960:3	O
symptoms	SIMPONI.xml:S3:2964:8	O
of	SIMPONI.xml:S3:2973:2	O
infection	SIMPONI.xml:S3:2976:9	O
during	SIMPONI.xml:S3:2986:6	O
and	SIMPONI.xml:S3:2993:3	O
after	SIMPONI.xml:S3:2997:5	O
treatment	SIMPONI.xml:S3:3003:9	O
with	SIMPONI.xml:S3:3013:4	O
SIMPONI	SIMPONI.xml:S3:3018:7	O
ARIA	SIMPONI.xml:S3:3026:4	O
.	SIMPONI.xml:S3:3030:1	O

Discontinue	SIMPONI.xml:S3:3032:11	O
SIMPONI	SIMPONI.xml:S3:3044:7	O
ARIA	SIMPONI.xml:S3:3052:4	O
if	SIMPONI.xml:S3:3057:2	O
a	SIMPONI.xml:S3:3060:1	O
patient	SIMPONI.xml:S3:3062:7	O
develops	SIMPONI.xml:S3:3070:8	O
a	SIMPONI.xml:S3:3079:1	O
serious	SIMPONI.xml:S3:3081:7	O
infection	SIMPONI.xml:S3:3089:9	O
,	SIMPONI.xml:S3:3098:1	O
an	SIMPONI.xml:S3:3100:2	O
opportunistic	SIMPONI.xml:S3:3103:13	O
infection	SIMPONI.xml:S3:3117:9	O
,	SIMPONI.xml:S3:3126:1	O
or	SIMPONI.xml:S3:3128:2	O
sepsis	SIMPONI.xml:S3:3131:6	O
.	SIMPONI.xml:S3:3137:1	O

For	SIMPONI.xml:S3:3139:3	O
patients	SIMPONI.xml:S3:3143:8	O
who	SIMPONI.xml:S3:3152:3	O
develop	SIMPONI.xml:S3:3156:7	O
a	SIMPONI.xml:S3:3164:1	O
new	SIMPONI.xml:S3:3166:3	O
infection	SIMPONI.xml:S3:3170:9	O
during	SIMPONI.xml:S3:3180:6	O
treatment	SIMPONI.xml:S3:3187:9	O
with	SIMPONI.xml:S3:3197:4	O
SIMPONI	SIMPONI.xml:S3:3202:7	O
ARIA	SIMPONI.xml:S3:3210:4	O
,	SIMPONI.xml:S3:3214:1	O
perform	SIMPONI.xml:S3:3216:7	O
a	SIMPONI.xml:S3:3224:1	O
prompt	SIMPONI.xml:S3:3226:6	O
and	SIMPONI.xml:S3:3233:3	O
complete	SIMPONI.xml:S3:3237:8	O
diagnostic	SIMPONI.xml:S3:3246:10	O
workup	SIMPONI.xml:S3:3257:6	O
appropriate	SIMPONI.xml:S3:3264:11	O
for	SIMPONI.xml:S3:3276:3	O
an	SIMPONI.xml:S3:3280:2	O
immunocompromised	SIMPONI.xml:S3:3283:17	O
patient	SIMPONI.xml:S3:3301:7	O
and	SIMPONI.xml:S3:3309:3	O
initiate	SIMPONI.xml:S3:3313:8	O
appropriate	SIMPONI.xml:S3:3322:11	O
antimicrobial	SIMPONI.xml:S3:3334:13	O
therapy	SIMPONI.xml:S3:3348:7	O
and	SIMPONI.xml:S3:3356:3	O
closely	SIMPONI.xml:S3:3360:7	O
monitor	SIMPONI.xml:S3:3368:7	O
them	SIMPONI.xml:S3:3376:4	O
.	SIMPONI.xml:S3:3380:1	O

Tuberculosis	SIMPONI.xml:S3:3389:12	O

Cases	SIMPONI.xml:S3:3408:5	O
of	SIMPONI.xml:S3:3414:2	O
reactivation	SIMPONI.xml:S3:3417:12	B-AdverseReaction
of	SIMPONI.xml:S3:3430:2	I-AdverseReaction
tuberculosis	SIMPONI.xml:S3:3433:12	I-AdverseReaction
or	SIMPONI.xml:S3:3446:2	O
new	SIMPONI.xml:S3:3449:3	B-AdverseReaction
tuberculosis	SIMPONI.xml:S3:3453:12	I-AdverseReaction
infections	SIMPONI.xml:S3:3466:10	I-AdverseReaction
have	SIMPONI.xml:S3:3477:4	O
been	SIMPONI.xml:S3:3482:4	O
observed	SIMPONI.xml:S3:3487:8	O
in	SIMPONI.xml:S3:3496:2	O
patients	SIMPONI.xml:S3:3499:8	O
receiving	SIMPONI.xml:S3:3508:9	O
TNF	SIMPONI.xml:S3:3518:3	O
-	SIMPONI.xml:S3:3521:1	O
blockers	SIMPONI.xml:S3:3522:8	O
,	SIMPONI.xml:S3:3530:1	O
including	SIMPONI.xml:S3:3532:9	O
patients	SIMPONI.xml:S3:3542:8	O
who	SIMPONI.xml:S3:3551:3	O
have	SIMPONI.xml:S3:3555:4	O
previously	SIMPONI.xml:S3:3560:10	O
received	SIMPONI.xml:S3:3571:8	O
treatment	SIMPONI.xml:S3:3580:9	O
for	SIMPONI.xml:S3:3590:3	O
latent	SIMPONI.xml:S3:3594:6	O
or	SIMPONI.xml:S3:3601:2	O
active	SIMPONI.xml:S3:3604:6	O
tuberculosis	SIMPONI.xml:S3:3611:12	O
.	SIMPONI.xml:S3:3623:1	O

Evaluate	SIMPONI.xml:S3:3625:8	O
patients	SIMPONI.xml:S3:3634:8	O
for	SIMPONI.xml:S3:3643:3	O
tuberculosis	SIMPONI.xml:S3:3647:12	O
risk	SIMPONI.xml:S3:3660:4	O
factors	SIMPONI.xml:S3:3665:7	O
and	SIMPONI.xml:S3:3673:3	O
test	SIMPONI.xml:S3:3677:4	O
for	SIMPONI.xml:S3:3682:3	O
latent	SIMPONI.xml:S3:3686:6	O
infection	SIMPONI.xml:S3:3693:9	O
prior	SIMPONI.xml:S3:3703:5	O
to	SIMPONI.xml:S3:3709:2	O
initiating	SIMPONI.xml:S3:3712:10	O
SIMPONI	SIMPONI.xml:S3:3723:7	O
ARIA	SIMPONI.xml:S3:3731:4	O
and	SIMPONI.xml:S3:3736:3	O
periodically	SIMPONI.xml:S3:3740:12	O
during	SIMPONI.xml:S3:3753:6	O
therapy	SIMPONI.xml:S3:3760:7	O
.	SIMPONI.xml:S3:3767:1	O

Treatment	SIMPONI.xml:S3:3773:9	O
of	SIMPONI.xml:S3:3783:2	O
latent	SIMPONI.xml:S3:3786:6	O
tuberculosis	SIMPONI.xml:S3:3793:12	O
infection	SIMPONI.xml:S3:3806:9	O
prior	SIMPONI.xml:S3:3816:5	O
to	SIMPONI.xml:S3:3822:2	O
therapy	SIMPONI.xml:S3:3825:7	O
with	SIMPONI.xml:S3:3833:4	O
TNF	SIMPONI.xml:S3:3838:3	O
-	SIMPONI.xml:S3:3841:1	O
blockers	SIMPONI.xml:S3:3842:8	O
has	SIMPONI.xml:S3:3851:3	O
been	SIMPONI.xml:S3:3855:4	O
shown	SIMPONI.xml:S3:3860:5	O
to	SIMPONI.xml:S3:3866:2	O
reduce	SIMPONI.xml:S3:3869:6	O
the	SIMPONI.xml:S3:3876:3	O
risk	SIMPONI.xml:S3:3880:4	O
of	SIMPONI.xml:S3:3885:2	O
tuberculosis	SIMPONI.xml:S3:3888:12	O
reactivation	SIMPONI.xml:S3:3901:12	O
during	SIMPONI.xml:S3:3914:6	O
therapy	SIMPONI.xml:S3:3921:7	O
.	SIMPONI.xml:S3:3928:1	O

Prior	SIMPONI.xml:S3:3930:5	O
to	SIMPONI.xml:S3:3936:2	O
initiating	SIMPONI.xml:S3:3939:10	O
SIMPONI	SIMPONI.xml:S3:3950:7	O
ARIA	SIMPONI.xml:S3:3958:4	O
,	SIMPONI.xml:S3:3962:1	O
assess	SIMPONI.xml:S3:3964:6	O
if	SIMPONI.xml:S3:3971:2	O
treatment	SIMPONI.xml:S3:3974:9	O
for	SIMPONI.xml:S3:3984:3	O
latent	SIMPONI.xml:S3:3988:6	O
tuberculosis	SIMPONI.xml:S3:3995:12	O
is	SIMPONI.xml:S3:4008:2	O
needed	SIMPONI.xml:S3:4011:6	O
;	SIMPONI.xml:S3:4017:1	O
An	SIMPONI.xml:S3:4019:2	O
induration	SIMPONI.xml:S3:4022:10	O
of	SIMPONI.xml:S3:4033:2	O
5	SIMPONI.xml:S3:4036:1	O
mm	SIMPONI.xml:S3:4038:2	O
or	SIMPONI.xml:S3:4041:2	O
greater	SIMPONI.xml:S3:4044:7	O
is	SIMPONI.xml:S3:4052:2	O
a	SIMPONI.xml:S3:4055:1	O
positive	SIMPONI.xml:S3:4057:8	O
tuberculin	SIMPONI.xml:S3:4066:10	O
skin	SIMPONI.xml:S3:4077:4	O
test	SIMPONI.xml:S3:4082:4	O
,	SIMPONI.xml:S3:4086:1	O
even	SIMPONI.xml:S3:4088:4	O
for	SIMPONI.xml:S3:4093:3	O
patients	SIMPONI.xml:S3:4097:8	O
previously	SIMPONI.xml:S3:4106:10	O
vaccinated	SIMPONI.xml:S3:4117:10	O
with	SIMPONI.xml:S3:4128:4	O
Bacille	SIMPONI.xml:S3:4133:7	O
Calmette	SIMPONI.xml:S3:4141:8	O
-	SIMPONI.xml:S3:4149:1	O
Guerin	SIMPONI.xml:S3:4150:6	O
(	SIMPONI.xml:S3:4157:1	O
BCG	SIMPONI.xml:S3:4158:3	O
)	SIMPONI.xml:S3:4161:1	O
.	SIMPONI.xml:S3:4162:1	O

Consider	SIMPONI.xml:S3:4168:8	O
anti	SIMPONI.xml:S3:4177:4	O
-	SIMPONI.xml:S3:4181:1	O
tuberculosis	SIMPONI.xml:S3:4182:12	O
therapy	SIMPONI.xml:S3:4195:7	O
prior	SIMPONI.xml:S3:4203:5	O
to	SIMPONI.xml:S3:4209:2	O
initiation	SIMPONI.xml:S3:4212:10	O
of	SIMPONI.xml:S3:4223:2	O
SIMPONI	SIMPONI.xml:S3:4226:7	O
ARIA	SIMPONI.xml:S3:4234:4	O
in	SIMPONI.xml:S3:4239:2	O
patients	SIMPONI.xml:S3:4242:8	O
with	SIMPONI.xml:S3:4251:4	O
a	SIMPONI.xml:S3:4256:1	O
past	SIMPONI.xml:S3:4258:4	O
history	SIMPONI.xml:S3:4263:7	O
of	SIMPONI.xml:S3:4271:2	O
latent	SIMPONI.xml:S3:4274:6	O
or	SIMPONI.xml:S3:4281:2	O
active	SIMPONI.xml:S3:4284:6	O
tuberculosis	SIMPONI.xml:S3:4291:12	O
in	SIMPONI.xml:S3:4304:2	O
whom	SIMPONI.xml:S3:4307:4	O
an	SIMPONI.xml:S3:4312:2	O
adequate	SIMPONI.xml:S3:4315:8	O
course	SIMPONI.xml:S3:4324:6	O
of	SIMPONI.xml:S3:4331:2	O
treatment	SIMPONI.xml:S3:4334:9	O
cannot	SIMPONI.xml:S3:4344:6	O
be	SIMPONI.xml:S3:4351:2	O
confirmed	SIMPONI.xml:S3:4354:9	O
,	SIMPONI.xml:S3:4363:1	O
and	SIMPONI.xml:S3:4365:3	O
for	SIMPONI.xml:S3:4369:3	O
patients	SIMPONI.xml:S3:4373:8	O
with	SIMPONI.xml:S3:4382:4	O
a	SIMPONI.xml:S3:4387:1	O
negative	SIMPONI.xml:S3:4389:8	O
test	SIMPONI.xml:S3:4398:4	O
for	SIMPONI.xml:S3:4403:3	O
latent	SIMPONI.xml:S3:4407:6	O
tuberculosis	SIMPONI.xml:S3:4414:12	O
but	SIMPONI.xml:S3:4427:3	O
having	SIMPONI.xml:S3:4431:6	O
risk	SIMPONI.xml:S3:4438:4	O
factors	SIMPONI.xml:S3:4443:7	O
for	SIMPONI.xml:S3:4451:3	O
tuberculosis	SIMPONI.xml:S3:4455:12	O
infection	SIMPONI.xml:S3:4468:9	O
.	SIMPONI.xml:S3:4477:1	O

Consultation	SIMPONI.xml:S3:4479:12	O
with	SIMPONI.xml:S3:4492:4	O
a	SIMPONI.xml:S3:4497:1	O
physician	SIMPONI.xml:S3:4499:9	O
with	SIMPONI.xml:S3:4509:4	O
expertise	SIMPONI.xml:S3:4514:9	O
in	SIMPONI.xml:S3:4524:2	O
the	SIMPONI.xml:S3:4527:3	O
treatment	SIMPONI.xml:S3:4531:9	O
of	SIMPONI.xml:S3:4541:2	O
tuberculosis	SIMPONI.xml:S3:4544:12	O
is	SIMPONI.xml:S3:4557:2	O
recommended	SIMPONI.xml:S3:4560:11	O
to	SIMPONI.xml:S3:4572:2	O
aid	SIMPONI.xml:S3:4575:3	O
in	SIMPONI.xml:S3:4579:2	O
the	SIMPONI.xml:S3:4582:3	O
decision	SIMPONI.xml:S3:4586:8	O
whether	SIMPONI.xml:S3:4595:7	O
initiating	SIMPONI.xml:S3:4603:10	O
anti	SIMPONI.xml:S3:4614:4	O
-	SIMPONI.xml:S3:4618:1	O
tuberculosis	SIMPONI.xml:S3:4619:12	O
therapy	SIMPONI.xml:S3:4632:7	O
is	SIMPONI.xml:S3:4640:2	O
appropriate	SIMPONI.xml:S3:4643:11	O
for	SIMPONI.xml:S3:4655:3	O
an	SIMPONI.xml:S3:4659:2	O
individual	SIMPONI.xml:S3:4662:10	O
patient	SIMPONI.xml:S3:4673:7	O
.	SIMPONI.xml:S3:4680:1	O

Cases	SIMPONI.xml:S3:4687:5	O
of	SIMPONI.xml:S3:4693:2	O
active	SIMPONI.xml:S3:4696:6	O
tuberculosis	SIMPONI.xml:S3:4703:12	O
have	SIMPONI.xml:S3:4716:4	O
occurred	SIMPONI.xml:S3:4721:8	O
in	SIMPONI.xml:S3:4730:2	O
patients	SIMPONI.xml:S3:4733:8	O
treated	SIMPONI.xml:S3:4742:7	O
with	SIMPONI.xml:S3:4750:4	O
the	SIMPONI.xml:S3:4755:3	O
subcutaneous	SIMPONI.xml:S3:4759:12	O
formulation	SIMPONI.xml:S3:4772:11	O
of	SIMPONI.xml:S3:4784:2	O
golimumab	SIMPONI.xml:S3:4787:9	O
during	SIMPONI.xml:S3:4797:6	O
and	SIMPONI.xml:S3:4804:3	O
after	SIMPONI.xml:S3:4808:5	O
treatment	SIMPONI.xml:S3:4814:9	O
for	SIMPONI.xml:S3:4824:3	O
latent	SIMPONI.xml:S3:4828:6	O
tuberculosis	SIMPONI.xml:S3:4835:12	O
.	SIMPONI.xml:S3:4847:1	O

Monitor	SIMPONI.xml:S3:4849:7	O
patients	SIMPONI.xml:S3:4857:8	O
for	SIMPONI.xml:S3:4866:3	O
the	SIMPONI.xml:S3:4870:3	O
development	SIMPONI.xml:S3:4874:11	O
of	SIMPONI.xml:S3:4886:2	O
signs	SIMPONI.xml:S3:4889:5	O
and	SIMPONI.xml:S3:4895:3	O
symptoms	SIMPONI.xml:S3:4899:8	O
of	SIMPONI.xml:S3:4908:2	O
tuberculosis	SIMPONI.xml:S3:4911:12	O
including	SIMPONI.xml:S3:4924:9	O
patients	SIMPONI.xml:S3:4934:8	O
who	SIMPONI.xml:S3:4943:3	O
tested	SIMPONI.xml:S3:4947:6	O
negative	SIMPONI.xml:S3:4954:8	O
for	SIMPONI.xml:S3:4963:3	O
latent	SIMPONI.xml:S3:4967:6	O
tuberculosis	SIMPONI.xml:S3:4974:12	O
infection	SIMPONI.xml:S3:4987:9	O
prior	SIMPONI.xml:S3:4997:5	O
to	SIMPONI.xml:S3:5003:2	O
initiating	SIMPONI.xml:S3:5006:10	O
therapy	SIMPONI.xml:S3:5017:7	O
,	SIMPONI.xml:S3:5024:1	O
patients	SIMPONI.xml:S3:5026:8	O
who	SIMPONI.xml:S3:5035:3	O
are	SIMPONI.xml:S3:5039:3	O
on	SIMPONI.xml:S3:5043:2	O
treatment	SIMPONI.xml:S3:5046:9	O
for	SIMPONI.xml:S3:5056:3	O
latent	SIMPONI.xml:S3:5060:6	O
tuberculosis	SIMPONI.xml:S3:5067:12	O
,	SIMPONI.xml:S3:5079:1	O
or	SIMPONI.xml:S3:5081:2	O
patients	SIMPONI.xml:S3:5084:8	O
who	SIMPONI.xml:S3:5093:3	O
were	SIMPONI.xml:S3:5097:4	O
previously	SIMPONI.xml:S3:5102:10	O
treated	SIMPONI.xml:S3:5113:7	O
for	SIMPONI.xml:S3:5121:3	O
tuberculosis	SIMPONI.xml:S3:5125:12	O
infection	SIMPONI.xml:S3:5138:9	O
.	SIMPONI.xml:S3:5147:1	O

Consider	SIMPONI.xml:S3:5155:8	O
tuberculosis	SIMPONI.xml:S3:5164:12	O
in	SIMPONI.xml:S3:5177:2	O
the	SIMPONI.xml:S3:5180:3	O
differential	SIMPONI.xml:S3:5184:12	O
diagnosis	SIMPONI.xml:S3:5197:9	O
in	SIMPONI.xml:S3:5207:2	O
patients	SIMPONI.xml:S3:5210:8	O
who	SIMPONI.xml:S3:5219:3	O
develop	SIMPONI.xml:S3:5223:7	O
a	SIMPONI.xml:S3:5231:1	O
new	SIMPONI.xml:S3:5233:3	O
infection	SIMPONI.xml:S3:5237:9	O
during	SIMPONI.xml:S3:5247:6	O
SIMPONI	SIMPONI.xml:S3:5254:7	O
ARIA	SIMPONI.xml:S3:5262:4	O
treatment	SIMPONI.xml:S3:5267:9	O
,	SIMPONI.xml:S3:5276:1	O
especially	SIMPONI.xml:S3:5278:10	O
in	SIMPONI.xml:S3:5289:2	O
patients	SIMPONI.xml:S3:5292:8	O
who	SIMPONI.xml:S3:5301:3	O
have	SIMPONI.xml:S3:5305:4	O
previously	SIMPONI.xml:S3:5310:10	O
or	SIMPONI.xml:S3:5321:2	O
recently	SIMPONI.xml:S3:5324:8	O
traveled	SIMPONI.xml:S3:5333:8	O
to	SIMPONI.xml:S3:5342:2	O
countries	SIMPONI.xml:S3:5345:9	O
with	SIMPONI.xml:S3:5355:4	O
a	SIMPONI.xml:S3:5360:1	O
high	SIMPONI.xml:S3:5362:4	O
prevalence	SIMPONI.xml:S3:5367:10	O
of	SIMPONI.xml:S3:5378:2	O
tuberculosis	SIMPONI.xml:S3:5381:12	O
,	SIMPONI.xml:S3:5393:1	O
or	SIMPONI.xml:S3:5395:2	O
who	SIMPONI.xml:S3:5398:3	O
have	SIMPONI.xml:S3:5402:4	O
had	SIMPONI.xml:S3:5407:3	O
close	SIMPONI.xml:S3:5411:5	O
contact	SIMPONI.xml:S3:5417:7	O
with	SIMPONI.xml:S3:5425:4	O
a	SIMPONI.xml:S3:5430:1	O
person	SIMPONI.xml:S3:5432:6	O
with	SIMPONI.xml:S3:5439:4	O
active	SIMPONI.xml:S3:5444:6	O
tuberculosis	SIMPONI.xml:S3:5451:12	O
.	SIMPONI.xml:S3:5463:1	O

Invasive	SIMPONI.xml:S3:5472:8	O
Fungal	SIMPONI.xml:S3:5481:6	O
Infections	SIMPONI.xml:S3:5488:10	O

If	SIMPONI.xml:S3:5505:2	O
patients	SIMPONI.xml:S3:5508:8	O
develop	SIMPONI.xml:S3:5517:7	O
a	SIMPONI.xml:S3:5525:1	O
serious	SIMPONI.xml:S3:5527:7	O
systemic	SIMPONI.xml:S3:5535:8	O
illness	SIMPONI.xml:S3:5544:7	O
and	SIMPONI.xml:S3:5552:3	O
they	SIMPONI.xml:S3:5556:4	O
reside	SIMPONI.xml:S3:5561:6	O
or	SIMPONI.xml:S3:5568:2	O
travel	SIMPONI.xml:S3:5571:6	O
in	SIMPONI.xml:S3:5578:2	O
regions	SIMPONI.xml:S3:5581:7	O
where	SIMPONI.xml:S3:5589:5	O
mycoses	SIMPONI.xml:S3:5595:7	O
are	SIMPONI.xml:S3:5603:3	O
endemic	SIMPONI.xml:S3:5607:7	O
,	SIMPONI.xml:S3:5614:1	O
consider	SIMPONI.xml:S3:5616:8	O
invasive	SIMPONI.xml:S3:5625:8	O
fungal	SIMPONI.xml:S3:5634:6	O
infection	SIMPONI.xml:S3:5641:9	O
in	SIMPONI.xml:S3:5651:2	O
the	SIMPONI.xml:S3:5654:3	O
differential	SIMPONI.xml:S3:5658:12	O
diagnosis	SIMPONI.xml:S3:5671:9	O
.	SIMPONI.xml:S3:5680:1	O

Consider	SIMPONI.xml:S3:5682:8	O
appropriate	SIMPONI.xml:S3:5691:11	O
empiric	SIMPONI.xml:S3:5703:7	O
antifungal	SIMPONI.xml:S3:5711:10	O
therapy	SIMPONI.xml:S3:5722:7	O
and	SIMPONI.xml:S3:5730:3	O
take	SIMPONI.xml:S3:5734:4	O
into	SIMPONI.xml:S3:5739:4	O
account	SIMPONI.xml:S3:5744:7	O
both	SIMPONI.xml:S3:5752:4	O
the	SIMPONI.xml:S3:5757:3	O
risk	SIMPONI.xml:S3:5761:4	O
for	SIMPONI.xml:S3:5766:3	O
severe	SIMPONI.xml:S3:5770:6	O
fungal	SIMPONI.xml:S3:5777:6	O
infection	SIMPONI.xml:S3:5784:9	O
and	SIMPONI.xml:S3:5794:3	O
the	SIMPONI.xml:S3:5798:3	O
risks	SIMPONI.xml:S3:5802:5	O
of	SIMPONI.xml:S3:5808:2	O
antifungal	SIMPONI.xml:S3:5811:10	O
therapy	SIMPONI.xml:S3:5822:7	O
while	SIMPONI.xml:S3:5830:5	O
a	SIMPONI.xml:S3:5836:1	O
diagnostic	SIMPONI.xml:S3:5838:10	O
workup	SIMPONI.xml:S3:5849:6	O
is	SIMPONI.xml:S3:5856:2	O
being	SIMPONI.xml:S3:5859:5	O
performed	SIMPONI.xml:S3:5865:9	O
.	SIMPONI.xml:S3:5874:1	O

Antigen	SIMPONI.xml:S3:5876:7	O
and	SIMPONI.xml:S3:5884:3	O
antibody	SIMPONI.xml:S3:5888:8	O
testing	SIMPONI.xml:S3:5897:7	O
for	SIMPONI.xml:S3:5905:3	O
histoplasmosis	SIMPONI.xml:S3:5909:14	O
may	SIMPONI.xml:S3:5924:3	O
be	SIMPONI.xml:S3:5928:2	O
negative	SIMPONI.xml:S3:5931:8	O
in	SIMPONI.xml:S3:5940:2	O
some	SIMPONI.xml:S3:5943:4	O
patients	SIMPONI.xml:S3:5948:8	O
with	SIMPONI.xml:S3:5957:4	O
active	SIMPONI.xml:S3:5962:6	O
infection	SIMPONI.xml:S3:5969:9	O
.	SIMPONI.xml:S3:5978:1	O

To	SIMPONI.xml:S3:5980:2	O
aid	SIMPONI.xml:S3:5983:3	O
in	SIMPONI.xml:S3:5987:2	O
the	SIMPONI.xml:S3:5990:3	O
management	SIMPONI.xml:S3:5994:10	O
of	SIMPONI.xml:S3:6005:2	O
such	SIMPONI.xml:S3:6008:4	O
patients	SIMPONI.xml:S3:6013:8	O
,	SIMPONI.xml:S3:6021:1	O
consider	SIMPONI.xml:S3:6023:8	O
consultation	SIMPONI.xml:S3:6032:12	O
with	SIMPONI.xml:S3:6045:4	O
a	SIMPONI.xml:S3:6050:1	O
physician	SIMPONI.xml:S3:6052:9	O
with	SIMPONI.xml:S3:6062:4	O
expertise	SIMPONI.xml:S3:6067:9	O
in	SIMPONI.xml:S3:6077:2	O
the	SIMPONI.xml:S3:6080:3	O
diagnosis	SIMPONI.xml:S3:6084:9	O
and	SIMPONI.xml:S3:6094:3	O
treatment	SIMPONI.xml:S3:6098:9	O
of	SIMPONI.xml:S3:6108:2	O
invasive	SIMPONI.xml:S3:6111:8	O
fungal	SIMPONI.xml:S3:6120:6	O
infections	SIMPONI.xml:S3:6127:10	O
.	SIMPONI.xml:S3:6137:1	O

Hepatitis	SIMPONI.xml:S3:6146:9	O
B	SIMPONI.xml:S3:6156:1	O
Virus	SIMPONI.xml:S3:6158:5	O
Reactivation	SIMPONI.xml:S3:6164:12	O

The	SIMPONI.xml:S3:6183:3	O
use	SIMPONI.xml:S3:6187:3	O
of	SIMPONI.xml:S3:6191:2	O
TNF	SIMPONI.xml:S3:6194:3	O
-	SIMPONI.xml:S3:6197:1	O
blockers	SIMPONI.xml:S3:6198:8	O
,	SIMPONI.xml:S3:6206:1	O
of	SIMPONI.xml:S3:6208:2	O
which	SIMPONI.xml:S3:6211:5	O
SIMPONI	SIMPONI.xml:S3:6217:7	O
ARIA	SIMPONI.xml:S3:6225:4	O
is	SIMPONI.xml:S3:6230:2	O
a	SIMPONI.xml:S3:6233:1	O
member	SIMPONI.xml:S3:6235:6	O
,	SIMPONI.xml:S3:6241:1	O
has	SIMPONI.xml:S3:6243:3	O
been	SIMPONI.xml:S3:6247:4	O
associated	SIMPONI.xml:S3:6252:10	O
with	SIMPONI.xml:S3:6263:4	O
reactivation	SIMPONI.xml:S3:6268:12	B-AdverseReaction
of	SIMPONI.xml:S3:6281:2	I-AdverseReaction
hepatitis	SIMPONI.xml:S3:6284:9	I-AdverseReaction
B	SIMPONI.xml:S3:6294:1	I-AdverseReaction
virus	SIMPONI.xml:S3:6296:5	I-AdverseReaction
(	SIMPONI.xml:S3:6302:1	O
HBV	SIMPONI.xml:S3:6303:3	I-AdverseReaction
)	SIMPONI.xml:S3:6306:1	O
in	SIMPONI.xml:S3:6308:2	O
patients	SIMPONI.xml:S3:6311:8	O
who	SIMPONI.xml:S3:6320:3	O
are	SIMPONI.xml:S3:6324:3	O
chronic	SIMPONI.xml:S3:6328:7	O
hepatitis	SIMPONI.xml:S3:6336:9	O
B	SIMPONI.xml:S3:6346:1	O
carriers	SIMPONI.xml:S3:6348:8	O
(	SIMPONI.xml:S3:6357:1	O
i	SIMPONI.xml:S3:6358:1	O
.	SIMPONI.xml:S3:6359:1	O
e	SIMPONI.xml:S3:6360:1	O
.	SIMPONI.xml:S3:6361:1	O
,	SIMPONI.xml:S3:6362:1	O
surface	SIMPONI.xml:S3:6364:7	O
antigen	SIMPONI.xml:S3:6372:7	O
positive	SIMPONI.xml:S3:6380:8	O
)	SIMPONI.xml:S3:6388:1	O
.	SIMPONI.xml:S3:6389:1	O

In	SIMPONI.xml:S3:6391:2	O
some	SIMPONI.xml:S3:6394:4	O
instances	SIMPONI.xml:S3:6399:9	O
,	SIMPONI.xml:S3:6408:1	O
HBV	SIMPONI.xml:S3:6410:3	B-AdverseReaction
reactivation	SIMPONI.xml:S3:6414:12	I-AdverseReaction
occurring	SIMPONI.xml:S3:6427:9	O
in	SIMPONI.xml:S3:6437:2	O
conjunction	SIMPONI.xml:S3:6440:11	O
with	SIMPONI.xml:S3:6452:4	O
TNF	SIMPONI.xml:S3:6457:3	O
-	SIMPONI.xml:S3:6460:1	O
blocker	SIMPONI.xml:S3:6461:7	O
therapy	SIMPONI.xml:S3:6469:7	O
has	SIMPONI.xml:S3:6477:3	O
been	SIMPONI.xml:S3:6481:4	O
fatal	SIMPONI.xml:S3:6486:5	B-AdverseReaction
.	SIMPONI.xml:S3:6491:1	O

The	SIMPONI.xml:S3:6493:3	O
majority	SIMPONI.xml:S3:6497:8	O
of	SIMPONI.xml:S3:6506:2	O
these	SIMPONI.xml:S3:6509:5	O
reports	SIMPONI.xml:S3:6515:7	O
have	SIMPONI.xml:S3:6523:4	O
occurred	SIMPONI.xml:S3:6528:8	O
in	SIMPONI.xml:S3:6537:2	O
patients	SIMPONI.xml:S3:6540:8	O
who	SIMPONI.xml:S3:6549:3	O
received	SIMPONI.xml:S3:6553:8	O
concomitant	SIMPONI.xml:S3:6562:11	O
immunosuppressants	SIMPONI.xml:S3:6574:18	O
.	SIMPONI.xml:S3:6592:1	O

All	SIMPONI.xml:S3:6598:3	O
patients	SIMPONI.xml:S3:6602:8	O
should	SIMPONI.xml:S3:6611:6	O
be	SIMPONI.xml:S3:6618:2	O
tested	SIMPONI.xml:S3:6621:6	O
for	SIMPONI.xml:S3:6628:3	O
HBV	SIMPONI.xml:S3:6632:3	O
infection	SIMPONI.xml:S3:6636:9	O
before	SIMPONI.xml:S3:6646:6	O
initiating	SIMPONI.xml:S3:6653:10	O
TNF	SIMPONI.xml:S3:6664:3	O
-	SIMPONI.xml:S3:6667:1	O
blocker	SIMPONI.xml:S3:6668:7	O
therapy	SIMPONI.xml:S3:6676:7	O
.	SIMPONI.xml:S3:6683:1	O

For	SIMPONI.xml:S3:6685:3	O
patients	SIMPONI.xml:S3:6689:8	O
who	SIMPONI.xml:S3:6698:3	O
test	SIMPONI.xml:S3:6702:4	O
positive	SIMPONI.xml:S3:6707:8	O
for	SIMPONI.xml:S3:6716:3	O
hepatitis	SIMPONI.xml:S3:6720:9	O
B	SIMPONI.xml:S3:6730:1	O
surface	SIMPONI.xml:S3:6732:7	O
antigen	SIMPONI.xml:S3:6740:7	O
,	SIMPONI.xml:S3:6747:1	O
consultation	SIMPONI.xml:S3:6749:12	O
with	SIMPONI.xml:S3:6762:4	O
a	SIMPONI.xml:S3:6767:1	O
physician	SIMPONI.xml:S3:6769:9	O
with	SIMPONI.xml:S3:6779:4	O
expertise	SIMPONI.xml:S3:6784:9	O
in	SIMPONI.xml:S3:6794:2	O
the	SIMPONI.xml:S3:6797:3	O
treatment	SIMPONI.xml:S3:6801:9	O
of	SIMPONI.xml:S3:6811:2	O
hepatitis	SIMPONI.xml:S3:6814:9	O
B	SIMPONI.xml:S3:6824:1	O
is	SIMPONI.xml:S3:6826:2	O
recommended	SIMPONI.xml:S3:6829:11	O
before	SIMPONI.xml:S3:6841:6	O
initiating	SIMPONI.xml:S3:6848:10	O
TNF	SIMPONI.xml:S3:6859:3	O
-	SIMPONI.xml:S3:6862:1	O
blocker	SIMPONI.xml:S3:6863:7	O
therapy	SIMPONI.xml:S3:6871:7	O
.	SIMPONI.xml:S3:6878:1	O

The	SIMPONI.xml:S3:6880:3	O
risks	SIMPONI.xml:S3:6884:5	O
and	SIMPONI.xml:S3:6890:3	O
benefits	SIMPONI.xml:S3:6894:8	O
of	SIMPONI.xml:S3:6903:2	O
treatment	SIMPONI.xml:S3:6906:9	O
should	SIMPONI.xml:S3:6916:6	O
be	SIMPONI.xml:S3:6923:2	O
considered	SIMPONI.xml:S3:6926:10	O
prior	SIMPONI.xml:S3:6937:5	O
to	SIMPONI.xml:S3:6943:2	O
prescribing	SIMPONI.xml:S3:6946:11	O
TNF	SIMPONI.xml:S3:6958:3	O
-	SIMPONI.xml:S3:6961:1	O
blockers	SIMPONI.xml:S3:6962:8	O
,	SIMPONI.xml:S3:6970:1	O
including	SIMPONI.xml:S3:6972:9	O
SIMPONI	SIMPONI.xml:S3:6982:7	O
ARIA	SIMPONI.xml:S3:6990:4	O
,	SIMPONI.xml:S3:6994:1	O
to	SIMPONI.xml:S3:6996:2	O
patients	SIMPONI.xml:S3:6999:8	O
who	SIMPONI.xml:S3:7008:3	O
are	SIMPONI.xml:S3:7012:3	O
carriers	SIMPONI.xml:S3:7016:8	O
of	SIMPONI.xml:S3:7025:2	O
HBV	SIMPONI.xml:S3:7028:3	O
.	SIMPONI.xml:S3:7031:1	O

Adequate	SIMPONI.xml:S3:7033:8	O
data	SIMPONI.xml:S3:7042:4	O
are	SIMPONI.xml:S3:7047:3	O
not	SIMPONI.xml:S3:7051:3	O
available	SIMPONI.xml:S3:7055:9	O
on	SIMPONI.xml:S3:7065:2	O
whether	SIMPONI.xml:S3:7068:7	O
anti	SIMPONI.xml:S3:7076:4	O
-	SIMPONI.xml:S3:7080:1	O
viral	SIMPONI.xml:S3:7081:5	O
therapy	SIMPONI.xml:S3:7087:7	O
can	SIMPONI.xml:S3:7095:3	O
reduce	SIMPONI.xml:S3:7099:6	O
the	SIMPONI.xml:S3:7106:3	O
risk	SIMPONI.xml:S3:7110:4	O
of	SIMPONI.xml:S3:7115:2	O
HBV	SIMPONI.xml:S3:7118:3	O
reactivation	SIMPONI.xml:S3:7122:12	O
in	SIMPONI.xml:S3:7135:2	O
HBV	SIMPONI.xml:S3:7138:3	O
carriers	SIMPONI.xml:S3:7142:8	O
who	SIMPONI.xml:S3:7151:3	O
are	SIMPONI.xml:S3:7155:3	O
treated	SIMPONI.xml:S3:7159:7	O
with	SIMPONI.xml:S3:7167:4	O
TNF	SIMPONI.xml:S3:7172:3	O
-	SIMPONI.xml:S3:7175:1	O
blockers	SIMPONI.xml:S3:7176:8	O
.	SIMPONI.xml:S3:7184:1	O

Patients	SIMPONI.xml:S3:7186:8	O
who	SIMPONI.xml:S3:7195:3	O
are	SIMPONI.xml:S3:7199:3	O
carriers	SIMPONI.xml:S3:7203:8	O
of	SIMPONI.xml:S3:7212:2	O
HBV	SIMPONI.xml:S3:7215:3	O
and	SIMPONI.xml:S3:7219:3	O
require	SIMPONI.xml:S3:7223:7	O
treatment	SIMPONI.xml:S3:7231:9	O
with	SIMPONI.xml:S3:7241:4	O
TNF	SIMPONI.xml:S3:7246:3	O
-	SIMPONI.xml:S3:7249:1	O
blockers	SIMPONI.xml:S3:7250:8	O
should	SIMPONI.xml:S3:7259:6	O
be	SIMPONI.xml:S3:7266:2	O
closely	SIMPONI.xml:S3:7269:7	O
monitored	SIMPONI.xml:S3:7277:9	O
for	SIMPONI.xml:S3:7287:3	O
clinical	SIMPONI.xml:S3:7291:8	O
and	SIMPONI.xml:S3:7300:3	O
laboratory	SIMPONI.xml:S3:7304:10	O
signs	SIMPONI.xml:S3:7315:5	O
of	SIMPONI.xml:S3:7321:2	O
active	SIMPONI.xml:S3:7324:6	O
HBV	SIMPONI.xml:S3:7331:3	O
infection	SIMPONI.xml:S3:7335:9	O
throughout	SIMPONI.xml:S3:7345:10	O
therapy	SIMPONI.xml:S3:7356:7	O
and	SIMPONI.xml:S3:7364:3	O
for	SIMPONI.xml:S3:7368:3	O
several	SIMPONI.xml:S3:7372:7	O
months	SIMPONI.xml:S3:7380:6	O
following	SIMPONI.xml:S3:7387:9	O
termination	SIMPONI.xml:S3:7397:11	O
of	SIMPONI.xml:S3:7409:2	O
therapy	SIMPONI.xml:S3:7412:7	O
.	SIMPONI.xml:S3:7419:1	O

In	SIMPONI.xml:S3:7425:2	O
patients	SIMPONI.xml:S3:7428:8	O
who	SIMPONI.xml:S3:7437:3	O
develop	SIMPONI.xml:S3:7441:7	O
HBV	SIMPONI.xml:S3:7449:3	O
reactivation	SIMPONI.xml:S3:7453:12	O
,	SIMPONI.xml:S3:7465:1	O
TNF	SIMPONI.xml:S3:7467:3	O
-	SIMPONI.xml:S3:7470:1	O
blockers	SIMPONI.xml:S3:7471:8	O
should	SIMPONI.xml:S3:7480:6	O
be	SIMPONI.xml:S3:7487:2	O
stopped	SIMPONI.xml:S3:7490:7	O
and	SIMPONI.xml:S3:7498:3	O
antiviral	SIMPONI.xml:S3:7502:9	O
therapy	SIMPONI.xml:S3:7512:7	O
with	SIMPONI.xml:S3:7520:4	O
appropriate	SIMPONI.xml:S3:7525:11	O
supportive	SIMPONI.xml:S3:7537:10	O
treatment	SIMPONI.xml:S3:7548:9	O
should	SIMPONI.xml:S3:7558:6	O
be	SIMPONI.xml:S3:7565:2	O
initiated	SIMPONI.xml:S3:7568:9	O
.	SIMPONI.xml:S3:7577:1	O

The	SIMPONI.xml:S3:7579:3	O
safety	SIMPONI.xml:S3:7583:6	O
of	SIMPONI.xml:S3:7590:2	O
resuming	SIMPONI.xml:S3:7593:8	O
TNF	SIMPONI.xml:S3:7602:3	O
-	SIMPONI.xml:S3:7605:1	O
blockers	SIMPONI.xml:S3:7606:8	O
after	SIMPONI.xml:S3:7615:5	O
HBV	SIMPONI.xml:S3:7621:3	O
reactivation	SIMPONI.xml:S3:7625:12	O
has	SIMPONI.xml:S3:7638:3	O
been	SIMPONI.xml:S3:7642:4	O
controlled	SIMPONI.xml:S3:7647:10	O
is	SIMPONI.xml:S3:7658:2	O
not	SIMPONI.xml:S3:7661:3	O
known	SIMPONI.xml:S3:7665:5	O
.	SIMPONI.xml:S3:7670:1	O

Therefore	SIMPONI.xml:S3:7672:9	O
,	SIMPONI.xml:S3:7681:1	O
prescribers	SIMPONI.xml:S3:7683:11	O
should	SIMPONI.xml:S3:7695:6	O
exercise	SIMPONI.xml:S3:7702:8	O
caution	SIMPONI.xml:S3:7711:7	O
when	SIMPONI.xml:S3:7719:4	O
considering	SIMPONI.xml:S3:7724:11	O
resumption	SIMPONI.xml:S3:7736:10	O
of	SIMPONI.xml:S3:7747:2	O
TNF	SIMPONI.xml:S3:7750:3	O
-	SIMPONI.xml:S3:7753:1	O
blockers	SIMPONI.xml:S3:7754:8	O
in	SIMPONI.xml:S3:7763:2	O
this	SIMPONI.xml:S3:7766:4	O
situation	SIMPONI.xml:S3:7771:9	O
and	SIMPONI.xml:S3:7781:3	O
monitor	SIMPONI.xml:S3:7785:7	O
patients	SIMPONI.xml:S3:7793:8	O
closely	SIMPONI.xml:S3:7802:7	O
.	SIMPONI.xml:S3:7809:1	O

5.2	SIMPONI.xml:S3:7818:3	O
Malignancies	SIMPONI.xml:S3:7822:12	O

Malignancies	SIMPONI.xml:S3:7841:12	O
in	SIMPONI.xml:S3:7854:2	O
Pediatric	SIMPONI.xml:S3:7857:9	O
Patients	SIMPONI.xml:S3:7867:8	O

Malignancies	SIMPONI.xml:S3:7882:12	B-AdverseReaction
,	SIMPONI.xml:S3:7894:1	O
some	SIMPONI.xml:S3:7896:4	O
fatal	SIMPONI.xml:S3:7901:5	B-AdverseReaction
,	SIMPONI.xml:S3:7906:1	O
have	SIMPONI.xml:S3:7908:4	O
been	SIMPONI.xml:S3:7913:4	O
reported	SIMPONI.xml:S3:7918:8	O
among	SIMPONI.xml:S3:7927:5	O
children	SIMPONI.xml:S3:7933:8	O
,	SIMPONI.xml:S3:7941:1	O
adolescents	SIMPONI.xml:S3:7943:11	O
,	SIMPONI.xml:S3:7954:1	O
and	SIMPONI.xml:S3:7956:3	O
young	SIMPONI.xml:S3:7960:5	O
adults	SIMPONI.xml:S3:7966:6	O
who	SIMPONI.xml:S3:7973:3	O
received	SIMPONI.xml:S3:7977:8	O
treatment	SIMPONI.xml:S3:7986:9	O
with	SIMPONI.xml:S3:7996:4	O
TNF	SIMPONI.xml:S3:8001:3	O
-	SIMPONI.xml:S3:8004:1	O
blocking	SIMPONI.xml:S3:8005:8	O
agents	SIMPONI.xml:S3:8014:6	O
(	SIMPONI.xml:S3:8021:1	O
initiation	SIMPONI.xml:S3:8022:10	O
of	SIMPONI.xml:S3:8033:2	O
therapy	SIMPONI.xml:S3:8036:7	O
18	SIMPONI.xml:S3:8047:2	O
years	SIMPONI.xml:S3:8050:5	O
of	SIMPONI.xml:S3:8056:2	O
age	SIMPONI.xml:S3:8059:3	O
)	SIMPONI.xml:S3:8062:1	O
,	SIMPONI.xml:S3:8063:1	O
of	SIMPONI.xml:S3:8065:2	O
which	SIMPONI.xml:S3:8068:5	O
SIMPONI	SIMPONI.xml:S3:8074:7	O
ARIA	SIMPONI.xml:S3:8082:4	O
is	SIMPONI.xml:S3:8087:2	O
a	SIMPONI.xml:S3:8090:1	O
member	SIMPONI.xml:S3:8092:6	O
.	SIMPONI.xml:S3:8098:1	O

Approximately	SIMPONI.xml:S3:8100:13	O
half	SIMPONI.xml:S3:8114:4	O
the	SIMPONI.xml:S3:8119:3	O
cases	SIMPONI.xml:S3:8123:5	O
were	SIMPONI.xml:S3:8129:4	O
lymphomas	SIMPONI.xml:S3:8134:9	B-AdverseReaction
,	SIMPONI.xml:S3:8143:1	O
including	SIMPONI.xml:S3:8145:9	O
Hodgkin	SIMPONI.xml:S3:8155:7	B-AdverseReaction
's	SIMPONI.xml:S3:8162:2	I-AdverseReaction
and	SIMPONI.xml:S3:8165:3	O
non	SIMPONI.xml:S3:8169:3	B-AdverseReaction
-	SIMPONI.xml:S3:8172:1	I-AdverseReaction
Hodgkin	SIMPONI.xml:S3:8173:7	I-AdverseReaction
's	SIMPONI.xml:S3:8180:2	I-AdverseReaction
lymphoma	SIMPONI.xml:S3:8183:8	I-AdverseReaction
.	SIMPONI.xml:S3:8191:1	O

The	SIMPONI.xml:S3:8193:3	O
other	SIMPONI.xml:S3:8197:5	O
cases	SIMPONI.xml:S3:8203:5	O
represented	SIMPONI.xml:S3:8209:11	O
a	SIMPONI.xml:S3:8221:1	O
variety	SIMPONI.xml:S3:8223:7	O
of	SIMPONI.xml:S3:8231:2	O
malignancies	SIMPONI.xml:S3:8234:12	B-AdverseReaction
,	SIMPONI.xml:S3:8246:1	O
including	SIMPONI.xml:S3:8248:9	O
rare	SIMPONI.xml:S3:8258:4	B-AdverseReaction
malignancies	SIMPONI.xml:S3:8263:12	I-AdverseReaction
that	SIMPONI.xml:S3:8276:4	O
are	SIMPONI.xml:S3:8281:3	O
usually	SIMPONI.xml:S3:8285:7	O
associated	SIMPONI.xml:S3:8293:10	O
with	SIMPONI.xml:S3:8304:4	O
immunosuppression	SIMPONI.xml:S3:8309:17	B-AdverseReaction
,	SIMPONI.xml:S3:8326:1	O
and	SIMPONI.xml:S3:8328:3	O
malignancies	SIMPONI.xml:S3:8332:12	O
that	SIMPONI.xml:S3:8345:4	O
are	SIMPONI.xml:S3:8350:3	O
not	SIMPONI.xml:S3:8354:3	O
usually	SIMPONI.xml:S3:8358:7	O
observed	SIMPONI.xml:S3:8366:8	O
in	SIMPONI.xml:S3:8375:2	O
children	SIMPONI.xml:S3:8378:8	O
and	SIMPONI.xml:S3:8387:3	O
adolescents	SIMPONI.xml:S3:8391:11	O
.	SIMPONI.xml:S3:8402:1	O

The	SIMPONI.xml:S3:8404:3	O
malignancies	SIMPONI.xml:S3:8408:12	O
occurred	SIMPONI.xml:S3:8421:8	O
after	SIMPONI.xml:S3:8430:5	O
a	SIMPONI.xml:S3:8436:1	O
median	SIMPONI.xml:S3:8438:6	O
of	SIMPONI.xml:S3:8445:2	O
30	SIMPONI.xml:S3:8448:2	O
months	SIMPONI.xml:S3:8451:6	O
(	SIMPONI.xml:S3:8458:1	O
range	SIMPONI.xml:S3:8459:5	O
1	SIMPONI.xml:S3:8465:1	O
to	SIMPONI.xml:S3:8467:2	O
84	SIMPONI.xml:S3:8470:2	O
months	SIMPONI.xml:S3:8473:6	O
)	SIMPONI.xml:S3:8479:1	O
after	SIMPONI.xml:S3:8481:5	O
the	SIMPONI.xml:S3:8487:3	O
first	SIMPONI.xml:S3:8491:5	O
dose	SIMPONI.xml:S3:8497:4	O
of	SIMPONI.xml:S3:8502:2	O
TNF	SIMPONI.xml:S3:8505:3	O
-	SIMPONI.xml:S3:8508:1	O
blocker	SIMPONI.xml:S3:8509:7	O
therapy	SIMPONI.xml:S3:8517:7	O
.	SIMPONI.xml:S3:8524:1	O

Most	SIMPONI.xml:S3:8526:4	O
of	SIMPONI.xml:S3:8531:2	O
the	SIMPONI.xml:S3:8534:3	O
patients	SIMPONI.xml:S3:8538:8	O
were	SIMPONI.xml:S3:8547:4	O
receiving	SIMPONI.xml:S3:8552:9	O
concomitant	SIMPONI.xml:S3:8562:11	O
immunosuppressants	SIMPONI.xml:S3:8574:18	O
.	SIMPONI.xml:S3:8592:1	O

These	SIMPONI.xml:S3:8594:5	O
cases	SIMPONI.xml:S3:8600:5	O
were	SIMPONI.xml:S3:8606:4	O
reported	SIMPONI.xml:S3:8611:8	O
post	SIMPONI.xml:S3:8620:4	O
-	SIMPONI.xml:S3:8624:1	O
marketing	SIMPONI.xml:S3:8625:9	O
and	SIMPONI.xml:S3:8635:3	O
are	SIMPONI.xml:S3:8639:3	O
derived	SIMPONI.xml:S3:8643:7	O
from	SIMPONI.xml:S3:8651:4	O
a	SIMPONI.xml:S3:8656:1	O
variety	SIMPONI.xml:S3:8658:7	O
of	SIMPONI.xml:S3:8666:2	O
sources	SIMPONI.xml:S3:8669:7	O
,	SIMPONI.xml:S3:8676:1	O
including	SIMPONI.xml:S3:8678:9	O
registries	SIMPONI.xml:S3:8688:10	O
and	SIMPONI.xml:S3:8699:3	O
spontaneous	SIMPONI.xml:S3:8703:11	O
post	SIMPONI.xml:S3:8715:4	O
-	SIMPONI.xml:S3:8719:1	O
marketing	SIMPONI.xml:S3:8720:9	O
reports	SIMPONI.xml:S3:8730:7	O
.	SIMPONI.xml:S3:8737:1	O

Use	SIMPONI.xml:S3:8739:3	O
of	SIMPONI.xml:S3:8743:2	O
SIMPONI	SIMPONI.xml:S3:8746:7	O
ARIA	SIMPONI.xml:S3:8754:4	O
in	SIMPONI.xml:S3:8759:2	O
patients	SIMPONI.xml:S3:8762:8	O
under	SIMPONI.xml:S3:8771:5	O
18	SIMPONI.xml:S3:8777:2	O
years	SIMPONI.xml:S3:8780:5	O
of	SIMPONI.xml:S3:8786:2	O
age	SIMPONI.xml:S3:8789:3	O
has	SIMPONI.xml:S3:8793:3	O
not	SIMPONI.xml:S3:8797:3	O
been	SIMPONI.xml:S3:8801:4	O
established	SIMPONI.xml:S3:8806:11	O
.	SIMPONI.xml:S3:8817:1	O

Malignancies	SIMPONI.xml:S3:8826:12	O
in	SIMPONI.xml:S3:8839:2	O
Adult	SIMPONI.xml:S3:8842:5	O
Patients	SIMPONI.xml:S3:8848:8	O

The	SIMPONI.xml:S3:8863:3	O
risks	SIMPONI.xml:S3:8867:5	O
and	SIMPONI.xml:S3:8873:3	O
benefits	SIMPONI.xml:S3:8877:8	O
of	SIMPONI.xml:S3:8886:2	O
TNF	SIMPONI.xml:S3:8889:3	O
-	SIMPONI.xml:S3:8892:1	O
blocker	SIMPONI.xml:S3:8893:7	O
treatment	SIMPONI.xml:S3:8901:9	O
including	SIMPONI.xml:S3:8911:9	O
SIMPONI	SIMPONI.xml:S3:8921:7	O
ARIA	SIMPONI.xml:S3:8929:4	O
should	SIMPONI.xml:S3:8934:6	O
be	SIMPONI.xml:S3:8941:2	O
considered	SIMPONI.xml:S3:8944:10	O
prior	SIMPONI.xml:S3:8955:5	O
to	SIMPONI.xml:S3:8961:2	O
initiating	SIMPONI.xml:S3:8964:10	O
therapy	SIMPONI.xml:S3:8975:7	O
in	SIMPONI.xml:S3:8983:2	O
patients	SIMPONI.xml:S3:8986:8	O
with	SIMPONI.xml:S3:8995:4	O
a	SIMPONI.xml:S3:9000:1	O
known	SIMPONI.xml:S3:9002:5	O
malignancy	SIMPONI.xml:S3:9008:10	O
other	SIMPONI.xml:S3:9019:5	O
than	SIMPONI.xml:S3:9025:4	O
a	SIMPONI.xml:S3:9030:1	O
successfully	SIMPONI.xml:S3:9032:12	O
treated	SIMPONI.xml:S3:9045:7	O
non	SIMPONI.xml:S3:9053:3	O
-	SIMPONI.xml:S3:9056:1	O
melanoma	SIMPONI.xml:S3:9057:8	O
skin	SIMPONI.xml:S3:9066:4	O
cancer	SIMPONI.xml:S3:9071:6	O
(	SIMPONI.xml:S3:9078:1	O
NMSC	SIMPONI.xml:S3:9079:4	O
)	SIMPONI.xml:S3:9083:1	O
or	SIMPONI.xml:S3:9085:2	O
when	SIMPONI.xml:S3:9088:4	O
considering	SIMPONI.xml:S3:9093:11	O
continuing	SIMPONI.xml:S3:9105:10	O
a	SIMPONI.xml:S3:9116:1	O
TNF	SIMPONI.xml:S3:9118:3	O
-	SIMPONI.xml:S3:9121:1	O
blocker	SIMPONI.xml:S3:9122:7	O
in	SIMPONI.xml:S3:9130:2	O
patients	SIMPONI.xml:S3:9133:8	O
who	SIMPONI.xml:S3:9142:3	O
develop	SIMPONI.xml:S3:9146:7	O
a	SIMPONI.xml:S3:9154:1	O
malignancy	SIMPONI.xml:S3:9156:10	O
.	SIMPONI.xml:S3:9166:1	O

In	SIMPONI.xml:S3:9172:2	O
the	SIMPONI.xml:S3:9175:3	O
controlled	SIMPONI.xml:S3:9179:10	O
portions	SIMPONI.xml:S3:9190:8	O
of	SIMPONI.xml:S3:9199:2	O
clinical	SIMPONI.xml:S3:9202:8	O
trials	SIMPONI.xml:S3:9211:6	O
of	SIMPONI.xml:S3:9218:2	O
TNF	SIMPONI.xml:S3:9221:3	O
-	SIMPONI.xml:S3:9224:1	O
blockers	SIMPONI.xml:S3:9225:8	O
including	SIMPONI.xml:S3:9234:9	O
the	SIMPONI.xml:S3:9244:3	O
subcutaneous	SIMPONI.xml:S3:9248:12	O
formulation	SIMPONI.xml:S3:9261:11	O
of	SIMPONI.xml:S3:9273:2	O
golimumab	SIMPONI.xml:S3:9276:9	O
more	SIMPONI.xml:S3:9286:4	O
cases	SIMPONI.xml:S3:9291:5	O
of	SIMPONI.xml:S3:9297:2	O
lymphoma	SIMPONI.xml:S3:9300:8	B-AdverseReaction
have	SIMPONI.xml:S3:9309:4	O
been	SIMPONI.xml:S3:9314:4	O
observed	SIMPONI.xml:S3:9319:8	O
among	SIMPONI.xml:S3:9328:5	O
patients	SIMPONI.xml:S3:9334:8	O
receiving	SIMPONI.xml:S3:9343:9	O
anti	SIMPONI.xml:S3:9353:4	O
-	SIMPONI.xml:S3:9357:1	O
TNF	SIMPONI.xml:S3:9358:3	O
treatment	SIMPONI.xml:S3:9362:9	O
compared	SIMPONI.xml:S3:9372:8	O
with	SIMPONI.xml:S3:9381:4	O
patients	SIMPONI.xml:S3:9386:8	O
in	SIMPONI.xml:S3:9395:2	O
the	SIMPONI.xml:S3:9398:3	O
control	SIMPONI.xml:S3:9402:7	O
groups	SIMPONI.xml:S3:9410:6	O
.	SIMPONI.xml:S3:9416:1	O

Patients	SIMPONI.xml:S3:9418:8	O
with	SIMPONI.xml:S3:9427:4	O
RA	SIMPONI.xml:S3:9432:2	O
and	SIMPONI.xml:S3:9435:3	O
other	SIMPONI.xml:S3:9439:5	O
chronic	SIMPONI.xml:S3:9445:7	O
inflammatory	SIMPONI.xml:S3:9453:12	O
diseases	SIMPONI.xml:S3:9466:8	O
,	SIMPONI.xml:S3:9474:1	O
particularly	SIMPONI.xml:S3:9476:12	O
patients	SIMPONI.xml:S3:9489:8	O
with	SIMPONI.xml:S3:9498:4	O
highly	SIMPONI.xml:S3:9503:6	O
active	SIMPONI.xml:S3:9510:6	O
disease	SIMPONI.xml:S3:9517:7	O
and	SIMPONI.xml:S3:9525:3	O
or	SIMPONI.xml:S3:9529:2	O
chronic	SIMPONI.xml:S3:9532:7	O
exposure	SIMPONI.xml:S3:9540:8	O
to	SIMPONI.xml:S3:9549:2	O
immunosuppressant	SIMPONI.xml:S3:9552:17	O
therapies	SIMPONI.xml:S3:9570:9	O
,	SIMPONI.xml:S3:9579:1	O
may	SIMPONI.xml:S3:9581:3	O
be	SIMPONI.xml:S3:9585:2	O
at	SIMPONI.xml:S3:9588:2	O
higher	SIMPONI.xml:S3:9591:6	O
risk	SIMPONI.xml:S3:9598:4	B-Factor
(	SIMPONI.xml:S3:9603:1	O
up	SIMPONI.xml:S3:9604:2	O
to	SIMPONI.xml:S3:9607:2	O
several	SIMPONI.xml:S3:9610:7	O
fold	SIMPONI.xml:S3:9618:4	O
)	SIMPONI.xml:S3:9622:1	O
than	SIMPONI.xml:S3:9624:4	O
the	SIMPONI.xml:S3:9629:3	O
general	SIMPONI.xml:S3:9633:7	O
population	SIMPONI.xml:S3:9641:10	O
for	SIMPONI.xml:S3:9652:3	O
the	SIMPONI.xml:S3:9656:3	O
development	SIMPONI.xml:S3:9660:11	O
of	SIMPONI.xml:S3:9672:2	O
lymphoma	SIMPONI.xml:S3:9675:8	B-AdverseReaction
,	SIMPONI.xml:S3:9683:1	O
even	SIMPONI.xml:S3:9685:4	O
in	SIMPONI.xml:S3:9690:2	O
the	SIMPONI.xml:S3:9693:3	O
absence	SIMPONI.xml:S3:9697:7	O
of	SIMPONI.xml:S3:9705:2	O
TNF	SIMPONI.xml:S3:9708:3	O
-	SIMPONI.xml:S3:9711:1	O
blocking	SIMPONI.xml:S3:9712:8	O
therapy	SIMPONI.xml:S3:9721:7	O
.	SIMPONI.xml:S3:9728:1	O

Cases	SIMPONI.xml:S3:9730:5	O
of	SIMPONI.xml:S3:9736:2	O
acute	SIMPONI.xml:S3:9739:5	B-AdverseReaction
and	SIMPONI.xml:S3:9745:3	O
chronic	SIMPONI.xml:S3:9749:7	B-AdverseReaction
leukemia	SIMPONI.xml:S3:9757:8	I-AdverseReaction
have	SIMPONI.xml:S3:9766:4	O
been	SIMPONI.xml:S3:9771:4	O
reported	SIMPONI.xml:S3:9776:8	O
with	SIMPONI.xml:S3:9785:4	O
post	SIMPONI.xml:S3:9790:4	O
-	SIMPONI.xml:S3:9794:1	O
marketing	SIMPONI.xml:S3:9795:9	O
TNF	SIMPONI.xml:S3:9805:3	O
-	SIMPONI.xml:S3:9808:1	O
blocker	SIMPONI.xml:S3:9809:7	O
use	SIMPONI.xml:S3:9817:3	O
in	SIMPONI.xml:S3:9821:2	O
rheumatoid	SIMPONI.xml:S3:9824:10	O
arthritis	SIMPONI.xml:S3:9835:9	O
and	SIMPONI.xml:S3:9845:3	O
other	SIMPONI.xml:S3:9849:5	O
indications	SIMPONI.xml:S3:9855:11	O
.	SIMPONI.xml:S3:9866:1	O

Even	SIMPONI.xml:S3:9868:4	O
in	SIMPONI.xml:S3:9873:2	O
the	SIMPONI.xml:S3:9876:3	O
absence	SIMPONI.xml:S3:9880:7	O
of	SIMPONI.xml:S3:9888:2	O
TNF	SIMPONI.xml:S3:9891:3	O
-	SIMPONI.xml:S3:9894:1	O
blocker	SIMPONI.xml:S3:9895:7	O
therapy	SIMPONI.xml:S3:9903:7	O
,	SIMPONI.xml:S3:9910:1	O
patients	SIMPONI.xml:S3:9912:8	O
with	SIMPONI.xml:S3:9921:4	O
rheumatoid	SIMPONI.xml:S3:9926:10	O
arthritis	SIMPONI.xml:S3:9937:9	O
may	SIMPONI.xml:S3:9947:3	O
be	SIMPONI.xml:S3:9951:2	O
at	SIMPONI.xml:S3:9954:2	O
a	SIMPONI.xml:S3:9957:1	O
higher	SIMPONI.xml:S3:9959:6	O
risk	SIMPONI.xml:S3:9966:4	O
(	SIMPONI.xml:S3:9971:1	O
approximately	SIMPONI.xml:S3:9972:13	O
2	SIMPONI.xml:S3:9986:1	O
-	SIMPONI.xml:S3:9987:1	O
fold	SIMPONI.xml:S3:9988:4	O
)	SIMPONI.xml:S3:9992:1	O
than	SIMPONI.xml:S3:9994:4	O
the	SIMPONI.xml:S3:9999:3	O
general	SIMPONI.xml:S3:10003:7	O
population	SIMPONI.xml:S3:10011:10	O
for	SIMPONI.xml:S3:10022:3	O
the	SIMPONI.xml:S3:10026:3	O
development	SIMPONI.xml:S3:10030:11	O
of	SIMPONI.xml:S3:10042:2	O
leukemia	SIMPONI.xml:S3:10045:8	O
.	SIMPONI.xml:S3:10053:1	O

Rare	SIMPONI.xml:S3:10060:4	O
post	SIMPONI.xml:S3:10065:4	O
-	SIMPONI.xml:S3:10069:1	O
marketing	SIMPONI.xml:S3:10070:9	O
cases	SIMPONI.xml:S3:10080:5	O
of	SIMPONI.xml:S3:10086:2	O
hepatosplenic	SIMPONI.xml:S3:10089:13	B-AdverseReaction
T	SIMPONI.xml:S3:10103:1	I-AdverseReaction
-	SIMPONI.xml:S3:10104:1	I-AdverseReaction
cell	SIMPONI.xml:S3:10105:4	I-AdverseReaction
lymphoma	SIMPONI.xml:S3:10110:8	I-AdverseReaction
(	SIMPONI.xml:S3:10119:1	O
HSTCL	SIMPONI.xml:S3:10120:5	B-AdverseReaction
)	SIMPONI.xml:S3:10125:1	O
have	SIMPONI.xml:S3:10127:4	O
been	SIMPONI.xml:S3:10132:4	O
reported	SIMPONI.xml:S3:10137:8	O
in	SIMPONI.xml:S3:10146:2	O
patients	SIMPONI.xml:S3:10149:8	O
treated	SIMPONI.xml:S3:10158:7	O
with	SIMPONI.xml:S3:10166:4	O
TNF	SIMPONI.xml:S3:10171:3	O
-	SIMPONI.xml:S3:10174:1	O
blocking	SIMPONI.xml:S3:10175:8	O
agents	SIMPONI.xml:S3:10184:6	O
.	SIMPONI.xml:S3:10190:1	O

This	SIMPONI.xml:S3:10192:4	O
rare	SIMPONI.xml:S3:10197:4	B-AdverseReaction
type	SIMPONI.xml:S3:10202:4	I-AdverseReaction
of	SIMPONI.xml:S3:10207:2	I-AdverseReaction
T	SIMPONI.xml:S3:10210:1	I-AdverseReaction
-	SIMPONI.xml:S3:10211:1	I-AdverseReaction
cell	SIMPONI.xml:S3:10212:4	I-AdverseReaction
lymphoma	SIMPONI.xml:S3:10217:8	I-AdverseReaction
has	SIMPONI.xml:S3:10226:3	O
a	SIMPONI.xml:S3:10230:1	O
very	SIMPONI.xml:S3:10232:4	O
aggressive	SIMPONI.xml:S3:10237:10	O
disease	SIMPONI.xml:S3:10248:7	O
course	SIMPONI.xml:S3:10256:6	O
and	SIMPONI.xml:S3:10263:3	O
is	SIMPONI.xml:S3:10267:2	O
usually	SIMPONI.xml:S3:10270:7	O
fatal	SIMPONI.xml:S3:10278:5	B-AdverseReaction
.	SIMPONI.xml:S3:10283:1	O

Nearly	SIMPONI.xml:S3:10285:6	O
all	SIMPONI.xml:S3:10292:3	O
of	SIMPONI.xml:S3:10296:2	O
the	SIMPONI.xml:S3:10299:3	O
reported	SIMPONI.xml:S3:10303:8	O
TNF	SIMPONI.xml:S3:10312:3	O
-	SIMPONI.xml:S3:10315:1	O
blocker	SIMPONI.xml:S3:10316:7	O
associated	SIMPONI.xml:S3:10324:10	O
cases	SIMPONI.xml:S3:10335:5	O
have	SIMPONI.xml:S3:10341:4	O
occurred	SIMPONI.xml:S3:10346:8	O
in	SIMPONI.xml:S3:10355:2	O
patients	SIMPONI.xml:S3:10358:8	O
with	SIMPONI.xml:S3:10367:4	O
Crohn	SIMPONI.xml:S3:10372:5	O
's	SIMPONI.xml:S3:10377:2	O
disease	SIMPONI.xml:S3:10380:7	O
or	SIMPONI.xml:S3:10388:2	O
ulcerative	SIMPONI.xml:S3:10391:10	O
colitis	SIMPONI.xml:S3:10402:7	O
.	SIMPONI.xml:S3:10409:1	O

The	SIMPONI.xml:S3:10411:3	O
majority	SIMPONI.xml:S3:10415:8	O
were	SIMPONI.xml:S3:10424:4	O
in	SIMPONI.xml:S3:10429:2	O
adolescent	SIMPONI.xml:S3:10432:10	O
and	SIMPONI.xml:S3:10443:3	O
young	SIMPONI.xml:S3:10447:5	O
adult	SIMPONI.xml:S3:10453:5	O
males	SIMPONI.xml:S3:10459:5	O
.	SIMPONI.xml:S3:10464:1	O

Almost	SIMPONI.xml:S3:10466:6	O
all	SIMPONI.xml:S3:10473:3	O
these	SIMPONI.xml:S3:10477:5	O
patients	SIMPONI.xml:S3:10483:8	O
had	SIMPONI.xml:S3:10492:3	O
received	SIMPONI.xml:S3:10496:8	O
treatment	SIMPONI.xml:S3:10505:9	O
with	SIMPONI.xml:S3:10515:4	O
azathioprine	SIMPONI.xml:S3:10520:12	O
(	SIMPONI.xml:S3:10533:1	O
AZA	SIMPONI.xml:S3:10534:3	O
)	SIMPONI.xml:S3:10537:1	O
or	SIMPONI.xml:S3:10539:2	O
6	SIMPONI.xml:S3:10542:1	O
-	SIMPONI.xml:S3:10543:1	O
mercaptopurine	SIMPONI.xml:S3:10544:14	O
(	SIMPONI.xml:S3:10559:1	O
6	SIMPONI.xml:S3:10560:1	O
-	SIMPONI.xml:S3:10561:1	O
MP	SIMPONI.xml:S3:10562:2	O
)	SIMPONI.xml:S3:10564:1	O
concomitantly	SIMPONI.xml:S3:10566:13	O
with	SIMPONI.xml:S3:10580:4	O
a	SIMPONI.xml:S3:10585:1	O
TNF	SIMPONI.xml:S3:10587:3	O
-	SIMPONI.xml:S3:10590:1	O
blocker	SIMPONI.xml:S3:10591:7	O
at	SIMPONI.xml:S3:10599:2	O
or	SIMPONI.xml:S3:10602:2	O
prior	SIMPONI.xml:S3:10605:5	O
to	SIMPONI.xml:S3:10611:2	O
diagnosis	SIMPONI.xml:S3:10614:9	O
.	SIMPONI.xml:S3:10623:1	O

A	SIMPONI.xml:S3:10625:1	O
risk	SIMPONI.xml:S3:10627:4	O
for	SIMPONI.xml:S3:10632:3	O
the	SIMPONI.xml:S3:10636:3	O
development	SIMPONI.xml:S3:10640:11	O
for	SIMPONI.xml:S3:10652:3	O
hepatosplenic	SIMPONI.xml:S3:10656:13	O
T	SIMPONI.xml:S3:10670:1	O
-	SIMPONI.xml:S3:10671:1	O
cell	SIMPONI.xml:S3:10672:4	O
lymphoma	SIMPONI.xml:S3:10677:8	O
in	SIMPONI.xml:S3:10686:2	O
patients	SIMPONI.xml:S3:10689:8	O
treated	SIMPONI.xml:S3:10698:7	O
with	SIMPONI.xml:S3:10706:4	O
TNF	SIMPONI.xml:S3:10711:3	O
-	SIMPONI.xml:S3:10714:1	O
blockers	SIMPONI.xml:S3:10715:8	O
cannot	SIMPONI.xml:S3:10724:6	O
be	SIMPONI.xml:S3:10731:2	O
excluded	SIMPONI.xml:S3:10734:8	O
.	SIMPONI.xml:S3:10742:1	O

Melanoma	SIMPONI.xml:S3:10750:8	B-AdverseReaction
has	SIMPONI.xml:S3:10759:3	O
been	SIMPONI.xml:S3:10763:4	O
reported	SIMPONI.xml:S3:10768:8	O
in	SIMPONI.xml:S3:10777:2	O
patients	SIMPONI.xml:S3:10780:8	O
treated	SIMPONI.xml:S3:10789:7	O
with	SIMPONI.xml:S3:10797:4	O
TNF	SIMPONI.xml:S3:10802:3	O
-	SIMPONI.xml:S3:10805:1	O
blocking	SIMPONI.xml:S3:10806:8	O
agents	SIMPONI.xml:S3:10815:6	O
,	SIMPONI.xml:S3:10821:1	O
including	SIMPONI.xml:S3:10823:9	O
the	SIMPONI.xml:S3:10833:3	O
subcutaneous	SIMPONI.xml:S3:10837:12	O
formulation	SIMPONI.xml:S3:10850:11	O
of	SIMPONI.xml:S3:10862:2	O
golimumab	SIMPONI.xml:S3:10865:9	O
.	SIMPONI.xml:S3:10874:1	O

Merkel	SIMPONI.xml:S3:10876:6	B-AdverseReaction
cell	SIMPONI.xml:S3:10883:4	I-AdverseReaction
carcinoma	SIMPONI.xml:S3:10888:9	I-AdverseReaction
has	SIMPONI.xml:S3:10898:3	O
been	SIMPONI.xml:S3:10902:4	O
reported	SIMPONI.xml:S3:10907:8	O
in	SIMPONI.xml:S3:10916:2	O
patients	SIMPONI.xml:S3:10919:8	O
treated	SIMPONI.xml:S3:10928:7	O
with	SIMPONI.xml:S3:10936:4	O
TNF	SIMPONI.xml:S3:10941:3	O
-	SIMPONI.xml:S3:10944:1	O
blocking	SIMPONI.xml:S3:10945:8	O
agents	SIMPONI.xml:S3:10954:6	O
.	SIMPONI.xml:S3:10960:1	O

Periodic	SIMPONI.xml:S3:10962:8	O
skin	SIMPONI.xml:S3:10971:4	O
examination	SIMPONI.xml:S3:10976:11	O
is	SIMPONI.xml:S3:10988:2	O
recommended	SIMPONI.xml:S3:10991:11	O
for	SIMPONI.xml:S3:11003:3	O
all	SIMPONI.xml:S3:11007:3	O
patients	SIMPONI.xml:S3:11011:8	O
,	SIMPONI.xml:S3:11019:1	O
particularly	SIMPONI.xml:S3:11021:12	O
those	SIMPONI.xml:S3:11034:5	O
with	SIMPONI.xml:S3:11040:4	O
risk	SIMPONI.xml:S3:11045:4	O
factors	SIMPONI.xml:S3:11050:7	O
for	SIMPONI.xml:S3:11058:3	O
skin	SIMPONI.xml:S3:11062:4	O
cancer	SIMPONI.xml:S3:11067:6	O
.	SIMPONI.xml:S3:11073:1	O

In	SIMPONI.xml:S3:11079:2	O
controlled	SIMPONI.xml:S3:11082:10	O
trials	SIMPONI.xml:S3:11093:6	O
of	SIMPONI.xml:S3:11100:2	O
other	SIMPONI.xml:S3:11103:5	O
TNF	SIMPONI.xml:S3:11109:3	O
-	SIMPONI.xml:S3:11112:1	O
blockers	SIMPONI.xml:S3:11113:8	O
in	SIMPONI.xml:S3:11122:2	O
patients	SIMPONI.xml:S3:11125:8	O
at	SIMPONI.xml:S3:11134:2	O
higher	SIMPONI.xml:S3:11137:6	O
risk	SIMPONI.xml:S3:11144:4	O
for	SIMPONI.xml:S3:11149:3	O
malignancies	SIMPONI.xml:S3:11153:12	O
(	SIMPONI.xml:S3:11166:1	O
e	SIMPONI.xml:S3:11167:1	O
.	SIMPONI.xml:S3:11168:1	O
g	SIMPONI.xml:S3:11169:1	O
.	SIMPONI.xml:S3:11170:1	O
,	SIMPONI.xml:S3:11171:1	O
patients	SIMPONI.xml:S3:11173:8	O
with	SIMPONI.xml:S3:11182:4	O
COPD	SIMPONI.xml:S3:11187:4	O
,	SIMPONI.xml:S3:11191:1	O
patients	SIMPONI.xml:S3:11193:8	O
with	SIMPONI.xml:S3:11202:4	O
Wegener	SIMPONI.xml:S3:11207:7	O
's	SIMPONI.xml:S3:11214:2	O
granulomatosis	SIMPONI.xml:S3:11217:14	O
treated	SIMPONI.xml:S3:11232:7	O
with	SIMPONI.xml:S3:11240:4	O
concomitant	SIMPONI.xml:S3:11245:11	O
cyclophosphamide	SIMPONI.xml:S3:11257:16	O
)	SIMPONI.xml:S3:11273:1	O
a	SIMPONI.xml:S3:11275:1	O
greater	SIMPONI.xml:S3:11277:7	O
portion	SIMPONI.xml:S3:11285:7	O
of	SIMPONI.xml:S3:11293:2	O
malignancies	SIMPONI.xml:S3:11296:12	B-AdverseReaction
occurred	SIMPONI.xml:S3:11309:8	O
in	SIMPONI.xml:S3:11318:2	O
the	SIMPONI.xml:S3:11321:3	O
TNF	SIMPONI.xml:S3:11325:3	O
-	SIMPONI.xml:S3:11328:1	O
blocker	SIMPONI.xml:S3:11329:7	O
group	SIMPONI.xml:S3:11337:5	O
compared	SIMPONI.xml:S3:11343:8	O
to	SIMPONI.xml:S3:11352:2	O
the	SIMPONI.xml:S3:11355:3	O
controlled	SIMPONI.xml:S3:11359:10	O
group	SIMPONI.xml:S3:11370:5	O
.	SIMPONI.xml:S3:11375:1	O

In	SIMPONI.xml:S3:11377:2	O
an	SIMPONI.xml:S3:11380:2	O
exploratory	SIMPONI.xml:S3:11383:11	O
clinical	SIMPONI.xml:S3:11395:8	O
trial	SIMPONI.xml:S3:11404:5	O
evaluating	SIMPONI.xml:S3:11410:10	O
the	SIMPONI.xml:S3:11421:3	O
use	SIMPONI.xml:S3:11425:3	O
of	SIMPONI.xml:S3:11429:2	O
the	SIMPONI.xml:S3:11432:3	O
subcutaneous	SIMPONI.xml:S3:11436:12	O
formulation	SIMPONI.xml:S3:11449:11	O
of	SIMPONI.xml:S3:11461:2	O
golimumab	SIMPONI.xml:S3:11464:9	O
in	SIMPONI.xml:S3:11474:2	O
patients	SIMPONI.xml:S3:11477:8	O
with	SIMPONI.xml:S3:11486:4	O
severe	SIMPONI.xml:S3:11491:6	O
persistent	SIMPONI.xml:S3:11498:10	O
asthma	SIMPONI.xml:S3:11509:6	O
,	SIMPONI.xml:S3:11515:1	O
more	SIMPONI.xml:S3:11517:4	O
patients	SIMPONI.xml:S3:11522:8	O
treated	SIMPONI.xml:S3:11531:7	O
with	SIMPONI.xml:S3:11539:4	O
golimumab	SIMPONI.xml:S3:11544:9	O
reported	SIMPONI.xml:S3:11554:8	O
malignancies	SIMPONI.xml:S3:11563:12	B-AdverseReaction
compared	SIMPONI.xml:S3:11576:8	O
with	SIMPONI.xml:S3:11585:4	O
control	SIMPONI.xml:S3:11590:7	O
patients	SIMPONI.xml:S3:11598:8	O
.	SIMPONI.xml:S3:11606:1	O

The	SIMPONI.xml:S3:11608:3	O
significance	SIMPONI.xml:S3:11612:12	O
of	SIMPONI.xml:S3:11625:2	O
this	SIMPONI.xml:S3:11628:4	O
finding	SIMPONI.xml:S3:11633:7	O
is	SIMPONI.xml:S3:11641:2	O
unknown	SIMPONI.xml:S3:11644:7	O
.	SIMPONI.xml:S3:11651:1	O

During	SIMPONI.xml:S3:11657:6	O
the	SIMPONI.xml:S3:11664:3	O
controlled	SIMPONI.xml:S3:11668:10	O
portion	SIMPONI.xml:S3:11679:7	O
of	SIMPONI.xml:S3:11687:2	O
the	SIMPONI.xml:S3:11690:3	O
Phase	SIMPONI.xml:S3:11694:5	O
3	SIMPONI.xml:S3:11700:1	O
trial	SIMPONI.xml:S3:11702:5	O
in	SIMPONI.xml:S3:11708:2	O
RA	SIMPONI.xml:S3:11711:2	O
for	SIMPONI.xml:S3:11714:3	O
SIMPONI	SIMPONI.xml:S3:11718:7	O
ARIA	SIMPONI.xml:S3:11726:4	O
,	SIMPONI.xml:S3:11730:1	O
the	SIMPONI.xml:S3:11732:3	O
incidence	SIMPONI.xml:S3:11736:9	O
of	SIMPONI.xml:S3:11746:2	O
malignancies	SIMPONI.xml:S3:11749:12	B-AdverseReaction
other	SIMPONI.xml:S3:11762:5	O
than	SIMPONI.xml:S3:11768:4	O
lymphoma	SIMPONI.xml:S3:11773:8	O
and	SIMPONI.xml:S3:11782:3	O
NMSC	SIMPONI.xml:S3:11786:4	O
per	SIMPONI.xml:S3:11791:3	O
100	SIMPONI.xml:S3:11795:3	O
-	SIMPONI.xml:S3:11798:1	O
patient	SIMPONI.xml:S3:11799:7	O
-	SIMPONI.xml:S3:11806:1	O
years	SIMPONI.xml:S3:11807:5	O
of	SIMPONI.xml:S3:11813:2	O
follow	SIMPONI.xml:S3:11816:6	O
-	SIMPONI.xml:S3:11822:1	O
up	SIMPONI.xml:S3:11823:2	O
was	SIMPONI.xml:S3:11826:3	O
0.56	SIMPONI.xml:S3:11830:4	O
(	SIMPONI.xml:S3:11835:1	O
95%	SIMPONI.xml:S3:11836:3	O
CI	SIMPONI.xml:S3:11840:2	O
:	SIMPONI.xml:S3:11842:1	O
0.01	SIMPONI.xml:S3:11844:4	O
,	SIMPONI.xml:S3:11848:1	O
3.11	SIMPONI.xml:S3:11850:4	O
)	SIMPONI.xml:S3:11854:1	O
in	SIMPONI.xml:S3:11856:2	O
the	SIMPONI.xml:S3:11859:3	O
SIMPONI	SIMPONI.xml:S3:11863:7	O
ARIA	SIMPONI.xml:S3:11871:4	O
group	SIMPONI.xml:S3:11876:5	O
compared	SIMPONI.xml:S3:11882:8	O
with	SIMPONI.xml:S3:11891:4	O
an	SIMPONI.xml:S3:11896:2	O
incidence	SIMPONI.xml:S3:11899:9	O
of	SIMPONI.xml:S3:11909:2	O
0	SIMPONI.xml:S3:11912:1	O
(	SIMPONI.xml:S3:11914:1	O
95%	SIMPONI.xml:S3:11915:3	O
CI	SIMPONI.xml:S3:11919:2	O
:	SIMPONI.xml:S3:11921:1	O
0.00	SIMPONI.xml:S3:11923:4	O
,	SIMPONI.xml:S3:11927:1	O
3.79	SIMPONI.xml:S3:11929:4	O
)	SIMPONI.xml:S3:11933:1	O
in	SIMPONI.xml:S3:11935:2	O
the	SIMPONI.xml:S3:11938:3	O
placebo	SIMPONI.xml:S3:11942:7	O
group	SIMPONI.xml:S3:11950:5	O
.	SIMPONI.xml:S3:11955:1	O

5.3	SIMPONI.xml:S3:11964:3	O
Congestive	SIMPONI.xml:S3:11968:10	O
Heart	SIMPONI.xml:S3:11979:5	O
Failure	SIMPONI.xml:S3:11985:7	O

Cases	SIMPONI.xml:S3:11998:5	O
of	SIMPONI.xml:S3:12004:2	O
worsening	SIMPONI.xml:S3:12007:9	B-AdverseReaction
congestive	SIMPONI.xml:S3:12017:10	I-AdverseReaction
heart	SIMPONI.xml:S3:12028:5	I-AdverseReaction
failure	SIMPONI.xml:S3:12034:7	I-AdverseReaction
(	SIMPONI.xml:S3:12042:1	O
CHF	SIMPONI.xml:S3:12043:3	I-AdverseReaction
)	SIMPONI.xml:S3:12046:1	O
and	SIMPONI.xml:S3:12048:3	O
new	SIMPONI.xml:S3:12052:3	B-AdverseReaction
onset	SIMPONI.xml:S3:12056:5	I-AdverseReaction
CHF	SIMPONI.xml:S3:12062:3	I-AdverseReaction
have	SIMPONI.xml:S3:12066:4	O
been	SIMPONI.xml:S3:12071:4	O
reported	SIMPONI.xml:S3:12076:8	O
with	SIMPONI.xml:S3:12085:4	O
TNF	SIMPONI.xml:S3:12090:3	O
-	SIMPONI.xml:S3:12093:1	O
blockers	SIMPONI.xml:S3:12094:8	O
,	SIMPONI.xml:S3:12102:1	O
including	SIMPONI.xml:S3:12104:9	O
SIMPONI	SIMPONI.xml:S3:12114:7	O
ARIA	SIMPONI.xml:S3:12122:4	O
.	SIMPONI.xml:S3:12126:1	O

In	SIMPONI.xml:S3:12128:2	O
several	SIMPONI.xml:S3:12131:7	O
exploratory	SIMPONI.xml:S3:12139:11	O
trials	SIMPONI.xml:S3:12151:6	O
of	SIMPONI.xml:S3:12158:2	O
other	SIMPONI.xml:S3:12161:5	O
TNF	SIMPONI.xml:S3:12167:3	O
-	SIMPONI.xml:S3:12170:1	O
blockers	SIMPONI.xml:S3:12171:8	O
in	SIMPONI.xml:S3:12180:2	O
the	SIMPONI.xml:S3:12183:3	O
treatment	SIMPONI.xml:S3:12187:9	O
of	SIMPONI.xml:S3:12197:2	O
CHF	SIMPONI.xml:S3:12200:3	O
,	SIMPONI.xml:S3:12203:1	O
there	SIMPONI.xml:S3:12205:5	O
were	SIMPONI.xml:S3:12211:4	O
greater	SIMPONI.xml:S3:12216:7	O
proportions	SIMPONI.xml:S3:12224:11	O
of	SIMPONI.xml:S3:12236:2	O
TNF	SIMPONI.xml:S3:12239:3	O
-	SIMPONI.xml:S3:12242:1	O
blocker	SIMPONI.xml:S3:12243:7	O
treated	SIMPONI.xml:S3:12251:7	O
patients	SIMPONI.xml:S3:12259:8	O
who	SIMPONI.xml:S3:12268:3	O
had	SIMPONI.xml:S3:12272:3	O
CHF	SIMPONI.xml:S3:12276:3	B-AdverseReaction
exacerbations	SIMPONI.xml:S3:12280:13	I-AdverseReaction
requiring	SIMPONI.xml:S3:12294:9	O
hospitalization	SIMPONI.xml:S3:12304:15	O
or	SIMPONI.xml:S3:12320:2	O
increased	SIMPONI.xml:S3:12323:9	B-AdverseReaction
mortality	SIMPONI.xml:S3:12333:9	I-AdverseReaction
.	SIMPONI.xml:S3:12342:1	O

SIMPONI	SIMPONI.xml:S3:12344:7	O
ARIA	SIMPONI.xml:S3:12352:4	O
has	SIMPONI.xml:S3:12357:3	O
not	SIMPONI.xml:S3:12361:3	O
been	SIMPONI.xml:S3:12365:4	O
studied	SIMPONI.xml:S3:12370:7	O
in	SIMPONI.xml:S3:12378:2	O
patients	SIMPONI.xml:S3:12381:8	O
with	SIMPONI.xml:S3:12390:4	O
a	SIMPONI.xml:S3:12395:1	O
history	SIMPONI.xml:S3:12397:7	O
of	SIMPONI.xml:S3:12405:2	O
CHF	SIMPONI.xml:S3:12408:3	O
and	SIMPONI.xml:S3:12412:3	O
SIMPONI	SIMPONI.xml:S3:12416:7	O
ARIA	SIMPONI.xml:S3:12424:4	O
should	SIMPONI.xml:S3:12429:6	O
be	SIMPONI.xml:S3:12436:2	O
used	SIMPONI.xml:S3:12439:4	O
with	SIMPONI.xml:S3:12444:4	O
caution	SIMPONI.xml:S3:12449:7	O
in	SIMPONI.xml:S3:12457:2	O
patients	SIMPONI.xml:S3:12460:8	O
with	SIMPONI.xml:S3:12469:4	O
CHF	SIMPONI.xml:S3:12474:3	O
.	SIMPONI.xml:S3:12477:1	O

If	SIMPONI.xml:S3:12479:2	O
a	SIMPONI.xml:S3:12482:1	O
decision	SIMPONI.xml:S3:12484:8	O
is	SIMPONI.xml:S3:12493:2	O
made	SIMPONI.xml:S3:12496:4	O
to	SIMPONI.xml:S3:12501:2	O
administer	SIMPONI.xml:S3:12504:10	O
SIMPONI	SIMPONI.xml:S3:12515:7	O
ARIA	SIMPONI.xml:S3:12523:4	O
to	SIMPONI.xml:S3:12528:2	O
RA	SIMPONI.xml:S3:12531:2	O
patients	SIMPONI.xml:S3:12534:8	O
with	SIMPONI.xml:S3:12543:4	O
CHF	SIMPONI.xml:S3:12548:3	O
,	SIMPONI.xml:S3:12551:1	O
these	SIMPONI.xml:S3:12553:5	O
patients	SIMPONI.xml:S3:12559:8	O
should	SIMPONI.xml:S3:12568:6	O
be	SIMPONI.xml:S3:12575:2	O
closely	SIMPONI.xml:S3:12578:7	O
monitored	SIMPONI.xml:S3:12586:9	O
during	SIMPONI.xml:S3:12596:6	O
therapy	SIMPONI.xml:S3:12603:7	O
,	SIMPONI.xml:S3:12610:1	O
and	SIMPONI.xml:S3:12612:3	O
SIMPONI	SIMPONI.xml:S3:12616:7	O
ARIA	SIMPONI.xml:S3:12624:4	O
should	SIMPONI.xml:S3:12629:6	O
be	SIMPONI.xml:S3:12636:2	O
discontinued	SIMPONI.xml:S3:12639:12	O
if	SIMPONI.xml:S3:12652:2	O
new	SIMPONI.xml:S3:12655:3	O
or	SIMPONI.xml:S3:12659:2	O
worsening	SIMPONI.xml:S3:12662:9	O
symptoms	SIMPONI.xml:S3:12672:8	O
of	SIMPONI.xml:S3:12681:2	O
CHF	SIMPONI.xml:S3:12684:3	O
appear	SIMPONI.xml:S3:12688:6	O
.	SIMPONI.xml:S3:12694:1	O

5.4	SIMPONI.xml:S3:12703:3	O
Demyelinating	SIMPONI.xml:S3:12707:13	O
Disorders	SIMPONI.xml:S3:12721:9	O

Use	SIMPONI.xml:S3:12736:3	O
of	SIMPONI.xml:S3:12740:2	O
TNF	SIMPONI.xml:S3:12743:3	O
-	SIMPONI.xml:S3:12746:1	O
blockers	SIMPONI.xml:S3:12747:8	O
,	SIMPONI.xml:S3:12755:1	O
of	SIMPONI.xml:S3:12757:2	O
which	SIMPONI.xml:S3:12760:5	O
SIMPONI	SIMPONI.xml:S3:12766:7	O
ARIA	SIMPONI.xml:S3:12774:4	O
is	SIMPONI.xml:S3:12779:2	O
a	SIMPONI.xml:S3:12782:1	O
member	SIMPONI.xml:S3:12784:6	O
,	SIMPONI.xml:S3:12790:1	O
has	SIMPONI.xml:S3:12792:3	O
been	SIMPONI.xml:S3:12796:4	O
associated	SIMPONI.xml:S3:12801:10	O
with	SIMPONI.xml:S3:12812:4	O
rare	SIMPONI.xml:S3:12817:4	O
cases	SIMPONI.xml:S3:12822:5	O
of	SIMPONI.xml:S3:12828:2	O
new	SIMPONI.xml:S3:12831:3	B-AdverseReaction
onset	SIMPONI.xml:S3:12835:5	I-AdverseReaction
or	SIMPONI.xml:S3:12841:2	O
exacerbation	SIMPONI.xml:S3:12844:12	B-AdverseReaction
of	SIMPONI.xml:S3:12857:2	I-AdverseReaction
central	SIMPONI.xml:S3:12860:7	I-AdverseReaction
nervous	SIMPONI.xml:S3:12868:7	I-AdverseReaction
system	SIMPONI.xml:S3:12876:6	I-AdverseReaction
(	SIMPONI.xml:S3:12883:1	O
CNS	SIMPONI.xml:S3:12884:3	I-AdverseReaction
)	SIMPONI.xml:S3:12887:1	O
demyelinating	SIMPONI.xml:S3:12889:13	I-AdverseReaction
disorders	SIMPONI.xml:S3:12903:9	I-AdverseReaction
,	SIMPONI.xml:S3:12912:1	O
including	SIMPONI.xml:S3:12914:9	O
multiple	SIMPONI.xml:S3:12924:8	B-AdverseReaction
sclerosis	SIMPONI.xml:S3:12933:9	I-AdverseReaction
(	SIMPONI.xml:S3:12943:1	O
MS	SIMPONI.xml:S3:12944:2	B-AdverseReaction
)	SIMPONI.xml:S3:12946:1	O
and	SIMPONI.xml:S3:12948:3	O
peripheral	SIMPONI.xml:S3:12952:10	B-AdverseReaction
demyelinating	SIMPONI.xml:S3:12963:13	I-AdverseReaction
disorders	SIMPONI.xml:S3:12977:9	I-AdverseReaction
,	SIMPONI.xml:S3:12986:1	O
including	SIMPONI.xml:S3:12988:9	O
Guillain	SIMPONI.xml:S3:12998:8	B-AdverseReaction
-	SIMPONI.xml:S3:13006:1	I-AdverseReaction
Barre	SIMPONI.xml:S3:13007:5	I-AdverseReaction
syndrome	SIMPONI.xml:S3:13013:8	I-AdverseReaction
.	SIMPONI.xml:S3:13021:1	O

Cases	SIMPONI.xml:S3:13023:5	O
of	SIMPONI.xml:S3:13029:2	O
central	SIMPONI.xml:S3:13032:7	B-AdverseReaction
demyelination	SIMPONI.xml:S3:13040:13	I-AdverseReaction
,	SIMPONI.xml:S3:13053:1	O
MS	SIMPONI.xml:S3:13055:2	B-AdverseReaction
,	SIMPONI.xml:S3:13057:1	O
optic	SIMPONI.xml:S3:13059:5	B-AdverseReaction
neuritis	SIMPONI.xml:S3:13065:8	I-AdverseReaction
,	SIMPONI.xml:S3:13073:1	O
and	SIMPONI.xml:S3:13075:3	O
peripheral	SIMPONI.xml:S3:13079:10	B-AdverseReaction
demyelinating	SIMPONI.xml:S3:13090:13	I-AdverseReaction
polyneuropathy	SIMPONI.xml:S3:13104:14	I-AdverseReaction
have	SIMPONI.xml:S3:13119:4	O
rarely	SIMPONI.xml:S3:13124:6	O
been	SIMPONI.xml:S3:13131:4	O
reported	SIMPONI.xml:S3:13136:8	O
in	SIMPONI.xml:S3:13145:2	O
patients	SIMPONI.xml:S3:13148:8	O
treated	SIMPONI.xml:S3:13157:7	O
with	SIMPONI.xml:S3:13165:4	O
the	SIMPONI.xml:S3:13170:3	O
subcutaneous	SIMPONI.xml:S3:13174:12	O
formulation	SIMPONI.xml:S3:13187:11	O
of	SIMPONI.xml:S3:13199:2	O
golimumab	SIMPONI.xml:S3:13202:9	O
.	SIMPONI.xml:S3:13211:1	O

Prescribers	SIMPONI.xml:S3:13213:11	O
should	SIMPONI.xml:S3:13225:6	O
exercise	SIMPONI.xml:S3:13232:8	O
caution	SIMPONI.xml:S3:13241:7	O
in	SIMPONI.xml:S3:13249:2	O
considering	SIMPONI.xml:S3:13252:11	O
the	SIMPONI.xml:S3:13264:3	O
use	SIMPONI.xml:S3:13268:3	O
of	SIMPONI.xml:S3:13272:2	O
TNF	SIMPONI.xml:S3:13275:3	O
-	SIMPONI.xml:S3:13278:1	O
blockers	SIMPONI.xml:S3:13279:8	O
,	SIMPONI.xml:S3:13287:1	O
including	SIMPONI.xml:S3:13289:9	O
SIMPONI	SIMPONI.xml:S3:13299:7	O
ARIA	SIMPONI.xml:S3:13307:4	O
,	SIMPONI.xml:S3:13311:1	O
in	SIMPONI.xml:S3:13313:2	O
patients	SIMPONI.xml:S3:13316:8	O
with	SIMPONI.xml:S3:13325:4	O
central	SIMPONI.xml:S3:13330:7	O
or	SIMPONI.xml:S3:13338:2	O
peripheral	SIMPONI.xml:S3:13341:10	O
nervous	SIMPONI.xml:S3:13352:7	O
system	SIMPONI.xml:S3:13360:6	O
demyelinating	SIMPONI.xml:S3:13367:13	O
disorders	SIMPONI.xml:S3:13381:9	O
.	SIMPONI.xml:S3:13390:1	O

Discontinuation	SIMPONI.xml:S3:13392:15	O
of	SIMPONI.xml:S3:13408:2	O
SIMPONI	SIMPONI.xml:S3:13411:7	O
ARIA	SIMPONI.xml:S3:13419:4	O
should	SIMPONI.xml:S3:13424:6	O
be	SIMPONI.xml:S3:13431:2	O
considered	SIMPONI.xml:S3:13434:10	O
if	SIMPONI.xml:S3:13445:2	O
these	SIMPONI.xml:S3:13448:5	O
disorders	SIMPONI.xml:S3:13454:9	O
develop	SIMPONI.xml:S3:13464:7	O
.	SIMPONI.xml:S3:13471:1	O

5.5	SIMPONI.xml:S3:13480:3	O
Use	SIMPONI.xml:S3:13484:3	O
with	SIMPONI.xml:S3:13488:4	O
Abatacept	SIMPONI.xml:S3:13493:9	O

In	SIMPONI.xml:S3:13508:2	O
controlled	SIMPONI.xml:S3:13511:10	O
trials	SIMPONI.xml:S3:13522:6	O
,	SIMPONI.xml:S3:13528:1	O
the	SIMPONI.xml:S3:13530:3	O
concurrent	SIMPONI.xml:S3:13534:10	O
administration	SIMPONI.xml:S3:13545:14	O
of	SIMPONI.xml:S3:13560:2	O
another	SIMPONI.xml:S3:13563:7	O
TNF	SIMPONI.xml:S3:13571:3	O
-	SIMPONI.xml:S3:13574:1	O
blocker	SIMPONI.xml:S3:13575:7	O
and	SIMPONI.xml:S3:13583:3	O
abatacept	SIMPONI.xml:S3:13587:9	O
was	SIMPONI.xml:S3:13597:3	O
associated	SIMPONI.xml:S3:13601:10	O
with	SIMPONI.xml:S3:13612:4	O
a	SIMPONI.xml:S3:13617:1	O
greater	SIMPONI.xml:S3:13619:7	O
proportion	SIMPONI.xml:S3:13627:10	O
of	SIMPONI.xml:S3:13638:2	O
serious	SIMPONI.xml:S3:13641:7	O
infections	SIMPONI.xml:S3:13649:10	O
than	SIMPONI.xml:S3:13660:4	O
the	SIMPONI.xml:S3:13665:3	O
use	SIMPONI.xml:S3:13669:3	O
of	SIMPONI.xml:S3:13673:2	O
a	SIMPONI.xml:S3:13676:1	O
TNF	SIMPONI.xml:S3:13678:3	O
-	SIMPONI.xml:S3:13681:1	O
blocker	SIMPONI.xml:S3:13682:7	O
alone	SIMPONI.xml:S3:13690:5	O
;	SIMPONI.xml:S3:13695:1	O
and	SIMPONI.xml:S3:13697:3	O
the	SIMPONI.xml:S3:13701:3	O
combination	SIMPONI.xml:S3:13705:11	O
therapy	SIMPONI.xml:S3:13717:7	O
,	SIMPONI.xml:S3:13724:1	O
compared	SIMPONI.xml:S3:13726:8	O
to	SIMPONI.xml:S3:13735:2	O
the	SIMPONI.xml:S3:13738:3	O
use	SIMPONI.xml:S3:13742:3	O
of	SIMPONI.xml:S3:13746:2	O
a	SIMPONI.xml:S3:13749:1	O
TNF	SIMPONI.xml:S3:13751:3	O
-	SIMPONI.xml:S3:13754:1	O
blocker	SIMPONI.xml:S3:13755:7	O
alone	SIMPONI.xml:S3:13763:5	O
,	SIMPONI.xml:S3:13768:1	O
has	SIMPONI.xml:S3:13770:3	O
not	SIMPONI.xml:S3:13774:3	O
demonstrated	SIMPONI.xml:S3:13778:12	O
improved	SIMPONI.xml:S3:13791:8	O
clinical	SIMPONI.xml:S3:13800:8	O
benefit	SIMPONI.xml:S3:13809:7	O
in	SIMPONI.xml:S3:13817:2	O
the	SIMPONI.xml:S3:13820:3	O
treatment	SIMPONI.xml:S3:13824:9	O
of	SIMPONI.xml:S3:13834:2	O
RA	SIMPONI.xml:S3:13837:2	O
.	SIMPONI.xml:S3:13839:1	O

Therefore	SIMPONI.xml:S3:13841:9	O
,	SIMPONI.xml:S3:13850:1	O
the	SIMPONI.xml:S3:13852:3	O
combination	SIMPONI.xml:S3:13856:11	O
of	SIMPONI.xml:S3:13868:2	O
TNF	SIMPONI.xml:S3:13871:3	O
-	SIMPONI.xml:S3:13874:1	O
blockers	SIMPONI.xml:S3:13875:8	O
including	SIMPONI.xml:S3:13884:9	O
SIMPONI	SIMPONI.xml:S3:13894:7	O
ARIA	SIMPONI.xml:S3:13902:4	O
and	SIMPONI.xml:S3:13907:3	O
abatacept	SIMPONI.xml:S3:13911:9	O
is	SIMPONI.xml:S3:13921:2	O
not	SIMPONI.xml:S3:13924:3	O
recommended	SIMPONI.xml:S3:13928:11	O
[	SIMPONI.xml:S3:13940:1	O
see	SIMPONI.xml:S3:13941:3	O
Drug	SIMPONI.xml:S3:13946:4	O
Interactions	SIMPONI.xml:S3:13951:12	O
(	SIMPONI.xml:S3:13964:1	O
7.2	SIMPONI.xml:S3:13965:3	O
)	SIMPONI.xml:S3:13968:1	O
]	SIMPONI.xml:S3:13971:1	O
.	SIMPONI.xml:S3:13974:1	O

5.6	SIMPONI.xml:S3:13983:3	O
Use	SIMPONI.xml:S3:13987:3	O
with	SIMPONI.xml:S3:13991:4	O
Anakinra	SIMPONI.xml:S3:13996:8	O

Concurrent	SIMPONI.xml:S3:14010:10	O
administration	SIMPONI.xml:S3:14021:14	O
of	SIMPONI.xml:S3:14036:2	O
anakinra	SIMPONI.xml:S3:14039:8	O
(	SIMPONI.xml:S3:14048:1	O
an	SIMPONI.xml:S3:14049:2	O
interleukin	SIMPONI.xml:S3:14052:11	O
-	SIMPONI.xml:S3:14063:1	O
1	SIMPONI.xml:S3:14064:1	O
antagonist	SIMPONI.xml:S3:14066:10	O
)	SIMPONI.xml:S3:14076:1	O
and	SIMPONI.xml:S3:14078:3	O
another	SIMPONI.xml:S3:14082:7	O
TNF	SIMPONI.xml:S3:14090:3	O
-	SIMPONI.xml:S3:14093:1	O
blocker	SIMPONI.xml:S3:14094:7	O
,	SIMPONI.xml:S3:14101:1	O
was	SIMPONI.xml:S3:14103:3	O
associated	SIMPONI.xml:S3:14107:10	O
with	SIMPONI.xml:S3:14118:4	O
a	SIMPONI.xml:S3:14123:1	O
greater	SIMPONI.xml:S3:14125:7	O
portion	SIMPONI.xml:S3:14133:7	O
of	SIMPONI.xml:S3:14141:2	O
serious	SIMPONI.xml:S3:14144:7	O
infections	SIMPONI.xml:S3:14152:10	O
and	SIMPONI.xml:S3:14163:3	O
neutropenia	SIMPONI.xml:S3:14167:11	O
and	SIMPONI.xml:S3:14179:3	O
no	SIMPONI.xml:S3:14183:2	O
additional	SIMPONI.xml:S3:14186:10	O
benefits	SIMPONI.xml:S3:14197:8	O
compared	SIMPONI.xml:S3:14206:8	O
with	SIMPONI.xml:S3:14215:4	O
the	SIMPONI.xml:S3:14220:3	O
TNF	SIMPONI.xml:S3:14224:3	O
-	SIMPONI.xml:S3:14227:1	O
blocker	SIMPONI.xml:S3:14228:7	O
alone	SIMPONI.xml:S3:14236:5	O
.	SIMPONI.xml:S3:14241:1	O

Therefore	SIMPONI.xml:S3:14243:9	O
,	SIMPONI.xml:S3:14252:1	O
the	SIMPONI.xml:S3:14254:3	O
combination	SIMPONI.xml:S3:14258:11	O
of	SIMPONI.xml:S3:14270:2	O
anakinra	SIMPONI.xml:S3:14273:8	O
with	SIMPONI.xml:S3:14282:4	O
TNF	SIMPONI.xml:S3:14287:3	O
-	SIMPONI.xml:S3:14290:1	O
blockers	SIMPONI.xml:S3:14291:8	O
,	SIMPONI.xml:S3:14299:1	O
including	SIMPONI.xml:S3:14301:9	O
SIMPONI	SIMPONI.xml:S3:14311:7	O
ARIA	SIMPONI.xml:S3:14319:4	O
,	SIMPONI.xml:S3:14323:1	O
is	SIMPONI.xml:S3:14325:2	O
not	SIMPONI.xml:S3:14328:3	O
recommended	SIMPONI.xml:S3:14332:11	O
[	SIMPONI.xml:S3:14344:1	O
see	SIMPONI.xml:S3:14345:3	O
Drug	SIMPONI.xml:S3:14350:4	O
Interactions	SIMPONI.xml:S3:14355:12	O
(	SIMPONI.xml:S3:14368:1	O
7.2	SIMPONI.xml:S3:14369:3	O
)	SIMPONI.xml:S3:14372:1	O
]	SIMPONI.xml:S3:14375:1	O
.	SIMPONI.xml:S3:14378:1	O

5.7	SIMPONI.xml:S3:14387:3	O
Switching	SIMPONI.xml:S3:14391:9	O
Between	SIMPONI.xml:S3:14401:7	O
Biological	SIMPONI.xml:S3:14409:10	O
Disease	SIMPONI.xml:S3:14420:7	O
Modifying	SIMPONI.xml:S3:14428:9	O
Antirheumatic	SIMPONI.xml:S3:14438:13	O
Drugs	SIMPONI.xml:S3:14452:5	O
(	SIMPONI.xml:S3:14458:1	O
DMARDs	SIMPONI.xml:S3:14459:6	O
)	SIMPONI.xml:S3:14465:1	O

Care	SIMPONI.xml:S3:14472:4	O
should	SIMPONI.xml:S3:14477:6	O
be	SIMPONI.xml:S3:14484:2	O
taken	SIMPONI.xml:S3:14487:5	O
when	SIMPONI.xml:S3:14493:4	O
switching	SIMPONI.xml:S3:14498:9	O
from	SIMPONI.xml:S3:14508:4	O
one	SIMPONI.xml:S3:14513:3	O
biologic	SIMPONI.xml:S3:14517:8	O
product	SIMPONI.xml:S3:14526:7	O
to	SIMPONI.xml:S3:14534:2	O
another	SIMPONI.xml:S3:14537:7	O
biologic	SIMPONI.xml:S3:14545:8	O
product	SIMPONI.xml:S3:14554:7	O
since	SIMPONI.xml:S3:14562:5	O
overlapping	SIMPONI.xml:S3:14568:11	O
biological	SIMPONI.xml:S3:14580:10	O
activity	SIMPONI.xml:S3:14591:8	O
may	SIMPONI.xml:S3:14600:3	O
further	SIMPONI.xml:S3:14604:7	O
increase	SIMPONI.xml:S3:14612:8	O
the	SIMPONI.xml:S3:14621:3	O
risk	SIMPONI.xml:S3:14625:4	O
of	SIMPONI.xml:S3:14630:2	O
infection	SIMPONI.xml:S3:14633:9	O
.	SIMPONI.xml:S3:14642:1	O

5.8	SIMPONI.xml:S3:14651:3	O
Hematologic	SIMPONI.xml:S3:14655:11	O
Cytopenias	SIMPONI.xml:S3:14667:10	O

There	SIMPONI.xml:S3:14683:5	O
have	SIMPONI.xml:S3:14689:4	O
been	SIMPONI.xml:S3:14694:4	O
post	SIMPONI.xml:S3:14699:4	O
-	SIMPONI.xml:S3:14703:1	O
marketing	SIMPONI.xml:S3:14704:9	O
reports	SIMPONI.xml:S3:14714:7	O
of	SIMPONI.xml:S3:14722:2	O
pancytopenia	SIMPONI.xml:S3:14725:12	B-AdverseReaction
,	SIMPONI.xml:S3:14737:1	O
leukopenia	SIMPONI.xml:S3:14739:10	B-AdverseReaction
,	SIMPONI.xml:S3:14749:1	O
neutropenia	SIMPONI.xml:S3:14751:11	B-AdverseReaction
,	SIMPONI.xml:S3:14762:1	O
aplastic	SIMPONI.xml:S3:14764:8	B-AdverseReaction
anemia	SIMPONI.xml:S3:14773:6	I-AdverseReaction
,	SIMPONI.xml:S3:14779:1	O
and	SIMPONI.xml:S3:14781:3	O
thrombocytopenia	SIMPONI.xml:S3:14785:16	B-AdverseReaction
in	SIMPONI.xml:S3:14802:2	O
patients	SIMPONI.xml:S3:14805:8	O
receiving	SIMPONI.xml:S3:14814:9	O
TNF	SIMPONI.xml:S3:14824:3	O
-	SIMPONI.xml:S3:14827:1	O
blockers	SIMPONI.xml:S3:14828:8	O
.	SIMPONI.xml:S3:14836:1	O

In	SIMPONI.xml:S3:14838:2	O
clinical	SIMPONI.xml:S3:14841:8	O
studies	SIMPONI.xml:S3:14850:7	O
,	SIMPONI.xml:S3:14857:1	O
cases	SIMPONI.xml:S3:14859:5	O
of	SIMPONI.xml:S3:14865:2	O
pancytopenia	SIMPONI.xml:S3:14868:12	B-AdverseReaction
,	SIMPONI.xml:S3:14880:1	O
leukopenia	SIMPONI.xml:S3:14882:10	B-AdverseReaction
,	SIMPONI.xml:S3:14892:1	O
neutropenia	SIMPONI.xml:S3:14894:11	B-AdverseReaction
,	SIMPONI.xml:S3:14905:1	O
and	SIMPONI.xml:S3:14907:3	O
thrombocytopenia	SIMPONI.xml:S3:14911:16	B-AdverseReaction
have	SIMPONI.xml:S3:14928:4	O
also	SIMPONI.xml:S3:14933:4	O
occurred	SIMPONI.xml:S3:14938:8	O
in	SIMPONI.xml:S3:14947:2	O
SIMPONI	SIMPONI.xml:S3:14950:7	O
ARIA	SIMPONI.xml:S3:14958:4	O
-	SIMPONI.xml:S3:14962:1	O
treated	SIMPONI.xml:S3:14963:7	O
patients	SIMPONI.xml:S3:14971:8	O
.	SIMPONI.xml:S3:14979:1	O

Caution	SIMPONI.xml:S3:14981:7	O
should	SIMPONI.xml:S3:14989:6	O
be	SIMPONI.xml:S3:14996:2	O
exercised	SIMPONI.xml:S3:14999:9	O
when	SIMPONI.xml:S3:15009:4	O
using	SIMPONI.xml:S3:15014:5	O
TNF	SIMPONI.xml:S3:15020:3	O
-	SIMPONI.xml:S3:15023:1	O
blockers	SIMPONI.xml:S3:15024:8	O
,	SIMPONI.xml:S3:15032:1	O
including	SIMPONI.xml:S3:15034:9	O
SIMPONI	SIMPONI.xml:S3:15044:7	O
ARIA	SIMPONI.xml:S3:15052:4	O
,	SIMPONI.xml:S3:15056:1	O
in	SIMPONI.xml:S3:15058:2	O
patients	SIMPONI.xml:S3:15061:8	O
who	SIMPONI.xml:S3:15070:3	O
have	SIMPONI.xml:S3:15074:4	O
or	SIMPONI.xml:S3:15079:2	O
have	SIMPONI.xml:S3:15082:4	O
had	SIMPONI.xml:S3:15087:3	O
significant	SIMPONI.xml:S3:15091:11	O
cytopenias	SIMPONI.xml:S3:15103:10	O
.	SIMPONI.xml:S3:15113:1	O

5.9	SIMPONI.xml:S3:15122:3	O
Vaccinations	SIMPONI.xml:S3:15126:12	O
Therapeutic	SIMPONI.xml:S3:15139:11	O
Infectious	SIMPONI.xml:S3:15151:10	O
Agents	SIMPONI.xml:S3:15162:6	O

Live	SIMPONI.xml:S3:15176:4	O
Vaccines	SIMPONI.xml:S3:15181:8	O

Patients	SIMPONI.xml:S3:15199:8	O
treated	SIMPONI.xml:S3:15208:7	O
with	SIMPONI.xml:S3:15216:4	O
SIMPONI	SIMPONI.xml:S3:15221:7	O
ARIA	SIMPONI.xml:S3:15229:4	O
may	SIMPONI.xml:S3:15234:3	O
receive	SIMPONI.xml:S3:15238:7	O
vaccinations	SIMPONI.xml:S3:15246:12	O
,	SIMPONI.xml:S3:15258:1	O
except	SIMPONI.xml:S3:15260:6	O
for	SIMPONI.xml:S3:15267:3	O
live	SIMPONI.xml:S3:15271:4	O
vaccines	SIMPONI.xml:S3:15276:8	O
.	SIMPONI.xml:S3:15284:1	O

In	SIMPONI.xml:S3:15286:2	O
patients	SIMPONI.xml:S3:15289:8	O
receiving	SIMPONI.xml:S3:15298:9	O
anti	SIMPONI.xml:S3:15308:4	O
-	SIMPONI.xml:S3:15312:1	O
TNF	SIMPONI.xml:S3:15313:3	O
therapy	SIMPONI.xml:S3:15317:7	O
,	SIMPONI.xml:S3:15324:1	O
limited	SIMPONI.xml:S3:15326:7	O
data	SIMPONI.xml:S3:15334:4	O
are	SIMPONI.xml:S3:15339:3	O
available	SIMPONI.xml:S3:15343:9	O
on	SIMPONI.xml:S3:15353:2	O
the	SIMPONI.xml:S3:15356:3	O
response	SIMPONI.xml:S3:15360:8	O
to	SIMPONI.xml:S3:15369:2	O
live	SIMPONI.xml:S3:15372:4	O
vaccination	SIMPONI.xml:S3:15377:11	O
,	SIMPONI.xml:S3:15388:1	O
or	SIMPONI.xml:S3:15390:2	O
on	SIMPONI.xml:S3:15393:2	O
the	SIMPONI.xml:S3:15396:3	O
secondary	SIMPONI.xml:S3:15400:9	O
transmission	SIMPONI.xml:S3:15410:12	O
of	SIMPONI.xml:S3:15423:2	O
infection	SIMPONI.xml:S3:15426:9	O
by	SIMPONI.xml:S3:15436:2	O
live	SIMPONI.xml:S3:15439:4	O
vaccines	SIMPONI.xml:S3:15444:8	O
.	SIMPONI.xml:S3:15452:1	O

Use	SIMPONI.xml:S3:15454:3	O
of	SIMPONI.xml:S3:15458:2	O
live	SIMPONI.xml:S3:15461:4	O
vaccines	SIMPONI.xml:S3:15466:8	O
could	SIMPONI.xml:S3:15475:5	O
result	SIMPONI.xml:S3:15481:6	O
in	SIMPONI.xml:S3:15488:2	O
clinical	SIMPONI.xml:S3:15491:8	O
infections	SIMPONI.xml:S3:15500:10	O
,	SIMPONI.xml:S3:15510:1	O
including	SIMPONI.xml:S3:15512:9	O
disseminated	SIMPONI.xml:S3:15522:12	O
infections	SIMPONI.xml:S3:15535:10	O
.	SIMPONI.xml:S3:15545:1	O

Therapeutic	SIMPONI.xml:S3:15557:11	O
Infectious	SIMPONI.xml:S3:15569:10	O
Agents	SIMPONI.xml:S3:15580:6	O

Other	SIMPONI.xml:S3:15596:5	O
uses	SIMPONI.xml:S3:15602:4	O
of	SIMPONI.xml:S3:15607:2	O
therapeutic	SIMPONI.xml:S3:15610:11	O
infectious	SIMPONI.xml:S3:15622:10	O
agents	SIMPONI.xml:S3:15633:6	O
such	SIMPONI.xml:S3:15640:4	O
as	SIMPONI.xml:S3:15645:2	O
live	SIMPONI.xml:S3:15648:4	O
attenuated	SIMPONI.xml:S3:15653:10	O
bacteria	SIMPONI.xml:S3:15664:8	O
(	SIMPONI.xml:S3:15673:1	O
e	SIMPONI.xml:S3:15674:1	O
.	SIMPONI.xml:S3:15675:1	O
g	SIMPONI.xml:S3:15676:1	O
.	SIMPONI.xml:S3:15677:1	O
,	SIMPONI.xml:S3:15678:1	O
BCG	SIMPONI.xml:S3:15680:3	O
bladder	SIMPONI.xml:S3:15684:7	O
instillation	SIMPONI.xml:S3:15692:12	O
for	SIMPONI.xml:S3:15705:3	O
the	SIMPONI.xml:S3:15709:3	O
treatment	SIMPONI.xml:S3:15713:9	O
of	SIMPONI.xml:S3:15723:2	O
cancer	SIMPONI.xml:S3:15726:6	O
)	SIMPONI.xml:S3:15732:1	O
could	SIMPONI.xml:S3:15734:5	O
result	SIMPONI.xml:S3:15740:6	O
in	SIMPONI.xml:S3:15747:2	O
clinical	SIMPONI.xml:S3:15750:8	O
infections	SIMPONI.xml:S3:15759:10	O
,	SIMPONI.xml:S3:15769:1	O
including	SIMPONI.xml:S3:15771:9	O
disseminated	SIMPONI.xml:S3:15781:12	O
infections	SIMPONI.xml:S3:15794:10	O
.	SIMPONI.xml:S3:15804:1	O

It	SIMPONI.xml:S3:15806:2	O
is	SIMPONI.xml:S3:15809:2	O
recommended	SIMPONI.xml:S3:15812:11	O
that	SIMPONI.xml:S3:15824:4	O
therapeutic	SIMPONI.xml:S3:15829:11	O
infectious	SIMPONI.xml:S3:15841:10	O
agents	SIMPONI.xml:S3:15852:6	O
not	SIMPONI.xml:S3:15859:3	O
be	SIMPONI.xml:S3:15863:2	O
given	SIMPONI.xml:S3:15866:5	O
concurrently	SIMPONI.xml:S3:15872:12	O
with	SIMPONI.xml:S3:15885:4	O
SIMPONI	SIMPONI.xml:S3:15890:7	O
ARIA	SIMPONI.xml:S3:15898:4	O
.	SIMPONI.xml:S3:15902:1	O

5.10	SIMPONI.xml:S3:15913:4	O
Hypersensitivity	SIMPONI.xml:S3:15918:16	O
Reactions	SIMPONI.xml:S3:15935:9	O

In	SIMPONI.xml:S3:15950:2	O
post	SIMPONI.xml:S3:15953:4	O
-	SIMPONI.xml:S3:15957:1	O
marketing	SIMPONI.xml:S3:15958:9	O
experience	SIMPONI.xml:S3:15968:10	O
,	SIMPONI.xml:S3:15978:1	O
serious	SIMPONI.xml:S3:15980:7	B-Severity
systemic	SIMPONI.xml:S3:15988:8	O
hypersensitivity	SIMPONI.xml:S3:15997:16	B-AdverseReaction
reactions	SIMPONI.xml:S3:16014:9	I-AdverseReaction
(	SIMPONI.xml:S3:16024:1	O
including	SIMPONI.xml:S3:16025:9	O
anaphylactic	SIMPONI.xml:S3:16035:12	B-AdverseReaction
reaction	SIMPONI.xml:S3:16048:8	I-AdverseReaction
)	SIMPONI.xml:S3:16056:1	O
have	SIMPONI.xml:S3:16058:4	O
been	SIMPONI.xml:S3:16063:4	O
reported	SIMPONI.xml:S3:16068:8	O
following	SIMPONI.xml:S3:16077:9	O
administration	SIMPONI.xml:S3:16087:14	O
of	SIMPONI.xml:S3:16102:2	O
the	SIMPONI.xml:S3:16105:3	O
subcutaneous	SIMPONI.xml:S3:16109:12	O
formulation	SIMPONI.xml:S3:16122:11	O
of	SIMPONI.xml:S3:16134:2	O
golimumab	SIMPONI.xml:S3:16137:9	O
.	SIMPONI.xml:S3:16146:1	O

Some	SIMPONI.xml:S3:16148:4	O
of	SIMPONI.xml:S3:16153:2	O
these	SIMPONI.xml:S3:16156:5	O
reactions	SIMPONI.xml:S3:16162:9	O
occurred	SIMPONI.xml:S3:16172:8	O
after	SIMPONI.xml:S3:16181:5	O
the	SIMPONI.xml:S3:16187:3	O
first	SIMPONI.xml:S3:16191:5	O
administration	SIMPONI.xml:S3:16197:14	O
of	SIMPONI.xml:S3:16212:2	O
golimumab	SIMPONI.xml:S3:16215:9	O
.	SIMPONI.xml:S3:16224:1	O

If	SIMPONI.xml:S3:16226:2	O
an	SIMPONI.xml:S3:16229:2	O
anaphylactic	SIMPONI.xml:S3:16232:12	O
or	SIMPONI.xml:S3:16245:2	O
other	SIMPONI.xml:S3:16248:5	O
serious	SIMPONI.xml:S3:16254:7	O
allergic	SIMPONI.xml:S3:16262:8	O
reaction	SIMPONI.xml:S3:16271:8	O
occurs	SIMPONI.xml:S3:16280:6	O
,	SIMPONI.xml:S3:16286:1	O
administration	SIMPONI.xml:S3:16288:14	O
of	SIMPONI.xml:S3:16303:2	O
SIMPONI	SIMPONI.xml:S3:16306:7	O
ARIA	SIMPONI.xml:S3:16314:4	O
should	SIMPONI.xml:S3:16319:6	O
be	SIMPONI.xml:S3:16326:2	O
discontinued	SIMPONI.xml:S3:16329:12	O
immediately	SIMPONI.xml:S3:16342:11	O
and	SIMPONI.xml:S3:16354:3	O
appropriate	SIMPONI.xml:S3:16358:11	O
therapy	SIMPONI.xml:S3:16370:7	O
instituted	SIMPONI.xml:S3:16378:10	O
.	SIMPONI.xml:S3:16388:1	O
6	SIRTURO.xml:S1:4:1	O
ADVERSE	SIRTURO.xml:S1:6:7	O
REACTIONS	SIRTURO.xml:S1:14:9	O

The	SIRTURO.xml:S1:27:3	O
following	SIRTURO.xml:S1:31:9	O
serious	SIRTURO.xml:S1:41:7	O
adverse	SIRTURO.xml:S1:49:7	O
reactions	SIRTURO.xml:S1:57:9	O
are	SIRTURO.xml:S1:67:3	O
discussed	SIRTURO.xml:S1:71:9	O
elsewhere	SIRTURO.xml:S1:81:9	O
in	SIRTURO.xml:S1:91:2	O
the	SIRTURO.xml:S1:94:3	O
labeling	SIRTURO.xml:S1:98:8	O
:	SIRTURO.xml:S1:106:1	O

Increased	SIRTURO.xml:S1:115:9	B-AdverseReaction
mortality	SIRTURO.xml:S1:125:9	I-AdverseReaction
[	SIRTURO.xml:S1:135:1	O
see	SIRTURO.xml:S1:136:3	O
Warnings	SIRTURO.xml:S1:141:8	O
and	SIRTURO.xml:S1:150:3	O
Precautions	SIRTURO.xml:S1:154:11	O
(	SIRTURO.xml:S1:166:1	O
5.1	SIRTURO.xml:S1:167:3	O
)	SIRTURO.xml:S1:170:1	O
]	SIRTURO.xml:S1:173:1	O

QT	SIRTURO.xml:S1:181:2	B-AdverseReaction
Prolongation	SIRTURO.xml:S1:184:12	I-AdverseReaction
[	SIRTURO.xml:S1:197:1	O
see	SIRTURO.xml:S1:198:3	O
Warnings	SIRTURO.xml:S1:203:8	O
and	SIRTURO.xml:S1:212:3	O
Precautions	SIRTURO.xml:S1:216:11	O
(	SIRTURO.xml:S1:228:1	O
5.2	SIRTURO.xml:S1:229:3	O
)	SIRTURO.xml:S1:232:1	O
and	SIRTURO.xml:S1:236:3	O
Clinical	SIRTURO.xml:S1:242:8	O
Pharmacology	SIRTURO.xml:S1:251:12	O
(	SIRTURO.xml:S1:264:1	O
12.2	SIRTURO.xml:S1:265:4	O
)	SIRTURO.xml:S1:269:1	O
]	SIRTURO.xml:S1:272:1	O

Hepatotoxicity	SIRTURO.xml:S1:280:14	B-AdverseReaction
[	SIRTURO.xml:S1:295:1	O
see	SIRTURO.xml:S1:296:3	O
Warnings	SIRTURO.xml:S1:301:8	O
and	SIRTURO.xml:S1:310:3	O
Precautions	SIRTURO.xml:S1:314:11	O
(	SIRTURO.xml:S1:326:1	O
5.3	SIRTURO.xml:S1:327:3	O
)	SIRTURO.xml:S1:330:1	O
]	SIRTURO.xml:S1:333:1	O

Drug	SIRTURO.xml:S1:341:4	O
Interactions	SIRTURO.xml:S1:346:12	O
[	SIRTURO.xml:S1:359:1	O
see	SIRTURO.xml:S1:360:3	O
Warnings	SIRTURO.xml:S1:365:8	O
and	SIRTURO.xml:S1:374:3	O
Precautions	SIRTURO.xml:S1:378:11	O
(	SIRTURO.xml:S1:390:1	O
5.4	SIRTURO.xml:S1:391:3	O
)	SIRTURO.xml:S1:394:1	O
]	SIRTURO.xml:S1:397:1	O

The	SIRTURO.xml:S1:407:3	O
most	SIRTURO.xml:S1:411:4	O
common	SIRTURO.xml:S1:416:6	O
adverse	SIRTURO.xml:S1:423:7	O
reactions	SIRTURO.xml:S1:431:9	O
reported	SIRTURO.xml:S1:441:8	O
in	SIRTURO.xml:S1:450:2	O
10%	SIRTURO.xml:S1:453:3	O
or	SIRTURO.xml:S1:457:2	O
more	SIRTURO.xml:S1:460:4	O
of	SIRTURO.xml:S1:465:2	O
patients	SIRTURO.xml:S1:468:8	O
treated	SIRTURO.xml:S1:477:7	O
with	SIRTURO.xml:S1:485:4	O
SIRTURO	SIRTURO.xml:S1:490:7	O
were	SIRTURO.xml:S1:498:4	O
nausea	SIRTURO.xml:S1:503:6	B-AdverseReaction
,	SIRTURO.xml:S1:509:1	O
arthralgia	SIRTURO.xml:S1:511:10	B-AdverseReaction
,	SIRTURO.xml:S1:521:1	O
headache	SIRTURO.xml:S1:523:8	B-AdverseReaction
,	SIRTURO.xml:S1:531:1	O
hemoptysis	SIRTURO.xml:S1:533:10	B-AdverseReaction
and	SIRTURO.xml:S1:544:3	O
chest	SIRTURO.xml:S1:548:5	B-AdverseReaction
pain	SIRTURO.xml:S1:554:4	I-AdverseReaction
.	SIRTURO.xml:S1:558:1	O

(	SIRTURO.xml:S1:560:1	O
6.1	SIRTURO.xml:S1:563:3	O
)	SIRTURO.xml:S1:568:1	O

EXCERPT	SIRTURO.xml:S1:577:7	O
:	SIRTURO.xml:S1:584:1	O
To	SIRTURO.xml:S1:590:2	O
report	SIRTURO.xml:S1:593:6	O
SUSPECTED	SIRTURO.xml:S1:600:9	O
ADVERSE	SIRTURO.xml:S1:610:7	O
REACTIONS	SIRTURO.xml:S1:618:9	O
,	SIRTURO.xml:S1:627:1	O
contact	SIRTURO.xml:S1:629:7	O
Janssen	SIRTURO.xml:S1:637:7	O
Therapeutics	SIRTURO.xml:S1:645:12	O
,	SIRTURO.xml:S1:657:1	O
Division	SIRTURO.xml:S1:659:8	O
of	SIRTURO.xml:S1:668:2	O
Janssen	SIRTURO.xml:S1:671:7	O
Products	SIRTURO.xml:S1:679:8	O
,	SIRTURO.xml:S1:687:1	O
LP	SIRTURO.xml:S1:689:2	O
at	SIRTURO.xml:S1:695:2	O
1	SIRTURO.xml:S1:698:1	O
-	SIRTURO.xml:S1:699:1	O
800	SIRTURO.xml:S1:700:3	O
-	SIRTURO.xml:S1:703:1	O
JANSSEN	SIRTURO.xml:S1:704:7	O
(	SIRTURO.xml:S1:712:1	O
1	SIRTURO.xml:S1:713:1	O
-	SIRTURO.xml:S1:714:1	O
800	SIRTURO.xml:S1:715:3	O
-	SIRTURO.xml:S1:718:1	O
526	SIRTURO.xml:S1:719:3	O
-	SIRTURO.xml:S1:722:1	O
7736	SIRTURO.xml:S1:723:4	O
)	SIRTURO.xml:S1:731:1	O
or	SIRTURO.xml:S1:733:2	O
FDA	SIRTURO.xml:S1:736:3	O
at	SIRTURO.xml:S1:740:2	O
1	SIRTURO.xml:S1:743:1	O
-	SIRTURO.xml:S1:744:1	O
800	SIRTURO.xml:S1:745:3	O
-	SIRTURO.xml:S1:748:1	O
FDA	SIRTURO.xml:S1:749:3	O
-	SIRTURO.xml:S1:752:1	O
1088	SIRTURO.xml:S1:753:4	O
or	SIRTURO.xml:S1:758:2	O
www	SIRTURO.xml:S1:764:3	O
.	SIRTURO.xml:S1:767:1	O
fda	SIRTURO.xml:S1:768:3	O
.	SIRTURO.xml:S1:771:1	O
gov	SIRTURO.xml:S1:772:3	O
medwatch	SIRTURO.xml:S1:776:8	O
.	SIRTURO.xml:S1:786:1	O

6.1	SIRTURO.xml:S1:800:3	O

Clinical	SIRTURO.xml:S1:804:8	O

Studies	SIRTURO.xml:S1:813:7	O
Experience	SIRTURO.xml:S1:821:10	O

Because	SIRTURO.xml:S1:835:7	O
clinical	SIRTURO.xml:S1:843:8	O
studies	SIRTURO.xml:S1:852:7	O
are	SIRTURO.xml:S1:860:3	O
conducted	SIRTURO.xml:S1:864:9	O
under	SIRTURO.xml:S1:874:5	O
widely	SIRTURO.xml:S1:880:6	O
varying	SIRTURO.xml:S1:887:7	O
conditions	SIRTURO.xml:S1:895:10	O
,	SIRTURO.xml:S1:905:1	O
adverse	SIRTURO.xml:S1:907:7	O
reaction	SIRTURO.xml:S1:915:8	O
rates	SIRTURO.xml:S1:924:5	O
observed	SIRTURO.xml:S1:930:8	O
in	SIRTURO.xml:S1:939:2	O
the	SIRTURO.xml:S1:942:3	O
clinical	SIRTURO.xml:S1:946:8	O
studies	SIRTURO.xml:S1:955:7	O
of	SIRTURO.xml:S1:963:2	O
a	SIRTURO.xml:S1:966:1	O
drug	SIRTURO.xml:S1:968:4	O
cannot	SIRTURO.xml:S1:973:6	O
be	SIRTURO.xml:S1:980:2	O
directly	SIRTURO.xml:S1:983:8	O
compared	SIRTURO.xml:S1:992:8	O
to	SIRTURO.xml:S1:1001:2	O
the	SIRTURO.xml:S1:1004:3	O
rates	SIRTURO.xml:S1:1008:5	O
in	SIRTURO.xml:S1:1014:2	O
the	SIRTURO.xml:S1:1017:3	O
clinical	SIRTURO.xml:S1:1021:8	O
studies	SIRTURO.xml:S1:1030:7	O
of	SIRTURO.xml:S1:1038:2	O
another	SIRTURO.xml:S1:1041:7	O
drug	SIRTURO.xml:S1:1049:4	O
and	SIRTURO.xml:S1:1054:3	O
may	SIRTURO.xml:S1:1058:3	O
not	SIRTURO.xml:S1:1062:3	O
reflect	SIRTURO.xml:S1:1066:7	O
the	SIRTURO.xml:S1:1074:3	O
rates	SIRTURO.xml:S1:1078:5	O
observed	SIRTURO.xml:S1:1084:8	O
in	SIRTURO.xml:S1:1093:2	O
clinical	SIRTURO.xml:S1:1096:8	O
practice	SIRTURO.xml:S1:1105:8	O
.	SIRTURO.xml:S1:1113:1	O

Adverse	SIRTURO.xml:S1:1119:7	O
drug	SIRTURO.xml:S1:1127:4	O
reactions	SIRTURO.xml:S1:1132:9	O
for	SIRTURO.xml:S1:1142:3	O
SIRTURO	SIRTURO.xml:S1:1146:7	O
were	SIRTURO.xml:S1:1154:4	O
identified	SIRTURO.xml:S1:1159:10	O
from	SIRTURO.xml:S1:1170:4	O
the	SIRTURO.xml:S1:1175:3	O
pooled	SIRTURO.xml:S1:1179:6	O
safety	SIRTURO.xml:S1:1186:6	O
data	SIRTURO.xml:S1:1193:4	O
from	SIRTURO.xml:S1:1198:4	O
335	SIRTURO.xml:S1:1203:3	O
SIRTURO	SIRTURO.xml:S1:1207:7	O
-	SIRTURO.xml:S1:1214:1	O
exposed	SIRTURO.xml:S1:1215:7	O
patients	SIRTURO.xml:S1:1223:8	O
who	SIRTURO.xml:S1:1232:3	O
received	SIRTURO.xml:S1:1236:8	O
8	SIRTURO.xml:S1:1245:1	O
weeks	SIRTURO.xml:S1:1247:5	O
(	SIRTURO.xml:S1:1253:1	O
Study	SIRTURO.xml:S1:1254:5	O
2	SIRTURO.xml:S1:1260:1	O
)	SIRTURO.xml:S1:1261:1	O
and	SIRTURO.xml:S1:1263:3	O
24	SIRTURO.xml:S1:1267:2	O
weeks	SIRTURO.xml:S1:1270:5	O
(	SIRTURO.xml:S1:1276:1	O
Studies	SIRTURO.xml:S1:1277:7	O
1	SIRTURO.xml:S1:1285:1	O
and	SIRTURO.xml:S1:1287:3	O
3	SIRTURO.xml:S1:1291:1	O
)	SIRTURO.xml:S1:1292:1	O
at	SIRTURO.xml:S1:1294:2	O
the	SIRTURO.xml:S1:1297:3	O
proposed	SIRTURO.xml:S1:1301:8	O
dose	SIRTURO.xml:S1:1310:4	O
.	SIRTURO.xml:S1:1314:1	O

Studies	SIRTURO.xml:S1:1316:7	O
1	SIRTURO.xml:S1:1324:1	O
and	SIRTURO.xml:S1:1326:3	O
2	SIRTURO.xml:S1:1330:1	O
were	SIRTURO.xml:S1:1332:4	O
randomized	SIRTURO.xml:S1:1337:10	O
,	SIRTURO.xml:S1:1347:1	O
double	SIRTURO.xml:S1:1349:6	O
-	SIRTURO.xml:S1:1355:1	O
blind	SIRTURO.xml:S1:1356:5	O
,	SIRTURO.xml:S1:1361:1	O
placebo	SIRTURO.xml:S1:1363:7	O
-	SIRTURO.xml:S1:1370:1	O
controlled	SIRTURO.xml:S1:1371:10	O
trial	SIRTURO.xml:S1:1382:5	O
in	SIRTURO.xml:S1:1388:2	O
newly	SIRTURO.xml:S1:1391:5	O
diagnosed	SIRTURO.xml:S1:1397:9	O
patients	SIRTURO.xml:S1:1407:8	O
with	SIRTURO.xml:S1:1416:4	O
pulmonary	SIRTURO.xml:S1:1421:9	O
MDR	SIRTURO.xml:S1:1431:3	O
-	SIRTURO.xml:S1:1434:1	O
TB	SIRTURO.xml:S1:1435:2	O
.	SIRTURO.xml:S1:1437:1	O

In	SIRTURO.xml:S1:1439:2	O
both	SIRTURO.xml:S1:1442:4	O
treatment	SIRTURO.xml:S1:1447:9	O
arms	SIRTURO.xml:S1:1457:4	O
,	SIRTURO.xml:S1:1461:1	O
patients	SIRTURO.xml:S1:1463:8	O
received	SIRTURO.xml:S1:1472:8	O
SIRTURO	SIRTURO.xml:S1:1481:7	O
or	SIRTURO.xml:S1:1489:2	O
placebo	SIRTURO.xml:S1:1492:7	O
in	SIRTURO.xml:S1:1500:2	O
combination	SIRTURO.xml:S1:1503:11	O
with	SIRTURO.xml:S1:1515:4	O
other	SIRTURO.xml:S1:1520:5	O
drugs	SIRTURO.xml:S1:1526:5	O
used	SIRTURO.xml:S1:1532:4	O
to	SIRTURO.xml:S1:1537:2	O
treat	SIRTURO.xml:S1:1540:5	O
MDR	SIRTURO.xml:S1:1546:3	O
-	SIRTURO.xml:S1:1549:1	O
TB	SIRTURO.xml:S1:1550:2	O
.	SIRTURO.xml:S1:1552:1	O

Study	SIRTURO.xml:S1:1554:5	O
3	SIRTURO.xml:S1:1560:1	O
was	SIRTURO.xml:S1:1562:3	O
an	SIRTURO.xml:S1:1566:2	O
open	SIRTURO.xml:S1:1569:4	O
-	SIRTURO.xml:S1:1573:1	O
label	SIRTURO.xml:S1:1574:5	O
,	SIRTURO.xml:S1:1579:1	O
noncomparative	SIRTURO.xml:S1:1581:14	O
study	SIRTURO.xml:S1:1596:5	O
with	SIRTURO.xml:S1:1602:4	O
SIRTURO	SIRTURO.xml:S1:1607:7	O
administered	SIRTURO.xml:S1:1615:12	O
as	SIRTURO.xml:S1:1628:2	O
part	SIRTURO.xml:S1:1631:4	O
of	SIRTURO.xml:S1:1636:2	O
an	SIRTURO.xml:S1:1639:2	O
individualized	SIRTURO.xml:S1:1642:14	O
pulmonary	SIRTURO.xml:S1:1657:9	O
MDR	SIRTURO.xml:S1:1667:3	O
-	SIRTURO.xml:S1:1670:1	O
TB	SIRTURO.xml:S1:1671:2	O
treatment	SIRTURO.xml:S1:1674:9	O
regimen	SIRTURO.xml:S1:1684:7	O
in	SIRTURO.xml:S1:1692:2	O
previously	SIRTURO.xml:S1:1695:10	O
treated	SIRTURO.xml:S1:1706:7	O
patients	SIRTURO.xml:S1:1714:8	O
.	SIRTURO.xml:S1:1722:1	O

In	SIRTURO.xml:S1:1728:2	O
Study	SIRTURO.xml:S1:1731:5	O
1	SIRTURO.xml:S1:1737:1	O
,	SIRTURO.xml:S1:1738:1	O
35%	SIRTURO.xml:S1:1740:3	O
were	SIRTURO.xml:S1:1744:4	O
Black	SIRTURO.xml:S1:1749:5	O
,	SIRTURO.xml:S1:1754:1	O
17.5%	SIRTURO.xml:S1:1756:5	O
were	SIRTURO.xml:S1:1762:4	O
Hispanic	SIRTURO.xml:S1:1767:8	O
,	SIRTURO.xml:S1:1775:1	O
12.5%	SIRTURO.xml:S1:1777:5	O
were	SIRTURO.xml:S1:1783:4	O
White	SIRTURO.xml:S1:1788:5	O
,	SIRTURO.xml:S1:1793:1	O
9.4%	SIRTURO.xml:S1:1795:4	O
were	SIRTURO.xml:S1:1800:4	O
Asian	SIRTURO.xml:S1:1805:5	O
,	SIRTURO.xml:S1:1810:1	O
and	SIRTURO.xml:S1:1812:3	O
25.6%	SIRTURO.xml:S1:1816:5	O
were	SIRTURO.xml:S1:1822:4	O
of	SIRTURO.xml:S1:1827:2	O
another	SIRTURO.xml:S1:1830:7	O
race	SIRTURO.xml:S1:1838:4	O
.	SIRTURO.xml:S1:1842:1	O

Eight	SIRTURO.xml:S1:1844:5	O
of	SIRTURO.xml:S1:1850:2	O
79	SIRTURO.xml:S1:1853:2	O
(	SIRTURO.xml:S1:1856:1	O
10.1%	SIRTURO.xml:S1:1857:5	O
)	SIRTURO.xml:S1:1862:1	O
patients	SIRTURO.xml:S1:1864:8	O
in	SIRTURO.xml:S1:1873:2	O
the	SIRTURO.xml:S1:1876:3	O
SIRTURO	SIRTURO.xml:S1:1880:7	O
group	SIRTURO.xml:S1:1888:5	O
and	SIRTURO.xml:S1:1894:3	O
16	SIRTURO.xml:S1:1898:2	O
of	SIRTURO.xml:S1:1901:2	O
81	SIRTURO.xml:S1:1904:2	O
(	SIRTURO.xml:S1:1907:1	O
19.8%	SIRTURO.xml:S1:1908:5	O
)	SIRTURO.xml:S1:1913:1	O
patients	SIRTURO.xml:S1:1915:8	O
in	SIRTURO.xml:S1:1924:2	O
the	SIRTURO.xml:S1:1927:3	O
placebo	SIRTURO.xml:S1:1931:7	O
treatment	SIRTURO.xml:S1:1939:9	O
group	SIRTURO.xml:S1:1949:5	O
were	SIRTURO.xml:S1:1955:4	O
HIV	SIRTURO.xml:S1:1960:3	O
-	SIRTURO.xml:S1:1963:1	O
infected	SIRTURO.xml:S1:1964:8	O
.	SIRTURO.xml:S1:1972:1	O

Seven	SIRTURO.xml:S1:1974:5	O
(	SIRTURO.xml:S1:1980:1	O
8.9%	SIRTURO.xml:S1:1981:4	O
)	SIRTURO.xml:S1:1985:1	O
SIRTURO	SIRTURO.xml:S1:1987:7	O
-	SIRTURO.xml:S1:1994:1	O
treated	SIRTURO.xml:S1:1995:7	O
patients	SIRTURO.xml:S1:2003:8	O
and	SIRTURO.xml:S1:2012:3	O
six	SIRTURO.xml:S1:2016:3	O
(	SIRTURO.xml:S1:2020:1	O
7.4%	SIRTURO.xml:S1:2021:4	O
)	SIRTURO.xml:S1:2025:1	O
placebo	SIRTURO.xml:S1:2027:7	O
-	SIRTURO.xml:S1:2034:1	O
treated	SIRTURO.xml:S1:2035:7	O
patients	SIRTURO.xml:S1:2043:8	O
discontinued	SIRTURO.xml:S1:2052:12	O
Study	SIRTURO.xml:S1:2065:5	O
1	SIRTURO.xml:S1:2071:1	O
because	SIRTURO.xml:S1:2073:7	O
of	SIRTURO.xml:S1:2081:2	O
an	SIRTURO.xml:S1:2084:2	O
adverse	SIRTURO.xml:S1:2087:7	O
reaction	SIRTURO.xml:S1:2095:8	O
.	SIRTURO.xml:S1:2103:1	O

Table	SIRTURO.xml:S1:2109:5	O
1	SIRTURO.xml:S1:2115:1	O
:	SIRTURO.xml:S1:2116:1	O
Select	SIRTURO.xml:S1:2118:6	O
Adverse	SIRTURO.xml:S1:2125:7	O
Reactions	SIRTURO.xml:S1:2133:9	O
from	SIRTURO.xml:S1:2143:4	O
Study	SIRTURO.xml:S1:2148:5	O
1	SIRTURO.xml:S1:2154:1	O
That	SIRTURO.xml:S1:2156:4	O
Occurred	SIRTURO.xml:S1:2161:8	O
More	SIRTURO.xml:S1:2170:4	O
Frequently	SIRTURO.xml:S1:2175:10	O
Than	SIRTURO.xml:S1:2186:4	O
Placebo	SIRTURO.xml:S1:2191:7	O
During	SIRTURO.xml:S1:2199:6	O
Treatment	SIRTURO.xml:S1:2206:9	O
with	SIRTURO.xml:S1:2216:4	O
SIRTURO	SIRTURO.xml:S1:2221:7	O

Adverse	SIRTURO.xml:S1:2231:7	O
Reactions	SIRTURO.xml:S1:2239:9	O
SIRTURO	SIRTURO.xml:S1:2267:7	O
Treatment	SIRTURO.xml:S1:2275:9	O
GroupN	SIRTURO.xml:S1:2285:6	O
79	SIRTURO.xml:S1:2292:2	O
n	SIRTURO.xml:S1:2294:1	O
(	SIRTURO.xml:S1:2296:1	O
)	SIRTURO.xml:S1:2298:1	O
Placebo	SIRTURO.xml:S1:2302:7	O
Treatment	SIRTURO.xml:S1:2310:9	O
GroupN	SIRTURO.xml:S1:2320:6	O
81	SIRTURO.xml:S1:2327:2	O
n	SIRTURO.xml:S1:2329:1	O
(	SIRTURO.xml:S1:2331:1	O
)	SIRTURO.xml:S1:2333:1	O

Nausea	SIRTURO.xml:S1:2343:6	B-AdverseReaction

30	SIRTURO.xml:S1:2391:2	O
(	SIRTURO.xml:S1:2394:1	O
38	SIRTURO.xml:S1:2395:2	O
)	SIRTURO.xml:S1:2397:1	O
26	SIRTURO.xml:S1:2427:2	O
(	SIRTURO.xml:S1:2430:1	O
32	SIRTURO.xml:S1:2431:2	O
)	SIRTURO.xml:S1:2433:1	O

Arthralgia	SIRTURO.xml:S1:2452:10	B-AdverseReaction
26	SIRTURO.xml:S1:2500:2	O
(	SIRTURO.xml:S1:2503:1	O
33	SIRTURO.xml:S1:2504:2	O
)	SIRTURO.xml:S1:2506:1	O
18	SIRTURO.xml:S1:2536:2	O
(	SIRTURO.xml:S1:2539:1	O
22	SIRTURO.xml:S1:2540:2	O
)	SIRTURO.xml:S1:2542:1	O

Headache	SIRTURO.xml:S1:2561:8	B-AdverseReaction
22	SIRTURO.xml:S1:2609:2	O
(	SIRTURO.xml:S1:2612:1	O
28	SIRTURO.xml:S1:2613:2	O
)	SIRTURO.xml:S1:2615:1	O
10	SIRTURO.xml:S1:2645:2	O
(	SIRTURO.xml:S1:2648:1	O
12	SIRTURO.xml:S1:2649:2	O
)	SIRTURO.xml:S1:2651:1	O

Hemoptysis	SIRTURO.xml:S1:2670:10	B-AdverseReaction
14	SIRTURO.xml:S1:2718:2	O
(	SIRTURO.xml:S1:2721:1	O
18	SIRTURO.xml:S1:2722:2	O
)	SIRTURO.xml:S1:2724:1	O
9	SIRTURO.xml:S1:2754:1	O
(	SIRTURO.xml:S1:2756:1	O
11	SIRTURO.xml:S1:2757:2	O
)	SIRTURO.xml:S1:2759:1	O

Chest	SIRTURO.xml:S1:2779:5	B-AdverseReaction
Pain	SIRTURO.xml:S1:2785:4	I-AdverseReaction
9	SIRTURO.xml:S1:2828:1	O
(	SIRTURO.xml:S1:2830:1	O
11	SIRTURO.xml:S1:2831:2	O
)	SIRTURO.xml:S1:2833:1	O
6	SIRTURO.xml:S1:2864:1	O
(	SIRTURO.xml:S1:2866:1	O
7	SIRTURO.xml:S1:2867:1	O
)	SIRTURO.xml:S1:2868:1	O

Anorexia	SIRTURO.xml:S1:2888:8	B-AdverseReaction
7	SIRTURO.xml:S1:2937:1	O
(	SIRTURO.xml:S1:2939:1	O
9	SIRTURO.xml:S1:2940:1	O
)	SIRTURO.xml:S1:2941:1	O
3	SIRTURO.xml:S1:2973:1	O
(	SIRTURO.xml:S1:2975:1	O
4	SIRTURO.xml:S1:2976:1	O
)	SIRTURO.xml:S1:2977:1	O

Transaminases	SIRTURO.xml:S1:2997:13	B-AdverseReaction
Increased	SIRTURO.xml:S1:3011:9	I-AdverseReaction
7	SIRTURO.xml:S1:3046:1	O
(	SIRTURO.xml:S1:3048:1	O
9	SIRTURO.xml:S1:3049:1	O
)	SIRTURO.xml:S1:3050:1	O
1	SIRTURO.xml:S1:3082:1	O
(	SIRTURO.xml:S1:3084:1	O
1	SIRTURO.xml:S1:3085:1	O
)	SIRTURO.xml:S1:3086:1	O

Rash	SIRTURO.xml:S1:3106:4	B-AdverseReaction
6	SIRTURO.xml:S1:3155:1	O
(	SIRTURO.xml:S1:3157:1	O
8	SIRTURO.xml:S1:3158:1	O
)	SIRTURO.xml:S1:3159:1	O
3	SIRTURO.xml:S1:3191:1	O
(	SIRTURO.xml:S1:3193:1	O
4	SIRTURO.xml:S1:3194:1	O
)	SIRTURO.xml:S1:3195:1	O

Blood	SIRTURO.xml:S1:3215:5	B-AdverseReaction
Amylase	SIRTURO.xml:S1:3221:7	I-AdverseReaction
Increased	SIRTURO.xml:S1:3229:9	I-AdverseReaction
2	SIRTURO.xml:S1:3264:1	O
(	SIRTURO.xml:S1:3266:1	O
3	SIRTURO.xml:S1:3267:1	O
)	SIRTURO.xml:S1:3268:1	O
1	SIRTURO.xml:S1:3300:1	O
(	SIRTURO.xml:S1:3302:1	O
1	SIRTURO.xml:S1:3303:1	O
)	SIRTURO.xml:S1:3304:1	O

No	SIRTURO.xml:S1:3332:2	O
additional	SIRTURO.xml:S1:3335:10	O
unique	SIRTURO.xml:S1:3346:6	O
Adverse	SIRTURO.xml:S1:3353:7	O
Reactions	SIRTURO.xml:S1:3361:9	O
were	SIRTURO.xml:S1:3371:4	O
identified	SIRTURO.xml:S1:3376:10	O
from	SIRTURO.xml:S1:3387:4	O
the	SIRTURO.xml:S1:3392:3	O
uncontrolled	SIRTURO.xml:S1:3396:12	O
Study	SIRTURO.xml:S1:3409:5	O
3	SIRTURO.xml:S1:3415:1	O
.	SIRTURO.xml:S1:3416:1	O

In	SIRTURO.xml:S1:3422:2	O

both	SIRTURO.xml:S1:3425:4	O
Studies	SIRTURO.xml:S1:3430:7	O
1	SIRTURO.xml:S1:3438:1	O
and	SIRTURO.xml:S1:3440:3	O
2	SIRTURO.xml:S1:3444:1	O
,	SIRTURO.xml:S1:3445:1	O
aminotransferase	SIRTURO.xml:S1:3447:16	B-AdverseReaction
elevations	SIRTURO.xml:S1:3464:10	I-AdverseReaction
of	SIRTURO.xml:S1:3475:2	O
at	SIRTURO.xml:S1:3478:2	O
least	SIRTURO.xml:S1:3481:5	O
3	SIRTURO.xml:S1:3487:1	B-Severity
times	SIRTURO.xml:S1:3489:5	I-Severity
the	SIRTURO.xml:S1:3495:3	I-Severity
upper	SIRTURO.xml:S1:3499:5	I-Severity
limit	SIRTURO.xml:S1:3505:5	I-Severity
of	SIRTURO.xml:S1:3511:2	I-Severity
normal	SIRTURO.xml:S1:3514:6	I-Severity
developed	SIRTURO.xml:S1:3521:9	O
more	SIRTURO.xml:S1:3531:4	O
frequently	SIRTURO.xml:S1:3536:10	O
in	SIRTURO.xml:S1:3547:2	O
the	SIRTURO.xml:S1:3550:3	O
SIRTURO	SIRTURO.xml:S1:3554:7	O
treatment	SIRTURO.xml:S1:3562:9	O
group	SIRTURO.xml:S1:3572:5	O
(	SIRTURO.xml:S1:3578:1	O
11	SIRTURO.xml:S1:3579:2	O
102	SIRTURO.xml:S1:3582:3	O
[	SIRTURO.xml:S1:3586:1	O
10.8%	SIRTURO.xml:S1:3587:5	O
]	SIRTURO.xml:S1:3592:1	O
vs	SIRTURO.xml:S1:3594:2	O
6	SIRTURO.xml:S1:3597:1	O
105	SIRTURO.xml:S1:3599:3	O
[	SIRTURO.xml:S1:3603:1	O
5.7%	SIRTURO.xml:S1:3604:4	O
])	SIRTURO.xml:S1:3608:2	O
than	SIRTURO.xml:S1:3611:4	O
in	SIRTURO.xml:S1:3616:2	O
the	SIRTURO.xml:S1:3619:3	O
placebo	SIRTURO.xml:S1:3623:7	O
treatment	SIRTURO.xml:S1:3631:9	O
group	SIRTURO.xml:S1:3641:5	O
.	SIRTURO.xml:S1:3646:1	O

In	SIRTURO.xml:S1:3648:2	O
Study	SIRTURO.xml:S1:3651:5	O
3	SIRTURO.xml:S1:3657:1	O
,	SIRTURO.xml:S1:3658:1	O
22	SIRTURO.xml:S1:3660:2	O
230	SIRTURO.xml:S1:3663:3	O
(	SIRTURO.xml:S1:3667:1	O
9.6%	SIRTURO.xml:S1:3668:4	O
)	SIRTURO.xml:S1:3672:1	O
patients	SIRTURO.xml:S1:3674:8	O
had	SIRTURO.xml:S1:3683:3	O
alanine	SIRTURO.xml:S1:3687:7	B-AdverseReaction
aminotransferase	SIRTURO.xml:S1:3695:16	I-AdverseReaction
or	SIRTURO.xml:S1:3712:2	O
aspartate	SIRTURO.xml:S1:3715:9	B-AdverseReaction
aminotransferase	SIRTURO.xml:S1:3725:16	I-AdverseReaction
greater	SIRTURO.xml:S1:3742:7	O
than	SIRTURO.xml:S1:3750:4	O
or	SIRTURO.xml:S1:3755:2	O
equal	SIRTURO.xml:S1:3758:5	O
to	SIRTURO.xml:S1:3764:2	O
3	SIRTURO.xml:S1:3767:1	I-AdverseReaction
times	SIRTURO.xml:S1:3769:5	I-AdverseReaction
the	SIRTURO.xml:S1:3775:3	I-AdverseReaction
upper	SIRTURO.xml:S1:3779:5	I-AdverseReaction
limit	SIRTURO.xml:S1:3785:5	I-AdverseReaction
of	SIRTURO.xml:S1:3791:2	I-AdverseReaction
normal	SIRTURO.xml:S1:3794:6	I-AdverseReaction
during	SIRTURO.xml:S1:3801:6	O
the	SIRTURO.xml:S1:3808:3	O
overall	SIRTURO.xml:S1:3812:7	O
treatment	SIRTURO.xml:S1:3820:9	O
period	SIRTURO.xml:S1:3830:6	O
.	SIRTURO.xml:S1:3836:1	O

Increased	SIRTURO.xml:S1:3846:9	O
Mortality	SIRTURO.xml:S1:3856:9	O

In	SIRTURO.xml:S1:3872:2	O
Study	SIRTURO.xml:S1:3875:5	O
1	SIRTURO.xml:S1:3881:1	O
,	SIRTURO.xml:S1:3882:1	O
there	SIRTURO.xml:S1:3884:5	O
was	SIRTURO.xml:S1:3890:3	O
a	SIRTURO.xml:S1:3894:1	O
statistically	SIRTURO.xml:S1:3896:13	O
significant	SIRTURO.xml:S1:3910:11	O
increased	SIRTURO.xml:S1:3922:9	B-AdverseReaction
mortality	SIRTURO.xml:S1:3932:9	I-AdverseReaction
risk	SIRTURO.xml:S1:3942:4	B-Factor
by	SIRTURO.xml:S1:3947:2	O
Week	SIRTURO.xml:S1:3950:4	O
120	SIRTURO.xml:S1:3955:3	O
in	SIRTURO.xml:S1:3959:2	O
the	SIRTURO.xml:S1:3962:3	O
SIRTURO	SIRTURO.xml:S1:3966:7	O
treatment	SIRTURO.xml:S1:3974:9	O
group	SIRTURO.xml:S1:3984:5	O
compared	SIRTURO.xml:S1:3990:8	O
to	SIRTURO.xml:S1:3999:2	O
the	SIRTURO.xml:S1:4002:3	O
placebo	SIRTURO.xml:S1:4006:7	O
treatment	SIRTURO.xml:S1:4014:9	O
group	SIRTURO.xml:S1:4024:5	O
(	SIRTURO.xml:S1:4030:1	O
9	SIRTURO.xml:S1:4031:1	O
79	SIRTURO.xml:S1:4033:2	O
(	SIRTURO.xml:S1:4036:1	O
11.4%	SIRTURO.xml:S1:4037:5	O
)	SIRTURO.xml:S1:4042:1	O
versus	SIRTURO.xml:S1:4044:6	O
2	SIRTURO.xml:S1:4051:1	O
81	SIRTURO.xml:S1:4053:2	O
(	SIRTURO.xml:S1:4056:1	O
2.5%	SIRTURO.xml:S1:4057:4	O
)	SIRTURO.xml:S1:4061:1	O
,	SIRTURO.xml:S1:4062:1	O
p	SIRTURO.xml:S1:4064:1	O
-	SIRTURO.xml:S1:4065:1	O
value	SIRTURO.xml:S1:4066:5	O
0.03	SIRTURO.xml:S1:4072:4	O
,	SIRTURO.xml:S1:4076:1	O
an	SIRTURO.xml:S1:4078:2	O
exact	SIRTURO.xml:S1:4081:5	O
95%	SIRTURO.xml:S1:4087:3	O
confidence	SIRTURO.xml:S1:4091:10	O
interval	SIRTURO.xml:S1:4102:8	O
of	SIRTURO.xml:S1:4111:2	O
the	SIRTURO.xml:S1:4114:3	O
difference	SIRTURO.xml:S1:4118:10	O
[	SIRTURO.xml:S1:4129:1	O
1.1%	SIRTURO.xml:S1:4130:4	O
,	SIRTURO.xml:S1:4134:1	O
18.2%	SIRTURO.xml:S1:4136:5	O
])	SIRTURO.xml:S1:4141:2	O
.	SIRTURO.xml:S1:4143:1	O

Five	SIRTURO.xml:S1:4145:4	O
of	SIRTURO.xml:S1:4150:2	O
the	SIRTURO.xml:S1:4153:3	O
9	SIRTURO.xml:S1:4157:1	O
SIRTURO	SIRTURO.xml:S1:4159:7	O
deaths	SIRTURO.xml:S1:4167:6	B-AdverseReaction
and	SIRTURO.xml:S1:4174:3	O
the	SIRTURO.xml:S1:4178:3	O
2	SIRTURO.xml:S1:4182:1	O
placebo	SIRTURO.xml:S1:4184:7	B-Factor
deaths	SIRTURO.xml:S1:4192:6	B-AdverseReaction
were	SIRTURO.xml:S1:4199:4	O
tuberculosis	SIRTURO.xml:S1:4204:12	O
-	SIRTURO.xml:S1:4216:1	O
related	SIRTURO.xml:S1:4217:7	O
.	SIRTURO.xml:S1:4224:1	O

One	SIRTURO.xml:S1:4226:3	O
death	SIRTURO.xml:S1:4230:5	B-AdverseReaction
occurred	SIRTURO.xml:S1:4236:8	O
during	SIRTURO.xml:S1:4245:6	O
the	SIRTURO.xml:S1:4252:3	O
24	SIRTURO.xml:S1:4256:2	O
-	SIRTURO.xml:S1:4258:1	O
week	SIRTURO.xml:S1:4259:4	O
SIRTURO	SIRTURO.xml:S1:4264:7	O
treatment	SIRTURO.xml:S1:4272:9	O
period	SIRTURO.xml:S1:4282:6	O
.	SIRTURO.xml:S1:4288:1	O

The	SIRTURO.xml:S1:4290:3	O
median	SIRTURO.xml:S1:4294:6	O
time	SIRTURO.xml:S1:4301:4	O
to	SIRTURO.xml:S1:4306:2	O
death	SIRTURO.xml:S1:4309:5	B-AdverseReaction
for	SIRTURO.xml:S1:4315:3	O
the	SIRTURO.xml:S1:4319:3	O
remaining	SIRTURO.xml:S1:4323:9	O
eight	SIRTURO.xml:S1:4333:5	O
subjects	SIRTURO.xml:S1:4339:8	O
in	SIRTURO.xml:S1:4348:2	O
the	SIRTURO.xml:S1:4351:3	O
SIRTURO	SIRTURO.xml:S1:4355:7	O
treatment	SIRTURO.xml:S1:4363:9	O
group	SIRTURO.xml:S1:4373:5	O
was	SIRTURO.xml:S1:4379:3	O
329	SIRTURO.xml:S1:4383:3	O
days	SIRTURO.xml:S1:4387:4	O
after	SIRTURO.xml:S1:4392:5	O
last	SIRTURO.xml:S1:4398:4	O
intake	SIRTURO.xml:S1:4403:6	O
of	SIRTURO.xml:S1:4410:2	O
SIRTURO	SIRTURO.xml:S1:4413:7	O
.	SIRTURO.xml:S1:4420:1	O

The	SIRTURO.xml:S1:4422:3	O
imbalance	SIRTURO.xml:S1:4426:9	O
in	SIRTURO.xml:S1:4436:2	O
deaths	SIRTURO.xml:S1:4439:6	B-AdverseReaction
is	SIRTURO.xml:S1:4446:2	O
unexplained	SIRTURO.xml:S1:4449:11	O
;	SIRTURO.xml:S1:4460:1	O
no	SIRTURO.xml:S1:4462:2	O
discernible	SIRTURO.xml:S1:4465:11	O
pattern	SIRTURO.xml:S1:4477:7	O
between	SIRTURO.xml:S1:4485:7	O
death	SIRTURO.xml:S1:4493:5	B-AdverseReaction
and	SIRTURO.xml:S1:4499:3	O
sputum	SIRTURO.xml:S1:4503:6	O
conversion	SIRTURO.xml:S1:4510:10	O
,	SIRTURO.xml:S1:4520:1	O
relapse	SIRTURO.xml:S1:4522:7	O
,	SIRTURO.xml:S1:4529:1	O
sensitivity	SIRTURO.xml:S1:4531:11	O
to	SIRTURO.xml:S1:4543:2	O
other	SIRTURO.xml:S1:4546:5	O
drugs	SIRTURO.xml:S1:4552:5	O
used	SIRTURO.xml:S1:4558:4	O
to	SIRTURO.xml:S1:4563:2	O
treat	SIRTURO.xml:S1:4566:5	O
tuberculosis	SIRTURO.xml:S1:4572:12	O
,	SIRTURO.xml:S1:4584:1	O
HIV	SIRTURO.xml:S1:4586:3	O
status	SIRTURO.xml:S1:4590:6	O
,	SIRTURO.xml:S1:4596:1	O
and	SIRTURO.xml:S1:4598:3	O
severity	SIRTURO.xml:S1:4602:8	O
of	SIRTURO.xml:S1:4611:2	O
disease	SIRTURO.xml:S1:4614:7	O
was	SIRTURO.xml:S1:4622:3	O
observed	SIRTURO.xml:S1:4626:8	O
.	SIRTURO.xml:S1:4634:1	O

In	SIRTURO.xml:S1:4640:2	O
the	SIRTURO.xml:S1:4643:3	O
open	SIRTURO.xml:S1:4647:4	O
-	SIRTURO.xml:S1:4651:1	O
label	SIRTURO.xml:S1:4652:5	O
Study	SIRTURO.xml:S1:4658:5	O
3	SIRTURO.xml:S1:4664:1	O
,	SIRTURO.xml:S1:4665:1	O
6.9%	SIRTURO.xml:S1:4667:4	O
(	SIRTURO.xml:S1:4672:1	O
16	SIRTURO.xml:S1:4673:2	O
233	SIRTURO.xml:S1:4676:3	O
)	SIRTURO.xml:S1:4679:1	O
subjects	SIRTURO.xml:S1:4681:8	O
died	SIRTURO.xml:S1:4690:4	B-AdverseReaction
.	SIRTURO.xml:S1:4694:1	O

The	SIRTURO.xml:S1:4696:3	O
most	SIRTURO.xml:S1:4700:4	O
common	SIRTURO.xml:S1:4705:6	O
cause	SIRTURO.xml:S1:4712:5	O
of	SIRTURO.xml:S1:4718:2	O
death	SIRTURO.xml:S1:4721:5	B-AdverseReaction
as	SIRTURO.xml:S1:4727:2	O
reported	SIRTURO.xml:S1:4730:8	O
by	SIRTURO.xml:S1:4739:2	O
the	SIRTURO.xml:S1:4742:3	O
investigator	SIRTURO.xml:S1:4746:12	O
was	SIRTURO.xml:S1:4759:3	O
TB	SIRTURO.xml:S1:4763:2	O
(	SIRTURO.xml:S1:4766:1	O
9	SIRTURO.xml:S1:4767:1	O
subjects	SIRTURO.xml:S1:4769:8	O
)	SIRTURO.xml:S1:4777:1	O
.	SIRTURO.xml:S1:4778:1	O

All	SIRTURO.xml:S1:4780:3	O
but	SIRTURO.xml:S1:4784:3	O
one	SIRTURO.xml:S1:4788:3	O
subject	SIRTURO.xml:S1:4792:7	O
who	SIRTURO.xml:S1:4800:3	O
died	SIRTURO.xml:S1:4804:4	B-AdverseReaction
of	SIRTURO.xml:S1:4809:2	O
TB	SIRTURO.xml:S1:4812:2	O
had	SIRTURO.xml:S1:4815:3	O
not	SIRTURO.xml:S1:4819:3	O
converted	SIRTURO.xml:S1:4823:9	O
or	SIRTURO.xml:S1:4833:2	O
had	SIRTURO.xml:S1:4836:3	O
relapsed	SIRTURO.xml:S1:4840:8	O
.	SIRTURO.xml:S1:4848:1	O

The	SIRTURO.xml:S1:4850:3	O
causes	SIRTURO.xml:S1:4854:6	O
of	SIRTURO.xml:S1:4861:2	O
death	SIRTURO.xml:S1:4864:5	B-AdverseReaction
in	SIRTURO.xml:S1:4870:2	O
the	SIRTURO.xml:S1:4873:3	O
remaining	SIRTURO.xml:S1:4877:9	O
subjects	SIRTURO.xml:S1:4887:8	O
varied	SIRTURO.xml:S1:4896:6	O
.	SIRTURO.xml:S1:4902:1	O
\n\n	SIRTURO.xml:S2:0:2	O
BOXED	SIRTURO.xml:S2:6:5	O
WARNING	SIRTURO.xml:S2:12:7	O
:	SIRTURO.xml:S2:19:1	O
WARNINGS	SIRTURO.xml:S2:21:8	O
:	SIRTURO.xml:S2:29:1	O
INCREASED	SIRTURO.xml:S2:31:9	B-AdverseReaction
MORTALITY	SIRTURO.xml:S2:41:9	I-AdverseReaction
;	SIRTURO.xml:S2:50:1	O
QT	SIRTURO.xml:S2:52:2	B-AdverseReaction
PROLONGATION	SIRTURO.xml:S2:55:12	I-AdverseReaction
\n\n	SIRTURO.xml:S2:67:2	O
WARNINGS	SIRTURO.xml:S2:71:8	O
:	SIRTURO.xml:S2:79:1	O
INCREASED	SIRTURO.xml:S2:81:9	B-AdverseReaction
MORTALITY	SIRTURO.xml:S2:91:9	I-AdverseReaction
;	SIRTURO.xml:S2:100:1	O
QT	SIRTURO.xml:S2:102:2	B-AdverseReaction
PROLONGATION	SIRTURO.xml:S2:105:12	I-AdverseReaction
\n\n	SIRTURO.xml:S2:117:2	O
EXCERPT	SIRTURO.xml:S2:121:7	O
:	SIRTURO.xml:S2:128:1	O
WARNINGS	SIRTURO.xml:S2:132:8	O
:	SIRTURO.xml:S2:140:1	O
INCREASED	SIRTURO.xml:S2:142:9	B-AdverseReaction
MORTALITY	SIRTURO.xml:S2:152:9	I-AdverseReaction
;	SIRTURO.xml:S2:161:1	O
QT	SIRTURO.xml:S2:163:2	B-AdverseReaction
PROLONGATION	SIRTURO.xml:S2:166:12	I-AdverseReaction
\n\n\n\n	SIRTURO.xml:S2:178:4	O
See	SIRTURO.xml:S2:185:3	O
full	SIRTURO.xml:S2:189:4	O
prescribing	SIRTURO.xml:S2:194:11	O
information	SIRTURO.xml:S2:206:11	O
for	SIRTURO.xml:S2:218:3	O
complete	SIRTURO.xml:S2:222:8	O
boxed	SIRTURO.xml:S2:231:5	O
warning	SIRTURO.xml:S2:237:7	O
.	SIRTURO.xml:S2:244:1	O

Increased	SIRTURO.xml:S2:254:9	O
Mortality	SIRTURO.xml:S2:264:9	O
\n\n\n\n	SIRTURO.xml:S2:275:4	O
An	SIRTURO.xml:S2:283:2	O
increased	SIRTURO.xml:S2:286:9	O
risk	SIRTURO.xml:S2:296:4	B-Factor
of	SIRTURO.xml:S2:301:2	O
death	SIRTURO.xml:S2:304:5	B-AdverseReaction
was	SIRTURO.xml:S2:310:3	O
seen	SIRTURO.xml:S2:314:4	O
in	SIRTURO.xml:S2:319:2	O
the	SIRTURO.xml:S2:322:3	O
SIRTURO	SIRTURO.xml:S2:326:7	O
treatment	SIRTURO.xml:S2:334:9	O
group	SIRTURO.xml:S2:344:5	O
(	SIRTURO.xml:S2:350:1	O
9	SIRTURO.xml:S2:351:1	O
79	SIRTURO.xml:S2:353:2	O
,	SIRTURO.xml:S2:355:1	O
11.4%	SIRTURO.xml:S2:357:5	O
)	SIRTURO.xml:S2:362:1	O
compared	SIRTURO.xml:S2:364:8	O
to	SIRTURO.xml:S2:373:2	O
the	SIRTURO.xml:S2:376:3	O
placebo	SIRTURO.xml:S2:380:7	O
treatment	SIRTURO.xml:S2:388:9	O
group	SIRTURO.xml:S2:398:5	O
(	SIRTURO.xml:S2:404:1	O
2	SIRTURO.xml:S2:405:1	O
81	SIRTURO.xml:S2:407:2	O
,	SIRTURO.xml:S2:409:1	O
2.5%	SIRTURO.xml:S2:411:4	O
)	SIRTURO.xml:S2:415:1	O
in	SIRTURO.xml:S2:417:2	O
one	SIRTURO.xml:S2:420:3	O
placebo	SIRTURO.xml:S2:424:7	O
-	SIRTURO.xml:S2:431:1	O
controlled	SIRTURO.xml:S2:432:10	O
trial	SIRTURO.xml:S2:443:5	O
.	SIRTURO.xml:S2:448:1	O

Only	SIRTURO.xml:S2:450:4	O
use	SIRTURO.xml:S2:455:3	O
SIRTURO	SIRTURO.xml:S2:459:7	O
when	SIRTURO.xml:S2:467:4	O
an	SIRTURO.xml:S2:472:2	O
effective	SIRTURO.xml:S2:475:9	O
treatment	SIRTURO.xml:S2:485:9	O
regimen	SIRTURO.xml:S2:495:7	O
cannot	SIRTURO.xml:S2:503:6	O
otherwise	SIRTURO.xml:S2:510:9	O
be	SIRTURO.xml:S2:520:2	O
provided	SIRTURO.xml:S2:523:8	O
.	SIRTURO.xml:S2:531:1	O

(	SIRTURO.xml:S2:533:1	O
5.1	SIRTURO.xml:S2:534:3	O
)	SIRTURO.xml:S2:537:1	O
\n	SIRTURO.xml:S2:539:1	O
QT	SIRTURO.xml:S2:546:2	O
Prolongation	SIRTURO.xml:S2:549:12	O
\n	SIRTURO.xml:S2:563:1	O
\n\n	SIRTURO.xml:S2:565:2	O
QT	SIRTURO.xml:S2:571:2	B-AdverseReaction
prolongation	SIRTURO.xml:S2:574:12	I-AdverseReaction
can	SIRTURO.xml:S2:587:3	B-Factor
occur	SIRTURO.xml:S2:591:5	O
with	SIRTURO.xml:S2:597:4	O
SIRTURO	SIRTURO.xml:S2:602:7	O
.	SIRTURO.xml:S2:609:1	O

Use	SIRTURO.xml:S2:611:3	O
with	SIRTURO.xml:S2:615:4	O
drugs	SIRTURO.xml:S2:620:5	O
that	SIRTURO.xml:S2:626:4	O
prolong	SIRTURO.xml:S2:631:7	O
the	SIRTURO.xml:S2:639:3	O
QT	SIRTURO.xml:S2:643:2	O
interval	SIRTURO.xml:S2:646:8	O
may	SIRTURO.xml:S2:655:3	B-Factor
cause	SIRTURO.xml:S2:659:5	O
additive	SIRTURO.xml:S2:665:8	O
QT	SIRTURO.xml:S2:674:2	B-AdverseReaction
prolongation	SIRTURO.xml:S2:677:12	I-AdverseReaction
.	SIRTURO.xml:S2:689:1	O

Monitor	SIRTURO.xml:S2:691:7	O
ECGs	SIRTURO.xml:S2:699:4	O
.	SIRTURO.xml:S2:703:1	O

Discontinue	SIRTURO.xml:S2:705:11	O
SIRTURO	SIRTURO.xml:S2:717:7	O
if	SIRTURO.xml:S2:725:2	O
significant	SIRTURO.xml:S2:728:11	O
ventricular	SIRTURO.xml:S2:740:11	O
arrhythmia	SIRTURO.xml:S2:752:10	O
or	SIRTURO.xml:S2:763:2	O
QTcF	SIRTURO.xml:S2:766:4	O
interval	SIRTURO.xml:S2:771:8	O
500	SIRTURO.xml:S2:781:3	O
ms	SIRTURO.xml:S2:785:2	O
develops	SIRTURO.xml:S2:788:8	O
.	SIRTURO.xml:S2:796:1	O

(	SIRTURO.xml:S2:798:1	O
5.2	SIRTURO.xml:S2:799:3	O
)	SIRTURO.xml:S2:802:1	O
\n	SIRTURO.xml:S2:804:1	O
\n	SIRTURO.xml:S2:809:1	O
\n\n	SIRTURO.xml:S2:811:2	O
Increased	SIRTURO.xml:S2:817:9	O
Mortality	SIRTURO.xml:S2:827:9	O
\n\n\n\n	SIRTURO.xml:S2:838:4	O
An	SIRTURO.xml:S2:846:2	O
increased	SIRTURO.xml:S2:849:9	O
risk	SIRTURO.xml:S2:859:4	B-Factor
of	SIRTURO.xml:S2:864:2	O
death	SIRTURO.xml:S2:867:5	B-AdverseReaction
was	SIRTURO.xml:S2:873:3	O
seen	SIRTURO.xml:S2:877:4	O
in	SIRTURO.xml:S2:882:2	O
the	SIRTURO.xml:S2:885:3	O
SIRTURO	SIRTURO.xml:S2:889:7	O
treatment	SIRTURO.xml:S2:897:9	O
group	SIRTURO.xml:S2:907:5	O
(	SIRTURO.xml:S2:913:1	O
9	SIRTURO.xml:S2:914:1	O
79	SIRTURO.xml:S2:916:2	O
,	SIRTURO.xml:S2:918:1	O
11.4%	SIRTURO.xml:S2:920:5	O
)	SIRTURO.xml:S2:925:1	O
compared	SIRTURO.xml:S2:927:8	O
to	SIRTURO.xml:S2:936:2	O
the	SIRTURO.xml:S2:939:3	O
placebo	SIRTURO.xml:S2:943:7	O
treatment	SIRTURO.xml:S2:951:9	O
group	SIRTURO.xml:S2:961:5	O
(	SIRTURO.xml:S2:967:1	O
2	SIRTURO.xml:S2:968:1	O
81	SIRTURO.xml:S2:970:2	O
,	SIRTURO.xml:S2:972:1	O
2.5%	SIRTURO.xml:S2:974:4	O
)	SIRTURO.xml:S2:978:1	O
in	SIRTURO.xml:S2:980:2	O
one	SIRTURO.xml:S2:983:3	O
placebo	SIRTURO.xml:S2:987:7	O
-	SIRTURO.xml:S2:994:1	O
controlled	SIRTURO.xml:S2:995:10	O
trial	SIRTURO.xml:S2:1006:5	O
.	SIRTURO.xml:S2:1011:1	O

Only	SIRTURO.xml:S2:1013:4	O
use	SIRTURO.xml:S2:1018:3	O
SIRTURO	SIRTURO.xml:S2:1022:7	O
when	SIRTURO.xml:S2:1030:4	O
an	SIRTURO.xml:S2:1035:2	O
effective	SIRTURO.xml:S2:1038:9	O
treatment	SIRTURO.xml:S2:1048:9	O
regimen	SIRTURO.xml:S2:1058:7	O
cannot	SIRTURO.xml:S2:1066:6	O
otherwise	SIRTURO.xml:S2:1073:9	O
be	SIRTURO.xml:S2:1083:2	O
provided	SIRTURO.xml:S2:1086:8	O
[	SIRTURO.xml:S2:1095:1	O
see	SIRTURO.xml:S2:1096:3	O
Indications	SIRTURO.xml:S2:1100:11	O
and	SIRTURO.xml:S2:1112:3	O
Usage	SIRTURO.xml:S2:1116:5	O
(	SIRTURO.xml:S2:1122:1	O
1	SIRTURO.xml:S2:1123:1	O
)	SIRTURO.xml:S2:1124:1	O
and	SIRTURO.xml:S2:1126:3	O
Warnings	SIRTURO.xml:S2:1130:8	O
and	SIRTURO.xml:S2:1139:3	O
Precautions	SIRTURO.xml:S2:1143:11	O
(	SIRTURO.xml:S2:1155:1	O
5.1	SIRTURO.xml:S2:1156:3	O
)]	SIRTURO.xml:S2:1159:2	O
.	SIRTURO.xml:S2:1161:1	O

QT	SIRTURO.xml:S2:1172:2	O
Prolongation	SIRTURO.xml:S2:1175:12	O
\n	SIRTURO.xml:S2:1189:1	O
\n\n	SIRTURO.xml:S2:1191:2	O
QT	SIRTURO.xml:S2:1197:2	B-AdverseReaction
prolongation	SIRTURO.xml:S2:1200:12	I-AdverseReaction
can	SIRTURO.xml:S2:1213:3	B-Factor
occur	SIRTURO.xml:S2:1217:5	O
with	SIRTURO.xml:S2:1223:4	O
SIRTURO	SIRTURO.xml:S2:1228:7	O
.	SIRTURO.xml:S2:1235:1	O

Use	SIRTURO.xml:S2:1237:3	O
with	SIRTURO.xml:S2:1241:4	O
drugs	SIRTURO.xml:S2:1246:5	O
that	SIRTURO.xml:S2:1252:4	O
prolong	SIRTURO.xml:S2:1257:7	O
the	SIRTURO.xml:S2:1265:3	O
QT	SIRTURO.xml:S2:1269:2	O
interval	SIRTURO.xml:S2:1272:8	O
may	SIRTURO.xml:S2:1281:3	B-Factor
cause	SIRTURO.xml:S2:1285:5	O
additive	SIRTURO.xml:S2:1291:8	B-AdverseReaction
QT	SIRTURO.xml:S2:1300:2	I-AdverseReaction
prolongation	SIRTURO.xml:S2:1303:12	I-AdverseReaction
.	SIRTURO.xml:S2:1315:1	O

Monitor	SIRTURO.xml:S2:1317:7	O
ECGs	SIRTURO.xml:S2:1325:4	O
.	SIRTURO.xml:S2:1329:1	O

Discontinue	SIRTURO.xml:S2:1331:11	O
SIRTURO	SIRTURO.xml:S2:1343:7	O
if	SIRTURO.xml:S2:1351:2	O
significant	SIRTURO.xml:S2:1354:11	O
ventricular	SIRTURO.xml:S2:1366:11	O
arrhythmia	SIRTURO.xml:S2:1378:10	O
or	SIRTURO.xml:S2:1389:2	O
if	SIRTURO.xml:S2:1392:2	O
QTcF	SIRTURO.xml:S2:1395:4	O
interval	SIRTURO.xml:S2:1400:8	O
prolongation	SIRTURO.xml:S2:1409:12	O
of	SIRTURO.xml:S2:1422:2	O
greater	SIRTURO.xml:S2:1425:7	O
than	SIRTURO.xml:S2:1433:4	O
500	SIRTURO.xml:S2:1438:3	O
ms	SIRTURO.xml:S2:1442:2	O
develops	SIRTURO.xml:S2:1445:8	O
[	SIRTURO.xml:S2:1454:1	O
see	SIRTURO.xml:S2:1455:3	O
Warnings	SIRTURO.xml:S2:1459:8	O
and	SIRTURO.xml:S2:1468:3	O
Precautions	SIRTURO.xml:S2:1472:11	O
(	SIRTURO.xml:S2:1484:1	O
5.2	SIRTURO.xml:S2:1485:3	O
)]	SIRTURO.xml:S2:1488:2	O
.	SIRTURO.xml:S2:1490:1	O
\n	SIRTURO.xml:S2:1492:1	O
5	SIRTURO.xml:S3:4:1	O
WARNINGS	SIRTURO.xml:S3:6:8	O
AND	SIRTURO.xml:S3:15:3	O
PRECAUTIONS	SIRTURO.xml:S3:19:11	O

EXCERPT	SIRTURO.xml:S3:37:7	O
:	SIRTURO.xml:S3:44:1	O
QT	SIRTURO.xml:S3:52:2	B-AdverseReaction
prolongation	SIRTURO.xml:S3:55:12	I-AdverseReaction
can	SIRTURO.xml:S3:68:3	B-Factor
occur	SIRTURO.xml:S3:72:5	O
with	SIRTURO.xml:S3:78:4	O
SIRTURO	SIRTURO.xml:S3:83:7	O
.	SIRTURO.xml:S3:90:1	O

Monitor	SIRTURO.xml:S3:92:7	O
ECGs	SIRTURO.xml:S3:100:4	O
and	SIRTURO.xml:S3:105:3	O
discontinue	SIRTURO.xml:S3:109:11	O
SIRTURO	SIRTURO.xml:S3:121:7	O
if	SIRTURO.xml:S3:129:2	O
significant	SIRTURO.xml:S3:132:11	O
ventricular	SIRTURO.xml:S3:144:11	O
arrhythmia	SIRTURO.xml:S3:156:10	O
or	SIRTURO.xml:S3:167:2	O
QTcF	SIRTURO.xml:S3:170:4	O
interval	SIRTURO.xml:S3:175:8	O
500	SIRTURO.xml:S3:186:3	O
ms	SIRTURO.xml:S3:190:2	O
develops	SIRTURO.xml:S3:193:8	O
.	SIRTURO.xml:S3:201:1	O

(	SIRTURO.xml:S3:203:1	O
5.2	SIRTURO.xml:S3:206:3	O
)	SIRTURO.xml:S3:211:1	O

Hepatotoxicity	SIRTURO.xml:S3:218:14	B-AdverseReaction
may	SIRTURO.xml:S3:233:3	B-Factor
occur	SIRTURO.xml:S3:237:5	O
with	SIRTURO.xml:S3:243:4	O
use	SIRTURO.xml:S3:248:3	O
of	SIRTURO.xml:S3:252:2	O
SIRTURO	SIRTURO.xml:S3:255:7	O
.	SIRTURO.xml:S3:262:1	O

Monitor	SIRTURO.xml:S3:264:7	O
liver	SIRTURO.xml:S3:272:5	O
-	SIRTURO.xml:S3:277:1	O
related	SIRTURO.xml:S3:278:7	O
laboratory	SIRTURO.xml:S3:286:10	O
tests	SIRTURO.xml:S3:297:5	O
.	SIRTURO.xml:S3:302:1	O

Discontinue	SIRTURO.xml:S3:304:11	O
if	SIRTURO.xml:S3:316:2	O
evidence	SIRTURO.xml:S3:319:8	O
of	SIRTURO.xml:S3:328:2	O
liver	SIRTURO.xml:S3:331:5	O
injury	SIRTURO.xml:S3:337:6	O
.	SIRTURO.xml:S3:343:1	O

(	SIRTURO.xml:S3:345:1	O
5.3	SIRTURO.xml:S3:348:3	O
)	SIRTURO.xml:S3:353:1	O

5.1	SIRTURO.xml:S3:367:3	O

Increased	SIRTURO.xml:S3:371:9	O

Mortality	SIRTURO.xml:S3:381:9	O

An	SIRTURO.xml:S3:396:2	O
increased	SIRTURO.xml:S3:399:9	O
risk	SIRTURO.xml:S3:409:4	B-Factor
of	SIRTURO.xml:S3:414:2	O
death	SIRTURO.xml:S3:417:5	B-AdverseReaction
was	SIRTURO.xml:S3:423:3	O
seen	SIRTURO.xml:S3:427:4	O
in	SIRTURO.xml:S3:432:2	O
the	SIRTURO.xml:S3:435:3	O
SIRTURO	SIRTURO.xml:S3:439:7	O
treatment	SIRTURO.xml:S3:447:9	O
group	SIRTURO.xml:S3:457:5	O
(	SIRTURO.xml:S3:463:1	O
9	SIRTURO.xml:S3:464:1	O
79	SIRTURO.xml:S3:466:2	O
,	SIRTURO.xml:S3:468:1	O
11.4%	SIRTURO.xml:S3:470:5	O
)	SIRTURO.xml:S3:475:1	O
compared	SIRTURO.xml:S3:477:8	O
to	SIRTURO.xml:S3:486:2	O
the	SIRTURO.xml:S3:489:3	O
placebo	SIRTURO.xml:S3:493:7	O
treatment	SIRTURO.xml:S3:501:9	O
group	SIRTURO.xml:S3:511:5	O
(	SIRTURO.xml:S3:517:1	O
2	SIRTURO.xml:S3:518:1	O
81	SIRTURO.xml:S3:520:2	O
,	SIRTURO.xml:S3:522:1	O
2.5%	SIRTURO.xml:S3:524:4	O
)	SIRTURO.xml:S3:528:1	O
in	SIRTURO.xml:S3:530:2	O
one	SIRTURO.xml:S3:533:3	O
placebo	SIRTURO.xml:S3:537:7	O
-	SIRTURO.xml:S3:544:1	O
controlled	SIRTURO.xml:S3:545:10	O
trial	SIRTURO.xml:S3:556:5	O
(	SIRTURO.xml:S3:562:1	O
based	SIRTURO.xml:S3:563:5	O
on	SIRTURO.xml:S3:569:2	O
the	SIRTURO.xml:S3:572:3	O
120	SIRTURO.xml:S3:576:3	O
-	SIRTURO.xml:S3:579:1	O
week	SIRTURO.xml:S3:580:4	O
visit	SIRTURO.xml:S3:585:5	O
window	SIRTURO.xml:S3:591:6	O
)	SIRTURO.xml:S3:597:1	O
.	SIRTURO.xml:S3:598:1	O

One	SIRTURO.xml:S3:600:3	O
death	SIRTURO.xml:S3:604:5	B-AdverseReaction
occurred	SIRTURO.xml:S3:610:8	O
during	SIRTURO.xml:S3:619:6	O
the	SIRTURO.xml:S3:626:3	O
24	SIRTURO.xml:S3:630:2	O
weeks	SIRTURO.xml:S3:633:5	O
of	SIRTURO.xml:S3:639:2	O
administration	SIRTURO.xml:S3:642:14	O
of	SIRTURO.xml:S3:657:2	O
SIRTURO	SIRTURO.xml:S3:660:7	O
.	SIRTURO.xml:S3:667:1	O

The	SIRTURO.xml:S3:669:3	O
imbalance	SIRTURO.xml:S3:673:9	O
in	SIRTURO.xml:S3:683:2	O
deaths	SIRTURO.xml:S3:686:6	B-AdverseReaction
is	SIRTURO.xml:S3:693:2	O
unexplained	SIRTURO.xml:S3:696:11	O
.	SIRTURO.xml:S3:707:1	O

No	SIRTURO.xml:S3:709:2	O
discernible	SIRTURO.xml:S3:712:11	O
pattern	SIRTURO.xml:S3:724:7	O
between	SIRTURO.xml:S3:732:7	O
death	SIRTURO.xml:S3:740:5	B-AdverseReaction
and	SIRTURO.xml:S3:746:3	O
sputum	SIRTURO.xml:S3:750:6	O
culture	SIRTURO.xml:S3:757:7	O
conversion	SIRTURO.xml:S3:765:10	O
,	SIRTURO.xml:S3:775:1	O
relapse	SIRTURO.xml:S3:777:7	O
,	SIRTURO.xml:S3:784:1	O
sensitivity	SIRTURO.xml:S3:786:11	O
to	SIRTURO.xml:S3:798:2	O
other	SIRTURO.xml:S3:801:5	O
drugs	SIRTURO.xml:S3:807:5	O
used	SIRTURO.xml:S3:813:4	O
to	SIRTURO.xml:S3:818:2	O
treat	SIRTURO.xml:S3:821:5	O
tuberculosis	SIRTURO.xml:S3:827:12	O
,	SIRTURO.xml:S3:839:1	O
HIV	SIRTURO.xml:S3:841:3	O
status	SIRTURO.xml:S3:845:6	O
,	SIRTURO.xml:S3:851:1	O
or	SIRTURO.xml:S3:853:2	O
severity	SIRTURO.xml:S3:856:8	O
of	SIRTURO.xml:S3:865:2	O
disease	SIRTURO.xml:S3:868:7	O
could	SIRTURO.xml:S3:876:5	O
be	SIRTURO.xml:S3:882:2	O
observed	SIRTURO.xml:S3:885:8	O
.	SIRTURO.xml:S3:893:1	O

Only	SIRTURO.xml:S3:895:4	O
use	SIRTURO.xml:S3:900:3	O
SIRTURO	SIRTURO.xml:S3:904:7	O
when	SIRTURO.xml:S3:912:4	O
an	SIRTURO.xml:S3:917:2	O
effective	SIRTURO.xml:S3:920:9	O
treatment	SIRTURO.xml:S3:930:9	O
regimen	SIRTURO.xml:S3:940:7	O
cannot	SIRTURO.xml:S3:948:6	O
otherwise	SIRTURO.xml:S3:955:9	O
be	SIRTURO.xml:S3:965:2	O
provided	SIRTURO.xml:S3:968:8	O
[	SIRTURO.xml:S3:977:1	O
see	SIRTURO.xml:S3:978:3	O
Adverse	SIRTURO.xml:S3:983:7	O
Reactions	SIRTURO.xml:S3:991:9	O
(	SIRTURO.xml:S3:1001:1	O
6	SIRTURO.xml:S3:1002:1	O
)	SIRTURO.xml:S3:1003:1	O
]	SIRTURO.xml:S3:1006:1	O
.	SIRTURO.xml:S3:1009:1	O

5.2	SIRTURO.xml:S3:1018:3	O
QT	SIRTURO.xml:S3:1022:2	O
Prolongation	SIRTURO.xml:S3:1025:12	O

SIRTURO	SIRTURO.xml:S3:1043:7	O
prolongs	SIRTURO.xml:S3:1051:8	B-AdverseReaction
the	SIRTURO.xml:S3:1060:3	I-AdverseReaction
QT	SIRTURO.xml:S3:1064:2	I-AdverseReaction
interval	SIRTURO.xml:S3:1067:8	I-AdverseReaction
.	SIRTURO.xml:S3:1075:1	O

Obtain	SIRTURO.xml:S3:1077:6	O
an	SIRTURO.xml:S3:1084:2	O
ECG	SIRTURO.xml:S3:1087:3	O
before	SIRTURO.xml:S3:1091:6	O
initiation	SIRTURO.xml:S3:1098:10	O
of	SIRTURO.xml:S3:1109:2	O
treatment	SIRTURO.xml:S3:1112:9	O
,	SIRTURO.xml:S3:1121:1	O
and	SIRTURO.xml:S3:1123:3	O
at	SIRTURO.xml:S3:1127:2	O
least	SIRTURO.xml:S3:1130:5	O
2	SIRTURO.xml:S3:1136:1	O
,	SIRTURO.xml:S3:1137:1	O
12	SIRTURO.xml:S3:1139:2	O
,	SIRTURO.xml:S3:1141:1	O
and	SIRTURO.xml:S3:1143:3	O
24	SIRTURO.xml:S3:1147:2	O
weeks	SIRTURO.xml:S3:1150:5	O
after	SIRTURO.xml:S3:1156:5	O
starting	SIRTURO.xml:S3:1162:8	O
treatment	SIRTURO.xml:S3:1171:9	O
with	SIRTURO.xml:S3:1181:4	O
SIRTURO	SIRTURO.xml:S3:1186:7	O
.	SIRTURO.xml:S3:1193:1	O

Obtain	SIRTURO.xml:S3:1195:6	O
serum	SIRTURO.xml:S3:1202:5	O
potassium	SIRTURO.xml:S3:1208:9	O
,	SIRTURO.xml:S3:1217:1	O
calcium	SIRTURO.xml:S3:1219:7	O
,	SIRTURO.xml:S3:1226:1	O
and	SIRTURO.xml:S3:1228:3	O
magnesium	SIRTURO.xml:S3:1232:9	O
at	SIRTURO.xml:S3:1242:2	O
baseline	SIRTURO.xml:S3:1245:8	O
and	SIRTURO.xml:S3:1254:3	O
correct	SIRTURO.xml:S3:1258:7	O
if	SIRTURO.xml:S3:1266:2	O
abnormal	SIRTURO.xml:S3:1269:8	O
.	SIRTURO.xml:S3:1277:1	O

Monitor	SIRTURO.xml:S3:1279:7	O
electrolytes	SIRTURO.xml:S3:1287:12	O
if	SIRTURO.xml:S3:1300:2	O
QT	SIRTURO.xml:S3:1303:2	O
prolongation	SIRTURO.xml:S3:1306:12	O
is	SIRTURO.xml:S3:1319:2	O
detected	SIRTURO.xml:S3:1322:8	O
[	SIRTURO.xml:S3:1331:1	O
see	SIRTURO.xml:S3:1332:3	O
Adverse	SIRTURO.xml:S3:1337:7	O
Reactions	SIRTURO.xml:S3:1345:9	O
(	SIRTURO.xml:S3:1355:1	O
6.1	SIRTURO.xml:S3:1356:3	O
)	SIRTURO.xml:S3:1359:1	O
and	SIRTURO.xml:S3:1364:3	O
Drug	SIRTURO.xml:S3:1370:4	O
Interactions	SIRTURO.xml:S3:1375:12	O
(	SIRTURO.xml:S3:1388:1	O
7.4	SIRTURO.xml:S3:1389:3	O
)	SIRTURO.xml:S3:1392:1	O
]	SIRTURO.xml:S3:1395:1	O
.	SIRTURO.xml:S3:1398:1	O

SIRTURO	SIRTURO.xml:S3:1400:7	O
has	SIRTURO.xml:S3:1408:3	O
not	SIRTURO.xml:S3:1412:3	O
been	SIRTURO.xml:S3:1416:4	O
studied	SIRTURO.xml:S3:1421:7	O
in	SIRTURO.xml:S3:1429:2	O
patients	SIRTURO.xml:S3:1432:8	O
with	SIRTURO.xml:S3:1441:4	O
ventricular	SIRTURO.xml:S3:1446:11	O
arrhythmias	SIRTURO.xml:S3:1458:11	O
or	SIRTURO.xml:S3:1470:2	O
recent	SIRTURO.xml:S3:1473:6	O
myocardial	SIRTURO.xml:S3:1480:10	O
infarction	SIRTURO.xml:S3:1491:10	O
.	SIRTURO.xml:S3:1501:1	O

The	SIRTURO.xml:S3:1507:3	O
following	SIRTURO.xml:S3:1511:9	O
may	SIRTURO.xml:S3:1521:3	O
increase	SIRTURO.xml:S3:1525:8	O
the	SIRTURO.xml:S3:1534:3	O
risk	SIRTURO.xml:S3:1538:4	B-Factor
for	SIRTURO.xml:S3:1543:3	O
QT	SIRTURO.xml:S3:1547:2	B-AdverseReaction
prolongation	SIRTURO.xml:S3:1550:12	I-AdverseReaction
when	SIRTURO.xml:S3:1563:4	O
patients	SIRTURO.xml:S3:1568:8	O
are	SIRTURO.xml:S3:1577:3	O
receiving	SIRTURO.xml:S3:1581:9	O
SIRTURO	SIRTURO.xml:S3:1591:7	O
:	SIRTURO.xml:S3:1598:1	O

use	SIRTURO.xml:S3:1607:3	O
with	SIRTURO.xml:S3:1611:4	O
other	SIRTURO.xml:S3:1616:5	O
QT	SIRTURO.xml:S3:1622:2	O
prolonging	SIRTURO.xml:S3:1625:10	O
drugs	SIRTURO.xml:S3:1636:5	O
including	SIRTURO.xml:S3:1642:9	O
fluoroquinolones	SIRTURO.xml:S3:1652:16	O
and	SIRTURO.xml:S3:1669:3	O
macrolide	SIRTURO.xml:S3:1673:9	O
antibacterial	SIRTURO.xml:S3:1683:13	O
drugs	SIRTURO.xml:S3:1697:5	O
and	SIRTURO.xml:S3:1703:3	O
the	SIRTURO.xml:S3:1707:3	O
antimycobacterial	SIRTURO.xml:S3:1711:17	O
drug	SIRTURO.xml:S3:1729:4	O
,	SIRTURO.xml:S3:1733:1	O
clofazimine	SIRTURO.xml:S3:1735:11	O

a	SIRTURO.xml:S3:1752:1	O
history	SIRTURO.xml:S3:1754:7	O
of	SIRTURO.xml:S3:1762:2	O
Torsade	SIRTURO.xml:S3:1765:7	O
de	SIRTURO.xml:S3:1773:2	O
Pointes	SIRTURO.xml:S3:1776:7	O

a	SIRTURO.xml:S3:1789:1	O
history	SIRTURO.xml:S3:1791:7	O
of	SIRTURO.xml:S3:1799:2	O
congenital	SIRTURO.xml:S3:1802:10	O
long	SIRTURO.xml:S3:1813:4	O
QT	SIRTURO.xml:S3:1818:2	O
syndrome	SIRTURO.xml:S3:1821:8	O

a	SIRTURO.xml:S3:1835:1	O
history	SIRTURO.xml:S3:1837:7	O
of	SIRTURO.xml:S3:1845:2	O
or	SIRTURO.xml:S3:1848:2	O
ongoing	SIRTURO.xml:S3:1851:7	O
hypothyroidism	SIRTURO.xml:S3:1859:14	O

a	SIRTURO.xml:S3:1879:1	O
history	SIRTURO.xml:S3:1881:7	O
of	SIRTURO.xml:S3:1889:2	O
or	SIRTURO.xml:S3:1892:2	O
ongoing	SIRTURO.xml:S3:1895:7	O
bradyarrhythmias	SIRTURO.xml:S3:1903:16	O

a	SIRTURO.xml:S3:1925:1	O
history	SIRTURO.xml:S3:1927:7	O
of	SIRTURO.xml:S3:1935:2	O
uncompensated	SIRTURO.xml:S3:1938:13	O
heart	SIRTURO.xml:S3:1952:5	O
failure	SIRTURO.xml:S3:1958:7	O

serum	SIRTURO.xml:S3:1971:5	O
calcium	SIRTURO.xml:S3:1977:7	O
,	SIRTURO.xml:S3:1984:1	O
magnesium	SIRTURO.xml:S3:1986:9	O
,	SIRTURO.xml:S3:1995:1	O
or	SIRTURO.xml:S3:1997:2	O
potassium	SIRTURO.xml:S3:2000:9	O
levels	SIRTURO.xml:S3:2010:6	O
below	SIRTURO.xml:S3:2017:5	O
the	SIRTURO.xml:S3:2023:3	O
lower	SIRTURO.xml:S3:2027:5	O
limits	SIRTURO.xml:S3:2033:6	O
of	SIRTURO.xml:S3:2040:2	O
normal	SIRTURO.xml:S3:2043:6	O

If	SIRTURO.xml:S3:2055:2	O
necessary	SIRTURO.xml:S3:2058:9	O
,	SIRTURO.xml:S3:2067:1	O
bedaquiline	SIRTURO.xml:S3:2069:11	O
treatment	SIRTURO.xml:S3:2081:9	O
initiation	SIRTURO.xml:S3:2091:10	O
could	SIRTURO.xml:S3:2102:5	O
be	SIRTURO.xml:S3:2108:2	O
considered	SIRTURO.xml:S3:2111:10	O
in	SIRTURO.xml:S3:2122:2	O
these	SIRTURO.xml:S3:2125:5	O
patients	SIRTURO.xml:S3:2131:8	O
after	SIRTURO.xml:S3:2140:5	O
a	SIRTURO.xml:S3:2146:1	O
favorable	SIRTURO.xml:S3:2148:9	O
benefit	SIRTURO.xml:S3:2158:7	O
risk	SIRTURO.xml:S3:2166:4	O
assessment	SIRTURO.xml:S3:2171:10	O
and	SIRTURO.xml:S3:2182:3	O
with	SIRTURO.xml:S3:2186:4	O
frequent	SIRTURO.xml:S3:2191:8	O
ECG	SIRTURO.xml:S3:2200:3	O
monitoring	SIRTURO.xml:S3:2204:10	O
.	SIRTURO.xml:S3:2214:1	O

Discontinue	SIRTURO.xml:S3:2220:11	O

SIRTURO	SIRTURO.xml:S3:2232:7	O
and	SIRTURO.xml:S3:2240:3	O
all	SIRTURO.xml:S3:2244:3	O
other	SIRTURO.xml:S3:2248:5	O
QT	SIRTURO.xml:S3:2254:2	O
prolonging	SIRTURO.xml:S3:2257:10	O
drugs	SIRTURO.xml:S3:2268:5	O
if	SIRTURO.xml:S3:2274:2	O
the	SIRTURO.xml:S3:2277:3	O
patient	SIRTURO.xml:S3:2281:7	O
develops	SIRTURO.xml:S3:2289:8	O
:	SIRTURO.xml:S3:2297:1	O

Clinically	SIRTURO.xml:S3:2306:10	O
significant	SIRTURO.xml:S3:2317:11	O
ventricular	SIRTURO.xml:S3:2329:11	O
arrhythmia	SIRTURO.xml:S3:2341:10	O

A	SIRTURO.xml:S3:2357:1	O
QTcF	SIRTURO.xml:S3:2359:4	O
interval	SIRTURO.xml:S3:2364:8	O
of	SIRTURO.xml:S3:2373:2	O
greater	SIRTURO.xml:S3:2376:7	O
than	SIRTURO.xml:S3:2384:4	O
500	SIRTURO.xml:S3:2389:3	O
ms	SIRTURO.xml:S3:2393:2	O
(	SIRTURO.xml:S3:2396:1	O
confirmed	SIRTURO.xml:S3:2397:9	O
by	SIRTURO.xml:S3:2407:2	O
repeat	SIRTURO.xml:S3:2410:6	O
ECG	SIRTURO.xml:S3:2417:3	O
)	SIRTURO.xml:S3:2420:1	O

If	SIRTURO.xml:S3:2427:2	O
syncope	SIRTURO.xml:S3:2430:7	O
occurs	SIRTURO.xml:S3:2438:6	O
,	SIRTURO.xml:S3:2444:1	O
obtain	SIRTURO.xml:S3:2446:6	O
an	SIRTURO.xml:S3:2453:2	O
ECG	SIRTURO.xml:S3:2456:3	O
to	SIRTURO.xml:S3:2460:2	O
detect	SIRTURO.xml:S3:2463:6	O
QT	SIRTURO.xml:S3:2470:2	O
prolongation	SIRTURO.xml:S3:2473:12	O
.	SIRTURO.xml:S3:2485:1	O

5.3	SIRTURO.xml:S3:2494:3	O

Hepatotoxicity	SIRTURO.xml:S3:2498:14	O

More	SIRTURO.xml:S3:2518:4	O
hepatic	SIRTURO.xml:S3:2523:7	B-AdverseReaction
-	SIRTURO.xml:S3:2530:1	I-AdverseReaction
related	SIRTURO.xml:S3:2531:7	I-AdverseReaction
adverse	SIRTURO.xml:S3:2539:7	I-AdverseReaction
reactions	SIRTURO.xml:S3:2547:9	I-AdverseReaction
were	SIRTURO.xml:S3:2557:4	O
reported	SIRTURO.xml:S3:2562:8	O
with	SIRTURO.xml:S3:2571:4	O
the	SIRTURO.xml:S3:2576:3	O
use	SIRTURO.xml:S3:2580:3	O
of	SIRTURO.xml:S3:2584:2	O
SIRTURO	SIRTURO.xml:S3:2587:7	O
plus	SIRTURO.xml:S3:2595:4	O
other	SIRTURO.xml:S3:2600:5	O
drugs	SIRTURO.xml:S3:2606:5	O
used	SIRTURO.xml:S3:2612:4	O
to	SIRTURO.xml:S3:2617:2	O
treat	SIRTURO.xml:S3:2620:5	O
tuberculosis	SIRTURO.xml:S3:2626:12	O
compared	SIRTURO.xml:S3:2639:8	O
to	SIRTURO.xml:S3:2648:2	O
other	SIRTURO.xml:S3:2651:5	O
drugs	SIRTURO.xml:S3:2657:5	O
used	SIRTURO.xml:S3:2663:4	O
to	SIRTURO.xml:S3:2668:2	O
treat	SIRTURO.xml:S3:2671:5	O
tuberculosis	SIRTURO.xml:S3:2677:12	O
without	SIRTURO.xml:S3:2690:7	O
the	SIRTURO.xml:S3:2698:3	O
addition	SIRTURO.xml:S3:2702:8	O
of	SIRTURO.xml:S3:2711:2	O
SIRTURO	SIRTURO.xml:S3:2714:7	O
.	SIRTURO.xml:S3:2721:1	O

Alcohol	SIRTURO.xml:S3:2723:7	O
and	SIRTURO.xml:S3:2731:3	O
other	SIRTURO.xml:S3:2735:5	O
hepatotoxic	SIRTURO.xml:S3:2741:11	O
drugs	SIRTURO.xml:S3:2753:5	O
should	SIRTURO.xml:S3:2759:6	O
be	SIRTURO.xml:S3:2766:2	O
avoided	SIRTURO.xml:S3:2769:7	O
while	SIRTURO.xml:S3:2777:5	O
on	SIRTURO.xml:S3:2783:2	O
SIRTURO	SIRTURO.xml:S3:2786:7	O
,	SIRTURO.xml:S3:2793:1	O
especially	SIRTURO.xml:S3:2795:10	O
in	SIRTURO.xml:S3:2806:2	O
patients	SIRTURO.xml:S3:2809:8	O
with	SIRTURO.xml:S3:2818:4	O
impaired	SIRTURO.xml:S3:2823:8	O
hepatic	SIRTURO.xml:S3:2832:7	O
function	SIRTURO.xml:S3:2840:8	O
.	SIRTURO.xml:S3:2848:1	O

Monitor	SIRTURO.xml:S3:2854:7	O
symptoms	SIRTURO.xml:S3:2862:8	O
(	SIRTURO.xml:S3:2871:1	O
such	SIRTURO.xml:S3:2872:4	O
as	SIRTURO.xml:S3:2877:2	O
fatigue	SIRTURO.xml:S3:2880:7	O
,	SIRTURO.xml:S3:2887:1	O
anorexia	SIRTURO.xml:S3:2889:8	O
,	SIRTURO.xml:S3:2897:1	O
nausea	SIRTURO.xml:S3:2899:6	O
,	SIRTURO.xml:S3:2905:1	O
jaundice	SIRTURO.xml:S3:2907:8	O
,	SIRTURO.xml:S3:2915:1	O
dark	SIRTURO.xml:S3:2917:4	O
urine	SIRTURO.xml:S3:2922:5	O
,	SIRTURO.xml:S3:2927:1	O
liver	SIRTURO.xml:S3:2929:5	O
tenderness	SIRTURO.xml:S3:2935:10	O
and	SIRTURO.xml:S3:2946:3	O
hepatomegaly	SIRTURO.xml:S3:2950:12	O
)	SIRTURO.xml:S3:2962:1	O
and	SIRTURO.xml:S3:2964:3	O
laboratory	SIRTURO.xml:S3:2968:10	O
tests	SIRTURO.xml:S3:2979:5	O
(	SIRTURO.xml:S3:2985:1	O
ALT	SIRTURO.xml:S3:2986:3	O
,	SIRTURO.xml:S3:2989:1	O
AST	SIRTURO.xml:S3:2991:3	O
,	SIRTURO.xml:S3:2994:1	O
alkaline	SIRTURO.xml:S3:2996:8	O
phosphatase	SIRTURO.xml:S3:3005:11	O
,	SIRTURO.xml:S3:3016:1	O
and	SIRTURO.xml:S3:3018:3	O
bilirubin	SIRTURO.xml:S3:3022:9	O
)	SIRTURO.xml:S3:3031:1	O
at	SIRTURO.xml:S3:3033:2	O
baseline	SIRTURO.xml:S3:3036:8	O
,	SIRTURO.xml:S3:3044:1	O
monthly	SIRTURO.xml:S3:3046:7	O
while	SIRTURO.xml:S3:3054:5	O
on	SIRTURO.xml:S3:3060:2	O
treatment	SIRTURO.xml:S3:3063:9	O
,	SIRTURO.xml:S3:3072:1	O
and	SIRTURO.xml:S3:3074:3	O
as	SIRTURO.xml:S3:3078:2	O
needed	SIRTURO.xml:S3:3081:6	O
.	SIRTURO.xml:S3:3087:1	O

Test	SIRTURO.xml:S3:3089:4	O
for	SIRTURO.xml:S3:3094:3	O
viral	SIRTURO.xml:S3:3098:5	O
hepatitis	SIRTURO.xml:S3:3104:9	O
and	SIRTURO.xml:S3:3114:3	O
discontinue	SIRTURO.xml:S3:3118:11	O
other	SIRTURO.xml:S3:3130:5	O
hepatotoxic	SIRTURO.xml:S3:3136:11	O
medications	SIRTURO.xml:S3:3148:11	O
if	SIRTURO.xml:S3:3160:2	O
evidence	SIRTURO.xml:S3:3163:8	O
of	SIRTURO.xml:S3:3172:2	O
new	SIRTURO.xml:S3:3175:3	O
or	SIRTURO.xml:S3:3179:2	O
worsening	SIRTURO.xml:S3:3182:9	O
liver	SIRTURO.xml:S3:3192:5	O
dysfunction	SIRTURO.xml:S3:3198:11	O
occurs	SIRTURO.xml:S3:3210:6	O
.	SIRTURO.xml:S3:3216:1	O

Discontinue	SIRTURO.xml:S3:3218:11	O
SIRTURO	SIRTURO.xml:S3:3230:7	O
if	SIRTURO.xml:S3:3238:2	O
:	SIRTURO.xml:S3:3240:1	O

aminotransferase	SIRTURO.xml:S3:3249:16	O
elevations	SIRTURO.xml:S3:3266:10	O
are	SIRTURO.xml:S3:3277:3	O
accompanied	SIRTURO.xml:S3:3281:11	O
by	SIRTURO.xml:S3:3293:2	O
total	SIRTURO.xml:S3:3296:5	O
bilirubin	SIRTURO.xml:S3:3302:9	O
elevation	SIRTURO.xml:S3:3312:9	O
greater	SIRTURO.xml:S3:3322:7	O
than	SIRTURO.xml:S3:3330:4	O
two	SIRTURO.xml:S3:3335:3	O
times	SIRTURO.xml:S3:3339:5	O
the	SIRTURO.xml:S3:3345:3	O
upper	SIRTURO.xml:S3:3349:5	O
limit	SIRTURO.xml:S3:3355:5	O
of	SIRTURO.xml:S3:3361:2	O
normal	SIRTURO.xml:S3:3364:6	O

aminotransferase	SIRTURO.xml:S3:3376:16	O
elevations	SIRTURO.xml:S3:3393:10	O
are	SIRTURO.xml:S3:3404:3	O
greater	SIRTURO.xml:S3:3408:7	O
than	SIRTURO.xml:S3:3416:4	O
eight	SIRTURO.xml:S3:3421:5	O
times	SIRTURO.xml:S3:3427:5	O
the	SIRTURO.xml:S3:3433:3	O
upper	SIRTURO.xml:S3:3437:5	O
limit	SIRTURO.xml:S3:3443:5	O
of	SIRTURO.xml:S3:3449:2	O
normal	SIRTURO.xml:S3:3452:6	O

aminotransferase	SIRTURO.xml:S3:3464:16	O
elevations	SIRTURO.xml:S3:3481:10	O
are	SIRTURO.xml:S3:3492:3	O
greater	SIRTURO.xml:S3:3496:7	O
than	SIRTURO.xml:S3:3504:4	O
five	SIRTURO.xml:S3:3509:4	O
times	SIRTURO.xml:S3:3514:5	O
the	SIRTURO.xml:S3:3520:3	O
upper	SIRTURO.xml:S3:3524:5	O
limit	SIRTURO.xml:S3:3530:5	O
of	SIRTURO.xml:S3:3536:2	O
normal	SIRTURO.xml:S3:3539:6	O
and	SIRTURO.xml:S3:3546:3	O
persist	SIRTURO.xml:S3:3550:7	O
beyond	SIRTURO.xml:S3:3558:6	O
two	SIRTURO.xml:S3:3565:3	O
weeks	SIRTURO.xml:S3:3569:5	O

5.4	SIRTURO.xml:S3:3583:3	O
Drug	SIRTURO.xml:S3:3587:4	O
Interactions	SIRTURO.xml:S3:3592:12	O

CYP3A4	SIRTURO.xml:S3:3611:6	O

inducers	SIRTURO.xml:S3:3618:8	O
inhibitors	SIRTURO.xml:S3:3627:10	O

Bedaquiline	SIRTURO.xml:S3:3644:11	O
is	SIRTURO.xml:S3:3656:2	O
metabolized	SIRTURO.xml:S3:3659:11	O
by	SIRTURO.xml:S3:3671:2	O
CYP3A4	SIRTURO.xml:S3:3674:6	O
and	SIRTURO.xml:S3:3681:3	O
its	SIRTURO.xml:S3:3685:3	O
systemic	SIRTURO.xml:S3:3689:8	O
exposure	SIRTURO.xml:S3:3698:8	O
and	SIRTURO.xml:S3:3707:3	O
therapeutic	SIRTURO.xml:S3:3711:11	O
effect	SIRTURO.xml:S3:3723:6	O
may	SIRTURO.xml:S3:3730:3	O
therefore	SIRTURO.xml:S3:3734:9	O
be	SIRTURO.xml:S3:3744:2	O
reduced	SIRTURO.xml:S3:3747:7	O
during	SIRTURO.xml:S3:3755:6	O
co	SIRTURO.xml:S3:3762:2	O
-	SIRTURO.xml:S3:3764:1	O
administration	SIRTURO.xml:S3:3765:14	O
with	SIRTURO.xml:S3:3780:4	O
inducers	SIRTURO.xml:S3:3785:8	O
of	SIRTURO.xml:S3:3794:2	O
CYP3A4	SIRTURO.xml:S3:3797:6	O
.	SIRTURO.xml:S3:3803:1	O

Avoid	SIRTURO.xml:S3:3805:5	O
co	SIRTURO.xml:S3:3811:2	O
-	SIRTURO.xml:S3:3813:1	O
administration	SIRTURO.xml:S3:3814:14	O
of	SIRTURO.xml:S3:3829:2	O
strong	SIRTURO.xml:S3:3832:6	O
CYP3A4	SIRTURO.xml:S3:3839:6	O
inducers	SIRTURO.xml:S3:3846:8	O
,	SIRTURO.xml:S3:3854:1	O
such	SIRTURO.xml:S3:3856:4	O
as	SIRTURO.xml:S3:3861:2	O
rifamycins	SIRTURO.xml:S3:3864:10	O
(	SIRTURO.xml:S3:3875:1	O
i	SIRTURO.xml:S3:3876:1	O
.	SIRTURO.xml:S3:3877:1	O
e	SIRTURO.xml:S3:3878:1	O
.	SIRTURO.xml:S3:3879:1	O
,	SIRTURO.xml:S3:3880:1	O
rifampin	SIRTURO.xml:S3:3882:8	O
,	SIRTURO.xml:S3:3890:1	O
rifapentine	SIRTURO.xml:S3:3892:11	O
and	SIRTURO.xml:S3:3904:3	O
rifabutin	SIRTURO.xml:S3:3908:9	O
)	SIRTURO.xml:S3:3917:1	O
,	SIRTURO.xml:S3:3918:1	O
or	SIRTURO.xml:S3:3920:2	O
moderate	SIRTURO.xml:S3:3923:8	O
CYP3A4	SIRTURO.xml:S3:3932:6	O
inducers	SIRTURO.xml:S3:3939:8	O
,	SIRTURO.xml:S3:3947:1	O
such	SIRTURO.xml:S3:3949:4	O
as	SIRTURO.xml:S3:3954:2	O
efavirenz	SIRTURO.xml:S3:3957:9	O
,	SIRTURO.xml:S3:3966:1	O
during	SIRTURO.xml:S3:3968:6	O
treatment	SIRTURO.xml:S3:3975:9	O
with	SIRTURO.xml:S3:3985:4	O
SIRTURO	SIRTURO.xml:S3:3990:7	O
[	SIRTURO.xml:S3:3998:1	O
see	SIRTURO.xml:S3:3999:3	O
Drug	SIRTURO.xml:S3:4004:4	O
Interactions	SIRTURO.xml:S3:4009:12	O
(	SIRTURO.xml:S3:4022:1	O
7.1	SIRTURO.xml:S3:4023:3	O
)	SIRTURO.xml:S3:4026:1	O
]	SIRTURO.xml:S3:4029:1	O
.	SIRTURO.xml:S3:4032:1	O

Co	SIRTURO.xml:S3:4038:2	O
-	SIRTURO.xml:S3:4040:1	O
administration	SIRTURO.xml:S3:4041:14	O
of	SIRTURO.xml:S3:4056:2	O
SIRTURO	SIRTURO.xml:S3:4059:7	O
with	SIRTURO.xml:S3:4067:4	O
strong	SIRTURO.xml:S3:4072:6	O
CYP3A4	SIRTURO.xml:S3:4079:6	O
inhibitors	SIRTURO.xml:S3:4086:10	O
may	SIRTURO.xml:S3:4097:3	O
increase	SIRTURO.xml:S3:4101:8	O
the	SIRTURO.xml:S3:4110:3	O
systemic	SIRTURO.xml:S3:4114:8	O
exposure	SIRTURO.xml:S3:4123:8	O
to	SIRTURO.xml:S3:4132:2	O
bedaquiline	SIRTURO.xml:S3:4135:11	O
,	SIRTURO.xml:S3:4146:1	O
which	SIRTURO.xml:S3:4148:5	O
could	SIRTURO.xml:S3:4154:5	O
potentially	SIRTURO.xml:S3:4160:11	O
increase	SIRTURO.xml:S3:4172:8	O
the	SIRTURO.xml:S3:4181:3	O
risk	SIRTURO.xml:S3:4185:4	O
of	SIRTURO.xml:S3:4190:2	O
adverse	SIRTURO.xml:S3:4193:7	O
reactions	SIRTURO.xml:S3:4201:9	O
.	SIRTURO.xml:S3:4210:1	O

Therefore	SIRTURO.xml:S3:4212:9	O
,	SIRTURO.xml:S3:4221:1	O
avoid	SIRTURO.xml:S3:4223:5	O
the	SIRTURO.xml:S3:4229:3	O
use	SIRTURO.xml:S3:4233:3	O
of	SIRTURO.xml:S3:4237:2	O
strong	SIRTURO.xml:S3:4240:6	O
CYP3A4	SIRTURO.xml:S3:4247:6	O
inhibitors	SIRTURO.xml:S3:4254:10	O
for	SIRTURO.xml:S3:4265:3	O
more	SIRTURO.xml:S3:4269:4	O
than	SIRTURO.xml:S3:4274:4	O
14	SIRTURO.xml:S3:4279:2	O
consecutive	SIRTURO.xml:S3:4282:11	O
days	SIRTURO.xml:S3:4294:4	O
while	SIRTURO.xml:S3:4299:5	O
on	SIRTURO.xml:S3:4305:2	O
SIRTURO	SIRTURO.xml:S3:4308:7	O
,	SIRTURO.xml:S3:4315:1	O
unless	SIRTURO.xml:S3:4317:6	O
the	SIRTURO.xml:S3:4324:3	O
benefit	SIRTURO.xml:S3:4328:7	O
of	SIRTURO.xml:S3:4336:2	O
treatment	SIRTURO.xml:S3:4339:9	O
with	SIRTURO.xml:S3:4349:4	O
the	SIRTURO.xml:S3:4354:3	O
drug	SIRTURO.xml:S3:4358:4	O
combination	SIRTURO.xml:S3:4363:11	O
outweighs	SIRTURO.xml:S3:4375:9	O
the	SIRTURO.xml:S3:4385:3	O
risk	SIRTURO.xml:S3:4389:4	O
[	SIRTURO.xml:S3:4394:1	O
see	SIRTURO.xml:S3:4395:3	O
Drug	SIRTURO.xml:S3:4400:4	O
Interactions	SIRTURO.xml:S3:4405:12	O
(	SIRTURO.xml:S3:4418:1	O
7.1	SIRTURO.xml:S3:4419:3	O
)	SIRTURO.xml:S3:4422:1	O
]	SIRTURO.xml:S3:4425:1	O
.	SIRTURO.xml:S3:4428:1	O

Appropriate	SIRTURO.xml:S3:4430:11	O
clinical	SIRTURO.xml:S3:4442:8	O
monitoring	SIRTURO.xml:S3:4451:10	O
for	SIRTURO.xml:S3:4462:3	O
SIRTURO	SIRTURO.xml:S3:4466:7	O
-	SIRTURO.xml:S3:4473:1	O
related	SIRTURO.xml:S3:4474:7	O
adverse	SIRTURO.xml:S3:4482:7	O
reactions	SIRTURO.xml:S3:4490:9	O
is	SIRTURO.xml:S3:4500:2	O
recommended	SIRTURO.xml:S3:4503:11	O
.	SIRTURO.xml:S3:4514:1	O
6	STENDRA.xml:S1:4:1	O
ADVERSE	STENDRA.xml:S1:6:7	O
REACTIONS	STENDRA.xml:S1:14:9	O

EXCERPT	STENDRA.xml:S1:27:7	O
:	STENDRA.xml:S1:34:1	O
Most	STENDRA.xml:S1:38:4	O
common	STENDRA.xml:S1:43:6	O
adverse	STENDRA.xml:S1:50:7	O
reactions	STENDRA.xml:S1:58:9	O
(	STENDRA.xml:S1:68:1	O
greater	STENDRA.xml:S1:69:7	O
than	STENDRA.xml:S1:77:4	O
or	STENDRA.xml:S1:82:2	O
equal	STENDRA.xml:S1:85:5	O
to	STENDRA.xml:S1:91:2	O
2%	STENDRA.xml:S1:94:2	O
)	STENDRA.xml:S1:96:1	O
include	STENDRA.xml:S1:98:7	O
headache	STENDRA.xml:S1:106:8	B-AdverseReaction
,	STENDRA.xml:S1:114:1	O
flushing	STENDRA.xml:S1:116:8	B-AdverseReaction
,	STENDRA.xml:S1:124:1	O
nasal	STENDRA.xml:S1:126:5	B-AdverseReaction
congestion	STENDRA.xml:S1:132:10	I-AdverseReaction
,	STENDRA.xml:S1:142:1	O
nasopharyngitis	STENDRA.xml:S1:144:15	B-AdverseReaction
,	STENDRA.xml:S1:159:1	O
and	STENDRA.xml:S1:161:3	O
back	STENDRA.xml:S1:165:4	B-AdverseReaction
pain	STENDRA.xml:S1:170:4	I-AdverseReaction
(	STENDRA.xml:S1:175:1	O
6.1	STENDRA.xml:S1:176:3	O
)	STENDRA.xml:S1:179:1	O

To	STENDRA.xml:S1:187:2	O
report	STENDRA.xml:S1:190:6	O
SUSPECTED	STENDRA.xml:S1:197:9	O
ADVERSE	STENDRA.xml:S1:207:7	O
REACTIONS	STENDRA.xml:S1:215:9	O
,	STENDRA.xml:S1:224:1	O
contact	STENDRA.xml:S1:226:7	O
1	STENDRA.xml:S1:234:1	O
-	STENDRA.xml:S1:235:1	O
877	STENDRA.xml:S1:236:3	O
-	STENDRA.xml:S1:239:1	O
663	STENDRA.xml:S1:240:3	O
-	STENDRA.xml:S1:243:1	O
0412	STENDRA.xml:S1:244:4	O
or	STENDRA.xml:S1:249:2	O
FDA	STENDRA.xml:S1:252:3	O
at	STENDRA.xml:S1:256:2	O
1	STENDRA.xml:S1:259:1	O
-	STENDRA.xml:S1:260:1	O
800	STENDRA.xml:S1:261:3	O
-	STENDRA.xml:S1:264:1	O
FDA	STENDRA.xml:S1:265:3	O
-	STENDRA.xml:S1:268:1	O
1088	STENDRA.xml:S1:269:4	O
or	STENDRA.xml:S1:274:2	O
www	STENDRA.xml:S1:278:3	O
.	STENDRA.xml:S1:281:1	O
fda	STENDRA.xml:S1:282:3	O
.	STENDRA.xml:S1:285:1	O
gov	STENDRA.xml:S1:286:3	O
medwatch	STENDRA.xml:S1:290:8	O
.	STENDRA.xml:S1:298:1	O

6.1	STENDRA.xml:S1:312:3	O

Clinical	STENDRA.xml:S1:316:8	O
Trials	STENDRA.xml:S1:325:6	O
Experience	STENDRA.xml:S1:332:10	O

Because	STENDRA.xml:S1:346:7	O
clinical	STENDRA.xml:S1:354:8	O
trials	STENDRA.xml:S1:363:6	O
are	STENDRA.xml:S1:370:3	O
conducted	STENDRA.xml:S1:374:9	O
under	STENDRA.xml:S1:384:5	O
widely	STENDRA.xml:S1:390:6	O
varying	STENDRA.xml:S1:397:7	O
conditions	STENDRA.xml:S1:405:10	O
,	STENDRA.xml:S1:415:1	O
adverse	STENDRA.xml:S1:417:7	O
reaction	STENDRA.xml:S1:425:8	O
rates	STENDRA.xml:S1:434:5	O
observed	STENDRA.xml:S1:440:8	O
in	STENDRA.xml:S1:449:2	O
the	STENDRA.xml:S1:452:3	O
clinical	STENDRA.xml:S1:456:8	O
trials	STENDRA.xml:S1:465:6	O
of	STENDRA.xml:S1:472:2	O
a	STENDRA.xml:S1:475:1	O
drug	STENDRA.xml:S1:477:4	O
cannot	STENDRA.xml:S1:482:6	O
be	STENDRA.xml:S1:489:2	O
directly	STENDRA.xml:S1:492:8	O
compared	STENDRA.xml:S1:501:8	O
to	STENDRA.xml:S1:510:2	O
rates	STENDRA.xml:S1:513:5	O
in	STENDRA.xml:S1:519:2	O
the	STENDRA.xml:S1:522:3	O
clinical	STENDRA.xml:S1:526:8	O
trials	STENDRA.xml:S1:535:6	O
of	STENDRA.xml:S1:542:2	O
another	STENDRA.xml:S1:545:7	O
drug	STENDRA.xml:S1:553:4	O
and	STENDRA.xml:S1:558:3	O
may	STENDRA.xml:S1:562:3	O
not	STENDRA.xml:S1:566:3	O
reflect	STENDRA.xml:S1:570:7	O
the	STENDRA.xml:S1:578:3	O
rates	STENDRA.xml:S1:582:5	O
observed	STENDRA.xml:S1:588:8	O
in	STENDRA.xml:S1:597:2	O
practice	STENDRA.xml:S1:600:8	O
.	STENDRA.xml:S1:608:1	O

STENDRA	STENDRA.xml:S1:614:7	O
was	STENDRA.xml:S1:622:3	O
administered	STENDRA.xml:S1:626:12	O
to	STENDRA.xml:S1:639:2	O
2215	STENDRA.xml:S1:642:4	O
men	STENDRA.xml:S1:647:3	O
during	STENDRA.xml:S1:651:6	O
clinical	STENDRA.xml:S1:658:8	O
trials	STENDRA.xml:S1:667:6	O
.	STENDRA.xml:S1:673:1	O

In	STENDRA.xml:S1:675:2	O
trials	STENDRA.xml:S1:678:6	O
of	STENDRA.xml:S1:685:2	O
STENDRA	STENDRA.xml:S1:688:7	O
for	STENDRA.xml:S1:696:3	O
use	STENDRA.xml:S1:700:3	O
as	STENDRA.xml:S1:704:2	O
needed	STENDRA.xml:S1:707:6	O
,	STENDRA.xml:S1:713:1	O
a	STENDRA.xml:S1:715:1	O
total	STENDRA.xml:S1:717:5	O
of	STENDRA.xml:S1:723:2	O
493	STENDRA.xml:S1:726:3	O
patients	STENDRA.xml:S1:730:8	O
were	STENDRA.xml:S1:739:4	O
exposed	STENDRA.xml:S1:744:7	O
for	STENDRA.xml:S1:752:3	O
greater	STENDRA.xml:S1:756:7	O
than	STENDRA.xml:S1:764:4	O
or	STENDRA.xml:S1:769:2	O
equal	STENDRA.xml:S1:772:5	O
to	STENDRA.xml:S1:778:2	O
6	STENDRA.xml:S1:781:1	O
months	STENDRA.xml:S1:783:6	O
,	STENDRA.xml:S1:789:1	O
and	STENDRA.xml:S1:791:3	O
153	STENDRA.xml:S1:795:3	O
patients	STENDRA.xml:S1:799:8	O
were	STENDRA.xml:S1:808:4	O
treated	STENDRA.xml:S1:813:7	O
for	STENDRA.xml:S1:821:3	O
greater	STENDRA.xml:S1:825:7	O
than	STENDRA.xml:S1:833:4	O
or	STENDRA.xml:S1:838:2	O
equal	STENDRA.xml:S1:841:5	O
to	STENDRA.xml:S1:847:2	O
12	STENDRA.xml:S1:850:2	O
months	STENDRA.xml:S1:853:6	O
.	STENDRA.xml:S1:859:1	O

In	STENDRA.xml:S1:865:2	O
three	STENDRA.xml:S1:868:5	O
randomized	STENDRA.xml:S1:874:10	O
,	STENDRA.xml:S1:884:1	O
double	STENDRA.xml:S1:886:6	O
-	STENDRA.xml:S1:892:1	O
blind	STENDRA.xml:S1:893:5	O
,	STENDRA.xml:S1:898:1	O
placebo	STENDRA.xml:S1:900:7	O
-	STENDRA.xml:S1:907:1	O
controlled	STENDRA.xml:S1:908:10	O
trials	STENDRA.xml:S1:919:6	O
lasting	STENDRA.xml:S1:926:7	O
up	STENDRA.xml:S1:934:2	O
to	STENDRA.xml:S1:937:2	O
3	STENDRA.xml:S1:940:1	O
months	STENDRA.xml:S1:942:6	O
in	STENDRA.xml:S1:949:2	O
duration	STENDRA.xml:S1:952:8	O
,	STENDRA.xml:S1:960:1	O
the	STENDRA.xml:S1:962:3	O
mean	STENDRA.xml:S1:966:4	O
age	STENDRA.xml:S1:971:3	O
of	STENDRA.xml:S1:975:2	O
patients	STENDRA.xml:S1:978:8	O
was	STENDRA.xml:S1:987:3	O
56.4	STENDRA.xml:S1:991:4	O
years	STENDRA.xml:S1:996:5	O
(	STENDRA.xml:S1:1002:1	O
range	STENDRA.xml:S1:1003:5	O
from	STENDRA.xml:S1:1009:4	O
23	STENDRA.xml:S1:1014:2	O
to	STENDRA.xml:S1:1017:2	O
88	STENDRA.xml:S1:1020:2	O
years	STENDRA.xml:S1:1023:5	O
)	STENDRA.xml:S1:1028:1	O
.	STENDRA.xml:S1:1029:1	O

83.9%	STENDRA.xml:S1:1031:5	O
of	STENDRA.xml:S1:1037:2	O
patients	STENDRA.xml:S1:1040:8	O
were	STENDRA.xml:S1:1049:4	O
White	STENDRA.xml:S1:1054:5	O
,	STENDRA.xml:S1:1059:1	O
13.8%	STENDRA.xml:S1:1061:5	O
were	STENDRA.xml:S1:1067:4	O
Black	STENDRA.xml:S1:1072:5	O
,	STENDRA.xml:S1:1077:1	O
1.4%	STENDRA.xml:S1:1079:4	O
Asian	STENDRA.xml:S1:1084:5	O
,	STENDRA.xml:S1:1089:1	O
and	STENDRA.xml:S1:1091:3	O
1%	STENDRA.xml:S1:1097:2	O
Hispanic	STENDRA.xml:S1:1100:8	O
.	STENDRA.xml:S1:1108:1	O

41.1%	STENDRA.xml:S1:1110:5	O
were	STENDRA.xml:S1:1116:4	O
current	STENDRA.xml:S1:1121:7	O
or	STENDRA.xml:S1:1129:2	O
previous	STENDRA.xml:S1:1132:8	O
smokers	STENDRA.xml:S1:1141:7	O
.	STENDRA.xml:S1:1148:1	O

30.6%	STENDRA.xml:S1:1150:5	O
had	STENDRA.xml:S1:1156:3	O
diabetes	STENDRA.xml:S1:1160:8	O
mellitus	STENDRA.xml:S1:1169:8	O
.	STENDRA.xml:S1:1177:1	O

The	STENDRA.xml:S1:1183:3	O
discontinuation	STENDRA.xml:S1:1187:15	O
rate	STENDRA.xml:S1:1203:4	O
due	STENDRA.xml:S1:1208:3	O
to	STENDRA.xml:S1:1212:2	O
adverse	STENDRA.xml:S1:1215:7	O
reactions	STENDRA.xml:S1:1223:9	O
for	STENDRA.xml:S1:1233:3	O
patients	STENDRA.xml:S1:1237:8	O
treated	STENDRA.xml:S1:1246:7	O
with	STENDRA.xml:S1:1254:4	O
STENDRA	STENDRA.xml:S1:1259:7	O
50	STENDRA.xml:S1:1267:2	O
mg	STENDRA.xml:S1:1270:2	O
,	STENDRA.xml:S1:1272:1	O
100	STENDRA.xml:S1:1274:3	O
mg	STENDRA.xml:S1:1278:2	O
,	STENDRA.xml:S1:1280:1	O
or	STENDRA.xml:S1:1282:2	O
200	STENDRA.xml:S1:1285:3	O
mg	STENDRA.xml:S1:1289:2	O
was	STENDRA.xml:S1:1292:3	O
1.4%	STENDRA.xml:S1:1296:4	O
,	STENDRA.xml:S1:1300:1	O
2.0%	STENDRA.xml:S1:1302:4	O
,	STENDRA.xml:S1:1306:1	O
and	STENDRA.xml:S1:1308:3	O
2.0%	STENDRA.xml:S1:1312:4	O
,	STENDRA.xml:S1:1316:1	O
respectively	STENDRA.xml:S1:1318:12	O
,	STENDRA.xml:S1:1330:1	O
compared	STENDRA.xml:S1:1332:8	O
to	STENDRA.xml:S1:1341:2	O
1.7%	STENDRA.xml:S1:1344:4	O
for	STENDRA.xml:S1:1349:3	O
placebo	STENDRA.xml:S1:1353:7	O
-	STENDRA.xml:S1:1360:1	O
treated	STENDRA.xml:S1:1361:7	O
patients	STENDRA.xml:S1:1369:8	O
.	STENDRA.xml:S1:1377:1	O

Table	STENDRA.xml:S1:1383:5	O
1	STENDRA.xml:S1:1389:1	O
presents	STENDRA.xml:S1:1391:8	O
the	STENDRA.xml:S1:1400:3	O
adverse	STENDRA.xml:S1:1404:7	O
reactions	STENDRA.xml:S1:1412:9	O
reported	STENDRA.xml:S1:1422:8	O
when	STENDRA.xml:S1:1431:4	O
STENDRA	STENDRA.xml:S1:1436:7	O
was	STENDRA.xml:S1:1444:3	O
taken	STENDRA.xml:S1:1448:5	O
as	STENDRA.xml:S1:1454:2	O
recommended	STENDRA.xml:S1:1457:11	O
(	STENDRA.xml:S1:1469:1	O
on	STENDRA.xml:S1:1470:2	O
an	STENDRA.xml:S1:1473:2	O
as	STENDRA.xml:S1:1476:2	O
-	STENDRA.xml:S1:1478:1	O
needed	STENDRA.xml:S1:1479:6	O
basis	STENDRA.xml:S1:1486:5	O
)	STENDRA.xml:S1:1491:1	O
from	STENDRA.xml:S1:1493:4	O
these	STENDRA.xml:S1:1498:5	O
3	STENDRA.xml:S1:1504:1	O
clinical	STENDRA.xml:S1:1506:8	O
trials	STENDRA.xml:S1:1515:6	O
.	STENDRA.xml:S1:1521:1	O

Table	STENDRA.xml:S1:1527:5	O
1	STENDRA.xml:S1:1533:1	O
:	STENDRA.xml:S1:1534:1	O
Adverse	STENDRA.xml:S1:1536:7	O
Reactions	STENDRA.xml:S1:1544:9	O
Reported	STENDRA.xml:S1:1554:8	O
by	STENDRA.xml:S1:1563:2	O
Greater	STENDRA.xml:S1:1566:7	O
Than	STENDRA.xml:S1:1574:4	O
or	STENDRA.xml:S1:1579:2	O
Equal	STENDRA.xml:S1:1582:5	O
to	STENDRA.xml:S1:1588:2	O
2%	STENDRA.xml:S1:1591:2	O
of	STENDRA.xml:S1:1594:2	O
Patients	STENDRA.xml:S1:1597:8	O
Treated	STENDRA.xml:S1:1606:7	O
with	STENDRA.xml:S1:1614:4	O
STENDRA	STENDRA.xml:S1:1619:7	O
From	STENDRA.xml:S1:1627:4	O
3	STENDRA.xml:S1:1632:1	O
Placebo	STENDRA.xml:S1:1634:7	O
-	STENDRA.xml:S1:1641:1	O
Controlled	STENDRA.xml:S1:1642:10	O
Clinical	STENDRA.xml:S1:1653:8	O
Trials	STENDRA.xml:S1:1662:6	O
Lasting	STENDRA.xml:S1:1669:7	O
3	STENDRA.xml:S1:1677:1	O
Months	STENDRA.xml:S1:1679:6	O
for	STENDRA.xml:S1:1686:3	O
STENDRA	STENDRA.xml:S1:1690:7	O
Use	STENDRA.xml:S1:1698:3	O
as	STENDRA.xml:S1:1702:2	O
Needed	STENDRA.xml:S1:1705:6	O

Adverse	STENDRA.xml:S1:1714:7	O
Reaction	STENDRA.xml:S1:1722:8	O
Placebo	STENDRA.xml:S1:1741:7	O
(	STENDRA.xml:S1:1748:1	O
N	STENDRA.xml:S1:1749:1	O
349	STENDRA.xml:S1:1753:3	O
)	STENDRA.xml:S1:1756:1	O
STENDRA	STENDRA.xml:S1:1759:7	O
50	STENDRA.xml:S1:1767:2	O
mg	STENDRA.xml:S1:1770:2	O
(	STENDRA.xml:S1:1772:1	O
N	STENDRA.xml:S1:1773:1	O
217	STENDRA.xml:S1:1777:3	O
)	STENDRA.xml:S1:1780:1	O
STENDRA	STENDRA.xml:S1:1783:7	O
100	STENDRA.xml:S1:1791:3	O
mg	STENDRA.xml:S1:1795:2	O
(	STENDRA.xml:S1:1797:1	O
N	STENDRA.xml:S1:1798:1	O
349	STENDRA.xml:S1:1802:3	O
)	STENDRA.xml:S1:1805:1	O
STENDRA	STENDRA.xml:S1:1808:7	O
200	STENDRA.xml:S1:1816:3	O
mg	STENDRA.xml:S1:1820:2	O
(	STENDRA.xml:S1:1822:1	O
N	STENDRA.xml:S1:1823:1	O
352	STENDRA.xml:S1:1827:3	O
)	STENDRA.xml:S1:1830:1	O

Headache	STENDRA.xml:S1:1839:8	B-AdverseReaction

1.7%	STENDRA.xml:S1:1871:4	O
5.1%	STENDRA.xml:S1:1891:4	O
6.9%	STENDRA.xml:S1:1913:4	O
10.5%	STENDRA.xml:S1:1934:5	O

Flushing	STENDRA.xml:S1:1952:8	B-AdverseReaction
0.0%	STENDRA.xml:S1:1984:4	O
3.2%	STENDRA.xml:S1:2004:4	O
4.3%	STENDRA.xml:S1:2026:4	O
4.0%	STENDRA.xml:S1:2048:4	O

Nasal	STENDRA.xml:S1:2065:5	B-AdverseReaction
congestion	STENDRA.xml:S1:2071:10	I-AdverseReaction
1.1%	STENDRA.xml:S1:2097:4	O
1.8%	STENDRA.xml:S1:2117:4	O
2.9%	STENDRA.xml:S1:2139:4	O
2.0%	STENDRA.xml:S1:2161:4	O

Nasopharyngitis	STENDRA.xml:S1:2178:15	B-AdverseReaction
2.9%	STENDRA.xml:S1:2210:4	O
0.9%	STENDRA.xml:S1:2230:4	O
2.6%	STENDRA.xml:S1:2252:4	O
3.4%	STENDRA.xml:S1:2274:4	O

Back	STENDRA.xml:S1:2291:4	B-AdverseReaction
pain	STENDRA.xml:S1:2296:4	I-AdverseReaction
1.1%	STENDRA.xml:S1:2323:4	O
3.2%	STENDRA.xml:S1:2343:4	O
2.0%	STENDRA.xml:S1:2365:4	O
1.1%	STENDRA.xml:S1:2387:4	O

Adverse	STENDRA.xml:S1:2414:7	O
reactions	STENDRA.xml:S1:2422:9	O
reported	STENDRA.xml:S1:2432:8	O
by	STENDRA.xml:S1:2441:2	O
greater	STENDRA.xml:S1:2444:7	O
than	STENDRA.xml:S1:2452:4	O
or	STENDRA.xml:S1:2457:2	O
equal	STENDRA.xml:S1:2460:5	O
to	STENDRA.xml:S1:2466:2	O
1%	STENDRA.xml:S1:2469:2	O
,	STENDRA.xml:S1:2471:1	O
but	STENDRA.xml:S1:2473:3	O
less	STENDRA.xml:S1:2477:4	O
than	STENDRA.xml:S1:2482:4	O
2%	STENDRA.xml:S1:2487:2	O
of	STENDRA.xml:S1:2490:2	O
patients	STENDRA.xml:S1:2493:8	O
in	STENDRA.xml:S1:2502:2	O
any	STENDRA.xml:S1:2505:3	O
STENDRA	STENDRA.xml:S1:2509:7	O
dose	STENDRA.xml:S1:2517:4	O
group	STENDRA.xml:S1:2522:5	O
,	STENDRA.xml:S1:2527:1	O
and	STENDRA.xml:S1:2529:3	O
greater	STENDRA.xml:S1:2533:7	O
than	STENDRA.xml:S1:2541:4	O
placebo	STENDRA.xml:S1:2546:7	O
included	STENDRA.xml:S1:2554:8	O
:	STENDRA.xml:S1:2562:1	O
upper	STENDRA.xml:S1:2564:5	B-AdverseReaction
respiratory	STENDRA.xml:S1:2570:11	I-AdverseReaction
infection	STENDRA.xml:S1:2582:9	I-AdverseReaction
(	STENDRA.xml:S1:2592:1	O
URI	STENDRA.xml:S1:2593:3	B-AdverseReaction
)	STENDRA.xml:S1:2596:1	O
,	STENDRA.xml:S1:2597:1	O
bronchitis	STENDRA.xml:S1:2599:10	B-AdverseReaction
,	STENDRA.xml:S1:2609:1	O
influenza	STENDRA.xml:S1:2611:9	B-AdverseReaction
,	STENDRA.xml:S1:2620:1	O
sinusitis	STENDRA.xml:S1:2622:9	B-AdverseReaction
,	STENDRA.xml:S1:2631:1	O
sinus	STENDRA.xml:S1:2633:5	B-AdverseReaction
congestion	STENDRA.xml:S1:2639:10	I-AdverseReaction
,	STENDRA.xml:S1:2649:1	O
hypertension	STENDRA.xml:S1:2651:12	B-AdverseReaction
,	STENDRA.xml:S1:2663:1	O
dyspepsia	STENDRA.xml:S1:2665:9	B-AdverseReaction
,	STENDRA.xml:S1:2674:1	O
nausea	STENDRA.xml:S1:2676:6	B-AdverseReaction
,	STENDRA.xml:S1:2682:1	O
constipation	STENDRA.xml:S1:2684:12	B-AdverseReaction
,	STENDRA.xml:S1:2696:1	O
and	STENDRA.xml:S1:2698:3	O
rash	STENDRA.xml:S1:2702:4	B-AdverseReaction
.	STENDRA.xml:S1:2706:1	O

In	STENDRA.xml:S1:2712:2	O

an	STENDRA.xml:S1:2715:2	O
open	STENDRA.xml:S1:2718:4	O
-	STENDRA.xml:S1:2722:1	O
label	STENDRA.xml:S1:2723:5	O
,	STENDRA.xml:S1:2728:1	O
long	STENDRA.xml:S1:2730:4	O
-	STENDRA.xml:S1:2734:1	O
term	STENDRA.xml:S1:2735:4	O
extension	STENDRA.xml:S1:2740:9	O
study	STENDRA.xml:S1:2750:5	O
of	STENDRA.xml:S1:2756:2	O
two	STENDRA.xml:S1:2759:3	O
of	STENDRA.xml:S1:2763:2	O
these	STENDRA.xml:S1:2766:5	O
randomized	STENDRA.xml:S1:2772:10	O
,	STENDRA.xml:S1:2782:1	O
double	STENDRA.xml:S1:2784:6	O
-	STENDRA.xml:S1:2790:1	O
blind	STENDRA.xml:S1:2791:5	O
,	STENDRA.xml:S1:2796:1	O
placebo	STENDRA.xml:S1:2798:7	O
-	STENDRA.xml:S1:2805:1	O
controlled	STENDRA.xml:S1:2806:10	O
trials	STENDRA.xml:S1:2817:6	O
,	STENDRA.xml:S1:2823:1	O
the	STENDRA.xml:S1:2825:3	O
total	STENDRA.xml:S1:2829:5	O
duration	STENDRA.xml:S1:2835:8	O
of	STENDRA.xml:S1:2844:2	O
treatment	STENDRA.xml:S1:2847:9	O
was	STENDRA.xml:S1:2857:3	O
up	STENDRA.xml:S1:2861:2	O
to	STENDRA.xml:S1:2864:2	O
52	STENDRA.xml:S1:2867:2	O
weeks	STENDRA.xml:S1:2870:5	O
.	STENDRA.xml:S1:2875:1	O

Among	STENDRA.xml:S1:2877:5	O
the	STENDRA.xml:S1:2883:3	O
712	STENDRA.xml:S1:2887:3	O
patients	STENDRA.xml:S1:2891:8	O
who	STENDRA.xml:S1:2900:3	O
participated	STENDRA.xml:S1:2904:12	O
in	STENDRA.xml:S1:2917:2	O
this	STENDRA.xml:S1:2920:4	O
open	STENDRA.xml:S1:2925:4	O
-	STENDRA.xml:S1:2929:1	O
label	STENDRA.xml:S1:2930:5	O
extension	STENDRA.xml:S1:2936:9	O
study	STENDRA.xml:S1:2946:5	O
,	STENDRA.xml:S1:2951:1	O
the	STENDRA.xml:S1:2953:3	O
mean	STENDRA.xml:S1:2957:4	O
age	STENDRA.xml:S1:2962:3	O
of	STENDRA.xml:S1:2966:2	O
the	STENDRA.xml:S1:2969:3	O
population	STENDRA.xml:S1:2973:10	O
was	STENDRA.xml:S1:2984:3	O
56.4	STENDRA.xml:S1:2988:4	O
years	STENDRA.xml:S1:2993:5	O
(	STENDRA.xml:S1:2999:1	O
range	STENDRA.xml:S1:3000:5	O
from	STENDRA.xml:S1:3006:4	O
23	STENDRA.xml:S1:3011:2	O
to	STENDRA.xml:S1:3014:2	O
88	STENDRA.xml:S1:3017:2	O
years	STENDRA.xml:S1:3020:5	O
)	STENDRA.xml:S1:3025:1	O
.	STENDRA.xml:S1:3026:1	O

The	STENDRA.xml:S1:3028:3	O
discontinuation	STENDRA.xml:S1:3032:15	O
rate	STENDRA.xml:S1:3048:4	O
due	STENDRA.xml:S1:3053:3	O
to	STENDRA.xml:S1:3057:2	O
adverse	STENDRA.xml:S1:3060:7	O
reactions	STENDRA.xml:S1:3068:9	O
for	STENDRA.xml:S1:3078:3	O
patients	STENDRA.xml:S1:3082:8	O
treated	STENDRA.xml:S1:3091:7	O
with	STENDRA.xml:S1:3099:4	O
STENDRA	STENDRA.xml:S1:3104:7	O
(	STENDRA.xml:S1:3112:1	O
50	STENDRA.xml:S1:3113:2	O
mg	STENDRA.xml:S1:3116:2	O
,	STENDRA.xml:S1:3118:1	O
100	STENDRA.xml:S1:3120:3	O
mg	STENDRA.xml:S1:3124:2	O
,	STENDRA.xml:S1:3126:1	O
or	STENDRA.xml:S1:3128:2	O
200	STENDRA.xml:S1:3131:3	O
mg	STENDRA.xml:S1:3135:2	O
)	STENDRA.xml:S1:3137:1	O
was	STENDRA.xml:S1:3139:3	O
2.8%	STENDRA.xml:S1:3143:4	O
.	STENDRA.xml:S1:3147:1	O

In	STENDRA.xml:S1:3153:2	O
this	STENDRA.xml:S1:3156:4	O
extension	STENDRA.xml:S1:3161:9	O
trial	STENDRA.xml:S1:3171:5	O
,	STENDRA.xml:S1:3176:1	O
all	STENDRA.xml:S1:3178:3	O
eligible	STENDRA.xml:S1:3182:8	O
patients	STENDRA.xml:S1:3191:8	O
were	STENDRA.xml:S1:3200:4	O
initially	STENDRA.xml:S1:3205:9	O
assigned	STENDRA.xml:S1:3215:8	O
to	STENDRA.xml:S1:3224:2	O
STENDRA	STENDRA.xml:S1:3227:7	O
100	STENDRA.xml:S1:3235:3	O
mg	STENDRA.xml:S1:3239:2	O
.	STENDRA.xml:S1:3241:1	O

At	STENDRA.xml:S1:3243:2	O
any	STENDRA.xml:S1:3246:3	O
point	STENDRA.xml:S1:3250:5	O
during	STENDRA.xml:S1:3256:6	O
the	STENDRA.xml:S1:3263:3	O
trial	STENDRA.xml:S1:3267:5	O
,	STENDRA.xml:S1:3272:1	O
patients	STENDRA.xml:S1:3274:8	O
could	STENDRA.xml:S1:3283:5	O
request	STENDRA.xml:S1:3289:7	O
to	STENDRA.xml:S1:3297:2	O
have	STENDRA.xml:S1:3300:4	O
their	STENDRA.xml:S1:3305:5	O
dose	STENDRA.xml:S1:3311:4	O
of	STENDRA.xml:S1:3316:2	O
STENDRA	STENDRA.xml:S1:3319:7	O
increased	STENDRA.xml:S1:3327:9	O
to	STENDRA.xml:S1:3337:2	O
200	STENDRA.xml:S1:3340:3	O
mg	STENDRA.xml:S1:3344:2	O
or	STENDRA.xml:S1:3347:2	O
decreased	STENDRA.xml:S1:3350:9	O
to	STENDRA.xml:S1:3360:2	O
50	STENDRA.xml:S1:3363:2	O
mg	STENDRA.xml:S1:3366:2	O
based	STENDRA.xml:S1:3369:5	O
on	STENDRA.xml:S1:3375:2	O
their	STENDRA.xml:S1:3378:5	O
individual	STENDRA.xml:S1:3384:10	O
response	STENDRA.xml:S1:3395:8	O
to	STENDRA.xml:S1:3404:2	O
treatment	STENDRA.xml:S1:3407:9	O
.	STENDRA.xml:S1:3416:1	O

In	STENDRA.xml:S1:3418:2	O
total	STENDRA.xml:S1:3421:5	O
,	STENDRA.xml:S1:3426:1	O
536	STENDRA.xml:S1:3428:3	O
(	STENDRA.xml:S1:3432:1	O
approximately	STENDRA.xml:S1:3433:13	O
75%	STENDRA.xml:S1:3447:3	O
)	STENDRA.xml:S1:3450:1	O
patients	STENDRA.xml:S1:3452:8	O
increased	STENDRA.xml:S1:3461:9	O
their	STENDRA.xml:S1:3471:5	O
dose	STENDRA.xml:S1:3477:4	O
to	STENDRA.xml:S1:3482:2	O
200	STENDRA.xml:S1:3485:3	O
mg	STENDRA.xml:S1:3489:2	O
and	STENDRA.xml:S1:3492:3	O
5	STENDRA.xml:S1:3496:1	O
(	STENDRA.xml:S1:3498:1	O
less	STENDRA.xml:S1:3499:4	O
than	STENDRA.xml:S1:3504:4	O
1%	STENDRA.xml:S1:3509:2	O
)	STENDRA.xml:S1:3511:1	O
patients	STENDRA.xml:S1:3513:8	O
reduced	STENDRA.xml:S1:3522:7	O
their	STENDRA.xml:S1:3530:5	O
dose	STENDRA.xml:S1:3536:4	O
to	STENDRA.xml:S1:3541:2	O
50	STENDRA.xml:S1:3544:2	O
mg	STENDRA.xml:S1:3547:2	O
.	STENDRA.xml:S1:3549:1	O

Table	STENDRA.xml:S1:3555:5	O
2	STENDRA.xml:S1:3561:1	O
presents	STENDRA.xml:S1:3563:8	O
the	STENDRA.xml:S1:3572:3	O
adverse	STENDRA.xml:S1:3576:7	O
reactions	STENDRA.xml:S1:3584:9	O
reported	STENDRA.xml:S1:3594:8	O
when	STENDRA.xml:S1:3603:4	O
STENDRA	STENDRA.xml:S1:3608:7	O
was	STENDRA.xml:S1:3616:3	O
taken	STENDRA.xml:S1:3620:5	O
as	STENDRA.xml:S1:3626:2	O
recommended	STENDRA.xml:S1:3629:11	O
(	STENDRA.xml:S1:3641:1	O
on	STENDRA.xml:S1:3642:2	O
an	STENDRA.xml:S1:3645:2	O
as	STENDRA.xml:S1:3648:2	O
-	STENDRA.xml:S1:3650:1	O
needed	STENDRA.xml:S1:3651:6	O
basis	STENDRA.xml:S1:3658:5	O
)	STENDRA.xml:S1:3663:1	O
in	STENDRA.xml:S1:3665:2	O
this	STENDRA.xml:S1:3668:4	O
open	STENDRA.xml:S1:3673:4	O
-	STENDRA.xml:S1:3677:1	O
label	STENDRA.xml:S1:3678:5	O
extension	STENDRA.xml:S1:3684:9	O
trial	STENDRA.xml:S1:3694:5	O
.	STENDRA.xml:S1:3699:1	O

Table	STENDRA.xml:S1:3705:5	O
2	STENDRA.xml:S1:3711:1	O
:	STENDRA.xml:S1:3712:1	O
Adverse	STENDRA.xml:S1:3714:7	O
Reactions	STENDRA.xml:S1:3722:9	O
Reported	STENDRA.xml:S1:3732:8	O
by	STENDRA.xml:S1:3741:2	O
Greater	STENDRA.xml:S1:3744:7	O
Than	STENDRA.xml:S1:3752:4	O
or	STENDRA.xml:S1:3757:2	O
Equal	STENDRA.xml:S1:3760:5	O
to	STENDRA.xml:S1:3766:2	O
2%	STENDRA.xml:S1:3769:2	O
of	STENDRA.xml:S1:3772:2	O
Patients	STENDRA.xml:S1:3775:8	O
Treated	STENDRA.xml:S1:3784:7	O
With	STENDRA.xml:S1:3792:4	O
STENDRA	STENDRA.xml:S1:3797:7	O
in	STENDRA.xml:S1:3805:2	O
an	STENDRA.xml:S1:3808:2	O
Open	STENDRA.xml:S1:3811:4	O
-	STENDRA.xml:S1:3815:1	O
Label	STENDRA.xml:S1:3816:5	O
Extension	STENDRA.xml:S1:3822:9	O
Trial	STENDRA.xml:S1:3832:5	O

Adverse	STENDRA.xml:S1:3840:7	O
Reaction	STENDRA.xml:S1:3848:8	O
STENDRA	STENDRA.xml:S1:3909:7	O
(	STENDRA.xml:S1:3916:1	O
N	STENDRA.xml:S1:3917:1	O
711	STENDRA.xml:S1:3921:3	O
)	STENDRA.xml:S1:3924:1	O

Headache	STENDRA.xml:S1:3950:8	B-AdverseReaction

5.6%	STENDRA.xml:S1:4025:4	O

Flushing	STENDRA.xml:S1:4057:8	B-AdverseReaction
3.5%	STENDRA.xml:S1:4132:4	O

Nasopharyngitis	STENDRA.xml:S1:4164:15	B-AdverseReaction
3.4%	STENDRA.xml:S1:4239:4	O

Nasal	STENDRA.xml:S1:4271:5	B-AdverseReaction
congestion	STENDRA.xml:S1:4277:10	I-AdverseReaction
2.1%	STENDRA.xml:S1:4346:4	O

Adverse	STENDRA.xml:S1:4385:7	O
reactions	STENDRA.xml:S1:4393:9	O
reported	STENDRA.xml:S1:4403:8	O
by	STENDRA.xml:S1:4412:2	O
greater	STENDRA.xml:S1:4415:7	O
than	STENDRA.xml:S1:4423:4	O
or	STENDRA.xml:S1:4428:2	O
equal	STENDRA.xml:S1:4431:5	O
to	STENDRA.xml:S1:4437:2	O
1%	STENDRA.xml:S1:4440:2	O
,	STENDRA.xml:S1:4442:1	O
but	STENDRA.xml:S1:4444:3	O
less	STENDRA.xml:S1:4448:4	O
than	STENDRA.xml:S1:4453:4	O
2%	STENDRA.xml:S1:4458:2	O
of	STENDRA.xml:S1:4461:2	O
patients	STENDRA.xml:S1:4464:8	O
in	STENDRA.xml:S1:4473:2	O
the	STENDRA.xml:S1:4476:3	O
open	STENDRA.xml:S1:4480:4	O
-	STENDRA.xml:S1:4484:1	O
label	STENDRA.xml:S1:4485:5	O
extension	STENDRA.xml:S1:4491:9	O
study	STENDRA.xml:S1:4501:5	O
included	STENDRA.xml:S1:4507:8	O
:	STENDRA.xml:S1:4515:1	O
upper	STENDRA.xml:S1:4517:5	B-AdverseReaction
respiratory	STENDRA.xml:S1:4523:11	I-AdverseReaction
infection	STENDRA.xml:S1:4535:9	I-AdverseReaction
(	STENDRA.xml:S1:4545:1	O
URI	STENDRA.xml:S1:4546:3	B-AdverseReaction
)	STENDRA.xml:S1:4549:1	O
,	STENDRA.xml:S1:4550:1	O
influenza	STENDRA.xml:S1:4552:9	B-AdverseReaction
,	STENDRA.xml:S1:4561:1	O
sinusitis	STENDRA.xml:S1:4563:9	B-AdverseReaction
,	STENDRA.xml:S1:4572:1	O
bronchitis	STENDRA.xml:S1:4574:10	B-AdverseReaction
,	STENDRA.xml:S1:4584:1	O
dizziness	STENDRA.xml:S1:4586:9	B-AdverseReaction
,	STENDRA.xml:S1:4595:1	O
back	STENDRA.xml:S1:4597:4	B-AdverseReaction
pain	STENDRA.xml:S1:4602:4	I-AdverseReaction
,	STENDRA.xml:S1:4606:1	O
arthralgia	STENDRA.xml:S1:4608:10	B-AdverseReaction
,	STENDRA.xml:S1:4618:1	O
hypertension	STENDRA.xml:S1:4620:12	B-AdverseReaction
,	STENDRA.xml:S1:4632:1	O
and	STENDRA.xml:S1:4634:3	O
diarrhea	STENDRA.xml:S1:4638:8	B-AdverseReaction
.	STENDRA.xml:S1:4646:1	O

The	STENDRA.xml:S1:4652:3	O

following	STENDRA.xml:S1:4656:9	O
events	STENDRA.xml:S1:4666:6	O
occurred	STENDRA.xml:S1:4673:8	O
in	STENDRA.xml:S1:4682:2	O
less	STENDRA.xml:S1:4685:4	O
than	STENDRA.xml:S1:4690:4	O
1%	STENDRA.xml:S1:4695:2	O
of	STENDRA.xml:S1:4698:2	O
patients	STENDRA.xml:S1:4701:8	O
in	STENDRA.xml:S1:4710:2	O
the	STENDRA.xml:S1:4713:3	O
three	STENDRA.xml:S1:4717:5	O
placebo	STENDRA.xml:S1:4723:7	O
-	STENDRA.xml:S1:4730:1	O
controlled	STENDRA.xml:S1:4731:10	O
3	STENDRA.xml:S1:4742:1	O
-	STENDRA.xml:S1:4743:1	O
month	STENDRA.xml:S1:4744:5	O
clinical	STENDRA.xml:S1:4750:8	O
trials	STENDRA.xml:S1:4759:6	O
and	STENDRA.xml:S1:4766:3	O
or	STENDRA.xml:S1:4770:2	O
the	STENDRA.xml:S1:4773:3	O
open	STENDRA.xml:S1:4777:4	O
-	STENDRA.xml:S1:4781:1	O
label	STENDRA.xml:S1:4782:5	O
,	STENDRA.xml:S1:4787:1	O
long	STENDRA.xml:S1:4789:4	O
-	STENDRA.xml:S1:4793:1	O
term	STENDRA.xml:S1:4794:4	O
extension	STENDRA.xml:S1:4799:9	O
study	STENDRA.xml:S1:4809:5	O
lasting	STENDRA.xml:S1:4815:7	O
12	STENDRA.xml:S1:4823:2	O
months	STENDRA.xml:S1:4826:6	O
.	STENDRA.xml:S1:4832:1	O

A	STENDRA.xml:S1:4834:1	O
causal	STENDRA.xml:S1:4836:6	O
relationship	STENDRA.xml:S1:4843:12	O
to	STENDRA.xml:S1:4856:2	O
STENDRA	STENDRA.xml:S1:4859:7	O
is	STENDRA.xml:S1:4867:2	O
uncertain	STENDRA.xml:S1:4870:9	O
.	STENDRA.xml:S1:4879:1	O

Excluded	STENDRA.xml:S1:4881:8	O
from	STENDRA.xml:S1:4890:4	O
this	STENDRA.xml:S1:4895:4	O
list	STENDRA.xml:S1:4900:4	O
are	STENDRA.xml:S1:4905:3	O
those	STENDRA.xml:S1:4909:5	O
events	STENDRA.xml:S1:4915:6	O
that	STENDRA.xml:S1:4922:4	O
were	STENDRA.xml:S1:4927:4	O
minor	STENDRA.xml:S1:4932:5	O
,	STENDRA.xml:S1:4937:1	O
those	STENDRA.xml:S1:4939:5	O
with	STENDRA.xml:S1:4945:4	O
no	STENDRA.xml:S1:4950:2	O
plausible	STENDRA.xml:S1:4953:9	O
relation	STENDRA.xml:S1:4963:8	O
to	STENDRA.xml:S1:4972:2	O
drug	STENDRA.xml:S1:4975:4	O
use	STENDRA.xml:S1:4980:3	O
,	STENDRA.xml:S1:4983:1	O
and	STENDRA.xml:S1:4985:3	O
reports	STENDRA.xml:S1:4989:7	O
too	STENDRA.xml:S1:4997:3	O
imprecise	STENDRA.xml:S1:5001:9	O
to	STENDRA.xml:S1:5011:2	O
be	STENDRA.xml:S1:5014:2	O
meaningful	STENDRA.xml:S1:5017:10	O
.	STENDRA.xml:S1:5027:1	O

Body	STENDRA.xml:S1:5035:4	O
as	STENDRA.xml:S1:5040:2	O
a	STENDRA.xml:S1:5043:1	O
whole	STENDRA.xml:S1:5045:5	O
-	STENDRA.xml:S1:5052:1	O
edema	STENDRA.xml:S1:5054:5	B-AdverseReaction
peripheral	STENDRA.xml:S1:5060:10	I-AdverseReaction
,	STENDRA.xml:S1:5070:1	O
fatigue	STENDRA.xml:S1:5072:7	B-AdverseReaction

Cardiovascular	STENDRA.xml:S1:5086:14	O
-	STENDRA.xml:S1:5102:1	O
angina	STENDRA.xml:S1:5104:6	B-AdverseReaction
,	STENDRA.xml:S1:5110:1	O
unstable	STENDRA.xml:S1:5112:8	B-AdverseReaction
angina	STENDRA.xml:S1:5121:6	I-AdverseReaction
,	STENDRA.xml:S1:5127:1	O
deep	STENDRA.xml:S1:5129:4	B-AdverseReaction
vein	STENDRA.xml:S1:5134:4	I-AdverseReaction
thrombosis	STENDRA.xml:S1:5139:10	I-AdverseReaction
,	STENDRA.xml:S1:5149:1	O
palpitations	STENDRA.xml:S1:5151:12	B-AdverseReaction

Digestive	STENDRA.xml:S1:5170:9	O
-	STENDRA.xml:S1:5181:1	O
gastritis	STENDRA.xml:S1:5183:9	B-AdverseReaction
,	STENDRA.xml:S1:5192:1	O
gastroesophageal	STENDRA.xml:S1:5194:16	B-AdverseReaction
reflux	STENDRA.xml:S1:5211:6	I-AdverseReaction
disease	STENDRA.xml:S1:5218:7	I-AdverseReaction
,	STENDRA.xml:S1:5225:1	O
hypoglycemia	STENDRA.xml:S1:5227:12	B-AdverseReaction
,	STENDRA.xml:S1:5239:1	O
blood	STENDRA.xml:S1:5241:5	B-AdverseReaction
glucose	STENDRA.xml:S1:5247:7	I-AdverseReaction
increased	STENDRA.xml:S1:5255:9	I-AdverseReaction
,	STENDRA.xml:S1:5264:1	O
alanine	STENDRA.xml:S1:5266:7	B-AdverseReaction
aminotransferase	STENDRA.xml:S1:5274:16	I-AdverseReaction
increased	STENDRA.xml:S1:5291:9	I-AdverseReaction
,	STENDRA.xml:S1:5300:1	O
oropharyngeal	STENDRA.xml:S1:5302:13	B-AdverseReaction
pain	STENDRA.xml:S1:5316:4	I-AdverseReaction
,	STENDRA.xml:S1:5320:1	O
stomach	STENDRA.xml:S1:5322:7	B-AdverseReaction
discomfort	STENDRA.xml:S1:5330:10	I-AdverseReaction
,	STENDRA.xml:S1:5340:1	O
vomiting	STENDRA.xml:S1:5342:8	B-AdverseReaction

Musculoskeletal	STENDRA.xml:S1:5357:15	O
-	STENDRA.xml:S1:5374:1	O
muscle	STENDRA.xml:S1:5376:6	B-AdverseReaction
spasms	STENDRA.xml:S1:5383:6	I-AdverseReaction
,	STENDRA.xml:S1:5389:1	O
musculoskeletal	STENDRA.xml:S1:5391:15	B-AdverseReaction
pain	STENDRA.xml:S1:5407:4	I-AdverseReaction
,	STENDRA.xml:S1:5411:1	O
myalgia	STENDRA.xml:S1:5413:7	B-AdverseReaction
,	STENDRA.xml:S1:5420:1	O
pain	STENDRA.xml:S1:5422:4	B-AdverseReaction
in	STENDRA.xml:S1:5427:2	I-AdverseReaction
extremity	STENDRA.xml:S1:5430:9	I-AdverseReaction

Nervous	STENDRA.xml:S1:5446:7	O
-	STENDRA.xml:S1:5455:1	O
depression	STENDRA.xml:S1:5457:10	B-AdverseReaction
,	STENDRA.xml:S1:5467:1	O
insomnia	STENDRA.xml:S1:5469:8	B-AdverseReaction
,	STENDRA.xml:S1:5477:1	O
somnolence	STENDRA.xml:S1:5479:10	B-AdverseReaction
,	STENDRA.xml:S1:5489:1	O
vertigo	STENDRA.xml:S1:5491:7	B-AdverseReaction

Respiratory	STENDRA.xml:S1:5505:11	O
-	STENDRA.xml:S1:5517:1	O
cough	STENDRA.xml:S1:5520:5	B-AdverseReaction
,	STENDRA.xml:S1:5525:1	O
dyspnea	STENDRA.xml:S1:5527:7	B-AdverseReaction
exertional	STENDRA.xml:S1:5535:10	I-AdverseReaction
,	STENDRA.xml:S1:5545:1	O
epistaxis	STENDRA.xml:S1:5547:9	B-AdverseReaction
,	STENDRA.xml:S1:5556:1	O
wheezing	STENDRA.xml:S1:5558:8	B-AdverseReaction

Skin	STENDRA.xml:S1:5573:4	O
and	STENDRA.xml:S1:5578:3	O
Appendages	STENDRA.xml:S1:5582:10	O
-	STENDRA.xml:S1:5594:1	O
pruritus	STENDRA.xml:S1:5596:8	B-AdverseReaction

Urogenital	STENDRA.xml:S1:5611:10	O
-	STENDRA.xml:S1:5623:1	O
balanitis	STENDRA.xml:S1:5625:9	B-AdverseReaction
,	STENDRA.xml:S1:5634:1	O
erection	STENDRA.xml:S1:5636:8	B-AdverseReaction
increased	STENDRA.xml:S1:5645:9	I-AdverseReaction
,	STENDRA.xml:S1:5654:1	O
hematuria	STENDRA.xml:S1:5656:9	B-AdverseReaction
,	STENDRA.xml:S1:5665:1	O
nephrolithiasis	STENDRA.xml:S1:5667:15	B-AdverseReaction
,	STENDRA.xml:S1:5682:1	O
pollakiuria	STENDRA.xml:S1:5684:11	B-AdverseReaction
,	STENDRA.xml:S1:5695:1	O
urinary	STENDRA.xml:S1:5697:7	B-AdverseReaction
tract	STENDRA.xml:S1:5705:5	I-AdverseReaction
infection	STENDRA.xml:S1:5711:9	I-AdverseReaction

In	STENDRA.xml:S1:5725:2	O
an	STENDRA.xml:S1:5728:2	O
additional	STENDRA.xml:S1:5731:10	O
randomized	STENDRA.xml:S1:5742:10	O
,	STENDRA.xml:S1:5752:1	O
double	STENDRA.xml:S1:5754:6	O
-	STENDRA.xml:S1:5760:1	O
blind	STENDRA.xml:S1:5761:5	O
,	STENDRA.xml:S1:5766:1	O
placebo	STENDRA.xml:S1:5768:7	O
-	STENDRA.xml:S1:5775:1	O
controlled	STENDRA.xml:S1:5776:10	O
study	STENDRA.xml:S1:5787:5	O
lasting	STENDRA.xml:S1:5793:7	O
up	STENDRA.xml:S1:5801:2	O
to	STENDRA.xml:S1:5804:2	O
3	STENDRA.xml:S1:5807:1	O
months	STENDRA.xml:S1:5809:6	O
in	STENDRA.xml:S1:5816:2	O
298	STENDRA.xml:S1:5819:3	O
men	STENDRA.xml:S1:5823:3	O
who	STENDRA.xml:S1:5827:3	O
had	STENDRA.xml:S1:5831:3	O
undergone	STENDRA.xml:S1:5835:9	O
bilateral	STENDRA.xml:S1:5845:9	O
nerve	STENDRA.xml:S1:5855:5	O
-	STENDRA.xml:S1:5860:1	O
sparing	STENDRA.xml:S1:5861:7	O
radical	STENDRA.xml:S1:5869:7	O
prostatectomy	STENDRA.xml:S1:5877:13	O
for	STENDRA.xml:S1:5891:3	O
prostate	STENDRA.xml:S1:5895:8	O
cancer	STENDRA.xml:S1:5904:6	O
,	STENDRA.xml:S1:5910:1	O
the	STENDRA.xml:S1:5912:3	O
mean	STENDRA.xml:S1:5916:4	O
age	STENDRA.xml:S1:5921:3	O
of	STENDRA.xml:S1:5925:2	O
patients	STENDRA.xml:S1:5928:8	O
was	STENDRA.xml:S1:5937:3	O
58.4	STENDRA.xml:S1:5941:4	O
years	STENDRA.xml:S1:5946:5	O
(	STENDRA.xml:S1:5952:1	O
range	STENDRA.xml:S1:5953:5	O
40	STENDRA.xml:S1:5959:2	O
-	STENDRA.xml:S1:5962:1	O
70	STENDRA.xml:S1:5964:2	O
)	STENDRA.xml:S1:5966:1	O
.	STENDRA.xml:S1:5967:1	O

Table	STENDRA.xml:S1:5969:5	O
3	STENDRA.xml:S1:5975:1	O
presents	STENDRA.xml:S1:5977:8	O
the	STENDRA.xml:S1:5986:3	O
adverse	STENDRA.xml:S1:5990:7	O
reactions	STENDRA.xml:S1:5998:9	O
reported	STENDRA.xml:S1:6008:8	O
in	STENDRA.xml:S1:6017:2	O
this	STENDRA.xml:S1:6020:4	O
study	STENDRA.xml:S1:6025:5	O
.	STENDRA.xml:S1:6030:1	O

Table	STENDRA.xml:S1:6036:5	O
3	STENDRA.xml:S1:6042:1	O
:	STENDRA.xml:S1:6043:1	O
Adverse	STENDRA.xml:S1:6045:7	O
Reactions	STENDRA.xml:S1:6053:9	O
Reported	STENDRA.xml:S1:6063:8	O
by	STENDRA.xml:S1:6072:2	O
Greater	STENDRA.xml:S1:6075:7	O
than	STENDRA.xml:S1:6083:4	O
or	STENDRA.xml:S1:6088:2	O
Equal	STENDRA.xml:S1:6091:5	O
to	STENDRA.xml:S1:6097:2	O
2%	STENDRA.xml:S1:6100:2	O
of	STENDRA.xml:S1:6103:2	O
Patients	STENDRA.xml:S1:6106:8	O
Treated	STENDRA.xml:S1:6115:7	O
with	STENDRA.xml:S1:6123:4	O
STENDRA	STENDRA.xml:S1:6128:7	O
in	STENDRA.xml:S1:6136:2	O
a	STENDRA.xml:S1:6139:1	O
Placebo	STENDRA.xml:S1:6141:7	O
-	STENDRA.xml:S1:6148:1	O
Controlled	STENDRA.xml:S1:6149:10	O
Clinical	STENDRA.xml:S1:6160:8	O
Trial	STENDRA.xml:S1:6169:5	O
Lasting	STENDRA.xml:S1:6175:7	O
3	STENDRA.xml:S1:6183:1	O
Months	STENDRA.xml:S1:6185:6	O
in	STENDRA.xml:S1:6192:2	O
Patients	STENDRA.xml:S1:6195:8	O
Who	STENDRA.xml:S1:6204:3	O
Underwent	STENDRA.xml:S1:6208:9	O
Bilateral	STENDRA.xml:S1:6218:9	O
Nerve	STENDRA.xml:S1:6228:5	O
-	STENDRA.xml:S1:6233:1	O
Sparing	STENDRA.xml:S1:6234:7	O
Radical	STENDRA.xml:S1:6242:7	O
Prostatectomy	STENDRA.xml:S1:6250:13	O

Adverse	STENDRA.xml:S1:6266:7	O
Reaction	STENDRA.xml:S1:6274:8	O
Placebo	STENDRA.xml:S1:6310:7	O
(	STENDRA.xml:S1:6317:1	O
N	STENDRA.xml:S1:6318:1	O
100	STENDRA.xml:S1:6322:3	O
)	STENDRA.xml:S1:6325:1	O
STENDRA	STENDRA.xml:S1:6328:7	O
100	STENDRA.xml:S1:6336:3	O
mg	STENDRA.xml:S1:6340:2	O
(	STENDRA.xml:S1:6342:1	O
N	STENDRA.xml:S1:6343:1	O
99	STENDRA.xml:S1:6347:2	O
)	STENDRA.xml:S1:6349:1	O
STENDRA	STENDRA.xml:S1:6352:7	O
200	STENDRA.xml:S1:6360:3	O
mg	STENDRA.xml:S1:6364:2	O
(	STENDRA.xml:S1:6366:1	O
N	STENDRA.xml:S1:6367:1	O
99	STENDRA.xml:S1:6371:2	O
)	STENDRA.xml:S1:6373:1	O

Headache	STENDRA.xml:S1:6382:8	B-AdverseReaction

1.0%	STENDRA.xml:S1:6431:4	O
8.1%	STENDRA.xml:S1:6451:4	O
12.1%	STENDRA.xml:S1:6474:5	O

Flushing	STENDRA.xml:S1:6493:8	B-AdverseReaction
0.0%	STENDRA.xml:S1:6542:4	O
5.1%	STENDRA.xml:S1:6562:4	O
10.1%	STENDRA.xml:S1:6585:5	O

Nasopharyngitis	STENDRA.xml:S1:6604:15	B-AdverseReaction
0.0%	STENDRA.xml:S1:6653:4	O
3.0%	STENDRA.xml:S1:6673:4	O
5.1%	STENDRA.xml:S1:6697:4	O

Upper	STENDRA.xml:S1:6715:5	B-AdverseReaction
respiratory	STENDRA.xml:S1:6721:11	I-AdverseReaction
infection	STENDRA.xml:S1:6733:9	I-AdverseReaction
0.0%	STENDRA.xml:S1:6764:4	O
2.0%	STENDRA.xml:S1:6784:4	O
3.0%	STENDRA.xml:S1:6808:4	O

Nasal	STENDRA.xml:S1:6826:5	B-AdverseReaction
congestion	STENDRA.xml:S1:6832:10	I-AdverseReaction
1.0%	STENDRA.xml:S1:6875:4	O
3.0%	STENDRA.xml:S1:6895:4	O
1.0%	STENDRA.xml:S1:6919:4	O

Back	STENDRA.xml:S1:6937:4	B-AdverseReaction
pain	STENDRA.xml:S1:6942:4	I-AdverseReaction
1.0%	STENDRA.xml:S1:6986:4	O
3.0%	STENDRA.xml:S1:7006:4	O
2.0%	STENDRA.xml:S1:7030:4	O

Electrocardiogram	STENDRA.xml:S1:7048:17	B-AdverseReaction
abnormal	STENDRA.xml:S1:7066:8	I-AdverseReaction
0.0%	STENDRA.xml:S1:7097:4	O
1.0%	STENDRA.xml:S1:7117:4	O
3.0%	STENDRA.xml:S1:7141:4	O

Dizziness	STENDRA.xml:S1:7159:9	B-AdverseReaction
0.0%	STENDRA.xml:S1:7208:4	O
1.0%	STENDRA.xml:S1:7228:4	O
2.0%	STENDRA.xml:S1:7252:4	O

A	STENDRA.xml:S1:7279:1	O
randomized	STENDRA.xml:S1:7281:10	O
,	STENDRA.xml:S1:7291:1	O
double	STENDRA.xml:S1:7293:6	O
-	STENDRA.xml:S1:7299:1	O
blind	STENDRA.xml:S1:7300:5	O
,	STENDRA.xml:S1:7305:1	O
placebo	STENDRA.xml:S1:7307:7	O
-	STENDRA.xml:S1:7314:1	O
controlled	STENDRA.xml:S1:7315:10	O
2	STENDRA.xml:S1:7326:1	O
months	STENDRA.xml:S1:7328:6	O
study	STENDRA.xml:S1:7335:5	O
was	STENDRA.xml:S1:7341:3	O
conducted	STENDRA.xml:S1:7345:9	O
in	STENDRA.xml:S1:7355:2	O
435	STENDRA.xml:S1:7358:3	O
subjects	STENDRA.xml:S1:7362:8	O
with	STENDRA.xml:S1:7371:4	O
a	STENDRA.xml:S1:7376:1	O
mean	STENDRA.xml:S1:7378:4	O
age	STENDRA.xml:S1:7383:3	O
of	STENDRA.xml:S1:7387:2	O
58.2	STENDRA.xml:S1:7390:4	O
years	STENDRA.xml:S1:7395:5	O
(	STENDRA.xml:S1:7401:1	O
range	STENDRA.xml:S1:7402:5	O
24	STENDRA.xml:S1:7408:2	O
to	STENDRA.xml:S1:7411:2	O
86	STENDRA.xml:S1:7414:2	O
years	STENDRA.xml:S1:7417:5	O
)	STENDRA.xml:S1:7422:1	O
to	STENDRA.xml:S1:7424:2	O
determine	STENDRA.xml:S1:7427:9	O
the	STENDRA.xml:S1:7437:3	O
time	STENDRA.xml:S1:7441:4	O
to	STENDRA.xml:S1:7446:2	O
onset	STENDRA.xml:S1:7449:5	O
of	STENDRA.xml:S1:7455:2	O
effect	STENDRA.xml:S1:7458:6	O
of	STENDRA.xml:S1:7465:2	O
STENDRA	STENDRA.xml:S1:7468:7	O
,	STENDRA.xml:S1:7475:1	O
defined	STENDRA.xml:S1:7477:7	O
as	STENDRA.xml:S1:7485:2	O
the	STENDRA.xml:S1:7488:3	O
time	STENDRA.xml:S1:7492:4	O
to	STENDRA.xml:S1:7497:2	O
the	STENDRA.xml:S1:7500:3	O
first	STENDRA.xml:S1:7504:5	O
occurrence	STENDRA.xml:S1:7510:10	O
of	STENDRA.xml:S1:7521:2	O
an	STENDRA.xml:S1:7524:2	O
erection	STENDRA.xml:S1:7527:8	O
sufficient	STENDRA.xml:S1:7536:10	O
for	STENDRA.xml:S1:7547:3	O
sexual	STENDRA.xml:S1:7551:6	O
intercourse	STENDRA.xml:S1:7558:11	O
.	STENDRA.xml:S1:7569:1	O

Table	STENDRA.xml:S1:7571:5	O
4	STENDRA.xml:S1:7577:1	O
presents	STENDRA.xml:S1:7579:8	O
the	STENDRA.xml:S1:7588:3	O
adverse	STENDRA.xml:S1:7592:7	O
reactions	STENDRA.xml:S1:7600:9	O
occurring	STENDRA.xml:S1:7610:9	O
in	STENDRA.xml:S1:7620:2	O
2%	STENDRA.xml:S1:7626:2	O
of	STENDRA.xml:S1:7629:2	O
subjects	STENDRA.xml:S1:7632:8	O
treated	STENDRA.xml:S1:7641:7	O
with	STENDRA.xml:S1:7649:4	O
STENDRA	STENDRA.xml:S1:7654:7	O
.	STENDRA.xml:S1:7661:1	O

Table	STENDRA.xml:S1:7667:5	O

4	STENDRA.xml:S1:7673:1	O
:	STENDRA.xml:S1:7674:1	O
Adverse	STENDRA.xml:S1:7676:7	O
Reactions	STENDRA.xml:S1:7684:9	O
Reported	STENDRA.xml:S1:7694:8	O
by	STENDRA.xml:S1:7703:2	O
2%	STENDRA.xml:S1:7709:2	O
of	STENDRA.xml:S1:7712:2	O
Patients	STENDRA.xml:S1:7715:8	O
Treated	STENDRA.xml:S1:7724:7	O
with	STENDRA.xml:S1:7732:4	O
STENDRA	STENDRA.xml:S1:7737:7	O
in	STENDRA.xml:S1:7745:2	O
a	STENDRA.xml:S1:7748:1	O
Placebo	STENDRA.xml:S1:7750:7	O
-	STENDRA.xml:S1:7757:1	O
Controlled	STENDRA.xml:S1:7758:10	O
Clinical	STENDRA.xml:S1:7769:8	O
Trial	STENDRA.xml:S1:7778:5	O
Lasting	STENDRA.xml:S1:7784:7	O
2	STENDRA.xml:S1:7792:1	O
Months	STENDRA.xml:S1:7794:6	O
to	STENDRA.xml:S1:7801:2	O
Determine	STENDRA.xml:S1:7804:9	O
the	STENDRA.xml:S1:7814:3	O
Time	STENDRA.xml:S1:7818:4	O
to	STENDRA.xml:S1:7823:2	O
Onset	STENDRA.xml:S1:7826:5	O
of	STENDRA.xml:S1:7832:2	O
Effect	STENDRA.xml:S1:7835:6	O
(	STENDRA.xml:S1:7842:1	O
Study	STENDRA.xml:S1:7843:5	O
3	STENDRA.xml:S1:7849:1	O
)	STENDRA.xml:S1:7850:1	O

Adverse	STENDRA.xml:S1:7854:7	O
Reaction	STENDRA.xml:S1:7862:8	O
Placebon	STENDRA.xml:S1:7900:8	O
143	STENDRA.xml:S1:7909:3	O
STENDRA	STENDRA.xml:S1:7918:7	O
100	STENDRA.xml:S1:7926:3	O
mgn	STENDRA.xml:S1:7930:3	O
146	STENDRA.xml:S1:7934:3	O
STENDRA	STENDRA.xml:S1:7940:7	O
200	STENDRA.xml:S1:7948:3	O
mgn	STENDRA.xml:S1:7952:3	O
146	STENDRA.xml:S1:7956:3	O

Headache	STENDRA.xml:S1:7968:8	B-AdverseReaction

0.7%	STENDRA.xml:S1:8018:4	O
1.4%	STENDRA.xml:S1:8040:4	O
8.9%	STENDRA.xml:S1:8062:4	O

Nasal	STENDRA.xml:S1:8079:5	B-AdverseReaction
congestion	STENDRA.xml:S1:8085:10	I-AdverseReaction
0.0%	STENDRA.xml:S1:8129:4	O
0.7%	STENDRA.xml:S1:8151:4	O
4.1%	STENDRA.xml:S1:8173:4	O

Gastroenteritis	STENDRA.xml:S1:8190:15	B-AdverseReaction
viral	STENDRA.xml:S1:8206:5	I-AdverseReaction
0.0%	STENDRA.xml:S1:8240:4	O
0.0%	STENDRA.xml:S1:8262:4	O
2.1%	STENDRA.xml:S1:8284:4	O

Across	STENDRA.xml:S1:8310:6	O
all	STENDRA.xml:S1:8317:3	O
trials	STENDRA.xml:S1:8321:6	O
with	STENDRA.xml:S1:8328:4	O
any	STENDRA.xml:S1:8333:3	O
STENDRA	STENDRA.xml:S1:8337:7	O
dose	STENDRA.xml:S1:8345:4	O
,	STENDRA.xml:S1:8349:1	O
1	STENDRA.xml:S1:8351:1	O
subject	STENDRA.xml:S1:8353:7	O
reported	STENDRA.xml:S1:8361:8	O
a	STENDRA.xml:S1:8370:1	O
change	STENDRA.xml:S1:8372:6	B-AdverseReaction
in	STENDRA.xml:S1:8379:2	I-AdverseReaction
color	STENDRA.xml:S1:8382:5	I-AdverseReaction
vision	STENDRA.xml:S1:8388:6	I-AdverseReaction
.	STENDRA.xml:S1:8394:1	O

6.2	STENDRA.xml:S1:8402:3	O

Postmarketing	STENDRA.xml:S1:8406:13	O
Experience	STENDRA.xml:S1:8420:10	O

Ophthalmologic	STENDRA.xml:S1:8434:14	O
:	STENDRA.xml:S1:8448:1	O

Non	STENDRA.xml:S1:8454:3	B-AdverseReaction
-	STENDRA.xml:S1:8457:1	I-AdverseReaction
arteritic	STENDRA.xml:S1:8458:9	I-AdverseReaction
anterior	STENDRA.xml:S1:8468:8	I-AdverseReaction
ischemic	STENDRA.xml:S1:8477:8	I-AdverseReaction
optic	STENDRA.xml:S1:8486:5	I-AdverseReaction
neuropathy	STENDRA.xml:S1:8492:10	I-AdverseReaction
(	STENDRA.xml:S1:8503:1	O
NAION	STENDRA.xml:S1:8504:5	B-AdverseReaction
)	STENDRA.xml:S1:8509:1	O
,	STENDRA.xml:S1:8510:1	O
a	STENDRA.xml:S1:8512:1	O
cause	STENDRA.xml:S1:8514:5	O
of	STENDRA.xml:S1:8520:2	O
decreased	STENDRA.xml:S1:8523:9	B-AdverseReaction
vision	STENDRA.xml:S1:8533:6	I-AdverseReaction
including	STENDRA.xml:S1:8540:9	O
permanent	STENDRA.xml:S1:8550:9	B-AdverseReaction
loss	STENDRA.xml:S1:8560:4	I-AdverseReaction
of	STENDRA.xml:S1:8565:2	I-AdverseReaction
vision	STENDRA.xml:S1:8568:6	I-AdverseReaction
,	STENDRA.xml:S1:8574:1	O
has	STENDRA.xml:S1:8576:3	O
been	STENDRA.xml:S1:8580:4	O
reported	STENDRA.xml:S1:8585:8	O
rarely	STENDRA.xml:S1:8594:6	O
post	STENDRA.xml:S1:8601:4	O
-	STENDRA.xml:S1:8605:1	O
marketing	STENDRA.xml:S1:8606:9	O
in	STENDRA.xml:S1:8616:2	O
temporal	STENDRA.xml:S1:8619:8	O
association	STENDRA.xml:S1:8628:11	O
with	STENDRA.xml:S1:8640:4	O
the	STENDRA.xml:S1:8645:3	O
use	STENDRA.xml:S1:8649:3	O
of	STENDRA.xml:S1:8653:2	O
phosphodiesterase	STENDRA.xml:S1:8656:17	B-DrugClass
type	STENDRA.xml:S1:8674:4	I-DrugClass
5	STENDRA.xml:S1:8679:1	I-DrugClass
(	STENDRA.xml:S1:8681:1	I-DrugClass
PDE5	STENDRA.xml:S1:8682:4	I-DrugClass
)	STENDRA.xml:S1:8686:1	I-DrugClass
inhibitors	STENDRA.xml:S1:8688:10	I-DrugClass
.	STENDRA.xml:S1:8698:1	O

Most	STENDRA.xml:S1:8700:4	O
,	STENDRA.xml:S1:8704:1	O
but	STENDRA.xml:S1:8706:3	O
not	STENDRA.xml:S1:8710:3	O
all	STENDRA.xml:S1:8714:3	O
,	STENDRA.xml:S1:8717:1	O
of	STENDRA.xml:S1:8719:2	O
these	STENDRA.xml:S1:8722:5	O
patients	STENDRA.xml:S1:8728:8	O
had	STENDRA.xml:S1:8737:3	O
underlying	STENDRA.xml:S1:8741:10	O
anatomic	STENDRA.xml:S1:8752:8	O
or	STENDRA.xml:S1:8761:2	O
vascular	STENDRA.xml:S1:8764:8	O
risk	STENDRA.xml:S1:8773:4	O
factors	STENDRA.xml:S1:8778:7	O
for	STENDRA.xml:S1:8786:3	O
developing	STENDRA.xml:S1:8790:10	O
NAION	STENDRA.xml:S1:8801:5	O
,	STENDRA.xml:S1:8806:1	O
including	STENDRA.xml:S1:8808:9	O
but	STENDRA.xml:S1:8818:3	O
not	STENDRA.xml:S1:8822:3	O
necessarily	STENDRA.xml:S1:8826:11	O
limited	STENDRA.xml:S1:8838:7	O
to	STENDRA.xml:S1:8846:2	O
:	STENDRA.xml:S1:8848:1	O
low	STENDRA.xml:S1:8850:3	O
cup	STENDRA.xml:S1:8854:3	O
to	STENDRA.xml:S1:8858:2	O
disc	STENDRA.xml:S1:8861:4	O
ratio	STENDRA.xml:S1:8866:5	O
(	STENDRA.xml:S1:8872:1	O
"	STENDRA.xml:S1:8873:1	O
crowded	STENDRA.xml:S1:8874:7	O
disc	STENDRA.xml:S1:8882:4	O
"	STENDRA.xml:S1:8886:1	O
)	STENDRA.xml:S1:8887:1	O
,	STENDRA.xml:S1:8888:1	O
age	STENDRA.xml:S1:8890:3	O
over	STENDRA.xml:S1:8894:4	O
50	STENDRA.xml:S1:8899:2	O
,	STENDRA.xml:S1:8901:1	O
diabetes	STENDRA.xml:S1:8903:8	O
,	STENDRA.xml:S1:8911:1	O
hypertension	STENDRA.xml:S1:8913:12	O
,	STENDRA.xml:S1:8925:1	O
coronary	STENDRA.xml:S1:8927:8	O
artery	STENDRA.xml:S1:8936:6	O
disease	STENDRA.xml:S1:8943:7	O
,	STENDRA.xml:S1:8950:1	O
hyperlipidemia	STENDRA.xml:S1:8952:14	O
,	STENDRA.xml:S1:8966:1	O
and	STENDRA.xml:S1:8968:3	O
smoking	STENDRA.xml:S1:8972:7	O
.	STENDRA.xml:S1:8979:1	O

It	STENDRA.xml:S1:8981:2	O
is	STENDRA.xml:S1:8984:2	O
not	STENDRA.xml:S1:8987:3	O
possible	STENDRA.xml:S1:8991:8	O
to	STENDRA.xml:S1:9000:2	O
determine	STENDRA.xml:S1:9003:9	O
whether	STENDRA.xml:S1:9013:7	O
these	STENDRA.xml:S1:9021:5	O
events	STENDRA.xml:S1:9027:6	O
are	STENDRA.xml:S1:9034:3	O
related	STENDRA.xml:S1:9038:7	O
directly	STENDRA.xml:S1:9046:8	O
to	STENDRA.xml:S1:9055:2	O
the	STENDRA.xml:S1:9058:3	O
use	STENDRA.xml:S1:9062:3	O
of	STENDRA.xml:S1:9066:2	O
PDE5	STENDRA.xml:S1:9069:4	O
inhibitors	STENDRA.xml:S1:9074:10	O
,	STENDRA.xml:S1:9084:1	O
to	STENDRA.xml:S1:9086:2	O
the	STENDRA.xml:S1:9089:3	O
patient	STENDRA.xml:S1:9093:7	O
's	STENDRA.xml:S1:9100:2	O
underlying	STENDRA.xml:S1:9103:10	O
vascular	STENDRA.xml:S1:9114:8	O
risk	STENDRA.xml:S1:9123:4	O
factors	STENDRA.xml:S1:9128:7	O
or	STENDRA.xml:S1:9136:2	O
anatomical	STENDRA.xml:S1:9139:10	O
defects	STENDRA.xml:S1:9150:7	O
,	STENDRA.xml:S1:9157:1	O
to	STENDRA.xml:S1:9159:2	O
a	STENDRA.xml:S1:9162:1	O
combination	STENDRA.xml:S1:9164:11	O
of	STENDRA.xml:S1:9176:2	O
these	STENDRA.xml:S1:9179:5	O
factors	STENDRA.xml:S1:9185:7	O
,	STENDRA.xml:S1:9192:1	O
or	STENDRA.xml:S1:9194:2	O
to	STENDRA.xml:S1:9197:2	O
other	STENDRA.xml:S1:9200:5	O
factors	STENDRA.xml:S1:9206:7	O
[	STENDRA.xml:S1:9214:1	O
see	STENDRA.xml:S1:9215:3	O
Warnings	STENDRA.xml:S1:9220:8	O
and	STENDRA.xml:S1:9229:3	O
Precautions	STENDRA.xml:S1:9233:11	O
(	STENDRA.xml:S1:9245:1	O
5.4	STENDRA.xml:S1:9246:3	O
)	STENDRA.xml:S1:9249:1	O
andPatient	STENDRA.xml:S1:9250:10	O
Counseling	STENDRA.xml:S1:9261:10	O
Information	STENDRA.xml:S1:9272:11	O
(	STENDRA.xml:S1:9284:1	O
17.6	STENDRA.xml:S1:9285:4	O
)	STENDRA.xml:S1:9289:1	O
]	STENDRA.xml:S1:9292:1	O
.	STENDRA.xml:S1:9293:1	O
5	STENDRA.xml:S2:4:1	O
WARNINGS	STENDRA.xml:S2:6:8	O
AND	STENDRA.xml:S2:15:3	O
PRECAUTIONS	STENDRA.xml:S2:19:11	O

Evaluation	STENDRA.xml:S2:34:10	O
of	STENDRA.xml:S2:45:2	O
erectile	STENDRA.xml:S2:48:8	O
dysfunction	STENDRA.xml:S2:57:11	O
(	STENDRA.xml:S2:69:1	O
ED	STENDRA.xml:S2:70:2	O
)	STENDRA.xml:S2:72:1	O
should	STENDRA.xml:S2:74:6	O
include	STENDRA.xml:S2:81:7	O
an	STENDRA.xml:S2:89:2	O
appropriate	STENDRA.xml:S2:92:11	O
medical	STENDRA.xml:S2:104:7	O
assessment	STENDRA.xml:S2:112:10	O
to	STENDRA.xml:S2:123:2	O
identify	STENDRA.xml:S2:126:8	O
potential	STENDRA.xml:S2:135:9	O
underlying	STENDRA.xml:S2:145:10	O
causes	STENDRA.xml:S2:156:6	O
,	STENDRA.xml:S2:162:1	O
as	STENDRA.xml:S2:164:2	O
well	STENDRA.xml:S2:167:4	O
as	STENDRA.xml:S2:172:2	O
treatment	STENDRA.xml:S2:175:9	O
options	STENDRA.xml:S2:185:7	O
.	STENDRA.xml:S2:192:1	O

Before	STENDRA.xml:S2:198:6	O
prescribing	STENDRA.xml:S2:205:11	O
STENDRA	STENDRA.xml:S2:217:7	O
,	STENDRA.xml:S2:224:1	O
it	STENDRA.xml:S2:226:2	O
is	STENDRA.xml:S2:229:2	O
important	STENDRA.xml:S2:232:9	O
to	STENDRA.xml:S2:242:2	O
note	STENDRA.xml:S2:245:4	O
the	STENDRA.xml:S2:250:3	O
following	STENDRA.xml:S2:254:9	O
:	STENDRA.xml:S2:263:1	O

EXCERPT	STENDRA.xml:S2:272:7	O
:	STENDRA.xml:S2:279:1	O
Patients	STENDRA.xml:S2:287:8	O
should	STENDRA.xml:S2:296:6	O
not	STENDRA.xml:S2:303:3	O
use	STENDRA.xml:S2:307:3	O
STENDRA	STENDRA.xml:S2:311:7	O
if	STENDRA.xml:S2:319:2	O
sexual	STENDRA.xml:S2:322:6	O
activity	STENDRA.xml:S2:329:8	O
is	STENDRA.xml:S2:338:2	O
inadvisable	STENDRA.xml:S2:341:11	O
due	STENDRA.xml:S2:353:3	O
to	STENDRA.xml:S2:357:2	O
cardiovascular	STENDRA.xml:S2:360:14	O
status	STENDRA.xml:S2:375:6	O
or	STENDRA.xml:S2:382:2	O
any	STENDRA.xml:S2:385:3	O
other	STENDRA.xml:S2:389:5	O
reason	STENDRA.xml:S2:395:6	O
(	STENDRA.xml:S2:402:1	O
5.1	STENDRA.xml:S2:403:3	O
)	STENDRA.xml:S2:406:1	O

Use	STENDRA.xml:S2:413:3	O
of	STENDRA.xml:S2:417:2	O
STENDRA	STENDRA.xml:S2:420:7	O
with	STENDRA.xml:S2:428:4	O
alpha	STENDRA.xml:S2:433:5	O
-	STENDRA.xml:S2:438:1	O
blockers	STENDRA.xml:S2:439:8	O
,	STENDRA.xml:S2:447:1	O
other	STENDRA.xml:S2:449:5	O
antihypertensives	STENDRA.xml:S2:455:17	O
,	STENDRA.xml:S2:472:1	O
or	STENDRA.xml:S2:474:2	O
substantial	STENDRA.xml:S2:477:11	O
amounts	STENDRA.xml:S2:489:7	O
of	STENDRA.xml:S2:497:2	O
alcohol	STENDRA.xml:S2:500:7	O
(	STENDRA.xml:S2:508:1	O
greater	STENDRA.xml:S2:509:7	O
than	STENDRA.xml:S2:517:4	O
3	STENDRA.xml:S2:522:1	O
units	STENDRA.xml:S2:524:5	O
)	STENDRA.xml:S2:529:1	O
may	STENDRA.xml:S2:531:3	O
lead	STENDRA.xml:S2:535:4	O
to	STENDRA.xml:S2:540:2	O
hypotension	STENDRA.xml:S2:543:11	B-AdverseReaction
(	STENDRA.xml:S2:555:1	O
2.3	STENDRA.xml:S2:556:3	O
,	STENDRA.xml:S2:559:1	O
5.6	STENDRA.xml:S2:560:3	O
,	STENDRA.xml:S2:563:1	O
5.7	STENDRA.xml:S2:564:3	O
)	STENDRA.xml:S2:567:1	O

Patients	STENDRA.xml:S2:574:8	O
should	STENDRA.xml:S2:583:6	O
seek	STENDRA.xml:S2:590:4	O
emergency	STENDRA.xml:S2:595:9	O
treatment	STENDRA.xml:S2:605:9	O
if	STENDRA.xml:S2:615:2	O
an	STENDRA.xml:S2:618:2	O
erection	STENDRA.xml:S2:621:8	O
lasts	STENDRA.xml:S2:630:5	O
greater	STENDRA.xml:S2:636:7	O
than	STENDRA.xml:S2:644:4	O
4	STENDRA.xml:S2:649:1	O
hours	STENDRA.xml:S2:651:5	O
(	STENDRA.xml:S2:657:1	O
5.3	STENDRA.xml:S2:658:3	O
)	STENDRA.xml:S2:661:1	O

Patients	STENDRA.xml:S2:668:8	O
should	STENDRA.xml:S2:677:6	O
stop	STENDRA.xml:S2:684:4	O
STENDRA	STENDRA.xml:S2:689:7	O
and	STENDRA.xml:S2:697:3	O
seek	STENDRA.xml:S2:701:4	O
medical	STENDRA.xml:S2:706:7	O
care	STENDRA.xml:S2:714:4	O
if	STENDRA.xml:S2:719:2	O
a	STENDRA.xml:S2:722:1	O
sudden	STENDRA.xml:S2:724:6	O
loss	STENDRA.xml:S2:731:4	O
of	STENDRA.xml:S2:736:2	O
vision	STENDRA.xml:S2:739:6	O
occurs	STENDRA.xml:S2:746:6	O
in	STENDRA.xml:S2:753:2	O
one	STENDRA.xml:S2:756:3	O
or	STENDRA.xml:S2:760:2	O
both	STENDRA.xml:S2:763:4	O
eyes	STENDRA.xml:S2:768:4	O
,	STENDRA.xml:S2:772:1	O
which	STENDRA.xml:S2:774:5	O
could	STENDRA.xml:S2:780:5	O
be	STENDRA.xml:S2:786:2	O
a	STENDRA.xml:S2:789:1	O
sign	STENDRA.xml:S2:791:4	O
of	STENDRA.xml:S2:796:2	O
Non	STENDRA.xml:S2:799:3	O
Arteritic	STENDRA.xml:S2:803:9	O
Ischemic	STENDRA.xml:S2:813:8	O
Optic	STENDRA.xml:S2:822:5	O
Neuropathy	STENDRA.xml:S2:828:10	O
(	STENDRA.xml:S2:839:1	O
NAION	STENDRA.xml:S2:840:5	O
)	STENDRA.xml:S2:845:1	O
.	STENDRA.xml:S2:846:1	O

STENDRA	STENDRA.xml:S2:848:7	O
should	STENDRA.xml:S2:856:6	O
be	STENDRA.xml:S2:863:2	O
used	STENDRA.xml:S2:866:4	O
with	STENDRA.xml:S2:871:4	O
caution	STENDRA.xml:S2:876:7	O
,	STENDRA.xml:S2:883:1	O
and	STENDRA.xml:S2:885:3	O
only	STENDRA.xml:S2:889:4	O
when	STENDRA.xml:S2:894:4	O
the	STENDRA.xml:S2:899:3	O
anticipated	STENDRA.xml:S2:903:11	O
benefits	STENDRA.xml:S2:915:8	O
outweigh	STENDRA.xml:S2:924:8	O
the	STENDRA.xml:S2:933:3	O
risks	STENDRA.xml:S2:937:5	O
,	STENDRA.xml:S2:942:1	O
in	STENDRA.xml:S2:944:2	O
patients	STENDRA.xml:S2:947:8	O
with	STENDRA.xml:S2:956:4	O
a	STENDRA.xml:S2:961:1	O
history	STENDRA.xml:S2:963:7	O
of	STENDRA.xml:S2:971:2	O
NAION	STENDRA.xml:S2:974:5	O
.	STENDRA.xml:S2:979:1	O

Patients	STENDRA.xml:S2:981:8	O
with	STENDRA.xml:S2:990:4	O
a	STENDRA.xml:S2:995:1	O
"	STENDRA.xml:S2:997:1	O
crowded	STENDRA.xml:S2:998:7	O
"	STENDRA.xml:S2:1005:1	O
optic	STENDRA.xml:S2:1007:5	O
disc	STENDRA.xml:S2:1013:4	O
may	STENDRA.xml:S2:1018:3	O
also	STENDRA.xml:S2:1022:4	O
be	STENDRA.xml:S2:1027:2	O
at	STENDRA.xml:S2:1030:2	O
an	STENDRA.xml:S2:1033:2	O
increased	STENDRA.xml:S2:1036:9	O
risk	STENDRA.xml:S2:1046:4	O
of	STENDRA.xml:S2:1051:2	O
NAION	STENDRA.xml:S2:1054:5	O
(	STENDRA.xml:S2:1060:1	O
5.4	STENDRA.xml:S2:1061:3	O
,	STENDRA.xml:S2:1064:1	O
6.2	STENDRA.xml:S2:1065:3	O
)	STENDRA.xml:S2:1068:1	O

Patients	STENDRA.xml:S2:1075:8	O
should	STENDRA.xml:S2:1084:6	O
stop	STENDRA.xml:S2:1091:4	O
taking	STENDRA.xml:S2:1096:6	O
STENDRA	STENDRA.xml:S2:1103:7	O
and	STENDRA.xml:S2:1111:3	O
seek	STENDRA.xml:S2:1115:4	O
prompt	STENDRA.xml:S2:1120:6	O
medical	STENDRA.xml:S2:1127:7	O
attention	STENDRA.xml:S2:1135:9	O
in	STENDRA.xml:S2:1145:2	O
the	STENDRA.xml:S2:1148:3	O
event	STENDRA.xml:S2:1152:5	O
of	STENDRA.xml:S2:1158:2	O
sudden	STENDRA.xml:S2:1161:6	O
decrease	STENDRA.xml:S2:1168:8	O
or	STENDRA.xml:S2:1177:2	O
loss	STENDRA.xml:S2:1180:4	O
of	STENDRA.xml:S2:1185:2	O
hearing	STENDRA.xml:S2:1188:7	O
(	STENDRA.xml:S2:1196:1	O
5.5	STENDRA.xml:S2:1197:3	O
)	STENDRA.xml:S2:1200:1	O

5.1	STENDRA.xml:S2:1211:3	O

Cardiovascular	STENDRA.xml:S2:1215:14	O
Risks	STENDRA.xml:S2:1230:5	O

There	STENDRA.xml:S2:1239:5	O
is	STENDRA.xml:S2:1245:2	O
a	STENDRA.xml:S2:1248:1	O
potential	STENDRA.xml:S2:1250:9	B-Factor
for	STENDRA.xml:S2:1260:3	O
cardiac	STENDRA.xml:S2:1264:7	B-AdverseReaction
risk	STENDRA.xml:S2:1272:4	I-AdverseReaction
during	STENDRA.xml:S2:1277:6	O
sexual	STENDRA.xml:S2:1284:6	O
activity	STENDRA.xml:S2:1291:8	O
in	STENDRA.xml:S2:1300:2	O
patients	STENDRA.xml:S2:1303:8	O
with	STENDRA.xml:S2:1312:4	O
pre	STENDRA.xml:S2:1317:3	O
-	STENDRA.xml:S2:1320:1	O
existing	STENDRA.xml:S2:1321:8	O
cardiovascular	STENDRA.xml:S2:1330:14	O
disease	STENDRA.xml:S2:1345:7	O
.	STENDRA.xml:S2:1352:1	O

Therefore	STENDRA.xml:S2:1354:9	O
,	STENDRA.xml:S2:1363:1	O
treatments	STENDRA.xml:S2:1365:10	O
for	STENDRA.xml:S2:1376:3	O
ED	STENDRA.xml:S2:1380:2	O
,	STENDRA.xml:S2:1382:1	O
including	STENDRA.xml:S2:1384:9	O
STENDRA	STENDRA.xml:S2:1394:7	O
,	STENDRA.xml:S2:1401:1	O
should	STENDRA.xml:S2:1403:6	O
not	STENDRA.xml:S2:1410:3	O
be	STENDRA.xml:S2:1414:2	O
used	STENDRA.xml:S2:1417:4	O
in	STENDRA.xml:S2:1422:2	O
men	STENDRA.xml:S2:1425:3	O
for	STENDRA.xml:S2:1429:3	O
whom	STENDRA.xml:S2:1433:4	O
sexual	STENDRA.xml:S2:1438:6	O
activity	STENDRA.xml:S2:1445:8	O
is	STENDRA.xml:S2:1454:2	O
inadvisable	STENDRA.xml:S2:1457:11	O
because	STENDRA.xml:S2:1469:7	O
of	STENDRA.xml:S2:1477:2	O
their	STENDRA.xml:S2:1480:5	O
underlying	STENDRA.xml:S2:1486:10	O
cardiovascular	STENDRA.xml:S2:1497:14	O
status	STENDRA.xml:S2:1512:6	O
.	STENDRA.xml:S2:1518:1	O

Patients	STENDRA.xml:S2:1524:8	O
with	STENDRA.xml:S2:1533:4	O
left	STENDRA.xml:S2:1538:4	O
ventricular	STENDRA.xml:S2:1543:11	O
outflow	STENDRA.xml:S2:1555:7	O
obstruction	STENDRA.xml:S2:1563:11	O
(	STENDRA.xml:S2:1575:1	O
e	STENDRA.xml:S2:1576:1	O
.	STENDRA.xml:S2:1577:1	O
g	STENDRA.xml:S2:1578:1	O
.	STENDRA.xml:S2:1579:1	O
,	STENDRA.xml:S2:1580:1	O
aortic	STENDRA.xml:S2:1582:6	O
stenosis	STENDRA.xml:S2:1589:8	O
,	STENDRA.xml:S2:1597:1	O
idiopathic	STENDRA.xml:S2:1599:10	O
hypertrophic	STENDRA.xml:S2:1610:12	O
subaortic	STENDRA.xml:S2:1623:9	O
stenosis	STENDRA.xml:S2:1633:8	O
)	STENDRA.xml:S2:1641:1	O
and	STENDRA.xml:S2:1643:3	O
those	STENDRA.xml:S2:1647:5	O
with	STENDRA.xml:S2:1653:4	O
severely	STENDRA.xml:S2:1658:8	O
impaired	STENDRA.xml:S2:1667:8	O
autonomic	STENDRA.xml:S2:1676:9	O
control	STENDRA.xml:S2:1686:7	O
of	STENDRA.xml:S2:1694:2	O
blood	STENDRA.xml:S2:1697:5	O
pressure	STENDRA.xml:S2:1703:8	O
can	STENDRA.xml:S2:1712:3	O
be	STENDRA.xml:S2:1716:2	O
particularly	STENDRA.xml:S2:1719:12	O
sensitive	STENDRA.xml:S2:1732:9	O
to	STENDRA.xml:S2:1742:2	O
the	STENDRA.xml:S2:1745:3	O
actions	STENDRA.xml:S2:1749:7	O
of	STENDRA.xml:S2:1757:2	O
vasodilators	STENDRA.xml:S2:1760:12	O
,	STENDRA.xml:S2:1772:1	O
including	STENDRA.xml:S2:1774:9	O
STENDRA	STENDRA.xml:S2:1784:7	O
.	STENDRA.xml:S2:1791:1	O

The	STENDRA.xml:S2:1797:3	O
following	STENDRA.xml:S2:1801:9	O
groups	STENDRA.xml:S2:1811:6	O
of	STENDRA.xml:S2:1818:2	O
patients	STENDRA.xml:S2:1821:8	O
were	STENDRA.xml:S2:1830:4	O
not	STENDRA.xml:S2:1835:3	O
included	STENDRA.xml:S2:1839:8	O
in	STENDRA.xml:S2:1848:2	O
clinical	STENDRA.xml:S2:1851:8	O
safety	STENDRA.xml:S2:1860:6	O
and	STENDRA.xml:S2:1867:3	O
efficacy	STENDRA.xml:S2:1871:8	O
trials	STENDRA.xml:S2:1880:6	O
for	STENDRA.xml:S2:1887:3	O
STENDRA	STENDRA.xml:S2:1891:7	O
,	STENDRA.xml:S2:1898:1	O
and	STENDRA.xml:S2:1900:3	O
therefore	STENDRA.xml:S2:1904:9	O
until	STENDRA.xml:S2:1914:5	O
further	STENDRA.xml:S2:1920:7	O
information	STENDRA.xml:S2:1928:11	O
is	STENDRA.xml:S2:1940:2	O
available	STENDRA.xml:S2:1943:9	O
,	STENDRA.xml:S2:1952:1	O
STENDRA	STENDRA.xml:S2:1954:7	O
is	STENDRA.xml:S2:1962:2	O
not	STENDRA.xml:S2:1965:3	O
recommended	STENDRA.xml:S2:1969:11	O
for	STENDRA.xml:S2:1981:3	O
the	STENDRA.xml:S2:1985:3	O
following	STENDRA.xml:S2:1989:9	O
groups	STENDRA.xml:S2:1999:6	O
:	STENDRA.xml:S2:2005:1	O

Patients	STENDRA.xml:S2:2014:8	O
who	STENDRA.xml:S2:2023:3	O
have	STENDRA.xml:S2:2027:4	O
suffered	STENDRA.xml:S2:2032:8	O
a	STENDRA.xml:S2:2041:1	O
myocardial	STENDRA.xml:S2:2043:10	O
infarction	STENDRA.xml:S2:2054:10	O
,	STENDRA.xml:S2:2064:1	O
stroke	STENDRA.xml:S2:2066:6	O
,	STENDRA.xml:S2:2072:1	O
life	STENDRA.xml:S2:2074:4	O
-	STENDRA.xml:S2:2078:1	O
threatening	STENDRA.xml:S2:2079:11	O
arrhythmia	STENDRA.xml:S2:2091:10	O
,	STENDRA.xml:S2:2101:1	O
or	STENDRA.xml:S2:2103:2	O
coronary	STENDRA.xml:S2:2106:8	O
revascularization	STENDRA.xml:S2:2115:17	O
within	STENDRA.xml:S2:2133:6	O
the	STENDRA.xml:S2:2140:3	O
last	STENDRA.xml:S2:2144:4	O
6	STENDRA.xml:S2:2149:1	O
months	STENDRA.xml:S2:2151:6	O
;	STENDRA.xml:S2:2157:1	O

Patients	STENDRA.xml:S2:2164:8	O
with	STENDRA.xml:S2:2173:4	O
resting	STENDRA.xml:S2:2178:7	O
hypotension	STENDRA.xml:S2:2186:11	O
(	STENDRA.xml:S2:2198:1	O
blood	STENDRA.xml:S2:2199:5	O
pressure	STENDRA.xml:S2:2205:8	O
less	STENDRA.xml:S2:2214:4	O
than	STENDRA.xml:S2:2219:4	O
90	STENDRA.xml:S2:2224:2	O
50	STENDRA.xml:S2:2227:2	O
mmHg	STENDRA.xml:S2:2230:4	O
)	STENDRA.xml:S2:2234:1	O
or	STENDRA.xml:S2:2236:2	O
hypertension	STENDRA.xml:S2:2239:12	O
(	STENDRA.xml:S2:2252:1	O
blood	STENDRA.xml:S2:2253:5	O
pressure	STENDRA.xml:S2:2259:8	O
greater	STENDRA.xml:S2:2268:7	O
than	STENDRA.xml:S2:2276:4	O
170	STENDRA.xml:S2:2281:3	O
100	STENDRA.xml:S2:2285:3	O
mmHg	STENDRA.xml:S2:2289:4	O
)	STENDRA.xml:S2:2293:1	O
;	STENDRA.xml:S2:2294:1	O

Patients	STENDRA.xml:S2:2301:8	O
with	STENDRA.xml:S2:2310:4	O
unstable	STENDRA.xml:S2:2315:8	O
angina	STENDRA.xml:S2:2324:6	O
,	STENDRA.xml:S2:2330:1	O
angina	STENDRA.xml:S2:2332:6	O
with	STENDRA.xml:S2:2339:4	O
sexual	STENDRA.xml:S2:2344:6	O
intercourse	STENDRA.xml:S2:2351:11	O
,	STENDRA.xml:S2:2362:1	O
or	STENDRA.xml:S2:2364:2	O
New	STENDRA.xml:S2:2367:3	O
York	STENDRA.xml:S2:2371:4	O
Heart	STENDRA.xml:S2:2376:5	O
Association	STENDRA.xml:S2:2382:11	O
Class	STENDRA.xml:S2:2394:5	O
2	STENDRA.xml:S2:2400:1	O
or	STENDRA.xml:S2:2402:2	O
greater	STENDRA.xml:S2:2405:7	O
congestive	STENDRA.xml:S2:2413:10	O
heart	STENDRA.xml:S2:2424:5	O
failure	STENDRA.xml:S2:2430:7	O
.	STENDRA.xml:S2:2437:1	O

As	STENDRA.xml:S2:2444:2	O
with	STENDRA.xml:S2:2447:4	O
other	STENDRA.xml:S2:2452:5	O
PDE5	STENDRA.xml:S2:2458:4	O
inhibitors	STENDRA.xml:S2:2463:10	O
STENDRA	STENDRA.xml:S2:2474:7	O
has	STENDRA.xml:S2:2482:3	O
systemic	STENDRA.xml:S2:2486:8	O
vasodilatory	STENDRA.xml:S2:2495:12	O
properties	STENDRA.xml:S2:2508:10	O
and	STENDRA.xml:S2:2519:3	O
may	STENDRA.xml:S2:2523:3	O
augment	STENDRA.xml:S2:2527:7	O
the	STENDRA.xml:S2:2535:3	O
blood	STENDRA.xml:S2:2539:5	O
pressure	STENDRA.xml:S2:2545:8	O
-	STENDRA.xml:S2:2553:1	O
lowering	STENDRA.xml:S2:2554:8	O
effect	STENDRA.xml:S2:2563:6	O
of	STENDRA.xml:S2:2570:2	O
other	STENDRA.xml:S2:2573:5	O
anti	STENDRA.xml:S2:2579:4	O
-	STENDRA.xml:S2:2583:1	O
hypertensive	STENDRA.xml:S2:2584:12	O
medications	STENDRA.xml:S2:2597:11	O
.	STENDRA.xml:S2:2608:1	O

STENDRA	STENDRA.xml:S2:2610:7	O
200	STENDRA.xml:S2:2618:3	O
mg	STENDRA.xml:S2:2622:2	O
resulted	STENDRA.xml:S2:2625:8	O
in	STENDRA.xml:S2:2634:2	O
transient	STENDRA.xml:S2:2637:9	B-AdverseReaction
decreases	STENDRA.xml:S2:2647:9	I-AdverseReaction
in	STENDRA.xml:S2:2657:2	I-AdverseReaction
sitting	STENDRA.xml:S2:2660:7	I-AdverseReaction
blood	STENDRA.xml:S2:2668:5	I-AdverseReaction
pressure	STENDRA.xml:S2:2674:8	I-AdverseReaction
in	STENDRA.xml:S2:2683:2	O
healthy	STENDRA.xml:S2:2686:7	O
volunteers	STENDRA.xml:S2:2694:10	O
of	STENDRA.xml:S2:2705:2	O
8.0	STENDRA.xml:S2:2708:3	B-Severity
mmHg	STENDRA.xml:S2:2712:4	I-Severity
systolic	STENDRA.xml:S2:2717:8	I-Severity
and	STENDRA.xml:S2:2726:3	I-Severity
3.3	STENDRA.xml:S2:2730:3	I-Severity
mmHg	STENDRA.xml:S2:2734:4	I-Severity
diastolic	STENDRA.xml:S2:2739:9	I-Severity
[	STENDRA.xml:S2:2750:1	O
seeClinical	STENDRA.xml:S2:2751:11	O
Pharmacology	STENDRA.xml:S2:2763:12	O
(	STENDRA.xml:S2:2776:1	O
12.2	STENDRA.xml:S2:2777:4	O
)]	STENDRA.xml:S2:2781:2	O
,	STENDRA.xml:S2:2785:1	O
with	STENDRA.xml:S2:2787:4	O
the	STENDRA.xml:S2:2792:3	O
maximum	STENDRA.xml:S2:2796:7	O
decrease	STENDRA.xml:S2:2804:8	O
observed	STENDRA.xml:S2:2813:8	O
at	STENDRA.xml:S2:2822:2	O
1	STENDRA.xml:S2:2825:1	O
hour	STENDRA.xml:S2:2827:4	O
after	STENDRA.xml:S2:2832:5	O
dosing	STENDRA.xml:S2:2838:6	O
.	STENDRA.xml:S2:2844:1	O

While	STENDRA.xml:S2:2846:5	O
this	STENDRA.xml:S2:2852:4	O
normally	STENDRA.xml:S2:2857:8	O
would	STENDRA.xml:S2:2866:5	O
be	STENDRA.xml:S2:2872:2	O
expected	STENDRA.xml:S2:2875:8	O
to	STENDRA.xml:S2:2884:2	O
be	STENDRA.xml:S2:2887:2	O
of	STENDRA.xml:S2:2890:2	O
little	STENDRA.xml:S2:2893:6	O
consequence	STENDRA.xml:S2:2900:11	O
in	STENDRA.xml:S2:2912:2	O
most	STENDRA.xml:S2:2915:4	O
patients	STENDRA.xml:S2:2920:8	O
,	STENDRA.xml:S2:2928:1	O
prior	STENDRA.xml:S2:2930:5	O
to	STENDRA.xml:S2:2936:2	O
prescribing	STENDRA.xml:S2:2939:11	O
STENDRA	STENDRA.xml:S2:2951:7	O
,	STENDRA.xml:S2:2958:1	O
physicians	STENDRA.xml:S2:2960:10	O
should	STENDRA.xml:S2:2971:6	O
carefully	STENDRA.xml:S2:2978:9	O
consider	STENDRA.xml:S2:2988:8	O
whether	STENDRA.xml:S2:2997:7	O
patients	STENDRA.xml:S2:3005:8	O
with	STENDRA.xml:S2:3014:4	O
underlying	STENDRA.xml:S2:3019:10	O
cardiovascular	STENDRA.xml:S2:3030:14	O
disease	STENDRA.xml:S2:3045:7	O
could	STENDRA.xml:S2:3053:5	O
be	STENDRA.xml:S2:3059:2	O
affected	STENDRA.xml:S2:3062:8	O
adversely	STENDRA.xml:S2:3071:9	O
by	STENDRA.xml:S2:3081:2	O
such	STENDRA.xml:S2:3084:4	O
vasodilatory	STENDRA.xml:S2:3089:12	O
effects	STENDRA.xml:S2:3102:7	O
,	STENDRA.xml:S2:3109:1	O
especially	STENDRA.xml:S2:3111:10	O
in	STENDRA.xml:S2:3122:2	O
combination	STENDRA.xml:S2:3125:11	O
with	STENDRA.xml:S2:3137:4	O
sexual	STENDRA.xml:S2:3142:6	O
activity	STENDRA.xml:S2:3149:8	O
.	STENDRA.xml:S2:3157:1	O

5.2	STENDRA.xml:S2:3165:3	O

Concomitant	STENDRA.xml:S2:3169:11	O
Use	STENDRA.xml:S2:3181:3	O
of	STENDRA.xml:S2:3185:2	O
CYP3A4	STENDRA.xml:S2:3188:6	O
Inhibitors	STENDRA.xml:S2:3195:10	O

STENDRA	STENDRA.xml:S2:3209:7	O
metabolism	STENDRA.xml:S2:3217:10	O
is	STENDRA.xml:S2:3228:2	O
principally	STENDRA.xml:S2:3231:11	O
mediated	STENDRA.xml:S2:3243:8	O
by	STENDRA.xml:S2:3252:2	O
the	STENDRA.xml:S2:3255:3	O
CYP450	STENDRA.xml:S2:3259:6	O
isoform	STENDRA.xml:S2:3266:7	O
3	STENDRA.xml:S2:3274:1	O
A4	STENDRA.xml:S2:3275:2	O
(	STENDRA.xml:S2:3278:1	O
CYP3A4	STENDRA.xml:S2:3279:6	O
)	STENDRA.xml:S2:3285:1	O
.	STENDRA.xml:S2:3286:1	O

Inhibitors	STENDRA.xml:S2:3288:10	O
of	STENDRA.xml:S2:3299:2	O
CYP3A4	STENDRA.xml:S2:3302:6	O
may	STENDRA.xml:S2:3309:3	O
reduce	STENDRA.xml:S2:3313:6	O
STENDRA	STENDRA.xml:S2:3320:7	O
clearance	STENDRA.xml:S2:3328:9	O
and	STENDRA.xml:S2:3338:3	O
increase	STENDRA.xml:S2:3342:8	O
plasma	STENDRA.xml:S2:3351:6	O
concentrations	STENDRA.xml:S2:3358:14	O
of	STENDRA.xml:S2:3373:2	O
avanafil	STENDRA.xml:S2:3376:8	O
.	STENDRA.xml:S2:3384:1	O

For	STENDRA.xml:S2:3390:3	O
patients	STENDRA.xml:S2:3394:8	O
taking	STENDRA.xml:S2:3403:6	O
concomitant	STENDRA.xml:S2:3410:11	O
strong	STENDRA.xml:S2:3422:6	O
CYP3A4	STENDRA.xml:S2:3429:6	O
inhibitors	STENDRA.xml:S2:3436:10	O
(	STENDRA.xml:S2:3447:1	O
including	STENDRA.xml:S2:3448:9	O
ketoconazole	STENDRA.xml:S2:3458:12	O
,	STENDRA.xml:S2:3470:1	O
ritonavir	STENDRA.xml:S2:3472:9	O
,	STENDRA.xml:S2:3481:1	O
atazanavir	STENDRA.xml:S2:3483:10	O
,	STENDRA.xml:S2:3493:1	O
clarithromycin	STENDRA.xml:S2:3495:14	O
,	STENDRA.xml:S2:3509:1	O
indinavir	STENDRA.xml:S2:3511:9	O
,	STENDRA.xml:S2:3520:1	O
itraconazole	STENDRA.xml:S2:3522:12	O
,	STENDRA.xml:S2:3534:1	O
nefazodone	STENDRA.xml:S2:3536:10	O
,	STENDRA.xml:S2:3546:1	O
nelfinavir	STENDRA.xml:S2:3548:10	O
,	STENDRA.xml:S2:3558:1	O
saquinavir	STENDRA.xml:S2:3560:10	O
,	STENDRA.xml:S2:3570:1	O
and	STENDRA.xml:S2:3572:3	O
telithromycin	STENDRA.xml:S2:3576:13	O
)	STENDRA.xml:S2:3589:1	O
,	STENDRA.xml:S2:3590:1	O
do	STENDRA.xml:S2:3592:2	O
not	STENDRA.xml:S2:3595:3	O
use	STENDRA.xml:S2:3599:3	O
STENDRA	STENDRA.xml:S2:3603:7	O
[	STENDRA.xml:S2:3612:1	O
seeDrug	STENDRA.xml:S2:3613:7	O
Interactions	STENDRA.xml:S2:3621:12	O
(	STENDRA.xml:S2:3634:1	O
7.2	STENDRA.xml:S2:3635:3	O
)]	STENDRA.xml:S2:3638:2	O
.	STENDRA.xml:S2:3640:1	O

For	STENDRA.xml:S2:3648:3	O
patients	STENDRA.xml:S2:3652:8	O
taking	STENDRA.xml:S2:3661:6	O
concomitant	STENDRA.xml:S2:3668:11	O
moderate	STENDRA.xml:S2:3680:8	O
CYP3A4	STENDRA.xml:S2:3689:6	O
inhibitors	STENDRA.xml:S2:3696:10	O
(	STENDRA.xml:S2:3707:1	O
including	STENDRA.xml:S2:3708:9	O
erythromycin	STENDRA.xml:S2:3718:12	O
,	STENDRA.xml:S2:3730:1	O
amprenavir	STENDRA.xml:S2:3732:10	O
,	STENDRA.xml:S2:3742:1	O
aprepitant	STENDRA.xml:S2:3744:10	O
,	STENDRA.xml:S2:3754:1	O
diltiazem	STENDRA.xml:S2:3756:9	O
,	STENDRA.xml:S2:3765:1	O
fluconazole	STENDRA.xml:S2:3767:11	O
,	STENDRA.xml:S2:3778:1	O
fosamprenavir	STENDRA.xml:S2:3780:13	O
,	STENDRA.xml:S2:3793:1	O
and	STENDRA.xml:S2:3795:3	O
verapamil	STENDRA.xml:S2:3799:9	O
)	STENDRA.xml:S2:3808:1	O
,	STENDRA.xml:S2:3809:1	O
the	STENDRA.xml:S2:3811:3	O
maximum	STENDRA.xml:S2:3815:7	O
recommended	STENDRA.xml:S2:3823:11	O
dose	STENDRA.xml:S2:3835:4	O
of	STENDRA.xml:S2:3840:2	O
STENDRA	STENDRA.xml:S2:3843:7	O
is	STENDRA.xml:S2:3851:2	O
50	STENDRA.xml:S2:3854:2	O
mg	STENDRA.xml:S2:3857:2	O
,	STENDRA.xml:S2:3859:1	O
not	STENDRA.xml:S2:3861:3	O
to	STENDRA.xml:S2:3865:2	O
exceed	STENDRA.xml:S2:3868:6	O
once	STENDRA.xml:S2:3875:4	O
every	STENDRA.xml:S2:3880:5	O
24	STENDRA.xml:S2:3886:2	O
hours	STENDRA.xml:S2:3889:5	O
[	STENDRA.xml:S2:3896:1	O
seeDrug	STENDRA.xml:S2:3897:7	O
Interactions	STENDRA.xml:S2:3905:12	O
(	STENDRA.xml:S2:3918:1	O
7.2	STENDRA.xml:S2:3919:3	O
)]	STENDRA.xml:S2:3922:2	O
.	STENDRA.xml:S2:3924:1	O

5.3	STENDRA.xml:S2:3934:3	O
Prolonged	STENDRA.xml:S2:3938:9	O
Erection	STENDRA.xml:S2:3948:8	O

Prolonged	STENDRA.xml:S2:3960:9	B-AdverseReaction
erection	STENDRA.xml:S2:3970:8	I-AdverseReaction
greater	STENDRA.xml:S2:3979:7	O
than	STENDRA.xml:S2:3987:4	O
4	STENDRA.xml:S2:3992:1	B-Severity
hours	STENDRA.xml:S2:3994:5	I-Severity
and	STENDRA.xml:S2:4000:3	O
priapism	STENDRA.xml:S2:4004:8	B-AdverseReaction
(	STENDRA.xml:S2:4013:1	O
painful	STENDRA.xml:S2:4014:7	B-AdverseReaction
erections	STENDRA.xml:S2:4022:9	I-AdverseReaction
greater	STENDRA.xml:S2:4032:7	O
than	STENDRA.xml:S2:4040:4	O
6	STENDRA.xml:S2:4045:1	B-Severity
hours	STENDRA.xml:S2:4047:5	I-Severity
in	STENDRA.xml:S2:4053:2	O
duration	STENDRA.xml:S2:4056:8	O
)	STENDRA.xml:S2:4064:1	O
have	STENDRA.xml:S2:4066:4	O
been	STENDRA.xml:S2:4071:4	O
reported	STENDRA.xml:S2:4076:8	O
with	STENDRA.xml:S2:4085:4	O
other	STENDRA.xml:S2:4090:5	O
PDE5	STENDRA.xml:S2:4096:4	B-DrugClass
inhibitors	STENDRA.xml:S2:4101:10	I-DrugClass
.	STENDRA.xml:S2:4111:1	O

In	STENDRA.xml:S2:4113:2	O
the	STENDRA.xml:S2:4116:3	O
event	STENDRA.xml:S2:4120:5	O
of	STENDRA.xml:S2:4126:2	O
an	STENDRA.xml:S2:4129:2	O
erection	STENDRA.xml:S2:4132:8	O
that	STENDRA.xml:S2:4141:4	O
persists	STENDRA.xml:S2:4146:8	O
longer	STENDRA.xml:S2:4155:6	O
than	STENDRA.xml:S2:4162:4	O
4	STENDRA.xml:S2:4167:1	O
hours	STENDRA.xml:S2:4169:5	O
,	STENDRA.xml:S2:4174:1	O
the	STENDRA.xml:S2:4176:3	O
patient	STENDRA.xml:S2:4180:7	O
should	STENDRA.xml:S2:4188:6	O
seek	STENDRA.xml:S2:4195:4	O
immediate	STENDRA.xml:S2:4200:9	O
medical	STENDRA.xml:S2:4210:7	O
assistance	STENDRA.xml:S2:4218:10	O
.	STENDRA.xml:S2:4228:1	O

If	STENDRA.xml:S2:4230:2	O
not	STENDRA.xml:S2:4233:3	O
treated	STENDRA.xml:S2:4237:7	O
immediately	STENDRA.xml:S2:4245:11	O
,	STENDRA.xml:S2:4256:1	O
penile	STENDRA.xml:S2:4258:6	O
tissue	STENDRA.xml:S2:4265:6	O
damage	STENDRA.xml:S2:4272:6	O
and	STENDRA.xml:S2:4279:3	O
permanent	STENDRA.xml:S2:4283:9	O
loss	STENDRA.xml:S2:4293:4	O
of	STENDRA.xml:S2:4298:2	O
potency	STENDRA.xml:S2:4301:7	O
could	STENDRA.xml:S2:4309:5	O
result	STENDRA.xml:S2:4315:6	O
.	STENDRA.xml:S2:4321:1	O

STENDRA	STENDRA.xml:S2:4327:7	O
should	STENDRA.xml:S2:4335:6	O
be	STENDRA.xml:S2:4342:2	O
used	STENDRA.xml:S2:4345:4	O
with	STENDRA.xml:S2:4350:4	O
caution	STENDRA.xml:S2:4355:7	O
in	STENDRA.xml:S2:4363:2	O
patients	STENDRA.xml:S2:4366:8	O
with	STENDRA.xml:S2:4375:4	O
anatomical	STENDRA.xml:S2:4380:10	O
deformation	STENDRA.xml:S2:4391:11	O
of	STENDRA.xml:S2:4403:2	O
the	STENDRA.xml:S2:4406:3	O
penis	STENDRA.xml:S2:4410:5	O
(	STENDRA.xml:S2:4416:1	O
such	STENDRA.xml:S2:4417:4	O
as	STENDRA.xml:S2:4422:2	O
angulation	STENDRA.xml:S2:4425:10	O
,	STENDRA.xml:S2:4435:1	O
cavernosal	STENDRA.xml:S2:4437:10	O
fibrosis	STENDRA.xml:S2:4448:8	O
,	STENDRA.xml:S2:4456:1	O
or	STENDRA.xml:S2:4458:2	O
Peyronie	STENDRA.xml:S2:4461:8	O
's	STENDRA.xml:S2:4469:2	O
disease	STENDRA.xml:S2:4472:7	O
)	STENDRA.xml:S2:4479:1	O
,	STENDRA.xml:S2:4480:1	O
or	STENDRA.xml:S2:4482:2	O
in	STENDRA.xml:S2:4485:2	O
patients	STENDRA.xml:S2:4488:8	O
who	STENDRA.xml:S2:4497:3	O
have	STENDRA.xml:S2:4501:4	O
conditions	STENDRA.xml:S2:4506:10	O
which	STENDRA.xml:S2:4517:5	O
may	STENDRA.xml:S2:4523:3	O
predispose	STENDRA.xml:S2:4527:10	O
them	STENDRA.xml:S2:4538:4	O
to	STENDRA.xml:S2:4543:2	O
priapism	STENDRA.xml:S2:4546:8	O
(	STENDRA.xml:S2:4555:1	O
such	STENDRA.xml:S2:4556:4	O
as	STENDRA.xml:S2:4561:2	O
sickle	STENDRA.xml:S2:4564:6	O
cell	STENDRA.xml:S2:4571:4	O
anemia	STENDRA.xml:S2:4576:6	O
,	STENDRA.xml:S2:4582:1	O
multiple	STENDRA.xml:S2:4584:8	O
myeloma	STENDRA.xml:S2:4593:7	O
,	STENDRA.xml:S2:4600:1	O
or	STENDRA.xml:S2:4602:2	O
leukemia	STENDRA.xml:S2:4605:8	O
)	STENDRA.xml:S2:4613:1	O
.	STENDRA.xml:S2:4614:1	O

5.4	STENDRA.xml:S2:4622:3	O
Effects	STENDRA.xml:S2:4626:7	O
on	STENDRA.xml:S2:4634:2	O
Eye	STENDRA.xml:S2:4637:3	O

Physicians	STENDRA.xml:S2:4646:10	O
should	STENDRA.xml:S2:4657:6	O
advise	STENDRA.xml:S2:4664:6	O
patients	STENDRA.xml:S2:4671:8	O
to	STENDRA.xml:S2:4680:2	O
stop	STENDRA.xml:S2:4683:4	O
use	STENDRA.xml:S2:4688:3	O
of	STENDRA.xml:S2:4692:2	O
all	STENDRA.xml:S2:4695:3	O
PDE5	STENDRA.xml:S2:4699:4	O
inhibitors	STENDRA.xml:S2:4704:10	O
,	STENDRA.xml:S2:4714:1	O
including	STENDRA.xml:S2:4716:9	O
STENDRA	STENDRA.xml:S2:4726:7	O
,	STENDRA.xml:S2:4733:1	O
and	STENDRA.xml:S2:4735:3	O
seek	STENDRA.xml:S2:4739:4	O
medical	STENDRA.xml:S2:4744:7	O
attention	STENDRA.xml:S2:4752:9	O
in	STENDRA.xml:S2:4762:2	O
the	STENDRA.xml:S2:4765:3	O
event	STENDRA.xml:S2:4769:5	O
of	STENDRA.xml:S2:4775:2	O
a	STENDRA.xml:S2:4778:1	O
sudden	STENDRA.xml:S2:4780:6	O
loss	STENDRA.xml:S2:4787:4	O
of	STENDRA.xml:S2:4792:2	O
vision	STENDRA.xml:S2:4795:6	O
in	STENDRA.xml:S2:4802:2	O
one	STENDRA.xml:S2:4805:3	O
or	STENDRA.xml:S2:4809:2	O
both	STENDRA.xml:S2:4812:4	O
eyes	STENDRA.xml:S2:4817:4	O
.	STENDRA.xml:S2:4821:1	O

Such	STENDRA.xml:S2:4823:4	O
an	STENDRA.xml:S2:4828:2	O
event	STENDRA.xml:S2:4831:5	O
may	STENDRA.xml:S2:4837:3	O
be	STENDRA.xml:S2:4841:2	O
a	STENDRA.xml:S2:4844:1	O
sign	STENDRA.xml:S2:4846:4	O
of	STENDRA.xml:S2:4851:2	O
non	STENDRA.xml:S2:4854:3	B-AdverseReaction
-	STENDRA.xml:S2:4857:1	I-AdverseReaction
arteritic	STENDRA.xml:S2:4858:9	I-AdverseReaction
anterior	STENDRA.xml:S2:4868:8	I-AdverseReaction
ischemic	STENDRA.xml:S2:4877:8	I-AdverseReaction
optic	STENDRA.xml:S2:4886:5	I-AdverseReaction
neuropathy	STENDRA.xml:S2:4892:10	I-AdverseReaction
(	STENDRA.xml:S2:4903:1	O
NAION	STENDRA.xml:S2:4904:5	B-AdverseReaction
)	STENDRA.xml:S2:4909:1	O
,	STENDRA.xml:S2:4910:1	O
a	STENDRA.xml:S2:4912:1	O
rare	STENDRA.xml:S2:4914:4	O
condition	STENDRA.xml:S2:4919:9	O
and	STENDRA.xml:S2:4929:3	O
a	STENDRA.xml:S2:4933:1	O
cause	STENDRA.xml:S2:4935:5	O
of	STENDRA.xml:S2:4941:2	O
decreased	STENDRA.xml:S2:4944:9	B-AdverseReaction
vision	STENDRA.xml:S2:4954:6	I-AdverseReaction
including	STENDRA.xml:S2:4961:9	O
permanent	STENDRA.xml:S2:4971:9	B-AdverseReaction
loss	STENDRA.xml:S2:4981:4	I-AdverseReaction
of	STENDRA.xml:S2:4986:2	I-AdverseReaction
vision	STENDRA.xml:S2:4989:6	I-AdverseReaction
that	STENDRA.xml:S2:4996:4	O
has	STENDRA.xml:S2:5001:3	O
been	STENDRA.xml:S2:5005:4	O
reported	STENDRA.xml:S2:5010:8	O
rarely	STENDRA.xml:S2:5019:6	O
postmarketing	STENDRA.xml:S2:5026:13	O
in	STENDRA.xml:S2:5040:2	O
temporal	STENDRA.xml:S2:5043:8	O
association	STENDRA.xml:S2:5052:11	O
with	STENDRA.xml:S2:5064:4	O
the	STENDRA.xml:S2:5069:3	O
use	STENDRA.xml:S2:5073:3	O
of	STENDRA.xml:S2:5077:2	O
all	STENDRA.xml:S2:5080:3	O
PDE5	STENDRA.xml:S2:5084:4	B-DrugClass
inhibitors	STENDRA.xml:S2:5089:10	I-DrugClass
.	STENDRA.xml:S2:5099:1	O

Based	STENDRA.xml:S2:5107:5	O
on	STENDRA.xml:S2:5113:2	O
published	STENDRA.xml:S2:5116:9	O
literature	STENDRA.xml:S2:5126:10	O
,	STENDRA.xml:S2:5136:1	O
the	STENDRA.xml:S2:5138:3	O
annual	STENDRA.xml:S2:5142:6	O
incidence	STENDRA.xml:S2:5149:9	O
of	STENDRA.xml:S2:5159:2	O
NAION	STENDRA.xml:S2:5162:5	O
is	STENDRA.xml:S2:5168:2	O
2.5	STENDRA.xml:S2:5171:3	O
-	STENDRA.xml:S2:5174:1	O
11.8	STENDRA.xml:S2:5175:4	O
cases	STENDRA.xml:S2:5180:5	O
per	STENDRA.xml:S2:5186:3	O
100	STENDRA.xml:S2:5190:3	O
,	STENDRA.xml:S2:5193:1	O
000	STENDRA.xml:S2:5194:3	O
in	STENDRA.xml:S2:5198:2	O
males	STENDRA.xml:S2:5201:5	O
aged	STENDRA.xml:S2:5207:4	O
50	STENDRA.xml:S2:5215:2	O
.	STENDRA.xml:S2:5217:1	O

An	STENDRA.xml:S2:5219:2	O
observational	STENDRA.xml:S2:5222:13	O
study	STENDRA.xml:S2:5236:5	O
evaluated	STENDRA.xml:S2:5242:9	O
whether	STENDRA.xml:S2:5252:7	O
recent	STENDRA.xml:S2:5260:6	O
use	STENDRA.xml:S2:5267:3	O
of	STENDRA.xml:S2:5271:2	O
PDE5	STENDRA.xml:S2:5274:4	B-DrugClass
inhibitors	STENDRA.xml:S2:5279:10	I-DrugClass
,	STENDRA.xml:S2:5289:1	O
as	STENDRA.xml:S2:5291:2	O
a	STENDRA.xml:S2:5294:1	O
class	STENDRA.xml:S2:5296:5	O
,	STENDRA.xml:S2:5301:1	O
was	STENDRA.xml:S2:5303:3	O
associated	STENDRA.xml:S2:5307:10	O
with	STENDRA.xml:S2:5318:4	O
acute	STENDRA.xml:S2:5323:5	O
onset	STENDRA.xml:S2:5329:5	O
of	STENDRA.xml:S2:5335:2	O
NAION	STENDRA.xml:S2:5338:5	B-AdverseReaction
.	STENDRA.xml:S2:5343:1	O

The	STENDRA.xml:S2:5345:3	O
results	STENDRA.xml:S2:5349:7	O
suggest	STENDRA.xml:S2:5357:7	O
an	STENDRA.xml:S2:5365:2	O
approximate	STENDRA.xml:S2:5368:11	O
2	STENDRA.xml:S2:5380:1	O
-	STENDRA.xml:S2:5381:1	O
fold	STENDRA.xml:S2:5382:4	O
increase	STENDRA.xml:S2:5387:8	O
in	STENDRA.xml:S2:5396:2	O
the	STENDRA.xml:S2:5399:3	O
risk	STENDRA.xml:S2:5403:4	O
of	STENDRA.xml:S2:5408:2	O
NAION	STENDRA.xml:S2:5411:5	B-AdverseReaction
within	STENDRA.xml:S2:5417:6	O
5	STENDRA.xml:S2:5424:1	O
half	STENDRA.xml:S2:5426:4	O
-	STENDRA.xml:S2:5430:1	O
lives	STENDRA.xml:S2:5431:5	O
of	STENDRA.xml:S2:5437:2	O
PDE5	STENDRA.xml:S2:5440:4	B-DrugClass
inhibitor	STENDRA.xml:S2:5445:9	I-DrugClass
use	STENDRA.xml:S2:5455:3	O
.	STENDRA.xml:S2:5458:1	O

From	STENDRA.xml:S2:5460:4	O
this	STENDRA.xml:S2:5465:4	O
information	STENDRA.xml:S2:5470:11	O
,	STENDRA.xml:S2:5481:1	O
it	STENDRA.xml:S2:5483:2	O
is	STENDRA.xml:S2:5486:2	O
not	STENDRA.xml:S2:5489:3	O
possible	STENDRA.xml:S2:5493:8	O
to	STENDRA.xml:S2:5502:2	O
determine	STENDRA.xml:S2:5505:9	O
whether	STENDRA.xml:S2:5515:7	O
these	STENDRA.xml:S2:5523:5	O
events	STENDRA.xml:S2:5529:6	O
are	STENDRA.xml:S2:5536:3	O
related	STENDRA.xml:S2:5540:7	O
directly	STENDRA.xml:S2:5548:8	O
to	STENDRA.xml:S2:5557:2	O
the	STENDRA.xml:S2:5560:3	O
use	STENDRA.xml:S2:5564:3	O
of	STENDRA.xml:S2:5568:2	O
PDE5	STENDRA.xml:S2:5571:4	O
inhibitors	STENDRA.xml:S2:5576:10	O
or	STENDRA.xml:S2:5587:2	O
to	STENDRA.xml:S2:5590:2	O
other	STENDRA.xml:S2:5593:5	O
factors	STENDRA.xml:S2:5599:7	O
[	STENDRA.xml:S2:5607:1	O
seeAdverse	STENDRA.xml:S2:5610:10	O
Reactions	STENDRA.xml:S2:5621:9	O
(	STENDRA.xml:S2:5631:1	O
6.2	STENDRA.xml:S2:5632:3	O
)	STENDRA.xml:S2:5635:1	O
]	STENDRA.xml:S2:5638:1	O
.	STENDRA.xml:S2:5639:1	O

Physicians	STENDRA.xml:S2:5645:10	O
should	STENDRA.xml:S2:5656:6	O
consider	STENDRA.xml:S2:5663:8	O
whether	STENDRA.xml:S2:5672:7	O
their	STENDRA.xml:S2:5680:5	O
patients	STENDRA.xml:S2:5686:8	O
with	STENDRA.xml:S2:5695:4	O
underlying	STENDRA.xml:S2:5700:10	O
NAION	STENDRA.xml:S2:5711:5	O
risk	STENDRA.xml:S2:5717:4	O
factors	STENDRA.xml:S2:5722:7	O
could	STENDRA.xml:S2:5730:5	O
be	STENDRA.xml:S2:5736:2	O
adversely	STENDRA.xml:S2:5739:9	O
affected	STENDRA.xml:S2:5749:8	O
by	STENDRA.xml:S2:5758:2	O
use	STENDRA.xml:S2:5761:3	O
of	STENDRA.xml:S2:5765:2	O
PDE5	STENDRA.xml:S2:5768:4	O
inhibitors	STENDRA.xml:S2:5773:10	O
.	STENDRA.xml:S2:5783:1	O

Individuals	STENDRA.xml:S2:5785:11	O
who	STENDRA.xml:S2:5797:3	O
have	STENDRA.xml:S2:5801:4	O
already	STENDRA.xml:S2:5806:7	O
experienced	STENDRA.xml:S2:5814:11	O
NAION	STENDRA.xml:S2:5826:5	O
are	STENDRA.xml:S2:5832:3	O
at	STENDRA.xml:S2:5836:2	O
increased	STENDRA.xml:S2:5839:9	O
risk	STENDRA.xml:S2:5849:4	O
of	STENDRA.xml:S2:5854:2	O
NAION	STENDRA.xml:S2:5857:5	O
recurrence	STENDRA.xml:S2:5863:10	O
.	STENDRA.xml:S2:5873:1	O

Therefore	STENDRA.xml:S2:5875:9	O
,	STENDRA.xml:S2:5884:1	O
PDE5	STENDRA.xml:S2:5886:4	O
inhibitors	STENDRA.xml:S2:5891:10	O
,	STENDRA.xml:S2:5901:1	O
including	STENDRA.xml:S2:5903:9	O
STENDRA	STENDRA.xml:S2:5913:7	O
,	STENDRA.xml:S2:5920:1	O
should	STENDRA.xml:S2:5922:6	O
be	STENDRA.xml:S2:5929:2	O
used	STENDRA.xml:S2:5932:4	O
with	STENDRA.xml:S2:5937:4	O
caution	STENDRA.xml:S2:5942:7	O
in	STENDRA.xml:S2:5950:2	O
these	STENDRA.xml:S2:5953:5	O
patients	STENDRA.xml:S2:5959:8	O
and	STENDRA.xml:S2:5968:3	O
only	STENDRA.xml:S2:5972:4	O
when	STENDRA.xml:S2:5977:4	O
the	STENDRA.xml:S2:5982:3	O
anticipated	STENDRA.xml:S2:5986:11	O
benefits	STENDRA.xml:S2:5998:8	O
outweigh	STENDRA.xml:S2:6007:8	O
the	STENDRA.xml:S2:6016:3	O
risks	STENDRA.xml:S2:6020:5	O
.	STENDRA.xml:S2:6025:1	O

Individuals	STENDRA.xml:S2:6027:11	O
with	STENDRA.xml:S2:6039:4	O
"	STENDRA.xml:S2:6044:1	O
crowded	STENDRA.xml:S2:6045:7	O
"	STENDRA.xml:S2:6052:1	O
optic	STENDRA.xml:S2:6054:5	O
disc	STENDRA.xml:S2:6060:4	O
are	STENDRA.xml:S2:6065:3	O
also	STENDRA.xml:S2:6069:4	O
considered	STENDRA.xml:S2:6074:10	O
at	STENDRA.xml:S2:6085:2	O
greater	STENDRA.xml:S2:6088:7	O
risk	STENDRA.xml:S2:6096:4	O
for	STENDRA.xml:S2:6101:3	O
NAION	STENDRA.xml:S2:6105:5	O
compared	STENDRA.xml:S2:6111:8	O
to	STENDRA.xml:S2:6120:2	O
the	STENDRA.xml:S2:6123:3	O
general	STENDRA.xml:S2:6127:7	O
population	STENDRA.xml:S2:6135:10	O
,	STENDRA.xml:S2:6145:1	O
however	STENDRA.xml:S2:6147:7	O
,	STENDRA.xml:S2:6154:1	O
evidence	STENDRA.xml:S2:6156:8	O
is	STENDRA.xml:S2:6165:2	O
insufficient	STENDRA.xml:S2:6168:12	O
to	STENDRA.xml:S2:6181:2	O
support	STENDRA.xml:S2:6184:7	O
screening	STENDRA.xml:S2:6192:9	O
of	STENDRA.xml:S2:6202:2	O
prospective	STENDRA.xml:S2:6205:11	O
users	STENDRA.xml:S2:6217:5	O
of	STENDRA.xml:S2:6223:2	O
PDE5	STENDRA.xml:S2:6226:4	O
inhibitors	STENDRA.xml:S2:6231:10	O
,	STENDRA.xml:S2:6241:1	O
including	STENDRA.xml:S2:6243:9	O
STENDRA	STENDRA.xml:S2:6253:7	O
,	STENDRA.xml:S2:6260:1	O
for	STENDRA.xml:S2:6262:3	O
this	STENDRA.xml:S2:6266:4	O
uncommon	STENDRA.xml:S2:6271:8	O
condition	STENDRA.xml:S2:6280:9	O
.	STENDRA.xml:S2:6289:1	O

5.5	STENDRA.xml:S2:6297:3	O
Sudden	STENDRA.xml:S2:6301:6	O
Hearing	STENDRA.xml:S2:6308:7	O
Loss	STENDRA.xml:S2:6316:4	O

Use	STENDRA.xml:S2:6324:3	O
of	STENDRA.xml:S2:6328:2	O
PDE5	STENDRA.xml:S2:6331:4	B-DrugClass
inhibitors	STENDRA.xml:S2:6336:10	I-DrugClass
has	STENDRA.xml:S2:6347:3	O
been	STENDRA.xml:S2:6351:4	O
associated	STENDRA.xml:S2:6356:10	O
with	STENDRA.xml:S2:6367:4	O
sudden	STENDRA.xml:S2:6372:6	B-AdverseReaction
decrease	STENDRA.xml:S2:6379:8	I-AdverseReaction
or	STENDRA.xml:S2:6388:2	O
loss	STENDRA.xml:S2:6391:4	B-AdverseReaction
of	STENDRA.xml:S2:6396:2	I-AdverseReaction
hearing	STENDRA.xml:S2:6399:7	I-AdverseReaction
,	STENDRA.xml:S2:6406:1	O
which	STENDRA.xml:S2:6408:5	O
may	STENDRA.xml:S2:6414:3	O
be	STENDRA.xml:S2:6418:2	O
accompanied	STENDRA.xml:S2:6421:11	O
by	STENDRA.xml:S2:6433:2	O
tinnitus	STENDRA.xml:S2:6436:8	B-AdverseReaction
or	STENDRA.xml:S2:6445:2	O
dizziness	STENDRA.xml:S2:6448:9	B-AdverseReaction
.	STENDRA.xml:S2:6457:1	O

It	STENDRA.xml:S2:6459:2	O
is	STENDRA.xml:S2:6462:2	O
not	STENDRA.xml:S2:6465:3	O
possible	STENDRA.xml:S2:6469:8	O
to	STENDRA.xml:S2:6478:2	O
determine	STENDRA.xml:S2:6481:9	O
whether	STENDRA.xml:S2:6491:7	O
these	STENDRA.xml:S2:6499:5	O
events	STENDRA.xml:S2:6505:6	O
are	STENDRA.xml:S2:6512:3	O
related	STENDRA.xml:S2:6516:7	O
directly	STENDRA.xml:S2:6524:8	O
to	STENDRA.xml:S2:6533:2	O
the	STENDRA.xml:S2:6536:3	O
use	STENDRA.xml:S2:6540:3	O
of	STENDRA.xml:S2:6544:2	O
PDE5	STENDRA.xml:S2:6547:4	O
inhibitors	STENDRA.xml:S2:6552:10	O
or	STENDRA.xml:S2:6563:2	O
to	STENDRA.xml:S2:6566:2	O
other	STENDRA.xml:S2:6569:5	O
factors	STENDRA.xml:S2:6575:7	O
[	STENDRA.xml:S2:6584:1	O
seeAdverse	STENDRA.xml:S2:6585:10	O
Reactions	STENDRA.xml:S2:6596:9	O
(	STENDRA.xml:S2:6606:1	O
6	STENDRA.xml:S2:6607:1	O
)]	STENDRA.xml:S2:6608:2	O
.	STENDRA.xml:S2:6612:1	O

Patients	STENDRA.xml:S2:6614:8	O
experiencing	STENDRA.xml:S2:6623:12	O
these	STENDRA.xml:S2:6636:5	O
symptoms	STENDRA.xml:S2:6642:8	O
should	STENDRA.xml:S2:6651:6	O
be	STENDRA.xml:S2:6658:2	O
advised	STENDRA.xml:S2:6661:7	O
to	STENDRA.xml:S2:6669:2	O
stop	STENDRA.xml:S2:6672:4	O
taking	STENDRA.xml:S2:6677:6	O
STENDRA	STENDRA.xml:S2:6684:7	O
and	STENDRA.xml:S2:6692:3	O
seek	STENDRA.xml:S2:6696:4	O
prompt	STENDRA.xml:S2:6701:6	O
medical	STENDRA.xml:S2:6708:7	O
attention	STENDRA.xml:S2:6716:9	O
.	STENDRA.xml:S2:6725:1	O

5.6	STENDRA.xml:S2:6733:3	O
Alpha	STENDRA.xml:S2:6737:5	O
-	STENDRA.xml:S2:6742:1	O
Blockers	STENDRA.xml:S2:6743:8	O
and	STENDRA.xml:S2:6752:3	O
Other	STENDRA.xml:S2:6756:5	O
Antihypertensives	STENDRA.xml:S2:6762:17	O

Physicians	STENDRA.xml:S2:6783:10	O
should	STENDRA.xml:S2:6794:6	O
discuss	STENDRA.xml:S2:6801:7	O
with	STENDRA.xml:S2:6809:4	O
patients	STENDRA.xml:S2:6814:8	O
the	STENDRA.xml:S2:6823:3	O
potential	STENDRA.xml:S2:6827:9	O
for	STENDRA.xml:S2:6837:3	O
STENDRA	STENDRA.xml:S2:6841:7	O
to	STENDRA.xml:S2:6849:2	O
augment	STENDRA.xml:S2:6852:7	O
the	STENDRA.xml:S2:6860:3	O
blood	STENDRA.xml:S2:6864:5	O
pressure	STENDRA.xml:S2:6870:8	O
-	STENDRA.xml:S2:6878:1	O
lowering	STENDRA.xml:S2:6879:8	O
effect	STENDRA.xml:S2:6888:6	O
of	STENDRA.xml:S2:6895:2	O
alpha	STENDRA.xml:S2:6898:5	O
-	STENDRA.xml:S2:6903:1	O
blockers	STENDRA.xml:S2:6904:8	O
and	STENDRA.xml:S2:6913:3	O
other	STENDRA.xml:S2:6917:5	O
antihypertensive	STENDRA.xml:S2:6923:16	O
medications	STENDRA.xml:S2:6940:11	O
[	STENDRA.xml:S2:6953:1	O
seeDrug	STENDRA.xml:S2:6954:7	O
Interactions	STENDRA.xml:S2:6962:12	O
(	STENDRA.xml:S2:6975:1	O
7.1	STENDRA.xml:S2:6976:3	O
)	STENDRA.xml:S2:6979:1	O
andClinical	STENDRA.xml:S2:6980:11	O
Pharmacology	STENDRA.xml:S2:6992:12	O
(	STENDRA.xml:S2:7005:1	O
12.2	STENDRA.xml:S2:7006:4	O
)]	STENDRA.xml:S2:7010:2	O
.	STENDRA.xml:S2:7012:1	O

Caution	STENDRA.xml:S2:7020:7	O
is	STENDRA.xml:S2:7028:2	O
advised	STENDRA.xml:S2:7031:7	O
when	STENDRA.xml:S2:7039:4	O
PDE5	STENDRA.xml:S2:7044:4	O
inhibitors	STENDRA.xml:S2:7049:10	O
are	STENDRA.xml:S2:7060:3	O
co	STENDRA.xml:S2:7064:2	O
-	STENDRA.xml:S2:7066:1	O
administered	STENDRA.xml:S2:7067:12	O
with	STENDRA.xml:S2:7080:4	O
alpha	STENDRA.xml:S2:7085:5	O
-	STENDRA.xml:S2:7090:1	O
blockers	STENDRA.xml:S2:7091:8	O
.	STENDRA.xml:S2:7099:1	O

Phosphodiesterase	STENDRA.xml:S2:7101:17	O
type	STENDRA.xml:S2:7119:4	O
5	STENDRA.xml:S2:7124:1	O
inhibitors	STENDRA.xml:S2:7126:10	O
,	STENDRA.xml:S2:7136:1	O
including	STENDRA.xml:S2:7138:9	O
STENDRA	STENDRA.xml:S2:7148:7	O
,	STENDRA.xml:S2:7155:1	O
and	STENDRA.xml:S2:7157:3	O
alpha	STENDRA.xml:S2:7161:5	O
-	STENDRA.xml:S2:7166:1	O
adrenergic	STENDRA.xml:S2:7167:10	O
blocking	STENDRA.xml:S2:7178:8	O
agents	STENDRA.xml:S2:7187:6	O
are	STENDRA.xml:S2:7194:3	O
both	STENDRA.xml:S2:7198:4	O
vasodilators	STENDRA.xml:S2:7203:12	O
with	STENDRA.xml:S2:7216:4	O
blood	STENDRA.xml:S2:7221:5	O
pressure	STENDRA.xml:S2:7227:8	O
-	STENDRA.xml:S2:7235:1	O
lowering	STENDRA.xml:S2:7236:8	O
effects	STENDRA.xml:S2:7245:7	O
.	STENDRA.xml:S2:7252:1	O

When	STENDRA.xml:S2:7254:4	O
vasodilators	STENDRA.xml:S2:7259:12	O
are	STENDRA.xml:S2:7272:3	O
used	STENDRA.xml:S2:7276:4	O
in	STENDRA.xml:S2:7281:2	O
combination	STENDRA.xml:S2:7284:11	O
,	STENDRA.xml:S2:7295:1	O
an	STENDRA.xml:S2:7297:2	O
additive	STENDRA.xml:S2:7300:8	O
effect	STENDRA.xml:S2:7309:6	O
on	STENDRA.xml:S2:7316:2	O
blood	STENDRA.xml:S2:7319:5	O
pressure	STENDRA.xml:S2:7325:8	O
may	STENDRA.xml:S2:7334:3	O
be	STENDRA.xml:S2:7338:2	O
anticipated	STENDRA.xml:S2:7341:11	O
.	STENDRA.xml:S2:7352:1	O

In	STENDRA.xml:S2:7354:2	O
some	STENDRA.xml:S2:7357:4	O
patients	STENDRA.xml:S2:7362:8	O
,	STENDRA.xml:S2:7370:1	O
concomitant	STENDRA.xml:S2:7372:11	O
use	STENDRA.xml:S2:7384:3	O
of	STENDRA.xml:S2:7388:2	O
these	STENDRA.xml:S2:7391:5	O
two	STENDRA.xml:S2:7397:3	O
drug	STENDRA.xml:S2:7401:4	O
classes	STENDRA.xml:S2:7406:7	O
can	STENDRA.xml:S2:7414:3	B-Factor
lower	STENDRA.xml:S2:7418:5	O
blood	STENDRA.xml:S2:7424:5	O
pressure	STENDRA.xml:S2:7430:8	O
significantly	STENDRA.xml:S2:7439:13	O
leading	STENDRA.xml:S2:7453:7	O
to	STENDRA.xml:S2:7461:2	O
symptomatic	STENDRA.xml:S2:7464:11	B-AdverseReaction
hypotension	STENDRA.xml:S2:7476:11	I-AdverseReaction
(	STENDRA.xml:S2:7488:1	O
e	STENDRA.xml:S2:7489:1	O
.	STENDRA.xml:S2:7490:1	O
g	STENDRA.xml:S2:7491:1	O
.	STENDRA.xml:S2:7492:1	O
,	STENDRA.xml:S2:7493:1	O
dizziness	STENDRA.xml:S2:7495:9	B-AdverseReaction
,	STENDRA.xml:S2:7504:1	O
lightheadedness	STENDRA.xml:S2:7506:15	B-AdverseReaction
,	STENDRA.xml:S2:7521:1	O
fainting	STENDRA.xml:S2:7523:8	B-AdverseReaction
)	STENDRA.xml:S2:7531:1	O
.	STENDRA.xml:S2:7532:1	O

Consideration	STENDRA.xml:S2:7538:13	O
should	STENDRA.xml:S2:7552:6	O
be	STENDRA.xml:S2:7559:2	O
given	STENDRA.xml:S2:7562:5	O
to	STENDRA.xml:S2:7568:2	O
the	STENDRA.xml:S2:7571:3	O
following	STENDRA.xml:S2:7575:9	O
:	STENDRA.xml:S2:7584:1	O

Patients	STENDRA.xml:S2:7593:8	O
should	STENDRA.xml:S2:7602:6	O
be	STENDRA.xml:S2:7609:2	O
stable	STENDRA.xml:S2:7612:6	O
on	STENDRA.xml:S2:7619:2	O
alpha	STENDRA.xml:S2:7622:5	O
-	STENDRA.xml:S2:7627:1	O
blocker	STENDRA.xml:S2:7628:7	O
therapy	STENDRA.xml:S2:7636:7	O
prior	STENDRA.xml:S2:7644:5	O
to	STENDRA.xml:S2:7650:2	O
initiating	STENDRA.xml:S2:7653:10	O
treatment	STENDRA.xml:S2:7664:9	O
with	STENDRA.xml:S2:7674:4	O
a	STENDRA.xml:S2:7679:1	O
PDE5	STENDRA.xml:S2:7681:4	O
inhibitor	STENDRA.xml:S2:7686:9	O
.	STENDRA.xml:S2:7695:1	O

Patients	STENDRA.xml:S2:7697:8	O
who	STENDRA.xml:S2:7706:3	O
demonstrate	STENDRA.xml:S2:7710:11	O
hemodynamic	STENDRA.xml:S2:7722:11	O
instability	STENDRA.xml:S2:7734:11	O
on	STENDRA.xml:S2:7746:2	O
alpha	STENDRA.xml:S2:7749:5	O
-	STENDRA.xml:S2:7754:1	O
blocker	STENDRA.xml:S2:7755:7	O
therapy	STENDRA.xml:S2:7763:7	O
alone	STENDRA.xml:S2:7771:5	O
are	STENDRA.xml:S2:7777:3	O
at	STENDRA.xml:S2:7781:2	O
increased	STENDRA.xml:S2:7784:9	O
risk	STENDRA.xml:S2:7794:4	O
of	STENDRA.xml:S2:7799:2	O
symptomatic	STENDRA.xml:S2:7802:11	B-AdverseReaction
hypotension	STENDRA.xml:S2:7814:11	I-AdverseReaction
with	STENDRA.xml:S2:7826:4	O
concomitant	STENDRA.xml:S2:7831:11	O
use	STENDRA.xml:S2:7843:3	O
of	STENDRA.xml:S2:7847:2	O
PDE5	STENDRA.xml:S2:7850:4	B-DrugClass
inhibitors	STENDRA.xml:S2:7855:10	I-DrugClass
.	STENDRA.xml:S2:7865:1	O

In	STENDRA.xml:S2:7872:2	O
those	STENDRA.xml:S2:7875:5	O
patients	STENDRA.xml:S2:7881:8	O
who	STENDRA.xml:S2:7890:3	O
are	STENDRA.xml:S2:7894:3	O
stable	STENDRA.xml:S2:7898:6	O
on	STENDRA.xml:S2:7905:2	O
alpha	STENDRA.xml:S2:7908:5	O
-	STENDRA.xml:S2:7913:1	O
blocker	STENDRA.xml:S2:7914:7	O
therapy	STENDRA.xml:S2:7922:7	O
,	STENDRA.xml:S2:7929:1	O
PDE5	STENDRA.xml:S2:7931:4	O
inhibitors	STENDRA.xml:S2:7936:10	O
should	STENDRA.xml:S2:7947:6	O
be	STENDRA.xml:S2:7954:2	O
initiated	STENDRA.xml:S2:7957:9	O
at	STENDRA.xml:S2:7967:2	O
the	STENDRA.xml:S2:7970:3	O
lowest	STENDRA.xml:S2:7974:6	O
dose	STENDRA.xml:S2:7981:4	O
(	STENDRA.xml:S2:7986:1	O
STENDRA	STENDRA.xml:S2:7987:7	O
50	STENDRA.xml:S2:7995:2	O
mg	STENDRA.xml:S2:7998:2	O
)	STENDRA.xml:S2:8000:1	O
.	STENDRA.xml:S2:8001:1	O

In	STENDRA.xml:S2:8008:2	O
those	STENDRA.xml:S2:8011:5	O
patients	STENDRA.xml:S2:8017:8	O
already	STENDRA.xml:S2:8026:7	O
taking	STENDRA.xml:S2:8034:6	O
an	STENDRA.xml:S2:8041:2	O
optimized	STENDRA.xml:S2:8044:9	O
dose	STENDRA.xml:S2:8054:4	O
of	STENDRA.xml:S2:8059:2	O
a	STENDRA.xml:S2:8062:1	O
PDE5	STENDRA.xml:S2:8064:4	O
inhibitor	STENDRA.xml:S2:8069:9	O
,	STENDRA.xml:S2:8078:1	O
alpha	STENDRA.xml:S2:8080:5	O
-	STENDRA.xml:S2:8085:1	O
blocker	STENDRA.xml:S2:8086:7	O
therapy	STENDRA.xml:S2:8094:7	O
should	STENDRA.xml:S2:8102:6	O
be	STENDRA.xml:S2:8109:2	O
initiated	STENDRA.xml:S2:8112:9	O
at	STENDRA.xml:S2:8122:2	O
the	STENDRA.xml:S2:8125:3	O
lowest	STENDRA.xml:S2:8129:6	O
dose	STENDRA.xml:S2:8136:4	O
.	STENDRA.xml:S2:8140:1	O

Stepwise	STENDRA.xml:S2:8142:8	O
increase	STENDRA.xml:S2:8151:8	O
in	STENDRA.xml:S2:8160:2	O
alpha	STENDRA.xml:S2:8163:5	O
-	STENDRA.xml:S2:8168:1	O
blocker	STENDRA.xml:S2:8169:7	O
dose	STENDRA.xml:S2:8177:4	O
may	STENDRA.xml:S2:8182:3	O
be	STENDRA.xml:S2:8186:2	O
associated	STENDRA.xml:S2:8189:10	O
with	STENDRA.xml:S2:8200:4	O
further	STENDRA.xml:S2:8205:7	O
lowering	STENDRA.xml:S2:8213:8	O
of	STENDRA.xml:S2:8222:2	O
blood	STENDRA.xml:S2:8225:5	O
pressure	STENDRA.xml:S2:8231:8	O
when	STENDRA.xml:S2:8240:4	O
taking	STENDRA.xml:S2:8245:6	O
a	STENDRA.xml:S2:8252:1	O
PDE5	STENDRA.xml:S2:8254:4	O
inhibitor	STENDRA.xml:S2:8259:9	O
.	STENDRA.xml:S2:8268:1	O

Safety	STENDRA.xml:S2:8275:6	O
of	STENDRA.xml:S2:8282:2	O
combined	STENDRA.xml:S2:8285:8	O
use	STENDRA.xml:S2:8294:3	O
of	STENDRA.xml:S2:8298:2	O
PDE5	STENDRA.xml:S2:8301:4	O
inhibitors	STENDRA.xml:S2:8306:10	O
and	STENDRA.xml:S2:8317:3	O
alpha	STENDRA.xml:S2:8321:5	O
-	STENDRA.xml:S2:8326:1	O
blockers	STENDRA.xml:S2:8327:8	O
may	STENDRA.xml:S2:8336:3	O
be	STENDRA.xml:S2:8340:2	O
affected	STENDRA.xml:S2:8343:8	O
by	STENDRA.xml:S2:8352:2	O
other	STENDRA.xml:S2:8355:5	O
variables	STENDRA.xml:S2:8361:9	O
,	STENDRA.xml:S2:8370:1	O
including	STENDRA.xml:S2:8372:9	O
intravascular	STENDRA.xml:S2:8382:13	O
volume	STENDRA.xml:S2:8396:6	O
depletion	STENDRA.xml:S2:8403:9	O
and	STENDRA.xml:S2:8413:3	O
other	STENDRA.xml:S2:8417:5	O
anti	STENDRA.xml:S2:8423:4	O
-	STENDRA.xml:S2:8427:1	O
hypertensive	STENDRA.xml:S2:8428:12	O
drugs	STENDRA.xml:S2:8441:5	O
[	STENDRA.xml:S2:8447:1	O
see	STENDRA.xml:S2:8448:3	O
Dosage	STENDRA.xml:S2:8453:6	O
and	STENDRA.xml:S2:8460:3	O
Administration	STENDRA.xml:S2:8464:14	O
(	STENDRA.xml:S2:8479:1	O
2	STENDRA.xml:S2:8480:1	O
)	STENDRA.xml:S2:8481:1	O
and	STENDRA.xml:S2:8484:3	O
Drug	STENDRA.xml:S2:8489:4	O
Interactions	STENDRA.xml:S2:8494:12	O
(	STENDRA.xml:S2:8507:1	O
7.1	STENDRA.xml:S2:8508:3	O
)	STENDRA.xml:S2:8511:1	O
]	STENDRA.xml:S2:8514:1	O
.	STENDRA.xml:S2:8515:1	O

5.7	STENDRA.xml:S2:8523:3	O

Alcohol	STENDRA.xml:S2:8527:7	O

Patients	STENDRA.xml:S2:8538:8	O
should	STENDRA.xml:S2:8547:6	O
be	STENDRA.xml:S2:8554:2	O
made	STENDRA.xml:S2:8557:4	O
aware	STENDRA.xml:S2:8562:5	O
that	STENDRA.xml:S2:8568:4	O
both	STENDRA.xml:S2:8573:4	O
alcohol	STENDRA.xml:S2:8578:7	O
and	STENDRA.xml:S2:8586:3	O
PDE5	STENDRA.xml:S2:8590:4	O
inhibitors	STENDRA.xml:S2:8595:10	O
including	STENDRA.xml:S2:8606:9	O
STENDRA	STENDRA.xml:S2:8616:7	O
act	STENDRA.xml:S2:8624:3	O
as	STENDRA.xml:S2:8628:2	O
vasodilators	STENDRA.xml:S2:8631:12	O
.	STENDRA.xml:S2:8643:1	O

When	STENDRA.xml:S2:8645:4	O
vasodilators	STENDRA.xml:S2:8650:12	O
are	STENDRA.xml:S2:8663:3	O
taken	STENDRA.xml:S2:8667:5	O
in	STENDRA.xml:S2:8673:2	O
combination	STENDRA.xml:S2:8676:11	O
,	STENDRA.xml:S2:8687:1	O
blood	STENDRA.xml:S2:8689:5	O
-	STENDRA.xml:S2:8694:1	O
pressure	STENDRA.xml:S2:8695:8	O
-	STENDRA.xml:S2:8703:1	O
lowering	STENDRA.xml:S2:8704:8	O
effects	STENDRA.xml:S2:8713:7	O
of	STENDRA.xml:S2:8721:2	O
each	STENDRA.xml:S2:8724:4	O
individual	STENDRA.xml:S2:8729:10	O
compound	STENDRA.xml:S2:8740:8	O
may	STENDRA.xml:S2:8749:3	O
be	STENDRA.xml:S2:8753:2	O
increased	STENDRA.xml:S2:8756:9	O
.	STENDRA.xml:S2:8765:1	O

Therefore	STENDRA.xml:S2:8767:9	O
,	STENDRA.xml:S2:8776:1	O
physicians	STENDRA.xml:S2:8778:10	O
should	STENDRA.xml:S2:8789:6	O
inform	STENDRA.xml:S2:8796:6	O
patients	STENDRA.xml:S2:8803:8	O
that	STENDRA.xml:S2:8812:4	O
substantial	STENDRA.xml:S2:8817:11	O
consumption	STENDRA.xml:S2:8829:11	O
of	STENDRA.xml:S2:8841:2	O
alcohol	STENDRA.xml:S2:8844:7	O
(	STENDRA.xml:S2:8852:1	O
e	STENDRA.xml:S2:8853:1	O
.	STENDRA.xml:S2:8854:1	O
g	STENDRA.xml:S2:8855:1	O
.	STENDRA.xml:S2:8856:1	O
,	STENDRA.xml:S2:8857:1	O
greater	STENDRA.xml:S2:8859:7	O
than	STENDRA.xml:S2:8867:4	O
3	STENDRA.xml:S2:8872:1	O
units	STENDRA.xml:S2:8874:5	O
)	STENDRA.xml:S2:8879:1	O
in	STENDRA.xml:S2:8881:2	O
combination	STENDRA.xml:S2:8884:11	O
with	STENDRA.xml:S2:8896:4	O
STENDRA	STENDRA.xml:S2:8901:7	O
may	STENDRA.xml:S2:8909:3	O
increase	STENDRA.xml:S2:8913:8	O
the	STENDRA.xml:S2:8922:3	O
potential	STENDRA.xml:S2:8926:9	O
for	STENDRA.xml:S2:8936:3	O
orthostatic	STENDRA.xml:S2:8940:11	O
signs	STENDRA.xml:S2:8952:5	O
and	STENDRA.xml:S2:8958:3	O
symptoms	STENDRA.xml:S2:8962:8	O
,	STENDRA.xml:S2:8970:1	O
including	STENDRA.xml:S2:8972:9	O
increase	STENDRA.xml:S2:8982:8	O
in	STENDRA.xml:S2:8991:2	O
heart	STENDRA.xml:S2:8994:5	O
rate	STENDRA.xml:S2:9000:4	O
,	STENDRA.xml:S2:9004:1	O
decrease	STENDRA.xml:S2:9006:8	O
in	STENDRA.xml:S2:9015:2	O
standing	STENDRA.xml:S2:9018:8	O
blood	STENDRA.xml:S2:9027:5	O
pressure	STENDRA.xml:S2:9033:8	O
,	STENDRA.xml:S2:9041:1	O
dizziness	STENDRA.xml:S2:9043:9	O
,	STENDRA.xml:S2:9052:1	O
and	STENDRA.xml:S2:9054:3	O
headache	STENDRA.xml:S2:9058:8	O
[	STENDRA.xml:S2:9068:1	O
seeDrug	STENDRA.xml:S2:9069:7	O
Interactions	STENDRA.xml:S2:9077:12	O
(	STENDRA.xml:S2:9090:1	O
7.1	STENDRA.xml:S2:9091:3	O
)	STENDRA.xml:S2:9094:1	O
andClinical	STENDRA.xml:S2:9095:11	O
Pharmacology	STENDRA.xml:S2:9107:12	O
(	STENDRA.xml:S2:9120:1	O
12.2	STENDRA.xml:S2:9121:4	O
)]	STENDRA.xml:S2:9125:2	O
.	STENDRA.xml:S2:9129:1	O

5.8	STENDRA.xml:S2:9137:3	O
Combination	STENDRA.xml:S2:9141:11	O
with	STENDRA.xml:S2:9153:4	O
Other	STENDRA.xml:S2:9158:5	O
PDE5	STENDRA.xml:S2:9164:4	O
Inhibitors	STENDRA.xml:S2:9169:10	O
or	STENDRA.xml:S2:9180:2	O
Erectile	STENDRA.xml:S2:9183:8	O
Dysfunction	STENDRA.xml:S2:9192:11	O
Therapies	STENDRA.xml:S2:9204:9	O

The	STENDRA.xml:S2:9217:3	O
safety	STENDRA.xml:S2:9221:6	O
and	STENDRA.xml:S2:9228:3	O
efficacy	STENDRA.xml:S2:9232:8	O
of	STENDRA.xml:S2:9241:2	O
combinations	STENDRA.xml:S2:9244:12	O
of	STENDRA.xml:S2:9257:2	O
STENDRA	STENDRA.xml:S2:9260:7	O
with	STENDRA.xml:S2:9268:4	O
other	STENDRA.xml:S2:9273:5	O
treatments	STENDRA.xml:S2:9279:10	O
for	STENDRA.xml:S2:9290:3	O
ED	STENDRA.xml:S2:9294:2	O
has	STENDRA.xml:S2:9297:3	O
not	STENDRA.xml:S2:9301:3	O
been	STENDRA.xml:S2:9305:4	O
studied	STENDRA.xml:S2:9310:7	O
.	STENDRA.xml:S2:9317:1	O

Therefore	STENDRA.xml:S2:9319:9	O
,	STENDRA.xml:S2:9328:1	O
the	STENDRA.xml:S2:9330:3	O
use	STENDRA.xml:S2:9334:3	O
of	STENDRA.xml:S2:9338:2	O
such	STENDRA.xml:S2:9341:4	O
combinations	STENDRA.xml:S2:9346:12	O
is	STENDRA.xml:S2:9359:2	O
not	STENDRA.xml:S2:9362:3	O
recommended	STENDRA.xml:S2:9366:11	O
.	STENDRA.xml:S2:9377:1	O

5.9	STENDRA.xml:S2:9385:3	O
Effects	STENDRA.xml:S2:9389:7	O
on	STENDRA.xml:S2:9397:2	O
Bleeding	STENDRA.xml:S2:9400:8	O

The	STENDRA.xml:S2:9412:3	O
safety	STENDRA.xml:S2:9416:6	O
of	STENDRA.xml:S2:9423:2	O
STENDRA	STENDRA.xml:S2:9426:7	O
is	STENDRA.xml:S2:9434:2	O
unknown	STENDRA.xml:S2:9437:7	O
in	STENDRA.xml:S2:9445:2	O
patients	STENDRA.xml:S2:9448:8	O
with	STENDRA.xml:S2:9457:4	O
bleeding	STENDRA.xml:S2:9462:8	O
disorders	STENDRA.xml:S2:9471:9	O
and	STENDRA.xml:S2:9481:3	O
patients	STENDRA.xml:S2:9485:8	O
with	STENDRA.xml:S2:9494:4	O
active	STENDRA.xml:S2:9499:6	O
peptic	STENDRA.xml:S2:9506:6	O
ulceration	STENDRA.xml:S2:9513:10	O
.	STENDRA.xml:S2:9523:1	O

In	STENDRA.xml:S2:9526:2	B-Factor
vitro	STENDRA.xml:S2:9529:5	I-Factor
studies	STENDRA.xml:S2:9536:7	I-Factor
with	STENDRA.xml:S2:9544:4	O
human	STENDRA.xml:S2:9549:5	O
platelets	STENDRA.xml:S2:9555:9	O
indicate	STENDRA.xml:S2:9565:8	O
that	STENDRA.xml:S2:9574:4	O
STENDRA	STENDRA.xml:S2:9579:7	O
potentiates	STENDRA.xml:S2:9587:11	B-AdverseReaction
the	STENDRA.xml:S2:9599:3	I-AdverseReaction
anti	STENDRA.xml:S2:9603:4	I-AdverseReaction
-	STENDRA.xml:S2:9607:1	I-AdverseReaction
aggregatory	STENDRA.xml:S2:9608:11	I-AdverseReaction
effect	STENDRA.xml:S2:9620:6	I-AdverseReaction
of	STENDRA.xml:S2:9627:2	I-AdverseReaction
sodium	STENDRA.xml:S2:9630:6	I-AdverseReaction
nitroprusside	STENDRA.xml:S2:9637:13	I-AdverseReaction
(	STENDRA.xml:S2:9651:1	O
a	STENDRA.xml:S2:9652:1	O
nitric	STENDRA.xml:S2:9654:6	O
oxide	STENDRA.xml:S2:9661:5	O
[	STENDRA.xml:S2:9667:1	O
NO	STENDRA.xml:S2:9668:2	O
]	STENDRA.xml:S2:9670:1	O
donor	STENDRA.xml:S2:9672:5	O
)	STENDRA.xml:S2:9677:1	O
.	STENDRA.xml:S2:9678:1	O

5.10	STENDRA.xml:S2:9686:4	O
Counseling	STENDRA.xml:S2:9691:10	O
Patients	STENDRA.xml:S2:9702:8	O
about	STENDRA.xml:S2:9711:5	O
Sexually	STENDRA.xml:S2:9717:8	O
Transmitted	STENDRA.xml:S2:9726:11	O
Diseases	STENDRA.xml:S2:9738:8	O

The	STENDRA.xml:S2:9750:3	O
use	STENDRA.xml:S2:9754:3	O
of	STENDRA.xml:S2:9758:2	O
STENDRA	STENDRA.xml:S2:9761:7	O
offers	STENDRA.xml:S2:9769:6	O
no	STENDRA.xml:S2:9776:2	O
protection	STENDRA.xml:S2:9779:10	O
against	STENDRA.xml:S2:9790:7	O
sexually	STENDRA.xml:S2:9798:8	O
transmitted	STENDRA.xml:S2:9807:11	O
diseases	STENDRA.xml:S2:9819:8	O
.	STENDRA.xml:S2:9827:1	O

Counseling	STENDRA.xml:S2:9829:10	O
patients	STENDRA.xml:S2:9840:8	O
about	STENDRA.xml:S2:9849:5	O
the	STENDRA.xml:S2:9855:3	O
protective	STENDRA.xml:S2:9859:10	O
measures	STENDRA.xml:S2:9870:8	O
necessary	STENDRA.xml:S2:9879:9	O
to	STENDRA.xml:S2:9889:2	O
guard	STENDRA.xml:S2:9892:5	O
against	STENDRA.xml:S2:9898:7	O
sexually	STENDRA.xml:S2:9906:8	O
transmitted	STENDRA.xml:S2:9915:11	O
diseases	STENDRA.xml:S2:9927:8	O
,	STENDRA.xml:S2:9935:1	O
including	STENDRA.xml:S2:9937:9	O
Human	STENDRA.xml:S2:9947:5	O
Immunodeficiency	STENDRA.xml:S2:9953:16	O
Virus	STENDRA.xml:S2:9970:5	O
(	STENDRA.xml:S2:9976:1	O
HIV	STENDRA.xml:S2:9977:3	O
)	STENDRA.xml:S2:9980:1	O
,	STENDRA.xml:S2:9981:1	O
should	STENDRA.xml:S2:9983:6	O
be	STENDRA.xml:S2:9990:2	O
considered	STENDRA.xml:S2:9993:10	O
.	STENDRA.xml:S2:10003:1	O
6	STRIBILD.xml:S1:4:1	O
ADVERSE	STRIBILD.xml:S1:6:7	O
REACTIONS	STRIBILD.xml:S1:14:9	O

The	STRIBILD.xml:S1:27:3	O
following	STRIBILD.xml:S1:31:9	O
adverse	STRIBILD.xml:S1:41:7	O
drug	STRIBILD.xml:S1:49:4	O
reactions	STRIBILD.xml:S1:54:9	O
are	STRIBILD.xml:S1:64:3	O
discussed	STRIBILD.xml:S1:68:9	O
in	STRIBILD.xml:S1:78:2	O
other	STRIBILD.xml:S1:81:5	O
sections	STRIBILD.xml:S1:87:8	O
of	STRIBILD.xml:S1:96:2	O
the	STRIBILD.xml:S1:99:3	O
labeling	STRIBILD.xml:S1:103:8	O
:	STRIBILD.xml:S1:111:1	O

Lactic	STRIBILD.xml:S1:120:6	B-AdverseReaction
Acidosis	STRIBILD.xml:S1:127:8	I-AdverseReaction
Severe	STRIBILD.xml:S1:136:6	B-Severity
Hepatomegaly	STRIBILD.xml:S1:143:12	B-AdverseReaction
with	STRIBILD.xml:S1:156:4	O
Steatosis	STRIBILD.xml:S1:161:9	B-AdverseReaction
[	STRIBILD.xml:S1:171:1	O
see	STRIBILD.xml:S1:172:3	O
Boxed	STRIBILD.xml:S1:177:5	O
Warning	STRIBILD.xml:S1:183:7	O
,	STRIBILD.xml:S1:192:1	O
Warnings	STRIBILD.xml:S1:195:8	O
and	STRIBILD.xml:S1:204:3	O
Precautions	STRIBILD.xml:S1:208:11	O
(	STRIBILD.xml:S1:220:1	O
5.1	STRIBILD.xml:S1:221:3	O
)	STRIBILD.xml:S1:224:1	O
]	STRIBILD.xml:S1:227:1	O
.	STRIBILD.xml:S1:229:1	O

Severe	STRIBILD.xml:S1:236:6	B-Severity
Acute	STRIBILD.xml:S1:243:5	B-AdverseReaction
Exacerbations	STRIBILD.xml:S1:249:13	I-AdverseReaction
of	STRIBILD.xml:S1:263:2	I-AdverseReaction
Hepatitis	STRIBILD.xml:S1:266:9	I-AdverseReaction
B	STRIBILD.xml:S1:276:1	I-AdverseReaction
[	STRIBILD.xml:S1:278:1	O
see	STRIBILD.xml:S1:279:3	O
Boxed	STRIBILD.xml:S1:284:5	O
Warning	STRIBILD.xml:S1:290:7	O
,	STRIBILD.xml:S1:299:1	O
Warnings	STRIBILD.xml:S1:302:8	O
and	STRIBILD.xml:S1:311:3	O
Precautions	STRIBILD.xml:S1:315:11	O
(	STRIBILD.xml:S1:327:1	O
5.2	STRIBILD.xml:S1:328:3	O
)	STRIBILD.xml:S1:331:1	O
]	STRIBILD.xml:S1:334:1	O
.	STRIBILD.xml:S1:336:1	O

New	STRIBILD.xml:S1:343:3	B-AdverseReaction
Onset	STRIBILD.xml:S1:347:5	I-AdverseReaction
or	STRIBILD.xml:S1:353:2	O
Worsening	STRIBILD.xml:S1:356:9	B-AdverseReaction
Renal	STRIBILD.xml:S1:366:5	I-AdverseReaction
Impairment	STRIBILD.xml:S1:372:10	I-AdverseReaction
[	STRIBILD.xml:S1:383:1	O
see	STRIBILD.xml:S1:384:3	O
Warnings	STRIBILD.xml:S1:389:8	O
and	STRIBILD.xml:S1:398:3	O
Precautions	STRIBILD.xml:S1:402:11	O
(	STRIBILD.xml:S1:414:1	O
5.3	STRIBILD.xml:S1:415:3	O
)	STRIBILD.xml:S1:418:1	O
]	STRIBILD.xml:S1:421:1	O
.	STRIBILD.xml:S1:423:1	O

Bone	STRIBILD.xml:S1:430:4	B-AdverseReaction
Effects	STRIBILD.xml:S1:435:7	I-AdverseReaction
of	STRIBILD.xml:S1:443:2	O
Tenofovir	STRIBILD.xml:S1:446:9	O
DF	STRIBILD.xml:S1:456:2	O
[	STRIBILD.xml:S1:459:1	O
see	STRIBILD.xml:S1:460:3	O
Warnings	STRIBILD.xml:S1:465:8	O
and	STRIBILD.xml:S1:474:3	O
Precautions	STRIBILD.xml:S1:478:11	O
(	STRIBILD.xml:S1:490:1	O
5.6	STRIBILD.xml:S1:491:3	O
)	STRIBILD.xml:S1:494:1	O
]	STRIBILD.xml:S1:497:1	O
.	STRIBILD.xml:S1:499:1	O

Immune	STRIBILD.xml:S1:506:6	B-AdverseReaction
Reconstitution	STRIBILD.xml:S1:513:14	I-AdverseReaction
Syndrome	STRIBILD.xml:S1:528:8	I-AdverseReaction
[	STRIBILD.xml:S1:537:1	O
see	STRIBILD.xml:S1:538:3	O
Warnings	STRIBILD.xml:S1:543:8	O
and	STRIBILD.xml:S1:552:3	O
Precautions	STRIBILD.xml:S1:556:11	O
(	STRIBILD.xml:S1:568:1	O
5.8	STRIBILD.xml:S1:569:3	O
)	STRIBILD.xml:S1:572:1	O
]	STRIBILD.xml:S1:575:1	O
.	STRIBILD.xml:S1:577:1	O

EXCERPT	STRIBILD.xml:S1:586:7	O
:	STRIBILD.xml:S1:593:1	O
Most	STRIBILD.xml:S1:597:4	O
common	STRIBILD.xml:S1:602:6	O
adverse	STRIBILD.xml:S1:609:7	O
drug	STRIBILD.xml:S1:617:4	O
reactions	STRIBILD.xml:S1:622:9	O
to	STRIBILD.xml:S1:632:2	O
STRIBILD	STRIBILD.xml:S1:635:8	O
(	STRIBILD.xml:S1:644:1	O
incidence	STRIBILD.xml:S1:645:9	O
greater	STRIBILD.xml:S1:655:7	O
than	STRIBILD.xml:S1:663:4	O
or	STRIBILD.xml:S1:668:2	O
equal	STRIBILD.xml:S1:671:5	O
to	STRIBILD.xml:S1:677:2	O
10%	STRIBILD.xml:S1:680:3	O
,	STRIBILD.xml:S1:683:1	O
all	STRIBILD.xml:S1:685:3	O
grades	STRIBILD.xml:S1:689:6	O
)	STRIBILD.xml:S1:695:1	O
are	STRIBILD.xml:S1:697:3	O
nausea	STRIBILD.xml:S1:701:6	B-AdverseReaction
and	STRIBILD.xml:S1:708:3	O
diarrhea	STRIBILD.xml:S1:712:8	B-AdverseReaction
.	STRIBILD.xml:S1:720:1	O

(	STRIBILD.xml:S1:722:1	O
6.1	STRIBILD.xml:S1:725:3	O
)	STRIBILD.xml:S1:730:1	O

To	STRIBILD.xml:S1:738:2	O

report	STRIBILD.xml:S1:741:6	O
SUSPECTED	STRIBILD.xml:S1:748:9	O
ADVERSE	STRIBILD.xml:S1:758:7	O
REACTIONS	STRIBILD.xml:S1:766:9	O
,	STRIBILD.xml:S1:775:1	O
contact	STRIBILD.xml:S1:777:7	O
Gilead	STRIBILD.xml:S1:785:6	O
Sciences	STRIBILD.xml:S1:792:8	O
,	STRIBILD.xml:S1:800:1	O
Inc	STRIBILD.xml:S1:802:3	O
.	STRIBILD.xml:S1:805:1	O

at	STRIBILD.xml:S1:807:2	O
1	STRIBILD.xml:S1:810:1	O
-	STRIBILD.xml:S1:811:1	O
800	STRIBILD.xml:S1:812:3	O
-	STRIBILD.xml:S1:815:1	O
GILEAD	STRIBILD.xml:S1:816:6	O
-	STRIBILD.xml:S1:822:1	O
5	STRIBILD.xml:S1:823:1	O
or	STRIBILD.xml:S1:825:2	O
FDA	STRIBILD.xml:S1:828:3	O
at	STRIBILD.xml:S1:832:2	O
1	STRIBILD.xml:S1:835:1	O
-	STRIBILD.xml:S1:836:1	O
800	STRIBILD.xml:S1:837:3	O
-	STRIBILD.xml:S1:840:1	O
FDA	STRIBILD.xml:S1:841:3	O
-	STRIBILD.xml:S1:844:1	O
1088	STRIBILD.xml:S1:845:4	O
or	STRIBILD.xml:S1:850:2	O
www	STRIBILD.xml:S1:853:3	O
.	STRIBILD.xml:S1:856:1	O
fda	STRIBILD.xml:S1:857:3	O
.	STRIBILD.xml:S1:860:1	O
gov	STRIBILD.xml:S1:861:3	O
medwatch	STRIBILD.xml:S1:865:8	O
.	STRIBILD.xml:S1:873:1	O

6.1	STRIBILD.xml:S1:885:3	O

Adverse	STRIBILD.xml:S1:889:7	O
Reactions	STRIBILD.xml:S1:897:9	O
from	STRIBILD.xml:S1:907:4	O
Clinical	STRIBILD.xml:S1:912:8	O
Trials	STRIBILD.xml:S1:921:6	O
Experience	STRIBILD.xml:S1:928:10	O

Because	STRIBILD.xml:S1:942:7	O
clinical	STRIBILD.xml:S1:950:8	O
trials	STRIBILD.xml:S1:959:6	O
are	STRIBILD.xml:S1:966:3	O
conducted	STRIBILD.xml:S1:970:9	O
under	STRIBILD.xml:S1:980:5	O
widely	STRIBILD.xml:S1:986:6	O
varying	STRIBILD.xml:S1:993:7	O
conditions	STRIBILD.xml:S1:1001:10	O
,	STRIBILD.xml:S1:1011:1	O
adverse	STRIBILD.xml:S1:1013:7	O
reaction	STRIBILD.xml:S1:1021:8	O
rates	STRIBILD.xml:S1:1030:5	O
observed	STRIBILD.xml:S1:1036:8	O
in	STRIBILD.xml:S1:1045:2	O
the	STRIBILD.xml:S1:1048:3	O
clinical	STRIBILD.xml:S1:1052:8	O
trials	STRIBILD.xml:S1:1061:6	O
of	STRIBILD.xml:S1:1068:2	O
a	STRIBILD.xml:S1:1071:1	O
drug	STRIBILD.xml:S1:1073:4	O
cannot	STRIBILD.xml:S1:1078:6	O
be	STRIBILD.xml:S1:1085:2	O
directly	STRIBILD.xml:S1:1088:8	O
compared	STRIBILD.xml:S1:1097:8	O
to	STRIBILD.xml:S1:1106:2	O
rates	STRIBILD.xml:S1:1109:5	O
in	STRIBILD.xml:S1:1115:2	O
the	STRIBILD.xml:S1:1118:3	O
clinical	STRIBILD.xml:S1:1122:8	O
trials	STRIBILD.xml:S1:1131:6	O
of	STRIBILD.xml:S1:1138:2	O
another	STRIBILD.xml:S1:1141:7	O
drug	STRIBILD.xml:S1:1149:4	O
and	STRIBILD.xml:S1:1154:3	O
may	STRIBILD.xml:S1:1158:3	O
not	STRIBILD.xml:S1:1162:3	O
reflect	STRIBILD.xml:S1:1166:7	O
the	STRIBILD.xml:S1:1174:3	O
rates	STRIBILD.xml:S1:1178:5	O
observed	STRIBILD.xml:S1:1184:8	O
in	STRIBILD.xml:S1:1193:2	O
practice	STRIBILD.xml:S1:1196:8	O
.	STRIBILD.xml:S1:1204:1	O

In	STRIBILD.xml:S1:1214:2	O
HIV	STRIBILD.xml:S1:1217:3	O
-	STRIBILD.xml:S1:1220:1	O
1	STRIBILD.xml:S1:1221:1	O
-	STRIBILD.xml:S1:1222:1	O
Infected	STRIBILD.xml:S1:1223:8	O
Subjects	STRIBILD.xml:S1:1232:8	O
With	STRIBILD.xml:S1:1241:4	O
No	STRIBILD.xml:S1:1246:2	O
Antiretroviral	STRIBILD.xml:S1:1249:14	O
Treatment	STRIBILD.xml:S1:1264:9	O
History	STRIBILD.xml:S1:1274:7	O

The	STRIBILD.xml:S1:1288:3	O
safety	STRIBILD.xml:S1:1292:6	O
assessment	STRIBILD.xml:S1:1299:10	O
of	STRIBILD.xml:S1:1310:2	O
STRIBILD	STRIBILD.xml:S1:1313:8	O
is	STRIBILD.xml:S1:1322:2	O
based	STRIBILD.xml:S1:1325:5	O
on	STRIBILD.xml:S1:1331:2	O
the	STRIBILD.xml:S1:1334:3	O
Week	STRIBILD.xml:S1:1338:4	O
144	STRIBILD.xml:S1:1343:3	O
pooled	STRIBILD.xml:S1:1347:6	O
data	STRIBILD.xml:S1:1354:4	O
from	STRIBILD.xml:S1:1359:4	O
1408	STRIBILD.xml:S1:1364:4	O
subjects	STRIBILD.xml:S1:1369:8	O
in	STRIBILD.xml:S1:1378:2	O
two	STRIBILD.xml:S1:1381:3	O
randomized	STRIBILD.xml:S1:1385:10	O
,	STRIBILD.xml:S1:1395:1	O
double	STRIBILD.xml:S1:1397:6	O
-	STRIBILD.xml:S1:1403:1	O
blind	STRIBILD.xml:S1:1404:5	O
,	STRIBILD.xml:S1:1409:1	O
active	STRIBILD.xml:S1:1411:6	O
-	STRIBILD.xml:S1:1417:1	O
controlled	STRIBILD.xml:S1:1418:10	O
clinical	STRIBILD.xml:S1:1429:8	O
trials	STRIBILD.xml:S1:1438:6	O
,	STRIBILD.xml:S1:1444:1	O
Study	STRIBILD.xml:S1:1446:5	O
102	STRIBILD.xml:S1:1452:3	O
and	STRIBILD.xml:S1:1456:3	O
Study	STRIBILD.xml:S1:1460:5	O
103	STRIBILD.xml:S1:1466:3	O
,	STRIBILD.xml:S1:1469:1	O
in	STRIBILD.xml:S1:1471:2	O
antiretroviral	STRIBILD.xml:S1:1474:14	O
treatment	STRIBILD.xml:S1:1489:9	O
-	STRIBILD.xml:S1:1498:1	O
naive	STRIBILD.xml:S1:1499:5	O
HIV	STRIBILD.xml:S1:1505:3	O
-	STRIBILD.xml:S1:1508:1	O
1	STRIBILD.xml:S1:1509:1	O
infected	STRIBILD.xml:S1:1511:8	O
adult	STRIBILD.xml:S1:1520:5	O
subjects	STRIBILD.xml:S1:1526:8	O
[	STRIBILD.xml:S1:1536:1	O
see	STRIBILD.xml:S1:1537:3	O
Clinical	STRIBILD.xml:S1:1542:8	O
Studies	STRIBILD.xml:S1:1551:7	O
(	STRIBILD.xml:S1:1559:1	O
14	STRIBILD.xml:S1:1560:2	O
)	STRIBILD.xml:S1:1562:1	O
]	STRIBILD.xml:S1:1565:1	O
.	STRIBILD.xml:S1:1566:1	O

A	STRIBILD.xml:S1:1569:1	O
total	STRIBILD.xml:S1:1571:5	O
of	STRIBILD.xml:S1:1577:2	O
701	STRIBILD.xml:S1:1580:3	O
subjects	STRIBILD.xml:S1:1584:8	O
received	STRIBILD.xml:S1:1593:8	O
STRIBILD	STRIBILD.xml:S1:1602:8	O
once	STRIBILD.xml:S1:1611:4	O
daily	STRIBILD.xml:S1:1616:5	O
in	STRIBILD.xml:S1:1622:2	O
these	STRIBILD.xml:S1:1625:5	O
two	STRIBILD.xml:S1:1631:3	O
studies	STRIBILD.xml:S1:1635:7	O
.	STRIBILD.xml:S1:1642:1	O

The	STRIBILD.xml:S1:1648:3	O
proportion	STRIBILD.xml:S1:1652:10	O
of	STRIBILD.xml:S1:1663:2	O
subjects	STRIBILD.xml:S1:1666:8	O
who	STRIBILD.xml:S1:1675:3	O
discontinued	STRIBILD.xml:S1:1679:12	O
treatment	STRIBILD.xml:S1:1692:9	O
with	STRIBILD.xml:S1:1702:4	O
STRIBILD	STRIBILD.xml:S1:1707:8	O
(	STRIBILD.xml:S1:1716:1	O
elvitegravir	STRIBILD.xml:S1:1717:12	O
150	STRIBILD.xml:S1:1730:3	O
mg	STRIBILD.xml:S1:1734:2	O
cobicistat	STRIBILD.xml:S1:1737:10	O
150	STRIBILD.xml:S1:1748:3	O
mg	STRIBILD.xml:S1:1752:2	O
emtricitabine	STRIBILD.xml:S1:1755:13	O
200	STRIBILD.xml:S1:1769:3	O
mg	STRIBILD.xml:S1:1773:2	O
tenofovir	STRIBILD.xml:S1:1776:9	O
DF	STRIBILD.xml:S1:1786:2	O
300	STRIBILD.xml:S1:1789:3	O
mg	STRIBILD.xml:S1:1793:2	O
)	STRIBILD.xml:S1:1795:1	O
;	STRIBILD.xml:S1:1796:1	O
ATRIPLA	STRIBILD.xml:S1:1798:7	O
(	STRIBILD.xml:S1:1806:1	O
efavirenz	STRIBILD.xml:S1:1807:9	O
600	STRIBILD.xml:S1:1817:3	O
mg	STRIBILD.xml:S1:1821:2	O
emtricitabine	STRIBILD.xml:S1:1824:13	O
200	STRIBILD.xml:S1:1838:3	O
mg	STRIBILD.xml:S1:1842:2	O
tenofovir	STRIBILD.xml:S1:1845:9	O
DF	STRIBILD.xml:S1:1855:2	O
300	STRIBILD.xml:S1:1858:3	O
mg	STRIBILD.xml:S1:1862:2	O
)	STRIBILD.xml:S1:1864:1	O
;	STRIBILD.xml:S1:1865:1	O
or	STRIBILD.xml:S1:1867:2	O
atazanavir	STRIBILD.xml:S1:1870:10	O
(	STRIBILD.xml:S1:1881:1	O
ATV	STRIBILD.xml:S1:1882:3	O
)	STRIBILD.xml:S1:1885:1	O
ritonavir	STRIBILD.xml:S1:1889:9	O
(	STRIBILD.xml:S1:1899:1	O
RTV	STRIBILD.xml:S1:1900:3	O
)	STRIBILD.xml:S1:1903:1	O
TRUVADA	STRIBILD.xml:S1:1907:7	O
(	STRIBILD.xml:S1:1915:1	O
emtricitabine	STRIBILD.xml:S1:1916:13	O
200	STRIBILD.xml:S1:1930:3	O
mg	STRIBILD.xml:S1:1934:2	O
tenofovir	STRIBILD.xml:S1:1937:9	O
DF	STRIBILD.xml:S1:1947:2	O
300	STRIBILD.xml:S1:1950:3	O
mg	STRIBILD.xml:S1:1954:2	O
)	STRIBILD.xml:S1:1956:1	O
due	STRIBILD.xml:S1:1958:3	O
to	STRIBILD.xml:S1:1962:2	O
adverse	STRIBILD.xml:S1:1965:7	O
events	STRIBILD.xml:S1:1973:6	O
,	STRIBILD.xml:S1:1979:1	O
regardless	STRIBILD.xml:S1:1981:10	O
of	STRIBILD.xml:S1:1992:2	O
severity	STRIBILD.xml:S1:1995:8	O
,	STRIBILD.xml:S1:2003:1	O
was	STRIBILD.xml:S1:2005:3	O
6.0%	STRIBILD.xml:S1:2009:4	O
,	STRIBILD.xml:S1:2013:1	O
7.4%	STRIBILD.xml:S1:2015:4	O
and	STRIBILD.xml:S1:2020:3	O
8.5%	STRIBILD.xml:S1:2024:4	O
,	STRIBILD.xml:S1:2028:1	O
respectively	STRIBILD.xml:S1:2030:12	O
.	STRIBILD.xml:S1:2042:1	O

Table	STRIBILD.xml:S1:2044:5	O
2	STRIBILD.xml:S1:2050:1	O
displays	STRIBILD.xml:S1:2052:8	O
the	STRIBILD.xml:S1:2061:3	O
frequency	STRIBILD.xml:S1:2065:9	O
of	STRIBILD.xml:S1:2075:2	O
adverse	STRIBILD.xml:S1:2078:7	O
drug	STRIBILD.xml:S1:2086:4	O
reactions	STRIBILD.xml:S1:2091:9	O
greater	STRIBILD.xml:S1:2101:7	O
than	STRIBILD.xml:S1:2109:4	O
or	STRIBILD.xml:S1:2114:2	O
equal	STRIBILD.xml:S1:2117:5	O
to	STRIBILD.xml:S1:2123:2	O
5%	STRIBILD.xml:S1:2126:2	O
of	STRIBILD.xml:S1:2129:2	O
subjects	STRIBILD.xml:S1:2132:8	O
in	STRIBILD.xml:S1:2141:2	O
any	STRIBILD.xml:S1:2144:3	O
treatment	STRIBILD.xml:S1:2148:9	O
arm	STRIBILD.xml:S1:2158:3	O
.	STRIBILD.xml:S1:2161:1	O

Table	STRIBILD.xml:S1:2167:5	O
2	STRIBILD.xml:S1:2173:1	O
Adverse	STRIBILD.xml:S1:2175:7	O
Drug	STRIBILD.xml:S1:2183:4	O
ReactionsFrequencies	STRIBILD.xml:S1:2188:20	O
of	STRIBILD.xml:S1:2209:2	O
adverse	STRIBILD.xml:S1:2212:7	O
reactions	STRIBILD.xml:S1:2220:9	O
are	STRIBILD.xml:S1:2230:3	O
based	STRIBILD.xml:S1:2234:5	O
on	STRIBILD.xml:S1:2240:2	O
all	STRIBILD.xml:S1:2243:3	O
treatment	STRIBILD.xml:S1:2247:9	O
-	STRIBILD.xml:S1:2256:1	O
emergent	STRIBILD.xml:S1:2257:8	O
adverse	STRIBILD.xml:S1:2266:7	O
events	STRIBILD.xml:S1:2274:6	O
,	STRIBILD.xml:S1:2280:1	O
attributed	STRIBILD.xml:S1:2282:10	O
to	STRIBILD.xml:S1:2293:2	O
study	STRIBILD.xml:S1:2296:5	O
drugs	STRIBILD.xml:S1:2302:5	O
.	STRIBILD.xml:S1:2307:1	O

(	STRIBILD.xml:S1:2309:1	O
all	STRIBILD.xml:S1:2310:3	O
grades	STRIBILD.xml:S1:2314:6	O
)	STRIBILD.xml:S1:2320:1	O
Reported	STRIBILD.xml:S1:2322:8	O
in	STRIBILD.xml:S1:2331:2	O
5%	STRIBILD.xml:S1:2337:2	O
of	STRIBILD.xml:S1:2340:2	O
Subjects	STRIBILD.xml:S1:2343:8	O
in	STRIBILD.xml:S1:2352:2	O
Any	STRIBILD.xml:S1:2355:3	O
Treatment	STRIBILD.xml:S1:2359:9	O
Arm	STRIBILD.xml:S1:2369:3	O
in	STRIBILD.xml:S1:2373:2	O
Studies	STRIBILD.xml:S1:2376:7	O
102	STRIBILD.xml:S1:2384:3	O
and	STRIBILD.xml:S1:2388:3	O
103	STRIBILD.xml:S1:2392:3	O
(	STRIBILD.xml:S1:2396:1	O
Week	STRIBILD.xml:S1:2397:4	O
144	STRIBILD.xml:S1:2402:3	O
analysis	STRIBILD.xml:S1:2406:8	O
)	STRIBILD.xml:S1:2414:1	O
.	STRIBILD.xml:S1:2415:1	O

STRIBILDN	STRIBILD.xml:S1:2472:9	O
701	STRIBILD.xml:S1:2482:3	O
ATRIPLAN	STRIBILD.xml:S1:2491:8	O
352	STRIBILD.xml:S1:2500:3	O
ATV	STRIBILD.xml:S1:2508:3	O
RTV	STRIBILD.xml:S1:2514:3	O
TRUVADAN	STRIBILD.xml:S1:2520:8	O
355	STRIBILD.xml:S1:2529:3	O

EYE	STRIBILD.xml:S1:2540:3	O

DISORDERS	STRIBILD.xml:S1:2544:9	O

Ocular	STRIBILD.xml:S1:2653:6	B-AdverseReaction
icterus	STRIBILD.xml:S1:2660:7	I-AdverseReaction
1%	STRIBILD.xml:S1:2710:2	O
0%	STRIBILD.xml:S1:2728:2	O
13%	STRIBILD.xml:S1:2747:3	O

GASTROINTESTINAL	STRIBILD.xml:S1:2762:16	O
DISORDERS	STRIBILD.xml:S1:2779:9	O

Diarrhea	STRIBILD.xml:S1:2875:8	B-AdverseReaction
12%	STRIBILD.xml:S1:2931:3	O
11%	STRIBILD.xml:S1:2950:3	O
17%	STRIBILD.xml:S1:2969:3	O

Flatulence	STRIBILD.xml:S1:2986:10	B-AdverseReaction
2%	STRIBILD.xml:S1:3042:2	O
1%	STRIBILD.xml:S1:3062:2	O
8%	STRIBILD.xml:S1:3080:2	O

Nausea	STRIBILD.xml:S1:3097:6	B-AdverseReaction
16%	STRIBILD.xml:S1:3153:3	O
9%	STRIBILD.xml:S1:3172:2	O
14%	STRIBILD.xml:S1:3191:3	O

GENERAL	STRIBILD.xml:S1:3206:7	O
DISORDERS	STRIBILD.xml:S1:3214:9	O
AND	STRIBILD.xml:S1:3224:3	O
ADMINISTRATION	STRIBILD.xml:S1:3228:14	O
SITE	STRIBILD.xml:S1:3243:4	O
CONDITIONS	STRIBILD.xml:S1:3248:10	O

Fatigue	STRIBILD.xml:S1:3322:7	B-AdverseReaction
4%	STRIBILD.xml:S1:3378:2	O
8%	STRIBILD.xml:S1:3397:2	O
6%	STRIBILD.xml:S1:3416:2	O

HEPATOBILIARY	STRIBILD.xml:S1:3431:13	O
DISORDERS	STRIBILD.xml:S1:3445:9	O

Jaundice	STRIBILD.xml:S1:3544:8	B-AdverseReaction
0%	STRIBILD.xml:S1:3600:2	O
1%	STRIBILD.xml:S1:3620:2	O
9%	STRIBILD.xml:S1:3638:2	O

NERVOUS	STRIBILD.xml:S1:3653:7	O
SYSTEM	STRIBILD.xml:S1:3661:6	O
DISORDERS	STRIBILD.xml:S1:3668:9	O

Somnolence	STRIBILD.xml:S1:3766:10	B-AdverseReaction
1%	STRIBILD.xml:S1:3822:2	O
7%	STRIBILD.xml:S1:3841:2	O
1%	STRIBILD.xml:S1:3860:2	O

Headache	STRIBILD.xml:S1:3877:8	B-AdverseReaction
7%	STRIBILD.xml:S1:3933:2	O
4%	STRIBILD.xml:S1:3952:2	O
6%	STRIBILD.xml:S1:3971:2	O

Dizziness	STRIBILD.xml:S1:3988:9	B-AdverseReaction
3%	STRIBILD.xml:S1:4044:2	O
21%	STRIBILD.xml:S1:4063:3	O
5%	STRIBILD.xml:S1:4082:2	O

PSYCHIATRIC	STRIBILD.xml:S1:4097:11	O
DISORDERS	STRIBILD.xml:S1:4109:9	O

Insomnia	STRIBILD.xml:S1:4210:8	B-AdverseReaction
3%	STRIBILD.xml:S1:4266:2	O
9%	STRIBILD.xml:S1:4285:2	O
1%	STRIBILD.xml:S1:4304:2	O

Abnormal	STRIBILD.xml:S1:4321:8	B-AdverseReaction
dreams	STRIBILD.xml:S1:4330:6	I-AdverseReaction
9%	STRIBILD.xml:S1:4377:2	O
27%	STRIBILD.xml:S1:4396:3	O
4%	STRIBILD.xml:S1:4415:2	O

SKIN	STRIBILD.xml:S1:4430:4	O
AND	STRIBILD.xml:S1:4435:3	O
SUBCUTANEOUS	STRIBILD.xml:S1:4439:12	O
TISSUE	STRIBILD.xml:S1:4452:6	O
DISORDERS	STRIBILD.xml:S1:4459:9	O

Rash	STRIBILD.xml:S1:4543:4	B-AdverseReaction
4%	STRIBILD.xml:S1:4599:2	O
15%	STRIBILD.xml:S1:4618:3	O
6%	STRIBILD.xml:S1:4637:2	O

See	STRIBILD.xml:S1:4661:3	O
Warnings	STRIBILD.xml:S1:4668:8	O
and	STRIBILD.xml:S1:4677:3	O
Precautions	STRIBILD.xml:S1:4681:11	O
(	STRIBILD.xml:S1:4693:1	O
5.3	STRIBILD.xml:S1:4694:3	O
)	STRIBILD.xml:S1:4697:1	O
,	STRIBILD.xml:S1:4702:1	O
for	STRIBILD.xml:S1:4704:3	O
a	STRIBILD.xml:S1:4708:1	O
discussion	STRIBILD.xml:S1:4710:10	O
of	STRIBILD.xml:S1:4721:2	O
renal	STRIBILD.xml:S1:4724:5	B-AdverseReaction
adverse	STRIBILD.xml:S1:4730:7	I-AdverseReaction
reactions	STRIBILD.xml:S1:4738:9	I-AdverseReaction
from	STRIBILD.xml:S1:4748:4	O
clinical	STRIBILD.xml:S1:4753:8	O
trials	STRIBILD.xml:S1:4762:6	O
experience	STRIBILD.xml:S1:4769:10	O
with	STRIBILD.xml:S1:4780:4	O
STRIBILD	STRIBILD.xml:S1:4785:8	O
.	STRIBILD.xml:S1:4793:1	O

Additional	STRIBILD.xml:S1:4799:10	O

adverse	STRIBILD.xml:S1:4810:7	O
drug	STRIBILD.xml:S1:4818:4	O
reactions	STRIBILD.xml:S1:4823:9	O
observed	STRIBILD.xml:S1:4833:8	O
with	STRIBILD.xml:S1:4842:4	O
STRIBILD	STRIBILD.xml:S1:4847:8	O
included	STRIBILD.xml:S1:4856:8	O
suicidal	STRIBILD.xml:S1:4865:8	B-AdverseReaction
ideation	STRIBILD.xml:S1:4874:8	I-AdverseReaction
and	STRIBILD.xml:S1:4883:3	O
suicide	STRIBILD.xml:S1:4887:7	B-AdverseReaction
attempt	STRIBILD.xml:S1:4895:7	I-AdverseReaction
(	STRIBILD.xml:S1:4903:1	O
0.3%	STRIBILD.xml:S1:4904:4	O
)	STRIBILD.xml:S1:4908:1	O
,	STRIBILD.xml:S1:4909:1	O
all	STRIBILD.xml:S1:4911:3	O
in	STRIBILD.xml:S1:4915:2	O
subjects	STRIBILD.xml:S1:4918:8	O
with	STRIBILD.xml:S1:4927:4	O
a	STRIBILD.xml:S1:4932:1	O
pre	STRIBILD.xml:S1:4934:3	O
-	STRIBILD.xml:S1:4937:1	O
existing	STRIBILD.xml:S1:4938:8	O
history	STRIBILD.xml:S1:4947:7	O
of	STRIBILD.xml:S1:4955:2	O
depression	STRIBILD.xml:S1:4958:10	O
or	STRIBILD.xml:S1:4969:2	O
psychiatric	STRIBILD.xml:S1:4972:11	O
illness	STRIBILD.xml:S1:4984:7	O
.	STRIBILD.xml:S1:4991:1	O

In	STRIBILD.xml:S1:5001:2	O
Virologically	STRIBILD.xml:S1:5004:13	O
-	STRIBILD.xml:S1:5017:1	O
Suppressed	STRIBILD.xml:S1:5018:10	O
HIV	STRIBILD.xml:S1:5029:3	O
-	STRIBILD.xml:S1:5032:1	O
1	STRIBILD.xml:S1:5033:1	O
-	STRIBILD.xml:S1:5034:1	O
Infected	STRIBILD.xml:S1:5035:8	O
Subjects	STRIBILD.xml:S1:5044:8	O

No	STRIBILD.xml:S1:5059:2	O
new	STRIBILD.xml:S1:5062:3	O
adverse	STRIBILD.xml:S1:5066:7	O
reactions	STRIBILD.xml:S1:5074:9	O
to	STRIBILD.xml:S1:5084:2	O
STRIBILD	STRIBILD.xml:S1:5087:8	O
through	STRIBILD.xml:S1:5096:7	O
Week	STRIBILD.xml:S1:5104:4	O
48	STRIBILD.xml:S1:5109:2	O
were	STRIBILD.xml:S1:5112:4	O
identified	STRIBILD.xml:S1:5117:10	O
in	STRIBILD.xml:S1:5128:2	O
584	STRIBILD.xml:S1:5131:3	O
virologically	STRIBILD.xml:S1:5135:13	O
stably	STRIBILD.xml:S1:5149:6	O
suppressed	STRIBILD.xml:S1:5156:10	O
subjects	STRIBILD.xml:S1:5167:8	O
switching	STRIBILD.xml:S1:5176:9	O
to	STRIBILD.xml:S1:5186:2	O
STRIBILD	STRIBILD.xml:S1:5189:8	O
from	STRIBILD.xml:S1:5198:4	O
a	STRIBILD.xml:S1:5203:1	O
regimen	STRIBILD.xml:S1:5205:7	O
containing	STRIBILD.xml:S1:5213:10	O
a	STRIBILD.xml:S1:5224:1	O
RTV	STRIBILD.xml:S1:5226:3	O
-	STRIBILD.xml:S1:5229:1	O
boosted	STRIBILD.xml:S1:5230:7	O
protease	STRIBILD.xml:S1:5238:8	O
inhibitor	STRIBILD.xml:S1:5247:9	O
(	STRIBILD.xml:S1:5257:1	O
PI	STRIBILD.xml:S1:5258:2	O
)	STRIBILD.xml:S1:5260:1	O
or	STRIBILD.xml:S1:5262:2	O
a	STRIBILD.xml:S1:5265:1	O
non	STRIBILD.xml:S1:5267:3	O
-	STRIBILD.xml:S1:5270:1	O
nucleoside	STRIBILD.xml:S1:5271:10	O
reverse	STRIBILD.xml:S1:5282:7	O
transcriptase	STRIBILD.xml:S1:5290:13	O
inhibitor	STRIBILD.xml:S1:5304:9	O
(	STRIBILD.xml:S1:5314:1	O
NNRTI	STRIBILD.xml:S1:5315:5	O
)	STRIBILD.xml:S1:5320:1	O
.	STRIBILD.xml:S1:5321:1	O

In	STRIBILD.xml:S1:5323:2	O
a	STRIBILD.xml:S1:5326:1	O
combined	STRIBILD.xml:S1:5328:8	O
analysis	STRIBILD.xml:S1:5337:8	O
of	STRIBILD.xml:S1:5346:2	O
Studies	STRIBILD.xml:S1:5349:7	O
115	STRIBILD.xml:S1:5357:3	O
and	STRIBILD.xml:S1:5361:3	O
121	STRIBILD.xml:S1:5365:3	O
,	STRIBILD.xml:S1:5368:1	O
the	STRIBILD.xml:S1:5370:3	O
frequency	STRIBILD.xml:S1:5374:9	O
of	STRIBILD.xml:S1:5384:2	O
adverse	STRIBILD.xml:S1:5387:7	O
reactions	STRIBILD.xml:S1:5395:9	O
(	STRIBILD.xml:S1:5405:1	O
all	STRIBILD.xml:S1:5406:3	O
grades	STRIBILD.xml:S1:5410:6	O
)	STRIBILD.xml:S1:5416:1	O
was	STRIBILD.xml:S1:5418:3	O
24%	STRIBILD.xml:S1:5422:3	O
in	STRIBILD.xml:S1:5426:2	O
subjects	STRIBILD.xml:S1:5429:8	O
switching	STRIBILD.xml:S1:5438:9	O
to	STRIBILD.xml:S1:5448:2	O
STRIBILD	STRIBILD.xml:S1:5451:8	O
compared	STRIBILD.xml:S1:5460:8	O
to	STRIBILD.xml:S1:5469:2	O
6%	STRIBILD.xml:S1:5472:2	O
of	STRIBILD.xml:S1:5475:2	O
subjects	STRIBILD.xml:S1:5478:8	O
in	STRIBILD.xml:S1:5487:2	O
either	STRIBILD.xml:S1:5490:6	O
group	STRIBILD.xml:S1:5497:5	O
who	STRIBILD.xml:S1:5503:3	O
stayed	STRIBILD.xml:S1:5507:6	O
on	STRIBILD.xml:S1:5514:2	O
their	STRIBILD.xml:S1:5517:5	O
baseline	STRIBILD.xml:S1:5523:8	O
antiretroviral	STRIBILD.xml:S1:5532:14	O
regimen	STRIBILD.xml:S1:5547:7	O
,	STRIBILD.xml:S1:5554:1	O
RTV	STRIBILD.xml:S1:5556:3	O
-	STRIBILD.xml:S1:5559:1	O
boosted	STRIBILD.xml:S1:5560:7	O
PI	STRIBILD.xml:S1:5568:2	O
TRUVADA	STRIBILD.xml:S1:5573:7	O
or	STRIBILD.xml:S1:5581:2	O
NNRTI	STRIBILD.xml:S1:5584:5	O
TRUVADA	STRIBILD.xml:S1:5592:7	O
.	STRIBILD.xml:S1:5599:1	O

Common	STRIBILD.xml:S1:5601:6	O
adverse	STRIBILD.xml:S1:5608:7	O
reactions	STRIBILD.xml:S1:5616:9	O
that	STRIBILD.xml:S1:5626:4	O
occurred	STRIBILD.xml:S1:5631:8	O
in	STRIBILD.xml:S1:5640:2	O
greater	STRIBILD.xml:S1:5643:7	O
than	STRIBILD.xml:S1:5651:4	O
or	STRIBILD.xml:S1:5656:2	O
equal	STRIBILD.xml:S1:5659:5	O
to	STRIBILD.xml:S1:5665:2	O
2%	STRIBILD.xml:S1:5668:2	O
of	STRIBILD.xml:S1:5671:2	O
subjects	STRIBILD.xml:S1:5674:8	O
switching	STRIBILD.xml:S1:5683:9	O
to	STRIBILD.xml:S1:5693:2	O
STRIBILD	STRIBILD.xml:S1:5696:8	O
were	STRIBILD.xml:S1:5705:4	O
nausea	STRIBILD.xml:S1:5710:6	B-AdverseReaction
(	STRIBILD.xml:S1:5717:1	O
4%	STRIBILD.xml:S1:5718:2	O
)	STRIBILD.xml:S1:5720:1	O
,	STRIBILD.xml:S1:5721:1	O
flatulence	STRIBILD.xml:S1:5723:10	B-AdverseReaction
(	STRIBILD.xml:S1:5734:1	O
2%	STRIBILD.xml:S1:5735:2	O
)	STRIBILD.xml:S1:5737:1	O
,	STRIBILD.xml:S1:5738:1	O
and	STRIBILD.xml:S1:5740:3	O
headache	STRIBILD.xml:S1:5744:8	B-AdverseReaction
(	STRIBILD.xml:S1:5753:1	O
2%	STRIBILD.xml:S1:5754:2	O
)	STRIBILD.xml:S1:5756:1	O
.	STRIBILD.xml:S1:5757:1	O

The	STRIBILD.xml:S1:5759:3	O
proportion	STRIBILD.xml:S1:5763:10	O
of	STRIBILD.xml:S1:5774:2	O
subjects	STRIBILD.xml:S1:5777:8	O
who	STRIBILD.xml:S1:5786:3	O
discontinued	STRIBILD.xml:S1:5790:12	O
treatment	STRIBILD.xml:S1:5803:9	O
with	STRIBILD.xml:S1:5813:4	O
STRIBILD	STRIBILD.xml:S1:5818:8	O
,	STRIBILD.xml:S1:5826:1	O
the	STRIBILD.xml:S1:5828:3	O
RTV	STRIBILD.xml:S1:5832:3	O
-	STRIBILD.xml:S1:5835:1	O
boosted	STRIBILD.xml:S1:5836:7	O
PI	STRIBILD.xml:S1:5844:2	O
,	STRIBILD.xml:S1:5846:1	O
or	STRIBILD.xml:S1:5848:2	O
the	STRIBILD.xml:S1:5851:3	O
NNRTI	STRIBILD.xml:S1:5855:5	O
due	STRIBILD.xml:S1:5861:3	O
to	STRIBILD.xml:S1:5865:2	O
adverse	STRIBILD.xml:S1:5868:7	O
events	STRIBILD.xml:S1:5876:6	O
,	STRIBILD.xml:S1:5882:1	O
was	STRIBILD.xml:S1:5884:3	O
2%	STRIBILD.xml:S1:5888:2	O
,	STRIBILD.xml:S1:5890:1	O
3%	STRIBILD.xml:S1:5892:2	O
and	STRIBILD.xml:S1:5895:3	O
1%	STRIBILD.xml:S1:5899:2	O
,	STRIBILD.xml:S1:5901:1	O
respectively	STRIBILD.xml:S1:5903:12	O
.	STRIBILD.xml:S1:5915:1	O

Adverse	STRIBILD.xml:S1:5925:7	O
Reactions	STRIBILD.xml:S1:5933:9	O
from	STRIBILD.xml:S1:5943:4	O
Clinical	STRIBILD.xml:S1:5948:8	O
Trials	STRIBILD.xml:S1:5957:6	O
of	STRIBILD.xml:S1:5964:2	O
the	STRIBILD.xml:S1:5967:3	O
Components	STRIBILD.xml:S1:5971:10	O
of	STRIBILD.xml:S1:5982:2	O
STRIBILD	STRIBILD.xml:S1:5985:8	O

Emtricitabine	STRIBILD.xml:S1:6004:13	O
and	STRIBILD.xml:S1:6018:3	O
Tenofovir	STRIBILD.xml:S1:6022:9	O
Disoproxil	STRIBILD.xml:S1:6032:10	O
Fumarate	STRIBILD.xml:S1:6043:8	O
:	STRIBILD.xml:S1:6051:1	O
In	STRIBILD.xml:S1:6054:2	O
addition	STRIBILD.xml:S1:6057:8	O
to	STRIBILD.xml:S1:6066:2	O
the	STRIBILD.xml:S1:6069:3	O
adverse	STRIBILD.xml:S1:6073:7	O
reactions	STRIBILD.xml:S1:6081:9	O
observed	STRIBILD.xml:S1:6091:8	O
with	STRIBILD.xml:S1:6100:4	O
STRIBILD	STRIBILD.xml:S1:6105:8	O
,	STRIBILD.xml:S1:6113:1	O
the	STRIBILD.xml:S1:6115:3	O
following	STRIBILD.xml:S1:6119:9	O
adverse	STRIBILD.xml:S1:6129:7	O
reactions	STRIBILD.xml:S1:6137:9	O
occurred	STRIBILD.xml:S1:6147:8	O
in	STRIBILD.xml:S1:6156:2	O
at	STRIBILD.xml:S1:6159:2	O
least	STRIBILD.xml:S1:6162:5	O
5%	STRIBILD.xml:S1:6168:2	O
of	STRIBILD.xml:S1:6171:2	O
treatment	STRIBILD.xml:S1:6174:9	O
-	STRIBILD.xml:S1:6183:1	O
experienced	STRIBILD.xml:S1:6184:11	O
or	STRIBILD.xml:S1:6196:2	O
treatment	STRIBILD.xml:S1:6199:9	O
-	STRIBILD.xml:S1:6208:1	O
naive	STRIBILD.xml:S1:6209:5	O
subjects	STRIBILD.xml:S1:6215:8	O
receiving	STRIBILD.xml:S1:6224:9	O
emtricitabine	STRIBILD.xml:S1:6234:13	O
or	STRIBILD.xml:S1:6248:2	O
tenofovir	STRIBILD.xml:S1:6251:9	O
DF	STRIBILD.xml:S1:6261:2	O
with	STRIBILD.xml:S1:6264:4	O
other	STRIBILD.xml:S1:6269:5	O
antiretroviral	STRIBILD.xml:S1:6275:14	O
agents	STRIBILD.xml:S1:6290:6	O
in	STRIBILD.xml:S1:6297:2	O
other	STRIBILD.xml:S1:6300:5	O
clinical	STRIBILD.xml:S1:6306:8	O
trials	STRIBILD.xml:S1:6315:6	O
:	STRIBILD.xml:S1:6321:1	O
depression	STRIBILD.xml:S1:6323:10	B-AdverseReaction
,	STRIBILD.xml:S1:6333:1	O
abdominal	STRIBILD.xml:S1:6335:9	B-AdverseReaction
pain	STRIBILD.xml:S1:6345:4	I-AdverseReaction
,	STRIBILD.xml:S1:6349:1	O
dyspepsia	STRIBILD.xml:S1:6351:9	B-AdverseReaction
,	STRIBILD.xml:S1:6360:1	O
vomiting	STRIBILD.xml:S1:6362:8	B-AdverseReaction
,	STRIBILD.xml:S1:6370:1	O
fever	STRIBILD.xml:S1:6372:5	B-AdverseReaction
,	STRIBILD.xml:S1:6377:1	O
pain	STRIBILD.xml:S1:6379:4	B-AdverseReaction
,	STRIBILD.xml:S1:6383:1	O
nasopharyngitis	STRIBILD.xml:S1:6385:15	B-AdverseReaction
,	STRIBILD.xml:S1:6400:1	O
pneumonia	STRIBILD.xml:S1:6402:9	B-AdverseReaction
,	STRIBILD.xml:S1:6411:1	O
sinusitis	STRIBILD.xml:S1:6413:9	B-AdverseReaction
,	STRIBILD.xml:S1:6422:1	O
upper	STRIBILD.xml:S1:6424:5	B-AdverseReaction
respiratory	STRIBILD.xml:S1:6430:11	I-AdverseReaction
tract	STRIBILD.xml:S1:6442:5	I-AdverseReaction
infection	STRIBILD.xml:S1:6448:9	I-AdverseReaction
,	STRIBILD.xml:S1:6457:1	O
arthralgia	STRIBILD.xml:S1:6459:10	B-AdverseReaction
,	STRIBILD.xml:S1:6469:1	O
back	STRIBILD.xml:S1:6471:4	B-AdverseReaction
pain	STRIBILD.xml:S1:6476:4	I-AdverseReaction
,	STRIBILD.xml:S1:6480:1	O
myalgia	STRIBILD.xml:S1:6482:7	B-AdverseReaction
,	STRIBILD.xml:S1:6489:1	O
paresthesia	STRIBILD.xml:S1:6491:11	B-AdverseReaction
,	STRIBILD.xml:S1:6502:1	O
peripheral	STRIBILD.xml:S1:6504:10	B-AdverseReaction
neuropathy	STRIBILD.xml:S1:6515:10	I-AdverseReaction
(	STRIBILD.xml:S1:6526:1	O
including	STRIBILD.xml:S1:6527:9	O
peripheral	STRIBILD.xml:S1:6537:10	B-AdverseReaction
neuritis	STRIBILD.xml:S1:6548:8	I-AdverseReaction
and	STRIBILD.xml:S1:6557:3	O
neuropathy	STRIBILD.xml:S1:6561:10	I-AdverseReaction
)	STRIBILD.xml:S1:6571:1	O
,	STRIBILD.xml:S1:6572:1	O
anxiety	STRIBILD.xml:S1:6574:7	B-AdverseReaction
,	STRIBILD.xml:S1:6581:1	O
increased	STRIBILD.xml:S1:6583:9	B-AdverseReaction
cough	STRIBILD.xml:S1:6593:5	I-AdverseReaction
,	STRIBILD.xml:S1:6598:1	O
and	STRIBILD.xml:S1:6600:3	O
rhinitis	STRIBILD.xml:S1:6604:8	B-AdverseReaction
.	STRIBILD.xml:S1:6612:1	O

Skin	STRIBILD.xml:S1:6618:4	B-AdverseReaction
discoloration	STRIBILD.xml:S1:6623:13	I-AdverseReaction
has	STRIBILD.xml:S1:6637:3	O
been	STRIBILD.xml:S1:6641:4	O
reported	STRIBILD.xml:S1:6646:8	O
with	STRIBILD.xml:S1:6655:4	O
higher	STRIBILD.xml:S1:6660:6	O
frequency	STRIBILD.xml:S1:6667:9	O
among	STRIBILD.xml:S1:6677:5	O
emtricitabine	STRIBILD.xml:S1:6683:13	O
-	STRIBILD.xml:S1:6696:1	O
treated	STRIBILD.xml:S1:6697:7	O
subjects	STRIBILD.xml:S1:6705:8	O
;	STRIBILD.xml:S1:6713:1	O
it	STRIBILD.xml:S1:6715:2	O
was	STRIBILD.xml:S1:6718:3	O
manifested	STRIBILD.xml:S1:6722:10	O
by	STRIBILD.xml:S1:6733:2	O
hyperpigmentation	STRIBILD.xml:S1:6736:17	B-AdverseReaction
on	STRIBILD.xml:S1:6754:2	I-AdverseReaction
the	STRIBILD.xml:S1:6757:3	I-AdverseReaction
palms	STRIBILD.xml:S1:6761:5	I-AdverseReaction
and	STRIBILD.xml:S1:6767:3	O
or	STRIBILD.xml:S1:6771:2	O
soles	STRIBILD.xml:S1:6774:5	I-AdverseReaction
and	STRIBILD.xml:S1:6780:3	O
was	STRIBILD.xml:S1:6784:3	O
generally	STRIBILD.xml:S1:6788:9	O
mild	STRIBILD.xml:S1:6798:4	B-Severity
and	STRIBILD.xml:S1:6803:3	O
asymptomatic	STRIBILD.xml:S1:6807:12	O
.	STRIBILD.xml:S1:6819:1	O

The	STRIBILD.xml:S1:6821:3	O
mechanism	STRIBILD.xml:S1:6825:9	O
and	STRIBILD.xml:S1:6835:3	O
clinical	STRIBILD.xml:S1:6839:8	O
significance	STRIBILD.xml:S1:6848:12	O
are	STRIBILD.xml:S1:6861:3	O
unknown	STRIBILD.xml:S1:6865:7	O
.	STRIBILD.xml:S1:6872:1	O

Laboratory	STRIBILD.xml:S1:6882:10	O
Abnormalities	STRIBILD.xml:S1:6893:13	O

The	STRIBILD.xml:S1:6913:3	O
frequency	STRIBILD.xml:S1:6917:9	O
of	STRIBILD.xml:S1:6927:2	O
laboratory	STRIBILD.xml:S1:6930:10	O
abnormalities	STRIBILD.xml:S1:6941:13	O
(	STRIBILD.xml:S1:6955:1	O
Grades	STRIBILD.xml:S1:6956:6	O
3	STRIBILD.xml:S1:6963:1	O
-	STRIBILD.xml:S1:6964:1	O
4	STRIBILD.xml:S1:6965:1	O
)	STRIBILD.xml:S1:6966:1	O
occurring	STRIBILD.xml:S1:6968:9	O
in	STRIBILD.xml:S1:6978:2	O
at	STRIBILD.xml:S1:6981:2	O
least	STRIBILD.xml:S1:6984:5	O
2%	STRIBILD.xml:S1:6990:2	O
of	STRIBILD.xml:S1:6993:2	O
subjects	STRIBILD.xml:S1:6996:8	O
receiving	STRIBILD.xml:S1:7005:9	O
STRIBILD	STRIBILD.xml:S1:7015:8	O
in	STRIBILD.xml:S1:7024:2	O
Studies	STRIBILD.xml:S1:7027:7	O
102	STRIBILD.xml:S1:7035:3	O
and	STRIBILD.xml:S1:7039:3	O
103	STRIBILD.xml:S1:7043:3	O
are	STRIBILD.xml:S1:7047:3	O
presented	STRIBILD.xml:S1:7051:9	O
in	STRIBILD.xml:S1:7061:2	O
Table	STRIBILD.xml:S1:7064:5	O
3	STRIBILD.xml:S1:7070:1	O
.	STRIBILD.xml:S1:7071:1	O

Table	STRIBILD.xml:S1:7077:5	O
3	STRIBILD.xml:S1:7083:1	O
Laboratory	STRIBILD.xml:S1:7085:10	O
Abnormalities	STRIBILD.xml:S1:7096:13	O
(	STRIBILD.xml:S1:7110:1	O
Grades	STRIBILD.xml:S1:7111:6	O
3	STRIBILD.xml:S1:7118:1	O
-	STRIBILD.xml:S1:7119:1	O
4	STRIBILD.xml:S1:7120:1	O
)	STRIBILD.xml:S1:7121:1	O
Reported	STRIBILD.xml:S1:7123:8	O
in	STRIBILD.xml:S1:7132:2	O
2%	STRIBILD.xml:S1:7138:2	O
of	STRIBILD.xml:S1:7141:2	O
Subjects	STRIBILD.xml:S1:7144:8	O
Receiving	STRIBILD.xml:S1:7153:9	O
STRIBILD	STRIBILD.xml:S1:7163:8	O
in	STRIBILD.xml:S1:7172:2	O
Studies	STRIBILD.xml:S1:7175:7	O
102	STRIBILD.xml:S1:7183:3	O
and	STRIBILD.xml:S1:7187:3	O
103	STRIBILD.xml:S1:7191:3	O
(	STRIBILD.xml:S1:7195:1	O
Week	STRIBILD.xml:S1:7196:4	O
144	STRIBILD.xml:S1:7201:3	O
analysis	STRIBILD.xml:S1:7205:8	O
)	STRIBILD.xml:S1:7213:1	O

STRIBILD	STRIBILD.xml:S1:7267:8	O
ATRIPLA	STRIBILD.xml:S1:7287:7	O
ATV	STRIBILD.xml:S1:7303:3	O
RTV	STRIBILD.xml:S1:7309:3	O
TRUVADA	STRIBILD.xml:S1:7315:7	O

Laboratory	STRIBILD.xml:S1:7333:10	O

Parameter	STRIBILD.xml:S1:7344:9	O
Abnormality	STRIBILD.xml:S1:7354:11	O
,	STRIBILD.xml:S1:7369:1	O
N	STRIBILD.xml:S1:7382:1	O
701	STRIBILD.xml:S1:7384:3	O
N	STRIBILD.xml:S1:7402:1	O
352	STRIBILD.xml:S1:7404:3	O
N	STRIBILD.xml:S1:7424:1	O
355	STRIBILD.xml:S1:7426:3	O

AST	STRIBILD.xml:S1:7442:3	B-AdverseReaction
(	STRIBILD.xml:S1:7446:1	O
5.0	STRIBILD.xml:S1:7448:3	I-AdverseReaction
ULN	STRIBILD.xml:S1:7454:3	I-AdverseReaction
)	STRIBILD.xml:S1:7457:1	O
3%	STRIBILD.xml:S1:7495:2	O
6%	STRIBILD.xml:S1:7515:2	O
6%	STRIBILD.xml:S1:7536:2	O

ALT	STRIBILD.xml:S1:7553:3	B-AdverseReaction
(	STRIBILD.xml:S1:7557:1	O
3.0	STRIBILD.xml:S1:7559:3	I-AdverseReaction
ULN	STRIBILD.xml:S1:7565:3	I-AdverseReaction
)	STRIBILD.xml:S1:7568:1	O
2%	STRIBILD.xml:S1:7606:2	O
5%	STRIBILD.xml:S1:7626:2	O
4%	STRIBILD.xml:S1:7647:2	O

Amylase	STRIBILD.xml:S1:7664:7	B-AdverseReaction
(	STRIBILD.xml:S1:7671:1	O
2.0	STRIBILD.xml:S1:7673:3	I-AdverseReaction
ULN	STRIBILD.xml:S1:7679:3	I-AdverseReaction
)	STRIBILD.xml:S1:7682:1	O
3%	STRIBILD.xml:S1:7717:2	O
3%	STRIBILD.xml:S1:7737:2	O
5%	STRIBILD.xml:S1:7758:2	O

Creatine	STRIBILD.xml:S1:7775:8	B-AdverseReaction
Kinase	STRIBILD.xml:S1:7784:6	I-AdverseReaction
(	STRIBILD.xml:S1:7791:1	O
10.0	STRIBILD.xml:S1:7795:4	I-AdverseReaction
ULN	STRIBILD.xml:S1:7802:3	I-AdverseReaction
)	STRIBILD.xml:S1:7805:1	O
8%	STRIBILD.xml:S1:7828:2	O
15%	STRIBILD.xml:S1:7847:3	O
11%	STRIBILD.xml:S1:7869:3	O

Urine	STRIBILD.xml:S1:7886:5	B-AdverseReaction
RBC	STRIBILD.xml:S1:7892:3	I-AdverseReaction
(	STRIBILD.xml:S1:7896:1	O
Hematuria	STRIBILD.xml:S1:7897:9	B-AdverseReaction
)	STRIBILD.xml:S1:7906:1	O
(	STRIBILD.xml:S1:7908:1	O
75	STRIBILD.xml:S1:7911:2	O
RBC	STRIBILD.xml:S1:7914:3	O
HPF	STRIBILD.xml:S1:7918:3	O
)	STRIBILD.xml:S1:7921:1	O
4%	STRIBILD.xml:S1:7939:2	O
2%	STRIBILD.xml:S1:7959:2	O
4%	STRIBILD.xml:S1:7980:2	O

In	STRIBILD.xml:S1:8006:2	O
Study	STRIBILD.xml:S1:8009:5	O
103	STRIBILD.xml:S1:8015:3	O
,	STRIBILD.xml:S1:8018:1	O
BMD	STRIBILD.xml:S1:8020:3	O
was	STRIBILD.xml:S1:8024:3	O
assessed	STRIBILD.xml:S1:8028:8	O
by	STRIBILD.xml:S1:8037:2	O
DEXA	STRIBILD.xml:S1:8040:4	O
in	STRIBILD.xml:S1:8045:2	O
a	STRIBILD.xml:S1:8048:1	O
non	STRIBILD.xml:S1:8050:3	O
-	STRIBILD.xml:S1:8053:1	O
random	STRIBILD.xml:S1:8054:6	O
subset	STRIBILD.xml:S1:8061:6	O
of	STRIBILD.xml:S1:8068:2	O
120	STRIBILD.xml:S1:8071:3	O
subjects	STRIBILD.xml:S1:8075:8	O
(	STRIBILD.xml:S1:8084:1	O
STRIBILD	STRIBILD.xml:S1:8085:8	O
group	STRIBILD.xml:S1:8094:5	O
N	STRIBILD.xml:S1:8100:1	O
54	STRIBILD.xml:S1:8104:2	O
;	STRIBILD.xml:S1:8106:1	O
ATV	STRIBILD.xml:S1:8108:3	O
RTV	STRIBILD.xml:S1:8114:3	O
TRUVADA	STRIBILD.xml:S1:8120:7	O
group	STRIBILD.xml:S1:8128:5	O
N	STRIBILD.xml:S1:8134:1	O
66	STRIBILD.xml:S1:8138:2	O
)	STRIBILD.xml:S1:8140:1	O
.	STRIBILD.xml:S1:8141:1	O

Mean	STRIBILD.xml:S1:8143:4	O
percentage	STRIBILD.xml:S1:8148:10	O
decreases	STRIBILD.xml:S1:8159:9	B-AdverseReaction
in	STRIBILD.xml:S1:8169:2	I-AdverseReaction
BMD	STRIBILD.xml:S1:8172:3	I-AdverseReaction
from	STRIBILD.xml:S1:8176:4	O
baseline	STRIBILD.xml:S1:8181:8	O
to	STRIBILD.xml:S1:8190:2	O
Week	STRIBILD.xml:S1:8193:4	O
144	STRIBILD.xml:S1:8198:3	O
in	STRIBILD.xml:S1:8202:2	O
the	STRIBILD.xml:S1:8205:3	O
STRIBILD	STRIBILD.xml:S1:8209:8	O
group	STRIBILD.xml:S1:8218:5	O
were	STRIBILD.xml:S1:8224:4	O
comparable	STRIBILD.xml:S1:8229:10	O
to	STRIBILD.xml:S1:8240:2	O
the	STRIBILD.xml:S1:8243:3	O
ATV	STRIBILD.xml:S1:8247:3	O
RTV	STRIBILD.xml:S1:8253:3	O
TRUVADA	STRIBILD.xml:S1:8259:7	O
group	STRIBILD.xml:S1:8267:5	O
at	STRIBILD.xml:S1:8273:2	O
the	STRIBILD.xml:S1:8276:3	O
lumbar	STRIBILD.xml:S1:8280:6	O
spine	STRIBILD.xml:S1:8287:5	O
(-	STRIBILD.xml:S1:8293:2	O
1.43%	STRIBILD.xml:S1:8295:5	O
versus	STRIBILD.xml:S1:8301:6	O
-	STRIBILD.xml:S1:8308:1	O
3.68%	STRIBILD.xml:S1:8309:5	O
,	STRIBILD.xml:S1:8314:1	O
respectively	STRIBILD.xml:S1:8316:12	O
)	STRIBILD.xml:S1:8328:1	O
and	STRIBILD.xml:S1:8330:3	O
at	STRIBILD.xml:S1:8334:2	O
the	STRIBILD.xml:S1:8337:3	O
hip	STRIBILD.xml:S1:8341:3	O
(-	STRIBILD.xml:S1:8345:2	O
2.83%	STRIBILD.xml:S1:8347:5	O
versus	STRIBILD.xml:S1:8353:6	O
-	STRIBILD.xml:S1:8360:1	O
3.77%	STRIBILD.xml:S1:8361:5	O
,	STRIBILD.xml:S1:8366:1	O
respectively	STRIBILD.xml:S1:8368:12	O
)	STRIBILD.xml:S1:8380:1	O
.	STRIBILD.xml:S1:8381:1	O

In	STRIBILD.xml:S1:8383:2	O
Studies	STRIBILD.xml:S1:8386:7	O
102	STRIBILD.xml:S1:8394:3	O
and	STRIBILD.xml:S1:8398:3	O
103	STRIBILD.xml:S1:8402:3	O
,	STRIBILD.xml:S1:8405:1	O
bone	STRIBILD.xml:S1:8407:4	B-AdverseReaction
fractures	STRIBILD.xml:S1:8412:9	I-AdverseReaction
occurred	STRIBILD.xml:S1:8422:8	O
in	STRIBILD.xml:S1:8431:2	O
27	STRIBILD.xml:S1:8434:2	O
subjects	STRIBILD.xml:S1:8437:8	O
(	STRIBILD.xml:S1:8446:1	O
3.9%	STRIBILD.xml:S1:8447:4	O
)	STRIBILD.xml:S1:8451:1	O
in	STRIBILD.xml:S1:8453:2	O
the	STRIBILD.xml:S1:8456:3	O
STRIBILD	STRIBILD.xml:S1:8460:8	O
group	STRIBILD.xml:S1:8469:5	O
,	STRIBILD.xml:S1:8474:1	O
8	STRIBILD.xml:S1:8476:1	O
subjects	STRIBILD.xml:S1:8478:8	O
(	STRIBILD.xml:S1:8487:1	O
2.3%	STRIBILD.xml:S1:8488:4	O
)	STRIBILD.xml:S1:8492:1	O
in	STRIBILD.xml:S1:8494:2	O
the	STRIBILD.xml:S1:8497:3	O
ATRIPLA	STRIBILD.xml:S1:8501:7	O
group	STRIBILD.xml:S1:8509:5	O
,	STRIBILD.xml:S1:8514:1	O
and	STRIBILD.xml:S1:8516:3	O
19	STRIBILD.xml:S1:8520:2	O
subjects	STRIBILD.xml:S1:8523:8	O
(	STRIBILD.xml:S1:8532:1	O
5.4%	STRIBILD.xml:S1:8533:4	O
)	STRIBILD.xml:S1:8537:1	O
in	STRIBILD.xml:S1:8539:2	O
the	STRIBILD.xml:S1:8542:3	O
ATV	STRIBILD.xml:S1:8546:3	O
RTV	STRIBILD.xml:S1:8552:3	O
TRUVADA	STRIBILD.xml:S1:8558:7	O
group	STRIBILD.xml:S1:8566:5	O
.	STRIBILD.xml:S1:8571:1	O

These	STRIBILD.xml:S1:8573:5	O
findings	STRIBILD.xml:S1:8579:8	O
were	STRIBILD.xml:S1:8588:4	O
consistent	STRIBILD.xml:S1:8593:10	O
with	STRIBILD.xml:S1:8604:4	O
data	STRIBILD.xml:S1:8609:4	O
from	STRIBILD.xml:S1:8614:4	O
an	STRIBILD.xml:S1:8619:2	O
earlier	STRIBILD.xml:S1:8622:7	O
144	STRIBILD.xml:S1:8630:3	O
-	STRIBILD.xml:S1:8633:1	O
week	STRIBILD.xml:S1:8634:4	O
trial	STRIBILD.xml:S1:8639:5	O
of	STRIBILD.xml:S1:8645:2	O
treatment	STRIBILD.xml:S1:8648:9	O
-	STRIBILD.xml:S1:8657:1	O
naive	STRIBILD.xml:S1:8658:5	O
subjects	STRIBILD.xml:S1:8664:8	O
receiving	STRIBILD.xml:S1:8673:9	O
tenofovir	STRIBILD.xml:S1:8683:9	O
DF	STRIBILD.xml:S1:8693:2	O
lamivudine	STRIBILD.xml:S1:8698:10	O
efavirenz	STRIBILD.xml:S1:8711:9	O
.	STRIBILD.xml:S1:8720:1	O

Proteinuria	STRIBILD.xml:S1:8726:11	B-AdverseReaction

(	STRIBILD.xml:S1:8738:1	O
all	STRIBILD.xml:S1:8739:3	O
grades	STRIBILD.xml:S1:8743:6	O
)	STRIBILD.xml:S1:8749:1	O
occurred	STRIBILD.xml:S1:8751:8	O
in	STRIBILD.xml:S1:8760:2	O
52%	STRIBILD.xml:S1:8763:3	O
of	STRIBILD.xml:S1:8767:2	O
subjects	STRIBILD.xml:S1:8770:8	O
receiving	STRIBILD.xml:S1:8779:9	O
STRIBILD	STRIBILD.xml:S1:8789:8	O
,	STRIBILD.xml:S1:8797:1	O
41%	STRIBILD.xml:S1:8799:3	O
of	STRIBILD.xml:S1:8803:2	O
subjects	STRIBILD.xml:S1:8806:8	O
receiving	STRIBILD.xml:S1:8815:9	O
ATRIPLA	STRIBILD.xml:S1:8825:7	O
,	STRIBILD.xml:S1:8832:1	O
and	STRIBILD.xml:S1:8834:3	O
42%	STRIBILD.xml:S1:8838:3	O
of	STRIBILD.xml:S1:8842:2	O
subjects	STRIBILD.xml:S1:8845:8	O
receiving	STRIBILD.xml:S1:8854:9	O
ATV	STRIBILD.xml:S1:8864:3	O
RTV	STRIBILD.xml:S1:8870:3	O
TRUVADA	STRIBILD.xml:S1:8876:7	O
.	STRIBILD.xml:S1:8883:1	O

The	STRIBILD.xml:S1:8889:3	O
cobicistat	STRIBILD.xml:S1:8893:10	O
component	STRIBILD.xml:S1:8904:9	O
of	STRIBILD.xml:S1:8914:2	O
STRIBILD	STRIBILD.xml:S1:8917:8	O
has	STRIBILD.xml:S1:8926:3	O
been	STRIBILD.xml:S1:8930:4	O
shown	STRIBILD.xml:S1:8935:5	O
to	STRIBILD.xml:S1:8941:2	O
increase	STRIBILD.xml:S1:8944:8	B-AdverseReaction
serum	STRIBILD.xml:S1:8953:5	I-AdverseReaction
creatinine	STRIBILD.xml:S1:8959:10	I-AdverseReaction
and	STRIBILD.xml:S1:8970:3	O
decrease	STRIBILD.xml:S1:8974:8	B-AdverseReaction
estimated	STRIBILD.xml:S1:8983:9	I-AdverseReaction
creatinine	STRIBILD.xml:S1:8993:10	I-AdverseReaction
clearance	STRIBILD.xml:S1:9004:9	I-AdverseReaction
due	STRIBILD.xml:S1:9014:3	O
to	STRIBILD.xml:S1:9018:2	O
inhibition	STRIBILD.xml:S1:9021:10	O
of	STRIBILD.xml:S1:9032:2	O
tubular	STRIBILD.xml:S1:9035:7	O
secretion	STRIBILD.xml:S1:9043:9	O
of	STRIBILD.xml:S1:9053:2	O
creatinine	STRIBILD.xml:S1:9056:10	O
without	STRIBILD.xml:S1:9067:7	B-Negation
affecting	STRIBILD.xml:S1:9075:9	B-AdverseReaction
renal	STRIBILD.xml:S1:9085:5	I-AdverseReaction
glomerular	STRIBILD.xml:S1:9091:10	I-AdverseReaction
function	STRIBILD.xml:S1:9102:8	I-AdverseReaction
.	STRIBILD.xml:S1:9110:1	O

In	STRIBILD.xml:S1:9112:2	O
Studies	STRIBILD.xml:S1:9115:7	O
102	STRIBILD.xml:S1:9123:3	O
and	STRIBILD.xml:S1:9127:3	O
103	STRIBILD.xml:S1:9131:3	O
,	STRIBILD.xml:S1:9134:1	O
increases	STRIBILD.xml:S1:9136:9	B-AdverseReaction
in	STRIBILD.xml:S1:9146:2	I-AdverseReaction
serum	STRIBILD.xml:S1:9149:5	I-AdverseReaction
creatinine	STRIBILD.xml:S1:9155:10	I-AdverseReaction
and	STRIBILD.xml:S1:9166:3	O
decreases	STRIBILD.xml:S1:9170:9	B-AdverseReaction
in	STRIBILD.xml:S1:9180:2	I-AdverseReaction
estimated	STRIBILD.xml:S1:9183:9	I-AdverseReaction
creatinine	STRIBILD.xml:S1:9193:10	I-AdverseReaction
clearance	STRIBILD.xml:S1:9204:9	I-AdverseReaction
occurred	STRIBILD.xml:S1:9214:8	O
early	STRIBILD.xml:S1:9223:5	O
in	STRIBILD.xml:S1:9229:2	O
treatment	STRIBILD.xml:S1:9232:9	O
with	STRIBILD.xml:S1:9242:4	O
STRIBILD	STRIBILD.xml:S1:9247:8	O
,	STRIBILD.xml:S1:9255:1	O
after	STRIBILD.xml:S1:9257:5	O
which	STRIBILD.xml:S1:9263:5	O
they	STRIBILD.xml:S1:9269:4	O
stabilized	STRIBILD.xml:S1:9274:10	O
.	STRIBILD.xml:S1:9284:1	O

Table	STRIBILD.xml:S1:9286:5	O
4	STRIBILD.xml:S1:9292:1	O
displays	STRIBILD.xml:S1:9294:8	O
the	STRIBILD.xml:S1:9303:3	O
mean	STRIBILD.xml:S1:9307:4	O
changes	STRIBILD.xml:S1:9312:7	O
in	STRIBILD.xml:S1:9320:2	O
serum	STRIBILD.xml:S1:9323:5	O
creatinine	STRIBILD.xml:S1:9329:10	O
and	STRIBILD.xml:S1:9340:3	O
eGFR	STRIBILD.xml:S1:9344:4	O
levels	STRIBILD.xml:S1:9349:6	O
at	STRIBILD.xml:S1:9356:2	O
Week	STRIBILD.xml:S1:9359:4	O
144	STRIBILD.xml:S1:9364:3	O
and	STRIBILD.xml:S1:9368:3	O
the	STRIBILD.xml:S1:9372:3	O
percentage	STRIBILD.xml:S1:9376:10	O
of	STRIBILD.xml:S1:9387:2	O
subjects	STRIBILD.xml:S1:9390:8	O
with	STRIBILD.xml:S1:9399:4	O
elevations	STRIBILD.xml:S1:9404:10	B-AdverseReaction
in	STRIBILD.xml:S1:9415:2	I-AdverseReaction
serum	STRIBILD.xml:S1:9418:5	I-AdverseReaction
creatinine	STRIBILD.xml:S1:9424:10	I-AdverseReaction
(	STRIBILD.xml:S1:9435:1	O
All	STRIBILD.xml:S1:9436:3	O
Grades	STRIBILD.xml:S1:9440:6	O
)	STRIBILD.xml:S1:9446:1	O
.	STRIBILD.xml:S1:9447:1	O

Table	STRIBILD.xml:S1:9453:5	O
4	STRIBILD.xml:S1:9459:1	O
Change	STRIBILD.xml:S1:9461:6	O
from	STRIBILD.xml:S1:9468:4	O
Baseline	STRIBILD.xml:S1:9473:8	O
in	STRIBILD.xml:S1:9482:2	O
Serum	STRIBILD.xml:S1:9485:5	O
Creatinine	STRIBILD.xml:S1:9491:10	O
and	STRIBILD.xml:S1:9502:3	O
eGFR	STRIBILD.xml:S1:9506:4	O
and	STRIBILD.xml:S1:9511:3	O
Incidence	STRIBILD.xml:S1:9515:9	O
of	STRIBILD.xml:S1:9525:2	O
Elevated	STRIBILD.xml:S1:9528:8	B-AdverseReaction
Serum	STRIBILD.xml:S1:9537:5	I-AdverseReaction
Creatinine	STRIBILD.xml:S1:9543:10	I-AdverseReaction
(	STRIBILD.xml:S1:9554:1	O
All	STRIBILD.xml:S1:9555:3	O
Grades	STRIBILD.xml:S1:9559:6	O
)	STRIBILD.xml:S1:9565:1	O
in	STRIBILD.xml:S1:9567:2	O
Studies	STRIBILD.xml:S1:9570:7	O
102	STRIBILD.xml:S1:9578:3	O
and	STRIBILD.xml:S1:9582:3	O
103	STRIBILD.xml:S1:9586:3	O
at	STRIBILD.xml:S1:9590:2	O
Week	STRIBILD.xml:S1:9593:4	O
144	STRIBILD.xml:S1:9598:3	O

STRIBILD	STRIBILD.xml:S1:9650:8	O
(	STRIBILD.xml:S1:9658:1	O
N	STRIBILD.xml:S1:9659:1	O
701	STRIBILD.xml:S1:9661:3	O
)	STRIBILD.xml:S1:9664:1	O
ATRIPLA	STRIBILD.xml:S1:9671:7	O
(	STRIBILD.xml:S1:9678:1	O
N	STRIBILD.xml:S1:9679:1	O
352	STRIBILD.xml:S1:9681:3	O
)	STRIBILD.xml:S1:9684:1	O
ATV	STRIBILD.xml:S1:9689:3	O
RTV	STRIBILD.xml:S1:9695:3	O
TRUVADA	STRIBILD.xml:S1:9701:7	O
(	STRIBILD.xml:S1:9708:1	O
N	STRIBILD.xml:S1:9709:1	O
355	STRIBILD.xml:S1:9711:3	O
)	STRIBILD.xml:S1:9714:1	O

Serum	STRIBILD.xml:S1:9723:5	O

Creatinine	STRIBILD.xml:S1:9729:10	O
(	STRIBILD.xml:S1:9740:1	O
mg	STRIBILD.xml:S1:9741:2	O
dL	STRIBILD.xml:S1:9744:2	O
)	STRIBILD.xml:S1:9746:1	O
0.14	STRIBILD.xml:S1:9770:4	O
(	STRIBILD.xml:S1:9775:1	O
-	STRIBILD.xml:S1:9778:1	O
0.14	STRIBILD.xml:S1:9779:4	O
)	STRIBILD.xml:S1:9783:1	O
0.01	STRIBILD.xml:S1:9790:4	O
(	STRIBILD.xml:S1:9795:1	O
-	STRIBILD.xml:S1:9798:1	O
0.12	STRIBILD.xml:S1:9799:4	O
)	STRIBILD.xml:S1:9803:1	O
0.09	STRIBILD.xml:S1:9811:4	O
(	STRIBILD.xml:S1:9816:1	O
-	STRIBILD.xml:S1:9819:1	O
0.15	STRIBILD.xml:S1:9820:4	O
)	STRIBILD.xml:S1:9824:1	O

eGFR	STRIBILD.xml:S1:9834:4	O
by	STRIBILD.xml:S1:9839:2	O
Cockcroft	STRIBILD.xml:S1:9842:9	O
-	STRIBILD.xml:S1:9851:1	O
Gault	STRIBILD.xml:S1:9852:5	O
(	STRIBILD.xml:S1:9858:1	O
mL	STRIBILD.xml:S1:9859:2	O
minute	STRIBILD.xml:S1:9862:6	O
)	STRIBILD.xml:S1:9868:1	O
-	STRIBILD.xml:S1:9880:1	O
14.0	STRIBILD.xml:S1:9881:4	O
(	STRIBILD.xml:S1:9886:1	O
-	STRIBILD.xml:S1:9889:1	O
16.6	STRIBILD.xml:S1:9890:4	O
)	STRIBILD.xml:S1:9894:1	O
-	STRIBILD.xml:S1:9901:1	O
1.9	STRIBILD.xml:S1:9902:3	O
(	STRIBILD.xml:S1:9906:1	O
-	STRIBILD.xml:S1:9909:1	O
17.9	STRIBILD.xml:S1:9910:4	O
)	STRIBILD.xml:S1:9914:1	O
-	STRIBILD.xml:S1:9922:1	O
9.8	STRIBILD.xml:S1:9923:3	O
(	STRIBILD.xml:S1:9927:1	O
-	STRIBILD.xml:S1:9930:1	O
19.4	STRIBILD.xml:S1:9931:4	O
)	STRIBILD.xml:S1:9935:1	O

Subjects	STRIBILD.xml:S1:9945:8	O
with	STRIBILD.xml:S1:9954:4	O
Elevations	STRIBILD.xml:S1:9959:10	B-AdverseReaction
in	STRIBILD.xml:S1:9970:2	I-AdverseReaction
Serum	STRIBILD.xml:S1:9973:5	I-AdverseReaction
Creatinine	STRIBILD.xml:S1:9979:10	I-AdverseReaction
(	STRIBILD.xml:S1:9990:1	O
All	STRIBILD.xml:S1:9991:3	O
Grades	STRIBILD.xml:S1:9995:6	O
)(	STRIBILD.xml:S1:10001:2	O
)	STRIBILD.xml:S1:10004:1	O
12	STRIBILD.xml:S1:10015:2	O
2	STRIBILD.xml:S1:10035:1	O
6	STRIBILD.xml:S1:10057:1	O

Emtricitabine	STRIBILD.xml:S1:10086:13	O
or	STRIBILD.xml:S1:10100:2	O
Tenofovir	STRIBILD.xml:S1:10103:9	O
DF	STRIBILD.xml:S1:10113:2	O
:	STRIBILD.xml:S1:10115:1	O
In	STRIBILD.xml:S1:10118:2	O
addition	STRIBILD.xml:S1:10121:8	O
to	STRIBILD.xml:S1:10130:2	O
the	STRIBILD.xml:S1:10133:3	O
laboratory	STRIBILD.xml:S1:10137:10	O
abnormalities	STRIBILD.xml:S1:10148:13	O
observed	STRIBILD.xml:S1:10162:8	O
with	STRIBILD.xml:S1:10171:4	O
STRIBILD	STRIBILD.xml:S1:10176:8	O
,	STRIBILD.xml:S1:10184:1	O
the	STRIBILD.xml:S1:10186:3	O
following	STRIBILD.xml:S1:10190:9	O
laboratory	STRIBILD.xml:S1:10200:10	O
abnormalities	STRIBILD.xml:S1:10211:13	O
have	STRIBILD.xml:S1:10225:4	O
been	STRIBILD.xml:S1:10230:4	O
previously	STRIBILD.xml:S1:10235:10	O
reported	STRIBILD.xml:S1:10246:8	O
in	STRIBILD.xml:S1:10255:2	O
subjects	STRIBILD.xml:S1:10258:8	O
treated	STRIBILD.xml:S1:10267:7	O
with	STRIBILD.xml:S1:10275:4	O
emtricitabine	STRIBILD.xml:S1:10280:13	O
or	STRIBILD.xml:S1:10294:2	O
tenofovir	STRIBILD.xml:S1:10297:9	O
DF	STRIBILD.xml:S1:10307:2	O
with	STRIBILD.xml:S1:10310:4	O
other	STRIBILD.xml:S1:10315:5	O
antiretroviral	STRIBILD.xml:S1:10321:14	O
agents	STRIBILD.xml:S1:10336:6	O
in	STRIBILD.xml:S1:10343:2	O
other	STRIBILD.xml:S1:10346:5	O
clinical	STRIBILD.xml:S1:10352:8	O
trials	STRIBILD.xml:S1:10361:6	O
:	STRIBILD.xml:S1:10367:1	O
Grade	STRIBILD.xml:S1:10369:5	B-Severity
3	STRIBILD.xml:S1:10375:1	I-Severity
or	STRIBILD.xml:S1:10377:2	O
4	STRIBILD.xml:S1:10380:1	I-Severity
laboratory	STRIBILD.xml:S1:10382:10	O
abnormalities	STRIBILD.xml:S1:10393:13	B-AdverseReaction
of	STRIBILD.xml:S1:10407:2	I-AdverseReaction
ALT	STRIBILD.xml:S1:10410:3	I-AdverseReaction
(	STRIBILD.xml:S1:10414:1	O
M	STRIBILD.xml:S1:10415:1	O
:	STRIBILD.xml:S1:10416:1	O
greater	STRIBILD.xml:S1:10418:7	O
than	STRIBILD.xml:S1:10426:4	O
215	STRIBILD.xml:S1:10431:3	B-Severity
U	STRIBILD.xml:S1:10435:1	I-Severity
per	STRIBILD.xml:S1:10437:3	I-Severity
L	STRIBILD.xml:S1:10441:1	I-Severity
;	STRIBILD.xml:S1:10442:1	O
F	STRIBILD.xml:S1:10444:1	O
:	STRIBILD.xml:S1:10445:1	O
greater	STRIBILD.xml:S1:10447:7	O
than	STRIBILD.xml:S1:10455:4	O
170	STRIBILD.xml:S1:10460:3	B-Severity
U	STRIBILD.xml:S1:10464:1	I-Severity
per	STRIBILD.xml:S1:10466:3	I-Severity
L	STRIBILD.xml:S1:10470:1	I-Severity
)	STRIBILD.xml:S1:10471:1	O
,	STRIBILD.xml:S1:10472:1	O
alkaline	STRIBILD.xml:S1:10474:8	I-AdverseReaction
phosphatase	STRIBILD.xml:S1:10483:11	I-AdverseReaction
(	STRIBILD.xml:S1:10495:1	O
greater	STRIBILD.xml:S1:10496:7	O
than	STRIBILD.xml:S1:10504:4	O
550	STRIBILD.xml:S1:10509:3	B-Severity
U	STRIBILD.xml:S1:10513:1	I-Severity
per	STRIBILD.xml:S1:10515:3	I-Severity
L	STRIBILD.xml:S1:10519:1	I-Severity
)	STRIBILD.xml:S1:10520:1	O
,	STRIBILD.xml:S1:10521:1	O
bilirubin	STRIBILD.xml:S1:10523:9	I-AdverseReaction
(	STRIBILD.xml:S1:10533:1	O
greater	STRIBILD.xml:S1:10534:7	O
than	STRIBILD.xml:S1:10542:4	O
2.5	STRIBILD.xml:S1:10547:3	B-Severity
ULN	STRIBILD.xml:S1:10553:3	I-Severity
)	STRIBILD.xml:S1:10556:1	O
,	STRIBILD.xml:S1:10557:1	O
serum	STRIBILD.xml:S1:10559:5	I-AdverseReaction
glucose	STRIBILD.xml:S1:10565:7	I-AdverseReaction
(	STRIBILD.xml:S1:10573:1	O
less	STRIBILD.xml:S1:10574:4	O
than	STRIBILD.xml:S1:10579:4	O
40	STRIBILD.xml:S1:10584:2	B-Severity
or	STRIBILD.xml:S1:10587:2	O
greater	STRIBILD.xml:S1:10590:7	O
than	STRIBILD.xml:S1:10598:4	O
250	STRIBILD.xml:S1:10603:3	B-Severity
mg	STRIBILD.xml:S1:10607:2	I-Severity
per	STRIBILD.xml:S1:10610:3	I-Severity
dL	STRIBILD.xml:S1:10614:2	I-Severity
)	STRIBILD.xml:S1:10616:1	O
,	STRIBILD.xml:S1:10617:1	O
glycosuria	STRIBILD.xml:S1:10619:10	I-AdverseReaction
(	STRIBILD.xml:S1:10630:1	O
greater	STRIBILD.xml:S1:10631:7	O
than	STRIBILD.xml:S1:10639:4	O
or	STRIBILD.xml:S1:10644:2	O
equal	STRIBILD.xml:S1:10647:5	O
to	STRIBILD.xml:S1:10653:2	O
3	STRIBILD.xml:S1:10656:1	B-Severity
)	STRIBILD.xml:S1:10658:1	O
,	STRIBILD.xml:S1:10659:1	O
neutrophils	STRIBILD.xml:S1:10661:11	I-AdverseReaction
(	STRIBILD.xml:S1:10673:1	O
less	STRIBILD.xml:S1:10674:4	O
than	STRIBILD.xml:S1:10679:4	O
750	STRIBILD.xml:S1:10684:3	B-Severity
per	STRIBILD.xml:S1:10688:3	I-Severity
mm	STRIBILD.xml:S1:10692:2	I-Severity
3	STRIBILD.xml:S1:10696:1	I-Severity
)	STRIBILD.xml:S1:10699:1	O
,	STRIBILD.xml:S1:10700:1	O
fasting	STRIBILD.xml:S1:10702:7	I-AdverseReaction
cholesterol	STRIBILD.xml:S1:10710:11	I-AdverseReaction
(	STRIBILD.xml:S1:10722:1	O
greater	STRIBILD.xml:S1:10723:7	O
than	STRIBILD.xml:S1:10731:4	O
240	STRIBILD.xml:S1:10736:3	B-Severity
mg	STRIBILD.xml:S1:10740:2	I-Severity
per	STRIBILD.xml:S1:10743:3	I-Severity
dL	STRIBILD.xml:S1:10747:2	I-Severity
)	STRIBILD.xml:S1:10749:1	O
,	STRIBILD.xml:S1:10750:1	O
and	STRIBILD.xml:S1:10752:3	O
fasting	STRIBILD.xml:S1:10756:7	I-AdverseReaction
triglycerides	STRIBILD.xml:S1:10764:13	I-AdverseReaction
(	STRIBILD.xml:S1:10778:1	O
greater	STRIBILD.xml:S1:10779:7	O
than	STRIBILD.xml:S1:10787:4	O
750	STRIBILD.xml:S1:10792:3	B-Severity
mg	STRIBILD.xml:S1:10796:2	I-Severity
per	STRIBILD.xml:S1:10799:3	I-Severity
dL	STRIBILD.xml:S1:10803:2	I-Severity
)	STRIBILD.xml:S1:10805:1	O
.	STRIBILD.xml:S1:10806:1	O

Serum	STRIBILD.xml:S1:10816:5	O

Lipids	STRIBILD.xml:S1:10822:6	O
:	STRIBILD.xml:S1:10828:1	O
In	STRIBILD.xml:S1:10831:2	O
the	STRIBILD.xml:S1:10834:3	O
clinical	STRIBILD.xml:S1:10838:8	O
trials	STRIBILD.xml:S1:10847:6	O
of	STRIBILD.xml:S1:10854:2	O
STRIBILD	STRIBILD.xml:S1:10857:8	O
,	STRIBILD.xml:S1:10865:1	O
a	STRIBILD.xml:S1:10867:1	O
similar	STRIBILD.xml:S1:10869:7	O
percentage	STRIBILD.xml:S1:10877:10	O
of	STRIBILD.xml:S1:10888:2	O
subjects	STRIBILD.xml:S1:10891:8	O
receiving	STRIBILD.xml:S1:10900:9	O
STRIBILD	STRIBILD.xml:S1:10910:8	O
,	STRIBILD.xml:S1:10918:1	O
ATRIPLA	STRIBILD.xml:S1:10920:7	O
,	STRIBILD.xml:S1:10927:1	O
and	STRIBILD.xml:S1:10929:3	O
ATV	STRIBILD.xml:S1:10933:3	O
RTV	STRIBILD.xml:S1:10939:3	O
TRUVADA	STRIBILD.xml:S1:10945:7	O
were	STRIBILD.xml:S1:10953:4	O
on	STRIBILD.xml:S1:10958:2	O
lipid	STRIBILD.xml:S1:10961:5	O
lowering	STRIBILD.xml:S1:10967:8	O
agents	STRIBILD.xml:S1:10976:6	O
at	STRIBILD.xml:S1:10983:2	O
baseline	STRIBILD.xml:S1:10986:8	O
(	STRIBILD.xml:S1:10995:1	O
12%	STRIBILD.xml:S1:10996:3	O
,	STRIBILD.xml:S1:10999:1	O
12%	STRIBILD.xml:S1:11001:3	O
,	STRIBILD.xml:S1:11004:1	O
and	STRIBILD.xml:S1:11006:3	O
13%	STRIBILD.xml:S1:11010:3	O
,	STRIBILD.xml:S1:11013:1	O
respectively	STRIBILD.xml:S1:11015:12	O
)	STRIBILD.xml:S1:11027:1	O
.	STRIBILD.xml:S1:11028:1	O

While	STRIBILD.xml:S1:11030:5	O
receiving	STRIBILD.xml:S1:11036:9	O
study	STRIBILD.xml:S1:11046:5	O
drug	STRIBILD.xml:S1:11052:4	O
through	STRIBILD.xml:S1:11057:7	O
Week	STRIBILD.xml:S1:11065:4	O
144	STRIBILD.xml:S1:11070:3	O
,	STRIBILD.xml:S1:11073:1	O
an	STRIBILD.xml:S1:11075:2	O
additional	STRIBILD.xml:S1:11078:10	O
11%	STRIBILD.xml:S1:11089:3	O
of	STRIBILD.xml:S1:11093:2	O
STRIBILD	STRIBILD.xml:S1:11096:8	O
subjects	STRIBILD.xml:S1:11105:8	O
were	STRIBILD.xml:S1:11114:4	O
started	STRIBILD.xml:S1:11119:7	O
on	STRIBILD.xml:S1:11127:2	O
lipid	STRIBILD.xml:S1:11130:5	O
lowering	STRIBILD.xml:S1:11136:8	O
agents	STRIBILD.xml:S1:11145:6	O
,	STRIBILD.xml:S1:11151:1	O
compared	STRIBILD.xml:S1:11153:8	O
to	STRIBILD.xml:S1:11162:2	O
13%	STRIBILD.xml:S1:11165:3	O
of	STRIBILD.xml:S1:11169:2	O
ATRIPLA	STRIBILD.xml:S1:11172:7	O
and	STRIBILD.xml:S1:11180:3	O
12%	STRIBILD.xml:S1:11184:3	O
of	STRIBILD.xml:S1:11188:2	O
ATV	STRIBILD.xml:S1:11191:3	O
RTV	STRIBILD.xml:S1:11197:3	O
TRUVADA	STRIBILD.xml:S1:11203:7	O
subjects	STRIBILD.xml:S1:11211:8	O
.	STRIBILD.xml:S1:11219:1	O

Changes	STRIBILD.xml:S1:11225:7	O
from	STRIBILD.xml:S1:11233:4	O
baseline	STRIBILD.xml:S1:11238:8	O
in	STRIBILD.xml:S1:11247:2	O
total	STRIBILD.xml:S1:11250:5	O
cholesterol	STRIBILD.xml:S1:11256:11	O
,	STRIBILD.xml:S1:11267:1	O
HDL	STRIBILD.xml:S1:11269:3	O
-	STRIBILD.xml:S1:11272:1	O
cholesterol	STRIBILD.xml:S1:11273:11	O
,	STRIBILD.xml:S1:11284:1	O
LDL	STRIBILD.xml:S1:11286:3	O
-	STRIBILD.xml:S1:11289:1	O
cholesterol	STRIBILD.xml:S1:11290:11	O
,	STRIBILD.xml:S1:11301:1	O
and	STRIBILD.xml:S1:11303:3	O
triglycerides	STRIBILD.xml:S1:11307:13	O
are	STRIBILD.xml:S1:11321:3	O
presented	STRIBILD.xml:S1:11325:9	O
in	STRIBILD.xml:S1:11335:2	O
Table	STRIBILD.xml:S1:11338:5	O
5	STRIBILD.xml:S1:11344:1	O
.	STRIBILD.xml:S1:11345:1	O

Table	STRIBILD.xml:S1:11351:5	O
5	STRIBILD.xml:S1:11357:1	O
Lipid	STRIBILD.xml:S1:11359:5	O
Values	STRIBILD.xml:S1:11365:6	O
,	STRIBILD.xml:S1:11371:1	O
Mean	STRIBILD.xml:S1:11373:4	O
Change	STRIBILD.xml:S1:11378:6	O
from	STRIBILD.xml:S1:11385:4	O
Baseline	STRIBILD.xml:S1:11390:8	O
at	STRIBILD.xml:S1:11399:2	O
Week	STRIBILD.xml:S1:11402:4	O
144	STRIBILD.xml:S1:11407:3	O
in	STRIBILD.xml:S1:11411:2	O
Subjects	STRIBILD.xml:S1:11414:8	O
Receiving	STRIBILD.xml:S1:11423:9	O
STRIBILD	STRIBILD.xml:S1:11433:8	O
or	STRIBILD.xml:S1:11442:2	O
Comparator	STRIBILD.xml:S1:11445:10	O
in	STRIBILD.xml:S1:11456:2	O
Studies	STRIBILD.xml:S1:11459:7	O
102	STRIBILD.xml:S1:11467:3	O
and	STRIBILD.xml:S1:11471:3	O
103	STRIBILD.xml:S1:11475:3	O

STRIBILDN	STRIBILD.xml:S1:11502:9	O
701	STRIBILD.xml:S1:11512:3	O
ATRIPLAN	STRIBILD.xml:S1:11518:8	O
352	STRIBILD.xml:S1:11527:3	O
ATV	STRIBILD.xml:S1:11533:3	O
RTV	STRIBILD.xml:S1:11539:3	O
TRUVADAN	STRIBILD.xml:S1:11545:8	O
355	STRIBILD.xml:S1:11554:3	O

Baseline	STRIBILD.xml:S1:11562:8	O
Week	STRIBILD.xml:S1:11585:4	O
144	STRIBILD.xml:S1:11590:3	O
Baseline	STRIBILD.xml:S1:11601:8	O
Week	STRIBILD.xml:S1:11616:4	O
144	STRIBILD.xml:S1:11621:3	O
Baseline	STRIBILD.xml:S1:11632:8	O
Week	STRIBILD.xml:S1:11647:4	O
144	STRIBILD.xml:S1:11652:3	O

mg	STRIBILD.xml:S1:11663:2	O
dL	STRIBILD.xml:S1:11666:2	O
Change	STRIBILD.xml:S1:11687:6	O
mg	STRIBILD.xml:S1:11703:2	O
dL	STRIBILD.xml:S1:11706:2	O
Change	STRIBILD.xml:S1:11718:6	O
mg	STRIBILD.xml:S1:11734:2	O
dL	STRIBILD.xml:S1:11737:2	O
Change	STRIBILD.xml:S1:11749:6	O

Total	STRIBILD.xml:S1:11767:5	O

Cholesterol	STRIBILD.xml:S1:11773:11	O
(	STRIBILD.xml:S1:11785:1	O
fasted	STRIBILD.xml:S1:11786:6	O
)	STRIBILD.xml:S1:11792:1	O
166	STRIBILD.xml:S1:11796:3	O
[	STRIBILD.xml:S1:11799:1	O
N	STRIBILD.xml:S1:11800:1	O
675	STRIBILD.xml:S1:11802:3	O
]	STRIBILD.xml:S1:11805:1	O
17	STRIBILD.xml:S1:11813:2	O
[	STRIBILD.xml:S1:11815:1	O
N	STRIBILD.xml:S1:11816:1	O
535	STRIBILD.xml:S1:11818:3	O
]	STRIBILD.xml:S1:11821:1	O
161	STRIBILD.xml:S1:11827:3	O
[	STRIBILD.xml:S1:11830:1	O
N	STRIBILD.xml:S1:11831:1	O
343	STRIBILD.xml:S1:11833:3	O
]	STRIBILD.xml:S1:11836:1	O
22	STRIBILD.xml:S1:11844:2	O
[	STRIBILD.xml:S1:11846:1	O
N	STRIBILD.xml:S1:11847:1	O
262	STRIBILD.xml:S1:11849:3	O
]	STRIBILD.xml:S1:11852:1	O
168	STRIBILD.xml:S1:11858:3	O
[	STRIBILD.xml:S1:11861:1	O
N	STRIBILD.xml:S1:11862:1	O
337	STRIBILD.xml:S1:11864:3	O
]	STRIBILD.xml:S1:11867:1	O
16	STRIBILD.xml:S1:11875:2	O
[	STRIBILD.xml:S1:11877:1	O
N	STRIBILD.xml:S1:11878:1	O
243	STRIBILD.xml:S1:11880:3	O
]	STRIBILD.xml:S1:11883:1	O

HDL	STRIBILD.xml:S1:11891:3	O
-	STRIBILD.xml:S1:11894:1	O
cholesterol	STRIBILD.xml:S1:11895:11	O
(	STRIBILD.xml:S1:11907:1	O
fasted	STRIBILD.xml:S1:11908:6	O
)	STRIBILD.xml:S1:11914:1	O
43	STRIBILD.xml:S1:11919:2	O
[	STRIBILD.xml:S1:11921:1	O
N	STRIBILD.xml:S1:11922:1	O
675	STRIBILD.xml:S1:11924:3	O
]	STRIBILD.xml:S1:11927:1	O
7	STRIBILD.xml:S1:11935:1	O
[	STRIBILD.xml:S1:11936:1	O
N	STRIBILD.xml:S1:11937:1	O
535	STRIBILD.xml:S1:11939:3	O
]	STRIBILD.xml:S1:11942:1	O
43	STRIBILD.xml:S1:11950:2	O
[	STRIBILD.xml:S1:11952:1	O
N	STRIBILD.xml:S1:11953:1	O
343	STRIBILD.xml:S1:11955:3	O
]	STRIBILD.xml:S1:11958:1	O
9	STRIBILD.xml:S1:11966:1	O
[	STRIBILD.xml:S1:11967:1	O
N	STRIBILD.xml:S1:11968:1	O
262	STRIBILD.xml:S1:11970:3	O
]	STRIBILD.xml:S1:11973:1	O
42	STRIBILD.xml:S1:11981:2	O
[	STRIBILD.xml:S1:11983:1	O
N	STRIBILD.xml:S1:11984:1	O
335	STRIBILD.xml:S1:11986:3	O
]	STRIBILD.xml:S1:11989:1	O
7	STRIBILD.xml:S1:11997:1	O
[	STRIBILD.xml:S1:11998:1	O
N	STRIBILD.xml:S1:11999:1	O
242	STRIBILD.xml:S1:12001:3	O
]	STRIBILD.xml:S1:12004:1	O

LDL	STRIBILD.xml:S1:12013:3	O
-	STRIBILD.xml:S1:12016:1	O
cholesterol	STRIBILD.xml:S1:12017:11	O
(	STRIBILD.xml:S1:12029:1	O
fasted	STRIBILD.xml:S1:12030:6	O
)	STRIBILD.xml:S1:12036:1	O
100	STRIBILD.xml:S1:12040:3	O
[	STRIBILD.xml:S1:12043:1	O
N	STRIBILD.xml:S1:12044:1	O
675	STRIBILD.xml:S1:12046:3	O
]	STRIBILD.xml:S1:12049:1	O
15	STRIBILD.xml:S1:12057:2	O
[	STRIBILD.xml:S1:12059:1	O
N	STRIBILD.xml:S1:12060:1	O
535	STRIBILD.xml:S1:12062:3	O
]	STRIBILD.xml:S1:12065:1	O
97	STRIBILD.xml:S1:12072:2	O
[	STRIBILD.xml:S1:12074:1	O
N	STRIBILD.xml:S1:12075:1	O
343	STRIBILD.xml:S1:12077:3	O
]	STRIBILD.xml:S1:12080:1	O
19	STRIBILD.xml:S1:12088:2	O
[	STRIBILD.xml:S1:12090:1	O
N	STRIBILD.xml:S1:12091:1	O
262	STRIBILD.xml:S1:12093:3	O
]	STRIBILD.xml:S1:12096:1	O
101	STRIBILD.xml:S1:12102:3	O
[	STRIBILD.xml:S1:12105:1	O
N	STRIBILD.xml:S1:12106:1	O
337	STRIBILD.xml:S1:12108:3	O
]	STRIBILD.xml:S1:12111:1	O
18	STRIBILD.xml:S1:12119:2	O
[	STRIBILD.xml:S1:12121:1	O
N	STRIBILD.xml:S1:12122:1	O
242	STRIBILD.xml:S1:12124:3	O
]	STRIBILD.xml:S1:12127:1	O

Triglycerides	STRIBILD.xml:S1:12135:13	O
(	STRIBILD.xml:S1:12149:1	O
fasted	STRIBILD.xml:S1:12150:6	O
)	STRIBILD.xml:S1:12156:1	O
122	STRIBILD.xml:S1:12160:3	O
[	STRIBILD.xml:S1:12163:1	O
N	STRIBILD.xml:S1:12164:1	O
675	STRIBILD.xml:S1:12166:3	O
]	STRIBILD.xml:S1:12169:1	O
12	STRIBILD.xml:S1:12177:2	O
[	STRIBILD.xml:S1:12179:1	O
N	STRIBILD.xml:S1:12180:1	O
535	STRIBILD.xml:S1:12182:3	O
]	STRIBILD.xml:S1:12185:1	O
121	STRIBILD.xml:S1:12191:3	O
[	STRIBILD.xml:S1:12194:1	O
N	STRIBILD.xml:S1:12195:1	O
343	STRIBILD.xml:S1:12197:3	O
]	STRIBILD.xml:S1:12200:1	O
5	STRIBILD.xml:S1:12208:1	O
[	STRIBILD.xml:S1:12209:1	O
N	STRIBILD.xml:S1:12210:1	O
262	STRIBILD.xml:S1:12212:3	O
]	STRIBILD.xml:S1:12215:1	O
132	STRIBILD.xml:S1:12222:3	O
[	STRIBILD.xml:S1:12225:1	O
N	STRIBILD.xml:S1:12226:1	O
337	STRIBILD.xml:S1:12228:3	O
]	STRIBILD.xml:S1:12231:1	O
22	STRIBILD.xml:S1:12239:2	O
[	STRIBILD.xml:S1:12241:1	O
N	STRIBILD.xml:S1:12242:1	O
242	STRIBILD.xml:S1:12244:3	O
]	STRIBILD.xml:S1:12247:1	O

6.2	STRIBILD.xml:S1:12269:3	O
Postmarketing	STRIBILD.xml:S1:12273:13	O
Experience	STRIBILD.xml:S1:12287:10	O

The	STRIBILD.xml:S1:12301:3	O
following	STRIBILD.xml:S1:12305:9	O
adverse	STRIBILD.xml:S1:12315:7	O
reactions	STRIBILD.xml:S1:12323:9	O
have	STRIBILD.xml:S1:12333:4	O
been	STRIBILD.xml:S1:12338:4	O
identified	STRIBILD.xml:S1:12343:10	O
during	STRIBILD.xml:S1:12354:6	O
post	STRIBILD.xml:S1:12361:4	O
approval	STRIBILD.xml:S1:12366:8	O
use	STRIBILD.xml:S1:12375:3	O
of	STRIBILD.xml:S1:12379:2	O
tenofovir	STRIBILD.xml:S1:12382:9	O
DF	STRIBILD.xml:S1:12392:2	O
.	STRIBILD.xml:S1:12394:1	O

Because	STRIBILD.xml:S1:12396:7	O
postmarketing	STRIBILD.xml:S1:12404:13	O
reactions	STRIBILD.xml:S1:12418:9	O
are	STRIBILD.xml:S1:12428:3	O
reported	STRIBILD.xml:S1:12432:8	O
voluntarily	STRIBILD.xml:S1:12441:11	O
from	STRIBILD.xml:S1:12453:4	O
a	STRIBILD.xml:S1:12458:1	O
population	STRIBILD.xml:S1:12460:10	O
of	STRIBILD.xml:S1:12471:2	O
uncertain	STRIBILD.xml:S1:12474:9	O
size	STRIBILD.xml:S1:12484:4	O
,	STRIBILD.xml:S1:12488:1	O
it	STRIBILD.xml:S1:12490:2	O
is	STRIBILD.xml:S1:12493:2	O
not	STRIBILD.xml:S1:12496:3	O
always	STRIBILD.xml:S1:12500:6	O
possible	STRIBILD.xml:S1:12507:8	O
to	STRIBILD.xml:S1:12516:2	O
reliably	STRIBILD.xml:S1:12519:8	O
estimate	STRIBILD.xml:S1:12528:8	O
their	STRIBILD.xml:S1:12537:5	O
frequency	STRIBILD.xml:S1:12543:9	O
or	STRIBILD.xml:S1:12553:2	O
establish	STRIBILD.xml:S1:12556:9	O
a	STRIBILD.xml:S1:12566:1	O
causal	STRIBILD.xml:S1:12568:6	O
relationship	STRIBILD.xml:S1:12575:12	O
to	STRIBILD.xml:S1:12588:2	O
drug	STRIBILD.xml:S1:12591:4	O
exposure	STRIBILD.xml:S1:12596:8	O
.	STRIBILD.xml:S1:12604:1	O

No	STRIBILD.xml:S1:12606:2	O
additional	STRIBILD.xml:S1:12609:10	O
postmarketing	STRIBILD.xml:S1:12620:13	O
adverse	STRIBILD.xml:S1:12634:7	O
reactions	STRIBILD.xml:S1:12642:9	O
specific	STRIBILD.xml:S1:12652:8	O
for	STRIBILD.xml:S1:12661:3	O
emtricitabine	STRIBILD.xml:S1:12665:13	O
have	STRIBILD.xml:S1:12679:4	O
been	STRIBILD.xml:S1:12684:4	O
identified	STRIBILD.xml:S1:12689:10	O
.	STRIBILD.xml:S1:12699:1	O

Immune	STRIBILD.xml:S1:12707:6	O
System	STRIBILD.xml:S1:12714:6	O
Disorders	STRIBILD.xml:S1:12721:9	O

allergic	STRIBILD.xml:S1:12737:8	B-AdverseReaction
reaction	STRIBILD.xml:S1:12746:8	I-AdverseReaction
,	STRIBILD.xml:S1:12754:1	O
including	STRIBILD.xml:S1:12756:9	O
angioedema	STRIBILD.xml:S1:12766:10	B-AdverseReaction

Metabolism	STRIBILD.xml:S1:12783:10	O
and	STRIBILD.xml:S1:12794:3	O
Nutrition	STRIBILD.xml:S1:12798:9	O
Disorders	STRIBILD.xml:S1:12808:9	O

lactic	STRIBILD.xml:S1:12824:6	B-AdverseReaction
acidosis	STRIBILD.xml:S1:12831:8	I-AdverseReaction
,	STRIBILD.xml:S1:12839:1	O
hypokalemia	STRIBILD.xml:S1:12841:11	B-AdverseReaction
,	STRIBILD.xml:S1:12852:1	O
hypophosphatemia	STRIBILD.xml:S1:12854:16	B-AdverseReaction

Respiratory	STRIBILD.xml:S1:12877:11	O
,	STRIBILD.xml:S1:12888:1	O
Thoracic	STRIBILD.xml:S1:12890:8	O
,	STRIBILD.xml:S1:12898:1	O
and	STRIBILD.xml:S1:12900:3	O
Mediastinal	STRIBILD.xml:S1:12904:11	O
Disorders	STRIBILD.xml:S1:12916:9	O

dyspnea	STRIBILD.xml:S1:12932:7	B-AdverseReaction

Gastrointestinal	STRIBILD.xml:S1:12946:16	O
Disorders	STRIBILD.xml:S1:12963:9	O

pancreatitis	STRIBILD.xml:S1:12979:12	B-AdverseReaction
,	STRIBILD.xml:S1:12991:1	O
increased	STRIBILD.xml:S1:12993:9	B-AdverseReaction
amylase	STRIBILD.xml:S1:13003:7	I-AdverseReaction
,	STRIBILD.xml:S1:13010:1	O
abdominal	STRIBILD.xml:S1:13012:9	B-AdverseReaction
pain	STRIBILD.xml:S1:13022:4	I-AdverseReaction

Hepatobiliary	STRIBILD.xml:S1:13033:13	O
Disorders	STRIBILD.xml:S1:13047:9	O

hepatic	STRIBILD.xml:S1:13063:7	B-AdverseReaction
steatosis	STRIBILD.xml:S1:13071:9	I-AdverseReaction
,	STRIBILD.xml:S1:13080:1	O
hepatitis	STRIBILD.xml:S1:13082:9	B-AdverseReaction
,	STRIBILD.xml:S1:13091:1	O
increased	STRIBILD.xml:S1:13093:9	B-AdverseReaction
liver	STRIBILD.xml:S1:13103:5	I-AdverseReaction
enzymes	STRIBILD.xml:S1:13109:7	I-AdverseReaction
(	STRIBILD.xml:S1:13117:1	O
most	STRIBILD.xml:S1:13118:4	O
commonly	STRIBILD.xml:S1:13123:8	O
AST	STRIBILD.xml:S1:13132:3	I-AdverseReaction
,	STRIBILD.xml:S1:13135:1	O
ALT	STRIBILD.xml:S1:13137:3	I-AdverseReaction
gamma	STRIBILD.xml:S1:13141:5	I-AdverseReaction
GT	STRIBILD.xml:S1:13147:2	I-AdverseReaction
)	STRIBILD.xml:S1:13149:1	O

Skin	STRIBILD.xml:S1:13157:4	O
and	STRIBILD.xml:S1:13162:3	O
Subcutaneous	STRIBILD.xml:S1:13166:12	O
Tissue	STRIBILD.xml:S1:13179:6	O
Disorders	STRIBILD.xml:S1:13186:9	O

rash	STRIBILD.xml:S1:13202:4	B-AdverseReaction

Musculoskeletal	STRIBILD.xml:S1:13213:15	O
and	STRIBILD.xml:S1:13229:3	O
Connective	STRIBILD.xml:S1:13233:10	O
Tissue	STRIBILD.xml:S1:13244:6	O
Disorders	STRIBILD.xml:S1:13251:9	O

rhabdomyolysis	STRIBILD.xml:S1:13267:14	B-AdverseReaction
,	STRIBILD.xml:S1:13281:1	O
osteomalacia	STRIBILD.xml:S1:13283:12	B-AdverseReaction
(	STRIBILD.xml:S1:13296:1	O
manifested	STRIBILD.xml:S1:13297:10	O
as	STRIBILD.xml:S1:13308:2	O
bone	STRIBILD.xml:S1:13311:4	B-AdverseReaction
pain	STRIBILD.xml:S1:13316:4	I-AdverseReaction
and	STRIBILD.xml:S1:13321:3	O
which	STRIBILD.xml:S1:13325:5	O
may	STRIBILD.xml:S1:13331:3	O
contribute	STRIBILD.xml:S1:13335:10	O
to	STRIBILD.xml:S1:13346:2	O
fractures	STRIBILD.xml:S1:13349:9	B-AdverseReaction
)	STRIBILD.xml:S1:13358:1	O
,	STRIBILD.xml:S1:13359:1	O
muscular	STRIBILD.xml:S1:13361:8	B-AdverseReaction
weakness	STRIBILD.xml:S1:13370:8	I-AdverseReaction
,	STRIBILD.xml:S1:13378:1	O
myopathy	STRIBILD.xml:S1:13380:8	B-AdverseReaction

Renal	STRIBILD.xml:S1:13395:5	O
and	STRIBILD.xml:S1:13401:3	O
Urinary	STRIBILD.xml:S1:13405:7	O
Disorders	STRIBILD.xml:S1:13413:9	O

acute	STRIBILD.xml:S1:13429:5	B-AdverseReaction
renal	STRIBILD.xml:S1:13435:5	I-AdverseReaction
failure	STRIBILD.xml:S1:13441:7	I-AdverseReaction
,	STRIBILD.xml:S1:13448:1	O
renal	STRIBILD.xml:S1:13450:5	B-AdverseReaction
failure	STRIBILD.xml:S1:13456:7	I-AdverseReaction
,	STRIBILD.xml:S1:13463:1	O
acute	STRIBILD.xml:S1:13465:5	B-AdverseReaction
tubular	STRIBILD.xml:S1:13471:7	I-AdverseReaction
necrosis	STRIBILD.xml:S1:13479:8	I-AdverseReaction
,	STRIBILD.xml:S1:13487:1	O
Fanconi	STRIBILD.xml:S1:13489:7	B-AdverseReaction
syndrome	STRIBILD.xml:S1:13497:8	I-AdverseReaction
,	STRIBILD.xml:S1:13505:1	O
proximal	STRIBILD.xml:S1:13507:8	B-AdverseReaction
renal	STRIBILD.xml:S1:13516:5	I-AdverseReaction
tubulopathy	STRIBILD.xml:S1:13522:11	I-AdverseReaction
,	STRIBILD.xml:S1:13533:1	O
interstitial	STRIBILD.xml:S1:13535:12	B-AdverseReaction
nephritis	STRIBILD.xml:S1:13548:9	I-AdverseReaction
(	STRIBILD.xml:S1:13558:1	O
including	STRIBILD.xml:S1:13559:9	O
acute	STRIBILD.xml:S1:13569:5	I-AdverseReaction
cases	STRIBILD.xml:S1:13575:5	O
)	STRIBILD.xml:S1:13580:1	O
,	STRIBILD.xml:S1:13581:1	O
nephrogenic	STRIBILD.xml:S1:13583:11	B-AdverseReaction
diabetes	STRIBILD.xml:S1:13595:8	I-AdverseReaction
insipidus	STRIBILD.xml:S1:13604:9	I-AdverseReaction
,	STRIBILD.xml:S1:13613:1	O
renal	STRIBILD.xml:S1:13615:5	B-AdverseReaction
insufficiency	STRIBILD.xml:S1:13621:13	I-AdverseReaction
,	STRIBILD.xml:S1:13634:1	O
increased	STRIBILD.xml:S1:13636:9	B-AdverseReaction
creatinine	STRIBILD.xml:S1:13646:10	I-AdverseReaction
,	STRIBILD.xml:S1:13656:1	O
proteinuria	STRIBILD.xml:S1:13658:11	B-AdverseReaction
,	STRIBILD.xml:S1:13669:1	O
polyuria	STRIBILD.xml:S1:13671:8	B-AdverseReaction

General	STRIBILD.xml:S1:13686:7	O
Disorders	STRIBILD.xml:S1:13694:9	O
and	STRIBILD.xml:S1:13704:3	O
Administration	STRIBILD.xml:S1:13708:14	O
Site	STRIBILD.xml:S1:13723:4	O
Conditions	STRIBILD.xml:S1:13728:10	O

asthenia	STRIBILD.xml:S1:13745:8	B-AdverseReaction

The	STRIBILD.xml:S1:13758:3	O
following	STRIBILD.xml:S1:13762:9	O
adverse	STRIBILD.xml:S1:13772:7	O
reactions	STRIBILD.xml:S1:13780:9	O
,	STRIBILD.xml:S1:13789:1	O
listed	STRIBILD.xml:S1:13791:6	O
under	STRIBILD.xml:S1:13798:5	O
the	STRIBILD.xml:S1:13804:3	O
body	STRIBILD.xml:S1:13808:4	O
system	STRIBILD.xml:S1:13813:6	O
headings	STRIBILD.xml:S1:13820:8	O
above	STRIBILD.xml:S1:13829:5	O
,	STRIBILD.xml:S1:13834:1	O
may	STRIBILD.xml:S1:13836:3	O
occur	STRIBILD.xml:S1:13840:5	O
as	STRIBILD.xml:S1:13846:2	O
a	STRIBILD.xml:S1:13849:1	O
consequence	STRIBILD.xml:S1:13851:11	O
of	STRIBILD.xml:S1:13863:2	O
proximal	STRIBILD.xml:S1:13866:8	B-AdverseReaction
renal	STRIBILD.xml:S1:13875:5	I-AdverseReaction
tubulopathy	STRIBILD.xml:S1:13881:11	I-AdverseReaction
:	STRIBILD.xml:S1:13892:1	O
rhabdomyolysis	STRIBILD.xml:S1:13894:14	B-AdverseReaction
,	STRIBILD.xml:S1:13908:1	O
osteomalacia	STRIBILD.xml:S1:13910:12	B-AdverseReaction
,	STRIBILD.xml:S1:13922:1	O
hypokalemia	STRIBILD.xml:S1:13924:11	B-AdverseReaction
,	STRIBILD.xml:S1:13935:1	O
muscular	STRIBILD.xml:S1:13937:8	B-AdverseReaction
weakness	STRIBILD.xml:S1:13946:8	I-AdverseReaction
,	STRIBILD.xml:S1:13954:1	O
myopathy	STRIBILD.xml:S1:13956:8	B-AdverseReaction
,	STRIBILD.xml:S1:13964:1	O
hypophosphatemia	STRIBILD.xml:S1:13966:16	B-AdverseReaction
.	STRIBILD.xml:S1:13982:1	O
\n\n	STRIBILD.xml:S2:0:2	O
BOXED	STRIBILD.xml:S2:6:5	O
WARNING	STRIBILD.xml:S2:12:7	O
:	STRIBILD.xml:S2:19:1	O
WARNING	STRIBILD.xml:S2:21:7	O
:	STRIBILD.xml:S2:28:1	O
LACTIC	STRIBILD.xml:S2:30:6	B-AdverseReaction
ACIDOSIS	STRIBILD.xml:S2:37:8	I-AdverseReaction
SEVERE	STRIBILD.xml:S2:46:6	B-Severity
HEPATOMEGALY	STRIBILD.xml:S2:53:12	B-AdverseReaction
WITH	STRIBILD.xml:S2:66:4	O
STEATOSIS	STRIBILD.xml:S2:71:9	B-AdverseReaction
and	STRIBILD.xml:S2:81:3	O
POST	STRIBILD.xml:S2:85:4	O
TREATMENT	STRIBILD.xml:S2:90:9	O
ACUTE	STRIBILD.xml:S2:100:5	B-AdverseReaction
EXACERBATION	STRIBILD.xml:S2:106:12	I-AdverseReaction
OF	STRIBILD.xml:S2:119:2	I-AdverseReaction
HEPATITIS	STRIBILD.xml:S2:122:9	I-AdverseReaction
B	STRIBILD.xml:S2:132:1	I-AdverseReaction
\n\n	STRIBILD.xml:S2:133:2	O
WARNING	STRIBILD.xml:S2:139:7	O
:	STRIBILD.xml:S2:146:1	O
LACTIC	STRIBILD.xml:S2:148:6	B-AdverseReaction
ACIDOSIS	STRIBILD.xml:S2:155:8	I-AdverseReaction
SEVERE	STRIBILD.xml:S2:164:6	B-Severity
HEPATOMEGALY	STRIBILD.xml:S2:171:12	B-AdverseReaction
WITH	STRIBILD.xml:S2:184:4	O
STEATOSIS	STRIBILD.xml:S2:189:9	B-AdverseReaction
and	STRIBILD.xml:S2:199:3	O
POST	STRIBILD.xml:S2:203:4	O
TREATMENT	STRIBILD.xml:S2:208:9	O
ACUTE	STRIBILD.xml:S2:218:5	B-AdverseReaction
EXACERBATION	STRIBILD.xml:S2:224:12	I-AdverseReaction
OF	STRIBILD.xml:S2:237:2	I-AdverseReaction
HEPATITIS	STRIBILD.xml:S2:240:9	I-AdverseReaction
B	STRIBILD.xml:S2:250:1	I-AdverseReaction
\n\n	STRIBILD.xml:S2:253:2	O
Lactic	STRIBILD.xml:S2:259:6	B-AdverseReaction
acidosis	STRIBILD.xml:S2:266:8	I-AdverseReaction
and	STRIBILD.xml:S2:275:3	O
severe	STRIBILD.xml:S2:279:6	B-Severity
hepatomegaly	STRIBILD.xml:S2:286:12	B-AdverseReaction
with	STRIBILD.xml:S2:299:4	O
steatosis	STRIBILD.xml:S2:304:9	B-AdverseReaction
,	STRIBILD.xml:S2:313:1	O
including	STRIBILD.xml:S2:315:9	O
fatal	STRIBILD.xml:S2:325:5	B-AdverseReaction
cases	STRIBILD.xml:S2:331:5	O
,	STRIBILD.xml:S2:336:1	O
have	STRIBILD.xml:S2:338:4	O
been	STRIBILD.xml:S2:343:4	O
reported	STRIBILD.xml:S2:348:8	O
with	STRIBILD.xml:S2:357:4	O
the	STRIBILD.xml:S2:362:3	O
use	STRIBILD.xml:S2:366:3	O
of	STRIBILD.xml:S2:370:2	O
nucleoside	STRIBILD.xml:S2:373:10	O
analogs	STRIBILD.xml:S2:384:7	O
,	STRIBILD.xml:S2:391:1	O
including	STRIBILD.xml:S2:393:9	O
tenofovir	STRIBILD.xml:S2:403:9	O
disoproxil	STRIBILD.xml:S2:413:10	O
fumarate	STRIBILD.xml:S2:424:8	O
,	STRIBILD.xml:S2:432:1	O
a	STRIBILD.xml:S2:434:1	O
component	STRIBILD.xml:S2:436:9	O
of	STRIBILD.xml:S2:446:2	O
STRIBILD	STRIBILD.xml:S2:449:8	O
,	STRIBILD.xml:S2:457:1	O
in	STRIBILD.xml:S2:459:2	O
combination	STRIBILD.xml:S2:462:11	O
with	STRIBILD.xml:S2:474:4	O
other	STRIBILD.xml:S2:479:5	O
antiretrovirals	STRIBILD.xml:S2:485:15	O
[	STRIBILD.xml:S2:503:1	O
see	STRIBILD.xml:S2:504:3	O
Warnings	STRIBILD.xml:S2:510:8	O
and	STRIBILD.xml:S2:519:3	O
Precautions	STRIBILD.xml:S2:523:11	O
(	STRIBILD.xml:S2:535:1	O
5.1	STRIBILD.xml:S2:536:3	O
)	STRIBILD.xml:S2:539:1	O
]	STRIBILD.xml:S2:542:1	O
.	STRIBILD.xml:S2:545:1	O

STRIBILD	STRIBILD.xml:S2:555:8	O
is	STRIBILD.xml:S2:564:2	O
not	STRIBILD.xml:S2:567:3	O
approved	STRIBILD.xml:S2:571:8	O
for	STRIBILD.xml:S2:580:3	O
the	STRIBILD.xml:S2:584:3	O
treatment	STRIBILD.xml:S2:588:9	O
of	STRIBILD.xml:S2:598:2	O
chronic	STRIBILD.xml:S2:601:7	O
hepatitis	STRIBILD.xml:S2:609:9	O
B	STRIBILD.xml:S2:619:1	O
virus	STRIBILD.xml:S2:621:5	O
(	STRIBILD.xml:S2:627:1	O
HBV	STRIBILD.xml:S2:628:3	O
)	STRIBILD.xml:S2:631:1	O
infection	STRIBILD.xml:S2:633:9	O
and	STRIBILD.xml:S2:643:3	O
the	STRIBILD.xml:S2:647:3	O
safety	STRIBILD.xml:S2:651:6	O
and	STRIBILD.xml:S2:658:3	O
efficacy	STRIBILD.xml:S2:662:8	O
of	STRIBILD.xml:S2:671:2	O
STRIBILD	STRIBILD.xml:S2:674:8	O
have	STRIBILD.xml:S2:683:4	O
not	STRIBILD.xml:S2:688:3	O
been	STRIBILD.xml:S2:692:4	O
established	STRIBILD.xml:S2:697:11	O
in	STRIBILD.xml:S2:709:2	O
patients	STRIBILD.xml:S2:712:8	O
coinfected	STRIBILD.xml:S2:721:10	O
with	STRIBILD.xml:S2:732:4	O
HBV	STRIBILD.xml:S2:737:3	O
and	STRIBILD.xml:S2:741:3	O
HIV	STRIBILD.xml:S2:745:3	O
-	STRIBILD.xml:S2:748:1	O
1	STRIBILD.xml:S2:749:1	O
.	STRIBILD.xml:S2:750:1	O

Severe	STRIBILD.xml:S2:752:6	B-Severity
acute	STRIBILD.xml:S2:759:5	B-AdverseReaction
exacerbations	STRIBILD.xml:S2:765:13	I-AdverseReaction
of	STRIBILD.xml:S2:779:2	I-AdverseReaction
hepatitis	STRIBILD.xml:S2:782:9	I-AdverseReaction
B	STRIBILD.xml:S2:792:1	I-AdverseReaction
have	STRIBILD.xml:S2:794:4	O
been	STRIBILD.xml:S2:799:4	O
reported	STRIBILD.xml:S2:804:8	O
in	STRIBILD.xml:S2:813:2	O
patients	STRIBILD.xml:S2:816:8	O
who	STRIBILD.xml:S2:825:3	O
are	STRIBILD.xml:S2:829:3	O
coinfected	STRIBILD.xml:S2:833:10	O
with	STRIBILD.xml:S2:844:4	O
HBV	STRIBILD.xml:S2:849:3	O
and	STRIBILD.xml:S2:853:3	O
human	STRIBILD.xml:S2:857:5	O
immunodeficiency	STRIBILD.xml:S2:863:16	O
virus	STRIBILD.xml:S2:880:5	O
-	STRIBILD.xml:S2:885:1	O
1	STRIBILD.xml:S2:886:1	O
(	STRIBILD.xml:S2:888:1	O
HIV	STRIBILD.xml:S2:889:3	O
-	STRIBILD.xml:S2:892:1	O
1	STRIBILD.xml:S2:893:1	O
)	STRIBILD.xml:S2:894:1	O
and	STRIBILD.xml:S2:896:3	O
have	STRIBILD.xml:S2:900:4	O
discontinued	STRIBILD.xml:S2:905:12	O
EMTRIVA	STRIBILD.xml:S2:918:7	O
or	STRIBILD.xml:S2:926:2	O
VIREAD	STRIBILD.xml:S2:929:6	O
,	STRIBILD.xml:S2:935:1	O
which	STRIBILD.xml:S2:937:5	O
are	STRIBILD.xml:S2:943:3	O
components	STRIBILD.xml:S2:947:10	O
of	STRIBILD.xml:S2:958:2	O
STRIBILD	STRIBILD.xml:S2:961:8	O
.	STRIBILD.xml:S2:969:1	O

Hepatic	STRIBILD.xml:S2:971:7	O
function	STRIBILD.xml:S2:979:8	O
should	STRIBILD.xml:S2:988:6	O
be	STRIBILD.xml:S2:995:2	O
monitored	STRIBILD.xml:S2:998:9	O
closely	STRIBILD.xml:S2:1008:7	O
with	STRIBILD.xml:S2:1016:4	O
both	STRIBILD.xml:S2:1021:4	O
clinical	STRIBILD.xml:S2:1026:8	O
and	STRIBILD.xml:S2:1035:3	O
laboratory	STRIBILD.xml:S2:1039:10	O
follow	STRIBILD.xml:S2:1050:6	O
-	STRIBILD.xml:S2:1056:1	O
up	STRIBILD.xml:S2:1057:2	O
for	STRIBILD.xml:S2:1060:3	O
at	STRIBILD.xml:S2:1064:2	O
least	STRIBILD.xml:S2:1067:5	O
several	STRIBILD.xml:S2:1073:7	O
months	STRIBILD.xml:S2:1081:6	O
in	STRIBILD.xml:S2:1088:2	O
patients	STRIBILD.xml:S2:1091:8	O
who	STRIBILD.xml:S2:1100:3	O
are	STRIBILD.xml:S2:1104:3	O
coinfected	STRIBILD.xml:S2:1108:10	O
with	STRIBILD.xml:S2:1119:4	O
HIV	STRIBILD.xml:S2:1124:3	O
-	STRIBILD.xml:S2:1127:1	O
1	STRIBILD.xml:S2:1128:1	O
and	STRIBILD.xml:S2:1130:3	O
HBV	STRIBILD.xml:S2:1134:3	O
and	STRIBILD.xml:S2:1138:3	O
discontinue	STRIBILD.xml:S2:1142:11	O
STRIBILD	STRIBILD.xml:S2:1154:8	O
.	STRIBILD.xml:S2:1162:1	O

If	STRIBILD.xml:S2:1164:2	O
appropriate	STRIBILD.xml:S2:1167:11	O
,	STRIBILD.xml:S2:1178:1	O
initiation	STRIBILD.xml:S2:1180:10	O
of	STRIBILD.xml:S2:1191:2	O
anti	STRIBILD.xml:S2:1194:4	O
-	STRIBILD.xml:S2:1198:1	O
hepatitis	STRIBILD.xml:S2:1199:9	O
B	STRIBILD.xml:S2:1209:1	O
therapy	STRIBILD.xml:S2:1211:7	O
may	STRIBILD.xml:S2:1219:3	O
be	STRIBILD.xml:S2:1223:2	O
warranted	STRIBILD.xml:S2:1226:9	O
[	STRIBILD.xml:S2:1238:1	O
see	STRIBILD.xml:S2:1239:3	O
Warnings	STRIBILD.xml:S2:1245:8	O
and	STRIBILD.xml:S2:1254:3	O
Precautions	STRIBILD.xml:S2:1258:11	O
(	STRIBILD.xml:S2:1270:1	O
5.2	STRIBILD.xml:S2:1271:3	O
)	STRIBILD.xml:S2:1274:1	O
]	STRIBILD.xml:S2:1277:1	O
.	STRIBILD.xml:S2:1280:1	O

EXCERPT	STRIBILD.xml:S2:1290:7	O
:	STRIBILD.xml:S2:1297:1	O
WARNING	STRIBILD.xml:S2:1301:7	O
:	STRIBILD.xml:S2:1308:1	O
LACTIC	STRIBILD.xml:S2:1310:6	B-AdverseReaction
ACIDOSIS	STRIBILD.xml:S2:1317:8	I-AdverseReaction
SEVERE	STRIBILD.xml:S2:1326:6	B-Severity
HEPATOMEGALY	STRIBILD.xml:S2:1333:12	B-AdverseReaction
WITH	STRIBILD.xml:S2:1346:4	O
STEATOSIS	STRIBILD.xml:S2:1351:9	B-AdverseReaction
and	STRIBILD.xml:S2:1361:3	O
POST	STRIBILD.xml:S2:1365:4	O
TREATMENT	STRIBILD.xml:S2:1370:9	O
ACUTE	STRIBILD.xml:S2:1380:5	B-AdverseReaction
EXACERBATION	STRIBILD.xml:S2:1386:12	I-AdverseReaction
OF	STRIBILD.xml:S2:1399:2	I-AdverseReaction
HEPATITIS	STRIBILD.xml:S2:1402:9	I-AdverseReaction
B	STRIBILD.xml:S2:1412:1	I-AdverseReaction
\n\n\n\n	STRIBILD.xml:S2:1413:4	O
See	STRIBILD.xml:S2:1420:3	O
full	STRIBILD.xml:S2:1424:4	O
prescribing	STRIBILD.xml:S2:1429:11	O
information	STRIBILD.xml:S2:1441:11	O
for	STRIBILD.xml:S2:1453:3	O
complete	STRIBILD.xml:S2:1457:8	O
boxed	STRIBILD.xml:S2:1466:5	O
warning	STRIBILD.xml:S2:1472:7	O
.	STRIBILD.xml:S2:1479:1	O

Lactic	STRIBILD.xml:S2:1490:6	B-AdverseReaction
acidosis	STRIBILD.xml:S2:1497:8	I-AdverseReaction
and	STRIBILD.xml:S2:1506:3	O
severe	STRIBILD.xml:S2:1510:6	B-Severity
hepatomegaly	STRIBILD.xml:S2:1517:12	B-AdverseReaction
with	STRIBILD.xml:S2:1530:4	O
steatosis	STRIBILD.xml:S2:1535:9	B-AdverseReaction
,	STRIBILD.xml:S2:1544:1	O
including	STRIBILD.xml:S2:1546:9	O
fatal	STRIBILD.xml:S2:1556:5	B-AdverseReaction
cases	STRIBILD.xml:S2:1562:5	O
,	STRIBILD.xml:S2:1567:1	O
have	STRIBILD.xml:S2:1569:4	O
been	STRIBILD.xml:S2:1574:4	O
reported	STRIBILD.xml:S2:1579:8	O
with	STRIBILD.xml:S2:1588:4	O
the	STRIBILD.xml:S2:1593:3	O
use	STRIBILD.xml:S2:1597:3	O
of	STRIBILD.xml:S2:1601:2	O
nucleoside	STRIBILD.xml:S2:1604:10	O
analogs	STRIBILD.xml:S2:1615:7	O
,	STRIBILD.xml:S2:1622:1	O
including	STRIBILD.xml:S2:1624:9	O
tenofovir	STRIBILD.xml:S2:1634:9	O
disoproxil	STRIBILD.xml:S2:1644:10	O
fumarate	STRIBILD.xml:S2:1655:8	O
(	STRIBILD.xml:S2:1664:1	O
DF	STRIBILD.xml:S2:1665:2	O
)	STRIBILD.xml:S2:1667:1	O
,	STRIBILD.xml:S2:1668:1	O
a	STRIBILD.xml:S2:1670:1	O
component	STRIBILD.xml:S2:1672:9	O
of	STRIBILD.xml:S2:1682:2	O
STRIBILD	STRIBILD.xml:S2:1685:8	O
.	STRIBILD.xml:S2:1693:1	O

(	STRIBILD.xml:S2:1695:1	O
5.1	STRIBILD.xml:S2:1696:3	O
)	STRIBILD.xml:S2:1699:1	O
\n	STRIBILD.xml:S2:1701:1	O
STRIBILD	STRIBILD.xml:S2:1706:8	O
is	STRIBILD.xml:S2:1715:2	O
not	STRIBILD.xml:S2:1718:3	O
approved	STRIBILD.xml:S2:1722:8	O
for	STRIBILD.xml:S2:1731:3	O
the	STRIBILD.xml:S2:1735:3	O
treatment	STRIBILD.xml:S2:1739:9	O
of	STRIBILD.xml:S2:1749:2	O
chronic	STRIBILD.xml:S2:1752:7	O
hepatitis	STRIBILD.xml:S2:1760:9	O
B	STRIBILD.xml:S2:1770:1	O
virus	STRIBILD.xml:S2:1772:5	O
(	STRIBILD.xml:S2:1778:1	O
HBV	STRIBILD.xml:S2:1779:3	O
)	STRIBILD.xml:S2:1782:1	O
infection	STRIBILD.xml:S2:1784:9	O
.	STRIBILD.xml:S2:1793:1	O

Severe	STRIBILD.xml:S2:1795:6	B-Severity
acute	STRIBILD.xml:S2:1802:5	B-AdverseReaction
exacerbations	STRIBILD.xml:S2:1808:13	I-AdverseReaction
of	STRIBILD.xml:S2:1822:2	I-AdverseReaction
hepatitis	STRIBILD.xml:S2:1825:9	I-AdverseReaction
B	STRIBILD.xml:S2:1835:1	I-AdverseReaction
have	STRIBILD.xml:S2:1837:4	O
been	STRIBILD.xml:S2:1842:4	O
reported	STRIBILD.xml:S2:1847:8	O
in	STRIBILD.xml:S2:1856:2	O
patients	STRIBILD.xml:S2:1859:8	O
coinfected	STRIBILD.xml:S2:1868:10	O
with	STRIBILD.xml:S2:1879:4	O
HIV	STRIBILD.xml:S2:1884:3	O
-	STRIBILD.xml:S2:1887:1	O
1	STRIBILD.xml:S2:1888:1	O
and	STRIBILD.xml:S2:1890:3	O
HBV	STRIBILD.xml:S2:1894:3	O
who	STRIBILD.xml:S2:1898:3	O
have	STRIBILD.xml:S2:1902:4	O
discontinued	STRIBILD.xml:S2:1907:12	O
EMTRIVA	STRIBILD.xml:S2:1920:7	O
or	STRIBILD.xml:S2:1928:2	O
VIREAD	STRIBILD.xml:S2:1931:6	O
,	STRIBILD.xml:S2:1937:1	O
two	STRIBILD.xml:S2:1939:3	O
of	STRIBILD.xml:S2:1943:2	O
the	STRIBILD.xml:S2:1946:3	O
components	STRIBILD.xml:S2:1950:10	O
of	STRIBILD.xml:S2:1961:2	O
STRIBILD	STRIBILD.xml:S2:1964:8	O
.	STRIBILD.xml:S2:1972:1	O

Hepatic	STRIBILD.xml:S2:1974:7	O
function	STRIBILD.xml:S2:1982:8	O
should	STRIBILD.xml:S2:1991:6	O
be	STRIBILD.xml:S2:1998:2	O
monitored	STRIBILD.xml:S2:2001:9	O
closely	STRIBILD.xml:S2:2011:7	O
in	STRIBILD.xml:S2:2019:2	O
these	STRIBILD.xml:S2:2022:5	O
patients	STRIBILD.xml:S2:2028:8	O
.	STRIBILD.xml:S2:2036:1	O

If	STRIBILD.xml:S2:2038:2	O
appropriate	STRIBILD.xml:S2:2041:11	O
,	STRIBILD.xml:S2:2052:1	O
initiation	STRIBILD.xml:S2:2054:10	O
of	STRIBILD.xml:S2:2065:2	O
anti	STRIBILD.xml:S2:2068:4	O
-	STRIBILD.xml:S2:2072:1	O
hepatitis	STRIBILD.xml:S2:2073:9	O
B	STRIBILD.xml:S2:2083:1	O
therapy	STRIBILD.xml:S2:2085:7	O
may	STRIBILD.xml:S2:2093:3	O
be	STRIBILD.xml:S2:2097:2	O
warranted	STRIBILD.xml:S2:2100:9	O
.	STRIBILD.xml:S2:2109:1	O

(	STRIBILD.xml:S2:2111:1	O
5.2	STRIBILD.xml:S2:2112:3	O
)	STRIBILD.xml:S2:2115:1	O
\n	STRIBILD.xml:S2:2117:1	O
5	STRIBILD.xml:S3:4:1	O
WARNINGS	STRIBILD.xml:S3:6:8	O
AND	STRIBILD.xml:S3:15:3	O
PRECAUTIONS	STRIBILD.xml:S3:19:11	O

EXCERPT	STRIBILD.xml:S3:37:7	O
:	STRIBILD.xml:S3:44:1	O
New	STRIBILD.xml:S3:52:3	B-AdverseReaction
onset	STRIBILD.xml:S3:56:5	I-AdverseReaction
or	STRIBILD.xml:S3:62:2	O
worsening	STRIBILD.xml:S3:65:9	B-AdverseReaction
renal	STRIBILD.xml:S3:75:5	I-AdverseReaction
impairment	STRIBILD.xml:S3:81:10	I-AdverseReaction
:	STRIBILD.xml:S3:91:1	O
Can	STRIBILD.xml:S3:93:3	B-Factor
include	STRIBILD.xml:S3:97:7	O
acute	STRIBILD.xml:S3:105:5	B-AdverseReaction
renal	STRIBILD.xml:S3:111:5	I-AdverseReaction
failure	STRIBILD.xml:S3:117:7	I-AdverseReaction
and	STRIBILD.xml:S3:125:3	O
Fanconi	STRIBILD.xml:S3:129:7	B-AdverseReaction
syndrome	STRIBILD.xml:S3:137:8	I-AdverseReaction
.	STRIBILD.xml:S3:145:1	O

Assess	STRIBILD.xml:S3:147:6	O
creatinine	STRIBILD.xml:S3:154:10	O
clearance	STRIBILD.xml:S3:165:9	O
(	STRIBILD.xml:S3:175:1	O
CLcr	STRIBILD.xml:S3:176:4	O
)	STRIBILD.xml:S3:180:1	O
,	STRIBILD.xml:S3:181:1	O
urine	STRIBILD.xml:S3:183:5	O
glucose	STRIBILD.xml:S3:189:7	O
and	STRIBILD.xml:S3:197:3	O
urine	STRIBILD.xml:S3:201:5	O
protein	STRIBILD.xml:S3:207:7	O
before	STRIBILD.xml:S3:215:6	O
initiating	STRIBILD.xml:S3:222:10	O
treatment	STRIBILD.xml:S3:233:9	O
with	STRIBILD.xml:S3:243:4	O
STRIBILD	STRIBILD.xml:S3:248:8	O
.	STRIBILD.xml:S3:256:1	O

Monitor	STRIBILD.xml:S3:258:7	O
CLcr	STRIBILD.xml:S3:266:4	O
,	STRIBILD.xml:S3:270:1	O
urine	STRIBILD.xml:S3:272:5	O
glucose	STRIBILD.xml:S3:278:7	O
,	STRIBILD.xml:S3:285:1	O
and	STRIBILD.xml:S3:287:3	O
urine	STRIBILD.xml:S3:291:5	O
protein	STRIBILD.xml:S3:297:7	O
in	STRIBILD.xml:S3:305:2	O
all	STRIBILD.xml:S3:308:3	O
patients	STRIBILD.xml:S3:312:8	O
.	STRIBILD.xml:S3:320:1	O

Monitor	STRIBILD.xml:S3:322:7	O
serum	STRIBILD.xml:S3:330:5	O
phosphorus	STRIBILD.xml:S3:336:10	O
in	STRIBILD.xml:S3:347:2	O
patients	STRIBILD.xml:S3:350:8	O
at	STRIBILD.xml:S3:359:2	O
risk	STRIBILD.xml:S3:362:4	O
for	STRIBILD.xml:S3:367:3	O
renal	STRIBILD.xml:S3:371:5	O
impairment	STRIBILD.xml:S3:377:10	O
.	STRIBILD.xml:S3:387:1	O

Avoid	STRIBILD.xml:S3:389:5	O
administering	STRIBILD.xml:S3:395:13	O
STRIBILD	STRIBILD.xml:S3:409:8	O
with	STRIBILD.xml:S3:418:4	O
concurrent	STRIBILD.xml:S3:423:10	O
or	STRIBILD.xml:S3:434:2	O
recent	STRIBILD.xml:S3:437:6	O
use	STRIBILD.xml:S3:444:3	O
of	STRIBILD.xml:S3:448:2	O
nephrotoxic	STRIBILD.xml:S3:451:11	O
drugs	STRIBILD.xml:S3:463:5	O
.	STRIBILD.xml:S3:468:1	O

(	STRIBILD.xml:S3:470:1	O
5.3	STRIBILD.xml:S3:473:3	O
)	STRIBILD.xml:S3:478:1	O

Avoid	STRIBILD.xml:S3:485:5	O
coadministration	STRIBILD.xml:S3:491:16	O
with	STRIBILD.xml:S3:508:4	O
other	STRIBILD.xml:S3:513:5	O
anti	STRIBILD.xml:S3:519:4	O
-	STRIBILD.xml:S3:523:1	O
retroviral	STRIBILD.xml:S3:524:10	O
products	STRIBILD.xml:S3:535:8	O
:	STRIBILD.xml:S3:543:1	O
Do	STRIBILD.xml:S3:545:2	O
not	STRIBILD.xml:S3:548:3	O
use	STRIBILD.xml:S3:552:3	O
with	STRIBILD.xml:S3:556:4	O
products	STRIBILD.xml:S3:561:8	O
containing	STRIBILD.xml:S3:570:10	O
any	STRIBILD.xml:S3:581:3	O
of	STRIBILD.xml:S3:585:2	O
the	STRIBILD.xml:S3:588:3	O
components	STRIBILD.xml:S3:592:10	O
of	STRIBILD.xml:S3:603:2	O
STRIBILD	STRIBILD.xml:S3:606:8	O
(	STRIBILD.xml:S3:615:1	O
cobicistat	STRIBILD.xml:S3:616:10	O
,	STRIBILD.xml:S3:626:1	O
elvitegravir	STRIBILD.xml:S3:628:12	O
,	STRIBILD.xml:S3:640:1	O
emtricitabine	STRIBILD.xml:S3:642:13	O
,	STRIBILD.xml:S3:655:1	O
and	STRIBILD.xml:S3:657:3	O
tenofovir	STRIBILD.xml:S3:661:9	O
disoproxil	STRIBILD.xml:S3:671:10	O
fumarate	STRIBILD.xml:S3:682:8	O
)	STRIBILD.xml:S3:690:1	O
,	STRIBILD.xml:S3:691:1	O
including	STRIBILD.xml:S3:693:9	O
ATRIPLA	STRIBILD.xml:S3:703:7	O
,	STRIBILD.xml:S3:710:1	O
COMPLERA	STRIBILD.xml:S3:712:8	O
,	STRIBILD.xml:S3:720:1	O
EMTRIVA	STRIBILD.xml:S3:722:7	O
,	STRIBILD.xml:S3:729:1	O
TRUVADA	STRIBILD.xml:S3:731:7	O
,	STRIBILD.xml:S3:738:1	O
TYBOST	STRIBILD.xml:S3:740:6	O
,	STRIBILD.xml:S3:746:1	O
VIREAD	STRIBILD.xml:S3:748:6	O
,	STRIBILD.xml:S3:754:1	O
or	STRIBILD.xml:S3:756:2	O
VITEKTA	STRIBILD.xml:S3:759:7	O
;	STRIBILD.xml:S3:766:1	O
with	STRIBILD.xml:S3:768:4	O
drugs	STRIBILD.xml:S3:773:5	O
containing	STRIBILD.xml:S3:779:10	O
lamivudine	STRIBILD.xml:S3:790:10	O
;	STRIBILD.xml:S3:800:1	O
or	STRIBILD.xml:S3:802:2	O
with	STRIBILD.xml:S3:805:4	O
drugs	STRIBILD.xml:S3:810:5	O
or	STRIBILD.xml:S3:816:2	O
regimens	STRIBILD.xml:S3:819:8	O
containing	STRIBILD.xml:S3:828:10	O
ritonavir	STRIBILD.xml:S3:839:9	O
.	STRIBILD.xml:S3:848:1	O

Do	STRIBILD.xml:S3:850:2	O
not	STRIBILD.xml:S3:853:3	O
administer	STRIBILD.xml:S3:857:10	O
in	STRIBILD.xml:S3:868:2	O
combination	STRIBILD.xml:S3:871:11	O
with	STRIBILD.xml:S3:883:4	O
HEPSERA	STRIBILD.xml:S3:888:7	O
.	STRIBILD.xml:S3:895:1	O

(	STRIBILD.xml:S3:897:1	O
5.4	STRIBILD.xml:S3:900:3	O
)	STRIBILD.xml:S3:905:1	O

Risk	STRIBILD.xml:S3:912:4	O
of	STRIBILD.xml:S3:917:2	O
adverse	STRIBILD.xml:S3:920:7	O
reactions	STRIBILD.xml:S3:928:9	O
or	STRIBILD.xml:S3:938:2	O
loss	STRIBILD.xml:S3:941:4	O
of	STRIBILD.xml:S3:946:2	O
virologic	STRIBILD.xml:S3:949:9	O
response	STRIBILD.xml:S3:959:8	O
due	STRIBILD.xml:S3:968:3	O
to	STRIBILD.xml:S3:972:2	O
drug	STRIBILD.xml:S3:975:4	O
interactions	STRIBILD.xml:S3:980:12	O
:	STRIBILD.xml:S3:992:1	O
The	STRIBILD.xml:S3:994:3	O
concomitant	STRIBILD.xml:S3:998:11	O
use	STRIBILD.xml:S3:1010:3	O
of	STRIBILD.xml:S3:1014:2	O
STRIBILD	STRIBILD.xml:S3:1017:8	O
and	STRIBILD.xml:S3:1026:3	O
other	STRIBILD.xml:S3:1030:5	O
drugs	STRIBILD.xml:S3:1036:5	O
may	STRIBILD.xml:S3:1042:3	O
result	STRIBILD.xml:S3:1046:6	O
in	STRIBILD.xml:S3:1053:2	O
known	STRIBILD.xml:S3:1056:5	O
or	STRIBILD.xml:S3:1062:2	O
potentially	STRIBILD.xml:S3:1065:11	O
significant	STRIBILD.xml:S3:1077:11	O
drug	STRIBILD.xml:S3:1089:4	O
interactions	STRIBILD.xml:S3:1094:12	O
,	STRIBILD.xml:S3:1106:1	O
some	STRIBILD.xml:S3:1108:4	O
of	STRIBILD.xml:S3:1113:2	O
which	STRIBILD.xml:S3:1116:5	O
may	STRIBILD.xml:S3:1122:3	O
lead	STRIBILD.xml:S3:1126:4	O
to	STRIBILD.xml:S3:1131:2	O
loss	STRIBILD.xml:S3:1134:4	O
of	STRIBILD.xml:S3:1139:2	O
therapeutic	STRIBILD.xml:S3:1142:11	O
effect	STRIBILD.xml:S3:1154:6	O
of	STRIBILD.xml:S3:1161:2	O
STRIBILD	STRIBILD.xml:S3:1164:8	O
and	STRIBILD.xml:S3:1173:3	O
possible	STRIBILD.xml:S3:1177:8	O
development	STRIBILD.xml:S3:1186:11	O
of	STRIBILD.xml:S3:1198:2	O
resistance	STRIBILD.xml:S3:1201:10	O
;	STRIBILD.xml:S3:1211:1	O
and	STRIBILD.xml:S3:1213:3	O
possible	STRIBILD.xml:S3:1217:8	O
clinically	STRIBILD.xml:S3:1226:10	O
significant	STRIBILD.xml:S3:1237:11	O
adverse	STRIBILD.xml:S3:1249:7	O
reactions	STRIBILD.xml:S3:1257:9	O
from	STRIBILD.xml:S3:1267:4	O
greater	STRIBILD.xml:S3:1272:7	O
exposures	STRIBILD.xml:S3:1280:9	O
of	STRIBILD.xml:S3:1290:2	O
concomitant	STRIBILD.xml:S3:1293:11	O
drugs	STRIBILD.xml:S3:1305:5	O
.	STRIBILD.xml:S3:1310:1	O

(	STRIBILD.xml:S3:1312:1	O
5.5	STRIBILD.xml:S3:1315:3	O
)	STRIBILD.xml:S3:1320:1	O

Decreases	STRIBILD.xml:S3:1327:9	B-AdverseReaction
in	STRIBILD.xml:S3:1337:2	I-AdverseReaction
bone	STRIBILD.xml:S3:1340:4	I-AdverseReaction
mineral	STRIBILD.xml:S3:1345:7	I-AdverseReaction
density	STRIBILD.xml:S3:1353:7	I-AdverseReaction
(	STRIBILD.xml:S3:1361:1	O
BMD	STRIBILD.xml:S3:1362:3	I-AdverseReaction
)	STRIBILD.xml:S3:1365:1	O
:	STRIBILD.xml:S3:1366:1	O
Consider	STRIBILD.xml:S3:1368:8	O
monitoring	STRIBILD.xml:S3:1377:10	O
BMD	STRIBILD.xml:S3:1388:3	O
in	STRIBILD.xml:S3:1392:2	O
patients	STRIBILD.xml:S3:1395:8	O
with	STRIBILD.xml:S3:1404:4	O
a	STRIBILD.xml:S3:1409:1	O
history	STRIBILD.xml:S3:1411:7	O
of	STRIBILD.xml:S3:1419:2	O
pathologic	STRIBILD.xml:S3:1422:10	O
fracture	STRIBILD.xml:S3:1433:8	O
or	STRIBILD.xml:S3:1442:2	O
other	STRIBILD.xml:S3:1445:5	O
risk	STRIBILD.xml:S3:1451:4	O
factors	STRIBILD.xml:S3:1456:7	O
of	STRIBILD.xml:S3:1464:2	O
osteoporosis	STRIBILD.xml:S3:1467:12	O
or	STRIBILD.xml:S3:1480:2	O
bone	STRIBILD.xml:S3:1483:4	O
loss	STRIBILD.xml:S3:1488:4	O
.	STRIBILD.xml:S3:1492:1	O

(	STRIBILD.xml:S3:1494:1	O
5.6	STRIBILD.xml:S3:1497:3	O
)	STRIBILD.xml:S3:1502:1	O

Redistribution	STRIBILD.xml:S3:1509:14	B-AdverseReaction
accumulation	STRIBILD.xml:S3:1524:12	B-AdverseReaction
of	STRIBILD.xml:S3:1537:2	I-AdverseReaction
body	STRIBILD.xml:S3:1540:4	I-AdverseReaction
fat	STRIBILD.xml:S3:1545:3	I-AdverseReaction
:	STRIBILD.xml:S3:1548:1	O
Observed	STRIBILD.xml:S3:1550:8	O
in	STRIBILD.xml:S3:1559:2	O
patients	STRIBILD.xml:S3:1562:8	O
receiving	STRIBILD.xml:S3:1571:9	O
antiretroviral	STRIBILD.xml:S3:1581:14	O
therapy	STRIBILD.xml:S3:1596:7	O
.	STRIBILD.xml:S3:1603:1	O

(	STRIBILD.xml:S3:1605:1	O
5.7	STRIBILD.xml:S3:1608:3	O
)	STRIBILD.xml:S3:1613:1	O

Immune	STRIBILD.xml:S3:1620:6	B-AdverseReaction
reconstitution	STRIBILD.xml:S3:1627:14	I-AdverseReaction
syndrome	STRIBILD.xml:S3:1642:8	I-AdverseReaction
:	STRIBILD.xml:S3:1650:1	O
May	STRIBILD.xml:S3:1652:3	O
necessitate	STRIBILD.xml:S3:1656:11	O
further	STRIBILD.xml:S3:1668:7	O
evaluation	STRIBILD.xml:S3:1676:10	O
and	STRIBILD.xml:S3:1687:3	O
treatment	STRIBILD.xml:S3:1691:9	O
.	STRIBILD.xml:S3:1700:1	O

(	STRIBILD.xml:S3:1702:1	O
5.8	STRIBILD.xml:S3:1705:3	O
)	STRIBILD.xml:S3:1710:1	O

5.1	STRIBILD.xml:S3:1724:3	O

Lactic	STRIBILD.xml:S3:1728:6	O

Acidosis	STRIBILD.xml:S3:1735:8	O
Severe	STRIBILD.xml:S3:1744:6	O
Hepatomegaly	STRIBILD.xml:S3:1751:12	O
with	STRIBILD.xml:S3:1764:4	O
Steatosis	STRIBILD.xml:S3:1769:9	O

Lactic	STRIBILD.xml:S3:1784:6	B-AdverseReaction
acidosis	STRIBILD.xml:S3:1791:8	I-AdverseReaction
and	STRIBILD.xml:S3:1800:3	O
severe	STRIBILD.xml:S3:1804:6	B-Severity
hepatomegaly	STRIBILD.xml:S3:1811:12	B-AdverseReaction
with	STRIBILD.xml:S3:1824:4	O
steatosis	STRIBILD.xml:S3:1829:9	B-AdverseReaction
,	STRIBILD.xml:S3:1838:1	O
including	STRIBILD.xml:S3:1840:9	O
fatal	STRIBILD.xml:S3:1850:5	B-AdverseReaction
cases	STRIBILD.xml:S3:1856:5	O
,	STRIBILD.xml:S3:1861:1	O
have	STRIBILD.xml:S3:1863:4	O
been	STRIBILD.xml:S3:1868:4	O
reported	STRIBILD.xml:S3:1873:8	O
with	STRIBILD.xml:S3:1882:4	O
the	STRIBILD.xml:S3:1887:3	O
use	STRIBILD.xml:S3:1891:3	O
of	STRIBILD.xml:S3:1895:2	O
nucleoside	STRIBILD.xml:S3:1898:10	O
analogs	STRIBILD.xml:S3:1909:7	O
,	STRIBILD.xml:S3:1916:1	O
including	STRIBILD.xml:S3:1918:9	O
tenofovir	STRIBILD.xml:S3:1928:9	O
DF	STRIBILD.xml:S3:1938:2	O
,	STRIBILD.xml:S3:1940:1	O
a	STRIBILD.xml:S3:1942:1	O
component	STRIBILD.xml:S3:1944:9	O
of	STRIBILD.xml:S3:1954:2	O
STRIBILD	STRIBILD.xml:S3:1957:8	O
,	STRIBILD.xml:S3:1965:1	O
in	STRIBILD.xml:S3:1967:2	O
combination	STRIBILD.xml:S3:1970:11	O
with	STRIBILD.xml:S3:1982:4	O
other	STRIBILD.xml:S3:1987:5	O
antiretrovirals	STRIBILD.xml:S3:1993:15	O
.	STRIBILD.xml:S3:2008:1	O

A	STRIBILD.xml:S3:2010:1	O
majority	STRIBILD.xml:S3:2012:8	O
of	STRIBILD.xml:S3:2021:2	O
these	STRIBILD.xml:S3:2024:5	O
cases	STRIBILD.xml:S3:2030:5	O
have	STRIBILD.xml:S3:2036:4	O
been	STRIBILD.xml:S3:2041:4	O
in	STRIBILD.xml:S3:2046:2	O
women	STRIBILD.xml:S3:2049:5	O
.	STRIBILD.xml:S3:2054:1	O

Obesity	STRIBILD.xml:S3:2056:7	O
and	STRIBILD.xml:S3:2064:3	O
prolonged	STRIBILD.xml:S3:2068:9	O
nucleoside	STRIBILD.xml:S3:2078:10	O
exposure	STRIBILD.xml:S3:2089:8	O
may	STRIBILD.xml:S3:2098:3	O
be	STRIBILD.xml:S3:2102:2	O
risk	STRIBILD.xml:S3:2105:4	O
factors	STRIBILD.xml:S3:2110:7	O
.	STRIBILD.xml:S3:2117:1	O

Particular	STRIBILD.xml:S3:2119:10	O
caution	STRIBILD.xml:S3:2130:7	O
should	STRIBILD.xml:S3:2138:6	O
be	STRIBILD.xml:S3:2145:2	O
exercised	STRIBILD.xml:S3:2148:9	O
when	STRIBILD.xml:S3:2158:4	O
administering	STRIBILD.xml:S3:2163:13	O
nucleoside	STRIBILD.xml:S3:2177:10	O
analogs	STRIBILD.xml:S3:2188:7	O
to	STRIBILD.xml:S3:2196:2	O
any	STRIBILD.xml:S3:2199:3	O
patient	STRIBILD.xml:S3:2203:7	O
with	STRIBILD.xml:S3:2211:4	O
known	STRIBILD.xml:S3:2216:5	O
risk	STRIBILD.xml:S3:2222:4	O
factors	STRIBILD.xml:S3:2227:7	O
for	STRIBILD.xml:S3:2235:3	O
liver	STRIBILD.xml:S3:2239:5	O
disease	STRIBILD.xml:S3:2245:7	O
;	STRIBILD.xml:S3:2252:1	O
however	STRIBILD.xml:S3:2254:7	O
,	STRIBILD.xml:S3:2261:1	O
cases	STRIBILD.xml:S3:2263:5	O
have	STRIBILD.xml:S3:2269:4	O
also	STRIBILD.xml:S3:2274:4	O
been	STRIBILD.xml:S3:2279:4	O
reported	STRIBILD.xml:S3:2284:8	O
in	STRIBILD.xml:S3:2293:2	O
patients	STRIBILD.xml:S3:2296:8	O
with	STRIBILD.xml:S3:2305:4	O
no	STRIBILD.xml:S3:2310:2	O
known	STRIBILD.xml:S3:2313:5	O
risk	STRIBILD.xml:S3:2319:4	O
factors	STRIBILD.xml:S3:2324:7	O
.	STRIBILD.xml:S3:2331:1	O

Treatment	STRIBILD.xml:S3:2333:9	O
with	STRIBILD.xml:S3:2343:4	O
STRIBILD	STRIBILD.xml:S3:2348:8	O
should	STRIBILD.xml:S3:2357:6	O
be	STRIBILD.xml:S3:2364:2	O
suspended	STRIBILD.xml:S3:2367:9	O
in	STRIBILD.xml:S3:2377:2	O
any	STRIBILD.xml:S3:2380:3	O
patient	STRIBILD.xml:S3:2384:7	O
who	STRIBILD.xml:S3:2392:3	O
develops	STRIBILD.xml:S3:2396:8	O
clinical	STRIBILD.xml:S3:2405:8	O
or	STRIBILD.xml:S3:2414:2	O
laboratory	STRIBILD.xml:S3:2417:10	O
findings	STRIBILD.xml:S3:2428:8	O
suggestive	STRIBILD.xml:S3:2437:10	O
of	STRIBILD.xml:S3:2448:2	O
lactic	STRIBILD.xml:S3:2451:6	O
acidosis	STRIBILD.xml:S3:2458:8	O
or	STRIBILD.xml:S3:2467:2	O
pronounced	STRIBILD.xml:S3:2470:10	O
hepatotoxicity	STRIBILD.xml:S3:2481:14	O
(	STRIBILD.xml:S3:2496:1	O
which	STRIBILD.xml:S3:2497:5	O
may	STRIBILD.xml:S3:2503:3	O
include	STRIBILD.xml:S3:2507:7	O
hepatomegaly	STRIBILD.xml:S3:2515:12	O
and	STRIBILD.xml:S3:2528:3	O
steatosis	STRIBILD.xml:S3:2532:9	O
even	STRIBILD.xml:S3:2542:4	O
in	STRIBILD.xml:S3:2547:2	O
the	STRIBILD.xml:S3:2550:3	O
absence	STRIBILD.xml:S3:2554:7	O
of	STRIBILD.xml:S3:2562:2	O
marked	STRIBILD.xml:S3:2565:6	O
transaminase	STRIBILD.xml:S3:2572:12	O
elevations	STRIBILD.xml:S3:2585:10	O
)	STRIBILD.xml:S3:2595:1	O
.	STRIBILD.xml:S3:2596:1	O

5.2	STRIBILD.xml:S3:2605:3	O
Patients	STRIBILD.xml:S3:2609:8	O
Coinfected	STRIBILD.xml:S3:2618:10	O
with	STRIBILD.xml:S3:2629:4	O
HIV	STRIBILD.xml:S3:2634:3	O
-	STRIBILD.xml:S3:2637:1	O
1	STRIBILD.xml:S3:2638:1	O
and	STRIBILD.xml:S3:2640:3	O
HBV	STRIBILD.xml:S3:2644:3	O

It	STRIBILD.xml:S3:2653:2	O
is	STRIBILD.xml:S3:2656:2	O
recommended	STRIBILD.xml:S3:2659:11	O
that	STRIBILD.xml:S3:2671:4	O
all	STRIBILD.xml:S3:2676:3	O
patients	STRIBILD.xml:S3:2680:8	O
with	STRIBILD.xml:S3:2689:4	O
HIV	STRIBILD.xml:S3:2694:3	O
-	STRIBILD.xml:S3:2697:1	O
1	STRIBILD.xml:S3:2698:1	O
be	STRIBILD.xml:S3:2700:2	O
tested	STRIBILD.xml:S3:2703:6	O
for	STRIBILD.xml:S3:2710:3	O
the	STRIBILD.xml:S3:2714:3	O
presence	STRIBILD.xml:S3:2718:8	O
of	STRIBILD.xml:S3:2727:2	O
chronic	STRIBILD.xml:S3:2730:7	O
hepatitis	STRIBILD.xml:S3:2738:9	O
B	STRIBILD.xml:S3:2748:1	O
virus	STRIBILD.xml:S3:2750:5	O
(	STRIBILD.xml:S3:2756:1	O
HBV	STRIBILD.xml:S3:2757:3	O
)	STRIBILD.xml:S3:2760:1	O
before	STRIBILD.xml:S3:2762:6	O
initiating	STRIBILD.xml:S3:2769:10	O
antiretroviral	STRIBILD.xml:S3:2780:14	O
therapy	STRIBILD.xml:S3:2795:7	O
.	STRIBILD.xml:S3:2802:1	O

STRIBILD	STRIBILD.xml:S3:2804:8	O
is	STRIBILD.xml:S3:2813:2	O
not	STRIBILD.xml:S3:2816:3	O
approved	STRIBILD.xml:S3:2820:8	O
for	STRIBILD.xml:S3:2829:3	O
the	STRIBILD.xml:S3:2833:3	O
treatment	STRIBILD.xml:S3:2837:9	O
of	STRIBILD.xml:S3:2847:2	O
chronic	STRIBILD.xml:S3:2850:7	O
HBV	STRIBILD.xml:S3:2858:3	O
infection	STRIBILD.xml:S3:2862:9	O
and	STRIBILD.xml:S3:2872:3	O
the	STRIBILD.xml:S3:2876:3	O
safety	STRIBILD.xml:S3:2880:6	O
and	STRIBILD.xml:S3:2887:3	O
efficacy	STRIBILD.xml:S3:2891:8	O
of	STRIBILD.xml:S3:2900:2	O
STRIBILD	STRIBILD.xml:S3:2903:8	O
have	STRIBILD.xml:S3:2912:4	O
not	STRIBILD.xml:S3:2917:3	O
been	STRIBILD.xml:S3:2921:4	O
established	STRIBILD.xml:S3:2926:11	O
in	STRIBILD.xml:S3:2938:2	O
patients	STRIBILD.xml:S3:2941:8	O
coinfected	STRIBILD.xml:S3:2950:10	O
with	STRIBILD.xml:S3:2961:4	O
HBV	STRIBILD.xml:S3:2966:3	O
and	STRIBILD.xml:S3:2970:3	O
HIV	STRIBILD.xml:S3:2974:3	O
-	STRIBILD.xml:S3:2977:1	O
1	STRIBILD.xml:S3:2978:1	O
.	STRIBILD.xml:S3:2979:1	O

Severe	STRIBILD.xml:S3:2981:6	O
acute	STRIBILD.xml:S3:2988:5	O
exacerbations	STRIBILD.xml:S3:2994:13	O
of	STRIBILD.xml:S3:3008:2	O
hepatitis	STRIBILD.xml:S3:3011:9	O
B	STRIBILD.xml:S3:3021:1	O
have	STRIBILD.xml:S3:3023:4	O
been	STRIBILD.xml:S3:3028:4	O
reported	STRIBILD.xml:S3:3033:8	O
in	STRIBILD.xml:S3:3042:2	O
patients	STRIBILD.xml:S3:3045:8	O
who	STRIBILD.xml:S3:3054:3	O
are	STRIBILD.xml:S3:3058:3	O
coinfected	STRIBILD.xml:S3:3062:10	O
with	STRIBILD.xml:S3:3073:4	O
HBV	STRIBILD.xml:S3:3078:3	O
and	STRIBILD.xml:S3:3082:3	O
HIV	STRIBILD.xml:S3:3086:3	O
-	STRIBILD.xml:S3:3089:1	O
1	STRIBILD.xml:S3:3090:1	O
and	STRIBILD.xml:S3:3092:3	O
have	STRIBILD.xml:S3:3096:4	O
discontinued	STRIBILD.xml:S3:3101:12	O
emtricitabine	STRIBILD.xml:S3:3114:13	O
or	STRIBILD.xml:S3:3128:2	O
tenofovir	STRIBILD.xml:S3:3131:9	O
DF	STRIBILD.xml:S3:3141:2	O
,	STRIBILD.xml:S3:3143:1	O
two	STRIBILD.xml:S3:3145:3	O
of	STRIBILD.xml:S3:3149:2	O
the	STRIBILD.xml:S3:3152:3	O
components	STRIBILD.xml:S3:3156:10	O
of	STRIBILD.xml:S3:3167:2	O
STRIBILD	STRIBILD.xml:S3:3170:8	O
.	STRIBILD.xml:S3:3178:1	O

In	STRIBILD.xml:S3:3180:2	O
some	STRIBILD.xml:S3:3183:4	O
patients	STRIBILD.xml:S3:3188:8	O
infected	STRIBILD.xml:S3:3197:8	O
with	STRIBILD.xml:S3:3206:4	O
HBV	STRIBILD.xml:S3:3211:3	O
and	STRIBILD.xml:S3:3215:3	O
treated	STRIBILD.xml:S3:3219:7	O
with	STRIBILD.xml:S3:3227:4	O
EMTRIVA	STRIBILD.xml:S3:3232:7	O
,	STRIBILD.xml:S3:3239:1	O
the	STRIBILD.xml:S3:3241:3	O
exacerbations	STRIBILD.xml:S3:3245:13	B-AdverseReaction
of	STRIBILD.xml:S3:3259:2	I-AdverseReaction
hepatitis	STRIBILD.xml:S3:3262:9	I-AdverseReaction
B	STRIBILD.xml:S3:3272:1	I-AdverseReaction
were	STRIBILD.xml:S3:3274:4	O
associated	STRIBILD.xml:S3:3279:10	O
with	STRIBILD.xml:S3:3290:4	O
liver	STRIBILD.xml:S3:3295:5	B-AdverseReaction
decompensation	STRIBILD.xml:S3:3301:14	I-AdverseReaction
and	STRIBILD.xml:S3:3316:3	O
liver	STRIBILD.xml:S3:3320:5	B-AdverseReaction
failure	STRIBILD.xml:S3:3326:7	I-AdverseReaction
.	STRIBILD.xml:S3:3333:1	O

Patients	STRIBILD.xml:S3:3335:8	O
who	STRIBILD.xml:S3:3344:3	O
are	STRIBILD.xml:S3:3348:3	O
coinfected	STRIBILD.xml:S3:3352:10	O
with	STRIBILD.xml:S3:3363:4	O
HIV	STRIBILD.xml:S3:3368:3	O
-	STRIBILD.xml:S3:3371:1	O
1	STRIBILD.xml:S3:3372:1	O
and	STRIBILD.xml:S3:3374:3	O
HBV	STRIBILD.xml:S3:3378:3	O
should	STRIBILD.xml:S3:3382:6	O
be	STRIBILD.xml:S3:3389:2	O
closely	STRIBILD.xml:S3:3392:7	O
monitored	STRIBILD.xml:S3:3400:9	O
with	STRIBILD.xml:S3:3410:4	O
both	STRIBILD.xml:S3:3415:4	O
clinical	STRIBILD.xml:S3:3420:8	O
and	STRIBILD.xml:S3:3429:3	O
laboratory	STRIBILD.xml:S3:3433:10	O
follow	STRIBILD.xml:S3:3444:6	O
-	STRIBILD.xml:S3:3450:1	O
up	STRIBILD.xml:S3:3451:2	O
for	STRIBILD.xml:S3:3454:3	O
at	STRIBILD.xml:S3:3458:2	O
least	STRIBILD.xml:S3:3461:5	O
several	STRIBILD.xml:S3:3467:7	O
months	STRIBILD.xml:S3:3475:6	O
after	STRIBILD.xml:S3:3482:5	O
stopping	STRIBILD.xml:S3:3488:8	O
treatment	STRIBILD.xml:S3:3497:9	O
with	STRIBILD.xml:S3:3507:4	O
STRIBILD	STRIBILD.xml:S3:3512:8	O
.	STRIBILD.xml:S3:3520:1	O

If	STRIBILD.xml:S3:3522:2	O
appropriate	STRIBILD.xml:S3:3525:11	O
,	STRIBILD.xml:S3:3536:1	O
initiation	STRIBILD.xml:S3:3538:10	O
of	STRIBILD.xml:S3:3549:2	O
anti	STRIBILD.xml:S3:3552:4	O
-	STRIBILD.xml:S3:3556:1	O
hepatitis	STRIBILD.xml:S3:3557:9	O
B	STRIBILD.xml:S3:3567:1	O
therapy	STRIBILD.xml:S3:3569:7	O
may	STRIBILD.xml:S3:3577:3	O
be	STRIBILD.xml:S3:3581:2	O
warranted	STRIBILD.xml:S3:3584:9	O
.	STRIBILD.xml:S3:3593:1	O

5.3	STRIBILD.xml:S3:3602:3	O
New	STRIBILD.xml:S3:3606:3	O
Onset	STRIBILD.xml:S3:3610:5	O
or	STRIBILD.xml:S3:3616:2	O
Worsening	STRIBILD.xml:S3:3619:9	O
Renal	STRIBILD.xml:S3:3629:5	O
Impairment	STRIBILD.xml:S3:3635:10	O

Renal	STRIBILD.xml:S3:3651:5	B-AdverseReaction
impairment	STRIBILD.xml:S3:3657:10	I-AdverseReaction
,	STRIBILD.xml:S3:3667:1	O
including	STRIBILD.xml:S3:3669:9	O
cases	STRIBILD.xml:S3:3679:5	O
of	STRIBILD.xml:S3:3685:2	O
acute	STRIBILD.xml:S3:3688:5	B-AdverseReaction
renal	STRIBILD.xml:S3:3694:5	I-AdverseReaction
failure	STRIBILD.xml:S3:3700:7	I-AdverseReaction
and	STRIBILD.xml:S3:3708:3	O
Fanconi	STRIBILD.xml:S3:3712:7	B-AdverseReaction
syndrome	STRIBILD.xml:S3:3720:8	I-AdverseReaction
(	STRIBILD.xml:S3:3729:1	O
renal	STRIBILD.xml:S3:3730:5	B-AdverseReaction
tubular	STRIBILD.xml:S3:3736:7	I-AdverseReaction
injury	STRIBILD.xml:S3:3744:6	I-AdverseReaction
with	STRIBILD.xml:S3:3751:4	O
severe	STRIBILD.xml:S3:3756:6	B-Severity
hypophosphatemia	STRIBILD.xml:S3:3763:16	B-AdverseReaction
)	STRIBILD.xml:S3:3779:1	O
,	STRIBILD.xml:S3:3780:1	O
has	STRIBILD.xml:S3:3782:3	O
been	STRIBILD.xml:S3:3786:4	O
reported	STRIBILD.xml:S3:3791:8	O
with	STRIBILD.xml:S3:3800:4	O
the	STRIBILD.xml:S3:3805:3	O
use	STRIBILD.xml:S3:3809:3	O
of	STRIBILD.xml:S3:3813:2	O
tenofovir	STRIBILD.xml:S3:3816:9	O
DF	STRIBILD.xml:S3:3826:2	O
,	STRIBILD.xml:S3:3828:1	O
a	STRIBILD.xml:S3:3830:1	O
component	STRIBILD.xml:S3:3832:9	O
of	STRIBILD.xml:S3:3842:2	O
STRIBILD	STRIBILD.xml:S3:3845:8	O
,	STRIBILD.xml:S3:3853:1	O
and	STRIBILD.xml:S3:3855:3	O
with	STRIBILD.xml:S3:3859:4	O
the	STRIBILD.xml:S3:3864:3	O
use	STRIBILD.xml:S3:3868:3	O
of	STRIBILD.xml:S3:3872:2	O
STRIBILD	STRIBILD.xml:S3:3875:8	O
[	STRIBILD.xml:S3:3884:1	O
see	STRIBILD.xml:S3:3885:3	O
Adverse	STRIBILD.xml:S3:3890:7	O
Reactions	STRIBILD.xml:S3:3898:9	O
(	STRIBILD.xml:S3:3908:1	O
6.2	STRIBILD.xml:S3:3909:3	O
)	STRIBILD.xml:S3:3912:1	O
]	STRIBILD.xml:S3:3915:1	O
.	STRIBILD.xml:S3:3918:1	O

In	STRIBILD.xml:S3:3925:2	O
the	STRIBILD.xml:S3:3928:3	O
clinical	STRIBILD.xml:S3:3932:8	O
trials	STRIBILD.xml:S3:3941:6	O
of	STRIBILD.xml:S3:3948:2	O
STRIBILD	STRIBILD.xml:S3:3951:8	O
over	STRIBILD.xml:S3:3960:4	O
144	STRIBILD.xml:S3:3965:3	O
weeks	STRIBILD.xml:S3:3969:5	O
,	STRIBILD.xml:S3:3974:1	O
13	STRIBILD.xml:S3:3976:2	O
(	STRIBILD.xml:S3:3979:1	O
1.9%	STRIBILD.xml:S3:3980:4	O
)	STRIBILD.xml:S3:3984:1	O
subjects	STRIBILD.xml:S3:3986:8	O
in	STRIBILD.xml:S3:3995:2	O
the	STRIBILD.xml:S3:3998:3	O
STRIBILD	STRIBILD.xml:S3:4002:8	O
group	STRIBILD.xml:S3:4011:5	O
(	STRIBILD.xml:S3:4017:1	O
N	STRIBILD.xml:S3:4018:1	O
701	STRIBILD.xml:S3:4020:3	O
)	STRIBILD.xml:S3:4023:1	O
,	STRIBILD.xml:S3:4024:1	O
8	STRIBILD.xml:S3:4026:1	O
(	STRIBILD.xml:S3:4028:1	O
2.3%	STRIBILD.xml:S3:4029:4	O
)	STRIBILD.xml:S3:4033:1	O
subjects	STRIBILD.xml:S3:4035:8	O
in	STRIBILD.xml:S3:4044:2	O
the	STRIBILD.xml:S3:4047:3	O
ATV	STRIBILD.xml:S3:4051:3	O
RTV	STRIBILD.xml:S3:4057:3	O
TRUVADA	STRIBILD.xml:S3:4063:7	O
group	STRIBILD.xml:S3:4071:5	O
(	STRIBILD.xml:S3:4077:1	O
N	STRIBILD.xml:S3:4078:1	O
355	STRIBILD.xml:S3:4080:3	O
)	STRIBILD.xml:S3:4083:1	O
and	STRIBILD.xml:S3:4085:3	O
no	STRIBILD.xml:S3:4089:2	O
subjects	STRIBILD.xml:S3:4092:8	O
in	STRIBILD.xml:S3:4101:2	O
the	STRIBILD.xml:S3:4104:3	O
ATRIPLA	STRIBILD.xml:S3:4108:7	O
group	STRIBILD.xml:S3:4116:5	O
(	STRIBILD.xml:S3:4122:1	O
N	STRIBILD.xml:S3:4123:1	O
352	STRIBILD.xml:S3:4127:3	O
)	STRIBILD.xml:S3:4130:1	O
discontinued	STRIBILD.xml:S3:4132:12	O
study	STRIBILD.xml:S3:4145:5	O
drug	STRIBILD.xml:S3:4151:4	O
due	STRIBILD.xml:S3:4156:3	O
to	STRIBILD.xml:S3:4160:2	O
a	STRIBILD.xml:S3:4163:1	O
renal	STRIBILD.xml:S3:4165:5	B-AdverseReaction
adverse	STRIBILD.xml:S3:4171:7	I-AdverseReaction
reaction	STRIBILD.xml:S3:4179:8	I-AdverseReaction
.	STRIBILD.xml:S3:4187:1	O

Of	STRIBILD.xml:S3:4189:2	O
these	STRIBILD.xml:S3:4192:5	O
discontinuations	STRIBILD.xml:S3:4198:16	O
,	STRIBILD.xml:S3:4214:1	O
8	STRIBILD.xml:S3:4216:1	O
in	STRIBILD.xml:S3:4218:2	O
the	STRIBILD.xml:S3:4221:3	O
STRIBILD	STRIBILD.xml:S3:4225:8	O
group	STRIBILD.xml:S3:4234:5	O
and	STRIBILD.xml:S3:4240:3	O
1	STRIBILD.xml:S3:4244:1	O
in	STRIBILD.xml:S3:4246:2	O
the	STRIBILD.xml:S3:4249:3	O
ATV	STRIBILD.xml:S3:4253:3	O
RTV	STRIBILD.xml:S3:4259:3	O
TRUVADA	STRIBILD.xml:S3:4265:7	O
group	STRIBILD.xml:S3:4273:5	O
occurred	STRIBILD.xml:S3:4279:8	O
during	STRIBILD.xml:S3:4288:6	O
the	STRIBILD.xml:S3:4295:3	O
first	STRIBILD.xml:S3:4299:5	O
48	STRIBILD.xml:S3:4305:2	O
weeks	STRIBILD.xml:S3:4308:5	O
.	STRIBILD.xml:S3:4313:1	O

Four	STRIBILD.xml:S3:4315:4	O
(	STRIBILD.xml:S3:4320:1	O
0.6%	STRIBILD.xml:S3:4321:4	O
)	STRIBILD.xml:S3:4325:1	O
subjects	STRIBILD.xml:S3:4327:8	O
who	STRIBILD.xml:S3:4336:3	O
received	STRIBILD.xml:S3:4340:8	O
STRIBILD	STRIBILD.xml:S3:4349:8	O
developed	STRIBILD.xml:S3:4358:9	O
laboratory	STRIBILD.xml:S3:4368:10	O
findings	STRIBILD.xml:S3:4379:8	O
consistent	STRIBILD.xml:S3:4388:10	O
with	STRIBILD.xml:S3:4399:4	O
proximal	STRIBILD.xml:S3:4404:8	B-AdverseReaction
renal	STRIBILD.xml:S3:4413:5	I-AdverseReaction
tubular	STRIBILD.xml:S3:4419:7	I-AdverseReaction
dysfunction	STRIBILD.xml:S3:4427:11	I-AdverseReaction
leading	STRIBILD.xml:S3:4439:7	O
to	STRIBILD.xml:S3:4447:2	O
discontinuation	STRIBILD.xml:S3:4450:15	O
of	STRIBILD.xml:S3:4466:2	O
STRIBILD	STRIBILD.xml:S3:4469:8	O
during	STRIBILD.xml:S3:4478:6	O
the	STRIBILD.xml:S3:4485:3	O
first	STRIBILD.xml:S3:4489:5	O
48	STRIBILD.xml:S3:4495:2	O
weeks	STRIBILD.xml:S3:4498:5	O
of	STRIBILD.xml:S3:4504:2	O
treatment	STRIBILD.xml:S3:4507:9	O
.	STRIBILD.xml:S3:4516:1	O

Two	STRIBILD.xml:S3:4518:3	O
of	STRIBILD.xml:S3:4522:2	O
the	STRIBILD.xml:S3:4525:3	O
four	STRIBILD.xml:S3:4529:4	O
subjects	STRIBILD.xml:S3:4534:8	O
had	STRIBILD.xml:S3:4543:3	O
renal	STRIBILD.xml:S3:4547:5	O
impairment	STRIBILD.xml:S3:4553:10	O
(	STRIBILD.xml:S3:4564:1	O
i	STRIBILD.xml:S3:4565:1	O
.	STRIBILD.xml:S3:4566:1	O
e	STRIBILD.xml:S3:4567:1	O
.	STRIBILD.xml:S3:4568:1	O

estimated	STRIBILD.xml:S3:4570:9	O
creatinine	STRIBILD.xml:S3:4580:10	O
clearance	STRIBILD.xml:S3:4591:9	O
less	STRIBILD.xml:S3:4601:4	O
than	STRIBILD.xml:S3:4606:4	O
70	STRIBILD.xml:S3:4611:2	O
mL	STRIBILD.xml:S3:4614:2	O
per	STRIBILD.xml:S3:4617:3	O
minute	STRIBILD.xml:S3:4621:6	O
)	STRIBILD.xml:S3:4627:1	O
at	STRIBILD.xml:S3:4629:2	O
baseline	STRIBILD.xml:S3:4632:8	O
.	STRIBILD.xml:S3:4640:1	O

The	STRIBILD.xml:S3:4642:3	O
laboratory	STRIBILD.xml:S3:4646:10	O
findings	STRIBILD.xml:S3:4657:8	O
in	STRIBILD.xml:S3:4666:2	O
these	STRIBILD.xml:S3:4669:5	O
4	STRIBILD.xml:S3:4675:1	O
subjects	STRIBILD.xml:S3:4677:8	O
improved	STRIBILD.xml:S3:4686:8	O
but	STRIBILD.xml:S3:4695:3	O
did	STRIBILD.xml:S3:4699:3	O
not	STRIBILD.xml:S3:4703:3	O
completely	STRIBILD.xml:S3:4707:10	O
resolve	STRIBILD.xml:S3:4718:7	O
in	STRIBILD.xml:S3:4726:2	O
all	STRIBILD.xml:S3:4729:3	O
subjects	STRIBILD.xml:S3:4733:8	O
upon	STRIBILD.xml:S3:4742:4	O
discontinuation	STRIBILD.xml:S3:4747:15	O
of	STRIBILD.xml:S3:4763:2	O
STRIBILD	STRIBILD.xml:S3:4766:8	O
.	STRIBILD.xml:S3:4774:1	O

Renal	STRIBILD.xml:S3:4776:5	O
replacement	STRIBILD.xml:S3:4782:11	O
therapy	STRIBILD.xml:S3:4794:7	O
was	STRIBILD.xml:S3:4802:3	O
not	STRIBILD.xml:S3:4806:3	O
required	STRIBILD.xml:S3:4810:8	O
for	STRIBILD.xml:S3:4819:3	O
these	STRIBILD.xml:S3:4823:5	O
subjects	STRIBILD.xml:S3:4829:8	O
.	STRIBILD.xml:S3:4837:1	O

One	STRIBILD.xml:S3:4839:3	O
(	STRIBILD.xml:S3:4843:1	O
0.3%	STRIBILD.xml:S3:4844:4	O
)	STRIBILD.xml:S3:4848:1	O
subject	STRIBILD.xml:S3:4850:7	O
who	STRIBILD.xml:S3:4858:3	O
received	STRIBILD.xml:S3:4862:8	O
ATV	STRIBILD.xml:S3:4871:3	O
RTV	STRIBILD.xml:S3:4877:3	O
TRUVADA	STRIBILD.xml:S3:4883:7	O
developed	STRIBILD.xml:S3:4891:9	O
laboratory	STRIBILD.xml:S3:4901:10	O
findings	STRIBILD.xml:S3:4912:8	O
consistent	STRIBILD.xml:S3:4921:10	O
with	STRIBILD.xml:S3:4932:4	O
proximal	STRIBILD.xml:S3:4937:8	B-AdverseReaction
renal	STRIBILD.xml:S3:4946:5	I-AdverseReaction
tubular	STRIBILD.xml:S3:4952:7	I-AdverseReaction
dysfunction	STRIBILD.xml:S3:4960:11	I-AdverseReaction
leading	STRIBILD.xml:S3:4972:7	O
to	STRIBILD.xml:S3:4980:2	O
discontinuation	STRIBILD.xml:S3:4983:15	O
of	STRIBILD.xml:S3:4999:2	O
ATV	STRIBILD.xml:S3:5002:3	O
RTV	STRIBILD.xml:S3:5008:3	O
TRUVADA	STRIBILD.xml:S3:5014:7	O
after	STRIBILD.xml:S3:5022:5	O
Week	STRIBILD.xml:S3:5028:4	O
96	STRIBILD.xml:S3:5033:2	O
.	STRIBILD.xml:S3:5035:1	O

STRIBILD	STRIBILD.xml:S3:5043:8	O
should	STRIBILD.xml:S3:5052:6	O
be	STRIBILD.xml:S3:5059:2	O
avoided	STRIBILD.xml:S3:5062:7	O
with	STRIBILD.xml:S3:5070:4	O
concurrent	STRIBILD.xml:S3:5075:10	O
or	STRIBILD.xml:S3:5086:2	O
recent	STRIBILD.xml:S3:5089:6	O
use	STRIBILD.xml:S3:5096:3	O
of	STRIBILD.xml:S3:5100:2	O
a	STRIBILD.xml:S3:5103:1	O
nephrotoxic	STRIBILD.xml:S3:5105:11	O
agent	STRIBILD.xml:S3:5117:5	O
.	STRIBILD.xml:S3:5122:1	O

(	STRIBILD.xml:S3:5124:1	O
e	STRIBILD.xml:S3:5125:1	O
.	STRIBILD.xml:S3:5126:1	O
g	STRIBILD.xml:S3:5127:1	O
.	STRIBILD.xml:S3:5128:1	O
,	STRIBILD.xml:S3:5129:1	O
high	STRIBILD.xml:S3:5131:4	O
-	STRIBILD.xml:S3:5135:1	O
dose	STRIBILD.xml:S3:5136:4	O
or	STRIBILD.xml:S3:5141:2	O
multiple	STRIBILD.xml:S3:5144:8	O
non	STRIBILD.xml:S3:5153:3	O
-	STRIBILD.xml:S3:5156:1	O
steroidal	STRIBILD.xml:S3:5157:9	O
anti	STRIBILD.xml:S3:5167:4	O
-	STRIBILD.xml:S3:5171:1	O
inflammatory	STRIBILD.xml:S3:5172:12	O
drugs	STRIBILD.xml:S3:5185:5	O
(	STRIBILD.xml:S3:5191:1	O
NSAIDs	STRIBILD.xml:S3:5192:6	O
))	STRIBILD.xml:S3:5198:2	O
[	STRIBILD.xml:S3:5201:1	O
see	STRIBILD.xml:S3:5202:3	O
Drug	STRIBILD.xml:S3:5207:4	O
Interactions	STRIBILD.xml:S3:5212:12	O
(	STRIBILD.xml:S3:5225:1	O
7.4	STRIBILD.xml:S3:5226:3	O
)	STRIBILD.xml:S3:5229:1	O
]	STRIBILD.xml:S3:5232:1	O
.	STRIBILD.xml:S3:5235:1	O

Cases	STRIBILD.xml:S3:5237:5	O
of	STRIBILD.xml:S3:5243:2	O
acute	STRIBILD.xml:S3:5246:5	O
renal	STRIBILD.xml:S3:5252:5	O
failure	STRIBILD.xml:S3:5258:7	O
after	STRIBILD.xml:S3:5266:5	O
initiation	STRIBILD.xml:S3:5272:10	O
of	STRIBILD.xml:S3:5283:2	O
high	STRIBILD.xml:S3:5286:4	O
dose	STRIBILD.xml:S3:5291:4	O
or	STRIBILD.xml:S3:5296:2	O
multiple	STRIBILD.xml:S3:5299:8	O
NSAIDs	STRIBILD.xml:S3:5308:6	O
have	STRIBILD.xml:S3:5315:4	O
been	STRIBILD.xml:S3:5320:4	O
reported	STRIBILD.xml:S3:5325:8	O
in	STRIBILD.xml:S3:5334:2	O
HIV	STRIBILD.xml:S3:5337:3	O
-	STRIBILD.xml:S3:5340:1	O
infected	STRIBILD.xml:S3:5341:8	O
patients	STRIBILD.xml:S3:5350:8	O
with	STRIBILD.xml:S3:5359:4	O
risk	STRIBILD.xml:S3:5364:4	O
factors	STRIBILD.xml:S3:5369:7	O
for	STRIBILD.xml:S3:5377:3	O
renal	STRIBILD.xml:S3:5381:5	O
dysfunction	STRIBILD.xml:S3:5387:11	O
who	STRIBILD.xml:S3:5399:3	O
appeared	STRIBILD.xml:S3:5403:8	O
stable	STRIBILD.xml:S3:5412:6	O
on	STRIBILD.xml:S3:5419:2	O
tenofovir	STRIBILD.xml:S3:5422:9	O
DF	STRIBILD.xml:S3:5432:2	O
.	STRIBILD.xml:S3:5434:1	O

Some	STRIBILD.xml:S3:5436:4	O
patients	STRIBILD.xml:S3:5441:8	O
required	STRIBILD.xml:S3:5450:8	O
hospitalization	STRIBILD.xml:S3:5459:15	O
and	STRIBILD.xml:S3:5475:3	O
renal	STRIBILD.xml:S3:5479:5	O
replacement	STRIBILD.xml:S3:5485:11	O
therapy	STRIBILD.xml:S3:5497:7	O
.	STRIBILD.xml:S3:5504:1	O

Alternatives	STRIBILD.xml:S3:5506:12	O
to	STRIBILD.xml:S3:5519:2	O
NSAIDs	STRIBILD.xml:S3:5522:6	O
should	STRIBILD.xml:S3:5529:6	O
be	STRIBILD.xml:S3:5536:2	O
considered	STRIBILD.xml:S3:5539:10	O
,	STRIBILD.xml:S3:5549:1	O
if	STRIBILD.xml:S3:5551:2	O
needed	STRIBILD.xml:S3:5554:6	O
,	STRIBILD.xml:S3:5560:1	O
in	STRIBILD.xml:S3:5562:2	O
patients	STRIBILD.xml:S3:5565:8	O
at	STRIBILD.xml:S3:5574:2	O
risk	STRIBILD.xml:S3:5577:4	O
for	STRIBILD.xml:S3:5582:3	O
renal	STRIBILD.xml:S3:5586:5	O
dysfunction	STRIBILD.xml:S3:5592:11	O
.	STRIBILD.xml:S3:5603:1	O

Persistent	STRIBILD.xml:S3:5609:10	O
or	STRIBILD.xml:S3:5620:2	O
worsening	STRIBILD.xml:S3:5623:9	O
bone	STRIBILD.xml:S3:5633:4	O
pain	STRIBILD.xml:S3:5638:4	O
,	STRIBILD.xml:S3:5642:1	O
pain	STRIBILD.xml:S3:5644:4	O
in	STRIBILD.xml:S3:5649:2	O
extremities	STRIBILD.xml:S3:5652:11	O
,	STRIBILD.xml:S3:5663:1	O
fractures	STRIBILD.xml:S3:5665:9	O
and	STRIBILD.xml:S3:5675:3	O
or	STRIBILD.xml:S3:5679:2	O
muscular	STRIBILD.xml:S3:5682:8	O
pain	STRIBILD.xml:S3:5691:4	O
or	STRIBILD.xml:S3:5696:2	O
weakness	STRIBILD.xml:S3:5699:8	O
may	STRIBILD.xml:S3:5708:3	O
be	STRIBILD.xml:S3:5712:2	O
manifestations	STRIBILD.xml:S3:5715:14	O
of	STRIBILD.xml:S3:5730:2	O
proximal	STRIBILD.xml:S3:5733:8	O
renal	STRIBILD.xml:S3:5742:5	O
tubulopathy	STRIBILD.xml:S3:5748:11	O
and	STRIBILD.xml:S3:5760:3	O
should	STRIBILD.xml:S3:5764:6	O
prompt	STRIBILD.xml:S3:5771:6	O
an	STRIBILD.xml:S3:5778:2	O
evaluation	STRIBILD.xml:S3:5781:10	O
of	STRIBILD.xml:S3:5792:2	O
renal	STRIBILD.xml:S3:5795:5	O
function	STRIBILD.xml:S3:5801:8	O
in	STRIBILD.xml:S3:5810:2	O
at	STRIBILD.xml:S3:5813:2	O
-	STRIBILD.xml:S3:5815:1	O
risk	STRIBILD.xml:S3:5816:4	O
patients	STRIBILD.xml:S3:5821:8	O
.	STRIBILD.xml:S3:5829:1	O

Estimated	STRIBILD.xml:S3:5835:9	O
creatinine	STRIBILD.xml:S3:5845:10	O
clearance	STRIBILD.xml:S3:5856:9	O
,	STRIBILD.xml:S3:5865:1	O
urine	STRIBILD.xml:S3:5867:5	O
glucose	STRIBILD.xml:S3:5873:7	O
and	STRIBILD.xml:S3:5881:3	O
urine	STRIBILD.xml:S3:5885:5	O
protein	STRIBILD.xml:S3:5891:7	O
should	STRIBILD.xml:S3:5899:6	O
be	STRIBILD.xml:S3:5906:2	O
documented	STRIBILD.xml:S3:5909:10	O
in	STRIBILD.xml:S3:5920:2	O
all	STRIBILD.xml:S3:5923:3	O
patients	STRIBILD.xml:S3:5927:8	O
prior	STRIBILD.xml:S3:5936:5	O
to	STRIBILD.xml:S3:5942:2	O
initiating	STRIBILD.xml:S3:5945:10	O
therapy	STRIBILD.xml:S3:5956:7	O
.	STRIBILD.xml:S3:5963:1	O

Initiation	STRIBILD.xml:S3:5965:10	O
of	STRIBILD.xml:S3:5976:2	O
STRIBILD	STRIBILD.xml:S3:5979:8	O
in	STRIBILD.xml:S3:5988:2	O
patients	STRIBILD.xml:S3:5991:8	O
with	STRIBILD.xml:S3:6000:4	O
estimated	STRIBILD.xml:S3:6005:9	O
creatinine	STRIBILD.xml:S3:6015:10	O
clearance	STRIBILD.xml:S3:6026:9	O
below	STRIBILD.xml:S3:6036:5	O
70	STRIBILD.xml:S3:6042:2	O
mL	STRIBILD.xml:S3:6045:2	O
per	STRIBILD.xml:S3:6048:3	O
minute	STRIBILD.xml:S3:6052:6	O
is	STRIBILD.xml:S3:6059:2	O
not	STRIBILD.xml:S3:6062:3	O
recommended	STRIBILD.xml:S3:6066:11	O
.	STRIBILD.xml:S3:6077:1	O

Routine	STRIBILD.xml:S3:6083:7	O
monitoring	STRIBILD.xml:S3:6091:10	O
of	STRIBILD.xml:S3:6102:2	O
estimated	STRIBILD.xml:S3:6105:9	O
creatinine	STRIBILD.xml:S3:6115:10	O
clearance	STRIBILD.xml:S3:6126:9	O
,	STRIBILD.xml:S3:6135:1	O
urine	STRIBILD.xml:S3:6137:5	O
glucose	STRIBILD.xml:S3:6143:7	O
,	STRIBILD.xml:S3:6150:1	O
and	STRIBILD.xml:S3:6152:3	O
urine	STRIBILD.xml:S3:6156:5	O
protein	STRIBILD.xml:S3:6162:7	O
should	STRIBILD.xml:S3:6170:6	O
be	STRIBILD.xml:S3:6177:2	O
performed	STRIBILD.xml:S3:6180:9	O
during	STRIBILD.xml:S3:6190:6	O
STRIBILD	STRIBILD.xml:S3:6197:8	O
therapy	STRIBILD.xml:S3:6206:7	O
in	STRIBILD.xml:S3:6214:2	O
all	STRIBILD.xml:S3:6217:3	O
patients	STRIBILD.xml:S3:6221:8	O
.	STRIBILD.xml:S3:6229:1	O

Additionally	STRIBILD.xml:S3:6231:12	O
,	STRIBILD.xml:S3:6243:1	O
serum	STRIBILD.xml:S3:6245:5	O
phosphorus	STRIBILD.xml:S3:6251:10	O
should	STRIBILD.xml:S3:6262:6	O
be	STRIBILD.xml:S3:6269:2	O
measured	STRIBILD.xml:S3:6272:8	O
in	STRIBILD.xml:S3:6281:2	O
patients	STRIBILD.xml:S3:6284:8	O
at	STRIBILD.xml:S3:6293:2	O
risk	STRIBILD.xml:S3:6296:4	O
for	STRIBILD.xml:S3:6301:3	O
renal	STRIBILD.xml:S3:6305:5	O
impairment	STRIBILD.xml:S3:6311:10	O
.	STRIBILD.xml:S3:6321:1	O

Although	STRIBILD.xml:S3:6323:8	O
cobicistat	STRIBILD.xml:S3:6332:10	O
(	STRIBILD.xml:S3:6343:1	O
a	STRIBILD.xml:S3:6344:1	O
component	STRIBILD.xml:S3:6346:9	O
of	STRIBILD.xml:S3:6356:2	O
STRIBILD	STRIBILD.xml:S3:6359:8	O
)	STRIBILD.xml:S3:6367:1	O
may	STRIBILD.xml:S3:6369:3	B-Factor
cause	STRIBILD.xml:S3:6373:5	O
modest	STRIBILD.xml:S3:6379:6	B-Severity
increases	STRIBILD.xml:S3:6386:9	B-AdverseReaction
in	STRIBILD.xml:S3:6396:2	I-AdverseReaction
serum	STRIBILD.xml:S3:6399:5	I-AdverseReaction
creatinine	STRIBILD.xml:S3:6405:10	I-AdverseReaction
and	STRIBILD.xml:S3:6416:3	O
modest	STRIBILD.xml:S3:6420:6	B-Severity
declines	STRIBILD.xml:S3:6427:8	B-AdverseReaction
in	STRIBILD.xml:S3:6436:2	I-AdverseReaction
estimated	STRIBILD.xml:S3:6439:9	I-AdverseReaction
creatinine	STRIBILD.xml:S3:6449:10	I-AdverseReaction
clearance	STRIBILD.xml:S3:6460:9	I-AdverseReaction
without	STRIBILD.xml:S3:6470:7	O
affecting	STRIBILD.xml:S3:6478:9	O
renal	STRIBILD.xml:S3:6488:5	O
glomerular	STRIBILD.xml:S3:6494:10	O
function	STRIBILD.xml:S3:6505:8	O
[	STRIBILD.xml:S3:6514:1	O
see	STRIBILD.xml:S3:6515:3	O
Adverse	STRIBILD.xml:S3:6520:7	O
Reactions	STRIBILD.xml:S3:6528:9	O
(	STRIBILD.xml:S3:6538:1	O
6.1	STRIBILD.xml:S3:6539:3	O
)	STRIBILD.xml:S3:6542:1	O
]	STRIBILD.xml:S3:6545:1	O
,	STRIBILD.xml:S3:6548:1	O
patients	STRIBILD.xml:S3:6550:8	O
who	STRIBILD.xml:S3:6559:3	O
experience	STRIBILD.xml:S3:6563:10	O
a	STRIBILD.xml:S3:6574:1	O
confirmed	STRIBILD.xml:S3:6576:9	O
increase	STRIBILD.xml:S3:6586:8	O
in	STRIBILD.xml:S3:6595:2	O
serum	STRIBILD.xml:S3:6598:5	O
creatinine	STRIBILD.xml:S3:6604:10	O
of	STRIBILD.xml:S3:6615:2	O
greater	STRIBILD.xml:S3:6618:7	O
than	STRIBILD.xml:S3:6626:4	O
0.4	STRIBILD.xml:S3:6631:3	O
mg	STRIBILD.xml:S3:6635:2	O
per	STRIBILD.xml:S3:6638:3	O
dL	STRIBILD.xml:S3:6642:2	O
from	STRIBILD.xml:S3:6645:4	O
baseline	STRIBILD.xml:S3:6650:8	O
should	STRIBILD.xml:S3:6659:6	O
be	STRIBILD.xml:S3:6666:2	O
closely	STRIBILD.xml:S3:6669:7	O
monitored	STRIBILD.xml:S3:6677:9	O
for	STRIBILD.xml:S3:6687:3	O
renal	STRIBILD.xml:S3:6691:5	O
safety	STRIBILD.xml:S3:6697:6	O
.	STRIBILD.xml:S3:6703:1	O

The	STRIBILD.xml:S3:6709:3	O
emtricitabine	STRIBILD.xml:S3:6713:13	O
and	STRIBILD.xml:S3:6727:3	O
tenofovir	STRIBILD.xml:S3:6731:9	O
DF	STRIBILD.xml:S3:6741:2	O
components	STRIBILD.xml:S3:6744:10	O
of	STRIBILD.xml:S3:6755:2	O
STRIBILD	STRIBILD.xml:S3:6758:8	O
are	STRIBILD.xml:S3:6767:3	O
primarily	STRIBILD.xml:S3:6771:9	O
excreted	STRIBILD.xml:S3:6781:8	O
by	STRIBILD.xml:S3:6790:2	O
the	STRIBILD.xml:S3:6793:3	O
kidney	STRIBILD.xml:S3:6797:6	O
.	STRIBILD.xml:S3:6803:1	O

STRIBILD	STRIBILD.xml:S3:6805:8	O
should	STRIBILD.xml:S3:6814:6	O
be	STRIBILD.xml:S3:6821:2	O
discontinued	STRIBILD.xml:S3:6824:12	O
if	STRIBILD.xml:S3:6837:2	O
estimated	STRIBILD.xml:S3:6840:9	O
creatinine	STRIBILD.xml:S3:6850:10	O
clearance	STRIBILD.xml:S3:6861:9	O
declines	STRIBILD.xml:S3:6871:8	O
below	STRIBILD.xml:S3:6880:5	O
50	STRIBILD.xml:S3:6886:2	O
mL	STRIBILD.xml:S3:6889:2	O
per	STRIBILD.xml:S3:6892:3	O
minute	STRIBILD.xml:S3:6896:6	O
as	STRIBILD.xml:S3:6903:2	O
dose	STRIBILD.xml:S3:6906:4	O
interval	STRIBILD.xml:S3:6911:8	O
adjustment	STRIBILD.xml:S3:6920:10	O
required	STRIBILD.xml:S3:6931:8	O
for	STRIBILD.xml:S3:6940:3	O
emtricitabine	STRIBILD.xml:S3:6944:13	O
and	STRIBILD.xml:S3:6958:3	O
tenofovir	STRIBILD.xml:S3:6962:9	O
DF	STRIBILD.xml:S3:6972:2	O
cannot	STRIBILD.xml:S3:6975:6	O
be	STRIBILD.xml:S3:6982:2	O
achieved	STRIBILD.xml:S3:6985:8	O
with	STRIBILD.xml:S3:6994:4	O
the	STRIBILD.xml:S3:6999:3	O
fixed	STRIBILD.xml:S3:7003:5	O
-	STRIBILD.xml:S3:7008:1	O
dose	STRIBILD.xml:S3:7009:4	O
combination	STRIBILD.xml:S3:7014:11	O
tablet	STRIBILD.xml:S3:7026:6	O
.	STRIBILD.xml:S3:7032:1	O

5.4	STRIBILD.xml:S3:7041:3	O
Avoid	STRIBILD.xml:S3:7045:5	O
Use	STRIBILD.xml:S3:7051:3	O
with	STRIBILD.xml:S3:7055:4	O
Other	STRIBILD.xml:S3:7060:5	O
Antiretroviral	STRIBILD.xml:S3:7066:14	O
Products	STRIBILD.xml:S3:7081:8	O

STRIBILD	STRIBILD.xml:S3:7095:8	O
is	STRIBILD.xml:S3:7104:2	O
indicated	STRIBILD.xml:S3:7107:9	O
for	STRIBILD.xml:S3:7117:3	O
use	STRIBILD.xml:S3:7121:3	O
as	STRIBILD.xml:S3:7125:2	O
a	STRIBILD.xml:S3:7128:1	O
complete	STRIBILD.xml:S3:7130:8	O
regimen	STRIBILD.xml:S3:7139:7	O
for	STRIBILD.xml:S3:7147:3	O
the	STRIBILD.xml:S3:7151:3	O
treatment	STRIBILD.xml:S3:7155:9	O
of	STRIBILD.xml:S3:7165:2	O
HIV	STRIBILD.xml:S3:7168:3	O
-	STRIBILD.xml:S3:7171:1	O
1	STRIBILD.xml:S3:7172:1	O
infection	STRIBILD.xml:S3:7174:9	O
and	STRIBILD.xml:S3:7184:3	O
coadministration	STRIBILD.xml:S3:7188:16	O
with	STRIBILD.xml:S3:7205:4	O
other	STRIBILD.xml:S3:7210:5	O
antiretroviral	STRIBILD.xml:S3:7216:14	O
products	STRIBILD.xml:S3:7231:8	O
is	STRIBILD.xml:S3:7240:2	O
not	STRIBILD.xml:S3:7243:3	O
recommended	STRIBILD.xml:S3:7247:11	O
.	STRIBILD.xml:S3:7258:1	O

STRIBILD	STRIBILD.xml:S3:7264:8	O
is	STRIBILD.xml:S3:7273:2	O
not	STRIBILD.xml:S3:7276:3	O
recommended	STRIBILD.xml:S3:7280:11	O
for	STRIBILD.xml:S3:7292:3	O
coadministration	STRIBILD.xml:S3:7296:16	O
with	STRIBILD.xml:S3:7313:4	O
the	STRIBILD.xml:S3:7318:3	O
following	STRIBILD.xml:S3:7322:9	O
:	STRIBILD.xml:S3:7331:1	O

cobicistat	STRIBILD.xml:S3:7341:10	O
(	STRIBILD.xml:S3:7352:1	O
TYBOST	STRIBILD.xml:S3:7353:6	O
)	STRIBILD.xml:S3:7359:1	O
;	STRIBILD.xml:S3:7360:1	O

elvitegravir	STRIBILD.xml:S3:7369:12	O
(	STRIBILD.xml:S3:7382:1	O
VITEKTA	STRIBILD.xml:S3:7383:7	O
)	STRIBILD.xml:S3:7390:1	O
;	STRIBILD.xml:S3:7391:1	O

products	STRIBILD.xml:S3:7400:8	O
containing	STRIBILD.xml:S3:7409:10	O
emtricitabine	STRIBILD.xml:S3:7420:13	O
or	STRIBILD.xml:S3:7434:2	O
tenofovir	STRIBILD.xml:S3:7437:9	O
DF	STRIBILD.xml:S3:7447:2	O
(	STRIBILD.xml:S3:7450:1	O
ATRIPLA	STRIBILD.xml:S3:7451:7	O
,	STRIBILD.xml:S3:7458:1	O
COMPLERA	STRIBILD.xml:S3:7460:8	O
,	STRIBILD.xml:S3:7468:1	O
EMTRIVA	STRIBILD.xml:S3:7470:7	O
,	STRIBILD.xml:S3:7477:1	O
TRUVADA	STRIBILD.xml:S3:7479:7	O
,	STRIBILD.xml:S3:7486:1	O
VIREAD	STRIBILD.xml:S3:7488:6	O
)	STRIBILD.xml:S3:7494:1	O
;	STRIBILD.xml:S3:7495:1	O

products	STRIBILD.xml:S3:7504:8	O
containing	STRIBILD.xml:S3:7513:10	O
lamivudine	STRIBILD.xml:S3:7524:10	O
(	STRIBILD.xml:S3:7535:1	O
COMBIVIR	STRIBILD.xml:S3:7536:8	O
,	STRIBILD.xml:S3:7544:1	O
EPIVIR	STRIBILD.xml:S3:7546:6	O
,	STRIBILD.xml:S3:7552:1	O
EPIVIR	STRIBILD.xml:S3:7554:6	O
-	STRIBILD.xml:S3:7560:1	O
HBV	STRIBILD.xml:S3:7561:3	O
,	STRIBILD.xml:S3:7564:1	O
EPZICOM	STRIBILD.xml:S3:7566:7	O
,	STRIBILD.xml:S3:7573:1	O
TRIUMEQ	STRIBILD.xml:S3:7575:7	O
,	STRIBILD.xml:S3:7582:1	O
TRIZIVIR	STRIBILD.xml:S3:7584:8	O
)	STRIBILD.xml:S3:7592:1	O
;	STRIBILD.xml:S3:7593:1	O

adefovir	STRIBILD.xml:S3:7602:8	O
dipivoxil	STRIBILD.xml:S3:7611:9	O
(	STRIBILD.xml:S3:7621:1	O
HEPSERA	STRIBILD.xml:S3:7622:7	O
)	STRIBILD.xml:S3:7629:1	O
;	STRIBILD.xml:S3:7630:1	O

products	STRIBILD.xml:S3:7639:8	O
containing	STRIBILD.xml:S3:7648:10	O
ritonavir	STRIBILD.xml:S3:7659:9	O
(	STRIBILD.xml:S3:7669:1	O
NORVIR	STRIBILD.xml:S3:7670:6	O
,	STRIBILD.xml:S3:7676:1	O
KALETRA	STRIBILD.xml:S3:7678:7	O
)	STRIBILD.xml:S3:7685:1	O

5.5	STRIBILD.xml:S3:7696:3	O
Risk	STRIBILD.xml:S3:7700:4	O
of	STRIBILD.xml:S3:7705:2	O
Adverse	STRIBILD.xml:S3:7708:7	O
Reactions	STRIBILD.xml:S3:7716:9	O
or	STRIBILD.xml:S3:7726:2	O
Loss	STRIBILD.xml:S3:7729:4	O
of	STRIBILD.xml:S3:7734:2	O
Virologic	STRIBILD.xml:S3:7737:9	O
Response	STRIBILD.xml:S3:7747:8	O
Due	STRIBILD.xml:S3:7756:3	O
to	STRIBILD.xml:S3:7760:2	O
Drug	STRIBILD.xml:S3:7763:4	O
Interactions	STRIBILD.xml:S3:7768:12	O

The	STRIBILD.xml:S3:7787:3	O

concomitant	STRIBILD.xml:S3:7791:11	O
use	STRIBILD.xml:S3:7803:3	O
of	STRIBILD.xml:S3:7807:2	O
STRIBILD	STRIBILD.xml:S3:7810:8	O
and	STRIBILD.xml:S3:7819:3	O
other	STRIBILD.xml:S3:7823:5	O
drugs	STRIBILD.xml:S3:7829:5	O
may	STRIBILD.xml:S3:7835:3	O
result	STRIBILD.xml:S3:7839:6	O
in	STRIBILD.xml:S3:7846:2	O
known	STRIBILD.xml:S3:7849:5	O
or	STRIBILD.xml:S3:7855:2	O
potentially	STRIBILD.xml:S3:7858:11	O
significant	STRIBILD.xml:S3:7870:11	O
drug	STRIBILD.xml:S3:7882:4	O
interactions	STRIBILD.xml:S3:7887:12	O
,	STRIBILD.xml:S3:7899:1	O
some	STRIBILD.xml:S3:7901:4	O
of	STRIBILD.xml:S3:7906:2	O
which	STRIBILD.xml:S3:7909:5	O
may	STRIBILD.xml:S3:7915:3	O
lead	STRIBILD.xml:S3:7919:4	O
to	STRIBILD.xml:S3:7924:2	O
[	STRIBILD.xml:S3:7927:1	O
see	STRIBILD.xml:S3:7928:3	O
Contraindications	STRIBILD.xml:S3:7933:17	O
(	STRIBILD.xml:S3:7951:1	O
4	STRIBILD.xml:S3:7952:1	O
)	STRIBILD.xml:S3:7953:1	O
,	STRIBILD.xml:S3:7956:1	O
Drug	STRIBILD.xml:S3:7959:4	O
Interactions	STRIBILD.xml:S3:7964:12	O
(	STRIBILD.xml:S3:7977:1	O
7.5	STRIBILD.xml:S3:7978:3	O
)	STRIBILD.xml:S3:7981:1	O
]	STRIBILD.xml:S3:7984:1	O
:	STRIBILD.xml:S3:7985:1	O

Loss	STRIBILD.xml:S3:7999:4	O
of	STRIBILD.xml:S3:8004:2	O
therapeutic	STRIBILD.xml:S3:8007:11	O
effect	STRIBILD.xml:S3:8019:6	O
of	STRIBILD.xml:S3:8026:2	O
STRIBILD	STRIBILD.xml:S3:8029:8	O
and	STRIBILD.xml:S3:8038:3	O
possible	STRIBILD.xml:S3:8042:8	O
development	STRIBILD.xml:S3:8051:11	O
of	STRIBILD.xml:S3:8063:2	O
resistance	STRIBILD.xml:S3:8066:10	O
.	STRIBILD.xml:S3:8076:1	O

Possible	STRIBILD.xml:S3:8085:8	O
clinically	STRIBILD.xml:S3:8094:10	O
significant	STRIBILD.xml:S3:8105:11	O
adverse	STRIBILD.xml:S3:8117:7	O
reactions	STRIBILD.xml:S3:8125:9	O
from	STRIBILD.xml:S3:8135:4	O
greater	STRIBILD.xml:S3:8140:7	O
exposures	STRIBILD.xml:S3:8148:9	O
of	STRIBILD.xml:S3:8158:2	O
concomitant	STRIBILD.xml:S3:8161:11	O
drugs	STRIBILD.xml:S3:8173:5	O
.	STRIBILD.xml:S3:8178:1	O

See	STRIBILD.xml:S3:8187:3	O
Table	STRIBILD.xml:S3:8192:5	O
6	STRIBILD.xml:S3:8198:1	O
for	STRIBILD.xml:S3:8201:3	O
steps	STRIBILD.xml:S3:8205:5	O
to	STRIBILD.xml:S3:8211:2	O
prevent	STRIBILD.xml:S3:8214:7	O
or	STRIBILD.xml:S3:8222:2	O
manage	STRIBILD.xml:S3:8225:6	O
these	STRIBILD.xml:S3:8232:5	O
possible	STRIBILD.xml:S3:8238:8	O
and	STRIBILD.xml:S3:8247:3	O
known	STRIBILD.xml:S3:8251:5	O
significant	STRIBILD.xml:S3:8257:11	O
drug	STRIBILD.xml:S3:8269:4	O
interactions	STRIBILD.xml:S3:8274:12	O
,	STRIBILD.xml:S3:8286:1	O
including	STRIBILD.xml:S3:8288:9	O
dosing	STRIBILD.xml:S3:8298:6	O
recommendations	STRIBILD.xml:S3:8305:15	O
[	STRIBILD.xml:S3:8321:1	O
see	STRIBILD.xml:S3:8322:3	O
Drug	STRIBILD.xml:S3:8327:4	O
Interactions	STRIBILD.xml:S3:8332:12	O
(	STRIBILD.xml:S3:8345:1	O
7.5	STRIBILD.xml:S3:8346:3	O
)	STRIBILD.xml:S3:8349:1	O
]	STRIBILD.xml:S3:8352:1	O
.	STRIBILD.xml:S3:8355:1	O

Consider	STRIBILD.xml:S3:8357:8	O
the	STRIBILD.xml:S3:8366:3	O
potential	STRIBILD.xml:S3:8370:9	O
for	STRIBILD.xml:S3:8380:3	O
drug	STRIBILD.xml:S3:8384:4	O
interactions	STRIBILD.xml:S3:8389:12	O
prior	STRIBILD.xml:S3:8402:5	O
to	STRIBILD.xml:S3:8408:2	O
and	STRIBILD.xml:S3:8411:3	O
during	STRIBILD.xml:S3:8415:6	O
STRIBILD	STRIBILD.xml:S3:8422:8	O
therapy	STRIBILD.xml:S3:8431:7	O
;	STRIBILD.xml:S3:8438:1	O
review	STRIBILD.xml:S3:8440:6	O
concomitant	STRIBILD.xml:S3:8447:11	O
medications	STRIBILD.xml:S3:8459:11	O
during	STRIBILD.xml:S3:8471:6	O
STRIBILD	STRIBILD.xml:S3:8478:8	O
therapy	STRIBILD.xml:S3:8487:7	O
;	STRIBILD.xml:S3:8494:1	O
and	STRIBILD.xml:S3:8496:3	O
monitor	STRIBILD.xml:S3:8500:7	O
for	STRIBILD.xml:S3:8508:3	O
the	STRIBILD.xml:S3:8512:3	O
adverse	STRIBILD.xml:S3:8516:7	O
reactions	STRIBILD.xml:S3:8524:9	O
associated	STRIBILD.xml:S3:8534:10	O
with	STRIBILD.xml:S3:8545:4	O
the	STRIBILD.xml:S3:8550:3	O
concomitant	STRIBILD.xml:S3:8554:11	O
drugs	STRIBILD.xml:S3:8566:5	O
.	STRIBILD.xml:S3:8571:1	O

5.6	STRIBILD.xml:S3:8582:3	O

Bone	STRIBILD.xml:S3:8586:4	O
Effects	STRIBILD.xml:S3:8591:7	O
of	STRIBILD.xml:S3:8599:2	O
Tenofovir	STRIBILD.xml:S3:8602:9	O
DF	STRIBILD.xml:S3:8612:2	O

Bone	STRIBILD.xml:S3:8621:4	O
Mineral	STRIBILD.xml:S3:8626:7	O
Density	STRIBILD.xml:S3:8634:7	O
:	STRIBILD.xml:S3:8641:1	O

In	STRIBILD.xml:S3:8649:2	O
clinical	STRIBILD.xml:S3:8652:8	O
trials	STRIBILD.xml:S3:8661:6	O
in	STRIBILD.xml:S3:8668:2	O
HIV	STRIBILD.xml:S3:8671:3	O
-	STRIBILD.xml:S3:8674:1	O
1	STRIBILD.xml:S3:8675:1	O
infected	STRIBILD.xml:S3:8677:8	O
adults	STRIBILD.xml:S3:8686:6	O
,	STRIBILD.xml:S3:8692:1	O
tenofovir	STRIBILD.xml:S3:8694:9	O
DF	STRIBILD.xml:S3:8704:2	O
(	STRIBILD.xml:S3:8707:1	O
a	STRIBILD.xml:S3:8708:1	O
component	STRIBILD.xml:S3:8710:9	O
of	STRIBILD.xml:S3:8720:2	O
STRIBILD	STRIBILD.xml:S3:8723:8	O
)	STRIBILD.xml:S3:8731:1	O
was	STRIBILD.xml:S3:8733:3	O
associated	STRIBILD.xml:S3:8737:10	O
with	STRIBILD.xml:S3:8748:4	O
slightly	STRIBILD.xml:S3:8753:8	O
greater	STRIBILD.xml:S3:8762:7	O
decreases	STRIBILD.xml:S3:8770:9	B-AdverseReaction
in	STRIBILD.xml:S3:8780:2	I-AdverseReaction
bone	STRIBILD.xml:S3:8783:4	I-AdverseReaction
mineral	STRIBILD.xml:S3:8788:7	I-AdverseReaction
density	STRIBILD.xml:S3:8796:7	I-AdverseReaction
(	STRIBILD.xml:S3:8804:1	O
BMD	STRIBILD.xml:S3:8805:3	I-AdverseReaction
)	STRIBILD.xml:S3:8808:1	O
and	STRIBILD.xml:S3:8810:3	O
increases	STRIBILD.xml:S3:8814:9	B-AdverseReaction
in	STRIBILD.xml:S3:8824:2	I-AdverseReaction
biochemical	STRIBILD.xml:S3:8827:11	I-AdverseReaction
markers	STRIBILD.xml:S3:8839:7	I-AdverseReaction
of	STRIBILD.xml:S3:8847:2	I-AdverseReaction
bone	STRIBILD.xml:S3:8850:4	I-AdverseReaction
metabolism	STRIBILD.xml:S3:8855:10	I-AdverseReaction
,	STRIBILD.xml:S3:8865:1	O
suggesting	STRIBILD.xml:S3:8867:10	O
increased	STRIBILD.xml:S3:8878:9	B-AdverseReaction
bone	STRIBILD.xml:S3:8888:4	I-AdverseReaction
turnover	STRIBILD.xml:S3:8893:8	I-AdverseReaction
relative	STRIBILD.xml:S3:8902:8	O
to	STRIBILD.xml:S3:8911:2	O
comparators	STRIBILD.xml:S3:8914:11	O
.	STRIBILD.xml:S3:8925:1	O

Serum	STRIBILD.xml:S3:8927:5	O
parathyroid	STRIBILD.xml:S3:8933:11	O
hormone	STRIBILD.xml:S3:8945:7	O
levels	STRIBILD.xml:S3:8953:6	O
and	STRIBILD.xml:S3:8960:3	O
1.25	STRIBILD.xml:S3:8964:4	O
Vitamin	STRIBILD.xml:S3:8969:7	O
D	STRIBILD.xml:S3:8977:1	O
levels	STRIBILD.xml:S3:8979:6	O
were	STRIBILD.xml:S3:8986:4	O
also	STRIBILD.xml:S3:8991:4	O
higher	STRIBILD.xml:S3:8996:6	O
in	STRIBILD.xml:S3:9003:2	O
subjects	STRIBILD.xml:S3:9006:8	O
receiving	STRIBILD.xml:S3:9015:9	O
tenofovir	STRIBILD.xml:S3:9025:9	O
DF	STRIBILD.xml:S3:9035:2	O
.	STRIBILD.xml:S3:9037:1	O

For	STRIBILD.xml:S3:9039:3	O
additional	STRIBILD.xml:S3:9043:10	O
information	STRIBILD.xml:S3:9054:11	O
,	STRIBILD.xml:S3:9065:1	O
see	STRIBILD.xml:S3:9067:3	O
Adverse	STRIBILD.xml:S3:9071:7	O
Reactions	STRIBILD.xml:S3:9079:9	O
(	STRIBILD.xml:S3:9089:1	O
6.1	STRIBILD.xml:S3:9090:3	O
)	STRIBILD.xml:S3:9093:1	O
and	STRIBILD.xml:S3:9095:3	O
consult	STRIBILD.xml:S3:9099:7	O
the	STRIBILD.xml:S3:9107:3	O
VIREAD	STRIBILD.xml:S3:9111:6	O
prescribing	STRIBILD.xml:S3:9118:11	O
information	STRIBILD.xml:S3:9130:11	O
.	STRIBILD.xml:S3:9141:1	O

The	STRIBILD.xml:S3:9147:3	O
effects	STRIBILD.xml:S3:9151:7	O
of	STRIBILD.xml:S3:9159:2	O
tenofovir	STRIBILD.xml:S3:9162:9	O
DF	STRIBILD.xml:S3:9172:2	O
-	STRIBILD.xml:S3:9174:1	O
associated	STRIBILD.xml:S3:9175:10	O
changes	STRIBILD.xml:S3:9186:7	O
in	STRIBILD.xml:S3:9194:2	O
BMD	STRIBILD.xml:S3:9197:3	O
and	STRIBILD.xml:S3:9201:3	O
biochemical	STRIBILD.xml:S3:9205:11	O
markers	STRIBILD.xml:S3:9217:7	O
on	STRIBILD.xml:S3:9225:2	O
long	STRIBILD.xml:S3:9228:4	O
-	STRIBILD.xml:S3:9232:1	O
term	STRIBILD.xml:S3:9233:4	O
bone	STRIBILD.xml:S3:9238:4	O
health	STRIBILD.xml:S3:9243:6	O
and	STRIBILD.xml:S3:9250:3	O
future	STRIBILD.xml:S3:9254:6	O
fracture	STRIBILD.xml:S3:9261:8	O
risk	STRIBILD.xml:S3:9270:4	O
are	STRIBILD.xml:S3:9275:3	O
unknown	STRIBILD.xml:S3:9279:7	O
.	STRIBILD.xml:S3:9286:1	O

Assessment	STRIBILD.xml:S3:9288:10	O
of	STRIBILD.xml:S3:9299:2	O
BMD	STRIBILD.xml:S3:9302:3	O
should	STRIBILD.xml:S3:9306:6	O
be	STRIBILD.xml:S3:9313:2	O
considered	STRIBILD.xml:S3:9316:10	O
for	STRIBILD.xml:S3:9327:3	O
HIV	STRIBILD.xml:S3:9331:3	O
-	STRIBILD.xml:S3:9334:1	O
1	STRIBILD.xml:S3:9335:1	O
infected	STRIBILD.xml:S3:9337:8	O
patients	STRIBILD.xml:S3:9346:8	O
who	STRIBILD.xml:S3:9355:3	O
have	STRIBILD.xml:S3:9359:4	O
a	STRIBILD.xml:S3:9364:1	O
history	STRIBILD.xml:S3:9366:7	O
of	STRIBILD.xml:S3:9374:2	O
pathologic	STRIBILD.xml:S3:9377:10	O
bone	STRIBILD.xml:S3:9388:4	O
fracture	STRIBILD.xml:S3:9393:8	O
or	STRIBILD.xml:S3:9402:2	O
other	STRIBILD.xml:S3:9405:5	O
risk	STRIBILD.xml:S3:9411:4	O
factors	STRIBILD.xml:S3:9416:7	O
for	STRIBILD.xml:S3:9424:3	O
osteoporosis	STRIBILD.xml:S3:9428:12	O
or	STRIBILD.xml:S3:9441:2	O
bone	STRIBILD.xml:S3:9444:4	O
loss	STRIBILD.xml:S3:9449:4	O
.	STRIBILD.xml:S3:9453:1	O

Although	STRIBILD.xml:S3:9455:8	O
the	STRIBILD.xml:S3:9464:3	O
effect	STRIBILD.xml:S3:9468:6	O
of	STRIBILD.xml:S3:9475:2	O
supplementation	STRIBILD.xml:S3:9478:15	O
with	STRIBILD.xml:S3:9494:4	O
calcium	STRIBILD.xml:S3:9499:7	O
and	STRIBILD.xml:S3:9507:3	O
vitamin	STRIBILD.xml:S3:9511:7	O
D	STRIBILD.xml:S3:9519:1	O
was	STRIBILD.xml:S3:9521:3	O
not	STRIBILD.xml:S3:9525:3	O
studied	STRIBILD.xml:S3:9529:7	O
,	STRIBILD.xml:S3:9536:1	O
such	STRIBILD.xml:S3:9538:4	O
supplementation	STRIBILD.xml:S3:9543:15	O
may	STRIBILD.xml:S3:9559:3	O
be	STRIBILD.xml:S3:9563:2	O
beneficial	STRIBILD.xml:S3:9566:10	O
in	STRIBILD.xml:S3:9577:2	O
all	STRIBILD.xml:S3:9580:3	O
patients	STRIBILD.xml:S3:9584:8	O
.	STRIBILD.xml:S3:9592:1	O

If	STRIBILD.xml:S3:9594:2	O
bone	STRIBILD.xml:S3:9597:4	O
abnormalities	STRIBILD.xml:S3:9602:13	O
are	STRIBILD.xml:S3:9616:3	O
suspected	STRIBILD.xml:S3:9620:9	O
,	STRIBILD.xml:S3:9629:1	O
then	STRIBILD.xml:S3:9631:4	O
appropriate	STRIBILD.xml:S3:9636:11	O
consultation	STRIBILD.xml:S3:9648:12	O
should	STRIBILD.xml:S3:9661:6	O
be	STRIBILD.xml:S3:9668:2	O
obtained	STRIBILD.xml:S3:9671:8	O
.	STRIBILD.xml:S3:9679:1	O

Mineralization	STRIBILD.xml:S3:9688:14	O
Defects	STRIBILD.xml:S3:9703:7	O
:	STRIBILD.xml:S3:9710:1	O

Cases	STRIBILD.xml:S3:9718:5	O
of	STRIBILD.xml:S3:9724:2	O
osteomalacia	STRIBILD.xml:S3:9727:12	B-AdverseReaction
associated	STRIBILD.xml:S3:9740:10	O
with	STRIBILD.xml:S3:9751:4	O
proximal	STRIBILD.xml:S3:9756:8	B-AdverseReaction
renal	STRIBILD.xml:S3:9765:5	I-AdverseReaction
tubulopathy	STRIBILD.xml:S3:9771:11	I-AdverseReaction
,	STRIBILD.xml:S3:9782:1	O
manifested	STRIBILD.xml:S3:9784:10	O
as	STRIBILD.xml:S3:9795:2	O
bone	STRIBILD.xml:S3:9798:4	B-AdverseReaction
pain	STRIBILD.xml:S3:9803:4	I-AdverseReaction
or	STRIBILD.xml:S3:9808:2	O
pain	STRIBILD.xml:S3:9811:4	B-AdverseReaction
in	STRIBILD.xml:S3:9816:2	I-AdverseReaction
extremities	STRIBILD.xml:S3:9819:11	I-AdverseReaction
and	STRIBILD.xml:S3:9831:3	O
which	STRIBILD.xml:S3:9835:5	O
may	STRIBILD.xml:S3:9841:3	B-Factor
contribute	STRIBILD.xml:S3:9845:10	O
to	STRIBILD.xml:S3:9856:2	O
fractures	STRIBILD.xml:S3:9859:9	B-AdverseReaction
,	STRIBILD.xml:S3:9868:1	O
have	STRIBILD.xml:S3:9870:4	O
been	STRIBILD.xml:S3:9875:4	O
reported	STRIBILD.xml:S3:9880:8	O
in	STRIBILD.xml:S3:9889:2	O
association	STRIBILD.xml:S3:9892:11	O
with	STRIBILD.xml:S3:9904:4	O
the	STRIBILD.xml:S3:9909:3	O
use	STRIBILD.xml:S3:9913:3	O
of	STRIBILD.xml:S3:9917:2	O
tenofovir	STRIBILD.xml:S3:9920:9	O
DF	STRIBILD.xml:S3:9930:2	O
[	STRIBILD.xml:S3:9933:1	O
see	STRIBILD.xml:S3:9934:3	O
Adverse	STRIBILD.xml:S3:9939:7	O
Reactions	STRIBILD.xml:S3:9947:9	O
(	STRIBILD.xml:S3:9957:1	O
6.2	STRIBILD.xml:S3:9958:3	O
)	STRIBILD.xml:S3:9961:1	O
]	STRIBILD.xml:S3:9964:1	O
.	STRIBILD.xml:S3:9967:1	O

Arthralgias	STRIBILD.xml:S3:9969:11	B-AdverseReaction
and	STRIBILD.xml:S3:9981:3	O
muscle	STRIBILD.xml:S3:9985:6	B-AdverseReaction
pain	STRIBILD.xml:S3:9992:4	I-AdverseReaction
or	STRIBILD.xml:S3:9997:2	O
weakness	STRIBILD.xml:S3:10000:8	I-AdverseReaction
have	STRIBILD.xml:S3:10009:4	O
also	STRIBILD.xml:S3:10014:4	O
been	STRIBILD.xml:S3:10019:4	O
reported	STRIBILD.xml:S3:10024:8	O
in	STRIBILD.xml:S3:10033:2	O
cases	STRIBILD.xml:S3:10036:5	O
of	STRIBILD.xml:S3:10042:2	O
proximal	STRIBILD.xml:S3:10045:8	B-AdverseReaction
renal	STRIBILD.xml:S3:10054:5	I-AdverseReaction
tubulopathy	STRIBILD.xml:S3:10060:11	I-AdverseReaction
.	STRIBILD.xml:S3:10071:1	O

Hypophosphatemia	STRIBILD.xml:S3:10073:16	O
and	STRIBILD.xml:S3:10090:3	O
osteomalacia	STRIBILD.xml:S3:10094:12	O
secondary	STRIBILD.xml:S3:10107:9	O
to	STRIBILD.xml:S3:10117:2	O
proximal	STRIBILD.xml:S3:10120:8	O
renal	STRIBILD.xml:S3:10129:5	O
tubulopathy	STRIBILD.xml:S3:10135:11	O
should	STRIBILD.xml:S3:10147:6	O
be	STRIBILD.xml:S3:10154:2	O
considered	STRIBILD.xml:S3:10157:10	O
in	STRIBILD.xml:S3:10168:2	O
patients	STRIBILD.xml:S3:10171:8	O
at	STRIBILD.xml:S3:10180:2	O
risk	STRIBILD.xml:S3:10183:4	O
of	STRIBILD.xml:S3:10188:2	O
renal	STRIBILD.xml:S3:10191:5	O
dysfunction	STRIBILD.xml:S3:10197:11	O
who	STRIBILD.xml:S3:10209:3	O
present	STRIBILD.xml:S3:10213:7	O
with	STRIBILD.xml:S3:10221:4	O
persistent	STRIBILD.xml:S3:10226:10	O
or	STRIBILD.xml:S3:10237:2	O
worsening	STRIBILD.xml:S3:10240:9	O
bone	STRIBILD.xml:S3:10250:4	O
or	STRIBILD.xml:S3:10255:2	O
muscle	STRIBILD.xml:S3:10258:6	O
symptoms	STRIBILD.xml:S3:10265:8	O
while	STRIBILD.xml:S3:10274:5	O
receiving	STRIBILD.xml:S3:10280:9	O
products	STRIBILD.xml:S3:10290:8	O
containing	STRIBILD.xml:S3:10299:10	O
tenofovir	STRIBILD.xml:S3:10310:9	O
DF	STRIBILD.xml:S3:10320:2	O
[	STRIBILD.xml:S3:10323:1	O
see	STRIBILD.xml:S3:10324:3	O
Warnings	STRIBILD.xml:S3:10329:8	O
and	STRIBILD.xml:S3:10338:3	O
Precautions	STRIBILD.xml:S3:10342:11	O
(	STRIBILD.xml:S3:10354:1	O
5.3	STRIBILD.xml:S3:10355:3	O
)	STRIBILD.xml:S3:10358:1	O
]	STRIBILD.xml:S3:10361:1	O
.	STRIBILD.xml:S3:10364:1	O

5.7	STRIBILD.xml:S3:10373:3	O
Fat	STRIBILD.xml:S3:10377:3	O
Redistribution	STRIBILD.xml:S3:10381:14	O

Redistribution	STRIBILD.xml:S3:10401:14	B-AdverseReaction
accumulation	STRIBILD.xml:S3:10416:12	B-AdverseReaction
of	STRIBILD.xml:S3:10429:2	I-AdverseReaction
body	STRIBILD.xml:S3:10432:4	I-AdverseReaction
fat	STRIBILD.xml:S3:10437:3	I-AdverseReaction
including	STRIBILD.xml:S3:10441:9	O
central	STRIBILD.xml:S3:10451:7	B-AdverseReaction
obesity	STRIBILD.xml:S3:10459:7	I-AdverseReaction
,	STRIBILD.xml:S3:10466:1	O
dorsocervical	STRIBILD.xml:S3:10468:13	B-AdverseReaction
fat	STRIBILD.xml:S3:10482:3	I-AdverseReaction
enlargement	STRIBILD.xml:S3:10486:11	I-AdverseReaction
(	STRIBILD.xml:S3:10498:1	O
buffalo	STRIBILD.xml:S3:10499:7	B-AdverseReaction
hump	STRIBILD.xml:S3:10507:4	I-AdverseReaction
)	STRIBILD.xml:S3:10511:1	O
,	STRIBILD.xml:S3:10512:1	O
peripheral	STRIBILD.xml:S3:10514:10	I-AdverseReaction
wasting	STRIBILD.xml:S3:10525:7	I-AdverseReaction
,	STRIBILD.xml:S3:10532:1	O
facial	STRIBILD.xml:S3:10534:6	B-AdverseReaction
wasting	STRIBILD.xml:S3:10541:7	I-AdverseReaction
,	STRIBILD.xml:S3:10548:1	O
breast	STRIBILD.xml:S3:10550:6	B-AdverseReaction
enlargement	STRIBILD.xml:S3:10557:11	I-AdverseReaction
,	STRIBILD.xml:S3:10568:1	O
and	STRIBILD.xml:S3:10570:3	O
"	STRIBILD.xml:S3:10574:1	O
cushingoid	STRIBILD.xml:S3:10575:10	B-AdverseReaction
appearance	STRIBILD.xml:S3:10586:10	I-AdverseReaction
"	STRIBILD.xml:S3:10596:1	O
have	STRIBILD.xml:S3:10598:4	O
been	STRIBILD.xml:S3:10603:4	O
observed	STRIBILD.xml:S3:10608:8	O
in	STRIBILD.xml:S3:10617:2	O
patients	STRIBILD.xml:S3:10620:8	O
receiving	STRIBILD.xml:S3:10629:9	O
antiretroviral	STRIBILD.xml:S3:10639:14	O
therapy	STRIBILD.xml:S3:10654:7	O
.	STRIBILD.xml:S3:10661:1	O

The	STRIBILD.xml:S3:10663:3	O
mechanism	STRIBILD.xml:S3:10667:9	O
and	STRIBILD.xml:S3:10677:3	O
long	STRIBILD.xml:S3:10681:4	O
-	STRIBILD.xml:S3:10685:1	O
term	STRIBILD.xml:S3:10686:4	O
consequences	STRIBILD.xml:S3:10691:12	O
of	STRIBILD.xml:S3:10704:2	O
these	STRIBILD.xml:S3:10707:5	O
events	STRIBILD.xml:S3:10713:6	O
are	STRIBILD.xml:S3:10720:3	O
currently	STRIBILD.xml:S3:10724:9	O
unknown	STRIBILD.xml:S3:10734:7	O
.	STRIBILD.xml:S3:10741:1	O

A	STRIBILD.xml:S3:10743:1	O
causal	STRIBILD.xml:S3:10745:6	O
relationship	STRIBILD.xml:S3:10752:12	O
has	STRIBILD.xml:S3:10765:3	O
not	STRIBILD.xml:S3:10769:3	O
been	STRIBILD.xml:S3:10773:4	O
established	STRIBILD.xml:S3:10778:11	O
.	STRIBILD.xml:S3:10789:1	O

5.8	STRIBILD.xml:S3:10798:3	O
Immune	STRIBILD.xml:S3:10802:6	O
Reconstitution	STRIBILD.xml:S3:10809:14	O
Syndrome	STRIBILD.xml:S3:10824:8	O

Immune	STRIBILD.xml:S3:10838:6	B-AdverseReaction
reconstitution	STRIBILD.xml:S3:10845:14	I-AdverseReaction
syndrome	STRIBILD.xml:S3:10860:8	I-AdverseReaction
has	STRIBILD.xml:S3:10869:3	O
been	STRIBILD.xml:S3:10873:4	O
reported	STRIBILD.xml:S3:10878:8	O
in	STRIBILD.xml:S3:10887:2	O
patients	STRIBILD.xml:S3:10890:8	O
treated	STRIBILD.xml:S3:10899:7	O
with	STRIBILD.xml:S3:10907:4	O
combination	STRIBILD.xml:S3:10912:11	O
antiretroviral	STRIBILD.xml:S3:10924:14	O
therapy	STRIBILD.xml:S3:10939:7	O
,	STRIBILD.xml:S3:10946:1	O
including	STRIBILD.xml:S3:10948:9	O
STRIBILD	STRIBILD.xml:S3:10958:8	O
.	STRIBILD.xml:S3:10966:1	O

During	STRIBILD.xml:S3:10968:6	O
the	STRIBILD.xml:S3:10975:3	O
initial	STRIBILD.xml:S3:10979:7	O
phase	STRIBILD.xml:S3:10987:5	O
of	STRIBILD.xml:S3:10993:2	O
combination	STRIBILD.xml:S3:10996:11	O
antiretroviral	STRIBILD.xml:S3:11008:14	O
treatment	STRIBILD.xml:S3:11023:9	O
,	STRIBILD.xml:S3:11032:1	O
patients	STRIBILD.xml:S3:11034:8	O
whose	STRIBILD.xml:S3:11043:5	O
immune	STRIBILD.xml:S3:11049:6	O
system	STRIBILD.xml:S3:11056:6	O
responds	STRIBILD.xml:S3:11063:8	O
may	STRIBILD.xml:S3:11072:3	B-Factor
develop	STRIBILD.xml:S3:11076:7	O
an	STRIBILD.xml:S3:11084:2	O
inflammatory	STRIBILD.xml:S3:11087:12	O
response	STRIBILD.xml:S3:11100:8	O
to	STRIBILD.xml:S3:11109:2	O
indolent	STRIBILD.xml:S3:11112:8	O
or	STRIBILD.xml:S3:11121:2	O
residual	STRIBILD.xml:S3:11124:8	B-AdverseReaction
opportunistic	STRIBILD.xml:S3:11133:13	I-AdverseReaction
infections	STRIBILD.xml:S3:11147:10	I-AdverseReaction
[	STRIBILD.xml:S3:11158:1	O
such	STRIBILD.xml:S3:11159:4	O
as	STRIBILD.xml:S3:11164:2	O
Mycobacterium	STRIBILD.xml:S3:11167:13	B-AdverseReaction
avium	STRIBILD.xml:S3:11181:5	I-AdverseReaction
infection	STRIBILD.xml:S3:11188:9	I-AdverseReaction
,	STRIBILD.xml:S3:11197:1	O
cytomegalovirus	STRIBILD.xml:S3:11199:15	B-AdverseReaction
,	STRIBILD.xml:S3:11214:1	O
Pneumocystis	STRIBILD.xml:S3:11216:12	B-AdverseReaction
jirovecii	STRIBILD.xml:S3:11229:9	I-AdverseReaction
pneumonia	STRIBILD.xml:S3:11240:9	I-AdverseReaction
(	STRIBILD.xml:S3:11250:1	O
PCP	STRIBILD.xml:S3:11251:3	B-AdverseReaction
)	STRIBILD.xml:S3:11254:1	O
,	STRIBILD.xml:S3:11255:1	O
or	STRIBILD.xml:S3:11257:2	O
tuberculosis	STRIBILD.xml:S3:11260:12	B-AdverseReaction
]	STRIBILD.xml:S3:11272:1	O
,	STRIBILD.xml:S3:11273:1	O
which	STRIBILD.xml:S3:11275:5	O
may	STRIBILD.xml:S3:11281:3	O
necessitate	STRIBILD.xml:S3:11285:11	O
further	STRIBILD.xml:S3:11297:7	O
evaluation	STRIBILD.xml:S3:11305:10	O
and	STRIBILD.xml:S3:11316:3	O
treatment	STRIBILD.xml:S3:11320:9	O
.	STRIBILD.xml:S3:11329:1	O

Autoimmune	STRIBILD.xml:S3:11335:10	B-AdverseReaction
disorders	STRIBILD.xml:S3:11346:9	I-AdverseReaction
(	STRIBILD.xml:S3:11356:1	O
such	STRIBILD.xml:S3:11357:4	O
as	STRIBILD.xml:S3:11362:2	O
Graves	STRIBILD.xml:S3:11365:6	B-AdverseReaction
disease	STRIBILD.xml:S3:11373:7	I-AdverseReaction
,	STRIBILD.xml:S3:11380:1	O
polymyositis	STRIBILD.xml:S3:11382:12	B-AdverseReaction
,	STRIBILD.xml:S3:11394:1	O
and	STRIBILD.xml:S3:11396:3	O
Guillain	STRIBILD.xml:S3:11400:8	B-AdverseReaction
-	STRIBILD.xml:S3:11408:1	I-AdverseReaction
Barre	STRIBILD.xml:S3:11409:5	I-AdverseReaction
syndrome	STRIBILD.xml:S3:11415:8	I-AdverseReaction
)	STRIBILD.xml:S3:11423:1	O
have	STRIBILD.xml:S3:11425:4	O
also	STRIBILD.xml:S3:11430:4	O
been	STRIBILD.xml:S3:11435:4	O
reported	STRIBILD.xml:S3:11440:8	O
to	STRIBILD.xml:S3:11449:2	O
occur	STRIBILD.xml:S3:11452:5	O
in	STRIBILD.xml:S3:11458:2	O
the	STRIBILD.xml:S3:11461:3	O
setting	STRIBILD.xml:S3:11465:7	O
of	STRIBILD.xml:S3:11473:2	O
immune	STRIBILD.xml:S3:11476:6	O
reconstitution	STRIBILD.xml:S3:11483:14	O
,	STRIBILD.xml:S3:11497:1	O
however	STRIBILD.xml:S3:11499:7	O
,	STRIBILD.xml:S3:11506:1	O
the	STRIBILD.xml:S3:11508:3	O
time	STRIBILD.xml:S3:11512:4	O
to	STRIBILD.xml:S3:11517:2	O
onset	STRIBILD.xml:S3:11520:5	O
is	STRIBILD.xml:S3:11526:2	O
more	STRIBILD.xml:S3:11529:4	O
variable	STRIBILD.xml:S3:11534:8	O
,	STRIBILD.xml:S3:11542:1	O
and	STRIBILD.xml:S3:11544:3	O
can	STRIBILD.xml:S3:11548:3	O
occur	STRIBILD.xml:S3:11552:5	O
many	STRIBILD.xml:S3:11558:4	O
months	STRIBILD.xml:S3:11563:6	O
after	STRIBILD.xml:S3:11570:5	O
initiation	STRIBILD.xml:S3:11576:10	O
of	STRIBILD.xml:S3:11587:2	O
treatment	STRIBILD.xml:S3:11590:9	O
.	STRIBILD.xml:S3:11599:1	O
6	TAFINLAR.xml:S1:4:1	O
ADVERSE	TAFINLAR.xml:S1:6:7	O
REACTIONS	TAFINLAR.xml:S1:14:9	O

The	TAFINLAR.xml:S1:27:3	O
following	TAFINLAR.xml:S1:31:9	O
adverse	TAFINLAR.xml:S1:41:7	O
reactions	TAFINLAR.xml:S1:49:9	O
are	TAFINLAR.xml:S1:59:3	O
discussed	TAFINLAR.xml:S1:63:9	O
in	TAFINLAR.xml:S1:73:2	O
greater	TAFINLAR.xml:S1:76:7	O
detail	TAFINLAR.xml:S1:84:6	O
in	TAFINLAR.xml:S1:91:2	O
another	TAFINLAR.xml:S1:94:7	O
section	TAFINLAR.xml:S1:102:7	O
of	TAFINLAR.xml:S1:110:2	O
the	TAFINLAR.xml:S1:113:3	O
label	TAFINLAR.xml:S1:117:5	O
:	TAFINLAR.xml:S1:122:1	O

New	TAFINLAR.xml:S1:133:3	O
Primary	TAFINLAR.xml:S1:137:7	B-AdverseReaction
Malignancies	TAFINLAR.xml:S1:145:12	I-AdverseReaction
[	TAFINLAR.xml:S1:158:1	O
see	TAFINLAR.xml:S1:159:3	O
Warnings	TAFINLAR.xml:S1:163:8	O
and	TAFINLAR.xml:S1:172:3	O
Precautions	TAFINLAR.xml:S1:176:11	O
(	TAFINLAR.xml:S1:188:1	O
5.1	TAFINLAR.xml:S1:189:3	O
)]	TAFINLAR.xml:S1:192:2	O

Tumor	TAFINLAR.xml:S1:203:5	B-AdverseReaction
Promotion	TAFINLAR.xml:S1:209:9	I-AdverseReaction
in	TAFINLAR.xml:S1:219:2	I-AdverseReaction
BRAF	TAFINLAR.xml:S1:222:4	I-AdverseReaction
Wild	TAFINLAR.xml:S1:227:4	I-AdverseReaction
-	TAFINLAR.xml:S1:231:1	I-AdverseReaction
Type	TAFINLAR.xml:S1:232:4	I-AdverseReaction
Melanoma	TAFINLAR.xml:S1:237:8	I-AdverseReaction
[	TAFINLAR.xml:S1:246:1	O
see	TAFINLAR.xml:S1:247:3	O
Warnings	TAFINLAR.xml:S1:251:8	O
and	TAFINLAR.xml:S1:260:3	O
Precautions	TAFINLAR.xml:S1:264:11	O
(	TAFINLAR.xml:S1:276:1	O
5.2	TAFINLAR.xml:S1:277:3	O
)]	TAFINLAR.xml:S1:280:2	O

Hemorrhage	TAFINLAR.xml:S1:291:10	B-AdverseReaction
[	TAFINLAR.xml:S1:302:1	O
see	TAFINLAR.xml:S1:303:3	O
Warnings	TAFINLAR.xml:S1:307:8	O
and	TAFINLAR.xml:S1:316:3	O
Precautions	TAFINLAR.xml:S1:320:11	O
(	TAFINLAR.xml:S1:332:1	O
5.3	TAFINLAR.xml:S1:333:3	O
)]	TAFINLAR.xml:S1:336:2	O

Venous	TAFINLAR.xml:S1:347:6	B-AdverseReaction
Thromboembolism	TAFINLAR.xml:S1:354:15	I-AdverseReaction
[	TAFINLAR.xml:S1:370:1	O
see	TAFINLAR.xml:S1:371:3	O
Warnings	TAFINLAR.xml:S1:375:8	O
and	TAFINLAR.xml:S1:384:3	O
Precautions	TAFINLAR.xml:S1:388:11	O
(	TAFINLAR.xml:S1:400:1	O
5.4	TAFINLAR.xml:S1:401:3	O
)]	TAFINLAR.xml:S1:404:2	O

Cardiomyopathy	TAFINLAR.xml:S1:415:14	B-AdverseReaction
[	TAFINLAR.xml:S1:430:1	O
see	TAFINLAR.xml:S1:431:3	O
Warnings	TAFINLAR.xml:S1:435:8	O
and	TAFINLAR.xml:S1:444:3	O
Precautions	TAFINLAR.xml:S1:448:11	O
(	TAFINLAR.xml:S1:460:1	O
5.5	TAFINLAR.xml:S1:461:3	O
)]	TAFINLAR.xml:S1:464:2	O

Ocular	TAFINLAR.xml:S1:475:6	B-AdverseReaction
Toxicities	TAFINLAR.xml:S1:482:10	I-AdverseReaction
[	TAFINLAR.xml:S1:493:1	O
see	TAFINLAR.xml:S1:494:3	O
Warnings	TAFINLAR.xml:S1:498:8	O
and	TAFINLAR.xml:S1:507:3	O
Precautions	TAFINLAR.xml:S1:511:11	O
(	TAFINLAR.xml:S1:523:1	O
5.6	TAFINLAR.xml:S1:524:3	O
)]	TAFINLAR.xml:S1:527:2	O

Serious	TAFINLAR.xml:S1:538:7	B-Severity
Febrile	TAFINLAR.xml:S1:546:7	B-AdverseReaction
Reactions	TAFINLAR.xml:S1:554:9	I-AdverseReaction
[	TAFINLAR.xml:S1:564:1	O
see	TAFINLAR.xml:S1:565:3	O
Warnings	TAFINLAR.xml:S1:569:8	O
and	TAFINLAR.xml:S1:578:3	O
Precautions	TAFINLAR.xml:S1:582:11	O
(	TAFINLAR.xml:S1:594:1	O
5.7	TAFINLAR.xml:S1:595:3	O
)]	TAFINLAR.xml:S1:598:2	O

Serious	TAFINLAR.xml:S1:609:7	B-Severity
Skin	TAFINLAR.xml:S1:617:4	B-AdverseReaction
Toxicity	TAFINLAR.xml:S1:622:8	I-AdverseReaction
[	TAFINLAR.xml:S1:631:1	O
see	TAFINLAR.xml:S1:632:3	O
Warnings	TAFINLAR.xml:S1:636:8	O
and	TAFINLAR.xml:S1:645:3	O
Precautions	TAFINLAR.xml:S1:649:11	O
(	TAFINLAR.xml:S1:661:1	O
5.8	TAFINLAR.xml:S1:662:3	O
)]	TAFINLAR.xml:S1:665:2	O

Hyperglycemia	TAFINLAR.xml:S1:676:13	B-AdverseReaction
[	TAFINLAR.xml:S1:690:1	O
see	TAFINLAR.xml:S1:691:3	O
Warnings	TAFINLAR.xml:S1:695:8	O
and	TAFINLAR.xml:S1:704:3	O
Precautions	TAFINLAR.xml:S1:708:11	O
(	TAFINLAR.xml:S1:720:1	O
5.9	TAFINLAR.xml:S1:721:3	O
)]	TAFINLAR.xml:S1:724:2	O

Glucose	TAFINLAR.xml:S1:735:7	B-AdverseReaction
-	TAFINLAR.xml:S1:742:1	I-AdverseReaction
6	TAFINLAR.xml:S1:743:1	I-AdverseReaction
-	TAFINLAR.xml:S1:744:1	I-AdverseReaction
Phosphate	TAFINLAR.xml:S1:745:9	I-AdverseReaction
Dehydrogenase	TAFINLAR.xml:S1:755:13	I-AdverseReaction
Deficiency	TAFINLAR.xml:S1:769:10	I-AdverseReaction
[	TAFINLAR.xml:S1:780:1	O
see	TAFINLAR.xml:S1:781:3	O
Warnings	TAFINLAR.xml:S1:785:8	O
and	TAFINLAR.xml:S1:794:3	O
Precautions	TAFINLAR.xml:S1:798:11	O
(	TAFINLAR.xml:S1:810:1	O
5.10	TAFINLAR.xml:S1:811:4	O
)]	TAFINLAR.xml:S1:815:2	O

Most	TAFINLAR.xml:S1:828:4	O
common	TAFINLAR.xml:S1:833:6	O
adverse	TAFINLAR.xml:S1:840:7	O
reactions	TAFINLAR.xml:S1:848:9	O
(	TAFINLAR.xml:S1:858:1	O
20%	TAFINLAR.xml:S1:861:3	O
)	TAFINLAR.xml:S1:864:1	O
for	TAFINLAR.xml:S1:866:3	O
TAFINLAR	TAFINLAR.xml:S1:870:8	O
as	TAFINLAR.xml:S1:879:2	O
a	TAFINLAR.xml:S1:882:1	O
single	TAFINLAR.xml:S1:884:6	O
agent	TAFINLAR.xml:S1:891:5	O
are	TAFINLAR.xml:S1:897:3	O
hyperkeratosis	TAFINLAR.xml:S1:901:14	B-AdverseReaction
,	TAFINLAR.xml:S1:915:1	O
headache	TAFINLAR.xml:S1:917:8	B-AdverseReaction
,	TAFINLAR.xml:S1:925:1	O
pyrexia	TAFINLAR.xml:S1:927:7	B-AdverseReaction
,	TAFINLAR.xml:S1:934:1	O
arthralgia	TAFINLAR.xml:S1:936:10	B-AdverseReaction
,	TAFINLAR.xml:S1:946:1	O
papilloma	TAFINLAR.xml:S1:948:9	B-AdverseReaction
,	TAFINLAR.xml:S1:957:1	O
alopecia	TAFINLAR.xml:S1:959:8	B-AdverseReaction
,	TAFINLAR.xml:S1:967:1	O
and	TAFINLAR.xml:S1:969:3	O
palmar	TAFINLAR.xml:S1:973:6	B-AdverseReaction
-	TAFINLAR.xml:S1:979:1	I-AdverseReaction
plantar	TAFINLAR.xml:S1:980:7	I-AdverseReaction
erythrodysesthesia	TAFINLAR.xml:S1:988:18	I-AdverseReaction
syndrome	TAFINLAR.xml:S1:1007:8	I-AdverseReaction
.	TAFINLAR.xml:S1:1015:1	O

(	TAFINLAR.xml:S1:1017:1	O
6.1	TAFINLAR.xml:S1:1020:3	O
)	TAFINLAR.xml:S1:1025:1	O

Most	TAFINLAR.xml:S1:1034:4	O
common	TAFINLAR.xml:S1:1039:6	O
adverse	TAFINLAR.xml:S1:1046:7	O
reactions	TAFINLAR.xml:S1:1054:9	O
(	TAFINLAR.xml:S1:1064:1	O
20%	TAFINLAR.xml:S1:1067:3	O
)	TAFINLAR.xml:S1:1070:1	O
for	TAFINLAR.xml:S1:1072:3	O
TAFINLAR	TAFINLAR.xml:S1:1076:8	O
in	TAFINLAR.xml:S1:1085:2	O
combination	TAFINLAR.xml:S1:1088:11	O
with	TAFINLAR.xml:S1:1100:4	O
trametinib	TAFINLAR.xml:S1:1105:10	O
are	TAFINLAR.xml:S1:1116:3	O
pyrexia	TAFINLAR.xml:S1:1120:7	B-AdverseReaction
,	TAFINLAR.xml:S1:1127:1	O
chills	TAFINLAR.xml:S1:1129:6	B-AdverseReaction
,	TAFINLAR.xml:S1:1135:1	O
fatigue	TAFINLAR.xml:S1:1137:7	B-AdverseReaction
,	TAFINLAR.xml:S1:1144:1	O
rash	TAFINLAR.xml:S1:1146:4	B-AdverseReaction
,	TAFINLAR.xml:S1:1150:1	O
nausea	TAFINLAR.xml:S1:1152:6	B-AdverseReaction
,	TAFINLAR.xml:S1:1158:1	O
vomiting	TAFINLAR.xml:S1:1160:8	B-AdverseReaction
,	TAFINLAR.xml:S1:1168:1	O
diarrhea	TAFINLAR.xml:S1:1170:8	B-AdverseReaction
,	TAFINLAR.xml:S1:1178:1	O
abdominal	TAFINLAR.xml:S1:1180:9	B-AdverseReaction
pain	TAFINLAR.xml:S1:1190:4	I-AdverseReaction
,	TAFINLAR.xml:S1:1194:1	O
peripheral	TAFINLAR.xml:S1:1196:10	B-AdverseReaction
edema	TAFINLAR.xml:S1:1207:5	I-AdverseReaction
,	TAFINLAR.xml:S1:1212:1	O
cough	TAFINLAR.xml:S1:1214:5	B-AdverseReaction
,	TAFINLAR.xml:S1:1219:1	O
headache	TAFINLAR.xml:S1:1221:8	B-AdverseReaction
,	TAFINLAR.xml:S1:1229:1	O
arthralgia	TAFINLAR.xml:S1:1231:10	B-AdverseReaction
,	TAFINLAR.xml:S1:1241:1	O
night	TAFINLAR.xml:S1:1243:5	B-AdverseReaction
sweats	TAFINLAR.xml:S1:1249:6	I-AdverseReaction
,	TAFINLAR.xml:S1:1255:1	O
decreased	TAFINLAR.xml:S1:1257:9	B-AdverseReaction
appetite	TAFINLAR.xml:S1:1267:8	I-AdverseReaction
,	TAFINLAR.xml:S1:1275:1	O
constipation	TAFINLAR.xml:S1:1277:12	B-AdverseReaction
,	TAFINLAR.xml:S1:1289:1	O
and	TAFINLAR.xml:S1:1291:3	O
myalgia	TAFINLAR.xml:S1:1295:7	B-AdverseReaction
.	TAFINLAR.xml:S1:1302:1	O

(	TAFINLAR.xml:S1:1304:1	O
6.1	TAFINLAR.xml:S1:1307:3	O
)	TAFINLAR.xml:S1:1312:1	O

EXCERPT	TAFINLAR.xml:S1:1321:7	O
:	TAFINLAR.xml:S1:1328:1	O
To	TAFINLAR.xml:S1:1334:2	O
report	TAFINLAR.xml:S1:1337:6	O
SUSPECTED	TAFINLAR.xml:S1:1344:9	O
ADVERSE	TAFINLAR.xml:S1:1354:7	O
REACTIONS	TAFINLAR.xml:S1:1362:9	O
,	TAFINLAR.xml:S1:1371:1	O
contact	TAFINLAR.xml:S1:1373:7	O
GlaxoSmithKline	TAFINLAR.xml:S1:1381:15	O
at	TAFINLAR.xml:S1:1397:2	O
1	TAFINLAR.xml:S1:1400:1	O
-	TAFINLAR.xml:S1:1401:1	O
888	TAFINLAR.xml:S1:1402:3	O
-	TAFINLAR.xml:S1:1405:1	O
825	TAFINLAR.xml:S1:1406:3	O
-	TAFINLAR.xml:S1:1409:1	O
5249	TAFINLAR.xml:S1:1410:4	O
or	TAFINLAR.xml:S1:1415:2	O
FDA	TAFINLAR.xml:S1:1418:3	O
at	TAFINLAR.xml:S1:1422:2	O
1	TAFINLAR.xml:S1:1425:1	O
-	TAFINLAR.xml:S1:1426:1	O
800	TAFINLAR.xml:S1:1427:3	O
-	TAFINLAR.xml:S1:1430:1	O
FDA	TAFINLAR.xml:S1:1431:3	O
-	TAFINLAR.xml:S1:1434:1	O
1088	TAFINLAR.xml:S1:1435:4	O
or	TAFINLAR.xml:S1:1440:2	O
www	TAFINLAR.xml:S1:1446:3	O
.	TAFINLAR.xml:S1:1449:1	O
fda	TAFINLAR.xml:S1:1450:3	O
.	TAFINLAR.xml:S1:1453:1	O
gov	TAFINLAR.xml:S1:1454:3	O
medwatch	TAFINLAR.xml:S1:1458:8	O
.	TAFINLAR.xml:S1:1466:1	O

6.1	TAFINLAR.xml:S1:1478:3	O

Clinical	TAFINLAR.xml:S1:1482:8	O

Trials	TAFINLAR.xml:S1:1491:6	O
Experience	TAFINLAR.xml:S1:1498:10	O

Because	TAFINLAR.xml:S1:1512:7	O
clinical	TAFINLAR.xml:S1:1520:8	O
trials	TAFINLAR.xml:S1:1529:6	O
are	TAFINLAR.xml:S1:1536:3	O
conducted	TAFINLAR.xml:S1:1540:9	O
under	TAFINLAR.xml:S1:1550:5	O
widely	TAFINLAR.xml:S1:1556:6	O
varying	TAFINLAR.xml:S1:1563:7	O
conditions	TAFINLAR.xml:S1:1571:10	O
,	TAFINLAR.xml:S1:1581:1	O
adverse	TAFINLAR.xml:S1:1583:7	O
reaction	TAFINLAR.xml:S1:1591:8	O
rates	TAFINLAR.xml:S1:1600:5	O
observed	TAFINLAR.xml:S1:1606:8	O
in	TAFINLAR.xml:S1:1615:2	O
the	TAFINLAR.xml:S1:1618:3	O
clinical	TAFINLAR.xml:S1:1622:8	O
trials	TAFINLAR.xml:S1:1631:6	O
of	TAFINLAR.xml:S1:1638:2	O
a	TAFINLAR.xml:S1:1641:1	O
drug	TAFINLAR.xml:S1:1643:4	O
cannot	TAFINLAR.xml:S1:1648:6	O
be	TAFINLAR.xml:S1:1655:2	O
directly	TAFINLAR.xml:S1:1658:8	O
compared	TAFINLAR.xml:S1:1667:8	O
to	TAFINLAR.xml:S1:1676:2	O
rates	TAFINLAR.xml:S1:1679:5	O
in	TAFINLAR.xml:S1:1685:2	O
the	TAFINLAR.xml:S1:1688:3	O
clinical	TAFINLAR.xml:S1:1692:8	O
trials	TAFINLAR.xml:S1:1701:6	O
of	TAFINLAR.xml:S1:1708:2	O
another	TAFINLAR.xml:S1:1711:7	O
drug	TAFINLAR.xml:S1:1719:4	O
and	TAFINLAR.xml:S1:1724:3	O
may	TAFINLAR.xml:S1:1728:3	O
not	TAFINLAR.xml:S1:1732:3	O
reflect	TAFINLAR.xml:S1:1736:7	O
the	TAFINLAR.xml:S1:1744:3	O
rates	TAFINLAR.xml:S1:1748:5	O
observed	TAFINLAR.xml:S1:1754:8	O
in	TAFINLAR.xml:S1:1763:2	O
practice	TAFINLAR.xml:S1:1766:8	O
.	TAFINLAR.xml:S1:1774:1	O

The	TAFINLAR.xml:S1:1780:3	O
data	TAFINLAR.xml:S1:1784:4	O
described	TAFINLAR.xml:S1:1789:9	O
in	TAFINLAR.xml:S1:1799:2	O
the	TAFINLAR.xml:S1:1802:3	O
Warnings	TAFINLAR.xml:S1:1806:8	O
and	TAFINLAR.xml:S1:1815:3	O
Precautions	TAFINLAR.xml:S1:1819:11	O
section	TAFINLAR.xml:S1:1831:7	O
and	TAFINLAR.xml:S1:1839:3	O
below	TAFINLAR.xml:S1:1843:5	O
reflect	TAFINLAR.xml:S1:1849:7	O
exposure	TAFINLAR.xml:S1:1857:8	O
to	TAFINLAR.xml:S1:1866:2	O
TAFINLAR	TAFINLAR.xml:S1:1869:8	O
as	TAFINLAR.xml:S1:1878:2	O
a	TAFINLAR.xml:S1:1881:1	O
single	TAFINLAR.xml:S1:1883:6	O
agent	TAFINLAR.xml:S1:1890:5	O
and	TAFINLAR.xml:S1:1896:3	O
in	TAFINLAR.xml:S1:1900:2	O
combination	TAFINLAR.xml:S1:1903:11	O
with	TAFINLAR.xml:S1:1915:4	O
trametinib	TAFINLAR.xml:S1:1920:10	O
.	TAFINLAR.xml:S1:1930:1	O

BRAF	TAFINLAR.xml:S1:1938:4	O
V600E	TAFINLAR.xml:S1:1943:5	O
Unresectable	TAFINLAR.xml:S1:1949:12	O
or	TAFINLAR.xml:S1:1962:2	O
Metastatic	TAFINLAR.xml:S1:1965:10	O
Melanoma	TAFINLAR.xml:S1:1976:8	O
:	TAFINLAR.xml:S1:1984:1	O

The	TAFINLAR.xml:S1:1992:3	O
safety	TAFINLAR.xml:S1:1996:6	O
of	TAFINLAR.xml:S1:2003:2	O
TAFINLAR	TAFINLAR.xml:S1:2006:8	O
as	TAFINLAR.xml:S1:2015:2	O
a	TAFINLAR.xml:S1:2018:1	O
single	TAFINLAR.xml:S1:2020:6	O
agent	TAFINLAR.xml:S1:2027:5	O
was	TAFINLAR.xml:S1:2033:3	O
evaluated	TAFINLAR.xml:S1:2037:9	O
in	TAFINLAR.xml:S1:2047:2	O
586	TAFINLAR.xml:S1:2050:3	O
patients	TAFINLAR.xml:S1:2054:8	O
with	TAFINLAR.xml:S1:2063:4	O
BRAF	TAFINLAR.xml:S1:2068:4	O
V600	TAFINLAR.xml:S1:2073:4	O
mutation	TAFINLAR.xml:S1:2078:8	O
-	TAFINLAR.xml:S1:2086:1	O
positive	TAFINLAR.xml:S1:2087:8	O
unresectable	TAFINLAR.xml:S1:2096:12	O
or	TAFINLAR.xml:S1:2109:2	O
metastatic	TAFINLAR.xml:S1:2112:10	O
melanoma	TAFINLAR.xml:S1:2123:8	O
,	TAFINLAR.xml:S1:2131:1	O
previously	TAFINLAR.xml:S1:2133:10	O
treated	TAFINLAR.xml:S1:2144:7	O
or	TAFINLAR.xml:S1:2152:2	O
untreated	TAFINLAR.xml:S1:2155:9	O
,	TAFINLAR.xml:S1:2164:1	O
who	TAFINLAR.xml:S1:2166:3	O
received	TAFINLAR.xml:S1:2170:8	O
TAFINLAR	TAFINLAR.xml:S1:2179:8	O
150	TAFINLAR.xml:S1:2188:3	O
mg	TAFINLAR.xml:S1:2192:2	O
orally	TAFINLAR.xml:S1:2195:6	O
twice	TAFINLAR.xml:S1:2202:5	O
daily	TAFINLAR.xml:S1:2208:5	O
until	TAFINLAR.xml:S1:2214:5	O
disease	TAFINLAR.xml:S1:2220:7	O
progression	TAFINLAR.xml:S1:2228:11	O
or	TAFINLAR.xml:S1:2240:2	O
unacceptable	TAFINLAR.xml:S1:2243:12	O
toxicity	TAFINLAR.xml:S1:2256:8	O
,	TAFINLAR.xml:S1:2264:1	O
including	TAFINLAR.xml:S1:2266:9	O
181	TAFINLAR.xml:S1:2276:3	O
patients	TAFINLAR.xml:S1:2280:8	O
treated	TAFINLAR.xml:S1:2289:7	O
for	TAFINLAR.xml:S1:2297:3	O
at	TAFINLAR.xml:S1:2301:2	O
least	TAFINLAR.xml:S1:2304:5	O
6	TAFINLAR.xml:S1:2310:1	O
months	TAFINLAR.xml:S1:2312:6	O
and	TAFINLAR.xml:S1:2319:3	O
86	TAFINLAR.xml:S1:2323:2	O
additional	TAFINLAR.xml:S1:2326:10	O
patients	TAFINLAR.xml:S1:2337:8	O
treated	TAFINLAR.xml:S1:2346:7	O
for	TAFINLAR.xml:S1:2354:3	O
more	TAFINLAR.xml:S1:2358:4	O
than	TAFINLAR.xml:S1:2363:4	O
12	TAFINLAR.xml:S1:2368:2	O
months	TAFINLAR.xml:S1:2371:6	O
.	TAFINLAR.xml:S1:2377:1	O

TAFINLAR	TAFINLAR.xml:S1:2379:8	O
was	TAFINLAR.xml:S1:2388:3	O
studied	TAFINLAR.xml:S1:2392:7	O
in	TAFINLAR.xml:S1:2400:2	O
open	TAFINLAR.xml:S1:2403:4	O
-	TAFINLAR.xml:S1:2407:1	O
label	TAFINLAR.xml:S1:2408:5	O
,	TAFINLAR.xml:S1:2413:1	O
single	TAFINLAR.xml:S1:2415:6	O
-	TAFINLAR.xml:S1:2421:1	O
arm	TAFINLAR.xml:S1:2422:3	O
trials	TAFINLAR.xml:S1:2426:6	O
and	TAFINLAR.xml:S1:2433:3	O
in	TAFINLAR.xml:S1:2437:2	O
an	TAFINLAR.xml:S1:2440:2	O
open	TAFINLAR.xml:S1:2443:4	O
-	TAFINLAR.xml:S1:2447:1	O
label	TAFINLAR.xml:S1:2448:5	O
,	TAFINLAR.xml:S1:2453:1	O
randomized	TAFINLAR.xml:S1:2455:10	O
,	TAFINLAR.xml:S1:2465:1	O
active	TAFINLAR.xml:S1:2467:6	O
-	TAFINLAR.xml:S1:2473:1	O
controlled	TAFINLAR.xml:S1:2474:10	O
trial	TAFINLAR.xml:S1:2485:5	O
.	TAFINLAR.xml:S1:2490:1	O

The	TAFINLAR.xml:S1:2492:3	O
median	TAFINLAR.xml:S1:2496:6	O
daily	TAFINLAR.xml:S1:2503:5	O
dose	TAFINLAR.xml:S1:2509:4	O
of	TAFINLAR.xml:S1:2514:2	O
TAFINLAR	TAFINLAR.xml:S1:2517:8	O
was	TAFINLAR.xml:S1:2526:3	O
300	TAFINLAR.xml:S1:2530:3	O
mg	TAFINLAR.xml:S1:2534:2	O
(	TAFINLAR.xml:S1:2537:1	O
range	TAFINLAR.xml:S1:2538:5	O
:	TAFINLAR.xml:S1:2543:1	O
118	TAFINLAR.xml:S1:2545:3	O
to	TAFINLAR.xml:S1:2549:2	O
300	TAFINLAR.xml:S1:2552:3	O
mg	TAFINLAR.xml:S1:2556:2	O
)	TAFINLAR.xml:S1:2558:1	O
.	TAFINLAR.xml:S1:2559:1	O

Table	TAFINLAR.xml:S1:2565:5	O
3	TAFINLAR.xml:S1:2571:1	O
and	TAFINLAR.xml:S1:2573:3	O
Table	TAFINLAR.xml:S1:2577:5	O
4	TAFINLAR.xml:S1:2583:1	O
present	TAFINLAR.xml:S1:2585:7	O
adverse	TAFINLAR.xml:S1:2593:7	O
drug	TAFINLAR.xml:S1:2601:4	O
reactions	TAFINLAR.xml:S1:2606:9	O
and	TAFINLAR.xml:S1:2616:3	O
laboratory	TAFINLAR.xml:S1:2620:10	O
abnormalities	TAFINLAR.xml:S1:2631:13	O
identified	TAFINLAR.xml:S1:2645:10	O
from	TAFINLAR.xml:S1:2656:4	O
analyses	TAFINLAR.xml:S1:2661:8	O
of	TAFINLAR.xml:S1:2670:2	O
Trial	TAFINLAR.xml:S1:2673:5	O
1	TAFINLAR.xml:S1:2679:1	O
[	TAFINLAR.xml:S1:2682:1	O
see	TAFINLAR.xml:S1:2683:3	O
Clinical	TAFINLAR.xml:S1:2687:8	O
Studies	TAFINLAR.xml:S1:2696:7	O
(	TAFINLAR.xml:S1:2704:1	O
14.1	TAFINLAR.xml:S1:2705:4	O
)]	TAFINLAR.xml:S1:2709:2	O
.	TAFINLAR.xml:S1:2711:1	O

Trial	TAFINLAR.xml:S1:2714:5	O
1	TAFINLAR.xml:S1:2720:1	O
,	TAFINLAR.xml:S1:2721:1	O
a	TAFINLAR.xml:S1:2723:1	O
multicenter	TAFINLAR.xml:S1:2725:11	O
,	TAFINLAR.xml:S1:2736:1	O
international	TAFINLAR.xml:S1:2738:13	O
,	TAFINLAR.xml:S1:2751:1	O
open	TAFINLAR.xml:S1:2753:4	O
-	TAFINLAR.xml:S1:2757:1	O
label	TAFINLAR.xml:S1:2758:5	O
,	TAFINLAR.xml:S1:2763:1	O
randomized	TAFINLAR.xml:S1:2765:10	O
(	TAFINLAR.xml:S1:2776:1	O
3	TAFINLAR.xml:S1:2777:1	O
:	TAFINLAR.xml:S1:2778:1	O
1	TAFINLAR.xml:S1:2779:1	O
)	TAFINLAR.xml:S1:2780:1	O
,	TAFINLAR.xml:S1:2781:1	O
controlled	TAFINLAR.xml:S1:2783:10	O
trial	TAFINLAR.xml:S1:2794:5	O
allocated	TAFINLAR.xml:S1:2800:9	O
250	TAFINLAR.xml:S1:2810:3	O
patients	TAFINLAR.xml:S1:2814:8	O
with	TAFINLAR.xml:S1:2823:4	O
unresectable	TAFINLAR.xml:S1:2828:12	O
or	TAFINLAR.xml:S1:2841:2	O
metastatic	TAFINLAR.xml:S1:2844:10	O
BRAF	TAFINLAR.xml:S1:2855:4	O
V600E	TAFINLAR.xml:S1:2860:5	O
mutation	TAFINLAR.xml:S1:2866:8	O
-	TAFINLAR.xml:S1:2874:1	O
positive	TAFINLAR.xml:S1:2875:8	O
melanoma	TAFINLAR.xml:S1:2884:8	O
to	TAFINLAR.xml:S1:2893:2	O
receive	TAFINLAR.xml:S1:2896:7	O
TAFINLAR	TAFINLAR.xml:S1:2904:8	O
150	TAFINLAR.xml:S1:2913:3	O
mg	TAFINLAR.xml:S1:2917:2	O
orally	TAFINLAR.xml:S1:2920:6	O
twice	TAFINLAR.xml:S1:2927:5	O
daily	TAFINLAR.xml:S1:2933:5	O
(	TAFINLAR.xml:S1:2939:1	O
n	TAFINLAR.xml:S1:2940:1	O
187	TAFINLAR.xml:S1:2944:3	O
)	TAFINLAR.xml:S1:2947:1	O
or	TAFINLAR.xml:S1:2949:2	O
dacarbazine	TAFINLAR.xml:S1:2952:11	O
1	TAFINLAR.xml:S1:2964:1	O
,	TAFINLAR.xml:S1:2965:1	O
000	TAFINLAR.xml:S1:2966:3	O
mg	TAFINLAR.xml:S1:2970:2	O
m	TAFINLAR.xml:S1:2973:1	O
2	TAFINLAR.xml:S1:2976:1	O
intravenously	TAFINLAR.xml:S1:2979:13	O
every	TAFINLAR.xml:S1:2993:5	O
3	TAFINLAR.xml:S1:2999:1	O
weeks	TAFINLAR.xml:S1:3001:5	O
(	TAFINLAR.xml:S1:3007:1	O
n	TAFINLAR.xml:S1:3008:1	O
63	TAFINLAR.xml:S1:3012:2	O
)	TAFINLAR.xml:S1:3014:1	O
.	TAFINLAR.xml:S1:3015:1	O

The	TAFINLAR.xml:S1:3017:3	O
trial	TAFINLAR.xml:S1:3021:5	O
excluded	TAFINLAR.xml:S1:3027:8	O
patients	TAFINLAR.xml:S1:3036:8	O
with	TAFINLAR.xml:S1:3045:4	O
abnormal	TAFINLAR.xml:S1:3050:8	O
left	TAFINLAR.xml:S1:3059:4	O
ventricular	TAFINLAR.xml:S1:3064:11	O
ejection	TAFINLAR.xml:S1:3076:8	O
fraction	TAFINLAR.xml:S1:3085:8	O
or	TAFINLAR.xml:S1:3094:2	O
cardiac	TAFINLAR.xml:S1:3097:7	O
valve	TAFINLAR.xml:S1:3105:5	O
morphology	TAFINLAR.xml:S1:3111:10	O
(	TAFINLAR.xml:S1:3122:1	O
Grade	TAFINLAR.xml:S1:3125:5	O
2	TAFINLAR.xml:S1:3131:1	O
)	TAFINLAR.xml:S1:3132:1	O
,	TAFINLAR.xml:S1:3133:1	O
corrected	TAFINLAR.xml:S1:3135:9	O
QT	TAFINLAR.xml:S1:3145:2	O
interval	TAFINLAR.xml:S1:3148:8	O
480	TAFINLAR.xml:S1:3159:3	O
milliseconds	TAFINLAR.xml:S1:3163:12	O
on	TAFINLAR.xml:S1:3176:2	O
electrocardiogram	TAFINLAR.xml:S1:3179:17	O
,	TAFINLAR.xml:S1:3196:1	O
or	TAFINLAR.xml:S1:3198:2	O
a	TAFINLAR.xml:S1:3201:1	O
known	TAFINLAR.xml:S1:3203:5	O
history	TAFINLAR.xml:S1:3209:7	O
of	TAFINLAR.xml:S1:3217:2	O
glucose	TAFINLAR.xml:S1:3220:7	O
-	TAFINLAR.xml:S1:3227:1	O
6	TAFINLAR.xml:S1:3228:1	O
-	TAFINLAR.xml:S1:3229:1	O
phosphate	TAFINLAR.xml:S1:3230:9	O
dehydrogenase	TAFINLAR.xml:S1:3240:13	O
deficiency	TAFINLAR.xml:S1:3254:10	O
.	TAFINLAR.xml:S1:3264:1	O

The	TAFINLAR.xml:S1:3266:3	O
median	TAFINLAR.xml:S1:3270:6	O
duration	TAFINLAR.xml:S1:3277:8	O
on	TAFINLAR.xml:S1:3286:2	O
treatment	TAFINLAR.xml:S1:3289:9	O
was	TAFINLAR.xml:S1:3299:3	O
4.9	TAFINLAR.xml:S1:3303:3	O
months	TAFINLAR.xml:S1:3307:6	O
for	TAFINLAR.xml:S1:3314:3	O
patients	TAFINLAR.xml:S1:3318:8	O
treated	TAFINLAR.xml:S1:3327:7	O
with	TAFINLAR.xml:S1:3335:4	O
TAFINLAR	TAFINLAR.xml:S1:3340:8	O
and	TAFINLAR.xml:S1:3349:3	O
2.8	TAFINLAR.xml:S1:3353:3	O
months	TAFINLAR.xml:S1:3357:6	O
for	TAFINLAR.xml:S1:3364:3	O
dacarbazine	TAFINLAR.xml:S1:3368:11	O
-	TAFINLAR.xml:S1:3379:1	O
treated	TAFINLAR.xml:S1:3380:7	O
patients	TAFINLAR.xml:S1:3388:8	O
.	TAFINLAR.xml:S1:3396:1	O

The	TAFINLAR.xml:S1:3398:3	O
population	TAFINLAR.xml:S1:3402:10	O
exposed	TAFINLAR.xml:S1:3413:7	O
to	TAFINLAR.xml:S1:3421:2	O
TAFINLAR	TAFINLAR.xml:S1:3424:8	O
was	TAFINLAR.xml:S1:3433:3	O
60%	TAFINLAR.xml:S1:3437:3	O
male	TAFINLAR.xml:S1:3441:4	O
,	TAFINLAR.xml:S1:3445:1	O
99%	TAFINLAR.xml:S1:3447:3	O
white	TAFINLAR.xml:S1:3451:5	O
,	TAFINLAR.xml:S1:3456:1	O
and	TAFINLAR.xml:S1:3458:3	O
had	TAFINLAR.xml:S1:3462:3	O
a	TAFINLAR.xml:S1:3466:1	O
median	TAFINLAR.xml:S1:3468:6	O
age	TAFINLAR.xml:S1:3475:3	O
of	TAFINLAR.xml:S1:3479:2	O
53	TAFINLAR.xml:S1:3482:2	O
years	TAFINLAR.xml:S1:3485:5	O
.	TAFINLAR.xml:S1:3490:1	O

The	TAFINLAR.xml:S1:3496:3	O
most	TAFINLAR.xml:S1:3500:4	O
commonly	TAFINLAR.xml:S1:3505:8	O
occurring	TAFINLAR.xml:S1:3514:9	O
adverse	TAFINLAR.xml:S1:3524:7	O
reactions	TAFINLAR.xml:S1:3532:9	O
(	TAFINLAR.xml:S1:3542:1	O
20%	TAFINLAR.xml:S1:3545:3	O
)	TAFINLAR.xml:S1:3548:1	O
in	TAFINLAR.xml:S1:3550:2	O
patients	TAFINLAR.xml:S1:3553:8	O
treated	TAFINLAR.xml:S1:3562:7	O
with	TAFINLAR.xml:S1:3570:4	O
TAFINLAR	TAFINLAR.xml:S1:3575:8	O
were	TAFINLAR.xml:S1:3584:4	O
,	TAFINLAR.xml:S1:3588:1	O
in	TAFINLAR.xml:S1:3590:2	O
order	TAFINLAR.xml:S1:3593:5	O
of	TAFINLAR.xml:S1:3599:2	O
decreasing	TAFINLAR.xml:S1:3602:10	O
frequency	TAFINLAR.xml:S1:3613:9	O
:	TAFINLAR.xml:S1:3622:1	O
hyperkeratosis	TAFINLAR.xml:S1:3624:14	B-AdverseReaction
,	TAFINLAR.xml:S1:3638:1	O
headache	TAFINLAR.xml:S1:3640:8	B-AdverseReaction
,	TAFINLAR.xml:S1:3648:1	O
pyrexia	TAFINLAR.xml:S1:3650:7	B-AdverseReaction
,	TAFINLAR.xml:S1:3657:1	O
arthralgia	TAFINLAR.xml:S1:3659:10	B-AdverseReaction
,	TAFINLAR.xml:S1:3669:1	O
papilloma	TAFINLAR.xml:S1:3671:9	B-AdverseReaction
,	TAFINLAR.xml:S1:3680:1	O
alopecia	TAFINLAR.xml:S1:3682:8	B-AdverseReaction
,	TAFINLAR.xml:S1:3690:1	O
and	TAFINLAR.xml:S1:3692:3	O
palmar	TAFINLAR.xml:S1:3696:6	B-AdverseReaction
-	TAFINLAR.xml:S1:3702:1	I-AdverseReaction
plantar	TAFINLAR.xml:S1:3703:7	I-AdverseReaction
erythrodysesthesia	TAFINLAR.xml:S1:3711:18	I-AdverseReaction
syndrome	TAFINLAR.xml:S1:3730:8	I-AdverseReaction
(	TAFINLAR.xml:S1:3739:1	O
PPES	TAFINLAR.xml:S1:3740:4	B-AdverseReaction
)	TAFINLAR.xml:S1:3744:1	O
.	TAFINLAR.xml:S1:3745:1	O

The	TAFINLAR.xml:S1:3751:3	O
incidence	TAFINLAR.xml:S1:3755:9	O
of	TAFINLAR.xml:S1:3765:2	O
adverse	TAFINLAR.xml:S1:3768:7	O
events	TAFINLAR.xml:S1:3776:6	O
resulting	TAFINLAR.xml:S1:3783:9	O
in	TAFINLAR.xml:S1:3793:2	O
permanent	TAFINLAR.xml:S1:3796:9	O
discontinuation	TAFINLAR.xml:S1:3806:15	O
of	TAFINLAR.xml:S1:3822:2	O
study	TAFINLAR.xml:S1:3825:5	O
medication	TAFINLAR.xml:S1:3831:10	O
in	TAFINLAR.xml:S1:3842:2	O
Trial	TAFINLAR.xml:S1:3845:5	O
1	TAFINLAR.xml:S1:3851:1	O
was	TAFINLAR.xml:S1:3853:3	O
3%	TAFINLAR.xml:S1:3857:2	O
for	TAFINLAR.xml:S1:3860:3	O
patients	TAFINLAR.xml:S1:3864:8	O
treated	TAFINLAR.xml:S1:3873:7	O
with	TAFINLAR.xml:S1:3881:4	O
TAFINLAR	TAFINLAR.xml:S1:3886:8	O
and	TAFINLAR.xml:S1:3895:3	O
3%	TAFINLAR.xml:S1:3899:2	O
for	TAFINLAR.xml:S1:3902:3	O
patients	TAFINLAR.xml:S1:3906:8	O
treated	TAFINLAR.xml:S1:3915:7	O
with	TAFINLAR.xml:S1:3923:4	O
dacarbazine	TAFINLAR.xml:S1:3928:11	O
.	TAFINLAR.xml:S1:3939:1	O

The	TAFINLAR.xml:S1:3941:3	O
most	TAFINLAR.xml:S1:3945:4	O
frequent	TAFINLAR.xml:S1:3950:8	O
(	TAFINLAR.xml:S1:3959:1	O
2%	TAFINLAR.xml:S1:3962:2	O
)	TAFINLAR.xml:S1:3964:1	O
adverse	TAFINLAR.xml:S1:3966:7	O
reactions	TAFINLAR.xml:S1:3974:9	O
leading	TAFINLAR.xml:S1:3984:7	O
to	TAFINLAR.xml:S1:3992:2	O
dose	TAFINLAR.xml:S1:3995:4	O
reduction	TAFINLAR.xml:S1:4000:9	O
of	TAFINLAR.xml:S1:4010:2	O
TAFINLAR	TAFINLAR.xml:S1:4013:8	O
were	TAFINLAR.xml:S1:4022:4	O
pyrexia	TAFINLAR.xml:S1:4027:7	B-AdverseReaction
(	TAFINLAR.xml:S1:4035:1	O
9%	TAFINLAR.xml:S1:4036:2	O
)	TAFINLAR.xml:S1:4038:1	O
,	TAFINLAR.xml:S1:4039:1	O
PPES	TAFINLAR.xml:S1:4041:4	B-AdverseReaction
(	TAFINLAR.xml:S1:4046:1	O
3%	TAFINLAR.xml:S1:4047:2	O
)	TAFINLAR.xml:S1:4049:1	O
,	TAFINLAR.xml:S1:4050:1	O
chills	TAFINLAR.xml:S1:4052:6	B-AdverseReaction
(	TAFINLAR.xml:S1:4059:1	O
3%	TAFINLAR.xml:S1:4060:2	O
)	TAFINLAR.xml:S1:4062:1	O
,	TAFINLAR.xml:S1:4063:1	O
fatigue	TAFINLAR.xml:S1:4065:7	B-AdverseReaction
(	TAFINLAR.xml:S1:4073:1	O
2%	TAFINLAR.xml:S1:4074:2	O
)	TAFINLAR.xml:S1:4076:1	O
,	TAFINLAR.xml:S1:4077:1	O
and	TAFINLAR.xml:S1:4079:3	O
headache	TAFINLAR.xml:S1:4083:8	B-AdverseReaction
(	TAFINLAR.xml:S1:4092:1	O
2%	TAFINLAR.xml:S1:4093:2	O
)	TAFINLAR.xml:S1:4095:1	O
.	TAFINLAR.xml:S1:4096:1	O

Table	TAFINLAR.xml:S1:4102:5	O
3	TAFINLAR.xml:S1:4108:1	O
.	TAFINLAR.xml:S1:4109:1	O

Selected	TAFINLAR.xml:S1:4111:8	O
Common	TAFINLAR.xml:S1:4120:6	O
Adverse	TAFINLAR.xml:S1:4127:7	O
Reactions	TAFINLAR.xml:S1:4135:9	O
Occurring	TAFINLAR.xml:S1:4145:9	O
in	TAFINLAR.xml:S1:4155:2	O
10%	TAFINLAR.xml:S1:4160:3	O
(	TAFINLAR.xml:S1:4164:1	O
All	TAFINLAR.xml:S1:4165:3	O
Grades	TAFINLAR.xml:S1:4169:6	O
)	TAFINLAR.xml:S1:4175:1	O
or	TAFINLAR.xml:S1:4177:2	O
2%	TAFINLAR.xml:S1:4182:2	O
(	TAFINLAR.xml:S1:4185:1	O
Grades	TAFINLAR.xml:S1:4186:6	O
3	TAFINLAR.xml:S1:4193:1	O
or	TAFINLAR.xml:S1:4195:2	O
4	TAFINLAR.xml:S1:4198:1	O
)	TAFINLAR.xml:S1:4199:1	O
of	TAFINLAR.xml:S1:4201:2	O
Patients	TAFINLAR.xml:S1:4204:8	O
Treated	TAFINLAR.xml:S1:4213:7	O
With	TAFINLAR.xml:S1:4221:4	O
TAFINLARa	TAFINLAR.xml:S1:4226:9	O

TAFINLARN	TAFINLAR.xml:S1:4301:9	O
187	TAFINLAR.xml:S1:4313:3	O
Dacarbazine	TAFINLAR.xml:S1:4320:11	O
N	TAFINLAR.xml:S1:4332:1	O
59	TAFINLAR.xml:S1:4336:2	O

Primary	TAFINLAR.xml:S1:4345:7	O
System	TAFINLAR.xml:S1:4353:6	O
Organ	TAFINLAR.xml:S1:4360:5	O
Class	TAFINLAR.xml:S1:4366:5	O
Preferred	TAFINLAR.xml:S1:4373:9	O
Term	TAFINLAR.xml:S1:4383:4	O
All	TAFINLAR.xml:S1:4407:3	O
Grades	TAFINLAR.xml:S1:4412:6	O
(	TAFINLAR.xml:S1:4419:1	O
)	TAFINLAR.xml:S1:4421:1	O
Grades	TAFINLAR.xml:S1:4426:6	O
3	TAFINLAR.xml:S1:4434:1	O
and	TAFINLAR.xml:S1:4436:3	O
4	TAFINLAR.xml:S1:4440:1	O
b	TAFINLAR.xml:S1:4441:1	O
(	TAFINLAR.xml:S1:4444:1	O
)	TAFINLAR.xml:S1:4446:1	O
All	TAFINLAR.xml:S1:4451:3	O
Grades	TAFINLAR.xml:S1:4456:6	O
(	TAFINLAR.xml:S1:4463:1	O
)	TAFINLAR.xml:S1:4465:1	O
Grades	TAFINLAR.xml:S1:4470:6	O
3	TAFINLAR.xml:S1:4478:1	O
and	TAFINLAR.xml:S1:4480:3	O
4	TAFINLAR.xml:S1:4484:1	O
(	TAFINLAR.xml:S1:4487:1	O
)	TAFINLAR.xml:S1:4489:1	O

Skin	TAFINLAR.xml:S1:4497:4	O
and	TAFINLAR.xml:S1:4502:3	O
subcutaneous	TAFINLAR.xml:S1:4506:12	O
tissue	TAFINLAR.xml:S1:4519:6	O
disorders	TAFINLAR.xml:S1:4526:9	O

Hyperkeratosis	TAFINLAR.xml:S1:4670:14	B-AdverseReaction

37	TAFINLAR.xml:S1:4858:2	O
1	TAFINLAR.xml:S1:4871:1	O
0	TAFINLAR.xml:S1:4882:1	O
0	TAFINLAR.xml:S1:4895:1	O

Alopecia	TAFINLAR.xml:S1:4969:8	B-AdverseReaction

22	TAFINLAR.xml:S1:5157:2	O
NAf	TAFINLAR.xml:S1:5170:3	O
2	TAFINLAR.xml:S1:5181:1	O
NAf	TAFINLAR.xml:S1:5194:3	O

Palmar	TAFINLAR.xml:S1:5268:6	B-AdverseReaction
-	TAFINLAR.xml:S1:5274:1	I-AdverseReaction
plantar	TAFINLAR.xml:S1:5275:7	I-AdverseReaction
erythrodysesthesia	TAFINLAR.xml:S1:5283:18	I-AdverseReaction
syndrome	TAFINLAR.xml:S1:5302:8	I-AdverseReaction

20	TAFINLAR.xml:S1:5456:2	O
2	TAFINLAR.xml:S1:5469:1	O
2	TAFINLAR.xml:S1:5480:1	O
0	TAFINLAR.xml:S1:5493:1	O

Rash	TAFINLAR.xml:S1:5567:4	B-AdverseReaction

17	TAFINLAR.xml:S1:5755:2	O
0	TAFINLAR.xml:S1:5768:1	O
0	TAFINLAR.xml:S1:5779:1	O
0	TAFINLAR.xml:S1:5792:1	O

Nervous	TAFINLAR.xml:S1:5805:7	O
system	TAFINLAR.xml:S1:5813:6	O
disorders	TAFINLAR.xml:S1:5820:9	O

Headache	TAFINLAR.xml:S1:5978:8	B-AdverseReaction

32	TAFINLAR.xml:S1:6166:2	O
0	TAFINLAR.xml:S1:6179:1	O
8	TAFINLAR.xml:S1:6190:1	O
0	TAFINLAR.xml:S1:6203:1	O

General	TAFINLAR.xml:S1:6216:7	O
disorders	TAFINLAR.xml:S1:6224:9	O
and	TAFINLAR.xml:S1:6234:3	O
administration	TAFINLAR.xml:S1:6238:14	O
site	TAFINLAR.xml:S1:6253:4	O
conditions	TAFINLAR.xml:S1:6258:10	O

Pyrexia	TAFINLAR.xml:S1:6389:7	B-AdverseReaction

28	TAFINLAR.xml:S1:6577:2	O
3	TAFINLAR.xml:S1:6590:1	O
10	TAFINLAR.xml:S1:6601:2	O
0	TAFINLAR.xml:S1:6614:1	O

Musculoskeletal	TAFINLAR.xml:S1:6627:15	O
and	TAFINLAR.xml:S1:6643:3	O
connective	TAFINLAR.xml:S1:6647:10	O
tissue	TAFINLAR.xml:S1:6658:6	O
disorders	TAFINLAR.xml:S1:6665:9	O

Arthralgia	TAFINLAR.xml:S1:6800:10	B-AdverseReaction

27	TAFINLAR.xml:S1:6988:2	O
1	TAFINLAR.xml:S1:7001:1	O
2	TAFINLAR.xml:S1:7012:1	O
0	TAFINLAR.xml:S1:7025:1	O

Back	TAFINLAR.xml:S1:7099:4	B-AdverseReaction
pain	TAFINLAR.xml:S1:7104:4	I-AdverseReaction

12	TAFINLAR.xml:S1:7287:2	O
3	TAFINLAR.xml:S1:7300:1	O
7	TAFINLAR.xml:S1:7311:1	O
0	TAFINLAR.xml:S1:7324:1	O

Myalgia	TAFINLAR.xml:S1:7398:7	B-AdverseReaction

11	TAFINLAR.xml:S1:7586:2	O
0	TAFINLAR.xml:S1:7599:1	O
0	TAFINLAR.xml:S1:7610:1	O
0	TAFINLAR.xml:S1:7623:1	O

Neoplasms	TAFINLAR.xml:S1:7636:9	O
benign	TAFINLAR.xml:S1:7646:6	O
,	TAFINLAR.xml:S1:7652:1	O
malignant	TAFINLAR.xml:S1:7654:9	O
,	TAFINLAR.xml:S1:7663:1	O
and	TAFINLAR.xml:S1:7665:3	O
unspecified	TAFINLAR.xml:S1:7669:11	O
(	TAFINLAR.xml:S1:7681:1	O
including	TAFINLAR.xml:S1:7682:9	O
cysts	TAFINLAR.xml:S1:7692:5	O
and	TAFINLAR.xml:S1:7698:3	O
polyps	TAFINLAR.xml:S1:7702:6	O
)	TAFINLAR.xml:S1:7708:1	O

Papilloma	TAFINLAR.xml:S1:7824:9	B-AdverseReaction
c	TAFINLAR.xml:S1:7835:1	O

27	TAFINLAR.xml:S1:8012:2	O
0	TAFINLAR.xml:S1:8025:1	O
2	TAFINLAR.xml:S1:8036:1	O
0	TAFINLAR.xml:S1:8049:1	O

cuSCC	TAFINLAR.xml:S1:8123:5	B-AdverseReaction
d	TAFINLAR.xml:S1:8130:1	O
,	TAFINLAR.xml:S1:8131:1	O
e	TAFINLAR.xml:S1:8133:1	O

7	TAFINLAR.xml:S1:8311:1	O
4	TAFINLAR.xml:S1:8324:1	O
0	TAFINLAR.xml:S1:8335:1	O
0	TAFINLAR.xml:S1:8348:1	O

Respiratory	TAFINLAR.xml:S1:8361:11	O
,	TAFINLAR.xml:S1:8372:1	O
thoracic	TAFINLAR.xml:S1:8374:8	O
,	TAFINLAR.xml:S1:8382:1	O
and	TAFINLAR.xml:S1:8384:3	O
mediastinal	TAFINLAR.xml:S1:8388:11	O
disorders	TAFINLAR.xml:S1:8400:9	O

Cough	TAFINLAR.xml:S1:8534:5	B-AdverseReaction

12	TAFINLAR.xml:S1:8722:2	O
0	TAFINLAR.xml:S1:8735:1	O
5	TAFINLAR.xml:S1:8746:1	O
0	TAFINLAR.xml:S1:8759:1	O

Gastrointestinal	TAFINLAR.xml:S1:8772:16	O
disorders	TAFINLAR.xml:S1:8789:9	O

Constipation	TAFINLAR.xml:S1:8945:12	B-AdverseReaction

11	TAFINLAR.xml:S1:9133:2	O
2	TAFINLAR.xml:S1:9146:1	O
14	TAFINLAR.xml:S1:9157:2	O
0	TAFINLAR.xml:S1:9170:1	O

Infections	TAFINLAR.xml:S1:9183:10	O
and	TAFINLAR.xml:S1:9194:3	O
infestations	TAFINLAR.xml:S1:9198:12	O

Nasopharyngitis	TAFINLAR.xml:S1:9356:15	B-AdverseReaction

10	TAFINLAR.xml:S1:9544:2	O
0	TAFINLAR.xml:S1:9557:1	O
3	TAFINLAR.xml:S1:9568:1	O
0	TAFINLAR.xml:S1:9581:1	O

a	TAFINLAR.xml:S1:9605:1	O
Adverse	TAFINLAR.xml:S1:9608:7	O
drug	TAFINLAR.xml:S1:9616:4	O
reactions	TAFINLAR.xml:S1:9621:9	O
,	TAFINLAR.xml:S1:9630:1	O
reported	TAFINLAR.xml:S1:9632:8	O
using	TAFINLAR.xml:S1:9641:5	O
MedDRA	TAFINLAR.xml:S1:9647:6	O
and	TAFINLAR.xml:S1:9654:3	O
graded	TAFINLAR.xml:S1:9658:6	O
using	TAFINLAR.xml:S1:9665:5	O
CTCAE	TAFINLAR.xml:S1:9671:5	O
version	TAFINLAR.xml:S1:9677:7	O
4.0	TAFINLAR.xml:S1:9685:3	O
for	TAFINLAR.xml:S1:9689:3	O
assessment	TAFINLAR.xml:S1:9693:10	O
of	TAFINLAR.xml:S1:9704:2	O
toxicity	TAFINLAR.xml:S1:9707:8	O
.	TAFINLAR.xml:S1:9715:1	O

b	TAFINLAR.xml:S1:9723:1	O

Grade	TAFINLAR.xml:S1:9726:5	B-Severity
4	TAFINLAR.xml:S1:9732:1	I-Severity
adverse	TAFINLAR.xml:S1:9734:7	O
reactions	TAFINLAR.xml:S1:9742:9	O
limited	TAFINLAR.xml:S1:9752:7	O
to	TAFINLAR.xml:S1:9760:2	O
hyperkeratosis	TAFINLAR.xml:S1:9763:14	B-AdverseReaction
(	TAFINLAR.xml:S1:9778:1	O
n	TAFINLAR.xml:S1:9779:1	O
1	TAFINLAR.xml:S1:9783:1	O
)	TAFINLAR.xml:S1:9784:1	O
and	TAFINLAR.xml:S1:9786:3	O
constipation	TAFINLAR.xml:S1:9790:12	B-AdverseReaction
(	TAFINLAR.xml:S1:9803:1	O
n	TAFINLAR.xml:S1:9804:1	O
1	TAFINLAR.xml:S1:9808:1	O
)	TAFINLAR.xml:S1:9809:1	O
.	TAFINLAR.xml:S1:9810:1	O

c	TAFINLAR.xml:S1:9818:1	O
Includes	TAFINLAR.xml:S1:9821:8	O
skin	TAFINLAR.xml:S1:9830:4	B-AdverseReaction
papilloma	TAFINLAR.xml:S1:9835:9	I-AdverseReaction
and	TAFINLAR.xml:S1:9845:3	O
papilloma	TAFINLAR.xml:S1:9849:9	B-AdverseReaction
.	TAFINLAR.xml:S1:9858:1	O

d	TAFINLAR.xml:S1:9866:1	O
Includes	TAFINLAR.xml:S1:9869:8	O
squamous	TAFINLAR.xml:S1:9878:8	B-AdverseReaction
cell	TAFINLAR.xml:S1:9887:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S1:9892:9	I-AdverseReaction
of	TAFINLAR.xml:S1:9902:2	I-AdverseReaction
the	TAFINLAR.xml:S1:9905:3	I-AdverseReaction
skin	TAFINLAR.xml:S1:9909:4	I-AdverseReaction
and	TAFINLAR.xml:S1:9914:3	O
keratoacanthoma	TAFINLAR.xml:S1:9918:15	B-AdverseReaction
.	TAFINLAR.xml:S1:9933:1	O

e	TAFINLAR.xml:S1:9941:1	O
Cases	TAFINLAR.xml:S1:9944:5	O
of	TAFINLAR.xml:S1:9950:2	O
cutaneous	TAFINLAR.xml:S1:9953:9	B-AdverseReaction
squamous	TAFINLAR.xml:S1:9963:8	I-AdverseReaction
cell	TAFINLAR.xml:S1:9972:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S1:9977:9	I-AdverseReaction
were	TAFINLAR.xml:S1:9987:4	O
required	TAFINLAR.xml:S1:9992:8	O
to	TAFINLAR.xml:S1:10001:2	O
be	TAFINLAR.xml:S1:10004:2	O
reported	TAFINLAR.xml:S1:10007:8	O
as	TAFINLAR.xml:S1:10016:2	O
Grade	TAFINLAR.xml:S1:10019:5	B-Severity
3	TAFINLAR.xml:S1:10025:1	I-Severity
per	TAFINLAR.xml:S1:10027:3	O
protocol	TAFINLAR.xml:S1:10031:8	O
.	TAFINLAR.xml:S1:10039:1	O

f	TAFINLAR.xml:S1:10047:1	O
NA	TAFINLAR.xml:S1:10050:2	O
not	TAFINLAR.xml:S1:10055:3	O
applicable	TAFINLAR.xml:S1:10059:10	O
.	TAFINLAR.xml:S1:10069:1	O

Table	TAFINLAR.xml:S1:10075:5	O
4	TAFINLAR.xml:S1:10081:1	O
.	TAFINLAR.xml:S1:10082:1	O

Incidence	TAFINLAR.xml:S1:10084:9	O
of	TAFINLAR.xml:S1:10094:2	O
Laboratory	TAFINLAR.xml:S1:10097:10	O
Abnormalities	TAFINLAR.xml:S1:10108:13	O
Increased	TAFINLAR.xml:S1:10122:9	O
From	TAFINLAR.xml:S1:10132:4	O
Baseline	TAFINLAR.xml:S1:10137:8	O
Occurring	TAFINLAR.xml:S1:10146:9	O
at	TAFINLAR.xml:S1:10156:2	O
a	TAFINLAR.xml:S1:10159:1	O
Higher	TAFINLAR.xml:S1:10161:6	O
Incidence	TAFINLAR.xml:S1:10168:9	O
in	TAFINLAR.xml:S1:10178:2	O
Patients	TAFINLAR.xml:S1:10181:8	O
Treated	TAFINLAR.xml:S1:10190:7	O
With	TAFINLAR.xml:S1:10198:4	O
TAFINLAR	TAFINLAR.xml:S1:10203:8	O
in	TAFINLAR.xml:S1:10212:2	O
Trial	TAFINLAR.xml:S1:10215:5	O
1	TAFINLAR.xml:S1:10221:1	O
[	TAFINLAR.xml:S1:10223:1	O
Between	TAFINLAR.xml:S1:10224:7	O
-	TAFINLAR.xml:S1:10231:1	O
Arm	TAFINLAR.xml:S1:10232:3	O
Difference	TAFINLAR.xml:S1:10236:10	O
of	TAFINLAR.xml:S1:10247:2	O
5%	TAFINLAR.xml:S1:10252:2	O
(	TAFINLAR.xml:S1:10255:1	O
All	TAFINLAR.xml:S1:10256:3	O
Grades	TAFINLAR.xml:S1:10260:6	O
)	TAFINLAR.xml:S1:10266:1	O
or	TAFINLAR.xml:S1:10268:2	O
2%	TAFINLAR.xml:S1:10273:2	O
(	TAFINLAR.xml:S1:10276:1	O
Grades	TAFINLAR.xml:S1:10277:6	O
3	TAFINLAR.xml:S1:10284:1	O
or	TAFINLAR.xml:S1:10286:2	O
4	TAFINLAR.xml:S1:10289:1	O
)]	TAFINLAR.xml:S1:10290:2	O

Test	TAFINLAR.xml:S1:10296:4	O
TAFINLAR	TAFINLAR.xml:S1:10343:8	O
N	TAFINLAR.xml:S1:10353:1	O
187	TAFINLAR.xml:S1:10357:3	O
DTIC	TAFINLAR.xml:S1:10364:4	O
N	TAFINLAR.xml:S1:10370:1	O
59	TAFINLAR.xml:S1:10374:2	O

All	TAFINLAR.xml:S1:10383:3	O
Grades	TAFINLAR.xml:S1:10388:6	O
(	TAFINLAR.xml:S1:10396:1	O
)	TAFINLAR.xml:S1:10398:1	O
Grades	TAFINLAR.xml:S1:10430:6	O
3	TAFINLAR.xml:S1:10438:1	O
and	TAFINLAR.xml:S1:10440:3	O
4	TAFINLAR.xml:S1:10444:1	O
(	TAFINLAR.xml:S1:10447:1	O
)	TAFINLAR.xml:S1:10449:1	O
All	TAFINLAR.xml:S1:10454:3	O
Grades	TAFINLAR.xml:S1:10459:6	O
(	TAFINLAR.xml:S1:10467:1	O
)	TAFINLAR.xml:S1:10469:1	O
Grades	TAFINLAR.xml:S1:10474:6	O
3	TAFINLAR.xml:S1:10482:1	O
and	TAFINLAR.xml:S1:10484:3	O
4	TAFINLAR.xml:S1:10488:1	O
(	TAFINLAR.xml:S1:10491:1	O
)	TAFINLAR.xml:S1:10493:1	O

Hyperglycemia	TAFINLAR.xml:S1:10501:13	B-AdverseReaction
50	TAFINLAR.xml:S1:10548:2	O
6	TAFINLAR.xml:S1:10564:1	O
43	TAFINLAR.xml:S1:10580:2	O
0	TAFINLAR.xml:S1:10596:1	O

Hypophosphatemia	TAFINLAR.xml:S1:10615:16	B-AdverseReaction
37	TAFINLAR.xml:S1:10662:2	O
6	TAFINLAR.xml:S1:10678:1	O
a	TAFINLAR.xml:S1:10679:1	O
14	TAFINLAR.xml:S1:10694:2	O
2	TAFINLAR.xml:S1:10710:1	O

Increased	TAFINLAR.xml:S1:10729:9	B-AdverseReaction
alkaline	TAFINLAR.xml:S1:10739:8	I-AdverseReaction
phosphatase	TAFINLAR.xml:S1:10748:11	I-AdverseReaction
19	TAFINLAR.xml:S1:10776:2	O
0	TAFINLAR.xml:S1:10792:1	O
14	TAFINLAR.xml:S1:10808:2	O
2	TAFINLAR.xml:S1:10824:1	O

Hyponatremia	TAFINLAR.xml:S1:10843:12	B-AdverseReaction
8	TAFINLAR.xml:S1:10890:1	O
2	TAFINLAR.xml:S1:10906:1	O
3	TAFINLAR.xml:S1:10922:1	O
0	TAFINLAR.xml:S1:10938:1	O

a	TAFINLAR.xml:S1:10968:1	O
Grade	TAFINLAR.xml:S1:10971:5	B-Severity
4	TAFINLAR.xml:S1:10977:1	I-Severity
laboratory	TAFINLAR.xml:S1:10979:10	O
abnormality	TAFINLAR.xml:S1:10990:11	O
limited	TAFINLAR.xml:S1:11002:7	O
to	TAFINLAR.xml:S1:11010:2	O
hypophosphatemia	TAFINLAR.xml:S1:11013:16	B-AdverseReaction
(	TAFINLAR.xml:S1:11030:1	O
n	TAFINLAR.xml:S1:11031:1	O
1	TAFINLAR.xml:S1:11035:1	O
)	TAFINLAR.xml:S1:11036:1	O
.	TAFINLAR.xml:S1:11037:1	O

Other	TAFINLAR.xml:S1:11043:5	O

clinically	TAFINLAR.xml:S1:11049:10	O
important	TAFINLAR.xml:S1:11060:9	O
adverse	TAFINLAR.xml:S1:11070:7	O
reactions	TAFINLAR.xml:S1:11078:9	O
observed	TAFINLAR.xml:S1:11088:8	O
in	TAFINLAR.xml:S1:11097:2	O
10%	TAFINLAR.xml:S1:11101:3	O
of	TAFINLAR.xml:S1:11105:2	O
patients	TAFINLAR.xml:S1:11108:8	O
(	TAFINLAR.xml:S1:11117:1	O
N	TAFINLAR.xml:S1:11118:1	O
586	TAFINLAR.xml:S1:11122:3	O
)	TAFINLAR.xml:S1:11125:1	O
treated	TAFINLAR.xml:S1:11127:7	O
with	TAFINLAR.xml:S1:11135:4	O
TAFINLAR	TAFINLAR.xml:S1:11140:8	O
were	TAFINLAR.xml:S1:11149:4	O
:	TAFINLAR.xml:S1:11153:1	O

Gastrointestinal	TAFINLAR.xml:S1:11161:16	O
Disorders	TAFINLAR.xml:S1:11178:9	O
:	TAFINLAR.xml:S1:11187:1	O
Pancreatitis	TAFINLAR.xml:S1:11190:12	B-AdverseReaction
.	TAFINLAR.xml:S1:11202:1	O

Immune	TAFINLAR.xml:S1:11210:6	O
System	TAFINLAR.xml:S1:11217:6	O
Disorders	TAFINLAR.xml:S1:11224:9	O
:	TAFINLAR.xml:S1:11233:1	O
Hypersensitivity	TAFINLAR.xml:S1:11236:16	B-AdverseReaction
manifesting	TAFINLAR.xml:S1:11253:11	O
as	TAFINLAR.xml:S1:11265:2	O
bullous	TAFINLAR.xml:S1:11268:7	B-AdverseReaction
rash	TAFINLAR.xml:S1:11276:4	I-AdverseReaction
.	TAFINLAR.xml:S1:11280:1	O

Renal	TAFINLAR.xml:S1:11288:5	O
and	TAFINLAR.xml:S1:11294:3	O
Urinary	TAFINLAR.xml:S1:11298:7	O
Disorders	TAFINLAR.xml:S1:11306:9	O
:	TAFINLAR.xml:S1:11315:1	O
Interstitial	TAFINLAR.xml:S1:11318:12	B-AdverseReaction
nephritis	TAFINLAR.xml:S1:11331:9	I-AdverseReaction
.	TAFINLAR.xml:S1:11340:1	O

BRAF	TAFINLAR.xml:S1:11348:4	O
V600E	TAFINLAR.xml:S1:11353:5	O
or	TAFINLAR.xml:S1:11359:2	O
V600K	TAFINLAR.xml:S1:11362:5	O
Unresectable	TAFINLAR.xml:S1:11368:12	O
or	TAFINLAR.xml:S1:11381:2	O
Metastatic	TAFINLAR.xml:S1:11384:10	O
Melanoma	TAFINLAR.xml:S1:11395:8	O
:	TAFINLAR.xml:S1:11403:1	O

The	TAFINLAR.xml:S1:11411:3	O
safety	TAFINLAR.xml:S1:11415:6	O
of	TAFINLAR.xml:S1:11422:2	O
TAFINLAR	TAFINLAR.xml:S1:11425:8	O
in	TAFINLAR.xml:S1:11434:2	O
combination	TAFINLAR.xml:S1:11437:11	O
with	TAFINLAR.xml:S1:11449:4	O
trametinib	TAFINLAR.xml:S1:11454:10	O
was	TAFINLAR.xml:S1:11465:3	O
evaluated	TAFINLAR.xml:S1:11469:9	O
in	TAFINLAR.xml:S1:11479:2	O
Trial	TAFINLAR.xml:S1:11482:5	O
2	TAFINLAR.xml:S1:11488:1	O
and	TAFINLAR.xml:S1:11490:3	O
other	TAFINLAR.xml:S1:11494:5	O
trials	TAFINLAR.xml:S1:11500:6	O
consisting	TAFINLAR.xml:S1:11507:10	O
of	TAFINLAR.xml:S1:11518:2	O
a	TAFINLAR.xml:S1:11521:1	O
total	TAFINLAR.xml:S1:11523:5	O
of	TAFINLAR.xml:S1:11529:2	O
202	TAFINLAR.xml:S1:11532:3	O
patients	TAFINLAR.xml:S1:11536:8	O
with	TAFINLAR.xml:S1:11545:4	O
BRAF	TAFINLAR.xml:S1:11550:4	O
V600	TAFINLAR.xml:S1:11555:4	O
mutation	TAFINLAR.xml:S1:11560:8	O
-	TAFINLAR.xml:S1:11568:1	O
positive	TAFINLAR.xml:S1:11569:8	O
unresectable	TAFINLAR.xml:S1:11578:12	O
or	TAFINLAR.xml:S1:11591:2	O
metastatic	TAFINLAR.xml:S1:11594:10	O
melanoma	TAFINLAR.xml:S1:11605:8	O
who	TAFINLAR.xml:S1:11614:3	O
received	TAFINLAR.xml:S1:11618:8	O
TAFINLAR	TAFINLAR.xml:S1:11627:8	O
150	TAFINLAR.xml:S1:11636:3	O
mg	TAFINLAR.xml:S1:11640:2	O
orally	TAFINLAR.xml:S1:11643:6	O
twice	TAFINLAR.xml:S1:11650:5	O
daily	TAFINLAR.xml:S1:11656:5	O
in	TAFINLAR.xml:S1:11662:2	O
combination	TAFINLAR.xml:S1:11665:11	O
with	TAFINLAR.xml:S1:11677:4	O
trametinib	TAFINLAR.xml:S1:11682:10	O
2	TAFINLAR.xml:S1:11693:1	O
mg	TAFINLAR.xml:S1:11695:2	O
orally	TAFINLAR.xml:S1:11698:6	O
once	TAFINLAR.xml:S1:11705:4	O
daily	TAFINLAR.xml:S1:11710:5	O
until	TAFINLAR.xml:S1:11716:5	O
disease	TAFINLAR.xml:S1:11722:7	O
progression	TAFINLAR.xml:S1:11730:11	O
or	TAFINLAR.xml:S1:11742:2	O
unacceptable	TAFINLAR.xml:S1:11745:12	O
toxicity	TAFINLAR.xml:S1:11758:8	O
.	TAFINLAR.xml:S1:11766:1	O

Among	TAFINLAR.xml:S1:11768:5	O
these	TAFINLAR.xml:S1:11774:5	O
202	TAFINLAR.xml:S1:11780:3	O
patients	TAFINLAR.xml:S1:11784:8	O
,	TAFINLAR.xml:S1:11792:1	O
66	TAFINLAR.xml:S1:11794:2	O
(	TAFINLAR.xml:S1:11797:1	O
33%	TAFINLAR.xml:S1:11798:3	O
)	TAFINLAR.xml:S1:11801:1	O
were	TAFINLAR.xml:S1:11803:4	O
exposed	TAFINLAR.xml:S1:11808:7	O
to	TAFINLAR.xml:S1:11816:2	O
TAFINLAR	TAFINLAR.xml:S1:11819:8	O
and	TAFINLAR.xml:S1:11828:3	O
68	TAFINLAR.xml:S1:11832:2	O
(	TAFINLAR.xml:S1:11835:1	O
34%	TAFINLAR.xml:S1:11836:3	O
)	TAFINLAR.xml:S1:11839:1	O
were	TAFINLAR.xml:S1:11841:4	O
exposed	TAFINLAR.xml:S1:11846:7	O
to	TAFINLAR.xml:S1:11854:2	O
trametinib	TAFINLAR.xml:S1:11857:10	O
for	TAFINLAR.xml:S1:11868:3	O
greater	TAFINLAR.xml:S1:11872:7	O
than	TAFINLAR.xml:S1:11880:4	O
6	TAFINLAR.xml:S1:11885:1	O
to	TAFINLAR.xml:S1:11887:2	O
12	TAFINLAR.xml:S1:11890:2	O
months	TAFINLAR.xml:S1:11893:6	O
while	TAFINLAR.xml:S1:11900:5	O
40	TAFINLAR.xml:S1:11906:2	O
(	TAFINLAR.xml:S1:11909:1	O
20%	TAFINLAR.xml:S1:11910:3	O
)	TAFINLAR.xml:S1:11913:1	O
were	TAFINLAR.xml:S1:11915:4	O
exposed	TAFINLAR.xml:S1:11920:7	O
to	TAFINLAR.xml:S1:11928:2	O
TAFINLAR	TAFINLAR.xml:S1:11931:8	O
and	TAFINLAR.xml:S1:11940:3	O
36	TAFINLAR.xml:S1:11944:2	O
(	TAFINLAR.xml:S1:11947:1	O
18%	TAFINLAR.xml:S1:11948:3	O
)	TAFINLAR.xml:S1:11951:1	O
were	TAFINLAR.xml:S1:11953:4	O
exposed	TAFINLAR.xml:S1:11958:7	O
to	TAFINLAR.xml:S1:11966:2	O
trametinib	TAFINLAR.xml:S1:11969:10	O
for	TAFINLAR.xml:S1:11980:3	O
greater	TAFINLAR.xml:S1:11984:7	O
than	TAFINLAR.xml:S1:11992:4	O
one	TAFINLAR.xml:S1:11997:3	O
year	TAFINLAR.xml:S1:12001:4	O
.	TAFINLAR.xml:S1:12005:1	O

The	TAFINLAR.xml:S1:12007:3	O
median	TAFINLAR.xml:S1:12011:6	O
age	TAFINLAR.xml:S1:12018:3	O
was	TAFINLAR.xml:S1:12022:3	O
54	TAFINLAR.xml:S1:12026:2	O
years	TAFINLAR.xml:S1:12029:5	O
,	TAFINLAR.xml:S1:12034:1	O
57%	TAFINLAR.xml:S1:12036:3	O
were	TAFINLAR.xml:S1:12040:4	O
male	TAFINLAR.xml:S1:12045:4	O
,	TAFINLAR.xml:S1:12049:1	O
and	TAFINLAR.xml:S1:12051:3	O
99%	TAFINLAR.xml:S1:12056:3	O
were	TAFINLAR.xml:S1:12060:4	O
white	TAFINLAR.xml:S1:12065:5	O
.	TAFINLAR.xml:S1:12070:1	O

Table	TAFINLAR.xml:S1:12076:5	O
5	TAFINLAR.xml:S1:12082:1	O
presents	TAFINLAR.xml:S1:12084:8	O
adverse	TAFINLAR.xml:S1:12093:7	O
reactions	TAFINLAR.xml:S1:12101:9	O
from	TAFINLAR.xml:S1:12111:4	O
Trial	TAFINLAR.xml:S1:12116:5	O
2	TAFINLAR.xml:S1:12122:1	O
,	TAFINLAR.xml:S1:12123:1	O
a	TAFINLAR.xml:S1:12125:1	O
multicenter	TAFINLAR.xml:S1:12127:11	O
,	TAFINLAR.xml:S1:12138:1	O
open	TAFINLAR.xml:S1:12140:4	O
-	TAFINLAR.xml:S1:12144:1	O
label	TAFINLAR.xml:S1:12145:5	O
,	TAFINLAR.xml:S1:12150:1	O
randomized	TAFINLAR.xml:S1:12152:10	O
trial	TAFINLAR.xml:S1:12163:5	O
of	TAFINLAR.xml:S1:12169:2	O
162	TAFINLAR.xml:S1:12172:3	O
patients	TAFINLAR.xml:S1:12176:8	O
with	TAFINLAR.xml:S1:12185:4	O
BRAF	TAFINLAR.xml:S1:12190:4	O
V600E	TAFINLAR.xml:S1:12195:5	O
or	TAFINLAR.xml:S1:12201:2	O
V600K	TAFINLAR.xml:S1:12204:5	O
mutation	TAFINLAR.xml:S1:12210:8	O
-	TAFINLAR.xml:S1:12218:1	O
positive	TAFINLAR.xml:S1:12219:8	O
melanoma	TAFINLAR.xml:S1:12228:8	O
receiving	TAFINLAR.xml:S1:12237:9	O
TAFINLAR	TAFINLAR.xml:S1:12247:8	O
150	TAFINLAR.xml:S1:12256:3	O
mg	TAFINLAR.xml:S1:12260:2	O
twice	TAFINLAR.xml:S1:12263:5	O
daily	TAFINLAR.xml:S1:12269:5	O
in	TAFINLAR.xml:S1:12275:2	O
combination	TAFINLAR.xml:S1:12278:11	O
with	TAFINLAR.xml:S1:12290:4	O
trametinib	TAFINLAR.xml:S1:12295:10	O
2	TAFINLAR.xml:S1:12306:1	O
mg	TAFINLAR.xml:S1:12308:2	O
orally	TAFINLAR.xml:S1:12311:6	O
once	TAFINLAR.xml:S1:12318:4	O
daily	TAFINLAR.xml:S1:12323:5	O
(	TAFINLAR.xml:S1:12329:1	O
n	TAFINLAR.xml:S1:12330:1	O
55	TAFINLAR.xml:S1:12334:2	O
)	TAFINLAR.xml:S1:12336:1	O
,	TAFINLAR.xml:S1:12337:1	O
TAFINLAR	TAFINLAR.xml:S1:12339:8	O
150	TAFINLAR.xml:S1:12348:3	O
mg	TAFINLAR.xml:S1:12352:2	O
orally	TAFINLAR.xml:S1:12355:6	O
twice	TAFINLAR.xml:S1:12362:5	O
daily	TAFINLAR.xml:S1:12368:5	O
in	TAFINLAR.xml:S1:12374:2	O
combination	TAFINLAR.xml:S1:12377:11	O
with	TAFINLAR.xml:S1:12389:4	O
trametinib	TAFINLAR.xml:S1:12394:10	O
1	TAFINLAR.xml:S1:12405:1	O
mg	TAFINLAR.xml:S1:12407:2	O
once	TAFINLAR.xml:S1:12410:4	O
daily	TAFINLAR.xml:S1:12415:5	O
(	TAFINLAR.xml:S1:12421:1	O
n	TAFINLAR.xml:S1:12422:1	O
54	TAFINLAR.xml:S1:12426:2	O
)	TAFINLAR.xml:S1:12428:1	O
,	TAFINLAR.xml:S1:12429:1	O
and	TAFINLAR.xml:S1:12431:3	O
TAFINLAR	TAFINLAR.xml:S1:12435:8	O
as	TAFINLAR.xml:S1:12444:2	O
a	TAFINLAR.xml:S1:12447:1	O
single	TAFINLAR.xml:S1:12449:6	O
agent	TAFINLAR.xml:S1:12456:5	O
150	TAFINLAR.xml:S1:12462:3	O
mg	TAFINLAR.xml:S1:12466:2	O
orally	TAFINLAR.xml:S1:12469:6	O
twice	TAFINLAR.xml:S1:12476:5	O
daily	TAFINLAR.xml:S1:12482:5	O
(	TAFINLAR.xml:S1:12488:1	O
n	TAFINLAR.xml:S1:12489:1	O
53	TAFINLAR.xml:S1:12493:2	O
)	TAFINLAR.xml:S1:12495:1	O
[	TAFINLAR.xml:S1:12498:1	O
see	TAFINLAR.xml:S1:12499:3	O
Clinical	TAFINLAR.xml:S1:12503:8	O
Studies	TAFINLAR.xml:S1:12512:7	O
(	TAFINLAR.xml:S1:12520:1	O
14.2	TAFINLAR.xml:S1:12521:4	O
)]	TAFINLAR.xml:S1:12525:2	O
.	TAFINLAR.xml:S1:12529:1	O

Patients	TAFINLAR.xml:S1:12531:8	O
with	TAFINLAR.xml:S1:12540:4	O
abnormal	TAFINLAR.xml:S1:12545:8	O
LVEF	TAFINLAR.xml:S1:12554:4	O
,	TAFINLAR.xml:S1:12558:1	O
history	TAFINLAR.xml:S1:12560:7	O
of	TAFINLAR.xml:S1:12568:2	O
acute	TAFINLAR.xml:S1:12571:5	O
coronary	TAFINLAR.xml:S1:12577:8	O
syndrome	TAFINLAR.xml:S1:12586:8	O
within	TAFINLAR.xml:S1:12595:6	O
6	TAFINLAR.xml:S1:12602:1	O
months	TAFINLAR.xml:S1:12604:6	O
,	TAFINLAR.xml:S1:12610:1	O
current	TAFINLAR.xml:S1:12612:7	O
evidence	TAFINLAR.xml:S1:12620:8	O
of	TAFINLAR.xml:S1:12629:2	O
Class	TAFINLAR.xml:S1:12632:5	O
II	TAFINLAR.xml:S1:12638:2	O
or	TAFINLAR.xml:S1:12641:2	O
greater	TAFINLAR.xml:S1:12644:7	O
congestive	TAFINLAR.xml:S1:12652:10	O
heart	TAFINLAR.xml:S1:12663:5	O
failure	TAFINLAR.xml:S1:12669:7	O
(	TAFINLAR.xml:S1:12677:1	O
New	TAFINLAR.xml:S1:12678:3	O
York	TAFINLAR.xml:S1:12682:4	O
Heart	TAFINLAR.xml:S1:12687:5	O
Association	TAFINLAR.xml:S1:12693:11	O
)	TAFINLAR.xml:S1:12704:1	O
,	TAFINLAR.xml:S1:12705:1	O
history	TAFINLAR.xml:S1:12707:7	O
RVO	TAFINLAR.xml:S1:12715:3	O
or	TAFINLAR.xml:S1:12719:2	O
RPED	TAFINLAR.xml:S1:12722:4	O
,	TAFINLAR.xml:S1:12726:1	O
QTc	TAFINLAR.xml:S1:12728:3	O
interval	TAFINLAR.xml:S1:12732:8	O
480	TAFINLAR.xml:S1:12743:3	O
msec	TAFINLAR.xml:S1:12747:4	O
,	TAFINLAR.xml:S1:12751:1	O
treatment	TAFINLAR.xml:S1:12753:9	O
refractory	TAFINLAR.xml:S1:12763:10	O
hypertension	TAFINLAR.xml:S1:12774:12	O
,	TAFINLAR.xml:S1:12786:1	O
uncontrolled	TAFINLAR.xml:S1:12788:12	O
arrhythmias	TAFINLAR.xml:S1:12801:11	O
,	TAFINLAR.xml:S1:12812:1	O
history	TAFINLAR.xml:S1:12814:7	O
of	TAFINLAR.xml:S1:12822:2	O
pneumonitis	TAFINLAR.xml:S1:12825:11	O
or	TAFINLAR.xml:S1:12837:2	O
interstitial	TAFINLAR.xml:S1:12840:12	O
lung	TAFINLAR.xml:S1:12853:4	O
disease	TAFINLAR.xml:S1:12858:7	O
,	TAFINLAR.xml:S1:12865:1	O
or	TAFINLAR.xml:S1:12867:2	O
a	TAFINLAR.xml:S1:12870:1	O
known	TAFINLAR.xml:S1:12872:5	O
history	TAFINLAR.xml:S1:12878:7	O
of	TAFINLAR.xml:S1:12886:2	O
G6PD	TAFINLAR.xml:S1:12889:4	O
deficiency	TAFINLAR.xml:S1:12894:10	O
were	TAFINLAR.xml:S1:12905:4	O
excluded	TAFINLAR.xml:S1:12910:8	O
.	TAFINLAR.xml:S1:12918:1	O

The	TAFINLAR.xml:S1:12920:3	O
median	TAFINLAR.xml:S1:12924:6	O
duration	TAFINLAR.xml:S1:12931:8	O
of	TAFINLAR.xml:S1:12940:2	O
treatment	TAFINLAR.xml:S1:12943:9	O
was	TAFINLAR.xml:S1:12953:3	O
10.9	TAFINLAR.xml:S1:12957:4	O
months	TAFINLAR.xml:S1:12962:6	O
for	TAFINLAR.xml:S1:12969:3	O
both	TAFINLAR.xml:S1:12973:4	O
TAFINLAR	TAFINLAR.xml:S1:12978:8	O
and	TAFINLAR.xml:S1:12987:3	O
trametinib	TAFINLAR.xml:S1:12991:10	O
(	TAFINLAR.xml:S1:13002:1	O
2	TAFINLAR.xml:S1:13003:1	O
-	TAFINLAR.xml:S1:13004:1	O
mg	TAFINLAR.xml:S1:13005:2	O
orally	TAFINLAR.xml:S1:13008:6	O
once	TAFINLAR.xml:S1:13015:4	O
-	TAFINLAR.xml:S1:13019:1	O
daily	TAFINLAR.xml:S1:13020:5	O
treatment	TAFINLAR.xml:S1:13026:9	O
group	TAFINLAR.xml:S1:13036:5	O
)	TAFINLAR.xml:S1:13041:1	O
when	TAFINLAR.xml:S1:13043:4	O
used	TAFINLAR.xml:S1:13048:4	O
in	TAFINLAR.xml:S1:13053:2	O
combination	TAFINLAR.xml:S1:13056:11	O
,	TAFINLAR.xml:S1:13067:1	O
10.6	TAFINLAR.xml:S1:13069:4	O
months	TAFINLAR.xml:S1:13074:6	O
for	TAFINLAR.xml:S1:13081:3	O
both	TAFINLAR.xml:S1:13085:4	O
TAFINLAR	TAFINLAR.xml:S1:13090:8	O
and	TAFINLAR.xml:S1:13099:3	O
trametinib	TAFINLAR.xml:S1:13103:10	O
(	TAFINLAR.xml:S1:13114:1	O
1	TAFINLAR.xml:S1:13115:1	O
-	TAFINLAR.xml:S1:13116:1	O
mg	TAFINLAR.xml:S1:13117:2	O
orally	TAFINLAR.xml:S1:13120:6	O
once	TAFINLAR.xml:S1:13127:4	O
-	TAFINLAR.xml:S1:13131:1	O
daily	TAFINLAR.xml:S1:13132:5	O
treatment	TAFINLAR.xml:S1:13138:9	O
group	TAFINLAR.xml:S1:13148:5	O
)	TAFINLAR.xml:S1:13153:1	O
when	TAFINLAR.xml:S1:13155:4	O
used	TAFINLAR.xml:S1:13160:4	O
in	TAFINLAR.xml:S1:13165:2	O
combination	TAFINLAR.xml:S1:13168:11	O
,	TAFINLAR.xml:S1:13179:1	O
and	TAFINLAR.xml:S1:13181:3	O
6.1	TAFINLAR.xml:S1:13185:3	O
months	TAFINLAR.xml:S1:13189:6	O
for	TAFINLAR.xml:S1:13196:3	O
TAFINLAR	TAFINLAR.xml:S1:13200:8	O
as	TAFINLAR.xml:S1:13209:2	O
a	TAFINLAR.xml:S1:13212:1	O
single	TAFINLAR.xml:S1:13214:6	O
agent	TAFINLAR.xml:S1:13221:5	O
.	TAFINLAR.xml:S1:13226:1	O

In	TAFINLAR.xml:S1:13232:2	O
Trial	TAFINLAR.xml:S1:13235:5	O
2	TAFINLAR.xml:S1:13241:1	O
,	TAFINLAR.xml:S1:13242:1	O
13%	TAFINLAR.xml:S1:13244:3	O
of	TAFINLAR.xml:S1:13248:2	O
patients	TAFINLAR.xml:S1:13251:8	O
receiving	TAFINLAR.xml:S1:13260:9	O
TAFINLAR	TAFINLAR.xml:S1:13270:8	O
in	TAFINLAR.xml:S1:13279:2	O
combination	TAFINLAR.xml:S1:13282:11	O
with	TAFINLAR.xml:S1:13294:4	O
trametinib	TAFINLAR.xml:S1:13299:10	O
experienced	TAFINLAR.xml:S1:13310:11	O
adverse	TAFINLAR.xml:S1:13322:7	O
reactions	TAFINLAR.xml:S1:13330:9	O
resulting	TAFINLAR.xml:S1:13340:9	O
in	TAFINLAR.xml:S1:13350:2	O
permanent	TAFINLAR.xml:S1:13353:9	O
discontinuation	TAFINLAR.xml:S1:13363:15	O
of	TAFINLAR.xml:S1:13379:2	O
trial	TAFINLAR.xml:S1:13382:5	O
medication	TAFINLAR.xml:S1:13388:10	O
(	TAFINLAR.xml:S1:13398:1	O
s	TAFINLAR.xml:S1:13399:1	O
)	TAFINLAR.xml:S1:13400:1	O
.	TAFINLAR.xml:S1:13401:1	O

The	TAFINLAR.xml:S1:13403:3	O
most	TAFINLAR.xml:S1:13407:4	O
common	TAFINLAR.xml:S1:13412:6	O
adverse	TAFINLAR.xml:S1:13419:7	O
reaction	TAFINLAR.xml:S1:13427:8	O
resulting	TAFINLAR.xml:S1:13436:9	O
in	TAFINLAR.xml:S1:13446:2	O
permanent	TAFINLAR.xml:S1:13449:9	O
discontinuation	TAFINLAR.xml:S1:13459:15	O
was	TAFINLAR.xml:S1:13475:3	O
pyrexia	TAFINLAR.xml:S1:13479:7	B-AdverseReaction
(	TAFINLAR.xml:S1:13487:1	O
4%	TAFINLAR.xml:S1:13488:2	O
)	TAFINLAR.xml:S1:13490:1	O
.	TAFINLAR.xml:S1:13491:1	O

Adverse	TAFINLAR.xml:S1:13493:7	O
reactions	TAFINLAR.xml:S1:13501:9	O
led	TAFINLAR.xml:S1:13511:3	O
to	TAFINLAR.xml:S1:13515:2	O
dose	TAFINLAR.xml:S1:13518:4	O
reductions	TAFINLAR.xml:S1:13523:10	O
in	TAFINLAR.xml:S1:13534:2	O
49%	TAFINLAR.xml:S1:13537:3	O
and	TAFINLAR.xml:S1:13541:3	O
dose	TAFINLAR.xml:S1:13545:4	O
interruptions	TAFINLAR.xml:S1:13550:13	O
in	TAFINLAR.xml:S1:13564:2	O
67%	TAFINLAR.xml:S1:13567:3	O
of	TAFINLAR.xml:S1:13571:2	O
patients	TAFINLAR.xml:S1:13574:8	O
treated	TAFINLAR.xml:S1:13583:7	O
with	TAFINLAR.xml:S1:13591:4	O
TAFINLAR	TAFINLAR.xml:S1:13596:8	O
in	TAFINLAR.xml:S1:13605:2	O
combination	TAFINLAR.xml:S1:13608:11	O
with	TAFINLAR.xml:S1:13620:4	O
trametinib	TAFINLAR.xml:S1:13625:10	O
.	TAFINLAR.xml:S1:13635:1	O

Pyrexia	TAFINLAR.xml:S1:13637:7	B-AdverseReaction
,	TAFINLAR.xml:S1:13644:1	O
chills	TAFINLAR.xml:S1:13646:6	B-AdverseReaction
,	TAFINLAR.xml:S1:13652:1	O
and	TAFINLAR.xml:S1:13654:3	O
nausea	TAFINLAR.xml:S1:13658:6	B-AdverseReaction
were	TAFINLAR.xml:S1:13665:4	O
the	TAFINLAR.xml:S1:13670:3	O
most	TAFINLAR.xml:S1:13674:4	O
common	TAFINLAR.xml:S1:13679:6	O
reasons	TAFINLAR.xml:S1:13686:7	O
cited	TAFINLAR.xml:S1:13694:5	O
for	TAFINLAR.xml:S1:13700:3	O
dose	TAFINLAR.xml:S1:13704:4	O
reductions	TAFINLAR.xml:S1:13709:10	O
and	TAFINLAR.xml:S1:13720:3	O
pyrexia	TAFINLAR.xml:S1:13724:7	B-AdverseReaction
,	TAFINLAR.xml:S1:13731:1	O
chills	TAFINLAR.xml:S1:13733:6	B-AdverseReaction
,	TAFINLAR.xml:S1:13739:1	O
and	TAFINLAR.xml:S1:13741:3	O
decreased	TAFINLAR.xml:S1:13745:9	B-AdverseReaction
ejection	TAFINLAR.xml:S1:13755:8	I-AdverseReaction
fraction	TAFINLAR.xml:S1:13764:8	I-AdverseReaction
were	TAFINLAR.xml:S1:13773:4	O
the	TAFINLAR.xml:S1:13778:3	O
most	TAFINLAR.xml:S1:13782:4	O
common	TAFINLAR.xml:S1:13787:6	O
reasons	TAFINLAR.xml:S1:13794:7	O
cited	TAFINLAR.xml:S1:13802:5	O
for	TAFINLAR.xml:S1:13808:3	O
dose	TAFINLAR.xml:S1:13812:4	O
interruptions	TAFINLAR.xml:S1:13817:13	O
of	TAFINLAR.xml:S1:13831:2	O
TAFINLAR	TAFINLAR.xml:S1:13834:8	O
and	TAFINLAR.xml:S1:13843:3	O
trametinib	TAFINLAR.xml:S1:13847:10	O
when	TAFINLAR.xml:S1:13858:4	O
used	TAFINLAR.xml:S1:13863:4	O
in	TAFINLAR.xml:S1:13868:2	O
combination	TAFINLAR.xml:S1:13871:11	O
.	TAFINLAR.xml:S1:13882:1	O

Table	TAFINLAR.xml:S1:13888:5	O
5	TAFINLAR.xml:S1:13894:1	O
.	TAFINLAR.xml:S1:13895:1	O

Common	TAFINLAR.xml:S1:13897:6	O
Adverse	TAFINLAR.xml:S1:13904:7	O
Drug	TAFINLAR.xml:S1:13912:4	O
Reactions	TAFINLAR.xml:S1:13917:9	O
Occurring	TAFINLAR.xml:S1:13927:9	O
in	TAFINLAR.xml:S1:13937:2	O
10%	TAFINLAR.xml:S1:13942:3	O
at	TAFINLAR.xml:S1:13946:2	O
(	TAFINLAR.xml:S1:13949:1	O
All	TAFINLAR.xml:S1:13950:3	O
Grades	TAFINLAR.xml:S1:13954:6	O
)	TAFINLAR.xml:S1:13960:1	O
or	TAFINLAR.xml:S1:13962:2	O
5%	TAFINLAR.xml:S1:13967:2	O
(	TAFINLAR.xml:S1:13970:1	O
Grades	TAFINLAR.xml:S1:13971:6	O
3	TAFINLAR.xml:S1:13978:1	O
or	TAFINLAR.xml:S1:13980:2	O
4	TAFINLAR.xml:S1:13983:1	O
)	TAFINLAR.xml:S1:13984:1	O
of	TAFINLAR.xml:S1:13986:2	O
Patients	TAFINLAR.xml:S1:13989:8	O
Treated	TAFINLAR.xml:S1:13998:7	O
With	TAFINLAR.xml:S1:14006:4	O
TAFINLAR	TAFINLAR.xml:S1:14011:8	O
in	TAFINLAR.xml:S1:14020:2	O
Combination	TAFINLAR.xml:S1:14023:11	O
With	TAFINLAR.xml:S1:14035:4	O
Trametinib	TAFINLAR.xml:S1:14040:10	O
in	TAFINLAR.xml:S1:14051:2	O
Trial	TAFINLAR.xml:S1:14054:5	O
2	TAFINLAR.xml:S1:14060:1	O

Adverse	TAFINLAR.xml:S1:14065:7	O
Reactions	TAFINLAR.xml:S1:14073:9	O
TAFINLAR	TAFINLAR.xml:S1:14092:8	O
plus	TAFINLAR.xml:S1:14101:4	O
Trametinib	TAFINLAR.xml:S1:14106:10	O
2	TAFINLAR.xml:S1:14117:1	O
mg	TAFINLAR.xml:S1:14119:2	O
N	TAFINLAR.xml:S1:14123:1	O
55	TAFINLAR.xml:S1:14127:2	O
TAFINLAR	TAFINLAR.xml:S1:14133:8	O
plus	TAFINLAR.xml:S1:14142:4	O
Trametinib	TAFINLAR.xml:S1:14147:10	O
1	TAFINLAR.xml:S1:14158:1	O
mg	TAFINLAR.xml:S1:14160:2	O
N	TAFINLAR.xml:S1:14164:1	O
54	TAFINLAR.xml:S1:14168:2	O
TAFINLAR	TAFINLAR.xml:S1:14174:8	O
N	TAFINLAR.xml:S1:14184:1	O
53	TAFINLAR.xml:S1:14188:2	O

All	TAFINLAR.xml:S1:14197:3	O
Gradesa	TAFINLAR.xml:S1:14201:7	O
Grades	TAFINLAR.xml:S1:14224:6	O
3	TAFINLAR.xml:S1:14232:1	O
and	TAFINLAR.xml:S1:14234:3	O
4	TAFINLAR.xml:S1:14238:1	O
All	TAFINLAR.xml:S1:14243:3	O
Gradesa	TAFINLAR.xml:S1:14247:7	O
Grades	TAFINLAR.xml:S1:14258:6	O
3	TAFINLAR.xml:S1:14266:1	O
and	TAFINLAR.xml:S1:14268:3	O
4	TAFINLAR.xml:S1:14272:1	O
All	TAFINLAR.xml:S1:14277:3	O
Gradesa	TAFINLAR.xml:S1:14282:7	O
Grades	TAFINLAR.xml:S1:14293:6	O
3	TAFINLAR.xml:S1:14301:1	O
and	TAFINLAR.xml:S1:14303:3	O
4	TAFINLAR.xml:S1:14307:1	O

General	TAFINLAR.xml:S1:14315:7	O
disorders	TAFINLAR.xml:S1:14323:9	O
and	TAFINLAR.xml:S1:14333:3	O
administrative	TAFINLAR.xml:S1:14337:14	O
site	TAFINLAR.xml:S1:14352:4	O
conditions	TAFINLAR.xml:S1:14357:10	O

Pyrexia	TAFINLAR.xml:S1:14400:7	B-AdverseReaction

71	TAFINLAR.xml:S1:14483:2	O
5	TAFINLAR.xml:S1:14502:1	O
69	TAFINLAR.xml:S1:14516:2	O
9	TAFINLAR.xml:S1:14535:1	O
26	TAFINLAR.xml:S1:14549:2	O
0	TAFINLAR.xml:S1:14560:1	O

Chills	TAFINLAR.xml:S1:14599:6	B-AdverseReaction

58	TAFINLAR.xml:S1:14682:2	O
2	TAFINLAR.xml:S1:14701:1	O
50	TAFINLAR.xml:S1:14715:2	O
2	TAFINLAR.xml:S1:14734:1	O
17	TAFINLAR.xml:S1:14748:2	O
0	TAFINLAR.xml:S1:14759:1	O

Fatigue	TAFINLAR.xml:S1:14798:7	B-AdverseReaction

53	TAFINLAR.xml:S1:14881:2	O
4	TAFINLAR.xml:S1:14900:1	O
57	TAFINLAR.xml:S1:14914:2	O
2	TAFINLAR.xml:S1:14933:1	O
40	TAFINLAR.xml:S1:14947:2	O
6	TAFINLAR.xml:S1:14958:1	O

Edema	TAFINLAR.xml:S1:14997:5	B-AdverseReaction
peripheral	TAFINLAR.xml:S1:15003:10	I-AdverseReaction
b	TAFINLAR.xml:S1:15015:1	O

31	TAFINLAR.xml:S1:15080:2	O
0	TAFINLAR.xml:S1:15099:1	O
28	TAFINLAR.xml:S1:15113:2	O
0	TAFINLAR.xml:S1:15132:1	O
17	TAFINLAR.xml:S1:15146:2	O
0	TAFINLAR.xml:S1:15157:1	O

Skin	TAFINLAR.xml:S1:15170:4	O
and	TAFINLAR.xml:S1:15175:3	O
subcutaneous	TAFINLAR.xml:S1:15179:12	O
tissue	TAFINLAR.xml:S1:15192:6	O
disorders	TAFINLAR.xml:S1:15199:9	O

Rash	TAFINLAR.xml:S1:15241:4	B-AdverseReaction
c	TAFINLAR.xml:S1:15247:1	O

45	TAFINLAR.xml:S1:15324:2	O
0	TAFINLAR.xml:S1:15343:1	O
43	TAFINLAR.xml:S1:15357:2	O
2	TAFINLAR.xml:S1:15376:1	O
53	TAFINLAR.xml:S1:15390:2	O
0	TAFINLAR.xml:S1:15401:1	O

Night	TAFINLAR.xml:S1:15440:5	B-AdverseReaction
Sweats	TAFINLAR.xml:S1:15446:6	I-AdverseReaction

24	TAFINLAR.xml:S1:15523:2	O
0	TAFINLAR.xml:S1:15542:1	O
15	TAFINLAR.xml:S1:15556:2	O
0	TAFINLAR.xml:S1:15575:1	O
6	TAFINLAR.xml:S1:15589:1	O
0	TAFINLAR.xml:S1:15600:1	O

Dry	TAFINLAR.xml:S1:15639:3	B-AdverseReaction
skin	TAFINLAR.xml:S1:15643:4	I-AdverseReaction

18	TAFINLAR.xml:S1:15722:2	O
0	TAFINLAR.xml:S1:15741:1	O
9	TAFINLAR.xml:S1:15755:1	O
0	TAFINLAR.xml:S1:15774:1	O
6	TAFINLAR.xml:S1:15788:1	O
0	TAFINLAR.xml:S1:15799:1	O

Dermatitis	TAFINLAR.xml:S1:15838:10	B-AdverseReaction
acneiform	TAFINLAR.xml:S1:15849:9	I-AdverseReaction

16	TAFINLAR.xml:S1:15921:2	O
0	TAFINLAR.xml:S1:15940:1	O
11	TAFINLAR.xml:S1:15954:2	O
0	TAFINLAR.xml:S1:15973:1	O
4	TAFINLAR.xml:S1:15987:1	O
0	TAFINLAR.xml:S1:15998:1	O

Actinic	TAFINLAR.xml:S1:16037:7	B-AdverseReaction
keratosis	TAFINLAR.xml:S1:16045:9	I-AdverseReaction

15	TAFINLAR.xml:S1:16120:2	O
0	TAFINLAR.xml:S1:16139:1	O
7	TAFINLAR.xml:S1:16153:1	O
0	TAFINLAR.xml:S1:16172:1	O
9	TAFINLAR.xml:S1:16186:1	O
0	TAFINLAR.xml:S1:16197:1	O

Erythema	TAFINLAR.xml:S1:16236:8	B-AdverseReaction

15	TAFINLAR.xml:S1:16319:2	O
0	TAFINLAR.xml:S1:16338:1	O
6	TAFINLAR.xml:S1:16352:1	O
0	TAFINLAR.xml:S1:16371:1	O
2	TAFINLAR.xml:S1:16385:1	O
0	TAFINLAR.xml:S1:16396:1	O

Pruritus	TAFINLAR.xml:S1:16435:8	B-AdverseReaction

11	TAFINLAR.xml:S1:16518:2	O
0	TAFINLAR.xml:S1:16537:1	O
11	TAFINLAR.xml:S1:16551:2	O
0	TAFINLAR.xml:S1:16570:1	O
13	TAFINLAR.xml:S1:16584:2	O
0	TAFINLAR.xml:S1:16595:1	O

Gastrointestinal	TAFINLAR.xml:S1:16608:16	O
disorders	TAFINLAR.xml:S1:16625:9	O

Nausea	TAFINLAR.xml:S1:16667:6	B-AdverseReaction

44	TAFINLAR.xml:S1:16750:2	O
2	TAFINLAR.xml:S1:16769:1	O
46	TAFINLAR.xml:S1:16783:2	O
6	TAFINLAR.xml:S1:16802:1	O
21	TAFINLAR.xml:S1:16816:2	O
0	TAFINLAR.xml:S1:16827:1	O

Vomiting	TAFINLAR.xml:S1:16866:8	B-AdverseReaction

40	TAFINLAR.xml:S1:16949:2	O
2	TAFINLAR.xml:S1:16968:1	O
43	TAFINLAR.xml:S1:16982:2	O
4	TAFINLAR.xml:S1:17001:1	O
15	TAFINLAR.xml:S1:17015:2	O
0	TAFINLAR.xml:S1:17026:1	O

Diarrhea	TAFINLAR.xml:S1:17065:8	B-AdverseReaction

36	TAFINLAR.xml:S1:17148:2	O
2	TAFINLAR.xml:S1:17167:1	O
26	TAFINLAR.xml:S1:17181:2	O
0	TAFINLAR.xml:S1:17200:1	O
28	TAFINLAR.xml:S1:17214:2	O
0	TAFINLAR.xml:S1:17225:1	O

Abdominal	TAFINLAR.xml:S1:17264:9	B-AdverseReaction
pain	TAFINLAR.xml:S1:17274:4	I-AdverseReaction
d	TAFINLAR.xml:S1:17280:1	O

33	TAFINLAR.xml:S1:17347:2	O
2	TAFINLAR.xml:S1:17366:1	O
24	TAFINLAR.xml:S1:17380:2	O
2	TAFINLAR.xml:S1:17399:1	O
21	TAFINLAR.xml:S1:17413:2	O
2	TAFINLAR.xml:S1:17424:1	O

Constipation	TAFINLAR.xml:S1:17463:12	B-AdverseReaction

22	TAFINLAR.xml:S1:17546:2	O
0	TAFINLAR.xml:S1:17565:1	O
17	TAFINLAR.xml:S1:17579:2	O
2	TAFINLAR.xml:S1:17598:1	O
11	TAFINLAR.xml:S1:17612:2	O
0	TAFINLAR.xml:S1:17623:1	O

Dry	TAFINLAR.xml:S1:17662:3	B-AdverseReaction
mouth	TAFINLAR.xml:S1:17666:5	I-AdverseReaction

11	TAFINLAR.xml:S1:17745:2	O
0	TAFINLAR.xml:S1:17764:1	O
11	TAFINLAR.xml:S1:17778:2	O
0	TAFINLAR.xml:S1:17797:1	O
6	TAFINLAR.xml:S1:17811:1	O
0	TAFINLAR.xml:S1:17822:1	O

Nervous	TAFINLAR.xml:S1:17835:7	O
system	TAFINLAR.xml:S1:17843:6	O
disorders	TAFINLAR.xml:S1:17850:9	O

Headache	TAFINLAR.xml:S1:17892:8	B-AdverseReaction

29	TAFINLAR.xml:S1:17975:2	O
0	TAFINLAR.xml:S1:17994:1	O
37	TAFINLAR.xml:S1:18008:2	O
2	TAFINLAR.xml:S1:18027:1	O
28	TAFINLAR.xml:S1:18041:2	O
0	TAFINLAR.xml:S1:18052:1	O

Dizziness	TAFINLAR.xml:S1:18091:9	B-AdverseReaction

16	TAFINLAR.xml:S1:18174:2	O
0	TAFINLAR.xml:S1:18193:1	O
13	TAFINLAR.xml:S1:18207:2	O
0	TAFINLAR.xml:S1:18226:1	O
9	TAFINLAR.xml:S1:18240:1	O
0	TAFINLAR.xml:S1:18251:1	O

Respiratory	TAFINLAR.xml:S1:18264:11	O
,	TAFINLAR.xml:S1:18275:1	O
thoracic	TAFINLAR.xml:S1:18277:8	O
,	TAFINLAR.xml:S1:18285:1	O
and	TAFINLAR.xml:S1:18287:3	O
mediastinal	TAFINLAR.xml:S1:18291:11	O
disorders	TAFINLAR.xml:S1:18303:9	O

Cough	TAFINLAR.xml:S1:18345:5	B-AdverseReaction

29	TAFINLAR.xml:S1:18428:2	O
0	TAFINLAR.xml:S1:18447:1	O
11	TAFINLAR.xml:S1:18461:2	O
0	TAFINLAR.xml:S1:18480:1	O
21	TAFINLAR.xml:S1:18494:2	O
0	TAFINLAR.xml:S1:18505:1	O

Oropharyngeal	TAFINLAR.xml:S1:18544:13	B-AdverseReaction
pain	TAFINLAR.xml:S1:18558:4	I-AdverseReaction

13	TAFINLAR.xml:S1:18627:2	O
0	TAFINLAR.xml:S1:18646:1	O
7	TAFINLAR.xml:S1:18660:1	O
0	TAFINLAR.xml:S1:18679:1	O
0	TAFINLAR.xml:S1:18693:1	O
0	TAFINLAR.xml:S1:18704:1	O

Musculoskeletal	TAFINLAR.xml:S1:18717:15	O
,	TAFINLAR.xml:S1:18732:1	O
connective	TAFINLAR.xml:S1:18734:10	O
tissue	TAFINLAR.xml:S1:18745:6	O
,	TAFINLAR.xml:S1:18751:1	O
and	TAFINLAR.xml:S1:18753:3	O
bone	TAFINLAR.xml:S1:18757:4	O
disorders	TAFINLAR.xml:S1:18762:9	O

Arthralgia	TAFINLAR.xml:S1:18804:10	B-AdverseReaction

27	TAFINLAR.xml:S1:18887:2	O
0	TAFINLAR.xml:S1:18906:1	O
44	TAFINLAR.xml:S1:18920:2	O
0	TAFINLAR.xml:S1:18939:1	O
34	TAFINLAR.xml:S1:18953:2	O
0	TAFINLAR.xml:S1:18964:1	O

Myalgia	TAFINLAR.xml:S1:19003:7	B-AdverseReaction

22	TAFINLAR.xml:S1:19086:2	O
2	TAFINLAR.xml:S1:19105:1	O
24	TAFINLAR.xml:S1:19119:2	O
0	TAFINLAR.xml:S1:19138:1	O
23	TAFINLAR.xml:S1:19152:2	O
2	TAFINLAR.xml:S1:19163:1	O

Back	TAFINLAR.xml:S1:19202:4	B-AdverseReaction
pain	TAFINLAR.xml:S1:19207:4	I-AdverseReaction

18	TAFINLAR.xml:S1:19285:2	O
5	TAFINLAR.xml:S1:19304:1	O
11	TAFINLAR.xml:S1:19318:2	O
0	TAFINLAR.xml:S1:19337:1	O
11	TAFINLAR.xml:S1:19351:2	O
2	TAFINLAR.xml:S1:19362:1	O

Muscle	TAFINLAR.xml:S1:19401:6	B-AdverseReaction
spasms	TAFINLAR.xml:S1:19408:6	I-AdverseReaction

16	TAFINLAR.xml:S1:19484:2	O
0	TAFINLAR.xml:S1:19503:1	O
2	TAFINLAR.xml:S1:19517:1	O
0	TAFINLAR.xml:S1:19536:1	O
4	TAFINLAR.xml:S1:19550:1	O
0	TAFINLAR.xml:S1:19561:1	O

Pain	TAFINLAR.xml:S1:19600:4	B-AdverseReaction
in	TAFINLAR.xml:S1:19605:2	I-AdverseReaction
extremity	TAFINLAR.xml:S1:19608:9	I-AdverseReaction

16	TAFINLAR.xml:S1:19683:2	O
0	TAFINLAR.xml:S1:19702:1	O
11	TAFINLAR.xml:S1:19716:2	O
2	TAFINLAR.xml:S1:19735:1	O
19	TAFINLAR.xml:S1:19749:2	O
0	TAFINLAR.xml:S1:19760:1	O

Metabolism	TAFINLAR.xml:S1:19773:10	O
and	TAFINLAR.xml:S1:19784:3	O
nutritional	TAFINLAR.xml:S1:19788:11	O
disorders	TAFINLAR.xml:S1:19800:9	O

Decreased	TAFINLAR.xml:S1:19842:9	B-AdverseReaction
appetite	TAFINLAR.xml:S1:19852:8	I-AdverseReaction

22	TAFINLAR.xml:S1:19925:2	O
0	TAFINLAR.xml:S1:19944:1	O
30	TAFINLAR.xml:S1:19958:2	O
0	TAFINLAR.xml:S1:19977:1	O
19	TAFINLAR.xml:S1:19991:2	O
0	TAFINLAR.xml:S1:20002:1	O

Dehydration	TAFINLAR.xml:S1:20041:11	B-AdverseReaction

11	TAFINLAR.xml:S1:20124:2	O
0	TAFINLAR.xml:S1:20143:1	O
6	TAFINLAR.xml:S1:20157:1	O
2	TAFINLAR.xml:S1:20176:1	O
2	TAFINLAR.xml:S1:20190:1	O
0	TAFINLAR.xml:S1:20201:1	O

Psychiatric	TAFINLAR.xml:S1:20214:11	O
Disorders	TAFINLAR.xml:S1:20226:9	O

Insomnia	TAFINLAR.xml:S1:20270:8	B-AdverseReaction

18	TAFINLAR.xml:S1:20353:2	O
0	TAFINLAR.xml:S1:20372:1	O
11	TAFINLAR.xml:S1:20386:2	O
0	TAFINLAR.xml:S1:20405:1	O
8	TAFINLAR.xml:S1:20419:1	O
2	TAFINLAR.xml:S1:20430:1	O

Vascular	TAFINLAR.xml:S1:20443:8	O
disorders	TAFINLAR.xml:S1:20452:9	O

Hemorrhage	TAFINLAR.xml:S1:20499:10	B-AdverseReaction
e	TAFINLAR.xml:S1:20511:1	O

16	TAFINLAR.xml:S1:20582:2	O
5	TAFINLAR.xml:S1:20601:1	O
11	TAFINLAR.xml:S1:20615:2	O
0	TAFINLAR.xml:S1:20634:1	O
2	TAFINLAR.xml:S1:20648:1	O
0	TAFINLAR.xml:S1:20659:1	O

Infections	TAFINLAR.xml:S1:20672:10	O
and	TAFINLAR.xml:S1:20683:3	O
infestations	TAFINLAR.xml:S1:20687:12	O

Urinary	TAFINLAR.xml:S1:20732:7	B-AdverseReaction
tract	TAFINLAR.xml:S1:20740:5	I-AdverseReaction
infection	TAFINLAR.xml:S1:20746:9	I-AdverseReaction

13	TAFINLAR.xml:S1:20815:2	O
2	TAFINLAR.xml:S1:20834:1	O
6	TAFINLAR.xml:S1:20848:1	O
0	TAFINLAR.xml:S1:20867:1	O
9	TAFINLAR.xml:S1:20881:1	O
2	TAFINLAR.xml:S1:20892:1	O

Renal	TAFINLAR.xml:S1:20905:5	O
and	TAFINLAR.xml:S1:20911:3	O
urinary	TAFINLAR.xml:S1:20915:7	O
disorders	TAFINLAR.xml:S1:20923:9	O

Renal	TAFINLAR.xml:S1:20965:5	B-AdverseReaction
failure	TAFINLAR.xml:S1:20971:7	I-AdverseReaction
f	TAFINLAR.xml:S1:20980:1	O

7	TAFINLAR.xml:S1:21048:1	O
7	TAFINLAR.xml:S1:21067:1	O
2	TAFINLAR.xml:S1:21081:1	O
0	TAFINLAR.xml:S1:21100:1	O
0	TAFINLAR.xml:S1:21114:1	O
0	TAFINLAR.xml:S1:21125:1	O

a	TAFINLAR.xml:S1:21151:1	O
National	TAFINLAR.xml:S1:21154:8	O
Cancer	TAFINLAR.xml:S1:21163:6	O
Institute	TAFINLAR.xml:S1:21170:9	O
Common	TAFINLAR.xml:S1:21180:6	O
Terminology	TAFINLAR.xml:S1:21187:11	O
Criteria	TAFINLAR.xml:S1:21199:8	O
for	TAFINLAR.xml:S1:21208:3	O
Adverse	TAFINLAR.xml:S1:21212:7	O
Events	TAFINLAR.xml:S1:21220:6	O
,	TAFINLAR.xml:S1:21226:1	O
version	TAFINLAR.xml:S1:21228:7	O
4	TAFINLAR.xml:S1:21236:1	O
.	TAFINLAR.xml:S1:21237:1	O

b	TAFINLAR.xml:S1:21245:1	O

Includes	TAFINLAR.xml:S1:21248:8	O
the	TAFINLAR.xml:S1:21257:3	O
following	TAFINLAR.xml:S1:21261:9	O
terms	TAFINLAR.xml:S1:21271:5	O
:	TAFINLAR.xml:S1:21276:1	O
peripheral	TAFINLAR.xml:S1:21278:10	B-AdverseReaction
edema	TAFINLAR.xml:S1:21289:5	I-AdverseReaction
,	TAFINLAR.xml:S1:21294:1	O
edema	TAFINLAR.xml:S1:21296:5	B-AdverseReaction
,	TAFINLAR.xml:S1:21301:1	O
and	TAFINLAR.xml:S1:21303:3	O
lymphedema	TAFINLAR.xml:S1:21307:10	B-AdverseReaction
.	TAFINLAR.xml:S1:21317:1	O

c	TAFINLAR.xml:S1:21325:1	O
Includes	TAFINLAR.xml:S1:21328:8	O
the	TAFINLAR.xml:S1:21337:3	O
following	TAFINLAR.xml:S1:21341:9	O
terms	TAFINLAR.xml:S1:21351:5	O
:	TAFINLAR.xml:S1:21356:1	O
rash	TAFINLAR.xml:S1:21358:4	B-AdverseReaction
,	TAFINLAR.xml:S1:21362:1	O
rash	TAFINLAR.xml:S1:21364:4	B-AdverseReaction
generalized	TAFINLAR.xml:S1:21369:11	I-AdverseReaction
,	TAFINLAR.xml:S1:21380:1	O
rash	TAFINLAR.xml:S1:21382:4	B-AdverseReaction
pruritic	TAFINLAR.xml:S1:21387:8	I-AdverseReaction
,	TAFINLAR.xml:S1:21395:1	O
rash	TAFINLAR.xml:S1:21397:4	B-AdverseReaction
erythematous	TAFINLAR.xml:S1:21402:12	I-AdverseReaction
,	TAFINLAR.xml:S1:21414:1	O
rash	TAFINLAR.xml:S1:21416:4	B-AdverseReaction
papular	TAFINLAR.xml:S1:21421:7	I-AdverseReaction
,	TAFINLAR.xml:S1:21428:1	O
rash	TAFINLAR.xml:S1:21430:4	B-AdverseReaction
vesicular	TAFINLAR.xml:S1:21435:9	I-AdverseReaction
,	TAFINLAR.xml:S1:21444:1	O
rash	TAFINLAR.xml:S1:21446:4	B-AdverseReaction
macular	TAFINLAR.xml:S1:21451:7	I-AdverseReaction
,	TAFINLAR.xml:S1:21458:1	O
and	TAFINLAR.xml:S1:21460:3	O
rash	TAFINLAR.xml:S1:21464:4	B-AdverseReaction
maculo	TAFINLAR.xml:S1:21469:6	I-AdverseReaction
-	TAFINLAR.xml:S1:21475:1	I-AdverseReaction
papular	TAFINLAR.xml:S1:21476:7	I-AdverseReaction
.	TAFINLAR.xml:S1:21483:1	O

d	TAFINLAR.xml:S1:21491:1	O
Includes	TAFINLAR.xml:S1:21494:8	O
the	TAFINLAR.xml:S1:21503:3	O
following	TAFINLAR.xml:S1:21507:9	O
terms	TAFINLAR.xml:S1:21517:5	O
:	TAFINLAR.xml:S1:21522:1	O
abdominal	TAFINLAR.xml:S1:21524:9	B-AdverseReaction
pain	TAFINLAR.xml:S1:21534:4	I-AdverseReaction
,	TAFINLAR.xml:S1:21538:1	O
abdominal	TAFINLAR.xml:S1:21540:9	B-AdverseReaction
pain	TAFINLAR.xml:S1:21550:4	I-AdverseReaction
upper	TAFINLAR.xml:S1:21555:5	I-AdverseReaction
,	TAFINLAR.xml:S1:21560:1	O
abdominal	TAFINLAR.xml:S1:21562:9	B-AdverseReaction
pain	TAFINLAR.xml:S1:21572:4	I-AdverseReaction
lower	TAFINLAR.xml:S1:21577:5	I-AdverseReaction
,	TAFINLAR.xml:S1:21582:1	O
and	TAFINLAR.xml:S1:21584:3	O
abdominal	TAFINLAR.xml:S1:21588:9	B-AdverseReaction
discomfort	TAFINLAR.xml:S1:21598:10	I-AdverseReaction
.	TAFINLAR.xml:S1:21608:1	O

e	TAFINLAR.xml:S1:21616:1	O
Includes	TAFINLAR.xml:S1:21619:8	O
the	TAFINLAR.xml:S1:21628:3	O
following	TAFINLAR.xml:S1:21632:9	O
terms	TAFINLAR.xml:S1:21642:5	O
:	TAFINLAR.xml:S1:21647:1	O
brain	TAFINLAR.xml:S1:21649:5	B-AdverseReaction
stem	TAFINLAR.xml:S1:21655:4	I-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21660:10	I-AdverseReaction
,	TAFINLAR.xml:S1:21670:1	O
cerebral	TAFINLAR.xml:S1:21672:8	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21681:10	I-AdverseReaction
,	TAFINLAR.xml:S1:21691:1	O
gastric	TAFINLAR.xml:S1:21693:7	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21701:10	I-AdverseReaction
,	TAFINLAR.xml:S1:21711:1	O
epistaxis	TAFINLAR.xml:S1:21713:9	B-AdverseReaction
,	TAFINLAR.xml:S1:21722:1	O
gingival	TAFINLAR.xml:S1:21724:8	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21733:10	I-AdverseReaction
,	TAFINLAR.xml:S1:21743:1	O
hematuria	TAFINLAR.xml:S1:21745:9	B-AdverseReaction
,	TAFINLAR.xml:S1:21754:1	O
vaginal	TAFINLAR.xml:S1:21756:7	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21764:10	I-AdverseReaction
,	TAFINLAR.xml:S1:21774:1	O
hemorrhage	TAFINLAR.xml:S1:21776:10	B-AdverseReaction
intracranial	TAFINLAR.xml:S1:21787:12	I-AdverseReaction
,	TAFINLAR.xml:S1:21799:1	O
eye	TAFINLAR.xml:S1:21801:3	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21805:10	I-AdverseReaction
,	TAFINLAR.xml:S1:21815:1	O
and	TAFINLAR.xml:S1:21817:3	O
vitreous	TAFINLAR.xml:S1:21821:8	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S1:21830:10	I-AdverseReaction
.	TAFINLAR.xml:S1:21840:1	O

f	TAFINLAR.xml:S1:21848:1	O
Includes	TAFINLAR.xml:S1:21851:8	O
the	TAFINLAR.xml:S1:21860:3	O
following	TAFINLAR.xml:S1:21864:9	O
terms	TAFINLAR.xml:S1:21874:5	O
:	TAFINLAR.xml:S1:21879:1	O
renal	TAFINLAR.xml:S1:21881:5	B-AdverseReaction
failure	TAFINLAR.xml:S1:21887:7	I-AdverseReaction
and	TAFINLAR.xml:S1:21895:3	O
renal	TAFINLAR.xml:S1:21899:5	B-AdverseReaction
failure	TAFINLAR.xml:S1:21905:7	I-AdverseReaction
acute	TAFINLAR.xml:S1:21913:5	I-AdverseReaction
.	TAFINLAR.xml:S1:21918:1	O

Other	TAFINLAR.xml:S1:21924:5	O
clinically	TAFINLAR.xml:S1:21930:10	O
important	TAFINLAR.xml:S1:21941:9	O
adverse	TAFINLAR.xml:S1:21951:7	O
reactions	TAFINLAR.xml:S1:21959:9	O
(	TAFINLAR.xml:S1:21969:1	O
N	TAFINLAR.xml:S1:21970:1	O
202	TAFINLAR.xml:S1:21974:3	O
)	TAFINLAR.xml:S1:21977:1	O
observed	TAFINLAR.xml:S1:21979:8	O
in	TAFINLAR.xml:S1:21988:2	O
10%	TAFINLAR.xml:S1:21992:3	O
of	TAFINLAR.xml:S1:21996:2	O
patients	TAFINLAR.xml:S1:21999:8	O
treated	TAFINLAR.xml:S1:22008:7	O
with	TAFINLAR.xml:S1:22016:4	O
TAFINLAR	TAFINLAR.xml:S1:22021:8	O
in	TAFINLAR.xml:S1:22030:2	O
combination	TAFINLAR.xml:S1:22033:11	O
with	TAFINLAR.xml:S1:22045:4	O
trametinib	TAFINLAR.xml:S1:22050:10	O
were	TAFINLAR.xml:S1:22061:4	O
:	TAFINLAR.xml:S1:22065:1	O

Eye	TAFINLAR.xml:S1:22073:3	O
Disorders	TAFINLAR.xml:S1:22077:9	O
:	TAFINLAR.xml:S1:22086:1	O
Vision	TAFINLAR.xml:S1:22089:6	B-AdverseReaction
blurred	TAFINLAR.xml:S1:22096:7	I-AdverseReaction
,	TAFINLAR.xml:S1:22103:1	O
transient	TAFINLAR.xml:S1:22105:9	B-AdverseReaction
blindness	TAFINLAR.xml:S1:22115:9	I-AdverseReaction
.	TAFINLAR.xml:S1:22124:1	O

Gastrointestinal	TAFINLAR.xml:S1:22132:16	O
Disorders	TAFINLAR.xml:S1:22149:9	O
:	TAFINLAR.xml:S1:22158:1	O
Stomatitis	TAFINLAR.xml:S1:22161:10	B-AdverseReaction
,	TAFINLAR.xml:S1:22171:1	O
pancreatitis	TAFINLAR.xml:S1:22173:12	B-AdverseReaction
.	TAFINLAR.xml:S1:22185:1	O

General	TAFINLAR.xml:S1:22193:7	O
Disorders	TAFINLAR.xml:S1:22201:9	O
and	TAFINLAR.xml:S1:22211:3	O
Administration	TAFINLAR.xml:S1:22215:14	O
Site	TAFINLAR.xml:S1:22230:4	O
Conditions	TAFINLAR.xml:S1:22235:10	O
:	TAFINLAR.xml:S1:22245:1	O
Asthenia	TAFINLAR.xml:S1:22248:8	B-AdverseReaction
.	TAFINLAR.xml:S1:22256:1	O

Infections	TAFINLAR.xml:S1:22264:10	O
and	TAFINLAR.xml:S1:22275:3	O
Infestations	TAFINLAR.xml:S1:22279:12	O
:	TAFINLAR.xml:S1:22291:1	O
Cellulitis	TAFINLAR.xml:S1:22294:10	B-AdverseReaction
,	TAFINLAR.xml:S1:22304:1	O
folliculitis	TAFINLAR.xml:S1:22306:12	B-AdverseReaction
,	TAFINLAR.xml:S1:22318:1	O
paronychia	TAFINLAR.xml:S1:22320:10	B-AdverseReaction
,	TAFINLAR.xml:S1:22330:1	O
rash	TAFINLAR.xml:S1:22332:4	B-AdverseReaction
pustular	TAFINLAR.xml:S1:22337:8	I-AdverseReaction
.	TAFINLAR.xml:S1:22345:1	O

Neoplasms	TAFINLAR.xml:S1:22353:9	O
Benign	TAFINLAR.xml:S1:22363:6	O
,	TAFINLAR.xml:S1:22369:1	O
Malignant	TAFINLAR.xml:S1:22371:9	O
,	TAFINLAR.xml:S1:22380:1	O
and	TAFINLAR.xml:S1:22382:3	O
Unspecified	TAFINLAR.xml:S1:22386:11	O
(	TAFINLAR.xml:S1:22398:1	O
including	TAFINLAR.xml:S1:22399:9	O
cysts	TAFINLAR.xml:S1:22409:5	O
and	TAFINLAR.xml:S1:22415:3	O
polyps	TAFINLAR.xml:S1:22419:6	O
)	TAFINLAR.xml:S1:22425:1	O
:	TAFINLAR.xml:S1:22426:1	O
Skin	TAFINLAR.xml:S1:22429:4	B-AdverseReaction
papilloma	TAFINLAR.xml:S1:22434:9	I-AdverseReaction
.	TAFINLAR.xml:S1:22443:1	O

Skin	TAFINLAR.xml:S1:22451:4	O
and	TAFINLAR.xml:S1:22456:3	O
Subcutaneous	TAFINLAR.xml:S1:22460:12	O
Tissue	TAFINLAR.xml:S1:22473:6	O
Disorders	TAFINLAR.xml:S1:22480:9	O
:	TAFINLAR.xml:S1:22489:1	O
Palmar	TAFINLAR.xml:S1:22492:6	B-AdverseReaction
-	TAFINLAR.xml:S1:22498:1	I-AdverseReaction
plantar	TAFINLAR.xml:S1:22499:7	I-AdverseReaction
erythrodysesthesia	TAFINLAR.xml:S1:22507:18	I-AdverseReaction
syndrome	TAFINLAR.xml:S1:22526:8	I-AdverseReaction
,	TAFINLAR.xml:S1:22534:1	O
hyperkeratosis	TAFINLAR.xml:S1:22536:14	B-AdverseReaction
,	TAFINLAR.xml:S1:22550:1	O
hyperhidrosis	TAFINLAR.xml:S1:22552:13	B-AdverseReaction
.	TAFINLAR.xml:S1:22565:1	O

Vascular	TAFINLAR.xml:S1:22573:8	O
Disorders	TAFINLAR.xml:S1:22582:9	O
:	TAFINLAR.xml:S1:22591:1	O
Hypertension	TAFINLAR.xml:S1:22594:12	B-AdverseReaction
.	TAFINLAR.xml:S1:22606:1	O

Table	TAFINLAR.xml:S1:22612:5	O
6	TAFINLAR.xml:S1:22618:1	O
.	TAFINLAR.xml:S1:22619:1	O

Treatment	TAFINLAR.xml:S1:22621:9	O
-	TAFINLAR.xml:S1:22630:1	O
Emergent	TAFINLAR.xml:S1:22631:8	O
Laboratory	TAFINLAR.xml:S1:22640:10	O
Abnormalities	TAFINLAR.xml:S1:22651:13	O
Occurring	TAFINLAR.xml:S1:22665:9	O
at	TAFINLAR.xml:S1:22675:2	O
10%	TAFINLAR.xml:S1:22680:3	O
(	TAFINLAR.xml:S1:22684:1	O
All	TAFINLAR.xml:S1:22685:3	O
Grades	TAFINLAR.xml:S1:22689:6	O
)	TAFINLAR.xml:S1:22695:1	O
or	TAFINLAR.xml:S1:22697:2	O
2%	TAFINLAR.xml:S1:22702:2	O
(	TAFINLAR.xml:S1:22705:1	O
Grades	TAFINLAR.xml:S1:22706:6	O
3	TAFINLAR.xml:S1:22713:1	O
or	TAFINLAR.xml:S1:22715:2	O
4	TAFINLAR.xml:S1:22718:1	O
)]	TAFINLAR.xml:S1:22719:2	O
of	TAFINLAR.xml:S1:22722:2	O
Patients	TAFINLAR.xml:S1:22725:8	O
Treated	TAFINLAR.xml:S1:22734:7	O
With	TAFINLAR.xml:S1:22742:4	O
TAFINLAR	TAFINLAR.xml:S1:22747:8	O
in	TAFINLAR.xml:S1:22756:2	O
Combination	TAFINLAR.xml:S1:22759:11	O
With	TAFINLAR.xml:S1:22771:4	O
Trametinib	TAFINLAR.xml:S1:22776:10	O
in	TAFINLAR.xml:S1:22787:2	O
Trial	TAFINLAR.xml:S1:22790:5	O
2	TAFINLAR.xml:S1:22796:1	O

Tests	TAFINLAR.xml:S1:22801:5	O
TAFINLAR	TAFINLAR.xml:S1:22838:8	O
plus	TAFINLAR.xml:S1:22847:4	O
Trametinib	TAFINLAR.xml:S1:22852:10	O
2	TAFINLAR.xml:S1:22863:1	O
mg	TAFINLAR.xml:S1:22865:2	O
N	TAFINLAR.xml:S1:22869:1	O
55	TAFINLAR.xml:S1:22873:2	O
TAFINLAR	TAFINLAR.xml:S1:22879:8	O
plus	TAFINLAR.xml:S1:22888:4	O
Trametinib	TAFINLAR.xml:S1:22893:10	O
1	TAFINLAR.xml:S1:22904:1	O
mg	TAFINLAR.xml:S1:22906:2	O
N	TAFINLAR.xml:S1:22910:1	O
54	TAFINLAR.xml:S1:22914:2	O
TAFINLAR	TAFINLAR.xml:S1:22920:8	O
N	TAFINLAR.xml:S1:22930:1	O
53	TAFINLAR.xml:S1:22934:2	O

All	TAFINLAR.xml:S1:22943:3	O
Grades	TAFINLAR.xml:S1:22948:6	O
Grades	TAFINLAR.xml:S1:22980:6	O
3	TAFINLAR.xml:S1:22988:1	O
and	TAFINLAR.xml:S1:22990:3	O
4	TAFINLAR.xml:S1:22994:1	O
All	TAFINLAR.xml:S1:22999:3	O
Grades	TAFINLAR.xml:S1:23004:6	O
Grades	TAFINLAR.xml:S1:23014:6	O
3	TAFINLAR.xml:S1:23022:1	O
and	TAFINLAR.xml:S1:23024:3	O
4	TAFINLAR.xml:S1:23028:1	O
All	TAFINLAR.xml:S1:23033:3	O
Grades	TAFINLAR.xml:S1:23038:6	O
Grades	TAFINLAR.xml:S1:23048:6	O
3	TAFINLAR.xml:S1:23056:1	O
and	TAFINLAR.xml:S1:23058:3	O
4	TAFINLAR.xml:S1:23062:1	O
a	TAFINLAR.xml:S1:23063:1	O

Hematology	TAFINLAR.xml:S1:23071:10	O

Leukopenia	TAFINLAR.xml:S1:23147:10	B-AdverseReaction

62	TAFINLAR.xml:S1:23260:2	O
5	TAFINLAR.xml:S1:23274:1	O
46	TAFINLAR.xml:S1:23288:2	O
4	TAFINLAR.xml:S1:23302:1	O
21	TAFINLAR.xml:S1:23316:2	O
0	TAFINLAR.xml:S1:23326:1	O

Lymphopenia	TAFINLAR.xml:S1:23376:11	B-AdverseReaction

55	TAFINLAR.xml:S1:23489:2	O
22	TAFINLAR.xml:S1:23503:2	O
59	TAFINLAR.xml:S1:23517:2	O
19	TAFINLAR.xml:S1:23531:2	O
40	TAFINLAR.xml:S1:23545:2	O
6	TAFINLAR.xml:S1:23555:1	O

Neutropenia	TAFINLAR.xml:S1:23605:11	B-AdverseReaction

55	TAFINLAR.xml:S1:23718:2	O
13	TAFINLAR.xml:S1:23732:2	O
37	TAFINLAR.xml:S1:23746:2	O
2	TAFINLAR.xml:S1:23760:1	O
9	TAFINLAR.xml:S1:23774:1	O
2	TAFINLAR.xml:S1:23784:1	O

Anemia	TAFINLAR.xml:S1:23834:6	B-AdverseReaction

55	TAFINLAR.xml:S1:23947:2	O
4	TAFINLAR.xml:S1:23961:1	O
46	TAFINLAR.xml:S1:23975:2	O
7	TAFINLAR.xml:S1:23989:1	O
28	TAFINLAR.xml:S1:24003:2	O
0	TAFINLAR.xml:S1:24013:1	O

Thrombocytopenia	TAFINLAR.xml:S1:24063:16	B-AdverseReaction

31	TAFINLAR.xml:S1:24176:2	O
4	TAFINLAR.xml:S1:24190:1	O
31	TAFINLAR.xml:S1:24204:2	O
2	TAFINLAR.xml:S1:24218:1	O
8	TAFINLAR.xml:S1:24232:1	O
0	TAFINLAR.xml:S1:24242:1	O

Liver	TAFINLAR.xml:S1:24256:5	O
Function	TAFINLAR.xml:S1:24262:8	O
Tests	TAFINLAR.xml:S1:24271:5	O

Increased	TAFINLAR.xml:S1:24332:9	B-AdverseReaction
AST	TAFINLAR.xml:S1:24342:3	I-AdverseReaction

60	TAFINLAR.xml:S1:24445:2	O
5	TAFINLAR.xml:S1:24459:1	O
54	TAFINLAR.xml:S1:24473:2	O
0	TAFINLAR.xml:S1:24487:1	O
15	TAFINLAR.xml:S1:24501:2	O
0	TAFINLAR.xml:S1:24511:1	O

Increased	TAFINLAR.xml:S1:24561:9	B-AdverseReaction
alkaline	TAFINLAR.xml:S1:24571:8	I-AdverseReaction
phosphatase	TAFINLAR.xml:S1:24580:11	I-AdverseReaction

60	TAFINLAR.xml:S1:24674:2	O
2	TAFINLAR.xml:S1:24688:1	O
67	TAFINLAR.xml:S1:24702:2	O
6	TAFINLAR.xml:S1:24716:1	O
26	TAFINLAR.xml:S1:24730:2	O
2	TAFINLAR.xml:S1:24740:1	O

Increased	TAFINLAR.xml:S1:24790:9	B-AdverseReaction
ALT	TAFINLAR.xml:S1:24800:3	I-AdverseReaction

42	TAFINLAR.xml:S1:24903:2	O
4	TAFINLAR.xml:S1:24917:1	O
35	TAFINLAR.xml:S1:24931:2	O
4	TAFINLAR.xml:S1:24945:1	O
11	TAFINLAR.xml:S1:24959:2	O
0	TAFINLAR.xml:S1:24969:1	O

Hyperbilirubinemia	TAFINLAR.xml:S1:25019:18	B-AdverseReaction

15	TAFINLAR.xml:S1:25132:2	O
0	TAFINLAR.xml:S1:25146:1	O
7	TAFINLAR.xml:S1:25160:1	O
4	TAFINLAR.xml:S1:25174:1	O
0	TAFINLAR.xml:S1:25188:1	O
0	TAFINLAR.xml:S1:25198:1	O

Chemistry	TAFINLAR.xml:S1:25212:9	O

Hyperglycemia	TAFINLAR.xml:S1:25288:13	B-AdverseReaction

58	TAFINLAR.xml:S1:25401:2	O
5	TAFINLAR.xml:S1:25415:1	O
67	TAFINLAR.xml:S1:25429:2	O
6	TAFINLAR.xml:S1:25443:1	O
49	TAFINLAR.xml:S1:25457:2	O
2	TAFINLAR.xml:S1:25467:1	O

Increased	TAFINLAR.xml:S1:25517:9	B-AdverseReaction
GGT	TAFINLAR.xml:S1:25527:3	I-AdverseReaction

56	TAFINLAR.xml:S1:25630:2	O
11	TAFINLAR.xml:S1:25644:2	O
54	TAFINLAR.xml:S1:25658:2	O
17	TAFINLAR.xml:S1:25672:2	O
38	TAFINLAR.xml:S1:25686:2	O
2	TAFINLAR.xml:S1:25696:1	O

Hyponatremia	TAFINLAR.xml:S1:25746:12	B-AdverseReaction

55	TAFINLAR.xml:S1:25859:2	O
11	TAFINLAR.xml:S1:25873:2	O
48	TAFINLAR.xml:S1:25887:2	O
15	TAFINLAR.xml:S1:25901:2	O
36	TAFINLAR.xml:S1:25915:2	O
2	TAFINLAR.xml:S1:25925:1	O

Hypoalbuminemia	TAFINLAR.xml:S1:25975:15	B-AdverseReaction

53	TAFINLAR.xml:S1:26088:2	O
0	TAFINLAR.xml:S1:26102:1	O
43	TAFINLAR.xml:S1:26116:2	O
2	TAFINLAR.xml:S1:26130:1	O
23	TAFINLAR.xml:S1:26144:2	O
0	TAFINLAR.xml:S1:26154:1	O

Hypophosphatemia	TAFINLAR.xml:S1:26204:16	B-AdverseReaction

47	TAFINLAR.xml:S1:26317:2	O
5	TAFINLAR.xml:S1:26331:1	O
41	TAFINLAR.xml:S1:26345:2	O
11	TAFINLAR.xml:S1:26359:2	O
40	TAFINLAR.xml:S1:26373:2	O
0	TAFINLAR.xml:S1:26383:1	O

Hypokalemia	TAFINLAR.xml:S1:26433:11	B-AdverseReaction

29	TAFINLAR.xml:S1:26546:2	O
2	TAFINLAR.xml:S1:26560:1	O
15	TAFINLAR.xml:S1:26574:2	O
2	TAFINLAR.xml:S1:26588:1	O
23	TAFINLAR.xml:S1:26602:2	O
6	TAFINLAR.xml:S1:26612:1	O

Increased	TAFINLAR.xml:S1:26662:9	B-AdverseReaction
creatinine	TAFINLAR.xml:S1:26672:10	I-AdverseReaction

24	TAFINLAR.xml:S1:26775:2	O
5	TAFINLAR.xml:S1:26789:1	O
20	TAFINLAR.xml:S1:26803:2	O
2	TAFINLAR.xml:S1:26817:1	O
9	TAFINLAR.xml:S1:26831:1	O
0	TAFINLAR.xml:S1:26841:1	O

Hypomagnesemia	TAFINLAR.xml:S1:26891:14	B-AdverseReaction

18	TAFINLAR.xml:S1:27004:2	O
2	TAFINLAR.xml:S1:27018:1	O
2	TAFINLAR.xml:S1:27032:1	O
0	TAFINLAR.xml:S1:27046:1	O
6	TAFINLAR.xml:S1:27060:1	O
0	TAFINLAR.xml:S1:27070:1	O

Hyperkalemia	TAFINLAR.xml:S1:27120:12	B-AdverseReaction

18	TAFINLAR.xml:S1:27233:2	O
0	TAFINLAR.xml:S1:27247:1	O
22	TAFINLAR.xml:S1:27261:2	O
0	TAFINLAR.xml:S1:27275:1	O
15	TAFINLAR.xml:S1:27289:2	O
4	TAFINLAR.xml:S1:27299:1	O

Hypercalcemia	TAFINLAR.xml:S1:27349:13	B-AdverseReaction

15	TAFINLAR.xml:S1:27462:2	O
0	TAFINLAR.xml:S1:27476:1	O
19	TAFINLAR.xml:S1:27490:2	O
2	TAFINLAR.xml:S1:27504:1	O
4	TAFINLAR.xml:S1:27518:1	O
0	TAFINLAR.xml:S1:27528:1	O

Hypocalcemia	TAFINLAR.xml:S1:27578:12	B-AdverseReaction

13	TAFINLAR.xml:S1:27691:2	O
0	TAFINLAR.xml:S1:27705:1	O
20	TAFINLAR.xml:S1:27719:2	O
0	TAFINLAR.xml:S1:27733:1	O
9	TAFINLAR.xml:S1:27747:1	O
0	TAFINLAR.xml:S1:27757:1	O

a	TAFINLAR.xml:S1:27784:1	O
No	TAFINLAR.xml:S1:27787:2	O
Grade	TAFINLAR.xml:S1:27790:5	O
4	TAFINLAR.xml:S1:27796:1	O
events	TAFINLAR.xml:S1:27798:6	O
were	TAFINLAR.xml:S1:27805:4	O
reported	TAFINLAR.xml:S1:27810:8	O
in	TAFINLAR.xml:S1:27819:2	O
patients	TAFINLAR.xml:S1:27822:8	O
receiving	TAFINLAR.xml:S1:27831:9	O
TAFINLAR	TAFINLAR.xml:S1:27841:8	O
as	TAFINLAR.xml:S1:27850:2	O
a	TAFINLAR.xml:S1:27853:1	O
single	TAFINLAR.xml:S1:27855:6	O
agent	TAFINLAR.xml:S1:27862:5	O
.	TAFINLAR.xml:S1:27867:1	O

ALT	TAFINLAR.xml:S1:27873:3	O

Alanine	TAFINLAR.xml:S1:27879:7	O
aminotransferase	TAFINLAR.xml:S1:27887:16	O
;	TAFINLAR.xml:S1:27903:1	O
AST	TAFINLAR.xml:S1:27905:3	O
Aspartate	TAFINLAR.xml:S1:27911:9	O
aminotransferase	TAFINLAR.xml:S1:27921:16	O
;	TAFINLAR.xml:S1:27937:1	O
GGT	TAFINLAR.xml:S1:27939:3	O
Gamma	TAFINLAR.xml:S1:27945:5	O
glutamyltransferase	TAFINLAR.xml:S1:27951:19	O
.	TAFINLAR.xml:S1:27970:1	O

QT	TAFINLAR.xml:S1:27978:2	O
Prolongation	TAFINLAR.xml:S1:27981:12	O
:	TAFINLAR.xml:S1:27993:1	O
In	TAFINLAR.xml:S1:27996:2	O
Trial	TAFINLAR.xml:S1:27999:5	O
2	TAFINLAR.xml:S1:28005:1	O
,	TAFINLAR.xml:S1:28006:1	O
QTcF	TAFINLAR.xml:S1:28008:4	B-AdverseReaction
prolongation	TAFINLAR.xml:S1:28013:12	I-AdverseReaction
to	TAFINLAR.xml:S1:28026:2	O
500	TAFINLAR.xml:S1:28030:3	B-Severity
msec	TAFINLAR.xml:S1:28034:4	I-Severity
occurred	TAFINLAR.xml:S1:28039:8	O
in	TAFINLAR.xml:S1:28048:2	O
4%	TAFINLAR.xml:S1:28051:2	O
(	TAFINLAR.xml:S1:28054:1	O
2	TAFINLAR.xml:S1:28055:1	O
55	TAFINLAR.xml:S1:28057:2	O
)	TAFINLAR.xml:S1:28059:1	O
of	TAFINLAR.xml:S1:28061:2	O
patients	TAFINLAR.xml:S1:28064:8	O
treated	TAFINLAR.xml:S1:28073:7	O
with	TAFINLAR.xml:S1:28081:4	O
TAFINLAR	TAFINLAR.xml:S1:28086:8	O
in	TAFINLAR.xml:S1:28095:2	O
combination	TAFINLAR.xml:S1:28098:11	O
with	TAFINLAR.xml:S1:28110:4	O
trametinib	TAFINLAR.xml:S1:28115:10	O
and	TAFINLAR.xml:S1:28126:3	O
in	TAFINLAR.xml:S1:28130:2	O
2%	TAFINLAR.xml:S1:28133:2	O
(	TAFINLAR.xml:S1:28136:1	O
1	TAFINLAR.xml:S1:28137:1	O
53	TAFINLAR.xml:S1:28139:2	O
)	TAFINLAR.xml:S1:28141:1	O
of	TAFINLAR.xml:S1:28143:2	O
patients	TAFINLAR.xml:S1:28146:8	O
treated	TAFINLAR.xml:S1:28155:7	O
with	TAFINLAR.xml:S1:28163:4	O
TAFINLAR	TAFINLAR.xml:S1:28168:8	O
as	TAFINLAR.xml:S1:28177:2	O
a	TAFINLAR.xml:S1:28180:1	O
single	TAFINLAR.xml:S1:28182:6	O
agent	TAFINLAR.xml:S1:28189:5	O
.	TAFINLAR.xml:S1:28194:1	O

The	TAFINLAR.xml:S1:28196:3	O
QTcF	TAFINLAR.xml:S1:28200:4	B-AdverseReaction
was	TAFINLAR.xml:S1:28205:3	I-AdverseReaction
increased	TAFINLAR.xml:S1:28209:9	I-AdverseReaction
more	TAFINLAR.xml:S1:28219:4	O
than	TAFINLAR.xml:S1:28224:4	O
60	TAFINLAR.xml:S1:28229:2	B-Severity
msec	TAFINLAR.xml:S1:28232:4	I-Severity
from	TAFINLAR.xml:S1:28237:4	I-Severity
baseline	TAFINLAR.xml:S1:28242:8	I-Severity
in	TAFINLAR.xml:S1:28251:2	O
13%	TAFINLAR.xml:S1:28254:3	O
(	TAFINLAR.xml:S1:28258:1	O
7	TAFINLAR.xml:S1:28259:1	O
55	TAFINLAR.xml:S1:28261:2	O
)	TAFINLAR.xml:S1:28263:1	O
of	TAFINLAR.xml:S1:28265:2	O
patients	TAFINLAR.xml:S1:28268:8	O
treated	TAFINLAR.xml:S1:28277:7	O
with	TAFINLAR.xml:S1:28285:4	O
TAFINLAR	TAFINLAR.xml:S1:28290:8	O
in	TAFINLAR.xml:S1:28299:2	O
combination	TAFINLAR.xml:S1:28302:11	O
with	TAFINLAR.xml:S1:28314:4	O
trametinib	TAFINLAR.xml:S1:28319:10	O
and	TAFINLAR.xml:S1:28330:3	O
2%	TAFINLAR.xml:S1:28334:2	O
(	TAFINLAR.xml:S1:28337:1	O
1	TAFINLAR.xml:S1:28338:1	O
53	TAFINLAR.xml:S1:28340:2	O
)	TAFINLAR.xml:S1:28342:1	O
of	TAFINLAR.xml:S1:28344:2	O
patients	TAFINLAR.xml:S1:28347:8	O
treated	TAFINLAR.xml:S1:28356:7	O
with	TAFINLAR.xml:S1:28364:4	O
TAFINLAR	TAFINLAR.xml:S1:28369:8	O
as	TAFINLAR.xml:S1:28378:2	O
a	TAFINLAR.xml:S1:28381:1	O
single	TAFINLAR.xml:S1:28383:6	O
agent	TAFINLAR.xml:S1:28390:5	O
.	TAFINLAR.xml:S1:28395:1	O
5	TAFINLAR.xml:S2:4:1	O
WARNINGS	TAFINLAR.xml:S2:6:8	O
AND	TAFINLAR.xml:S2:15:3	O
PRECAUTIONS	TAFINLAR.xml:S2:19:11	O

Review	TAFINLAR.xml:S2:37:6	O
the	TAFINLAR.xml:S2:44:3	O
Full	TAFINLAR.xml:S2:48:4	O
Prescribing	TAFINLAR.xml:S2:53:11	O
Information	TAFINLAR.xml:S2:65:11	O
for	TAFINLAR.xml:S2:77:3	O
trametinib	TAFINLAR.xml:S2:81:10	O
prior	TAFINLAR.xml:S2:92:5	O
to	TAFINLAR.xml:S2:98:2	O
initiation	TAFINLAR.xml:S2:101:10	O
of	TAFINLAR.xml:S2:112:2	O
TAFINLAR	TAFINLAR.xml:S2:115:8	O
in	TAFINLAR.xml:S2:124:2	O
combination	TAFINLAR.xml:S2:127:11	O
with	TAFINLAR.xml:S2:139:4	O
trametinib	TAFINLAR.xml:S2:144:10	O
.	TAFINLAR.xml:S2:154:1	O

The	TAFINLAR.xml:S2:156:3	O
following	TAFINLAR.xml:S2:160:9	O
serious	TAFINLAR.xml:S2:170:7	O
adverse	TAFINLAR.xml:S2:178:7	O
reactions	TAFINLAR.xml:S2:186:9	O
of	TAFINLAR.xml:S2:196:2	O
trametinib	TAFINLAR.xml:S2:199:10	O
as	TAFINLAR.xml:S2:210:2	O
a	TAFINLAR.xml:S2:213:1	O
single	TAFINLAR.xml:S2:215:6	O
agent	TAFINLAR.xml:S2:222:5	O
,	TAFINLAR.xml:S2:227:1	O
which	TAFINLAR.xml:S2:229:5	O
may	TAFINLAR.xml:S2:235:3	O
occur	TAFINLAR.xml:S2:239:5	O
when	TAFINLAR.xml:S2:245:4	O
TAFINLAR	TAFINLAR.xml:S2:250:8	O
is	TAFINLAR.xml:S2:259:2	O
used	TAFINLAR.xml:S2:262:4	O
in	TAFINLAR.xml:S2:267:2	O
combination	TAFINLAR.xml:S2:270:11	O
with	TAFINLAR.xml:S2:282:4	O
trametinib	TAFINLAR.xml:S2:287:10	O
,	TAFINLAR.xml:S2:297:1	O
are	TAFINLAR.xml:S2:299:3	O
not	TAFINLAR.xml:S2:303:3	O
described	TAFINLAR.xml:S2:307:9	O
in	TAFINLAR.xml:S2:317:2	O
the	TAFINLAR.xml:S2:320:3	O
Full	TAFINLAR.xml:S2:324:4	O
Prescribing	TAFINLAR.xml:S2:329:11	O
Information	TAFINLAR.xml:S2:341:11	O
for	TAFINLAR.xml:S2:353:3	O
TAFINLAR	TAFINLAR.xml:S2:357:8	O
:	TAFINLAR.xml:S2:365:1	O

Retinal	TAFINLAR.xml:S2:379:7	B-AdverseReaction
vein	TAFINLAR.xml:S2:387:4	I-AdverseReaction
occlusion	TAFINLAR.xml:S2:392:9	I-AdverseReaction

Interstitial	TAFINLAR.xml:S2:411:12	B-AdverseReaction
lung	TAFINLAR.xml:S2:424:4	I-AdverseReaction
disease	TAFINLAR.xml:S2:429:7	I-AdverseReaction

New	TAFINLAR.xml:S2:447:3	O
primary	TAFINLAR.xml:S2:451:7	B-AdverseReaction
malignancies	TAFINLAR.xml:S2:459:12	I-AdverseReaction
,	TAFINLAR.xml:S2:471:1	I-AdverseReaction
cutaneous	TAFINLAR.xml:S2:473:9	I-AdverseReaction
and	TAFINLAR.xml:S2:483:3	O
non	TAFINLAR.xml:S2:487:3	I-AdverseReaction
-	TAFINLAR.xml:S2:490:1	I-AdverseReaction
cutaneous	TAFINLAR.xml:S2:491:9	I-AdverseReaction
,	TAFINLAR.xml:S2:500:1	O
can	TAFINLAR.xml:S2:502:3	B-Factor
occur	TAFINLAR.xml:S2:506:5	O
when	TAFINLAR.xml:S2:512:4	O
TAFINLAR	TAFINLAR.xml:S2:517:8	O
is	TAFINLAR.xml:S2:526:2	O
administered	TAFINLAR.xml:S2:529:12	O
as	TAFINLAR.xml:S2:542:2	O
a	TAFINLAR.xml:S2:545:1	O
single	TAFINLAR.xml:S2:547:6	O
agent	TAFINLAR.xml:S2:554:5	O
or	TAFINLAR.xml:S2:560:2	O
in	TAFINLAR.xml:S2:563:2	O
combination	TAFINLAR.xml:S2:566:11	O
with	TAFINLAR.xml:S2:578:4	O
trametinib	TAFINLAR.xml:S2:583:10	O
.	TAFINLAR.xml:S2:593:1	O

Monitor	TAFINLAR.xml:S2:595:7	O
patients	TAFINLAR.xml:S2:603:8	O
for	TAFINLAR.xml:S2:612:3	O
new	TAFINLAR.xml:S2:616:3	O
malignancies	TAFINLAR.xml:S2:620:12	O
prior	TAFINLAR.xml:S2:633:5	O
to	TAFINLAR.xml:S2:639:2	O
initiation	TAFINLAR.xml:S2:642:10	O
of	TAFINLAR.xml:S2:653:2	O
therapy	TAFINLAR.xml:S2:656:7	O
,	TAFINLAR.xml:S2:663:1	O
while	TAFINLAR.xml:S2:665:5	O
on	TAFINLAR.xml:S2:671:2	O
therapy	TAFINLAR.xml:S2:674:7	O
,	TAFINLAR.xml:S2:681:1	O
and	TAFINLAR.xml:S2:683:3	O
following	TAFINLAR.xml:S2:687:9	O
discontinuation	TAFINLAR.xml:S2:697:15	O
of	TAFINLAR.xml:S2:713:2	O
TAFINLAR	TAFINLAR.xml:S2:716:8	O
or	TAFINLAR.xml:S2:725:2	O
the	TAFINLAR.xml:S2:728:3	O
combination	TAFINLAR.xml:S2:732:11	O
therapy	TAFINLAR.xml:S2:744:7	O
.	TAFINLAR.xml:S2:751:1	O

(	TAFINLAR.xml:S2:753:1	O
5.1	TAFINLAR.xml:S2:756:3	O
,	TAFINLAR.xml:S2:761:1	O
2.3	TAFINLAR.xml:S2:764:3	O
)	TAFINLAR.xml:S2:769:1	O

Tumor	TAFINLAR.xml:S2:778:5	B-AdverseReaction
Promotion	TAFINLAR.xml:S2:784:9	I-AdverseReaction
in	TAFINLAR.xml:S2:794:2	I-AdverseReaction
BRAF	TAFINLAR.xml:S2:797:4	I-AdverseReaction
Wild	TAFINLAR.xml:S2:802:4	I-AdverseReaction
-	TAFINLAR.xml:S2:806:1	I-AdverseReaction
Type	TAFINLAR.xml:S2:807:4	I-AdverseReaction
Melanoma	TAFINLAR.xml:S2:812:8	I-AdverseReaction
:	TAFINLAR.xml:S2:820:1	O
Increased	TAFINLAR.xml:S2:822:9	B-AdverseReaction
cell	TAFINLAR.xml:S2:832:4	I-AdverseReaction
proliferation	TAFINLAR.xml:S2:837:13	I-AdverseReaction
can	TAFINLAR.xml:S2:851:3	O
occur	TAFINLAR.xml:S2:855:5	O
with	TAFINLAR.xml:S2:861:4	O
BRAF	TAFINLAR.xml:S2:866:4	B-DrugClass
inhibitors	TAFINLAR.xml:S2:871:10	I-DrugClass
.	TAFINLAR.xml:S2:881:1	O

(	TAFINLAR.xml:S2:883:1	O
5.2	TAFINLAR.xml:S2:886:3	O
)	TAFINLAR.xml:S2:891:1	O

Hemorrhage	TAFINLAR.xml:S2:900:10	B-AdverseReaction
:	TAFINLAR.xml:S2:910:1	O
Major	TAFINLAR.xml:S2:912:5	B-Severity
hemorrhagic	TAFINLAR.xml:S2:918:11	B-AdverseReaction
events	TAFINLAR.xml:S2:930:6	I-AdverseReaction
can	TAFINLAR.xml:S2:937:3	B-Factor
occur	TAFINLAR.xml:S2:941:5	O
in	TAFINLAR.xml:S2:947:2	O
patients	TAFINLAR.xml:S2:950:8	O
receiving	TAFINLAR.xml:S2:959:9	O
TAFINLAR	TAFINLAR.xml:S2:969:8	O
in	TAFINLAR.xml:S2:978:2	O
combination	TAFINLAR.xml:S2:981:11	O
with	TAFINLAR.xml:S2:993:4	O
trametinib	TAFINLAR.xml:S2:998:10	O
.	TAFINLAR.xml:S2:1008:1	O

Monitor	TAFINLAR.xml:S2:1010:7	O
for	TAFINLAR.xml:S2:1018:3	O
signs	TAFINLAR.xml:S2:1022:5	O
and	TAFINLAR.xml:S2:1028:3	O
symptoms	TAFINLAR.xml:S2:1032:8	O
of	TAFINLAR.xml:S2:1041:2	O
bleeding	TAFINLAR.xml:S2:1044:8	O
.	TAFINLAR.xml:S2:1052:1	O

(	TAFINLAR.xml:S2:1054:1	O
5.3	TAFINLAR.xml:S2:1057:3	O
)	TAFINLAR.xml:S2:1062:1	O

Venous	TAFINLAR.xml:S2:1071:6	B-AdverseReaction
Thromboembolism	TAFINLAR.xml:S2:1078:15	I-AdverseReaction
:	TAFINLAR.xml:S2:1093:1	O
Deep	TAFINLAR.xml:S2:1095:4	B-AdverseReaction
vein	TAFINLAR.xml:S2:1100:4	I-AdverseReaction
thrombosis	TAFINLAR.xml:S2:1105:10	I-AdverseReaction
and	TAFINLAR.xml:S2:1116:3	O
pulmonary	TAFINLAR.xml:S2:1120:9	B-AdverseReaction
embolism	TAFINLAR.xml:S2:1130:8	I-AdverseReaction
can	TAFINLAR.xml:S2:1139:3	B-Factor
occur	TAFINLAR.xml:S2:1143:5	O
in	TAFINLAR.xml:S2:1149:2	O
patients	TAFINLAR.xml:S2:1152:8	O
receiving	TAFINLAR.xml:S2:1161:9	O
TAFINLAR	TAFINLAR.xml:S2:1171:8	O
in	TAFINLAR.xml:S2:1180:2	O
combination	TAFINLAR.xml:S2:1183:11	O
with	TAFINLAR.xml:S2:1195:4	O
trametinib	TAFINLAR.xml:S2:1200:10	O
.	TAFINLAR.xml:S2:1210:1	O

(	TAFINLAR.xml:S2:1212:1	O
5.4	TAFINLAR.xml:S2:1215:3	O
,	TAFINLAR.xml:S2:1220:1	O
2.3	TAFINLAR.xml:S2:1223:3	O
)	TAFINLAR.xml:S2:1228:1	O

Cardiomyopathy	TAFINLAR.xml:S2:1237:14	B-AdverseReaction
:	TAFINLAR.xml:S2:1251:1	O
Assess	TAFINLAR.xml:S2:1253:6	O
LVEF	TAFINLAR.xml:S2:1260:4	O
before	TAFINLAR.xml:S2:1265:6	O
treatment	TAFINLAR.xml:S2:1272:9	O
with	TAFINLAR.xml:S2:1282:4	O
TAFINLAR	TAFINLAR.xml:S2:1287:8	O
in	TAFINLAR.xml:S2:1296:2	O
combination	TAFINLAR.xml:S2:1299:11	O
with	TAFINLAR.xml:S2:1311:4	O
trametinib	TAFINLAR.xml:S2:1316:10	O
,	TAFINLAR.xml:S2:1326:1	O
after	TAFINLAR.xml:S2:1328:5	O
one	TAFINLAR.xml:S2:1334:3	O
month	TAFINLAR.xml:S2:1338:5	O
of	TAFINLAR.xml:S2:1344:2	O
treatment	TAFINLAR.xml:S2:1347:9	O
,	TAFINLAR.xml:S2:1356:1	O
then	TAFINLAR.xml:S2:1358:4	O
every	TAFINLAR.xml:S2:1363:5	O
2	TAFINLAR.xml:S2:1369:1	O
to	TAFINLAR.xml:S2:1371:2	O
3	TAFINLAR.xml:S2:1374:1	O
months	TAFINLAR.xml:S2:1376:6	O
thereafter	TAFINLAR.xml:S2:1383:10	O
.	TAFINLAR.xml:S2:1393:1	O

(	TAFINLAR.xml:S2:1395:1	O
5.5	TAFINLAR.xml:S2:1398:3	O
,	TAFINLAR.xml:S2:1403:1	O
2.3	TAFINLAR.xml:S2:1406:3	O
)	TAFINLAR.xml:S2:1411:1	O

Ocular	TAFINLAR.xml:S2:1420:6	B-AdverseReaction
Toxicities	TAFINLAR.xml:S2:1427:10	I-AdverseReaction
:	TAFINLAR.xml:S2:1437:1	O
Perform	TAFINLAR.xml:S2:1439:7	O
ophthalmologic	TAFINLAR.xml:S2:1447:14	O
evaluation	TAFINLAR.xml:S2:1462:10	O
for	TAFINLAR.xml:S2:1473:3	O
any	TAFINLAR.xml:S2:1477:3	O
visual	TAFINLAR.xml:S2:1481:6	O
disturbances	TAFINLAR.xml:S2:1488:12	O
.	TAFINLAR.xml:S2:1500:1	O

(	TAFINLAR.xml:S2:1502:1	O
5.6	TAFINLAR.xml:S2:1505:3	O
,	TAFINLAR.xml:S2:1510:1	O
2.3	TAFINLAR.xml:S2:1513:3	O
)	TAFINLAR.xml:S2:1518:1	O

Serious	TAFINLAR.xml:S2:1527:7	B-Severity
Febrile	TAFINLAR.xml:S2:1535:7	B-AdverseReaction
Reactions	TAFINLAR.xml:S2:1543:9	I-AdverseReaction
:	TAFINLAR.xml:S2:1552:1	O
Incidence	TAFINLAR.xml:S2:1554:9	O
and	TAFINLAR.xml:S2:1564:3	O
severity	TAFINLAR.xml:S2:1568:8	O
of	TAFINLAR.xml:S2:1577:2	O
pyrexia	TAFINLAR.xml:S2:1580:7	B-AdverseReaction
are	TAFINLAR.xml:S2:1588:3	O
increased	TAFINLAR.xml:S2:1592:9	O
with	TAFINLAR.xml:S2:1602:4	O
TAFINLAR	TAFINLAR.xml:S2:1607:8	O
in	TAFINLAR.xml:S2:1616:2	O
combination	TAFINLAR.xml:S2:1619:11	O
with	TAFINLAR.xml:S2:1631:4	O
trametinib	TAFINLAR.xml:S2:1636:10	O
.	TAFINLAR.xml:S2:1646:1	O

(	TAFINLAR.xml:S2:1648:1	O
5.7	TAFINLAR.xml:S2:1651:3	O
,	TAFINLAR.xml:S2:1656:1	O
2.3	TAFINLAR.xml:S2:1659:3	O
)	TAFINLAR.xml:S2:1664:1	O

Serious	TAFINLAR.xml:S2:1673:7	B-Severity
Skin	TAFINLAR.xml:S2:1681:4	B-AdverseReaction
Toxicity	TAFINLAR.xml:S2:1686:8	I-AdverseReaction
:	TAFINLAR.xml:S2:1694:1	O
Monitor	TAFINLAR.xml:S2:1696:7	O
for	TAFINLAR.xml:S2:1704:3	O
skin	TAFINLAR.xml:S2:1708:4	O
toxicities	TAFINLAR.xml:S2:1713:10	O
and	TAFINLAR.xml:S2:1724:3	O
for	TAFINLAR.xml:S2:1728:3	O
secondary	TAFINLAR.xml:S2:1732:9	O
infections	TAFINLAR.xml:S2:1742:10	O
.	TAFINLAR.xml:S2:1752:1	O

Discontinue	TAFINLAR.xml:S2:1754:11	O
for	TAFINLAR.xml:S2:1766:3	O
intolerable	TAFINLAR.xml:S2:1770:11	O
Grade	TAFINLAR.xml:S2:1782:5	O
2	TAFINLAR.xml:S2:1788:1	O
,	TAFINLAR.xml:S2:1789:1	O
or	TAFINLAR.xml:S2:1791:2	O
Grade	TAFINLAR.xml:S2:1794:5	O
3	TAFINLAR.xml:S2:1800:1	O
or	TAFINLAR.xml:S2:1802:2	O
4	TAFINLAR.xml:S2:1805:1	O
rash	TAFINLAR.xml:S2:1807:4	O
not	TAFINLAR.xml:S2:1812:3	O
improving	TAFINLAR.xml:S2:1816:9	O
within	TAFINLAR.xml:S2:1826:6	O
3	TAFINLAR.xml:S2:1833:1	O
weeks	TAFINLAR.xml:S2:1835:5	O
despite	TAFINLAR.xml:S2:1841:7	O
interruption	TAFINLAR.xml:S2:1849:12	O
of	TAFINLAR.xml:S2:1862:2	O
TAFINLAR	TAFINLAR.xml:S2:1865:8	O
.	TAFINLAR.xml:S2:1873:1	O

(	TAFINLAR.xml:S2:1875:1	O
5.8	TAFINLAR.xml:S2:1878:3	O
,	TAFINLAR.xml:S2:1883:1	O
2.3	TAFINLAR.xml:S2:1886:3	O
)	TAFINLAR.xml:S2:1891:1	O

Hyperglycemia	TAFINLAR.xml:S2:1900:13	B-AdverseReaction
:	TAFINLAR.xml:S2:1913:1	O
Monitor	TAFINLAR.xml:S2:1915:7	O
serum	TAFINLAR.xml:S2:1923:5	O
glucose	TAFINLAR.xml:S2:1929:7	O
levels	TAFINLAR.xml:S2:1937:6	O
in	TAFINLAR.xml:S2:1944:2	O
patients	TAFINLAR.xml:S2:1947:8	O
with	TAFINLAR.xml:S2:1956:4	O
pre	TAFINLAR.xml:S2:1961:3	O
-	TAFINLAR.xml:S2:1964:1	O
existing	TAFINLAR.xml:S2:1965:8	O
diabetes	TAFINLAR.xml:S2:1974:8	O
or	TAFINLAR.xml:S2:1983:2	O
hyperglycemia	TAFINLAR.xml:S2:1986:13	O
.	TAFINLAR.xml:S2:1999:1	O

(	TAFINLAR.xml:S2:2001:1	O
5.9	TAFINLAR.xml:S2:2004:3	O
)	TAFINLAR.xml:S2:2009:1	O

Glucose	TAFINLAR.xml:S2:2018:7	B-AdverseReaction
-	TAFINLAR.xml:S2:2025:1	I-AdverseReaction
6	TAFINLAR.xml:S2:2026:1	I-AdverseReaction
-	TAFINLAR.xml:S2:2027:1	I-AdverseReaction
Phosphate	TAFINLAR.xml:S2:2028:9	I-AdverseReaction
Dehydrogenase	TAFINLAR.xml:S2:2038:13	I-AdverseReaction
Deficiency	TAFINLAR.xml:S2:2052:10	I-AdverseReaction
:	TAFINLAR.xml:S2:2062:1	O
Closely	TAFINLAR.xml:S2:2064:7	O
monitor	TAFINLAR.xml:S2:2072:7	O
for	TAFINLAR.xml:S2:2080:3	O
hemolytic	TAFINLAR.xml:S2:2084:9	O
anemia	TAFINLAR.xml:S2:2094:6	O
.	TAFINLAR.xml:S2:2100:1	O

(	TAFINLAR.xml:S2:2102:1	O
5.10	TAFINLAR.xml:S2:2105:4	O
)	TAFINLAR.xml:S2:2111:1	O

Embryofetal	TAFINLAR.xml:S2:2120:11	B-AdverseReaction
Toxicity	TAFINLAR.xml:S2:2132:8	I-AdverseReaction
:	TAFINLAR.xml:S2:2140:1	O
Can	TAFINLAR.xml:S2:2142:3	B-Factor
cause	TAFINLAR.xml:S2:2146:5	O
fetal	TAFINLAR.xml:S2:2152:5	B-AdverseReaction
harm	TAFINLAR.xml:S2:2158:4	I-AdverseReaction
.	TAFINLAR.xml:S2:2162:1	O

Advise	TAFINLAR.xml:S2:2164:6	O
females	TAFINLAR.xml:S2:2171:7	O
of	TAFINLAR.xml:S2:2179:2	O
reproductive	TAFINLAR.xml:S2:2182:12	O
potential	TAFINLAR.xml:S2:2195:9	O
of	TAFINLAR.xml:S2:2205:2	O
potential	TAFINLAR.xml:S2:2208:9	O
risk	TAFINLAR.xml:S2:2218:4	O
to	TAFINLAR.xml:S2:2223:2	O
a	TAFINLAR.xml:S2:2226:1	O
fetus	TAFINLAR.xml:S2:2228:5	O
.	TAFINLAR.xml:S2:2233:1	O

TAFINLAR	TAFINLAR.xml:S2:2235:8	O
may	TAFINLAR.xml:S2:2244:3	O
render	TAFINLAR.xml:S2:2248:6	O
hormonal	TAFINLAR.xml:S2:2255:8	O
contraceptives	TAFINLAR.xml:S2:2264:14	O
less	TAFINLAR.xml:S2:2279:4	O
effective	TAFINLAR.xml:S2:2284:9	O
and	TAFINLAR.xml:S2:2294:3	O
an	TAFINLAR.xml:S2:2298:2	O
alternative	TAFINLAR.xml:S2:2301:11	O
method	TAFINLAR.xml:S2:2313:6	O
of	TAFINLAR.xml:S2:2320:2	O
contraception	TAFINLAR.xml:S2:2323:13	O
should	TAFINLAR.xml:S2:2337:6	O
be	TAFINLAR.xml:S2:2344:2	O
used	TAFINLAR.xml:S2:2347:4	O
.	TAFINLAR.xml:S2:2351:1	O

(	TAFINLAR.xml:S2:2353:1	O
5.11	TAFINLAR.xml:S2:2356:4	O
,	TAFINLAR.xml:S2:2362:1	O
8.1	TAFINLAR.xml:S2:2365:3	O
)	TAFINLAR.xml:S2:2370:1	O

EXCERPT	TAFINLAR.xml:S2:2379:7	O
:	TAFINLAR.xml:S2:2386:1	O

5.1	TAFINLAR.xml:S2:2397:3	O

New	TAFINLAR.xml:S2:2401:3	O
Primary	TAFINLAR.xml:S2:2405:7	O
Malignancies	TAFINLAR.xml:S2:2413:12	O

New	TAFINLAR.xml:S2:2431:3	O
primary	TAFINLAR.xml:S2:2435:7	B-AdverseReaction
malignancies	TAFINLAR.xml:S2:2443:12	I-AdverseReaction
,	TAFINLAR.xml:S2:2455:1	I-AdverseReaction
cutaneous	TAFINLAR.xml:S2:2457:9	I-AdverseReaction
and	TAFINLAR.xml:S2:2467:3	O
non	TAFINLAR.xml:S2:2471:3	I-AdverseReaction
-	TAFINLAR.xml:S2:2474:1	I-AdverseReaction
cutaneous	TAFINLAR.xml:S2:2475:9	I-AdverseReaction
,	TAFINLAR.xml:S2:2484:1	O
can	TAFINLAR.xml:S2:2486:3	B-Factor
occur	TAFINLAR.xml:S2:2490:5	O
when	TAFINLAR.xml:S2:2496:4	O
TAFINLAR	TAFINLAR.xml:S2:2501:8	O
is	TAFINLAR.xml:S2:2510:2	O
administered	TAFINLAR.xml:S2:2513:12	O
as	TAFINLAR.xml:S2:2526:2	O
a	TAFINLAR.xml:S2:2529:1	O
single	TAFINLAR.xml:S2:2531:6	O
agent	TAFINLAR.xml:S2:2538:5	O
or	TAFINLAR.xml:S2:2544:2	O
when	TAFINLAR.xml:S2:2547:4	O
used	TAFINLAR.xml:S2:2552:4	O
in	TAFINLAR.xml:S2:2557:2	O
combination	TAFINLAR.xml:S2:2560:11	O
with	TAFINLAR.xml:S2:2572:4	O
trametinib	TAFINLAR.xml:S2:2577:10	O
.	TAFINLAR.xml:S2:2587:1	O

Cutaneous	TAFINLAR.xml:S2:2594:9	O
Malignancies	TAFINLAR.xml:S2:2604:12	O
:	TAFINLAR.xml:S2:2616:1	O

TAFINLAR	TAFINLAR.xml:S2:2624:8	O
results	TAFINLAR.xml:S2:2633:7	O
in	TAFINLAR.xml:S2:2641:2	O
an	TAFINLAR.xml:S2:2644:2	O
increased	TAFINLAR.xml:S2:2647:9	O
incidence	TAFINLAR.xml:S2:2657:9	O
of	TAFINLAR.xml:S2:2667:2	O
cutaneous	TAFINLAR.xml:S2:2670:9	B-AdverseReaction
squamous	TAFINLAR.xml:S2:2680:8	I-AdverseReaction
cell	TAFINLAR.xml:S2:2689:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:2694:9	I-AdverseReaction
,	TAFINLAR.xml:S2:2703:1	O
keratoacanthoma	TAFINLAR.xml:S2:2705:15	B-AdverseReaction
,	TAFINLAR.xml:S2:2720:1	O
and	TAFINLAR.xml:S2:2722:3	O
melanoma	TAFINLAR.xml:S2:2726:8	B-AdverseReaction
.	TAFINLAR.xml:S2:2734:1	O

TAFINLAR	TAFINLAR.xml:S2:2736:8	O
when	TAFINLAR.xml:S2:2745:4	O
used	TAFINLAR.xml:S2:2750:4	O
in	TAFINLAR.xml:S2:2755:2	O
combination	TAFINLAR.xml:S2:2758:11	O
with	TAFINLAR.xml:S2:2770:4	O
trametinib	TAFINLAR.xml:S2:2775:10	O
results	TAFINLAR.xml:S2:2786:7	O
in	TAFINLAR.xml:S2:2794:2	O
an	TAFINLAR.xml:S2:2797:2	O
increased	TAFINLAR.xml:S2:2800:9	O
incidence	TAFINLAR.xml:S2:2810:9	O
of	TAFINLAR.xml:S2:2820:2	O
basal	TAFINLAR.xml:S2:2823:5	B-AdverseReaction
cell	TAFINLAR.xml:S2:2829:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:2834:9	I-AdverseReaction
.	TAFINLAR.xml:S2:2843:1	O

In	TAFINLAR.xml:S2:2851:2	O
Trial	TAFINLAR.xml:S2:2854:5	O
1	TAFINLAR.xml:S2:2860:1	O
,	TAFINLAR.xml:S2:2861:1	O
cutaneous	TAFINLAR.xml:S2:2863:9	B-AdverseReaction
squamous	TAFINLAR.xml:S2:2873:8	I-AdverseReaction
cell	TAFINLAR.xml:S2:2882:4	I-AdverseReaction
carcinomas	TAFINLAR.xml:S2:2887:10	I-AdverseReaction
and	TAFINLAR.xml:S2:2898:3	O
keratoacanthomas	TAFINLAR.xml:S2:2902:16	B-AdverseReaction
(	TAFINLAR.xml:S2:2919:1	O
cuSCC	TAFINLAR.xml:S2:2920:5	B-AdverseReaction
)	TAFINLAR.xml:S2:2925:1	O
occurred	TAFINLAR.xml:S2:2927:8	O
in	TAFINLAR.xml:S2:2936:2	O
7%	TAFINLAR.xml:S2:2939:2	O
(	TAFINLAR.xml:S2:2942:1	O
14	TAFINLAR.xml:S2:2943:2	O
187	TAFINLAR.xml:S2:2946:3	O
)	TAFINLAR.xml:S2:2949:1	O
of	TAFINLAR.xml:S2:2951:2	O
patients	TAFINLAR.xml:S2:2954:8	O
treated	TAFINLAR.xml:S2:2963:7	O
with	TAFINLAR.xml:S2:2971:4	O
TAFINLAR	TAFINLAR.xml:S2:2976:8	O
and	TAFINLAR.xml:S2:2985:3	O
in	TAFINLAR.xml:S2:2989:2	O
none	TAFINLAR.xml:S2:2992:4	O
of	TAFINLAR.xml:S2:2997:2	O
the	TAFINLAR.xml:S2:3000:3	O
patients	TAFINLAR.xml:S2:3004:8	O
treated	TAFINLAR.xml:S2:3013:7	O
with	TAFINLAR.xml:S2:3021:4	O
dacarbazine	TAFINLAR.xml:S2:3026:11	O
.	TAFINLAR.xml:S2:3037:1	O

Across	TAFINLAR.xml:S2:3043:6	O
clinical	TAFINLAR.xml:S2:3050:8	O
trials	TAFINLAR.xml:S2:3059:6	O
of	TAFINLAR.xml:S2:3066:2	O
TAFINLAR	TAFINLAR.xml:S2:3069:8	O
(	TAFINLAR.xml:S2:3078:1	O
N	TAFINLAR.xml:S2:3079:1	O
586	TAFINLAR.xml:S2:3083:3	O
)	TAFINLAR.xml:S2:3086:1	O
,	TAFINLAR.xml:S2:3087:1	O
the	TAFINLAR.xml:S2:3089:3	O
incidence	TAFINLAR.xml:S2:3093:9	O
of	TAFINLAR.xml:S2:3103:2	O
cuSCC	TAFINLAR.xml:S2:3106:5	B-AdverseReaction
was	TAFINLAR.xml:S2:3112:3	O
11%	TAFINLAR.xml:S2:3116:3	O
.	TAFINLAR.xml:S2:3119:1	O

The	TAFINLAR.xml:S2:3121:3	O
median	TAFINLAR.xml:S2:3125:6	O
time	TAFINLAR.xml:S2:3132:4	O
to	TAFINLAR.xml:S2:3137:2	O
first	TAFINLAR.xml:S2:3140:5	O
cuSCC	TAFINLAR.xml:S2:3146:5	B-AdverseReaction
was	TAFINLAR.xml:S2:3152:3	O
9	TAFINLAR.xml:S2:3156:1	O
weeks	TAFINLAR.xml:S2:3158:5	O
(	TAFINLAR.xml:S2:3164:1	O
range	TAFINLAR.xml:S2:3165:5	O
:	TAFINLAR.xml:S2:3170:1	O
1	TAFINLAR.xml:S2:3172:1	O
to	TAFINLAR.xml:S2:3174:2	O
53	TAFINLAR.xml:S2:3177:2	O
weeks	TAFINLAR.xml:S2:3180:5	O
)	TAFINLAR.xml:S2:3185:1	O
.	TAFINLAR.xml:S2:3186:1	O

Of	TAFINLAR.xml:S2:3188:2	O
those	TAFINLAR.xml:S2:3191:5	O
patients	TAFINLAR.xml:S2:3197:8	O
who	TAFINLAR.xml:S2:3206:3	O
developed	TAFINLAR.xml:S2:3210:9	O
new	TAFINLAR.xml:S2:3220:3	O
cuSCC	TAFINLAR.xml:S2:3224:5	B-AdverseReaction
,	TAFINLAR.xml:S2:3229:1	O
approximately	TAFINLAR.xml:S2:3231:13	O
33%	TAFINLAR.xml:S2:3245:3	O
developed	TAFINLAR.xml:S2:3249:9	O
one	TAFINLAR.xml:S2:3259:3	O
or	TAFINLAR.xml:S2:3263:2	O
more	TAFINLAR.xml:S2:3266:4	O
cuSCC	TAFINLAR.xml:S2:3271:5	B-AdverseReaction
with	TAFINLAR.xml:S2:3277:4	O
continued	TAFINLAR.xml:S2:3282:9	O
administration	TAFINLAR.xml:S2:3292:14	O
of	TAFINLAR.xml:S2:3307:2	O
TAFINLAR	TAFINLAR.xml:S2:3310:8	O
.	TAFINLAR.xml:S2:3318:1	O

The	TAFINLAR.xml:S2:3320:3	O
median	TAFINLAR.xml:S2:3324:6	O
time	TAFINLAR.xml:S2:3331:4	O
between	TAFINLAR.xml:S2:3336:7	O
diagnosis	TAFINLAR.xml:S2:3344:9	O
of	TAFINLAR.xml:S2:3354:2	O
the	TAFINLAR.xml:S2:3357:3	O
first	TAFINLAR.xml:S2:3361:5	O
cuSCC	TAFINLAR.xml:S2:3367:5	B-AdverseReaction
and	TAFINLAR.xml:S2:3373:3	O
the	TAFINLAR.xml:S2:3377:3	O
second	TAFINLAR.xml:S2:3381:6	O
cuSCC	TAFINLAR.xml:S2:3388:5	B-AdverseReaction
was	TAFINLAR.xml:S2:3394:3	O
6	TAFINLAR.xml:S2:3398:1	O
weeks	TAFINLAR.xml:S2:3400:5	O
.	TAFINLAR.xml:S2:3405:1	O

In	TAFINLAR.xml:S2:3411:2	O
Trial	TAFINLAR.xml:S2:3414:5	O
1	TAFINLAR.xml:S2:3420:1	O
,	TAFINLAR.xml:S2:3421:1	O
the	TAFINLAR.xml:S2:3423:3	O
incidence	TAFINLAR.xml:S2:3427:9	O
of	TAFINLAR.xml:S2:3437:2	O
new	TAFINLAR.xml:S2:3440:3	O
primary	TAFINLAR.xml:S2:3444:7	B-AdverseReaction
malignant	TAFINLAR.xml:S2:3452:9	I-AdverseReaction
melanomas	TAFINLAR.xml:S2:3462:9	I-AdverseReaction
was	TAFINLAR.xml:S2:3472:3	O
2%	TAFINLAR.xml:S2:3476:2	O
(	TAFINLAR.xml:S2:3479:1	O
3	TAFINLAR.xml:S2:3480:1	O
187	TAFINLAR.xml:S2:3482:3	O
)	TAFINLAR.xml:S2:3485:1	O
for	TAFINLAR.xml:S2:3487:3	O
patients	TAFINLAR.xml:S2:3491:8	O
receiving	TAFINLAR.xml:S2:3500:9	O
TAFINLAR	TAFINLAR.xml:S2:3510:8	O
while	TAFINLAR.xml:S2:3519:5	O
no	TAFINLAR.xml:S2:3525:2	O
dacarbazine	TAFINLAR.xml:S2:3528:11	O
-	TAFINLAR.xml:S2:3539:1	O
treated	TAFINLAR.xml:S2:3540:7	O
patient	TAFINLAR.xml:S2:3548:7	O
was	TAFINLAR.xml:S2:3556:3	O
diagnosed	TAFINLAR.xml:S2:3560:9	O
with	TAFINLAR.xml:S2:3570:4	O
new	TAFINLAR.xml:S2:3575:3	O
primary	TAFINLAR.xml:S2:3579:7	O
malignant	TAFINLAR.xml:S2:3587:9	O
melanoma	TAFINLAR.xml:S2:3597:8	O
.	TAFINLAR.xml:S2:3605:1	O

In	TAFINLAR.xml:S2:3612:2	O
Trial	TAFINLAR.xml:S2:3615:5	O
2	TAFINLAR.xml:S2:3621:1	O
,	TAFINLAR.xml:S2:3622:1	O
the	TAFINLAR.xml:S2:3624:3	O
incidence	TAFINLAR.xml:S2:3628:9	O
of	TAFINLAR.xml:S2:3638:2	O
basal	TAFINLAR.xml:S2:3641:5	B-AdverseReaction
cell	TAFINLAR.xml:S2:3647:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:3652:9	I-AdverseReaction
was	TAFINLAR.xml:S2:3662:3	O
increased	TAFINLAR.xml:S2:3666:9	O
in	TAFINLAR.xml:S2:3676:2	O
patients	TAFINLAR.xml:S2:3679:8	O
receiving	TAFINLAR.xml:S2:3688:9	O
TAFINLAR	TAFINLAR.xml:S2:3698:8	O
in	TAFINLAR.xml:S2:3707:2	O
combination	TAFINLAR.xml:S2:3710:11	O
with	TAFINLAR.xml:S2:3722:4	O
trametinib	TAFINLAR.xml:S2:3727:10	O
:	TAFINLAR.xml:S2:3737:1	O
9%	TAFINLAR.xml:S2:3739:2	O
(	TAFINLAR.xml:S2:3742:1	O
5	TAFINLAR.xml:S2:3743:1	O
55	TAFINLAR.xml:S2:3745:2	O
)	TAFINLAR.xml:S2:3747:1	O
of	TAFINLAR.xml:S2:3749:2	O
patients	TAFINLAR.xml:S2:3752:8	O
receiving	TAFINLAR.xml:S2:3761:9	O
TAFINLAR	TAFINLAR.xml:S2:3771:8	O
in	TAFINLAR.xml:S2:3780:2	O
combination	TAFINLAR.xml:S2:3783:11	O
with	TAFINLAR.xml:S2:3795:4	O
trametinib	TAFINLAR.xml:S2:3800:10	O
compared	TAFINLAR.xml:S2:3811:8	O
with	TAFINLAR.xml:S2:3820:4	O
2%	TAFINLAR.xml:S2:3825:2	O
(	TAFINLAR.xml:S2:3828:1	O
1	TAFINLAR.xml:S2:3829:1	O
53	TAFINLAR.xml:S2:3831:2	O
)	TAFINLAR.xml:S2:3833:1	O
of	TAFINLAR.xml:S2:3835:2	O
patients	TAFINLAR.xml:S2:3838:8	O
receiving	TAFINLAR.xml:S2:3847:9	O
TAFINLAR	TAFINLAR.xml:S2:3857:8	O
as	TAFINLAR.xml:S2:3866:2	O
a	TAFINLAR.xml:S2:3869:1	O
single	TAFINLAR.xml:S2:3871:6	O
agent	TAFINLAR.xml:S2:3878:5	O
.	TAFINLAR.xml:S2:3883:1	O

The	TAFINLAR.xml:S2:3885:3	O
range	TAFINLAR.xml:S2:3889:5	O
of	TAFINLAR.xml:S2:3895:2	O
time	TAFINLAR.xml:S2:3898:4	O
to	TAFINLAR.xml:S2:3903:2	O
diagnosis	TAFINLAR.xml:S2:3906:9	O
of	TAFINLAR.xml:S2:3916:2	O
basal	TAFINLAR.xml:S2:3919:5	B-AdverseReaction
cell	TAFINLAR.xml:S2:3925:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:3930:9	I-AdverseReaction
was	TAFINLAR.xml:S2:3940:3	O
28	TAFINLAR.xml:S2:3944:2	O
to	TAFINLAR.xml:S2:3947:2	O
249	TAFINLAR.xml:S2:3950:3	O
days	TAFINLAR.xml:S2:3954:4	O
in	TAFINLAR.xml:S2:3959:2	O
patients	TAFINLAR.xml:S2:3962:8	O
receiving	TAFINLAR.xml:S2:3971:9	O
TAFINLAR	TAFINLAR.xml:S2:3981:8	O
in	TAFINLAR.xml:S2:3990:2	O
combination	TAFINLAR.xml:S2:3993:11	O
with	TAFINLAR.xml:S2:4005:4	O
trametinib	TAFINLAR.xml:S2:4010:10	O
and	TAFINLAR.xml:S2:4021:3	O
was	TAFINLAR.xml:S2:4025:3	O
197	TAFINLAR.xml:S2:4029:3	O
days	TAFINLAR.xml:S2:4033:4	O
for	TAFINLAR.xml:S2:4038:3	O
the	TAFINLAR.xml:S2:4042:3	O
patient	TAFINLAR.xml:S2:4046:7	O
receiving	TAFINLAR.xml:S2:4054:9	O
TAFINLAR	TAFINLAR.xml:S2:4064:8	O
as	TAFINLAR.xml:S2:4073:2	O
a	TAFINLAR.xml:S2:4076:1	O
single	TAFINLAR.xml:S2:4078:6	O
agent	TAFINLAR.xml:S2:4085:5	O
.	TAFINLAR.xml:S2:4090:1	O

Cutaneous	TAFINLAR.xml:S2:4099:9	B-AdverseReaction
squamous	TAFINLAR.xml:S2:4109:8	I-AdverseReaction
cell	TAFINLAR.xml:S2:4118:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:4123:9	I-AdverseReaction
(	TAFINLAR.xml:S2:4133:1	O
SCC	TAFINLAR.xml:S2:4134:3	B-AdverseReaction
)	TAFINLAR.xml:S2:4137:1	O
,	TAFINLAR.xml:S2:4138:1	O
including	TAFINLAR.xml:S2:4140:9	O
keratoacanthoma	TAFINLAR.xml:S2:4150:15	B-AdverseReaction
,	TAFINLAR.xml:S2:4165:1	O
occurred	TAFINLAR.xml:S2:4167:8	O
in	TAFINLAR.xml:S2:4176:2	O
7%	TAFINLAR.xml:S2:4179:2	O
of	TAFINLAR.xml:S2:4182:2	O
patients	TAFINLAR.xml:S2:4185:8	O
receiving	TAFINLAR.xml:S2:4194:9	O
TAFINLAR	TAFINLAR.xml:S2:4204:8	O
in	TAFINLAR.xml:S2:4213:2	O
combination	TAFINLAR.xml:S2:4216:11	O
with	TAFINLAR.xml:S2:4228:4	O
trametinib	TAFINLAR.xml:S2:4233:10	O
and	TAFINLAR.xml:S2:4244:3	O
19%	TAFINLAR.xml:S2:4248:3	O
of	TAFINLAR.xml:S2:4252:2	O
patients	TAFINLAR.xml:S2:4255:8	O
receiving	TAFINLAR.xml:S2:4264:9	O
TAFINLAR	TAFINLAR.xml:S2:4274:8	O
as	TAFINLAR.xml:S2:4283:2	O
a	TAFINLAR.xml:S2:4286:1	O
single	TAFINLAR.xml:S2:4288:6	O
agent	TAFINLAR.xml:S2:4295:5	O
.	TAFINLAR.xml:S2:4300:1	O

The	TAFINLAR.xml:S2:4302:3	O
range	TAFINLAR.xml:S2:4306:5	O
of	TAFINLAR.xml:S2:4312:2	O
time	TAFINLAR.xml:S2:4315:4	O
to	TAFINLAR.xml:S2:4320:2	O
diagnosis	TAFINLAR.xml:S2:4323:9	O
of	TAFINLAR.xml:S2:4333:2	O
cuSCC	TAFINLAR.xml:S2:4336:5	B-AdverseReaction
was	TAFINLAR.xml:S2:4342:3	O
136	TAFINLAR.xml:S2:4346:3	O
to197	TAFINLAR.xml:S2:4350:5	O
days	TAFINLAR.xml:S2:4356:4	O
in	TAFINLAR.xml:S2:4361:2	O
the	TAFINLAR.xml:S2:4364:3	O
combination	TAFINLAR.xml:S2:4368:11	O
arm	TAFINLAR.xml:S2:4380:3	O
and	TAFINLAR.xml:S2:4384:3	O
was	TAFINLAR.xml:S2:4388:3	O
9	TAFINLAR.xml:S2:4392:1	O
to	TAFINLAR.xml:S2:4394:2	O
197	TAFINLAR.xml:S2:4397:3	O
days	TAFINLAR.xml:S2:4401:4	O
in	TAFINLAR.xml:S2:4406:2	O
the	TAFINLAR.xml:S2:4409:3	O
arm	TAFINLAR.xml:S2:4413:3	O
receiving	TAFINLAR.xml:S2:4417:9	O
TAFINLAR	TAFINLAR.xml:S2:4427:8	O
as	TAFINLAR.xml:S2:4436:2	O
a	TAFINLAR.xml:S2:4439:1	O
single	TAFINLAR.xml:S2:4441:6	O
agent	TAFINLAR.xml:S2:4448:5	O
.	TAFINLAR.xml:S2:4453:1	O

New	TAFINLAR.xml:S2:4462:3	O
primary	TAFINLAR.xml:S2:4466:7	B-AdverseReaction
melanoma	TAFINLAR.xml:S2:4474:8	I-AdverseReaction
occurred	TAFINLAR.xml:S2:4483:8	O
in	TAFINLAR.xml:S2:4492:2	O
2%	TAFINLAR.xml:S2:4495:2	O
(	TAFINLAR.xml:S2:4498:1	O
1	TAFINLAR.xml:S2:4499:1	O
53	TAFINLAR.xml:S2:4501:2	O
)	TAFINLAR.xml:S2:4503:1	O
of	TAFINLAR.xml:S2:4505:2	O
patients	TAFINLAR.xml:S2:4508:8	O
receiving	TAFINLAR.xml:S2:4517:9	O
TAFINLAR	TAFINLAR.xml:S2:4527:8	O
as	TAFINLAR.xml:S2:4536:2	O
a	TAFINLAR.xml:S2:4539:1	O
single	TAFINLAR.xml:S2:4541:6	O
agent	TAFINLAR.xml:S2:4548:5	O
and	TAFINLAR.xml:S2:4554:3	O
in	TAFINLAR.xml:S2:4558:2	O
none	TAFINLAR.xml:S2:4561:4	O
of	TAFINLAR.xml:S2:4566:2	O
the	TAFINLAR.xml:S2:4569:3	O
55	TAFINLAR.xml:S2:4573:2	O
patients	TAFINLAR.xml:S2:4576:8	O
receiving	TAFINLAR.xml:S2:4585:9	O
TAFINLAR	TAFINLAR.xml:S2:4595:8	O
in	TAFINLAR.xml:S2:4604:2	O
combination	TAFINLAR.xml:S2:4607:11	O
with	TAFINLAR.xml:S2:4619:4	O
trametinib	TAFINLAR.xml:S2:4624:10	O
.	TAFINLAR.xml:S2:4634:1	O

Perform	TAFINLAR.xml:S2:4643:7	O
dermatologic	TAFINLAR.xml:S2:4651:12	O
evaluations	TAFINLAR.xml:S2:4664:11	O
prior	TAFINLAR.xml:S2:4676:5	O
to	TAFINLAR.xml:S2:4682:2	O
initiation	TAFINLAR.xml:S2:4685:10	O
of	TAFINLAR.xml:S2:4696:2	O
TAFINLAR	TAFINLAR.xml:S2:4699:8	O
as	TAFINLAR.xml:S2:4708:2	O
a	TAFINLAR.xml:S2:4711:1	O
single	TAFINLAR.xml:S2:4713:6	O
agent	TAFINLAR.xml:S2:4720:5	O
or	TAFINLAR.xml:S2:4726:2	O
in	TAFINLAR.xml:S2:4729:2	O
combination	TAFINLAR.xml:S2:4732:11	O
with	TAFINLAR.xml:S2:4744:4	O
trametinib	TAFINLAR.xml:S2:4749:10	O
,	TAFINLAR.xml:S2:4759:1	O
every	TAFINLAR.xml:S2:4761:5	O
2	TAFINLAR.xml:S2:4767:1	O
months	TAFINLAR.xml:S2:4769:6	O
while	TAFINLAR.xml:S2:4776:5	O
on	TAFINLAR.xml:S2:4782:2	O
therapy	TAFINLAR.xml:S2:4785:7	O
,	TAFINLAR.xml:S2:4792:1	O
and	TAFINLAR.xml:S2:4794:3	O
for	TAFINLAR.xml:S2:4798:3	O
up	TAFINLAR.xml:S2:4802:2	O
to	TAFINLAR.xml:S2:4805:2	O
6	TAFINLAR.xml:S2:4808:1	O
months	TAFINLAR.xml:S2:4810:6	O
following	TAFINLAR.xml:S2:4817:9	O
discontinuation	TAFINLAR.xml:S2:4827:15	O
of	TAFINLAR.xml:S2:4843:2	O
TAFINLAR	TAFINLAR.xml:S2:4846:8	O
.	TAFINLAR.xml:S2:4854:1	O

No	TAFINLAR.xml:S2:4856:2	O
dose	TAFINLAR.xml:S2:4859:4	O
modifications	TAFINLAR.xml:S2:4864:13	O
of	TAFINLAR.xml:S2:4878:2	O
TAFINLAR	TAFINLAR.xml:S2:4881:8	O
or	TAFINLAR.xml:S2:4890:2	O
trametinib	TAFINLAR.xml:S2:4893:10	O
are	TAFINLAR.xml:S2:4904:3	O
required	TAFINLAR.xml:S2:4908:8	O
in	TAFINLAR.xml:S2:4917:2	O
patients	TAFINLAR.xml:S2:4920:8	O
who	TAFINLAR.xml:S2:4929:3	O
develop	TAFINLAR.xml:S2:4933:7	O
new	TAFINLAR.xml:S2:4941:3	O
primary	TAFINLAR.xml:S2:4945:7	O
cutaneous	TAFINLAR.xml:S2:4953:9	O
malignancies	TAFINLAR.xml:S2:4963:12	O
.	TAFINLAR.xml:S2:4975:1	O

Non	TAFINLAR.xml:S2:4985:3	O
-	TAFINLAR.xml:S2:4988:1	O
cutaneous	TAFINLAR.xml:S2:4989:9	O
Malignancies	TAFINLAR.xml:S2:4999:12	O
:	TAFINLAR.xml:S2:5011:1	O

Based	TAFINLAR.xml:S2:5022:5	O
on	TAFINLAR.xml:S2:5028:2	O
its	TAFINLAR.xml:S2:5031:3	O
mechanism	TAFINLAR.xml:S2:5035:9	O
of	TAFINLAR.xml:S2:5045:2	O
action	TAFINLAR.xml:S2:5048:6	O
,	TAFINLAR.xml:S2:5054:1	O
TAFINLAR	TAFINLAR.xml:S2:5056:8	O
may	TAFINLAR.xml:S2:5065:3	B-Factor
promote	TAFINLAR.xml:S2:5069:7	O
the	TAFINLAR.xml:S2:5077:3	O
growth	TAFINLAR.xml:S2:5081:6	O
and	TAFINLAR.xml:S2:5088:3	O
development	TAFINLAR.xml:S2:5092:11	O
of	TAFINLAR.xml:S2:5104:2	O
malignancies	TAFINLAR.xml:S2:5107:12	B-AdverseReaction
with	TAFINLAR.xml:S2:5120:4	O
activation	TAFINLAR.xml:S2:5125:10	O
of	TAFINLAR.xml:S2:5136:2	O
RAS	TAFINLAR.xml:S2:5139:3	O
through	TAFINLAR.xml:S2:5143:7	O
mutation	TAFINLAR.xml:S2:5151:8	O
or	TAFINLAR.xml:S2:5160:2	O
other	TAFINLAR.xml:S2:5163:5	O
mechanisms	TAFINLAR.xml:S2:5169:10	O
[	TAFINLAR.xml:S2:5180:1	O
see	TAFINLAR.xml:S2:5181:3	O
Warnings	TAFINLAR.xml:S2:5185:8	O
and	TAFINLAR.xml:S2:5194:3	O
Precautions	TAFINLAR.xml:S2:5198:11	O
(	TAFINLAR.xml:S2:5210:1	O
5.2	TAFINLAR.xml:S2:5211:3	O
)]	TAFINLAR.xml:S2:5214:2	O
.	TAFINLAR.xml:S2:5218:1	O

In	TAFINLAR.xml:S2:5220:2	O
patients	TAFINLAR.xml:S2:5223:8	O
receiving	TAFINLAR.xml:S2:5232:9	O
TAFINLAR	TAFINLAR.xml:S2:5242:8	O
in	TAFINLAR.xml:S2:5251:2	O
combination	TAFINLAR.xml:S2:5254:11	O
with	TAFINLAR.xml:S2:5266:4	O
trametinib	TAFINLAR.xml:S2:5271:10	O
four	TAFINLAR.xml:S2:5282:4	O
cases	TAFINLAR.xml:S2:5287:5	O
of	TAFINLAR.xml:S2:5293:2	O
non	TAFINLAR.xml:S2:5296:3	B-AdverseReaction
-	TAFINLAR.xml:S2:5299:1	I-AdverseReaction
cutaneous	TAFINLAR.xml:S2:5300:9	I-AdverseReaction
malignancies	TAFINLAR.xml:S2:5310:12	I-AdverseReaction
were	TAFINLAR.xml:S2:5323:4	O
identified	TAFINLAR.xml:S2:5328:10	O
:	TAFINLAR.xml:S2:5338:1	O
KRAS	TAFINLAR.xml:S2:5340:4	B-AdverseReaction
mutation	TAFINLAR.xml:S2:5345:8	I-AdverseReaction
-	TAFINLAR.xml:S2:5353:1	I-AdverseReaction
positive	TAFINLAR.xml:S2:5354:8	I-AdverseReaction
pancreatic	TAFINLAR.xml:S2:5363:10	I-AdverseReaction
adenocarcinoma	TAFINLAR.xml:S2:5374:14	I-AdverseReaction
(	TAFINLAR.xml:S2:5389:1	O
n	TAFINLAR.xml:S2:5390:1	O
1	TAFINLAR.xml:S2:5394:1	O
)	TAFINLAR.xml:S2:5395:1	O
,	TAFINLAR.xml:S2:5396:1	O
recurrent	TAFINLAR.xml:S2:5398:9	B-AdverseReaction
NRAS	TAFINLAR.xml:S2:5408:4	I-AdverseReaction
mutation	TAFINLAR.xml:S2:5413:8	I-AdverseReaction
-	TAFINLAR.xml:S2:5421:1	I-AdverseReaction
positive	TAFINLAR.xml:S2:5422:8	I-AdverseReaction
colorectal	TAFINLAR.xml:S2:5431:10	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:5442:9	I-AdverseReaction
(	TAFINLAR.xml:S2:5452:1	O
n	TAFINLAR.xml:S2:5453:1	O
1	TAFINLAR.xml:S2:5457:1	O
)	TAFINLAR.xml:S2:5458:1	O
,	TAFINLAR.xml:S2:5459:1	O
head	TAFINLAR.xml:S2:5461:4	B-AdverseReaction
and	TAFINLAR.xml:S2:5466:3	I-AdverseReaction
neck	TAFINLAR.xml:S2:5470:4	I-AdverseReaction
carcinoma	TAFINLAR.xml:S2:5475:9	I-AdverseReaction
(	TAFINLAR.xml:S2:5485:1	O
n	TAFINLAR.xml:S2:5486:1	O
1	TAFINLAR.xml:S2:5490:1	O
)	TAFINLAR.xml:S2:5491:1	O
,	TAFINLAR.xml:S2:5492:1	O
and	TAFINLAR.xml:S2:5494:3	O
glioblastoma	TAFINLAR.xml:S2:5498:12	B-AdverseReaction
(	TAFINLAR.xml:S2:5511:1	O
n	TAFINLAR.xml:S2:5512:1	O
1	TAFINLAR.xml:S2:5516:1	O
)	TAFINLAR.xml:S2:5517:1	O
.	TAFINLAR.xml:S2:5518:1	O

Monitor	TAFINLAR.xml:S2:5520:7	O
patients	TAFINLAR.xml:S2:5528:8	O
receiving	TAFINLAR.xml:S2:5537:9	O
the	TAFINLAR.xml:S2:5547:3	O
combination	TAFINLAR.xml:S2:5551:11	O
closely	TAFINLAR.xml:S2:5563:7	O
for	TAFINLAR.xml:S2:5571:3	O
signs	TAFINLAR.xml:S2:5575:5	O
or	TAFINLAR.xml:S2:5581:2	O
symptoms	TAFINLAR.xml:S2:5584:8	O
of	TAFINLAR.xml:S2:5593:2	O
non	TAFINLAR.xml:S2:5596:3	O
-	TAFINLAR.xml:S2:5599:1	O
cutaneous	TAFINLAR.xml:S2:5600:9	O
malignancies	TAFINLAR.xml:S2:5610:12	O
.	TAFINLAR.xml:S2:5622:1	O

Permanently	TAFINLAR.xml:S2:5624:11	O
discontinue	TAFINLAR.xml:S2:5636:11	O
TAFINLAR	TAFINLAR.xml:S2:5648:8	O
for	TAFINLAR.xml:S2:5657:3	O
RAS	TAFINLAR.xml:S2:5661:3	O
mutation	TAFINLAR.xml:S2:5665:8	O
-	TAFINLAR.xml:S2:5673:1	O
positive	TAFINLAR.xml:S2:5674:8	O
non	TAFINLAR.xml:S2:5683:3	O
-	TAFINLAR.xml:S2:5686:1	O
cutaneous	TAFINLAR.xml:S2:5687:9	O
malignancies	TAFINLAR.xml:S2:5697:12	O
.	TAFINLAR.xml:S2:5709:1	O

If	TAFINLAR.xml:S2:5711:2	O
used	TAFINLAR.xml:S2:5714:4	O
in	TAFINLAR.xml:S2:5719:2	O
combination	TAFINLAR.xml:S2:5722:11	O
with	TAFINLAR.xml:S2:5734:4	O
trametinib	TAFINLAR.xml:S2:5739:10	O
,	TAFINLAR.xml:S2:5749:1	O
no	TAFINLAR.xml:S2:5751:2	O
dose	TAFINLAR.xml:S2:5754:4	O
modification	TAFINLAR.xml:S2:5759:12	O
of	TAFINLAR.xml:S2:5772:2	O
trametinib	TAFINLAR.xml:S2:5775:10	O
is	TAFINLAR.xml:S2:5786:2	O
required	TAFINLAR.xml:S2:5789:8	O
for	TAFINLAR.xml:S2:5798:3	O
patients	TAFINLAR.xml:S2:5802:8	O
who	TAFINLAR.xml:S2:5811:3	O
develop	TAFINLAR.xml:S2:5815:7	O
non	TAFINLAR.xml:S2:5823:3	O
-	TAFINLAR.xml:S2:5826:1	O
cutaneous	TAFINLAR.xml:S2:5827:9	O
malignancies	TAFINLAR.xml:S2:5837:12	O
.	TAFINLAR.xml:S2:5849:1	O

5.2	TAFINLAR.xml:S2:5860:3	O
Tumor	TAFINLAR.xml:S2:5864:5	O
Promotion	TAFINLAR.xml:S2:5870:9	O
in	TAFINLAR.xml:S2:5880:2	O
BRAF	TAFINLAR.xml:S2:5883:4	O
Wild	TAFINLAR.xml:S2:5888:4	O
-	TAFINLAR.xml:S2:5892:1	O
Type	TAFINLAR.xml:S2:5893:4	O
Melanoma	TAFINLAR.xml:S2:5898:8	O

In	TAFINLAR.xml:S2:5912:2	O
vitro	TAFINLAR.xml:S2:5915:5	O
experiments	TAFINLAR.xml:S2:5921:11	O
have	TAFINLAR.xml:S2:5933:4	O
demonstrated	TAFINLAR.xml:S2:5938:12	O
paradoxical	TAFINLAR.xml:S2:5951:11	O
activation	TAFINLAR.xml:S2:5963:10	O
of	TAFINLAR.xml:S2:5974:2	O
MAP	TAFINLAR.xml:S2:5977:3	O
-	TAFINLAR.xml:S2:5980:1	O
kinase	TAFINLAR.xml:S2:5981:6	O
signaling	TAFINLAR.xml:S2:5988:9	O
and	TAFINLAR.xml:S2:5998:3	O
increased	TAFINLAR.xml:S2:6002:9	B-AdverseReaction
cell	TAFINLAR.xml:S2:6012:4	I-AdverseReaction
proliferation	TAFINLAR.xml:S2:6017:13	I-AdverseReaction
in	TAFINLAR.xml:S2:6031:2	O
BRAF	TAFINLAR.xml:S2:6034:4	O
wild	TAFINLAR.xml:S2:6039:4	O
-	TAFINLAR.xml:S2:6043:1	O
type	TAFINLAR.xml:S2:6044:4	O
cells	TAFINLAR.xml:S2:6049:5	O
which	TAFINLAR.xml:S2:6055:5	O
are	TAFINLAR.xml:S2:6061:3	O
exposed	TAFINLAR.xml:S2:6065:7	O
to	TAFINLAR.xml:S2:6073:2	O
BRAF	TAFINLAR.xml:S2:6076:4	B-DrugClass
inhibitors	TAFINLAR.xml:S2:6081:10	I-DrugClass
.	TAFINLAR.xml:S2:6091:1	O

Confirm	TAFINLAR.xml:S2:6093:7	O
evidence	TAFINLAR.xml:S2:6101:8	O
of	TAFINLAR.xml:S2:6110:2	O
BRAF	TAFINLAR.xml:S2:6113:4	O
V600E	TAFINLAR.xml:S2:6118:5	O
or	TAFINLAR.xml:S2:6124:2	O
V600K	TAFINLAR.xml:S2:6127:5	O
mutation	TAFINLAR.xml:S2:6134:8	O
status	TAFINLAR.xml:S2:6143:6	O
prior	TAFINLAR.xml:S2:6150:5	O
to	TAFINLAR.xml:S2:6156:2	O
initiation	TAFINLAR.xml:S2:6159:10	O
of	TAFINLAR.xml:S2:6170:2	O
TAFINLAR	TAFINLAR.xml:S2:6173:8	O
as	TAFINLAR.xml:S2:6182:2	O
a	TAFINLAR.xml:S2:6186:1	O
single	TAFINLAR.xml:S2:6188:6	O
agent	TAFINLAR.xml:S2:6195:5	O
or	TAFINLAR.xml:S2:6201:2	O
combination	TAFINLAR.xml:S2:6204:11	O
therapy	TAFINLAR.xml:S2:6216:7	O
[	TAFINLAR.xml:S2:6226:1	O
see	TAFINLAR.xml:S2:6227:3	O
Indications	TAFINLAR.xml:S2:6231:11	O
and	TAFINLAR.xml:S2:6243:3	O
Usage	TAFINLAR.xml:S2:6247:5	O
(	TAFINLAR.xml:S2:6253:1	O
1	TAFINLAR.xml:S2:6254:1	O
)	TAFINLAR.xml:S2:6255:1	O
,	TAFINLAR.xml:S2:6256:1	O
Dosage	TAFINLAR.xml:S2:6258:6	O
and	TAFINLAR.xml:S2:6265:3	O
Administration	TAFINLAR.xml:S2:6269:14	O
(	TAFINLAR.xml:S2:6284:1	O
2.1	TAFINLAR.xml:S2:6285:3	O
)]	TAFINLAR.xml:S2:6288:2	O
.	TAFINLAR.xml:S2:6292:1	O

5.3	TAFINLAR.xml:S2:6302:3	O
Hemorrhage	TAFINLAR.xml:S2:6306:10	O

Hemorrhages	TAFINLAR.xml:S2:6325:11	B-AdverseReaction
,	TAFINLAR.xml:S2:6336:1	O
including	TAFINLAR.xml:S2:6338:9	O
major	TAFINLAR.xml:S2:6348:5	B-Severity
hemorrhages	TAFINLAR.xml:S2:6354:11	B-AdverseReaction
defined	TAFINLAR.xml:S2:6366:7	O
as	TAFINLAR.xml:S2:6374:2	O
symptomatic	TAFINLAR.xml:S2:6377:11	B-AdverseReaction
bleeding	TAFINLAR.xml:S2:6389:8	I-AdverseReaction
in	TAFINLAR.xml:S2:6398:2	O
a	TAFINLAR.xml:S2:6401:1	O
critical	TAFINLAR.xml:S2:6403:8	O
area	TAFINLAR.xml:S2:6412:4	O
or	TAFINLAR.xml:S2:6417:2	O
organ	TAFINLAR.xml:S2:6420:5	O
,	TAFINLAR.xml:S2:6425:1	O
can	TAFINLAR.xml:S2:6427:3	B-Factor
occur	TAFINLAR.xml:S2:6431:5	O
when	TAFINLAR.xml:S2:6437:4	O
TAFINLAR	TAFINLAR.xml:S2:6442:8	O
is	TAFINLAR.xml:S2:6451:2	O
used	TAFINLAR.xml:S2:6454:4	O
in	TAFINLAR.xml:S2:6459:2	O
combination	TAFINLAR.xml:S2:6462:11	O
with	TAFINLAR.xml:S2:6474:4	O
trametinib	TAFINLAR.xml:S2:6479:10	O
.	TAFINLAR.xml:S2:6489:1	O

In	TAFINLAR.xml:S2:6498:2	O
Trial	TAFINLAR.xml:S2:6501:5	O
2	TAFINLAR.xml:S2:6507:1	O
,	TAFINLAR.xml:S2:6508:1	O
treatment	TAFINLAR.xml:S2:6510:9	O
with	TAFINLAR.xml:S2:6520:4	O
TAFINLAR	TAFINLAR.xml:S2:6525:8	O
in	TAFINLAR.xml:S2:6534:2	O
combination	TAFINLAR.xml:S2:6537:11	O
with	TAFINLAR.xml:S2:6549:4	O
trametinib	TAFINLAR.xml:S2:6554:10	O
resulted	TAFINLAR.xml:S2:6565:8	O
in	TAFINLAR.xml:S2:6574:2	O
an	TAFINLAR.xml:S2:6577:2	O
increased	TAFINLAR.xml:S2:6580:9	O
incidence	TAFINLAR.xml:S2:6590:9	O
and	TAFINLAR.xml:S2:6600:3	O
severity	TAFINLAR.xml:S2:6604:8	O
of	TAFINLAR.xml:S2:6613:2	O
any	TAFINLAR.xml:S2:6616:3	O
hemorrhagic	TAFINLAR.xml:S2:6620:11	B-AdverseReaction
event	TAFINLAR.xml:S2:6632:5	I-AdverseReaction
:	TAFINLAR.xml:S2:6637:1	O
16%	TAFINLAR.xml:S2:6639:3	O
(	TAFINLAR.xml:S2:6643:1	O
9	TAFINLAR.xml:S2:6644:1	O
55	TAFINLAR.xml:S2:6646:2	O
)	TAFINLAR.xml:S2:6648:1	O
of	TAFINLAR.xml:S2:6650:2	O
patients	TAFINLAR.xml:S2:6653:8	O
treated	TAFINLAR.xml:S2:6662:7	O
with	TAFINLAR.xml:S2:6670:4	O
TAFINLAR	TAFINLAR.xml:S2:6675:8	O
in	TAFINLAR.xml:S2:6684:2	O
combination	TAFINLAR.xml:S2:6687:11	O
with	TAFINLAR.xml:S2:6699:4	O
trametinib	TAFINLAR.xml:S2:6704:10	O
compared	TAFINLAR.xml:S2:6715:8	O
with	TAFINLAR.xml:S2:6724:4	O
2%	TAFINLAR.xml:S2:6729:2	O
(	TAFINLAR.xml:S2:6732:1	O
1	TAFINLAR.xml:S2:6733:1	O
53	TAFINLAR.xml:S2:6735:2	O
)	TAFINLAR.xml:S2:6737:1	O
of	TAFINLAR.xml:S2:6739:2	O
patients	TAFINLAR.xml:S2:6742:8	O
treated	TAFINLAR.xml:S2:6751:7	O
with	TAFINLAR.xml:S2:6759:4	O
TAFINLAR	TAFINLAR.xml:S2:6764:8	O
as	TAFINLAR.xml:S2:6773:2	O
a	TAFINLAR.xml:S2:6776:1	O
single	TAFINLAR.xml:S2:6778:6	O
agent	TAFINLAR.xml:S2:6785:5	O
.	TAFINLAR.xml:S2:6790:1	O

The	TAFINLAR.xml:S2:6792:3	O
major	TAFINLAR.xml:S2:6796:5	B-Severity
hemorrhagic	TAFINLAR.xml:S2:6802:11	B-AdverseReaction
events	TAFINLAR.xml:S2:6814:6	I-AdverseReaction
of	TAFINLAR.xml:S2:6821:2	O
intracranial	TAFINLAR.xml:S2:6824:12	B-AdverseReaction
or	TAFINLAR.xml:S2:6837:2	O
gastric	TAFINLAR.xml:S2:6840:7	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S2:6848:10	I-AdverseReaction
occurred	TAFINLAR.xml:S2:6859:8	O
in	TAFINLAR.xml:S2:6868:2	O
5%	TAFINLAR.xml:S2:6871:2	O
(	TAFINLAR.xml:S2:6874:1	O
3	TAFINLAR.xml:S2:6875:1	O
55	TAFINLAR.xml:S2:6877:2	O
)	TAFINLAR.xml:S2:6879:1	O
of	TAFINLAR.xml:S2:6881:2	O
patients	TAFINLAR.xml:S2:6884:8	O
treated	TAFINLAR.xml:S2:6893:7	O
with	TAFINLAR.xml:S2:6901:4	O
TAFINLAR	TAFINLAR.xml:S2:6906:8	O
in	TAFINLAR.xml:S2:6915:2	O
combination	TAFINLAR.xml:S2:6918:11	O
with	TAFINLAR.xml:S2:6930:4	O
trametinib	TAFINLAR.xml:S2:6935:10	O
compared	TAFINLAR.xml:S2:6946:8	O
with	TAFINLAR.xml:S2:6955:4	O
none	TAFINLAR.xml:S2:6960:4	O
of	TAFINLAR.xml:S2:6965:2	O
the	TAFINLAR.xml:S2:6968:3	O
53	TAFINLAR.xml:S2:6972:2	O
patients	TAFINLAR.xml:S2:6975:8	O
treated	TAFINLAR.xml:S2:6984:7	O
with	TAFINLAR.xml:S2:6992:4	O
TAFINLAR	TAFINLAR.xml:S2:6997:8	O
as	TAFINLAR.xml:S2:7006:2	O
a	TAFINLAR.xml:S2:7009:1	O
single	TAFINLAR.xml:S2:7011:6	O
agent	TAFINLAR.xml:S2:7018:5	O
.	TAFINLAR.xml:S2:7023:1	O

Intracranial	TAFINLAR.xml:S2:7025:12	B-AdverseReaction
hemorrhage	TAFINLAR.xml:S2:7038:10	I-AdverseReaction
was	TAFINLAR.xml:S2:7049:3	O
fatal	TAFINLAR.xml:S2:7053:5	B-AdverseReaction
in	TAFINLAR.xml:S2:7059:2	O
4%	TAFINLAR.xml:S2:7062:2	O
(	TAFINLAR.xml:S2:7065:1	O
2	TAFINLAR.xml:S2:7066:1	O
55	TAFINLAR.xml:S2:7068:2	O
)	TAFINLAR.xml:S2:7070:1	O
of	TAFINLAR.xml:S2:7072:2	O
patients	TAFINLAR.xml:S2:7075:8	O
receiving	TAFINLAR.xml:S2:7084:9	O
TAFINLAR	TAFINLAR.xml:S2:7094:8	O
in	TAFINLAR.xml:S2:7103:2	O
combination	TAFINLAR.xml:S2:7106:11	O
with	TAFINLAR.xml:S2:7118:4	O
trametinib	TAFINLAR.xml:S2:7123:10	O
.	TAFINLAR.xml:S2:7133:1	O

Permanently	TAFINLAR.xml:S2:7142:11	O
discontinue	TAFINLAR.xml:S2:7154:11	O
TAFINLAR	TAFINLAR.xml:S2:7166:8	O
and	TAFINLAR.xml:S2:7175:3	O
trametinib	TAFINLAR.xml:S2:7179:10	O
for	TAFINLAR.xml:S2:7190:3	O
all	TAFINLAR.xml:S2:7194:3	O
Grade	TAFINLAR.xml:S2:7198:5	O
4	TAFINLAR.xml:S2:7204:1	O
hemorrhagic	TAFINLAR.xml:S2:7206:11	O
events	TAFINLAR.xml:S2:7218:6	O
and	TAFINLAR.xml:S2:7225:3	O
for	TAFINLAR.xml:S2:7229:3	O
any	TAFINLAR.xml:S2:7233:3	O
Grade	TAFINLAR.xml:S2:7237:5	O
3	TAFINLAR.xml:S2:7243:1	O
hemorrhagic	TAFINLAR.xml:S2:7245:11	O
events	TAFINLAR.xml:S2:7257:6	O
that	TAFINLAR.xml:S2:7264:4	O
do	TAFINLAR.xml:S2:7269:2	O
not	TAFINLAR.xml:S2:7272:3	O
improve	TAFINLAR.xml:S2:7276:7	O
.	TAFINLAR.xml:S2:7283:1	O

Withhold	TAFINLAR.xml:S2:7285:8	O
TAFINLAR	TAFINLAR.xml:S2:7294:8	O
for	TAFINLAR.xml:S2:7303:3	O
Grade	TAFINLAR.xml:S2:7307:5	O
3	TAFINLAR.xml:S2:7313:1	O
hemorrhagic	TAFINLAR.xml:S2:7315:11	O
events	TAFINLAR.xml:S2:7327:6	O
;	TAFINLAR.xml:S2:7333:1	O
if	TAFINLAR.xml:S2:7335:2	O
improved	TAFINLAR.xml:S2:7338:8	O
resume	TAFINLAR.xml:S2:7347:6	O
at	TAFINLAR.xml:S2:7354:2	O
a	TAFINLAR.xml:S2:7357:1	O
lower	TAFINLAR.xml:S2:7359:5	O
dose	TAFINLAR.xml:S2:7365:4	O
level	TAFINLAR.xml:S2:7370:5	O
.	TAFINLAR.xml:S2:7375:1	O

Withhold	TAFINLAR.xml:S2:7377:8	O
trametinib	TAFINLAR.xml:S2:7386:10	O
for	TAFINLAR.xml:S2:7397:3	O
up	TAFINLAR.xml:S2:7401:2	O
to	TAFINLAR.xml:S2:7404:2	O
3	TAFINLAR.xml:S2:7407:1	O
weeks	TAFINLAR.xml:S2:7409:5	O
for	TAFINLAR.xml:S2:7415:3	O
Grade	TAFINLAR.xml:S2:7419:5	O
3	TAFINLAR.xml:S2:7425:1	O
hemorrhagic	TAFINLAR.xml:S2:7427:11	O
events	TAFINLAR.xml:S2:7439:6	O
;	TAFINLAR.xml:S2:7445:1	O
if	TAFINLAR.xml:S2:7447:2	O
improved	TAFINLAR.xml:S2:7450:8	O
,	TAFINLAR.xml:S2:7458:1	O
resume	TAFINLAR.xml:S2:7460:6	O
at	TAFINLAR.xml:S2:7467:2	O
a	TAFINLAR.xml:S2:7470:1	O
lower	TAFINLAR.xml:S2:7472:5	O
dose	TAFINLAR.xml:S2:7478:4	O
level	TAFINLAR.xml:S2:7483:5	O
.	TAFINLAR.xml:S2:7488:1	O

5.4	TAFINLAR.xml:S2:7500:3	O
Venous	TAFINLAR.xml:S2:7504:6	O
Thromboembolism	TAFINLAR.xml:S2:7511:15	O

Venous	TAFINLAR.xml:S2:7535:6	B-AdverseReaction
thromboembolism	TAFINLAR.xml:S2:7542:15	I-AdverseReaction
can	TAFINLAR.xml:S2:7558:3	B-Factor
occur	TAFINLAR.xml:S2:7562:5	O
when	TAFINLAR.xml:S2:7568:4	O
TAFINLAR	TAFINLAR.xml:S2:7573:8	O
is	TAFINLAR.xml:S2:7582:2	O
used	TAFINLAR.xml:S2:7585:4	O
in	TAFINLAR.xml:S2:7590:2	O
combination	TAFINLAR.xml:S2:7593:11	O
with	TAFINLAR.xml:S2:7605:4	O
trametinib	TAFINLAR.xml:S2:7610:10	O
.	TAFINLAR.xml:S2:7620:1	O

In	TAFINLAR.xml:S2:7629:2	O
Trial	TAFINLAR.xml:S2:7632:5	O
2	TAFINLAR.xml:S2:7638:1	O
,	TAFINLAR.xml:S2:7639:1	O
treatment	TAFINLAR.xml:S2:7641:9	O
with	TAFINLAR.xml:S2:7651:4	O
TAFINLAR	TAFINLAR.xml:S2:7656:8	O
in	TAFINLAR.xml:S2:7665:2	O
combination	TAFINLAR.xml:S2:7668:11	O
with	TAFINLAR.xml:S2:7680:4	O
trametinib	TAFINLAR.xml:S2:7685:10	O
resulted	TAFINLAR.xml:S2:7696:8	O
in	TAFINLAR.xml:S2:7705:2	O
an	TAFINLAR.xml:S2:7708:2	O
increased	TAFINLAR.xml:S2:7711:9	O
incidence	TAFINLAR.xml:S2:7721:9	O
of	TAFINLAR.xml:S2:7731:2	O
deep	TAFINLAR.xml:S2:7734:4	B-AdverseReaction
venous	TAFINLAR.xml:S2:7739:6	I-AdverseReaction
thrombosis	TAFINLAR.xml:S2:7746:10	I-AdverseReaction
(	TAFINLAR.xml:S2:7757:1	O
DVT	TAFINLAR.xml:S2:7758:3	B-AdverseReaction
)	TAFINLAR.xml:S2:7761:1	O
and	TAFINLAR.xml:S2:7763:3	O
pulmonary	TAFINLAR.xml:S2:7767:9	B-AdverseReaction
embolism	TAFINLAR.xml:S2:7777:8	I-AdverseReaction
(	TAFINLAR.xml:S2:7786:1	O
PE	TAFINLAR.xml:S2:7787:2	B-AdverseReaction
)	TAFINLAR.xml:S2:7789:1	O
:	TAFINLAR.xml:S2:7790:1	O
7%	TAFINLAR.xml:S2:7792:2	O
(	TAFINLAR.xml:S2:7795:1	O
4	TAFINLAR.xml:S2:7796:1	O
55	TAFINLAR.xml:S2:7798:2	O
)	TAFINLAR.xml:S2:7800:1	O
of	TAFINLAR.xml:S2:7802:2	O
patients	TAFINLAR.xml:S2:7805:8	O
treated	TAFINLAR.xml:S2:7814:7	O
with	TAFINLAR.xml:S2:7822:4	O
TAFINLAR	TAFINLAR.xml:S2:7827:8	O
in	TAFINLAR.xml:S2:7836:2	O
combination	TAFINLAR.xml:S2:7839:11	O
with	TAFINLAR.xml:S2:7851:4	O
trametinib	TAFINLAR.xml:S2:7856:10	O
compared	TAFINLAR.xml:S2:7867:8	O
with	TAFINLAR.xml:S2:7876:4	O
none	TAFINLAR.xml:S2:7881:4	O
of	TAFINLAR.xml:S2:7886:2	O
the	TAFINLAR.xml:S2:7889:3	O
53	TAFINLAR.xml:S2:7893:2	O
patients	TAFINLAR.xml:S2:7896:8	O
treated	TAFINLAR.xml:S2:7905:7	O
with	TAFINLAR.xml:S2:7913:4	O
TAFINLAR	TAFINLAR.xml:S2:7918:8	O
as	TAFINLAR.xml:S2:7927:2	O
a	TAFINLAR.xml:S2:7930:1	O
single	TAFINLAR.xml:S2:7932:6	O
agent	TAFINLAR.xml:S2:7939:5	O
.	TAFINLAR.xml:S2:7944:1	O

Pulmonary	TAFINLAR.xml:S2:7946:9	B-AdverseReaction
embolism	TAFINLAR.xml:S2:7956:8	I-AdverseReaction
was	TAFINLAR.xml:S2:7965:3	O
fatal	TAFINLAR.xml:S2:7969:5	B-AdverseReaction
in	TAFINLAR.xml:S2:7975:2	O
2%	TAFINLAR.xml:S2:7978:2	O
(	TAFINLAR.xml:S2:7981:1	O
1	TAFINLAR.xml:S2:7982:1	O
55	TAFINLAR.xml:S2:7984:2	O
)	TAFINLAR.xml:S2:7986:1	O
of	TAFINLAR.xml:S2:7988:2	O
patients	TAFINLAR.xml:S2:7991:8	O
receiving	TAFINLAR.xml:S2:8000:9	O
TAFINLAR	TAFINLAR.xml:S2:8010:8	O
in	TAFINLAR.xml:S2:8019:2	O
combination	TAFINLAR.xml:S2:8022:11	O
with	TAFINLAR.xml:S2:8034:4	O
trametinib	TAFINLAR.xml:S2:8039:10	O
.	TAFINLAR.xml:S2:8049:1	O

Advise	TAFINLAR.xml:S2:8058:6	O
patients	TAFINLAR.xml:S2:8065:8	O
to	TAFINLAR.xml:S2:8074:2	O
immediately	TAFINLAR.xml:S2:8077:11	O
seek	TAFINLAR.xml:S2:8089:4	O
medical	TAFINLAR.xml:S2:8094:7	O
care	TAFINLAR.xml:S2:8102:4	O
if	TAFINLAR.xml:S2:8107:2	O
they	TAFINLAR.xml:S2:8110:4	O
develop	TAFINLAR.xml:S2:8115:7	O
symptoms	TAFINLAR.xml:S2:8123:8	O
of	TAFINLAR.xml:S2:8132:2	O
DVT	TAFINLAR.xml:S2:8135:3	O
or	TAFINLAR.xml:S2:8139:2	O
PE	TAFINLAR.xml:S2:8142:2	O
,	TAFINLAR.xml:S2:8144:1	O
such	TAFINLAR.xml:S2:8146:4	O
as	TAFINLAR.xml:S2:8151:2	O
shortness	TAFINLAR.xml:S2:8154:9	O
of	TAFINLAR.xml:S2:8164:2	O
breath	TAFINLAR.xml:S2:8167:6	O
,	TAFINLAR.xml:S2:8173:1	O
chest	TAFINLAR.xml:S2:8175:5	O
pain	TAFINLAR.xml:S2:8181:4	O
,	TAFINLAR.xml:S2:8185:1	O
or	TAFINLAR.xml:S2:8187:2	O
arm	TAFINLAR.xml:S2:8190:3	O
or	TAFINLAR.xml:S2:8194:2	O
leg	TAFINLAR.xml:S2:8197:3	O
swelling	TAFINLAR.xml:S2:8201:8	O
.	TAFINLAR.xml:S2:8209:1	O

Permanently	TAFINLAR.xml:S2:8211:11	O
discontinue	TAFINLAR.xml:S2:8223:11	O
TAFINLAR	TAFINLAR.xml:S2:8235:8	O
and	TAFINLAR.xml:S2:8244:3	O
trametinib	TAFINLAR.xml:S2:8248:10	O
for	TAFINLAR.xml:S2:8259:3	O
life	TAFINLAR.xml:S2:8263:4	O
-	TAFINLAR.xml:S2:8267:1	O
threatening	TAFINLAR.xml:S2:8268:11	O
PE	TAFINLAR.xml:S2:8280:2	O
.	TAFINLAR.xml:S2:8282:1	O

Withhold	TAFINLAR.xml:S2:8284:8	O
trametinib	TAFINLAR.xml:S2:8293:10	O
and	TAFINLAR.xml:S2:8304:3	O
continue	TAFINLAR.xml:S2:8308:8	O
TAFINLAR	TAFINLAR.xml:S2:8317:8	O
at	TAFINLAR.xml:S2:8326:2	O
the	TAFINLAR.xml:S2:8329:3	O
same	TAFINLAR.xml:S2:8333:4	O
dose	TAFINLAR.xml:S2:8338:4	O
for	TAFINLAR.xml:S2:8343:3	O
uncomplicated	TAFINLAR.xml:S2:8347:13	O
DVT	TAFINLAR.xml:S2:8361:3	O
or	TAFINLAR.xml:S2:8365:2	O
PE	TAFINLAR.xml:S2:8368:2	O
;	TAFINLAR.xml:S2:8370:1	O
if	TAFINLAR.xml:S2:8372:2	O
improved	TAFINLAR.xml:S2:8375:8	O
within	TAFINLAR.xml:S2:8384:6	O
3	TAFINLAR.xml:S2:8391:1	O
weeks	TAFINLAR.xml:S2:8393:5	O
,	TAFINLAR.xml:S2:8398:1	O
trametinib	TAFINLAR.xml:S2:8400:10	O
may	TAFINLAR.xml:S2:8411:3	O
be	TAFINLAR.xml:S2:8415:2	O
resumed	TAFINLAR.xml:S2:8418:7	O
at	TAFINLAR.xml:S2:8426:2	O
a	TAFINLAR.xml:S2:8429:1	O
lower	TAFINLAR.xml:S2:8431:5	O
dose	TAFINLAR.xml:S2:8437:4	O
level	TAFINLAR.xml:S2:8442:5	O
[	TAFINLAR.xml:S2:8448:1	O
see	TAFINLAR.xml:S2:8449:3	O
Dosage	TAFINLAR.xml:S2:8453:6	O
and	TAFINLAR.xml:S2:8460:3	O
Administration	TAFINLAR.xml:S2:8464:14	O
(	TAFINLAR.xml:S2:8479:1	O
2.3	TAFINLAR.xml:S2:8480:3	O
)]	TAFINLAR.xml:S2:8483:2	O
.	TAFINLAR.xml:S2:8489:1	O

5.5	TAFINLAR.xml:S2:8499:3	O
Cardiomyopathy	TAFINLAR.xml:S2:8503:14	O

Cardiomyopathy	TAFINLAR.xml:S2:8526:14	B-AdverseReaction
can	TAFINLAR.xml:S2:8541:3	B-Factor
occur	TAFINLAR.xml:S2:8545:5	O
when	TAFINLAR.xml:S2:8551:4	O
TAFINLAR	TAFINLAR.xml:S2:8556:8	O
is	TAFINLAR.xml:S2:8565:2	O
used	TAFINLAR.xml:S2:8568:4	O
in	TAFINLAR.xml:S2:8573:2	O
combination	TAFINLAR.xml:S2:8576:11	O
with	TAFINLAR.xml:S2:8588:4	O
trametinib	TAFINLAR.xml:S2:8593:10	O
and	TAFINLAR.xml:S2:8604:3	O
with	TAFINLAR.xml:S2:8608:4	O
trametinib	TAFINLAR.xml:S2:8613:10	O
as	TAFINLAR.xml:S2:8624:2	O
a	TAFINLAR.xml:S2:8627:1	O
single	TAFINLAR.xml:S2:8629:6	O
agent	TAFINLAR.xml:S2:8636:5	O
[	TAFINLAR.xml:S2:8642:1	O
refer	TAFINLAR.xml:S2:8643:5	O
to	TAFINLAR.xml:S2:8649:2	O
Full	TAFINLAR.xml:S2:8652:4	O
Prescribing	TAFINLAR.xml:S2:8657:11	O
Information	TAFINLAR.xml:S2:8669:11	O
for	TAFINLAR.xml:S2:8681:3	O
trametinib	TAFINLAR.xml:S2:8685:10	O
]	TAFINLAR.xml:S2:8695:1	O
.	TAFINLAR.xml:S2:8698:1	O

In	TAFINLAR.xml:S2:8707:2	O
Trial	TAFINLAR.xml:S2:8710:5	O
2	TAFINLAR.xml:S2:8716:1	O
,	TAFINLAR.xml:S2:8717:1	O
cardiomyopathy	TAFINLAR.xml:S2:8719:14	B-AdverseReaction
occurred	TAFINLAR.xml:S2:8734:8	O
in	TAFINLAR.xml:S2:8743:2	O
9%	TAFINLAR.xml:S2:8746:2	O
(	TAFINLAR.xml:S2:8749:1	O
5	TAFINLAR.xml:S2:8750:1	O
55	TAFINLAR.xml:S2:8752:2	O
)	TAFINLAR.xml:S2:8754:1	O
of	TAFINLAR.xml:S2:8756:2	O
patients	TAFINLAR.xml:S2:8759:8	O
treated	TAFINLAR.xml:S2:8768:7	O
with	TAFINLAR.xml:S2:8776:4	O
TAFINLAR	TAFINLAR.xml:S2:8781:8	O
in	TAFINLAR.xml:S2:8790:2	O
combination	TAFINLAR.xml:S2:8793:11	O
with	TAFINLAR.xml:S2:8805:4	O
trametinib	TAFINLAR.xml:S2:8810:10	O
and	TAFINLAR.xml:S2:8821:3	O
in	TAFINLAR.xml:S2:8825:2	O
none	TAFINLAR.xml:S2:8828:4	O
of	TAFINLAR.xml:S2:8833:2	O
patients	TAFINLAR.xml:S2:8836:8	O
treated	TAFINLAR.xml:S2:8845:7	O
with	TAFINLAR.xml:S2:8853:4	O
TAFINLAR	TAFINLAR.xml:S2:8858:8	O
as	TAFINLAR.xml:S2:8867:2	O
a	TAFINLAR.xml:S2:8870:1	O
single	TAFINLAR.xml:S2:8872:6	O
agent	TAFINLAR.xml:S2:8879:5	O
.	TAFINLAR.xml:S2:8884:1	O

The	TAFINLAR.xml:S2:8886:3	O
median	TAFINLAR.xml:S2:8890:6	O
time	TAFINLAR.xml:S2:8897:4	O
to	TAFINLAR.xml:S2:8902:2	O
onset	TAFINLAR.xml:S2:8905:5	O
of	TAFINLAR.xml:S2:8911:2	O
cardiomyopathy	TAFINLAR.xml:S2:8914:14	B-AdverseReaction
in	TAFINLAR.xml:S2:8929:2	O
patients	TAFINLAR.xml:S2:8932:8	O
treated	TAFINLAR.xml:S2:8941:7	O
with	TAFINLAR.xml:S2:8949:4	O
TAFINLAR	TAFINLAR.xml:S2:8954:8	O
in	TAFINLAR.xml:S2:8963:2	O
combination	TAFINLAR.xml:S2:8966:11	O
with	TAFINLAR.xml:S2:8978:4	O
trametinib	TAFINLAR.xml:S2:8983:10	O
was	TAFINLAR.xml:S2:8994:3	O
86	TAFINLAR.xml:S2:8998:2	O
days	TAFINLAR.xml:S2:9001:4	O
(	TAFINLAR.xml:S2:9006:1	O
range	TAFINLAR.xml:S2:9007:5	O
:	TAFINLAR.xml:S2:9012:1	O
27	TAFINLAR.xml:S2:9014:2	O
to	TAFINLAR.xml:S2:9017:2	O
253	TAFINLAR.xml:S2:9020:3	O
days	TAFINLAR.xml:S2:9024:4	O
)	TAFINLAR.xml:S2:9028:1	O
.	TAFINLAR.xml:S2:9029:1	O

Cardiomyopathy	TAFINLAR.xml:S2:9031:14	B-AdverseReaction
was	TAFINLAR.xml:S2:9046:3	O
identified	TAFINLAR.xml:S2:9050:10	O
within	TAFINLAR.xml:S2:9061:6	O
the	TAFINLAR.xml:S2:9068:3	O
first	TAFINLAR.xml:S2:9072:5	O
month	TAFINLAR.xml:S2:9078:5	O
of	TAFINLAR.xml:S2:9084:2	O
treatment	TAFINLAR.xml:S2:9087:9	O
with	TAFINLAR.xml:S2:9097:4	O
TAFINLAR	TAFINLAR.xml:S2:9102:8	O
in	TAFINLAR.xml:S2:9111:2	O
combination	TAFINLAR.xml:S2:9114:11	O
with	TAFINLAR.xml:S2:9126:4	O
trametinib	TAFINLAR.xml:S2:9131:10	O
in	TAFINLAR.xml:S2:9142:2	O
two	TAFINLAR.xml:S2:9145:3	O
of	TAFINLAR.xml:S2:9149:2	O
five	TAFINLAR.xml:S2:9152:4	O
patients	TAFINLAR.xml:S2:9157:8	O
.	TAFINLAR.xml:S2:9165:1	O

Development	TAFINLAR.xml:S2:9167:11	O
of	TAFINLAR.xml:S2:9179:2	O
cardiomyopathy	TAFINLAR.xml:S2:9182:14	B-AdverseReaction
resolved	TAFINLAR.xml:S2:9197:8	O
in	TAFINLAR.xml:S2:9206:2	O
all	TAFINLAR.xml:S2:9209:3	O
five	TAFINLAR.xml:S2:9213:4	O
patients	TAFINLAR.xml:S2:9218:8	O
following	TAFINLAR.xml:S2:9227:9	O
dose	TAFINLAR.xml:S2:9237:4	O
reduction	TAFINLAR.xml:S2:9242:9	O
(	TAFINLAR.xml:S2:9252:1	O
4	TAFINLAR.xml:S2:9253:1	O
55	TAFINLAR.xml:S2:9255:2	O
)	TAFINLAR.xml:S2:9257:1	O
and	TAFINLAR.xml:S2:9259:3	O
or	TAFINLAR.xml:S2:9263:2	O
dose	TAFINLAR.xml:S2:9266:4	O
interruption	TAFINLAR.xml:S2:9271:12	O
(	TAFINLAR.xml:S2:9284:1	O
1	TAFINLAR.xml:S2:9285:1	O
55	TAFINLAR.xml:S2:9287:2	O
)	TAFINLAR.xml:S2:9289:1	O
.	TAFINLAR.xml:S2:9290:1	O

Across	TAFINLAR.xml:S2:9299:6	O
clinical	TAFINLAR.xml:S2:9306:8	O
trials	TAFINLAR.xml:S2:9315:6	O
of	TAFINLAR.xml:S2:9322:2	O
TAFINLAR	TAFINLAR.xml:S2:9325:8	O
administered	TAFINLAR.xml:S2:9334:12	O
in	TAFINLAR.xml:S2:9347:2	O
combination	TAFINLAR.xml:S2:9350:11	O
with	TAFINLAR.xml:S2:9362:4	O
trametinib	TAFINLAR.xml:S2:9367:10	O
(	TAFINLAR.xml:S2:9378:1	O
N	TAFINLAR.xml:S2:9379:1	O
202	TAFINLAR.xml:S2:9383:3	O
)	TAFINLAR.xml:S2:9386:1	O
,	TAFINLAR.xml:S2:9387:1	O
8%	TAFINLAR.xml:S2:9389:2	O
of	TAFINLAR.xml:S2:9392:2	O
patients	TAFINLAR.xml:S2:9395:8	O
developed	TAFINLAR.xml:S2:9404:9	O
evidence	TAFINLAR.xml:S2:9414:8	O
of	TAFINLAR.xml:S2:9423:2	O
cardiomyopathy	TAFINLAR.xml:S2:9426:14	B-AdverseReaction
(	TAFINLAR.xml:S2:9441:1	O
decrease	TAFINLAR.xml:S2:9442:8	B-AdverseReaction
in	TAFINLAR.xml:S2:9451:2	I-AdverseReaction
LVEF	TAFINLAR.xml:S2:9454:4	I-AdverseReaction
below	TAFINLAR.xml:S2:9459:5	O
institutional	TAFINLAR.xml:S2:9465:13	B-Severity
lower	TAFINLAR.xml:S2:9479:5	I-Severity
limits	TAFINLAR.xml:S2:9485:6	I-Severity
of	TAFINLAR.xml:S2:9492:2	I-Severity
normal	TAFINLAR.xml:S2:9495:6	I-Severity
with	TAFINLAR.xml:S2:9502:4	O
an	TAFINLAR.xml:S2:9507:2	O
absolute	TAFINLAR.xml:S2:9510:8	B-AdverseReaction
decrease	TAFINLAR.xml:S2:9519:8	I-AdverseReaction
in	TAFINLAR.xml:S2:9528:2	I-AdverseReaction
LVEF	TAFINLAR.xml:S2:9531:4	I-AdverseReaction
10%	TAFINLAR.xml:S2:9538:3	B-Severity
below	TAFINLAR.xml:S2:9542:5	I-Severity
baseline	TAFINLAR.xml:S2:9548:8	I-Severity
)	TAFINLAR.xml:S2:9556:1	O
.	TAFINLAR.xml:S2:9557:1	O

Two	TAFINLAR.xml:S2:9559:3	O
percent	TAFINLAR.xml:S2:9563:7	O
demonstrated	TAFINLAR.xml:S2:9571:12	O
a	TAFINLAR.xml:S2:9584:1	O
decrease	TAFINLAR.xml:S2:9586:8	B-AdverseReaction
in	TAFINLAR.xml:S2:9595:2	I-AdverseReaction
LVEF	TAFINLAR.xml:S2:9598:4	I-AdverseReaction
below	TAFINLAR.xml:S2:9603:5	O
institutional	TAFINLAR.xml:S2:9609:13	B-Severity
lower	TAFINLAR.xml:S2:9623:5	I-Severity
limits	TAFINLAR.xml:S2:9629:6	I-Severity
of	TAFINLAR.xml:S2:9636:2	I-Severity
normal	TAFINLAR.xml:S2:9639:6	I-Severity
with	TAFINLAR.xml:S2:9646:4	O
an	TAFINLAR.xml:S2:9651:2	O
absolute	TAFINLAR.xml:S2:9654:8	B-AdverseReaction
decrease	TAFINLAR.xml:S2:9663:8	I-AdverseReaction
in	TAFINLAR.xml:S2:9672:2	I-AdverseReaction
LVEF	TAFINLAR.xml:S2:9675:4	I-AdverseReaction
of	TAFINLAR.xml:S2:9680:2	O
20%	TAFINLAR.xml:S2:9685:3	B-Severity
below	TAFINLAR.xml:S2:9689:5	I-Severity
baseline	TAFINLAR.xml:S2:9695:8	I-Severity
.	TAFINLAR.xml:S2:9703:1	O

Assess	TAFINLAR.xml:S2:9712:6	O
LVEF	TAFINLAR.xml:S2:9719:4	O
by	TAFINLAR.xml:S2:9724:2	O
echocardiogram	TAFINLAR.xml:S2:9727:14	O
or	TAFINLAR.xml:S2:9742:2	O
multigated	TAFINLAR.xml:S2:9745:10	O
acquisition	TAFINLAR.xml:S2:9756:11	O
(	TAFINLAR.xml:S2:9768:1	O
MUGA	TAFINLAR.xml:S2:9769:4	O
)	TAFINLAR.xml:S2:9773:1	O
scan	TAFINLAR.xml:S2:9775:4	O
before	TAFINLAR.xml:S2:9780:6	O
initiation	TAFINLAR.xml:S2:9787:10	O
of	TAFINLAR.xml:S2:9798:2	O
TAFINLAR	TAFINLAR.xml:S2:9801:8	O
in	TAFINLAR.xml:S2:9810:2	O
combination	TAFINLAR.xml:S2:9813:11	O
with	TAFINLAR.xml:S2:9825:4	O
trametinib	TAFINLAR.xml:S2:9830:10	O
,	TAFINLAR.xml:S2:9840:1	O
one	TAFINLAR.xml:S2:9842:3	O
month	TAFINLAR.xml:S2:9846:5	O
after	TAFINLAR.xml:S2:9852:5	O
initiation	TAFINLAR.xml:S2:9858:10	O
,	TAFINLAR.xml:S2:9868:1	O
and	TAFINLAR.xml:S2:9870:3	O
then	TAFINLAR.xml:S2:9874:4	O
at	TAFINLAR.xml:S2:9879:2	O
2	TAFINLAR.xml:S2:9882:1	O
-	TAFINLAR.xml:S2:9883:1	O
to	TAFINLAR.xml:S2:9885:2	O
3	TAFINLAR.xml:S2:9888:1	O
-	TAFINLAR.xml:S2:9889:1	O
month	TAFINLAR.xml:S2:9890:5	O
intervals	TAFINLAR.xml:S2:9896:9	O
while	TAFINLAR.xml:S2:9906:5	O
on	TAFINLAR.xml:S2:9912:2	O
treatment	TAFINLAR.xml:S2:9915:9	O
with	TAFINLAR.xml:S2:9925:4	O
the	TAFINLAR.xml:S2:9930:3	O
combination	TAFINLAR.xml:S2:9934:11	O
.	TAFINLAR.xml:S2:9945:1	O

Withhold	TAFINLAR.xml:S2:9947:8	O
treatment	TAFINLAR.xml:S2:9956:9	O
with	TAFINLAR.xml:S2:9966:4	O
trametinib	TAFINLAR.xml:S2:9971:10	O
and	TAFINLAR.xml:S2:9982:3	O
continue	TAFINLAR.xml:S2:9986:8	O
TAFINLAR	TAFINLAR.xml:S2:9995:8	O
at	TAFINLAR.xml:S2:10004:2	O
the	TAFINLAR.xml:S2:10007:3	O
same	TAFINLAR.xml:S2:10011:4	O
dose	TAFINLAR.xml:S2:10016:4	O
if	TAFINLAR.xml:S2:10021:2	O
absolute	TAFINLAR.xml:S2:10024:8	O
LVEF	TAFINLAR.xml:S2:10033:4	O
value	TAFINLAR.xml:S2:10038:5	O
decreases	TAFINLAR.xml:S2:10044:9	O
by	TAFINLAR.xml:S2:10054:2	O
10%	TAFINLAR.xml:S2:10057:3	O
from	TAFINLAR.xml:S2:10061:4	O
pretreatment	TAFINLAR.xml:S2:10066:12	O
values	TAFINLAR.xml:S2:10079:6	O
and	TAFINLAR.xml:S2:10086:3	O
is	TAFINLAR.xml:S2:10090:2	O
less	TAFINLAR.xml:S2:10093:4	O
than	TAFINLAR.xml:S2:10098:4	O
the	TAFINLAR.xml:S2:10103:3	O
lower	TAFINLAR.xml:S2:10107:5	O
limit	TAFINLAR.xml:S2:10113:5	O
of	TAFINLAR.xml:S2:10119:2	O
normal	TAFINLAR.xml:S2:10122:6	O
.	TAFINLAR.xml:S2:10128:1	O

For	TAFINLAR.xml:S2:10130:3	O
symptomatic	TAFINLAR.xml:S2:10134:11	O
cardiomyopathy	TAFINLAR.xml:S2:10146:14	O
or	TAFINLAR.xml:S2:10161:2	O
persistent	TAFINLAR.xml:S2:10164:10	O
,	TAFINLAR.xml:S2:10174:1	O
asymptomatic	TAFINLAR.xml:S2:10176:12	O
LV	TAFINLAR.xml:S2:10189:2	O
dysfunction	TAFINLAR.xml:S2:10192:11	O
that	TAFINLAR.xml:S2:10204:4	O
does	TAFINLAR.xml:S2:10209:4	O
not	TAFINLAR.xml:S2:10214:3	O
resolve	TAFINLAR.xml:S2:10218:7	O
within	TAFINLAR.xml:S2:10226:6	O
4	TAFINLAR.xml:S2:10233:1	O
weeks	TAFINLAR.xml:S2:10235:5	O
,	TAFINLAR.xml:S2:10240:1	O
permanently	TAFINLAR.xml:S2:10242:11	O
discontinue	TAFINLAR.xml:S2:10254:11	O
trametinib	TAFINLAR.xml:S2:10266:10	O
and	TAFINLAR.xml:S2:10277:3	O
withhold	TAFINLAR.xml:S2:10281:8	O
TAFINLAR	TAFINLAR.xml:S2:10290:8	O
.	TAFINLAR.xml:S2:10298:1	O

Resume	TAFINLAR.xml:S2:10300:6	O
TAFINLAR	TAFINLAR.xml:S2:10307:8	O
at	TAFINLAR.xml:S2:10316:2	O
the	TAFINLAR.xml:S2:10319:3	O
same	TAFINLAR.xml:S2:10323:4	O
dose	TAFINLAR.xml:S2:10328:4	O
level	TAFINLAR.xml:S2:10333:5	O
upon	TAFINLAR.xml:S2:10339:4	O
recovery	TAFINLAR.xml:S2:10344:8	O
of	TAFINLAR.xml:S2:10353:2	O
cardiac	TAFINLAR.xml:S2:10356:7	O
function	TAFINLAR.xml:S2:10364:8	O
[	TAFINLAR.xml:S2:10373:1	O
see	TAFINLAR.xml:S2:10374:3	O
Dosage	TAFINLAR.xml:S2:10378:6	O
and	TAFINLAR.xml:S2:10385:3	O
Administration	TAFINLAR.xml:S2:10389:14	O
(	TAFINLAR.xml:S2:10404:1	O
2.3	TAFINLAR.xml:S2:10405:3	O
)]	TAFINLAR.xml:S2:10408:2	O
.	TAFINLAR.xml:S2:10414:1	O

5.6	TAFINLAR.xml:S2:10424:3	O
Ocular	TAFINLAR.xml:S2:10428:6	O
Toxicities	TAFINLAR.xml:S2:10435:10	O

Retinal	TAFINLAR.xml:S2:10455:7	O
Pigment	TAFINLAR.xml:S2:10463:7	O
Epithelial	TAFINLAR.xml:S2:10471:10	O
Detachment	TAFINLAR.xml:S2:10482:10	O
(	TAFINLAR.xml:S2:10493:1	O
RPED	TAFINLAR.xml:S2:10494:4	O
)	TAFINLAR.xml:S2:10498:1	O
:	TAFINLAR.xml:S2:10499:1	O

Retinal	TAFINLAR.xml:S2:10510:7	B-AdverseReaction
pigment	TAFINLAR.xml:S2:10518:7	I-AdverseReaction
epithelial	TAFINLAR.xml:S2:10526:10	I-AdverseReaction
detachments	TAFINLAR.xml:S2:10537:11	I-AdverseReaction
(	TAFINLAR.xml:S2:10549:1	O
RPED	TAFINLAR.xml:S2:10550:4	B-AdverseReaction
)	TAFINLAR.xml:S2:10554:1	O
can	TAFINLAR.xml:S2:10556:3	B-Factor
occur	TAFINLAR.xml:S2:10560:5	O
when	TAFINLAR.xml:S2:10566:4	O
TAFINLAR	TAFINLAR.xml:S2:10571:8	O
is	TAFINLAR.xml:S2:10580:2	O
used	TAFINLAR.xml:S2:10583:4	O
in	TAFINLAR.xml:S2:10588:2	O
combination	TAFINLAR.xml:S2:10591:11	O
with	TAFINLAR.xml:S2:10603:4	O
trametinib	TAFINLAR.xml:S2:10608:10	O
and	TAFINLAR.xml:S2:10619:3	O
with	TAFINLAR.xml:S2:10623:4	O
trametinib	TAFINLAR.xml:S2:10628:10	O
as	TAFINLAR.xml:S2:10639:2	O
a	TAFINLAR.xml:S2:10642:1	O
single	TAFINLAR.xml:S2:10644:6	O
agent	TAFINLAR.xml:S2:10651:5	O
[	TAFINLAR.xml:S2:10657:1	O
refer	TAFINLAR.xml:S2:10658:5	O
to	TAFINLAR.xml:S2:10664:2	O
Full	TAFINLAR.xml:S2:10667:4	O
Prescribing	TAFINLAR.xml:S2:10672:11	O
Information	TAFINLAR.xml:S2:10684:11	O
for	TAFINLAR.xml:S2:10696:3	O
trametinib	TAFINLAR.xml:S2:10700:10	O
]	TAFINLAR.xml:S2:10710:1	O
.	TAFINLAR.xml:S2:10713:1	O

Retinal	TAFINLAR.xml:S2:10715:7	B-AdverseReaction
detachments	TAFINLAR.xml:S2:10723:11	I-AdverseReaction
resulting	TAFINLAR.xml:S2:10735:9	O
from	TAFINLAR.xml:S2:10745:4	O
trametinib	TAFINLAR.xml:S2:10750:10	O
are	TAFINLAR.xml:S2:10761:3	O
often	TAFINLAR.xml:S2:10765:5	O
bilateral	TAFINLAR.xml:S2:10771:9	O
and	TAFINLAR.xml:S2:10781:3	O
multifocal	TAFINLAR.xml:S2:10785:10	O
,	TAFINLAR.xml:S2:10795:1	O
occurring	TAFINLAR.xml:S2:10797:9	O
in	TAFINLAR.xml:S2:10807:2	O
the	TAFINLAR.xml:S2:10810:3	O
macular	TAFINLAR.xml:S2:10814:7	O
region	TAFINLAR.xml:S2:10822:6	O
of	TAFINLAR.xml:S2:10829:2	O
the	TAFINLAR.xml:S2:10832:3	O
retina	TAFINLAR.xml:S2:10836:6	O
.	TAFINLAR.xml:S2:10842:1	O

In	TAFINLAR.xml:S2:10851:2	O
Trial	TAFINLAR.xml:S2:10854:5	O
2	TAFINLAR.xml:S2:10860:1	O
,	TAFINLAR.xml:S2:10861:1	O
ophthalmologic	TAFINLAR.xml:S2:10863:14	O
examinations	TAFINLAR.xml:S2:10878:12	O
including	TAFINLAR.xml:S2:10891:9	O
retinal	TAFINLAR.xml:S2:10901:7	O
evaluation	TAFINLAR.xml:S2:10909:10	O
were	TAFINLAR.xml:S2:10920:4	O
performed	TAFINLAR.xml:S2:10925:9	O
pretreatment	TAFINLAR.xml:S2:10935:12	O
and	TAFINLAR.xml:S2:10948:3	O
at	TAFINLAR.xml:S2:10952:2	O
regular	TAFINLAR.xml:S2:10955:7	O
intervals	TAFINLAR.xml:S2:10963:9	O
during	TAFINLAR.xml:S2:10973:6	O
treatment	TAFINLAR.xml:S2:10980:9	O
.	TAFINLAR.xml:S2:10989:1	O

RPED	TAFINLAR.xml:S2:10991:4	B-AdverseReaction
occurred	TAFINLAR.xml:S2:10996:8	O
in	TAFINLAR.xml:S2:11005:2	O
2%	TAFINLAR.xml:S2:11008:2	O
(	TAFINLAR.xml:S2:11011:1	O
1	TAFINLAR.xml:S2:11012:1	O
55	TAFINLAR.xml:S2:11014:2	O
)	TAFINLAR.xml:S2:11016:1	O
of	TAFINLAR.xml:S2:11018:2	O
patients	TAFINLAR.xml:S2:11021:8	O
receiving	TAFINLAR.xml:S2:11030:9	O
TAFINLAR	TAFINLAR.xml:S2:11040:8	O
in	TAFINLAR.xml:S2:11049:2	O
combination	TAFINLAR.xml:S2:11052:11	O
with	TAFINLAR.xml:S2:11064:4	O
trametinib	TAFINLAR.xml:S2:11069:10	O
.	TAFINLAR.xml:S2:11079:1	O

Across	TAFINLAR.xml:S2:11081:6	O
clinical	TAFINLAR.xml:S2:11088:8	O
trials	TAFINLAR.xml:S2:11097:6	O
of	TAFINLAR.xml:S2:11104:2	O
TAFINLAR	TAFINLAR.xml:S2:11107:8	O
administered	TAFINLAR.xml:S2:11116:12	O
in	TAFINLAR.xml:S2:11129:2	O
combination	TAFINLAR.xml:S2:11132:11	O
with	TAFINLAR.xml:S2:11144:4	O
trametinib	TAFINLAR.xml:S2:11149:10	O
(	TAFINLAR.xml:S2:11160:1	O
N	TAFINLAR.xml:S2:11161:1	O
202	TAFINLAR.xml:S2:11165:3	O
)	TAFINLAR.xml:S2:11168:1	O
,	TAFINLAR.xml:S2:11169:1	O
the	TAFINLAR.xml:S2:11171:3	O
incidence	TAFINLAR.xml:S2:11175:9	O
of	TAFINLAR.xml:S2:11185:2	O
RPED	TAFINLAR.xml:S2:11188:4	B-AdverseReaction
was	TAFINLAR.xml:S2:11193:3	O
1%	TAFINLAR.xml:S2:11197:2	O
(	TAFINLAR.xml:S2:11200:1	O
2	TAFINLAR.xml:S2:11201:1	O
202	TAFINLAR.xml:S2:11203:3	O
)	TAFINLAR.xml:S2:11206:1	O
.	TAFINLAR.xml:S2:11207:1	O

Perform	TAFINLAR.xml:S2:11216:7	O
ophthalmological	TAFINLAR.xml:S2:11224:16	O
evaluation	TAFINLAR.xml:S2:11241:10	O
at	TAFINLAR.xml:S2:11252:2	O
any	TAFINLAR.xml:S2:11255:3	O
time	TAFINLAR.xml:S2:11259:4	O
a	TAFINLAR.xml:S2:11264:1	O
patient	TAFINLAR.xml:S2:11266:7	O
reports	TAFINLAR.xml:S2:11274:7	O
visual	TAFINLAR.xml:S2:11282:6	O
disturbances	TAFINLAR.xml:S2:11289:12	O
and	TAFINLAR.xml:S2:11302:3	O
compare	TAFINLAR.xml:S2:11306:7	O
with	TAFINLAR.xml:S2:11314:4	O
baseline	TAFINLAR.xml:S2:11319:8	O
,	TAFINLAR.xml:S2:11327:1	O
if	TAFINLAR.xml:S2:11329:2	O
available	TAFINLAR.xml:S2:11332:9	O
.	TAFINLAR.xml:S2:11341:1	O

If	TAFINLAR.xml:S2:11343:2	O
TAFINLAR	TAFINLAR.xml:S2:11346:8	O
is	TAFINLAR.xml:S2:11355:2	O
used	TAFINLAR.xml:S2:11358:4	O
in	TAFINLAR.xml:S2:11363:2	O
combination	TAFINLAR.xml:S2:11366:11	O
with	TAFINLAR.xml:S2:11378:4	O
trametinib	TAFINLAR.xml:S2:11383:10	O
,	TAFINLAR.xml:S2:11393:1	O
do	TAFINLAR.xml:S2:11395:2	O
not	TAFINLAR.xml:S2:11398:3	O
modify	TAFINLAR.xml:S2:11402:6	O
the	TAFINLAR.xml:S2:11409:3	O
dose	TAFINLAR.xml:S2:11413:4	O
of	TAFINLAR.xml:S2:11418:2	O
TAFINLAR	TAFINLAR.xml:S2:11421:8	O
.	TAFINLAR.xml:S2:11429:1	O

Withhold	TAFINLAR.xml:S2:11431:8	O
trametinib	TAFINLAR.xml:S2:11440:10	O
if	TAFINLAR.xml:S2:11451:2	O
RPED	TAFINLAR.xml:S2:11454:4	O
is	TAFINLAR.xml:S2:11459:2	O
diagnosed	TAFINLAR.xml:S2:11462:9	O
.	TAFINLAR.xml:S2:11471:1	O

If	TAFINLAR.xml:S2:11473:2	O
resolution	TAFINLAR.xml:S2:11476:10	O
of	TAFINLAR.xml:S2:11487:2	O
the	TAFINLAR.xml:S2:11490:3	O
RPED	TAFINLAR.xml:S2:11494:4	O
is	TAFINLAR.xml:S2:11499:2	O
documented	TAFINLAR.xml:S2:11502:10	O
on	TAFINLAR.xml:S2:11513:2	O
repeat	TAFINLAR.xml:S2:11516:6	O
ophthalmological	TAFINLAR.xml:S2:11523:16	O
evaluation	TAFINLAR.xml:S2:11540:10	O
within	TAFINLAR.xml:S2:11551:6	O
3	TAFINLAR.xml:S2:11558:1	O
weeks	TAFINLAR.xml:S2:11560:5	O
,	TAFINLAR.xml:S2:11565:1	O
resume	TAFINLAR.xml:S2:11567:6	O
trametinib	TAFINLAR.xml:S2:11574:10	O
at	TAFINLAR.xml:S2:11585:2	O
a	TAFINLAR.xml:S2:11588:1	O
lower	TAFINLAR.xml:S2:11590:5	O
dose	TAFINLAR.xml:S2:11596:4	O
level	TAFINLAR.xml:S2:11601:5	O
.	TAFINLAR.xml:S2:11606:1	O

Discontinue	TAFINLAR.xml:S2:11608:11	O
trametinib	TAFINLAR.xml:S2:11620:10	O
if	TAFINLAR.xml:S2:11631:2	O
no	TAFINLAR.xml:S2:11634:2	O
improvement	TAFINLAR.xml:S2:11637:11	O
after	TAFINLAR.xml:S2:11649:5	O
3	TAFINLAR.xml:S2:11655:1	O
weeks	TAFINLAR.xml:S2:11657:5	O
[	TAFINLAR.xml:S2:11663:1	O
see	TAFINLAR.xml:S2:11664:3	O
Dosage	TAFINLAR.xml:S2:11668:6	O
and	TAFINLAR.xml:S2:11675:3	O
Administration	TAFINLAR.xml:S2:11679:14	O
(	TAFINLAR.xml:S2:11694:1	O
2.3	TAFINLAR.xml:S2:11695:3	O
)]	TAFINLAR.xml:S2:11698:2	O
.	TAFINLAR.xml:S2:11700:1	O

Uveitis	TAFINLAR.xml:S2:11712:7	O
and	TAFINLAR.xml:S2:11720:3	O
Iritis	TAFINLAR.xml:S2:11724:6	O
:	TAFINLAR.xml:S2:11730:1	O

Uveitis	TAFINLAR.xml:S2:11741:7	B-AdverseReaction
and	TAFINLAR.xml:S2:11749:3	O
iritis	TAFINLAR.xml:S2:11753:6	B-AdverseReaction
can	TAFINLAR.xml:S2:11760:3	B-Factor
occur	TAFINLAR.xml:S2:11764:5	O
when	TAFINLAR.xml:S2:11770:4	O
TAFINLAR	TAFINLAR.xml:S2:11775:8	O
is	TAFINLAR.xml:S2:11784:2	O
administered	TAFINLAR.xml:S2:11787:12	O
as	TAFINLAR.xml:S2:11800:2	O
a	TAFINLAR.xml:S2:11803:1	O
single	TAFINLAR.xml:S2:11805:6	O
agent	TAFINLAR.xml:S2:11812:5	O
or	TAFINLAR.xml:S2:11818:2	O
when	TAFINLAR.xml:S2:11821:4	O
used	TAFINLAR.xml:S2:11826:4	O
in	TAFINLAR.xml:S2:11831:2	O
combination	TAFINLAR.xml:S2:11834:11	O
with	TAFINLAR.xml:S2:11846:4	O
trametinib	TAFINLAR.xml:S2:11851:10	O
.	TAFINLAR.xml:S2:11861:1	O

Uveitis	TAFINLAR.xml:S2:11870:7	B-AdverseReaction
(	TAFINLAR.xml:S2:11878:1	O
including	TAFINLAR.xml:S2:11879:9	O
iritis	TAFINLAR.xml:S2:11889:6	B-AdverseReaction
)	TAFINLAR.xml:S2:11895:1	O
occurred	TAFINLAR.xml:S2:11897:8	O
in	TAFINLAR.xml:S2:11906:2	O
1%	TAFINLAR.xml:S2:11909:2	O
(	TAFINLAR.xml:S2:11912:1	O
6	TAFINLAR.xml:S2:11913:1	O
586	TAFINLAR.xml:S2:11915:3	O
)	TAFINLAR.xml:S2:11918:1	O
of	TAFINLAR.xml:S2:11920:2	O
patients	TAFINLAR.xml:S2:11923:8	O
treated	TAFINLAR.xml:S2:11932:7	O
with	TAFINLAR.xml:S2:11940:4	O
TAFINLAR	TAFINLAR.xml:S2:11945:8	O
as	TAFINLAR.xml:S2:11954:2	O
a	TAFINLAR.xml:S2:11957:1	O
single	TAFINLAR.xml:S2:11959:6	O
agent	TAFINLAR.xml:S2:11966:5	O
and	TAFINLAR.xml:S2:11972:3	O
uveitis	TAFINLAR.xml:S2:11976:7	B-AdverseReaction
occurred	TAFINLAR.xml:S2:11984:8	O
in	TAFINLAR.xml:S2:11993:2	O
1%	TAFINLAR.xml:S2:11996:2	O
(	TAFINLAR.xml:S2:11999:1	O
2	TAFINLAR.xml:S2:12000:1	O
202	TAFINLAR.xml:S2:12002:3	O
)	TAFINLAR.xml:S2:12005:1	O
of	TAFINLAR.xml:S2:12007:2	O
patients	TAFINLAR.xml:S2:12010:8	O
treated	TAFINLAR.xml:S2:12019:7	O
with	TAFINLAR.xml:S2:12027:4	O
TAFINLAR	TAFINLAR.xml:S2:12032:8	O
in	TAFINLAR.xml:S2:12041:2	O
combination	TAFINLAR.xml:S2:12044:11	O
with	TAFINLAR.xml:S2:12056:4	O
trametinib	TAFINLAR.xml:S2:12061:10	O
.	TAFINLAR.xml:S2:12071:1	O

Symptomatic	TAFINLAR.xml:S2:12073:11	O
treatment	TAFINLAR.xml:S2:12085:9	O
employed	TAFINLAR.xml:S2:12095:8	O
in	TAFINLAR.xml:S2:12104:2	O
clinical	TAFINLAR.xml:S2:12107:8	O
trials	TAFINLAR.xml:S2:12116:6	O
included	TAFINLAR.xml:S2:12123:8	O
steroid	TAFINLAR.xml:S2:12132:7	O
and	TAFINLAR.xml:S2:12140:3	O
mydriatic	TAFINLAR.xml:S2:12144:9	O
ophthalmic	TAFINLAR.xml:S2:12154:10	O
drops	TAFINLAR.xml:S2:12165:5	O
.	TAFINLAR.xml:S2:12170:1	O

Monitor	TAFINLAR.xml:S2:12172:7	O
patients	TAFINLAR.xml:S2:12180:8	O
for	TAFINLAR.xml:S2:12189:3	O
visual	TAFINLAR.xml:S2:12193:6	O
signs	TAFINLAR.xml:S2:12200:5	O
and	TAFINLAR.xml:S2:12206:3	O
symptoms	TAFINLAR.xml:S2:12210:8	O
of	TAFINLAR.xml:S2:12219:2	O
uveitis	TAFINLAR.xml:S2:12222:7	O
(	TAFINLAR.xml:S2:12230:1	O
e	TAFINLAR.xml:S2:12231:1	O
.	TAFINLAR.xml:S2:12232:1	O
g	TAFINLAR.xml:S2:12233:1	O
.	TAFINLAR.xml:S2:12234:1	O
,	TAFINLAR.xml:S2:12235:1	O
change	TAFINLAR.xml:S2:12237:6	O
in	TAFINLAR.xml:S2:12244:2	O
vision	TAFINLAR.xml:S2:12247:6	O
,	TAFINLAR.xml:S2:12253:1	O
photophobia	TAFINLAR.xml:S2:12255:11	O
,	TAFINLAR.xml:S2:12266:1	O
eye	TAFINLAR.xml:S2:12268:3	O
pain	TAFINLAR.xml:S2:12272:4	O
)	TAFINLAR.xml:S2:12276:1	O
.	TAFINLAR.xml:S2:12277:1	O

If	TAFINLAR.xml:S2:12279:2	O
diagnosed	TAFINLAR.xml:S2:12282:9	O
,	TAFINLAR.xml:S2:12291:1	O
withhold	TAFINLAR.xml:S2:12293:8	O
TAFINLAR	TAFINLAR.xml:S2:12302:8	O
for	TAFINLAR.xml:S2:12311:3	O
up	TAFINLAR.xml:S2:12315:2	O
to	TAFINLAR.xml:S2:12318:2	O
6	TAFINLAR.xml:S2:12321:1	O
weeks	TAFINLAR.xml:S2:12323:5	O
until	TAFINLAR.xml:S2:12329:5	O
uveitis	TAFINLAR.xml:S2:12335:7	O
iritis	TAFINLAR.xml:S2:12343:6	O
resolves	TAFINLAR.xml:S2:12350:8	O
to	TAFINLAR.xml:S2:12359:2	O
Grade	TAFINLAR.xml:S2:12362:5	O
0	TAFINLAR.xml:S2:12368:1	O
-	TAFINLAR.xml:S2:12369:1	O
1	TAFINLAR.xml:S2:12370:1	O
.	TAFINLAR.xml:S2:12371:1	O

If	TAFINLAR.xml:S2:12373:2	O
TAFINLAR	TAFINLAR.xml:S2:12376:8	O
is	TAFINLAR.xml:S2:12385:2	O
used	TAFINLAR.xml:S2:12388:4	O
in	TAFINLAR.xml:S2:12393:2	O
combination	TAFINLAR.xml:S2:12396:11	O
with	TAFINLAR.xml:S2:12408:4	O
trametinib	TAFINLAR.xml:S2:12413:10	O
,	TAFINLAR.xml:S2:12423:1	O
do	TAFINLAR.xml:S2:12425:2	O
not	TAFINLAR.xml:S2:12428:3	O
modify	TAFINLAR.xml:S2:12432:6	O
the	TAFINLAR.xml:S2:12439:3	O
dose	TAFINLAR.xml:S2:12443:4	O
of	TAFINLAR.xml:S2:12448:2	O
trametinib	TAFINLAR.xml:S2:12451:10	O
.	TAFINLAR.xml:S2:12461:1	O

5.7	TAFINLAR.xml:S2:12472:3	O
Serious	TAFINLAR.xml:S2:12476:7	O
Febrile	TAFINLAR.xml:S2:12484:7	O
Reactions	TAFINLAR.xml:S2:12492:9	O

Serious	TAFINLAR.xml:S2:12508:7	B-Severity
febrile	TAFINLAR.xml:S2:12516:7	B-AdverseReaction
reactions	TAFINLAR.xml:S2:12524:9	I-AdverseReaction
and	TAFINLAR.xml:S2:12534:3	O
fever	TAFINLAR.xml:S2:12538:5	B-AdverseReaction
of	TAFINLAR.xml:S2:12544:2	O
any	TAFINLAR.xml:S2:12547:3	O
severity	TAFINLAR.xml:S2:12551:8	O
complicated	TAFINLAR.xml:S2:12560:11	O
by	TAFINLAR.xml:S2:12572:2	O
hypotension	TAFINLAR.xml:S2:12575:11	B-AdverseReaction
,	TAFINLAR.xml:S2:12586:1	O
rigors	TAFINLAR.xml:S2:12588:6	B-AdverseReaction
or	TAFINLAR.xml:S2:12595:2	O
chills	TAFINLAR.xml:S2:12598:6	B-AdverseReaction
,	TAFINLAR.xml:S2:12604:1	O
dehydration	TAFINLAR.xml:S2:12606:11	B-AdverseReaction
,	TAFINLAR.xml:S2:12617:1	O
or	TAFINLAR.xml:S2:12619:2	O
renal	TAFINLAR.xml:S2:12622:5	B-AdverseReaction
failure	TAFINLAR.xml:S2:12628:7	I-AdverseReaction
,	TAFINLAR.xml:S2:12635:1	O
can	TAFINLAR.xml:S2:12637:3	B-Factor
occur	TAFINLAR.xml:S2:12641:5	O
when	TAFINLAR.xml:S2:12647:4	O
TAFINLAR	TAFINLAR.xml:S2:12652:8	O
is	TAFINLAR.xml:S2:12661:2	O
administered	TAFINLAR.xml:S2:12664:12	O
as	TAFINLAR.xml:S2:12677:2	O
a	TAFINLAR.xml:S2:12680:1	O
single	TAFINLAR.xml:S2:12682:6	O
agent	TAFINLAR.xml:S2:12689:5	O
or	TAFINLAR.xml:S2:12695:2	O
when	TAFINLAR.xml:S2:12698:4	O
used	TAFINLAR.xml:S2:12703:4	O
in	TAFINLAR.xml:S2:12708:2	O
combination	TAFINLAR.xml:S2:12711:11	O
with	TAFINLAR.xml:S2:12723:4	O
trametinib	TAFINLAR.xml:S2:12728:10	O
.	TAFINLAR.xml:S2:12738:1	O

The	TAFINLAR.xml:S2:12740:3	O
incidence	TAFINLAR.xml:S2:12744:9	O
and	TAFINLAR.xml:S2:12754:3	O
severity	TAFINLAR.xml:S2:12758:8	O
of	TAFINLAR.xml:S2:12767:2	O
pyrexia	TAFINLAR.xml:S2:12770:7	B-AdverseReaction
are	TAFINLAR.xml:S2:12778:3	O
increased	TAFINLAR.xml:S2:12782:9	O
when	TAFINLAR.xml:S2:12792:4	O
TAFINLAR	TAFINLAR.xml:S2:12797:8	O
is	TAFINLAR.xml:S2:12806:2	O
used	TAFINLAR.xml:S2:12809:4	O
in	TAFINLAR.xml:S2:12814:2	O
combination	TAFINLAR.xml:S2:12817:11	O
with	TAFINLAR.xml:S2:12829:4	O
trametinib	TAFINLAR.xml:S2:12834:10	O
compared	TAFINLAR.xml:S2:12845:8	O
with	TAFINLAR.xml:S2:12854:4	O
TAFINLAR	TAFINLAR.xml:S2:12859:8	O
as	TAFINLAR.xml:S2:12868:2	O
a	TAFINLAR.xml:S2:12871:1	O
single	TAFINLAR.xml:S2:12873:6	O
agent	TAFINLAR.xml:S2:12880:5	O
[	TAFINLAR.xml:S2:12886:1	O
see	TAFINLAR.xml:S2:12887:3	O
Adverse	TAFINLAR.xml:S2:12891:7	O
Reactions	TAFINLAR.xml:S2:12899:9	O
(	TAFINLAR.xml:S2:12909:1	O
6.1	TAFINLAR.xml:S2:12910:3	O
)]	TAFINLAR.xml:S2:12913:2	O
.	TAFINLAR.xml:S2:12915:1	O

In	TAFINLAR.xml:S2:12925:2	O
Trial	TAFINLAR.xml:S2:12928:5	O
1	TAFINLAR.xml:S2:12934:1	O
,	TAFINLAR.xml:S2:12935:1	O
the	TAFINLAR.xml:S2:12937:3	O
incidence	TAFINLAR.xml:S2:12941:9	O
of	TAFINLAR.xml:S2:12951:2	O
fever	TAFINLAR.xml:S2:12954:5	B-AdverseReaction
(	TAFINLAR.xml:S2:12960:1	O
serious	TAFINLAR.xml:S2:12961:7	B-Severity
and	TAFINLAR.xml:S2:12969:3	O
non	TAFINLAR.xml:S2:12973:3	O
-	TAFINLAR.xml:S2:12976:1	O
serious	TAFINLAR.xml:S2:12977:7	O
)	TAFINLAR.xml:S2:12984:1	O
was	TAFINLAR.xml:S2:12986:3	O
28%	TAFINLAR.xml:S2:12990:3	O
in	TAFINLAR.xml:S2:12994:2	O
patients	TAFINLAR.xml:S2:12997:8	O
treated	TAFINLAR.xml:S2:13006:7	O
with	TAFINLAR.xml:S2:13014:4	O
TAFINLAR	TAFINLAR.xml:S2:13019:8	O
and	TAFINLAR.xml:S2:13028:3	O
10%	TAFINLAR.xml:S2:13032:3	O
in	TAFINLAR.xml:S2:13036:2	O
patients	TAFINLAR.xml:S2:13039:8	O
treated	TAFINLAR.xml:S2:13048:7	O
with	TAFINLAR.xml:S2:13056:4	O
dacarbazine	TAFINLAR.xml:S2:13061:11	O
.	TAFINLAR.xml:S2:13072:1	O

In	TAFINLAR.xml:S2:13074:2	O
patients	TAFINLAR.xml:S2:13077:8	O
treated	TAFINLAR.xml:S2:13086:7	O
with	TAFINLAR.xml:S2:13094:4	O
TAFINLAR	TAFINLAR.xml:S2:13099:8	O
,	TAFINLAR.xml:S2:13107:1	O
the	TAFINLAR.xml:S2:13109:3	O
median	TAFINLAR.xml:S2:13113:6	O
time	TAFINLAR.xml:S2:13120:4	O
to	TAFINLAR.xml:S2:13125:2	O
initial	TAFINLAR.xml:S2:13128:7	O
onset	TAFINLAR.xml:S2:13136:5	O
of	TAFINLAR.xml:S2:13142:2	O
fever	TAFINLAR.xml:S2:13145:5	B-AdverseReaction
(	TAFINLAR.xml:S2:13151:1	O
any	TAFINLAR.xml:S2:13152:3	O
severity	TAFINLAR.xml:S2:13156:8	O
)	TAFINLAR.xml:S2:13164:1	O
was	TAFINLAR.xml:S2:13166:3	O
11	TAFINLAR.xml:S2:13170:2	O
days	TAFINLAR.xml:S2:13173:4	O
(	TAFINLAR.xml:S2:13178:1	O
range	TAFINLAR.xml:S2:13179:5	O
:	TAFINLAR.xml:S2:13184:1	O
1	TAFINLAR.xml:S2:13186:1	O
to	TAFINLAR.xml:S2:13188:2	O
202	TAFINLAR.xml:S2:13191:3	O
days	TAFINLAR.xml:S2:13195:4	O
)	TAFINLAR.xml:S2:13199:1	O
and	TAFINLAR.xml:S2:13201:3	O
the	TAFINLAR.xml:S2:13205:3	O
median	TAFINLAR.xml:S2:13209:6	O
duration	TAFINLAR.xml:S2:13216:8	O
of	TAFINLAR.xml:S2:13225:2	O
fever	TAFINLAR.xml:S2:13228:5	B-AdverseReaction
was	TAFINLAR.xml:S2:13234:3	O
3	TAFINLAR.xml:S2:13238:1	O
days	TAFINLAR.xml:S2:13240:4	O
(	TAFINLAR.xml:S2:13245:1	O
range	TAFINLAR.xml:S2:13246:5	O
:	TAFINLAR.xml:S2:13251:1	O
1	TAFINLAR.xml:S2:13253:1	O
to	TAFINLAR.xml:S2:13255:2	O
129	TAFINLAR.xml:S2:13258:3	O
days	TAFINLAR.xml:S2:13262:4	O
)	TAFINLAR.xml:S2:13266:1	O
.	TAFINLAR.xml:S2:13267:1	O

Serious	TAFINLAR.xml:S2:13269:7	B-Severity
febrile	TAFINLAR.xml:S2:13277:7	B-AdverseReaction
reactions	TAFINLAR.xml:S2:13285:9	I-AdverseReaction
and	TAFINLAR.xml:S2:13295:3	O
fever	TAFINLAR.xml:S2:13299:5	B-AdverseReaction
of	TAFINLAR.xml:S2:13305:2	O
any	TAFINLAR.xml:S2:13308:3	O
severity	TAFINLAR.xml:S2:13312:8	O
complicated	TAFINLAR.xml:S2:13321:11	O
by	TAFINLAR.xml:S2:13333:2	O
hypotension	TAFINLAR.xml:S2:13336:11	B-AdverseReaction
,	TAFINLAR.xml:S2:13347:1	O
rigors	TAFINLAR.xml:S2:13349:6	B-AdverseReaction
or	TAFINLAR.xml:S2:13356:2	O
chills	TAFINLAR.xml:S2:13359:6	B-AdverseReaction
occurred	TAFINLAR.xml:S2:13366:8	O
in	TAFINLAR.xml:S2:13375:2	O
3.7%	TAFINLAR.xml:S2:13378:4	O
(	TAFINLAR.xml:S2:13383:1	O
7	TAFINLAR.xml:S2:13384:1	O
187	TAFINLAR.xml:S2:13386:3	O
)	TAFINLAR.xml:S2:13389:1	O
of	TAFINLAR.xml:S2:13391:2	O
patients	TAFINLAR.xml:S2:13394:8	O
treated	TAFINLAR.xml:S2:13403:7	O
with	TAFINLAR.xml:S2:13411:4	O
TAFINLAR	TAFINLAR.xml:S2:13416:8	O
and	TAFINLAR.xml:S2:13425:3	O
in	TAFINLAR.xml:S2:13429:2	O
none	TAFINLAR.xml:S2:13432:4	O
of	TAFINLAR.xml:S2:13437:2	O
the	TAFINLAR.xml:S2:13440:3	O
59	TAFINLAR.xml:S2:13444:2	O
patients	TAFINLAR.xml:S2:13447:8	O
treated	TAFINLAR.xml:S2:13456:7	O
with	TAFINLAR.xml:S2:13464:4	O
dacarbazine	TAFINLAR.xml:S2:13469:11	O
.	TAFINLAR.xml:S2:13480:1	O

In	TAFINLAR.xml:S2:13489:2	O
Trial	TAFINLAR.xml:S2:13492:5	O
2	TAFINLAR.xml:S2:13498:1	O
,	TAFINLAR.xml:S2:13499:1	O
the	TAFINLAR.xml:S2:13501:3	O
incidence	TAFINLAR.xml:S2:13505:9	O
of	TAFINLAR.xml:S2:13515:2	O
fever	TAFINLAR.xml:S2:13518:5	B-AdverseReaction
(	TAFINLAR.xml:S2:13524:1	O
serious	TAFINLAR.xml:S2:13525:7	B-Severity
and	TAFINLAR.xml:S2:13533:3	O
non	TAFINLAR.xml:S2:13537:3	O
-	TAFINLAR.xml:S2:13540:1	O
serious	TAFINLAR.xml:S2:13541:7	O
)	TAFINLAR.xml:S2:13548:1	O
was	TAFINLAR.xml:S2:13550:3	O
71%	TAFINLAR.xml:S2:13554:3	O
(	TAFINLAR.xml:S2:13558:1	O
39	TAFINLAR.xml:S2:13559:2	O
55	TAFINLAR.xml:S2:13562:2	O
)	TAFINLAR.xml:S2:13564:1	O
in	TAFINLAR.xml:S2:13566:2	O
patients	TAFINLAR.xml:S2:13569:8	O
treated	TAFINLAR.xml:S2:13578:7	O
with	TAFINLAR.xml:S2:13586:4	O
TAFINLAR	TAFINLAR.xml:S2:13591:8	O
in	TAFINLAR.xml:S2:13600:2	O
combination	TAFINLAR.xml:S2:13603:11	O
with	TAFINLAR.xml:S2:13615:4	O
trametinib	TAFINLAR.xml:S2:13620:10	O
and	TAFINLAR.xml:S2:13631:3	O
26%	TAFINLAR.xml:S2:13635:3	O
(	TAFINLAR.xml:S2:13639:1	O
14	TAFINLAR.xml:S2:13640:2	O
53	TAFINLAR.xml:S2:13643:2	O
)	TAFINLAR.xml:S2:13645:1	O
in	TAFINLAR.xml:S2:13647:2	O
patients	TAFINLAR.xml:S2:13650:8	O
treated	TAFINLAR.xml:S2:13659:7	O
with	TAFINLAR.xml:S2:13667:4	O
TAFINLAR	TAFINLAR.xml:S2:13672:8	O
as	TAFINLAR.xml:S2:13681:2	O
a	TAFINLAR.xml:S2:13684:1	O
single	TAFINLAR.xml:S2:13686:6	O
agent	TAFINLAR.xml:S2:13693:5	O
.	TAFINLAR.xml:S2:13698:1	O

Serious	TAFINLAR.xml:S2:13700:7	B-Severity
febrile	TAFINLAR.xml:S2:13708:7	B-AdverseReaction
reactions	TAFINLAR.xml:S2:13716:9	I-AdverseReaction
and	TAFINLAR.xml:S2:13726:3	O
fever	TAFINLAR.xml:S2:13730:5	B-AdverseReaction
of	TAFINLAR.xml:S2:13736:2	O
any	TAFINLAR.xml:S2:13739:3	O
severity	TAFINLAR.xml:S2:13743:8	O
complicated	TAFINLAR.xml:S2:13752:11	O
by	TAFINLAR.xml:S2:13764:2	O
hypotension	TAFINLAR.xml:S2:13767:11	B-AdverseReaction
,	TAFINLAR.xml:S2:13778:1	O
rigors	TAFINLAR.xml:S2:13780:6	B-AdverseReaction
or	TAFINLAR.xml:S2:13787:2	O
chills	TAFINLAR.xml:S2:13790:6	B-AdverseReaction
occurred	TAFINLAR.xml:S2:13797:8	O
in	TAFINLAR.xml:S2:13806:2	O
25%	TAFINLAR.xml:S2:13809:3	O
(	TAFINLAR.xml:S2:13813:1	O
14	TAFINLAR.xml:S2:13814:2	O
55	TAFINLAR.xml:S2:13817:2	O
)	TAFINLAR.xml:S2:13819:1	O
of	TAFINLAR.xml:S2:13821:2	O
patients	TAFINLAR.xml:S2:13824:8	O
treated	TAFINLAR.xml:S2:13833:7	O
with	TAFINLAR.xml:S2:13841:4	O
TAFINLAR	TAFINLAR.xml:S2:13846:8	O
in	TAFINLAR.xml:S2:13855:2	O
combination	TAFINLAR.xml:S2:13858:11	O
with	TAFINLAR.xml:S2:13870:4	O
trametinib	TAFINLAR.xml:S2:13875:10	O
compared	TAFINLAR.xml:S2:13886:8	O
with	TAFINLAR.xml:S2:13895:4	O
2%	TAFINLAR.xml:S2:13900:2	O
(	TAFINLAR.xml:S2:13903:1	O
1	TAFINLAR.xml:S2:13904:1	O
53	TAFINLAR.xml:S2:13906:2	O
)	TAFINLAR.xml:S2:13908:1	O
of	TAFINLAR.xml:S2:13910:2	O
patients	TAFINLAR.xml:S2:13913:8	O
treated	TAFINLAR.xml:S2:13922:7	O
with	TAFINLAR.xml:S2:13930:4	O
TAFINLAR	TAFINLAR.xml:S2:13935:8	O
as	TAFINLAR.xml:S2:13944:2	O
a	TAFINLAR.xml:S2:13947:1	O
single	TAFINLAR.xml:S2:13949:6	O
agent	TAFINLAR.xml:S2:13956:5	O
.	TAFINLAR.xml:S2:13961:1	O

Fever	TAFINLAR.xml:S2:13963:5	B-AdverseReaction
was	TAFINLAR.xml:S2:13969:3	O
complicated	TAFINLAR.xml:S2:13973:11	O
with	TAFINLAR.xml:S2:13985:4	O
chills	TAFINLAR.xml:S2:13990:6	B-AdverseReaction
rigors	TAFINLAR.xml:S2:13997:6	B-AdverseReaction
in	TAFINLAR.xml:S2:14004:2	O
51%	TAFINLAR.xml:S2:14007:3	O
(	TAFINLAR.xml:S2:14011:1	O
28	TAFINLAR.xml:S2:14012:2	O
55	TAFINLAR.xml:S2:14015:2	O
)	TAFINLAR.xml:S2:14017:1	O
,	TAFINLAR.xml:S2:14018:1	O
dehydration	TAFINLAR.xml:S2:14020:11	B-AdverseReaction
in	TAFINLAR.xml:S2:14032:2	O
9%	TAFINLAR.xml:S2:14035:2	O
(	TAFINLAR.xml:S2:14038:1	O
5	TAFINLAR.xml:S2:14039:1	O
55	TAFINLAR.xml:S2:14041:2	O
)	TAFINLAR.xml:S2:14043:1	O
,	TAFINLAR.xml:S2:14044:1	O
renal	TAFINLAR.xml:S2:14046:5	B-AdverseReaction
failure	TAFINLAR.xml:S2:14052:7	I-AdverseReaction
in	TAFINLAR.xml:S2:14060:2	O
4%	TAFINLAR.xml:S2:14063:2	O
(	TAFINLAR.xml:S2:14066:1	O
2	TAFINLAR.xml:S2:14067:1	O
55	TAFINLAR.xml:S2:14069:2	O
)	TAFINLAR.xml:S2:14071:1	O
,	TAFINLAR.xml:S2:14072:1	O
and	TAFINLAR.xml:S2:14074:3	O
syncope	TAFINLAR.xml:S2:14078:7	B-AdverseReaction
in	TAFINLAR.xml:S2:14086:2	O
4%	TAFINLAR.xml:S2:14089:2	O
(	TAFINLAR.xml:S2:14092:1	O
2	TAFINLAR.xml:S2:14093:1	O
55	TAFINLAR.xml:S2:14095:2	O
)	TAFINLAR.xml:S2:14097:1	O
of	TAFINLAR.xml:S2:14099:2	O
patients	TAFINLAR.xml:S2:14102:8	O
in	TAFINLAR.xml:S2:14111:2	O
Trial	TAFINLAR.xml:S2:14114:5	O
2	TAFINLAR.xml:S2:14120:1	O
.	TAFINLAR.xml:S2:14121:1	O

In	TAFINLAR.xml:S2:14130:2	O
patients	TAFINLAR.xml:S2:14133:8	O
treated	TAFINLAR.xml:S2:14142:7	O
with	TAFINLAR.xml:S2:14150:4	O
TAFINLAR	TAFINLAR.xml:S2:14155:8	O
in	TAFINLAR.xml:S2:14164:2	O
combination	TAFINLAR.xml:S2:14167:11	O
with	TAFINLAR.xml:S2:14179:4	O
trametinib	TAFINLAR.xml:S2:14184:10	O
,	TAFINLAR.xml:S2:14194:1	O
the	TAFINLAR.xml:S2:14196:3	O
median	TAFINLAR.xml:S2:14200:6	O
time	TAFINLAR.xml:S2:14207:4	O
to	TAFINLAR.xml:S2:14212:2	O
initial	TAFINLAR.xml:S2:14215:7	O
onset	TAFINLAR.xml:S2:14223:5	O
of	TAFINLAR.xml:S2:14229:2	O
fever	TAFINLAR.xml:S2:14232:5	B-AdverseReaction
was	TAFINLAR.xml:S2:14238:3	O
30	TAFINLAR.xml:S2:14242:2	O
days	TAFINLAR.xml:S2:14245:4	O
compared	TAFINLAR.xml:S2:14250:8	O
with	TAFINLAR.xml:S2:14259:4	O
19	TAFINLAR.xml:S2:14264:2	O
days	TAFINLAR.xml:S2:14267:4	O
in	TAFINLAR.xml:S2:14272:2	O
patients	TAFINLAR.xml:S2:14275:8	O
treated	TAFINLAR.xml:S2:14284:7	O
with	TAFINLAR.xml:S2:14292:4	O
TAFINLAR	TAFINLAR.xml:S2:14297:8	O
as	TAFINLAR.xml:S2:14306:2	O
a	TAFINLAR.xml:S2:14309:1	O
single	TAFINLAR.xml:S2:14311:6	O
agent	TAFINLAR.xml:S2:14318:5	O
;	TAFINLAR.xml:S2:14323:1	O
the	TAFINLAR.xml:S2:14325:3	O
median	TAFINLAR.xml:S2:14329:6	O
duration	TAFINLAR.xml:S2:14336:8	O
of	TAFINLAR.xml:S2:14345:2	O
fever	TAFINLAR.xml:S2:14348:5	B-AdverseReaction
was	TAFINLAR.xml:S2:14354:3	O
6	TAFINLAR.xml:S2:14358:1	O
days	TAFINLAR.xml:S2:14360:4	O
with	TAFINLAR.xml:S2:14365:4	O
the	TAFINLAR.xml:S2:14370:3	O
combination	TAFINLAR.xml:S2:14374:11	O
compared	TAFINLAR.xml:S2:14386:8	O
with	TAFINLAR.xml:S2:14395:4	O
4	TAFINLAR.xml:S2:14400:1	O
days	TAFINLAR.xml:S2:14402:4	O
with	TAFINLAR.xml:S2:14407:4	O
TAFINLAR	TAFINLAR.xml:S2:14412:8	O
as	TAFINLAR.xml:S2:14421:2	O
a	TAFINLAR.xml:S2:14424:1	O
single	TAFINLAR.xml:S2:14426:6	O
agent	TAFINLAR.xml:S2:14433:5	O
.	TAFINLAR.xml:S2:14438:1	O

Across	TAFINLAR.xml:S2:14447:6	O
clinical	TAFINLAR.xml:S2:14454:8	O
trials	TAFINLAR.xml:S2:14463:6	O
of	TAFINLAR.xml:S2:14470:2	O
TAFINLAR	TAFINLAR.xml:S2:14473:8	O
administered	TAFINLAR.xml:S2:14482:12	O
in	TAFINLAR.xml:S2:14495:2	O
combination	TAFINLAR.xml:S2:14498:11	O
with	TAFINLAR.xml:S2:14510:4	O
trametinib	TAFINLAR.xml:S2:14515:10	O
(	TAFINLAR.xml:S2:14526:1	O
N	TAFINLAR.xml:S2:14527:1	O
202	TAFINLAR.xml:S2:14531:3	O
)	TAFINLAR.xml:S2:14534:1	O
,	TAFINLAR.xml:S2:14535:1	O
the	TAFINLAR.xml:S2:14537:3	O
incidence	TAFINLAR.xml:S2:14541:9	O
of	TAFINLAR.xml:S2:14551:2	O
pyrexia	TAFINLAR.xml:S2:14554:7	B-AdverseReaction
was	TAFINLAR.xml:S2:14562:3	O
57%	TAFINLAR.xml:S2:14566:3	O
(	TAFINLAR.xml:S2:14570:1	O
116	TAFINLAR.xml:S2:14571:3	O
202	TAFINLAR.xml:S2:14575:3	O
)	TAFINLAR.xml:S2:14578:1	O
.	TAFINLAR.xml:S2:14579:1	O

Withhold	TAFINLAR.xml:S2:14587:8	O
TAFINLAR	TAFINLAR.xml:S2:14596:8	O
for	TAFINLAR.xml:S2:14605:3	O
fever	TAFINLAR.xml:S2:14609:5	O
of	TAFINLAR.xml:S2:14615:2	O
101.3	TAFINLAR.xml:S2:14618:5	O
oF	TAFINLAR.xml:S2:14623:2	O
or	TAFINLAR.xml:S2:14626:2	O
higher	TAFINLAR.xml:S2:14629:6	O
.	TAFINLAR.xml:S2:14635:1	O

Withhold	TAFINLAR.xml:S2:14637:8	O
trametinib	TAFINLAR.xml:S2:14646:10	O
for	TAFINLAR.xml:S2:14657:3	O
any	TAFINLAR.xml:S2:14661:3	O
fever	TAFINLAR.xml:S2:14665:5	O
higher	TAFINLAR.xml:S2:14671:6	O
than	TAFINLAR.xml:S2:14678:4	O
104	TAFINLAR.xml:S2:14683:3	O
oF	TAFINLAR.xml:S2:14686:2	O
.	TAFINLAR.xml:S2:14688:1	O

Withhold	TAFINLAR.xml:S2:14690:8	O
TAFINLAR	TAFINLAR.xml:S2:14699:8	O
,	TAFINLAR.xml:S2:14707:1	O
and	TAFINLAR.xml:S2:14709:3	O
trametinib	TAFINLAR.xml:S2:14713:10	O
if	TAFINLAR.xml:S2:14724:2	O
used	TAFINLAR.xml:S2:14727:4	O
in	TAFINLAR.xml:S2:14732:2	O
combination	TAFINLAR.xml:S2:14735:11	O
,	TAFINLAR.xml:S2:14746:1	O
for	TAFINLAR.xml:S2:14748:3	O
any	TAFINLAR.xml:S2:14752:3	O
serious	TAFINLAR.xml:S2:14756:7	O
febrile	TAFINLAR.xml:S2:14764:7	O
reaction	TAFINLAR.xml:S2:14772:8	O
or	TAFINLAR.xml:S2:14781:2	O
fever	TAFINLAR.xml:S2:14784:5	O
complicated	TAFINLAR.xml:S2:14790:11	O
by	TAFINLAR.xml:S2:14802:2	O
hypotension	TAFINLAR.xml:S2:14805:11	O
,	TAFINLAR.xml:S2:14816:1	O
rigors	TAFINLAR.xml:S2:14818:6	O
or	TAFINLAR.xml:S2:14825:2	O
chills	TAFINLAR.xml:S2:14828:6	O
,	TAFINLAR.xml:S2:14834:1	O
dehydration	TAFINLAR.xml:S2:14836:11	O
,	TAFINLAR.xml:S2:14847:1	O
or	TAFINLAR.xml:S2:14849:2	O
renal	TAFINLAR.xml:S2:14852:5	O
failure	TAFINLAR.xml:S2:14858:7	O
and	TAFINLAR.xml:S2:14866:3	O
evaluate	TAFINLAR.xml:S2:14870:8	O
for	TAFINLAR.xml:S2:14879:3	O
signs	TAFINLAR.xml:S2:14883:5	O
and	TAFINLAR.xml:S2:14889:3	O
symptoms	TAFINLAR.xml:S2:14893:8	O
of	TAFINLAR.xml:S2:14902:2	O
infection	TAFINLAR.xml:S2:14905:9	O
.	TAFINLAR.xml:S2:14914:1	O

Refer	TAFINLAR.xml:S2:14916:5	O
to	TAFINLAR.xml:S2:14922:2	O
Table	TAFINLAR.xml:S2:14925:5	O
2	TAFINLAR.xml:S2:14931:1	O
for	TAFINLAR.xml:S2:14933:3	O
recommended	TAFINLAR.xml:S2:14937:11	O
dose	TAFINLAR.xml:S2:14949:4	O
modifications	TAFINLAR.xml:S2:14954:13	O
for	TAFINLAR.xml:S2:14968:3	O
adverse	TAFINLAR.xml:S2:14972:7	O
reactions	TAFINLAR.xml:S2:14980:9	O
[	TAFINLAR.xml:S2:14990:1	O
see	TAFINLAR.xml:S2:14991:3	O
Dosage	TAFINLAR.xml:S2:14995:6	O
and	TAFINLAR.xml:S2:15002:3	O
Administration	TAFINLAR.xml:S2:15006:14	O
(	TAFINLAR.xml:S2:15021:1	O
2.3	TAFINLAR.xml:S2:15022:3	O
)]	TAFINLAR.xml:S2:15025:2	O
.	TAFINLAR.xml:S2:15027:1	O

Prophylaxis	TAFINLAR.xml:S2:15030:11	O
with	TAFINLAR.xml:S2:15042:4	O
antipyretics	TAFINLAR.xml:S2:15047:12	O
may	TAFINLAR.xml:S2:15060:3	O
be	TAFINLAR.xml:S2:15064:2	O
required	TAFINLAR.xml:S2:15067:8	O
when	TAFINLAR.xml:S2:15076:4	O
resuming	TAFINLAR.xml:S2:15081:8	O
TAFINLAR	TAFINLAR.xml:S2:15090:8	O
or	TAFINLAR.xml:S2:15099:2	O
trametinib	TAFINLAR.xml:S2:15102:10	O
.	TAFINLAR.xml:S2:15112:1	O

5.8	TAFINLAR.xml:S2:15124:3	O
Serious	TAFINLAR.xml:S2:15128:7	O
Skin	TAFINLAR.xml:S2:15136:4	O
Toxicity	TAFINLAR.xml:S2:15141:8	O

Serious	TAFINLAR.xml:S2:15158:7	B-Severity
skin	TAFINLAR.xml:S2:15166:4	B-AdverseReaction
toxicity	TAFINLAR.xml:S2:15171:8	I-AdverseReaction
can	TAFINLAR.xml:S2:15180:3	B-Factor
occur	TAFINLAR.xml:S2:15184:5	O
when	TAFINLAR.xml:S2:15190:4	O
TAFINLAR	TAFINLAR.xml:S2:15195:8	O
is	TAFINLAR.xml:S2:15204:2	O
used	TAFINLAR.xml:S2:15207:4	O
in	TAFINLAR.xml:S2:15212:2	O
combination	TAFINLAR.xml:S2:15215:11	O
with	TAFINLAR.xml:S2:15227:4	O
trametinib	TAFINLAR.xml:S2:15232:10	O
and	TAFINLAR.xml:S2:15243:3	O
with	TAFINLAR.xml:S2:15247:4	O
trametinib	TAFINLAR.xml:S2:15252:10	O
as	TAFINLAR.xml:S2:15263:2	O
a	TAFINLAR.xml:S2:15266:1	O
single	TAFINLAR.xml:S2:15268:6	O
agent	TAFINLAR.xml:S2:15275:5	O
[	TAFINLAR.xml:S2:15281:1	O
refer	TAFINLAR.xml:S2:15282:5	O
to	TAFINLAR.xml:S2:15288:2	O
Full	TAFINLAR.xml:S2:15291:4	O
Prescribing	TAFINLAR.xml:S2:15296:11	O
Information	TAFINLAR.xml:S2:15308:11	O
for	TAFINLAR.xml:S2:15320:3	O
trametinib	TAFINLAR.xml:S2:15324:10	O
]	TAFINLAR.xml:S2:15334:1	O
.	TAFINLAR.xml:S2:15337:1	O

In	TAFINLAR.xml:S2:15346:2	O
Trial	TAFINLAR.xml:S2:15349:5	O
2	TAFINLAR.xml:S2:15355:1	O
,	TAFINLAR.xml:S2:15356:1	O
the	TAFINLAR.xml:S2:15358:3	O
incidence	TAFINLAR.xml:S2:15362:9	O
of	TAFINLAR.xml:S2:15372:2	O
any	TAFINLAR.xml:S2:15375:3	O
skin	TAFINLAR.xml:S2:15379:4	B-AdverseReaction
toxicity	TAFINLAR.xml:S2:15384:8	I-AdverseReaction
was	TAFINLAR.xml:S2:15393:3	O
similar	TAFINLAR.xml:S2:15397:7	O
for	TAFINLAR.xml:S2:15405:3	O
patients	TAFINLAR.xml:S2:15409:8	O
receiving	TAFINLAR.xml:S2:15418:9	O
TAFINLAR	TAFINLAR.xml:S2:15428:8	O
in	TAFINLAR.xml:S2:15437:2	O
combination	TAFINLAR.xml:S2:15440:11	O
with	TAFINLAR.xml:S2:15452:4	O
trametinib	TAFINLAR.xml:S2:15457:10	O
(	TAFINLAR.xml:S2:15468:1	O
65%	TAFINLAR.xml:S2:15469:3	O
[	TAFINLAR.xml:S2:15473:1	O
36	TAFINLAR.xml:S2:15474:2	O
55	TAFINLAR.xml:S2:15477:2	O
])	TAFINLAR.xml:S2:15479:2	O
compared	TAFINLAR.xml:S2:15482:8	O
with	TAFINLAR.xml:S2:15491:4	O
patients	TAFINLAR.xml:S2:15496:8	O
receiving	TAFINLAR.xml:S2:15505:9	O
TAFINLAR	TAFINLAR.xml:S2:15515:8	O
as	TAFINLAR.xml:S2:15524:2	O
a	TAFINLAR.xml:S2:15527:1	O
single	TAFINLAR.xml:S2:15529:6	O
agent	TAFINLAR.xml:S2:15536:5	O
(	TAFINLAR.xml:S2:15542:1	O
68%	TAFINLAR.xml:S2:15543:3	O
[	TAFINLAR.xml:S2:15547:1	O
36	TAFINLAR.xml:S2:15548:2	O
53	TAFINLAR.xml:S2:15551:2	O
])	TAFINLAR.xml:S2:15553:2	O
.	TAFINLAR.xml:S2:15555:1	O

The	TAFINLAR.xml:S2:15557:3	O
median	TAFINLAR.xml:S2:15561:6	O
time	TAFINLAR.xml:S2:15568:4	O
to	TAFINLAR.xml:S2:15573:2	O
onset	TAFINLAR.xml:S2:15576:5	O
of	TAFINLAR.xml:S2:15582:2	O
skin	TAFINLAR.xml:S2:15585:4	B-AdverseReaction
toxicity	TAFINLAR.xml:S2:15590:8	I-AdverseReaction
in	TAFINLAR.xml:S2:15599:2	O
patients	TAFINLAR.xml:S2:15602:8	O
treated	TAFINLAR.xml:S2:15611:7	O
with	TAFINLAR.xml:S2:15619:4	O
TAFINLAR	TAFINLAR.xml:S2:15624:8	O
in	TAFINLAR.xml:S2:15633:2	O
combination	TAFINLAR.xml:S2:15636:11	O
with	TAFINLAR.xml:S2:15648:4	O
trametinib	TAFINLAR.xml:S2:15653:10	O
was	TAFINLAR.xml:S2:15664:3	O
37	TAFINLAR.xml:S2:15668:2	O
days	TAFINLAR.xml:S2:15671:4	O
(	TAFINLAR.xml:S2:15676:1	O
range	TAFINLAR.xml:S2:15677:5	O
:	TAFINLAR.xml:S2:15682:1	O
1	TAFINLAR.xml:S2:15684:1	O
to	TAFINLAR.xml:S2:15686:2	O
225	TAFINLAR.xml:S2:15689:3	O
days	TAFINLAR.xml:S2:15693:4	O
)	TAFINLAR.xml:S2:15697:1	O
and	TAFINLAR.xml:S2:15699:3	O
median	TAFINLAR.xml:S2:15703:6	O
time	TAFINLAR.xml:S2:15710:4	O
to	TAFINLAR.xml:S2:15715:2	O
resolution	TAFINLAR.xml:S2:15718:10	O
of	TAFINLAR.xml:S2:15729:2	O
skin	TAFINLAR.xml:S2:15732:4	B-AdverseReaction
toxicity	TAFINLAR.xml:S2:15737:8	I-AdverseReaction
was	TAFINLAR.xml:S2:15746:3	O
33	TAFINLAR.xml:S2:15750:2	O
days	TAFINLAR.xml:S2:15753:4	O
(	TAFINLAR.xml:S2:15758:1	O
range	TAFINLAR.xml:S2:15759:5	O
:	TAFINLAR.xml:S2:15764:1	O
3	TAFINLAR.xml:S2:15766:1	O
to	TAFINLAR.xml:S2:15768:2	O
421	TAFINLAR.xml:S2:15771:3	O
days	TAFINLAR.xml:S2:15775:4	O
)	TAFINLAR.xml:S2:15779:1	O
.	TAFINLAR.xml:S2:15780:1	O

No	TAFINLAR.xml:S2:15782:2	O
patient	TAFINLAR.xml:S2:15785:7	O
required	TAFINLAR.xml:S2:15793:8	O
dose	TAFINLAR.xml:S2:15802:4	O
reduction	TAFINLAR.xml:S2:15807:9	O
or	TAFINLAR.xml:S2:15817:2	O
permanent	TAFINLAR.xml:S2:15820:9	O
discontinuation	TAFINLAR.xml:S2:15830:15	O
of	TAFINLAR.xml:S2:15846:2	O
TAFINLAR	TAFINLAR.xml:S2:15849:8	O
or	TAFINLAR.xml:S2:15858:2	O
trametinib	TAFINLAR.xml:S2:15861:10	O
for	TAFINLAR.xml:S2:15872:3	O
skin	TAFINLAR.xml:S2:15876:4	O
toxicity	TAFINLAR.xml:S2:15881:8	O
.	TAFINLAR.xml:S2:15889:1	O

Across	TAFINLAR.xml:S2:15898:6	O
clinical	TAFINLAR.xml:S2:15905:8	O
trials	TAFINLAR.xml:S2:15914:6	O
of	TAFINLAR.xml:S2:15921:2	O
TAFINLAR	TAFINLAR.xml:S2:15924:8	O
in	TAFINLAR.xml:S2:15933:2	O
combination	TAFINLAR.xml:S2:15936:11	O
with	TAFINLAR.xml:S2:15948:4	O
trametinib	TAFINLAR.xml:S2:15953:10	O
(	TAFINLAR.xml:S2:15964:1	O
N	TAFINLAR.xml:S2:15965:1	O
202	TAFINLAR.xml:S2:15969:3	O
)	TAFINLAR.xml:S2:15972:1	O
,	TAFINLAR.xml:S2:15973:1	O
severe	TAFINLAR.xml:S2:15975:6	B-Severity
skin	TAFINLAR.xml:S2:15982:4	B-AdverseReaction
toxicity	TAFINLAR.xml:S2:15987:8	I-AdverseReaction
and	TAFINLAR.xml:S2:15996:3	O
secondary	TAFINLAR.xml:S2:16000:9	B-AdverseReaction
infections	TAFINLAR.xml:S2:16010:10	I-AdverseReaction
of	TAFINLAR.xml:S2:16021:2	I-AdverseReaction
the	TAFINLAR.xml:S2:16024:3	I-AdverseReaction
skin	TAFINLAR.xml:S2:16028:4	I-AdverseReaction
requiring	TAFINLAR.xml:S2:16033:9	O
hospitalization	TAFINLAR.xml:S2:16043:15	O
occurred	TAFINLAR.xml:S2:16059:8	O
in	TAFINLAR.xml:S2:16068:2	O
2.5%	TAFINLAR.xml:S2:16071:4	O
(	TAFINLAR.xml:S2:16076:1	O
5	TAFINLAR.xml:S2:16077:1	O
202	TAFINLAR.xml:S2:16079:3	O
)	TAFINLAR.xml:S2:16082:1	O
of	TAFINLAR.xml:S2:16084:2	O
patients	TAFINLAR.xml:S2:16087:8	O
treated	TAFINLAR.xml:S2:16096:7	O
with	TAFINLAR.xml:S2:16104:4	O
TAFINLAR	TAFINLAR.xml:S2:16109:8	O
in	TAFINLAR.xml:S2:16118:2	O
combination	TAFINLAR.xml:S2:16121:11	O
with	TAFINLAR.xml:S2:16133:4	O
trametinib	TAFINLAR.xml:S2:16138:10	O
.	TAFINLAR.xml:S2:16148:1	O

Withhold	TAFINLAR.xml:S2:16157:8	O
TAFINLAR	TAFINLAR.xml:S2:16166:8	O
,	TAFINLAR.xml:S2:16174:1	O
and	TAFINLAR.xml:S2:16176:3	O
trametinib	TAFINLAR.xml:S2:16180:10	O
if	TAFINLAR.xml:S2:16191:2	O
used	TAFINLAR.xml:S2:16194:4	O
in	TAFINLAR.xml:S2:16199:2	O
combination	TAFINLAR.xml:S2:16202:11	O
,	TAFINLAR.xml:S2:16213:1	O
for	TAFINLAR.xml:S2:16215:3	O
intolerable	TAFINLAR.xml:S2:16219:11	O
or	TAFINLAR.xml:S2:16231:2	O
severe	TAFINLAR.xml:S2:16234:6	O
skin	TAFINLAR.xml:S2:16241:4	O
toxicity	TAFINLAR.xml:S2:16246:8	O
.	TAFINLAR.xml:S2:16254:1	O

TAFINLAR	TAFINLAR.xml:S2:16256:8	O
and	TAFINLAR.xml:S2:16265:3	O
trametinib	TAFINLAR.xml:S2:16269:10	O
may	TAFINLAR.xml:S2:16280:3	O
be	TAFINLAR.xml:S2:16284:2	O
resumed	TAFINLAR.xml:S2:16287:7	O
at	TAFINLAR.xml:S2:16295:2	O
lower	TAFINLAR.xml:S2:16298:5	O
dose	TAFINLAR.xml:S2:16304:4	O
levels	TAFINLAR.xml:S2:16309:6	O
in	TAFINLAR.xml:S2:16316:2	O
patients	TAFINLAR.xml:S2:16319:8	O
with	TAFINLAR.xml:S2:16328:4	O
improvement	TAFINLAR.xml:S2:16333:11	O
or	TAFINLAR.xml:S2:16345:2	O
recovery	TAFINLAR.xml:S2:16348:8	O
from	TAFINLAR.xml:S2:16357:4	O
skin	TAFINLAR.xml:S2:16362:4	O
toxicity	TAFINLAR.xml:S2:16367:8	O
within	TAFINLAR.xml:S2:16376:6	O
3	TAFINLAR.xml:S2:16383:1	O
weeks	TAFINLAR.xml:S2:16385:5	O
[	TAFINLAR.xml:S2:16391:1	O
see	TAFINLAR.xml:S2:16392:3	O
Dosage	TAFINLAR.xml:S2:16396:6	O
and	TAFINLAR.xml:S2:16403:3	O
Administration	TAFINLAR.xml:S2:16407:14	O
(	TAFINLAR.xml:S2:16422:1	O
2.3	TAFINLAR.xml:S2:16423:3	O
)]	TAFINLAR.xml:S2:16426:2	O
.	TAFINLAR.xml:S2:16430:1	O

5.9	TAFINLAR.xml:S2:16441:3	O
Hyperglycemia	TAFINLAR.xml:S2:16445:13	O

Hyperglycemia	TAFINLAR.xml:S2:16465:13	B-AdverseReaction
can	TAFINLAR.xml:S2:16479:3	B-Factor
occur	TAFINLAR.xml:S2:16483:5	O
when	TAFINLAR.xml:S2:16489:4	O
TAFINLAR	TAFINLAR.xml:S2:16494:8	O
is	TAFINLAR.xml:S2:16503:2	O
administered	TAFINLAR.xml:S2:16506:12	O
as	TAFINLAR.xml:S2:16519:2	O
a	TAFINLAR.xml:S2:16522:1	O
single	TAFINLAR.xml:S2:16524:6	O
agent	TAFINLAR.xml:S2:16531:5	O
or	TAFINLAR.xml:S2:16537:2	O
when	TAFINLAR.xml:S2:16540:4	O
used	TAFINLAR.xml:S2:16545:4	O
in	TAFINLAR.xml:S2:16550:2	O
combination	TAFINLAR.xml:S2:16553:11	O
with	TAFINLAR.xml:S2:16565:4	O
trametinib	TAFINLAR.xml:S2:16570:10	O
.	TAFINLAR.xml:S2:16582:1	O

In	TAFINLAR.xml:S2:16588:2	O
Trial	TAFINLAR.xml:S2:16591:5	O
1	TAFINLAR.xml:S2:16597:1	O
,	TAFINLAR.xml:S2:16598:1	O
5	TAFINLAR.xml:S2:16600:1	O
of	TAFINLAR.xml:S2:16602:2	O
12	TAFINLAR.xml:S2:16605:2	O
patients	TAFINLAR.xml:S2:16608:8	O
with	TAFINLAR.xml:S2:16617:4	O
a	TAFINLAR.xml:S2:16622:1	O
history	TAFINLAR.xml:S2:16624:7	O
of	TAFINLAR.xml:S2:16632:2	O
diabetes	TAFINLAR.xml:S2:16635:8	O
required	TAFINLAR.xml:S2:16644:8	O
more	TAFINLAR.xml:S2:16653:4	O
intensive	TAFINLAR.xml:S2:16658:9	O
hypoglycemic	TAFINLAR.xml:S2:16668:12	O
therapy	TAFINLAR.xml:S2:16681:7	O
while	TAFINLAR.xml:S2:16689:5	O
taking	TAFINLAR.xml:S2:16695:6	O
TAFINLAR	TAFINLAR.xml:S2:16702:8	O
.	TAFINLAR.xml:S2:16710:1	O

The	TAFINLAR.xml:S2:16712:3	O
incidence	TAFINLAR.xml:S2:16716:9	O
of	TAFINLAR.xml:S2:16726:2	O
Grade	TAFINLAR.xml:S2:16729:5	B-Severity
3	TAFINLAR.xml:S2:16735:1	I-Severity
hyperglycemia	TAFINLAR.xml:S2:16737:13	B-AdverseReaction
based	TAFINLAR.xml:S2:16751:5	O
on	TAFINLAR.xml:S2:16757:2	O
laboratory	TAFINLAR.xml:S2:16760:10	O
values	TAFINLAR.xml:S2:16771:6	O
was	TAFINLAR.xml:S2:16778:3	O
6%	TAFINLAR.xml:S2:16782:2	O
(	TAFINLAR.xml:S2:16785:1	O
12	TAFINLAR.xml:S2:16786:2	O
187	TAFINLAR.xml:S2:16789:3	O
)	TAFINLAR.xml:S2:16792:1	O
in	TAFINLAR.xml:S2:16794:2	O
patients	TAFINLAR.xml:S2:16797:8	O
treated	TAFINLAR.xml:S2:16806:7	O
with	TAFINLAR.xml:S2:16814:4	O
TAFINLAR	TAFINLAR.xml:S2:16819:8	O
compared	TAFINLAR.xml:S2:16828:8	O
with	TAFINLAR.xml:S2:16837:4	O
none	TAFINLAR.xml:S2:16842:4	O
of	TAFINLAR.xml:S2:16847:2	O
the	TAFINLAR.xml:S2:16850:3	O
dacarbazine	TAFINLAR.xml:S2:16854:11	O
-	TAFINLAR.xml:S2:16865:1	O
treated	TAFINLAR.xml:S2:16866:7	O
patients	TAFINLAR.xml:S2:16874:8	O
.	TAFINLAR.xml:S2:16882:1	O

In	TAFINLAR.xml:S2:16889:2	O
Trial	TAFINLAR.xml:S2:16892:5	O
2	TAFINLAR.xml:S2:16898:1	O
,	TAFINLAR.xml:S2:16899:1	O
the	TAFINLAR.xml:S2:16901:3	O
incidence	TAFINLAR.xml:S2:16905:9	O
of	TAFINLAR.xml:S2:16915:2	O
Grade	TAFINLAR.xml:S2:16918:5	B-Severity
3	TAFINLAR.xml:S2:16924:1	I-Severity
hyperglycemia	TAFINLAR.xml:S2:16926:13	B-AdverseReaction
based	TAFINLAR.xml:S2:16940:5	O
on	TAFINLAR.xml:S2:16946:2	O
laboratory	TAFINLAR.xml:S2:16949:10	O
values	TAFINLAR.xml:S2:16960:6	O
was	TAFINLAR.xml:S2:16967:3	O
5%	TAFINLAR.xml:S2:16971:2	O
(	TAFINLAR.xml:S2:16974:1	O
3	TAFINLAR.xml:S2:16975:1	O
55	TAFINLAR.xml:S2:16977:2	O
)	TAFINLAR.xml:S2:16979:1	O
in	TAFINLAR.xml:S2:16981:2	O
patients	TAFINLAR.xml:S2:16984:8	O
treated	TAFINLAR.xml:S2:16993:7	O
with	TAFINLAR.xml:S2:17001:4	O
TAFINLAR	TAFINLAR.xml:S2:17006:8	O
in	TAFINLAR.xml:S2:17015:2	O
combination	TAFINLAR.xml:S2:17018:11	O
with	TAFINLAR.xml:S2:17030:4	O
trametinib	TAFINLAR.xml:S2:17035:10	O
compared	TAFINLAR.xml:S2:17046:8	O
with	TAFINLAR.xml:S2:17055:4	O
2%	TAFINLAR.xml:S2:17060:2	O
(	TAFINLAR.xml:S2:17063:1	O
1	TAFINLAR.xml:S2:17064:1	O
53	TAFINLAR.xml:S2:17066:2	O
)	TAFINLAR.xml:S2:17068:1	O
in	TAFINLAR.xml:S2:17070:2	O
patients	TAFINLAR.xml:S2:17073:8	O
treated	TAFINLAR.xml:S2:17082:7	O
with	TAFINLAR.xml:S2:17090:4	O
TAFINLAR	TAFINLAR.xml:S2:17095:8	O
as	TAFINLAR.xml:S2:17104:2	O
a	TAFINLAR.xml:S2:17107:1	O
single	TAFINLAR.xml:S2:17109:6	O
agent	TAFINLAR.xml:S2:17116:5	O
.	TAFINLAR.xml:S2:17121:1	O

Monitor	TAFINLAR.xml:S2:17130:7	O
serum	TAFINLAR.xml:S2:17138:5	O
glucose	TAFINLAR.xml:S2:17144:7	O
levels	TAFINLAR.xml:S2:17152:6	O
as	TAFINLAR.xml:S2:17159:2	O
clinically	TAFINLAR.xml:S2:17162:10	O
appropriate	TAFINLAR.xml:S2:17173:11	O
when	TAFINLAR.xml:S2:17185:4	O
TAFINLAR	TAFINLAR.xml:S2:17190:8	O
is	TAFINLAR.xml:S2:17199:2	O
administered	TAFINLAR.xml:S2:17202:12	O
as	TAFINLAR.xml:S2:17215:2	O
a	TAFINLAR.xml:S2:17218:1	O
single	TAFINLAR.xml:S2:17220:6	O
agent	TAFINLAR.xml:S2:17227:5	O
or	TAFINLAR.xml:S2:17233:2	O
when	TAFINLAR.xml:S2:17236:4	O
used	TAFINLAR.xml:S2:17241:4	O
in	TAFINLAR.xml:S2:17246:2	O
combination	TAFINLAR.xml:S2:17249:11	O
with	TAFINLAR.xml:S2:17261:4	O
trametinib	TAFINLAR.xml:S2:17266:10	O
in	TAFINLAR.xml:S2:17277:2	O
patients	TAFINLAR.xml:S2:17280:8	O
with	TAFINLAR.xml:S2:17289:4	O
pre	TAFINLAR.xml:S2:17294:3	O
-	TAFINLAR.xml:S2:17297:1	O
existing	TAFINLAR.xml:S2:17298:8	O
diabetes	TAFINLAR.xml:S2:17307:8	O
or	TAFINLAR.xml:S2:17316:2	O
hyperglycemia	TAFINLAR.xml:S2:17319:13	O
.	TAFINLAR.xml:S2:17332:1	O

Advise	TAFINLAR.xml:S2:17334:6	O
patients	TAFINLAR.xml:S2:17341:8	O
to	TAFINLAR.xml:S2:17350:2	O
report	TAFINLAR.xml:S2:17353:6	O
symptoms	TAFINLAR.xml:S2:17360:8	O
of	TAFINLAR.xml:S2:17369:2	O
severe	TAFINLAR.xml:S2:17372:6	O
hyperglycemia	TAFINLAR.xml:S2:17379:13	O
such	TAFINLAR.xml:S2:17393:4	O
as	TAFINLAR.xml:S2:17398:2	O
excessive	TAFINLAR.xml:S2:17401:9	O
thirst	TAFINLAR.xml:S2:17411:6	O
or	TAFINLAR.xml:S2:17418:2	O
any	TAFINLAR.xml:S2:17421:3	O
increase	TAFINLAR.xml:S2:17425:8	O
in	TAFINLAR.xml:S2:17434:2	O
the	TAFINLAR.xml:S2:17437:3	O
volume	TAFINLAR.xml:S2:17441:6	O
or	TAFINLAR.xml:S2:17448:2	O
frequency	TAFINLAR.xml:S2:17451:9	O
of	TAFINLAR.xml:S2:17461:2	O
urination	TAFINLAR.xml:S2:17464:9	O
.	TAFINLAR.xml:S2:17475:1	O

5.10	TAFINLAR.xml:S2:17484:4	O
Glucose	TAFINLAR.xml:S2:17489:7	O
-	TAFINLAR.xml:S2:17496:1	O
6	TAFINLAR.xml:S2:17497:1	O
-	TAFINLAR.xml:S2:17498:1	O
Phosphate	TAFINLAR.xml:S2:17499:9	O
Dehydrogenase	TAFINLAR.xml:S2:17509:13	O
Deficiency	TAFINLAR.xml:S2:17523:10	O

TAFINLAR	TAFINLAR.xml:S2:17539:8	O
,	TAFINLAR.xml:S2:17547:1	O
which	TAFINLAR.xml:S2:17549:5	O
contains	TAFINLAR.xml:S2:17555:8	O
a	TAFINLAR.xml:S2:17564:1	O
sulfonamide	TAFINLAR.xml:S2:17566:11	O
moiety	TAFINLAR.xml:S2:17578:6	O
,	TAFINLAR.xml:S2:17584:1	O
confers	TAFINLAR.xml:S2:17586:7	O
a	TAFINLAR.xml:S2:17594:1	O
potential	TAFINLAR.xml:S2:17596:9	O
risk	TAFINLAR.xml:S2:17606:4	B-Factor
of	TAFINLAR.xml:S2:17611:2	O
hemolytic	TAFINLAR.xml:S2:17614:9	B-AdverseReaction
anemia	TAFINLAR.xml:S2:17624:6	I-AdverseReaction
in	TAFINLAR.xml:S2:17631:2	O
patients	TAFINLAR.xml:S2:17634:8	O
with	TAFINLAR.xml:S2:17643:4	O
glucose	TAFINLAR.xml:S2:17648:7	O
-	TAFINLAR.xml:S2:17655:1	O
6	TAFINLAR.xml:S2:17656:1	O
-	TAFINLAR.xml:S2:17657:1	O
phosphate	TAFINLAR.xml:S2:17658:9	O
dehydrogenase	TAFINLAR.xml:S2:17668:13	O
(	TAFINLAR.xml:S2:17682:1	O
G6PD	TAFINLAR.xml:S2:17683:4	O
)	TAFINLAR.xml:S2:17687:1	O
deficiency	TAFINLAR.xml:S2:17689:10	O
.	TAFINLAR.xml:S2:17699:1	O

Closely	TAFINLAR.xml:S2:17701:7	O
observe	TAFINLAR.xml:S2:17709:7	O
patients	TAFINLAR.xml:S2:17717:8	O
with	TAFINLAR.xml:S2:17726:4	O
G6PD	TAFINLAR.xml:S2:17731:4	O
deficiency	TAFINLAR.xml:S2:17736:10	O
for	TAFINLAR.xml:S2:17747:3	O
signs	TAFINLAR.xml:S2:17751:5	O
of	TAFINLAR.xml:S2:17757:2	O
hemolytic	TAFINLAR.xml:S2:17760:9	O
anemia	TAFINLAR.xml:S2:17770:6	O
.	TAFINLAR.xml:S2:17776:1	O

5.11	TAFINLAR.xml:S2:17785:4	O
Embryofetal	TAFINLAR.xml:S2:17790:11	O
Toxicity	TAFINLAR.xml:S2:17802:8	O

Based	TAFINLAR.xml:S2:17816:5	O
on	TAFINLAR.xml:S2:17822:2	O
its	TAFINLAR.xml:S2:17825:3	O
mechanism	TAFINLAR.xml:S2:17829:9	O
of	TAFINLAR.xml:S2:17839:2	O
action	TAFINLAR.xml:S2:17842:6	O
,	TAFINLAR.xml:S2:17848:1	O
TAFINLAR	TAFINLAR.xml:S2:17850:8	O
can	TAFINLAR.xml:S2:17859:3	B-Factor
cause	TAFINLAR.xml:S2:17863:5	O
fetal	TAFINLAR.xml:S2:17869:5	B-AdverseReaction
harm	TAFINLAR.xml:S2:17875:4	I-AdverseReaction
when	TAFINLAR.xml:S2:17880:4	O
administered	TAFINLAR.xml:S2:17885:12	O
to	TAFINLAR.xml:S2:17898:2	O
a	TAFINLAR.xml:S2:17901:1	O
pregnant	TAFINLAR.xml:S2:17903:8	O
woman	TAFINLAR.xml:S2:17912:5	O
.	TAFINLAR.xml:S2:17917:1	O

Dabrafenib	TAFINLAR.xml:S2:17919:10	O
was	TAFINLAR.xml:S2:17930:3	O
teratogenic	TAFINLAR.xml:S2:17934:11	B-AdverseReaction
and	TAFINLAR.xml:S2:17946:3	O
embryotoxic	TAFINLAR.xml:S2:17950:11	B-AdverseReaction
in	TAFINLAR.xml:S2:17962:2	O
rats	TAFINLAR.xml:S2:17965:4	B-Animal
at	TAFINLAR.xml:S2:17970:2	O
doses	TAFINLAR.xml:S2:17973:5	O
three	TAFINLAR.xml:S2:17979:5	O
times	TAFINLAR.xml:S2:17985:5	O
greater	TAFINLAR.xml:S2:17991:7	O
than	TAFINLAR.xml:S2:17999:4	O
the	TAFINLAR.xml:S2:18004:3	O
human	TAFINLAR.xml:S2:18008:5	O
exposure	TAFINLAR.xml:S2:18014:8	O
at	TAFINLAR.xml:S2:18023:2	O
the	TAFINLAR.xml:S2:18026:3	O
recommended	TAFINLAR.xml:S2:18030:11	O
clinical	TAFINLAR.xml:S2:18042:8	O
dose	TAFINLAR.xml:S2:18051:4	O
.	TAFINLAR.xml:S2:18055:1	O

If	TAFINLAR.xml:S2:18057:2	O
this	TAFINLAR.xml:S2:18060:4	O
drug	TAFINLAR.xml:S2:18065:4	O
is	TAFINLAR.xml:S2:18070:2	O
used	TAFINLAR.xml:S2:18073:4	O
during	TAFINLAR.xml:S2:18078:6	O
pregnancy	TAFINLAR.xml:S2:18085:9	O
or	TAFINLAR.xml:S2:18095:2	O
if	TAFINLAR.xml:S2:18098:2	O
the	TAFINLAR.xml:S2:18101:3	O
patient	TAFINLAR.xml:S2:18105:7	O
becomes	TAFINLAR.xml:S2:18113:7	O
pregnant	TAFINLAR.xml:S2:18121:8	O
while	TAFINLAR.xml:S2:18130:5	O
taking	TAFINLAR.xml:S2:18136:6	O
this	TAFINLAR.xml:S2:18143:4	O
drug	TAFINLAR.xml:S2:18148:4	O
,	TAFINLAR.xml:S2:18152:1	O
the	TAFINLAR.xml:S2:18154:3	O
patient	TAFINLAR.xml:S2:18158:7	O
should	TAFINLAR.xml:S2:18166:6	O
be	TAFINLAR.xml:S2:18173:2	O
apprised	TAFINLAR.xml:S2:18176:8	O
of	TAFINLAR.xml:S2:18185:2	O
the	TAFINLAR.xml:S2:18188:3	O
potential	TAFINLAR.xml:S2:18192:9	O
hazard	TAFINLAR.xml:S2:18202:6	O
to	TAFINLAR.xml:S2:18209:2	O
a	TAFINLAR.xml:S2:18212:1	O
fetus	TAFINLAR.xml:S2:18214:5	O
[	TAFINLAR.xml:S2:18220:1	O
see	TAFINLAR.xml:S2:18221:3	O
Use	TAFINLAR.xml:S2:18225:3	O
in	TAFINLAR.xml:S2:18229:2	O
Specific	TAFINLAR.xml:S2:18232:8	O
Populations	TAFINLAR.xml:S2:18241:11	O
(	TAFINLAR.xml:S2:18253:1	O
8.1	TAFINLAR.xml:S2:18254:3	O
)]	TAFINLAR.xml:S2:18257:2	O
.	TAFINLAR.xml:S2:18261:1	O

Advise	TAFINLAR.xml:S2:18267:6	O
female	TAFINLAR.xml:S2:18274:6	O
patients	TAFINLAR.xml:S2:18281:8	O
of	TAFINLAR.xml:S2:18290:2	O
reproductive	TAFINLAR.xml:S2:18293:12	O
potential	TAFINLAR.xml:S2:18306:9	O
to	TAFINLAR.xml:S2:18316:2	O
use	TAFINLAR.xml:S2:18319:3	O
a	TAFINLAR.xml:S2:18323:1	O
highly	TAFINLAR.xml:S2:18325:6	O
effective	TAFINLAR.xml:S2:18332:9	O
non	TAFINLAR.xml:S2:18342:3	O
-	TAFINLAR.xml:S2:18345:1	O
hormonal	TAFINLAR.xml:S2:18346:8	O
method	TAFINLAR.xml:S2:18355:6	O
of	TAFINLAR.xml:S2:18362:2	O
contraception	TAFINLAR.xml:S2:18365:13	O
since	TAFINLAR.xml:S2:18379:5	O
TAFINLAR	TAFINLAR.xml:S2:18385:8	O
can	TAFINLAR.xml:S2:18394:3	O
render	TAFINLAR.xml:S2:18398:6	O
hormonal	TAFINLAR.xml:S2:18405:8	O
contraceptives	TAFINLAR.xml:S2:18414:14	O
ineffective	TAFINLAR.xml:S2:18429:11	O
,	TAFINLAR.xml:S2:18441:1	O
during	TAFINLAR.xml:S2:18443:6	O
treatment	TAFINLAR.xml:S2:18450:9	O
and	TAFINLAR.xml:S2:18460:3	O
for	TAFINLAR.xml:S2:18464:3	O
at	TAFINLAR.xml:S2:18468:2	O
least	TAFINLAR.xml:S2:18471:5	O
2	TAFINLAR.xml:S2:18477:1	O
weeks	TAFINLAR.xml:S2:18479:5	O
after	TAFINLAR.xml:S2:18485:5	O
treatment	TAFINLAR.xml:S2:18491:9	O
with	TAFINLAR.xml:S2:18501:4	O
TAFINLAR	TAFINLAR.xml:S2:18506:8	O
or	TAFINLAR.xml:S2:18515:2	O
for	TAFINLAR.xml:S2:18518:3	O
4	TAFINLAR.xml:S2:18522:1	O
months	TAFINLAR.xml:S2:18524:6	O
after	TAFINLAR.xml:S2:18531:5	O
treatment	TAFINLAR.xml:S2:18537:9	O
with	TAFINLAR.xml:S2:18547:4	O
TAFINLAR	TAFINLAR.xml:S2:18552:8	O
in	TAFINLAR.xml:S2:18561:2	O
combination	TAFINLAR.xml:S2:18564:11	O
with	TAFINLAR.xml:S2:18576:4	O
trametinib	TAFINLAR.xml:S2:18581:10	O
.	TAFINLAR.xml:S2:18593:1	O

Advise	TAFINLAR.xml:S2:18595:6	O
patients	TAFINLAR.xml:S2:18602:8	O
to	TAFINLAR.xml:S2:18611:2	O
contact	TAFINLAR.xml:S2:18614:7	O
their	TAFINLAR.xml:S2:18622:5	O
healthcare	TAFINLAR.xml:S2:18628:10	O
provider	TAFINLAR.xml:S2:18639:8	O
if	TAFINLAR.xml:S2:18648:2	O
they	TAFINLAR.xml:S2:18651:4	O
become	TAFINLAR.xml:S2:18656:6	O
pregnant	TAFINLAR.xml:S2:18663:8	O
,	TAFINLAR.xml:S2:18671:1	O
or	TAFINLAR.xml:S2:18673:2	O
if	TAFINLAR.xml:S2:18676:2	O
pregnancy	TAFINLAR.xml:S2:18679:9	O
is	TAFINLAR.xml:S2:18689:2	O
suspected	TAFINLAR.xml:S2:18692:9	O
,	TAFINLAR.xml:S2:18701:1	O
while	TAFINLAR.xml:S2:18703:5	O
taking	TAFINLAR.xml:S2:18709:6	O
TAFINLAR	TAFINLAR.xml:S2:18716:8	O
[	TAFINLAR.xml:S2:18725:1	O
see	TAFINLAR.xml:S2:18726:3	O
Drug	TAFINLAR.xml:S2:18730:4	O
Interactions	TAFINLAR.xml:S2:18735:12	O
(	TAFINLAR.xml:S2:18748:1	O
7.2	TAFINLAR.xml:S2:18749:3	O
)	TAFINLAR.xml:S2:18752:1	O
,	TAFINLAR.xml:S2:18753:1	O
Use	TAFINLAR.xml:S2:18755:3	O
in	TAFINLAR.xml:S2:18759:2	O
Specific	TAFINLAR.xml:S2:18762:8	O
Populations	TAFINLAR.xml:S2:18771:11	O
(	TAFINLAR.xml:S2:18783:1	O
8.6	TAFINLAR.xml:S2:18784:3	O
)]	TAFINLAR.xml:S2:18787:2	O
.	TAFINLAR.xml:S2:18789:1	O
6	TANZEUM.xml:S1:4:1	O
ADVERSE	TANZEUM.xml:S1:6:7	O
REACTIONS	TANZEUM.xml:S1:14:9	O

The	TANZEUM.xml:S1:27:3	O
following	TANZEUM.xml:S1:31:9	O
serious	TANZEUM.xml:S1:41:7	O
reactions	TANZEUM.xml:S1:49:9	O
are	TANZEUM.xml:S1:59:3	O
described	TANZEUM.xml:S1:63:9	O
below	TANZEUM.xml:S1:73:5	O
or	TANZEUM.xml:S1:79:2	O
elsewhere	TANZEUM.xml:S1:82:9	O
in	TANZEUM.xml:S1:92:2	O
the	TANZEUM.xml:S1:95:3	O
prescribing	TANZEUM.xml:S1:99:11	O
information	TANZEUM.xml:S1:111:11	O
:	TANZEUM.xml:S1:122:1	O

Risk	TANZEUM.xml:S1:133:4	B-Factor
of	TANZEUM.xml:S1:138:2	O
Thyroid	TANZEUM.xml:S1:141:7	B-AdverseReaction
C	TANZEUM.xml:S1:149:1	I-AdverseReaction
-	TANZEUM.xml:S1:150:1	I-AdverseReaction
cell	TANZEUM.xml:S1:151:4	I-AdverseReaction
Tumors	TANZEUM.xml:S1:156:6	I-AdverseReaction
[	TANZEUM.xml:S1:163:1	O
see	TANZEUM.xml:S1:164:3	O
Warnings	TANZEUM.xml:S1:168:8	O
and	TANZEUM.xml:S1:177:3	O
Precautions	TANZEUM.xml:S1:181:11	O
(	TANZEUM.xml:S1:193:1	O
5.1	TANZEUM.xml:S1:194:3	O
)]	TANZEUM.xml:S1:197:2	O

Acute	TANZEUM.xml:S1:208:5	B-AdverseReaction
Pancreatitis	TANZEUM.xml:S1:214:12	I-AdverseReaction
[	TANZEUM.xml:S1:227:1	O
see	TANZEUM.xml:S1:228:3	O
Warnings	TANZEUM.xml:S1:232:8	O
and	TANZEUM.xml:S1:241:3	O
Precautions	TANZEUM.xml:S1:245:11	O
(	TANZEUM.xml:S1:257:1	O
5.2	TANZEUM.xml:S1:258:3	O
)]	TANZEUM.xml:S1:261:2	O

Hypoglycemia	TANZEUM.xml:S1:272:12	B-AdverseReaction
with	TANZEUM.xml:S1:285:4	O
Concomitant	TANZEUM.xml:S1:290:11	O
Use	TANZEUM.xml:S1:302:3	O
of	TANZEUM.xml:S1:306:2	O
Insulin	TANZEUM.xml:S1:309:7	O
Secretagogues	TANZEUM.xml:S1:317:13	O
or	TANZEUM.xml:S1:331:2	O
Insulin	TANZEUM.xml:S1:334:7	O
[	TANZEUM.xml:S1:342:1	O
see	TANZEUM.xml:S1:343:3	O
Warnings	TANZEUM.xml:S1:347:8	O
and	TANZEUM.xml:S1:356:3	O
Precautions	TANZEUM.xml:S1:360:11	O
(	TANZEUM.xml:S1:372:1	O
5.3	TANZEUM.xml:S1:373:3	O
)]	TANZEUM.xml:S1:376:2	O

Hypersensitivity	TANZEUM.xml:S1:387:16	B-AdverseReaction
Reactions	TANZEUM.xml:S1:404:9	I-AdverseReaction
[	TANZEUM.xml:S1:414:1	O
see	TANZEUM.xml:S1:415:3	O
Warnings	TANZEUM.xml:S1:419:8	O
and	TANZEUM.xml:S1:428:3	O
Precautions	TANZEUM.xml:S1:432:11	O
(	TANZEUM.xml:S1:444:1	O
5.4	TANZEUM.xml:S1:445:3	O
)]	TANZEUM.xml:S1:448:2	O

Renal	TANZEUM.xml:S1:459:5	B-AdverseReaction
Impairment	TANZEUM.xml:S1:465:10	I-AdverseReaction
[	TANZEUM.xml:S1:476:1	O
see	TANZEUM.xml:S1:477:3	O
Warnings	TANZEUM.xml:S1:481:8	O
and	TANZEUM.xml:S1:490:3	O
Precautions	TANZEUM.xml:S1:494:11	O
(	TANZEUM.xml:S1:506:1	O
5.5	TANZEUM.xml:S1:507:3	O
)]	TANZEUM.xml:S1:510:2	O

EXCERPT	TANZEUM.xml:S1:521:7	O
:	TANZEUM.xml:S1:528:1	O
Adverse	TANZEUM.xml:S1:532:7	O
reactions	TANZEUM.xml:S1:540:9	O
,	TANZEUM.xml:S1:549:1	O
reported	TANZEUM.xml:S1:551:8	O
in	TANZEUM.xml:S1:560:2	O
5%	TANZEUM.xml:S1:565:2	O
of	TANZEUM.xml:S1:568:2	O
patients	TANZEUM.xml:S1:571:8	O
treated	TANZEUM.xml:S1:580:7	O
with	TANZEUM.xml:S1:588:4	O
TANZEUM	TANZEUM.xml:S1:593:7	O
and	TANZEUM.xml:S1:601:3	O
more	TANZEUM.xml:S1:605:4	O
frequently	TANZEUM.xml:S1:610:10	O
than	TANZEUM.xml:S1:621:4	O
in	TANZEUM.xml:S1:626:2	O
patients	TANZEUM.xml:S1:629:8	O
on	TANZEUM.xml:S1:638:2	O
placebo	TANZEUM.xml:S1:641:7	O
,	TANZEUM.xml:S1:648:1	O
were	TANZEUM.xml:S1:650:4	O
upper	TANZEUM.xml:S1:655:5	B-AdverseReaction
respiratory	TANZEUM.xml:S1:661:11	I-AdverseReaction
tract	TANZEUM.xml:S1:673:5	I-AdverseReaction
infection	TANZEUM.xml:S1:679:9	I-AdverseReaction
,	TANZEUM.xml:S1:688:1	O
diarrhea	TANZEUM.xml:S1:690:8	B-AdverseReaction
,	TANZEUM.xml:S1:698:1	O
nausea	TANZEUM.xml:S1:700:6	B-AdverseReaction
,	TANZEUM.xml:S1:706:1	O
injection	TANZEUM.xml:S1:708:9	B-AdverseReaction
site	TANZEUM.xml:S1:718:4	I-AdverseReaction
reaction	TANZEUM.xml:S1:723:8	I-AdverseReaction
,	TANZEUM.xml:S1:731:1	O
cough	TANZEUM.xml:S1:733:5	B-AdverseReaction
,	TANZEUM.xml:S1:738:1	O
back	TANZEUM.xml:S1:740:4	B-AdverseReaction
pain	TANZEUM.xml:S1:745:4	I-AdverseReaction
,	TANZEUM.xml:S1:749:1	O
arthralgia	TANZEUM.xml:S1:751:10	B-AdverseReaction
,	TANZEUM.xml:S1:761:1	O
sinusitis	TANZEUM.xml:S1:763:9	B-AdverseReaction
,	TANZEUM.xml:S1:772:1	O
and	TANZEUM.xml:S1:774:3	O
influenza	TANZEUM.xml:S1:778:9	B-AdverseReaction
.	TANZEUM.xml:S1:787:1	O

(	TANZEUM.xml:S1:789:1	O
6.1	TANZEUM.xml:S1:790:3	O
)	TANZEUM.xml:S1:793:1	O

To	TANZEUM.xml:S1:801:2	O

report	TANZEUM.xml:S1:804:6	O
SUSPECTED	TANZEUM.xml:S1:811:9	O
ADVERSE	TANZEUM.xml:S1:821:7	O
REACTIONS	TANZEUM.xml:S1:829:9	O
,	TANZEUM.xml:S1:838:1	O
contact	TANZEUM.xml:S1:840:7	O
GlaxoSmithKline	TANZEUM.xml:S1:848:15	O
at	TANZEUM.xml:S1:864:2	O
1	TANZEUM.xml:S1:867:1	O
-	TANZEUM.xml:S1:868:1	O
888	TANZEUM.xml:S1:869:3	O
-	TANZEUM.xml:S1:872:1	O
825	TANZEUM.xml:S1:873:3	O
-	TANZEUM.xml:S1:876:1	O
5249	TANZEUM.xml:S1:877:4	O
or	TANZEUM.xml:S1:882:2	O
FDA	TANZEUM.xml:S1:885:3	O
at	TANZEUM.xml:S1:889:2	O
1	TANZEUM.xml:S1:892:1	O
-	TANZEUM.xml:S1:893:1	O
800	TANZEUM.xml:S1:894:3	O
-	TANZEUM.xml:S1:897:1	O
FDA	TANZEUM.xml:S1:898:3	O
-	TANZEUM.xml:S1:901:1	O
1088	TANZEUM.xml:S1:902:4	O
or	TANZEUM.xml:S1:907:2	O
www	TANZEUM.xml:S1:911:3	O
.	TANZEUM.xml:S1:914:1	O
fda	TANZEUM.xml:S1:915:3	O
.	TANZEUM.xml:S1:918:1	O
gov	TANZEUM.xml:S1:919:3	O
medwatch	TANZEUM.xml:S1:923:8	O

6.1	TANZEUM.xml:S1:940:3	O

Clinical	TANZEUM.xml:S1:944:8	O
Trials	TANZEUM.xml:S1:953:6	O
Experience	TANZEUM.xml:S1:960:10	O

Because	TANZEUM.xml:S1:974:7	O
clinical	TANZEUM.xml:S1:982:8	O
trials	TANZEUM.xml:S1:991:6	O
are	TANZEUM.xml:S1:998:3	O
conducted	TANZEUM.xml:S1:1002:9	O
under	TANZEUM.xml:S1:1012:5	O
widely	TANZEUM.xml:S1:1018:6	O
varying	TANZEUM.xml:S1:1025:7	O
conditions	TANZEUM.xml:S1:1033:10	O
,	TANZEUM.xml:S1:1043:1	O
adverse	TANZEUM.xml:S1:1045:7	O
reaction	TANZEUM.xml:S1:1053:8	O
rates	TANZEUM.xml:S1:1062:5	O
observed	TANZEUM.xml:S1:1068:8	O
in	TANZEUM.xml:S1:1077:2	O
the	TANZEUM.xml:S1:1080:3	O
clinical	TANZEUM.xml:S1:1084:8	O
trials	TANZEUM.xml:S1:1093:6	O
of	TANZEUM.xml:S1:1100:2	O
a	TANZEUM.xml:S1:1103:1	O
drug	TANZEUM.xml:S1:1105:4	O
cannot	TANZEUM.xml:S1:1110:6	O
be	TANZEUM.xml:S1:1117:2	O
directly	TANZEUM.xml:S1:1120:8	O
compared	TANZEUM.xml:S1:1129:8	O
with	TANZEUM.xml:S1:1138:4	O
rates	TANZEUM.xml:S1:1143:5	O
in	TANZEUM.xml:S1:1149:2	O
the	TANZEUM.xml:S1:1152:3	O
clinical	TANZEUM.xml:S1:1156:8	O
trials	TANZEUM.xml:S1:1165:6	O
of	TANZEUM.xml:S1:1172:2	O
another	TANZEUM.xml:S1:1175:7	O
drug	TANZEUM.xml:S1:1183:4	O
and	TANZEUM.xml:S1:1188:3	O
may	TANZEUM.xml:S1:1192:3	O
not	TANZEUM.xml:S1:1196:3	O
reflect	TANZEUM.xml:S1:1200:7	O
the	TANZEUM.xml:S1:1208:3	O
rates	TANZEUM.xml:S1:1212:5	O
observed	TANZEUM.xml:S1:1218:8	O
in	TANZEUM.xml:S1:1227:2	O
practice	TANZEUM.xml:S1:1230:8	O
.	TANZEUM.xml:S1:1238:1	O

Pool	TANZEUM.xml:S1:1246:4	O
of	TANZEUM.xml:S1:1251:2	O
Placebo	TANZEUM.xml:S1:1254:7	O
-	TANZEUM.xml:S1:1261:1	O
Controlled	TANZEUM.xml:S1:1262:10	O
Trials	TANZEUM.xml:S1:1273:6	O

The	TANZEUM.xml:S1:1286:3	O
data	TANZEUM.xml:S1:1290:4	O
in	TANZEUM.xml:S1:1295:2	O
Table	TANZEUM.xml:S1:1298:5	O
1	TANZEUM.xml:S1:1304:1	O
are	TANZEUM.xml:S1:1306:3	O
derived	TANZEUM.xml:S1:1310:7	O
from	TANZEUM.xml:S1:1318:4	O
4	TANZEUM.xml:S1:1323:1	O
placebo	TANZEUM.xml:S1:1325:7	O
-	TANZEUM.xml:S1:1332:1	O
controlled	TANZEUM.xml:S1:1333:10	O
trials	TANZEUM.xml:S1:1344:6	O
.	TANZEUM.xml:S1:1350:1	O

TANZEUM	TANZEUM.xml:S1:1352:7	O
was	TANZEUM.xml:S1:1360:3	O
used	TANZEUM.xml:S1:1364:4	O
as	TANZEUM.xml:S1:1369:2	O
monotherapy	TANZEUM.xml:S1:1372:11	O
in	TANZEUM.xml:S1:1384:2	O
1	TANZEUM.xml:S1:1387:1	O
trial	TANZEUM.xml:S1:1389:5	O
and	TANZEUM.xml:S1:1395:3	O
as	TANZEUM.xml:S1:1399:2	O
add	TANZEUM.xml:S1:1402:3	O
-	TANZEUM.xml:S1:1405:1	O
on	TANZEUM.xml:S1:1406:2	O
therapy	TANZEUM.xml:S1:1409:7	O
in	TANZEUM.xml:S1:1417:2	O
3	TANZEUM.xml:S1:1420:1	O
trials	TANZEUM.xml:S1:1422:6	O
[	TANZEUM.xml:S1:1430:1	O
see	TANZEUM.xml:S1:1431:3	O
Clinical	TANZEUM.xml:S1:1435:8	O
Studies	TANZEUM.xml:S1:1444:7	O
(	TANZEUM.xml:S1:1452:1	O
14	TANZEUM.xml:S1:1453:2	O
)]	TANZEUM.xml:S1:1455:2	O
.	TANZEUM.xml:S1:1459:1	O

These	TANZEUM.xml:S1:1461:5	O
data	TANZEUM.xml:S1:1467:4	O
reflect	TANZEUM.xml:S1:1472:7	O
exposure	TANZEUM.xml:S1:1480:8	O
of	TANZEUM.xml:S1:1489:2	O
923	TANZEUM.xml:S1:1492:3	O
patients	TANZEUM.xml:S1:1496:8	O
to	TANZEUM.xml:S1:1505:2	O
TANZEUM	TANZEUM.xml:S1:1508:7	O
and	TANZEUM.xml:S1:1516:3	O
a	TANZEUM.xml:S1:1520:1	O
mean	TANZEUM.xml:S1:1522:4	O
duration	TANZEUM.xml:S1:1527:8	O
of	TANZEUM.xml:S1:1536:2	O
exposure	TANZEUM.xml:S1:1539:8	O
to	TANZEUM.xml:S1:1548:2	O
TANZEUM	TANZEUM.xml:S1:1551:7	O
of	TANZEUM.xml:S1:1559:2	O
93	TANZEUM.xml:S1:1562:2	O
weeks	TANZEUM.xml:S1:1565:5	O
.	TANZEUM.xml:S1:1570:1	O

The	TANZEUM.xml:S1:1572:3	O
mean	TANZEUM.xml:S1:1576:4	O
age	TANZEUM.xml:S1:1581:3	O
of	TANZEUM.xml:S1:1585:2	O
participants	TANZEUM.xml:S1:1588:12	O
was	TANZEUM.xml:S1:1601:3	O
55	TANZEUM.xml:S1:1605:2	O
years	TANZEUM.xml:S1:1608:5	O
,	TANZEUM.xml:S1:1613:1	O
1%	TANZEUM.xml:S1:1615:2	O
of	TANZEUM.xml:S1:1618:2	O
participants	TANZEUM.xml:S1:1621:12	O
were	TANZEUM.xml:S1:1634:4	O
75	TANZEUM.xml:S1:1639:2	O
years	TANZEUM.xml:S1:1642:5	O
or	TANZEUM.xml:S1:1648:2	O
older	TANZEUM.xml:S1:1651:5	O
and	TANZEUM.xml:S1:1657:3	O
53%	TANZEUM.xml:S1:1661:3	O
of	TANZEUM.xml:S1:1665:2	O
participants	TANZEUM.xml:S1:1668:12	O
were	TANZEUM.xml:S1:1681:4	O
male	TANZEUM.xml:S1:1686:4	O
.	TANZEUM.xml:S1:1690:1	O

The	TANZEUM.xml:S1:1692:3	O
population	TANZEUM.xml:S1:1696:10	O
in	TANZEUM.xml:S1:1707:2	O
these	TANZEUM.xml:S1:1710:5	O
studies	TANZEUM.xml:S1:1716:7	O
was	TANZEUM.xml:S1:1724:3	O
48%	TANZEUM.xml:S1:1728:3	O
white	TANZEUM.xml:S1:1732:5	O
,	TANZEUM.xml:S1:1737:1	O
13%	TANZEUM.xml:S1:1739:3	O
African	TANZEUM.xml:S1:1743:7	O
African	TANZEUM.xml:S1:1751:7	O
American	TANZEUM.xml:S1:1759:8	O
,	TANZEUM.xml:S1:1767:1	O
7%	TANZEUM.xml:S1:1769:2	O
Asian	TANZEUM.xml:S1:1772:5	O
,	TANZEUM.xml:S1:1777:1	O
and	TANZEUM.xml:S1:1779:3	O
29%	TANZEUM.xml:S1:1783:3	O
Hispanic	TANZEUM.xml:S1:1787:8	O
Latino	TANZEUM.xml:S1:1796:6	O
.	TANZEUM.xml:S1:1802:1	O

At	TANZEUM.xml:S1:1804:2	O
baseline	TANZEUM.xml:S1:1807:8	O
,	TANZEUM.xml:S1:1815:1	O
the	TANZEUM.xml:S1:1817:3	O
population	TANZEUM.xml:S1:1821:10	O
had	TANZEUM.xml:S1:1832:3	O
type	TANZEUM.xml:S1:1836:4	O
2	TANZEUM.xml:S1:1841:1	O
diabetes	TANZEUM.xml:S1:1843:8	O
for	TANZEUM.xml:S1:1852:3	O
an	TANZEUM.xml:S1:1856:2	O
average	TANZEUM.xml:S1:1859:7	O
of	TANZEUM.xml:S1:1867:2	O
7	TANZEUM.xml:S1:1870:1	O
years	TANZEUM.xml:S1:1872:5	O
and	TANZEUM.xml:S1:1878:3	O
had	TANZEUM.xml:S1:1882:3	O
a	TANZEUM.xml:S1:1886:1	O
mean	TANZEUM.xml:S1:1888:4	O
HbA1c	TANZEUM.xml:S1:1893:5	O
of	TANZEUM.xml:S1:1899:2	O
8.1%	TANZEUM.xml:S1:1902:4	O
.	TANZEUM.xml:S1:1906:1	O

At	TANZEUM.xml:S1:1908:2	O
baseline	TANZEUM.xml:S1:1911:8	O
,	TANZEUM.xml:S1:1919:1	O
17%	TANZEUM.xml:S1:1921:3	O
of	TANZEUM.xml:S1:1925:2	O
the	TANZEUM.xml:S1:1928:3	O
population	TANZEUM.xml:S1:1932:10	O
in	TANZEUM.xml:S1:1943:2	O
these	TANZEUM.xml:S1:1946:5	O
studies	TANZEUM.xml:S1:1952:7	O
reported	TANZEUM.xml:S1:1960:8	O
peripheral	TANZEUM.xml:S1:1969:10	O
neuropathy	TANZEUM.xml:S1:1980:10	O
and	TANZEUM.xml:S1:1991:3	O
4%	TANZEUM.xml:S1:1995:2	O
reported	TANZEUM.xml:S1:1998:8	O
retinopathy	TANZEUM.xml:S1:2007:11	O
.	TANZEUM.xml:S1:2018:1	O

Baseline	TANZEUM.xml:S1:2020:8	O
estimated	TANZEUM.xml:S1:2029:9	O
renal	TANZEUM.xml:S1:2039:5	O
function	TANZEUM.xml:S1:2045:8	O
was	TANZEUM.xml:S1:2054:3	O
normal	TANZEUM.xml:S1:2058:6	O
or	TANZEUM.xml:S1:2065:2	O
mildly	TANZEUM.xml:S1:2068:6	O
impaired	TANZEUM.xml:S1:2075:8	O
(	TANZEUM.xml:S1:2084:1	O
eGFR	TANZEUM.xml:S1:2085:4	O
60	TANZEUM.xml:S1:2091:2	O
mL	TANZEUM.xml:S1:2094:2	O
min	TANZEUM.xml:S1:2097:3	O
1.73	TANZEUM.xml:S1:2101:4	O
m	TANZEUM.xml:S1:2106:1	O
2	TANZEUM.xml:S1:2109:1	O
)	TANZEUM.xml:S1:2112:1	O
in	TANZEUM.xml:S1:2114:2	O
91%	TANZEUM.xml:S1:2117:3	O
of	TANZEUM.xml:S1:2121:2	O
the	TANZEUM.xml:S1:2124:3	O
study	TANZEUM.xml:S1:2128:5	O
population	TANZEUM.xml:S1:2134:10	O
and	TANZEUM.xml:S1:2145:3	O
moderately	TANZEUM.xml:S1:2149:10	O
impaired	TANZEUM.xml:S1:2160:8	O
(	TANZEUM.xml:S1:2169:1	O
eGFR	TANZEUM.xml:S1:2170:4	O
30	TANZEUM.xml:S1:2175:2	O
to	TANZEUM.xml:S1:2178:2	O
60	TANZEUM.xml:S1:2181:2	O
mL	TANZEUM.xml:S1:2184:2	O
min	TANZEUM.xml:S1:2187:3	O
1.73	TANZEUM.xml:S1:2191:4	O
m	TANZEUM.xml:S1:2196:1	O
2	TANZEUM.xml:S1:2199:1	O
)	TANZEUM.xml:S1:2202:1	O
in	TANZEUM.xml:S1:2204:2	O
9%	TANZEUM.xml:S1:2207:2	O
.	TANZEUM.xml:S1:2209:1	O

Table	TANZEUM.xml:S1:2215:5	O
1	TANZEUM.xml:S1:2221:1	O
shows	TANZEUM.xml:S1:2223:5	O
common	TANZEUM.xml:S1:2229:6	O
adverse	TANZEUM.xml:S1:2236:7	O
reactions	TANZEUM.xml:S1:2244:9	O
excluding	TANZEUM.xml:S1:2254:9	O
hypoglycemia	TANZEUM.xml:S1:2264:12	B-AdverseReaction
associated	TANZEUM.xml:S1:2277:10	O
with	TANZEUM.xml:S1:2288:4	O
the	TANZEUM.xml:S1:2293:3	O
use	TANZEUM.xml:S1:2297:3	O
of	TANZEUM.xml:S1:2301:2	O
TANZEUM	TANZEUM.xml:S1:2304:7	O
in	TANZEUM.xml:S1:2312:2	O
the	TANZEUM.xml:S1:2315:3	O
pool	TANZEUM.xml:S1:2319:4	O
of	TANZEUM.xml:S1:2324:2	O
placebo	TANZEUM.xml:S1:2327:7	O
-	TANZEUM.xml:S1:2334:1	O
controlled	TANZEUM.xml:S1:2335:10	O
trials	TANZEUM.xml:S1:2346:6	O
.	TANZEUM.xml:S1:2352:1	O

These	TANZEUM.xml:S1:2354:5	O
adverse	TANZEUM.xml:S1:2360:7	O
reactions	TANZEUM.xml:S1:2368:9	O
were	TANZEUM.xml:S1:2378:4	O
not	TANZEUM.xml:S1:2383:3	O
present	TANZEUM.xml:S1:2387:7	O
at	TANZEUM.xml:S1:2395:2	O
baseline	TANZEUM.xml:S1:2398:8	O
,	TANZEUM.xml:S1:2406:1	O
occurred	TANZEUM.xml:S1:2408:8	O
more	TANZEUM.xml:S1:2417:4	O
commonly	TANZEUM.xml:S1:2422:8	O
on	TANZEUM.xml:S1:2431:2	O
TANZEUM	TANZEUM.xml:S1:2434:7	O
than	TANZEUM.xml:S1:2442:4	O
on	TANZEUM.xml:S1:2447:2	O
placebo	TANZEUM.xml:S1:2450:7	O
,	TANZEUM.xml:S1:2457:1	O
and	TANZEUM.xml:S1:2459:3	O
occurred	TANZEUM.xml:S1:2463:8	O
in	TANZEUM.xml:S1:2472:2	O
at	TANZEUM.xml:S1:2475:2	O
least	TANZEUM.xml:S1:2478:5	O
5%	TANZEUM.xml:S1:2484:2	O
of	TANZEUM.xml:S1:2487:2	O
patients	TANZEUM.xml:S1:2490:8	O
treated	TANZEUM.xml:S1:2499:7	O
with	TANZEUM.xml:S1:2507:4	O
TANZEUM	TANZEUM.xml:S1:2512:7	O
.	TANZEUM.xml:S1:2519:1	O

Table	TANZEUM.xml:S1:2527:5	O
1	TANZEUM.xml:S1:2533:1	O
.	TANZEUM.xml:S1:2534:1	O

Adverse	TANZEUM.xml:S1:2536:7	O
Reactions	TANZEUM.xml:S1:2544:9	O
in	TANZEUM.xml:S1:2554:2	O
Placebo	TANZEUM.xml:S1:2557:7	O
-	TANZEUM.xml:S1:2564:1	O
controlled	TANZEUM.xml:S1:2565:10	O
Trials	TANZEUM.xml:S1:2576:6	O
Reported	TANZEUM.xml:S1:2583:8	O
in	TANZEUM.xml:S1:2592:2	O
5%	TANZEUM.xml:S1:2597:2	O
of	TANZEUM.xml:S1:2600:2	O
Patients	TANZEUM.xml:S1:2603:8	O
Treated	TANZEUM.xml:S1:2612:7	O
with	TANZEUM.xml:S1:2620:4	O
TANZEUM	TANZEUM.xml:S1:2625:7	O
a	TANZEUM.xml:S1:2634:1	O

Adverse	TANZEUM.xml:S1:2646:7	O
Reaction	TANZEUM.xml:S1:2654:8	O
Placebo	TANZEUM.xml:S1:2704:7	O
(	TANZEUM.xml:S1:2713:1	O
N	TANZEUM.xml:S1:2714:1	O
468	TANZEUM.xml:S1:2718:3	O
)	TANZEUM.xml:S1:2721:1	O
TANZEUM	TANZEUM.xml:S1:2729:7	O
(	TANZEUM.xml:S1:2738:1	O
N	TANZEUM.xml:S1:2739:1	O
923	TANZEUM.xml:S1:2743:3	O
)	TANZEUM.xml:S1:2746:1	O

Upper	TANZEUM.xml:S1:2758:5	B-AdverseReaction
respiratory	TANZEUM.xml:S1:2764:11	I-AdverseReaction
tract	TANZEUM.xml:S1:2776:5	I-AdverseReaction
infection	TANZEUM.xml:S1:2782:9	I-AdverseReaction
13.0	TANZEUM.xml:S1:2816:4	O
14.2	TANZEUM.xml:S1:2838:4	O

Diarrhea	TANZEUM.xml:S1:2867:8	B-AdverseReaction
10.5	TANZEUM.xml:S1:2925:4	O
13.1	TANZEUM.xml:S1:2947:4	O

Nausea	TANZEUM.xml:S1:2976:6	B-AdverseReaction
9.6	TANZEUM.xml:S1:3034:3	O
11.1	TANZEUM.xml:S1:3056:4	O

Injection	TANZEUM.xml:S1:3085:9	B-AdverseReaction
site	TANZEUM.xml:S1:3095:4	I-AdverseReaction
reactionb	TANZEUM.xml:S1:3100:9	I-AdverseReaction
2.1	TANZEUM.xml:S1:3143:3	O
10.5	TANZEUM.xml:S1:3165:4	O

Cough	TANZEUM.xml:S1:3194:5	B-AdverseReaction
6.2	TANZEUM.xml:S1:3252:3	O
6.9	TANZEUM.xml:S1:3274:3	O

Back	TANZEUM.xml:S1:3303:4	B-AdverseReaction
pain	TANZEUM.xml:S1:3308:4	I-AdverseReaction
5.8	TANZEUM.xml:S1:3361:3	O
6.7	TANZEUM.xml:S1:3383:3	O

Arthralgia	TANZEUM.xml:S1:3412:10	B-AdverseReaction
6.4	TANZEUM.xml:S1:3470:3	O
6.6	TANZEUM.xml:S1:3492:3	O

Sinusitis	TANZEUM.xml:S1:3521:9	B-AdverseReaction
5.8	TANZEUM.xml:S1:3579:3	O
6.2	TANZEUM.xml:S1:3601:3	O

Influenza	TANZEUM.xml:S1:3630:9	B-AdverseReaction
3.2	TANZEUM.xml:S1:3688:3	O
5.2	TANZEUM.xml:S1:3710:3	O

a	TANZEUM.xml:S1:3753:1	O
Adverse	TANZEUM.xml:S1:3756:7	O
reactions	TANZEUM.xml:S1:3764:9	O
reported	TANZEUM.xml:S1:3774:8	O
includes	TANZEUM.xml:S1:3783:8	O
adverse	TANZEUM.xml:S1:3792:7	O
reactions	TANZEUM.xml:S1:3800:9	O
occurring	TANZEUM.xml:S1:3810:9	O
with	TANZEUM.xml:S1:3820:4	O
the	TANZEUM.xml:S1:3825:3	O
use	TANZEUM.xml:S1:3829:3	O
of	TANZEUM.xml:S1:3833:2	O
glycemic	TANZEUM.xml:S1:3836:8	O
rescue	TANZEUM.xml:S1:3845:6	O
medications	TANZEUM.xml:S1:3852:11	O
which	TANZEUM.xml:S1:3864:5	O
included	TANZEUM.xml:S1:3870:8	O
metformin	TANZEUM.xml:S1:3879:9	O
(	TANZEUM.xml:S1:3889:1	O
17%	TANZEUM.xml:S1:3890:3	O
for	TANZEUM.xml:S1:3894:3	O
placebo	TANZEUM.xml:S1:3898:7	O
and	TANZEUM.xml:S1:3906:3	O
10%	TANZEUM.xml:S1:3910:3	O
for	TANZEUM.xml:S1:3914:3	O
TANZEUM	TANZEUM.xml:S1:3918:7	O
)	TANZEUM.xml:S1:3925:1	O
and	TANZEUM.xml:S1:3927:3	O
insulin	TANZEUM.xml:S1:3931:7	O
(	TANZEUM.xml:S1:3939:1	O
24%	TANZEUM.xml:S1:3940:3	O
for	TANZEUM.xml:S1:3944:3	O
placebo	TANZEUM.xml:S1:3948:7	O
and	TANZEUM.xml:S1:3956:3	O
14%	TANZEUM.xml:S1:3960:3	O
for	TANZEUM.xml:S1:3964:3	O
TANZEUM	TANZEUM.xml:S1:3968:7	O
)	TANZEUM.xml:S1:3975:1	O
.	TANZEUM.xml:S1:3976:1	O

b	TANZEUM.xml:S1:3988:1	O
See	TANZEUM.xml:S1:3991:3	O
below	TANZEUM.xml:S1:3995:5	O
for	TANZEUM.xml:S1:4001:3	O
other	TANZEUM.xml:S1:4005:5	O
events	TANZEUM.xml:S1:4011:6	O
of	TANZEUM.xml:S1:4018:2	O
injection	TANZEUM.xml:S1:4021:9	B-AdverseReaction
site	TANZEUM.xml:S1:4031:4	I-AdverseReaction
reactions	TANZEUM.xml:S1:4036:9	I-AdverseReaction
reported	TANZEUM.xml:S1:4046:8	O
.	TANZEUM.xml:S1:4054:1	O

Gastrointestinal	TANZEUM.xml:S1:4063:16	O
Adverse	TANZEUM.xml:S1:4080:7	O
Reactions	TANZEUM.xml:S1:4088:9	O

In	TANZEUM.xml:S1:4104:2	O

the	TANZEUM.xml:S1:4107:3	O
pool	TANZEUM.xml:S1:4111:4	O
of	TANZEUM.xml:S1:4116:2	O
placebo	TANZEUM.xml:S1:4119:7	O
-	TANZEUM.xml:S1:4126:1	O
controlled	TANZEUM.xml:S1:4127:10	O
trials	TANZEUM.xml:S1:4138:6	O
,	TANZEUM.xml:S1:4144:1	O
gastrointestinal	TANZEUM.xml:S1:4146:16	B-AdverseReaction
complaints	TANZEUM.xml:S1:4163:10	I-AdverseReaction
occurred	TANZEUM.xml:S1:4174:8	O
more	TANZEUM.xml:S1:4183:4	O
frequently	TANZEUM.xml:S1:4188:10	O
among	TANZEUM.xml:S1:4199:5	O
patients	TANZEUM.xml:S1:4205:8	O
receiving	TANZEUM.xml:S1:4214:9	O
TANZEUM	TANZEUM.xml:S1:4224:7	O
(	TANZEUM.xml:S1:4232:1	O
39%	TANZEUM.xml:S1:4233:3	O
)	TANZEUM.xml:S1:4236:1	O
than	TANZEUM.xml:S1:4238:4	O
patients	TANZEUM.xml:S1:4243:8	O
receiving	TANZEUM.xml:S1:4252:9	O
placebo	TANZEUM.xml:S1:4262:7	O
(	TANZEUM.xml:S1:4270:1	O
33%	TANZEUM.xml:S1:4271:3	O
)	TANZEUM.xml:S1:4274:1	O
.	TANZEUM.xml:S1:4275:1	O

In	TANZEUM.xml:S1:4277:2	O
addition	TANZEUM.xml:S1:4280:8	O
to	TANZEUM.xml:S1:4289:2	O
diarrhea	TANZEUM.xml:S1:4292:8	B-AdverseReaction
and	TANZEUM.xml:S1:4301:3	O
nausea	TANZEUM.xml:S1:4305:6	B-AdverseReaction
(	TANZEUM.xml:S1:4312:1	O
see	TANZEUM.xml:S1:4313:3	O
Table	TANZEUM.xml:S1:4317:5	O
1	TANZEUM.xml:S1:4323:1	O
)	TANZEUM.xml:S1:4324:1	O
,	TANZEUM.xml:S1:4325:1	O
the	TANZEUM.xml:S1:4327:3	O
following	TANZEUM.xml:S1:4331:9	O
gastrointestinal	TANZEUM.xml:S1:4341:16	B-AdverseReaction
adverse	TANZEUM.xml:S1:4358:7	I-AdverseReaction
reactions	TANZEUM.xml:S1:4366:9	I-AdverseReaction
also	TANZEUM.xml:S1:4376:4	O
occurred	TANZEUM.xml:S1:4381:8	O
more	TANZEUM.xml:S1:4390:4	O
frequently	TANZEUM.xml:S1:4395:10	O
in	TANZEUM.xml:S1:4406:2	O
patients	TANZEUM.xml:S1:4409:8	O
receiving	TANZEUM.xml:S1:4418:9	O
TANZEUM	TANZEUM.xml:S1:4428:7	O
:	TANZEUM.xml:S1:4435:1	O
vomiting	TANZEUM.xml:S1:4437:8	B-AdverseReaction
(	TANZEUM.xml:S1:4446:1	O
2.6%	TANZEUM.xml:S1:4447:4	O
versus	TANZEUM.xml:S1:4452:6	O
4.2%	TANZEUM.xml:S1:4459:4	O
for	TANZEUM.xml:S1:4464:3	O
placebo	TANZEUM.xml:S1:4468:7	O
versus	TANZEUM.xml:S1:4476:6	O
TANZEUM	TANZEUM.xml:S1:4483:7	O
)	TANZEUM.xml:S1:4490:1	O
,	TANZEUM.xml:S1:4491:1	O
gastroesophageal	TANZEUM.xml:S1:4493:16	B-AdverseReaction
reflux	TANZEUM.xml:S1:4510:6	I-AdverseReaction
disease	TANZEUM.xml:S1:4517:7	I-AdverseReaction
(	TANZEUM.xml:S1:4525:1	O
1.9%	TANZEUM.xml:S1:4526:4	O
versus	TANZEUM.xml:S1:4531:6	O
3.5%	TANZEUM.xml:S1:4538:4	O
for	TANZEUM.xml:S1:4543:3	O
placebo	TANZEUM.xml:S1:4547:7	O
versus	TANZEUM.xml:S1:4555:6	O
TANZEUM	TANZEUM.xml:S1:4562:7	O
)	TANZEUM.xml:S1:4569:1	O
,	TANZEUM.xml:S1:4570:1	O
and	TANZEUM.xml:S1:4572:3	O
dyspepsia	TANZEUM.xml:S1:4576:9	B-AdverseReaction
(	TANZEUM.xml:S1:4586:1	O
2.8%	TANZEUM.xml:S1:4587:4	O
versus	TANZEUM.xml:S1:4592:6	O
3.4%	TANZEUM.xml:S1:4599:4	O
for	TANZEUM.xml:S1:4604:3	O
placebo	TANZEUM.xml:S1:4608:7	O
versus	TANZEUM.xml:S1:4616:6	O
TANZEUM	TANZEUM.xml:S1:4623:7	O
)	TANZEUM.xml:S1:4630:1	O
.	TANZEUM.xml:S1:4631:1	O

Constipation	TANZEUM.xml:S1:4633:12	B-AdverseReaction
also	TANZEUM.xml:S1:4646:4	O
contributed	TANZEUM.xml:S1:4651:11	O
to	TANZEUM.xml:S1:4663:2	O
the	TANZEUM.xml:S1:4666:3	O
frequently	TANZEUM.xml:S1:4670:10	O
reported	TANZEUM.xml:S1:4681:8	O
reactions	TANZEUM.xml:S1:4690:9	O
.	TANZEUM.xml:S1:4699:1	O

In	TANZEUM.xml:S1:4701:2	O
the	TANZEUM.xml:S1:4704:3	O
group	TANZEUM.xml:S1:4708:5	O
treated	TANZEUM.xml:S1:4714:7	O
with	TANZEUM.xml:S1:4722:4	O
TANZEUM	TANZEUM.xml:S1:4727:7	O
,	TANZEUM.xml:S1:4734:1	O
investigators	TANZEUM.xml:S1:4736:13	O
graded	TANZEUM.xml:S1:4750:6	O
the	TANZEUM.xml:S1:4757:3	O
severity	TANZEUM.xml:S1:4761:8	O
of	TANZEUM.xml:S1:4770:2	O
GI	TANZEUM.xml:S1:4773:2	B-AdverseReaction
reactions	TANZEUM.xml:S1:4776:9	I-AdverseReaction
as	TANZEUM.xml:S1:4786:2	O
"	TANZEUM.xml:S1:4789:1	O
mild	TANZEUM.xml:S1:4790:4	B-Severity
"	TANZEUM.xml:S1:4794:1	O
in	TANZEUM.xml:S1:4796:2	O
56%	TANZEUM.xml:S1:4799:3	O
of	TANZEUM.xml:S1:4803:2	O
cases	TANZEUM.xml:S1:4806:5	O
,	TANZEUM.xml:S1:4811:1	O
"	TANZEUM.xml:S1:4813:1	O
moderate	TANZEUM.xml:S1:4814:8	B-Severity
"	TANZEUM.xml:S1:4822:1	O
in	TANZEUM.xml:S1:4824:2	O
37%	TANZEUM.xml:S1:4827:3	O
of	TANZEUM.xml:S1:4831:2	O
cases	TANZEUM.xml:S1:4834:5	O
,	TANZEUM.xml:S1:4839:1	O
and	TANZEUM.xml:S1:4841:3	O
"	TANZEUM.xml:S1:4845:1	O
severe	TANZEUM.xml:S1:4846:6	B-Severity
"	TANZEUM.xml:S1:4852:1	O
in	TANZEUM.xml:S1:4854:2	O
7%	TANZEUM.xml:S1:4857:2	O
of	TANZEUM.xml:S1:4860:2	O
cases	TANZEUM.xml:S1:4863:5	O
.	TANZEUM.xml:S1:4868:1	O

Discontinuation	TANZEUM.xml:S1:4870:15	O
due	TANZEUM.xml:S1:4886:3	O
to	TANZEUM.xml:S1:4890:2	O
GI	TANZEUM.xml:S1:4893:2	B-AdverseReaction
adverse	TANZEUM.xml:S1:4896:7	I-AdverseReaction
reactions	TANZEUM.xml:S1:4904:9	I-AdverseReaction
occurred	TANZEUM.xml:S1:4914:8	O
in	TANZEUM.xml:S1:4923:2	O
2%	TANZEUM.xml:S1:4926:2	O
of	TANZEUM.xml:S1:4929:2	O
individuals	TANZEUM.xml:S1:4932:11	O
on	TANZEUM.xml:S1:4944:2	O
TANZEUM	TANZEUM.xml:S1:4947:7	O
or	TANZEUM.xml:S1:4955:2	O
placebo	TANZEUM.xml:S1:4958:7	O
.	TANZEUM.xml:S1:4965:1	O

Injection	TANZEUM.xml:S1:4973:9	O
Site	TANZEUM.xml:S1:4983:4	O
Reactions	TANZEUM.xml:S1:4988:9	O

In	TANZEUM.xml:S1:5004:2	O
the	TANZEUM.xml:S1:5007:3	O
pool	TANZEUM.xml:S1:5011:4	O
of	TANZEUM.xml:S1:5016:2	O
placebo	TANZEUM.xml:S1:5019:7	O
-	TANZEUM.xml:S1:5026:1	O
controlled	TANZEUM.xml:S1:5027:10	O
trials	TANZEUM.xml:S1:5038:6	O
,	TANZEUM.xml:S1:5044:1	O
injection	TANZEUM.xml:S1:5046:9	B-AdverseReaction
site	TANZEUM.xml:S1:5056:4	I-AdverseReaction
reactions	TANZEUM.xml:S1:5061:9	I-AdverseReaction
occurred	TANZEUM.xml:S1:5071:8	O
more	TANZEUM.xml:S1:5080:4	O
frequently	TANZEUM.xml:S1:5085:10	O
on	TANZEUM.xml:S1:5096:2	O
TANZEUM	TANZEUM.xml:S1:5099:7	O
(	TANZEUM.xml:S1:5107:1	O
18%	TANZEUM.xml:S1:5108:3	O
)	TANZEUM.xml:S1:5111:1	O
than	TANZEUM.xml:S1:5113:4	O
on	TANZEUM.xml:S1:5118:2	O
placebo	TANZEUM.xml:S1:5121:7	O
(	TANZEUM.xml:S1:5129:1	O
8%	TANZEUM.xml:S1:5130:2	O
)	TANZEUM.xml:S1:5132:1	O
.	TANZEUM.xml:S1:5133:1	O

In	TANZEUM.xml:S1:5135:2	O
addition	TANZEUM.xml:S1:5138:8	O
to	TANZEUM.xml:S1:5147:2	O
the	TANZEUM.xml:S1:5150:3	O
term	TANZEUM.xml:S1:5154:4	O
injection	TANZEUM.xml:S1:5159:9	B-AdverseReaction
site	TANZEUM.xml:S1:5169:4	I-AdverseReaction
reaction	TANZEUM.xml:S1:5174:8	I-AdverseReaction
(	TANZEUM.xml:S1:5183:1	O
see	TANZEUM.xml:S1:5184:3	O
Table	TANZEUM.xml:S1:5188:5	O
1	TANZEUM.xml:S1:5194:1	O
)	TANZEUM.xml:S1:5195:1	O
,	TANZEUM.xml:S1:5196:1	O
the	TANZEUM.xml:S1:5198:3	O
following	TANZEUM.xml:S1:5202:9	O
other	TANZEUM.xml:S1:5212:5	O
types	TANZEUM.xml:S1:5218:5	O
of	TANZEUM.xml:S1:5224:2	O
injection	TANZEUM.xml:S1:5227:9	B-AdverseReaction
site	TANZEUM.xml:S1:5237:4	I-AdverseReaction
reactions	TANZEUM.xml:S1:5242:9	I-AdverseReaction
also	TANZEUM.xml:S1:5252:4	O
occurred	TANZEUM.xml:S1:5257:8	O
more	TANZEUM.xml:S1:5266:4	O
frequently	TANZEUM.xml:S1:5271:10	O
on	TANZEUM.xml:S1:5282:2	O
TANZEUM	TANZEUM.xml:S1:5285:7	O
:	TANZEUM.xml:S1:5292:1	O
injection	TANZEUM.xml:S1:5294:9	B-AdverseReaction
site	TANZEUM.xml:S1:5304:4	I-AdverseReaction
hematoma	TANZEUM.xml:S1:5309:8	I-AdverseReaction
(	TANZEUM.xml:S1:5318:1	O
1.9%	TANZEUM.xml:S1:5319:4	O
versus	TANZEUM.xml:S1:5324:6	O
2.1%	TANZEUM.xml:S1:5331:4	O
for	TANZEUM.xml:S1:5336:3	O
placebo	TANZEUM.xml:S1:5340:7	O
versus	TANZEUM.xml:S1:5348:6	O
TANZEUM	TANZEUM.xml:S1:5355:7	O
)	TANZEUM.xml:S1:5363:1	O
,	TANZEUM.xml:S1:5364:1	O
injection	TANZEUM.xml:S1:5366:9	B-AdverseReaction
site	TANZEUM.xml:S1:5376:4	I-AdverseReaction
erythema	TANZEUM.xml:S1:5381:8	I-AdverseReaction
(	TANZEUM.xml:S1:5390:1	O
0.4%	TANZEUM.xml:S1:5391:4	O
versus	TANZEUM.xml:S1:5396:6	O
1.7%	TANZEUM.xml:S1:5403:4	O
for	TANZEUM.xml:S1:5408:3	O
placebo	TANZEUM.xml:S1:5412:7	O
versus	TANZEUM.xml:S1:5420:6	O
TANZEUM	TANZEUM.xml:S1:5427:7	O
)	TANZEUM.xml:S1:5434:1	O
,	TANZEUM.xml:S1:5435:1	O
injection	TANZEUM.xml:S1:5437:9	B-AdverseReaction
site	TANZEUM.xml:S1:5447:4	I-AdverseReaction
rash	TANZEUM.xml:S1:5452:4	I-AdverseReaction
(	TANZEUM.xml:S1:5457:1	O
0%	TANZEUM.xml:S1:5458:2	O
versus	TANZEUM.xml:S1:5461:6	O
1.4%	TANZEUM.xml:S1:5468:4	O
for	TANZEUM.xml:S1:5473:3	O
placebo	TANZEUM.xml:S1:5477:7	O
versus	TANZEUM.xml:S1:5485:6	O
TANZEUM	TANZEUM.xml:S1:5492:7	O
)	TANZEUM.xml:S1:5499:1	O
,	TANZEUM.xml:S1:5500:1	O
injection	TANZEUM.xml:S1:5502:9	B-AdverseReaction
site	TANZEUM.xml:S1:5512:4	I-AdverseReaction
hypersensitivity	TANZEUM.xml:S1:5517:16	I-AdverseReaction
(	TANZEUM.xml:S1:5534:1	O
0%	TANZEUM.xml:S1:5535:2	O
versus	TANZEUM.xml:S1:5538:6	O
0.8%	TANZEUM.xml:S1:5545:4	O
for	TANZEUM.xml:S1:5550:3	O
placebo	TANZEUM.xml:S1:5554:7	O
versus	TANZEUM.xml:S1:5562:6	O
TANZEUM	TANZEUM.xml:S1:5569:7	O
)	TANZEUM.xml:S1:5576:1	O
,	TANZEUM.xml:S1:5577:1	O
and	TANZEUM.xml:S1:5579:3	O
injection	TANZEUM.xml:S1:5583:9	B-AdverseReaction
site	TANZEUM.xml:S1:5593:4	I-AdverseReaction
hemorrhage	TANZEUM.xml:S1:5598:10	I-AdverseReaction
(	TANZEUM.xml:S1:5609:1	O
0.6%	TANZEUM.xml:S1:5610:4	O
versus	TANZEUM.xml:S1:5615:6	O
0.7%	TANZEUM.xml:S1:5622:4	O
for	TANZEUM.xml:S1:5627:3	O
placebo	TANZEUM.xml:S1:5631:7	O
versus	TANZEUM.xml:S1:5639:6	O
TANZEUM	TANZEUM.xml:S1:5646:7	O
)	TANZEUM.xml:S1:5653:1	O
.	TANZEUM.xml:S1:5654:1	O

Injection	TANZEUM.xml:S1:5656:9	B-AdverseReaction
site	TANZEUM.xml:S1:5666:4	I-AdverseReaction
pruritus	TANZEUM.xml:S1:5671:8	I-AdverseReaction
also	TANZEUM.xml:S1:5680:4	O
contributed	TANZEUM.xml:S1:5685:11	O
to	TANZEUM.xml:S1:5697:2	O
the	TANZEUM.xml:S1:5700:3	O
frequently	TANZEUM.xml:S1:5704:10	O
reported	TANZEUM.xml:S1:5715:8	O
reactions	TANZEUM.xml:S1:5724:9	O
.	TANZEUM.xml:S1:5733:1	O

The	TANZEUM.xml:S1:5735:3	O
majority	TANZEUM.xml:S1:5739:8	O
of	TANZEUM.xml:S1:5748:2	O
injection	TANZEUM.xml:S1:5751:9	B-AdverseReaction
site	TANZEUM.xml:S1:5761:4	I-AdverseReaction
reactions	TANZEUM.xml:S1:5766:9	I-AdverseReaction
were	TANZEUM.xml:S1:5776:4	O
judged	TANZEUM.xml:S1:5781:6	O
as	TANZEUM.xml:S1:5788:2	O
"	TANZEUM.xml:S1:5791:1	O
mild	TANZEUM.xml:S1:5792:4	B-Severity
"	TANZEUM.xml:S1:5796:1	O
by	TANZEUM.xml:S1:5798:2	O
investigators	TANZEUM.xml:S1:5801:13	O
in	TANZEUM.xml:S1:5815:2	O
both	TANZEUM.xml:S1:5818:4	O
groups	TANZEUM.xml:S1:5823:6	O
(	TANZEUM.xml:S1:5830:1	O
73%	TANZEUM.xml:S1:5831:3	O
for	TANZEUM.xml:S1:5835:3	O
TANZEUM	TANZEUM.xml:S1:5839:7	O
versus	TANZEUM.xml:S1:5847:6	O
94%	TANZEUM.xml:S1:5854:3	O
for	TANZEUM.xml:S1:5858:3	O
placebo	TANZEUM.xml:S1:5862:7	O
)	TANZEUM.xml:S1:5869:1	O
.	TANZEUM.xml:S1:5870:1	O

More	TANZEUM.xml:S1:5872:4	O
patients	TANZEUM.xml:S1:5877:8	O
on	TANZEUM.xml:S1:5886:2	O
TANZEUM	TANZEUM.xml:S1:5889:7	O
than	TANZEUM.xml:S1:5897:4	O
on	TANZEUM.xml:S1:5902:2	O
placebo	TANZEUM.xml:S1:5905:7	O
:	TANZEUM.xml:S1:5912:1	O
discontinued	TANZEUM.xml:S1:5914:12	O
due	TANZEUM.xml:S1:5927:3	O
to	TANZEUM.xml:S1:5931:2	O
an	TANZEUM.xml:S1:5934:2	O
injection	TANZEUM.xml:S1:5937:9	B-AdverseReaction
site	TANZEUM.xml:S1:5947:4	I-AdverseReaction
reaction	TANZEUM.xml:S1:5952:8	I-AdverseReaction
(	TANZEUM.xml:S1:5961:1	O
2%	TANZEUM.xml:S1:5962:2	O
versus	TANZEUM.xml:S1:5965:6	O
0.2%	TANZEUM.xml:S1:5972:4	O
)	TANZEUM.xml:S1:5976:1	O
,	TANZEUM.xml:S1:5977:1	O
experienced	TANZEUM.xml:S1:5979:11	O
more	TANZEUM.xml:S1:5991:4	O
than	TANZEUM.xml:S1:5996:4	O
2	TANZEUM.xml:S1:6001:1	O
reactions	TANZEUM.xml:S1:6003:9	O
(	TANZEUM.xml:S1:6013:1	O
38%	TANZEUM.xml:S1:6014:3	O
versus	TANZEUM.xml:S1:6018:6	O
20%	TANZEUM.xml:S1:6025:3	O
)	TANZEUM.xml:S1:6028:1	O
,	TANZEUM.xml:S1:6029:1	O
had	TANZEUM.xml:S1:6031:3	O
a	TANZEUM.xml:S1:6035:1	O
reaction	TANZEUM.xml:S1:6037:8	O
judged	TANZEUM.xml:S1:6046:6	O
by	TANZEUM.xml:S1:6053:2	O
investigators	TANZEUM.xml:S1:6056:13	O
to	TANZEUM.xml:S1:6070:2	O
be	TANZEUM.xml:S1:6073:2	O
"	TANZEUM.xml:S1:6076:1	O
moderate	TANZEUM.xml:S1:6077:8	O
"	TANZEUM.xml:S1:6085:1	O
or	TANZEUM.xml:S1:6087:2	O
"	TANZEUM.xml:S1:6090:1	O
severe	TANZEUM.xml:S1:6091:6	O
"	TANZEUM.xml:S1:6097:1	O
(	TANZEUM.xml:S1:6099:1	O
27%	TANZEUM.xml:S1:6100:3	O
versus	TANZEUM.xml:S1:6104:6	O
6%	TANZEUM.xml:S1:6111:2	O
)	TANZEUM.xml:S1:6113:1	O
and	TANZEUM.xml:S1:6115:3	O
required	TANZEUM.xml:S1:6119:8	O
local	TANZEUM.xml:S1:6128:5	O
or	TANZEUM.xml:S1:6134:2	O
systemic	TANZEUM.xml:S1:6137:8	O
treatment	TANZEUM.xml:S1:6146:9	O
for	TANZEUM.xml:S1:6156:3	O
the	TANZEUM.xml:S1:6160:3	O
reactions	TANZEUM.xml:S1:6164:9	O
(	TANZEUM.xml:S1:6174:1	O
36%	TANZEUM.xml:S1:6175:3	O
versus	TANZEUM.xml:S1:6179:6	O
11%	TANZEUM.xml:S1:6186:3	O
)	TANZEUM.xml:S1:6189:1	O
.	TANZEUM.xml:S1:6190:1	O

Pool	TANZEUM.xml:S1:6198:4	O
of	TANZEUM.xml:S1:6203:2	O
Placebo	TANZEUM.xml:S1:6206:7	O
-	TANZEUM.xml:S1:6213:1	O
and	TANZEUM.xml:S1:6215:3	O
Active	TANZEUM.xml:S1:6219:6	O
-	TANZEUM.xml:S1:6225:1	O
controlled	TANZEUM.xml:S1:6226:10	O
Trials	TANZEUM.xml:S1:6237:6	O

The	TANZEUM.xml:S1:6250:3	O
occurrence	TANZEUM.xml:S1:6254:10	O
of	TANZEUM.xml:S1:6265:2	O
adverse	TANZEUM.xml:S1:6268:7	O
reactions	TANZEUM.xml:S1:6276:9	O
was	TANZEUM.xml:S1:6286:3	O
also	TANZEUM.xml:S1:6290:4	O
evaluated	TANZEUM.xml:S1:6295:9	O
in	TANZEUM.xml:S1:6305:2	O
a	TANZEUM.xml:S1:6308:1	O
larger	TANZEUM.xml:S1:6310:6	O
pool	TANZEUM.xml:S1:6317:4	O
of	TANZEUM.xml:S1:6322:2	O
patients	TANZEUM.xml:S1:6325:8	O
with	TANZEUM.xml:S1:6334:4	O
type	TANZEUM.xml:S1:6339:4	O
2	TANZEUM.xml:S1:6344:1	O
diabetes	TANZEUM.xml:S1:6346:8	O
participating	TANZEUM.xml:S1:6355:13	O
in	TANZEUM.xml:S1:6369:2	O
7	TANZEUM.xml:S1:6372:1	O
placebo	TANZEUM.xml:S1:6374:7	O
-	TANZEUM.xml:S1:6381:1	O
and	TANZEUM.xml:S1:6383:3	O
active	TANZEUM.xml:S1:6387:6	O
-	TANZEUM.xml:S1:6393:1	O
controlled	TANZEUM.xml:S1:6394:10	O
trials	TANZEUM.xml:S1:6405:6	O
.	TANZEUM.xml:S1:6411:1	O

These	TANZEUM.xml:S1:6413:5	O
trials	TANZEUM.xml:S1:6419:6	O
evaluated	TANZEUM.xml:S1:6426:9	O
the	TANZEUM.xml:S1:6436:3	O
use	TANZEUM.xml:S1:6440:3	O
of	TANZEUM.xml:S1:6444:2	O
TANZEUM	TANZEUM.xml:S1:6447:7	O
as	TANZEUM.xml:S1:6455:2	O
monotherapy	TANZEUM.xml:S1:6458:11	O
,	TANZEUM.xml:S1:6469:1	O
and	TANZEUM.xml:S1:6471:3	O
as	TANZEUM.xml:S1:6475:2	O
add	TANZEUM.xml:S1:6478:3	O
-	TANZEUM.xml:S1:6481:1	O
on	TANZEUM.xml:S1:6482:2	O
therapy	TANZEUM.xml:S1:6485:7	O
to	TANZEUM.xml:S1:6493:2	O
oral	TANZEUM.xml:S1:6496:4	O
antidiabetic	TANZEUM.xml:S1:6501:12	O
agents	TANZEUM.xml:S1:6514:6	O
,	TANZEUM.xml:S1:6520:1	O
and	TANZEUM.xml:S1:6522:3	O
as	TANZEUM.xml:S1:6526:2	O
add	TANZEUM.xml:S1:6529:3	O
-	TANZEUM.xml:S1:6532:1	O
on	TANZEUM.xml:S1:6533:2	O
therapy	TANZEUM.xml:S1:6536:7	O
to	TANZEUM.xml:S1:6544:2	O
basal	TANZEUM.xml:S1:6547:5	O
insulin	TANZEUM.xml:S1:6553:7	O
[	TANZEUM.xml:S1:6562:1	O
see	TANZEUM.xml:S1:6563:3	O
Clinical	TANZEUM.xml:S1:6567:8	O
Studies	TANZEUM.xml:S1:6576:7	O
(	TANZEUM.xml:S1:6584:1	O
14	TANZEUM.xml:S1:6585:2	O
)]	TANZEUM.xml:S1:6587:2	O
.	TANZEUM.xml:S1:6591:1	O

In	TANZEUM.xml:S1:6593:2	O
this	TANZEUM.xml:S1:6596:4	O
pool	TANZEUM.xml:S1:6601:4	O
,	TANZEUM.xml:S1:6605:1	O
a	TANZEUM.xml:S1:6607:1	O
total	TANZEUM.xml:S1:6609:5	O
of	TANZEUM.xml:S1:6615:2	O
2	TANZEUM.xml:S1:6618:1	O
,	TANZEUM.xml:S1:6619:1	O
116	TANZEUM.xml:S1:6620:3	O
patients	TANZEUM.xml:S1:6624:8	O
with	TANZEUM.xml:S1:6633:4	O
type	TANZEUM.xml:S1:6638:4	O
2	TANZEUM.xml:S1:6643:1	O
diabetes	TANZEUM.xml:S1:6645:8	O
were	TANZEUM.xml:S1:6654:4	O
treated	TANZEUM.xml:S1:6659:7	O
with	TANZEUM.xml:S1:6667:4	O
TANZEUM	TANZEUM.xml:S1:6672:7	O
for	TANZEUM.xml:S1:6680:3	O
a	TANZEUM.xml:S1:6684:1	O
mean	TANZEUM.xml:S1:6686:4	O
duration	TANZEUM.xml:S1:6691:8	O
of	TANZEUM.xml:S1:6700:2	O
75	TANZEUM.xml:S1:6703:2	O
weeks	TANZEUM.xml:S1:6706:5	O
.	TANZEUM.xml:S1:6711:1	O

The	TANZEUM.xml:S1:6713:3	O
mean	TANZEUM.xml:S1:6717:4	O
age	TANZEUM.xml:S1:6722:3	O
of	TANZEUM.xml:S1:6726:2	O
patients	TANZEUM.xml:S1:6729:8	O
treated	TANZEUM.xml:S1:6738:7	O
with	TANZEUM.xml:S1:6746:4	O
TANZEUM	TANZEUM.xml:S1:6751:7	O
was	TANZEUM.xml:S1:6759:3	O
55	TANZEUM.xml:S1:6763:2	O
years	TANZEUM.xml:S1:6766:5	O
,	TANZEUM.xml:S1:6771:1	O
1.5%	TANZEUM.xml:S1:6773:4	O
of	TANZEUM.xml:S1:6778:2	O
the	TANZEUM.xml:S1:6781:3	O
population	TANZEUM.xml:S1:6785:10	O
in	TANZEUM.xml:S1:6796:2	O
these	TANZEUM.xml:S1:6799:5	O
studies	TANZEUM.xml:S1:6805:7	O
was	TANZEUM.xml:S1:6813:3	O
75	TANZEUM.xml:S1:6817:2	O
years	TANZEUM.xml:S1:6820:5	O
or	TANZEUM.xml:S1:6826:2	O
older	TANZEUM.xml:S1:6829:5	O
and	TANZEUM.xml:S1:6835:3	O
51%	TANZEUM.xml:S1:6839:3	O
of	TANZEUM.xml:S1:6843:2	O
participants	TANZEUM.xml:S1:6846:12	O
were	TANZEUM.xml:S1:6859:4	O
male	TANZEUM.xml:S1:6864:4	O
.	TANZEUM.xml:S1:6868:1	O

Forty	TANZEUM.xml:S1:6870:5	O
-	TANZEUM.xml:S1:6875:1	O
eight	TANZEUM.xml:S1:6876:5	O
percent	TANZEUM.xml:S1:6882:7	O
of	TANZEUM.xml:S1:6890:2	O
patients	TANZEUM.xml:S1:6893:8	O
were	TANZEUM.xml:S1:6902:4	O
white	TANZEUM.xml:S1:6907:5	O
,	TANZEUM.xml:S1:6912:1	O
15%	TANZEUM.xml:S1:6914:3	O
African	TANZEUM.xml:S1:6918:7	O
African	TANZEUM.xml:S1:6926:7	O
American	TANZEUM.xml:S1:6934:8	O
,	TANZEUM.xml:S1:6942:1	O
9%	TANZEUM.xml:S1:6944:2	O
Asian	TANZEUM.xml:S1:6947:5	O
,	TANZEUM.xml:S1:6952:1	O
and	TANZEUM.xml:S1:6954:3	O
26%	TANZEUM.xml:S1:6958:3	O
were	TANZEUM.xml:S1:6962:4	O
Hispanic	TANZEUM.xml:S1:6967:8	O
Latino	TANZEUM.xml:S1:6976:6	O
.	TANZEUM.xml:S1:6982:1	O

At	TANZEUM.xml:S1:6984:2	O
baseline	TANZEUM.xml:S1:6987:8	O
,	TANZEUM.xml:S1:6995:1	O
the	TANZEUM.xml:S1:6997:3	O
population	TANZEUM.xml:S1:7001:10	O
had	TANZEUM.xml:S1:7012:3	O
diabetes	TANZEUM.xml:S1:7016:8	O
for	TANZEUM.xml:S1:7025:3	O
an	TANZEUM.xml:S1:7029:2	O
average	TANZEUM.xml:S1:7032:7	O
of	TANZEUM.xml:S1:7040:2	O
8	TANZEUM.xml:S1:7043:1	O
years	TANZEUM.xml:S1:7045:5	O
and	TANZEUM.xml:S1:7051:3	O
had	TANZEUM.xml:S1:7055:3	O
a	TANZEUM.xml:S1:7059:1	O
mean	TANZEUM.xml:S1:7061:4	O
HbA1c	TANZEUM.xml:S1:7066:5	O
of	TANZEUM.xml:S1:7072:2	O
8.2%	TANZEUM.xml:S1:7075:4	O
.	TANZEUM.xml:S1:7079:1	O

At	TANZEUM.xml:S1:7081:2	O
baseline	TANZEUM.xml:S1:7084:8	O
,	TANZEUM.xml:S1:7092:1	O
21%	TANZEUM.xml:S1:7094:3	O
of	TANZEUM.xml:S1:7098:2	O
the	TANZEUM.xml:S1:7101:3	O
population	TANZEUM.xml:S1:7105:10	O
reported	TANZEUM.xml:S1:7116:8	O
peripheral	TANZEUM.xml:S1:7125:10	O
neuropathy	TANZEUM.xml:S1:7136:10	O
and	TANZEUM.xml:S1:7147:3	O
5%	TANZEUM.xml:S1:7151:2	O
reported	TANZEUM.xml:S1:7154:8	O
retinopathy	TANZEUM.xml:S1:7163:11	O
.	TANZEUM.xml:S1:7174:1	O

Baseline	TANZEUM.xml:S1:7176:8	O
estimated	TANZEUM.xml:S1:7185:9	O
renal	TANZEUM.xml:S1:7195:5	O
function	TANZEUM.xml:S1:7201:8	O
was	TANZEUM.xml:S1:7210:3	O
normal	TANZEUM.xml:S1:7214:6	O
or	TANZEUM.xml:S1:7221:2	O
mildly	TANZEUM.xml:S1:7224:6	O
impaired	TANZEUM.xml:S1:7231:8	O
(	TANZEUM.xml:S1:7240:1	O
eGFR	TANZEUM.xml:S1:7241:4	O
60	TANZEUM.xml:S1:7247:2	O
mL	TANZEUM.xml:S1:7250:2	O
min	TANZEUM.xml:S1:7253:3	O
1.73	TANZEUM.xml:S1:7257:4	O
m	TANZEUM.xml:S1:7262:1	O
2	TANZEUM.xml:S1:7265:1	O
)	TANZEUM.xml:S1:7268:1	O
in	TANZEUM.xml:S1:7270:2	O
92%	TANZEUM.xml:S1:7273:3	O
of	TANZEUM.xml:S1:7277:2	O
the	TANZEUM.xml:S1:7280:3	O
population	TANZEUM.xml:S1:7284:10	O
and	TANZEUM.xml:S1:7295:3	O
moderately	TANZEUM.xml:S1:7299:10	O
impaired	TANZEUM.xml:S1:7310:8	O
(	TANZEUM.xml:S1:7319:1	O
eGFR	TANZEUM.xml:S1:7320:4	O
30	TANZEUM.xml:S1:7325:2	O
to	TANZEUM.xml:S1:7328:2	O
60	TANZEUM.xml:S1:7331:2	O
mL	TANZEUM.xml:S1:7334:2	O
min	TANZEUM.xml:S1:7337:3	O
1.73	TANZEUM.xml:S1:7341:4	O
m	TANZEUM.xml:S1:7346:1	O
2	TANZEUM.xml:S1:7349:1	O
)	TANZEUM.xml:S1:7352:1	O
in	TANZEUM.xml:S1:7354:2	O
8%	TANZEUM.xml:S1:7357:2	O
of	TANZEUM.xml:S1:7360:2	O
the	TANZEUM.xml:S1:7363:3	O
population	TANZEUM.xml:S1:7367:10	O
.	TANZEUM.xml:S1:7377:1	O

In	TANZEUM.xml:S1:7383:2	O
the	TANZEUM.xml:S1:7386:3	O
pool	TANZEUM.xml:S1:7390:4	O
of	TANZEUM.xml:S1:7395:2	O
placebo	TANZEUM.xml:S1:7398:7	O
-	TANZEUM.xml:S1:7405:1	O
and	TANZEUM.xml:S1:7407:3	O
active	TANZEUM.xml:S1:7411:6	O
-	TANZEUM.xml:S1:7417:1	O
controlled	TANZEUM.xml:S1:7418:10	O
trials	TANZEUM.xml:S1:7429:6	O
,	TANZEUM.xml:S1:7435:1	O
the	TANZEUM.xml:S1:7437:3	O
types	TANZEUM.xml:S1:7441:5	O
and	TANZEUM.xml:S1:7447:3	O
frequency	TANZEUM.xml:S1:7451:9	O
of	TANZEUM.xml:S1:7461:2	O
common	TANZEUM.xml:S1:7464:6	O
adverse	TANZEUM.xml:S1:7471:7	O
reactions	TANZEUM.xml:S1:7479:9	O
excluding	TANZEUM.xml:S1:7489:9	O
hypoglycemia	TANZEUM.xml:S1:7499:12	B-AdverseReaction
were	TANZEUM.xml:S1:7512:4	O
similar	TANZEUM.xml:S1:7517:7	O
to	TANZEUM.xml:S1:7525:2	O
those	TANZEUM.xml:S1:7528:5	O
listed	TANZEUM.xml:S1:7534:6	O
in	TANZEUM.xml:S1:7541:2	O
Table	TANZEUM.xml:S1:7544:5	O
1	TANZEUM.xml:S1:7550:1	O
.	TANZEUM.xml:S1:7551:1	O

Other	TANZEUM.xml:S1:7559:5	O
Adverse	TANZEUM.xml:S1:7565:7	O
Reactions	TANZEUM.xml:S1:7573:9	O

Hypoglycemia	TANZEUM.xml:S1:7591:12	O

The	TANZEUM.xml:S1:7610:3	O
proportion	TANZEUM.xml:S1:7614:10	O
of	TANZEUM.xml:S1:7625:2	O
patients	TANZEUM.xml:S1:7628:8	O
experiencing	TANZEUM.xml:S1:7637:12	O
at	TANZEUM.xml:S1:7650:2	O
least	TANZEUM.xml:S1:7653:5	O
one	TANZEUM.xml:S1:7659:3	O
documented	TANZEUM.xml:S1:7663:10	O
symptomatic	TANZEUM.xml:S1:7674:11	B-Severity
hypoglycemic	TANZEUM.xml:S1:7686:12	B-AdverseReaction
episode	TANZEUM.xml:S1:7699:7	I-AdverseReaction
on	TANZEUM.xml:S1:7707:2	O
TANZEUM	TANZEUM.xml:S1:7710:7	O
and	TANZEUM.xml:S1:7718:3	O
the	TANZEUM.xml:S1:7722:3	O
proportion	TANZEUM.xml:S1:7726:10	O
of	TANZEUM.xml:S1:7737:2	O
patients	TANZEUM.xml:S1:7740:8	O
experiencing	TANZEUM.xml:S1:7749:12	O
at	TANZEUM.xml:S1:7762:2	O
least	TANZEUM.xml:S1:7765:5	O
one	TANZEUM.xml:S1:7771:3	O
severe	TANZEUM.xml:S1:7775:6	B-Severity
hypoglycemic	TANZEUM.xml:S1:7782:12	B-AdverseReaction
episode	TANZEUM.xml:S1:7795:7	I-AdverseReaction
on	TANZEUM.xml:S1:7803:2	O
TANZEUM	TANZEUM.xml:S1:7806:7	O
in	TANZEUM.xml:S1:7814:2	O
clinical	TANZEUM.xml:S1:7817:8	O
trials	TANZEUM.xml:S1:7826:6	O
[	TANZEUM.xml:S1:7834:1	O
see	TANZEUM.xml:S1:7835:3	O
Clinical	TANZEUM.xml:S1:7839:8	O
Studies	TANZEUM.xml:S1:7848:7	O
(	TANZEUM.xml:S1:7856:1	O
14	TANZEUM.xml:S1:7857:2	O
)]	TANZEUM.xml:S1:7859:2	O
is	TANZEUM.xml:S1:7863:2	O
shown	TANZEUM.xml:S1:7866:5	O
in	TANZEUM.xml:S1:7872:2	O
Table	TANZEUM.xml:S1:7875:5	O
2	TANZEUM.xml:S1:7881:1	O
.	TANZEUM.xml:S1:7882:1	O

Hypoglycemia	TANZEUM.xml:S1:7884:12	B-AdverseReaction
was	TANZEUM.xml:S1:7897:3	O
more	TANZEUM.xml:S1:7901:4	O
frequent	TANZEUM.xml:S1:7906:8	O
when	TANZEUM.xml:S1:7915:4	O
TANZEUM	TANZEUM.xml:S1:7920:7	O
was	TANZEUM.xml:S1:7928:3	O
added	TANZEUM.xml:S1:7932:5	O
to	TANZEUM.xml:S1:7938:2	O
sulfonylurea	TANZEUM.xml:S1:7941:12	O
or	TANZEUM.xml:S1:7954:2	O
insulin	TANZEUM.xml:S1:7957:7	O
[	TANZEUM.xml:S1:7966:1	O
see	TANZEUM.xml:S1:7967:3	O
Warnings	TANZEUM.xml:S1:7971:8	O
and	TANZEUM.xml:S1:7980:3	O
Precautions	TANZEUM.xml:S1:7984:11	O
(	TANZEUM.xml:S1:7996:1	O
5.3	TANZEUM.xml:S1:7997:3	O
)]	TANZEUM.xml:S1:8000:2	O
.	TANZEUM.xml:S1:8004:1	O

Table	TANZEUM.xml:S1:8012:5	O
2	TANZEUM.xml:S1:8018:1	O
.	TANZEUM.xml:S1:8019:1	O

Incidence	TANZEUM.xml:S1:8021:9	O
(	TANZEUM.xml:S1:8031:1	O
)	TANZEUM.xml:S1:8033:1	O
of	TANZEUM.xml:S1:8035:2	O
Hypoglycemia	TANZEUM.xml:S1:8038:12	O
in	TANZEUM.xml:S1:8051:2	O
Clinical	TANZEUM.xml:S1:8054:8	O
Trials	TANZEUM.xml:S1:8063:6	O
of	TANZEUM.xml:S1:8070:2	O
TANZEUM	TANZEUM.xml:S1:8073:7	O
a	TANZEUM.xml:S1:8082:1	O

TANZEUM	TANZEUM.xml:S1:8176:7	O

Monotherapyb	TANZEUM.xml:S1:8203:12	O
Placebo	TANZEUM.xml:S1:8258:7	O
30	TANZEUM.xml:S1:8285:2	O
mg	TANZEUM.xml:S1:8288:2	O
Weekly	TANZEUM.xml:S1:8291:6	O

(	TANZEUM.xml:S1:8312:1	O
52	TANZEUM.xml:S1:8313:2	O
Weeks	TANZEUM.xml:S1:8316:5	O
)	TANZEUM.xml:S1:8321:1	O
N	TANZEUM.xml:S1:8367:1	O
101	TANZEUM.xml:S1:8371:3	O
N	TANZEUM.xml:S1:8394:1	O
101	TANZEUM.xml:S1:8398:3	O

Documented	TANZEUM.xml:S1:8421:10	O
symptomaticc	TANZEUM.xml:S1:8432:12	O
2%	TANZEUM.xml:S1:8476:2	O
2%	TANZEUM.xml:S1:8503:2	O

Severed	TANZEUM.xml:S1:8530:7	O
-	TANZEUM.xml:S1:8585:1	O
-	TANZEUM.xml:S1:8612:1	O

In	TANZEUM.xml:S1:8639:2	O
Combination	TANZEUM.xml:S1:8642:11	O
with	TANZEUM.xml:S1:8654:4	O
Metformin	TANZEUM.xml:S1:8659:9	O
Trial	TANZEUM.xml:S1:8669:5	O
Placebo	TANZEUM.xml:S1:8694:7	O
TANZEUM	TANZEUM.xml:S1:8721:7	O

(	TANZEUM.xml:S1:8748:1	O
104	TANZEUM.xml:S1:8749:3	O
Weeks	TANZEUM.xml:S1:8753:5	O
)	TANZEUM.xml:S1:8758:1	O
e	TANZEUM.xml:S1:8759:1	O
N	TANZEUM.xml:S1:8803:1	O
101	TANZEUM.xml:S1:8807:3	O
N	TANZEUM.xml:S1:8830:1	O
302	TANZEUM.xml:S1:8834:3	O

Documented	TANZEUM.xml:S1:8857:10	O
symptomatic	TANZEUM.xml:S1:8868:11	O
4%	TANZEUM.xml:S1:8912:2	O
3%	TANZEUM.xml:S1:8939:2	O

Severe	TANZEUM.xml:S1:8966:6	O
-	TANZEUM.xml:S1:9021:1	O
-	TANZEUM.xml:S1:9048:1	O

In	TANZEUM.xml:S1:9075:2	O
Combination	TANZEUM.xml:S1:9078:11	O
with	TANZEUM.xml:S1:9090:4	O
Pioglitazone	TANZEUM.xml:S1:9095:12	O
-	TANZEUM.xml:S1:9110:1	O
Placebo	TANZEUM.xml:S1:9130:7	O
TANZEUM	TANZEUM.xml:S1:9157:7	O

Metformin	TANZEUM.xml:S1:9184:9	O
(	TANZEUM.xml:S1:9194:1	O
52	TANZEUM.xml:S1:9195:2	O
Weeks	TANZEUM.xml:S1:9198:5	O
)	TANZEUM.xml:S1:9203:1	O
N	TANZEUM.xml:S1:9239:1	O
151	TANZEUM.xml:S1:9243:3	O
N	TANZEUM.xml:S1:9266:1	O
150	TANZEUM.xml:S1:9270:3	O

Documented	TANZEUM.xml:S1:9293:10	O
symptomatic	TANZEUM.xml:S1:9304:11	O
1%	TANZEUM.xml:S1:9348:2	O
3%	TANZEUM.xml:S1:9375:2	O

Severe	TANZEUM.xml:S1:9402:6	O
-	TANZEUM.xml:S1:9457:1	O
1%	TANZEUM.xml:S1:9484:2	O

In	TANZEUM.xml:S1:9511:2	O
Combination	TANZEUM.xml:S1:9514:11	O
with	TANZEUM.xml:S1:9526:4	O
Metformin	TANZEUM.xml:S1:9531:9	O
and	TANZEUM.xml:S1:9541:3	O
Placebo	TANZEUM.xml:S1:9566:7	O
TANZEUM	TANZEUM.xml:S1:9593:7	O

Sulfonylurea	TANZEUM.xml:S1:9620:12	O
(	TANZEUM.xml:S1:9633:1	O
52	TANZEUM.xml:S1:9634:2	O
Weeks	TANZEUM.xml:S1:9637:5	O
)	TANZEUM.xml:S1:9642:1	O
N	TANZEUM.xml:S1:9675:1	O
115	TANZEUM.xml:S1:9679:3	O
N	TANZEUM.xml:S1:9702:1	O
271	TANZEUM.xml:S1:9706:3	O

Documented	TANZEUM.xml:S1:9729:10	O
symptomatic	TANZEUM.xml:S1:9740:11	O
7%	TANZEUM.xml:S1:9784:2	O
13%	TANZEUM.xml:S1:9811:3	O

Severe	TANZEUM.xml:S1:9838:6	O
-	TANZEUM.xml:S1:9893:1	O
0.4%	TANZEUM.xml:S1:9920:4	O

In	TANZEUM.xml:S1:9947:2	O
Combination	TANZEUM.xml:S1:9950:11	O
with	TANZEUM.xml:S1:9962:4	O
Insulin	TANZEUM.xml:S1:10002:7	O
Lispro	TANZEUM.xml:S1:10010:6	O
TANZEUM	TANZEUM.xml:S1:10029:7	O

Insulin	TANZEUM.xml:S1:10056:7	O
Glargine	TANZEUM.xml:S1:10064:8	O
(	TANZEUM.xml:S1:10073:1	O
26	TANZEUM.xml:S1:10074:2	O
Weeks	TANZEUM.xml:S1:10077:5	O
)	TANZEUM.xml:S1:10082:1	O
N	TANZEUM.xml:S1:10111:1	O
281	TANZEUM.xml:S1:10115:3	O
N	TANZEUM.xml:S1:10138:1	O
285	TANZEUM.xml:S1:10142:3	O

Documented	TANZEUM.xml:S1:10165:10	O
symptomatic	TANZEUM.xml:S1:10176:11	O
30%	TANZEUM.xml:S1:10220:3	O
16%	TANZEUM.xml:S1:10247:3	O

Severe	TANZEUM.xml:S1:10274:6	O
0.7%	TANZEUM.xml:S1:10329:4	O
-	TANZEUM.xml:S1:10356:1	O

In	TANZEUM.xml:S1:10383:2	O
Combination	TANZEUM.xml:S1:10386:11	O
with	TANZEUM.xml:S1:10398:4	O
Insulin	TANZEUM.xml:S1:10438:7	O
Glargine	TANZEUM.xml:S1:10446:8	O
TANZEUM	TANZEUM.xml:S1:10465:7	O

Metformin	TANZEUM.xml:S1:10492:9	O
-	TANZEUM.xml:S1:10504:1	O
Sulfonylurea	TANZEUM.xml:S1:10506:12	O
(	TANZEUM.xml:S1:10519:1	O
52	TANZEUM.xml:S1:10520:2	O
Weeks	TANZEUM.xml:S1:10523:5	O
)	TANZEUM.xml:S1:10528:1	O
N	TANZEUM.xml:S1:10547:1	O
241	TANZEUM.xml:S1:10551:3	O
N	TANZEUM.xml:S1:10574:1	O
504	TANZEUM.xml:S1:10578:3	O

Documented	TANZEUM.xml:S1:10601:10	O
symptomatic	TANZEUM.xml:S1:10612:11	O
27%	TANZEUM.xml:S1:10656:3	O
17%	TANZEUM.xml:S1:10683:3	O

Severe	TANZEUM.xml:S1:10710:6	O
0.4%	TANZEUM.xml:S1:10765:4	O
0.4%	TANZEUM.xml:S1:10792:4	O

In	TANZEUM.xml:S1:10819:2	O
Combination	TANZEUM.xml:S1:10822:11	O
with	TANZEUM.xml:S1:10834:4	O
OADs	TANZEUM.xml:S1:10839:4	O
in	TANZEUM.xml:S1:10844:2	O
Renal	TANZEUM.xml:S1:10847:5	O
Sitagliptin	TANZEUM.xml:S1:10874:11	O
TANZEUM	TANZEUM.xml:S1:10901:7	O

Impairment	TANZEUM.xml:S1:10928:10	O
(	TANZEUM.xml:S1:10939:1	O
26	TANZEUM.xml:S1:10940:2	O
Weeks	TANZEUM.xml:S1:10943:5	O
)	TANZEUM.xml:S1:10948:1	O
N	TANZEUM.xml:S1:10983:1	O
246	TANZEUM.xml:S1:10987:3	O
N	TANZEUM.xml:S1:11010:1	O
249	TANZEUM.xml:S1:11014:3	O

Documented	TANZEUM.xml:S1:11037:10	O
symptomatic	TANZEUM.xml:S1:11048:11	O
6%	TANZEUM.xml:S1:11092:2	O
10%	TANZEUM.xml:S1:11119:3	O

Severe	TANZEUM.xml:S1:11146:6	O
0.8%	TANZEUM.xml:S1:11201:4	O
-	TANZEUM.xml:S1:11228:1	O

OAD	TANZEUM.xml:S1:11267:3	O
Oral	TANZEUM.xml:S1:11273:4	O
antidiabetic	TANZEUM.xml:S1:11278:12	O
agents	TANZEUM.xml:S1:11291:6	O
.	TANZEUM.xml:S1:11297:1	O

a	TANZEUM.xml:S1:11309:1	O
Data	TANZEUM.xml:S1:11312:4	O
presented	TANZEUM.xml:S1:11317:9	O
are	TANZEUM.xml:S1:11327:3	O
to	TANZEUM.xml:S1:11331:2	O
the	TANZEUM.xml:S1:11334:3	O
primary	TANZEUM.xml:S1:11338:7	O
endpoint	TANZEUM.xml:S1:11346:8	O
and	TANZEUM.xml:S1:11355:3	O
include	TANZEUM.xml:S1:11359:7	O
only	TANZEUM.xml:S1:11367:4	O
events	TANZEUM.xml:S1:11372:6	O
occurring	TANZEUM.xml:S1:11379:9	O
on	TANZEUM.xml:S1:11389:2	O
-	TANZEUM.xml:S1:11391:1	O
therapy	TANZEUM.xml:S1:11392:7	O
with	TANZEUM.xml:S1:11400:4	O
randomized	TANZEUM.xml:S1:11405:10	O
medications	TANZEUM.xml:S1:11416:11	O
and	TANZEUM.xml:S1:11428:3	O
excludes	TANZEUM.xml:S1:11432:8	O
events	TANZEUM.xml:S1:11441:6	O
occurring	TANZEUM.xml:S1:11448:9	O
after	TANZEUM.xml:S1:11458:5	O
use	TANZEUM.xml:S1:11464:3	O
of	TANZEUM.xml:S1:11468:2	O
glycemic	TANZEUM.xml:S1:11471:8	O
rescue	TANZEUM.xml:S1:11480:6	O
medications	TANZEUM.xml:S1:11487:11	O
(	TANZEUM.xml:S1:11499:1	O
i	TANZEUM.xml:S1:11500:1	O
.	TANZEUM.xml:S1:11501:1	O
e	TANZEUM.xml:S1:11502:1	O
.	TANZEUM.xml:S1:11503:1	O
,	TANZEUM.xml:S1:11504:1	O
primarily	TANZEUM.xml:S1:11506:9	O
metformin	TANZEUM.xml:S1:11516:9	O
or	TANZEUM.xml:S1:11526:2	O
insulin	TANZEUM.xml:S1:11529:7	O
)	TANZEUM.xml:S1:11536:1	O
.	TANZEUM.xml:S1:11537:1	O

b	TANZEUM.xml:S1:11549:1	O
In	TANZEUM.xml:S1:11552:2	O
this	TANZEUM.xml:S1:11555:4	O
trial	TANZEUM.xml:S1:11560:5	O
,	TANZEUM.xml:S1:11565:1	O
no	TANZEUM.xml:S1:11567:2	B-Negation
documented	TANZEUM.xml:S1:11570:10	O
symptomatic	TANZEUM.xml:S1:11581:11	B-Severity
or	TANZEUM.xml:S1:11593:2	O
severe	TANZEUM.xml:S1:11596:6	B-Severity
hypoglycemia	TANZEUM.xml:S1:11603:12	B-AdverseReaction
were	TANZEUM.xml:S1:11616:4	O
reported	TANZEUM.xml:S1:11621:8	O
for	TANZEUM.xml:S1:11630:3	O
TANZEUM	TANZEUM.xml:S1:11634:7	O
50	TANZEUM.xml:S1:11642:2	O
mg	TANZEUM.xml:S1:11645:2	O
and	TANZEUM.xml:S1:11648:3	O
these	TANZEUM.xml:S1:11652:5	O
data	TANZEUM.xml:S1:11658:4	O
are	TANZEUM.xml:S1:11663:3	O
omitted	TANZEUM.xml:S1:11667:7	O
from	TANZEUM.xml:S1:11675:4	O
the	TANZEUM.xml:S1:11680:3	O
table	TANZEUM.xml:S1:11684:5	O
.	TANZEUM.xml:S1:11689:1	O

c	TANZEUM.xml:S1:11701:1	O
Plasma	TANZEUM.xml:S1:11704:6	B-AdverseReaction
glucose	TANZEUM.xml:S1:11711:7	I-AdverseReaction
concentration	TANZEUM.xml:S1:11719:13	I-AdverseReaction
70	TANZEUM.xml:S1:11735:2	I-AdverseReaction
mg	TANZEUM.xml:S1:11738:2	I-AdverseReaction
dL	TANZEUM.xml:S1:11741:2	I-AdverseReaction
and	TANZEUM.xml:S1:11744:3	O
presence	TANZEUM.xml:S1:11748:8	O
of	TANZEUM.xml:S1:11757:2	O
hypoglycemic	TANZEUM.xml:S1:11760:12	B-AdverseReaction
symptoms	TANZEUM.xml:S1:11773:8	I-AdverseReaction
.	TANZEUM.xml:S1:11781:1	O

d	TANZEUM.xml:S1:11793:1	O
Event	TANZEUM.xml:S1:11796:5	O
requiring	TANZEUM.xml:S1:11802:9	O
another	TANZEUM.xml:S1:11812:7	O
person	TANZEUM.xml:S1:11820:6	O
to	TANZEUM.xml:S1:11827:2	O
administer	TANZEUM.xml:S1:11830:10	O
a	TANZEUM.xml:S1:11841:1	O
resuscitative	TANZEUM.xml:S1:11843:13	O
action	TANZEUM.xml:S1:11857:6	O
.	TANZEUM.xml:S1:11863:1	O

e	TANZEUM.xml:S1:11875:1	O
Rate	TANZEUM.xml:S1:11878:4	O
of	TANZEUM.xml:S1:11883:2	O
documented	TANZEUM.xml:S1:11886:10	O
symptomatic	TANZEUM.xml:S1:11897:11	B-Severity
hypoglycemia	TANZEUM.xml:S1:11909:12	B-AdverseReaction
for	TANZEUM.xml:S1:11922:3	O
active	TANZEUM.xml:S1:11926:6	O
controls	TANZEUM.xml:S1:11933:8	O
18%	TANZEUM.xml:S1:11942:3	O
(	TANZEUM.xml:S1:11946:1	O
glimepiride	TANZEUM.xml:S1:11947:11	O
)	TANZEUM.xml:S1:11958:1	O
and	TANZEUM.xml:S1:11960:3	O
2%	TANZEUM.xml:S1:11964:2	O
(	TANZEUM.xml:S1:11967:1	O
sitagliptin	TANZEUM.xml:S1:11968:11	O
)	TANZEUM.xml:S1:11979:1	O
.	TANZEUM.xml:S1:11980:1	O

Pneumonia	TANZEUM.xml:S1:11989:9	O

In	TANZEUM.xml:S1:12005:2	O

the	TANZEUM.xml:S1:12008:3	O
pool	TANZEUM.xml:S1:12012:4	O
of	TANZEUM.xml:S1:12017:2	O
7	TANZEUM.xml:S1:12020:1	O
placebo	TANZEUM.xml:S1:12022:7	O
-	TANZEUM.xml:S1:12029:1	O
and	TANZEUM.xml:S1:12031:3	O
active	TANZEUM.xml:S1:12035:6	O
-	TANZEUM.xml:S1:12041:1	O
controlled	TANZEUM.xml:S1:12042:10	O
trials	TANZEUM.xml:S1:12053:6	O
,	TANZEUM.xml:S1:12059:1	O
the	TANZEUM.xml:S1:12061:3	O
adverse	TANZEUM.xml:S1:12065:7	O
reaction	TANZEUM.xml:S1:12073:8	O
of	TANZEUM.xml:S1:12082:2	O
pneumonia	TANZEUM.xml:S1:12085:9	B-AdverseReaction
was	TANZEUM.xml:S1:12095:3	O
reported	TANZEUM.xml:S1:12099:8	O
more	TANZEUM.xml:S1:12108:4	O
frequently	TANZEUM.xml:S1:12113:10	O
in	TANZEUM.xml:S1:12124:2	O
patients	TANZEUM.xml:S1:12127:8	O
receiving	TANZEUM.xml:S1:12136:9	O
TANZEUM	TANZEUM.xml:S1:12146:7	O
(	TANZEUM.xml:S1:12154:1	O
1.8%	TANZEUM.xml:S1:12155:4	O
)	TANZEUM.xml:S1:12159:1	O
than	TANZEUM.xml:S1:12161:4	O
in	TANZEUM.xml:S1:12166:2	O
patients	TANZEUM.xml:S1:12169:8	O
in	TANZEUM.xml:S1:12178:2	O
the	TANZEUM.xml:S1:12181:3	O
all	TANZEUM.xml:S1:12185:3	O
-	TANZEUM.xml:S1:12188:1	O
comparators	TANZEUM.xml:S1:12189:11	O
group	TANZEUM.xml:S1:12201:5	O
(	TANZEUM.xml:S1:12207:1	O
0.8%	TANZEUM.xml:S1:12208:4	O
)	TANZEUM.xml:S1:12212:1	O
.	TANZEUM.xml:S1:12213:1	O

More	TANZEUM.xml:S1:12215:4	O
cases	TANZEUM.xml:S1:12220:5	O
of	TANZEUM.xml:S1:12226:2	O
pneumonia	TANZEUM.xml:S1:12229:9	B-AdverseReaction
in	TANZEUM.xml:S1:12239:2	O
the	TANZEUM.xml:S1:12242:3	O
group	TANZEUM.xml:S1:12246:5	O
receiving	TANZEUM.xml:S1:12252:9	O
TANZEUM	TANZEUM.xml:S1:12262:7	O
were	TANZEUM.xml:S1:12270:4	O
serious	TANZEUM.xml:S1:12275:7	B-Severity
(	TANZEUM.xml:S1:12283:1	O
0.4%	TANZEUM.xml:S1:12284:4	O
for	TANZEUM.xml:S1:12289:3	O
TANZEUM	TANZEUM.xml:S1:12293:7	O
versus	TANZEUM.xml:S1:12301:6	O
0.1%	TANZEUM.xml:S1:12308:4	O
for	TANZEUM.xml:S1:12313:3	O
all	TANZEUM.xml:S1:12317:3	O
comparators	TANZEUM.xml:S1:12321:11	O
)	TANZEUM.xml:S1:12332:1	O
.	TANZEUM.xml:S1:12333:1	O

Atrial	TANZEUM.xml:S1:12341:6	O
Fibrillation	TANZEUM.xml:S1:12348:12	O
Flutte	TANZEUM.xml:S1:12361:6	O
r	TANZEUM.xml:S1:12369:1	O

In	TANZEUM.xml:S1:12375:2	O
the	TANZEUM.xml:S1:12378:3	O
pool	TANZEUM.xml:S1:12382:4	O
of	TANZEUM.xml:S1:12387:2	O
7	TANZEUM.xml:S1:12390:1	O
placebo	TANZEUM.xml:S1:12392:7	O
-	TANZEUM.xml:S1:12399:1	O
and	TANZEUM.xml:S1:12401:3	O
active	TANZEUM.xml:S1:12405:6	O
-	TANZEUM.xml:S1:12411:1	O
controlled	TANZEUM.xml:S1:12412:10	O
trials	TANZEUM.xml:S1:12423:6	O
,	TANZEUM.xml:S1:12429:1	O
adverse	TANZEUM.xml:S1:12431:7	O
reactions	TANZEUM.xml:S1:12439:9	O
of	TANZEUM.xml:S1:12449:2	O
atrial	TANZEUM.xml:S1:12452:6	B-AdverseReaction
fibrillation	TANZEUM.xml:S1:12459:12	I-AdverseReaction
(	TANZEUM.xml:S1:12472:1	O
1.0%	TANZEUM.xml:S1:12473:4	O
)	TANZEUM.xml:S1:12477:1	O
and	TANZEUM.xml:S1:12479:3	O
atrial	TANZEUM.xml:S1:12483:6	B-AdverseReaction
flutter	TANZEUM.xml:S1:12490:7	I-AdverseReaction
(	TANZEUM.xml:S1:12498:1	O
0.2%	TANZEUM.xml:S1:12499:4	O
)	TANZEUM.xml:S1:12503:1	O
were	TANZEUM.xml:S1:12505:4	O
reported	TANZEUM.xml:S1:12510:8	O
more	TANZEUM.xml:S1:12519:4	O
frequently	TANZEUM.xml:S1:12524:10	O
for	TANZEUM.xml:S1:12535:3	O
TANZEUM	TANZEUM.xml:S1:12539:7	O
than	TANZEUM.xml:S1:12547:4	O
for	TANZEUM.xml:S1:12552:3	O
all	TANZEUM.xml:S1:12556:3	O
comparators	TANZEUM.xml:S1:12560:11	O
(	TANZEUM.xml:S1:12572:1	O
0.5%	TANZEUM.xml:S1:12573:4	O
and	TANZEUM.xml:S1:12578:3	O
0%	TANZEUM.xml:S1:12582:2	O
,	TANZEUM.xml:S1:12584:1	O
respectively	TANZEUM.xml:S1:12586:12	O
)	TANZEUM.xml:S1:12598:1	O
.	TANZEUM.xml:S1:12599:1	O

In	TANZEUM.xml:S1:12601:2	O
both	TANZEUM.xml:S1:12604:4	O
groups	TANZEUM.xml:S1:12609:6	O
,	TANZEUM.xml:S1:12615:1	O
patients	TANZEUM.xml:S1:12617:8	O
with	TANZEUM.xml:S1:12626:4	O
events	TANZEUM.xml:S1:12631:6	O
were	TANZEUM.xml:S1:12638:4	O
generally	TANZEUM.xml:S1:12643:9	O
male	TANZEUM.xml:S1:12653:4	O
,	TANZEUM.xml:S1:12657:1	O
older	TANZEUM.xml:S1:12659:5	O
,	TANZEUM.xml:S1:12664:1	O
and	TANZEUM.xml:S1:12666:3	O
had	TANZEUM.xml:S1:12670:3	O
underlying	TANZEUM.xml:S1:12674:10	O
renal	TANZEUM.xml:S1:12685:5	O
impairment	TANZEUM.xml:S1:12691:10	O
or	TANZEUM.xml:S1:12702:2	O
cardiac	TANZEUM.xml:S1:12705:7	O
disease	TANZEUM.xml:S1:12713:7	O
(	TANZEUM.xml:S1:12721:1	O
e	TANZEUM.xml:S1:12722:1	O
.	TANZEUM.xml:S1:12723:1	O
g	TANZEUM.xml:S1:12724:1	O
.	TANZEUM.xml:S1:12725:1	O
,	TANZEUM.xml:S1:12726:1	O
history	TANZEUM.xml:S1:12728:7	O
of	TANZEUM.xml:S1:12736:2	O
arrhythmia	TANZEUM.xml:S1:12739:10	O
,	TANZEUM.xml:S1:12749:1	O
palpitations	TANZEUM.xml:S1:12751:12	O
,	TANZEUM.xml:S1:12763:1	O
congestive	TANZEUM.xml:S1:12765:10	O
heart	TANZEUM.xml:S1:12776:5	O
failure	TANZEUM.xml:S1:12782:7	O
,	TANZEUM.xml:S1:12789:1	O
cardiomyopathy	TANZEUM.xml:S1:12791:14	O
,	TANZEUM.xml:S1:12805:1	O
etc	TANZEUM.xml:S1:12807:3	O
.	TANZEUM.xml:S1:12810:1	O

)	TANZEUM.xml:S1:12811:1	O
.	TANZEUM.xml:S1:12812:1	O

Appendicitis	TANZEUM.xml:S1:12820:12	O

In	TANZEUM.xml:S1:12839:2	O
the	TANZEUM.xml:S1:12842:3	O
pool	TANZEUM.xml:S1:12846:4	O
of	TANZEUM.xml:S1:12851:2	O
placebo	TANZEUM.xml:S1:12854:7	O
-	TANZEUM.xml:S1:12861:1	O
and	TANZEUM.xml:S1:12863:3	O
active	TANZEUM.xml:S1:12867:6	O
-	TANZEUM.xml:S1:12873:1	O
controlled	TANZEUM.xml:S1:12874:10	O
trials	TANZEUM.xml:S1:12885:6	O
,	TANZEUM.xml:S1:12891:1	O
serious	TANZEUM.xml:S1:12893:7	B-Severity
events	TANZEUM.xml:S1:12901:6	O
of	TANZEUM.xml:S1:12908:2	O
appendicitis	TANZEUM.xml:S1:12911:12	B-AdverseReaction
occurred	TANZEUM.xml:S1:12924:8	O
in	TANZEUM.xml:S1:12933:2	O
0.3%	TANZEUM.xml:S1:12936:4	O
of	TANZEUM.xml:S1:12941:2	O
patients	TANZEUM.xml:S1:12944:8	O
treated	TANZEUM.xml:S1:12953:7	O
with	TANZEUM.xml:S1:12961:4	O
TANZEUM	TANZEUM.xml:S1:12966:7	O
compared	TANZEUM.xml:S1:12974:8	O
with	TANZEUM.xml:S1:12983:4	O
0%	TANZEUM.xml:S1:12988:2	O
among	TANZEUM.xml:S1:12991:5	O
all	TANZEUM.xml:S1:12997:3	O
comparators	TANZEUM.xml:S1:13001:11	O
.	TANZEUM.xml:S1:13012:1	O

Immunogenicity	TANZEUM.xml:S1:13020:14	O

In	TANZEUM.xml:S1:13041:2	O
the	TANZEUM.xml:S1:13044:3	O
pool	TANZEUM.xml:S1:13048:4	O
of	TANZEUM.xml:S1:13053:2	O
7	TANZEUM.xml:S1:13056:1	O
placebo	TANZEUM.xml:S1:13058:7	O
-	TANZEUM.xml:S1:13065:1	O
and	TANZEUM.xml:S1:13067:3	O
active	TANZEUM.xml:S1:13071:6	O
-	TANZEUM.xml:S1:13077:1	O
controlled	TANZEUM.xml:S1:13078:10	O
trials	TANZEUM.xml:S1:13089:6	O
,	TANZEUM.xml:S1:13095:1	O
116	TANZEUM.xml:S1:13097:3	O
(	TANZEUM.xml:S1:13101:1	O
5.5%	TANZEUM.xml:S1:13102:4	O
)	TANZEUM.xml:S1:13106:1	O
of	TANZEUM.xml:S1:13108:2	O
2	TANZEUM.xml:S1:13111:1	O
,	TANZEUM.xml:S1:13112:1	O
098	TANZEUM.xml:S1:13113:3	O
patients	TANZEUM.xml:S1:13117:8	O
exposed	TANZEUM.xml:S1:13126:7	O
to	TANZEUM.xml:S1:13134:2	O
TANZEUM	TANZEUM.xml:S1:13137:7	O
tested	TANZEUM.xml:S1:13145:6	O
positive	TANZEUM.xml:S1:13152:8	O
for	TANZEUM.xml:S1:13161:3	O
anti	TANZEUM.xml:S1:13165:4	O
-	TANZEUM.xml:S1:13169:1	O
albiglutide	TANZEUM.xml:S1:13170:11	O
antibodies	TANZEUM.xml:S1:13182:10	O
at	TANZEUM.xml:S1:13193:2	O
any	TANZEUM.xml:S1:13196:3	O
time	TANZEUM.xml:S1:13200:4	O
during	TANZEUM.xml:S1:13205:6	O
the	TANZEUM.xml:S1:13212:3	O
trials	TANZEUM.xml:S1:13216:6	O
.	TANZEUM.xml:S1:13222:1	O

None	TANZEUM.xml:S1:13224:4	O
of	TANZEUM.xml:S1:13229:2	O
these	TANZEUM.xml:S1:13232:5	O
antibodies	TANZEUM.xml:S1:13238:10	O
were	TANZEUM.xml:S1:13249:4	O
shown	TANZEUM.xml:S1:13254:5	O
to	TANZEUM.xml:S1:13260:2	O
neutralize	TANZEUM.xml:S1:13263:10	O
the	TANZEUM.xml:S1:13274:3	O
activity	TANZEUM.xml:S1:13278:8	O
of	TANZEUM.xml:S1:13287:2	O
albiglutide	TANZEUM.xml:S1:13290:11	O
in	TANZEUM.xml:S1:13302:2	O
an	TANZEUM.xml:S1:13305:2	O
in	TANZEUM.xml:S1:13308:2	O
vitro	TANZEUM.xml:S1:13311:5	O
bioassay	TANZEUM.xml:S1:13317:8	O
.	TANZEUM.xml:S1:13325:1	O

Presence	TANZEUM.xml:S1:13327:8	O
of	TANZEUM.xml:S1:13336:2	O
antibody	TANZEUM.xml:S1:13339:8	O
did	TANZEUM.xml:S1:13348:3	O
not	TANZEUM.xml:S1:13352:3	O
correlate	TANZEUM.xml:S1:13356:9	O
with	TANZEUM.xml:S1:13366:4	O
reduced	TANZEUM.xml:S1:13371:7	O
efficacy	TANZEUM.xml:S1:13379:8	O
as	TANZEUM.xml:S1:13388:2	O
measured	TANZEUM.xml:S1:13391:8	O
by	TANZEUM.xml:S1:13400:2	O
HbA1c	TANZEUM.xml:S1:13403:5	O
and	TANZEUM.xml:S1:13409:3	O
fasting	TANZEUM.xml:S1:13413:7	O
plasma	TANZEUM.xml:S1:13421:6	O
glucose	TANZEUM.xml:S1:13428:7	O
or	TANZEUM.xml:S1:13436:2	O
specific	TANZEUM.xml:S1:13439:8	O
adverse	TANZEUM.xml:S1:13448:7	O
reactions	TANZEUM.xml:S1:13456:9	O
.	TANZEUM.xml:S1:13465:1	O

Consistent	TANZEUM.xml:S1:13471:10	O
with	TANZEUM.xml:S1:13482:4	O
the	TANZEUM.xml:S1:13487:3	O
high	TANZEUM.xml:S1:13491:4	O
homology	TANZEUM.xml:S1:13496:8	O
of	TANZEUM.xml:S1:13505:2	O
albiglutide	TANZEUM.xml:S1:13508:11	O
with	TANZEUM.xml:S1:13520:4	O
human	TANZEUM.xml:S1:13525:5	O
GLP	TANZEUM.xml:S1:13531:3	O
-	TANZEUM.xml:S1:13534:1	O
1	TANZEUM.xml:S1:13535:1	O
,	TANZEUM.xml:S1:13536:1	O
the	TANZEUM.xml:S1:13538:3	O
majority	TANZEUM.xml:S1:13542:8	O
of	TANZEUM.xml:S1:13551:2	O
patients	TANZEUM.xml:S1:13554:8	O
(	TANZEUM.xml:S1:13563:1	O
approximately	TANZEUM.xml:S1:13564:13	O
79%	TANZEUM.xml:S1:13578:3	O
)	TANZEUM.xml:S1:13581:1	O
with	TANZEUM.xml:S1:13583:4	O
anti	TANZEUM.xml:S1:13588:4	O
-	TANZEUM.xml:S1:13592:1	O
albiglutide	TANZEUM.xml:S1:13593:11	O
antibodies	TANZEUM.xml:S1:13605:10	O
also	TANZEUM.xml:S1:13616:4	O
tested	TANZEUM.xml:S1:13621:6	O
positive	TANZEUM.xml:S1:13628:8	O
for	TANZEUM.xml:S1:13637:3	O
anti	TANZEUM.xml:S1:13641:4	O
-	TANZEUM.xml:S1:13645:1	O
GLP	TANZEUM.xml:S1:13646:3	O
-	TANZEUM.xml:S1:13649:1	O
1	TANZEUM.xml:S1:13650:1	O
antibodies	TANZEUM.xml:S1:13652:10	O
;	TANZEUM.xml:S1:13662:1	O
none	TANZEUM.xml:S1:13664:4	O
were	TANZEUM.xml:S1:13669:4	O
neutralizing	TANZEUM.xml:S1:13674:12	O
.	TANZEUM.xml:S1:13686:1	O

A	TANZEUM.xml:S1:13688:1	O
minority	TANZEUM.xml:S1:13690:8	O
of	TANZEUM.xml:S1:13699:2	O
patients	TANZEUM.xml:S1:13702:8	O
(	TANZEUM.xml:S1:13711:1	O
approximately	TANZEUM.xml:S1:13712:13	O
17%	TANZEUM.xml:S1:13726:3	O
)	TANZEUM.xml:S1:13729:1	O
who	TANZEUM.xml:S1:13731:3	O
tested	TANZEUM.xml:S1:13735:6	O
positive	TANZEUM.xml:S1:13742:8	O
for	TANZEUM.xml:S1:13751:3	O
anti	TANZEUM.xml:S1:13755:4	O
-	TANZEUM.xml:S1:13759:1	O
albiglutide	TANZEUM.xml:S1:13760:11	O
antibodies	TANZEUM.xml:S1:13772:10	O
also	TANZEUM.xml:S1:13783:4	O
transiently	TANZEUM.xml:S1:13788:11	O
tested	TANZEUM.xml:S1:13800:6	O
positive	TANZEUM.xml:S1:13807:8	O
for	TANZEUM.xml:S1:13816:3	O
antibodies	TANZEUM.xml:S1:13820:10	O
to	TANZEUM.xml:S1:13831:2	O
human	TANZEUM.xml:S1:13834:5	O
albumin	TANZEUM.xml:S1:13840:7	O
.	TANZEUM.xml:S1:13847:1	O

The	TANZEUM.xml:S1:13853:3	O
detection	TANZEUM.xml:S1:13857:9	O
of	TANZEUM.xml:S1:13867:2	O
antibody	TANZEUM.xml:S1:13870:8	O
formation	TANZEUM.xml:S1:13879:9	O
is	TANZEUM.xml:S1:13889:2	O
highly	TANZEUM.xml:S1:13892:6	O
dependent	TANZEUM.xml:S1:13899:9	O
on	TANZEUM.xml:S1:13909:2	O
the	TANZEUM.xml:S1:13912:3	O
sensitivity	TANZEUM.xml:S1:13916:11	O
and	TANZEUM.xml:S1:13928:3	O
specificity	TANZEUM.xml:S1:13932:11	O
of	TANZEUM.xml:S1:13944:2	O
the	TANZEUM.xml:S1:13947:3	O
assay	TANZEUM.xml:S1:13951:5	O
.	TANZEUM.xml:S1:13956:1	O

Additionally	TANZEUM.xml:S1:13958:12	O
,	TANZEUM.xml:S1:13970:1	O
the	TANZEUM.xml:S1:13972:3	O
observed	TANZEUM.xml:S1:13976:8	O
incidence	TANZEUM.xml:S1:13985:9	O
of	TANZEUM.xml:S1:13995:2	O
antibody	TANZEUM.xml:S1:13998:8	O
(	TANZEUM.xml:S1:14007:1	O
including	TANZEUM.xml:S1:14008:9	O
neutralizing	TANZEUM.xml:S1:14018:12	O
antibody	TANZEUM.xml:S1:14031:8	O
)	TANZEUM.xml:S1:14039:1	O
positivity	TANZEUM.xml:S1:14041:10	O
in	TANZEUM.xml:S1:14052:2	O
an	TANZEUM.xml:S1:14055:2	O
assay	TANZEUM.xml:S1:14058:5	O
may	TANZEUM.xml:S1:14064:3	O
be	TANZEUM.xml:S1:14068:2	O
influenced	TANZEUM.xml:S1:14071:10	O
by	TANZEUM.xml:S1:14082:2	O
several	TANZEUM.xml:S1:14085:7	O
factors	TANZEUM.xml:S1:14093:7	O
including	TANZEUM.xml:S1:14101:9	O
assay	TANZEUM.xml:S1:14111:5	O
methodology	TANZEUM.xml:S1:14117:11	O
,	TANZEUM.xml:S1:14128:1	O
sample	TANZEUM.xml:S1:14130:6	O
handling	TANZEUM.xml:S1:14137:8	O
,	TANZEUM.xml:S1:14145:1	O
timing	TANZEUM.xml:S1:14147:6	O
of	TANZEUM.xml:S1:14154:2	O
sample	TANZEUM.xml:S1:14157:6	O
collection	TANZEUM.xml:S1:14164:10	O
,	TANZEUM.xml:S1:14174:1	O
concomitant	TANZEUM.xml:S1:14176:11	O
medications	TANZEUM.xml:S1:14188:11	O
,	TANZEUM.xml:S1:14199:1	O
and	TANZEUM.xml:S1:14201:3	O
underlying	TANZEUM.xml:S1:14205:10	O
disease	TANZEUM.xml:S1:14216:7	O
.	TANZEUM.xml:S1:14223:1	O

For	TANZEUM.xml:S1:14225:3	O
these	TANZEUM.xml:S1:14229:5	O
reasons	TANZEUM.xml:S1:14235:7	O
,	TANZEUM.xml:S1:14242:1	O
the	TANZEUM.xml:S1:14244:3	O
incidence	TANZEUM.xml:S1:14248:9	O
of	TANZEUM.xml:S1:14258:2	O
antibodies	TANZEUM.xml:S1:14261:10	O
to	TANZEUM.xml:S1:14272:2	O
albiglutide	TANZEUM.xml:S1:14275:11	O
cannot	TANZEUM.xml:S1:14287:6	O
be	TANZEUM.xml:S1:14294:2	O
directly	TANZEUM.xml:S1:14297:8	O
compared	TANZEUM.xml:S1:14306:8	O
with	TANZEUM.xml:S1:14315:4	O
the	TANZEUM.xml:S1:14320:3	O
incidence	TANZEUM.xml:S1:14324:9	O
of	TANZEUM.xml:S1:14334:2	O
antibodies	TANZEUM.xml:S1:14337:10	O
of	TANZEUM.xml:S1:14348:2	O
other	TANZEUM.xml:S1:14351:5	O
products	TANZEUM.xml:S1:14357:8	O
.	TANZEUM.xml:S1:14365:1	O

Liver	TANZEUM.xml:S1:14373:5	O
Enzyme	TANZEUM.xml:S1:14379:6	O
Abnormalities	TANZEUM.xml:S1:14386:13	O

In	TANZEUM.xml:S1:14406:2	O
the	TANZEUM.xml:S1:14409:3	O
pool	TANZEUM.xml:S1:14413:4	O
of	TANZEUM.xml:S1:14418:2	O
placebo	TANZEUM.xml:S1:14421:7	O
-	TANZEUM.xml:S1:14428:1	O
and	TANZEUM.xml:S1:14430:3	O
active	TANZEUM.xml:S1:14434:6	O
-	TANZEUM.xml:S1:14440:1	O
controlled	TANZEUM.xml:S1:14441:10	O
trials	TANZEUM.xml:S1:14452:6	O
,	TANZEUM.xml:S1:14458:1	O
a	TANZEUM.xml:S1:14460:1	O
similar	TANZEUM.xml:S1:14462:7	O
proportion	TANZEUM.xml:S1:14470:10	O
of	TANZEUM.xml:S1:14481:2	O
patients	TANZEUM.xml:S1:14484:8	O
experienced	TANZEUM.xml:S1:14493:11	O
at	TANZEUM.xml:S1:14505:2	O
least	TANZEUM.xml:S1:14508:5	O
one	TANZEUM.xml:S1:14514:3	O
event	TANZEUM.xml:S1:14518:5	O
of	TANZEUM.xml:S1:14524:2	O
alanine	TANZEUM.xml:S1:14527:7	B-AdverseReaction
aminotransferase	TANZEUM.xml:S1:14535:16	I-AdverseReaction
(	TANZEUM.xml:S1:14552:1	O
ALT	TANZEUM.xml:S1:14553:3	B-AdverseReaction
)	TANZEUM.xml:S1:14556:1	O
increase	TANZEUM.xml:S1:14558:8	I-AdverseReaction
of	TANZEUM.xml:S1:14567:2	O
3	TANZEUM.xml:S1:14570:1	O
-	TANZEUM.xml:S1:14571:1	O
fold	TANZEUM.xml:S1:14572:4	O
or	TANZEUM.xml:S1:14577:2	O
greater	TANZEUM.xml:S1:14580:7	O
above	TANZEUM.xml:S1:14588:5	O
the	TANZEUM.xml:S1:14594:3	O
upper	TANZEUM.xml:S1:14598:5	O
limit	TANZEUM.xml:S1:14604:5	O
of	TANZEUM.xml:S1:14610:2	O
normal	TANZEUM.xml:S1:14613:6	O
(	TANZEUM.xml:S1:14620:1	O
0.9%	TANZEUM.xml:S1:14621:4	O
and	TANZEUM.xml:S1:14626:3	O
0.9%	TANZEUM.xml:S1:14630:4	O
for	TANZEUM.xml:S1:14635:3	O
all	TANZEUM.xml:S1:14639:3	O
comparators	TANZEUM.xml:S1:14643:11	O
versus	TANZEUM.xml:S1:14655:6	O
TANZEUM	TANZEUM.xml:S1:14662:7	O
)	TANZEUM.xml:S1:14669:1	O
.	TANZEUM.xml:S1:14670:1	O

Three	TANZEUM.xml:S1:14672:5	O
subjects	TANZEUM.xml:S1:14678:8	O
on	TANZEUM.xml:S1:14687:2	O
TANZEUM	TANZEUM.xml:S1:14690:7	O
and	TANZEUM.xml:S1:14698:3	O
one	TANZEUM.xml:S1:14702:3	O
subject	TANZEUM.xml:S1:14706:7	O
in	TANZEUM.xml:S1:14714:2	O
the	TANZEUM.xml:S1:14717:3	O
all	TANZEUM.xml:S1:14721:3	O
-	TANZEUM.xml:S1:14724:1	O
comparator	TANZEUM.xml:S1:14725:10	O
group	TANZEUM.xml:S1:14736:5	O
experienced	TANZEUM.xml:S1:14742:11	O
at	TANZEUM.xml:S1:14754:2	O
least	TANZEUM.xml:S1:14757:5	O
one	TANZEUM.xml:S1:14763:3	O
event	TANZEUM.xml:S1:14767:5	O
of	TANZEUM.xml:S1:14773:2	O
ALT	TANZEUM.xml:S1:14776:3	B-AdverseReaction
increase	TANZEUM.xml:S1:14780:8	I-AdverseReaction
of	TANZEUM.xml:S1:14789:2	O
10	TANZEUM.xml:S1:14792:2	O
-	TANZEUM.xml:S1:14794:1	O
fold	TANZEUM.xml:S1:14795:4	O
or	TANZEUM.xml:S1:14800:2	O
greater	TANZEUM.xml:S1:14803:7	O
above	TANZEUM.xml:S1:14811:5	O
the	TANZEUM.xml:S1:14817:3	O
upper	TANZEUM.xml:S1:14821:5	O
limit	TANZEUM.xml:S1:14827:5	O
of	TANZEUM.xml:S1:14833:2	O
normal	TANZEUM.xml:S1:14836:6	O
.	TANZEUM.xml:S1:14844:1	O

In	TANZEUM.xml:S1:14847:2	O
one	TANZEUM.xml:S1:14850:3	O
of	TANZEUM.xml:S1:14854:2	O
the	TANZEUM.xml:S1:14857:3	O
3	TANZEUM.xml:S1:14861:1	O
cases	TANZEUM.xml:S1:14863:5	O
an	TANZEUM.xml:S1:14869:2	O
alternate	TANZEUM.xml:S1:14872:9	B-Negation
etiology	TANZEUM.xml:S1:14882:8	I-Negation
was	TANZEUM.xml:S1:14891:3	O
identified	TANZEUM.xml:S1:14895:10	O
to	TANZEUM.xml:S1:14906:2	O
explain	TANZEUM.xml:S1:14909:7	O
the	TANZEUM.xml:S1:14917:3	O
rise	TANZEUM.xml:S1:14921:4	B-AdverseReaction
in	TANZEUM.xml:S1:14926:2	I-AdverseReaction
liver	TANZEUM.xml:S1:14929:5	I-AdverseReaction
enzyme	TANZEUM.xml:S1:14935:6	I-AdverseReaction
(	TANZEUM.xml:S1:14942:1	O
acute	TANZEUM.xml:S1:14943:5	O
viral	TANZEUM.xml:S1:14949:5	O
hepatitis	TANZEUM.xml:S1:14955:9	O
)	TANZEUM.xml:S1:14964:1	O
.	TANZEUM.xml:S1:14965:1	O

In	TANZEUM.xml:S1:14967:2	O
one	TANZEUM.xml:S1:14970:3	O
case	TANZEUM.xml:S1:14974:4	O
,	TANZEUM.xml:S1:14978:1	O
insufficient	TANZEUM.xml:S1:14980:12	O
information	TANZEUM.xml:S1:14993:11	O
was	TANZEUM.xml:S1:15005:3	O
obtained	TANZEUM.xml:S1:15009:8	O
to	TANZEUM.xml:S1:15018:2	O
establish	TANZEUM.xml:S1:15021:9	O
or	TANZEUM.xml:S1:15031:2	O
refute	TANZEUM.xml:S1:15034:6	O
a	TANZEUM.xml:S1:15041:1	O
drug	TANZEUM.xml:S1:15043:4	O
-	TANZEUM.xml:S1:15047:1	O
related	TANZEUM.xml:S1:15048:7	O
causality	TANZEUM.xml:S1:15056:9	O
.	TANZEUM.xml:S1:15065:1	O

In	TANZEUM.xml:S1:15067:2	O
the	TANZEUM.xml:S1:15070:3	O
third	TANZEUM.xml:S1:15074:5	O
case	TANZEUM.xml:S1:15080:4	O
,	TANZEUM.xml:S1:15084:1	O
elevation	TANZEUM.xml:S1:15086:9	B-AdverseReaction
in	TANZEUM.xml:S1:15096:2	I-AdverseReaction
ALT	TANZEUM.xml:S1:15099:3	I-AdverseReaction
(	TANZEUM.xml:S1:15103:1	O
10	TANZEUM.xml:S1:15104:2	B-Severity
times	TANZEUM.xml:S1:15107:5	I-Severity
the	TANZEUM.xml:S1:15113:3	I-Severity
upper	TANZEUM.xml:S1:15117:5	I-Severity
limit	TANZEUM.xml:S1:15123:5	I-Severity
of	TANZEUM.xml:S1:15129:2	I-Severity
normal	TANZEUM.xml:S1:15132:6	I-Severity
)	TANZEUM.xml:S1:15138:1	O
was	TANZEUM.xml:S1:15140:3	O
accompanied	TANZEUM.xml:S1:15144:11	O
by	TANZEUM.xml:S1:15156:2	O
an	TANZEUM.xml:S1:15159:2	O
increase	TANZEUM.xml:S1:15162:8	B-AdverseReaction
in	TANZEUM.xml:S1:15171:2	I-AdverseReaction
total	TANZEUM.xml:S1:15174:5	I-AdverseReaction
bilirubin	TANZEUM.xml:S1:15180:9	I-AdverseReaction
(	TANZEUM.xml:S1:15190:1	O
4	TANZEUM.xml:S1:15191:1	B-Severity
times	TANZEUM.xml:S1:15193:5	I-Severity
the	TANZEUM.xml:S1:15199:3	I-Severity
upper	TANZEUM.xml:S1:15203:5	I-Severity
limit	TANZEUM.xml:S1:15209:5	I-Severity
of	TANZEUM.xml:S1:15215:2	I-Severity
normal	TANZEUM.xml:S1:15218:6	I-Severity
)	TANZEUM.xml:S1:15224:1	O
and	TANZEUM.xml:S1:15226:3	O
occurred	TANZEUM.xml:S1:15230:8	O
8	TANZEUM.xml:S1:15239:1	O
days	TANZEUM.xml:S1:15241:4	O
after	TANZEUM.xml:S1:15246:5	O
the	TANZEUM.xml:S1:15252:3	O
first	TANZEUM.xml:S1:15256:5	O
dose	TANZEUM.xml:S1:15262:4	O
of	TANZEUM.xml:S1:15267:2	O
TANZEUM	TANZEUM.xml:S1:15270:7	O
.	TANZEUM.xml:S1:15277:1	O

The	TANZEUM.xml:S1:15279:3	O
etiology	TANZEUM.xml:S1:15283:8	O
of	TANZEUM.xml:S1:15292:2	O
hepatocellular	TANZEUM.xml:S1:15295:14	B-AdverseReaction
injury	TANZEUM.xml:S1:15310:6	I-AdverseReaction
was	TANZEUM.xml:S1:15317:3	O
possibly	TANZEUM.xml:S1:15321:8	O
related	TANZEUM.xml:S1:15330:7	O
to	TANZEUM.xml:S1:15338:2	O
TANZEUM	TANZEUM.xml:S1:15341:7	O
but	TANZEUM.xml:S1:15349:3	O
direct	TANZEUM.xml:S1:15353:6	O
attribution	TANZEUM.xml:S1:15360:11	O
to	TANZEUM.xml:S1:15372:2	O
TANZEUM	TANZEUM.xml:S1:15375:7	O
was	TANZEUM.xml:S1:15383:3	O
confounded	TANZEUM.xml:S1:15387:10	O
by	TANZEUM.xml:S1:15398:2	O
the	TANZEUM.xml:S1:15401:3	O
presence	TANZEUM.xml:S1:15405:8	O
of	TANZEUM.xml:S1:15414:2	O
gallstone	TANZEUM.xml:S1:15417:9	O
disease	TANZEUM.xml:S1:15427:7	O
diagnosed	TANZEUM.xml:S1:15435:9	O
on	TANZEUM.xml:S1:15445:2	O
ultrasound	TANZEUM.xml:S1:15448:10	O
3	TANZEUM.xml:S1:15459:1	O
weeks	TANZEUM.xml:S1:15461:5	O
after	TANZEUM.xml:S1:15467:5	O
the	TANZEUM.xml:S1:15473:3	O
event	TANZEUM.xml:S1:15477:5	O
.	TANZEUM.xml:S1:15484:1	O

Gamma	TANZEUM.xml:S1:15494:5	O
Glutamyltransferase	TANZEUM.xml:S1:15500:19	O
(	TANZEUM.xml:S1:15520:1	O
GGT	TANZEUM.xml:S1:15521:3	O
)	TANZEUM.xml:S1:15524:1	O
Increase	TANZEUM.xml:S1:15526:8	O

In	TANZEUM.xml:S1:15541:2	O
the	TANZEUM.xml:S1:15544:3	O
pool	TANZEUM.xml:S1:15548:4	O
of	TANZEUM.xml:S1:15553:2	O
placebo	TANZEUM.xml:S1:15556:7	O
-	TANZEUM.xml:S1:15563:1	O
controlled	TANZEUM.xml:S1:15564:10	O
trials	TANZEUM.xml:S1:15575:6	O
,	TANZEUM.xml:S1:15581:1	O
the	TANZEUM.xml:S1:15583:3	O
adverse	TANZEUM.xml:S1:15587:7	O
event	TANZEUM.xml:S1:15595:5	O
of	TANZEUM.xml:S1:15601:2	O
increased	TANZEUM.xml:S1:15604:9	B-AdverseReaction
GGT	TANZEUM.xml:S1:15614:3	I-AdverseReaction
occurred	TANZEUM.xml:S1:15618:8	O
more	TANZEUM.xml:S1:15627:4	O
frequently	TANZEUM.xml:S1:15632:10	O
in	TANZEUM.xml:S1:15643:2	O
the	TANZEUM.xml:S1:15646:3	O
group	TANZEUM.xml:S1:15650:5	O
treated	TANZEUM.xml:S1:15656:7	O
with	TANZEUM.xml:S1:15664:4	O
TANZEUM	TANZEUM.xml:S1:15669:7	O
(	TANZEUM.xml:S1:15677:1	O
0.9%	TANZEUM.xml:S1:15678:4	O
and	TANZEUM.xml:S1:15683:3	O
1.5%	TANZEUM.xml:S1:15687:4	O
for	TANZEUM.xml:S1:15692:3	O
placebo	TANZEUM.xml:S1:15696:7	O
versus	TANZEUM.xml:S1:15704:6	O
TANZEUM	TANZEUM.xml:S1:15711:7	O
)	TANZEUM.xml:S1:15718:1	O
.	TANZEUM.xml:S1:15719:1	O

Heart	TANZEUM.xml:S1:15727:5	O
Rate	TANZEUM.xml:S1:15733:4	O
Increase	TANZEUM.xml:S1:15738:8	O

In	TANZEUM.xml:S1:15753:2	O
the	TANZEUM.xml:S1:15756:3	O
pool	TANZEUM.xml:S1:15760:4	O
of	TANZEUM.xml:S1:15765:2	O
placebo	TANZEUM.xml:S1:15768:7	O
-	TANZEUM.xml:S1:15775:1	O
controlled	TANZEUM.xml:S1:15776:10	O
trials	TANZEUM.xml:S1:15787:6	O
,	TANZEUM.xml:S1:15793:1	O
mean	TANZEUM.xml:S1:15795:4	B-AdverseReaction
heart	TANZEUM.xml:S1:15800:5	I-AdverseReaction
rate	TANZEUM.xml:S1:15806:4	I-AdverseReaction
in	TANZEUM.xml:S1:15811:2	O
patients	TANZEUM.xml:S1:15814:8	O
treated	TANZEUM.xml:S1:15823:7	O
with	TANZEUM.xml:S1:15831:4	O
TANZEUM	TANZEUM.xml:S1:15836:7	O
was	TANZEUM.xml:S1:15844:3	O
higher	TANZEUM.xml:S1:15848:6	I-AdverseReaction
by	TANZEUM.xml:S1:15855:2	I-AdverseReaction
an	TANZEUM.xml:S1:15858:2	I-AdverseReaction
average	TANZEUM.xml:S1:15861:7	I-AdverseReaction
of	TANZEUM.xml:S1:15869:2	I-AdverseReaction
1	TANZEUM.xml:S1:15872:1	I-AdverseReaction
to	TANZEUM.xml:S1:15874:2	I-AdverseReaction
2	TANZEUM.xml:S1:15877:1	I-AdverseReaction
bpm	TANZEUM.xml:S1:15879:3	I-AdverseReaction
compared	TANZEUM.xml:S1:15883:8	O
with	TANZEUM.xml:S1:15892:4	O
mean	TANZEUM.xml:S1:15897:4	O
heart	TANZEUM.xml:S1:15902:5	O
rate	TANZEUM.xml:S1:15908:4	O
in	TANZEUM.xml:S1:15913:2	O
patients	TANZEUM.xml:S1:15916:8	O
treated	TANZEUM.xml:S1:15925:7	O
with	TANZEUM.xml:S1:15933:4	O
placebo	TANZEUM.xml:S1:15938:7	O
across	TANZEUM.xml:S1:15946:6	O
study	TANZEUM.xml:S1:15953:5	O
visits	TANZEUM.xml:S1:15959:6	O
.	TANZEUM.xml:S1:15965:1	O

The	TANZEUM.xml:S1:15967:3	O
long	TANZEUM.xml:S1:15971:4	O
-	TANZEUM.xml:S1:15975:1	O
term	TANZEUM.xml:S1:15976:4	O
clinical	TANZEUM.xml:S1:15981:8	O
effects	TANZEUM.xml:S1:15990:7	O
of	TANZEUM.xml:S1:15998:2	O
the	TANZEUM.xml:S1:16001:3	O
increase	TANZEUM.xml:S1:16005:8	B-AdverseReaction
in	TANZEUM.xml:S1:16014:2	I-AdverseReaction
heart	TANZEUM.xml:S1:16017:5	I-AdverseReaction
rate	TANZEUM.xml:S1:16023:4	I-AdverseReaction
have	TANZEUM.xml:S1:16028:4	O
not	TANZEUM.xml:S1:16033:3	O
been	TANZEUM.xml:S1:16037:4	O
established	TANZEUM.xml:S1:16042:11	O
[	TANZEUM.xml:S1:16055:1	O
see	TANZEUM.xml:S1:16056:3	O
Warnings	TANZEUM.xml:S1:16060:8	O
and	TANZEUM.xml:S1:16069:3	O
Precautions	TANZEUM.xml:S1:16073:11	O
(	TANZEUM.xml:S1:16085:1	O
5.6	TANZEUM.xml:S1:16086:3	O
)]	TANZEUM.xml:S1:16089:2	O
.	TANZEUM.xml:S1:16093:1	O
\n\n	TANZEUM.xml:S2:0:2	O
BOXED	TANZEUM.xml:S2:6:5	O
WARNING	TANZEUM.xml:S2:12:7	O
:	TANZEUM.xml:S2:19:1	O
WARNING	TANZEUM.xml:S2:21:7	O
:	TANZEUM.xml:S2:28:1	O
RISK	TANZEUM.xml:S2:30:4	B-Factor
OF	TANZEUM.xml:S2:35:2	O
THYROID	TANZEUM.xml:S2:38:7	B-AdverseReaction
C	TANZEUM.xml:S2:46:1	I-AdverseReaction
-	TANZEUM.xml:S2:47:1	I-AdverseReaction
CELL	TANZEUM.xml:S2:48:4	I-AdverseReaction
TUMORS	TANZEUM.xml:S2:53:6	I-AdverseReaction
\n\n	TANZEUM.xml:S2:59:2	O
WARNING	TANZEUM.xml:S2:63:7	O
:	TANZEUM.xml:S2:70:1	O
RISK	TANZEUM.xml:S2:72:4	B-Factor
OF	TANZEUM.xml:S2:77:2	O
THYROID	TANZEUM.xml:S2:80:7	B-AdverseReaction
C	TANZEUM.xml:S2:88:1	I-AdverseReaction
-	TANZEUM.xml:S2:89:1	I-AdverseReaction
CELL	TANZEUM.xml:S2:90:4	I-AdverseReaction
TUMORS	TANZEUM.xml:S2:95:6	I-AdverseReaction
\n\n	TANZEUM.xml:S2:101:2	O
Carcinogenicity	TANZEUM.xml:S2:110:15	O
of	TANZEUM.xml:S2:126:2	O
albiglutide	TANZEUM.xml:S2:129:11	O
could	TANZEUM.xml:S2:141:5	O
not	TANZEUM.xml:S2:147:3	O
be	TANZEUM.xml:S2:151:2	O
assessed	TANZEUM.xml:S2:154:8	O
in	TANZEUM.xml:S2:163:2	O
rodents	TANZEUM.xml:S2:166:7	O
,	TANZEUM.xml:S2:173:1	O
but	TANZEUM.xml:S2:175:3	O
other	TANZEUM.xml:S2:179:5	O
glucagon	TANZEUM.xml:S2:185:8	B-DrugClass
-	TANZEUM.xml:S2:193:1	I-DrugClass
like	TANZEUM.xml:S2:194:4	I-DrugClass
peptide	TANZEUM.xml:S2:199:7	I-DrugClass
-	TANZEUM.xml:S2:206:1	I-DrugClass
1	TANZEUM.xml:S2:207:1	I-DrugClass
(	TANZEUM.xml:S2:209:1	I-DrugClass
GLP	TANZEUM.xml:S2:210:3	I-DrugClass
-	TANZEUM.xml:S2:213:1	I-DrugClass
1	TANZEUM.xml:S2:214:1	I-DrugClass
)	TANZEUM.xml:S2:215:1	I-DrugClass
receptor	TANZEUM.xml:S2:217:8	I-DrugClass
agonists	TANZEUM.xml:S2:226:8	I-DrugClass
have	TANZEUM.xml:S2:235:4	O
caused	TANZEUM.xml:S2:240:6	O
thyroid	TANZEUM.xml:S2:247:7	B-AdverseReaction
C	TANZEUM.xml:S2:255:1	I-AdverseReaction
-	TANZEUM.xml:S2:256:1	I-AdverseReaction
cell	TANZEUM.xml:S2:257:4	I-AdverseReaction
tumors	TANZEUM.xml:S2:262:6	I-AdverseReaction
in	TANZEUM.xml:S2:269:2	O
rodents	TANZEUM.xml:S2:272:7	B-Animal
at	TANZEUM.xml:S2:280:2	O
clinically	TANZEUM.xml:S2:283:10	O
relevant	TANZEUM.xml:S2:294:8	O
exposures	TANZEUM.xml:S2:303:9	O
.	TANZEUM.xml:S2:312:1	O

Human	TANZEUM.xml:S2:314:5	O
relevance	TANZEUM.xml:S2:320:9	O
of	TANZEUM.xml:S2:330:2	O
GLP	TANZEUM.xml:S2:333:3	B-DrugClass
-	TANZEUM.xml:S2:336:1	I-DrugClass
1	TANZEUM.xml:S2:337:1	I-DrugClass
receptor	TANZEUM.xml:S2:339:8	I-DrugClass
agonist	TANZEUM.xml:S2:348:7	I-DrugClass
induced	TANZEUM.xml:S2:356:7	O
C	TANZEUM.xml:S2:364:1	B-AdverseReaction
-	TANZEUM.xml:S2:365:1	I-AdverseReaction
cell	TANZEUM.xml:S2:366:4	I-AdverseReaction
tumors	TANZEUM.xml:S2:371:6	I-AdverseReaction
in	TANZEUM.xml:S2:378:2	O
rodents	TANZEUM.xml:S2:381:7	B-Animal
has	TANZEUM.xml:S2:389:3	O
not	TANZEUM.xml:S2:393:3	O
been	TANZEUM.xml:S2:397:4	O
determined	TANZEUM.xml:S2:402:10	O
.	TANZEUM.xml:S2:412:1	O

It	TANZEUM.xml:S2:414:2	O
is	TANZEUM.xml:S2:417:2	O
unknown	TANZEUM.xml:S2:420:7	B-Factor
whether	TANZEUM.xml:S2:428:7	O
TANZEUM	TANZEUM.xml:S2:436:7	O
(	TANZEUM.xml:S2:443:1	O
r	TANZEUM.xml:S2:444:1	O
)	TANZEUM.xml:S2:445:1	O
causes	TANZEUM.xml:S2:447:6	O
thyroid	TANZEUM.xml:S2:454:7	B-AdverseReaction
C	TANZEUM.xml:S2:462:1	I-AdverseReaction
-	TANZEUM.xml:S2:463:1	I-AdverseReaction
cell	TANZEUM.xml:S2:464:4	I-AdverseReaction
tumors	TANZEUM.xml:S2:469:6	I-AdverseReaction
,	TANZEUM.xml:S2:475:1	O
including	TANZEUM.xml:S2:477:9	O
medullary	TANZEUM.xml:S2:487:9	B-AdverseReaction
thyroid	TANZEUM.xml:S2:497:7	I-AdverseReaction
carcinoma	TANZEUM.xml:S2:505:9	I-AdverseReaction
(	TANZEUM.xml:S2:515:1	O
MTC	TANZEUM.xml:S2:516:3	B-AdverseReaction
)	TANZEUM.xml:S2:519:1	O
,	TANZEUM.xml:S2:520:1	O
in	TANZEUM.xml:S2:522:2	O
humans	TANZEUM.xml:S2:525:6	O
[	TANZEUM.xml:S2:532:1	O
see	TANZEUM.xml:S2:533:3	O
Warnings	TANZEUM.xml:S2:537:8	O
and	TANZEUM.xml:S2:546:3	O
Precautions	TANZEUM.xml:S2:550:11	O
(	TANZEUM.xml:S2:562:1	O
5.1	TANZEUM.xml:S2:563:3	O
)	TANZEUM.xml:S2:566:1	O
,	TANZEUM.xml:S2:567:1	O
Nonclinical	TANZEUM.xml:S2:569:11	O
Toxicology	TANZEUM.xml:S2:581:10	O
(	TANZEUM.xml:S2:592:1	O
13.1	TANZEUM.xml:S2:593:4	O
)]	TANZEUM.xml:S2:597:2	O
.	TANZEUM.xml:S2:599:1	O

TANZEUM	TANZEUM.xml:S2:606:7	O
is	TANZEUM.xml:S2:614:2	O
contraindicated	TANZEUM.xml:S2:617:15	O
in	TANZEUM.xml:S2:633:2	O
patients	TANZEUM.xml:S2:636:8	O
with	TANZEUM.xml:S2:645:4	O
a	TANZEUM.xml:S2:650:1	O
personal	TANZEUM.xml:S2:652:8	O
or	TANZEUM.xml:S2:661:2	O
family	TANZEUM.xml:S2:664:6	O
history	TANZEUM.xml:S2:671:7	O
of	TANZEUM.xml:S2:679:2	O
MTC	TANZEUM.xml:S2:682:3	O
or	TANZEUM.xml:S2:686:2	O
in	TANZEUM.xml:S2:689:2	O
patients	TANZEUM.xml:S2:692:8	O
with	TANZEUM.xml:S2:701:4	O
Multiple	TANZEUM.xml:S2:706:8	O
Endocrine	TANZEUM.xml:S2:715:9	O
Neoplasia	TANZEUM.xml:S2:725:9	O
syndrome	TANZEUM.xml:S2:735:8	O
type	TANZEUM.xml:S2:744:4	O
2	TANZEUM.xml:S2:749:1	O
(	TANZEUM.xml:S2:751:1	O
MEN	TANZEUM.xml:S2:752:3	O
2	TANZEUM.xml:S2:756:1	O
)	TANZEUM.xml:S2:757:1	O
.	TANZEUM.xml:S2:758:1	O

Counsel	TANZEUM.xml:S2:760:7	O
patients	TANZEUM.xml:S2:768:8	O
regarding	TANZEUM.xml:S2:777:9	O
the	TANZEUM.xml:S2:787:3	O
potential	TANZEUM.xml:S2:791:9	O
risk	TANZEUM.xml:S2:801:4	O
of	TANZEUM.xml:S2:806:2	O
MTC	TANZEUM.xml:S2:809:3	O
with	TANZEUM.xml:S2:813:4	O
the	TANZEUM.xml:S2:818:3	O
use	TANZEUM.xml:S2:822:3	O
of	TANZEUM.xml:S2:826:2	O
TANZEUM	TANZEUM.xml:S2:829:7	O
and	TANZEUM.xml:S2:837:3	O
inform	TANZEUM.xml:S2:841:6	O
them	TANZEUM.xml:S2:848:4	O
of	TANZEUM.xml:S2:853:2	O
the	TANZEUM.xml:S2:856:3	O
symptoms	TANZEUM.xml:S2:860:8	O
of	TANZEUM.xml:S2:869:2	O
thyroid	TANZEUM.xml:S2:872:7	O
tumors	TANZEUM.xml:S2:880:6	O
(	TANZEUM.xml:S2:887:1	O
e	TANZEUM.xml:S2:888:1	O
.	TANZEUM.xml:S2:889:1	O
g	TANZEUM.xml:S2:890:1	O
.	TANZEUM.xml:S2:891:1	O
,	TANZEUM.xml:S2:892:1	O
mass	TANZEUM.xml:S2:894:4	O
in	TANZEUM.xml:S2:899:2	O
the	TANZEUM.xml:S2:902:3	O
neck	TANZEUM.xml:S2:906:4	O
,	TANZEUM.xml:S2:910:1	O
dysphagia	TANZEUM.xml:S2:912:9	O
,	TANZEUM.xml:S2:921:1	O
dyspnea	TANZEUM.xml:S2:923:7	O
,	TANZEUM.xml:S2:930:1	O
persistent	TANZEUM.xml:S2:932:10	O
hoarseness	TANZEUM.xml:S2:943:10	O
)	TANZEUM.xml:S2:953:1	O
.	TANZEUM.xml:S2:954:1	O

Routine	TANZEUM.xml:S2:956:7	O
monitoring	TANZEUM.xml:S2:964:10	O
of	TANZEUM.xml:S2:975:2	O
serum	TANZEUM.xml:S2:978:5	O
calcitonin	TANZEUM.xml:S2:984:10	O
or	TANZEUM.xml:S2:995:2	O
using	TANZEUM.xml:S2:998:5	O
thyroid	TANZEUM.xml:S2:1004:7	O
ultrasound	TANZEUM.xml:S2:1012:10	O
monitoring	TANZEUM.xml:S2:1023:10	O
is	TANZEUM.xml:S2:1034:2	O
of	TANZEUM.xml:S2:1037:2	O
uncertain	TANZEUM.xml:S2:1040:9	O
value	TANZEUM.xml:S2:1050:5	O
for	TANZEUM.xml:S2:1056:3	O
early	TANZEUM.xml:S2:1060:5	O
detection	TANZEUM.xml:S2:1066:9	O
of	TANZEUM.xml:S2:1076:2	O
MTC	TANZEUM.xml:S2:1079:3	O
in	TANZEUM.xml:S2:1083:2	O
patients	TANZEUM.xml:S2:1086:8	O
treated	TANZEUM.xml:S2:1095:7	O
with	TANZEUM.xml:S2:1103:4	O
TANZEUM	TANZEUM.xml:S2:1108:7	O
[	TANZEUM.xml:S2:1116:1	O
see	TANZEUM.xml:S2:1117:3	O
Contraindications	TANZEUM.xml:S2:1121:17	O
(	TANZEUM.xml:S2:1139:1	O
4.1	TANZEUM.xml:S2:1140:3	O
)	TANZEUM.xml:S2:1143:1	O
,	TANZEUM.xml:S2:1144:1	O
Warnings	TANZEUM.xml:S2:1146:8	O
and	TANZEUM.xml:S2:1155:3	O
Precautions	TANZEUM.xml:S2:1159:11	O
(	TANZEUM.xml:S2:1171:1	O
5.1	TANZEUM.xml:S2:1172:3	O
)]	TANZEUM.xml:S2:1175:2	O
.	TANZEUM.xml:S2:1177:1	O

WARNING	TANZEUM.xml:S2:1186:7	O
:	TANZEUM.xml:S2:1193:1	O
RISK	TANZEUM.xml:S2:1195:4	B-Factor
OF	TANZEUM.xml:S2:1200:2	O
THYROID	TANZEUM.xml:S2:1203:7	B-AdverseReaction
C	TANZEUM.xml:S2:1211:1	I-AdverseReaction
-	TANZEUM.xml:S2:1212:1	I-AdverseReaction
CELL	TANZEUM.xml:S2:1213:4	I-AdverseReaction
TUMORS	TANZEUM.xml:S2:1218:6	I-AdverseReaction
\n	TANZEUM.xml:S2:1224:1	O
\n\n	TANZEUM.xml:S2:1226:2	O
See	TANZEUM.xml:S2:1231:3	O
full	TANZEUM.xml:S2:1235:4	O
prescribing	TANZEUM.xml:S2:1240:11	O
information	TANZEUM.xml:S2:1252:11	O
for	TANZEUM.xml:S2:1264:3	O
complete	TANZEUM.xml:S2:1268:8	O
boxed	TANZEUM.xml:S2:1277:5	O
warning	TANZEUM.xml:S2:1283:7	O
.	TANZEUM.xml:S2:1290:1	O

Carcinogenicity	TANZEUM.xml:S2:1301:15	O
of	TANZEUM.xml:S2:1317:2	O
albiglutide	TANZEUM.xml:S2:1320:11	O
could	TANZEUM.xml:S2:1332:5	O
not	TANZEUM.xml:S2:1338:3	O
be	TANZEUM.xml:S2:1342:2	O
assessed	TANZEUM.xml:S2:1345:8	O
in	TANZEUM.xml:S2:1354:2	O
rodents	TANZEUM.xml:S2:1357:7	O
,	TANZEUM.xml:S2:1364:1	O
but	TANZEUM.xml:S2:1366:3	O
other	TANZEUM.xml:S2:1370:5	O
glucagon	TANZEUM.xml:S2:1376:8	B-DrugClass
-	TANZEUM.xml:S2:1384:1	I-DrugClass
like	TANZEUM.xml:S2:1385:4	I-DrugClass
peptide	TANZEUM.xml:S2:1390:7	I-DrugClass
-	TANZEUM.xml:S2:1397:1	I-DrugClass
1	TANZEUM.xml:S2:1398:1	I-DrugClass
(	TANZEUM.xml:S2:1400:1	I-DrugClass
GLP	TANZEUM.xml:S2:1401:3	I-DrugClass
-	TANZEUM.xml:S2:1404:1	I-DrugClass
1	TANZEUM.xml:S2:1405:1	I-DrugClass
)	TANZEUM.xml:S2:1406:1	I-DrugClass
receptor	TANZEUM.xml:S2:1408:8	I-DrugClass
agonists	TANZEUM.xml:S2:1417:8	I-DrugClass
have	TANZEUM.xml:S2:1426:4	O
caused	TANZEUM.xml:S2:1431:6	O
thyroid	TANZEUM.xml:S2:1438:7	B-AdverseReaction
C	TANZEUM.xml:S2:1446:1	I-AdverseReaction
-	TANZEUM.xml:S2:1447:1	I-AdverseReaction
cell	TANZEUM.xml:S2:1448:4	I-AdverseReaction
tumors	TANZEUM.xml:S2:1453:6	I-AdverseReaction
in	TANZEUM.xml:S2:1460:2	O
rodents	TANZEUM.xml:S2:1463:7	B-Animal
at	TANZEUM.xml:S2:1471:2	O
clinically	TANZEUM.xml:S2:1474:10	O
relevant	TANZEUM.xml:S2:1485:8	O
exposures	TANZEUM.xml:S2:1494:9	O
.	TANZEUM.xml:S2:1503:1	O

Human	TANZEUM.xml:S2:1505:5	O
relevance	TANZEUM.xml:S2:1511:9	O
of	TANZEUM.xml:S2:1521:2	O
GLP	TANZEUM.xml:S2:1524:3	B-DrugClass
-	TANZEUM.xml:S2:1527:1	I-DrugClass
1	TANZEUM.xml:S2:1528:1	I-DrugClass
receptor	TANZEUM.xml:S2:1530:8	I-DrugClass
agonist	TANZEUM.xml:S2:1539:7	I-DrugClass
induced	TANZEUM.xml:S2:1547:7	O
C	TANZEUM.xml:S2:1555:1	B-AdverseReaction
-	TANZEUM.xml:S2:1556:1	I-AdverseReaction
cell	TANZEUM.xml:S2:1557:4	I-AdverseReaction
tumors	TANZEUM.xml:S2:1562:6	I-AdverseReaction
in	TANZEUM.xml:S2:1569:2	O
rodents	TANZEUM.xml:S2:1572:7	B-Animal
has	TANZEUM.xml:S2:1580:3	O
not	TANZEUM.xml:S2:1584:3	O
been	TANZEUM.xml:S2:1588:4	O
determined	TANZEUM.xml:S2:1593:10	O
.	TANZEUM.xml:S2:1603:1	O

It	TANZEUM.xml:S2:1605:2	O
is	TANZEUM.xml:S2:1608:2	O
unknown	TANZEUM.xml:S2:1611:7	B-Factor
whether	TANZEUM.xml:S2:1619:7	O
TANZEUM	TANZEUM.xml:S2:1627:7	O
causes	TANZEUM.xml:S2:1635:6	O
thyroid	TANZEUM.xml:S2:1642:7	B-AdverseReaction
C	TANZEUM.xml:S2:1650:1	I-AdverseReaction
-	TANZEUM.xml:S2:1651:1	I-AdverseReaction
cell	TANZEUM.xml:S2:1652:4	I-AdverseReaction
tumors	TANZEUM.xml:S2:1657:6	I-AdverseReaction
,	TANZEUM.xml:S2:1663:1	O
including	TANZEUM.xml:S2:1665:9	O
medullary	TANZEUM.xml:S2:1675:9	B-AdverseReaction
thyroid	TANZEUM.xml:S2:1685:7	I-AdverseReaction
carcinoma	TANZEUM.xml:S2:1693:9	I-AdverseReaction
(	TANZEUM.xml:S2:1703:1	O
MTC	TANZEUM.xml:S2:1704:3	B-AdverseReaction
)	TANZEUM.xml:S2:1707:1	O
,	TANZEUM.xml:S2:1708:1	O
in	TANZEUM.xml:S2:1710:2	O
humans	TANZEUM.xml:S2:1713:6	O
.	TANZEUM.xml:S2:1719:1	O

(	TANZEUM.xml:S2:1721:1	O
5.1	TANZEUM.xml:S2:1722:3	O
,	TANZEUM.xml:S2:1725:1	O
13.1	TANZEUM.xml:S2:1727:4	O
)	TANZEUM.xml:S2:1731:1	O
\n	TANZEUM.xml:S2:1733:1	O
TANZEUM	TANZEUM.xml:S2:1738:7	O
is	TANZEUM.xml:S2:1746:2	O
contraindicated	TANZEUM.xml:S2:1749:15	O
in	TANZEUM.xml:S2:1765:2	O
patients	TANZEUM.xml:S2:1768:8	O
with	TANZEUM.xml:S2:1777:4	O
a	TANZEUM.xml:S2:1782:1	O
personal	TANZEUM.xml:S2:1784:8	O
or	TANZEUM.xml:S2:1793:2	O
family	TANZEUM.xml:S2:1796:6	O
history	TANZEUM.xml:S2:1803:7	O
of	TANZEUM.xml:S2:1811:2	O
MTC	TANZEUM.xml:S2:1814:3	O
or	TANZEUM.xml:S2:1818:2	O
in	TANZEUM.xml:S2:1821:2	O
patients	TANZEUM.xml:S2:1824:8	O
with	TANZEUM.xml:S2:1833:4	O
Multiple	TANZEUM.xml:S2:1838:8	O
Endocrine	TANZEUM.xml:S2:1847:9	O
Neoplasia	TANZEUM.xml:S2:1857:9	O
syndrome	TANZEUM.xml:S2:1867:8	O
type	TANZEUM.xml:S2:1876:4	O
2	TANZEUM.xml:S2:1881:1	O
(	TANZEUM.xml:S2:1883:1	O
MEN	TANZEUM.xml:S2:1884:3	O
2	TANZEUM.xml:S2:1888:1	O
)	TANZEUM.xml:S2:1889:1	O
.	TANZEUM.xml:S2:1890:1	O

Counsel	TANZEUM.xml:S2:1892:7	O
patients	TANZEUM.xml:S2:1900:8	O
regarding	TANZEUM.xml:S2:1909:9	O
the	TANZEUM.xml:S2:1919:3	O
potential	TANZEUM.xml:S2:1923:9	O
risk	TANZEUM.xml:S2:1933:4	O
of	TANZEUM.xml:S2:1938:2	O
MTC	TANZEUM.xml:S2:1941:3	O
and	TANZEUM.xml:S2:1945:3	O
symptoms	TANZEUM.xml:S2:1949:8	O
of	TANZEUM.xml:S2:1958:2	O
thyroid	TANZEUM.xml:S2:1961:7	O
tumors	TANZEUM.xml:S2:1969:6	O
(	TANZEUM.xml:S2:1976:1	O
4.1	TANZEUM.xml:S2:1977:3	O
,	TANZEUM.xml:S2:1980:1	O
5.1	TANZEUM.xml:S2:1982:3	O
)	TANZEUM.xml:S2:1985:1	O
.	TANZEUM.xml:S2:1986:1	O
\n	TANZEUM.xml:S2:1988:1	O
5	TANZEUM.xml:S3:4:1	O
WARNINGS	TANZEUM.xml:S3:6:8	O
AND	TANZEUM.xml:S3:15:3	O
PRECAUTIONS	TANZEUM.xml:S3:19:11	O

EXCERPT	TANZEUM.xml:S3:35:7	O
:	TANZEUM.xml:S3:42:1	O
Thyroid	TANZEUM.xml:S3:53:7	B-AdverseReaction
C	TANZEUM.xml:S3:61:1	I-AdverseReaction
-	TANZEUM.xml:S3:62:1	I-AdverseReaction
cell	TANZEUM.xml:S3:63:4	I-AdverseReaction
Tumors	TANZEUM.xml:S3:68:6	I-AdverseReaction
:	TANZEUM.xml:S3:74:1	O
See	TANZEUM.xml:S3:76:3	O
Boxed	TANZEUM.xml:S3:80:5	O
Warning	TANZEUM.xml:S3:86:7	O
.	TANZEUM.xml:S3:93:1	O

(	TANZEUM.xml:S3:95:1	O
5.1	TANZEUM.xml:S3:96:3	O
)	TANZEUM.xml:S3:99:1	O

Pancreatitis	TANZEUM.xml:S3:109:12	B-AdverseReaction
:	TANZEUM.xml:S3:121:1	O
Discontinue	TANZEUM.xml:S3:123:11	O
promptly	TANZEUM.xml:S3:135:8	O
if	TANZEUM.xml:S3:144:2	O
suspected	TANZEUM.xml:S3:147:9	O
.	TANZEUM.xml:S3:156:1	O

Do	TANZEUM.xml:S3:158:2	O
not	TANZEUM.xml:S3:161:3	O
restart	TANZEUM.xml:S3:165:7	O
if	TANZEUM.xml:S3:173:2	O
confirmed	TANZEUM.xml:S3:176:9	O
.	TANZEUM.xml:S3:185:1	O

Consider	TANZEUM.xml:S3:187:8	O
other	TANZEUM.xml:S3:196:5	O
antidiabetic	TANZEUM.xml:S3:202:12	O
therapies	TANZEUM.xml:S3:215:9	O
in	TANZEUM.xml:S3:225:2	O
patients	TANZEUM.xml:S3:228:8	O
with	TANZEUM.xml:S3:237:4	O
a	TANZEUM.xml:S3:242:1	O
history	TANZEUM.xml:S3:244:7	O
of	TANZEUM.xml:S3:252:2	O
pancreatitis	TANZEUM.xml:S3:255:12	O
.	TANZEUM.xml:S3:267:1	O

(	TANZEUM.xml:S3:269:1	O
5.2	TANZEUM.xml:S3:270:3	O
)	TANZEUM.xml:S3:273:1	O

Hypoglycemia	TANZEUM.xml:S3:283:12	B-AdverseReaction
:	TANZEUM.xml:S3:295:1	O
Can	TANZEUM.xml:S3:297:3	O
occur	TANZEUM.xml:S3:301:5	O
when	TANZEUM.xml:S3:307:4	O
used	TANZEUM.xml:S3:312:4	O
in	TANZEUM.xml:S3:317:2	O
combination	TANZEUM.xml:S3:320:11	O
with	TANZEUM.xml:S3:332:4	O
insulin	TANZEUM.xml:S3:337:7	O
secretagogues	TANZEUM.xml:S3:345:13	O
(	TANZEUM.xml:S3:359:1	O
e	TANZEUM.xml:S3:360:1	O
.	TANZEUM.xml:S3:361:1	O
g	TANZEUM.xml:S3:362:1	O
.	TANZEUM.xml:S3:363:1	O
,	TANZEUM.xml:S3:364:1	O
sulfonylureas	TANZEUM.xml:S3:366:13	O
)	TANZEUM.xml:S3:379:1	O
or	TANZEUM.xml:S3:381:2	O
insulin	TANZEUM.xml:S3:384:7	O
.	TANZEUM.xml:S3:391:1	O

Consider	TANZEUM.xml:S3:393:8	O
lowering	TANZEUM.xml:S3:402:8	O
sulfonylurea	TANZEUM.xml:S3:411:12	O
or	TANZEUM.xml:S3:424:2	O
insulin	TANZEUM.xml:S3:427:7	O
dosage	TANZEUM.xml:S3:435:6	O
when	TANZEUM.xml:S3:442:4	O
starting	TANZEUM.xml:S3:447:8	O
TANZEUM	TANZEUM.xml:S3:456:7	O
.	TANZEUM.xml:S3:463:1	O

(	TANZEUM.xml:S3:465:1	O
5.3	TANZEUM.xml:S3:466:3	O
)	TANZEUM.xml:S3:469:1	O

Hypersensitivity	TANZEUM.xml:S3:479:16	B-AdverseReaction
Reactions	TANZEUM.xml:S3:496:9	I-AdverseReaction
:	TANZEUM.xml:S3:505:1	O
Discontinue	TANZEUM.xml:S3:507:11	O
TANZEUM	TANZEUM.xml:S3:519:7	O
if	TANZEUM.xml:S3:527:2	O
suspected	TANZEUM.xml:S3:530:9	O
.	TANZEUM.xml:S3:539:1	O

Monitor	TANZEUM.xml:S3:541:7	O
and	TANZEUM.xml:S3:549:3	O
treat	TANZEUM.xml:S3:553:5	O
promptly	TANZEUM.xml:S3:559:8	O
per	TANZEUM.xml:S3:568:3	O
standard	TANZEUM.xml:S3:572:8	O
of	TANZEUM.xml:S3:581:2	O
care	TANZEUM.xml:S3:584:4	O
until	TANZEUM.xml:S3:589:5	O
signs	TANZEUM.xml:S3:595:5	O
and	TANZEUM.xml:S3:601:3	O
symptoms	TANZEUM.xml:S3:605:8	O
resolve	TANZEUM.xml:S3:614:7	O
.	TANZEUM.xml:S3:621:1	O

(	TANZEUM.xml:S3:623:1	O
5.4	TANZEUM.xml:S3:624:3	O
)	TANZEUM.xml:S3:627:1	O

Renal	TANZEUM.xml:S3:637:5	B-AdverseReaction
Impairment	TANZEUM.xml:S3:643:10	I-AdverseReaction
:	TANZEUM.xml:S3:653:1	O
Monitor	TANZEUM.xml:S3:655:7	O
renal	TANZEUM.xml:S3:663:5	O
function	TANZEUM.xml:S3:669:8	O
in	TANZEUM.xml:S3:678:2	O
patients	TANZEUM.xml:S3:681:8	O
with	TANZEUM.xml:S3:690:4	O
renal	TANZEUM.xml:S3:695:5	O
impairment	TANZEUM.xml:S3:701:10	O
reporting	TANZEUM.xml:S3:712:9	O
severe	TANZEUM.xml:S3:722:6	O
adverse	TANZEUM.xml:S3:729:7	O
gastrointestinal	TANZEUM.xml:S3:737:16	O
reactions	TANZEUM.xml:S3:754:9	O
.	TANZEUM.xml:S3:763:1	O

(	TANZEUM.xml:S3:765:1	O
5.5	TANZEUM.xml:S3:766:3	O
)	TANZEUM.xml:S3:769:1	O

Macrovascular	TANZEUM.xml:S3:779:13	O
Outcomes	TANZEUM.xml:S3:793:8	O
:	TANZEUM.xml:S3:801:1	O
There	TANZEUM.xml:S3:803:5	O
have	TANZEUM.xml:S3:809:4	O
been	TANZEUM.xml:S3:814:4	O
no	TANZEUM.xml:S3:819:2	O
clinical	TANZEUM.xml:S3:822:8	O
trials	TANZEUM.xml:S3:831:6	O
establishing	TANZEUM.xml:S3:838:12	O
conclusive	TANZEUM.xml:S3:851:10	O
evidence	TANZEUM.xml:S3:862:8	O
of	TANZEUM.xml:S3:871:2	O
macrovascular	TANZEUM.xml:S3:874:13	O
risk	TANZEUM.xml:S3:888:4	O
reduction	TANZEUM.xml:S3:893:9	O
with	TANZEUM.xml:S3:903:4	O
TANZEUM	TANZEUM.xml:S3:908:7	O
or	TANZEUM.xml:S3:916:2	O
any	TANZEUM.xml:S3:919:3	O
other	TANZEUM.xml:S3:923:5	O
antidiabetic	TANZEUM.xml:S3:929:12	O
drug	TANZEUM.xml:S3:942:4	O
.	TANZEUM.xml:S3:946:1	O

(	TANZEUM.xml:S3:948:1	O
5.6	TANZEUM.xml:S3:949:3	O
)	TANZEUM.xml:S3:952:1	O

5.1	TANZEUM.xml:S3:963:3	O

Risk	TANZEUM.xml:S3:967:4	O
of	TANZEUM.xml:S3:972:2	O
Thyroid	TANZEUM.xml:S3:975:7	O
C	TANZEUM.xml:S3:983:1	O
-	TANZEUM.xml:S3:984:1	O
cell	TANZEUM.xml:S3:985:4	O
Tumors	TANZEUM.xml:S3:990:6	O

Carcinogenicity	TANZEUM.xml:S3:1002:15	O
of	TANZEUM.xml:S3:1018:2	O
albiglutide	TANZEUM.xml:S3:1021:11	O
could	TANZEUM.xml:S3:1033:5	O
not	TANZEUM.xml:S3:1039:3	O
be	TANZEUM.xml:S3:1043:2	O
assessed	TANZEUM.xml:S3:1046:8	O
in	TANZEUM.xml:S3:1055:2	O
rodents	TANZEUM.xml:S3:1058:7	O
due	TANZEUM.xml:S3:1066:3	O
to	TANZEUM.xml:S3:1070:2	O
the	TANZEUM.xml:S3:1073:3	O
rapid	TANZEUM.xml:S3:1077:5	O
development	TANZEUM.xml:S3:1083:11	O
of	TANZEUM.xml:S3:1095:2	O
drug	TANZEUM.xml:S3:1098:4	O
-	TANZEUM.xml:S3:1102:1	O
clearing	TANZEUM.xml:S3:1103:8	O
,	TANZEUM.xml:S3:1111:1	O
anti	TANZEUM.xml:S3:1113:4	O
-	TANZEUM.xml:S3:1117:1	O
drug	TANZEUM.xml:S3:1118:4	O
antibodies	TANZEUM.xml:S3:1123:10	O
[	TANZEUM.xml:S3:1135:1	O
see	TANZEUM.xml:S3:1136:3	O
Nonclinical	TANZEUM.xml:S3:1140:11	O
Toxicology	TANZEUM.xml:S3:1152:10	O
(	TANZEUM.xml:S3:1163:1	O
13.1	TANZEUM.xml:S3:1164:4	O
)]	TANZEUM.xml:S3:1168:2	O
.	TANZEUM.xml:S3:1172:1	O

Other	TANZEUM.xml:S3:1174:5	O
GLP	TANZEUM.xml:S3:1180:3	B-DrugClass
-	TANZEUM.xml:S3:1183:1	I-DrugClass
1	TANZEUM.xml:S3:1184:1	I-DrugClass
receptor	TANZEUM.xml:S3:1186:8	I-DrugClass
agonists	TANZEUM.xml:S3:1195:8	I-DrugClass
have	TANZEUM.xml:S3:1204:4	O
caused	TANZEUM.xml:S3:1209:6	O
dose	TANZEUM.xml:S3:1216:4	O
-	TANZEUM.xml:S3:1220:1	O
related	TANZEUM.xml:S3:1221:7	O
and	TANZEUM.xml:S3:1229:3	O
treatment	TANZEUM.xml:S3:1233:9	O
-	TANZEUM.xml:S3:1242:1	O
duration	TANZEUM.xml:S3:1243:8	O
-	TANZEUM.xml:S3:1251:1	O
dependent	TANZEUM.xml:S3:1252:9	O
thyroid	TANZEUM.xml:S3:1262:7	B-AdverseReaction
C	TANZEUM.xml:S3:1270:1	I-AdverseReaction
-	TANZEUM.xml:S3:1271:1	I-AdverseReaction
cell	TANZEUM.xml:S3:1272:4	I-AdverseReaction
tumors	TANZEUM.xml:S3:1277:6	I-AdverseReaction
(	TANZEUM.xml:S3:1284:1	O
adenomas	TANZEUM.xml:S3:1285:8	I-AdverseReaction
or	TANZEUM.xml:S3:1294:2	O
carcinomas	TANZEUM.xml:S3:1297:10	I-AdverseReaction
)	TANZEUM.xml:S3:1307:1	O
in	TANZEUM.xml:S3:1309:2	O
rodents	TANZEUM.xml:S3:1312:7	B-Animal
.	TANZEUM.xml:S3:1319:1	O

Human	TANZEUM.xml:S3:1321:5	O
relevance	TANZEUM.xml:S3:1327:9	O
of	TANZEUM.xml:S3:1337:2	O
GLP	TANZEUM.xml:S3:1340:3	B-DrugClass
-	TANZEUM.xml:S3:1343:1	I-DrugClass
1	TANZEUM.xml:S3:1344:1	I-DrugClass
receptor	TANZEUM.xml:S3:1346:8	I-DrugClass
agonist	TANZEUM.xml:S3:1355:7	I-DrugClass
induced	TANZEUM.xml:S3:1363:7	O
C	TANZEUM.xml:S3:1371:1	B-AdverseReaction
-	TANZEUM.xml:S3:1372:1	I-AdverseReaction
cell	TANZEUM.xml:S3:1373:4	I-AdverseReaction
tumors	TANZEUM.xml:S3:1378:6	I-AdverseReaction
in	TANZEUM.xml:S3:1385:2	O
rodents	TANZEUM.xml:S3:1388:7	B-Animal
has	TANZEUM.xml:S3:1396:3	O
not	TANZEUM.xml:S3:1400:3	O
been	TANZEUM.xml:S3:1404:4	O
determined	TANZEUM.xml:S3:1409:10	O
.	TANZEUM.xml:S3:1419:1	O

It	TANZEUM.xml:S3:1421:2	O
is	TANZEUM.xml:S3:1424:2	O
unknown	TANZEUM.xml:S3:1427:7	B-Factor
whether	TANZEUM.xml:S3:1435:7	O
TANZEUM	TANZEUM.xml:S3:1443:7	O
causes	TANZEUM.xml:S3:1451:6	O
thyroid	TANZEUM.xml:S3:1458:7	B-AdverseReaction
C	TANZEUM.xml:S3:1466:1	I-AdverseReaction
-	TANZEUM.xml:S3:1467:1	I-AdverseReaction
cell	TANZEUM.xml:S3:1468:4	I-AdverseReaction
tumors	TANZEUM.xml:S3:1473:6	I-AdverseReaction
,	TANZEUM.xml:S3:1479:1	O
including	TANZEUM.xml:S3:1481:9	O
MTC	TANZEUM.xml:S3:1491:3	B-AdverseReaction
,	TANZEUM.xml:S3:1494:1	O
in	TANZEUM.xml:S3:1496:2	O
humans	TANZEUM.xml:S3:1499:6	O
[	TANZEUM.xml:S3:1507:1	O
see	TANZEUM.xml:S3:1508:3	O
Boxed	TANZEUM.xml:S3:1512:5	O
Warning	TANZEUM.xml:S3:1518:7	O
,	TANZEUM.xml:S3:1525:1	O
Contraindications	TANZEUM.xml:S3:1527:17	O
(	TANZEUM.xml:S3:1545:1	O
4.1	TANZEUM.xml:S3:1546:3	O
)]	TANZEUM.xml:S3:1549:2	O
.	TANZEUM.xml:S3:1553:1	O

Across	TANZEUM.xml:S3:1563:6	O
8	TANZEUM.xml:S3:1570:1	O
Phase	TANZEUM.xml:S3:1572:5	O
III	TANZEUM.xml:S3:1578:3	O
clinical	TANZEUM.xml:S3:1582:8	O
trials	TANZEUM.xml:S3:1591:6	O
[	TANZEUM.xml:S3:1599:1	O
see	TANZEUM.xml:S3:1600:3	O
Clinical	TANZEUM.xml:S3:1604:8	O
Studies	TANZEUM.xml:S3:1613:7	O
(	TANZEUM.xml:S3:1621:1	O
14	TANZEUM.xml:S3:1622:2	O
)]	TANZEUM.xml:S3:1624:2	O
,	TANZEUM.xml:S3:1628:1	O
MTC	TANZEUM.xml:S3:1630:3	B-AdverseReaction
was	TANZEUM.xml:S3:1634:3	O
diagnosed	TANZEUM.xml:S3:1638:9	O
in	TANZEUM.xml:S3:1648:2	O
1	TANZEUM.xml:S3:1651:1	O
patient	TANZEUM.xml:S3:1653:7	O
receiving	TANZEUM.xml:S3:1661:9	O
TANZEUM	TANZEUM.xml:S3:1671:7	O
and	TANZEUM.xml:S3:1679:3	O
1	TANZEUM.xml:S3:1683:1	O
patient	TANZEUM.xml:S3:1685:7	O
receiving	TANZEUM.xml:S3:1693:9	O
placebo	TANZEUM.xml:S3:1703:7	O
.	TANZEUM.xml:S3:1710:1	O

Both	TANZEUM.xml:S3:1712:4	O
patients	TANZEUM.xml:S3:1717:8	O
had	TANZEUM.xml:S3:1726:3	O
markedly	TANZEUM.xml:S3:1730:8	O
elevated	TANZEUM.xml:S3:1739:8	O
serum	TANZEUM.xml:S3:1748:5	O
calcitonin	TANZEUM.xml:S3:1754:10	O
levels	TANZEUM.xml:S3:1765:6	O
at	TANZEUM.xml:S3:1772:2	O
baseline	TANZEUM.xml:S3:1775:8	O
.	TANZEUM.xml:S3:1783:1	O

Cases	TANZEUM.xml:S3:1785:5	O
of	TANZEUM.xml:S3:1791:2	O
MTC	TANZEUM.xml:S3:1794:3	B-AdverseReaction
in	TANZEUM.xml:S3:1798:2	O
patients	TANZEUM.xml:S3:1801:8	O
treated	TANZEUM.xml:S3:1810:7	O
with	TANZEUM.xml:S3:1818:4	O
liraglutide	TANZEUM.xml:S3:1823:11	B-DrugClass
,	TANZEUM.xml:S3:1834:1	O
another	TANZEUM.xml:S3:1836:7	O
GLP	TANZEUM.xml:S3:1844:3	O
-	TANZEUM.xml:S3:1847:1	O
1	TANZEUM.xml:S3:1848:1	O
receptor	TANZEUM.xml:S3:1850:8	O
agonist	TANZEUM.xml:S3:1859:7	O
,	TANZEUM.xml:S3:1866:1	O
have	TANZEUM.xml:S3:1868:4	O
been	TANZEUM.xml:S3:1873:4	O
reported	TANZEUM.xml:S3:1878:8	O
in	TANZEUM.xml:S3:1887:2	O
the	TANZEUM.xml:S3:1890:3	O
postmarketing	TANZEUM.xml:S3:1894:13	O
period	TANZEUM.xml:S3:1908:6	O
;	TANZEUM.xml:S3:1914:1	O
the	TANZEUM.xml:S3:1916:3	O
data	TANZEUM.xml:S3:1920:4	O
in	TANZEUM.xml:S3:1925:2	O
these	TANZEUM.xml:S3:1928:5	O
reports	TANZEUM.xml:S3:1934:7	O
are	TANZEUM.xml:S3:1942:3	O
insufficient	TANZEUM.xml:S3:1946:12	O
to	TANZEUM.xml:S3:1959:2	O
establish	TANZEUM.xml:S3:1962:9	O
or	TANZEUM.xml:S3:1972:2	O
exclude	TANZEUM.xml:S3:1975:7	O
a	TANZEUM.xml:S3:1983:1	O
causal	TANZEUM.xml:S3:1985:6	O
relationship	TANZEUM.xml:S3:1992:12	O
between	TANZEUM.xml:S3:2005:7	O
MTC	TANZEUM.xml:S3:2013:3	B-AdverseReaction
and	TANZEUM.xml:S3:2017:3	O
GLP	TANZEUM.xml:S3:2021:3	B-DrugClass
-	TANZEUM.xml:S3:2024:1	I-DrugClass
1	TANZEUM.xml:S3:2025:1	I-DrugClass
receptor	TANZEUM.xml:S3:2027:8	I-DrugClass
agonist	TANZEUM.xml:S3:2036:7	I-DrugClass
use	TANZEUM.xml:S3:2044:3	O
in	TANZEUM.xml:S3:2048:2	O
humans	TANZEUM.xml:S3:2051:6	O
.	TANZEUM.xml:S3:2057:1	O

TANZEUM	TANZEUM.xml:S3:2067:7	O
is	TANZEUM.xml:S3:2075:2	O
contraindicated	TANZEUM.xml:S3:2078:15	O
in	TANZEUM.xml:S3:2094:2	O
patients	TANZEUM.xml:S3:2097:8	O
with	TANZEUM.xml:S3:2106:4	O
a	TANZEUM.xml:S3:2111:1	O
personal	TANZEUM.xml:S3:2113:8	O
or	TANZEUM.xml:S3:2122:2	O
family	TANZEUM.xml:S3:2125:6	O
history	TANZEUM.xml:S3:2132:7	O
of	TANZEUM.xml:S3:2140:2	O
MTC	TANZEUM.xml:S3:2143:3	O
or	TANZEUM.xml:S3:2147:2	O
in	TANZEUM.xml:S3:2150:2	O
patients	TANZEUM.xml:S3:2153:8	O
with	TANZEUM.xml:S3:2162:4	O
MEN	TANZEUM.xml:S3:2167:3	O
2	TANZEUM.xml:S3:2171:1	O
.	TANZEUM.xml:S3:2172:1	O

Counsel	TANZEUM.xml:S3:2174:7	O
patients	TANZEUM.xml:S3:2182:8	O
regarding	TANZEUM.xml:S3:2191:9	O
the	TANZEUM.xml:S3:2201:3	O
potential	TANZEUM.xml:S3:2205:9	O
risk	TANZEUM.xml:S3:2215:4	O
for	TANZEUM.xml:S3:2220:3	O
MTC	TANZEUM.xml:S3:2224:3	O
with	TANZEUM.xml:S3:2228:4	O
the	TANZEUM.xml:S3:2233:3	O
use	TANZEUM.xml:S3:2237:3	O
of	TANZEUM.xml:S3:2241:2	O
TANZEUM	TANZEUM.xml:S3:2244:7	O
and	TANZEUM.xml:S3:2252:3	O
inform	TANZEUM.xml:S3:2256:6	O
them	TANZEUM.xml:S3:2263:4	O
of	TANZEUM.xml:S3:2268:2	O
symptoms	TANZEUM.xml:S3:2271:8	O
of	TANZEUM.xml:S3:2280:2	O
thyroid	TANZEUM.xml:S3:2283:7	O
tumors	TANZEUM.xml:S3:2291:6	O
(	TANZEUM.xml:S3:2298:1	O
e	TANZEUM.xml:S3:2299:1	O
.	TANZEUM.xml:S3:2300:1	O
g	TANZEUM.xml:S3:2301:1	O
.	TANZEUM.xml:S3:2302:1	O
,	TANZEUM.xml:S3:2303:1	O
a	TANZEUM.xml:S3:2305:1	O
mass	TANZEUM.xml:S3:2307:4	O
in	TANZEUM.xml:S3:2312:2	O
the	TANZEUM.xml:S3:2315:3	O
neck	TANZEUM.xml:S3:2319:4	O
,	TANZEUM.xml:S3:2323:1	O
dysphagia	TANZEUM.xml:S3:2325:9	O
,	TANZEUM.xml:S3:2334:1	O
dyspnea	TANZEUM.xml:S3:2336:7	O
,	TANZEUM.xml:S3:2343:1	O
or	TANZEUM.xml:S3:2345:2	O
persistent	TANZEUM.xml:S3:2348:10	O
hoarseness	TANZEUM.xml:S3:2359:10	O
)	TANZEUM.xml:S3:2369:1	O
.	TANZEUM.xml:S3:2370:1	O

Routine	TANZEUM.xml:S3:2380:7	O
monitoring	TANZEUM.xml:S3:2388:10	O
of	TANZEUM.xml:S3:2399:2	O
serum	TANZEUM.xml:S3:2402:5	O
calcitonin	TANZEUM.xml:S3:2408:10	O
or	TANZEUM.xml:S3:2419:2	O
using	TANZEUM.xml:S3:2422:5	O
thyroid	TANZEUM.xml:S3:2428:7	O
ultrasound	TANZEUM.xml:S3:2436:10	O
is	TANZEUM.xml:S3:2447:2	O
of	TANZEUM.xml:S3:2450:2	O
uncertain	TANZEUM.xml:S3:2453:9	O
value	TANZEUM.xml:S3:2463:5	O
for	TANZEUM.xml:S3:2469:3	O
early	TANZEUM.xml:S3:2473:5	O
detection	TANZEUM.xml:S3:2479:9	O
of	TANZEUM.xml:S3:2489:2	O
MTC	TANZEUM.xml:S3:2492:3	O
in	TANZEUM.xml:S3:2496:2	O
patients	TANZEUM.xml:S3:2499:8	O
treated	TANZEUM.xml:S3:2508:7	O
with	TANZEUM.xml:S3:2516:4	O
TANZEUM	TANZEUM.xml:S3:2521:7	O
.	TANZEUM.xml:S3:2528:1	O

Such	TANZEUM.xml:S3:2530:4	O
monitoring	TANZEUM.xml:S3:2535:10	O
may	TANZEUM.xml:S3:2546:3	O
increase	TANZEUM.xml:S3:2550:8	O
the	TANZEUM.xml:S3:2559:3	O
risk	TANZEUM.xml:S3:2563:4	O
of	TANZEUM.xml:S3:2568:2	O
unnecessary	TANZEUM.xml:S3:2571:11	O
procedures	TANZEUM.xml:S3:2583:10	O
,	TANZEUM.xml:S3:2593:1	O
due	TANZEUM.xml:S3:2595:3	O
to	TANZEUM.xml:S3:2599:2	O
the	TANZEUM.xml:S3:2602:3	O
low	TANZEUM.xml:S3:2606:3	O
specificity	TANZEUM.xml:S3:2610:11	O
of	TANZEUM.xml:S3:2622:2	O
serum	TANZEUM.xml:S3:2625:5	O
calcitonin	TANZEUM.xml:S3:2631:10	O
testing	TANZEUM.xml:S3:2642:7	O
for	TANZEUM.xml:S3:2650:3	O
MTC	TANZEUM.xml:S3:2654:3	O
and	TANZEUM.xml:S3:2658:3	O
a	TANZEUM.xml:S3:2662:1	O
high	TANZEUM.xml:S3:2664:4	O
background	TANZEUM.xml:S3:2669:10	O
incidence	TANZEUM.xml:S3:2680:9	O
of	TANZEUM.xml:S3:2690:2	O
thyroid	TANZEUM.xml:S3:2693:7	O
disease	TANZEUM.xml:S3:2701:7	O
.	TANZEUM.xml:S3:2708:1	O

Significantly	TANZEUM.xml:S3:2710:13	O
elevated	TANZEUM.xml:S3:2724:8	O
serum	TANZEUM.xml:S3:2733:5	O
calcitonin	TANZEUM.xml:S3:2739:10	O
may	TANZEUM.xml:S3:2750:3	O
indicate	TANZEUM.xml:S3:2754:8	O
MTC	TANZEUM.xml:S3:2763:3	O
and	TANZEUM.xml:S3:2767:3	O
patients	TANZEUM.xml:S3:2771:8	O
with	TANZEUM.xml:S3:2780:4	O
MTC	TANZEUM.xml:S3:2785:3	O
usually	TANZEUM.xml:S3:2789:7	O
have	TANZEUM.xml:S3:2797:4	O
calcitonin	TANZEUM.xml:S3:2802:10	O
values	TANZEUM.xml:S3:2813:6	O
50	TANZEUM.xml:S3:2821:2	O
ng	TANZEUM.xml:S3:2824:2	O
L.	TANZEUM.xml:S3:2827:2	O

If	TANZEUM.xml:S3:2830:2	O
serum	TANZEUM.xml:S3:2833:5	O
calcitonin	TANZEUM.xml:S3:2839:10	O
is	TANZEUM.xml:S3:2850:2	O
measured	TANZEUM.xml:S3:2853:8	O
and	TANZEUM.xml:S3:2862:3	O
found	TANZEUM.xml:S3:2866:5	O
to	TANZEUM.xml:S3:2872:2	O
be	TANZEUM.xml:S3:2875:2	O
elevated	TANZEUM.xml:S3:2878:8	O
,	TANZEUM.xml:S3:2886:1	O
the	TANZEUM.xml:S3:2888:3	O
patient	TANZEUM.xml:S3:2892:7	O
should	TANZEUM.xml:S3:2900:6	O
be	TANZEUM.xml:S3:2907:2	O
further	TANZEUM.xml:S3:2910:7	O
evaluated	TANZEUM.xml:S3:2918:9	O
.	TANZEUM.xml:S3:2927:1	O

Patients	TANZEUM.xml:S3:2929:8	O
with	TANZEUM.xml:S3:2938:4	O
thyroid	TANZEUM.xml:S3:2943:7	O
nodules	TANZEUM.xml:S3:2951:7	O
noted	TANZEUM.xml:S3:2959:5	O
on	TANZEUM.xml:S3:2965:2	O
physical	TANZEUM.xml:S3:2968:8	O
examination	TANZEUM.xml:S3:2977:11	O
or	TANZEUM.xml:S3:2989:2	O
neck	TANZEUM.xml:S3:2992:4	O
imaging	TANZEUM.xml:S3:2997:7	O
should	TANZEUM.xml:S3:3005:6	O
also	TANZEUM.xml:S3:3012:4	O
be	TANZEUM.xml:S3:3017:2	O
further	TANZEUM.xml:S3:3020:7	O
evaluated	TANZEUM.xml:S3:3028:9	O
.	TANZEUM.xml:S3:3037:1	O

5.2	TANZEUM.xml:S3:3047:3	O
Acute	TANZEUM.xml:S3:3051:5	O
Pancreatitis	TANZEUM.xml:S3:3057:12	O

In	TANZEUM.xml:S3:3073:2	O
clinical	TANZEUM.xml:S3:3076:8	O
trials	TANZEUM.xml:S3:3085:6	O
,	TANZEUM.xml:S3:3091:1	O
acute	TANZEUM.xml:S3:3093:5	B-AdverseReaction
pancreatitis	TANZEUM.xml:S3:3099:12	I-AdverseReaction
has	TANZEUM.xml:S3:3112:3	O
been	TANZEUM.xml:S3:3116:4	O
reported	TANZEUM.xml:S3:3121:8	O
in	TANZEUM.xml:S3:3130:2	O
association	TANZEUM.xml:S3:3133:11	O
with	TANZEUM.xml:S3:3145:4	O
TANZEUM	TANZEUM.xml:S3:3150:7	O
.	TANZEUM.xml:S3:3157:1	O

Across	TANZEUM.xml:S3:3163:6	O
8	TANZEUM.xml:S3:3170:1	O
Phase	TANZEUM.xml:S3:3172:5	O
III	TANZEUM.xml:S3:3178:3	O
clinical	TANZEUM.xml:S3:3182:8	O
trials	TANZEUM.xml:S3:3191:6	O
[	TANZEUM.xml:S3:3199:1	O
see	TANZEUM.xml:S3:3200:3	O
Clinical	TANZEUM.xml:S3:3204:8	O
Studies	TANZEUM.xml:S3:3213:7	O
(	TANZEUM.xml:S3:3221:1	O
14	TANZEUM.xml:S3:3222:2	O
)]	TANZEUM.xml:S3:3224:2	O
,	TANZEUM.xml:S3:3228:1	O
pancreatitis	TANZEUM.xml:S3:3230:12	B-AdverseReaction
adjudicated	TANZEUM.xml:S3:3243:11	O
as	TANZEUM.xml:S3:3255:2	O
likely	TANZEUM.xml:S3:3258:6	O
related	TANZEUM.xml:S3:3265:7	O
to	TANZEUM.xml:S3:3273:2	O
therapy	TANZEUM.xml:S3:3276:7	O
occurred	TANZEUM.xml:S3:3284:8	O
more	TANZEUM.xml:S3:3293:4	O
frequently	TANZEUM.xml:S3:3298:10	O
in	TANZEUM.xml:S3:3309:2	O
patients	TANZEUM.xml:S3:3312:8	O
receiving	TANZEUM.xml:S3:3321:9	O
TANZEUM	TANZEUM.xml:S3:3331:7	O
(	TANZEUM.xml:S3:3339:1	O
6	TANZEUM.xml:S3:3340:1	O
of	TANZEUM.xml:S3:3342:2	O
2	TANZEUM.xml:S3:3345:1	O
,	TANZEUM.xml:S3:3346:1	O
365	TANZEUM.xml:S3:3347:3	O
[	TANZEUM.xml:S3:3351:1	O
0.3%	TANZEUM.xml:S3:3352:4	O
])	TANZEUM.xml:S3:3356:2	O
than	TANZEUM.xml:S3:3359:4	O
in	TANZEUM.xml:S3:3364:2	O
patients	TANZEUM.xml:S3:3367:8	O
receiving	TANZEUM.xml:S3:3376:9	O
placebo	TANZEUM.xml:S3:3386:7	O
(	TANZEUM.xml:S3:3394:1	O
0	TANZEUM.xml:S3:3395:1	O
of	TANZEUM.xml:S3:3397:2	O
468	TANZEUM.xml:S3:3400:3	O
[	TANZEUM.xml:S3:3404:1	O
0%	TANZEUM.xml:S3:3405:2	O
])	TANZEUM.xml:S3:3407:2	O
or	TANZEUM.xml:S3:3410:2	O
active	TANZEUM.xml:S3:3413:6	O
comparators	TANZEUM.xml:S3:3420:11	O
(	TANZEUM.xml:S3:3432:1	O
2	TANZEUM.xml:S3:3433:1	O
of	TANZEUM.xml:S3:3435:2	O
2	TANZEUM.xml:S3:3438:1	O
,	TANZEUM.xml:S3:3439:1	O
065	TANZEUM.xml:S3:3440:3	O
[	TANZEUM.xml:S3:3444:1	O
0.1%	TANZEUM.xml:S3:3445:4	O
])	TANZEUM.xml:S3:3449:2	O
.	TANZEUM.xml:S3:3451:1	O

After	TANZEUM.xml:S3:3457:5	O
initiation	TANZEUM.xml:S3:3463:10	O
of	TANZEUM.xml:S3:3474:2	O
TANZEUM	TANZEUM.xml:S3:3477:7	O
,	TANZEUM.xml:S3:3484:1	O
observe	TANZEUM.xml:S3:3486:7	O
patients	TANZEUM.xml:S3:3494:8	O
carefully	TANZEUM.xml:S3:3503:9	O
for	TANZEUM.xml:S3:3513:3	O
signs	TANZEUM.xml:S3:3517:5	O
and	TANZEUM.xml:S3:3523:3	O
symptoms	TANZEUM.xml:S3:3527:8	O
of	TANZEUM.xml:S3:3536:2	O
pancreatitis	TANZEUM.xml:S3:3539:12	O
(	TANZEUM.xml:S3:3552:1	O
including	TANZEUM.xml:S3:3553:9	O
persistent	TANZEUM.xml:S3:3563:10	O
severe	TANZEUM.xml:S3:3574:6	O
abdominal	TANZEUM.xml:S3:3581:9	O
pain	TANZEUM.xml:S3:3591:4	O
,	TANZEUM.xml:S3:3595:1	O
sometimes	TANZEUM.xml:S3:3597:9	O
radiating	TANZEUM.xml:S3:3607:9	O
to	TANZEUM.xml:S3:3617:2	O
the	TANZEUM.xml:S3:3620:3	O
back	TANZEUM.xml:S3:3624:4	O
and	TANZEUM.xml:S3:3629:3	O
which	TANZEUM.xml:S3:3633:5	O
may	TANZEUM.xml:S3:3639:3	O
or	TANZEUM.xml:S3:3643:2	O
may	TANZEUM.xml:S3:3646:3	O
not	TANZEUM.xml:S3:3650:3	O
be	TANZEUM.xml:S3:3654:2	O
accompanied	TANZEUM.xml:S3:3657:11	O
by	TANZEUM.xml:S3:3669:2	O
vomiting	TANZEUM.xml:S3:3672:8	O
)	TANZEUM.xml:S3:3680:1	O
.	TANZEUM.xml:S3:3681:1	O

If	TANZEUM.xml:S3:3683:2	O
pancreatitis	TANZEUM.xml:S3:3686:12	O
is	TANZEUM.xml:S3:3699:2	O
suspected	TANZEUM.xml:S3:3702:9	O
,	TANZEUM.xml:S3:3711:1	O
promptly	TANZEUM.xml:S3:3713:8	O
discontinue	TANZEUM.xml:S3:3722:11	O
TANZEUM	TANZEUM.xml:S3:3734:7	O
.	TANZEUM.xml:S3:3741:1	O

If	TANZEUM.xml:S3:3743:2	O
pancreatitis	TANZEUM.xml:S3:3746:12	O
is	TANZEUM.xml:S3:3759:2	O
confirmed	TANZEUM.xml:S3:3762:9	O
,	TANZEUM.xml:S3:3771:1	O
TANZEUM	TANZEUM.xml:S3:3773:7	O
should	TANZEUM.xml:S3:3781:6	O
not	TANZEUM.xml:S3:3788:3	O
be	TANZEUM.xml:S3:3792:2	O
restarted	TANZEUM.xml:S3:3795:9	O
.	TANZEUM.xml:S3:3804:1	O

TANZEUM	TANZEUM.xml:S3:3810:7	O
has	TANZEUM.xml:S3:3818:3	O
not	TANZEUM.xml:S3:3822:3	O
been	TANZEUM.xml:S3:3826:4	O
studied	TANZEUM.xml:S3:3831:7	O
in	TANZEUM.xml:S3:3839:2	O
patients	TANZEUM.xml:S3:3842:8	O
with	TANZEUM.xml:S3:3851:4	O
a	TANZEUM.xml:S3:3856:1	O
history	TANZEUM.xml:S3:3858:7	O
of	TANZEUM.xml:S3:3866:2	O
pancreatitis	TANZEUM.xml:S3:3869:12	O
to	TANZEUM.xml:S3:3882:2	O
determine	TANZEUM.xml:S3:3885:9	O
whether	TANZEUM.xml:S3:3895:7	O
these	TANZEUM.xml:S3:3903:5	O
patients	TANZEUM.xml:S3:3909:8	O
are	TANZEUM.xml:S3:3918:3	O
at	TANZEUM.xml:S3:3922:2	O
increased	TANZEUM.xml:S3:3925:9	O
risk	TANZEUM.xml:S3:3935:4	O
for	TANZEUM.xml:S3:3940:3	O
pancreatitis	TANZEUM.xml:S3:3944:12	O
.	TANZEUM.xml:S3:3956:1	O

Consider	TANZEUM.xml:S3:3958:8	O
other	TANZEUM.xml:S3:3967:5	O
antidiabetic	TANZEUM.xml:S3:3973:12	O
therapies	TANZEUM.xml:S3:3986:9	O
in	TANZEUM.xml:S3:3996:2	O
patients	TANZEUM.xml:S3:3999:8	O
with	TANZEUM.xml:S3:4008:4	O
a	TANZEUM.xml:S3:4013:1	O
history	TANZEUM.xml:S3:4015:7	O
of	TANZEUM.xml:S3:4023:2	O
pancreatitis	TANZEUM.xml:S3:4026:12	O
.	TANZEUM.xml:S3:4038:1	O

5.3	TANZEUM.xml:S3:4046:3	O
Hypoglycemia	TANZEUM.xml:S3:4050:12	O
with	TANZEUM.xml:S3:4063:4	O
Concomitant	TANZEUM.xml:S3:4068:11	O
Use	TANZEUM.xml:S3:4080:3	O
of	TANZEUM.xml:S3:4084:2	O
Insulin	TANZEUM.xml:S3:4087:7	O
Secretagogues	TANZEUM.xml:S3:4095:13	O
or	TANZEUM.xml:S3:4109:2	O
Insulin	TANZEUM.xml:S3:4112:7	O

The	TANZEUM.xml:S3:4123:3	O
risk	TANZEUM.xml:S3:4127:4	B-Factor
of	TANZEUM.xml:S3:4132:2	O
hypoglycemia	TANZEUM.xml:S3:4135:12	B-AdverseReaction
is	TANZEUM.xml:S3:4148:2	O
increased	TANZEUM.xml:S3:4151:9	O
when	TANZEUM.xml:S3:4161:4	O
TANZEUM	TANZEUM.xml:S3:4166:7	O
is	TANZEUM.xml:S3:4174:2	O
used	TANZEUM.xml:S3:4177:4	O
in	TANZEUM.xml:S3:4182:2	O
combination	TANZEUM.xml:S3:4185:11	O
with	TANZEUM.xml:S3:4197:4	O
insulin	TANZEUM.xml:S3:4202:7	O
secretagogues	TANZEUM.xml:S3:4210:13	O
(	TANZEUM.xml:S3:4224:1	O
e	TANZEUM.xml:S3:4225:1	O
.	TANZEUM.xml:S3:4226:1	O
g	TANZEUM.xml:S3:4227:1	O
.	TANZEUM.xml:S3:4228:1	O
,	TANZEUM.xml:S3:4229:1	O
sulfonylureas	TANZEUM.xml:S3:4231:13	O
)	TANZEUM.xml:S3:4244:1	O
or	TANZEUM.xml:S3:4246:2	O
insulin	TANZEUM.xml:S3:4249:7	O
.	TANZEUM.xml:S3:4256:1	O

Therefore	TANZEUM.xml:S3:4258:9	O
,	TANZEUM.xml:S3:4267:1	O
patients	TANZEUM.xml:S3:4269:8	O
may	TANZEUM.xml:S3:4278:3	O
require	TANZEUM.xml:S3:4282:7	O
a	TANZEUM.xml:S3:4290:1	O
lower	TANZEUM.xml:S3:4292:5	O
dose	TANZEUM.xml:S3:4298:4	O
of	TANZEUM.xml:S3:4303:2	O
sulfonylurea	TANZEUM.xml:S3:4306:12	O
or	TANZEUM.xml:S3:4319:2	O
insulin	TANZEUM.xml:S3:4322:7	O
to	TANZEUM.xml:S3:4330:2	O
reduce	TANZEUM.xml:S3:4333:6	O
the	TANZEUM.xml:S3:4340:3	O
risk	TANZEUM.xml:S3:4344:4	B-Factor
of	TANZEUM.xml:S3:4349:2	O
hypoglycemia	TANZEUM.xml:S3:4352:12	B-AdverseReaction
in	TANZEUM.xml:S3:4365:2	O
this	TANZEUM.xml:S3:4368:4	O
setting	TANZEUM.xml:S3:4373:7	O
[	TANZEUM.xml:S3:4382:1	O
see	TANZEUM.xml:S3:4383:3	O
Dosage	TANZEUM.xml:S3:4387:6	O
and	TANZEUM.xml:S3:4394:3	O
Administration	TANZEUM.xml:S3:4398:14	O
(	TANZEUM.xml:S3:4413:1	O
2.2	TANZEUM.xml:S3:4414:3	O
)	TANZEUM.xml:S3:4417:1	O
,	TANZEUM.xml:S3:4418:1	O
Adverse	TANZEUM.xml:S3:4420:7	O
Reactions	TANZEUM.xml:S3:4428:9	O
(	TANZEUM.xml:S3:4438:1	O
6.1	TANZEUM.xml:S3:4439:3	O
)]	TANZEUM.xml:S3:4442:2	O
.	TANZEUM.xml:S3:4446:1	O

5.4	TANZEUM.xml:S3:4454:3	O
Hypersensitivity	TANZEUM.xml:S3:4458:16	O
Reactions	TANZEUM.xml:S3:4475:9	O

Across	TANZEUM.xml:S3:4488:6	O
8	TANZEUM.xml:S3:4495:1	O
Phase	TANZEUM.xml:S3:4497:5	O
III	TANZEUM.xml:S3:4503:3	O
clinical	TANZEUM.xml:S3:4507:8	O
trials	TANZEUM.xml:S3:4516:6	O
[	TANZEUM.xml:S3:4524:1	O
see	TANZEUM.xml:S3:4525:3	O
Clinical	TANZEUM.xml:S3:4529:8	O
Studies	TANZEUM.xml:S3:4538:7	O
(	TANZEUM.xml:S3:4546:1	O
14	TANZEUM.xml:S3:4547:2	O
)]	TANZEUM.xml:S3:4549:2	O
,	TANZEUM.xml:S3:4553:1	O
a	TANZEUM.xml:S3:4555:1	O
serious	TANZEUM.xml:S3:4557:7	B-Severity
hypersensitivity	TANZEUM.xml:S3:4565:16	B-AdverseReaction
reaction	TANZEUM.xml:S3:4582:8	I-AdverseReaction
with	TANZEUM.xml:S3:4591:4	O
pruritus	TANZEUM.xml:S3:4596:8	B-AdverseReaction
,	TANZEUM.xml:S3:4604:1	O
rash	TANZEUM.xml:S3:4606:4	B-AdverseReaction
,	TANZEUM.xml:S3:4610:1	O
and	TANZEUM.xml:S3:4612:3	O
dyspnea	TANZEUM.xml:S3:4616:7	B-AdverseReaction
occurred	TANZEUM.xml:S3:4624:8	O
in	TANZEUM.xml:S3:4633:2	O
a	TANZEUM.xml:S3:4636:1	O
patient	TANZEUM.xml:S3:4638:7	O
treated	TANZEUM.xml:S3:4646:7	O
with	TANZEUM.xml:S3:4654:4	O
TANZEUM	TANZEUM.xml:S3:4659:7	O
.	TANZEUM.xml:S3:4666:1	O

If	TANZEUM.xml:S3:4668:2	O
hypersensitivity	TANZEUM.xml:S3:4671:16	O
reactions	TANZEUM.xml:S3:4688:9	O
occur	TANZEUM.xml:S3:4698:5	O
,	TANZEUM.xml:S3:4703:1	O
discontinue	TANZEUM.xml:S3:4705:11	O
use	TANZEUM.xml:S3:4717:3	O
of	TANZEUM.xml:S3:4721:2	O
TANZEUM	TANZEUM.xml:S3:4724:7	O
;	TANZEUM.xml:S3:4731:1	O
treat	TANZEUM.xml:S3:4733:5	O
promptly	TANZEUM.xml:S3:4739:8	O
per	TANZEUM.xml:S3:4748:3	O
standard	TANZEUM.xml:S3:4752:8	O
of	TANZEUM.xml:S3:4761:2	O
care	TANZEUM.xml:S3:4764:4	O
and	TANZEUM.xml:S3:4769:3	O
monitor	TANZEUM.xml:S3:4773:7	O
until	TANZEUM.xml:S3:4781:5	O
signs	TANZEUM.xml:S3:4787:5	O
and	TANZEUM.xml:S3:4793:3	O
symptoms	TANZEUM.xml:S3:4797:8	O
resolve	TANZEUM.xml:S3:4806:7	O
[	TANZEUM.xml:S3:4815:1	O
see	TANZEUM.xml:S3:4816:3	O
Contraindications	TANZEUM.xml:S3:4820:17	O
(	TANZEUM.xml:S3:4838:1	O
4.2	TANZEUM.xml:S3:4839:3	O
)]	TANZEUM.xml:S3:4842:2	O
.	TANZEUM.xml:S3:4846:1	O

5.5	TANZEUM.xml:S3:4854:3	O
Renal	TANZEUM.xml:S3:4858:5	O
Impairment	TANZEUM.xml:S3:4864:10	O

In	TANZEUM.xml:S3:4878:2	O
patients	TANZEUM.xml:S3:4881:8	O
treated	TANZEUM.xml:S3:4890:7	O
with	TANZEUM.xml:S3:4898:4	O
GLP	TANZEUM.xml:S3:4903:3	B-DrugClass
-	TANZEUM.xml:S3:4906:1	I-DrugClass
1	TANZEUM.xml:S3:4907:1	I-DrugClass
receptor	TANZEUM.xml:S3:4909:8	I-DrugClass
agonists	TANZEUM.xml:S3:4918:8	I-DrugClass
,	TANZEUM.xml:S3:4926:1	O
there	TANZEUM.xml:S3:4928:5	O
have	TANZEUM.xml:S3:4934:4	O
been	TANZEUM.xml:S3:4939:4	O
postmarketing	TANZEUM.xml:S3:4944:13	O
reports	TANZEUM.xml:S3:4958:7	O
of	TANZEUM.xml:S3:4966:2	O
acute	TANZEUM.xml:S3:4969:5	B-AdverseReaction
renal	TANZEUM.xml:S3:4975:5	I-AdverseReaction
failure	TANZEUM.xml:S3:4981:7	I-AdverseReaction
and	TANZEUM.xml:S3:4989:3	O
worsening	TANZEUM.xml:S3:4993:9	B-AdverseReaction
of	TANZEUM.xml:S3:5003:2	I-AdverseReaction
chronic	TANZEUM.xml:S3:5006:7	I-AdverseReaction
renal	TANZEUM.xml:S3:5014:5	I-AdverseReaction
failure	TANZEUM.xml:S3:5020:7	I-AdverseReaction
,	TANZEUM.xml:S3:5027:1	O
which	TANZEUM.xml:S3:5029:5	O
may	TANZEUM.xml:S3:5035:3	O
sometimes	TANZEUM.xml:S3:5039:9	O
require	TANZEUM.xml:S3:5049:7	O
hemodialysis	TANZEUM.xml:S3:5057:12	O
.	TANZEUM.xml:S3:5069:1	O

Some	TANZEUM.xml:S3:5071:4	O
of	TANZEUM.xml:S3:5076:2	O
these	TANZEUM.xml:S3:5079:5	O
events	TANZEUM.xml:S3:5085:6	O
were	TANZEUM.xml:S3:5092:4	O
reported	TANZEUM.xml:S3:5097:8	O
in	TANZEUM.xml:S3:5106:2	O
patients	TANZEUM.xml:S3:5109:8	O
without	TANZEUM.xml:S3:5118:7	O
known	TANZEUM.xml:S3:5126:5	O
underlying	TANZEUM.xml:S3:5132:10	O
renal	TANZEUM.xml:S3:5143:5	O
disease	TANZEUM.xml:S3:5149:7	O
.	TANZEUM.xml:S3:5156:1	O

A	TANZEUM.xml:S3:5158:1	O
majority	TANZEUM.xml:S3:5160:8	O
of	TANZEUM.xml:S3:5169:2	O
reported	TANZEUM.xml:S3:5172:8	O
events	TANZEUM.xml:S3:5181:6	O
occurred	TANZEUM.xml:S3:5188:8	O
in	TANZEUM.xml:S3:5197:2	O
patients	TANZEUM.xml:S3:5200:8	O
who	TANZEUM.xml:S3:5209:3	O
had	TANZEUM.xml:S3:5213:3	O
experienced	TANZEUM.xml:S3:5217:11	O
nausea	TANZEUM.xml:S3:5229:6	B-AdverseReaction
,	TANZEUM.xml:S3:5235:1	O
vomiting	TANZEUM.xml:S3:5237:8	B-AdverseReaction
,	TANZEUM.xml:S3:5245:1	O
diarrhea	TANZEUM.xml:S3:5247:8	B-AdverseReaction
,	TANZEUM.xml:S3:5255:1	O
or	TANZEUM.xml:S3:5257:2	O
dehydration	TANZEUM.xml:S3:5260:11	B-AdverseReaction
.	TANZEUM.xml:S3:5271:1	O

In	TANZEUM.xml:S3:5273:2	O
a	TANZEUM.xml:S3:5276:1	O
trial	TANZEUM.xml:S3:5278:5	O
of	TANZEUM.xml:S3:5284:2	O
TANZEUM	TANZEUM.xml:S3:5287:7	O
in	TANZEUM.xml:S3:5295:2	O
patients	TANZEUM.xml:S3:5298:8	O
with	TANZEUM.xml:S3:5307:4	O
renal	TANZEUM.xml:S3:5312:5	O
impairment	TANZEUM.xml:S3:5318:10	O
[	TANZEUM.xml:S3:5330:1	O
see	TANZEUM.xml:S3:5331:3	O
Clinical	TANZEUM.xml:S3:5335:8	O
Studies	TANZEUM.xml:S3:5344:7	O
(	TANZEUM.xml:S3:5352:1	O
14.3	TANZEUM.xml:S3:5353:4	O
)]	TANZEUM.xml:S3:5357:2	O
,	TANZEUM.xml:S3:5361:1	O
the	TANZEUM.xml:S3:5363:3	O
frequency	TANZEUM.xml:S3:5367:9	O
of	TANZEUM.xml:S3:5377:2	O
such	TANZEUM.xml:S3:5380:4	O
gastrointestinal	TANZEUM.xml:S3:5385:16	B-AdverseReaction
reactions	TANZEUM.xml:S3:5402:9	I-AdverseReaction
increased	TANZEUM.xml:S3:5412:9	O
as	TANZEUM.xml:S3:5422:2	O
renal	TANZEUM.xml:S3:5425:5	B-AdverseReaction
function	TANZEUM.xml:S3:5431:8	I-AdverseReaction
declined	TANZEUM.xml:S3:5440:8	I-AdverseReaction
[	TANZEUM.xml:S3:5450:1	O
see	TANZEUM.xml:S3:5451:3	O
Use	TANZEUM.xml:S3:5455:3	O
in	TANZEUM.xml:S3:5459:2	O
Specific	TANZEUM.xml:S3:5462:8	O
Populations	TANZEUM.xml:S3:5471:11	O
(	TANZEUM.xml:S3:5483:1	O
8.6	TANZEUM.xml:S3:5484:3	O
)]	TANZEUM.xml:S3:5487:2	O
.	TANZEUM.xml:S3:5491:1	O

Because	TANZEUM.xml:S3:5493:7	O
these	TANZEUM.xml:S3:5501:5	O
reactions	TANZEUM.xml:S3:5507:9	O
may	TANZEUM.xml:S3:5517:3	O
worsen	TANZEUM.xml:S3:5521:6	O
renal	TANZEUM.xml:S3:5528:5	O
function	TANZEUM.xml:S3:5534:8	O
,	TANZEUM.xml:S3:5542:1	O
use	TANZEUM.xml:S3:5544:3	O
caution	TANZEUM.xml:S3:5548:7	O
when	TANZEUM.xml:S3:5556:4	O
initiating	TANZEUM.xml:S3:5561:10	O
or	TANZEUM.xml:S3:5572:2	O
escalating	TANZEUM.xml:S3:5575:10	O
doses	TANZEUM.xml:S3:5586:5	O
of	TANZEUM.xml:S3:5592:2	O
TANZEUM	TANZEUM.xml:S3:5595:7	O
in	TANZEUM.xml:S3:5603:2	O
patients	TANZEUM.xml:S3:5606:8	O
with	TANZEUM.xml:S3:5615:4	O
renal	TANZEUM.xml:S3:5620:5	O
impairment	TANZEUM.xml:S3:5626:10	O
[	TANZEUM.xml:S3:5638:1	O
see	TANZEUM.xml:S3:5639:3	O
Dosage	TANZEUM.xml:S3:5643:6	O
and	TANZEUM.xml:S3:5650:3	O
Administration	TANZEUM.xml:S3:5654:14	O
(	TANZEUM.xml:S3:5669:1	O
2.3	TANZEUM.xml:S3:5670:3	O
)	TANZEUM.xml:S3:5673:1	O
,	TANZEUM.xml:S3:5674:1	O
Use	TANZEUM.xml:S3:5676:3	O
in	TANZEUM.xml:S3:5680:2	O
Specific	TANZEUM.xml:S3:5683:8	O
Populations	TANZEUM.xml:S3:5692:11	O
(	TANZEUM.xml:S3:5704:1	O
8.6	TANZEUM.xml:S3:5705:3	O
)]	TANZEUM.xml:S3:5708:2	O
.	TANZEUM.xml:S3:5710:1	O

5.6	TANZEUM.xml:S3:5720:3	O
Macrovascular	TANZEUM.xml:S3:5724:13	O
Outcomes	TANZEUM.xml:S3:5738:8	O

There	TANZEUM.xml:S3:5750:5	O
have	TANZEUM.xml:S3:5756:4	O
been	TANZEUM.xml:S3:5761:4	O
no	TANZEUM.xml:S3:5766:2	O
clinical	TANZEUM.xml:S3:5769:8	O
trials	TANZEUM.xml:S3:5778:6	O
establishing	TANZEUM.xml:S3:5785:12	O
conclusive	TANZEUM.xml:S3:5798:10	O
evidence	TANZEUM.xml:S3:5809:8	O
of	TANZEUM.xml:S3:5818:2	O
macrovascular	TANZEUM.xml:S3:5821:13	O
risk	TANZEUM.xml:S3:5835:4	O
reduction	TANZEUM.xml:S3:5840:9	O
with	TANZEUM.xml:S3:5850:4	O
TANZEUM	TANZEUM.xml:S3:5855:7	O
or	TANZEUM.xml:S3:5863:2	O
any	TANZEUM.xml:S3:5866:3	O
other	TANZEUM.xml:S3:5870:5	O
antidiabetic	TANZEUM.xml:S3:5876:12	O
drug	TANZEUM.xml:S3:5889:4	O
.	TANZEUM.xml:S3:5893:1	O
6	TECFIDERA.xml:S1:4:1	O
ADVERSE	TECFIDERA.xml:S1:6:7	O
REACTIONS	TECFIDERA.xml:S1:14:9	O

The	TECFIDERA.xml:S1:27:3	O
following	TECFIDERA.xml:S1:31:9	O
important	TECFIDERA.xml:S1:41:9	O
adverse	TECFIDERA.xml:S1:51:7	O
reactions	TECFIDERA.xml:S1:59:9	O
are	TECFIDERA.xml:S1:69:3	O
described	TECFIDERA.xml:S1:73:9	O
elsewhere	TECFIDERA.xml:S1:83:9	O
in	TECFIDERA.xml:S1:93:2	O
labeling	TECFIDERA.xml:S1:96:8	O
:	TECFIDERA.xml:S1:104:1	O

Anaphylaxis	TECFIDERA.xml:S1:113:11	B-AdverseReaction
and	TECFIDERA.xml:S1:125:3	O
Angioedema	TECFIDERA.xml:S1:129:10	B-AdverseReaction
[	TECFIDERA.xml:S1:140:1	O
see	TECFIDERA.xml:S1:141:3	O
Warnings	TECFIDERA.xml:S1:145:8	O
and	TECFIDERA.xml:S1:154:3	O
Precautions	TECFIDERA.xml:S1:158:11	O
(	TECFIDERA.xml:S1:170:1	O
5.1	TECFIDERA.xml:S1:173:3	O
)]	TECFIDERA.xml:S1:178:2	O
.	TECFIDERA.xml:S1:180:1	O

Progressive	TECFIDERA.xml:S1:188:11	B-AdverseReaction
multifocal	TECFIDERA.xml:S1:200:10	I-AdverseReaction
leukoencephalopathy	TECFIDERA.xml:S1:211:19	I-AdverseReaction
[	TECFIDERA.xml:S1:231:1	O
see	TECFIDERA.xml:S1:232:3	O
Warnings	TECFIDERA.xml:S1:236:8	O
and	TECFIDERA.xml:S1:245:3	O
Precautions	TECFIDERA.xml:S1:249:11	O
(	TECFIDERA.xml:S1:261:1	O
5.2	TECFIDERA.xml:S1:264:3	O
)]	TECFIDERA.xml:S1:269:2	O
.	TECFIDERA.xml:S1:271:1	O

Lymphopenia	TECFIDERA.xml:S1:279:11	B-AdverseReaction
[	TECFIDERA.xml:S1:291:1	O
see	TECFIDERA.xml:S1:292:3	O
Warnings	TECFIDERA.xml:S1:296:8	O
and	TECFIDERA.xml:S1:305:3	O
Precautions	TECFIDERA.xml:S1:309:11	O
(	TECFIDERA.xml:S1:321:1	O
5.3	TECFIDERA.xml:S1:324:3	O
)]	TECFIDERA.xml:S1:329:2	O
.	TECFIDERA.xml:S1:331:1	O

Flushing	TECFIDERA.xml:S1:339:8	B-AdverseReaction
[	TECFIDERA.xml:S1:348:1	O
see	TECFIDERA.xml:S1:349:3	O
Warnings	TECFIDERA.xml:S1:353:8	O
and	TECFIDERA.xml:S1:362:3	O
Precautions	TECFIDERA.xml:S1:366:11	O
(	TECFIDERA.xml:S1:378:1	O
5.4	TECFIDERA.xml:S1:381:3	O
)]	TECFIDERA.xml:S1:386:2	O
.	TECFIDERA.xml:S1:388:1	O

EXCERPT	TECFIDERA.xml:S1:398:7	O
:	TECFIDERA.xml:S1:405:1	O
Most	TECFIDERA.xml:S1:409:4	O
common	TECFIDERA.xml:S1:414:6	O
adverse	TECFIDERA.xml:S1:421:7	O
reactions	TECFIDERA.xml:S1:429:9	O
(	TECFIDERA.xml:S1:439:1	O
incidence	TECFIDERA.xml:S1:440:9	O
10%	TECFIDERA.xml:S1:452:3	O
and	TECFIDERA.xml:S1:456:3	O
2%	TECFIDERA.xml:S1:462:2	O
placebo	TECFIDERA.xml:S1:465:7	O
)	TECFIDERA.xml:S1:472:1	O
were	TECFIDERA.xml:S1:474:4	O
flushing	TECFIDERA.xml:S1:479:8	B-AdverseReaction
,	TECFIDERA.xml:S1:487:1	O
abdominal	TECFIDERA.xml:S1:489:9	B-AdverseReaction
pain	TECFIDERA.xml:S1:499:4	I-AdverseReaction
,	TECFIDERA.xml:S1:503:1	O
diarrhea	TECFIDERA.xml:S1:505:8	B-AdverseReaction
,	TECFIDERA.xml:S1:513:1	O
and	TECFIDERA.xml:S1:515:3	O
nausea	TECFIDERA.xml:S1:519:6	B-AdverseReaction
.	TECFIDERA.xml:S1:525:1	O

(	TECFIDERA.xml:S1:527:1	O
6.1	TECFIDERA.xml:S1:530:3	O
)	TECFIDERA.xml:S1:535:1	O

To	TECFIDERA.xml:S1:543:2	O

report	TECFIDERA.xml:S1:546:6	O
SUSPECTED	TECFIDERA.xml:S1:553:9	O
ADVERSE	TECFIDERA.xml:S1:563:7	O
REACTIONS	TECFIDERA.xml:S1:571:9	O
,	TECFIDERA.xml:S1:580:1	O
contact	TECFIDERA.xml:S1:582:7	O
Biogen	TECFIDERA.xml:S1:590:6	O
at	TECFIDERA.xml:S1:597:2	O
1	TECFIDERA.xml:S1:600:1	O
-	TECFIDERA.xml:S1:601:1	O
800	TECFIDERA.xml:S1:602:3	O
-	TECFIDERA.xml:S1:605:1	O
456	TECFIDERA.xml:S1:606:3	O
-	TECFIDERA.xml:S1:609:1	O
2255	TECFIDERA.xml:S1:610:4	O
or	TECFIDERA.xml:S1:615:2	O
FDA	TECFIDERA.xml:S1:618:3	O
at	TECFIDERA.xml:S1:622:2	O
1	TECFIDERA.xml:S1:625:1	O
-	TECFIDERA.xml:S1:626:1	O
800	TECFIDERA.xml:S1:627:3	O
-	TECFIDERA.xml:S1:630:1	O
FDA	TECFIDERA.xml:S1:631:3	O
-	TECFIDERA.xml:S1:634:1	O
1088	TECFIDERA.xml:S1:635:4	O
or	TECFIDERA.xml:S1:640:2	O
www	TECFIDERA.xml:S1:643:3	O
.	TECFIDERA.xml:S1:646:1	O
fda	TECFIDERA.xml:S1:647:3	O
.	TECFIDERA.xml:S1:650:1	O
gov	TECFIDERA.xml:S1:651:3	O
medwatch	TECFIDERA.xml:S1:655:8	O
.	TECFIDERA.xml:S1:663:1	O

6.1	TECFIDERA.xml:S1:675:3	O

Clinical	TECFIDERA.xml:S1:679:8	O
Trials	TECFIDERA.xml:S1:688:6	O
Experience	TECFIDERA.xml:S1:695:10	O

Because	TECFIDERA.xml:S1:709:7	O
clinical	TECFIDERA.xml:S1:717:8	O
trials	TECFIDERA.xml:S1:726:6	O
are	TECFIDERA.xml:S1:733:3	O
conducted	TECFIDERA.xml:S1:737:9	O
under	TECFIDERA.xml:S1:747:5	O
widely	TECFIDERA.xml:S1:753:6	O
varying	TECFIDERA.xml:S1:760:7	O
conditions	TECFIDERA.xml:S1:768:10	O
,	TECFIDERA.xml:S1:778:1	O
adverse	TECFIDERA.xml:S1:780:7	O
reaction	TECFIDERA.xml:S1:788:8	O
rates	TECFIDERA.xml:S1:797:5	O
observed	TECFIDERA.xml:S1:803:8	O
in	TECFIDERA.xml:S1:812:2	O
clinical	TECFIDERA.xml:S1:815:8	O
trials	TECFIDERA.xml:S1:824:6	O
of	TECFIDERA.xml:S1:831:2	O
a	TECFIDERA.xml:S1:834:1	O
drug	TECFIDERA.xml:S1:836:4	O
cannot	TECFIDERA.xml:S1:841:6	O
be	TECFIDERA.xml:S1:848:2	O
directly	TECFIDERA.xml:S1:851:8	O
compared	TECFIDERA.xml:S1:860:8	O
to	TECFIDERA.xml:S1:869:2	O
rates	TECFIDERA.xml:S1:872:5	O
in	TECFIDERA.xml:S1:878:2	O
the	TECFIDERA.xml:S1:881:3	O
clinical	TECFIDERA.xml:S1:885:8	O
trials	TECFIDERA.xml:S1:894:6	O
of	TECFIDERA.xml:S1:901:2	O
another	TECFIDERA.xml:S1:904:7	O
drug	TECFIDERA.xml:S1:912:4	O
and	TECFIDERA.xml:S1:917:3	O
may	TECFIDERA.xml:S1:921:3	O
not	TECFIDERA.xml:S1:925:3	O
reflect	TECFIDERA.xml:S1:929:7	O
the	TECFIDERA.xml:S1:937:3	O
rates	TECFIDERA.xml:S1:941:5	O
observed	TECFIDERA.xml:S1:947:8	O
in	TECFIDERA.xml:S1:956:2	O
clinical	TECFIDERA.xml:S1:959:8	O
practice	TECFIDERA.xml:S1:968:8	O
.	TECFIDERA.xml:S1:976:1	O

The	TECFIDERA.xml:S1:982:3	O
most	TECFIDERA.xml:S1:986:4	O
common	TECFIDERA.xml:S1:991:6	O
adverse	TECFIDERA.xml:S1:998:7	O
reactions	TECFIDERA.xml:S1:1006:9	O
(	TECFIDERA.xml:S1:1016:1	O
incidence	TECFIDERA.xml:S1:1017:9	O
10%	TECFIDERA.xml:S1:1029:3	O
and	TECFIDERA.xml:S1:1033:3	O
2%	TECFIDERA.xml:S1:1039:2	O
more	TECFIDERA.xml:S1:1042:4	O
than	TECFIDERA.xml:S1:1047:4	O
placebo	TECFIDERA.xml:S1:1052:7	O
)	TECFIDERA.xml:S1:1059:1	O
for	TECFIDERA.xml:S1:1061:3	O
TECFIDERA	TECFIDERA.xml:S1:1065:9	O
were	TECFIDERA.xml:S1:1075:4	O
flushing	TECFIDERA.xml:S1:1080:8	B-AdverseReaction
,	TECFIDERA.xml:S1:1088:1	O
abdominal	TECFIDERA.xml:S1:1090:9	B-AdverseReaction
pain	TECFIDERA.xml:S1:1100:4	I-AdverseReaction
,	TECFIDERA.xml:S1:1104:1	O
diarrhea	TECFIDERA.xml:S1:1106:8	B-AdverseReaction
,	TECFIDERA.xml:S1:1114:1	O
and	TECFIDERA.xml:S1:1116:3	O
nausea	TECFIDERA.xml:S1:1120:6	B-AdverseReaction
.	TECFIDERA.xml:S1:1126:1	O

Adverse	TECFIDERA.xml:S1:1136:7	O
Reactions	TECFIDERA.xml:S1:1144:9	O
in	TECFIDERA.xml:S1:1154:2	O
Placebo	TECFIDERA.xml:S1:1157:7	O
-	TECFIDERA.xml:S1:1164:1	O
Controlled	TECFIDERA.xml:S1:1165:10	O
Trials	TECFIDERA.xml:S1:1176:6	O

In	TECFIDERA.xml:S1:1189:2	O
the	TECFIDERA.xml:S1:1192:3	O
two	TECFIDERA.xml:S1:1196:3	O
well	TECFIDERA.xml:S1:1200:4	O
-	TECFIDERA.xml:S1:1204:1	O
controlled	TECFIDERA.xml:S1:1205:10	O
studies	TECFIDERA.xml:S1:1216:7	O
demonstrating	TECFIDERA.xml:S1:1224:13	O
effectiveness	TECFIDERA.xml:S1:1238:13	O
,	TECFIDERA.xml:S1:1251:1	O
1529	TECFIDERA.xml:S1:1253:4	O
patients	TECFIDERA.xml:S1:1258:8	O
received	TECFIDERA.xml:S1:1267:8	O
TECFIDERA	TECFIDERA.xml:S1:1276:9	O
with	TECFIDERA.xml:S1:1286:4	O
an	TECFIDERA.xml:S1:1291:2	O
overall	TECFIDERA.xml:S1:1294:7	O
exposure	TECFIDERA.xml:S1:1302:8	O
of	TECFIDERA.xml:S1:1311:2	O
2244	TECFIDERA.xml:S1:1314:4	O
person	TECFIDERA.xml:S1:1319:6	O
-	TECFIDERA.xml:S1:1325:1	O
years	TECFIDERA.xml:S1:1326:5	O
[	TECFIDERA.xml:S1:1333:1	O
see	TECFIDERA.xml:S1:1334:3	O
Clinical	TECFIDERA.xml:S1:1338:8	O
Studies	TECFIDERA.xml:S1:1347:7	O
(	TECFIDERA.xml:S1:1355:1	O
14	TECFIDERA.xml:S1:1358:2	O
)]	TECFIDERA.xml:S1:1362:2	O
.	TECFIDERA.xml:S1:1364:1	O

The	TECFIDERA.xml:S1:1372:3	O
adverse	TECFIDERA.xml:S1:1376:7	O
reactions	TECFIDERA.xml:S1:1384:9	O
presented	TECFIDERA.xml:S1:1394:9	O
in	TECFIDERA.xml:S1:1404:2	O
the	TECFIDERA.xml:S1:1407:3	O
table	TECFIDERA.xml:S1:1411:5	O
below	TECFIDERA.xml:S1:1417:5	O
are	TECFIDERA.xml:S1:1423:3	O
based	TECFIDERA.xml:S1:1427:5	O
on	TECFIDERA.xml:S1:1433:2	O
safety	TECFIDERA.xml:S1:1436:6	O
information	TECFIDERA.xml:S1:1443:11	O
from	TECFIDERA.xml:S1:1455:4	O
769	TECFIDERA.xml:S1:1460:3	O
patients	TECFIDERA.xml:S1:1464:8	O
treated	TECFIDERA.xml:S1:1473:7	O
with	TECFIDERA.xml:S1:1481:4	O
TECFIDERA	TECFIDERA.xml:S1:1486:9	O
240	TECFIDERA.xml:S1:1496:3	O
mg	TECFIDERA.xml:S1:1500:2	O
twice	TECFIDERA.xml:S1:1503:5	O
a	TECFIDERA.xml:S1:1509:1	O
day	TECFIDERA.xml:S1:1511:3	O
and	TECFIDERA.xml:S1:1515:3	O
771	TECFIDERA.xml:S1:1519:3	O
placebo	TECFIDERA.xml:S1:1523:7	O
-	TECFIDERA.xml:S1:1530:1	O
treated	TECFIDERA.xml:S1:1531:7	O
patients	TECFIDERA.xml:S1:1539:8	O
.	TECFIDERA.xml:S1:1547:1	O

Table	TECFIDERA.xml:S1:1553:5	O
1	TECFIDERA.xml:S1:1559:1	O
:	TECFIDERA.xml:S1:1560:1	O
Adverse	TECFIDERA.xml:S1:1562:7	O
Reactions	TECFIDERA.xml:S1:1570:9	O
in	TECFIDERA.xml:S1:1580:2	O
Study	TECFIDERA.xml:S1:1583:5	O
1	TECFIDERA.xml:S1:1589:1	O
and	TECFIDERA.xml:S1:1591:3	O
2	TECFIDERA.xml:S1:1595:1	O
reported	TECFIDERA.xml:S1:1597:8	O
for	TECFIDERA.xml:S1:1606:3	O
TECFIDERA	TECFIDERA.xml:S1:1610:9	O
240	TECFIDERA.xml:S1:1620:3	O
mg	TECFIDERA.xml:S1:1624:2	O
BID	TECFIDERA.xml:S1:1627:3	O
at	TECFIDERA.xml:S1:1631:2	O
2%	TECFIDERA.xml:S1:1637:2	O
higher	TECFIDERA.xml:S1:1640:6	O
incidence	TECFIDERA.xml:S1:1647:9	O
than	TECFIDERA.xml:S1:1657:4	O
placebo	TECFIDERA.xml:S1:1662:7	O

TECFIDERA	TECFIDERA.xml:S1:1723:9	O
N	TECFIDERA.xml:S1:1736:1	O
769	TECFIDERA.xml:S1:1738:3	O
Placebo	TECFIDERA.xml:S1:1752:7	O
N	TECFIDERA.xml:S1:1763:1	O
771	TECFIDERA.xml:S1:1765:3	O

Flushing	TECFIDERA.xml:S1:1887:8	B-AdverseReaction

40	TECFIDERA.xml:S1:1936:2	O
6	TECFIDERA.xml:S1:1964:1	O

Abdominal	TECFIDERA.xml:S1:1994:9	B-AdverseReaction
pain	TECFIDERA.xml:S1:2004:4	I-AdverseReaction
18	TECFIDERA.xml:S1:2043:2	O
10	TECFIDERA.xml:S1:2071:2	O

Diarrhea	TECFIDERA.xml:S1:2101:8	B-AdverseReaction
14	TECFIDERA.xml:S1:2150:2	O
11	TECFIDERA.xml:S1:2178:2	O

Nausea	TECFIDERA.xml:S1:2208:6	B-AdverseReaction
12	TECFIDERA.xml:S1:2257:2	O
9	TECFIDERA.xml:S1:2285:1	O

Vomiting	TECFIDERA.xml:S1:2315:8	B-AdverseReaction
9	TECFIDERA.xml:S1:2364:1	O
5	TECFIDERA.xml:S1:2392:1	O

Pruritus	TECFIDERA.xml:S1:2422:8	B-AdverseReaction
8	TECFIDERA.xml:S1:2471:1	O
4	TECFIDERA.xml:S1:2499:1	O

Rash	TECFIDERA.xml:S1:2529:4	B-AdverseReaction
8	TECFIDERA.xml:S1:2578:1	O
3	TECFIDERA.xml:S1:2606:1	O

Albumin	TECFIDERA.xml:S1:2636:7	B-AdverseReaction
urine	TECFIDERA.xml:S1:2644:5	I-AdverseReaction
present	TECFIDERA.xml:S1:2650:7	I-AdverseReaction
6	TECFIDERA.xml:S1:2685:1	O
4	TECFIDERA.xml:S1:2713:1	O

Erythema	TECFIDERA.xml:S1:2743:8	B-AdverseReaction
5	TECFIDERA.xml:S1:2792:1	O
1	TECFIDERA.xml:S1:2820:1	O

Dyspepsia	TECFIDERA.xml:S1:2850:9	B-AdverseReaction
5	TECFIDERA.xml:S1:2899:1	O
3	TECFIDERA.xml:S1:2927:1	O

Aspartate	TECFIDERA.xml:S1:2957:9	B-AdverseReaction
aminotransferase	TECFIDERA.xml:S1:2967:16	I-AdverseReaction
increased	TECFIDERA.xml:S1:2984:9	I-AdverseReaction
4	TECFIDERA.xml:S1:3006:1	O
2	TECFIDERA.xml:S1:3034:1	O

Lymphopenia	TECFIDERA.xml:S1:3064:11	B-AdverseReaction
2	TECFIDERA.xml:S1:3113:1	O
1	TECFIDERA.xml:S1:3142:1	O

Gastrointestinal	TECFIDERA.xml:S1:3183:16	O

TECFIDERA	TECFIDERA.xml:S1:3206:9	O

caused	TECFIDERA.xml:S1:3216:6	O
GI	TECFIDERA.xml:S1:3223:2	B-AdverseReaction
events	TECFIDERA.xml:S1:3226:6	I-AdverseReaction
(	TECFIDERA.xml:S1:3233:1	O
e	TECFIDERA.xml:S1:3234:1	O
.	TECFIDERA.xml:S1:3235:1	O
g	TECFIDERA.xml:S1:3236:1	O
.	TECFIDERA.xml:S1:3237:1	O
,	TECFIDERA.xml:S1:3238:1	O
nausea	TECFIDERA.xml:S1:3240:6	B-AdverseReaction
,	TECFIDERA.xml:S1:3246:1	O
vomiting	TECFIDERA.xml:S1:3248:8	B-AdverseReaction
,	TECFIDERA.xml:S1:3256:1	O
diarrhea	TECFIDERA.xml:S1:3258:8	B-AdverseReaction
,	TECFIDERA.xml:S1:3266:1	O
abdominal	TECFIDERA.xml:S1:3268:9	B-AdverseReaction
pain	TECFIDERA.xml:S1:3278:4	I-AdverseReaction
,	TECFIDERA.xml:S1:3282:1	O
and	TECFIDERA.xml:S1:3284:3	O
dyspepsia	TECFIDERA.xml:S1:3288:9	B-AdverseReaction
)	TECFIDERA.xml:S1:3297:1	O
.	TECFIDERA.xml:S1:3298:1	O

The	TECFIDERA.xml:S1:3300:3	O
incidence	TECFIDERA.xml:S1:3304:9	O
of	TECFIDERA.xml:S1:3314:2	O
GI	TECFIDERA.xml:S1:3317:2	B-AdverseReaction
events	TECFIDERA.xml:S1:3320:6	I-AdverseReaction
was	TECFIDERA.xml:S1:3327:3	O
higher	TECFIDERA.xml:S1:3331:6	O
early	TECFIDERA.xml:S1:3338:5	O
in	TECFIDERA.xml:S1:3344:2	O
the	TECFIDERA.xml:S1:3347:3	O
course	TECFIDERA.xml:S1:3351:6	O
of	TECFIDERA.xml:S1:3358:2	O
treatment	TECFIDERA.xml:S1:3361:9	O
(	TECFIDERA.xml:S1:3371:1	O
primarily	TECFIDERA.xml:S1:3372:9	O
in	TECFIDERA.xml:S1:3382:2	O
month	TECFIDERA.xml:S1:3385:5	O
1	TECFIDERA.xml:S1:3391:1	O
)	TECFIDERA.xml:S1:3392:1	O
and	TECFIDERA.xml:S1:3394:3	O
usually	TECFIDERA.xml:S1:3398:7	O
decreased	TECFIDERA.xml:S1:3406:9	O
over	TECFIDERA.xml:S1:3416:4	O
time	TECFIDERA.xml:S1:3421:4	O
in	TECFIDERA.xml:S1:3426:2	O
patients	TECFIDERA.xml:S1:3429:8	O
treated	TECFIDERA.xml:S1:3438:7	O
with	TECFIDERA.xml:S1:3446:4	O
TECFIDERA	TECFIDERA.xml:S1:3451:9	O
compared	TECFIDERA.xml:S1:3461:8	O
with	TECFIDERA.xml:S1:3470:4	O
placebo	TECFIDERA.xml:S1:3475:7	O
.	TECFIDERA.xml:S1:3482:1	O

Four	TECFIDERA.xml:S1:3484:4	O
percent	TECFIDERA.xml:S1:3489:7	O
(	TECFIDERA.xml:S1:3497:1	O
4%	TECFIDERA.xml:S1:3498:2	O
)	TECFIDERA.xml:S1:3500:1	O
of	TECFIDERA.xml:S1:3502:2	O
patients	TECFIDERA.xml:S1:3505:8	O
treated	TECFIDERA.xml:S1:3514:7	O
with	TECFIDERA.xml:S1:3522:4	O
TECFIDERA	TECFIDERA.xml:S1:3527:9	O
and	TECFIDERA.xml:S1:3537:3	O
less	TECFIDERA.xml:S1:3541:4	O
than	TECFIDERA.xml:S1:3546:4	O
1%	TECFIDERA.xml:S1:3551:2	O
of	TECFIDERA.xml:S1:3554:2	O
placebo	TECFIDERA.xml:S1:3557:7	O
patients	TECFIDERA.xml:S1:3565:8	O
discontinued	TECFIDERA.xml:S1:3574:12	O
due	TECFIDERA.xml:S1:3587:3	O
to	TECFIDERA.xml:S1:3591:2	O
gastrointestinal	TECFIDERA.xml:S1:3594:16	B-AdverseReaction
events	TECFIDERA.xml:S1:3611:6	I-AdverseReaction
.	TECFIDERA.xml:S1:3617:1	O

The	TECFIDERA.xml:S1:3619:3	O
incidence	TECFIDERA.xml:S1:3623:9	O
of	TECFIDERA.xml:S1:3633:2	O
serious	TECFIDERA.xml:S1:3636:7	B-Severity
GI	TECFIDERA.xml:S1:3644:2	B-AdverseReaction
events	TECFIDERA.xml:S1:3647:6	I-AdverseReaction
was	TECFIDERA.xml:S1:3654:3	O
1%	TECFIDERA.xml:S1:3658:2	O
in	TECFIDERA.xml:S1:3661:2	O
patients	TECFIDERA.xml:S1:3664:8	O
treated	TECFIDERA.xml:S1:3673:7	O
with	TECFIDERA.xml:S1:3681:4	O
TECFIDERA	TECFIDERA.xml:S1:3686:9	O
.	TECFIDERA.xml:S1:3695:1	O

Hepatic	TECFIDERA.xml:S1:3705:7	O
Transaminases	TECFIDERA.xml:S1:3713:13	O

An	TECFIDERA.xml:S1:3733:2	O
increased	TECFIDERA.xml:S1:3736:9	O
incidence	TECFIDERA.xml:S1:3746:9	O
of	TECFIDERA.xml:S1:3756:2	O
elevations	TECFIDERA.xml:S1:3759:10	B-AdverseReaction
of	TECFIDERA.xml:S1:3770:2	I-AdverseReaction
hepatic	TECFIDERA.xml:S1:3773:7	I-AdverseReaction
transaminases	TECFIDERA.xml:S1:3781:13	I-AdverseReaction
in	TECFIDERA.xml:S1:3795:2	O
patients	TECFIDERA.xml:S1:3798:8	O
treated	TECFIDERA.xml:S1:3807:7	O
with	TECFIDERA.xml:S1:3815:4	O
TECFIDERA	TECFIDERA.xml:S1:3820:9	O
was	TECFIDERA.xml:S1:3830:3	O
seen	TECFIDERA.xml:S1:3834:4	O
primarily	TECFIDERA.xml:S1:3839:9	O
during	TECFIDERA.xml:S1:3849:6	O
the	TECFIDERA.xml:S1:3856:3	O
first	TECFIDERA.xml:S1:3860:5	O
six	TECFIDERA.xml:S1:3866:3	O
months	TECFIDERA.xml:S1:3870:6	O
of	TECFIDERA.xml:S1:3877:2	O
treatment	TECFIDERA.xml:S1:3880:9	O
,	TECFIDERA.xml:S1:3889:1	O
and	TECFIDERA.xml:S1:3891:3	O
most	TECFIDERA.xml:S1:3895:4	O
patients	TECFIDERA.xml:S1:3900:8	O
with	TECFIDERA.xml:S1:3909:4	O
elevations	TECFIDERA.xml:S1:3914:10	O
had	TECFIDERA.xml:S1:3925:3	O
levels	TECFIDERA.xml:S1:3929:6	O
3	TECFIDERA.xml:S1:3938:1	O
times	TECFIDERA.xml:S1:3940:5	O
the	TECFIDERA.xml:S1:3946:3	O
upper	TECFIDERA.xml:S1:3950:5	O
limit	TECFIDERA.xml:S1:3956:5	O
of	TECFIDERA.xml:S1:3962:2	O
normal	TECFIDERA.xml:S1:3965:6	O
(	TECFIDERA.xml:S1:3972:1	O
ULN	TECFIDERA.xml:S1:3973:3	O
)	TECFIDERA.xml:S1:3976:1	O
.	TECFIDERA.xml:S1:3977:1	O

Elevations	TECFIDERA.xml:S1:3979:10	B-AdverseReaction
of	TECFIDERA.xml:S1:3990:2	I-AdverseReaction
alanine	TECFIDERA.xml:S1:3993:7	I-AdverseReaction
aminotransferase	TECFIDERA.xml:S1:4001:16	I-AdverseReaction
and	TECFIDERA.xml:S1:4018:3	O
aspartate	TECFIDERA.xml:S1:4022:9	I-AdverseReaction
aminotransferase	TECFIDERA.xml:S1:4032:16	I-AdverseReaction
to	TECFIDERA.xml:S1:4049:2	O
3	TECFIDERA.xml:S1:4055:1	O
times	TECFIDERA.xml:S1:4057:5	O
the	TECFIDERA.xml:S1:4063:3	O
ULN	TECFIDERA.xml:S1:4067:3	O
occurred	TECFIDERA.xml:S1:4071:8	O
in	TECFIDERA.xml:S1:4080:2	O
a	TECFIDERA.xml:S1:4083:1	O
small	TECFIDERA.xml:S1:4085:5	O
number	TECFIDERA.xml:S1:4091:6	O
of	TECFIDERA.xml:S1:4098:2	O
patients	TECFIDERA.xml:S1:4101:8	O
treated	TECFIDERA.xml:S1:4110:7	O
with	TECFIDERA.xml:S1:4118:4	O
both	TECFIDERA.xml:S1:4123:4	O
TECFIDERA	TECFIDERA.xml:S1:4128:9	O
and	TECFIDERA.xml:S1:4138:3	O
placebo	TECFIDERA.xml:S1:4142:7	O
and	TECFIDERA.xml:S1:4150:3	O
were	TECFIDERA.xml:S1:4154:4	O
balanced	TECFIDERA.xml:S1:4159:8	O
between	TECFIDERA.xml:S1:4168:7	O
groups	TECFIDERA.xml:S1:4176:6	O
.	TECFIDERA.xml:S1:4182:1	O

There	TECFIDERA.xml:S1:4184:5	O
were	TECFIDERA.xml:S1:4190:4	O
no	TECFIDERA.xml:S1:4195:2	B-Negation
elevations	TECFIDERA.xml:S1:4198:10	B-AdverseReaction
in	TECFIDERA.xml:S1:4209:2	I-AdverseReaction
transaminases	TECFIDERA.xml:S1:4212:13	I-AdverseReaction
3	TECFIDERA.xml:S1:4229:1	B-Severity
times	TECFIDERA.xml:S1:4231:5	I-Severity
the	TECFIDERA.xml:S1:4237:3	I-Severity
ULN	TECFIDERA.xml:S1:4241:3	I-Severity
with	TECFIDERA.xml:S1:4245:4	O
concomitant	TECFIDERA.xml:S1:4250:11	O
elevations	TECFIDERA.xml:S1:4262:10	B-AdverseReaction
in	TECFIDERA.xml:S1:4273:2	I-AdverseReaction
total	TECFIDERA.xml:S1:4276:5	I-AdverseReaction
bilirubin	TECFIDERA.xml:S1:4282:9	I-AdverseReaction
2	TECFIDERA.xml:S1:4294:1	B-Severity
times	TECFIDERA.xml:S1:4296:5	I-Severity
the	TECFIDERA.xml:S1:4302:3	I-Severity
ULN	TECFIDERA.xml:S1:4306:3	I-Severity
.	TECFIDERA.xml:S1:4309:1	O

Discontinuations	TECFIDERA.xml:S1:4311:16	O
due	TECFIDERA.xml:S1:4328:3	O
to	TECFIDERA.xml:S1:4332:2	O
elevated	TECFIDERA.xml:S1:4335:8	B-AdverseReaction
hepatic	TECFIDERA.xml:S1:4344:7	I-AdverseReaction
transaminases	TECFIDERA.xml:S1:4352:13	I-AdverseReaction
were	TECFIDERA.xml:S1:4366:4	O
1%	TECFIDERA.xml:S1:4373:2	O
and	TECFIDERA.xml:S1:4376:3	O
were	TECFIDERA.xml:S1:4380:4	O
similar	TECFIDERA.xml:S1:4385:7	O
in	TECFIDERA.xml:S1:4393:2	O
patients	TECFIDERA.xml:S1:4396:8	O
treated	TECFIDERA.xml:S1:4405:7	O
with	TECFIDERA.xml:S1:4413:4	O
TECFIDERA	TECFIDERA.xml:S1:4418:9	O
or	TECFIDERA.xml:S1:4428:2	O
placebo	TECFIDERA.xml:S1:4431:7	O
.	TECFIDERA.xml:S1:4438:1	O

Eosinophilia	TECFIDERA.xml:S1:4448:12	O

A	TECFIDERA.xml:S1:4467:1	O
transient	TECFIDERA.xml:S1:4469:9	B-Severity
increase	TECFIDERA.xml:S1:4479:8	B-AdverseReaction
in	TECFIDERA.xml:S1:4488:2	I-AdverseReaction
mean	TECFIDERA.xml:S1:4491:4	I-AdverseReaction
eosinophil	TECFIDERA.xml:S1:4496:10	I-AdverseReaction
counts	TECFIDERA.xml:S1:4507:6	I-AdverseReaction
was	TECFIDERA.xml:S1:4514:3	O
seen	TECFIDERA.xml:S1:4518:4	O
during	TECFIDERA.xml:S1:4523:6	O
the	TECFIDERA.xml:S1:4530:3	O
first	TECFIDERA.xml:S1:4534:5	O
2	TECFIDERA.xml:S1:4540:1	O
months	TECFIDERA.xml:S1:4542:6	O
of	TECFIDERA.xml:S1:4549:2	O
therapy	TECFIDERA.xml:S1:4552:7	O
.	TECFIDERA.xml:S1:4559:1	O

Adverse	TECFIDERA.xml:S1:4569:7	O
Reactions	TECFIDERA.xml:S1:4577:9	O
in	TECFIDERA.xml:S1:4587:2	O
Placebo	TECFIDERA.xml:S1:4590:7	O
-	TECFIDERA.xml:S1:4597:1	O
Controlled	TECFIDERA.xml:S1:4598:10	O
and	TECFIDERA.xml:S1:4609:3	O
Uncontrolled	TECFIDERA.xml:S1:4613:12	O
Studies	TECFIDERA.xml:S1:4626:7	O

In	TECFIDERA.xml:S1:4640:2	O
placebo	TECFIDERA.xml:S1:4643:7	O
-	TECFIDERA.xml:S1:4650:1	O
controlled	TECFIDERA.xml:S1:4651:10	O
and	TECFIDERA.xml:S1:4662:3	O
uncontrolled	TECFIDERA.xml:S1:4666:12	O
clinical	TECFIDERA.xml:S1:4679:8	O
studies	TECFIDERA.xml:S1:4688:7	O
,	TECFIDERA.xml:S1:4695:1	O
a	TECFIDERA.xml:S1:4697:1	O
total	TECFIDERA.xml:S1:4699:5	O
of	TECFIDERA.xml:S1:4705:2	O
2513	TECFIDERA.xml:S1:4708:4	O
patients	TECFIDERA.xml:S1:4713:8	O
have	TECFIDERA.xml:S1:4722:4	O
received	TECFIDERA.xml:S1:4727:8	O
TECFIDERA	TECFIDERA.xml:S1:4736:9	O
and	TECFIDERA.xml:S1:4746:3	O
been	TECFIDERA.xml:S1:4750:4	O
followed	TECFIDERA.xml:S1:4755:8	O
for	TECFIDERA.xml:S1:4764:3	O
periods	TECFIDERA.xml:S1:4768:7	O
up	TECFIDERA.xml:S1:4776:2	O
to	TECFIDERA.xml:S1:4779:2	O
4	TECFIDERA.xml:S1:4782:1	O
years	TECFIDERA.xml:S1:4784:5	O
with	TECFIDERA.xml:S1:4790:4	O
an	TECFIDERA.xml:S1:4795:2	O
overall	TECFIDERA.xml:S1:4798:7	O
exposure	TECFIDERA.xml:S1:4806:8	O
of	TECFIDERA.xml:S1:4815:2	O
4603	TECFIDERA.xml:S1:4818:4	O
person	TECFIDERA.xml:S1:4823:6	O
-	TECFIDERA.xml:S1:4829:1	O
years	TECFIDERA.xml:S1:4830:5	O
.	TECFIDERA.xml:S1:4835:1	O

Approximately	TECFIDERA.xml:S1:4837:13	O
1162	TECFIDERA.xml:S1:4851:4	O
patients	TECFIDERA.xml:S1:4856:8	O
have	TECFIDERA.xml:S1:4865:4	O
received	TECFIDERA.xml:S1:4870:8	O
more	TECFIDERA.xml:S1:4879:4	O
than	TECFIDERA.xml:S1:4884:4	O
2	TECFIDERA.xml:S1:4889:1	O
years	TECFIDERA.xml:S1:4891:5	O
of	TECFIDERA.xml:S1:4897:2	O
treatment	TECFIDERA.xml:S1:4900:9	O
with	TECFIDERA.xml:S1:4910:4	O
TECFIDERA	TECFIDERA.xml:S1:4915:9	O
.	TECFIDERA.xml:S1:4924:1	O

The	TECFIDERA.xml:S1:4926:3	O
adverse	TECFIDERA.xml:S1:4930:7	O
reaction	TECFIDERA.xml:S1:4938:8	O
profile	TECFIDERA.xml:S1:4947:7	O
of	TECFIDERA.xml:S1:4955:2	O
TECFIDERA	TECFIDERA.xml:S1:4958:9	O
in	TECFIDERA.xml:S1:4968:2	O
the	TECFIDERA.xml:S1:4971:3	O
uncontrolled	TECFIDERA.xml:S1:4975:12	O
clinical	TECFIDERA.xml:S1:4988:8	O
studies	TECFIDERA.xml:S1:4997:7	O
was	TECFIDERA.xml:S1:5005:3	O
consistent	TECFIDERA.xml:S1:5009:10	O
with	TECFIDERA.xml:S1:5020:4	O
the	TECFIDERA.xml:S1:5025:3	O
experience	TECFIDERA.xml:S1:5029:10	O
in	TECFIDERA.xml:S1:5040:2	O
the	TECFIDERA.xml:S1:5043:3	O
placebo	TECFIDERA.xml:S1:5047:7	O
-	TECFIDERA.xml:S1:5054:1	O
controlled	TECFIDERA.xml:S1:5055:10	O
clinical	TECFIDERA.xml:S1:5066:8	O
trials	TECFIDERA.xml:S1:5075:6	O
.	TECFIDERA.xml:S1:5081:1	O
5	TECFIDERA.xml:S2:4:1	O
WARNINGS	TECFIDERA.xml:S2:6:8	O
AND	TECFIDERA.xml:S2:15:3	O
PRECAUTIONS	TECFIDERA.xml:S2:19:11	O

EXCERPT	TECFIDERA.xml:S2:37:7	O
:	TECFIDERA.xml:S2:44:1	O
Anaphylaxis	TECFIDERA.xml:S2:52:11	B-AdverseReaction
and	TECFIDERA.xml:S2:64:3	O
angioedema	TECFIDERA.xml:S2:68:10	B-AdverseReaction
:	TECFIDERA.xml:S2:78:1	O
Discontinue	TECFIDERA.xml:S2:80:11	O
and	TECFIDERA.xml:S2:92:3	O
do	TECFIDERA.xml:S2:96:2	O
not	TECFIDERA.xml:S2:99:3	O
restart	TECFIDERA.xml:S2:103:7	O
TECFIDERA	TECFIDERA.xml:S2:111:9	O
if	TECFIDERA.xml:S2:121:2	O
these	TECFIDERA.xml:S2:124:5	O
occur	TECFIDERA.xml:S2:130:5	O
.	TECFIDERA.xml:S2:135:1	O

(	TECFIDERA.xml:S2:137:1	O
5.1	TECFIDERA.xml:S2:140:3	O
)	TECFIDERA.xml:S2:145:1	O

Progressive	TECFIDERA.xml:S2:152:11	B-AdverseReaction
multifocal	TECFIDERA.xml:S2:164:10	I-AdverseReaction
leukoencephalopathy	TECFIDERA.xml:S2:175:19	I-AdverseReaction
(	TECFIDERA.xml:S2:195:1	O
PML	TECFIDERA.xml:S2:196:3	B-AdverseReaction
)	TECFIDERA.xml:S2:199:1	O
:	TECFIDERA.xml:S2:200:1	O
Withhold	TECFIDERA.xml:S2:202:8	O
TECFIDERA	TECFIDERA.xml:S2:211:9	O
at	TECFIDERA.xml:S2:221:2	O
the	TECFIDERA.xml:S2:224:3	O
first	TECFIDERA.xml:S2:228:5	O
sign	TECFIDERA.xml:S2:234:4	O
or	TECFIDERA.xml:S2:239:2	O
symptom	TECFIDERA.xml:S2:242:7	O
suggestive	TECFIDERA.xml:S2:250:10	O
of	TECFIDERA.xml:S2:261:2	O
PML	TECFIDERA.xml:S2:264:3	O
.	TECFIDERA.xml:S2:267:1	O

(	TECFIDERA.xml:S2:269:1	O
5.2	TECFIDERA.xml:S2:272:3	O
)	TECFIDERA.xml:S2:277:1	O

Lymphopenia	TECFIDERA.xml:S2:284:11	B-AdverseReaction
:	TECFIDERA.xml:S2:295:1	O
Obtain	TECFIDERA.xml:S2:297:6	O
a	TECFIDERA.xml:S2:304:1	O
CBC	TECFIDERA.xml:S2:306:3	O
including	TECFIDERA.xml:S2:310:9	O
lymphocyte	TECFIDERA.xml:S2:320:10	O
count	TECFIDERA.xml:S2:331:5	O
before	TECFIDERA.xml:S2:337:6	O
initiating	TECFIDERA.xml:S2:344:10	O
TECFIDERA	TECFIDERA.xml:S2:355:9	O
,	TECFIDERA.xml:S2:364:1	O
after	TECFIDERA.xml:S2:366:5	O
6	TECFIDERA.xml:S2:372:1	O
months	TECFIDERA.xml:S2:374:6	O
,	TECFIDERA.xml:S2:380:1	O
and	TECFIDERA.xml:S2:382:3	O
every	TECFIDERA.xml:S2:386:5	O
6	TECFIDERA.xml:S2:392:1	O
to	TECFIDERA.xml:S2:394:2	O
12	TECFIDERA.xml:S2:397:2	O
months	TECFIDERA.xml:S2:400:6	O
thereafter	TECFIDERA.xml:S2:407:10	O
.	TECFIDERA.xml:S2:417:1	O

Consider	TECFIDERA.xml:S2:419:8	O
interruption	TECFIDERA.xml:S2:428:12	O
of	TECFIDERA.xml:S2:441:2	O
TECFIDERA	TECFIDERA.xml:S2:444:9	O
if	TECFIDERA.xml:S2:454:2	O
lymphocyte	TECFIDERA.xml:S2:457:10	O
counts	TECFIDERA.xml:S2:468:6	O
0.5	TECFIDERA.xml:S2:476:3	O
x	TECFIDERA.xml:S2:480:1	O
10	TECFIDERA.xml:S2:482:2	O
9	TECFIDERA.xml:S2:486:1	O
L	TECFIDERA.xml:S2:490:1	O
persist	TECFIDERA.xml:S2:492:7	O
for	TECFIDERA.xml:S2:500:3	O
more	TECFIDERA.xml:S2:504:4	O
than	TECFIDERA.xml:S2:509:4	O
six	TECFIDERA.xml:S2:514:3	O
months	TECFIDERA.xml:S2:518:6	O
.	TECFIDERA.xml:S2:524:1	O

(	TECFIDERA.xml:S2:526:1	O
5.3	TECFIDERA.xml:S2:529:3	O
)	TECFIDERA.xml:S2:534:1	O

5.1	TECFIDERA.xml:S2:551:3	O

Anaphylaxis	TECFIDERA.xml:S2:555:11	O

and	TECFIDERA.xml:S2:567:3	O
Angioedema	TECFIDERA.xml:S2:571:10	O

TECFIDERA	TECFIDERA.xml:S2:590:9	O
can	TECFIDERA.xml:S2:600:3	B-Factor
cause	TECFIDERA.xml:S2:604:5	O
anaphylaxis	TECFIDERA.xml:S2:610:11	B-AdverseReaction
and	TECFIDERA.xml:S2:622:3	O
angioedema	TECFIDERA.xml:S2:626:10	B-AdverseReaction
after	TECFIDERA.xml:S2:637:5	O
the	TECFIDERA.xml:S2:643:3	O
first	TECFIDERA.xml:S2:647:5	O
dose	TECFIDERA.xml:S2:653:4	O
or	TECFIDERA.xml:S2:658:2	O
at	TECFIDERA.xml:S2:661:2	O
any	TECFIDERA.xml:S2:664:3	O
time	TECFIDERA.xml:S2:668:4	O
during	TECFIDERA.xml:S2:673:6	O
treatment	TECFIDERA.xml:S2:680:9	O
.	TECFIDERA.xml:S2:689:1	O

Signs	TECFIDERA.xml:S2:691:5	O
and	TECFIDERA.xml:S2:697:3	O
symptoms	TECFIDERA.xml:S2:701:8	O
have	TECFIDERA.xml:S2:710:4	O
included	TECFIDERA.xml:S2:715:8	O
difficulty	TECFIDERA.xml:S2:724:10	B-AdverseReaction
breathing	TECFIDERA.xml:S2:735:9	I-AdverseReaction
,	TECFIDERA.xml:S2:744:1	O
urticaria	TECFIDERA.xml:S2:746:9	B-AdverseReaction
,	TECFIDERA.xml:S2:755:1	O
and	TECFIDERA.xml:S2:757:3	O
swelling	TECFIDERA.xml:S2:761:8	B-AdverseReaction
of	TECFIDERA.xml:S2:770:2	I-AdverseReaction
the	TECFIDERA.xml:S2:773:3	I-AdverseReaction
throat	TECFIDERA.xml:S2:777:6	I-AdverseReaction
and	TECFIDERA.xml:S2:784:3	O
tongue	TECFIDERA.xml:S2:788:6	I-AdverseReaction
.	TECFIDERA.xml:S2:794:1	O

Patients	TECFIDERA.xml:S2:796:8	O
should	TECFIDERA.xml:S2:805:6	O
be	TECFIDERA.xml:S2:812:2	O
instructed	TECFIDERA.xml:S2:815:10	O
to	TECFIDERA.xml:S2:826:2	O
discontinue	TECFIDERA.xml:S2:829:11	O
TECFIDERA	TECFIDERA.xml:S2:841:9	O
and	TECFIDERA.xml:S2:851:3	O
seek	TECFIDERA.xml:S2:855:4	O
immediate	TECFIDERA.xml:S2:860:9	O
medical	TECFIDERA.xml:S2:870:7	O
care	TECFIDERA.xml:S2:878:4	O
should	TECFIDERA.xml:S2:883:6	O
they	TECFIDERA.xml:S2:890:4	O
experience	TECFIDERA.xml:S2:895:10	O
signs	TECFIDERA.xml:S2:906:5	O
and	TECFIDERA.xml:S2:912:3	O
symptoms	TECFIDERA.xml:S2:916:8	O
of	TECFIDERA.xml:S2:925:2	O
anaphylaxis	TECFIDERA.xml:S2:928:11	O
or	TECFIDERA.xml:S2:940:2	O
angioedema	TECFIDERA.xml:S2:943:10	O
.	TECFIDERA.xml:S2:953:1	O

5.2	TECFIDERA.xml:S2:965:3	O
Progressive	TECFIDERA.xml:S2:969:11	O
Multifocal	TECFIDERA.xml:S2:981:10	O
Leukoencephalopathy	TECFIDERA.xml:S2:992:19	O

A	TECFIDERA.xml:S2:1020:1	O
fatal	TECFIDERA.xml:S2:1022:5	B-AdverseReaction
case	TECFIDERA.xml:S2:1028:4	O
of	TECFIDERA.xml:S2:1033:2	O
progressive	TECFIDERA.xml:S2:1036:11	B-AdverseReaction
multifocal	TECFIDERA.xml:S2:1048:10	I-AdverseReaction
leukoencephalopathy	TECFIDERA.xml:S2:1059:19	I-AdverseReaction
(	TECFIDERA.xml:S2:1079:1	O
PML	TECFIDERA.xml:S2:1080:3	B-AdverseReaction
)	TECFIDERA.xml:S2:1083:1	O
occurred	TECFIDERA.xml:S2:1085:8	O
in	TECFIDERA.xml:S2:1094:2	O
a	TECFIDERA.xml:S2:1097:1	O
patient	TECFIDERA.xml:S2:1099:7	O
with	TECFIDERA.xml:S2:1107:4	O
MS	TECFIDERA.xml:S2:1112:2	O
who	TECFIDERA.xml:S2:1115:3	O
received	TECFIDERA.xml:S2:1119:8	O
TECFIDERA	TECFIDERA.xml:S2:1128:9	O
for	TECFIDERA.xml:S2:1138:3	O
4	TECFIDERA.xml:S2:1142:1	O
years	TECFIDERA.xml:S2:1144:5	O
while	TECFIDERA.xml:S2:1150:5	O
enrolled	TECFIDERA.xml:S2:1156:8	O
in	TECFIDERA.xml:S2:1165:2	O
a	TECFIDERA.xml:S2:1168:1	O
clinical	TECFIDERA.xml:S2:1170:8	O
trial	TECFIDERA.xml:S2:1179:5	O
.	TECFIDERA.xml:S2:1184:1	O

PML	TECFIDERA.xml:S2:1186:3	O
is	TECFIDERA.xml:S2:1190:2	O
an	TECFIDERA.xml:S2:1193:2	O
opportunistic	TECFIDERA.xml:S2:1196:13	O
viral	TECFIDERA.xml:S2:1210:5	O
infection	TECFIDERA.xml:S2:1216:9	O
of	TECFIDERA.xml:S2:1226:2	O
the	TECFIDERA.xml:S2:1229:3	O
brain	TECFIDERA.xml:S2:1233:5	O
caused	TECFIDERA.xml:S2:1239:6	O
by	TECFIDERA.xml:S2:1246:2	O
the	TECFIDERA.xml:S2:1249:3	O
JC	TECFIDERA.xml:S2:1253:2	O
virus	TECFIDERA.xml:S2:1256:5	O
(	TECFIDERA.xml:S2:1262:1	O
JCV	TECFIDERA.xml:S2:1263:3	O
)	TECFIDERA.xml:S2:1266:1	O
that	TECFIDERA.xml:S2:1268:4	O
typically	TECFIDERA.xml:S2:1273:9	O
only	TECFIDERA.xml:S2:1283:4	O
occurs	TECFIDERA.xml:S2:1288:6	O
in	TECFIDERA.xml:S2:1295:2	O
patients	TECFIDERA.xml:S2:1298:8	O
who	TECFIDERA.xml:S2:1307:3	O
are	TECFIDERA.xml:S2:1311:3	O
immunocompromised	TECFIDERA.xml:S2:1315:17	O
,	TECFIDERA.xml:S2:1332:1	O
and	TECFIDERA.xml:S2:1334:3	O
that	TECFIDERA.xml:S2:1338:4	O
usually	TECFIDERA.xml:S2:1343:7	O
leads	TECFIDERA.xml:S2:1351:5	O
to	TECFIDERA.xml:S2:1357:2	O
death	TECFIDERA.xml:S2:1360:5	O
or	TECFIDERA.xml:S2:1366:2	O
severe	TECFIDERA.xml:S2:1369:6	O
disability	TECFIDERA.xml:S2:1376:10	O
.	TECFIDERA.xml:S2:1386:1	O

During	TECFIDERA.xml:S2:1388:6	O
the	TECFIDERA.xml:S2:1395:3	O
clinical	TECFIDERA.xml:S2:1399:8	O
trial	TECFIDERA.xml:S2:1408:5	O
,	TECFIDERA.xml:S2:1413:1	O
the	TECFIDERA.xml:S2:1415:3	O
patient	TECFIDERA.xml:S2:1419:7	O
experienced	TECFIDERA.xml:S2:1427:11	O
prolonged	TECFIDERA.xml:S2:1439:9	B-Severity
lymphopenia	TECFIDERA.xml:S2:1449:11	B-AdverseReaction
(	TECFIDERA.xml:S2:1461:1	O
lymphocyte	TECFIDERA.xml:S2:1462:10	O
counts	TECFIDERA.xml:S2:1473:6	O
predominantly	TECFIDERA.xml:S2:1480:13	O
0.5	TECFIDERA.xml:S2:1495:3	O
x10	TECFIDERA.xml:S2:1498:3	O
9	TECFIDERA.xml:S2:1503:1	O
L	TECFIDERA.xml:S2:1507:1	O
for	TECFIDERA.xml:S2:1509:3	O
3.5	TECFIDERA.xml:S2:1513:3	O
years	TECFIDERA.xml:S2:1517:5	O
)	TECFIDERA.xml:S2:1522:1	O
while	TECFIDERA.xml:S2:1524:5	O
taking	TECFIDERA.xml:S2:1530:6	O
TECFIDERA	TECFIDERA.xml:S2:1537:9	O
[	TECFIDERA.xml:S2:1547:1	O
see	TECFIDERA.xml:S2:1548:3	O
Warnings	TECFIDERA.xml:S2:1552:8	O
and	TECFIDERA.xml:S2:1561:3	O
Precautions	TECFIDERA.xml:S2:1565:11	O
(	TECFIDERA.xml:S2:1577:1	O
5.3	TECFIDERA.xml:S2:1580:3	O
)]	TECFIDERA.xml:S2:1585:2	O
.	TECFIDERA.xml:S2:1589:1	O

The	TECFIDERA.xml:S2:1591:3	O
role	TECFIDERA.xml:S2:1595:4	O
of	TECFIDERA.xml:S2:1600:2	O
lymphopenia	TECFIDERA.xml:S2:1603:11	B-AdverseReaction
in	TECFIDERA.xml:S2:1615:2	O
this	TECFIDERA.xml:S2:1618:4	O
case	TECFIDERA.xml:S2:1623:4	O
is	TECFIDERA.xml:S2:1628:2	O
unknown	TECFIDERA.xml:S2:1631:7	O
.	TECFIDERA.xml:S2:1638:1	O

The	TECFIDERA.xml:S2:1640:3	O
patient	TECFIDERA.xml:S2:1644:7	O
had	TECFIDERA.xml:S2:1652:3	O
no	TECFIDERA.xml:S2:1656:2	O
other	TECFIDERA.xml:S2:1659:5	O
identified	TECFIDERA.xml:S2:1665:10	O
systemic	TECFIDERA.xml:S2:1676:8	O
medical	TECFIDERA.xml:S2:1685:7	O
conditions	TECFIDERA.xml:S2:1693:10	O
resulting	TECFIDERA.xml:S2:1704:9	O
in	TECFIDERA.xml:S2:1714:2	O
compromised	TECFIDERA.xml:S2:1717:11	O
immune	TECFIDERA.xml:S2:1729:6	O
system	TECFIDERA.xml:S2:1736:6	O
function	TECFIDERA.xml:S2:1743:8	O
and	TECFIDERA.xml:S2:1752:3	O
had	TECFIDERA.xml:S2:1756:3	O
not	TECFIDERA.xml:S2:1760:3	O
previously	TECFIDERA.xml:S2:1764:10	O
been	TECFIDERA.xml:S2:1775:4	O
treated	TECFIDERA.xml:S2:1780:7	O
with	TECFIDERA.xml:S2:1788:4	O
natalizumab	TECFIDERA.xml:S2:1793:11	O
,	TECFIDERA.xml:S2:1804:1	O
which	TECFIDERA.xml:S2:1806:5	O
has	TECFIDERA.xml:S2:1812:3	O
a	TECFIDERA.xml:S2:1816:1	O
known	TECFIDERA.xml:S2:1818:5	O
association	TECFIDERA.xml:S2:1824:11	O
with	TECFIDERA.xml:S2:1836:4	O
PML	TECFIDERA.xml:S2:1841:3	O
.	TECFIDERA.xml:S2:1844:1	O

The	TECFIDERA.xml:S2:1846:3	O
patient	TECFIDERA.xml:S2:1850:7	O
was	TECFIDERA.xml:S2:1858:3	O
also	TECFIDERA.xml:S2:1862:4	O
not	TECFIDERA.xml:S2:1867:3	O
taking	TECFIDERA.xml:S2:1871:6	O
any	TECFIDERA.xml:S2:1878:3	O
immunosuppressive	TECFIDERA.xml:S2:1882:17	O
or	TECFIDERA.xml:S2:1900:2	O
immunomodulatory	TECFIDERA.xml:S2:1903:16	O
medications	TECFIDERA.xml:S2:1920:11	O
concomitantly	TECFIDERA.xml:S2:1932:13	O
.	TECFIDERA.xml:S2:1945:1	O

At	TECFIDERA.xml:S2:1951:2	O
the	TECFIDERA.xml:S2:1954:3	O
first	TECFIDERA.xml:S2:1958:5	O
sign	TECFIDERA.xml:S2:1964:4	O
or	TECFIDERA.xml:S2:1969:2	O
symptom	TECFIDERA.xml:S2:1972:7	O
suggestive	TECFIDERA.xml:S2:1980:10	O
of	TECFIDERA.xml:S2:1991:2	O
PML	TECFIDERA.xml:S2:1994:3	O
,	TECFIDERA.xml:S2:1997:1	O
withhold	TECFIDERA.xml:S2:1999:8	O
TECFIDERA	TECFIDERA.xml:S2:2008:9	O
and	TECFIDERA.xml:S2:2018:3	O
perform	TECFIDERA.xml:S2:2022:7	O
an	TECFIDERA.xml:S2:2030:2	O
appropriate	TECFIDERA.xml:S2:2033:11	O
diagnostic	TECFIDERA.xml:S2:2045:10	O
evaluation	TECFIDERA.xml:S2:2056:10	O
.	TECFIDERA.xml:S2:2066:1	O

Typical	TECFIDERA.xml:S2:2068:7	O
symptoms	TECFIDERA.xml:S2:2076:8	O
associated	TECFIDERA.xml:S2:2085:10	O
with	TECFIDERA.xml:S2:2096:4	O
PML	TECFIDERA.xml:S2:2101:3	O
are	TECFIDERA.xml:S2:2105:3	O
diverse	TECFIDERA.xml:S2:2109:7	O
,	TECFIDERA.xml:S2:2116:1	O
progress	TECFIDERA.xml:S2:2118:8	O
over	TECFIDERA.xml:S2:2127:4	O
days	TECFIDERA.xml:S2:2132:4	O
to	TECFIDERA.xml:S2:2137:2	O
weeks	TECFIDERA.xml:S2:2140:5	O
,	TECFIDERA.xml:S2:2145:1	O
and	TECFIDERA.xml:S2:2147:3	O
include	TECFIDERA.xml:S2:2151:7	O
progressive	TECFIDERA.xml:S2:2159:11	O
weakness	TECFIDERA.xml:S2:2171:8	O
on	TECFIDERA.xml:S2:2180:2	O
one	TECFIDERA.xml:S2:2183:3	O
side	TECFIDERA.xml:S2:2187:4	O
of	TECFIDERA.xml:S2:2192:2	O
the	TECFIDERA.xml:S2:2195:3	O
body	TECFIDERA.xml:S2:2199:4	O
or	TECFIDERA.xml:S2:2204:2	O
clumsiness	TECFIDERA.xml:S2:2207:10	O
of	TECFIDERA.xml:S2:2218:2	O
limbs	TECFIDERA.xml:S2:2221:5	O
,	TECFIDERA.xml:S2:2226:1	O
disturbance	TECFIDERA.xml:S2:2228:11	O
of	TECFIDERA.xml:S2:2240:2	O
vision	TECFIDERA.xml:S2:2243:6	O
,	TECFIDERA.xml:S2:2249:1	O
and	TECFIDERA.xml:S2:2251:3	O
changes	TECFIDERA.xml:S2:2255:7	O
in	TECFIDERA.xml:S2:2263:2	O
thinking	TECFIDERA.xml:S2:2266:8	O
,	TECFIDERA.xml:S2:2274:1	O
memory	TECFIDERA.xml:S2:2276:6	O
,	TECFIDERA.xml:S2:2282:1	O
and	TECFIDERA.xml:S2:2284:3	O
orientation	TECFIDERA.xml:S2:2288:11	O
leading	TECFIDERA.xml:S2:2300:7	O
to	TECFIDERA.xml:S2:2308:2	O
confusion	TECFIDERA.xml:S2:2311:9	O
and	TECFIDERA.xml:S2:2321:3	O
personality	TECFIDERA.xml:S2:2325:11	O
changes	TECFIDERA.xml:S2:2337:7	O
.	TECFIDERA.xml:S2:2344:1	O

5.3	TECFIDERA.xml:S2:2353:3	O
Lymphopenia	TECFIDERA.xml:S2:2357:11	O

TECFIDERA	TECFIDERA.xml:S2:2377:9	O
may	TECFIDERA.xml:S2:2387:3	B-Factor
decrease	TECFIDERA.xml:S2:2391:8	B-AdverseReaction
lymphocyte	TECFIDERA.xml:S2:2400:10	I-AdverseReaction
counts	TECFIDERA.xml:S2:2411:6	I-AdverseReaction
.	TECFIDERA.xml:S2:2417:1	O

In	TECFIDERA.xml:S2:2419:2	O
the	TECFIDERA.xml:S2:2422:3	O
MS	TECFIDERA.xml:S2:2426:2	O
placebo	TECFIDERA.xml:S2:2429:7	O
controlled	TECFIDERA.xml:S2:2437:10	O
trials	TECFIDERA.xml:S2:2448:6	O
,	TECFIDERA.xml:S2:2454:1	O
mean	TECFIDERA.xml:S2:2456:4	O
lymphocyte	TECFIDERA.xml:S2:2461:10	B-AdverseReaction
counts	TECFIDERA.xml:S2:2472:6	I-AdverseReaction
decreased	TECFIDERA.xml:S2:2479:9	I-AdverseReaction
by	TECFIDERA.xml:S2:2489:2	O
approximately	TECFIDERA.xml:S2:2492:13	O
30%	TECFIDERA.xml:S2:2506:3	O
during	TECFIDERA.xml:S2:2510:6	O
the	TECFIDERA.xml:S2:2517:3	O
first	TECFIDERA.xml:S2:2521:5	O
year	TECFIDERA.xml:S2:2527:4	O
of	TECFIDERA.xml:S2:2532:2	O
treatment	TECFIDERA.xml:S2:2535:9	O
with	TECFIDERA.xml:S2:2545:4	O
TECFIDERA	TECFIDERA.xml:S2:2550:9	O
and	TECFIDERA.xml:S2:2560:3	O
then	TECFIDERA.xml:S2:2564:4	O
remained	TECFIDERA.xml:S2:2569:8	O
stable	TECFIDERA.xml:S2:2578:6	O
.	TECFIDERA.xml:S2:2584:1	O

Four	TECFIDERA.xml:S2:2586:4	O
weeks	TECFIDERA.xml:S2:2591:5	O
after	TECFIDERA.xml:S2:2597:5	O
stopping	TECFIDERA.xml:S2:2603:8	O
TECFIDERA	TECFIDERA.xml:S2:2612:9	O
,	TECFIDERA.xml:S2:2621:1	O
mean	TECFIDERA.xml:S2:2623:4	O
lymphocyte	TECFIDERA.xml:S2:2628:10	O
counts	TECFIDERA.xml:S2:2639:6	O
increased	TECFIDERA.xml:S2:2646:9	O
but	TECFIDERA.xml:S2:2656:3	O
did	TECFIDERA.xml:S2:2660:3	O
not	TECFIDERA.xml:S2:2664:3	O
return	TECFIDERA.xml:S2:2668:6	O
to	TECFIDERA.xml:S2:2675:2	O
baseline	TECFIDERA.xml:S2:2678:8	O
.	TECFIDERA.xml:S2:2686:1	O

Six	TECFIDERA.xml:S2:2688:3	O
percent	TECFIDERA.xml:S2:2692:7	O
(	TECFIDERA.xml:S2:2700:1	O
6%	TECFIDERA.xml:S2:2701:2	O
)	TECFIDERA.xml:S2:2703:1	O
of	TECFIDERA.xml:S2:2705:2	O
TECFIDERA	TECFIDERA.xml:S2:2708:9	O
patients	TECFIDERA.xml:S2:2718:8	O
and	TECFIDERA.xml:S2:2727:3	O
1%	TECFIDERA.xml:S2:2732:2	O
of	TECFIDERA.xml:S2:2735:2	O
placebo	TECFIDERA.xml:S2:2738:7	O
patients	TECFIDERA.xml:S2:2746:8	O
experienced	TECFIDERA.xml:S2:2755:11	O
lymphocyte	TECFIDERA.xml:S2:2767:10	B-AdverseReaction
counts	TECFIDERA.xml:S2:2778:6	I-AdverseReaction
0.5	TECFIDERA.xml:S2:2786:3	I-AdverseReaction
x10	TECFIDERA.xml:S2:2789:3	I-AdverseReaction
9	TECFIDERA.xml:S2:2794:1	I-AdverseReaction
L	TECFIDERA.xml:S2:2798:1	I-AdverseReaction
(	TECFIDERA.xml:S2:2800:1	O
lower	TECFIDERA.xml:S2:2801:5	O
limit	TECFIDERA.xml:S2:2807:5	O
of	TECFIDERA.xml:S2:2813:2	O
normal	TECFIDERA.xml:S2:2816:6	O
0.91	TECFIDERA.xml:S2:2823:4	O
x10	TECFIDERA.xml:S2:2827:3	O
9	TECFIDERA.xml:S2:2832:1	O
L	TECFIDERA.xml:S2:2836:1	O
)	TECFIDERA.xml:S2:2837:1	O
.	TECFIDERA.xml:S2:2838:1	O

The	TECFIDERA.xml:S2:2840:3	O
incidence	TECFIDERA.xml:S2:2844:9	O
of	TECFIDERA.xml:S2:2854:2	O
infections	TECFIDERA.xml:S2:2857:10	B-AdverseReaction
(	TECFIDERA.xml:S2:2868:1	O
60%	TECFIDERA.xml:S2:2869:3	O
vs	TECFIDERA.xml:S2:2873:2	O
58%	TECFIDERA.xml:S2:2876:3	O
)	TECFIDERA.xml:S2:2879:1	O
and	TECFIDERA.xml:S2:2881:3	O
serious	TECFIDERA.xml:S2:2885:7	B-Severity
infections	TECFIDERA.xml:S2:2893:10	B-AdverseReaction
(	TECFIDERA.xml:S2:2904:1	O
2%	TECFIDERA.xml:S2:2905:2	O
vs	TECFIDERA.xml:S2:2908:2	O
2%	TECFIDERA.xml:S2:2911:2	O
)	TECFIDERA.xml:S2:2913:1	O
was	TECFIDERA.xml:S2:2915:3	O
similar	TECFIDERA.xml:S2:2919:7	O
in	TECFIDERA.xml:S2:2927:2	O
patients	TECFIDERA.xml:S2:2930:8	O
treated	TECFIDERA.xml:S2:2939:7	O
with	TECFIDERA.xml:S2:2947:4	O
TECFIDERA	TECFIDERA.xml:S2:2952:9	O
or	TECFIDERA.xml:S2:2962:2	O
placebo	TECFIDERA.xml:S2:2965:7	O
,	TECFIDERA.xml:S2:2972:1	O
respectively	TECFIDERA.xml:S2:2974:12	O
.	TECFIDERA.xml:S2:2986:1	O

There	TECFIDERA.xml:S2:2988:5	O
was	TECFIDERA.xml:S2:2994:3	O
no	TECFIDERA.xml:S2:2998:2	B-Negation
increased	TECFIDERA.xml:S2:3001:9	B-AdverseReaction
incidence	TECFIDERA.xml:S2:3011:9	O
of	TECFIDERA.xml:S2:3021:2	O
serious	TECFIDERA.xml:S2:3024:7	B-Severity
infections	TECFIDERA.xml:S2:3032:10	I-AdverseReaction
observed	TECFIDERA.xml:S2:3043:8	O
in	TECFIDERA.xml:S2:3052:2	O
patients	TECFIDERA.xml:S2:3055:8	O
with	TECFIDERA.xml:S2:3064:4	O
lymphocyte	TECFIDERA.xml:S2:3069:10	O
counts	TECFIDERA.xml:S2:3080:6	O
0.8	TECFIDERA.xml:S2:3088:3	O
x10	TECFIDERA.xml:S2:3091:3	O
9	TECFIDERA.xml:S2:3096:1	O
L	TECFIDERA.xml:S2:3100:1	O
or	TECFIDERA.xml:S2:3102:2	O
0.5	TECFIDERA.xml:S2:3105:3	O
x10	TECFIDERA.xml:S2:3108:3	O
9	TECFIDERA.xml:S2:3113:1	O
L	TECFIDERA.xml:S2:3117:1	O
in	TECFIDERA.xml:S2:3119:2	O
controlled	TECFIDERA.xml:S2:3122:10	O
trials	TECFIDERA.xml:S2:3133:6	O
,	TECFIDERA.xml:S2:3139:1	O
although	TECFIDERA.xml:S2:3141:8	O
one	TECFIDERA.xml:S2:3150:3	O
patient	TECFIDERA.xml:S2:3154:7	O
in	TECFIDERA.xml:S2:3162:2	O
an	TECFIDERA.xml:S2:3165:2	O
extension	TECFIDERA.xml:S2:3168:9	O
study	TECFIDERA.xml:S2:3178:5	O
developed	TECFIDERA.xml:S2:3184:9	O
PML	TECFIDERA.xml:S2:3194:3	B-AdverseReaction
in	TECFIDERA.xml:S2:3198:2	O
the	TECFIDERA.xml:S2:3201:3	O
setting	TECFIDERA.xml:S2:3205:7	O
of	TECFIDERA.xml:S2:3213:2	O
prolonged	TECFIDERA.xml:S2:3216:9	B-AdverseReaction
lymphopenia	TECFIDERA.xml:S2:3226:11	I-AdverseReaction
(	TECFIDERA.xml:S2:3238:1	O
lymphocyte	TECFIDERA.xml:S2:3239:10	O
counts	TECFIDERA.xml:S2:3250:6	O
predominantly	TECFIDERA.xml:S2:3257:13	O
0.5	TECFIDERA.xml:S2:3272:3	O
x10	TECFIDERA.xml:S2:3275:3	O
9	TECFIDERA.xml:S2:3280:1	O
L	TECFIDERA.xml:S2:3284:1	O
for	TECFIDERA.xml:S2:3286:3	O
3.5	TECFIDERA.xml:S2:3290:3	O
years	TECFIDERA.xml:S2:3294:5	O
)	TECFIDERA.xml:S2:3299:1	O
[	TECFIDERA.xml:S2:3301:1	O
see	TECFIDERA.xml:S2:3302:3	O
Warnings	TECFIDERA.xml:S2:3306:8	O
and	TECFIDERA.xml:S2:3315:3	O
Precautions	TECFIDERA.xml:S2:3319:11	O
(	TECFIDERA.xml:S2:3331:1	O
5.2	TECFIDERA.xml:S2:3334:3	O
)]	TECFIDERA.xml:S2:3339:2	O
.	TECFIDERA.xml:S2:3343:1	O

In	TECFIDERA.xml:S2:3345:2	O
controlled	TECFIDERA.xml:S2:3348:10	O
and	TECFIDERA.xml:S2:3359:3	O
uncontrolled	TECFIDERA.xml:S2:3363:12	O
clinical	TECFIDERA.xml:S2:3376:8	O
trials	TECFIDERA.xml:S2:3385:6	O
,	TECFIDERA.xml:S2:3391:1	O
2%	TECFIDERA.xml:S2:3393:2	O
of	TECFIDERA.xml:S2:3396:2	O
patients	TECFIDERA.xml:S2:3399:8	O
experienced	TECFIDERA.xml:S2:3408:11	O
lymphocyte	TECFIDERA.xml:S2:3420:10	B-AdverseReaction
counts	TECFIDERA.xml:S2:3431:6	I-AdverseReaction
0.5	TECFIDERA.xml:S2:3439:3	I-AdverseReaction
x	TECFIDERA.xml:S2:3443:1	I-AdverseReaction
10	TECFIDERA.xml:S2:3445:2	I-AdverseReaction
9	TECFIDERA.xml:S2:3449:1	I-AdverseReaction
L	TECFIDERA.xml:S2:3453:1	I-AdverseReaction
for	TECFIDERA.xml:S2:3455:3	O
at	TECFIDERA.xml:S2:3459:2	O
least	TECFIDERA.xml:S2:3462:5	O
six	TECFIDERA.xml:S2:3468:3	O
months	TECFIDERA.xml:S2:3472:6	O
.	TECFIDERA.xml:S2:3478:1	O

In	TECFIDERA.xml:S2:3480:2	O
these	TECFIDERA.xml:S2:3483:5	O
patients	TECFIDERA.xml:S2:3489:8	O
,	TECFIDERA.xml:S2:3497:1	O
the	TECFIDERA.xml:S2:3499:3	O
majority	TECFIDERA.xml:S2:3503:8	O
of	TECFIDERA.xml:S2:3512:2	O
lymphocyte	TECFIDERA.xml:S2:3515:10	B-AdverseReaction
counts	TECFIDERA.xml:S2:3526:6	I-AdverseReaction
remained	TECFIDERA.xml:S2:3533:8	O
0.5	TECFIDERA.xml:S2:3543:3	I-AdverseReaction
x10	TECFIDERA.xml:S2:3546:3	I-AdverseReaction
9	TECFIDERA.xml:S2:3551:1	I-AdverseReaction
L	TECFIDERA.xml:S2:3555:1	I-AdverseReaction
with	TECFIDERA.xml:S2:3557:4	O
continued	TECFIDERA.xml:S2:3562:9	O
therapy	TECFIDERA.xml:S2:3572:7	O
.	TECFIDERA.xml:S2:3579:1	O

TECFIDERA	TECFIDERA.xml:S2:3581:9	O
has	TECFIDERA.xml:S2:3591:3	O
not	TECFIDERA.xml:S2:3595:3	O
been	TECFIDERA.xml:S2:3599:4	O
studied	TECFIDERA.xml:S2:3604:7	O
in	TECFIDERA.xml:S2:3612:2	O
patients	TECFIDERA.xml:S2:3615:8	O
with	TECFIDERA.xml:S2:3624:4	O
pre	TECFIDERA.xml:S2:3629:3	O
-	TECFIDERA.xml:S2:3632:1	O
existing	TECFIDERA.xml:S2:3633:8	O
low	TECFIDERA.xml:S2:3642:3	O
lymphocyte	TECFIDERA.xml:S2:3646:10	O
counts	TECFIDERA.xml:S2:3657:6	O
.	TECFIDERA.xml:S2:3663:1	O

Before	TECFIDERA.xml:S2:3672:6	O
initiating	TECFIDERA.xml:S2:3679:10	O
treatment	TECFIDERA.xml:S2:3690:9	O
with	TECFIDERA.xml:S2:3700:4	O
TECFIDERA	TECFIDERA.xml:S2:3705:9	O
,	TECFIDERA.xml:S2:3714:1	O
a	TECFIDERA.xml:S2:3716:1	O
CBC	TECFIDERA.xml:S2:3718:3	O
including	TECFIDERA.xml:S2:3722:9	O
lymphocyte	TECFIDERA.xml:S2:3732:10	O
count	TECFIDERA.xml:S2:3743:5	O
should	TECFIDERA.xml:S2:3749:6	O
be	TECFIDERA.xml:S2:3756:2	O
obtained	TECFIDERA.xml:S2:3759:8	O
.	TECFIDERA.xml:S2:3767:1	O

A	TECFIDERA.xml:S2:3769:1	O
CBC	TECFIDERA.xml:S2:3771:3	O
including	TECFIDERA.xml:S2:3775:9	O
lymphocyte	TECFIDERA.xml:S2:3785:10	O
count	TECFIDERA.xml:S2:3796:5	O
should	TECFIDERA.xml:S2:3802:6	O
also	TECFIDERA.xml:S2:3809:4	O
be	TECFIDERA.xml:S2:3814:2	O
obtained	TECFIDERA.xml:S2:3817:8	O
after	TECFIDERA.xml:S2:3826:5	O
6	TECFIDERA.xml:S2:3832:1	O
months	TECFIDERA.xml:S2:3834:6	O
of	TECFIDERA.xml:S2:3841:2	O
treatment	TECFIDERA.xml:S2:3844:9	O
,	TECFIDERA.xml:S2:3853:1	O
every	TECFIDERA.xml:S2:3855:5	O
6	TECFIDERA.xml:S2:3861:1	O
to	TECFIDERA.xml:S2:3863:2	O
12	TECFIDERA.xml:S2:3866:2	O
months	TECFIDERA.xml:S2:3869:6	O
thereafter	TECFIDERA.xml:S2:3876:10	O
,	TECFIDERA.xml:S2:3886:1	O
and	TECFIDERA.xml:S2:3888:3	O
as	TECFIDERA.xml:S2:3892:2	O
clinically	TECFIDERA.xml:S2:3895:10	O
indicated	TECFIDERA.xml:S2:3906:9	O
.	TECFIDERA.xml:S2:3915:1	O

Consider	TECFIDERA.xml:S2:3917:8	O
interruption	TECFIDERA.xml:S2:3926:12	O
of	TECFIDERA.xml:S2:3939:2	O
TECFIDERA	TECFIDERA.xml:S2:3942:9	O
in	TECFIDERA.xml:S2:3952:2	O
patients	TECFIDERA.xml:S2:3955:8	O
with	TECFIDERA.xml:S2:3964:4	O
lymphocyte	TECFIDERA.xml:S2:3969:10	O
counts	TECFIDERA.xml:S2:3980:6	O
0.5	TECFIDERA.xml:S2:3988:3	O
x	TECFIDERA.xml:S2:3992:1	O
10	TECFIDERA.xml:S2:3994:2	O
9	TECFIDERA.xml:S2:3998:1	O
L	TECFIDERA.xml:S2:4002:1	O
persisting	TECFIDERA.xml:S2:4004:10	O
for	TECFIDERA.xml:S2:4015:3	O
more	TECFIDERA.xml:S2:4019:4	O
than	TECFIDERA.xml:S2:4024:4	O
six	TECFIDERA.xml:S2:4029:3	O
months	TECFIDERA.xml:S2:4033:6	O
.	TECFIDERA.xml:S2:4039:1	O

Given	TECFIDERA.xml:S2:4041:5	O
the	TECFIDERA.xml:S2:4047:3	O
potential	TECFIDERA.xml:S2:4051:9	O
for	TECFIDERA.xml:S2:4061:3	O
delay	TECFIDERA.xml:S2:4065:5	O
in	TECFIDERA.xml:S2:4071:2	O
lymphocyte	TECFIDERA.xml:S2:4074:10	O
recovery	TECFIDERA.xml:S2:4085:8	O
after	TECFIDERA.xml:S2:4094:5	O
discontinuation	TECFIDERA.xml:S2:4100:15	O
of	TECFIDERA.xml:S2:4116:2	O
TECFIDERA	TECFIDERA.xml:S2:4119:9	O
,	TECFIDERA.xml:S2:4128:1	O
consider	TECFIDERA.xml:S2:4130:8	O
following	TECFIDERA.xml:S2:4139:9	O
lymphocyte	TECFIDERA.xml:S2:4149:10	O
counts	TECFIDERA.xml:S2:4160:6	O
until	TECFIDERA.xml:S2:4167:5	O
lymphopenia	TECFIDERA.xml:S2:4173:11	O
is	TECFIDERA.xml:S2:4185:2	O
resolved	TECFIDERA.xml:S2:4188:8	O
.	TECFIDERA.xml:S2:4196:1	O

Withholding	TECFIDERA.xml:S2:4198:11	O
treatment	TECFIDERA.xml:S2:4210:9	O
should	TECFIDERA.xml:S2:4220:6	O
be	TECFIDERA.xml:S2:4227:2	O
considered	TECFIDERA.xml:S2:4230:10	O
in	TECFIDERA.xml:S2:4241:2	O
patients	TECFIDERA.xml:S2:4244:8	O
with	TECFIDERA.xml:S2:4253:4	O
serious	TECFIDERA.xml:S2:4258:7	O
infections	TECFIDERA.xml:S2:4266:10	O
until	TECFIDERA.xml:S2:4277:5	O
the	TECFIDERA.xml:S2:4283:3	O
infection	TECFIDERA.xml:S2:4287:9	O
(	TECFIDERA.xml:S2:4296:1	O
s	TECFIDERA.xml:S2:4297:1	O
)	TECFIDERA.xml:S2:4298:1	O
is	TECFIDERA.xml:S2:4300:2	O
resolved	TECFIDERA.xml:S2:4303:8	O
.	TECFIDERA.xml:S2:4311:1	O

Decisions	TECFIDERA.xml:S2:4313:9	O
about	TECFIDERA.xml:S2:4323:5	O
whether	TECFIDERA.xml:S2:4329:7	O
or	TECFIDERA.xml:S2:4337:2	O
not	TECFIDERA.xml:S2:4340:3	O
to	TECFIDERA.xml:S2:4344:2	O
restart	TECFIDERA.xml:S2:4347:7	O
TECFIDERA	TECFIDERA.xml:S2:4355:9	O
should	TECFIDERA.xml:S2:4365:6	O
be	TECFIDERA.xml:S2:4372:2	O
individualized	TECFIDERA.xml:S2:4375:14	O
based	TECFIDERA.xml:S2:4390:5	O
on	TECFIDERA.xml:S2:4396:2	O
clinical	TECFIDERA.xml:S2:4399:8	O
circumstances	TECFIDERA.xml:S2:4408:13	O
.	TECFIDERA.xml:S2:4421:1	O

5.4	TECFIDERA.xml:S2:4430:3	O
Flushing	TECFIDERA.xml:S2:4434:8	O

TECFIDERA	TECFIDERA.xml:S2:4451:9	O
may	TECFIDERA.xml:S2:4461:3	O
cause	TECFIDERA.xml:S2:4465:5	O
flushing	TECFIDERA.xml:S2:4471:8	B-AdverseReaction
(	TECFIDERA.xml:S2:4480:1	O
e	TECFIDERA.xml:S2:4481:1	O
.	TECFIDERA.xml:S2:4482:1	O
g	TECFIDERA.xml:S2:4483:1	O
.	TECFIDERA.xml:S2:4484:1	O
,	TECFIDERA.xml:S2:4485:1	O
warmth	TECFIDERA.xml:S2:4487:6	B-AdverseReaction
,	TECFIDERA.xml:S2:4493:1	O
redness	TECFIDERA.xml:S2:4495:7	B-AdverseReaction
,	TECFIDERA.xml:S2:4502:1	O
itching	TECFIDERA.xml:S2:4504:7	B-AdverseReaction
,	TECFIDERA.xml:S2:4511:1	O
and	TECFIDERA.xml:S2:4513:3	O
or	TECFIDERA.xml:S2:4517:2	O
burning	TECFIDERA.xml:S2:4520:7	B-AdverseReaction
sensation	TECFIDERA.xml:S2:4528:9	I-AdverseReaction
)	TECFIDERA.xml:S2:4537:1	O
.	TECFIDERA.xml:S2:4538:1	O

In	TECFIDERA.xml:S2:4540:2	O
clinical	TECFIDERA.xml:S2:4543:8	O
trials	TECFIDERA.xml:S2:4552:6	O
,	TECFIDERA.xml:S2:4558:1	O
40%	TECFIDERA.xml:S2:4560:3	O
of	TECFIDERA.xml:S2:4564:2	O
TECFIDERA	TECFIDERA.xml:S2:4567:9	O
treated	TECFIDERA.xml:S2:4577:7	O
patients	TECFIDERA.xml:S2:4585:8	O
experienced	TECFIDERA.xml:S2:4594:11	O
flushing	TECFIDERA.xml:S2:4606:8	B-AdverseReaction
.	TECFIDERA.xml:S2:4614:1	O

Flushing	TECFIDERA.xml:S2:4616:8	B-AdverseReaction
symptoms	TECFIDERA.xml:S2:4625:8	O
generally	TECFIDERA.xml:S2:4634:9	O
began	TECFIDERA.xml:S2:4644:5	O
soon	TECFIDERA.xml:S2:4650:4	O
after	TECFIDERA.xml:S2:4655:5	O
initiating	TECFIDERA.xml:S2:4661:10	O
TECFIDERA	TECFIDERA.xml:S2:4672:9	O
and	TECFIDERA.xml:S2:4682:3	O
usually	TECFIDERA.xml:S2:4686:7	O
improved	TECFIDERA.xml:S2:4694:8	O
or	TECFIDERA.xml:S2:4703:2	O
resolved	TECFIDERA.xml:S2:4706:8	O
over	TECFIDERA.xml:S2:4715:4	O
time	TECFIDERA.xml:S2:4720:4	O
.	TECFIDERA.xml:S2:4724:1	O

In	TECFIDERA.xml:S2:4726:2	O
the	TECFIDERA.xml:S2:4729:3	O
majority	TECFIDERA.xml:S2:4733:8	O
of	TECFIDERA.xml:S2:4742:2	O
patients	TECFIDERA.xml:S2:4745:8	O
who	TECFIDERA.xml:S2:4754:3	O
experienced	TECFIDERA.xml:S2:4758:11	O
flushing	TECFIDERA.xml:S2:4770:8	B-AdverseReaction
,	TECFIDERA.xml:S2:4778:1	O
it	TECFIDERA.xml:S2:4780:2	O
was	TECFIDERA.xml:S2:4783:3	O
mild	TECFIDERA.xml:S2:4787:4	B-Severity
or	TECFIDERA.xml:S2:4792:2	O
moderate	TECFIDERA.xml:S2:4795:8	B-Severity
in	TECFIDERA.xml:S2:4804:2	O
severity	TECFIDERA.xml:S2:4807:8	O
.	TECFIDERA.xml:S2:4815:1	O

Three	TECFIDERA.xml:S2:4817:5	O
percent	TECFIDERA.xml:S2:4823:7	O
(	TECFIDERA.xml:S2:4831:1	O
3%	TECFIDERA.xml:S2:4832:2	O
)	TECFIDERA.xml:S2:4834:1	O
of	TECFIDERA.xml:S2:4836:2	O
patients	TECFIDERA.xml:S2:4839:8	O
discontinued	TECFIDERA.xml:S2:4848:12	O
TECFIDERA	TECFIDERA.xml:S2:4861:9	O
for	TECFIDERA.xml:S2:4871:3	O
flushing	TECFIDERA.xml:S2:4875:8	B-AdverseReaction
and	TECFIDERA.xml:S2:4884:3	O
1%	TECFIDERA.xml:S2:4889:2	O
had	TECFIDERA.xml:S2:4892:3	O
serious	TECFIDERA.xml:S2:4896:7	B-Severity
flushing	TECFIDERA.xml:S2:4904:8	B-AdverseReaction
symptoms	TECFIDERA.xml:S2:4913:8	O
that	TECFIDERA.xml:S2:4922:4	O
were	TECFIDERA.xml:S2:4927:4	O
not	TECFIDERA.xml:S2:4932:3	B-Severity
life	TECFIDERA.xml:S2:4936:4	I-Severity
-	TECFIDERA.xml:S2:4940:1	I-Severity
threatening	TECFIDERA.xml:S2:4941:11	I-Severity
but	TECFIDERA.xml:S2:4953:3	O
led	TECFIDERA.xml:S2:4957:3	O
to	TECFIDERA.xml:S2:4961:2	O
hospitalization	TECFIDERA.xml:S2:4964:15	O
.	TECFIDERA.xml:S2:4979:1	O

Administration	TECFIDERA.xml:S2:4981:14	O
of	TECFIDERA.xml:S2:4996:2	O
TECFIDERA	TECFIDERA.xml:S2:4999:9	O
with	TECFIDERA.xml:S2:5009:4	O
food	TECFIDERA.xml:S2:5014:4	O
may	TECFIDERA.xml:S2:5019:3	O
reduce	TECFIDERA.xml:S2:5023:6	O
the	TECFIDERA.xml:S2:5030:3	O
incidence	TECFIDERA.xml:S2:5034:9	O
of	TECFIDERA.xml:S2:5044:2	O
flushing	TECFIDERA.xml:S2:5047:8	B-AdverseReaction
.	TECFIDERA.xml:S2:5055:1	O

Alternatively	TECFIDERA.xml:S2:5057:13	O
,	TECFIDERA.xml:S2:5070:1	O
administration	TECFIDERA.xml:S2:5072:14	O
of	TECFIDERA.xml:S2:5087:2	O
non	TECFIDERA.xml:S2:5090:3	O
-	TECFIDERA.xml:S2:5093:1	O
enteric	TECFIDERA.xml:S2:5094:7	O
coated	TECFIDERA.xml:S2:5102:6	O
aspirin	TECFIDERA.xml:S2:5109:7	O
(	TECFIDERA.xml:S2:5117:1	O
up	TECFIDERA.xml:S2:5118:2	O
to	TECFIDERA.xml:S2:5121:2	O
a	TECFIDERA.xml:S2:5124:1	O
dose	TECFIDERA.xml:S2:5126:4	O
of	TECFIDERA.xml:S2:5131:2	O
325	TECFIDERA.xml:S2:5134:3	O
mg	TECFIDERA.xml:S2:5138:2	O
)	TECFIDERA.xml:S2:5140:1	O
30	TECFIDERA.xml:S2:5142:2	O
minutes	TECFIDERA.xml:S2:5145:7	O
prior	TECFIDERA.xml:S2:5153:5	O
to	TECFIDERA.xml:S2:5159:2	O
TECFIDERA	TECFIDERA.xml:S2:5162:9	O
dosing	TECFIDERA.xml:S2:5172:6	O
may	TECFIDERA.xml:S2:5179:3	O
reduce	TECFIDERA.xml:S2:5183:6	O
the	TECFIDERA.xml:S2:5190:3	O
incidence	TECFIDERA.xml:S2:5194:9	O
or	TECFIDERA.xml:S2:5204:2	O
severity	TECFIDERA.xml:S2:5207:8	O
of	TECFIDERA.xml:S2:5216:2	O
flushing	TECFIDERA.xml:S2:5219:8	B-AdverseReaction
[	TECFIDERA.xml:S2:5228:1	O
see	TECFIDERA.xml:S2:5229:3	O
Dosing	TECFIDERA.xml:S2:5233:6	O
and	TECFIDERA.xml:S2:5240:3	O
Administration	TECFIDERA.xml:S2:5244:14	O
(	TECFIDERA.xml:S2:5259:1	O
2.1	TECFIDERA.xml:S2:5262:3	O
)	TECFIDERA.xml:S2:5267:1	O
and	TECFIDERA.xml:S2:5269:3	O
Clinical	TECFIDERA.xml:S2:5273:8	O
Pharmacology	TECFIDERA.xml:S2:5282:12	O
(	TECFIDERA.xml:S2:5295:1	O
12.3	TECFIDERA.xml:S2:5298:4	O
)]	TECFIDERA.xml:S2:5304:2	O
.	TECFIDERA.xml:S2:5308:1	O
